-DOCSTART- (26797704)

The	O	O	O
Impact	O	O	O
of	O	O	O
Deployment	O	O	B-Entity
on	O	O	O
Parental	O	O	B-Entity
,	O	O	O
Family	O	O	B-Entity
and	O	O	O
Child	O	O	B-Entity
Adjustment	O	O	B-Entity
in	O	O	O
Military	O	O	O
Families	O	O	O

Since	O	O	O
9/11	O	O	O
,	O	O	O
military	O	O	B-Entity
service	O	O	I-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
has	O	O	O
been	O	O	O
characterized	O	O	O
by	O	O	O
wartime	O	O	B-Entity
deployments	O	O	B-Entity
and	O	O	O
reintegration	O	O	O
challenges	O	O	O
that	O	O	O
contribute	O	O	O
to	O	O	O
a	O	O	O
context	O	O	O
of	O	O	O
stress	O	O	B-Entity
for	O	O	O
military	O	O	B-Entity
families	O	O	I-Entity
.	O	O	O

Research	O	O	B-Entity
indicates	O	O	O
the	O	O	O
negative	O	O	B-Entity
impact	O	O	I-Entity
of	O	O	O
wartime	O	O	O
deployment	O	O	B-Entity
on	O	O	O
the	O	O	O
well	O	O	B-Entity
being	O	O	I-Entity
of	O	O	O
service	O	O	B-Entity
members	O	O	B-Entity
,	O	O	O
military	O	O	B-Entity
spouses	O	O	B-Entity
,	O	O	O
and	O	O	O
children	O	O	B-Entity
.	O	O	O

Yet	O	O	O
,	O	O	O
few	O	O	O
studies	O	O	O
have	O	O	O
considered	O	O	O
how	O	O	O
parental	O	O	B-Entity
deployments	O	O	B-Entity
may	O	O	O
affect	O	O	O
adjustment	O	O	B-Entity
in	O	O	O
young	O	O	B-Entity
children	O	O	I-Entity
and	O	O	O
their	O	O	O
families	O	O	B-Entity
.	O	O	O

Using	O	O	O
deployment	O	O	B-Entity
records	O	O	O
and	O	O	O
parent	O	O	B-Entity
-	O	O	O
reported	O	O	B-Entity
measures	O	O	O
from	O	O	O
primary	O	O	O
caregiving	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
680	O	O	O
)	O	O	O
and	O	O	O
military	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
310	O	O	O
)	O	O	O
parents	O	O	B-Entity
,	O	O	O
we	O	O	O
examined	O	O	O
the	O	O	O
influence	O	O	O
of	O	O	O
deployment	O	O	O
on	O	O	O
adjustment	O	O	B-Entity
in	O	O	O
military	O	O	B-Entity
families	O	O	I-Entity
with	O	O	O
children	O	O	B-Entity
ages	O	O	O
0	O	O	O
-	O	O	O
10	O	O	O
years	O	O	O
.	O	O	O

Greater	O	O	O
deployment	O	O	B-Entity
exposure	O	O	O
was	O	O	O
related	O	O	O
to	O	O	O
impaired	O	O	B-Entity
family	O	O	B-Entity
functioning	O	O	I-Entity
and	O	O	O
marital	O	O	B-Entity
instability	O	O	B-Entity
.	O	O	O

Parental	O	O	B-Entity
depressive	O	O	B-Entity
and	O	O	O
posttraumatic	O	O	B-Entity
stress	O	O	I-Entity
symptoms	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
impairments	O	O	B-Entity
in	O	O	O
social	O	O	B-Entity
emotional	O	O	B-Entity
adjustment	O	O	B-Entity
in	O	O	O
young	O	O	B-Entity
children	O	O	I-Entity
,	O	O	O
increased	O	O	O
anxiety	O	O	B-Entity
in	O	O	O
early	O	O	O
childhood	O	O	B-Entity
,	O	O	O
and	O	O	O
adjustment	O	O	O
problems	O	O	O
in	O	O	O
school-age	O	O	B-Entity
children	O	O	I-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
parental	O	O	B-Entity
sensitivity	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
improved	O	O	O
social	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
outcomes	O	O	I-Entity
across	O	O	O
childhood	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
provide	O	O	O
guidance	O	O	O
to	O	O	O
developing	O	O	O
preventive	O	O	B-Entity
approaches	O	O	O
for	O	O	O
military	O	O	B-Entity
families	O	O	I-Entity
with	O	O	O
young	O	O	O
children	O	O	B-Entity
.	O	O	O

-DOCSTART- (26931495)

Beyond	O	O	O
neutral	O	O	B-Entity
and	O	O	O
forbidden	O	O	B-Entity
links	O	O	I-Entity
:	O	O	O
morphological	O	O	B-Entity
matches	O	O	B-Entity
and	O	O	O
the	O	O	O
assembly	O	O	B-Entity
of	O	O	O
mutualistic	O	O	B-Entity
hawkmoth	O	O	B-Entity
-	O	O	O
plant	O	O	B-Entity
networks	O	O	O

A	O	O	O
major	O	O	O
challenge	O	O	O
in	O	O	O
evolutionary	O	O	B-Entity
ecology	O	O	I-Entity
is	O	O	O
to	O	O	O
understand	O	O	O
how	O	O	O
co-evolutionary	O	O	B-Entity
processes	O	O	I-Entity
shape	O	O	O
patterns	O	O	B-Entity
of	O	O	O
interactions	O	O	B-Entity
between	O	O	O
species	O	O	B-Entity
at	O	O	O
community	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

Pollination	O	O	B-Entity
of	O	O	O
flowers	O	O	B-Entity
with	O	O	O
long	O	O	B-Entity
corolla	O	O	I-Entity
tubes	O	O	I-Entity
by	O	O	O
long-tongued	O	O	B-Entity
hawkmoths	O	O	I-Entity
has	O	O	O
been	O	O	O
invoked	O	O	O
as	O	O	O
a	O	O	O
showcase	O	O	O
model	O	O	B-Entity
of	O	O	O
co-evolution	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
optimal	O	O	O
foraging	O	O	O
models	O	O	B-Entity
have	O	O	O
predicted	O	O	O
that	O	O	O
there	O	O	O
might	O	O	O
be	O	O	O
a	O	O	O
close	O	O	O
association	O	O	B-Entity
between	O	O	O
mouthparts	O	O	B-Entity
'	O	O	I-Entity
length	O	O	I-Entity
and	O	O	O
the	O	O	O
corolla	O	O	B-Entity
depth	O	O	B-Entity
of	O	O	O
the	O	O	O
visited	O	O	O
flowers	O	O	B-Entity
,	O	O	O
thus	O	O	O
favouring	O	O	O
trait	O	O	B-Entity
convergence	O	O	B-Entity
and	O	O	O
specialization	O	O	B-Entity
at	O	O	O
community	O	O	B-Entity
level	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
assessed	O	O	B-Entity
whether	O	O	O
hawkmoths	O	O	B-Entity
more	O	O	O
frequently	O	O	O
pollinate	O	O	B-Entity
plants	O	O	I-Entity
with	O	O	O
floral	O	O	B-Entity
tube	O	O	I-Entity
lengths	O	O	B-Entity
similar	O	O	O
to	O	O	O
their	O	O	O
proboscis	O	O	B-Entity
lengths	O	O	O
(	O	O	O
morphological	O	O	B-Entity
match	O	O	B-Entity
hypothesis	O	O	B-Entity
)	O	O	O
against	O	O	O
abundance	O	O	B-Entity
-based	O	O	O
processes	O	O	B-Entity
(	O	O	O
neutral	O	O	B-Entity
hypothesis	O	O	I-Entity
)	O	O	O
and	O	O	O
ecological	O	O	B-Entity
trait	O	O	I-Entity
mismatches	O	O	B-Entity
constraints	O	O	B-Entity
(	O	O	O
forbidden	O	O	B-Entity
links	O	O	I-Entity
hypothesis	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
how	O	O	O
these	O	O	O
processes	O	O	O
structure	O	O	B-Entity
hawkmoth	O	O	B-Entity
-	O	O	O
plant	O	O	B-Entity
mutualistic	O	O	B-Entity
networks	O	O	I-Entity
from	O	O	O
five	O	O	O
communities	O	O	B-Entity
in	O	O	O
four	O	O	O
biogeographical	O	O	B-Entity
regions	O	O	I-Entity
of	O	O	O
South	O	O	B-Entity
America	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
convergence	O	O	B-Entity
in	O	O	O
morphological	O	O	B-Entity
traits	O	O	B-Entity
across	O	O	O
the	O	O	O
five	O	O	O
communities	O	O	B-Entity
and	O	O	O
that	O	O	O
the	O	O	O
distribution	O	O	B-Entity
of	O	O	O
morphological	O	O	O
differences	O	O	O
between	O	O	O
hawkmoths	O	O	B-Entity
and	O	O	O
plants	O	O	B-Entity
is	O	O	O
consistent	O	O	O
with	O	O	O
expectations	O	O	O
under	O	O	O
the	O	O	O
morphological	O	O	O
match	O	O	B-Entity
hypothesis	O	O	B-Entity
in	O	O	O
three	O	O	O
of	O	O	O
the	O	O	O
five	O	O	O
communities	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
two	O	O	O
remaining	O	O	O
communities	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
ecotones	O	O	O
between	O	O	O
two	O	O	O
distinct	O	O	O
biogeographical	O	O	B-Entity
areas	O	O	I-Entity
,	O	O	O
interactions	O	O	B-Entity
are	O	O	O
better	O	O	O
predicted	O	O	O
by	O	O	O
the	O	O	O
neutral	O	O	B-Entity
hypothesis	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
are	O	O	O
consistent	O	O	O
with	O	O	O
the	O	O	O
idea	O	O	O
that	O	O	O
diffuse	O	O	O
co-evolution	O	O	B-Entity
drives	O	O	O
the	O	O	O
evolution	O	O	B-Entity
of	O	O	O
extremely	O	O	O
long	O	O	B-Entity
proboscises	O	O	I-Entity
and	O	O	O
flower	O	O	B-Entity
tubes	O	O	I-Entity
,	O	O	O
and	O	O	O
highlight	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
morphological	O	O	B-Entity
traits	O	O	B-Entity
,	O	O	O
beyond	O	O	O
the	O	O	O
forbidden	O	O	B-Entity
links	O	O	I-Entity
hypothesis	O	O	B-Entity
,	O	O	O
in	O	O	O
structuring	O	O	O
interactions	O	O	B-Entity
between	O	O	O
mutualistic	O	O	B-Entity
partners	O	O	I-Entity
,	O	O	O
revealing	O	O	O
that	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
niche-based	O	O	B-Entity
processes	O	O	I-Entity
can	O	O	O
be	O	O	O
much	O	O	O
more	O	O	O
complex	O	O	O
than	O	O	O
previously	O	O	O
known	O	O	O
.	O	O	O

-DOCSTART- (27061776)

Nosocomial	O	O	B-Entity
pneumonia	O	O	I-Entity
caused	O	O	O
by	O	O	O
methicillin-resistant	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
linezolid	O	O	B-Entity
or	O	O	O
vancomycin	O	O	B-Entity
:	O	O	O
A	O	O	O
secondary	O	O	O
economic	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
resource	O	O	B-Entity
use	O	O	I-Entity
from	O	O	O
a	O	O	O
Spanish	O	O	B-Entity
perspective	O	O	O

Adopting	O	O	O
a	O	O	O
unique	O	O	O
Spanish	O	O	B-Entity
perspective	O	O	B-Entity
,	O	O	O
this	O	O	O
study	O	O	B-Entity
aims	O	O	O
to	O	O	O
assess	O	O	O
healthcare	O	O	B-Entity
resource	O	O	I-Entity
utilization	O	O	I-Entity
(	O	O	O
HCRU	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
costs	O	O	B-Entity
of	O	O	O
treating	O	O	B-Entity
nosocomial	O	O	B-Entity
pneumonia	O	O	I-Entity
(	O	O	O
NP	O	O	B-Entity
)	O	O	O
produced	O	O	O
by	O	O	O
methicillin-resistant	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
(	O	O	O
MRSA	O	O	B-Entity
)	O	O	O
in	O	O	O
hospitalized	O	O	B-Entity
adults	O	O	I-Entity
using	O	O	O
linezolid	O	O	B-Entity
or	O	O	O
vancomycin	O	O	B-Entity
.	O	O	O

An	O	O	O
evaluation	O	O	O
is	O	O	O
also	O	O	O
made	O	O	O
of	O	O	O
the	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
rate	O	O	B-Entity
and	O	O	O
related	O	O	O
economic	O	O	B-Entity
outcomes	O	O	I-Entity
between	O	O	O
study	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

An	O	O	O
economic	O	O	O
post	O	O	B-Entity
hoc	O	O	I-Entity
evaluation	O	O	I-Entity
of	O	O	O
a	O	O	O
randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
multicenter	O	O	B-Entity
phase	O	O	I-Entity
4	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
.	O	O	O

Nosocomial	O	O	B-Entity
pneumonia	O	O	I-Entity
due	O	O	O
to	O	O	O
MRSA	O	O	B-Entity
in	O	O	O
hospitalized	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

The	O	O	O
modified	O	O	B-Entity
intent	O	O	I-Entity
to	O	O	I-Entity
treat	O	O	I-Entity
(	O	O	O
mITT	O	O	B-Entity
)	O	O	O
population	O	O	B-Entity
comprised	O	O	O
224	O	O	O
linezolid	O	O	B-Entity
-	O	O	O
and	O	O	O
224	O	O	O
vancomycin	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Costs	O	O	B-Entity
and	O	O	O
HCRU	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
between	O	O	O
patients	O	O	B-Entity
administered	O	O	B-Entity
either	O	O	O
linezolid	O	O	B-Entity
or	O	O	O
vancomycin	O	O	B-Entity
,	O	O	O
and	O	O	O
between	O	O	O
patients	O	O	O
who	O	O	O
developed	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
and	O	O	O
those	O	O	O
who	O	O	O
did	O	O	O
not	O	O	O
.	O	O	O

Analysis	O	O	O
of	O	O	O
HCRU	O	O	B-Entity
outcomes	O	O	B-Entity
and	O	O	O
costs	O	O	B-Entity
.	O	O	O

Total	O	O	O
costs	O	O	B-Entity
were	O	O	O
similar	O	O	O
between	O	O	O
the	O	O	O
linezolid	O	O	B-Entity
-	O	O	O
(	O	O	O
€	O	O	O
17,782±€9,615	O	O	O
)	O	O	O
and	O	O	O
vancomycin	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
€	O	O	O
17,423±€9,460	O	O	O
)	O	O	O
(	O	O	O
P=.69	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
rate	O	O	B-Entity
was	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
the	O	O	O
linezolid	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
4	O	O	O
%	O	O	O
vs.	O	O	O
15	O	O	O
%	O	O	O
;	O	O	O
P<.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
total	O	O	O
costs	O	O	B-Entity
tended	O	O	O
to	O	O	O
be	O	O	O
higher	O	O	O
in	O	O	O
patients	O	O	B-Entity
who	O	O	O
developed	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
(	O	O	O
€	O	O	O
19,626±€10,840	O	O	O
vs.	O	O	O
€	O	O	O
17,388±€9,369	O	O	O
;	O	O	O
P=.14	O	O	O
)	O	O	O
.	O	O	O

Among	O	O	O
the	O	O	O
patients	O	O	B-Entity
who	O	O	O
developed	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
HCRU	O	O	B-Entity
(	O	O	O
days	O	O	B-Entity
on	O	O	O
mechanical	O	O	B-Entity
ventilation	O	O	I-Entity
:	O	O	O
13.2±10.7	O	O	O
vs.	O	O	O
7.6±3.6	O	O	O
days	O	O	O
;	O	O	O
P=.21	O	O	O
;	O	O	O
ICU	O	O	B-Entity
stay	O	O	I-Entity
:	O	O	O
14.4±10.5	O	O	O
vs.	O	O	O
9.9±6.6	O	O	O
days	O	O	O
;	O	O	O
P=.30	O	O	O
;	O	O	O
hospital	O	O	B-Entity
stay	O	O	I-Entity
:	O	O	O
19.5±9.5	O	O	O
vs.	O	O	O
16.1±11.0	O	O	O
days	O	O	O
;	O	O	O
P=.26	O	O	O
)	O	O	O
and	O	O	O
cost	O	O	B-Entity
(	O	O	O
€	O	O	O
17,219±€8,792	O	O	O
vs.	O	O	O
€	O	O	O
20,263±€11,350	O	O	O
;	O	O	O
P=.51	O	O	O
)	O	O	O
tended	O	O	O
to	O	O	O
be	O	O	O
lower	O	O	O
in	O	O	O
the	O	O	O
linezolid	O	O	B-Entity
-	O	O	O
vs.	O	O	O
vancomycin	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
patients	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
statistically	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
costs	O	O	B-Entity
per	O	O	O
patient	O	O	B-Entity
-	O	O	O
day	O	O	B-Entity
between	O	O	O
cohorts	O	O	B-Entity
after	O	O	O
correcting	O	O	O
for	O	O	O
mortality	O	O	B-Entity
(	O	O	O
€	O	O	O
1000	O	O	O
vs.	O	O	O
€	O	O	O
1,010	O	O	O
;	O	O	O
P=.98	O	O	O
)	O	O	O
.	O	O	O

From	O	O	O
a	O	O	O
Spanish	O	O	B-Entity
perspective	O	O	B-Entity
,	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
statistically	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
total	O	O	O
costs	O	O	B-Entity
between	O	O	O
the	O	O	O
linezolid	O	O	B-Entity
and	O	O	O
vancomycin	O	O	B-Entity
pneumonia	O	O	B-Entity
cohorts	O	O	B-Entity
.	O	O	O

The	O	O	O
drug	O	O	B-Entity
cost	O	O	I-Entity
corresponding	O	O	O
to	O	O	O
linezolid	O	O	B-Entity
was	O	O	O
partially	O	O	O
offset	O	O	B-Entity
by	O	O	O
fewer	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
adverse	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

-DOCSTART- (27131339)

HERG1	O	O	B-Entity
potassium	O	O	B-Entity
channel	O	O	I-Entity
expression	O	O	B-Entity
in	O	O	O
potentially	O	O	B-Entity
malignant	O	O	B-Entity
disorders	O	O	I-Entity
of	O	O	O
the	O	O	O
oral	O	O	B-Entity
mucosa	O	O	I-Entity
and	O	O	O
prognostic	O	O	B-Entity
relevance	O	O	B-Entity
in	O	O	O
oral	O	O	O
squamous	O	O	O
cell	O	O	O
carcinoma	O	O	O

HERG1	O	O	B-Entity
potassium	O	O	B-Entity
channel	O	O	I-Entity
plays	O	O	O
a	O	O	O
critical	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
the	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
.	O	O	O

HERG1	O	O	B-Entity
protein	O	O	I-Entity
expression	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
immunohistochemistry	O	O	B-Entity
(	O	O	O
IHC	O	O	B-Entity
)	O	O	O
in	O	O	O
62	O	O	O
patients	O	O	B-Entity
with	O	O	O
oral	O	O	B-Entity
leukoplakias	O	O	I-Entity
and	O	O	O
100	O	O	O
patients	O	O	O
with	O	O	O
oral	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinomas	O	O	I-Entity
(	O	O	O
OSCC	O	O	B-Entity
)	O	O	O
.	O	O	O

HERG1	O	O	B-Entity
mRNA	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
by	O	O	O
real-time	O	O	B-Entity
reverse	O	O	I-Entity
transcriptase-polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
RT-PCR	O	O	B-Entity
)	O	O	O
in	O	O	O
22	O	O	O
patients	O	O	B-Entity
with	O	O	O
primary	O	O	B-Entity
head	O	O	B-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HNSCC	O	O	B-Entity
)	O	O	O
.	O	O	O

Statistically	O	O	B-Entity
significant	O	O	I-Entity
associations	O	O	B-Entity
were	O	O	O
found	O	O	O
between	O	O	O
HERG1	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
tobacco	O	O	B-Entity
consumption	O	O	I-Entity
,	O	O	O
disease	O	O	B-Entity
stage	O	O	I-Entity
,	O	O	O
tumor	O	O	B-Entity
differentiation	O	O	B-Entity
,	O	O	O
tumor	O	O	B-Entity
recurrence	O	O	I-Entity
,	O	O	O
and	O	O	O
reduced	O	O	B-Entity
survival	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
association	O	O	B-Entity
between	O	O	O
HERG1	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
progression	O	O	B-Entity
from	O	O	O
oral	O	O	B-Entity
leukoplakia	O	O	I-Entity
to	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
a	O	O	O
high	O	O	B-Entity
proportion	O	O	B-Entity
of	O	O	O
tumors	O	O	B-Entity
(	O	O	O
80	O	O	O
%	O	O	O
)	O	O	O
showed	O	O	O
increased	O	O	B-Entity
HERG1	O	O	B-Entity
mRNA	O	O	B-Entity
levels	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
normal	O	O	B-Entity
mucosa	O	O	I-Entity
from	O	O	O
nononcologic	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

Aberrant	O	O	B-Entity
HERG1	O	O	B-Entity
expression	O	O	B-Entity
increases	O	O	B-Entity
as	O	O	O
oral	O	O	O
tumorigenesis	O	O	B-Entity
progresses	O	O	I-Entity
from	O	O	O
oral	O	O	B-Entity
hyperplasia	O	O	I-Entity
to	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

Increased	O	O	B-Entity
HERG1	O	O	B-Entity
mRNA	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
also	O	O	O
frequently	O	O	O
detected	O	O	B-Entity
in	O	O	O
OSCC	O	O	B-Entity
and	O	O	O
other	O	O	O
HNSCC	O	O	B-Entity
subsites	O	O	B-Entity
.	O	O	O

HERG1	O	O	B-Entity
expression	O	O	B-Entity
emerges	O	O	O
as	O	O	O
a	O	O	O
clinically	O	O	B-Entity
relevant	O	O	B-Entity
feature	O	O	B-Entity
during	O	O	O
tumor	O	O	B-Entity
progression	O	O	I-Entity
and	O	O	O
a	O	O	O
potential	O	O	B-Entity
poor	O	O	B-Entity
prognostic	O	O	B-Entity
biomarker	O	O	B-Entity
for	O	O	O
OSCC	O	O	B-Entity
.	O	O	O

©	O	O	O
2016	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O
Head	O	O	O
Neck	O	O	O
38	O	O	O
:	O	O	O
1708	O	O	O
-	O	O	O
1716	O	O	O
,	O	O	O
2016	O	O	O
.	O	O	O

-DOCSTART- (27213687)

Nationwide	O	O	B-Entity
reduction	O	O	B-Entity
in	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
corneal	O	O	B-Entity
transplantations	O	O	I-Entity
for	O	O	O
keratoconus	O	O	B-Entity
following	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
cross-linking	O	O	O

Keratoconus	O	O	B-Entity
is	O	O	O
characterized	O	O	O
by	O	O	O
corneal	O	O	B-Entity
ectasia	O	O	I-Entity
and	O	O	O
irregular	O	O	B-Entity
astigmatism	O	O	I-Entity
,	O	O	O
which	O	O	O
can	O	O	O
lead	O	O	O
to	O	O	O
diminished	O	O	B-Entity
vision	O	O	I-Entity
and	O	O	O
corneal	O	O	B-Entity
scarring	O	O	I-Entity
.	O	O	O

Approximately	O	O	O
10	O	O	O
-	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
keratoconus	O	O	B-Entity
eventually	O	O	O
require	O	O	O
a	O	O	O
corneal	O	O	B-Entity
transplant	O	O	I-Entity
.	O	O	O

Corneal	O	O	B-Entity
cross-linking	O	O	I-Entity
(	O	O	O
CXL	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
relatively	O	O	O
new	O	O	O
treatment	O	O	B-Entity
that	O	O	O
may	O	O	O
help	O	O	O
prevent	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
corneal	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
the	O	O	O
introduction	O	O	B-Entity
of	O	O	O
CXL	O	O	B-Entity
has	O	O	O
reduced	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
corneal	O	O	B-Entity
transplants	O	O	I-Entity
performed	O	O	B-Entity
annually	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
regarding	O	O	O
the	O	O	O
transplantation	O	O	B-Entity
procedures	O	O	I-Entity
performed	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
under	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
50	O	O	O
years	O	O	B-Entity
were	O	O	O
extracted	O	O	O
from	O	O	O
the	O	O	O
Dutch	O	O	B-Entity
National	O	O	I-Entity
Organ	O	O	I-Entity
Transplant	O	O	I-Entity
Registry	O	O	I-Entity
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
corneal	O	O	B-Entity
transplants	O	O	I-Entity
performed	O	O	B-Entity
prior	O	O	O
to	O	O	O
(	O	O	O
i.e.	O	O	O
in	O	O	O
2005	O	O	O
through	O	O	O
2007	O	O	O
)	O	O	O
and	O	O	O
following	O	O	O
the	O	O	O
introduction	O	O	B-Entity
of	O	O	O
CXL	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
in	O	O	O
2012	O	O	O
through	O	O	O
2014	O	O	O
)	O	O	O
were	O	O	O
compared	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
trend	O	O	B-Entity
analysis	O	O	I-Entity
on	O	O	O
annual	O	O	B-Entity
keratoplasties	O	O	B-Entity
over	O	O	O
time	O	O	O
was	O	O	O
performed	O	O	B-Entity
.	O	O	O

Approximately	O	O	O
25	O	O	O
%	O	O	O
fewer	O	O	O
corneal	O	O	B-Entity
transplants	O	O	B-Entity
were	O	O	O
performed	O	O	B-Entity
in	O	O	O
the	O	O	O
3-	O	O	O
year	O	O	B-Entity
period	O	O	O
following	O	O	O
the	O	O	O
introduction	O	O	B-Entity
of	O	O	O
CXL	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
3-	O	O	O
year	O	O	O
period	O	O	O
prior	O	O	O
to	O	O	O
the	O	O	O
introduction	O	O	O
of	O	O	O
CXL	O	O	O
(	O	O	O
201	O	O	O
versus	O	O	O
269	O	O	O
transplants	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.005	O	O	O
)	O	O	O
.	O	O	O

Age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
and	O	O	O
visual	O	O	B-Entity
acuity	O	O	I-Entity
were	O	O	O
similar	O	O	O
between	O	O	O
the	O	O	O
patient	O	O	B-Entity
groups	O	O	O
in	O	O	O
the	O	O	O
two	O	O	O
time	O	O	B-Entity
periods	O	O	I-Entity
.	O	O	O

Trend	O	O	B-Entity
analysis	O	O	I-Entity
also	O	O	O
demonstrated	O	O	O
a	O	O	O
significant	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
amount	O	O	O
of	O	O	O
corneal	O	O	B-Entity
transplants	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Significantly	O	O	O
fewer	O	O	O
corneal	O	O	B-Entity
transplants	O	O	I-Entity
were	O	O	O
performed	O	O	O
for	O	O	O
treating	O	O	O
keratoconus	O	O	B-Entity
following	O	O	O
the	O	O	O
nationwide	O	O	B-Entity
introduction	O	O	B-Entity
of	O	O	O
CXL	O	O	B-Entity
.	O	O	O

This	O	O	O
reduction	O	O	B-Entity
suggests	O	O	O
that	O	O	O
corneal	O	O	B-Entity
cross-linking	O	O	I-Entity
can	O	O	O
significantly	O	O	O
reduce	O	O	B-Entity
the	O	O	O
need	O	O	O
for	O	O	O
corneal	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27233918)

Basal	O	O	B-Entity
and	O	O	O
maximal	O	O	B-Entity
metabolic	O	O	B-Entity
rates	O	O	I-Entity
differ	O	O	O
in	O	O	O
their	O	O	O
response	O	O	B-Entity
to	O	O	O
rapid	O	O	O
temperature	O	O	B-Entity
change	O	O	I-Entity
among	O	O	O
avian	O	O	B-Entity
species	O	O	O

In	O	O	O
birds	O	O	B-Entity
,	O	O	O
acclimation	O	O	B-Entity
and	O	O	O
acclimatization	O	O	B-Entity
to	O	O	O
temperature	O	O	B-Entity
are	O	O	O
associated	O	O	O
with	O	O	O
changes	O	O	O
in	O	O	O
basal	O	O	B-Entity
(	O	O	O
BMR	O	O	B-Entity
)	O	O	O
,	O	O	O
summit	O	O	B-Entity
(	O	O	O
Msum	O	O	B-Entity
)	O	O	O
and	O	O	O
maximal	O	O	B-Entity
(	O	O	O
MMR	O	O	B-Entity
)	O	O	O
metabolic	O	O	B-Entity
rates	O	O	I-Entity
but	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
rate	O	O	B-Entity
at	O	O	O
which	O	O	O
species	O	O	B-Entity
adjust	O	O	O
their	O	O	O
phenotype	O	O	B-Entity
to	O	O	O
short-term	O	O	B-Entity
temperature	O	O	O
variations	O	O	B-Entity
.	O	O	O

Our	O	O	O
aims	O	O	B-Entity
were	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
pattern	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
adjustments	O	O	O
following	O	O	O
a	O	O	O
rapid	O	O	O
temperature	O	O	B-Entity
change	O	O	I-Entity
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
performance	O	O	O
varies	O	O	O
at	O	O	O
similar	O	O	O
rates	O	O	B-Entity
during	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
warm	O	O	B-Entity
or	O	O	O
cold	O	O	B-Entity
environments	O	O	I-Entity
,	O	O	O
and	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
BMR	O	O	B-Entity
,	O	O	O
Msum	O	O	B-Entity
and	O	O	O
MMR	O	O	B-Entity
change	O	O	O
at	O	O	O
comparable	O	O	O
rates	O	O	O
during	O	O	O
thermal	O	O	B-Entity
acclimation	O	O	B-Entity
.	O	O	O

We	O	O	O
measured	O	O	O
these	O	O	O
parameters	O	O	O
in	O	O	O
white-throated	O	O	B-Entity
sparrows	O	O	I-Entity
(	O	O	O
Zonotrichia	O	O	B-Entity
albicollis	O	O	I-Entity
)	O	O	O
,	O	O	O
black-capped	O	O	B-Entity
chickadees	O	O	I-Entity
(	O	O	O
Poecile	O	O	B-Entity
atricapillus	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
snow	O	O	B-Entity
buntings	O	O	I-Entity
(	O	O	O
Plectrophenax	O	O	B-Entity
nivalis	O	O	I-Entity
)	O	O	O
after	O	O	O
acclimation	O	O	B-Entity
to	O	O	O
10	O	O	O
°	O	O	O
C	O	O	O
(	O	O	O
day	O	O	B-Entity
0	O	O	O
)	O	O	O
and	O	O	O
on	O	O	O
the	O	O	O
4th	O	O	O
and	O	O	O
8th	O	O	O
days	O	O	B-Entity
of	O	O	O
acclimation	O	O	O
to	O	O	O
either	O	O	O
-5	O	O	O
or	O	O	O
28	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Birds	O	O	B-Entity
changed	O	O	O
their	O	O	O
metabolic	O	O	B-Entity
phenotype	O	O	B-Entity
within	O	O	O
8	O	O	O
days	O	O	B-Entity
with	O	O	O
patterns	O	O	B-Entity
differing	O	O	O
among	O	O	O
species	O	O	B-Entity
.	O	O	O

Sparrows	O	O	B-Entity
expressed	O	O	O
the	O	O	O
expected	O	O	O
metabolic	O	O	B-Entity
increases	O	O	B-Entity
in	O	O	O
the	O	O	O
cold	O	O	B-Entity
and	O	O	O
decreases	O	O	O
at	O	O	O
thermoneutrality	O	O	B-Entity
while	O	O	O
performance	O	O	O
in	O	O	O
chickadees	O	O	B-Entity
and	O	O	O
buntings	O	O	B-Entity
was	O	O	O
not	O	O	O
influenced	O	O	B-Entity
by	O	O	O
temperature	O	O	B-Entity
but	O	O	O
changed	O	O	O
over	O	O	O
time	O	O	O
with	O	O	O
inverse	O	O	O
patterns	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
BMR	O	O	B-Entity
varies	O	O	O
at	O	O	O
comparable	O	O	O
rates	O	O	B-Entity
in	O	O	O
warm	O	O	B-Entity
and	O	O	O
cold	O	O	B-Entity
environments	O	O	I-Entity
but	O	O	O
changes	O	O	O
faster	O	O	O
than	O	O	O
Msum	O	O	B-Entity
and	O	O	O
MMR	O	O	B-Entity
,	O	O	O
likely	O	O	O
due	O	O	O
to	O	O	O
limitations	O	O	B-Entity
in	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
change	O	O	O
in	O	O	O
organ	O	O	B-Entity
size	O	O	I-Entity
and	O	O	O
function	O	O	B-Entity
.	O	O	O

They	O	O	O
also	O	O	O
suggest	O	O	O
that	O	O	O
maximal	O	O	B-Entity
metabolic	O	O	B-Entity
capacity	O	O	B-Entity
is	O	O	O
lost	O	O	B-Entity
faster	O	O	O
in	O	O	O
a	O	O	O
warm	O	O	B-Entity
environment	O	O	I-Entity
than	O	O	O
it	O	O	O
is	O	O	O
gained	O	O	B-Entity
in	O	O	O
a	O	O	O
cold	O	O	B-Entity
environment	O	O	I-Entity
.	O	O	O

With	O	O	O
the	O	O	O
expected	O	O	O
increase	O	O	O
in	O	O	O
temperature	O	O	B-Entity
stochasticity	O	O	B-Entity
at	O	O	O
northern	O	O	B-Entity
latitudes	O	O	I-Entity
,	O	O	O
a	O	O	O
loss	O	O	B-Entity
of	O	O	O
thermogenic	O	O	B-Entity
capacity	O	O	B-Entity
during	O	O	O
warm	O	O	B-Entity
winter	O	O	B-Entity
days	O	O	B-Entity
could	O	O	O
,	O	O	O
therefore	O	O	O
,	O	O	O
be	O	O	O
detrimental	O	O	O
if	O	O	O
birds	O	O	B-Entity
are	O	O	O
slow	O	O	O
to	O	O	O
readjust	O	O	O
their	O	O	O
phenotype	O	O	B-Entity
with	O	O	O
the	O	O	O
return	O	O	O
of	O	O	O
cold	O	O	B-Entity
days	O	O	O
.	O	O	O

-DOCSTART- (27235824)

A	O	O	O
prime	O	O	B-Entity
a	O	O	O
day	O	O	O
keeps	O	O	O
calories	O	O	B-Entity
away	O	O	O
:	O	O	O
The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
supraliminal	O	O	B-Entity
priming	O	O	I-Entity
on	O	O	O
food	O	O	B-Entity
consumption	O	O	I-Entity
and	O	O	O
the	O	O	O
moderating	O	O	B-Entity
role	O	O	I-Entity
of	O	O	O
gender	O	O	B-Entity
and	O	O	O
eating	O	O	O
restraint	O	O	O

The	O	O	O
link	O	O	O
between	O	O	O
intentions	O	O	B-Entity
and	O	O	O
action	O	O	B-Entity
in	O	O	O
weight	O	O	B-Entity
control	O	O	I-Entity
is	O	O	O
weaker	O	O	O
than	O	O	O
previously	O	O	O
thought	O	O	O
,	O	O	O
so	O	O	O
recent	O	O	O
research	O	O	B-Entity
has	O	O	O
called	O	O	O
for	O	O	O
further	O	O	O
investigation	O	O	O
of	O	O	O
ways	O	O	O
to	O	O	O
improve	O	O	O
weight	O	O	O
control	O	O	O
that	O	O	O
bypass	O	O	O
conscious	O	O	B-Entity
intentions	O	O	O
.	O	O	O

Priming	O	O	B-Entity
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
have	O	O	O
effects	O	O	O
on	O	O	O
individual	O	O	O
behavior	O	O	O
in	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
contexts	O	O	O
by	O	O	O
influencing	O	O	O
subconscious	O	O	B-Entity
cognition	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
investigates	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
semantic	O	O	B-Entity
priming	O	O	I-Entity
using	O	O	O
healthy	O	O	B-Entity
body	O	O	B-Entity
image	O	O	I-Entity
,	O	O	O
goal-oriented	O	O	B-Entity
words	O	O	I-Entity
on	O	O	O
food	O	O	B-Entity
consumption	O	O	I-Entity
.	O	O	O

The	O	O	O
moderating	O	O	B-Entity
role	O	O	I-Entity
of	O	O	O
both	O	O	O
restrained	O	O	B-Entity
eating	O	O	I-Entity
and	O	O	O
gender	O	O	B-Entity
is	O	O	O
investigated	O	O	O
.	O	O	O

161	O	O	O
participants	O	O	B-Entity
were	O	O	O
involved	O	O	O
in	O	O	O
an	O	O	O
experiment	O	O	B-Entity
using	O	O	O
a	O	O	O
novel	O	O	O
version	O	O	O
of	O	O	O
a	O	O	O
scrambled	O	O	O
sentence	O	O	B-Entity
priming	O	O	B-Entity
game	O	O	B-Entity
.	O	O	O

The	O	O	O
outcome	O	O	O
measure	O	O	O
was	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
kilocalories	O	O	B-Entity
consumed	O	O	B-Entity
,	O	O	O
examined	O	O	O
using	O	O	O
a	O	O	O
between	O	O	O
subjects	O	O	O
ANCOVA	O	O	B-Entity
with	O	O	O
priming	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
restrained	O	O	B-Entity
eating	O	O	I-Entity
index	O	O	I-Entity
,	O	O	O
self-reported	O	O	B-Entity
BMI	O	O	B-Entity
,	O	O	O
and	O	O	O
two	O	O	O
interaction	O	O	B-Entity
terms	O	O	O
(	O	O	O
priming	O	O	O
x	O	O	O
gender	O	O	O
,	O	O	O
and	O	O	O
priming	O	O	O
x	O	O	O
restrained	O	O	O
eating	O	O	O
index	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
main	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
priming	O	O	B-Entity
but	O	O	O
there	O	O	O
was	O	O	O
an	O	O	O
interaction	O	O	B-Entity
of	O	O	O
priming	O	O	O
with	O	O	O
gender	O	O	B-Entity
.	O	O	O

Females	O	O	B-Entity
consumed	O	O	O
significantly	O	O	O
fewer	O	O	O
kilocalories	O	O	B-Entity
after	O	O	O
being	O	O	O
exposed	O	O	O
to	O	O	O
priming	O	O	B-Entity
words	O	O	B-Entity
related	O	O	O
to	O	O	O
a	O	O	O
healthy	O	O	B-Entity
body	O	O	B-Entity
image	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
"	O	O	O
slim	O	O	O
"	O	O	O
,	O	O	O
"	O	O	O
fit	O	O	O
,	O	O	O
"	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
females	O	O	B-Entity
receiving	O	O	O
the	O	O	O
neutral	O	O	O
prime	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
medium	O	O	O
effect	O	O	O
size	O	O	O
(	O	O	O
d	O	O	O
=	O	O	O
0.58	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
body	O	O	B-Entity
image	O	O	I-Entity
prime	O	O	B-Entity
did	O	O	O
not	O	O	O
significantly	O	O	O
affect	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
for	O	O	O
males	O	O	B-Entity
,	O	O	O
nor	O	O	O
did	O	O	O
it	O	O	O
have	O	O	O
a	O	O	O
differential	O	O	O
effect	O	O	O
on	O	O	O
restrained	O	O	B-Entity
eaters	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
shows	O	O	O
that	O	O	O
priming	O	O	B-Entity
can	O	O	O
be	O	O	O
an	O	O	O
effective	O	O	O
method	O	O	O
for	O	O	O
influencing	O	O	O
females	O	O	B-Entity
to	O	O	O
reduce	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
,	O	O	O
regardless	O	O	O
of	O	O	O
whether	O	O	O
they	O	O	O
are	O	O	O
restrained	O	O	B-Entity
or	O	O	O
unrestrained	O	O	B-Entity
eaters	O	O	I-Entity
.	O	O	O

Future	O	O	O
studies	O	O	O
could	O	O	O
investigate	O	O	O
whether	O	O	O
different	O	O	O
priming	O	O	B-Entity
words	O	O	B-Entity
related	O	O	O
to	O	O	O
a	O	O	O
male	O	O	B-Entity
's	O	O	I-Entity
healthy	O	O	B-Entity
body	O	O	B-Entity
image	O	O	I-Entity
goal	O	O	O
(	O	O	O
i.e.	O	O	O
"	O	O	O
buff	O	O	O
,	O	O	O
"	O	O	O
"	O	O	O
muscles	O	O	B-Entity
,	O	O	O
"	O	O	O
etc	O	O	O
.	O	O	O
)	O	O	O
would	O	O	O
similarly	O	O	O
reduce	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
for	O	O	O
males	O	O	B-Entity
.	O	O	O

-DOCSTART- (27235870)

Neurotrophins	O	O	B-Entity
and	O	O	O
specific	O	O	B-Entity
receptors	O	O	I-Entity
in	O	O	O
the	O	O	O
oviduct	O	O	B-Entity
tracts	O	O	I-Entity
of	O	O	O
Japanese	O	O	B-Entity
quail	O	O	I-Entity
(	O	O	O
Coturnix	O	O	B-Entity
coturnix	O	O	I-Entity
japonica	O	O	I-Entity
)	O	O	O

Neurotrophins	O	O	B-Entity
(	O	O	O
NGF	O	O	B-Entity
,	O	O	O
BDNF	O	O	B-Entity
and	O	O	O
NT-3	O	O	B-Entity
)	O	O	O
and	O	O	O
their	O	O	O
specific	O	O	B-Entity
receptors	O	O	I-Entity
(	O	O	O
TrkA	O	O	B-Entity
,	O	O	O
TrkB	O	O	B-Entity
and	O	O	O
TrkC	O	O	B-Entity
)	O	O	O
were	O	O	O
studied	O	O	B-Entity
in	O	O	O
the	O	O	O
oviduct	O	O	B-Entity
of	O	O	O
egg	O	O	B-Entity
laying	O	O	I-Entity
quails	O	O	B-Entity
.	O	O	O

Neurotrophins	O	O	B-Entity
(	O	O	O
NTs	O	O	B-Entity
)	O	O	O
are	O	O	O
mainly	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
and	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
neuronal	O	O	B-Entity
populations	O	O	I-Entity
in	O	O	O
the	O	O	O
central	O	O	B-Entity
and	O	O	O
peripheral	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
in	O	O	O
reproductive	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
survey	O	O	O
,	O	O	O
we	O	O	O
first	O	O	O
studied	O	O	B-Entity
the	O	O	O
morphological	O	O	B-Entity
organization	O	O	B-Entity
of	O	O	O
the	O	O	O
quail	O	O	B-Entity
oviduct	O	O	B-Entity
,	O	O	O
distinguished	O	O	O
in	O	O	O
infundibulum	O	O	B-Entity
,	O	O	O
magnum	O	O	B-Entity
,	O	O	O
isthmus	O	O	B-Entity
,	O	O	O
uterus	O	O	B-Entity
and	O	O	O
vagina	O	O	B-Entity
,	O	O	O
and	O	O	O
then	O	O	O
we	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
and	O	O	O
localization	O	O	B-Entity
of	O	O	O
NTs	O	O	B-Entity
and	O	O	O
Trks	O	O	B-Entity
receptors	O	O	I-Entity
in	O	O	O
the	O	O	O
whole	O	O	O
tracts	O	O	B-Entity
.	O	O	O

By	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
we	O	O	O
detected	O	O	O
that	O	O	O
the	O	O	O
investigated	O	O	B-Entity
NTs	O	O	B-Entity
and	O	O	O
Trks	O	O	B-Entity
receptors	O	O	I-Entity
are	O	O	O
expressed	O	O	B-Entity
in	O	O	O
all	O	O	O
oviductal	O	O	B-Entity
tracts	O	O	I-Entity
.	O	O	O

By	O	O	O
immunohistochemistry	O	O	B-Entity
we	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
define	O	O	O
the	O	O	O
distribution	O	O	B-Entity
of	O	O	O
NTs	O	O	B-Entity
and	O	O	O
Trks	O	O	B-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
NGF	O	O	B-Entity
,	O	O	O
BDNF	O	O	B-Entity
and	O	O	O
NT3	O	O	B-Entity
were	O	O	O
localized	O	O	O
in	O	O	O
lining	O	O	B-Entity
and	O	O	O
ductal	O	O	B-Entity
epithelial	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
NGF	O	O	O
was	O	O	O
also	O	O	O
detected	O	O	O
in	O	O	O
secretory	O	O	B-Entity
cells	O	O	I-Entity
of	O	O	O
tubular	O	O	B-Entity
glands	O	O	I-Entity
and	O	O	O
in	O	O	O
nervous	O	O	B-Entity
fibers	O	O	I-Entity
of	O	O	O
vessel	O	O	B-Entity
wall	O	O	I-Entity
.	O	O	O

TrkA	O	O	B-Entity
and	O	O	O
TrkB	O	O	B-Entity
were	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
lining	O	O	B-Entity
and	O	O	O
ductal	O	O	B-Entity
epithelium	O	O	I-Entity
;	O	O	O
TrkA	O	O	O
and	O	O	O
TrkC	O	O	B-Entity
were	O	O	O
present	O	O	O
in	O	O	O
nervous	O	O	B-Entity
fibers	O	O	I-Entity
of	O	O	O
vessel	O	O	B-Entity
wall	O	O	I-Entity
in	O	O	O
all	O	O	O
oviductal	O	O	B-Entity
tracts	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
also	O	O	O
observed	O	O	O
NGF	O	O	B-Entity
and	O	O	O
BDNF	O	O	B-Entity
co-localized	O	O	O
with	O	O	O
TrkA	O	O	B-Entity
and	O	O	O
TrkB	O	O	B-Entity
in	O	O	O
cells	O	O	B-Entity
of	O	O	O
the	O	O	O
lining	O	O	B-Entity
and	O	O	O
ductal	O	O	B-Entity
epithelium	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
an	O	O	O
autocrine	O	O	B-Entity
mechanism	O	O	I-Entity
of	O	O	O
action	O	O	B-Entity
.	O	O	O

-DOCSTART- (27236097)

The	O	O	O
influence	O	O	O
of	O	O	O
liposomal	O	O	B-Entity
formulation	O	O	B-Entity
on	O	O	O
the	O	O	O
incorporation	O	O	B-Entity
and	O	O	O
retention	O	O	B-Entity
of	O	O	O
PNA	O	O	O
oligomers	O	O	O

Liposomal	O	O	B-Entity
formulations	O	O	B-Entity
composed	O	O	O
of	O	O	O
phospholipids	O	O	B-Entity
with	O	O	O
different	O	O	O
unsaturation	O	O	B-Entity
degrees	O	O	I-Entity
,	O	O	O
head	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
at	O	O	O
different	O	O	O
cholesterol	O	O	B-Entity
content	O	O	I-Entity
have	O	O	I-Entity
been	O	O	I-Entity
tested	O	O	I-Entity
for	O	O	O
the	O	O	O
encapsulation	O	O	B-Entity
of	O	O	O
Peptide	O	O	B-Entity
Nucleic	O	O	I-Entity
Acid	O	O	I-Entity
(	O	O	I-Entity
PNA	O	O	I-Entity
)	O	O	I-Entity
oligomers	O	O	I-Entity
.	O	O	O

The	O	O	O
best	O	O	B-Entity
loading	O	O	I-Entity
capability	O	O	I-Entity
(	O	O	O
177μg	O	O	O
,	O	O	O
ER	O	O	B-Entity
%	O	O	O
=	O	O	O
87.2	O	O	O
)	O	O	O
was	O	O	O
obtained	O	O	O
for	O	O	O
pure	O	O	O
liposomes	O	O	B-Entity
of	O	O	O
phosphatidylglycerol	O	O	B-Entity
(	O	O	O
DOPG	O	O	B-Entity
)	O	O	O
with	O	O	O
negatively	O	O	B-Entity
charged	O	O	I-Entity
head	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
insertion	O	O	B-Entity
of	O	O	O
a	O	O	O
10	O	O	O
-	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
cholesterol	O	O	B-Entity
in	O	O	O
DOPG	O	O	B-Entity
based	O	O	O
liposomes	O	O	B-Entity
provides	O	O	O
a	O	O	O
slight	O	O	O
decrease	O	O	B-Entity
(	O	O	O
∼160μg	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
PNA	O	O	B-Entity
loading	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
the	O	O	O
cholesterol	O	O	B-Entity
addition	O	O	B-Entity
(	O	O	O
20	O	O	O
-	O	O	O
30	O	O	O
%	O	O	O
)	O	O	O
slows	O	O	O
down	O	O	O
the	O	O	O
PNA	O	O	B-Entity
's	O	O	I-Entity
release	O	O	B-Entity
(	O	O	O
∼27	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
fetal	O	O	B-Entity
bovine	O	O	I-Entity
serum	O	O	I-Entity
from	O	O	O
the	O	O	O
liposomal	O	O	B-Entity
formulation	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
encapsulation	O	O	B-Entity
and	O	O	O
the	O	O	O
release	O	O	B-Entity
properties	O	O	I-Entity
,	O	O	O
PEGylated	O	O	B-Entity
DOPG	O	O	B-Entity
liposomes	O	O	B-Entity
with	O	O	O
a	O	O	O
percentage	O	O	O
of	O	O	O
cholesterol	O	O	B-Entity
of	O	O	O
10	O	O	O
-	O	O	O
20	O	O	O
%	O	O	O
are	O	O	O
the	O	O	O
optimal	O	O	B-Entity
formulation	O	O	I-Entity
for	O	O	O
the	O	O	O
loading	O	O	B-Entity
of	O	O	O
PNA-a210	O	O	B-Entity
.	O	O	O

-DOCSTART- (27236780)

Histopathology	O	O	B-Entity
of	O	O	O
the	O	O	O
filum	O	O	B-Entity
terminale	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	B-Entity
tethered	O	O	B-Entity
cord	O	O	I-Entity
syndrome	O	O	I-Entity
with	O	O	O
attention	O	O	O
to	O	O	O
the	O	O	O
elastic	O	O	B-Entity
tissue	O	O	I-Entity
within	O	O	O
the	O	O	O
filum	O	O	O

To	O	O	O
compare	O	O	B-Entity
histologically	O	O	B-Entity
transected	O	O	B-Entity
fila	O	O	B-Entity
from	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
tethered	O	O	B-Entity
cord	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
TCS	O	O	B-Entity
)	O	O	O
,	O	O	O
with	O	O	O
and	O	O	O
without	O	O	B-Entity
a	O	O	O
low	O	O	B-Entity
conus	O	O	B-Entity
,	O	O	O
with	O	O	O
controls	O	O	O
,	O	O	O
focusing	O	O	O
on	O	O	O
collagenous	O	O	B-Entity
and	O	O	O
elastic	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

Thirty	O	O	O
fila	O	O	B-Entity
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
TCS	O	O	B-Entity
,	O	O	O
including	O	O	O
5	O	O	O
where	O	O	O
minimal	O	O	B-Entity
cautery	O	O	B-Entity
was	O	O	O
used	O	O	O
prior	O	O	O
to	O	O	O
filum	O	O	B-Entity
section	O	O	B-Entity
,	O	O	O
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
fila	O	O	O
from	O	O	O
27	O	O	O
pediatric	O	O	B-Entity
cadavers	O	O	B-Entity
without	O	O	B-Entity
TCS	O	O	O
(	O	O	O
controls	O	O	B-Entity
)	O	O	O
.	O	O	O

Sections	O	O	B-Entity
of	O	O	O
fila	O	O	B-Entity
were	O	O	O
stained	O	O	B-Entity
with	O	O	O
H&E	O	O	B-Entity
,	O	O	O
Masson	O	O	B-Entity
trichrome	O	O	I-Entity
and	O	O	O
Verhoeff	O	O	B-Entity
von	O	O	I-Entity
Gieson	O	O	I-Entity
elastic	O	O	I-Entity
stains	O	O	I-Entity
,	O	O	O
and	O	O	O
7	O	O	O
with	O	O	O
Gordon	O	O	B-Entity
and	O	O	I-Entity
Sweet	O	O	I-Entity
's	O	O	I-Entity
reticulin	O	O	I-Entity
stain	O	O	I-Entity
.	O	O	O

Fila	O	O	B-Entity
from	O	O	O
controls	O	O	B-Entity
showed	O	O	O
loose	O	O	B-Entity
fibrous	O	O	B-Entity
connective	O	O	I-Entity
tissue	O	O	I-Entity
(	O	O	O
FCT	O	O	B-Entity
)	O	O	O
with	O	O	O
thin	O	O	B-Entity
and	O	O	O
evenly	O	O	B-Entity
dispersed	O	O	I-Entity
elastic	O	O	B-Entity
fibers	O	O	I-Entity
(	O	O	O
EFs	O	O	B-Entity
)	O	O	O
.	O	O	O

Reticulin	O	O	B-Entity
fibers	O	O	I-Entity
(	O	O	O
RFs	O	O	B-Entity
)	O	O	O
were	O	O	O
seen	O	O	O
in	O	O	O
blood	O	O	B-Entity
vessel	O	O	I-Entity
walls	O	O	I-Entity
and	O	O	O
nerve	O	O	B-Entity
twigs	O	O	O
.	O	O	O

Fat	O	O	B-Entity
was	O	O	O
identified	O	O	B-Entity
microscopically	O	O	B-Entity
in	O	O	O
2	O	O	O
fila	O	O	B-Entity
.	O	O	O

All	O	O	O
fila	O	O	B-Entity
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
TCS	O	O	B-Entity
had	O	O	O
dense	O	O	B-Entity
FCT	O	O	I-Entity
.	O	O	O

The	O	O	O
EFs	O	O	B-Entity
were	O	O	O
in	O	O	O
normal	O	O	B-Entity
numbers	O	O	O
in	O	O	O
17	O	O	O
,	O	O	O
and	O	O	O
focally	O	O	B-Entity
or	O	O	O
diffusely	O	O	B-Entity
decreased	O	O	B-Entity
in	O	O	O
13	O	O	O
.	O	O	O

All	O	O	O
25	O	O	O
patients	O	O	B-Entity
where	O	O	O
the	O	O	O
fila	O	O	B-Entity
were	O	O	O
cauterized	O	O	B-Entity
during	O	O	O
resection	O	O	B-Entity
had	O	O	O
thick	O	O	B-Entity
and	O	O	O
coiled	O	O	B-Entity
EFs	O	O	B-Entity
.	O	O	O

Coiling	O	O	B-Entity
was	O	O	O
not	O	O	O
seen	O	O	O
when	O	O	O
minimal	O	O	B-Entity
cautery	O	O	B-Entity
was	O	O	O
applied	O	O	O
.	O	O	O

RFs	O	O	B-Entity
were	O	O	O
seen	O	O	O
in	O	O	O
blood	O	O	B-Entity
vessel	O	O	I-Entity
walls	O	O	I-Entity
and	O	O	O
nerve	O	O	O
twigs	O	O	O
.	O	O	O

Fat	O	O	B-Entity
was	O	O	O
identified	O	O	B-Entity
in	O	O	O
19	O	O	O
patients	O	O	B-Entity
.	O	O	O

Findings	O	O	B-Entity
were	O	O	O
similar	O	O	B-Entity
,	O	O	O
whether	O	O	O
the	O	O	O
conus	O	O	B-Entity
termination	O	O	O
was	O	O	O
normal	O	O	B-Entity
or	O	O	O
low	O	O	B-Entity
.	O	O	O

The	O	O	O
fila	O	O	B-Entity
of	O	O	O
all	O	O	O
patients	O	O	B-Entity
with	O	O	O
TCS	O	O	B-Entity
,	O	O	O
whether	O	O	O
or	O	O	O
not	O	O	O
the	O	O	O
conus	O	O	B-Entity
was	O	O	O
low	O	O	B-Entity
,	O	O	O
showed	O	O	O
abnormal	O	O	B-Entity
FCT	O	O	B-Entity
.	O	O	O

EFs	O	O	B-Entity
were	O	O	O
decreased	O	O	B-Entity
in	O	O	O
48	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
there	O	O	O
were	O	O	O
thick	O	O	B-Entity
and	O	O	O
coiled	O	O	B-Entity
EFs	O	O	O
in	O	O	O
all	O	O	O
patients	O	O	O
.	O	O	O

Coiling	O	O	B-Entity
of	O	O	O
EFs	O	O	B-Entity
,	O	O	O
initially	O	O	O
thought	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
abnormality	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
,	O	O	O
is	O	O	O
considered	O	O	O
most	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
result	O	O	B-Entity
of	O	O	O
cautery	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
artifactual	O	O	B-Entity
/	O	O	O
iatrogenic	O	O	B-Entity
coiling	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27237301)

Clinical	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
pathologic	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	O
non-neoplastic	O	O	B-Entity
kidney	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
upper	O	O	B-Entity
urinary	O	O	I-Entity
tract	O	O	I-Entity
malignancies	O	O	O

While	O	O	O
surgical	O	O	B-Entity
resection	O	O	I-Entity
remains	O	O	O
the	O	O	O
standard	O	O	O
of	O	O	O
care	O	O	B-Entity
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
upper	O	O	B-Entity
urinary	O	O	I-Entity
tract	O	O	I-Entity
malignancies	O	O	B-Entity
,	O	O	O
nephrectomy	O	O	B-Entity
is	O	O	O
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CKD	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
histologic	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
non-neoplastic	O	O	B-Entity
kidney	O	O	I-Entity
could	O	O	O
enable	O	O	O
early	O	O	B-Entity
identification	O	O	I-Entity
of	O	O	O
unrecognized	O	O	O
kidney	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
could	O	O	O
be	O	O	O
of	O	O	O
prognostic	O	O	B-Entity
value	O	O	O
in	O	O	O
predicting	O	O	O
postoperative	O	O	B-Entity
renal	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
analyzed	O	O	I-Entity
51	O	O	O
patients	O	O	B-Entity
with	O	O	O
upper	O	O	B-Entity
urinary	O	O	I-Entity
tract	O	O	I-Entity
malignancies	O	O	B-Entity
who	O	O	O
received	O	O	O
uninephrectomy	O	O	B-Entity
or	O	O	O
uninephroureterectomy	O	O	B-Entity
.	O	O	O

A	O	O	O
thorough	O	O	O
pathologic	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
non-neoplastic	O	O	B-Entity
kidney	O	O	I-Entity
including	O	O	O
special	O	O	B-Entity
stains	O	O	I-Entity
,	O	O	O
immunofluorescence	O	O	B-Entity
,	O	O	O
and	O	O	O
electron	O	O	B-Entity
microscopic	O	O	I-Entity
studies	O	O	I-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

The	O	O	O
degree	O	O	B-Entity
of	O	O	O
parenchymal	O	O	B-Entity
changes	O	O	B-Entity
was	O	O	O
graded	O	O	O
from	O	O	O
0	O	O	O
to	O	O	O
15	O	O	O
.	O	O	O

Of	O	O	O
51	O	O	O
patients	O	O	B-Entity
,	O	O	O
only	O	O	O
13	O	O	O
showed	O	O	O
normal	O	O	O
kidney	O	O	B-Entity
pathology	O	O	B-Entity
.	O	O	O

Fifteen	O	O	O
patients	O	O	B-Entity
showed	O	O	O
glomerular	O	O	B-Entity
abnormalities	O	O	I-Entity
,	O	O	O
14	O	O	O
showed	O	O	O
diabetic	O	O	B-Entity
nephropathy	O	O	B-Entity
,	O	O	O
and	O	O	O
11	O	O	O
showed	O	O	O
vascular	O	O	B-Entity
nephropathy	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
one	O	O	O
case	O	O	O
each	O	O	O
of	O	O	O
reflux	O	O	B-Entity
nephropathy	O	O	I-Entity
and	O	O	O
chronic	O	O	B-Entity
pyelonephritis	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	O
histologic	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
5	O	O	O
points	O	O	O
.	O	O	O

Only	O	O	O
25.4	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
had	O	O	O
≤	O	O	O
3	O	O	O
points	O	O	O
.	O	O	O

Score	O	O	B-Entity
more	O	O	O
than	O	O	O
5	O	O	O
was	O	O	O
observed	O	O	O
in	O	O	O
47.1	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

Postoperative	O	O	B-Entity
estimated	O	O	B-Entity
glomerular	O	O	I-Entity
filtration	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
eGFR	O	O	B-Entity
)	O	O	O
at	O	O	O
3	O	O	O
to	O	O	O
36	O	O	O
months	O	O	B-Entity
were	O	O	O
obtained	O	O	O
from	O	O	O
90.2	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
of	O	O	O
those	O	O	O
,	O	O	O
34.8	O	O	O
%	O	O	O
had	O	O	O
de	O	O	O
novo	O	O	O
CKD	O	O	B-Entity
.	O	O	O

Since	O	O	O
no	O	O	O
one	O	O	O
had	O	O	O
CKD	O	O	B-Entity
in	O	O	O
partial	O	O	O
nephrectomized	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
we	O	O	O
determined	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
CKD	O	O	O
in	O	O	O
radical	O	O	O
nephrectomized	O	O	O
patients	O	O	O
.	O	O	O

Cox	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
postoperative	O	O	B-Entity
AKI	O	O	B-Entity
,	O	O	O
preoperative	O	O	B-Entity
eGFR	O	O	B-Entity
,	O	O	O
and	O	O	O
histologic	O	O	B-Entity
score	O	O	O
of	O	O	O
non-neoplastic	O	O	B-Entity
kidney	O	O	I-Entity
were	O	O	O
the	O	O	O
independent	O	O	O
predictors	O	O	B-Entity
for	O	O	O
CKD	O	O	B-Entity
.	O	O	O

We	O	O	O
conclude	O	O	O
that	O	O	O
routine	O	O	O
pathologic	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
non-neoplastic	O	O	B-Entity
kidney	O	O	I-Entity
provides	O	O	O
valuable	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
prognostic	O	O	B-Entity
information	O	O	O
.	O	O	O

-DOCSTART- (27239027)

Concordant	O	O	O
but	O	O	O
Varied	O	O	O
Phenotypes	O	O	B-Entity
among	O	O	O
Duchenne	O	O	B-Entity
Muscular	O	O	I-Entity
Dystrophy	O	O	I-Entity
Patient	O	O	B-Entity
-Specific	O	O	O
Myoblasts	O	O	B-Entity
Derived	O	O	O
using	O	O	O
a	O	O	O
Human	O	O	B-Entity
iPSC	O	O	B-Entity
-Based	O	O	O
Model	O	O	O

Duchenne	O	O	B-Entity
muscular	O	O	I-Entity
dystrophy	O	O	I-Entity
(	O	O	O
DMD	O	O	B-Entity
)	O	O	O
remains	O	O	O
an	O	O	O
intractable	O	O	O
genetic	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

Althogh	O	O	O
there	O	O	O
are	O	O	O
several	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
DMD	O	O	B-Entity
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
human	O	O	B-Entity
cell	O	O	I-Entity
model	O	O	O
that	O	O	O
carries	O	O	O
patient	O	O	B-Entity
-specific	O	O	O
DYSTROPHIN	O	O	B-Entity
mutations	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
a	O	O	O
human	O	O	B-Entity
DMD	O	O	B-Entity
model	O	O	B-Entity
using	O	O	O
human	O	O	B-Entity
induced	O	O	I-Entity
pluripotent	O	O	I-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
hiPSCs	O	O	B-Entity
)	O	O	O
.	O	O	O

Our	O	O	O
model	O	O	O
reveals	O	O	O
concordant	O	O	O
disease	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
phenotypes	O	O	B-Entity
with	O	O	O
patient	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
variation	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
partially	O	O	O
reversed	O	O	O
by	O	O	O
genetic	O	O	B-Entity
and	O	O	O
pharmacological	O	O	B-Entity
approaches	O	O	O
.	O	O	O

Our	O	O	O
"	O	O	O
chemical-compound	O	O	B-Entity
-based	O	O	O
"	O	O	O
strategy	O	O	B-Entity
successfully	O	O	O
directs	O	O	O
hiPSCs	O	O	B-Entity
into	O	O	O
expandable	O	O	O
myoblasts	O	O	B-Entity
,	O	O	O
which	O	O	O
exhibit	O	O	O
a	O	O	O
myogenic	O	O	B-Entity
transcriptional	O	O	I-Entity
program	O	O	B-Entity
,	O	O	O
forming	O	O	O
striated	O	O	B-Entity
contractile	O	O	B-Entity
myofibers	O	O	B-Entity
and	O	O	O
participating	O	O	O
in	O	O	O
muscle	O	O	B-Entity
regeneration	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

DMD	O	O	B-Entity
-	O	O	O
hiPSC	O	O	B-Entity
-derived	O	O	O
myoblasts	O	O	B-Entity
show	O	O	O
disease	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
phenotypes	O	O	B-Entity
with	O	O	O
patient	O	O	B-Entity
-to-	O	O	O
patient	O	O	O
variability	O	O	B-Entity
,	O	O	O
including	O	O	O
aberrant	O	O	B-Entity
expression	O	O	O
of	O	O	O
inflammation	O	O	B-Entity
or	O	O	O
immune-response	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
collagens	O	O	B-Entity
,	O	O	O
increased	O	O	O
BMP	O	O	B-Entity
/	O	O	O
TGFβ	O	O	B-Entity
signaling	O	O	I-Entity
,	O	O	O
and	O	O	O
reduced	O	O	O
fusion	O	O	O
competence	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
by	O	O	O
genetic	O	O	B-Entity
correction	O	O	B-Entity
and	O	O	O
pharmacological	O	O	B-Entity
"	O	O	O
dual-	O	O	O
SMAD	O	O	B-Entity
"	O	O	O
inhibition	O	O	B-Entity
,	O	O	O
the	O	O	O
DMD	O	O	B-Entity
-	O	O	O
hiPSC	O	O	B-Entity
-derived	O	O	O
myoblasts	O	O	B-Entity
and	O	O	O
genetically	O	O	B-Entity
corrected	O	O	O
isogenic	O	O	B-Entity
myoblasts	O	O	O
form	O	O	O
"	O	O	O
rescued	O	O	O
"	O	O	O
multi	O	O	B-Entity
-	O	O	O
nucleated	O	O	B-Entity
myotubes	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	O
demonstrate	O	O	O
the	O	O	O
feasibility	O	O	O
of	O	O	O
establishing	O	O	O
a	O	O	O
human	O	O	B-Entity
"	O	O	O
DMD	O	O	B-Entity
-in-a-dish	O	O	O
"	O	O	O
model	O	O	B-Entity
using	O	O	O
hiPSC	O	O	B-Entity
-based	O	O	O
disease	O	O	B-Entity
modeling	O	O	I-Entity
.	O	O	O

-DOCSTART- (27239445)

SNAI1	O	O	B-Entity
promotes	O	O	B-Entity
the	O	O	O
development	O	O	B-Entity
of	O	O	O
HCC	O	O	B-Entity
through	O	O	O
the	O	O	O
enhancement	O	O	B-Entity
of	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
inhibition	O	O	O
of	O	O	O
apoptosis	O	O	O

SNAI1	O	O	B-Entity
,	O	O	O
a	O	O	O
zinc-finger	O	O	B-Entity
transcription	O	O	I-Entity
factor	O	O	I-Entity
,	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
epithelial-mesenchymal	O	O	B-Entity
transition	O	O	I-Entity
(	O	O	O
EMT	O	O	B-Entity
)	O	O	O
in	O	O	O
various	O	O	O
cancers	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
possible	O	O	O
functions	O	O	O
of	O	O	O
SNAI1	O	O	B-Entity
in	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
have	O	O	O
not	O	O	O
been	O	O	O
clearly	O	O	O
identified	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	B-Entity
and	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
SNAI1	O	O	B-Entity
in	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
using	O	O	O
clinical	O	O	B-Entity
samples	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
SNAI1	O	O	B-Entity
is	O	O	O
highly	O	O	O
expressed	O	O	B-Entity
in	O	O	O
the	O	O	O
tissues	O	O	B-Entity
of	O	O	O
liver	O	O	B-Entity
cancer	O	O	I-Entity
compared	O	O	O
with	O	O	O
adjacent	O	O	O
nontumor	O	O	B-Entity
tissues	O	O	I-Entity
.	O	O	O

SNAI1	O	O	B-Entity
is	O	O	O
also	O	O	O
highly	O	O	O
expressed	O	O	B-Entity
in	O	O	O
the	O	O	O
hepatoma	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
HepG2	O	O	I-Entity
,	O	O	O
SMMC-7721	O	O	B-Entity
,	O	O	O
and	O	O	O
BEL-7402	O	O	B-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
human	O	O	B-Entity
normal	O	O	I-Entity
liver	O	O	I-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
L02	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
observed	O	O	O
that	O	O	O
SNAI1	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
correlated	O	O	O
with	O	O	O
distal	O	O	B-Entity
metastasis	O	O	I-Entity
,	O	O	O
incomplete	O	O	O
tumor	O	O	B-Entity
capsule	O	O	I-Entity
formation	O	O	I-Entity
,	O	O	O
and	O	O	O
histological	O	O	B-Entity
differentiation	O	O	I-Entity
in	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HCC	O	O	B-Entity
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
we	O	O	O
demonstrated	O	O	O
that	O	O	O
knockdown	O	O	B-Entity
of	O	O	O
SNAI1	O	O	B-Entity
via	O	O	O
lentiviral	O	O	B-Entity
vectors	O	O	B-Entity
of	O	O	O
RNAi	O	O	B-Entity
against	O	O	O
SNAI	O	O	B-Entity
inhibited	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
by	O	O	O
inducing	O	O	O
G1	O	O	B-Entity
arrest	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
accompanied	O	O	O
by	O	O	O
the	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
cyclin	O	O	B-Entity
D1	O	O	I-Entity
but	O	O	O
not	O	O	O
that	O	O	O
of	O	O	O
cyclin	O	O	O
A.	O	O	O
In	O	O	O
addition	O	O	O
,	O	O	O
knockdown	O	O	O
of	O	O	O
SNAI1	O	O	O
promoted	O	O	B-Entity
apoptosis	O	O	B-Entity
by	O	O	O
decreasing	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
Bcl-2	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	O
revealed	O	O	O
that	O	O	O
SNAI1	O	O	B-Entity
is	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
via	O	O	O
regulating	O	O	B-Entity
the	O	O	I-Entity
growth	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (27240257)

Quantitative	O	O	B-Entity
assessment	O	O	I-Entity
of	O	O	O
fluorescent	O	O	O
proteins	O	O	O

The	O	O	O
advent	O	O	O
of	O	O	O
fluorescent	O	O	B-Entity
proteins	O	O	I-Entity
(	O	O	O
FPs	O	O	B-Entity
)	O	O	O
for	O	O	O
genetic	O	O	B-Entity
labeling	O	O	I-Entity
of	O	O	O
molecules	O	O	B-Entity
and	O	O	O
cells	O	O	B-Entity
has	O	O	O
revolutionized	O	O	O
fluorescence	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

Genetic	O	O	B-Entity
manipulations	O	O	I-Entity
have	O	O	O
created	O	O	O
a	O	O	O
vast	O	O	O
array	O	O	O
of	O	O	O
bright	O	O	O
and	O	O	O
stable	O	O	O
FPs	O	O	B-Entity
spanning	O	O	O
blue	O	O	B-Entity
to	O	O	I-Entity
red	O	O	I-Entity
spectral	O	O	I-Entity
regions	O	O	I-Entity
.	O	O	O

Common	O	O	O
to	O	O	O
autofluorescent	O	O	B-Entity
FPs	O	O	B-Entity
is	O	O	O
their	O	O	O
tight	O	O	O
β-barrel	O	O	B-Entity
structure	O	O	I-Entity
,	O	O	O
which	O	O	O
provides	O	O	O
the	O	O	O
rigidity	O	O	B-Entity
and	O	O	O
chemical	O	O	B-Entity
environment	O	O	B-Entity
needed	O	O	O
for	O	O	O
effectual	O	O	O
fluorescence	O	O	B-Entity
.	O	O	O

Despite	O	O	O
the	O	O	O
common	O	O	O
structure	O	O	B-Entity
,	O	O	O
each	O	O	O
FP	O	O	B-Entity
has	O	O	O
unique	O	O	O
properties	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
single	O	O	O
'	O	O	O
best	O	O	O
'	O	O	O
FP	O	O	B-Entity
for	O	O	O
every	O	O	O
circumstance	O	O	O
,	O	O	O
and	O	O	O
each	O	O	O
FP	O	O	O
has	O	O	O
advantages	O	O	O
and	O	O	O
disadvantages	O	O	O
.	O	O	O

To	O	O	O
guide	O	O	O
decisions	O	O	O
about	O	O	O
which	O	O	O
FP	O	O	B-Entity
is	O	O	O
right	O	O	O
for	O	O	O
a	O	O	O
given	O	O	O
application	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
quantitatively	O	O	B-Entity
characterized	O	O	O
the	O	O	O
brightness	O	O	B-Entity
,	O	O	O
photostability	O	O	B-Entity
,	O	O	O
pH	O	O	B-Entity
stability	O	O	B-Entity
and	O	O	O
monomeric	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
more	O	O	O
than	O	O	O
40	O	O	O
FPs	O	O	B-Entity
to	O	O	O
enable	O	O	O
straightforward	O	O	B-Entity
and	O	O	O
direct	O	O	O
comparison	O	O	B-Entity
between	O	O	O
them	O	O	O
.	O	O	O

We	O	O	O
focus	O	O	O
on	O	O	O
popular	O	O	O
and/or	O	O	O
top-performing	O	O	O
FPs	O	O	B-Entity
in	O	O	O
each	O	O	O
spectral	O	O	B-Entity
region	O	O	I-Entity
.	O	O	O

-DOCSTART- (27240560)

Consumption	O	O	B-Entity
of	O	O	I-Entity
fruits	O	O	I-Entity
and	O	O	I-Entity
vegetables	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
other	O	O	O
risk	O	O	B-Entity
behaviors	O	O	I-Entity
among	O	O	O
adolescents	O	O	B-Entity
in	O	O	O
Northeast	O	O	O
Brazil	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
consumption	O	O	B-Entity
of	O	O	I-Entity
fruits	O	O	I-Entity
and	O	O	I-Entity
vegetables	O	O	I-Entity
and	O	O	O
identify	O	O	O
the	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
low	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
sedentary	O	O	B-Entity
behavior	O	O	I-Entity
,	O	O	O
consumption	O	O	O
of	O	O	O
soft	O	O	B-Entity
drinks	O	O	I-Entity
and	O	O	O
overweight	O	O	B-Entity
/	O	O	O
obesity	O	O	B-Entity
in	O	O	O
adolescents	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
school-based	O	O	I-Entity
study	O	O	I-Entity
with	O	O	O
a	O	O	O
representative	O	O	O
sample	O	O	B-Entity
of	O	O	O
3992	O	O	O
students	O	O	B-Entity
aged	O	O	O
14	O	O	O
-	O	O	O
19	O	O	O
years	O	O	B-Entity
from	O	O	O
the	O	O	O
state	O	O	B-Entity
of	O	O	I-Entity
Sergipe	O	O	I-Entity
,	O	O	O
Brazil	O	O	B-Entity
.	O	O	O

The	O	O	O
outcome	O	O	B-Entity
was	O	O	O
low	O	O	B-Entity
consumption	O	O	B-Entity
of	O	O	I-Entity
fruits	O	O	I-Entity
and	O	O	I-Entity
vegetables	O	O	I-Entity
(	O	O	O
<	O	O	O
5	O	O	O
servings/day	O	O	B-Entity
)	O	O	O
.	O	O	O

Independent	O	O	B-Entity
variables	O	O	I-Entity
were	O	O	O
:	O	O	O
level	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
sedentary	O	O	B-Entity
behavior	O	O	I-Entity
,	O	O	O
consumption	O	O	B-Entity
of	O	O	O
soft	O	O	B-Entity
drinks	O	O	I-Entity
,	O	O	O
and	O	O	O
overweight	O	O	B-Entity
/	O	O	O
obesity	O	O	B-Entity
.	O	O	O

Global	O	O	B-Entity
Student	O	O	I-Entity
Health	O	O	I-Entity
Survey	O	O	I-Entity
questionnaire	O	O	I-Entity
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
and	O	O	O
height	O	O	B-Entity
measurements	O	O	B-Entity
were	O	O	O
used	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
chi-square	O	O	B-Entity
test	O	O	I-Entity
and	O	O	O
crude	O	O	B-Entity
and	O	O	I-Entity
adjusted	O	O	I-Entity
binary	O	O	I-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
.	O	O	O

The	O	O	O
significance	O	O	B-Entity
level	O	O	I-Entity
adopted	O	O	O
was	O	O	O
5	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
inadequate	O	O	B-Entity
consumption	O	O	B-Entity
of	O	O	I-Entity
fruits	O	O	I-Entity
and	O	O	I-Entity
vegetables	O	O	I-Entity
was	O	O	O
high	O	O	B-Entity
-	O	O	O
88.6	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
87.6	O	O	O
-	O	O	O
89.5	O	O	O
)	O	O	O
.	O	O	O

Higher	O	O	B-Entity
likelihood	O	O	O
of	O	O	O
low	O	O	B-Entity
consumption	O	O	B-Entity
of	O	O	I-Entity
fruits	O	O	I-Entity
and	O	O	I-Entity
vegetables	O	O	I-Entity
was	O	O	O
verified	O	O	O
among	O	O	O
boys	O	O	B-Entity
who	O	O	O
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
sedentary	O	O	B-Entity
behavior	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
1.63	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.18	O	O	O
-	O	O	O
2.24	O	O	O
)	O	O	O
,	O	O	O
who	O	O	O
consumed	O	O	B-Entity
soft	O	O	B-Entity
drinks	O	O	I-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
3.04	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
2.10	O	O	O
-	O	O	O
4.40	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
insufficiently	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
1.98	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.43	O	O	O
-	O	O	O
2.73	O	O	O
)	O	O	O
and	O	O	O
girls	O	O	B-Entity
who	O	O	O
consumed	O	O	O
soft	O	O	O
drinks	O	O	O
(	O	O	O
OR	O	O	O
=	O	O	O
1.88	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.43	O	O	O
-	O	O	O
2.47	O	O	O
)	O	O	O
and	O	O	O
those	O	O	O
with	O	O	O
overweight	O	O	B-Entity
/	O	O	O
obesity	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
1.63	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.19	O	O	O
-	O	O	O
2.23	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
need	O	O	O
of	O	O	O
public	O	O	B-Entity
policies	O	O	I-Entity
aimed	O	O	O
at	O	O	O
encouraging	O	O	O
the	O	O	O
consumption	O	O	B-Entity
of	O	O	I-Entity
healthy	O	O	I-Entity
foods	O	O	I-Entity
among	O	O	O
adolescents	O	O	B-Entity
.	O	O	O

-DOCSTART- (27242761)

Cobalamin	O	O	B-Entity
Protection	O	O	B-Entity
against	O	O	O
Oxidative	O	O	B-Entity
Stress	O	O	I-Entity
in	O	O	O
the	O	O	O
Acidophilic	O	O	B-Entity
Iron-oxidizing	O	O	B-Entity
Bacterium	O	O	I-Entity
Leptospirillum	O	O	O
Group	O	O	O
II	O	O	O
CF-1	O	O	O

Members	O	O	O
of	O	O	O
the	O	O	O
genus	O	O	O
Leptospirillum	O	O	B-Entity
are	O	O	O
aerobic	O	O	B-Entity
iron-oxidizing	O	O	B-Entity
bacteria	O	O	I-Entity
belonging	O	O	O
to	O	O	O
the	O	O	O
phylum	O	O	B-Entity
Nitrospira	O	O	I-Entity
.	O	O	O

They	O	O	O
are	O	O	O
important	O	O	O
members	O	O	O
of	O	O	O
microbial	O	O	B-Entity
communities	O	O	B-Entity
that	O	O	O
catalyze	O	O	B-Entity
the	O	O	O
biomining	O	O	B-Entity
of	O	O	O
sulfidic	O	O	B-Entity
ores	O	O	I-Entity
,	O	O	O
thereby	O	O	O
solubilizing	O	O	O
metal	O	O	B-Entity
ions	O	O	I-Entity
.	O	O	O

These	O	O	O
microorganisms	O	O	B-Entity
live	O	O	O
under	O	O	O
extremely	O	O	O
acidic	O	O	O
and	O	O	O
metal	O	O	B-Entity
-loaded	O	O	O
environments	O	O	B-Entity
and	O	O	O
thus	O	O	O
must	O	O	O
tolerate	O	O	O
high	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
.	O	O	O

Cobalamin	O	O	B-Entity
(	O	O	O
vitamin	O	O	B-Entity
B12	O	O	I-Entity
)	O	O	O
is	O	O	O
a	O	O	O
cobalt	O	O	B-Entity
-containing	O	O	O
tetrapyrrole	O	O	B-Entity
cofactor	O	O	B-Entity
involved	O	O	O
in	O	O	O
intramolecular	O	O	B-Entity
rearrangement	O	O	I-Entity
reactions	O	O	I-Entity
and	O	O	O
has	O	O	O
recently	O	O	O
been	O	O	O
suggested	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
intracellular	O	O	B-Entity
antioxidant	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
the	O	O	O
exogenous	O	O	B-Entity
addition	O	O	O
of	O	O	O
cobalamin	O	O	B-Entity
on	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
parameters	O	O	B-Entity
in	O	O	O
Leptospirillum	O	O	B-Entity
group	O	O	I-Entity
II	O	O	I-Entity
strain	O	O	I-Entity
CF-1	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
revealed	O	O	B-Entity
that	O	O	O
the	O	O	O
external	O	O	B-Entity
supplementation	O	O	I-Entity
of	O	O	O
cobalamin	O	O	B-Entity
reduces	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
intracellular	O	O	B-Entity
ROSs	O	O	B-Entity
and	O	O	O
the	O	O	O
damage	O	O	B-Entity
to	O	O	O
biomolecules	O	O	B-Entity
,	O	O	O
and	O	O	O
also	O	O	O
stimulates	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
of	O	O	I-Entity
cells	O	O	I-Entity
exposed	O	O	O
to	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
exerted	O	O	O
by	O	O	O
ferric	O	O	B-Entity
ion	O	O	I-Entity
,	O	O	O
hydrogen	O	O	B-Entity
peroxide	O	O	I-Entity
,	O	O	O
chromate	O	O	B-Entity
and	O	O	O
diamide	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
exposure	O	O	O
of	O	O	O
strain	O	O	B-Entity
CF-1	O	O	I-Entity
to	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
elicitors	O	O	O
resulted	O	O	O
in	O	O	O
the	O	O	O
transcriptional	O	O	B-Entity
activation	O	O	I-Entity
of	O	O	O
the	O	O	O
cbiA	O	O	B-Entity
gene	O	O	I-Entity
encoding	O	O	O
CbiA	O	O	B-Entity
of	O	O	O
the	O	O	O
cobalamin	O	O	B-Entity
biosynthetic	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Altogether	O	O	O
,	O	O	O
these	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
cobalamin	O	O	B-Entity
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
redox	O	O	B-Entity
protection	O	O	B-Entity
of	O	O	O
Leptospirillum	O	O	B-Entity
strain	O	O	I-Entity
CF-1	O	O	I-Entity
,	O	O	O
supporting	O	O	O
survival	O	O	O
of	O	O	O
this	O	O	O
microorganism	O	O	B-Entity
under	O	O	O
extremely	O	O	O
oxidative	O	O	B-Entity
environmental	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

Understanding	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
underlying	O	O	O
the	O	O	O
protective	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
cobalamin	O	O	B-Entity
against	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
may	O	O	O
help	O	O	O
to	O	O	O
develop	O	O	O
strategies	O	O	O
to	O	O	O
make	O	O	O
biomining	O	O	B-Entity
processes	O	O	B-Entity
more	O	O	O
effective	O	O	B-Entity
.	O	O	O

-DOCSTART- (27244222)

A	O	O	O
longitudinal	O	O	B-Entity
study	O	O	I-Entity
assessing	O	O	O
childcare	O	O	B-Entity
services	O	O	B-Entity
'	O	O	I-Entity
adoption	O	O	O
of	O	O	O
obesity	O	O	B-Entity
prevention	O	O	O
policies	O	O	O
and	O	O	O
practices	O	O	O

Despite	O	O	O
ongoing	O	O	O
investments	O	O	O
to	O	O	O
improve	O	O	O
the	O	O	O
obesogenic	O	O	B-Entity
environments	O	O	B-Entity
of	O	O	O
childcare	O	O	B-Entity
settings	O	O	O
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
regarding	O	O	O
how	O	O	O
these	O	O	O
services	O	O	B-Entity
have	O	O	O
changed	O	O	O
their	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
nutrition-promoting	O	O	B-Entity
practices	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aims	O	O	O
to	O	O	O
describe	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
proportion	O	O	O
of	O	O	O
Australian	O	O	B-Entity
childcare	O	O	B-Entity
services	O	O	B-Entity
that	O	O	O
have	O	O	O
adopted	O	O	O
best-practice	O	O	B-Entity
healthy	O	O	B-Entity
eating	O	O	I-Entity
and	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
practices	O	O	B-Entity
between	O	O	O
2006	O	O	O
and	O	O	O
2013	O	O	O
and	O	O	O
to	O	O	O
assess	O	O	O
whether	O	O	O
adoption	O	O	O
varied	O	O	O
by	O	O	O
socio-economic	O	O	B-Entity
status	O	O	I-Entity
and	O	O	O
locality	O	O	B-Entity
.	O	O	O

A	O	O	O
randomly	O	O	B-Entity
selected	O	O	I-Entity
sample	O	O	I-Entity
of	O	O	O
nominated	O	O	O
supervisors	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
358	O	O	O
)	O	O	O
from	O	O	O
childcare	O	O	B-Entity
services	O	O	B-Entity
located	O	O	O
in	O	O	O
New	O	O	B-Entity
South	O	O	I-Entity
Wales	O	O	I-Entity
,	O	O	O
Australia	O	O	B-Entity
,	O	O	O
participated	O	O	O
in	O	O	O
a	O	O	O
telephone	O	O	B-Entity
survey	O	O	I-Entity
in	O	O	O
2006	O	O	O
,	O	O	O
2009	O	O	O
,	O	O	O
2010	O	O	O
and	O	O	O
2013	O	O	O
.	O	O	O

Supervisors	O	O	B-Entity
reported	O	O	O
on	O	O	O
their	O	O	O
service	O	O	B-Entity
's	O	O	I-Entity
adoption	O	O	O
of	O	O	O
six	O	O	O
practices	O	O	B-Entity
:	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
having	O	O	O
written	O	O	O
nutrition	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
policies	O	O	B-Entity
;	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
staff	O	O	B-Entity
trained	O	O	O
in	O	O	O
physical	O	O	O
activity	O	O	O
and	O	O	O
nutrition	O	O	O
in	O	O	O
the	O	O	O
past	O	O	O
year	O	O	O
;	O	O	O
(	O	O	O
iii	O	O	O
)	O	O	O
scheduled	O	O	O
time	O	O	B-Entity
for	O	O	O
fundamental	O	O	O
movement	O	O	B-Entity
skills	O	O	B-Entity
and	O	O	O
(	O	O	O
iv	O	O	O
)	O	O	O
outdoor	O	O	B-Entity
play	O	O	I-Entity
;	O	O	O
(	O	O	O
v	O	O	O
)	O	O	O
weekly	O	O	B-Entity
or	O	O	O
less	O	O	O
screen	O	O	B-Entity
time	O	O	I-Entity
opportunitie	O	O	I-Entity
s	O	O	O
;	O	O	O
and	O	O	O
(	O	O	O
vi	O	O	O
)	O	O	O
serving	O	O	O
only	O	O	O
non-sweetened	O	O	B-Entity
beverages	O	O	I-Entity
.	O	O	O

A	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
services	O	O	B-Entity
adopting	O	O	O
all	O	O	O
but	O	O	O
one	O	O	O
practice	O	O	B-Entity
,	O	O	O
between	O	O	O
2006	O	O	O
and	O	O	O
2013	O	O	O
was	O	O	O
identified	O	O	O
.	O	O	O

Ninety	O	O	O
one	O	O	O
percent	O	O	O
of	O	O	O
services	O	O	B-Entity
adopted	O	O	O
four	O	O	O
or	O	O	O
more	O	O	O
practices	O	O	B-Entity
,	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
from	O	O	O
38	O	O	O
%	O	O	O
in	O	O	O
2006	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
proportion	O	O	O
of	O	O	O
services	O	O	B-Entity
adopting	O	O	O
each	O	O	O
practice	O	O	B-Entity
by	O	O	O
locality	O	O	B-Entity
and	O	O	O
socio-economic	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

Government	O	O	B-Entity
investment	O	O	B-Entity
in	O	O	O
obesity	O	O	B-Entity
prevention	O	O	B-Entity
programmes	O	O	I-Entity
can	O	O	O
equitably	O	O	O
improve	O	O	O
childcare	O	O	B-Entity
service	O	O	O
's	O	O	O
adoption	O	O	O
of	O	O	O
healthy	O	O	B-Entity
eating	O	O	I-Entity
and	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
promoting	O	O	O
practices	O	O	B-Entity
on	O	O	O
a	O	O	O
jurisdiction	O	O	B-Entity
-wide	O	O	O
basis	O	O	O
.	O	O	O

The	O	O	O
establishment	O	O	O
of	O	O	O
a	O	O	O
routine	O	O	O
system	O	O	O
to	O	O	O
monitor	O	O	O
adoption	O	O	O
of	O	O	O
a	O	O	O
broader	O	O	O
range	O	O	O
of	O	O	O
practices	O	O	B-Entity
by	O	O	O
childcare	O	O	B-Entity
services	O	O	B-Entity
is	O	O	O
warranted	O	O	O
.	O	O	O

-DOCSTART- (27247892)

Isolation	O	O	B-Entity
and	O	O	O
characterization	O	O	B-Entity
of	O	O	O
Burkholderia	O	O	B-Entity
sp.	O	O	I-Entity
strain	O	O	I-Entity
CCA53	O	O	I-Entity
exhibiting	O	O	O
ligninolytic	O	O	B-Entity
potential	O	O	O

Microbial	O	O	B-Entity
degradation	O	O	B-Entity
of	O	O	O
lignin	O	O	B-Entity
releases	O	O	O
fermentable	O	O	B-Entity
sugars	O	O	I-Entity
,	O	O	O
effective	O	O	B-Entity
utilization	O	O	B-Entity
of	O	O	O
which	O	O	O
could	O	O	O
support	O	O	O
biofuel	O	O	B-Entity
production	O	O	B-Entity
from	O	O	O
lignocellulosic	O	O	B-Entity
biomass	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
lignin-degrading	O	O	B-Entity
bacterium	O	O	B-Entity
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
leaf	O	O	B-Entity
soil	O	O	B-Entity
and	O	O	O
identified	O	O	O
as	O	O	O
Burkholderia	O	O	B-Entity
sp.	O	O	I-Entity
based	O	O	O
on	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	B-Entity
sequencing	O	O	I-Entity
.	O	O	O

This	O	O	O
strain	O	O	B-Entity
was	O	O	O
named	O	O	O
CCA53	O	O	B-Entity
,	O	O	O
and	O	O	O
its	O	O	O
lignin-degrading	O	O	B-Entity
capability	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
by	O	O	O
observing	O	O	O
its	O	O	O
growth	O	O	B-Entity
on	O	O	O
medium	O	O	B-Entity
containing	O	O	O
alkali	O	O	B-Entity
lignin	O	O	B-Entity
or	O	O	O
lignin	O	O	O
-associated	O	O	O
aromatic	O	O	B-Entity
monomers	O	O	I-Entity
as	O	O	O
the	O	O	O
sole	O	O	O
carbon	O	O	B-Entity
source	O	O	B-Entity
.	O	O	O

Alkali	O	O	B-Entity
lignin	O	O	B-Entity
and	O	O	O
at	O	O	O
least	O	O	O
eight	O	O	O
lignin	O	O	O
-associated	O	O	O
aromatic	O	O	B-Entity
monomers	O	O	I-Entity
supported	O	O	O
growth	O	O	B-Entity
of	O	O	O
this	O	O	O
strain	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
most	O	O	O
effective	O	O	B-Entity
utilization	O	O	B-Entity
was	O	O	O
observed	O	O	O
for	O	O	O
p-hydroxybenzene	O	O	B-Entity
monomers	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
indicate	O	O	O
that	O	O	O
Burkholderia	O	O	B-Entity
sp.	O	O	I-Entity
strain	O	O	I-Entity
CCA53	O	O	I-Entity
has	O	O	O
fragmentary	O	O	B-Entity
activity	O	O	I-Entity
for	O	O	O
lignin	O	O	B-Entity
degradation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27250823)

Diagnostic	O	O	B-Entity
utility	O	O	B-Entity
of	O	O	O
additional	O	O	O
conventional	O	O	B-Entity
techniques	O	O	B-Entity
after	O	O	O
endobronchial	O	O	B-Entity
ultrasonography	O	O	I-Entity
guidance	O	O	B-Entity
during	O	O	O
transbronchial	O	O	O
biopsy	O	O	O

Endobronchial	O	O	B-Entity
ultrasonography	O	O	I-Entity
with	O	O	O
a	O	O	O
guide	O	O	B-Entity
sheath	O	O	I-Entity
transbronchial	O	O	B-Entity
biopsy	O	O	I-Entity
(	O	O	O
EBUS	O	O	B-Entity
-	O	O	O
GS	O	O	B-Entity
TBB	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
used	O	O	O
to	O	O	O
diagnose	O	O	B-Entity
peripheral	O	O	B-Entity
pulmonary	O	O	I-Entity
lesions	O	O	I-Entity
(	O	O	O
PPLs	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
evaluated	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
utility	O	O	B-Entity
of	O	O	O
conventional	O	O	B-Entity
TBB	O	O	B-Entity
after	O	O	O
EBUS	O	O	B-Entity
-	O	O	O
GS	O	O	B-Entity
TBB	O	O	O
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
conventional	O	O	B-Entity
TBB	O	O	B-Entity
after	O	O	O
EBUS	O	O	B-Entity
-	O	O	O
GS	O	O	B-Entity
TBB	O	O	O
for	O	O	O
PPL	O	O	B-Entity
between	O	O	O
August	O	O	O
1	O	O	O
,	O	O	O
2012	O	O	O
and	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2014	O	O	O
.	O	O	O

We	O	O	O
performed	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
to	O	O	O
examine	O	O	O
the	O	O	O
association	O	O	B-Entity
of	O	O	O
various	O	O	O
clinical	O	O	B-Entity
factors	O	O	B-Entity
,	O	O	O
including	O	O	O
EBUS	O	O	B-Entity
probe	O	O	B-Entity
distance	O	O	B-Entity
and	O	O	O
sample	O	O	B-Entity
size	O	O	I-Entity
area	O	O	B-Entity
,	O	O	O
with	O	O	O
diagnostic	O	O	B-Entity
yield	O	O	I-Entity
.	O	O	O

Of	O	O	O
88	O	O	O
eligible	O	O	O
patients	O	O	B-Entity
,	O	O	O
57	O	O	O
(	O	O	O
65	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
successfully	O	O	O
diagnosed	O	O	B-Entity
by	O	O	O
EBUS	O	O	B-Entity
-	O	O	O
GS	O	O	B-Entity
TBB	O	O	B-Entity
.	O	O	O

In	O	O	O
31	O	O	O
patients	O	O	B-Entity
not	O	O	O
diagnosed	O	O	B-Entity
by	O	O	O
EBUS	O	O	B-Entity
-	O	O	O
GS	O	O	B-Entity
TBB	O	O	B-Entity
,	O	O	O
15	O	O	O
(	O	O	O
48	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
successfully	O	O	O
diagnosed	O	O	O
by	O	O	O
additional	O	O	O
conventional	O	O	B-Entity
TBB	O	O	O
.	O	O	O

Ground	O	O	B-Entity
glass	O	O	I-Entity
opacity	O	O	I-Entity
(	O	O	O
GGO	O	O	B-Entity
)	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
factor	O	O	B-Entity
associated	O	O	O
with	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
yield	O	O	I-Entity
of	O	O	O
additional	O	O	O
conventional	O	O	B-Entity
TBB	O	O	B-Entity
following	O	O	O
EBUS	O	O	B-Entity
-	O	O	O
GS	O	O	B-Entity
TBB	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
receiver	O	O	B-Entity
operator	O	O	I-Entity
curves	O	O	I-Entity
revealed	O	O	O
that	O	O	O
distance	O	O	B-Entity
between	O	O	O
the	O	O	O
PPL	O	O	B-Entity
and	O	O	O
the	O	O	O
EBUS	O	O	B-Entity
probe	O	O	B-Entity
of	O	O	O
less	O	O	O
than	O	O	O
2.55	O	O	O
mm	O	O	O
favored	O	O	O
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
conventional	O	O	B-Entity
TBB	O	O	B-Entity
.	O	O	O

Additional	O	O	O
conventional	O	O	B-Entity
TBB	O	O	B-Entity
after	O	O	O
EBUS	O	O	B-Entity
-	O	O	O
GS	O	O	B-Entity
TBB	O	O	O
could	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
procedure	O	O	B-Entity
for	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
ground	O	O	B-Entity
glass	O	O	I-Entity
opacity	O	O	I-Entity
PPLs	O	O	B-Entity
and	O	O	O
in	O	O	O
cases	O	O	B-Entity
of	O	O	O
a	O	O	O
distance	O	O	B-Entity
of	O	O	O
less	O	O	O
than	O	O	O
2.55	O	O	O
mm	O	O	O
between	O	O	O
the	O	O	O
EBUS	O	O	O
probe	O	O	B-Entity
and	O	O	O
the	O	O	O
lesion	O	O	B-Entity
.	O	O	O

-DOCSTART- (27251117)

Active	O	O	B-Entity
diffusion	O	O	B-Entity
and	O	O	O
microtubule-based	O	O	B-Entity
transport	O	O	I-Entity
oppose	O	O	O
myosin	O	O	B-Entity
forces	O	O	B-Entity
to	O	O	O
position	O	O	B-Entity
organelles	O	O	B-Entity
in	O	O	O
cells	O	O	O

Even	O	O	O
distribution	O	O	B-Entity
of	O	O	O
peroxisomes	O	O	B-Entity
(	O	O	O
POs	O	O	B-Entity
)	O	O	O
and	O	O	O
lipid	O	O	B-Entity
droplets	O	O	I-Entity
(	O	O	O
LDs	O	O	B-Entity
)	O	O	O
is	O	O	O
critical	O	O	O
to	O	O	O
their	O	O	O
role	O	O	B-Entity
in	O	O	O
lipid	O	O	O
and	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
homeostasis	O	O	B-Entity
.	O	O	O

How	O	O	O
even	O	O	O
distribution	O	O	B-Entity
is	O	O	O
achieved	O	O	O
remains	O	O	O
elusive	O	O	O
,	O	O	O
but	O	O	O
diffusive	O	O	B-Entity
motion	O	O	I-Entity
and	O	O	O
directed	O	O	O
motility	O	O	B-Entity
may	O	O	O
play	O	O	O
a	O	O	O
role	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
fungus	O	O	B-Entity
Ustilago	O	O	B-Entity
maydis	O	O	I-Entity
~95	O	O	O
%	O	O	O
of	O	O	O
POs	O	O	B-Entity
and	O	O	O
LDs	O	O	B-Entity
undergo	O	O	O
diffusive	O	O	B-Entity
motions	O	O	I-Entity
.	O	O	O

These	O	O	O
movements	O	O	B-Entity
require	O	O	O
ATP	O	O	B-Entity
and	O	O	O
involve	O	O	O
bidirectional	O	O	B-Entity
early	O	O	O
endosome	O	O	B-Entity
motility	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
microtubule	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
membrane	O	O	B-Entity
trafficking	O	O	B-Entity
enhances	O	O	B-Entity
diffusion	O	O	B-Entity
of	O	O	O
organelles	O	O	B-Entity
.	O	O	O

When	O	O	O
early	O	O	O
endosome	O	O	B-Entity
transport	O	O	I-Entity
is	O	O	O
abolished	O	O	O
,	O	O	O
POs	O	O	B-Entity
and	O	O	O
LDs	O	O	B-Entity
drift	O	O	O
slowly	O	O	O
towards	O	O	O
the	O	O	O
growing	O	O	B-Entity
cell	O	O	I-Entity
end	O	O	I-Entity
.	O	O	O

This	O	O	O
pole-ward	O	O	B-Entity
drift	O	O	I-Entity
is	O	O	O
facilitated	O	O	O
by	O	O	O
anterograde	O	O	B-Entity
delivery	O	O	I-Entity
of	O	O	O
secretory	O	O	B-Entity
cargo	O	O	I-Entity
to	O	O	O
the	O	O	O
cell	O	O	B-Entity
tip	O	O	I-Entity
by	O	O	O
myosin-5	O	O	B-Entity
.	O	O	O

Modelling	O	O	B-Entity
reveals	O	O	O
that	O	O	O
microtubule-based	O	O	B-Entity
directed	O	O	I-Entity
transport	O	O	I-Entity
and	O	O	O
active	O	O	B-Entity
diffusion	O	O	B-Entity
support	O	O	O
distribution	O	O	B-Entity
,	O	O	O
mobility	O	O	B-Entity
and	O	O	O
mixing	O	O	O
of	O	O	O
POs	O	O	B-Entity
.	O	O	O

In	O	O	O
mammalian	O	O	B-Entity
COS-7	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
microtubules	O	O	B-Entity
and	O	O	O
F-actin	O	O	B-Entity
also	O	O	O
counteract	O	O	O
each	O	O	O
other	O	O	O
to	O	O	O
distribute	O	O	B-Entity
POs	O	O	B-Entity
.	O	O	O

This	O	O	O
highlights	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
opposing	O	O	O
cytoskeletal	O	O	B-Entity
forces	O	O	B-Entity
in	O	O	O
organelle	O	O	B-Entity
positioning	O	O	B-Entity
in	O	O	O
eukaryotes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27251918)

The	O	O	O
role	O	O	O
of	O	O	O
catheter	O	O	B-Entity
ablation	O	O	I-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
atrial	O	O	O
fibrillation	O	O	O

Atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
is	O	O	O
driven	O	O	O
by	O	O	O
spontaneous	O	O	O
electrical	O	O	B-Entity
activation	O	O	I-Entity
emerging	O	O	O
from	O	O	O
the	O	O	O
pulmonary	O	O	B-Entity
veins	O	O	I-Entity
.	O	O	O

Catheter	O	O	B-Entity
ablation	O	O	I-Entity
using	O	O	O
either	O	O	O
radiofrequency	O	O	B-Entity
or	O	O	O
cryothermal	O	O	B-Entity
energy	O	O	I-Entity
electrically	O	O	B-Entity
isolates	O	O	B-Entity
these	O	O	O
veins	O	O	B-Entity
from	O	O	O
the	O	O	O
left	O	O	B-Entity
atrium	O	O	I-Entity
,	O	O	O
both	O	O	O
reducing	O	O	B-Entity
the	O	O	O
burden	O	O	B-Entity
of	O	O	O
atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
episodes	O	O	B-Entity
and	O	O	O
improving	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
symptoms	O	O	B-Entity
.	O	O	O

Catheter	O	O	B-Entity
ablation	O	O	I-Entity
is	O	O	O
superior	O	O	O
to	O	O	O
antiarryhthmic	O	O	B-Entity
drugs	O	O	I-Entity
when	O	O	O
patients	O	O	B-Entity
are	O	O	O
carefully	O	O	O
selected	O	O	O
.	O	O	O

Underlying	O	O	O
medical	O	O	B-Entity
problems	O	O	I-Entity
-	O	O	O
including	O	O	O
obesity	O	O	B-Entity
,	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
obstructive	O	O	B-Entity
sleep	O	O	I-Entity
apnoea	O	O	I-Entity
-	O	O	O
should	O	O	O
be	O	O	O
optimally	O	O	O
treated	O	O	B-Entity
before	O	O	O
considering	O	O	O
ablation	O	O	B-Entity
.	O	O	O

Although	O	O	O
this	O	O	O
treatment	O	O	B-Entity
has	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
cure	O	O	B-Entity
patients	O	O	B-Entity
of	O	O	O
their	O	O	O
symptoms	O	O	B-Entity
,	O	O	O
they	O	O	O
should	O	O	O
be	O	O	O
aware	O	O	O
of	O	O	O
the	O	O	O
important	O	O	O
associated	O	O	O
procedural	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

-DOCSTART- (27252074)

The	O	O	O
Chinese	O	O	B-Entity
Herbal	O	O	I-Entity
Mixture	O	O	B-Entity
Tien-Hsien	O	O	B-Entity
Liquid	O	O	I-Entity
Augments	O	O	B-Entity
the	O	O	O
Anticancer	O	O	B-Entity
Immunity	O	O	B-Entity
in	O	O	O
Tumor	O	O	B-Entity
Cell	O	O	I-Entity
-	O	O	O
Vaccinated	O	O	B-Entity
Mice	O	O	O

Background	O	O	O
The	O	O	O
Chinese	O	O	B-Entity
herbal	O	O	I-Entity
mixture	O	O	B-Entity
,	O	O	O
Tien-Hsien	O	O	B-Entity
liquid	O	O	I-Entity
(	O	O	O
THL	O	O	B-Entity
)	O	O	O
,	O	O	O
has	O	O	O
been	O	O	O
used	O	O	O
as	O	O	O
an	O	O	O
anticancer	O	O	B-Entity
dietary	O	O	B-Entity
supplement	O	O	I-Entity
for	O	O	O
more	O	O	O
than	O	O	O
20	O	O	O
years	O	O	B-Entity
.	O	O	O

Our	O	O	O
previous	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
shown	O	O	O
that	O	O	O
THL	O	O	B-Entity
can	O	O	O
modulate	O	O	B-Entity
immune	O	O	B-Entity
response	O	O	I-Entity
and	O	O	O
inhibit	O	O	B-Entity
tumor	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
further	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
THL	O	O	B-Entity
on	O	O	O
anticancer	O	O	B-Entity
immune	O	O	B-Entity
response	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
vaccinated	O	O	B-Entity
with	O	O	O
γ-ray	O	O	B-Entity
-	O	O	O
irradiated	O	O	B-Entity
tumor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Methods	O	O	O
The	O	O	O
antitumor	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
THL	O	O	B-Entity
was	O	O	O
determined	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
vaccinated	O	O	B-Entity
with	O	O	O
low-tumorigenic	O	O	B-Entity
CT-26-low	O	O	I-Entity
colon	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
or	O	O	O
γ-ray-irradiated	O	O	B-Entity
high-tumorigenic	O	O	B-Entity
CT-26-high	O	O	I-Entity
colon	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
number	O	O	B-Entity
of	O	O	O
natural	O	O	B-Entity
killer	O	O	I-Entity
(	O	O	I-Entity
NK	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
T	O	O	B-Entity
lymphocytes	O	O	I-Entity
in	O	O	O
the	O	O	O
spleen	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

The	O	O	O
tumor	O	O	B-Entity
-	O	O	O
killing	O	O	B-Entity
activities	O	O	B-Entity
of	O	O	O
NK	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
cytotoxic	O	O	B-Entity
T	O	O	I-Entity
lymphocytes	O	O	I-Entity
(	O	O	O
CTLs	O	O	B-Entity
)	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
using	O	O	O
YAC-1	O	O	B-Entity
and	O	O	O
CT-26-high	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
as	O	O	O
target	O	O	B-Entity
cells	O	O	O
.	O	O	O

The	O	O	O
levels	O	O	B-Entity
of	O	O	O
IFN-γ	O	O	B-Entity
,	O	O	O
IL-2	O	O	B-Entity
,	O	O	O
and	O	O	O
TNF-α	O	O	B-Entity
were	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
ELISA	O	O	B-Entity
.	O	O	O

Results	O	O	O
THL	O	O	B-Entity
suppressed	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
CT-26-high	O	O	B-Entity
tumor	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
previously	O	O	O
vaccinated	O	O	B-Entity
with	O	O	O
low-tumorigenic	O	O	B-Entity
CT-26-low	O	O	I-Entity
cells	O	O	I-Entity
or	O	O	O
γ-irradiated	O	O	B-Entity
CT-26-high	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

THL	O	O	B-Entity
increased	O	O	B-Entity
the	O	O	O
populations	O	O	O
of	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
CD4	O	O	B-Entity
+	O	O	I-Entity
T	O	O	I-Entity
lymphocytes	O	O	I-Entity
in	O	O	O
the	O	O	O
spleen	O	O	B-Entity
and	O	O	O
enhanced	O	O	B-Entity
the	O	O	O
tumor	O	O	B-Entity
-	O	O	O
killing	O	O	B-Entity
activities	O	O	B-Entity
of	O	O	O
NK	O	O	O
cells	O	O	O
and	O	O	O
CTL	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
vaccinated	O	O	B-Entity
with	O	O	O
γ-irradiated	O	O	B-Entity
CT-26-high	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

THL	O	O	B-Entity
increased	O	O	B-Entity
the	O	O	O
production	O	O	B-Entity
of	O	O	O
IFN-γ	O	O	B-Entity
,	O	O	O
IL-2	O	O	B-Entity
,	O	O	O
and	O	O	O
TNF-α	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
vaccinated	O	O	B-Entity
with	O	O	O
γ-irradiated	O	O	B-Entity
CT-26-high	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Conclusion	O	O	O
THL	O	O	B-Entity
can	O	O	O
enhance	O	O	B-Entity
the	O	O	O
antitumor	O	O	B-Entity
immune	O	O	B-Entity
responses	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
vaccinated	O	O	B-Entity
with	O	O	O
killed	O	O	B-Entity
tumor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
THL	O	O	B-Entity
may	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
complementary	O	O	B-Entity
medicine	O	O	I-Entity
for	O	O	O
cancer	O	O	B-Entity
patients	O	O	B-Entity
previously	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
killed	O	O	B-Entity
tumor	O	O	I-Entity
cell	O	O	I-Entity
vaccines	O	O	I-Entity
,	O	O	O
radiotherapy	O	O	B-Entity
,	O	O	O
or	O	O	O
chemotherapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27252721)

Timing	O	O	B-Entity
of	O	O	O
False	O	O	O
Ring	O	O	B-Entity
Formation	O	O	I-Entity
in	O	O	O
Pinus	O	O	B-Entity
halepensis	O	O	I-Entity
and	O	O	O
Arbutus	O	O	B-Entity
unedo	O	O	I-Entity
in	O	O	O
Southern	O	O	B-Entity
Italy	O	O	B-Entity
:	O	O	O
Outlook	O	O	B-Entity
from	O	O	O
an	O	O	O
Analysis	O	O	B-Entity
of	O	O	O
Xylogenesis	O	O	B-Entity
and	O	O	O
Tree-Ring	O	O	B-Entity
Chronologies	O	O	O

Mediterranean	O	O	B-Entity
tree	O	O	B-Entity
rings	O	O	I-Entity
are	O	O	O
characterized	O	O	B-Entity
by	O	O	O
intra-annual	O	O	B-Entity
density	O	O	I-Entity
fluctuations	O	O	I-Entity
(	O	O	O
IADFs	O	O	B-Entity
)	O	O	O
due	O	O	O
to	O	O	O
partly	O	O	O
climate-driven	O	O	B-Entity
cambial	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

IADFs	O	O	B-Entity
are	O	O	O
used	O	O	O
as	O	O	O
structural	O	O	B-Entity
signals	O	O	B-Entity
to	O	O	O
gain	O	O	O
information	O	O	B-Entity
on	O	O	O
relations	O	O	B-Entity
between	O	O	B-Entity
environmental	O	O	B-Entity
conditions	O	O	B-Entity
and	O	O	O
eco-physiological	O	O	B-Entity
processes	O	O	B-Entity
during	O	O	B-Entity
xylogenesis	O	O	B-Entity
,	O	O	O
with	O	O	O
intra-annual	O	O	B-Entity
resolution	O	O	B-Entity
.	O	O	O

To	O	O	O
reach	O	O	O
an	O	O	O
unbiased	O	O	B-Entity
synchronization	O	O	B-Entity
of	O	O	O
the	O	O	O
IADF	O	O	B-Entity
position	O	O	B-Entity
within	O	O	O
tree	O	O	B-Entity
rings	O	O	B-Entity
and	O	O	O
seasonal	O	O	B-Entity
fluctuations	O	O	B-Entity
in	O	O	O
environmental	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
necessary	O	O	O
to	O	O	O
know	O	O	O
the	O	O	O
timing	O	O	B-Entity
of	O	O	O
cambial	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
wood	O	O	B-Entity
formation	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
species-	O	O	B-Entity
and	O	O	O
site-specific	O	O	B-Entity
processes	O	O	B-Entity
.	O	O	O

We	O	O	O
applied	O	O	B-Entity
the	O	O	O
microcoring	O	O	B-Entity
technique	O	O	I-Entity
to	O	O	O
analyze	O	O	B-Entity
xylogenesis	O	O	B-Entity
in	O	O	O
Pinus	O	O	B-Entity
halepensis	O	O	I-Entity
and	O	O	O
Arbutus	O	O	B-Entity
unedo	O	O	I-Entity
.	O	O	O

To	O	O	O
the	O	O	O
best	O	O	O
of	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
this	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
attempt	O	O	B-Entity
to	O	O	O
study	O	O	B-Entity
xylogenesis	O	O	B-Entity
in	O	O	O
a	O	O	O
hardwood	O	O	B-Entity
species	O	O	B-Entity
forming	O	O	O
frequent	O	O	B-Entity
IADFs	O	O	B-Entity
.	O	O	O

Both	O	O	O
species	O	O	B-Entity
co-occur	O	O	B-Entity
at	O	O	O
a	O	O	O
site	O	O	B-Entity
in	O	O	O
southern	O	O	B-Entity
Italy	O	O	B-Entity
characterized	O	O	B-Entity
by	O	O	O
a	O	O	O
Mediterranean	O	O	B-Entity
climate	O	O	B-Entity
.	O	O	O

To	O	O	O
facilitate	O	O	O
tree-ring	O	O	B-Entity
dating	O	O	I-Entity
and	O	O	O
identification	O	O	B-Entity
of	O	O	O
IADFs	O	O	B-Entity
,	O	O	O
we	O	O	O
performed	O	O	B-Entity
traditional	O	O	B-Entity
dendroecological	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
xylogenesis	O	O	B-Entity
during	O	O	B-Entity
summer	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
considered	O	O	B-Entity
a	O	O	O
constraint	O	O	B-Entity
for	O	O	O
xylogenesis	O	O	O
and	O	O	O
a	O	O	O
trigger	O	O	O
for	O	O	O
IADF	O	O	B-Entity
formation	O	O	B-Entity
.	O	O	O

We	O	O	O
followed	O	O	O
the	O	O	O
different	O	O	B-Entity
phases	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
the	O	O	O
current	O	O	B-Entity
wood	O	O	B-Entity
increment	O	O	B-Entity
with	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
evaluating	O	O	O
whether	O	O	O
and	O	O	O
which	O	O	O
type	O	O	O
of	O	O	O
IADFs	O	O	B-Entity
were	O	O	O
formed	O	O	B-Entity
.	O	O	O

We	O	O	O
additionally	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
same	O	O	O
phases	O	O	B-Entity
again	O	O	O
in	O	O	O
September	O	O	B-Entity
and	O	O	O
in	O	O	O
winter	O	O	B-Entity
to	O	O	O
verify	O	O	B-Entity
the	O	O	O
possible	O	O	B-Entity
formation	O	O	B-Entity
of	O	O	O
IADFs	O	O	B-Entity
in	O	O	O
fall	O	O	B-Entity
and	O	O	O
whether	O	O	O
cell	O	O	B-Entity
production	O	O	B-Entity
and	O	O	O
differentiation	O	O	B-Entity
was	O	O	O
completed	O	O	B-Entity
by	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
calendar	O	O	B-Entity
year	O	O	I-Entity
.	O	O	O

Both	O	O	O
species	O	O	B-Entity
formed	O	O	B-Entity
the	O	O	O
same	O	O	O
type	O	O	O
of	O	O	O
IADFs	O	O	B-Entity
(	O	O	O
earlywood	O	O	B-Entity
-like	O	O	O
cells	O	O	B-Entity
within	O	O	O
latewood	O	O	B-Entity
)	O	O	O
,	O	O	O
due	O	O	O
to	O	O	O
temporary	O	O	B-Entity
growth	O	O	B-Entity
restoration	O	O	B-Entity
triggered	O	O	B-Entity
by	O	O	I-Entity
rain	O	O	B-Entity
events	O	O	B-Entity
during	O	O	B-Entity
the	O	O	O
period	O	O	B-Entity
of	O	O	O
summer	O	O	B-Entity
drought	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
calendar	O	O	B-Entity
year	O	O	I-Entity
,	O	O	O
no	O	O	O
cells	O	O	B-Entity
in	O	O	O
the	O	O	O
phases	O	O	B-Entity
of	O	O	O
enlargement	O	O	B-Entity
and	O	O	O
secondary	O	O	B-Entity
cell	O	O	I-Entity
wall	O	O	I-Entity
deposition	O	O	B-Entity
occurred	O	O	B-Entity
.	O	O	O

A.	O	O	B-Entity
unedo	O	O	I-Entity
was	O	O	O
more	O	O	O
sensitive	O	O	B-Entity
than	O	O	O
P.	O	O	B-Entity
halepensis	O	O	I-Entity
because	O	O	O
IADF	O	O	B-Entity
s	O	O	O
were	O	O	O
formed	O	O	B-Entity
earlier	O	O	B-Entity
in	O	O	O
the	O	O	O
season	O	O	B-Entity
and	O	O	O
were	O	O	O
more	O	O	O
frequent	O	O	B-Entity
in	O	O	O
the	O	O	O
tree-ring	O	O	B-Entity
series	O	O	O
.	O	O	O

The	O	O	O
dendro-anatomical	O	O	B-Entity
approach	O	O	O
,	O	O	O
combining	O	O	O
analysis	O	O	B-Entity
of	O	O	O
tree-ring	O	O	B-Entity
series	O	O	O
and	O	O	O
of	O	O	O
xylogenesis	O	O	B-Entity
,	O	O	O
helped	O	O	O
to	O	O	O
detect	O	O	B-Entity
the	O	O	O
period	O	O	B-Entity
of	O	O	O
IADF	O	O	B-Entity
formation	O	O	B-Entity
in	O	O	O
the	O	O	O
two	O	O	O
species	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
are	O	O	O
discussed	O	O	O
in	O	O	O
functional	O	O	B-Entity
terms	O	O	B-Entity
,	O	O	O
highlighting	O	O	O
the	O	O	O
environmental	O	O	B-Entity
conditions	O	O	B-Entity
triggering	O	O	B-Entity
IADFs	O	O	B-Entity
,	O	O	O
and	O	O	O
also	O	O	O
in	O	O	O
methodological	O	O	B-Entity
terms	O	O	O
,	O	O	O
evaluating	O	O	O
the	O	O	O
applicability	O	O	B-Entity
of	O	O	O
xylogenesis	O	O	B-Entity
analysis	O	O	B-Entity
in	O	O	O
Mediterranean	O	O	B-Entity
woods	O	O	B-Entity
,	O	O	O
especially	O	O	O
when	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
IADFs	O	O	O
is	O	O	O
not	O	O	O
uniform	O	O	B-Entity
around	O	O	O
the	O	O	O
stem	O	O	B-Entity
.	O	O	O

-DOCSTART- (27254792)

Emergence	O	O	B-Entity
of	O	O	O
family	O	O	B-Entity
medicine	O	O	I-Entity
in	O	O	O
Ethiopia	O	O	B-Entity
[	O	O	O
corrected	O	O	O
]	O	O	O
:	O	O	O
an	O	O	O
international	O	O	B-Entity
collaborative	O	O	B-Entity
education	O	O	O
model	O	O	O

Family	O	O	B-Entity
Medicine	O	O	I-Entity
(	O	O	O
FM	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
new	O	O	O
specialty	O	O	B-Entity
in	O	O	O
Ethiopia	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	B-Entity
seven	O	O	I-Entity
family	O	O	I-Entity
physicians	O	O	I-Entity
graduated	O	O	B-Entity
in	O	O	O
February	O	O	B-Entity
2016	O	O	O
from	O	O	O
the	O	O	O
inaugural	O	O	O
residency	O	O	B-Entity
programme	O	O	B-Entity
at	O	O	O
Addis	O	O	B-Entity
Ababa	O	O	I-Entity
University	O	O	I-Entity
.	O	O	O

Cooperation	O	O	B-Entity
amongst	O	O	O
Ethiopian	O	O	B-Entity
and	O	O	O
expatriate	O	O	B-Entity
decision-makers	O	O	B-Entity
and	O	O	O
physicians	O	O	B-Entity
was	O	O	O
needed	O	O	O
to	O	O	O
begin	O	O	B-Entity
the	O	O	O
programme	O	O	B-Entity
.	O	O	O

Intentional	O	O	B-Entity
replacement	O	O	B-Entity
of	O	O	O
expatriates	O	O	B-Entity
with	O	O	O
Ethiopian	O	O	B-Entity
family	O	O	B-Entity
physicians	O	O	I-Entity
has	O	O	O
begun	O	O	B-Entity
.	O	O	O

Barriers	O	O	B-Entity
include	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
understanding	O	O	B-Entity
of	O	O	O
FM	O	O	B-Entity
and	O	O	O
the	O	O	O
human	O	O	B-Entity
and	O	O	O
financial	O	O	B-Entity
resources	O	O	I-Entity
needed	O	O	O
for	O	O	O
scaling	O	O	B-Entity
up	O	O	I-Entity
the	O	O	O
programme	O	O	B-Entity
.	O	O	O

Regular	O	O	B-Entity
programme	O	O	B-Entity
review	O	O	B-Entity
with	O	O	O
resident	O	O	B-Entity
physician	O	O	I-Entity
involvement	O	O	B-Entity
has	O	O	O
allowed	O	O	O
the	O	O	O
FM	O	O	B-Entity
training	O	O	B-Entity
programme	O	O	I-Entity
to	O	O	O
adapt	O	O	B-Entity
and	O	O	O
fit	O	O	B-Entity
the	O	O	O
Ethiopian	O	O	B-Entity
context	O	O	B-Entity
.	O	O	O

Further	O	O	O
successes	O	O	B-Entity
will	O	O	O
result	O	O	B-Entity
from	O	O	O
ongoing	O	O	O
support	O	O	B-Entity
and	O	O	O
advocacy	O	O	B-Entity
from	O	O	O
the	O	O	O
Federal	O	O	B-Entity
Ministry	O	O	I-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
and	O	O	O
other	O	O	O
Ethiopian	O	O	B-Entity
,	O	O	O
African	O	O	B-Entity
,	O	O	O
and	O	O	O
international	O	O	B-Entity
primary	O	O	I-Entity
care	O	O	I-Entity
organisations	O	O	I-Entity
.	O	O	O

-DOCSTART- (27256947)

The	O	O	O
Experience	O	O	B-Entity
of	O	O	O
Women	O	O	B-Entity
Veterans	O	O	B-Entity
Coming	O	O	O
Back	O	O	O
from	O	O	O
War	O	O	O

Issues	O	O	B-Entity
surrounding	O	O	I-Entity
mental	O	O	I-Entity
health	O	O	I-Entity
are	O	O	O
common	O	O	O
for	O	O	O
women	O	O	B-Entity
veterans	O	O	B-Entity
who	O	O	O
have	O	O	O
served	O	O	O
in	O	O	O
Iraq	O	O	B-Entity
and	O	O	O
Afghanistan	O	O	B-Entity
wars	O	O	B-Entity
.	O	O	O

The	O	O	O
goal	O	O	O
of	O	O	O
this	O	O	O
phenomenological	O	O	B-Entity
study	O	O	B-Entity
was	O	O	O
to	O	O	O
document	O	O	B-Entity
themes	O	O	B-Entity
in	O	O	O
the	O	O	O
stories	O	O	B-Entity
gathered	O	O	O
from	O	O	O
eight	O	O	O
women	O	O	B-Entity
veterans	O	O	B-Entity
who	O	O	O
had	O	O	O
come	O	O	O
back	O	O	O
from	O	O	O
war	O	O	B-Entity
.	O	O	O

Themes	O	O	B-Entity
in	O	O	O
the	O	O	O
stories	O	O	B-Entity
were	O	O	O
:	O	O	O
arriving	O	O	O
with	O	O	O
mixed	O	O	O
sentiments	O	O	B-Entity
;	O	O	O
evolving	O	O	O
to	O	O	O
a	O	O	O
changed	O	O	B-Entity
view	O	O	B-Entity
of	O	O	I-Entity
self	O	O	I-Entity
;	O	O	O
permeating	O	O	B-Entity
aggravation	O	O	I-Entity
;	O	O	O
confounding	O	O	B-Entity
broken	O	O	I-Entity
relationships	O	O	I-Entity
,	O	O	O
frequent	O	O	B-Entity
deployments	O	O	I-Entity
,	O	O	O
and	O	O	O
change	O	O	B-Entity
in	O	O	I-Entity
military	O	O	I-Entity
status	O	O	I-Entity
;	O	O	O
remembering	O	O	B-Entity
war	O	O	B-Entity
experiences	O	O	B-Entity
;	O	O	O
and	O	O	O
seeking	O	O	B-Entity
opportunity	O	O	I-Entity
for	O	O	I-Entity
what	O	O	I-Entity
is	O	O	I-Entity
possible	O	O	I-Entity
.	O	O	O

Mental	O	O	B-Entity
health	O	O	I-Entity
issues	O	O	I-Entity
can	O	O	O
be	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
themes	O	O	B-Entity
.	O	O	O

Including	O	O	O
story	O	O	B-Entity
as	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
visit	O	O	O
with	O	O	O
veterans	O	O	B-Entity
may	O	O	O
be	O	O	O
beneficial	O	O	O
to	O	O	O
veterans	O	O	O
as	O	O	O
they	O	O	O
deal	O	O	O
with	O	O	O
the	O	O	O
transition	O	O	B-Entity
of	O	O	I-Entity
coming	O	O	I-Entity
back	O	O	I-Entity
.	O	O	O

-DOCSTART- (27257353)

Trajectories	O	O	B-Entity
of	O	O	O
Health	O	O	B-Entity
and	O	O	O
Behavioral	O	O	B-Entity
Health	O	O	I-Entity
Services	O	O	I-Entity
Use	O	O	B-Entity
among	O	O	O
Community	O	O	B-Entity
Corrections	O	O	B-Entity
-Involved	O	O	O
Rural	O	O	B-Entity
Adults	O	O	O

This	O	O	O
article	O	O	O
seeks	O	O	O
to	O	O	O
establish	O	O	O
time-based	O	O	O
trajectories	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
and	O	O	O
behavioral	O	O	B-Entity
health	O	O	I-Entity
services	O	O	I-Entity
utilization	O	O	B-Entity
for	O	O	O
community	O	O	B-Entity
corrections-involved	O	O	I-Entity
(	O	O	O
CCI	O	O	B-Entity
)	O	O	O
adults	O	O	B-Entity
and	O	O	O
to	O	O	O
examine	O	O	O
demographic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
correlates	O	O	O
associated	O	O	O
with	O	O	O
these	O	O	O
trajectories	O	O	O
.	O	O	O

To	O	O	O
accomplish	O	O	O
this	O	O	O
aim	O	O	O
,	O	O	O
the	O	O	O
authors	O	O	O
applied	O	O	O
a	O	O	O
latent	O	O	B-Entity
class	O	O	I-Entity
growth	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
LCGA	O	O	B-Entity
)	O	O	O
to	O	O	O
services	O	O	B-Entity
use	O	O	O
data	O	O	O
from	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
rural	O	O	B-Entity
CCI	O	O	B-Entity
adults	O	O	B-Entity
who	O	O	O
reported	O	O	O
their	O	O	O
medical	O	O	B-Entity
,	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
and	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
treatment	O	O	B-Entity
utilization	O	O	I-Entity
behavior	O	O	B-Entity
every	O	O	O
60	O	O	O
days	O	O	B-Entity
for	O	O	O
1.5	O	O	O
years	O	O	B-Entity
.	O	O	O

LCGA	O	O	B-Entity
established	O	O	O
1.5-year	O	O	B-Entity
trajectories	O	O	B-Entity
and	O	O	O
demographic	O	O	B-Entity
correlates	O	O	O
of	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
among	O	O	O
rural	O	O	B-Entity
CCI	O	O	B-Entity
adults	O	O	B-Entity
.	O	O	O

For	O	O	O
medical	O	O	B-Entity
services	O	O	I-Entity
,	O	O	O
three	O	O	O
classes	O	O	O
emerged	O	O	O
(	O	O	O
stable-low	O	O	O
users	O	O	B-Entity
,	O	O	O
13	O	O	O
%	O	O	O
;	O	O	O
stable-intermediate	O	O	O
users	O	O	O
,	O	O	O
40	O	O	O
%	O	O	O
;	O	O	O
and	O	O	O
stable-high	O	O	O
users	O	O	O
,	O	O	O
47	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

For	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
services	O	O	B-Entity
,	O	O	O
three	O	O	O
classes	O	O	O
emerged	O	O	O
(	O	O	O
stable-low	O	O	O
,	O	O	O
69	O	O	O
%	O	O	O
and	O	O	O
61	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
low-baseline-increase	O	O	O
,	O	O	O
10	O	O	O
%	O	O	O
and	O	O	O
12	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
high-baseline	O	O	O
decline	O	O	O
,	O	O	O
21	O	O	O
%	O	O	O
and	O	O	O
28	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Employment	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
medication	O	O	B-Entity
usage	O	O	I-Entity
,	O	O	O
and	O	O	O
depression	O	O	B-Entity
severity	O	O	B-Entity
predicted	O	O	O
membership	O	O	B-Entity
across	O	O	O
all	O	O	O
services	O	O	B-Entity
.	O	O	O

Results	O	O	O
underscore	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
social	O	O	B-Entity
workers	O	O	I-Entity
and	O	O	O
other	O	O	O
community	O	O	B-Entity
services	O	O	I-Entity
providers	O	O	B-Entity
aligning	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
access	O	O	O
with	O	O	O
the	O	O	O
needs	O	O	O
of	O	O	O
the	O	O	O
CCI	O	O	B-Entity
population	O	O	O
,	O	O	O
and	O	O	O
highlight	O	O	O
CCI	O	O	O
adults	O	O	B-Entity
as	O	O	O
being	O	O	O
at	O	O	O
risk	O	O	B-Entity
of	O	O	O
underservice	O	O	O
in	O	O	O
critical	O	O	O
prevention	O	O	B-Entity
and	O	O	O
intervention	O	O	B-Entity
domains	O	O	I-Entity
.	O	O	O

-DOCSTART- (27257613)

Data	O	O	B-Entity
set	O	O	I-Entity
of	O	O	O
interactomes	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
pathways	O	O	I-Entity
of	O	O	O
proteins	O	O	B-Entity
differentially	O	O	O
expressed	O	O	B-Entity
in	O	O	O
brains	O	O	B-Entity
with	O	O	O
Alzheimer׳s	O	O	O
disease	O	O	O

Alzheimer׳s	O	O	B-Entity
disease	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
main	O	O	O
causes	O	O	O
of	O	O	O
dementia	O	O	B-Entity
in	O	O	O
the	O	O	O
elderly	O	O	B-Entity
and	O	O	O
its	O	O	O
frequency	O	O	B-Entity
is	O	O	O
on	O	O	O
the	O	O	O
rise	O	O	O
worldwide	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
considered	O	O	O
the	O	O	O
result	O	O	O
of	O	O	O
complex	O	O	B-Entity
interactions	O	O	B-Entity
between	O	O	O
genetic	O	O	B-Entity
and	O	O	O
environmental	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
being	O	O	O
many	O	O	O
of	O	O	O
them	O	O	O
unknown	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
dire	O	O	O
necessity	O	O	O
for	O	O	O
the	O	O	O
identification	O	O	O
of	O	O	O
novel	O	O	O
molecular	O	O	B-Entity
players	O	O	I-Entity
for	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
this	O	O	O
disease	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
data	O	O	B-Entity
article	O	O	B-Entity
we	O	O	O
determined	O	O	O
the	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
profiles	O	O	O
of	O	O	O
whole	O	O	O
protein	O	O	O
extracts	O	O	B-Entity
from	O	O	O
cortex	O	O	B-Entity
regions	O	O	I-Entity
of	O	O	I-Entity
brains	O	O	I-Entity
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
Alzheimer׳s	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
comparison	O	O	O
to	O	O	O
a	O	O	O
normal	O	O	B-Entity
brain	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
721	O	O	O
iTRAQ-labeled	O	O	B-Entity
polypeptides	O	O	B-Entity
with	O	O	O
more	O	O	O
than	O	O	O
95	O	O	O
%	O	O	O
in	O	O	O
confidence	O	O	O
.	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
all	O	O	O
proteins	O	O	B-Entity
that	O	O	O
changed	O	O	O
in	O	O	O
their	O	O	O
expression	O	O	B-Entity
level	O	O	I-Entity
and	O	O	O
located	O	O	O
them	O	O	O
in	O	O	O
the	O	O	O
KEGG	O	O	B-Entity
metabolic	O	O	I-Entity
pathways	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
complexes	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
electron	O	O	I-Entity
transport	O	O	I-Entity
chain	O	O	I-Entity
and	O	O	O
ATP	O	O	B-Entity
synthase	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
over-	O	O	B-Entity
and	O	O	I-Entity
sub-expressed	O	O	I-Entity
polypeptides	O	O	I-Entity
through	O	O	O
IPA	O	O	B-Entity
software	O	O	I-Entity
,	O	O	O
specifically	O	O	O
Core	O	O	B-Entity
I	O	O	I-Entity
and	O	O	I-Entity
Biomarkers	O	O	I-Entity
I	O	O	I-Entity
modules	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
in	O	O	O
this	O	O	O
article	O	O	B-Entity
is	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
research	O	O	B-Entity
article	O	O	O
"	O	O	O
Identification	O	O	O
of	O	O	O
proteins	O	O	B-Entity
that	O	O	O
are	O	O	O
differentially	O	O	O
expressed	O	O	B-Entity
in	O	O	O
brains	O	O	B-Entity
with	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
using	O	O	O
iTRAQ	O	O	B-Entity
labeling	O	O	I-Entity
and	O	O	O
tandem	O	O	B-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
"	O	O	O
(	O	O	O
Minjarez	O	O	O
et	O	O	O
al.	O	O	O
,	O	O	O
2016	O	O	O
)	O	O	O
[	O	O	O
1	O	O	O
]	O	O	O
.	O	O	O

-DOCSTART- (27257694)

Emergency	O	O	B-Entity
general	O	O	I-Entity
surgery	O	O	I-Entity
specific	O	O	B-Entity
frailty	O	O	I-Entity
index	O	O	I-Entity
:	O	O	O
A	O	O	O
validation	O	O	O
study	O	O	O

Assessment	O	O	B-Entity
of	O	O	O
operative	O	O	B-Entity
risk	O	O	I-Entity
in	O	O	O
geriatric	O	O	B-Entity
patients	O	O	I-Entity
undergoing	O	O	O
emergency	O	O	B-Entity
general	O	O	I-Entity
surgery	O	O	I-Entity
(	O	O	O
EGS	O	O	B-Entity
)	O	O	O
is	O	O	O
challenging	O	O	O
.	O	O	O

Frailty	O	O	B-Entity
is	O	O	O
an	O	O	O
established	O	O	O
measure	O	O	B-Entity
for	O	O	O
risk	O	O	B-Entity
assessment	O	O	I-Entity
in	O	O	O
surgical	O	O	B-Entity
cases	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
our	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
validate	O	O	B-Entity
a	O	O	O
modified	O	O	O
15	O	O	O
variable	O	O	B-Entity
emergency	O	O	B-Entity
general	O	O	I-Entity
surgery	O	O	I-Entity
specific	O	O	I-Entity
frailty	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
EGSFI	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
prospectively	O	O	O
collected	O	O	B-Entity
geriatric	O	O	B-Entity
(	O	O	O
age	O	O	B-Entity
>	O	O	I-Entity
65	O	O	I-Entity
)	O	O	O
emergency	O	O	B-Entity
general	O	O	I-Entity
surgery	O	O	I-Entity
patients	O	O	B-Entity
for	O	O	O
1-	O	O	O
year	O	O	B-Entity
.	O	O	O

Post-operative	O	O	B-Entity
complications	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
.	O	O	O

Frailty	O	O	B-Entity
Index	O	O	I-Entity
was	O	O	O
calculated	O	O	B-Entity
for	O	O	O
200	O	O	O
patients	O	O	B-Entity
based	O	O	O
on	O	O	O
their	O	O	O
pre-admission	O	O	B-Entity
condition	O	O	B-Entity
using	O	O	O
50-	O	O	O
variable	O	O	B-Entity
modified	O	O	O
Rockwood	O	O	B-Entity
Frailty	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
FI	O	O	B-Entity
)	O	O	O
.	O	O	O

EGSFI	O	O	B-Entity
was	O	O	O
developed	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
regression	O	O	B-Entity
model	O	O	I-Entity
for	O	O	O
complications	O	O	B-Entity
and	O	O	O
the	O	O	O
most	O	O	O
significant	O	O	O
factors	O	O	O
in	O	O	O
the	O	O	O
FI	O	O	B-Entity
.	O	O	O

ROC	O	O	B-Entity
curve	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
determine	O	O	O
cutoff	O	O	B-Entity
for	O	O	O
frail	O	O	B-Entity
status	O	O	B-Entity
.	O	O	O

We	O	O	O
validated	O	O	B-Entity
our	O	O	O
results	O	O	B-Entity
using	O	O	O
60	O	O	O
patients	O	O	B-Entity
for	O	O	O
predicting	O	O	B-Entity
complications	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
260	O	O	O
patients	O	O	B-Entity
(	O	O	O
200	O	O	O
developing	O	O	O
,	O	O	O
60	O	O	O
Validation	O	O	B-Entity
)	O	O	O
were	O	O	O
enrolled	O	O	B-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Mean	O	O	B-Entity
age	O	O	I-Entity
was	O	O	O
71	O	O	O
±	O	O	O
11	O	O	O
years	O	O	B-Entity
,	O	O	O
and	O	O	O
33	O	O	O
%	O	O	O
developed	O	O	O
complications	O	O	B-Entity
.	O	O	O

Most	O	O	O
common	O	O	B-Entity
complications	O	O	B-Entity
were	O	O	O
pneumonia	O	O	B-Entity
(	O	O	O
12	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
UTI	O	O	B-Entity
(	O	O	O
9	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
wound	O	O	B-Entity
infection	O	O	I-Entity
(	O	O	O
7	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Univariate	O	O	B-Entity
analysis	O	O	I-Entity
identified	O	O	O
15	O	O	O
variables	O	O	B-Entity
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
complications	O	O	B-Entity
that	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
develop	O	O	O
the	O	O	O
EGSFI	O	O	B-Entity
.	O	O	O

A	O	O	O
cutoff	O	O	B-Entity
frailty	O	O	B-Entity
score	O	O	I-Entity
of	O	O	O
0.325	O	O	O
was	O	O	O
identified	O	O	O
using	O	O	O
ROC	O	O	B-Entity
curve	O	O	I-Entity
analysis	O	O	I-Entity
for	O	O	O
frail	O	O	B-Entity
status	O	O	B-Entity
.Sixty-	O	O	O
patients	O	O	B-Entity
(	O	O	O
frail	O	O	O
:	O	O	O
18	O	O	O
,	O	O	O
non-frail	O	O	B-Entity
:	O	O	O
42	O	O	O
)	O	O	O
were	O	O	O
enrolled	O	O	B-Entity
in	O	O	O
the	O	O	O
validation	O	O	B-Entity
cohort	O	O	B-Entity
.	O	O	O

Frail	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
post-operative	O	O	B-Entity
complications	O	O	I-Entity
(	O	O	O
47	O	O	O
%	O	O	O
vs.	O	O	O
20	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
nonfrail	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

Frail	O	O	B-Entity
status	O	O	B-Entity
based	O	O	O
on	O	O	O
EGSFI	O	O	B-Entity
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
predictor	O	O	I-Entity
of	O	O	O
post-operative	O	O	B-Entity
complications	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
7.3	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.7	O	O	O
-	O	O	O
19.8	O	O	O
;	O	O	O
p=0.006	O	O	O
)	O	O	O
.	O	O	O

Age	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
postoperative	O	O	B-Entity
complications	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
0.99	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
0.92	O	O	O
-1.06	O	O	O
;	O	O	O
p=0.86	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
15-	O	O	O
variable	O	O	B-Entity
validated	O	O	B-Entity
EGSFI	O	O	B-Entity
is	O	O	O
a	O	O	O
simple	O	O	O
and	O	O	O
reliable	O	O	O
bedside	O	O	B-Entity
tool	O	O	I-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
frailty	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
emergency	O	O	B-Entity
general	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

Frail	O	O	B-Entity
status	O	O	B-Entity
as	O	O	O
determined	O	O	O
by	O	O	O
Abstract	O	O	O
the	O	O	O
EGSFI	O	O	B-Entity
is	O	O	O
an	O	O	O
independent	O	O	B-Entity
predictor	O	O	I-Entity
of	O	O	O
post-operative	O	O	B-Entity
complications	O	O	I-Entity
and	O	O	O
mortality	O	O	B-Entity
in	O	O	O
geriatric	O	O	B-Entity
emergency	O	O	B-Entity
general	O	O	I-Entity
surgery	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Level	O	O	O
II	O	O	O
,	O	O	O
Prognostic	O	O	B-Entity
Studies	O	O	I-Entity
-	O	O	O
Investigating	O	O	B-Entity
the	O	O	O
Effect	O	O	B-Entity
of	O	O	O
a	O	O	O
Patient	O	O	B-Entity
Characteristic	O	O	I-Entity
on	O	O	O
the	O	O	O
Outcome	O	O	B-Entity
of	O	O	I-Entity
Disease	O	O	I-Entity
.	O	O	O

-DOCSTART- (27257822)

Comparative	O	O	O
Epidemiologic	O	O	B-Entity
Characteristics	O	O	B-Entity
of	O	O	O
Pertussis	O	O	B-Entity
in	O	O	O
10	O	O	O
Central	O	O	B-Entity
and	O	O	O
Eastern	O	O	B-Entity
European	O	O	I-Entity
Countries	O	O	I-Entity
,	O	O	O
2000	O	O	O
-	O	O	O
2013	O	O	O

We	O	O	O
undertook	O	O	O
an	O	O	O
epidemiological	O	O	B-Entity
survey	O	O	I-Entity
of	O	O	O
the	O	O	O
annual	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
pertussis	O	O	B-Entity
reported	O	O	B-Entity
from	O	O	O
2000	O	O	O
to	O	O	O
2013	O	O	O
in	O	O	O
ten	O	O	O
Central	O	O	B-Entity
and	O	O	O
Eastern	O	O	B-Entity
European	O	O	I-Entity
countries	O	O	B-Entity
to	O	O	O
ascertain	O	O	O
whether	O	O	O
increased	O	O	O
pertussis	O	O	O
reports	O	O	B-Entity
in	O	O	O
some	O	O	O
countries	O	O	O
share	O	O	O
common	O	O	O
underlying	O	O	O
drivers	O	O	O
or	O	O	O
whether	O	O	O
there	O	O	O
are	O	O	O
specific	O	O	O
features	O	O	B-Entity
in	O	O	O
each	O	O	O
country	O	O	B-Entity
.	O	O	O

The	O	O	O
annual	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
pertussis	O	O	B-Entity
in	O	O	O
the	O	O	O
participating	O	O	O
countries	O	O	B-Entity
was	O	O	O
obtained	O	O	O
from	O	O	O
relevant	O	O	O
government	O	O	B-Entity
institutions	O	O	I-Entity
and/or	O	O	O
national	O	O	B-Entity
surveillance	O	O	I-Entity
systems	O	O	I-Entity
.	O	O	O

We	O	O	O
reviewed	O	O	B-Entity
the	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
pertussis	O	O	B-Entity
incidence	O	O	B-Entity
rates	O	O	I-Entity
in	O	O	O
each	O	O	O
country	O	O	B-Entity
to	O	O	O
explore	O	O	O
differences	O	O	B-Entity
and/or	O	O	O
similarities	O	O	B-Entity
between	O	O	O
countries	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
pertussis	O	O	O
surveillance	O	O	B-Entity
;	O	O	O
case	O	O	B-Entity
definitions	O	O	I-Entity
for	O	O	O
detection	O	O	B-Entity
and	O	O	O
confirmation	O	O	B-Entity
of	O	O	O
pertussis	O	O	O
;	O	O	O
incidence	O	O	O
and	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
cases	O	O	I-Entity
of	O	O	O
pertussis	O	O	O
by	O	O	O
year	O	O	B-Entity
,	O	O	O
overall	O	O	O
and	O	O	O
by	O	O	O
age	O	O	B-Entity
group	O	O	I-Entity
;	O	O	O
population	O	O	B-Entity
by	O	O	O
year	O	O	O
,	O	O	O
overall	O	O	O
and	O	O	O
by	O	O	O
age	O	O	O
group	O	O	O
;	O	O	O
pertussis	O	O	O
immunization	O	O	B-Entity
schedule	O	O	I-Entity
and	O	O	O
coverage	O	O	B-Entity
,	O	O	O
and	O	O	O
switch	O	O	O
from	O	O	O
whole-cell	O	O	B-Entity
pertussis	O	O	I-Entity
vaccines	O	O	I-Entity
(	O	O	O
wP	O	O	B-Entity
)	O	O	O
to	O	O	O
acellular	O	O	B-Entity
pertussis	O	O	I-Entity
vaccines	O	O	I-Entity
(	O	O	O
aP	O	O	B-Entity
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
heterogeneity	O	O	B-Entity
in	O	O	O
the	O	O	O
reported	O	O	B-Entity
annual	O	O	B-Entity
incidence	O	O	B-Entity
rates	O	O	I-Entity
and	O	O	O
trends	O	O	O
observed	O	O	O
across	O	O	O
countries	O	O	B-Entity
.	O	O	O

Reported	O	O	B-Entity
pertussis	O	O	B-Entity
incidence	O	O	B-Entity
rates	O	O	B-Entity
varied	O	O	O
considerably	O	O	O
,	O	O	O
ranging	O	O	O
from	O	O	O
0.01	O	O	O
to	O	O	O
96	O	O	O
per	O	O	O
100,000	O	O	O
population	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
highest	O	O	B-Entity
rates	O	O	O
generally	O	O	O
reported	O	O	B-Entity
in	O	O	O
Estonia	O	O	B-Entity
and	O	O	O
the	O	O	O
lowest	O	O	B-Entity
in	O	O	O
Hungary	O	O	B-Entity
and	O	O	O
Serbia	O	O	B-Entity
.	O	O	O

The	O	O	O
greatest	O	O	O
burden	O	O	B-Entity
appears	O	O	O
for	O	O	O
the	O	O	O
most	O	O	O
part	O	O	O
in	O	O	O
infants	O	O	B-Entity
(	O	O	O
<	O	O	O
1	O	O	O
year	O	O	B-Entity
)	O	O	O
in	O	O	O
Bulgaria	O	O	B-Entity
,	O	O	O
Hungary	O	O	B-Entity
,	O	O	O
Latvia	O	O	B-Entity
,	O	O	O
Romania	O	O	B-Entity
,	O	O	O
and	O	O	O
Serbia	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
the	O	O	O
other	O	O	O
participating	O	O	O
countries	O	O	B-Entity
where	O	O	O
the	O	O	O
burden	O	O	O
may	O	O	O
have	O	O	O
shifted	O	O	O
to	O	O	O
older	O	O	B-Entity
children	O	O	I-Entity
,	O	O	O
though	O	O	O
surveillance	O	O	B-Entity
of	O	O	O
adults	O	O	B-Entity
may	O	O	O
be	O	O	O
inappropriate	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
consistent	O	O	O
pattern	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
switch	O	O	O
from	O	O	O
wP	O	O	B-Entity
to	O	O	O
aP	O	O	B-Entity
vaccines	O	O	I-Entity
on	O	O	O
reported	O	O	B-Entity
pertussis	O	O	B-Entity
incidence	O	O	B-Entity
rates	O	O	I-Entity
.	O	O	O

The	O	O	O
heterogeneity	O	O	B-Entity
in	O	O	O
reported	O	O	B-Entity
data	O	O	B-Entity
may	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
factors	O	O	B-Entity
including	O	O	O
surveillance	O	O	B-Entity
system	O	O	B-Entity
characteristics	O	O	B-Entity
or	O	O	O
capabilities	O	O	B-Entity
,	O	O	O
different	O	O	O
case	O	O	B-Entity
definitions	O	O	I-Entity
,	O	O	O
type	O	O	B-Entity
of	O	O	O
pertussis	O	O	B-Entity
confirmation	O	O	B-Entity
tests	O	O	I-Entity
used	O	O	O
,	O	O	O
public	O	O	B-Entity
awareness	O	O	B-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
real	O	O	O
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
magnitude	O	O	B-Entity
of	O	O	O
the	O	O	O
disease	O	O	O
,	O	O	O
or	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
these	O	O	O
factors	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	O
highlights	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
standardize	O	O	O
pertussis	O	O	B-Entity
detection	O	O	B-Entity
and	O	O	O
confirmation	O	O	B-Entity
in	O	O	O
surveillance	O	O	B-Entity
programs	O	O	I-Entity
across	O	O	O
Europe	O	O	B-Entity
,	O	O	O
complemented	O	O	O
with	O	O	O
carefully-designed	O	O	O
seroprevalence	O	O	B-Entity
studies	O	O	I-Entity
using	O	O	O
the	O	O	O
same	O	O	O
protocols	O	O	B-Entity
and	O	O	O
methodologies	O	O	B-Entity
.	O	O	O

-DOCSTART- (27259362)

Identification	O	O	B-Entity
and	O	O	O
characterization	O	O	B-Entity
of	O	O	O
Dichelobacter	O	O	B-Entity
nodosus	O	O	I-Entity
serogroup	O	O	B-Entity
H	O	O	I-Entity
from	O	O	O
ovine	O	O	B-Entity
footrot	O	O	B-Entity
in	O	O	O
India	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
56	O	O	O
foot	O	O	B-Entity
swabs	O	O	I-Entity
were	O	O	O
collected	O	O	O
from	O	O	O
inter	O	O	B-Entity
digital	O	O	I-Entity
spaces	O	O	I-Entity
of	O	O	O
sheep	O	O	B-Entity
with	O	O	O
footrot	O	O	B-Entity
lesions	O	O	B-Entity
were	O	O	O
screened	O	O	B-Entity
for	O	O	O
16	O	O	O
rRNA	O	O	B-Entity
of	O	O	O
Dichelobacter	O	O	B-Entity
nodosus	O	O	I-Entity
by	O	O	O
PCR	O	O	B-Entity
.	O	O	O

Out	O	O	O
of	O	O	O
the	O	O	O
56	O	O	O
samples	O	O	B-Entity
,	O	O	O
38(67.85	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
positive	O	O	B-Entity
.	O	O	O

All	O	O	O
the	O	O	O
positive	O	O	B-Entity
samples	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
multiplex	O	O	B-Entity
PCR	O	O	I-Entity
targeting	O	O	B-Entity
fimA	O	O	I-Entity
gene	O	O	I-Entity
for	O	O	O
identification	O	O	B-Entity
of	O	O	O
serogroups	O	O	B-Entity
of	O	O	O
D.	O	O	B-Entity
nodosus	O	O	I-Entity
.	O	O	O

Serogroup	O	O	B-Entity
H	O	O	I-Entity
was	O	O	O
found	O	O	O
along	O	O	O
with	O	O	O
serogroup	O	O	B-Entity
B	O	O	I-Entity
in	O	O	O
12	O	O	O
(	O	O	O
55.26	O	O	O
%	O	O	O
)	O	O	O
samples	O	O	B-Entity
and	O	O	O
with	O	O	O
serogroup	O	O	B-Entity
I	O	O	I-Entity
in	O	O	O
8	O	O	O
(	O	O	O
22.2	O	O	O
%	O	O	O
)	O	O	O
samples	O	O	O
.	O	O	O

The	O	O	O
serogroup	O	O	B-Entity
H	O	O	I-Entity
was	O	O	O
identified	O	O	B-Entity
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
from	O	O	O
the	O	O	O
Indian	O	O	B-Entity
subcontinent	O	O	I-Entity
.	O	O	O

The	O	O	O
phylogenetic	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
present	O	O	O
sequence	O	O	B-Entity
with	O	O	O
the	O	O	O
available	O	O	O
serogroup	O	O	B-Entity
H	O	O	I-Entity
sequences	O	O	B-Entity
of	O	O	O
GenBank	O	O	B-Entity
revealed	O	O	O
to	O	O	O
be	O	O	O
in	O	O	O
close	O	O	O
association	O	O	O
with	O	O	O
the	O	O	O
serotype	O	O	B-Entity
H1	O	O	I-Entity
.	O	O	O

-DOCSTART- (27265654)

Conservation	O	O	B-Entity
education	O	O	I-Entity
and	O	O	O
habitat	O	O	B-Entity
restoration	O	O	B-Entity
for	O	O	O
the	O	O	O
endangered	O	O	B-Entity
Sagalla	O	O	B-Entity
caecilian	O	O	I-Entity
(	O	O	O
Boulengerula	O	O	B-Entity
niedeni	O	O	I-Entity
)	O	O	O
in	O	O	O
Sagalla	O	O	B-Entity
Hill	O	O	I-Entity
,	O	O	O
Kenya	O	O	O

The	O	O	O
Sagalla	O	O	B-Entity
caecilian	O	O	I-Entity
(	O	O	O
Boulengerula	O	O	B-Entity
niedeni	O	O	I-Entity
)	O	O	O
is	O	O	O
an	O	O	O
endangered	O	O	B-Entity
amphibian	O	O	B-Entity
endemic	O	O	B-Entity
to	O	O	O
Sagalla	O	O	B-Entity
Hill	O	O	I-Entity
in	O	O	O
the	O	O	O
Taita	O	O	B-Entity
Hills	O	O	I-Entity
.	O	O	O

This	O	O	O
burrowing	O	O	B-Entity
worm	O	O	I-Entity
-like	O	O	O
species	O	O	B-Entity
prefers	O	O	O
soft	O	O	B-Entity
soil	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
moisture	O	O	B-Entity
and	O	O	O
organic	O	O	B-Entity
matter	O	O	I-Entity
.	O	O	O

The	O	O	O
major	O	O	B-Entity
threats	O	O	B-Entity
to	O	O	O
the	O	O	O
Sagalla	O	O	B-Entity
caecilian	O	O	I-Entity
are	O	O	O
soil	O	O	B-Entity
erosion	O	O	I-Entity
caused	O	O	B-Entity
by	O	O	O
steep	O	O	B-Entity
slopes	O	O	I-Entity
,	O	O	O
bare	O	O	O
ground	O	O	B-Entity
and	O	O	O
water	O	O	B-Entity
siphoning	O	O	I-Entity
/	O	O	O
soil	O	O	B-Entity
hardening	O	O	I-Entity
from	O	O	O
exotic	O	O	B-Entity
eucalyptus	O	O	I-Entity
trees	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
get	O	O	O
a	O	O	O
better	O	O	B-Entity
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
local	O	O	B-Entity
people	O	O	B-Entity
's	O	O	I-Entity
attitude	O	O	B-Entity
towards	O	O	O
this	O	O	O
species	O	O	B-Entity
and	O	O	O
how	O	O	O
they	O	O	O
can	O	O	O
contribute	O	O	B-Entity
to	O	O	O
its	O	O	O
continued	O	O	B-Entity
conservation	O	O	B-Entity
through	O	O	O
restoration	O	O	B-Entity
of	O	O	O
its	O	O	O
remaining	O	O	B-Entity
habitat	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
it	O	O	O
was	O	O	O
found	O	O	B-Entity
that	O	O	O
96	O	O	O
%	O	O	O
of	O	O	O
Sagalla	O	O	B-Entity
people	O	O	B-Entity
are	O	O	O
aware	O	O	B-Entity
of	O	O	O
the	O	O	O
species	O	O	B-Entity
,	O	O	O
its	O	O	O
habits	O	O	B-Entity
and	O	O	O
its	O	O	O
association	O	O	O
with	O	O	O
soils	O	O	B-Entity
high	O	O	B-Entity
in	O	O	O
organic	O	O	B-Entity
matter	O	O	I-Entity
.	O	O	O

It	O	O	O
was	O	O	O
also	O	O	O
found	O	O	B-Entity
that	O	O	O
96	O	O	O
%	O	O	O
of	O	O	O
Sagalla	O	O	B-Entity
people	O	O	B-Entity
use	O	O	O
organic	O	O	B-Entity
manure	O	O	B-Entity
from	O	O	O
cow	O	O	B-Entity
dung	O	O	B-Entity
in	O	O	O
their	O	O	O
farms	O	O	B-Entity
.	O	O	O

Habitat	O	O	B-Entity
restoration	O	O	B-Entity
through	O	O	O
planting	O	O	B-Entity
of	O	O	O
indigenous	O	O	B-Entity
plants	O	O	B-Entity
was	O	O	O
found	O	O	B-Entity
to	O	O	O
be	O	O	O
ongoing	O	O	B-Entity
,	O	O	O
especially	O	O	B-Entity
on	O	O	O
compounds	O	O	B-Entity
of	O	O	O
public	O	O	B-Entity
institutions	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
on	O	O	O
private	O	O	B-Entity
lands	O	O	I-Entity
.	O	O	O

Although	O	O	O
drought	O	O	B-Entity
was	O	O	O
found	O	O	B-Entity
to	O	O	O
be	O	O	O
a	O	O	O
challenge	O	O	O
for	O	O	O
seedlings	O	O	B-Entity
development	O	O	B-Entity
especially	O	O	O
on	O	O	O
the	O	O	O
low	O	O	B-Entity
elevation	O	O	B-Entity
sites	O	O	B-Entity
,	O	O	O
destruction	O	O	B-Entity
by	O	O	O
livestock	O	O	B-Entity
especially	O	O	O
during	O	O	B-Entity
the	O	O	O
dry	O	O	B-Entity
season	O	O	B-Entity
is	O	O	O
also	O	O	O
a	O	O	O
major	O	O	B-Entity
threat	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
it	O	O	O
was	O	O	O
recommended	O	O	B-Entity
that	O	O	O
any	O	O	O
future	O	O	B-Entity
habitat	O	O	B-Entity
restoration	O	O	B-Entity
initiative	O	O	B-Entity
should	O	O	O
include	O	O	B-Entity
strong	O	O	B-Entity
chain-link	O	O	B-Entity
fencing	O	O	B-Entity
to	O	O	O
protect	O	O	O
the	O	O	O
seedlings	O	O	B-Entity
from	O	O	O
livestock	O	O	B-Entity
activity	O	O	B-Entity
.	O	O	O

Recognizing	O	O	O
that	O	O	O
the	O	O	O
preferred	O	O	B-Entity
habitats	O	O	B-Entity
for	O	O	O
the	O	O	O
species	O	O	B-Entity
are	O	O	O
in	O	O	O
the	O	O	O
valleys	O	O	B-Entity
,	O	O	O
systematic	O	O	B-Entity
planting	O	O	B-Entity
of	O	O	O
keystone	O	O	B-Entity
plant	O	O	I-Entity
species	O	O	O
such	O	O	O
as	O	O	O
fig	O	O	B-Entity
trees	O	O	I-Entity
(	O	O	O
Ficus	O	O	B-Entity
)	O	O	O
creates	O	O	B-Entity
the	O	O	O
best	O	O	O
microhabitats	O	O	B-Entity
.	O	O	O

These	O	O	O
are	O	O	O
better	O	O	B-Entity
than	O	O	O
general	O	O	B-Entity
woodlots	O	O	B-Entity
of	O	O	O
indigenous	O	O	B-Entity
trees	O	O	B-Entity
.	O	O	O

-DOCSTART- (27266753)

The	O	O	O
clinical	O	O	B-Entity
and	O	O	O
economic	O	O	B-Entity
burden	O	O	B-Entity
of	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
during	O	O	B-Entity
lung	O	O	B-Entity
resection	O	O	I-Entity
surgery	O	O	I-Entity
:	O	O	O
A	O	O	O
retrospective	O	O	B-Entity
matched	O	O	I-Entity
cohort	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
real	O	O	B-Entity
-	O	O	O
world	O	O	B-Entity
data	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
quantify	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
and	O	O	O
economic	O	O	B-Entity
burden	O	O	B-Entity
of	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
in	O	O	O
lung	O	O	B-Entity
resection	O	O	I-Entity
surgery	O	O	I-Entity
in	O	O	O
the	O	O	O
US	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
utilized	O	O	B-Entity
2009	O	O	O
-	O	O	O
2012	O	O	O
data	O	O	B-Entity
from	O	O	O
the	O	O	O
Premier	O	O	B-Entity
Perspective	O	O	I-Entity
Database(TM	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
primary	O	O	B-Entity
pulmonary	O	O	I-Entity
lobectomy	O	O	I-Entity
or	O	O	O
segmentectomy	O	O	B-Entity
procedures	O	O	I-Entity
were	O	O	O
categorized	O	O	B-Entity
by	O	O	O
the	O	O	O
surgical	O	O	B-Entity
approach	O	O	I-Entity
(	O	O	O
VATS	O	O	B-Entity
vs	O	O	O
open	O	O	B-Entity
)	O	O	O
and	O	O	O
primary	O	O	B-Entity
diagnosis	O	O	I-Entity
(	O	O	O
primary	O	O	O
or	O	O	O
metastatic	O	O	B-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
vs	O	O	O
non-lung	O	O	B-Entity
cancer	O	O	I-Entity
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
requiring	O	O	O
≥3	O	O	O
units	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
products	O	O	I-Entity
with	O	O	O
at	O	O	B-Entity
least	O	O	I-Entity
1	O	O	O
unit	O	O	B-Entity
of	O	O	O
PRBCs	O	O	B-Entity
:	O	O	O
"	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
"	O	O	O
cohort	O	O	B-Entity
;	O	O	O
those	O	O	O
requiring	O	O	O
<3	O	O	O
units	O	O	O
:	O	O	O
"	O	O	O
non-significant	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
cohort	O	O	O
;	O	O	O
and	O	O	O
those	O	O	O
not	O	O	O
requiring	O	O	O
blood	O	O	O
products	O	O	O
:	O	O	O
"	O	O	O
no	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
cohort	O	O	O
.	O	O	O

A	O	O	O
matched	O	O	O
cohort	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
between	O	O	O
the	O	O	O
"	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
"	O	O	O
and	O	O	O
the	O	O	O
"	O	O	O
no	O	O	B-Entity
bleeding	O	O	O
cohort	O	O	O
"	O	O	O
using	O	O	O
matching	O	O	B-Entity
variables	O	O	I-Entity
:	O	O	O
hospital	O	O	B-Entity
,	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
diagnosis	O	O	I-Entity
,	O	O	O
year	O	O	B-Entity
of	O	O	I-Entity
surgery	O	O	I-Entity
,	O	O	O
APR-DRG	O	O	B-Entity
severity	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
procedure	O	O	B-Entity
type	O	O	I-Entity
and	O	O	O
approach	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
and	O	O	O
gender	O	O	B-Entity
.	O	O	O

The	O	O	O
"	O	O	O
All	O	O	B-Entity
-	O	O	O
patient	O	O	B-Entity
"	O	O	O
cohort	O	O	B-Entity
comprised	O	O	O
21,429	O	O	O
patients	O	O	B-Entity
:	O	O	O
213	O	O	O
"	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
"	O	O	O
;	O	O	O
2,780	O	O	O
"	O	O	O
non-significant	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
;	O	O	O
and	O	O	O
18,436	O	O	O
"	O	O	O
no	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
.	O	O	O

Overall	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
significant	O	O	B-Entity
chest	O	O	B-Entity
bleeding	O	O	B-Entity
was	O	O	O
0.99	O	O	O
%	O	O	O
.	O	O	O

Patients	O	O	B-Entity
from	O	O	O
"	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
"	O	O	O
cohort	O	O	B-Entity
and	O	O	O
"	O	O	O
non-significant	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
cohort	O	O	O
had	O	O	O
2.5	O	O	O
days	O	O	B-Entity
and	O	O	O
2	O	O	O
days	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
longer	O	O	B-Entity
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
in	O	O	O
the	O	O	O
hospital	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
"	O	O	O
no	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
cohort	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Overall	O	O	B-Entity
,	O	O	O
hospital	O	O	B-Entity
costs	O	O	I-Entity
for	O	O	O
"	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
"	O	O	O
cohort	O	O	B-Entity
were	O	O	O
higher	O	O	B-Entity
than	O	O	O
"	O	O	O
no	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
cohort	O	O	O
for	O	O	O
those	O	O	O
who	O	O	O
were	O	O	O
covered	O	O	B-Entity
under	O	O	O
Medicare	O	O	B-Entity
(	O	O	O
$	O	O	O
59,871	O	O	O
vs	O	O	O
$	O	O	O
23,641	O	O	O
)	O	O	O
,	O	O	O
were	O	O	O
≥76	O	O	O
years	O	O	B-Entity
of	O	O	I-Entity
age	O	O	I-Entity
(	O	O	O
$	O	O	O
64,010	O	O	O
vs	O	O	O
$	O	O	O
24,243	O	O	O
)	O	O	O
,	O	O	O
had	O	O	O
greater	O	O	B-Entity
severity	O	O	B-Entity
of	O	O	I-Entity
illness	O	O	I-Entity
(	O	O	O
$	O	O	O
97,813	O	O	O
vs	O	O	O
$	O	O	O
51,871	O	O	O
)	O	O	O
and	O	O	O
underwent	O	O	O
open	O	O	O
segmentectomy	O	O	B-Entity
(	O	O	O
$	O	O	O
74,220	O	O	O
vs	O	O	O
$	O	O	O
21,903	O	O	O
)	O	O	O
.	O	O	O

Hospital	O	O	B-Entity
costs	O	O	I-Entity
for	O	O	O
"	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
"	O	O	O
cohort	O	O	B-Entity
and	O	O	O
"	O	O	O
non-significant	O	O	B-Entity
bleeding	O	O	O
"	O	O	O
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	B-Entity
(	O	O	O
$	O	O	O
11,589	O	O	O
and	O	O	O
$	O	O	O
5,280	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
than	O	O	O
no	O	O	B-Entity
bleeding	O	O	O
cohort	O	O	O
.	O	O	O

Although	O	O	O
significant	O	O	B-Entity
bleeding	O	O	B-Entity
during	O	O	B-Entity
lung	O	O	B-Entity
resection	O	O	I-Entity
surgery	O	O	I-Entity
is	O	O	O
rare	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
such	O	O	O
complication	O	O	B-Entity
could	O	O	O
stay	O	O	B-Entity
longer	O	O	B-Entity
at	O	O	O
the	O	O	O
hospital	O	O	B-Entity
and	O	O	O
cost	O	O	B-Entity
an	O	O	O
average	O	O	O
of	O	O	O
$	O	O	O
13,103	O	O	O
more	O	O	O
than	O	O	O
those	O	O	O
without	O	O	O
.	O	O	O

-DOCSTART- (27266840)

Laceration	O	O	B-Entity
of	O	O	O
a	O	O	O
branch	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
profunda	O	O	B-Entity
femoris	O	O	I-Entity
artery	O	O	I-Entity
caused	O	O	B-Entity
by	O	O	O
a	O	O	O
spike	O	O	B-Entity
of	O	O	O
the	O	O	O
displaced	O	O	B-Entity
lesser	O	O	B-Entity
trochanter	O	O	I-Entity
in	O	O	O
an	O	O	O
inter-trochanteric	O	O	B-Entity
femoral	O	O	B-Entity
fracture	O	O	I-Entity
.	O	O	O
A	O	O	O
case	O	O	O
report	O	O	O

A	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
Injury	O	O	B-Entity
of	O	O	O
femoral	O	O	B-Entity
vessels	O	O	I-Entity
is	O	O	O
an	O	O	O
extremely	O	O	B-Entity
rare	O	O	B-Entity
complication	O	O	B-Entity
in	O	O	O
intertrochanteric	O	O	B-Entity
femoral	O	O	B-Entity
fractures	O	O	I-Entity
.	O	O	O

In	O	O	O
most	O	O	O
cases	O	O	B-Entity
reported	O	O	B-Entity
,	O	O	O
the	O	O	O
vascular	O	O	B-Entity
lesion	O	O	I-Entity
involves	O	O	B-Entity
the	O	O	O
superficial	O	O	B-Entity
femoral	O	O	I-Entity
artery	O	O	I-Entity
,	O	O	O
whereas	O	O	O
in	O	O	O
very	O	O	O
few	O	O	O
cases	O	O	O
does	O	O	O
it	O	O	O
involve	O	O	B-Entity
the	O	O	O
profunda	O	O	B-Entity
femoris	O	O	I-Entity
artery	O	O	I-Entity
.	O	O	O

We	O	O	O
report	O	O	B-Entity
a	O	O	O
case	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
bleeding	O	O	I-Entity
due	O	O	O
to	O	O	O
laceration	O	O	B-Entity
of	O	O	O
a	O	O	O
perforating	O	O	B-Entity
branch	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
profunda	O	O	B-Entity
femoris	O	O	I-Entity
artery	O	O	I-Entity
caused	O	O	B-Entity
by	O	O	O
a	O	O	O
sharp	O	O	B-Entity
fragment	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
displaced	O	O	B-Entity
lesser	O	O	B-Entity
trochanter	O	O	I-Entity
in	O	O	O
an	O	O	O
intertrochanteric	O	O	B-Entity
femoral	O	O	B-Entity
fracture	O	O	I-Entity
;	O	O	O
the	O	O	O
lesion	O	O	B-Entity
was	O	O	O
treated	O	O	B-Entity
by	O	O	O
transcatheter	O	O	B-Entity
embolization	O	O	I-Entity
.	O	O	O

The	O	O	O
arterial	O	O	B-Entity
injury	O	O	B-Entity
may	O	O	O
be	O	O	O
iatrogenic	O	O	B-Entity
,	O	O	O
occurring	O	O	B-Entity
during	O	O	O
intramedullary	O	O	B-Entity
internal	O	O	B-Entity
fixation	O	O	I-Entity
,	O	O	O
or	O	O	O
less	O	O	O
frequently	O	O	B-Entity
,	O	O	O
the	O	O	O
injury	O	O	O
may	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
fracture	O	O	B-Entity
itself	O	O	O
,	O	O	O
caused	O	O	B-Entity
by	O	O	O
a	O	O	O
sharp	O	O	B-Entity
bone	O	O	B-Entity
fragment	O	O	I-Entity
that	O	O	O
damages	O	O	B-Entity
the	O	O	O
profunda	O	O	B-Entity
femoris	O	O	I-Entity
artery	O	O	I-Entity
or	O	O	O
one	O	O	O
of	O	O	O
its	O	O	O
perforating	O	O	B-Entity
branches	O	O	B-Entity
.	O	O	O

We	O	O	O
believe	O	O	O
that	O	O	O
intertrochanteric	O	O	B-Entity
femoral	O	O	B-Entity
fractures	O	O	I-Entity
with	O	O	O
avulsed	O	O	B-Entity
lesser	O	O	B-Entity
trochanter	O	O	I-Entity
are	O	O	O
at	O	O	B-Entity
risk	O	O	I-Entity
for	O	O	O
femoral	O	O	B-Entity
vessel	O	O	I-Entity
injuries	O	O	B-Entity
caused	O	O	B-Entity
by	O	O	O
the	O	O	O
displaced	O	O	B-Entity
bone	O	O	B-Entity
spike	O	O	B-Entity
,	O	O	O
and	O	O	O
we	O	O	O
advise	O	O	O
meticulous	O	O	B-Entity
clinical	O	O	B-Entity
and	O	O	O
laboratory	O	O	B-Entity
monitoring	O	O	I-Entity
pre-	O	O	B-Entity
and	O	O	O
post-operatively	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
serious	O	O	I-Entity
complications	O	O	I-Entity
.	O	O	O

-DOCSTART- (27270311)

Direct	O	O	O
contact	O	O	O
with	O	O	O
perivascular	O	O	B-Entity
tumor	O	O	B-Entity
cells	O	O	I-Entity
enhances	O	O	O
integrin	O	O	B-Entity
αvβ3	O	O	I-Entity
signaling	O	O	B-Entity
and	O	O	O
migration	O	O	B-Entity
of	O	O	O
endothelial	O	O	O
cells	O	O	O

The	O	O	O
secretion	O	O	B-Entity
of	O	O	O
soluble	O	O	O
pro-angiogenic	O	O	B-Entity
factors	O	O	I-Entity
by	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
stromal	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
the	O	O	O
perivascular	O	O	B-Entity
niche	O	O	O
promotes	O	O	O
the	O	O	O
aggressive	O	O	B-Entity
angiogenesis	O	O	I-Entity
that	O	O	O
is	O	O	O
typical	O	O	O
of	O	O	O
glioblastoma	O	O	B-Entity
(	O	O	O
GBM	O	O	B-Entity
)	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
angiogenesis	O	O	B-Entity
also	O	O	O
can	O	O	O
be	O	O	O
promoted	O	O	O
by	O	O	O
a	O	O	O
direct	O	O	O
interaction	O	O	O
between	O	O	O
brain	O	O	B-Entity
tumor	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
including	O	O	O
tumor	O	O	O
cells	O	O	O
with	O	O	O
cancer	O	O	B-Entity
stem	O	O	I-Entity
-like	O	O	O
properties	O	O	O
(	O	O	O
CSCs	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
endothelial	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
ECs	O	O	B-Entity
)	O	O	O
.	O	O	O

As	O	O	O
shown	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
this	O	O	O
direct	O	O	O
interaction	O	O	O
is	O	O	O
mediated	O	O	O
by	O	O	O
binding	O	O	B-Entity
of	O	O	O
integrin	O	O	B-Entity
αvβ3	O	O	I-Entity
expressed	O	O	B-Entity
on	O	O	O
ECs	O	O	B-Entity
to	O	O	O
the	O	O	O
RGD-peptide	O	O	B-Entity
in	O	O	O
L1CAM	O	O	B-Entity
expressed	O	O	O
on	O	O	O
CSCs	O	O	B-Entity
.	O	O	O

It	O	O	O
promotes	O	O	O
both	O	O	O
EC	O	O	B-Entity
network	O	O	B-Entity
formation	O	O	I-Entity
and	O	O	O
enhances	O	O	O
directed	O	O	O
migration	O	O	B-Entity
toward	O	O	O
basic	O	O	O
fibroblast	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
.	O	O	O

Activation	O	O	B-Entity
of	O	O	O
αvβ3	O	O	B-Entity
and	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
tyrosine	O	O	I-Entity
kinase	O	O	I-Entity
on	O	O	I-Entity
chromosome	O	O	I-Entity
X	O	O	I-Entity
(	O	O	O
BMX	O	O	B-Entity
)	O	O	O
is	O	O	O
required	O	O	O
for	O	O	O
migration	O	O	B-Entity
stimulated	O	O	O
by	O	O	O
direct	O	O	O
binding	O	O	B-Entity
but	O	O	O
not	O	O	O
for	O	O	O
migration	O	O	O
stimulated	O	O	O
by	O	O	O
soluble	O	O	O
factors	O	O	O
.	O	O	O

RGD-peptide	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
mice	O	O	B-Entity
with	O	O	O
established	O	O	O
intracerebral	O	O	B-Entity
GBM	O	O	B-Entity
xenografts	O	O	B-Entity
significantly	O	O	O
reduced	O	O	O
the	O	O	O
percentage	O	O	O
of	O	O	O
Sox2	O	O	B-Entity
-positive	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
CSCs	O	O	B-Entity
in	O	O	O
close	O	O	O
proximity	O	O	O
to	O	O	O
ECs	O	O	B-Entity
,	O	O	O
decreased	O	O	O
integrin	O	O	B-Entity
αvβ3	O	O	I-Entity
and	O	O	O
BMX	O	O	B-Entity
activation	O	O	O
and	O	O	O
p130CAS	O	O	B-Entity
phosphorylation	O	O	B-Entity
in	O	O	O
the	O	O	O
ECs	O	O	O
,	O	O	O
and	O	O	O
reduced	O	O	O
the	O	O	O
vessel	O	O	B-Entity
surface	O	O	B-Entity
area	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
reveal	O	O	O
a	O	O	O
previously	O	O	O
unrecognized	O	O	O
aspect	O	O	O
of	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
angiogenesis	O	O	B-Entity
in	O	O	O
GBM	O	O	B-Entity
that	O	O	O
can	O	O	O
impact	O	O	O
therapeutic	O	O	B-Entity
anti-angiogenic	O	O	B-Entity
targeting	O	O	O
.	O	O	O

-DOCSTART- (27270753)

The	O	O	O
use	O	O	O
of	O	O	O
Ocimum	O	O	B-Entity
americanum	O	O	I-Entity
essential	O	O	B-Entity
oil	O	O	I-Entity
against	O	O	O
the	O	O	O
pathogens	O	O	B-Entity
Aeromonas	O	O	B-Entity
hydrophila	O	O	I-Entity
and	O	O	O
Gyrodactylus	O	O	B-Entity
sp.	O	O	I-Entity
in	O	O	O
silver	O	O	B-Entity
catfish	O	O	I-Entity
(	O	O	O
Rhamdia	O	O	B-Entity
quelen	O	O	I-Entity
)	O	O	O

The	O	O	O
bactericidal	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
MIC-test	O	O	B-Entity
)	O	O	O
of	O	O	O
Ocimum	O	O	B-Entity
americanum	O	O	I-Entity
(	O	O	O
inflorescences	O	O	B-Entity
)	O	O	O
essential	O	O	B-Entity
oil	O	O	I-Entity
(	O	O	O
OAEO	O	O	B-Entity
)	O	O	O
against	O	O	O
Aeromonas	O	O	B-Entity
hydrophila	O	O	I-Entity
was	O	O	O
determined	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
also	O	O	O
investigated	O	O	O
the	O	O	O
potential	O	O	O
of	O	O	O
OAEO	O	O	B-Entity
and	O	O	O
the	O	O	O
main	O	O	O
compound	O	O	B-Entity
found	O	O	O
in	O	O	O
the	O	O	O
oil	O	O	B-Entity
(	O	O	O
linalool	O	O	B-Entity
)	O	O	O
at	O	O	O
subinhibitory	O	O	O
concentrations	O	O	O
to	O	O	O
be	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
hemolysis	O	O	B-Entity
caused	O	O	O
by	O	O	O
Aer	O	O	O
.	O	O	O

hydrophila	O	O	O
in	O	O	O
fish	O	O	B-Entity
erythrocytes	O	O	B-Entity
.	O	O	O

An	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
experiment	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
evaluate	O	O	O
survival	O	O	B-Entity
of	O	O	O
fish	O	O	B-Entity
(	O	O	O
Rhamdia	O	O	B-Entity
quelen	O	O	I-Entity
)	O	O	O
experimentally	O	O	B-Entity
infected	O	O	B-Entity
with	O	O	O
Aer	O	O	O
.	O	O	O

hydrophila	O	O	O
and	O	O	O
exposed	O	O	B-Entity
to	O	O	O
OAEO	O	O	B-Entity
.	O	O	O

A	O	O	O
second	O	O	O
experiment	O	O	B-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
activity	O	O	O
of	O	O	O
OAEO	O	O	B-Entity
(	O	O	O
mix	O	O	O
from	O	O	O
inflorescences	O	O	B-Entity
and	O	O	O
leaves	O	O	B-Entity
)	O	O	O
against	O	O	O
the	O	O	O
parasite	O	O	B-Entity
Gyrodactylus	O	O	I-Entity
sp.	O	O	I-Entity
The	O	O	O
OAEO	O	O	O
showed	O	O	O
weak	O	O	B-Entity
in	O	O	O
vitro	O	O	O
activity	O	O	O
against	O	O	O
Aer	O	O	O
.	O	O	O

hydrophila	O	O	O
(	O	O	O
6400	O	O	O
μg	O	O	O
ml(-1	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

At	O	O	O
subinhibitory	O	O	O
concentrations	O	O	O
OAEO	O	O	B-Entity
(	O	O	O
100	O	O	O
μg	O	O	O
ml(-1	O	O	O
)	O	O	O
)	O	O	O
inhibited	O	O	B-Entity
hemolysis	O	O	B-Entity
(	O	O	O
90	O	O	O
%	O	O	O
)	O	O	O
caused	O	O	O
by	O	O	O
Aer	O	O	O
.	O	O	O

hydrophila	O	O	O
in	O	O	O
fish	O	O	B-Entity
erythrocytes	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
linalool	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
present	O	O	I-Entity
hemolysis	O	O	B-Entity
inhibition	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

At	O	O	O
low	O	O	O
concentrations	O	O	O
(	O	O	O
10	O	O	O
and	O	O	O
20	O	O	O
mg	O	O	O
l(-1	O	O	O
)	O	O	O
)	O	O	O
added	O	O	O
to	O	O	O
the	O	O	O
water	O	O	B-Entity
OAEO	O	O	B-Entity
promoted	O	O	B-Entity
survival	O	O	B-Entity
of	O	O	O
experimentally	O	O	O
infected	O	O	B-Entity
fish	O	O	B-Entity
with	O	O	O
Aer	O	O	O
.	O	O	O

hydrophila	O	O	O
.	O	O	O

Lastly	O	O	O
,	O	O	O
OAEO	O	O	B-Entity
-mix	O	O	O
(	O	O	O
50	O	O	O
mg	O	O	O
l(-1	O	O	O
)	O	O	O
)	O	O	O
was	O	O	O
effective	O	O	B-Entity
against	O	O	O
Gyrodactylus	O	O	B-Entity
sp.	O	O	I-Entity
significantly	O	O	B-Entity
reducing	O	O	I-Entity
(	O	O	O
60	O	O	O
%	O	O	O
)	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
parasites	O	O	B-Entity
in	O	O	O
the	O	O	O
fish	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (27271770)

Interleukin-1β	O	O	B-Entity
induced	O	O	O
Stress	O	O	B-Entity
Granules	O	O	I-Entity
Sequester	O	O	B-Entity
COX-2	O	O	B-Entity
mRNA	O	O	B-Entity
and	O	O	O
Regulates	O	O	B-Entity
its	O	O	O
Stability	O	O	B-Entity
and	O	O	O
Translation	O	O	B-Entity
in	O	O	O
Human	O	O	B-Entity
OA	O	O	B-Entity
Chondrocytes	O	O	O

Enhanced	O	O	B-Entity
and	O	O	O
immediate	O	O	O
expression	O	O	B-Entity
of	O	O	O
cyclooxygenase-2	O	O	B-Entity
(	O	O	O
COX-2	O	O	B-Entity
)	O	O	O
mRNA	O	O	B-Entity
is	O	O	O
observed	O	O	O
in	O	O	O
IL-1β	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
OA	O	O	B-Entity
chondrocytes	O	O	B-Entity
but	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
of	O	O	I-Entity
protein	O	O	I-Entity
found	O	O	O
significantly	O	O	O
delayed	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
stress	O	O	B-Entity
granules	O	O	I-Entity
(	O	O	O
SGs	O	O	B-Entity
)	O	O	O
,	O	O	O
ribonucleoprotein	O	O	B-Entity
complexes	O	O	I-Entity
that	O	O	O
regulate	O	O	B-Entity
mRNA	O	O	B-Entity
translation	O	O	B-Entity
,	O	O	O
in	O	O	O
the	O	O	O
delayed	O	O	B-Entity
translation	O	O	O
of	O	O	O
COX-2	O	O	B-Entity
mRNAs	O	O	B-Entity
in	O	O	O
IL-1β	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
OA	O	O	B-Entity
chondrocytes	O	O	B-Entity
.	O	O	O

Stimulation	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
chondrocytes	O	O	B-Entity
with	O	O	O
IL-1β	O	O	B-Entity
activated	O	O	O
the	O	O	O
stress	O	O	B-Entity
response	O	O	I-Entity
genes	O	O	B-Entity
and	O	O	O
the	O	O	O
phosphorylation	O	O	B-Entity
of	O	O	O
eIF2α	O	O	B-Entity
that	O	O	O
triggered	O	O	B-Entity
the	O	O	O
assembly	O	O	B-Entity
of	O	O	I-Entity
SGs	O	O	I-Entity
.	O	O	O

Using	O	O	O
combined	O	O	O
immunofluorescence	O	O	B-Entity
staining	O	O	I-Entity
of	O	O	O
SGs	O	O	B-Entity
markers	O	O	B-Entity
and	O	O	O
COX-2	O	O	B-Entity
protein	O	O	I-Entity
,	O	O	O
RNA	O	O	B-Entity
fluorescence	O	O	B-Entity
in	O	O	I-Entity
situ	O	O	I-Entity
hybridization	O	O	I-Entity
and	O	O	O
RNA	O	O	O
immunoprecipitation	O	O	B-Entity
,	O	O	O
the	O	O	O
COX-2	O	O	O
mRNAs	O	O	B-Entity
were	O	O	O
found	O	O	O
sequestered	O	O	B-Entity
in	O	O	O
SGs	O	O	O
in	O	O	O
IL-1β	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
OA	O	O	B-Entity
chondrocytes	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
COX-2	O	O	B-Entity
protein	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
observed	O	O	O
during	O	O	O
the	O	O	O
persistence	O	O	B-Entity
of	O	O	O
SGs	O	O	B-Entity
but	O	O	O
enhanced	O	O	B-Entity
expression	O	O	O
of	O	O	O
COX-2	O	O	B-Entity
protein	O	O	I-Entity
was	O	O	O
noted	O	O	O
upon	O	O	O
clearance	O	O	B-Entity
of	O	O	O
the	O	O	O
SGs	O	O	O
.	O	O	O

Inhibition	O	O	B-Entity
of	O	O	O
SGs	O	O	B-Entity
clearance	O	O	B-Entity
blocked	O	O	B-Entity
COX-2	O	O	B-Entity
mRNA	O	O	B-Entity
translation	O	O	B-Entity
whereas	O	O	O
blocking	O	O	B-Entity
the	O	O	O
assembly	O	O	B-Entity
of	O	O	I-Entity
SGs	O	O	I-Entity
by	O	O	O
TIA-1	O	O	B-Entity
depletion	O	O	B-Entity
resulted	O	O	O
in	O	O	O
rapid	O	O	O
and	O	O	O
increased	O	O	B-Entity
production	O	O	B-Entity
of	O	O	O
COX-2	O	O	O
and	O	O	O
PGE2	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	O
show	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
assembly	O	O	B-Entity
of	O	O	I-Entity
SGs	O	O	I-Entity
and	O	O	O
sequestration	O	O	B-Entity
of	O	O	O
COX-2	O	O	B-Entity
mRNAs	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
OA	O	O	B-Entity
chondrocytes	O	O	B-Entity
under	O	O	O
pathological	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

Post-transcriptional	O	O	B-Entity
regulation	O	O	I-Entity
of	O	O	O
COX-2	O	O	B-Entity
mRNAs	O	O	B-Entity
translation	O	O	I-Entity
by	O	O	O
SGs	O	O	B-Entity
indicates	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
IL-1β	O	O	B-Entity
-mediated	O	O	O
catabolic	O	O	B-Entity
response	O	O	B-Entity
that	O	O	O
could	O	O	O
be	O	O	O
therapeutically	O	O	B-Entity
targeted	O	O	O
in	O	O	O
OA	O	O	B-Entity
.	O	O	O

-DOCSTART- (27271969)

Spatio-Temporal	O	O	B-Entity
Distribution	O	O	I-Entity
of	O	O	O
Bark	O	O	B-Entity
and	O	O	O
Ambrosia	O	O	B-Entity
Beetles	O	O	B-Entity
in	O	O	O
a	O	O	O
Brazilian	O	O	B-Entity
Tropical	O	O	O
Dry	O	O	O
Forest	O	O	O

Bark	O	O	B-Entity
and	O	O	O
the	O	O	O
ambrosia	O	O	B-Entity
beetles	O	O	B-Entity
dig	O	O	O
into	O	O	O
host	O	O	B-Entity
plants	O	O	I-Entity
and	O	O	O
live	O	O	O
most	O	O	O
of	O	O	O
their	O	O	O
lives	O	O	O
in	O	O	O
concealed	O	O	O
tunnels	O	O	B-Entity
.	O	O	O

We	O	O	O
assessed	O	O	B-Entity
beetle	O	O	B-Entity
community	O	O	B-Entity
dynamics	O	O	B-Entity
in	O	O	O
tropical	O	O	B-Entity
dry	O	O	I-Entity
forest	O	O	I-Entity
sites	O	O	B-Entity
in	O	O	O
early	O	O	B-Entity
,	O	O	O
intermediate	O	O	B-Entity
,	O	O	O
and	O	O	O
late	O	O	B-Entity
successional	O	O	B-Entity
stages	O	O	I-Entity
,	O	O	O
evaluating	O	O	O
the	O	O	O
influence	O	O	O
of	O	O	O
resource	O	O	B-Entity
availability	O	O	B-Entity
and	O	O	O
seasonal	O	O	B-Entity
variations	O	O	I-Entity
in	O	O	O
guild	O	O	B-Entity
structure	O	O	I-Entity
.	O	O	O

We	O	O	O
collected	O	O	B-Entity
a	O	O	O
total	O	O	O
of	O	O	O
763	O	O	O
beetles	O	O	B-Entity
from	O	O	O
23	O	O	O
species	O	O	B-Entity
,	O	O	O
including	O	O	O
14	O	O	O
bark	O	O	B-Entity
beetle	O	O	B-Entity
species	O	O	O
,	O	O	O
and	O	O	O
9	O	O	O
ambrosia	O	O	B-Entity
beetle	O	O	O
species	O	O	O
.	O	O	O

Local	O	O	B-Entity
richness	O	O	B-Entity
of	O	O	O
bark	O	O	B-Entity
and	O	O	O
ambrosia	O	O	B-Entity
beetles	O	O	B-Entity
was	O	O	O
estimated	O	O	O
at	O	O	O
31	O	O	O
species	O	O	B-Entity
.	O	O	O

Bark	O	O	B-Entity
and	O	O	O
ambrosia	O	O	B-Entity
composition	O	O	B-Entity
was	O	O	O
similar	O	O	O
over	O	O	O
the	O	O	O
successional	O	O	B-Entity
stages	O	O	I-Entity
gradient	O	O	B-Entity
,	O	O	O
and	O	O	O
beta	O	O	B-Entity
diversity	O	O	I-Entity
among	O	O	O
sites	O	O	B-Entity
was	O	O	O
primarily	O	O	O
determined	O	O	O
by	O	O	O
species	O	O	B-Entity
turnover	O	O	O
,	O	O	O
mainly	O	O	O
in	O	O	O
the	O	O	O
bark	O	O	B-Entity
beetle	O	O	B-Entity
community	O	O	B-Entity
.	O	O	O

Bark	O	O	B-Entity
beetle	O	O	B-Entity
richness	O	O	B-Entity
and	O	O	O
abundance	O	O	B-Entity
were	O	O	O
higher	O	O	O
at	O	O	O
intermediate	O	O	B-Entity
stages	O	O	I-Entity
;	O	O	O
availability	O	O	B-Entity
of	O	O	I-Entity
wood	O	O	B-Entity
was	O	O	O
the	O	O	O
main	O	O	O
spatial	O	O	B-Entity
mechanism	O	O	I-Entity
.	O	O	O

Climate	O	O	B-Entity
factors	O	O	B-Entity
were	O	O	O
effectively	O	O	O
non-seasonal	O	O	B-Entity
.	O	O	O

Ambrosia	O	O	B-Entity
beetles	O	O	B-Entity
were	O	O	O
not	O	O	O
influenced	O	O	O
by	O	O	O
successional	O	O	B-Entity
stages	O	O	I-Entity
,	O	O	O
however	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
wood	O	O	B-Entity
resulted	O	O	O
in	O	O	O
increased	O	O	B-Entity
abundance	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
higher	O	O	O
richness	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
dry	O	O	B-Entity
and	O	O	O
wet	O	O	B-Entity
seasons	O	O	I-Entity
,	O	O	O
and	O	O	O
abundance	O	O	B-Entity
increased	O	O	B-Entity
with	O	O	O
air	O	O	B-Entity
moisture	O	O	B-Entity
and	O	O	O
decreased	O	O	O
with	O	O	O
higher	O	O	O
temperatures	O	O	B-Entity
and	O	O	O
greater	O	O	O
rainfall	O	O	B-Entity
.	O	O	O

In	O	O	O
summary	O	O	O
,	O	O	O
bark	O	O	B-Entity
beetle	O	O	B-Entity
species	O	O	B-Entity
accumulation	O	O	B-Entity
was	O	O	O
higher	O	O	O
at	O	O	O
sites	O	O	B-Entity
with	O	O	O
better	O	O	O
wood	O	O	B-Entity
production	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
needs	O	O	O
of	O	O	O
fungi	O	O	B-Entity
(	O	O	O
host	O	O	B-Entity
and	O	O	O
air	O	O	B-Entity
moisture	O	O	B-Entity
)	O	O	O
,	O	O	O
resulted	O	O	O
in	O	O	O
a	O	O	O
favorable	O	O	O
conditions	O	O	B-Entity
for	O	O	O
species	O	O	O
accumulation	O	O	O
of	O	O	O
ambrosia	O	O	B-Entity
.	O	O	O

The	O	O	O
overall	O	O	O
biological	O	O	B-Entity
pattern	O	O	B-Entity
among	O	O	O
guilds	O	O	O
differed	O	O	O
from	O	O	O
tropical	O	O	B-Entity
rain	O	O	I-Entity
forests	O	O	I-Entity
,	O	O	O
showing	O	O	O
patterns	O	O	O
similar	O	O	O
to	O	O	O
dry	O	O	B-Entity
forest	O	O	I-Entity
areas	O	O	I-Entity
.	O	O	O

-DOCSTART- (27272784)

Detection	O	O	B-Entity
and	O	O	O
Characterization	O	O	O
of	O	O	O
Flat	O	O	B-Entity
Aberrant	O	O	I-Entity
Crypt	O	O	I-Entity
Foci	O	O	I-Entity
(	O	O	I-Entity
Flat	O	O	I-Entity
ACF	O	O	I-Entity
)	O	O	I-Entity
in	O	O	O
the	O	O	O
Novel	O	O	O
A/J	O	O	O
Min/+	O	O	O
Mouse	O	O	O

Flat	O	O	B-Entity
aberrant	O	O	I-Entity
crypt	O	O	I-Entity
foci	O	O	I-Entity
(	O	O	O
flat	O	O	B-Entity
ACF	O	O	I-Entity
)	O	O	O
and	O	O	O
mucin-depleted	O	O	B-Entity
foci	O	O	I-Entity
(	O	O	O
MDF	O	O	B-Entity
)	O	O	O
have	O	O	O
previously	O	O	O
been	O	O	O
described	O	O	O
as	O	O	O
preneoplastic	O	O	B-Entity
colonic	O	O	I-Entity
lesions	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
the	O	O	O
novel	O	O	O
A/J	O	O	B-Entity
Min/+	O	O	I-Entity
mouse	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
that	O	O	O
demonstrates	O	O	O
extensive	O	O	O
spontaneous	O	O	O
colon	O	O	B-Entity
carcinogenesis	O	O	I-Entity
to	O	O	O
refine	O	O	O
the	O	O	O
method	O	O	O
of	O	O	O
detection	O	O	B-Entity
of	O	O	O
flat	O	O	B-Entity
ACF	O	O	I-Entity
and	O	O	O
further	O	O	O
characterize	O	O	O
and	O	O	O
define	O	O	O
them	O	O	O
as	O	O	O
early	O	O	O
lesions	O	O	B-Entity
by	O	O	O
histological	O	O	B-Entity
examination	O	O	I-Entity
and	O	O	O
comparison	O	O	O
with	O	O	O
MDF	O	O	B-Entity
.	O	O	O

Colons	O	O	B-Entity
were	O	O	O
stained	O	O	B-Entity
with	O	O	I-Entity
methylene	O	O	I-Entity
blue	O	O	I-Entity
(	O	O	O
MB	O	O	B-Entity
)	O	O	O
for	O	O	O
flat	O	O	B-Entity
ACF	O	O	I-Entity
detection	O	O	B-Entity
and	O	O	O
restained	O	O	B-Entity
with	O	O	O
high-iron	O	O	B-Entity
diamine-alcian	O	O	I-Entity
blue	O	O	I-Entity
(	O	O	O
HID-AB	O	O	B-Entity
)	O	O	O
for	O	O	O
MDF	O	O	B-Entity
detection	O	O	O
.	O	O	O

Optimal	O	O	O
flat	O	O	B-Entity
ACF	O	O	I-Entity
recognition	O	O	O
required	O	O	O
at	O	O	O
least	O	O	O
24	O	O	O
h	O	O	O
of	O	O	O
storage	O	O	O
post-	O	O	O
MB	O	O	B-Entity
staining	O	O	I-Entity
and	O	O	O
adherence	O	O	O
to	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
characteristics	O	O	O
.	O	O	O

The	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
flat	O	O	B-Entity
ACF	O	O	I-Entity
corresponding	O	O	O
with	O	O	O
MDF	O	O	B-Entity
was	O	O	O
93	O	O	O
%	O	O	O
.	O	O	O

Flat	O	O	B-Entity
ACF	O	O	I-Entity
/	O	O	O
MDF	O	O	B-Entity
displayed	O	O	O
the	O	O	O
same	O	O	O
picture	O	O	O
of	O	O	O
severe	O	O	B-Entity
dysplasia	O	O	I-Entity
,	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
mucus	O	O	B-Entity
and	O	O	O
goblet	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
cytoplasmic	O	O	B-Entity
β-catenin	O	O	B-Entity
.	O	O	O

The	O	O	O
easily	O	O	O
detectable	O	O	O
flat	O	O	B-Entity
ACF	O	O	I-Entity
are	O	O	O
reliable	O	O	O
surface	O	O	B-Entity
biomarkers	O	O	B-Entity
of	O	O	O
Apc	O	O	B-Entity
-driven	O	O	O
colon	O	O	B-Entity
carcinogenesis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27273160)

Transcriptional	O	O	B-Entity
enhancement	O	O	I-Entity
of	O	O	O
Smn	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
motoneurons	O	O	B-Entity
is	O	O	O
crucial	O	O	O
for	O	O	O
proper	O	O	O
axon	O	O	B-Entity
morphology	O	O	B-Entity
in	O	O	O
zebrafish	O	O	O

An	O	O	O
unresolved	O	O	O
mystery	O	O	O
in	O	O	O
the	O	O	O
field	O	O	O
of	O	O	O
spinal	O	O	B-Entity
muscular	O	O	I-Entity
atrophy	O	O	I-Entity
(	O	O	O
SMA	O	O	B-Entity
)	O	O	O
is	O	O	O
why	O	O	O
a	O	O	O
reduction	O	O	O
of	O	O	O
the	O	O	O
ubiquitously	O	O	O
expressed	O	O	O
Smn	O	O	B-Entity
protein	O	O	I-Entity
causes	O	O	O
defects	O	O	B-Entity
mostly	O	O	O
in	O	O	O
motoneurons	O	O	B-Entity
.	O	O	O

We	O	O	O
addressed	O	O	O
the	O	O	O
possibility	O	O	O
that	O	O	O
this	O	O	O
restricted	O	O	O
vulnerability	O	O	O
stems	O	O	O
from	O	O	O
elevated	O	O	O
Smn	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
motoneurons	O	O	B-Entity
.	O	O	O

To	O	O	O
explore	O	O	O
this	O	O	O
,	O	O	O
we	O	O	O
established	O	O	O
an	O	O	O
ex	O	O	B-Entity
vivo	O	O	I-Entity
zebrafish	O	O	B-Entity
culture	O	O	I-Entity
system	O	O	I-Entity
of	O	O	O
GFP	O	O	B-Entity
-	O	O	O
marked	O	O	B-Entity
motoneurons	O	O	B-Entity
to	O	O	O
quantitatively	O	O	O
measure	O	O	O
Smn	O	O	B-Entity
protein	O	O	I-Entity
and	O	O	O
smn	O	O	B-Entity
mRNA	O	O	I-Entity
levels	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
promoter	O	O	O
activity	O	O	O
in	O	O	O
motoneurons	O	O	O
versus	O	O	O
other	O	O	O
cell	O	O	B-Entity
types	O	O	O
.	O	O	O

Importantly	O	O	O
,	O	O	O
we	O	O	O
uncovered	O	O	O
that	O	O	O
Smn	O	O	B-Entity
levels	O	O	I-Entity
are	O	O	O
elevated	O	O	O
in	O	O	O
motoneurons	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
transcriptional	O	O	B-Entity
activation	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	O
the	O	O	O
ETS	O	O	B-Entity
family	O	O	I-Entity
transcription	O	O	I-Entity
factor	O	O	I-Entity
Etv5b	O	O	I-Entity
to	O	O	O
be	O	O	O
responsible	O	O	O
for	O	O	O
increased	O	O	O
smn	O	O	B-Entity
transcription	O	O	I-Entity
in	O	O	O
motoneurons	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
we	O	O	O
established	O	O	O
that	O	O	O
the	O	O	O
additional	O	O	O
supply	O	O	O
of	O	O	O
Smn	O	O	B-Entity
protein	O	O	I-Entity
in	O	O	O
motoneurons	O	O	B-Entity
is	O	O	O
necessary	O	O	O
for	O	O	O
proper	O	O	O
axonogenesis	O	O	B-Entity
in	O	O	O
a	O	O	O
cell-autonomous	O	O	B-Entity
manner	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
demonstrate	O	O	O
the	O	O	O
reliance	O	O	O
of	O	O	O
motoneurons	O	O	B-Entity
on	O	O	O
more	O	O	O
Smn	O	O	B-Entity
,	O	O	O
thereby	O	O	O
adding	O	O	O
a	O	O	O
novel	O	O	O
piece	O	O	O
of	O	O	O
evidence	O	O	B-Entity
for	O	O	O
their	O	O	O
increased	O	O	B-Entity
vulnerability	O	O	B-Entity
under	O	O	O
SMA	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

-DOCSTART- (27274281)

Evaluation	O	O	B-Entity
of	O	O	O
response	O	O	O
from	O	O	O
axitinib	O	O	B-Entity
per	O	O	O
Response	O	O	B-Entity
Evaluation	O	O	I-Entity
Criteria	O	O	I-Entity
in	O	O	I-Entity
Solid	O	O	I-Entity
Tumors	O	O	I-Entity
versus	O	O	O
Choi	O	O	B-Entity
criteria	O	O	I-Entity
in	O	O	O
previously	O	O	O
treated	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
metastatic	O	O	O
renal	O	O	O
cell	O	O	O
carcinoma	O	O	O

Axitinib	O	O	B-Entity
,	O	O	O
a	O	O	O
selective	O	O	O
and	O	O	O
potent	O	O	O
tyrosine	O	O	B-Entity
kinase	O	O	I-Entity
inhibitor	O	O	I-Entity
of	O	O	O
vascular	O	O	B-Entity
endothelial	O	O	I-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
receptors	O	O	I-Entity
,	O	O	O
was	O	O	O
available	O	O	O
to	O	O	O
patients	O	O	B-Entity
from	O	O	O
Canada	O	O	B-Entity
and	O	O	O
Australia	O	O	B-Entity
,	O	O	O
prior	O	O	O
to	O	O	O
regulatory	O	O	O
approval	O	O	B-Entity
of	O	O	O
axitinib	O	O	B-Entity
in	O	O	O
these	O	O	O
countries	O	O	B-Entity
,	O	O	O
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
clear-cell	O	O	B-Entity
metastatic	O	O	I-Entity
renal	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
mRCC	O	O	B-Entity
)	O	O	O
after	O	O	O
failure	O	O	O
of	O	O	O
one	O	O	O
prior	O	O	O
systemic	O	O	O
regimen	O	O	B-Entity
.	O	O	O

This	O	O	O
single-arm	O	O	B-Entity
,	O	O	O
open-label	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
axitinib	O	O	B-Entity
evaluated	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
,	O	O	O
safety	O	O	B-Entity
,	O	O	O
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
QoL	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
mRCC	O	O	B-Entity
whose	O	O	O
disease	O	O	B-Entity
progressed	O	O	B-Entity
after	O	O	O
one	O	O	O
prior	O	O	O
systemic	O	O	O
first-line	O	O	B-Entity
regimen	O	O	I-Entity
.	O	O	O

Primary	O	O	O
objective	O	O	O
was	O	O	O
objective	O	O	O
response	O	O	B-Entity
rate	O	O	I-Entity
evaluated	O	O	B-Entity
per	O	O	O
Response	O	O	B-Entity
Evaluation	O	O	I-Entity
Criteria	O	O	I-Entity
in	O	O	I-Entity
Solid	O	O	I-Entity
Tumors	O	O	I-Entity
(	O	O	O
RECIST	O	O	B-Entity
)	O	O	O
and	O	O	O
Choi	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

Progression-free	O	O	B-Entity
survival	O	O	I-Entity
,	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
,	O	O	O
safety	O	O	B-Entity
,	O	O	O
and	O	O	O
QoL	O	O	B-Entity
were	O	O	O
secondary	O	O	O
end	O	O	O
points	O	O	O
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
small	O	O	O
study	O	O	B-Entity
size	O	O	O
,	O	O	O
analyses	O	O	O
comprised	O	O	O
of	O	O	O
descriptive	O	O	O
statistics	O	O	B-Entity
.	O	O	O

Fifteen	O	O	O
patients	O	O	B-Entity
were	O	O	O
recruited	O	O	O
,	O	O	O
five	O	O	O
from	O	O	O
Canada	O	O	B-Entity
and	O	O	O
ten	O	O	O
from	O	O	O
Australia	O	O	B-Entity
,	O	O	O
over	O	O	O
a	O	O	O
limited	O	O	O
recruitment	O	O	O
period	O	O	O
.	O	O	O

Thirteen	O	O	O
patients	O	O	B-Entity
received	O	O	O
sunitinib	O	O	B-Entity
as	O	O	O
prior	O	O	O
therapy	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
had	O	O	O
clear-cell	O	O	B-Entity
carcinoma	O	O	I-Entity
,	O	O	O
eleven	O	O	O
had	O	O	O
prior	O	O	O
nephrectomy	O	O	B-Entity
.	O	O	O

Liver	O	O	B-Entity
,	O	O	O
lung	O	O	B-Entity
,	O	O	O
and	O	O	O
lymph	O	O	B-Entity
nodes	O	O	I-Entity
were	O	O	O
the	O	O	O
most	O	O	O
frequent	O	O	O
sites	O	O	O
of	O	O	O
metastases	O	O	B-Entity
;	O	O	O
one	O	O	O
patient	O	O	B-Entity
had	O	O	O
brain	O	O	B-Entity
metastasis	O	O	I-Entity
.	O	O	O

Median	O	O	B-Entity
time	O	O	O
on	O	O	O
axitinib	O	O	B-Entity
was	O	O	O
118.0	O	O	O
days	O	O	B-Entity
(	O	O	O
range	O	O	B-Entity
:	O	O	O
3.5	O	O	O
-	O	O	O
645.0	O	O	O
days	O	O	O
)	O	O	O
;	O	O	O
estimated	O	O	O
survival	O	O	B-Entity
probability	O	O	O
at	O	O	O
12	O	O	O
months	O	O	B-Entity
was	O	O	O
57.8	O	O	O
%	O	O	O
.	O	O	O

Two	O	O	O
(	O	O	O
13.3	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
had	O	O	O
objective	O	O	O
responses	O	O	B-Entity
per	O	O	O
RECIST	O	O	B-Entity
versus	O	O	O
nine	O	O	O
(	O	O	O
60.0	O	O	O
%	O	O	O
)	O	O	O
per	O	O	O
Choi	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

Six	O	O	O
patients	O	O	B-Entity
had	O	O	O
progressive	O	O	B-Entity
disease	O	O	B-Entity
based	O	O	O
on	O	O	O
RECIST	O	O	B-Entity
versus	O	O	O
three	O	O	O
per	O	O	O
Choi	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

Nine	O	O	O
(	O	O	O
60.0	O	O	O
%	O	O	O
)	O	O	O
events	O	O	O
of	O	O	O
progression	O	O	B-Entity
or	O	O	O
death	O	O	B-Entity
occurred	O	O	O
by	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
study	O	O	B-Entity
,	O	O	O
and	O	O	O
three	O	O	O
patients	O	O	B-Entity
continued	O	O	O
to	O	O	O
receive	O	O	O
the	O	O	O
study	O	O	O
drug	O	O	B-Entity
.	O	O	O

Fatigue	O	O	B-Entity
(	O	O	O
33	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
diarrhea	O	O	B-Entity
(	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
grade	O	O	O
≥3	O	O	O
all-causality	O	O	O
,	O	O	O
treatment	O	O	B-Entity
-emergent	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
change	O	O	O
in	O	O	O
European	O	O	B-Entity
Quality	O	O	B-Entity
of	O	O	I-Entity
Life	O	O	I-Entity
-	O	O	O
5	O	O	O
Dimensions	O	O	O
score	O	O	B-Entity
from	O	O	O
baseline	O	O	B-Entity
to	O	O	O
end	O	O	O
of	O	O	O
treatment	O	O	B-Entity
was	O	O	O
-0.0837	O	O	O
.	O	O	O

The	O	O	O
small	O	O	O
number	O	O	O
of	O	O	O
patients	O	O	B-Entity
and	O	O	O
lack	O	O	O
of	O	O	O
a	O	O	O
comparator	O	O	O
arm	O	O	O
limit	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
draw	O	O	O
definitive	O	O	B-Entity
conclusions	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
profiles	O	O	O
of	O	O	O
axitinib	O	O	B-Entity
were	O	O	O
consistent	O	O	O
with	O	O	O
reports	O	O	O
from	O	O	O
previous	O	O	O
studies	O	O	B-Entity
in	O	O	O
patients	O	O	O
with	O	O	O
mRCC	O	O	B-Entity
,	O	O	O
and	O	O	O
patients	O	O	O
generally	O	O	O
maintained	O	O	O
QoL.	O	O	O
The	O	O	O
sizeable	O	O	O
difference	O	O	O
observed	O	O	O
in	O	O	O
objective	O	O	O
response	O	O	B-Entity
rate	O	O	I-Entity
by	O	O	O
RECIST	O	O	B-Entity
versus	O	O	O
Choi	O	O	B-Entity
criteria	O	O	I-Entity
merits	O	O	O
further	O	O	O
research	O	O	B-Entity
.	O	O	O

-DOCSTART- (27274541)

Biochemical	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
AtFAR2	O	O	B-Entity
,	O	O	O
a	O	O	O
fatty	O	O	B-Entity
acid	O	O	I-Entity
reductase	O	O	I-Entity
from	O	O	O
Arabidopsis	O	O	B-Entity
thaliana	O	O	I-Entity
that	O	O	O
reduces	O	O	O
fatty	O	O	B-Entity
acyl-CoA	O	O	I-Entity
and	O	O	O
-	O	O	O
ACP	O	O	B-Entity
substrates	O	O	I-Entity
into	O	O	O
fatty	O	O	O
alcohols	O	O	O

Fatty	O	O	B-Entity
alcohols	O	O	I-Entity
and	O	O	O
derivatives	O	O	B-Entity
are	O	O	O
important	O	O	B-Entity
for	O	O	O
proper	O	O	O
deposition	O	O	B-Entity
of	O	O	O
a	O	O	O
functional	O	O	B-Entity
pollen	O	O	B-Entity
wall	O	O	I-Entity
.	O	O	O

Mutations	O	O	B-Entity
in	O	O	O
specific	O	O	O
genes	O	O	B-Entity
encoding	O	O	O
fatty	O	O	B-Entity
acid	O	O	I-Entity
reductases	O	O	I-Entity
(	O	O	O
FAR	O	O	B-Entity
)	O	O	O
responsible	O	O	O
for	O	O	O
fatty	O	O	B-Entity
alcohol	O	O	I-Entity
production	O	O	B-Entity
cause	O	O	O
abnormal	O	O	B-Entity
development	O	O	B-Entity
of	O	O	O
pollen	O	O	B-Entity
.	O	O	O

A	O	O	O
disrupted	O	O	B-Entity
AtFAR2	O	O	B-Entity
(	O	O	I-Entity
MS2	O	O	I-Entity
)	O	O	I-Entity
gene	O	O	I-Entity
in	O	O	O
Arabidopsis	O	O	B-Entity
thaliana	O	O	I-Entity
results	O	O	B-Entity
in	O	O	O
pollen	O	O	B-Entity
developing	O	O	B-Entity
an	O	O	O
abnormal	O	O	B-Entity
exine	O	O	B-Entity
layer	O	O	I-Entity
and	O	O	O
a	O	O	O
reduced	O	O	B-Entity
fertility	O	O	I-Entity
phenotype	O	O	B-Entity
.	O	O	O

AtFAR2	O	O	B-Entity
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
targeted	O	O	B-Entity
to	O	O	O
chloroplasts	O	O	B-Entity
and	O	O	O
in	O	O	O
a	O	O	O
purified	O	O	B-Entity
form	O	O	I-Entity
to	O	O	O
be	O	O	O
specific	O	O	B-Entity
for	O	O	O
acyl-ACP	O	O	B-Entity
substrates	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
data	O	O	B-Entity
on	O	O	O
the	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	O
planta	O	O	B-Entity
characterizations	O	O	B-Entity
of	O	O	O
AtFAR2	O	O	B-Entity
from	O	O	O
A.	O	O	B-Entity
thaliana	O	O	I-Entity
and	O	O	O
show	O	O	O
that	O	O	O
this	O	O	O
enzyme	O	O	B-Entity
has	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
use	O	O	O
both	O	O	O
,	O	O	O
C16:0-ACP	O	O	B-Entity
and	O	O	O
C16:0-CoA	O	O	B-Entity
,	O	O	O
as	O	O	O
substrates	O	O	B-Entity
to	O	O	O
produce	O	O	O
C16:0-alcohol	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
further	O	O	O
show	O	O	O
that	O	O	O
AtFAR2	O	O	B-Entity
is	O	O	O
highly	O	O	O
similar	O	O	O
in	O	O	O
properties	O	O	B-Entity
and	O	O	O
substrate	O	O	B-Entity
specificity	O	O	B-Entity
to	O	O	O
AtFAR6	O	O	B-Entity
for	O	O	O
which	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
data	O	O	B-Entity
has	O	O	O
been	O	O	O
published	O	O	O
,	O	O	O
and	O	O	O
which	O	O	O
is	O	O	O
also	O	O	O
a	O	O	O
chloroplast	O	O	B-Entity
localized	O	O	B-Entity
enzyme	O	O	B-Entity
.	O	O	O

This	O	O	O
suggests	O	O	O
that	O	O	O
although	O	O	O
AtFAR2	O	O	B-Entity
is	O	O	O
the	O	O	O
major	O	O	O
enzyme	O	O	B-Entity
responsible	O	O	O
for	O	O	O
exine	O	O	B-Entity
layer	O	O	I-Entity
functionality	O	O	B-Entity
,	O	O	O
AtFAR6	O	O	B-Entity
might	O	O	O
provide	O	O	O
functional	O	O	B-Entity
redundancy	O	O	B-Entity
to	O	O	O
AtFAR2	O	O	O
.	O	O	O

-DOCSTART- (27274791)

Comparing	O	O	B-Entity
Time	O	O	B-Entity
Perception	O	O	I-Entity
among	O	O	O
Morphine	O	O	B-Entity
-	O	O	O
Derived	O	O	B-Entity
Drugs	O	O	B-Entity
Addicts	O	O	B-Entity
and	O	O	O
Controls	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
compare	O	O	B-Entity
time	O	O	B-Entity
perception	O	O	I-Entity
among	O	O	O
drug	O	O	B-Entity
addicts	O	O	I-Entity
and	O	O	O
controls	O	O	B-Entity
.	O	O	O

30	O	O	O
drug	O	O	B-Entity
addicts	O	O	I-Entity
were	O	O	O
selected	O	O	B-Entity
,	O	O	O
and	O	O	O
30	O	O	O
non-addict	O	O	B-Entity
individuals	O	O	I-Entity
were	O	O	O
selected	O	O	O
as	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
two	O	O	O
groups	O	O	B-Entity
performed	O	O	O
three	O	O	O
tests	O	O	B-Entity
of	O	O	O
time	O	O	B-Entity
reproduction	O	O	B-Entity
,	O	O	O
time	O	O	B-Entity
estimation	O	O	I-Entity
,	O	O	O
and	O	O	O
time	O	O	O
discrimination	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
addicts	O	O	B-Entity
group	O	O	B-Entity
and	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
regarding	O	O	O
the	O	O	O
error	O	O	B-Entity
of	O	O	O
time	O	O	B-Entity
reproduction	O	O	B-Entity
and	O	O	O
time	O	O	B-Entity
estimation	O	O	I-Entity
.	O	O	O

The	O	O	O
addict	O	O	B-Entity
group	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
had	O	O	O
a	O	O	O
lower	O	O	B-Entity
under-	O	O	O
reproduction	O	O	B-Entity
and	O	O	O
a	O	O	O
higher	O	O	B-Entity
over-	O	O	O
reproduction	O	O	O
error	O	O	B-Entity
,	O	O	O
and	O	O	O
also	O	O	O
a	O	O	O
lower	O	O	O
under-	O	O	O
estimation	O	O	B-Entity
and	O	O	O
higher	O	O	O
over-	O	O	O
estimation	O	O	O
error	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
regarding	O	O	O
time	O	O	B-Entity
discrimination	O	O	B-Entity
,	O	O	O
no	O	O	O
significant	O	O	B-Entity
difference	O	O	B-Entity
was	O	O	O
observed	O	O	O
between	O	O	O
the	O	O	O
errors	O	O	B-Entity
committed	O	O	O
by	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
when	O	O	O
showing	O	O	O
images	O	O	B-Entity
of	O	O	O
drug	O	O	B-Entity
consumption	O	O	I-Entity
tools	O	O	B-Entity
and	O	O	O
normal	O	O	B-Entity
images	O	O	O
with	O	O	O
same	O	O	O
durations	O	O	B-Entity
,	O	O	O
the	O	O	O
normal	O	O	O
group	O	O	B-Entity
believed	O	O	O
that	O	O	O
the	O	O	O
images	O	O	O
related	O	O	O
to	O	O	O
drug	O	O	O
consumption	O	O	O
tools	O	O	O
were	O	O	O
shown	O	O	O
for	O	O	O
a	O	O	O
shorter	O	O	B-Entity
period	O	O	B-Entity
of	O	O	O
time	O	O	B-Entity
.	O	O	O

Time	O	O	B-Entity
perception	O	O	I-Entity
is	O	O	O
different	O	O	B-Entity
between	O	O	O
morphine	O	O	B-Entity
-	O	O	O
derived	O	O	B-Entity
drugs	O	O	B-Entity
addicts	O	O	B-Entity
and	O	O	O
controls	O	O	B-Entity
.	O	O	O

-DOCSTART- (27277750)

Co-delivery	O	O	B-Entity
of	O	O	O
pemetrexed	O	O	B-Entity
and	O	O	O
miR-21	O	O	B-Entity
antisense	O	O	I-Entity
oligonucleotide	O	O	I-Entity
by	O	O	O
lipid	O	O	B-Entity
-	O	O	O
polymer	O	O	B-Entity
hybrid	O	O	B-Entity
nanoparticles	O	O	I-Entity
and	O	O	O
effects	O	O	B-Entity
on	O	O	O
glioblastoma	O	O	B-Entity
cells	O	O	O

Combination	O	O	B-Entity
therapy	O	O	I-Entity
using	O	O	O
anticancer	O	O	B-Entity
drugs	O	O	I-Entity
and	O	O	O
nucleic	O	O	B-Entity
acid	O	O	I-Entity
is	O	O	O
a	O	O	O
more	O	O	O
promising	O	O	O
strategy	O	O	O
to	O	O	O
overcome	O	O	O
multidrug	O	O	B-Entity
resistance	O	O	I-Entity
in	O	O	O
cancer	O	O	B-Entity
and	O	O	O
to	O	O	O
enhance	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
lipid	O	O	B-Entity
-	O	O	O
polymer	O	O	B-Entity
hybrid	O	O	B-Entity
nanoparticles	O	O	I-Entity
(	O	O	O
LPNs	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
contain	O	O	O
both	O	O	O
pemetrexed	O	O	B-Entity
and	O	O	O
miR-21	O	O	B-Entity
antisense	O	O	I-Entity
oligonucleotide	O	O	I-Entity
(	O	O	O
anti-miR-21	O	O	B-Entity
)	O	O	O
,	O	O	O
have	O	O	O
been	O	O	O
developed	O	O	O
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
glioblastoma	O	O	B-Entity
,	O	O	O
the	O	O	O
most	O	O	O
aggressive	O	O	B-Entity
type	O	O	O
of	O	O	O
brain	O	O	B-Entity
tumor	O	O	I-Entity
.	O	O	O

Prepared	O	O	O
LPNs	O	O	B-Entity
have	O	O	O
been	O	O	O
well	O	O	O
characterized	O	O	O
by	O	O	O
particle	O	O	B-Entity
size	O	O	I-Entity
distribution	O	O	B-Entity
and	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
measurements	O	O	B-Entity
,	O	O	O
determination	O	O	O
of	O	O	O
encapsulation	O	O	B-Entity
efficiency	O	O	B-Entity
,	O	O	O
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
release	O	O	B-Entity
experiments	O	O	I-Entity
.	O	O	O

Morphology	O	O	B-Entity
of	O	O	O
LPNs	O	O	B-Entity
was	O	O	O
determined	O	O	O
by	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

LPNs	O	O	B-Entity
had	O	O	O
a	O	O	O
hydrodynamic	O	O	B-Entity
size	O	O	B-Entity
below	O	O	O
100	O	O	O
nm	O	O	O
and	O	O	O
exhibited	O	O	O
sustained	O	O	B-Entity
release	O	O	I-Entity
of	O	O	O
pemetrexed	O	O	B-Entity
up	O	O	O
to	O	O	O
10	O	O	O
h.	O	O	O
Encapsulation	O	O	B-Entity
of	O	O	O
pemetrexed	O	O	O
in	O	O	O
LPNs	O	O	O
increased	O	O	O
cellular	O	O	B-Entity
uptake	O	O	I-Entity
from	O	O	O
6	O	O	O
%	O	O	O
to	O	O	O
78	O	O	O
%	O	O	O
.	O	O	O

Results	O	O	O
of	O	O	O
confocal	O	O	B-Entity
microscopy	O	O	I-Entity
analysis	O	O	I-Entity
have	O	O	O
shown	O	O	O
that	O	O	O
co-delivery	O	O	B-Entity
of	O	O	O
anti-miR-21	O	O	B-Entity
significantly	O	O	O
improved	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
LPNs	O	O	B-Entity
in	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
of	O	O	O
U87MG	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
more	O	O	O
effective	O	O	O
cytotoxicity	O	O	B-Entity
results	O	O	B-Entity
could	O	O	O
not	O	O	O
be	O	O	O
obtained	O	O	O
due	O	O	O
to	O	O	O
low	O	O	O
concentration	O	O	B-Entity
of	O	O	O
anti-miR-21	O	O	B-Entity
,	O	O	O
loaded	O	O	O
in	O	O	O
LPNs	O	O	B-Entity
.	O	O	O

We	O	O	O
expect	O	O	O
that	O	O	O
the	O	O	O
effective	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
systems	O	O	I-Entity
can	O	O	O
be	O	O	O
obtained	O	O	O
with	O	O	O
higher	O	O	O
concentration	O	O	B-Entity
of	O	O	O
anti-miR-21	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
glioblastoma	O	O	B-Entity
.	O	O	O

-DOCSTART- (27278134)

Expert	O	O	B-Entity
position	O	O	B-Entity
paper	O	O	I-Entity
on	O	O	O
prolonged	O	O	B-Entity
dual	O	O	B-Entity
antiplatelet	O	O	I-Entity
therapy	O	O	I-Entity
in	O	O	O
secondary	O	O	B-Entity
prevention	O	O	I-Entity
following	O	O	O
myocardial	O	O	O
infarction	O	O	O

The	O	O	O
protective	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
dual	O	O	B-Entity
antiplatelet	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
DAPT	O	O	B-Entity
)	O	O	O
following	O	O	O
acute	O	O	B-Entity
coronary	O	O	I-Entity
syndrome	O	O	I-Entity
is	O	O	O
undisputed	O	O	O
,	O	O	O
but	O	O	O
its	O	O	O
duration	O	O	B-Entity
is	O	O	O
subject	O	O	O
of	O	O	O
debate	O	O	B-Entity
.	O	O	O

Several	O	O	O
studies	O	O	B-Entity
show	O	O	O
that	O	O	O
prolonged	O	O	B-Entity
therapy	O	O	B-Entity
provides	O	O	O
a	O	O	O
clinical	O	O	B-Entity
benefit	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
following	O	O	O
acute	O	O	B-Entity
coronary	O	O	I-Entity
syndrome	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
position	O	O	B-Entity
paper	O	O	I-Entity
authored	O	O	O
by	O	O	O
Austrian	O	O	B-Entity
experts	O	O	B-Entity
is	O	O	O
to	O	O	O
outline	O	O	O
the	O	O	O
current	O	O	B-Entity
evidence	O	O	B-Entity
and	O	O	O
provide	O	O	O
an	O	O	O
overview	O	O	O
of	O	O	O
recent	O	O	O
studies	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
also	O	O	O
intended	O	O	O
to	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
practical	O	O	B-Entity
guide	O	O	I-Entity
to	O	O	O
identify	O	O	O
those	O	O	O
patients	O	O	B-Entity
who	O	O	O
may	O	O	O
benefit	O	O	B-Entity
from	O	O	O
prolonged	O	O	B-Entity
DAPT	O	O	B-Entity
.	O	O	O

-DOCSTART- (27279861)

Medulloblastoma	O	O	B-Entity
:	O	O	O
molecular	O	O	B-Entity
pathways	O	O	I-Entity
and	O	O	O
histopathological	O	O	B-Entity
classification	O	O	O

Malignant	O	O	B-Entity
brain	O	O	I-Entity
tumors	O	O	I-Entity
are	O	O	O
the	O	O	O
leading	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
death	O	O	B-Entity
among	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
medulloblastoma	O	O	B-Entity
constitutes	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
them	O	O	O
.	O	O	O

Currently	O	O	O
,	O	O	O
the	O	O	O
treatment	O	O	B-Entity
is	O	O	O
risk-adapted	O	O	O
.	O	O	O

Maximum	O	O	O
surgical	O	O	B-Entity
resection	O	O	I-Entity
is	O	O	O
recommended	O	O	B-Entity
,	O	O	O
always	O	O	O
followed	O	O	O
by	O	O	O
chemotherapy	O	O	B-Entity
and	O	O	O
neuroaxis	O	O	B-Entity
radiotherapy	O	O	B-Entity
.	O	O	O

In	O	O	O
spite	O	O	O
of	O	O	O
the	O	O	O
improving	O	O	B-Entity
survival	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
survivors	O	O	B-Entity
succumb	O	O	O
to	O	O	O
treatment	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
side	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

To	O	O	O
reduce	O	O	B-Entity
toxic	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
molecular-targeted	O	O	B-Entity
treatment	O	O	I-Entity
is	O	O	O
proposed	O	O	O
.	O	O	O

Medulloblastoma	O	O	B-Entity
research	O	O	B-Entity
is	O	O	O
very	O	O	O
robust	O	O	B-Entity
,	O	O	O
and	O	O	O
new	O	O	O
articles	O	O	B-Entity
on	O	O	O
the	O	O	O
subject	O	O	O
are	O	O	O
published	O	O	B-Entity
daily	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
review	O	O	B-Entity
we	O	O	O
have	O	O	O
tried	O	O	O
to	O	O	O
bring	O	O	O
together	O	O	O
molecular	O	O	B-Entity
pathophysiology	O	O	B-Entity
of	O	O	O
the	O	O	O
neoplasm	O	O	B-Entity
and	O	O	O
current	O	O	O
pathological	O	O	B-Entity
classification	O	O	B-Entity
,	O	O	O
thus	O	O	O
making	O	O	O
an	O	O	O
effort	O	O	O
to	O	O	O
relate	O	O	O
tumor	O	O	B-Entity
biology	O	O	I-Entity
and	O	O	O
the	O	O	O
histological	O	O	B-Entity
picture	O	O	I-Entity
.	O	O	O

-DOCSTART- (27280293)

Spatio-Temporal	O	O	B-Entity
History	O	O	I-Entity
of	O	O	O
HIV-1	O	O	B-Entity
CRF35_AD	O	O	I-Entity
in	O	O	O
Afghanistan	O	O	B-Entity
and	O	O	O
Iran	O	O	O

HIV-1	O	O	B-Entity
Circulating	O	O	I-Entity
Recombinant	O	O	I-Entity
Form	O	O	I-Entity
35_AD	O	O	I-Entity
(	O	O	O
CRF35_AD	O	O	B-Entity
)	O	O	O
has	O	O	O
an	O	O	O
important	O	O	O
position	O	O	O
in	O	O	O
the	O	O	O
epidemiological	O	O	B-Entity
profile	O	O	B-Entity
of	O	O	O
Afghanistan	O	O	B-Entity
and	O	O	O
Iran	O	O	B-Entity
.	O	O	O

Despite	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
this	O	O	O
clade	O	O	B-Entity
in	O	O	O
Afghanistan	O	O	B-Entity
and	O	O	O
Iran	O	O	B-Entity
for	O	O	O
over	O	O	O
a	O	O	O
decade	O	O	O
,	O	O	O
our	O	O	O
understanding	O	O	O
of	O	O	O
its	O	O	O
origin	O	O	O
and	O	O	O
dissemination	O	O	B-Entity
patterns	O	O	O
is	O	O	O
limited	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
performed	O	O	O
a	O	O	O
Bayesian	O	O	B-Entity
phylogeographic	O	O	I-Entity
analysis	O	O	I-Entity
to	O	O	O
reconstruct	O	O	O
the	O	O	O
spatio-temporal	O	O	B-Entity
dispersion	O	O	I-Entity
pattern	O	O	I-Entity
of	O	O	O
this	O	O	O
clade	O	O	B-Entity
using	O	O	O
eligible	O	O	O
CRF35_AD	O	O	B-Entity
gag	O	O	B-Entity
and	O	O	I-Entity
pol	O	O	I-Entity
sequences	O	O	B-Entity
available	O	O	O
in	O	O	O
the	O	O	O
Los	O	O	B-Entity
Alamos	O	O	I-Entity
HIV	O	O	B-Entity
database	O	O	I-Entity
(	O	O	O
432	O	O	O
sequences	O	O	O
available	O	O	O
from	O	O	O
Iran	O	O	B-Entity
,	O	O	O
16	O	O	O
sequences	O	O	O
available	O	O	O
from	O	O	O
Afghanistan	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
single	O	O	O
CRF35_AD	O	O	O
-like	O	O	O
pol	O	O	B-Entity
sequence	O	O	I-Entity
available	O	O	O
from	O	O	O
USA	O	O	B-Entity
)	O	O	O
.	O	O	O

Bayesian	O	O	B-Entity
Markov	O	O	I-Entity
Chain	O	O	I-Entity
Monte	O	O	I-Entity
Carlo	O	O	I-Entity
algorithm	O	O	I-Entity
was	O	O	O
implemented	O	O	O
in	O	O	O
BEAST	O	O	B-Entity
v1.8.1	O	O	I-Entity
.	O	O	O

Between-country	O	O	O
dispersion	O	O	O
rates	O	O	O
were	O	O	O
tested	O	O	O
with	O	O	O
Bayesian	O	O	B-Entity
stochastic	O	O	I-Entity
search	O	O	I-Entity
variable	O	O	I-Entity
selection	O	O	I-Entity
method	O	O	I-Entity
and	O	O	O
were	O	O	O
considered	O	O	O
significant	O	O	O
where	O	O	O
Bayes	O	O	B-Entity
factor	O	O	I-Entity
values	O	O	I-Entity
were	O	O	O
greater	O	O	O
than	O	O	O
three	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	O
suggested	O	O	O
that	O	O	O
CRF35_AD	O	O	B-Entity
sequences	O	O	B-Entity
were	O	O	O
genetically	O	O	O
similar	O	O	O
to	O	O	O
parental	O	O	B-Entity
sequences	O	O	I-Entity
from	O	O	O
Kenya	O	O	B-Entity
and	O	O	O
Uganda	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
subtype	O	O	B-Entity
A1	O	O	I-Entity
sequences	O	O	O
available	O	O	O
from	O	O	O
Afghan	O	O	B-Entity
refugees	O	O	B-Entity
living	O	O	O
in	O	O	O
Pakistan	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
also	O	O	O
showed	O	O	O
that	O	O	O
across	O	O	O
all	O	O	O
phylogenies	O	O	B-Entity
,	O	O	O
Afghan	O	O	B-Entity
and	O	O	O
Iranian	O	O	B-Entity
CRF35_AD	O	O	B-Entity
sequences	O	O	B-Entity
formed	O	O	O
a	O	O	O
monophyletic	O	O	B-Entity
cluster	O	O	I-Entity
(	O	O	O
posterior	O	O	O
clade	O	O	O
credibility	O	O	O
>	O	O	O
0.7	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
divergence	O	O	O
date	O	O	O
of	O	O	O
this	O	O	O
cluster	O	O	B-Entity
was	O	O	O
estimated	O	O	O
to	O	O	O
be	O	O	O
between	O	O	O
1990	O	O	O
and	O	O	O
1992	O	O	O
.	O	O	O

Within	O	O	O
this	O	O	O
cluster	O	O	B-Entity
,	O	O	O
a	O	O	O
bidirectional	O	O	B-Entity
dispersion	O	O	B-Entity
of	O	O	O
the	O	O	O
virus	O	O	B-Entity
was	O	O	O
observed	O	O	O
across	O	O	O
Afghanistan	O	O	B-Entity
and	O	O	O
Iran	O	O	B-Entity
.	O	O	O

We	O	O	O
could	O	O	O
not	O	O	O
clearly	O	O	O
identify	O	O	O
if	O	O	O
Afghanistan	O	O	B-Entity
or	O	O	O
Iran	O	O	B-Entity
first	O	O	O
established	O	O	O
or	O	O	O
received	O	O	O
this	O	O	O
epidemic	O	O	B-Entity
,	O	O	O
as	O	O	O
the	O	O	O
root	O	O	O
location	O	O	O
of	O	O	O
this	O	O	O
cluster	O	O	B-Entity
could	O	O	O
not	O	O	O
be	O	O	O
robustly	O	O	O
estimated	O	O	O
.	O	O	O

Three	O	O	O
CRF35_AD	O	O	B-Entity
sequences	O	O	B-Entity
from	O	O	O
Afghan	O	O	B-Entity
refugees	O	O	B-Entity
living	O	O	B-Entity
in	O	O	I-Entity
Pakistan	O	O	B-Entity
nested	O	O	O
among	O	O	O
Afghan	O	O	O
and	O	O	O
Iranian	O	O	B-Entity
CRF35_AD	O	O	O
branches	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
CRF35_AD	O	O	B-Entity
-like	O	O	O
sequence	O	O	B-Entity
available	O	O	O
from	O	O	O
USA	O	O	B-Entity
diverged	O	O	O
independently	O	O	O
from	O	O	O
Kenyan	O	O	B-Entity
subtype	O	O	B-Entity
A1	O	O	I-Entity
sequences	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
it	O	O	O
not	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
true	O	O	O
CRF35_AD	O	O	O
lineage	O	O	O
.	O	O	O

Potential	O	O	B-Entity
factors	O	O	B-Entity
contributing	O	O	O
to	O	O	O
viral	O	O	B-Entity
exchange	O	O	O
between	O	O	O
Afghanistan	O	O	B-Entity
and	O	O	O
Iran	O	O	B-Entity
could	O	O	O
be	O	O	O
injection	O	O	O
drug	O	O	O
networks	O	O	O
and	O	O	O
mass	O	O	B-Entity
migration	O	O	I-Entity
of	O	O	O
Afghan	O	O	B-Entity
refugees	O	O	B-Entity
and	O	O	O
labours	O	O	B-Entity
to	O	O	O
Iran	O	O	O
,	O	O	O
which	O	O	O
calls	O	O	O
for	O	O	O
extensive	O	O	B-Entity
preventive	O	O	B-Entity
efforts	O	O	O
.	O	O	O

-DOCSTART- (27282265)

The	O	O	O
Benefits	O	O	B-Entity
of	O	O	O
Combination	O	O	B-Entity
Therapy	O	O	I-Entity
with	O	O	O
Esomeprazole	O	O	B-Entity
and	O	O	O
Rebamipide	O	O	B-Entity
in	O	O	O
Symptom	O	O	B-Entity
Improvement	O	O	B-Entity
in	O	O	O
Reflux	O	O	B-Entity
Esophagitis	O	O	I-Entity
:	O	O	O
An	O	O	O
International	O	O	B-Entity
Multicenter	O	O	O
Study	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
esomeprazole	O	O	B-Entity
and	O	O	O
rebamipide	O	O	B-Entity
combination	O	O	B-Entity
therapy	O	O	I-Entity
on	O	O	O
symptomatic	O	O	B-Entity
improvement	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
reflux	O	O	B-Entity
esophagitis	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
501	O	O	O
patients	O	O	B-Entity
with	O	O	O
reflux	O	O	B-Entity
esophagitis	O	O	I-Entity
were	O	O	O
randomized	O	O	B-Entity
into	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
following	O	O	O
two	O	O	O
treatment	O	O	B-Entity
regimens	O	O	I-Entity
:	O	O	O
40	O	O	O
mg	O	O	O
esomeprazole	O	O	B-Entity
plus	O	O	O
300	O	O	O
mg	O	O	O
rebamipide	O	O	B-Entity
daily	O	O	B-Entity
(	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
group	O	O	B-Entity
)	O	O	O
or	O	O	O
40	O	O	O
mg	O	O	O
esomeprazole	O	O	O
daily	O	O	O
(	O	O	O
monotherapy	O	O	B-Entity
group	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
used	O	O	O
a	O	O	O
symptom	O	O	B-Entity
questionnaire	O	O	B-Entity
that	O	O	O
evaluated	O	O	B-Entity
heartburn	O	O	B-Entity
,	O	O	O
acid	O	O	B-Entity
regurgitation	O	O	I-Entity
,	O	O	O
and	O	O	O
four	O	O	O
upper	O	O	B-Entity
gastrointestinal	O	O	I-Entity
symptoms	O	O	I-Entity
.	O	O	O

The	O	O	O
primary	O	O	O
efficacy	O	O	B-Entity
end	O	O	O
point	O	O	O
was	O	O	O
the	O	O	O
mean	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
total	O	O	O
symptom	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
decreases	O	O	B-Entity
in	O	O	O
the	O	O	O
total	O	O	O
symptom	O	O	B-Entity
score	O	O	I-Entity
at	O	O	O
4	O	O	O
weeks	O	O	B-Entity
were	O	O	O
estimated	O	O	O
to	O	O	O
be	O	O	O
-18.1±13.8	O	O	O
in	O	O	O
the	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
group	O	O	B-Entity
and	O	O	O
-15.1±11.9	O	O	O
in	O	O	O
the	O	O	O
monotherapy	O	O	B-Entity
group	O	O	O
(	O	O	O
p=0.011	O	O	O
)	O	O	O
.	O	O	O

Changes	O	O	O
in	O	O	O
reflux	O	O	B-Entity
symptom	O	O	B-Entity
s	O	O	O
from	O	O	O
baseline	O	O	B-Entity
after	O	O	O
4	O	O	O
weeks	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
were	O	O	O
-8.4±6.6	O	O	O
in	O	O	O
the	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
group	O	O	B-Entity
and	O	O	O
-6.8±5.9	O	O	O
in	O	O	O
the	O	O	O
monotherapy	O	O	B-Entity
group	O	O	O
(	O	O	O
p=0.009	O	O	O
)	O	O	O
.	O	O	O

Over	O	O	O
a	O	O	O
4-	O	O	O
week	O	O	B-Entity
treatment	O	O	B-Entity
course	O	O	O
,	O	O	O
esomeprazole	O	O	B-Entity
and	O	O	O
rebamipide	O	O	B-Entity
combination	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
more	O	O	O
effective	O	O	B-Entity
in	O	O	O
decreasing	O	O	B-Entity
the	O	O	O
symptoms	O	O	B-Entity
of	O	O	O
reflux	O	O	B-Entity
esophagitis	O	O	I-Entity
than	O	O	O
esomeprazole	O	O	O
monotherapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27283167)

Integrating	O	O	B-Entity
Palliative	O	O	B-Entity
Care	O	O	I-Entity
in	O	O	O
Pediatric	O	O	B-Entity
Oncology	O	O	I-Entity
:	O	O	O
Evidence	O	O	O
for	O	O	O
an	O	O	O
Evolving	O	O	B-Entity
Paradigm	O	O	B-Entity
for	O	O	O
Comprehensive	O	O	B-Entity
Cancer	O	O	O
Care	O	O	O

The	O	O	O
demonstrated	O	O	O
benefit	O	O	O
of	O	O	O
integrating	O	O	B-Entity
palliative	O	O	B-Entity
care	O	O	I-Entity
(	O	O	O
PC	O	O	B-Entity
)	O	O	O
into	O	O	O
cancer	O	O	B-Entity
treatment	O	O	I-Entity
has	O	O	O
triggered	O	O	O
an	O	O	O
increased	O	O	B-Entity
need	O	O	O
for	O	O	O
PC	O	O	O
services	O	O	O
.	O	O	O

The	O	O	O
trajectory	O	O	O
of	O	O	O
integrating	O	O	B-Entity
PC	O	O	B-Entity
in	O	O	O
comprehensive	O	O	B-Entity
cancer	O	O	B-Entity
centers	O	O	I-Entity
,	O	O	I-Entity
particularly	O	O	O
pediatric	O	O	B-Entity
centers	O	O	I-Entity
,	O	O	O
is	O	O	O
unknown	O	O	O
.	O	O	O

We	O	O	O
describe	O	O	O
our	O	O	O
8-	O	O	O
year	O	O	B-Entity
experience	O	O	O
of	O	O	O
initiating	O	O	O
and	O	O	O
establishing	O	O	B-Entity
PC	O	O	B-Entity
with	O	O	O
the	O	O	O
Quality	O	O	B-Entity
of	O	O	I-Entity
Life	O	O	I-Entity
Service	O	O	I-Entity
(	O	O	O
QoLS	O	O	B-Entity
)	O	O	O
at	O	O	O
St.	O	O	B-Entity
Jude	O	O	I-Entity
Children	O	O	I-Entity
's	O	O	I-Entity
Research	O	O	I-Entity
Hospital	O	O	I-Entity
.	O	O	O

We	O	O	O
retrospectively	O	O	O
reviewed	O	O	O
records	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
seen	O	O	O
by	O	O	O
the	O	O	O
QoLS	O	O	B-Entity
(	O	O	O
n=615	O	O	O
)	O	O	O
from	O	O	O
March	O	O	B-Entity
2007	O	O	O
to	O	O	O
December	O	O	B-Entity
2014	O	O	O
.	O	O	O

Variables	O	O	B-Entity
analyzed	O	O	O
for	O	O	O
each	O	O	O
year	O	O	B-Entity
,	O	O	O
using	O	O	O
descriptive	O	O	O
statistics	O	O	B-Entity
,	O	O	O
included	O	O	O
diagnostic	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
QoLS	O	O	B-Entity
encounters	O	O	B-Entity
,	O	O	O
goals	O	O	B-Entity
of	O	O	I-Entity
care	O	O	I-Entity
,	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
survival	O	O	I-Entity
,	O	O	O
and	O	O	O
location	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
.	O	O	O

Total	O	O	O
QoLS	O	O	B-Entity
patient	O	O	B-Entity
encounters	O	O	B-Entity
increased	O	O	B-Entity
from	O	O	O
58	O	O	O
(	O	O	O
2007	O	O	O
)	O	O	O
to	O	O	O
1,297	O	O	O
(	O	O	O
2014	O	O	O
)	O	O	O
,	O	O	O
new	O	O	O
consults	O	O	B-Entity
increased	O	O	O
from	O	O	O
17	O	O	O
(	O	O	O
2007	O	O	O
)	O	O	O
to	O	O	O
115	O	O	O
(	O	O	O
2014	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
mean	O	O	O
encounters	O	O	O
per	O	O	O
patient	O	O	O
increased	O	O	O
from	O	O	O
5.06	O	O	O
(	O	O	O
2007	O	O	O
)	O	O	O
to	O	O	O
16.11	O	O	O
(	O	O	O
2014	O	O	O
)	O	O	O
.	O	O	O

Goal	O	O	B-Entity
of	O	O	I-Entity
care	O	O	I-Entity
at	O	O	O
initial	O	O	B-Entity
consultation	O	O	I-Entity
shifted	O	O	O
from	O	O	O
primarily	O	O	O
comfort	O	O	B-Entity
to	O	O	O
an	O	O	O
increasing	O	O	B-Entity
goal	O	O	B-Entity
of	O	O	I-Entity
cure	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	O
number	O	O	O
of	O	O	O
days	O	O	O
from	O	O	O
initial	O	O	B-Entity
consult	O	O	I-Entity
to	O	O	O
death	O	O	B-Entity
increased	O	O	B-Entity
from	O	O	O
52	O	O	O
days	O	O	O
(	O	O	O
2008	O	O	O
)	O	O	O
to	O	O	O
223	O	O	O
days	O	O	O
(	O	O	O
2014	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
trend	O	O	O
toward	O	O	O
increased	O	O	B-Entity
outpatient	O	O	B-Entity
location	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
was	O	O	O
noted	O	O	O
with	O	O	O
42	O	O	O
%	O	O	O
outpatient	O	O	O
deaths	O	O	B-Entity
in	O	O	O
2007	O	O	O
,	O	O	O
increasing	O	O	B-Entity
to	O	O	O
a	O	O	O
majority	O	O	B-Entity
in	O	O	O
each	O	O	O
subsequent	O	O	O
year	O	O	B-Entity
(	O	O	O
range	O	O	O
,	O	O	O
51%-74	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Hospital-wide	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
receiving	O	O	O
PC	O	O	B-Entity
services	O	O	O
before	O	O	O
death	O	O	B-Entity
increased	O	O	B-Entity
from	O	O	O
approximately	O	O	B-Entity
50	O	O	O
%	O	O	O
to	O	O	O
nearly	O	O	O
100	O	O	O
%	O	O	O
.	O	O	O

Since	O	O	O
its	O	O	O
inception	O	O	O
,	O	O	O
the	O	O	O
QoLS	O	O	B-Entity
experienced	O	O	O
a	O	O	O
dramatic	O	O	O
increase	O	O	B-Entity
in	O	O	O
referrals	O	O	B-Entity
and	O	O	O
encounters	O	O	B-Entity
per	O	O	O
patient	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
use	O	O	O
by	O	O	O
all	O	O	O
clinical	O	O	B-Entity
services	O	O	I-Entity
,	O	O	O
a	O	O	O
trend	O	O	O
toward	O	O	O
earlier	O	O	B-Entity
consultation	O	O	B-Entity
and	O	O	O
longer	O	O	B-Entity
term	O	O	I-Entity
follow-up	O	O	B-Entity
,	O	O	O
increasing	O	O	B-Entity
outpatient	O	O	B-Entity
location	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
,	O	O	O
and	O	O	O
near-	O	O	O
universal	O	O	B-Entity
PC	O	O	B-Entity
involvement	O	O	O
at	O	O	O
the	O	O	O
end-of-life	O	O	B-Entity
.	O	O	O

The	O	O	O
successful	O	O	O
integration	O	O	B-Entity
of	O	O	O
PC	O	O	B-Entity
in	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
cancer	O	O	B-Entity
center	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
resulting	O	O	O
potential	O	O	O
for	O	O	O
improved	O	O	O
care	O	O	B-Entity
provision	O	O	I-Entity
over	O	O	O
time	O	O	B-Entity
,	O	O	O
can	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
model	O	O	B-Entity
for	O	O	O
other	O	O	O
programs	O	O	B-Entity
on	O	O	O
a	O	O	O
broad	O	O	O
scale	O	O	O
.	O	O	O

-DOCSTART- (27285457)

PROTECTIVE	O	O	B-Entity
EFFECTS	O	O	I-Entity
OF	O	O	I-Entity
DIPEPTIDYL	O	O	B-Entity
PEPTIDASE-4	O	O	I-Entity
INHIBITORS	O	O	I-Entity
ON	O	O	O
PROGRESSION	O	O	B-Entity
OF	O	O	O
DIABETIC	O	O	B-Entity
RETINOPATHY	O	O	I-Entity
IN	O	O	O
PATIENTS	O	O	B-Entity
WITH	O	O	O
TYPE	O	O	O
2	O	O	O
DIABETES	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
dipeptidyl	O	O	B-Entity
peptidase-4	O	O	I-Entity
inhibitors	O	O	I-Entity
(	O	O	O
DPP4	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
retinopathy	O	O	I-Entity
(	O	O	O
DR	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
Type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
DR	O	O	O
severity	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

The	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
82	O	O	O
patients	O	O	B-Entity
with	O	O	O
Type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
enrolled	O	O	O
from	O	O	O
2005	O	O	O
to	O	O	O
2015	O	O	O
were	O	O	O
retrospectively	O	O	B-Entity
reviewed	O	O	B-Entity
.	O	O	O

Fundus	O	O	B-Entity
photographs	O	O	I-Entity
were	O	O	O
graded	O	O	B-Entity
using	O	O	O
Early	O	O	B-Entity
Treatment	O	O	I-Entity
Diabetic	O	O	I-Entity
Retinopathy	O	O	I-Entity
Study	O	O	I-Entity
methods	O	O	I-Entity
.	O	O	O

The	O	O	O
associations	O	O	B-Entity
between	O	O	O
baseline	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
progression	O	O	B-Entity
of	O	O	O
DR	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
.	O	O	O

Seven	O	O	O
of	O	O	O
28	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
DPP4	O	O	B-Entity
inhibitors	O	O	I-Entity
and	O	O	O
26	O	O	O
of	O	O	O
54	O	O	O
treated	O	O	O
with	O	O	O
other	O	O	O
hypoglycemic	O	O	B-Entity
agents	O	O	I-Entity
showed	O	O	O
progression	O	O	B-Entity
of	O	O	O
retinopathy	O	O	B-Entity
,	O	O	O
defined	O	O	O
as	O	O	O
one	O	O	O
or	O	O	O
more	O	O	O
steps	O	O	O
on	O	O	O
the	O	O	O
Early	O	O	B-Entity
Treatment	O	O	I-Entity
Diabetic	O	O	I-Entity
Retinopathy	O	O	I-Entity
Study	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.043	O	O	O
)	O	O	O
.	O	O	O

Only	O	O	O
treatment	O	O	B-Entity
with	O	O	O
DPP4	O	O	B-Entity
inhibitors	O	O	I-Entity
significantly	O	O	O
reduced	O	O	B-Entity
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
DR	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
after	O	O	O
propensity	O	O	B-Entity
score	O	O	I-Entity
matching	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.009	O	O	O
)	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
with	O	O	O
DPP4	O	O	B-Entity
inhibitors	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
lower	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
DR	O	O	B-Entity
progression	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.011	O	O	O
)	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
with	O	O	O
DPP4	O	O	B-Entity
inhibitors	O	O	I-Entity
was	O	O	O
the	O	O	O
independent	O	O	B-Entity
protective	O	O	B-Entity
factor	O	O	I-Entity
against	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
DR	O	O	B-Entity
,	O	O	O
aside	O	O	O
from	O	O	O
improving	O	O	B-Entity
glycemic	O	O	I-Entity
control	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	O
to	O	O	O
show	O	O	O
the	O	O	O
benefits	O	O	B-Entity
of	O	O	O
DPP4	O	O	B-Entity
inhibitors	O	O	I-Entity
in	O	O	O
reducing	O	O	B-Entity
DR	O	O	B-Entity
progression	O	O	B-Entity
,	O	O	O
and	O	O	O
provides	O	O	O
encouraging	O	O	O
preliminary	O	O	B-Entity
data	O	O	B-Entity
for	O	O	O
further	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
DPP4	O	O	O
inhibitors	O	O	O
in	O	O	O
the	O	O	O
progression	O	O	O
of	O	O	O
DR	O	O	O
in	O	O	O
a	O	O	O
randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
trial	O	O	I-Entity
.	O	O	O

-DOCSTART- (27293894)

Production	O	O	B-Entity
of	O	O	O
Laccase	O	O	B-Entity
by	O	O	O
Cochliobolus	O	O	B-Entity
sp.	O	O	I-Entity
Isolated	O	O	B-Entity
from	O	O	O
Plastic	O	O	B-Entity
Dumped	O	O	B-Entity
Soils	O	O	I-Entity
and	O	O	O
Their	O	O	O
Ability	O	O	B-Entity
to	O	O	O
Degrade	O	O	B-Entity
Low	O	O	O
Molecular	O	O	O
Weight	O	O	O
PVC	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
utmost	O	O	O
man-made	O	O	B-Entity
problems	O	O	I-Entity
faced	O	O	O
today	O	O	O
has	O	O	O
been	O	O	O
the	O	O	O
ever	O	O	B-Entity
-	O	O	O
increasing	O	O	B-Entity
plastic	O	O	B-Entity
waste	O	O	B-Entity
filling	O	O	B-Entity
the	O	O	O
world	O	O	O
.	O	O	O

It	O	O	O
accounts	O	O	O
for	O	O	O
an	O	O	O
estimated	O	O	O
20	O	O	O
-	O	O	O
30	O	O	O
%	O	O	O
(	O	O	O
by	O	O	O
volume	O	O	O
)	O	O	O
of	O	O	O
municipal	O	O	B-Entity
solid	O	O	I-Entity
waste	O	O	I-Entity
in	O	O	O
landfill	O	O	B-Entity
sites	O	O	I-Entity
worldwide	O	O	O
.	O	O	O

Research	O	O	O
on	O	O	O
plastic	O	O	B-Entity
biodegradation	O	O	B-Entity
has	O	O	O
been	O	O	O
steadily	O	O	O
growing	O	O	O
over	O	O	O
the	O	O	O
past	O	O	O
four	O	O	O
decades	O	O	O
.	O	O	O

Several	O	O	O
fungi	O	O	B-Entity
have	O	O	O
been	O	O	O
identified	O	O	O
that	O	O	O
produce	O	O	O
enzymes	O	O	B-Entity
capable	O	O	O
of	O	O	O
plastic	O	O	B-Entity
degradation	O	O	B-Entity
in	O	O	O
various	O	O	O
laboratory	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
presents	O	O	O
a	O	O	O
study	O	O	O
that	O	O	O
determined	O	O	O
the	O	O	O
ability	O	O	B-Entity
of	O	O	O
fungi	O	O	B-Entity
to	O	O	O
degrade	O	O	B-Entity
low	O	O	B-Entity
molecular	O	O	I-Entity
weight	O	O	I-Entity
polyvinyl	O	O	I-Entity
chloride	O	O	I-Entity
(	O	O	O
PVC	O	O	B-Entity
)	O	O	O
by	O	O	O
the	O	O	O
enzyme	O	O	B-Entity
laccase	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
isolated	O	O	B-Entity
a	O	O	O
fungal	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
Cochliobolus	O	O	B-Entity
sp.	O	O	I-Entity
,	O	O	O
from	O	O	O
plastic	O	O	B-Entity
dumped	O	O	B-Entity
soils	O	O	I-Entity
and	O	O	O
they	O	O	O
were	O	O	O
cultured	O	O	B-Entity
on	O	O	O
Czapek	O	O	B-Entity
Dox	O	O	I-Entity
Agar	O	O	I-Entity
slants	O	O	I-Entity
at	O	O	O
30	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

The	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
this	O	O	O
fungal	O	O	B-Entity
species	O	O	B-Entity
on	O	O	O
the	O	O	O
degradation	O	O	B-Entity
of	O	O	O
commercial	O	O	O
low	O	O	B-Entity
molecular	O	O	I-Entity
weight	O	O	I-Entity
polyvinyl	O	O	I-Entity
chloride	O	O	I-Entity
(	O	O	O
PVC	O	O	B-Entity
)	O	O	O
was	O	O	O
studied	O	O	O
under	O	O	O
laboratory	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

Significant	O	O	O
differences	O	O	O
were	O	O	O
observed	O	O	O
from	O	O	O
the	O	O	O
FTIR	O	O	B-Entity
,	O	O	O
GC-MS	O	O	B-Entity
,	O	O	O
and	O	O	O
SEM	O	O	B-Entity
results	O	O	O
in	O	O	O
between	O	O	O
control	O	O	B-Entity
and	O	O	O
Cochliobolus	O	O	B-Entity
sp.	O	O	I-Entity
treated	O	O	O
PVC	O	O	B-Entity
.	O	O	O

-DOCSTART- (27294945)

Effects	O	O	B-Entity
of	O	O	I-Entity
Cerium	O	O	B-Entity
and	O	O	O
Titanium	O	O	B-Entity
Oxide	O	O	I-Entity
Nanoparticles	O	O	B-Entity
in	O	O	O
Soil	O	O	B-Entity
on	O	O	O
the	O	O	O
Nutrient	O	O	B-Entity
Composition	O	O	B-Entity
of	O	O	O
Barley	O	O	B-Entity
(	O	O	O
Hordeum	O	O	B-Entity
vulgare	O	O	I-Entity
L	O	O	I-Entity
.	O	O	O
)	O	O	O
Kernels	O	O	O

The	O	O	O
implications	O	O	B-Entity
of	O	O	O
metal	O	O	B-Entity
nanoparticles	O	O	I-Entity
(	O	O	O
MeNPs	O	O	B-Entity
)	O	O	I-Entity
are	O	O	O
still	O	O	O
unknown	O	O	B-Entity
for	O	O	O
many	O	O	B-Entity
food	O	O	B-Entity
crops	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
cerium	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
nCeO₂	O	O	B-Entity
)	O	O	O
and	O	O	O
titanium	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
nTiO₂	O	O	B-Entity
)	O	O	O
nanoparticles	O	O	B-Entity
in	O	O	O
soil	O	O	B-Entity
at	O	O	O
0	O	O	O
,	O	O	O
500	O	O	O
and	O	O	O
1000	O	O	O
mg·kg(-1	O	O	O
)	O	O	O
on	O	O	O
the	O	O	O
nutritional	O	O	B-Entity
parameters	O	O	I-Entity
of	O	O	O
barley	O	O	B-Entity
(	O	O	O
Hordeum	O	O	B-Entity
vulgare	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
kernels	O	O	B-Entity
.	O	O	O

Mineral	O	O	B-Entity
nutrients	O	O	I-Entity
,	O	O	O
amylose	O	O	B-Entity
,	O	O	O
β-glucans	O	O	B-Entity
,	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
and	O	O	O
crude	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
CP	O	O	B-Entity
)	O	O	O
concentrations	O	O	B-Entity
were	O	O	I-Entity
measured	O	O	I-Entity
in	O	O	O
kernels	O	O	B-Entity
.	O	O	O

Whole	O	O	B-Entity
flour	O	O	B-Entity
samples	O	O	O
were	O	O	O
analyzed	O	O	O
by	O	O	O
ICP-AES/MS	O	O	B-Entity
,	O	O	O
HPLC	O	O	B-Entity
and	O	O	O
Elemental	O	O	B-Entity
CHNS	O	O	I-Entity
Analyzer	O	O	I-Entity
.	O	O	O

Results	O	O	O
showed	O	O	O
that	O	O	O
Ce	O	O	B-Entity
and	O	O	O
Ti	O	O	B-Entity
accumulation	O	O	B-Entity
under	O	O	O
MeNPs	O	O	B-Entity
treatments	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
from	O	O	O
the	O	O	O
control	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
nCeO₂	O	O	B-Entity
and	O	O	O
nTiO₂	O	O	B-Entity
had	O	O	O
an	O	O	O
impact	O	O	B-Entity
on	O	O	O
composition	O	O	B-Entity
and	O	O	O
nutritional	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	O
barley	O	O	B-Entity
kernels	O	O	B-Entity
in	O	O	O
contrasting	O	O	B-Entity
ways	O	O	I-Entity
.	O	O	O

Both	O	O	O
MeNPs	O	O	B-Entity
left	O	O	O
β-glucans	O	O	B-Entity
unaffected	O	O	B-Entity
but	O	O	O
reduced	O	O	O
amylose	O	O	B-Entity
content	O	O	O
by	O	O	O
approximately	O	O	O
21	O	O	O
%	O	O	O
.	O	O	O

Most	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
and	O	O	O
CP	O	O	B-Entity
increased	O	O	B-Entity
.	O	O	O

Among	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
,	O	O	O
lysine	O	O	B-Entity
followed	O	O	O
by	O	O	O
proline	O	O	B-Entity
saw	O	O	O
the	O	O	O
largest	O	O	B-Entity
increase	O	O	I-Entity
(	O	O	O
51	O	O	O
%	O	O	O
and	O	O	O
37	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Potassium	O	O	B-Entity
and	O	O	O
S	O	O	B-Entity
were	O	O	O
both	O	O	O
negatively	O	O	B-Entity
impacted	O	O	I-Entity
by	O	O	O
MeNPs	O	O	B-Entity
,	O	O	O
while	O	O	O
B	O	O	O
was	O	O	O
only	O	O	O
affected	O	O	B-Entity
by	O	O	O
500	O	O	O
mg	O	O	O
nCeO₂	O	O	B-Entity
·	O	O	O
kg(-1	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
contrary	O	O	O
Zn	O	O	B-Entity
and	O	O	O
Mn	O	O	B-Entity
concentrations	O	O	I-Entity
were	O	O	O
improved	O	O	O
by	O	O	O
500	O	O	O
mg	O	O	O
nTiO₂	O	O	B-Entity
·	O	O	O
kg(-1	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
Ca	O	O	O
by	O	O	O
both	O	O	O
nTiO₂	O	O	O
treatments	O	O	B-Entity
.	O	O	O

Generally	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	O
demonstrated	O	O	B-Entity
that	O	O	O
kernels	O	O	B-Entity
are	O	O	O
negatively	O	O	B-Entity
affected	O	O	I-Entity
by	O	O	O
nCeO₂	O	O	B-Entity
while	O	O	O
nTiO₂	O	O	B-Entity
can	O	O	O
potentially	O	O	O
have	O	O	O
beneficial	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
both	O	O	O
MeNPs	O	O	B-Entity
have	O	O	O
the	O	O	O
potential	O	O	O
to	O	O	O
negatively	O	O	B-Entity
impact	O	O	I-Entity
malt	O	O	B-Entity
and	O	O	O
feed	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

-DOCSTART- (27305683)

Quantifying	O	O	B-Entity
Nonlinear	O	O	O
Contributions	O	O	B-Entity
to	O	O	O
Cortical	O	O	B-Entity
Responses	O	O	I-Entity
Evoked	O	O	I-Entity
by	O	O	O
Continuous	O	O	O
Wrist	O	O	O
Manipulation	O	O	O

Cortical	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
continuous	O	O	B-Entity
stimuli	O	O	I-Entity
as	O	O	O
recorded	O	O	O
using	O	O	O
either	O	O	O
magneto-	O	O	B-Entity
or	O	O	O
electroencephalography	O	O	B-Entity
(	O	O	O
EEG	O	O	B-Entity
)	O	O	O
have	O	O	O
shown	O	O	O
power	O	O	O
at	O	O	O
harmonics	O	O	O
of	O	O	O
the	O	O	O
stimulated	O	O	B-Entity
frequency	O	O	I-Entity
,	O	O	O
indicating	O	O	O
nonlinear	O	O	B-Entity
behavior	O	O	I-Entity
.	O	O	O

Even	O	O	O
though	O	O	O
the	O	O	O
selection	O	O	O
of	O	O	O
analysis	O	O	B-Entity
techniques	O	O	B-Entity
depends	O	O	O
on	O	O	O
the	O	O	O
linearity	O	O	B-Entity
of	O	O	O
the	O	O	O
system	O	O	O
under	O	O	O
study	O	O	O
,	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
nonlinear	O	O	O
contributions	O	O	B-Entity
to	O	O	O
cortical	O	O	B-Entity
responses	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
formally	O	O	O
addressed	O	O	O
.	O	O	O

The	O	O	O
goal	O	O	B-Entity
of	O	O	I-Entity
this	O	O	I-Entity
paper	O	O	I-Entity
is	O	O	O
to	O	O	O
quantify	O	O	B-Entity
the	O	O	O
nonlinear	O	O	O
contributions	O	O	B-Entity
to	O	O	O
the	O	O	O
cortical	O	O	B-Entity
response	O	O	I-Entity
obtained	O	O	O
from	O	O	O
continuous	O	O	B-Entity
sensory	O	O	B-Entity
stimulation	O	O	I-Entity
.	O	O	O

EEG	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
record	O	O	O
the	O	O	O
cortical	O	O	B-Entity
response	O	O	I-Entity
evoked	O	O	I-Entity
by	O	O	O
continuous	O	O	B-Entity
movement	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
wrist	O	O	I-Entity
joint	O	O	I-Entity
of	O	O	O
healthy	O	O	O
subjects	O	O	O
applied	O	O	O
with	O	O	O
a	O	O	O
robotic	O	O	B-Entity
manipulator	O	O	I-Entity
.	O	O	O

Multisine	O	O	O
stimulus	O	O	B-Entity
signals	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
the	O	O	O
sum	O	O	O
of	O	O	O
several	O	O	B-Entity
sinusoids	O	O	B-Entity
)	O	O	O
elicit	O	O	O
a	O	O	O
periodic	O	O	B-Entity
cortical	O	O	B-Entity
response	O	O	I-Entity
and	O	O	O
allow	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
nonlinear	O	O	O
contributions	O	O	B-Entity
to	O	O	O
the	O	O	O
response	O	O	O
.	O	O	O

Wrist	O	O	B-Entity
dynamics	O	O	I-Entity
(	O	O	O
relation	O	O	O
between	O	O	O
joint	O	O	B-Entity
angle	O	O	I-Entity
and	O	O	O
torque	O	O	B-Entity
)	O	O	O
were	O	O	O
successfully	O	O	O
linearized	O	O	B-Entity
,	O	O	O
explaining	O	O	O
99	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
response	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
cortical	O	O	B-Entity
response	O	O	I-Entity
revealed	O	O	O
a	O	O	O
highly	O	O	O
nonlinear	O	O	O
relation	O	O	O
;	O	O	O
where	O	O	O
most	O	O	O
power	O	O	O
(	O	O	O
∼	O	O	O
80	O	O	O
%	O	O	O
)	O	O	O
occurred	O	O	O
at	O	O	O
non-stimulated	O	O	O
frequencies	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
only	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
response	O	O	O
could	O	O	O
be	O	O	O
explained	O	O	O
using	O	O	O
a	O	O	O
nonparametric	O	O	B-Entity
linear	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
the	O	O	O
recorded	O	O	O
evoked	O	O	B-Entity
cortical	O	O	I-Entity
responses	O	O	I-Entity
are	O	O	O
governed	O	O	O
by	O	O	O
nonlinearities	O	O	O
and	O	O	O
that	O	O	O
linear	O	O	B-Entity
methods	O	O	O
do	O	O	O
not	O	O	O
suffice	O	O	O
when	O	O	O
describing	O	O	O
the	O	O	O
relation	O	O	O
between	O	O	O
mechanical	O	O	B-Entity
stimulus	O	O	I-Entity
and	O	O	O
cortical	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

-DOCSTART- (27306679)

Using	O	O	B-Entity
melanopsin	O	O	B-Entity
to	O	O	O
study	O	O	B-Entity
G	O	O	B-Entity
protein	O	O	I-Entity
signaling	O	O	I-Entity
in	O	O	O
cortical	O	O	B-Entity
neurons	O	O	O

Our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
G	O	O	B-Entity
protein-coupled	O	O	I-Entity
receptors	O	O	I-Entity
(	O	O	O
GPCRs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
CNS	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
hampered	O	O	O
by	O	O	O
the	O	O	O
limited	O	O	O
availability	O	O	O
of	O	O	O
tools	O	O	B-Entity
allowing	O	O	O
for	O	O	O
the	O	O	O
study	O	O	B-Entity
of	O	O	O
their	O	O	O
signaling	O	O	B-Entity
with	O	O	O
precise	O	O	B-Entity
temporal	O	O	I-Entity
control	O	O	B-Entity
.	O	O	O

To	O	O	O
overcome	O	O	B-Entity
this	O	O	O
,	O	O	O
we	O	O	O
tested	O	O	B-Entity
the	O	O	O
utility	O	O	O
of	O	O	O
the	O	O	O
bistable	O	O	B-Entity
mammalian	O	O	B-Entity
opsin	O	O	B-Entity
melanopsin	O	O	B-Entity
to	O	O	O
examine	O	O	O
G	O	O	B-Entity
protein	O	O	I-Entity
signaling	O	O	I-Entity
in	O	O	O
CNS	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
we	O	O	O
used	O	O	B-Entity
biolistic	O	O	B-Entity
(	O	O	O
gene	O	O	B-Entity
gun	O	O	I-Entity
)	O	O	O
approaches	O	O	O
to	O	O	O
transfect	O	O	B-Entity
melanopsin	O	O	I-Entity
into	O	O	O
cortical	O	O	B-Entity
pyramidal	O	O	B-Entity
cells	O	O	I-Entity
maintained	O	O	B-Entity
in	O	O	O
organotypic	O	O	B-Entity
slice	O	O	I-Entity
culture	O	O	I-Entity
.	O	O	O

Whole	O	O	B-Entity
cell	O	O	I-Entity
recordings	O	O	I-Entity
from	O	O	O
transfected	O	O	B-Entity
neurons	O	O	I-Entity
indicated	O	O	O
that	O	O	O
application	O	O	O
of	O	O	O
blue	O	O	B-Entity
light	O	O	I-Entity
effectively	O	O	B-Entity
activated	O	O	B-Entity
the	O	O	O
transfected	O	O	B-Entity
melanopsin	O	O	B-Entity
to	O	O	O
elicit	O	O	B-Entity
the	O	O	O
canonical	O	O	O
biphasic	O	O	B-Entity
modulation	O	O	B-Entity
of	O	O	O
membrane	O	O	B-Entity
excitability	O	O	B-Entity
previously	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
GPCRs	O	O	B-Entity
coupling	O	O	B-Entity
to	O	O	O
Gαq-11	O	O	B-Entity
Remarkably	O	O	O
,	O	O	O
full	O	O	O
mimicry	O	O	O
of	O	O	O
exogenous	O	O	B-Entity
agonist	O	O	B-Entity
concentration	O	O	B-Entity
could	O	O	O
be	O	O	O
obtained	O	O	B-Entity
with	O	O	O
pulses	O	O	B-Entity
as	O	O	O
short	O	O	O
as	O	O	O
a	O	O	O
few	O	O	B-Entity
milliseconds	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
their	O	O	O
triggering	O	O	B-Entity
required	O	O	O
a	O	O	O
single	O	O	B-Entity
melanopsin	O	O	O
activation-deactivation	O	O	B-Entity
cycle	O	O	I-Entity
.	O	O	O

The	O	O	O
resulting	O	O	B-Entity
temporal	O	O	B-Entity
control	O	O	I-Entity
over	O	O	O
melanopsin	O	O	B-Entity
activation	O	O	B-Entity
allowed	O	O	O
us	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
activation	O	O	O
kinetics	O	O	B-Entity
of	O	O	O
different	O	O	O
components	O	O	O
of	O	O	O
the	O	O	O
electrophysiological	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
replaced	O	O	O
the	O	O	O
intracellular	O	O	B-Entity
loops	O	O	B-Entity
of	O	O	O
melanopsin	O	O	B-Entity
with	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
5-HT2A	O	O	B-Entity
receptor	O	O	I-Entity
to	O	O	O
create	O	O	O
a	O	O	O
light-activated	O	O	B-Entity
GPCR	O	O	B-Entity
capable	O	O	O
of	O	O	O
interacting	O	O	B-Entity
with	O	O	O
the	O	O	O
5-HT2A	O	O	O
receptor	O	O	O
interacting	O	O	O
proteins	O	O	B-Entity
.	O	O	O

The	O	O	O
resulting	O	O	B-Entity
chimera	O	O	B-Entity
expressed	O	O	B-Entity
weak	O	O	B-Entity
activity	O	O	B-Entity
but	O	O	O
validated	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
usefulness	O	O	B-Entity
of	O	O	O
melanopsin	O	O	B-Entity
as	O	O	O
a	O	O	O
tool	O	O	B-Entity
for	O	O	O
the	O	O	O
study	O	O	B-Entity
of	O	O	O
G	O	O	B-Entity
protein	O	O	I-Entity
signaling	O	O	I-Entity
in	O	O	O
CNS	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

-DOCSTART- (27308854)

Maternal	O	O	B-Entity
vitamin	O	O	B-Entity
D	O	O	I-Entity
levels	O	O	B-Entity
and	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
perinatal	O	O	O
death	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
maternal	O	O	B-Entity
vitamin	O	O	B-Entity
D	O	O	I-Entity
levels	O	O	B-Entity
and	O	O	O
perinatal	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
all	O	O	O
non-anomalous	O	O	O
,	O	O	O
singleton	O	O	B-Entity
births	O	O	B-Entity
(	O	O	O
≥24	O	O	O
weeks	O	O	B-Entity
)	O	O	O
with	O	O	O
perinatal	O	O	B-Entity
death	O	O	I-Entity
compared	O	O	O
to	O	O	O
a	O	O	O
matched	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Only	O	O	O
pregnancies	O	O	B-Entity
with	O	O	O
a	O	O	O
recorded	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
level	O	O	B-Entity
at	O	O	O
booking	O	O	O
(	O	O	O
8	O	O	O
-	O	O	O
19	O	O	O
weeks	O	O	B-Entity
gestation	O	O	B-Entity
)	O	O	O
were	O	O	O
included	O	O	O
for	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Maternal	O	O	B-Entity
vitamin	O	O	B-Entity
D	O	O	I-Entity
levels	O	O	B-Entity
were	O	O	O
categorized	O	O	O
into	O	O	O
normal	O	O	B-Entity
,	O	O	O
deficient	O	O	B-Entity
and	O	O	O
insufficient	O	O	B-Entity
cohorts	O	O	B-Entity
and	O	O	O
variables	O	O	B-Entity
compared	O	O	O
between	O	O	O
the	O	O	O
three	O	O	O
groups	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
31	O	O	O
perinatal	O	O	B-Entity
deaths	O	O	I-Entity
which	O	O	O
were	O	O	O
compared	O	O	O
to	O	O	O
111	O	O	O
controls	O	O	B-Entity
.	O	O	O

Median	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
levels	O	O	B-Entity
were	O	O	O
lower	O	O	O
in	O	O	O
the	O	O	O
perinatal	O	O	B-Entity
death	O	O	I-Entity
cohort	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
55	O	O	O
nmol/L	O	O	O
versus	O	O	O
64	O	O	O
nmol/L	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.43	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
deaths	O	O	B-Entity
between	O	O	O
the	O	O	O
normal	O	O	B-Entity
and	O	O	O
deficient	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.33	O	O	O
)	O	O	O
or	O	O	O
insufficient	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.09	O	O	O
)	O	O	O
groups	O	O	B-Entity
.	O	O	O

Low	O	O	O
maternal	O	O	B-Entity
vitamin	O	O	B-Entity
D	O	O	I-Entity
levels	O	O	B-Entity
at	O	O	O
booking	O	O	O
were	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
perinatal	O	O	B-Entity
demise	O	O	I-Entity
.	O	O	O

-DOCSTART- (27312354)

Effect	O	O	B-Entity
of	O	O	O
constitutive	O	O	B-Entity
inactivation	O	O	I-Entity
of	O	O	O
the	O	O	O
myostatin	O	O	B-Entity
gene	O	O	I-Entity
on	O	O	O
the	O	O	O
gain	O	O	B-Entity
in	O	O	O
muscle	O	O	B-Entity
strength	O	O	I-Entity
during	O	O	O
postnatal	O	O	B-Entity
growth	O	O	I-Entity
in	O	O	O
two	O	O	O
murine	O	O	B-Entity
models	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	O
constitutive	O	O	B-Entity
inactivation	O	O	I-Entity
of	O	O	O
the	O	O	O
gene	O	O	B-Entity
encoding	O	O	I-Entity
myostatin	O	O	I-Entity
on	O	O	O
the	O	O	O
gain	O	O	B-Entity
in	O	O	O
muscle	O	O	B-Entity
performance	O	O	I-Entity
during	O	O	O
postnatal	O	O	B-Entity
growth	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
well	O	O	O
characterized	O	O	O
.	O	O	O

We	O	O	O
analyzed	O	O	O
2	O	O	O
murine	O	O	B-Entity
myostatin	O	O	B-Entity
knockout	O	O	B-Entity
(	O	O	I-Entity
KO	O	O	I-Entity
)	O	O	I-Entity
models	O	O	I-Entity
,	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
the	O	O	O
Lee	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
KO(Lee	O	O	B-Entity
)	O	O	O
)	O	O	O
and	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
the	O	O	O
Grobet	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
KO(Grobet	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
measured	O	O	B-Entity
the	O	O	O
contraction	O	O	B-Entity
of	O	O	O
tibialis	O	O	B-Entity
anterior	O	O	I-Entity
muscle	O	O	I-Entity
in	O	O	B-Entity
situ	O	O	I-Entity
.	O	O	O

Absolute	O	O	B-Entity
maximal	O	O	I-Entity
isometric	O	O	I-Entity
force	O	O	I-Entity
was	O	O	O
increased	O	O	B-Entity
in	O	O	O
6-month-old	O	O	O
KO(Lee	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
KO(Grobet	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
,	O	O	O
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
wild-type	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Similarly	O	O	O
,	O	O	O
absolute	O	O	B-Entity
maximal	O	O	I-Entity
power	O	O	I-Entity
was	O	O	O
increased	O	O	B-Entity
in	O	O	O
6-month-old	O	O	O
KO(Lee	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
specific	O	O	B-Entity
maximal	O	O	B-Entity
force	O	O	I-Entity
(	O	O	O
relative	O	O	B-Entity
maximal	O	O	O
force	O	O	O
per	O	O	O
unit	O	O	O
of	O	O	O
muscle	O	O	B-Entity
mass	O	O	B-Entity
was	O	O	O
decreased	O	O	B-Entity
in	O	O	O
all	O	O	O
6-month-old	O	O	O
male	O	O	B-Entity
and	O	O	O
female	O	O	B-Entity
KO	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
except	O	O	B-Entity
in	O	O	O
6-month	O	O	B-Entity
-old	O	O	O
female	O	O	O
KO(Grobet	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
,	O	O	O
whereas	O	O	O
specific	O	O	O
maximal	O	O	B-Entity
power	O	O	I-Entity
was	O	O	O
reduced	O	O	B-Entity
only	O	O	O
in	O	O	O
male	O	O	O
KO(Lee	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
.	O	O	O

Genetic	O	O	B-Entity
inactivation	O	O	I-Entity
of	O	O	O
myostatin	O	O	B-Entity
increases	O	O	B-Entity
maximal	O	O	B-Entity
force	O	O	I-Entity
and	O	O	O
power	O	O	B-Entity
,	O	O	O
but	O	O	O
in	O	O	O
return	O	O	B-Entity
it	O	O	O
reduces	O	O	B-Entity
muscle	O	O	B-Entity
quality	O	O	B-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
male	O	O	B-Entity
mice	O	O	B-Entity
.	O	O	O

Muscle	O	O	O
Nerve	O	O	O
55	O	O	O
:	O	O	O
254	O	O	O
-	O	O	O
261	O	O	O
,	O	O	O
2017	O	O	O
.	O	O	O

-DOCSTART- (27314612)

Methylation	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
the	O	O	O
promoter	O	O	B-Entity
region	O	O	I-Entity
of	O	O	O
the	O	O	O
human	O	O	B-Entity
frizzled	O	O	B-Entity
9	O	O	I-Entity
gene	O	O	I-Entity
in	O	O	O
acute	O	O	O
myeloid	O	O	O
leukemia	O	O	O

The	O	O	O
FZD9	O	O	B-Entity
gene	O	O	I-Entity
is	O	O	O
located	O	O	O
at	O	O	O
chromosome	O	O	B-Entity
7q11.23	O	O	I-Entity
,	O	O	O
and	O	O	O
has	O	O	O
been	O	O	O
indicated	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
gene	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
examined	O	O	B-Entity
the	O	O	O
involvement	O	O	B-Entity
of	O	O	O
FZD9	O	O	B-Entity
promoter	O	O	B-Entity
methylation	O	O	B-Entity
in	O	O	O
the	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
FZD9	O	O	O
expression	O	O	B-Entity
in	O	O	O
leukemia	O	O	B-Entity
cells	O	O	B-Entity
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
FZD9	O	O	B-Entity
gene	O	O	I-Entity
was	O	O	O
absent	O	O	B-Entity
in	O	O	O
various	O	O	O
leukemic	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
while	O	O	O
it	O	O	O
was	O	O	O
restored	O	O	O
following	O	O	O
treatment	O	O	B-Entity
with	O	O	O
DNA	O	O	B-Entity
demethylating	O	O	I-Entity
agent	O	O	I-Entity
5-aza-2'-deoxycytidine	O	O	B-Entity
.	O	O	O

Bisulfite	O	O	B-Entity
sequencing	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
FZD9	O	O	B-Entity
promoter	O	O	B-Entity
region	O	O	I-Entity
showed	O	O	O
that	O	O	O
it	O	O	O
was	O	O	O
partially	O	O	O
methylated	O	O	B-Entity
in	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
in	O	O	O
which	O	O	O
FZD9	O	O	B-Entity
gene	O	O	I-Entity
was	O	O	O
not	O	O	O
expressed	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
in	O	O	O
the	O	O	O
promoter	O	O	B-Entity
region	O	O	I-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
inactivation	O	O	B-Entity
of	O	O	O
the	O	O	O
FZD9	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
represent	O	O	O
and	O	O	O
aberration	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
leukemia	O	O	B-Entity
,	O	O	O
since	O	O	O
DNA	O	O	O
was	O	O	O
not	O	O	O
methylated	O	O	B-Entity
in	O	O	O
normal	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Methylation	O	O	B-Entity
-specific	O	O	O
polymerase	O	O	B-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
promoter	O	O	B-Entity
region	O	O	I-Entity
of	O	O	O
the	O	O	O
FZD9	O	O	B-Entity
gene	O	O	I-Entity
was	O	O	O
frequently	O	O	B-Entity
methylated	O	O	B-Entity
in	O	O	O
primary	O	O	B-Entity
or	O	O	O
relapse	O	O	B-Entity
acute	O	O	B-Entity
myeloid	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
52.9	O	O	O
%	O	O	O
;	O	O	O
excluding	O	O	O
acute	O	O	B-Entity
promyelocytic	O	O	I-Entity
leukemia	O	O	I-Entity
)	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
methylation	O	O	B-Entity
was	O	O	O
infrequent	O	O	O
in	O	O	O
B-cell	O	O	B-Entity
acute	O	O	B-Entity
lymphocytic	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
5.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
methylation	O	O	B-Entity
profile	O	O	B-Entity
of	O	O	O
the	O	O	O
FZD9	O	O	B-Entity
gene	O	O	I-Entity
corresponded	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
a	O	O	O
candidate	O	O	O
tumor-suppressor	O	O	B-Entity
gene	O	O	I-Entity
in	O	O	O
acute	O	O	B-Entity
myeloid	O	O	I-Entity
leukemia	O	O	I-Entity
.	O	O	O

-DOCSTART- (27318197)

Identification	O	O	B-Entity
of	O	O	O
a	O	O	O
group	O	O	B-Entity
of	O	O	O
XTHs	O	O	B-Entity
genes	O	O	B-Entity
responding	O	O	O
to	O	O	O
heavy	O	O	B-Entity
metal	O	O	I-Entity
mercury	O	O	B-Entity
,	O	O	O
salinity	O	O	B-Entity
and	O	O	I-Entity
drought	O	O	I-Entity
stresses	O	O	I-Entity
in	O	O	O
Medicago	O	O	O
truncatula	O	O	O

Xyloglucan	O	O	B-Entity
endotransglucosylase/hydrolases	O	O	I-Entity
(	O	O	O
XTH	O	O	B-Entity
)	O	O	O
are	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
key	O	O	O
enzymes	O	O	B-Entity
regulating	O	O	B-Entity
cell	O	O	B-Entity
wall	O	O	I-Entity
construction	O	O	I-Entity
,	O	O	O
extension	O	O	B-Entity
and	O	O	O
metabolism	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
study	O	O	B-Entity
,	O	O	O
44	O	O	O
XTH	O	O	B-Entity
protein	O	O	I-Entity
genes	O	O	B-Entity
from	O	O	O
Medicago	O	O	B-Entity
truncatula	O	O	I-Entity
genome	O	O	B-Entity
were	O	O	O
identified	O	O	O
using	O	O	O
bioinformatics	O	O	B-Entity
,	O	O	O
microarray	O	O	B-Entity
and	O	O	O
RT-PCR	O	O	B-Entity
.	O	O	O

Each	O	O	O
XTH	O	O	B-Entity
was	O	O	O
showed	O	O	O
to	O	O	O
possess	O	O	O
a	O	O	O
highly	O	O	B-Entity
conserved	O	O	I-Entity
domain	O	O	I-Entity
(	O	O	O
(D/N)-E-(I/L/F/V)-D-(F/I/L)-E-(F/L)-L-G	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
most	O	O	O
of	O	O	O
XTHs	O	O	B-Entity
possess	O	O	O
four	O	O	O
Cys	O	O	B-Entity
in	O	O	O
the	O	O	O
C	O	O	B-Entity
terminal	O	O	I-Entity
region	O	O	I-Entity
,	O	O	O
which	O	O	O
suggests	O	O	O
the	O	O	O
potential	O	O	B-Entity
for	O	O	O
generating	O	O	O
disulfide	O	O	B-Entity
bonds	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
XTH	O	O	B-Entity
protein	O	O	B-Entity
sequences	O	O	I-Entity
,	O	O	O
these	O	O	O
XTHs	O	O	B-Entity
can	O	O	O
be	O	O	O
classified	O	O	O
into	O	O	O
three	O	O	O
major	O	O	O
families	O	O	B-Entity
and	O	O	O
each	O	O	O
family	O	O	B-Entity
can	O	O	O
be	O	O	O
subdivided	O	O	O
into	O	O	O
more	O	O	O
groups	O	O	B-Entity
.	O	O	O

Examination	O	O	O
of	O	O	O
the	O	O	O
genomic	O	O	B-Entity
location	O	O	I-Entity
of	O	O	O
XTH	O	O	B-Entity
genes	O	O	B-Entity
on	O	O	O
M.	O	O	B-Entity
truncatula	O	O	I-Entity
chromosomes	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
evolutional	O	O	B-Entity
expansion	O	O	I-Entity
of	O	O	O
the	O	O	O
genes	O	O	O
was	O	O	O
possibly	O	O	O
attributed	O	O	O
to	O	O	O
localized	O	O	B-Entity
gene	O	O	B-Entity
duplications	O	O	I-Entity
.	O	O	O

To	O	O	O
investigate	O	O	O
the	O	O	O
possible	O	O	O
involvement	O	O	B-Entity
of	O	O	O
the	O	O	O
XTHs	O	O	B-Entity
responding	O	O	O
to	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
and	O	O	O
other	O	O	O
abiotic	O	O	B-Entity
stresses	O	O	I-Entity
,	O	O	O
the	O	O	O
XTH	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
exposed	O	O	O
to	O	O	O
heavy	O	O	B-Entity
metal	O	O	I-Entity
(	O	O	O
Hg	O	O	B-Entity
or	O	O	O
Cu	O	O	B-Entity
)	O	O	O
,	O	O	O
salt	O	O	B-Entity
and	O	O	I-Entity
drought	O	O	I-Entity
stresses	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
28	O	O	O
,	O	O	O
21	O	O	O
and	O	O	O
21	O	O	O
MtXTH	O	O	B-Entity
genes	O	O	I-Entity
found	O	O	O
to	O	O	O
respond	O	O	O
to	O	O	O
HgCl2	O	O	B-Entity
,	O	O	O
salt	O	O	B-Entity
and	O	O	I-Entity
drought	O	O	I-Entity
stresses	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
but	O	O	O
their	O	O	O
expression	O	O	B-Entity
were	O	O	O
different	O	O	O
under	O	O	O
the	O	O	O
stresses	O	O	O
.	O	O	O

Some	O	O	O
of	O	O	O
the	O	O	O
XTH	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
well	O	O	O
confirmed	O	O	O
by	O	O	O
quantitative	O	O	B-Entity
RT-PCR	O	O	B-Entity
(	O	O	O
qRT-PCR	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
further	O	O	O
specified	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
a	O	O	O
XTH	O	O	B-Entity
gene	O	O	I-Entity
Medtr4g128580	O	O	B-Entity
(	O	O	O
MtXTH3	O	O	B-Entity
)	O	O	O
under	O	O	O
different	O	O	O
environmental	O	O	B-Entity
stresses	O	O	I-Entity
,	O	O	O
and	O	O	O
showed	O	O	O
that	O	O	O
MtXTH3	O	O	O
was	O	O	O
induced	O	O	O
by	O	O	O
Hg	O	O	B-Entity
exposure	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
indicated	O	O	O
that	O	O	O
a	O	O	O
group	O	O	B-Entity
of	O	O	O
MtXTHs	O	O	B-Entity
could	O	O	O
be	O	O	O
differentially	O	O	O
expressed	O	O	B-Entity
under	O	O	O
the	O	O	O
environmental	O	O	B-Entity
stresses	O	O	I-Entity
.	O	O	O

-DOCSTART- (27318553)

Vestibular	O	O	B-Entity
disorders	O	O	I-Entity
and	O	O	O
nausea	O	O	B-Entity
during	O	O	O
head	O	O	B-Entity
and	O	O	O
neck	O	O	B-Entity
intensity-modulated	O	O	O
radiation	O	O	O
therapy	O	O	O

We	O	O	O
studied	O	O	O
whether	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
relationship	O	O	B-Entity
between	O	O	O
nausea	O	O	B-Entity
and	O	O	O
vestibular	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
intensity	O	O	B-Entity
modulated	O	O	I-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
IMRT	O	O	B-Entity
)	O	O	O
for	O	O	O
head	O	O	B-Entity
and	O	O	O
neck	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
prospective	O	O	B-Entity
single-centre	O	O	I-Entity
study	O	O	I-Entity
that	O	O	O
enrolled	O	O	B-Entity
31	O	O	O
patients	O	O	B-Entity
.	O	O	O

A	O	O	O
videonystagmography	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
before	O	O	O
and	O	O	O
within	O	O	O
15	O	O	O
days	O	O	O
after	O	O	O
radiation	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
each	O	O	O
patient	O	O	B-Entity
.	O	O	O

Nausea	O	O	B-Entity
was	O	O	O
assessed	O	O	O
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
every	O	O	O
week	O	O	O
,	O	O	O
and	O	O	O
at	O	O	O
the	O	O	O
post-radiotherapy	O	O	B-Entity
videonystagmography	O	O	B-Entity
visit	O	O	O
.	O	O	O

Twenty-six	O	O	O
patients	O	O	B-Entity
had	O	O	O
benefited	O	O	O
from	O	O	O
a	O	O	O
complete	O	O	O
interpretable	O	O	O
videonystagmography	O	O	B-Entity
.	O	O	O

For	O	O	O
14	O	O	O
of	O	O	O
these	O	O	O
patients	O	O	B-Entity
vestibular	O	O	B-Entity
damage	O	O	I-Entity
was	O	O	O
diagnosed	O	O	B-Entity
post-radiotherapy	O	O	B-Entity
.	O	O	O

During	O	O	O
irradiation	O	O	B-Entity
,	O	O	O
six	O	O	O
patients	O	O	B-Entity
felt	O	O	O
nauseous	O	O	B-Entity
,	O	O	O
but	O	O	O
without	O	O	O
dizziness	O	O	B-Entity
.	O	O	O

In	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
a	O	O	O
relationship	O	O	B-Entity
statistically	O	O	B-Entity
significant	O	O	I-Entity
between	O	O	O
the	O	O	O
average	O	O	O
dose	O	O	B-Entity
received	O	O	O
by	O	O	O
the	O	O	O
vestibules	O	O	B-Entity
and	O	O	O
vestibular	O	O	B-Entity
disorder	O	O	I-Entity
videonystagmography	O	O	B-Entity
(	O	O	O
P=0.001	O	O	O
,	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
OR	O	O	B-Entity
]	O	O	O
:	O	O	O
1.08	O	O	O
[	O	O	O
1.025-.138	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
relationship	O	O	O
between	O	O	O
vestibular	O	O	O
disorder	O	O	O
videonystagmography	O	O	O
and	O	O	O
nausea	O	O	B-Entity
(	O	O	O
P=0.701	O	O	O
)	O	O	O
.	O	O	O

Irradiation	O	O	B-Entity
of	O	O	O
the	O	O	O
vestibular	O	O	B-Entity
system	O	O	I-Entity
during	O	O	O
IMRT	O	O	B-Entity
does	O	O	O
not	O	O	O
seem	O	O	O
to	O	O	O
explain	O	O	O
the	O	O	O
nausea	O	O	B-Entity
.	O	O	O

-DOCSTART- (27318951)

Preventing	O	O	O
Youth	O	O	B-Entity
Internalizing	O	O	B-Entity
Symptoms	O	O	I-Entity
Through	O	O	O
the	O	O	O
Familias	O	O	B-Entity
Unidas	O	O	I-Entity
Intervention	O	O	B-Entity
:	O	O	O
Examining	O	O	O
Variation	O	O	B-Entity
in	O	O	O
Response	O	O	O

Prevention	O	O	B-Entity
programs	O	O	I-Entity
that	O	O	O
strengthen	O	O	O
parenting	O	O	B-Entity
and	O	O	O
family	O	O	B-Entity
functioning	O	O	I-Entity
have	O	O	O
been	O	O	O
found	O	O	O
to	O	O	O
reduce	O	O	B-Entity
poor	O	O	B-Entity
behavioral	O	O	I-Entity
outcomes	O	O	O
in	O	O	O
adolescents	O	O	B-Entity
,	O	O	O
including	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
HIV	O	O	B-Entity
risk	O	O	I-Entity
,	O	O	O
externalizing	O	O	O
and	O	O	O
internalizing	O	O	B-Entity
problems	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
evidence	O	O	O
that	O	O	O
not	O	O	O
all	O	O	O
youth	O	O	B-Entity
benefit	O	O	O
similarly	O	O	O
from	O	O	O
these	O	O	O
programs	O	O	B-Entity
.	O	O	O

Familias	O	O	B-Entity
Unidas	O	O	I-Entity
is	O	O	O
a	O	O	O
family-focused	O	O	B-Entity
intervention	O	O	I-Entity
designed	O	O	O
to	O	O	O
prevent	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
and	O	O	O
sexual	O	O	B-Entity
risk	O	O	I-Entity
among	O	O	O
Hispanic	O	O	B-Entity
youth	O	O	B-Entity
and	O	O	O
has	O	O	O
recently	O	O	O
demonstrated	O	O	O
unanticipated	O	O	O
reductions	O	O	B-Entity
in	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
for	O	O	O
some	O	O	O
youth	O	O	O
.	O	O	O

This	O	O	O
paper	O	O	O
examines	O	O	O
variation	O	O	O
in	O	O	O
intervention	O	O	B-Entity
response	O	O	O
for	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
using	O	O	O
individual-level	O	O	B-Entity
data	O	O	I-Entity
pooled	O	O	O
across	O	O	O
four	O	O	O
distinct	O	O	O
Familias	O	O	B-Entity
Unidas	O	O	I-Entity
trials	O	O	B-Entity
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
266	O	O	O
eighth	O	O	B-Entity
grade	O	O	I-Entity
students	O	O	B-Entity
recruited	O	O	O
from	O	O	O
the	O	O	O
general	O	O	O
school	O	O	B-Entity
population	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
160	O	O	O
ninth	O	O	B-Entity
grade	O	O	I-Entity
students	O	O	O
from	O	O	O
the	O	O	O
general	O	O	O
school	O	O	O
population	O	O	O
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
213	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
conduct	O	O	B-Entity
,	O	O	O
aggression	O	O	B-Entity
,	O	O	O
and/or	O	O	O
attention	O	O	B-Entity
problems	O	O	I-Entity
;	O	O	O
and	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
242	O	O	O
adolescents	O	O	O
with	O	O	O
a	O	O	O
delinquency	O	O	B-Entity
history	O	O	O
.	O	O	O

Causal	O	O	B-Entity
inference	O	O	I-Entity
growth	O	O	I-Entity
mixture	O	O	I-Entity
modeling	O	O	I-Entity
suggests	O	O	O
a	O	O	O
three-	O	O	O
class	O	O	B-Entity
model	O	O	B-Entity
.	O	O	O

The	O	O	O
two	O	O	O
largest	O	O	O
classes	O	O	B-Entity
represent	O	O	O
youth	O	O	B-Entity
with	O	O	O
low	O	O	B-Entity
(	O	O	O
60	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
medium	O	O	B-Entity
(	O	O	O
27	O	O	O
%	O	O	O
)	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
and	O	O	O
both	O	O	O
intervention	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
participants	O	O	B-Entity
show	O	O	O
reductions	O	O	B-Entity
in	O	O	O
internalizing	O	O	O
symptoms	O	O	O
.	O	O	O

The	O	O	O
third	O	O	O
class	O	O	B-Entity
(	O	O	O
13	O	O	O
%	O	O	O
)	O	O	O
represents	O	O	O
youth	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
baseline	O	O	B-Entity
internalizing	O	O	B-Entity
symptoms	O	O	B-Entity
who	O	O	O
remain	O	O	O
at	O	O	O
steady	O	O	B-Entity
levels	O	O	O
of	O	O	O
internalizing	O	O	O
symptoms	O	O	O
when	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
intervention	O	O	B-Entity
,	O	O	O
but	O	O	O
who	O	O	O
experience	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
symptoms	O	O	O
under	O	O	O
the	O	O	O
control	O	O	B-Entity
condition	O	O	I-Entity
.	O	O	O

Female	O	O	B-Entity
gender	O	O	I-Entity
,	O	O	O
low	O	O	B-Entity
baseline	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
parent	O	O	B-Entity
-	O	O	O
adolescent	O	O	B-Entity
communication	O	O	B-Entity
,	O	O	O
and	O	O	O
older	O	O	B-Entity
age	O	O	I-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
membership	O	O	O
in	O	O	O
the	O	O	O
high-risk	O	O	B-Entity
class	O	O	B-Entity
.	O	O	O

These	O	O	O
synthesis	O	O	O
analyses	O	O	O
involving	O	O	O
a	O	O	O
large	O	O	O
sample	O	O	O
of	O	O	O
youth	O	O	B-Entity
with	O	O	O
varying	O	O	O
initial	O	O	B-Entity
risk	O	O	I-Entity
levels	O	O	I-Entity
represent	O	O	O
a	O	O	O
further	O	O	O
step	O	O	O
toward	O	O	O
strengthening	O	O	O
our	O	O	O
knowledge	O	O	O
of	O	O	O
preventive	O	O	B-Entity
intervention	O	O	I-Entity
response	O	O	B-Entity
and	O	O	O
improving	O	O	O
preventive	O	O	B-Entity
interventions	O	O	I-Entity
.	O	O	O

-DOCSTART- (27319985)

Acute	O	O	B-Entity
Kidney	O	O	I-Entity
Injury	O	O	I-Entity
Severity	O	O	B-Entity
and	O	O	O
Long-Term	O	O	B-Entity
Readmission	O	O	B-Entity
and	O	O	O
Mortality	O	O	B-Entity
After	O	O	O
Cardiac	O	O	O
Surgery	O	O	O

Acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
AKI	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
common	O	O	O
complication	O	O	B-Entity
after	O	O	O
cardiac	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

While	O	O	O
AKI	O	O	B-Entity
severity	O	O	B-Entity
is	O	O	O
known	O	O	O
to	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
short-term	O	O	B-Entity
outcomes	O	O	O
,	O	O	O
its	O	O	O
long-term	O	O	B-Entity
impact	O	O	O
is	O	O	O
less	O	O	O
well	O	O	O
understood	O	O	O
.	O	O	O

Adult	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
isolated	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
bypass	O	O	I-Entity
graft	O	O	I-Entity
surgery	O	O	I-Entity
at	O	O	O
eight	O	O	O
centers	O	O	O
were	O	O	O
enrolled	O	O	O
into	O	O	O
the	O	O	O
Northern	O	O	B-Entity
New	O	O	I-Entity
England	O	O	I-Entity
biomarker	O	O	I-Entity
registry	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1,610	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
excluded	O	O	O
if	O	O	O
they	O	O	O
had	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
15	O	O	O
)	O	O	O
or	O	O	O
died	O	O	B-Entity
during	O	O	O
index	O	O	B-Entity
admission	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
38	O	O	O
)	O	O	O
.	O	O	O

Severity	O	O	B-Entity
of	O	O	O
AKI	O	O	B-Entity
was	O	O	O
defined	O	O	O
using	O	O	O
the	O	O	O
Acute	O	O	B-Entity
Kidney	O	O	I-Entity
Injury	O	O	I-Entity
Network	O	O	I-Entity
(	O	O	O
AKIN	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
linked	O	O	O
our	O	O	O
cohort	O	O	B-Entity
to	O	O	O
national	O	O	B-Entity
Medicare	O	O	I-Entity
and	O	O	O
state	O	O	B-Entity
all-payer	O	O	I-Entity
claims	O	O	I-Entity
to	O	O	O
ascertain	O	O	O
readmissions	O	O	B-Entity
and	O	O	O
to	O	O	O
the	O	O	O
National	O	O	B-Entity
Death	O	O	I-Entity
Index	O	O	I-Entity
to	O	O	O
ascertain	O	O	O
survival	O	O	B-Entity
.	O	O	O

Kaplan-Meier	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
Cox	O	O	I-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
modeling	O	O	I-Entity
was	O	O	O
conducted	O	O	O
for	O	O	O
time	O	O	O
to	O	O	O
readmission	O	O	B-Entity
and	O	O	O
death	O	O	B-Entity
over	O	O	O
5	O	O	O
years	O	O	O
.	O	O	O

Within	O	O	O
5	O	O	O
years	O	O	O
,	O	O	O
513	O	O	O
patients	O	O	B-Entity
(	O	O	O
33.8	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
AKI	O	O	B-Entity
with	O	O	O
AKIN	O	O	B-Entity
stage	O	O	O
1	O	O	O
(	O	O	O
29.9	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
stage	O	O	O
2	O	O	O
to	O	O	O
3	O	O	O
(	O	O	O
3.9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
620	O	O	O
readmissions	O	O	B-Entity
(	O	O	O
39.9	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
370	O	O	O
deaths	O	O	B-Entity
(	O	O	O
23.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
adjustment	O	O	O
,	O	O	O
stage	O	O	O
1	O	O	O
AKI	O	O	B-Entity
patients	O	O	B-Entity
had	O	O	O
a	O	O	O
31	O	O	O
%	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
readmission	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
:	O	O	O
1.10	O	O	O
to	O	O	O
1.57	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
stage	O	O	O
2	O	O	O
or	O	O	O
3	O	O	O
patients	O	O	O
had	O	O	O
a	O	O	O
98	O	O	O
%	O	O	O
increased	O	O	O
risk	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.41	O	O	O
to	O	O	O
2.78	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
patients	O	O	O
having	O	O	O
no	O	O	B-Entity
AKI	O	O	O
.	O	O	O

Relative	O	O	O
to	O	O	O
patients	O	O	B-Entity
without	O	O	O
AKI	O	O	B-Entity
,	O	O	O
stage	O	O	O
1	O	O	O
patients	O	O	O
had	O	O	O
a	O	O	O
56	O	O	O
%	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
1.14	O	O	O
to	O	O	O
2.13	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
stage	O	O	O
2	O	O	O
or	O	O	O
3	O	O	O
patients	O	O	O
had	O	O	O
a	O	O	O
3.5	O	O	O
times	O	O	O
higher	O	O	O
risk	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
2.16	O	O	O
to	O	O	O
5.60	O	O	O
)	O	O	O
.	O	O	O

Severity	O	O	B-Entity
of	O	O	O
AKI	O	O	B-Entity
using	O	O	O
the	O	O	O
AKIN	O	O	B-Entity
stage	O	O	O
criteria	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
significantly	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
5-year	O	O	O
readmission	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
efforts	O	O	O
to	O	O	O
reduce	O	O	O
AKI	O	O	B-Entity
in	O	O	O
the	O	O	O
perioperative	O	O	B-Entity
period	O	O	I-Entity
may	O	O	O
have	O	O	O
a	O	O	O
significant	O	O	O
long-term	O	O	B-Entity
impact	O	O	O
on	O	O	O
patients	O	O	B-Entity
and	O	O	O
payers	O	O	O
in	O	O	O
reducing	O	O	O
mortality	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
utilization	O	O	I-Entity
.	O	O	O

-DOCSTART- (27321338)

Association	O	O	B-Entity
of	O	O	O
abdominal	O	O	B-Entity
fat	O	O	I-Entity
with	O	O	O
serum	O	O	B-Entity
amylase	O	O	B-Entity
in	O	O	O
an	O	O	O
older	O	O	B-Entity
cohort	O	O	B-Entity
:	O	O	O
The	O	O	O
Baltimore	O	O	B-Entity
Longitudinal	O	O	B-Entity
Study	O	O	I-Entity
of	O	O	O
Aging	O	O	O

Abdominal	O	O	B-Entity
fat	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
determinant	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
diseases	O	O	I-Entity
in	O	O	O
older	O	O	B-Entity
individuals	O	O	B-Entity
.	O	O	O

Obesity	O	O	B-Entity
and	O	O	O
diabetes	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
low	O	O	B-Entity
serum	O	O	B-Entity
amylase	O	O	I-Entity
(	O	O	I-Entity
SA	O	O	B-Entity
)	O	O	I-Entity
levels	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
SA	O	O	O
and	O	O	O
metabolic	O	O	B-Entity
disease	O	O	I-Entity
is	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
of	O	O	O
low	O	O	B-Entity
SA	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
and	O	O	O
sex	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
associations	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
amylase	O	O	B-Entity
with	O	O	O
abdominal	O	O	B-Entity
fat	O	O	I-Entity
in	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

In	O	O	O
community-dwelling	O	O	B-Entity
volunteers	O	O	B-Entity
from	O	O	O
the	O	O	O
Baltimore	O	O	B-Entity
Longitudinal	O	O	B-Entity
Study	O	O	I-Entity
of	O	O	O
Aging	O	O	B-Entity
(	O	O	O
778	O	O	O
participants	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
66.8±13.6	O	O	O
years	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
assessed	O	O	B-Entity
abdominal	O	O	B-Entity
fat	O	O	I-Entity
by	O	O	O
computed	O	O	B-Entity
tomography	O	O	I-Entity
and	O	O	O
diabetes	O	O	B-Entity
status	O	O	I-Entity
using	O	O	O
the	O	O	O
American	O	O	B-Entity
Diabetes	O	O	I-Entity
Association	O	O	I-Entity
criteria	O	O	B-Entity
.	O	O	O

Linear	O	O	B-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
assessed	O	O	B-Entity
the	O	O	O
cross-sectional	O	O	B-Entity
associations	O	O	I-Entity
between	O	O	O
abdominal	O	O	B-Entity
fat	O	O	I-Entity
and	O	O	O
SA	O	O	B-Entity
,	O	O	O
and	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
assessed	O	O	O
the	O	O	O
odds	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
given	O	O	O
low	O	O	B-Entity
SA	O	O	O
.	O	O	O

In	O	O	O
unadjusted	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
individuals	O	O	B-Entity
in	O	O	O
the	O	O	O
lowest	O	O	B-Entity
SA	O	O	B-Entity
quartile	O	O	B-Entity
(	O	O	O
<	O	O	O
48μ/L	O	O	O
)	O	O	O
had	O	O	O
1.97	O	O	O
greater	O	O	O
odds	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
1.01	O	O	O
-	O	O	O
3.83	O	O	O
)	O	O	O
than	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
highest	O	O	O
quartile	O	O	O
(	O	O	O
⩾80μ/L	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
association	O	O	B-Entity
was	O	O	O
no	O	O	O
longer	O	O	O
significant	O	O	B-Entity
after	O	O	O
adjusting	O	O	O
for	O	O	O
visceral	O	O	B-Entity
adipose	O	O	I-Entity
tissue	O	O	I-Entity
area	O	O	I-Entity
(	O	O	O
VAT	O	O	B-Entity
,	O	O	O
dm(2	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
abdominal	O	O	B-Entity
subcutaneous	O	O	I-Entity
adipose	O	O	I-Entity
tissue	O	O	I-Entity
(	O	O	O
SAT	O	O	B-Entity
,	O	O	O
dm(2	O	O	O
)	O	O	O
)	O	O	O
or	O	O	O
BMI	O	O	B-Entity
.	O	O	O

In	O	O	O
adjusted	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
VAT	O	O	B-Entity
and	O	O	O
SAT	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
SA	O	O	B-Entity
in	O	O	O
both	O	O	O
sexes	O	O	B-Entity
.	O	O	O

Among	O	O	O
women	O	O	B-Entity
,	O	O	O
SA	O	O	B-Entity
was	O	O	O
more	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
VAT	O	O	B-Entity
than	O	O	O
with	O	O	O
SAT	O	O	B-Entity
or	O	O	O
BMI	O	O	B-Entity
;	O	O	O
VAT	O	O	O
(	O	O	O
β=-0.117±0.048	O	O	O
,	O	O	O
P<0.001	O	O	O
)	O	O	O
,	O	O	O
SAT	O	O	O
(	O	O	O
β=-0.023±0.025	O	O	O
,	O	O	O
P=0.346	O	O	O
)	O	O	O
and	O	O	O
BMI	O	O	O
(	O	O	O
β=-0.0052±0.075	O	O	O
,	O	O	O
P=0.49	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
association	O	O	B-Entity
between	O	O	O
SA	O	O	B-Entity
and	O	O	O
diabetes	O	O	B-Entity
was	O	O	O
explained	O	O	O
mainly	O	O	O
by	O	O	O
abdominal	O	O	B-Entity
visceral	O	O	I-Entity
fat	O	O	I-Entity
.	O	O	O

In	O	O	O
women	O	O	B-Entity
,	O	O	O
SA	O	O	B-Entity
was	O	O	O
more	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
VAT	O	O	B-Entity
than	O	O	O
with	O	O	O
BMI	O	O	B-Entity
or	O	O	O
SAT	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
provide	O	O	O
motivation	O	O	O
for	O	O	O
future	O	O	O
mechanistic	O	O	B-Entity
studies	O	O	I-Entity
on	O	O	O
SA	O	O	B-Entity
's	O	O	I-Entity
role	O	O	O
in	O	O	O
metabolic	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

-DOCSTART- (27321568)

Efficacy	O	O	B-Entity
of	O	O	O
Intravenous	O	O	B-Entity
Chlorothiazide	O	O	B-Entity
for	O	O	O
Refractory	O	O	B-Entity
Acute	O	O	B-Entity
Decompensated	O	O	I-Entity
Heart	O	O	I-Entity
Failure	O	O	I-Entity
Unresponsive	O	O	B-Entity
to	O	O	O
Adjunct	O	O	B-Entity
Metolazone	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
intravenous	O	O	B-Entity
chlorothiazide	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
decompensated	O	O	I-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
(	O	O	O
ADHF	O	O	B-Entity
)	O	O	O
who	O	O	O
were	O	O	O
determined	O	O	O
to	O	O	O
be	O	O	O
loop	O	O	B-Entity
diuretic	O	O	I-Entity
resistant	O	O	B-Entity
and	O	O	O
refractory	O	O	B-Entity
to	O	O	O
metolazone	O	O	B-Entity
.	O	O	O

Retrospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
with	O	O	O
patients	O	O	B-Entity
serving	O	O	O
as	O	O	O
their	O	O	O
own	O	O	O
controls	O	O	B-Entity
.	O	O	O

Large	O	O	B-Entity
,	O	O	O
academic	O	O	B-Entity
,	O	O	O
tertiary	O	O	B-Entity
care	O	O	I-Entity
hospital	O	O	I-Entity
.	O	O	O

Forty-five	O	O	O
patients	O	O	B-Entity
with	O	O	O
ADHF	O	O	B-Entity
who	O	O	O
had	O	O	O
an	O	O	O
inadequate	O	O	B-Entity
response	O	O	B-Entity
to	O	O	O
high-dose	O	O	B-Entity
loop	O	O	B-Entity
diuretics	O	O	I-Entity
and	O	O	O
then	O	O	O
received	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
dose	O	O	B-Entity
of	O	O	O
oral	O	O	B-Entity
metolazone	O	O	B-Entity
5	O	O	O
mg	O	O	O
or	O	O	O
greater	O	O	B-Entity
(	O	O	O
metolazone	O	O	O
index	O	O	B-Entity
dose	O	O	I-Entity
)	O	O	O
followed	O	O	O
by	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
dose	O	O	O
of	O	O	O
intravenous	O	O	B-Entity
chlorothiazide	O	O	B-Entity
500	O	O	O
mg	O	O	O
(	O	O	O
chlorothiazide	O	O	O
index	O	O	O
dose	O	O	O
)	O	O	O
if	O	O	O
the	O	O	O
response	O	O	O
to	O	O	O
metolazone	O	O	O
was	O	O	O
considered	O	O	O
inadequate	O	O	O
,	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
institutional	O	O	B-Entity
protocol	O	O	I-Entity
,	O	O	O
between	O	O	O
February	O	O	O
4	O	O	O
,	O	O	O
2013	O	O	O
,	O	O	O
and	O	O	O
February	O	O	O
28	O	O	O
,	O	O	O
2015	O	O	O
,	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

If	O	O	O
multiple	O	O	O
doses	O	O	B-Entity
of	O	O	O
metolazone	O	O	B-Entity
were	O	O	O
administered	O	O	B-Entity
,	O	O	O
the	O	O	O
last	O	O	O
dose	O	O	B-Entity
given	O	O	O
before	O	O	O
the	O	O	O
chlorothiazide	O	O	B-Entity
index	O	O	B-Entity
dose	O	O	I-Entity
was	O	O	O
considered	O	O	O
the	O	O	O
index	O	O	O
dose	O	O	O
;	O	O	O
the	O	O	O
metolazone	O	O	O
index	O	O	O
dose	O	O	O
had	O	O	O
to	O	O	O
have	O	O	O
been	O	O	O
administered	O	O	O
more	O	O	O
than	O	O	O
2	O	O	O
hours	O	O	B-Entity
before	O	O	O
the	O	O	O
chlorothiazide	O	O	O
index	O	O	O
dose	O	O	O
.	O	O	O

Data	O	O	B-Entity
for	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
90	O	O	O
diuretic	O	O	B-Entity
doses	O	O	B-Entity
(	O	O	O
45	O	O	O
metolazone	O	O	B-Entity
,	O	O	O
45	O	O	O
chlorothiazide	O	O	B-Entity
)	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
median	O	O	O
dose	O	O	B-Entity
of	O	O	O
loop	O	O	B-Entity
diuretic	O	O	I-Entity
in	O	O	O
intravenous	O	O	B-Entity
furosemide	O	O	B-Entity
equivalents	O	O	O
given	O	O	O
over	O	O	O
the	O	O	O
24-	O	O	O
hour	O	O	B-Entity
period	O	O	B-Entity
before	O	O	O
the	O	O	O
metolazone	O	O	B-Entity
index	O	O	B-Entity
dose	O	O	I-Entity
was	O	O	O
400	O	O	O
mg	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
length	O	O	O
of	O	O	O
stay	O	O	B-Entity
was	O	O	O
34.7	O	O	O
days	O	O	B-Entity
,	O	O	O
and	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
was	O	O	O
35.6	O	O	O
%	O	O	O
(	O	O	O
16/45	O	O	O
patients	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	O
end	O	O	B-Entity
point	O	O	I-Entity
of	O	O	O
a	O	O	O
net-negative	O	O	B-Entity
urine	O	O	B-Entity
output	O	O	I-Entity
of	O	O	O
500	O	O	O
ml	O	O	O
or	O	O	O
greater	O	O	O
during	O	O	O
the	O	O	O
12	O	O	O
hours	O	O	B-Entity
after	O	O	O
the	O	O	O
index	O	O	B-Entity
dose	O	O	I-Entity
occurred	O	O	O
in	O	O	O
42.2	O	O	O
%	O	O	O
(	O	O	O
19/45	O	O	O
patients	O	O	B-Entity
)	O	O	O
and	O	O	O
35.5	O	O	O
%	O	O	O
(	O	O	O
16/45	O	O	O
patients	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
chlorothiazide	O	O	B-Entity
and	O	O	O
metolazone	O	O	B-Entity
doses	O	O	B-Entity
,	O	O	O
respectively	O	O	O
(	O	O	O
p=0.581	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
median	O	O	O
12-	O	O	O
hour	O	O	B-Entity
urine	O	O	B-Entity
output	O	O	I-Entity
following	O	O	O
administration	O	O	B-Entity
of	O	O	O
metolazone	O	O	B-Entity
was	O	O	O
810	O	O	O
ml	O	O	O
(	O	O	O
interquartile	O	O	B-Entity
range	O	O	I-Entity
[	O	O	O
IQR	O	O	B-Entity
]	O	O	O
866	O	O	O
ml	O	O	O
)	O	O	O
versus	O	O	O
1075	O	O	O
ml	O	O	O
(	O	O	O
IQR	O	O	O
940	O	O	O
ml	O	O	O
)	O	O	O
following	O	O	O
administration	O	O	O
of	O	O	O
chlorothiazide	O	O	B-Entity
(	O	O	O
p=0.363	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
metolazone	O	O	B-Entity
,	O	O	O
the	O	O	O
chlorothiazide	O	O	B-Entity
doses	O	O	B-Entity
did	O	O	O
not	O	O	O
result	O	O	O
in	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
urine	O	O	B-Entity
output	O	O	I-Entity
of	O	O	O
at	O	O	O
least	O	O	O
500	O	O	O
ml	O	O	O
during	O	O	O
the	O	O	O
12	O	O	O
hours	O	O	B-Entity
following	O	O	O
the	O	O	O
dose	O	O	B-Entity
relative	O	O	O
to	O	O	O
the	O	O	O
12	O	O	O
hours	O	O	O
before	O	O	O
the	O	O	O
dose	O	O	O
(	O	O	O
31.1	O	O	O
%	O	O	O
vs	O	O	O
22.2	O	O	O
%	O	O	O
,	O	O	O
p=0.754	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
achievement	O	O	O
of	O	O	O
net-negative	O	O	B-Entity
urine	O	O	B-Entity
output	O	O	I-Entity
of	O	O	O
500	O	O	O
ml	O	O	O
or	O	O	O
greater	O	O	O
during	O	O	O
the	O	O	O
12	O	O	O
hours	O	O	B-Entity
following	O	O	O
the	O	O	O
chlorothiazide	O	O	B-Entity
or	O	O	O
metolazone	O	O	B-Entity
dose	O	O	B-Entity
was	O	O	O
noted	O	O	O
(	O	O	O
42.2	O	O	O
%	O	O	O
for	O	O	O
chlorothiazide	O	O	O
vs	O	O	O
35.5	O	O	O
%	O	O	O
for	O	O	O
metolazone	O	O	O
,	O	O	O
p=0.581	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
addition	O	O	O
of	O	O	O
intravenous	O	O	B-Entity
chlorothiazide	O	O	B-Entity
did	O	O	O
not	O	O	O
result	O	O	O
in	O	O	O
improved	O	O	B-Entity
diuresis	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
ADHF	O	O	B-Entity
determined	O	O	O
to	O	O	O
be	O	O	O
refractory	O	O	B-Entity
to	O	O	O
loop	O	O	B-Entity
diuretic	O	O	I-Entity
s	O	O	O
and	O	O	O
adjunctive	O	O	B-Entity
oral	O	O	B-Entity
metolazone	O	O	B-Entity
.	O	O	O

-DOCSTART- (27322653)

Comparisons	O	O	B-Entity
of	O	O	O
Safety	O	O	B-Entity
and	O	O	O
Clinical	O	O	B-Entity
Outcomes	O	O	B-Entity
Between	O	O	O
Multiple-level	O	O	B-Entity
and	O	O	O
Single-level	O	O	B-Entity
Cervical	O	O	I-Entity
Disk	O	O	I-Entity
Replacement	O	O	I-Entity
for	O	O	O
Cervical	O	O	B-Entity
Spondylosis	O	O	I-Entity
:	O	O	O
A	O	O	O
Systematic	O	O	B-Entity
Review	O	O	I-Entity
and	O	O	O
Meta-analysis	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
meta-analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
multiple-level	O	O	B-Entity
cervical	O	O	I-Entity
disk	O	O	I-Entity
replacement	O	O	I-Entity
(	O	O	O
CDR	O	O	B-Entity
)	O	O	O
over	O	O	O
single-level	O	O	B-Entity
CDR	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
cervical	O	O	B-Entity
spondylosis	O	O	I-Entity
.	O	O	O

Some	O	O	O
authors	O	O	O
advocate	O	O	O
for	O	O	O
the	O	O	O
multiple-level	O	O	B-Entity
CDR	O	O	I-Entity
instead	O	O	O
of	O	O	O
anterior	O	O	B-Entity
decompression	O	O	B-Entity
and	O	O	O
fusion	O	O	B-Entity
in	O	O	O
cervical	O	O	B-Entity
multiple-level	O	O	I-Entity
spondylosis	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
whether	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
multi-level	O	O	B-Entity
CDR	O	O	I-Entity
are	O	O	O
as	O	O	O
favorable	O	O	O
as	O	O	O
that	O	O	O
of	O	O	O
single-level	O	O	B-Entity
CDR	O	O	I-Entity
remains	O	O	O
controversial	O	O	O
.	O	O	O

MEDLINE	O	O	B-Entity
,	O	O	O
EMBASE	O	O	B-Entity
,	O	O	O
and	O	O	O
Cochrane	O	O	B-Entity
library	O	O	I-Entity
databases	O	O	I-Entity
were	O	O	O
searched	O	O	O
up	O	O	O
to	O	O	O
November	O	O	O
2015	O	O	O
for	O	O	O
controlled	O	O	B-Entity
studies	O	O	I-Entity
that	O	O	O
compared	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	B-Entity
of	O	O	O
single-level	O	O	B-Entity
and	O	O	O
multiple-level	O	O	B-Entity
CDR	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
cervical	O	O	B-Entity
spondylosis	O	O	I-Entity
.	O	O	O

The	O	O	O
following	O	O	O
outcomes	O	O	B-Entity
were	O	O	O
extracted	O	O	O
and	O	O	O
analyzed	O	O	B-Entity
:	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
and	O	O	O
reoperation	O	O	B-Entity
,	O	O	O
preoperative	O	O	B-Entity
and	O	O	O
postoperative	O	O	B-Entity
Neck	O	O	B-Entity
Disability	O	O	I-Entity
Index	O	O	I-Entity
scores	O	O	I-Entity
,	O	O	O
preoperative	O	O	O
and	O	O	O
postoperative	O	O	O
Visual	O	O	B-Entity
Analog	O	O	I-Entity
Scale	O	O	I-Entity
scores	O	O	I-Entity
,	O	O	O
and	O	O	O
success	O	O	B-Entity
rate	O	O	B-Entity
using	O	O	O
the	O	O	O
Odom	O	O	B-Entity
grading	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Ten	O	O	O
studies	O	O	B-Entity
involving	O	O	O
1402	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
:	O	O	O
including	O	O	O
3	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
,	O	O	O
5	O	O	O
prospective	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
and	O	O	O
3	O	O	O
retrospective	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

No	O	O	O
significant	O	O	O
differences	O	O	O
between	O	O	O
single-level	O	O	B-Entity
and	O	O	O
multiple-level	O	O	B-Entity
groups	O	O	O
were	O	O	O
found	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
and	O	O	O
reoperation	O	O	B-Entity
rate	O	O	B-Entity
,	O	O	O
Neck	O	O	B-Entity
Disability	O	O	I-Entity
Index	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
Visual	O	O	B-Entity
Analog	O	O	I-Entity
Scale	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
and	O	O	O
success	O	O	B-Entity
rate	O	O	O
using	O	O	O
the	O	O	O
Odom	O	O	B-Entity
grading	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
this	O	O	O
meta-analysis	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	B-Entity
of	O	O	O
multiple-level	O	O	B-Entity
CDR	O	O	I-Entity
are	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
single-level	O	O	B-Entity
CDR	O	O	I-Entity
for	O	O	O
cervical	O	O	B-Entity
spondylosis	O	O	I-Entity
,	O	O	O
which	O	O	O
suggests	O	O	O
the	O	O	O
multiple-level	O	O	O
CDR	O	O	O
is	O	O	O
as	O	O	O
effective	O	O	B-Entity
and	O	O	O
safe	O	O	B-Entity
as	O	O	O
the	O	O	O
single-level	O	O	O
CDR	O	O	O
.	O	O	O

Nonetheless	O	O	O
,	O	O	O
more	O	O	O
well-designed	O	O	O
studies	O	O	B-Entity
are	O	O	O
needed	O	O	O
for	O	O	O
further	O	O	O
evaluation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27330692)

Evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
Effects	O	O	B-Entity
of	O	O	I-Entity
Intravenous	O	O	B-Entity
and	O	O	O
Percutaneous	O	O	B-Entity
Low	O	O	B-Entity
Level	O	O	I-Entity
Laser	O	O	I-Entity
Therapy	O	O	I-Entity
in	O	O	O
the	O	O	O
Management	O	O	B-Entity
of	O	O	O
Shoulder	O	O	B-Entity
Myofascial	O	O	O
Pain	O	O	O
Syndrome	O	O	O

Myofascial	O	O	B-Entity
pain	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
MPS	O	O	B-Entity
)	O	O	O
treatment	O	O	B-Entity
is	O	O	O
challenging	O	O	O
with	O	O	O
a	O	O	O
high	O	O	O
recurrence	O	O	O
rate	O	O	O
and	O	O	O
still	O	O	O
lacks	O	O	O
a	O	O	O
clear	O	O	O
treatment	O	O	B-Entity
frame	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
research	O	O	O
on	O	O	O
new	O	O	O
,	O	O	O
more	O	O	O
efficient	O	O	B-Entity
and	O	O	O
long	O	O	O
lasting	O	O	O
effect	O	O	O
treatment	O	O	B-Entity
modalities	O	O	B-Entity
is	O	O	O
necessary	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
looked	O	O	O
at	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
intravenous	O	O	B-Entity
laser	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
IVL	O	O	B-Entity
)	O	O	O
and	O	O	O
percutaneous	O	O	B-Entity
low	O	O	B-Entity
level	O	O	I-Entity
laser	O	O	I-Entity
(	O	O	O
PLLL	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
shoulder	O	O	B-Entity
MPS	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
,	O	O	O
30	O	O	O
patients	O	O	B-Entity
fulfilling	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
were	O	O	O
randomly	O	O	O
equally	O	O	O
allocated	O	O	O
to	O	O	O
3	O	O	O
groups	O	O	O
,	O	O	O
control	O	O	B-Entity
,	O	O	O
IVL	O	O	B-Entity
and	O	O	O
PLLL	O	O	B-Entity
.	O	O	O

Control	O	O	B-Entity
group	O	O	I-Entity
received	O	O	O
12	O	O	O
sessions	O	O	O
of	O	O	O
placebo	O	O	B-Entity
low	O	O	B-Entity
level	O	O	I-Entity
laser	O	O	I-Entity
,	O	O	O
IVL	O	O	B-Entity
group	O	O	I-Entity
received	O	O	O
12	O	O	O
sessions	O	O	O
of	O	O	O
IVL	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
and	O	O	O
PLLL	O	O	B-Entity
group	O	O	I-Entity
received	O	O	O
12	O	O	O
sessions	O	O	O
of	O	O	O
PLLL	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
trained	O	O	O
for	O	O	O
better	O	O	B-Entity
body	O	O	B-Entity
posture	O	O	I-Entity
,	O	O	O
body	O	O	B-Entity
mechanics	O	O	I-Entity
,	O	O	O
gentle	O	O	B-Entity
massage	O	O	I-Entity
of	O	O	O
trigger	O	O	B-Entity
points	O	O	I-Entity
,	O	O	O
stretching	O	O	B-Entity
exercises	O	O	I-Entity
of	O	O	O
affected	O	O	B-Entity
muscle	O	O	B-Entity
(	O	O	O
trapezius	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
received	O	O	O
10	O	O	O
mg	O	O	O
of	O	O	O
oral	O	O	B-Entity
nortriptyline	O	O	B-Entity
regimen	O	O	B-Entity
every	O	O	O
night	O	O	O
for	O	O	O
3	O	O	O
months	O	O	O
.	O	O	O

Outcomes	O	O	O
included	O	O	O
pain	O	O	B-Entity
severity	O	O	I-Entity
,	O	O	O
functional	O	O	B-Entity
disability	O	O	I-Entity
,	O	O	O
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
assessed	O	O	O
using	O	O	O
Numeric	O	O	B-Entity
Rating	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
NRS	O	O	B-Entity
)	O	O	O
,	O	O	O
Pain	O	O	B-Entity
Disability	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
PDI	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
Short	O	O	B-Entity
Form	O	O	I-Entity
Health	O	O	I-Entity
Survey	O	O	I-Entity
(	O	O	O
SF-12	O	O	B-Entity
)	O	O	O
.	O	O	O

Data	O	O	B-Entity
collected	O	O	I-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
analysis	O	O	B-Entity
of	O	O	I-Entity
variance	O	O	I-Entity
(	O	O	O
ANOVA	O	O	B-Entity
)	O	O	O
,	O	O	O
Mann-Whitney	O	O	B-Entity
and	O	O	O
t	O	O	B-Entity
tests	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
of	O	O	O
PDI	O	O	B-Entity
and	O	O	O
maximum	O	O	O
pain	O	O	B-Entity
intensity	O	O	I-Entity
during	O	O	O
day	O	O	O
and	O	O	O
night	O	O	O
significantly	O	O	O
reduced	O	O	B-Entity
in	O	O	O
both	O	O	O
PLLL	O	O	B-Entity
and	O	O	O
IVL	O	O	B-Entity
groups	O	O	I-Entity
compared	O	O	O
to	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Although	O	O	O
pain	O	O	O
severity	O	O	O
and	O	O	O
PDI	O	O	B-Entity
reduction	O	O	O
was	O	O	O
more	O	O	O
pronounced	O	O	O
in	O	O	O
IVL	O	O	B-Entity
group	O	O	I-Entity
compared	O	O	O
to	O	O	O
PLLL	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
the	O	O	O
differences	O	O	O
were	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
statistically	O	O	B-Entity
significantly	O	O	I-Entity
improved	O	O	O
in	O	O	O
both	O	O	O
IVL	O	O	B-Entity
and	O	O	O
PLLL	O	O	B-Entity
groups	O	O	I-Entity
compared	O	O	O
to	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
more	O	O	O
,	O	O	O
and	O	O	O
although	O	O	O
higher	O	O	O
in	O	O	O
IVL	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
the	O	O	O
difference	O	O	O
was	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
when	O	O	O
compared	O	O	O
to	O	O	O
PLLL	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
side	O	O	I-Entity
effects	O	O	I-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

Intravenous	O	O	B-Entity
laser	O	O	B-Entity
and	O	O	O
PLLL	O	O	B-Entity
therapy	O	O	I-Entity
had	O	O	O
a	O	O	O
positive	O	O	O
effect	O	O	B-Entity
on	O	O	O
pain	O	O	B-Entity
severity	O	O	I-Entity
and	O	O	O
PDI	O	O	B-Entity
reduction	O	O	O
,	O	O	O
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
in	O	O	O
this	O	O	O
study	O	O	O
.	O	O	O

Also	O	O	O
no	O	O	B-Entity
adverse	O	O	I-Entity
event	O	O	I-Entity
was	O	O	O
recorded	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
intravenous	O	O	B-Entity
lasers	O	O	B-Entity
and	O	O	O
PLLL	O	O	B-Entity
therapy	O	O	I-Entity
seem	O	O	O
to	O	O	O
be	O	O	O
effective	O	O	B-Entity
complementary	O	O	O
modalities	O	O	B-Entity
in	O	O	O
managing	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
shoulder	O	O	B-Entity
MPS	O	O	B-Entity
.	O	O	O

-DOCSTART- (27331407)

Structural	O	O	B-Entity
Insights	O	O	B-Entity
into	O	O	O
5-HT1A	O	O	B-Entity
/	O	O	O
D4	O	O	B-Entity
Selectivity	O	O	B-Entity
of	O	O	O
WAY-100635	O	O	B-Entity
Analogues	O	O	B-Entity
:	O	O	O
Molecular	O	O	B-Entity
Modeling	O	O	I-Entity
,	O	O	O
Synthesis	O	O	B-Entity
,	O	O	O
and	O	O	O
in	O	O	B-Entity
Vitro	O	O	I-Entity
Binding	O	O	O

The	O	O	O
resurgence	O	O	O
of	O	O	O
interest	O	O	O
in	O	O	O
5-HT1A	O	O	B-Entity
receptors	O	O	I-Entity
as	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
requires	O	O	O
the	O	O	O
existence	O	O	O
of	O	O	O
highly	O	O	O
selective	O	O	B-Entity
5-HT1A	O	O	O
ligands	O	O	B-Entity
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
WAY-100635	O	O	B-Entity
has	O	O	O
been	O	O	O
the	O	O	O
prototypical	O	O	B-Entity
antagonist	O	O	I-Entity
of	O	O	O
these	O	O	O
receptors	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
this	O	O	O
compound	O	O	B-Entity
also	O	O	O
has	O	O	O
significant	O	O	O
affinity	O	O	B-Entity
for	O	O	O
and	O	O	O
activity	O	O	O
at	O	O	O
D4	O	O	B-Entity
dopamine	O	O	I-Entity
receptors	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
context	O	O	O
,	O	O	O
this	O	O	O
work	O	O	O
was	O	O	O
aimed	O	O	O
at	O	O	O
better	O	O	O
understanding	O	O	O
the	O	O	O
5-HT1A	O	O	B-Entity
/	O	O	O
D4	O	O	B-Entity
selectivity	O	O	B-Entity
of	O	O	O
WAY-100635	O	O	B-Entity
and	O	O	O
analogues	O	O	B-Entity
from	O	O	O
a	O	O	O
structural	O	O	B-Entity
point	O	O	O
of	O	O	O
view	O	O	O
.	O	O	O

In	O	O	B-Entity
silico	O	O	I-Entity
investigations	O	O	B-Entity
revealed	O	O	O
two	O	O	O
key	O	O	O
interactions	O	O	B-Entity
for	O	O	O
the	O	O	O
5-HT1A	O	O	B-Entity
/	O	O	O
D4	O	O	B-Entity
selectivity	O	O	B-Entity
of	O	O	O
WAY-100635	O	O	B-Entity
and	O	O	O
analogues	O	O	B-Entity
.	O	O	O

First	O	O	O
,	O	O	O
a	O	O	O
hydrogen	O	O	B-Entity
bond	O	O	I-Entity
only	O	O	O
found	O	O	O
with	O	O	O
the	O	O	O
Ser	O	O	B-Entity
7.36	O	O	I-Entity
of	O	O	O
D4	O	O	B-Entity
receptor	O	O	I-Entity
appeared	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
key	O	O	O
for	O	O	O
a	O	O	O
higher	O	O	O
D4	O	O	O
affinity	O	O	B-Entity
for	O	O	O
newly	O	O	O
synthesized	O	O	B-Entity
aza	O	O	B-Entity
analogues	O	O	B-Entity
.	O	O	O

The	O	O	O
role	O	O	O
of	O	O	O
Ser	O	O	B-Entity
7.36	O	O	I-Entity
was	O	O	O
confirmed	O	O	O
as	O	O	O
the	O	O	O
affinity	O	O	B-Entity
of	O	O	O
aza	O	O	B-Entity
analogues	O	O	B-Entity
for	O	O	O
the	O	O	O
mutant	O	O	B-Entity
D4	O	O	B-Entity
receptor	O	O	I-Entity
S7.36A	O	O	I-Entity
was	O	O	O
reduced	O	O	O
.	O	O	O

Then	O	O	O
,	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
another	O	O	O
hydrogen	O	O	B-Entity
bond	O	O	I-Entity
with	O	O	O
the	O	O	O
conserved	O	O	O
Ser	O	O	B-Entity
5.42	O	O	I-Entity
residue	O	O	I-Entity
appeared	O	O	O
to	O	O	O
be	O	O	O
also	O	O	O
critical	O	O	O
for	O	O	O
D4	O	O	B-Entity
binding	O	O	B-Entity
.	O	O	O

-DOCSTART- (27334470)

Genomic	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
nontypeable	O	O	B-Entity
pneumococci	O	O	I-Entity
causing	O	O	O
invasive	O	O	B-Entity
pneumococcal	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
South	O	O	B-Entity
Africa	O	O	I-Entity
,	O	O	O
2003	O	O	O
-	O	O	O
2013	O	O	O

The	O	O	O
capsular	O	O	B-Entity
polysaccharide	O	O	I-Entity
is	O	O	O
the	O	O	O
principal	O	O	O
virulence	O	O	B-Entity
factor	O	O	I-Entity
of	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
and	O	O	O
a	O	O	O
target	O	O	B-Entity
for	O	O	O
current	O	O	O
pneumococcal	O	O	B-Entity
vaccines	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
some	O	O	O
pathogenic	O	O	B-Entity
pneumococci	O	O	B-Entity
are	O	O	O
serologically	O	O	B-Entity
nontypeable	O	O	I-Entity
[	O	O	O
nontypeable	O	O	B-Entity
pneumococci	O	O	I-Entity
(	O	O	O
NTPn	O	O	B-Entity
)	O	O	O
]	O	O	O
.	O	O	O

Due	O	O	O
to	O	O	O
their	O	O	O
relative	O	O	O
rarity	O	O	B-Entity
,	O	O	O
NTPn	O	O	B-Entity
are	O	O	O
poorly	O	O	O
characterized	O	O	B-Entity
,	O	O	O
and	O	O	O
,	O	O	O
as	O	O	O
such	O	O	O
,	O	O	O
limited	O	O	O
data	O	O	B-Entity
exist	O	O	O
which	O	O	O
describe	O	O	O
these	O	O	O
organisms	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
describe	O	O	O
disease	O	O	B-Entity
and	O	O	O
genotypically	O	O	B-Entity
characterize	O	O	B-Entity
NTPn	O	O	B-Entity
causing	O	O	O
invasive	O	O	B-Entity
pneumococcal	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
South	O	O	B-Entity
Africa	O	O	I-Entity
.	O	O	O

Isolates	O	O	B-Entity
were	O	O	O
detected	O	O	O
through	O	O	O
national	O	O	O
,	O	O	O
laboratory	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
surveillance	O	O	B-Entity
for	O	O	O
invasive	O	O	B-Entity
pneumococcal	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
South	O	O	B-Entity
Africa	O	O	I-Entity
and	O	O	O
characterized	O	O	B-Entity
by	O	O	O
whole	O	O	O
genome	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

We	O	O	O
predicted	O	O	O
ancestral	O	O	B-Entity
serotypes	O	O	B-Entity
(	O	O	O
serotypes	O	O	O
from	O	O	O
which	O	O	O
NTPn	O	O	B-Entity
may	O	O	O
have	O	O	O
originated	O	O	O
)	O	O	O
for	O	O	O
Group	O	O	B-Entity
I	O	O	I-Entity
NTPn	O	O	O
using	O	O	O
multilocus	O	O	B-Entity
sequence	O	O	I-Entity
typing	O	O	I-Entity
and	O	O	O
capsular	O	O	B-Entity
region	O	O	I-Entity
sequence	O	O	B-Entity
analyses	O	O	I-Entity
.	O	O	O

Antimicrobial	O	O	B-Entity
resistance	O	O	I-Entity
patterns	O	O	B-Entity
and	O	O	O
mutations	O	O	B-Entity
potentially	O	O	B-Entity
causing	O	O	O
nontypeability	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

From	O	O	O
2003	O	O	O
-	O	O	O
2013	O	O	O
,	O	O	O
39	O	O	O
(	O	O	O
0.1	O	O	O
%	O	O	O
,	O	O	O
39/32,824	O	O	O
)	O	O	O
NTPn	O	O	B-Entity
were	O	O	O
reported	O	O	O
.	O	O	O

Twenty-two	O	O	B-Entity
(	O	O	O
56	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
partial	O	O	B-Entity
capsular	O	O	B-Entity
genes	O	O	B-Entity
(	O	O	O
Group	O	O	B-Entity
I	O	O	I-Entity
)	O	O	O
and	O	O	O
17	O	O	O
(	O	O	O
44	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
complete	O	O	B-Entity
capsular	O	O	B-Entity
deletion	O	O	I-Entity
of	O	O	O
which	O	O	O
15	O	O	O
had	O	O	O
replacement	O	O	B-Entity
by	O	O	O
other	O	O	O
genes	O	O	O
(	O	O	O
Group	O	O	B-Entity
II	O	O	I-Entity
)	O	O	O
.	O	O	O

Seventy-nine	O	O	B-Entity
percent	O	O	B-Entity
(	O	O	O
31/39	O	O	O
)	O	O	O
of	O	O	O
our	O	O	O
NTPn	O	O	B-Entity
isolates	O	O	B-Entity
were	O	O	O
derived	O	O	O
from	O	O	O
encapsulated	O	O	B-Entity
S.	O	O	B-Entity
pneumoniae	O	O	I-Entity
.	O	O	O

Ancestral	O	O	O
serotypes	O	O	B-Entity
1	O	O	O
(	O	O	O
27	O	O	O
%	O	O	O
,	O	O	O
6/22	O	O	O
)	O	O	O
and	O	O	O
8	O	O	O
(	O	O	O
14	O	O	O
%	O	O	O
,	O	O	O
3/22	O	O	O
)	O	O	O
were	O	O	O
most	O	O	O
prevalent	O	O	O
,	O	O	O
and	O	O	O
59	O	O	O
%	O	O	O
(	O	O	O
13/22	O	O	O
)	O	O	O
of	O	O	O
ancestral	O	O	B-Entity
serotypes	O	O	O
were	O	O	O
serotypes	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
13-valent	O	O	B-Entity
pneumococcal	O	O	I-Entity
conjugate	O	O	I-Entity
vaccine	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
mutations	O	O	B-Entity
within	O	O	O
the	O	O	O
capsular	O	O	B-Entity
region	O	O	I-Entity
of	O	O	O
Group	O	O	B-Entity
I	O	O	I-Entity
NTPn	O	O	B-Entity
,	O	O	O
some	O	O	O
of	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
nontypeable	O	O	B-Entity
phenotype	O	O	B-Entity
.	O	O	O

Nonsusceptibility	O	O	B-Entity
to	O	O	O
tetracycline	O	O	B-Entity
and	O	O	O
erythromycin	O	O	B-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
NTPn	O	O	B-Entity
than	O	O	O
encapsulated	O	O	B-Entity
S.	O	O	B-Entity
pneumoniae	O	O	I-Entity
.	O	O	O

NTPn	O	O	B-Entity
are	O	O	O
currently	O	O	O
a	O	O	O
rare	O	O	O
cause	O	O	O
of	O	O	O
invasive	O	O	B-Entity
pneumococcal	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
South	O	O	B-Entity
Africa	O	O	I-Entity
and	O	O	O
represent	O	O	O
a	O	O	O
genetically	O	O	O
diverse	O	O	O
collection	O	O	O
of	O	O	O
isolates	O	O	O
.	O	O	O

-DOCSTART- (27334522)

Pre-hypertension	O	O	B-Entity
,	O	O	O
pre-diabetes	O	O	B-Entity
or	O	O	O
both	O	O	O
:	O	O	O
which	O	O	O
is	O	O	O
best	O	O	O
at	O	O	O
predicting	O	O	B-Entity
cardiovascular	O	O	B-Entity
events	O	O	I-Entity
in	O	O	O
the	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
?	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
value	O	O	O
of	O	O	O
pre-diabetes	O	O	B-Entity
and	O	O	O
pre-hypertension	O	O	B-Entity
in	O	O	O
predicting	O	O	B-Entity
cardiovascular	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

A	O	O	O
population	O	O	B-Entity
-based	O	O	O
,	O	O	O
cross-sectional	O	O	B-Entity
survey	O	O	I-Entity
was	O	O	O
conducted	O	O	O
,	O	O	O
representing	O	O	O
a	O	O	O
large	O	O	O
sample	O	O	O
of	O	O	O
the	O	O	O
general	O	O	O
Iranian	O	O	B-Entity
population	O	O	O
aged	O	O	O
35	O	O	O
years	O	O	B-Entity
and	O	O	O
older	O	O	O
from	O	O	O
the	O	O	O
Isfahan	O	O	B-Entity
Province	O	O	I-Entity
and	O	O	O
determined	O	O	O
using	O	O	O
a	O	O	O
random	O	O	B-Entity
,	O	O	I-Entity
multistage	O	O	I-Entity
cluster-sampling	O	O	I-Entity
10-year	O	O	O
cohort	O	O	B-Entity
.	O	O	O

The	O	O	O
five	O	O	O
end	O	O	O
points	O	O	O
considered	O	O	O
as	O	O	O
study	O	O	B-Entity
outcome	O	O	I-Entity
were	O	O	O
unstable	O	O	B-Entity
angina	O	O	I-Entity
(	O	O	O
UA	O	O	B-Entity
)	O	O	O
,	O	O	O
acute	O	O	B-Entity
occurrence	O	O	B-Entity
of	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
(	O	O	O
MI	O	O	B-Entity
)	O	O	O
,	O	O	O
sudden	O	O	B-Entity
cardiac	O	O	I-Entity
death	O	O	I-Entity
(	O	O	O
SCD	O	O	B-Entity
)	O	O	O
,	O	O	O
brain	O	O	B-Entity
stroke	O	O	I-Entity
and	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
CVD	O	O	B-Entity
)	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
6323	O	O	O
subjects	O	O	O
scheduled	O	O	O
for	O	O	O
assessment	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
state	O	O	I-Entity
617	O	O	O
were	O	O	O
diabetics	O	O	B-Entity
and	O	O	O
712	O	O	O
were	O	O	O
pre-diabetic	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
of	O	O	O
these	O	O	O
subjects	O	O	O
,	O	O	O
1754	O	O	O
had	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
2500	O	O	O
had	O	O	O
pre-hypertension	O	O	B-Entity
.	O	O	O

Analysing	O	O	O
only	O	O	O
pre-hypertension	O	O	B-Entity
,	O	O	O
pre-diabetes	O	O	B-Entity
and	O	O	O
its	O	O	O
combination	O	O	O
and	O	O	O
adjusted	O	O	O
for	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	O
variables	O	O	O
,	O	O	O
pre-hypertension	O	O	O
and	O	O	O
pre-diabetes	O	O	O
status	O	O	O
together	O	O	O
,	O	O	O
could	O	O	O
only	O	O	O
effectively	O	O	O
predict	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
MI	O	O	B-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
(HR)=3.21	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
):	O	O	O
1.06	O	O	O
-	O	O	O
9.76	O	O	O
,	O	O	O
P=0.04	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
same	O	O	O
COX	O	O	B-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
,	O	O	O
pre-hypertension	O	O	B-Entity
status	O	O	O
could	O	O	O
predict	O	O	O
UA	O	O	B-Entity
and	O	O	O
CVD	O	O	B-Entity
occurrence	O	O	B-Entity
(	O	O	O
HR	O	O	B-Entity
=	O	O	O
2.94	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
1.68	O	O	O
-	O	O	O
5.14	O	O	O
,	O	O	O
P<0.001	O	O	O
and	O	O	O
HR	O	O	O
=	O	O	O
1.74	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.23	O	O	O
-	O	O	O
2.47	O	O	O
,	O	O	O
P=0.002	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
pre-diabetes	O	O	B-Entity
status	O	O	O
could	O	O	O
not	O	O	O
predict	O	O	O
any	O	O	O
of	O	O	O
these	O	O	O
events	O	O	O
after	O	O	O
adjustment	O	O	O
for	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
provide	O	O	O
valuable	O	O	O
evidence	O	O	B-Entity
of	O	O	O
the	O	O	O
triggering	O	O	O
role	O	O	O
of	O	O	O
pre-hypertension	O	O	B-Entity
and	O	O	O
pre-diabetes	O	O	B-Entity
together	O	O	O
,	O	O	O
on	O	O	O
appearance	O	O	B-Entity
and	O	O	O
progression	O	O	B-Entity
of	O	O	O
MI	O	O	B-Entity
even	O	O	O
in	O	O	O
healthy	O	O	B-Entity
individuals	O	O	I-Entity
and	O	O	O
the	O	O	O
significant	O	O	O
predicting	O	O	B-Entity
value	O	O	O
of	O	O	O
pre-hypertension	O	O	O
on	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
UA	O	O	B-Entity
and	O	O	O
CVD	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
regard	O	O	O
,	O	O	O
the	O	O	O
value	O	O	O
of	O	O	O
pre-hypertension	O	O	B-Entity
and	O	O	O
pre-diabetes	O	O	B-Entity
together	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
pre-hypertension	O	O	O
state	O	O	O
alone	O	O	O
,	O	O	O
are	O	O	O
clearly	O	O	O
superior	O	O	O
to	O	O	O
pre-diabetes	O	O	O
state	O	O	O
alone	O	O	O
in	O	O	O
predicting	O	O	B-Entity
cardiovascular	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

-DOCSTART- (27336997)

Strategies	O	O	B-Entity
for	O	O	O
Successful	O	O	B-Entity
Clinical	O	O	B-Entity
Teaching	O	O	O

This	O	O	O
article	O	O	B-Entity
is	O	O	O
one	O	O	O
in	O	O	O
a	O	O	O
series	O	O	O
on	O	O	O
the	O	O	O
roles	O	O	B-Entity
of	O	O	O
adjunct	O	O	B-Entity
clinical	O	O	I-Entity
faculty	O	O	I-Entity
and	O	O	O
preceptors	O	O	B-Entity
,	O	O	O
who	O	O	O
teach	O	O	B-Entity
nursing	O	O	B-Entity
students	O	O	I-Entity
and	O	O	O
new	O	O	B-Entity
graduates	O	O	B-Entity
to	O	O	O
apply	O	O	B-Entity
knowledge	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
settings	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	B-Entity
describes	O	O	O
teaching	O	O	B-Entity
strategies	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
the	O	O	O
learning	O	O	B-Entity
environment	O	O	I-Entity
.	O	O	O

-DOCSTART- (27337390)

Learned	O	O	B-Entity
helplessness	O	O	I-Entity
at	O	O	O
fifty	O	O	O
:	O	O	O
Insights	O	O	B-Entity
from	O	O	O
neuroscience	O	O	O

Learned	O	O	B-Entity
helplessness	O	O	I-Entity
,	O	O	O
the	O	O	O
failure	O	O	B-Entity
to	O	O	O
escape	O	O	B-Entity
shock	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
uncontrollable	O	O	O
aversive	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
was	O	O	O
discovered	O	O	O
half	O	O	O
a	O	O	O
century	O	O	O
ago	O	O	O
.	O	O	O

Seligman	O	O	B-Entity
and	O	O	I-Entity
Maier	O	O	I-Entity
(	O	O	O
1967	O	O	O
)	O	O	O
theorized	O	O	B-Entity
that	O	O	O
animals	O	O	B-Entity
learned	O	O	B-Entity
that	O	O	O
outcomes	O	O	B-Entity
were	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
their	O	O	O
responses	O	O	B-Entity
-that	O	O	O
nothing	O	O	O
they	O	O	O
did	O	O	O
mattered-and	O	O	O
that	O	O	O
this	O	O	O
learning	O	O	B-Entity
undermined	O	O	O
trying	O	O	O
to	O	O	O
escape	O	O	B-Entity
.	O	O	O

The	O	O	O
mechanism	O	O	O
of	O	O	O
learned	O	O	B-Entity
helplessness	O	O	I-Entity
is	O	O	O
now	O	O	O
very	O	O	O
well-charted	O	O	B-Entity
biologically	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
original	O	O	O
theory	O	O	B-Entity
got	O	O	O
it	O	O	O
backward	O	O	O
.	O	O	O

Passivity	O	O	B-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
shock	O	O	B-Entity
is	O	O	O
not	O	O	O
learned	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
the	O	O	O
default	O	O	O
,	O	O	O
unlearned	O	O	O
response	O	O	B-Entity
to	O	O	O
prolonged	O	O	B-Entity
aversive	O	O	B-Entity
events	O	O	I-Entity
and	O	O	O
it	O	O	O
is	O	O	O
mediated	O	O	O
by	O	O	O
the	O	O	O
serotonergic	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
the	O	O	O
dorsal	O	O	B-Entity
raphe	O	O	I-Entity
nucleus	O	O	I-Entity
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
inhibits	O	O	B-Entity
escape	O	O	B-Entity
.	O	O	O

This	O	O	O
passivity	O	O	B-Entity
can	O	O	O
be	O	O	O
overcome	O	O	O
by	O	O	O
learning	O	O	B-Entity
control	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
activity	O	O	O
of	O	O	O
the	O	O	O
medial	O	O	B-Entity
prefrontal	O	O	I-Entity
cortex	O	O	I-Entity
,	O	O	O
which	O	O	O
subserves	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
control	O	O	O
leading	O	O	O
to	O	O	O
the	O	O	O
automatic	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
the	O	O	O
dorsal	O	O	B-Entity
raphe	O	O	I-Entity
nucleus	O	O	I-Entity
.	O	O	O

So	O	O	O
animals	O	O	B-Entity
learn	O	O	B-Entity
that	O	O	O
they	O	O	O
can	O	O	O
control	O	O	B-Entity
aversive	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
passive	O	O	B-Entity
failure	O	O	B-Entity
to	O	O	O
learn	O	O	O
to	O	O	O
escape	O	O	B-Entity
is	O	O	O
an	O	O	O
unlearned	O	O	O
reaction	O	O	B-Entity
to	O	O	O
prolonged	O	O	B-Entity
aversive	O	O	B-Entity
stimulation	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
alterations	O	O	B-Entity
of	O	O	O
the	O	O	O
ventromedial	O	O	B-Entity
prefrontal	O	O	I-Entity
cortex	O	O	I-Entity
-	O	O	O
dorsal	O	O	B-Entity
raphe	O	O	I-Entity
pathway	O	O	B-Entity
can	O	O	O
come	O	O	O
to	O	O	O
subserve	O	O	O
the	O	O	O
expectation	O	O	B-Entity
of	O	O	O
control	O	O	B-Entity
.	O	O	O

We	O	O	O
speculate	O	O	O
that	O	O	O
default	O	O	O
passivity	O	O	B-Entity
and	O	O	O
the	O	O	O
compensating	O	O	B-Entity
detection	O	O	B-Entity
and	O	O	O
expectation	O	O	B-Entity
of	O	O	O
control	O	O	B-Entity
may	O	O	O
have	O	O	O
substantial	O	O	O
implications	O	O	O
for	O	O	O
how	O	O	O
to	O	O	O
treat	O	O	B-Entity
depression	O	O	B-Entity
.	O	O	O

(	O	O	O
PsycINFO	O	O	O
Database	O	O	O
Record	O	O	O

-DOCSTART- (27339305)

A	O	O	O
peptide	O	O	B-Entity
from	O	O	O
human	O	O	B-Entity
β	O	O	I-Entity
thymosin	O	O	I-Entity
as	O	O	O
a	O	O	O
platform	O	O	O
for	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
new	O	O	O
anti-biofilm	O	O	B-Entity
agents	O	O	O
for	O	O	O
Staphylococcus	O	O	B-Entity
spp	O	O	I-Entity
.	O	O	I-Entity
and	O	O	O
Pseudomonas	O	O	O
aeruginosa	O	O	O

and	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
Conventional	O	O	O
antibiotics	O	O	B-Entity
might	O	O	O
fail	O	O	O
in	O	O	O
the	O	O	O
treatment	O	O	O
of	O	O	O
biofilm	O	O	B-Entity
-associated	O	O	O
infections	O	O	B-Entity
causing	O	O	O
infection	O	O	B-Entity
recurrence	O	O	B-Entity
and	O	O	O
chronicity	O	O	B-Entity
.	O	O	O

The	O	O	O
search	O	O	O
for	O	O	O
antimicrobial	O	O	B-Entity
peptides	O	O	I-Entity
has	O	O	O
been	O	O	O
performed	O	O	O
with	O	O	O
the	O	O	O
aim	O	O	O
to	O	O	O
discover	O	O	B-Entity
novel	O	O	O
anti-infective	O	O	B-Entity
agents	O	O	I-Entity
active	O	O	B-Entity
on	O	O	O
pathogens	O	O	B-Entity
in	O	O	O
both	O	O	O
planktonic	O	O	B-Entity
and	O	O	O
biofilm	O	O	B-Entity
associated	O	O	O
forms	O	O	O
.	O	O	O

The	O	O	O
fragment	O	O	B-Entity
9	O	O	O
-	O	O	O
19	O	O	O
of	O	O	O
human	O	O	B-Entity
thymosin	O	O	I-Entity
β4	O	O	I-Entity
was	O	O	O
studied	O	O	B-Entity
through	O	O	O
1	O	O	O
μs	O	O	O
MD	O	O	B-Entity
simulation	O	O	I-Entity
.	O	O	O

Two	O	O	O
main	O	O	O
conformations	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
peptide	O	O	I-Entity
were	O	O	O
detected	O	O	O
,	O	O	O
both	O	O	O
constituted	O	O	O
by	O	O	O
a	O	O	O
central	O	O	B-Entity
hydrophobic	O	O	I-Entity
core	O	O	I-Entity
and	O	O	O
by	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
peripheral	O	O	B-Entity
charged	O	O	O
residues	O	O	B-Entity
suggesting	O	O	O
a	O	O	O
possible	O	O	O
mechanism	O	O	O
of	O	O	O
interaction	O	O	B-Entity
with	O	O	O
two	O	O	O
models	O	O	B-Entity
of	O	O	O
biological	O	O	B-Entity
membranes	O	O	I-Entity
,	O	O	O
related	O	O	O
to	O	O	O
eukaryotic	O	O	B-Entity
or	O	O	O
bacterial	O	O	B-Entity
membrane	O	O	I-Entity
respectively	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
peptide	O	O	B-Entity
was	O	O	O
chemically	O	O	O
synthesized	O	O	O
and	O	O	O
its	O	O	O
antimicrobial	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
tested	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
against	O	O	O
planktonic	O	O	B-Entity
and	O	O	O
biofilm	O	O	B-Entity
form	O	O	O
of	O	O	O
a	O	O	O
group	O	O	B-Entity
of	O	O	O
reference	O	O	O
strains	O	O	B-Entity
of	O	O	O
Staphylococcus	O	O	O
spp	O	O	O
.	O	O	O

and	O	O	O

one	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
strain	O	O	B-Entity
.	O	O	O

The	O	O	O
human	O	O	B-Entity
thymosin	O	O	I-Entity
β4	O	O	I-Entity
fragment	O	O	B-Entity
EIEKFDKSKLK	O	O	B-Entity
showed	O	O	O
antibacterial	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
staphylococcal	O	O	B-Entity
strains	O	O	B-Entity
and	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
ATCC	O	O	O
15442	O	O	O
at	O	O	O
concentrations	O	O	B-Entity
from	O	O	O
12.5	O	O	O
to	O	O	O
6.2	O	O	O
mg/ml	O	O	O
and	O	O	O
inhibited	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
at	O	O	O
sub-inhibitory	O	O	B-Entity
concentrations	O	O	I-Entity
(	O	O	O
3.1	O	O	O
-	O	O	O
0.75	O	O	O
mg/ml	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
activity	O	O	B-Entity
of	O	O	O
the	O	O	O
fragment	O	O	B-Entity
in	O	O	O
inhibiting	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
,	O	O	O
could	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
conformations	O	O	B-Entity
highlighted	O	O	O
by	O	O	O
the	O	O	O
MD	O	O	B-Entity
simulations	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
its	O	O	O
interaction	O	O	B-Entity
with	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
membrane	O	O	I-Entity
.	O	O	O

Human	O	O	B-Entity
thymosin	O	O	I-Entity
β4	O	O	I-Entity
fragment	O	O	B-Entity
can	O	O	O
be	O	O	O
considered	O	O	O
a	O	O	O
promising	O	O	O
lead	O	O	B-Entity
compound	O	O	I-Entity
to	O	O	O
develop	O	O	O
novel	O	O	O
synthetic	O	O	O
or	O	O	O
recombinant	O	O	B-Entity
derivatives	O	O	I-Entity
with	O	O	O
improved	O	O	O
pharmaceutical	O	O	B-Entity
potential	O	O	O
.	O	O	O

-DOCSTART- (27339893)

Structural	O	O	B-Entity
Basis	O	O	B-Entity
for	O	O	O
Simvastatin	O	O	B-Entity
Competitive	O	O	B-Entity
Antagonism	O	O	I-Entity
of	O	O	O
Complement	O	O	O
Receptor	O	O	O
3	O	O	O

The	O	O	O
complement	O	O	B-Entity
system	O	O	I-Entity
is	O	O	O
an	O	O	O
important	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
response	O	O	I-Entity
to	O	O	O
infection	O	O	B-Entity
but	O	O	O
may	O	O	O
also	O	O	O
cause	O	O	O
severe	O	O	B-Entity
complications	O	O	I-Entity
during	O	O	O
inflammation	O	O	B-Entity
.	O	O	O

Small	O	O	B-Entity
molecule	O	O	I-Entity
antagonists	O	O	B-Entity
to	O	O	O
complement	O	O	B-Entity
receptor	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
CR3	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
widely	O	O	O
sought	O	O	O
,	O	O	O
but	O	O	O
a	O	O	O
structural	O	O	B-Entity
basis	O	O	B-Entity
for	O	O	O
their	O	O	O
mode	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
is	O	O	O
not	O	O	O
available	O	O	O
.	O	O	O

We	O	O	O
report	O	O	B-Entity
here	O	O	O
on	O	O	O
the	O	O	O
structure	O	O	B-Entity
of	O	O	O
the	O	O	O
human	O	O	B-Entity
CR3	O	O	B-Entity
ligand-binding	O	O	B-Entity
I	O	O	I-Entity
domain	O	O	I-Entity
in	O	O	O
complex	O	O	B-Entity
with	O	O	O
simvastatin	O	O	B-Entity
.	O	O	O

Simvastatin	O	O	B-Entity
targets	O	O	B-Entity
the	O	O	O
metal	O	O	B-Entity
ion-dependent	O	O	B-Entity
adhesion	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
the	O	O	O
open	O	O	O
,	O	O	O
ligand-binding	O	O	B-Entity
conformation	O	O	B-Entity
of	O	O	O
the	O	O	O
CR3	O	O	B-Entity
I	O	O	B-Entity
domain	O	O	I-Entity
by	O	O	O
direct	O	O	O
contact	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
chelated	O	O	B-Entity
Mg(2	O	O	I-Entity
+	O	O	I-Entity
)	O	O	I-Entity
ion	O	O	I-Entity
.	O	O	O

Simvastatin	O	O	B-Entity
antagonizes	O	O	B-Entity
I	O	O	B-Entity
domain	O	O	I-Entity
binding	O	O	I-Entity
to	O	O	O
the	O	O	O
complement	O	O	B-Entity
fragments	O	O	I-Entity
iC3b	O	O	B-Entity
and	O	O	O
C3d	O	O	B-Entity
but	O	O	O
not	O	O	O
to	O	O	O
intercellular	O	O	B-Entity
adhesion	O	O	I-Entity
molecule-1	O	O	I-Entity
.	O	O	O

By	O	O	O
virtue	O	O	B-Entity
of	O	O	O
the	O	O	O
I	O	O	B-Entity
domain	O	O	I-Entity
's	O	O	I-Entity
wide	O	O	O
distribution	O	O	B-Entity
in	O	O	O
binding	O	O	B-Entity
kinetics	O	O	B-Entity
to	O	O	O
ligands	O	O	B-Entity
,	O	O	O
it	O	O	O
was	O	O	O
possible	O	O	B-Entity
to	O	O	O
identify	O	O	O
ligand	O	O	B-Entity
binding	O	O	I-Entity
kinetics	O	O	O
as	O	O	O
discriminator	O	O	O
for	O	O	O
simvastatin	O	O	B-Entity
antagonism	O	O	B-Entity
.	O	O	O

In	O	O	O
static	O	O	B-Entity
cellular	O	O	B-Entity
experiments	O	O	B-Entity
,	O	O	O
15	O	O	O
-	O	O	O
25	O	O	O
μm	O	O	O
simvastatin	O	O	B-Entity
reduced	O	O	B-Entity
adhesion	O	O	B-Entity
by	O	O	O
K562	O	O	B-Entity
cells	O	O	I-Entity
expressing	O	O	B-Entity
recombinant	O	O	B-Entity
CR3	O	O	B-Entity
and	O	O	O
by	O	O	O
primary	O	O	B-Entity
human	O	O	B-Entity
monocytes	O	O	B-Entity
,	O	O	O
with	O	O	O
an	O	O	O
endogenous	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
this	O	O	O
receptor	O	O	B-Entity
.	O	O	O

Application	O	O	B-Entity
of	O	O	O
force	O	O	B-Entity
to	O	O	O
adhering	O	O	B-Entity
monocytes	O	O	B-Entity
potentiated	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
simvastatin	O	O	B-Entity
where	O	O	O
only	O	O	O
a	O	O	O
50	O	O	O
-	O	O	O
100	O	O	O
nm	O	O	O
concentration	O	O	B-Entity
of	O	O	O
the	O	O	O
drug	O	O	B-Entity
reduced	O	O	B-Entity
the	O	O	O
adhesion	O	O	B-Entity
by	O	O	O
20	O	O	O
-	O	O	O
40	O	O	O
%	O	O	O
compared	O	O	B-Entity
with	O	O	O
untreated	O	O	B-Entity
cells	O	O	B-Entity
.	O	O	O

The	O	O	O
ability	O	O	B-Entity
of	O	O	O
simvastatin	O	O	B-Entity
to	O	O	O
target	O	O	B-Entity
CR3	O	O	B-Entity
in	O	O	O
its	O	O	O
ligand	O	O	B-Entity
binding	O	O	I-Entity
-	O	O	O
activated	O	O	B-Entity
conformation	O	O	B-Entity
is	O	O	O
a	O	O	O
novel	O	O	B-Entity
mechanism	O	O	B-Entity
to	O	O	O
explain	O	O	O
the	O	O	O
known	O	O	O
anti-inflammatory	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
this	O	O	O
compound	O	O	B-Entity
,	O	O	O
in	O	O	O
particular	O	O	O
because	O	O	O
this	O	O	O
CR3	O	O	O
conformation	O	O	O
is	O	O	O
found	O	O	O
in	O	O	O
pro-inflammatory	O	O	B-Entity
environments	O	O	B-Entity
.	O	O	O

Our	O	O	O
report	O	O	B-Entity
points	O	O	O
to	O	O	O
new	O	O	O
designs	O	O	B-Entity
of	O	O	O
CR3	O	O	B-Entity
antagonists	O	O	B-Entity
and	O	O	O
opens	O	O	O
new	O	O	O
perspectives	O	O	O
and	O	O	O
identifies	O	O	B-Entity
druggable	O	O	B-Entity
receptors	O	O	B-Entity
from	O	O	O
characterization	O	O	B-Entity
of	O	O	O
the	O	O	O
ligand	O	O	B-Entity
binding	O	O	I-Entity
kinetics	O	O	B-Entity
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
antagonists	O	O	O
.	O	O	O

-DOCSTART- (27346336)

Common	O	O	B-Entity
Laboratory	O	O	B-Entity
Parameters	O	O	B-Entity
for	O	O	O
Differentiating	O	O	B-Entity
Between	O	O	O
Community-Acquired	O	O	B-Entity
and	O	O	O
Healthcare-Associated	O	O	O
Pneumonia	O	O	O

The	O	O	O
correct	O	O	B-Entity
diagnosis	O	O	B-Entity
of	O	O	O
healthcare-associated	O	O	B-Entity
pneumonia	O	O	I-Entity
(	O	O	O
HCAP	O	O	B-Entity
)	O	O	O
as	O	O	O
opposed	O	O	O
to	O	O	O
community-acquired	O	O	B-Entity
pneumonia	O	O	I-Entity
is	O	O	O
essential	O	O	B-Entity
for	O	O	O
the	O	O	O
selection	O	O	B-Entity
of	O	O	O
a	O	O	O
correct	O	O	O
empirical	O	O	B-Entity
antimicrobial	O	O	B-Entity
approach	O	O	O
,	O	O	O
reserving	O	O	O
the	O	O	O
broad-spectrum	O	O	B-Entity
or	O	O	O
highly	O	O	B-Entity
potent	O	O	I-Entity
antimicrobial	O	O	B-Entity
therapies	O	O	I-Entity
for	O	O	O
resistant	O	O	B-Entity
strains	O	O	B-Entity
most	O	O	O
commonly	O	O	O
present	O	O	O
in	O	O	O
HCAP	O	O	O
,	O	O	O
whereas	O	O	O
treating	O	O	B-Entity
the	O	O	O
less	O	O	O
resistant	O	O	O
strains	O	O	O
,	O	O	O
most	O	O	O
commonly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
community	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
care	O	O	I-Entity
facility	O	O	I-Entity
-	O	O	O
acquired	O	O	B-Entity
infections	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
more	O	O	O
targeted	O	O	B-Entity
empirical	O	O	B-Entity
approach	O	O	I-Entity
.	O	O	O

The	O	O	O
standard	O	O	B-Entity
approach	O	O	I-Entity
today	O	O	B-Entity
is	O	O	O
to	O	O	O
differentiate	O	O	B-Entity
between	O	O	O
the	O	O	O
two	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
medical	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
the	O	O	O
past	O	O	B-Entity
90	O	O	O
days	O	O	B-Entity
prior	O	O	O
to	O	O	O
admission	O	O	B-Entity
.	O	O	O

Measurable	O	O	B-Entity
,	O	O	O
quantitative	O	O	B-Entity
assessment	O	O	B-Entity
may	O	O	O
be	O	O	O
able	O	O	O
to	O	O	O
assist	O	O	B-Entity
in	O	O	O
this	O	O	O
decision	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
is	O	O	O
to	O	O	O
find	O	O	O
a	O	O	O
measurable	O	O	B-Entity
method	O	O	B-Entity
of	O	O	O
differentiating	O	O	B-Entity
between	O	O	O
community-acquired	O	O	B-Entity
and	O	O	O
healthcare-associated	O	O	B-Entity
pneumonias	O	O	I-Entity
.	O	O	O

The	O	O	O
records	O	O	B-Entity
of	O	O	O
126	O	O	O
patients	O	O	B-Entity
admitted	O	O	B-Entity
with	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
pneumonia	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
probable	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
their	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
in	O	O	O
accordance	O	O	O
with	O	O	O
common	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

The	O	O	O
routine	O	O	B-Entity
laboratory	O	O	B-Entity
work	O	O	I-Entity
taken	O	O	O
upon	O	O	O
admittance	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
logistical	O	O	B-Entity
regression	O	O	I-Entity
and	O	O	O
Student	O	O	B-Entity
's	O	O	I-Entity
t-test	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
red	O	O	B-Entity
blood	O	O	I-Entity
cell	O	O	I-Entity
distribution	O	O	I-Entity
width	O	O	I-Entity
and	O	O	O
the	O	O	O
neutrophil	O	O	B-Entity
-to-	O	O	I-Entity
lymphocyte	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
both	O	O	O
routine	O	O	B-Entity
parameters	O	O	I-Entity
obtained	O	O	O
in	O	O	O
a	O	O	O
simple	O	O	O
blood	O	O	B-Entity
count	O	O	I-Entity
,	O	O	O
can	O	O	O
each	O	O	O
assist	O	O	B-Entity
in	O	O	O
differentiating	O	O	B-Entity
between	O	O	O
community-acquired	O	O	B-Entity
and	O	O	O
healthcare-associated	O	O	B-Entity
pneumonias	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
found	O	O	O
two	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
parameters	O	O	I-Entity
that	O	O	O
may	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
adjuncts	O	O	O
to	O	O	O
the	O	O	O
medical	O	O	B-Entity
history	O	O	I-Entity
,	O	O	O
chest	O	O	B-Entity
radiography	O	O	I-Entity
and	O	O	O
other	O	O	B-Entity
parameters	O	O	I-Entity
in	O	O	O
forming	O	O	O
an	O	O	O
immediate	O	O	B-Entity
clinical	O	O	B-Entity
impression	O	O	I-Entity
of	O	O	O
a	O	O	O
patient	O	O	B-Entity
presenting	O	O	O
with	O	O	O
pneumonia	O	O	B-Entity
.	O	O	O

-DOCSTART- (27347792)

A	O	O	O
quasi-experimental	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
a	O	O	O
reminiscence	O	O	B-Entity
program	O	O	I-Entity
focused	O	O	O
on	O	O	O
autobiographical	O	O	B-Entity
memory	O	O	I-Entity
in	O	O	O
institutionalized	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
with	O	O	O
cognitive	O	O	O
impairment	O	O	O

Working	O	O	O
with	O	O	O
past	O	O	B-Entity
memories	O	O	I-Entity
through	O	O	O
reminiscence	O	O	B-Entity
interventions	O	O	I-Entity
has	O	O	O
been	O	O	O
practiced	O	O	O
for	O	O	O
several	O	O	B-Entity
decades	O	O	I-Entity
with	O	O	O
successful	O	O	O
outcomes	O	O	B-Entity
on	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
in	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Few	O	O	O
studies	O	O	B-Entity
however	O	O	O
have	O	O	O
focused	O	O	O
on	O	O	O
autobiographical	O	O	B-Entity
memory	O	O	I-Entity
recall	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
individuals	O	O	I-Entity
with	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aims	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
impact	O	O	O
of	O	O	O
an	O	O	O
individual	O	O	B-Entity
reminiscence	O	O	B-Entity
program	O	O	I-Entity
in	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
older	O	O	B-Entity
persons	O	O	I-Entity
with	O	O	O
cognitive	O	O	B-Entity
decline	O	O	I-Entity
living	O	O	O
in	O	O	O
nursing	O	O	B-Entity
homes	O	O	I-Entity
on	O	O	O
the	O	O	O
dimensions	O	O	O
of	O	O	O
cognition	O	O	B-Entity
,	O	O	O
autobiographical	O	O	B-Entity
memory	O	O	I-Entity
,	O	O	O
mood	O	O	B-Entity
,	O	O	O
behavior	O	O	B-Entity
and	O	O	O
anxiety	O	O	B-Entity
.	O	O	O

A	O	O	O
two-group	O	O	O
pre-test	O	O	B-Entity
and	O	O	I-Entity
post-test	O	O	I-Entity
design	O	O	I-Entity
with	O	O	O
single	O	O	B-Entity
blinded	O	O	I-Entity
assessment	O	O	I-Entity
was	O	O	O
conducted	O	O	O
.	O	O	O

Forty-one	O	O	O
participants	O	O	B-Entity
were	O	O	O
randomized	O	O	O
to	O	O	O
an	O	O	O
experimental	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
n=20	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
n=21	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
first	O	O	O
group	O	O	O
attended	O	O	O
five	O	O	O
weekly	O	O	O
individual	O	O	B-Entity
reminiscence	O	O	B-Entity
sessions	O	O	B-Entity
.	O	O	O

Changes	O	O	O
in	O	O	O
the	O	O	O
outcome	O	O	B-Entity
measures	O	O	I-Entity
were	O	O	O
examined	O	O	B-Entity
for	O	O	O
cognition	O	O	B-Entity
(	O	O	O
Montreal	O	O	B-Entity
Cognitive	O	O	I-Entity
Assessment	O	O	I-Entity
;	O	O	O
Autobiographical	O	O	B-Entity
Memory	O	O	I-Entity
Test	O	O	I-Entity
)	O	O	O
,	O	O	O
behavior	O	O	B-Entity
(	O	O	O
Alzheimer	O	O	B-Entity
Disease	O	O	I-Entity
Assessment	O	O	I-Entity
Subscale	O	O	I-Entity
Non-Cog	O	O	I-Entity
)	O	O	O
and	O	O	O
emotional	O	O	B-Entity
status	O	O	I-Entity
(	O	O	O
Cornell	O	O	B-Entity
Scale	O	O	I-Entity
for	O	O	I-Entity
Depression	O	O	I-Entity
in	O	O	O
Dementia	O	O	B-Entity
;	O	O	O
Geriatric	O	O	B-Entity
Depression	O	O	I-Entity
Scale	O	O	I-Entity
,	O	O	O
and	O	O	O
Geriatric	O	O	B-Entity
Anxiety	O	O	I-Entity
Inventory	O	O	I-Entity
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
attending	O	O	O
reminiscence	O	O	B-Entity
sessions	O	O	I-Entity
exhibited	O	O	O
better	O	O	O
outcomes	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
in	O	O	O
cognition	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
depression	O	O	B-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
presented	O	O	O
a	O	O	O
higher	O	O	O
number	O	O	O
of	O	O	O
retrieved	O	O	B-Entity
autobiographical	O	O	B-Entity
events	O	O	B-Entity
,	O	O	O
specificity	O	O	O
of	O	O	O
evoked	O	O	O
memories	O	O	B-Entity
and	O	O	O
positive	O	O	O
valence	O	O	O
of	O	O	O
events	O	O	O
(	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
also	O	O	O
presented	O	O	O
lower	O	O	O
latency	O	O	O
time	O	O	O
for	O	O	O
recalling	O	O	B-Entity
events	O	O	O
,	O	O	O
and	O	O	O
lower	O	O	O
negative	O	O	O
recalled	O	O	B-Entity
events	O	O	O
(	O	O	O
p<0.01	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
supports	O	O	O
the	O	O	O
potential	O	O	O
value	O	O	O
of	O	O	O
reminiscence	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
improving	O	O	O
the	O	O	O
recall	O	O	B-Entity
of	O	O	O
autobiographical	O	O	B-Entity
memory	O	O	I-Entity
.	O	O	O

Reminiscence	O	O	B-Entity
therapy	O	O	I-Entity
can	O	O	O
be	O	O	O
helpful	O	O	O
to	O	O	O
maintain	O	O	O
or	O	O	O
improve	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
decrease	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
manage	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
and	O	O	O
altered	O	O	B-Entity
behavior	O	O	I-Entity
,	O	O	O
but	O	O	O
further	O	O	O
investigation	O	O	O
is	O	O	O
needed	O	O	O
to	O	O	O
clarify	O	O	O
long-term	O	O	O
effects	O	O	O
.	O	O	O

-DOCSTART- (27348285)

Economic	O	O	B-Entity
Burden	O	O	I-Entity
of	O	O	O
Illness	O	O	B-Entity
Among	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Severe	O	O	B-Entity
Asthma	O	O	I-Entity
in	O	O	O
a	O	O	O
Managed	O	O	O
Care	O	O	O
Setting	O	O	O

Despite	O	O	O
intensive	O	O	O
pharmacotherapy	O	O	B-Entity
,	O	O	O
a	O	O	O
considerable	O	O	O
number	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
asthma	O	O	I-Entity
have	O	O	O
inadequate	O	O	B-Entity
disease	O	O	B-Entity
control	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
asthma	O	O	I-Entity
who	O	O	O
experience	O	O	B-Entity
exacerbations	O	O	B-Entity
consume	O	O	O
significant	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
resources	O	O	I-Entity
.	O	O	O

To	O	O	O
assess	O	O	B-Entity
health	O	O	B-Entity
care	O	O	I-Entity
resource	O	O	I-Entity
utilization	O	O	B-Entity
and	O	O	O
associated	O	O	O
costs	O	O	B-Entity
among	O	O	O
patients	O	O	B-Entity
with	O	O	O
persistent	O	O	B-Entity
severe	O	O	B-Entity
asthma	O	O	B-Entity
who	O	O	O
experienced	O	O	B-Entity
exacerbations	O	O	B-Entity
compared	O	O	O
with	O	O	O
patients	O	O	O
with	O	O	O
persistent	O	O	O
but	O	O	O
nonsevere	O	O	O
asthma	O	O	O
.	O	O	O

This	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
a	O	O	O
national	O	O	B-Entity
administrative	O	O	I-Entity
claims	O	O	I-Entity
database	O	O	I-Entity
identified	O	O	B-Entity
patients	O	O	B-Entity
aged	O	O	B-Entity
≥	O	O	O
12	O	O	O
years	O	O	B-Entity
who	O	O	O
had	O	O	O
at	O	O	O
least	O	O	O
1	O	O	O
medical	O	O	B-Entity
claim	O	O	I-Entity
with	O	O	O
an	O	O	O
asthma	O	O	B-Entity
diagnosis	O	O	B-Entity
in	O	O	O
2012	O	O	O
and	O	O	O
had	O	O	O
continuous	O	O	O
medical	O	O	O
and	O	O	O
pharmacy	O	O	B-Entity
coverage	O	O	I-Entity
under	O	O	O
a	O	O	O
commercial	O	O	B-Entity
or	O	O	O
Medicare	O	O	B-Entity
Advantage	O	O	I-Entity
plan	O	O	I-Entity
from	O	O	O
January	O	O	O
1	O	O	O
,	O	O	O
2012	O	O	O
,	O	O	O
to	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2013	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
assigned	O	O	B-Entity
to	O	O	O
1	O	O	O
of	O	O	O
2	O	O	O
mutually	O	O	O
exclusive	O	O	O
cohorts	O	O	B-Entity
-	O	O	O
persistent	O	O	B-Entity
asthma	O	O	B-Entity
(	O	O	O
PA	O	O	B-Entity
)	O	O	O
or	O	O	O
severe	O	O	B-Entity
asthma	O	O	I-Entity
(SA)-according	O	O	O
to	O	O	O
an	O	O	O
established	O	O	O
algorithm	O	O	B-Entity
based	O	O	O
on	O	O	O
asthma	O	O	O
-related	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
resource	O	O	I-Entity
use	O	O	B-Entity
and	O	O	O
pharmacy	O	O	B-Entity
claims	O	O	I-Entity
for	O	O	O
controller	O	O	B-Entity
medication	O	O	I-Entity
.	O	O	O

SA	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
required	O	O	O
to	O	O	O
meet	O	O	B-Entity
PA	O	O	B-Entity
criteria	O	O	B-Entity
and	O	O	O
also	O	O	O
have	O	O	O
evidence	O	O	B-Entity
of	O	O	O
≥2	O	O	O
asthma	O	O	B-Entity
exacerbations	O	O	I-Entity
in	O	O	O
2012	O	O	O
.	O	O	O

Asthma	O	O	B-Entity
-related	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
resource	O	O	I-Entity
utilization	O	O	B-Entity
and	O	O	O
costs	O	O	B-Entity
were	O	O	O
computed	O	O	B-Entity
from	O	O	O
asthma	O	O	B-Entity
medication	O	O	B-Entity
use	O	O	B-Entity
(	O	O	O
rescue	O	O	B-Entity
and	O	O	O
controller	O	O	B-Entity
therapy	O	O	I-Entity
)	O	O	O
and	O	O	O
medical	O	O	B-Entity
claims	O	O	I-Entity
with	O	O	O
an	O	O	O
asthma	O	O	O
diagnosis	O	O	B-Entity
in	O	O	O
the	O	O	O
primary	O	O	B-Entity
position	O	O	I-Entity
in	O	O	O
2012	O	O	O
and	O	O	O
2013	O	O	O
.	O	O	O

Adherence	O	O	B-Entity
to	O	O	O
controller	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
over	O	O	O
365	O	O	O
days	O	O	B-Entity
by	O	O	O
using	O	O	O
the	O	O	O
proportion	O	O	B-Entity
of	O	O	I-Entity
days	O	O	I-Entity
covered	O	O	I-Entity
(	O	O	O
PDC	O	O	B-Entity
)	O	O	O
,	O	O	O
starting	O	O	O
with	O	O	O
the	O	O	O
first	O	O	O
claim	O	O	B-Entity
for	O	O	O
controller	O	O	O
therapy	O	O	O
in	O	O	O
2012	O	O	O
.	O	O	O

Differences	O	O	B-Entity
between	O	O	O
the	O	O	O
PA	O	O	B-Entity
and	O	O	O
SA	O	O	B-Entity
cohorts	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
t-test	O	O	B-Entity
for	O	O	O
continuous	O	O	B-Entity
variables	O	O	I-Entity
and	O	O	O
chi-square	O	O	B-Entity
test	O	O	I-Entity
for	O	O	O
categorical	O	O	B-Entity
variables	O	O	I-Entity
.	O	O	O

Asthma	O	O	B-Entity
-related	O	O	O
costs	O	O	B-Entity
in	O	O	O
2013	O	O	O
were	O	O	O
also	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
a	O	O	O
generalized	O	O	O
linear	O	O	B-Entity
model	O	O	I-Entity
with	O	O	O
a	O	O	O
gamma	O	O	B-Entity
distribution	O	O	I-Entity
and	O	O	O
log	O	O	B-Entity
link	O	O	I-Entity
,	O	O	O
adjusted	O	O	B-Entity
for	O	O	O
patient	O	O	B-Entity
demographics	O	O	B-Entity
(	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
region	O	O	B-Entity
,	O	O	O
and	O	O	O
insurance	O	O	B-Entity
type	O	O	I-Entity
)	O	O	O
and	O	O	O
Quan-Charlson	O	O	B-Entity
comorbidity	O	O	I-Entity
score	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
65,359	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
:	O	O	O
63,597	O	O	O
(	O	O	O
97.3	O	O	O
%	O	O	O
)	O	O	O
PA	O	O	B-Entity
patients	O	O	O
and	O	O	O
1,762	O	O	O
SA	O	O	B-Entity
patients	O	O	O
(	O	O	O
2.7	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
the	O	O	O
PA	O	O	B-Entity
cohort	O	O	B-Entity
,	O	O	O
the	O	O	O
SA	O	O	B-Entity
cohort	O	O	O
was	O	O	O
older	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
age	O	O	I-Entity
=	O	O	O
50.8	O	O	O
years	O	O	B-Entity
vs.	O	O	O
46.5	O	O	O
years	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
had	O	O	O
higher	O	O	O
mean	O	O	O
comorbidity	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
1.47	O	O	O
vs.	O	O	O
1.31	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
count	O	O	O
of	O	O	O
all	O	O	O
asthma	O	O	B-Entity
medications	O	O	B-Entity
fills	O	O	O
was	O	O	O
2.2-fold	O	O	O
(	O	O	O
2012	O	O	O
)	O	O	O
and	O	O	O
2.1-fold	O	O	O
(	O	O	O
2013	O	O	O
)	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
SA	O	O	B-Entity
cohort	O	O	B-Entity
,	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
PA	O	O	B-Entity
cohort	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Mean	O	O	O
PDC	O	O	B-Entity
for	O	O	O
all	O	O	O
oral	O	O	B-Entity
and	O	O	O
inhaled	O	O	B-Entity
controller	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
also	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
SA	O	O	B-Entity
cohort	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
PA	O	O	B-Entity
cohort	O	O	O
(	O	O	O
0.80	O	O	O
vs.	O	O	O
0.65	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

SA	O	O	B-Entity
patients	O	O	B-Entity
had	O	O	O
a	O	O	O
significantly	O	O	O
greater	O	O	B-Entity
mean	O	O	I-Entity
count	O	O	I-Entity
of	O	O	O
asthma	O	O	B-Entity
-related	O	O	O
hospitalizations	O	O	B-Entity
,	O	O	O
emergency	O	O	B-Entity
room	O	O	I-Entity
visits	O	O	I-Entity
,	O	O	O
and	O	O	O
ambulatory	O	O	B-Entity
visits	O	O	I-Entity
in	O	O	O
2012	O	O	O
and	O	O	O
2013	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Unadjusted	O	O	O
mean	O	O	O
annual	O	O	O
asthma	O	O	B-Entity
-related	O	O	O
costs	O	O	B-Entity
in	O	O	O
the	O	O	O
SA	O	O	B-Entity
versus	O	O	O
PA	O	O	B-Entity
cohorts	O	O	B-Entity
were	O	O	O
$	O	O	O
6,496	O	O	O
versus	O	O	O
$	O	O	O
2,739	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
in	O	O	O
2012	O	O	O
and	O	O	O
$	O	O	O
5,174	O	O	O
versus	O	O	O
$	O	O	O
1,775	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
in	O	O	O
2013	O	O	O
.	O	O	O

Higher	O	O	O
asthma	O	O	B-Entity
-related	O	O	O
costs	O	O	B-Entity
were	O	O	O
driven	O	O	O
by	O	O	O
greater	O	O	O
mean	O	O	O
annual	O	O	O
asthma	O	O	O
medication	O	O	B-Entity
costs	O	O	O
in	O	O	O
2012	O	O	O
(	O	O	O
$	O	O	O
4,545	O	O	O
vs.	O	O	O
$	O	O	O
1,738	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
2013	O	O	O
(	O	O	O
$	O	O	O
4,068	O	O	O
vs.	O	O	O
$	O	O	O
1,348	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Adjusted	O	O	B-Entity
mean	O	O	O
annual	O	O	O
asthma	O	O	B-Entity
-related	O	O	O
costs	O	O	B-Entity
in	O	O	O
2013	O	O	O
were	O	O	O
$	O	O	O
3,336	O	O	O
greater	O	O	O
(	O	O	O
cost	O	O	B-Entity
ratio	O	O	I-Entity
=	O	O	O
2.878	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
SA	O	O	B-Entity
cohort	O	O	B-Entity
,	O	O	O
and	O	O	O
adjusted	O	O	B-Entity
mean	O	O	O
annual	O	O	O
asthma	O	O	O
medication	O	O	B-Entity
costs	O	O	O
were	O	O	O
$	O	O	O
2,672	O	O	O
higher	O	O	O
(	O	O	O
cost	O	O	O
ratio=2.982	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
SA	O	O	O
cohort	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
SA	O	O	B-Entity
who	O	O	O
experienced	O	O	B-Entity
2	O	O	O
or	O	O	O
more	O	O	O
exacerbations	O	O	B-Entity
had	O	O	O
2.1-fold	O	O	O
greater	O	O	O
use	O	O	B-Entity
of	O	O	O
controller	O	O	B-Entity
medications	O	O	I-Entity
across	O	O	O
both	O	O	O
study	O	O	O
years	O	O	B-Entity
and	O	O	O
were	O	O	O
more	O	O	O
adherent	O	O	B-Entity
to	O	O	O
controller	O	O	B-Entity
therapy	O	O	I-Entity
than	O	O	O
patients	O	O	B-Entity
with	O	O	O
PA	O	O	B-Entity
.	O	O	O

Despite	O	O	O
more	O	O	O
intensive	O	O	O
pharmacotherapy	O	O	B-Entity
,	O	O	O
SA	O	O	B-Entity
patients	O	O	B-Entity
incurred	O	O	O
2.9-fold	O	O	O
higher	O	O	O
adjusted	O	O	B-Entity
asthma	O	O	B-Entity
-related	O	O	O
costs	O	O	B-Entity
and	O	O	O
3-fold	O	O	O
higher	O	O	O
adjusted	O	O	O
asthma	O	O	O
medication	O	O	B-Entity
costs	O	O	O
than	O	O	O
PA	O	O	B-Entity
patients	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
SA	O	O	B-Entity
consistently	O	O	B-Entity
demonstrated	O	O	O
a	O	O	O
higher	O	O	O
rate	O	O	O
of	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
utilization	O	O	B-Entity
.	O	O	O

Funding	O	O	B-Entity
for	O	O	O
this	O	O	O
study	O	O	B-Entity
(	O	O	O
HO-14	O	O	O
-	O	O	O
14443	O	O	O
)	O	O	O
was	O	O	O
provided	O	O	O
by	O	O	O
GlaxoSmithKline	O	O	B-Entity
(	O	O	O
GSK	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
listed	O	O	O
authors	O	O	B-Entity
meet	O	O	B-Entity
the	O	O	O
criteria	O	O	B-Entity
for	O	O	O
authorship	O	O	B-Entity
set	O	O	O
forth	O	O	O
by	O	O	O
the	O	O	O
International	O	O	B-Entity
Committee	O	O	I-Entity
for	O	O	I-Entity
Medical	O	O	I-Entity
Journal	O	O	I-Entity
Editors	O	O	I-Entity
.	O	O	O

Albers	O	O	B-Entity
,	O	O	O
Forshag	O	O	B-Entity
,	O	O	O
and	O	O	O
Yancey	O	O	B-Entity
are	O	O	O
employees	O	O	B-Entity
of	O	O	O
GSK	O	O	B-Entity
and	O	O	O
hold	O	O	O
stock	O	O	O
in	O	O	O
GSK	O	O	O
.	O	O	O

Dalal	O	O	B-Entity
,	O	O	O
Nagar	O	O	B-Entity
,	O	O	O
and	O	O	O
Ortega	O	O	B-Entity
were	O	O	O
employees	O	O	B-Entity
of	O	O	O
GSK	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
this	O	O	O
research	O	O	B-Entity
was	O	O	O
conducted	O	O	O
.	O	O	O

Chastek	O	O	B-Entity
and	O	O	O
Korrer	O	O	B-Entity
are	O	O	O
employees	O	O	B-Entity
of	O	O	O
Optum	O	O	B-Entity
,	O	O	O
which	O	O	O
received	O	O	O
consulting	O	O	B-Entity
fees	O	O	I-Entity
from	O	O	O
GSK	O	O	B-Entity
for	O	O	O
research	O	O	B-Entity
related	O	O	O
to	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Study	O	O	B-Entity
concept	O	O	I-Entity
and	O	O	O
design	O	O	B-Entity
were	O	O	O
contributed	O	O	B-Entity
by	O	O	O
Chastek	O	O	B-Entity
,	O	O	O
Nagar	O	O	B-Entity
,	O	O	O
and	O	O	O
Dalal	O	O	B-Entity
.	O	O	O

Korrer	O	O	B-Entity
took	O	O	O
the	O	O	O
lead	O	O	O
in	O	O	O
data	O	O	B-Entity
collection	O	O	I-Entity
,	O	O	O
along	O	O	O
with	O	O	O
Chastek	O	O	B-Entity
,	O	O	O
and	O	O	O
data	O	O	B-Entity
interpretation	O	O	I-Entity
was	O	O	O
performed	O	O	O
by	O	O	O
Chastek	O	O	O
,	O	O	O
Ortega	O	O	B-Entity
,	O	O	O
Forshag	O	O	B-Entity
,	O	O	O
and	O	O	O
Dalal	O	O	B-Entity
.	O	O	O

The	O	O	O
manuscript	O	O	B-Entity
was	O	O	O
written	O	O	O
by	O	O	O
Chastek	O	O	B-Entity
and	O	O	O
Dalal	O	O	B-Entity
and	O	O	O
revised	O	O	B-Entity
by	O	O	O
Albers	O	O	B-Entity
and	O	O	O
Yancy	O	O	B-Entity
,	O	O	O
assisted	O	O	B-Entity
by	O	O	O
the	O	O	O
other	O	O	O
authors	O	O	B-Entity
.	O	O	O

-DOCSTART- (27348405)

Differential	O	O	B-Entity
regulation	O	O	I-Entity
of	O	O	O
spontaneous	O	O	B-Entity
and	O	O	O
evoked	O	O	B-Entity
inhibitory	O	O	B-Entity
synaptic	O	O	I-Entity
transmission	O	O	I-Entity
in	O	O	O
somatosensory	O	O	B-Entity
cortex	O	O	I-Entity
by	O	O	O
retinoic	O	O	O
acid	O	O	O

Retinoic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
RA	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
developmental	O	O	B-Entity
morphogen	O	O	B-Entity
,	O	O	O
has	O	O	O
emerged	O	O	O
in	O	O	O
recent	O	O	O
studies	O	O	O
as	O	O	O
a	O	O	O
novel	O	O	B-Entity
synaptic	O	O	B-Entity
signaling	O	O	B-Entity
molecule	O	O	I-Entity
that	O	O	O
acts	O	O	O
in	O	O	O
mature	O	O	B-Entity
hippocampal	O	O	B-Entity
neurons	O	O	B-Entity
to	O	O	O
modulate	O	O	B-Entity
excitatory	O	O	B-Entity
and	O	O	O
inhibitory	O	O	B-Entity
synaptic	O	O	I-Entity
transmission	O	O	I-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
homeostatic	O	O	B-Entity
synaptic	O	O	B-Entity
plasticity	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
unclear	O	O	O
whether	O	O	O
RA	O	O	B-Entity
is	O	O	O
capable	O	O	O
of	O	O	O
modulating	O	O	B-Entity
neural	O	O	B-Entity
circuits	O	O	I-Entity
outside	O	O	B-Entity
of	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
,	O	O	O
and	O	O	O
if	O	O	O
so	O	O	O
,	O	O	O
whether	O	O	O
the	O	O	O
mode	O	O	B-Entity
of	O	O	I-Entity
RA	O	O	I-Entity
's	O	O	I-Entity
action	O	O	I-Entity
at	O	O	O
synapses	O	O	B-Entity
is	O	O	O
similar	O	O	B-Entity
to	O	O	O
that	O	O	O
within	O	O	B-Entity
the	O	O	O
hippocampal	O	O	B-Entity
network	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
explore	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
RA	O	O	B-Entity
's	O	O	O
synaptic	O	O	B-Entity
function	O	O	B-Entity
outside	O	O	B-Entity
the	O	O	O
hippocampus	O	O	B-Entity
and	O	O	O
uncover	O	O	O
a	O	O	O
novel	O	O	B-Entity
function	O	O	O
of	O	O	O
all-trans	O	O	B-Entity
retinoic	O	O	I-Entity
acid	O	O	I-Entity
at	O	O	O
inhibitory	O	O	B-Entity
synapses	O	O	I-Entity
.	O	O	O

Acute	O	O	B-Entity
RA	O	O	B-Entity
treatment	O	O	B-Entity
increases	O	O	B-Entity
spontaneous	O	O	B-Entity
inhibitory	O	O	B-Entity
synaptic	O	O	I-Entity
transmission	O	O	I-Entity
in	O	O	O
L2/3	O	O	B-Entity
pyramidal	O	O	I-Entity
neurons	O	O	I-Entity
of	O	O	O
the	O	O	O
somatosensory	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
and	O	O	O
this	O	O	O
effect	O	O	B-Entity
requires	O	O	O
expression	O	O	B-Entity
of	O	O	O
RA	O	O	B-Entity
's	O	O	I-Entity
receptor	O	O	I-Entity
RARα	O	O	B-Entity
both	O	O	O
pre-	O	O	B-Entity
and	O	O	I-Entity
post-synaptically	O	O	I-Entity
.	O	O	O

Intriguingly	O	O	O
,	O	O	O
RA	O	O	B-Entity
does	O	O	O
not	O	O	O
seem	O	O	O
to	O	O	O
affect	O	O	O
evoked	O	O	B-Entity
inhibitory	O	O	B-Entity
transmission	O	O	I-Entity
assayed	O	O	O
with	O	O	O
either	O	O	O
extracellular	O	O	B-Entity
stimulation	O	O	O
or	O	O	O
direct	O	O	O
activation	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
potentials	O	O	I-Entity
in	O	O	O
presynaptic	O	O	B-Entity
interneurons	O	O	B-Entity
at	O	O	O
connected	O	O	O
pairs	O	O	O
of	O	O	O
interneurons	O	O	O
and	O	O	O
pyramidal	O	O	B-Entity
neurons	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
RA	O	O	B-Entity
's	O	O	I-Entity
action	O	O	B-Entity
at	O	O	O
synapses	O	O	B-Entity
is	O	O	O
not	O	O	O
monotonous	O	O	O
,	O	O	O
but	O	O	O
is	O	O	O
diverse	O	O	B-Entity
depending	O	O	O
on	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
synaptic	O	O	B-Entity
connection	O	O	I-Entity
(	O	O	O
excitatory	O	O	B-Entity
versus	O	O	O
inhibitory	O	O	B-Entity
)	O	O	O
and	O	O	O
circuit	O	O	B-Entity
(	O	O	O
hippocampal	O	O	B-Entity
versus	O	O	O
cortical	O	O	B-Entity
)	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
synaptic	O	O	B-Entity
signaling	O	O	I-Entity
of	O	O	O
RA	O	O	B-Entity
may	O	O	O
mediate	O	O	O
multi-faceted	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
synaptic	O	O	I-Entity
plasticity	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
its	O	O	O
classic	O	O	B-Entity
roles	O	O	I-Entity
in	O	O	O
brain	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
retinoic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
RA	O	O	B-Entity
)	O	O	O
has	O	O	O
recently	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
regulate	O	O	B-Entity
excitatory	O	O	B-Entity
and	O	O	O
inhibitory	O	O	B-Entity
transmission	O	O	I-Entity
in	O	O	O
the	O	O	O
adult	O	O	B-Entity
brain	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
the	O	O	O
authors	O	O	B-Entity
show	O	O	O
that	O	O	O
in	O	O	O
layer	O	O	B-Entity
2/3	O	O	I-Entity
(	O	O	O
L2/3	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
somatosensory	O	O	B-Entity
cortex	O	O	I-Entity
(	O	O	O
S1	O	O	B-Entity
)	O	O	O
,	O	O	O
acute	O	O	B-Entity
RA	O	O	B-Entity
induces	O	O	B-Entity
increases	O	O	B-Entity
in	O	O	O
spontaneous	O	O	B-Entity
but	O	O	O
not	O	O	O
action-potential	O	O	B-Entity
evoked	O	O	B-Entity
transmission	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
this	O	O	O
requires	O	O	O
retinoic	O	O	B-Entity
acid	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	O
RARα	O	O	B-Entity
)	O	O	O
both	O	O	O
in	O	O	O
presynaptic	O	O	B-Entity
PV	O	O	B-Entity
-positive	O	O	O
interneurons	O	O	B-Entity
and	O	O	O
postsynaptic	O	O	B-Entity
pyramidal	O	O	B-Entity
(	O	O	I-Entity
PN	O	O	I-Entity
)	O	O	I-Entity
neurons	O	O	I-Entity
.	O	O	O

-DOCSTART- (27348711)

Utilization	O	O	B-Entity
Pattern	O	O	B-Entity
and	O	O	O
Drug	O	O	B-Entity
Use	O	O	I-Entity
of	O	O	O
Traditional	O	O	B-Entity
Chinese	O	O	B-Entity
Medicine	O	O	I-Entity
,	O	O	O
Western	O	O	B-Entity
Medicine	O	O	I-Entity
,	O	O	O
and	O	O	O
Integrated	O	O	B-Entity
Chinese-Western	O	O	I-Entity
Medicine	O	O	I-Entity
Treatments	O	O	B-Entity
for	O	O	O
Allergic	O	O	B-Entity
Rhinitis	O	O	I-Entity
Under	O	O	O
the	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
Insurance	O	O	I-Entity
Program	O	O	I-Entity
in	O	O	O
Taiwan	O	O	O

Patients	O	O	B-Entity
in	O	O	O
Taiwan	O	O	B-Entity
with	O	O	O
allergic	O	O	B-Entity
rhinitis	O	O	I-Entity
seek	O	O	O
not	O	O	O
only	O	O	O
Western	O	O	B-Entity
medicine	O	O	I-Entity
treatment	O	O	B-Entity
but	O	O	O
also	O	O	O
Traditional	O	O	B-Entity
Chinese	O	O	I-Entity
Medicine	O	O	I-Entity
treatment	O	O	O
or	O	O	O
integrated	O	O	B-Entity
Chinese-Western	O	O	I-Entity
medicine	O	O	I-Entity
treatment	O	O	O
.	O	O	O

Various	O	O	O
studies	O	O	O
have	O	O	O
conducted	O	O	O
pairwise	O	O	B-Entity
comparison	O	O	I-Entity
on	O	O	O
Traditional	O	O	B-Entity
Chinese	O	O	I-Entity
Medicine	O	O	I-Entity
,	O	O	O
Western	O	O	B-Entity
medicine	O	O	I-Entity
,	O	O	O
and	O	O	O
integrated	O	O	B-Entity
Chinese-Western	O	O	I-Entity
medicine	O	O	I-Entity
treatments	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
none	O	O	O
conducted	O	O	O
simultaneous	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
three	O	O	O
treatments	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
analyzed	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
allergic	O	O	B-Entity
rhinitis	O	O	I-Entity
receiving	O	O	O
the	O	O	O
three	O	O	O
treatments	O	O	B-Entity
to	O	O	O
identify	O	O	O
differences	O	O	O
in	O	O	O
demographic	O	O	B-Entity
characteristic	O	O	B-Entity
and	O	O	O
medical	O	O	B-Entity
use	O	O	B-Entity
and	O	O	O
thereby	O	O	O
to	O	O	O
determine	O	O	O
drug	O	O	B-Entity
use	O	O	I-Entity
patterns	O	O	I-Entity
of	O	O	O
different	O	O	O
treatments	O	O	O
.	O	O	O

The	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
Insurance	O	O	I-Entity
Research	O	O	I-Entity
Database	O	O	I-Entity
was	O	O	O
the	O	O	O
data	O	O	B-Entity
source	O	O	I-Entity
,	O	O	O
and	O	O	O
included	O	O	O
patients	O	O	B-Entity
were	O	O	O
those	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
allergic	O	O	B-Entity
rhinitis	O	O	I-Entity
(	O	O	O
International	O	O	B-Entity
Classification	O	O	I-Entity
of	O	O	I-Entity
Diseases	O	O	I-Entity
,	O	O	I-Entity
Ninth	O	O	I-Entity
Revision	O	O	I-Entity
,	O	O	O
Clinical	O	O	B-Entity
Modification	O	O	I-Entity
codes	O	O	I-Entity
470	O	O	I-Entity
-	O	O	I-Entity
478	O	O	I-Entity
)	O	O	O
.	O	O	O

Chi-square	O	O	B-Entity
test	O	O	I-Entity
and	O	O	O
Tukey	O	O	B-Entity
studentized	O	O	I-Entity
range	O	O	I-Entity
(	O	O	I-Entity
honest	O	O	I-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
)	O	O	I-Entity
test	O	O	I-Entity
were	O	O	O
conducted	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
differences	O	O	O
among	O	O	O
the	O	O	O
three	O	O	O
treatments	O	O	B-Entity
.	O	O	O

Visit	O	O	B-Entity
frequency	O	O	I-Entity
for	O	O	O
allergic	O	O	B-Entity
rhinitis	O	O	I-Entity
treatment	O	O	B-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
female	O	O	B-Entity
than	O	O	O
male	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
regardless	O	O	O
of	O	O	O
treatment	O	O	O
with	O	O	O
Traditional	O	O	B-Entity
Chinese	O	O	I-Entity
Medicine	O	O	I-Entity
,	O	O	O
Western	O	O	B-Entity
medicine	O	O	I-Entity
,	O	O	O
or	O	O	O
integrated	O	O	B-Entity
Chinese-Western	O	O	I-Entity
medicine	O	O	I-Entity
.	O	O	O

Persons	O	O	B-Entity
aged	O	O	O
0	O	O	O
-	O	O	O
19	O	O	O
years	O	O	O
ranked	O	O	O
the	O	O	O
highest	O	O	B-Entity
in	O	O	O
proportion	O	O	B-Entity
of	O	O	O
visits	O	O	B-Entity
for	O	O	O
allergic	O	O	B-Entity
rhinitis	O	O	I-Entity
.	O	O	O

Traditional	O	O	B-Entity
Chinese	O	O	I-Entity
Medicine	O	O	I-Entity
treatment	O	O	B-Entity
had	O	O	O
more	O	O	O
medical	O	O	B-Entity
items	O	O	O
per	O	O	O
person-time	O	O	B-Entity
and	O	O	O
daily	O	O	B-Entity
drug	O	O	B-Entity
cost	O	O	I-Entity
per	O	O	O
person-time	O	O	O
and	O	O	O
had	O	O	O
the	O	O	O
lowest	O	O	B-Entity
total	O	O	B-Entity
expenditure	O	O	B-Entity
per	O	O	O
person-time	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
Western	O	O	B-Entity
medicine	O	O	I-Entity
had	O	O	O
the	O	O	O
lowest	O	O	B-Entity
daily	O	O	B-Entity
drug	O	O	B-Entity
cost	O	O	I-Entity
per	O	O	O
person-time	O	O	B-Entity
and	O	O	O
the	O	O	O
highest	O	O	B-Entity
total	O	O	B-Entity
expenditure	O	O	B-Entity
per	O	O	O
person-time	O	O	O
.	O	O	O

The	O	O	O
total	O	O	B-Entity
expenditure	O	O	B-Entity
per	O	O	O
person-time	O	O	B-Entity
,	O	O	O
daily	O	O	B-Entity
drug	O	O	B-Entity
cost	O	O	I-Entity
per	O	O	O
person-time	O	O	O
,	O	O	O
and	O	O	O
medical	O	O	B-Entity
items	O	O	B-Entity
per	O	O	O
person-time	O	O	O
of	O	O	O
integrated	O	O	B-Entity
Chinese-Western	O	O	I-Entity
medicine	O	O	I-Entity
treatment	O	O	B-Entity
lay	O	O	O
between	O	O	O
those	O	O	O
seen	O	O	O
with	O	O	O
Traditional	O	O	B-Entity
Chinese	O	O	I-Entity
Medicine	O	O	I-Entity
and	O	O	O
Western	O	O	B-Entity
medicine	O	O	I-Entity
treatments	O	O	B-Entity
.	O	O	O

Although	O	O	O
only	O	O	O
6.82	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
allergic	O	O	B-Entity
rhinitis	O	O	I-Entity
chose	O	O	O
integrated	O	O	B-Entity
Chinese-Western	O	O	I-Entity
medicine	O	O	I-Entity
treatment	O	O	B-Entity
,	O	O	O
the	O	O	O
visit	O	O	B-Entity
frequency	O	O	I-Entity
per	O	O	O
person-year	O	O	O
of	O	O	O
integrated	O	O	O
Chinese-Western	O	O	O
medicine	O	O	O
ranked	O	O	O
highest	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
multiple-composition	O	O	B-Entity
medicines	O	O	B-Entity
were	O	O	O
used	O	O	O
more	O	O	O
frequently	O	O	B-Entity
than	O	O	O
single-composition	O	O	B-Entity
medicines	O	O	O
,	O	O	O
and	O	O	O
mar	O	O	B-Entity
huang	O	O	I-Entity
(	O	O	O
Ephedra	O	O	B-Entity
sinica	O	O	I-Entity
Stapf	O	O	I-Entity
)	O	O	O
was	O	O	O
seldom	O	O	O
used	O	O	O
to	O	O	O
decrease	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
combining	O	O	O
medications	O	O	B-Entity
.	O	O	O

-DOCSTART- (27354219)

TLR9	O	O	B-Entity
Deficiency	O	O	B-Entity
Leads	O	O	O
to	O	O	O
Accelerated	O	O	B-Entity
Renal	O	O	B-Entity
Disease	O	O	I-Entity
and	O	O	O
Myeloid	O	O	B-Entity
Lineage	O	O	I-Entity
Abnormalities	O	O	B-Entity
in	O	O	O
Pristane	O	O	B-Entity
-Induced	O	O	O
Murine	O	O	B-Entity
Lupus	O	O	O

Systemic	O	O	B-Entity
lupus	O	O	I-Entity
erythematosus	O	O	I-Entity
(	O	O	O
SLE	O	O	B-Entity
)	O	O	I-Entity
is	O	O	O
a	O	O	O
chronic	O	O	B-Entity
,	O	O	O
life-threatening	O	O	B-Entity
autoimmune	O	O	B-Entity
disorder	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
multiple	O	O	O
organ	O	O	B-Entity
pathologies	O	O	B-Entity
and	O	O	O
kidney	O	O	B-Entity
destruction	O	O	B-Entity
.	O	O	O

Analyses	O	O	O
of	O	O	O
numerous	O	O	O
murine	O	O	B-Entity
models	O	O	B-Entity
of	O	O	O
spontaneous	O	O	O
SLE	O	O	B-Entity
have	O	O	O
revealed	O	O	O
a	O	O	O
critical	O	O	O
role	O	O	O
for	O	O	O
endosomal	O	O	B-Entity
TLRs	O	O	B-Entity
in	O	O	O
the	O	O	O
production	O	O	O
of	O	O	O
autoantibodies	O	O	B-Entity
and	O	O	O
development	O	O	O
of	O	O	O
other	O	O	O
clinical	O	O	B-Entity
disease	O	O	B-Entity
manifestations	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
the	O	O	O
corresponding	O	O	O
TLR9	O	O	B-Entity
-	O	O	O
deficient	O	O	B-Entity
autoimmune	O	O	B-Entity
-prone	O	O	O
strains	O	O	B-Entity
consistently	O	O	O
develop	O	O	O
more	O	O	O
severe	O	O	O
disease	O	O	B-Entity
pathology	O	O	B-Entity
.	O	O	O

Injection	O	O	B-Entity
of	O	O	O
BALB/c	O	O	B-Entity
mice	O	O	I-Entity
with	O	O	O
2,6,10,14-tetramethylpentadecane	O	O	B-Entity
(	O	O	O
TMPD	O	O	B-Entity
)	O	O	O
,	O	O	O
commonly	O	O	O
known	O	O	O
as	O	O	O
pristane	O	O	B-Entity
,	O	O	O
also	O	O	O
results	O	O	O
in	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
SLE-like	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

We	O	O	O
now	O	O	O
show	O	O	O
that	O	O	O
Tlr9(-/-	O	O	B-Entity
)	O	O	I-Entity
BALB/c	O	O	B-Entity
mice	O	O	I-Entity
injected	O	O	O
i.p	O	O	O
.	O	O	O

with	O	O	O
TMPD	O	O	B-Entity
develop	O	O	O
more	O	O	O
severe	O	O	O
autoimmunity	O	O	B-Entity
than	O	O	O
do	O	O	O
their	O	O	O
TLR	O	O	B-Entity
-sufficient	O	O	O
cohorts	O	O	O
.	O	O	O

Early	O	O	O
indications	O	O	O
include	O	O	O
an	O	O	O
increased	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
TLR7	O	O	B-Entity
-	O	O	O
expressing	O	O	B-Entity
Ly6C(hi	O	O	B-Entity
)	O	O	I-Entity
inflammatory	O	O	B-Entity
monocytes	O	O	B-Entity
at	O	O	O
the	O	O	O
site	O	O	B-Entity
of	O	O	I-Entity
injection	O	O	I-Entity
,	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
IFN	O	O	B-Entity
-regulated	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
the	O	O	O
peritoneal	O	O	B-Entity
cavity	O	O	I-Entity
,	O	O	O
and	O	O	O
an	O	O	O
increased	O	O	O
production	O	O	O
of	O	O	O
myeloid	O	O	B-Entity
lineage	O	O	I-Entity
precursors	O	O	I-Entity
(	O	O	O
common	O	O	B-Entity
myeloid	O	O	I-Entity
progenitors	O	O	I-Entity
and	O	O	O
granulocyte	O	O	B-Entity
myeloid	O	O	B-Entity
precursors	O	O	I-Entity
)	O	O	O
in	O	O	O
the	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
.	O	O	O

TMPD	O	O	B-Entity
-	O	O	O
injected	O	O	B-Entity
Tlr9(-/-	O	O	B-Entity
)	O	O	I-Entity
BALB/c	O	O	B-Entity
mice	O	O	I-Entity
develop	O	O	O
higher	O	O	O
autoantibody	O	O	B-Entity
titers	O	O	O
against	O	O	O
RNA	O	O	B-Entity
,	O	O	O
neutrophil	O	O	B-Entity
cytoplasmic	O	O	B-Entity
Ags	O	O	B-Entity
,	O	O	O
and	O	O	O
myeloperoxidase	O	O	B-Entity
than	O	O	O
do	O	O	O
TMPD	O	O	O
-	O	O	O
injected	O	O	O
wild-type	O	O	B-Entity
BALB/c	O	O	I-Entity
mice	O	O	I-Entity
.	O	O	O

The	O	O	O
TMP	O	O	B-Entity
-	O	O	O
injected	O	O	B-Entity
Tlr9(-/-	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	B-Entity
,	O	O	O
and	O	O	O
not	O	O	O
the	O	O	O
wild-type	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
also	O	O	O
develop	O	O	O
a	O	O	O
marked	O	O	O
increase	O	O	O
in	O	O	O
glomerular	O	O	B-Entity
IgG	O	O	I-Entity
deposition	O	O	B-Entity
and	O	O	O
infiltrating	O	O	O
granulocytes	O	O	B-Entity
,	O	O	O
much	O	O	O
more	O	O	O
severe	O	O	O
glomerulonephritis	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
reduced	O	O	B-Entity
lifespan	O	O	B-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
the	O	O	O
data	O	O	O
point	O	O	O
to	O	O	O
a	O	O	O
major	O	O	O
role	O	O	O
for	O	O	O
TLR7	O	O	B-Entity
in	O	O	O
the	O	O	O
response	O	O	B-Entity
to	O	O	O
self-antigens	O	O	B-Entity
in	O	O	O
this	O	O	O
model	O	O	B-Entity
of	O	O	O
experimental	O	O	O
autoimmunity	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
BALB/c	O	O	B-Entity
pristane	O	O	B-Entity
model	O	O	B-Entity
recapitulates	O	O	O
other	O	O	O
TLR7	O	O	B-Entity
-driven	O	O	O
spontaneous	O	O	O
models	O	O	B-Entity
of	O	O	O
SLE	O	O	B-Entity
and	O	O	O
is	O	O	O
negatively	O	O	B-Entity
regulated	O	O	O
by	O	O	O
TLR9	O	O	B-Entity
.	O	O	O

-DOCSTART- (27354640)

Effect	O	O	B-Entity
of	O	O	O
Xenotransplantation	O	O	B-Entity
Site	O	O	B-Entity
on	O	O	O
MicroRNA	O	O	B-Entity
Expression	O	O	B-Entity
of	O	O	O
Human	O	O	B-Entity
Colon	O	O	B-Entity
Cancer	O	O	I-Entity
Stem	O	O	O
Cells	O	O	O

Cancer	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
CSCs	O	O	B-Entity
)	O	O	O
have	O	O	O
a	O	O	O
high	O	O	B-Entity
tumorigenic	O	O	B-Entity
ability	O	O	B-Entity
to	O	O	O
form	O	O	O
patient-derived	O	O	B-Entity
tumor	O	O	I-Entity
xenografts	O	O	I-Entity
(	O	O	O
PDXs	O	O	B-Entity
)	O	O	O
.	O	O	O

PDXs	O	O	B-Entity
are	O	O	O
an	O	O	O
attractive	O	O	B-Entity
pre-clinical	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
but	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
biological	O	O	B-Entity
behavior	O	O	I-Entity
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
the	O	O	O
tumor	O	O	B-Entity
will	O	O	O
change	O	O	B-Entity
during	O	O	O
establishment	O	O	B-Entity
and	O	O	O
passage	O	O	O
of	O	O	O
PDXs	O	O	O
.	O	O	O

Human	O	O	B-Entity
colon	O	O	B-Entity
cancer	O	O	I-Entity
PDX	O	O	B-Entity
was	O	O	O
established	O	O	B-Entity
and	O	O	O
passaged	O	O	B-Entity
either	O	O	O
subcutaneously	O	O	B-Entity
or	O	O	O
orthotopically	O	O	B-Entity
into	O	O	O
the	O	O	O
murine	O	O	B-Entity
intestine	O	O	B-Entity
.	O	O	O

Histology	O	O	B-Entity
and	O	O	O
flow	O	O	B-Entity
cytometric	O	O	I-Entity
profile	O	O	B-Entity
of	O	O	O
the	O	O	O
surgical	O	O	B-Entity
specimen	O	O	B-Entity
and	O	O	O
the	O	O	O
PDX	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

CSCs	O	O	B-Entity
were	O	O	O
then	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
tumors	O	O	B-Entity
and	O	O	O
their	O	O	O
microRNA	O	O	B-Entity
(	O	O	O
miRNA	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
semi-quantitative	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
.	O	O	O

The	O	O	O
surgical	O	O	B-Entity
specimens	O	O	B-Entity
and	O	O	O
PDXs	O	O	B-Entity
were	O	O	O
histologically	O	O	B-Entity
similar	O	O	B-Entity
.	O	O	O

The	O	O	O
size	O	O	B-Entity
of	O	O	O
CSC	O	O	B-Entity
population	O	O	B-Entity
increased	O	O	B-Entity
and	O	O	O
expression	O	O	B-Entity
of	O	O	O
miRNA	O	O	B-Entity
s	O	O	O
in	O	O	O
CSCs	O	O	B-Entity
changed	O	O	B-Entity
in	O	O	O
the	O	O	O
passaged	O	O	B-Entity
PDXs	O	O	B-Entity
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
oncogenic	O	O	B-Entity
miRNAs	O	O	B-Entity
was	O	O	O
highly	O	O	B-Entity
up-regulated	O	O	B-Entity
in	O	O	O
the	O	O	O
CSCs	O	O	B-Entity
of	O	O	O
the	O	O	O
orthotopically	O	O	B-Entity
passaged	O	O	B-Entity
PDXs	O	O	B-Entity
.	O	O	O

The	O	O	O
xenotransplantation	O	O	B-Entity
site	O	O	B-Entity
and	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
passages	O	O	B-Entity
affect	O	O	B-Entity
the	O	O	O
miRNA	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
colon	O	O	B-Entity
CSCs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27355356)

Chemosensitivity	O	O	B-Entity
,	O	O	O
Cardiovascular	O	O	B-Entity
Risk	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
Ventilatory	O	O	B-Entity
Response	O	O	I-Entity
to	O	O	O
Exercise	O	O	B-Entity
in	O	O	O
COPD	O	O	O

COPD	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
elevated	O	O	B-Entity
cardiovascular	O	O	B-Entity
risk	O	O	I-Entity
and	O	O	O
a	O	O	O
potentiated	O	O	B-Entity
ventilatory	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
exercise	O	O	B-Entity
.	O	O	O

Enhanced	O	O	O
carotid	O	O	B-Entity
chemoreceptor	O	O	B-Entity
(	O	O	O
CC	O	O	B-Entity
)	O	O	O
activity	O	O	B-Entity
/	O	O	O
sensitivity	O	O	B-Entity
is	O	O	O
present	O	O	O
in	O	O	O
other	O	O	O
clinical	O	O	B-Entity
conditions	O	O	I-Entity
,	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
contribute	O	O	O
to	O	O	O
sympathetic	O	O	B-Entity
vasoconstrictor	O	O	B-Entity
outflow	O	O	I-Entity
,	O	O	O
and	O	O	O
is	O	O	O
predictive	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
.	O	O	O

CC	O	O	B-Entity
activity	O	O	B-Entity
/	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
resulting	O	O	O
functional	O	O	B-Entity
significance	O	O	B-Entity
,	O	O	O
has	O	O	O
not	O	O	B-Entity
been	O	O	I-Entity
well	O	O	I-Entity
examined	O	O	I-Entity
in	O	O	O
COPD	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
CC	O	O	B-Entity
activity	O	O	B-Entity
/	O	O	O
sensitivity	O	O	B-Entity
would	O	O	O
be	O	O	O
elevated	O	O	B-Entity
in	O	O	O
COPD	O	O	B-Entity
,	O	O	O
and	O	O	O
related	O	O	O
to	O	O	O
increased	O	O	B-Entity
pulse	O	O	B-Entity
wave	O	O	I-Entity
velocity	O	O	I-Entity
(	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
CV	O	O	B-Entity
risk	O	O	I-Entity
)	O	O	O
and	O	O	O
the	O	O	O
ventilatory	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
exercise	O	O	B-Entity
.	O	O	O

30	O	O	O
COPD	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
10	O	O	O
healthy	O	O	B-Entity
age-matched	O	O	O
controls	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
performed	O	O	O
baseline	O	O	B-Entity
cardiopulmonary	O	O	B-Entity
exercise	O	O	I-Entity
and	O	O	O
pulmonary	O	O	B-Entity
function	O	O	I-Entity
testing	O	O	I-Entity
.	O	O	O

CC	O	O	B-Entity
activity	O	O	B-Entity
was	O	O	O
later	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
the	O	O	O
drop	O	O	B-Entity
in	O	O	I-Entity
ventilation	O	O	B-Entity
with	O	O	O
breathing	O	O	B-Entity
100	O	O	O
%	O	O	O
O2	O	O	B-Entity
,	O	O	O
and	O	O	O
CC	O	O	O
sensitivity	O	O	B-Entity
was	O	O	O
then	O	O	O
assessed	O	O	O
by	O	O	O
the	O	O	O
ventilatory	O	O	B-Entity
response	O	O	I-Entity
to	O	O	I-Entity
hypoxia	O	O	I-Entity
(	O	O	O
ΔVE/ΔS	O	O	O
pO2	O	O	B-Entity
)	O	O	O
.	O	O	O

Peripheral	O	O	B-Entity
arterial	O	O	B-Entity
stiffness	O	O	I-Entity
was	O	O	O
subsequently	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
measurement	O	O	B-Entity
of	O	O	O
pulse	O	O	B-Entity
wave	O	O	I-Entity
velocity	O	O	I-Entity
(	O	O	O
PWV	O	O	B-Entity
)	O	O	O
using	O	O	O
applanation	O	O	B-Entity
tonometry	O	O	I-Entity
while	O	O	O
the	O	O	O
subjects	O	O	O
were	O	O	O
breathing	O	O	B-Entity
room	O	O	B-Entity
air	O	O	I-Entity
,	O	O	O
and	O	O	O
then	O	O	O
following	O	O	O
chemoreceptor	O	O	B-Entity
inhibition	O	O	B-Entity
by	O	O	O
breathing	O	O	O
100	O	O	B-Entity
%	O	O	I-Entity
O2	O	O	B-Entity
for	O	O	O
2	O	O	O
minutes	O	O	O
.	O	O	O

CC	O	O	B-Entity
activity	O	O	B-Entity
,	O	O	O
CC	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
PWV	O	O	B-Entity
and	O	O	O
the	O	O	O
ventilatory	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
exercise	O	O	B-Entity
were	O	O	O
all	O	O	O
increased	O	O	O
in	O	O	O
COPD	O	O	B-Entity
relative	O	O	O
to	O	O	O
controls	O	O	B-Entity
.	O	O	O

CC	O	O	B-Entity
sensitivity	O	O	B-Entity
was	O	O	O
related	O	O	O
to	O	O	O
PWV	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
neither	O	O	O
CC	O	O	O
activity	O	O	B-Entity
nor	O	O	O
CC	O	O	O
sensitivity	O	O	O
was	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
ventilatory	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
exercise	O	O	B-Entity
in	O	O	O
COPD	O	O	B-Entity
.	O	O	O

CC	O	O	B-Entity
inhibition	O	O	O
by	O	O	O
breathing	O	O	B-Entity
100	O	O	B-Entity
%	O	O	I-Entity
O2	O	O	B-Entity
normalized	O	O	O
PWV	O	O	B-Entity
in	O	O	O
COPD	O	O	B-Entity
,	O	O	O
while	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
controls	O	O	B-Entity
.	O	O	O

CC	O	O	B-Entity
activity	O	O	B-Entity
and	O	O	O
sensitivity	O	O	B-Entity
are	O	O	O
elevated	O	O	B-Entity
in	O	O	O
COPD	O	O	B-Entity
,	O	O	O
and	O	O	O
appear	O	O	O
related	O	O	O
to	O	O	O
cardiovascular	O	O	B-Entity
risk	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
CC	O	O	O
activity	O	O	O
/	O	O	O
sensitivity	O	O	O
does	O	O	O
not	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
potentiated	O	O	B-Entity
ventilatory	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
exercise	O	O	B-Entity
.	O	O	O

-DOCSTART- (27356972)

Isolation	O	O	B-Entity
of	O	O	I-Entity
Cells	O	O	I-Entity
Specialized	O	O	B-Entity
in	O	O	O
Anticancer	O	O	B-Entity
Alkaloid	O	O	B-Entity
Metabolism	O	O	I-Entity
by	O	O	O
Fluorescence-Activated	O	O	O
Cell	O	O	O
Sorting	O	O	O

Plant	O	O	B-Entity
specialized	O	O	B-Entity
metabolism	O	O	B-Entity
often	O	O	O
presents	O	O	O
a	O	O	O
complex	O	O	B-Entity
cell	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
compartmentation	O	O	B-Entity
essential	O	O	O
to	O	O	O
accomplish	O	O	O
the	O	O	O
biosynthesis	O	O	B-Entity
of	O	O	O
valuable	O	O	O
plant	O	O	B-Entity
natural	O	O	B-Entity
products	O	O	I-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
the	O	O	O
disclosure	O	O	O
and	O	O	O
potential	O	O	O
manipulation	O	O	B-Entity
of	O	O	O
such	O	O	O
pathways	O	O	B-Entity
may	O	O	O
depend	O	O	O
on	O	O	O
the	O	O	O
capacity	O	O	O
to	O	O	O
isolate	O	O	B-Entity
and	O	O	O
characterize	O	O	B-Entity
specific	O	O	B-Entity
cell	O	O	B-Entity
types	O	O	I-Entity
.	O	O	O

Catharanthus	O	O	B-Entity
roseus	O	O	I-Entity
is	O	O	O
the	O	O	O
source	O	O	O
of	O	O	O
several	O	O	O
medicinal	O	O	B-Entity
terpenoid	O	O	B-Entity
indole	O	O	I-Entity
alkaloids	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
low-level	O	O	O
anticancer	O	O	B-Entity
vinblastine	O	O	B-Entity
and	O	O	O
vincristine	O	O	B-Entity
,	O	O	O
for	O	O	O
which	O	O	O
the	O	O	O
late	O	O	O
biosynthetic	O	O	B-Entity
steps	O	O	I-Entity
occur	O	O	O
in	O	O	O
specialized	O	O	B-Entity
mesophyll	O	O	B-Entity
cells	O	O	I-Entity
called	O	O	O
idioblasts	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
the	O	O	O
optical	O	O	B-Entity
,	O	O	O
fluorescence	O	O	B-Entity
,	O	O	O
and	O	O	O
alkaloid	O	O	B-Entity
-	O	O	O
accumulating	O	O	B-Entity
properties	O	O	O
of	O	O	O
C.	O	O	B-Entity
roseus	O	O	I-Entity
leaf	O	O	B-Entity
idioblasts	O	O	B-Entity
are	O	O	O
characterized	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
methodology	O	O	B-Entity
for	O	O	O
the	O	O	O
isolation	O	O	B-Entity
of	O	O	O
idioblast	O	O	B-Entity
protoplasts	O	O	B-Entity
by	O	O	O
fluorescence-activated	O	O	B-Entity
cell	O	O	I-Entity
sorting	O	O	I-Entity
is	O	O	O
established	O	O	O
,	O	O	O
taking	O	O	O
advantage	O	O	O
of	O	O	O
the	O	O	O
distinctive	O	O	O
autofluorescence	O	O	B-Entity
of	O	O	O
these	O	O	O
cells	O	O	B-Entity
.	O	O	O

This	O	O	O
achievement	O	O	O
represents	O	O	O
a	O	O	O
crucial	O	O	O
step	O	O	O
for	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
differential	O	O	O
omic	O	O	B-Entity
strategies	O	O	I-Entity
leading	O	O	O
to	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
candidate	O	O	B-Entity
genes	O	O	I-Entity
putatively	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
biosynthesis	O	O	B-Entity
,	O	O	O
pathway	O	O	B-Entity
regulation	O	O	B-Entity
,	O	O	O
and	O	O	O
transmembrane	O	O	B-Entity
transport	O	O	I-Entity
leading	O	O	O
to	O	O	O
the	O	O	O
anticancer	O	O	B-Entity
alkaloids	O	O	B-Entity
from	O	O	O
C.	O	O	B-Entity
roseus	O	O	I-Entity
.	O	O	O

-DOCSTART- (27357217)

Interaction	O	O	B-Entity
of	O	O	O
the	O	O	O
Antimicrobial	O	O	B-Entity
Peptides	O	O	I-Entity
Rhesus	O	O	B-Entity
θ-Defensin	O	O	I-Entity
and	O	O	O
Porcine	O	O	B-Entity
Protegrin-1	O	O	B-Entity
with	O	O	O
Anionic	O	O	O
Phospholipid	O	O	O
Monolayers	O	O	O

A	O	O	O
combination	O	O	O
of	O	O	O
Langmuir	O	O	B-Entity
isotherm	O	O	I-Entity
,	O	O	O
Brewster	O	O	B-Entity
angle	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
BAM	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
neutron	O	O	B-Entity
reflectivity	O	O	I-Entity
studies	O	O	I-Entity
have	O	O	O
been	O	O	O
performed	O	O	O
to	O	O	O
gain	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
effects	O	O	O
on	O	O	O
model	O	O	B-Entity
bacterial	O	O	B-Entity
cell	O	O	I-Entity
membranes	O	O	I-Entity
of	O	O	O
the	O	O	O
antimicrobial	O	O	B-Entity
peptides	O	O	I-Entity
,	O	O	O
Rhesus	O	O	B-Entity
θ-defensin	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
RTD-1	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
porcine	O	O	B-Entity
protegrin	O	O	B-Entity
1	O	O	I-Entity
(	O	O	O
PG-1	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
peptides	O	O	B-Entity
were	O	O	O
interacted	O	O	B-Entity
with	O	O	O
monolayers	O	O	B-Entity
spread	O	O	O
at	O	O	O
the	O	O	O
air	O	O	B-Entity
-	O	O	O
water	O	O	B-Entity
interface	O	O	O
and	O	O	O
prepared	O	O	O
from	O	O	O
a	O	O	O
3:1	O	O	O
molar	O	O	O
mixture	O	O	O
of	O	O	O
phosphatidylethanolamine	O	O	B-Entity
and	O	O	O
phosphatidylglycerol	O	O	B-Entity
used	O	O	O
to	O	O	O
approximate	O	O	B-Entity
the	O	O	O
cell	O	O	B-Entity
membranes	O	O	I-Entity
of	O	O	O
Gram	O	O	B-Entity
positive	O	O	I-Entity
bacteria	O	O	I-Entity
.	O	O	O

The	O	O	O
Langmuir	O	O	B-Entity
film	O	O	I-Entity
balance	O	O	O
measurements	O	O	B-Entity
show	O	O	O
that	O	O	O
both	O	O	O
peptides	O	O	B-Entity
perturb	O	O	B-Entity
the	O	O	O
lipid	O	O	B-Entity
monolayers	O	O	I-Entity
causing	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
surface	O	O	B-Entity
pressure	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
BAM	O	O	B-Entity
studies	O	O	O
show	O	O	O
that	O	O	O
each	O	O	O
results	O	O	O
in	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
small	O	O	B-Entity
domains	O	O	I-Entity
within	O	O	O
the	O	O	O
lipid	O	O	B-Entity
films	O	O	I-Entity
,	O	O	O
around	O	O	O
5	O	O	O
μm	O	O	O
diameter	O	O	O
.	O	O	O

The	O	O	O
overall	O	O	O
change	O	O	O
in	O	O	O
monolayer	O	O	B-Entity
surface	O	O	B-Entity
pressure	O	O	I-Entity
caused	O	O	O
by	O	O	O
PG-1	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
is	O	O	O
a	O	O	O
little	O	O	O
more	O	O	O
pronounced	O	O	O
than	O	O	O
that	O	O	O
due	O	O	O
to	O	O	O
RTD-1	O	O	B-Entity
(	O	O	O
+	O	O	O
8.5	O	O	O
mN·m(-1	O	O	O
)	O	O	O
vs	O	O	O
+	O	O	O
5.5	O	O	O
mN·m(-1	O	O	O
)	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
its	O	O	O
initial	O	O	O
interaction	O	O	B-Entity
with	O	O	O
the	O	O	O
monolayer	O	O	O
is	O	O	O
a	O	O	O
little	O	O	O
more	O	O	O
rapid	O	O	O
than	O	O	O
that	O	O	O
for	O	O	O
RTD-1	O	O	O
.	O	O	O

The	O	O	O
neutron	O	O	B-Entity
reflectivity	O	O	I-Entity
studies	O	O	I-Entity
also	O	O	O
show	O	O	O
differences	O	O	O
for	O	O	O
PG-1	O	O	B-Entity
and	O	O	O
RTD-1	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
model	O	O	B-Entity
fits	O	O	O
to	O	O	O
these	O	O	O
data	O	O	O
showing	O	O	O
that	O	O	O
the	O	O	O
more	O	O	O
amphiphilic	O	O	B-Entity
PG-1	O	O	O
becomes	O	O	O
fully	O	O	O
embedded	O	O	B-Entity
within	O	O	O
the	O	O	O
lipid	O	O	B-Entity
film	O	O	I-Entity
-causing	O	O	O
an	O	O	O
extension	O	O	O
of	O	O	O
the	O	O	O
lipid	O	O	B-Entity
acyl	O	O	I-Entity
chains	O	O	I-Entity
but	O	O	O
leaving	O	O	O
the	O	O	O
thickness	O	O	B-Entity
of	O	O	O
the	O	O	O
lipid	O	O	B-Entity
headgroup	O	O	I-Entity
layer	O	O	I-Entity
unaffected-while	O	O	O
RTD-1	O	O	O
is	O	O	O
seen	O	O	O
to	O	O	O
insert	O	O	O
less	O	O	O
deeply-causing	O	O	O
the	O	O	O
same	O	O	O
extension	O	O	O
of	O	O	O
the	O	O	O
lipid	O	O	O
acyl	O	O	O
chains	O	O	O
as	O	O	O
PG-1	O	O	O
but	O	O	O
also	O	O	O
causing	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
thickness	O	O	O
of	O	O	O
the	O	O	O
lipid	O	O	O
headgroup	O	O	O
layer	O	O	O
.	O	O	O

The	O	O	O
various	O	O	O
differing	O	O	O
effects	O	O	O
of	O	O	O
the	O	O	O
two	O	O	O
peptides	O	O	B-Entity
on	O	O	O
anionic	O	O	B-Entity
lipid	O	O	I-Entity
monolayers	O	O	I-Entity
are	O	O	O
discussed	O	O	O
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
their	O	O	O
differing	O	O	O
hemolytic	O	O	B-Entity
activities	O	O	I-Entity
,	O	O	O
and	O	O	O
their	O	O	O
proposed	O	O	O
differing	O	O	B-Entity
propensities	O	O	I-Entity
to	O	O	O
form	O	O	O
transmembrane	O	O	B-Entity
pores	O	O	B-Entity
.	O	O	O

-DOCSTART- (27357607)

Development	O	O	B-Entity
of	O	O	O
chrysin	O	O	B-Entity
loaded	O	O	O
poloxamer	O	O	B-Entity
micelles	O	O	O
and	O	O	O
toxicity	O	O	B-Entity
evaluation	O	O	B-Entity
in	O	O	O
fish	O	O	B-Entity
embryos	O	O	O

Poloxamer	O	O	B-Entity
micelles	O	O	B-Entity
promise	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
for	O	O	O
many	O	O	O
water	O	O	B-Entity
insoluble	O	O	B-Entity
drugs	O	O	B-Entity
.	O	O	O

Chrysin	O	O	B-Entity
has	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
have	O	O	O
anticancer	O	O	B-Entity
,	O	O	O
anti-inflammatory	O	O	B-Entity
,	O	O	O
antioxidant	O	O	B-Entity
,	O	O	O
and	O	O	O
anti-aromatase	O	O	B-Entity
activities	O	O	I-Entity
but	O	O	O
its	O	O	O
water	O	O	B-Entity
insoluble	O	O	B-Entity
properties	O	O	B-Entity
limit	O	O	O
its	O	O	O
pharmaceutical	O	O	B-Entity
application	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
chrysin	O	O	B-Entity
loaded	O	O	O
poloxamer	O	O	B-Entity
micelles	O	O	B-Entity
were	O	O	O
developed	O	O	O
.	O	O	O

Two	O	O	O
types	O	O	O
of	O	O	O
poloxamers	O	O	B-Entity
,	O	O	O
Pluronic	O	O	B-Entity
F-68	O	O	I-Entity
and	O	O	O
Pluronic	O	O	B-Entity
F-127	O	O	I-Entity
were	O	O	O
compared	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
found	O	O	O
that	O	O	O
chrysin	O	O	B-Entity
loaded	O	O	O
Pluronic	O	O	B-Entity
F-68	O	O	I-Entity
micelles	O	O	B-Entity
(	O	O	O
CS-P68	O	O	B-Entity
)	O	O	O
and	O	O	O
chrysin	O	O	O
loaded	O	O	O
Pluronic	O	O	B-Entity
F-127	O	O	I-Entity
micelles	O	O	O
(	O	O	O
CS-P127	O	O	B-Entity
)	O	O	O
obviously	O	O	O
increase	O	O	B-Entity
the	O	O	O
aqueous	O	O	B-Entity
solubility	O	O	B-Entity
of	O	O	O
chrysin	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
also	O	O	O
indicated	O	O	O
that	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
polymer	O	O	B-Entity
and	O	O	O
ratio	O	O	O
of	O	O	O
drug	O	O	B-Entity
to	O	O	O
polymer	O	O	O
affected	O	O	O
size	O	O	B-Entity
and	O	O	O
desirable	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
the	O	O	O
micelles	O	O	B-Entity
.	O	O	O

The	O	O	O
micelle	O	O	B-Entity
system	O	O	I-Entity
of	O	O	O
CS-P68	O	O	B-Entity
and	O	O	O
CS-P127	O	O	B-Entity
formed	O	O	O
at	O	O	O
drug	O	O	B-Entity
to	O	O	O
polymer	O	O	B-Entity
ratios	O	O	B-Entity
of	O	O	O
1:4	O	O	O
and	O	O	O
1:2	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
most	O	O	O
suitable	O	O	O
monodispersed	O	O	O
system	O	O	O
with	O	O	O
a	O	O	O
nanosize-range	O	O	B-Entity
diameter	O	O	I-Entity
.	O	O	O

The	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
study	O	O	I-Entity
in	O	O	O
zebrafish	O	O	B-Entity
eggs	O	O	B-Entity
indicates	O	O	O
that	O	O	O
the	O	O	O
toxicity	O	O	B-Entity
of	O	O	O
CS-P68	O	O	B-Entity
and	O	O	O
CS-P127	O	O	B-Entity
is	O	O	O
a	O	O	O
dose	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

CS-P68	O	O	B-Entity
and	O	O	O
CS-P127	O	O	B-Entity
at	O	O	O
a	O	O	O
drug	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
10	O	O	O
ng/mL	O	O	O
or	O	O	O
less	O	O	B-Entity
is	O	O	O
safe	O	O	O
for	O	O	O
zebrafish	O	O	B-Entity
embryo	O	O	B-Entity
growth	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
indicate	O	O	O
enhanced	O	O	B-Entity
water	O	O	B-Entity
solubility	O	O	I-Entity
of	O	O	O
chrysin	O	O	B-Entity
.	O	O	O

Chrysin	O	O	B-Entity
loaded	O	O	O
poloxamer	O	O	B-Entity
micelles	O	O	B-Entity
are	O	O	O
promising	O	O	O
for	O	O	O
further	O	O	O
use	O	O	O
in	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
studies	O	O	I-Entity
in	O	O	O
mammalian	O	O	B-Entity
animals	O	O	B-Entity
and	O	O	O
humans	O	O	B-Entity
.	O	O	O

-DOCSTART- (27357626)

Adenoviral	O	O	B-Entity
Delivery	O	O	B-Entity
of	O	O	O
Tumor	O	O	B-Entity
Necrosis	O	O	I-Entity
Factor-α	O	O	I-Entity
and	O	O	O
Interleukin-2	O	O	B-Entity
Enables	O	O	O
Successful	O	O	O
Adoptive	O	O	B-Entity
Cell	O	O	I-Entity
Therapy	O	O	I-Entity
of	O	O	O
Immunosuppressive	O	O	B-Entity
Melanoma	O	O	O

Adoptive	O	O	B-Entity
T-cell	O	O	I-Entity
transfer	O	O	I-Entity
is	O	O	O
a	O	O	O
promising	O	O	O
treatment	O	O	B-Entity
approach	O	O	I-Entity
for	O	O	O
metastatic	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
but	O	O	O
efficacy	O	O	B-Entity
in	O	O	O
solid	O	O	B-Entity
tumors	O	O	I-Entity
has	O	O	O
only	O	O	O
been	O	O	O
achieved	O	O	O
with	O	O	O
toxic	O	O	B-Entity
pre-	O	O	O
and	O	O	O
postconditioning	O	O	O
regimens	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
adoptive	O	O	B-Entity
T-cell	O	O	I-Entity
therapies	O	O	I-Entity
would	O	O	O
benefit	O	O	B-Entity
from	O	O	O
complementary	O	O	O
modalities	O	O	B-Entity
that	O	O	O
enable	O	O	O
their	O	O	O
full	O	O	B-Entity
potential	O	O	B-Entity
without	O	O	O
excessive	O	O	B-Entity
toxicity	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
adoptive	O	O	B-Entity
T-cell	O	O	I-Entity
transfer	O	O	I-Entity
by	O	O	O
using	O	O	O
adenoviral	O	O	B-Entity
vectors	O	O	I-Entity
for	O	O	O
direct	O	O	O
delivery	O	O	B-Entity
of	O	O	O
immunomodulatory	O	O	B-Entity
murine	O	O	B-Entity
cytokines	O	O	B-Entity
into	O	O	O
B16.OVA	O	O	B-Entity
melanoma	O	O	B-Entity
tumors	O	O	B-Entity
with	O	O	O
concomitant	O	O	B-Entity
T-cell	O	O	B-Entity
receptor	O	O	I-Entity
transgenic	O	O	B-Entity
OT-I	O	O	I-Entity
T-cell	O	O	I-Entity
transfer	O	O	I-Entity
.	O	O	O

Armed	O	O	O
adenoviruses	O	O	B-Entity
expressed	O	O	O
high	O	O	O
local	O	O	O
and	O	O	O
low	O	O	O
systemic	O	O	O
levels	O	O	O
of	O	O	O
cytokine	O	O	B-Entity
when	O	O	O
injected	O	O	B-Entity
into	O	O	O
B16.OVA	O	O	B-Entity
tumors	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
safety	O	O	B-Entity
of	O	O	O
virus-mediated	O	O	B-Entity
cytokine	O	O	I-Entity
delivery	O	O	I-Entity
.	O	O	O

Antitumor	O	O	B-Entity
efficacy	O	O	B-Entity
was	O	O	O
significantly	O	O	O
enhanced	O	O	B-Entity
with	O	O	O
adenoviruses	O	O	B-Entity
coding	O	O	O
for	O	O	O
murine	O	O	B-Entity
interleukin-2	O	O	B-Entity
(	O	O	O
mIL-2	O	O	B-Entity
)	O	O	O
and	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor-α	O	O	I-Entity
(	O	O	O
mTNFα	O	O	B-Entity
)	O	O	O
when	O	O	O
compared	O	O	O
with	O	O	O
T-cell	O	O	B-Entity
transfer	O	O	I-Entity
alone	O	O	O
or	O	O	O
viruses	O	O	B-Entity
alone	O	O	O
.	O	O	O

Further	O	O	O
improvement	O	O	B-Entity
in	O	O	O
efficacy	O	O	B-Entity
was	O	O	O
achieved	O	O	O
with	O	O	O
a	O	O	O
triple	O	O	B-Entity
combination	O	O	B-Entity
of	O	O	O
mIL-2	O	O	B-Entity
,	O	O	O
mTNFα	O	O	B-Entity
,	O	O	O
and	O	O	O
OT-I	O	O	B-Entity
T-cells	O	O	I-Entity
.	O	O	O

Mechanistic	O	O	B-Entity
studies	O	O	I-Entity
suggest	O	O	O
that	O	O	O
mIL-2	O	O	B-Entity
has	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
activating	O	O	B-Entity
T-cells	O	O	B-Entity
at	O	O	O
the	O	O	O
tumor	O	O	B-Entity
,	O	O	O
while	O	O	O
mTNFα	O	O	B-Entity
induces	O	O	O
chemokine	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
adenovirus	O	O	B-Entity
treatments	O	O	B-Entity
enhanced	O	O	B-Entity
tumor	O	O	B-Entity
-	O	O	O
infiltration	O	O	O
of	O	O	O
OT-I	O	O	B-Entity
T-cells	O	O	I-Entity
as	O	O	O
demonstrated	O	O	B-Entity
by	O	O	O
SPECT/CT	O	O	B-Entity
imaging	O	O	I-Entity
of	O	O	O
(111)In-labeled	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
suggest	O	O	B-Entity
the	O	O	O
utility	O	O	O
of	O	O	O
cytokine-coding	O	O	B-Entity
adenoviruses	O	O	B-Entity
for	O	O	O
improving	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
adoptive	O	O	B-Entity
T-cell	O	O	I-Entity
therapies	O	O	I-Entity
.	O	O	O

-DOCSTART- (27363786)

The	O	O	O
Maternal	O	O	B-Entity
Legacy	O	O	B-Entity
:	O	O	O
Female	O	O	B-Entity
Identity	O	O	B-Entity
Predicts	O	O	O
Offspring	O	O	B-Entity
Sex	O	O	B-Entity
Ratio	O	O	I-Entity
in	O	O	O
the	O	O	O
Loggerhead	O	O	O
Sea	O	O	O
Turtle	O	O	O

In	O	O	O
organisms	O	O	B-Entity
with	O	O	O
temperature-dependent	O	O	B-Entity
sex	O	O	B-Entity
determination	O	O	I-Entity
,	O	O	O
the	O	O	O
incubation	O	O	B-Entity
environment	O	O	I-Entity
plays	O	O	O
a	O	O	O
key	O	O	O
role	O	O	O
in	O	O	O
determining	O	O	O
offspring	O	O	B-Entity
sex	O	O	B-Entity
ratios	O	O	I-Entity
.	O	O	O

Given	O	O	O
that	O	O	O
global	O	O	B-Entity
temperatures	O	O	B-Entity
have	O	O	O
warmed	O	O	B-Entity
approximately	O	O	O
0.6	O	O	O
°	O	O	O
C	O	O	O
in	O	O	O
the	O	O	O
last	O	O	O
century	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
necessary	O	O	O
to	O	O	O
consider	O	O	O
how	O	O	O
organisms	O	O	B-Entity
will	O	O	O
adjust	O	O	B-Entity
to	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

To	O	O	O
better	O	O	O
understand	O	O	O
the	O	O	O
degree	O	O	B-Entity
to	O	O	O
which	O	O	O
mothers	O	O	B-Entity
influence	O	O	B-Entity
the	O	O	O
sex	O	O	B-Entity
ratios	O	O	I-Entity
of	O	O	O
their	O	O	O
offspring	O	O	B-Entity
,	O	O	O
we	O	O	O
use	O	O	O
24	O	O	O
years	O	O	B-Entity
of	O	O	O
nesting	O	O	B-Entity
data	O	O	I-Entity
for	O	O	O
individual	O	O	B-Entity
female	O	O	B-Entity
loggerhead	O	O	B-Entity
sea	O	O	I-Entity
turtles	O	O	I-Entity
(	O	O	O
Caretta	O	O	B-Entity
caretta	O	O	I-Entity
)	O	O	O
observed	O	O	O
on	O	O	O
Bald	O	O	B-Entity
Head	O	O	I-Entity
Island	O	O	I-Entity
,	O	O	O
North	O	O	B-Entity
Carolina	O	O	I-Entity
.	O	O	O

We	O	O	O
find	O	O	O
that	O	O	O
maternal	O	O	B-Entity
identity	O	O	B-Entity
is	O	O	O
the	O	O	O
best	O	O	O
predictor	O	O	O
of	O	O	O
nest	O	O	B-Entity
sex	O	O	B-Entity
ratio	O	O	I-Entity
in	O	O	O
univariate	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
predictive	O	O	I-Entity
models	O	O	I-Entity
.	O	O	O

We	O	O	O
find	O	O	O
significant	O	O	O
variability	O	O	B-Entity
in	O	O	O
estimated	O	O	O
nest	O	O	B-Entity
sex	O	O	B-Entity
ratios	O	O	I-Entity
among	O	O	O
mothers	O	O	B-Entity
,	O	O	O
but	O	O	O
a	O	O	O
high	O	O	O
degree	O	O	O
of	O	O	O
consistency	O	O	B-Entity
within	O	O	O
mothers	O	O	O
,	O	O	O
despite	O	O	O
substantial	O	O	O
spatial	O	O	B-Entity
and	O	O	O
temporal	O	O	B-Entity
thermal	O	O	B-Entity
variation	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
individual	O	O	B-Entity
differences	O	O	O
in	O	O	O
nesting	O	O	B-Entity
preferences	O	O	I-Entity
are	O	O	O
the	O	O	O
main	O	O	O
driver	O	O	O
behind	O	O	O
divergences	O	O	B-Entity
in	O	O	O
nest	O	O	B-Entity
sex	O	O	B-Entity
ratios	O	O	I-Entity
.	O	O	O

As	O	O	O
such	O	O	O
,	O	O	O
a	O	O	O
female	O	O	B-Entity
's	O	O	I-Entity
ability	O	O	O
to	O	O	O
plastically	O	O	O
adjust	O	O	O
her	O	O	O
nest	O	O	B-Entity
sex	O	O	B-Entity
ratios	O	O	I-Entity
in	O	O	O
response	O	O	O
to	O	O	O
environmental	O	O	B-Entity
conditions	O	O	B-Entity
is	O	O	O
constrained	O	O	B-Entity
,	O	O	O
potentially	O	O	O
limiting	O	O	O
how	O	O	O
individuals	O	O	B-Entity
behaviorally	O	O	O
mitigate	O	O	B-Entity
the	O	O	O
effects	O	O	O
of	O	O	O
environmental	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

Given	O	O	O
that	O	O	O
many	O	O	O
loggerhead	O	O	B-Entity
populations	O	O	B-Entity
already	O	O	O
show	O	O	O
female-biased	O	O	B-Entity
offspring	O	O	B-Entity
sex	O	O	B-Entity
ratios	O	O	I-Entity
,	O	O	O
understanding	O	O	O
maternal	O	O	B-Entity
behavioral	O	O	I-Entity
responses	O	O	O
is	O	O	O
critical	O	O	B-Entity
for	O	O	O
predicting	O	O	O
the	O	O	O
future	O	O	O
of	O	O	O
long-lived	O	O	O
species	O	O	B-Entity
vulnerable	O	O	B-Entity
to	O	O	O
extinction	O	O	B-Entity
.	O	O	O

-DOCSTART- (27364501)

Increased	O	O	O
RhoA	O	O	B-Entity
Activity	O	O	B-Entity
Predicts	O	O	O
Worse	O	O	B-Entity
Overall	O	O	B-Entity
Survival	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
Undergoing	O	O	O
Surgical	O	O	B-Entity
Resection	O	O	I-Entity
for	O	O	O
Lauren	O	O	B-Entity
Diffuse-Type	O	O	O
Gastric	O	O	O
Adenocarcinoma	O	O	O

Several	O	O	O
studies	O	O	O
have	O	O	O
reported	O	O	O
a	O	O	O
high	O	O	O
rate	O	O	O
of	O	O	O
RHOA	O	O	B-Entity
mutations	O	O	B-Entity
in	O	O	O
the	O	O	O
Lauren	O	O	B-Entity
diffuse-type	O	O	B-Entity
gastric	O	O	I-Entity
adenocarcinoma	O	O	I-Entity
(	O	O	O
GA	O	O	B-Entity
)	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
intestinal-type	O	O	B-Entity
GA	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
RhoA	O	O	B-Entity
activity	O	O	B-Entity
is	O	O	O
prognostic	O	O	B-Entity
for	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
resectable	O	O	O
GA	O	O	B-Entity
.	O	O	O

Retrospective	O	O	B-Entity
review	O	O	I-Entity
was	O	O	O
performed	O	O	O
on	O	O	O
a	O	O	O
prospective	O	O	O
database	O	O	O
of	O	O	O
GA	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
potentially	O	O	O
curative	O	O	B-Entity
resection	O	O	I-Entity
between	O	O	O
2003	O	O	O
and	O	O	O
2012	O	O	O
at	O	O	O
a	O	O	O
single	O	O	B-Entity
institution	O	O	I-Entity
.	O	O	O

Tissue	O	O	B-Entity
microarrays	O	O	B-Entity
were	O	O	O
constructed	O	O	O
from	O	O	O
surgical	O	O	B-Entity
specimens	O	O	I-Entity
and	O	O	O
analyzed	O	O	O
for	O	O	O
phosphorylated	O	O	B-Entity
RhoA	O	O	B-Entity
,	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
inactive	O	O	O
RhoA	O	O	O
signaling	O	O	B-Entity
.	O	O	O

OS	O	O	B-Entity
was	O	O	O
estimated	O	O	O
by	O	O	O
the	O	O	O
Kaplan-Meier	O	O	B-Entity
method	O	O	I-Entity
,	O	O	O
and	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	O
by	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
regression	O	O	I-Entity
modeling	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
thirty-six	O	O	O
patients	O	O	B-Entity
with	O	O	O
diffuse-type	O	O	B-Entity
GA	O	O	I-Entity
and	O	O	O
129	O	O	O
patients	O	O	O
with	O	O	O
intestinal-type	O	O	B-Entity
GA	O	O	I-Entity
were	O	O	O
examined	O	O	O
.	O	O	O

Compared	O	O	O
to	O	O	O
intestinal-type	O	O	B-Entity
GA	O	O	I-Entity
,	O	O	O
diffuse-type	O	O	B-Entity
GA	O	O	I-Entity
tumors	O	O	B-Entity
were	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	O
tumor	O	O	B-Entity
size	O	O	I-Entity
and	O	O	O
advanced	O	O	B-Entity
tumor	O	O	I-Entity
,	O	O	I-Entity
node	O	O	I-Entity
,	O	O	I-Entity
metastasis	O	O	I-Entity
(	O	O	I-Entity
TNM	O	O	I-Entity
)	O	O	I-Entity
classification	O	O	I-Entity
system	O	O	I-Entity
stage	O	O	I-Entity
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
diffuse-type	O	O	B-Entity
GA	O	O	I-Entity
,	O	O	O
high	O	O	O
RhoA	O	O	B-Entity
activity	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
significantly	O	O	O
worse	O	O	B-Entity
OS	O	O	B-Entity
when	O	O	O
compared	O	O	O
to	O	O	O
low	O	O	O
RhoA	O	O	O
activity	O	O	O
(	O	O	O
5-year	O	O	O
OS	O	O	O
52.5	O	O	O
vs.	O	O	O
81.0	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.017	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
difference	O	O	O
in	O	O	O
OS	O	O	B-Entity
was	O	O	O
not	O	O	O
observed	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
intestinal-type	O	O	B-Entity
GA	O	O	I-Entity
(	O	O	O
5-year	O	O	O
OS	O	O	O
83.9	O	O	O
vs.	O	O	O
81.6	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.766	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
diffuse-type	O	O	B-Entity
GA	O	O	I-Entity
patients	O	O	B-Entity
,	O	O	O
high	O	O	O
RhoA	O	O	B-Entity
activity	O	O	B-Entity
was	O	O	O
an	O	O	O
independent	O	O	O
negative	O	O	O
prognostic	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
OS	O	O	B-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
2.38	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
1.07	O	O	O
-	O	O	O
5.28	O	O	O
)	O	O	O
.	O	O	O

Increased	O	O	O
RhoA	O	O	B-Entity
activity	O	O	B-Entity
is	O	O	O
predictive	O	O	O
of	O	O	O
worse	O	O	B-Entity
OS	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
diffuse-type	O	O	B-Entity
GA	O	O	I-Entity
who	O	O	O
undergo	O	O	O
potentially	O	O	O
curative	O	O	B-Entity
surgical	O	O	I-Entity
resection	O	O	I-Entity
.	O	O	O

Along	O	O	O
with	O	O	O
findings	O	O	O
from	O	O	O
genomic	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
these	O	O	O
results	O	O	O
suggest	O	O	O
RhoA	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
novel	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
in	O	O	O
diffuse-type	O	O	B-Entity
GA	O	O	I-Entity
.	O	O	O

-DOCSTART- (27364610)

Doxifluridine	O	O	B-Entity
-	O	O	O
conjugated	O	O	B-Entity
2	O	O	B-Entity
-	O	O	I-Entity
5A	O	O	I-Entity
analog	O	O	B-Entity
shows	O	O	O
strong	O	O	B-Entity
RNase	O	O	B-Entity
L	O	O	I-Entity
activation	O	O	B-Entity
ability	O	O	B-Entity
and	O	O	O
tumor	O	O	B-Entity
suppressive	O	O	I-Entity
effect	O	O	O

RNase	O	O	B-Entity
L	O	O	I-Entity
is	O	O	O
activated	O	O	B-Entity
by	O	O	O
2',5'-oligoadenylates	O	O	B-Entity
(	O	O	O
2	O	O	B-Entity
-	O	O	I-Entity
5A	O	O	I-Entity
)	O	O	O
at	O	O	O
subnanomolar	O	O	B-Entity
levels	O	O	B-Entity
to	O	O	O
cleave	O	O	B-Entity
single-stranded	O	O	B-Entity
RNA	O	O	I-Entity
.	O	O	O

We	O	O	O
previously	O	O	O
reported	O	O	B-Entity
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
the	O	O	O
introduction	O	O	B-Entity
of	O	O	O
an	O	O	O
8-methyladenosine	O	O	B-Entity
residue	O	O	O
at	O	O	O
the	O	O	O
2'-	O	O	O
terminus	O	O	B-Entity
of	O	O	O
the	O	O	O
2	O	O	B-Entity
-	O	O	I-Entity
5A	O	O	I-Entity
tetramer	O	O	I-Entity
shifts	O	O	B-Entity
the	O	O	O
2	O	O	O
-	O	O	O
5A	O	O	O
binding	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
RNase	O	O	O
L.	O	O	O
In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
synthesized	O	O	B-Entity
various	O	O	O
5'-	O	O	O
modified	O	O	B-Entity
2	O	O	O
-	O	O	O
5A	O	O	O
analog	O	O	B-Entity
s	O	O	O
with	O	O	O
8-methyladenosine	O	O	O
at	O	O	O
the	O	O	O
2'-	O	O	O
terminus	O	O	O
.	O	O	O

The	O	O	O
doxifluridine	O	O	B-Entity
-	O	O	O
conjugated	O	O	B-Entity
8-methyladenosine	O	O	B-Entity
-	O	O	O
substituted	O	O	B-Entity
2	O	O	B-Entity
-	O	O	I-Entity
5A	O	O	I-Entity
analog	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
more	O	O	I-Entity
effective	O	O	B-Entity
as	O	O	O
an	O	O	O
activator	O	O	B-Entity
of	O	O	O
RNase	O	O	B-Entity
L	O	O	I-Entity
than	O	O	O
the	O	O	O
parent	O	O	B-Entity
5'-	O	O	O
monophophorylated	O	O	B-Entity
2	O	O	B-Entity
-	O	O	I-Entity
5A	O	O	I-Entity
tetramer	O	O	I-Entity
and	O	O	O
showed	O	O	O
a	O	O	O
tumor	O	O	B-Entity
suppressive	O	O	I-Entity
effect	O	O	B-Entity
against	O	O	B-Entity
human	O	O	B-Entity
cervical	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
.	O	O	O

-DOCSTART- (27366508)

Does	O	O	O
Video	O	O	B-Entity
Laryngoscopy	O	O	I-Entity
Offer	O	O	O
Advantages	O	O	B-Entity
over	O	O	O
Direct	O	O	B-Entity
Laryngoscopy	O	O	I-Entity
during	O	O	B-Entity
Cardiopulmonary	O	O	B-Entity
Resuscitation	O	O	I-Entity
?	O	O	O

Interruption	O	O	B-Entity
of	O	O	O
chest	O	O	B-Entity
compressions	O	O	I-Entity
should	O	O	O
be	O	O	O
minimized	O	O	B-Entity
because	O	O	O
of	O	O	O
its	O	O	O
negative	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
survival	O	O	B-Entity
.	O	O	O

This	O	O	O
randomized	O	O	B-Entity
,	O	O	O
controlled	O	O	B-Entity
,	O	O	O
cross-over	O	O	B-Entity
study	O	O	I-Entity
aimed	O	O	B-Entity
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
Macintosh	O	O	B-Entity
,	O	O	O
Miller	O	O	B-Entity
,	O	O	O
McCoy	O	O	B-Entity
and	O	O	O
McGrath	O	O	B-Entity
laryngoscopes	O	O	I-Entity
during	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
chest	O	O	B-Entity
compressions	O	O	I-Entity
in	O	O	O
the	O	O	O
scope	O	O	B-Entity
of	O	O	O
a	O	O	O
simulated	O	O	O
cardiopulmonary	O	O	B-Entity
resuscitation	O	O	I-Entity
scenario	O	O	B-Entity
.	O	O	O

The	O	O	O
time	O	O	B-Entity
required	O	O	B-Entity
for	O	O	O
successful	O	O	B-Entity
tracheal	O	O	B-Entity
intubation	O	O	I-Entity
,	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
attempts	O	O	I-Entity
,	O	O	O
dental	O	O	B-Entity
trauma	O	O	I-Entity
severity	O	O	B-Entity
and	O	O	O
the	O	O	O
need	O	O	B-Entity
for	O	O	O
optimization	O	O	B-Entity
manoeuvres	O	O	B-Entity
were	O	O	O
recorded	O	O	B-Entity
during	O	O	B-Entity
cardiopulmonary	O	O	B-Entity
resuscitation	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	O
chest	O	O	B-Entity
compressions	O	O	I-Entity
.	O	O	O

The	O	O	O
experience	O	O	B-Entity
with	O	O	O
computer	O	O	B-Entity
games	O	O	I-Entity
during	O	O	B-Entity
the	O	O	O
last	O	O	O
10	O	O	O
years	O	O	B-Entity
were	O	O	O
asked	O	O	O
to	O	O	O
the	O	O	O
participants	O	O	B-Entity
and	O	O	O
recorded	O	O	B-Entity
.	O	O	O

McCoy	O	O	B-Entity
laryngoscope	O	O	I-Entity
yielded	O	O	O
the	O	O	O
shortest	O	O	B-Entity
time	O	O	I-Entity
for	O	O	O
successful	O	O	B-Entity
tracheal	O	O	B-Entity
intubation	O	O	I-Entity
both	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
and	O	O	O
without	O	O	O
chest	O	O	B-Entity
compressions	O	O	I-Entity
.	O	O	O

During	O	O	B-Entity
the	O	O	O
use	O	O	B-Entity
of	O	O	O
McCoy	O	O	B-Entity
laryngoscopes	O	O	I-Entity
,	O	O	O
fewer	O	O	B-Entity
tracheal	O	O	B-Entity
intubation	O	O	B-Entity
attempts	O	O	B-Entity
,	O	O	O
lower	O	O	B-Entity
incidence	O	O	I-Entity
of	O	O	O
dental	O	O	B-Entity
trauma	O	O	I-Entity
and	O	O	O
lower	O	O	O
visual	O	O	B-Entity
analogue	O	O	I-Entity
scale	O	O	I-Entity
scores	O	O	I-Entity
on	O	O	O
the	O	O	O
ease	O	O	O
of	O	O	O
intubation	O	O	O
were	O	O	O
recorded	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
who	O	O	O
are	O	O	O
experienced	O	O	B-Entity
computer	O	O	B-Entity
game	O	O	I-Entity
players	O	O	B-Entity
using	O	O	O
Macintosh	O	O	B-Entity
,	O	O	O
McCoy	O	O	B-Entity
and	O	O	O
McGrath	O	O	B-Entity
achieved	O	O	B-Entity
successful	O	O	B-Entity
tracheal	O	O	B-Entity
intubation	O	O	I-Entity
in	O	O	O
a	O	O	O
significantly	O	O	B-Entity
shorter	O	O	B-Entity
time	O	O	I-Entity
during	O	O	B-Entity
resuscitation	O	O	B-Entity
without	O	O	O
chest	O	O	B-Entity
compressions	O	O	I-Entity
.	O	O	O

Dental	O	O	B-Entity
trauma	O	O	I-Entity
incidence	O	O	B-Entity
and	O	O	O
number	O	O	B-Entity
of	O	O	O
tracheal	O	O	B-Entity
intubation	O	O	I-Entity
attempts	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
any	O	O	O
significant	O	O	B-Entity
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
four	O	O	B-Entity
laryngoscopes	O	O	B-Entity
being	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
playing	O	O	B-Entity
computer	O	O	B-Entity
games	O	O	I-Entity
.	O	O	O

McGrath	O	O	B-Entity
video	O	O	I-Entity
laryngoscopes	O	O	I-Entity
do	O	O	O
not	O	O	O
appear	O	O	O
to	O	O	O
have	O	O	O
advantages	O	O	B-Entity
over	O	O	O
direct	O	O	B-Entity
laryngoscopes	O	O	I-Entity
for	O	O	O
securing	O	O	O
a	O	O	O
smooth	O	O	B-Entity
and	O	O	O
successful	O	O	B-Entity
tracheal	O	O	B-Entity
intubation	O	O	I-Entity
during	O	O	B-Entity
rhythmic	O	O	B-Entity
chest	O	O	I-Entity
compressions	O	O	I-Entity
.	O	O	O

We	O	O	O
believe	O	O	O
that	O	O	O
as	O	O	O
McCoy	O	O	B-Entity
laryngoscope	O	O	B-Entity
provided	O	O	B-Entity
tracheal	O	O	B-Entity
intubation	O	O	I-Entity
in	O	O	O
a	O	O	O
shorter	O	O	B-Entity
time	O	O	I-Entity
and	O	O	O
with	O	O	O
fewer	O	O	B-Entity
attempts	O	O	B-Entity
,	O	O	O
this	O	O	O
laryngoscope	O	O	O
may	O	O	O
increase	O	O	B-Entity
the	O	O	O
success	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
resuscitation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27371819)

The	O	O	O
nurse-patient	O	O	B-Entity
communication	O	O	I-Entity
:	O	O	O
voices	O	O	O
from	O	O	O
nursing	O	O	O
students	O	O	O

Effective	O	O	B-Entity
communication	O	O	I-Entity
skills	O	O	I-Entity
have	O	O	O
been	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
pivotal	O	O	B-Entity
factors	O	O	I-Entity
in	O	O	O
building	O	O	O
positive	O	O	B-Entity
interpersonal	O	O	I-Entity
relationships	O	O	I-Entity
.	O	O	O

Little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
nursing	O	O	B-Entity
undergraduates	O	O	I-Entity
'	O	O	O
perspectives	O	O	B-Entity
on	O	O	O
communicating	O	O	B-Entity
with	O	O	O
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
explore	O	O	O
nursing	O	O	B-Entity
students	O	O	I-Entity
'	O	O	I-Entity
perspectives	O	O	B-Entity
and	O	O	O
experiences	O	O	B-Entity
of	O	O	O
nurse-patient	O	O	B-Entity
communication	O	O	I-Entity
in	O	O	O
their	O	O	O
clinical	O	O	B-Entity
placement	O	O	B-Entity
.	O	O	O

The	O	O	O
participants	O	O	B-Entity
included	O	O	O
21	O	O	O
second-year	O	O	B-Entity
undergraduates	O	O	I-Entity
and	O	O	O
21	O	O	O
first-year	O	O	B-Entity
master	O	O	I-Entity
's	O	O	I-Entity
students	O	O	I-Entity
.	O	O	O

Interviews	O	O	B-Entity
were	O	O	O
conducted	O	O	O
in	O	O	O
Cantonese	O	O	B-Entity
and	O	O	O
then	O	O	O
transcribed	O	O	O
in	O	O	O
Chinese	O	O	B-Entity
and	O	O	O
translated	O	O	O
into	O	O	O
English	O	O	B-Entity
.	O	O	O

A	O	O	O
content	O	O	B-Entity
analysis	O	O	I-Entity
approach	O	O	B-Entity
was	O	O	O
adopted	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
data	O	O	B-Entity
.	O	O	O

Five	O	O	O
themes	O	O	B-Entity
emerged	O	O	O
from	O	O	O
the	O	O	O
interview	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O
'	O	O	O
The	O	O	O
necessity	O	O	O
of	O	O	O
nurse-patient	O	O	B-Entity
communication	O	O	I-Entity
'	O	O	O
reveals	O	O	B-Entity
why	O	O	O
the	O	O	O
students	O	O	B-Entity
valued	O	O	O
nurse-patient	O	O	O
communication	O	O	O
.	O	O	O
'	O	O	O
The	O	O	O
conversation	O	O	B-Entity
contents	O	O	I-Entity
'	O	O	O
describes	O	O	O
the	O	O	O
content	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
conversations	O	O	I-Entity
that	O	O	O
students	O	O	O
typically	O	O	O
had	O	O	O
with	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
third	O	O	O
theme	O	O	B-Entity
is	O	O	O
'	O	O	O
self-reflection	O	O	B-Entity
on	O	O	O
the	O	O	O
nurse-patient	O	O	B-Entity
communication	O	O	I-Entity
'	O	O	O
.	O	O	O

The	O	O	O
last	O	O	O
two	O	O	O
themes	O	O	B-Entity
,	O	O	O
'	O	O	O
the	O	O	O
communication	O	O	B-Entity
pattern	O	O	I-Entity
in	O	O	I-Entity
different	O	O	I-Entity
hospital	O	O	B-Entity
settings	O	O	I-Entity
'	O	O	O
and	O	O	O
'	O	O	O
the	O	O	O
obstacles	O	O	O
impeding	O	O	O
nurse-patient	O	O	B-Entity
communication	O	O	I-Entity
'	O	O	O
,	O	O	O
are	O	O	O
about	O	O	O
the	O	O	O
students	O	O	B-Entity
'	O	O	I-Entity
communication	O	O	B-Entity
styles	O	O	I-Entity
in	O	O	O
different	O	O	O
hospitals	O	O	B-Entity
and	O	O	O
the	O	O	O
barriers	O	O	O
they	O	O	O
encounter	O	O	B-Entity
.	O	O	O

To	O	O	O
improve	O	O	B-Entity
students	O	O	B-Entity
'	O	O	I-Entity
communication	O	O	B-Entity
skills	O	O	I-Entity
,	O	O	O
educators	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
staff	O	O	I-Entity
should	O	O	O
listen	O	O	O
to	O	O	O
students	O	O	O
,	O	O	O
enhance	O	O	B-Entity
students	O	O	B-Entity
'	O	O	I-Entity
reflective	O	O	B-Entity
skills	O	O	I-Entity
and	O	O	O
strengthen	O	O	O
their	O	O	O
confidence	O	O	B-Entity
.	O	O	O

Through	O	O	O
understanding	O	O	B-Entity
students	O	O	B-Entity
'	O	O	I-Entity
difficulties	O	O	B-Entity
in	O	O	O
the	O	O	O
nurse-patient	O	O	B-Entity
communication	O	O	I-Entity
experience	O	O	B-Entity
and	O	O	O
the	O	O	O
skills	O	O	B-Entity
that	O	O	O
they	O	O	O
lack	O	O	O
,	O	O	O
educators	O	O	B-Entity
can	O	O	O
provide	O	O	O
them	O	O	O
with	O	O	O
helpful	O	O	O
recommendations	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
their	O	O	O
communication	O	O	B-Entity
skills	O	O	I-Entity
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
reveal	O	O	B-Entity
that	O	O	O
students	O	O	B-Entity
'	O	O	I-Entity
nurse-patient	O	O	B-Entity
communication	O	O	I-Entity
skills	O	O	B-Entity
need	O	O	O
to	O	O	O
be	O	O	O
improved	O	O	B-Entity
.	O	O	O

-DOCSTART- (27374165)

Early	O	O	O
hippocampal	O	O	B-Entity
volume	O	O	B-Entity
loss	O	O	I-Entity
as	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
eventual	O	O	O
memory	O	O	B-Entity
deficits	O	O	I-Entity
caused	O	O	O
by	O	O	O
repeated	O	O	O
stress	O	O	O

Exposure	O	O	B-Entity
to	O	O	I-Entity
severe	O	O	B-Entity
and	O	O	O
prolonged	O	O	B-Entity
stress	O	O	B-Entity
has	O	O	O
detrimental	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
relatively	O	O	B-Entity
little	O	O	B-Entity
is	O	O	O
known	O	O	B-Entity
about	O	O	O
the	O	O	O
gradual	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
hippocampal	O	O	B-Entity
structure	O	O	I-Entity
,	O	O	O
and	O	O	O
its	O	O	O
behavioral	O	O	B-Entity
consequences	O	O	B-Entity
,	O	O	O
over	O	O	O
the	O	O	O
course	O	O	O
of	O	O	O
repeated	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

Behavioral	O	O	B-Entity
analyses	O	O	I-Entity
during	O	O	O
10	O	O	O
days	O	O	O
of	O	O	O
chronic	O	O	B-Entity
stress	O	O	B-Entity
pointed	O	O	O
to	O	O	O
a	O	O	O
delayed	O	O	O
decline	O	O	B-Entity
in	O	O	O
spatial	O	O	B-Entity
memory	O	O	I-Entity
,	O	O	O
the	O	O	O
full	O	O	O
impact	O	O	B-Entity
of	O	O	O
which	O	O	O
is	O	O	O
evident	O	O	O
only	O	O	O
after	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
stress	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
concurrent	O	O	B-Entity
volumetric	O	O	B-Entity
measurements	O	O	I-Entity
in	O	O	O
the	O	O	O
same	O	O	O
animals	O	O	B-Entity
revealed	O	O	O
significant	O	O	O
reduction	O	O	B-Entity
in	O	O	O
hippocampal	O	O	B-Entity
volumes	O	O	B-Entity
in	O	O	O
stressed	O	O	B-Entity
animals	O	O	O
relative	O	O	O
to	O	O	O
their	O	O	O
unstressed	O	O	B-Entity
counterparts	O	O	I-Entity
,	O	O	O
as	O	O	O
early	O	O	O
as	O	O	O
the	O	O	O
third	O	O	O
day	O	O	O
of	O	O	O
stress	O	O	B-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
animals	O	O	B-Entity
that	O	O	O
were	O	O	O
behaviorally	O	O	B-Entity
the	O	O	O
worst	O	O	B-Entity
affected	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
chronic	O	O	B-Entity
stress	O	O	I-Entity
suffered	O	O	B-Entity
the	O	O	O
most	O	O	O
pronounced	O	O	O
early	O	O	B-Entity
loss	O	O	I-Entity
in	O	O	I-Entity
hippocampal	O	O	I-Entity
volume	O	O	I-Entity
.	O	O	O

Together	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	O
support	O	O	O
the	O	O	O
view	O	O	O
that	O	O	O
not	O	O	O
only	O	O	O
is	O	O	O
smaller	O	O	O
hippocampal	O	O	B-Entity
volume	O	O	B-Entity
linked	O	O	O
to	O	O	O
stress	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
memory	O	O	B-Entity
deficits	O	O	I-Entity
,	O	O	O
but	O	O	O
it	O	O	O
may	O	O	O
also	O	O	O
act	O	O	O
as	O	O	O
an	O	O	O
early	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
the	O	O	O
eventual	O	O	O
development	O	O	O
of	O	O	O
cognitive	O	O	B-Entity
impairments	O	O	I-Entity
seen	O	O	O
in	O	O	O
stress-related	O	O	B-Entity
psychiatric	O	O	I-Entity
disorders	O	O	I-Entity
.	O	O	O

-DOCSTART- (27375918)

The	O	O	O
Association	O	O	B-Entity
between	O	O	O
C9orf72	O	O	B-Entity
Repeats	O	O	B-Entity
and	O	O	O
Risk	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
and	O	O	O
Amyotrophic	O	O	B-Entity
Lateral	O	O	I-Entity
Sclerosis	O	O	I-Entity
:	O	O	O
A	O	O	O
Meta-Analysis	O	O	O

C9orf72	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
genetic	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	O
amyotrophic	O	O	B-Entity
lateral	O	O	I-Entity
sclerosis	O	O	I-Entity
(	O	O	O
ALS	O	O	B-Entity
)	O	O	O
and	O	O	O
frontotemporal	O	O	B-Entity
dementia	O	O	I-Entity
(	O	O	O
FTD	O	O	B-Entity
)	O	O	O
in	O	O	O
Caucasian	O	O	B-Entity
populations	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
C9orf72	O	O	B-Entity
repeats	O	O	B-Entity
and	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
was	O	O	O
not	O	O	B-Entity
clear	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
there	O	O	O
were	O	O	O
few	O	O	O
articles	O	O	B-Entity
assessing	O	O	B-Entity
C9orf72	O	O	B-Entity
in	O	O	O
other	O	O	O
ethnicities	O	O	B-Entity
with	O	O	O
ALS	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
meta-analysis	O	O	B-Entity
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
C9orf72	O	O	B-Entity
repeat	O	O	B-Entity
expansions	O	O	I-Entity
(	O	O	O
≥30	O	O	O
repeats	O	O	B-Entity
)	O	O	O
and	O	O	O
intermediate	O	O	B-Entity
repeat	O	O	B-Entity
copies	O	O	I-Entity
(	O	O	O
20	O	O	O
-	O	O	O
29	O	O	O
repeats	O	O	O
)	O	O	O
and	O	O	O
AD	O	O	B-Entity
or	O	O	O
ALS	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
suggested	O	O	O
positive	O	O	B-Entity
correlations	O	O	B-Entity
between	O	O	O
C9orf72	O	O	B-Entity
repeat	O	O	B-Entity
expansions	O	O	I-Entity
and	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
6.36	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
3.13	O	O	O
-	O	O	O
12.92	O	O	O
,	O	O	O
and	O	O	O
p	O	O	B-Entity
<	O	O	O
0.00001	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
intermediate	O	O	B-Entity
repeat	O	O	B-Entity
copies	O	O	I-Entity
of	O	O	O
C9orf72	O	O	B-Entity
gene	O	O	I-Entity
were	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
risk	O	O	O
of	O	O	O
the	O	O	O
disease	O	O	O
.	O	O	O

C9orf72	O	O	B-Entity
repeat	O	O	B-Entity
expansions	O	O	I-Entity
were	O	O	O
positively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
familial	O	O	B-Entity
and	O	O	O
sporadic	O	O	B-Entity
ALS	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
293.25	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
148.17	O	O	O
-	O	O	O
580.38	O	O	O
,	O	O	O
and	O	O	O
p	O	O	B-Entity
<	O	O	O
0.00001	O	O	O
;	O	O	O
OR	O	O	O
=	O	O	O
35.57	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
19.61	O	O	O
-	O	O	O
64.51	O	O	O
,	O	O	O
and	O	O	O
p	O	O	O
<	O	O	O
0.00001	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
positive	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
gene	O	O	B-Entity
variations	O	O	I-Entity
and	O	O	O
ALS	O	O	B-Entity
risk	O	O	B-Entity
among	O	O	O
Caucasians	O	O	B-Entity
and	O	O	O
Asians	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
57.56	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
36.73	O	O	O
-	O	O	O
90.22	O	O	O
,	O	O	O
and	O	O	O
p	O	O	B-Entity
<	O	O	O
0.00001	O	O	O
;	O	O	O
OR	O	O	O
=	O	O	O
6.35	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.39	O	O	O
-	O	O	O
29.02	O	O	O
,	O	O	O
and	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27378028)

Demonstration	O	O	O
and	O	O	O
validation	O	O	B-Entity
of	O	O	O
a	O	O	O
new	O	O	O
pressure	O	O	B-Entity
-based	O	O	O
MRI	O	O	B-Entity
-safe	O	O	O
pain	O	O	B-Entity
tolerance	O	O	I-Entity
device	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
barriers	O	O	O
to	O	O	O
studying	O	O	O
the	O	O	O
behavioral	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
pain	O	O	B-Entity
using	O	O	O
functional	O	O	B-Entity
Magnetic	O	O	I-Entity
Resonance	O	O	I-Entity
Imaging	O	O	I-Entity
(	O	O	O
fMRI	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
a	O	O	O
commercially	O	O	O
available	O	O	O
,	O	O	O
MRI	O	O	B-Entity
-	O	O	O
compatible	O	O	B-Entity
,	O	O	O
pressure	O	O	B-Entity
-based	O	O	O
algometer	O	O	B-Entity
to	O	O	O
elicit	O	O	B-Entity
pain	O	O	O
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
sought	O	O	O
to	O	O	O
address	O	O	O
this	O	O	O
barrier	O	O	O
through	O	O	O
creation	O	O	O
and	O	O	O
validation	O	O	O
of	O	O	O
a	O	O	O
novel	O	O	O
MRI	O	O	B-Entity
-safe	O	O	O
apparatus	O	O	B-Entity
capable	O	O	O
of	O	O	O
delivering	O	O	O
incremental	O	O	B-Entity
,	O	O	O
measurable	O	O	B-Entity
amounts	O	O	O
of	O	O	O
pressure	O	O	B-Entity
inside	O	O	O
a	O	O	O
scanning	O	O	B-Entity
bore	O	O	I-Entity
.	O	O	O

We	O	O	O
introduced	O	O	O
an	O	O	O
MR-safe	O	O	O
device	O	O	B-Entity
used	O	O	O
to	O	O	O
administer	O	O	O
pressure	O	O	B-Entity
-based	O	O	O
pain	O	O	B-Entity
.	O	O	O

To	O	O	O
test	O	O	B-Entity
against	O	O	O
a	O	O	O
commercially	O	O	O
available	O	O	O
,	O	O	O
MRI	O	O	B-Entity
-	O	O	O
incompatible	O	O	B-Entity
algometer	O	O	B-Entity
(	O	O	O
AlgoMed	O	O	B-Entity
)	O	O	O
,	O	O	O
199	O	O	O
participants	O	O	O
reported	O	O	O
their	O	O	O
pain	O	O	B-Entity
tolerance	O	O	I-Entity
for	O	O	O
both	O	O	O
devices	O	O	O
.	O	O	O

A	O	O	O
second	O	O	O
experiment	O	O	O
tested	O	O	B-Entity
the	O	O	O
validity	O	O	O
of	O	O	O
pressure	O	O	B-Entity
-based	O	O	O
pain	O	O	B-Entity
in	O	O	O
an	O	O	O
MRI	O	O	B-Entity
environment	O	O	B-Entity
by	O	O	O
comparing	O	O	O
brain	O	O	B-Entity
activation	O	O	B-Entity
with	O	O	O
established	O	O	O
neural	O	O	B-Entity
networks	O	O	I-Entity
for	O	O	O
pain	O	O	O
.	O	O	O

10	O	O	O
participants	O	O	O
performed	O	O	O
an	O	O	O
identical	O	O	O
procedure	O	O	O
to	O	O	O
test	O	O	B-Entity
for	O	O	O
pain	O	O	B-Entity
tolerance	O	O	O
while	O	O	O
being	O	O	O
scanned	O	O	B-Entity
in	O	O	O
a	O	O	O
7	O	O	O
T	O	O	O
MRI	O	O	B-Entity
scanner	O	O	I-Entity
.	O	O	O

Results	O	O	O
support	O	O	O
the	O	O	O
validity	O	O	B-Entity
and	O	O	I-Entity
reliability	O	O	I-Entity
of	O	O	O
our	O	O	O
novel	O	O	O
device	O	O	B-Entity
.	O	O	O

In	O	O	O
Study	O	O	O
1	O	O	O
,	O	O	O
pain	O	O	B-Entity
tolerance	O	O	I-Entity
with	O	O	O
this	O	O	O
device	O	O	B-Entity
was	O	O	O
strongly	O	O	O
correlated	O	O	O
with	O	O	O
pain	O	O	O
tolerance	O	O	O
as	O	O	O
measured	O	O	O
by	O	O	O
a	O	O	O
commercially	O	O	O
available	O	O	O
algometer	O	O	B-Entity
(	O	O	O
r=0.78	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
Study	O	O	O
2	O	O	O
,	O	O	O
this	O	O	O
device	O	O	B-Entity
yielded	O	O	O
BOLD	O	O	B-Entity
activation	O	O	O
within	O	O	O
the	O	O	O
insula	O	O	B-Entity
(	O	O	O
BA	O	O	B-Entity
13	O	O	I-Entity
)	O	O	O
and	O	O	O
anterior	O	O	B-Entity
cingulate	O	O	I-Entity
gyrus	O	O	I-Entity
(	O	O	O
BA	O	O	B-Entity
24	O	O	I-Entity
)	O	O	O
;	O	O	O
as	O	O	O
pressure	O	O	B-Entity
increased	O	O	B-Entity
,	O	O	O
activation	O	O	O
in	O	O	O
these	O	O	O
areas	O	O	O
parametrically	O	O	B-Entity
increased	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
correspond	O	O	O
to	O	O	O
other	O	O	O
studies	O	O	O
using	O	O	O
thermal	O	O	B-Entity
,	O	O	O
electrical	O	O	B-Entity
,	O	O	O
or	O	O	O
mechanical	O	O	B-Entity
pain	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

Behavioral	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
data	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
this	O	O	O
new	O	O	O
device	O	O	B-Entity
is	O	O	O
a	O	O	O
valid	O	O	O
method	O	O	O
of	O	O	O
administering	O	O	B-Entity
pressure	O	O	B-Entity
-related	O	O	O
pain	O	O	B-Entity
in	O	O	O
MRI	O	O	B-Entity
environments	O	O	B-Entity
.	O	O	O

Our	O	O	O
novel	O	O	O
MRI	O	O	B-Entity
-safe	O	O	O
device	O	O	B-Entity
is	O	O	O
a	O	O	O
valid	O	O	O
instrument	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
and	O	O	O
administer	O	O	B-Entity
pressure	O	O	B-Entity
-based	O	O	O
pain	O	O	B-Entity
.	O	O	O

-DOCSTART- (27378927)

Anti-Inflammatory	O	O	B-Entity
Properties	O	O	I-Entity
of	O	O	O
Menthol	O	O	B-Entity
and	O	O	O
Menthone	O	O	B-Entity
in	O	O	O
Schistosoma	O	O	O
mansoni	O	O	O
Infection	O	O	O

Schistosomiasis	O	O	B-Entity
is	O	O	O
a	O	O	O
parasitic	O	O	B-Entity
disease	O	O	I-Entity
caused	O	O	O
by	O	O	O
several	O	O	O
species	O	O	B-Entity
of	O	O	O
trematode	O	O	B-Entity
worms	O	O	I-Entity
and	O	O	O
it	O	O	O
is	O	O	O
believed	O	O	O
that	O	O	O
more	O	O	O
than	O	O	O
261	O	O	O
million	O	O	O
people	O	O	B-Entity
are	O	O	O
affected	O	O	B-Entity
worldwide	O	O	O
.	O	O	O

New	O	O	O
drug	O	O	B-Entity
development	O	O	I-Entity
has	O	O	O
become	O	O	O
essential	O	O	B-Entity
because	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
risk	O	O	O
of	O	O	O
the	O	O	O
parasite	O	O	B-Entity
becoming	O	O	O
resistant	O	O	B-Entity
to	O	O	O
Praziquantel	O	O	B-Entity
,	O	O	O
the	O	O	O
only	O	O	O
drug	O	O	O
available	O	O	O
for	O	O	O
this	O	O	O
infection	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluated	O	O	B-Entity
parasitological	O	O	B-Entity
,	O	O	O
immunological	O	O	B-Entity
and	O	O	O
histological	O	O	B-Entity
parameters	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
infected	O	O	B-Entity
with	O	O	O
Schistosoma	O	O	B-Entity
mansoni	O	O	I-Entity
and	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
herbal	O	O	B-Entity
commercial	O	O	I-Entity
medicine	O	O	I-Entity
.	O	O	O

This	O	O	O
drug	O	O	B-Entity
consists	O	O	O
of	O	O	O
menthol	O	O	B-Entity
(	O	O	O
30	O	O	O
-	O	O	O
55	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
menthone	O	O	B-Entity
(	O	O	O
14	O	O	O
-	O	O	O
32	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
60	O	O	O
day	O	O	O
treatment	O	O	B-Entity
regimen	O	O	I-Entity
with	O	O	O
the	O	O	O
herbal	O	O	B-Entity
medicine	O	O	I-Entity
decreased	O	O	B-Entity
the	O	O	O
number	O	O	O
of	O	O	O
S.	O	O	B-Entity
mansoni	O	O	I-Entity
eggs	O	O	B-Entity
in	O	O	O
the	O	O	O
feces	O	O	B-Entity
,	O	O	O
liver	O	O	B-Entity
,	O	O	O
and	O	O	O
intestine	O	O	B-Entity
and	O	O	O
reduced	O	O	B-Entity
the	O	O	O
number	O	O	O
of	O	O	O
hepatic	O	O	B-Entity
granulomas	O	O	I-Entity
.	O	O	O

We	O	O	O
observed	O	O	B-Entity
a	O	O	O
reduction	O	O	B-Entity
of	O	O	O
84	O	O	O
%	O	O	O
in	O	O	O
blood	O	O	B-Entity
eosinophilia	O	O	I-Entity
and	O	O	O
a	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
IL-4	O	O	B-Entity
and	O	O	O
IL-10	O	O	B-Entity
blood	O	O	B-Entity
levels	O	O	I-Entity
after	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
that	O	O	O
schistosomiasis	O	O	B-Entity
treatment	O	O	B-Entity
with	O	O	O
this	O	O	O
herbal	O	O	B-Entity
medicine	O	O	I-Entity
for	O	O	O
60	O	O	O
days	O	O	O
has	O	O	O
an	O	O	O
immunomodulatory	O	O	B-Entity
and	O	O	O
anti-inflammatory	O	O	B-Entity
action	O	O	I-Entity
in	O	O	O
this	O	O	O
animal	O	O	B-Entity
model	O	O	I-Entity
for	O	O	O
schistosomiasis	O	O	O
thus	O	O	O
contributing	O	O	B-Entity
to	O	O	O
the	O	O	O
decrease	O	O	B-Entity
in	O	O	O
physio	O	O	O
pathological	O	O	B-Entity
effects	O	O	B-Entity
caused	O	O	O
by	O	O	O
S.	O	O	B-Entity
mansoni	O	O	I-Entity
infection	O	O	I-Entity
.	O	O	O

-DOCSTART- (27381206)

Catastrophic	O	O	B-Entity
health	O	O	B-Entity
expenditure	O	O	I-Entity
:	O	O	O
a	O	O	O
comparative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
empty-nest	O	O	B-Entity
and	O	O	O
non-empty-nest	O	O	B-Entity
households	O	O	B-Entity
with	O	O	O
seniors	O	O	B-Entity
in	O	O	O
Shandong	O	O	O
,	O	O	O
China	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
catastrophic	O	O	B-Entity
health	O	O	B-Entity
expenditure	O	O	I-Entity
(	O	O	O
CHE	O	O	B-Entity
)	O	O	O
prevalence	O	O	B-Entity
and	O	O	O
its	O	O	O
determinants	O	O	B-Entity
between	O	O	O
empty-nest	O	O	B-Entity
and	O	O	O
non-empty-nest	O	O	B-Entity
elderly	O	O	B-Entity
households	O	O	B-Entity
.	O	O	O

Shandong	O	O	B-Entity
province	O	O	I-Entity
of	O	O	I-Entity
China	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
2761	O	O	O
elderly	O	O	B-Entity
households	O	O	B-Entity
are	O	O	O
included	O	O	B-Entity
in	O	O	O
the	O	O	O
analysis	O	O	B-Entity
.	O	O	O

CHE	O	O	B-Entity
incidence	O	O	B-Entity
among	O	O	O
elderly	O	O	B-Entity
households	O	O	B-Entity
was	O	O	O
44.9	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
CHE	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
empty-nest	O	O	B-Entity
singles	O	O	B-Entity
(	O	O	O
59.3	O	O	O
%	O	O	O
,	O	O	O
p=0.000	O	O	O
,	O	O	O
OR=3.19	O	O	O
)	O	O	O
and	O	O	O
empty-nest	O	O	O
couples	O	O	B-Entity
(	O	O	O
52.9	O	O	O
%	O	O	O
,	O	O	O
p=0.000	O	O	O
,	O	O	O
OR=2.45	O	O	O
)	O	O	O
are	O	O	O
both	O	O	O
statistically	O	O	B-Entity
higher	O	O	B-Entity
than	O	O	O
that	O	O	O
of	O	O	O
non-empty-nest	O	O	B-Entity
elderly	O	O	B-Entity
households	O	O	B-Entity
(	O	O	O
31.4	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

An	O	O	O
inverse	O	O	B-Entity
association	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
between	O	O	O
CHE	O	O	B-Entity
incidence	O	O	B-Entity
and	O	O	O
income	O	O	B-Entity
level	O	O	I-Entity
in	O	O	O
all	O	O	O
elderly	O	O	B-Entity
household	O	O	B-Entity
types	O	O	B-Entity
.	O	O	O

Factors	O	O	B-Entity
including	O	O	B-Entity
1	O	O	O
or	O	O	O
more	O	O	O
household	O	O	B-Entity
elderly	O	O	B-Entity
members	O	O	I-Entity
with	O	O	O
non-communicable	O	O	B-Entity
chronic	O	O	I-Entity
diseases	O	O	I-Entity
in	O	O	O
the	O	O	O
past	O	O	O
6	O	O	O
months	O	O	O
,	O	O	O
1	O	O	O
or	O	O	O
more	O	O	O
elderly	O	O	O
household	O	O	B-Entity
members	O	O	I-Entity
being	O	O	O
hospitalised	O	O	B-Entity
in	O	O	O
the	O	O	O
past	O	O	B-Entity
year	O	O	I-Entity
and	O	O	O
lower	O	O	B-Entity
household	O	O	O
income	O	O	B-Entity
,	O	O	O
are	O	O	O
significant	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
CHE	O	O	B-Entity
in	O	O	O
all	O	O	O
3	O	O	O
household	O	O	O
types	O	O	B-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Health	O	O	B-Entity
insurance	O	O	I-Entity
status	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
significant	O	O	B-Entity
determinant	O	O	B-Entity
of	O	O	O
CHE	O	O	B-Entity
among	O	O	O
empty-nest	O	O	B-Entity
singles	O	O	B-Entity
and	O	O	O
non-empty-nest	O	O	B-Entity
households	O	O	B-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

CHE	O	O	B-Entity
incidence	O	O	B-Entity
among	O	O	O
elderly	O	O	B-Entity
households	O	O	B-Entity
is	O	O	O
high	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
.	O	O	O

Empty-nest	O	O	B-Entity
households	O	O	B-Entity
are	O	O	O
at	O	O	O
higher	O	O	B-Entity
risk	O	O	B-Entity
for	O	O	O
CHE	O	O	B-Entity
than	O	O	O
non-empty-nest	O	O	B-Entity
households	O	O	O
.	O	O	O

Based	O	O	O
on	O	O	O
these	O	O	O
findings	O	O	B-Entity
,	O	O	O
we	O	O	O
suggest	O	O	B-Entity
that	O	O	O
special	O	O	B-Entity
insurance	O	O	B-Entity
be	O	O	O
developed	O	O	O
to	O	O	O
broaden	O	O	B-Entity
the	O	O	O
coverage	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
and	O	O	O
heighten	O	O	B-Entity
the	O	O	O
reimbursement	O	O	B-Entity
rate	O	O	I-Entity
for	O	O	O
empty-nest	O	O	B-Entity
elderly	O	O	B-Entity
in	O	O	O
the	O	O	O
existing	O	O	O
health	O	O	B-Entity
insurance	O	O	I-Entity
schemes	O	O	B-Entity
.	O	O	O

Financial	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
protection	O	O	I-Entity
interventions	O	O	B-Entity
are	O	O	O
also	O	O	O
essential	O	O	B-Entity
for	O	O	O
identifie	O	O	B-Entity
d	O	O	O
at-risk	O	O	B-Entity
subgroups	O	O	B-Entity
among	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
elderly	O	O	B-Entity
households	O	O	B-Entity
.	O	O	O

-DOCSTART- (27381670)

Role	O	O	O
of	O	O	O
agonistic	O	O	B-Entity
autoantibodies	O	O	I-Entity
against	O	O	O
type-1	O	O	B-Entity
angiotensin	O	O	I-Entity
II	O	O	I-Entity
receptor	O	O	I-Entity
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
retinopathy	O	O	B-Entity
in	O	O	O
preeclampsia	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
mechanism	O	O	B-Entity
underlying	O	O	O
AT1-AA	O	O	B-Entity
-induced	O	O	O
retinopathy	O	O	B-Entity
in	O	O	O
severe	O	O	B-Entity
preeclampsia	O	O	I-Entity
by	O	O	O
measuring	O	O	O
the	O	O	O
positive	O	O	B-Entity
rate	O	O	I-Entity
and	O	O	O
titer	O	O	B-Entity
of	O	O	O
AT1-AA	O	O	O
in	O	O	O
plasma	O	O	B-Entity
from	O	O	O
women	O	O	B-Entity
with	O	O	O
severe	O	O	O
preeclampsia	O	O	O
and	O	O	O
normal	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
to	O	O	O
see	O	O	O
whether	O	O	O
AT1-AA	O	O	O
titer	O	O	O
was	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
grade	O	O	O
of	O	O	O
retinopathy	O	O	O
.	O	O	O

A	O	O	O
preeclampsia	O	O	B-Entity
rat	O	O	B-Entity
model	O	O	B-Entity
was	O	O	O
also	O	O	O
established	O	O	O
by	O	O	O
intravenous	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
AT1-AA	O	O	B-Entity
extracted	O	O	O
from	O	O	O
the	O	O	O
plasma	O	O	B-Entity
of	O	O	O
patient	O	O	B-Entity
suffering	O	O	O
from	O	O	O
severe	O	O	B-Entity
preeclampsia	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
plasma	O	O	B-Entity
titer	O	O	B-Entity
and	O	O	O
positive	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
AT1-AA	O	O	B-Entity
were	O	O	O
significantly	O	O	O
higher	O	O	O
in	O	O	O
women	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
preeclampsia	O	O	I-Entity
than	O	O	O
normal	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
.	O	O	O

The	O	O	O
antibody	O	O	B-Entity
titer	O	O	B-Entity
in	O	O	O
cases	O	O	O
of	O	O	O
severe	O	O	O
preeclampsia	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
the	O	O	O
grade	O	O	O
of	O	O	O
retinopathy	O	O	B-Entity
,	O	O	O
and	O	O	O
positively	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
level	O	O	O
of	O	O	O
TNF-α	O	O	B-Entity
and	O	O	O
VEGF	O	O	B-Entity
.	O	O	O

The	O	O	O
animal	O	O	B-Entity
experiment	O	O	I-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
modeled	O	O	B-Entity
rats	O	O	I-Entity
presented	O	O	O
symptoms	O	O	B-Entity
very	O	O	O
similar	O	O	O
to	O	O	O
symptoms	O	O	O
of	O	O	O
human	O	O	B-Entity
preeclampsia	O	O	B-Entity
,	O	O	O
including	O	O	O
retinopathy	O	O	B-Entity
.	O	O	O

Ocular	O	O	B-Entity
fundus	O	O	I-Entity
examination	O	O	B-Entity
showed	O	O	O
retinal	O	O	B-Entity
microvascular	O	O	I-Entity
abnormalities	O	O	I-Entity
,	O	O	O
hemorrhaging	O	O	B-Entity
and	O	O	O
leakage	O	O	B-Entity
in	O	O	O
the	O	O	O
severe	O	O	B-Entity
preeclampsia	O	O	I-Entity
.	O	O	O

Morphological	O	O	B-Entity
changes	O	O	I-Entity
included	O	O	O
edema	O	O	B-Entity
,	O	O	O
thickening	O	O	B-Entity
of	O	O	O
the	O	O	O
INL	O	O	B-Entity
and	O	O	O
ONL	O	O	B-Entity
,	O	O	O
and	O	O	O
pigment	O	O	B-Entity
atrophy	O	O	I-Entity
.	O	O	O

TNF-α	O	O	B-Entity
and	O	O	O
VEGF	O	O	B-Entity
levels	O	O	O
were	O	O	O
increased	O	O	O
in	O	O	O
the	O	O	O
vitreous	O	O	B-Entity
humor	O	O	I-Entity
and	O	O	O
retina	O	O	B-Entity
of	O	O	O
the	O	O	O
model	O	O	B-Entity
rats	O	O	I-Entity
.	O	O	O

Our	O	O	O
studies	O	O	B-Entity
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
abnormal	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
AT1-AA	O	O	B-Entity
could	O	O	O
induce	O	O	O
damage	O	O	B-Entity
to	O	O	O
retinal	O	O	B-Entity
capillary	O	O	I-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
increase	O	O	O
vascular	O	O	B-Entity
permeability	O	O	I-Entity
,	O	O	O
resulting	O	O	B-Entity
in	O	O	I-Entity
retinopathy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27382289)

Characterizing	O	O	B-Entity
sexual	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
generalized	O	O	B-Entity
anxiety	O	O	I-Entity
disorder	O	O	I-Entity
:	O	O	O
a	O	O	O
pooled	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
three	O	O	O
vilazodone	O	O	B-Entity
studies	O	O	O

Vilazodone	O	O	B-Entity
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
reduce	O	O	B-Entity
core	O	O	B-Entity
symptoms	O	O	I-Entity
of	O	O	O
generalized	O	O	B-Entity
anxiety	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
GAD	O	O	B-Entity
)	O	O	O
in	O	O	O
three	O	O	O
randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
trials	O	O	I-Entity
.	O	O	O

Since	O	O	O
sexual	O	O	B-Entity
dysfunction	O	O	I-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
is	O	O	O
not	O	O	O
well	O	O	O
characterized	O	O	O
in	O	O	O
GAD	O	O	B-Entity
,	O	O	O
a	O	O	O
post	O	O	B-Entity
hoc	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
these	O	O	O
trials	O	O	B-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
vilazodone	O	O	B-Entity
on	O	O	O
sexual	O	O	B-Entity
functioning	O	O	I-Entity
in	O	O	O
GAD	O	O	O
patients	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
pooled	O	O	B-Entity
from	O	O	O
one	O	O	O
fixed-dose	O	O	B-Entity
trial	O	O	I-Entity
of	O	O	O
vilazodone	O	O	B-Entity
20	O	O	O
and	O	O	O
40	O	O	O
mg/day	O	O	B-Entity
(	O	O	O
NCT01629966	O	O	B-Entity
)	O	O	O
and	O	O	O
two	O	O	O
flexible-dose	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
vilazodone	O	O	O
20	O	O	O
-	O	O	O
40	O	O	O
mg/day	O	O	O
(	O	O	O
NCT01766401	O	O	B-Entity
,	O	O	O
NCT01844115	O	O	B-Entity
)	O	O	O
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
GAD	O	O	B-Entity
.	O	O	O

Sexual	O	O	B-Entity
functioning	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Changes	O	O	B-Entity
in	O	O	I-Entity
Sexual	O	O	I-Entity
Functioning	O	O	I-Entity
Questionnaire	O	O	I-Entity
(	O	O	O
CSFQ	O	O	B-Entity
)	O	O	O
.	O	O	O

Outcomes	O	O	B-Entity
included	O	O	O
mean	O	O	B-Entity
change	O	O	I-Entity
from	O	O	I-Entity
baseline	O	O	B-Entity
to	O	O	I-Entity
end	O	O	I-Entity
of	O	O	I-Entity
treatment	O	O	I-Entity
(	O	O	O
EOT	O	O	B-Entity
)	O	O	O
in	O	O	O
CSFQ	O	O	B-Entity
total	O	O	I-Entity
score	O	O	I-Entity
and	O	O	O
percentage	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
shifting	O	O	B-Entity
from	O	O	O
SD	O	O	B-Entity
at	O	O	O
baseline	O	O	O
(	O	O	O
CSFQ	O	O	O
total	O	O	O
score	O	O	O
≤47	O	O	O
for	O	O	O
males	O	O	B-Entity
,	O	O	O
≤41	O	O	O
for	O	O	O
females	O	O	B-Entity
)	O	O	O
to	O	O	O
normal	O	O	B-Entity
functioning	O	O	I-Entity
at	O	O	O
EOT	O	O	O
.	O	O	O

Treatment-emergent	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
related	O	O	O
to	O	O	O
sexual	O	O	B-Entity
functioning	O	O	I-Entity
were	O	O	O
also	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
1,373	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analyses	O	O	B-Entity
.	O	O	O

SD	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
was	O	O	O
more	O	O	O
common	O	O	O
in	O	O	O
females	O	O	B-Entity
(	O	O	O
placebo	O	O	B-Entity
,	O	O	O
46.4	O	O	O
%	O	O	O
;	O	O	O
vilazodone	O	O	B-Entity
,	O	O	O
49	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
in	O	O	O
males	O	O	B-Entity
(	O	O	O
placebo	O	O	O
,	O	O	O
35.1	O	O	O
%	O	O	O
;	O	O	O
vilazodone	O	O	O
,	O	O	O
40.9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

CSFQ	O	O	B-Entity
total	O	O	I-Entity
score	O	O	I-Entity
improvement	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
both	O	O	O
females	O	O	B-Entity
(	O	O	O
placebo	O	O	B-Entity
,	O	O	O
+	O	O	O
1.2	O	O	O
;	O	O	O
vilazodone	O	O	B-Entity
,	O	O	O
+	O	O	O
1.6	O	O	O
)	O	O	O
and	O	O	O
males	O	O	B-Entity
(	O	O	O
placebo	O	O	O
,	O	O	O
+	O	O	O
2.1	O	O	O
;	O	O	O
vilazodone	O	O	O
,	O	O	O
+	O	O	O
1.0	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
no	O	O	B-Entity
statistically	O	O	I-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
between	O	O	O
treatment	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
percentage	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
shifted	O	O	B-Entity
from	O	O	O
SD	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
to	O	O	O
normal	O	O	B-Entity
sexual	O	O	B-Entity
functioning	O	O	I-Entity
at	O	O	O
EOT	O	O	B-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
males	O	O	B-Entity
(	O	O	O
placebo	O	O	B-Entity
,	O	O	O
40.6	O	O	O
%	O	O	O
;	O	O	O
vilazodone	O	O	B-Entity
,	O	O	O
35.7	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
in	O	O	O
females	O	O	B-Entity
(	O	O	O
placebo	O	O	O
,	O	O	O
24.9	O	O	O
%	O	O	O
;	O	O	O
vilazodone	O	O	O
,	O	O	O
34.9	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
no	O	O	B-Entity
statistical	O	O	I-Entity
testing	O	O	I-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

Except	O	O	O
for	O	O	O
erectile	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
delayed	O	O	B-Entity
ejaculation	O	O	I-Entity
in	O	O	O
vilazodone	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
males	O	O	B-Entity
(	O	O	O
2.4	O	O	O
%	O	O	O
and	O	O	O
2.1	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
no	O	O	B-Entity
treatment-emergent	O	O	I-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
related	O	O	O
to	O	O	O
sexual	O	O	B-Entity
functioning	O	O	I-Entity
occurred	O	O	B-Entity
in	O	O	O
≥2	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
in	O	O	O
either	O	O	O
treatment	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

Approximately	O	O	B-Entity
35%-50	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
vilazodone	O	O	B-Entity
GAD	O	O	B-Entity
studies	O	O	B-Entity
had	O	O	O
SD	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
.	O	O	O

Vilazodone	O	O	B-Entity
and	O	O	O
placebo	O	O	B-Entity
had	O	O	O
similar	O	O	O
effects	O	O	B-Entity
on	O	O	O
CSFQ	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
both	O	O	O
females	O	O	B-Entity
and	O	O	O
males	O	O	B-Entity
,	O	O	O
indicating	O	O	O
a	O	O	O
limited	O	O	B-Entity
adverse	O	O	B-Entity
impact	O	O	I-Entity
on	O	O	O
sexual	O	O	B-Entity
functioning	O	O	I-Entity
with	O	O	O
vilazodone	O	O	B-Entity
.	O	O	O

-DOCSTART- (27385165)

Biogeochemical	O	O	B-Entity
Controls	O	O	B-Entity
of	O	O	O
Uranium	O	O	B-Entity
Bioavailability	O	O	B-Entity
from	O	O	O
the	O	O	O
Dissolved	O	O	B-Entity
Phase	O	O	I-Entity
in	O	O	O
Natural	O	O	B-Entity
Freshwaters	O	O	O

To	O	O	O
gain	O	O	O
insights	O	O	O
into	O	O	O
the	O	O	O
risks	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
uranium	O	O	B-Entity
(	O	O	O
U	O	O	B-Entity
)	O	O	O
mining	O	O	B-Entity
and	O	O	O
processing	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
biogeochemical	O	O	B-Entity
controls	O	O	B-Entity
of	O	O	O
U	O	O	O
bioavailability	O	O	B-Entity
in	O	O	O
the	O	O	O
model	O	O	O
freshwater	O	O	B-Entity
species	O	O	B-Entity
Lymnaea	O	O	B-Entity
stagnalis	O	O	I-Entity
(	O	O	O
Gastropoda	O	O	B-Entity
)	O	O	O
.	O	O	O

Bioavailability	O	O	B-Entity
of	O	O	O
dissolved	O	O	B-Entity
U(VI	O	O	I-Entity
)	O	O	I-Entity
was	O	O	O
characterized	O	O	B-Entity
in	O	O	O
controlled	O	O	B-Entity
laboratory	O	O	B-Entity
experiments	O	O	B-Entity
over	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
water	O	O	B-Entity
hardness	O	O	B-Entity
,	O	O	O
pH	O	O	B-Entity
,	O	O	O
and	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
complexing	O	O	B-Entity
ligands	O	O	I-Entity
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
dissolved	O	O	B-Entity
natural	O	O	I-Entity
organic	O	O	I-Entity
matter	O	O	I-Entity
(	O	O	O
DOM	O	O	B-Entity
)	O	O	O
.	O	O	O

Results	O	O	B-Entity
show	O	O	O
that	O	O	O
dissolved	O	O	B-Entity
U	O	O	I-Entity
is	O	O	O
bioavailable	O	O	B-Entity
under	O	O	O
all	O	O	O
the	O	O	O
geochemical	O	O	B-Entity
conditions	O	O	I-Entity
tested	O	O	B-Entity
.	O	O	O

Uranium	O	O	B-Entity
uptake	O	O	B-Entity
rates	O	O	B-Entity
follow	O	O	O
first	O	O	B-Entity
order	O	O	I-Entity
kinetics	O	O	I-Entity
over	O	O	O
a	O	O	O
range	O	O	O
encompassing	O	O	O
most	O	O	O
environmental	O	O	B-Entity
concentrations	O	O	B-Entity
.	O	O	O

Uranium	O	O	B-Entity
uptake	O	O	B-Entity
rates	O	O	B-Entity
in	O	O	O
L.	O	O	B-Entity
stagnalis	O	O	I-Entity
ultimately	O	O	O
demonstrate	O	O	O
saturation	O	O	B-Entity
uptake	O	O	O
kinetics	O	O	B-Entity
when	O	O	O
exposure	O	O	B-Entity
concentrations	O	O	B-Entity
exceed	O	O	O
100	O	O	O
nM	O	O	O
,	O	O	O
suggesting	O	O	B-Entity
uptake	O	O	O
via	O	O	O
a	O	O	O
finite	O	O	O
number	O	O	O
of	O	O	O
carriers	O	O	O
or	O	O	O
ion	O	O	B-Entity
channels	O	O	I-Entity
.	O	O	O

The	O	O	O
lack	O	O	O
of	O	O	O
a	O	O	O
relationship	O	O	O
between	O	O	O
U	O	O	B-Entity
uptake	O	O	B-Entity
rate	O	O	O
constants	O	O	B-Entity
and	O	O	O
Ca	O	O	B-Entity
uptake	O	O	O
rates	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
U	O	O	O
does	O	O	O
not	O	O	O
exclusively	O	O	O
use	O	O	O
Ca	O	O	O
membrane	O	O	B-Entity
transporters	O	O	I-Entity
.	O	O	O

In	O	O	O
general	O	O	O
,	O	O	O
U	O	O	B-Entity
bioavailability	O	O	B-Entity
decreases	O	O	B-Entity
with	O	O	O
increasing	O	O	B-Entity
pH	O	O	B-Entity
,	O	O	O
increasing	O	O	O
Ca	O	O	B-Entity
and	O	O	O
Mg	O	O	B-Entity
concentrations	O	O	B-Entity
,	O	O	O
and	O	O	O
when	O	O	O
DOM	O	O	B-Entity
is	O	O	O
present	O	O	B-Entity
.	O	O	O

Competing	O	O	O
ions	O	O	B-Entity
did	O	O	O
not	O	O	O
affect	O	O	O
U	O	O	B-Entity
uptake	O	O	B-Entity
rates	O	O	B-Entity
.	O	O	O

Speciation	O	O	B-Entity
modeling	O	O	I-Entity
that	O	O	O
includes	O	O	O
formation	O	O	B-Entity
constants	O	O	B-Entity
for	O	O	O
U	O	O	B-Entity
ternary	O	O	B-Entity
complexes	O	O	I-Entity
reveals	O	O	B-Entity
that	O	O	O
the	O	O	O
aqueous	O	O	B-Entity
concentration	O	O	B-Entity
of	O	O	O
dicarbonato	O	O	B-Entity
U	O	O	I-Entity
species	O	O	B-Entity
(	O	O	O
UO2(CO3)2(-2	O	O	O
)	O	O	O
)	O	O	O
best	O	O	O
predicts	O	O	O
U	O	O	O
bioavailability	O	O	B-Entity
to	O	O	O
L.	O	O	B-Entity
stagnalis	O	O	I-Entity
,	O	O	O
challenging	O	O	O
the	O	O	O
free-ion	O	O	B-Entity
activity	O	O	I-Entity
model	O	O	O
postulate	O	O	O
.	O	O	O

-DOCSTART- (27386263)

Interleukin-21	O	O	B-Entity
plays	O	O	O
a	O	O	O
critical	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
and	O	O	O
severity	O	O	O
of	O	O	O
type	O	O	O
I	O	O	O
autoimmune	O	O	O
hepatitis	O	O	O

Recently	O	O	O
,	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
follicular	O	O	B-Entity
helper	O	O	B-Entity
T	O	O	I-Entity
(	O	O	I-Entity
Tfh	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
expressing	O	O	O
interleukin	O	O	B-Entity
(IL)-21	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
increase	O	O	O
in	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
of	O	O	O
human	O	O	B-Entity
and	O	O	O
murine	O	O	B-Entity
models	O	O	B-Entity
of	O	O	O
autoimmune	O	O	B-Entity
hepatitis	O	O	I-Entity
(	O	O	O
AIH	O	O	B-Entity
)	O	O	O
.	O	O	O

IL-21	O	O	B-Entity
,	O	O	O
the	O	O	O
most	O	O	O
recently	O	O	O
discovered	O	O	O
member	O	O	O
of	O	O	O
the	O	O	O
type-I	O	O	B-Entity
cytokine	O	O	I-Entity
family	O	O	I-Entity
,	O	O	O
exerts	O	O	O
various	O	O	O
effects	O	O	O
on	O	O	O
the	O	O	O
immune	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
including	O	O	O
B	O	O	B-Entity
cell	O	O	I-Entity
activation	O	O	I-Entity
,	O	O	O
plasma	O	O	B-Entity
cell	O	O	I-Entity
differentiation	O	O	I-Entity
,	O	O	O
and	O	O	O
immunoglobulin	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
relationship	O	O	O
of	O	O	O
serum	O	O	B-Entity
IL-21	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
I	O	O	I-Entity
AIH	O	O	I-Entity
with	O	O	O
clinical	O	O	B-Entity
and	O	O	O
laboratory	O	O	B-Entity
parameters	O	O	B-Entity
and	O	O	O
histology	O	O	B-Entity
.	O	O	O

Ninety-two	O	O	O
Japanese	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
liver	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
22	O	O	O
AIH	O	O	B-Entity
,	O	O	O
20	O	O	O
primary	O	O	B-Entity
biliary	O	O	I-Entity
cholangitis	O	O	I-Entity
,	O	O	O
19	O	O	O
drug-induced	O	O	B-Entity
liver	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
8	O	O	O
acute	O	O	B-Entity
hepatitis	O	O	I-Entity
B	O	O	I-Entity
,	O	O	O
8	O	O	O
chronic	O	O	B-Entity
hepatitis	O	O	I-Entity
C	O	O	I-Entity
,	O	O	O
10	O	O	O
non-alcoholic	O	O	B-Entity
steatohepatitis	O	O	I-Entity
,	O	O	O
5	O	O	O
viral	O	O	B-Entity
hepatitis	O	O	I-Entity
)	O	O	O
and	O	O	O
10	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
were	O	O	O
recruited	O	O	O
.	O	O	O

Serum	O	O	B-Entity
IL-21	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
detected	O	O	O
by	O	O	O
enzyme-linked	O	O	B-Entity
immunosorbent	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

Real-time	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
measured	O	O	O
mRNA	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
Bcl-6	O	O	B-Entity
,	O	O	O
IL-21	O	O	B-Entity
,	O	O	O
and	O	O	O
CXCR5	O	O	B-Entity
(	O	O	O
Tfh-related	O	O	B-Entity
factors	O	O	I-Entity
)	O	O	O
in	O	O	O
peripheral	O	O	B-Entity
mononuclear	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Mean	O	O	O
age	O	O	O
at	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
AIH	O	O	B-Entity
was	O	O	O
58.6	O	O	O
years	O	O	O
,	O	O	O
male-to-female	O	O	B-Entity
ratio	O	O	I-Entity
was	O	O	O
4:18	O	O	O
,	O	O	O
18.2	O	O	O
%	O	O	O
of	O	O	O
participants	O	O	O
had	O	O	O
cirrhosis	O	O	B-Entity
,	O	O	O
and	O	O	O
22.7	O	O	O
%	O	O	O
had	O	O	O
severe	O	O	B-Entity
disease	O	O	B-Entity
.	O	O	O

IL-21	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
the	O	O	O
serum	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
AIH	O	O	B-Entity
compared	O	O	O
to	O	O	O
those	O	O	O
with	O	O	O
other	O	O	B-Entity
liver	O	O	I-Entity
diseases	O	O	I-Entity
and	O	O	O
controls	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
.	O	O	O

Particularly	O	O	O
,	O	O	O
serum	O	O	B-Entity
IL-21	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
severe	O	O	B-Entity
AIH	O	O	B-Entity
cases	O	O	O
compared	O	O	O
to	O	O	O
non-severe	O	O	O
cases	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Serum	O	O	B-Entity
IL-21	O	O	B-Entity
levels	O	O	B-Entity
correlated	O	O	O
positively	O	O	O
with	O	O	O
total	O	O	O
serum	O	O	B-Entity
bilirubin	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.46	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
grading	O	O	B-Entity
of	O	O	I-Entity
necroinflammatory	O	O	I-Entity
activity	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.68	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.005	O	O	O
)	O	O	O
and	O	O	O
negatively	O	O	O
with	O	O	O
serum	O	O	B-Entity
albumin	O	O	I-Entity
levels	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
AIH	O	O	B-Entity
(	O	O	O
r	O	O	O
=	O	O	O
-0.49	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
biochemical	O	O	B-Entity
remission	O	O	B-Entity
of	O	O	O
AIH	O	O	B-Entity
,	O	O	O
serum	O	O	B-Entity
IL-21	O	O	B-Entity
levels	O	O	B-Entity
remained	O	O	O
elevated	O	O	B-Entity
and	O	O	O
correlated	O	O	B-Entity
positively	O	O	B-Entity
with	O	O	O
serum	O	O	B-Entity
IgG	O	O	I-Entity
levels	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
0.84	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
Tfh-related	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
Bcl-6	O	O	B-Entity
and	O	O	O
IL-21	O	O	B-Entity
,	O	O	O
in	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
AIH	O	O	B-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	B-Entity
than	O	O	O
that	O	O	O
in	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
.	O	O	O

IL-21	O	O	B-Entity
may	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
and	O	O	O
severity	O	O	O
of	O	O	O
AIH	O	O	B-Entity
,	O	O	O
and	O	O	O
may	O	O	O
present	O	O	O
a	O	O	O
promising	O	O	O
target	O	O	O
for	O	O	O
AIH	O	O	O
therapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27388962)

Resistance	O	O	B-Entity
Exercise	O	O	B-Entity
in	O	O	O
Pregnancy	O	O	B-Entity
and	O	O	O
Outcome	O	O	O

As	O	O	O
the	O	O	O
health	O	O	B-Entity
benefits	O	O	I-Entity
of	O	O	O
exercise	O	O	B-Entity
are	O	O	O
increasingly	O	O	O
recognized	O	O	O
,	O	O	O
the	O	O	O
traditional	O	O	B-Entity
advice	O	O	I-Entity
to	O	O	O
rest	O	O	B-Entity
during	O	O	O
pregnancy	O	O	B-Entity
has	O	O	O
changed	O	O	B-Entity
toward	O	O	O
a	O	O	O
more	O	O	O
healthy	O	O	B-Entity
and	O	O	O
active	O	O	B-Entity
pregnancy	O	O	O
,	O	O	O
therefore	O	O	O
different	O	O	O
forms	O	O	O
of	O	O	O
exercise	O	O	O
have	O	O	O
been	O	O	O
integrated	O	O	O
into	O	O	O
the	O	O	O
life	O	O	B-Entity
of	O	O	O
the	O	O	O
pregnant	O	O	B-Entity
woman	O	O	I-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
benefits	O	O	B-Entity
of	O	O	O
using	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
resistance	O	O	B-Entity
and	O	O	O
aerobic	O	O	B-Entity
exercises	O	O	I-Entity
are	O	O	O
not	O	O	O
yet	O	O	O
determined	O	O	O
,	O	O	O
studies	O	O	B-Entity
about	O	O	O
resistance	O	O	O
and	O	O	O
strengthen	O	O	O
training	O	O	B-Entity
programs	O	O	I-Entity
are	O	O	O
few	O	O	O
although	O	O	O
no	O	O	B-Entity
adverse	O	O	I-Entity
outcomes	O	O	B-Entity
were	O	O	O
reported	O	O	O
.	O	O	O

-DOCSTART- (27390504)

Custom	O	O	O
ocular	O	O	B-Entity
prosthesis	O	O	I-Entity
in	O	O	O
rehabilitation	O	O	B-Entity
of	O	O	O
a	O	O	O
child	O	O	B-Entity
operated	O	O	O
for	O	O	O
retinoblastoma	O	O	O

A	O	O	O
maxillofacial	O	O	B-Entity
prosthodontist	O	O	I-Entity
forms	O	O	O
an	O	O	O
important	O	O	B-Entity
link	O	O	O
in	O	O	O
the	O	O	O
interdisciplinary	O	O	O
management	O	O	B-Entity
of	O	O	I-Entity
a	O	O	I-Entity
patient	O	O	I-Entity
with	O	O	O
anopthalmosis	O	O	B-Entity
.	O	O	O

Prosthetic	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
an	O	O	O
anopthalmic	O	O	B-Entity
defect	O	O	I-Entity
aims	O	O	O
to	O	O	O
deliver	O	O	O
a	O	O	O
well-fitting	O	O	O
ocular	O	O	B-Entity
prosthesis	O	O	I-Entity
that	O	O	O
can	O	O	O
mimic	O	O	O
the	O	O	O
original	O	O	O
eye	O	O	B-Entity
as	O	O	O
closely	O	O	O
as	O	O	O
possible	O	O	O
,	O	O	O
and	O	O	O
thus	O	O	O
restoring	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
self-confidence	O	O	B-Entity
and	O	O	O
thereby	O	O	O
rehabilitating	O	O	B-Entity
them	O	O	O
in	O	O	O
the	O	O	O
society	O	O	B-Entity
.	O	O	O

The	O	O	O
fabrication	O	O	B-Entity
of	O	O	O
a	O	O	O
custom	O	O	O
ocular	O	O	B-Entity
prosthesis	O	O	I-Entity
is	O	O	O
a	O	O	O
demanding	O	O	O
art	O	O	O
.	O	O	O

This	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
presents	O	O	O
a	O	O	O
simplified	O	O	O
technique	O	O	B-Entity
for	O	O	O
the	O	O	O
fabrication	O	O	B-Entity
of	O	O	O
a	O	O	O
custom	O	O	O
ocular	O	O	B-Entity
prosthesis	O	O	I-Entity
for	O	O	O
a	O	O	O
child	O	O	B-Entity
who	O	O	O
had	O	O	O
lost	O	O	B-Entity
his	O	O	O
eye	O	O	B-Entity
to	O	O	O
enucleation	O	O	B-Entity
following	O	O	O
retinoblastoma	O	O	B-Entity
.	O	O	O

Early	O	O	O
and	O	O	O
effective	O	O	O
rehabilitation	O	O	B-Entity
of	O	O	O
the	O	O	O
defect	O	O	O
goes	O	O	O
a	O	O	O
long	O	O	O
way	O	O	O
in	O	O	O
restoring	O	O	O
the	O	O	O
self-image	O	O	B-Entity
of	O	O	O
a	O	O	O
child	O	O	B-Entity
in	O	O	O
its	O	O	O
early	O	O	O
character	O	O	O
building	O	O	O
age	O	O	O
.	O	O	O

-DOCSTART- (27390849)

Pulmonary	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
1-	O	O	O
year	O	O	B-Entity
follow	O	O	B-Entity
up	O	O	I-Entity
after	O	O	O
cardiac	O	O	O
surgery	O	O	O

Pulmonary	O	O	B-Entity
function	O	O	I-Entity
is	O	O	O
severely	O	O	B-Entity
reduced	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
period	O	O	B-Entity
after	O	O	O
cardiac	O	O	B-Entity
surgery	O	O	I-Entity
,	O	O	O
and	O	O	O
impairments	O	O	B-Entity
have	O	O	O
been	O	O	O
described	O	O	O
up	O	O	O
to	O	O	O
4	O	O	O
-	O	O	O
6	O	O	O
months	O	O	B-Entity
after	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Evaluation	O	O	B-Entity
of	O	O	O
pulmonary	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
a	O	O	O
longer	O	O	O
perspective	O	O	O
is	O	O	O
lacking	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
pulmonary	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
1	O	O	O
year	O	O	B-Entity
after	O	O	O
cardiac	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Pulmonary	O	O	B-Entity
function	O	O	I-Entity
measurements	O	O	B-Entity
,	O	O	O
health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
SF-36	O	O	B-Entity
)	O	O	O
,	O	O	O
dyspnoea	O	O	B-Entity
,	O	O	O
subjective	O	O	B-Entity
breathing	O	O	B-Entity
and	O	O	O
coughing	O	O	B-Entity
ability	O	O	B-Entity
and	O	O	O
pain	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
before	O	O	B-Entity
and	O	O	O
1	O	O	O
year	O	O	B-Entity
after	O	O	B-Entity
surgery	O	O	B-Entity
in	O	O	O
150	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
bypass	O	O	I-Entity
grafting	O	O	I-Entity
,	O	O	O
valve	O	O	B-Entity
surgery	O	O	I-Entity
or	O	O	O
combined	O	O	O
surgery	O	O	O
.	O	O	O

One	O	O	O
year	O	O	B-Entity
after	O	O	B-Entity
surgery	O	O	I-Entity
the	O	O	O
forced	O	O	B-Entity
vital	O	O	I-Entity
capacity	O	O	I-Entity
and	O	O	O
forced	O	O	B-Entity
expiratory	O	O	I-Entity
volume	O	O	I-Entity
in	O	O	O
1	O	O	O
s	O	O	O
were	O	O	O
significantly	O	O	O
decreased	O	O	B-Entity
(	O	O	O
by	O	O	O
4	O	O	O
-	O	O	O
5	O	O	O
%	O	O	O
)	O	O	O
compared	O	O	B-Entity
to	O	O	O
preoperative	O	O	B-Entity
values	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Saturation	O	O	B-Entity
of	O	O	I-Entity
peripheral	O	O	I-Entity
oxygen	O	O	I-Entity
was	O	O	O
unchanged	O	O	B-Entity
1	O	O	O
year	O	O	B-Entity
postoperatively	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
baseline	O	O	B-Entity
.	O	O	O

A	O	O	O
significantly	O	O	O
improved	O	O	B-Entity
health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
was	O	O	O
found	O	O	O
1	O	O	O
year	O	O	B-Entity
after	O	O	B-Entity
surgery	O	O	I-Entity
,	O	O	O
with	O	O	O
improvements	O	O	B-Entity
in	O	O	O
all	O	O	O
eight	O	O	O
aspects	O	O	B-Entity
of	O	O	O
SF-36	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Sternotomy	O	O	B-Entity
-related	O	O	O
pain	O	O	B-Entity
was	O	O	O
low	O	O	B-Entity
1	O	O	O
year	O	O	B-Entity
postoperatively	O	O	B-Entity
at	O	O	B-Entity
rest	O	O	I-Entity
(	O	O	O
median	O	O	O
0	O	O	O
[	O	O	O
min-max	O	O	O
;	O	O	O
0	O	O	O
-	O	O	O
7	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
taking	O	O	O
a	O	O	O
deep	O	O	B-Entity
breath	O	O	I-Entity
(	O	O	O
0	O	O	O
[	O	O	O
0	O	O	O
-	O	O	O
4	O	O	O
]	O	O	O
)	O	O	O
and	O	O	O
while	O	O	O
coughing	O	O	B-Entity
(	O	O	O
0	O	O	O
[	O	O	O
0	O	O	O
-	O	O	O
8	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
more	O	O	O
pronounced	O	O	O
decrease	O	O	O
in	O	O	O
pulmonary	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
dyspnoea	O	O	B-Entity
limitations	O	O	B-Entity
and	O	O	O
impaired	O	O	B-Entity
subjective	O	O	B-Entity
breathing	O	O	B-Entity
and	O	O	O
coughing	O	O	B-Entity
ability	O	O	B-Entity
.	O	O	O

One	O	O	O
year	O	O	B-Entity
after	O	O	O
cardiac	O	O	B-Entity
surgery	O	O	I-Entity
static	O	O	B-Entity
and	O	O	O
dynamic	O	O	B-Entity
lung	O	O	B-Entity
function	O	O	I-Entity
measurements	O	O	I-Entity
were	O	O	O
slightly	O	O	O
decreased	O	O	B-Entity
,	O	O	O
while	O	O	O
health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
was	O	O	O
improved	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
preoperative	O	O	B-Entity
values	O	O	B-Entity
.	O	O	O

Measured	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
pain	O	O	B-Entity
were	O	O	O
low	O	O	B-Entity
and	O	O	O
saturation	O	O	B-Entity
of	O	O	I-Entity
peripheral	O	O	I-Entity
oxygen	O	O	I-Entity
was	O	O	O
same	O	O	B-Entity
as	O	O	O
preoperatively	O	O	B-Entity
.	O	O	O

-DOCSTART- (27391592)

Impact	O	O	B-Entity
of	O	O	O
Soil	O	O	B-Entity
Salinity	O	O	B-Entity
on	O	O	O
the	O	O	O
Structure	O	O	B-Entity
of	O	O	O
the	O	O	O
Bacterial	O	O	B-Entity
Endophytic	O	O	B-Entity
Community	O	O	B-Entity
Identified	O	O	B-Entity
from	O	O	O
the	O	O	O
Roots	O	O	B-Entity
of	O	O	O
Caliph	O	O	B-Entity
Medic	O	O	I-Entity
(	O	O	O
Medicago	O	O	B-Entity
truncatula	O	O	I-Entity
)	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
being	O	O	O
a	O	O	O
forage	O	O	B-Entity
crop	O	O	I-Entity
,	O	O	O
Caliph	O	O	B-Entity
medic	O	O	I-Entity
(	O	O	O
Medicago	O	O	B-Entity
truncatula	O	O	I-Entity
)	O	O	O
is	O	O	O
also	O	O	O
a	O	O	O
model	O	O	B-Entity
legume	O	O	I-Entity
plant	O	O	I-Entity
and	O	O	O
is	O	O	O
used	O	O	O
for	O	O	O
research	O	O	O
focusing	O	O	O
on	O	O	O
the	O	O	O
molecular	O	O	B-Entity
characterization	O	O	I-Entity
of	O	O	O
the	O	O	O
interaction	O	O	B-Entity
between	O	O	O
rhizobia	O	O	B-Entity
and	O	O	O
plants	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
endophytic	O	O	B-Entity
microbiome	O	O	I-Entity
in	O	O	O
this	O	O	O
plant	O	O	B-Entity
is	O	O	O
poorly	O	O	O
defined	O	O	O
.	O	O	O

Endophytic	O	O	B-Entity
bacteria	O	O	B-Entity
play	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
supplying	O	O	O
plants	O	O	B-Entity
with	O	O	O
the	O	O	O
basic	O	O	O
requirements	O	O	B-Entity
necessary	O	O	O
for	O	O	O
growth	O	O	B-Entity
and	O	O	O
development	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
these	O	O	O
bacteria	O	O	B-Entity
also	O	O	O
play	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
salinity	O	O	B-Entity
stress	O	O	I-Entity
adaptation	O	O	B-Entity
in	O	O	O
plants	O	O	B-Entity
.	O	O	O

As	O	O	O
a	O	O	O
prelude	O	O	O
to	O	O	O
the	O	O	O
isolation	O	O	B-Entity
and	O	O	O
utilization	O	O	B-Entity
of	O	O	O
these	O	O	O
bacteria	O	O	B-Entity
in	O	O	O
Caliph	O	O	B-Entity
medic	O	O	I-Entity
farming	O	O	B-Entity
,	O	O	O
41	O	O	O
bacterial	O	O	B-Entity
OTUs	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
this	O	O	O
project	O	O	O
from	O	O	O
within	O	O	O
the	O	O	O
interior	O	O	B-Entity
of	O	O	O
the	O	O	O
roots	O	O	B-Entity
of	O	O	O
this	O	O	O
plant	O	O	B-Entity
by	O	O	O
pyrosequencing	O	O	B-Entity
of	O	O	O
the	O	O	O
small	O	O	B-Entity
ribosomal	O	O	I-Entity
subunit	O	O	I-Entity
gene	O	O	I-Entity
(	O	O	O
16S	O	O	B-Entity
rDNA	O	O	I-Entity
)	O	O	O
using	O	O	O
a	O	O	O
cultivation-independent	O	O	B-Entity
approach	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
differential	O	O	B-Entity
abundance	O	O	B-Entity
of	O	O	O
these	O	O	O
bacteria	O	O	B-Entity
was	O	O	O
studied	O	O	O
following	O	O	O
exposure	O	O	O
of	O	O	O
the	O	O	O
plants	O	O	B-Entity
to	O	O	O
salinity	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

About	O	O	O
29,064	O	O	O
high-quality	O	O	B-Entity
reads	O	O	I-Entity
were	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
sequencing	O	O	B-Entity
of	O	O	O
six	O	O	O
libraries	O	O	B-Entity
prepared	O	O	O
from	O	O	O
control	O	O	B-Entity
and	O	O	O
salinity-treated	O	O	B-Entity
tissues	O	O	I-Entity
.	O	O	O

Statistical	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
abundance	O	O	B-Entity
of	O	O	O
~70	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
OTUs	O	O	B-Entity
was	O	O	O
significantly	O	O	O
(	O	O	O
p	O	O	O
≤	O	O	O
0.05	O	O	O
)	O	O	O
altered	O	O	O
in	O	O	O
roots	O	O	B-Entity
that	O	O	O
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
salinity	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

Sequence	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
a	O	O	O
similarity	O	O	O
between	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
identified	O	O	B-Entity
species	O	O	B-Entity
and	O	O	O
other	O	O	O
,	O	O	O
known	O	O	O
,	O	O	O
growth-promoting	O	O	B-Entity
bacteria	O	O	I-Entity
,	O	O	O
marine	O	O	B-Entity
and	O	O	O
salt-stressed	O	O	B-Entity
soil-borne	O	O	I-Entity
bacteria	O	O	I-Entity
,	O	O	O
and	O	O	O
nitrogen-fixing	O	O	B-Entity
bacterial	O	O	I-Entity
isolates	O	O	B-Entity
.	O	O	O

Determination	O	O	O
of	O	O	O
the	O	O	O
amendments	O	O	O
to	O	O	O
the	O	O	O
bacteria	O	O	B-Entity
l	O	O	O
community	O	O	B-Entity
due	O	O	O
to	O	O	O
salinity	O	O	B-Entity
stress	O	O	I-Entity
in	O	O	O
Caliph	O	O	B-Entity
medic	O	O	I-Entity
provides	O	O	O
a	O	O	O
crucial	O	O	O
step	O	O	O
toward	O	O	O
developing	O	O	O
an	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
association	O	O	B-Entity
of	O	O	O
these	O	O	O
endophytes	O	O	B-Entity
,	O	O	O
under	O	O	O
salt	O	O	B-Entity
stress	O	O	I-Entity
conditions	O	O	I-Entity
,	O	O	O
in	O	O	O
this	O	O	O
model	O	O	B-Entity
plant	O	O	I-Entity
.	O	O	O

To	O	O	O
provide	O	O	O
direct	O	O	O
evidence	O	O	B-Entity
regarding	O	O	O
their	O	O	O
growth	O	O	B-Entity
promoting	O	O	I-Entity
activity	O	O	I-Entity
,	O	O	O
a	O	O	O
group	O	O	B-Entity
of	O	O	O
endophytic	O	O	B-Entity
bacteria	O	O	B-Entity
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
inside	O	O	O
of	O	O	O
plant	O	O	B-Entity
roots	O	O	I-Entity
using	O	O	O
a	O	O	O
cultivation-dependent	O	O	B-Entity
approach	O	O	I-Entity
.	O	O	O

Several	O	O	O
of	O	O	O
these	O	O	O
isolates	O	O	B-Entity
were	O	O	O
able	O	O	O
to	O	O	O
produce	O	O	O
ACC-deaminase	O	O	B-Entity
,	O	O	O
ammonia	O	O	B-Entity
and	O	O	O
IAA	O	O	B-Entity
;	O	O	O
and	O	O	O
to	O	O	O
solubilize	O	O	B-Entity
Zn+2	O	O	B-Entity
and	O	O	O
PO4	O	O	B-Entity
-	O	O	I-Entity
3	O	O	I-Entity
.	O	O	O

This	O	O	O
data	O	O	B-Entity
is	O	O	O
consistent	O	O	O
with	O	O	O
the	O	O	O
predicted	O	O	O
occurrence	O	O	B-Entity
(	O	O	O
based	O	O	O
on	O	O	O
cultivation-independent	O	O	B-Entity
techniques	O	O	I-Entity
)	O	O	O
of	O	O	O
these	O	O	O
bacteria	O	O	B-Entity
and	O	O	O
provides	O	O	O
some	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
the	O	O	O
endophytic	O	O	B-Entity
bacteria	O	O	O
in	O	O	O
Caliph	O	O	B-Entity
medic	O	O	I-Entity
when	O	O	O
grown	O	O	O
under	O	O	O
normal	O	O	B-Entity
and	O	O	O
saline	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27392220)

Eliminating	O	O	O
Cancer	O	O	B-Entity
Stem	O	O	I-Entity
Cells	O	O	I-Entity
in	O	O	O
CML	O	O	B-Entity
with	O	O	O
Combination	O	O	O
Transcriptional	O	O	B-Entity
Therapy	O	O	O

Leukemia	O	O	B-Entity
stem	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
LSCs	O	O	B-Entity
)	O	O	O
are	O	O	O
resistant	O	O	O
to	O	O	O
current	O	O	O
therapies	O	O	B-Entity
used	O	O	O
to	O	O	O
treat	O	O	O
chronic	O	O	B-Entity
myeloid	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
CML	O	O	B-Entity
)	O	O	O
.	O	O	O

Abraham	O	O	O
et	O	O	O
al.	O	O	O
(	O	O	O
2016	O	O	O
)	O	O	O
have	O	O	O
identified	O	O	O
a	O	O	O
molecular	O	O	B-Entity
network	O	O	I-Entity
critical	O	O	B-Entity
for	O	O	O
CML	O	O	B-Entity
LSC	O	O	B-Entity
survival	O	O	B-Entity
and	O	O	O
propose	O	O	O
that	O	O	O
simultaneously	O	O	O
targeting	O	O	O
two	O	O	O
of	O	O	O
their	O	O	O
major	O	O	O
transcriptional	O	O	B-Entity
regulators	O	O	I-Entity
,	O	O	O
p53	O	O	B-Entity
and	O	O	O
c-Myc	O	O	B-Entity
,	O	O	O
may	O	O	O
facilitate	O	O	O
their	O	O	O
eradication	O	O	B-Entity
.	O	O	O

-DOCSTART- (27393222)

Crocetin	O	O	B-Entity
improves	O	O	B-Entity
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
-	O	O	O
produced	O	O	B-Entity
bovine	O	O	B-Entity
embryos	O	O	B-Entity
:	O	O	O
Implications	O	O	O
for	O	O	O
blastocyst	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
cryotolerance	O	O	B-Entity
,	O	O	O
and	O	O	O
apoptosis	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
work	O	O	O
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
supplementation	O	O	B-Entity
of	O	O	O
bovine	O	O	B-Entity
culture	O	O	B-Entity
medium	O	O	I-Entity
with	O	O	O
the	O	O	O
natural	O	O	B-Entity
antioxidant	O	O	I-Entity
crocetin	O	O	B-Entity
on	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
blastocyst	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
quality	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
evaluated	O	O	B-Entity
as	O	O	O
cryotolerance	O	O	B-Entity
,	O	O	O
apoptosis	O	O	B-Entity
index	O	O	I-Entity
,	O	O	O
and	O	O	O
total	O	O	B-Entity
cells	O	O	I-Entity
number	O	O	I-Entity
and	O	O	O
allocation	O	O	B-Entity
.	O	O	O

Abattoir	O	O	B-Entity
-derived	O	O	O
oocytes	O	O	B-Entity
were	O	O	O
matured	O	O	B-Entity
and	O	O	O
fertilized	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
according	O	O	O
to	O	O	O
standard	O	O	B-Entity
procedure	O	O	I-Entity
.	O	O	O

Twenty	O	O	O
hours	O	O	B-Entity
after	O	O	O
IVF	O	O	B-Entity
,	O	O	O
presumptive	O	O	B-Entity
zygotes	O	O	B-Entity
were	O	O	O
cultured	O	O	B-Entity
in	O	O	O
synthetic	O	O	B-Entity
oviduct	O	O	I-Entity
fluid	O	O	B-Entity
medium	O	O	I-Entity
,	O	O	O
supplemented	O	O	O
with	O	O	O
0	O	O	O
,	O	O	O
1	O	O	O
,	O	O	O
2.5	O	O	O
,	O	O	O
and	O	O	O
5	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
(	O	O	O
experiment	O	O	O
1	O	O	O
)	O	O	O
at	O	O	O
39	O	O	O
°	O	O	O
C	O	O	O
under	O	O	O
humidified	O	O	B-Entity
air	O	O	I-Entity
with	O	O	O
5	O	O	O
%	O	O	O
CO2	O	O	B-Entity
,	O	O	O
7	O	O	O
%	O	O	O
O2	O	O	B-Entity
,	O	O	O
and	O	O	O
88	O	O	O
%	O	O	O
N2	O	O	B-Entity
.	O	O	O

On	O	O	O
Day	O	O	B-Entity
7	O	O	O
,	O	O	O
embryo	O	O	B-Entity
yields	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
and	O	O	O
the	O	O	O
blastocysts	O	O	B-Entity
were	O	O	O
vitrified	O	O	O
by	O	O	O
Cryotop	O	O	B-Entity
method	O	O	I-Entity
in	O	O	O
16.5	O	O	O
%	O	O	O
ethylene	O	O	B-Entity
glycol	O	O	I-Entity
,	O	O	O
16.5	O	O	O
%	O	O	O
DMSO	O	O	B-Entity
,	O	O	O
and	O	O	O
0.5	O	O	O
M	O	O	O
sucrose	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
blastocysts	O	O	B-Entity
produced	O	O	O
on	O	O	O
Day	O	O	B-Entity
8	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
(	O	O	O
control	O	O	B-Entity
)	O	O	O
and	O	O	O
presence	O	O	B-Entity
of	O	O	O
1	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
were	O	O	O
used	O	O	O
for	O	O	O
terminal	O	O	B-Entity
deoxynucleotidyl	O	O	I-Entity
transferase-mediated	O	O	I-Entity
dUTP	O	O	I-Entity
nick	O	O	I-Entity
end	O	O	I-Entity
labelling	O	O	I-Entity
and	O	O	O
differential	O	O	B-Entity
staining	O	O	I-Entity
to	O	O	O
evaluate	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
the	O	O	O
apoptotic	O	O	B-Entity
rate	O	O	I-Entity
and	O	O	O
the	O	O	O
allocation	O	O	B-Entity
of	O	O	O
cells	O	O	B-Entity
into	O	O	O
inner	O	O	B-Entity
cell	O	O	I-Entity
mass	O	O	I-Entity
(	O	O	O
ICM	O	O	B-Entity
)	O	O	O
and	O	O	O
trophectoderm	O	O	B-Entity
(	O	O	O
TE	O	O	B-Entity
)	O	O	O
lineages	O	O	B-Entity
(	O	O	O
experiment	O	O	O
2	O	O	O
)	O	O	O
.	O	O	O

Embryo	O	O	B-Entity
development	O	O	I-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
1	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
group	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
,	O	O	O
both	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
total	O	O	B-Entity
embryo	O	O	B-Entity
output	O	O	B-Entity
(	O	O	O
37.7	O	O	O
±	O	O	O
4.2	O	O	O
%	O	O	O
,	O	O	O
52.9	O	O	O
±	O	O	O
6.3	O	O	O
%	O	O	O
,	O	O	O
40.9	O	O	O
±	O	O	O
7.6	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
42.4	O	O	O
±	O	O	O
8.7	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
0	O	O	O
,	O	O	O
1	O	O	O
,	O	O	O
2.5	O	O	O
,	O	O	O
and	O	O	O
5	O	O	O
μM	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
grade	O	O	B-Entity
1	O	O	I-Entity
and	O	O	O
2	O	O	B-Entity
blastocysts	O	O	B-Entity
(	O	O	O
33.6	O	O	O
±	O	O	O
4.9	O	O	O
%	O	O	O
,	O	O	O
46.1	O	O	O
±	O	O	O
7.3	O	O	O
%	O	O	O
,	O	O	O
37.8	O	O	O
±	O	O	O
7.9	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
39.4	O	O	O
±	O	O	O
7.9	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
0	O	O	O
,	O	O	O
1	O	O	O
,	O	O	O
2.5	O	O	O
,	O	O	O
and	O	O	O
5	O	O	O
μM	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
fast-developing	O	O	B-Entity
embryos	O	O	I-Entity
increased	O	O	B-Entity
in	O	O	O
1	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
group	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
(	O	O	O
23.4	O	O	O
±	O	O	O
4.7	O	O	O
%	O	O	O
,	O	O	O
32.7	O	O	O
±	O	O	O
6.6	O	O	O
%	O	O	O
,	O	O	O
27.2	O	O	O
±	O	O	O
6.6	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
30.1	O	O	O
±	O	O	O
7.2	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
0	O	O	O
,	O	O	O
1	O	O	O
,	O	O	O
2.5	O	O	O
,	O	O	O
and	O	O	O
5	O	O	O
μM	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
enrichment	O	O	B-Entity
of	O	O	I-Entity
culture	O	O	I-Entity
medium	O	O	I-Entity
with	O	O	O
1	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
improved	O	O	B-Entity
embryo	O	O	B-Entity
cryotolerance	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
,	O	O	O
as	O	O	O
indicated	O	O	O
by	O	O	O
higher	O	O	O
hatching	O	O	B-Entity
rates	O	O	B-Entity
recorded	O	O	O
after	O	O	O
48	O	O	O
hours	O	O	B-Entity
postwarming	O	O	B-Entity
culture	O	O	I-Entity
(	O	O	O
46.5	O	O	O
%	O	O	O
vs.	O	O	O
60.4	O	O	O
%	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
1	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
decreased	O	O	B-Entity
both	O	O	O
the	O	O	O
average	O	O	O
number	O	O	O
(	O	O	O
9.9	O	O	O
±	O	O	O
0.4	O	O	O
vs.	O	O	O
7.1	O	O	O
±	O	O	O
0.3	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
apoptotic	O	O	B-Entity
cells	O	O	B-Entity
(	O	O	O
7.1	O	O	O
±	O	O	O
0.4	O	O	O
vs.	O	O	O
4.2	O	O	O
±	O	O	O
0.2	O	O	O
)	O	O	O
in	O	O	O
blastocysts	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
control	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
differences	O	O	O
were	O	O	O
recorded	O	O	O
in	O	O	O
the	O	O	O
average	O	O	O
number	O	O	O
of	O	O	O
ICM	O	O	B-Entity
,	O	O	O
TE	O	O	B-Entity
,	O	O	O
and	O	O	O
total	O	O	B-Entity
cells	O	O	B-Entity
between	O	O	O
1	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
groups	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
enrichment	O	O	B-Entity
of	O	O	I-Entity
bovine	O	O	I-Entity
culture	O	O	I-Entity
medium	O	O	I-Entity
with	O	O	O
1	O	O	O
μM	O	O	O
crocetin	O	O	B-Entity
increased	O	O	B-Entity
both	O	O	O
blastocyst	O	O	B-Entity
yield	O	O	I-Entity
and	O	O	O
quality	O	O	B-Entity
,	O	O	O
as	O	O	O
indicated	O	O	O
by	O	O	O
the	O	O	O
improved	O	O	B-Entity
chronology	O	O	B-Entity
of	O	O	O
embryo	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
increased	O	O	O
resistance	O	O	B-Entity
to	O	O	O
cryopreservation	O	O	B-Entity
,	O	O	O
and	O	O	O
reduced	O	O	B-Entity
incidence	O	O	I-Entity
of	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27401811)

Matrix	O	O	B-Entity
solid-phase	O	O	I-Entity
dispersion	O	O	I-Entity
combined	O	O	O
to	O	O	O
liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
for	O	O	O
the	O	O	O
determination	O	O	B-Entity
of	O	O	O
paraben	O	O	B-Entity
preservatives	O	O	B-Entity
in	O	O	O
mollusks	O	O	O

A	O	O	O
method	O	O	B-Entity
for	O	O	I-Entity
the	O	O	I-Entity
extraction	O	O	I-Entity
and	O	O	O
determination	O	O	B-Entity
of	O	O	O
seven	O	O	O
parabens	O	O	B-Entity
,	O	O	O
esters	O	O	B-Entity
of	O	O	O
4-hydroxybenzoic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
widely	O	O	O
used	O	O	O
as	O	O	O
preservatives	O	O	B-Entity
in	O	O	O
personal	O	O	B-Entity
care	O	O	I-Entity
products	O	O	I-Entity
,	O	O	O
pharmaceuticals	O	O	B-Entity
,	O	O	O
etc	O	O	O
.	O	O	O
,	O	O	O
and	O	O	O
two	O	O	O
chlorinated	O	O	B-Entity
derivatives	O	O	I-Entity
(	O	O	O
mono-	O	O	B-Entity
and	O	O	O
di-chloro	O	O	B-Entity
methyl	O	O	I-Entity
paraben	O	O	I-Entity
)	O	O	O
from	O	O	O
mollusk	O	O	B-Entity
samples	O	O	B-Entity
was	O	O	O
developed	O	O	O
by	O	O	O
combining	O	O	O
matrix	O	O	B-Entity
solid-phase	O	O	I-Entity
dispersion	O	O	I-Entity
(	O	O	O
MSPD	O	O	B-Entity
)	O	O	O
and	O	O	O
liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
.	O	O	O

MSPD	O	O	B-Entity
parameters	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
solvent	O	O	B-Entity
,	O	O	O
solid	O	O	B-Entity
support	O	O	I-Entity
and	O	O	O
clean-up	O	O	B-Entity
sorbent	O	O	I-Entity
,	O	O	O
were	O	O	O
optimized	O	O	B-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
since	O	O	O
blank	O	O	O
problems	O	O	O
were	O	O	O
observed	O	O	O
for	O	O	O
some	O	O	O
parabens	O	O	B-Entity
,	O	O	O
these	O	O	O
were	O	O	O
investigated	O	O	B-Entity
and	O	O	O
blanks	O	O	O
were	O	O	O
tackled	O	O	O
by	O	O	O
precleaning	O	O	B-Entity
all	O	O	O
sorbents	O	O	B-Entity
prior	O	O	O
to	O	O	O
use	O	O	O
.	O	O	O

Under	O	O	O
final	O	O	O
conditions	O	O	O
,	O	O	O
0.5	O	O	O
g	O	O	O
of	O	O	O
freeze-dried	O	O	B-Entity
mollusk	O	O	B-Entity
were	O	O	O
dispersed	O	O	B-Entity
with	O	O	O
1.2	O	O	O
g	O	O	O
of	O	O	O
silica	O	O	B-Entity
and	O	O	O
packed	O	O	B-Entity
into	O	O	O
a	O	O	O
cartridge	O	O	B-Entity
containing	O	O	O
3	O	O	O
g	O	O	O
of	O	O	O
C18	O	O	B-Entity
,	O	O	O
as	O	O	O
on-line	O	O	O
clean-up	O	O	B-Entity
sorbent	O	O	I-Entity
.	O	O	O

This	O	O	O
cartridge	O	O	B-Entity
was	O	O	O
eluted	O	O	O
with	O	O	O
10mL	O	O	O
of	O	O	O
acetonitrile	O	O	B-Entity
,	O	O	O
evaporated	O	O	B-Entity
and	O	O	O
reconstituted	O	O	B-Entity
in	O	O	O
methanol	O	O	B-Entity
for	O	O	O
analysis	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
validation	O	O	B-Entity
stage	O	O	O
,	O	O	O
successful	O	O	O
linearity	O	O	O
(	O	O	O
R(2)>0.999	O	O	O
)	O	O	O
,	O	O	O
recoveries	O	O	B-Entity
(	O	O	O
between	O	O	O
71	O	O	O
and	O	O	O
117	O	O	O
%	O	O	O
for	O	O	O
most	O	O	O
analytes	O	O	B-Entity
)	O	O	O
,	O	O	O
precision	O	O	B-Entity
(	O	O	O
RSD	O	O	O
lower	O	O	O
than	O	O	O
21	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
limits	O	O	B-Entity
of	O	O	I-Entity
detection	O	O	I-Entity
and	O	O	O
quantification	O	O	B-Entity
(	O	O	O
LOD	O	O	B-Entity
and	O	O	O
LOQ	O	O	B-Entity
,	O	O	O
lower	O	O	O
than	O	O	O
0.4	O	O	O
and	O	O	O
1.4ngg(-1	O	O	O
)	O	O	O
dry	O	O	B-Entity
weight	O	O	I-Entity
respectively	O	O	O
)	O	O	O
levels	O	O	B-Entity
were	O	O	O
achieved	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
new	O	O	O
methodology	O	O	B-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
mussel	O	O	B-Entity
,	O	O	O
clam	O	O	B-Entity
and	O	O	O
cockle	O	O	B-Entity
samples	O	O	B-Entity
.	O	O	O

Methyl	O	O	B-Entity
paraben	O	O	I-Entity
was	O	O	O
above	O	O	O
the	O	O	O
LOQ	O	O	B-Entity
in	O	O	O
five	O	O	O
of	O	O	O
the	O	O	O
six	O	O	O
samples	O	O	B-Entity
(	O	O	O
not	O	O	O
found	O	O	O
in	O	O	O
one	O	O	O
clam	O	O	B-Entity
sample	O	O	B-Entity
)	O	O	O
at	O	O	O
concentrations	O	O	B-Entity
up	O	O	O
to	O	O	O
7ngg(-1	O	O	O
)	O	O	O
dry	O	O	B-Entity
weight	O	O	I-Entity
.	O	O	O

Ethyl	O	O	B-Entity
paraben	O	O	I-Entity
was	O	O	O
found	O	O	O
above	O	O	O
the	O	O	O
LOQ	O	O	B-Entity
in	O	O	O
mussel	O	O	B-Entity
and	O	O	O
cockle	O	O	B-Entity
samples	O	O	B-Entity
at	O	O	O
a	O	O	O
concentration	O	O	B-Entity
level	O	O	I-Entity
around	O	O	O
0.3ngg(-1	O	O	O
)	O	O	O
.	O	O	O

n-Propyl	O	O	B-Entity
paraben	O	O	I-Entity
was	O	O	O
only	O	O	O
above	O	O	O
the	O	O	O
LOQ	O	O	B-Entity
in	O	O	O
one	O	O	O
mussel	O	O	B-Entity
sample	O	O	B-Entity
.	O	O	O

-DOCSTART- (27402799)

Two-stage	O	O	O
reconstructive	O	O	B-Entity
overlapping	O	O	B-Entity
stent	O	O	I-Entity
LEO+	O	O	B-Entity
and	O	O	O
SILK	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
intracranial	O	O	B-Entity
circumferential	O	O	B-Entity
fusiform	O	O	B-Entity
aneurysms	O	O	I-Entity
in	O	O	O
the	O	O	O
posterior	O	O	B-Entity
circulation	O	O	O

Intracranial	O	O	B-Entity
circumferential	O	O	B-Entity
fusiform	O	O	B-Entity
aneurysms	O	O	I-Entity
of	O	O	O
the	O	O	O
posterior	O	O	B-Entity
circulation	O	O	B-Entity
involving	O	O	O
arterial	O	O	B-Entity
branches	O	O	I-Entity
or	O	O	O
perforating	O	O	B-Entity
vessels	O	O	B-Entity
are	O	O	O
difficult	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	O
shows	O	O	O
an	O	O	O
endovascular	O	O	B-Entity
reconstruction	O	O	B-Entity
technique	O	O	I-Entity
not	O	O	O
yet	O	O	O
described	O	O	O
,	O	O	O
using	O	O	O
a	O	O	O
telescoping	O	O	B-Entity
self-expandable	O	O	I-Entity
stent	O	O	I-Entity
(	O	O	O
LEO+	O	O	B-Entity
)	O	O	O
and	O	O	O
flow-diverter	O	O	B-Entity
device	O	O	I-Entity
(	O	O	O
SILK	O	O	B-Entity
)	O	O	O
at	O	O	O
different	O	O	B-Entity
surgical	O	O	B-Entity
times	O	O	I-Entity
.	O	O	O

Two	O	O	O
patients	O	O	B-Entity
with	O	O	O
circumferential	O	O	B-Entity
fusiform	O	O	B-Entity
aneurysm	O	O	B-Entity
,	O	O	O
one	O	O	O
being	O	O	O
an	O	O	O
aneurysm	O	O	O
of	O	O	O
the	O	O	O
segments	O	O	O
P2	O	O	O
and	O	O	O
P3	O	O	O
of	O	O	O
the	O	O	O
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
,	O	O	O
diagnosed	O	O	B-Entity
after	O	O	O
a	O	O	O
headache	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
other	O	O	O
a	O	O	O
partially	O	O	B-Entity
thrombosed	O	O	B-Entity
aneurysm	O	O	I-Entity
of	O	O	O
the	O	O	O
lower	O	O	B-Entity
basilar	O	O	B-Entity
artery	O	O	I-Entity
,	O	O	O
diagnosed	O	O	O
following	O	O	O
ischemia	O	O	B-Entity
of	O	O	O
the	O	O	O
brain	O	O	B-Entity
stem	O	O	I-Entity
.	O	O	O

Endovascular	O	O	B-Entity
treatment	O	O	B-Entity
was	O	O	O
performed	O	O	O
by	O	O	O
means	O	O	O
of	O	O	O
a	O	O	O
vascular	O	O	B-Entity
reconstruction	O	O	B-Entity
technique	O	O	I-Entity
that	O	O	O
used	O	O	O
at	O	O	O
different	O	O	B-Entity
surgical	O	O	B-Entity
times	O	O	I-Entity
:	O	O	O
overlapping	O	O	B-Entity
;	O	O	I-Entity
a	O	O	I-Entity
telescoped	O	O	I-Entity
self-expandable	O	O	I-Entity
stent	O	O	I-Entity
,	O	O	O
LEO+	O	O	B-Entity
;	O	O	O
and	O	O	O
a	O	O	O
flow-diverter	O	O	B-Entity
device	O	O	I-Entity
,	O	O	O
SILK	O	O	B-Entity
.	O	O	O

Angiographic	O	O	B-Entity
control	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
at	O	O	O
6	O	O	O
and	O	O	O
12	O	O	O
months	O	O	B-Entity
,	O	O	O
to	O	O	O
evaluate	O	O	O
arterial	O	O	B-Entity
patency	O	O	I-Entity
,	O	O	O
flow	O	O	B-Entity
maintenance	O	O	B-Entity
in	O	O	O
the	O	O	O
arterial	O	O	B-Entity
branches	O	O	I-Entity
and	O	O	O
perforating	O	O	B-Entity
vessels	O	O	B-Entity
,	O	O	O
and	O	O	O
thrombosis	O	O	B-Entity
of	O	O	O
the	O	O	O
aneurysm	O	O	B-Entity
.	O	O	O

The	O	O	O
combined	O	O	B-Entity
use	O	O	O
at	O	O	O
different	O	O	B-Entity
surgical	O	O	B-Entity
times	O	O	I-Entity
of	O	O	O
the	O	O	O
self-expandable	O	O	B-Entity
stent	O	O	I-Entity
and	O	O	O
flow-diverter	O	O	B-Entity
device	O	O	I-Entity
was	O	O	O
technically	O	O	O
successful	O	O	B-Entity
in	O	O	O
both	O	O	O
patients	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
complications	O	O	B-Entity
during	O	O	O
the	O	O	O
procedure	O	O	B-Entity
,	O	O	O
nor	O	O	O
in	O	O	O
the	O	O	O
long-term	O	O	B-Entity
follow-up	O	O	B-Entity
with	O	O	O
full	O	O	O
arterial	O	O	B-Entity
vascular	O	O	B-Entity
reconstruction	O	O	B-Entity
,	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
cerebral	O	O	B-Entity
perfusion	O	O	I-Entity
and	O	O	O
complete	O	O	B-Entity
aneurysm	O	O	B-Entity
occlusion	O	O	B-Entity
at	O	O	O
the	O	O	O
6-	O	O	O
and	O	O	O
12-	O	O	O
month	O	O	B-Entity
angiographic	O	O	B-Entity
follow-up	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
aneurysm	O	O	B-Entity
recanalization	O	O	I-Entity
nor	O	O	O
intra-stent	O	O	B-Entity
stenosis	O	O	I-Entity
.	O	O	O

Circumferential	O	O	B-Entity
fusiform	O	O	B-Entity
aneurysm	O	O	I-Entity
of	O	O	O
the	O	O	O
posterior	O	O	B-Entity
circulation	O	O	B-Entity
involving	O	O	O
arterial	O	O	B-Entity
branches	O	O	I-Entity
or	O	O	O
perforating	O	O	B-Entity
vessels	O	O	B-Entity
to	O	O	O
the	O	O	O
brain	O	O	B-Entity
stem	O	O	I-Entity
may	O	O	O
be	O	O	O
treated	O	O	B-Entity
with	O	O	O
this	O	O	O
arterial	O	O	B-Entity
reconstruction	O	O	I-Entity
technique	O	O	B-Entity
at	O	O	O
different	O	O	B-Entity
surgical	O	O	B-Entity
times	O	O	I-Entity
,	O	O	O
using	O	O	O
the	O	O	O
self-expandable	O	O	B-Entity
stent	O	O	I-Entity
called	O	O	O
LEO+	O	O	B-Entity
and	O	O	O
the	O	O	O
flow-diverter	O	O	B-Entity
device	O	O	I-Entity
SILK	O	O	B-Entity
,	O	O	O
minimizing	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
complications	O	O	B-Entity
and	O	O	O
failure	O	O	B-Entity
of	O	O	O
the	O	O	O
endovascular	O	O	B-Entity
technique	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
potential	O	O	B-Entity
for	O	O	O
arterial	O	O	O
reconstruction	O	O	O
with	O	O	O
thrombosis	O	O	B-Entity
of	O	O	O
the	O	O	O
aneurysmatic	O	O	B-Entity
sac	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
flow	O	O	B-Entity
maintenance	O	O	B-Entity
in	O	O	O
the	O	O	O
eloquent	O	O	B-Entity
arteries	O	O	I-Entity
,	O	O	O
in	O	O	O
this	O	O	O
type	O	O	O
of	O	O	O
cerebral	O	O	B-Entity
aneurysm	O	O	I-Entity
.	O	O	O

-DOCSTART- (27403678)

Polysaccharide	O	O	B-Entity
-	O	O	O
Specific	O	O	B-Entity
Memory	O	O	B-Entity
B	O	O	I-Entity
Cells	O	O	I-Entity
Predict	O	O	O
Protection	O	O	B-Entity
against	O	O	O
Experimental	O	O	B-Entity
Human	O	O	B-Entity
Pneumococcal	O	O	B-Entity
Carriage	O	O	O

We	O	O	O
have	O	O	O
previously	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
experimental	O	O	B-Entity
pneumococcal	O	O	B-Entity
carriage	O	O	B-Entity
enhances	O	O	B-Entity
immunity	O	O	B-Entity
and	O	O	O
protects	O	O	B-Entity
healthy	O	O	B-Entity
adults	O	O	B-Entity
against	O	O	B-Entity
carriage	O	O	O
reacquisition	O	O	B-Entity
after	O	O	O
rechallenge	O	O	B-Entity
with	O	O	O
a	O	O	O
homologous	O	O	B-Entity
strain	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
naturally	O	O	B-Entity
acquired	O	O	B-Entity
pneumococcal	O	O	B-Entity
protein	O	O	I-Entity
and	O	O	O
polysaccharide	O	O	B-Entity
(PS)-	O	O	O
specific	O	O	B-Entity
immunity	O	O	B-Entity
in	O	O	O
protection	O	O	B-Entity
against	O	O	B-Entity
carriage	O	O	B-Entity
acquisition	O	O	B-Entity
using	O	O	O
a	O	O	O
heterologous	O	O	B-Entity
challenge	O	O	I-Entity
model	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
that	O	O	O
were	O	O	O
naturally	O	O	B-Entity
colonized	O	O	B-Entity
with	O	O	O
pneumococcus	O	O	B-Entity
and	O	O	O
,	O	O	O
after	O	O	O
clearance	O	O	B-Entity
of	O	O	O
their	O	O	O
natural	O	O	B-Entity
carriage	O	O	B-Entity
episode	O	O	B-Entity
,	O	O	O
challenged	O	O	O
them	O	O	O
with	O	O	O
a	O	O	O
heterologous	O	O	B-Entity
6B	O	O	B-Entity
strain	O	O	I-Entity
.	O	O	O

In	O	O	O
another	O	O	O
cohort	O	O	B-Entity
of	O	O	O
volunteers	O	O	B-Entity
we	O	O	O
assessed	O	O	O
6BPS	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
,	O	O	O
PspA	O	O	B-Entity
-	O	O	O
specific	O	O	O
,	O	O	O
and	O	O	O
PspC	O	O	B-Entity
-	O	O	O
specific	O	O	O
IgG	O	O	B-Entity
and	O	O	O
IgA	O	O	B-Entity
plasma	O	O	B-Entity
and	O	O	O
memory	O	O	B-Entity
B-cell	O	O	I-Entity
populations	O	O	I-Entity
before	O	O	B-Entity
and	O	O	O
7	O	O	O
,	O	O	O
14	O	O	O
,	O	O	O
and	O	O	O
35	O	O	O
days	O	O	O
after	O	O	B-Entity
experimental	O	O	B-Entity
pneumococcal	O	O	B-Entity
inoculation	O	O	B-Entity
.	O	O	O

Heterologous	O	O	B-Entity
challenge	O	O	I-Entity
with	O	O	O
6B	O	O	B-Entity
resulted	O	O	O
in	O	O	O
50	O	O	O
%	O	O	O
carriage	O	O	B-Entity
among	O	O	O
volunteers	O	O	B-Entity
with	O	O	O
previous	O	O	B-Entity
natural	O	O	B-Entity
pneumococcal	O	O	B-Entity
carriage	O	O	O
.	O	O	O

Protection	O	O	B-Entity
from	O	O	O
carriage	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
high	O	O	B-Entity
number	O	O	O
of	O	O	O
circulating	O	O	B-Entity
6BPS	O	O	B-Entity
IgG	O	O	B-Entity
-	O	O	O
secreting	O	O	B-Entity
memory	O	O	B-Entity
B	O	O	I-Entity
cells	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
associations	O	O	B-Entity
between	O	O	O
protection	O	O	B-Entity
from	O	O	O
carriage	O	O	B-Entity
and	O	O	O
baseline	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
6BPS	O	O	B-Entity
IgG	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
or	O	O	O
nasal	O	O	B-Entity
wash	O	O	I-Entity
,	O	O	O
PspA	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
,	O	O	O
or	O	O	O
PspC	O	O	B-Entity
-	O	O	O
specific	O	O	O
memory	O	O	B-Entity
B	O	O	I-Entity
cells	O	O	I-Entity
or	O	O	O
plasma	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

In	O	O	O
volunteers	O	O	B-Entity
who	O	O	O
did	O	O	O
not	O	O	B-Entity
develop	O	O	I-Entity
carriage	O	O	B-Entity
,	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
circulating	O	O	B-Entity
6BPS	O	O	B-Entity
memory	O	O	B-Entity
B	O	O	I-Entity
cells	O	O	I-Entity
decreased	O	O	B-Entity
and	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
6BPS	O	O	O
plasma	O	O	B-Entity
cells	O	O	I-Entity
increased	O	O	B-Entity
postinoculation	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	O
indicate	O	O	O
that	O	O	O
naturally	O	O	B-Entity
acquired	O	O	B-Entity
PS	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
memory	O	O	B-Entity
B	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
circulating	O	O	B-Entity
IgG	O	O	B-Entity
at	O	O	O
time	O	O	O
of	O	O	O
pneumococcal	O	O	B-Entity
exposure	O	O	B-Entity
,	O	O	O
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
protection	O	O	B-Entity
against	O	O	B-Entity
carriage	O	O	B-Entity
acquisition	O	O	B-Entity
.	O	O	O

-DOCSTART- (27405692)

Hounsfield	O	O	B-Entity
unit	O	O	I-Entity
recovery	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
cone	O	O	B-Entity
beam	O	O	I-Entity
CT	O	O	I-Entity
images	O	O	B-Entity
of	O	O	O
the	O	O	O
thorax	O	O	B-Entity
acquired	O	O	O
for	O	O	O
image	O	O	O
guided	O	O	O
radiation	O	O	O
therapy	O	O	O

A	O	O	O
comprehensive	O	O	B-Entity
artefact	O	O	B-Entity
correction	O	O	B-Entity
method	O	O	B-Entity
for	O	O	O
clinical	O	O	B-Entity
cone	O	O	B-Entity
beam	O	O	I-Entity
CT	O	O	I-Entity
(	O	O	O
CBCT	O	O	B-Entity
)	O	O	O
images	O	O	B-Entity
acquired	O	O	O
for	O	O	O
image	O	O	B-Entity
guided	O	O	I-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
IGRT	O	O	B-Entity
)	O	O	O
on	O	O	O
a	O	O	O
commercial	O	O	O
system	O	O	O
is	O	O	O
presented	O	O	O
.	O	O	O

The	O	O	O
method	O	O	B-Entity
is	O	O	O
demonstrated	O	O	O
to	O	O	O
reduce	O	O	B-Entity
artefacts	O	O	B-Entity
and	O	O	O
recover	O	O	B-Entity
CT	O	O	B-Entity
-like	O	O	O
Hounsfield	O	O	B-Entity
units	O	O	I-Entity
(	O	O	O
HU	O	O	B-Entity
)	O	O	O
in	O	O	O
reconstructed	O	O	B-Entity
CBCT	O	O	B-Entity
images	O	O	B-Entity
of	O	O	O
five	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Projection	O	O	B-Entity
image	O	O	I-Entity
based	O	O	O
artefact	O	O	B-Entity
corrections	O	O	B-Entity
of	O	O	O
image	O	O	B-Entity
lag	O	O	I-Entity
,	O	O	O
detector	O	O	B-Entity
scatter	O	O	I-Entity
,	O	O	O
body	O	O	B-Entity
scatter	O	O	I-Entity
and	O	O	O
beam	O	O	B-Entity
hardening	O	O	I-Entity
are	O	O	O
described	O	O	O
and	O	O	O
applied	O	O	O
to	O	O	O
CBCT	O	O	B-Entity
images	O	O	B-Entity
of	O	O	O
five	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Image	O	O	B-Entity
quality	O	O	I-Entity
is	O	O	O
evaluated	O	O	B-Entity
through	O	O	O
visual	O	O	B-Entity
appearance	O	O	B-Entity
of	O	O	O
the	O	O	O
reconstructed	O	O	B-Entity
images	O	O	B-Entity
,	O	O	O
HU	O	O	B-Entity
-correspondence	O	O	O
with	O	O	O
the	O	O	O
planning	O	O	O
CT	O	O	B-Entity
images	O	O	O
,	O	O	O
and	O	O	O
total	O	O	B-Entity
volume	O	O	I-Entity
HU	O	O	O
error	O	O	B-Entity
.	O	O	O

Artefacts	O	O	B-Entity
are	O	O	O
reduced	O	O	B-Entity
and	O	O	O
CT	O	O	B-Entity
-like	O	O	O
HUs	O	O	B-Entity
are	O	O	O
recovered	O	O	B-Entity
in	O	O	O
the	O	O	O
artefact	O	O	B-Entity
corrected	O	O	B-Entity
CBCT	O	O	B-Entity
images	O	O	B-Entity
.	O	O	O

Visual	O	O	B-Entity
inspection	O	O	I-Entity
confirms	O	O	B-Entity
that	O	O	O
artefacts	O	O	B-Entity
are	O	O	O
indeed	O	O	O
suppressed	O	O	B-Entity
by	O	O	O
the	O	O	O
proposed	O	O	O
method	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
HU	O	O	B-Entity
root	O	O	B-Entity
mean	O	O	I-Entity
square	O	O	I-Entity
difference	O	O	B-Entity
between	O	O	O
reconstructed	O	O	B-Entity
CBCTs	O	O	B-Entity
and	O	O	O
the	O	O	O
reference	O	O	B-Entity
CT	O	O	B-Entity
images	O	O	B-Entity
are	O	O	O
reduced	O	O	B-Entity
by	O	O	O
31	O	O	O
%	O	O	O
when	O	O	O
using	O	O	O
the	O	O	O
artefact	O	O	B-Entity
corrections	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
standard	O	O	B-Entity
clinical	O	O	B-Entity
CBCT	O	O	B-Entity
reconstruction	O	O	B-Entity
.	O	O	O

A	O	O	O
versatile	O	O	O
artefact	O	O	B-Entity
correction	O	O	B-Entity
method	O	O	B-Entity
for	O	O	O
clinical	O	O	B-Entity
CBCT	O	O	B-Entity
images	O	O	B-Entity
acquired	O	O	O
for	O	O	O
IGRT	O	O	B-Entity
has	O	O	O
been	O	O	O
developed	O	O	O
.	O	O	O

HU	O	O	B-Entity
values	O	O	B-Entity
are	O	O	O
recovered	O	O	B-Entity
in	O	O	O
the	O	O	O
corrected	O	O	B-Entity
CBCT	O	O	B-Entity
images	O	O	B-Entity
.	O	O	O

The	O	O	O
proposed	O	O	O
method	O	O	B-Entity
relies	O	O	O
on	O	O	O
post	O	O	B-Entity
processing	O	O	I-Entity
of	O	O	O
clinical	O	O	B-Entity
projection	O	O	B-Entity
images	O	O	I-Entity
,	O	O	O
and	O	O	O
does	O	O	O
not	O	O	O
require	O	O	O
patient	O	O	B-Entity
specific	O	O	B-Entity
optimisation	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
thus	O	O	O
a	O	O	O
powerful	O	O	O
tool	O	O	B-Entity
for	O	O	O
image	O	O	B-Entity
quality	O	O	B-Entity
improvement	O	O	B-Entity
of	O	O	O
large	O	O	B-Entity
numbers	O	O	B-Entity
of	O	O	O
CBCT	O	O	B-Entity
images	O	O	B-Entity
.	O	O	O

-DOCSTART- (27407027)

Risk	O	O	B-Entity
Factors	O	O	I-Entity
for	O	O	O
Infection	O	O	B-Entity
After	O	O	O
Knee	O	O	B-Entity
Arthroscopy	O	O	I-Entity
:	O	O	O
Analysis	O	O	B-Entity
of	O	O	O
595,083	O	O	O
Cases	O	O	B-Entity
From	O	O	O
3	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
Databases	O	O	O

To	O	O	O
identify	O	O	B-Entity
and	O	O	O
quantify	O	O	B-Entity
patient-	O	O	B-Entity
and	O	O	O
procedure-related	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
for	O	O	O
post-arthroscopic	O	O	B-Entity
knee	O	O	B-Entity
infections	O	O	I-Entity
using	O	O	O
a	O	O	O
large	O	O	O
dataset	O	O	B-Entity
.	O	O	O

An	O	O	O
administrative	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
database	O	O	I-Entity
including	O	O	O
8	O	O	O
years	O	O	B-Entity
of	O	O	O
records	O	O	O
from	O	O	O
2	O	O	O
large	O	O	O
commercial	O	O	O
insurers	O	O	B-Entity
and	O	O	O
Medicare	O	O	B-Entity
(	O	O	O
a	O	O	O
5	O	O	O
%	O	O	O
random	O	O	B-Entity
sample	O	O	I-Entity
)	O	O	O
was	O	O	O
queried	O	O	O
to	O	O	O
identify	O	O	O
all	O	O	O
knee	O	O	B-Entity
arthroscopies	O	O	I-Entity
performed	O	O	B-Entity
on	O	O	O
patients	O	O	B-Entity
aged	O	O	B-Entity
at	O	O	O
least	O	O	O
15	O	O	O
years	O	O	O
using	O	O	O
Current	O	O	B-Entity
Procedural	O	O	I-Entity
Terminology	O	O	I-Entity
(	O	O	I-Entity
CPT	O	O	I-Entity
)	O	O	I-Entity
codes	O	O	I-Entity
.	O	O	O

Each	O	O	O
CPT	O	O	B-Entity
code	O	O	I-Entity
was	O	O	O
designated	O	O	O
as	O	O	O
a	O	O	O
high-	O	O	B-Entity
or	O	O	O
low-complexity	O	O	B-Entity
procedure	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
former	O	O	O
typically	O	O	O
requiring	O	O	O
accessory	O	O	O
incisions	O	O	B-Entity
or	O	O	O
increased	O	O	O
operative	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

Deep	O	O	O
infections	O	O	B-Entity
were	O	O	O
identified	O	O	O
by	O	O	O
a	O	O	O
CPT	O	O	B-Entity
code	O	O	I-Entity
for	O	O	O
incision	O	O	B-Entity
and	O	O	O
drainage	O	O	B-Entity
within	O	O	O
90	O	O	O
days	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
.	O	O	O

Superficial	O	O	B-Entity
infections	O	O	I-Entity
were	O	O	O
identified	O	O	O
by	O	O	O
International	O	O	B-Entity
Classification	O	O	I-Entity
of	O	O	I-Entity
Diseases	O	O	I-Entity
,	O	O	I-Entity
Ninth	O	O	I-Entity
Revision	O	O	I-Entity
infection	O	O	I-Entity
codes	O	O	I-Entity
without	O	O	O
any	O	O	O
record	O	O	B-Entity
of	O	O	O
incision	O	O	B-Entity
and	O	O	O
drainage	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
compared	O	O	O
based	O	O	O
on	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
,	O	O	O
tobacco	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
presence	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
and	O	O	O
Charlson	O	O	B-Entity
Comorbidity	O	O	I-Entity
Index	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
526,537	O	O	O
patients	O	O	B-Entity
underwent	O	O	O
595,083	O	O	O
arthroscopic	O	O	B-Entity
knee	O	O	I-Entity
procedures	O	O	I-Entity
.	O	O	O

Deep	O	O	O
postoperative	O	O	B-Entity
infections	O	O	I-Entity
occurred	O	O	O
at	O	O	O
a	O	O	O
rate	O	O	O
of	O	O	O
0.22	O	O	O
%	O	O	O
.	O	O	O

Superficial	O	O	B-Entity
infections	O	O	I-Entity
occurred	O	O	O
at	O	O	O
a	O	O	O
rate	O	O	O
of	O	O	O
0.29	O	O	O
%	O	O	O
.	O	O	O

Tobacco	O	O	B-Entity
use	O	O	I-Entity
and	O	O	O
morbid	O	O	B-Entity
obesity	O	O	I-Entity
were	O	O	O
the	O	O	O
largest	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
deep	O	O	B-Entity
and	O	O	O
superficial	O	O	B-Entity
infections	O	O	I-Entity
,	O	O	O
respectively	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
;	O	O	O
relative	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
1.90	O	O	O
and	O	O	O
2.19	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
also	O	O	O
higher	O	O	O
infection	O	O	B-Entity
rates	O	O	I-Entity
among	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
relatively	O	O	O
high-complexity	O	O	B-Entity
arthroscopies	O	O	I-Entity
,	O	O	O
men	O	O	B-Entity
,	O	O	O
obese	O	O	B-Entity
patients	O	O	O
,	O	O	O
diabetic	O	O	B-Entity
patients	O	O	O
,	O	O	O
and	O	O	O
younger	O	O	B-Entity
patients	O	O	O
(	O	O	O
in	O	O	O
order	O	O	O
of	O	O	O
decreasing	O	O	O
relative	O	O	B-Entity
risk	O	O	I-Entity
)	O	O	O
.	O	O	O

Increased	O	O	O
Charlson	O	O	B-Entity
Comorbidity	O	O	I-Entity
Index	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
superficial	O	O	B-Entity
and	O	O	O
total	O	O	B-Entity
infections	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

Post-arthroscopic	O	O	B-Entity
knee	O	O	B-Entity
infections	O	O	I-Entity
were	O	O	O
more	O	O	O
frequent	O	O	O
among	O	O	O
morbidly	O	O	B-Entity
obese	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
tobacco	O	O	B-Entity
users	O	O	I-Entity
,	O	O	O
patients	O	O	O
undergoing	O	O	O
relatively	O	O	O
complex	O	O	B-Entity
procedures	O	O	I-Entity
,	O	O	O
men	O	O	B-Entity
,	O	O	O
obese	O	O	O
patients	O	O	O
,	O	O	O
diabetic	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
relatively	O	O	O
young	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
and	O	O	O
patients	O	O	O
with	O	O	O
increased	O	O	O
comorbidity	O	O	B-Entity
burdens	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
population	O	O	B-Entity
.	O	O	O

This	O	O	O
knowledge	O	O	O
may	O	O	O
allow	O	O	O
more	O	O	O
informed	O	O	O
preoperative	O	O	B-Entity
counseling	O	O	I-Entity
,	O	O	O
aid	O	O	B-Entity
surgeons	O	O	I-Entity
in	O	O	O
patient	O	O	B-Entity
selection	O	O	I-Entity
,	O	O	O
and	O	O	O
facilitate	O	O	O
infection	O	O	B-Entity
prevention	O	O	I-Entity
by	O	O	O
targeting	O	O	O
individuals	O	O	B-Entity
with	O	O	O
higher	O	O	O
inherent	O	O	B-Entity
risk	O	O	I-Entity
.	O	O	O

Level	O	O	O
IV	O	O	O
,	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

-DOCSTART- (27412368)

Association	O	O	B-Entity
of	O	O	O
prenatal	O	O	B-Entity
and	O	O	O
early	O	O	O
life	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
tetrachloroethylene	O	O	B-Entity
(	O	O	O
PCE	O	O	B-Entity
)	O	O	O
with	O	O	O
polycystic	O	O	B-Entity
ovary	O	O	I-Entity
syndrome	O	O	I-Entity
and	O	O	O
other	O	O	O
reproductive	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
the	O	O	O
cape	O	O	B-Entity
cod	O	O	I-Entity
health	O	O	B-Entity
study	O	O	I-Entity
:	O	O	O
A	O	O	O
retrospective	O	O	O
cohort	O	O	O
study	O	O	O

Tetrachloroethylene	O	O	B-Entity
(	O	O	O
PCE	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
organic	O	O	B-Entity
lipophilic	O	O	B-Entity
solvent	O	O	B-Entity
with	O	O	O
possible	O	O	O
neuroendocrine	O	O	B-Entity
toxicity	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
association	O	O	B-Entity
of	O	O	O
prenatal	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
childhood	O	O	I-Entity
exposure	O	O	B-Entity
to	O	O	I-Entity
PCE	O	O	B-Entity
-	O	O	O
contaminated	O	O	B-Entity
drinking	O	O	B-Entity
water	O	O	I-Entity
and	O	O	O
development	O	O	B-Entity
of	O	O	O
adult-onset	O	O	B-Entity
Polycystic	O	O	B-Entity
Ovary	O	O	I-Entity
Syndrome	O	O	I-Entity
(	O	O	O
PCOS	O	O	B-Entity
)	O	O	O
,	O	O	O
endometriosis	O	O	B-Entity
,	O	O	O
difficulty	O	O	B-Entity
conceiving	O	O	I-Entity
and	O	O	O
miscarriage	O	O	B-Entity
.	O	O	O

Five-hundred	O	O	O
exposed	O	O	B-Entity
and	O	O	O
331	O	O	O
unexposed	O	O	B-Entity
female	O	O	B-Entity
participants	O	O	B-Entity
born	O	O	O
between	O	O	O
1969	O	O	O
and	O	O	O
1983	O	O	O
completed	O	O	B-Entity
questionnaires	O	O	B-Entity
on	O	O	O
demographic	O	O	B-Entity
and	O	O	O
lifestyle	O	O	B-Entity
characteristics	O	O	B-Entity
,	O	O	O
and	O	O	O
reproductive	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Residential	O	O	B-Entity
locations	O	O	I-Entity
from	O	O	O
the	O	O	O
prenatal	O	O	B-Entity
period	O	O	B-Entity
through	O	O	O
five	O	O	O
years	O	O	O
of	O	O	O
age	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	B-Entity
early	O	O	O
life	O	O	O
PCE	O	O	B-Entity
exposure	O	O	B-Entity
with	O	O	O
water	O	O	B-Entity
modeling	O	O	I-Entity
software	O	O	I-Entity
.	O	O	O

For	O	O	O
any	O	O	O
early	O	O	O
life	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
PCE	O	O	B-Entity
,	O	O	O
the	O	O	O
adjusted	O	O	B-Entity
risk	O	O	I-Entity
ratio	O	O	I-Entity
for	O	O	O
PCOS	O	O	B-Entity
was	O	O	O
0.9	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.5	O	O	O
-	O	O	O
1.6	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
statistically	O	O	B-Entity
significan	O	O	I-Entity
t	O	O	O
associations	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
for	O	O	O
increasing	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
or	O	O	O
the	O	O	O
other	O	O	O
reproductive	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

No	O	O	O
meaningful	O	O	O
associations	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
among	O	O	O
adult	O	O	B-Entity
women	O	O	B-Entity
with	O	O	O
early	O	O	O
life	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
PCE	O	O	B-Entity
-	O	O	O
contaminated	O	O	B-Entity
drinking	O	O	B-Entity
water	O	O	I-Entity
and	O	O	O
adult-onset	O	O	B-Entity
reproductive	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

-DOCSTART- (27412452)

Host	O	O	B-Entity
plant	O	O	I-Entity
affects	O	O	O
the	O	O	O
sexual	O	O	B-Entity
attractiveness	O	O	I-Entity
of	O	O	O
the	O	O	O
female	O	O	B-Entity
white-spotted	O	O	B-Entity
longicorn	O	O	I-Entity
beetle	O	O	I-Entity
,	O	O	O
Anoplophora	O	O	O
malasiaca	O	O	O

Anoplophora	O	O	B-Entity
malasiaca	O	O	I-Entity
(	O	O	O
Coleoptera	O	O	B-Entity
:	O	O	O
Cerambycidae	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
serious	O	O	O
pest	O	O	O
that	O	O	O
destroys	O	O	O
various	O	O	O
landscape	O	O	B-Entity
and	O	O	O
crop	O	O	B-Entity
trees	O	O	B-Entity
in	O	O	O
Japan	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	O
the	O	O	O
precopulatory	O	O	B-Entity
responses	O	O	B-Entity
of	O	O	O
three	O	O	O
different	O	O	O
A.	O	O	B-Entity
malasiaca	O	O	I-Entity
populations	O	O	B-Entity
collected	O	O	O
from	O	O	O
mandarin	O	O	B-Entity
orange	O	O	I-Entity
,	O	O	O
willow	O	O	B-Entity
and	O	O	O
blueberry	O	O	B-Entity
trees	O	O	I-Entity
.	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
males	O	O	B-Entity
accepted	O	O	O
mates	O	O	O
from	O	O	O
within	O	O	O
the	O	O	O
same	O	O	O
host	O	O	B-Entity
plant	O	O	I-Entity
population	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
females	O	O	B-Entity
from	O	O	O
the	O	O	O
willow	O	O	B-Entity
and	O	O	O
blueberry	O	O	B-Entity
populations	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
significant	O	O	O
number	O	O	O
of	O	O	O
males	O	O	B-Entity
from	O	O	O
the	O	O	O
blueberry	O	O	B-Entity
and	O	O	O
willow	O	O	B-Entity
populations	O	O	B-Entity
rejected	O	O	O
females	O	O	B-Entity
from	O	O	O
the	O	O	O
mandarin	O	O	B-Entity
orange	O	O	I-Entity
population	O	O	B-Entity
immediately	O	O	O
after	O	O	O
touching	O	O	O
them	O	O	O
with	O	O	O
their	O	O	O
antennae	O	O	B-Entity
.	O	O	O

Because	O	O	O
all	O	O	O
three	O	O	O
of	O	O	O
the	O	O	O
female	O	O	B-Entity
populations	O	O	B-Entity
produced	O	O	O
contact	O	O	O
sex	O	O	B-Entity
pheromones	O	O	I-Entity
on	O	O	O
their	O	O	O
elytra	O	O	B-Entity
,	O	O	O
the	O	O	O
females	O	O	B-Entity
of	O	O	O
the	O	O	O
mandarin	O	O	B-Entity
orange	O	O	I-Entity
population	O	O	B-Entity
were	O	O	O
predicted	O	O	O
to	O	O	O
possess	O	O	O
extra	O	O	O
chemicals	O	O	B-Entity
that	O	O	O
repelled	O	O	O
the	O	O	O
males	O	O	B-Entity
of	O	O	O
the	O	O	O
other	O	O	O
two	O	O	O
populations	O	O	O
.	O	O	O

β-Elemene	O	O	B-Entity
was	O	O	O
identified	O	O	O
as	O	O	O
a	O	O	O
key	O	O	O
component	O	O	O
that	O	O	O
was	O	O	O
only	O	O	O
found	O	O	O
in	O	O	O
mandarin	O	O	B-Entity
orange	O	O	I-Entity
-fed	O	O	O
females	O	O	B-Entity
and	O	O	O
induced	O	O	O
a	O	O	O
rejection	O	O	B-Entity
response	O	O	B-Entity
in	O	O	O
willow	O	O	B-Entity
-fed	O	O	O
males	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
represent	O	O	O
the	O	O	O
first	O	O	O
example	O	O	O
of	O	O	O
a	O	O	O
female	O	O	B-Entity
-acquired	O	O	O
repellent	O	O	B-Entity
against	O	O	O
conspecific	O	O	O
males	O	O	B-Entity
of	O	O	O
different	O	O	O
host	O	O	B-Entity
plant	O	O	I-Entity
populations	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
the	O	O	O
host	O	O	O
plant	O	O	O
greatly	O	O	O
affects	O	O	O
the	O	O	O
female	O	O	B-Entity
's	O	O	I-Entity
sexual	O	O	B-Entity
attractiveness	O	O	I-Entity
.	O	O	O

-DOCSTART- (27412759)

Molecular	O	O	B-Entity
detection	O	O	B-Entity
of	O	O	O
infection	O	O	B-Entity
homogeneity	O	O	B-Entity
and	O	O	O
impact	O	O	B-Entity
of	O	O	O
miltefosine	O	O	B-Entity
treatment	O	O	B-Entity
in	O	O	O
a	O	O	O
Syrian	O	O	B-Entity
golden	O	O	I-Entity
hamster	O	O	I-Entity
model	O	O	O
of	O	O	O
Leishmania	O	O	B-Entity
donovani	O	O	I-Entity
and	O	O	O
L.	O	O	B-Entity
infantum	O	O	I-Entity
visceral	O	O	O
leishmaniasis	O	O	O

Control	O	O	B-Entity
of	O	O	O
visceral	O	O	B-Entity
leishmaniasis	O	O	I-Entity
caused	O	O	O
by	O	O	O
Leishmania	O	O	B-Entity
infantum	O	O	I-Entity
and	O	O	O
Leishmania	O	O	B-Entity
donovani	O	O	I-Entity
primarily	O	O	O
relies	O	O	O
on	O	O	O
chemotherapy	O	O	B-Entity
using	O	O	O
an	O	O	O
increasingly	O	O	O
compromised	O	O	B-Entity
repertoire	O	O	O
of	O	O	O
antileishmanial	O	O	B-Entity
compounds	O	O	I-Entity
.	O	O	O

For	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
novel	O	O	B-Entity
drugs	O	O	B-Entity
,	O	O	O
the	O	O	O
Syrian	O	O	B-Entity
golden	O	O	I-Entity
hamster	O	O	I-Entity
is	O	O	O
considered	O	O	O
as	O	O	O
a	O	O	O
clinically	O	O	B-Entity
relevant	O	O	B-Entity
laboratory	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
two	O	O	O
molecular	O	O	B-Entity
parasite	O	O	I-Entity
detection	O	O	I-Entity
assays	O	O	I-Entity
were	O	O	O
developed	O	O	O
targeting	O	O	B-Entity
cathepsin-like	O	O	B-Entity
cysteine	O	O	I-Entity
protease	O	O	I-Entity
B	O	O	I-Entity
(	O	O	O
CPB	O	O	B-Entity
)	O	O	O
DNA	O	O	B-Entity
and	O	O	O
18S	O	O	O
rRNA	O	O	B-Entity
to	O	O	O
achieve	O	O	O
absolute	O	O	B-Entity
amastigote	O	O	B-Entity
quantification	O	O	B-Entity
in	O	O	O
the	O	O	O
major	O	O	O
target	O	O	B-Entity
organs	O	O	B-Entity
liver	O	O	B-Entity
and	O	O	O
spleen	O	O	B-Entity
.	O	O	O

Both	O	O	O
quantitative	O	O	B-Entity
PCR	O	O	I-Entity
(	O	O	B-Entity
qPCR	O	O	I-Entity
)	O	O	I-Entity
techniques	O	O	I-Entity
showed	O	O	O
excellent	O	O	O
agreement	O	O	O
with	O	O	O
a	O	O	O
strong	O	O	O
correlation	O	O	B-Entity
with	O	O	O
the	O	O	O
conventional	O	O	O
microscopic	O	O	B-Entity
reading	O	O	I-Entity
of	O	O	O
Giemsa-stained	O	O	B-Entity
tissue	O	O	B-Entity
smears	O	O	B-Entity
.	O	O	O

Using	O	O	O
multiple	O	O	B-Entity
single	O	O	B-Entity
tissue	O	O	B-Entity
pieces	O	O	I-Entity
and	O	O	O
all	O	O	O
three	O	O	O
detection	O	O	B-Entity
methods	O	O	B-Entity
,	O	O	O
we	O	O	O
confirmed	O	O	O
homogeneity	O	O	B-Entity
of	O	O	O
infection	O	O	B-Entity
in	O	O	O
liver	O	O	B-Entity
and	O	O	O
spleen	O	O	B-Entity
and	O	O	O
the	O	O	O
robustness	O	O	B-Entity
of	O	O	O
extrapolating	O	O	O
whole	O	O	B-Entity
organ	O	O	I-Entity
burdens	O	O	I-Entity
from	O	O	O
a	O	O	O
small	O	O	B-Entity
single	O	O	O
tissue	O	O	B-Entity
piece	O	O	I-Entity
.	O	O	O

Comparison	O	O	B-Entity
of	O	O	O
pre	O	O	B-Entity
-	O	O	O
and	O	O	O
post-treatment	O	O	B-Entity
burdens	O	O	B-Entity
in	O	O	O
infected	O	O	B-Entity
hamsters	O	O	B-Entity
using	O	O	O
the	O	O	O
three	O	O	O
detection	O	O	B-Entity
methods	O	O	B-Entity
consistently	O	O	O
revealed	O	O	B-Entity
a	O	O	O
stronger	O	O	O
parasite	O	O	B-Entity
reduction	O	O	B-Entity
in	O	O	O
the	O	O	O
spleen	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
liver	O	O	B-Entity
,	O	O	O
indicating	O	O	O
an	O	O	O
organ	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
clearance	O	O	B-Entity
efficacy	O	O	B-Entity
for	O	O	O
miltefosine	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
this	O	O	O
study	O	O	B-Entity
in	O	O	O
the	O	O	O
hamster	O	O	B-Entity
demonstrated	O	O	O
high	O	O	B-Entity
homogeneity	O	O	B-Entity
of	O	O	O
infection	O	O	B-Entity
in	O	O	O
liver	O	O	B-Entity
and	O	O	O
spleen	O	O	B-Entity
and	O	O	O
advocates	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
molecular	O	O	B-Entity
detection	O	O	B-Entity
methods	O	O	B-Entity
for	O	O	O
assessment	O	O	B-Entity
of	O	O	O
low	O	O	B-Entity
(	O	O	O
post-treatment	O	O	B-Entity
)	O	O	O
tissue	O	O	B-Entity
burdens	O	O	B-Entity
.	O	O	O

-DOCSTART- (27415391)

Approximate	O	O	B-Entity
Bayesian	O	O	B-Entity
computation	O	O	I-Entity
for	O	O	O
estimating	O	O	B-Entity
number	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
monodisperse	O	O	B-Entity
nanoparticles	O	O	B-Entity
in	O	O	O
suspension	O	O	B-Entity
by	O	O	O
optical	O	O	O
microscopy	O	O	O

We	O	O	O
present	O	O	B-Entity
an	O	O	O
approximate	O	O	B-Entity
Bayesian	O	O	B-Entity
computation	O	O	I-Entity
scheme	O	O	B-Entity
for	O	O	O
estimating	O	O	B-Entity
number	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
monodisperse	O	O	B-Entity
diffusing	O	O	B-Entity
nanoparticles	O	O	B-Entity
in	O	O	O
suspension	O	O	B-Entity
by	O	O	O
optical	O	O	B-Entity
particle	O	O	I-Entity
tracking	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

The	O	O	O
method	O	O	B-Entity
is	O	O	O
based	O	O	B-Entity
on	O	O	O
the	O	O	O
probability	O	O	B-Entity
distribution	O	O	I-Entity
of	O	O	O
the	O	O	O
time	O	O	B-Entity
spent	O	O	B-Entity
by	O	O	O
a	O	O	O
particle	O	O	B-Entity
inside	O	O	B-Entity
a	O	O	O
detection	O	O	B-Entity
region	O	O	B-Entity
.	O	O	O

We	O	O	O
validate	O	O	O
the	O	O	O
method	O	O	B-Entity
on	O	O	O
suspensions	O	O	B-Entity
of	O	O	O
well-controlled	O	O	B-Entity
reference	O	O	B-Entity
particles	O	O	B-Entity
.	O	O	O

We	O	O	O
illustrate	O	O	O
its	O	O	O
usefulness	O	O	B-Entity
with	O	O	O
an	O	O	O
application	O	O	B-Entity
in	O	O	O
gene	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
applying	O	O	B-Entity
the	O	O	O
method	O	O	B-Entity
to	O	O	O
estimate	O	O	B-Entity
number	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
plasmid	O	O	B-Entity
DNA	O	O	B-Entity
molecules	O	O	I-Entity
and	O	O	O
the	O	O	O
average	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
DNA	O	O	O
molecules	O	O	O
complexed	O	O	B-Entity
with	O	O	O
liposomal	O	O	B-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
particles	O	O	B-Entity
.	O	O	O

-DOCSTART- (27417076)

Gestational	O	O	B-Entity
age	O	O	I-Entity
specific	O	O	O
stillbirth	O	O	B-Entity
risk	O	O	B-Entity
among	O	O	O
Indigenous	O	O	B-Entity
and	O	O	O
non	O	O	B-Entity
-	O	O	O
Indigenous	O	O	O
women	O	O	B-Entity
in	O	O	O
Queensland	O	O	B-Entity
,	O	O	O
Australia	O	O	B-Entity
:	O	O	O
a	O	O	O
population	O	O	O
based	O	O	O
study	O	O	O

In	O	O	O
Australia	O	O	B-Entity
,	O	O	O
significant	O	O	O
disparity	O	O	O
persists	O	O	O
in	O	O	O
stillbirth	O	O	B-Entity
rates	O	O	B-Entity
between	O	O	O
Aboriginal	O	O	B-Entity
and	O	O	O
Torres	O	O	B-Entity
Strait	O	O	I-Entity
Islander	O	O	I-Entity
(	O	O	O
Indigenous	O	O	B-Entity
Australian	O	O	I-Entity
)	O	O	O
and	O	O	O
non	O	O	B-Entity
-	O	O	O
Indigenous	O	O	O
women	O	O	B-Entity
.	O	O	O

Diabetes	O	O	B-Entity
,	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
antepartum	O	O	B-Entity
haemorrhage	O	O	I-Entity
and	O	O	O
small-for-gestational	O	O	B-Entity
age	O	O	I-Entity
(	O	O	O
SGA	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
identified	O	O	B-Entity
as	O	O	O
important	O	O	B-Entity
contributors	O	O	O
to	O	O	O
higher	O	O	O
rates	O	O	B-Entity
among	O	O	O
Indigenous	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
examine	O	O	O
gestational	O	O	B-Entity
age	O	O	I-Entity
specific	O	O	O
risk	O	O	B-Entity
of	O	O	O
stillbirth	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
these	O	O	O
conditions	O	O	B-Entity
among	O	O	O
Indigenous	O	O	B-Entity
and	O	O	O
non	O	O	B-Entity
-	O	O	O
Indigenous	O	O	O
women	O	O	B-Entity
.	O	O	O

Retrospective	O	O	B-Entity
population-based	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
all	O	O	O
singleton	O	O	B-Entity
births	O	O	B-Entity
of	O	O	O
at	O	O	O
least	O	O	O
20	O	O	O
weeks	O	O	B-Entity
gestation	O	O	B-Entity
or	O	O	O
at	O	O	O
least	O	O	O
400	O	O	O
grams	O	O	B-Entity
birthweight	O	O	B-Entity
in	O	O	O
Queensland	O	O	B-Entity
between	O	O	O
July	O	O	B-Entity
2005	O	O	O
and	O	O	O
December	O	O	B-Entity
2011	O	O	O
using	O	O	O
data	O	O	B-Entity
from	O	O	O
the	O	O	O
Queensland	O	O	O
Perinatal	O	O	B-Entity
Data	O	O	B-Entity
Collection	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
routinely-maintained	O	O	B-Entity
database	O	O	I-Entity
that	O	O	O
collects	O	O	O
data	O	O	O
on	O	O	O
all	O	O	O
births	O	O	O
in	O	O	O
Queensland	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
calculate	O	O	O
adjusted	O	O	B-Entity
odds	O	O	I-Entity
ratios	O	O	I-Entity
(	O	O	O
aOR	O	O	B-Entity
)	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
,	O	O	O
adjusting	O	O	O
for	O	O	O
maternal	O	O	B-Entity
demographic	O	O	B-Entity
and	O	O	O
pregnancy	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Of	O	O	O
360987	O	O	O
births	O	O	B-Entity
analysed	O	O	B-Entity
,	O	O	O
20273	O	O	O
(	O	O	O
5.6	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
to	O	O	O
Indigenous	O	O	B-Entity
women	O	O	B-Entity
and	O	O	O
340714	O	O	O
(	O	O	O
94.4	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
to	O	O	O
non	O	O	B-Entity
-	O	O	O
Indigenous	O	O	O
women	O	O	O
.	O	O	O

Stillbirth	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
7.9	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
6.8	O	O	O
-	O	O	O
9.2	O	O	O
)	O	O	O
and	O	O	O
4.1	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
3.9	O	O	O
-	O	O	O
4.3	O	O	O
)	O	O	O
per	O	O	O
1000	O	O	O
births	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

For	O	O	O
both	O	O	O
Indigenous	O	O	B-Entity
and	O	O	O
non	O	O	B-Entity
-	O	O	O
Indigenous	O	O	O
women	O	O	B-Entity
across	O	O	O
most	O	O	O
gestational	O	O	B-Entity
age	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
antepartum	O	O	B-Entity
haemorrhage	O	O	I-Entity
,	O	O	O
SGA	O	O	B-Entity
,	O	O	O
pre-existing	O	O	B-Entity
diabetes	O	O	I-Entity
and	O	O	O
pre-existing	O	O	B-Entity
hypertension	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
stillbirth	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
mixed	O	O	O
results	O	O	O
for	O	O	O
pre-eclampsia	O	O	B-Entity
and	O	O	O
eclampsia	O	O	B-Entity
and	O	O	O
a	O	O	O
consistently	O	O	O
raised	O	O	O
risk	O	O	B-Entity
of	O	O	O
stillbirth	O	O	B-Entity
was	O	O	O
not	O	O	O
seen	O	O	O
for	O	O	O
gestational	O	O	B-Entity
diabetes	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
highlights	O	O	O
gestational	O	O	B-Entity
age	O	O	I-Entity
specific	O	O	O
stillbirth	O	O	B-Entity
risk	O	O	B-Entity
for	O	O	O
Indigenous	O	O	B-Entity
and	O	O	O
non	O	O	B-Entity
-	O	O	O
Indigenous	O	O	O
women	O	O	B-Entity
;	O	O	O
and	O	O	O
disparity	O	O	O
in	O	O	O
risk	O	O	O
at	O	O	O
term	O	O	B-Entity
gestations	O	O	I-Entity
.	O	O	O

Improving	O	O	O
access	O	O	O
to	O	O	O
and	O	O	O
utilisation	O	O	O
of	O	O	O
appropriate	O	O	B-Entity
and	O	O	O
responsive	O	O	B-Entity
healthcare	O	O	B-Entity
may	O	O	O
help	O	O	O
to	O	O	O
address	O	O	O
disparities	O	O	O
in	O	O	O
stillbirth	O	O	B-Entity
risk	O	O	B-Entity
for	O	O	O
Indigenous	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

-DOCSTART- (27417211)

Defining	O	O	B-Entity
,	O	O	O
Describing	O	O	B-Entity
,	O	O	O
and	O	O	O
Categorizing	O	O	B-Entity
Public	O	O	B-Entity
Health	O	O	I-Entity
Infrastructure	O	O	I-Entity
Priorities	O	O	B-Entity
for	O	O	O
Tropical	O	O	B-Entity
Cyclone	O	O	I-Entity
,	O	O	O
Flood	O	O	B-Entity
,	O	O	O
Storm	O	O	B-Entity
,	O	O	O
Tornado	O	O	B-Entity
,	O	O	O
and	O	O	O
Tsunami-Related	O	O	O
Disasters	O	O	O

The	O	O	O
study	O	O	B-Entity
aim	O	O	O
was	O	O	O
to	O	O	O
undertake	O	O	O
a	O	O	O
qualitative	O	O	O
research	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
to	O	O	O
analyze	O	O	O
available	O	O	O
databases	O	O	B-Entity
to	O	O	O
define	O	O	B-Entity
,	O	O	O
describe	O	O	B-Entity
,	O	O	O
and	O	O	O
categorize	O	O	B-Entity
public	O	O	B-Entity
health	O	O	I-Entity
infrastructure	O	O	I-Entity
(	O	O	O
PHI	O	O	B-Entity
)	O	O	O
priorities	O	O	B-Entity
for	O	O	O
tropical	O	O	B-Entity
cyclone	O	O	I-Entity
,	O	O	O
flood	O	O	B-Entity
,	O	O	O
storm	O	O	B-Entity
,	O	O	O
tornado	O	O	B-Entity
,	O	O	O
and	O	O	O
tsunami-related	O	O	B-Entity
disasters	O	O	I-Entity
.	O	O	O

Five	O	O	O
electronic	O	O	O
publication	O	O	B-Entity
databases	O	O	I-Entity
were	O	O	O
searched	O	O	O
to	O	O	O
define	O	O	B-Entity
,	O	O	O
describe	O	O	B-Entity
,	O	O	O
or	O	O	O
categorize	O	O	B-Entity
PHI	O	O	B-Entity
and	O	O	O
discuss	O	O	B-Entity
tropical	O	O	B-Entity
cyclone	O	O	I-Entity
,	O	O	O
flood	O	O	B-Entity
,	O	O	O
storm	O	O	B-Entity
,	O	O	O
tornado	O	O	B-Entity
,	O	O	O
and	O	O	O
tsunami-related	O	O	B-Entity
disasters	O	O	I-Entity
and	O	O	O
their	O	O	O
impact	O	O	B-Entity
on	O	O	O
PHI	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
through	O	O	O
aggregation	O	O	B-Entity
of	O	O	O
individual	O	O	O
articles	O	O	B-Entity
to	O	O	O
create	O	O	O
an	O	O	O
overall	O	O	O
data	O	O	O
description	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
were	O	O	O
grouped	O	O	B-Entity
into	O	O	O
PHI	O	O	B-Entity
themes	O	O	B-Entity
,	O	O	O
which	O	O	O
were	O	O	O
then	O	O	O
prioritized	O	O	B-Entity
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
degree	O	O	O
of	O	O	O
interdependency	O	O	O
.	O	O	O

Sixty-seven	O	O	O
relevant	O	O	O
articles	O	O	B-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

PHI	O	O	B-Entity
was	O	O	O
categorized	O	O	B-Entity
into	O	O	O
13	O	O	O
themes	O	O	B-Entity
with	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
158	O	O	O
descriptors	O	O	B-Entity
.	O	O	O

The	O	O	O
highest	O	O	O
priority	O	O	B-Entity
PHI	O	O	B-Entity
identified	O	O	O
was	O	O	O
workforce	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
followed	O	O	O
by	O	O	O
water	O	O	B-Entity
,	O	O	O
sanitation	O	O	B-Entity
,	O	O	O
equipment	O	O	B-Entity
,	O	O	O
communication	O	O	B-Entity
,	O	O	O
physical	O	O	B-Entity
structure	O	O	I-Entity
,	O	O	O
power	O	O	B-Entity
,	O	O	O
governance	O	O	B-Entity
,	O	O	O
prevention	O	O	B-Entity
,	O	O	O
supplies	O	O	B-Entity
,	O	O	O
service	O	O	B-Entity
,	O	O	O
transport	O	O	B-Entity
,	O	O	O
and	O	O	O
surveillance	O	O	B-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
identified	O	O	O
workforce	O	O	B-Entity
as	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
of	O	O	O
the	O	O	O
13	O	O	O
thematic	O	O	B-Entity
areas	O	O	I-Entity
related	O	O	O
to	O	O	O
PHI	O	O	B-Entity
and	O	O	O
disasters	O	O	B-Entity
.	O	O	O

If	O	O	O
its	O	O	O
functionality	O	O	O
fails	O	O	O
,	O	O	O
workforce	O	O	B-Entity
has	O	O	O
the	O	O	O
greatest	O	O	O
impact	O	O	O
on	O	O	O
the	O	O	O
performance	O	O	O
of	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

If	O	O	O
addressed	O	O	O
post-disaster	O	O	B-Entity
,	O	O	O
the	O	O	O
remaining	O	O	O
forms	O	O	O
of	O	O	O
PHI	O	O	B-Entity
will	O	O	O
then	O	O	O
be	O	O	O
progressively	O	O	O
addressed	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
are	O	O	O
a	O	O	O
step	O	O	O
toward	O	O	O
providing	O	O	O
an	O	O	O
evidence	O	O	O
base	O	O	O
to	O	O	O
inform	O	O	O
PHI	O	O	B-Entity
priorities	O	O	B-Entity
in	O	O	O
the	O	O	O
disaster	O	O	B-Entity
setting	O	O	O
.	O	O	O

(	O	O	O
Disaster	O	O	O
Med	O	O	O
Public	O	O	O
Health	O	O	O
Preparedness	O	O	O
.	O	O	O

2016;10:598	O	O	O
-	O	O	O
610	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27418256)

Fragment	O	O	B-Entity
-Based	O	O	O
Discovery	O	O	B-Entity
of	O	O	O
5-Arylisatin	O	O	B-Entity
-Based	O	O	O
Inhibitors	O	O	B-Entity
of	O	O	O
Matrix	O	O	B-Entity
Metalloproteinases	O	O	I-Entity
2	O	O	I-Entity
and	O	O	O
13	O	O	O

Matrix	O	O	B-Entity
metalloproteinases	O	O	I-Entity
(	O	O	O
MMPs	O	O	B-Entity
)	O	O	O
are	O	O	O
well-established	O	O	O
targets	O	O	O
for	O	O	O
several	O	O	O
pathologies	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
MMP-2	O	O	B-Entity
and	O	O	O
MMP-13	O	O	B-Entity
play	O	O	O
a	O	O	O
prominent	O	O	O
role	O	O	O
in	O	O	O
cancer	O	O	B-Entity
progression	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
structure-based	O	O	B-Entity
screening	O	O	I-Entity
campaign	O	O	O
was	O	O	O
applied	O	O	O
to	O	O	O
prioritize	O	O	O
metalloproteinase	O	O	B-Entity
-oriented	O	O	O
fragments	O	O	B-Entity
.	O	O	O

This	O	O	O
computational	O	O	B-Entity
model	O	O	I-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
a	O	O	O
representative	O	O	O
fragment	O	O	B-Entity
set	O	O	B-Entity
from	O	O	O
the	O	O	O
publically	O	O	O
available	O	O	O
EDASA	O	O	B-Entity
Scientific	O	O	I-Entity
compound	O	O	I-Entity
library	O	O	I-Entity
.	O	O	O

These	O	O	O
fragments	O	O	B-Entity
were	O	O	O
prioritized	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
top-ranking	O	O	O
hits	O	O	O
were	O	O	O
tested	O	O	O
in	O	O	O
a	O	O	O
biological	O	O	B-Entity
assay	O	O	I-Entity
to	O	O	O
validate	O	O	B-Entity
the	O	O	O
model	O	O	B-Entity
.	O	O	O

Two	O	O	O
scaffolds	O	O	B-Entity
showed	O	O	O
consistent	O	O	O
activity	O	O	B-Entity
in	O	O	O
the	O	O	O
assay	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
isatin-based	O	O	B-Entity
compounds	O	O	I-Entity
were	O	O	O
the	O	O	O
most	O	O	O
interesting	O	O	O
.	O	O	O

These	O	O	O
latter	O	O	O
fragments	O	O	B-Entity
have	O	O	O
significant	O	O	O
potential	O	O	O
as	O	O	O
tools	O	O	O
for	O	O	O
the	O	O	O
design	O	O	B-Entity
and	O	O	O
realization	O	O	O
of	O	O	O
novel	O	O	O
MMP	O	O	B-Entity
inhibitors	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
their	O	O	O
micromolar	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
the	O	O	O
chemical	O	O	B-Entity
synthesis	O	O	I-Entity
affords	O	O	O
flexible	O	O	B-Entity
and	O	O	O
creative	O	O	B-Entity
access	O	O	I-Entity
to	O	O	O
their	O	O	O
analogues	O	O	B-Entity
.	O	O	O

-DOCSTART- (27427129)

Incidence	O	O	B-Entity
of	O	O	O
environmental	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
factors	O	O	I-Entity
causing	O	O	O
congenital	O	O	B-Entity
cataract	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
of	O	O	O
Lahore	O	O	O

To	O	O	O
check	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
environmental	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
factors	O	O	I-Entity
causing	O	O	O
congenital	O	O	B-Entity
cataract	O	O	I-Entity
in	O	O	O
infants	O	O	B-Entity
.	O	O	O

The	O	O	O
descriptive	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
at	O	O	O
Layton	O	O	B-Entity
Rahmatullah	O	O	I-Entity
Benevolent	O	O	I-Entity
Trust	O	O	I-Entity
,	O	O	O
Lahore	O	O	B-Entity
,	O	O	O
Pakistan	O	O	B-Entity
,	O	O	O
from	O	O	O
October	O	O	O
2013	O	O	O
to	O	O	O
April	O	O	O
2014	O	O	O
,	O	O	O
and	O	O	O
comprised	O	O	O
children	O	O	B-Entity
under	O	O	O
15	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
who	O	O	O
had	O	O	O
rubella	O	O	B-Entity
syndrome	O	O	I-Entity
,	O	O	O
herpes	O	O	B-Entity
simplex	O	O	I-Entity
,	O	O	O
birth	O	O	B-Entity
trauma	O	O	I-Entity
,	O	O	O
trisomy	O	O	B-Entity
21	O	O	I-Entity
,	O	O	O
Nance-Horan	O	O	B-Entity
syndrome	O	O	I-Entity
or	O	O	O
Lowe	O	O	B-Entity
's	O	O	I-Entity
syndrome	O	O	I-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
38,000	O	O	O
cases	O	O	B-Entity
examined	O	O	O
,	O	O	O
120(0.3	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
cataract	O	O	I-Entity
.	O	O	O

Of	O	O	O
them	O	O	O
,	O	O	O
52(43.33%)were	O	O	O
aged	O	O	B-Entity
between	O	O	O
2	O	O	O
and	O	O	O
5	O	O	O
years	O	O	B-Entity
,	O	O	O
22(18.33	O	O	O
%	O	O	O
)	O	O	O
<	O	O	O
11	O	O	O
years	O	O	O
and	O	O	O
10(8.33	O	O	O
%	O	O	O
)	O	O	O
?	O	O	O
15	O	O	O
years	O	O	O
.	O	O	O

Bilateral	O	O	B-Entity
congenital	O	O	I-Entity
cataract	O	O	I-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
91(75.83	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
and	O	O	O
unilateral	O	O	B-Entity
congenital	O	O	I-Entity
cataract	O	O	I-Entity
in	O	O	O
29(24.17	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Environmental	O	O	B-Entity
factors	O	O	I-Entity
caused	O	O	O
72(62.07	O	O	O
%	O	O	O
)	O	O	O
cases	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
factors	O	O	I-Entity
caused	O	O	O
44(37.93	O	O	O
%	O	O	O
)	O	O	O
..	O	O	O

Congenital	O	O	B-Entity
cataract	O	O	I-Entity
predominated	O	O	B-Entity
in	O	O	O
boys	O	O	B-Entity
compared	O	O	O
to	O	O	O
girls	O	O	B-Entity
.	O	O	O

Early	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
adequate	O	O	O
therapy	O	O	B-Entity
requires	O	O	O
specific	O	O	O
technology	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
long-term	O	O	B-Entity
and	O	O	O
permanent	O	O	B-Entity
care	O	O	B-Entity
..	O	O	O

-DOCSTART- (27428958)

Transcriptome	O	O	B-Entity
and	O	O	O
Metabolome	O	O	B-Entity
Analyses	O	O	B-Entity
of	O	O	O
Glucosinolates	O	O	B-Entity
in	O	O	O
Two	O	O	O
Broccoli	O	O	B-Entity
Cultivars	O	O	I-Entity
Following	O	O	O
Jasmonate	O	O	B-Entity
Treatment	O	O	B-Entity
for	O	O	O
the	O	O	O
Induction	O	O	B-Entity
of	O	O	O
Glucosinolate	O	O	B-Entity
Defense	O	O	B-Entity
to	O	O	O
Trichoplusia	O	O	B-Entity
ni	O	O	I-Entity
(	O	O	O
Hübner	O	O	B-Entity
)	O	O	O

Lepidopteran	O	O	B-Entity
larvae	O	O	B-Entity
growth	O	O	B-Entity
is	O	O	O
influenced	O	O	B-Entity
by	O	O	O
host	O	O	B-Entity
plant	O	O	B-Entity
glucosinolate	O	O	B-Entity
(	O	O	O
GS	O	O	B-Entity
)	O	O	O
concentrations	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
,	O	O	O
in	O	O	O
turn	O	O	O
,	O	O	O
influenced	O	O	O
by	O	O	O
the	O	O	O
phytohormone	O	O	B-Entity
jasmonate	O	O	B-Entity
(	O	O	O
JA	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
elucidate	O	O	O
insect	O	O	B-Entity
resistance	O	O	B-Entity
biomarkers	O	O	B-Entity
to	O	O	O
lepidopteran	O	O	B-Entity
pests	O	O	B-Entity
,	O	O	O
transcriptome	O	O	B-Entity
and	O	O	O
metabolome	O	O	B-Entity
analyses	O	O	B-Entity
following	O	O	O
JA	O	O	B-Entity
treatments	O	O	B-Entity
were	O	O	O
conducted	O	O	O
with	O	O	O
two	O	O	O
broccoli	O	O	B-Entity
cultivars	O	O	I-Entity
,	O	O	O
Green	O	O	B-Entity
Magic	O	O	I-Entity
and	O	O	O
VI-158	O	O	B-Entity
,	O	O	O
which	O	O	O
have	O	O	O
differentially	O	O	O
induced	O	O	B-Entity
indole	O	O	B-Entity
GSs	O	O	I-Entity
,	O	O	O
neoglucobrassicin	O	O	B-Entity
and	O	O	O
glucobrassicin	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

To	O	O	O
test	O	O	B-Entity
these	O	O	O
two	O	O	O
inducible	O	O	B-Entity
GSs	O	O	B-Entity
on	O	O	O
growth	O	O	B-Entity
of	O	O	O
cabbage	O	O	B-Entity
looper	O	O	I-Entity
(	O	O	O
Trichoplusia	O	O	B-Entity
ni	O	O	I-Entity
)	O	O	O
,	O	O	O
eight	O	O	O
neonate	O	O	O
cabbage	O	O	B-Entity
looper	O	O	I-Entity
larvae	O	O	I-Entity
were	O	O	O
placed	O	O	O
onto	O	O	O
each	O	O	O
of	O	O	O
three	O	O	O
plants	O	O	B-Entity
per	O	O	O
JA	O	O	B-Entity
treatments	O	O	B-Entity
(	O	O	O
0	O	O	O
,	O	O	O
100	O	O	O
,	O	O	O
200	O	O	O
,	O	O	O
400	O	O	O
µM	O	O	O
)	O	O	O
three	O	O	O
days	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
.	O	O	O

After	O	O	O
five	O	O	O
days	O	O	B-Entity
of	O	O	O
feeding	O	O	B-Entity
,	O	O	O
weight	O	O	B-Entity
of	O	O	O
larvae	O	O	B-Entity
and	O	O	O
their	O	O	O
survival	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
decrease	O	O	B-Entity
with	O	O	O
increasing	O	O	B-Entity
JA	O	O	B-Entity
concentrations	O	O	B-Entity
in	O	O	O
both	O	O	O
broccoli	O	O	B-Entity
cultivars	O	O	I-Entity
.	O	O	O

JA	O	O	B-Entity
-	O	O	O
inducible	O	O	B-Entity
GSs	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
high	O	O	B-Entity
performance	O	O	I-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
.	O	O	O

Neoglucobrassicin	O	O	B-Entity
in	O	O	O
Green	O	O	B-Entity
Magic	O	O	I-Entity
and	O	O	O
glucobrassicin	O	O	B-Entity
in	O	O	O
VI-158	O	O	B-Entity
leaves	O	O	B-Entity
were	O	O	O
increased	O	O	B-Entity
in	O	O	O
a	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

One	O	O	O
or	O	O	O
both	O	O	O
of	O	O	O
these	O	O	O
glucosinolates	O	O	B-Entity
and/or	O	O	O
their	O	O	O
hydrolysis	O	O	B-Entity
products	O	O	B-Entity
showed	O	O	O
significant	O	O	O
inverse	O	O	B-Entity
correlations	O	O	B-Entity
with	O	O	O
larval	O	O	B-Entity
weight	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
(	O	O	O
five	O	O	O
days	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
)	O	O	O
while	O	O	O
being	O	O	O
positively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
days	O	O	O
to	O	O	O
pupation	O	O	B-Entity
.	O	O	O

This	O	O	O
implies	O	O	O
that	O	O	O
these	O	O	O
two	O	O	O
JA	O	O	B-Entity
-	O	O	O
inducible	O	O	B-Entity
glucosinolates	O	O	B-Entity
can	O	O	O
influence	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
of	O	O	O
cabbage	O	O	B-Entity
looper	O	O	I-Entity
larvae	O	O	I-Entity
.	O	O	O

Transcriptome	O	O	B-Entity
profiling	O	O	I-Entity
supported	O	O	O
the	O	O	O
observed	O	O	O
changes	O	O	B-Entity
in	O	O	O
glucosinolate	O	O	B-Entity
and	O	O	O
their	O	O	O
hydrolysis	O	O	B-Entity
product	O	O	B-Entity
concentrations	O	O	B-Entity
following	O	O	O
JA	O	O	B-Entity
treatments	O	O	B-Entity
.	O	O	O

Several	O	O	O
genes	O	O	B-Entity
related	O	O	O
to	O	O	O
GS	O	O	B-Entity
metabolism	O	O	B-Entity
differentiate	O	O	B-Entity
the	O	O	O
two	O	O	O
broccoli	O	O	B-Entity
cultivars	O	O	I-Entity
in	O	O	O
their	O	O	O
pattern	O	O	B-Entity
of	O	O	O
transcriptional	O	O	B-Entity
response	O	O	B-Entity
to	O	O	O
JA	O	O	B-Entity
treatments	O	O	B-Entity
.	O	O	O

Indicative	O	O	O
of	O	O	O
the	O	O	O
corresponding	O	O	O
change	O	O	B-Entity
in	O	O	O
indole	O	O	B-Entity
GS	O	O	I-Entity
concentrations	O	O	B-Entity
,	O	O	O
transcripts	O	O	B-Entity
of	O	O	O
the	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
MYB122	O	O	B-Entity
,	O	O	O
core	O	O	O
structure	O	O	O
biosynthesis	O	O	B-Entity
genes	O	O	B-Entity
(	O	O	O
CYP79B2	O	O	B-Entity
,	O	O	O
UGT74B1	O	O	B-Entity
,	O	O	O
SUR1	O	O	B-Entity
,	O	O	O
SOT16	O	O	B-Entity
,	O	O	O
SOT17	O	O	B-Entity
,	O	O	O
and	O	O	O
SOT18	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
indole	O	O	B-Entity
glucosinolate	O	O	B-Entity
side	O	O	O
chain	O	O	O
modification	O	O	B-Entity
gene	O	O	B-Entity
(	O	O	O
IGMT1	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
several	O	O	O
glucosinolate	O	O	O
hydrolysis	O	O	B-Entity
genes	O	O	O
(	O	O	O
TGG1	O	O	B-Entity
,	O	O	O
TGG2	O	O	B-Entity
,	O	O	O
and	O	O	O
ESM1	O	O	B-Entity
)	O	O	O
were	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
Green	O	O	B-Entity
Magic	O	O	I-Entity
(	O	O	O
statistically	O	O	O
significant	O	O	O
in	O	O	O
most	O	O	O
cases	O	O	O
at	O	O	O
400	O	O	O
µM	O	O	O
)	O	O	O
while	O	O	O
UGT74B1	O	O	O
and	O	O	O
MYB122	O	O	O
were	O	O	O
significantly	O	O	O
increased	O	O	O
in	O	O	O
VI-158	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
these	O	O	O
metabolite	O	O	B-Entity
and	O	O	O
transcript	O	O	B-Entity
biomarker	O	O	B-Entity
results	O	O	O
indicate	O	O	O
that	O	O	O
transcriptome	O	O	B-Entity
profiling	O	O	I-Entity
can	O	O	O
identify	O	O	B-Entity
genes	O	O	B-Entity
associated	O	O	O
with	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
two	O	O	O
different	O	O	O
indole	O	O	B-Entity
GS	O	O	I-Entity
and	O	O	O
their	O	O	O
hydrolysis	O	O	B-Entity
products	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
these	O	O	O
metabolite	O	O	B-Entity
and	O	O	O
transcript	O	O	B-Entity
biomarkers	O	O	B-Entity
could	O	O	O
be	O	O	O
useful	O	O	O
in	O	O	O
an	O	O	O
effective	O	O	B-Entity
marker	O	O	B-Entity
-	O	O	O
assisted	O	O	B-Entity
breeding	O	O	B-Entity
strategy	O	O	O
for	O	O	O
resistance	O	O	B-Entity
to	O	O	O
generalist	O	O	O
lepidopteran	O	O	B-Entity
pests	O	O	B-Entity
in	O	O	O
broccoli	O	O	B-Entity
and	O	O	O
potentially	O	O	O
other	O	O	O
Brassica	O	O	B-Entity
vegetables	O	O	I-Entity
.	O	O	O

-DOCSTART- (27429935)

The	O	O	O
clinical	O	O	B-Entity
prognosis	O	O	I-Entity
of	O	O	O
implants	O	O	B-Entity
that	O	O	O
are	O	O	O
placed	O	O	O
against	O	O	O
super-erupted	O	O	B-Entity
opposing	O	O	O
dentition	O	O	O

If	O	O	O
teeth	O	O	B-Entity
are	O	O	O
missing	O	O	B-Entity
,	O	O	O
super-eruption	O	O	B-Entity
of	O	O	I-Entity
teeth	O	O	I-Entity
in	O	O	O
the	O	O	O
opposing	O	O	B-Entity
arch	O	O	I-Entity
can	O	O	O
occur	O	O	O
in	O	O	O
the	O	O	O
area	O	O	B-Entity
and	O	O	O
can	O	O	O
change	O	O	O
the	O	O	O
occlusal	O	O	B-Entity
plane	O	O	I-Entity
.	O	O	O

When	O	O	O
missing	O	O	B-Entity
teeth	O	O	I-Entity
are	O	O	O
replaced	O	O	O
with	O	O	O
implants	O	O	B-Entity
,	O	O	O
the	O	O	O
oral	O	O	B-Entity
surgeon	O	O	I-Entity
must	O	O	O
determine	O	O	O
whether	O	O	O
or	O	O	O
not	O	O	O
the	O	O	O
super-erupted	O	O	B-Entity
teeth	O	O	I-Entity
need	O	O	O
to	O	O	O
be	O	O	O
treated	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
normalize	O	O	B-Entity
the	O	O	O
occlusal	O	O	B-Entity
plane	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
prognosis	O	O	I-Entity
of	O	O	O
dentition	O	O	B-Entity
after	O	O	O
implant	O	O	B-Entity
placement	O	O	I-Entity
and	O	O	O
prosthetic	O	O	B-Entity
treatment	O	O	B-Entity
were	O	O	O
completed	O	O	B-Entity
in	O	O	O
an	O	O	O
occlusal	O	O	B-Entity
plane	O	O	I-Entity
altered	O	O	O
by	O	O	O
super-erupted	O	O	B-Entity
teeth	O	O	I-Entity
in	O	O	O
the	O	O	O
opposing	O	O	B-Entity
arch	O	O	I-Entity
without	O	O	O
additional	O	O	O
treatment	O	O	O
of	O	O	O
the	O	O	O
super-erupted	O	O	O
teeth	O	O	O
.	O	O	O

Twenty-two	O	O	O
patients	O	O	B-Entity
(	O	O	O
9	O	O	O
males	O	O	B-Entity
,	O	O	O
13	O	O	O
females	O	O	B-Entity
)	O	O	O
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
implants	O	O	B-Entity
and	O	O	O
prosthetics	O	O	B-Entity
without	O	O	O
addressing	O	O	O
the	O	O	O
super-erupted	O	O	B-Entity
opposing	O	O	O
dentition	O	O	B-Entity
from	O	O	O
April	O	O	O
2004	O	O	O
to	O	O	O
August	O	O	O
2012	O	O	O
at	O	O	O
Seoul	O	O	B-Entity
National	O	O	B-Entity
University	O	O	I-Entity
Bundang	O	O	I-Entity
Hospital	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
33	O	O	O
implants	O	O	B-Entity
were	O	O	O
placed	O	O	O
.	O	O	O

Values	O	O	O
of	O	O	O
crestal	O	O	B-Entity
bone	O	O	I-Entity
loss	O	O	I-Entity
,	O	O	O
survival	O	O	B-Entity
rates	O	O	I-Entity
,	O	O	O
and	O	O	O
surgical	O	O	B-Entity
and	O	O	O
prosthetic	O	O	B-Entity
complications	O	O	I-Entity
for	O	O	O
an	O	O	O
average	O	O	O
of	O	O	O
29.6	O	O	O
months	O	O	B-Entity
after	O	O	O
prosthetic	O	O	B-Entity
loading	O	O	I-Entity
were	O	O	O
recorded	O	O	O
.	O	O	O

In	O	O	O
one	O	O	O
case	O	O	B-Entity
,	O	O	O
the	O	O	O
cover	O	O	B-Entity
screw	O	O	I-Entity
was	O	O	O
exposed	O	O	O
after	O	O	O
implant	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
crestal	O	O	B-Entity
bone	O	O	I-Entity
loss	O	O	I-Entity
was	O	O	O
0.09±0.30	O	O	O
mm	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
33	O	O	O
implants	O	O	B-Entity
,	O	O	O
31	O	O	O
survived	O	O	B-Entity
,	O	O	O
a	O	O	O
survival	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
93.94	O	O	O
%	O	O	O
.	O	O	O

A	O	O	O
prosthetic	O	O	B-Entity
complication	O	O	I-Entity
occurred	O	O	O
in	O	O	O
one	O	O	O
case	O	O	B-Entity
but	O	O	O
functioned	O	O	O
well	O	O	O
after	O	O	O
correction	O	O	O
.	O	O	O

Favorable	O	O	O
clinical	O	O	B-Entity
results	O	O	I-Entity
from	O	O	O
prosthetic	O	O	B-Entity
complications	O	O	I-Entity
,	O	O	O
crestal	O	O	B-Entity
bone	O	O	I-Entity
loss	O	O	I-Entity
,	O	O	O
and	O	O	O
implant	O	O	B-Entity
survival	O	O	B-Entity
rates	O	O	I-Entity
were	O	O	O
exhibited	O	O	O
in	O	O	O
implants	O	O	B-Entity
next	O	O	O
to	O	O	O
a	O	O	O
super-erupted	O	O	B-Entity
opposing	O	O	I-Entity
tooth	O	O	I-Entity
.	O	O	O

-DOCSTART- (27430662)

Evaluation	O	O	B-Entity
of	O	O	O
Mathisen	O	O	B-Entity
's	O	O	I-Entity
technique	O	O	I-Entity
for	O	O	O
ureteral	O	O	B-Entity
reimplantation	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
primary	O	O	B-Entity
vesicoureteral	O	O	O
reflux	O	O	O

Although	O	O	O
cross-trigonal	O	O	B-Entity
ureteral	O	O	I-Entity
reimplantation	O	O	I-Entity
(	O	O	I-Entity
Cohen	O	O	I-Entity
)	O	O	I-Entity
is	O	O	O
a	O	O	O
commonly	O	O	O
used	O	O	O
technique	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
,	O	O	O
it	O	O	O
represents	O	O	O
a	O	O	O
non-physiological	O	O	B-Entity
transfer	O	O	I-Entity
of	O	O	O
the	O	O	O
ureteral	O	O	B-Entity
orifices	O	O	I-Entity
and	O	O	O
may	O	O	O
prove	O	O	O
challenging	O	O	O
with	O	O	O
regard	O	O	O
to	O	O	O
endoscopic	O	O	B-Entity
ureteral	O	O	I-Entity
operations	O	O	I-Entity
in	O	O	O
later	O	O	B-Entity
life	O	O	B-Entity
.	O	O	O

In	O	O	O
1964	O	O	O
,	O	O	O
Mathisen	O	O	O
described	O	O	B-Entity
an	O	O	O
alternative	O	O	B-Entity
method	O	O	B-Entity
of	O	O	O
ureteral	O	O	B-Entity
reimplantation	O	O	I-Entity
with	O	O	O
lateralization	O	O	B-Entity
of	O	O	O
the	O	O	O
neohiatus	O	O	B-Entity
,	O	O	O
creating	O	O	O
an	O	O	O
orthotopic	O	O	B-Entity
course	O	O	B-Entity
of	O	O	O
the	O	O	O
submucosal	O	O	B-Entity
ureter	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
evaluated	O	O	B-Entity
success	O	O	B-Entity
and	O	O	O
complication	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
both	O	O	O
techniques	O	O	B-Entity
that	O	O	O
were	O	O	O
applied	O	O	B-Entity
sequentially	O	O	B-Entity
at	O	O	O
our	O	O	O
departments	O	O	B-Entity
.	O	O	O

Forty-eight	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
83	O	O	O
ureters	O	O	B-Entity
,	O	O	O
24	O	O	O
males	O	O	B-Entity
/24	O	O	O
females	O	O	B-Entity
)	O	O	O
following	O	O	O
Mathisen	O	O	B-Entity
reimplantation	O	O	I-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
53	O	O	O
consecutive	O	O	O
patients	O	O	O
(	O	O	O
98	O	O	O
ureters	O	O	O
,	O	O	O
30	O	O	O
males	O	O	O
/23	O	O	O
females	O	O	O
)	O	O	O
following	O	O	O
Cohen	O	O	B-Entity
reimplantation	O	O	I-Entity
.	O	O	O

Inclusion	O	O	B-Entity
criteria	O	O	B-Entity
were	O	O	O
primary	O	O	B-Entity
vesicoureteral	O	O	B-Entity
reflux	O	O	I-Entity
(	O	O	O
VUR	O	O	B-Entity
)	O	O	O
and	O	O	O
no	O	O	O
previous	O	O	B-Entity
intervention	O	O	B-Entity
.	O	O	O

Reflux	O	O	B-Entity
grades	O	O	B-Entity
(	O	O	O
Mathisen	O	O	O
58	O	O	O
ureters	O	O	B-Entity
/69.9	O	O	O
%	O	O	O
VUR	O	O	B-Entity
≥	O	O	I-Entity
III	O	O	I-Entity
;	O	O	O
Cohen	O	O	O
66	O	O	O
ureters	O	O	O
/66.7	O	O	O
%	O	O	O
VUR	O	O	O
≥	O	O	O
III	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
occurence	O	O	O
of	O	O	O
other	O	O	O
complicating	O	O	B-Entity
factors	O	O	B-Entity
(	O	O	O
ureteroceles	O	O	B-Entity
,	O	O	O
megaureters	O	O	B-Entity
,	O	O	O
posterior	O	O	B-Entity
urethral	O	O	I-Entity
valves	O	O	I-Entity
)	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
were	O	O	O
comparable	O	O	B-Entity
.	O	O	O

After	O	O	O
Cohen	O	O	B-Entity
's	O	O	I-Entity
reimplantation	O	O	I-Entity
there	O	O	O
were	O	O	O
no	O	O	O
immediate	O	O	B-Entity
complications	O	O	B-Entity
requiring	O	O	O
intervention	O	O	B-Entity
;	O	O	O
during	O	O	B-Entity
follow-up	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
28.2	O	O	O
months	O	O	B-Entity
)	O	O	O
three	O	O	O
patients	O	O	B-Entity
(	O	O	O
5.6	O	O	O
%	O	O	O
)	O	O	O
suffered	O	O	B-Entity
febrile	O	O	B-Entity
urinary	O	O	I-Entity
tract	O	O	I-Entity
infections	O	O	I-Entity
(	O	O	O
UTIs	O	O	B-Entity
)	O	O	O
,	O	O	O
of	O	O	O
which	O	O	O
one	O	O	O
(	O	O	O
1.8	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
a	O	O	O
persisting	O	O	B-Entity
VUR	O	O	B-Entity
.	O	O	O

Persistent	O	O	B-Entity
hydronephroses	O	O	B-Entity
(	O	O	O
≥II	O	O	O
SFU	O	O	B-Entity
)	O	O	O
were	O	O	O
recorded	O	O	O
in	O	O	O
six	O	O	O
patients	O	O	B-Entity
(	O	O	O
13.2	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
reimplantation	O	O	B-Entity
using	O	O	O
Mathisen	O	O	B-Entity
's	O	O	I-Entity
technique	O	O	I-Entity
,	O	O	O
two	O	O	O
patients	O	O	B-Entity
(	O	O	O
4.1	O	O	O
%	O	O	O
)	O	O	O
suffered	O	O	B-Entity
significant	O	O	B-Entity
intravesical	O	O	B-Entity
bleeding	O	O	I-Entity
;	O	O	O
during	O	O	O
follow-up	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
23.06	O	O	O
months	O	O	B-Entity
)	O	O	O
four	O	O	O
patients	O	O	O
(	O	O	O
8.3	O	O	O
%	O	O	O
)	O	O	O
suffered	O	O	O
febrile	O	O	B-Entity
UTIs	O	O	I-Entity
,	O	O	O
and	O	O	O
seven	O	O	O
patients	O	O	O
(	O	O	O
14.5	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
persisting	O	O	B-Entity
VUR	O	O	B-Entity
after	O	O	O
a	O	O	O
mean	O	O	O
follow-up	O	O	O
of	O	O	O
10.8	O	O	O
months	O	O	O
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
with	O	O	O
persistent	O	O	B-Entity
VUR	O	O	B-Entity
had	O	O	O
more	O	O	O
commonly	O	O	O
high-grade	O	O	B-Entity
(	O	O	O
IV	O	O	O
and	O	O	O
V	O	O	O
)	O	O	O
VUR	O	O	O
initially	O	O	O
,	O	O	O
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
whole	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Two	O	O	O
patients	O	O	B-Entity
(	O	O	O
4.1	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
persistent	O	O	B-Entity
hydronephroses	O	O	B-Entity
(	O	O	O
≥II	O	O	O
SFU	O	O	B-Entity
)	O	O	O
.	O	O	O

Mathisen	O	O	B-Entity
's	O	O	I-Entity
technique	O	O	I-Entity
for	O	O	O
ureteral	O	O	B-Entity
reimplantation	O	O	I-Entity
yielded	O	O	O
a	O	O	O
significantly	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0256	O	O	O
patients	O	O	B-Entity
,	O	O	O
p	O	O	O
=	O	O	O
0.006	O	O	O
ureterorenal	O	O	B-Entity
units	O	O	I-Entity
)	O	O	O
lower	O	O	B-Entity
success	O	O	B-Entity
rate	O	O	B-Entity
(	O	O	O
85.5	O	O	O
%	O	O	O
patients	O	O	O
,	O	O	O
89.2	O	O	O
%	O	O	O
ureterorenal	O	O	O
units	O	O	O
)	O	O	O
in	O	O	O
comparison	O	O	B-Entity
with	O	O	O
Cohen	O	O	B-Entity
's	O	O	I-Entity
technique	O	O	I-Entity
(	O	O	O
98.2	O	O	O
%	O	O	O
patients	O	O	O
,	O	O	O
99	O	O	O
%	O	O	O
ureterorenal	O	O	O
units	O	O	O
)	O	O	O
.	O	O	O

Although	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
intervention	O	O	B-Entity
for	O	O	O
obstruction	O	O	B-Entity
,	O	O	O
persistent	O	O	B-Entity
hydronephrosis	O	O	B-Entity
was	O	O	O
more	O	O	O
common	O	O	O
in	O	O	O
the	O	O	O
Cohen	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
13.2	O	O	O
%	O	O	O
vs.	O	O	O
4.1	O	O	O
%	O	O	O
,	O	O	O
n.s	O	O	O
.	O	O	O
)	O	O	O
.	O	O	O

Despite	O	O	O
the	O	O	O
advantages	O	O	O
of	O	O	O
an	O	O	O
orthotopic	O	O	B-Entity
ureteral	O	O	B-Entity
orifice	O	O	I-Entity
close	O	O	O
to	O	O	O
the	O	O	O
bladder	O	O	B-Entity
neck	O	O	I-Entity
,	O	O	O
as	O	O	O
achieved	O	O	O
by	O	O	O
Mathisen	O	O	B-Entity
's	O	O	I-Entity
reimplantation	O	O	I-Entity
,	O	O	O
cross-trigonal	O	O	B-Entity
ureteral	O	O	I-Entity
reimplantation	O	O	I-Entity
proved	O	O	O
more	O	O	O
reliable	O	O	B-Entity
for	O	O	O
VUR	O	O	B-Entity
correction	O	O	B-Entity
.	O	O	O

As	O	O	O
regards	O	O	O
optimizing	O	O	O
the	O	O	O
results	O	O	O
,	O	O	O
patient	O	O	B-Entity
selection	O	O	I-Entity
for	O	O	O
either	O	O	O
technique	O	O	B-Entity
could	O	O	O
prove	O	O	B-Entity
essential	O	O	I-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
as	O	O	O
regards	O	O	O
the	O	O	O
difficulties	O	O	B-Entity
with	O	O	O
ectopic	O	O	B-Entity
ureteral	O	O	B-Entity
orifices	O	O	I-Entity
in	O	O	O
the	O	O	O
Cohen	O	O	B-Entity
technique	O	O	B-Entity
in	O	O	O
the	O	O	O
long-term	O	O	B-Entity
follow-up	O	O	B-Entity
,	O	O	O
the	O	O	O
concept	O	O	B-Entity
of	O	O	O
anatomic	O	O	B-Entity
,	O	O	O
orthotopic	O	O	B-Entity
ureteral	O	O	B-Entity
reimplantation	O	O	I-Entity
should	O	O	O
be	O	O	O
pursued	O	O	O
and	O	O	O
the	O	O	O
technique	O	O	O
should	O	O	O
be	O	O	O
further	O	O	O
refined	O	O	O
.	O	O	O

-DOCSTART- (27432486)

The	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
neonatal	O	O	B-Entity
extracorporeal	O	O	B-Entity
life	O	O	I-Entity
support	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
cardiac	O	O	O
intensive	O	O	O
care	O	O	O
unit	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	O
is	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
extracorporeal	O	O	B-Entity
life	O	O	I-Entity
support	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
ECLS	O	O	B-Entity
)	O	O	O
employed	O	O	O
in	O	O	O
neonates	O	O	B-Entity
in	O	O	O
pediatric	O	O	B-Entity
cardiac	O	O	B-Entity
intensive	O	O	I-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
.	O	O	O

Twenty-five	O	O	O
neonates	O	O	B-Entity
that	O	O	O
required	O	O	O
ECLS	O	O	B-Entity
in	O	O	O
between	O	O	O
November	O	O	O
2010	O	O	O
and	O	O	O
November	O	O	O
2015	O	O	O
were	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

The	O	O	O
median	O	O	B-Entity
age	O	O	B-Entity
was	O	O	O
12	O	O	O
days	O	O	B-Entity
(	O	O	O
range	O	O	B-Entity
3	O	O	O
-	O	O	O
28	O	O	O
days	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
median	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
was	O	O	O
3	O	O	O
kg	O	O	O
(	O	O	O
range	O	O	O
2.5	O	O	O
-	O	O	O
5	O	O	O
kg	O	O	O
)	O	O	O
.	O	O	O

Venoarterial	O	O	B-Entity
ECLS	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
in	O	O	O
all	O	O	O
of	O	O	O
the	O	O	O
cases	O	O	O
.	O	O	O

Ascendan	O	O	B-Entity
aorta	O	O	I-Entity
-	O	O	O
right	O	O	B-Entity
atrial	O	O	I-Entity
cannulation	O	O	B-Entity
in	O	O	O
22	O	O	O
patients	O	O	B-Entity
and	O	O	O
neck	O	O	B-Entity
cannulation	O	O	O
in	O	O	O
three	O	O	O
patients	O	O	O
were	O	O	O
performed	O	O	B-Entity
.	O	O	O

The	O	O	O
reason	O	O	O
for	O	O	O
ECLS	O	O	B-Entity
was	O	O	O
E-CPR	O	O	B-Entity
in	O	O	O
two	O	O	O
patients	O	O	B-Entity
,	O	O	O
inability	O	O	B-Entity
to	O	O	I-Entity
wean	O	O	I-Entity
from	O	O	O
cardiopulmonary	O	O	B-Entity
bypass	O	O	I-Entity
(	O	O	O
CPB	O	O	B-Entity
)	O	O	O
in	O	O	O
seven	O	O	O
patients	O	O	O
,	O	O	O
respiratory	O	O	B-Entity
insufficiency	O	O	I-Entity
and	O	O	O
hypoxia	O	O	B-Entity
in	O	O	O
nine	O	O	O
patients	O	O	O
,	O	O	O
low	O	O	B-Entity
cardiac	O	O	I-Entity
output	O	O	I-Entity
(	O	O	O
LCOS	O	O	B-Entity
)	O	O	O
in	O	O	O
seven	O	O	O
patients	O	O	O
.	O	O	O

Median	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	O
ECLS	O	O	B-Entity
was	O	O	O
four	O	O	O
days	O	O	B-Entity
(	O	O	O
range	O	O	B-Entity
1	O	O	O
-	O	O	O
15	O	O	O
)	O	O	O
.	O	O	O

Hemorrhagic	O	O	B-Entity
complications	O	O	B-Entity
developed	O	O	O
in	O	O	O
15	O	O	O
,	O	O	O
renal	O	O	B-Entity
complications	O	O	I-Entity
in	O	O	O
13	O	O	O
,	O	O	O
pulmonary	O	O	B-Entity
complications	O	O	I-Entity
in	O	O	O
12	O	O	O
,	O	O	O
infectious	O	O	B-Entity
complications	O	O	O
in	O	O	O
11	O	O	O
,	O	O	O
neurologic	O	O	B-Entity
complications	O	O	I-Entity
in	O	O	O
three	O	O	O
and	O	O	O
mechanical	O	O	B-Entity
complications	O	O	I-Entity
in	O	O	O
two	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
.	O	O	O

Weaning	O	O	B-Entity
was	O	O	O
successful	O	O	B-Entity
in	O	O	O
15	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
.	O	O	O

Eleven	O	O	O
patients	O	O	B-Entity
were	O	O	O
successfully	O	O	B-Entity
discharged	O	O	B-Entity
.	O	O	O

ECLS	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	B-Entity
treatment	O	O	B-Entity
option	O	O	I-Entity
that	O	O	O
is	O	O	O
performed	O	O	B-Entity
successfully	O	O	B-Entity
in	O	O	O
many	O	O	O
centers	O	O	B-Entity
around	O	O	O
the	O	O	O
world	O	O	B-Entity
to	O	O	O
maintain	O	O	B-Entity
life	O	O	B-Entity
support	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
unresponsive	O	O	B-Entity
to	O	O	I-Entity
medical	O	O	I-Entity
treatment	O	O	I-Entity
.	O	O	O

The	O	O	O
utilization	O	O	B-Entity
of	O	O	O
this	O	O	O
modality	O	O	B-Entity
especially	O	O	O
in	O	O	O
newborns	O	O	B-Entity
with	O	O	O
congenital	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
should	O	O	O
be	O	O	O
taken	O	O	O
into	O	O	O
consideration	O	O	O
.	O	O	O

-DOCSTART- (27435204)

Medicare	O	O	B-Entity
claims	O	O	B-Entity
indicators	O	O	B-Entity
of	O	O	O
healthcare	O	O	B-Entity
utilization	O	O	B-Entity
differences	O	O	B-Entity
after	O	O	O
hospitalization	O	O	B-Entity
for	O	O	O
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
:	O	O	O
Race	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
and	O	O	O
caregiving	O	O	B-Entity
effects	O	O	O

Background	O	O	B-Entity
Differences	O	O	B-Entity
in	O	O	O
healthcare	O	O	B-Entity
utilization	O	O	B-Entity
after	O	O	O
stroke	O	O	B-Entity
may	O	O	O
partly	O	O	O
explain	O	O	O
race	O	O	B-Entity
or	O	O	O
gender	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
stroke	O	O	O
outcomes	O	O	O
and	O	O	O
identify	O	O	O
factors	O	O	B-Entity
that	O	O	O
might	O	O	O
reduce	O	O	B-Entity
post	O	O	B-Entity
-	O	O	O
acute	O	O	B-Entity
stroke	O	O	I-Entity
care	O	O	B-Entity
costs	O	O	I-Entity
.	O	O	O

Aim	O	O	O
To	O	O	O
examine	O	O	O
systematic	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
Medicare	O	O	B-Entity
claims	O	O	B-Entity
for	O	O	O
healthcare	O	O	B-Entity
utilization	O	O	B-Entity
after	O	O	O
hospitalization	O	O	B-Entity
for	O	O	O
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
in	O	O	O
a	O	O	O
US	O	O	B-Entity
population	O	O	B-Entity
-based	O	O	O
sample	O	O	B-Entity
.	O	O	O

Methods	O	O	O
Claims	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
over	O	O	O
a	O	O	O
six-month	O	O	B-Entity
period	O	O	B-Entity
after	O	O	O
hospitalization	O	O	B-Entity
for	O	O	O
279	O	O	O
ischemic	O	O	B-Entity
stroke	O	O	I-Entity
survivors	O	O	B-Entity
65	O	O	O
years	O	O	B-Entity
or	O	O	O
older	O	O	B-Entity
from	O	O	O
the	O	O	O
REasons	O	O	B-Entity
for	O	O	O
Geographic	O	O	B-Entity
And	O	O	O
Racial	O	O	B-Entity
Differences	O	O	I-Entity
in	O	O	O
Stroke	O	O	B-Entity
(	O	O	O
REGARDS	O	O	B-Entity
)	O	O	O
study	O	O	O
.	O	O	O

Statistical	O	O	B-Entity
analyses	O	O	I-Entity
examined	O	O	B-Entity
differences	O	O	B-Entity
in	O	O	O
post	O	O	B-Entity
-	O	O	O
acute	O	O	B-Entity
healthcare	O	O	I-Entity
utilization	O	O	B-Entity
,	O	O	O
adjusted	O	O	O
for	O	O	O
pre	O	O	B-Entity
-	O	O	O
stroke	O	O	B-Entity
utilization	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
race	O	O	B-Entity
(	O	O	O
African-American	O	O	B-Entity
vs.	O	O	O
White	O	O	B-Entity
)	O	O	O
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
stroke	O	O	B-Entity
belt	O	O	I-Entity
residence	O	O	B-Entity
,	O	O	O
income	O	O	B-Entity
,	O	O	O
Medicaid	O	O	B-Entity
dual-eligibility	O	O	I-Entity
,	O	O	O
Charlson	O	O	B-Entity
comorbidity	O	O	I-Entity
index	O	O	I-Entity
,	O	O	O
and	O	O	O
whether	O	O	O
the	O	O	O
person	O	O	B-Entity
lived	O	O	B-Entity
with	O	O	O
an	O	O	O
available	O	O	B-Entity
caregiver	O	O	B-Entity
.	O	O	O

Results	O	O	O
After	O	O	O
adjusting	O	O	O
for	O	O	O
covariates	O	O	O
,	O	O	O
women	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
than	O	O	O
men	O	O	B-Entity
to	O	O	O
receive	O	O	B-Entity
home	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
and	O	O	O
to	O	O	O
use	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
services	O	O	I-Entity
during	O	O	O
the	O	O	O
post	O	O	B-Entity
-	O	O	O
acute	O	O	B-Entity
care	O	O	I-Entity
period	O	O	B-Entity
.	O	O	O

These	O	O	O
effects	O	O	B-Entity
were	O	O	O
maintained	O	O	B-Entity
even	O	O	O
after	O	O	O
further	O	O	B-Entity
adjustment	O	O	B-Entity
for	O	O	O
acute	O	O	B-Entity
stroke	O	O	I-Entity
severity	O	O	B-Entity
.	O	O	O

African-Americans	O	O	B-Entity
had	O	O	O
more	O	O	O
home	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
visits	O	O	B-Entity
than	O	O	O
Whites	O	O	B-Entity
among	O	O	O
patients	O	O	B-Entity
who	O	O	O
received	O	O	B-Entity
some	O	O	O
home	O	O	O
health	O	O	O
care	O	O	O
.	O	O	O

Having	O	O	O
a	O	O	O
co-residing	O	O	B-Entity
caregiver	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
reduced	O	O	B-Entity
acute	O	O	B-Entity
hospitalization	O	O	I-Entity
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
and	O	O	O
fewer	O	O	O
post	O	O	B-Entity
-	O	O	O
acute	O	O	B-Entity
emergency	O	O	I-Entity
department	O	O	I-Entity
and	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
physician	O	O	I-Entity
visits	O	O	I-Entity
.	O	O	O

Conclusions	O	O	O
Underutilization	O	O	B-Entity
of	O	O	I-Entity
healthcare	O	O	I-Entity
after	O	O	O
stroke	O	O	B-Entity
does	O	O	O
not	O	O	O
appear	O	O	O
to	O	O	O
explain	O	O	O
poorer	O	O	O
long-term	O	O	B-Entity
stroke	O	O	O
outcomes	O	O	O
for	O	O	O
women	O	O	B-Entity
and	O	O	O
African-Americans	O	O	B-Entity
in	O	O	O
this	O	O	O
epidemiologically	O	O	B-Entity
-derived	O	O	O
sample	O	O	B-Entity
.	O	O	O

Caregiver	O	O	B-Entity
availability	O	O	B-Entity
may	O	O	O
contribute	O	O	B-Entity
to	O	O	O
reduced	O	O	B-Entity
formal	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
cost	O	O	B-Entity
during	O	O	O
the	O	O	O
post	O	O	B-Entity
-	O	O	O
acute	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

-DOCSTART- (27436068)

Do	O	O	O
dynamic	O	O	B-Entity
global	O	O	I-Entity
vegetation	O	O	I-Entity
models	O	O	I-Entity
capture	O	O	O
the	O	O	O
seasonality	O	O	B-Entity
of	O	O	O
carbon	O	O	B-Entity
fluxes	O	O	I-Entity
in	O	O	O
the	O	O	O
Amazon	O	O	B-Entity
basin	O	O	I-Entity
?	O	O	O
A	O	O	O
data	O	O	B-Entity
-	O	O	O
model	O	O	B-Entity
intercomparison	O	O	O

To	O	O	O
predict	O	O	O
forest	O	O	B-Entity
response	O	O	B-Entity
to	O	O	O
long-term	O	O	B-Entity
climate	O	O	B-Entity
change	O	O	I-Entity
with	O	O	O
high	O	O	O
confidence	O	O	O
requires	O	O	O
that	O	O	O
dynamic	O	O	B-Entity
global	O	O	I-Entity
vegetation	O	O	I-Entity
models	O	O	I-Entity
(	O	O	O
DGVMs	O	O	B-Entity
)	O	O	O
be	O	O	O
successfully	O	O	O
tested	O	O	O
against	O	O	O
ecosystem	O	O	B-Entity
response	O	O	O
to	O	O	O
short-term	O	O	B-Entity
variations	O	O	B-Entity
in	O	O	O
environmental	O	O	B-Entity
drivers	O	O	I-Entity
,	O	O	O
including	O	O	O
regular	O	O	O
seasonal	O	O	B-Entity
patterns	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
an	O	O	O
integrated	O	O	O
dataset	O	O	B-Entity
from	O	O	O
four	O	O	O
forests	O	O	B-Entity
in	O	O	O
the	O	O	O
Brasil	O	O	B-Entity
flux	O	O	I-Entity
network	O	O	I-Entity
,	O	O	O
spanning	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
dry-season	O	O	B-Entity
intensities	O	O	B-Entity
and	O	O	O
lengths	O	O	B-Entity
,	O	O	O
to	O	O	O
determine	O	O	O
how	O	O	O
well	O	O	O
four	O	O	O
state-of-the-art	O	O	O
models	O	O	B-Entity
(	O	O	O
IBIS	O	O	B-Entity
,	O	O	O
ED2	O	O	B-Entity
,	O	O	O
JULES	O	O	B-Entity
,	O	O	O
and	O	O	O
CLM3.5	O	O	B-Entity
)	O	O	O
simulated	O	O	O
the	O	O	O
seasonality	O	O	B-Entity
of	O	O	O
carbon	O	O	B-Entity
exchanges	O	O	I-Entity
in	O	O	O
Amazonian	O	O	B-Entity
tropical	O	O	B-Entity
forests	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
most	O	O	O
DGVMs	O	O	B-Entity
poorly	O	O	O
represented	O	O	O
the	O	O	O
annual	O	O	O
cycle	O	O	O
of	O	O	O
gross	O	O	B-Entity
primary	O	O	I-Entity
productivity	O	O	I-Entity
(	O	O	O
GPP	O	O	B-Entity
)	O	O	O
,	O	O	O
of	O	O	O
photosynthetic	O	O	B-Entity
capacity	O	O	I-Entity
(	O	O	O
Pc	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
of	O	O	O
other	O	O	O
fluxes	O	O	B-Entity
and	O	O	O
pools	O	O	O
.	O	O	O

Models	O	O	B-Entity
simulated	O	O	O
consistent	O	O	O
dry-season	O	O	B-Entity
declines	O	O	B-Entity
in	O	O	O
GPP	O	O	B-Entity
in	O	O	O
the	O	O	O
equatorial	O	O	B-Entity
Amazon	O	O	I-Entity
(	O	O	O
Manaus	O	O	B-Entity
K34	O	O	I-Entity
,	O	O	O
Santarem	O	O	B-Entity
K67	O	O	I-Entity
,	O	O	O
and	O	O	O
Caxiuanã	O	O	B-Entity
CAX	O	O	I-Entity
)	O	O	O
;	O	O	O
a	O	O	O
contrast	O	O	O
to	O	O	O
observed	O	O	O
GPP	O	O	O
increases	O	O	O
.	O	O	O

Model	O	O	B-Entity
simulated	O	O	O
dry-season	O	O	B-Entity
GPP	O	O	B-Entity
reductions	O	O	B-Entity
were	O	O	O
driven	O	O	O
by	O	O	O
an	O	O	O
external	O	O	O
environmental	O	O	B-Entity
factor	O	O	B-Entity
,	O	O	O
'	O	O	O
soil	O	O	B-Entity
water	O	O	I-Entity
stress	O	O	I-Entity
'	O	O	O
and	O	O	O
consequently	O	O	O
by	O	O	O
a	O	O	O
constant	O	O	O
or	O	O	O
decreasing	O	O	O
photosynthetic	O	O	B-Entity
infrastructure	O	O	I-Entity
(	O	O	O
Pc	O	O	B-Entity
)	O	O	O
,	O	O	O
while	O	O	O
observed	O	O	O
dry-season	O	O	O
GPP	O	O	O
resulted	O	O	O
from	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
internal	O	O	O
biological	O	O	B-Entity
(	O	O	O
leaf	O	O	B-Entity
-flush	O	O	O
and	O	O	O
abscission	O	O	B-Entity
and	O	O	O
increased	O	O	O
Pc	O	O	O
)	O	O	O
and	O	O	O
environmental	O	O	O
(	O	O	O
incoming	O	O	O
radiation	O	O	B-Entity
)	O	O	O
causes	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
models	O	O	B-Entity
generally	O	O	O
overestimated	O	O	O
observed	O	O	O
seasonal	O	O	O
net	O	O	B-Entity
ecosystem	O	O	I-Entity
exchange	O	O	I-Entity
(	O	O	O
NEE	O	O	B-Entity
)	O	O	O
and	O	O	O
respiration	O	O	B-Entity
(	O	O	O
Re	O	O	B-Entity
)	O	O	O
at	O	O	O
equatorial	O	O	O
locations	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
a	O	O	O
southern	O	O	B-Entity
Amazon	O	O	I-Entity
forest	O	O	B-Entity
(	O	O	O
Jarú	O	O	O
RJA	O	O	O
)	O	O	O
exhibited	O	O	O
dry-season	O	O	B-Entity
declines	O	O	B-Entity
in	O	O	O
GPP	O	O	B-Entity
and	O	O	O
Re	O	O	B-Entity
consistent	O	O	O
with	O	O	O
most	O	O	O
DGVMs	O	O	B-Entity
simulations	O	O	B-Entity
.	O	O	O

While	O	O	O
water	O	O	O
limitation	O	O	O
was	O	O	O
represented	O	O	O
in	O	O	O
models	O	O	B-Entity
and	O	O	O
the	O	O	O
primary	O	O	O
driver	O	O	O
of	O	O	O
seasonal	O	O	O
photosynthesis	O	O	B-Entity
in	O	O	O
southern	O	O	B-Entity
Amazonia	O	O	I-Entity
,	O	O	O
changes	O	O	O
in	O	O	O
internal	O	O	O
biophysical	O	O	B-Entity
processes	O	O	I-Entity
,	O	O	O
light-harvesting	O	O	B-Entity
adaptations	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
variations	O	O	O
in	O	O	O
leaf	O	O	B-Entity
area	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
LAI	O	O	B-Entity
)	O	O	O
and	O	O	O
increasing	O	O	O
leaf	O	O	O
-level	O	O	O
assimilation	O	O	B-Entity
rate	O	O	B-Entity
related	O	O	O
to	O	O	O
leaf	O	O	B-Entity
demography	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
allocation	O	O	O
lags	O	O	O
between	O	O	O
leaf	O	O	O
and	O	O	O
wood	O	O	B-Entity
,	O	O	O
dominated	O	O	O
equatorial	O	O	B-Entity
Amazon	O	O	I-Entity
carbon	O	O	B-Entity
flux	O	O	I-Entity
dynamics	O	O	O
and	O	O	O
were	O	O	O
deficient	O	O	O
or	O	O	O
absent	O	O	O
from	O	O	O
current	O	O	O
model	O	O	B-Entity
formulations	O	O	O
.	O	O	O

Correctly	O	O	O
simulating	O	O	O
flux	O	O	B-Entity
seasonality	O	O	B-Entity
at	O	O	O
tropical	O	O	B-Entity
forests	O	O	I-Entity
requires	O	O	O
a	O	O	O
greater	O	O	O
understanding	O	O	O
and	O	O	O
the	O	O	O
incorporation	O	O	O
of	O	O	O
internal	O	O	O
biophysical	O	O	B-Entity
mechanisms	O	O	I-Entity
in	O	O	O
future	O	O	O
model	O	O	B-Entity
developments	O	O	I-Entity
.	O	O	O

-DOCSTART- (27436635)

Blood	O	O	B-Entity
Pressure	O	O	I-Entity
and	O	O	O
All-Cause	O	O	B-Entity
Mortality	O	O	I-Entity
by	O	O	O
Level	O	O	B-Entity
of	O	O	O
Cognitive	O	O	B-Entity
Function	O	O	I-Entity
in	O	O	O
the	O	O	O
Elderly	O	O	B-Entity
:	O	O	O
Results	O	O	B-Entity
From	O	O	O
a	O	O	O
Population-Based	O	O	B-Entity
Study	O	O	I-Entity
in	O	O	O
Rural	O	O	O
Greece	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
(	O	O	O
BP	O	O	B-Entity
)	O	O	O
on	O	O	O
mortality	O	O	B-Entity
differs	O	O	O
by	O	O	O
levels	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

The	O	O	O
associations	O	O	B-Entity
of	O	O	O
brachial	O	O	B-Entity
systolic	O	O	B-Entity
BP	O	O	I-Entity
,	O	O	O
diastolic	O	O	B-Entity
BP	O	O	I-Entity
,	O	O	O
mean	O	O	B-Entity
arterial	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
MAP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
with	O	O	O
all-cause	O	O	B-Entity
mortality	O	O	I-Entity
were	O	O	O
prospectively	O	O	B-Entity
explored	O	O	I-Entity
(	O	O	O
follow-up	O	O	B-Entity
7.0±2.2	O	O	O
years	O	O	B-Entity
)	O	O	O
in	O	O	O
660	O	O	O
community-dwelling	O	O	B-Entity
individuals	O	O	B-Entity
(	O	O	O
≥60	O	O	B-Entity
years	O	O	I-Entity
)	O	O	O
using	O	O	O
adjusted	O	O	B-Entity
Cox	O	O	I-Entity
models	O	O	I-Entity
,	O	O	O
stratified	O	O	B-Entity
by	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
(	O	O	O
Mini-Mental	O	O	B-Entity
State	O	O	I-Entity
Examination	O	O	I-Entity
[	O	O	O
MMSE	O	O	B-Entity
]	O	O	O
<	O	O	O
24	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
association	O	O	I-Entity
between	O	O	O
brachial	O	O	B-Entity
BP	O	O	B-Entity
variables	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
was	O	O	O
shown	O	O	O
for	O	O	O
the	O	O	O
total	O	O	B-Entity
sample	O	O	B-Entity
in	O	O	O
quartiles	O	O	B-Entity
analysis	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
MAP	O	O	B-Entity
in	O	O	O
the	O	O	O
highest	O	O	B-Entity
quartile	O	O	I-Entity
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
second	O	O	B-Entity
,	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
mortality	O	O	O
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
1.85	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
,	O	O	O
1.09	O	O	O
-	O	O	O
3.12	O	O	O
)	O	O	O
among	O	O	O
cognitively	O	O	B-Entity
impaired	O	O	I-Entity
individuals	O	O	B-Entity
.	O	O	O

The	O	O	O
fractional-polynomials	O	O	B-Entity
approach	O	O	I-Entity
for	O	O	O
BP	O	O	B-Entity
confirmed	O	O	B-Entity
this	O	O	O
finding	O	O	B-Entity
and	O	O	O
further	O	O	B-Entity
showed	O	O	O
,	O	O	O
solely	O	O	B-Entity
in	O	O	O
the	O	O	O
MMSE	O	O	B-Entity
<	O	O	O
24	O	O	O
subcohort	O	O	B-Entity
,	O	O	O
U-shaped	O	O	B-Entity
trends	O	O	I-Entity
of	O	O	O
MAP	O	O	B-Entity
and	O	O	O
systolic	O	O	B-Entity
BP	O	O	I-Entity
,	O	O	O
with	O	O	O
increased	O	O	B-Entity
mortality	O	O	B-Entity
risk	O	O	I-Entity
in	O	O	O
extremely	O	O	B-Entity
low	O	O	B-Entity
or	O	O	I-Entity
high	O	O	I-Entity
values	O	O	I-Entity
;	O	O	O
no	O	O	O
such	O	O	O
pattern	O	O	B-Entity
was	O	O	O
evident	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
MMSE	O	O	O
≥24	O	O	O
.	O	O	O

Elderly	O	O	B-Entity
individuals	O	O	B-Entity
with	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
might	O	O	O
be	O	O	O
more	O	O	B-Entity
susceptible	O	O	B-Entity
to	O	O	O
the	O	O	O
detrimental	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
low	O	O	B-Entity
and	O	O	O
elevated	O	O	B-Entity
MAP	O	O	B-Entity
and	O	O	O
systolic	O	O	B-Entity
BP	O	O	I-Entity
.	O	O	O

-DOCSTART- (27437203)

Hypovitaminosis	O	O	B-Entity
D	O	O	I-Entity
and	O	O	O
Associated	O	O	O
Cardiometabolic	O	O	B-Entity
Risk	O	O	I-Entity
in	O	O	O
Women	O	O	B-Entity
with	O	O	O
PCOS	O	O	O

Women	O	O	B-Entity
with	O	O	O
Polycystic	O	O	B-Entity
Ovary	O	O	I-Entity
Syndrome	O	O	I-Entity
(	O	O	O
PCOS	O	O	B-Entity
)	O	O	O
frequently	O	O	O
suffer	O	O	O
from	O	O	O
metabolic	O	O	B-Entity
disturbances	O	O	I-Entity
like	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
atherogenic	O	O	B-Entity
dyslipidemia	O	O	I-Entity
.	O	O	O

Accumulating	O	O	B-Entity
evidences	O	O	O
suggest	O	O	O
that	O	O	O
Vitamin	O	O	B-Entity
D	O	O	I-Entity
deficiency	O	O	I-Entity
is	O	O	O
common	O	O	O
in	O	O	O
PCOS	O	O	B-Entity
and	O	O	O
may	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
metabolic	O	O	B-Entity
and	O	O	O
endocrinal	O	O	B-Entity
dysfunctions	O	O	I-Entity
in	O	O	O
PCOS	O	O	O
.	O	O	O

Thus	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
may	O	O	O
be	O	O	O
at	O	O	O
elevated	O	O	O
risk	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

Present	O	O	O
study	O	O	B-Entity
aims	O	O	O
to	O	O	O
evaluate	O	O	O
Vitamin	O	O	B-Entity
D	O	O	I-Entity
status	O	O	O
and	O	O	O
to	O	O	O
assess	O	O	O
its	O	O	O
association	O	O	O
with	O	O	O
metabolic	O	O	B-Entity
and	O	O	O
endocrinal	O	O	B-Entity
dysregulations	O	O	I-Entity
in	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
,	O	O	O
which	O	O	O
might	O	O	O
help	O	O	O
in	O	O	O
early	O	O	B-Entity
identification	O	O	I-Entity
and	O	O	O
prevention	O	O	B-Entity
of	O	O	O
future	O	O	O
symptomatic	O	O	B-Entity
cardiac	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
44	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
,	O	O	O
diagnosed	O	O	O
by	O	O	O
Rotterdam	O	O	B-Entity
criteria	O	O	I-Entity
and	O	O	O
45	O	O	O
healthy	O	O	B-Entity
control	O	O	I-Entity
without	O	O	O
PCOS	O	O	O
,	O	O	O
were	O	O	O
evaluated	O	O	O
for	O	O	O
Vitamin	O	O	B-Entity
D	O	O	I-Entity
and	O	O	O
cardiometabolic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
,	O	O	O
including	O	O	O
fasting	O	O	B-Entity
plasma	O	O	I-Entity
glucose	O	O	I-Entity
,	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
dyslipidemia	O	O	B-Entity
,	O	O	O
hs-CRP	O	O	B-Entity
.	O	O	O

That	O	O	O
apart	O	O	O
,	O	O	O
several	O	O	O
endocrinal	O	O	B-Entity
parameters	O	O	B-Entity
of	O	O	O
hyperandrogenism	O	O	B-Entity
were	O	O	O
also	O	O	O
examined	O	O	O
.	O	O	O

Several	O	O	O
correlation	O	O	B-Entity
studies	O	O	I-Entity
were	O	O	O
determined	O	O	O
to	O	O	O
establish	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
Vitamin	O	O	B-Entity
D	O	O	I-Entity
as	O	O	O
a	O	O	O
cardiometabolic	O	O	B-Entity
risk	O	O	I-Entity
factor	O	O	I-Entity
in	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

Results	O	O	O
were	O	O	O
expressed	O	O	O
as	O	O	O
mean±SD	O	O	O
and	O	O	O
were	O	O	O
statistically	O	O	B-Entity
analysed	O	O	I-Entity
using	O	O	O
SPSS	O	O	B-Entity
software	O	O	I-Entity
version	O	O	I-Entity
16	O	O	I-Entity
,	O	O	O
unpaired	O	O	B-Entity
student	O	O	I-Entity
's	O	O	I-Entity
t-test	O	O	I-Entity
and	O	O	O
Pearson	O	O	B-Entity
's	O	O	I-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
lower	O	O	O
levels	O	O	O
of	O	O	O
Vitamin	O	O	B-Entity
D	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
statistically	O	O	O
significant	O	O	O
as	O	O	O
compared	O	O	O
to	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Hyperinsulinemia	O	O	B-Entity
,	O	O	O
rise	O	O	O
in	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
marked	O	O	O
dyslipidemia	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
.	O	O	O

Another	O	O	O
relevant	O	O	O
finding	O	O	O
was	O	O	O
significant	O	O	O
correlation	O	O	O
of	O	O	O
Vitamin	O	O	B-Entity
D	O	O	I-Entity
with	O	O	O
insulin	O	O	B-Entity
and	O	O	O
Homeostatic	O	O	B-Entity
Model	O	O	I-Entity
of	O	O	I-Entity
Assessment-	O	O	I-Entity
Insulin	O	O	I-Entity
Resistance	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
HOMA-IR	O	O	B-Entity
)	O	O	O
.	O	O	O

Hypovitaminosis	O	O	B-Entity
D	O	O	I-Entity
was	O	O	O
prevalent	O	O	O
in	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
related	O	O	O
to	O	O	O
metabolic	O	O	B-Entity
and	O	O	O
hormonal	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

Possibly	O	O	O
this	O	O	O
combined	O	O	O
with	O	O	O
impaired	O	O	B-Entity
fasting	O	O	I-Entity
glucose	O	O	I-Entity
,	O	O	O
IR	O	O	B-Entity
and	O	O	O
dyslipidemia	O	O	B-Entity
,	O	O	O
could	O	O	O
account	O	O	O
for	O	O	O
Cardio	O	O	B-Entity
vascular	O	O	I-Entity
risks	O	O	I-Entity
in	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

Further	O	O	O
prospective	O	O	O
observational	O	O	B-Entity
studies	O	O	I-Entity
and	O	O	O
randomized	O	O	B-Entity
control	O	O	I-Entity
trials	O	O	I-Entity
are	O	O	O
required	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
above	O	O	O
hypothesis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27438380)

Family	O	O	B-Entity
close	O	O	B-Entity
but	O	O	O
friends	O	O	B-Entity
closer	O	O	B-Entity
:	O	O	O
exploring	O	O	O
social	O	O	B-Entity
support	O	O	I-Entity
and	O	O	O
resilience	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
spousal	O	O	B-Entity
dementia	O	O	B-Entity
carers	O	O	O

Spousal	O	O	B-Entity
dementia	O	O	B-Entity
carers	O	O	B-Entity
have	O	O	O
unique	O	O	O
support	O	O	B-Entity
needs	O	O	B-Entity
;	O	O	O
they	O	O	O
are	O	O	O
likely	O	O	O
to	O	O	O
disengage	O	O	B-Entity
from	O	O	O
their	O	O	O
existing	O	O	B-Entity
social	O	O	B-Entity
networks	O	O	I-Entity
as	O	O	O
they	O	O	O
need	O	O	O
to	O	O	O
devote	O	O	O
more	O	O	O
time	O	O	B-Entity
to	O	O	O
caring	O	O	B-Entity
as	O	O	O
the	O	O	O
disease	O	O	B-Entity
progresses	O	O	I-Entity
.	O	O	O

Previously	O	O	O
we	O	O	O
showed	O	O	O
that	O	O	O
support	O	O	B-Entity
resources	O	O	B-Entity
can	O	O	O
facilitate	O	O	O
resilience	O	O	B-Entity
in	O	O	O
carers	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
relationship	O	O	B-Entity
is	O	O	O
complex	O	O	B-Entity
and	O	O	O
varies	O	O	O
by	O	O	O
relationship	O	O	B-Entity
type	O	O	I-Entity
.	O	O	O

The	O	O	O
current	O	O	O
paper	O	O	O
aims	O	O	O
to	O	O	O
explore	O	O	O
social	O	O	B-Entity
support	O	O	B-Entity
as	O	O	O
a	O	O	O
key	O	O	O
component	O	O	O
of	O	O	O
resilience	O	O	B-Entity
to	O	O	O
identify	O	O	O
the	O	O	O
availability	O	O	B-Entity
,	O	O	O
function	O	O	B-Entity
and	O	O	O
perceived	O	O	B-Entity
functional	O	O	I-Entity
aspects	O	O	I-Entity
of	O	O	O
support	O	O	O
provided	O	O	O
to	O	O	O
older	O	O	B-Entity
spousal	O	O	B-Entity
dementia	O	O	B-Entity
carers	O	O	B-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
23	O	O	O
in-depth	O	O	B-Entity
qualitative	O	O	I-Entity
interviews	O	O	I-Entity
with	O	O	O
spousal	O	O	B-Entity
carers	O	O	B-Entity
from	O	O	O
two	O	O	O
carer	O	O	B-Entity
support	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
a	O	O	O
care	O	O	O
home	O	O	O
in	O	O	O
North	O	O	B-Entity
West	O	O	I-Entity
England	O	O	I-Entity
.	O	O	O

Family	O	O	B-Entity
and	O	O	O
friends	O	O	B-Entity
served	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
functions	O	O	B-Entity
but	O	O	O
were	O	O	O
equally	O	O	O
available	O	O	O
to	O	O	O
resilient	O	O	B-Entity
and	O	O	O
non-resilient	O	O	B-Entity
participants	O	O	I-Entity
.	O	O	O

Family	O	O	B-Entity
support	O	O	I-Entity
was	O	O	O
perceived	O	O	B-Entity
as	O	O	O
unhelpful	O	O	O
if	O	O	O
it	O	O	O
created	O	O	B-Entity
feelings	O	O	B-Entity
of	O	O	O
over-dependence	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
less	O	O	O
likely	O	O	O
to	O	O	O
resist	O	O	B-Entity
involvement	O	O	I-Entity
of	O	O	O
grandchildren	O	O	B-Entity
due	O	O	O
to	O	O	O
their	O	O	O
relatively	O	O	O
narrow	O	O	B-Entity
and	O	O	I-Entity
low-level	O	O	I-Entity
support	O	O	I-Entity
functions	O	O	I-Entity
.	O	O	O

Friend	O	O	B-Entity
support	O	O	B-Entity
was	O	O	O
perceived	O	O	B-Entity
as	O	O	O
most	O	O	O
helpful	O	O	B-Entity
when	O	O	O
it	O	O	O
derived	O	O	O
from	O	O	O
those	O	O	O
in	O	O	O
similar	O	O	O
circumstances	O	O	B-Entity
.	O	O	O

Neighbours	O	O	B-Entity
played	O	O	O
a	O	O	O
functionally	O	O	O
unique	O	O	O
role	O	O	O
of	O	O	O
crisis	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

These	O	O	O
perceptions	O	O	B-Entity
may	O	O	O
moderate	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
support	O	O	B-Entity
on	O	O	O
resilience	O	O	B-Entity
.	O	O	O

Family	O	O	B-Entity
and	O	O	O
friend	O	O	B-Entity
support	O	O	B-Entity
is	O	O	O
not	O	O	O
always	O	O	O
sufficient	O	O	B-Entity
to	O	O	O
facilitate	O	O	O
resilience	O	O	B-Entity
.	O	O	O

Support	O	O	B-Entity
functions	O	O	I-Entity
facilitate	O	O	O
resilience	O	O	B-Entity
only	O	O	O
if	O	O	O
they	O	O	O
are	O	O	O
perceived	O	O	B-Entity
to	O	O	O
match	O	O	O
need	O	O	B-Entity
.	O	O	O

Implications	O	O	B-Entity
of	O	O	O
these	O	O	O
findings	O	O	B-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27440782)

Measure	O	O	B-Entity
Up	O	O	I-Entity
Pressure	O	O	I-Entity
Down	O	O	I-Entity
:	O	O	I-Entity
Provider	O	O	I-Entity
Toolkit	O	O	I-Entity
to	O	O	O
Improve	O	O	B-Entity
Hypertension	O	O	B-Entity
Control	O	O	O

Hypertension	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
heart	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
stroke	O	O	B-Entity
,	O	O	O
kidney	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
and	O	O	O
diabetes	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

Nearly	O	O	O
one	O	O	O
in	O	O	O
three	O	O	O
Americans	O	O	B-Entity
adults	O	O	B-Entity
has	O	O	O
high	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
cost	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
treating	O	O	B-Entity
this	O	O	O
condition	O	O	B-Entity
is	O	O	O
staggering	O	O	O
.	O	O	O

The	O	O	O
Measure	O	O	B-Entity
Up	O	O	I-Entity
Pressure	O	O	I-Entity
Down	O	O	I-Entity
:	O	O	I-Entity
Provider	O	O	I-Entity
Toolkit	O	O	I-Entity
to	O	O	O
Improve	O	O	B-Entity
Hypertension	O	O	B-Entity
Control	O	O	B-Entity
is	O	O	O
a	O	O	O
resource	O	O	B-Entity
developed	O	O	B-Entity
by	O	O	O
the	O	O	O
American	O	O	B-Entity
Medical	O	O	I-Entity
Group	O	O	I-Entity
Foundation	O	O	I-Entity
in	O	O	O
partnership	O	O	B-Entity
with	O	O	O
the	O	O	O
American	O	O	B-Entity
Medical	O	O	I-Entity
Group	O	O	I-Entity
Association	O	O	I-Entity
.	O	O	O

The	O	O	O
goal	O	O	B-Entity
of	O	O	O
this	O	O	O
toolkit	O	O	B-Entity
is	O	O	O
to	O	O	O
mobilize	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
practitioners	O	O	I-Entity
to	O	O	O
work	O	O	B-Entity
together	O	O	B-Entity
through	O	O	O
team	O	O	B-Entity
-based	O	O	O
approaches	O	O	O
to	O	O	O
achieve	O	O	O
an	O	O	O
80	O	O	O
%	O	O	O
control	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
high	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
among	O	O	O
their	O	O	O
patient	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

The	O	O	O
toolkit	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
by	O	O	O
health	O	O	B-Entity
educators	O	O	I-Entity
,	O	O	O
clinic	O	O	B-Entity
administrators	O	O	I-Entity
,	O	O	O
physicians	O	O	B-Entity
,	O	O	O
students	O	O	B-Entity
,	O	O	O
and	O	O	O
other	O	O	O
clinic	O	O	B-Entity
staff	O	O	I-Entity
as	O	O	O
a	O	O	O
step-by-step	O	O	O
resource	O	O	B-Entity
for	O	O	O
developing	O	O	B-Entity
the	O	O	O
infrastructure	O	O	B-Entity
needed	O	O	O
to	O	O	O
better	O	O	O
identify	O	O	O
and	O	O	O
treat	O	O	B-Entity
individuals	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
or	O	O	O
other	O	O	O
chronic	O	O	O
conditions	O	O	O
.	O	O	O

-DOCSTART- (27441638)

Potentiation	O	O	B-Entity
of	O	O	O
LPS	O	O	B-Entity
-	O	O	O
Induced	O	O	B-Entity
Apoptotic	O	O	B-Entity
Cell	O	O	I-Entity
Death	O	O	I-Entity
in	O	O	O
Human	O	O	B-Entity
Hepatoma	O	O	I-Entity
HepG2	O	O	I-Entity
Cells	O	O	I-Entity
by	O	O	O
Aspirin	O	O	B-Entity
via	O	O	O
ROS	O	O	B-Entity
and	O	O	O
Mitochondrial	O	O	B-Entity
Dysfunction	O	O	I-Entity
:	O	O	O
Protection	O	O	B-Entity
by	O	O	O
N-Acetyl	O	O	O
Cysteine	O	O	O

Cytotoxicity	O	O	B-Entity
and	O	O	O
inflammation	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
toxic	O	O	B-Entity
responses	O	O	B-Entity
have	O	O	O
been	O	O	O
observed	O	O	B-Entity
to	O	O	O
be	O	O	O
induced	O	O	B-Entity
by	O	O	O
bacterial	O	O	B-Entity
lipopolysaccharides	O	O	B-Entity
(	O	O	O
LPS	O	O	B-Entity
)	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
respectively	O	O	O
.	O	O	O

Use	O	O	O
of	O	O	O
nonsteroidal	O	O	B-Entity
anti-inflammatory	O	O	I-Entity
drugs	O	O	I-Entity
(	O	O	O
NSAIDs	O	O	B-Entity
)	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
aspirin	O	O	B-Entity
,	O	O	O
has	O	O	O
been	O	O	O
reported	O	O	B-Entity
to	O	O	O
be	O	O	O
beneficial	O	O	O
in	O	O	O
inflammation	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
diseases	O	O	I-Entity
like	O	O	O
cancer	O	O	B-Entity
,	O	O	O
diabetes	O	O	B-Entity
and	O	O	O
cardiovascular	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Their	O	O	O
precise	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
are	O	O	O
not	O	O	O
clearly	O	O	O
understood	O	O	O
.	O	O	O

Our	O	O	O
previous	O	O	O
studies	O	O	B-Entity
on	O	O	O
aspirin	O	O	B-Entity
treated	O	O	B-Entity
HepG2	O	O	B-Entity
cells	O	O	I-Entity
strongly	O	O	O
suggest	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
arrest	O	O	I-Entity
and	O	O	O
induction	O	O	B-Entity
of	O	O	O
apoptosis	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
mitochondrial	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
have	O	O	O
further	O	O	O
demonstrated	O	O	O
that	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
LPS	O	O	B-Entity
alone	O	O	O
or	O	O	O
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
aspirin	O	O	B-Entity
induces	O	O	B-Entity
subcellular	O	O	B-Entity
toxic	O	O	B-Entity
responses	O	O	I-Entity
which	O	O	O
are	O	O	O
accompanied	O	O	O
by	O	O	O
increase	O	O	B-Entity
in	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
production	O	O	O
,	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
mitochondrial	O	O	B-Entity
respiratory	O	O	I-Entity
dysfunction	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

The	O	O	O
LPS	O	O	B-Entity
/	O	O	O
Aspirin	O	O	B-Entity
induced	O	O	B-Entity
toxicity	O	O	B-Entity
was	O	O	O
attenuated	O	O	B-Entity
by	O	O	O
pre-treatment	O	O	B-Entity
of	O	O	O
cells	O	O	B-Entity
with	O	O	O
N-acetyl	O	O	B-Entity
cysteine	O	O	I-Entity
(	O	O	O
NAC	O	O	B-Entity
)	O	O	O
.	O	O	O

Alterations	O	O	O
in	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
glutathione	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
redox-homeostasis	O	O	B-Entity
were	O	O	O
more	O	O	O
pronounced	O	O	O
in	O	O	O
mitochondria	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
extra	O	O	B-Entity
-	O	O	O
mitochondrial	O	O	B-Entity
cellular	O	O	B-Entity
compartments	O	O	I-Entity
.	O	O	O

Pre-treatment	O	O	B-Entity
of	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
with	O	O	O
NAC	O	O	B-Entity
exhibited	O	O	O
a	O	O	O
selective	O	O	O
protection	O	O	B-Entity
in	O	O	O
redox	O	O	B-Entity
homeostasis	O	O	I-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
altered	O	O	B-Entity
redox	O	O	B-Entity
metabolism	O	O	I-Entity
,	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
function	O	O	B-Entity
in	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
play	O	O	O
a	O	O	O
critical	O	O	O
role	O	O	O
in	O	O	O
LPS	O	O	B-Entity
/	O	O	O
aspirin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
cytotoxicity	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
may	O	O	O
help	O	O	O
in	O	O	O
better	O	O	O
understanding	O	O	O
the	O	O	O
pharmacological	O	O	B-Entity
,	O	O	O
toxicological	O	O	B-Entity
and	O	O	O
therapeutic	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
NSAIDs	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
exposed	O	O	B-Entity
to	O	O	O
bacterial	O	O	B-Entity
endotoxins	O	O	I-Entity
.	O	O	O

-DOCSTART- (27442784)

Placental	O	O	B-Entity
Pathologic	O	O	B-Entity
Associations	O	O	B-Entity
with	O	O	O
Morbidly	O	O	B-Entity
Adherent	O	O	I-Entity
Placenta	O	O	I-Entity
:	O	O	O
Potential	O	O	O
insights	O	O	O
into	O	O	O
Pathogenesis	O	O	O

The	O	O	O
pathology	O	O	B-Entity
that	O	O	O
underlies	O	O	O
morbidly	O	O	B-Entity
adherent	O	O	I-Entity
placenta	O	O	I-Entity
(	O	O	O
MAP	O	O	B-Entity
)	O	O	O
is	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
placental	O	O	B-Entity
pathology	O	O	B-Entity
,	O	O	O
especially	O	O	O
implantation	O	O	B-Entity
site	O	O	I-Entity
pathology	O	O	O
,	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
MAP	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
a	O	O	O
single	O	O	B-Entity
institution	O	O	B-Entity
,	O	O	O
retrospective	O	O	B-Entity
case-control	O	O	I-Entity
study	O	O	I-Entity
design	O	O	O
examining	O	O	O
placentas	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
delivered	O	O	B-Entity
between	O	O	O
January	O	O	O
2008	O	O	O
and	O	O	O
September	O	O	O
2013	O	O	O
.	O	O	O

MAP	O	O	B-Entity
cases	O	O	B-Entity
were	O	O	O
defined	O	O	O
by	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
clinical	O	O	B-Entity
intervention	O	O	B-Entity
at	O	O	O
delivery	O	O	B-Entity
beyond	O	O	O
spontaneous	O	O	B-Entity
placental	O	O	B-Entity
delivery	O	O	I-Entity
or	O	O	O
simple	O	O	O
manual	O	O	B-Entity
extraction	O	O	I-Entity
of	O	O	O
the	O	O	O
placenta	O	O	B-Entity
.	O	O	O

Controls	O	O	B-Entity
consisted	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
placentas	O	O	B-Entity
sent	O	O	O
for	O	O	O
examination	O	O	B-Entity
due	O	O	O
to	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
maternal	O	O	B-Entity
malignancy	O	O	B-Entity
with	O	O	O
no	O	O	B-Entity
clinical	O	O	B-Entity
suspicion	O	O	B-Entity
of	O	O	O
accreta	O	O	B-Entity
.	O	O	O

Placental	O	O	B-Entity
pathologic	O	O	B-Entity
findings	O	O	I-Entity
of	O	O	O
maternal	O	O	B-Entity
vascular	O	O	I-Entity
underperfusion	O	O	I-Entity
(	O	O	O
MVU	O	O	B-Entity
)	O	O	O
,	O	O	O
acute	O	O	B-Entity
inflammation	O	O	I-Entity
,	O	O	O
chronic	O	O	B-Entity
inflammation	O	O	I-Entity
,	O	O	O
fetal	O	O	B-Entity
vascular	O	O	B-Entity
obstruction	O	O	I-Entity
and	O	O	O
hemorrhage	O	O	B-Entity
were	O	O	O
recorded	O	O	O
and	O	O	O
compared	O	O	O
using	O	O	O
bivariable	O	O	B-Entity
and	O	O	I-Entity
multivariable	O	O	I-Entity
analyses	O	O	I-Entity
.	O	O	O

Three	O	O	O
categories	O	O	B-Entity
of	O	O	O
pathologic	O	O	B-Entity
changes	O	O	B-Entity
were	O	O	O
seen	O	O	O
more	O	O	O
commonly	O	O	O
in	O	O	O
MAP	O	O	B-Entity
placentas	O	O	B-Entity
(	O	O	O
N=101	O	O	O
)	O	O	O
than	O	O	O
control	O	O	B-Entity
placentas	O	O	O
(	O	O	O
N=110	O	O	O
):	O	O	O
chronic	O	O	B-Entity
basal	O	O	I-Entity
inflammation	O	O	I-Entity
,	O	O	O
villous	O	O	O
changes	O	O	O
of	O	O	O
MVU	O	O	B-Entity
and	O	O	O
retromembranous	O	O	B-Entity
and	O	O	O
retromembranous	O	O	O
/	O	O	O
intervillous	O	O	B-Entity
hemorrhage	O	O	I-Entity
.	O	O	O

In	O	O	O
multivariable	O	O	B-Entity
analyses	O	O	I-Entity
adjusted	O	O	O
for	O	O	O
confounders	O	O	B-Entity
,	O	O	O
chronic	O	O	B-Entity
basal	O	O	I-Entity
villitis	O	O	I-Entity
(	O	O	O
aOR	O	O	B-Entity
5.6	O	O	O
,	O	O	O
1.73	O	O	O
-	O	O	O
18.18	O	O	O
)	O	O	O
,	O	O	O
plasma	O	O	B-Entity
cell	O	O	I-Entity
deciduitis	O	O	I-Entity
(	O	O	O
aOR	O	O	O
2.63	O	O	O
,	O	O	O
1.08	O	O	O
-	O	O	O
6.39	O	O	O
)	O	O	O
,	O	O	O
increased	O	O	B-Entity
syncytial	O	O	I-Entity
knots	O	O	I-Entity
(	O	O	O
aOR	O	O	O
3.92	O	O	O
,	O	O	O
1.57	O	O	O
-	O	O	O
9.75	O	O	O
)	O	O	O
,	O	O	O
villous	O	O	O
agglutination	O	O	O
(	O	O	O
aOR	O	O	O
24.85	O	O	O
,	O	O	O
2.78	O	O	O
-	O	O	O
221.75	O	O	O
)	O	O	O
,	O	O	O
increased	O	O	B-Entity
perivillous	O	O	I-Entity
fibrin	O	O	I-Entity
(	O	O	O
aOR	O	O	O
5.08	O	O	O
,	O	O	O
1.49	O	O	O
-	O	O	O
17.34	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
subchorionic	O	O	B-Entity
/	O	O	O
intervillous	O	O	B-Entity
thrombi	O	O	I-Entity
(	O	O	O
aOR	O	O	O
4.01	O	O	O
,	O	O	O
1.63	O	O	O
-	O	O	O
9.86	O	O	O
)	O	O	O
remained	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
MAP	O	O	B-Entity
.	O	O	O

MAP	O	O	B-Entity
is	O	O	O
highly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
evidence	O	O	O
of	O	O	O
intraparenchymal	O	O	B-Entity
placental	O	O	I-Entity
hemorrhage	O	O	I-Entity
villous	O	O	B-Entity
changes	O	O	B-Entity
of	O	O	O
MVU	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
lymphoplasmacytic	O	O	B-Entity
infiltrate	O	O	I-Entity
at	O	O	O
the	O	O	O
implantation	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

The	O	O	O
contribution	O	O	O
of	O	O	O
this	O	O	O
basal	O	O	B-Entity
chronic	O	O	I-Entity
inflammatory	O	O	I-Entity
infiltrate	O	O	I-Entity
to	O	O	O
MAP	O	O	B-Entity
requires	O	O	O
further	O	O	O
investigation	O	O	O
.	O	O	O

-DOCSTART- (27443504)

An	O	O	O
ion-gating	O	O	O
multinanochannel	O	O	O
system	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
copper	O	O	B-Entity
-	O	O	O
responsive	O	O	B-Entity
self	O	O	B-Entity
-	O	O	O
cleaving	O	O	B-Entity
DNAzyme	O	O	O

We	O	O	O
developed	O	O	O
an	O	O	O
ion-gating	O	O	O
nanochannel	O	O	O
composite	O	O	O
system	O	O	O
by	O	O	O
immobilizing	O	O	B-Entity
a	O	O	O
Cu(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-	O	O	O
responsive	O	O	B-Entity
self	O	O	B-Entity
-	O	O	O
cleaving	O	O	B-Entity
DNAzyme	O	O	B-Entity
into	O	O	O
PET	O	O	B-Entity
conical	O	O	B-Entity
multinanochannels	O	O	I-Entity
,	O	O	O
which	O	O	O
could	O	O	O
control	O	O	B-Entity
the	O	O	O
ion	O	O	B-Entity
transport	O	O	I-Entity
by	O	O	O
regulating	O	O	B-Entity
the	O	O	O
surface	O	O	B-Entity
charge	O	O	B-Entity
density	O	O	B-Entity
of	O	O	O
the	O	O	O
channels	O	O	B-Entity
.	O	O	O

-DOCSTART- (27445856)

High-Intensity	O	O	B-Entity
Intermittent	O	O	I-Entity
Training	O	O	I-Entity
Positively	O	O	B-Entity
Affects	O	O	B-Entity
Aerobic	O	O	B-Entity
and	O	O	O
Anaerobic	O	O	B-Entity
Performance	O	O	I-Entity
in	O	O	O
Judo	O	O	B-Entity
Athletes	O	O	B-Entity
Independently	O	O	O
of	O	O	O
Exercise	O	O	O
Mode	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
high-intensity	O	O	B-Entity
intermittent	O	O	I-Entity
training	O	O	I-Entity
(	O	O	O
HIIT	O	O	B-Entity
)	O	O	O
on	O	O	O
lower	O	O	B-Entity
-	O	O	O
and	O	O	O
upper-body	O	O	B-Entity
graded	O	O	B-Entity
exercise	O	O	I-Entity
and	O	O	O
high-intensity	O	O	B-Entity
intermittent	O	O	I-Entity
exercise	O	O	I-Entity
(	O	O	O
HIIE	O	O	B-Entity
,	O	O	O
four	O	O	O
Wingate	O	O	O
bouts	O	O	O
)	O	O	O
performance	O	O	B-Entity
,	O	O	O
and	O	O	O
on	O	O	O
physiological	O	O	B-Entity
and	O	O	O
muscle	O	O	B-Entity
damage	O	O	I-Entity
markers	O	O	B-Entity
responses	O	O	I-Entity
in	O	O	O
judo	O	O	B-Entity
athletes	O	O	B-Entity
.	O	O	O

Thirty-five	O	O	O
subjects	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
allocated	O	O	I-Entity
to	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8)	O	O	O
or	O	O	O
to	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
following	O	O	O
HIIT	O	O	B-Entity
groups	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
9	O	O	O
for	O	O	O
each	O	O	O
)	O	O	O
and	O	O	O
tested	O	O	B-Entity
pre-	O	O	I-Entity
and	O	O	I-Entity
post	O	O	I-Entity
-four	O	O	O
weeks	O	O	O
(	O	O	O
2	O	O	O
training	O	O	O
d·wk(-1	O	O	O
)	O	O	O
):	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
lower-body	O	O	B-Entity
cycle-ergometer	O	O	B-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
upper-body	O	O	O
cycle-ergometer	O	O	O
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
uchi-komi	O	O	B-Entity
(	O	O	O
judo	O	O	B-Entity
technique	O	O	I-Entity
entrance	O	O	I-Entity
)	O	O	O
.	O	O	O

All	O	O	O
HIIT	O	O	B-Entity
were	O	O	O
constituted	O	O	O
by	O	O	O
two	O	O	O
blocks	O	O	O
of	O	O	O
10	O	O	O
sets	O	O	O
of	O	O	O
20	O	O	O
s	O	O	O
of	O	O	O
all	O	O	O
out	O	O	O
effort	O	O	O
interspersed	O	O	O
by	O	O	O
10	O	O	O
s	O	O	O
set	O	O	O
intervals	O	O	O
and	O	O	O
5-min	O	O	O
between	O	O	O
blocks	O	O	O
.	O	O	O

For	O	O	O
the	O	O	O
upper-body	O	O	B-Entity
group	O	O	B-Entity
there	O	O	O
was	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
maximal	O	O	B-Entity
aerobic	O	O	I-Entity
power	O	O	I-Entity
in	O	O	O
graded	O	O	O
upper-body	O	O	O
exercise	O	O	B-Entity
test	O	O	I-Entity
(	O	O	O
12.3	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
lower-body	O	O	B-Entity
group	O	O	B-Entity
increased	O	O	B-Entity
power	O	O	B-Entity
at	O	O	O
onset	O	O	B-Entity
blood	O	O	I-Entity
lactate	O	O	I-Entity
in	O	O	O
graded	O	O	O
upper-body	O	O	B-Entity
exercise	O	O	B-Entity
test	O	O	I-Entity
(	O	O	O
22.1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
uchi-komi	O	O	B-Entity
group	O	O	I-Entity
increased	O	O	B-Entity
peak	O	O	O
power	O	O	O
in	O	O	O
upper	O	O	B-Entity
-	O	O	O
(	O	O	O
16.7	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
lower-body	O	O	B-Entity
(	O	O	O
8.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
lower-body	O	O	O
group	O	O	O
increased	O	O	O
lower-body	O	O	O
mean	O	O	O
power	O	O	O
(	O	O	O
14.2	O	O	O
%	O	O	O
)	O	O	O
during	O	O	O
the	O	O	O
HIIE	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
delta	O	O	B-Entity
blood	O	O	I-Entity
lactate	O	O	I-Entity
for	O	O	O
the	O	O	O
uchi-komi	O	O	B-Entity
training	O	O	B-Entity
group	O	O	B-Entity
and	O	O	O
in	O	O	O
the	O	O	O
third	O	O	O
and	O	O	O
fourth	O	O	O
bouts	O	O	O
for	O	O	O
the	O	O	O
upper-body	O	O	B-Entity
training	O	O	O
group	O	O	O
.	O	O	O

Training	O	O	B-Entity
induced	O	O	O
testosterone-cortisol	O	O	B-Entity
ratio	O	O	B-Entity
increased	O	O	B-Entity
in	O	O	O
the	O	O	O
lower-body	O	O	B-Entity
HIIE	O	O	B-Entity
for	O	O	O
the	O	O	O
lower-body	O	O	O
(	O	O	O
14.9	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
uchi-komi	O	O	B-Entity
(	O	O	I-Entity
61.4	O	O	I-Entity
%	O	O	I-Entity
)	O	O	I-Entity
training	O	O	I-Entity
groups	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
short-duration	O	O	B-Entity
low-volume	O	O	O
HIIT	O	O	B-Entity
added	O	O	O
to	O	O	O
regular	O	O	B-Entity
judo	O	O	I-Entity
training	O	O	I-Entity
was	O	O	O
able	O	O	O
to	O	O	O
increase	O	O	B-Entity
upper-body	O	O	B-Entity
aerobic	O	O	B-Entity
power	O	O	I-Entity
,	O	O	O
lower	O	O	B-Entity
-	O	O	O
and	O	O	O
upper-body	O	O	O
HIIE	O	O	B-Entity
performance	O	O	B-Entity
.	O	O	O

-DOCSTART- (27445997)

Microbiomes	O	O	B-Entity
of	O	O	O
Muricea	O	O	B-Entity
californica	O	O	I-Entity
and	O	O	O
M.	O	O	B-Entity
fruticosa	O	O	I-Entity
:	O	O	O
Comparative	O	O	B-Entity
Analyses	O	O	I-Entity
of	O	O	O
Two	O	O	O
Co-occurring	O	O	O
Eastern	O	O	B-Entity
Pacific	O	O	I-Entity
Octocorals	O	O	O

Octocorals	O	O	B-Entity
are	O	O	O
sources	O	O	O
of	O	O	O
novel	O	O	O
but	O	O	O
understudied	O	O	B-Entity
microbial	O	O	B-Entity
diversity	O	O	B-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
scleractinian	O	O	B-Entity
or	O	O	O
reef-building	O	O	B-Entity
coral	O	O	I-Entity
microbiomes	O	O	I-Entity
have	O	O	O
been	O	O	O
heavily	O	O	O
examined	O	O	B-Entity
in	O	O	O
light	O	O	O
of	O	O	O
the	O	O	O
threats	O	O	B-Entity
of	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

Muricea	O	O	B-Entity
californica	O	O	I-Entity
and	O	O	O
Muricea	O	O	B-Entity
fruticosa	O	O	I-Entity
are	O	O	O
two	O	O	O
co-occurring	O	O	B-Entity
species	O	O	I-Entity
of	O	O	O
gorgonian	O	O	B-Entity
octocoral	O	O	B-Entity
abundantly	O	O	B-Entity
found	O	O	I-Entity
in	O	O	O
the	O	O	O
kelp	O	O	B-Entity
forests	O	O	B-Entity
of	O	O	O
southern	O	O	B-Entity
California	O	O	I-Entity
,	O	O	O
and	O	O	O
thus	O	O	O
provide	O	O	O
an	O	O	O
excellent	O	O	B-Entity
basis	O	O	I-Entity
to	O	O	O
determine	O	O	O
if	O	O	O
octocoral	O	O	O
microbiomes	O	O	B-Entity
are	O	O	O
host	O	O	B-Entity
specific	O	O	B-Entity
.	O	O	O

Using	O	O	O
Illumina	O	O	B-Entity
MiSeq	O	O	I-Entity
amplicon	O	O	I-Entity
sequencing	O	O	I-Entity
and	O	O	O
replicate	O	O	B-Entity
samples	O	O	I-Entity
,	O	O	O
we	O	O	O
evaluated	O	O	O
the	O	O	O
microbiomes	O	O	B-Entity
collected	O	O	O
from	O	O	O
multiple	O	O	B-Entity
colonies	O	O	I-Entity
of	O	O	O
both	O	O	O
species	O	O	B-Entity
of	O	O	O
Muricea	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
both	O	O	O
inter-	O	O	B-Entity
and	O	O	O
intra-colony	O	O	B-Entity
microbiome	O	O	B-Entity
variabilities	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
microbiomes	O	O	B-Entity
from	O	O	O
overlying	O	O	O
sea	O	O	B-Entity
water	O	O	I-Entity
and	O	O	O
nearby	O	O	O
zoanthids	O	O	B-Entity
(	O	O	O
another	O	O	O
benthic	O	O	B-Entity
invertebrate	O	O	I-Entity
)	O	O	O
were	O	O	O
also	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analysis	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
whether	O	O	O
bacterial	O	O	B-Entity
taxa	O	O	I-Entity
specifically	O	O	O
associate	O	O	B-Entity
with	O	O	I-Entity
octocorals	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
also	O	O	O
the	O	O	O
first	O	O	B-Entity
report	O	O	I-Entity
of	O	O	O
microbiomes	O	O	B-Entity
from	O	O	O
these	O	O	O
species	O	O	B-Entity
of	O	O	O
Muricea	O	O	B-Entity
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
microbiomes	O	O	B-Entity
isolated	O	O	B-Entity
from	O	O	O
each	O	O	O
sample	O	O	B-Entity
type	O	O	B-Entity
are	O	O	O
distinct	O	O	B-Entity
,	O	O	O
and	O	O	O
specifically	O	O	O
,	O	O	O
that	O	O	O
octocoral	O	O	B-Entity
species	O	O	B-Entity
type	O	O	O
had	O	O	O
the	O	O	O
greatest	O	O	O
effect	O	O	O
on	O	O	O
predicting	O	O	B-Entity
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
the	O	O	O
Muricea	O	O	B-Entity
microbiome	O	O	B-Entity
.	O	O	O

Bacterial	O	O	B-Entity
taxa	O	O	I-Entity
contributing	O	O	O
to	O	O	O
compositional	O	O	B-Entity
differences	O	O	I-Entity
include	O	O	O
distinct	O	O	B-Entity
strains	O	O	B-Entity
of	O	O	O
Mycoplasma	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
either	O	O	O
M.	O	O	B-Entity
californica	O	O	I-Entity
or	O	O	O
M.	O	O	B-Entity
fruticosa	O	O	I-Entity
,	O	O	O
an	O	O	O
abundance	O	O	B-Entity
of	O	O	O
Spirochaetes	O	O	B-Entity
observed	O	O	B-Entity
on	O	O	O
M.	O	O	O
californica	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
greater	O	O	B-Entity
diversity	O	O	B-Entity
of	O	O	O
γ-Proteobacteria	O	O	B-Entity
associated	O	O	O
with	O	O	O
M.	O	O	O
fruticosa	O	O	O
.	O	O	O

Many	O	O	O
of	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
taxa	O	O	I-Entity
contributing	O	O	O
to	O	O	O
these	O	O	O
differences	O	O	B-Entity
are	O	O	O
known	O	O	O
for	O	O	O
their	O	O	O
presence	O	O	B-Entity
in	O	O	O
photosymbiont-containing	O	O	B-Entity
invertebrate	O	O	I-Entity
microbiomes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27447713)

2,8-Dihydroxyadenine	O	O	B-Entity
Nephropathy	O	O	B-Entity
Identified	O	O	O
as	O	O	O
Cause	O	O	B-Entity
of	O	O	O
End-Stage	O	O	B-Entity
Renal	O	O	I-Entity
Disease	O	O	I-Entity
After	O	O	O
Renal	O	O	O
Transplant	O	O	O

Adenine	O	O	B-Entity
phosphoribosyltransferase	O	O	I-Entity
deficiency	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	O
autosomal	O	O	B-Entity
recessive	O	O	I-Entity
disorder	O	O	I-Entity
of	O	O	O
uric	O	O	B-Entity
acid	O	O	I-Entity
metabolism	O	O	B-Entity
that	O	O	O
leads	O	O	O
to	O	O	O
formation	O	O	B-Entity
and	O	O	O
excretion	O	O	B-Entity
of	O	O	O
2,8-dihydroxyadenine	O	O	B-Entity
into	O	O	O
urine	O	O	B-Entity
.	O	O	O

The	O	O	O
low	O	O	O
solubility	O	O	B-Entity
of	O	O	O
2,8-dihydroxyadenine	O	O	B-Entity
results	O	O	O
in	O	O	O
precipitation	O	O	B-Entity
and	O	O	O
formation	O	O	B-Entity
of	O	O	O
urinary	O	O	B-Entity
crystals	O	O	I-Entity
and	O	O	O
renal	O	O	B-Entity
stones	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
this	O	O	O
disorder	O	O	B-Entity
usually	O	O	O
have	O	O	O
recurrent	O	O	B-Entity
nephrolithiasis	O	O	I-Entity
and	O	O	O
can	O	O	O
develop	O	O	O
nephropathy	O	O	B-Entity
secondary	O	O	I-Entity
to	O	O	O
crystal	O	O	B-Entity
precipitation	O	O	B-Entity
in	O	O	O
the	O	O	O
renal	O	O	B-Entity
parenchyma	O	O	I-Entity
.	O	O	O

The	O	O	O
disease	O	O	B-Entity
is	O	O	O
most	O	O	O
often	O	O	O
underdiagnosed	O	O	B-Entity
and	O	O	O
can	O	O	O
recur	O	O	B-Entity
in	O	O	O
renal	O	O	B-Entity
transplant	O	O	I-Entity
,	O	O	O
causing	O	O	B-Entity
graft	O	O	B-Entity
failure	O	O	I-Entity
.	O	O	O

Lack	O	O	O
of	O	O	O
specific	O	O	O
clinical	O	O	B-Entity
manifestations	O	O	B-Entity
,	O	O	O
chemical	O	O	B-Entity
and	O	O	O
radiologic	O	O	B-Entity
features	O	O	I-Entity
identical	O	O	O
to	O	O	O
those	O	O	O
shown	O	O	O
with	O	O	O
uric	O	O	B-Entity
acid	O	O	I-Entity
stones	O	O	O
,	O	O	O
and	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
awareness	O	O	I-Entity
among	O	O	O
clinicians	O	O	B-Entity
are	O	O	O
among	O	O	O
the	O	O	O
causes	O	O	B-Entity
for	O	O	O
the	O	O	O
underdiagnoses	O	O	B-Entity
of	O	O	O
this	O	O	O
treatable	O	O	B-Entity
disease	O	O	B-Entity
.	O	O	O

Allopurinol	O	O	B-Entity
,	O	O	O
a	O	O	O
xanthine	O	O	B-Entity
dehydrogenase	O	O	I-Entity
inhibitor	O	O	B-Entity
,	O	O	O
is	O	O	O
the	O	O	O
mainstay	O	O	O
of	O	O	O
treatment	O	O	B-Entity
,	O	O	O
supported	O	O	O
by	O	O	O
high	O	O	O
fluid	O	O	B-Entity
intake	O	O	I-Entity
and	O	O	O
dietary	O	O	B-Entity
modifications	O	O	I-Entity
.	O	O	O

The	O	O	O
possibility	O	O	O
of	O	O	O
adenine	O	O	B-Entity
phosphoribosyl	O	O	I-Entity
transferase	O	O	I-Entity
deficiency	O	O	O
should	O	O	O
be	O	O	O
considered	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	O
of	O	O	O
urolithiasis	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
recurrent	O	O	B-Entity
urolithiasis	O	O	I-Entity
,	O	O	O
and	O	O	O
patients	O	O	O
with	O	O	O
urolithiasis	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
renal	O	O	B-Entity
failure	O	O	I-Entity
of	O	O	O
unknown	O	O	O
cause	O	O	B-Entity
,	O	O	O
including	O	O	O
patients	O	O	O
with	O	O	O
end-stage	O	O	B-Entity
renal	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
renal	O	O	B-Entity
transplant	O	O	I-Entity
recipients	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
41-year-old	O	O	O
female	O	O	B-Entity
patient	O	O	I-Entity
who	O	O	O
had	O	O	O
a	O	O	O
late	O	O	B-Entity
diagnosis	O	O	I-Entity
of	O	O	O
2,8-dihydroxyadenine	O	O	B-Entity
nephropathy	O	O	B-Entity
-induced	O	O	O
end-stage	O	O	B-Entity
renal	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
made	O	O	O
on	O	O	O
the	O	O	O
native	O	O	B-Entity
nephrectomy	O	O	B-Entity
that	O	O	O
accompanied	O	O	O
the	O	O	O
renal	O	O	B-Entity
transplant	O	O	I-Entity
,	O	O	O
and	O	O	O
who	O	O	O
had	O	O	O
a	O	O	O
timely	O	O	O
intervention	O	O	O
that	O	O	O
prevented	O	O	B-Entity
recurrence	O	O	B-Entity
in	O	O	O
the	O	O	O
graft	O	O	B-Entity
.	O	O	O

-DOCSTART- (27449022)

Social	O	O	B-Entity
capital	O	O	I-Entity
and	O	O	O
healthy	O	O	B-Entity
ageing	O	O	B-Entity
in	O	O	O
Indonesia	O	O	O

A	O	O	O
large	O	O	B-Entity
international	O	O	B-Entity
literature	O	O	B-Entity
has	O	O	O
found	O	O	O
a	O	O	O
positive	O	O	B-Entity
association	O	O	B-Entity
between	O	O	O
social	O	O	B-Entity
capital	O	O	I-Entity
and	O	O	O
measures	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
paucity	O	O	O
of	O	O	O
research	O	O	B-Entity
on	O	O	O
the	O	O	O
links	O	O	B-Entity
between	O	O	O
social	O	O	B-Entity
capital	O	O	I-Entity
and	O	O	O
healthy	O	O	B-Entity
ageing	O	O	B-Entity
in	O	O	O
a	O	O	O
developing	O	O	B-Entity
country	O	O	I-Entity
environment	O	O	B-Entity
,	O	O	O
where	O	O	O
universal	O	O	B-Entity
social	O	O	I-Entity
security	O	O	I-Entity
coverage	O	O	I-Entity
is	O	O	O
absent	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
infrastructure	O	O	I-Entity
is	O	O	O
poor	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
develop	O	O	O
and	O	O	O
empirically	O	O	O
test	O	O	B-Entity
a	O	O	O
model	O	O	B-Entity
of	O	O	O
the	O	O	O
linkages	O	O	B-Entity
between	O	O	O
social	O	O	B-Entity
capital	O	O	I-Entity
and	O	O	O
the	O	O	O
health	O	O	B-Entity
outcomes	O	O	I-Entity
for	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
in	O	O	O
Indonesia	O	O	B-Entity
,	O	O	O
using	O	O	O
data	O	O	B-Entity
from	O	O	O
the	O	O	O
Indonesian	O	O	B-Entity
Family	O	O	I-Entity
Life	O	O	I-Entity
Survey-East	O	O	I-Entity
(	O	O	O
IFLS-East	O	O	B-Entity
)	O	O	O
,	O	O	O
conducted	O	O	O
in	O	O	O
2012	O	O	O
.	O	O	O

Using	O	O	O
multivariate	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
we	O	O	O
examine	O	O	O
whether	O	O	O
social	O	O	B-Entity
capital	O	O	I-Entity
plays	O	O	O
a	O	O	O
role	O	O	B-Entity
in	O	O	O
mitigating	O	O	B-Entity
poor	O	O	B-Entity
health	O	O	I-Entity
among	O	O	O
older	O	O	B-Entity
individuals	O	O	B-Entity
aged	O	O	B-Entity
50	O	O	O
years	O	O	B-Entity
and	O	O	O
above	O	O	O
in	O	O	O
Indonesia	O	O	B-Entity
's	O	O	O
most	O	O	O
vulnerable	O	O	B-Entity
provinces	O	O	I-Entity
.	O	O	O

We	O	O	O
test	O	O	B-Entity
the	O	O	O
robustness	O	O	B-Entity
of	O	O	O
these	O	O	O
social	O	O	B-Entity
capital	O	O	I-Entity
variables	O	O	B-Entity
across	O	O	O
different	O	O	O
health	O	O	B-Entity
measures	O	O	B-Entity
(	O	O	O
self-assessed	O	O	B-Entity
health	O	O	O
,	O	O	O
Activities	O	O	B-Entity
of	O	O	I-Entity
Daily	O	O	I-Entity
Living	O	O	I-Entity
(	O	O	O
ADL	O	O	B-Entity
)	O	O	O
,	O	O	O
measures	O	O	O
of	O	O	O
chronic	O	O	B-Entity
illness	O	O	I-Entity
and	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
measures	O	O	O
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
across	O	O	O
different	O	O	O
demographic	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
after	O	O	O
controlling	O	O	B-Entity
for	O	O	O
an	O	O	O
array	O	O	B-Entity
of	O	O	O
socio-economic	O	O	B-Entity
,	O	O	O
demographic	O	O	O
and	O	O	O
geographic	O	O	B-Entity
characteristics	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
show	O	O	O
that	O	O	O
access	O	O	B-Entity
to	O	O	O
better	O	O	O
social	O	O	B-Entity
capital	O	O	I-Entity
(	O	O	O
using	O	O	O
measures	O	O	B-Entity
of	O	O	O
neighbourhood	O	O	B-Entity
trust	O	O	B-Entity
and	O	O	O
community	O	O	B-Entity
participation	O	O	I-Entity
)	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
higher	O	O	B-Entity
degree	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
mobility	O	O	I-Entity
,	O	O	O
independence	O	O	B-Entity
,	O	O	O
and	O	O	O
mental	O	O	B-Entity
well-being	O	O	I-Entity
among	O	O	O
older	O	O	B-Entity
individuals	O	O	B-Entity
but	O	O	O
has	O	O	O
no	O	O	O
influence	O	O	B-Entity
on	O	O	O
chronic	O	O	B-Entity
illnesses	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
are	O	O	O
consistent	O	O	B-Entity
when	O	O	O
we	O	O	O
estimate	O	O	B-Entity
samples	O	O	B-Entity
disaggregated	O	O	O
by	O	O	O
gender	O	O	B-Entity
,	O	O	O
rural	O	O	B-Entity
/	O	O	O
urban	O	O	B-Entity
residence	O	O	B-Entity
,	O	O	O
and	O	O	O
by	O	O	O
age	O	O	B-Entity
categories	O	O	B-Entity
.	O	O	O

From	O	O	O
a	O	O	O
policy	O	O	B-Entity
perspective	O	O	O
these	O	O	O
results	O	O	B-Entity
point	O	O	O
to	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
social	O	O	B-Entity
capital	O	O	I-Entity
measures	O	O	B-Entity
in	O	O	O
moderating	O	O	B-Entity
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
poor	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
the	O	O	O
Activities	O	O	B-Entity
of	O	O	I-Entity
Daily	O	O	I-Entity
Living	O	O	I-Entity
.	O	O	O

-DOCSTART- (27449508)

Modulation	O	O	B-Entity
of	O	O	O
Interleukins	O	O	B-Entity
in	O	O	O
Sepsis	O	O	B-Entity
-	O	O	O
Associated	O	O	B-Entity
Clotting	O	O	B-Entity
Disorders	O	O	I-Entity
:	O	O	O
Interplay	O	O	O
With	O	O	O
Hemostatic	O	O	O
Derangement	O	O	O

Interleukins	O	O	B-Entity
play	O	O	O
a	O	O	O
central	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
the	O	O	O
immune	O	O	B-Entity
system	O	O	I-Entity
and	O	O	O
are	O	O	O
involved	O	O	B-Entity
in	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
immunological	O	O	B-Entity
,	O	O	O
inflammatory	O	O	B-Entity
,	O	O	O
and	O	O	O
infectious	O	O	B-Entity
disease	O	O	I-Entity
states	O	O	B-Entity
including	O	O	O
sepsis	O	O	B-Entity
syndrome	O	O	I-Entity
.	O	O	O

Levels	O	O	B-Entity
of	O	O	O
interleukins	O	O	B-Entity
may	O	O	O
correlate	O	O	B-Entity
with	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
and	O	O	O
may	O	O	O
directly	O	O	B-Entity
or	O	O	O
indirectly	O	O	B-Entity
affect	O	O	B-Entity
some	O	O	O
of	O	O	O
the	O	O	O
regulators	O	O	B-Entity
of	O	O	O
coagulation	O	O	B-Entity
and	O	O	O
fibrinolysis	O	O	B-Entity
,	O	O	O
thereby	O	O	O
disrupting	O	O	O
hemostasis	O	O	B-Entity
and	O	O	O
thrombosis	O	O	B-Entity
.	O	O	O

Our	O	O	O
hypothesis	O	O	B-Entity
is	O	O	O
that	O	O	O
in	O	O	O
sepsis-associated	O	O	B-Entity
coagulopathies	O	O	I-Entity
(	O	O	O
SACs	O	O	B-Entity
)	O	O	O
,	O	O	O
interleukins	O	O	B-Entity
may	O	O	O
be	O	O	O
upregulated	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
hemostatic	O	O	B-Entity
imbalance	O	O	I-Entity
by	O	O	O
generating	O	O	O
thrombogenic	O	O	B-Entity
mediators	O	O	I-Entity
.	O	O	O

We	O	O	O
profiled	O	O	B-Entity
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
interleukins	O	O	B-Entity
IL-1α	O	O	B-Entity
,	O	O	O
IL-1β	O	O	B-Entity
,	O	O	O
IL-2	O	O	B-Entity
,	O	O	O
IL-4	O	O	B-Entity
,	O	O	O
IL-6	O	O	B-Entity
,	O	O	O
IL-8	O	O	B-Entity
,	O	O	O
and	O	O	O
IL-10	O	O	B-Entity
in	O	O	B-Entity
addition	O	O	I-Entity
to	O	O	I-Entity
d-dimer	O	O	B-Entity
(	O	O	O
DD	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
SAC	O	O	B-Entity
and	O	O	O
in	O	O	O
normal	O	O	B-Entity
donors	O	O	B-Entity
.	O	O	O

We	O	O	O
observed	O	O	B-Entity
the	O	O	O
highest	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
interleukins	O	O	B-Entity
IL-6	O	O	B-Entity
(	O	O	O
322-fold	O	O	B-Entity
)	O	O	O
,	O	O	O
IL-8	O	O	B-Entity
(	O	O	O
48-fold	O	O	B-Entity
)	O	O	O
,	O	O	O
IL-10	O	O	B-Entity
(	O	O	O
72-fold	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
DD	O	O	B-Entity
(	O	O	O
18-fold	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
suggests	O	O	B-Entity
that	O	O	O
interleukins	O	O	B-Entity
such	O	O	O
as	O	O	O
IL-6	O	O	B-Entity
and	O	O	O
IL-10	O	O	B-Entity
have	O	O	O
a	O	O	O
close	O	O	O
association	O	O	B-Entity
with	O	O	I-Entity
coagulopathy	O	O	B-Entity
and	O	O	O
fibrinolytic	O	O	B-Entity
dysregulation	O	O	I-Entity
in	O	O	O
sepsis	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
considered	O	O	B-Entity
as	O	O	O
candidates	O	O	B-Entity
for	O	O	O
potential	O	O	B-Entity
therapeutic	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	O
SAC	O	O	B-Entity
.	O	O	O

-DOCSTART- (27450737)

Thymosin	O	O	B-Entity
β4	O	O	I-Entity
:	O	O	O
Roles	O	O	O
in	O	O	O
Development	O	O	B-Entity
,	O	O	O
Repair	O	O	B-Entity
,	O	O	O
and	O	O	O
Engineering	O	O	B-Entity
of	O	O	O
the	O	O	O
Cardiovascular	O	O	O
System	O	O	O

The	O	O	O
burden	O	O	O
of	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
is	O	O	O
a	O	O	O
growing	O	O	O
worldwide	O	O	O
issue	O	O	O
that	O	O	O
demands	O	O	O
attention	O	O	O
.	O	O	O

While	O	O	O
many	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
are	O	O	O
ongoing	O	O	O
to	O	O	O
test	O	O	B-Entity
therapies	O	O	B-Entity
for	O	O	O
treating	O	O	B-Entity
the	O	O	O
heart	O	O	B-Entity
after	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
(	O	O	O
MI	O	O	B-Entity
)	O	O	O
and	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
there	O	O	O
are	O	O	O
few	O	O	O
options	O	O	O
doctors	O	O	B-Entity
able	O	O	O
to	O	O	O
currently	O	O	O
give	O	O	O
patients	O	O	B-Entity
to	O	O	O
repair	O	O	B-Entity
the	O	O	I-Entity
heart	O	O	I-Entity
.	O	O	O

This	O	O	O
eventually	O	O	O
leads	O	O	O
to	O	O	O
decreased	O	O	O
ventricular	O	O	B-Entity
contractility	O	O	I-Entity
and	O	O	O
increased	O	O	O
systemic	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
including	O	O	O
vascular	O	O	B-Entity
disorders	O	O	I-Entity
that	O	O	O
could	O	O	O
result	O	O	O
in	O	O	O
stroke	O	O	B-Entity
.	O	O	O

Small	O	O	O
peptides	O	O	B-Entity
such	O	O	O
as	O	O	O
thymosin	O	O	B-Entity
β4	O	O	I-Entity
(	O	O	O
Tβ4	O	O	B-Entity
)	O	O	O
are	O	O	O
upregulated	O	O	O
in	O	O	O
the	O	O	O
cardiovascular	O	O	B-Entity
niche	O	O	B-Entity
during	O	O	O
fetal	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
after	O	O	O
injuries	O	O	B-Entity
such	O	O	O
as	O	O	O
MI	O	O	B-Entity
,	O	O	O
providing	O	O	O
increased	O	O	O
neovasculogenesis	O	O	B-Entity
and	O	O	O
paracrine	O	O	B-Entity
signals	O	O	I-Entity
for	O	O	O
endogenous	O	O	B-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
recruitment	O	O	O
to	O	O	O
aid	O	O	O
in	O	O	O
wound	O	O	B-Entity
repair	O	O	I-Entity
.	O	O	O

New	O	O	O
research	O	O	B-Entity
is	O	O	O
looking	O	O	O
into	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
administration	O	O	B-Entity
of	O	O	O
Tβ4	O	O	B-Entity
through	O	O	O
injections	O	O	B-Entity
and	O	O	O
coatings	O	O	B-Entity
on	O	O	O
implants	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
its	O	O	O
effect	O	O	O
on	O	O	O
cell	O	O	B-Entity
differentiation	O	O	I-Entity
.	O	O	O

Results	O	O	O
so	O	O	O
far	O	O	O
demonstrate	O	O	O
Tβ4	O	O	B-Entity
administration	O	O	B-Entity
leads	O	O	O
to	O	O	O
robust	O	O	O
increases	O	O	O
in	O	O	O
angiogenesis	O	O	B-Entity
and	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
in	O	O	O
the	O	O	O
heart	O	O	B-Entity
after	O	O	O
MI	O	O	B-Entity
and	O	O	O
the	O	O	O
brain	O	O	B-Entity
after	O	O	O
stroke	O	O	B-Entity
,	O	O	O
and	O	O	O
can	O	O	O
differentiate	O	O	O
adult	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
toward	O	O	O
the	O	O	O
cardiac	O	O	B-Entity
lineage	O	O	B-Entity
for	O	O	O
implantation	O	O	B-Entity
to	O	O	O
the	O	O	O
heart	O	O	O
to	O	O	O
increase	O	O	O
contractility	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
.	O	O	O

Future	O	O	O
work	O	O	O
,	O	O	O
some	O	O	O
of	O	O	O
which	O	O	O
is	O	O	O
currently	O	O	O
in	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
,	O	O	O
will	O	O	O
demonstrate	O	O	O
the	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
effect	O	O	B-Entity
of	O	O	O
these	O	O	O
therapies	O	O	B-Entity
on	O	O	O
human	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
goal	O	O	B-Entity
of	O	O	O
helping	O	O	O
the	O	O	O
millions	O	O	O
of	O	O	O
people	O	O	B-Entity
worldwide	O	O	O
affected	O	O	O
by	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

-DOCSTART- (27451448)

Yersinia	O	O	B-Entity
ruckeri	O	O	I-Entity
Isolates	O	O	B-Entity
Recovered	O	O	B-Entity
from	O	O	I-Entity
Diseased	O	O	B-Entity
Atlantic	O	O	B-Entity
Salmon	O	O	I-Entity
(	O	O	O
Salmo	O	O	B-Entity
salar	O	O	I-Entity
)	O	O	O
in	O	O	O
Scotland	O	O	B-Entity
Are	O	O	O
More	O	O	O
Diverse	O	O	O
than	O	O	O
Those	O	O	O
from	O	O	O
Rainbow	O	O	B-Entity
Trout	O	O	I-Entity
(	O	O	O
Oncorhynchus	O	O	B-Entity
mykiss	O	O	I-Entity
)	O	O	O
and	O	O	O
Represent	O	O	B-Entity
Distinct	O	O	O
Subpopulations	O	O	O

Yersinia	O	O	B-Entity
ruckeri	O	O	I-Entity
is	O	O	O
the	O	O	O
etiological	O	O	B-Entity
agent	O	O	I-Entity
of	O	O	O
enteric	O	O	B-Entity
redmouth	O	O	I-Entity
(	O	O	O
ERM	O	O	B-Entity
)	O	O	O
disease	O	O	B-Entity
of	O	O	O
farmed	O	O	O
salmonids	O	O	B-Entity
.	O	O	O

Enteric	O	O	B-Entity
redmouth	O	O	I-Entity
disease	O	O	I-Entity
is	O	O	O
traditionally	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
rainbow	O	O	B-Entity
trout	O	O	I-Entity
(	O	O	O
Oncorhynchus	O	O	B-Entity
mykiss	O	O	I-Entity
,	O	O	O
Walbaum	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
its	O	O	O
incidence	O	O	B-Entity
in	O	O	O
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
(	O	O	O
Salmo	O	O	B-Entity
salar	O	O	I-Entity
)	O	O	O
is	O	O	O
increasing	O	O	B-Entity
.	O	O	O

Yersinia	O	O	B-Entity
ruckeri	O	O	I-Entity
isolates	O	O	B-Entity
recovered	O	O	B-Entity
from	O	O	I-Entity
diseased	O	O	B-Entity
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
have	O	O	O
been	O	O	O
poorly	O	O	B-Entity
characterized	O	O	I-Entity
,	O	O	O
and	O	O	O
very	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
relationship	O	O	B-Entity
of	O	O	O
the	O	O	O
isolates	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
these	O	O	O
two	O	O	O
species	O	O	B-Entity
.	O	O	O

Phenotypic	O	O	B-Entity
approaches	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
characterize	O	O	O
109	O	O	O
Y.	O	O	B-Entity
ruckeri	O	O	I-Entity
isolates	O	O	B-Entity
recovered	O	O	O
over	O	O	O
a	O	O	O
14-year	O	O	O
period	O	O	O
from	O	O	O
infected	O	O	B-Entity
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
in	O	O	O
Scotland	O	O	B-Entity
;	O	O	O
26	O	O	O
isolates	O	O	O
from	O	O	O
infected	O	O	O
rainbow	O	O	B-Entity
trout	O	O	I-Entity
were	O	O	O
also	O	O	O
characterized	O	O	B-Entity
.	O	O	O

Biotyping	O	O	B-Entity
,	O	O	O
serotyping	O	O	B-Entity
,	O	O	O
and	O	O	O
comparison	O	O	B-Entity
of	O	O	O
outer	O	O	B-Entity
membrane	O	O	I-Entity
protein	O	O	B-Entity
profiles	O	O	I-Entity
identified	O	O	O
19	O	O	O
Y.	O	O	B-Entity
ruckeri	O	O	I-Entity
clones	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
but	O	O	O
only	O	O	O
five	O	O	O
associated	O	O	O
with	O	O	O
rainbow	O	O	B-Entity
trout	O	O	I-Entity
;	O	O	O
none	O	O	O
of	O	O	O
the	O	O	O
Atlantic	O	O	O
salmon	O	O	O
clones	O	O	O
occurred	O	O	O
in	O	O	O
rainbow	O	O	O
trout	O	O	O
and	O	O	O
vice	O	O	O
versa	O	O	O
These	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
distinct	O	O	O
subpopulations	O	O	B-Entity
of	O	O	O
Y.	O	O	O
ruckeri	O	O	O
are	O	O	O
associated	O	O	O
with	O	O	O
each	O	O	O
species	O	O	B-Entity
.	O	O	O

A	O	O	O
new	O	O	O
O	O	O	B-Entity
serotype	O	O	B-Entity
(	O	O	O
designated	O	O	O
O8	O	O	O
)	O	O	O
was	O	O	O
identified	O	O	O
in	O	O	O
56	O	O	B-Entity
biotype	O	O	I-Entity
1	O	O	I-Entity
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
isolates	O	O	B-Entity
and	O	O	O
was	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
serotype	O	O	O
identified	O	O	O
from	O	O	O
2006	O	O	O
to	O	O	O
2011	O	O	O
and	O	O	O
in	O	O	O
2014	O	O	O
,	O	O	O
suggesting	O	O	O
an	O	O	O
increased	O	O	B-Entity
prevalence	O	O	I-Entity
during	O	O	O
the	O	O	O
time	O	O	O
period	O	O	O
sampled	O	O	O
.	O	O	O

Rainbow	O	O	B-Entity
trout	O	O	I-Entity
isolates	O	O	B-Entity
were	O	O	O
represented	O	O	B-Entity
almost	O	O	O
exclusively	O	O	O
by	O	O	O
the	O	O	O
same	O	O	O
biotype	O	O	B-Entity
2	O	O	I-Entity
,	O	O	O
serotype	O	O	B-Entity
O1	O	O	I-Entity
clone	O	O	O
that	O	O	O
has	O	O	O
been	O	O	O
responsible	O	O	O
for	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
ERM	O	O	B-Entity
outbreaks	O	O	O
in	O	O	O
this	O	O	O
species	O	O	B-Entity
within	O	O	O
the	O	O	O
United	O	O	B-Entity
Kingdom	O	O	I-Entity
since	O	O	O
the	O	O	O
1980s	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
identification	O	O	O
of	O	O	O
two	O	O	O
biotype	O	O	B-Entity
2	O	O	I-Entity
,	O	O	O
serotype	O	O	B-Entity
O8	O	O	I-Entity
isolates	O	O	B-Entity
in	O	O	O
rainbow	O	O	B-Entity
trout	O	O	I-Entity
suggests	O	O	O
that	O	O	O
vaccines	O	O	B-Entity
containing	O	O	O
serotypes	O	O	B-Entity
O1	O	O	I-Entity
and	O	O	I-Entity
O8	O	O	I-Entity
should	O	O	O
be	O	O	O
evaluated	O	O	O
in	O	O	O
both	O	O	O
rainbow	O	O	O
trout	O	O	O
and	O	O	O
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
for	O	O	O
application	O	O	O
in	O	O	O
Scotland	O	O	B-Entity
.	O	O	O

Vaccination	O	O	B-Entity
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
protecting	O	O	O
Atlantic	O	O	B-Entity
salmon	O	O	B-Entity
against	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
pathogen	O	O	O
Yersinia	O	O	B-Entity
ruckeri	O	O	I-Entity
,	O	O	O
but	O	O	O
,	O	O	O
in	O	O	O
recent	O	O	O
years	O	O	O
,	O	O	O
there	O	O	O
has	O	O	O
been	O	O	O
an	O	O	O
increasing	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
vaccine	O	O	B-Entity
breakdown	O	O	O
in	O	O	O
salmon	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
largely	O	O	O
because	O	O	O
current	O	O	O
vaccines	O	O	B-Entity
are	O	O	O
aimed	O	O	O
at	O	O	O
rainbow	O	O	B-Entity
trout	O	O	I-Entity
and	O	O	O
are	O	O	O
based	O	O	O
on	O	O	O
serotypes	O	O	B-Entity
specific	O	O	O
for	O	O	O
this	O	O	O
species	O	O	B-Entity
.	O	O	O

A	O	O	O
wider	O	O	O
range	O	O	O
of	O	O	O
serotypes	O	O	B-Entity
is	O	O	O
responsible	O	O	O
for	O	O	O
infection	O	O	B-Entity
in	O	O	O
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
,	O	O	O
but	O	O	O
very	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
diversity	O	O	O
of	O	O	O
these	O	O	O
strains	O	O	B-Entity
and	O	O	O
their	O	O	O
relationships	O	O	B-Entity
to	O	O	O
those	O	O	O
recovered	O	O	B-Entity
from	O	O	I-Entity
rainbow	O	O	B-Entity
trout	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
Y.	O	O	B-Entity
ruckeri	O	O	I-Entity
isolates	O	O	B-Entity
recovered	O	O	B-Entity
from	O	O	I-Entity
diseased	O	O	B-Entity
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
in	O	O	O
Scotland	O	O	B-Entity
are	O	O	O
more	O	O	O
diverse	O	O	O
than	O	O	O
those	O	O	O
from	O	O	O
rainbow	O	O	B-Entity
trout	O	O	I-Entity
;	O	O	O
furthermore	O	O	O
,	O	O	O
isolates	O	O	O
from	O	O	O
the	O	O	O
two	O	O	O
species	O	O	B-Entity
represent	O	O	B-Entity
distinct	O	O	O
subpopulations	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
a	O	O	O
new	O	O	O
O	O	O	B-Entity
serotype	O	O	I-Entity
was	O	O	O
identified	O	O	O
that	O	O	O
is	O	O	O
responsible	O	O	O
for	O	O	O
a	O	O	O
significant	O	O	B-Entity
proportion	O	O	B-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
in	O	O	O
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
are	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
important	O	O	O
implications	O	O	O
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	I-Entity
improved	O	O	I-Entity
vaccines	O	O	I-Entity
against	O	O	O
Y.	O	O	B-Entity
ruckeri	O	O	I-Entity
.	O	O	O

-DOCSTART- (27452524)

CD84	O	O	B-Entity
mediates	O	O	O
CLL	O	O	B-Entity
-	O	O	O
microenvironment	O	O	B-Entity
interactions	O	O	O

Chronic	O	O	B-Entity
lymphocytic	O	O	I-Entity
leukemia	O	O	I-Entity
(	O	O	O
CLL	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
malignant	O	O	B-Entity
disease	O	O	I-Entity
of	O	O	O
small	O	O	O
mature	O	O	B-Entity
lymphocytes	O	O	I-Entity
.	O	O	O

Signals	O	O	B-Entity
from	O	O	O
the	O	O	O
CLL	O	O	B-Entity
microenvironment	O	O	B-Entity
promote	O	O	B-Entity
progression	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
induce	O	O	B-Entity
drug	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

This	O	O	O
phenomenon	O	O	B-Entity
is	O	O	O
largely	O	O	O
dependent	O	O	B-Entity
on	O	O	O
direct	O	O	O
contact	O	O	O
between	O	O	O
the	O	O	O
malignant	O	O	B-Entity
B	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
stromal	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

CD84	O	O	B-Entity
belongs	O	O	O
to	O	O	O
the	O	O	O
signaling	O	O	B-Entity
lymphocyte	O	O	I-Entity
activation	O	O	I-Entity
molecule	O	O	I-Entity
family	O	O	I-Entity
of	O	O	O
immunoreceptors	O	O	B-Entity
,	O	O	O
which	O	O	O
self-associates	O	O	B-Entity
,	O	O	O
forming	O	O	O
an	O	O	O
orthogonal	O	O	B-Entity
homophilic	O	O	I-Entity
dimer	O	O	I-Entity
.	O	O	O

We	O	O	O
therefore	O	O	O
hypothesized	O	O	O
that	O	O	O
CD84	O	O	B-Entity
may	O	O	O
bridge	O	O	O
between	O	O	O
CLL	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
their	O	O	O
microenvironment	O	O	B-Entity
,	O	O	O
promoting	O	O	B-Entity
cell	O	O	B-Entity
survival	O	O	I-Entity
.	O	O	O

Our	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
results	O	O	B-Entity
show	O	O	O
that	O	O	O
CD84	O	O	B-Entity
expressed	O	O	I-Entity
on	O	O	O
CLL	O	O	B-Entity
cells	O	O	B-Entity
interact	O	O	B-Entity
with	O	O	O
CD84	O	O	O
expressed	O	O	O
on	O	O	O
cells	O	O	O
in	O	O	O
their	O	O	O
microenvironment	O	O	B-Entity
,	O	O	O
inducing	O	O	B-Entity
cell	O	O	B-Entity
survival	O	O	I-Entity
in	O	O	O
both	O	O	O
sides	O	O	O
.	O	O	O

Blocking	O	O	B-Entity
CD84	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
disrupt	O	O	B-Entity
the	O	O	O
interaction	O	O	B-Entity
of	O	O	O
CLL	O	O	B-Entity
cells	O	O	B-Entity
with	O	O	O
their	O	O	O
microenvironment	O	O	B-Entity
,	O	O	O
resulting	O	O	B-Entity
in	O	O	I-Entity
induced	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
novel	O	O	B-Entity
therapeutic	O	O	B-Entity
strategies	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
blockade	O	O	B-Entity
of	O	O	O
this	O	O	O
CD84	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
survival	O	O	B-Entity
pathway	O	O	B-Entity
.	O	O	O

-DOCSTART- (27453213)

Aurantimonas	O	O	B-Entity
endophytica	O	O	I-Entity
sp.	O	O	I-Entity
nov.	O	O	I-Entity
,	O	O	O
a	O	O	O
novel	O	O	O
endophytic	O	O	B-Entity
bacterium	O	O	I-Entity
isolated	O	O	O
from	O	O	O
roots	O	O	B-Entity
of	O	O	O
Anabasis	O	O	O
elatior	O	O	O
(	O	O	O
C.	O	O	O
A.	O	O	O
Mey	O	O	O
.	O	O	O
)	O	O	O
Schischk	O	O	O

An	O	O	O
orange-coloured	O	O	B-Entity
,	O	O	O
aerobic	O	O	B-Entity
,	O	O	O
motile	O	O	B-Entity
and	O	O	O
short-rods	O	O	B-Entity
bacterial	O	O	I-Entity
strain	O	O	I-Entity
,	O	O	O
designated	O	O	O
EGI	O	O	B-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
,	O	O	O
was	O	O	O
isolated	O	O	O
from	O	O	O
the	O	O	O
surface-sterilized	O	O	O
root	O	O	B-Entity
of	O	O	O
a	O	O	O
halophyte	O	O	B-Entity
Anabasis	O	O	B-Entity
elatior	O	O	I-Entity
(	O	O	I-Entity
C.	O	O	I-Entity
A.	O	O	I-Entity
Mey	O	O	I-Entity
.	O	O	I-Entity
)	O	O	I-Entity
Schischk	O	O	I-Entity
collected	O	O	O
from	O	O	O
Urumqi	O	O	B-Entity
,	O	O	O
Xinjiang	O	O	B-Entity
province	O	O	I-Entity
,	O	O	O
north-west	O	O	B-Entity
China	O	O	I-Entity
.	O	O	O

Growth	O	O	B-Entity
occurred	O	O	O
at	O	O	O
5	O	O	O
-	O	O	O
35	O	O	O
°	O	O	O
C	O	O	O
(	O	O	O
optimum	O	O	O
30	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
,	O	O	O
at	O	O	O
pH	O	O	B-Entity
6.0	O	O	O
-	O	O	O
9.0	O	O	O
(	O	O	O
optimum	O	O	O
pH	O	O	O
7.0	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
0	O	O	O
-	O	O	O
6	O	O	O
%	O	O	O
NaCl	O	O	B-Entity
(	O	O	O
w/v	O	O	O
)	O	O	O
(	O	O	O
optimum	O	O	O
0	O	O	O
-	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Phylogenetic	O	O	B-Entity
tree	O	O	I-Entity
based	O	O	O
on	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	B-Entity
sequences	O	O	I-Entity
indicated	O	O	O
that	O	O	O
strain	O	O	B-Entity
EGI	O	O	I-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
formed	O	O	O
a	O	O	O
distinct	O	O	O
lineage	O	O	O
in	O	O	O
the	O	O	O
cluster	O	O	O
that	O	O	O
comprised	O	O	O
the	O	O	O
genera	O	O	B-Entity
Aurantimonas	O	O	I-Entity
and	O	O	O
Aureimonas	O	O	B-Entity
in	O	O	O
the	O	O	O
family	O	O	B-Entity
Aurantimonadaceae	O	O	I-Entity
.	O	O	O

The	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	B-Entity
sequence	O	O	I-Entity
of	O	O	O
strain	O	O	B-Entity
EGI	O	O	I-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
shared	O	O	O
the	O	O	O
highest	O	O	O
similarities	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
Aurantimonas	O	O	B-Entity
coralicida	O	O	I-Entity
DSM	O	O	I-Entity
14790	O	O	I-Entity
T	O	O	I-Entity
(	O	O	O
97.15	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
Aurantimonas	O	O	B-Entity
manganoxydans	O	O	I-Entity
DSM	O	O	I-Entity
21871	O	O	I-Entity
T	O	O	I-Entity
(	O	O	O
97.15	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Strain	O	O	B-Entity
EGI	O	O	I-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
contained	O	O	O
Q-10	O	O	B-Entity
as	O	O	O
the	O	O	O
dominant	O	O	O
isoprenoid	O	O	B-Entity
quinone	O	O	I-Entity
.	O	O	O

The	O	O	O
major	O	O	O
cellular	O	O	O
fatty	O	O	B-Entity
acids	O	O	I-Entity
were	O	O	O
C18:1	O	O	B-Entity
7c	O	O	I-Entity
(	O	O	O
66.4	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
C19:0	O	O	B-Entity
8c	O	O	I-Entity
cyclo	O	O	I-Entity
(	O	O	O
23.3	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
polar	O	O	O
lipid	O	O	B-Entity
profile	O	O	I-Entity
of	O	O	O
strain	O	O	B-Entity
EGI	O	O	I-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
contained	O	O	O
diphosphatidylglycerol	O	O	B-Entity
,	O	O	O
phosphatidylglycerol	O	O	B-Entity
,	O	O	O
phosphatidylcholine	O	O	B-Entity
,	O	O	O
phosphatidylethanolamine	O	O	B-Entity
as	O	O	O
major	O	O	O
components	O	O	O
,	O	O	O
similarly	O	O	O
to	O	O	O
the	O	O	O
members	O	O	O
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
Aurantimonas	O	O	I-Entity
.	O	O	O

The	O	O	O
DNA	O	O	B-Entity
G+C	O	O	B-Entity
content	O	O	I-Entity
of	O	O	O
strain	O	O	B-Entity
EGI	O	O	I-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
was	O	O	O
66.8	O	O	O
mol%	O	O	O
.	O	O	O

The	O	O	O
DNA	O	O	B-Entity
-	O	O	O
DNA	O	O	O
relatedness	O	O	O
between	O	O	O
strain	O	O	B-Entity
EGI	O	O	I-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
and	O	O	O
Aurantimonas	O	O	B-Entity
coralicida	O	O	I-Entity
DSM	O	O	I-Entity
14790	O	O	I-Entity
T	O	O	I-Entity
was	O	O	O
24.7	O	O	O
±	O	O	O
2.9	O	O	O
%	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
phylogenetic	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
chemotaxonomic	O	O	B-Entity
data	O	O	I-Entity
and	O	O	O
phenotypic	O	O	B-Entity
characteristics	O	O	I-Entity
,	O	O	O
strain	O	O	B-Entity
EGI	O	O	I-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
represents	O	O	O
a	O	O	O
novel	O	O	O
species	O	O	O
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
Aurantimonas	O	O	I-Entity
,	O	O	O
for	O	O	O
which	O	O	O
the	O	O	O
name	O	O	O
Aurantimonas	O	O	B-Entity
endophytica	O	O	I-Entity
sp.	O	O	I-Entity
nov.	O	O	I-Entity
is	O	O	O
proposed	O	O	O
.	O	O	O

The	O	O	O
type	O	O	O
strain	O	O	B-Entity
is	O	O	O
EGI	O	O	B-Entity
6500337	O	O	I-Entity
T	O	O	I-Entity
(=	O	O	O
KCTC	O	O	B-Entity
52296	O	O	I-Entity
T	O	O	I-Entity
=	O	O	O
CPCC	O	O	B-Entity
100904	O	O	I-Entity
T	O	O	I-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27453830)

Assessment	O	O	B-Entity
and	O	O	O
classification	O	O	B-Entity
of	O	O	O
protocol	O	O	O
deviations	O	O	O

Deviations	O	O	B-Entity
from	O	O	O
the	O	O	O
approved	O	O	O
trial	O	O	B-Entity
protocol	O	O	I-Entity
are	O	O	O
common	O	O	O
during	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
.	O	O	O

They	O	O	O
have	O	O	O
been	O	O	O
conventionally	O	O	O
classified	O	O	B-Entity
as	O	O	O
deviations	O	O	B-Entity
or	O	O	O
violations	O	O	B-Entity
,	O	O	O
depending	O	O	O
on	O	O	O
their	O	O	O
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
trial	O	O	B-Entity
.	O	O	O

A	O	O	O
new	O	O	O
method	O	O	O
has	O	O	O
been	O	O	O
proposed	O	O	O
by	O	O	O
which	O	O	O
deviations	O	O	B-Entity
are	O	O	O
classified	O	O	B-Entity
in	O	O	O
five	O	O	O
grades	O	O	B-Entity
from	O	O	I-Entity
1	O	O	I-Entity
to	O	O	I-Entity
5	O	O	I-Entity
.	O	O	O

A	O	O	O
deviation	O	O	B-Entity
of	O	O	O
Grade	O	O	B-Entity
1	O	O	I-Entity
has	O	O	O
no	O	O	B-Entity
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
subjects	O	O	B-Entity
'	O	O	I-Entity
well-being	O	O	B-Entity
or	O	O	O
on	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
data	O	O	I-Entity
.	O	O	O

At	O	O	O
the	O	O	O
maximum	O	O	O
,	O	O	O
a	O	O	O
deviation	O	O	B-Entity
Grade	O	O	B-Entity
5	O	O	I-Entity
leads	O	O	O
to	O	O	O
the	O	O	O
death	O	O	B-Entity
of	O	O	O
the	O	O	O
subject	O	O	B-Entity
.	O	O	O

This	O	O	O
method	O	O	O
of	O	O	O
classification	O	O	B-Entity
was	O	O	O
applied	O	O	O
to	O	O	O
deviations	O	O	B-Entity
noted	O	O	O
in	O	O	O
the	O	O	O
center	O	O	O
over	O	O	O
the	O	O	O
last	O	O	O
3	O	O	O
years	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
observed	O	O	O
that	O	O	O
most	O	O	O
deviations	O	O	B-Entity
were	O	O	O
of	O	O	O
Grades	O	O	B-Entity
1	O	O	I-Entity
and	O	O	I-Entity
2	O	O	I-Entity
,	O	O	O
with	O	O	O
fewer	O	O	O
falling	O	O	O
in	O	O	O
Grades	O	O	B-Entity
3	O	O	I-Entity
and	O	O	I-Entity
4	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
deviations	O	O	B-Entity
that	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
death	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
subject	O	O	I-Entity
(	O	O	O
Grade	O	O	O
5	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
method	O	O	O
of	O	O	O
classification	O	O	B-Entity
would	O	O	O
help	O	O	O
trial	O	O	B-Entity
managers	O	O	B-Entity
decide	O	O	O
on	O	O	O
the	O	O	O
action	O	O	O
to	O	O	O
be	O	O	O
taken	O	O	O
on	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
deviations	O	O	B-Entity
,	O	O	O
which	O	O	O
would	O	O	O
be	O	O	O
based	O	O	O
on	O	O	O
their	O	O	O
impact	O	O	B-Entity
.	O	O	O

-DOCSTART- (27454401)

Fabrication	O	O	B-Entity
and	O	O	O
modelling	O	O	B-Entity
of	O	O	O
fractal	O	O	B-Entity
,	O	O	O
biomimetic	O	O	B-Entity
,	O	O	O
micro	O	O	B-Entity
and	O	O	O
nano-topographical	O	O	O
surfaces	O	O	O

Natural	O	O	B-Entity
surface	O	O	B-Entity
topographies	O	O	I-Entity
are	O	O	O
often	O	O	O
self-similar	O	O	O
with	O	O	O
hierarchical	O	O	B-Entity
features	O	O	I-Entity
at	O	O	O
the	O	O	O
micro	O	O	B-Entity
and	O	O	O
nanoscale	O	O	B-Entity
,	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
mimicked	O	O	O
to	O	O	O
overcome	O	O	O
modern	O	O	B-Entity
tissue	O	O	B-Entity
engineering	O	O	I-Entity
and	O	O	O
biomaterial	O	O	B-Entity
design	O	O	B-Entity
limitations	O	O	B-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
a	O	O	O
cell	O	O	B-Entity
's	O	O	I-Entity
microenvironment	O	O	I-Entity
within	O	O	O
the	O	O	O
human	O	O	B-Entity
body	O	O	I-Entity
contains	O	O	O
highly	O	O	O
optimised	O	O	O
,	O	O	O
fractal	O	O	B-Entity
topographical	O	O	I-Entity
cues	O	O	I-Entity
,	O	O	O
which	O	O	O
directs	O	O	O
precise	O	O	O
cell	O	O	O
behaviour	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
recreating	O	O	B-Entity
biomimetic	O	O	B-Entity
,	O	O	O
fractal	O	O	B-Entity
topographies	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
is	O	O	O
not	O	O	O
a	O	O	O
trivial	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
fabrication	O	O	B-Entity
methods	O	O	I-Entity
have	O	O	O
been	O	O	O
proposed	O	O	O
but	O	O	O
often	O	O	O
fail	O	O	B-Entity
to	O	O	O
precisely	O	O	O
control	O	O	B-Entity
the	O	O	O
spatial	O	O	B-Entity
resolution	O	O	I-Entity
of	O	O	O
features	O	O	B-Entity
at	O	O	O
different	O	O	B-Entity
lengths	O	O	B-Entity
scales	O	O	B-Entity
and	O	O	O
hence	O	O	O
,	O	O	O
to	O	O	O
provide	O	O	O
true	O	O	O
biomimetic	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
a	O	O	O
method	O	O	B-Entity
of	O	O	O
accurately	O	O	B-Entity
reproducing	O	O	B-Entity
the	O	O	O
self-similar	O	O	O
,	O	O	O
micro	O	O	B-Entity
and	O	O	O
nanoscale	O	O	B-Entity
topography	O	O	I-Entity
of	O	O	O
a	O	O	O
human	O	O	B-Entity
biological	O	O	B-Entity
tissue	O	O	I-Entity
into	O	O	O
a	O	O	O
synthetic	O	O	B-Entity
polymer	O	O	I-Entity
through	O	O	O
an	O	O	O
innovative	O	O	O
fabrication	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

The	O	O	O
biological	O	O	B-Entity
tissue	O	O	I-Entity
surface	O	O	B-Entity
was	O	O	O
characterised	O	O	B-Entity
using	O	O	O
atomic	O	O	B-Entity
force	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
AFM	O	O	B-Entity
)	O	O	O
to	O	O	O
obtain	O	O	O
spatial	O	O	B-Entity
data	O	O	B-Entity
in	O	O	O
X	O	O	O
,	O	O	O
Y	O	O	O
and	O	O	O
Z	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
converted	O	O	O
into	O	O	O
a	O	O	O
grayscale	O	O	B-Entity
'	O	O	I-Entity
digital	O	O	I-Entity
photomask	O	O	I-Entity
'	O	O	I-Entity
.	O	O	O

As	O	O	O
a	O	O	O
result	O	O	O
of	O	O	O
maskless	O	O	B-Entity
grayscale	O	O	I-Entity
optical	O	O	I-Entity
lithography	O	O	I-Entity
followed	O	O	O
by	O	O	O
modified	O	O	B-Entity
deep	O	O	I-Entity
reactive	O	O	I-Entity
ion	O	O	I-Entity
etching	O	O	I-Entity
and	O	O	O
replica	O	O	B-Entity
molding	O	O	I-Entity
,	O	O	O
we	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
accurately	O	O	B-Entity
reproduce	O	O	O
the	O	O	O
fractal	O	O	B-Entity
topography	O	O	I-Entity
of	O	O	O
acellular	O	O	B-Entity
dermal	O	O	I-Entity
matrix	O	O	I-Entity
(	O	O	O
ADM	O	O	B-Entity
)	O	O	O
into	O	O	O
polydimethylsiloxane	O	O	B-Entity
(	O	O	O
PDMS	O	O	B-Entity
)	O	O	O
.	O	O	O

Characterisation	O	O	B-Entity
using	O	O	O
AFM	O	O	B-Entity
at	O	O	O
three	O	O	O
different	O	O	B-Entity
length	O	O	B-Entity
scales	O	O	B-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
nano	O	O	B-Entity
and	O	O	O
micro-topographical	O	O	B-Entity
features	O	O	B-Entity
,	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
the	O	O	O
fractal	O	O	B-Entity
dimension	O	O	I-Entity
,	O	O	O
of	O	O	O
native	O	O	B-Entity
ADM	O	O	B-Entity
were	O	O	O
reproduced	O	O	B-Entity
in	O	O	O
PDMS	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
fractal	O	O	B-Entity
topography	O	O	I-Entity
of	O	O	O
biological	O	O	B-Entity
surfaces	O	O	I-Entity
can	O	O	O
be	O	O	O
mimicked	O	O	O
in	O	O	O
synthetic	O	O	B-Entity
materials	O	O	I-Entity
using	O	O	O
the	O	O	O
novel	O	O	B-Entity
fabrication	O	O	B-Entity
process	O	O	I-Entity
outlined	O	O	O
,	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
applied	O	O	O
to	O	O	O
significantly	O	O	O
enhance	O	O	O
medical	O	O	B-Entity
device	O	O	I-Entity
biocompatibility	O	O	B-Entity
and	O	O	O
performance	O	O	B-Entity
.	O	O	O

-DOCSTART- (27457339)

Investigating	O	O	B-Entity
Effects	O	O	B-Entity
of	O	O	I-Entity
Acidic	O	O	B-Entity
pH	O	O	I-Entity
on	O	O	O
Proliferation	O	O	B-Entity
,	O	O	O
Invasion	O	O	B-Entity
and	O	O	O
Drug	O	O	B-Entity
-	O	O	O
Induced	O	O	B-Entity
Apoptosis	O	O	B-Entity
in	O	O	O
Lymphoblastic	O	O	O
Leukemia	O	O	O

Some	O	O	O
studies	O	O	O
have	O	O	O
shown	O	O	O
that	O	O	O
extracellular	O	O	B-Entity
pH	O	O	B-Entity
in	O	O	O
tumors	O	O	B-Entity
,	O	O	O
which	O	O	O
results	O	O	O
in	O	O	O
tumor	O	O	B-Entity
progression	O	O	I-Entity
,	O	O	O
is	O	O	O
less	O	O	O
than	O	O	O
that	O	O	O
in	O	O	O
normal	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
extracellular	O	O	B-Entity
acidic	O	O	B-Entity
pH	O	O	I-Entity
on	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
invasion	O	O	B-Entity
,	O	O	O
and	O	O	O
drug	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
in	O	O	O
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
cells	O	O	B-Entity
were	O	O	O
cultured	O	O	O
in	O	O	O
different	O	O	B-Entity
pH	O	O	B-Entity
(	O	O	O
pH	O	O	O
6.6	O	O	O
and	O	O	O
pH	O	O	O
7.4	O	O	O
)	O	O	O
for	O	O	O
12	O	O	O
days	O	O	B-Entity
.	O	O	O

Cell	O	O	B-Entity
proliferation	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
by	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
invasion	O	O	I-Entity
was	O	O	O
assayed	O	O	O
by	O	O	O
invasion	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
MMP-9	O	O	B-Entity
.	O	O	O

Drug	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
after	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
doxorubicin	O	O	B-Entity
for	O	O	O
24	O	O	O
hours	O	O	O
by	O	O	O
annexin	O	O	B-Entity
V	O	O	I-Entity
/	O	O	O
PI	O	O	B-Entity
staining	O	O	B-Entity
and	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
BAX	O	O	B-Entity
pro-apoptotic	O	O	I-Entity
protein	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicated	O	O	O
the	O	O	O
enhanced	O	O	O
growth	O	O	B-Entity
and	O	O	O
invasion	O	O	B-Entity
of	O	O	O
leukemic	O	O	B-Entity
cells	O	O	B-Entity
at	O	O	O
pH	O	O	B-Entity
6.6	O	O	O
(	O	O	O
P	O	O	O
≤	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
cells	O	O	B-Entity
at	O	O	O
pH	O	O	B-Entity
6.6	O	O	O
were	O	O	O
resistant	O	O	B-Entity
to	O	O	O
apoptosis	O	O	B-Entity
by	O	O	O
doxorubicin	O	O	B-Entity
(	O	O	O
P	O	O	O
≤	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

It	O	O	O
can	O	O	O
be	O	O	O
concluded	O	O	O
that	O	O	O
acidic	O	O	B-Entity
pH	O	O	I-Entity
increases	O	O	B-Entity
the	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
invasion	O	O	B-Entity
and	O	O	O
reduces	O	O	B-Entity
the	O	O	O
drug	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
in	O	O	O
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
.	O	O	O

Extracellular	O	O	B-Entity
acidity	O	O	B-Entity
can	O	O	O
influence	O	O	O
the	O	O	O
behavior	O	O	O
of	O	O	O
leukemic	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
therefore	O	O	O
,	O	O	O
the	O	O	O
manipulation	O	O	B-Entity
of	O	O	O
extracellular	O	O	B-Entity
liquid	O	O	I-Entity
can	O	O	O
be	O	O	O
selected	O	O	O
as	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
strategy	O	O	I-Entity
for	O	O	O
leukemia	O	O	B-Entity
,	O	O	O
especially	O	O	O
for	O	O	O
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
.	O	O	O

-DOCSTART- (27459898)

Gold	O	O	B-Entity
-	O	O	O
Nanosponge	O	O	B-Entity
-Based	O	O	O
Multistimuli-Responsive	O	O	B-Entity
Drug	O	O	I-Entity
Vehicles	O	O	I-Entity
for	O	O	O
Targeted	O	O	B-Entity
Chemo-Photothermal	O	O	O
Therapy	O	O	O

Gold	O	O	B-Entity
-	O	O	O
nanosponge	O	O	B-Entity
-based	O	O	O
multistimuli-responsive	O	O	B-Entity
drug	O	O	B-Entity
vehicles	O	O	I-Entity
are	O	O	O
constructed	O	O	O
for	O	O	O
combined	O	O	O
chemo-photothermal	O	O	B-Entity
therapy	O	O	I-Entity
with	O	O	O
pinpointed	O	O	O
drug	O	O	O
delivery	O	O	B-Entity
and	O	O	O
release	O	O	B-Entity
capabilities	O	O	O
and	O	O	O
minimized	O	O	O
nonspecific	O	O	B-Entity
systemic	O	O	B-Entity
spread	O	O	B-Entity
of	O	O	O
drugs	O	O	B-Entity
,	O	O	O
remarkably	O	O	O
enhancing	O	O	B-Entity
the	O	O	O
therapeutic	O	O	B-Entity
efficiency	O	O	I-Entity
while	O	O	O
minimizing	O	O	O
acute	O	O	B-Entity
side	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

-DOCSTART- (27462099)

Hemodynamic	O	O	B-Entity
correlates	O	O	O
of	O	O	O
transient	O	O	B-Entity
cognitive	O	O	I-Entity
impairment	O	O	I-Entity
after	O	O	O
transient	O	O	B-Entity
ischemic	O	O	I-Entity
attack	O	O	I-Entity
and	O	O	O
minor	O	O	B-Entity
stroke	O	O	I-Entity
:	O	O	O
A	O	O	O
transcranial	O	O	O
Doppler	O	O	O
study	O	O	O

Transient	O	O	B-Entity
cognitive	O	O	I-Entity
impairment	O	O	I-Entity
(	O	O	O
TCI	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
Mini	O	O	B-Entity
Mental	O	O	I-Entity
State	O	O	I-Entity
Evaluation	O	O	I-Entity
score	O	O	B-Entity
is	O	O	O
common	O	O	O
after	O	O	O
transient	O	O	B-Entity
ischemic	O	O	I-Entity
attack	O	O	I-Entity
/	O	O	O
minor	O	O	B-Entity
stroke	O	O	I-Entity
and	O	O	O
might	O	O	O
identify	O	O	B-Entity
patients	O	O	B-Entity
at	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
dementia	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	B-Entity
to	O	O	O
replicate	O	O	B-Entity
TCI	O	O	B-Entity
using	O	O	O
the	O	O	O
Montreal	O	O	B-Entity
Cognitive	O	O	I-Entity
Assessment	O	O	I-Entity
(	O	O	O
MoCA	O	O	B-Entity
)	O	O	O
,	O	O	O
compare	O	O	B-Entity
it	O	O	O
with	O	O	O
persistent	O	O	B-Entity
Mild	O	O	I-Entity
Cognitive	O	O	I-Entity
Impairment	O	O	I-Entity
(	O	O	O
PMCI	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
global	O	O	B-Entity
cerebral	O	O	B-Entity
hemodynamic	O	O	B-Entity
changes	O	O	B-Entity
could	O	O	O
explain	O	O	O
transient	O	O	B-Entity
impairment	O	O	B-Entity
.	O	O	O

Consecutive	O	O	O
patients	O	O	B-Entity
with	O	O	O
transient	O	O	B-Entity
ischemic	O	O	I-Entity
attack	O	O	I-Entity
/	O	O	O
minor	O	O	B-Entity
stroke	O	O	I-Entity
(	O	O	O
NIHSS	O	O	O
≤	O	O	O
3	O	O	O
)	O	O	O
were	O	O	O
assessed	O	O	B-Entity
with	O	O	O
the	O	O	O
MoCA	O	O	B-Entity
and	O	O	O
transcranial	O	O	B-Entity
Doppler	O	O	I-Entity
ultrasound	O	O	I-Entity
acutely	O	O	B-Entity
and	O	O	O
at	O	O	O
1	O	O	O
month	O	O	O
.	O	O	O

We	O	O	O
compared	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
TCI	O	O	B-Entity
(	O	O	O
baseline	O	O	B-Entity
MoCA	O	O	B-Entity
<	O	O	O
26	O	O	O
with	O	O	O
≥	O	O	O
2	O	O	O
points	O	O	B-Entity
increase	O	O	B-Entity
at	O	O	O
1	O	O	O
month	O	O	O
)	O	O	O
,	O	O	O
PMCI	O	O	B-Entity
(	O	O	O
MoCA	O	O	O
<	O	O	O
26	O	O	O
with	O	O	O
<	O	O	O
2	O	O	O
points	O	O	O
increase	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
no	O	O	B-Entity
cognitive	O	O	I-Entity
impairment	O	O	I-Entity
(	O	O	O
NCI	O	O	B-Entity
;	O	O	O
MoCA	O	O	O
≥	O	O	O
26	O	O	O
)	O	O	O
.	O	O	O

Of	O	O	O
326	O	O	O
patients	O	O	B-Entity
,	O	O	O
46	O	O	O
(	O	O	O
14.1	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
PMCI	O	O	B-Entity
,	O	O	O
98	O	O	O
(	O	O	O
30.1	O	O	O
%	O	O	O
)	O	O	O
TCI	O	O	B-Entity
,	O	O	O
and	O	O	O
182	O	O	O
(	O	O	O
55.8	O	O	O
%	O	O	O
)	O	O	O
NCI	O	O	B-Entity
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
,	O	O	O
TCI	O	O	B-Entity
patients	O	O	B-Entity
had	O	O	O
higher	O	O	B-Entity
systolic	O	O	I-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
150.95	O	O	O
±	O	O	O
21.52	O	O	O
vs	O	O	O
144.86	O	O	O
±	O	O	O
22.44	O	O	O
mmHg	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
and	O	O	O
lower	O	O	B-Entity
cerebral	O	O	B-Entity
blood	O	O	I-Entity
flow	O	O	I-Entity
velocities	O	O	I-Entity
,	O	O	O
particularly	O	O	O
end-diastolic	O	O	B-Entity
velocity	O	O	I-Entity
(	O	O	O
30.16	O	O	O
±	O	O	O
9.63	O	O	O
vs	O	O	O
35.02	O	O	O
±	O	O	O
9.01	O	O	O
cm/s	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
mean	O	O	B-Entity
flow	O	O	I-Entity
velocity	O	O	I-Entity
(	O	O	O
48.95	O	O	O
±	O	O	O
12.72	O	O	O
vs	O	O	O
54	O	O	O
±	O	O	O
12.46	O	O	O
cm/s	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
than	O	O	O
those	O	O	O
with	O	O	O
NCI	O	O	B-Entity
,	O	O	O
but	O	O	O
similar	O	O	O
clinical	O	O	B-Entity
and	O	O	O
hemodynamic	O	O	B-Entity
profiles	O	O	B-Entity
to	O	O	O
those	O	O	O
with	O	O	O
PMCI	O	O	B-Entity
.	O	O	O

Systolic	O	O	B-Entity
BP	O	O	I-Entity
fell	O	O	I-Entity
between	O	O	O
baseline	O	O	B-Entity
and	O	O	O
1	O	O	O
month	O	O	O
(	O	O	O
mean	O	O	B-Entity
reduction	O	O	B-Entity
=	O	O	O
14.01	O	O	O
±	O	O	O
21.26	O	O	O
mmHg	O	O	O
)	O	O	O
and	O	O	O
end-diastolic	O	O	B-Entity
velocity	O	O	I-Entity
and	O	O	O
mean	O	O	B-Entity
flow	O	O	I-Entity
velocity	O	O	I-Entity
increased	O	O	B-Entity
(	O	O	O
mean	O	O	O
increase	O	O	B-Entity
=	O	O	O
+	O	O	O
2.42	O	O	O
±	O	O	O
6.41	O	O	O
and	O	O	O
1.89	O	O	O
±	O	O	O
8.77	O	O	O
cm/s	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
these	O	O	O
changes	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
differ	O	O	I-Entity
between	O	O	O
patients	O	O	B-Entity
with	O	O	O
TCI	O	O	B-Entity
,	O	O	O
PMCI	O	O	B-Entity
,	O	O	O
and	O	O	O
NCI	O	O	B-Entity
.	O	O	O

TCI	O	O	B-Entity
is	O	O	O
detectable	O	O	B-Entity
with	O	O	O
the	O	O	O
MoCA	O	O	B-Entity
after	O	O	O
transient	O	O	B-Entity
ischemic	O	O	I-Entity
attack	O	O	I-Entity
and	O	O	O
minor	O	O	B-Entity
stroke	O	O	I-Entity
and	O	O	O
has	O	O	O
similar	O	O	O
clinical	O	O	B-Entity
and	O	O	O
hemodynamic	O	O	B-Entity
profile	O	O	B-Entity
to	O	O	O
PMCI	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
TCI	O	O	B-Entity
does	O	O	O
not	O	O	B-Entity
appear	O	O	I-Entity
to	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
exaggerated	O	O	B-Entity
acute	O	O	B-Entity
reversible	O	O	B-Entity
global	O	O	B-Entity
hemodynamic	O	O	B-Entity
changes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27463942)

Apixaban	O	O	B-Entity
5	O	O	O
mg	O	O	O
Twice	O	O	B-Entity
Daily	O	O	B-Entity
and	O	O	O
Clinical	O	O	B-Entity
Outcomes	O	O	B-Entity
in	O	O	O
Patients	O	O	B-Entity
With	O	O	O
Atrial	O	O	B-Entity
Fibrillation	O	O	I-Entity
and	O	O	O
Advanced	O	O	B-Entity
Age	O	O	B-Entity
,	O	O	O
Low	O	O	B-Entity
Body	O	O	B-Entity
Weight	O	O	I-Entity
,	O	O	O
or	O	O	O
High	O	O	B-Entity
Creatinine	O	O	B-Entity
:	O	O	O
A	O	O	O
Secondary	O	O	B-Entity
Analysis	O	O	I-Entity
of	O	O	O
a	O	O	O
Randomized	O	O	O
Clinical	O	O	O
Trial	O	O	O

In	O	O	O
the	O	O	O
Apixaban	O	O	B-Entity
for	O	O	O
Reduction	O	O	B-Entity
of	O	O	O
Stroke	O	O	B-Entity
and	O	O	O
Other	O	O	O
Thromboembolic	O	O	B-Entity
Complications	O	O	I-Entity
in	O	O	O
Atrial	O	O	B-Entity
Fibrillation	O	O	I-Entity
(	O	O	O
ARISTOTLE	O	O	B-Entity
)	O	O	O
trial	O	O	B-Entity
,	O	O	O
the	O	O	O
standard	O	O	O
dose	O	O	B-Entity
of	O	O	O
apixaban	O	O	B-Entity
was	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
;	O	O	O
patients	O	O	B-Entity
with	O	O	O
at	O	O	O
least	O	O	O
2	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	B-Entity
criteria-80	O	O	O
years	O	O	B-Entity
or	O	O	O
older	O	O	O
,	O	O	O
weight	O	O	B-Entity
60	O	O	O
kg	O	O	O
or	O	O	O
less	O	O	O
,	O	O	O
and	O	O	O
creatinine	O	O	B-Entity
level	O	O	B-Entity
1.5	O	O	O
mg/dL	O	O	O
or	O	O	O
higher-received	O	O	O
a	O	O	O
reduced	O	O	B-Entity
dose	O	O	O
of	O	O	O
apixaban	O	O	O
of	O	O	O
2.5	O	O	O
mg	O	O	O
twice	O	O	O
daily	O	O	O
.	O	O	O

Little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
patients	O	O	B-Entity
with	O	O	O
1	O	O	O
dose	O	O	B-Entity
-	O	O	O
reduction	O	O	B-Entity
criterion	O	O	O
who	O	O	O
received	O	O	O
the	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
dose	O	O	O
of	O	O	O
apixaban	O	O	B-Entity
.	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
frequency	O	O	B-Entity
of	O	O	O
1	O	O	O
dose	O	O	B-Entity
-	O	O	O
reduction	O	O	B-Entity
criterion	O	O	O
and	O	O	O
whether	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
dose	O	O	O
of	O	O	O
apixaban	O	O	B-Entity
on	O	O	O
stroke	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
embolism	O	O	I-Entity
and	O	O	O
bleeding	O	O	B-Entity
varied	O	O	O
among	O	O	O
patients	O	O	B-Entity
with	O	O	O
1	O	O	O
or	O	O	O
no	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	O
criteria	O	O	O
.	O	O	O

Among	O	O	O
18	O	O	O
201	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
ARISTOTLE	O	O	B-Entity
trial	O	O	I-Entity
,	O	O	O
17	O	O	O
322	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
this	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Annualized	O	O	O
event	O	O	O
rates	O	O	O
of	O	O	O
stroke	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
embolism	O	O	I-Entity
and	O	O	O
major	O	O	O
bleeding	O	O	B-Entity
and	O	O	O
hazard	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
HRs	O	O	B-Entity
)	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
CIs	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

Interactions	O	O	B-Entity
between	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
apixaban	O	O	B-Entity
vs	O	O	O
warfarin	O	O	B-Entity
and	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
1	O	O	O
or	O	O	O
no	O	O	O
dose	O	O	B-Entity
-	O	O	O
reduction	O	O	B-Entity
criteria	O	O	O
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	O
patient	O	O	B-Entity
was	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
ARISTOTLE	O	O	B-Entity
trial	O	O	I-Entity
on	O	O	O
December	O	O	O
19	O	O	O
,	O	O	O
2006	O	O	O
,	O	O	O
and	O	O	O
follow-up	O	O	B-Entity
was	O	O	O
completed	O	O	O
on	O	O	O
January	O	O	O
30	O	O	O
,	O	O	O
2011	O	O	O
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
from	O	O	O
January	O	O	O
2015	O	O	O
to	O	O	O
May	O	O	O
30	O	O	O
,	O	O	O
2016	O	O	O
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
major	O	O	O
bleeding	O	O	B-Entity
included	O	O	O
events	O	O	O
during	O	O	O
study	O	O	B-Entity
drug	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
stroke	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
embolism	O	O	I-Entity
was	O	O	O
based	O	O	O
on	O	O	O
intention	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
patients	O	O	B-Entity
with	O	O	O
1	O	O	O
or	O	O	O
no	O	O	O
dose	O	O	B-Entity
-	O	O	O
reduction	O	O	B-Entity
criteria	O	O	O
assigned	O	O	O
to	O	O	O
receive	O	O	O
the	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
dose	O	O	O
of	O	O	O
apixaban	O	O	B-Entity
or	O	O	O
warfarin	O	O	B-Entity
,	O	O	O
3966	O	O	O
had	O	O	O
1	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	O
criterion	O	O	O
;	O	O	O
these	O	O	O
patients	O	O	O
had	O	O	O
higher	O	O	O
rates	O	O	O
of	O	O	O
stroke	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
embolism	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
1.47	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
1.20	O	O	O
-	O	O	O
1.81	O	O	O
)	O	O	O
and	O	O	O
major	O	O	O
bleeding	O	O	B-Entity
(	O	O	O
HR	O	O	O
,	O	O	O
1.89	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.62	O	O	O
-	O	O	O
2.20	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
those	O	O	O
with	O	O	O
no	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	O
criteria	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
13	O	O	O
356	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
benefit	O	O	B-Entity
of	O	O	O
the	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
dose	O	O	B-Entity
of	O	O	O
apixaban	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8665	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
warfarin	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8657	O	O	O
)	O	O	O
on	O	O	O
stroke	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
embolism	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
1	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	B-Entity
criterion	O	O	O
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
0.94	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.66	O	O	O
-	O	O	O
1.32	O	O	O
)	O	O	O
and	O	O	O
no	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	O
criterion	O	O	O
(	O	O	O
HR	O	O	O
,	O	O	O
0.77	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.62	O	O	O
-	O	O	O
0.97	O	O	O
)	O	O	O
were	O	O	O
similar	O	O	O
(	O	O	O
P	O	O	O
for	O	O	O
interaction	O	O	O
=	O	O	O
.36	O	O	O
)	O	O	O
.	O	O	O

Similarly	O	O	O
,	O	O	O
the	O	O	O
benefit	O	O	B-Entity
of	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
dose	O	O	B-Entity
of	O	O	O
apixaban	O	O	B-Entity
compared	O	O	O
with	O	O	O
warfarin	O	O	B-Entity
on	O	O	O
major	O	O	O
bleeding	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
1	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	B-Entity
criterion	O	O	O
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
0.68	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.53	O	O	O
-	O	O	O
0.87	O	O	O
)	O	O	O
and	O	O	O
no	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	O
criterion	O	O	O
(	O	O	O
HR	O	O	O
,	O	O	O
0.72	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.60	O	O	O
-	O	O	O
0.86	O	O	O
)	O	O	O
were	O	O	O
similar	O	O	O
(	O	O	O
P	O	O	O
for	O	O	O
interaction	O	O	O
=	O	O	O
.71	O	O	O
)	O	O	O
.	O	O	O

Similar	O	O	O
patterns	O	O	O
were	O	O	O
seen	O	O	O
for	O	O	O
each	O	O	O
dose	O	O	B-Entity
-	O	O	O
reduction	O	O	B-Entity
criterion	O	O	O
and	O	O	O
across	O	O	O
the	O	O	O
spectrum	O	O	O
of	O	O	O
age	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
creatinine	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
and	O	O	O
creatinine	O	O	O
clearance	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
atrial	O	O	B-Entity
fibrillation	O	O	I-Entity
and	O	O	O
isolated	O	O	O
advanced	O	O	O
age	O	O	B-Entity
,	O	O	O
low	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
or	O	O	O
renal	O	O	B-Entity
dysfunction	O	O	I-Entity
have	O	O	O
a	O	O	O
higher	O	O	O
risk	O	O	B-Entity
of	O	O	O
stroke	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
embolism	O	O	I-Entity
and	O	O	O
major	O	O	O
bleeding	O	O	B-Entity
but	O	O	O
show	O	O	O
consistent	O	O	O
benefits	O	O	B-Entity
with	O	O	O
the	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
dose	O	O	B-Entity
of	O	O	O
apixaban	O	O	B-Entity
vs	O	O	O
warfarin	O	O	B-Entity
compared	O	O	O
with	O	O	O
patients	O	O	B-Entity
without	O	O	O
these	O	O	O
characteristics	O	O	O
.	O	O	O

The	O	O	O
5	O	O	O
mg	O	O	O
twice	O	O	B-Entity
daily	O	O	B-Entity
dose	O	O	B-Entity
of	O	O	O
apixaban	O	O	B-Entity
is	O	O	O
safe	O	O	O
,	O	O	O
efficacious	O	O	O
,	O	O	O
and	O	O	O
appropriate	O	O	O
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
only	O	O	O
1	O	O	O
dose	O	O	O
-	O	O	O
reduction	O	O	B-Entity
criterion	O	O	O
.	O	O	O

clinicaltrials.gov	O	O	O
Identifier	O	O	O
:	O	O	O
NCT00412984	O	O	O
.	O	O	O

-DOCSTART- (27465464)

Transition	O	O	B-Entity
From	O	O	O
Hospital	O	O	B-Entity
to	O	O	O
Home	O	O	B-Entity
in	O	O	O
Preterm	O	O	B-Entity
Infants	O	O	I-Entity
and	O	O	O
Their	O	O	O
Families	O	O	O

When	O	O	O
the	O	O	O
day	O	O	B-Entity
of	O	O	O
discharge	O	O	B-Entity
from	O	O	O
a	O	O	O
neonatal	O	O	B-Entity
intensive	O	O	I-Entity
care	O	O	I-Entity
unit	O	O	I-Entity
(	O	O	O
NICU	O	O	B-Entity
)	O	O	O
comes	O	O	O
for	O	O	O
the	O	O	O
parents	O	O	B-Entity
of	O	O	O
newborn	O	O	B-Entity
infants	O	O	I-Entity
,	O	O	O
they	O	O	O
are	O	O	O
filled	O	O	O
with	O	O	O
long-awaited	O	O	O
joy	O	O	B-Entity
and	O	O	O
happiness	O	O	B-Entity
.	O	O	O

They	O	O	O
go	O	O	O
home	O	O	B-Entity
feeling	O	O	B-Entity
as	O	O	O
parents	O	O	B-Entity
,	O	O	O
away	O	O	O
from	O	O	O
scheduled	O	O	B-Entity
routines	O	O	I-Entity
of	O	O	O
the	O	O	O
hospital	O	O	B-Entity
,	O	O	O
monitor	O	O	B-Entity
alarms	O	O	I-Entity
,	O	O	O
clinical	O	O	B-Entity
rounds	O	O	I-Entity
,	O	O	O
numerous	O	O	B-Entity
tests	O	O	B-Entity
,	O	O	O
and	O	O	O
so	O	O	O
on	O	O	O
.	O	O	O
What	O	O	O
do	O	O	O
we	O	O	O
know	O	O	O
about	O	O	O
what	O	O	O
happens	O	O	B-Entity
after	O	O	O
these	O	O	O
little	O	O	B-Entity
patients	O	O	I-Entity
and	O	O	O
their	O	O	O
families	O	O	B-Entity
leave	O	O	B-Entity
the	O	O	O
NICU	O	O	B-Entity
?	O	O	O
What	O	O	O
happens	O	O	O
from	O	O	O
the	O	O	O
point	O	O	O
of	O	O	O
leaving	O	O	B-Entity
the	O	O	O
hospital	O	O	O
until	O	O	O
when	O	O	O
things	O	O	O
get	O	O	O
settled	O	O	O
and	O	O	O
life	O	O	B-Entity
becomes	O	O	O
perceived	O	O	B-Entity
as	O	O	O
normal	O	O	B-Entity
?	O	O	O

This	O	O	O
article	O	O	B-Entity
presents	O	O	O
a	O	O	O
short	O	O	O
summary	O	O	B-Entity
of	O	O	O
research	O	O	B-Entity
conducted	O	O	O
with	O	O	O
the	O	O	O
vulnerable	O	O	B-Entity
population	O	O	I-Entity
of	O	O	O
high-risk	O	O	B-Entity
and	O	O	O
preterm	O	O	B-Entity
infants	O	O	I-Entity
and	O	O	O
their	O	O	O
families	O	O	B-Entity
postdischarge	O	O	B-Entity
.	O	O	O

Available	O	O	O
evidence	O	O	B-Entity
suggests	O	O	O
that	O	O	O
transition	O	O	B-Entity
to	O	O	O
home	O	O	B-Entity
after	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
,	O	O	O
a	O	O	O
phenomenon	O	O	B-Entity
that	O	O	O
many	O	O	O
families	O	O	B-Entity
experience	O	O	B-Entity
,	O	O	O
is	O	O	O
challenging	O	O	B-Entity
and	O	O	O
requires	O	O	O
attention	O	O	B-Entity
from	O	O	O
clinicians	O	O	B-Entity
and	O	O	O
researchers	O	O	B-Entity
if	O	O	O
we	O	O	O
are	O	O	O
to	O	O	O
provide	O	O	O
effective	O	O	B-Entity
,	O	O	O
efficient	O	O	B-Entity
,	O	O	O
and	O	O	O
high-quality	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

-DOCSTART- (27466053)

Visual	O	O	B-Entity
Analytics	O	O	I-Entity
for	O	O	O
Pattern	O	O	B-Entity
Discovery	O	O	I-Entity
in	O	O	O
Home	O	O	B-Entity
Care	O	O	I-Entity
.	O	O	O
Clinical	O	O	B-Entity
Relevance	O	O	I-Entity
for	O	O	O
Quality	O	O	O
Improvement	O	O	O

Clinical	O	O	B-Entity
Relevance	O	O	I-Entity
for	O	O	O
Quality	O	O	B-Entity
Improvement	O	O	I-Entity
Visualization	O	O	B-Entity
can	O	O	O
reduce	O	O	O
the	O	O	O
cognitive	O	O	B-Entity
load	O	O	I-Entity
of	O	O	I-Entity
information	O	O	I-Entity
,	O	O	O
allowing	O	O	O
users	O	O	O
to	O	O	O
easily	O	O	O
interpret	O	O	B-Entity
and	O	O	O
assess	O	O	B-Entity
large	O	O	I-Entity
amounts	O	O	I-Entity
of	O	O	I-Entity
data	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
our	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	O
home	O	O	B-Entity
health	O	O	I-Entity
data	O	O	I-Entity
using	O	O	O
visual	O	O	B-Entity
analysis	O	O	I-Entity
techniques	O	O	I-Entity
to	O	O	O
discover	O	O	O
clinically	O	O	B-Entity
salient	O	O	I-Entity
associations	O	O	B-Entity
between	O	O	O
patient	O	O	B-Entity
characteristics	O	O	I-Entity
with	O	O	O
problem-oriented	O	O	B-Entity
health	O	O	I-Entity
outcomes	O	O	I-Entity
of	O	O	O
older	O	O	B-Entity
adult	O	O	I-Entity
home	O	O	I-Entity
health	O	O	I-Entity
patients	O	O	I-Entity
during	O	O	O
the	O	O	O
home	O	O	B-Entity
health	O	O	I-Entity
service	O	O	I-Entity
period	O	O	O
.	O	O	O

Knowledge	O	O	B-Entity
,	O	O	O
Behavior	O	O	B-Entity
and	O	O	O
Status	O	O	B-Entity
ratings	O	O	I-Entity
at	O	O	O
discharge	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
change	O	O	O
from	O	O	O
admission	O	O	B-Entity
to	O	O	O
discharge	O	O	O
that	O	O	O
was	O	O	O
coded	O	O	O
using	O	O	O
the	O	O	O
Omaha	O	O	B-Entity
System	O	O	I-Entity
was	O	O	O
collected	O	O	O
from	O	O	O
a	O	O	O
dataset	O	O	B-Entity
on	O	O	O
988	O	O	O
de-identified	O	O	O
patient	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
15	O	O	O
home	O	O	B-Entity
health	O	O	I-Entity
agencies	O	O	I-Entity
.	O	O	O

SPSS	O	O	B-Entity
Visualization	O	O	I-Entity
Designer	O	O	I-Entity
v1.0	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
visually	O	O	B-Entity
analyze	O	O	I-Entity
patterns	O	O	I-Entity
between	O	O	O
independent	O	O	O
and	O	O	O
outcome	O	O	O
variables	O	O	O
using	O	O	O
heat	O	O	B-Entity
maps	O	O	I-Entity
and	O	O	O
histograms	O	O	B-Entity
.	O	O	O

Visualizations	O	O	B-Entity
suggesting	O	O	O
clinical	O	O	B-Entity
salience	O	O	I-Entity
were	O	O	O
tested	O	O	B-Entity
for	O	O	O
significance	O	O	O
using	O	O	O
correlation	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
age	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
was	O	O	O
80	O	O	O
years	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
majority	O	O	O
female	O	O	B-Entity
(	O	O	O
66	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
150	O	O	O
visualizations	O	O	B-Entity
,	O	O	O
69	O	O	O
potentially	O	O	O
meaningful	O	O	B-Entity
patterns	O	O	I-Entity
were	O	O	O
statistically	O	O	O
evaluated	O	O	O
through	O	O	O
bivariate	O	O	B-Entity
associations	O	O	B-Entity
,	O	O	O
revealing	O	O	O
21	O	O	O
significant	O	O	O
associations	O	O	O
.	O	O	O

Further	O	O	O
,	O	O	O
14	O	O	O
associations	O	O	B-Entity
between	O	O	O
episode	O	O	O
length	O	O	O
and	O	O	O
Charlson	O	O	B-Entity
co-morbidity	O	O	I-Entity
index	O	O	I-Entity
mainly	O	O	O
with	O	O	O
urinary	O	O	B-Entity
related	O	O	O
diagnoses	O	O	B-Entity
and	O	O	I-Entity
problems	O	O	I-Entity
remained	O	O	O
significant	O	O	O
after	O	O	O
adjustment	O	O	O
analyses	O	O	O
.	O	O	O

Through	O	O	O
visual	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
the	O	O	O
adverse	O	O	O
association	O	O	B-Entity
of	O	O	O
the	O	O	O
longer	O	O	O
home	O	O	B-Entity
health	O	O	I-Entity
episode	O	O	I-Entity
length	O	O	O
and	O	O	O
higher	O	O	O
Charlson	O	O	B-Entity
co-morbidity	O	O	I-Entity
index	O	O	I-Entity
with	O	O	O
behavior	O	O	B-Entity
or	O	O	I-Entity
status	O	O	I-Entity
outcomes	O	O	I-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
impaired	O	O	B-Entity
urinary	O	O	I-Entity
function	O	O	I-Entity
was	O	O	O
revealed	O	O	O
.	O	O	O

We	O	O	O
have	O	O	O
demonstrated	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
visual	O	O	B-Entity
analysis	O	O	I-Entity
to	O	O	O
discover	O	O	O
novel	O	O	O
patterns	O	O	O
that	O	O	O
described	O	O	O
high-needs	O	O	O
subgroups	O	O	B-Entity
among	O	O	O
the	O	O	O
older	O	O	B-Entity
home	O	O	I-Entity
health	O	O	I-Entity
patient	O	O	I-Entity
population	O	O	I-Entity
.	O	O	O

The	O	O	O
effective	O	O	O
presentation	O	O	O
of	O	O	O
these	O	O	O
data	O	O	B-Entity
patterns	O	O	I-Entity
can	O	O	O
allow	O	O	O
clinicians	O	O	B-Entity
to	O	O	O
identify	O	O	O
areas	O	O	O
of	O	O	O
patient	O	O	B-Entity
improvement	O	O	I-Entity
,	O	O	O
and	O	O	O
time	O	O	O
periods	O	O	O
that	O	O	O
are	O	O	O
most	O	O	O
effective	O	O	O
for	O	O	O
implementing	O	O	O
home	O	O	B-Entity
health	O	O	I-Entity
interventions	O	O	I-Entity
to	O	O	O
improve	O	O	O
patient	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27466300)

Transforming	O	O	B-Entity
Growth	O	O	I-Entity
Factor	O	O	I-Entity
Beta	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
TGF-β1	O	O	B-Entity
)	O	O	O
in	O	O	O
Thyroid	O	O	B-Entity
Cancer	O	O	I-Entity
Patients	O	O	B-Entity
:	O	O	O
a	O	O	O
View	O	O	O
from	O	O	O
the	O	O	O
Peripheral	O	O	O
Blood	O	O	O

Transforming	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
beta	O	O	I-Entity
(	O	O	O
TGF-β	O	O	B-Entity
)	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
many	O	O	O
pathophysiological	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
including	O	O	O
cancer	O	O	B-Entity
.	O	O	O

The	O	O	O
level	O	O	B-Entity
of	O	O	O
TGF-β	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
differentiated	O	O	B-Entity
thyroid	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
DTC	O	O	B-Entity
)	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
examined	O	O	B-Entity
so	O	O	O
far	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
measure	O	O	O
TGF-β	O	O	B-Entity
concentration	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
samples	O	O	I-Entity
and	O	O	O
in	O	O	O
PHA	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
whole	O	O	B-Entity
blood	O	O	I-Entity
culture	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
to	O	O	O
analyze	O	O	B-Entity
possible	O	O	O
associations	O	O	O
of	O	O	O
TGF-β1	O	O	B-Entity
levels	O	O	B-Entity
with	O	O	O
leukocyte	O	O	B-Entity
,	O	O	O
lymphocyte	O	O	B-Entity
and	O	O	O
platelets	O	O	B-Entity
counts	O	O	B-Entity
,	O	O	O
the	O	O	O
histological	O	O	B-Entity
type	O	O	O
of	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
and	O	O	O
stage	O	O	B-Entity
of	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

TGF-β1	O	O	B-Entity
was	O	O	O
measured	O	O	O
in	O	O	O
22	O	O	O
DTC	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
20	O	O	O
healthy	O	O	B-Entity
controls	O	O	B-Entity
using	O	O	O
the	O	O	O
duoSet	O	O	B-Entity
ELISA	O	O	I-Entity
Development	O	O	I-Entity
kit	O	O	I-Entity
for	O	O	O
human	O	O	B-Entity
TGF-β1	O	O	I-Entity
.	O	O	O

The	O	O	O
concentration	O	O	B-Entity
of	O	O	O
TGF-β1	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
both	O	O	O
groups	O	O	B-Entity
correlated	O	O	O
positively	O	O	O
with	O	O	O
the	O	O	O
platelet	O	O	B-Entity
counts	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	O
in	O	O	O
the	O	O	O
serum	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
TGF-β1	O	O	B-Entity
between	O	O	O
DTC	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
subjects	O	O	I-Entity
,	O	O	O
but	O	O	O
PHA	O	O	B-Entity
stimulated	O	O	B-Entity
whole	O	O	B-Entity
blood	O	O	I-Entity
cultures	O	O	B-Entity
of	O	O	O
DTC	O	O	O
patients	O	O	O
produced	O	O	O
less	O	O	O
TGF-β1	O	O	O
than	O	O	O
those	O	O	O
from	O	O	O
controls	O	O	B-Entity
.	O	O	O

Additional	O	O	O
studies	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
significance	O	O	B-Entity
of	O	O	O
these	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
findings	O	O	B-Entity
.	O	O	O

-DOCSTART- (27466374)

P-glycoprotein	O	O	B-Entity
traffics	O	O	B-Entity
from	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
to	O	O	O
the	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
in	O	O	O
rat	O	O	B-Entity
brain	O	O	I-Entity
endothelium	O	O	B-Entity
during	O	O	O
inflammatory	O	O	O
pain	O	O	O

P-glycoprotein	O	O	B-Entity
(	O	O	O
PgP	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
drug	O	O	B-Entity
efflux	O	O	B-Entity
pump	O	O	I-Entity
in	O	O	O
blood-brain	O	O	B-Entity
barrier	O	O	I-Entity
endothelial	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
major	O	O	O
clinical	O	O	B-Entity
obstacle	O	O	B-Entity
for	O	O	O
effective	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

Identifying	O	O	B-Entity
PgP	O	O	B-Entity
regulatory	O	O	B-Entity
pathways	O	O	I-Entity
that	O	O	O
can	O	O	O
be	O	O	O
exploited	O	O	O
clinically	O	O	O
is	O	O	O
critical	O	O	O
for	O	O	O
improving	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

We	O	O	O
previously	O	O	O
found	O	O	O
that	O	O	O
PgP	O	O	B-Entity
activity	O	O	I-Entity
increases	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
brain	O	O	I-Entity
microvessels	O	O	B-Entity
concomitant	O	O	B-Entity
with	O	O	O
decreased	O	O	B-Entity
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
in	O	O	O
response	O	O	O
to	O	O	O
acute	O	O	B-Entity
peripheral	O	O	B-Entity
inflammatory	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
tested	O	O	O
the	O	O	O
hypothesis	O	O	O
that	O	O	O
PgP	O	O	B-Entity
traffics	O	O	B-Entity
to	O	O	O
the	O	O	O
luminal	O	O	B-Entity
plasma	O	O	B-Entity
membrane	O	O	I-Entity
of	O	O	O
the	O	O	O
microvessel	O	O	B-Entity
endothelial	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
intracellular	O	O	B-Entity
stores	O	O	B-Entity
during	O	O	O
peripheral	O	O	B-Entity
inflammatory	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

Using	O	O	O
immunofluorescence	O	O	B-Entity
microscopy	O	O	I-Entity
,	O	O	O
we	O	O	O
detected	O	O	B-Entity
PgP	O	O	B-Entity
in	O	O	O
endothelial	O	O	B-Entity
cell	O	O	I-Entity
nuclei	O	O	B-Entity
and	O	O	O
in	O	O	O
the	O	O	O
luminal	O	O	B-Entity
plasma	O	O	B-Entity
membrane	O	O	I-Entity
in	O	O	O
control	O	O	B-Entity
animals	O	O	I-Entity
.	O	O	O

Following	O	O	O
peripheral	O	O	B-Entity
inflammatory	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
luminal	O	O	B-Entity
PgP	O	O	B-Entity
staining	O	O	B-Entity
increased	O	O	B-Entity
while	O	O	O
staining	O	O	O
in	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
decreased	O	O	B-Entity
.	O	O	O

Biochemical	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
nuclear	O	O	B-Entity
PgP	O	O	B-Entity
content	O	O	B-Entity
confirmed	O	O	O
our	O	O	O
visual	O	O	B-Entity
observations	O	O	I-Entity
.	O	O	O

Peripheral	O	O	B-Entity
inflammatory	O	O	B-Entity
pain	O	O	I-Entity
also	O	O	O
increased	O	O	B-Entity
endothelial	O	O	B-Entity
cell	O	O	I-Entity
luminal	O	O	B-Entity
staining	O	O	B-Entity
of	O	O	O
polymerase	O	O	B-Entity
1	O	O	I-Entity
and	O	O	I-Entity
transcript	O	O	I-Entity
release	O	O	I-Entity
factor	O	O	I-Entity
/	O	O	O
cavin1	O	O	B-Entity
and	O	O	O
serum	O	O	B-Entity
deprivation	O	O	I-Entity
response	O	O	I-Entity
protein	O	O	I-Entity
/	O	O	O
cavin2	O	O	B-Entity
,	O	O	O
two	O	O	O
caveolar	O	O	B-Entity
scaffold	O	O	I-Entity
proteins	O	O	I-Entity
,	O	O	O
without	O	O	O
changing	O	O	O
caveolin1	O	O	B-Entity
or	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
C	O	O	I-Entity
delta	O	O	I-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
/	O	O	O
cavin3	O	O	B-Entity
location	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
(	O	O	O
a	O	O	O
)	O	O	O
indicate	O	O	O
that	O	O	O
PgP	O	O	B-Entity
traffics	O	O	B-Entity
from	O	O	O
stores	O	O	B-Entity
in	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
to	O	O	O
the	O	O	O
endothelial	O	O	B-Entity
cell	O	O	I-Entity
luminal	O	O	B-Entity
membrane	O	O	I-Entity
in	O	O	O
response	O	O	O
to	O	O	O
peripheral	O	O	B-Entity
inflammatory	O	O	B-Entity
pain	O	O	I-Entity
;	O	O	O
(	O	O	O
b	O	O	O
)	O	O	O
provide	O	O	O
an	O	O	O
explanation	O	O	O
for	O	O	O
our	O	O	O
previous	O	O	O
observation	O	O	B-Entity
that	O	O	O
peripheral	O	O	O
inflammatory	O	O	O
pain	O	O	O
inhibits	O	O	B-Entity
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
drug	O	O	B-Entity
uptake	O	O	B-Entity
;	O	O	O
and	O	O	O
(	O	O	O
c	O	O	O
)	O	O	O
suggest	O	O	O
a	O	O	O
novel	O	O	B-Entity
regulatory	O	O	B-Entity
mechanism	O	O	I-Entity
for	O	O	O
PgP	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
rat	O	O	B-Entity
brain	O	O	I-Entity
.	O	O	O

-DOCSTART- (27469396)

Functional	O	O	B-Entity
Impairment	O	O	B-Entity
in	O	O	O
Children	O	O	B-Entity
With	O	O	O
Externalizing	O	O	B-Entity
Behavior	O	O	I-Entity
Disorders	O	O	I-Entity
:	O	O	O
Psychometric	O	O	B-Entity
Properties	O	O	B-Entity
of	O	O	O
the	O	O	O
Weiss	O	O	B-Entity
Functional	O	O	I-Entity
Impairment	O	O	I-Entity
Rating	O	O	I-Entity
Scale-Parent	O	O	I-Entity
Report	O	O	I-Entity
in	O	O	O
a	O	O	O
German	O	O	B-Entity
Clinical	O	O	O
Sample	O	O	O

To	O	O	O
examine	O	O	O
the	O	O	O
psychometric	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
a	O	O	O
German	O	O	B-Entity
adaptation	O	O	O
of	O	O	O
the	O	O	O
Weiss	O	O	B-Entity
Functional	O	O	I-Entity
Impairment	O	O	I-Entity
Rating	O	O	I-Entity
Scale-Parent	O	O	I-Entity
Report	O	O	I-Entity
(	O	O	O
WFIRS-P	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
clinical	O	O	B-Entity
sample	O	O	I-Entity
of	O	O	O
children	O	O	B-Entity
(	O	O	O
4	O	O	O
-	O	O	O
12	O	O	O
years	O	O	B-Entity
)	O	O	O
with	O	O	O
externalizing	O	O	B-Entity
behavior	O	O	I-Entity
disorders	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
within	O	O	O
two	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
264	O	O	O
)	O	O	O
.	O	O	O

Factorial	O	O	B-Entity
validity	O	O	I-Entity
,	O	O	O
reliability	O	O	B-Entity
,	O	O	O
and	O	O	O
divergent	O	O	B-Entity
validity	O	O	I-Entity
from	O	O	O
symptoms	O	O	B-Entity
of	O	O	O
ADHD	O	O	B-Entity
and	O	O	O
oppositional	O	O	B-Entity
defiant	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
ODD	O	O	B-Entity
)	O	O	O
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Confirmatory	O	O	B-Entity
factor	O	O	I-Entity
analyses	O	O	I-Entity
revealed	O	O	B-Entity
that	O	O	O
a	O	O	O
bifactor	O	O	B-Entity
model	O	O	I-Entity
consistent	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
theoretical	O	O	B-Entity
assumption	O	O	I-Entity
of	O	O	O
a	O	O	O
general	O	O	B-Entity
construct	O	O	I-Entity
of	O	O	O
impairment	O	O	B-Entity
(	O	O	O
total	O	O	O
scale	O	O	O
)	O	O	O
and	O	O	O
additional	O	O	B-Entity
specific	O	O	B-Entity
factors	O	O	I-Entity
(	O	O	O
subscales	O	O	O
)	O	O	O
provided	O	O	O
satisfactory	O	O	B-Entity
data	O	O	B-Entity
fit	O	O	I-Entity
.	O	O	O

Model	O	O	B-Entity
-based	O	O	O
reliability	O	O	B-Entity
estimates	O	O	B-Entity
showed	O	O	O
that	O	O	O
both	O	O	O
the	O	O	O
general	O	O	B-Entity
construct	O	O	I-Entity
and	O	O	O
specific	O	O	B-Entity
factors	O	O	I-Entity
accounted	O	O	O
for	O	O	O
item	O	O	O
variance	O	O	B-Entity
.	O	O	O

Internal	O	O	O
consistencies	O	O	B-Entity
were	O	O	O
>	O	O	O
.70	O	O	O
,	O	O	O
part-whole	O	O	O
corrected	O	O	O
item-scale	O	O	O
correlations	O	O	B-Entity
mostly	O	O	O
>	O	O	O
.30	O	O	O
.	O	O	O

Correlations	O	O	B-Entity
between	O	O	O
the	O	O	O
WFIRS-P	O	O	B-Entity
Scales	O	O	I-Entity
and	O	O	O
ADHD	O	O	B-Entity
and	O	O	O
ODD	O	O	B-Entity
symptoms	O	O	B-Entity
were	O	O	O
low	O	O	B-Entity
to	O	O	O
moderate	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
support	O	O	O
the	O	O	O
factorial	O	O	B-Entity
validity	O	O	I-Entity
,	O	O	O
reliability	O	O	B-Entity
,	O	O	O
and	O	O	O
divergent	O	O	B-Entity
validity	O	O	I-Entity
of	O	O	O
the	O	O	O
WFIRS-P.	O	O	O

-DOCSTART- (27469581)

What	O	O	O
can	O	O	O
the	O	O	O
Canadians	O	O	B-Entity
and	O	O	O
Americans	O	O	B-Entity
learn	O	O	B-Entity
from	O	O	O
each	O	O	O
other	O	O	O
's	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
systems	O	O	I-Entity
?	O	O	O

Numerous	O	O	O
papers	O	O	B-Entity
have	O	O	O
been	O	O	O
written	O	O	O
comparing	O	O	B-Entity
the	O	O	O
Canadian	O	O	B-Entity
and	O	O	O
US	O	O	B-Entity
healthcare	O	O	B-Entity
systems	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
health	O	O	B-Entity
policy	O	O	I-Entity
experts	O	O	B-Entity
have	O	O	O
recommended	O	O	B-Entity
that	O	O	O
the	O	O	O
Americans	O	O	B-Entity
implement	O	O	B-Entity
their	O	O	O
single-payer	O	O	B-Entity
system	O	O	I-Entity
to	O	O	O
save	O	O	O
12	O	O	O
-	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
its	O	O	O
healthcare	O	O	B-Entity
expenditures	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	B-Entity
is	O	O	O
different	O	O	O
in	O	O	O
that	O	O	O
it	O	O	O
assumes	O	O	O
that	O	O	O
neither	O	O	O
country	O	O	B-Entity
will	O	O	O
undertake	O	O	O
a	O	O	O
significant	O	O	B-Entity
philosophic	O	O	B-Entity
or	O	O	O
structural	O	O	B-Entity
change	O	O	B-Entity
in	O	O	O
their	O	O	O
healthcare	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
but	O	O	O
there	O	O	O
are	O	O	O
lessons	O	O	O
to	O	O	O
be	O	O	O
learned	O	O	B-Entity
that	O	O	O
are	O	O	O
inherent	O	O	O
in	O	O	O
one	O	O	O
that	O	O	O
could	O	O	O
be	O	O	O
a	O	O	O
major	O	O	O
breakthrough	O	O	B-Entity
for	O	O	O
the	O	O	O
other	O	O	O
.	O	O	O

Following	O	O	O
the	O	O	O
model	O	O	B-Entity
in	O	O	O
Canada	O	O	B-Entity
and	O	O	O
in	O	O	O
Western	O	O	B-Entity
Europe	O	O	I-Entity
,	O	O	O
the	O	O	O
USA	O	O	B-Entity
could	O	O	O
implement	O	O	B-Entity
universal	O	O	B-Entity
health	O	O	B-Entity
insurance	O	O	I-Entity
so	O	O	O
that	O	O	O
the	O	O	O
32.0	O	O	O
million	O	O	O
(	O	O	O
2015	O	O	O
)	O	O	O
Americans	O	O	B-Entity
still	O	O	O
uninsured	O	O	B-Entity
would	O	O	O
have	O	O	O
at	O	O	O
least	O	O	O
minimal	O	O	B-Entity
coverage	O	O	B-Entity
when	O	O	O
incurring	O	O	O
medical	O	O	B-Entity
expenditures	O	O	I-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
the	O	O	O
USA	O	O	B-Entity
could	O	O	O
use	O	O	O
smart	O	O	B-Entity
cards	O	O	I-Entity
to	O	O	O
evaluate	O	O	B-Entity
eligibility	O	O	I-Entity
and	O	O	O
to	O	O	O
process	O	O	B-Entity
health	O	O	B-Entity
insurance	O	O	I-Entity
claims	O	O	I-Entity
;	O	O	O
these	O	O	O
changes	O	O	O
resulting	O	O	B-Entity
in	O	O	I-Entity
an	O	O	O
estimated	O	O	B-Entity
15	O	O	O
%	O	O	O
reduction	O	O	B-Entity
in	O	O	O
US	O	O	B-Entity
health	O	O	B-Entity
expenditures	O	O	I-Entity
without	O	O	O
adversely	O	O	O
effecting	O	O	B-Entity
access	O	O	B-Entity
or	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
care	O	O	I-Entity
.	O	O	O

Such	O	O	O
a	O	O	O
strategy	O	O	O
would	O	O	O
result	O	O	B-Entity
in	O	O	O
the	O	O	O
eventual	O	O	O
loss	O	O	B-Entity
of	O	O	O
2.5	O	O	O
million	O	O	O
white-collar	O	O	B-Entity
jobs	O	O	I-Entity
at	O	O	O
hospitals	O	O	B-Entity
,	O	O	O
physician	O	O	B-Entity
offices	O	O	I-Entity
and	O	O	O
insurance	O	O	B-Entity
companies	O	O	I-Entity
,	O	O	O
a	O	O	O
long-term	O	O	B-Entity
economic	O	O	B-Entity
gain	O	O	B-Entity
.	O	O	O

Only	O	O	O
a	O	O	O
few	O	O	O
would	O	O	O
agree	O	O	O
with	O	O	O
the	O	O	O
statement	O	O	O
that	O	O	O
Canada	O	O	B-Entity
already	O	O	O
functions	O	O	B-Entity
with	O	O	O
a	O	O	O
multi-payer	O	O	B-Entity
reimbursement	O	O	B-Entity
system	O	O	I-Entity
as	O	O	O
evidenced	O	O	O
by	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
a	O	O	O
federal	O	O	B-Entity
-	O	O	O
provincial	O	O	B-Entity
,	O	O	O
tax	O	O	B-Entity
-	O	O	O
supported	O	O	B-Entity
plan	O	O	B-Entity
,	O	O	O
administered	O	O	O
by	O	O	O
each	O	O	O
of	O	O	O
the	O	O	O
provinces	O	O	B-Entity
,	O	O	O
providing	O	O	O
universal	O	O	B-Entity
coverage	O	O	I-Entity
for	O	O	O
hospital	O	O	B-Entity
and	O	O	O
physician	O	O	B-Entity
services	O	O	I-Entity
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
roughly	O	O	O
60	O	O	O
%	O	O	O
of	O	O	O
its	O	O	O
residents	O	O	B-Entity
receiving	O	O	O
employer-paid	O	O	B-Entity
health	O	O	B-Entity
insurance	O	O	I-Entity
benefits	O	O	B-Entity
,	O	O	O
underwritten	O	O	O
primarily	O	O	O
by	O	O	O
investor-owned	O	O	O
plans	O	O	O
,	O	O	O
that	O	O	O
are	O	O	O
less	O	O	O
than	O	O	O
effective	O	O	B-Entity
to	O	O	O
reimburse	O	O	B-Entity
for	O	O	O
pharmaceuticals	O	O	B-Entity
,	O	O	O
dental	O	O	B-Entity
and	O	O	O
other	O	O	O
healthcare	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

What	O	O	O
could	O	O	O
be	O	O	O
learned	O	O	O
from	O	O	O
the	O	O	O
USA	O	O	B-Entity
and	O	O	O
particularly	O	O	O
from	O	O	O
Western	O	O	B-Entity
European	O	O	I-Entity
countries	O	O	I-Entity
is	O	O	O
possibly	O	O	O
implementing	O	O	B-Entity
an	O	O	O
approach	O	O	O
,	O	O	O
whereby	O	O	O
at	O	O	O
least	O	O	O
upper-income	O	O	B-Entity
Canadians	O	O	B-Entity
could	O	O	O
opt	O	O	O
out	O	O	O
of	O	O	O
their	O	O	O
federal	O	O	B-Entity
-	O	O	O
provincial	O	O	B-Entity
plan	O	O	B-Entity
and	O	O	O
purchase	O	O	O
private	O	O	B-Entity
insurance	O	O	B-Entity
coverage	O	O	I-Entity
-	O	O	O
being	O	O	O
eligible	O	O	O
for	O	O	O
far	O	O	O
more	O	O	O
comprehensive	O	O	O
"	O	O	O
private	O	O	O
"	O	O	O
benefits	O	O	O
for	O	O	O
hospital	O	O	B-Entity
,	O	O	O
physician	O	O	B-Entity
,	O	O	O
pharmaceutical	O	O	B-Entity
,	O	O	O
dental	O	O	B-Entity
and	O	O	O
other	O	O	O
healthcare	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

Aside	O	O	O
from	O	O	O
generating	O	O	O
billions	O	O	O
of	O	O	O
additional	O	O	O
needed	O	O	O
revenues	O	O	B-Entity
from	O	O	O
the	O	O	O
private	O	O	B-Entity
sector	O	O	I-Entity
,	O	O	O
it	O	O	O
could	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
help	O	O	O
eliminate	O	O	B-Entity
long	O	O	O
waits	O	O	O
for	O	O	O
non-emergent	O	O	O
physicians	O	O	O
'	O	O	O
care	O	O	O
by	O	O	O
appointing	O	O	O
newly	O	O	O
minted	O	O	O
specialists	O	O	B-Entity
to	O	O	O
their	O	O	O
medical	O	O	B-Entity
staffs	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
offer	O	O	O
prompt	O	O	B-Entity
admissions	O	O	B-Entity
for	O	O	O
elective	O	O	B-Entity
cases	O	O	I-Entity
to	O	O	O
"	O	O	O
private	O	O	O
"	O	O	O
wings	O	O	B-Entity
of	O	O	I-Entity
hospitals	O	O	I-Entity
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
increase	O	O	B-Entity
available	O	O	O
funding	O	O	B-Entity
for	O	O	O
what	O	O	O
is	O	O	O
currently	O	O	B-Entity
an	O	O	O
undercapitalized	O	O	B-Entity
system	O	O	B-Entity
;	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
enhance	O	O	B-Entity
the	O	O	O
system	O	O	O
's	O	O	O
sluggish	O	O	B-Entity
operations	O	O	B-Entity
;	O	O	O
and	O	O	O
(	O	O	O
5	O	O	O
)	O	O	O
encourage	O	O	O
more	O	O	O
competition	O	O	B-Entity
among	O	O	O
various	O	O	O
providers	O	O	O
.	O	O	O

Although	O	O	O
such	O	O	O
a	O	O	O
two-tier	O	O	B-Entity
approach	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
available	O	O	O
in	O	O	O
the	O	O	O
USA	O	O	B-Entity
and	O	O	O
elsewhere	O	O	O
,	O	O	O
is	O	O	O
politically	O	O	O
dead	O	O	O
on	O	O	O
arrival	O	O	O
in	O	O	O
Canada	O	O	B-Entity
today	O	O	O
,	O	O	O
private	O	O	B-Entity
insurance	O	O	I-Entity
being	O	O	O
already	O	O	O
legal	O	O	B-Entity
and	O	O	O
commonly	O	O	O
available	O	O	O
there	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
this	O	O	O
recommended	O	O	B-Entity
solution	O	O	O
is	O	O	O
utilized	O	O	O
in	O	O	O
most	O	O	O
western	O	O	B-Entity
European	O	O	I-Entity
countries	O	O	I-Entity
where	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
higher	O	O	O
percentagea	O	O	B-Entity
than	O	O	O
in	O	O	O
Canada	O	O	B-Entity
of	O	O	O
public	O	O	B-Entity
(	O	O	O
versus	O	O	O
private	O	O	O
)	O	O	O
funding	O	O	B-Entity
of	O	O	O
their	O	O	O
total	O	O	O
health	O	O	B-Entity
expenditures	O	O	I-Entity
.	O	O	O

Because	O	O	O
of	O	O	O
various	O	O	O
vested	O	O	O
interests	O	O	O
,	O	O	O
attempts	O	O	B-Entity
to	O	O	O
implement	O	O	B-Entity
any	O	O	O
of	O	O	O
the	O	O	O
aforementioned	O	O	O
proposals	O	O	O
will	O	O	O
undoubtedly	O	O	O
result	O	O	B-Entity
in	O	O	O
considerable	O	O	O
political	O	O	B-Entity
rancor	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
greater	O	O	O
likelihood	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
that	O	O	O
the	O	O	O
Canadians	O	O	B-Entity
because	O	O	O
their	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
effective	O	O	B-Entity
and	O	O	O
efficient	O	O	B-Entity
in	O	O	O
their	O	O	O
delivery	O	O	B-Entity
of	O	O	I-Entity
care	O	O	I-Entity
,	O	O	O
and	O	O	O
their	O	O	O
overall	O	O	O
long-term	O	O	B-Entity
fiscal	O	O	B-Entity
outlook	O	O	O
will	O	O	O
agree	O	O	B-Entity
to	O	O	O
the	O	O	O
further	O	O	O
privatization	O	O	B-Entity
of	O	O	O
their	O	O	O
healthcare	O	O	B-Entity
system	O	O	I-Entity
before	O	O	O
the	O	O	O
Americans	O	O	B-Entity
will	O	O	O
mandate	O	O	O
universal	O	O	O
access	O	O	O
,	O	O	O
use	O	O	O
the	O	O	O
smart	O	O	B-Entity
card	O	O	I-Entity
to	O	O	O
process	O	O	O
insurance	O	O	B-Entity
eligibility	O	O	I-Entity
and	O	O	O
claims	O	O	O
or	O	O	O
will	O	O	O
impose	O	O	O
price	O	O	O
controls	O	O	B-Entity
on	O	O	O
high-tech	O	O	O
services	O	O	O
and	O	O	O
on	O	O	O
pharmaceuticals	O	O	B-Entity
.	O	O	O

Copyright	O	O	O
©	O	O	O
2016	O	O	O
John	O	O	O
Wiley	O	O	O
&	O	O	O
Sons	O	O	O
,	O	O	O
Ltd.	O	O	O

-DOCSTART- (27471363)

Optimal	O	O	B-Entity
Duration	O	O	B-Entity
of	O	O	O
Coronary	O	O	B-Entity
Ligation	O	O	I-Entity
and	O	O	O
Reperfusion	O	O	B-Entity
for	O	O	O
Reperfusion	O	O	B-Entity
Injury	O	O	I-Entity
Study	O	O	B-Entity
in	O	O	O
a	O	O	O
Rat	O	O	B-Entity
Model	O	O	O

Reperfusion	O	O	B-Entity
injury	O	O	I-Entity
(	O	O	O
RI	O	O	B-Entity
)	O	O	O
has	O	O	O
an	O	O	O
important	O	O	B-Entity
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
clinical	O	O	B-Entity
prognosis	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
myocardial	O	O	I-Entity
injury	O	O	I-Entity
who	O	O	O
had	O	O	O
their	O	O	O
coronary	O	O	B-Entity
blood	O	O	B-Entity
flow	O	O	I-Entity
reestablished	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
studies	O	O	B-Entity
to	O	O	O
date	O	O	O
have	O	O	O
investigated	O	O	B-Entity
the	O	O	O
timeframe	O	O	B-Entity
of	O	O	O
coronary	O	O	B-Entity
occlusion	O	O	I-Entity
and	O	O	O
reperfusion	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
RI	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
100	O	O	O
rats	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
4	O	O	O
groups	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
coronary	O	O	B-Entity
ligation	O	O	I-Entity
period	O	O	B-Entity
:	O	O	O
30	O	O	O
,	O	O	O
60	O	O	O
,	O	O	O
120	O	O	O
,	O	O	O
and	O	O	O
180	O	O	O
min	O	O	O
,	O	O	O
and	O	O	O
each	O	O	O
group	O	O	B-Entity
was	O	O	O
further	O	O	O
divided	O	O	O
into	O	O	O
5	O	O	O
subgroups	O	O	B-Entity
with	O	O	O
different	O	O	B-Entity
reperfusion	O	O	B-Entity
periods	O	O	B-Entity
:	O	O	O
0	O	O	O
,	O	O	O
30	O	O	O
,	O	O	O
60	O	O	O
,	O	O	O
120	O	O	O
,	O	O	O
and	O	O	O
180	O	O	O
min	O	O	O
.	O	O	O

R0	O	O	O
was	O	O	O
the	O	O	O
baseline	O	O	B-Entity
of	O	O	O
each	O	O	O
subgroup	O	O	B-Entity
.	O	O	O

All	O	O	O
animals	O	O	B-Entity
received	O	O	O
the	O	O	O
same	O	O	O
protocols	O	O	B-Entity
for	O	O	O
designed	O	O	B-Entity
ligation	O	O	B-Entity
and	O	O	O
reperfusion	O	O	B-Entity
periods	O	O	B-Entity
.	O	O	O

Evans	O	O	B-Entity
blue	O	O	I-Entity
and	O	O	O
2,3,5-triphenyltetrazolium	O	O	B-Entity
chloride	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
distinguish	O	O	O
different	O	O	B-Entity
myocardial	O	O	B-Entity
injury	O	O	I-Entity
areas	O	O	B-Entity
:	O	O	O
area	O	O	B-Entity
at	O	O	B-Entity
risk	O	O	I-Entity
(	O	O	O
AAR	O	O	B-Entity
)	O	O	O
and	O	O	O
myocardial	O	O	B-Entity
necrosis	O	O	I-Entity
.	O	O	O

The	O	O	O
differences	O	O	B-Entity
of	O	O	O
the	O	O	O
ratios	O	O	B-Entity
of	O	O	O
the	O	O	O
necrotic	O	O	B-Entity
area	O	O	B-Entity
to	O	O	O
AAR	O	O	B-Entity
between	O	O	O
each	O	O	O
subgroup	O	O	B-Entity
and	O	O	O
baseline	O	O	B-Entity
were	O	O	O
further	O	O	O
averaged	O	O	B-Entity
to	O	O	O
calculate	O	O	B-Entity
an	O	O	O
overall	O	O	B-Entity
value	O	O	B-Entity
of	O	O	O
each	O	O	O
heart	O	O	B-Entity
.	O	O	O

The	O	O	O
relative	O	O	O
RI	O	O	B-Entity
percentages	O	O	B-Entity
showed	O	O	O
significant	O	O	B-Entity
differences	O	O	B-Entity
(	O	O	O
0.8	O	O	O
±	O	O	O
2.3	O	O	O
%	O	O	O
,	O	O	O
4.9	O	O	O
±	O	O	O
3.3	O	O	O
%	O	O	O
,	O	O	O
10.8	O	O	O
±	O	O	O
3.1	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
20.3	O	O	O
±	O	O	O
3.6	O	O	O
%	O	O	O
respectively	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
at	O	O	O
different	O	O	B-Entity
time	O	O	B-Entity
points	O	O	I-Entity
of	O	O	O
reperfusion	O	O	B-Entity
but	O	O	O
not	O	O	O
at	O	O	O
different	O	O	O
time	O	O	O
points	O	O	O
of	O	O	O
ligation	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.593	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
effects	O	O	B-Entity
of	O	O	O
different	O	O	B-Entity
time	O	O	B-Entity
courses	O	O	I-Entity
in	O	O	O
RI	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
L120R180	O	O	O
group	O	O	B-Entity
(	O	O	O
43.4	O	O	O
±	O	O	O
2.3	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
the	O	O	O
highest	O	O	B-Entity
RI	O	O	O
difference	O	O	B-Entity
with	O	O	O
the	O	O	O
baseline	O	O	B-Entity
group	O	O	O
.	O	O	O

Maximal	O	O	B-Entity
RI	O	O	B-Entity
occurred	O	O	O
at	O	O	O
the	O	O	O
timeframe	O	O	B-Entity
of	O	O	O
L120R180	O	O	O
in	O	O	O
our	O	O	O
animal	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

This	O	O	O
result	O	O	B-Entity
may	O	O	O
be	O	O	O
utilized	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
substantial	O	O	O
benefits	O	O	B-Entity
of	O	O	O
RI	O	O	B-Entity
therapies	O	O	I-Entity
in	O	O	O
an	O	O	O
experimental	O	O	B-Entity
rat	O	O	I-Entity
model	O	O	I-Entity
setting	O	O	O
.	O	O	O

-DOCSTART- (27473209)

Derivation	O	O	B-Entity
of	O	O	O
a	O	O	O
Predictive	O	O	B-Entity
Score	O	O	B-Entity
for	O	O	O
Hemorrhagic	O	O	B-Entity
Progression	O	O	B-Entity
of	O	O	O
Cerebral	O	O	B-Entity
Contusions	O	O	I-Entity
in	O	O	O
Moderate	O	O	B-Entity
and	O	O	O
Severe	O	O	O
Traumatic	O	O	O
Brain	O	O	O
Injury	O	O	O

After	O	O	O
traumatic	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
TBI	O	O	B-Entity
)	O	O	O
,	O	O	O
hemorrhagic	O	O	B-Entity
progression	O	O	B-Entity
of	O	O	O
contusions	O	O	B-Entity
(	O	O	O
HPCs	O	O	B-Entity
)	O	O	O
occurs	O	O	O
frequently	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
established	O	O	B-Entity
predictive	O	O	B-Entity
score	O	O	B-Entity
to	O	O	O
identify	O	O	O
high-risk	O	O	B-Entity
patients	O	O	B-Entity
for	O	O	O
HPC	O	O	B-Entity
.	O	O	O

Consecutive	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
hospitalized	O	O	B-Entity
(	O	O	O
2008	O	O	O
-	O	O	O
2013	O	O	O
)	O	O	O
with	O	O	O
non-penetrating	O	O	O
moderate	O	O	B-Entity
or	O	O	O
severe	O	O	B-Entity
TBI	O	O	I-Entity
were	O	O	O
studied	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
was	O	O	O
HPC	O	O	B-Entity
,	O	O	O
defined	O	O	O
by	O	O	O
both	O	O	O
a	O	O	O
relative	O	O	O
increase	O	O	B-Entity
in	O	O	O
contusion	O	O	B-Entity
volume	O	O	B-Entity
by	O	O	O
≥30	O	O	O
%	O	O	O
and	O	O	O
an	O	O	O
absolute	O	O	B-Entity
increase	O	O	O
by	O	O	O
≥10	O	O	O
mL	O	O	O
on	O	O	O
serial	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

Logistic	O	O	B-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
were	O	O	O
created	O	O	B-Entity
to	O	O	O
identify	O	O	O
independent	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
HPC	O	O	B-Entity
.	O	O	O

The	O	O	O
HPC	O	O	B-Entity
Score	O	O	B-Entity
was	O	O	O
then	O	O	O
derived	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
final	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

Among	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
286	O	O	O
eligible	O	O	O
patients	O	O	B-Entity
,	O	O	O
61	O	O	O
(	O	O	O
21	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	O
developed	O	O	O
HPC	O	O	B-Entity
.	O	O	O

On	O	O	O
univariate	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
HPC	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
older	O	O	B-Entity
age	O	O	I-Entity
,	O	O	O
higher	O	O	B-Entity
initial	O	O	I-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
,	O	O	O
antiplatelet	O	O	B-Entity
medications	O	O	I-Entity
,	O	O	O
anticoagulants	O	O	B-Entity
,	O	O	O
subarachnoid	O	O	B-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
SAH	O	O	B-Entity
)	O	O	O
subdural	O	O	B-Entity
hematoma	O	O	I-Entity
(	O	O	O
SDH	O	O	B-Entity
)	O	O	O
,	O	O	O
skull	O	O	B-Entity
fracture	O	O	I-Entity
,	O	O	O
frontal	O	O	B-Entity
contusion	O	O	B-Entity
,	O	O	O
larger	O	O	B-Entity
contusion	O	O	O
volume	O	O	B-Entity
,	O	O	O
and	O	O	O
shorter	O	O	B-Entity
interval	O	O	I-Entity
from	O	O	O
injury	O	O	B-Entity
to	O	O	O
initial	O	O	B-Entity
CT	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
final	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
SAH	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
6.33	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
1.80	O	O	O
-	O	O	O
22.23	O	O	O
)	O	O	O
,	O	O	O
SDH	O	O	B-Entity
(	O	O	O
OR	O	O	O
3.46	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.39	O	O	O
-	O	O	O
8.63	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
skull	O	O	B-Entity
fracture	O	O	I-Entity
(	O	O	O
OR	O	O	O
2.67	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.28	O	O	O
-	O	O	O
5.58	O	O	O
)	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
HPC	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
these	O	O	O
factors	O	O	B-Entity
,	O	O	O
the	O	O	O
HPC	O	O	B-Entity
Score	O	O	B-Entity
was	O	O	O
derived	O	O	B-Entity
(	O	O	O
SAH	O	O	B-Entity
=	O	O	O
2	O	O	O
points	O	O	O
,	O	O	O
SDH	O	O	B-Entity
=	O	O	O
1	O	O	O
point	O	O	O
,	O	O	O
and	O	O	O
skull	O	O	B-Entity
fracture	O	O	I-Entity
=	O	O	O
1	O	O	O
point	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
score	O	O	B-Entity
had	O	O	O
an	O	O	O
area	O	O	O
under	O	O	O
the	O	O	O
receiver	O	O	B-Entity
operating	O	O	I-Entity
curve	O	O	I-Entity
of	O	O	O
0.77	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
a	O	O	O
score	O	O	B-Entity
of	O	O	O
0	O	O	O
-	O	O	O
2	O	O	O
had	O	O	O
a	O	O	O
4.0	O	O	O
%	O	O	O
incidence	O	O	B-Entity
of	O	O	O
HPC	O	O	B-Entity
,	O	O	O
while	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
score	O	O	O
of	O	O	O
3	O	O	O
-	O	O	O
4	O	O	O
had	O	O	O
a	O	O	O
34.6	O	O	O
%	O	O	O
incidence	O	O	O
of	O	O	O
HPC	O	O	O
.	O	O	O

A	O	O	O
simple	O	O	O
HPC	O	O	B-Entity
Score	O	O	B-Entity
was	O	O	O
developed	O	O	O
for	O	O	O
early	O	O	O
risk	O	O	B-Entity
stratification	O	O	B-Entity
of	O	O	O
HPC	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
moderate	O	O	B-Entity
or	O	O	O
severe	O	O	B-Entity
TBI	O	O	I-Entity
.	O	O	O

-DOCSTART- (27473877)

Expressing	O	O	B-Entity
sexuality	O	O	B-Entity
in	O	O	O
nursing	O	O	B-Entity
homes	O	O	I-Entity
.	O	O	O
The	O	O	O
experience	O	O	B-Entity
of	O	O	O
older	O	O	B-Entity
women	O	O	I-Entity
:	O	O	O
A	O	O	O
qualitative	O	O	O
study	O	O	O

The	O	O	O
experience	O	O	B-Entity
of	O	O	O
older	O	O	B-Entity
women	O	O	I-Entity
:	O	O	O
A	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
In	O	O	O
nursing	O	O	B-Entity
homes	O	O	I-Entity
,	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
barriers	O	O	B-Entity
to	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
sexuality	O	O	B-Entity
exist	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
privacy	O	O	I-Entity
,	O	O	O
certain	O	O	O
attitudes	O	O	B-Entity
on	O	O	O
behalf	O	O	O
of	O	O	O
the	O	O	O
staff	O	O	B-Entity
and	O	O	O
the	O	O	O
family	O	O	B-Entity
,	O	O	O
the	O	O	O
lack	O	O	O
of	O	O	O
a	O	O	O
sexual	O	O	B-Entity
partner	O	O	I-Entity
,	O	O	O
and	O	O	O
physical	O	O	B-Entity
limitations	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
lived	O	O	B-Entity
experience	O	O	I-Entity
of	O	O	O
sexuality	O	O	B-Entity
in	O	O	O
elderly	O	O	B-Entity
Spanish	O	O	I-Entity
women	O	O	I-Entity
residing	O	O	O
in	O	O	O
nursing	O	O	B-Entity
homes	O	O	I-Entity
.	O	O	O

A	O	O	O
qualitative	O	O	B-Entity
phenomenological	O	O	I-Entity
approach	O	O	I-Entity
was	O	O	O
followed	O	O	O
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
over	O	O	O
an	O	O	O
18-	O	O	O
month	O	O	B-Entity
period	O	O	I-Entity
between	O	O	O
2013	O	O	O
and	O	O	O
2015	O	O	O
.	O	O	O

Purposeful	O	O	O
sampling	O	O	B-Entity
was	O	O	O
conducted	O	O	O
with	O	O	O
Spanish	O	O	B-Entity
residents	O	O	I-Entity
in	O	O	O
nursing	O	O	B-Entity
homes	O	O	I-Entity
in	O	O	O
Madrid	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
collected	O	O	O
using	O	O	O
unstructured	O	O	B-Entity
and	O	O	I-Entity
semi-structured	O	O	I-Entity
interviews	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
thematic	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Twenty	O	O	O
female	O	O	B-Entity
residents	O	O	B-Entity
participated	O	O	O
.	O	O	O

Three	O	O	O
main	O	O	O
themes	O	O	B-Entity
emerged	O	O	O
from	O	O	O
the	O	O	O
data	O	O	B-Entity
:	O	O	O
a	O	O	O
)	O	O	O
expressing	O	O	B-Entity
sexuality	O	O	B-Entity
,	O	O	O
b	O	O	O
)	O	O	O
sexuality	O	O	O
as	O	O	O
a	O	O	O
duty	O	O	B-Entity
and	O	O	O
c	O	O	O
)	O	O	O
respecting	O	O	O
vows	O	O	B-Entity
.	O	O	O

Female	O	O	B-Entity
residents	O	O	B-Entity
reported	O	O	O
key	O	O	O
elements	O	O	O
influencing	O	O	O
how	O	O	O
they	O	O	O
manage	O	O	B-Entity
their	O	O	O
sexuality	O	O	B-Entity
in	O	O	O
Nursing	O	O	B-Entity
Homes	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
serve	O	O	O
to	O	O	O
improve	O	O	O
our	O	O	O
understanding	O	O	O
regarding	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
sexuality	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
female	O	O	I-Entity
nursing	O	O	B-Entity
home	O	O	I-Entity
residents	O	O	B-Entity
.	O	O	O

-DOCSTART- (27474557)

Xylan-based	O	O	B-Entity
temperature	O	O	B-Entity
/	O	O	O
pH	O	O	B-Entity
sensitive	O	O	B-Entity
hydrogels	O	O	B-Entity
for	O	O	O
drug	O	O	O
controlled	O	O	O
release	O	O	O

Xylan-based	O	O	B-Entity
temperature	O	O	B-Entity
/	O	O	O
pH	O	O	B-Entity
sensitive	O	O	B-Entity
hydrogels	O	O	B-Entity
were	O	O	O
prepared	O	O	O
by	O	O	O
the	O	O	O
crosslinking	O	O	B-Entity
copolymerization	O	O	I-Entity
of	O	O	O
xylan	O	O	B-Entity
with	O	O	O
N-isopropylacrylamide	O	O	B-Entity
(	O	O	O
NIPAm	O	O	B-Entity
)	O	O	O
and	O	O	O
acrylic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
AA	O	O	B-Entity
)	O	O	O
using	O	O	O
N	O	O	B-Entity
,	O	O	I-Entity
Ń-methylenebis-acrylamide	O	O	I-Entity
(	O	O	O
MBA	O	O	B-Entity
)	O	O	O
as	O	O	O
a	O	O	O
cross-linker	O	O	B-Entity
and	O	O	O
2,2-dimethoxy-2-phenylacetophenone	O	O	B-Entity
as	O	O	O
a	O	O	O
photoinitiator	O	O	B-Entity
via	O	O	O
ultraviolet	O	O	B-Entity
irradiation	O	O	I-Entity
.	O	O	O

The	O	O	O
influence	O	O	B-Entity
of	O	O	O
the	O	O	O
NIPAm	O	O	B-Entity
,	O	O	O
AA	O	O	B-Entity
and	O	O	O
MBA	O	O	B-Entity
amount	O	O	O
on	O	O	O
properties	O	O	O
of	O	O	O
xylan-based	O	O	B-Entity
hydrogels	O	O	B-Entity
was	O	O	O
discussed	O	O	O
.	O	O	O

The	O	O	O
morphology	O	O	B-Entity
and	O	O	O
interactions	O	O	B-Entity
of	O	O	O
hydrogels	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
SEM	O	O	B-Entity
and	O	O	O
FTIR	O	O	B-Entity
.	O	O	O

The	O	O	O
lower	O	O	B-Entity
critical	O	O	I-Entity
solution	O	O	I-Entity
temperature	O	O	I-Entity
(	O	O	O
LCST	O	O	B-Entity
)	O	O	O
of	O	O	O
hydrogels	O	O	B-Entity
was	O	O	O
investigated	O	O	B-Entity
by	O	O	O
DSC	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
LCST	O	O	B-Entity
of	O	O	O
hydrogels	O	O	B-Entity
emerged	O	O	O
at	O	O	O
around	O	O	O
34	O	O	O
°	O	O	O
C	O	O	O
and	O	O	O
increased	O	O	O
with	O	O	O
increasing	O	O	O
the	O	O	O
AA	O	O	B-Entity
content	O	O	O
.	O	O	O

The	O	O	O
drug	O	O	B-Entity
encapsulation	O	O	B-Entity
efficiency	O	O	B-Entity
of	O	O	O
as-prepared	O	O	O
hydrogels	O	O	B-Entity
reached	O	O	O
to	O	O	O
97.60	O	O	O
%	O	O	O
and	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
release	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
acetylsalicylic	O	O	B-Entity
acid	O	O	I-Entity
was	O	O	O
90.12	O	O	O
%	O	O	O
and	O	O	O
26.35	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
and	O	O	O
gastric	O	O	B-Entity
fluid	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Xylan-based	O	O	B-Entity
hydrogels	O	O	B-Entity
were	O	O	O
proved	O	O	O
to	O	O	O
be	O	O	O
biocompatible	O	O	B-Entity
with	O	O	O
NIH3T3	O	O	B-Entity
cell	O	O	I-Entity
by	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
showed	O	O	O
the	O	O	O
promising	O	O	O
application	O	O	O
as	O	O	O
drug	O	O	B-Entity
carriers	O	O	I-Entity
for	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
-	O	O	O
targeted	O	O	B-Entity
oral	O	O	B-Entity
drug	O	O	I-Entity
delivery	O	O	I-Entity
.	O	O	O

-DOCSTART- (27474570)

Isolation	O	O	B-Entity
and	O	O	O
prebiotic	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
water-soluble	O	O	B-Entity
polysaccharides	O	O	B-Entity
fractions	O	O	B-Entity
from	O	O	O
the	O	O	O
bamboo	O	O	B-Entity
shoots	O	O	I-Entity
(	O	O	O
Phyllostachys	O	O	B-Entity
praecox	O	O	I-Entity
)	O	O	O

The	O	O	O
water-soluble	O	O	B-Entity
polysaccharides	O	O	B-Entity
from	O	O	O
bamboo	O	O	B-Entity
shoots	O	O	I-Entity
(	O	O	O
Phyllostachys	O	O	B-Entity
praecox	O	O	I-Entity
)	O	O	O
(	O	O	O
WBP	O	O	B-Entity
)	O	O	O
were	O	O	O
isolated	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
characterizations	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
prebiotic	O	O	B-Entity
activities	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
.	O	O	O

The	O	O	O
yield	O	O	B-Entity
of	O	O	O
WBP	O	O	B-Entity
was	O	O	O
7.58±0.31	O	O	O
%	O	O	O
under	O	O	O
optimal	O	O	O
hot-water	O	O	B-Entity
extraction	O	O	B-Entity
conditions	O	O	O
.	O	O	O

Two	O	O	O
fractions	O	O	B-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
WBP-1	O	O	B-Entity
and	O	O	O
WBP-2	O	O	B-Entity
with	O	O	O
molecular	O	O	B-Entity
weight	O	O	I-Entity
of	O	O	O
83.50kDa	O	O	O
and	O	O	O
80.08kDa	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
were	O	O	O
purified	O	O	O
by	O	O	O
chromatography	O	O	B-Entity
.	O	O	O

Both	O	O	O
the	O	O	O
polysaccharides	O	O	B-Entity
fractions	O	O	B-Entity
were	O	O	O
identified	O	O	O
as	O	O	O
heteropolysaccharides-protein	O	O	B-Entity
complexes	O	O	I-Entity
composed	O	O	O
of	O	O	O
15	O	O	O
kinds	O	O	O
of	O	O	O
common	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
in	O	O	O
protein	O	O	B-Entity
part	O	O	O
and	O	O	O
rhamnose	O	O	B-Entity
,	O	O	O
arabinose	O	O	B-Entity
,	O	O	O
xylose	O	O	B-Entity
,	O	O	O
mannose	O	O	B-Entity
,	O	O	O
glucose	O	O	B-Entity
and	O	O	O
galactose	O	O	B-Entity
in	O	O	O
different	O	O	O
molar	O	O	B-Entity
ratios	O	O	I-Entity
in	O	O	O
polysaccharide	O	O	B-Entity
part	O	O	O
.	O	O	O

The	O	O	O
existence	O	O	O
of	O	O	O
α-	O	O	B-Entity
and	O	O	O
β-glycosidic	O	O	B-Entity
linkages	O	O	I-Entity
between	O	O	O
the	O	O	O
sugar	O	O	B-Entity
units	O	O	O
was	O	O	O
confirmed	O	O	O
by	O	O	O
FTIR	O	O	B-Entity
and	O	O	O
NMR	O	O	B-Entity
spectra	O	O	I-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
the	O	O	O
blank	O	O	O
control	O	O	O
and	O	O	O
the	O	O	O
reference	O	O	O
of	O	O	O
FOS	O	O	O
,	O	O	O
WBP-1	O	O	B-Entity
and	O	O	O
WBP-2	O	O	B-Entity
significantly	O	O	O
increased	O	O	O
the	O	O	O
numbers	O	O	O
of	O	O	O
Bifidobacterium	O	O	B-Entity
adolescentis	O	O	I-Entity
and	O	O	O
Bifidobacterium	O	O	B-Entity
bifidum	O	O	I-Entity
(	O	O	O
P<0.05	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
contributed	O	O	O
to	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
organic	O	O	B-Entity
acids	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
polysaccharides	O	O	B-Entity
have	O	O	O
potential	O	O	B-Entity
prebiotic	O	O	B-Entity
properties	O	O	B-Entity
.	O	O	O

-DOCSTART- (27478234)

Evaluation	O	O	O
of	O	O	O
nutraceutical	O	O	B-Entity
and	O	O	O
antinutritional	O	O	B-Entity
properties	O	O	I-Entity
in	O	O	O
barnyard	O	O	B-Entity
and	O	O	O
finger	O	O	B-Entity
millet	O	O	I-Entity
varieties	O	O	B-Entity
grown	O	O	O
in	O	O	O
Himalayan	O	O	O
region	O	O	O

Five	O	O	O
elite	O	O	O
varieties	O	O	B-Entity
of	O	O	O
barnyard	O	O	B-Entity
(	O	O	O
Echinochloa	O	O	B-Entity
frumentacea	O	O	I-Entity
)	O	O	O
and	O	O	O
finger	O	O	B-Entity
(	O	O	O
Eleusine	O	O	B-Entity
coracana	O	O	I-Entity
)	O	O	O
growing	O	O	O
at	O	O	O
northwestern	O	O	B-Entity
Himalaya	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
for	O	O	O
nutraceutical	O	O	B-Entity
and	O	O	O
antinutritional	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Barnyard	O	O	B-Entity
millet	O	O	I-Entity
contained	O	O	O
higher	O	O	O
amount	O	O	B-Entity
of	O	O	O
crude	O	O	B-Entity
fiber	O	O	I-Entity
,	O	O	O
total	O	O	B-Entity
dietary	O	O	I-Entity
fiber	O	O	I-Entity
,	O	O	O
tryptophan	O	O	B-Entity
content	O	O	B-Entity
,	O	O	O
total	O	O	B-Entity
carotenoids	O	O	I-Entity
,	O	O	O
α-tocopherol	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
finger	O	O	B-Entity
millet	O	O	I-Entity
whereas	O	O	O
the	O	O	O
finger	O	O	O
millet	O	O	O
contains	O	O	O
higher	O	O	O
amount	O	O	O
of	O	O	O
methionine	O	O	B-Entity
and	O	O	O
ascorbic	O	O	B-Entity
acid	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
barnyard	O	O	B-Entity
millet	O	O	I-Entity
.	O	O	O

The	O	O	O
secondary	O	O	B-Entity
metabolites	O	O	I-Entity
of	O	O	O
biological	O	O	B-Entity
functions	O	O	I-Entity
were	O	O	O
analyzed	O	O	O
and	O	O	O
found	O	O	O
that	O	O	O
barnyard	O	O	B-Entity
millet	O	O	I-Entity
contained	O	O	O
the	O	O	O
higher	O	O	O
amount	O	O	B-Entity
of	O	O	O
polyphenols	O	O	B-Entity
,	O	O	O
tannins	O	O	B-Entity
and	O	O	O
ortho-dihydroxy	O	O	B-Entity
phenol	O	O	I-Entity
content	O	O	B-Entity
compared	O	O	O
to	O	O	O
finger	O	O	B-Entity
millet	O	O	I-Entity
.	O	O	O

Among	O	O	O
antinutitional	O	O	B-Entity
compounds	O	O	I-Entity
barnyard	O	O	B-Entity
millet	O	O	I-Entity
contained	O	O	O
lower	O	O	O
phytic	O	O	B-Entity
acid	O	O	I-Entity
content	O	O	B-Entity
compare	O	O	O
to	O	O	O
finger	O	O	B-Entity
millet	O	O	I-Entity
whereas	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
in	O	O	O
trypsin	O	O	B-Entity
inhibition	O	O	I-Entity
activity	O	O	I-Entity
of	O	O	O
barnyard	O	O	O
millet	O	O	O
and	O	O	O
finger	O	O	O
millet	O	O	O
varieties	O	O	B-Entity
were	O	O	O
found	O	O	O
.	O	O	O

Barnyard	O	O	B-Entity
millet	O	O	I-Entity
contained	O	O	O
higher	O	O	O
acid	O	O	B-Entity
phosphatase	O	O	I-Entity
,	O	O	O
α-galactosidase	O	O	B-Entity
and	O	O	O
α-amylase	O	O	B-Entity
inhibitor	O	O	I-Entity
activity	O	O	I-Entity
compared	O	O	O
to	O	O	O
finger	O	O	B-Entity
millet	O	O	I-Entity
.	O	O	O

Finger	O	O	B-Entity
millet	O	O	I-Entity
seeds	O	O	I-Entity
contained	O	O	O
about	O	O	O
10	O	O	O
-	O	O	O
13	O	O	O
folds	O	O	O
higher	O	O	O
calcium	O	O	B-Entity
content	O	O	B-Entity
and	O	O	O
double	O	O	O
amount	O	O	B-Entity
of	O	O	O
manganese	O	O	B-Entity
content	O	O	O
in	O	O	O
comparison	O	O	O
to	O	O	O
barnyard	O	O	B-Entity
millet	O	O	I-Entity
seeds	O	O	I-Entity
.	O	O	O

Present	O	O	O
study	O	O	O
suggests	O	O	O
that	O	O	O
barnyard	O	O	B-Entity
millet	O	O	I-Entity
varieties	O	O	B-Entity
studied	O	O	O
under	O	O	O
present	O	O	O
investigation	O	O	O
were	O	O	O
found	O	O	O
nutritionally	O	O	O
superior	O	O	O
compared	O	O	O
to	O	O	O
finger	O	O	B-Entity
millet	O	O	I-Entity
varieties	O	O	O
.	O	O	O

-DOCSTART- (27481922)

Polymorphisms	O	O	B-Entity
in	O	O	O
Inflammatory	O	O	B-Entity
Mediator	O	O	B-Entity
Genes	O	O	I-Entity
and	O	O	O
Risk	O	O	B-Entity
of	O	O	O
Preeclampsia	O	O	B-Entity
in	O	O	O
Taiyuan	O	O	B-Entity
,	O	O	O
China	O	O	O

Excessive	O	O	B-Entity
maternal	O	O	B-Entity
inflammatory	O	O	B-Entity
response	O	O	I-Entity
is	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
preeclampsia	O	O	B-Entity
.	O	O	O

Few	O	O	O
epidemiologic	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
investigated	O	O	B-Entity
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
genetic	O	O	B-Entity
variations	O	O	I-Entity
in	O	O	O
the	O	O	O
inflammatory	O	O	B-Entity
mediator	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
preeclampsia	O	O	B-Entity
risk	O	O	B-Entity
,	O	O	O
and	O	O	O
these	O	O	O
studies	O	O	O
have	O	O	O
reached	O	O	O
inconsistent	O	O	O
results	O	O	O
.	O	O	O

We	O	O	O
examined	O	O	O
31	O	O	O
single-nucleotide	O	O	B-Entity
polymorphisms	O	O	I-Entity
in	O	O	O
IL-1A	O	O	B-Entity
,	O	O	O
IL-1B	O	O	B-Entity
,	O	O	O
IL-1R1	O	O	B-Entity
,	O	O	O
IL-2RA	O	O	B-Entity
,	O	O	O
IL-5RA	O	O	B-Entity
,	O	O	O
IL-6	O	O	B-Entity
,	O	O	O
IL-6R	O	O	B-Entity
,	O	O	O
TNFSF11	O	O	B-Entity
,	O	O	O
TNFRSF11A	O	O	B-Entity
,	O	O	O
IL-28RA	O	O	B-Entity
,	O	O	O
IRAK4	O	O	B-Entity
,	O	O	O
and	O	O	O
KIT	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
preeclampsia	O	O	B-Entity
and	O	O	O
its	O	O	O
clinical	O	O	B-Entity
subtypes	O	O	B-Entity
in	O	O	O
a	O	O	O
nested	O	O	B-Entity
case-control	O	O	I-Entity
study	O	O	I-Entity
including	O	O	O
203	O	O	O
preeclampsia	O	O	O
cases	O	O	B-Entity
and	O	O	O
233	O	O	O
controls	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
IL-1R1	O	O	B-Entity
,	O	O	O
IL-5RA	O	O	B-Entity
,	O	O	O
IL-6R	O	O	B-Entity
,	O	O	O
and	O	O	O
TNFSF11	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
preeclampsia	O	O	B-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
significant	O	O	B-Entity
associations	O	O	B-Entity
observed	O	O	O
for	O	O	O
preeclampsia	O	O	B-Entity
overall	O	O	B-Entity
were	O	O	O
mainly	O	O	O
seen	O	O	O
for	O	O	O
late-onset	O	O	B-Entity
preeclampsia	O	O	O
and	O	O	O
severe	O	O	B-Entity
preeclampsia	O	O	O
,	O	O	O
IL-6R	O	O	B-Entity
(	O	O	O
rs2229238	O	O	B-Entity
)	O	O	O
and	O	O	O
TNFSF11	O	O	B-Entity
(	O	O	O
rs9525643	O	O	B-Entity
)	O	O	O
polymorphisms	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
early-onset	O	O	O
preeclampsia	O	O	O
.	O	O	O

TNFSF11	O	O	B-Entity
(	O	O	O
rs2200287	O	O	B-Entity
and	O	O	O
rs2148072	O	O	B-Entity
)	O	O	O
polymorphisms	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
risk	O	O	B-Entity
of	O	O	O
mild	O	O	O
preeclampsia	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
provided	O	O	O
the	O	O	O
first	O	O	O
evidence	O	O	B-Entity
that	O	O	O
genetic	O	O	B-Entity
variations	O	O	I-Entity
in	O	O	O
inflammatory	O	O	B-Entity
mediator	O	O	B-Entity
genes	O	O	I-Entity
IL-1R1	O	O	B-Entity
,	O	O	O
IL-6R	O	O	B-Entity
,	O	O	O
TNFSF11	O	O	B-Entity
,	O	O	O
and	O	O	O
IL-5RA	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
preeclampsia	O	O	B-Entity
risk	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
risk	O	O	O
varied	O	O	O
by	O	O	O
preeclampsia	O	O	O
subtypes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27484091)

A	O	O	O
closer	O	O	O
look	O	O	O
at	O	O	O
school	O	O	B-Entity
bonding	O	O	B-Entity
among	O	O	O
African	O	O	B-Entity
American	O	O	I-Entity
adolescents	O	O	B-Entity
in	O	O	O
low-income	O	O	B-Entity
communities	O	O	I-Entity
:	O	O	O
A	O	O	O
latent	O	O	O
class	O	O	O
analysis	O	O	O

Positive	O	O	B-Entity
school	O	O	B-Entity
bonding	O	O	B-Entity
is	O	O	O
a	O	O	O
significant	O	O	B-Entity
precursor	O	O	B-Entity
to	O	O	O
students	O	O	B-Entity
'	O	O	O
school	O	O	O
success	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
African	O	O	B-Entity
American	O	O	I-Entity
youth	O	O	B-Entity
report	O	O	O
lower	O	O	B-Entity
school	O	O	B-Entity
success	O	O	B-Entity
compared	O	O	O
with	O	O	O
their	O	O	O
White	O	O	B-Entity
counterparts	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
examined	O	O	O
correlates	O	O	B-Entity
of	O	O	O
school	O	O	B-Entity
bonding	O	O	B-Entity
among	O	O	O
633	O	O	O
African	O	O	B-Entity
American	O	O	I-Entity
youth	O	O	B-Entity
who	O	O	O
were	O	O	O
recruited	O	O	B-Entity
from	O	O	O
community	O	O	B-Entity
settings	O	O	I-Entity
in	O	O	O
Chicago	O	O	B-Entity
.	O	O	O

Major	O	O	B-Entity
findings	O	O	B-Entity
indicated	O	O	O
that	O	O	O
negative	O	O	B-Entity
peer	O	O	I-Entity
norms	O	O	I-Entity
,	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
community	O	O	B-Entity
violence	O	O	I-Entity
,	O	O	O
and	O	O	O
poor	O	O	B-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
were	O	O	O
negatively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
school	O	O	B-Entity
bonding	O	O	B-Entity
,	O	O	O
while	O	O	O
parental	O	O	B-Entity
monitoring	O	O	I-Entity
,	O	O	O
positive	O	O	B-Entity
self-regard	O	O	I-Entity
,	O	O	O
and	O	O	O
future	O	O	B-Entity
orientation	O	O	B-Entity
were	O	O	O
correlated	O	O	O
with	O	O	O
higher	O	O	B-Entity
school	O	O	O
motivation	O	O	B-Entity
.	O	O	O

Students	O	O	B-Entity
classified	O	O	B-Entity
as	O	O	O
having	O	O	O
high	O	O	B-Entity
or	O	O	O
moderate	O	O	B-Entity
school	O	O	B-Entity
bonding	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
live	O	O	B-Entity
with	O	O	O
both	O	O	O
parents	O	O	B-Entity
,	O	O	O
experience	O	O	B-Entity
higher	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
parental	O	O	B-Entity
monitoring	O	O	I-Entity
,	O	O	O
and	O	O	O
exhibit	O	O	B-Entity
positive	O	O	I-Entity
self-regard	O	O	I-Entity
.	O	O	O

Implications	O	O	O
are	O	O	O
discussed	O	O	O
in	O	O	O
view	O	O	O
of	O	O	O
these	O	O	O
findings	O	O	B-Entity
.	O	O	O

-DOCSTART- (27487593)

DEPRESSION	O	O	B-Entity
,	O	O	O
ANXIETY	O	O	B-Entity
,	O	O	O
STRESS	O	O	B-Entity
,	O	O	O
AND	O	O	O
THEIR	O	O	O
ASSOCIATED	O	O	B-Entity
FACTORS	O	O	B-Entity
AMONG	O	O	O
CORPS	O	O	B-Entity
MEMBERS	O	O	I-Entity
SERVING	O	O	O
IN	O	O	O
KEBBI	O	O	O
STATE	O	O	O

Depression	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
stress	O	O	B-Entity
,	O	O	O
are	O	O	O
not	O	O	O
only	O	O	O
health	O	O	B-Entity
problems	O	O	I-Entity
by	O	O	O
themselves	O	O	O
,	O	O	O
but	O	O	O
also	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
other	O	O	O
negative	O	O	B-Entity
health	O	O	O
consequences	O	O	B-Entity
.	O	O	O

The	O	O	O
national	O	O	B-Entity
youth	O	O	I-Entity
service	O	O	I-Entity
is	O	O	O
usually	O	O	O
characterized	O	O	B-Entity
by	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
new	O	O	O
challenges	O	O	O
and	O	O	O
experiences	O	O	B-Entity
which	O	O	O
may	O	O	O
require	O	O	O
life	O	O	B-Entity
style	O	O	I-Entity
adjustments	O	O	B-Entity
by	O	O	O
the	O	O	O
corps	O	O	B-Entity
member	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
previous	O	O	O
study	O	O	O
on	O	O	O
psychological	O	O	B-Entity
factors	O	O	I-Entity
has	O	O	O
been	O	O	O
conducted	O	O	O
among	O	O	O
corps	O	O	B-Entity
members	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
,	O	O	O
stress	O	O	B-Entity
and	O	O	O
their	O	O	O
associated	O	O	B-Entity
factors	O	O	B-Entity
among	O	O	O
corps	O	O	B-Entity
members	O	O	I-Entity
serving	O	O	O
in	O	O	O
Kebbi	O	O	B-Entity
state	O	O	I-Entity
.	O	O	O

A	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
among	O	O	O
264	O	O	O
corps	O	O	B-Entity
members	O	O	I-Entity
from	O	O	O
four	O	O	O
local	O	O	B-Entity
government	O	O	I-Entity
areas	O	O	I-Entity
of	O	O	O
the	O	O	O
state	O	O	B-Entity
.	O	O	O

Selection	O	O	O
of	O	O	O
the	O	O	O
local	O	O	B-Entity
government	O	O	I-Entity
areas	O	O	I-Entity
and	O	O	O
the	O	O	O
individual	O	O	O
participants	O	O	B-Entity
was	O	O	O
by	O	O	O
simple	O	O	B-Entity
random	O	O	I-Entity
sampling	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
was	O	O	O
collected	O	O	O
from	O	O	O
May	O	O	B-Entity
to	O	O	O
June	O	O	B-Entity
2014	O	O	O
using	O	O	O
a	O	O	O
self-administered	O	O	B-Entity
questionnaire	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
analysis	O	O	I-Entity
used	O	O	O
chi-square	O	O	B-Entity
test	O	O	I-Entity
to	O	O	O
identify	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
categorical	O	O	B-Entity
variables	O	O	I-Entity
and	O	O	O
multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
to	O	O	O
identify	O	O	O
the	O	O	O
independent	O	O	O
factors	O	O	B-Entity
for	O	O	O
depression	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
stress	O	O	B-Entity
each	O	O	O
.	O	O	O

The	O	O	O
response	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
97	O	O	O
%	O	O	O
.	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
respondents	O	O	B-Entity
were	O	O	O
males	O	O	B-Entity
(	O	O	O
63.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
single	O	O	B-Entity
(	O	O	O
85.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
above	O	O	O
20	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
(	O	O	O
71.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
overall	O	O	O
prevalences	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
stress	O	O	B-Entity
among	O	O	O
the	O	O	O
respondents	O	O	B-Entity
were	O	O	O
36.4	O	O	O
%	O	O	O
,	O	O	O
54.5	O	O	O
%	O	O	O
and	O	O	O
18.2	O	O	O
%	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
independent	O	O	O
factors	O	O	B-Entity
for	O	O	O
depression	O	O	B-Entity
were	O	O	O
;	O	O	O
being	O	O	O
from	O	O	O
the	O	O	O
North	O	O	B-Entity
central	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
5.99	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
2.194	O	O	O
-	O	O	O
16.354	O	O	O
)	O	O	O
or	O	O	O
South-south	O	O	B-Entity
;	O	O	O
and	O	O	O
the	O	O	O
perception	O	O	B-Entity
of	O	O	O
earning	O	O	B-Entity
enough	O	O	O
income	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
2.987	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.062	O	O	O
-	O	O	O
8.400	O	O	O
)	O	O	O
.	O	O	O

For	O	O	O
anxiety	O	O	B-Entity
,	O	O	O
male	O	O	B-Entity
gender	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
0.411	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.169	O	O	O
-	O	O	O
0.999	O	O	O
)	O	O	O
;	O	O	O
and	O	O	O
being	O	O	O
from	O	O	O
the	O	O	O
North	O	O	B-Entity
central	O	O	I-Entity
were	O	O	O
significant	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
3.731	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.450	O	O	O
-	O	O	O
9.599	O	O	O
)	O	O	O
.	O	O	O

Being	O	O	O
above	O	O	O
26	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
was	O	O	O
an	O	O	O
independent	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
stress	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
0.083	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.018	O	O	O
-	O	O	O
0.381	O	O	O
)	O	O	O
.	O	O	O

Also	O	O	O
,	O	O	O
those	O	O	O
who	O	O	O
had	O	O	O
ever	O	O	O
schooled	O	O	B-Entity
outside	O	O	O
their	O	O	O
towns	O	O	B-Entity
of	O	O	O
residence	O	O	B-Entity
were	O	O	O
less	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
stressed	O	O	B-Entity
compared	O	O	O
to	O	O	O
those	O	O	O
who	O	O	O
had	O	O	O
never	O	O	O
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
0.30	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.110	O	O	O
-	O	O	O
0.855	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
other	O	O	O
factors	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
any	O	O	O
significant	O	O	B-Entity
association	O	O	I-Entity
with	O	O	O
any	O	O	O
of	O	O	O
the	O	O	O
outcome	O	O	B-Entity
variables	O	O	I-Entity
in	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
the	O	O	O
prevalences	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
stress	O	O	B-Entity
are	O	O	O
high	O	O	B-Entity
among	O	O	O
corps	O	O	B-Entity
members	O	O	I-Entity
serving	O	O	O
in	O	O	O
Kebbi	O	O	B-Entity
state	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
need	O	O	O
to	O	O	O
expand	O	O	O
the	O	O	O
scope	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
to	O	O	O
a	O	O	O
national	O	O	B-Entity
level	O	O	I-Entity
so	O	O	O
as	O	O	O
to	O	O	O
get	O	O	O
a	O	O	O
bigger	O	O	O
picture	O	O	O
of	O	O	O
the	O	O	O
problem	O	O	B-Entity
.	O	O	O

-DOCSTART- (27489015)

Trans-oral	O	O	B-Entity
fine	O	O	B-Entity
needle	O	O	I-Entity
aspiration	O	O	I-Entity
cytology	O	O	I-Entity
in	O	O	O
cervical	O	O	B-Entity
(	O	O	I-Entity
C1	O	O	I-Entity
and	O	O	I-Entity
C2	O	O	I-Entity
)	O	O	I-Entity
vertebral	O	O	I-Entity
lesions	O	O	B-Entity
:	O	O	O
a	O	O	O
novel	O	O	O
diagnostic	O	O	O
approach	O	O	O

Fine	O	O	B-Entity
needle	O	O	I-Entity
aspiration	O	O	I-Entity
(	O	O	I-Entity
FNA	O	O	I-Entity
)	O	O	I-Entity
cytology	O	O	I-Entity
is	O	O	O
a	O	O	O
relatively	O	O	O
non-invasive	O	O	B-Entity
method	O	O	O
for	O	O	O
diagnosing	O	O	B-Entity
both	O	O	O
superficial	O	O	B-Entity
and	O	O	O
deep-seated	O	O	B-Entity
neoplastic	O	O	I-Entity
and	O	O	O
non-neoplastic	O	O	B-Entity
lesions	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
evaluated	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
utility	O	O	I-Entity
of	O	O	O
trans-oral	O	O	B-Entity
FNA	O	O	B-Entity
in	O	O	O
cervical	O	O	B-Entity
(	O	O	I-Entity
C1	O	O	I-Entity
and	O	O	I-Entity
C2	O	O	I-Entity
)	O	O	I-Entity
vertebral	O	O	I-Entity
and	O	O	O
paravertebral	O	O	B-Entity
lesions	O	O	B-Entity
.	O	O	O

Eighteen	O	O	O
FNA	O	O	B-Entity
cases	O	O	O
of	O	O	O
cervical	O	O	B-Entity
vertebral	O	O	I-Entity
and	O	O	O
paravertebral	O	O	B-Entity
lesions	O	O	B-Entity
performed	O	O	O
by	O	O	O
a	O	O	O
trans-oral	O	O	B-Entity
route	O	O	I-Entity
without	O	O	O
any	O	O	O
image-guidance	O	O	B-Entity
between	O	O	O
1995	O	O	O
and	O	O	O
2014	O	O	O
were	O	O	O
retrieved	O	O	O
from	O	O	O
the	O	O	O
archives	O	O	O
of	O	O	O
the	O	O	O
cytology	O	O	B-Entity
department	O	O	B-Entity
at	O	O	O
PGIMER	O	O	B-Entity
,	O	O	O
Chandigarh	O	O	B-Entity
and	O	O	O
reviewed	O	O	O
.	O	O	O

Out	O	O	O
of	O	O	O
18	O	O	O
cases	O	O	O
,	O	O	O
a	O	O	O
definite	O	O	O
diagnosis	O	O	B-Entity
was	O	O	O
given	O	O	O
in	O	O	O
15	O	O	O
cases	O	O	O
(	O	O	O
83.3	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
commonest	O	O	O
diagnosis	O	O	B-Entity
seen	O	O	O
was	O	O	O
granulomatous	O	O	B-Entity
inflammation	O	O	I-Entity
consistent	O	O	O
with	O	O	O
tuberculosis	O	O	B-Entity
(	O	O	O
33.3	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Trans-oral	O	O	B-Entity
FNA	O	O	B-Entity
is	O	O	O
a	O	O	O
quick	O	O	O
,	O	O	O
inexpensive	O	O	O
and	O	O	O
relatively	O	O	O
safe	O	O	O
outpatient	O	O	B-Entity
procedure	O	O	I-Entity
for	O	O	O
sampling	O	O	O
C1	O	O	B-Entity
and	O	O	I-Entity
C2	O	O	I-Entity
vertebral	O	O	I-Entity
and	O	O	O
paravertebral	O	O	B-Entity
lesions	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
clinically	O	O	B-Entity
and	O	O	O
radiologically	O	O	B-Entity
difficult	O	O	O
to	O	O	O
approach	O	O	O
.	O	O	O

It	O	O	O
helps	O	O	O
in	O	O	O
the	O	O	O
early	O	O	B-Entity
diagnosis	O	O	I-Entity
and	O	O	O
management	O	O	B-Entity
of	O	O	I-Entity
these	O	O	I-Entity
patients	O	O	I-Entity
.	O	O	O

-DOCSTART- (27491687)

Neonatal	O	O	B-Entity
infections	O	O	I-Entity
:	O	O	O
Case	O	O	B-Entity
definition	O	O	I-Entity
and	O	O	O
guidelines	O	O	B-Entity
for	O	O	O
data	O	O	B-Entity
collection	O	O	I-Entity
,	O	O	O
analysis	O	O	B-Entity
,	O	O	O
and	O	O	O
presentation	O	O	B-Entity
of	O	O	O
immunisation	O	O	B-Entity
safety	O	O	O
data	O	O	O

Maternal	O	O	B-Entity
vaccination	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	O
area	O	O	O
of	O	O	O
research	O	O	B-Entity
and	O	O	O
requires	O	O	O
appropriate	O	O	O
and	O	O	O
internationally	O	O	O
comparable	O	O	O
definitions	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
standards	O	O	I-Entity
.	O	O	O

The	O	O	O
GAIA	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
Brighton	O	O	B-Entity
Collaboration	O	O	I-Entity
was	O	O	O
created	O	O	O
with	O	O	O
the	O	O	O
mandate	O	O	O
of	O	O	O
proposing	O	O	O
standardised	O	O	O
definitions	O	O	B-Entity
applicable	O	O	O
to	O	O	O
maternal	O	O	B-Entity
vaccine	O	O	B-Entity
research	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
proposes	O	O	O
international	O	O	O
definitions	O	O	B-Entity
for	O	O	O
neonatal	O	O	B-Entity
infections	O	O	I-Entity
.	O	O	O

The	O	O	O
neonatal	O	O	B-Entity
infections	O	O	I-Entity
GAIA	O	O	B-Entity
working	O	O	B-Entity
group	O	O	I-Entity
performed	O	O	O
a	O	O	O
literature	O	O	B-Entity
review	O	O	B-Entity
using	O	O	O
Medline	O	O	B-Entity
,	O	O	O
EMBASE	O	O	B-Entity
and	O	O	O
the	O	O	O
Cochrane	O	O	B-Entity
collaboration	O	O	I-Entity
and	O	O	O
collected	O	O	O
definitions	O	O	B-Entity
in	O	O	O
use	O	O	O
in	O	O	O
neonatal	O	O	O
and	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
networks	O	O	I-Entity
.	O	O	O

The	O	O	O
common	O	O	O
criteria	O	O	B-Entity
derived	O	O	B-Entity
from	O	O	O
the	O	O	O
extensive	O	O	O
search	O	O	O
formed	O	O	O
the	O	O	O
basis	O	O	O
for	O	O	O
a	O	O	O
consensus	O	O	B-Entity
process	O	O	I-Entity
that	O	O	O
resulted	O	O	O
in	O	O	O
three	O	O	O
separate	O	O	O
definitions	O	O	B-Entity
for	O	O	O
neonatal	O	O	B-Entity
blood	O	O	B-Entity
stream	O	O	I-Entity
infections	O	O	I-Entity
(	O	O	O
BSI	O	O	B-Entity
)	O	O	O
,	O	O	O
meningitis	O	O	B-Entity
and	O	O	O
lower	O	O	B-Entity
respiratory	O	O	I-Entity
tract	O	O	I-Entity
infections	O	O	I-Entity
(	O	O	O
LRTI	O	O	B-Entity
)	O	O	O
.	O	O	O

For	O	O	O
each	O	O	O
definition	O	O	B-Entity
three	O	O	O
levels	O	O	O
of	O	O	O
evidence	O	O	O
are	O	O	O
proposed	O	O	O
to	O	O	O
ensure	O	O	O
the	O	O	O
applicability	O	O	O
of	O	O	O
the	O	O	O
definitions	O	O	B-Entity
to	O	O	O
different	O	O	O
settings	O	O	O
.	O	O	O

Recommendations	O	O	O
about	O	O	O
data	O	O	B-Entity
collection	O	O	I-Entity
,	O	O	O
analysis	O	O	B-Entity
and	O	O	O
presentation	O	O	B-Entity
are	O	O	O
presented	O	O	O
and	O	O	O
harmonized	O	O	B-Entity
with	O	O	O
the	O	O	O
Brighton	O	O	B-Entity
Collaboration	O	O	I-Entity
and	O	O	O
GAIA	O	O	B-Entity
format	O	O	B-Entity
and	O	O	O
other	O	O	O
existing	O	O	O
international	O	O	B-Entity
standards	O	O	I-Entity
for	O	O	O
study	O	O	B-Entity
reporting	O	O	B-Entity
.	O	O	O

-DOCSTART- (27491778)

Beneficial	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
dark	O	O	B-Entity
chocolate	O	O	I-Entity
on	O	O	O
exercise	O	O	B-Entity
capacity	O	O	B-Entity
in	O	O	O
sedentary	O	O	B-Entity
subjects	O	O	B-Entity
:	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
.	O	O	O
A	O	O	O
double	O	O	B-Entity
blind	O	O	I-Entity
,	O	O	O
randomized	O	O	B-Entity
,	O	O	O
placebo	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	O

A	O	O	O
double	O	O	B-Entity
blind	O	O	I-Entity
,	O	O	O
randomized	O	O	B-Entity
,	O	O	O
placebo	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	B-Entity
In	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
patients	O	O	B-Entity
the	O	O	O
consumption	O	O	B-Entity
of	O	O	O
(-)-epicatechin	O	O	B-Entity
(	O	O	O
(-)-Epi)-rich	O	O	O
cocoa	O	O	B-Entity
can	O	O	O
restore	O	O	O
skeletal	O	O	B-Entity
muscle	O	O	I-Entity
(	O	O	O
SkM	O	O	B-Entity
)	O	O	O
mitochondrial	O	O	B-Entity
structure	O	O	B-Entity
and	O	O	O
decrease	O	O	B-Entity
biomarkers	O	O	B-Entity
of	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
nothing	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
its	O	O	O
effects	O	O	B-Entity
on	O	O	O
exercise	O	O	B-Entity
capacity	O	O	B-Entity
and	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
in	O	O	O
normal	O	O	B-Entity
,	O	O	O
sedentary	O	O	B-Entity
subjects	O	O	B-Entity
.	O	O	O

Twenty	O	O	O
normal	O	O	B-Entity
,	O	O	O
sedentary	O	O	B-Entity
subjects	O	O	B-Entity
(	O	O	O
∼50	O	O	O
years	O	O	B-Entity
old	O	O	I-Entity
)	O	O	O
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
placebo	O	O	B-Entity
or	O	O	O
dark	O	O	B-Entity
chocolate	O	O	I-Entity
(	O	O	O
DC	O	O	B-Entity
)	O	O	O
groups	O	O	B-Entity
and	O	O	O
consumed	O	O	B-Entity
20	O	O	O
g	O	O	O
of	O	O	O
the	O	O	O
products	O	O	O
for	O	O	O
3	O	O	O
months	O	O	B-Entity
.	O	O	O

Subjects	O	O	B-Entity
underwent	O	O	O
before	O	O	O
and	O	O	O
after	O	O	O
treatment	O	O	B-Entity
,	O	O	O
bicycle	O	O	B-Entity
ergometry	O	O	I-Entity
to	O	O	O
assess	O	O	B-Entity
VO2	O	O	B-Entity
max	O	O	I-Entity
and	O	O	O
work	O	O	B-Entity
,	O	O	O
SkM	O	O	B-Entity
biopsy	O	O	I-Entity
to	O	O	O
assess	O	O	O
changes	O	O	O
in	O	O	O
mitochondrial	O	O	B-Entity
density	O	O	B-Entity
,	O	O	O
function	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
sampling	O	O	I-Entity
to	O	O	O
assess	O	O	O
metabolic	O	O	B-Entity
endpoints	O	O	B-Entity
.	O	O	O

Seventeen	O	O	O
subjects	O	O	B-Entity
completed	O	O	O
the	O	O	O
trial	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
DC	O	O	B-Entity
group	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
9	O	O	O
)	O	O	O
,	O	O	O
VO2	O	O	B-Entity
max	O	O	I-Entity
increased	O	O	B-Entity
(	O	O	O
17	O	O	O
%	O	O	O
increase	O	O	B-Entity
,	O	O	O
p	O	O	O
=	O	O	O
0.056	O	O	O
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
maximum	O	O	O
work	O	O	B-Entity
(	O	O	O
watts	O	O	B-Entity
)	O	O	O
achieved	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.026	O	O	O
)	O	O	O
with	O	O	O
no	O	O	O
changes	O	O	O
with	O	O	O
placebo	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8)	O	O	O
.	O	O	O

The	O	O	O
DC	O	O	B-Entity
group	O	O	O
evidenced	O	O	O
increases	O	O	B-Entity
in	O	O	O
HDL	O	O	B-Entity
levels	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.005	O	O	O
)	O	O	O
and	O	O	O
decreased	O	O	B-Entity
triglycerides	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.07	O	O	O
)	O	O	O
.	O	O	O

With	O	O	O
DC	O	O	B-Entity
,	O	O	O
SkM	O	O	B-Entity
evidenced	O	O	O
significant	O	O	B-Entity
increases	O	O	B-Entity
in	O	O	O
protein	O	O	B-Entity
levels	O	O	O
for	O	O	O
LKB1	O	O	B-Entity
,	O	O	O
AMPK	O	O	B-Entity
and	O	O	O
PGC1α	O	O	B-Entity
and	O	O	O
in	O	O	O
their	O	O	O
active	O	O	B-Entity
forms	O	O	O
(	O	O	O
phosphorylated	O	O	B-Entity
AMPK	O	O	O
and	O	O	O
LKB1	O	O	O
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
citrate	O	O	B-Entity
synthase	O	O	I-Entity
activity	O	O	I-Entity
while	O	O	O
no	O	O	O
changes	O	O	O
were	O	O	O
observed	O	O	O
in	O	O	O
mitochondrial	O	O	B-Entity
density	O	O	B-Entity
.	O	O	O

With	O	O	O
DC	O	O	B-Entity
,	O	O	O
significant	O	O	B-Entity
increases	O	O	B-Entity
in	O	O	O
SkM	O	O	B-Entity
reduced	O	O	O
glutathione	O	O	B-Entity
levels	O	O	O
and	O	O	O
decreases	O	O	B-Entity
in	O	O	O
protein	O	O	B-Entity
carbonylation	O	O	I-Entity
were	O	O	O
observed	O	O	O
.	O	O	O

Improvements	O	O	O
in	O	O	O
maximum	O	O	O
work	O	O	B-Entity
achieved	O	O	O
and	O	O	O
VO2	O	O	B-Entity
max	O	O	I-Entity
may	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
DC	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
upstream	O	O	O
control	O	O	O
systems	O	O	O
and	O	O	O
enhancement	O	O	O
of	O	O	O
SkM	O	O	B-Entity
mitochondria	O	O	B-Entity
efficiency	O	O	B-Entity
.	O	O	O

Larger	O	O	O
clinical	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
warranted	O	O	O
to	O	O	O
confirm	O	O	O
these	O	O	O
observations	O	O	B-Entity
.	O	O	O

-DOCSTART- (27494020)

Reduction	O	O	B-Entity
in	O	O	O
Hospital-Wide	O	O	B-Entity
Clinical	O	O	B-Entity
Laboratory	O	O	I-Entity
Specimen	O	O	I-Entity
Identification	O	O	I-Entity
Errors	O	O	B-Entity
following	O	O	O
Process	O	O	B-Entity
Interventions	O	O	I-Entity
:	O	O	O
A	O	O	O
10-	O	O	O
Year	O	O	B-Entity
Retrospective	O	O	O
Observational	O	O	O
Study	O	O	O

Accurate	O	O	B-Entity
patient	O	O	B-Entity
identification	O	O	I-Entity
and	O	O	O
specimen	O	O	B-Entity
labeling	O	O	I-Entity
at	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
collection	O	O	O
are	O	O	O
crucial	O	O	B-Entity
steps	O	O	I-Entity
in	O	O	O
the	O	O	O
prevention	O	O	B-Entity
of	O	O	O
medical	O	O	B-Entity
errors	O	O	I-Entity
,	O	O	O
thereby	O	O	O
improving	O	O	B-Entity
patient	O	O	B-Entity
safety	O	O	I-Entity
.	O	O	O

All	O	O	O
patient	O	O	B-Entity
specimen	O	O	I-Entity
identification	O	O	B-Entity
errors	O	O	B-Entity
that	O	O	O
occurred	O	O	B-Entity
in	O	O	O
the	O	O	O
outpatient	O	O	B-Entity
department	O	O	I-Entity
(	O	O	O
OPD	O	O	B-Entity
)	O	O	O
,	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
(	O	O	O
ED	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
inpatient	O	O	B-Entity
department	O	O	I-Entity
(	O	O	O
IPD	O	O	B-Entity
)	O	O	O
of	O	O	O
a	O	O	O
3,800-	O	O	O
bed	O	O	B-Entity
academic	O	O	B-Entity
medical	O	O	I-Entity
center	O	O	I-Entity
in	O	O	O
Taiwan	O	O	B-Entity
were	O	O	O
documented	O	O	B-Entity
and	O	O	O
analyzed	O	O	B-Entity
retrospectively	O	O	O
from	O	O	O
2005	O	O	O
to	O	O	O
2014	O	O	O
.	O	O	O

To	O	O	O
reduce	O	O	B-Entity
such	O	O	O
errors	O	O	B-Entity
,	O	O	O
the	O	O	O
following	O	O	O
series	O	O	B-Entity
of	O	O	O
strategies	O	O	B-Entity
were	O	O	O
implemented	O	O	O
:	O	O	O
a	O	O	O
restrictive	O	O	B-Entity
specimen	O	O	I-Entity
acceptance	O	O	I-Entity
policy	O	O	I-Entity
for	O	O	O
the	O	O	O
ED	O	O	B-Entity
and	O	O	O
IPD	O	O	B-Entity
in	O	O	O
2006	O	O	O
;	O	O	O
a	O	O	O
computer-assisted	O	O	B-Entity
barcode	O	O	B-Entity
positive	O	O	B-Entity
patient	O	O	I-Entity
identification	O	O	I-Entity
system	O	O	I-Entity
for	O	O	O
the	O	O	O
ED	O	O	O
and	O	O	O
IPD	O	O	O
in	O	O	O
2007	O	O	O
and	O	O	O
2010	O	O	O
,	O	O	O
and	O	O	O
automated	O	O	B-Entity
sample	O	O	B-Entity
labeling	O	O	I-Entity
combined	O	O	B-Entity
with	O	O	O
electronic	O	O	B-Entity
identification	O	O	I-Entity
systems	O	O	I-Entity
introduced	O	O	B-Entity
to	O	O	O
the	O	O	O
OPD	O	O	B-Entity
in	O	O	O
2009	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
2000345	O	O	O
specimens	O	O	B-Entity
collected	O	O	B-Entity
in	O	O	O
2005	O	O	O
,	O	O	O
1023	O	O	O
(	O	O	O
0.0511	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
identified	O	O	B-Entity
as	O	O	O
having	O	O	O
patient	O	O	B-Entity
identification	O	O	I-Entity
errors	O	O	B-Entity
,	O	O	O
compared	O	O	O
with	O	O	O
58	O	O	O
errors	O	O	O
(	O	O	O
0.0015	O	O	O
%	O	O	O
)	O	O	O
among	O	O	O
3761238	O	O	O
specimens	O	O	O
collected	O	O	O
in	O	O	O
2014	O	O	O
,	O	O	O
after	O	O	O
serial	O	O	O
interventions	O	O	B-Entity
;	O	O	O
this	O	O	O
represents	O	O	O
a	O	O	O
97	O	O	O
%	O	O	O
relative	O	O	B-Entity
reduction	O	O	B-Entity
.	O	O	O

The	O	O	O
total	O	O	B-Entity
number	O	O	I-Entity
(	O	O	O
rate	O	O	B-Entity
)	O	O	O
of	O	O	O
institutional	O	O	B-Entity
identification	O	O	I-Entity
errors	O	O	B-Entity
contributed	O	O	O
from	O	O	O
the	O	O	O
ED	O	O	B-Entity
,	O	O	O
IPD	O	O	B-Entity
,	O	O	O
and	O	O	O
OPD	O	O	B-Entity
over	O	O	O
a	O	O	O
10-	O	O	O
year	O	O	B-Entity
period	O	O	B-Entity
were	O	O	O
423	O	O	O
(	O	O	O
0.1058	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
556	O	O	O
(	O	O	O
0.0587	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
44	O	O	O
(	O	O	O
0.0067	O	O	O
%	O	O	O
)	O	O	O
errors	O	O	O
before	O	O	B-Entity
the	O	O	O
interventions	O	O	B-Entity
,	O	O	O
and	O	O	O
3	O	O	O
(	O	O	O
0.0007	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
52	O	O	O
(	O	O	O
0.0045	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
3	O	O	O
(	O	O	O
0.0001	O	O	O
%	O	O	O
)	O	O	O
after	O	O	B-Entity
interventions	O	O	O
,	O	O	O
representing	O	O	O
relative	O	O	B-Entity
99	O	O	O
%	O	O	O
,	O	O	O
92	O	O	O
%	O	O	O
and	O	O	O
98	O	O	O
%	O	O	O
reductions	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Accurate	O	O	B-Entity
patient	O	O	B-Entity
identification	O	O	I-Entity
is	O	O	O
a	O	O	O
challenge	O	O	O
of	O	O	O
patient	O	O	B-Entity
safety	O	O	I-Entity
in	O	O	O
different	O	O	O
health	O	O	B-Entity
settings	O	O	B-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
collected	O	O	I-Entity
in	O	O	O
our	O	O	O
study	O	O	B-Entity
indicate	O	O	O
that	O	O	O
a	O	O	O
restrictive	O	O	B-Entity
specimen	O	O	I-Entity
acceptance	O	O	I-Entity
policy	O	O	I-Entity
,	O	O	O
computer-generated	O	O	B-Entity
positive	O	O	B-Entity
identification	O	O	I-Entity
systems	O	O	I-Entity
,	O	O	O
and	O	O	O
interdisciplinary	O	O	O
cooperation	O	O	O
can	O	O	O
significantly	O	O	O
reduce	O	O	B-Entity
patient	O	O	B-Entity
identification	O	O	I-Entity
errors	O	O	B-Entity
.	O	O	O

-DOCSTART- (27494908)

Management	O	O	B-Entity
of	O	O	O
skin	O	O	B-Entity
and	O	O	I-Entity
soft-tissue	O	O	I-Entity
infections	O	O	I-Entity
at	O	O	O
a	O	O	O
community	O	O	O
teaching	O	O	B-Entity
hospital	O	O	I-Entity
using	O	O	O
a	O	O	O
severity-of-illness	O	O	O
tool	O	O	O

Skin	O	O	B-Entity
and	O	O	I-Entity
soft-tissue	O	O	I-Entity
infections	O	O	B-Entity
(	O	O	O
SSTIs	O	O	B-Entity
)	O	O	O
encompass	O	O	O
a	O	O	O
diverse	O	O	B-Entity
range	O	O	B-Entity
of	O	O	O
infections	O	O	O
of	O	O	O
varying	O	O	O
severity	O	O	B-Entity
.	O	O	O

The	O	O	O
Clinical	O	O	B-Entity
Resource	O	O	I-Entity
Efficiency	O	O	I-Entity
Support	O	O	I-Entity
Team	O	O	I-Entity
(	O	O	I-Entity
CREST	O	O	I-Entity
)	O	O	I-Entity
scoring	O	O	I-Entity
system	O	O	I-Entity
stratifies	O	O	B-Entity
patients	O	O	B-Entity
into	O	O	O
four	O	O	O
classes	O	O	B-Entity
(	O	O	O
I	O	O	O
=	O	O	O
least	O	O	O
severe	O	O	B-Entity
to	O	O	O
IV	O	O	O
=	O	O	O
most	O	O	O
severe	O	O	O
)	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
Standardized	O	O	B-Entity
Early	O	O	I-Entity
Warning	O	O	I-Entity
Score	O	O	I-Entity
(	O	O	O
SEWS	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
apply	O	O	O
CREST	O	O	B-Entity
to	O	O	O
hospitalized	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
SSTIs	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
quantify	O	O	O
disease	O	O	B-Entity
severity	O	O	I-Entity
and	O	O	O
evaluate	O	O	B-Entity
appropriateness	O	O	O
of	O	O	O
antibiotic	O	O	B-Entity
management	O	O	O
.	O	O	O

This	O	O	O
was	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
,	O	O	O
hypothesis	O	O	B-Entity
-generating	O	O	O
,	O	O	O
single-centre	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
hospitalized	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
SSTIs	O	O	B-Entity
admitted	O	O	B-Entity
in	O	O	O
2011	O	O	O
.	O	O	O

Based	O	O	O
on	O	O	O
CREST	O	O	B-Entity
classification	O	O	O
,	O	O	O
the	O	O	O
empirical	O	O	B-Entity
antimicrobial	O	O	B-Entity
choices	O	O	O
were	O	O	O
categorized	O	O	B-Entity
as	O	O	O
appropriate	O	O	O
,	O	O	O
over-treatment	O	O	B-Entity
or	O	O	O
under-treatment	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
369	O	O	O
patients	O	O	B-Entity
were	O	O	O
screened	O	O	O
and	O	O	O
200	O	O	O
met	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
patients	O	O	B-Entity
were	O	O	O
classified	O	O	B-Entity
as	O	O	O
either	O	O	O
CREST	O	O	B-Entity
class	O	O	B-Entity
I	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
68	O	O	O
)	O	O	O
or	O	O	O
class	O	O	O
I	O	O	O
I	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
102	O	O	O
)	O	O	O
.	O	O	O

Over-treatment	O	O	B-Entity
was	O	O	O
more	O	O	O
common	O	O	O
in	O	O	O
the	O	O	O
less	O	O	O
severe	O	O	B-Entity
classes	O	O	B-Entity
(	O	O	O
88	O	O	O
%	O	O	O
and	O	O	O
32	O	O	O
%	O	O	O
in	O	O	O
class	O	O	B-Entity
I	O	O	I-Entity
and	O	O	O
class	O	O	B-Entity
II	O	O	I-Entity
,	O	O	O
respectively	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Sixty-three	O	O	O
percent	O	O	B-Entity
of	O	O	O
class	O	O	B-Entity
I	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
43	O	O	O
)	O	O	O
were	O	O	O
over-treated	O	O	B-Entity
due	O	O	O
to	O	O	O
both	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
intravenous	O	O	B-Entity
antibiotic	O	O	B-Entity
s	O	O	O
when	O	O	O
oral	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
sufficient	O	O	O
and	O	O	O
use	O	O	O
of	O	O	O
unnecessarily	O	O	O
broad-spectrum	O	O	B-Entity
antibiotics	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
25	O	O	O
%	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
26	O	O	O
)	O	O	O
of	O	O	O
class	O	O	B-Entity
II	O	O	I-Entity
were	O	O	O
over-treated	O	O	B-Entity
due	O	O	O
to	O	O	O
use	O	O	O
of	O	O	O
unnecessarily	O	O	O
broad-spectrum	O	O	B-Entity
antibiotics	O	O	I-Entity
.	O	O	O

Overall	O	O	O
clinical	O	O	B-Entity
failure	O	O	I-Entity
rates	O	O	O
remained	O	O	O
low	O	O	O
with	O	O	O
only	O	O	O
1	O	O	O
%	O	O	O
,	O	O	O
4	O	O	O
%	O	O	O
and	O	O	O
17	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
unable	O	O	O
to	O	O	O
achieve	O	O	O
initial	O	O	O
response	O	O	B-Entity
in	O	O	O
class	O	O	B-Entity
II	O	O	I-Entity
,	O	O	O
class	O	O	B-Entity
III	O	O	I-Entity
and	O	O	O
class	O	O	B-Entity
IV	O	O	I-Entity
.	O	O	O

Retrospective	O	O	B-Entity
application	O	O	B-Entity
of	O	O	O
CREST	O	O	B-Entity
identified	O	O	O
opportunities	O	O	O
to	O	O	O
improve	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
SSTIs	O	O	B-Entity
.	O	O	O

CREST	O	O	B-Entity
can	O	O	O
be	O	O	O
of	O	O	O
great	O	O	O
value	O	O	O
in	O	O	O
discriminating	O	O	O
less-	O	O	O
severe	O	O	B-Entity
SSTIs	O	O	B-Entity
,	O	O	O
which	O	O	O
can	O	O	O
be	O	O	O
treated	O	O	B-Entity
on	O	O	O
an	O	O	O
outpatient	O	O	B-Entity
basis	O	O	O
.	O	O	O

-DOCSTART- (27495798)

Breakthrough	O	O	B-Entity
viridans	O	O	B-Entity
streptococcal	O	O	I-Entity
bacteremia	O	O	I-Entity
in	O	O	O
allogeneic	O	O	B-Entity
hematopoietic	O	O	I-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
transplant	O	O	I-Entity
recipients	O	O	B-Entity
receiving	O	O	B-Entity
levofloxacin	O	O	B-Entity
prophylaxis	O	O	B-Entity
in	O	O	O
a	O	O	O
Japanese	O	O	B-Entity
hospital	O	O	O

Breakthrough	O	O	B-Entity
viridans	O	O	B-Entity
streptococcal	O	O	I-Entity
bacteremia	O	O	I-Entity
(	O	O	O
VSB	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
hematological	O	O	B-Entity
malignancy	O	O	I-Entity
receiving	O	O	B-Entity
levofloxacin	O	O	B-Entity
prophylaxis	O	O	B-Entity
is	O	O	O
a	O	O	O
major	O	O	B-Entity
blood	O	O	B-Entity
stream	O	O	I-Entity
infection	O	O	I-Entity
(	O	O	O
BSI	O	O	B-Entity
)	O	O	O
occurring	O	O	B-Entity
during	O	O	B-Entity
febrile	O	O	B-Entity
neutropenia	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
clinical	O	O	B-Entity
data	O	O	I-Entity
focused	O	O	B-Entity
on	O	O	O
VSB	O	O	B-Entity
in	O	O	O
allogeneic	O	O	B-Entity
hematopoietic	O	O	I-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
transplant	O	O	I-Entity
(	O	O	O
allo-HSCT	O	O	B-Entity
)	O	O	O
recipients	O	O	B-Entity
are	O	O	O
lacking	O	O	B-Entity
.	O	O	O

The	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
allo-HSCT	O	O	B-Entity
recipients	O	O	B-Entity
who	O	O	O
received	O	O	B-Entity
oral	O	O	B-Entity
levofloxacin	O	O	B-Entity
prophylaxis	O	O	B-Entity
between	O	O	O
January	O	O	O
2011	O	O	O
and	O	O	O
August	O	O	O
2013	O	O	O
at	O	O	O
Toranomon	O	O	B-Entity
Hospital	O	O	I-Entity
were	O	O	O
reviewed	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
breakthrough	O	O	B-Entity
VSB	O	O	B-Entity
.	O	O	O

Stored	O	O	O
viridans	O	O	B-Entity
streptococcal	O	O	I-Entity
(	O	O	O
VGS	O	O	B-Entity
)	O	O	O
species	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
by	O	O	O
using	O	O	B-Entity
sodA	O	O	B-Entity
gene	O	O	I-Entity
sequencing	O	O	B-Entity
,	O	O	O
and	O	O	O
were	O	O	O
assessed	O	O	B-Entity
for	O	O	O
drug	O	O	B-Entity
susceptibility	O	O	I-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
184	O	O	O
allo-HSCT	O	O	B-Entity
recipients	O	O	B-Entity
on	O	O	O
levofloxacin	O	O	B-Entity
prophylaxis	O	O	B-Entity
,	O	O	O
28	O	O	O
(	O	O	O
15.2	O	O	O
%	O	O	O
)	O	O	O
experienced	O	O	O
breakthrough	O	O	B-Entity
VSB	O	O	B-Entity
.	O	O	O

All	O	O	O
of	O	O	O
the	O	O	O
28	O	O	O
recipients	O	O	B-Entity
with	O	O	O
VSB	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
a	O	O	O
cefepime	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
or	O	O	O
piperacillin/tazobactam	O	O	B-Entity
-	O	O	O
based	O	O	O
regimen	O	O	B-Entity
.	O	O	O

The	O	O	O
susceptibility	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
the	O	O	O
VGS	O	O	B-Entity
strains	O	O	B-Entity
for	O	O	O
levofloxacin	O	O	B-Entity
,	O	O	O
cefepime	O	O	B-Entity
,	O	O	O
piperacillin/tazobactam	O	O	B-Entity
,	O	O	O
meropenem	O	O	B-Entity
,	O	O	O
and	O	O	O
vancomycin	O	O	B-Entity
were	O	O	O
0	O	O	O
%	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
,	O	O	O
100	O	O	O
%	O	O	O
,	O	O	O
100	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
100	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Both	O	O	O
the	O	O	O
MIC50	O	O	B-Entity
(	O	O	O
minimum	O	O	B-Entity
inhibitory	O	O	I-Entity
concentration	O	O	I-Entity
)	O	O	O
and	O	O	O
the	O	O	O
MIC90	O	O	B-Entity
of	O	O	O
ceftazidim	O	O	B-Entity
(	O	O	O
0.5	O	O	O
μg/mL	O	O	O
and	O	O	O
2	O	O	O
μg/mL	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
were	O	O	O
higher	O	O	B-Entity
than	O	O	O
the	O	O	O
MIC90	O	O	O
of	O	O	O
all	O	O	O
the	O	O	O
other	O	O	O
anti-pseudomonal	O	O	B-Entity
beta-lactams	O	O	I-Entity
(	O	O	O
APBLs	O	O	B-Entity
)	O	O	O
.	O	O	O

Only	O	O	O
1	O	O	O
VGS	O	O	B-Entity
strain	O	O	B-Entity
had	O	O	O
a	O	O	O
penicillin	O	O	B-Entity
MIC	O	O	B-Entity
≥	O	O	O
2	O	O	O
μg/mL	O	O	O
by	O	O	O
the	O	O	O
Etest	O	O	B-Entity
(	O	O	O
3.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
cases	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
respiratory	O	O	I-Entity
distress	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
ARDS	O	O	B-Entity
)	O	O	O
that	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
VSB	O	O	B-Entity
,	O	O	O
although	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
viridans	O	O	B-Entity
group	O	O	I-Entity
streptococcal	O	O	I-Entity
shock	O	O	I-Entity
syndrome	O	O	I-Entity
was	O	O	O
high	O	O	B-Entity
(	O	O	O
26	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
crude	O	O	O
30-day	O	O	B-Entity
mortality	O	O	B-Entity
rate	O	O	I-Entity
in	O	O	O
the	O	O	O
VSB	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
10.7	O	O	O
%	O	O	O
)	O	O	O
did	O	O	O
not	O	O	B-Entity
differ	O	O	B-Entity
significantly	O	O	B-Entity
from	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
BSI	O	O	B-Entity
without	O	O	B-Entity
VSB	O	O	O
group	O	O	O
(	O	O	O
9.3	O	O	O
%	O	O	O
)	O	O	O
or	O	O	O
non	O	O	B-Entity
-	O	O	O
BSI	O	O	O
group	O	O	O
(	O	O	O
7.0	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.77	O	O	O
)	O	O	O
.	O	O	O

Also	O	O	O
,	O	O	O
VSB	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
all-cause	O	O	O
mortality	O	O	B-Entity
up	O	O	O
to	O	O	O
60	O	O	B-Entity
days	O	O	I-Entity
following	O	O	B-Entity
allo-HSCT	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.43	O	O	O
)	O	O	O
.	O	O	O

APBL	O	O	B-Entity
with	O	O	O
increased	O	O	B-Entity
anti-VGS	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
APBL-VA	O	O	B-Entity
)	O	O	O
monotherapy	O	O	B-Entity
would	O	O	O
typically	O	O	O
be	O	O	O
optimal	O	O	B-Entity
for	O	O	O
treating	O	O	B-Entity
the	O	O	O
VGS	O	O	B-Entity
strains	O	O	B-Entity
in	O	O	O
this	O	O	O
setting	O	O	O
.	O	O	O

Indication	O	O	O
of	O	O	O
adding	O	O	O
an	O	O	O
empiric	O	O	O
anti-gram-positive	O	O	B-Entity
agent	O	O	I-Entity
to	O	O	O
APBL-VA	O	O	B-Entity
for	O	O	O
treating	O	O	B-Entity
VSB	O	O	B-Entity
should	O	O	O
depend	O	O	O
on	O	O	O
local	O	O	B-Entity
factors	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
susceptibility	O	O	B-Entity
results	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
breakthrough	O	O	B-Entity
VSB	O	O	B-Entity
is	O	O	O
probably	O	O	O
not	O	O	B-Entity
a	O	O	O
major	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
in	O	O	O
allo-HSCT	O	O	B-Entity
settings	O	O	O
,	O	O	O
where	O	O	O
beta-lactam	O	O	B-Entity
non-susceptible	O	O	B-Entity
VGS	O	O	I-Entity
and	O	O	O
the	O	O	O
ARDS	O	O	B-Entity
are	O	O	O
rare	O	O	B-Entity
.	O	O	O

-DOCSTART- (27497497)

The	O	O	O
lost	O	O	O
art	O	O	O
of	O	O	O
the	O	O	O
splenorrhaphy	O	O	O

In	O	O	O
the	O	O	O
case	O	O	O
of	O	O	O
the	O	O	O
hemodynamically	O	O	B-Entity
unstable	O	O	I-Entity
child	O	O	B-Entity
,	O	O	O
splenorrhaphy	O	O	B-Entity
is	O	O	O
preferred	O	O	O
to	O	O	O
splenectomy	O	O	B-Entity
to	O	O	O
avert	O	O	O
postsplenectomy	O	O	B-Entity
sepsis	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
successful	O	O	O
splenorrhaphy	O	O	B-Entity
requires	O	O	O
familiarity	O	O	B-Entity
with	O	O	O
the	O	O	O
procedure	O	O	B-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
determine	O	O	O
how	O	O	O
many	O	O	O
splenectomies	O	O	B-Entity
or	O	O	O
splenorrhaphies	O	O	B-Entity
for	O	O	O
trauma	O	O	B-Entity
the	O	O	O
average	O	O	O
pediatric	O	O	B-Entity
surgeon	O	O	I-Entity
can	O	O	O
be	O	O	O
expected	O	O	O
to	O	O	O
perform	O	O	B-Entity
during	O	O	O
their	O	O	O
career	O	O	B-Entity
.	O	O	O

The	O	O	O
Pediatric	O	O	B-Entity
Health	O	O	I-Entity
Information	O	O	I-Entity
System	O	O	I-Entity
(	O	O	I-Entity
PHIS	O	O	I-Entity
)	O	O	I-Entity
Database	O	O	I-Entity
was	O	O	O
queried	O	O	O
for	O	O	O
patients	O	O	B-Entity
≤18	O	O	O
years	O	O	B-Entity
coded	O	O	O
with	O	O	O
an	O	O	O
International	O	O	B-Entity
Classification	O	O	I-Entity
of	O	O	I-Entity
Diseases	O	O	I-Entity
9th	O	O	I-Entity
Edition	O	O	I-Entity
diagnosis	O	O	B-Entity
code	O	O	I-Entity
of	O	O	O
a	O	O	O
splenic	O	O	B-Entity
injury	O	O	I-Entity
from	O	O	O
2004	O	O	O
to	O	O	O
2013	O	O	O
.	O	O	O

Age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
grade	O	O	B-Entity
of	O	O	O
splenic	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
and	O	O	O
operations	O	O	B-Entity
performed	O	O	B-Entity
were	O	O	O
extracted	O	O	B-Entity
.	O	O	O

Numbers	O	O	O
of	O	O	O
pediatric	O	O	B-Entity
surgeons	O	O	I-Entity
per	O	O	O
hospital	O	O	B-Entity
were	O	O	O
obtained	O	O	O
.	O	O	O

9567	O	O	O
children	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

2.1	O	O	O
%	O	O	O
underwent	O	O	O
a	O	O	O
splenectomy	O	O	B-Entity
and	O	O	O
0.8	O	O	O
%	O	O	O
underwent	O	O	O
a	O	O	O
splenorrhaphy	O	O	B-Entity
.	O	O	O

The	O	O	O
average	O	O	O
surgeon	O	O	B-Entity
performed	O	O	B-Entity
0.6	O	O	O
(	O	O	O
SD=0.6	O	O	O
)	O	O	O
splenectomies	O	O	B-Entity
and	O	O	O
0.2	O	O	O
(	O	O	O
SD=0.4	O	O	O
)	O	O	O
splenorrhaphies	O	O	B-Entity
for	O	O	O
trauma	O	O	B-Entity
.	O	O	O

If	O	O	O
these	O	O	O
rates	O	O	B-Entity
remain	O	O	O
constant	O	O	B-Entity
over	O	O	O
time	O	O	O
,	O	O	O
the	O	O	O
average	O	O	O
surgeon	O	O	B-Entity
would	O	O	O
perform	O	O	B-Entity
1.8	O	O	O
(	O	O	O
SD	O	O	O
=	O	O	O
1.7	O	O	O
)	O	O	O
splenectomies	O	O	B-Entity
and	O	O	O
0.6	O	O	O
(	O	O	O
SD	O	O	O
=	O	O	O
1.1	O	O	O
)	O	O	O
splenorrhaphies	O	O	B-Entity
for	O	O	O
trauma	O	O	B-Entity
over	O	O	O
a	O	O	O
30-	O	O	O
year	O	O	B-Entity
surgical	O	O	B-Entity
career	O	O	I-Entity
.	O	O	O

Nonoperative	O	O	B-Entity
management	O	O	I-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
host	O	O	O
of	O	O	O
benefits	O	O	O
,	O	O	O
but	O	O	O
has	O	O	O
resulted	O	O	O
in	O	O	O
a	O	O	O
decrease	O	O	O
in	O	O	O
the	O	O	O
experience	O	O	B-Entity
level	O	O	I-Entity
of	O	O	O
the	O	O	O
pediatric	O	O	B-Entity
surgeons	O	O	I-Entity
expected	O	O	O
to	O	O	O
perform	O	O	B-Entity
an	O	O	O
emergency	O	O	O
splenectomy	O	O	B-Entity
or	O	O	O
splenorrhaphy	O	O	B-Entity
when	O	O	O
the	O	O	O
unusual	O	O	O
occasion	O	O	O
arises	O	O	O
.	O	O	O

-DOCSTART- (27498399)

Vestibular	O	O	B-Entity
-dependent	O	O	O
inter-stimulus	O	O	B-Entity
interval	O	O	I-Entity
effects	O	O	B-Entity
on	O	O	O
sound	O	O	B-Entity
evoked	O	O	I-Entity
potentials	O	O	I-Entity
of	O	O	O
central	O	O	B-Entity
origin	O	O	O

Todd	O	O	O
et	O	O	O
al.	O	O	O
(	O	O	O
2014ab	O	O	O
)	O	O	O
have	O	O	O
recently	O	O	O
demonstrated	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
vestibular	O	O	B-Entity
-dependent	O	O	O
contributions	O	O	B-Entity
to	O	O	O
auditory	O	O	B-Entity
evoked	O	O	I-Entity
potentials	O	O	I-Entity
(	O	O	O
AEPs	O	O	B-Entity
)	O	O	O
when	O	O	O
passing	O	O	O
through	O	O	O
the	O	O	O
vestibular	O	O	O
threshold	O	O	B-Entity
as	O	O	O
determined	O	O	O
by	O	O	O
vestibular	O	O	B-Entity
evoked	O	O	I-Entity
myogenic	O	O	I-Entity
potentials	O	O	I-Entity
(	O	O	O
VEMPs	O	O	B-Entity
)	O	O	O
,	O	O	O
including	O	O	O
a	O	O	O
particular	O	O	O
deflection	O	O	B-Entity
labeled	O	O	B-Entity
as	O	O	O
an	O	O	O
N42/P52	O	O	O
prior	O	O	B-Entity
to	O	O	O
the	O	O	O
long	O	O	B-Entity
-	O	O	O
latency	O	O	B-Entity
AEPs	O	O	O
N1	O	O	O
and	O	O	O
P2	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
we	O	O	O
report	O	O	B-Entity
the	O	O	O
results	O	O	B-Entity
of	O	O	O
an	O	O	O
experiment	O	O	B-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
inter-stimulus	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
ISI	O	O	B-Entity
)	O	O	O
and	O	O	O
regularity	O	O	B-Entity
on	O	O	O
potentials	O	O	B-Entity
recorded	O	O	O
above	O	O	B-Entity
and	O	O	O
below	O	O	B-Entity
VEMP	O	O	B-Entity
threshold	O	O	B-Entity
.	O	O	O

Five	O	O	O
healthy	O	O	B-Entity
,	O	O	O
right-handed	O	O	B-Entity
subjects	O	O	B-Entity
were	O	O	O
recruited	O	O	O
and	O	O	O
evoked	O	O	B-Entity
potentials	O	O	I-Entity
were	O	O	O
recorded	O	O	O
to	O	O	O
binaurally	O	O	O
presented	O	O	O
sound	O	O	B-Entity
stimulation	O	O	I-Entity
,	O	O	O
above	O	O	B-Entity
and	O	O	O
below	O	O	B-Entity
vestibular	O	O	B-Entity
threshold	O	O	B-Entity
,	O	O	O
at	O	O	O
seven	O	O	O
stimulus	O	O	B-Entity
rates	O	O	B-Entity
with	O	O	O
ISIs	O	O	B-Entity
of	O	O	O
212	O	O	O
,	O	O	O
300	O	O	O
,	O	O	O
424	O	O	O
,	O	O	O
600	O	O	O
,	O	O	O
848	O	O	O
,	O	O	O
1200	O	O	O
and	O	O	O
1696	O	O	O
ms	O	O	O
.	O	O	O

The	O	O	O
inner	O	O	O
five	O	O	O
intervals	O	O	B-Entity
,	O	O	O
i.e.	O	O	O
300	O	O	O
,	O	O	O
424	O	O	O
,	O	O	O
600	O	O	O
,	O	O	O
848	O	O	O
,	O	O	O
1200	O	O	O
ms	O	O	O
,	O	O	O
were	O	O	O
presented	O	O	B-Entity
twice	O	O	O
in	O	O	O
both	O	O	O
regular	O	O	B-Entity
and	O	O	O
irregular	O	O	B-Entity
conditions	O	O	O
.	O	O	O

ANOVA	O	O	B-Entity
on	O	O	O
the	O	O	O
global	O	O	B-Entity
field	O	O	I-Entity
power	O	O	I-Entity
(	O	O	O
GFP	O	O	B-Entity
)	O	O	O
were	O	O	O
conducted	O	O	O
for	O	O	O
each	O	O	O
of	O	O	O
four	O	O	O
waves	O	O	O
,	O	O	O
N42	O	O	O
,	O	O	O
P52	O	O	O
,	O	O	O
N1	O	O	O
and	O	O	O
P2	O	O	O
with	O	O	O
factors	O	O	O
of	O	O	O
intensity	O	O	B-Entity
,	O	O	O
ISI	O	O	B-Entity
and	O	O	O
regularity	O	O	B-Entity
.	O	O	O

Both	O	O	O
N42	O	O	O
and	O	O	O
P52	O	O	O
waves	O	O	O
showed	O	O	O
significant	O	O	B-Entity
ANOVA	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
intensity	O	O	B-Entity
but	O	O	O
no	O	O	O
other	O	O	O
main	O	O	O
effects	O	O	O
or	O	O	O
interactions	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
both	O	O	O
N1	O	O	O
and	O	O	O
P2	O	O	O
showed	O	O	O
additional	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
ISI	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
intensity	O	O	B-Entity
,	O	O	O
and	O	O	O
evidence	O	O	B-Entity
of	O	O	I-Entity
non	O	O	B-Entity
-	O	O	O
linear	O	O	B-Entity
interactions	O	O	B-Entity
between	O	O	O
ISI	O	O	O
and	O	O	O
intensity	O	O	O
.	O	O	O

A	O	O	O
source	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
prior	O	O	B-Entity
work	O	O	O
suggesting	O	O	O
that	O	O	O
when	O	O	O
above	O	O	B-Entity
vestibular	O	O	B-Entity
threshold	O	O	B-Entity
,	O	O	O
in	O	O	B-Entity
addition	O	O	I-Entity
to	O	O	I-Entity
bilateral	O	O	B-Entity
superior	O	O	B-Entity
temporal	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
ocular	O	O	B-Entity
,	O	O	O
cerebellar	O	O	B-Entity
and	O	O	O
cingulate	O	O	B-Entity
sources	O	O	B-Entity
are	O	O	O
recruited	O	O	O
.	O	O	O

Further	O	O	O
statistical	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
source	O	O	B-Entity
currents	O	O	B-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
origin	O	O	O
of	O	O	O
the	O	O	O
interactions	O	O	B-Entity
with	O	O	O
intensity	O	O	B-Entity
may	O	O	O
be	O	O	O
the	O	O	O
ISI	O	O	B-Entity
sensitivity	O	O	B-Entity
of	O	O	O
the	O	O	O
vestibular	O	O	B-Entity
-dependent	O	O	O
sources	O	O	B-Entity
.	O	O	O

This	O	O	O
in	O	O	O
turn	O	O	O
may	O	O	O
reflect	O	O	O
a	O	O	O
specific	O	O	B-Entity
vestibular	O	O	B-Entity
preference	O	O	B-Entity
for	O	O	O
stimulus	O	O	B-Entity
rates	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
locomotion	O	O	B-Entity
,	O	O	O
i.e.	O	O	O
rates	O	O	O
close	O	O	O
to	O	O	O
2	O	O	O
Hz	O	O	O
,	O	O	O
or	O	O	O
ISIs	O	O	B-Entity
close	O	O	O
to	O	O	O
500	O	O	O
ms	O	O	O
,	O	O	O
where	O	O	O
saccular	O	O	B-Entity
afferents	O	O	B-Entity
show	O	O	O
increased	O	O	B-Entity
gain	O	O	B-Entity
and	O	O	O
the	O	O	O
corresponding	O	O	O
reflexes	O	O	B-Entity
are	O	O	O
most	O	O	O
sensitive	O	O	B-Entity
.	O	O	O

-DOCSTART- (27500198)

A	O	O	O
Systematic	O	O	B-Entity
Review	O	O	I-Entity
of	O	O	O
the	O	O	O
Diagnostic	O	O	B-Entity
and	O	O	O
Prognostic	O	O	B-Entity
Value	O	O	I-Entity
of	O	O	O
Urinary	O	O	B-Entity
Protein	O	O	B-Entity
Biomarkers	O	O	B-Entity
in	O	O	O
Urothelial	O	O	O
Bladder	O	O	O
Cancer	O	O	O

For	O	O	O
over	O	O	O
80	O	O	O
years	O	O	O
,	O	O	O
cystoscopy	O	O	B-Entity
has	O	O	O
remained	O	O	O
the	O	O	O
gold-standard	O	O	B-Entity
for	O	O	O
detecting	O	O	B-Entity
tumours	O	O	B-Entity
of	O	O	O
the	O	O	O
urinary	O	O	B-Entity
bladder	O	O	I-Entity
.	O	O	O

Since	O	O	O
bladder	O	O	B-Entity
tumours	O	O	I-Entity
have	O	O	O
a	O	O	O
tendency	O	O	O
to	O	O	O
recur	O	O	B-Entity
and	O	O	O
progress	O	O	B-Entity
,	O	O	O
many	O	O	O
patients	O	O	B-Entity
are	O	O	O
subjected	O	O	O
to	O	O	O
repeated	O	O	O
cystoscopies	O	O	B-Entity
during	O	O	O
long-term	O	O	B-Entity
surveillance	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
procedure	O	O	B-Entity
being	O	O	O
both	O	O	O
unpleasant	O	O	O
for	O	O	O
the	O	O	O
patient	O	O	B-Entity
and	O	O	O
expensive	O	O	O
for	O	O	O
healthcare	O	O	B-Entity
providers	O	O	I-Entity
.	O	O	O

The	O	O	O
identification	O	O	B-Entity
and	O	O	O
validation	O	O	B-Entity
of	O	O	O
bladder	O	O	B-Entity
tumour	O	O	B-Entity
specific	O	O	O
molecular	O	O	B-Entity
markers	O	O	I-Entity
in	O	O	O
urine	O	O	B-Entity
could	O	O	O
enable	O	O	O
tumour	O	O	O
detection	O	O	B-Entity
and	O	O	O
reduce	O	O	O
reliance	O	O	B-Entity
on	O	O	O
cystoscopy	O	O	B-Entity
,	O	O	O
and	O	O	O
numerous	O	O	O
classes	O	O	O
of	O	O	O
biomarkers	O	O	B-Entity
have	O	O	O
been	O	O	O
studied	O	O	O
.	O	O	O

Proteins	O	O	B-Entity
represent	O	O	O
the	O	O	O
most	O	O	O
intensively	O	O	O
studied	O	O	B-Entity
class	O	O	I-Entity
of	O	O	I-Entity
biomolecule	O	O	I-Entity
in	O	O	O
this	O	O	O
setting	O	O	O
.	O	O	O

As	O	O	O
an	O	O	O
aid	O	O	O
to	O	O	O
researchers	O	O	B-Entity
searching	O	O	O
for	O	O	O
better	O	O	O
urinary	O	O	B-Entity
biomarkers	O	O	B-Entity
,	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
systematic	O	O	I-Entity
review	O	O	I-Entity
of	O	O	O
the	O	O	O
literature	O	O	B-Entity
and	O	O	O
a	O	O	O
searchable	O	O	O
database	O	O	B-Entity
of	O	O	O
proteins	O	O	B-Entity
that	O	O	O
have	O	O	O
been	O	O	O
investigated	O	O	B-Entity
to	O	O	O
date	O	O	O
.	O	O	O

Our	O	O	O
objective	O	O	O
was	O	O	O
to	O	O	O
classify	O	O	O
these	O	O	O
proteins	O	O	B-Entity
as	O	O	O
:	O	O	O
1	O	O	O
)	O	O	O
those	O	O	O
with	O	O	O
robustly	O	O	O
characterised	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
for	O	O	O
bladder	O	O	B-Entity
cancer	O	O	I-Entity
detection	O	O	B-Entity
;	O	O	O
2	O	O	O
)	O	O	O
those	O	O	O
that	O	O	O
show	O	O	O
potential	O	O	O
but	O	O	O
further	O	O	O
investigation	O	O	B-Entity
is	O	O	O
required	O	O	O
;	O	O	O
3	O	O	O
)	O	O	O
those	O	O	O
unlikely	O	O	O
to	O	O	O
warrant	O	O	O
further	O	O	O
investigation	O	O	O
;	O	O	O
and	O	O	O
4	O	O	O
)	O	O	O
those	O	O	O
investigated	O	O	B-Entity
as	O	O	O
prognostic	O	O	B-Entity
markers	O	O	I-Entity
.	O	O	O

This	O	O	O
work	O	O	O
should	O	O	O
help	O	O	O
to	O	O	O
prioritise	O	O	O
certain	O	O	O
biomarkers	O	O	B-Entity
for	O	O	O
rigorous	O	O	B-Entity
validation	O	O	B-Entity
,	O	O	O
whilst	O	O	O
preventing	O	O	B-Entity
wasted	O	O	O
effort	O	O	O
on	O	O	O
proteins	O	O	B-Entity
that	O	O	O
have	O	O	O
shown	O	O	O
no	O	O	O
association	O	O	O
whatsoever	O	O	O
with	O	O	O
the	O	O	O
disease	O	O	B-Entity
,	O	O	O
or	O	O	O
only	O	O	O
modest	O	O	O
biomarker	O	O	B-Entity
performance	O	O	O
despite	O	O	O
large-scale	O	O	B-Entity
efforts	O	O	I-Entity
at	O	O	O
validation	O	O	O
.	O	O	O

-DOCSTART- (27500262)

Well	O	O	O
,	O	O	O
I	O	O	O
Would	O	O	O
n't	O	O	O
be	O	O	O
Any	O	O	O
Worse	O	O	O
Off	O	O	O
,	O	O	O
Would	O	O	O
I	O	O	O
,	O	O	O
Than	O	O	O
I	O	O	O
am	O	O	O
Now	O	O	O
?	O	O	O
A	O	O	O
Qualitative	O	O	B-Entity
Study	O	O	I-Entity
of	O	O	O
Decision-Making	O	O	B-Entity
,	O	O	O
Hopes	O	O	B-Entity
,	O	O	O
and	O	O	O
Realities	O	O	B-Entity
of	O	O	O
Adults	O	O	B-Entity
With	O	O	O
Type	O	O	B-Entity
1	O	O	I-Entity
Diabetes	O	O	I-Entity
Undergoing	O	O	O
Islet	O	O	O
Cell	O	O	O
Transplantation	O	O	O

For	O	O	O
selected	O	O	O
individuals	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
,	O	O	O
pancreatic	O	O	B-Entity
islet	O	O	I-Entity
transplantation	O	O	I-Entity
(	O	O	O
IT	O	O	B-Entity
)	O	O	O
prevents	O	O	O
recurrent	O	O	O
severe	O	O	O
hypoglycemia	O	O	B-Entity
and	O	O	O
optimizes	O	O	B-Entity
glycemia	O	O	I-Entity
,	O	O	O
although	O	O	O
ongoing	O	O	O
systemic	O	O	B-Entity
immunosuppression	O	O	I-Entity
is	O	O	O
needed	O	O	O
.	O	O	O

Our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
explore	O	O	O
candidates	O	O	B-Entity
and	O	O	O
recipients	O	O	B-Entity
'	O	O	O
expectations	O	O	O
of	O	O	O
transplantation	O	O	B-Entity
,	O	O	O
their	O	O	O
experience	O	O	O
of	O	O	O
being	O	O	O
on	O	O	O
the	O	O	O
waiting	O	O	B-Entity
list	O	O	I-Entity
,	O	O	O
and	O	O	O
(	O	O	O
for	O	O	O
recipients	O	O	O
)	O	O	O
the	O	O	O
procedure	O	O	O
and	O	O	O
life	O	O	O
posttransplant	O	O	B-Entity
.	O	O	O

Cross-sectional	O	O	O
qualitative	O	O	B-Entity
research	O	O	B-Entity
design	O	O	I-Entity
using	O	O	O
semistructured	O	O	O
interviews	O	O	B-Entity
with	O	O	O
16	O	O	O
adults	O	O	B-Entity
(	O	O	O
8	O	O	O
pretransplant	O	O	B-Entity
,	O	O	O
8	O	O	O
posttransplant	O	O	B-Entity
;	O	O	O
from	O	O	O
4	O	O	O
UK	O	O	B-Entity
centers	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
13	O	O	O
)	O	O	O
and	O	O	O
1	O	O	O
Canadian	O	O	B-Entity
center	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
3	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

Interviews	O	O	B-Entity
were	O	O	O
audio-recorded	O	O	B-Entity
,	O	O	O
transcribed	O	O	O
,	O	O	O
and	O	O	O
underwent	O	O	O
inductive	O	O	B-Entity
thematic	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

Interviewees	O	O	B-Entity
were	O	O	O
aged	O	O	O
(	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	O
)	O	O	O
52	O	O	O
±	O	O	O
10	O	O	O
years	O	O	B-Entity
(	O	O	O
range	O	O	O
,	O	O	O
30	O	O	O
-	O	O	O
64	O	O	O
)	O	O	O
;	O	O	O
duration	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
36	O	O	O
±	O	O	O
9	O	O	O
years	O	O	O
(	O	O	O
range	O	O	O
,	O	O	O
21	O	O	O
-	O	O	O
56	O	O	O
)	O	O	O
;	O	O	O
12	O	O	O
(	O	O	O
75	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
women	O	O	B-Entity
.	O	O	O

Narrative	O	O	O
accounts	O	O	O
centered	O	O	O
on	O	O	O
expectations	O	O	B-Entity
,	O	O	O
hopes	O	O	B-Entity
,	O	O	O
and	O	O	O
realities	O	O	B-Entity
;	O	O	O
decision-making	O	O	B-Entity
;	O	O	O
waiting	O	O	O
and	O	O	O
uncertainty	O	O	O
;	O	O	O
the	O	O	O
procedure	O	O	O
,	O	O	O
hospital	O	O	B-Entity
stay	O	O	I-Entity
,	O	O	O
and	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Expected	O	O	O
benefits	O	O	O
included	O	O	O
fewer	O	O	O
severe	O	O	O
hypoglycemic	O	O	B-Entity
episodes	O	O	I-Entity
,	O	O	O
reduced	O	O	B-Entity
need	O	O	O
for	O	O	O
insulin	O	O	B-Entity
,	O	O	O
preventing	O	O	O
onset/progression	O	O	O
of	O	O	O
complications	O	O	B-Entity
and	O	O	O
improved	O	O	O
psychological	O	O	B-Entity
well-being	O	O	I-Entity
.	O	O	O

These	O	O	O
were	O	O	O
realized	O	O	O
for	O	O	O
most	O	O	O
,	O	O	O
at	O	O	O
least	O	O	O
in	O	O	O
the	O	O	O
short	O	O	O
term	O	O	O
.	O	O	O

Most	O	O	O
interviewees	O	O	B-Entity
described	O	O	O
well-informed	O	O	O
,	O	O	O
shared	O	O	O
decision-making	O	O	B-Entity
with	O	O	O
clinicians	O	O	B-Entity
and	O	O	O
family	O	O	B-Entity
,	O	O	O
and	O	O	O
managing	O	O	O
their	O	O	O
expectations	O	O	O
.	O	O	O

Although	O	O	O
life	O	O	O
"	O	O	O
on	O	O	O
the	O	O	O
list	O	O	O
"	O	O	O
could	O	O	O
be	O	O	O
stressful	O	O	B-Entity
,	O	O	O
and	O	O	O
immunosuppressant	O	O	B-Entity
side	O	O	B-Entity
effects	O	O	I-Entity
were	O	O	O
severe	O	O	B-Entity
,	O	O	O
interviewees	O	O	B-Entity
reported	O	O	O
"	O	O	O
no	O	O	B-Entity
regrets	O	O	B-Entity
.	O	O	O
"	O	O	O
Posttransplant	O	O	B-Entity
,	O	O	O
interviewees	O	O	O
experienced	O	O	O
increased	O	O	O
confidence	O	O	B-Entity
,	O	O	O
through	O	O	O
freedom	O	O	B-Entity
from	O	O	I-Entity
hypoglycemia	O	O	I-Entity
and	O	O	O
regained	O	O	O
glycemic	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
which	O	O	O
tempered	O	O	O
any	O	O	O
disappointment	O	O	O
about	O	O	O
continued	O	O	O
reliance	O	O	O
on	O	O	O
insulin	O	O	B-Entity
.	O	O	O

Most	O	O	O
viewed	O	O	O
their	O	O	O
transplant	O	O	B-Entity
as	O	O	O
a	O	O	O
success	O	O	O
,	O	O	O
though	O	O	O
several	O	O	O
reflected	O	O	O
upon	O	O	O
setbacks	O	O	O
and	O	O	O
hidden	O	O	O
hopes	O	O	B-Entity
for	O	O	O
becoming	O	O	O
"	O	O	O
insulin-free	O	O	B-Entity
.	O	O	O
"	O	O	O
Independently	O	O	O
undertaken	O	O	O
interviews	O	O	B-Entity
demonstrated	O	O	O
realistic	O	O	O
and	O	O	O
balanced	O	O	O
expectations	O	O	O
of	O	O	O
IT	O	O	B-Entity
and	O	O	O
indicate	O	O	O
how	O	O	O
to	O	O	O
optimize	O	O	O
the	O	O	O
process	O	O	O
and	O	O	O
support	O	O	O
for	O	O	O
future	O	O	O
IT	O	O	O
candidates	O	O	B-Entity
.	O	O	O

-DOCSTART- (27500809)

The	O	O	O
nanocomposite	O	O	B-Entity
nature	O	O	O
of	O	O	O
bone	O	O	B-Entity
drives	O	O	O
its	O	O	O
strength	O	O	B-Entity
and	O	O	O
damage	O	O	B-Entity
resistance	O	O	O

In	O	O	O
human	O	O	B-Entity
bone	O	O	I-Entity
,	O	O	O
an	O	O	O
amorphous	O	O	B-Entity
mineral	O	O	B-Entity
serves	O	O	O
as	O	O	O
a	O	O	O
precursor	O	O	B-Entity
to	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
a	O	O	O
highly	O	O	O
substituted	O	O	O
nanocrystalline	O	O	B-Entity
apatite	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
precise	O	O	O
role	O	O	O
of	O	O	O
this	O	O	O
amorphous	O	O	B-Entity
mineral	O	O	B-Entity
remains	O	O	O
unknown	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
by	O	O	O
using	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
that	O	O	O
100	O	O	O
-	O	O	O
300	O	O	O
nm	O	O	O
amorphous	O	O	B-Entity
calcium	O	O	B-Entity
phosphate	O	O	I-Entity
regions	O	O	B-Entity
are	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
disordered	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	O
trabecular	O	O	B-Entity
bone	O	O	I-Entity
.	O	O	O

Nanomechanical	O	O	B-Entity
experiments	O	O	I-Entity
on	O	O	O
cylindrical	O	O	B-Entity
samples	O	O	B-Entity
,	O	O	O
with	O	O	O
diameters	O	O	B-Entity
between	O	O	O
250	O	O	O
nm	O	O	O
and	O	O	O
3,000	O	O	O
nm	O	O	O
,	O	O	O
of	O	O	O
the	O	O	O
bone	O	O	B-Entity
's	O	O	I-Entity
ordered	O	O	B-Entity
and	O	O	O
disordered	O	O	B-Entity
phases	O	O	I-Entity
revealed	O	O	O
a	O	O	O
transition	O	O	B-Entity
from	O	O	O
plastic	O	O	B-Entity
deformation	O	O	B-Entity
to	O	O	O
brittle	O	O	B-Entity
failure	O	O	B-Entity
and	O	O	O
at	O	O	O
least	O	O	O
a	O	O	O
factor-of-2	O	O	O
higher	O	O	O
strength	O	O	B-Entity
in	O	O	O
the	O	O	O
smaller	O	O	B-Entity
samples	O	O	O
.	O	O	O

We	O	O	O
postulate	O	O	O
that	O	O	O
this	O	O	O
transition	O	O	B-Entity
in	O	O	O
failure	O	O	B-Entity
mechanism	O	O	B-Entity
is	O	O	O
caused	O	O	O
by	O	O	O
the	O	O	O
suppression	O	O	B-Entity
of	O	O	O
extrafibrillar	O	O	B-Entity
shearing	O	O	B-Entity
in	O	O	O
the	O	O	O
smaller	O	O	B-Entity
samples	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
the	O	O	O
emergent	O	O	O
smaller	O	O	O
-is-	O	O	O
stronger	O	O	B-Entity
size	O	O	B-Entity
effect	O	O	I-Entity
is	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
sample-size	O	O	B-Entity
scaling	O	O	B-Entity
of	O	O	O
the	O	O	O
distribution	O	O	O
of	O	O	O
flaws	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
should	O	O	O
help	O	O	O
in	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
multi-scale	O	O	B-Entity
nature	O	O	I-Entity
of	O	O	O
bone	O	O	B-Entity
and	O	O	O
provide	O	O	O
insights	O	O	O
into	O	O	O
the	O	O	O
biomineralization	O	O	B-Entity
process	O	O	B-Entity
.	O	O	O

-DOCSTART- (27501910)

Assessing	O	O	B-Entity
the	O	O	O
physiological	O	O	B-Entity
relevance	O	O	B-Entity
of	O	O	O
alternate	O	O	O
architectures	O	O	B-Entity
of	O	O	O
the	O	O	O
p7	O	O	B-Entity
protein	O	O	I-Entity
of	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
in	O	O	O
different	O	O	O
environments	O	O	O

The	O	O	O
viroporin	O	O	B-Entity
p7	O	O	B-Entity
of	O	O	O
the	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
forms	O	O	O
multimeric	O	O	B-Entity
channels	O	O	I-Entity
eligible	O	O	O
for	O	O	O
ion	O	O	B-Entity
transport	O	O	I-Entity
across	O	O	O
the	O	O	O
endoplasmic	O	O	B-Entity
reticulum	O	O	I-Entity
membrane	O	O	I-Entity
.	O	O	O

Currently	O	O	O
the	O	O	O
subject	O	O	B-Entity
of	O	O	O
many	O	O	O
studies	O	O	B-Entity
and	O	O	O
discussion	O	O	O
,	O	O	O
the	O	O	O
molecular	O	O	B-Entity
assembly	O	O	I-Entity
of	O	O	O
the	O	O	O
ion	O	O	B-Entity
channel	O	O	I-Entity
and	O	O	O
the	O	O	O
structural	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
the	O	O	O
p7	O	O	B-Entity
monomer	O	O	B-Entity
are	O	O	O
not	O	O	O
yet	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

Structural	O	O	B-Entity
investigation	O	O	B-Entity
of	O	O	O
p7	O	O	B-Entity
has	O	O	O
been	O	O	O
carried	O	O	O
out	O	O	O
only	O	O	O
in	O	O	O
detergent	O	O	B-Entity
environments	O	O	B-Entity
,	O	O	O
making	O	O	O
the	O	O	O
interpretation	O	O	O
of	O	O	O
the	O	O	O
experimental	O	O	O
results	O	O	O
somewhat	O	O	O
questionable	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
analyze	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
molecular	O	O	B-Entity
dynamics	O	O	I-Entity
simulations	O	O	I-Entity
the	O	O	O
structure	O	O	B-Entity
of	O	O	O
the	O	O	O
p7	O	O	B-Entity
monomer	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	O
of	O	O	O
its	O	O	O
sequence	O	O	B-Entity
,	O	O	O
initial	O	O	O
conformation	O	O	B-Entity
and	O	O	O
environment	O	O	B-Entity
.	O	O	O

We	O	O	O
investigate	O	O	O
the	O	O	O
conductance	O	O	B-Entity
properties	O	O	O
of	O	O	O
three	O	O	O
models	O	O	B-Entity
of	O	O	O
a	O	O	O
hexameric	O	O	B-Entity
p7	O	O	B-Entity
ion	O	O	B-Entity
channel	O	O	I-Entity
by	O	O	O
examining	O	O	O
ion	O	O	B-Entity
translocation	O	O	I-Entity
in	O	O	O
a	O	O	O
pure	O	O	O
lipid	O	O	B-Entity
bilayer	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
noteworthy	O	O	O
that	O	O	O
although	O	O	O
none	O	O	O
of	O	O	O
the	O	O	O
models	O	O	B-Entity
reflects	O	O	O
the	O	O	O
experimentally	O	O	O
observed	O	O	O
trend	O	O	O
to	O	O	O
conduct	O	O	O
preferentially	O	O	O
cations	O	O	B-Entity
,	O	O	O
we	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
position	O	O	B-Entity
and	O	O	O
orientation	O	O	B-Entity
of	O	O	O
titratable	O	O	O
acidic	O	O	B-Entity
or	O	O	I-Entity
basic	O	O	I-Entity
residues	O	O	I-Entity
playing	O	O	O
a	O	O	O
crucial	O	O	O
role	O	O	O
in	O	O	O
ion	O	O	B-Entity
selectivity	O	O	B-Entity
and	O	O	O
in	O	O	O
the	O	O	O
overall	O	O	O
conductance	O	O	B-Entity
of	O	O	O
the	O	O	O
channel	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
too	O	O	O
compact	O	O	O
a	O	O	O
packing	O	O	B-Entity
of	O	O	O
the	O	O	O
monomers	O	O	B-Entity
leads	O	O	O
to	O	O	O
channel	O	O	B-Entity
collapse	O	O	B-Entity
rather	O	O	O
than	O	O	O
formation	O	O	O
of	O	O	O
a	O	O	O
reasonable	O	O	O
pore	O	O	B-Entity
,	O	O	O
amenable	O	O	O
to	O	O	O
ion	O	O	B-Entity
translocation	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
findings	O	O	O
are	O	O	O
envisioned	O	O	O
to	O	O	O
help	O	O	O
assess	O	O	O
the	O	O	O
physiological	O	O	B-Entity
relevance	O	O	B-Entity
of	O	O	O
p7	O	O	B-Entity
ion	O	O	B-Entity
channel	O	O	I-Entity
models	O	O	B-Entity
consisting	O	O	O
of	O	O	O
multimeric	O	O	B-Entity
structures	O	O	I-Entity
obtained	O	O	O
in	O	O	O
non-native	O	O	O
environments	O	O	B-Entity
.	O	O	O

-DOCSTART- (27502941)

The	O	O	O
genome	O	O	B-Entity
-scale	O	O	O
DNA-binding	O	O	B-Entity
profile	O	O	B-Entity
of	O	O	O
BarR	O	O	B-Entity
,	O	O	O
a	O	O	O
β-alanine	O	O	B-Entity
responsive	O	O	B-Entity
transcription	O	O	B-Entity
factor	O	O	I-Entity
in	O	O	O
the	O	O	O
archaeon	O	O	B-Entity
Sulfolobus	O	O	O
acidocaldarius	O	O	O

The	O	O	O
Leucine-responsive	O	O	B-Entity
Regulatory	O	O	I-Entity
Protein	O	O	I-Entity
(	O	O	O
Lrp	O	O	B-Entity
)	O	O	O
family	O	O	B-Entity
is	O	O	O
a	O	O	O
widespread	O	O	O
family	O	O	O
of	O	O	O
regulatory	O	O	B-Entity
transcription	O	O	I-Entity
factors	O	O	I-Entity
in	O	O	O
prokaryotes	O	O	B-Entity
.	O	O	O

BarR	O	O	B-Entity
is	O	O	O
an	O	O	O
Lrp	O	O	B-Entity
-like	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
in	O	O	O
the	O	O	O
model	O	O	O
archaeon	O	O	B-Entity
Sulfolobus	O	O	B-Entity
acidocaldarius	O	O	I-Entity
that	O	O	O
activates	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
a	O	O	O
β-alanine	O	O	B-Entity
aminotransferase	O	O	I-Entity
gene	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
involved	O	O	O
in	O	O	O
β-alanine	O	O	B-Entity
degradation	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
to	O	O	O
classical	O	O	O
Lrp	O	O	B-Entity
-like	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
BarR	O	O	B-Entity
is	O	O	O
not	O	O	B-Entity
responsive	O	O	I-Entity
to	O	O	O
any	O	O	O
of	O	O	O
the	O	O	O
α-amino	O	O	B-Entity
acids	O	O	I-Entity
but	O	O	O
interacts	O	O	O
specifically	O	O	O
with	O	O	O
β-alanine	O	O	B-Entity
.	O	O	O

Besides	O	O	O
the	O	O	O
juxtaposed	O	O	O
β-alanine	O	O	B-Entity
aminotransferase	O	O	I-Entity
gene	O	O	I-Entity
,	O	O	O
other	O	O	O
regulatory	O	O	O
targets	O	O	O
of	O	O	O
BarR	O	O	B-Entity
have	O	O	O
not	O	O	O
yet	O	O	O
been	O	O	O
identified	O	O	O
although	O	O	O
β-alanine	O	O	O
is	O	O	O
the	O	O	O
precursor	O	O	B-Entity
of	O	O	O
coenzyme	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
thus	O	O	O
an	O	O	O
important	O	O	O
central	O	O	O
metabolite	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
extend	O	O	O
the	O	O	O
knowledge	O	O	O
of	O	O	O
the	O	O	O
DNA-binding	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
BarR	O	O	B-Entity
and	O	O	O
of	O	O	O
its	O	O	O
corresponding	O	O	O
regulon	O	O	B-Entity
from	O	O	O
a	O	O	O
local	O	O	B-Entity
to	O	O	O
a	O	O	O
genome	O	O	B-Entity
-wide	O	O	O
perspective	O	O	O
.	O	O	O

We	O	O	O
characterized	O	O	O
the	O	O	O
genome-wide	O	O	B-Entity
binding	O	O	I-Entity
profile	O	O	I-Entity
of	O	O	O
BarR	O	O	B-Entity
using	O	O	O
chromatin	O	O	B-Entity
immunoprecipation	O	O	I-Entity
combined	O	O	O
with	O	O	O
high-throughput	O	O	B-Entity
sequencing	O	O	I-Entity
(	O	O	O
ChIP-seq	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
revealed	O	O	O
21	O	O	O
genomic	O	O	B-Entity
binding	O	O	B-Entity
loci	O	O	B-Entity
.	O	O	O

High-enrichment	O	O	O
binding	O	O	B-Entity
regions	O	O	I-Entity
were	O	O	O
validated	O	O	O
to	O	O	O
interact	O	O	O
with	O	O	O
purified	O	O	O
BarR	O	O	B-Entity
protein	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
using	O	O	O
electrophoretic	O	O	B-Entity
mobility	O	O	I-Entity
shift	O	O	I-Entity
assays	O	O	I-Entity
and	O	O	O
almost	O	O	O
all	O	O	O
targets	O	O	O
were	O	O	O
also	O	O	O
shown	O	O	O
to	O	O	O
harbour	O	O	O
a	O	O	O
conserved	O	O	B-Entity
semi-palindromic	O	O	B-Entity
binding	O	O	B-Entity
motif	O	O	I-Entity
.	O	O	O

Only	O	O	O
a	O	O	O
small	O	O	O
subset	O	O	O
of	O	O	O
enriched	O	O	O
genomic	O	O	B-Entity
sites	O	O	I-Entity
are	O	O	O
located	O	O	O
in	O	O	O
intergenic	O	O	B-Entity
regions	O	O	I-Entity
at	O	O	O
a	O	O	O
relative	O	O	O
short	O	O	O
distance	O	O	O
to	O	O	O
a	O	O	O
promoter	O	O	B-Entity
,	O	O	O
and	O	O	O
qRT-PCR	O	O	B-Entity
analysis	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
only	O	O	O
one	O	O	O
additional	O	O	O
operon	O	O	B-Entity
is	O	O	O
under	O	O	O
activation	O	O	B-Entity
of	O	O	O
BarR	O	O	B-Entity
,	O	O	O
namely	O	O	O
the	O	O	O
glutamine	O	O	B-Entity
synthase	O	O	I-Entity
operon	O	O	I-Entity
.	O	O	O

The	O	O	O
latter	O	O	O
is	O	O	O
also	O	O	O
a	O	O	O
target	O	O	O
of	O	O	O
other	O	O	O
Lrp	O	O	B-Entity
-like	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Detailed	O	O	O
inspection	O	O	O
of	O	O	O
the	O	O	O
BarR	O	O	B-Entity
ChIP-seq	O	O	B-Entity
profile	O	O	I-Entity
at	O	O	O
the	O	O	O
β-alanine	O	O	B-Entity
aminotransferase	O	O	I-Entity
promoter	O	O	I-Entity
region	O	O	I-Entity
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
binding	O	O	B-Entity
motif	O	O	I-Entity
predictions	O	O	O
indicate	O	O	O
that	O	O	O
the	O	O	O
operator	O	O	B-Entity
structure	O	O	I-Entity
is	O	O	O
more	O	O	O
complicated	O	O	B-Entity
than	O	O	O
previously	O	O	O
anticipated	O	O	O
,	O	O	O
consisting	O	O	O
of	O	O	O
multiple	O	O	B-Entity
(	O	O	I-Entity
major	O	O	I-Entity
and	O	O	I-Entity
auxiliary	O	O	I-Entity
)	O	O	I-Entity
operators	O	O	I-Entity
.	O	O	O

BarR	O	O	B-Entity
has	O	O	O
a	O	O	O
limited	O	O	B-Entity
regulon	O	O	B-Entity
,	O	O	O
and	O	O	O
includes	O	O	O
also	O	O	O
glutamine	O	O	B-Entity
synthase	O	O	I-Entity
genes	O	O	I-Entity
besides	O	O	O
the	O	O	O
previously	O	O	O
characterized	O	O	O
β-alanine	O	O	B-Entity
aminotransferase	O	O	I-Entity
.	O	O	O

Regulation	O	O	B-Entity
of	O	O	O
glutamine	O	O	B-Entity
synthase	O	O	I-Entity
is	O	O	O
suggestive	O	O	O
of	O	O	O
a	O	O	O
link	O	O	O
between	O	O	O
β-alanine	O	O	B-Entity
and	O	O	O
α-amino	O	O	B-Entity
acid	O	O	I-Entity
metabolism	O	O	I-Entity
in	O	O	O
S.	O	O	B-Entity
acidocaldarius	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
this	O	O	O
work	O	O	O
reveals	O	O	O
that	O	O	O
the	O	O	O
BarR	O	O	B-Entity
regulon	O	O	B-Entity
overlaps	O	O	O
with	O	O	O
that	O	O	O
of	O	O	O
other	O	O	O
Lrp	O	O	B-Entity
-like	O	O	O
regulators	O	O	B-Entity
.	O	O	O

-DOCSTART- (27503472)

GH32	O	O	B-Entity
family	O	O	I-Entity
activity	O	O	B-Entity
:	O	O	O
a	O	O	O
topological	O	O	B-Entity
approach	O	O	O
through	O	O	O
protein	O	O	O
contact	O	O	O
networks	O	O	O

The	O	O	O
application	O	O	O
of	O	O	O
Protein	O	O	B-Entity
Contact	O	O	I-Entity
Networks	O	O	I-Entity
methodology	O	O	I-Entity
allowed	O	O	O
to	O	O	O
highlight	O	O	O
a	O	O	O
novel	O	O	O
response	O	O	O
of	O	O	O
border	O	O	B-Entity
region	O	O	I-Entity
between	O	O	O
the	O	O	O
two	O	O	O
domains	O	O	B-Entity
to	O	O	I-Entity
substrate	O	O	I-Entity
binding	O	O	I-Entity
.	O	O	O

Glycoside	O	O	B-Entity
hydrolases	O	O	I-Entity
(	O	O	O
GH	O	O	B-Entity
)	O	O	O
are	O	O	O
enzymes	O	O	B-Entity
that	O	O	O
mainly	O	O	O
hydrolyze	O	O	B-Entity
the	O	O	O
glycosidic	O	O	B-Entity
bond	O	O	I-Entity
between	O	O	O
two	O	O	O
carbohydrates	O	O	B-Entity
or	O	O	O
a	O	O	O
carbohydrate	O	O	B-Entity
and	O	O	O
a	O	O	O
non-carbohydrate	O	O	B-Entity
moiety	O	O	I-Entity
.	O	O	O

These	O	O	O
enzymes	O	O	B-Entity
are	O	O	O
involved	O	O	O
in	O	O	O
many	O	O	O
fundamental	O	O	O
and	O	O	O
diverse	O	O	O
biological	O	O	B-Entity
processes	O	O	I-Entity
in	O	O	O
plants	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
focused	O	O	O
on	O	O	O
the	O	O	O
GH32	O	O	B-Entity
family	O	O	I-Entity
,	O	O	O
including	O	O	O
enzymes	O	O	B-Entity
very	O	O	O
similar	O	O	O
in	O	O	O
both	O	O	O
sequence	O	O	B-Entity
and	O	O	O
structure	O	O	B-Entity
,	O	O	O
each	O	O	O
having	O	O	O
however	O	O	O
clear	O	O	O
specificities	O	O	O
of	O	O	O
substrate	O	O	B-Entity
preferences	O	O	B-Entity
and	O	O	O
kinetic	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Structural	O	O	B-Entity
and	O	O	O
topological	O	O	B-Entity
differences	O	O	O
among	O	O	O
proteins	O	O	B-Entity
of	O	O	O
the	O	O	O
GH32	O	O	B-Entity
family	O	O	I-Entity
have	O	O	O
been	O	O	O
here	O	O	O
identified	O	O	O
by	O	O	O
means	O	O	O
of	O	O	O
an	O	O	O
emerging	O	O	O
approach	O	O	O
(	O	O	O
Protein	O	O	B-Entity
Contact	O	O	I-Entity
network	O	O	I-Entity
,	O	O	O
PCN	O	O	B-Entity
)	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
formalization	O	O	O
of	O	O	O
3D	O	O	B-Entity
structures	O	O	I-Entity
as	O	O	O
contact	O	O	B-Entity
networks	O	O	I-Entity
among	O	O	O
amino-acid	O	O	B-Entity
residues	O	O	I-Entity
.	O	O	O

The	O	O	O
PCN	O	O	B-Entity
approach	O	O	O
proved	O	O	O
successful	O	O	O
in	O	O	O
both	O	O	O
reconstructing	O	O	O
the	O	O	O
already	O	O	O
known	O	O	O
functional	O	O	B-Entity
domains	O	O	B-Entity
and	O	O	O
in	O	O	O
identifying	O	O	O
the	O	O	O
structural	O	O	B-Entity
counterpart	O	O	O
of	O	O	O
the	O	O	O
properties	O	O	O
of	O	O	O
GH32	O	O	B-Entity
enzymes	O	O	I-Entity
,	O	O	O
which	O	O	O
remain	O	O	O
uncertain	O	O	O
,	O	O	O
like	O	O	O
their	O	O	O
allosteric	O	O	B-Entity
character	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
outcome	O	O	O
of	O	O	O
the	O	O	O
study	O	O	O
was	O	O	O
the	O	O	O
discovery	O	O	O
of	O	O	O
the	O	O	O
activation	O	O	B-Entity
upon	O	O	O
binding	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
border	O	O	I-Entity
(	O	O	I-Entity
cleft	O	O	I-Entity
)	O	O	I-Entity
region	O	O	I-Entity
between	O	O	O
the	O	O	O
two	O	O	O
domains	O	O	B-Entity
.	O	O	O

This	O	O	O
reveals	O	O	O
the	O	O	O
allosteric	O	O	B-Entity
nature	O	O	O
of	O	O	O
the	O	O	O
enzymatic	O	O	B-Entity
activity	O	O	I-Entity
for	O	O	O
all	O	O	O
the	O	O	O
analyzed	O	O	O
forms	O	O	O
in	O	O	O
the	O	O	O
GH32	O	O	B-Entity
family	O	O	I-Entity
,	O	O	O
a	O	O	O
character	O	O	O
yet	O	O	O
to	O	O	O
be	O	O	O
highlighted	O	O	O
in	O	O	O
biochemical	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
been	O	O	O
able	O	O	O
to	O	O	O
recognize	O	O	O
a	O	O	O
topological	O	O	B-Entity
signature	O	O	I-Entity
(	O	O	O
graph	O	O	O
energy	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
different	O	O	O
affinity	O	O	B-Entity
of	O	O	O
the	O	O	O
enzymes	O	O	B-Entity
towards	O	O	O
small	O	O	O
and	O	O	O
large	O	O	O
substrates	O	O	B-Entity
.	O	O	O

-DOCSTART- (27503979)

Grasping	O	O	B-Entity
At	O	O	O
The	O	O	O
Moon	O	O	B-Entity
:	O	O	O
Enhancing	O	O	B-Entity
Access	O	O	B-Entity
To	O	O	O
Careers	O	O	B-Entity
In	O	O	O
The	O	O	O
Health	O	O	O
Professions	O	O	O

A	O	O	O
former	O	O	B-Entity
HHS	O	O	B-Entity
secretary	O	O	B-Entity
reflects	O	O	B-Entity
on	O	O	O
what	O	O	O
's	O	O	O
needed	O	O	O
to	O	O	O
enable	O	O	O
more	O	O	O
minorities	O	O	B-Entity
to	O	O	O
become	O	O	O
doctors	O	O	B-Entity
and	O	O	O
other	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
.	O	O	O

-DOCSTART- (27504100)

Multivariate	O	O	B-Entity
Imaging	O	O	B-Entity
Genetics	O	O	B-Entity
Study	O	O	I-Entity
of	O	O	O
MRI	O	O	B-Entity
Gray	O	O	B-Entity
Matter	O	O	I-Entity
Volume	O	O	B-Entity
and	O	O	O
SNPs	O	O	B-Entity
Reveals	O	O	O
Biological	O	O	B-Entity
Pathways	O	O	B-Entity
Correlated	O	O	B-Entity
with	O	O	O
Brain	O	O	B-Entity
Structural	O	O	B-Entity
Differences	O	O	B-Entity
in	O	O	O
Attention	O	O	O
Deficit	O	O	O
Hyperactivity	O	O	O
Disorder	O	O	O

Attention	O	O	B-Entity
deficit	O	O	I-Entity
hyperactivity	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
ADHD	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
prevalent	O	O	B-Entity
neurodevelopmental	O	O	B-Entity
disorder	O	O	I-Entity
affecting	O	O	B-Entity
children	O	O	B-Entity
,	O	O	O
adolescents	O	O	B-Entity
,	O	O	O
and	O	O	O
adults	O	O	B-Entity
.	O	O	O

Its	O	O	O
etiology	O	O	B-Entity
is	O	O	O
not	O	O	O
well	O	O	O
understood	O	O	O
,	O	O	O
but	O	O	O
it	O	O	O
is	O	O	O
increasingly	O	O	O
believed	O	O	O
to	O	O	O
result	O	O	B-Entity
from	O	O	O
diverse	O	O	B-Entity
pathophysiologies	O	O	B-Entity
that	O	O	O
affect	O	O	B-Entity
the	O	O	O
structure	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
of	O	O	O
specific	O	O	B-Entity
brain	O	O	B-Entity
circuits	O	O	I-Entity
.	O	O	O

Although	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
best-studied	O	O	O
neurobiological	O	O	B-Entity
abnormalities	O	O	I-Entity
in	O	O	O
ADHD	O	O	B-Entity
is	O	O	O
reduced	O	O	B-Entity
fronto-striatal-cerebellar	O	O	B-Entity
gray	O	O	I-Entity
matter	O	O	I-Entity
(	O	O	O
GM	O	O	B-Entity
)	O	O	O
volume	O	O	B-Entity
,	O	O	O
its	O	O	O
specific	O	O	O
genetic	O	O	B-Entity
correlates	O	O	B-Entity
are	O	O	O
largely	O	O	O
unknown	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
T1-weighted	O	O	B-Entity
MR	O	O	I-Entity
images	O	O	I-Entity
of	O	O	I-Entity
brain	O	O	I-Entity
structure	O	O	I-Entity
were	O	O	O
collected	O	O	O
from	O	O	O
198	O	O	O
adolescents	O	O	B-Entity
(	O	O	O
63	O	O	O
ADHD	O	O	B-Entity
-	O	O	O
diagnosed	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
multivariate	O	O	B-Entity
parallel	O	O	I-Entity
independent	O	O	I-Entity
component	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
Para-ICA	O	O	B-Entity
)	O	O	O
technique	O	O	B-Entity
-identified	O	O	O
imaging	O	O	B-Entity
genetic	O	O	B-Entity
relationships	O	O	B-Entity
between	O	O	O
regional	O	O	B-Entity
GM	O	O	B-Entity
volume	O	O	B-Entity
and	O	O	O
single	O	O	B-Entity
nucleotide	O	O	I-Entity
polymorphism	O	O	I-Entity
data	O	O	B-Entity
.	O	O	O

Para-ICA	O	O	B-Entity
analyses	O	O	I-Entity
extracted	O	O	O
14	O	O	O
components	O	O	O
from	O	O	O
genetic	O	O	B-Entity
data	O	O	B-Entity
and	O	O	O
9	O	O	O
from	O	O	O
MR	O	O	B-Entity
data	O	O	O
.	O	O	O

An	O	O	O
iterative	O	O	B-Entity
cross-validation	O	O	I-Entity
using	O	O	O
randomly	O	O	O
chosen	O	O	O
subsamples	O	O	O
indicated	O	O	O
acceptable	O	O	O
stability	O	O	B-Entity
of	O	O	O
these	O	O	O
ICA	O	O	B-Entity
solutions	O	O	B-Entity
.	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
partial	O	O	B-Entity
correlation	O	O	I-Entity
analyses	O	O	I-Entity
controlling	O	O	B-Entity
for	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
and	O	O	O
ethnicity	O	O	B-Entity
revealed	O	O	O
two	O	O	O
genotype-phenotype	O	O	B-Entity
component	O	O	B-Entity
pairs	O	O	B-Entity
significantly	O	O	O
differed	O	O	O
between	O	O	O
ADHD	O	O	B-Entity
and	O	O	O
non-ADHD	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
after	O	O	O
a	O	O	O
Bonferroni	O	O	B-Entity
correction	O	O	I-Entity
for	O	O	O
multiple	O	O	B-Entity
comparisons	O	O	B-Entity
.	O	O	O

The	O	O	O
brain	O	O	B-Entity
phenotype	O	O	B-Entity
component	O	O	B-Entity
not	O	O	O
only	O	O	O
included	O	O	O
structures	O	O	B-Entity
frequently	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
abnormally	O	O	B-Entity
low	O	O	I-Entity
volume	O	O	B-Entity
in	O	O	O
previous	O	O	O
ADHD	O	O	B-Entity
studies	O	O	B-Entity
but	O	O	O
was	O	O	O
also	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
ADHD	O	O	O
differences	O	O	O
in	O	O	O
symptom	O	O	B-Entity
severity	O	O	I-Entity
and	O	O	O
performance	O	O	B-Entity
on	O	O	O
cognitive	O	O	B-Entity
tests	O	O	I-Entity
frequently	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
impaired	O	O	O
in	O	O	O
patients	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
the	O	O	O
disorder	O	O	B-Entity
.	O	O	O

Pathway	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
genotype	O	O	B-Entity
component	O	O	B-Entity
identified	O	O	O
several	O	O	O
different	O	O	O
biological	O	O	B-Entity
pathways	O	O	B-Entity
linked	O	O	O
to	O	O	O
these	O	O	O
structural	O	O	B-Entity
abnormalities	O	O	B-Entity
in	O	O	O
ADHD	O	O	B-Entity
.	O	O	O

Some	O	O	O
of	O	O	O
these	O	O	O
pathways	O	O	B-Entity
implicate	O	O	O
well-known	O	O	O
dopaminergic	O	O	B-Entity
neurotransmission	O	O	I-Entity
and	O	O	O
neurodevelopment	O	O	B-Entity
hypothesized	O	O	B-Entity
to	O	O	O
be	O	O	O
abnormal	O	O	B-Entity
in	O	O	O
ADHD	O	O	B-Entity
.	O	O	O

Other	O	O	O
more	O	O	O
recently	O	O	O
implicated	O	O	O
pathways	O	O	B-Entity
included	O	O	O
glutamatergic	O	O	B-Entity
and	O	O	O
GABA-eric	O	O	B-Entity
physiological	O	O	I-Entity
systems	O	O	I-Entity
;	O	O	O
others	O	O	O
might	O	O	O
reflect	O	O	O
sources	O	O	O
of	O	O	O
shared	O	O	O
liability	O	O	O
to	O	O	O
disturbances	O	O	O
commonly	O	O	O
found	O	O	O
in	O	O	O
ADHD	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
sleep	O	O	B-Entity
abnormalities	O	O	I-Entity
.	O	O	O

-DOCSTART- (27504422)

Clinicopathological	O	O	B-Entity
and	O	O	O
Immunohistochemical	O	O	B-Entity
Characteristics	O	O	O
of	O	O	O
Verruciform	O	O	B-Entity
Xanthoma	O	O	I-Entity
of	O	O	O
the	O	O	O
Lower	O	O	B-Entity
Gingiva	O	O	I-Entity
:	O	O	O
A	O	O	O
Case	O	O	O
Report	O	O	O

Verruciform	O	O	B-Entity
xanthoma	O	O	I-Entity
(	O	O	O
VX	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	O
benign	O	O	B-Entity
lesion	O	O	I-Entity
and	O	O	O
mainly	O	O	O
effects	O	O	O
the	O	O	O
oral	O	O	B-Entity
mucosa	O	O	I-Entity
.	O	O	O

This	O	O	O
slow-growing	O	O	B-Entity
asymptomatic	O	O	B-Entity
lesion	O	O	B-Entity
typically	O	O	O
develops	O	O	O
along	O	O	O
the	O	O	O
gingival	O	O	B-Entity
margin	O	O	I-Entity
of	O	O	O
the	O	O	O
masticatory	O	O	B-Entity
mucosa	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
hard	O	O	B-Entity
palate	O	O	I-Entity
,	O	O	O
tongue	O	O	B-Entity
,	O	O	O
buccal	O	O	B-Entity
mucosa	O	O	I-Entity
,	O	O	O
floor	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
mouth	O	O	I-Entity
,	O	O	O
alveolar	O	O	B-Entity
mucosa	O	O	I-Entity
,	O	O	O
soft	O	O	B-Entity
palate	O	O	I-Entity
and	O	O	O
junction	O	O	B-Entity
between	O	O	O
the	O	O	O
hard	O	O	O
and	O	O	O
soft	O	O	O
palate	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
this	O	O	O
lesion	O	O	B-Entity
can	O	O	O
also	O	O	O
affect	O	O	O
the	O	O	O
skin	O	O	B-Entity
and	O	O	O
genital	O	O	B-Entity
organs	O	O	I-Entity
.	O	O	O

Clinically	O	O	B-Entity
,	O	O	O
VX	O	O	B-Entity
generally	O	O	O
presents	O	O	O
a	O	O	O
sessile	O	O	B-Entity
or	O	O	O
pedunculated	O	O	B-Entity
appearance	O	O	I-Entity
,	O	O	O
forming	O	O	O
a	O	O	O
papule	O	O	B-Entity
or	O	O	O
single	O	O	B-Entity
plaque	O	O	I-Entity
with	O	O	O
verrucous	O	O	B-Entity
or	O	O	O
papillomatous	O	O	B-Entity
mucosal	O	O	B-Entity
growth	O	O	B-Entity
.	O	O	O

The	O	O	O
colour	O	O	B-Entity
(	O	O	O
white	O	O	B-Entity
,	O	O	O
pink	O	O	B-Entity
,	O	O	O
grey	O	O	B-Entity
,	O	O	O
or	O	O	O
yellow	O	O	B-Entity
)	O	O	O
depends	O	O	O
on	O	O	O
the	O	O	O
thickness	O	O	B-Entity
of	O	O	O
the	O	O	O
overlying	O	O	O
epidermis	O	O	B-Entity
.	O	O	O

In	O	O	O
fact	O	O	O
,	O	O	O
the	O	O	O
clinical	O	O	B-Entity
findings	O	O	B-Entity
of	O	O	O
VX	O	O	B-Entity
are	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
verrucous	O	O	B-Entity
carcinoma	O	O	I-Entity
and	O	O	O
other	O	O	O
benign	O	O	B-Entity
tumours	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
squamous	O	O	B-Entity
papilloma	O	O	I-Entity
,	O	O	O
verruca	O	O	B-Entity
vulgaris	O	O	I-Entity
and	O	O	O
mucosal	O	O	B-Entity
fibroma	O	O	I-Entity
.	O	O	O

For	O	O	O
this	O	O	O
reason	O	O	O
,	O	O	O
clinical	O	O	B-Entity
and	O	O	O
histopathological	O	O	B-Entity
examinations	O	O	B-Entity
are	O	O	O
essential	O	O	O
for	O	O	O
accurate	O	O	B-Entity
differential	O	O	I-Entity
diagnosis	O	O	I-Entity
.	O	O	O

Histologically	O	O	B-Entity
,	O	O	O
VX	O	O	B-Entity
is	O	O	O
characterized	O	O	O
by	O	O	O
parakeratosis	O	O	B-Entity
,	O	O	O
rete	O	O	B-Entity
ridges	O	O	I-Entity
of	O	O	O
uniform	O	O	O
depth	O	O	O
and	O	O	O
the	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
foam	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
which	O	O	O
are	O	O	O
also	O	O	O
called	O	O	O
"	O	O	O
xanthoma	O	O	B-Entity
cells	O	O	I-Entity
"	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
clinicopathological	O	O	B-Entity
and	O	O	O
immunohistochemical	O	O	B-Entity
findings	O	O	B-Entity
of	O	O	O
a	O	O	O
VX	O	O	B-Entity
located	O	O	O
on	O	O	O
the	O	O	O
lower	O	O	B-Entity
gingiva	O	O	I-Entity
of	O	O	O
a	O	O	O
64-year-old	O	O	O
male	O	O	B-Entity
patient	O	O	I-Entity
.	O	O	O

-DOCSTART- (27507301)

MicroRNA	O	O	B-Entity
101b	O	O	I-Entity
Is	O	O	O
Downregulated	O	O	B-Entity
in	O	O	O
the	O	O	O
Prefrontal	O	O	B-Entity
Cortex	O	O	I-Entity
of	O	O	O
a	O	O	O
Genetic	O	O	B-Entity
Model	O	O	I-Entity
of	O	O	O
Depression	O	O	B-Entity
and	O	O	O
Targets	O	O	B-Entity
the	O	O	O
Glutamate	O	O	B-Entity
Transporter	O	O	I-Entity
SLC1A1	O	O	B-Entity
(	O	O	O
EAAT3	O	O	B-Entity
)	O	O	O
in	O	O	O
Vitro	O	O	O

MicroRNAs	O	O	B-Entity
(	O	O	O
miRNAs	O	O	B-Entity
)	O	O	O
are	O	O	O
small	O	O	B-Entity
regulatory	O	O	B-Entity
molecules	O	O	B-Entity
that	O	O	O
cause	O	O	O
translational	O	O	B-Entity
repression	O	O	I-Entity
by	O	O	O
base	O	O	B-Entity
pairing	O	O	I-Entity
with	O	O	I-Entity
target	O	O	I-Entity
mRNAs	O	O	I-Entity
.	O	O	O

Cumulative	O	O	B-Entity
evidence	O	O	B-Entity
suggests	O	O	O
that	O	O	O
changes	O	O	B-Entity
in	O	O	O
miRNA	O	O	B-Entity
expression	O	O	B-Entity
may	O	O	O
in	O	O	O
part	O	O	O
underlie	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
neuropsychiatric	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
including	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
MDD	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
miRNA	O	O	B-Entity
expression	O	O	B-Entity
assay	O	O	B-Entity
that	O	O	O
can	O	O	O
simultaneously	O	O	B-Entity
detect	O	O	O
423	O	O	O
rat	O	O	O
miRNAs	O	O	B-Entity
(	O	O	O
miRBase	O	O	O
v.17	O	O	O
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
profile	O	O	B-Entity
the	O	O	O
prefrontal	O	O	B-Entity
cortex	O	O	I-Entity
(	O	O	O
PFC	O	O	B-Entity
)	O	O	O
of	O	O	O
a	O	O	O
genetic	O	O	B-Entity
rat	O	O	I-Entity
model	O	O	I-Entity
of	O	O	O
MDD	O	O	B-Entity
(	O	O	O
the	O	O	O
Flinders	O	O	B-Entity
Sensitive	O	O	I-Entity
Line	O	O	I-Entity
[	O	O	O
FSL	O	O	B-Entity
]	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
controls	O	O	B-Entity
,	O	O	O
the	O	O	O
Flinders	O	O	B-Entity
Resistant	O	O	I-Entity
Line	O	O	I-Entity
(	O	O	O
FRL	O	O	B-Entity
)	O	O	O
.	O	O	O

Gene	O	O	B-Entity
expression	O	O	I-Entity
data	O	O	B-Entity
from	O	O	O
the	O	O	O
PFC	O	O	B-Entity
of	O	O	O
FSL	O	O	B-Entity
/	O	O	O
FRL	O	O	B-Entity
animals	O	O	B-Entity
(	O	O	O
GEO	O	O	O
accession	O	O	O
no.	O	O	O
GSE20388	O	O	O
)	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
guide	O	O	O
mRNA	O	O	B-Entity
target	O	O	B-Entity
selection	O	O	B-Entity
.	O	O	O

Luciferase	O	O	B-Entity
reporter	O	O	I-Entity
assays	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
verify	O	O	B-Entity
miRNA	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
23	O	O	O
miRNAs	O	O	B-Entity
that	O	O	O
were	O	O	O
downregulated	O	O	B-Entity
in	O	O	O
the	O	O	O
PFC	O	O	B-Entity
of	O	O	O
the	O	O	O
FSL	O	O	B-Entity
model	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
controls	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
identified	O	O	B-Entity
miRNAs	O	O	B-Entity
(	O	O	O
miR-101b	O	O	B-Entity
)	O	O	O
is	O	O	O
highly	O	O	O
conserved	O	O	B-Entity
between	O	O	O
rat	O	O	B-Entity
and	O	O	O
human	O	O	B-Entity
and	O	O	O
was	O	O	O
recently	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
downregulated	O	O	B-Entity
in	O	O	O
the	O	O	O
PFC	O	O	B-Entity
of	O	O	O
depressed	O	O	B-Entity
suicide	O	O	B-Entity
subjects	O	O	B-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
in	O	O	B-Entity
silico	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
analyses	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
miR-101b	O	O	B-Entity
targets	O	O	B-Entity
the	O	O	O
neuronal	O	O	B-Entity
glutamate	O	O	B-Entity
transporter	O	O	I-Entity
SLC1A1	O	O	B-Entity
(	O	O	O
also	O	O	O
known	O	O	O
as	O	O	O
EAAC1	O	O	B-Entity
or	O	O	O
EAAT3	O	O	B-Entity
)	O	O	O
.	O	O	O

Accordingly	O	O	O
,	O	O	O
both	O	O	O
mRNA	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
SLC1A1	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
upregulated	O	O	B-Entity
in	O	O	O
the	O	O	O
PFC	O	O	B-Entity
of	O	O	O
the	O	O	O
FSL	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

Besides	O	O	O
providing	O	O	O
a	O	O	O
list	O	O	O
of	O	O	O
novel	O	O	O
miRNAs	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
depression-like	O	O	B-Entity
states	O	O	I-Entity
,	O	O	O
this	O	O	O
preclinical	O	O	B-Entity
study	O	O	I-Entity
replicated	O	O	B-Entity
the	O	O	O
human	O	O	B-Entity
association	O	O	B-Entity
of	O	O	O
miR-101	O	O	B-Entity
with	O	O	O
depression	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
since	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
targets	O	O	B-Entity
of	O	O	O
miR-101b	O	O	B-Entity
appears	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
glutamate	O	O	B-Entity
transporter	O	O	I-Entity
,	O	O	O
our	O	O	O
preclinical	O	O	B-Entity
data	O	O	B-Entity
support	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
of	O	O	O
a	O	O	O
glutamatergic	O	O	B-Entity
dysregulation	O	O	B-Entity
being	O	O	O
implicated	O	O	O
in	O	O	O
the	O	O	O
etiology	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
.	O	O	O

-DOCSTART- (27507385)

A	O	O	O
Practical	O	O	B-Entity
Guide	O	O	I-Entity
to	O	O	O
Forensic	O	O	B-Entity
Nursing	O	O	I-Entity
:	O	O	O
Incorporating	O	O	B-Entity
forensic	O	O	B-Entity
principles	O	O	B-Entity
into	O	O	O
nursing	O	O	B-Entity
practice	O	O	I-Entity
Amar	O	O	B-Entity
Angela	O	O	I-Entity
F	O	O	I-Entity
and	O	O	O
Sekula	O	O	B-Entity
L	O	O	I-Entity
Kathleen	O	O	I-Entity
A	O	O	O
Practical	O	O	O
Guide	O	O	O
to	O	O	O
Forensic	O	O	O
Nursing	O	O	O
:	O	O	O
Incorporating	O	O	O
forensic	O	O	O
principles	O	O	O
into	O	O	O
nursing	O	O	O
practice	O	O	O
392pp	O	O	O
US$	O	O	O
59.95	O	O	O
Sigma	O	O	O
Theta	O	O	O
Tau	O	O	O
International	O	O	O
Honor	O	O	O
Society	O	O	O
of	O	O	O
Nursing	O	O	O
9781940446349	O	O	O
1940446341	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O

George	O	O	B-Entity
Bernard	O	O	I-Entity
Shaw	O	O	I-Entity
described	O	O	O
Britons	O	O	B-Entity
and	O	O	O
Americans	O	O	B-Entity
as	O	O	O
'	O	O	O
divided	O	O	B-Entity
by	O	O	O
a	O	O	O
common	O	O	B-Entity
language	O	O	I-Entity
'	O	O	O
,	O	O	O
and	O	O	O
that	O	O	O
is	O	O	O
made	O	O	O
very	O	O	O
clear	O	O	O
in	O	O	O
this	O	O	O
fascinating	O	O	B-Entity
publication	O	O	I-Entity
that	O	O	O
describes	O	O	O
in	O	O	O
depth	O	O	O
the	O	O	O
roles	O	O	B-Entity
and	O	O	I-Entity
responsibilities	O	O	I-Entity
of	O	O	O
forensic	O	O	B-Entity
nurses	O	O	I-Entity
in	O	O	O
the	O	O	O
US	O	O	B-Entity
.	O	O	O

-DOCSTART- (27508301)

Incidence	O	O	B-Entity
of	O	O	O
Diabetes	O	O	B-Entity
Mellitus	O	O	I-Entity
and	O	O	O
Obesity	O	O	B-Entity
and	O	O	O
the	O	O	O
Overlap	O	O	B-Entity
of	O	O	O
Comorbidities	O	O	B-Entity
in	O	O	O
HIV+	O	O	B-Entity
Hispanics	O	O	B-Entity
Initiating	O	O	B-Entity
Antiretroviral	O	O	O
Therapy	O	O	O

Cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
CVD	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
leading	O	O	O
health	O	O	B-Entity
threat	O	O	B-Entity
for	O	O	O
HIV+	O	O	B-Entity
patients	O	O	B-Entity
on	O	O	O
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
ART	O	O	B-Entity
)	O	O	O
;	O	O	O
cardiometabolic	O	O	B-Entity
comorbidities	O	O	B-Entity
are	O	O	O
key	O	O	O
predictors	O	O	B-Entity
of	O	O	I-Entity
risk	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
are	O	O	O
limited	O	O	O
on	O	O	O
incidence	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
comorbidities	O	O	B-Entity
in	O	O	O
HIV+	O	O	B-Entity
individuals	O	O	B-Entity
initiating	O	O	B-Entity
ART	O	O	B-Entity
in	O	O	O
low	O	O	B-Entity
and	O	O	O
middle	O	O	B-Entity
income	O	O	I-Entity
countries	O	O	B-Entity
(	O	O	O
LMICs	O	O	B-Entity
)	O	O	O
,	O	O	O
particularly	O	O	B-Entity
for	O	O	O
Hispanics	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
and	O	O	O
obesity	O	O	B-Entity
in	O	O	O
a	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
of	O	O	O
those	O	O	O
initiating	O	O	B-Entity
ART	O	O	B-Entity
in	O	O	O
the	O	O	O
Dominican	O	O	B-Entity
Republic	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
≥18	O	O	O
years	O	O	B-Entity
,	O	O	O
initiating	O	O	B-Entity
ART	O	O	B-Entity
<	O	O	O
90	O	O	O
days	O	O	B-Entity
prior	O	O	O
to	O	O	O
study	O	O	B-Entity
enrollment	O	O	B-Entity
,	O	O	O
were	O	O	O
examined	O	O	B-Entity
for	O	O	O
incidence	O	O	B-Entity
of	O	O	O
impaired	O	O	B-Entity
fasting	O	O	I-Entity
glucose	O	O	I-Entity
(	O	O	O
IFG	O	O	B-Entity
)	O	O	O
,	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
(	O	O	O
DM	O	O	B-Entity
)	O	O	O
,	O	O	O
overweight	O	O	B-Entity
,	O	O	I-Entity
and	O	O	I-Entity
obesity	O	O	I-Entity
.	O	O	O

Fasting	O	O	B-Entity
plasma	O	O	I-Entity
glucose	O	O	I-Entity
(	O	O	O
FPG	O	O	B-Entity
)	O	O	O
100	O	O	O
-	O	O	O
125mg/dl	O	O	O
defined	O	O	O
IFG	O	O	B-Entity
;	O	O	O
FPG	O	O	O
≥126	O	O	O
mg/dl	O	O	O
,	O	O	O
diagnosis	O	O	B-Entity
per	O	O	O
medical	O	O	B-Entity
record	O	O	I-Entity
,	O	O	O
or	O	O	O
use	O	O	O
of	O	O	O
hypoglycemic	O	O	B-Entity
medication	O	O	I-Entity
defined	O	O	O
DM	O	O	B-Entity
.	O	O	O

Overweight	O	O	B-Entity
and	O	O	I-Entity
obesity	O	O	I-Entity
were	O	O	O
BMI	O	O	B-Entity
25	O	O	O
-	O	O	O
30	O	O	O
and	O	O	O
≥30kg/m2	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Dyslipidemia	O	O	B-Entity
was	O	O	O
total	O	O	B-Entity
cholesterol	O	O	I-Entity
≥240mg/dl	O	O	O
or	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
lipid-lowering	O	O	B-Entity
medication	O	O	I-Entity
.	O	O	O

Framingham	O	O	B-Entity
risk	O	O	B-Entity
equation	O	O	I-Entity
was	O	O	O
used	O	O	B-Entity
to	O	O	O
determine	O	O	B-Entity
ten-year	O	O	B-Entity
CVD	O	O	B-Entity
risk	O	O	O
at	O	O	O
the	O	O	O
end	O	O	B-Entity
of	O	O	I-Entity
observation	O	O	I-Entity
.	O	O	O

Of	O	O	O
153	O	O	O
initiating	O	O	B-Entity
ART	O	O	B-Entity
,	O	O	O
8	O	O	O
(	O	O	O
6	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
DM	O	O	B-Entity
and	O	O	O
23	O	O	O
(	O	O	O
16	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
IFG	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
6	O	O	O
developed	O	O	O
DM	O	O	O
(	O	O	O
28/1000	O	O	O
person	O	O	B-Entity
-	O	O	O
years	O	O	B-Entity
follow	O	O	B-Entity
up	O	O	I-Entity
[	O	O	O
PYFU	O	O	B-Entity
]	O	O	O
)	O	O	O
and	O	O	O
46	O	O	O
developed	O	O	O
IFG	O	O	O
(	O	O	O
329/1000	O	O	O
PYFU	O	O	O
)	O	O	O
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
,	O	O	O
24	O	O	O
(	O	O	O
18	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
obese	O	O	B-Entity
and	O	O	O
36	O	O	O
(	O	O	O
27	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
overweight	O	O	B-Entity
,	O	O	O
15	O	O	O
became	O	O	O
obese	O	O	O
(	O	O	O
69/1000	O	O	O
PYFU	O	O	B-Entity
)	O	O	O
and	O	O	O
22	O	O	O
became	O	O	O
overweight	O	O	O
(	O	O	O
163/1000	O	O	O
PYFU	O	O	O
)	O	O	O
.	O	O	O

Median	O	O	B-Entity
observation	O	O	B-Entity
periods	O	O	B-Entity
for	O	O	O
the	O	O	O
diabetes	O	O	B-Entity
and	O	O	O
obesity	O	O	B-Entity
analyses	O	O	B-Entity
were	O	O	O
23.5	O	O	O
months	O	O	B-Entity
and	O	O	O
24.3	O	O	O
months	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Increased	O	O	B-Entity
CVD	O	O	B-Entity
risk	O	O	B-Entity
(	O	O	O
≥10	O	O	O
%	O	O	O
10-year	O	O	B-Entity
Framingham	O	O	I-Entity
risk	O	O	I-Entity
score	O	O	I-Entity
)	O	O	O
was	O	O	O
present	O	O	B-Entity
for	O	O	O
13	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
cohort	O	O	B-Entity
;	O	O	O
79	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
cohort	O	O	O
had	O	O	O
≥1	O	O	O
cardiometabolic	O	O	B-Entity
comorbidity	O	O	I-Entity
,	O	O	O
48	O	O	O
%	O	O	O
had	O	O	O
≥2	O	O	O
,	O	O	O
and	O	O	O
13	O	O	O
%	O	O	O
had	O	O	O
all	O	O	O
three	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
Hispanic	O	O	B-Entity
cohort	O	O	B-Entity
in	O	O	O
an	O	O	O
LMIC	O	O	B-Entity
,	O	O	O
incidences	O	O	B-Entity
of	O	O	O
IFG	O	O	B-Entity
/	O	O	O
DM	O	O	B-Entity
and	O	O	O
overweight	O	O	B-Entity
/	O	O	O
obesity	O	O	B-Entity
were	O	O	O
similar	O	O	B-Entity
to	O	O	O
or	O	O	O
higher	O	O	B-Entity
than	O	O	I-Entity
that	O	O	O
found	O	O	B-Entity
in	O	O	O
high	O	O	B-Entity
income	O	O	I-Entity
countries	O	O	B-Entity
,	O	O	O
and	O	O	O
cardiometabolic	O	O	B-Entity
disorders	O	O	I-Entity
affected	O	O	B-Entity
three-quarters	O	O	O
of	O	O	O
those	O	O	O
initiating	O	O	B-Entity
ART	O	O	B-Entity
.	O	O	O

Care	O	O	B-Entity
models	O	O	I-Entity
incorporating	O	O	O
cardiovascular	O	O	B-Entity
risk	O	O	I-Entity
reduction	O	O	B-Entity
into	O	O	O
HIV	O	O	B-Entity
treatment	O	O	B-Entity
programs	O	O	I-Entity
are	O	O	O
needed	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
CVD	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
mortality	O	O	B-Entity
in	O	O	O
this	O	O	O
vulnerable	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

-DOCSTART- (27508328)

Laparoscopic	O	O	B-Entity
Approach	O	O	I-Entity
for	O	O	O
Thermoablation	O	O	B-Entity
Microwave	O	O	I-Entity
in	O	O	O
the	O	O	O
Treatment	O	O	B-Entity
of	O	O	O
Hepatocellular	O	O	B-Entity
Carcinoma	O	O	I-Entity
:	O	O	O
A	O	O	O
Single	O	O	O
Center	O	O	O
Experience	O	O	O

The	O	O	O
surgical	O	O	B-Entity
therapy	O	O	I-Entity
of	O	O	O
choice	O	O	O
for	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HCC	O	O	B-Entity
)	O	O	O
is	O	O	O
liver	O	O	B-Entity
transplantation	O	O	I-Entity
(	O	O	O
LT	O	O	B-Entity
)	O	O	O
or	O	O	O
hepatic	O	O	B-Entity
resection	O	O	I-Entity
,	O	O	O
although	O	O	O
only	O	O	O
a	O	O	O
small	O	O	B-Entity
percentage	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
can	O	O	O
undergo	O	O	O
these	O	O	O
procedures	O	O	B-Entity
.	O	O	O

Microwave	O	O	B-Entity
thermal	O	O	I-Entity
ablation	O	O	I-Entity
(	O	O	O
MWTA	O	O	B-Entity
)	O	O	O
can	O	O	O
be	O	O	O
an	O	O	O
effective	O	O	B-Entity
alternative	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
HCC	O	O	B-Entity
that	O	O	O
complicates	O	O	B-Entity
a	O	O	O
cirrhotic	O	O	B-Entity
liver	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
either	O	O	O
as	O	O	O
a	O	O	O
final	O	O	B-Entity
procedure	O	O	B-Entity
or	O	O	O
for	O	O	O
downstaging	O	O	B-Entity
patients	O	O	B-Entity
on	O	O	O
the	O	O	O
waiting	O	O	O
list	O	O	O
for	O	O	O
LT	O	O	B-Entity
,	O	O	O
or	O	O	O
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
resective	O	O	B-Entity
surgery	O	O	B-Entity
to	O	O	O
achieve	O	O	O
oncological	O	O	B-Entity
radicality	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
experience	O	O	B-Entity
with	O	O	O
the	O	O	O
laparoscopic	O	O	B-Entity
approach	O	O	I-Entity
of	O	O	O
MWTA	O	O	B-Entity
at	O	O	O
our	O	O	O
center	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
35	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
undergoing	O	O	O
MWTA	O	O	B-Entity
with	O	O	O
laparoscopic	O	O	B-Entity
approach	O	O	I-Entity
between	O	O	O
January	O	O	O
,	O	O	O
2013	O	O	O
and	O	O	O
May	O	O	O
,	O	O	O
2016	O	O	O
,	O	O	O
we	O	O	O
reviewed	O	O	O
the	O	O	O
demographic	O	O	B-Entity
data	O	O	I-Entity
,	O	O	O
the	O	O	O
Barcelona	O	O	B-Entity
clinic	O	O	I-Entity
liver	O	O	I-Entity
cancer	O	O	I-Entity
stage	O	O	I-Entity
,	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
cirrhotic	O	O	B-Entity
liver	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
the	O	O	O
size	O	O	B-Entity
of	O	O	O
the	O	O	O
ablated	O	O	B-Entity
lesion	O	O	B-Entity
,	O	O	O
the	O	O	O
duration	O	O	B-Entity
of	O	O	O
the	O	O	O
procedure	O	O	B-Entity
,	O	O	O
and	O	O	O
complications	O	O	B-Entity
occurring	O	O	O
within	O	O	O
90	O	O	O
days	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
.	O	O	O

MWTA	O	O	B-Entity
was	O	O	O
performed	O	O	O
by	O	O	O
applying	O	O	O
one	O	O	O
to	O	O	O
three	O	O	O
hepatic	O	O	B-Entity
parenchymal	O	O	B-Entity
insertions	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
1.8	O	O	O
)	O	O	O
per	O	O	O
patient	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
was	O	O	O
163	O	O	O
±	O	O	O
18	O	O	O
minutes	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
blood	O	O	B-Entity
loss	O	O	I-Entity
in	O	O	O
any	O	O	O
of	O	O	O
the	O	O	O
procedures	O	O	B-Entity
.	O	O	O

Complete	O	O	O
necrosis	O	O	B-Entity
on	O	O	O
CT	O	O	B-Entity
scan	O	O	I-Entity
was	O	O	O
achieved	O	O	O
in	O	O	O
26/35	O	O	O
patients	O	O	B-Entity
(	O	O	O
75	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
hospital	O	O	B-Entity
stay	O	O	I-Entity
was	O	O	O
4.6	O	O	O
(	O	O	O
range	O	O	O
2	O	O	O
-	O	O	O
7	O	O	O
)	O	O	O
days	O	O	B-Entity
;	O	O	O
major	O	O	O
complications	O	O	B-Entity
were	O	O	O
postablation	O	O	B-Entity
syndrome	O	O	B-Entity
in	O	O	O
2/35	O	O	O
(	O	O	O
5.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
peritoneal	O	O	B-Entity
fluid	O	O	I-Entity
in	O	O	O
4/35	O	O	O
(	O	O	O
11.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
transient	O	O	B-Entity
jaundice	O	O	B-Entity
in	O	O	O
1/35	O	O	O
(	O	O	O
2.8	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
mortality	O	O	I-Entity
.	O	O	O

Laparoscopic	O	O	B-Entity
MWTA	O	O	B-Entity
is	O	O	O
a	O	O	O
safe	O	O	O
and	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
unresectable	O	O	B-Entity
HCC	O	O	B-Entity
and	O	O	O
when	O	O	O
a	O	O	O
percutaneous	O	O	B-Entity
procedure	O	O	B-Entity
is	O	O	O
not	O	O	O
feasible	O	O	O
.	O	O	O

-DOCSTART- (27510571)

Structured	O	O	B-Entity
Instruction	O	O	B-Entity
With	O	O	O
Modified	O	O	B-Entity
Storybooks	O	O	B-Entity
to	O	O	O
Teach	O	O	B-Entity
Morphosyntax	O	O	B-Entity
and	O	O	O
Vocabulary	O	O	B-Entity
to	O	O	O
Preschoolers	O	O	B-Entity
Who	O	O	O
are	O	O	O
Deaf	O	O	B-Entity
/	O	O	O
Hard	O	O	O
of	O	O	O
Hearing	O	O	O

Children	O	O	B-Entity
who	O	O	O
are	O	O	O
deaf	O	O	B-Entity
/	O	O	O
hard	O	O	B-Entity
of	O	O	I-Entity
hearing	O	O	I-Entity
(	O	O	O
D	O	O	B-Entity
/	O	O	O
HH	O	O	B-Entity
)	O	O	O
are	O	O	O
at	O	O	B-Entity
risk	O	O	I-Entity
for	O	O	O
diminished	O	O	B-Entity
morphosyntactical	O	O	B-Entity
and	O	O	O
vocabulary	O	O	B-Entity
development	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
repeated	O	O	B-Entity
reading	O	O	B-Entity
combined	O	O	B-Entity
with	O	O	O
structured	O	O	B-Entity
instruction	O	O	B-Entity
.	O	O	O

Targets	O	O	B-Entity
were	O	O	O
a	O	O	O
morphosyntactical	O	O	B-Entity
form	O	O	I-Entity
and	O	O	O
novel	O	O	O
vocabulary	O	O	B-Entity
words	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
3	O	O	O
preschoolers	O	O	B-Entity
who	O	O	O
are	O	O	O
D	O	O	B-Entity
/	O	O	O
HH	O	O	B-Entity
who	O	O	O
were	O	O	O
receiving	O	O	B-Entity
instruction	O	O	B-Entity
with	O	O	O
an	O	O	O
oral	O	O	B-Entity
approach	O	O	O
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
a	O	O	O
multiple	O	O	B-Entity
baseline	O	O	B-Entity
design	O	O	I-Entity
indicated	O	O	O
that	O	O	O
all	O	O	O
children	O	O	B-Entity
acquired	O	O	B-Entity
the	O	O	O
targeted	O	O	B-Entity
skills	O	O	B-Entity
and	O	O	O
demonstrated	O	O	O
high	O	O	O
levels	O	O	O
of	O	O	O
generalization	O	O	B-Entity
of	O	O	O
these	O	O	O
skills	O	O	O
to	O	O	O
untrained	O	O	B-Entity
context	O	O	B-Entity
.	O	O	O

Implications	O	O	B-Entity
for	O	O	O
teaching	O	O	B-Entity
young	O	O	B-Entity
children	O	O	B-Entity
who	O	O	O
are	O	O	O
D	O	O	B-Entity
/	O	O	O
HH	O	O	B-Entity
using	O	O	B-Entity
repeated	O	O	B-Entity
storybook	O	O	B-Entity
reading	O	O	B-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27510784)

Application	O	O	B-Entity
of	O	O	O
BRAF	O	O	B-Entity
V600E	O	O	I-Entity
mutation	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
immunohistochemistry	O	O	B-Entity
in	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
gastrointestinal	O	O	O
stromal	O	O	O
tumors	O	O	O

To	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
utility	O	O	O
of	O	O	O
BRAF	O	O	B-Entity
V600E	O	O	I-Entity
allele	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
antibody	O	O	B-Entity
in	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
gastrointestinal	O	O	B-Entity
stromal	O	O	I-Entity
tumors	O	O	I-Entity
(	O	O	O
GISTs	O	O	B-Entity
)	O	O	O
.	O	O	O

BRAF	O	O	B-Entity
V600E	O	O	I-Entity
mutation	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
immunohistochemistry	O	O	B-Entity
and	O	O	O
BRAF	O	O	O
sequencing	O	O	B-Entity
were	O	O	O
performed	O	O	O
in	O	O	O
24	O	O	O
consecutive	O	O	B-Entity
GISTs	O	O	B-Entity
,	O	O	O
including	O	O	O
14	O	O	O
cases	O	O	B-Entity
of	O	O	O
KIT	O	O	B-Entity
or	O	O	O
PDGFRA	O	O	B-Entity
mutations	O	O	I-Entity
and	O	O	O
10	O	O	O
cases	O	O	O
of	O	O	O
KIT	O	O	O
/	O	O	O
PDGFRA	O	O	B-Entity
wild	O	O	I-Entity
GISTs	O	O	O
.	O	O	O

GISTs	O	O	B-Entity
of	O	O	O
11	O	O	O
men	O	O	B-Entity
and	O	O	O
13	O	O	O
women	O	O	B-Entity
with	O	O	O
a	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
54	O	O	O
years(range	O	O	O
29	O	O	O
-	O	O	O
75	O	O	O
years	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
with	O	O	O
tumors	O	O	B-Entity
arising	O	O	O
from	O	O	O
stomach	O	O	B-Entity
(	O	O	O
16	O	O	O
cases	O	O	B-Entity
)	O	O	O
,	O	O	O
small	O	O	B-Entity
bowel	O	O	I-Entity
(	O	O	O
7	O	O	O
cases	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
peritoneal	O	O	B-Entity
cavity	O	O	I-Entity
(	O	O	O
1	O	O	O
case	O	O	B-Entity
)	O	O	O
.	O	O	O

Strong	O	O	B-Entity
and	O	O	O
diffuse	O	O	B-Entity
cytoplasmic	O	O	B-Entity
BRAF	O	O	B-Entity
staining	O	O	B-Entity
was	O	O	O
noted	O	O	B-Entity
in	O	O	O
4	O	O	O
of	O	O	O
24	O	O	O
cases	O	O	B-Entity
(	O	O	O
17	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
1	O	O	O
of	O	O	O
24	O	O	O
cases	O	O	O
(	O	O	O
4	O	O	O
%	O	O	O
)	O	O	O
showed	O	O	O
weak	O	O	B-Entity
staining	O	O	O
,	O	O	O
and	O	O	O
19	O	O	O
of	O	O	O
24	O	O	O
cases	O	O	O
(	O	O	O
79	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
no	O	O	B-Entity
staining	O	O	O
.	O	O	O

The	O	O	O
four	O	O	O
cases	O	O	B-Entity
with	O	O	O
strong	O	O	B-Entity
BRAF	O	O	B-Entity
immunostain	O	O	B-Entity
were	O	O	O
confirmed	O	O	B-Entity
to	O	O	O
have	O	O	O
BRAF	O	O	B-Entity
mutations	O	O	I-Entity
,	O	O	O
including	O	O	O
3	O	O	O
cases	O	O	O
in	O	O	O
the	O	O	O
stomach	O	O	B-Entity
and	O	O	O
1	O	O	O
case	O	O	B-Entity
in	O	O	O
the	O	O	O
small	O	O	B-Entity
intestine	O	O	I-Entity
.	O	O	O

All	O	O	O
tumors	O	O	B-Entity
showed	O	O	O
spindle	O	O	B-Entity
cell	O	O	I-Entity
morphology	O	O	B-Entity
.	O	O	O

Only	O	O	O
one	O	O	O
case	O	O	B-Entity
had	O	O	O
progressive	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
BRAF	O	O	B-Entity
mutations	O	O	I-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
cases	O	O	B-Entity
with	O	O	O
weak	O	O	B-Entity
or	O	O	O
negative	O	O	B-Entity
BRAF	O	O	O
immunostain	O	O	B-Entity
.	O	O	O

BRAF	O	O	B-Entity
V600E	O	O	I-Entity
mutation	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
immunohistochemistry	O	O	B-Entity
is	O	O	O
a	O	O	O
highly	O	O	B-Entity
sensitive	O	O	I-Entity
and	O	O	O
specific	O	O	O
marker	O	O	B-Entity
for	O	O	O
detecting	O	O	B-Entity
BRAF-mutated	O	O	B-Entity
GISTs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27511525)

Efficacy	O	O	O
of	O	O	O
pegylated	O	O	B-Entity
liposomal	O	O	I-Entity
etoposide	O	O	I-Entity
nanoparticles	O	O	I-Entity
on	O	O	O
breast	O	O	O
cancer	O	O	O
cell	O	O	O
lines	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	I-Entity
pegylated	O	O	B-Entity
liposomal	O	O	I-Entity
etoposide	O	O	I-Entity
nanoparticles	O	O	I-Entity
(	O	O	O
NPs	O	O	O
)	O	O	O
against	O	O	O
T-47D	O	O	B-Entity
and	O	O	O
MCF-7	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
.	O	O	O

Pegylated	O	O	B-Entity
liposomal	O	O	I-Entity
etoposide	O	O	I-Entity
NPs	O	O	I-Entity
were	O	O	O
prepared	O	O	O
by	O	O	O
reverse	O	O	B-Entity
phase	O	O	I-Entity
evaporation	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

The	O	O	O
size	O	O	B-Entity
,	O	O	O
size	O	O	B-Entity
distribution	O	O	I-Entity
,	O	O	O
and	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
of	O	O	O
the	O	O	O
NPs	O	O	B-Entity
was	O	O	O
measured	O	O	O
by	O	O	O
a	O	O	O
Zetasizer	O	O	B-Entity
instrument	O	O	I-Entity
.	O	O	O

The	O	O	O
cytotoxicity	O	O	B-Entity
of	O	O	O
NPs	O	O	B-Entity
was	O	O	O
inspected	O	O	O
by	O	O	O
methyl	O	O	B-Entity
thiazol	O	O	I-Entity
tetrazolium	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

The	O	O	O
release	O	O	B-Entity
pattern	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
drug	O	O	I-Entity
from	O	O	I-Entity
the	O	O	I-Entity
vesicles	O	O	I-Entity
was	O	O	O
studied	O	O	O
by	O	O	O
the	O	O	O
dialysis	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

Drug	O	O	B-Entity
loading	O	O	I-Entity
and	O	O	O
encapsulation	O	O	B-Entity
efficiency	O	O	I-Entity
(	O	O	O
EE	O	O	B-Entity
)	O	O	O
were	O	O	O
also	O	O	O
measured	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
size	O	O	I-Entity
,	O	O	O
size	O	O	B-Entity
distribution	O	O	I-Entity
,	O	O	O
and	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
of	O	O	O
pegylated	O	O	B-Entity
liposomal	O	O	I-Entity
etoposide	O	O	I-Entity
NPs	O	O	I-Entity
were	O	O	O
491	O	O	O
±	O	O	O
15.5	O	O	O
nm	O	O	O
,	O	O	O
0.504	O	O	O
±	O	O	O
0.14	O	O	O
,	O	O	O
and	O	O	O
-35.8	O	O	O
±	O	O	O
2.5	O	O	O
mV	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Drug	O	O	B-Entity
loading	O	O	I-Entity
and	O	O	O
EE	O	O	B-Entity
were	O	O	O
10.3	O	O	O
±	O	O	O
1.6	O	O	O
%	O	O	O
and	O	O	O
99.1	O	O	O
±	O	O	O
2.8	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
etoposide	O	O	B-Entity
release	O	O	I-Entity
in	O	O	I-Entity
the	O	O	I-Entity
formulation	O	O	I-Entity
was	O	O	O
estimated	O	O	O
at	O	O	O
about	O	O	O
3.48	O	O	O
%	O	O	O
after	O	O	O
48	O	O	O
h.	O	O	O
The	O	O	O
cytotoxicity	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
etoposide	O	O	B-Entity
NPs	O	O	I-Entity
on	O	O	O
T-47D	O	O	B-Entity
and	O	O	O
MCF-7	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
of	O	O	I-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
showed	O	O	O
higher	O	O	O
antitumor	O	O	B-Entity
activity	O	O	I-Entity
as	O	O	O
compared	O	O	O
with	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
free	O	O	B-Entity
drug	O	O	I-Entity
.	O	O	O

Liposome-based	O	O	B-Entity
NPs	O	O	I-Entity
may	O	O	O
hold	O	O	O
great	O	O	O
potential	O	O	O
as	O	O	O
a	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

-DOCSTART- (27511629)

The	O	O	O
Bindex	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
ultrasound	O	O	I-Entity
device	O	O	I-Entity
:	O	O	O
reliability	O	O	B-Entity
of	O	O	O
cortical	O	O	B-Entity
bone	O	O	I-Entity
thickness	O	O	B-Entity
measures	O	O	B-Entity
and	O	O	O
their	O	O	O
relationship	O	O	B-Entity
to	O	O	O
regional	O	O	B-Entity
bone	O	O	O
mineral	O	O	O
density	O	O	O

The	O	O	O
Bindex	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
quantitative	O	O	I-Entity
ultrasound	O	O	I-Entity
(	O	O	I-Entity
QUS	O	O	I-Entity
)	O	O	I-Entity
device	O	O	I-Entity
is	O	O	O
currently	O	O	O
available	O	O	O
and	O	O	O
this	O	O	O
study	O	O	B-Entity
analyzed	O	O	B-Entity
(	O	O	O
I	O	O	O
)	O	O	O
its	O	O	O
relative	O	O	B-Entity
and	O	O	O
absolute	O	O	B-Entity
intra-	O	O	B-Entity
and	O	O	I-Entity
inter-session	O	O	I-Entity
reliability	O	O	I-Entity
and	O	O	O
(	O	O	O
II	O	O	O
)	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
data	O	O	B-Entity
provided	O	O	O
by	O	O	O
Bindex(	O	O	B-Entity
®	O	O	I-Entity
)-QUS	O	O	I-Entity
and	O	O	O
the	O	O	O
bone	O	O	B-Entity
mineral	O	O	I-Entity
density	O	O	I-Entity
(	O	O	O
BMD	O	O	B-Entity
)	O	O	O
measured	O	O	B-Entity
by	O	O	O
dual-energy	O	O	B-Entity
x-ray	O	O	I-Entity
absorptiometry	O	O	I-Entity
at	O	O	O
corresponding	O	O	O
skeletal	O	O	B-Entity
sites	O	O	I-Entity
in	O	O	O
young	O	O	B-Entity
and	O	O	O
healthy	O	O	B-Entity
subjects	O	O	I-Entity
(	O	O	O
age	O	O	B-Entity
:	O	O	O
25.0	O	O	O
±	O	O	O
3.6	O	O	O
years	O	O	B-Entity
)	O	O	O
.	O	O	O

Bindex(	O	O	B-Entity
®	O	O	I-Entity
)-QUS	O	O	I-Entity
calculates	O	O	B-Entity
a	O	O	O
density	O	O	B-Entity
index	O	O	I-Entity
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
thickness	O	O	B-Entity
of	O	O	O
cortical	O	O	B-Entity
bone	O	O	I-Entity
measured	O	O	B-Entity
at	O	O	O
the	O	O	O
distal	O	O	B-Entity
radius	O	O	I-Entity
and	O	O	O
the	O	O	O
distal	O	O	O
plus	O	O	O
proximal	O	O	B-Entity
tibia	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
show	O	O	O
a	O	O	O
very	O	O	O
good	O	O	O
relative	O	O	B-Entity
and	O	O	O
absolute	O	O	B-Entity
intra-	O	O	B-Entity
(	O	O	O
ICC	O	O	B-Entity
=	O	O	O
0.977	O	O	O
,	O	O	O
CV	O	O	B-Entity
=	O	O	O
1.5	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
inter-session	O	O	B-Entity
reliability	O	O	I-Entity
(	O	O	O
ICC	O	O	O
=	O	O	O
0.978	O	O	O
,	O	O	O
CV	O	O	O
=	O	O	O
1.4	O	O	O
%	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
density	O	O	B-Entity
index	O	O	I-Entity
.	O	O	O

The	O	O	O
highest	O	O	B-Entity
positive	O	O	B-Entity
correlations	O	O	B-Entity
were	O	O	O
found	O	O	O
between	O	O	O
cortical	O	O	B-Entity
thickness	O	O	B-Entity
and	O	O	O
BMD	O	O	B-Entity
for	O	O	O
the	O	O	O
distal	O	O	B-Entity
radius	O	O	I-Entity
and	O	O	O
distal	O	O	B-Entity
tibia	O	O	I-Entity
(	O	O	O
r	O	O	O
⩾	O	O	O
0.71	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
indicate	O	O	O
that	O	O	O
the	O	O	O
Bindex(	O	O	B-Entity
®	O	O	I-Entity
)-QUS	O	O	I-Entity
parameters	O	O	B-Entity
are	O	O	O
repeatable	O	O	O
within	O	O	O
and	O	O	O
between	O	O	O
measurement	O	O	B-Entity
sessions	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
measurements	O	O	B-Entity
reflect	O	O	O
the	O	O	O
BMD	O	O	B-Entity
at	O	O	O
specific	O	O	B-Entity
skeletal	O	O	B-Entity
sites	O	O	I-Entity
.	O	O	O

Bindex(	O	O	B-Entity
®	O	O	I-Entity
)-QUS	O	O	I-Entity
might	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
tool	O	O	O
for	O	O	O
the	O	O	O
measurement	O	O	B-Entity
of	O	O	O
skeletal	O	O	B-Entity
adaptations	O	O	I-Entity
.	O	O	O

-DOCSTART- (27514242)

Botulinum	O	O	B-Entity
Toxin	O	O	I-Entity
Use	O	O	O
in	O	O	O
Refractory	O	O	B-Entity
Pain	O	O	I-Entity
and	O	O	O
Other	O	O	O
Symptoms	O	O	B-Entity
in	O	O	O
Parkinsonism	O	O	O

Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
and	O	O	O
other	O	O	O
parkinsonian	O	O	B-Entity
syndromes	O	O	I-Entity
are	O	O	O
chronic	O	O	B-Entity
,	O	O	O
progressive	O	O	B-Entity
neurodegenerative	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

With	O	O	O
advancing	O	O	O
disease	O	O	B-Entity
,	O	O	O
both	O	O	O
motor	O	O	B-Entity
and	O	O	O
non-motor	O	O	B-Entity
symptoms	O	O	I-Entity
represent	O	O	O
a	O	O	O
considerable	O	O	O
burden	O	O	B-Entity
and	O	O	O
symptom	O	O	B-Entity
relief	O	O	B-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
improvement	O	O	B-Entity
become	O	O	O
the	O	O	O
main	O	O	O
goal	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Botulinum	O	O	B-Entity
toxins	O	O	I-Entity
(	O	O	O
BTX	O	O	B-Entity
)	O	O	O
are	O	O	O
an	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
modality	O	O	B-Entity
for	O	O	O
many	O	O	O
neurological	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

To	O	O	O
understand	O	O	O
the	O	O	O
potential	O	O	B-Entity
usefulness	O	O	B-Entity
of	O	O	O
BTX	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
,	O	O	O
we	O	O	O
performed	O	O	B-Entity
a	O	O	O
retrospective	O	O	B-Entity
chart	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
all	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
clinical	O	O	B-Entity
diagnosis	O	O	I-Entity
of	O	O	O
idiopathic	O	O	B-Entity
PD	O	O	I-Entity
and	O	O	O
atypical	O	O	B-Entity
parkinsonism	O	O	I-Entity
who	O	O	O
received	O	O	O
treatment	O	O	B-Entity
with	O	O	O
BTX	O	O	B-Entity
injections	O	O	I-Entity
in	O	O	O
our	O	O	O
center	O	O	B-Entity
from	O	O	O
1995	O	O	O
to	O	O	O
2014	O	O	O
for	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
symptoms	O	O	B-Entity
.	O	O	O

Response	O	O	B-Entity
to	O	O	O
BTX	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
a	O	O	O
subjective	O	O	B-Entity
Clinical	O	O	I-Entity
Global	O	O	I-Entity
Impression	O	O	I-Entity
.	O	O	O

Records	O	O	B-Entity
of	O	O	O
160	O	O	O
patients	O	O	B-Entity
were	O	O	O
reviewed	O	O	B-Entity
.	O	O	O

Probable	O	O	O
idiopathic	O	O	B-Entity
PD	O	O	I-Entity
was	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
in	O	O	O
117	O	O	O
patients	O	O	B-Entity
(	O	O	O
73.1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
indication	O	O	B-Entity
for	O	O	O
BTX	O	O	B-Entity
treatment	O	O	B-Entity
was	O	O	O
pain	O	O	B-Entity
(	O	O	O
50.6	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	O
)	O	O	O
.	O	O	O

Other	O	O	O
indications	O	O	B-Entity
were	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
functional	O	O	B-Entity
impairment	O	O	I-Entity
resulting	O	O	B-Entity
from	O	O	O
dystonia	O	O	B-Entity
(	O	O	O
26.25	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
sialorrhea	O	O	B-Entity
(	O	O	O
18.75	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
freezing	O	O	B-Entity
of	O	O	I-Entity
gait	O	O	I-Entity
,	O	O	O
and	O	O	O
camptocormia	O	O	B-Entity
.	O	O	O

Considering	O	O	O
pain	O	O	B-Entity
as	O	O	O
indication	O	O	B-Entity
,	O	O	O
81	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
patients	O	O	B-Entity
with	O	O	O
PD	O	O	B-Entity
reported	O	O	B-Entity
benefits	O	O	B-Entity
after	O	O	O
the	O	O	O
first	O	O	O
BTX	O	O	B-Entity
injections	O	O	I-Entity
.	O	O	O

This	O	O	O
benefit	O	O	B-Entity
was	O	O	O
maintained	O	O	B-Entity
after	O	O	O
the	O	O	O
last	O	O	B-Entity
recorded	O	O	I-Entity
visit	O	O	I-Entity
without	O	O	O
significant	O	O	O
difference	O	O	B-Entity
in	O	O	O
outcome	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
first	O	O	O
injection	O	O	B-Entity
(	O	O	O
p=0.067	O	O	O
)	O	O	O
.	O	O	O

Similar	O	O	O
results	O	O	B-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
atypical	O	O	B-Entity
parkinsonism	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
confirm	O	O	O
the	O	O	O
safety	O	O	O
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
different	O	O	B-Entity
uses	O	O	B-Entity
of	O	O	O
BTX	O	O	B-Entity
in	O	O	O
the	O	O	O
symptomatic	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
parkinsonism	O	O	B-Entity
even	O	O	O
in	O	O	O
advanced	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
,	O	O	O
and	O	O	O
suggest	O	O	B-Entity
BTX	O	O	O
treatment	O	O	O
could	O	O	O
have	O	O	O
a	O	O	O
safe	O	O	O
and	O	O	O
useful	O	O	O
role	O	O	B-Entity
in	O	O	O
the	O	O	O
treatment	O	O	O
of	O	O	O
pain	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

-DOCSTART- (27516217)

Chronic	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	I-Entity
haloperidol	O	O	B-Entity
and	O	O	O
olanzapine	O	O	B-Entity
leads	O	O	O
to	O	O	O
common	O	O	O
and	O	O	O
divergent	O	O	O
shape	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
the	O	O	O
rat	O	O	B-Entity
hippocampus	O	O	B-Entity
in	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
grey-matter	O	O	B-Entity
volume	O	O	O
loss	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
consistently	O	O	O
reported	O	O	O
brain	O	O	B-Entity
abnormalities	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
(	O	O	O
SCZ	O	O	B-Entity
)	O	O	O
is	O	O	O
decreased	O	O	O
volume	O	O	B-Entity
and	O	O	I-Entity
shape	O	O	I-Entity
deformation	O	O	I-Entity
of	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
potential	O	O	O
contribution	O	O	O
of	O	O	O
chronic	O	O	B-Entity
antipsychotic	O	O	I-Entity
medication	O	O	I-Entity
exposure	O	O	B-Entity
to	O	O	O
these	O	O	O
phenomena	O	O	O
remains	O	O	O
unclear	O	O	O
.	O	O	O

We	O	O	O
examined	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
chronic	O	O	B-Entity
exposure	O	O	I-Entity
(	O	O	O
8	O	O	O
weeks	O	O	O
)	O	O	O
to	O	O	O
clinically	O	O	O
relevant	O	O	B-Entity
doses	O	O	I-Entity
of	O	O	O
either	O	O	O
haloperidol	O	O	B-Entity
(	O	O	O
HAL	O	O	B-Entity
)	O	O	O
or	O	O	O
olanzapine	O	O	B-Entity
(	O	O	O
OLZ	O	O	B-Entity
)	O	O	O
on	O	O	O
adult	O	O	O
rat	O	O	B-Entity
hippocampal	O	O	B-Entity
volume	O	O	B-Entity
and	O	O	I-Entity
shape	O	O	I-Entity
using	O	O	O
ex	O	O	B-Entity
vivo	O	O	I-Entity
structural	O	O	B-Entity
MRI	O	O	I-Entity
with	O	O	O
the	O	O	O
brain	O	O	B-Entity
retained	O	O	I-Entity
inside	O	O	I-Entity
the	O	O	I-Entity
cranium	O	O	I-Entity
to	O	O	O
prevent	O	O	O
distortions	O	O	B-Entity
due	O	O	O
to	O	O	O
dissection	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
tensor-based	O	O	B-Entity
morphometry	O	O	I-Entity
(	O	O	O
TBM	O	O	B-Entity
)	O	O	O
and	O	O	O
elastic	O	O	B-Entity
surface-based	O	O	I-Entity
shape	O	O	I-Entity
deformation	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

The	O	O	O
volume	O	O	O
of	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
was	O	O	O
also	O	O	O
measured	O	O	O
post-mortem	O	O	B-Entity
from	O	O	O
brain	O	O	B-Entity
tissue	O	O	I-Entity
sections	O	O	O
in	O	O	O
each	O	O	O
group	O	O	O
.	O	O	O

Chronic	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	O
either	O	O	O
HAL	O	O	B-Entity
or	O	O	O
OLZ	O	O	B-Entity
had	O	O	O
no	O	O	O
effect	O	O	O
on	O	O	O
the	O	O	O
volume	O	O	O
of	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
,	O	O	O
even	O	O	O
at	O	O	O
exploratory	O	O	B-Entity
thresholds	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
confirmed	O	O	O
post-mortem	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
shape	O	O	B-Entity
deformation	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
chronic	O	O	O
HAL	O	O	B-Entity
and	O	O	O
OLZ	O	O	B-Entity
exposure	O	O	B-Entity
lead	O	O	O
to	O	O	O
both	O	O	O
common	O	O	O
and	O	O	O
divergent	O	O	B-Entity
shape	O	O	I-Entity
deformations	O	O	I-Entity
(	O	O	O
q	O	O	O
=	O	O	O
0.05	O	O	O
,	O	O	O
FDR-corrected	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
rat	O	O	B-Entity
hippocampus	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
dorsal	O	O	B-Entity
hippocampus	O	O	I-Entity
,	O	O	O
HAL	O	O	B-Entity
exposure	O	O	B-Entity
led	O	O	O
to	O	O	O
inward	O	O	B-Entity
shape	O	O	I-Entity
deformation	O	O	I-Entity
,	O	O	O
whereas	O	O	O
OLZ	O	O	B-Entity
exposure	O	O	O
led	O	O	O
to	O	O	O
outward	O	O	B-Entity
shape	O	O	I-Entity
deformation	O	O	I-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
outward	O	O	B-Entity
shape	O	O	I-Entity
deformations	O	O	I-Entity
that	O	O	O
were	O	O	O
common	O	O	O
to	O	O	O
both	O	O	O
drugs	O	O	B-Entity
occurred	O	O	O
in	O	O	O
the	O	O	O
ventral	O	O	B-Entity
hippocampus	O	O	I-Entity
.	O	O	O

These	O	O	O
effects	O	O	O
remained	O	O	O
significant	O	O	O
after	O	O	O
controlling	O	O	O
for	O	O	O
hippocampal	O	O	B-Entity
volume	O	O	O
suggesting	O	O	O
true	O	O	O
shape	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

Chronic	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	O
either	O	O	O
HAL	O	O	B-Entity
or	O	O	O
OLZ	O	O	B-Entity
leads	O	O	O
to	O	O	O
both	O	O	O
common	O	O	O
and	O	O	O
divergent	O	O	O
effects	O	O	O
on	O	O	O
rat	O	O	B-Entity
hippocampal	O	O	B-Entity
shape	O	O	I-Entity
in	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
volume	O	O	O
change	O	O	O
.	O	O	O

The	O	O	O
implications	O	O	O
of	O	O	O
these	O	O	O
findings	O	O	O
for	O	O	O
the	O	O	O
clinic	O	O	O
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27516254)

Shear	O	O	B-Entity
and	O	O	O
extensional	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
kefiran	O	O	O

Kefiran	O	O	B-Entity
is	O	O	O
a	O	O	O
neutral	O	O	B-Entity
polysaccharide	O	O	I-Entity
constituted	O	O	O
by	O	O	O
glucose	O	O	B-Entity
and	O	O	O
galactose	O	O	B-Entity
produced	O	O	O
by	O	O	O
Lactobacillus	O	O	B-Entity
kefiranofaciens	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
included	O	O	O
into	O	O	O
kefir	O	O	B-Entity
grains	O	O	I-Entity
and	O	O	O
has	O	O	O
several	O	O	O
health	O	O	B-Entity
promoting	O	O	I-Entity
properties	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
work	O	O	O
,	O	O	O
shear	O	O	B-Entity
and	O	O	O
extensional	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
different	O	O	B-Entity
kefiran	O	O	B-Entity
aqueous	O	O	B-Entity
dispersions	O	O	I-Entity
(	O	O	O
0.5	O	O	O
,	O	O	O
1	O	O	O
and	O	O	O
2	O	O	O
%	O	O	O
wt	O	O	O
.	O	O	O
)	O	O	O
were	O	O	O
assessed	O	O	B-Entity
and	O	O	O
compared	O	O	B-Entity
to	O	O	O
other	O	O	O
neutral	O	O	B-Entity
gums	O	O	I-Entity
commonly	O	O	O
used	O	O	O
in	O	O	O
food	O	O	B-Entity
,	O	O	O
cosmetic	O	O	B-Entity
and	O	O	O
pharmaceutics	O	O	B-Entity
industries	O	O	I-Entity
(	O	O	O
methylcellulose	O	O	B-Entity
,	O	O	O
locust	O	O	B-Entity
bean	O	O	I-Entity
gum	O	O	I-Entity
and	O	O	O
guar	O	O	B-Entity
gum	O	O	I-Entity
)	O	O	O
.	O	O	O

Kefiran	O	O	B-Entity
showed	O	O	O
shear	O	O	B-Entity
flow	O	O	I-Entity
characteristics	O	O	I-Entity
similar	O	O	O
to	O	O	O
that	O	O	O
displayed	O	O	O
by	O	O	O
other	O	O	O
representative	O	O	O
neutral	O	O	B-Entity
gums	O	O	I-Entity
,	O	O	O
although	O	O	O
it	O	O	O
always	O	O	O
yielded	O	O	O
lower	O	O	B-Entity
viscosities	O	O	B-Entity
at	O	O	O
a	O	O	O
given	O	O	O
concentration	O	O	B-Entity
.	O	O	O

For	O	O	O
each	O	O	O
gum	O	O	B-Entity
system	O	O	B-Entity
it	O	O	O
was	O	O	O
possible	O	O	O
to	O	O	O
find	O	O	O
a	O	O	O
correlation	O	O	B-Entity
between	O	O	O
dynamic	O	O	B-Entity
and	O	O	I-Entity
steady	O	O	I-Entity
shear	O	O	I-Entity
properties	O	O	I-Entity
by	O	O	O
a	O	O	O
master	O	O	B-Entity
curve	O	O	I-Entity
including	O	O	O
both	O	O	O
the	O	O	O
apparent	O	O	B-Entity
and	O	O	O
complex	O	O	B-Entity
viscosities	O	O	B-Entity
.	O	O	O

When	O	O	O
studying	O	O	O
extensional	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
selected	O	O	O
gums	O	O	B-Entity
at	O	O	O
2	O	O	O
%	O	O	O
wt	O	O	O
.	O	O	O

by	O	O	O
means	O	O	O
of	O	O	O
a	O	O	O
capillary	O	O	B-Entity
break-up	O	O	I-Entity
rheometer	O	O	I-Entity
,	O	O	O
kefiran	O	O	B-Entity
solutions	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
important	O	O	O
extensional	O	O	B-Entity
properties	O	O	I-Entity
,	O	O	O
displaying	O	O	O
a	O	O	O
behaviour	O	O	B-Entity
close	O	O	O
the	O	O	O
Newtonian	O	O	B-Entity
.	O	O	O

-DOCSTART- (27516791)

Air	O	O	B-Entity
tamponade	O	O	B-Entity
of	O	O	O
the	O	O	O
heart	O	O	O

Pneumopericardium	O	O	B-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
defined	O	O	O
as	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
or	O	O	O
gas	O	O	B-Entity
in	O	O	O
the	O	O	O
pericardial	O	O	B-Entity
sac	O	O	I-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
etiological	O	O	B-Entity
factors	O	O	B-Entity
,	O	O	O
the	O	O	O
following	O	O	O
stand	O	O	O
out	O	O	O
:	O	O	O
chest	O	O	B-Entity
trauma	O	O	I-Entity
,	O	O	O
barotrauma	O	O	B-Entity
,	O	O	O
air	O	O	B-Entity
-containing	O	O	O
fistulas	O	O	B-Entity
between	O	O	O
the	O	O	O
pericardium	O	O	B-Entity
and	O	O	O
the	O	O	O
surrounding	O	O	B-Entity
structures	O	O	B-Entity
,	O	O	O
secondary	O	O	B-Entity
gas	O	O	I-Entity
production	O	O	I-Entity
by	O	O	O
microorganisms	O	O	B-Entity
growing	O	O	O
in	O	O	O
the	O	O	O
pericardial	O	O	B-Entity
sac	O	O	I-Entity
,	O	O	O
and	O	O	O
iatrogenic	O	O	B-Entity
factors	O	O	O
.	O	O	O

Until	O	O	O
now	O	O	O
,	O	O	O
spontaneous	O	O	B-Entity
pneumopericardium	O	O	B-Entity
has	O	O	O
been	O	O	O
considered	O	O	B-Entity
a	O	O	O
harmless	O	O	B-Entity
and	O	O	O
temporary	O	O	B-Entity
state	O	O	B-Entity
,	O	O	O
but	O	O	O
a	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
clinical	O	O	B-Entity
cases	O	O	I-Entity
indicates	O	O	O
that	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
in	O	O	O
the	O	O	O
pericardium	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
cardiac	O	O	B-Entity
tamponade	O	O	I-Entity
and	O	O	O
life-threatening	O	O	B-Entity
hemodynamic	O	O	B-Entity
disturbances	O	O	B-Entity
.	O	O	O

We	O	O	O
present	O	O	B-Entity
the	O	O	O
case	O	O	O
of	O	O	O
an	O	O	O
80-	O	O	O
year-old	O	O	B-Entity
patient	O	O	B-Entity
with	O	O	O
a	O	O	O
chronic	O	O	B-Entity
bronchopericardial	O	O	B-Entity
fistula	O	O	B-Entity
,	O	O	O
who	O	O	O
suffered	O	O	O
from	O	O	O
a	O	O	O
cardiac	O	O	B-Entity
arrest	O	O	I-Entity
due	O	O	O
to	O	O	O
air	O	O	B-Entity
tamponade	O	O	B-Entity
of	O	O	O
the	O	O	O
heart	O	O	B-Entity
.	O	O	O

-DOCSTART- (27517885)

The	O	O	O
Complete	O	O	B-Entity
Chloroplast	O	O	B-Entity
Genome	O	O	I-Entity
Sequence	O	O	B-Entity
of	O	O	O
the	O	O	O
Medicinal	O	O	B-Entity
Plant	O	O	I-Entity
Swertia	O	O	B-Entity
mussotii	O	O	I-Entity
Using	O	O	O
the	O	O	O
PacBio	O	O	O
RS	O	O	O
II	O	O	O
Platform	O	O	O

Swertia	O	O	B-Entity
mussotii	O	O	I-Entity
is	O	O	O
an	O	O	O
important	O	O	O
medicinal	O	O	B-Entity
plant	O	O	I-Entity
that	O	O	O
has	O	O	O
great	O	O	B-Entity
economic	O	O	B-Entity
and	O	O	O
medicinal	O	O	B-Entity
value	O	O	I-Entity
and	O	O	O
is	O	O	O
found	O	O	O
on	O	O	O
the	O	O	O
Qinghai	O	O	B-Entity
Tibetan	O	O	I-Entity
Plateau	O	O	I-Entity
.	O	O	O

The	O	O	O
complete	O	O	B-Entity
chloroplast	O	O	B-Entity
(	O	O	I-Entity
cp	O	O	I-Entity
)	O	O	I-Entity
genome	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
mussotii	O	O	I-Entity
is	O	O	O
153,431	O	O	O
bp	O	O	O
in	O	O	O
size	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
pair	O	O	B-Entity
of	O	O	O
inverted	O	O	B-Entity
repeat	O	O	I-Entity
(	O	O	I-Entity
IR	O	O	I-Entity
)	O	O	I-Entity
regions	O	O	I-Entity
of	O	O	O
25,761	O	O	O
bp	O	O	O
each	O	O	O
that	O	O	O
separate	O	O	B-Entity
an	O	O	O
large	O	O	B-Entity
single-copy	O	O	I-Entity
(	O	O	I-Entity
LSC	O	O	I-Entity
)	O	O	I-Entity
region	O	O	I-Entity
of	O	O	O
83,567	O	O	O
bp	O	O	O
and	O	O	O
an	O	O	O
a	O	O	O
small	O	O	B-Entity
single-copy	O	O	I-Entity
(	O	O	I-Entity
SSC	O	O	I-Entity
)	O	O	I-Entity
region	O	O	I-Entity
of	O	O	O
18,342	O	O	O
bp	O	O	O
.	O	O	O

The	O	O	O
S.	O	O	B-Entity
mussotii	O	O	I-Entity
cp	O	O	B-Entity
genome	O	O	I-Entity
encodes	O	O	B-Entity
84	O	O	O
protein-coding	O	O	B-Entity
genes	O	O	B-Entity
,	O	O	O
37	O	O	O
transfer	O	O	B-Entity
RNA	O	O	I-Entity
(	O	O	O
tRNA	O	O	B-Entity
)	O	O	O
genes	O	O	O
,	O	O	O
and	O	O	O
eight	O	O	O
ribosomal	O	O	B-Entity
RNA	O	O	I-Entity
(	O	O	I-Entity
rRNA	O	O	I-Entity
)	O	O	I-Entity
genes	O	O	I-Entity
.	O	O	O

The	O	O	O
identity	O	O	O
,	O	O	O
number	O	O	O
,	O	O	O
and	O	O	O
GC	O	O	B-Entity
content	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
mussotii	O	O	I-Entity
cp	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
genomes	O	O	B-Entity
of	O	O	O
other	O	O	O
Gentianales	O	O	B-Entity
species	O	O	B-Entity
.	O	O	O

Via	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
repeat	O	O	B-Entity
structure	O	O	I-Entity
,	O	O	O
11	O	O	O
forward	O	O	O
repeats	O	O	B-Entity
,	O	O	O
eight	O	O	O
palindromic	O	O	B-Entity
repeats	O	O	I-Entity
,	O	O	O
and	O	O	O
one	O	O	O
reverse	O	O	O
repeat	O	O	O
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
the	O	O	O
S.	O	O	B-Entity
mussotii	O	O	I-Entity
cp	O	O	B-Entity
genome	O	O	I-Entity
.	O	O	O

There	O	O	O
are	O	O	O
45	O	O	O
SSRs	O	O	B-Entity
in	O	O	O
the	O	O	O
S.	O	O	B-Entity
mussotii	O	O	I-Entity
cp	O	O	B-Entity
genome	O	O	I-Entity
,	O	O	O

the	O	O	O
majority	O	O	B-Entity
of	O	O	O
which	O	O	O
are	O	O	O
mononucleotides	O	O	B-Entity
found	O	O	O
in	O	O	O
all	O	O	O
other	O	O	O
Gentianales	O	O	B-Entity
species	O	O	B-Entity
.	O	O	O

An	O	O	O
entire	O	O	B-Entity
cp	O	O	B-Entity
genome	O	O	I-Entity
comparison	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
mussotii	O	O	I-Entity
and	O	O	O
two	O	O	O
other	O	O	O
species	O	O	B-Entity
in	O	O	O
Gentianaceae	O	O	B-Entity
was	O	O	O
conducted	O	O	O
.	O	O	O

The	O	O	O
complete	O	O	B-Entity
cp	O	O	B-Entity
genome	O	O	I-Entity
sequence	O	O	B-Entity
provides	O	O	O
intragenic	O	O	B-Entity
information	O	O	B-Entity
for	O	O	O
the	O	O	O
cp	O	O	O
genetic	O	O	B-Entity
engineering	O	O	I-Entity
of	O	O	O
this	O	O	O
medicinal	O	O	B-Entity
plant	O	O	I-Entity
.	O	O	O

-DOCSTART- (27519886)

Meta-Analysis	O	O	B-Entity
of	O	O	O
29	O	O	O
Experiments	O	O	B-Entity
Evaluating	O	O	B-Entity
the	O	O	O
Effects	O	O	B-Entity
of	O	O	I-Entity
Rapamycin	O	O	B-Entity
on	O	O	O
Life	O	O	B-Entity
Span	O	O	I-Entity
in	O	O	O
the	O	O	O
Laboratory	O	O	O
Mouse	O	O	O

Rapamycin	O	O	B-Entity
has	O	O	O
favorable	O	O	O
effects	O	O	B-Entity
on	O	O	O
aging	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
and	O	O	O
may	O	O	O
eventually	O	O	O
be	O	O	O
applied	O	O	B-Entity
to	O	O	O
encourage	O	O	O
"	O	O	O
healthy	O	O	B-Entity
aging	O	O	O
"	O	O	O
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
analyzed	O	O	B-Entity
raw	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
29	O	O	O
survival	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
rapamycin	O	O	B-Entity
-	O	O	O
and	O	O	O
control	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
goals	O	O	B-Entity
of	O	O	O
estimating	O	O	B-Entity
summary	O	O	B-Entity
statistics	O	O	B-Entity
and	O	O	O
identifying	O	O	B-Entity
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
effect	O	O	B-Entity
size	O	O	I-Entity
heterogeneity	O	O	B-Entity
.	O	O	O

Meta-analysis	O	O	B-Entity
demonstrated	O	O	B-Entity
significant	O	O	B-Entity
heterogeneity	O	O	B-Entity
across	O	O	O
studies	O	O	B-Entity
,	O	O	O
with	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	B-Entity
HR	O	O	I-Entity
)	O	O	I-Entity
estimates	O	O	B-Entity
ranging	O	O	B-Entity
from	O	O	O
0.22	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	B-Entity
CI	O	O	B-Entity
]	O	O	I-Entity
:	O	O	O
0.06	O	O	O
-	O	O	O
0.82	O	O	O
)	O	O	O
to	O	O	O
0.92	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.65	O	O	O
-	O	O	O
1.28	O	O	O
)	O	O	O
.	O	O	O

Sex	O	O	B-Entity
was	O	O	O
the	O	O	O
major	O	O	B-Entity
factor	O	O	B-Entity
accounting	O	O	B-Entity
for	O	O	O
effect	O	O	B-Entity
size	O	O	I-Entity
variation	O	O	B-Entity
,	O	O	O
and	O	O	O
mortality	O	O	B-Entity
was	O	O	O
decreased	O	O	B-Entity
more	O	O	B-Entity
in	O	O	O
females	O	O	B-Entity
(	O	O	O
HR	O	O	B-Entity
=	O	O	O
0.41	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.35	O	O	O
-	O	O	O
0.48	O	O	O
)	O	O	O
as	O	O	O
compared	O	O	B-Entity
with	O	O	O
males	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
0.63	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.55	O	O	O
-	O	O	O
0.71	O	O	O
)	O	O	O
.	O	O	O

Rapamycin	O	O	B-Entity
effects	O	O	B-Entity
were	O	O	O
also	O	O	O
genotype	O	O	B-Entity
dependent	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
with	O	O	O
stronger	O	O	B-Entity
survivorship	O	O	B-Entity
increases	O	O	B-Entity
in	O	O	O
hybrid	O	O	B-Entity
mice	O	O	B-Entity
(	O	O	O
14.4	O	O	O
%	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
12.5	O	O	O
-	O	O	O
16.3	O	O	O
%	O	O	O
)	O	O	O
relative	O	O	B-Entity
to	O	O	O
pure	O	O	B-Entity
inbred	O	O	B-Entity
strains	O	O	I-Entity
(	O	O	O
8.8	O	O	O
%	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
6.2	O	O	O
-	O	O	O
11.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Number	O	O	B-Entity
needed	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
was	O	O	O
applied	O	O	B-Entity
as	O	O	O
an	O	O	O
effect	O	O	B-Entity
size	O	O	I-Entity
metric	O	O	B-Entity
,	O	O	O
which	O	O	O
consistently	O	O	O
identified	O	O	B-Entity
early	O	O	O
senescence	O	O	B-Entity
as	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
peak	O	O	B-Entity
treatment	O	O	B-Entity
benefit	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
provide	O	O	B-Entity
synthesis	O	O	B-Entity
of	O	O	O
existing	O	O	B-Entity
data	O	O	B-Entity
to	O	O	O
support	O	O	B-Entity
the	O	O	O
potential	O	O	O
translation	O	O	B-Entity
of	O	O	O
findings	O	O	B-Entity
from	O	O	O
mouse	O	O	B-Entity
to	O	O	O
primate	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

Because	O	O	O
rapamycin	O	O	B-Entity
's	O	O	I-Entity
effect	O	O	B-Entity
on	O	O	O
survival	O	O	B-Entity
depends	O	O	B-Entity
on	O	O	O
sex	O	O	B-Entity
and	O	O	O
genotype	O	O	B-Entity
,	O	O	O
further	O	O	O
work	O	O	O
is	O	O	O
justified	O	O	O
to	O	O	O
understand	O	O	O
how	O	O	O
these	O	O	O
factors	O	O	B-Entity
shape	O	O	O
treatment	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

-DOCSTART- (27521864)

Transfusion	O	O	B-Entity
medicine	O	O	I-Entity
in	O	O	O
medical	O	O	B-Entity
education	O	O	I-Entity
:	O	O	O
an	O	O	O
analysis	O	O	B-Entity
of	O	O	O
curricular	O	O	B-Entity
grids	O	O	I-Entity
in	O	O	O
Brazil	O	O	B-Entity
and	O	O	O
a	O	O	O
review	O	O	B-Entity
of	O	O	O
the	O	O	O
current	O	O	O
literature	O	O	O

Blood	O	O	B-Entity
transfusions	O	O	I-Entity
are	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
performed	O	O	O
medical	O	O	B-Entity
procedures	O	O	I-Entity
in	O	O	O
the	O	O	O
world	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
as	O	O	O
education	O	O	B-Entity
in	O	O	O
transfusion	O	O	B-Entity
medicine	O	O	I-Entity
is	O	O	O
vital	O	O	B-Entity
to	O	O	O
medical	O	O	B-Entity
care	O	O	I-Entity
,	O	O	O
it	O	O	O
should	O	O	O
aim	O	O	O
to	O	O	O
promote	O	O	B-Entity
a	O	O	O
responsible	O	O	O
practice	O	O	B-Entity
with	O	O	O
the	O	O	O
rational	O	O	O
use	O	O	O
of	O	O	O
blood	O	O	B-Entity
by	O	O	O
doctors	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aims	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
situation	O	O	O
of	O	O	O
the	O	O	O
teaching	O	O	B-Entity
of	O	O	O
transfusion	O	O	B-Entity
medicine	O	O	I-Entity
in	O	O	O
medical	O	O	B-Entity
schools	O	O	I-Entity
in	O	O	O
Brazil	O	O	B-Entity
.	O	O	O

The	O	O	O
websites	O	O	B-Entity
of	O	O	O
the	O	O	O
249	O	O	O
Brazilian	O	O	B-Entity
medical	O	O	B-Entity
schools	O	O	I-Entity
in	O	O	O
operation	O	O	B-Entity
in	O	O	O
June	O	O	O
2015	O	O	O
were	O	O	O
visited	O	O	O
and	O	O	O
the	O	O	O
curricula	O	O	B-Entity
of	O	O	O
the	O	O	O
medical	O	O	B-Entity
courses	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
in	O	O	O
respect	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	O
or	O	O	O
absence	O	O	O
of	O	O	O
a	O	O	O
transfusion	O	O	B-Entity
medicine	O	O	I-Entity
discipline	O	O	I-Entity
.	O	O	O

When	O	O	O
available	O	O	O
,	O	O	O
the	O	O	O
subject	O	O	O
grids	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
to	O	O	O
verify	O	O	O
whether	O	O	O
a	O	O	O
description	O	O	B-Entity
of	O	O	I-Entity
content	O	O	I-Entity
regarding	O	O	O
transfusion	O	O	B-Entity
medicine	O	O	I-Entity
was	O	O	O
given	O	O	O
within	O	O	O
other	O	O	O
disciplines	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
249	O	O	O
medical	O	O	B-Entity
school	O	O	I-Entity
sites	O	O	O
visited	O	O	O
,	O	O	O
information	O	O	B-Entity
on	O	O	O
the	O	O	O
curriculum	O	O	B-Entity
was	O	O	O
obtained	O	O	O
from	O	O	O
178	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
medical	O	O	B-Entity
schools	O	O	I-Entity
that	O	O	O
published	O	O	B-Entity
their	O	O	O
curriculum	O	O	B-Entity
,	O	O	O
132	O	O	O
(	O	O	O
74.1	O	O	O
%	O	O	O
)	O	O	O
did	O	O	O
not	O	O	O
have	O	O	O
disciplines	O	O	B-Entity
of	O	O	I-Entity
transfusion	O	O	I-Entity
medicine	O	O	I-Entity
or	O	O	O
hematology	O	O	B-Entity
and	O	O	O
only	O	O	O
seven	O	O	O
(	O	O	O
3.9	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
discipline	O	O	B-Entity
of	O	O	I-Entity
transfusion	O	O	I-Entity
medicine	O	O	I-Entity
in	O	O	O
the	O	O	O
curricular	O	O	B-Entity
grid	O	O	I-Entity
.	O	O	O

Education	O	O	B-Entity
on	O	O	O
transfusion	O	O	B-Entity
medicine	O	O	I-Entity
is	O	O	O
of	O	O	O
fundamental	O	O	B-Entity
importance	O	O	I-Entity
for	O	O	O
safe	O	O	B-Entity
and	O	O	I-Entity
efficient	O	O	I-Entity
transfusion	O	O	I-Entity
practices	O	O	I-Entity
.	O	O	O

Deficiencies	O	O	B-Entity
in	O	O	O
medical	O	O	B-Entity
knowledge	O	O	B-Entity
of	O	O	O
this	O	O	O
subject	O	O	O
have	O	O	O
been	O	O	O
found	O	O	O
worldwide	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
indicate	O	O	O
a	O	O	O
possible	O	O	O
deficiency	O	O	B-Entity
in	O	O	O
teaching	O	O	B-Entity
the	O	O	O
basics	O	O	B-Entity
of	O	O	O
this	O	O	O
specialty	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
additional	O	O	O
prospective	O	O	B-Entity
studies	O	O	I-Entity
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
knowledge	O	O	B-Entity
and	O	O	O
practice	O	O	O
of	O	O	O
transfusion	O	O	B-Entity
medicine	O	O	I-Entity
in	O	O	O
Brazilian	O	O	B-Entity
medical	O	O	B-Entity
schools	O	O	I-Entity
are	O	O	O
warranted	O	O	O
,	O	O	O
which	O	O	O
could	O	O	O
prompt	O	O	O
a	O	O	O
discussion	O	O	O
on	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
offering	O	O	O
training	O	O	B-Entity
in	O	O	O
transfusion	O	O	O
medicine	O	O	O
to	O	O	O
medical	O	O	B-Entity
students	O	O	I-Entity
.	O	O	O

-DOCSTART- (27524031)

Advanced	O	O	B-Entity
interlocking	O	O	B-Entity
systems	O	O	I-Entity
to	O	O	O
improve	O	O	B-Entity
heavy	O	O	B-Entity
-	O	O	O
load-bearing	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
flexible	O	O	B-Entity
intramedullary	O	O	O
nailing	O	O	O

Flexible	O	O	B-Entity
intramedullary	O	O	B-Entity
nailing	O	O	I-Entity
(	O	O	O
FIN	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
and	O	O	O
widespread	O	O	B-Entity
standard	O	O	B-Entity
method	O	O	B-Entity
for	O	O	O
osteosynthesis	O	O	B-Entity
of	O	O	O
pediatric	O	O	B-Entity
long	O	O	B-Entity
bone	O	O	I-Entity
fractures	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
case	O	O	O
of	O	O	O
unstable	O	O	B-Entity
fractures	O	O	I-Entity
of	O	O	O
the	O	O	O
lower	O	O	B-Entity
extremity	O	O	I-Entity
,	O	O	O
interlocking	O	O	B-Entity
systems	O	O	I-Entity
need	O	O	O
to	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
prevent	O	O	O
axial	O	O	B-Entity
shortening	O	O	B-Entity
and	O	O	O
subsequent	O	O	B-Entity
perforation	O	O	B-Entity
of	O	O	O
the	O	O	O
nail	O	O	B-Entity
at	O	O	O
its	O	O	O
insertion	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
four	O	O	O
different	O	O	O
screw	O	O	B-Entity
-fixed	O	O	O
interlocking	O	O	B-Entity
systems	O	O	I-Entity
for	O	O	O
FINs	O	O	B-Entity
(	O	O	O
Hofer	O	O	B-Entity
TwinPlug	O	O	I-Entity
with	O	O	O
two	O	O	O
3-mm	O	O	O
titanium	O	O	B-Entity
interlocking	O	O	B-Entity
screws	O	O	I-Entity
,	O	O	O
Hofer	O	O	B-Entity
FixPlug	O	O	I-Entity
with	O	O	O
3-mm	O	O	O
titanium	O	O	O
interlocking	O	O	B-Entity
screw	O	O	I-Entity
,	O	O	O
Hofer	O	O	B-Entity
Plug	O	O	I-Entity
with	O	O	O
3.5-mm	O	O	O
titanium	O	O	O
interlocking	O	O	O
screw	O	O	O
,	O	O	O
and	O	O	O
Hofer	O	O	O
Plug	O	O	O
with	O	O	O
3-mm	O	O	O
titanium	O	O	O
interlocking	O	O	O
screw	O	O	O
)	O	O	O
in	O	O	O
comparison	O	O	B-Entity
with	O	O	O
the	O	O	O
commonly	O	O	O
used	O	O	O
Ender	O	O	O
stainless	O	O	B-Entity
steel	O	O	I-Entity
nails	O	O	B-Entity
(	O	O	O
locked	O	O	O
with	O	O	O
3.5-mm	O	O	O
screw	O	O	O
)	O	O	O
were	O	O	O
experimentally	O	O	B-Entity
investigated	O	O	I-Entity
in	O	O	O
cadaveric	O	O	B-Entity
lamb	O	O	B-Entity
tibiae	O	O	B-Entity
,	O	O	O
regarding	O	O	O
their	O	O	O
load	O	O	B-Entity
characteristics	O	O	B-Entity
and	O	O	O
failure	O	O	B-Entity
modes	O	O	B-Entity
in	O	O	O
the	O	O	O
case	O	O	O
of	O	O	O
heavy	O	O	B-Entity
loading	O	O	B-Entity
.	O	O	O

The	O	O	O
specimens	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
sequential	O	O	B-Entity
axial	O	O	B-Entity
cyclic	O	O	B-Entity
loading	O	O	B-Entity
of	O	O	O
5000	O	O	O
cycles	O	O	B-Entity
with	O	O	O
stepwise	O	O	B-Entity
increase	O	O	I-Entity
of	O	O	O
the	O	O	O
load	O	O	B-Entity
amplitude	O	O	B-Entity
until	O	O	O
failure	O	O	B-Entity
.	O	O	O

Migration	O	O	B-Entity
of	O	O	O
locking	O	O	B-Entity
screws	O	O	I-Entity
and	O	O	O
internal	O	O	B-Entity
damage	O	O	B-Entity
of	O	O	O
bone	O	O	B-Entity
tissue	O	O	I-Entity
was	O	O	O
quantified	O	O	O
by	O	O	O
micro-computed	O	O	B-Entity
tomography	O	O	I-Entity
(	O	O	I-Entity
CT	O	O	I-Entity
)	O	O	I-Entity
imaging	O	O	I-Entity
.	O	O	O

Ender	O	O	B-Entity
nails	O	O	I-Entity
failed	O	O	B-Entity
on	O	O	O
average	O	O	B-Entity
at	O	O	O
a	O	O	O
peak	O	O	B-Entity
load	O	O	B-Entity
of	O	O	O
800	O	O	O
N	O	O	O
,	O	O	O
TwinPlugs	O	O	B-Entity
at	O	O	O
1367	O	O	O
N	O	O	O
,	O	O	O
FixPlugs	O	O	B-Entity
at	O	O	O
1222	O	O	O
N	O	O	O
,	O	O	O
Plugs	O	O	B-Entity
3.5	O	O	O
mm	O	O	O
at	O	O	O
1225	O	O	O
N	O	O	O
and	O	O	O
Plugs	O	O	O
3.0	O	O	O
mm	O	O	O
at	O	O	O
971	O	O	O
N.	O	O	O
TwinPlugs	O	O	O
,	O	O	O
FixPlugs	O	O	O
,	O	O	O
and	O	O	O
Plugs	O	O	O
3.5	O	O	O
mm	O	O	O
failed	O	O	O
in	O	O	O
a	O	O	O
slow	O	O	O
manner	O	O	O
over	O	O	O
several	O	O	O
hundred	O	O	O
loading	O	O	B-Entity
cycles	O	O	B-Entity
,	O	O	O
whereas	O	O	O
Ender	O	O	O
nails	O	O	O
and	O	O	O
Plugs	O	O	O
3.0	O	O	O
mm	O	O	O
exhibited	O	O	O
abrupt	O	O	B-Entity
failure	O	O	B-Entity
without	O	O	O
any	O	O	O
prior	O	O	B-Entity
indication	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
confirm	O	O	O
that	O	O	O
axial	O	O	B-Entity
stability	O	O	B-Entity
of	O	O	O
FIN	O	O	B-Entity
can	O	O	O
be	O	O	O
further	O	O	O
improved	O	O	B-Entity
by	O	O	O
screw	O	O	B-Entity
-fixed	O	O	O
plugs	O	O	B-Entity
by	O	O	O
simultaneously	O	O	B-Entity
avoiding	O	O	O
shortcomings	O	O	O
of	O	O	O
an	O	O	O
eye-locked	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
which	O	O	O
the	O	O	O
Ender	O	O	B-Entity
nails	O	O	I-Entity
are	O	O	O
.	O	O	O

Considering	O	O	O
biomechanical	O	O	B-Entity
results	O	O	B-Entity
,	O	O	O
plug	O	O	B-Entity
interlocking	O	O	B-Entity
systems	O	O	I-Entity
with	O	O	O
3.5-mm	O	O	O
screws	O	O	B-Entity
should	O	O	O
be	O	O	O
favored	O	O	O
over	O	O	O
conventional	O	O	B-Entity
Ender	O	O	B-Entity
nails	O	O	I-Entity
and	O	O	O
plugs	O	O	B-Entity
with	O	O	O
3-mm	O	O	O
screws	O	O	O
.	O	O	O

-DOCSTART- (27524875)

Surgical	O	O	B-Entity
Guidance	O	O	B-Entity
via	O	O	O
Multiplexed	O	O	B-Entity
Molecular	O	O	I-Entity
Imaging	O	O	I-Entity
of	O	O	O
Fresh	O	O	O
Tissues	O	O	B-Entity
Labeled	O	O	B-Entity
with	O	O	O
SERS	O	O	B-Entity
-Coded	O	O	O
Nanoparticles	O	O	O

The	O	O	O
imaging	O	O	B-Entity
of	O	O	O
dysregulated	O	O	O
cell-surface	O	O	B-Entity
receptors	O	O	I-Entity
(	O	O	O
or	O	O	O
biomarkers	O	O	B-Entity
)	O	O	I-Entity
is	O	O	O
a	O	O	O
potential	O	O	O
means	O	O	O
of	O	O	O
identifying	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
with	O	O	O
high	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
due	O	O	O
to	O	O	O
heterogeneities	O	O	B-Entity
in	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	I-Entity
protein	O	O	I-Entity
biomarkers	O	O	B-Entity
in	O	O	O
tumors	O	O	B-Entity
,	O	O	O
molecular	O	O	B-Entity
imaging	O	O	I-Entity
technologies	O	O	B-Entity
should	O	O	O
ideally	O	O	O
be	O	O	O
capable	O	O	O
of	O	O	O
visualizing	O	O	O
a	O	O	O
multiplexed	O	O	B-Entity
panel	O	O	I-Entity
of	O	O	O
cancer	O	O	B-Entity
biomarkers	O	O	I-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
surface-enhanced	O	O	B-Entity
Raman-scattering	O	O	I-Entity
(	O	O	O
SERS	O	O	B-Entity
)	O	O	O
nanoparticles	O	O	B-Entity
(	O	O	O
NPs	O	O	B-Entity
)	O	O	O
have	O	O	O
attracted	O	O	O
wide	O	O	O
interest	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
potential	O	O	O
for	O	O	O
sensitive	O	O	B-Entity
and	O	O	O
multiplexed	O	O	B-Entity
biomarker	O	O	I-Entity
detection	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
review	O	O	B-Entity
,	O	O	O
we	O	O	O
focus	O	O	O
on	O	O	O
the	O	O	O
most	O	O	O
recent	O	O	O
advances	O	O	O
in	O	O	O
tumor	O	O	B-Entity
imaging	O	O	B-Entity
using	O	O	O
SERS	O	O	B-Entity
-coded	O	O	O
NPs	O	O	B-Entity
.	O	O	O

A	O	O	O
brief	O	O	O
introduction	O	O	O
of	O	O	O
the	O	O	O
structure	O	O	B-Entity
and	O	O	O
optical	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
SERS	O	O	B-Entity
NPs	O	O	B-Entity
is	O	O	O
provided	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
a	O	O	O
detailed	O	O	O
discussion	O	O	O
of	O	O	O
key	O	O	O
imaging	O	O	B-Entity
issues	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
administration	O	O	B-Entity
of	O	O	O
NPs	O	O	O
in	O	O	O
tissue	O	O	B-Entity
(	O	O	O
topical	O	O	B-Entity
versus	O	O	O
systemic	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
optical	O	O	B-Entity
configuration	O	O	I-Entity
and	O	O	O
imaging	O	O	O
approach	O	O	O
of	O	O	O
Raman	O	O	B-Entity
imaging	O	O	I-Entity
systems	O	O	I-Entity
,	O	O	O
spectral	O	O	B-Entity
demultiplexing	O	O	I-Entity
methods	O	O	I-Entity
for	O	O	O
quantifying	O	O	B-Entity
NP	O	O	B-Entity
concentrations	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
disambiguation	O	O	B-Entity
of	O	O	O
specific	O	O	B-Entity
vs.	O	O	O
nonspecific	O	O	B-Entity
sources	O	O	O
of	O	O	O
contrast	O	O	O
through	O	O	O
ratiometric	O	O	B-Entity
imaging	O	O	I-Entity
of	O	O	O
targeted	O	O	B-Entity
and	O	O	O
untargeted	O	O	B-Entity
(	O	O	O
control	O	O	B-Entity
)	O	O	O
NP	O	O	O
pairs	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
future	O	O	O
challenges	O	O	O
and	O	O	O
directions	O	O	O
are	O	O	O
briefly	O	O	O
outlined	O	O	O
.	O	O	O

-DOCSTART- (27526315)

Expression	O	O	B-Entity
and	O	O	O
methylation	O	O	B-Entity
in	O	O	O
posttraumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
and	O	O	O
resilience	O	O	B-Entity
;	O	O	O
evidence	O	O	B-Entity
of	O	O	O
a	O	O	O
role	O	O	B-Entity
for	O	O	O
odorant	O	O	O
receptors	O	O	O

Post-traumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
PTSD	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
common	O	O	O
and	O	O	O
potentially	O	O	B-Entity
disabling	O	O	B-Entity
disorder	O	O	I-Entity
that	O	O	O
develops	O	O	O
in	O	O	O
1/5	O	O	O
to	O	O	O
1/3	O	O	O
of	O	O	O
people	O	O	B-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
severe	O	O	B-Entity
trauma	O	O	B-Entity
.	O	O	O

Twin	O	O	B-Entity
studies	O	O	I-Entity
indicate	O	O	O
that	O	O	O
genetic	O	O	B-Entity
factors	O	O	B-Entity
account	O	O	O
for	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
third	O	O	O
of	O	O	O
the	O	O	O
variance	O	O	B-Entity
in	O	O	O
the	O	O	O
risk	O	O	O
for	O	O	O
developing	O	O	O
PTSD	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
specific	O	O	B-Entity
role	O	O	B-Entity
for	O	O	O
genetic	O	O	O
factors	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
PTSD	O	O	O
is	O	O	O
not	O	O	O
well	O	O	O
understood	O	O	O
.	O	O	O

We	O	O	O
studied	O	O	O
genome-wide	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
profiles	O	O	B-Entity
in	O	O	O
12	O	O	O
participants	O	O	B-Entity
with	O	O	O
PTSD	O	O	B-Entity
and	O	O	O
12	O	O	O
participants	O	O	O
who	O	O	O
were	O	O	O
resilient	O	O	B-Entity
to	O	O	O
similar	O	O	O
severity	O	O	B-Entity
trauma	O	O	B-Entity
exposure	O	O	B-Entity
.	O	O	O

Close	O	O	O
to	O	O	O
4000	O	O	O
genes	O	O	B-Entity
were	O	O	O
differentially	O	O	B-Entity
expressed	O	O	B-Entity
with	O	O	O
adjusted	O	O	B-Entity
p<0.05	O	O	O
,	O	O	O
fold-change	O	O	B-Entity
>	O	O	O
2	O	O	O
,	O	O	O
with	O	O	O
all	O	O	O
but	O	O	O
3	O	O	O
upregulated	O	O	B-Entity
with	O	O	O
PTSD	O	O	B-Entity
.	O	O	O

Eight	O	O	O
odorant/olfactory	O	O	B-Entity
receptor	O	O	I-Entity
related	O	O	O
genes	O	O	B-Entity
were	O	O	O
up-regulated	O	O	B-Entity
with	O	O	O
PTSD	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
genes	O	O	O
related	O	O	O
to	O	O	O
immune	O	O	B-Entity
activation	O	O	I-Entity
,	O	O	O
the	O	O	O
Gamma-Aminobutyric	O	O	B-Entity
Acid	O	O	I-Entity
A	O	O	I-Entity
(	O	O	I-Entity
GABAA	O	O	I-Entity
)	O	O	I-Entity
receptor	O	O	I-Entity
,	O	O	O
and	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
synthesis	O	O	I-Entity
.	O	O	O

No	O	O	O
differences	O	O	O
with	O	O	O
adjusted	O	O	B-Entity
significance	O	O	B-Entity
for	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
were	O	O	O
found	O	O	O
.	O	O	O

We	O	O	O
conclude	O	O	O
that	O	O	O
increased	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	B-Entity
may	O	O	O
play	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
PTSD	O	O	B-Entity
and	O	O	O
this	O	O	O
expression	O	O	O
may	O	O	O
not	O	O	O
be	O	O	O
a	O	O	O
consequence	O	O	B-Entity
of	O	O	I-Entity
DNA	O	O	B-Entity
methylation	O	O	I-Entity
.	O	O	O

The	O	O	O
role	O	O	B-Entity
of	O	O	O
odorant	O	O	B-Entity
receptor	O	O	I-Entity
expression	O	O	B-Entity
warrants	O	O	O
independent	O	O	B-Entity
replication	O	O	B-Entity
.	O	O	O

-DOCSTART- (27532629)

Absorption	O	O	B-Entity
Characteristics	O	O	I-Entity
of	O	O	O
Vertebrate	O	O	B-Entity
Non	O	O	B-Entity
-	O	O	O
Visual	O	O	B-Entity
Opsin	O	O	O
,	O	O	O
Opn3	O	O	O

Most	O	O	O
animals	O	O	B-Entity
possess	O	O	B-Entity
multiple	O	O	B-Entity
opsins	O	O	B-Entity
which	O	O	O
sense	O	O	B-Entity
light	O	O	B-Entity
for	O	O	O
visual	O	O	B-Entity
and	O	O	O
non	O	O	B-Entity
-	O	O	O
visual	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
spectral	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
non	O	O	B-Entity
-	O	O	O
visual	O	O	B-Entity
opsins	O	O	B-Entity
,	O	O	O
vertebrate	O	O	B-Entity
Opn3s	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
widely	O	O	O
distributed	O	O	B-Entity
among	O	O	O
vertebrates	O	O	B-Entity
.	O	O	O

We	O	O	O
successfully	O	O	B-Entity
expressed	O	O	B-Entity
zebrafish	O	O	B-Entity
Opn3	O	O	B-Entity
in	O	O	O
mammalian	O	O	B-Entity
cultured	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
measured	O	O	B-Entity
its	O	O	O
absorption	O	O	B-Entity
spectrum	O	O	I-Entity
spectroscopically	O	O	I-Entity
.	O	O	O

When	O	O	O
incubated	O	O	B-Entity
with	O	O	O
11-cis	O	O	B-Entity
retinal	O	O	I-Entity
,	O	O	O
zebrafish	O	O	B-Entity
Opn3	O	O	B-Entity
formed	O	O	O
a	O	O	O
blue-sensitive	O	O	B-Entity
photopigment	O	O	I-Entity
with	O	O	O
an	O	O	O
absorption	O	O	B-Entity
maximum	O	O	B-Entity
around	O	O	O
465	O	O	O
nm	O	O	O
.	O	O	O

The	O	O	O
Opn3	O	O	B-Entity
converts	O	O	B-Entity
to	O	O	O
an	O	O	O
all-trans	O	O	B-Entity
retinal-bearing	O	O	I-Entity
photoproduct	O	O	B-Entity
with	O	O	O
an	O	O	O
absorption	O	O	B-Entity
spectrum	O	O	I-Entity
similar	O	O	B-Entity
to	O	O	O
the	O	O	O
dark	O	O	B-Entity
state	O	O	I-Entity
following	O	O	O
brief	O	O	B-Entity
blue-light	O	O	B-Entity
irradiation	O	O	B-Entity
.	O	O	O

The	O	O	O
photoproduct	O	O	B-Entity
experienced	O	O	O
a	O	O	O
remarkable	O	O	O
blue-shift	O	O	B-Entity
,	O	O	O
with	O	O	O
changes	O	O	O
in	O	O	B-Entity
position	O	O	I-Entity
of	O	O	O
the	O	O	O
isosbestic	O	O	B-Entity
point	O	O	I-Entity
,	O	O	O
during	O	O	O
further	O	O	O
irradiation	O	O	B-Entity
.	O	O	O

We	O	O	O
then	O	O	O
used	O	O	O
a	O	O	O
cAMP	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
luciferase	O	O	B-Entity
reporter	O	O	B-Entity
assay	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
light	O	O	B-Entity
-	O	O	O
dependent	O	O	O
cAMP	O	O	O
responses	O	O	B-Entity
in	O	O	O
cultured	O	O	B-Entity
cells	O	O	I-Entity
expressing	O	O	B-Entity
zebrafish	O	O	B-Entity
,	O	O	O
pufferfish	O	O	B-Entity
,	O	O	O
anole	O	O	B-Entity
and	O	O	O
chicken	O	O	B-Entity
Opn3	O	O	B-Entity
.	O	O	O

The	O	O	O
wild	O	O	B-Entity
type	O	O	I-Entity
opsins	O	O	B-Entity
did	O	O	O
not	O	O	O
produce	O	O	O
responses	O	O	B-Entity
,	O	O	O
but	O	O	O
cells	O	O	B-Entity
expressing	O	O	B-Entity
chimera	O	O	B-Entity
mutants	O	O	B-Entity
(	O	O	O
WT	O	O	B-Entity
Opn3s	O	O	I-Entity
in	O	O	O
which	O	O	O
the	O	O	O
third	O	O	B-Entity
intracellular	O	O	I-Entity
loops	O	O	B-Entity
were	O	O	O
replaced	O	O	B-Entity
with	O	O	O
the	O	O	O
third	O	O	O
intracellular	O	O	O
loop	O	O	B-Entity
of	O	O	O
a	O	O	O
Gs-coupled	O	O	B-Entity
jellyfish	O	O	B-Entity
opsin	O	O	B-Entity
)	O	O	O
displayed	O	O	B-Entity
light	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
cAMP	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
Opn3	O	O	B-Entity
is	O	O	O
capable	O	O	O
of	O	O	O
activating	O	O	B-Entity
G	O	O	B-Entity
protein(s	O	O	I-Entity
)	O	O	I-Entity
in	O	O	O
a	O	O	O
light	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
this	O	O	O
assay	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
relative	O	O	B-Entity
wavelength	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
response	O	O	B-Entity
of	O	O	O
cells	O	O	B-Entity
expressing	O	O	B-Entity
Opn3	O	O	B-Entity
chimeras	O	O	B-Entity
to	O	O	O
multiple	O	O	B-Entity
quantally	O	O	B-Entity
-	O	O	O
matched	O	O	B-Entity
stimuli	O	O	B-Entity
.	O	O	O

The	O	O	O
inferred	O	O	B-Entity
spectral	O	O	B-Entity
sensitivity	O	O	I-Entity
curve	O	O	B-Entity
of	O	O	O
zebrafish	O	O	B-Entity
Opn3	O	O	B-Entity
accurately	O	O	B-Entity
matched	O	O	B-Entity
the	O	O	O
measured	O	O	B-Entity
absorption	O	O	B-Entity
spectrum	O	O	I-Entity
.	O	O	O

We	O	O	O
were	O	O	O
unable	O	O	O
to	O	O	O
estimate	O	O	O
the	O	O	O
spectral	O	O	B-Entity
sensitivity	O	O	I-Entity
curve	O	O	B-Entity
of	O	O	O
mouse	O	O	B-Entity
or	O	O	O
anole	O	O	B-Entity
Opn3	O	O	B-Entity
,	O	O	O
but	O	O	O
,	O	O	O
like	O	O	O
zebrafish	O	O	B-Entity
Opn3	O	O	O
,	O	O	O
the	O	O	O
chicken	O	O	B-Entity
and	O	O	O
pufferfish	O	O	B-Entity
Opn3-JiL3	O	O	B-Entity
chimeras	O	O	B-Entity
also	O	O	O
formed	O	O	O
blue-sensitive	O	O	B-Entity
pigments	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
vertebrate	O	O	B-Entity
Opn3s	O	O	B-Entity
may	O	O	O
form	O	O	O
blue-sensitive	O	O	B-Entity
G	O	O	I-Entity
protein-coupled	O	O	I-Entity
pigments	O	O	I-Entity
.	O	O	O

Further	O	O	O
,	O	O	O
we	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
method	O	O	O
described	O	O	O
here	O	O	O
,	O	O	O
combining	O	O	O
a	O	O	O
cAMP	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
luciferase	O	O	B-Entity
reporter	O	O	B-Entity
assay	O	O	B-Entity
with	O	O	O
chimeric	O	O	B-Entity
opsins	O	O	B-Entity
possessing	O	O	O
the	O	O	O
third	O	O	B-Entity
intracellular	O	O	I-Entity
loop	O	O	B-Entity
of	O	O	O
jellyfish	O	O	B-Entity
opsin	O	O	B-Entity
,	O	O	O
is	O	O	O
a	O	O	O
versatile	O	O	O
approach	O	O	O
for	O	O	O
estimating	O	O	B-Entity
absorption	O	O	B-Entity
spectra	O	O	I-Entity
of	O	O	O
opsins	O	O	O
with	O	O	O
unknown	O	O	O
signaling	O	O	B-Entity
cascades	O	O	I-Entity
or	O	O	O
for	O	O	O
which	O	O	O
absorption	O	O	O
spectra	O	O	O
are	O	O	O
difficult	O	O	B-Entity
to	O	O	O
obtain	O	O	O
.	O	O	O

-DOCSTART- (27532798)

Effectiveness	O	O	B-Entity
of	O	O	O
offloading	O	O	B-Entity
methods	O	O	B-Entity
in	O	O	O
preventing	O	O	B-Entity
primary	O	O	B-Entity
diabetic	O	O	B-Entity
foot	O	O	I-Entity
ulcers	O	O	I-Entity
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
:	O	O	O
a	O	O	O
systematic	O	O	O
review	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
foot	O	O	B-Entity
ulceration	O	O	I-Entity
related	O	O	O
to	O	O	O
diabetes	O	O	B-Entity
is	O	O	O
increasing	O	O	B-Entity
.	O	O	O

Many	O	O	O
foot	O	O	B-Entity
care	O	O	I-Entity
professionals	O	O	B-Entity
recommend	O	O	O
offloading	O	O	B-Entity
measures	O	O	O
as	O	O	O
part	O	O	O
of	O	O	O
management	O	O	B-Entity
strategies	O	O	I-Entity
for	O	O	O
modulating	O	O	O
excess	O	O	B-Entity
pressure	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
development	O	O	O
of	O	O	O
diabetic	O	O	B-Entity
foot	O	O	I-Entity
ulcers	O	O	I-Entity
(	O	O	O
DFUs	O	O	B-Entity
)	O	O	O
.	O	O	O

These	O	O	O
measures	O	O	B-Entity
may	O	O	O
include	O	O	O
padding	O	O	B-Entity
,	O	O	O
insoles	O	O	B-Entity
/	O	O	O
orthotic	O	O	B-Entity
devices	O	O	I-Entity
and	O	O	O
footwear	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
lack	O	O	O
of	O	O	O
evidence	O	O	B-Entity
-based	O	O	O
guidance	O	O	O
on	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
the	O	O	O
different	O	O	O
offloading	O	O	B-Entity
options	O	O	O
for	O	O	O
preventing	O	O	B-Entity
primary	O	O	B-Entity
ulceration	O	O	B-Entity
in	O	O	O
those	O	O	O
with	O	O	O
diabetes	O	O	B-Entity
.	O	O	O

To	O	O	O
identify	O	O	O
,	O	O	O
critically	O	O	O
appraise	O	O	O
and	O	O	O
synthesize	O	O	O
the	O	O	O
best	O	O	O
available	O	O	O
evidence	O	O	B-Entity
on	O	O	O
methods	O	O	B-Entity
of	O	O	O
offloading	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
the	O	O	O
development	O	O	B-Entity
,	O	O	O
and	O	O	O
reduce	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
,	O	O	O
of	O	O	O
primary	O	O	B-Entity
foot	O	O	B-Entity
ulceration	O	O	I-Entity
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
.The	O	O	O
question	O	O	B-Entity
addressed	O	O	B-Entity
by	O	O	O
the	O	O	O
review	O	O	B-Entity
was	O	O	O
:	O	O	O
what	O	O	O
is	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
methods	O	O	O
of	O	O	O
offloading	O	O	O
in	O	O	O
preventing	O	O	B-Entity
primary	O	O	O
DFUs	O	O	B-Entity
in	O	O	O
adults	O	O	O
with	O	O	O
diabetes	O	O	O
?	O	O	O

Adults	O	O	B-Entity
18	O	O	O
years	O	O	B-Entity
and	O	O	O
older	O	O	O
with	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
,	O	O	O
regardless	O	O	O
of	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
ethnicity	O	O	B-Entity
,	O	O	O
duration	O	O	B-Entity
or	O	O	O
type	O	O	B-Entity
of	O	O	O
diabetes	O	O	O
,	O	O	O
with	O	O	O
no	O	O	O
history	O	O	B-Entity
of	O	O	O
DFUs	O	O	B-Entity
and	O	O	O
in	O	O	O
any	O	O	O
clinical	O	O	B-Entity
setting	O	O	I-Entity
will	O	O	O
be	O	O	O
included	O	O	O
.	O	O	O

Interventions	O	O	B-Entity
will	O	O	O
include	O	O	O
all	O	O	O
external	O	O	O
methods	O	O	B-Entity
of	O	O	O
offloading	O	O	B-Entity
.	O	O	O

All	O	O	O
comparators	O	O	O
will	O	O	O
be	O	O	O
considered	O	O	O
.	O	O	O

Studies	O	O	B-Entity
that	O	O	O
utilize	O	O	O
interventions	O	O	B-Entity
not	O	O	O
considered	O	O	O
usual	O	O	B-Entity
practice	O	O	B-Entity
in	O	O	O
the	O	O	O
prevention	O	O	B-Entity
of	O	O	O
DFUs	O	O	B-Entity
will	O	O	O
be	O	O	O
excluded	O	O	B-Entity
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	B-Entity
will	O	O	O
be	O	O	O
primary	O	O	O
foot	O	O	B-Entity
ulceration	O	O	I-Entity
.	O	O	O

The	O	O	O
secondary	O	O	B-Entity
outcome	O	O	B-Entity
will	O	O	O
be	O	O	O
indications	O	O	O
of	O	O	O
changes	O	O	O
in	O	O	O
plantar	O	O	B-Entity
pressure	O	O	B-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
will	O	O	O
consider	O	O	O
all	O	O	O
quantitative	O	O	B-Entity
study	O	O	B-Entity
designs	O	O	I-Entity
.	O	O	O

A	O	O	O
three-step	O	O	O
strategy	O	O	O
for	O	O	O
published	O	O	O
and	O	O	O
unpublished	O	O	O
literature	O	O	B-Entity
will	O	O	O
be	O	O	O
used	O	O	O
.	O	O	O

Fourteen	O	O	O
databases	O	O	B-Entity
will	O	O	O
be	O	O	O
searched	O	O	O
for	O	O	O
studies	O	O	B-Entity
in	O	O	O
English	O	O	B-Entity
up	O	O	O
to	O	O	O
November	O	O	O
2013	O	O	O
.	O	O	O

The	O	O	O
JBI-MAStARI	O	O	B-Entity
extraction	O	O	I-Entity
tool	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
extract	O	O	O
relevant	O	O	O
data	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
were	O	O	O
summarized	O	O	B-Entity
using	O	O	O
narrative	O	O	B-Entity
and	O	O	O
tables	O	O	B-Entity
.	O	O	O

Three	O	O	O
studies	O	O	B-Entity
which	O	O	O
examined	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
four	O	O	O
different	O	O	O
offloading	O	O	B-Entity
interventions	O	O	B-Entity
met	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
limited	O	O	O
evidence	O	O	B-Entity
that	O	O	O
use	O	O	O
of	O	O	O
a	O	O	O
footwear	O	O	B-Entity
system	O	O	O
(	O	O	O
prototype	O	O	B-Entity
shoe	O	O	B-Entity
plus	O	O	I-Entity
polyurethane	O	O	I-Entity
or	O	O	O
cork	O	O	B-Entity
insole	O	O	B-Entity
)	O	O	O
may	O	O	O
prevent	O	O	B-Entity
a	O	O	O
break	O	O	O
in	O	O	O
the	O	O	O
skin	O	O	B-Entity
;	O	O	O
use	O	O	O
of	O	O	O
customized	O	O	O
rigid	O	O	O
orthotic	O	O	B-Entity
devices	O	O	I-Entity
may	O	O	O
contribute	O	O	O
to	O	O	O
a	O	O	O
reduction	O	O	B-Entity
in	O	O	O
the	O	O	O
grade	O	O	B-Entity
and	O	O	O
number	O	O	B-Entity
of	O	O	O
calluses	O	O	B-Entity
;	O	O	O
and	O	O	O
a	O	O	O
manufactured	O	O	O
shoe	O	O	O
plus	O	O	O
customized	O	O	O
insole	O	O	O
may	O	O	O
reduce	O	O	O
plantar	O	O	B-Entity
pressure	O	O	B-Entity
and	O	O	O
therefore	O	O	O
reduce	O	O	O
the	O	O	O
potential	O	O	O
risk	O	O	B-Entity
of	O	O	O
skin	O	O	B-Entity
ulceration	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
limited	O	O	O
and	O	O	O
low-quality	O	O	O
evidence	O	O	B-Entity
that	O	O	O
in	O	O	O
a	O	O	O
population	O	O	B-Entity
of	O	O	O
adults	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
with	O	O	O
no	O	O	O
history	O	O	B-Entity
of	O	O	O
DFU	O	O	B-Entity
,	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
footwear	O	O	B-Entity
with	O	O	O
customized	O	O	O
or	O	O	O
prefabricated	O	O	O
orthotic	O	O	B-Entity
devices	O	O	I-Entity
may	O	O	O
provide	O	O	O
some	O	O	O
reduction	O	O	O
in	O	O	O
plantar	O	O	B-Entity
pressure	O	O	B-Entity
and	O	O	O
therefore	O	O	O
help	O	O	O
to	O	O	O
prevent	O	O	B-Entity
a	O	O	O
primary	O	O	B-Entity
DFU	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
lack	O	O	O
of	O	O	O
evidence	O	O	B-Entity
on	O	O	O
the	O	O	O
relative	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
different	O	O	O
offloading	O	O	B-Entity
options	O	O	O
.	O	O	O

-DOCSTART- (27534567)

Punch	O	O	B-Entity
injury	O	O	B-Entity
self-harm	O	O	B-Entity
in	O	O	O
young	O	O	O
people	O	O	O

Punch	O	O	B-Entity
injuries	O	O	B-Entity
are	O	O	O
a	O	O	O
form	O	O	B-Entity
of	O	O	O
self-harm	O	O	B-Entity
characterised	O	O	B-Entity
by	O	O	O
the	O	O	O
intentional	O	O	B-Entity
act	O	O	B-Entity
of	O	O	I-Entity
striking	O	O	I-Entity
an	O	O	O
object	O	O	B-Entity
with	O	O	O
a	O	O	O
closed	O	O	B-Entity
fist	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	B-Entity
to	O	O	O
describe	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
and	O	O	O
trends	O	O	B-Entity
in	O	O	O
young	O	O	B-Entity
people	O	O	I-Entity
presenting	O	O	B-Entity
with	O	O	O
injuries	O	O	B-Entity
sustained	O	O	B-Entity
via	O	O	O
the	O	O	O
punch	O	O	B-Entity
mechanism	O	O	B-Entity
.	O	O	O

A	O	O	O
comprehensive	O	O	B-Entity
retrospective	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
was	O	O	O
completed	O	O	B-Entity
of	O	O	O
all	O	O	O
young	O	O	B-Entity
people	O	O	I-Entity
aged	O	O	B-Entity
10	O	O	O
-	O	O	O
18	O	O	O
years	O	O	B-Entity
presenting	O	O	B-Entity
to	O	O	O
our	O	O	O
Central	O	O	B-Entity
London	O	O	I-Entity
Emergency	O	O	I-Entity
Department	O	O	I-Entity
over	O	O	O
a	O	O	O
12-month	O	O	B-Entity
period	O	O	I-Entity
.	O	O	O

A	O	O	O
subset	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
total	O	O	I-Entity
group	O	O	I-Entity
was	O	O	O
identified	O	O	B-Entity
as	O	O	O
the	O	O	O
punch	O	O	B-Entity
injury	O	O	B-Entity
subgroup	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
78	O	O	O
punch	O	O	B-Entity
injury	O	O	B-Entity
presentations	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
subgroup	O	O	B-Entity
,	O	O	O
the	O	O	O
male	O	O	B-Entity
:	O	O	O
female	O	O	B-Entity
ratio	O	O	B-Entity
is	O	O	O
4.57:1	O	O	O
;	O	O	O
37.18	O	O	O
%	O	O	O
of	O	O	O
presentations	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
fracture	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
29	O	O	O
)	O	O	O
and	O	O	O
35.90	O	O	O
%	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
28	O	O	O
)	O	O	O
of	O	O	O
patients	O	O	B-Entity
re-presented	O	O	B-Entity
following	O	O	O
another	O	O	O
punch	O	O	B-Entity
injury	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
victim	O	O	B-Entity
of	O	O	I-Entity
violence	O	O	I-Entity
,	O	O	O
or	O	O	O
by	O	O	O
other	O	O	O
psychiatric	O	O	B-Entity
presentation	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
a	O	O	O
male	O	O	B-Entity
preponderance	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
,	O	O	O
with	O	O	O
frequent	O	O	B-Entity
re-presentations	O	O	B-Entity
,	O	O	O
often	O	O	O
in	O	O	O
high-risk	O	O	B-Entity
circumstances	O	O	B-Entity
.	O	O	O

An	O	O	O
opportunity	O	O	O
for	O	O	O
screening	O	O	B-Entity
,	O	O	O
including	O	O	O
mental	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
social	O	O	B-Entity
and	O	O	O
substance	O	O	B-Entity
misuse	O	O	I-Entity
,	O	O	O
was	O	O	O
identified	O	O	B-Entity
.	O	O	O

Further	O	O	O
research	O	O	B-Entity
is	O	O	O
needed	O	O	B-Entity
to	O	O	O
enable	O	O	O
targeted	O	O	B-Entity
effective	O	O	B-Entity
interventions	O	O	B-Entity
in	O	O	O
this	O	O	O
group	O	O	B-Entity
.	O	O	O

-DOCSTART- (27537689)

Delayed	O	O	B-Entity
Recognition	O	O	B-Entity
of	O	O	O
Deterioration	O	O	B-Entity
of	O	O	O
Patients	O	O	B-Entity
in	O	O	O
General	O	O	B-Entity
Wards	O	O	I-Entity
Is	O	O	O
Mostly	O	O	O
Caused	O	O	O
by	O	O	O
Human	O	O	B-Entity
Related	O	O	O
Monitoring	O	O	B-Entity
Failures	O	O	B-Entity
:	O	O	O
A	O	O	O
Root	O	O	B-Entity
Cause	O	O	I-Entity
Analysis	O	O	I-Entity
of	O	O	O
Unplanned	O	O	O
ICU	O	O	O
Admissions	O	O	O

An	O	O	O
unplanned	O	O	O
ICU	O	O	B-Entity
admission	O	O	I-Entity
of	O	O	O
an	O	O	O
inpatient	O	O	B-Entity
is	O	O	O
a	O	O	O
serious	O	O	B-Entity
adverse	O	O	I-Entity
event	O	O	I-Entity
(	O	O	O
SAE	O	O	B-Entity
)	O	O	O
.	O	O	O

So	O	O	O
far	O	O	O
,	O	O	O
no	O	O	O
in	O	O	O
depth-study	O	O	O
has	O	O	O
been	O	O	O
performed	O	O	O
to	O	O	O
systematically	O	O	O
analyse	O	O	O
the	O	O	O
root	O	O	B-Entity
causes	O	O	I-Entity
of	O	O	O
unplanned	O	O	O
ICU-admissions	O	O	B-Entity
.	O	O	O

The	O	O	O
primary	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
healthcare	O	O	B-Entity
worker	O	O	I-Entity
-	O	O	O
,	O	O	O
organisational	O	O	B-Entity
-	O	O	O
,	O	O	O
technical	O	O	B-Entity
,	O	O	O
-	O	O	O
disease	O	O	B-Entity
-	O	O	O
and	O	O	O
patient	O	O	B-Entity
-	O	O	O
related	O	O	O
causes	O	O	O
that	O	O	O
contribute	O	O	O
to	O	O	O
acute	O	O	O
unplanned	O	O	O
ICU	O	O	B-Entity
admissions	O	O	I-Entity
from	O	O	O
general	O	O	B-Entity
wards	O	O	I-Entity
using	O	O	O
a	O	O	O
Root-Cause	O	O	B-Entity
Analysis	O	O	I-Entity
Tool	O	O	I-Entity
called	O	O	O
PRISMA-medical	O	O	B-Entity
.	O	O	O

Although	O	O	O
a	O	O	O
Track	O	O	B-Entity
and	O	O	I-Entity
Trigger	O	O	I-Entity
System	O	O	I-Entity
(	O	O	I-Entity
MEWS	O	O	I-Entity
)	O	O	I-Entity
was	O	O	O
introduced	O	O	O
in	O	O	O
our	O	O	O
hospital	O	O	B-Entity
a	O	O	O
few	O	O	O
years	O	O	O
ago	O	O	O
,	O	O	O
it	O	O	O
was	O	O	O
implemented	O	O	O
without	O	O	O
a	O	O	O
clear	O	O	O
protocol	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
secondary	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
adherence	O	O	O
to	O	O	O
a	O	O	O
Track	O	O	B-Entity
and	O	O	I-Entity
Trigger	O	O	I-Entity
system	O	O	I-Entity
to	O	O	O
identify	O	O	O
deterioration	O	O	B-Entity
on	O	O	O
general	O	O	B-Entity
hospital	O	O	I-Entity
wards	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
eventually	O	O	O
transferred	O	O	O
to	O	O	O
the	O	O	O
ICU	O	O	B-Entity
.	O	O	O

Retrospective	O	O	B-Entity
observational	O	O	I-Entity
study	O	O	I-Entity
in	O	O	O
49	O	O	O
consecutive	O	O	O
adult	O	O	O
patients	O	O	B-Entity
acutely	O	O	O
admitted	O	O	B-Entity
to	O	O	O
the	O	O	O
Intensive	O	O	B-Entity
Care	O	O	I-Entity
Unit	O	O	I-Entity
from	O	O	O
a	O	O	O
general	O	O	B-Entity
nursing	O	O	I-Entity
ward	O	O	I-Entity
.	O	O	O

1	O	O	O
.	O	O	O
PRISMA-analysis	O	O	B-Entity
on	O	O	O
root	O	O	B-Entity
causes	O	O	I-Entity
of	O	O	O
unplanned	O	O	O
ICU	O	O	B-Entity
admissions	O	O	I-Entity
2	O	O	O
.	O	O	O

Assessment	O	O	O
of	O	O	O
protocol	O	O	B-Entity
adherence	O	O	O
to	O	O	O
the	O	O	O
early	O	O	B-Entity
warning	O	O	I-Entity
score	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Out	O	O	O
of	O	O	O
49	O	O	O
cases	O	O	O
,	O	O	O
156	O	O	O
root	O	O	B-Entity
causes	O	O	I-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
frequent	O	O	O
root	O	O	B-Entity
causes	O	O	I-Entity
were	O	O	O
healthcare	O	O	B-Entity
worker	O	O	I-Entity
related	O	O	O
(	O	O	O
46	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
were	O	O	O
mainly	O	O	O
failures	O	O	B-Entity
in	O	O	O
monitoring	O	O	B-Entity
the	O	O	O
patient	O	O	B-Entity
.	O	O	O

They	O	O	O
were	O	O	O
followed	O	O	O
by	O	O	O
disease	O	O	B-Entity
-related	O	O	O
(	O	O	O
45	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
patient	O	O	B-Entity
-related	O	O	O
causes	O	O	O
(	O	O	O
7	O	O	O
,	O	O	O
5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
organisational	O	O	B-Entity
root	O	O	B-Entity
causes	O	O	I-Entity
(	O	O	O
3	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
only	O	O	O
40	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
vital	O	O	B-Entity
parameters	O	O	I-Entity
were	O	O	O
monitored	O	O	O
as	O	O	O
was	O	O	O
instructed	O	O	O
by	O	O	O
the	O	O	O
doctor	O	O	B-Entity
.	O	O	O

477	O	O	O
vital	O	O	B-Entity
parameter	O	O	I-Entity
sets	O	O	O
were	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
48	O	O	O
hours	O	O	O
before	O	O	O
ICU	O	O	B-Entity
admission	O	O	I-Entity
,	O	O	O
in	O	O	O
only	O	O	O
1	O	O	O
%	O	O	O
a	O	O	O
correct	O	O	O
MEWS	O	O	B-Entity
was	O	O	O
explicitly	O	O	O
documented	O	O	B-Entity
in	O	O	O
the	O	O	O
record	O	O	O
.	O	O	O

This	O	O	O
in-depth	O	O	B-Entity
analysis	O	O	I-Entity
demonstrates	O	O	O
that	O	O	O
almost	O	O	O
half	O	O	O
of	O	O	O
the	O	O	O
unplanned	O	O	O
ICU	O	O	B-Entity
admissions	O	O	I-Entity
from	O	O	O
the	O	O	O
general	O	O	B-Entity
ward	O	O	I-Entity
had	O	O	O
healthcare	O	O	B-Entity
worker	O	O	I-Entity
related	O	O	O
root	O	O	B-Entity
causes	O	O	I-Entity
,	O	O	O
mostly	O	O	O
due	O	O	O
to	O	O	O
monitoring	O	O	B-Entity
failures	O	O	B-Entity
in	O	O	O
clinically	O	O	B-Entity
deteriorating	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
reduce	O	O	O
unplanned	O	O	O
ICU	O	O	B-Entity
admissions	O	O	I-Entity
,	O	O	O
improving	O	O	O
the	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
is	O	O	O
therefore	O	O	O
warranted	O	O	O
.	O	O	O

-DOCSTART- (27539962)

Effects	O	O	O
of	O	O	O
a	O	O	O
novel	O	O	O
phosphodiesterase	O	O	B-Entity
10A	O	O	I-Entity
inhibitor	O	O	I-Entity
in	O	O	O
non-human	O	O	B-Entity
primates	O	O	I-Entity
:	O	O	O
A	O	O	O
therapeutic	O	O	B-Entity
approach	O	O	I-Entity
for	O	O	O
schizophrenia	O	O	B-Entity
with	O	O	O
improved	O	O	O
side	O	O	O
effect	O	O	O
profile	O	O	O

Schizophrenia	O	O	B-Entity
symptoms	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
alterations	O	O	B-Entity
in	O	O	I-Entity
basal	O	O	I-Entity
ganglia-cortical	O	O	I-Entity
networks	O	O	I-Entity
that	O	O	O
include	O	O	O
the	O	O	O
cyclic	O	O	B-Entity
nucleotides	O	O	I-Entity
(	O	O	O
cAMP	O	O	B-Entity
/	O	O	O
cGMP	O	O	B-Entity
)	O	O	O
signaling	O	O	B-Entity
pathways	O	O	I-Entity
.	O	O	O

Phosphodiesterase	O	O	B-Entity
10A	O	O	I-Entity
(	O	O	I-Entity
PDE10A	O	O	B-Entity
)	O	O	I-Entity
inhibitors	O	O	I-Entity
have	O	O	O
been	O	O	O
considered	O	O	O
as	O	O	O
therapeutic	O	O	B-Entity
agents	O	O	I-Entity
for	O	O	O
schizophrenia	O	O	B-Entity
because	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
cAMP	O	O	I-Entity
and	O	O	O
cGMP	O	O	B-Entity
in	O	O	O
the	O	O	O
striatum	O	O	B-Entity
by	O	O	O
PDE10A	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
signaling	O	O	B-Entity
mechanisms	O	O	I-Entity
of	O	O	O
the	O	O	O
striatal-cortical	O	O	B-Entity
network	O	O	I-Entity
,	O	O	O
and	O	O	O
thereby	O	O	O
in	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
we	O	O	O
assessed	O	O	O
in	O	O	O
non-human	O	O	B-Entity
primates	O	O	I-Entity
(	O	O	O
NHPs	O	O	B-Entity
)	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
a	O	O	O
novel	O	O	O
PDE10A	O	O	B-Entity
inhibitor	O	O	I-Entity
(	O	O	O
FRM-6308	O	O	B-Entity
)	O	O	O
that	O	O	O
has	O	O	O
demonstrated	O	O	O
high	O	O	B-Entity
potency	O	O	I-Entity
and	O	O	O
selectivity	O	O	O
for	O	O	O
human	O	O	B-Entity
recombinant	O	O	I-Entity
PDE10A	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

The	O	O	O
behavioral	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
FRM-6308	O	O	B-Entity
in	O	O	O
a	O	O	O
dose	O	O	B-Entity
range	O	O	I-Entity
were	O	O	O
determined	O	O	O
in	O	O	O
rhesus	O	O	B-Entity
monkeys	O	O	I-Entity
using	O	O	O
a	O	O	O
standardized	O	O	B-Entity
motor	O	O	I-Entity
disability	O	O	I-Entity
scale	O	O	I-Entity
for	O	O	O
primates	O	O	B-Entity
,	O	O	O
motor	O	O	B-Entity
tasks	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
"	O	O	O
drug	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	I-Entity
the	O	O	I-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
"	O	O	I-Entity
(	O	O	I-Entity
DENS	O	O	I-Entity
)	O	O	I-Entity
scale	O	O	I-Entity
.	O	O	O

The	O	O	O
neuronal	O	O	B-Entity
metabolic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
FRM-6308	O	O	B-Entity
were	O	O	O
determined	O	O	O
with	O	O	O
[(18)F]-fluorodeoxyglucose	O	O	B-Entity
PET	O	O	I-Entity
imaging	O	O	I-Entity
.	O	O	O

Results	O	O	O
showed	O	O	O
that	O	O	O
FRM-6308	O	O	B-Entity
did	O	O	O
not	O	O	O
have	O	O	O
any	O	O	O
specific	O	O	O
effects	O	O	O
on	O	O	O
the	O	O	O
motor	O	O	B-Entity
system	O	O	I-Entity
at	O	O	O
s.c	O	O	O
.	O	O	O

doses	O	O	O
up	O	O	O
to	O	O	O
0.32	O	O	O
mg/kg	O	O	O
in	O	O	O
NHPs	O	O	B-Entity
,	O	O	O
which	O	O	O
induced	O	O	O
a	O	O	O
significant	O	O	O
increase	O	O	O
in	O	O	O
the	O	O	O
FDG	O	O	B-Entity
-	O	O	O
SUV	O	O	B-Entity
in	O	O	O
striatum	O	O	B-Entity
(	O	O	O
F	O	O	O
16.069	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
and	O	O	O
cortical	O	O	B-Entity
(	O	O	O
F	O	O	O
15.181	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
regions	O	O	O
.	O	O	O

Higher	O	O	B-Entity
doses	O	O	I-Entity
induced	O	O	O
sedation	O	O	B-Entity
and	O	O	O
occasional	O	O	B-Entity
involuntary	O	O	I-Entity
movements	O	O	I-Entity
with	O	O	O
clear	O	O	O
development	O	O	O
of	O	O	O
tolerance	O	O	B-Entity
after	O	O	I-Entity
repeated	O	O	I-Entity
exposures	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
FRM-6308	O	O	B-Entity
has	O	O	O
the	O	O	O
adequate	O	O	B-Entity
pharmacological	O	O	I-Entity
profile	O	O	I-Entity
to	O	O	O
advance	O	O	O
testing	O	O	O
in	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
and	O	O	O
demonstrate	O	O	O
antipsychotic	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
PDE10A	O	O	B-Entity
inhibition	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
schizophrenia	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27541815)

Agglomeration	O	O	B-Entity
of	O	O	O
Luminescent	O	O	B-Entity
Porous	O	O	B-Entity
Silicon	O	O	B-Entity
Nanoparticles	O	O	B-Entity
in	O	O	O
Colloidal	O	O	O
Solutions	O	O	O

We	O	O	O
have	O	O	O
prepared	O	O	B-Entity
colloidal	O	O	B-Entity
solutions	O	O	I-Entity
of	O	O	O
clusters	O	O	B-Entity
composed	O	O	O
from	O	O	O
porous	O	O	B-Entity
silicon	O	O	B-Entity
nanoparticles	O	O	B-Entity
in	O	O	O
methanol	O	O	B-Entity
,	O	O	O
water	O	O	B-Entity
and	O	O	O
phosphate-buffered	O	O	B-Entity
saline	O	O	I-Entity
(	O	O	O
PBS	O	O	B-Entity
)	O	O	O
.	O	O	O

Even	O	O	O
if	O	O	O
the	O	O	O
size	O	O	B-Entity
of	O	O	O
the	O	O	O
nanoclusters	O	O	B-Entity
is	O	O	O
between	O	O	O
60	O	O	O
and	O	O	O
500	O	O	O
nm	O	O	O
,	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
highly	O	O	B-Entity
porous	O	O	B-Entity
"	O	O	B-Entity
cauliflower"-like	O	O	I-Entity
structure	O	O	I-Entity
,	O	O	O
the	O	O	O
porous	O	O	O
silicon	O	O	B-Entity
nanoparticles	O	O	B-Entity
are	O	O	O
composed	O	O	O
of	O	O	O
interconnected	O	O	B-Entity
nanocrystals	O	O	B-Entity
having	O	O	O
around	O	O	O
2.5	O	O	O
nm	O	O	O
in	O	O	O
size	O	O	O
and	O	O	O
showing	O	O	O
strong	O	O	B-Entity
visible	O	O	B-Entity
luminescence	O	O	B-Entity
in	O	O	O
the	O	O	O
orange	O	O	B-Entity
-	O	O	O
red	O	O	B-Entity
spectral	O	O	B-Entity
region	O	O	B-Entity
(	O	O	O
centred	O	O	O
at	O	O	O
600	O	O	O
-	O	O	O
700	O	O	O
nm	O	O	O
)	O	O	O
.	O	O	O

Hydrophilic	O	O	B-Entity
behaviour	O	O	I-Entity
and	O	O	O
good	O	O	B-Entity
solubility	O	O	B-Entity
of	O	O	O
the	O	O	O
nanoclusters	O	O	B-Entity
in	O	O	O
water	O	O	B-Entity
and	O	O	O
water	O	O	O
-	O	O	O
based	O	O	B-Entity
solutions	O	O	B-Entity
were	O	O	O
obtained	O	O	B-Entity
by	O	O	O
adding	O	O	O
hydrogen	O	O	B-Entity
peroxide	O	O	I-Entity
into	O	O	O
the	O	O	O
etching	O	O	B-Entity
solution	O	O	B-Entity
during	O	O	O
preparation	O	O	B-Entity
and	O	O	O
16	O	O	O
min	O	O	O
long	O	O	O
after-bath	O	O	B-Entity
in	O	O	O
hydrogen	O	O	O
peroxide	O	O	O
.	O	O	O

By	O	O	O
simple	O	O	B-Entity
filtration	O	O	B-Entity
of	O	O	O
the	O	O	O
solutions	O	O	B-Entity
with	O	O	O
syringe	O	O	B-Entity
filters	O	O	I-Entity
,	O	O	O
we	O	O	O
have	O	O	O
extracted	O	O	B-Entity
smaller	O	O	B-Entity
nanoclusters	O	O	B-Entity
with	O	O	O
sizes	O	O	B-Entity
of	O	O	O
approx	O	O	B-Entity
.	O	O	O

60	O	O	O
-	O	O	O
70	O	O	O
nm	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
these	O	O	O
nanoclusters	O	O	B-Entity
in	O	O	O
water	O	O	B-Entity
and	O	O	O
PBS	O	O	B-Entity
solution	O	O	I-Entity
(	O	O	O
pH	O	O	B-Entity
neutral	O	O	I-Entity
)	O	O	O
are	O	O	O
prone	O	O	B-Entity
to	O	O	O
agglomeration	O	O	B-Entity
,	O	O	O
as	O	O	O
was	O	O	O
confirmed	O	O	B-Entity
by	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
measurements	O	O	B-Entity
.	O	O	O

When	O	O	O
the	O	O	O
samples	O	O	B-Entity
were	O	O	O
left	O	O	O
at	O	O	O
ambient	O	O	B-Entity
conditions	O	O	I-Entity
for	O	O	O
several	O	O	B-Entity
weeks	O	O	O
,	O	O	O
the	O	O	O
typical	O	O	B-Entity
nanocluster	O	O	B-Entity
size	O	O	B-Entity
increased	O	O	B-Entity
to	O	O	O
approx	O	O	B-Entity
.	O	O	O

330	O	O	O
-	O	O	O
400	O	O	O
nm	O	O	O
and	O	O	O
then	O	O	O
remained	O	O	O
stable	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
both	O	O	O
freshly	O	O	B-Entity
filtered	O	O	B-Entity
and	O	O	O
aged	O	O	B-Entity
samples	O	O	B-Entity
(	O	O	O
with	O	O	O
agglomerated	O	O	B-Entity
porous	O	O	B-Entity
silicon	O	O	B-Entity
nanoparticles	O	O	B-Entity
)	O	O	O
of	O	O	O
porous	O	O	O
silicon	O	O	O
in	O	O	O
water	O	O	B-Entity
and	O	O	O
PBS	O	O	B-Entity
solutions	O	O	I-Entity
can	O	O	O
be	O	O	O
further	O	O	O
used	O	O	O
for	O	O	O
biological	O	O	B-Entity
studies	O	O	B-Entity
or	O	O	O
as	O	O	O
luminescent	O	O	B-Entity
markers	O	O	B-Entity
in	O	O	O
living	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (27542694)

Development	O	O	B-Entity
of	O	O	O
a	O	O	O
liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
method	O	O	B-Entity
for	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
trace	O	O	B-Entity
d-amino	O	O	O
acids	O	O	O

d-Amino	O	O	B-Entity
acids	O	O	I-Entity
have	O	O	O
recently	O	O	B-Entity
attracted	O	O	O
much	O	O	O
attention	O	O	B-Entity
in	O	O	O
various	O	O	O
research	O	O	B-Entity
fields	O	O	I-Entity
including	O	O	B-Entity
medical	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
and	O	O	O
food	O	O	B-Entity
industry	O	O	I-Entity
due	O	O	O
to	O	O	O
their	O	O	O
important	O	O	B-Entity
biological	O	O	B-Entity
functions	O	O	I-Entity
that	O	O	O
differ	O	O	O
from	O	O	O
l-amino	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

Most	O	O	O
chiral	O	O	B-Entity
amino	O	O	B-Entity
acid	O	O	I-Entity
separation	O	O	B-Entity
techniques	O	O	B-Entity
require	O	O	B-Entity
complicated	O	O	B-Entity
derivatization	O	O	B-Entity
procedures	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
achieve	O	O	O
the	O	O	O
desirable	O	O	B-Entity
chromatographic	O	O	B-Entity
behavior	O	O	O
and	O	O	O
detectability	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
research	O	O	B-Entity
is	O	O	O
to	O	O	O
develop	O	O	B-Entity
a	O	O	O
highly	O	O	B-Entity
sensitive	O	O	I-Entity
analytical	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
the	O	O	O
enantioseparation	O	O	B-Entity
of	O	O	O
chiral	O	O	B-Entity
amino	O	O	B-Entity
acids	O	O	I-Entity
without	O	O	O
any	O	O	O
derivatization	O	O	B-Entity
process	O	O	B-Entity
using	O	O	O
liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
LC-MS/MS	O	O	B-Entity
)	O	O	O
.	O	O	O

By	O	O	O
optimizing	O	O	B-Entity
MS/MS	O	O	B-Entity
parameters	O	O	B-Entity
,	O	O	O
we	O	O	O
established	O	O	B-Entity
a	O	O	O
quantification	O	O	B-Entity
method	O	O	B-Entity
that	O	O	O
allowed	O	O	O
the	O	O	O
simultaneous	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
18	O	O	O
d-amino	O	O	B-Entity
acids	O	O	I-Entity
with	O	O	O
high	O	O	B-Entity
sensitivity	O	O	I-Entity
and	O	O	O
reproducibility	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
we	O	O	O
applied	O	O	B-Entity
the	O	O	O
method	O	O	B-Entity
to	O	O	O
food	O	O	B-Entity
sample	O	O	I-Entity
(	O	O	O
vinegar	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
validation	O	O	B-Entity
,	O	O	O
and	O	O	O
successfully	O	O	O
quantified	O	O	B-Entity
trace	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
d-amino	O	O	B-Entity
acids	O	O	I-Entity
in	O	O	O
samples	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
demonstrated	O	O	O
the	O	O	O
applicability	O	O	B-Entity
and	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
the	O	O	O
LC-MS/MS	O	O	B-Entity
method	O	O	B-Entity
as	O	O	O
a	O	O	O
novel	O	O	B-Entity
,	O	O	O
effective	O	O	B-Entity
tool	O	O	O
for	O	O	O
d-amino	O	O	B-Entity
acid	O	O	I-Entity
measurement	O	O	B-Entity
in	O	O	O
various	O	O	O
biological	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

-DOCSTART- (27542782)

The	O	O	O
Multi-center	O	O	B-Entity
Evaluation	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Accuracy	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Contrast	O	O	I-Entity
MEdium	O	O	I-Entity
INduced	O	O	I-Entity
Pd/Pa	O	O	I-Entity
RaTiO	O	O	I-Entity
in	O	O	O
Predicting	O	O	O
FFR	O	O	B-Entity
(	O	O	O
MEMENTO	O	O	B-Entity
-	O	O	O
FFR	O	O	O
)	O	O	O
Study	O	O	O

Adenosine	O	O	B-Entity
administration	O	O	B-Entity
is	O	O	O
needed	O	O	O
for	O	O	O
the	O	O	O
achievement	O	O	O
of	O	O	O
maximal	O	O	B-Entity
hyperaemia	O	O	B-Entity
fractional	O	O	B-Entity
flow	O	O	I-Entity
reserve	O	O	I-Entity
(	O	O	O
FFR	O	O	B-Entity
)	O	O	O
assessment	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
was	O	O	O
to	O	O	O
test	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
Pd	O	O	B-Entity
/	O	O	O
Pa	O	O	B-Entity
ratio	O	O	B-Entity
registered	O	O	O
during	O	O	O
submaximal	O	O	B-Entity
hyperaemia	O	O	B-Entity
induced	O	O	O
by	O	O	O
non-ionic	O	O	B-Entity
contrast	O	O	I-Entity
medium	O	O	I-Entity
(	O	O	O
contrast	O	O	B-Entity
FFR	O	O	B-Entity
[	O	O	O
cFFR	O	O	B-Entity
]	O	O	O
)	O	O	O
in	O	O	O
predicting	O	O	O
FFR	O	O	O
and	O	O	O
comparing	O	O	O
it	O	O	O
to	O	O	O
the	O	O	O
performance	O	O	O
of	O	O	O
resting	O	O	B-Entity
Pd	O	O	O
/	O	O	O
Pa	O	O	O
in	O	O	O
a	O	O	O
collaborative	O	O	B-Entity
registry	O	O	O
of	O	O	O
926	O	O	O
patients	O	O	B-Entity
enrolled	O	O	O
in	O	O	O
10	O	O	O
hospitals	O	O	B-Entity
from	O	O	O
four	O	O	B-Entity
European	O	O	B-Entity
countries	O	O	I-Entity
(	O	O	O
Italy	O	O	B-Entity
,	O	O	O
Spain	O	O	B-Entity
,	O	O	O
France	O	O	B-Entity
and	O	O	O
Portugal	O	O	B-Entity
)	O	O	O
.	O	O	O

Resting	O	O	B-Entity
Pd	O	O	B-Entity
/	O	O	O
Pa	O	O	B-Entity
,	O	O	O
cFFR	O	O	B-Entity
and	O	O	O
FFR	O	O	B-Entity
were	O	O	O
measured	O	O	O
in	O	O	O
1,026	O	O	O
coronary	O	O	B-Entity
stenoses	O	O	I-Entity
functionally	O	O	B-Entity
evaluated	O	O	O
using	O	O	O
commercially	O	O	O
available	O	O	O
pressure	O	O	B-Entity
wires	O	O	I-Entity
.	O	O	O

cFFR	O	O	B-Entity
was	O	O	O
obtained	O	O	O
after	O	O	O
intracoronary	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
contrast	O	O	B-Entity
medium	O	O	I-Entity
,	O	O	O
while	O	O	O
FFR	O	O	B-Entity
was	O	O	O
measured	O	O	O
after	O	O	O
administration	O	O	B-Entity
of	O	O	O
adenosine	O	O	B-Entity
.	O	O	O

Resting	O	O	B-Entity
Pd	O	O	B-Entity
/	O	O	O
Pa	O	O	B-Entity
and	O	O	O
cFFR	O	O	B-Entity
were	O	O	O
significantly	O	O	O
higher	O	O	B-Entity
than	O	O	O
FFR	O	O	B-Entity
(	O	O	O
0.93±0.05	O	O	O
vs.	O	O	O
0.87±0.08	O	O	O
vs.	O	O	O
0.84±0.08	O	O	O
,	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
strong	O	O	O
correlation	O	O	B-Entity
and	O	O	O
a	O	O	O
close	O	O	O
agreement	O	O	O
at	O	O	O
Bland-Altman	O	O	B-Entity
analysis	O	O	I-Entity
between	O	O	O
cFFR	O	O	B-Entity
and	O	O	O
FFR	O	O	B-Entity
were	O	O	O
observed	O	O	O
(	O	O	O
r=0.90	O	O	O
,	O	O	O
p<0.001	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
of	O	O	O
disagreement	O	O	O
:	O	O	O
from	O	O	O
-0.042	O	O	O
to	O	O	O
0.11	O	O	O
)	O	O	O
.	O	O	O

ROC	O	O	B-Entity
curve	O	O	I-Entity
analysis	O	O	B-Entity
showed	O	O	O
an	O	O	O
excellent	O	O	O
accuracy	O	O	B-Entity
(	O	O	O
89	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
cFFR	O	O	B-Entity
cut-off	O	O	O
of	O	O	O
≤0.85	O	O	O
in	O	O	O
predicting	O	O	O
an	O	O	O
FFR	O	O	B-Entity
value	O	O	O
≤0.80	O	O	O
(	O	O	O
AUC	O	O	O
0.95	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.94	O	O	O
-	O	O	O
0.96	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
significantly	O	O	O
better	O	O	O
than	O	O	O
that	O	O	O
observed	O	O	O
using	O	O	O
resting	O	O	B-Entity
Pd	O	O	B-Entity
/	O	O	O
Pa	O	O	B-Entity
(	O	O	O
AUC	O	O	O
:	O	O	O
0.90	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.88	O	O	O
-	O	O	O
0.91	O	O	O
;	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
cFFR	O	O	B-Entity
/	O	O	O
FFR	O	O	B-Entity
hybrid	O	O	B-Entity
approach	O	O	I-Entity
showed	O	O	O
a	O	O	O
significantly	O	O	O
lower	O	O	B-Entity
number	O	O	O
of	O	O	O
lesions	O	O	B-Entity
requiring	O	O	O
adenosine	O	O	B-Entity
than	O	O	O
a	O	O	O
resting	O	O	B-Entity
Pd	O	O	B-Entity
/	O	O	O
Pa	O	O	B-Entity
/	O	O	O
FFR	O	O	O
hybrid	O	O	O
approach	O	O	O
(	O	O	O
22	O	O	O
%	O	O	O
vs.	O	O	O
44	O	O	O
%	O	O	O
,	O	O	O
p<0.0001	O	O	O
)	O	O	O
.	O	O	O

cFFR	O	O	B-Entity
is	O	O	O
accurate	O	O	B-Entity
in	O	O	O
predicting	O	O	O
the	O	O	O
functional	O	O	B-Entity
significance	O	O	O
of	O	O	O
coronary	O	O	B-Entity
stenosis	O	O	I-Entity
.	O	O	O

This	O	O	O
could	O	O	O
allow	O	O	O
limiting	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
adenosine	O	O	B-Entity
to	O	O	O
obtain	O	O	O
FFR	O	O	B-Entity
to	O	O	O
a	O	O	O
minority	O	O	O
of	O	O	O
stenoses	O	O	B-Entity
with	O	O	O
considerable	O	O	O
savings	O	O	O
of	O	O	O
time	O	O	B-Entity
and	O	O	O
costs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27542789)

Transfemoral	O	O	B-Entity
aortic	O	O	I-Entity
valve	O	O	I-Entity
implantation	O	O	I-Entity
with	O	O	O
the	O	O	O
repositionable	O	O	B-Entity
Lotus	O	O	I-Entity
valve	O	O	I-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
symptomatic	O	O	B-Entity
severe	O	O	B-Entity
aortic	O	O	B-Entity
stenosis	O	O	I-Entity
:	O	O	O
results	O	O	B-Entity
from	O	O	O
a	O	O	O
single-centre	O	O	O
experience	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
procedural	O	O	O
and	O	O	O
30-	O	O	O
day	O	O	B-Entity
results	O	O	B-Entity
for	O	O	O
the	O	O	O
repositionable	O	O	B-Entity
Lotus	O	O	I-Entity
valve	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
transfemoral	O	O	B-Entity
aortic	O	O	I-Entity
valve	O	O	I-Entity
implantation	O	O	I-Entity
in	O	O	O
a	O	O	O
single-centre	O	O	B-Entity
experience	O	O	I-Entity
.	O	O	O

We	O	O	O
prospectively	O	O	O
enrolled	O	O	O
110	O	O	O
patients	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
symptomatic	O	O	B-Entity
aortic	O	O	B-Entity
stenosis	O	O	I-Entity
(	O	O	O
NCT02162069	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
procedures	O	O	B-Entity
were	O	O	O
performed	O	O	O
without	O	O	O
general	O	O	B-Entity
anaesthesia	O	O	I-Entity
by	O	O	O
the	O	O	O
transfemoral	O	O	B-Entity
approach	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
followed	O	O	O
for	O	O	O
30	O	O	O
days	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
received	O	O	B-Entity
the	O	O	O
23	O	O	O
mm	O	O	O
(	O	O	O
n=20	O	O	O
)	O	O	O
,	O	O	O
25	O	O	O
mm	O	O	O
(	O	O	O
n=43	O	O	O
)	O	O	O
or	O	O	O
27	O	O	O
mm	O	O	O
(	O	O	O
n=47	O	O	O
)	O	O	O
Lotus	O	O	B-Entity
device	O	O	I-Entity
.	O	O	O

Mean	O	O	B-Entity
oversizing	O	O	I-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
annulus	O	O	B-Entity
or	O	O	O
left	O	O	B-Entity
ventricular	O	O	I-Entity
outflow	O	O	I-Entity
tract	O	O	I-Entity
(	O	O	O
LVOT	O	O	B-Entity
)	O	O	O
did	O	O	O
not	O	O	O
differ	O	O	O
among	O	O	O
groups	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
residual	O	O	I-Entity
moderate	O	O	B-Entity
or	O	O	O
severe	O	O	B-Entity
aortic	O	O	B-Entity
regurgitation	O	O	I-Entity
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	I-Entity
mild	O	O	I-Entity
aortic	O	O	B-Entity
regurgitation	O	O	I-Entity
was	O	O	O
low	O	O	O
at	O	O	O
9.1	O	O	O
%	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
valve	O	O	B-Entity
embolisation	O	O	B-Entity
,	O	O	O
no	O	O	O
need	O	O	O
for	O	O	O
a	O	O	O
second	O	O	B-Entity
valve	O	O	O
and	O	O	O
no	O	O	B-Entity
conversion	O	O	I-Entity
to	O	O	O
surgery	O	O	B-Entity
.	O	O	O

The	O	O	O
need	O	O	O
for	O	O	O
a	O	O	O
new	O	O	O
pacemaker	O	O	B-Entity
implantation	O	O	I-Entity
due	O	O	O
to	O	O	O
complete	O	O	B-Entity
(	O	O	O
third	O	O	B-Entity
degree	O	O	I-Entity
)	O	O	O
or	O	O	O
type	O	O	B-Entity
II	O	O	I-Entity
(	O	O	I-Entity
Mobitz	O	O	I-Entity
)	O	O	I-Entity
second	O	O	I-Entity
degree	O	O	I-Entity
atrioventricular	O	O	I-Entity
block	O	O	I-Entity
was	O	O	O
24.1	O	O	O
%	O	O	O
,	O	O	O
excluding	O	O	O
patients	O	O	B-Entity
with	O	O	O
previously	O	O	O
implanted	O	O	B-Entity
devices	O	O	I-Entity
.	O	O	O

Within	O	O	O
30	O	O	O
days	O	O	B-Entity
the	O	O	O
rates	O	O	B-Entity
of	O	O	O
all-cause	O	O	B-Entity
mortalit	O	O	I-Entity
y	O	O	O
and	O	O	O
stroke	O	O	B-Entity
were	O	O	O
low	O	O	B-Entity
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
aortic	O	O	B-Entity
stenosis	O	O	I-Entity
,	O	O	O
transfemoral	O	O	B-Entity
TAVI	O	O	I-Entity
with	O	O	O
the	O	O	O
repositionable	O	O	B-Entity
Lotus	O	O	I-Entity
valve	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
high	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
device	O	O	B-Entity
success	O	O	B-Entity
,	O	O	O
no	O	O	O
moderate	O	O	B-Entity
or	O	O	O
severe	O	O	O
residual	O	O	B-Entity
aortic	O	O	B-Entity
regurgitation	O	O	I-Entity
,	O	O	O
low	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
major	O	O	B-Entity
vascular	O	O	B-Entity
complications	O	O	I-Entity
and	O	O	O
mortality	O	O	B-Entity
within	O	O	O
30	O	O	O
days	O	O	B-Entity
.	O	O	O

-DOCSTART- (27542814)

A	O	O	O
Comparison	O	O	B-Entity
Between	O	O	O
Measured	O	O	B-Entity
Concentration	O	O	B-Entity
of	O	O	O
3H	O	O	B-Entity
in	O	O	O
Kalpakkam	O	O	B-Entity
Environment	O	O	I-Entity
with	O	O	O
Predicted	O	O	O
Atmospheric	O	O	O
Dispersion	O	O	O
Model	O	O	O

The	O	O	O
field	O	O	B-Entity
measurements	O	O	B-Entity
of	O	O	O
3H	O	O	B-Entity
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
HTO	O	O	B-Entity
present	O	O	O
in	O	O	O
air	O	O	B-Entity
moisture	O	O	B-Entity
carried	O	O	O
out	O	O	O
around	O	O	O
Madras	O	O	B-Entity
Atomic	O	O	I-Entity
Power	O	O	I-Entity
Station	O	O	I-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
predicted	O	O	O
values	O	O	O
using	O	O	O
atmospheric	O	O	B-Entity
dispersion	O	O	I-Entity
modeling	O	O	I-Entity
.	O	O	O

Air	O	O	B-Entity
3H	O	O	I-Entity
samples	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
from	O	O	O
different	O	O	O
sectors	O	O	B-Entity
at	O	O	O
the	O	O	O
site	O	O	B-Entity
boundary	O	O	B-Entity
of	O	O	O
the	O	O	O
operating	O	O	B-Entity
reactors	O	O	B-Entity
for	O	O	O
the	O	O	O
period	O	O	B-Entity
of	O	O	O
2	O	O	O
y	O	O	B-Entity
and	O	O	O
compared	O	O	B-Entity
with	O	O	O
Gaussian	O	O	B-Entity
Plume	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

The	O	O	O
predictions	O	O	B-Entity
were	O	O	O
comparable	O	O	O
with	O	O	O
the	O	O	O
measured	O	O	B-Entity
value	O	O	B-Entity
.	O	O	O

The	O	O	O
slight	O	O	B-Entity
variation	O	O	B-Entity
observed	O	O	B-Entity
between	O	O	O
the	O	O	O
two	O	O	O
methods	O	O	B-Entity
is	O	O	O
attributed	O	O	O
to	O	O	O
the	O	O	O
uncertainty	O	O	B-Entity
involved	O	O	O
in	O	O	O
the	O	O	O
measurement	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
3H	O	O	B-Entity
concentration	O	O	B-Entity
and	O	O	O
in	O	O	O
the	O	O	O
measurement	O	O	O
of	O	O	O
site-specific	O	O	B-Entity
meteorological	O	O	B-Entity
parameters	O	O	I-Entity
.	O	O	O

The	O	O	O
radiation	O	O	B-Entity
dose	O	O	I-Entity
imparted	O	O	B-Entity
to	O	O	O
members	O	O	B-Entity
of	O	O	I-Entity
public	O	O	I-Entity
due	O	O	O
to	O	O	O
the	O	O	O
levels	O	O	B-Entity
observed	O	O	B-Entity
is	O	O	O
well	O	O	O
within	O	O	O
station	O	O	B-Entity
technical	O	O	B-Entity
specification	O	O	I-Entity
limit	O	O	I-Entity
for	O	O	O
3H	O	O	B-Entity
.	O	O	O

-DOCSTART- (27543814)

The	O	O	O
four-component	O	O	O
aureocin	O	O	B-Entity
A70	O	O	I-Entity
as	O	O	O
a	O	O	O
promising	O	O	B-Entity
agent	O	O	I-Entity
for	O	O	O
food	O	O	O
biopreservation	O	O	O

Aureocin	O	O	B-Entity
A70	O	O	I-Entity
is	O	O	O
the	O	O	O
only	O	O	O
four-component	O	O	O
bacteriocin	O	O	B-Entity
described	O	O	O
to	O	O	O
date	O	O	O
.	O	O	O

As	O	O	O
it	O	O	O
inhibits	O	O	B-Entity
the	O	O	I-Entity
growth	O	O	I-Entity
of	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
Gram-positive	O	O	B-Entity
bacteria	O	O	I-Entity
,	O	O	O
including	O	O	O
Listeria	O	O	B-Entity
monocytogenes	O	O	I-Entity
strains	O	O	B-Entity
isolated	O	O	O
from	O	O	O
food	O	O	B-Entity
,	O	O	O
its	O	O	O
potential	O	O	O
for	O	O	O
improving	O	O	O
food	O	O	B-Entity
safety	O	O	I-Entity
was	O	O	O
investigated	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
.	O	O	O

Aureocin	O	O	B-Entity
A70	O	O	I-Entity
(	O	O	O
10,240AU/mL	O	O	O
)	O	O	O
proved	O	O	O
to	O	O	O
be	O	O	O
bactericidal	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
extensively	O	O	O
lytic	O	O	B-Entity
,	O	O	O
against	O	O	O
listerial	O	O	B-Entity
strains	O	O	B-Entity
.	O	O	O

The	O	O	O
antibacterial	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
aureocin	O	O	B-Entity
A70	O	O	I-Entity
(	O	O	O
16AU/mL	O	O	O
)	O	O	O
was	O	O	O
then	O	O	O
tested	O	O	O
in	O	O	O
UHT-treated	O	O	B-Entity
skimmed	O	O	B-Entity
milk	O	O	I-Entity
inoculated	O	O	B-Entity
with	O	O	O
the	O	O	O
food	O	O	B-Entity
-associated	O	O	O
L.	O	O	B-Entity
monocytogenes	O	O	I-Entity
L12	O	O	I-Entity
strain	O	O	I-Entity
(	O	O	O
4-log	O	O	O
CFU/mL	O	O	O
)	O	O	O
during	O	O	O
storage	O	O	B-Entity
at	O	O	O
4	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
one	O	O	O
week	O	O	O
.	O	O	O

Aureocin	O	O	B-Entity
A70	O	O	I-Entity
caused	O	O	O
a	O	O	O
time-dependent	O	O	O
reduction	O	O	B-Entity
in	O	O	O
the	O	O	O
listerial	O	O	B-Entity
viable	O	O	B-Entity
cell	O	O	I-Entity
counts	O	O	I-Entity
(	O	O	O
5.51-log	O	O	O
units	O	O	O
)	O	O	O
up	O	O	O
to	O	O	O
7days	O	O	O
of	O	O	O
incubation	O	O	B-Entity
.	O	O	O

Aureocin	O	O	B-Entity
A70	O	O	I-Entity
was	O	O	O
neither	O	O	O
toxic	O	O	B-Entity
to	O	O	O
the	O	O	O
Vero	O	O	B-Entity
and	O	O	O
the	O	O	O
L-929	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
nor	O	O	O
exhibited	O	O	O
a	O	O	O
hemolytic	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
sheep	O	O	B-Entity
red	O	O	B-Entity
blood	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Aureocin	O	O	B-Entity
A70	O	O	I-Entity
proved	O	O	O
to	O	O	O
be	O	O	O
completely	O	O	O
stable	O	O	O
for	O	O	O
one	O	O	O
month	O	O	O
at	O	O	O
25	O	O	O
°	O	O	O
C	O	O	O
,	O	O	O
16weeks	O	O	O
at	O	O	O
4	O	O	O
°	O	O	O
C	O	O	O
and	O	O	O
20weeks	O	O	O
at	O	O	O
-20	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Aureocin	O	O	B-Entity
A70	O	O	I-Entity
exhibited	O	O	O
a	O	O	O
time-dependent	O	O	O
susceptibility	O	O	B-Entity
to	O	O	O
simulated	O	O	B-Entity
gastric	O	O	B-Entity
juice	O	O	I-Entity
and	O	O	O
bile	O	O	B-Entity
salts	O	O	I-Entity
mimicking	O	O	O
gastrointestinal	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

The	O	O	O
entrapment	O	O	B-Entity
of	O	O	O
aureocin	O	O	B-Entity
A70	O	O	I-Entity
in	O	O	O
an	O	O	O
alginate	O	O	B-Entity
/	O	O	O
gelatin	O	O	B-Entity
matrix	O	O	I-Entity
revealed	O	O	O
that	O	O	O
this	O	O	O
bacteriocin	O	O	B-Entity
can	O	O	O
be	O	O	O
released	O	O	O
from	O	O	O
this	O	O	O
matrix	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
it	O	O	O
remained	O	O	O
adsorbed	O	O	O
to	O	O	O
and	O	O	O
active	O	O	O
on	O	O	O
a	O	O	O
low-density	O	O	B-Entity
polyethylene	O	O	I-Entity
plastic	O	O	I-Entity
surface	O	O	O
suggesting	O	O	O
that	O	O	O
aureocin	O	O	B-Entity
A70	O	O	I-Entity
may	O	O	O
be	O	O	O
employed	O	O	O
in	O	O	O
bioactive	O	O	B-Entity
packaging	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
the	O	O	I-Entity
growth	O	O	I-Entity
of	O	O	O
undesirable	O	O	O
bacteria	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
these	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
aureocin	O	O	B-Entity
A70	O	O	I-Entity
is	O	O	O
a	O	O	O
promising	O	O	B-Entity
alternative	O	O	I-Entity
to	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
food	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

-DOCSTART- (27544926)

Folate	O	O	B-Entity
-	O	O	O
conjugated	O	O	B-Entity
gene	O	O	B-Entity
-	O	O	O
carrying	O	O	B-Entity
microbubbles	O	O	B-Entity
with	O	O	O
focused	O	O	B-Entity
ultrasound	O	O	I-Entity
for	O	O	O
concurrent	O	O	B-Entity
blood-brain	O	O	B-Entity
barrier	O	O	I-Entity
opening	O	O	B-Entity
and	O	O	O
local	O	O	B-Entity
gene	O	O	O
delivery	O	O	O

Previous	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
demonstrated	O	O	O
that	O	O	O
circulating	O	O	B-Entity
DNA	O	O	B-Entity
-	O	O	O
encapsulated	O	O	B-Entity
microbubbles	O	O	B-Entity
(	O	O	O
MBs	O	O	B-Entity
)	O	O	O
combined	O	O	B-Entity
with	O	O	O
focused	O	O	B-Entity
ultrasound	O	O	I-Entity
(	O	O	O
FUS	O	O	B-Entity
)	O	O	O
can	O	O	O
be	O	O	O
used	O	O	B-Entity
for	O	O	O
local	O	O	B-Entity
blood-brain	O	O	B-Entity
barrier	O	O	I-Entity
(	O	O	O
BBB	O	O	B-Entity
)	O	O	O
opening	O	O	B-Entity
and	O	O	O
gene	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
few	O	O	O
studies	O	O	B-Entity
focused	O	O	B-Entity
on	O	O	O
how	O	O	O
to	O	O	O
increase	O	O	B-Entity
the	O	O	O
efficiency	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
delivery	O	O	I-Entity
to	O	O	O
brain	O	O	B-Entity
tumors	O	O	I-Entity
after	O	O	O
the	O	O	O
released	O	O	B-Entity
gene	O	O	O
penetrating	O	O	B-Entity
the	O	O	O
BBB	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
proposed	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
folate	O	O	B-Entity
-	O	O	O
conjugated	O	O	O
DNA	O	O	O
-	O	O	O
loaded	O	O	O
cationic	O	O	B-Entity
MBs	O	O	I-Entity
(	O	O	O
FCMBs	O	O	B-Entity
)	O	O	O
.	O	O	O

When	O	O	O
combined	O	O	B-Entity
with	O	O	O
FUS	O	O	B-Entity
as	O	O	O
a	O	O	O
trigger	O	O	B-Entity
for	O	O	O
BBB	O	O	B-Entity
opening	O	O	O
,	O	O	O
FCMBs	O	O	B-Entity
were	O	O	O
converted	O	O	O
into	O	O	O
nanometer	O	O	B-Entity
-	O	O	O
sized	O	O	B-Entity
vesicles	O	O	B-Entity
that	O	O	O
were	O	O	O
transported	O	O	B-Entity
to	O	O	O
the	O	O	O
brain	O	O	B-Entity
parenchyma	O	O	B-Entity
.	O	O	O

The	O	O	O
FCMBs	O	O	B-Entity
can	O	O	O
selectively	O	O	O
aggregate	O	O	B-Entity
around	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
that	O	O	O
overexpressed	O	O	B-Entity
the	O	O	O
folate	O	O	B-Entity
receptor	O	O	I-Entity
,	O	O	O
thus	O	O	O
enhancing	O	O	B-Entity
gene	O	O	B-Entity
delivery	O	O	I-Entity
via	O	O	O
folate	O	O	O
-	O	O	O
stimulated	O	O	B-Entity
endocytosis	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
confirmed	O	O	B-Entity
that	O	O	O
FCMBs	O	O	B-Entity
can	O	O	O
carry	O	O	B-Entity
DNA	O	O	B-Entity
on	O	O	O
the	O	O	O
surface	O	O	B-Entity
of	O	O	O
the	O	O	O
MB	O	O	B-Entity
shell	O	O	B-Entity
and	O	O	O
have	O	O	O
good	O	O	B-Entity
targeting	O	O	B-Entity
ability	O	O	B-Entity
on	O	O	O
C6	O	O	B-Entity
glioma	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
optimized	O	O	O
FUS	O	O	B-Entity
parameters	O	O	B-Entity
for	O	O	O
FCMBs	O	O	B-Entity
-	O	O	O
enhanced	O	O	B-Entity
gene	O	O	B-Entity
delivery	O	O	I-Entity
were	O	O	O
confirmed	O	O	B-Entity
by	O	O	I-Entity
cell	O	O	B-Entity
experiments	O	O	B-Entity
(	O	O	O
center	O	O	B-Entity
frequency	O	O	B-Entity
=	O	O	O
1	O	O	O
MHz	O	O	O
;	O	O	O
acoustic	O	O	B-Entity
pressure	O	O	I-Entity
=	O	O	O
700	O	O	O
kPa	O	O	O
;	O	O	O
pulse	O	O	B-Entity
repetition	O	O	B-Entity
frequency	O	O	O
=	O	O	O
5	O	O	O
Hz	O	O	O
;	O	O	O
cycle	O	O	B-Entity
number	O	O	B-Entity
=	O	O	O
10000	O	O	O
;	O	O	O
exposure	O	O	B-Entity
time	O	O	B-Entity
=	O	O	O
1	O	O	O
min	O	O	O
;	O	O	O
FCMBs	O	O	O
concentration	O	O	B-Entity
=	O	O	O
4	O	O	O
×	O	O	O
10(7	O	O	O
)	O	O	O
MB/mL	O	O	O
)	O	O	O
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
data	O	O	B-Entity
also	O	O	O
indicated	O	O	B-Entity
that	O	O	O
FCMBs	O	O	B-Entity
show	O	O	O
better	O	O	B-Entity
gene	O	O	B-Entity
transfection	O	O	B-Entity
efficiency	O	O	B-Entity
than	O	O	O
MBs	O	O	B-Entity
without	O	O	B-Entity
folate	O	O	B-Entity
conjugation	O	O	B-Entity
and	O	O	O
the	O	O	O
traditional	O	O	B-Entity
approach	O	O	B-Entity
of	O	O	O
directly	O	O	B-Entity
injecting	O	O	B-Entity
the	O	O	O
gene	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
described	O	O	O
our	O	O	O
novel	O	O	B-Entity
development	O	O	B-Entity
of	O	O	O
multifunctional	O	O	B-Entity
MBs	O	O	B-Entity
for	O	O	O
FUS	O	O	B-Entity
-	O	O	O
triggered	O	O	B-Entity
gene	O	O	B-Entity
delivery	O	O	I-Entity
/	O	O	O
therapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27550416)

Modulation	O	O	B-Entity
of	O	O	O
IL-6	O	O	B-Entity
induced	O	O	B-Entity
RANKL	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
arthritic	O	O	B-Entity
synovium	O	O	B-Entity
by	O	O	O
a	O	O	O
transcription	O	O	O
factor	O	O	O
SOX5	O	O	O

Receptor	O	O	B-Entity
activator	O	O	I-Entity
of	O	O	I-Entity
nuclear	O	O	I-Entity
factor	O	O	I-Entity
κB	O	O	I-Entity
ligand	O	O	I-Entity
(	O	O	O
RANKL	O	O	B-Entity
)	O	O	O
is	O	O	O
critically	O	O	B-Entity
involved	O	O	O
in	O	O	O
bone	O	O	B-Entity
erosion	O	O	I-Entity
of	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
(	O	O	O
RA	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
previously	O	O	B-Entity
reported	O	O	O
association	O	O	O
between	O	O	O
younger	O	O	B-Entity
age	O	O	I-Entity
at	O	O	O
onset	O	O	O
of	O	O	O
RA	O	O	B-Entity
and	O	O	O
a	O	O	O
RANKL	O	O	B-Entity
promoter	O	O	O
SNP	O	O	B-Entity
that	O	O	O
conferred	O	O	O
an	O	O	O
elevated	O	O	B-Entity
promoter	O	O	O
activity	O	O	O
via	O	O	O
binding	O	O	B-Entity
to	O	O	O
a	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
SOX5	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
study	O	O	B-Entity
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
SOX5	O	O	B-Entity
levels	O	O	O
in	O	O	O
relation	O	O	O
to	O	O	O
RANKL	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
RA	O	O	B-Entity
synovial	O	O	B-Entity
fibroblasts	O	O	B-Entity
(	O	O	O
SF	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
bone	O	O	B-Entity
erosion	O	O	I-Entity
in	O	O	O
the	O	O	O
collagen-induced	O	O	B-Entity
arthritis	O	O	I-Entity
(	O	O	O
CIA	O	O	B-Entity
)	O	O	O
mouse	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
indicated	O	O	B-Entity
SOX5	O	O	B-Entity
levels	O	O	O
were	O	O	O
higher	O	O	O
in	O	O	O
synovium	O	O	B-Entity
and	O	O	O
synovial	O	O	B-Entity
fluid	O	O	I-Entity
from	O	O	O
RA	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
osteoarthritis	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Pro-inflammatory	O	O	B-Entity
cytokines	O	O	B-Entity
upregulated	O	O	B-Entity
SOX5	O	O	B-Entity
and	O	O	O
RANKL	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
both	O	O	O
primary	O	O	O
RA	O	O	B-Entity
SF	O	O	B-Entity
and	O	O	O
the	O	O	O
rheumatoid	O	O	O
synovial	O	O	O
fibroblast	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
,	O	O	O
MH7A	O	O	B-Entity
.	O	O	O

Overexpression	O	O	B-Entity
of	O	O	O
SOX5	O	O	B-Entity
resulted	O	O	B-Entity
in	O	O	O
significantly	O	O	B-Entity
increased	O	O	I-Entity
RANKL	O	O	B-Entity
levels	O	O	O
,	O	O	O
while	O	O	O
knockdown	O	O	B-Entity
of	O	O	O
SOX5	O	O	O
resulted	O	O	O
in	O	O	O
diminished	O	O	B-Entity
IL-6	O	O	B-Entity
mediated	O	O	O
RANKL	O	O	O
upregulation	O	O	B-Entity
in	O	O	O
MH7A	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Chromatin	O	O	B-Entity
immunoprecipitation	O	O	I-Entity
(	O	O	O
ChIP	O	O	B-Entity
)	O	O	O
showed	O	O	O
approximately	O	O	B-Entity
3-fold	O	O	O
enrichment	O	O	O
of	O	O	O
RANKL-specific	O	O	B-Entity
DNA	O	O	I-Entity
in	O	O	O
anti-SOX5	O	O	B-Entity
immunoprecipitate	O	O	I-Entity
in	O	O	O
IL-6	O	O	B-Entity
treated	O	O	B-Entity
MH7A	O	O	B-Entity
cells	O	O	I-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
untreated	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Locally	O	O	O
silencing	O	O	B-Entity
SOX5	O	O	B-Entity
gene	O	O	I-Entity
significantly	O	O	B-Entity
diminished	O	O	I-Entity
RANKL	O	O	B-Entity
positive	O	O	B-Entity
cells	O	O	B-Entity
and	O	O	O
bone	O	O	B-Entity
erosion	O	O	I-Entity
in	O	O	O
CIA	O	O	B-Entity
mice	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	B-Entity
SOX5	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	O
regulator	O	O	B-Entity
of	O	O	O
IL-6	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
RANKL	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
RA	O	O	B-Entity
SF	O	O	B-Entity
.	O	O	O

-DOCSTART- (27553051)

Intracameral	O	O	B-Entity
cefuroxime	O	O	B-Entity
in	O	O	O
the	O	O	O
prevention	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
endophthalmitis	O	O	I-Entity
:	O	O	O
an	O	O	O
experience	O	O	B-Entity
from	O	O	O
Hong	O	O	O
Kong	O	O	O

The	O	O	O
purpose	O	O	O
was	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
introducing	O	O	B-Entity
intracameral	O	O	B-Entity
cefuroxime	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
compounded	O	O	B-Entity
by	O	O	O
a	O	O	O
hospital	O	O	B-Entity
pharmacy	O	O	I-Entity
,	O	O	O
on	O	O	O
postoperative	O	O	B-Entity
endophthalmitis	O	O	I-Entity
in	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
eye	O	O	I-Entity
centre	O	O	I-Entity
in	O	O	O
Hong	O	O	B-Entity
Kong	O	O	I-Entity
.	O	O	O

All	O	O	O
cases	O	O	O
that	O	O	O
underwent	O	O	O
cataract	O	O	B-Entity
surgeries	O	O	I-Entity
over	O	O	O
a	O	O	O
12-year	O	O	O
period	O	O	O
(	O	O	O
January	O	O	O
2004	O	O	O
to	O	O	O
December	O	O	O
2015	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

The	O	O	O
routine	O	O	B-Entity
use	O	O	B-Entity
of	O	O	O
intracameral	O	O	B-Entity
cefuroxime	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
cataract	O	O	B-Entity
surgery	O	O	I-Entity
was	O	O	O
introduced	O	O	O
at	O	O	O
our	O	O	O
centre	O	O	O
after	O	O	O
April	O	O	O
2010	O	O	O
.	O	O	O

All	O	O	O
cefuroxime	O	O	B-Entity
aliquots	O	O	B-Entity
were	O	O	O
prepared	O	O	O
by	O	O	O
the	O	O	O
hospital	O	O	B-Entity
pharmacy	O	O	I-Entity
using	O	O	O
an	O	O	O
aseptic	O	O	B-Entity
compounding	O	O	O
technique	O	O	O
.	O	O	O

The	O	O	O
rates	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
endophthalmitis	O	O	I-Entity
before	O	O	O
April	O	O	O
2010	O	O	O
(	O	O	O
Group	O	O	B-Entity
1	O	O	O
,	O	O	O
no	O	O	B-Entity
intracameral	O	O	B-Entity
cefuroxime	O	O	B-Entity
)	O	O	O
and	O	O	O
after	O	O	O
April	O	O	O
2010	O	O	O
(	O	O	O
Group	O	O	O
2	O	O	O
,	O	O	O
routine	O	O	O
use	O	O	O
of	O	O	O
intracameral	O	O	O
cefuroxime	O	O	O
)	O	O	O
were	O	O	O
compared	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
30,428	O	O	O
eyes	O	O	B-Entity
(	O	O	O
7,332	O	O	O
in	O	O	O
Group	O	O	B-Entity
1	O	O	O
and	O	O	O
23,096	O	O	O
in	O	O	O
Group	O	O	O
2	O	O	O
)	O	O	O
were	O	O	O
studied	O	O	O
.	O	O	O

Eight	O	O	O
cases	O	O	O
developed	O	O	O
postoperative	O	O	B-Entity
endophthalmitis	O	O	B-Entity
(	O	O	O
1.09	O	O	O
in	O	O	O
1000	O	O	O
;	O	O	O
0.11	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
Group	O	O	B-Entity
1	O	O	O
whereas	O	O	O
no	O	O	O
cases	O	O	O
developed	O	O	O
endophthalmitis	O	O	O
(	O	O	O
0	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
Group	O	O	O
2	O	O	O
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	O
reduction	O	O	B-Entity
was	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
.	O	O	O

Seven	O	O	O
out	O	O	O
of	O	O	O
eight	O	O	O
cases	O	O	O
of	O	O	O
endophthalmitis	O	O	B-Entity
were	O	O	O
confirmed	O	O	O
by	O	O	O
positive	O	O	B-Entity
culture	O	O	I-Entity
.	O	O	O

Organisms	O	O	B-Entity
identified	O	O	O
were	O	O	O
Group	O	O	B-Entity
G	O	O	I-Entity
Streptococcus	O	O	I-Entity
(	O	O	O
two	O	O	O
cases	O	O	O
)	O	O	O
,	O	O	O
Group	O	O	B-Entity
B	O	O	I-Entity
Streptococcus	O	O	I-Entity
,	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
,	O	O	O
Serratia	O	O	B-Entity
marcescens	O	O	I-Entity
,	O	O	O
and	O	O	O
coagulase-negative	O	O	B-Entity
Staphylococcus	O	O	I-Entity
(	O	O	O
two	O	O	O
cases	O	O	O
)	O	O	O
.	O	O	O

Antibiotic	O	O	B-Entity
susceptibility	O	O	I-Entity
testing	O	O	B-Entity
results	O	O	I-Entity
were	O	O	O
available	O	O	O
in	O	O	O
six	O	O	O
cases	O	O	O
.	O	O	O

Four	O	O	O
out	O	O	O
of	O	O	O
six	O	O	O
organisms	O	O	B-Entity
were	O	O	O
susceptible	O	O	B-Entity
to	O	O	O
the	O	O	O
penicillin	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
related	O	O	O
to	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	O
intracameral	O	O	B-Entity
cefuroxime	O	O	B-Entity
were	O	O	O
encountered	O	O	O
.	O	O	O

The	O	O	O
use	O	O	B-Entity
of	O	O	O
intracameral	O	O	B-Entity
cefuroxime	O	O	B-Entity
could	O	O	O
significantly	O	O	O
reduce	O	O	B-Entity
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
endophthalmitis	O	O	I-Entity
in	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
centre	O	O	I-Entity
in	O	O	O
Hong	O	O	B-Entity
Kong	O	O	I-Entity
.	O	O	O

The	O	O	O
use	O	O	B-Entity
of	O	O	O
aseptic	O	O	B-Entity
compounding	O	O	O
to	O	O	O
prepare	O	O	O
cefuroxime	O	O	B-Entity
aliquots	O	O	B-Entity
by	O	O	O
hospital	O	O	B-Entity
pharmacy	O	O	I-Entity
appeared	O	O	O
to	O	O	O
be	O	O	O
safe	O	O	O
and	O	O	O
efficacious	O	O	O
.	O	O	O

-DOCSTART- (27554917)

A	O	O	O
standardized	O	O	O
approach	O	O	O
for	O	O	O
the	O	O	O
assessment	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
internationally	O	O	B-Entity
adopted	O	O	B-Entity
children	O	O	I-Entity
with	O	O	O
a	O	O	O
previously	O	O	O
repaired	O	O	O
anorectal	O	O	B-Entity
malformation	O	O	I-Entity
(	O	O	O
ARM	O	O	B-Entity
)	O	O	O

A	O	O	O
significant	O	O	O
number	O	O	O
of	O	O	O
internationally	O	O	B-Entity
adopted	O	O	B-Entity
children	O	O	I-Entity
have	O	O	O
congenital	O	O	B-Entity
birth	O	O	I-Entity
defects	O	O	I-Entity
.	O	O	O

As	O	O	O
a	O	O	O
specialist	O	O	O
center	O	O	O
for	O	O	O
colorectal	O	O	B-Entity
diagnoses	O	O	B-Entity
,	O	O	O
we	O	O	O
evaluate	O	O	O
such	O	O	O
children	O	O	B-Entity
with	O	O	O
an	O	O	O
anorectal	O	O	B-Entity
malformation	O	O	I-Entity
(	O	O	O
ARM	O	O	B-Entity
)	O	O	O
and	O	O	O
have	O	O	O
found	O	O	O
that	O	O	O
a	O	O	O
significant	O	O	O
number	O	O	O
need	O	O	O
a	O	O	O
reoperation	O	O	B-Entity
.	O	O	O

Knowledge	O	O	B-Entity
of	O	O	O
the	O	O	O
common	O	O	O
complications	O	O	B-Entity
following	O	O	O
ARM	O	O	B-Entity
surgery	O	O	B-Entity
has	O	O	O
led	O	O	O
us	O	O	O
to	O	O	O
develop	O	O	O
treatment	O	O	B-Entity
algorithms	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
unknown	O	O	O
past	O	O	B-Entity
medical	O	O	I-Entity
and	O	O	O
surgical	O	O	B-Entity
history	O	O	I-Entity
,	O	O	O
a	O	O	O
situation	O	O	O
typically	O	O	O
encountered	O	O	O
in	O	O	O
the	O	O	O
adopted	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
investigations	O	O	B-Entity
,	O	O	O
indications	O	O	B-Entity
,	O	O	O
and	O	O	O
rate	O	O	B-Entity
of	O	O	O
reoperation	O	O	B-Entity
were	O	O	O
assessed	O	O	O
for	O	O	O
adopted	O	O	B-Entity
children	O	O	I-Entity
with	O	O	O
an	O	O	O
ARM	O	O	B-Entity
evaluated	O	O	O
between	O	O	O
2014	O	O	O
and	O	O	O
2016	O	O	O
.	O	O	O

56	O	O	O
patients	O	O	B-Entity
(	O	O	O
28	O	O	O
males	O	O	B-Entity
)	O	O	O
were	O	O	O
identified	O	O	O
.	O	O	O

76.8	O	O	O
%	O	O	O
required	O	O	O
reoperative	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Mislocation	O	O	O
of	O	O	O
the	O	O	O
anus	O	O	B-Entity
outside	O	O	B-Entity
the	O	O	O
sphincter	O	O	B-Entity
complex	O	O	O
was	O	O	O
seen	O	O	O
in	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
males	O	O	B-Entity
and	O	O	O
39.3	O	O	O
%	O	O	O
of	O	O	O
females	O	O	B-Entity
.	O	O	O

Anal	O	O	B-Entity
stricture	O	O	I-Entity
,	O	O	O
rectal	O	O	B-Entity
prolapse	O	O	I-Entity
,	O	O	O
retained	O	O	B-Entity
vaginal	O	O	B-Entity
septum	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
strictured	O	O	B-Entity
vaginal	O	O	B-Entity
introitus	O	O	I-Entity
were	O	O	O
also	O	O	O
common	O	O	O
.	O	O	O

The	O	O	O
reoperative	O	O	B-Entity
surgery	O	O	I-Entity
rate	O	O	B-Entity
in	O	O	O
the	O	O	O
internationally	O	O	B-Entity
adopted	O	O	B-Entity
child	O	O	I-Entity
with	O	O	O
an	O	O	O
ARM	O	O	B-Entity
is	O	O	O
high	O	O	O
.	O	O	O

Complete	O	O	O
,	O	O	O
systematic	O	O	O
evaluation	O	O	O
of	O	O	O
these	O	O	O
children	O	O	B-Entity
is	O	O	O
required	O	O	O
to	O	O	O
identify	O	O	O
complications	O	O	B-Entity
following	O	O	O
initial	O	O	O
repair	O	O	B-Entity
.	O	O	O

Development	O	O	O
of	O	O	O
mechanisms	O	O	O
to	O	O	O
improve	O	O	O
the	O	O	O
primary	O	O	O
surgical	O	O	B-Entity
care	O	O	I-Entity
these	O	O	O
children	O	O	B-Entity
receive	O	O	O
is	O	O	O
needed	O	O	O
.	O	O	O

-DOCSTART- (27558793)

Highly	O	O	O
fluorescent	O	O	B-Entity
gold	O	O	B-Entity
nanoclusters	O	O	B-Entity
stabilized	O	O	O
by	O	O	O
food	O	O	B-Entity
proteins	O	O	I-Entity
:	O	O	O
From	O	O	O
preparation	O	O	O
to	O	O	O
application	O	O	O
in	O	O	O
detection	O	O	B-Entity
of	O	O	O
food	O	O	O
contaminants	O	O	B-Entity
and	O	O	O
bioactive	O	O	O
nutrients	O	O	O

Applications	O	O	O
of	O	O	O
nanotechnology	O	O	B-Entity
in	O	O	O
food	O	O	B-Entity
have	O	O	O
rapidly	O	O	O
increased	O	O	O
in	O	O	O
the	O	O	O
past	O	O	O
decades	O	O	O
.	O	O	O

Ultra-small	O	O	B-Entity
gold	O	O	I-Entity
nanoclusters	O	O	I-Entity
(	O	O	O
Au	O	O	B-Entity
NCs	O	O	I-Entity
)	O	O	O
,	O	O	O
composed	O	O	O
of	O	O	O
several	O	O	O
to	O	O	O
roughly	O	O	O
a	O	O	O
hundred	O	O	O
atoms	O	O	O
,	O	O	O
represent	O	O	O
a	O	O	O
kind	O	O	O
of	O	O	O
novel	O	O	O
nanomaterials	O	O	B-Entity
.	O	O	O

The	O	O	O
Au	O	O	B-Entity
NCs	O	O	I-Entity
directed	O	O	O
by	O	O	O
food	O	O	B-Entity
proteins	O	O	I-Entity
have	O	O	O
drawn	O	O	O
considerable	O	O	O
research	O	O	O
attention	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
environmentally	O	O	B-Entity
friendly	O	O	I-Entity
preparation	O	O	I-Entity
,	O	O	O
strong	O	O	O
fluorescence	O	O	B-Entity
,	O	O	O
excellent	O	O	O
photo-stability	O	O	B-Entity
and	O	O	O
favorable	O	O	O
biocompatibility	O	O	B-Entity
.	O	O	O

These	O	O	O
interesting	O	O	O
protein-Au	O	O	B-Entity
hybrids	O	O	I-Entity
have	O	O	O
opened	O	O	O
up	O	O	O
a	O	O	O
new	O	O	O
area	O	O	O
at	O	O	O
the	O	O	O
nano-bio-food	O	O	B-Entity
interface	O	O	I-Entity
,	O	O	O
not	O	O	O
only	O	O	O
did	O	O	O
they	O	O	O
provide	O	O	O
the	O	O	O
missing	O	O	O
link	O	O	O
between	O	O	O
single	O	O	B-Entity
metal	O	O	I-Entity
atoms	O	O	I-Entity
and	O	O	O
plasmonic	O	O	B-Entity
metal	O	O	B-Entity
nanoparticles	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
developed	O	O	O
the	O	O	O
hybrid	O	O	B-Entity
system	O	O	I-Entity
between	O	O	O
biomacromolecule	O	O	B-Entity
and	O	O	O
inorganic	O	O	B-Entity
ions	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
review	O	O	O
,	O	O	O
we	O	O	O
highlighted	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
strategies	O	O	O
and	O	O	O
optical	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
the	O	O	O
Au	O	O	B-Entity
NCs	O	O	I-Entity
stabilized	O	O	O
by	O	O	O
typical	O	O	O
food	O	O	B-Entity
proteins	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
their	O	O	O
applications	O	O	O
in	O	O	O
detection	O	O	B-Entity
of	O	O	O
food	O	O	O
contaminants	O	O	B-Entity
or	O	O	O
bioactive	O	O	B-Entity
nutrients	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
discussed	O	O	O
current	O	O	O
challenges	O	O	O
and	O	O	O
future	O	O	O
development	O	O	O
in	O	O	O
food	O	O	B-Entity
proteins	O	O	I-Entity
directed	O	O	O
gold	O	O	B-Entity
nanoclusters	O	O	I-Entity
for	O	O	O
size-controlled	O	O	O
synthesis	O	O	B-Entity
and	O	O	O
multifunctional	O	O	O
applications	O	O	O
.	O	O	O

-DOCSTART- (27562025)

Sub-lethal	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
dietary	O	O	B-Entity
neonicotinoid	O	O	B-Entity
insecticide	O	O	I-Entity
exposure	O	O	B-Entity
on	O	O	O
honey	O	O	B-Entity
bee	O	O	I-Entity
queen	O	O	I-Entity
fecundity	O	O	B-Entity
and	O	O	O
colony	O	O	B-Entity
development	O	O	O

Many	O	O	O
factors	O	O	B-Entity
can	O	O	O
negatively	O	O	B-Entity
affect	O	O	O
honey	O	O	B-Entity
bee	O	O	I-Entity
(	O	O	O
Apis	O	O	B-Entity
mellifera	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
health	O	O	B-Entity
including	O	O	O
the	O	O	O
pervasive	O	O	B-Entity
use	O	O	O
of	O	O	O
systemic	O	O	B-Entity
neonicotinoid	O	O	B-Entity
insecticides	O	O	I-Entity
.	O	O	O

Through	O	O	O
direct	O	O	O
consumption	O	O	B-Entity
of	O	O	O
contaminated	O	O	B-Entity
nectar	O	O	B-Entity
and	O	O	O
pollen	O	O	B-Entity
from	O	O	O
treated	O	O	B-Entity
plants	O	O	B-Entity
,	O	O	O
neonicotinoids	O	O	B-Entity
can	O	O	O
affect	O	O	O
foraging	O	O	B-Entity
,	O	O	O
learning	O	O	B-Entity
,	O	O	O
and	O	O	O
memory	O	O	B-Entity
in	O	O	O
worker	O	O	B-Entity
bees	O	O	I-Entity
.	O	O	O

Less	O	O	O
well	O	O	O
studied	O	O	O
are	O	O	O
the	O	O	O
potential	O	O	O
effects	O	O	O
of	O	O	O
neonicotinoids	O	O	B-Entity
on	O	O	O
queen	O	O	B-Entity
bees	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
be	O	O	O
exposed	O	O	O
indirectly	O	O	O
through	O	O	O
trophallaxis	O	O	B-Entity
,	O	O	O
or	O	O	O
food	O	O	B-Entity
-	O	O	O
sharing	O	O	B-Entity
.	O	O	O

To	O	O	O
assess	O	O	B-Entity
effects	O	O	O
on	O	O	O
queen	O	O	B-Entity
productivity	O	O	B-Entity
,	O	O	O
small	O	O	B-Entity
colonies	O	O	B-Entity
of	O	O	O
different	O	O	O
sizes	O	O	B-Entity
(	O	O	O
1500	O	O	O
,	O	O	O
3000	O	O	O
,	O	O	O
and	O	O	O
7000	O	O	O
bees	O	O	B-Entity
)	O	O	O
were	O	O	O
fed	O	O	B-Entity
imidacloprid	O	O	B-Entity
(	O	O	O
0	O	O	O
,	O	O	O
10	O	O	O
,	O	O	O
20	O	O	O
,	O	O	O
50	O	O	O
,	O	O	O
and	O	O	O
100	O	O	O
ppb	O	O	O
)	O	O	O
in	O	O	O
syrup	O	O	B-Entity
for	O	O	O
three	O	O	O
weeks	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
adverse	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
imidacloprid	O	O	B-Entity
on	O	O	O
queens	O	O	B-Entity
(	O	O	O
egg-laying	O	O	B-Entity
and	O	O	O
locomotor	O	O	B-Entity
activity	O	O	I-Entity
)	O	O	O
,	O	O	O
worker	O	O	B-Entity
bees	O	O	I-Entity
(	O	O	O
foraging	O	O	B-Entity
and	O	O	O
hygienic	O	O	B-Entity
activities	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
colony	O	O	B-Entity
development	O	O	B-Entity
(	O	O	O
brood	O	O	B-Entity
production	O	O	O
and	O	O	O
pollen	O	O	B-Entity
stores	O	O	O
)	O	O	O
in	O	O	O
all	O	O	O
treated	O	O	B-Entity
colonies	O	O	B-Entity
.	O	O	O

Some	O	O	O
effects	O	O	O
were	O	O	O
less	O	O	B-Entity
evident	O	O	O
as	O	O	O
colony	O	O	B-Entity
size	O	O	B-Entity
increased	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
larger	O	O	B-Entity
colony	O	O	O
populations	O	O	B-Entity
may	O	O	O
act	O	O	O
as	O	O	O
a	O	O	O
buffer	O	O	O
to	O	O	O
pesticide	O	O	B-Entity
exposure	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
is	O	O	O
the	O	O	O
first	O	O	O
to	O	O	O
show	O	O	O
adverse	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
imidacloprid	O	O	B-Entity
on	O	O	O
queen	O	O	B-Entity
bee	O	O	I-Entity
fecundity	O	O	B-Entity
and	O	O	O
behavior	O	O	B-Entity
and	O	O	O
improves	O	O	B-Entity
our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
how	O	O	O
neonicotinoids	O	O	B-Entity
may	O	O	O
impair	O	O	B-Entity
short-term	O	O	O
colony	O	O	B-Entity
functioning	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
indicate	O	O	O
that	O	O	O
risk-mitigation	O	O	B-Entity
efforts	O	O	I-Entity
should	O	O	O
focus	O	O	O
on	O	O	O
reducing	O	O	B-Entity
neonicotinoid	O	O	B-Entity
exposure	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
spring	O	O	I-Entity
when	O	O	O
colonies	O	O	B-Entity
are	O	O	O
smallest	O	O	B-Entity
and	O	O	O
queens	O	O	B-Entity
are	O	O	O
most	O	O	O
vulnerable	O	O	B-Entity
to	O	O	O
exposure	O	O	O
.	O	O	O

-DOCSTART- (27562951)

Therapeutic	O	O	B-Entity
applications	O	O	I-Entity
of	O	O	O
CRISPR	O	O	B-Entity
RNA-guided	O	O	B-Entity
genome	O	O	O
editing	O	O	O

The	O	O	O
rapid	O	O	O
development	O	O	O
of	O	O	O
programmable	O	O	B-Entity
nuclease	O	O	I-Entity
-based	O	O	O
genome	O	O	B-Entity
editing	O	O	I-Entity
technologies	O	O	B-Entity
has	O	O	O
enabled	O	O	O
targeted	O	O	B-Entity
gene	O	O	B-Entity
disruption	O	O	B-Entity
and	O	O	O
correction	O	O	B-Entity
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
This	O	O	O
revolution	O	O	O
opens	O	O	O
up	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
precise	O	O	O
genome	O	O	O
editing	O	O	O
at	O	O	O
target	O	O	B-Entity
genomic	O	O	B-Entity
sites	O	O	I-Entity
to	O	O	O
modulate	O	O	O
gene	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
animals	O	O	B-Entity
and	O	O	O
plants	O	O	B-Entity
.	O	O	O

Among	O	O	O
several	O	O	O
programmable	O	O	B-Entity
nucleases	O	O	I-Entity
,	O	O	O
the	O	O	O
type	O	O	B-Entity
II	O	O	I-Entity
clustered	O	O	I-Entity
regularly	O	O	I-Entity
interspaced	O	O	I-Entity
short	O	O	I-Entity
palindromic	O	O	I-Entity
repeats	O	O	I-Entity
(CRISPR)-	O	O	O
CRISPR-associated	O	O	B-Entity
nuclease	O	O	I-Entity
9	O	O	I-Entity
(	O	O	I-Entity
Cas9	O	O	I-Entity
)	O	O	I-Entity
system	O	O	I-Entity
has	O	O	O
progressed	O	O	O
remarkably	O	O	O
in	O	O	O
recent	O	O	O
years	O	O	O
,	O	O	O
leading	O	O	O
to	O	O	O
its	O	O	O
widespread	O	O	O
use	O	O	O
in	O	O	O
research	O	O	B-Entity
,	O	O	O
medicine	O	O	B-Entity
and	O	O	O
biotechnology	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
CRISPR-Cas9	O	O	B-Entity
shows	O	O	O
highly	O	O	O
efficient	O	O	O
gene	O	O	B-Entity
editing	O	O	I-Entity
activity	O	O	O
for	O	O	O
therapeutic	O	O	B-Entity
purposes	O	O	I-Entity
in	O	O	O
systems	O	O	O
ranging	O	O	O
from	O	O	O
patient	O	O	B-Entity
stem	O	O	B-Entity
cells	O	O	I-Entity
to	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
therapeutic	O	O	B-Entity
approaches	O	O	I-Entity
and	O	O	O
delivery	O	O	B-Entity
methods	O	O	I-Entity
remains	O	O	O
a	O	O	O
great	O	O	O
challenge	O	O	O
for	O	O	O
biomedical	O	O	B-Entity
applications	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
review	O	O	O
therapeutic	O	O	B-Entity
applications	O	O	I-Entity
that	O	O	O
use	O	O	O
the	O	O	O
CRISPR-Cas9	O	O	B-Entity
system	O	O	I-Entity
and	O	O	O
discuss	O	O	O
the	O	O	O
possibilities	O	O	O
and	O	O	O
challenges	O	O	O
ahead	O	O	O
.	O	O	O

-DOCSTART- (27563235)

Design	O	O	B-Entity
and	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
cytotoxic	O	O	B-Entity
fibroblast	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
1	O	O	I-Entity
conjugate	O	O	B-Entity
for	O	O	O
fibroblast	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
receptor	O	O	I-Entity
-	O	O	O
targeted	O	O	O
cancer	O	O	O
therapy	O	O	O

Fibroblast	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
receptors	O	O	I-Entity
(	O	O	O
FGFRs	O	O	B-Entity
)	O	O	O
are	O	O	O
attractive	O	O	O
candidate	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
targets	O	O	B-Entity
as	O	O	O
they	O	O	O
are	O	O	O
overexpressed	O	O	B-Entity
in	O	O	O
multiple	O	O	B-Entity
types	O	O	O
of	O	O	O
tumors	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
breast	O	O	B-Entity
,	O	O	O
prostate	O	O	B-Entity
,	O	O	O
bladder	O	O	B-Entity
,	O	O	O
and	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
a	O	O	O
natural	O	O	B-Entity
ligand	O	O	I-Entity
of	O	O	O
FGFR	O	O	B-Entity
,	O	O	O
an	O	O	O
engineered	O	O	B-Entity
variant	O	O	I-Entity
of	O	O	O
fibroblast	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
FGF1V	O	O	B-Entity
)	O	O	O
,	O	O	O
was	O	O	O
conjugated	O	O	B-Entity
to	O	O	O
a	O	O	O
potent	O	O	B-Entity
cytotoxic	O	O	I-Entity
drug	O	O	I-Entity
,	O	O	O
monomethyl	O	O	B-Entity
auristatin	O	O	I-Entity
E	O	O	I-Entity
(	O	O	O
MMAE	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
targeting	O	O	B-Entity
agent	O	O	I-Entity
for	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
overexpressing	O	O	B-Entity
FGFRs	O	O	B-Entity
,	O	O	O
similar	O	O	O
to	O	O	O
antibodies	O	O	B-Entity
in	O	O	O
antibody-drug	O	O	B-Entity
conjugates	O	O	I-Entity
.	O	O	O

The	O	O	O
FGF1V-valine-citrulline-MMAE	O	O	B-Entity
conjugate	O	O	B-Entity
showed	O	O	O
a	O	O	O
favorable	O	O	O
stability	O	O	B-Entity
profile	O	O	I-Entity
,	O	O	O
bound	O	O	B-Entity
FGFRs	O	O	B-Entity
on	O	O	O
the	O	O	O
cell	O	O	B-Entity
surface	O	O	I-Entity
specifically	O	O	B-Entity
,	O	O	O
and	O	O	O
efficiently	O	O	B-Entity
released	O	O	B-Entity
the	O	O	O
drug	O	O	B-Entity
(	O	O	I-Entity
MMAE	O	O	I-Entity
)	O	O	I-Entity
upon	O	O	O
cleavage	O	O	B-Entity
by	O	O	O
the	O	O	O
lysosomal	O	O	O
protease	O	O	O
cathepsin	O	O	O
B.	O	O	O
Importantly	O	O	O
,	O	O	O
the	O	O	O
conjugate	O	O	O
showed	O	O	O
a	O	O	O
prominent	O	O	B-Entity
cytotoxic	O	O	B-Entity
effect	O	O	I-Entity
toward	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
expressing	O	O	B-Entity
FGFR	O	O	B-Entity
.	O	O	O

FGF1V-vcMMAE	O	O	B-Entity
was	O	O	O
highly	O	O	O
cytotoxic	O	O	B-Entity
at	O	O	O
concentrations	O	O	B-Entity
even	O	O	O
an	O	O	O
order	O	O	O
of	O	O	O
magnitude	O	O	O
lower	O	O	B-Entity
than	O	O	O
those	O	O	O
found	O	O	O
for	O	O	O
free	O	O	O
MMAE	O	O	B-Entity
.	O	O	O

This	O	O	O
effect	O	O	O
was	O	O	O
FGFR	O	O	B-Entity
-specific	O	O	O
as	O	O	O
cells	O	O	B-Entity
lacking	O	O	B-Entity
FGFR	O	O	O
did	O	O	B-Entity
not	O	O	I-Entity
show	O	O	I-Entity
any	O	O	O
increased	O	O	B-Entity
mortality	O	O	B-Entity
.	O	O	O

-DOCSTART- (27565311)

Effects	O	O	O
of	O	O	O
morphology	O	O	B-Entity
and	O	O	O
surface	O	O	B-Entity
hydroxyl	O	O	I-Entity
on	O	O	O
the	O	O	O
toxicity	O	O	B-Entity
of	O	O	O
BiOCl	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
HaCaT	O	O	O
cells	O	O	O

Recently	O	O	O
,	O	O	O
bismuth	O	O	B-Entity
oxychloride	O	O	I-Entity
nanomaterials	O	O	B-Entity
(	O	O	O
BiOCls	O	O	B-Entity
)	O	O	O
are	O	O	O
showing	O	O	O
great	O	O	O
promise	O	O	O
in	O	O	O
pollutant	O	O	B-Entity
removal	O	O	B-Entity
.	O	O	O

Residues	O	O	B-Entity
from	O	O	O
these	O	O	O
environmental	O	O	B-Entity
remediations	O	O	I-Entity
are	O	O	O
potential	O	O	O
hazardous	O	O	B-Entity
materials	O	O	I-Entity
.	O	O	O

Unfortunately	O	O	O
,	O	O	O
human	O	O	B-Entity
health	O	O	B-Entity
risks	O	O	I-Entity
of	O	O	O
BiOCls	O	O	B-Entity
are	O	O	O
still	O	O	O
unexplored	O	O	O
widely	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
focused	O	O	O
on	O	O	O
the	O	O	O
influence	O	O	O
of	O	O	O
physicochemical	O	O	B-Entity
properties	O	O	I-Entity
on	O	O	O
the	O	O	O
cytotoxicity	O	O	B-Entity
of	O	O	O
BiOCls	O	O	B-Entity
toward	O	O	O
a	O	O	O
human	O	O	B-Entity
skin	O	O	B-Entity
derived	O	O	O
cell	O	O	B-Entity
line	O	O	I-Entity
(	O	O	O
HaCaT	O	O	B-Entity
)	O	O	O
.	O	O	O

Results	O	O	O
showed	O	O	O
that	O	O	O
morphology	O	O	B-Entity
and	O	O	O
surface	O	O	B-Entity
hydroxyl	O	O	I-Entity
both	O	O	O
had	O	O	O
a	O	O	O
profound	O	O	O
effect	O	O	O
on	O	O	O
the	O	O	O
toxicity	O	O	B-Entity
of	O	O	O
BiOCls	O	O	B-Entity
.	O	O	O

Microsphere-shaped	O	O	B-Entity
BiOCl	O	O	B-Entity
caused	O	O	O
less	O	O	O
toxicity	O	O	B-Entity
than	O	O	O
nanosheet-shaped	O	O	B-Entity
BiOCl	O	O	O
because	O	O	O
of	O	O	O
weaker	O	O	B-Entity
particle-membrane	O	O	I-Entity
interactions	O	O	I-Entity
,	O	O	O
while	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
surface	O	O	B-Entity
hydroxyl	O	O	I-Entity
on	O	O	O
microsphere-shaped	O	O	B-Entity
BiOCl	O	O	O
significantly	O	O	O
raised	O	O	O
the	O	O	O
toxicity	O	O	O
owing	O	O	O
to	O	O	O
the	O	O	O
increased	O	O	O
interaction	O	O	B-Entity
with	O	O	O
cell	O	O	B-Entity
membrane	O	O	I-Entity
.	O	O	O

Both	O	O	O
microsphere-shaped	O	O	B-Entity
BiOCl	O	O	B-Entity
with	O	O	O
surface	O	O	B-Entity
hydroxyl	O	O	I-Entity
and	O	O	O
nanosheet-shaped	O	O	B-Entity
BiOCl	O	O	O
caused	O	O	O
significant	O	O	O
cell	O	O	B-Entity
membrane	O	O	I-Entity
damage	O	O	B-Entity
(	O	O	O
PI	O	O	B-Entity
uptake	O	O	O
and	O	O	O
LDH	O	O	B-Entity
release	O	O	O
)	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
different	O	O	O
mechanism	O	O	B-Entity
.	O	O	O

The	O	O	O
former	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
predominant	O	O	O
"	O	O	B-Entity
chemical	O	O	I-Entity
"	O	O	I-Entity
mechanism	O	O	I-Entity
involved	O	O	O
an	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
paradigm	O	O	I-Entity
,	O	O	O
as	O	O	O
manifested	O	O	O
by	O	O	O
elevated	O	O	O
ROS	O	O	B-Entity
and	O	O	O
depleted	O	O	O
GSH	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
latter	O	O	O
is	O	O	O
mainly	O	O	O
due	O	O	O
to	O	O	O
a	O	O	O
direct	O	O	O
"	O	O	O
physical	O	O	B-Entity
"	O	O	O
damage	O	O	B-Entity
to	O	O	O
cell	O	O	B-Entity
membrane	O	O	I-Entity
.	O	O	O

Both	O	O	O
"	O	O	O
physical	O	O	B-Entity
"	O	O	O
and	O	O	O
"	O	O	B-Entity
chemical	O	O	I-Entity
"	O	O	I-Entity
response	O	O	I-Entity
led	O	O	O
to	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
experiments	O	O	B-Entity
including	O	O	O
MMP	O	O	B-Entity
collapse	O	O	O
,	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
arrest	O	O	I-Entity
,	O	O	O
and	O	O	O
apoptosis	O	O	B-Entity
/	O	O	O
necrosis	O	O	B-Entity
were	O	O	O
conducted	O	O	O
to	O	O	O
propose	O	O	O
a	O	O	O
scenario	O	O	O
for	O	O	O
toxicological	O	O	B-Entity
aspects	O	O	I-Entity
of	O	O	O
BiOCls	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
presented	O	O	O
here	O	O	O
would	O	O	O
help	O	O	O
to	O	O	O
enable	O	O	O
the	O	O	O
rational	O	O	B-Entity
design	O	O	I-Entity
of	O	O	O
BiOCls	O	O	B-Entity
for	O	O	O
either	O	O	O
reducing	O	O	O
their	O	O	O
unintended	O	O	B-Entity
consequences	O	O	I-Entity
or	O	O	O
increasing	O	O	O
their	O	O	O
application	O	O	B-Entity
potentials	O	O	I-Entity
.	O	O	O

-DOCSTART- (27566296)

Reduced	O	O	B-Entity
haemodynamic	O	O	B-Entity
coupling	O	O	I-Entity
and	O	O	O
exercise	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
vascular	O	O	B-Entity
stiffening	O	O	I-Entity
in	O	O	O
pulmonary	O	O	O
arterial	O	O	O
hypertension	O	O	O

Inadequate	O	O	B-Entity
right	O	O	B-Entity
ventricular	O	O	I-Entity
(	O	O	O
RV	O	O	B-Entity
)	O	O	O
and	O	O	O
pulmonary	O	O	B-Entity
arterial	O	O	I-Entity
(	O	O	O
PA	O	O	B-Entity
)	O	O	O
functional	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
exercise	O	O	B-Entity
are	O	O	O
important	O	O	O
yet	O	O	O
poorly	O	O	O
understood	O	O	O
features	O	O	O
of	O	O	O
pulmonary	O	O	B-Entity
arterial	O	O	I-Entity
hypertension	O	O	I-Entity
(	O	O	O
PAH	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
combined	O	O	O
invasive	O	O	B-Entity
catheterisation	O	O	B-Entity
with	O	O	O
echocardiography	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
RV	O	O	B-Entity
afterload	O	O	O
,	O	O	O
RV	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
ventricular	O	O	B-Entity
-	O	O	O
vascular	O	O	B-Entity
coupling	O	O	B-Entity
in	O	O	O
subjects	O	O	B-Entity
with	O	O	O
PAH	O	O	B-Entity
.	O	O	O

Twenty-six	O	O	O
subjects	O	O	B-Entity
with	O	O	O
PAH	O	O	B-Entity
were	O	O	O
prospectively	O	O	O
recruited	O	O	O
to	O	O	O
undergo	O	O	O
right	O	O	B-Entity
heart	O	O	I-Entity
catheterisation	O	O	B-Entity
and	O	O	O
Doppler	O	O	B-Entity
echocardiography	O	O	I-Entity
at	O	O	O
rest	O	O	B-Entity
and	O	O	O
during	O	O	O
incremental	O	O	B-Entity
exercise	O	O	B-Entity
,	O	O	O
and	O	O	O
cardiac	O	O	B-Entity
MRI	O	O	I-Entity
at	O	O	O
rest	O	O	O
.	O	O	O

Measurements	O	O	B-Entity
at	O	O	O
rest	O	O	B-Entity
included	O	O	O
basic	O	O	O
haemodynamics	O	O	B-Entity
,	O	O	O
RV	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
coupling	O	O	B-Entity
efficiency	O	O	I-Entity
(	O	O	O
η	O	O	B-Entity
)	O	O	O
.	O	O	O

Measurements	O	O	B-Entity
during	O	O	O
incremental	O	O	B-Entity
exercise	O	O	B-Entity
included	O	O	O
pulmonary	O	O	B-Entity
vascular	O	O	I-Entity
resistance	O	O	I-Entity
(	O	O	O
Z0	O	O	B-Entity
)	O	O	O
,	O	O	O
characteristic	O	O	B-Entity
impedance	O	O	I-Entity
(	O	O	O
ZC	O	O	B-Entity
,	O	O	O
a	O	O	O
measure	O	O	B-Entity
of	O	O	O
proximal	O	O	B-Entity
PA	O	O	B-Entity
stiffness	O	O	B-Entity
)	O	O	O
and	O	O	O
proximal	O	O	O
and	O	O	O
distal	O	O	B-Entity
PA	O	O	O
compliance	O	O	O
(	O	O	O
CPA	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
PAH	O	O	B-Entity
,	O	O	O
the	O	O	O
proximal	O	O	B-Entity
PAs	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
stiffer	O	O	B-Entity
at	O	O	O
maximum	O	O	B-Entity
exercise	O	O	B-Entity
(	O	O	O
ZC	O	O	B-Entity
=	O	O	O
2.31±0.38	O	O	O
vs	O	O	O
1.33±0.15	O	O	O
WU	O	O	O
×	O	O	O
m(2	O	O	O
)	O	O	O
at	O	O	O
rest	O	O	B-Entity
;	O	O	O
p=0.003	O	O	O
)	O	O	O
and	O	O	O
PA	O	O	O
compliance	O	O	O
was	O	O	O
decreased	O	O	B-Entity
(	O	O	O
CPA	O	O	O
=	O	O	O
0.88±0.10	O	O	O
vs	O	O	O
1.32±0.17	O	O	O
mL/mm	O	O	O
Hg/m(2	O	O	O
)	O	O	O
at	O	O	O
rest	O	O	O
;	O	O	O
p=0.0002	O	O	O
)	O	O	O
.	O	O	O

Z0	O	O	B-Entity
did	O	O	O
not	O	O	O
change	O	O	O
with	O	O	O
exercise	O	O	B-Entity
.	O	O	O

As	O	O	O
a	O	O	O
result	O	O	O
,	O	O	O
the	O	O	O
resistance-compliance	O	O	B-Entity
(	O	O	I-Entity
RC	O	O	I-Entity
)	O	O	I-Entity
time	O	O	I-Entity
decreased	O	O	B-Entity
with	O	O	O
exercise	O	O	B-Entity
(	O	O	O
0.67±0.05	O	O	O
vs	O	O	O
1.00±0.07	O	O	O
s	O	O	O
at	O	O	O
rest	O	O	B-Entity
;	O	O	O
p<10(-6	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
patients	O	O	B-Entity
were	O	O	O
grouped	O	O	O
according	O	O	O
to	O	O	O
resting	O	O	B-Entity
coupling	O	O	B-Entity
efficiency	O	O	I-Entity
,	O	O	O
those	O	O	O
with	O	O	O
poorer	O	O	O
η	O	O	B-Entity
exhibited	O	O	O
stiffer	O	O	B-Entity
proximal	O	O	B-Entity
PAs	O	O	B-Entity
at	O	O	O
rest	O	O	B-Entity
,	O	O	O
a	O	O	O
lower	O	O	O
maximum	O	O	B-Entity
exercise	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
and	O	O	O
more	O	O	O
limited	O	O	O
CPA	O	O	O
reduction	O	O	B-Entity
at	O	O	O
maximum	O	O	O
exercise	O	O	O
.	O	O	O

In	O	O	O
PAH	O	O	B-Entity
,	O	O	O
exercise	O	O	B-Entity
causes	O	O	O
proximal	O	O	B-Entity
and	O	O	O
distal	O	O	B-Entity
PA	O	O	B-Entity
stiffening	O	O	B-Entity
,	O	O	O
which	O	O	O
combined	O	O	O
with	O	O	O
preserved	O	O	O
Z0	O	O	B-Entity
results	O	O	O
in	O	O	O
decreased	O	O	B-Entity
RC	O	O	B-Entity
time	O	O	I-Entity
with	O	O	O
exercise	O	O	O
.	O	O	O

Stiff	O	O	B-Entity
PAs	O	O	I-Entity
at	O	O	O
rest	O	O	B-Entity
may	O	O	O
also	O	O	O
contribute	O	O	O
to	O	O	O
poor	O	O	O
haemodynamic	O	O	B-Entity
coupling	O	O	I-Entity
,	O	O	O
reflecting	O	O	O
reduced	O	O	B-Entity
pulmonary	O	O	B-Entity
vascular	O	O	I-Entity
reserve	O	O	O
that	O	O	O
contributes	O	O	B-Entity
to	O	O	O
limit	O	O	O
the	O	O	O
maximum	O	O	B-Entity
exercise	O	O	B-Entity
level	O	O	B-Entity
tolerated	O	O	O
.	O	O	O

-DOCSTART- (27566564)

Altered	O	O	B-Entity
pH	O	O	I-Entity
gradient	O	O	I-Entity
at	O	O	O
the	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
of	O	O	O
osteosarcoma	O	O	B-Entity
cells	O	O	B-Entity
is	O	O	O
a	O	O	O
key	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
drug	O	O	O
resistance	O	O	O

Current	O	O	O
therapy	O	O	B-Entity
of	O	O	O
osteosarcoma	O	O	B-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
primary	O	O	B-Entity
bone	O	O	I-Entity
malignancy	O	O	I-Entity
,	O	O	O
is	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	I-Entity
surgery	O	O	I-Entity
and	O	O	I-Entity
chemotherapy	O	O	I-Entity
.	O	O	O

Multidrug	O	O	B-Entity
resistance	O	O	I-Entity
mediated	O	O	O
by	O	O	O
P-glycoprotein	O	O	B-Entity
(	O	O	O
P-gp	O	O	B-Entity
)	O	O	O
overexpression	O	O	B-Entity
has	O	O	O
been	O	O	O
previously	O	O	O
associated	O	O	O
with	O	O	O
treatment	O	O	B-Entity
failure	O	O	I-Entity
and	O	O	O
progression	O	O	B-Entity
of	O	O	O
OS	O	O	B-Entity
,	O	O	O
although	O	O	O
other	O	O	O
mechanisms	O	O	B-Entity
may	O	O	O
also	O	O	O
play	O	O	O
a	O	O	O
role	O	O	O
.	O	O	O

We	O	O	O
considered	O	O	O
the	O	O	O
typical	O	O	O
acidic	O	O	B-Entity
extracellular	O	O	I-Entity
pH	O	O	I-Entity
(	O	O	O
pHe	O	O	B-Entity
)	O	O	O
of	O	O	O
sarcomas	O	O	B-Entity
,	O	O	O
and	O	O	O
found	O	O	O
that	O	O	O
doxorubicin	O	O	B-Entity
(	O	O	O
DXR	O	O	B-Entity
)	O	O	O
cytotoxicity	O	O	B-Entity
is	O	O	O
reduced	O	O	B-Entity
in	O	O	O
P-gp	O	O	B-Entity
negative	O	O	O
OS	O	O	B-Entity
cells	O	O	B-Entity
cultured	O	O	I-Entity
at	O	O	O
pHe	O	O	O
6.5	O	O	O
compared	O	O	O
to	O	O	O
standard	O	O	O
7.4	O	O	O
.	O	O	O

Short-time	O	O	B-Entity
(	O	O	O
24	O	O	O
-	O	O	O
48	O	O	O
hours	O	O	O
)	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
low	O	O	O
pHe	O	O	B-Entity
significantly	O	O	B-Entity
increased	O	O	I-Entity
the	O	O	O
number	O	O	O
and	O	O	O
acidity	O	O	B-Entity
of	O	O	O
lysosomes	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
combination	O	O	B-Entity
of	O	O	O
DXR	O	O	B-Entity
with	O	O	O
omeprazole	O	O	B-Entity
,	O	O	O
a	O	O	O
proton	O	O	B-Entity
pump	O	O	I-Entity
inhibitor	O	O	I-Entity
targeting	O	O	O
lysosomal	O	O	B-Entity
acidity	O	O	I-Entity
,	O	O	O
significantly	O	O	B-Entity
enhanced	O	O	I-Entity
DXR	O	O	O
cytotoxicity	O	O	B-Entity
.	O	O	O

In	O	O	O
OS	O	O	B-Entity
xenografts	O	O	B-Entity
,	O	O	O
the	O	O	O
combination	O	O	B-Entity
treatment	O	O	I-Entity
of	O	O	O
DXR	O	O	B-Entity
and	O	O	O
omeprazole	O	O	B-Entity
significantly	O	O	B-Entity
reduced	O	O	I-Entity
tumor	O	O	B-Entity
volume	O	O	I-Entity
and	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
loss	O	O	I-Entity
.	O	O	O

The	O	O	O
impaired	O	O	B-Entity
toxicity	O	O	I-Entity
of	O	O	O
DXR	O	O	B-Entity
at	O	O	O
low	O	O	O
pHe	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	B-Entity
autophagy	O	O	B-Entity
or	O	O	O
lysosomal	O	O	B-Entity
acidification	O	O	I-Entity
,	O	O	O
but	O	O	O
rather	O	O	O
,	O	O	O
as	O	O	O
shown	O	O	O
by	O	O	O
SNARF	O	O	B-Entity
staining	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
reversal	O	O	B-Entity
of	O	O	O
the	O	O	O
pH	O	O	B-Entity
gradient	O	O	I-Entity
at	O	O	O
the	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
(	O	O	O
ΔpHcm	O	O	B-Entity
)	O	O	O
,	O	O	O
eventually	O	O	O
leading	O	O	O
to	O	O	O
a	O	O	O
reduced	O	O	B-Entity
DXR	O	O	O
intracellular	O	O	B-Entity
accumulation	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
reversal	O	O	B-Entity
of	O	O	O
ΔpHcm	O	O	B-Entity
in	O	O	O
OS	O	O	B-Entity
cells	O	O	B-Entity
promoted	O	O	O
resistance	O	O	B-Entity
not	O	O	O
only	O	O	O
to	O	O	O
DXR	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
to	O	O	O
cisplatin	O	O	B-Entity
and	O	O	O
methotrexate	O	O	B-Entity
,	O	O	O
and	O	O	O
,	O	O	O
to	O	O	O
a	O	O	O
lesser	O	O	O
extent	O	O	O
,	O	O	O
to	O	O	O
vincristine	O	O	B-Entity
.	O	O	O

Altogether	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	O
show	O	O	O
that	O	O	O
,	O	O	O
in	O	O	O
OS	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
short-term	O	O	B-Entity
acidosis	O	O	B-Entity
induces	O	O	O
resistance	O	O	B-Entity
to	O	O	O
different	O	O	O
chemotherapeutic	O	O	B-Entity
drugs	O	O	I-Entity
by	O	O	O
a	O	O	O
reversal	O	O	B-Entity
of	O	O	O
ΔpHcm	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
buffer	O	O	B-Entity
therapies	O	O	B-Entity
or	O	O	O
regimens	O	O	B-Entity
including	O	O	O
proton	O	O	B-Entity
pump	O	O	I-Entity
inhibitors	O	O	I-Entity
in	O	O	O
combination	O	O	B-Entity
to	O	O	O
low	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
conventional	O	O	O
anticancer	O	O	B-Entity
agents	O	O	I-Entity
may	O	O	O
offer	O	O	O
novel	O	O	B-Entity
solutions	O	O	O
to	O	O	O
overcome	O	O	B-Entity
drug	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

-DOCSTART- (27566854)

Boston	O	O	B-Entity
Keratoprosthesis	O	O	I-Entity
Type	O	O	I-Entity
1	O	O	I-Entity
:	O	O	O
A	O	O	O
Randomized	O	O	B-Entity
Controlled	O	O	I-Entity
Trial	O	O	I-Entity
of	O	O	O
Fresh	O	O	B-Entity
versus	O	O	O
Frozen	O	O	B-Entity
Corneal	O	O	B-Entity
Donor	O	O	I-Entity
Carriers	O	O	I-Entity
with	O	O	O
Long-Term	O	O	B-Entity
Follow-up	O	O	O

To	O	O	O
compare	O	O	B-Entity
the	O	O	O
long-term	O	O	B-Entity
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
of	O	O	O
fresh	O	O	B-Entity
versus	O	O	O
frozen	O	O	B-Entity
corneal	O	O	B-Entity
graft	O	O	I-Entity
carriers	O	O	I-Entity
for	O	O	O
the	O	O	O
Boston	O	O	B-Entity
Keratoprosthesis	O	O	I-Entity
type	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
B-KPro	O	O	B-Entity
)	O	O	O
.	O	O	O

Prospective	O	O	O
,	O	O	O
single-center	O	O	O
,	O	O	O
nonblinded	O	O	B-Entity
,	O	O	O
randomized	O	O	O
controlled	O	O	O
trial	O	O	O
.	O	O	O

All	O	O	O
participants	O	O	B-Entity
were	O	O	O
followed	O	O	O
through	O	O	O
the	O	O	O
initial	O	O	B-Entity
study	O	O	B-Entity
protocol	O	O	I-Entity
of	O	O	O
24	O	O	O
months	O	O	B-Entity
and	O	O	O
were	O	O	O
approached	O	O	O
to	O	O	O
enter	O	O	O
an	O	O	O
extension	O	O	B-Entity
phase	O	O	B-Entity
,	O	O	O
with	O	O	O
continuing	O	O	O
follow-up	O	O	B-Entity
visits	O	O	I-Entity
to	O	O	O
60	O	O	O
months	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
B-KPro	O	O	B-Entity
surgery	O	O	I-Entity
between	O	O	O
October	O	O	O
2008	O	O	O
and	O	O	O
December	O	O	O
2009	O	O	O
by	O	O	O
a	O	O	O
single	O	O	O
experienced	O	O	B-Entity
surgeon	O	O	I-Entity
at	O	O	O
the	O	O	O
Centre	O	O	O
Hospitalier	O	O	B-Entity
de	O	O	I-Entity
l'Université	O	O	I-Entity
de	O	O	I-Entity
Montréal	O	O	I-Entity
using	O	O	O
an	O	O	O
allograft	O	O	B-Entity
carrier	O	O	I-Entity
were	O	O	O
considered	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
excluded	O	O	B-Entity
if	O	O	O
they	O	O	O
had	O	O	O
previously	O	O	B-Entity
undergone	O	O	O
B-KPro	O	O	B-Entity
implantation	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
randomized	O	O	B-Entity
individually	O	O	O
to	O	O	O
receive	O	O	B-Entity
a	O	O	O
B-KPro	O	O	B-Entity
using	O	O	O
a	O	O	O
frozen	O	O	B-Entity
or	O	O	O
a	O	O	O
fresh	O	O	B-Entity
corneal	O	O	B-Entity
graft	O	O	I-Entity
carrier	O	O	I-Entity
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
tissue	O	O	B-Entity
availability	O	O	B-Entity
on	O	O	O
the	O	O	O
day	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
,	O	O	O
as	O	O	O
determined	O	O	O
by	O	O	O
the	O	O	O
local	O	O	O
eye	O	O	B-Entity
bank	O	O	I-Entity
.	O	O	O

The	O	O	O
primary	O	O	O
outcome	O	O	B-Entity
measure	O	O	I-Entity
was	O	O	O
device	O	O	B-Entity
retention	O	O	I-Entity
at	O	O	O
24	O	O	O
and	O	O	O
60	O	O	O
months	O	O	B-Entity
.	O	O	O

Secondary	O	O	O
outcome	O	O	O
measures	O	O	O
included	O	O	O
surgical	O	O	B-Entity
feasibility	O	O	I-Entity
,	O	O	O
visual	O	O	B-Entity
acuity	O	O	I-Entity
(	O	O	O
VA	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
complications	O	O	B-Entity
.	O	O	O

Thirty-seven	O	O	O
eyes	O	O	B-Entity
of	O	O	O
37	O	O	O
patients	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
initial	O	O	B-Entity
study	O	O	B-Entity
protocol	O	O	I-Entity
,	O	O	O
with	O	O	O
19	O	O	O
eyes	O	O	O
randomized	O	O	B-Entity
to	O	O	O
fresh	O	O	B-Entity
and	O	O	O
18	O	O	O
to	O	O	O
frozen	O	O	B-Entity
carrier	O	O	B-Entity
grafts	O	O	I-Entity
.	O	O	O

Thirty-six	O	O	O
eyes	O	O	B-Entity
were	O	O	O
followed	O	O	O
through	O	O	O
to	O	O	O
24	O	O	O
months	O	O	B-Entity
,	O	O	O
with	O	O	O
1	O	O	O
lost	O	O	O
to	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Of	O	O	O
these	O	O	O
,	O	O	O
26	O	O	O
were	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
extension	O	O	B-Entity
(	O	O	O
11	O	O	O
eyes	O	O	B-Entity
with	O	O	O
a	O	O	O
frozen	O	O	B-Entity
and	O	O	O
15	O	O	O
eyes	O	O	O
with	O	O	O
a	O	O	O
fresh	O	O	B-Entity
carrier	O	O	B-Entity
graft	O	O	I-Entity
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
differences	O	O	I-Entity
in	O	O	O
the	O	O	O
baseline	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
enrolled	O	O	O
in	O	O	O
the	O	O	O
extension	O	O	B-Entity
phase	O	O	B-Entity
versus	O	O	O
those	O	O	O
who	O	O	O
were	O	O	O
not	O	O	O
.	O	O	O

At	O	O	O
60	O	O	O
months	O	O	B-Entity
,	O	O	O
median	O	O	O
corrected	O	O	O
distance	O	O	O
VA	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
fresh	O	O	B-Entity
group	O	O	I-Entity
had	O	O	O
improved	O	O	B-Entity
to	O	O	O
20/150	O	O	O
from	O	O	O
a	O	O	O
baseline	O	O	B-Entity
of	O	O	O
counting	O	O	O
fingers	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
frozen	O	O	B-Entity
group	O	O	I-Entity
improved	O	O	O
to	O	O	O
20/400	O	O	O
from	O	O	O
a	O	O	O
baseline	O	O	O
of	O	O	O
hand	O	O	O
motions	O	O	O
.	O	O	O

Device	O	O	B-Entity
retention	O	O	I-Entity
was	O	O	O
100	O	O	O
%	O	O	O
at	O	O	O
24	O	O	O
months	O	O	B-Entity
and	O	O	O
96	O	O	O
%	O	O	O
at	O	O	O
60	O	O	O
months	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
significant	O	O	O
differences	O	O	B-Entity
in	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
complications	O	O	B-Entity
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

Fresh	O	O	B-Entity
and	O	O	O
frozen	O	O	B-Entity
corneal	O	O	B-Entity
donors	O	O	I-Entity
offer	O	O	O
similar	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
when	O	O	O
used	O	O	O
as	O	O	O
carriers	O	O	B-Entity
for	O	O	O
the	O	O	O
B-KPro	O	O	B-Entity
,	O	O	O
with	O	O	O
no	O	O	O
significant	O	O	O
differences	O	O	B-Entity
in	O	O	O
device	O	O	B-Entity
retention	O	O	I-Entity
,	O	O	O
visual	O	O	B-Entity
rehabilitation	O	O	I-Entity
,	O	O	O
or	O	O	O
rates	O	O	B-Entity
of	O	O	O
complications	O	O	B-Entity
at	O	O	O
24	O	O	O
or	O	O	O
60	O	O	O
months	O	O	B-Entity
.	O	O	O

-DOCSTART- (27567148)

Impact	O	O	B-Entity
of	O	O	O
an	O	O	O
Educational	O	O	B-Entity
Intervention	O	O	I-Entity
to	O	O	O
Improve	O	O	B-Entity
Antibiotic	O	O	B-Entity
Prescribing	O	O	B-Entity
for	O	O	O
Nurse	O	O	B-Entity
Practitioners	O	O	I-Entity
in	O	O	O
a	O	O	O
Pediatric	O	O	B-Entity
Urgent	O	O	O
Care	O	O	O
Center	O	O	O

Up	O	O	O
to	O	O	O
21	O	O	O
%	O	O	O
of	O	O	O
pediatric	O	O	B-Entity
visits	O	O	I-Entity
result	O	O	O
in	O	O	O
an	O	O	O
antibiotic	O	O	B-Entity
prescription	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
large	O	O	O
portion	O	O	O
of	O	O	O
these	O	O	O
are	O	O	O
unnecessary	O	O	O
.	O	O	O

To	O	O	O
determine	O	O	O
if	O	O	O
educational	O	O	B-Entity
sessions	O	O	I-Entity
would	O	O	O
reduce	O	O	B-Entity
inappropriate	O	O	B-Entity
antibiotic	O	O	B-Entity
use	O	O	B-Entity
.	O	O	O

Intervention	O	O	B-Entity
study	O	O	I-Entity
evaluating	O	O	B-Entity
antibiotic	O	O	B-Entity
prescribing	O	O	B-Entity
following	O	O	O
educational	O	O	B-Entity
sessions	O	O	I-Entity
for	O	O	O
urinary	O	O	B-Entity
tract	O	O	I-Entity
infection	O	O	I-Entity
,	O	O	O
skin	O	O	B-Entity
and	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
infection	O	O	I-Entity
,	O	O	O
pharyngitis	O	O	B-Entity
,	O	O	O
upper	O	O	B-Entity
respiratory	O	O	I-Entity
tract	O	O	I-Entity
infection	O	O	I-Entity
,	O	O	O
acute	O	O	B-Entity
otitis	O	O	I-Entity
media	O	O	I-Entity
,	O	O	O
and	O	O	O
acute	O	O	B-Entity
bacterial	O	O	I-Entity
sinusitis	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
26	O	O	O
out	O	O	O
of	O	O	O
43	O	O	O
(	O	O	O
60	O	O	O
%	O	O	O
)	O	O	O
nurse	O	O	B-Entity
practitioners	O	O	I-Entity
in	O	O	O
4	O	O	O
urgent	O	O	B-Entity
care	O	O	I-Entity
centers	O	O	I-Entity
were	O	O	O
enrolled	O	O	B-Entity
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	O
inappropriate	O	O	B-Entity
antibiotic	O	O	B-Entity
use	O	O	B-Entity
among	O	O	O
all	O	O	O
conditions	O	O	O
was	O	O	O
10	O	O	O
%	O	O	O
before	O	O	O
and	O	O	O
8	O	O	O
%	O	O	O
after	O	O	O
the	O	O	O
intervention	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
.02	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
decrease	O	O	B-Entity
in	O	O	O
inappropriate	O	O	B-Entity
antibiotic	O	O	B-Entity
prescribing	O	O	B-Entity
was	O	O	O
seen	O	O	O
after	O	O	O
the	O	O	O
educational	O	O	B-Entity
session	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
reasons	O	O	O
for	O	O	O
inappropriate	O	O	B-Entity
antibiotic	O	O	B-Entity
prescribing	O	O	B-Entity
were	O	O	O
too	O	O	O
broad	O	O	O
(	O	O	O
41	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
wrong	O	O	B-Entity
dosage	O	O	I-Entity
(	O	O	O
22	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
not	O	O	B-Entity
indicated	O	O	I-Entity
(	O	O	O
17	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Educational	O	O	B-Entity
sessions	O	O	I-Entity
led	O	O	O
to	O	O	O
improvement	O	O	B-Entity
in	O	O	O
overall	O	O	O
inappropriate	O	O	B-Entity
antibiotic	O	O	B-Entity
use	O	O	B-Entity
.	O	O	O

Additional	O	O	O
stewardship	O	O	B-Entity
interventions	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
further	O	O	O
reduce	O	O	B-Entity
unnecessary	O	O	O
antibiotic	O	O	B-Entity
use	O	O	B-Entity
.	O	O	O

-DOCSTART- (27568284)

Zika	O	O	B-Entity
Virus	O	O	I-Entity
Disrupts	O	O	B-Entity
Phospho-TBK1	O	O	B-Entity
Localization	O	O	B-Entity
and	O	O	O
Mitosis	O	O	B-Entity
in	O	O	O
Human	O	O	B-Entity
Neuroepithelial	O	O	B-Entity
Stem	O	O	B-Entity
Cells	O	O	I-Entity
and	O	O	O
Radial	O	O	O
Glia	O	O	O

The	O	O	O
mechanisms	O	O	B-Entity
underlying	O	O	O
Zika	O	O	B-Entity
virus	O	O	I-Entity
(ZIKV)-related	O	O	O
microcephaly	O	O	B-Entity
and	O	O	O
other	O	O	O
neurodevelopment	O	O	B-Entity
defects	O	O	B-Entity
remain	O	O	O
poorly	O	O	B-Entity
understood	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
derivation	O	O	B-Entity
and	O	O	O
characterization	O	O	B-Entity
,	O	O	O
including	O	O	O
single-cell	O	O	B-Entity
RNA-seq	O	O	I-Entity
,	O	O	O
of	O	O	O
neocortical	O	O	B-Entity
and	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
neuroepithelial	O	O	B-Entity
stem	O	O	B-Entity
(	O	O	I-Entity
NES	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
model	O	O	O
early	O	O	B-Entity
human	O	O	B-Entity
neurodevelopment	O	O	B-Entity
and	O	O	O
ZIKV	O	O	B-Entity
-related	O	O	O
neuropathogenesis	O	O	B-Entity
.	O	O	O

By	O	O	O
analyzing	O	O	O
human	O	O	B-Entity
NES	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
organotypic	O	O	B-Entity
fetal	O	O	B-Entity
brain	O	O	B-Entity
slices	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
ZIKV	O	O	B-Entity
-	O	O	O
infected	O	O	B-Entity
micrencephalic	O	O	B-Entity
brain	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
ZIKV	O	O	O
infects	O	O	B-Entity
both	O	O	O
neocortical	O	O	B-Entity
and	O	O	O
spinal	O	O	B-Entity
NES	O	O	O
cells	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
their	O	O	O
fetal	O	O	O
homolog	O	O	O
,	O	O	O
radial	O	O	B-Entity
glial	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
RGCs	O	O	B-Entity
)	O	O	O
,	O	O	O
causing	O	O	O
disrupted	O	O	B-Entity
mitoses	O	O	B-Entity
,	O	O	O
supernumerary	O	O	B-Entity
centrosomes	O	O	B-Entity
,	O	O	O
structural	O	O	B-Entity
disorganization	O	O	B-Entity
,	O	O	O
and	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

ZIKV	O	O	B-Entity
infection	O	O	I-Entity
of	O	O	O
NES	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
RGCs	O	O	B-Entity
causes	O	O	O
centrosomal	O	O	B-Entity
depletion	O	O	B-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
sequestration	O	O	B-Entity
of	O	O	O
phospho-TBK1	O	O	B-Entity
during	O	O	O
mitosis	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
found	O	O	O
that	O	O	O
nucleoside	O	O	B-Entity
analogs	O	O	I-Entity
inhibit	O	O	B-Entity
ZIKV	O	O	B-Entity
replication	O	O	B-Entity
in	O	O	O
NES	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
protecting	O	O	O
them	O	O	O
from	O	O	O
ZIKV	O	O	O
-	O	O	O
induced	O	O	B-Entity
pTBK1	O	O	B-Entity
relocalization	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

We	O	O	O
established	O	O	B-Entity
a	O	O	O
model	O	O	B-Entity
system	O	O	I-Entity
of	O	O	O
human	O	O	B-Entity
neural	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
reveal	O	O	O
cellular	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	B-Entity
underlying	O	O	O
neurodevelopmental	O	O	B-Entity
defects	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
ZIKV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
its	O	O	O
potential	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27569088)

Prevalence	O	O	B-Entity
of	O	O	O
HPV	O	O	B-Entity
genotypes	O	O	B-Entity
in	O	O	O
cervical	O	O	B-Entity
adenocarcinoma	O	O	I-Entity
:	O	O	O
a	O	O	O
study	O	O	B-Entity
in	O	O	O
Greek	O	O	B-Entity
women	O	O	O

To	O	O	O
study	O	O	B-Entity
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(	O	O	O
HPV	O	O	B-Entity
)	O	O	O
genotypes	O	O	B-Entity
among	O	O	O
cervical	O	O	B-Entity
adenocarcinomas	O	O	I-Entity
in	O	O	O
Greek	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
group	O	O	I-Entity
comprised	O	O	O
78	O	O	O
adenocarcinoma	O	O	B-Entity
cases	O	O	B-Entity
(	O	O	O
20	O	O	O
in	O	O	B-Entity
situ	O	O	I-Entity
and	O	O	O
58	O	O	O
invasive	O	O	B-Entity
)	O	O	O
.	O	O	O

HPV	O	O	B-Entity
DNA	O	O	I-Entity
was	O	O	O
amplified	O	O	B-Entity
using	O	O	O
polymerase	O	O	B-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
PCR	O	O	B-Entity
)	O	O	O
and	O	O	O
HPV	O	O	O
genotypes	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
by	O	O	O
reverse	O	O	B-Entity
hybridization	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
high	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
HPV	O	O	B-Entity
infection	O	O	I-Entity
both	O	O	O
for	O	O	O
in	O	O	B-Entity
situ	O	O	I-Entity
(	O	O	O
95	O	O	O
%	O	O	O
)	O	O	O
or	O	O	O
invasive	O	O	B-Entity
(	O	O	I-Entity
94.83	O	O	I-Entity
%	O	O	I-Entity
)	O	O	I-Entity
adenocarcinomas	O	O	I-Entity
,	O	O	O
comprising	O	O	O
also	O	O	O
cancers	O	O	B-Entity
of	O	O	O
unusual	O	O	B-Entity
morphology	O	O	I-Entity
.	O	O	O

HPV	O	O	B-Entity
16	O	O	I-Entity
was	O	O	O
the	O	O	O
commonest	O	O	B-Entity
strain	O	O	B-Entity
(	O	O	O
N=57	O	O	O
,	O	O	O
73.08	O	O	O
%	O	O	O
)	O	O	O
followed	O	O	O
by	O	O	O
HPV	O	O	B-Entity
18	O	O	I-Entity
(	O	O	O
N=28	O	O	O
,	O	O	O
35.90	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
13	O	O	O
cases	O	O	B-Entity
(	O	O	O
16.67	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
also	O	O	O
HPV	O	O	B-Entity
52	O	O	I-Entity
positive	O	O	I-Entity
(	O	O	O
as	O	O	O
co-infection	O	O	B-Entity
with	O	O	O
HPV	O	O	B-Entity
16	O	O	I-Entity
or	O	O	O
18	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
other	O	O	O
strains	O	O	B-Entity
with	O	O	O
the	O	O	O
exception	O	O	B-Entity
of	O	O	O
HPV	O	O	B-Entity
66	O	O	I-Entity
were	O	O	O
found	O	O	O
only	O	O	O
as	O	O	O
co-infections	O	O	B-Entity
.	O	O	O

No	O	O	O
significant	O	O	O
age	O	O	B-Entity
difference	O	O	I-Entity
was	O	O	O
noted	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
any	O	O	O
HPV	O	O	B-Entity
strain	O	O	B-Entity
positivity	O	O	B-Entity
.	O	O	O

HPV	O	O	B-Entity
DNA	O	O	I-Entity
was	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
large	O	O	B-Entity
majority	O	O	I-Entity
of	O	O	O
cervical	O	O	B-Entity
adenocarcinomas	O	O	I-Entity
.	O	O	O

As	O	O	O
opposed	O	O	O
to	O	O	O
other	O	O	O
studies	O	O	B-Entity
,	O	O	O
HPV	O	O	B-Entity
52	O	O	I-Entity
was	O	O	O
the	O	O	O
third	O	O	O
most	O	O	O
commonly	O	O	B-Entity
encountered	O	O	B-Entity
strain	O	O	B-Entity
after	O	O	O
HPV	O	O	B-Entity
16	O	O	I-Entity
and	O	O	O
HPV	O	O	B-Entity
18	O	O	I-Entity
.	O	O	O

The	O	O	O
above	O	O	O
findings	O	O	O
would	O	O	O
probably	O	O	O
be	O	O	O
of	O	O	O
help	O	O	B-Entity
in	O	O	O
decision	O	O	B-Entity
making	O	O	I-Entity
concerning	O	O	O
vaccination	O	O	B-Entity
policy	O	O	B-Entity
for	O	O	O
the	O	O	O
prevention	O	O	B-Entity
of	O	O	O
HPV	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
Greece	O	O	B-Entity
.	O	O	O

-DOCSTART- (27570111)

Glucose	O	O	B-Entity
metabolism	O	O	I-Entity
-	O	O	O
weighted	O	O	B-Entity
imaging	O	O	I-Entity
with	O	O	O
chemical	O	O	B-Entity
exchange-sensitive	O	O	I-Entity
MRI	O	O	I-Entity
of	O	O	O
2-deoxyglucose	O	O	B-Entity
(	O	O	O
2DG	O	O	B-Entity
)	O	O	O
in	O	O	O
brain	O	O	B-Entity
:	O	O	O
Sensitivity	O	O	B-Entity
and	O	O	O
biological	O	O	B-Entity
sources	O	O	O

Recent	O	O	B-Entity
proof-of-principle	O	O	I-Entity
studies	O	O	I-Entity
have	O	O	O
demonstrated	O	O	O
the	O	O	O
feasibility	O	O	O
of	O	O	O
measuring	O	O	O
the	O	O	O
uptake	O	O	B-Entity
and	O	O	O
metabolism	O	O	B-Entity
of	O	O	O
non-labeled	O	O	O
2-deoxy-D-glucose	O	O	B-Entity
(	O	O	O
2DG	O	O	B-Entity
)	O	O	O
by	O	O	O
a	O	O	O
chemical	O	O	B-Entity
exchange-sensitive	O	O	I-Entity
spin-lock	O	O	I-Entity
(	O	O	I-Entity
CESL	O	O	I-Entity
)	O	O	I-Entity
MRI	O	O	I-Entity
approach	O	O	I-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
gain	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
this	O	O	O
new	O	O	O
approach	O	O	O
,	O	O	O
we	O	O	O
performed	O	O	O
dynamic	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
CESL	O	O	B-Entity
MRI	O	O	I-Entity
on	O	O	O
healthy	O	O	B-Entity
rat	O	O	B-Entity
brains	O	O	B-Entity
with	O	O	O
an	O	O	O
intravenous	O	O	B-Entity
injection	O	O	I-Entity
of	O	O	O
2DG	O	O	B-Entity
under	O	O	O
various	O	O	O
conditions	O	O	O
at	O	O	O
9.4	O	O	O
T	O	O	O
.	O	O	O

For	O	O	O
three	O	O	O
2DG	O	O	B-Entity
doses	O	O	B-Entity
of	O	O	O
0.25	O	O	O
,	O	O	O
0.5	O	O	O
and	O	O	O
1g/kg	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
2DG	O	O	O
-	O	O	O
CESL	O	O	B-Entity
signals	O	O	B-Entity
increased	O	O	B-Entity
linearly	O	O	O
with	O	O	O
injection	O	O	B-Entity
dose	O	O	B-Entity
at	O	O	O
the	O	O	O
initial	O	O	O
(	O	O	O
<	O	O	O
20min	O	O	O
)	O	O	O
but	O	O	O
not	O	O	O
the	O	O	O
later	O	O	O
period	O	O	O
(	O	O	O
>	O	O	O
40min	O	O	O
)	O	O	O
suggesting	O	O	O
time-dependent	O	O	O
differential	O	O	O
weightings	O	O	O
of	O	O	O
2DG	O	O	O
transport	O	O	B-Entity
and	O	O	O
metabolism	O	O	B-Entity
.	O	O	O

Remaining	O	O	O
2DG	O	O	B-Entity
-	O	O	O
CESL	O	O	B-Entity
studies	O	O	O
were	O	O	O
performed	O	O	O
with	O	O	O
0.25g/kg	O	O	O
2DG	O	O	O
.	O	O	O

Since	O	O	O
a	O	O	O
higher	O	O	B-Entity
isoflurane	O	O	B-Entity
level	O	O	B-Entity
reduces	O	O	B-Entity
glucose	O	O	B-Entity
metabolism	O	O	I-Entity
and	O	O	O
increases	O	O	B-Entity
blood	O	O	B-Entity
flow	O	O	I-Entity
,	O	O	O
2DG	O	O	B-Entity
-	O	O	O
CESL	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
under	O	O	O
0.5	O	O	O
%	O	O	O
,	O	O	O
1.5	O	O	O
%	O	O	O
and	O	O	O
2.2	O	O	O
%	O	O	O
isoflurane	O	O	O
.	O	O	O

The	O	O	O
2DG	O	O	B-Entity
-	O	O	O
CESL	O	O	B-Entity
signal	O	O	B-Entity
was	O	O	O
reduced	O	O	B-Entity
at	O	O	O
higher	O	O	B-Entity
isoflurane	O	O	B-Entity
levels	O	O	O
correlating	O	O	O
well	O	O	O
with	O	O	O
the	O	O	O
2DG	O	O	O
phosphorylation	O	O	B-Entity
in	O	O	O
the	O	O	O
intracellular	O	O	B-Entity
space	O	O	I-Entity
.	O	O	O

To	O	O	O
detect	O	O	O
regional	O	O	B-Entity
heterogeneities	O	O	I-Entity
of	O	O	O
glucose	O	O	B-Entity
metabolism	O	O	I-Entity
,	O	O	O
2DG	O	O	B-Entity
-	O	O	O
CESL	O	O	B-Entity
with	O	O	O
0.33	O	O	O
×	O	O	O
0.33	O	O	O
×	O	O	O
1.50mm(3	O	O	O
)	O	O	O
resolution	O	O	O
was	O	O	O
obtained	O	O	O
,	O	O	O
which	O	O	O
indeed	O	O	O
showed	O	O	O
a	O	O	O
higher	O	O	B-Entity
response	O	O	O
in	O	O	O
the	O	O	O
cortex	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
corpus	O	O	B-Entity
callosum	O	O	I-Entity
.	O	O	O

Lastly	O	O	O
,	O	O	O
unlike	O	O	O
CESL	O	O	B-Entity
MRI	O	O	I-Entity
with	O	O	O
the	O	O	O
injection	O	O	B-Entity
of	O	O	O
non-transportable	O	O	B-Entity
mannitol	O	O	I-Entity
,	O	O	O
the	O	O	O
2DG	O	O	B-Entity
-	O	O	O
CESL	O	O	O
response	O	O	O
decreased	O	O	B-Entity
with	O	O	O
an	O	O	O
increased	O	O	B-Entity
spin-lock	O	O	B-Entity
pulse	O	O	I-Entity
power	O	O	I-Entity
confirming	O	O	O
that	O	O	O
2DG	O	O	O
-	O	O	O
CESL	O	O	O
is	O	O	O
dominated	O	O	O
by	O	O	O
chemical	O	O	B-Entity
exchange	O	O	B-Entity
processes	O	O	B-Entity
in	O	O	O
the	O	O	O
extravascular	O	O	B-Entity
space	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
showed	O	O	O
that	O	O	O
2DG	O	O	B-Entity
-	O	O	O
CESL	O	O	B-Entity
MRI	O	O	I-Entity
signals	O	O	B-Entity
mainly	O	O	O
indicate	O	O	O
glucose	O	O	B-Entity
transport	O	O	I-Entity
and	O	O	O
metabolism	O	O	B-Entity
and	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
metabolic	O	O	B-Entity
studies	O	O	B-Entity
of	O	O	O
normal	O	O	B-Entity
and	O	O	O
diseased	O	O	B-Entity
brains	O	O	B-Entity
.	O	O	O

-DOCSTART- (27570362)

Parental	O	O	B-Entity
perceptions	O	O	B-Entity
of	O	O	O
children´s	O	O	B-Entity
agency	O	O	I-Entity
:	O	O	O
Parental	O	O	B-Entity
warmth	O	O	I-Entity
,	O	O	O
school	O	O	B-Entity
achievement	O	O	I-Entity
and	O	O	O
adjustment	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
examined	O	O	O
Swedish	O	O	B-Entity
mothers	O	O	B-Entity
'	O	O	I-Entity
and	O	O	O
fathers	O	O	B-Entity
'	O	O	I-Entity
warmth	O	O	B-Entity
towards	O	O	O
their	O	O	O
children	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
their	O	O	O
children´s	O	O	B-Entity
agency	O	O	I-Entity
.	O	O	O

It	O	O	O
also	O	O	O
examined	O	O	O
the	O	O	O
longitudinal	O	O	O
relation	O	O	O
between	O	O	O
agency	O	O	B-Entity
and	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
externalizing	O	O	O
,	O	O	O
internalizing	O	O	O
,	O	O	O
and	O	O	O
school	O	O	B-Entity
achievement	O	O	I-Entity
.	O	O	O

Swedish	O	O	B-Entity
children	O	O	B-Entity
's	O	O	I-Entity
mothers	O	O	B-Entity
and	O	O	O
fathers	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
103	O	O	O
)	O	O	O
were	O	O	O
interviewed	O	O	B-Entity
at	O	O	O
three	O	O	O
time	O	O	B-Entity
points	O	O	I-Entity
(	O	O	O
when	O	O	O
children	O	O	O
were	O	O	O
8	O	O	O
,	O	O	O
9	O	O	O
,	O	O	O
and	O	O	O
10	O	O	O
years	O	O	B-Entity
old	O	O	O
)	O	O	O
about	O	O	O
their	O	O	O
warmth	O	O	B-Entity
towards	O	O	O
their	O	O	O
children	O	O	O
,	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
agency	O	O	I-Entity
,	O	O	O
and	O	O	O
children	O	O	O
's	O	O	O
externalizing	O	O	O
and	O	O	O
internalizing	O	O	O
behaviors	O	O	O
and	O	O	O
school	O	O	B-Entity
achievement	O	O	I-Entity
.	O	O	O

Parental	O	O	B-Entity
warmth	O	O	I-Entity
at	O	O	O
Time	O	O	B-Entity
1	O	O	O
was	O	O	O
significantly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
child	O	O	B-Entity
agency	O	O	I-Entity
at	O	O	O
Time	O	O	O
2	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
significantly	O	O	O
correlated	O	O	O
with	O	O	O
child	O	O	O
externalizing	O	O	O
and	O	O	O
internalizing	O	O	O
behaviors	O	O	O
and	O	O	O
academic	O	O	B-Entity
achievement	O	O	I-Entity
at	O	O	O
Time	O	O	O
3	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
differences	O	O	O
between	O	O	O
girls	O	O	B-Entity
and	O	O	O
boys	O	O	B-Entity
.	O	O	O

Results	O	O	O
from	O	O	O
this	O	O	O
study	O	O	B-Entity
indicate	O	O	O
that	O	O	O
Swedish	O	O	B-Entity
parents	O	O	B-Entity
'	O	O	I-Entity
warmth	O	O	I-Entity
is	O	O	O
directly	O	O	O
related	O	O	O
to	O	O	O
subsequent	O	O	O
perceptions	O	O	B-Entity
of	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
agency	O	O	I-Entity
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
are	O	O	O
related	O	O	O
to	O	O	O
subsequently	O	O	O
lower	O	O	O
child	O	O	B-Entity
externalizing	O	O	O
and	O	O	O
internalizing	O	O	O
problems	O	O	B-Entity
and	O	O	O
higher	O	O	O
academic	O	O	B-Entity
achievement	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
held	O	O	O
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
a	O	O	O
three-	O	O	O
year	O	O	B-Entity
longitudinal	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
for	O	O	O
both	O	O	O
boys	O	O	B-Entity
and	O	O	O
girls	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
child	O	O	B-Entity
agency	O	O	I-Entity
in	O	O	O
the	O	O	O
link	O	O	O
between	O	O	O
parental	O	O	B-Entity
warmth	O	O	I-Entity
and	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
adjustment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27571215)

Vasopressin	O	O	B-Entity
regulates	O	O	B-Entity
the	O	O	I-Entity
growth	O	O	I-Entity
of	O	O	O
the	O	O	O
biliary	O	O	B-Entity
epithelium	O	O	I-Entity
in	O	O	O
polycystic	O	O	O
liver	O	O	O
disease	O	O	O

The	O	O	O
neurohypophysial	O	O	B-Entity
hormone	O	O	I-Entity
arginine	O	O	B-Entity
vasopressin	O	O	I-Entity
(	O	O	O
AVP	O	O	B-Entity
)	O	O	O
acts	O	O	O
by	O	O	O
three	O	O	O
distinct	O	O	O
receptor	O	O	B-Entity
subtypes	O	O	O
:	O	O	O
V1a	O	O	B-Entity
,	O	O	O
V1b	O	O	B-Entity
,	O	O	O
and	O	O	O
V2	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
liver	O	O	B-Entity
,	O	O	O
AVP	O	O	B-Entity
is	O	O	O
involved	O	O	B-Entity
in	O	O	O
ureogenesis	O	O	B-Entity
,	O	O	O
glycogenolysis	O	O	B-Entity
,	O	O	O
neoglucogenesis	O	O	B-Entity
and	O	O	O
regeneration	O	O	B-Entity
.	O	O	O

No	O	O	O
data	O	O	O
exist	O	O	O
about	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
AVP	O	O	B-Entity
in	O	O	O
the	O	O	O
biliary	O	O	B-Entity
epithelium	O	O	I-Entity
.	O	O	O

Cholangiocytes	O	O	B-Entity
are	O	O	O
the	O	O	O
target	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
of	O	O	O
cholestasis	O	O	B-Entity
,	O	O	O
including	O	O	O
bile	O	O	B-Entity
duct	O	O	I-Entity
ligation	O	O	B-Entity
(	O	O	O
BDL	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
several	O	O	O
human	O	O	B-Entity
pathologies	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
polycystic	O	O	B-Entity
liver	O	O	I-Entity
disease	O	O	I-Entity
characterized	O	O	B-Entity
by	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
cysts	O	O	B-Entity
that	O	O	O
bud	O	O	O
from	O	O	O
the	O	O	O
biliary	O	O	B-Entity
epithelium	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
,	O	O	O
liver	O	O	B-Entity
fragments	O	O	B-Entity
from	O	O	O
normal	O	O	O
and	O	O	O
BDL	O	O	B-Entity
mice	O	O	B-Entity
and	O	O	O
rats	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
liver	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
normal	O	O	O
and	O	O	O
ADPKD	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
collected	O	O	O
to	O	O	O
evaluate	O	O	O
:	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
intrahepatic	O	O	B-Entity
bile	O	O	B-Entity
duct	O	O	I-Entity
mass	O	O	B-Entity
by	O	O	O
immunohistochemistry	O	O	B-Entity
for	O	O	O
cytokeratin-19	O	O	B-Entity
;	O	O	O
and	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
expression	O	O	B-Entity
of	O	O	O
V1a	O	O	B-Entity
,	O	O	O
V1b	O	O	B-Entity
and	O	O	O
V2	O	O	B-Entity
by	O	O	O
immunohistochemistry	O	O	O
,	O	O	O
immunofluorescence	O	O	B-Entity
and	O	O	O
real-time	O	O	B-Entity
PCR	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
small	O	O	O
and	O	O	O
large	O	O	O
mouse	O	O	B-Entity
cholangiocytes	O	O	B-Entity
,	O	O	O
H69	O	O	B-Entity
(	O	O	O
non-malignant	O	O	B-Entity
human	O	O	B-Entity
cholangiocytes	O	O	O
)	O	O	O
and	O	O	O
LCDE	O	O	B-Entity
(	O	O	O
human	O	O	O
cholangiocytes	O	O	O
from	O	O	O
the	O	O	O
cystic	O	O	B-Entity
epithelium	O	O	I-Entity
)	O	O	O
were	O	O	O
stimulated	O	O	B-Entity
with	O	O	O
vasopressin	O	O	B-Entity
in	O	O	O
the	O	O	O
absence/	O	O	O
presence	O	O	B-Entity
of	O	O	O
AVP	O	O	B-Entity
antagonists	O	O	I-Entity
such	O	O	O
as	O	O	O
OPC-31260	O	O	B-Entity
and	O	O	O
Tolvaptan	O	O	B-Entity
,	O	O	O
before	O	O	O
assessing	O	O	O
cellular	O	O	B-Entity
growth	O	O	I-Entity
by	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
cAMP	O	O	B-Entity
levels	O	O	O
.	O	O	O

Cholangiocytes	O	O	B-Entity
express	O	O	O
V2	O	O	B-Entity
receptor	O	O	I-Entity
that	O	O	O
was	O	O	O
upregulated	O	O	B-Entity
following	O	O	O
BDL	O	O	B-Entity
and	O	O	O
in	O	O	O
ADPKD	O	O	B-Entity
liver	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

Administration	O	O	B-Entity
of	O	O	O
AVP	O	O	B-Entity
increased	O	O	B-Entity
proliferation	O	O	B-Entity
and	O	O	O
cAMP	O	O	B-Entity
levels	O	O	O
of	O	O	O
small	O	O	O
cholangiocytes	O	O	B-Entity
and	O	O	O
LCDE	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
in	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
large	O	O	O
mouse	O	O	B-Entity
cholangiocytes	O	O	B-Entity
and	O	O	O
H69	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Increases	O	O	B-Entity
were	O	O	O
blocked	O	O	B-Entity
by	O	O	O
preincubation	O	O	B-Entity
with	O	O	O
the	O	O	O
AVP	O	O	B-Entity
antagonists	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
AVP	O	O	B-Entity
and	O	O	O
its	O	O	O
receptors	O	O	B-Entity
may	O	O	O
be	O	O	O
important	O	O	O
in	O	O	O
the	O	O	O
modulation	O	O	B-Entity
of	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
the	O	O	O
biliary	O	O	B-Entity
epithelium	O	O	I-Entity
.	O	O	O

-DOCSTART- (27571223)

Central	O	O	B-Entity
Corneal	O	O	I-Entity
Thickness	O	O	I-Entity
Reproducibility	O	O	B-Entity
among	O	O	O
Ten	O	O	O
Different	O	O	O
Instruments	O	O	O

To	O	O	O
assess	O	O	B-Entity
agreement	O	O	O
between	O	O	O
one	O	O	O
ultrasonic	O	O	B-Entity
(	O	O	O
US	O	O	B-Entity
)	O	O	O
and	O	O	O
nine	O	O	O
optical	O	O	B-Entity
instruments	O	O	I-Entity
for	O	O	O
the	O	O	O
measurement	O	O	B-Entity
of	O	O	O
central	O	O	B-Entity
corneal	O	O	I-Entity
thickness	O	O	I-Entity
(	O	O	O
CCT	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
intra-	O	O	B-Entity
and	O	O	I-Entity
inter-operator	O	O	I-Entity
reproducibility	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
observational	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
two	O	O	O
masked	O	O	O
operators	O	O	O
measured	O	O	O
CCT	O	O	B-Entity
thickness	O	O	O
twice	O	O	O
in	O	O	O
28	O	O	O
healthy	O	O	B-Entity
eyes	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
seven	O	O	O
spectral-domain	O	O	B-Entity
optical	O	O	I-Entity
coherence	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	I-Entity
SD-OCT	O	O	I-Entity
)	O	O	I-Entity
devices	O	O	I-Entity
,	O	O	O
one	O	O	B-Entity
time-domain	O	O	I-Entity
OCT	O	O	I-Entity
,	O	O	O
one	O	O	O
Scheimpflug	O	O	B-Entity
camera	O	O	I-Entity
,	O	O	O
and	O	O	O
one	O	O	O
US-based	O	O	B-Entity
instrument	O	O	I-Entity
.	O	O	O

Inter-	O	O	B-Entity
and	O	O	I-Entity
intra-operator	O	O	I-Entity
reproducibility	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
intraclass	O	O	B-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
(	O	O	O
ICC	O	O	B-Entity
)	O	O	O
,	O	O	O
coefficient	O	O	B-Entity
of	O	O	I-Entity
variation	O	O	I-Entity
(	O	O	O
CV	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
Bland-Altman	O	O	B-Entity
test	O	O	I-Entity
analysis	O	O	B-Entity
.	O	O	O

Instrument	O	O	B-Entity
-to-	O	O	O
instrument	O	O	B-Entity
reproducibility	O	O	B-Entity
was	O	O	O
determined	O	O	O
by	O	O	O
ANOVA	O	O	B-Entity
for	O	O	O
repeated	O	O	O
measurements	O	O	O
.	O	O	O

We	O	O	O
also	O	O	O
tested	O	O	B-Entity
how	O	O	O
the	O	O	O
devices	O	O	B-Entity
disagreed	O	O	O
regarding	O	O	O
systemic	O	O	B-Entity
bias	O	O	B-Entity
and	O	O	O
random	O	O	B-Entity
error	O	O	B-Entity
using	O	O	O
a	O	O	O
structural	O	O	B-Entity
equation	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

Mean	O	O	O
CCT	O	O	B-Entity
of	O	O	O
all	O	O	O
instruments	O	O	B-Entity
ranged	O	O	O
from	O	O	O
536	O	O	O
±	O	O	O
42	O	O	O
μm	O	O	O
to	O	O	O
577	O	O	O
±	O	O	O
40	O	O	O
μm	O	O	O
.	O	O	O

An	O	O	O
instrument	O	O	B-Entity
-to-	O	O	O
instrument	O	O	O
correlation	O	O	B-Entity
test	O	O	I-Entity
showed	O	O	O
high	O	O	B-Entity
values	O	O	B-Entity
among	O	O	O
the	O	O	O
10	O	O	O
investigated	O	O	B-Entity
devices	O	O	B-Entity
(	O	O	O
correlation	O	O	B-Entity
coefficient	O	O	I-Entity
range	O	O	B-Entity
0.852	O	O	O
-	O	O	O
0.995	O	O	O
;	O	O	O
p	O	O	B-Entity
values	O	O	I-Entity
<	O	O	O
0.0001	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
highest	O	O	O
correlation	O	O	O
coefficient	O	O	O
values	O	O	O
were	O	O	O
registered	O	O	O
between	O	O	O
3D	O	O	O
OCT-2000	O	O	O
Topcon-Spectral	O	O	B-Entity
OCT/SLO	O	O	I-Entity
Opko	O	O	I-Entity
(	O	O	O
0.995	O	O	O
)	O	O	O
and	O	O	O
Cirrus	O	O	B-Entity
HD-OCT	O	O	I-Entity
Zeiss-RS-3000	O	O	I-Entity
Nidek	O	O	I-Entity
(	O	O	O
0.995	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
lowest	O	O	O
were	O	O	O
seen	O	O	O
between	O	O	O
SS-1000	O	O	B-Entity
CASIA	O	O	I-Entity
and	O	O	O
Spectral	O	O	B-Entity
OCT/SLO	O	O	I-Entity
Opko	O	O	I-Entity
(	O	O	O
0.852	O	O	O
)	O	O	O
.	O	O	O

ICC	O	O	B-Entity
and	O	O	O
CV	O	O	B-Entity
showed	O	O	O
excellent	O	O	O
inter-	O	O	B-Entity
and	O	O	I-Entity
intra-operator	O	O	I-Entity
reproducibility	O	O	I-Entity
for	O	O	O
all	O	O	O
optic	O	O	B-Entity
-based	O	O	O
devices	O	O	B-Entity
,	O	O	O
except	O	O	O
for	O	O	O
the	O	O	O
US	O	O	B-Entity
-based	O	O	O
device	O	O	B-Entity
.	O	O	O

Bland-Altman	O	O	B-Entity
analysis	O	O	B-Entity
demonstrated	O	O	O
low	O	O	O
mean	O	O	O
biases	O	O	B-Entity
between	O	O	O
operators	O	O	O
.	O	O	O

Despite	O	O	O
highlighting	O	O	O
good	O	O	O
intra-	O	O	B-Entity
and	O	O	I-Entity
inter-operator	O	O	I-Entity
reproducibility	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
a	O	O	O
scale	O	O	B-Entity
bias	O	O	B-Entity
between	O	O	O
instruments	O	O	B-Entity
might	O	O	O
interfere	O	O	B-Entity
with	O	O	I-Entity
thorough	O	O	O
CCT	O	O	B-Entity
monitoring	O	O	B-Entity
.	O	O	O

We	O	O	O
suggest	O	O	O
that	O	O	O
optimal	O	O	B-Entity
monitoring	O	O	B-Entity
is	O	O	O
achieved	O	O	O
with	O	O	O
the	O	O	O
same	O	O	O
operator	O	O	O
and	O	O	O
the	O	O	O
same	O	O	O
device	O	O	B-Entity
.	O	O	O

-DOCSTART- (27571883)

Predictors	O	O	B-Entity
of	O	O	O
neurologic	O	O	B-Entity
and	O	O	O
nonneurologic	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
brain	O	O	B-Entity
metastasis	O	O	I-Entity
initially	O	O	O
treated	O	O	B-Entity
with	O	O	O
upfront	O	O	B-Entity
stereotactic	O	O	I-Entity
radiosurgery	O	O	I-Entity
without	O	O	O
whole-brain	O	O	O
radiation	O	O	O
therapy	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
we	O	O	O
attempted	O	O	O
to	O	O	O
discern	O	O	O
the	O	O	O
factors	O	O	B-Entity
predictive	O	O	B-Entity
of	O	O	O
neurologic	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
brain	O	O	B-Entity
metastasis	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
upfront	O	O	B-Entity
stereotactic	O	O	I-Entity
radiosurgery	O	O	I-Entity
(	O	O	O
SRS	O	O	B-Entity
)	O	O	O
without	O	O	O
whole	O	O	B-Entity
brain	O	O	I-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
WBRT	O	O	B-Entity
)	O	O	O
while	O	O	O
accounting	O	O	O
for	O	O	O
the	O	O	O
competing	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
nonneurologic	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
single-institution	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
brain	O	O	B-Entity
metastasis	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
upfront	O	O	O
SRS	O	O	B-Entity
without	O	O	O
WBRT	O	O	B-Entity
.	O	O	O

Competing	O	O	B-Entity
risks	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
estimate	O	O	O
the	O	O	O
subdistribution	O	O	O
hazard	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
HRs	O	O	B-Entity
)	O	O	O
for	O	O	O
neurologic	O	O	B-Entity
and	O	O	O
nonneurologic	O	O	B-Entity
death	O	O	I-Entity
for	O	O	O
predictor	O	O	B-Entity
variables	O	O	O
of	O	O	O
interest	O	O	O
.	O	O	O

Of	O	O	O
738	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
upfront	O	O	B-Entity
SRS	O	O	I-Entity
alone	O	O	O
,	O	O	O
neurologic	O	O	B-Entity
death	O	O	I-Entity
occurred	O	O	O
in	O	O	O
226	O	O	O
(	O	O	O
30.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
nonneurologic	O	O	B-Entity
death	O	O	I-Entity
occurred	O	O	O
in	O	O	O
309	O	O	O
(	O	O	O
41.9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
competing	O	O	I-Entity
risks	O	O	I-Entity
analysis	O	O	I-Entity
identified	O	O	O
an	O	O	O
increased	O	O	B-Entity
hazard	O	O	B-Entity
of	O	O	O
neurologic	O	O	B-Entity
death	O	O	I-Entity
associated	O	O	O
with	O	O	O
diagnosis-specific	O	O	B-Entity
graded	O	O	I-Entity
prognostic	O	O	I-Entity
assessment	O	O	I-Entity
(	O	O	O
DS-GPA	O	O	B-Entity
)	O	O	O
≤	O	O	O
2	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
.005	O	O	O
)	O	O	O
,	O	O	O
melanoma	O	O	B-Entity
histology	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.009	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
increased	O	O	O
number	O	O	O
of	O	O	O
brain	O	O	B-Entity
metastases	O	O	I-Entity
(	O	O	O
P<.001	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
decreased	O	O	B-Entity
hazard	O	O	O
associated	O	O	O
with	O	O	O
higher	O	O	O
SRS	O	O	B-Entity
dose	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.004	O	O	O
)	O	O	O
.	O	O	O

Targeted	O	O	B-Entity
agents	O	O	I-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
decreased	O	O	B-Entity
HR	O	O	B-Entity
of	O	O	O
neurologic	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
1.5	O	O	O
years	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.04	O	O	O
)	O	O	O
but	O	O	O
not	O	O	O
afterwards	O	O	O
.	O	O	O

An	O	O	O
increased	O	O	B-Entity
hazard	O	O	B-Entity
of	O	O	O
nonneurologic	O	O	B-Entity
death	O	O	I-Entity
was	O	O	O
seen	O	O	O
with	O	O	O
increasing	O	O	O
age	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.03	O	O	O
)	O	O	O
,	O	O	O
nonmelanoma	O	O	B-Entity
histology	O	O	I-Entity
(	O	O	O
P<.001	O	O	O
)	O	O	O
,	O	O	O
presence	O	O	O
of	O	O	O
extracranial	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
P<.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
progressive	O	O	B-Entity
systemic	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.004	O	O	O
)	O	O	O
.	O	O	O

Melanoma	O	O	B-Entity
,	O	O	O
DS-GPA	O	O	B-Entity
,	O	O	O
number	O	O	B-Entity
of	O	O	O
brain	O	O	B-Entity
metastases	O	O	I-Entity
,	O	O	O
and	O	O	O
SRS	O	O	B-Entity
dose	O	O	B-Entity
are	O	O	O
predictive	O	O	B-Entity
of	O	O	O
neurologic	O	O	B-Entity
death	O	O	I-Entity
,	O	O	O
while	O	O	O
age	O	O	B-Entity
,	O	O	O
nonmelanoma	O	O	B-Entity
histology	O	O	I-Entity
,	O	O	O
and	O	O	O
more	O	O	O
advanced	O	O	O
systemic	O	O	B-Entity
disease	O	O	I-Entity
are	O	O	O
predictive	O	O	O
of	O	O	O
nonneurologic	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

Targeted	O	O	B-Entity
agents	O	O	I-Entity
appear	O	O	O
to	O	O	O
delay	O	O	B-Entity
neurologic	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

-DOCSTART- (27572131)

Pharmacological	O	O	B-Entity
Actions	O	O	I-Entity
of	O	O	O
Glucagon-Like	O	O	B-Entity
Peptide-1	O	O	I-Entity
,	O	O	O
Gastric	O	O	B-Entity
Inhibitory	O	O	I-Entity
Polypeptide	O	O	I-Entity
,	O	O	O
and	O	O	O
Glucagon	O	O	O

Glucagon	O	O	B-Entity
family	O	O	I-Entity
of	O	O	O
peptide	O	O	B-Entity
hormones	O	O	I-Entity
is	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
structurally	O	O	O
related	O	O	O
brain-gut	O	O	B-Entity
peptides	O	O	I-Entity
that	O	O	O
exert	O	O	O
their	O	O	O
pleiotropic	O	O	B-Entity
actions	O	O	I-Entity
through	O	O	O
interactions	O	O	B-Entity
with	O	O	O
unique	O	O	B-Entity
members	O	O	I-Entity
of	O	O	I-Entity
class	O	O	I-Entity
B1	O	O	I-Entity
G	O	O	B-Entity
protein-coupled	O	O	I-Entity
receptors	O	O	I-Entity
(	O	O	O
GPCRs	O	O	B-Entity
)	O	O	O
.	O	O	O

They	O	O	O
are	O	O	O
key	O	O	O
regulators	O	O	B-Entity
of	O	O	O
hormonal	O	O	B-Entity
homeostasis	O	O	B-Entity
and	O	O	O
are	O	O	O
important	O	O	O
drug	O	O	B-Entity
targets	O	O	I-Entity
for	O	O	O
metabolic	O	O	B-Entity
disorders	O	O	I-Entity
such	O	O	O
as	O	O	O
type-2	O	O	B-Entity
diabetes	O	O	I-Entity
mellitus	O	O	I-Entity
(	O	O	O
T2DM	O	O	B-Entity
)	O	O	O
,	O	O	O
obesity	O	O	B-Entity
,	O	O	O
and	O	O	O
dysregulations	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
nervous	O	O	I-Entity
systems	O	O	I-Entity
such	O	O	O
as	O	O	O
migraine	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
,	O	O	O
depression	O	O	B-Entity
,	O	O	O
neurodegeneration	O	O	B-Entity
,	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
and	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

The	O	O	O
current	O	O	O
review	O	O	O
aims	O	O	O
to	O	O	O
provide	O	O	O
a	O	O	O
detailed	O	O	O
overview	O	O	B-Entity
of	O	O	O
the	O	O	O
current	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
pharmacological	O	O	B-Entity
actions	O	O	I-Entity
and	O	O	O
therapeutic	O	O	B-Entity
advances	O	O	I-Entity
of	O	O	O
three	O	O	O
members	O	O	O
within	O	O	O
this	O	O	O
family	O	O	O
including	O	O	O
glucagon-like	O	O	B-Entity
peptide-1	O	O	I-Entity
(	O	O	O
GLP-1	O	O	B-Entity
)	O	O	O
,	O	O	O
gastric	O	O	B-Entity
inhibitory	O	O	I-Entity
polypeptide	O	O	I-Entity
(	O	O	O
GIP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
glucagon	O	O	B-Entity
.	O	O	O

-DOCSTART- (27573109)

Endemic	O	O	B-Entity
hydrothermal	O	O	B-Entity
vent	O	O	I-Entity
species	O	O	B-Entity
identified	O	O	B-Entity
in	O	O	O
the	O	O	O
open	O	O	O
ocean	O	O	B-Entity
seed	O	O	O
bank	O	O	O

Hydrothermal	O	O	B-Entity
vent	O	O	I-Entity
systems	O	O	B-Entity
host	O	O	O
microbial	O	O	B-Entity
communities	O	O	B-Entity
among	O	O	O
which	O	O	O
several	O	O	B-Entity
microorganisms	O	O	B-Entity
have	O	O	O
been	O	O	O
considered	O	O	B-Entity
endemic	O	O	B-Entity
to	O	O	O
this	O	O	O
type	O	O	O
of	O	O	O
habitat	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
still	O	O	O
unclear	O	O	B-Entity
how	O	O	O
these	O	O	O
organisms	O	O	B-Entity
colonize	O	O	B-Entity
geographically	O	O	B-Entity
distant	O	O	B-Entity
hydrothermal	O	O	B-Entity
environments	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	B-Entity
sequences	O	O	I-Entity
,	O	O	O
we	O	O	O
compare	O	O	B-Entity
the	O	O	O
bacterial	O	O	B-Entity
communities	O	O	B-Entity
of	O	O	O
sixteen	O	O	O
Atlantic	O	O	B-Entity
hydrothermal	O	O	B-Entity
vent	O	O	I-Entity
samples	O	O	B-Entity
with	O	O	O
our	O	O	O
own	O	O	O
and	O	O	O
publicly	O	O	O
available	O	O	B-Entity
global	O	O	B-Entity
open	O	O	O
ocean	O	O	B-Entity
samples	O	O	O
.	O	O	O

Analysing	O	O	B-Entity
sequences	O	O	B-Entity
obtained	O	O	B-Entity
from	O	O	O
63	O	O	O
million	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
genes	O	O	B-Entity
,	O	O	O
the	O	O	O
genera	O	O	B-Entity
we	O	O	O
could	O	O	O
identify	O	O	O
in	O	O	O
the	O	O	O
open	O	O	O
ocean	O	O	B-Entity
waters	O	O	I-Entity
contained	O	O	B-Entity
99.9	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
vent	O	O	B-Entity
reads	O	O	O
.	O	O	O

This	O	O	O
suggests	O	O	B-Entity
that	O	O	O
previously	O	O	B-Entity
observed	O	O	B-Entity
vent	O	O	B-Entity
exclusiveness	O	O	B-Entity
is	O	O	O
,	O	O	O
in	O	O	O
most	O	O	O
cases	O	O	B-Entity
,	O	O	O
probably	O	O	B-Entity
an	O	O	O
artefact	O	O	B-Entity
of	O	O	O
lower	O	O	B-Entity
sequencing	O	O	B-Entity
depth	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
are	O	O	O
a	O	O	O
further	O	O	O
step	O	O	O
towards	O	O	O
elucidating	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
the	O	O	O
open	O	O	O
ocean	O	O	B-Entity
as	O	O	O
a	O	O	O
seed	O	O	B-Entity
bank	O	O	I-Entity
.	O	O	O

They	O	O	O
can	O	O	O
explain	O	O	O
the	O	O	O
predicament	O	O	B-Entity
of	O	O	O
how	O	O	O
species	O	O	B-Entity
expected	O	O	B-Entity
to	O	O	O
be	O	O	O
endemic	O	O	B-Entity
to	O	O	O
vent	O	O	B-Entity
systems	O	O	B-Entity
are	O	O	O
able	O	O	B-Entity
to	O	O	O
colonize	O	O	B-Entity
geographically	O	O	B-Entity
distant	O	O	B-Entity
hydrothermal	O	O	B-Entity
habitats	O	O	B-Entity
and	O	O	O
contribute	O	O	B-Entity
to	O	O	O
our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
whether	O	O	O
'	O	O	O
everything	O	O	O
is	O	O	O
really	O	O	O
everywhere	O	O	O
'	O	O	O
.	O	O	O

-DOCSTART- (27573702)

Cerebral	O	O	B-Entity
toxoplasmosis	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
acquired	O	O	B-Entity
immune	O	O	I-Entity
deficiency	O	O	I-Entity
syndrome	O	O	I-Entity
in	O	O	O
the	O	O	O
neurological	O	O	B-Entity
emergency	O	O	I-Entity
department	O	O	I-Entity
of	O	O	O
a	O	O	O
tertiary	O	O	O
hospital	O	O	O

Cerebral	O	O	B-Entity
toxoplasmosis	O	O	I-Entity
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
cause	O	O	B-Entity
of	O	O	O
space	O	O	B-Entity
occupying	O	O	O
brain	O	O	B-Entity
lesion	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
HIV/AIDS	O	O	B-Entity
in	O	O	O
Brazil	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
post-HAART	O	O	B-Entity
era	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
responsible	O	O	O
for	O	O	O
high	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
morbidity	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
worldwide	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
consists	O	O	O
of	O	O	O
a	O	O	O
case	O	O	B-Entity
series	O	O	I-Entity
of	O	O	O
56	O	O	O
patients	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
cerebral	O	O	B-Entity
toxoplasmosis	O	O	I-Entity
whose	O	O	O
clinical	O	O	B-Entity
features	O	O	B-Entity
,	O	O	O
brain	O	O	B-Entity
imaging	O	O	I-Entity
and	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
aspects	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Cerebral	O	O	B-Entity
toxoplasmosis	O	O	I-Entity
led	O	O	O
to	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
infection	O	O	B-Entity
by	O	O	O
the	O	O	O
human	O	O	B-Entity
immunodeficiency	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
HIV	O	O	B-Entity
)	O	O	O
in	O	O	O
27	O	O	O
(	O	O	O
48.2	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
,	O	O	O
while	O	O	O
29	O	O	O
(	O	O	O
51.2	O	O	O
%	O	O	O
)	O	O	O
others	O	O	O
already	O	O	O
knew	O	O	O
to	O	O	O
be	O	O	O
HIV	O	O	B-Entity
seropositive	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
cerebral	O	O	B-Entity
toxoplasmosis	O	O	B-Entity
,	O	O	O
only	O	O	O
9	O	O	O
(	O	O	O
16.6	O	O	O
%	O	O	O
)	O	O	O
reported	O	O	B-Entity
being	O	O	O
under	O	O	O
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
and	O	O	O
5	O	O	O
(	O	O	O
8.9	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
receiving	O	O	B-Entity
primary	O	O	B-Entity
prophylaxis	O	O	B-Entity
for	O	O	O
toxoplasmosis	O	O	O
.	O	O	O

Headache	O	O	B-Entity
,	O	O	O
strength	O	O	B-Entity
deficit	O	O	I-Entity
and	O	O	O
fever	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
frequent	O	O	O
signs	O	O	B-Entity
and	O	O	I-Entity
symptoms	O	O	I-Entity
throughout	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

Fifty-three	O	O	O
patients	O	O	B-Entity
showed	O	O	O
changes	O	O	B-Entity
consistent	O	O	B-Entity
with	O	O	I-Entity
toxoplasmosis	O	O	B-Entity
in	O	O	O
CT	O	O	B-Entity
or	O	O	O
MRI	O	O	B-Entity
.	O	O	O

Thirty-four	O	O	O
(	O	O	O
60.7	O	O	O
%	O	O	O
)	O	O	O
CSF	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
positive	O	O	B-Entity
in	O	O	O
the	O	O	O
indirect	O	O	B-Entity
haemagglutination	O	O	I-Entity
test	O	O	I-Entity
and	O	O	O
for	O	O	O
the	O	O	O
reaction	O	O	B-Entity
of	O	O	O
Toxoplasma	O	O	B-Entity
gondii	O	O	I-Entity
IgG	O	O	I-Entity
ELISA	O	O	B-Entity
,	O	O	O
while	O	O	O
31	O	O	O
(	O	O	O
55.4	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
positive	O	O	O
in	O	O	O
the	O	O	O
direct	O	O	B-Entity
haemagglutination	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Fifty	O	O	O
(	O	O	O
89.3	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
underwent	O	O	O
first-line	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
toxoplasmosis	O	O	B-Entity
.	O	O	O

Cerebral	O	O	B-Entity
toxoplasmosis	O	O	I-Entity
is	O	O	O
still	O	O	O
a	O	O	O
very	O	O	O
relevant	O	O	B-Entity
neurological	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
individuals	O	O	B-Entity
with	O	O	O
AIDS	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	O
neurology	O	O	B-Entity
emergency	O	O	B-Entity
departments	O	O	I-Entity
.	O	O	O

Early	O	O	B-Entity
diagnosis	O	O	I-Entity
and	O	O	O
initiation	O	O	B-Entity
of	O	O	O
empiric	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
are	O	O	O
important	O	O	O
for	O	O	O
good	O	O	O
prognosis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27575455)

Maf1	O	O	B-Entity
-mediated	O	O	O
regulation	O	O	B-Entity
of	O	O	O
yeast	O	O	B-Entity
RNA	O	O	B-Entity
polymerase	O	O	I-Entity
III	O	O	I-Entity
is	O	O	O
correlated	O	O	B-Entity
with	O	O	O
CCA	O	O	B-Entity
addition	O	O	I-Entity
at	O	O	I-Entity
the	O	O	I-Entity
3	O	O	I-Entity
'	O	O	I-Entity
end	O	O	I-Entity
of	O	O	I-Entity
tRNA	O	O	I-Entity
precursors	O	O	O

In	O	O	O
eukaryotic	O	O	B-Entity
cells	O	O	I-Entity
tRNA	O	O	B-Entity
synthesis	O	O	I-Entity
is	O	O	O
negatively	O	O	B-Entity
regulated	O	O	B-Entity
by	O	O	O
the	O	O	O
protein	O	O	B-Entity
Maf1	O	O	I-Entity
,	O	O	O
conserved	O	O	O
from	O	O	O
yeast	O	O	B-Entity
to	O	O	O
humans	O	O	B-Entity
.	O	O	O

Maf1	O	O	B-Entity
from	O	O	O
yeast	O	O	B-Entity
Saccharomyces	O	O	B-Entity
cerevisiae	O	O	I-Entity
mediates	O	O	O
repression	O	O	B-Entity
of	O	O	O
trna	O	O	B-Entity
transcription	O	O	I-Entity
when	O	O	O
cells	O	O	B-Entity
are	O	O	O
transferred	O	O	O
from	O	O	O
medium	O	O	B-Entity
with	O	O	O
glucose	O	O	B-Entity
to	O	O	O
medium	O	O	O
with	O	O	O
glycerol	O	O	B-Entity
,	O	O	O
a	O	O	O
non-fermentable	O	O	B-Entity
carbon	O	O	B-Entity
source	O	O	B-Entity
.	O	O	O

The	O	O	O
strain	O	O	B-Entity
with	O	O	O
deleted	O	O	B-Entity
gene	O	O	B-Entity
encoding	O	O	B-Entity
Maf1	O	O	B-Entity
(	O	O	O
maf1Δ	O	O	B-Entity
)	O	O	O
is	O	O	O
viable	O	O	B-Entity
but	O	O	O
accumulates	O	O	O
tRNA	O	O	B-Entity
precursors	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
tRNA	O	O	B-Entity
precursors	O	O	I-Entity
were	O	O	O
analysed	O	O	B-Entity
by	O	O	O
RNA-Seq	O	O	B-Entity
and	O	O	O
Northern	O	O	B-Entity
hybridization	O	O	I-Entity
in	O	O	O
wild	O	O	B-Entity
type	O	O	I-Entity
strain	O	O	B-Entity
and	O	O	O
maf1Δ	O	O	B-Entity
mutant	O	O	B-Entity
grown	O	O	O
in	O	O	O
glucose	O	O	B-Entity
medium	O	O	B-Entity
or	O	O	O
upon	O	O	O
shift	O	O	O
to	O	O	O
repressive	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

A	O	O	O
negative	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
maf1Δ	O	O	B-Entity
mutant	O	O	B-Entity
on	O	O	O
the	O	O	O
addition	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
auxiliary	O	O	I-Entity
CCA	O	O	I-Entity
nucleotides	O	O	I-Entity
to	O	O	I-Entity
the	O	O	I-Entity
3	O	O	I-Entity
'	O	O	I-Entity
end	O	O	I-Entity
of	O	O	I-Entity
pre-tRNAs	O	O	I-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
cells	O	O	B-Entity
shifted	O	O	O
to	O	O	O
unfavourable	O	O	O
growth	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

This	O	O	O
effect	O	O	B-Entity
was	O	O	O
reduced	O	O	B-Entity
by	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
the	O	O	O
yeast	O	O	B-Entity
CCA1	O	O	B-Entity
gene	O	O	I-Entity
encoding	O	O	B-Entity
ATP(CTP):tRNA	O	O	B-Entity
nucleotidyltransferase	O	O	I-Entity
.	O	O	O

The	O	O	O
CCA	O	O	B-Entity
sequence	O	O	I-Entity
at	O	O	O
the	O	O	O
3	O	O	O
'	O	O	O
end	O	O	O
is	O	O	O
important	O	O	O
for	O	O	O
export	O	O	B-Entity
of	O	O	O
tRNA	O	O	B-Entity
precursors	O	O	I-Entity
from	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
and	O	O	O
essential	O	O	O
for	O	O	O
tRNA	O	O	B-Entity
charging	O	O	I-Entity
with	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
presented	O	O	O
here	O	O	O
indicate	O	O	O
that	O	O	O
CCA-addition	O	O	B-Entity
to	O	O	I-Entity
intron	O	O	B-Entity
-containing	O	O	I-Entity
end-processed	O	O	I-Entity
tRNA	O	O	I-Entity
precursors	O	O	I-Entity
is	O	O	O
a	O	O	O
limiting	O	O	B-Entity
step	O	O	I-Entity
in	O	O	O
tRNA	O	O	B-Entity
maturation	O	O	I-Entity
when	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
Maf1	O	O	B-Entity
mediated	O	O	O
RNA	O	O	B-Entity
polymerase	O	O	I-Entity
III	O	O	I-Entity
(	O	O	O
Pol	O	O	B-Entity
III	O	O	I-Entity
)	O	O	O
repression	O	O	B-Entity
.	O	O	O

The	O	O	O
correlation	O	O	B-Entity
between	O	O	O
CCA	O	O	B-Entity
synthesis	O	O	B-Entity
and	O	O	O
Pol	O	O	B-Entity
III	O	O	I-Entity
regulation	O	O	B-Entity
by	O	O	O
Maf1	O	O	B-Entity
could	O	O	O
be	O	O	O
important	O	O	O
in	O	O	O
coordination	O	O	B-Entity
of	O	O	O
tRNA	O	O	B-Entity
transcription	O	O	I-Entity
,	O	O	O
processing	O	O	B-Entity
and	O	O	O
regulation	O	O	B-Entity
of	O	O	I-Entity
translation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27575503)

Pre-existing	O	O	B-Entity
renal	O	O	B-Entity
lesions	O	O	B-Entity
revealed	O	O	O
after	O	O	O
renal	O	O	O
trauma	O	O	B-Entity
,	O	O	O
Difficulties	O	O	O
in	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
accountability	O	O	B-Entity
:	O	O	O
About	O	O	O
14	O	O	O
cases	O	O	O

Pre-existing	O	O	B-Entity
renal	O	O	B-Entity
lesions	O	O	B-Entity
(	O	O	O
PERL	O	O	B-Entity
)	O	O	O
may	O	O	O
interfere	O	O	O
with	O	O	O
the	O	O	O
patho-physiology	O	O	B-Entity
of	O	O	O
trauma	O	O	B-Entity
,	O	O	O
alter	O	O	O
the	O	O	O
radiographic	O	O	B-Entity
imaging	O	O	I-Entity
and	O	O	O
influence	O	O	B-Entity
the	O	O	O
therapeutic	O	O	B-Entity
approach	O	O	O
.	O	O	O

The	O	O	O
aims	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
record	O	O	O
the	O	O	O
PERL	O	O	B-Entity
found	O	O	O
incidentally	O	O	O
during	O	O	O
blunt	O	O	B-Entity
renal	O	O	B-Entity
trauma	O	O	B-Entity
,	O	O	O
to	O	O	O
specify	O	O	O
the	O	O	O
place	O	O	O
for	O	O	O
effective	O	O	O
conservative	O	O	B-Entity
management	O	O	I-Entity
and	O	O	O
to	O	O	O
determin	O	O	O
the	O	O	O
estimated	O	O	O
partial	O	O	B-Entity
permanent	O	O	I-Entity
disability	O	O	I-Entity
(	O	O	O
PPD	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
14	O	O	O
patients	O	O	B-Entity
with	O	O	O
PERL	O	O	B-Entity
and	O	O	O
blunt	O	O	B-Entity
renal	O	O	B-Entity
trauma	O	O	B-Entity
were	O	O	O
reviewed	O	O	O
.	O	O	O

In	O	O	O
each	O	O	O
patient	O	O	B-Entity
,	O	O	O
pre-existing	O	O	B-Entity
renal	O	O	B-Entity
abnormalities	O	O	O
,	O	O	O
clinical	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
CT	O	O	B-Entity
scan	O	O	I-Entity
study	O	O	B-Entity
findings	O	O	B-Entity
,	O	O	O
associated	O	O	O
injuries	O	O	B-Entity
,	O	O	O
therapeutic	O	O	B-Entity
approach	O	O	O
,	O	O	O
the	O	O	O
accountability	O	O	B-Entity
criteria	O	O	O
and	O	O	O
the	O	O	O
estimated	O	O	O
PPD	O	O	B-Entity
were	O	O	O
recorded	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
11	O	O	O
men	O	O	B-Entity
and	O	O	O
3	O	O	O
women	O	O	B-Entity
with	O	O	O
a	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
of	O	O	O
35,6	O	O	O
years	O	O	B-Entity
(	O	O	O
range	O	O	O
19	O	O	O
-	O	O	O
66	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Renal	O	O	B-Entity
trauma	O	O	B-Entity
was	O	O	O
due	O	O	O
to	O	O	O
a	O	O	O
traffic	O	O	B-Entity
accident	O	O	I-Entity
in	O	O	O
8	O	O	O
patients	O	O	B-Entity
.	O	O	O

Renal	O	O	B-Entity
damage	O	O	O
appeared	O	O	O
to	O	O	O
be	O	O	O
disproportionate	O	O	O
to	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
the	O	O	O
trauma	O	O	B-Entity
(	O	O	O
minor	O	O	O
trauma	O	O	O
)	O	O	O
.	O	O	O

They	O	O	O
had	O	O	O
a	O	O	O
lower	O	O	O
rate	O	O	O
of	O	O	O
associated	O	O	O
trauma	O	O	B-Entity
to	O	O	O
other	O	O	O
abdominal	O	O	B-Entity
organs	O	O	I-Entity
(	O	O	O
four	O	O	O
patients	O	O	B-Entity
only	O	O	O
)	O	O	O
.	O	O	O

Urinary	O	O	B-Entity
stones	O	O	I-Entity
were	O	O	O
present	O	O	O
in	O	O	O
5	O	O	O
patients	O	O	B-Entity
,	O	O	O
pelvi-ureteric	O	O	B-Entity
junction	O	O	I-Entity
obstruction	O	O	I-Entity
in	O	O	O
3	O	O	O
,	O	O	O
horseshoe	O	O	B-Entity
kidny	O	O	I-Entity
in	O	O	O
3	O	O	O
,	O	O	O
ectopic	O	O	B-Entity
kidney	O	O	I-Entity
in	O	O	O
2	O	O	O
and	O	O	O
upper	O	O	O
urinary	O	O	B-Entity
tract	O	O	I-Entity
carcinoma	O	O	I-Entity
in	O	O	O
one	O	O	O
case	O	O	O
.	O	O	O

Early	O	O	O
nephrectomy	O	O	B-Entity
was	O	O	O
required	O	O	O
in	O	O	O
three	O	O	O
cases	O	O	B-Entity
for	O	O	O
hemodynamic	O	O	B-Entity
instability	O	O	I-Entity
.	O	O	O

Ureteral	O	O	B-Entity
stenting	O	O	I-Entity
was	O	O	O
indicated	O	O	O
in	O	O	O
3	O	O	O
cases	O	O	B-Entity
.	O	O	O

Six	O	O	O
patients	O	O	B-Entity
were	O	O	O
operated	O	O	B-Entity
later	O	O	O
because	O	O	O
of	O	O	O
their	O	O	O
underlying	O	O	O
renal	O	O	B-Entity
pathology	O	O	B-Entity
.	O	O	O

A	O	O	O
conservative	O	O	B-Entity
treatment	O	O	I-Entity
was	O	O	O
possible	O	O	O
only	O	O	O
in	O	O	O
7	O	O	O
of	O	O	O
cases	O	O	B-Entity
.	O	O	O

The	O	O	O
PPD	O	O	B-Entity
related	O	O	O
to	O	O	O
renal	O	O	B-Entity
trauma	O	O	B-Entity
varide	O	O	O
from	O	O	O
0	O	O	O
to	O	O	O
13	O	O	O
%	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	B-Entity
.	O	O	O

PERL	O	O	B-Entity
may	O	O	O
complicate	O	O	O
a	O	O	O
negligible	O	O	O
renal	O	O	B-Entity
trauma	O	O	B-Entity
while	O	O	O
in	O	O	O
some	O	O	O
cases	O	O	B-Entity
they	O	O	O
may	O	O	O
be	O	O	O
of	O	O	O
vital	O	O	O
importance	O	O	O
for	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
final	O	O	O
outcome	O	O	O
.	O	O	O

The	O	O	O
imaging	O	O	O
findings	O	O	B-Entity
are	O	O	O
crucial	O	O	O
but	O	O	O
may	O	O	O
be	O	O	O
confusing	O	O	O
.	O	O	O

The	O	O	O
therapeutic	O	O	B-Entity
approach	O	O	O
is	O	O	O
,	O	O	O
to	O	O	O
a	O	O	O
large	O	O	O
extent	O	O	O
,	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
PERL	O	O	B-Entity
and	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
damage	O	O	B-Entity
,	O	O	O
and	O	O	O
is	O	O	O
often	O	O	O
conservative	O	O	O
in	O	O	O
the	O	O	O
hemo-dynamically	O	O	B-Entity
stable	O	O	I-Entity
patient	O	O	B-Entity
.	O	O	O

Accountability	O	O	B-Entity
link	O	O	O
may	O	O	O
be	O	O	O
difficult	O	O	O
to	O	O	O
establish	O	O	O
and	O	O	O
the	O	O	O
PPD	O	O	B-Entity
depends	O	O	O
on	O	O	O
the	O	O	O
PERL	O	O	B-Entity
and	O	O	O
the	O	O	O
renal	O	O	B-Entity
injuries	O	O	I-Entity
severity	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
no	O	O	O
involvement	O	O	O
with	O	O	O
funding	O	O	O
in	O	O	O
this	O	O	O
case	O	O	O
.	O	O	O

Ethical	O	O	O
approval	O	O	O
:	O	O	O
Not	O	O	O
required	O	O	O
Conflicts	O	O	O
of	O	O	O
interest	O	O	O
:	O	O	O
None	O	O	O
.	O	O	O

-DOCSTART- (27576084)

Polymeric	O	O	B-Entity
Nanostructure	O	O	B-Entity
Compiled	O	O	O
with	O	O	O
Multifunctional	O	O	B-Entity
Components	O	O	I-Entity
To	O	O	O
Exert	O	O	O
Tumor	O	O	B-Entity
-	O	O	O
Targeted	O	O	B-Entity
Delivery	O	O	I-Entity
of	O	O	O
Antiangiogenic	O	O	B-Entity
Gene	O	O	B-Entity
for	O	O	O
Tumor	O	O	B-Entity
Growth	O	O	I-Entity
Suppression	O	O	O

Nucleic	O	O	B-Entity
acid-based	O	O	I-Entity
therapy	O	O	B-Entity
has	O	O	O
emerged	O	O	O
as	O	O	O
a	O	O	O
revolutionary	O	O	B-Entity
methodology	O	O	I-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
the	O	O	O
diseases	O	O	B-Entity
related	O	O	O
to	O	O	O
protein	O	O	B-Entity
dysfunction	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
systemically	O	O	B-Entity
applicable	O	O	B-Entity
synthetic	O	O	B-Entity
delivery	O	O	I-Entity
systems	O	O	I-Entity
limits	O	O	O
its	O	O	O
current	O	O	O
usage	O	O	O
in	O	O	O
local	O	O	B-Entity
applications	O	O	I-Entity
,	O	O	O
particularly	O	O	O
for	O	O	O
DNA-based	O	O	B-Entity
therapy	O	O	O
with	O	O	O
regard	O	O	O
to	O	O	O
the	O	O	O
poor	O	O	B-Entity
bioavailability	O	O	I-Entity
in	O	O	O
the	O	O	O
systemic	O	O	B-Entity
administrations	O	O	I-Entity
.	O	O	O

To	O	O	O
overcome	O	O	O
this	O	O	O
obstacle	O	O	O
,	O	O	O
we	O	O	O
compiled	O	O	O
multiple	O	O	B-Entity
chemistry-based	O	O	B-Entity
strategies	O	O	I-Entity
into	O	O	O
the	O	O	O
manufacture	O	O	B-Entity
of	O	O	O
the	O	O	O
gene	O	O	B-Entity
delivery	O	O	I-Entity
formulations	O	O	I-Entity
to	O	O	O
pursue	O	O	O
improved	O	O	B-Entity
tolerability	O	O	B-Entity
of	O	O	O
DNA	O	O	B-Entity
to	O	O	O
the	O	O	O
enzymatic	O	O	B-Entity
degradation	O	O	B-Entity
in	O	O	O
the	O	O	O
biological	O	O	B-Entity
milieu	O	O	B-Entity
and	O	O	O
prolonged	O	O	B-Entity
retention	O	O	I-Entity
in	O	O	O
the	O	O	O
systemic	O	O	O
circulation	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
constructed	O	O	O
a	O	O	O
distinctive	O	O	B-Entity
multilayered	O	O	I-Entity
functional	O	O	B-Entity
architecture	O	O	B-Entity
:	O	O	O
plasmid	O	O	B-Entity
DNA	O	O	I-Entity
(	O	O	O
pDNA	O	O	B-Entity
)	O	O	O
was	O	O	O
electrostatically	O	O	B-Entity
complexed	O	O	I-Entity
with	O	O	O
cationic	O	O	B-Entity
poly(lysine	O	O	B-Entity
)	O	O	I-Entity
(	O	O	O
polyplex	O	O	B-Entity
)	O	O	O
as	O	O	O
the	O	O	O
interior	O	O	B-Entity
pDNA	O	O	O
reservoir	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
further	O	O	O
cross-linked	O	O	B-Entity
by	O	O	O
redox	O	O	B-Entity
-	O	O	O
responsive	O	O	B-Entity
disulfide	O	O	B-Entity
cross-linking	O	O	B-Entity
to	O	O	O
minimize	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
polyplex	O	O	O
disassembly	O	O	B-Entity
through	O	O	O
exchange	O	O	B-Entity
reaction	O	O	I-Entity
with	O	O	O
the	O	O	O
biological	O	O	B-Entity
charged	O	O	B-Entity
components	O	O	I-Entity
.	O	O	O

Still	O	O	O
,	O	O	O
the	O	O	O
pDNA	O	O	B-Entity
reservoir	O	O	B-Entity
was	O	O	O
spatially	O	O	O
protected	O	O	O
by	O	O	O
a	O	O	O
sequential	O	O	B-Entity
thermoresponsive	O	O	B-Entity
poly(N-isopropylacrylamide	O	O	B-Entity
)	O	O	I-Entity
palisade	O	O	B-Entity
as	O	O	O
the	O	O	O
intermediate	O	O	B-Entity
barrier	O	O	I-Entity
and	O	O	O
a	O	O	O
biocompatible	O	O	B-Entity
hydrophilic	O	O	B-Entity
poly(ethylene	O	O	B-Entity
glycol	O	O	I-Entity
)	O	O	I-Entity
(	O	O	O
PEG	O	O	B-Entity
)	O	O	O
shell	O	O	B-Entity
with	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
preventing	O	O	O
the	O	O	O
accessibility	O	O	B-Entity
of	O	O	O
the	O	O	O
biological	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
particularly	O	O	O
the	O	O	O
nuclease	O	O	B-Entity
degradation	O	O	B-Entity
to	O	O	O
the	O	O	O
pDNA	O	O	O
payload	O	O	O
.	O	O	O

Subsequent	O	O	O
investigations	O	O	B-Entity
validated	O	O	O
the	O	O	O
utilities	O	O	O
of	O	O	O
these	O	O	O
strategies	O	O	B-Entity
in	O	O	O
accomplishing	O	O	O
prolonged	O	O	O
blood	O	O	B-Entity
retention	O	O	B-Entity
.	O	O	O

In	O	O	O
an	O	O	O
attempt	O	O	O
to	O	O	O
apply	O	O	O
this	O	O	O
method	O	O	B-Entity
for	O	O	O
tumor	O	O	B-Entity
therapy	O	O	B-Entity
,	O	O	O
ligand	O	O	B-Entity
cyclic	O	O	I-Entity
(	O	O	I-Entity
Arg-Gly-Asp	O	O	I-Entity
)	O	O	I-Entity
peptide	O	O	I-Entity
was	O	O	O
attached	O	O	O
at	O	O	O
the	O	O	O
distal	O	O	O
end	O	O	O
of	O	O	O
PEG	O	O	B-Entity
,	O	O	O
validating	O	O	O
prompted	O	O	O
tumor	O	O	O
-	O	O	O
targeted	O	O	B-Entity
delivery	O	O	B-Entity
and	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
the	O	O	O
loaded	O	O	O
antiangiogenic	O	O	B-Entity
gene	O	O	O
at	O	O	O
the	O	O	O
targeted	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
accordingly	O	O	O
exerting	O	O	B-Entity
antiangiogenesis	O	O	B-Entity
of	O	O	O
the	O	O	O
tumors	O	O	B-Entity
for	O	O	O
abrogation	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

Together	O	O	O
with	O	O	O
its	O	O	O
excellent	O	O	O
safe	O	O	O
profile	O	O	O
,	O	O	O
the	O	O	O
proposed	O	O	O
formulation	O	O	O
suggests	O	O	O
potential	O	O	B-Entity
utility	O	O	O
as	O	O	O
a	O	O	O
practical	O	O	O
gene	O	O	B-Entity
delivery	O	O	I-Entity
system	O	O	I-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
intractable	O	O	B-Entity
diseases	O	O	B-Entity
.	O	O	O

-DOCSTART- (27578508)

Evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
VIDAS	O	O	B-Entity
Anti-HCV	O	O	I-Entity
Assay	O	O	I-Entity
for	O	O	O
Detection	O	O	B-Entity
of	O	O	O
Hepatitis	O	O	O
C	O	O	O
Virus	O	O	O
Infection	O	O	O

Anti-hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
antibody	O	O	I-Entity
(	O	O	O
anti-HCV	O	O	B-Entity
)	O	O	O
assays	O	O	B-Entity
are	O	O	O
recommended	O	O	O
for	O	O	O
screening	O	O	B-Entity
HCV	O	O	B-Entity
-infected	O	O	I-Entity
persons	O	O	I-Entity
.	O	O	O

The	O	O	O
VIDAS	O	O	B-Entity
Anti-HCV	O	O	I-Entity
Assay	O	O	I-Entity
(	O	O	O
bioMérieux	O	O	O
,	O	O	O
France	O	O	B-Entity
)	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
enzyme-linked	O	O	B-Entity
fluorescence	O	O	I-Entity
test	O	O	I-Entity
principle	O	O	B-Entity
,	O	O	O
was	O	O	O
recently	O	O	O
introduced	O	O	O
in	O	O	O
Korea	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	O
the	O	O	O
clinical	O	O	B-Entity
performance	O	O	B-Entity
of	O	O	O
the	O	O	O
VIDAS	O	O	B-Entity
assay	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
HCV-positive	O	O	B-Entity
and	O	O	O
1,002	O	O	O
HCV-negative	O	O	B-Entity
blood	O	O	B-Entity
samples	O	O	I-Entity
confirmed	O	O	O
by	O	O	O
Architect	O	O	B-Entity
anti-HCV	O	O	I-Entity
(	O	O	O
Abbott	O	O	B-Entity
Laboratories	O	O	I-Entity
,	O	O	O
USA	O	O	B-Entity
)	O	O	O
and	O	O	O
COBAS	O	O	B-Entity
TaqMan	O	O	I-Entity
HCV	O	O	I-Entity
real-time	O	O	I-Entity
PCR	O	O	I-Entity
(	O	O	O
Roche	O	O	B-Entity
Diagnostics	O	O	I-Entity
,	O	O	O
USA	O	O	O
)	O	O	O
or	O	O	O
the	O	O	O
Procleix	O	O	B-Entity
Ultrio	O	O	I-Entity
Plus	O	O	I-Entity
Assay	O	O	I-Entity
(	O	O	O
Gen-Probe	O	O	O
Incorporated	O	O	O
,	O	O	O
USA	O	O	O
)	O	O	O
were	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
Human	O	O	B-Entity
Serum	O	O	I-Entity
Bank	O	O	I-Entity
(	O	O	O
HSB	O	O	B-Entity
)	O	O	O
and	O	O	O
tested	O	O	O
by	O	O	O
VIDAS	O	O	B-Entity
.	O	O	O

In	O	O	O
case	O	O	O
of	O	O	O
discrepant	O	O	B-Entity
results	O	O	I-Entity
,	O	O	O
we	O	O	O
conducted	O	O	O
a	O	O	O
recombinant	O	O	B-Entity
immunoblot	O	O	I-Entity
assay	O	O	I-Entity
(	O	O	O
RIBA	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
agreement	O	O	B-Entity
rates	O	O	I-Entity
for	O	O	O
known	O	O	O
HCV-positive	O	O	B-Entity
and	O	O	O
HCV-negative	O	O	B-Entity
samples	O	O	B-Entity
between	O	O	O
the	O	O	O
VIDAS	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
the	O	O	O
HSB	O	O	B-Entity
testing	O	O	O
were	O	O	O
100	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
:	O	O	O
96.4	O	O	O
-	O	O	O
100	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
99.5	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
98.8	O	O	O
-	O	O	O
99.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
five	O	O	O
discrepant	O	O	B-Entity
samples	O	O	B-Entity
was	O	O	O
positive	O	O	B-Entity
for	O	O	O
Core	O	O	B-Entity
2	O	O	I-Entity
+	O	O	I-Entity
and	O	O	O
NS3	O	O	B-Entity
-	O	O	I-Entity
2	O	O	I-Entity
2	O	O	I-Entity
+	O	O	I-Entity
reactivity	O	O	O
,	O	O	O
two	O	O	O
samples	O	O	O
were	O	O	O
negative	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
other	O	O	O
two	O	O	O
were	O	O	O
indeterminate	O	O	O
regarding	O	O	O
NS4	O	O	B-Entity
2	O	O	I-Entity
+	O	O	I-Entity
reactivity	O	O	O
in	O	O	O
RIBA	O	O	B-Entity
.	O	O	O

We	O	O	O
observed	O	O	O
a	O	O	O
significant	O	O	O
but	O	O	O
weak	O	O	O
positive	O	O	O
correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
titers	O	O	B-Entity
of	O	O	O
VIDAS	O	O	B-Entity
and	O	O	O
Architect	O	O	B-Entity
assays	O	O	I-Entity
(	O	O	O
r=0.315	O	O	O
,	O	O	O
P<0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
VIDAS	O	O	B-Entity
anti-HCV	O	O	I-Entity
assay	O	O	I-Entity
,	O	O	O
developed	O	O	O
on	O	O	O
the	O	O	O
VIDAS	O	O	O
automated	O	O	B-Entity
immunoassay	O	O	I-Entity
platform	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
ready-to-use	O	O	O
,	O	O	O
single-sample	O	O	O
test	O	O	O
concept	O	O	O
may	O	O	O
be	O	O	O
useful	O	O	O
in	O	O	O
small-to-medium-sized	O	O	O
laboratories	O	O	B-Entity
.	O	O	O

It	O	O	O
showed	O	O	O
good	O	O	O
agreement	O	O	O
with	O	O	O
Architect	O	O	B-Entity
anti-HCV	O	O	I-Entity
and	O	O	O
COBAS	O	O	B-Entity
PCR	O	O	I-Entity
assays	O	O	I-Entity
and	O	O	O
is	O	O	O
therefore	O	O	O
useful	O	O	O
for	O	O	O
detection	O	O	O
of	O	O	O
HCV	O	O	B-Entity
infection	O	O	I-Entity
.	O	O	O

Weakly	O	O	B-Entity
test-positive	O	O	I-Entity
(	O	O	I-Entity
ambiguous	O	O	I-Entity
)	O	O	I-Entity
samples	O	O	B-Entity
require	O	O	O
additional	O	O	O
testing	O	O	O
by	O	O	O
another	O	O	O
anti-HCV	O	O	B-Entity
,	O	O	O
RIBA	O	O	B-Entity
,	O	O	O
or	O	O	O
HCV	O	O	B-Entity
RNA	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

-DOCSTART- (27581456)

Reassembly	O	O	B-Entity
of	O	O	I-Entity
Excitable	O	O	I-Entity
Domains	O	O	I-Entity
after	O	O	O
CNS	O	O	B-Entity
Axon	O	O	O
Regeneration	O	O	O

Action	O	O	B-Entity
potential	O	O	I-Entity
initiation	O	O	I-Entity
and	O	O	O
propagation	O	O	B-Entity
in	O	O	O
myelinated	O	O	B-Entity
axons	O	O	I-Entity
require	O	O	O
ion	O	O	B-Entity
channel	O	O	I-Entity
clustering	O	O	I-Entity
at	O	O	O
axon	O	O	B-Entity
initial	O	O	I-Entity
segments	O	O	I-Entity
(	O	O	B-Entity
AIS	O	O	I-Entity
)	O	O	O
and	O	O	O
nodes	O	O	B-Entity
of	O	O	I-Entity
Ranvier	O	O	I-Entity
.	O	O	O

Disruption	O	O	B-Entity
of	O	O	O
these	O	O	O
domains	O	O	O
after	O	O	O
injury	O	O	B-Entity
impairs	O	O	B-Entity
nervous	O	O	B-Entity
system	O	O	I-Entity
function	O	O	I-Entity
.	O	O	O

Traditionally	O	O	O
,	O	O	O
injured	O	O	B-Entity
CNS	O	O	B-Entity
axons	O	O	B-Entity
are	O	O	O
considered	O	O	O
refractory	O	O	B-Entity
to	O	O	O
regeneration	O	O	B-Entity
,	O	O	O
but	O	O	O
some	O	O	O
recent	O	O	O
approaches	O	O	O
challenge	O	O	O
this	O	O	O
view	O	O	O
by	O	O	O
showing	O	O	O
robust	O	O	B-Entity
long-distance	O	O	B-Entity
regeneration	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
whether	O	O	O
these	O	O	O
approaches	O	O	O
allow	O	O	O
remyelination	O	O	B-Entity
and	O	O	O
promote	O	O	O
the	O	O	O
reestablishment	O	O	B-Entity
of	O	O	O
AIS	O	O	B-Entity
and	O	O	O
nodes	O	O	B-Entity
of	O	O	I-Entity
Ranvier	O	O	I-Entity
is	O	O	O
unknown	O	O	B-Entity
.	O	O	O

Using	O	O	O
mouse	O	O	B-Entity
optic	O	O	B-Entity
nerve	O	O	B-Entity
crush	O	O	I-Entity
as	O	O	O
a	O	O	O
model	O	O	B-Entity
for	O	O	O
CNS	O	O	B-Entity
traumatic	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
we	O	O	O
performed	O	O	O
a	O	O	O
detailed	O	O	O
analysis	O	O	B-Entity
of	O	O	O
AIS	O	O	B-Entity
and	O	O	O
node	O	O	B-Entity
disruption	O	O	B-Entity
after	O	O	O
nerve	O	O	O
crush	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
significant	O	O	O
disruption	O	O	B-Entity
of	O	O	O
AIS	O	O	B-Entity
and	O	O	O
loss	O	O	B-Entity
of	O	O	O
nodes	O	O	B-Entity
within	O	O	O
days	O	O	O
of	O	O	O
the	O	O	O
crush	O	O	B-Entity
,	O	O	O
and	O	O	O
complete	O	O	O
loss	O	O	O
of	O	O	O
nodes	O	O	O
1	O	O	O
week	O	O	O
after	O	O	O
injury	O	O	B-Entity
.	O	O	O

Genetic	O	O	B-Entity
deletion	O	O	I-Entity
of	O	O	O
the	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
phosphatase	O	O	I-Entity
and	O	O	I-Entity
tensin	O	O	I-Entity
homolog	O	O	I-Entity
(	O	O	O
Pten	O	O	B-Entity
)	O	O	O
in	O	O	O
retinal	O	O	B-Entity
ganglion	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
RGCs	O	O	B-Entity
)	O	O	O
,	O	O	O
coupled	O	O	O
with	O	O	O
stimulation	O	O	B-Entity
of	O	O	O
RGCs	O	O	O
by	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
cAMP	O	O	B-Entity
,	O	O	O
dramatically	O	O	O
enhanced	O	O	O
regeneration	O	O	B-Entity
.	O	O	O

With	O	O	O
this	O	O	O
treatmen	O	O	B-Entity
t	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
significant	O	O	O
reestablishment	O	O	B-Entity
of	O	O	O
RGC	O	O	B-Entity
AIS	O	O	B-Entity
,	O	O	O
remyelination	O	O	B-Entity
,	O	O	O
and	O	O	O
even	O	O	O
reassembly	O	O	B-Entity
of	O	O	O
nodes	O	O	B-Entity
in	O	O	O
regions	O	O	B-Entity
proximal	O	O	I-Entity
,	O	O	O
within	O	O	B-Entity
,	O	O	O
and	O	O	O
distal	O	O	B-Entity
to	O	O	O
the	O	O	O
crush	O	O	B-Entity
site	O	O	B-Entity
.	O	O	O

Remyelination	O	O	B-Entity
began	O	O	O
near	O	O	B-Entity
the	O	O	I-Entity
retina	O	O	I-Entity
,	O	O	O
progressed	O	O	B-Entity
distally	O	O	B-Entity
,	O	O	O
and	O	O	O
was	O	O	O
confirmed	O	O	O
by	O	O	O
electron	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

Although	O	O	O
axons	O	O	B-Entity
grew	O	O	B-Entity
rapidly	O	O	B-Entity
,	O	O	O
remyelination	O	O	B-Entity
and	O	O	O
nodal	O	O	B-Entity
ion	O	O	I-Entity
channel	O	O	I-Entity
clustering	O	O	I-Entity
was	O	O	O
much	O	O	O
slower	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
genetic	O	O	B-Entity
deletion	O	O	I-Entity
of	O	O	O
ankyrinG	O	O	B-Entity
from	O	O	O
RGCs	O	O	B-Entity
to	O	O	O
block	O	O	B-Entity
AIS	O	O	B-Entity
reassembly	O	O	B-Entity
did	O	O	O
not	O	O	O
affect	O	O	O
axon	O	O	B-Entity
regeneration	O	O	I-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
preservation	O	O	O
of	O	O	O
neuronal	O	O	B-Entity
polarity	O	O	I-Entity
is	O	O	O
not	O	O	B-Entity
required	O	O	I-Entity
for	O	O	O
axon	O	O	O
regeneration	O	O	O
.	O	O	O

Together	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
demonstrate	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
that	O	O	O
regenerating	O	O	B-Entity
CNS	O	O	B-Entity
axons	O	O	B-Entity
can	O	O	O
be	O	O	O
remyelinated	O	O	B-Entity
and	O	O	O
reassemble	O	O	B-Entity
new	O	O	O
AIS	O	O	B-Entity
and	O	O	O
nodes	O	O	B-Entity
of	O	O	I-Entity
Ranvier	O	O	I-Entity
.	O	O	O

We	O	O	O
show	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
that	O	O	O
regenerated	O	O	B-Entity
CNS	O	O	B-Entity
axons	O	O	B-Entity
have	O	O	O
the	O	O	O
capacity	O	O	B-Entity
to	O	O	O
both	O	O	O
remyelinate	O	O	B-Entity
and	O	O	O
reassemble	O	O	B-Entity
the	O	O	O
axon	O	O	B-Entity
initial	O	O	I-Entity
segments	O	O	I-Entity
and	O	O	O
nodes	O	O	B-Entity
of	O	O	I-Entity
Ranvier	O	O	I-Entity
necessary	O	O	O
for	O	O	O
rapid	O	O	B-Entity
and	O	O	O
efficient	O	O	B-Entity
action	O	O	B-Entity
potential	O	O	I-Entity
propagation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27588139)

Clinicopathological	O	O	B-Entity
relevance	O	O	O
of	O	O	O
kinesin	O	O	B-Entity
family	O	O	I-Entity
member	O	O	I-Entity
18A	O	O	I-Entity
expression	O	O	B-Entity
in	O	O	O
invasive	O	O	O
breast	O	O	O
cancer	O	O	O

Recently	O	O	O
,	O	O	O
kinesin	O	O	B-Entity
motor	O	O	B-Entity
proteins	O	O	I-Entity
have	O	O	O
been	O	O	O
focused	O	O	O
on	O	O	O
as	O	O	O
targets	O	O	B-Entity
for	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Kinesins	O	O	B-Entity
are	O	O	O
microtubule	O	O	B-Entity
-based	O	O	O
motor	O	O	B-Entity
proteins	O	O	I-Entity
that	O	O	O
mediate	O	O	O
diverse	O	O	B-Entity
functions	O	O	I-Entity
within	O	O	O
the	O	O	O
cell	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
transport	O	O	B-Entity
of	O	O	O
vesicles	O	O	B-Entity
,	O	O	O
organelles	O	O	B-Entity
,	O	O	O
chromosomes	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
complexes	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
movement	O	O	B-Entity
of	O	O	I-Entity
microtubules	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
study	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
kinesin	O	O	B-Entity
family	O	O	I-Entity
member	O	O	I-Entity
18A	O	O	I-Entity
(	O	O	O
KIF18A	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
member	O	O	B-Entity
of	O	O	I-Entity
kinesin	O	O	I-Entity
superfamily	O	O	I-Entity
,	O	O	O
was	O	O	O
investigated	O	O	B-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
using	O	O	O
immunohistochemistry	O	O	B-Entity
,	O	O	O
and	O	O	O
its	O	O	O
effect	O	O	O
on	O	O	O
breast	O	O	O
cancer	O	O	O
prognosis	O	O	O
was	O	O	O
examined	O	O	O
.	O	O	O

KIF18A	O	O	B-Entity
expression	O	O	B-Entity
level	O	O	I-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	I-Entity
(	O	O	O
P=0.047	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
high	O	O	O
levels	O	O	O
of	O	O	O
KIF18A	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
survival	O	O	B-Entity
was	O	O	O
significantly	O	O	O
poorer	O	O	O
compared	O	O	O
to	O	O	O
patients	O	O	O
with	O	O	O
low	O	O	O
levels	O	O	O
of	O	O	O
KIF18A	O	O	O
expression	O	O	O
(	O	O	O
disease-free	O	O	B-Entity
survival	O	O	I-Entity
,	O	O	O
P=0.030	O	O	O
)	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
venous	O	O	B-Entity
invasion	O	O	I-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
9.22	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
,	O	O	O
3.90	O	O	O
-	O	O	O
23.66	O	O	O
;	O	O	O
P<0.001	O	O	O
)	O	O	O
and	O	O	O
KIF18A	O	O	B-Entity
expression	O	O	B-Entity
(	O	O	O
hazard	O	O	O
ratio	O	O	O
,	O	O	O
3.20	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	O
interval	O	O	O
,	O	O	O
1.34	O	O	O
-	O	O	O
6.09	O	O	O
;	O	O	O
P=0.010	O	O	O
)	O	O	O
were	O	O	O
independent	O	O	O
predictive	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	I-Entity
.	O	O	O

KIF18A	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
predictive	O	O	B-Entity
marker	O	O	B-Entity
for	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	I-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
which	O	O	O
could	O	O	O
facilitate	O	O	O
curative	O	O	B-Entity
adjuvant	O	O	I-Entity
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27589009)

The	O	O	O
underlying	O	O	O
inflammatory	O	O	B-Entity
chronic	O	O	I-Entity
disease	O	O	I-Entity
influences	O	O	B-Entity
infliximab	O	O	B-Entity
pharmacokinetics	O	O	O

Infliximab	O	O	B-Entity
is	O	O	O
an	O	O	O
anti-tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor	O	O	I-Entity
monoclonal	O	O	B-Entity
antibody	O	O	I-Entity
approved	O	O	O
in	O	O	O
chronic	O	O	B-Entity
inflammatory	O	O	I-Entity
diseases	O	O	I-Entity
such	O	O	O
as	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
(	O	O	O
RA	O	O	B-Entity
)	O	O	O
,	O	O	O
psoriatic	O	O	B-Entity
arthritis	O	O	I-Entity
(	O	O	O
PsA	O	O	B-Entity
)	O	O	O
,	O	O	O
ankylosing	O	O	B-Entity
spondylitis	O	O	I-Entity
(	O	O	O
AS	O	O	B-Entity
)	O	O	O
,	O	O	O
Crohn	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CD	O	O	B-Entity
)	O	O	O
and	O	O	O
ulcerative	O	O	B-Entity
colitis	O	O	I-Entity
(	O	O	O
UC	O	O	B-Entity
)	O	O	O
.	O	O	O

Infliximab	O	O	B-Entity
pharmacokinetics	O	O	B-Entity
is	O	O	O
variable	O	O	O
between	O	O	O
patients	O	O	B-Entity
,	O	O	O
but	O	O	O
influence	O	O	B-Entity
of	O	O	O
the	O	O	O
underlying	O	O	B-Entity
disease	O	O	I-Entity
was	O	O	O
never	O	O	O
assessed	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
at	O	O	O
assessing	O	O	O
this	O	O	O
influence	O	O	B-Entity
using	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
monitored	O	O	I-Entity
in	O	O	O
a	O	O	O
single	O	O	O
center	O	O	O
and	O	O	O
with	O	O	O
the	O	O	O
same	O	O	O
assay	O	O	B-Entity
.	O	O	O

Infliximab	O	O	B-Entity
trough	O	O	O
concentrations	O	O	B-Entity
were	O	O	O
determined	O	O	B-Entity
on	O	O	O
samples	O	O	B-Entity
collected	O	O	I-Entity
between	O	O	O
weeks	O	O	O
0	O	O	O
and	O	O	O
22	O	O	O
after	O	O	O
treatment	O	O	B-Entity
initiation	O	O	B-Entity
in	O	O	O
218	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
for	O	O	O
RA	O	O	B-Entity
,	O	O	O
PsA	O	O	B-Entity
,	O	O	O
AS	O	O	B-Entity
,	O	O	O
CD	O	O	B-Entity
or	O	O	O
UC	O	O	B-Entity
.	O	O	O

Infliximab	O	O	B-Entity
pharmacokinetics	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
a	O	O	O
one-compartment	O	O	O
population	O	O	B-Entity
model	O	O	O
with	O	O	O
first-order	O	O	O
elimination	O	O	B-Entity
rate	O	O	B-Entity
constant	O	O	I-Entity
.	O	O	O

In	O	O	O
AS	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
volume	O	O	B-Entity
of	O	O	I-Entity
distribution	O	O	I-Entity
(	O	O	O
V	O	O	B-Entity
)	O	O	O
and	O	O	O
elimination	O	O	B-Entity
clearance	O	O	B-Entity
(	O	O	O
CL	O	O	B-Entity
)	O	O	O
were	O	O	O
5.4	O	O	O
L	O	O	O
and	O	O	O
0.24	O	O	O
L/day	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
CD	O	O	B-Entity
and	O	O	O
UC	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
V	O	O	O
was	O	O	O
49	O	O	O
%	O	O	O
and	O	O	O
52	O	O	O
%	O	O	O
higher	O	O	O
than	O	O	O
in	O	O	O
AS	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
and	O	O	O
CL	O	O	B-Entity
was	O	O	O
47	O	O	O
%	O	O	O
and	O	O	O
60	O	O	O
%	O	O	O
higher	O	O	O
than	O	O	O
in	O	O	O
AS	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
RA	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
CL	O	O	B-Entity
was	O	O	O
49	O	O	O
%	O	O	O
higher	O	O	O
than	O	O	O
in	O	O	O
AS	O	O	B-Entity
patients	O	O	O
.	O	O	O

Simulations	O	O	B-Entity
showed	O	O	O
that	O	O	O
without	O	O	O
methotrexate	O	O	B-Entity
,	O	O	O
a	O	O	O
3	O	O	O
mg/kg	O	O	O
dosing	O	O	B-Entity
regimen	O	O	B-Entity
would	O	O	O
lead	O	O	O
only	O	O	O
16	O	O	O
%	O	O	O
of	O	O	O
RA	O	O	B-Entity
patients	O	O	B-Entity
to	O	O	O
reach	O	O	O
the	O	O	O
target	O	O	B-Entity
concentration	O	O	B-Entity
(	O	O	O
2.5	O	O	O
mg/L	O	O	O
)	O	O	O
at	O	O	O
week	O	O	O
22	O	O	O
,	O	O	O
whereas	O	O	O
target	O	O	O
concentrations	O	O	B-Entity
would	O	O	O
be	O	O	O
reached	O	O	O
in	O	O	O
approximately	O	O	B-Entity
half	O	O	O
of	O	O	O
RA	O	O	O
patients	O	O	O
cotreated	O	O	B-Entity
with	O	O	O
methotrexate	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
half	O	O	O
of	O	O	O
CD	O	O	B-Entity
(	O	O	O
3.5	O	O	O
mg/L	O	O	O
)	O	O	O
and	O	O	O
UC	O	O	B-Entity
(	O	O	O
3.7	O	O	O
mg/L	O	O	O
)	O	O	O
patients	O	O	O
.	O	O	O

The	O	O	O
suboptimality	O	O	O
of	O	O	O
approved	O	O	O
dosing	O	O	B-Entity
regimens	O	O	B-Entity
supports	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
dosing	O	O	O
optimization	O	O	B-Entity
based	O	O	O
on	O	O	O
concentration	O	O	B-Entity
measurements	O	O	I-Entity
.	O	O	O

-DOCSTART- (27590021)

International	O	O	B-Entity
validation	O	O	B-Entity
of	O	O	O
a	O	O	O
urinary	O	O	B-Entity
biomarker	O	O	B-Entity
panel	O	O	B-Entity
for	O	O	O
identification	O	O	O
of	O	O	O
active	O	O	B-Entity
lupus	O	O	B-Entity
nephritis	O	O	I-Entity
in	O	O	O
children	O	O	O

Conventional	O	O	O
markers	O	O	B-Entity
of	O	O	O
juvenile-onset	O	O	B-Entity
systemic	O	O	I-Entity
lupus	O	O	I-Entity
erythematosus	O	O	I-Entity
(	O	O	O
JSLE	O	O	B-Entity
)	O	O	O
disease	O	O	B-Entity
activity	O	O	I-Entity
fail	O	O	O
to	O	O	O
adequately	O	O	O
identify	O	O	O
lupus	O	O	B-Entity
nephritis	O	O	I-Entity
(	O	O	O
LN	O	O	B-Entity
)	O	O	O
.	O	O	O

While	O	O	O
individual	O	O	O
novel	O	O	B-Entity
urine	O	O	B-Entity
biomarkers	O	O	B-Entity
are	O	O	O
good	O	O	O
at	O	O	O
detecting	O	O	B-Entity
LN	O	O	B-Entity
flares	O	O	B-Entity
,	O	O	O
biomarker	O	O	B-Entity
panels	O	O	B-Entity
may	O	O	O
improve	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
performance	O	O	O
of	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
panel	O	O	B-Entity
to	O	O	O
identify	O	O	O
active	O	O	B-Entity
LN	O	O	B-Entity
in	O	O	O
two	O	O	O
international	O	O	B-Entity
JSLE	O	O	B-Entity
cohorts	O	O	B-Entity
.	O	O	O

Novel	O	O	O
urinary	O	O	B-Entity
biomarkers	O	O	B-Entity
,	O	O	O
namely	O	O	O
vascular	O	O	B-Entity
cell	O	O	I-Entity
adhesion	O	O	I-Entity
molecule-1	O	O	I-Entity
(	O	O	O
VCAM-1	O	O	B-Entity
)	O	O	O
,	O	O	O
monocyte	O	O	B-Entity
chemoattractant	O	O	I-Entity
protein	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
MCP-1	O	O	B-Entity
)	O	O	O
,	O	O	O
lipocalin-like	O	O	B-Entity
prostaglandin	O	O	I-Entity
D	O	O	I-Entity
synthase	O	O	I-Entity
(	O	O	O
LPGDS	O	O	B-Entity
)	O	O	O
,	O	O	O
transferrin	O	O	B-Entity
(	O	O	O
TF	O	O	B-Entity
)	O	O	O
,	O	O	O
ceruloplasmin	O	O	B-Entity
,	O	O	O
alpha-1-acid	O	O	B-Entity
glycoprotein	O	O	I-Entity
(	O	O	O
AGP	O	O	B-Entity
)	O	O	O
and	O	O	O
neutrophil	O	O	B-Entity
gelatinase-associated	O	O	I-Entity
lipocalin	O	O	I-Entity
(	O	O	O
NGAL	O	O	B-Entity
)	O	O	O
,	O	O	O
were	O	O	O
quantified	O	O	B-Entity
in	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
that	O	O	O
included	O	O	O
participants	O	O	B-Entity
of	O	O	O
the	O	O	O
UK	O	O	B-Entity
JSLE	O	O	B-Entity
Cohort	O	O	B-Entity
Study	O	O	I-Entity
(	O	O	O
Cohort	O	O	B-Entity
1	O	O	I-Entity
)	O	O	O
and	O	O	O
validated	O	O	O
within	O	O	O
the	O	O	O
Einstein	O	O	B-Entity
Lupus	O	O	I-Entity
Cohort	O	O	O
(	O	O	O
Cohort	O	O	B-Entity
2	O	O	I-Entity
)	O	O	O
.	O	O	O

Binary	O	O	B-Entity
logistic	O	O	B-Entity
regression	O	O	I-Entity
modelling	O	O	I-Entity
and	O	O	O
receiver	O	O	B-Entity
operating	O	O	I-Entity
characteristic	O	O	I-Entity
curve	O	O	B-Entity
analysis	O	O	I-Entity
[	O	O	O
area	O	O	B-Entity
under	O	O	I-Entity
the	O	O	I-Entity
curve	O	O	I-Entity
(	O	O	O
AUC	O	O	B-Entity
)	O	O	O
]	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
identify	O	O	O
and	O	O	O
assess	O	O	B-Entity
combinations	O	O	B-Entity
of	O	O	O
biomarkers	O	O	B-Entity
for	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
91	O	O	O
JSLE	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
recruited	O	O	O
across	O	O	O
both	O	O	O
cohorts	O	O	B-Entity
,	O	O	O
of	O	O	O
whom	O	O	O
31	O	O	O
(	O	O	O
34	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
active	O	O	B-Entity
LN	O	O	B-Entity
and	O	O	O
60	O	O	O
(	O	O	O
66	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
no	O	O	O
LN	O	O	O
.	O	O	O

Urinary	O	O	B-Entity
AGP	O	O	B-Entity
,	O	O	O
ceruloplasmin	O	O	B-Entity
,	O	O	O
VCAM-1	O	O	B-Entity
,	O	O	O
MCP-1	O	O	B-Entity
and	O	O	O
LPGDS	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
those	O	O	O
patients	O	O	B-Entity
with	O	O	O
active	O	O	B-Entity
LN	O	O	B-Entity
than	O	O	O
in	O	O	O
non	O	O	B-Entity
-	O	O	O
LN	O	O	O
patients	O	O	O
[	O	O	O
all	O	O	O
corrected	O	O	O
p	O	O	O
values	O	O	O
(	O	O	O
p	O	O	O
c	O	O	O
)	O	O	O
<	O	O	O
0.05	O	O	O
]	O	O	O
across	O	O	O
both	O	O	O
cohorts	O	O	B-Entity
.	O	O	O

Urinary	O	O	B-Entity
TF	O	O	B-Entity
also	O	O	O
differed	O	O	O
between	O	O	O
patient	O	O	B-Entity
groups	O	O	O
in	O	O	O
Cohort	O	O	B-Entity
2	O	O	I-Entity
(	O	O	O
p	O	O	O
c	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Within	O	O	O
Cohort	O	O	B-Entity
1	O	O	I-Entity
,	O	O	O
the	O	O	O
optimal	O	O	B-Entity
biomarker	O	O	B-Entity
panel	O	O	B-Entity
included	O	O	O
AGP	O	O	B-Entity
,	O	O	O
ceruloplasmin	O	O	B-Entity
,	O	O	O
LPGDS	O	O	B-Entity
and	O	O	O
TF	O	O	B-Entity
(	O	O	O
AUC	O	O	B-Entity
0.920	O	O	O
for	O	O	O
active	O	O	B-Entity
LN	O	O	B-Entity
identification	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
were	O	O	O
validated	O	O	O
in	O	O	O
Cohort	O	O	B-Entity
2	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
same	O	O	O
markers	O	O	B-Entity
resulting	O	O	O
in	O	O	O
the	O	O	O
optimal	O	O	B-Entity
urine	O	O	B-Entity
biomarker	O	O	B-Entity
panel	O	O	B-Entity
(	O	O	O
AUC	O	O	B-Entity
0.991	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
two	O	O	O
international	O	O	B-Entity
JSLE	O	O	B-Entity
cohorts	O	O	B-Entity
,	O	O	O
urinary	O	O	B-Entity
AGP	O	O	B-Entity
,	O	O	O
ceruloplasmin	O	O	B-Entity
,	O	O	O
LPGDS	O	O	B-Entity
and	O	O	O
TF	O	O	B-Entity
demonstrate	O	O	O
an	O	O	O
'	O	O	O
excellent	O	O	O
'	O	O	O
ability	O	O	O
for	O	O	O
accurately	O	O	O
identifying	O	O	O
active	O	O	B-Entity
LN	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
.	O	O	O

-DOCSTART- (27593389)

Fine	O	O	O
structure	O	O	O
of	O	O	O
interleukin	O	O	B-Entity
18	O	O	I-Entity
(	O	O	I-Entity
IL-18	O	O	I-Entity
)	O	O	I-Entity
receptor	O	O	I-Entity
-	O	O	O
immunoreactive	O	O	B-Entity
neurons	O	O	B-Entity
in	O	O	O
the	O	O	O
retrosplenial	O	O	B-Entity
cortex	O	O	I-Entity
and	O	O	O
its	O	O	O
changes	O	O	O
in	O	O	O
IL18	O	O	B-Entity
knockout	O	O	O
mice	O	O	O

Interleukin	O	O	B-Entity
18	O	O	I-Entity
(	O	O	O
IL-18	O	O	B-Entity
)	O	O	O
participates	O	O	O
in	O	O	O
the	O	O	O
inflammatory	O	O	B-Entity
immune	O	O	B-Entity
response	O	O	I-Entity
of	O	O	O
lymphocytes	O	O	B-Entity
.	O	O	O

Delay	O	O	B-Entity
in	O	O	I-Entity
learning	O	O	I-Entity
or	O	O	I-Entity
memory	O	O	I-Entity
are	O	O	O
common	O	O	O
in	O	O	O
the	O	O	O
IL-18	O	O	B-Entity
knockout	O	O	B-Entity
mouse	O	O	I-Entity
.	O	O	O

Many	O	O	O
IL-18	O	O	B-Entity
-	O	O	O
immunoreactive	O	O	B-Entity
neurons	O	O	B-Entity
are	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
retrosplenial	O	O	B-Entity
cortex	O	O	I-Entity
(	O	O	O
RSC	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
subiculum	O	O	B-Entity
.	O	O	O

These	O	O	O
neurons	O	O	B-Entity
also	O	O	O
contain	O	O	O
the	O	O	O
IL-18	O	O	B-Entity
receptor	O	O	I-Entity
.	O	O	O

We	O	O	O
determined	O	O	O
the	O	O	O
location	O	O	O
and	O	O	O
the	O	O	O
ultrastructure	O	O	B-Entity
of	O	O	O
the	O	O	O
IL-18	O	O	B-Entity
receptor	O	O	I-Entity
-	O	O	O
immunoreactive	O	O	B-Entity
neurons	O	O	B-Entity
in	O	O	O
the	O	O	O
RSC	O	O	B-Entity
and	O	O	O
observed	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
IL-18	O	O	O
receptor	O	O	O
-	O	O	O
immunoreactive	O	O	O
neurons	O	O	O
of	O	O	O
the	O	O	O
IL-18	O	O	O
knockout	O	O	B-Entity
mouse	O	O	I-Entity
.	O	O	O

The	O	O	O
IL-18	O	O	B-Entity
receptor	O	O	I-Entity
-	O	O	O
immunoreactive	O	O	B-Entity
neurons	O	O	B-Entity
were	O	O	O
found	O	O	O
specifically	O	O	O
in	O	O	O
layer	O	O	B-Entity
V	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
granular	O	O	I-Entity
RSC	O	O	I-Entity
.	O	O	O

They	O	O	O
were	O	O	O
medium-sized	O	O	O
neurons	O	O	B-Entity
with	O	O	O
a	O	O	O
light	O	O	O
oval	O	O	B-Entity
nucleus	O	O	I-Entity
and	O	O	O
had	O	O	O
little	O	O	O
cytoplasm	O	O	B-Entity
with	O	O	O
many	O	O	O
free	O	O	B-Entity
ribosomes	O	O	I-Entity
,	O	O	O
rough	O	O	O
endoplasmic	O	O	B-Entity
reticulum	O	O	I-Entity
and	O	O	O
many	O	O	O
mitochondria	O	O	B-Entity
,	O	O	O
but	O	O	O
no	O	O	O
Nissl	O	O	B-Entity
bodies	O	O	I-Entity
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
axosomatic	O	O	B-Entity
terminals	O	O	I-Entity
was	O	O	O
about	O	O	O
six	O	O	O
per	O	O	O
section	O	O	O
.	O	O	O

The	O	O	O
IL-18	O	O	B-Entity
receptor	O	O	I-Entity
-	O	O	O
immunoreactive	O	O	B-Entity
neurons	O	O	B-Entity
were	O	O	O
not	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
RSC	O	O	B-Entity
in	O	O	O
the	O	O	O
IL-18	O	O	O
knockout	O	O	B-Entity
mouse	O	O	I-Entity
at	O	O	O
5	O	O	O
or	O	O	O
9	O	O	O
weeks	O	O	O
of	O	O	O
age	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
many	O	O	O
small	O	O	B-Entity
electron-dense	O	O	B-Entity
neurons	O	O	B-Entity
were	O	O	O
found	O	O	O
in	O	O	O
layer	O	O	O
V.	O	O	O
Both	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
and	O	O	O
cytoplasm	O	O	B-Entity
were	O	O	O
electron-dense	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
necrotic	O	O	O
.	O	O	O

The	O	O	O
mitochondria	O	O	B-Entity
and	O	O	O
rough	O	O	B-Entity
endoplasmic	O	O	I-Entity
reticulum	O	O	I-Entity
were	O	O	O
swollen	O	O	B-Entity
.	O	O	O

The	O	O	O
IL-18	O	O	B-Entity
receptor	O	O	I-Entity
-	O	O	O
immunoreactive	O	O	B-Entity
neurons	O	O	B-Entity
were	O	O	O
presumed	O	O	O
to	O	O	O
be	O	O	O
degenerating	O	O	B-Entity
.	O	O	O

The	O	O	O
degeneration	O	O	B-Entity
of	O	O	O
the	O	O	O
IL18-receptor	O	O	B-Entity
-	O	O	O
immunoreactive	O	O	B-Entity
neurons	O	O	B-Entity
in	O	O	O
the	O	O	O
RSC	O	O	B-Entity
may	O	O	O
cause	O	O	O
the	O	O	O
abnormal	O	O	B-Entity
behaviors	O	O	I-Entity
of	O	O	O
the	O	O	O
IL-18	O	O	B-Entity
knockout	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

-DOCSTART- (27593461)

Exploring	O	O	O
the	O	O	O
genetic	O	O	B-Entity
variability	O	O	B-Entity
in	O	O	O
water	O	O	B-Entity
use	O	O	B-Entity
efficiency	O	O	B-Entity
:	O	O	O
Evaluation	O	O	O
of	O	O	O
inter	O	O	B-Entity
and	O	O	O
intra	O	O	B-Entity
cultivar	O	O	I-Entity
genetic	O	O	B-Entity
diversity	O	O	I-Entity
in	O	O	O
grapevines	O	O	O

Genetic	O	O	B-Entity
improvement	O	O	B-Entity
of	O	O	O
crop	O	O	B-Entity
Water	O	O	B-Entity
Use	O	O	B-Entity
Efficiency	O	O	B-Entity
(	O	O	O
WUE	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
general	O	O	O
goal	O	O	B-Entity
because	O	O	O
the	O	O	O
increasing	O	O	B-Entity
water	O	O	B-Entity
scarcity	O	O	B-Entity
and	O	O	O
the	O	O	O
trend	O	O	O
to	O	O	O
a	O	O	O
more	O	O	O
sustainable	O	O	B-Entity
agriculture	O	O	B-Entity
.	O	O	O

For	O	O	O
grapevines	O	O	B-Entity
,	O	O	O
this	O	O	O
subject	O	O	B-Entity
is	O	O	O
relevant	O	O	B-Entity
and	O	O	O
need	O	O	O
an	O	O	O
urgent	O	O	O
response	O	O	O
because	O	O	O
their	O	O	O
wide	O	O	O
distribution	O	O	B-Entity
in	O	O	O
semi-arid	O	O	B-Entity
areas	O	O	B-Entity
.	O	O	O

New	O	O	O
cultivars	O	O	B-Entity
are	O	O	O
difficult	O	O	B-Entity
to	O	O	O
introduce	O	O	B-Entity
in	O	O	O
viticulture	O	O	B-Entity
due	O	O	O
to	O	O	O
the	O	O	O
narrow	O	O	O
dependency	O	O	O
of	O	O	O
consumer	O	O	B-Entity
appreciation	O	O	B-Entity
often	O	O	O
linked	O	O	O
to	O	O	O
a	O	O	O
certain	O	O	O
particular	O	O	O
wine	O	O	B-Entity
taste	O	O	B-Entity
.	O	O	O

Clones	O	O	B-Entity
of	O	O	O
reputed	O	O	O
cultivars	O	O	B-Entity
would	O	O	O
presumably	O	O	O
be	O	O	O
more	O	O	O
accepted	O	O	B-Entity
but	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
on	O	O	O
the	O	O	O
intra-cultivar	O	O	B-Entity
genetic	O	O	B-Entity
variability	O	O	B-Entity
of	O	O	O
the	O	O	O
WUE	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
work	O	O	O
compares	O	O	B-Entity
,	O	O	O
on	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
two	O	O	O
field	O	O	B-Entity
assays	O	O	O
,	O	O	O
the	O	O	O
variability	O	O	B-Entity
of	O	O	O
intrinsic	O	O	O
water	O	O	B-Entity
use	O	O	B-Entity
efficiency	O	O	B-Entity
(	O	O	O
WUEi	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
large	O	O	O
collection	O	O	B-Entity
of	O	O	O
cultivars	O	O	B-Entity
in	O	O	O
contrast	O	O	B-Entity
with	O	O	O
a	O	O	O
collection	O	O	O
of	O	O	O
clones	O	O	B-Entity
of	O	O	O
Tempranillo	O	O	B-Entity
cultivar	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
show	O	O	O
that	O	O	O
clonal	O	O	B-Entity
variability	O	O	B-Entity
of	O	O	O
WUEi	O	O	B-Entity
was	O	O	O
around	O	O	B-Entity
80	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
inter-cultivar	O	O	B-Entity
,	O	O	O
thus	O	O	O
providing	O	O	O
a	O	O	O
first	O	O	O
assessment	O	O	B-Entity
on	O	O	O
the	O	O	O
opportunity	O	O	O
for	O	O	O
clonal	O	O	O
selection	O	O	B-Entity
by	O	O	O
WUE	O	O	B-Entity
.	O	O	O

Plotting	O	O	O
the	O	O	O
WUEi	O	O	B-Entity
data	O	O	B-Entity
against	O	O	O
stem	O	O	B-Entity
water	O	O	B-Entity
potential	O	O	B-Entity
or	O	O	O
stomatal	O	O	B-Entity
conductance	O	O	I-Entity
it	O	O	O
was	O	O	O
possible	O	O	B-Entity
to	O	O	O
identify	O	O	B-Entity
cultivars	O	O	B-Entity
and	O	O	O
clones	O	O	B-Entity
out	O	O	O
of	O	O	O
the	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
of	O	O	O
this	O	O	O
linear	O	O	B-Entity
regression	O	O	I-Entity
thus	O	O	O
with	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
and	O	O	O
lower	O	O	B-Entity
WUEi	O	O	O
values	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
results	O	O	B-Entity
contribute	O	O	B-Entity
to	O	O	O
open	O	O	O
the	O	O	O
expectative	O	O	O
for	O	O	O
a	O	O	O
genetic	O	O	B-Entity
improvement	O	O	B-Entity
of	O	O	O
grapevine	O	O	B-Entity
WUE	O	O	B-Entity
.	O	O	O

-DOCSTART- (27596934)

Comparison	O	O	O
of	O	O	O
methods	O	O	O
for	O	O	O
isolating	O	O	B-Entity
primary	O	O	B-Entity
hepatocytes	O	O	B-Entity
from	O	O	O
mini	O	O	O
pigs	O	O	O

Successful	O	O	O
porcine	O	O	B-Entity
hepatocyte	O	O	B-Entity
isolation	O	O	B-Entity
is	O	O	O
crucial	O	O	O
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
bioartificial	O	O	B-Entity
liver	O	O	I-Entity
devices	O	O	I-Entity
and	O	O	O
hepatocyte	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

Serva	O	O	B-Entity
collagenase	O	O	I-Entity
NB	O	O	I-Entity
grades	O	O	I-Entity
are	O	O	O
formulated	O	O	O
collagenases	O	O	B-Entity
that	O	O	O
are	O	O	O
suitable	O	O	O
for	O	O	O
various	O	O	O
tissue	O	O	B-Entity
isolation	O	O	B-Entity
applications	O	O	O
.	O	O	O

N-acetylcysteine	O	O	B-Entity
(	O	O	O
NAC	O	O	B-Entity
)	O	O	O
can	O	O	O
improve	O	O	O
the	O	O	O
viability	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
hepatocytes	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
compare	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
two	O	O	O
collagenases	O	O	B-Entity
and	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
NAC	O	O	B-Entity
on	O	O	O
hepatocyte	O	O	B-Entity
isolation	O	O	B-Entity
from	O	O	O
porcine	O	O	B-Entity
liver	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

Porcine	O	O	B-Entity
hepatocytes	O	O	B-Entity
were	O	O	O
isolated	O	O	B-Entity
using	O	O	O
the	O	O	O
perfusion	O	O	B-Entity
method	O	O	I-Entity
from	O	O	O
Bama	O	O	O
mini	O	O	B-Entity
pigs	O	O	I-Entity
assigned	O	O	O
to	O	O	O
the	O	O	O
Serva	O	O	B-Entity
NB	O	O	I-Entity
4	O	O	I-Entity
group	O	O	B-Entity
(	O	O	O
n=6	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
Serva	O	O	B-Entity
NB	O	O	B-Entity
8	O	O	I-Entity
group	O	O	O
(	O	O	O
n=6	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
the	O	O	O
NB	O	O	O
8	O	O	O
+	O	O	O
NAC	O	O	B-Entity
group	O	O	O
(	O	O	O
n=6	O	O	O
)	O	O	O
.	O	O	O

Viability	O	O	B-Entity
and	O	O	O
yield	O	O	O
were	O	O	O
defined	O	O	O
as	O	O	O
fresh	O	O	O
hepatocytes	O	O	B-Entity
and	O	O	O
their	O	O	O
spheroids	O	O	B-Entity
formation	O	O	I-Entity
after	O	O	O
24-hour	O	O	O
rocker	O	O	B-Entity
culture	O	O	I-Entity
in	O	O	O
serum-free	O	O	B-Entity
medium	O	O	I-Entity
.	O	O	O

Metabolic	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
assessed	O	O	O
by	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
albumin	O	O	B-Entity
,	O	O	O
and	O	O	O
urea	O	O	B-Entity
synthesis	O	O	B-Entity
.	O	O	O

All	O	O	O
procedures	O	O	O
resulted	O	O	O
in	O	O	O
successful	O	O	O
hepatocyte	O	O	B-Entity
isolation	O	O	B-Entity
.	O	O	O

Cells	O	O	B-Entity
from	O	O	O
the	O	O	O
NB	O	O	B-Entity
8	O	O	I-Entity
+	O	O	O
NAC	O	O	B-Entity
group	O	O	B-Entity
had	O	O	O
(97.8±1.9)%	O	O	O
viability	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
higher	O	O	O
than	O	O	O
the	O	O	O
NB	O	O	O
8	O	O	O
group	O	O	O
with	O	O	O
(94.4±2.4)%	O	O	O
and	O	O	O
the	O	O	O
NB	O	O	B-Entity
4	O	O	I-Entity
group	O	O	O
with	O	O	O
(94.5±3.2)%	O	O	O
(	O	O	O
P<.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
final	O	O	O
cell	O	O	B-Entity
yield	O	O	O
reached	O	O	O
(11.8±1.0)	O	O	O
×	O	O	O
10(9	O	O	O
)	O	O	O
cells	O	O	B-Entity
in	O	O	O
the	O	O	O
NB	O	O	B-Entity
8	O	O	I-Entity
+	O	O	O
NAC	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
compared	O	O	O
to	O	O	O
(9.5±2.1)	O	O	O
×	O	O	O
10(9	O	O	O
)	O	O	O
cells	O	O	O
in	O	O	O
the	O	O	O
NB	O	O	O
8	O	O	O
group	O	O	O
(	O	O	O
P<.01	O	O	O
)	O	O	O
and	O	O	O
(	O	O	O
9.1±1.1	O	O	O
)	O	O	O
×10(9	O	O	O
)	O	O	O
cells	O	O	O
in	O	O	O
the	O	O	O
NB	O	O	B-Entity
4	O	O	I-Entity
group	O	O	O
(	O	O	O
P<.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
secretion	O	O	B-Entity
of	O	O	O
albumin	O	O	B-Entity
was	O	O	O
superior	O	O	O
in	O	O	O
the	O	O	O
NB	O	O	B-Entity
8	O	O	I-Entity
+	O	O	O
NAC	O	O	B-Entity
group	O	O	B-Entity
at	O	O	O
a	O	O	O
concentration	O	O	O
of	O	O	O
(	O	O	O
425.8±35.3	O	O	O
)	O	O	O
ng/mL	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
NB	O	O	O
8	O	O	O
group	O	O	O
(	O	O	O
339.1±32.6	O	O	O
)	O	O	O
ng/mL	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
and	O	O	O
NB	O	O	B-Entity
4	O	O	I-Entity
group	O	O	O
(	O	O	O
293.6±43.3	O	O	O
)	O	O	O
ng/mL	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
injury	O	O	B-Entity
of	O	O	O
hepatocytes	O	O	B-Entity
also	O	O	O
decreased	O	O	O
in	O	O	O
the	O	O	O
NB	O	O	B-Entity
8	O	O	I-Entity
+	O	O	O
NAC	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
P<.01	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
data	O	O	O
are	O	O	O
presented	O	O	O
as	O	O	O
means	O	O	B-Entity
±	O	O	I-Entity
SD	O	O	I-Entity
.	O	O	O

Formulated	O	O	O
collagenase	O	O	B-Entity
Serva	O	O	I-Entity
NB	O	O	I-Entity
8	O	O	I-Entity
and	O	O	O
NAC	O	O	B-Entity
could	O	O	O
improve	O	O	O
the	O	O	O
porcine	O	O	B-Entity
hepatocyte	O	O	B-Entity
isolation	O	O	B-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
higher	O	O	O
yields	O	O	O
of	O	O	O
viable	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (27598472)

Endothermal	O	O	B-Entity
venous	O	O	I-Entity
ablation	O	O	I-Entity
of	O	O	O
the	O	O	O
saphenous	O	O	B-Entity
vein	O	O	I-Entity
on	O	O	O
patients	O	O	B-Entity
who	O	O	O
are	O	O	O
on	O	O	O
anticoagulation	O	O	O
therapy	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
risks	O	O	B-Entity
of	O	O	O
bleeding	O	O	B-Entity
,	O	O	O
deep	O	O	B-Entity
venous	O	O	I-Entity
thrombosis	O	O	I-Entity
(	O	O	O
DVT	O	O	B-Entity
)	O	O	O
,	O	O	O
endovenous	O	O	B-Entity
heat	O	O	I-Entity
induced	O	O	I-Entity
thrombosis	O	O	I-Entity
(	O	O	O
EHIT	O	O	B-Entity
)	O	O	O
and	O	O	O
failure	O	O	B-Entity
of	O	O	O
ablation	O	O	B-Entity
on	O	O	O
patients	O	O	B-Entity
who	O	O	O
undergo	O	O	O
ablation	O	O	O
while	O	O	O
on	O	O	O
oral	O	O	B-Entity
anticoagulation	O	O	I-Entity
.	O	O	O

We	O	O	O
compared	O	O	B-Entity
378	O	O	O
(	O	O	O
3.4	O	O	O
%	O	O	O
)	O	O	O
out	O	O	O
of	O	O	O
11252	O	O	O
patients	O	O	B-Entity
(	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
)	O	O	O
who	O	O	O
had	O	O	O
undergone	O	O	O
724	O	O	O
endovenous	O	O	B-Entity
ablation	O	O	I-Entity
of	O	O	O
the	O	O	O
saphenous	O	O	B-Entity
veins	O	O	I-Entity
from	O	O	O
January	O	O	O
1	O	O	O
,	O	O	O
2011	O	O	O
to	O	O	O
September	O	O	O
30	O	O	O
,	O	O	O
2014	O	O	O
while	O	O	O
on	O	O	O
oral	O	O	B-Entity
anticoagulation	O	O	B-Entity
to	O	O	O
a	O	O	O
randomly	O	O	O
selected	O	O	O
375	O	O	O
patients	O	O	O
(	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
)	O	O	O
who	O	O	O
underwent	O	O	O
641	O	O	O
endovenous	O	O	O
ablation	O	O	O
in	O	O	O
the	O	O	O
same	O	O	O
time	O	O	B-Entity
period	O	O	I-Entity
but	O	O	O
were	O	O	O
not	O	O	O
on	O	O	O
anticoagulation	O	O	O
.	O	O	O

The	O	O	O
demographic	O	O	B-Entity
data	O	O	I-Entity
,	O	O	O
history	O	O	B-Entity
of	O	O	I-Entity
DVT	O	O	B-Entity
,	O	O	O
the	O	O	O
Clinical	O	O	B-Entity
,	O	O	O
Etiologic	O	O	B-Entity
,	O	O	O
Anatomic	O	O	B-Entity
,	O	O	O
Pathologic	O	O	B-Entity
(	O	O	O
CEAP	O	O	B-Entity
)	O	O	O
classification	O	O	B-Entity
and	O	O	O
the	O	O	O
VCSS	O	O	B-Entity
(	O	O	O
Venous	O	O	B-Entity
Clinical	O	O	I-Entity
Severity	O	O	I-Entity
Score	O	O	I-Entity
)	O	O	O
scores	O	O	O
were	O	O	O
analyzed	O	O	O
.	O	O	O

The	O	O	O
indications	O	O	B-Entity
for	O	O	O
anticoagulation	O	O	B-Entity
,	O	O	O
the	O	O	O
anticoagulants	O	O	B-Entity
used	O	O	O
were	O	O	O
recorded	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	O
endpoints	O	O	O
were	O	O	O
bleeding	O	O	B-Entity
,	O	O	O
development	O	O	O
of	O	O	O
DVT	O	O	B-Entity
or	O	O	O
EHIT	O	O	B-Entity
,	O	O	O
and	O	O	O
failure	O	O	B-Entity
of	O	O	O
ablation	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
were	O	O	O
older	O	O	B-Entity
,	O	O	O
had	O	O	O
more	O	O	O
men	O	O	B-Entity
,	O	O	O
more	O	O	O
history	O	O	O
of	O	O	O
DVT	O	O	B-Entity
and	O	O	O
PE	O	O	B-Entity
,	O	O	O
had	O	O	O
higher	O	O	O
CEAP	O	O	B-Entity
and	O	O	O
VCSS	O	O	B-Entity
scores	O	O	O
compared	O	O	O
to	O	O	O
group	O	O	O
B.	O	O	O
The	O	O	O
type	O	O	O
of	O	O	O
anticoagulation	O	O	B-Entity
used	O	O	O
was	O	O	O
warfarin	O	O	B-Entity
in	O	O	O
77.2	O	O	O
%	O	O	O
direct	O	O	B-Entity
oral	O	O	I-Entity
inhibitors	O	O	I-Entity
(	O	O	O
DOIs	O	O	B-Entity
)	O	O	O
in	O	O	O
22.8	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	O
failure	O	O	B-Entity
of	O	O	O
ablation	O	O	B-Entity
at	O	O	O
3	O	O	O
days	O	O	B-Entity
was	O	O	O
39	O	O	O
(	O	O	O
5.6	O	O	O
%	O	O	O
)	O	O	O
for	O	O	O
Group	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
3	O	O	O
(	O	O	O
0.5	O	O	O
%	O	O	O
)	O	O	O
for	O	O	O
Group	O	O	B-Entity
B	O	O	I-Entity
(	O	O	O
P<0.0001	O	O	O
)	O	O	O
and	O	O	O
at	O	O	O
one	O	O	B-Entity
month	O	O	I-Entity
it	O	O	O
was	O	O	O
46	O	O	O
(	O	O	O
10.1	O	O	O
%	O	O	O
)	O	O	O
vs.	O	O	O
27	O	O	O
(	O	O	O
6.7	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
P=0.086	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
EHIT	O	O	B-Entity
cases	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
at	O	O	O
3	O	O	O
days	O	O	B-Entity
was	O	O	O
2	O	O	O
(	O	O	O
0.3	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
compared	O	O	O
to	O	O	O
6	O	O	O
(	O	O	O
0.9	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
(	O	O	O
P=0.016	O	O	O
)	O	O	O
and	O	O	O
at	O	O	O
1	O	O	B-Entity
month	O	O	I-Entity
it	O	O	O
was	O	O	O
0	O	O	O
compared	O	O	O
to	O	O	O
4	O	O	O
(	O	O	O
1.0	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
P=0.0483	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
DVT	O	O	B-Entity
,	O	O	O
SVT	O	O	B-Entity
,	O	O	O
hematoma	O	O	B-Entity
and	O	O	O
wound	O	O	B-Entity
infection	O	O	I-Entity
rates	O	O	B-Entity
were	O	O	O
similar	O	O	O
in	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

Ablation	O	O	B-Entity
of	O	O	O
the	O	O	O
saphenous	O	O	B-Entity
veins	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
who	O	O	O
are	O	O	O
on	O	O	O
oral	O	O	B-Entity
anticoagulation	O	O	I-Entity
is	O	O	O
safe	O	O	O
and	O	O	O
does	O	O	O
not	O	O	O
increase	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
bleeding	O	O	B-Entity
or	O	O	O
hematoma	O	O	B-Entity
,	O	O	O
but	O	O	O
it	O	O	O
may	O	O	O
slightly	O	O	O
lower	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
EHIT	O	O	B-Entity
and	O	O	O
increase	O	O	O
the	O	O	O
incidence	O	O	O
of	O	O	O
failure	O	O	B-Entity
of	O	O	O
ablation	O	O	B-Entity
.	O	O	O

-DOCSTART- (27599756)

Variation	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
PRIM1	O	O	B-Entity
gene	O	O	I-Entity
in	O	O	O
Chinese	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
primary	O	O	O
ovarian	O	O	O
insufficiency	O	O	O

Insights	O	O	O
into	O	O	O
common	O	O	O
genetic	O	O	B-Entity
susceptibility	O	O	I-Entity
between	O	O	O
primary	O	O	B-Entity
ovarian	O	O	I-Entity
insufficiency	O	O	I-Entity
(	O	O	O
POI	O	O	B-Entity
)	O	O	O
and	O	O	O
natural	O	O	B-Entity
or	O	O	O
early	O	O	B-Entity
menopause	O	O	I-Entity
have	O	O	O
delivered	O	O	B-Entity
an	O	O	O
innovative	O	O	O
way	O	O	O
of	O	O	O
assessing	O	O	O
the	O	O	O
genetic	O	O	B-Entity
mechanisms	O	O	I-Entity
involved	O	O	O
in	O	O	O
POI	O	O	O
.	O	O	O

PRIM1	O	O	B-Entity
plays	O	O	O
a	O	O	O
crucial	O	O	O
role	O	O	O
in	O	O	O
DNA	O	O	B-Entity
replication	O	O	I-Entity
by	O	O	O
synthesizing	O	O	B-Entity
RNA	O	O	B-Entity
primers	O	O	I-Entity
for	O	O	O
Okazaki	O	O	B-Entity
fragments	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
closely	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
age	O	O	B-Entity
at	O	O	O
natural	O	O	B-Entity
menopause	O	O	I-Entity
,	O	O	O
early	O	O	B-Entity
menopause	O	O	I-Entity
and	O	O	O
POI	O	O	B-Entity
in	O	O	O
European	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
mutations	O	O	B-Entity
in	O	O	O
PRIM1	O	O	B-Entity
contribute	O	O	O
to	O	O	O
POI	O	O	B-Entity
in	O	O	O
Chinese	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

All	O	O	O
exons	O	O	B-Entity
and	O	O	O
exon-intron	O	O	B-Entity
boundaries	O	O	I-Entity
of	O	O	O
PRIM1	O	O	B-Entity
gene	O	O	I-Entity
were	O	O	O
sequenced	O	O	B-Entity
in	O	O	O
192	O	O	O
Han	O	O	B-Entity
Chinese	O	O	I-Entity
women	O	O	B-Entity
with	O	O	O
non-syndromic	O	O	O
POI	O	O	B-Entity
.	O	O	O

No	O	O	O
plausible	O	O	O
mutations	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
perturbations	O	O	B-Entity
in	O	O	O
PRIM1	O	O	B-Entity
gene	O	O	I-Entity
are	O	O	O
not	O	O	O
a	O	O	O
common	O	O	O
explanation	O	O	O
for	O	O	O
POI	O	O	B-Entity
in	O	O	O
Chinese	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

-DOCSTART- (27602302)

Selection	O	O	B-Entity
of	O	O	O
a	O	O	O
marker	O	O	B-Entity
gene	O	O	I-Entity
to	O	O	O
construct	O	O	O
a	O	O	O
reference	O	O	B-Entity
library	O	O	I-Entity
for	O	O	O
wetland	O	O	B-Entity
plants	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
metabarcoding	O	O	B-Entity
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
diet	O	O	B-Entity
of	O	O	O
wintering	O	O	B-Entity
herbivorous	O	O	B-Entity
waterbirds	O	O	O

Food	O	O	B-Entity
availability	O	O	B-Entity
and	O	O	O
diet	O	O	B-Entity
selection	O	O	B-Entity
are	O	O	O
important	O	O	O
factors	O	O	B-Entity
influencing	O	O	B-Entity
the	O	O	O
abundance	O	O	B-Entity
and	O	O	O
distribution	O	O	B-Entity
of	O	O	O
wild	O	O	B-Entity
waterbirds	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
better	O	O	O
understand	O	O	O
changes	O	O	B-Entity
in	O	O	O
waterbird	O	O	B-Entity
population	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
essential	O	O	O
to	O	O	O
figure	O	O	O
out	O	O	O
what	O	O	O
they	O	O	O
feed	O	O	B-Entity
on	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
analyzing	O	O	B-Entity
their	O	O	O
diet	O	O	B-Entity
could	O	O	O
be	O	O	O
difficult	O	O	B-Entity
and	O	O	O
inefficient	O	O	B-Entity
using	O	O	O
traditional	O	O	O
methods	O	O	B-Entity
such	O	O	O
as	O	O	O
microhistologic	O	O	B-Entity
observation	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
addressed	O	O	O
this	O	O	O
gap	O	O	O
of	O	O	O
knowledge	O	O	O
by	O	O	O
investigating	O	O	O
the	O	O	O
diet	O	O	B-Entity
of	O	O	O
greater	O	O	B-Entity
white-fronted	O	O	I-Entity
goose	O	O	I-Entity
Anser	O	O	I-Entity
albifrons	O	O	I-Entity
and	O	O	O
bean	O	O	B-Entity
goose	O	O	I-Entity
Anser	O	O	I-Entity
fabalis	O	O	I-Entity
,	O	O	O
which	O	O	O
are	O	O	O
obligate	O	O	B-Entity
herbivores	O	O	I-Entity
wintering	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
,	O	O	O
mostly	O	O	O
in	O	O	O
the	O	O	O
Middle	O	O	B-Entity
and	O	O	O
Lower	O	O	B-Entity
Yangtze	O	O	I-Entity
River	O	O	I-Entity
floodplain	O	O	I-Entity
.	O	O	O

First	O	O	O
,	O	O	O
we	O	O	O
selected	O	O	B-Entity
a	O	O	O
suitable	O	O	B-Entity
and	O	O	O
high-resolution	O	O	O
marker	O	O	B-Entity
gene	O	O	I-Entity
for	O	O	O
wetland	O	O	B-Entity
plants	O	O	B-Entity
that	O	O	O
these	O	O	O
geese	O	O	B-Entity
would	O	O	O
consume	O	O	O
during	O	O	O
the	O	O	O
wintering	O	O	B-Entity
period	O	O	I-Entity
.	O	O	O

Eight	O	O	O
candidate	O	O	B-Entity
genes	O	O	I-Entity
were	O	O	O
included	O	O	O
:	O	O	O
rbcL	O	O	B-Entity
,	O	O	O
rpoC1	O	O	B-Entity
,	O	O	O
rpoB	O	O	B-Entity
,	O	O	O
matK	O	O	B-Entity
,	O	O	O
trnH-psbA	O	O	B-Entity
,	O	O	O
trnL	O	O	B-Entity
(	O	O	O
UAA	O	O	B-Entity
)	O	O	O
,	O	O	O
atpF-atpH	O	O	B-Entity
,	O	O	O
and	O	O	O
psbK-psbI.	O	O	O
The	O	O	O
selection	O	O	B-Entity
was	O	O	O
performed	O	O	O
via	O	O	O
analysis	O	O	B-Entity
of	O	O	O
representative	O	O	B-Entity
sequences	O	O	B-Entity
from	O	O	O
NCBI	O	O	B-Entity
and	O	O	O
comparison	O	O	B-Entity
of	O	O	O
amplification	O	O	B-Entity
efficiency	O	O	B-Entity
and	O	O	O
resolution	O	O	O
power	O	O	O
of	O	O	O
plant	O	O	B-Entity
samples	O	O	B-Entity
collected	O	O	O
from	O	O	O
the	O	O	O
wintering	O	O	B-Entity
area	O	O	I-Entity
.	O	O	O

The	O	O	O
trnL	O	O	B-Entity
gene	O	O	B-Entity
was	O	O	O
chosen	O	O	O
at	O	O	O
last	O	O	O
with	O	O	O
c/h	O	O	B-Entity
primers	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
local	O	O	B-Entity
plant	O	O	B-Entity
reference	O	O	B-Entity
library	O	O	I-Entity
was	O	O	O
constructed	O	O	B-Entity
with	O	O	O
this	O	O	O
gene	O	O	O
.	O	O	O

Then	O	O	O
,	O	O	O
utilizing	O	O	O
DNA	O	O	B-Entity
metabarcoding	O	O	I-Entity
,	O	O	O
we	O	O	O
discovered	O	O	B-Entity
15	O	O	O
food	O	O	B-Entity
items	O	O	I-Entity
in	O	O	O
total	O	O	O
from	O	O	O
the	O	O	O
feces	O	O	B-Entity
of	O	O	O
these	O	O	O
birds	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
15	O	O	O
unique	O	O	O
dietary	O	O	B-Entity
sequences	O	O	B-Entity
,	O	O	O
10	O	O	O
could	O	O	O
be	O	O	O
identified	O	O	O
at	O	O	O
specie	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

As	O	O	O
for	O	O	O
greater	O	O	B-Entity
white-fronted	O	O	I-Entity
goose	O	O	I-Entity
,	O	O	O
73	O	O	O
%	O	O	O
of	O	O	O
sequences	O	O	B-Entity
belonged	O	O	O
to	O	O	O
Poaceae	O	O	B-Entity
spp	O	O	I-Entity
.	O	O	I-Entity
,	O	O	O
and	O	O	O
26	O	O	O
%	O	O	O
belonged	O	O	O
to	O	O	O
Carex	O	O	B-Entity
spp	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
almost	O	O	O
all	O	O	O
sequences	O	O	B-Entity
of	O	O	O
bean	O	O	B-Entity
goose	O	O	I-Entity
belonged	O	O	O
to	O	O	O
Carex	O	O	B-Entity
spp	O	O	I-Entity
.	O	O	O

(	O	O	O
99	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Using	O	O	O
the	O	O	O
same	O	O	O
samples	O	O	B-Entity
,	O	O	O
microhistology	O	O	B-Entity
provided	O	O	O
consistent	O	O	B-Entity
food	O	O	B-Entity
composition	O	O	I-Entity
with	O	O	O
metabarcoding	O	O	B-Entity
results	O	O	B-Entity
for	O	O	O
greater	O	O	B-Entity
white-fronted	O	O	I-Entity
goose	O	O	I-Entity
,	O	O	O
while	O	O	O
13	O	O	O
%	O	O	O
of	O	O	O
Poaceae	O	O	B-Entity
was	O	O	O
recovered	O	O	O
for	O	O	O
bean	O	O	B-Entity
goose	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
two	O	O	O
other	O	O	O
taxa	O	O	B-Entity
were	O	O	O
discovered	O	O	B-Entity
only	O	O	O
through	O	O	O
microhistologic	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Although	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
identified	O	O	O
taxa	O	O	B-Entity
matched	O	O	B-Entity
relatively	O	O	O
well	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
methods	O	O	B-Entity
,	O	O	O
DNA	O	O	B-Entity
metabarcoding	O	O	I-Entity
gave	O	O	O
taxonomically	O	O	B-Entity
more	O	O	O
detailed	O	O	B-Entity
information	O	O	I-Entity
.	O	O	O

Discrepancies	O	O	B-Entity
were	O	O	O
likely	O	O	O
due	O	O	O
to	O	O	O
biased	O	O	B-Entity
PCR	O	O	B-Entity
amplification	O	O	B-Entity
in	O	O	O
metabarcoding	O	O	B-Entity
,	O	O	O
low	O	O	O
discriminating	O	O	B-Entity
power	O	O	B-Entity
of	O	O	O
current	O	O	O
marker	O	O	B-Entity
genes	O	O	I-Entity
for	O	O	O
monocots	O	O	B-Entity
,	O	O	O
and	O	O	O
biases	O	O	B-Entity
in	O	O	O
microhistologic	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

The	O	O	O
diet	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
two	O	O	O
geese	O	O	B-Entity
species	O	O	B-Entity
might	O	O	O
indicate	O	O	O
deeper	O	O	O
ecological	O	O	B-Entity
significance	O	O	B-Entity
beyond	O	O	O
the	O	O	O
scope	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

We	O	O	O
concluded	O	O	O
that	O	O	O
DNA	O	O	B-Entity
metabarcoding	O	O	I-Entity
provides	O	O	O
new	O	O	O
perspectives	O	O	B-Entity
for	O	O	O
studies	O	O	B-Entity
of	O	O	O
herbivorous	O	O	B-Entity
waterbird	O	O	B-Entity
diets	O	O	B-Entity
and	O	O	O
inter-specific	O	O	B-Entity
interactions	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
new	O	O	O
possibilities	O	O	O
to	O	O	O
investigate	O	O	B-Entity
interactions	O	O	O
between	O	O	O
herbivores	O	O	B-Entity
and	O	O	O
plants	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
microhistologic	O	O	B-Entity
analysis	O	O	I-Entity
should	O	O	O
be	O	O	O
used	O	O	O
together	O	O	O
with	O	O	O
metabarcoding	O	O	B-Entity
methods	O	O	I-Entity
to	O	O	O
integrate	O	O	O
this	O	O	O
information	O	O	B-Entity
.	O	O	O

-DOCSTART- (27602763)

Expressions	O	O	B-Entity
of	O	O	O
CD8	O	O	B-Entity
+	O	O	O
TILs	O	O	B-Entity
,	O	O	O
PD-L1	O	O	B-Entity
and	O	O	O
Foxp3	O	O	B-Entity
+	O	O	O
TILs	O	O	O
in	O	O	O
stage	O	O	B-Entity
I	O	O	I-Entity
NSCLC	O	O	I-Entity
guiding	O	O	O
adjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
decisions	O	O	O

Currently	O	O	O
,	O	O	O
adjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
is	O	O	O
recommended	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
stage	O	O	B-Entity
I	O	O	I-Entity
non-small	O	O	I-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
NSCLC	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
identifying	O	O	B-Entity
high	O	O	B-Entity
risk	O	O	I-Entity
patients	O	O	B-Entity
remains	O	O	O
a	O	O	O
challenge	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aims	O	O	B-Entity
to	O	O	O
identify	O	O	B-Entity
the	O	O	O
patient	O	O	B-Entity
cohorts	O	O	B-Entity
more	O	O	O
likely	O	O	O
to	O	O	O
benefit	O	O	O
from	O	O	O
adjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
tumor	O	O	B-Entity
micro-immune	O	O	B-Entity
environment	O	O	B-Entity
.	O	O	O

CD8	O	O	B-Entity
+	O	O	O
TILs	O	O	B-Entity
significantly	O	O	B-Entity
associated	O	O	I-Entity
with	O	O	I-Entity
disease-free	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
DFS	O	O	B-Entity
)	O	O	O
and	O	O	O
overall	O	O	B-Entity
survial	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
(	O	O	O
p=0.002	O	O	O
;	O	O	O
0.040	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
may	O	O	O
also	O	O	O
predict	O	O	O
shorter	O	O	O
DFS	O	O	B-Entity
(	O	O	O
P=0.056	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
compared	O	O	B-Entity
together	O	O	O
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
-	O	O	O
CD8	O	O	B-Entity
+	O	O	O
TILs	O	O	B-Entity
showed	O	O	O
better	O	O	O
DFS	O	O	B-Entity
than	O	O	O
patients	O	O	O
with	O	O	O
low	O	O	B-Entity
-	O	O	O
CD8	O	O	O
+	O	O	O
TILs	O	O	O
,	O	O	O
no	O	O	O
matter	O	O	O
their	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
status	O	O	O
.	O	O	O

There	O	O	O
's	O	O	O
no	O	O	B-Entity
correlation	O	O	I-Entity
between	O	O	O
PD-L1	O	O	B-Entity
expressions	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
.	O	O	O

PD-L1	O	O	B-Entity
was	O	O	O
highly	O	O	B-Entity
expressed	O	O	B-Entity
in	O	O	O
men	O	O	B-Entity
,	O	O	O
squamous	O	O	B-Entity
and	O	O	O
well	O	O	B-Entity
differentiated	O	O	I-Entity
carcinoma	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
Foxp3	O	O	B-Entity
+	O	O	O
TILs	O	O	B-Entity
alone	O	O	O
did	O	O	O
n't	O	O	O
show	O	O	O
any	O	O	O
prognostic	O	O	O
effects	O	O	O
,	O	O	O
but	O	O	O
low	O	O	B-Entity
-	O	O	O
Foxp3	O	O	O
/	O	O	O
high	O	O	B-Entity
-	O	O	O
CD8	O	O	B-Entity
+	O	O	O
TILs	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
prolonged	O	O	B-Entity
DFS	O	O	B-Entity
(	O	O	O
p=0.031	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
126	O	O	O
patients	O	O	B-Entity
with	O	O	O
surgically	O	O	B-Entity
resected	O	O	I-Entity
stage	O	O	B-Entity
I	O	O	I-Entity
NSCLC	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
to	O	O	O
perform	O	O	O
immunohistochemistry	O	O	B-Entity
of	O	O	O
CD8	O	O	B-Entity
+	O	O	O
tumor	O	O	B-Entity
infiltrating	O	O	I-Entity
lymphocytes	O	O	I-Entity
(	O	O	O
TILs	O	O	B-Entity
)	O	O	O
,	O	O	O
programmed	O	O	B-Entity
death	O	O	I-Entity
ligand-1	O	O	I-Entity
(	O	O	O
PD-L1	O	O	B-Entity
)	O	O	O
and	O	O	O
forkhead	O	O	B-Entity
box	O	O	I-Entity
P3	O	O	I-Entity
(Foxp3)+	O	O	O
TILs	O	O	O
.	O	O	O

CD8	O	O	B-Entity
+	O	O	O
TILs	O	O	B-Entity
are	O	O	O
effective	O	O	B-Entity
prognostic	O	O	O
predictors	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
surgically	O	O	B-Entity
resected	O	O	I-Entity
stage	O	O	B-Entity
I	O	O	I-Entity
NSCLC	O	O	I-Entity
showing	O	O	O
low	O	O	O
CD8	O	O	B-Entity
+	O	O	O
TILs	O	O	B-Entity
could	O	O	O
be	O	O	O
considered	O	O	O
for	O	O	O
adjuvant	O	O	B-Entity
chemotherapy	O	O	I-Entity
,	O	O	O
even	O	O	O
if	O	O	O
they	O	O	O
have	O	O	O
no	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
features	O	O	O
.	O	O	O

-DOCSTART- (27604681)

Unaffected	O	O	O
twins	O	O	B-Entity
discordant	O	O	I-Entity
for	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
show	O	O	O
changes	O	O	O
in	O	O	O
anterior	O	O	B-Entity
callosal	O	O	I-Entity
white	O	O	B-Entity
matter	O	O	I-Entity
microstructure	O	O	O

The	O	O	O
neurobiological	O	O	B-Entity
mechanisms	O	O	B-Entity
mediating	O	O	O
an	O	O	O
increased	O	O	O
risk	O	O	B-Entity
to	O	O	O
develop	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
remain	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
group	O	O	B-Entity
of	O	O	I-Entity
individuals	O	O	I-Entity
with	O	O	O
a	O	O	O
family	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
(	O	O	O
MDD	O	O	B-Entity
)	O	O	O
or	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	O
BD	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
microstructural	O	O	O
properties	O	O	O
of	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
fiber	O	O	B-Entity
tracts	O	O	I-Entity
,	O	O	O
that	O	O	O
is	O	O	O
,	O	O	O
cingulum	O	O	B-Entity
bundle	O	O	I-Entity
,	O	O	O
uncinate	O	O	B-Entity
fasciculus	O	O	I-Entity
,	O	O	O
anterior	O	O	B-Entity
limb	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
internal	O	O	I-Entity
capsule	O	O	I-Entity
,	O	O	O
and	O	O	O
corpus	O	O	B-Entity
callosum	O	O	I-Entity
,	O	O	O
that	O	O	O
facilitate	O	O	O
the	O	O	O
communication	O	O	O
between	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
implicated	O	O	O
in	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Eighty-nine	O	O	O
healthy	O	O	B-Entity
mono	O	O	B-Entity
-	O	O	O
or	O	O	O
dizygotic	O	O	B-Entity
twins	O	O	B-Entity
with	O	O	O
a	O	O	O
co-twin	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
MDD	O	O	B-Entity
or	O	O	O
BD	O	O	B-Entity
(	O	O	O
high-risk	O	O	B-Entity
)	O	O	O
and	O	O	O
57	O	O	O
healthy	O	O	O
twins	O	O	O
with	O	O	O
a	O	O	O
co-twin	O	O	O
with	O	O	O
no	O	O	B-Entity
familial	O	O	I-Entity
history	O	O	I-Entity
of	O	O	I-Entity
affective	O	O	B-Entity
disorders	O	O	I-Entity
(	O	O	O
low-risk	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
a	O	O	O
diffusion	O	O	B-Entity
tensor	O	O	I-Entity
imaging	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

The	O	O	O
high-risk	O	O	B-Entity
group	O	O	I-Entity
showed	O	O	O
decreased	O	O	O
fractional	O	O	B-Entity
anisotropy	O	O	I-Entity
(	O	O	O
FA	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
measure	O	O	O
of	O	O	O
water	O	O	B-Entity
diffusion	O	O	B-Entity
directionality	O	O	B-Entity
,	O	O	O
and	O	O	O
increased	O	O	O
radial	O	O	B-Entity
diffusivity	O	O	B-Entity
in	O	O	O
the	O	O	O
anterior	O	O	B-Entity
region	O	O	I-Entity
of	O	O	I-Entity
corpus	O	O	I-Entity
callosum	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
low-risk	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

This	O	O	O
abnormality	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
zygosity	O	O	B-Entity
or	O	O	O
type	O	O	O
of	O	O	O
depressive	O	O	B-Entity
disorder	O	O	I-Entity
of	O	O	O
co-twin	O	O	B-Entity
.	O	O	O

The	O	O	O
observed	O	O	O
decreased	O	O	O
anterior	O	O	B-Entity
callosal	O	O	I-Entity
fiber	O	O	I-Entity
FA	O	O	B-Entity
in	O	O	O
the	O	O	O
high-risk	O	O	B-Entity
group	O	O	I-Entity
may	O	O	O
be	O	O	O
indicative	O	O	O
of	O	O	O
a	O	O	O
compromised	O	O	O
interhemispheric	O	O	B-Entity
communication	O	O	I-Entity
between	O	O	O
left	O	O	B-Entity
and	O	O	O
right	O	O	B-Entity
frontal	O	O	I-Entity
regions	O	O	I-Entity
critically	O	O	O
involved	O	O	O
in	O	O	O
mood	O	O	B-Entity
regulation	O	O	I-Entity
.	O	O	O

Reduced	O	O	O
anterior	O	O	B-Entity
callosal	O	O	I-Entity
FA	O	O	B-Entity
may	O	O	O
act	O	O	O
as	O	O	O
a	O	O	O
vulnerability	O	O	B-Entity
marker	O	O	B-Entity
for	O	O	O
affective	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
individuals	O	O	B-Entity
at	O	O	O
familial	O	O	B-Entity
risk	O	O	I-Entity
.	O	O	O

-DOCSTART- (27605910)

A	O	O	O
Window	O	O	O
on	O	O	O
the	O	O	O
Study	O	O	B-Entity
of	O	O	I-Entity
Aversive	O	O	I-Entity
Instrumental	O	O	B-Entity
Learning	O	O	I-Entity
:	O	O	O
Strains	O	O	B-Entity
,	O	O	O
Performance	O	O	B-Entity
,	O	O	O
Neuroendocrine	O	O	B-Entity
,	O	O	O
and	O	O	O
Immunologic	O	O	O
Systems	O	O	O

The	O	O	O
avoidance	O	O	B-Entity
response	O	O	B-Entity
is	O	O	O
present	O	O	O
in	O	O	O
pathological	O	O	B-Entity
anxiety	O	O	B-Entity
and	O	O	O
interferes	O	O	O
with	O	O	O
normal	O	O	B-Entity
daily	O	O	I-Entity
functions	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
article	O	O	O
is	O	O	O
to	O	O	O
shed	O	O	O
light	O	O	O
on	O	O	O
performance	O	O	B-Entity
markers	O	O	O
of	O	O	O
active	O	O	B-Entity
avoidance	O	O	I-Entity
(	O	O	O
AA	O	O	B-Entity
)	O	O	O
using	O	O	O
two	O	O	O
different	O	O	O
rat	O	O	B-Entity
strains	O	O	I-Entity
,	O	O	O
Sprague-Dawley	O	O	B-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
and	O	O	O
Wistar	O	O	B-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
good	O	O	O
and	O	O	O
poor	O	O	O
performers	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
regarding	O	O	O
anxiety	O	O	B-Entity
traits	O	O	B-Entity
exhibited	O	O	O
in	O	O	O
the	O	O	O
elevated	O	O	B-Entity
plus	O	O	I-Entity
maze	O	O	I-Entity
(	O	O	O
EPM	O	O	B-Entity
)	O	O	O
and	O	O	O
corticosterone	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
motor	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
the	O	O	O
open	O	O	B-Entity
field	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
plasma	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
Interleukin-6	O	O	B-Entity
(	O	O	O
IL-6	O	O	B-Entity
)	O	O	O
,	O	O	O
Interleukin-1Beta	O	O	B-Entity
(	O	O	O
IL-1beta	O	O	B-Entity
)	O	O	O
,	O	O	O
Nerve	O	O	B-Entity
Growth	O	O	I-Entity
Factor	O	O	I-Entity
Beta	O	O	I-Entity
(	O	O	O
NGF-beta	O	O	B-Entity
)	O	O	O
,	O	O	O
Tumor	O	O	B-Entity
Necrosis	O	O	I-Entity
Factor-Alpha	O	O	I-Entity
(	O	O	O
TNF-alpha	O	O	B-Entity
)	O	O	O
and	O	O	O
cytokine-induced	O	O	B-Entity
neutrophil	O	O	I-Entity
chemoattractant	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
CINC-1	O	O	B-Entity
)	O	O	O
were	O	O	O
compared	O	O	O
in	O	O	O
the	O	O	O
good	O	O	O
and	O	O	O
poor	O	O	O
performers	O	O	B-Entity
to	O	O	O
better	O	O	O
understand	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
immunologic	O	O	B-Entity
system	O	O	I-Entity
in	O	O	O
aversive	O	O	B-Entity
learning	O	O	I-Entity
.	O	O	O

Behavioral	O	O	B-Entity
criteria	O	O	I-Entity
were	O	O	O
employed	O	O	O
to	O	O	O
identify	O	O	O
subpopulations	O	O	B-Entity
of	O	O	O
SD	O	O	B-Entity
and	O	O	O
Wistar	O	O	B-Entity
rats	O	O	I-Entity
based	O	O	O
on	O	O	O
their	O	O	O
behavioral	O	O	B-Entity
scores	O	O	I-Entity
during	O	O	O
a	O	O	O
two-way	O	O	O
AA	O	O	B-Entity
test	O	O	B-Entity
.	O	O	O

The	O	O	O
animals	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
for	O	O	O
anxiety	O	O	B-Entity
-like	O	O	O
behavior	O	O	B-Entity
in	O	O	O
the	O	O	O
EPM	O	O	B-Entity
and	O	O	O
motor	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
the	O	O	O
open-field	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Plasma	O	O	B-Entity
corticosterone	O	O	I-Entity
levels	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
avoidance	O	O	B-Entity
test	O	O	B-Entity
.	O	O	O

Cytokine	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
IL-6	O	O	B-Entity
,	O	O	O
IL-1beta	O	O	B-Entity
,	O	O	O
NGF-beta	O	O	B-Entity
,	O	O	O
TNF-alpha	O	O	B-Entity
,	O	O	O
and	O	O	O
CINC-1	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
in	O	O	O
the	O	O	O
plasma	O	O	B-Entity
of	O	O	O
the	O	O	O
Wistar	O	O	B-Entity
rats	O	O	I-Entity
.	O	O	O

Sixty-six	O	O	O
percent	O	O	O
of	O	O	O
the	O	O	O
Wistar	O	O	B-Entity
rats	O	O	I-Entity
and	O	O	O
35	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
SD	O	O	B-Entity
rats	O	O	I-Entity
exhibited	O	O	O
a	O	O	O
poor	O	O	O
performance	O	O	B-Entity
.	O	O	O

This	O	O	O
feature	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
decrease	O	O	O
in	O	O	O
anxiety	O	O	B-Entity
-like	O	O	O
behavior	O	O	B-Entity
in	O	O	O
the	O	O	O
EPM	O	O	B-Entity
.	O	O	O

The	O	O	O
poor	O	O	O
and	O	O	O
good	O	O	O
performers	O	O	B-Entity
exhibited	O	O	O
lower	O	O	O
levels	O	O	B-Entity
of	O	O	I-Entity
corticosterone	O	O	I-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
control	O	O	B-Entity
animals	O	O	I-Entity
,	O	O	O
which	O	O	O
suggests	O	O	O
that	O	O	O
training	O	O	O
alters	O	O	O
corticosterone	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
thereby	O	O	O
leading	O	O	O
to	O	O	O
hypocortisolism	O	O	B-Entity
,	O	O	O
independent	O	O	O
of	O	O	O
the	O	O	O
performance	O	O	B-Entity
.	O	O	O

The	O	O	O
CINC-1	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
increased	O	O	O
in	O	O	O
the	O	O	O
poor	O	O	O
performers	O	O	B-Entity
,	O	O	O
which	O	O	O
reinforces	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
immunologic	O	O	B-Entity
system	O	O	I-Entity
activation	O	O	B-Entity
in	O	O	O
learning	O	O	B-Entity
deficits	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
provides	O	O	O
a	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
complex	O	O	B-Entity
interactions	O	O	B-Entity
that	O	O	O
underlie	O	O	O
neuroimmune	O	O	B-Entity
consequences	O	O	B-Entity
and	O	O	O
their	O	O	O
implications	O	O	O
for	O	O	O
performance	O	O	B-Entity
.	O	O	O

-DOCSTART- (27609696)

Costing	O	O	B-Entity
'	O	O	O
healthy	O	O	B-Entity
'	O	O	I-Entity
food	O	O	B-Entity
baskets	O	O	I-Entity
in	O	O	O
Australia	O	O	B-Entity
-	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
food	O	O	O
price	O	O	B-Entity
and	O	O	O
affordability	O	O	B-Entity
monitoring	O	O	B-Entity
tools	O	O	I-Entity
,	O	O	O
protocols	O	O	B-Entity
and	O	O	O
methods	O	O	O

To	O	O	O
undertake	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
to	O	O	O
determine	O	O	O
similarities	O	O	B-Entity
and	O	O	O
differences	O	O	B-Entity
in	O	O	O
metrics	O	O	B-Entity
and	O	O	O
results	O	O	B-Entity
between	O	O	O
recently	O	O	B-Entity
and/or	O	O	O
currently	O	O	B-Entity
used	O	O	O
tools	O	O	B-Entity
,	O	O	O
protocols	O	O	B-Entity
and	O	O	O
methods	O	O	B-Entity
for	O	O	O
monitoring	O	O	B-Entity
Australian	O	O	B-Entity
healthy	O	O	B-Entity
food	O	O	I-Entity
prices	O	O	B-Entity
and	O	O	O
affordability	O	O	B-Entity
.	O	O	O

Electronic	O	O	B-Entity
databases	O	O	I-Entity
of	O	O	O
peer-reviewed	O	O	B-Entity
literature	O	O	I-Entity
and	O	O	O
online	O	O	B-Entity
grey	O	O	I-Entity
literature	O	O	I-Entity
were	O	O	O
systematically	O	O	B-Entity
searched	O	O	B-Entity
using	O	O	O
the	O	O	O
PRISMA	O	O	B-Entity
approach	O	O	O
for	O	O	O
articles	O	O	B-Entity
and	O	O	O
reports	O	O	B-Entity
relating	O	O	O
to	O	O	O
healthy	O	O	B-Entity
food	O	O	I-Entity
and	O	O	O
diet	O	O	B-Entity
price	O	O	I-Entity
assessment	O	O	I-Entity
tools	O	O	I-Entity
,	O	O	O
protocols	O	O	B-Entity
,	O	O	O
methods	O	O	B-Entity
and	O	O	O
results	O	O	B-Entity
that	O	O	O
utilised	O	O	O
retail	O	O	B-Entity
pricing	O	O	I-Entity
.	O	O	O

National	O	O	B-Entity
,	O	O	O
state	O	O	B-Entity
,	O	O	O
regional	O	O	B-Entity
and	O	O	O
local	O	O	B-Entity
areas	O	O	I-Entity
of	O	O	O
Australia	O	O	B-Entity
from	O	O	O
1995	O	O	O
to	O	O	O
2015	O	O	O
.	O	O	O

Assessment	O	O	B-Entity
tools	O	O	I-Entity
,	O	O	O
protocols	O	O	B-Entity
and	O	O	O
methods	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
price	O	O	B-Entity
of	O	O	O
'	O	O	B-Entity
healthy	O	O	I-Entity
'	O	O	I-Entity
foods	O	O	I-Entity
and	O	O	O
diets	O	O	B-Entity
.	O	O	O

The	O	O	O
search	O	O	O
identified	O	O	B-Entity
fifty-nine	O	O	O
discrete	O	O	O
surveys	O	O	B-Entity
of	O	O	O
'	O	O	O
healthy	O	O	B-Entity
'	O	O	I-Entity
food	O	O	I-Entity
pricing	O	O	B-Entity
incorporating	O	O	O
six	O	O	O
major	O	O	O
food	O	O	B-Entity
pricing	O	O	I-Entity
tools	O	O	I-Entity
(	O	O	O
those	O	O	O
used	O	O	O
in	O	O	O
multiple	O	O	B-Entity
areas	O	O	I-Entity
and	O	O	O
time	O	O	B-Entity
periods	O	O	I-Entity
)	O	O	O
and	O	O	O
five	O	O	O
minor	O	O	B-Entity
food	O	O	O
pricing	O	O	O
tools	O	O	O
(	O	O	O
those	O	O	O
used	O	O	O
in	O	O	O
a	O	O	O
single	O	O	B-Entity
survey	O	O	I-Entity
area	O	O	I-Entity
or	O	O	O
time	O	O	B-Entity
period	O	O	I-Entity
)	O	O	O
.	O	O	O

Analysis	O	O	B-Entity
demonstrated	O	O	O
methodological	O	O	B-Entity
differences	O	O	B-Entity
regarding	O	O	O
:	O	O	O
included	O	O	B-Entity
foods	O	O	B-Entity
;	O	O	O
reference	O	O	B-Entity
households	O	O	I-Entity
;	O	O	O
use	O	O	O
of	O	O	O
availability	O	O	B-Entity
and/or	O	O	O
quality	O	O	B-Entity
measures	O	O	I-Entity
;	O	O	O
household	O	O	B-Entity
income	O	O	I-Entity
sources	O	O	B-Entity
;	O	O	O
store	O	O	B-Entity
sampling	O	O	B-Entity
methods	O	O	B-Entity
;	O	O	O
data	O	O	B-Entity
collection	O	O	I-Entity
protocols	O	O	B-Entity
;	O	O	O
analysis	O	O	B-Entity
methods	O	O	I-Entity
;	O	O	O
and	O	O	O
results	O	O	B-Entity
.	O	O	O
'	O	O	O
Healthy	O	O	B-Entity
'	O	O	I-Entity
food	O	O	I-Entity
price	O	O	B-Entity
assessment	O	O	B-Entity
methods	O	O	O
used	O	O	O
in	O	O	O
Australia	O	O	B-Entity
lack	O	O	B-Entity
comparability	O	O	B-Entity
across	O	O	O
all	O	O	O
metrics	O	O	B-Entity
and	O	O	O
most	O	O	O
do	O	O	O
not	O	O	O
fully	O	O	O
align	O	O	O
with	O	O	O
a	O	O	O
'	O	O	O
healthy	O	O	B-Entity
'	O	O	I-Entity
diet	O	O	I-Entity
as	O	O	O
recommended	O	O	B-Entity
by	O	O	O
the	O	O	O
current	O	O	O
Australian	O	O	B-Entity
Dietary	O	O	I-Entity
Guidelines	O	O	I-Entity
.	O	O	O

None	O	O	O
have	O	O	O
been	O	O	O
applied	O	O	O
nationally	O	O	O
.	O	O	O

Assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
price	O	O	B-Entity
,	O	O	O
price	O	O	B-Entity
differential	O	O	I-Entity
and	O	O	O
affordability	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
(	O	O	O
recommended	O	O	B-Entity
)	O	O	O
and	O	O	O
current	O	O	B-Entity
(	O	O	B-Entity
unhealthy	O	O	I-Entity
)	O	O	I-Entity
diets	O	O	I-Entity
would	O	O	O
provide	O	O	B-Entity
more	O	O	O
robust	O	O	B-Entity
and	O	O	O
meaningful	O	O	O
data	O	O	B-Entity
to	O	O	O
inform	O	O	O
health	O	O	B-Entity
and	O	O	I-Entity
fiscal	O	O	I-Entity
policy	O	O	I-Entity
in	O	O	O
Australia	O	O	B-Entity
.	O	O	O

The	O	O	O
INFORMAS	O	O	B-Entity
'	O	O	O
optimal	O	O	B-Entity
'	O	O	O
approach	O	O	O
provides	O	O	O
a	O	O	O
potential	O	O	B-Entity
framework	O	O	O
for	O	O	O
development	O	O	B-Entity
of	O	O	O
these	O	O	O
methods	O	O	B-Entity
.	O	O	O

-DOCSTART- (27610122)

Consecutive	O	O	B-Entity
Endovascular	O	O	B-Entity
Treatment	O	O	I-Entity
of	O	O	O
20	O	O	O
Ruptured	O	O	B-Entity
Very	O	O	O
Small	O	O	B-Entity
(	O	O	O
<3	O	O	O
mm	O	O	O
)	O	O	O
Anterior	O	O	O
Communicating	O	O	O
Artery	O	O	O
Aneurysms	O	O	O

Small	O	O	B-Entity
aneurysms	O	O	B-Entity
located	O	O	O
at	O	O	O
the	O	O	O
anterior	O	O	B-Entity
communicating	O	O	I-Entity
artery	O	O	I-Entity
carry	O	O	O
significant	O	O	O
procedural	O	O	O
challenges	O	O	O
due	O	O	O
to	O	O	O
a	O	O	O
complex	O	O	O
anatomy	O	O	B-Entity
.	O	O	O

Recent	O	O	O
advances	O	O	O
in	O	O	O
endovascular	O	O	B-Entity
technologies	O	O	I-Entity
have	O	O	O
expanded	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
coil	O	O	B-Entity
embolization	O	O	I-Entity
for	O	O	O
small	O	O	B-Entity
aneurysm	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
limited	O	O	O
reports	O	O	O
describe	O	O	O
their	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
profiles	O	O	O
in	O	O	O
very	O	O	O
small	O	O	B-Entity
anterior	O	O	B-Entity
communicating	O	O	I-Entity
artery	O	O	I-Entity
aneurysms	O	O	I-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
review	O	O	O
and	O	O	O
report	O	O	O
the	O	O	O
immediate	O	O	O
and	O	O	O
long-term	O	O	B-Entity
clinical	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
radiographic	O	O	B-Entity
outcomes	O	O	I-Entity
of	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
ruptured	O	O	B-Entity
very	O	O	O
small	O	O	B-Entity
anterior	O	O	B-Entity
communicating	O	O	I-Entity
artery	O	O	I-Entity
aneurysms	O	O	I-Entity
treated	O	O	O
with	O	O	O
current	O	O	O
endovascular	O	O	B-Entity
coil	O	O	I-Entity
embolization	O	O	I-Entity
techniques	O	O	I-Entity
.	O	O	O

A	O	O	O
prospectively	O	O	O
maintained	O	O	O
single-institution	O	O	O
neuroendovascular	O	O	B-Entity
database	O	O	I-Entity
was	O	O	O
accessed	O	O	O
to	O	O	O
identify	O	O	O
consecutive	O	O	O
cases	O	O	O
of	O	O	O
very	O	O	O
small	O	O	B-Entity
(	O	O	O
<3	O	O	O
mm	O	O	O
)	O	O	O
ruptured	O	O	B-Entity
anterior	O	O	B-Entity
communicating	O	O	I-Entity
artery	O	O	I-Entity
aneurysms	O	O	I-Entity
treated	O	O	O
endovascularly	O	O	O
between	O	O	O
2006	O	O	O
and	O	O	O
2013	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
20	O	O	O
patients	O	O	B-Entity
with	O	O	O
ruptured	O	O	B-Entity
very	O	O	O
small	O	O	B-Entity
(	O	O	O
<3	O	O	O
mm	O	O	O
)	O	O	O
anterior	O	O	B-Entity
communicating	O	O	I-Entity
artery	O	O	I-Entity
aneurysms	O	O	I-Entity
were	O	O	O
consecutively	O	O	B-Entity
treated	O	O	O
with	O	O	O
coil	O	O	B-Entity
embolization	O	O	I-Entity
.	O	O	O

The	O	O	O
average	O	O	O
maximum	O	O	O
diameter	O	O	B-Entity
was	O	O	O
2.66	O	O	O
±	O	O	O
0.41	O	O	O
mm	O	O	O
.	O	O	O

Complete	O	O	O
aneurysm	O	O	B-Entity
occlusion	O	O	I-Entity
was	O	O	O
achieved	O	O	O
for	O	O	O
17	O	O	O
(	O	O	O
85	O	O	O
%	O	O	O
)	O	O	O
aneurysms	O	O	B-Entity
and	O	O	O
near-complete	O	O	O
aneurysm	O	O	O
occlusion	O	O	O
for	O	O	O
3	O	O	O
(	O	O	O
15	O	O	O
%	O	O	O
)	O	O	O
aneurysms	O	O	O
.	O	O	O

Intraoperative	O	O	B-Entity
perforation	O	O	B-Entity
was	O	O	O
seen	O	O	O
in	O	O	O
2	O	O	O
(	O	O	O
10	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
without	O	O	O
any	O	O	O
clinical	O	O	B-Entity
worsening	O	O	I-Entity
or	O	O	O
need	O	O	O
for	O	O	O
an	O	O	O
external	O	O	B-Entity
ventricular	O	O	I-Entity
drain	O	O	I-Entity
.	O	O	O

A	O	O	O
thromboembolic	O	O	B-Entity
event	O	O	I-Entity
occurred	O	O	O
in	O	O	O
1	O	O	O
(	O	O	O
5	O	O	O
%	O	O	O
)	O	O	O
patient	O	O	B-Entity
without	O	O	O
clinical	O	O	B-Entity
worsening	O	O	I-Entity
or	O	O	O
radiologic	O	O	B-Entity
infarct	O	O	I-Entity
.	O	O	O

Median	O	O	O
clinical	O	O	O
follow-up	O	O	B-Entity
was	O	O	O
12	O	O	O
(	O	O	O
±14.1	O	O	O
)	O	O	O
months	O	O	B-Entity
and	O	O	O
median	O	O	O
imaging	O	O	O
follow-up	O	O	O
was	O	O	O
12	O	O	O
(	O	O	O
±18.4	O	O	O
)	O	O	O
months	O	O	O
.	O	O	O

This	O	O	O
report	O	O	O
describes	O	O	O
the	O	O	O
largest	O	O	O
series	O	O	O
of	O	O	O
consecutive	O	O	B-Entity
endovascular	O	O	B-Entity
treatments	O	O	I-Entity
of	O	O	O
ruptured	O	O	B-Entity
very	O	O	O
small	O	O	B-Entity
anterior	O	O	B-Entity
communicating	O	O	I-Entity
artery	O	O	I-Entity
aneurysms	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
coil	O	O	B-Entity
embolization	O	O	I-Entity
of	O	O	O
very	O	O	O
small	O	O	B-Entity
aneurysms	O	O	B-Entity
in	O	O	O
this	O	O	O
location	O	O	B-Entity
can	O	O	O
be	O	O	O
performed	O	O	O
with	O	O	O
acceptable	O	O	O
rates	O	O	O
of	O	O	O
complications	O	O	B-Entity
and	O	O	O
recanalization	O	O	B-Entity
.	O	O	O

-DOCSTART- (27613669)

Factors	O	O	B-Entity
affecting	O	O	B-Entity
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
nitrogenous	O	O	B-Entity
disinfection	O	O	I-Entity
by-products	O	O	B-Entity
during	O	O	O
chlorination	O	O	B-Entity
of	O	O	O
aspartic	O	O	B-Entity
acid	O	O	I-Entity
in	O	O	O
drinking	O	O	O
water	O	O	O

The	O	O	O
formation	O	O	B-Entity
of	O	O	O
emerging	O	O	O
nitrogenous	O	O	B-Entity
disinfection	O	O	I-Entity
by-products	O	O	B-Entity
(	O	O	O
N-DBPs	O	O	B-Entity
)	O	O	O
from	O	O	O
the	O	O	O
chlorination	O	O	B-Entity
of	O	O	O
aspartic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
Asp	O	O	B-Entity
)	O	O	O
was	O	O	O
investigated	O	O	B-Entity
.	O	O	O

The	O	O	O
yield	O	O	O
of	O	O	O
dichloroacetonitrile	O	O	B-Entity
(	O	O	O
DCAN	O	O	B-Entity
)	O	O	O
was	O	O	O
higher	O	O	O
than	O	O	O
other	O	O	O
N-DBPs	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
dichloroacetamide	O	O	B-Entity
(	O	O	O
DCAcAm	O	O	B-Entity
)	O	O	O
and	O	O	O
chloropicrin	O	O	B-Entity
(	O	O	O
TCNM	O	O	B-Entity
)	O	O	O
during	O	O	O
the	O	O	O
chlorination	O	O	B-Entity
of	O	O	O
Asp	O	O	B-Entity
.	O	O	O

The	O	O	O
formation	O	O	B-Entity
of	O	O	O
DCAN	O	O	B-Entity
,	O	O	O
DCAcAm	O	O	B-Entity
,	O	O	O
and	O	O	O
TCNM	O	O	B-Entity
all	O	O	O
showed	O	O	O
a	O	O	O
trend	O	O	O
of	O	O	O
first	O	O	O
increasing	O	O	B-Entity
and	O	O	O
then	O	O	O
decreasing	O	O	B-Entity
during	O	O	O
the	O	O	O
chlorination	O	O	B-Entity
of	O	O	O
Asp	O	O	B-Entity
with	O	O	O
increasing	O	O	O
contact	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

The	O	O	O
dosage	O	O	B-Entity
of	O	O	O
chlorine	O	O	B-Entity
had	O	O	O
an	O	O	O
impact	O	O	O
on	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
DCAN	O	O	B-Entity
,	O	O	O
DCAcAm	O	O	B-Entity
,	O	O	O
and	O	O	O
TCNM	O	O	B-Entity
.	O	O	O

The	O	O	O
highest	O	O	O
yields	O	O	B-Entity
of	O	O	O
DCAN	O	O	B-Entity
and	O	O	O
DCAcAm	O	O	B-Entity
appeared	O	O	O
when	O	O	O
the	O	O	O
Cl2	O	O	B-Entity
/	O	O	O
Asp	O	O	B-Entity
molar	O	O	B-Entity
ratio	O	O	B-Entity
was	O	O	O
about	O	O	O
20	O	O	O
,	O	O	O
the	O	O	O
yield	O	O	B-Entity
of	O	O	O
TCNM	O	O	B-Entity
increased	O	O	B-Entity
with	O	O	O
increasing	O	O	B-Entity
the	O	O	O
Cl2	O	O	O
/	O	O	O
Asp	O	O	O
molar	O	O	O
ratio	O	O	O
from	O	O	O
5	O	O	O
to	O	O	O
30	O	O	O
and	O	O	O
TCNM	O	O	O
was	O	O	O
not	O	O	O
produced	O	O	O
when	O	O	O
the	O	O	O
ratio	O	O	O
was	O	O	O
less	O	O	O
than	O	O	O
5	O	O	O
.	O	O	O

Cyanogen	O	O	B-Entity
chloride	O	O	I-Entity
(	O	O	O
CNCl	O	O	B-Entity
)	O	O	O
was	O	O	O
detected	O	O	O
when	O	O	O
the	O	O	O
Cl2	O	O	B-Entity
/	O	O	O
Asp	O	O	B-Entity
molar	O	O	B-Entity
ratio	O	O	I-Entity
was	O	O	O
lower	O	O	O
than	O	O	O
5	O	O	O
.	O	O	O

N-DBPs	O	O	B-Entity
formation	O	O	B-Entity
was	O	O	O
influenced	O	O	O
by	O	O	O
pH.	O	O	O
DCAN	O	O	B-Entity
formation	O	O	O
increased	O	O	B-Entity
with	O	O	O
increasing	O	O	B-Entity
pH	O	O	B-Entity
from	O	O	O
5	O	O	O
to	O	O	O
6	O	O	O
and	O	O	O
then	O	O	O
decreased	O	O	B-Entity
with	O	O	O
increasing	O	O	O
pH	O	O	O
from	O	O	O
6	O	O	O
to	O	O	O
9	O	O	O
,	O	O	O
but	O	O	O
DCAcAm	O	O	B-Entity
and	O	O	O
TCNM	O	O	B-Entity
increased	O	O	O
with	O	O	O
increasing	O	O	O
pH	O	O	O
from	O	O	O
5	O	O	O
to	O	O	O
8	O	O	O
and	O	O	O
then	O	O	O
decreased	O	O	O
.	O	O	O

Higher	O	O	O
temperatures	O	O	B-Entity
reduced	O	O	B-Entity
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
DCAN	O	O	B-Entity
and	O	O	O
DCAcAm	O	O	B-Entity
,	O	O	O
but	O	O	O
increased	O	O	B-Entity
TCNM	O	O	B-Entity
formation	O	O	O
.	O	O	O

DCAN	O	O	B-Entity
and	O	O	O
DCAcAm	O	O	B-Entity
formation	O	O	B-Entity
decreased	O	O	B-Entity
,	O	O	O
and	O	O	O
relatively	O	O	O
stable	O	O	B-Entity
TCNM	O	O	B-Entity
formation	O	O	O
increased	O	O	B-Entity
,	O	O	O
with	O	O	O
increasing	O	O	B-Entity
free	O	O	O
chlorine	O	O	B-Entity
contact	O	O	B-Entity
time	O	O	I-Entity
during	O	O	O
chloramination	O	O	B-Entity
.	O	O	O

N-nitrosodimethylamine	O	O	B-Entity
(	O	O	O
NDMA	O	O	B-Entity
)	O	O	O
was	O	O	O
produced	O	O	O
during	O	O	O
chloramination	O	O	B-Entity
of	O	O	O
Asp	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
with	O	O	O
prolonged	O	O	B-Entity
chloramination	O	O	O
contact	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

The	O	O	O
presence	O	O	O
of	O	O	O
bromide	O	O	B-Entity
ions	O	O	I-Entity
enhanced	O	O	B-Entity
the	O	O	O
yields	O	O	B-Entity
of	O	O	O
haloacetonitriles	O	O	B-Entity
and	O	O	O
shifted	O	O	O
N-DBPs	O	O	B-Entity
to	O	O	O
more	O	O	O
brominated	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

-DOCSTART- (27614145)

Midodrine	O	O	B-Entity
and	O	O	O
tolvaptan	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
cirrhosis	O	O	B-Entity
and	O	O	O
refractory	O	O	B-Entity
or	O	O	O
recurrent	O	O	B-Entity
ascites	O	O	I-Entity
:	O	O	O
a	O	O	O
randomised	O	O	B-Entity
pilot	O	O	O
study	O	O	O

Splanchnic	O	O	B-Entity
arterial	O	O	I-Entity
vasodilatation	O	O	I-Entity
and	O	O	O
subsequent	O	O	O
sodium	O	O	B-Entity
and	O	O	O
water	O	O	B-Entity
retention	O	O	I-Entity
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
cirrhotic	O	O	B-Entity
ascites	O	O	I-Entity
.	O	O	O

Midodrine	O	O	B-Entity
and	O	O	O
tolvaptan	O	O	B-Entity
have	O	O	O
been	O	O	O
used	O	O	O
separately	O	O	O
in	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
no	O	O	O
reports	O	O	O
on	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
combination	O	O	B-Entity
of	O	O	O
midodrine	O	O	B-Entity
and	O	O	O
tolvaptan	O	O	B-Entity
in	O	O	O
the	O	O	O
control	O	O	O
of	O	O	O
ascites	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
midodrine	O	O	B-Entity
,	O	O	O
tolvaptan	O	O	B-Entity
and	O	O	O
their	O	O	O
combination	O	O	B-Entity
in	O	O	O
control	O	O	O
of	O	O	O
refractory	O	O	B-Entity
or	O	O	O
recurrent	O	O	B-Entity
ascites	O	O	I-Entity
in	O	O	O
cirrhotics	O	O	B-Entity
.	O	O	O

Fifty	O	O	O
cirrhotic	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
refractory	O	O	B-Entity
or	O	O	O
recurrent	O	O	B-Entity
ascites	O	O	I-Entity
were	O	O	O
randomised	O	O	B-Entity
to	O	O	O
receive	O	O	O
midodrine	O	O	B-Entity
(	O	O	O
n=13	O	O	O
)	O	O	O
,	O	O	O
tolvaptan	O	O	B-Entity
(	O	O	O
n=12	O	O	O
)	O	O	O
or	O	O	O
both	O	O	O
(	O	O	O
n=13	O	O	O
)	O	O	O
plus	O	O	O
standard	O	O	O
medical	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
SMT	O	O	B-Entity
)	O	O	O
or	O	O	O
SMT	O	O	O
alone	O	O	O
(	O	O	O
n=12	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
significant	O	O	B-Entity
increase	O	O	I-Entity
in	O	O	I-Entity
urinary	O	O	I-Entity
volume	O	O	I-Entity
and	O	O	O
urinary	O	O	B-Entity
sodium	O	O	I-Entity
at	O	O	O
1	O	O	O
and	O	O	O
3	O	O	O
months	O	O	B-Entity
(	O	O	O
P<.05	O	O	O
)	O	O	O
was	O	O	O
observed	O	O	O
in	O	O	O
all	O	O	O
groups	O	O	B-Entity
except	O	O	O
SMT	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
worsening	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
or	O	O	O
hepatic	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
any	O	O	O
group	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
deterioration	O	O	B-Entity
of	O	O	O
model	O	O	B-Entity
for	O	O	I-Entity
end-stage	O	O	I-Entity
liver	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
MELD	O	O	B-Entity
)	O	O	O
in	O	O	O
SMT	O	O	O
.	O	O	O

Midodrine	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
combination	O	O	B-Entity
of	O	O	O
midodrine	O	O	B-Entity
and	O	O	O
tolvaptan	O	O	B-Entity
but	O	O	O
not	O	O	O
tolvaptan	O	O	O
alone	O	O	O
was	O	O	O
superior	O	O	O
to	O	O	O
SMT	O	O	B-Entity
in	O	O	O
control	O	O	O
of	O	O	O
ascites	O	O	B-Entity
at	O	O	O
3	O	O	O
months	O	O	B-Entity
(	O	O	O
P<.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
also	O	O	O
superior	O	O	O
to	O	O	O
midodrine	O	O	B-Entity
in	O	O	O
the	O	O	O
control	O	O	O
of	O	O	O
ascites	O	O	B-Entity
at	O	O	O
1	O	O	O
month	O	O	B-Entity
.	O	O	O

The	O	O	O
morbidity	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
were	O	O	O
similar	O	O	O
in	O	O	O
all	O	O	O
the	O	O	O
groups	O	O	B-Entity
except	O	O	O
SMT	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
this	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
suggest	O	O	O
that	O	O	O
midodrine	O	O	B-Entity
and	O	O	O
combination	O	O	B-Entity
with	O	O	O
tolvaptan	O	O	B-Entity
better	O	O	O
controls	O	O	O
ascites	O	O	B-Entity
without	O	O	O
any	O	O	O
renal	O	O	B-Entity
or	O	O	O
hepatic	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

The	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
rapidly	O	O	O
controls	O	O	O
ascites	O	O	B-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
midodrine	O	O	B-Entity
or	O	O	O
tolvaptan	O	O	B-Entity
alone	O	O	O
.	O	O	O

-DOCSTART- (27618138)

Acute	O	O	B-Entity
Complicated	O	O	I-Entity
Sinusitis	O	O	I-Entity
:	O	O	O
Ten	O	O	O
Years	O	O	B-Entity
Experience	O	O	B-Entity
from	O	O	O
the	O	O	O
University	O	O	B-Entity
Hospital	O	O	I-Entity
of	O	O	O
the	O	O	O
West	O	O	O
Indies	O	O	O

Complicated	O	O	B-Entity
sinusitis	O	O	I-Entity
is	O	O	O
rare	O	O	B-Entity
.	O	O	O

It	O	O	O
might	O	O	O
not	O	O	O
be	O	O	O
identified	O	O	O
early	O	O	O
and	O	O	O
might	O	O	O
expose	O	O	O
the	O	O	O
patient	O	O	B-Entity
to	O	O	O
an	O	O	O
unfavourable	O	O	B-Entity
outcome	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
paucity	O	O	O
of	O	O	O
data	O	O	B-Entity
regarding	O	O	O
this	O	O	O
condition	O	O	B-Entity
in	O	O	O
the	O	O	O
Caribbean	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
undertaken	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
clinical	O	O	B-Entity
characteristics	O	O	I-Entity
and	O	O	O
treatment	O	O	B-Entity
outcomes	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
admitted	O	O	B-Entity
with	O	O	O
this	O	O	O
condition	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
chart	O	O	B-Entity
review	O	O	I-Entity
was	O	O	O
performed	O	O	O
on	O	O	O
patients	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	O
the	O	O	O
University	O	O	B-Entity
Hospital	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
West	O	O	I-Entity
Indies	O	O	I-Entity
(	O	O	O
UHWI	O	O	B-Entity
)	O	O	O
with	O	O	O
complicated	O	O	B-Entity
sinusitis	O	O	I-Entity
between	O	O	O
1999	O	O	O
to	O	O	O
2011	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
was	O	O	O
analysed	O	O	B-Entity
using	O	O	O
SPSS	O	O	B-Entity
statistics	O	O	I-Entity
22	O	O	I-Entity
software	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
30	O	O	O
patients	O	O	B-Entity
(	O	O	O
23	O	O	O
males	O	O	B-Entity
and	O	O	O
7	O	O	O
females	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
age	O	O	B-Entity
was	O	O	O
19	O	O	O
(	O	O	O
13.96	O	O	O
)	O	O	O
years	O	O	B-Entity
.	O	O	O

Twenty-two	O	O	O
had	O	O	O
orbital	O	O	B-Entity
complications	O	O	B-Entity
,	O	O	O
two	O	O	O
had	O	O	O
intracranial	O	O	B-Entity
complications	O	O	O
and	O	O	O
one	O	O	O
had	O	O	O
both	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	B-Entity
organisms	O	O	B-Entity
isolated	O	O	B-Entity
were	O	O	O
streptococcus	O	O	B-Entity
and	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
sensitivity	O	O	B-Entity
was	O	O	O
to	O	O	O
amoxicillin	O	O	B-Entity
and	O	O	O
clavulinic	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

Sixteen	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
an	O	O	O
external	O	O	B-Entity
surgical	O	O	B-Entity
approach	O	O	I-Entity
had	O	O	O
a	O	O	O
mean	O	O	B-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
hospital	O	O	B-Entity
stay	O	O	I-Entity
of	O	O	O
8.8	O	O	O
(	O	O	O
3.71	O	O	O
)	O	O	O
days	O	O	B-Entity
compared	O	O	O
to	O	O	O
three	O	O	O
patients	O	O	O
who	O	O	O
had	O	O	O
a	O	O	O
purely	O	O	O
endoscopic	O	O	B-Entity
approach	O	O	I-Entity
who	O	O	O
had	O	O	O
a	O	O	O
mean	O	O	O
(	O	O	O
SD	O	O	O
)	O	O	O
hospital	O	O	O
stay	O	O	O
of	O	O	O
7.67	O	O	O
(	O	O	O
0.577	O	O	O
)	O	O	O
days	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
statistical	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
mean	O	O	B-Entity
hospital	O	O	B-Entity
stay	O	O	I-Entity
between	O	O	O
these	O	O	O
two	O	O	O
groups	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI,-3.49	O	O	O
-	O	O	O
5.78	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.609	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	O
hospital	O	O	B-Entity
stay	O	O	I-Entity
for	O	O	O
those	O	O	O
treated	O	O	B-Entity
medically	O	O	I-Entity
was	O	O	O
six	O	O	O
days	O	O	B-Entity
versus	O	O	O
ten	O	O	O
days	O	O	O
for	O	O	O
the	O	O	O
surgical	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
difference	O	O	B-Entity
was	O	O	O
three	O	O	O
days	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.193	O	O	O
-	O	O	O
6.595	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.039	O	O	O
)	O	O	O
.	O	O	O

Acute	O	O	B-Entity
complicated	O	O	I-Entity
sinusitis	O	O	I-Entity
is	O	O	O
seen	O	O	O
more	O	O	O
commonly	O	O	B-Entity
in	O	O	O
adolescent	O	O	B-Entity
males	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	B-Entity
complication	O	O	B-Entity
was	O	O	O
orbital	O	O	B-Entity
.	O	O	O

Surgical	O	O	B-Entity
treatment	O	O	I-Entity
is	O	O	O
indicated	O	O	O
for	O	O	O
those	O	O	O
patients	O	O	B-Entity
who	O	O	O
fail	O	O	B-Entity
medical	O	O	B-Entity
management	O	O	B-Entity
and	O	O	O
should	O	O	O
consist	O	O	O
of	O	O	O
an	O	O	O
endoscopic	O	O	B-Entity
approach	O	O	I-Entity
which	O	O	O
may	O	O	O
be	O	O	O
combined	O	O	O
with	O	O	O
open	O	O	O
approaches	O	O	O
if	O	O	O
indicated	O	O	O
.	O	O	O

-DOCSTART- (27619227)

Comparative	O	O	O
proteomic	O	O	B-Entity
analysis	O	O	I-Entity
reveals	O	O	O
alterations	O	O	B-Entity
in	O	O	O
development	O	O	B-Entity
and	O	O	O
photosynthesis	O	O	B-Entity
-related	O	O	O
proteins	O	O	B-Entity
in	O	O	O
diploid	O	O	B-Entity
and	O	O	O
triploid	O	O	B-Entity
rice	O	O	O

Polyploidy	O	O	B-Entity
has	O	O	O
pivotal	O	O	O
influences	O	O	B-Entity
on	O	O	O
rice	O	O	B-Entity
(	O	O	O
Oryza	O	O	B-Entity
sativa	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
morphology	O	O	B-Entity
and	O	O	O
physiology	O	O	B-Entity
,	O	O	O
and	O	O	O
is	O	O	O
very	O	O	O
important	O	O	O
for	O	O	O
understanding	O	O	O
rice	O	O	O
domestication	O	O	B-Entity
and	O	O	O
improving	O	O	O
agricultural	O	O	B-Entity
traits	O	O	I-Entity
.	O	O	O

Diploid	O	O	B-Entity
(	O	O	O
DP	O	O	B-Entity
)	O	O	O
and	O	O	O
triploid	O	O	B-Entity
(	O	O	O
TP	O	O	B-Entity
)	O	O	O
rice	O	O	B-Entity
shows	O	O	O
differences	O	O	B-Entity
in	O	O	O
morphological	O	O	B-Entity
parameters	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
plant	O	O	B-Entity
height	O	O	B-Entity
,	O	O	O
leaf	O	O	B-Entity
length	O	O	B-Entity
,	O	O	O
leaf	O	O	O
width	O	O	B-Entity
and	O	O	O
the	O	O	O
physiological	O	O	B-Entity
index	O	O	B-Entity
of	O	O	O
chlorophyll	O	O	B-Entity
content	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
determining	O	O	O
these	O	O	O
morphological	O	O	B-Entity
differences	O	O	B-Entity
are	O	O	O
remain	O	O	O
to	O	O	O
be	O	O	O
defined	O	O	O
.	O	O	O

To	O	O	O
better	O	O	O
understand	O	O	O
the	O	O	O
proteomic	O	O	B-Entity
changes	O	O	B-Entity
between	O	O	O
DP	O	O	B-Entity
and	O	O	O
TP	O	O	B-Entity
,	O	O	O
tandem	O	O	B-Entity
mass	O	O	I-Entity
tags	O	O	I-Entity
(	O	O	I-Entity
TMT	O	O	I-Entity
)	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	I-Entity
MS	O	O	B-Entity
)	O	O	I-Entity
/	O	O	O
MS	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
detect	O	O	O
the	O	O	O
significant	O	O	O
changes	O	O	O
to	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
between	O	O	O
DP	O	O	O
and	O	O	O
TP	O	O	O
.	O	O	O

Results	O	O	O
indicated	O	O	O
that	O	O	O
both	O	O	O
photosynthesis	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
pathways	O	O	B-Entity
were	O	O	O
highly	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
proteomic	O	O	B-Entity
alteration	O	O	I-Entity
between	O	O	O
DP	O	O	B-Entity
and	O	O	O
TP	O	O	B-Entity
based	O	O	O
on	O	O	O
biological	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
pathway	O	O	B-Entity
enrichment	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
and	O	O	O
13	O	O	O
higher	O	O	O
abundance	O	O	B-Entity
chloroplast	O	O	B-Entity
proteins	O	O	I-Entity
involving	O	O	O
in	O	O	O
these	O	O	O
two	O	O	O
pathways	O	O	O
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
TP	O	O	O
.	O	O	O

Quantitative	O	O	B-Entity
real-time	O	O	I-Entity
PCR	O	O	I-Entity
analysis	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
5	O	O	O
of	O	O	O
the	O	O	O
13	O	O	O
chloroplast	O	O	B-Entity
proteins	O	O	I-Entity
ATPF	O	O	B-Entity
,	O	O	O
PSAA	O	O	B-Entity
,	O	O	O
PSAB	O	O	B-Entity
,	O	O	O
PSBB	O	O	B-Entity
and	O	O	O
RBL	O	O	B-Entity
in	O	O	O
TP	O	O	B-Entity
were	O	O	O
higher	O	O	O
abundance	O	O	B-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
in	O	O	O
DP	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
integrates	O	O	O
morphology	O	O	B-Entity
,	O	O	O
physiology	O	O	B-Entity
and	O	O	O
proteomic	O	O	B-Entity
profiling	O	O	I-Entity
alteration	O	O	B-Entity
of	O	O	O
DP	O	O	B-Entity
and	O	O	O
TP	O	O	B-Entity
to	O	O	O
address	O	O	O
their	O	O	O
underlying	O	O	O
different	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	I-Entity
.	O	O	O

Our	O	O	O
finding	O	O	O
revealed	O	O	O
that	O	O	O
ATPF	O	O	B-Entity
,	O	O	O
PSAA	O	O	B-Entity
,	O	O	O
PSAB	O	O	B-Entity
,	O	O	O
PSBB	O	O	B-Entity
and	O	O	O
RBL	O	O	B-Entity
can	O	O	O
induce	O	O	O
considerable	O	O	O
expression	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
TP	O	O	B-Entity
and	O	O	O
may	O	O	O
affect	O	O	O
the	O	O	O
development	O	O	B-Entity
and	O	O	O
growth	O	O	B-Entity
of	O	O	O
rice	O	O	B-Entity
through	O	O	O
photosynthesis	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
pathways	O	O	I-Entity
.	O	O	O

-DOCSTART- (27621870)

Correlation	O	O	B-Entity
of	O	O	O
cardiopulmonary	O	O	B-Entity
exercise	O	O	I-Entity
testing	O	O	I-Entity
parameters	O	O	B-Entity
with	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
in	O	O	O
stable	O	O	B-Entity
COPD	O	O	B-Entity
patients	O	O	O

The	O	O	O
precise	O	O	O
head	O	O	O
to	O	O	O
head	O	O	O
relationships	O	O	B-Entity
between	O	O	O
Cardio-pulmonary	O	O	B-Entity
exercise	O	O	I-Entity
testing	O	O	I-Entity
(	O	O	O
CPET	O	O	B-Entity
)	O	O	O
parameters	O	O	B-Entity
and	O	O	O
patients	O	O	B-Entity
'	O	O	O
daily	O	O	B-Entity
symptoms	O	O	I-Entity
/	O	O	O
activities	O	O	B-Entity
and	O	O	O
the	O	O	O
disease	O	O	B-Entity
social	O	O	B-Entity
/	O	O	O
emotional	O	O	B-Entity
impact	O	O	I-Entity
are	O	O	O
less	O	O	O
well	O	O	O
defined	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
the	O	O	O
correlation	O	O	B-Entity
of	O	O	O
COPD	O	O	B-Entity
daily	O	O	B-Entity
symptoms	O	O	I-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
[	O	O	O
assessed	O	O	O
by	O	O	O
St.	O	O	B-Entity
George	O	O	I-Entity
's	O	O	I-Entity
Respiratory	O	O	I-Entity
Questionnaire	O	O	I-Entity
(	O	O	O
SGRQ	O	O	B-Entity
)	O	O	O
]	O	O	O
and	O	O	O
COPD	O	O	O
severity	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
BODE-index	O	O	B-Entity
)	O	O	O
with	O	O	O
CPET	O	O	B-Entity
parameters	O	O	B-Entity
were	O	O	O
investigated	O	O	O
.	O	O	O

Symptom	O	O	B-Entity
-limited	O	O	O
CPET	O	O	B-Entity
was	O	O	O
performed	O	O	O
in	O	O	O
37	O	O	O
consecutive	O	O	B-Entity
COPD	O	O	B-Entity
(	O	O	O
GOLD	O	O	B-Entity
I-III	O	O	I-Entity
)	O	O	O
subjects	O	O	O
during	O	O	O
non-	O	O	O
exacerbation	O	O	B-Entity
phase	O	O	B-Entity
.	O	O	O

The	O	O	O
SGRQ	O	O	B-Entity
was	O	O	O
also	O	O	O
completed	O	O	O
by	O	O	O
each	O	O	O
patient	O	O	B-Entity
.	O	O	O

SGRQ-score	O	O	B-Entity
correlated	O	O	B-Entity
negatively	O	O	B-Entity
with	O	O	O
FEV1	O	O	B-Entity
(	O	O	O
r=-0.49	O	O	O
,	O	O	O
P<0.01	O	O	O
)	O	O	O
,	O	O	O
predicted	O	O	B-Entity
maximal	O	O	B-Entity
work-rate	O	O	I-Entity
(	O	O	O
%	O	O	B-Entity
WR-max	O	O	I-Entity
)	O	O	O
(	O	O	O
r=-0.44	O	O	O
,	O	O	O
P<0.01	O	O	O
)	O	O	O
,	O	O	O
V'O2	O	O	B-Entity
/	O	O	O
WR	O	O	B-Entity
(	O	O	O
r=-0.52	O	O	O
,	O	O	O
P<0.01	O	O	O
)	O	O	O
and	O	O	O
breathing	O	O	B-Entity
reserve	O	O	I-Entity
(	O	O	O
r=-0.50	O	O	O
,	O	O	O
P<0.01	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
it	O	O	O
did	O	O	B-Entity
not	O	O	I-Entity
correlate	O	O	I-Entity
with	O	O	O
Peak-V'O2	O	O	B-Entity
%	O	O	O
predicted	O	O	O
(	O	O	O
r=-0.27	O	O	O
,	O	O	O
P=0.10	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
20	O	O	O
(	O	O	O
54.1	O	O	O
%	O	O	O
)	O	O	O
subjects	O	O	O
in	O	O	O
which	O	O	O
leg	O	O	B-Entity
fatigue	O	O	I-Entity
was	O	O	I-Entity
the	O	O	I-Entity
main	O	O	I-Entity
cause	O	O	I-Entity
for	O	O	I-Entity
stopping	O	O	I-Entity
the	O	O	I-Entity
test	O	O	I-Entity
,	O	O	O
Peak-V'O2	O	O	B-Entity
,	O	O	O
%	O	O	B-Entity
WR-max	O	O	I-Entity
,	O	O	O
HR-Reserve	O	O	B-Entity
and	O	O	O
Breathing	O	O	B-Entity
reserve	O	O	I-Entity
were	O	O	O
higher	O	O	O
(	O	O	O
P=0.04	O	O	O
,	O	O	O
<	O	O	O
0.01	O	O	O
,	O	O	O
0.04	O	O	O
and	O	O	O
<	O	O	O
0.01	O	O	O
respectively	O	O	O
)	O	O	O
than	O	O	O
the	O	O	O
others	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
also	O	O	O
a	O	O	O
significant	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
BODE-index	O	O	B-Entity
and	O	O	O
∆VO2	O	O	B-Entity
/	O	O	O
∆WR	O	O	B-Entity
(	O	O	O
r=-0.64	O	O	O
,	O	O	O
P<0.001	O	O	O
)	O	O	O
and	O	O	O
breathing-reserve	O	O	B-Entity
(	O	O	O
r=-0.38	O	O	O
,	O	O	O
P=0.018	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
observed	O	O	O
relationships	O	O	B-Entity
between	O	O	O
CPET	O	O	B-Entity
parameter	O	O	B-Entity
and	O	O	O
daily	O	O	B-Entity
subjective	O	O	B-Entity
complaints	O	O	I-Entity
in	O	O	O
COPD	O	O	B-Entity
were	O	O	O
not	O	O	O
strong	O	O	O
.	O	O	O

Those	O	O	O
who	O	O	O
discontinued	O	O	O
the	O	O	O
CPET	O	O	B-Entity
because	O	O	B-Entity
of	O	O	I-Entity
leg	O	O	I-Entity
fatigue	O	O	I-Entity
were	O	O	O
in	O	O	O
the	O	O	O
earlier	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
COPD	O	O	B-Entity
.	O	O	O

Significant	O	O	O
negative	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
∆VO2	O	O	B-Entity
/	O	O	O
∆WR	O	O	B-Entity
and	O	O	O
BODE-index	O	O	B-Entity
suggests	O	O	O
that	O	O	O
along	O	O	O
with	O	O	O
COPD	O	O	B-Entity
progression	O	O	B-Entity
,	O	O	O
regardless	O	O	O
of	O	O	O
negative	O	O	B-Entity
past	O	O	I-Entity
history	O	O	I-Entity
,	O	O	O
other	O	O	O
comorbidities	O	O	B-Entity
such	O	O	O
as	O	O	O
cardiac	O	O	B-Entity
/	O	O	O
musculoskeletal	O	O	B-Entity
problems	O	O	I-Entity
should	O	O	O
be	O	O	O
sought	O	O	O
.	O	O	O

-DOCSTART- (27621953)

Intrapartum	O	O	B-Entity
Cervical	O	O	B-Entity
Laceration	O	O	I-Entity
and	O	O	O
Subsequent	O	O	O
Pregnancy	O	O	O
Outcomes	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
describe	O	O	O
pregnancy	O	O	B-Entity
outcomes	O	O	I-Entity
,	O	O	O
including	O	O	O
cervical	O	O	B-Entity
insufficiency	O	O	I-Entity
and	O	O	O
preterm	O	O	B-Entity
birth	O	O	I-Entity
,	O	O	O
in	O	O	O
the	O	O	O
subsequent	O	O	O
pregnancy	O	O	O
following	O	O	B-Entity
an	O	O	O
intrapartum	O	O	B-Entity
cervical	O	O	B-Entity
laceration	O	O	I-Entity
.	O	O	O

Retrospective	O	O	O
cohort	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
their	O	O	O
first	O	O	O
two	O	O	O
consecutive	O	O	B-Entity
singleton	O	O	B-Entity
pregnancies	O	O	I-Entity
carried	O	O	O
to	O	O	O
≥	O	O	O
20(0/7	O	O	O
)	O	O	O
weeks	O	O	B-Entity
'	O	O	O
gestation	O	O	B-Entity
within	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
system	O	O	I-Entity
from	O	O	O
2002	O	O	O
to	O	O	O
2012	O	O	O
.	O	O	O

Cervical	O	O	B-Entity
laceration	O	O	I-Entity
cases	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
by	O	O	O
ICD9	O	O	B-Entity
codes	O	O	I-Entity
and	O	O	O
included	O	O	B-Entity
if	O	O	O
suture	O	O	B-Entity
repair	O	O	I-Entity
was	O	O	O
required	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
55	O	O	O
women	O	O	B-Entity
were	O	O	O
confirmed	O	O	B-Entity
to	O	O	O
have	O	O	O
a	O	O	O
cervical	O	O	B-Entity
laceration	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
delivery	O	O	B-Entity
;	O	O	O
43	O	O	O
lacerations	O	O	B-Entity
after	O	O	O
vaginal	O	O	B-Entity
delivery	O	O	I-Entity
(	O	O	B-Entity
VD	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
12	O	O	O
after	O	O	O
cesarean	O	O	B-Entity
delivery	O	O	I-Entity
(	O	O	B-Entity
CD	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	B-Entity
gestational	O	O	B-Entity
age	O	O	I-Entity
of	O	O	O
the	O	O	O
first	O	O	O
delivery	O	O	B-Entity
was	O	O	O
40(0/7	O	O	O
)	O	O	O
weeks	O	O	B-Entity
and	O	O	O
the	O	O	O
median	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
3,545	O	O	O
g	O	O	O
;	O	O	O
these	O	O	O
did	O	O	O
not	O	O	O
differ	O	O	B-Entity
between	O	O	O
VD	O	O	B-Entity
and	O	O	O
CD	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
second	O	O	O
pregnancy	O	O	B-Entity
,	O	O	O
2	O	O	O
of	O	O	O
55	O	O	O
women	O	O	B-Entity
(	O	O	O
4.6	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
prophylactic	O	O	B-Entity
cerclage	O	O	B-Entity
placed	O	O	O
;	O	O	O
1	O	O	O
carried	O	O	B-Entity
to	O	O	O
term	O	O	B-Entity
and	O	O	O
the	O	O	O
other	O	O	O
delivered	O	O	B-Entity
at	O	O	O
35(6/7	O	O	O
)	O	O	O
weeks	O	O	B-Entity
.	O	O	O

In	O	O	O
total	O	O	B-Entity
,	O	O	O
four	O	O	O
women	O	O	B-Entity
(	O	O	O
9.3	O	O	O
%	O	O	O
)	O	O	O
delivered	O	O	B-Entity
the	O	O	O
second	O	O	O
pregnancy	O	O	B-Entity
<	O	O	O
37	O	O	O
weeks	O	O	B-Entity
:	O	O	O
three	O	O	O
had	O	O	O
a	O	O	O
prior	O	O	B-Entity
term	O	O	B-Entity
VD	O	O	B-Entity
and	O	O	O
one	O	O	O
had	O	O	O
a	O	O	O
prior	O	O	O
34	O	O	O
weeks	O	O	O
VD	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
only	O	O	O
one	O	O	O
case	O	O	B-Entity
of	O	O	O
recurrent	O	O	B-Entity
cervical	O	O	B-Entity
laceration	O	O	I-Entity
,	O	O	O
occurring	O	O	B-Entity
in	O	O	O
the	O	O	O
setting	O	O	B-Entity
of	O	O	O
vaginal	O	O	B-Entity
deliveries	O	O	I-Entity
.	O	O	O

Obstetric	O	O	B-Entity
cervical	O	O	B-Entity
lacerations	O	O	I-Entity
are	O	O	O
uncommon	O	O	B-Entity
.	O	O	O

Complications	O	O	B-Entity
in	O	O	O
the	O	O	O
following	O	O	B-Entity
pregnancy	O	O	B-Entity
were	O	O	O
low	O	O	B-Entity
,	O	O	O
despite	O	O	O
lack	O	O	B-Entity
of	O	O	O
additional	O	O	O
prophylactic	O	O	B-Entity
cerclage	O	O	B-Entity
use	O	O	O
.	O	O	O

-DOCSTART- (27623760)

A	O	O	O
Wnt	O	O	B-Entity
Pathway	O	O	I-Entity
Activator	O	O	B-Entity
Induces	O	O	B-Entity
Apoptosis	O	O	I-Entity
and	O	O	O
Cell	O	O	B-Entity
Death	O	O	I-Entity
in	O	O	O
Mouse	O	O	B-Entity
Monocytic	O	O	I-Entity
Leukemia	O	O	I-Entity
Cells	O	O	O

A	O	O	O
Wnt	O	O	B-Entity
agonist	O	O	I-Entity
,	O	O	I-Entity
2-amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl	O	O	B-Entity
)	O	O	I-Entity
pyrimidine	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
cell-permeable	O	O	B-Entity
pyrimidine	O	O	B-Entity
compound	O	O	I-Entity
that	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
mimic	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
Wnt	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
leukemic	O	O	B-Entity
mouse	O	O	I-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
,	O	O	O
RAW	O	O	B-Entity
264.7	O	O	I-Entity
and	O	O	O
J774.1	O	O	B-Entity
,	O	O	O
were	O	O	O
incubated	O	O	O
with	O	O	O
the	O	O	O
Wnt	O	O	B-Entity
agonist	O	O	I-Entity
.	O	O	O

The	O	O	O
Wnt	O	O	B-Entity
agonist	O	O	I-Entity
showed	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
the	O	O	O
concentration	O	O	O
of	O	O	O
1	O	O	O
-	O	O	O
10	O	O	O
μM.	O	O	O
The	O	O	O
Wnt	O	O	O
agonist	O	O	O
did	O	O	O
not	O	O	O
show	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
GSK-3β	O	O	B-Entity
activity	O	O	B-Entity
but	O	O	O
induced	O	O	B-Entity
β-catenin	O	O	B-Entity
accumulation	O	O	I-Entity
in	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
.	O	O	O

The	O	O	O
Wnt	O	O	B-Entity
agonist	O	O	I-Entity
showed	O	O	O
caspase-independent	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
,	O	O	O
but	O	O	O
no	O	O	O
further	O	O	O
involvement	O	O	O
in	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
ER	O	O	I-Entity
stress	O	O	I-Entity
signaling	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
discuss	O	O	O
the	O	O	O
possible	O	O	O
mechanism	O	O	O
of	O	O	O
Wnt	O	O	B-Entity
agonist	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
apoptotic	O	O	I-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
in	O	O	O
RAW	O	O	B-Entity
264.7	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (27625333)

Extracorporeal	O	O	B-Entity
membrane	O	O	I-Entity
oxygenation	O	O	I-Entity
outcomes	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
with	O	O	O
hemophagocytic	O	O	O
lymphohistiocytosis	O	O	O

Pediatric	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
hemophagocytic	O	O	B-Entity
lymphohistiocytosis	O	O	I-Entity
(	O	O	O
HLH	O	O	B-Entity
)	O	O	O
may	O	O	O
develop	O	O	O
refractory	O	O	B-Entity
respiratory	O	O	B-Entity
or	O	O	O
cardiac	O	O	B-Entity
failure	O	O	I-Entity
that	O	O	O
warrants	O	O	O
consideration	O	O	B-Entity
for	O	O	O
extracorporeal	O	O	B-Entity
membrane	O	O	I-Entity
oxygenation	O	O	I-Entity
(	O	O	O
ECMO	O	O	B-Entity
)	O	O	O
support	O	O	B-Entity
.	O	O	O

The	O	O	O
purposes	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
use	O	O	B-Entity
and	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
ECMO	O	O	B-Entity
in	O	O	O
pediatric	O	O	B-Entity
HLH	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
to	O	O	O
identify	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
hospital	O	O	B-Entity
mortality	O	O	I-Entity
and	O	O	O
to	O	O	O
compare	O	O	B-Entity
their	O	O	O
ECMO	O	O	O
use	O	O	O
and	O	O	O
outcomes	O	O	O
to	O	O	O
the	O	O	O
ECMO	O	O	O
population	O	O	B-Entity
as	O	O	O
a	O	O	O
whole	O	O	O
.	O	O	O

Pediatric	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
⩽	O	O	O
18	O	O	O
years	O	O	B-Entity
)	O	O	O
with	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
HLH	O	O	B-Entity
in	O	O	O
the	O	O	O
Extracorporeal	O	O	B-Entity
Life	O	O	I-Entity
Support	O	O	I-Entity
Organization	O	O	I-Entity
(	O	O	O
ELSO	O	O	B-Entity
)	O	O	O
Registry	O	O	B-Entity
were	O	O	O
included	O	O	B-Entity
.	O	O	O

Between	O	O	O
1983	O	O	O
and	O	O	O
2014	O	O	O
,	O	O	O
data	O	O	B-Entity
for	O	O	O
30	O	O	O
children	O	O	B-Entity
with	O	O	O
HLH	O	O	B-Entity
were	O	O	O
available	O	O	O
in	O	O	O
the	O	O	O
ELSO	O	O	B-Entity
registry	O	O	B-Entity
and	O	O	O
all	O	O	O
were	O	O	O
included	O	O	B-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

All	O	O	O
cases	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
the	O	O	O
last	O	O	B-Entity
decade	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
30	O	O	O
HLH	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
24	O	O	O
(	O	O	O
80	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
respiratory	O	O	B-Entity
indication	O	O	B-Entity
for	O	O	O
ECMO	O	O	B-Entity
and	O	O	O
six	O	O	O
(	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
cardiac	O	O	B-Entity
indication	O	O	O
(	O	O	O
of	O	O	O
which	O	O	O
4	O	O	O
were	O	O	O
E	O	O	B-Entity
-	O	O	O
CPR	O	O	B-Entity
and	O	O	O
2	O	O	O
cardiac	O	O	B-Entity
failure	O	O	I-Entity
)	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
24	O	O	O
respiratory	O	O	B-Entity
ECMO	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
63	O	O	O
%	O	O	O
were	O	O	O
placed	O	O	O
on	O	O	O
VA	O	O	B-Entity
ECMO	O	O	I-Entity
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
all	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
ELSO	O	O	B-Entity
registry	O	O	B-Entity
during	O	O	O
the	O	O	O
study	O	O	B-Entity
period	O	O	I-Entity
(	O	O	O
n=17,007	O	O	O
)	O	O	O
,	O	O	O
HLH	O	O	B-Entity
patients	O	O	O
had	O	O	O
worse	O	O	O
hospital	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
non-HLH	O	O	O
59	O	O	O
%	O	O	O
vs	O	O	O
HLH	O	O	O
30	O	O	O
%	O	O	O
,	O	O	O
p	O	O	B-Entity
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
pediatric	O	O	B-Entity
HLH	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
no	O	O	O
pre-	O	O	O
ECMO	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
mortality	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

The	O	O	O
development	O	O	B-Entity
of	O	O	O
a	O	O	O
hemorrhagic	O	O	B-Entity
complication	O	O	B-Entity
on	O	O	O
ECMO	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
decreased	O	O	B-Entity
mortality	O	O	B-Entity
(	O	O	O
p	O	O	B-Entity
=	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Comparing	O	O	B-Entity
HLH	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
respiratory	O	O	B-Entity
failure	O	O	I-Entity
to	O	O	O
patients	O	O	O
with	O	O	O
other	O	O	O
immune	O	O	B-Entity
compromised	O	O	I-Entity
conditions	O	O	I-Entity
,	O	O	O
the	O	O	O
overall	O	O	O
survival	O	O	B-Entity
rate	O	O	I-Entity
is	O	O	O
similar	O	O	O
(	O	O	O
HLH	O	O	O
38	O	O	O
%	O	O	O
vs.	O	O	O
non-HLH	O	O	O
immune	O	O	O
compromised	O	O	O
31	O	O	O
%	O	O	O
,	O	O	O
p	O	O	B-Entity
=	O	O	O
0.64	O	O	O
)	O	O	O
.	O	O	O

HLH	O	O	B-Entity
is	O	O	O
an	O	O	O
uncommon	O	O	B-Entity
indication	O	O	B-Entity
for	O	O	O
ECMO	O	O	B-Entity
and	O	O	O
these	O	O	O
patients	O	O	B-Entity
have	O	O	O
increased	O	O	B-Entity
mortality	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
overall	O	O	O
pediatric	O	O	B-Entity
ECMO	O	O	O
population	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
should	O	O	O
be	O	O	O
factored	O	O	O
into	O	O	O
decision-making	O	O	B-Entity
when	O	O	O
considering	O	O	O
ECMO	O	O	B-Entity
for	O	O	O
pediatric	O	O	B-Entity
HLH	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27625705)

Gut	O	O	B-Entity
microbiome	O	O	I-Entity
alterations	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
stage	O	O	B-Entity
4	O	O	I-Entity
hepatitis	O	O	O
C	O	O	O

Hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
HCV	O	O	B-Entity
)	O	O	O
causes	O	O	O
debilitating	O	O	O
liver	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
progress	O	O	O
to	O	O	O
cirrhosis	O	O	B-Entity
and	O	O	O
cancer	O	O	B-Entity
,	O	O	O
and	O	O	O
claims	O	O	O
500,000	O	O	O
annual	O	O	O
lives	O	O	O
worldwide	O	O	B-Entity
.	O	O	O

While	O	O	O
HCV	O	O	B-Entity
epidemiology	O	O	B-Entity
,	O	O	O
pathophysiology	O	O	B-Entity
,	O	O	O
and	O	O	O
therapy	O	O	B-Entity
are	O	O	O
being	O	O	O
deeply	O	O	O
studied	O	O	O
,	O	O	O
rare	O	O	O
attention	O	O	O
is	O	O	O
given	O	O	O
to	O	O	O
reciprocal	O	O	B-Entity
interactions	O	O	I-Entity
between	O	O	O
HCV	O	O	B-Entity
infection	O	O	I-Entity
,	O	O	O
HCV	O	O	O
-induced	O	O	O
chronic	O	O	B-Entity
liver	O	O	I-Entity
diseases	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
human	O	O	B-Entity
gut	O	O	B-Entity
microbiome	O	O	I-Entity
.	O	O	O

As	O	O	O
Egypt	O	O	B-Entity
has	O	O	O
the	O	O	O
world	O	O	B-Entity
's	O	O	I-Entity
highest	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
HCV	O	O	B-Entity
infections	O	O	I-Entity
,	O	O	O
we	O	O	O
launched	O	O	O
this	O	O	O
study	O	O	B-Entity
to	O	O	O
monitor	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
gut	O	O	B-Entity
microbial	O	O	I-Entity
community	O	O	I-Entity
composition	O	O	B-Entity
of	O	O	O
Egyptian	O	O	B-Entity
HCV	O	O	O
patients	O	O	B-Entity
that	O	O	O
may	O	O	O
affect	O	O	O
,	O	O	O
or	O	O	O
result	O	O	O
from	O	O	O
,	O	O	O
the	O	O	O
patients	O	O	O
'	O	O	O
liver	O	O	B-Entity
state	O	O	B-Entity
.	O	O	O

To	O	O	O
this	O	O	O
end	O	O	O
,	O	O	O
we	O	O	O
analyzed	O	O	O
stool	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
six	O	O	O
stage	O	O	B-Entity
4	O	O	I-Entity
-	O	O	O
HCV	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
eight	O	O	O
healthy	O	O	B-Entity
individuals	O	O	I-Entity
by	O	O	O
high-throughput	O	O	B-Entity
16S	O	O	B-Entity
rRNA	O	O	I-Entity
gene	O	O	I-Entity
sequencing	O	O	I-Entity
using	O	O	O
Illumina	O	O	B-Entity
MiSeq	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
the	O	O	O
alpha-diversity	O	O	B-Entity
of	O	O	O
the	O	O	O
healthy	O	O	B-Entity
persons	O	O	I-Entity
'	O	O	I-Entity
gut	O	O	B-Entity
microbiomes	O	O	I-Entity
was	O	O	O
higher	O	O	B-Entity
than	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
HCV	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Whereas	O	O	O
members	O	O	O
of	O	O	O
phylum	O	O	B-Entity
Bacteroidetes	O	O	I-Entity
were	O	O	O
more	O	O	O
abundant	O	O	O
in	O	O	O
HCV	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
healthy	O	O	B-Entity
individuals	O	O	I-Entity
had	O	O	O
higher	O	O	B-Entity
abundance	O	O	B-Entity
of	O	O	O
Firmicutes	O	O	B-Entity
,	O	O	O
Proteobacteria	O	O	B-Entity
,	O	O	O
and	O	O	O
Actinobacteria	O	O	B-Entity
.	O	O	O

Genus	O	O	B-Entity
-level	O	O	O
analysis	O	O	B-Entity
showed	O	O	O
differential	O	O	O
abundance	O	O	B-Entity
of	O	O	O
Prevotella	O	O	B-Entity
and	O	O	O
Faecalibacterium	O	O	B-Entity
(	O	O	O
higher	O	O	B-Entity
in	O	O	O
HCV	O	O	B-Entity
patients	O	O	B-Entity
)	O	O	O
vs.	O	O	O

Ruminococcus	O	O	B-Entity
and	O	O	O
Clostridium	O	O	B-Entity
(	O	O	O
healthy	O	O	B-Entity
group	O	O	I-Entity
)	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
the	O	O	O
higher	O	O	B-Entity
abundance	O	O	B-Entity
of	O	O	O
Bacteroidetes	O	O	B-Entity
in	O	O	O
HCV	O	O	B-Entity
patients	O	O	B-Entity
is	O	O	O
most	O	O	O
likely	O	O	O
due	O	O	O
to	O	O	O
Prevotella	O	O	B-Entity
overabundance	O	O	B-Entity
.	O	O	O

The	O	O	O
probiotic	O	O	B-Entity
genus	O	O	I-Entity
,	O	O	O
Bifidobacterium	O	O	B-Entity
,	O	O	O
was	O	O	O
only	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
microbiotas	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
individuals	O	O	I-Entity
.	O	O	O

To	O	O	O
the	O	O	O
best	O	O	O
of	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
this	O	O	O
study	O	O	B-Entity
provides	O	O	O
a	O	O	O
first	O	O	O
overview	O	O	O
of	O	O	O
major	O	O	O
phyla	O	O	B-Entity
and	O	O	O
genera	O	O	B-Entity
differentiating	O	O	O
stage	O	O	B-Entity
4	O	O	I-Entity
-	O	O	O
HCV	O	O	B-Entity
patients	O	O	B-Entity
from	O	O	O
healthy	O	O	B-Entity
individuals	O	O	I-Entity
and	O	O	O
suggests	O	O	O
possible	O	O	O
microbiome	O	O	B-Entity
remodeling	O	O	O
in	O	O	O
chronic	O	O	B-Entity
hepatitis	O	O	I-Entity
C	O	O	I-Entity
,	O	O	O
possibly	O	O	O
shaped	O	O	O
by	O	O	O
bacterial	O	O	B-Entity
translocation	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
liver	O	O	B-Entity
's	O	O	I-Entity
impaired	O	O	B-Entity
role	O	O	I-Entity
in	O	O	O
digestion	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
synthesis	O	O	I-Entity
.	O	O	O

Future	O	O	O
studies	O	O	O
will	O	O	O
investigate	O	O	O
the	O	O	O
microbiome	O	O	B-Entity
composition	O	O	B-Entity
and	O	O	O
functional	O	O	O
capabilities	O	O	B-Entity
in	O	O	O
more	O	O	O
patients	O	O	B-Entity
while	O	O	O
tracing	O	O	O
some	O	O	O
potential	O	O	O
biomarker	O	O	B-Entity
taxa	O	O	O
(	O	O	O
e.g.	O	O	O
,	O	O	O
Prevotella	O	O	B-Entity
,	O	O	O
Faecalibacterium	O	O	B-Entity
vs.	O	O	O
Bifidobacterium	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27626099)

Peptide	O	O	B-Entity
-Mediated	O	O	O
Interference	O	O	B-Entity
of	O	O	O
PB2	O	O	B-Entity
-	O	O	O
eIF4G1	O	O	B-Entity
Interaction	O	O	B-Entity
Inhibits	O	O	B-Entity
Influenza	O	O	B-Entity
A	O	O	I-Entity
Viruses	O	O	I-Entity
'	O	O	O
Replication	O	O	B-Entity
in	O	O	B-Entity
Vitro	O	O	I-Entity
and	O	O	O
in	O	O	O
Vivo	O	O	O

Influenza	O	O	B-Entity
viruses	O	O	I-Entity
are	O	O	O
obligate	O	O	B-Entity
parasites	O	O	I-Entity
that	O	O	O
hijack	O	O	B-Entity
the	O	O	I-Entity
host	O	O	I-Entity
cellular	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Previous	O	O	O
results	O	O	O
have	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
influenza	O	O	B-Entity
virus	O	O	I-Entity
PB2	O	O	I-Entity
subunit	O	O	O
confers	O	O	O
a	O	O	O
dependence	O	O	O
of	O	O	O
host	O	O	B-Entity
eukaryotic	O	O	I-Entity
translation	O	O	I-Entity
initiation	O	O	I-Entity
factor	O	O	I-Entity
4-γ	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
eIF4G1	O	O	B-Entity
)	O	O	O
for	O	O	O
viral	O	O	B-Entity
mRNA	O	O	I-Entity
translation	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
demonstrated	O	O	O
that	O	O	O
peptide	O	O	B-Entity
-mediated	O	O	O
interference	O	O	B-Entity
of	O	O	O
the	O	O	O
PB2	O	O	B-Entity
-	O	O	O
eIF4G1	O	O	B-Entity
interaction	O	O	B-Entity
inhibited	O	O	B-Entity
virus	O	O	B-Entity
replication	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Remarkably	O	O	O
,	O	O	O
intranasal	O	O	B-Entity
administration	O	O	I-Entity
of	O	O	O
the	O	O	O
peptide	O	O	B-Entity
provided	O	O	O
100	O	O	O
%	O	O	O
protection	O	O	B-Entity
against	O	O	O
lethal	O	O	B-Entity
challenges	O	O	B-Entity
of	O	O	O
influenza	O	O	B-Entity
A	O	O	I-Entity
viruses	O	O	I-Entity
in	O	O	O
BALB/c	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
including	O	O	O
H1N1	O	O	B-Entity
,	O	O	O
H5N1	O	O	B-Entity
,	O	O	O
and	O	O	O
H7N9	O	O	B-Entity
influenza	O	O	I-Entity
virus	O	O	I-Entity
subtypes	O	O	I-Entity
.	O	O	O

Mapping	O	O	B-Entity
of	O	O	O
the	O	O	O
PB2	O	O	B-Entity
protein	O	O	I-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
eIF4G1	O	O	B-Entity
binding	O	O	B-Entity
sites	O	O	I-Entity
resided	O	O	O
within	O	O	O
the	O	O	O
PB2	O	O	B-Entity
cap	O	O	I-Entity
-	O	O	O
binding	O	O	B-Entity
domain	O	O	I-Entity
.	O	O	O

Virtual	O	O	B-Entity
docking	O	O	I-Entity
analysis	O	O	I-Entity
suggested	O	O	O
that	O	O	O

the	O	O	O
inhibitory	O	O	B-Entity
peptide	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
conserved	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
residues	O	O	I-Entity
that	O	O	O
were	O	O	O
essential	O	O	O
to	O	O	O
PB2	O	O	B-Entity
cap-binding	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
identified	O	O	O
the	O	O	O
PB2	O	O	B-Entity
-	O	O	O
eIF4G1	O	O	B-Entity
interactive	O	O	B-Entity
site	O	O	I-Entity
as	O	O	O
a	O	O	O
druggable	O	O	B-Entity
target	O	O	O
for	O	O	O
influenza	O	O	B-Entity
therapeutics	O	O	B-Entity
.	O	O	O

-DOCSTART- (27626498)

DRG1	O	O	B-Entity
is	O	O	O
a	O	O	O
potential	O	O	O
oncogene	O	O	B-Entity
in	O	O	O
lung	O	O	B-Entity
adenocarcinoma	O	O	I-Entity
and	O	O	O
promotes	O	O	B-Entity
tumor	O	O	B-Entity
progression	O	O	I-Entity
via	O	O	O
spindle	O	O	B-Entity
checkpoint	O	O	I-Entity
signaling	O	O	I-Entity
regulation	O	O	O

Developmentally	O	O	O
regulated	O	O	O
GTP	O	O	B-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
DRG1	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
member	O	O	O
of	O	O	O
the	O	O	O
DRG	O	O	B-Entity
family	O	O	I-Entity
,	O	O	O
plays	O	O	O
important	O	O	O
roles	O	O	O
in	O	O	O
regulating	O	O	B-Entity
cell	O	O	I-Entity
growth	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
molecular	O	O	B-Entity
basis	O	O	I-Entity
of	O	O	O
DRG1	O	O	B-Entity
in	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
regulation	O	O	I-Entity
and	O	O	O
the	O	O	O
relationship	O	O	O
between	O	O	O
DRG1	O	O	O
and	O	O	O
tumor	O	O	B-Entity
progression	O	O	I-Entity
remain	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
DRG1	O	O	B-Entity
is	O	O	O
elevated	O	O	O
in	O	O	O
lung	O	O	B-Entity
adenocarcinomas	O	O	I-Entity
while	O	O	O
weakly	O	O	O
expressed	O	O	B-Entity
in	O	O	O
adjacent	O	O	O
lung	O	O	O
tissues	O	O	B-Entity
.	O	O	O

DRG1	O	O	B-Entity
knockdown	O	O	B-Entity
causes	O	O	O
growth	O	O	B-Entity
inhibition	O	O	I-Entity
of	O	O	O
tumor	O	O	B-Entity
cells	O	O	B-Entity
by	O	O	O
significantly	O	O	O
increasing	O	O	O
the	O	O	O
proportion	O	O	O
of	O	O	O
cells	O	O	O
in	O	O	O
M	O	O	B-Entity
phase	O	O	I-Entity
.	O	O	O

Overexpression	O	O	B-Entity
of	O	O	O
DRG1	O	O	B-Entity
leads	O	O	O
to	O	O	O
chromosome	O	O	B-Entity
missegregation	O	O	B-Entity
which	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
index	O	O	O
for	O	O	O
tumorigenesis	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
ectopic	O	O	B-Entity
of	O	O	O
DRG1	O	O	B-Entity
reduces	O	O	O
taxol	O	O	B-Entity
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
of	O	O	O
lung	O	O	B-Entity
adenocarcinoma	O	O	I-Entity
cells	O	O	B-Entity
.	O	O	O

Mechanistic	O	O	B-Entity
analyses	O	O	B-Entity
confirm	O	O	O
that	O	O	O
DRG1	O	O	B-Entity
localizes	O	O	B-Entity
at	O	O	O
mitotic	O	O	B-Entity
spindles	O	O	I-Entity
in	O	O	O
dividing	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
binds	O	O	B-Entity
to	O	O	O
spindle	O	O	B-Entity
checkpoint	O	O	I-Entity
signaling	O	O	I-Entity
proteins	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

These	O	O	O
studies	O	O	B-Entity
highlight	O	O	O
the	O	O	O
expanding	O	O	O
role	O	O	O
of	O	O	O
DRG1	O	O	B-Entity
in	O	O	O
tumorigenesis	O	O	B-Entity
and	O	O	O
reveal	O	O	O
a	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
DRG1	O	O	O
in	O	O	O
taxol	O	O	B-Entity
resistance	O	O	O
.	O	O	O

-DOCSTART- (27627778)

Gelsolin	O	O	B-Entity
in	O	O	O
Onychophora	O	O	B-Entity
and	O	O	O
Tardigrada	O	O	B-Entity
with	O	O	O
notes	O	O	O
on	O	O	O
its	O	O	O
variability	O	O	B-Entity
in	O	O	O
the	O	O	O
Ecdysozoa	O	O	O

Rearrangements	O	O	B-Entity
of	O	O	O
the	O	O	O
filamentous	O	O	B-Entity
actin	O	O	I-Entity
network	O	O	I-Entity
involve	O	O	O
a	O	O	O
broad	O	O	O
range	O	O	B-Entity
of	O	O	O
actin	O	O	B-Entity
binding	O	O	I-Entity
proteins	O	O	I-Entity
.	O	O	O

Among	O	O	O
these	O	O	O
,	O	O	O
the	O	O	O
gelsolin	O	O	B-Entity
proteins	O	O	I-Entity
sever	O	O	O
actin	O	O	B-Entity
filaments	O	O	I-Entity
,	O	O	O
cap	O	O	O
their	O	O	O
fast	O	O	B-Entity
growing	O	O	I-Entity
end	O	O	O
and	O	O	O
nucleate	O	O	B-Entity
actin	O	O	B-Entity
assembly	O	O	I-Entity
in	O	O	O
a	O	O	O
calcium	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
focus	O	O	O
on	O	O	O
the	O	O	O
gelsolin	O	O	B-Entity
of	O	O	O
the	O	O	O
onychophoran	O	O	B-Entity
Peripatoides	O	O	B-Entity
novaezealandiae	O	O	I-Entity
and	O	O	O
the	O	O	O
eutardigrade	O	O	B-Entity
Hypsibius	O	O	B-Entity
dujardini	O	O	I-Entity
.	O	O	O

From	O	O	O
the	O	O	O
cDNA	O	O	B-Entity
of	O	O	O
P.	O	O	B-Entity
novaezealandiae	O	O	I-Entity
we	O	O	O
obtained	O	O	B-Entity
the	O	O	O
complete	O	O	O
coding	O	O	B-Entity
sequence	O	O	I-Entity
with	O	O	O
an	O	O	O
open	O	O	B-Entity
reading	O	O	I-Entity
frame	O	O	I-Entity
of	O	O	O
2178	O	O	O
bp	O	O	B-Entity
.	O	O	O

It	O	O	O
encodes	O	O	B-Entity
a	O	O	O
protein	O	O	B-Entity
of	O	O	O
726	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
with	O	O	O
a	O	O	O
calculated	O	O	B-Entity
molecular	O	O	B-Entity
mass	O	O	I-Entity
of	O	O	O
82,610.9Da	O	O	O
and	O	O	O
a	O	O	O
pI	O	O	O
of	O	O	O
5.57	O	O	O
.	O	O	O

This	O	O	O
sequence	O	O	B-Entity
is	O	O	O
comprised	O	O	B-Entity
of	O	O	O
six	O	O	O
segments	O	O	B-Entity
(	O	O	O
S1-S6	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
analysis	O	O	B-Entity
of	O	O	O
data	O	O	B-Entity
from	O	O	O
TardiBase	O	O	B-Entity
reveals	O	O	B-Entity
that	O	O	O
the	O	O	O
gelsolin	O	O	B-Entity
of	O	O	O
the	O	O	O
eutardigrade	O	O	B-Entity
Hypsibius	O	O	B-Entity
dujardini	O	O	I-Entity
has	O	O	O
only	O	O	O
three	O	O	O
segments	O	O	B-Entity
(	O	O	O
S1-S3	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
coding	O	O	B-Entity
sequence	O	O	I-Entity
consist	O	O	O
of	O	O	O
1119	O	O	O
bp	O	O	B-Entity
for	O	O	O
373	O	O	O
amino	O	O	B-Entity
acids	O	O	I-Entity
with	O	O	O
a	O	O	O
calculated	O	O	B-Entity
molecular	O	O	B-Entity
mass	O	O	I-Entity
of	O	O	O
42,440.95Da	O	O	O
and	O	O	O
a	O	O	O
pI	O	O	O
of	O	O	O
6.17	O	O	O
.	O	O	O

The	O	O	O
Peripatoides	O	O	B-Entity
and	O	O	O
Hypsibius	O	O	B-Entity
gelsolin	O	O	B-Entity
revealed	O	O	B-Entity
both	O	O	O
conserved	O	O	B-Entity
binding	O	O	B-Entity
motifs	O	O	I-Entity
for	O	O	O
G-actin	O	O	B-Entity
,	O	O	O
F-actin	O	O	B-Entity
and	O	O	O
phosphatidylinositol	O	O	B-Entity
4,5-bisphosphate	O	O	I-Entity
(	O	O	O
PIP2	O	O	B-Entity
)	O	O	O
,	O	O	O
along	O	O	O
with	O	O	O
a	O	O	O
full	O	O	O
set	O	O	O
of	O	O	O
type-1	O	O	B-Entity
and	O	O	O
type-2	O	O	B-Entity
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-	O	O	O
binding	O	O	B-Entity
sites	O	O	I-Entity
which	O	O	O
could	O	O	O
result	O	O	B-Entity
in	O	O	O
the	O	O	O
binding	O	O	O
of	O	O	O
eight	O	O	O
and	O	O	O
four	O	O	O
calcium	O	O	B-Entity
ions	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Both	O	O	O
gelsolin	O	O	B-Entity
proteins	O	O	I-Entity
lack	O	O	B-Entity
a	O	O	O
C-terminal	O	O	B-Entity
latch-helix	O	O	B-Entity
indicating	O	O	O
a	O	O	O
more	O	O	O
rapid	O	O	B-Entity
activation	O	O	B-Entity
in	O	O	O
the	O	O	O
submicromolar	O	O	O
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
range	O	O	I-Entity
.	O	O	O

We	O	O	O
suggest	O	O	O
that	O	O	O
a	O	O	O
gelsolin	O	O	B-Entity
with	O	O	O
three	O	O	O
segments	O	O	B-Entity
was	O	O	O
present	O	O	B-Entity
in	O	O	O
the	O	O	O
last	O	O	O
common	O	O	O
ancestor	O	O	B-Entity
of	O	O	O
the	O	O	O
ecdysozoan	O	O	B-Entity
clade	O	O	O
Panarthropoda	O	O	B-Entity
(	O	O	O
Onychophora	O	O	B-Entity
,	O	O	O
Tardigrada	O	O	B-Entity
,	O	O	O
Arthropoda	O	O	B-Entity
)	O	O	O
,	O	O	O
primarily	O	O	B-Entity
because	O	O	O
the	O	O	O
gelsolin	O	O	O
of	O	O	O
all	O	O	O
non-Ecdysozoa	O	O	O
studied	O	O	B-Entity
so	O	O	O
far	O	O	O
(	O	O	O
except	O	O	O
Chordata	O	O	B-Entity
)	O	O	O
reveals	O	O	B-Entity
this	O	O	O
number	O	O	O
of	O	O	O
segments	O	O	O
.	O	O	O

Mapping	O	O	B-Entity
of	O	O	O
our	O	O	O
molecular	O	O	B-Entity
data	O	O	I-Entity
onto	O	O	O
a	O	O	O
well-established	O	O	B-Entity
phylogeny	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
gelsolin	O	O	B-Entity
segments	O	O	B-Entity
does	O	O	O
not	O	O	O
correlate	O	O	B-Entity
with	O	O	O
the	O	O	O
phylogenetic	O	O	B-Entity
lineage	O	O	B-Entity
but	O	O	O
rather	O	O	O
with	O	O	O
particular	O	O	O
functional	O	O	B-Entity
demands	O	O	O
to	O	O	O
alter	O	O	B-Entity
the	O	O	O
kinetics	O	O	B-Entity
of	O	O	O
actin	O	O	B-Entity
polymerization	O	O	I-Entity
.	O	O	O

-DOCSTART- (27628042)

MiR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
participates	O	O	B-Entity
in	O	O	O
esophageal	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
invasion	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
via	O	O	O
SMAD7	O	O	B-Entity
pathway	O	O	B-Entity
mediated	O	O	O
EMT	O	O	O

ESCC	O	O	B-Entity
is	O	O	O
a	O	O	O
life-threatening	O	O	B-Entity
disease	O	O	B-Entity
due	O	O	O
to	O	O	O
invasion	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
stage	O	O	I-Entity
.	O	O	O

Great	O	O	O
efforts	O	O	O
had	O	O	O
been	O	O	O
made	O	O	O
to	O	O	O
detect	O	O	B-Entity
the	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	B-Entity
which	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
invasion	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
in	O	O	O
ESCC	O	O	B-Entity
.	O	O	O

Recent	O	O	O
evidence	O	O	B-Entity
had	O	O	O
suggested	O	O	O
that	O	O	O
deregulation	O	O	B-Entity
of	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
took	O	O	O
an	O	O	O
important	O	O	O
role	O	O	B-Entity
in	O	O	O
cancers	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
role	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
mechanism	O	O	B-Entity
in	O	O	O
ESCC	O	O	B-Entity
had	O	O	O
seldom	O	O	B-Entity
been	O	O	O
elucidated	O	O	O
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
ESCC	O	O	B-Entity
tissues	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
by	O	O	O
real-time	O	O	B-Entity
PCR	O	O	I-Entity
methods	O	O	I-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
the	O	O	O
invasion	O	O	B-Entity
,	O	O	O
metastasis	O	O	B-Entity
and	O	O	O
proliferation	O	O	B-Entity
ability	O	O	O
of	O	O	O
ESCC	O	O	B-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
transfected	O	O	B-Entity
with	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
mimics	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
separately	O	O	O
by	O	O	O
transwell	O	O	B-Entity
invasion	O	O	I-Entity
assay	O	O	I-Entity
,	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
assay	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
target	O	O	B-Entity
gene	O	O	I-Entity
of	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
was	O	O	O
studied	O	O	O
and	O	O	O
verified	O	O	B-Entity
by	O	O	O
luciferase	O	O	B-Entity
activity	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

And	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
in	O	O	O
EMT	O	O	B-Entity
was	O	O	O
also	O	O	O
investigated	O	O	B-Entity
by	O	O	O
real-time	O	O	B-Entity
PCR	O	O	I-Entity
and	O	O	O
western	O	O	B-Entity
blot	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

We	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
were	O	O	O
decreased	O	O	B-Entity
both	O	O	O
in	O	O	O
ESCC	O	O	B-Entity
tissues	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
were	O	O	O
negatively	O	O	O
linked	O	O	O
to	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	B-Entity
in	O	O	O
ESCC	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

Restoration	O	O	O
of	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
in	O	O	O
EC-1	O	O	B-Entity
cells	O	O	B-Entity
by	O	O	O
using	O	O	O
miR-424	O	O	O
-	O	O	O
5p	O	O	O
mimics	O	O	O
could	O	O	O
decrease	O	O	B-Entity
the	O	O	O
invasion	O	O	B-Entity
,	O	O	O
metastasis	O	O	B-Entity
and	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
EC-1	O	O	O
cells	O	O	O
,	O	O	O
indicating	O	O	O
its	O	O	O
role	O	O	B-Entity
in	O	O	O
inhibition	O	O	B-Entity
on	O	O	O
the	O	O	O
invasion	O	O	O
and	O	O	O
metastasis	O	O	O
ability	O	O	O
of	O	O	O
ESCC	O	O	B-Entity
cells	O	O	O
and	O	O	O
tissues	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
we	O	O	O
demonstrated	O	O	O
that	O	O	O
SMAD7	O	O	B-Entity
was	O	O	O
a	O	O	O
specific	O	O	O
target	O	O	B-Entity
gene	O	O	I-Entity
for	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
by	O	O	O
luciferase	O	O	B-Entity
activity	O	O	I-Entity
assay	O	O	I-Entity
and	O	O	O
miR-424	O	O	O
-	O	O	O
5p	O	O	O
could	O	O	O
not	O	O	O
only	O	O	O
negatively	O	O	B-Entity
regulate	O	O	B-Entity
SMAD7	O	O	O
expression	O	O	B-Entity
but	O	O	O
also	O	O	O
participate	O	O	O
in	O	O	O
EMT	O	O	B-Entity
via	O	O	O
SMAD7	O	O	O
,	O	O	O
because	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
SMAD7	O	O	O
could	O	O	O
partly	O	O	O
enhance	O	O	B-Entity
the	O	O	O
miR-424	O	O	O
-	O	O	O
5p	O	O	O
anti-EMT	O	O	B-Entity
function	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
described	O	O	O
that	O	O	O
miR-424	O	O	B-Entity
-	O	O	I-Entity
5p	O	O	I-Entity
-	O	O	O
SMAD7	O	O	B-Entity
pathway	O	O	B-Entity
contributed	O	O	O
to	O	O	O
ESCC	O	O	B-Entity
invasion	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
and	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
miR-424	O	O	O
-	O	O	O
5p	O	O	O
perhaps	O	O	O
provided	O	O	O
a	O	O	O
strategy	O	O	O
for	O	O	O
preventing	O	O	B-Entity
tumor	O	O	B-Entity
invasion	O	O	I-Entity
,	O	O	O
metastasis	O	O	O
.	O	O	O

-DOCSTART- (27628933)

Double-Network	O	O	B-Entity
Hydrogel	O	O	I-Entity
with	O	O	O
Tunable	O	O	B-Entity
Mechanical	O	O	B-Entity
Performance	O	O	I-Entity
and	O	O	O
Biocompatibility	O	O	B-Entity
for	O	O	O
the	O	O	O
Fabrication	O	O	B-Entity
of	O	O	O
Stem	O	O	B-Entity
Cells	O	O	I-Entity
-	O	O	O
Encapsulated	O	O	B-Entity
Fibers	O	O	I-Entity
and	O	O	O
3D	O	O	O
Assemble	O	O	O

Fabrication	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
-	O	O	O
encapsulated	O	O	B-Entity
fibers	O	O	I-Entity
could	O	O	O
greatly	O	O	O
contribute	O	O	B-Entity
to	O	O	O
tissue	O	O	B-Entity
engineering	O	O	I-Entity
and	O	O	O
regenerative	O	O	B-Entity
medicine	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
existing	O	O	B-Entity
methods	O	O	B-Entity
suffered	O	O	O
from	O	O	O
not	O	O	O
only	O	O	O
unavoidability	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
damaging	O	O	I-Entity
conditions	O	O	B-Entity
and/or	O	O	O
sophisticated	O	O	B-Entity
equipment	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
unavailability	O	O	B-Entity
of	O	O	O
proper	O	O	O
materials	O	O	B-Entity
to	O	O	O
satisfy	O	O	O
both	O	O	O
mechanical	O	O	B-Entity
and	O	O	O
biological	O	O	B-Entity
expectations	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	B-Entity
,	O	O	O
a	O	O	O
simple	O	O	B-Entity
method	O	O	B-Entity
is	O	O	O
proposed	O	O	B-Entity
to	O	O	O
prepare	O	O	B-Entity
cell	O	O	B-Entity
-	O	O	O
encapsulated	O	O	B-Entity
fibers	O	O	I-Entity
with	O	O	O
tunable	O	O	B-Entity
mechanical	O	O	B-Entity
strength	O	O	I-Entity
and	O	O	O
stretching	O	O	B-Entity
behavior	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
diameter	O	O	B-Entity
and	O	O	O
microstructure	O	O	B-Entity
.	O	O	O

The	O	O	O
hydrogel	O	O	B-Entity
fibers	O	O	B-Entity
are	O	O	O
made	O	O	O
from	O	O	O
optimal	O	O	B-Entity
combination	O	O	B-Entity
of	O	O	O
alginate	O	O	B-Entity
and	O	O	O
poly(N-iso-propylacrylamide)-poly(ethylene	O	O	B-Entity
glycol	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
characteristics	O	O	O
of	O	O	O
double-network	O	O	B-Entity
hydrogel	O	O	I-Entity
,	O	O	O
with	O	O	O
enough	O	O	O
stiffness	O	O	B-Entity
and	O	O	O
flexibility	O	O	B-Entity
to	O	O	O
create	O	O	B-Entity
a	O	O	O
variety	O	O	B-Entity
of	O	O	O
three	O	O	B-Entity
dimensional	O	O	I-Entity
structures	O	O	I-Entity
like	O	O	O
parallel	O	O	B-Entity
helical	O	O	I-Entity
and	O	O	O
different	O	O	B-Entity
knots	O	O	B-Entity
without	O	O	I-Entity
crack	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
such	O	O	O
hydrogel	O	O	B-Entity
fibers	O	O	B-Entity
exhibit	O	O	O
better	O	O	B-Entity
compatibility	O	O	B-Entity
as	O	O	O
indicated	O	O	B-Entity
by	O	O	O
the	O	O	O
viability	O	O	B-Entity
,	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
expression	O	O	B-Entity
of	O	O	O
pluripotency	O	O	B-Entity
markers	O	O	B-Entity
of	O	O	O
embryonic	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
encapsulated	O	O	B-Entity
after	O	O	O
4-day	O	O	B-Entity
culture	O	O	B-Entity
.	O	O	O

The	O	O	O
double-network	O	O	B-Entity
hydrogel	O	O	I-Entity
possesses	O	O	B-Entity
specific	O	O	B-Entity
quick	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
either	O	O	O
of	O	O	O
alginate	O	O	B-Entity
lyase	O	O	I-Entity
,	O	O	O
EDTA	O	O	B-Entity
or	O	O	O
lower	O	O	O
environmental	O	O	B-Entity
temperature	O	O	I-Entity
which	O	O	O
facilitate	O	O	O
the	O	O	O
optional	O	O	O
degradation	O	O	B-Entity
of	O	O	O
fibers	O	O	B-Entity
or	O	O	O
fibrous	O	O	B-Entity
assemblies	O	O	I-Entity
to	O	O	O
release	O	O	O
the	O	O	O
cells	O	O	B-Entity
encapsulated	O	O	B-Entity
for	O	O	O
subsequent	O	O	B-Entity
assay	O	O	B-Entity
or	O	O	O
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27629246)

Synchronous	O	O	B-Entity
vitellogenin	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
sexual	O	O	B-Entity
maturation	O	O	I-Entity
during	O	O	O
migration	O	O	B-Entity
are	O	O	O
negatively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
juvenile	O	O	B-Entity
hormone	O	O	I-Entity
levels	O	O	B-Entity
in	O	O	O
Mythimna	O	O	O
separata	O	O	O

Annual	O	O	O
migration	O	O	B-Entity
of	O	O	O
pests	O	O	B-Entity
between	O	O	O
different	O	O	B-Entity
seasonal	O	O	B-Entity
habitats	O	O	B-Entity
can	O	O	O
lead	O	O	B-Entity
to	O	O	O
serious	O	O	O
crop	O	O	B-Entity
damage	O	O	B-Entity
.	O	O	O

Reproductive	O	O	B-Entity
immaturity	O	O	B-Entity
is	O	O	O
generally	O	O	O
associated	O	O	O
with	O	O	O
the	O	O	O
migratory	O	O	B-Entity
process	O	O	I-Entity
(	O	O	O
oogenesis	O	O	B-Entity
-	O	O	O
flight	O	O	B-Entity
syndrome	O	O	I-Entity
)	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
reproductive	O	O	B-Entity
development	O	O	I-Entity
during	O	O	O
migration	O	O	B-Entity
varies	O	O	O
unpredictably	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
the	O	O	O
vitellogenin	O	O	B-Entity
gene	O	O	I-Entity
(	O	O	O
MsVg	O	O	B-Entity
)	O	O	O
and	O	O	O
three	O	O	O
key	O	O	B-Entity
regulatory	O	O	B-Entity
enzyme	O	O	I-Entity
genes	O	O	I-Entity
(	O	O	O
MsJhamt	O	O	B-Entity
,	O	O	O
MsJheh	O	O	B-Entity
and	O	O	O
MsJhe	O	O	B-Entity
)	O	O	O
related	O	O	O
to	O	O	O
juvenile	O	O	B-Entity
hormone	O	O	I-Entity
(	O	O	O
JH	O	O	B-Entity
)	O	O	O
synthesis	O	O	B-Entity
and	O	O	O
degradation	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
and	O	O	O
characterized	O	O	B-Entity
in	O	O	O
Mythimna	O	O	B-Entity
separata	O	O	I-Entity
.	O	O	O

The	O	O	O
relative	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
MsVg	O	O	B-Entity
varied	O	O	O
significantly	O	O	O
in	O	O	O
response	O	O	B-Entity
to	O	O	O
seasonal	O	O	B-Entity
changes	O	O	B-Entity
and	O	O	O
was	O	O	O
significantly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
stages	O	O	B-Entity
of	O	O	O
ovarian	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

The	O	O	O
relatively	O	O	O
low	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
JH	O	O	B-Entity
titer	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
differ	O	O	I-Entity
significantly	O	O	O
in	O	O	O
male	O	O	B-Entity
moths	O	O	B-Entity
but	O	O	O
slightly	O	O	O
increased	O	O	B-Entity
in	O	O	O
female	O	O	B-Entity
adults	O	O	I-Entity
during	O	O	O
the	O	O	O
migratory	O	O	B-Entity
season	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
changes	O	O	B-Entity
in	O	O	O
mRNA	O	O	B-Entity
levels	O	O	O
for	O	O	O
MsJhamt	O	O	B-Entity
,	O	O	O
MsJheh	O	O	B-Entity
and	O	O	O
MsJhe	O	O	B-Entity
.	O	O	O

JH	O	O	B-Entity
titer	O	O	B-Entity
was	O	O	O
negatively	O	O	B-Entity
associated	O	O	O
with	O	O	O
relative	O	O	O
seasonal	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
vitellogenin	O	O	B-Entity
mRNA	O	O	B-Entity
transcripts	O	O	B-Entity
and	O	O	O
with	O	O	O
ovarian	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
migrating	O	O	B-Entity
M.	O	O	B-Entity
separata	O	O	I-Entity
.	O	O	O

The	O	O	O
synchrony	O	O	B-Entity
of	O	O	O
MsVg	O	O	B-Entity
expression	O	O	I-Entity
with	O	O	O
sexual	O	O	B-Entity
maturation	O	O	I-Entity
highlighted	O	O	O
the	O	O	O
potential	O	O	B-Entity
of	O	O	O
MsVg	O	O	O
transcript	O	O	B-Entity
levels	O	O	B-Entity
to	O	O	O
serve	O	O	O
as	O	O	O
an	O	O	O
index	O	O	B-Entity
to	O	O	O
monitor	O	O	O
the	O	O	O
adult	O	O	B-Entity
reproductive	O	O	B-Entity
status	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
JH	O	O	B-Entity
and	O	O	O
sexual	O	O	B-Entity
maturity	O	O	I-Entity
were	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
extent	O	O	O
of	O	O	O
JH	O	O	O
in	O	O	O
regulating	O	O	B-Entity
the	O	O	O
MsVg	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
reproduction	O	O	B-Entity
during	O	O	O
seasonal	O	O	B-Entity
northern	O	O	B-Entity
and	O	O	I-Entity
southern	O	O	I-Entity
migration	O	O	B-Entity
.	O	O	O

-DOCSTART- (27631656)

Functional	O	O	B-Entity
Result	O	O	I-Entity
After	O	O	O
Cochlear	O	O	B-Entity
Implantation	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
and	O	O	O
Adults	O	O	B-Entity
With	O	O	O
Single-sided	O	O	O
Deafness	O	O	O

Patients	O	O	B-Entity
with	O	O	O
single-sided	O	O	B-Entity
deafness	O	O	I-Entity
(	O	O	O
SSD	O	O	B-Entity
)	O	O	O
suffer	O	O	O
from	O	O	O
reduced	O	O	B-Entity
binaural	O	O	B-Entity
hearing	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
sound	O	O	B-Entity
localization	O	O	I-Entity
and	O	O	O
speech	O	O	B-Entity
in	O	O	O
noise	O	O	B-Entity
discrimination	O	O	I-Entity
)	O	O	O
.	O	O	O

Cochlear	O	O	B-Entity
implantation	O	O	I-Entity
has	O	O	O
recently	O	O	O
been	O	O	O
introduced	O	O	O
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
SSD	O	O	B-Entity
,	O	O	O
as	O	O	O
an	O	O	O
alternative	O	O	B-Entity
to	O	O	O
hearing	O	O	B-Entity
devices	O	O	I-Entity
that	O	O	O
employ	O	O	O
contralateral	O	O	B-Entity
routing	O	O	O
of	O	O	O
the	O	O	O
signal	O	O	B-Entity
.	O	O	O

Application	O	O	B-Entity
to	O	O	O
children	O	O	B-Entity
has	O	O	O
also	O	O	O
been	O	O	O
started	O	O	O
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
analyze	O	O	O
a	O	O	O
case	O	O	O
series	O	O	O
of	O	O	O
4	O	O	O
children	O	O	B-Entity
and	O	O	O
17	O	O	O
adults	O	O	B-Entity
with	O	O	O
SSD	O	O	B-Entity
,	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
cochlear	O	O	B-Entity
implantation	O	O	I-Entity
.	O	O	O

The	O	O	O
outcome	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
was	O	O	O
compared	O	O	O
with	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
of	O	O	O
27	O	O	O
patients	O	O	O
with	O	O	O
bilateral	O	O	B-Entity
profound	O	O	I-Entity
hearing	O	O	I-Entity
loss	O	O	I-Entity
using	O	O	O
a	O	O	O
cochlear	O	O	B-Entity
implant	O	O	I-Entity
.	O	O	O

During	O	O	O
12	O	O	O
months	O	O	O
,	O	O	O
the	O	O	O
mean	O	O	B-Entity
speech	O	O	B-Entity
recognition	O	O	I-Entity
score	O	O	B-Entity
increased	O	O	O
from	O	O	O
30	O	O	O
to	O	O	O
41	O	O	O
%	O	O	O
for	O	O	O
monosyllabic	O	O	B-Entity
words	O	O	O
in	O	O	O
adults	O	O	B-Entity
,	O	O	O
and	O	O	O
from	O	O	O
58	O	O	O
to	O	O	O
89	O	O	O
%	O	O	O
for	O	O	O
multisyllabic	O	O	B-Entity
numbers	O	O	O
.	O	O	O

The	O	O	O
cochlear	O	O	B-Entity
implant	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
improved	O	O	B-Entity
hearing	O	O	I-Entity
in	O	O	O
noise	O	O	B-Entity
in	O	O	O
all	O	O	O
SSD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
as	O	O	O
was	O	O	O
demonstrated	O	O	O
by	O	O	O
a	O	O	O
significant	O	O	O
improvement	O	O	B-Entity
of	O	O	O
the	O	O	O
speech	O	O	B-Entity
reception	O	O	I-Entity
threshold	O	O	I-Entity
in	O	O	O
different	O	O	O
speech	O	O	O
and	O	O	O
noise	O	O	O
configurations	O	O	O
.	O	O	O

Sound	O	O	B-Entity
localization	O	O	I-Entity
-correlated	O	O	O
angle	O	O	B-Entity
detection	O	O	I-Entity
error	O	O	I-Entity
improved	O	O	B-Entity
with	O	O	O
CI	O	O	B-Entity
use	O	O	O
at	O	O	O
every	O	O	O
time	O	O	O
point	O	O	O
.	O	O	O

The	O	O	O
maximum	O	O	O
word	O	O	B-Entity
recognition	O	O	I-Entity
score	O	O	B-Entity
for	O	O	O
monosyllabic	O	O	B-Entity
words	O	O	O
in	O	O	O
quiet	O	O	O
correlated	O	O	O
with	O	O	O
the	O	O	O
logarithm	O	O	B-Entity
of	O	O	O
the	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
deafness	O	O	B-Entity
;	O	O	O
improvement	O	O	B-Entity
of	O	O	O
the	O	O	O
speech	O	O	B-Entity
reception	O	O	I-Entity
threshold	O	O	I-Entity
and	O	O	O
RMS	O	O	B-Entity
angle	O	O	I-Entity
detection	O	O	I-Entity
error	O	O	I-Entity
by	O	O	O
the	O	O	O
CI	O	O	B-Entity
did	O	O	O
not	O	O	O
.	O	O	O

All	O	O	O
SSD	O	O	B-Entity
patients	O	O	B-Entity
benefitted	O	O	O
from	O	O	O
the	O	O	O
CI	O	O	B-Entity
in	O	O	O
different	O	O	O
hearing	O	O	B-Entity
situations	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
SSD	O	O	B-Entity
for	O	O	O
a	O	O	O
long	O	O	O
period	O	O	O
can	O	O	O
improve	O	O	B-Entity
after	O	O	O
cochlear	O	O	B-Entity
implantation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27632714)

CHOROIDAL	O	O	B-Entity
VASCULARITY	O	O	I-Entity
INDEX	O	O	I-Entity
:	O	O	O
A	O	O	O
Novel	O	O	O
Optical	O	O	B-Entity
Coherence	O	O	I-Entity
Tomography	O	O	I-Entity
Based	O	O	O
Parameter	O	O	B-Entity
in	O	O	O
Patients	O	O	B-Entity
With	O	O	O
Exudative	O	O	O
Age-Related	O	O	O
Macular	O	O	O
Degeneration	O	O	O

To	O	O	O
evaluate	O	O	O
choroidal	O	O	B-Entity
structural	O	O	B-Entity
changes	O	O	O
in	O	O	O
exudative	O	O	B-Entity
age-related	O	O	I-Entity
macular	O	O	I-Entity
degeneration	O	O	I-Entity
(	O	O	O
AMD	O	O	B-Entity
)	O	O	O
using	O	O	O
choroidal	O	O	B-Entity
vascularity	O	O	I-Entity
index	O	O	I-Entity
computed	O	O	B-Entity
from	O	O	O
image	O	O	O
binarization	O	O	O
on	O	O	O
spectral	O	O	B-Entity
domain	O	O	I-Entity
optical	O	O	I-Entity
coherence	O	O	I-Entity
tomography	O	O	I-Entity
with	O	O	O
enhanced	O	O	O
depth	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

This	O	O	O
prospective	O	O	O
case	O	O	B-Entity
series	O	O	I-Entity
included	O	O	O
42	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
unilateral	O	O	B-Entity
exudative	O	O	B-Entity
AMD	O	O	I-Entity
.	O	O	O

Choroidal	O	O	B-Entity
images	O	O	B-Entity
were	O	O	O
segmented	O	O	O
into	O	O	O
luminal	O	O	B-Entity
area	O	O	B-Entity
and	O	O	O
stromal	O	O	O
area	O	O	O
.	O	O	O

Choroidal	O	O	B-Entity
vascularity	O	O	I-Entity
index	O	O	I-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
the	O	O	O
ratio	O	O	B-Entity
of	O	O	O
luminal	O	O	B-Entity
area	O	O	B-Entity
to	O	O	O
total	O	O	O
choroid	O	O	O
area	O	O	O
.	O	O	O

Mean	O	O	B-Entity
choroidal	O	O	B-Entity
vascularity	O	O	I-Entity
index	O	O	I-Entity
and	O	O	O
mean	O	O	B-Entity
choroidal	O	O	B-Entity
thickness	O	O	I-Entity
between	O	O	O
study	O	O	B-Entity
and	O	O	O
fellow	O	O	O
eyes	O	O	B-Entity
of	O	O	O
the	O	O	O
same	O	O	O
patient	O	O	B-Entity
with	O	O	O
dry	O	O	O
AMD	O	O	B-Entity
were	O	O	O
compared	O	O	O
using	O	O	O
Student	O	O	B-Entity
's	O	O	I-Entity
t-test	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
choroidal	O	O	B-Entity
vascularity	O	O	I-Entity
index	O	O	I-Entity
in	O	O	O
eyes	O	O	B-Entity
with	O	O	O
exudative	O	O	B-Entity
AMD	O	O	I-Entity
(	O	O	O
60.14	O	O	O
±	O	O	O
4.55	O	O	O
vs.	O	O	O
62.75	O	O	O
±	O	O	O
4.82	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Luminal	O	O	B-Entity
area	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
was	O	O	O
decreased	O	O	B-Entity
in	O	O	O
eyes	O	O	B-Entity
with	O	O	O
exudative	O	O	B-Entity
AMD	O	O	I-Entity
but	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
in	O	O	O
total	O	O	O
choroid	O	O	O
area	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.05	O	O	O
)	O	O	O
and	O	O	O
choroidal	O	O	O
thickness	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.93	O	O	O
)	O	O	O
between	O	O	O
study	O	O	B-Entity
and	O	O	O
fellow	O	O	O
eyes	O	O	O
.	O	O	O

Eyes	O	O	B-Entity
with	O	O	O
exudative	O	O	B-Entity
AMD	O	O	I-Entity
demonstrated	O	O	O
reduced	O	O	B-Entity
choroidal	O	O	B-Entity
vascularity	O	O	I-Entity
index	O	O	I-Entity
but	O	O	O
insignificant	O	O	O
differences	O	O	B-Entity
in	O	O	O
choroidal	O	O	O
thickness	O	O	O
compared	O	O	O
with	O	O	O
their	O	O	O
fellow	O	O	O
eyes	O	O	B-Entity
.	O	O	O

Choroidal	O	O	B-Entity
vascularity	O	O	I-Entity
index	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
potential	O	O	B-Entity
noninvasive	O	O	B-Entity
tool	O	O	I-Entity
for	O	O	O
studying	O	O	B-Entity
structural	O	O	B-Entity
changes	O	O	O
in	O	O	O
choroid	O	O	B-Entity
and	O	O	O
monitoring	O	O	O
choroidal	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
exudative	O	O	B-Entity
AMD	O	O	I-Entity
.	O	O	O

-DOCSTART- (27632886)

Comparison	O	O	B-Entity
of	O	O	O
Esophageal	O	O	B-Entity
,	O	O	O
Rectal	O	O	B-Entity
,	O	O	O
and	O	O	O
Gastrointestinal	O	O	B-Entity
Temperatures	O	O	B-Entity
During	O	O	O
Passive	O	O	B-Entity
Rest	O	O	I-Entity
After	O	O	O
Exercise	O	O	B-Entity
in	O	O	O
The	O	O	O
Heat	O	O	B-Entity
:	O	O	O
The	O	O	O
Influence	O	O	B-Entity
of	O	O	O
Hydration	O	O	O

It	O	O	O
is	O	O	O
unknown	O	O	O
how	O	O	O
valid	O	O	O
esophageal	O	O	B-Entity
,	O	O	O
rectal	O	O	B-Entity
,	O	O	O
and	O	O	O
gastrointestinal	O	O	B-Entity
temperatures	O	O	B-Entity
(	O	O	O
TES	O	O	B-Entity
,	O	O	O
TRE	O	O	B-Entity
,	O	O	O
and	O	O	O
TGI	O	O	B-Entity
)	O	O	O
compare	O	O	O
after	O	O	O
exercise-induced	O	O	B-Entity
hyperthermia	O	O	B-Entity
in	O	O	O
various	O	O	O
hydration	O	O	B-Entity
states	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
differences	O	O	O
between	O	O	O
TES	O	O	B-Entity
,	O	O	O
TRE	O	O	B-Entity
,	O	O	O
and	O	O	O
TGI	O	O	B-Entity
during	O	O	O
passive	O	O	B-Entity
rest	O	O	I-Entity
following	O	O	O
exercise-induced	O	O	B-Entity
hyperthermia	O	O	B-Entity
under	O	O	O
two	O	O	O
different	O	O	O
hydration	O	O	B-Entity
states	O	O	I-Entity
:	O	O	O
euhydrated	O	O	B-Entity
(	O	O	O
EU	O	O	B-Entity
)	O	O	O
and	O	O	O
hypohydrated	O	O	B-Entity
(	O	O	O
HY	O	O	B-Entity
)	O	O	O
.	O	O	O

Randomized-crossover	O	O	B-Entity
design	O	O	I-Entity
.	O	O	O

Controlled	O	O	B-Entity
laboratory	O	O	B-Entity
setting	O	O	I-Entity
.	O	O	O

Nine	O	O	O
recreationally	O	O	B-Entity
active	O	O	B-Entity
male	O	O	B-Entity
participants	O	O	B-Entity
(	O	O	O
mean±	O	O	O
SD	O	O	B-Entity
;	O	O	O
age	O	O	B-Entity
,	O	O	O
24±4	O	O	O
;	O	O	O
height	O	O	B-Entity
,	O	O	O
177.3±9.9	O	O	O
cm	O	O	O
;	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
,	O	O	O
76.7±11.6	O	O	O
kg	O	O	O
;	O	O	O
body	O	O	B-Entity
fat	O	O	I-Entity
,	O	O	O
14.7±5.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
completed	O	O	O
two	O	O	O
trials	O	O	B-Entity
(	O	O	O
EU	O	O	B-Entity
and	O	O	O
HY	O	O	B-Entity
)	O	O	O
consisting	O	O	O
of	O	O	O
a	O	O	O
bout	O	O	B-Entity
of	O	O	O
treadmill	O	O	B-Entity
exercise	O	O	I-Entity
(	O	O	O
a	O	O	O
10	O	O	O
minute	O	O	B-Entity
walk	O	O	O
ranging	O	O	B-Entity
4.8	O	O	O
-	O	O	O
7.2km·hr(-1	O	O	O
)	O	O	O
at	O	O	O
a	O	O	O
5	O	O	O
%	O	O	O
grade	O	O	B-Entity
followed	O	O	O
by	O	O	O
a	O	O	O
20	O	O	O
minute	O	O	O
jog	O	O	B-Entity
ranging	O	O	O
8.0	O	O	O
-	O	O	O
12.1km·hr(-1	O	O	O
)	O	O	O
at	O	O	O
a	O	O	O
1	O	O	O
%	O	O	O
grade	O	O	O
)	O	O	O
in	O	O	O
a	O	O	O
hot	O	O	B-Entity
environment	O	O	I-Entity
(	O	O	O
ambient	O	O	B-Entity
temperature	O	O	I-Entity
,	O	O	O
39.3±1.0	O	O	O
°	O	O	O
C	O	O	O
;	O	O	O
relative	O	O	B-Entity
humidity	O	O	I-Entity
,	O	O	O
37.6±6.0	O	O	O
%	O	O	O
;	O	O	O
wet	O	O	B-Entity
bulb	O	O	I-Entity
globe	O	O	I-Entity
temperature	O	O	I-Entity
,	O	O	O
31.3±1.5	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
followed	O	O	O
by	O	O	O
passive	O	O	B-Entity
rest	O	O	I-Entity
.	O	O	O

Root	O	O	B-Entity
mean	O	O	I-Entity
squared	O	O	I-Entity
difference	O	O	I-Entity
(	O	O	O
RMSD	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
compare	O	O	O
the	O	O	O
variance	O	O	B-Entity
of	O	O	O
temperature	O	O	B-Entity
readings	O	O	I-Entity
at	O	O	O
corresponding	O	O	O
time	O	O	B-Entity
points	O	O	I-Entity
for	O	O	O
TRE	O	O	B-Entity
vs	O	O	O
TGI	O	O	B-Entity
,	O	O	O
TRE	O	O	O
vs	O	O	O
TES	O	O	B-Entity
,	O	O	O
and	O	O	O
TGI	O	O	O
vs	O	O	O
TES	O	O	O
in	O	O	O
EU	O	O	B-Entity
and	O	O	O
HY	O	O	B-Entity
.	O	O	O

RMSD	O	O	B-Entity
values	O	O	O
were	O	O	O
compared	O	O	O
using	O	O	O
three-way	O	O	B-Entity
repeated	O	O	I-Entity
measures	O	O	I-Entity
ANOVA	O	O	I-Entity
.	O	O	O

Post	O	O	O
hoc	O	O	O
analysis	O	O	B-Entity
of	O	O	O
significant	O	O	O
main	O	O	O
effects	O	O	B-Entity
was	O	O	O
done	O	O	O
using	O	O	O
Tukey	O	O	B-Entity
's	O	O	I-Entity
HSD	O	O	I-Entity
with	O	O	O
significance	O	O	O
set	O	O	O
at	O	O	O
p<0.05	O	O	O
.	O	O	O

RMSD	O	O	B-Entity
values	O	O	I-Entity
(	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
for	O	O	O
all	O	O	O
device	O	O	B-Entity
comparisons	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
different	O	O	O
in	O	O	O
EU	O	O	B-Entity
(	O	O	O
TRE	O	O	B-Entity
-	O	O	O
TGI	O	O	B-Entity
,	O	O	O
0.11±0.12	O	O	O
;	O	O	O
TRE	O	O	O
-	O	O	O
TES	O	O	B-Entity
,	O	O	O
1.58±1.01	O	O	O
;	O	O	O
TGI	O	O	O
-	O	O	O
TES	O	O	O
,	O	O	O
2.04±1.19	O	O	O
)	O	O	O
than	O	O	O
HY	O	O	B-Entity
(	O	O	O
TRE	O	O	O
-	O	O	O
TGI	O	O	O
,	O	O	O
0.22±0.28	O	O	O
;	O	O	O
TRE	O	O	O
-	O	O	O
TES	O	O	O
,	O	O	O
1.27±0.61	O	O	O
;	O	O	O
TGI	O	O	O
-	O	O	O
TES	O	O	O
,	O	O	O
1.16±0.76	O	O	O
)	O	O	O
(	O	O	O
p<0.01	O	O	O
)	O	O	O
.	O	O	O

Across	O	O	O
the	O	O	O
45-	O	O	O
minute	O	O	B-Entity
bout	O	O	B-Entity
of	O	O	O
passive	O	O	B-Entity
rest	O	O	I-Entity
,	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
differences	O	O	O
in	O	O	O
TRE	O	O	B-Entity
,	O	O	O
TGI	O	O	B-Entity
and	O	O	O
TES	O	O	B-Entity
between	O	O	O
EU	O	O	B-Entity
and	O	O	O
HY	O	O	B-Entity
trials	O	O	B-Entity
(	O	O	O
p=0.468	O	O	O
)	O	O	O
.	O	O	O

During	O	O	O
passive	O	O	B-Entity
rest	O	O	I-Entity
after	O	O	O
exercise	O	O	B-Entity
in	O	O	O
the	O	O	O
heat	O	O	B-Entity
,	O	O	O
TRE	O	O	B-Entity
and	O	O	O
TGI	O	O	B-Entity
were	O	O	O
in	O	O	O
good	O	O	O
agreement	O	O	O
when	O	O	O
tracking	O	O	O
body	O	O	B-Entity
temperature	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
better	O	O	O
agreement	O	O	O
appearing	O	O	O
in	O	O	O
those	O	O	O
maintaining	O	O	O
a	O	O	O
state	O	O	O
of	O	O	O
euhydration	O	O	B-Entity
versus	O	O	O
those	O	O	O
who	O	O	O
became	O	O	O
hypohydrated	O	O	B-Entity
during	O	O	O
exercise	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
this	O	O	O
small	O	O	O
difference	O	O	O
does	O	O	O
not	O	O	O
appear	O	O	O
to	O	O	O
be	O	O	O
of	O	O	O
clinical	O	O	B-Entity
significance	O	O	I-Entity
.	O	O	O

-DOCSTART- (27633771)

Annexin	O	O	B-Entity
A1	O	O	I-Entity
restores	O	O	O
Aβ1	O	O	B-Entity
-	O	O	I-Entity
42	O	O	I-Entity
-induced	O	O	O
blood-brain	O	O	B-Entity
barrier	O	O	I-Entity
disruption	O	O	I-Entity
through	O	O	O
the	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
RhoA-ROCK	O	O	O
signaling	O	O	O
pathway	O	O	O

The	O	O	O
blood-brain	O	O	B-Entity
barrier	O	O	I-Entity
(	O	O	O
BBB	O	O	B-Entity
)	O	O	O
is	O	O	O
composed	O	O	O
of	O	O	O
brain	O	O	B-Entity
capillary	O	O	I-Entity
endothelial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
has	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
maintaining	O	O	O
homeostasis	O	O	B-Entity
of	O	O	O
the	O	O	O
brain	O	O	O
separating	O	O	O
the	O	O	O
blood	O	O	B-Entity
from	O	O	O
the	O	O	O
parenchyma	O	O	B-Entity
of	O	O	O
the	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
CNS	O	O	B-Entity
)	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
widely	O	O	O
known	O	O	O
that	O	O	O
disruption	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
BBB	O	O	I-Entity
occurs	O	O	O
in	O	O	O
various	O	O	O
neurodegenerative	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
including	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
.	O	O	O

Annexin	O	O	B-Entity
A1	O	O	I-Entity
(	O	O	O
ANXA1	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
anti-inflammatory	O	O	B-Entity
messenger	O	O	I-Entity
,	O	O	O
is	O	O	O
expressed	O	O	B-Entity
in	O	O	O
brain	O	O	B-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
regulates	O	O	O
the	O	O	O
BBB	O	O	B-Entity
integrity	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
role	O	O	O
and	O	O	O
mechanism	O	O	B-Entity
for	O	O	O
protecting	O	O	O
BBB	O	O	B-Entity
in	O	O	O
AD	O	O	B-Entity
have	O	O	O
not	O	O	O
been	O	O	O
identified	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
β-Amyloid	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
42	O	O	I-Entity
(Aβ42)-induced	O	O	O
BBB	O	O	B-Entity
disruption	O	O	I-Entity
was	O	O	O
rescued	O	O	O
by	O	O	O
human	O	O	B-Entity
recombinant	O	O	I-Entity
ANXA1	O	O	I-Entity
(	O	O	O
hrANXA1	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
murine	O	O	B-Entity
brain	O	O	O
endothelial	O	O	O
cell	O	O	O
line	O	O	O
bEnd.3	O	O	O
.	O	O	O

Also	O	O	O
,	O	O	O
ANXA1	O	O	B-Entity
was	O	O	O
decreased	O	O	O
in	O	O	O
the	O	O	O
bEnd.3	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
the	O	O	O
capillaries	O	O	B-Entity
of	O	O	O
5XFAD	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
human	O	O	B-Entity
serum	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
AD	O	O	B-Entity
.	O	O	O

To	O	O	O
find	O	O	O
out	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
by	O	O	O
which	O	O	O
ANXA1	O	O	B-Entity
recovers	O	O	O
the	O	O	O
BBB	O	O	B-Entity
integrity	O	O	O
in	O	O	O
AD	O	O	B-Entity
,	O	O	O
the	O	O	O
RhoA-ROCK	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
was	O	O	O
examined	O	O	O
in	O	O	O
both	O	O	O
Aβ42	O	O	B-Entity
-treated	O	O	O
bEnd.3	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
the	O	O	O
capillaries	O	O	B-Entity
of	O	O	O
5XFAD	O	O	B-Entity
mice	O	O	I-Entity
as	O	O	O
RhoA	O	O	B-Entity
was	O	O	O
activated	O	O	B-Entity
in	O	O	O
both	O	O	O
cases	O	O	O
.	O	O	O

RhoA	O	O	B-Entity
inhibitors	O	O	I-Entity
alleviated	O	O	O
Aβ42	O	O	B-Entity
-induced	O	O	O
BBB	O	O	B-Entity
disruption	O	O	I-Entity
and	O	O	O
constitutively	O	O	O
overexpressed	O	O	B-Entity
RhoA-GTP	O	O	B-Entity
(	O	O	O
active	O	O	O
form	O	O	O
of	O	O	O
RhoA	O	O	O
)	O	O	O
attenuated	O	O	O
the	O	O	O
protective	O	O	O
effect	O	O	O
of	O	O	O
ANXA1	O	O	B-Entity
.	O	O	O

When	O	O	O
pericytes	O	O	B-Entity
were	O	O	O
cocultured	O	O	B-Entity
with	O	O	O
bEnd.3	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
Aβ42	O	O	B-Entity
-induced	O	O	O
RhoA	O	O	B-Entity
activation	O	O	I-Entity
of	O	O	O
bEnd.3	O	O	O
cells	O	O	O
was	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
the	O	O	O
secretion	O	O	B-Entity
of	O	O	O
ANXA1	O	O	B-Entity
from	O	O	O
pericytes	O	O	O
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
ANXA1	O	O	B-Entity
restores	O	O	O
Aβ42	O	O	B-Entity
-induced	O	O	O
BBB	O	O	B-Entity
disruption	O	O	I-Entity
through	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
RhoA-ROCK	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
and	O	O	O
we	O	O	O
propose	O	O	O
ANXA1	O	O	O
as	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
reagent	O	O	I-Entity
,	O	O	O
protecting	O	O	O
against	O	O	O
the	O	O	O
breakdown	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
BBB	O	O	I-Entity
in	O	O	O
AD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27634799)

Association	O	O	B-Entity
of	O	O	O
kidney	O	O	B-Entity
disease	O	O	I-Entity
with	O	O	O
obstructive	O	O	B-Entity
sleep	O	O	I-Entity
apnea	O	O	I-Entity
in	O	O	O
a	O	O	O
population	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
men	O	O	O

To	O	O	O
determine	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
obstructive	O	O	B-Entity
sleep	O	O	I-Entity
apnea	O	O	I-Entity
(	O	O	O
OSA	O	O	B-Entity
)	O	O	O
and	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CKD	O	O	B-Entity
)	O	O	O
.	O	O	O

Previous	O	O	O
population	O	O	B-Entity
studies	O	O	B-Entity
of	O	O	O
the	O	O	O
association	O	O	B-Entity
are	O	O	O
sparse	O	O	B-Entity
,	O	O	O
conflicting	O	O	B-Entity
and	O	O	O
confined	O	O	B-Entity
largely	O	O	O
to	O	O	O
studies	O	O	O
of	O	O	O
administrative	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

Cross-sectional	O	O	B-Entity
analysis	O	O	I-Entity
in	O	O	O
unselected	O	O	O
participants	O	O	B-Entity
of	O	O	O
the	O	O	O
Men	O	O	B-Entity
Androgens	O	O	I-Entity
Inflammation	O	O	I-Entity
Lifestyle	O	O	I-Entity
Environment	O	O	I-Entity
and	O	O	I-Entity
Stress	O	O	I-Entity
(	O	O	I-Entity
MAILES	O	O	I-Entity
)	O	O	I-Entity
study	O	O	I-Entity
,	O	O	O
aged	O	O	B-Entity
>	O	O	O
40	O	O	O
y.	O	O	O
Renal	O	O	B-Entity
data	O	O	B-Entity
were	O	O	O
available	O	O	O
on	O	O	O
812	O	O	O
men	O	O	B-Entity
without	O	O	O
a	O	O	O
prior	O	O	B-Entity
OSA	O	O	B-Entity
diagnosis	O	O	B-Entity
who	O	O	O
underwent	O	O	O
full	O	O	O
in-home	O	O	B-Entity
polysomnography	O	O	B-Entity
(	O	O	O
Embletta	O	O	B-Entity
X100	O	O	I-Entity
)	O	O	O
in	O	O	O
2010	O	O	O
-	O	O	O
2011	O	O	O
.	O	O	O

CKD	O	O	B-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
an	O	O	O
estimated	O	O	B-Entity
glomerular	O	O	I-Entity
filtration	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
eGFR	O	O	B-Entity
)	O	O	O
<	O	O	O
60	O	O	O
mL/min/1.73m2	O	O	O
or	O	O	O
eGFR	O	O	O
≥60	O	O	O
and	O	O	O
albuminuria	O	O	B-Entity
(	O	O	O
albumin	O	O	B-Entity
creatinine	O	O	I-Entity
ratio	O	O	I-Entity
≥3.0	O	O	O
mg/mmol	O	O	O
)	O	O	O
.	O	O	O

CKD	O	O	B-Entity
[	O	O	O
10.5	O	O	O
%	O	O	O
,	O	O	O
n=85	O	O	O
(	O	O	O
Stage	O	O	B-Entity
1	O	O	O
-	O	O	O
3	O	O	O
,	O	O	O
9.7	O	O	O
%	O	O	O
;	O	O	O
Stage	O	O	O
4	O	O	O
-	O	O	O
5	O	O	O
,	O	O	O
0.7	O	O	O
%	O	O	O
)	O	O	O
]	O	O	O
of	O	O	O
predominantly	O	O	B-Entity
mild	O	O	B-Entity
severity	O	O	I-Entity
showed	O	O	O
significant	O	O	B-Entity
association	O	O	B-Entity
s	O	O	O
with	O	O	O
OSA	O	O	B-Entity
(	O	O	O
AHI≥10	O	O	O
):	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
(OR)=1.9	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(CI):1.02	O	O	O
-	O	O	O
3.5	O	O	O
,	O	O	O
severe	O	O	B-Entity
OSA	O	O	O
(	O	O	O
AHI	O	O	O
≥30/h	O	O	O
):	O	O	O
OR	O	O	B-Entity
=	O	O	O
2.6	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI:1.1	O	O	O
-	O	O	O
6.2	O	O	O
,	O	O	O
and	O	O	O
respiratory	O	O	B-Entity
related	O	O	O
arousal	O	O	B-Entity
index	O	O	B-Entity
:	O	O	O
≥7.6/h	O	O	O
OR	O	O	O
=	O	O	O
2.3	O	O	O
,	O	O	O
95%CI	O	O	O
:	O	O	O
1.1	O	O	O
-	O	O	O
4.7	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
measures	O	O	B-Entity
of	O	O	O
hypoxemia	O	O	B-Entity
after	O	O	O
adjustment	O	O	B-Entity
for	O	O	O
age	O	O	B-Entity
,	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
smoking	O	O	B-Entity
,	O	O	O
obesity	O	O	B-Entity
,	O	O	O
and	O	O	O
NSAID	O	O	B-Entity
use	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
association	O	O	B-Entity
of	O	O	O
CKD	O	O	B-Entity
with	O	O	O
daytime	O	O	B-Entity
sleepiness	O	O	I-Entity
.	O	O	O

In	O	O	O
men	O	O	B-Entity
with	O	O	O
CKD	O	O	B-Entity
,	O	O	O
those	O	O	O
with	O	O	O
OSA	O	O	B-Entity
were	O	O	O
not	O	O	B-Entity
significantly	O	O	I-Entity
more	O	O	B-Entity
likely	O	O	B-Entity
to	O	O	O
report	O	O	B-Entity
symptoms	O	O	B-Entity
(	O	O	O
sleepiness	O	O	B-Entity
,	O	O	O
snoring	O	O	B-Entity
,	O	O	O
apneas	O	O	B-Entity
)	O	O	O
or	O	O	O
be	O	O	O
identified	O	O	B-Entity
with	O	O	O
the	O	O	O
STOP	O	O	B-Entity
OSA	O	O	I-Entity
screening	O	O	I-Entity
questionnaire	O	O	I-Entity
,	O	O	O
compared	O	O	O
to	O	O	O
men	O	O	O
without	O	O	O
OSA	O	O	O
.	O	O	O

Predominantly	O	O	B-Entity
mild	O	O	B-Entity
CKD	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
severe	O	O	B-Entity
OSA	O	O	B-Entity
and	O	O	O
arousals	O	O	B-Entity
.	O	O	O

Further	O	O	O
population	O	O	B-Entity
studies	O	O	I-Entity
examining	O	O	B-Entity
the	O	O	O
longitudinal	O	O	B-Entity
relationship	O	O	B-Entity
between	O	O	O
CKD	O	O	B-Entity
and	O	O	O
OSA	O	O	B-Entity
are	O	O	O
warranted	O	O	B-Entity
.	O	O	O

Better	O	O	O
methods	O	O	B-Entity
are	O	O	O
needed	O	O	B-Entity
to	O	O	O
identify	O	O	B-Entity
OSA	O	O	B-Entity
in	O	O	O
CKD	O	O	B-Entity
which	O	O	O
may	O	O	O
have	O	O	O
few	O	O	B-Entity
symptoms	O	O	B-Entity
.	O	O	O

-DOCSTART- (27634880)

Evidence	O	O	O
that	O	O	O
vitronectin	O	O	B-Entity
is	O	O	O
a	O	O	O
potent	O	O	O
migration-enhancing	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
chaperoned	O	O	B-Entity
by	O	O	O
fibrinogen	O	O	B-Entity
:	O	O	O
a	O	O	O
novel	O	O	O
view	O	O	O
of	O	O	O
the	O	O	O
metastasis	O	O	B-Entity
of	O	O	O
cancer	O	O	O
cells	O	O	O
to	O	O	O
low-	O	O	O
fibrinogen	O	O	O
lymphatics	O	O	B-Entity
and	O	O	O
body	O	O	O
cavities	O	O	O

Diluted	O	O	B-Entity
(	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
plasma	O	O	B-Entity
induces	O	O	O
migration	O	O	B-Entity
of	O	O	O
malignant	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
much	O	O	O
more	O	O	O
strongly	O	O	O
than	O	O	O
potent	O	O	O
pro-metastatic	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

To	O	O	O
characterize	O	O	O
the	O	O	O
factor(s	O	O	B-Entity
)	O	O	I-Entity
present	O	O	O
in	O	O	O
diluted	O	O	B-Entity
plasma	O	O	B-Entity
responsible	O	O	O
for	O	O	O
this	O	O	O
phenomenon	O	O	B-Entity
we	O	O	O
performed	O	O	O
i	O	O	O
)	O	O	O
heat	O	O	B-Entity
inactivation	O	O	B-Entity
,	O	O	O
ii	O	O	O
)	O	O	O
dialysis	O	O	B-Entity
,	O	O	O
iii	O	O	O
)	O	O	O
proteinase	O	O	B-Entity
K	O	O	I-Entity
treatment	O	O	B-Entity
,	O	O	O
and	O	O	O
iv	O	O	O
)	O	O	O
molecular	O	O	B-Entity
size	O	O	I-Entity
filtration	O	O	I-Entity
studies	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
this	O	O	O
remarkable	O	O	O
pro-migratory	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
diluted	O	O	B-Entity
normal	O	O	O
plasma	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
~50	O	O	O
-	O	O	O
100-kD	O	O	O
protein	O	O	B-Entity
that	O	O	O
interacts	O	O	O
with	O	O	O
GαI	O	O	B-Entity
protein-coupled	O	O	I-Entity
receptors	O	O	I-Entity
and	O	O	O
activates	O	O	O
p42/44	O	O	B-Entity
MAPK	O	O	I-Entity
and	O	O	O
AKT	O	O	B-Entity
signaling	O	O	I-Entity
in	O	O	O
target	O	O	O
cells	O	O	B-Entity
.	O	O	O

Since	O	O	O
this	O	O	O
pro-migratory	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
1	O	O	O
%	O	O	O
plasma	O	O	B-Entity
decreases	O	O	O
at	O	O	O
higher	O	O	O
plasma	O	O	B-Entity
concentrations	O	O	I-Entity
(	O	O	O
>	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
is	O	O	O
retained	O	O	O
in	O	O	O
serum	O	O	B-Entity
,	O	O	O
we	O	O	O
hypothesized	O	O	O
that	O	O	O
fibrinogen	O	O	B-Entity
may	O	O	O
be	O	O	O
involved	O	O	O
as	O	O	O
a	O	O	O
chaperone	O	O	B-Entity
of	O	O	O
the	O	O	O
protein(s	O	O	B-Entity
)	O	O	I-Entity
.	O	O	O

To	O	O	O
identify	O	O	O
the	O	O	O
pro-migratory	O	O	B-Entity
protein(s	O	O	I-Entity
)	O	O	I-Entity
present	O	O	O
in	O	O	O
diluted	O	O	B-Entity
plasma	O	O	B-Entity
and	O	O	O
fibrinogen	O	O	B-Entity
-depleted	O	O	O
serum	O	O	B-Entity
,	O	O	O
we	O	O	O
performed	O	O	O
gel	O	O	B-Entity
filtration	O	O	I-Entity
and	O	O	O
hydrophobic	O	O	B-Entity
interaction	O	O	I-Entity
chromatography	O	O	I-Entity
followed	O	O	O
by	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
several	O	O	O
putative	O	O	O
protein	O	O	B-Entity
candidates	O	O	O
that	O	O	O
were	O	O	O
further	O	O	O
tested	O	O	O
in	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
experiments	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
this	O	O	O
pro-migratory	O	O	B-Entity
factor	O	O	I-Entity
chaperoned	O	O	B-Entity
by	O	O	O
fibrinogen	O	O	B-Entity
is	O	O	O
vitronectin	O	O	B-Entity
,	O	O	O
which	O	O	O
activates	O	O	O
uPAR	O	O	O
,	O	O	O
and	O	O	O
that	O	O	O
this	O	O	O
effect	O	O	O
can	O	O	O
be	O	O	O
inhibited	O	O	O
by	O	O	O
fibrinogen	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
provide	O	O	O
a	O	O	O
novel	O	O	O
mechanism	O	O	B-Entity
for	O	O	O
the	O	O	O
metastasis	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
to	O	O	O
lymphatics	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
cavities	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
fibrinogen	O	O	B-Entity
is	O	O	O
low	O	O	O
,	O	O	O
and	O	O	O
thus	O	O	O
suggests	O	O	O
that	O	O	O
free	O	O	O
vitronectin	O	O	B-Entity
stimulates	O	O	O
migration	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (27636378)

Development	O	O	B-Entity
and	O	O	O
initial	O	O	B-Entity
validation	O	O	B-Entity
of	O	O	O
the	O	O	O
Respirator	O	O	B-Entity
Comfort	O	O	B-Entity
,	O	O	O
Wearing	O	O	B-Entity
Experience	O	O	I-Entity
,	O	O	O
and	O	O	O
Function	O	O	B-Entity
Instrument	O	O	B-Entity
[	O	O	O
R-COMFI	O	O	O

Filtering	O	O	B-Entity
face-piece	O	O	I-Entity
respirators	O	O	I-Entity
(	O	O	O
FFRs	O	O	B-Entity
)	O	O	O
are	O	O	O
worn	O	O	O
to	O	O	O
protect	O	O	B-Entity
health	O	O	B-Entity
care	O	O	I-Entity
personnel	O	O	I-Entity
from	O	O	O
airborne	O	O	B-Entity
particles	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
clinical	O	O	B-Entity
studies	O	O	I-Entity
have	O	O	O
demonstrated	O	O	O
that	O	O	O
FFR	O	O	B-Entity
adherence	O	O	B-Entity
is	O	O	O
relatively	O	O	O
low	O	O	B-Entity
in	O	O	O
some	O	O	O
settings	O	O	O
,	O	O	O
in	O	O	O
part	O	O	B-Entity
,	O	O	O
due	O	O	O
to	O	O	O
discomfort	O	O	B-Entity
and	O	O	O
intolerance	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
develop	O	O	O
and	O	O	O
initially	O	O	B-Entity
evaluate	O	O	B-Entity
the	O	O	O
psychometric	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
an	O	O	O
instrument	O	O	B-Entity
designed	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
comfort	O	O	B-Entity
and	O	O	O
tolerability	O	O	B-Entity
of	O	O	O
FFRs	O	O	B-Entity
.	O	O	O

Instrument	O	O	B-Entity
items	O	O	O
were	O	O	O
developed	O	O	O
through	O	O	O
literature	O	O	B-Entity
reviews	O	O	I-Entity
,	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
and	O	O	O
several	O	O	B-Entity
iterations	O	O	B-Entity
of	O	O	O
ranking	O	O	B-Entity
and	O	O	O
refining	O	O	O
by	O	O	O
experts	O	O	B-Entity
.	O	O	O

Psychometric	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
the	O	O	O
instrument	O	O	B-Entity
was	O	O	O
conducted	O	O	O
using	O	O	O
Rasch	O	O	B-Entity
partial	O	O	I-Entity
credit	O	O	I-Entity
model	O	O	I-Entity
(	O	O	O
PCM	O	O	B-Entity
)	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Pivot	O	O	B-Entity
anchoring	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
specify	O	O	O
the	O	O	O
threshold	O	O	B-Entity
defining	O	O	O
item	O	O	O
difficulty	O	O	B-Entity
;	O	O	O
in	O	O	O
our	O	O	O
analyses	O	O	B-Entity
,	O	O	O
this	O	O	O
was	O	O	O
the	O	O	O
point	O	O	B-Entity
that	O	O	O
participants	O	O	B-Entity
moved	O	O	O
from	O	O	O
possessing	O	O	B-Entity
none	O	O	O
of	O	O	O
the	O	O	O
trait	O	O	B-Entity
to	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
trait	O	O	O
.	O	O	O

The	O	O	O
final	O	O	B-Entity
instrument	O	O	B-Entity
was	O	O	O
completed	O	O	B-Entity
by	O	O	O
165	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
personnel	O	O	I-Entity
from	O	O	O
3	O	O	O
Veterans	O	O	B-Entity
Health	O	O	B-Entity
Administration	O	O	I-Entity
facilities	O	O	I-Entity
,	O	O	O
and	O	O	O
data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
Rasch	O	O	B-Entity
PCM	O	O	I-Entity
.	O	O	O

Seven	O	O	O
items	O	O	O
were	O	O	O
removed	O	O	B-Entity
because	O	O	O
they	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
violated	O	O	B-Entity
the	O	O	I-Entity
assumption	O	O	I-Entity
of	O	O	I-Entity
independence	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
were	O	O	O
mis-fitting	O	O	B-Entity
;	O	O	O
and/or	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
were	O	O	O
deemed	O	O	O
not	O	O	B-Entity
relevant	O	O	I-Entity
.	O	O	O

Category	O	O	B-Entity
function	O	O	B-Entity
analysis	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
all	O	O	O
categories	O	O	B-Entity
progressed	O	O	B-Entity
monotonically	O	O	B-Entity
.	O	O	O

Principal	O	O	B-Entity
components	O	O	I-Entity
analysis	O	O	I-Entity
demonstrated	O	O	O
the	O	O	O
existence	O	O	B-Entity
of	O	O	O
three	O	O	O
subscales	O	O	B-Entity
(	O	O	O
Discomfort	O	O	B-Entity
,	O	O	O
General	O	O	O
Wearing	O	O	B-Entity
Experience	O	O	I-Entity
,	O	O	O
and	O	O	O
Function	O	O	B-Entity
)	O	O	O
.	O	O	O

Final	O	O	B-Entity
reliability	O	O	B-Entity
analyses	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
scale	O	O	B-Entity
had	O	O	O
moderate	O	O	B-Entity
to	O	O	O
high	O	O	B-Entity
person	O	O	I-Entity
reliability	O	O	I-Entity
and	O	O	O
high	O	O	O
item	O	O	O
reliability	O	O	O
.	O	O	O

The	O	O	O
final	O	O	O
instrument	O	O	B-Entity
contained	O	O	B-Entity
21	O	O	O
items	O	O	O
.	O	O	O

Until	O	O	O
now	O	O	O
,	O	O	O
to	O	O	O
our	O	O	O
knowledge	O	O	B-Entity
no	O	O	O
instrument	O	O	B-Entity
with	O	O	O
evidence	O	O	B-Entity
supporting	O	O	O
its	O	O	O
reliability	O	O	B-Entity
and	O	O	I-Entity
validity	O	O	I-Entity
to	O	O	O
assess	O	O	B-Entity
discomfort	O	O	B-Entity
and	O	O	O
tolerance	O	O	B-Entity
of	O	O	O
FFRs	O	O	B-Entity
among	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
personnel	O	O	I-Entity
has	O	O	O
been	O	O	O
published	O	O	B-Entity
.	O	O	O

A	O	O	O
21-item	O	O	O
psychometrically	O	O	B-Entity
sound	O	O	I-Entity
measure	O	O	I-Entity
of	O	O	O
comfort	O	O	B-Entity
and	O	O	O
tolerability	O	O	B-Entity
of	O	O	O
FFRs	O	O	B-Entity
,	O	O	O
Respirator	O	O	B-Entity
Comfort	O	O	B-Entity
,	O	O	O
Wearing	O	O	B-Entity
Experience	O	O	I-Entity
,	O	O	O
and	O	O	O
Function	O	O	B-Entity
Instrument	O	O	B-Entity
(	O	O	O
R-COMFI	O	O	B-Entity
)	O	O	O
,	O	O	O
was	O	O	O
developed	O	O	O
.	O	O	O

The	O	O	O
significance	O	O	B-Entity
of	O	O	O
developing	O	O	O
such	O	O	O
an	O	O	O
instrument	O	O	B-Entity
is	O	O	O
that	O	O	O
it	O	O	O
will	O	O	O
help	O	O	O
identify	O	O	O
respirators	O	O	B-Entity
that	O	O	O
are	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
better	O	O	O
adherence	O	O	B-Entity
in	O	O	O
practice	O	O	B-Entity
settings	O	O	O
.	O	O	O

The	O	O	O
R-COMFI	O	O	B-Entity
may	O	O	O
be	O	O	O
used	O	O	O
within	O	O	B-Entity
and	O	O	O
beyond	O	O	O
the	O	O	O
VA	O	O	B-Entity
healthcare	O	O	I-Entity
system	O	O	I-Entity
as	O	O	O
a	O	O	O
psychometrically	O	O	B-Entity
sound	O	O	I-Entity
instrument	O	O	I-Entity
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
comfort	O	O	B-Entity
and	O	O	O
tolerability	O	O	B-Entity
of	O	O	O
respirators	O	O	B-Entity
,	O	O	O
including	O	O	O
developmental	O	O	B-Entity
prototypes	O	O	O
.	O	O	O

-DOCSTART- (27638250)

Kidney	O	O	B-Entity
transplant	O	O	I-Entity
recipients	O	O	I-Entity
after	O	O	O
nonrenal	O	O	B-Entity
solid	O	O	I-Entity
organ	O	O	I-Entity
transplantation	O	O	I-Entity
show	O	O	O
low	O	O	O
alloreactivity	O	O	B-Entity
but	O	O	O
an	O	O	O
increased	O	O	O
risk	O	O	B-Entity
of	O	O	O
infection	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
kidney	O	O	B-Entity
transplant	O	O	I-Entity
recipients	O	O	I-Entity
(	O	O	O
KTRs	O	O	B-Entity
)	O	O	O
after	O	O	O
nonrenal	O	O	B-Entity
solid	O	O	I-Entity
organ	O	O	I-Entity
transplantation	O	O	I-Entity
(	O	O	O
SOT	O	O	B-Entity
)	O	O	O
has	O	O	O
increased	O	O	O
to	O	O	O
almost	O	O	O
5	O	O	O
%	O	O	O
.	O	O	O

Knowledge	O	O	O
on	O	O	O
patient	O	O	B-Entity
and	O	O	O
allograft	O	O	B-Entity
outcomes	O	O	B-Entity
,	O	O	O
infections	O	O	B-Entity
,	O	O	O
and	O	O	O
alloreactivity	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
remains	O	O	O
scarce	O	O	O
.	O	O	O

We	O	O	O
studied	O	O	B-Entity
40	O	O	O
KTRs	O	O	B-Entity
after	O	O	O
nonrenal	O	O	B-Entity
SOT	O	O	I-Entity
.	O	O	O

Seven	O	O	O
hundred	O	O	O
and	O	O	O
twenty	O	O	O
primary	O	O	O
KTRs	O	O	B-Entity
and	O	O	O
119	O	O	O
repeat	O	O	O
KTRs	O	O	O
were	O	O	O
used	O	O	O
for	O	O	O
comparison	O	O	O
.	O	O	O

Samples	O	O	B-Entity
were	O	O	O
collected	O	O	O
pretransplantation	O	O	B-Entity
,	O	O	O
at	O	O	O
+	O	O	O
1	O	O	O
,	O	O	O
+	O	O	O
2	O	O	O
,	O	O	O
and	O	O	O
+	O	O	O
3	O	O	O
months	O	O	O
post-transplantation	O	O	B-Entity
.	O	O	O

Alloreactive	O	O	B-Entity
and	O	O	O
CMV-specific	O	O	B-Entity
T	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
measured	O	O	O
by	O	O	O
interferon-γ	O	O	B-Entity
ELISPOT	O	O	I-Entity
assay	O	O	I-Entity
.	O	O	O

Patient	O	O	B-Entity
survival	O	O	B-Entity
in	O	O	O
KTRs	O	O	B-Entity
after	O	O	O
SOT	O	O	B-Entity
,	O	O	O
primary	O	O	O
and	O	O	O
repeat	O	O	O
KTRs	O	O	O
was	O	O	O
comparable	O	O	O
.	O	O	O

While	O	O	O
death	O	O	B-Entity
-censored	O	O	O
allograft	O	O	B-Entity
survival	O	O	B-Entity
was	O	O	O
comparable	O	O	O
between	O	O	O
KTRs	O	O	B-Entity
after	O	O	O
SOT	O	O	B-Entity
and	O	O	O
primary	O	O	O
KTRs	O	O	O
,	O	O	O
KTRs	O	O	O
after	O	O	O
SOT	O	O	O
showed	O	O	O
superior	O	O	O
5-year	O	O	B-Entity
death	O	O	O
-censored	O	O	O
allograft	O	O	O
survival	O	O	O
of	O	O	O
92.5	O	O	O
%	O	O	O
compared	O	O	O
to	O	O	O
81.2	O	O	O
%	O	O	O
in	O	O	O
repeat	O	O	O
KTRs	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
KTRs	O	O	B-Entity
after	O	O	O
SOT	O	O	B-Entity
show	O	O	O
less	O	O	O
preformed	O	O	O
panel-reactive	O	O	B-Entity
antibodies	O	O	I-Entity
,	O	O	O
frequencies	O	O	B-Entity
of	O	O	O
alloreactive	O	O	B-Entity
T	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
acute	O	O	B-Entity
rejections	O	O	I-Entity
compared	O	O	O
to	O	O	O
repeat	O	O	O
KTRs	O	O	O
.	O	O	O

KTRs	O	O	B-Entity
after	O	O	O
SOT	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
show	O	O	O
higher	O	O	O
incidences	O	O	B-Entity
of	O	O	O
EBV	O	O	B-Entity
viremia	O	O	I-Entity
and	O	O	O
PTLD	O	O	B-Entity
,	O	O	O
sepsis	O	O	B-Entity
,	O	O	O
and	O	O	O
death	O	O	B-Entity
from	O	O	O
sepsis	O	O	O
.	O	O	O

Impaired	O	O	O
CMV-specific	O	O	B-Entity
cellular	O	O	B-Entity
immunity	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
more	O	O	O
CMV	O	O	B-Entity
replication	O	O	B-Entity
compared	O	O	O
to	O	O	O
repeat	O	O	O
KTRs	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
comparable	O	O	O
patient	O	O	B-Entity
and	O	O	O
allograft	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
KTRs	O	O	B-Entity
after	O	O	O
SOT	O	O	B-Entity
and	O	O	O
primary	O	O	O
KTRs	O	O	O
.	O	O	O

The	O	O	O
observed	O	O	O
low	O	O	O
alloreactivity	O	O	B-Entity
may	O	O	O
contribute	O	O	O
to	O	O	O
excellent	O	O	O
allograft	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Caution	O	O	O
should	O	O	O
be	O	O	O
taken	O	O	O
in	O	O	O
KTRs	O	O	B-Entity
after	O	O	O
SOT	O	O	B-Entity
regarding	O	O	O
infectious	O	O	B-Entity
complications	O	O	I-Entity
due	O	O	O
to	O	O	O
overimmunosuppression	O	O	B-Entity
.	O	O	O

-DOCSTART- (27639061)

Improved	O	O	B-Entity
protocol	O	O	B-Entity
for	O	O	O
the	O	O	O
isolation	O	O	B-Entity
of	O	O	O
naïve	O	O	O
follicular	O	O	O
dendritic	O	O	O
cells	O	O	O

Follicular	O	O	B-Entity
dendritic	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
FDCs	O	O	B-Entity
)	O	O	O
in	O	O	O
lymphoid	O	O	B-Entity
organs	O	O	I-Entity
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	B-Entity
in	O	O	O
the	O	O	O
humoral	O	O	B-Entity
immune	O	O	I-Entity
response	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
because	O	O	O
the	O	O	O
isolation	O	O	B-Entity
of	O	O	O
FDCs	O	O	B-Entity
is	O	O	O
difficult	O	O	B-Entity
due	O	O	O
to	O	O	O
their	O	O	O
very	O	O	O
small	O	O	B-Entity
population	O	O	B-Entity
size	O	O	I-Entity
and	O	O	O
fragility	O	O	B-Entity
under	O	O	O
mechanical	O	O	B-Entity
and	O	O	O
chemical	O	O	B-Entity
stresses	O	O	I-Entity
,	O	O	O
the	O	O	O
genetic	O	O	B-Entity
and	O	O	O
biochemical	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
FDCs	O	O	O
remain	O	O	O
unclear	O	O	B-Entity
.	O	O	O

Previously	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	O
FDCs	O	O	B-Entity
as	O	O	O
ICAM-1(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	B-Entity
in	O	O	O
the	O	O	O
CD45	O	O	B-Entity
(	O	O	B-Entity
-	O	O	I-Entity
)	O	O	I-Entity
non-hematopoietic	O	O	B-Entity
cell	O	O	I-Entity
fraction	O	O	I-Entity
from	O	O	O
naïve	O	O	O
mouse	O	O	B-Entity
spleen	O	O	I-Entity
after	O	O	O
cell	O	O	B-Entity
separation	O	O	I-Entity
by	O	O	O
means	O	O	O
of	O	O	O
digestion	O	O	O
with	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
enzymes	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
using	O	O	O
a	O	O	O
new	O	O	B-Entity
combination	O	O	B-Entity
of	O	O	O
enzymes	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
FDCs	O	O	B-Entity
are	O	O	O
highly	O	O	O
enriched	O	O	O
in	O	O	O
the	O	O	O
CD45	O	O	B-Entity
(	O	O	B-Entity
-	O	O	I-Entity
)	O	O	I-Entity
ICAM-1(+	O	O	B-Entity
)	O	O	I-Entity
CD21	O	O	B-Entity
/	O	O	O
35(+	O	O	B-Entity
)	O	O	I-Entity
cell	O	O	B-Entity
fraction	O	O	I-Entity
.	O	O	O

CD45	O	O	B-Entity
(	O	O	B-Entity
-	O	O	I-Entity
)	O	O	I-Entity
ICAM-1(+	O	O	B-Entity
)	O	O	I-Entity
CD21	O	O	B-Entity
/	O	O	O
35(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	B-Entity
in	O	O	O
the	O	O	O
mouse	O	O	B-Entity
spleen	O	O	I-Entity
retained	O	O	O
an	O	O	O
antigen	O	O	B-Entity
administered	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
for	O	O	O
more	O	O	O
than	O	O	O
7	O	O	O
days	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
CD45	O	O	B-Entity
(	O	O	B-Entity
-	O	O	I-Entity
)	O	O	I-Entity
ICAM-1(+	O	O	B-Entity
)	O	O	I-Entity
CD21	O	O	B-Entity
/	O	O	O
35(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	B-Entity
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
spleen	O	O	B-Entity
of	O	O	I-Entity
mice	O	O	I-Entity
administered	O	O	O
with	O	O	O
a	O	O	O
cognate	O	O	B-Entity
antigen	O	O	I-Entity
enhanced	O	O	B-Entity
the	O	O	O
survival	O	O	B-Entity
and	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
antigen-specific	O	O	B-Entity
B	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

Our	O	O	O
improved	O	O	B-Entity
protocol	O	O	B-Entity
for	O	O	O
the	O	O	O
isolation	O	O	B-Entity
of	O	O	O
naïve	O	O	O
FDCs	O	O	B-Entity
will	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
FDCs	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

-DOCSTART- (27643784)

Dental	O	O	B-Entity
enamel	O	O	B-Entity
defects	O	O	I-Entity
in	O	O	O
German	O	O	B-Entity
medieval	O	O	B-Entity
and	O	O	O
early-modern-age	O	O	B-Entity
populations	O	O	O

Aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
frequency	O	O	B-Entity
and	O	O	O
type	O	O	B-Entity
of	O	O	O
developmental	O	O	B-Entity
defects	O	O	I-Entity
of	O	O	I-Entity
enamel	O	O	I-Entity
(	O	O	O
DDE	O	O	B-Entity
)	O	O	O
in	O	O	O
a	O	O	O
medieval	O	O	B-Entity
and	O	O	O
an	O	O	O
early-modern-age	O	O	B-Entity
population	O	O	B-Entity
from	O	O	O
Thuringia	O	O	B-Entity
,	O	O	I-Entity
Germany	O	O	I-Entity
.	O	O	O

Sixty-six	O	O	O
skeletons	O	O	B-Entity
subdivided	O	O	B-Entity
into	O	O	O
31	O	O	O
single	O	O	B-Entity
burials	O	O	B-Entity
(	O	O	O
12(th)/13(th	O	O	O
)	O	O	O
c.	O	O	O
)	O	O	O
and	O	O	O
35	O	O	O
individuals	O	O	B-Entity
buried	O	O	B-Entity
in	O	O	O
groups	O	O	B-Entity
(	O	O	O
15(th)/16(th	O	O	O
)	O	O	O
c.	O	O	O
)	O	O	O
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

DDE	O	O	B-Entity
were	O	O	O
classified	O	O	B-Entity
on	O	O	O
1,246	O	O	O
teeth	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
DDE	O	O	O
index	O	O	B-Entity
.	O	O	O

Molar-incisor-hypomineralisation	O	O	B-Entity
(	O	O	O
MIH	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
special	O	O	O
type	O	O	B-Entity
of	O	O	O
DDE	O	O	B-Entity
,	O	O	O
was	O	O	O
recorded	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
European	O	O	B-Entity
Academy	O	O	I-Entity
of	O	O	I-Entity
Paediatric	O	O	I-Entity
Dentistry	O	O	I-Entity
(	O	O	O
EAPD	O	O	B-Entity
)	O	O	O
criteria	O	O	B-Entity
.	O	O	O

DDE	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
89.4	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
individuals	O	O	B-Entity
(	O	O	O
single	O	O	B-Entity
burials	O	O	B-Entity
90.3	O	O	O
%	O	O	O
and	O	O	O
group	O	O	B-Entity
burials	O	O	O
88.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Hypoplastic	O	O	B-Entity
pits	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
frequent	O	O	B-Entity
defect	O	O	B-Entity
in	O	O	O
primary	O	O	B-Entity
teeth	O	O	I-Entity
and	O	O	O
linear	O	O	B-Entity
enamel	O	O	I-Entity
hypoplasia	O	O	I-Entity
(	O	O	O
LEH	O	O	B-Entity
)	O	O	O
in	O	O	O
permanent	O	O	B-Entity
teeth	O	O	I-Entity
.	O	O	O

13	O	O	O
individuals	O	O	B-Entity
(	O	O	O
24.1	O	O	O
%	O	O	O
)	O	O	O
showed	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
hypomineralised	O	O	B-Entity
permanent	O	O	B-Entity
tooth	O	O	I-Entity
,	O	O	O
12.2	O	O	O
%	O	O	O
had	O	O	O
MIH	O	O	B-Entity
on	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
first	O	O	O
permanent	O	O	B-Entity
molar	O	O	I-Entity
and	O	O	O
10.0	O	O	O
%	O	O	O
in	O	O	O
permanent	O	O	B-Entity
incisors	O	O	I-Entity
.	O	O	O

Second	O	O	B-Entity
primary	O	O	I-Entity
molars	O	O	I-Entity
were	O	O	O
affected	O	O	B-Entity
in	O	O	O
8.0	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
children	O	O	B-Entity
and	O	O	O
juveniles	O	O	B-Entity
.	O	O	O

No	O	O	O
individual	O	O	B-Entity
suffered	O	O	O
from	O	O	O
affected	O	O	B-Entity
molars	O	O	B-Entity
and	O	O	O
incisors	O	O	B-Entity
in	O	O	O
combination	O	O	B-Entity
.	O	O	O

Endogenous	O	O	B-Entity
factors	O	O	B-Entity
like	O	O	O
nutritional	O	O	B-Entity
deficiencies	O	O	I-Entity
and	O	O	O
health	O	O	B-Entity
problems	O	O	I-Entity
in	O	O	O
early	O	O	B-Entity
childhood	O	O	B-Entity
could	O	O	O
have	O	O	O
been	O	O	O
aetiological	O	O	B-Entity
reasons	O	O	B-Entity
of	O	O	O
DDE	O	O	B-Entity
and	O	O	O
MIH	O	O	B-Entity
.	O	O	O

The	O	O	O
frequency	O	O	B-Entity
of	O	O	O
DDE	O	O	B-Entity
and	O	O	O
MIH	O	O	B-Entity
might	O	O	O
have	O	O	O
been	O	O	O
masked	O	O	B-Entity
by	O	O	O
extended	O	O	B-Entity
carious	O	O	B-Entity
lesions	O	O	I-Entity
,	O	O	O
dental	O	O	B-Entity
wear	O	O	I-Entity
and	O	O	O
ante-mortem	O	O	B-Entity
tooth	O	O	B-Entity
loss	O	O	I-Entity
.	O	O	O

-DOCSTART- (27644674)

Breast	O	O	B-Entity
Cancer	O	O	B-Entity
Detection	O	O	B-Entity
Rate	O	O	I-Entity
,	O	O	O
Incidence	O	O	B-Entity
,	O	O	O
Prevalence	O	O	B-Entity
and	O	O	O
Interval	O	O	B-Entity
Cancer	O	O	O
-related	O	O	O
Mammography	O	O	B-Entity
Screening	O	O	I-Entity
Times	O	O	B-Entity
among	O	O	O
Thai	O	O	B-Entity
Women	O	O	O

A	O	O	O
recent	O	O	O
guideline	O	O	B-Entity
by	O	O	O
the	O	O	O
American	O	O	B-Entity
Cancer	O	O	I-Entity
Society	O	O	I-Entity
recommended	O	O	O
that	O	O	O
mammography	O	O	B-Entity
(	O	O	O
MMG	O	O	B-Entity
)	O	O	O
should	O	O	O
be	O	O	O
done	O	O	O
for	O	O	O
women	O	O	B-Entity
starting	O	O	O
in	O	O	O
their	O	O	O
mid-40s	O	O	O
.	O	O	O

In	O	O	O
Thailand	O	O	B-Entity
,	O	O	O
information	O	O	O
on	O	O	O
opportunistic	O	O	B-Entity
mammography	O	O	I-Entity
screening	O	O	I-Entity
is	O	O	O
limited	O	O	B-Entity
and	O	O	O
data	O	O	B-Entity
on	O	O	O
the	O	O	O
total	O	O	O
incidence	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
are	O	O	O
also	O	O	O
lacking	O	O	O
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
detection	O	O	B-Entity
,	O	O	O
incident	O	O	B-Entity
and	O	O	O
prevalence	O	O	B-Entity
rates	O	O	I-Entity
among	O	O	O
Thai	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

We	O	O	O
retrospectively	O	O	O
reviewed	O	O	O
the	O	O	O
opportunistic	O	O	B-Entity
mammography	O	O	I-Entity
screening	O	O	I-Entity
of	O	O	O
normal	O	O	O
women	O	O	B-Entity
between	O	O	O
30	O	O	O
and	O	O	O
80	O	O	O
years	O	O	B-Entity
who	O	O	O
underwent	O	O	O
the	O	O	O
procedure	O	O	B-Entity
between	O	O	O
2001	O	O	O
and	O	O	O
2010	O	O	O
.	O	O	O

All	O	O	O
cases	O	O	O
were	O	O	O
followed	O	O	O
until	O	O	O
2012	O	O	O
.	O	O	O

The	O	O	O
detection	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
calculated	O	O	O
for	O	O	O
the	O	O	O
whole	O	O	O
period	O	O	O
of	O	O	O
observation	O	O	B-Entity
using	O	O	O
'	O	O	O
number	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
positive	O	O	B-Entity
findings	O	O	I-Entity
'	O	O	O
divided	O	O	O
by	O	O	O
'	O	O	O
total	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
women	O	O	O
screened	O	O	B-Entity
'	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
calculated	O	O	B-Entity
only	O	O	O
at	O	O	O
the	O	O	O
first	O	O	O
MMG	O	O	B-Entity
while	O	O	O
the	O	O	O
subsequence	O	O	O
rate	O	O	O
was	O	O	O
calculated	O	O	O
based	O	O	O
on	O	O	O
all	O	O	O
new	O	O	O
cases	O	O	O
detected	O	O	B-Entity
at	O	O	O
each	O	O	O
subsequent	O	O	O
MMG	O	O	O
.	O	O	O

Among	O	O	O
the	O	O	O
47,430	O	O	O
women	O	O	B-Entity
,	O	O	O
there	O	O	O
were	O	O	O
152,091	O	O	O
MMGs	O	O	B-Entity
or	O	O	O
approximately	O	O	O
3.2	O	O	O
occasions	O	O	O
per	O	O	O
person	O	O	B-Entity
(	O	O	O
range	O	O	O
,	O	O	O
1	O	O	O
-	O	O	O
10	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
duration	O	O	B-Entity
of	O	O	O
the	O	O	O
interval	O	O	B-Entity
between	O	O	O
each	O	O	O
subsequence	O	O	O
visit	O	O	O
was	O	O	O
1.8	O	O	O
years	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
543	O	O	O
women	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
detection	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
10.3	O	O	O
per	O	O	O
1,000	O	O	O
persons	O	O	B-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
at	O	O	O
the	O	O	O
first	O	O	O
visit	O	O	O
was	O	O	O
5.78	O	O	O
per	O	O	O
1,000	O	O	O
person	O	O	B-Entity
s.	O	O	O
The	O	O	O
incidence	O	O	B-Entity
or	O	O	O
new	O	O	O
cases	O	O	O
detected	O	O	B-Entity
at	O	O	O
any	O	O	O
follow-up	O	O	O
visit	O	O	O
was	O	O	O
10.4	O	O	O
per	O	O	O
1,000	O	O	O
person	O	O	O
s.	O	O	O
The	O	O	O
overall	O	O	O
interval	O	O	B-Entity
cancer	O	O	O
was	O	O	O
0.91	O	O	O
per	O	O	O
1,000	O	O	O
women	O	O	B-Entity
,	O	O	O
mainly	O	O	O
detected	O	O	O
before	O	O	O
their	O	O	O
second	O	O	O
and	O	O	O
third	O	O	O
MMG	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
rate	O	O	O
of	O	O	O
0.0.47	O	O	O
and	O	O	O
0.76	O	O	O
per	O	O	O
1,000	O	O	O
women	O	O	O
.	O	O	O

Opportunistic	O	O	B-Entity
mammography	O	O	I-Entity
screening	O	O	I-Entity
in	O	O	O
Thailand	O	O	B-Entity
detected	O	O	B-Entity
10	O	O	O
cases	O	O	O
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
from	O	O	O
each	O	O	O
1,000	O	O	O
women	O	O	B-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
indicated	O	O	O
a	O	O	O
high	O	O	O
rate	O	O	O
of	O	O	O
cancer	O	O	B-Entity
detection	O	O	I-Entity
during	O	O	O
a	O	O	O
two	O	O	O
year	O	O	O
interval	O	O	B-Entity
,	O	O	O
hence	O	O	O
,	O	O	O
a	O	O	O
screening	O	O	B-Entity
mammogram	O	O	I-Entity
should	O	O	O
be	O	O	O
performed	O	O	O
more	O	O	O
often	O	O	O
.	O	O	O

-DOCSTART- (27644855)

Assessment	O	O	O
of	O	O	O
groundwater	O	O	B-Entity
vulnerability	O	O	B-Entity
in	O	O	O
the	O	O	O
Daule	O	O	B-Entity
aquifer	O	O	I-Entity
,	O	O	O
Ecuador	O	O	B-Entity
,	O	O	O
using	O	O	O
the	O	O	O
susceptibility	O	O	O
index	O	O	O
method	O	O	O

The	O	O	O
Guayas	O	O	B-Entity
region	O	O	I-Entity
in	O	O	O
Ecuador	O	O	B-Entity
is	O	O	O
economically	O	O	O
very	O	O	O
important	O	O	O
,	O	O	O
producing	O	O	O
68	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
national	O	O	B-Entity
crops	O	O	I-Entity
.	O	O	O

The	O	O	O
main	O	O	O
agricultural	O	O	B-Entity
activities	O	O	I-Entity
threaten	O	O	O
the	O	O	O
groundwater	O	O	B-Entity
therein	O	O	O
with	O	O	O
nitrate	O	O	B-Entity
contamination	O	O	B-Entity
given	O	O	O
the	O	O	O
large	O	O	O
fertiliser	O	O	B-Entity
and	O	O	O
water	O	O	B-Entity
needs	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
work	O	O	O
tests	O	O	O
the	O	O	O
applicability	O	O	O
of	O	O	O
the	O	O	O
susceptibility	O	O	B-Entity
index	O	O	I-Entity
assessment	O	O	I-Entity
method	O	O	I-Entity
in	O	O	O
evaluating	O	O	O
the	O	O	O
impact	O	O	O
of	O	O	O
agricultural	O	O	B-Entity
activities	O	O	I-Entity
on	O	O	O
groundwater	O	O	B-Entity
quality	O	O	B-Entity
,	O	O	O
using	O	O	O
as	O	O	O
a	O	O	O
case	O	O	O
study	O	O	O
an	O	O	O
aquifer	O	O	B-Entity
of	O	O	O
the	O	O	O
Guayas	O	O	B-Entity
river	O	O	B-Entity
basin	O	O	I-Entity
in	O	O	O
Ecuador	O	O	B-Entity
.	O	O	O

The	O	O	O
index	O	O	O
adapts	O	O	O
four	O	O	O
parameters	O	O	O
of	O	O	O
the	O	O	O
DRASTIC	O	O	B-Entity
method	O	O	I-Entity
and	O	O	O
incorporated	O	O	O
a	O	O	O
new	O	O	O
land	O	O	B-Entity
use	O	O	I-Entity
parameter	O	O	O
.	O	O	O

Results	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
areas	O	O	B-Entity
highly	O	O	B-Entity
vulnerable	O	O	B-Entity
to	O	O	O
contamination	O	O	B-Entity
are	O	O	O
located	O	O	O
in	O	O	O
irrigation	O	O	B-Entity
perimeters	O	O	B-Entity
of	O	O	O
dominant	O	O	O
paddy	O	O	B-Entity
fields	O	O	I-Entity
associated	O	O	O
with	O	O	O
the	O	O	O
high	O	O	O
recharge	O	O	O
rates	O	O	O
in	O	O	O
the	O	O	O
alluvial	O	O	B-Entity
deposits	O	O	I-Entity
.	O	O	O

Respectively	O	O	O
,	O	O	O
moderately	O	O	B-Entity
vulnerable	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
-	O	O	O
vulnerability	O	O	B-Entity
areas	O	O	B-Entity
correspond	O	O	O
to	O	O	O
aquatic	O	O	B-Entity
environments	O	O	I-Entity
and	O	O	O
forests	O	O	B-Entity
,	O	O	O
semi-natural	O	O	B-Entity
zones	O	O	I-Entity
and	O	O	O
water	O	O	B-Entity
bodies	O	O	I-Entity
.	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
main	O	O	O
contributions	O	O	O
of	O	O	O
the	O	O	O
Daule	O	O	B-Entity
aquifer	O	O	I-Entity
vulnerability	O	O	B-Entity
is	O	O	O
likely	O	O	O
its	O	O	O
wide	O	O	B-Entity
,	O	O	O
flat	O	O	B-Entity
topography	O	O	I-Entity
.	O	O	O

A	O	O	O
great	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
aquifer	O	O	B-Entity
is	O	O	O
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
contamination	O	O	I-Entity
by	O	O	O
nitrates	O	O	B-Entity
if	O	O	O
a	O	O	O
code	O	O	O
of	O	O	O
good	O	O	B-Entity
agricultural	O	O	B-Entity
practices	O	O	I-Entity
is	O	O	O
not	O	O	O
applied	O	O	O
.	O	O	O

Therefore	O	O	O
the	O	O	O
implementation	O	O	O
of	O	O	O
a	O	O	O
monitoring	O	O	B-Entity
network	O	O	I-Entity
to	O	O	I-Entity
control	O	O	I-Entity
the	O	O	O
nitrates	O	O	B-Entity
concentrations	O	O	B-Entity
is	O	O	O
the	O	O	O
first	O	O	O
step	O	O	O
to	O	O	O
assure	O	O	O
groundwater	O	O	B-Entity
quality	O	O	B-Entity
for	O	O	O
drinking	O	O	B-Entity
purposes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27645367)

Heterogeneous	O	O	B-Entity
depression	O	O	B-Entity
trajectories	O	O	B-Entity
in	O	O	O
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
patients	O	O	O

Trajectories	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
over	O	O	O
time	O	O	O
may	O	O	O
be	O	O	O
heterogeneous	O	O	B-Entity
in	O	O	O
Multiple	O	O	B-Entity
Sclerosis	O	O	I-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
.	O	O	O

Describing	O	O	O
these	O	O	O
trajectories	O	O	B-Entity
will	O	O	O
help	O	O	O
clinicians	O	O	B-Entity
understand	O	O	O
better	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
in	O	O	O
MS	O	O	B-Entity
patients	O	O	B-Entity
to	O	O	O
aid	O	O	O
in	O	O	O
patient	O	O	O
care	O	O	O
decisions	O	O	O
.	O	O	O

Latent	O	O	B-Entity
class	O	O	I-Entity
growth	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
LCGA	O	O	B-Entity
)	O	O	O
was	O	O	O
applied	O	O	O
to	O	O	O
3507	O	O	O
MS	O	O	B-Entity
patients	O	O	B-Entity
using	O	O	O
an	O	O	O
electronic	O	O	B-Entity
health	O	O	I-Entity
records	O	O	I-Entity
(	O	O	I-Entity
EHR	O	O	I-Entity
)	O	O	I-Entity
data	O	O	I-Entity
base	O	O	I-Entity
to	O	O	O
identify	O	O	O
subgroups	O	O	B-Entity
of	O	O	O
MS	O	O	O
patients	O	O	O
based	O	O	O
on	O	O	O
self-reported	O	O	O
depression	O	O	B-Entity
screening	O	O	I-Entity
(	O	O	O
PHQ-9	O	O	B-Entity
)	O	O	O
.	O	O	O

Latent	O	O	B-Entity
trajectory	O	O	B-Entity
classes	O	O	O
were	O	O	O
used	O	O	O
for	O	O	O
group	O	O	B-Entity
comparisons	O	O	O
based	O	O	O
on	O	O	O
baseline	O	O	B-Entity
clinical	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

Three	O	O	O
subgroups	O	O	B-Entity
were	O	O	O
found	O	O	O
characterized	O	O	O
by	O	O	O
high	O	O	B-Entity
(	O	O	O
10.0	O	O	O
%	O	O	O
[	O	O	O
of	O	O	O
participants	O	O	B-Entity
]	O	O	O
)	O	O	O
,	O	O	O
wavering	O	O	O
above	O	O	O
and	O	O	O
below	O	O	O
moderate	O	O	B-Entity
(	O	O	O
26.2	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
low	O	O	B-Entity
and	O	O	O
variable	O	O	B-Entity
(	O	O	O
63.8	O	O	O
%	O	O	O
)	O	O	O
depression	O	O	B-Entity
level	O	O	I-Entity
trajectories	O	O	B-Entity
.	O	O	O

The	O	O	O
subpopulation	O	O	B-Entity
trajectories	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
were	O	O	O
also	O	O	O
characterized	O	O	O
by	O	O	O
high	O	O	B-Entity
,	O	O	O
moderate	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
MS	O	O	B-Entity
disability	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
overall	O	O	O
average	O	O	O
trajectory	O	O	B-Entity
was	O	O	O
slightly	O	O	O
declining	O	O	O
and	O	O	O
below	O	O	O
the	O	O	O
moderate	O	O	B-Entity
depression	O	O	B-Entity
threshold	O	O	B-Entity
.	O	O	O

The	O	O	O
LCGA	O	O	B-Entity
approach	O	O	O
described	O	O	O
in	O	O	O
this	O	O	O
paper	O	O	O
and	O	O	O
applied	O	O	O
to	O	O	O
MS	O	O	B-Entity
patients	O	O	B-Entity
provides	O	O	O
a	O	O	O
template	O	O	B-Entity
for	O	O	O
improved	O	O	O
use	O	O	O
of	O	O	O
an	O	O	O
EHR	O	O	B-Entity
data	O	O	I-Entity
base	O	O	I-Entity
for	O	O	O
understanding	O	O	O
heterogeneous	O	O	B-Entity
depression	O	O	B-Entity
screening	O	O	I-Entity
trajectories	O	O	B-Entity
.	O	O	O

Clinicians	O	O	B-Entity
may	O	O	O
use	O	O	O
such	O	O	O
information	O	O	B-Entity
to	O	O	O
more	O	O	O
closely	O	O	O
monitor	O	O	B-Entity
patients	O	O	I-Entity
that	O	O	O
are	O	O	O
expected	O	O	O
to	O	O	O
maintain	O	O	O
high	O	O	B-Entity
or	O	O	O
unstable	O	O	B-Entity
depression	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

-DOCSTART- (27646139)

The	O	O	O
PLA2	O	O	B-Entity
gene	O	O	I-Entity
mediates	O	O	O
the	O	O	O
humoral	O	O	B-Entity
immune	O	O	I-Entity
responses	O	O	I-Entity
in	O	O	O
Bactrocera	O	O	O
dorsalis	O	O	O
(	O	O	O
Hendel	O	O	O
)	O	O	O

The	O	O	O
phospholipase	O	O	B-Entity
A2	O	O	I-Entity
(	O	O	I-Entity
PLA2	O	O	I-Entity
)	O	O	I-Entity
gene	O	O	I-Entity
encodes	O	O	B-Entity
the	O	O	O
enzyme	O	O	B-Entity
that	O	O	O
catalyzes	O	O	B-Entity
the	O	O	O
hydrolysis	O	O	B-Entity
of	O	O	O
phospholipids	O	O	B-Entity
(	O	O	O
PLs	O	O	B-Entity
)	O	O	O
from	O	O	O
the	O	O	O
sn-2	O	O	B-Entity
position	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
its	O	O	O
role	O	O	B-Entity
in	O	O	O
humoral	O	O	B-Entity
immune	O	O	I-Entity
responses	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
profile	O	O	I-Entity
of	O	O	O
PLA2	O	O	B-Entity
in	O	O	O
different	O	O	B-Entity
tissues	O	O	B-Entity
and	O	O	O
developmental	O	O	B-Entity
stages	O	O	I-Entity
in	O	O	O
Bactrocera	O	O	B-Entity
dorsalis	O	O	I-Entity
(	O	O	I-Entity
Hendel	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
results	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
transcriptional	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
PLA2	O	O	O
was	O	O	O
high	O	O	B-Entity
in	O	O	O
the	O	O	O
egg	O	O	B-Entity
and	O	O	O
mature	O	O	B-Entity
stage	O	O	I-Entity
and	O	O	O
in	O	O	O
the	O	O	O
testis	O	O	B-Entity
tissue	O	O	B-Entity
.	O	O	O

Bacterial	O	O	B-Entity
infection	O	O	I-Entity
increased	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
PLA2	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
highest	O	O	O
degree	O	O	O
of	O	O	O
up-regulation	O	O	B-Entity
appeared	O	O	O
in	O	O	O
the	O	O	O
fat	O	O	B-Entity
body	O	O	I-Entity
.	O	O	O

Silencing	O	O	B-Entity
PLA2	O	O	B-Entity
influenced	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
immune-related	O	O	B-Entity
genes	O	O	I-Entity
,	O	O	O
including	O	O	O
MyD88	O	O	B-Entity
and	O	O	O
defensin	O	O	B-Entity
in	O	O	O
the	O	O	O
Toll	O	O	B-Entity
pathway	O	O	I-Entity
and	O	O	O
relish	O	O	B-Entity
and	O	O	O
diptericin	O	O	B-Entity
in	O	O	O
the	O	O	O
Imd	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
MyD88	O	O	B-Entity
and	O	O	O
defensin	O	O	B-Entity
was	O	O	O
down-regulated	O	O	B-Entity
significantly	O	O	O
in	O	O	O
the	O	O	O
ds-PLA2	O	O	B-Entity
group	O	O	B-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
ds-egfp	O	O	B-Entity
group	O	O	O
when	O	O	O
B.	O	O	B-Entity
dorsalis	O	O	I-Entity
was	O	O	O
infected	O	O	B-Entity
with	O	O	O
L.	O	O	B-Entity
monocytogenes	O	O	I-Entity
and	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
PLA2	O	O	B-Entity
was	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
Toll	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
infection	O	O	B-Entity
with	O	O	O
L.	O	O	B-Entity
monocytogenes	O	O	I-Entity
and	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
,	O	O	O
which	O	O	O
activate	O	O	B-Entity
the	O	O	O
Imd	O	O	B-Entity
pathway	O	O	I-Entity
,	O	O	O
does	O	O	O
not	O	O	O
increase	O	O	B-Entity
the	O	O	O
mRNA	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
relish	O	O	B-Entity
and	O	O	O
diptericin	O	O	B-Entity
in	O	O	O
the	O	O	O
ds-PLA2	O	O	B-Entity
group	O	O	B-Entity
as	O	O	O
severely	O	O	O
as	O	O	O
it	O	O	O
increases	O	O	B-Entity
those	O	O	O
in	O	O	O
the	O	O	O
ds-egfp	O	O	B-Entity
group	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
the	O	O	O
Imd	O	O	O
pathway	O	O	O
was	O	O	O
also	O	O	O
repressed	O	O	B-Entity
after	O	O	O
silencing	O	O	B-Entity
PLA2	O	O	B-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
lipid	O	O	B-Entity
droplets	O	O	I-Entity
in	O	O	O
fat	O	O	B-Entity
body	O	O	I-Entity
cells	O	O	B-Entity
was	O	O	O
influenced	O	O	B-Entity
by	O	O	O
silencing	O	O	B-Entity
PLA2	O	O	B-Entity
,	O	O	O
implying	O	O	O
that	O	O	O
PLA2	O	O	O
affects	O	O	O
the	O	O	O
function	O	O	B-Entity
of	O	O	O
fat	O	O	O
body	O	O	O
tissue	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
PLA2	O	O	B-Entity
gene	O	O	O
may	O	O	O
mediate	O	O	O
humoral	O	O	B-Entity
immune	O	O	I-Entity
responses	O	O	I-Entity
by	O	O	O
reducing	O	O	B-Entity
lipid	O	O	B-Entity
storage	O	O	I-Entity
in	O	O	O
fat	O	O	B-Entity
body	O	O	I-Entity
cells	O	O	B-Entity
in	O	O	O
B.	O	O	B-Entity
dorsalis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27648744)

Gambling	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
gambling	O	O	B-Entity
type	O	O	O
preferences	O	O	O
,	O	O	O
and	O	O	O
psychiatric	O	O	B-Entity
comorbidity	O	O	B-Entity
among	O	O	O
the	O	O	O
Thai	O	O	B-Entity
general	O	O	I-Entity
population	O	O	I-Entity
:	O	O	O
Results	O	O	O
of	O	O	O
the	O	O	O
2013	O	O	O
National	O	O	O
Mental	O	O	O
Health	O	O	O
Survey	O	O	O

Background	O	O	O
and	O	O	O
aims	O	O	O
To	O	O	O
estimate	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
problem	O	O	B-Entity
and	O	O	O
pathological	O	O	B-Entity
gambling	O	O	I-Entity
,	O	O	O
gender	O	O	B-Entity
and	O	O	O
age-group	O	O	B-Entity
differences	O	O	O
in	O	O	O
gambling	O	O	B-Entity
types	O	O	I-Entity
,	O	O	O
and	O	O	O
comorbidities	O	O	B-Entity
with	O	O	O
other	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
among	O	O	O
the	O	O	O
Thai	O	O	B-Entity
general	O	O	I-Entity
population	O	O	I-Entity
.	O	O	O

Methods	O	O	O
Analysis	O	O	O
was	O	O	O
conducted	O	O	O
on	O	O	O
4,727	O	O	O
participants	O	O	B-Entity
of	O	O	O
Thailand	O	O	B-Entity
's	O	O	I-Entity
2013	O	O	O
National	O	O	B-Entity
Mental	O	O	I-Entity
Health	O	O	I-Entity
Survey	O	O	I-Entity
,	O	O	O
a	O	O	O
multistage	O	O	B-Entity
stratified	O	O	I-Entity
cluster	O	O	I-Entity
survey	O	O	I-Entity
,	O	O	O
using	O	O	O
the	O	O	O
Composite	O	O	B-Entity
International	O	O	I-Entity
Diagnostic	O	O	I-Entity
Interview	O	O	I-Entity
.	O	O	O

Diagnoses	O	O	B-Entity
of	O	O	O
problem	O	O	B-Entity
and	O	O	O
pathological	O	O	B-Entity
gambling	O	O	B-Entity
and	O	O	O
other	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
were	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
DSM-IV-TR	O	O	B-Entity
criteria	O	O	B-Entity
with	O	O	O
the	O	O	O
following	O	O	O
additional	O	O	O
criteria	O	O	O
for	O	O	O
gamblers	O	O	B-Entity
:	O	O	O
more	O	O	O
than	O	O	O
10	O	O	O
lifetime	O	O	B-Entity
gambling	O	O	O
episodes	O	O	O
and	O	O	O
a	O	O	O
single	O	O	B-Entity
year	O	O	I-Entity
loss	O	O	I-Entity
of	O	O	O
at	O	O	O
least	O	O	O
365	O	O	O
USD	O	O	B-Entity
from	O	O	O
gambling	O	O	O
.	O	O	O

Results	O	O	O
The	O	O	O
estimated	O	O	O
lifetime	O	O	B-Entity
prevalence	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
pathological	O	O	B-Entity
and	O	O	O
problem	O	O	B-Entity
gambling	O	O	I-Entity
were	O	O	O
0.90	O	O	O
%	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
):	O	O	O
0.51	O	O	O
-	O	O	O
1.29	O	O	O
]	O	O	O
and	O	O	O
1.14	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.58	O	O	O
-	O	O	O
1.70	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
popular	O	O	O
type	O	O	O
of	O	O	O
gambling	O	O	B-Entity
was	O	O	O
playing	O	O	B-Entity
lotteries	O	O	I-Entity
[	O	O	O
69.5	O	O	O
%	O	O	O
,	O	O	O
standard	O	O	B-Entity
error	O	O	I-Entity
(	O	O	O
SE	O	O	B-Entity
)	O	O	O
=	O	O	O
1.9	O	O	O
]	O	O	O
,	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
which	O	O	O
was	O	O	O
significantly	O	O	O
higher	O	O	O
among	O	O	O
females	O	O	B-Entity
and	O	O	O
older	O	O	B-Entity
age	O	O	I-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
seen	O	O	O
among	O	O	O
pathological	O	O	B-Entity
gamblers	O	O	I-Entity
were	O	O	O
alcohol	O	O	B-Entity
abuse	O	O	I-Entity
(	O	O	O
57.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
nicotine	O	O	B-Entity
dependence	O	O	I-Entity
(	O	O	O
49.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
any	O	O	O
drug	O	O	B-Entity
use	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
16.2	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Pathological	O	O	B-Entity
gambling	O	O	I-Entity
was	O	O	O
highly	O	O	O
prevalent	O	O	O
among	O	O	O
those	O	O	O
who	O	O	O
ever	O	O	O
experienced	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
episodes	O	O	I-Entity
(	O	O	O
5.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
any	O	O	O
drug	O	O	B-Entity
dependence	O	O	I-Entity
(	O	O	O
5.1	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
intermittent	O	O	B-Entity
explosive	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
4.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
association	O	O	O
between	O	O	O
pathological	O	O	B-Entity
gambling	O	O	I-Entity
was	O	O	O
strongest	O	O	O
with	O	O	O
a	O	O	O
history	O	O	O
of	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
episode	O	O	I-Entity
[	O	O	O
adjusted	O	O	B-Entity
odds	O	O	I-Entity
ratio	O	O	I-Entity
(	O	O	O
AOR	O	O	B-Entity
)	O	O	O
=	O	O	O
10.4	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
2.80	O	O	O
-	O	O	O
38.4	O	O	O
]	O	O	O
.	O	O	O

Conclusion	O	O	O
The	O	O	O
study	O	O	O
confirms	O	O	O
the	O	O	O
recognition	O	O	B-Entity
of	O	O	O
gambling	O	O	B-Entity
disorders	O	O	I-Entity
as	O	O	O
a	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
concern	O	O	O
in	O	O	O
Thailand	O	O	B-Entity
and	O	O	O
suggests	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
culturally	O	O	B-Entity
specific	O	O	O
preventive	O	O	B-Entity
measures	O	O	O
for	O	O	O
pathological	O	O	B-Entity
gamblers	O	O	I-Entity
and	O	O	O
those	O	O	O
with	O	O	O
a	O	O	O
history	O	O	O
of	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
disorders	O	O	I-Entity
or	O	O	O
major	O	O	B-Entity
depression	O	O	I-Entity
.	O	O	O

-DOCSTART- (27649458)

Synovial	O	O	B-Entity
sarcoma	O	O	I-Entity
of	O	O	O
the	O	O	O
hypopharynx	O	O	B-Entity
in	O	O	O
a	O	O	O
pediatric	O	O	B-Entity
patient	O	O	B-Entity
:	O	O	O
Case	O	O	O
report	O	O	O

Synovial	O	O	B-Entity
sarcoma	O	O	B-Entity
(	O	O	O
SS	O	O	B-Entity
)	O	O	O
is	O	O	O
uncommon	O	O	O
high	O	O	O
grade	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
sarcoma	O	O	O
,	O	O	O
accounting	O	O	O
for	O	O	O
less	O	O	O
than	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
head	O	O	B-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
sarcomas	O	O	I-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
about	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
SS	O	O	B-Entity
occur	O	O	O
within	O	O	O
the	O	O	O
Head	O	O	B-Entity
&	O	O	O
Neck	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
pediatric	O	O	B-Entity
population	O	O	B-Entity
,	O	O	O
SS	O	O	B-Entity
is	O	O	O
an	O	O	O
extremely	O	O	O
rare	O	O	B-Entity
head	O	O	B-Entity
&	O	O	I-Entity
neck	O	O	I-Entity
malignancy	O	O	I-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
sixteen	O	O	O
years	O	O	O
old	O	O	O
boy	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
SS	O	O	B-Entity
situated	O	O	O
of	O	O	O
the	O	O	O
hypopharynx	O	O	B-Entity
treated	O	O	B-Entity
by	O	O	I-Entity
surgical	O	O	B-Entity
excision	O	O	I-Entity
and	O	O	O
post	O	O	B-Entity
operative	O	O	I-Entity
radio	O	O	B-Entity
-	O	O	O
chemotherapy	O	O	B-Entity
.	O	O	O

This	O	O	O
anatomical	O	O	B-Entity
location	O	O	I-Entity
brings	O	O	O
additional	O	O	O
functional	O	O	B-Entity
challenges	O	O	B-Entity
(	O	O	O
swallowing	O	O	B-Entity
,	O	O	O
phonation	O	O	B-Entity
,	O	O	O
respiration	O	O	B-Entity
)	O	O	O
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
pediatric	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

Pre-operative	O	O	B-Entity
and	O	O	O
even	O	O	O
post-operative	O	O	B-Entity
histopathological	O	O	B-Entity
diagnosis	O	O	B-Entity
of	O	O	O
SS	O	O	B-Entity
remains	O	O	O
difficult	O	O	O
.	O	O	O

Optimal	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
Head	O	O	B-Entity
&	O	O	O
Neck	O	O	B-Entity
SS	O	O	B-Entity
has	O	O	O
to	O	O	O
balance	O	O	O
functional	O	O	B-Entity
and	O	O	O
oncologic	O	O	B-Entity
aspects	O	O	B-Entity
.	O	O	O

SS	O	O	B-Entity
is	O	O	O
an	O	O	O
extremely	O	O	O
rare	O	O	B-Entity
head	O	O	B-Entity
&	O	O	I-Entity
neck	O	O	I-Entity
malignancy	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

It	O	O	O
has	O	O	O
multifaceted	O	O	B-Entity
challenges	O	O	B-Entity
including	O	O	O
pre	O	O	O
and	O	O	O
post-operative	O	O	B-Entity
histopathological	O	O	B-Entity
diagnosis	O	O	B-Entity
and	O	O	O
optimal	O	O	B-Entity
modality	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Clinical	O	O	B-Entity
judgment	O	O	I-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
pediatric	O	O	B-Entity
population	O	O	B-Entity
,	O	O	O
needs	O	O	O
to	O	O	O
balance	O	O	O
tumor	O	O	B-Entity
free	O	O	I-Entity
margins	O	O	I-Entity
and	O	O	O
organ	O	O	B-Entity
preservation	O	O	I-Entity
in	O	O	O
head	O	O	B-Entity
and	O	O	O
neck	O	O	B-Entity
region	O	O	B-Entity
.	O	O	O

-DOCSTART- (27649982)

Ocular	O	O	B-Entity
hypotensive	O	O	I-Entity
effect	O	O	B-Entity
of	O	O	O
the	O	O	O
novel	O	O	O
EP3	O	O	B-Entity
/	O	O	O
FP	O	O	B-Entity
agonist	O	O	B-Entity
ONO-9054	O	O	B-Entity
versus	O	O	O
Xalatan	O	O	B-Entity
:	O	O	O
results	O	O	O
of	O	O	O
a	O	O	O
28-	O	O	O
day	O	O	B-Entity
,	O	O	O
double-masked	O	O	B-Entity
,	O	O	O
randomised	O	O	B-Entity
study	O	O	O

ONO-9054	O	O	B-Entity
is	O	O	O
being	O	O	O
developed	O	O	O
for	O	O	O
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
intraocular	O	O	B-Entity
pressure	O	O	I-Entity
(	O	O	O
IOP	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
ocular	O	O	B-Entity
hypertension	O	O	I-Entity
(	O	O	O
OHT	O	O	B-Entity
)	O	O	O
and	O	O	O
open-angle	O	O	B-Entity
glaucoma	O	O	I-Entity
(	O	O	O
OAG	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
compared	O	O	O
the	O	O	O
novel	O	O	O
dual	O	O	O
EP3	O	O	B-Entity
/	O	O	O
FP	O	O	B-Entity
agonist	O	O	B-Entity
ONO-9054	O	O	B-Entity
with	O	O	O
the	O	O	O
FP	O	O	O
agonist	O	O	O
Xalatan	O	O	B-Entity
.	O	O	O

Adults	O	O	B-Entity
(	O	O	O
n=123	O	O	O
)	O	O	O
with	O	O	O
bilateral	O	O	O
mild/moderate	O	O	O
OAG	O	O	B-Entity
or	O	O	O
OHT	O	O	B-Entity
,	O	O	O
with	O	O	O
unmedicated	O	O	O
IOP	O	O	B-Entity
of	O	O	O
≥24	O	O	O
mm	O	O	O
Hg	O	O	O
at	O	O	O
8:00	O	O	O
hours	O	O	O
,	O	O	O
≥21	O	O	O
mm	O	O	O
Hg	O	O	O
at	O	O	O
10:00	O	O	O
hours	O	O	O
and	O	O	O
≤36	O	O	O
mm	O	O	O
Hg	O	O	O
,	O	O	O
were	O	O	O
randomised	O	O	O
1:1	O	O	O
to	O	O	O
receive	O	O	O
ONO-9054	O	O	B-Entity
(	O	O	O
0.003	O	O	O
%	O	O	O
,	O	O	O
30	O	O	O
μg/mL	O	O	O
)	O	O	O
or	O	O	O
Xalatan	O	O	B-Entity
(	O	O	O
0.005	O	O	O
%	O	O	O
,	O	O	O
50	O	O	O
μg/mL	O	O	O
)	O	O	O
once	O	O	O
daily	O	O	B-Entity
for	O	O	O
28	O	O	O
days	O	O	B-Entity
.	O	O	O

Day	O	O	B-Entity
29	O	O	O
mean	O	O	O
diurnal	O	O	O
IOP	O	O	B-Entity
was	O	O	O
-7.2	O	O	O
mm	O	O	O
Hg	O	O	O
for	O	O	O
ONO-9054	O	O	B-Entity
vs	O	O	O
-6.6	O	O	O
mm	O	O	O
Hg	O	O	O
for	O	O	O
Xalatan	O	O	B-Entity
.	O	O	O

At	O	O	O
08:00	O	O	O
hours	O	O	O
,	O	O	O
the	O	O	O
IOPs	O	O	B-Entity
were	O	O	O
comparable	O	O	O
,	O	O	O
and	O	O	O
at	O	O	O
all	O	O	O
later	O	O	O
time	O	O	O
points	O	O	O
the	O	O	O
decrease	O	O	B-Entity
in	O	O	O
IOP	O	O	B-Entity
was	O	O	O
greater	O	O	O
for	O	O	O
ONO-9054	O	O	B-Entity
.	O	O	O

On	O	O	O
day	O	O	B-Entity
29	O	O	O
,	O	O	O
the	O	O	O
odds	O	O	O
of	O	O	O
a	O	O	O
mean	O	O	O
IOP	O	O	B-Entity
reduction	O	O	B-Entity
of	O	O	O
≤-25	O	O	O
%	O	O	O
,	O	O	O
≤-30	O	O	O
%	O	O	O
and	O	O	O
≤-35	O	O	O
%	O	O	O
for	O	O	O
ONO-9054	O	O	B-Entity
were	O	O	O
2.39	O	O	O
,	O	O	O
2.37	O	O	O
and	O	O	O
4.85	O	O	O
times	O	O	O
more	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
than	O	O	O
the	O	O	O
odds	O	O	O
for	O	O	O
Xalatan	O	O	B-Entity
(	O	O	O
p<0.05	O	O	O
,	O	O	O
post	O	O	B-Entity
hoc	O	O	I-Entity
analyses	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
percentage	O	O	O
of	O	O	O
subjects	O	O	O
achieving	O	O	O
target	O	O	O
IOPs	O	O	B-Entity
on	O	O	O
day	O	O	B-Entity
29	O	O	O
(	O	O	O
≤17	O	O	O
,	O	O	O
≤16	O	O	O
and	O	O	O
≤15	O	O	O
mm	O	O	O
Hg	O	O	O
)	O	O	O
was	O	O	O
greater	O	O	O
for	O	O	O
ONO-9054	O	O	B-Entity
than	O	O	O
for	O	O	O
Xalatan	O	O	B-Entity
;	O	O	O
the	O	O	O
odds	O	O	O
of	O	O	O
achieving	O	O	O
an	O	O	O
IOP	O	O	B-Entity
≤15	O	O	O
mm	O	O	O
Hg	O	O	O
for	O	O	O
ONO-9054	O	O	O
were	O	O	O
2.4	O	O	O
times	O	O	O
more	O	O	O
than	O	O	O
the	O	O	O
odds	O	O	O
for	O	O	O
Xalatan	O	O	O
(	O	O	O
p<0.01	O	O	O
,	O	O	O
post	O	O	B-Entity
hoc	O	O	I-Entity
analysis	O	O	I-Entity
)	O	O	O
.	O	O	O

Subjects	O	O	O
randomised	O	O	O
to	O	O	O
receive	O	O	O
ONO-9054	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
achieve	O	O	O
a	O	O	O
greater	O	O	O
per	O	O	O
cent	O	O	O
reduction	O	O	O
in	O	O	O
IOP	O	O	B-Entity
and	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
achieve	O	O	O
target	O	O	O
IOPs	O	O	B-Entity
than	O	O	O
those	O	O	O
receiving	O	O	O
Xalatan	O	O	B-Entity
.	O	O	O

The	O	O	O
effects	O	O	O
of	O	O	O
ONO-9054	O	O	B-Entity
in	O	O	O
reducing	O	O	O
IOP	O	O	B-Entity
appear	O	O	O
to	O	O	O
persist	O	O	O
longer	O	O	O
than	O	O	O
those	O	O	O
of	O	O	O
Xalatan	O	O	B-Entity
.	O	O	O

NCT02083289	O	O	O
,	O	O	O
Results	O	O	O
.	O	O	O

-DOCSTART- (27650531)

Whole-body	O	O	B-Entity
strength	O	O	I-Entity
training	O	O	I-Entity
with	O	O	O
Huber	O	O	B-Entity
Motion	O	O	I-Entity
Lab	O	O	I-Entity
and	O	O	O
traditional	O	O	B-Entity
strength	O	O	I-Entity
training	O	O	I-Entity
in	O	O	O
cardiac	O	O	B-Entity
rehabilitation	O	O	I-Entity
:	O	O	O
A	O	O	O
randomized	O	O	O
controlled	O	O	O
study	O	O	O

Isometric	O	O	B-Entity
strengthening	O	O	I-Entity
has	O	O	O
been	O	O	O
rarely	O	O	O
studied	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
coronary	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CHD	O	O	B-Entity
)	O	O	O
,	O	O	O
mainly	O	O	O
because	O	O	O
of	O	O	O
possible	O	O	O
potential	O	O	B-Entity
side	O	O	I-Entity
effects	O	O	I-Entity
and	O	O	O
lack	O	O	B-Entity
of	O	O	O
appropriate	O	O	B-Entity
and	O	O	O
reliable	O	O	B-Entity
devices	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
compare	O	O	O
2	O	O	O
different	O	O	O
modes	O	O	B-Entity
of	O	O	O
resistance	O	O	B-Entity
training	O	O	I-Entity
,	O	O	O
an	O	O	O
isometric	O	O	O
mode	O	O	B-Entity
with	O	O	O
the	O	O	O
Huber	O	O	B-Entity
Motion	O	O	I-Entity
Lab	O	O	I-Entity
(	O	O	O
HML	O	O	B-Entity
)	O	O	O
and	O	O	O
traditional	O	O	B-Entity
strength	O	O	I-Entity
training	O	O	I-Entity
(	O	O	O
TST	O	O	B-Entity
)	O	O	O
,	O	O	O
in	O	O	O
CHD	O	O	B-Entity
patients	O	O	B-Entity
undergoing	O	O	O
a	O	O	O
cardiac	O	O	B-Entity
rehabilitation	O	O	I-Entity
program	O	O	O
.	O	O	O

We	O	O	O
randomly	O	O	O
assigned	O	O	O
50	O	O	O
patients	O	O	B-Entity
to	O	O	O
HML	O	O	B-Entity
or	O	O	O
TST	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
underwent	O	O	O
complete	O	O	O
blinded	O	O	B-Entity
evaluation	O	O	B-Entity
before	O	O	O
and	O	O	O
after	O	O	O
the	O	O	O
rehabilitation	O	O	B-Entity
program	O	O	I-Entity
,	O	O	O
including	O	O	O
testing	O	O	B-Entity
for	O	O	I-Entity
cardiopulmonary	O	O	I-Entity
exercise	O	O	I-Entity
,	O	O	O
maximal	O	O	B-Entity
isometric	O	O	I-Entity
voluntary	O	O	I-Entity
contraction	O	O	I-Entity
,	O	O	O
endothelial	O	O	B-Entity
function	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
.	O	O	O

After	O	O	O
4	O	O	O
weeks	O	O	B-Entity
of	O	O	O
training	O	O	B-Entity
(	O	O	O
16	O	O	O
sessions	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
groups	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
in	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
anthropometric	O	O	B-Entity
characteristics	O	O	B-Entity
,	O	O	O
or	O	O	O
endothelial	O	O	B-Entity
function	O	O	B-Entity
.	O	O	O

With	O	O	O
HML	O	O	B-Entity
,	O	O	O
peak	O	O	B-Entity
power	O	O	B-Entity
output	O	O	I-Entity
(	O	O	O
P=0.035	O	O	O
)	O	O	O
,	O	O	O
maximal	O	O	B-Entity
heart	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
P<0.01	O	O	O
)	O	O	O
and	O	O	O
gain	O	O	B-Entity
of	O	O	O
force	O	O	B-Entity
measured	O	O	B-Entity
in	O	O	O
the	O	O	O
chest	O	O	O
press	O	O	O
position	O	O	O
(	O	O	O
P<0.02	O	O	O
)	O	O	O
were	O	O	O
greater	O	O	B-Entity
after	O	O	O
versus	O	O	O
before	O	O	O
training	O	O	B-Entity
.	O	O	O

Both	O	O	O
protocols	O	O	B-Entity
appeared	O	O	O
to	O	O	O
be	O	O	O
well	O	O	O
tolerated	O	O	O
,	O	O	O
safe	O	O	O
and	O	O	O
feasible	O	O	O
for	O	O	O
these	O	O	O
CHD	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

A	O	O	O
training	O	O	B-Entity
protocol	O	O	I-Entity
involving	O	O	O
6s	O	O	O
phases	O	O	O
of	O	O	O
isometric	O	O	B-Entity
contractions	O	O	I-Entity
with	O	O	O
10s	O	O	O
of	O	O	O
passive	O	O	B-Entity
recovery	O	O	B-Entity
on	O	O	O
an	O	O	O
HML	O	O	B-Entity
device	O	O	O
could	O	O	O
be	O	O	O
safely	O	O	O
implemented	O	O	O
in	O	O	O
rehabilitation	O	O	B-Entity
programs	O	O	I-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
CHD	O	O	B-Entity
and	O	O	O
improve	O	O	O
functional	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27653173)

Percutaneous	O	O	B-Entity
coronary	O	O	I-Entity
intervention	O	O	I-Entity
and	O	O	O
heart	O	O	B-Entity
surgery	O	O	I-Entity
learning	O	O	B-Entity
needs	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
in	O	O	O
Jordan	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
identify	O	O	O
and	O	O	O
prioritize	O	O	B-Entity
the	O	O	O
perceived	O	O	B-Entity
learning	O	O	B-Entity
needs	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
who	O	O	O
underwent	O	O	O
percutaneous	O	O	B-Entity
coronary	O	O	I-Entity
intervention	O	O	I-Entity
or	O	O	O
open-heart	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Identifying	O	O	O
learning	O	O	B-Entity
needs	O	O	O
for	O	O	O
post-cardiac	O	O	B-Entity
intervention	O	O	I-Entity
patients	O	O	B-Entity
is	O	O	O
essential	O	O	O
to	O	O	O
establish	O	O	O
successful	O	O	O
health	O	O	B-Entity
education	O	O	I-Entity
programmes	O	O	I-Entity
based	O	O	O
on	O	O	O
patient	O	O	B-Entity
central	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

A	O	O	O
descriptive	O	O	O
comparative	O	O	O
design	O	O	B-Entity
was	O	O	O
employed	O	O	O
on	O	O	O
a	O	O	O
convenience	O	O	B-Entity
sample	O	O	B-Entity
of	O	O	O
260	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
a	O	O	O
percutaneous	O	O	B-Entity
coronary	O	O	I-Entity
intervention	O	O	I-Entity
and	O	O	O
105	O	O	O
patients	O	O	O
who	O	O	O
underwent	O	O	O
open-heart	O	O	B-Entity
surgery	O	O	I-Entity
patients	O	O	O
.	O	O	O

Participants	O	O	B-Entity
had	O	O	O
completed	O	O	O
the	O	O	O
Patient	O	O	B-Entity
Learning	O	O	B-Entity
Needs	O	O	I-Entity
Scale	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
collected	O	O	O
between	O	O	O
1	O	O	O
October	O	O	O
2014	O	O	O
and	O	O	O
31	O	O	O
June	O	O	O
2015	O	O	O
.	O	O	O

Patients	O	O	B-Entity
from	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
highly	O	O	O
requesting	O	O	O
health	O	O	B-Entity
and	O	O	I-Entity
recovery	O	O	I-Entity
related	O	O	I-Entity
information	O	O	I-Entity
.	O	O	O

They	O	O	O
scored	O	O	O
all	O	O	O
learning	O	O	B-Entity
need	O	O	I-Entity
topics	O	O	B-Entity
as	O	O	O
important	O	O	O
or	O	O	O
highly	O	O	O
important	O	O	O
for	O	O	O
them	O	O	O
.	O	O	O

The	O	O	O
top	O	O	O
priority	O	O	B-Entity
learning	O	O	B-Entity
need	O	O	O
for	O	O	O
both	O	O	O
patient	O	O	B-Entity
groups	O	O	I-Entity
was	O	O	O
'	O	O	O
information	O	O	B-Entity
about	O	O	O
wound	O	O	B-Entity
care	O	O	I-Entity
'	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
lowest	O	O	O
priority	O	O	O
learning	O	O	O
need	O	O	O
topic	O	O	B-Entity
was	O	O	O
'	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
'	O	O	O
.	O	O	O

The	O	O	O
learning	O	O	B-Entity
needs	O	O	B-Entity
of	O	O	O
both	O	O	O
groups	O	O	B-Entity
were	O	O	O
very	O	O	O
close	O	O	O
,	O	O	O
which	O	O	O
indicated	O	O	O
that	O	O	O
educational	O	O	B-Entity
secondary	O	O	I-Entity
prevention	O	O	I-Entity
programmes	O	O	I-Entity
'	O	O	O
content	O	O	O
can	O	O	O
be	O	O	O
prepared	O	O	O
in	O	O	O
a	O	O	O
unified	O	O	O
structure	O	O	O
for	O	O	O
those	O	O	O
patients	O	O	B-Entity
.	O	O	O

Although	O	O	O
,	O	O	O
specific	O	O	O
headings	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
address	O	O	O
the	O	O	O
unique	O	O	O
needs	O	O	B-Entity
that	O	O	O
emerge	O	O	O
from	O	O	O
having	O	O	O
a	O	O	O
specific	O	O	O
cardiac	O	O	B-Entity
interventional	O	O	B-Entity
procedure	O	O	I-Entity
.	O	O	O

The	O	O	O
fact	O	O	O
that	O	O	O
wound	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
medications	O	O	B-Entity
are	O	O	O
areas	O	O	O
of	O	O	O
highest	O	O	O
learning	O	O	B-Entity
needs	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
requires	O	O	O
health	O	O	B-Entity
policy	O	O	I-Entity
decision	O	O	B-Entity
makers	O	O	I-Entity
to	O	O	O
address	O	O	O
these	O	O	O
topics	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
a	O	O	O
policy	O	O	B-Entity
focus	O	O	O
on	O	O	O
considering	O	O	O
patients	O	O	B-Entity
'	O	O	O
actual	O	O	O
learning	O	O	B-Entity
needs	O	O	B-Entity
requires	O	O	O
establishment	O	O	B-Entity
and	O	O	O
managerial	O	O	B-Entity
support	O	O	I-Entity
.	O	O	O

As	O	O	O
patients	O	O	B-Entity
'	O	O	O
learning	O	O	B-Entity
needs	O	O	B-Entity
might	O	O	O
change	O	O	O
later	O	O	O
after	O	O	O
discharge	O	O	B-Entity
,	O	O	O
the	O	O	O
health	O	O	B-Entity
services	O	O	I-Entity
should	O	O	O
be	O	O	O
proactive	O	O	O
and	O	O	O
focus	O	O	O
on	O	O	O
continuous	O	O	O
support	O	O	B-Entity
for	O	O	O
patients	O	O	O
after	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
.	O	O	O

Secondary	O	O	B-Entity
prevention	O	O	I-Entity
programmes	O	O	I-Entity
should	O	O	O
incorporate	O	O	O
health	O	O	B-Entity
education	O	O	I-Entity
topics	O	O	B-Entity
based	O	O	O
on	O	O	O
patients	O	O	B-Entity
'	O	O	O
own	O	O	O
views	O	O	O
.	O	O	O

This	O	O	O
can	O	O	O
be	O	O	O
done	O	O	O
by	O	O	O
giving	O	O	O
higher	O	O	O
priority	O	O	B-Entity
to	O	O	O
understand	O	O	O
patients	O	O	B-Entity
'	O	O	I-Entity
needs	O	O	B-Entity
,	O	O	O
put	O	O	O
much	O	O	O
more	O	O	O
effort	O	O	O
into	O	O	O
how	O	O	O
to	O	O	O
meet	O	O	O
patients	O	O	O
'	O	O	O
information	O	O	B-Entity
needs	O	O	O
and	O	O	O
to	O	O	O
create	O	O	O
a	O	O	O
more	O	O	O
engaging	O	O	O
learning	O	O	B-Entity
environment	O	O	B-Entity
for	O	O	O
patients	O	O	O
and	O	O	O
their	O	O	O
families	O	O	B-Entity
.	O	O	O

-DOCSTART- (27653736)

Complications	O	O	B-Entity
and	O	O	O
Near-Miss	O	O	O
Events	O	O	B-Entity
After	O	O	O
Hepatectomy	O	O	B-Entity
for	O	O	O
Living-Related	O	O	B-Entity
Liver	O	O	I-Entity
Donation	O	O	I-Entity
:	O	O	O
An	O	O	O
Italian	O	O	B-Entity
Single	O	O	B-Entity
Center	O	O	I-Entity
Report	O	O	B-Entity
of	O	O	O
One	O	O	O
Hundred	O	O	O
Cases	O	O	O

BACKGROUND	O	O	O
In	O	O	O
healthy	O	O	B-Entity
individuals	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
liver	O	O	B-Entity
living	O	O	I-Entity
donors	O	O	I-Entity
,	O	O	O
potential	O	O	O
complications	O	O	B-Entity
may	O	O	O
occur	O	O	O
during	O	O	O
surgery	O	O	B-Entity
.	O	O	O

Reporting	O	O	O
such	O	O	O
complications	O	O	B-Entity
and	O	O	O
near-miss	O	O	O
events	O	O	O
is	O	O	O
mandatory	O	O	O
to	O	O	O
improve	O	O	O
living	O	O	B-Entity
donor	O	O	I-Entity
management	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
.	O	O	O

MATERIAL	O	O	O
AND	O	O	O
METHODS	O	O	O
This	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
performed	O	O	O
on	O	O	O
a	O	O	O
prospective	O	O	O
database	O	O	B-Entity
with	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
providing	O	O	O
a	O	O	O
brief	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
perioperative	O	O	B-Entity
,	O	O	O
medium-term	O	O	B-Entity
,	O	O	O
and	O	O	O
long-term	O	O	B-Entity
complications	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
near-miss	O	O	O
events	O	O	B-Entity
in	O	O	O
a	O	O	O
single	O	O	B-Entity
center	O	O	I-Entity
series	O	O	O
of	O	O	O
100	O	O	O
consecutive	O	O	O
liver	O	O	B-Entity
resections	O	O	I-Entity
for	O	O	O
adult	O	O	B-Entity
-to-	O	O	O
adult	O	O	O
living-donor	O	O	B-Entity
liver	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

RESULTS	O	O	O
Only	O	O	O
23.3	O	O	O
%	O	O	O
of	O	O	O
potential	O	O	O
living	O	O	B-Entity
donors	O	O	I-Entity
underwent	O	O	O
surgery	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
living	O	O	B-Entity
donor	O	O	I-Entity
mortality	O	O	B-Entity
was	O	O	O
reported	O	O	O
;	O	O	O
29	O	O	O
patients	O	O	B-Entity
(	O	O	O
29	O	O	O
%	O	O	O
)	O	O	O
experienced	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
complication	O	O	B-Entity
.	O	O	O

Five	O	O	O
patients	O	O	B-Entity
developed	O	O	O
mild	O	O	B-Entity
long-term	O	O	B-Entity
dysfunction	O	O	B-Entity
;	O	O	O
two	O	O	O
aborted	O	O	O
hepatectomies	O	O	B-Entity
,	O	O	O
and	O	O	O
there	O	O	O
were	O	O	O
two	O	O	O
near-miss	O	O	O
events	O	O	B-Entity
reported	O	O	O
.	O	O	O

CONCLUSIONS	O	O	O
A	O	O	O
strategy	O	O	B-Entity
for	O	O	O
an	O	O	O
accurate	O	O	O
assessment	O	O	B-Entity
of	O	O	O
living	O	O	B-Entity
donor	O	O	I-Entity
complications	O	O	B-Entity
and	O	O	O
strict	O	O	O
selection	O	O	B-Entity
criterion	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
overemphasized	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
continuously	O	O	O
update	O	O	O
center	O	O	B-Entity
patient	O	O	B-Entity
outcome	O	O	I-Entity
reports	O	O	B-Entity
.	O	O	O

-DOCSTART- (27658531)

Tooth	O	O	B-Entity
wear	O	O	I-Entity
as	O	O	O
a	O	O	O
means	O	O	O
to	O	O	O
quantify	O	O	B-Entity
intra-specific	O	O	B-Entity
variations	O	O	B-Entity
in	O	O	O
diet	O	O	B-Entity
and	O	O	O
chewing	O	O	B-Entity
movements	O	O	O

In	O	O	O
mammals	O	O	B-Entity
,	O	O	O
tooth	O	O	B-Entity
function	O	O	B-Entity
,	O	O	O
and	O	O	O
its	O	O	O
efficiency	O	O	B-Entity
,	O	O	O
depends	O	O	O
both	O	O	O
on	O	O	O
the	O	O	O
mechanical	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
the	O	O	O
food	O	O	B-Entity
and	O	O	O
on	O	O	O
chewing	O	O	B-Entity
dynamics	O	O	B-Entity
.	O	O	O

These	O	O	O
aspects	O	O	B-Entity
have	O	O	O
rarely	O	O	O
been	O	O	O
studied	O	O	B-Entity
in	O	O	O
combination	O	O	O
and/or	O	O	O
at	O	O	O
the	O	O	O
intra-specific	O	O	B-Entity
level	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
applied	O	O	O
3D	O	O	B-Entity
dental	O	O	B-Entity
surface	O	O	B-Entity
texture	O	O	B-Entity
analysis	O	O	B-Entity
to	O	O	O
a	O	O	O
sample	O	O	B-Entity
of	O	O	O
field	O	O	B-Entity
voles	O	O	I-Entity
(	O	O	O
Microtus	O	O	B-Entity
agrestis	O	O	I-Entity
)	O	O	O
trapped	O	O	O
from	O	O	O
Finnish	O	O	B-Entity
Lapland	O	O	I-Entity
at	O	O	O
different	O	O	O
seasons	O	O	B-Entity
and	O	O	O
localities	O	O	B-Entity
to	O	O	O
test	O	O	B-Entity
for	O	O	O
inter-population	O	O	B-Entity
variations	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
explored	O	O	O
intra-individual	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
chewing	O	O	B-Entity
dynamics	O	O	B-Entity
by	O	O	O
analysing	O	O	B-Entity
two	O	O	O
facets	O	O	B-Entity
on	O	O	O
the	O	O	O
second	O	O	B-Entity
upper	O	O	I-Entity
molars	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
confirm	O	O	O
that	O	O	O
the	O	O	O
two	O	O	O
localities	O	O	B-Entity
have	O	O	O
similar	O	O	O
environments	O	O	B-Entity
and	O	O	O
that	O	O	O
the	O	O	O
voles	O	O	B-Entity
feed	O	O	B-Entity
on	O	O	O
the	O	O	O
same	O	O	O
items	O	O	O
there	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
the	O	O	O
texture	O	O	B-Entity
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
diets	O	O	B-Entity
are	O	O	O
seasonally	O	O	O
variable	O	O	B-Entity
,	O	O	O
probably	O	O	O
due	O	O	O
to	O	O	O
varying	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
abrasives	O	O	B-Entity
.	O	O	O

Lastly	O	O	O
,	O	O	O
the	O	O	O
textures	O	O	B-Entity
on	O	O	O
the	O	O	O
buccal	O	O	B-Entity
facets	O	O	B-Entity
are	O	O	O
more	O	O	O
isotropic	O	O	B-Entity
and	O	O	O
their	O	O	O
direction	O	O	B-Entity
deviates	O	O	B-Entity
more	O	O	O
from	O	O	O
the	O	O	O
mesial	O	O	B-Entity
chewing	O	O	B-Entity
direction	O	O	O
than	O	O	O
the	O	O	O
lingual	O	O	B-Entity
facets	O	O	O
.	O	O	O

We	O	O	O
interpret	O	O	B-Entity
these	O	O	O
results	O	O	B-Entity
as	O	O	O
reflecting	O	O	O
food	O	O	B-Entity
,	O	O	O
rather	O	O	O
than	O	O	O
chewing	O	O	B-Entity
,	O	O	O
movements	O	O	B-Entity
,	O	O	O
where	O	O	O
food	O	O	B-Entity
particles	O	O	I-Entity
are	O	O	O
more	O	O	O
guided	O	O	O
on	O	O	O
the	O	O	O
lingual	O	O	B-Entity
side	O	O	O
of	O	O	O
the	O	O	O
molars	O	O	B-Entity
.	O	O	O

This	O	O	O
has	O	O	O
implications	O	O	O
for	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
dental	O	O	B-Entity
microwear	O	O	I-Entity
analysis	O	O	B-Entity
to	O	O	O
fossils	O	O	B-Entity
:	O	O	O
only	O	O	O
homologous	O	O	B-Entity
facets	O	O	B-Entity
can	O	O	O
be	O	O	O
compared	O	O	O
,	O	O	O
even	O	O	O
when	O	O	O
the	O	O	O
molar	O	O	B-Entity
row	O	O	O
seems	O	O	O
to	O	O	O
constitute	O	O	O
a	O	O	O
functional	O	O	B-Entity
unit	O	O	I-Entity
.	O	O	O

-DOCSTART- (27659310)

Human	O	O	B-Entity
cathelicidin	O	O	I-Entity
LL-37	O	O	I-Entity
enhance	O	O	O
the	O	O	O
antibiofilm	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
EGCG	O	O	B-Entity
on	O	O	O
Streptococcus	O	O	O
mutans	O	O	O

Streptococcus	O	O	B-Entity
mutans	O	O	I-Entity
forms	O	O	O
biofilms	O	O	B-Entity
as	O	O	O
a	O	O	O
resistance	O	O	B-Entity
mechanism	O	O	B-Entity
against	O	O	O
antimicrobial	O	O	B-Entity
agents	O	O	I-Entity
in	O	O	O
the	O	O	O
human	O	O	B-Entity
oral	O	O	B-Entity
cavity	O	O	I-Entity
.	O	O	O

We	O	O	O
recently	O	O	O
showed	O	O	O
that	O	O	O
human	O	O	B-Entity
cathelicidin	O	O	I-Entity
LL-37	O	O	I-Entity
exhibits	O	O	O
inhibitory	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
through	O	O	O
interaction	O	O	B-Entity
with	O	O	O
lipoteichoic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
LTA	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
without	O	O	O
antibacterial	O	O	B-Entity
or	O	O	O
biofilm	O	O	O
dispersal	O	O	B-Entity
abilities	O	O	I-Entity
.	O	O	O

(-)-Epigallocatechin	O	O	B-Entity
gallate	O	O	I-Entity
(	O	O	O
EGCG	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
abundant	O	O	O
constituent	O	O	O
of	O	O	O
tea	O	O	B-Entity
catechins	O	O	B-Entity
that	O	O	O
has	O	O	O
the	O	O	O
greatest	O	O	O
anti-infective	O	O	B-Entity
potential	O	O	I-Entity
to	O	O	O
inhibit	O	O	B-Entity
the	O	O	I-Entity
growth	O	O	I-Entity
of	O	O	O
various	O	O	O
microorganisms	O	O	B-Entity
and	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
evaluated	O	O	B-Entity
whether	O	O	O
LL-37	O	O	B-Entity
interacts	O	O	O
with	O	O	O
EGCG	O	O	B-Entity
to	O	O	O
enhance	O	O	O
the	O	O	O
antibiofilm	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
EGCG	O	O	O
on	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
biofilm	O	O	B-Entity
formation	O	O	I-Entity
.	O	O	O

Clinical	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
strains	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
10	O	O	O
)	O	O	O
isolated	O	O	O
from	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
saliva	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
in	O	O	O
a	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
assay	O	O	B-Entity
.	O	O	O

The	O	O	O
antibiofilm	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
EGCG	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
LL-37	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
the	O	O	O
minimum	O	O	O
biofilm	O	O	B-Entity
eradication	O	O	B-Entity
concentration	O	O	B-Entity
assay	O	O	B-Entity
and	O	O	O
confirmed	O	O	O
using	O	O	O
field	O	O	O
emission-scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
interaction	O	O	B-Entity
among	O	O	O
EGCG	O	O	B-Entity
,	O	O	O
LL-37	O	O	B-Entity
,	O	O	O
and	O	O	O
LTA	O	O	B-Entity
of	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
was	O	O	O
determined	O	O	O
using	O	O	O
quartz	O	O	B-Entity
crystal	O	O	I-Entity
microbalance	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

EGCG	O	O	B-Entity
killed	O	O	O
100	O	O	O
%	O	O	O
of	O	O	O
planktonic	O	O	B-Entity
S.	O	O	B-Entity
mutans	O	O	I-Entity
within	O	O	O
5	O	O	O
h	O	O	O
,	O	O	O
inhibited	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
within	O	O	O
24	O	O	O
h	O	O	O
,	O	O	O
and	O	O	O
reduced	O	O	O
bacteria	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
preformed	O	O	O
biofilms	O	O	B-Entity
within	O	O	O
3	O	O	O
h	O	O	O
at	O	O	O
a	O	O	O
concentration	O	O	B-Entity
of	O	O	O
0.2	O	O	O
mg/mL.	O	O	O
However	O	O	O
,	O	O	O
EGCG	O	O	O
did	O	O	O
not	O	O	O
appear	O	O	O
to	O	O	O
interact	O	O	O
with	O	O	O
LTA	O	O	B-Entity
.	O	O	O

LL-37	O	O	B-Entity
effectively	O	O	O
enhanced	O	O	O
the	O	O	O
bactericidal	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
EGCG	O	O	B-Entity
against	O	O	O
biofilm	O	O	B-Entity
formation	O	O	I-Entity
and	O	O	O
preformed	O	O	O
biofilms	O	O	B-Entity
as	O	O	O
determined	O	O	O
by	O	O	O
quantitative	O	O	B-Entity
crystal	O	O	B-Entity
violet	O	O	I-Entity
staining	O	O	B-Entity
and	O	O	O
field	O	O	O
emission-scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
quartz	O	O	B-Entity
crystal	O	O	I-Entity
microbalance	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
LL-37	O	O	B-Entity
interacted	O	O	B-Entity
with	O	O	O
EGCG	O	O	B-Entity
and	O	O	O
promoted	O	O	O
binding	O	O	B-Entity
between	O	O	O
EGCG	O	O	O
and	O	O	O
LTA	O	O	B-Entity
of	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
LL-37	O	O	B-Entity
enhances	O	O	O
the	O	O	O
antibiofilm	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
EGCG	O	O	B-Entity
on	O	O	O
S.	O	O	B-Entity
mutans	O	O	I-Entity
.	O	O	O

This	O	O	O
finding	O	O	O
provides	O	O	O
new	O	O	O
knowledge	O	O	O
for	O	O	O
dental	O	O	B-Entity
treatment	O	O	I-Entity
by	O	O	O
using	O	O	O
LL-37	O	O	B-Entity
as	O	O	O
a	O	O	O
potential	O	O	O
antibiofilm	O	O	B-Entity
compound	O	O	I-Entity
.	O	O	O

-DOCSTART- (27660855)

Discovery	O	O	B-Entity
of	O	O	O
Orally	O	O	B-Entity
Efficacious	O	O	B-Entity
Phosphoinositide-3-Kinase	O	O	B-Entity
delta	O	O	I-Entity
Inhibitors	O	O	B-Entity
with	O	O	O
Improved	O	O	B-Entity
Metabolic	O	O	B-Entity
Stability	O	O	O

Aberrant	O	O	B-Entity
signaling	O	O	I-Entity
of	O	O	O
phosphoinositide-3-kinase	O	O	B-Entity
delta	O	O	I-Entity
(	O	O	O
PI3K-delta	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
implicated	O	O	O
in	O	O	O
numerous	O	O	O
pathologies	O	O	B-Entity
including	O	O	O
hematological	O	O	B-Entity
malignancies	O	O	I-Entity
and	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
.	O	O	O

Described	O	O	O
in	O	O	O
this	O	O	O
manuscript	O	O	O
is	O	O	O
the	O	O	O
discovery	O	O	B-Entity
,	O	O	O
optimization	O	O	B-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
evaluation	O	O	B-Entity
of	O	O	O
a	O	O	O
novel	O	O	O
series	O	O	O
of	O	O	O
pyridine-containing	O	O	B-Entity
PI3K-delta	O	O	B-Entity
inhibitors	O	O	B-Entity
.	O	O	O

This	O	O	O
work	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
35	O	O	B-Entity
,	O	O	O
a	O	O	O
highly	O	O	O
selective	O	O	O
inhibitor	O	O	B-Entity
of	O	O	O
PI3K-delta	O	O	B-Entity
which	O	O	O
displays	O	O	O
an	O	O	O
excellent	O	O	O
pharmacokinetic	O	O	B-Entity
profile	O	O	I-Entity
and	O	O	O
is	O	O	O
efficacious	O	O	B-Entity
in	O	O	O
a	O	O	O
rodent	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27665258)

Mobile	O	O	B-Entity
phone	O	O	I-Entity
use	O	O	B-Entity
,	O	O	O
behavioural	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
concentration	O	O	B-Entity
capacity	O	O	B-Entity
in	O	O	O
adolescents	O	O	B-Entity
:	O	O	O
A	O	O	O
prospective	O	O	O
study	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
prospectively	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
radiofrequency	O	O	B-Entity
electromagnetic	O	O	I-Entity
fields	O	O	I-Entity
(	O	O	O
RF-EMF	O	O	B-Entity
)	O	O	O
emitted	O	O	O
by	O	O	O
mobile	O	O	B-Entity
phones	O	O	I-Entity
and	O	O	O
other	O	O	O
wireless	O	O	B-Entity
communication	O	O	I-Entity
devices	O	O	I-Entity
is	O	O	O
related	O	O	O
to	O	O	O
behavioural	O	O	B-Entity
problems	O	O	I-Entity
or	O	O	O
concentration	O	O	B-Entity
capacity	O	O	B-Entity
in	O	O	O
adolescents	O	O	B-Entity
.	O	O	O

The	O	O	O
HERMES	O	O	B-Entity
(	O	O	O
Health	O	O	B-Entity
Effects	O	O	B-Entity
Related	O	O	B-Entity
to	O	O	O
Mobile	O	O	B-Entity
phonE	O	O	I-Entity
use	O	O	O
in	O	O	O
adolescentS	O	O	B-Entity
)	O	O	O
study	O	O	O
sample	O	O	B-Entity
consisted	O	O	O
of	O	O	O
439	O	O	O
Swiss	O	O	B-Entity
adolescents	O	O	B-Entity
aged	O	O	B-Entity
12	O	O	O
-	O	O	O
17	O	O	O
years	O	O	B-Entity
.	O	O	O

Behavioural	O	O	B-Entity
problems	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Strengths	O	O	B-Entity
and	O	O	I-Entity
Difficulties	O	O	I-Entity
Questionnaire	O	O	I-Entity
(	O	O	O
SDQ	O	O	B-Entity
)	O	O	O
,	O	O	O
concentration	O	O	B-Entity
capacity	O	O	B-Entity
of	O	O	O
the	O	O	O
adolescents	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
a	O	O	O
standardized	O	O	B-Entity
computerized	O	O	I-Entity
cognitive	O	O	I-Entity
test	O	O	I-Entity
named	O	O	O
FAKT	O	O	B-Entity
.	O	O	O

Cross-sectional	O	O	B-Entity
and	O	O	O
longitudinal	O	O	B-Entity
(	O	O	O
1year	O	O	B-Entity
of	O	O	O
follow-up	O	O	B-Entity
)	O	O	O
analyses	O	O	B-Entity
were	O	O	O
performed	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
possible	O	O	O
associations	O	O	B-Entity
between	O	O	O
behavioural	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
concentration	O	O	B-Entity
capacity	O	O	B-Entity
and	O	O	O
different	O	O	B-Entity
exposure	O	O	B-Entity
measures	O	O	B-Entity
:	O	O	O
self-reported	O	O	B-Entity
and	O	O	O
operator	O	O	B-Entity
-recorded	O	O	O
wireless	O	O	B-Entity
communication	O	O	I-Entity
device	O	O	I-Entity
use	O	O	O
,	O	O	O
cumulative	O	O	B-Entity
RF-EMF	O	O	B-Entity
brain	O	O	B-Entity
and	O	O	O
whole	O	O	B-Entity
body	O	O	I-Entity
dose	O	O	O
and	O	O	O
measured	O	O	B-Entity
personal	O	O	O
RF-EMF	O	O	O
exposure	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
cross-sectional	O	O	B-Entity
analyses	O	O	I-Entity
behavioural	O	O	B-Entity
problems	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
several	O	O	O
self-reported	O	O	B-Entity
wireless	O	O	B-Entity
device	O	O	I-Entity
use	O	O	B-Entity
measures	O	O	B-Entity
but	O	O	O
not	O	O	O
operator	O	O	B-Entity
-recorded	O	O	O
mobile	O	O	B-Entity
phone	O	O	I-Entity
use	O	O	O
measures	O	O	O
,	O	O	O
concentration	O	O	B-Entity
capacity	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
several	O	O	O
self-reported	O	O	O
and	O	O	O
operator	O	O	O
-recorded	O	O	O
exposures	O	O	B-Entity
.	O	O	O

The	O	O	O
longitudinal	O	O	B-Entity
analyses	O	O	I-Entity
point	O	O	O
towards	O	O	O
absence	O	O	B-Entity
of	O	O	O
associations	O	O	B-Entity
.	O	O	O

The	O	O	O
lack	O	O	B-Entity
of	O	O	O
consistent	O	O	B-Entity
exposure	O	O	B-Entity
-response	O	O	O
patterns	O	O	B-Entity
in	O	O	O
the	O	O	O
longitudinal	O	O	B-Entity
analyses	O	O	I-Entity
suggests	O	O	O
that	O	O	O
behavioural	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
concentration	O	O	B-Entity
capacity	O	O	B-Entity
are	O	O	O
not	O	O	O
affected	O	O	B-Entity
by	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
wireless	O	O	B-Entity
communication	O	O	I-Entity
devices	O	O	I-Entity
or	O	O	O
RF-EMF	O	O	B-Entity
exposure	O	O	O
.	O	O	O

Information	O	O	B-Entity
bias	O	O	B-Entity
and	O	O	O
reverse	O	O	O
causality	O	O	O
are	O	O	O
likely	O	O	O
explanations	O	O	B-Entity
for	O	O	O
the	O	O	O
observed	O	O	O
cross-sectional	O	O	B-Entity
findings	O	O	I-Entity
.	O	O	O

-DOCSTART- (27665545)

Twisting	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
reducing	O	O	B-Entity
friction	O	O	B-Entity
during	O	O	O
insertion	O	O	B-Entity
of	O	O	O
a	O	O	O
sheath	O	O	B-Entity
introducer	O	O	B-Entity
and	O	O	O
a	O	O	O
sheathless	O	O	O
guiding	O	O	O
catheter	O	O	O

A	O	O	O
sheathless	O	O	B-Entity
system	O	O	I-Entity
that	O	O	O
inserts	O	O	B-Entity
a	O	O	O
catheter	O	O	B-Entity
directly	O	O	B-Entity
into	O	O	O
the	O	O	O
artery	O	O	B-Entity
can	O	O	O
reduce	O	O	B-Entity
puncture	O	O	B-Entity
site	O	O	B-Entity
-related	O	O	O
complications	O	O	B-Entity
through	O	O	O
a	O	O	O
2-Fr	O	O	B-Entity
reduction	O	O	I-Entity
of	O	O	O
the	O	O	O
outer	O	O	B-Entity
diameter	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
gap	O	O	B-Entity
between	O	O	O
the	O	O	O
dilator	O	O	B-Entity
and	O	O	O
the	O	O	O
guiding	O	O	B-Entity
catheter	O	O	I-Entity
of	O	O	O
the	O	O	O
sheathless	O	O	B-Entity
system	O	O	I-Entity
is	O	O	O
larger	O	O	B-Entity
than	O	O	O
the	O	O	O
gap	O	O	O
between	O	O	O
the	O	O	O
dilator	O	O	O
and	O	O	O
sheath	O	O	B-Entity
of	O	O	O
the	O	O	O
introducer	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
stronger	O	O	O
insertion	O	O	B-Entity
resistance	O	O	B-Entity
.	O	O	O

A	O	O	O
twisting	O	O	B-Entity
method	O	O	I-Entity
with	O	O	O
rapid	O	O	B-Entity
alternating	O	O	B-Entity
rotation	O	O	B-Entity
of	O	O	O
a	O	O	O
device	O	O	B-Entity
to	O	O	O
the	O	O	O
left	O	O	O
and	O	O	O
right	O	O	O
during	O	O	O
insertion	O	O	B-Entity
can	O	O	O
reduce	O	O	B-Entity
the	O	O	O
insertion	O	O	O
resistance	O	O	B-Entity
.	O	O	O

This	O	O	O
method	O	O	O
can	O	O	O
be	O	O	O
effective	O	O	B-Entity
with	O	O	O
the	O	O	O
sheathless	O	O	B-Entity
system	O	O	I-Entity
which	O	O	O
has	O	O	O
a	O	O	O
larger	O	O	B-Entity
gap	O	O	B-Entity
.	O	O	O

To	O	O	O
examine	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
size	O	O	B-Entity
reduction	O	O	B-Entity
on	O	O	O
the	O	O	O
sheathless	O	O	B-Entity
system	O	O	I-Entity
and	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
insertion	O	O	B-Entity
resistance	O	O	B-Entity
reduction	O	O	O
using	O	O	O
the	O	O	O
twisting	O	O	B-Entity
method	O	O	I-Entity
,	O	O	O
we	O	O	O
developed	O	O	O
an	O	O	O
insertion	O	O	O
simulator	O	O	B-Entity
and	O	O	O
compared	O	O	B-Entity
insertion	O	O	O
resistance	O	O	O
to	O	O	O
a	O	O	O
5-Fr	O	O	B-Entity
sheath	O	O	I-Entity
introducer	O	O	B-Entity
and	O	O	O
a	O	O	O
5-Fr	O	O	B-Entity
sheathless	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
with	O	O	O
and	O	O	O
without	O	O	O
the	O	O	O
twisting	O	O	O
method	O	O	O
.	O	O	O

The	O	O	O
insertion	O	O	B-Entity
simulator	O	O	B-Entity
pushed	O	O	O
a	O	O	O
sheath	O	O	B-Entity
introducer	O	O	B-Entity
or	O	O	O
a	O	O	O
sheathless	O	O	B-Entity
system	O	O	I-Entity
toward	O	O	O
a	O	O	O
mock	O	O	B-Entity
artery	O	O	B-Entity
consisted	O	O	O
with	O	O	O
a	O	O	O
5-mm	O	O	B-Entity
urethane	O	O	I-Entity
and	O	O	O
a	O	O	O
1-mm	O	O	B-Entity
rubber	O	O	I-Entity
sheet	O	O	I-Entity
by	O	O	O
an	O	O	O
electrical	O	O	B-Entity
motor	O	O	I-Entity
with	O	O	O
or	O	O	O
without	O	O	O
twisting	O	O	B-Entity
motion	O	O	B-Entity
generated	O	O	O
by	O	O	O
a	O	O	O
crank	O	O	B-Entity
shaft	O	O	I-Entity
.	O	O	O

Insertion	O	O	B-Entity
resistance	O	O	B-Entity
during	O	O	O
the	O	O	O
penetration	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
by	O	O	O
a	O	O	O
tension	O	O	B-Entity
meter	O	O	I-Entity
.	O	O	O

The	O	O	O
insertion	O	O	B-Entity
resistance	O	O	B-Entity
was	O	O	O
less	O	O	O
with	O	O	O
the	O	O	O
5-Fr	O	O	B-Entity
sheathless	O	O	I-Entity
system	O	O	I-Entity
than	O	O	O
with	O	O	O
the	O	O	O
5-Fr	O	O	B-Entity
sheath	O	O	I-Entity
introducer	O	O	B-Entity
.	O	O	O

The	O	O	O
resistance	O	O	B-Entity
reduced	O	O	B-Entity
further	O	O	O
with	O	O	O
use	O	O	O
of	O	O	O
twisting	O	O	B-Entity
for	O	O	O
both	O	O	O
the	O	O	O
sheathed	O	O	B-Entity
and	O	O	O
sheathless	O	O	B-Entity
catheters	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
the	O	O	O
experiment	O	O	O
suggests	O	O	O
the	O	O	O
benefits	O	O	B-Entity
of	O	O	O
twisting	O	O	B-Entity
insertion	O	O	B-Entity
of	O	O	O
a	O	O	O
sheathless	O	O	B-Entity
guiding	O	O	I-Entity
catheter	O	O	I-Entity
for	O	O	O
reduction	O	O	B-Entity
of	O	O	O
puncture	O	O	B-Entity
site	O	O	B-Entity
-related	O	O	O
complications	O	O	B-Entity
.	O	O	O

-DOCSTART- (27665550)

Unconventional	O	O	B-Entity
Protein	O	O	B-Entity
Secretion	O	O	I-Entity
in	O	O	O
Plants	O	O	O

Unconventional	O	O	B-Entity
protein	O	O	B-Entity
secretion	O	O	B-Entity
(	O	O	O
UPS	O	O	B-Entity
)	O	O	O
describes	O	O	B-Entity
secretion	O	O	B-Entity
pathways	O	O	I-Entity
that	O	O	O
bypass	O	O	O
one	O	O	O
or	O	O	O
several	O	O	B-Entity
of	O	O	O
the	O	O	O
canonical	O	O	B-Entity
secretion	O	O	O
pit-stops	O	O	O
on	O	O	O
the	O	O	O
way	O	O	O
to	O	O	O
the	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
,	O	O	O
and/or	O	O	O
involve	O	O	B-Entity
the	O	O	O
secretion	O	O	O
of	O	O	O
leaderless	O	O	O
proteins	O	O	B-Entity
.	O	O	O

So	O	O	O
far	O	O	O
,	O	O	O
alternatives	O	O	B-Entity
to	O	O	O
conventional	O	O	B-Entity
secretion	O	O	B-Entity
were	O	O	O
primarily	O	O	B-Entity
observed	O	O	B-Entity
and	O	O	O
studied	O	O	B-Entity
in	O	O	O
yeast	O	O	B-Entity
and	O	O	O
animal	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
sessile	O	O	B-Entity
lifestyle	O	O	O
of	O	O	O
plants	O	O	B-Entity
brings	O	O	O
with	O	O	O
it	O	O	O
unique	O	O	B-Entity
restraints	O	O	O
on	O	O	O
how	O	O	O
they	O	O	O
adapt	O	O	B-Entity
to	O	O	I-Entity
adverse	O	O	I-Entity
conditions	O	O	I-Entity
and	O	O	O
environmental	O	O	B-Entity
challenges	O	O	I-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
attention	O	O	B-Entity
towards	O	O	O
unconventional	O	O	B-Entity
secretion	O	O	B-Entity
pathways	O	O	I-Entity
in	O	O	O
plant	O	O	B-Entity
cells	O	O	I-Entity
has	O	O	O
substantially	O	O	O
increased	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
large	O	O	O
number	O	O	O
of	O	O	O
leaderless	O	O	O
proteins	O	O	B-Entity
identified	O	O	B-Entity
through	O	O	O
proteomic	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

While	O	O	O
UPS	O	O	B-Entity
pathways	O	O	B-Entity
in	O	O	O
plants	O	O	B-Entity
are	O	O	O
certainly	O	O	O
not	O	O	O
yet	O	O	O
exhaustively	O	O	O
researched	O	O	O
,	O	O	O
an	O	O	O
emerging	O	O	O
notion	O	O	O
is	O	O	O
that	O	O	O
induction	O	O	B-Entity
of	O	O	O
UPS	O	O	O
pathways	O	O	O
is	O	O	O
correlated	O	O	B-Entity
with	O	O	O
pathogenesis	O	O	B-Entity
and	O	O	O
stress	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
multitude	O	O	O
UPS	O	O	B-Entity
events	O	O	O
observed	O	O	O
,	O	O	O
comprehensively	O	O	B-Entity
organizing	O	O	B-Entity
the	O	O	O
routes	O	O	O
proteins	O	O	B-Entity
take	O	O	O
to	O	O	O
the	O	O	O
apoplast	O	O	B-Entity
in	O	O	O
defined	O	O	O
UPS	O	O	O
categories	O	O	O
is	O	O	O
challenging	O	O	O
.	O	O	O

With	O	O	O
the	O	O	O
establishment	O	O	B-Entity
of	O	O	O
a	O	O	O
larger	O	O	O
collection	O	O	B-Entity
of	O	O	O
studied	O	O	O
plant	O	O	B-Entity
proteins	O	O	I-Entity
taking	O	O	O
these	O	O	O
UPS	O	O	B-Entity
pathways	O	O	B-Entity
,	O	O	O
a	O	O	O
clearer	O	O	O
picture	O	O	O
of	O	O	O
endomembrane	O	O	B-Entity
trafficking	O	O	B-Entity
as	O	O	O
a	O	O	O
whole	O	O	O
will	O	O	O
emerge	O	O	O
.	O	O	O

There	O	O	O
are	O	O	O
several	O	O	B-Entity
novel	O	O	B-Entity
enabling	O	O	B-Entity
technologies	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
vesicle	O	O	B-Entity
proteomics	O	O	B-Entity
and	O	O	O
chemical	O	O	B-Entity
genomics	O	O	B-Entity
,	O	O	O
with	O	O	O
great	O	O	O
potential	O	O	B-Entity
for	O	O	O
dissecting	O	O	B-Entity
secretion	O	O	B-Entity
pathways	O	O	I-Entity
,	O	O	O
providing	O	O	B-Entity
information	O	O	B-Entity
about	O	O	O
the	O	O	O
cargo	O	O	O
that	O	O	O
travels	O	O	O
along	O	O	O
them	O	O	O
and	O	O	O
the	O	O	O
conditions	O	O	O
that	O	O	O
induce	O	O	B-Entity
them	O	O	O
.	O	O	O

-DOCSTART- (27669010)

Neospora	O	O	B-Entity
caninum	O	O	I-Entity
in	O	O	O
Axis	O	O	B-Entity
Deer	O	O	I-Entity
(	O	O	O
Axis	O	O	B-Entity
axis	O	O	I-Entity
)	O	O	O
and	O	O	O
Fallow	O	O	B-Entity
Deer	O	O	I-Entity
(	O	O	O
Dama	O	O	B-Entity
dama	O	O	I-Entity
)	O	O	O
in	O	O	O
Northern	O	O	B-Entity
Mexico	O	O	O

Serum	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
18	O	O	O
axis	O	O	B-Entity
deer	O	O	I-Entity
(	O	O	O
Axis	O	O	B-Entity
axis	O	O	I-Entity
)	O	O	O
and	O	O	O
19	O	O	O
fallow	O	O	B-Entity
deer	O	O	I-Entity
(	O	O	O
Dama	O	O	B-Entity
dama	O	O	I-Entity
)	O	O	O
were	O	O	O
analyzed	O	O	O
with	O	O	O
an	O	O	O
enzyme-linked	O	O	B-Entity
immunosorbent	O	O	I-Entity
assay	O	O	I-Entity
for	O	O	O
Neospora	O	O	B-Entity
caninum	O	O	I-Entity
antibodies	O	O	I-Entity
.	O	O	O

Two	O	O	O
axis	O	O	B-Entity
(	O	O	O
11	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
two	O	O	O
fallow	O	O	B-Entity
deer	O	O	I-Entity
(	O	O	O
11	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
positive	O	O	B-Entity
for	O	O	O
N.	O	O	B-Entity
caninum	O	O	I-Entity
antibodies	O	O	I-Entity
.	O	O	O

-DOCSTART- (27670138)

The	O	O	O
ABBA	O	O	B-Entity
study	O	O	I-Entity
-	O	O	O
approach	O	O	O
bias	O	O	O
modification	O	O	O
in	O	O	O
bulimia	O	O	B-Entity
nervosa	O	O	I-Entity
and	O	O	O
binge	O	O	B-Entity
eating	O	O	I-Entity
disorder	O	O	I-Entity
:	O	O	O
study	O	O	O
protocol	O	O	O
for	O	O	O
a	O	O	O
randomised	O	O	O
controlled	O	O	O
trial	O	O	O

The	O	O	O
core	O	O	O
symptoms	O	O	B-Entity
of	O	O	O
bulimia	O	O	B-Entity
nervosa	O	O	I-Entity
(	O	O	O
BN	O	O	B-Entity
)	O	O	O
and	O	O	O
binge	O	O	B-Entity
eating	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
BED	O	O	B-Entity
)	O	O	O
are	O	O	O
recurrent	O	O	B-Entity
episodes	O	O	I-Entity
of	O	O	I-Entity
binge	O	O	I-Entity
eating	O	O	I-Entity
.	O	O	O

Despite	O	O	O
negative	O	O	B-Entity
psychological	O	O	I-Entity
and	O	O	O
physical	O	O	B-Entity
consequences	O	O	I-Entity
,	O	O	O
BN/BED	O	O	B-Entity
patients	O	O	B-Entity
show	O	O	O
uncontrollable	O	O	O
approach	O	O	O
tendencies	O	O	B-Entity
towards	O	O	I-Entity
food	O	O	I-Entity
.	O	O	O

This	O	O	O
cognitive	O	O	B-Entity
bias	O	O	I-Entity
occurs	O	O	O
at	O	O	O
an	O	O	O
early	O	O	O
stage	O	O	O
of	O	O	O
information	O	O	B-Entity
processing	O	O	I-Entity
.	O	O	O

Cognitive	O	O	B-Entity
bias	O	O	I-Entity
modification	O	O	I-Entity
(	O	O	O
CBM	O	O	B-Entity
)	O	O	O
directly	O	O	O
targets	O	O	O
such	O	O	O
biases	O	O	B-Entity
and	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
effective	O	O	O
in	O	O	O
treating	O	O	B-Entity
several	O	O	O
mental	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

In	O	O	O
alcohol	O	O	B-Entity
addiction	O	O	I-Entity
,	O	O	O
automatic	O	O	O
action	O	O	O
tendencies	O	O	O
towards	O	O	O
alcohol	O	O	B-Entity
cues	O	O	I-Entity
and	O	O	O
relapse	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
successfully	O	O	O
reduced	O	O	O
by	O	O	O
a	O	O	O
specific	O	O	O
form	O	O	O
of	O	O	O
CBM	O	O	B-Entity
,	O	O	O
termed	O	O	O
approach	O	O	O
bias	O	O	B-Entity
modification	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
these	O	O	O
findings	O	O	O
and	O	O	O
data	O	O	B-Entity
from	O	O	O
a	O	O	O
proof-of-concept	O	O	B-Entity
study	O	O	I-Entity
in	O	O	O
people	O	O	B-Entity
with	O	O	O
high	O	O	O
levels	O	O	O
of	O	O	O
food	O	O	B-Entity
craving	O	O	I-Entity
,	O	O	O
CBM	O	O	B-Entity
is	O	O	O
considered	O	O	O
a	O	O	O
promising	O	O	O
new	O	O	O
treatment	O	O	B-Entity
approach	O	O	I-Entity
for	O	O	O
BN/BED	O	O	B-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
similarities	O	O	O
between	O	O	O
BN/BED	O	O	B-Entity
and	O	O	O
addictive	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
the	O	O	O
rationale	O	O	B-Entity
for	O	O	O
using	O	O	O
approach	O	O	O
bias	O	O	B-Entity
modification	O	O	I-Entity
appears	O	O	O
to	O	O	O
be	O	O	O
particularly	O	O	O
strong	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
is	O	O	O
to	O	O	O
examine	O	O	O
whether	O	O	O
,	O	O	O
compared	O	O	O
to	O	O	O
a	O	O	O
sham	O	O	B-Entity
training	O	O	I-Entity
,	O	O	O
computerised	O	O	O
approach	O	O	O
bias	O	O	B-Entity
modification	O	O	I-Entity
(	O	O	O
10	O	O	O
sessions	O	O	O
)	O	O	O
can	O	O	O
reduce	O	O	O
binge-eating	O	O	B-Entity
episodes	O	O	I-Entity
in	O	O	O
BN/BED	O	O	B-Entity
patients	O	O	B-Entity
from	O	O	O
pre-treatment	O	O	B-Entity
to	O	O	O
follow-up	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
we	O	O	O
will	O	O	O
investigate	O	O	O
whether	O	O	O
this	O	O	O
CBM	O	O	B-Entity
programme	O	O	O
also	O	O	O
reduces	O	O	O
global	O	O	B-Entity
eating	O	O	B-Entity
disorder	O	O	I-Entity
psychopathology	O	O	I-Entity
,	O	O	O
trait	O	O	B-Entity
and	O	O	O
cue-elicited	O	O	B-Entity
food	O	O	I-Entity
craving	O	O	I-Entity
,	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
approach	O	O	O
and	O	O	O
attentional	O	O	B-Entity
bias	O	O	I-Entity
towards	O	O	O
visual	O	O	B-Entity
food	O	O	I-Entity
cues	O	O	I-Entity
.	O	O	O

Treatment	O	O	B-Entity
acceptance	O	O	I-Entity
will	O	O	O
be	O	O	O
determined	O	O	O
by	O	O	O
attrition	O	O	B-Entity
rates	O	O	I-Entity
and	O	O	O
responses	O	O	B-Entity
on	O	O	O
a	O	O	O
feedback	O	O	O
form	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
randomised	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
,	O	O	O
parallel-group	O	O	B-Entity
superiority	O	O	I-Entity
trial	O	O	I-Entity
with	O	O	O
two	O	O	O
parallel	O	O	O
arms	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
54	O	O	O
BN/BED	O	O	B-Entity
patients	O	O	B-Entity
will	O	O	O
be	O	O	O
recruited	O	O	O
.	O	O	O

Approach	O	O	O
bias	O	O	B-Entity
towards	O	O	I-Entity
food	O	O	I-Entity
will	O	O	O
be	O	O	O
retrained	O	O	O
by	O	O	O
a	O	O	O
computer	O	O	O
task	O	O	O
adopting	O	O	O
an	O	O	O
implicit	O	O	B-Entity
learning	O	O	I-Entity
paradigm	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
in	O	O	O
the	O	O	O
control	O	O	O
condition	O	O	O
(	O	O	O
sham	O	O	B-Entity
)	O	O	O
will	O	O	O
conduct	O	O	O
a	O	O	O
similar	O	O	B-Entity
task	O	O	I-Entity
but	O	O	O
will	O	O	O
not	O	O	O
be	O	O	O
trained	O	O	O
to	O	O	O
avoid	O	O	O
food	O	O	B-Entity
cues	O	O	I-Entity
.	O	O	O

Methods	O	O	O
against	O	O	O
bias	O	O	B-Entity
include	O	O	O
public	O	O	B-Entity
registration	O	O	I-Entity
,	O	O	O
randomisation	O	O	B-Entity
by	O	O	O
a	O	O	O
central	O	O	B-Entity
study	O	O	I-Entity
office	O	O	I-Entity
,	O	O	O
standardisation	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
treatments	O	O	I-Entity
and	O	O	O
blinding	O	O	B-Entity
of	O	O	I-Entity
assessors	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
session	O	O	O
number	O	O	O
and	O	O	O
duration	O	O	O
will	O	O	O
be	O	O	O
equivalent	O	O	O
in	O	O	O
the	O	O	O
two	O	O	O
conditions	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
registered	O	O	O
randomised	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
of	O	O	O
approach	O	O	O
bias	O	O	B-Entity
modification	O	O	I-Entity
in	O	O	O
a	O	O	O
clinical	O	O	B-Entity
BN/BED	O	O	I-Entity
sample	O	O	I-Entity
.	O	O	O

Results	O	O	O
from	O	O	O
this	O	O	O
study	O	O	O
will	O	O	O
provide	O	O	O
an	O	O	O
indication	O	O	O
of	O	O	O
the	O	O	O
efficacy	O	O	O
of	O	O	O
approach	O	O	O
bias	O	O	B-Entity
modification	O	O	I-Entity
training	O	O	O
for	O	O	O
BN/BED	O	O	B-Entity
and	O	O	O
the	O	O	O
potential	O	O	O
mechanisms	O	O	O
of	O	O	O
action	O	O	O
underlying	O	O	O
this	O	O	O
treatment	O	O	B-Entity
.	O	O	O

DRKS00010231	O	O	O
(	O	O	O
retrospectively	O	O	O
registered	O	O	O
on	O	O	O
24	O	O	O
March	O	O	O
2016	O	O	O
;	O	O	O
first	O	O	O
version	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27677517)

Protein	O	O	B-Entity
Design	O	O	B-Entity
for	O	O	O
Nanostructural	O	O	B-Entity
Engineering	O	O	I-Entity
:	O	O	O
Concluding	O	O	O
Remarks	O	O	B-Entity
and	O	O	O
Future	O	O	O
Directions	O	O	O

This	O	O	O
final	O	O	O
chapter	O	O	B-Entity
aims	O	O	O
to	O	O	O
summarize	O	O	O
the	O	O	O
main	O	O	O
conclusions	O	O	B-Entity
of	O	O	O
the	O	O	O
book	O	O	B-Entity
and	O	O	O
to	O	O	O
point	O	O	O
to	O	O	O
possible	O	O	O
directions	O	O	O
for	O	O	O
further	O	O	O
research	O	O	B-Entity
in	O	O	O
the	O	O	O
field	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
design	O	O	B-Entity
for	O	O	O
nanostructural	O	O	B-Entity
engineering	O	O	I-Entity
.	O	O	O

Even	O	O	O
though	O	O	O
this	O	O	O
research	O	O	B-Entity
field	O	O	I-Entity
is	O	O	O
still	O	O	O
at	O	O	O
its	O	O	O
infancy	O	O	O
,	O	O	O
multidisciplinary	O	O	B-Entity
research	O	O	B-Entity
efforts	O	O	I-Entity
in	O	O	O
the	O	O	O
design	O	O	B-Entity
of	O	O	O
synthetic	O	O	B-Entity
protein	O	O	I-Entity
-based	O	O	O
nanostructures	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
materials	O	O	B-Entity
have	O	O	O
resulted	O	O	O
in	O	O	O
significant	O	O	O
progress	O	O	B-Entity
.	O	O	O

The	O	O	O
chapters	O	O	B-Entity
in	O	O	O
this	O	O	O
book	O	O	B-Entity
cover	O	O	O
several	O	O	O
selected	O	O	O
examples	O	O	B-Entity
of	O	O	O
the	O	O	O
most	O	O	O
recent	O	O	O
advances	O	O	B-Entity
concerning	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
proteins	O	O	B-Entity
and	O	O	O
peptides	O	O	B-Entity
as	O	O	O
building	O	O	B-Entity
blocks	O	O	I-Entity
for	O	O	O
the	O	O	O
fabrication	O	O	B-Entity
of	O	O	O
architectures	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
nanostructures	O	O	B-Entity
,	O	O	O
assemblies	O	O	B-Entity
,	O	O	O
and	O	O	O
materials	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
provide	O	O	O
a	O	O	O
general	O	O	O
overview	O	O	O
of	O	O	O
the	O	O	O
strategies	O	O	B-Entity
that	O	O	O
can	O	O	O
be	O	O	O
employed	O	O	O
to	O	O	O
prepare	O	O	B-Entity
functional	O	O	B-Entity
protein	O	O	B-Entity
-based	O	O	O
nanostructures	O	O	B-Entity
,	O	O	O
and	O	O	O
nanostructured	O	O	B-Entity
materials	O	O	I-Entity
and	O	O	O
devices	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
highlight	O	O	O
some	O	O	O
of	O	O	O
the	O	O	O
main	O	O	O
aspects	O	O	B-Entity
to	O	O	O
be	O	O	O
considered	O	O	O
by	O	O	O
the	O	O	O
research	O	O	B-Entity
community	O	O	B-Entity
to	O	O	O
set	O	O	O
the	O	O	O
path	O	O	O
for	O	O	O
the	O	O	O
near	O	O	O
future	O	O	O
developments	O	O	B-Entity
.	O	O	O

-DOCSTART- (27677842)

Synthesis	O	O	B-Entity
,	O	O	O
characterization	O	O	B-Entity
and	O	O	O
drug	O	O	B-Entity
loading	O	O	B-Entity
property	O	O	B-Entity
of	O	O	O
Monomethoxy-Poly(ethylene	O	O	O
glycol)-Poly(ε-caprolactone)-Poly(D	O	O	O
,	O	O	O
L-lactide	O	O	O
)	O	O	O
(	O	O	O
MPEG-PCLA	O	O	O
)	O	O	O
copolymers	O	O	O

Amphiphilic	O	O	B-Entity
block	O	O	I-Entity
copolymers	O	O	I-Entity
have	O	O	O
attracted	O	O	O
a	O	O	O
great	O	O	O
deal	O	O	O
of	O	O	O
attention	O	O	O
in	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
systems	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
monomethoxy-poly	O	O	B-Entity
(	O	O	I-Entity
ethylene	O	O	I-Entity
glycol)-poly	O	O	I-Entity
(	O	O	I-Entity
ε-caprolactone-co-D	O	O	I-Entity
,	O	O	I-Entity
L-lactide	O	O	I-Entity
)	O	O	I-Entity
(	O	O	I-Entity
MPEG-PCLA	O	O	I-Entity
)	O	O	I-Entity
copolymers	O	O	I-Entity
with	O	O	O
variable	O	O	O
composition	O	O	B-Entity
of	O	O	O
poly	O	O	B-Entity
(	O	O	I-Entity
ε-caprolactone	O	O	I-Entity
)	O	O	I-Entity
(	O	O	O
PCL	O	O	B-Entity
)	O	O	O
and	O	O	O
poly	O	O	B-Entity
(	O	O	I-Entity
D	O	O	I-Entity
,	O	O	I-Entity
L-lactide	O	O	I-Entity
)	O	O	I-Entity
(	O	O	O
PDLLA	O	O	B-Entity
)	O	O	O
were	O	O	O
prepared	O	O	O
via	O	O	O
ring-opening	O	O	B-Entity
copolymerization	O	O	I-Entity
of	O	O	O
ε-CL	O	O	B-Entity
and	O	O	O
D	O	O	B-Entity
,	O	O	I-Entity
L-LA	O	O	I-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
MPEG	O	O	B-Entity
and	O	O	O
stannous	O	O	B-Entity
octoate	O	O	I-Entity
.	O	O	O

The	O	O	O
structure	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
weight	O	O	I-Entity
were	O	O	O
characterized	O	O	B-Entity
by	O	O	O
nuclear	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
(	O	O	O
NMR	O	O	B-Entity
)	O	O	O
and	O	O	O
gel	O	O	B-Entity
permeation	O	O	I-Entity
chromatography	O	O	I-Entity
(	O	O	O
GPC	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
crystallinity	O	O	B-Entity
,	O	O	O
hydrophilicity	O	O	B-Entity
,	O	O	O
thermal	O	O	B-Entity
stability	O	O	B-Entity
and	O	O	O
hydrolytic	O	O	B-Entity
degradation	O	O	B-Entity
behavior	O	O	I-Entity
were	O	O	O
investigated	O	O	O
in	O	O	O
detail	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
prepared	O	O	O
amphiphilic	O	O	B-Entity
MPEG-PCLA	O	O	I-Entity
copolymers	O	O	I-Entity
have	O	O	O
adjustable	O	O	O
properties	O	O	B-Entity
by	O	O	O
altering	O	O	O
the	O	O	O
composition	O	O	B-Entity
of	O	O	O
PCLA	O	O	B-Entity
,	O	O	O
which	O	O	O
make	O	O	O
it	O	O	O
convenient	O	O	O
for	O	O	O
clinical	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
the	O	O	O
drug	O	O	B-Entity
loading	O	O	B-Entity
properties	O	O	B-Entity
were	O	O	O
also	O	O	O
studied	O	O	O
.	O	O	O

Docetaxel	O	O	B-Entity
(	O	O	O
DTX	O	O	B-Entity
)	O	O	O
could	O	O	O
be	O	O	O
entrapped	O	O	O
in	O	O	O
MPEG-PCLA	O	O	B-Entity
micelles	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
loading	O	O	B-Entity
capacity	O	O	B-Entity
and	O	O	O
encapsulation	O	O	B-Entity
efficiency	O	O	B-Entity
.	O	O	O

And	O	O	O
all	O	O	O
lyophilized	O	O	B-Entity
DTX	O	O	B-Entity
-loaded	O	O	O
MPEG-PCLA	O	O	B-Entity
micelles	O	O	B-Entity
except	O	O	O
MPEG-PCL	O	O	B-Entity
micelles	O	O	O
were	O	O	O
readily	O	O	O
re-dissolved	O	O	B-Entity
in	O	O	O
normal	O	O	B-Entity
saline	O	O	I-Entity
at	O	O	O
25	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
DTX	O	O	B-Entity
-loaded	O	O	O
MPEG-PCLA	O	O	B-Entity
micelles	O	O	B-Entity
showed	O	O	O
a	O	O	O
slightly	O	O	O
enhanced	O	O	B-Entity
antitumor	O	O	B-Entity
activity	O	O	B-Entity
compared	O	O	O
with	O	O	O
free	O	O	O
DTX	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
DTX	O	O	B-Entity
micelles	O	O	B-Entity
exhibited	O	O	O
a	O	O	O
slower	O	O	B-Entity
and	O	O	O
sustained	O	O	B-Entity
release	O	O	B-Entity
behavior	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
and	O	O	O
higher	O	O	B-Entity
DTX	O	O	O
concentration	O	O	B-Entity
and	O	O	O
longer	O	O	O
retention	O	O	B-Entity
time	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
suggested	O	O	O
that	O	O	O
the	O	O	O
MPEG-PCLA	O	O	B-Entity
copolymer	O	O	I-Entity
with	O	O	O
the	O	O	O
adjustable	O	O	O
ratio	O	O	B-Entity
of	O	O	O
PCL	O	O	B-Entity
to	O	O	O
PDLLA	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
promising	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
carrier	O	O	I-Entity
for	O	O	O
DTX	O	O	B-Entity
.	O	O	O

-DOCSTART- (27678317)

Thyroid	O	O	B-Entity
cancer	O	O	I-Entity
burden	O	O	B-Entity
in	O	O	O
Central	O	O	B-Entity
and	O	O	O
South	O	O	O
America	O	O	O

Incidence	O	O	B-Entity
of	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
TC	O	O	B-Entity
)	O	O	O
is	O	O	O
rapidly	O	O	B-Entity
increasing	O	O	B-Entity
worldwide	O	O	B-Entity
,	O	O	O
but	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
TC	O	O	O
burden	O	O	B-Entity
in	O	O	O
Central	O	O	B-Entity
and	O	O	O
South	O	O	B-Entity
America	O	O	I-Entity
(	O	O	O
CSA	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
describe	O	O	O
the	O	O	O
geographic	O	O	B-Entity
patterns	O	O	I-Entity
and	O	O	O
trends	O	O	B-Entity
of	O	O	O
TC	O	O	B-Entity
by	O	O	O
sex	O	O	B-Entity
in	O	O	O
CSA	O	O	B-Entity
.	O	O	O

We	O	O	O
obtained	O	O	O
regional	O	O	B-Entity
-	O	O	O
and	O	O	O
national-level	O	O	B-Entity
incidence	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
48	O	O	O
population-based	O	O	B-Entity
cancer	O	O	I-Entity
registries	O	O	I-Entity
in	O	O	O
13	O	O	O
countries	O	O	B-Entity
and	O	O	O
nationwide	O	O	O
cancer	O	O	B-Entity
deaths	O	O	I-Entity
from	O	O	O
the	O	O	O
WHO	O	O	B-Entity
mortality	O	O	B-Entity
database	O	O	B-Entity
for	O	O	O
18	O	O	O
countries	O	O	O
.	O	O	O

We	O	O	O
estimated	O	O	O
world	O	O	B-Entity
population	O	O	O
age-standardized	O	O	B-Entity
incidence	O	O	I-Entity
rates	O	O	I-Entity
(	O	O	O
ASRs	O	O	B-Entity
)	O	O	O
and	O	O	O
age-standardized	O	O	B-Entity
mortality	O	O	I-Entity
rates	O	O	I-Entity
(	O	O	O
ASMRs	O	O	B-Entity
)	O	O	O
per	O	O	O
100,000	O	O	O
person	O	O	B-Entity
-	O	O	O
years	O	O	B-Entity
.	O	O	O

We	O	O	O
calculated	O	O	O
ASRs	O	O	B-Entity
by	O	O	O
histological	O	O	B-Entity
subtype	O	O	I-Entity
.	O	O	O

We	O	O	O
estimated	O	O	B-Entity
the	O	O	I-Entity
annual	O	O	I-Entity
percentage	O	O	I-Entity
change	O	O	I-Entity
(	O	O	O
EAPC	O	O	B-Entity
)	O	O	O
to	O	O	O
describe	O	O	O
time	O	O	B-Entity
trends	O	O	I-Entity
.	O	O	O

Between	O	O	O
CSA	O	O	B-Entity
countries	O	O	B-Entity
,	O	O	O
TC	O	O	B-Entity
incidence	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
rates	O	O	I-Entity
varied	O	O	O
from	O	O	O
8-fold	O	O	O
to	O	O	O
12-fold	O	O	O
and	O	O	O
from	O	O	O
2-fold	O	O	O
to	O	O	O
5-fold	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
2003	O	O	O
-	O	O	O
2007	O	O	O
,	O	O	O
the	O	O	O
highest	O	O	B-Entity
TC	O	O	B-Entity
ASRs	O	O	B-Entity
in	O	O	O
females	O	O	B-Entity
and	O	O	O
males	O	O	B-Entity
were	O	O	O
in	O	O	O
Ecuador	O	O	B-Entity
(	O	O	O
16.0	O	O	O
and	O	O	O
3.5	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
Brazil	O	O	B-Entity
(	O	O	O
14.4	O	O	O
and	O	O	O
3.4	O	O	O
)	O	O	O
,	O	O	O
Costa	O	O	B-Entity
Rica	O	O	I-Entity
(	O	O	O
12.6	O	O	O
and	O	O	O
2.1	O	O	O
)	O	O	O
and	O	O	O
Colombia	O	O	B-Entity
(	O	O	O
10.7	O	O	O
and	O	O	O
2.5	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
highest	O	O	B-Entity
ASMRs	O	O	B-Entity
were	O	O	O
in	O	O	O
Ecuador	O	O	B-Entity
,	O	O	O
Colombia	O	O	B-Entity
,	O	O	O
Mexico	O	O	B-Entity
,	O	O	O
Peru	O	O	B-Entity
and	O	O	O
Panama	O	O	B-Entity
(	O	O	O
0.68	O	O	O
-	O	O	O
0.91	O	O	O
in	O	O	O
females	O	O	B-Entity
and	O	O	O
0.41	O	O	O
-	O	O	O
0.48	O	O	O
in	O	O	O
males	O	O	B-Entity
)	O	O	O
.	O	O	O

Papillary	O	O	B-Entity
TC	O	O	B-Entity
was	O	O	O
the	O	O	O
most	O	O	O
commonly	O	O	O
diagnosed	O	O	B-Entity
histological	O	O	B-Entity
subtype	O	O	I-Entity
,	O	O	O
following	O	O	O
the	O	O	O
same	O	O	O
incidence	O	O	B-Entity
pattern	O	O	I-Entity
as	O	O	O
overall	O	O	O
TC	O	O	O
.	O	O	O

In	O	O	O
Argentinean	O	O	B-Entity
,	O	O	O
Brazilian	O	O	B-Entity
,	O	O	O
Chilean	O	O	B-Entity
and	O	O	O
Costa	O	O	B-Entity
Rican	O	O	I-Entity
females	O	O	B-Entity
TC	O	O	B-Entity
incidence	O	O	B-Entity
increased	O	O	B-Entity
by	O	O	O
2.2	O	O	O
-	O	O	O
17.9	O	O	O
%	O	O	O
annually	O	O	B-Entity
,	O	O	O
and	O	O	O
papillary	O	O	B-Entity
TC	O	O	I-Entity
increased	O	O	O
by	O	O	O
9.1	O	O	O
-	O	O	O
15.0	O	O	O
%	O	O	O
annually	O	O	O
,	O	O	O
while	O	O	O
mortality	O	O	B-Entity
remained	O	O	O
stable	O	O	B-Entity
between	O	O	O
1997	O	O	O
and	O	O	O
2008	O	O	O
.	O	O	O

In	O	O	O
males	O	O	B-Entity
,	O	O	O
trends	O	O	B-Entity
in	O	O	O
TC	O	O	B-Entity
were	O	O	O
stable	O	O	B-Entity
.	O	O	O

TC	O	O	B-Entity
occurred	O	O	B-Entity
more	O	O	O
frequently	O	O	B-Entity
in	O	O	O
females	O	O	B-Entity
than	O	O	O
in	O	O	O
males	O	O	B-Entity
.	O	O	O

The	O	O	O
overall	O	O	B-Entity
high	O	O	B-Entity
incidence	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
mortality	O	O	B-Entity
of	O	O	O
TC	O	O	B-Entity
suggest	O	O	B-Entity
identification	O	O	O
of	O	O	O
subclinical	O	O	B-Entity
disease	O	O	I-Entity
due	O	O	O
to	O	O	O
improved	O	O	B-Entity
detection	O	O	B-Entity
methods	O	O	I-Entity
.	O	O	O

-DOCSTART- (27679696)

Histopathological	O	O	B-Entity
Evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
Effectiveness	O	O	B-Entity
of	O	O	O
Glycyrrhizic	O	O	B-Entity
Acid	O	O	I-Entity
as	O	O	O
a	O	O	O
Radioprotector	O	O	B-Entity
Against	O	O	O
the	O	O	O
Development	O	O	B-Entity
of	O	O	O
Radiation-Induced	O	O	O
Lung	O	O	O
Fibrosis	O	O	O

Radiotherapy	O	O	B-Entity
of	O	O	O
the	O	O	O
thorax	O	O	B-Entity
often	O	O	O
causes	O	O	O
lung	O	O	B-Entity
inflammation	O	O	I-Entity
leading	O	O	O
to	O	O	O
fibrosis	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
glycyrrhizic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
GLA	O	O	B-Entity
)	O	O	O
could	O	O	O
improve	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
lung	O	O	B-Entity
fibrosis	O	O	I-Entity
in	O	O	O
irradiated	O	O	B-Entity
animals	O	O	B-Entity
.	O	O	O

Wistar	O	O	B-Entity
rats	O	O	I-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
four	O	O	O
groups	O	O	B-Entity
.	O	O	O

Group	O	O	B-Entity
A	O	O	I-Entity
rats	O	O	B-Entity
received	O	O	O
thoracic	O	O	B-Entity
irradiation	O	O	I-Entity
.	O	O	O

Rats	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
received	O	O	O
GLA	O	O	B-Entity
and	O	O	O
irradiation	O	O	B-Entity
.	O	O	O

Group	O	O	B-Entity
C	O	O	I-Entity
received	O	O	O
GLA	O	O	B-Entity
and	O	O	O
no	O	O	O
irradiation	O	O	B-Entity
.	O	O	O

Group	O	O	B-Entity
D	O	O	I-Entity
received	O	O	O
no	O	O	O
GLA	O	O	B-Entity
and	O	O	O
irradiation	O	O	B-Entity
.	O	O	O

GLA	O	O	B-Entity
was	O	O	O
administered	O	O	B-Entity
at	O	O	O
a	O	O	O
dose	O	O	B-Entity
of	O	O	O
4	O	O	O
mg/kg	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
using	O	O	O
an	O	O	O
intraperitoneal	O	O	B-Entity
injection	O	O	I-Entity
one	O	O	O
hour	O	O	O
before	O	O	O
thoracic	O	O	B-Entity
irradiation	O	O	I-Entity
.	O	O	O

Radiation	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
delivered	O	O	O
on	O	O	O
a	O	O	O
Cobalt-60	O	O	B-Entity
unit	O	O	O
using	O	O	O
a	O	O	O
single	O	O	O
fraction	O	O	O
of	O	O	O
16	O	O	O
Gy	O	O	O
.	O	O	O

The	O	O	O
animals	O	O	B-Entity
were	O	O	O
sacrificed	O	O	O
at	O	O	O
32	O	O	O
weeks	O	O	O
following	O	O	O
thoracic	O	O	B-Entity
irradiation	O	O	I-Entity
.	O	O	O

The	O	O	O
lungs	O	O	B-Entity
were	O	O	O
dissected	O	O	B-Entity
and	O	O	O
blind	O	O	O
histopathological	O	O	B-Entity
evaluation	O	O	B-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

Histopathologically	O	O	B-Entity
,	O	O	O
a	O	O	O
decrease	O	O	B-Entity
(	O	O	O
statistically	O	O	O
not	O	O	O
significant	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
thickening	O	O	B-Entity
of	O	O	O
alveolar	O	O	B-Entity
or	O	O	O
bronchial	O	O	B-Entity
wall	O	O	I-Entity
,	O	O	O
formation	O	O	O
of	O	O	O
fibrous	O	O	B-Entity
bands	O	O	I-Entity
,	O	O	O
and	O	O	O
superimposed	O	O	O
collagen	O	O	B-Entity
were	O	O	O
noted	O	O	O
in	O	O	O
the	O	O	O
animals	O	O	B-Entity
in	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
animals	O	O	O
in	O	O	O
group	O	O	O
A.	O	O	O
In	O	O	O
this	O	O	O
experimental	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
administration	O	O	B-Entity
of	O	O	O
GLA	O	O	B-Entity
one	O	O	O
hour	O	O	O
before	O	O	O
thoracic	O	O	B-Entity
irradiation	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
protective	O	O	B-Entity
agent	O	O	I-Entity
against	O	O	O
radiation-induced	O	O	B-Entity
fibrosis	O	O	I-Entity
in	O	O	O
animals	O	O	O
and	O	O	O
this	O	O	O
model	O	O	B-Entity
could	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
future	O	O	O
studies	O	O	O
.	O	O	O

-DOCSTART- (27682280)

Avulsions	O	O	B-Entity
of	O	O	O
Triceps	O	O	B-Entity
Brachii	O	O	I-Entity
:	O	O	O
associated	O	O	O
injuries	O	O	B-Entity
and	O	O	O
surgical	O	O	B-Entity
treatment	O	O	I-Entity
;	O	O	O
a	O	O	O
case	O	O	O
series	O	O	O

This	O	O	O
study	O	O	B-Entity
reports	O	O	O
the	O	O	O
clinical	O	O	B-Entity
presentations	O	O	I-Entity
,	O	O	O
intra	O	O	B-Entity
-operative	O	O	I-Entity
findings	O	O	B-Entity
,	O	O	O
type	O	O	O
of	O	O	O
the	O	O	O
treatments	O	O	B-Entity
,	O	O	O
outcome	O	O	B-Entity
of	O	O	O
the	O	O	O
treatment	O	O	B-Entity
and	O	O	O
specially	O	O	O
associated	O	O	O
injuries	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
the	O	O	O
avulsion	O	O	B-Entity
of	O	O	O
the	O	O	O
distal	O	O	B-Entity
end	O	O	I-Entity
of	O	O	O
the	O	O	O
triceps	O	O	B-Entity
brachii	O	O	I-Entity
(	O	O	I-Entity
TB	O	O	I-Entity
)	O	O	I-Entity
tendon	O	O	I-Entity
.	O	O	O

We	O	O	O
studied	O	O	O
6	O	O	O
patients	O	O	B-Entity
with	O	O	O
rupture	O	O	B-Entity
or	O	O	O
avulsion	O	O	B-Entity
of	O	O	O
the	O	O	O
distal	O	O	B-Entity
end	O	O	I-Entity
of	O	O	O
the	O	O	O
TB	O	O	B-Entity
tendon	O	O	I-Entity
.	O	O	O

The	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
,	O	O	O
imaging	O	O	B-Entity
files	O	O	I-Entity
,	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	B-Entity
at	O	O	O
the	O	O	O
final	O	O	O
follow	O	O	B-Entity
up	O	O	I-Entity
visit	O	O	I-Entity
were	O	O	O
reviewed	O	O	O
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	B-Entity
were	O	O	O
assessed	O	O	O
by	O	O	O
Mayo	O	O	B-Entity
Elbow	O	O	I-Entity
Score	O	O	I-Entity
at	O	O	O
the	O	O	O
final	O	O	O
follow-up	O	O	B-Entity
visit	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
male	O	O	B-Entity
,	O	O	O
4	O	O	O
of	O	O	O
them	O	O	O
having	O	O	O
injury	O	O	B-Entity
in	O	O	O
the	O	O	O
left	O	O	B-Entity
hand	O	O	B-Entity
as	O	O	O
the	O	O	O
non-dominant	O	O	O
hand	O	O	O
.	O	O	O

Mean	O	O	O
age	O	O	B-Entity
of	O	O	O
them	O	O	O
was	O	O	O
34.5	O	O	O
years	O	O	B-Entity
.	O	O	O

All	O	O	O
cases	O	O	O
had	O	O	O
small	O	O	O
bony	O	O	B-Entity
fleck	O	O	B-Entity
in	O	O	O
the	O	O	O
posterior	O	O	O
of	O	O	O
elbow	O	O	B-Entity
in	O	O	O
lateral	O	O	B-Entity
radiograph	O	O	I-Entity
.	O	O	O

Three	O	O	O
patients	O	O	B-Entity
had	O	O	O
associated	O	O	O
injuries	O	O	B-Entity
-including	O	O	O
intra-articular	O	O	B-Entity
fractures	O	O	B-Entity
and	O	O	O
medial	O	O	B-Entity
collateral	O	O	I-Entity
ligament	O	O	I-Entity
rupture	O	O	I-Entity
.	O	O	O

In	O	O	O
one	O	O	O
case	O	O	O
V-Y	O	O	B-Entity
plasty	O	O	I-Entity
of	O	O	O
the	O	O	O
distal	O	O	B-Entity
TB	O	O	B-Entity
was	O	O	O
done	O	O	O
.	O	O	O

In	O	O	O
4	O	O	O
patients	O	O	B-Entity
the	O	O	O
results	O	O	O
of	O	O	O
surgery	O	O	B-Entity
were	O	O	O
excellent	O	O	O
,	O	O	O
one	O	O	O
was	O	O	O
good	O	O	O
and	O	O	O
one	O	O	O
was	O	O	O
fair	O	O	O
.	O	O	O

Although	O	O	O
TB	O	O	B-Entity
tendon	O	O	I-Entity
rupture	O	O	B-Entity
is	O	O	O
rare	O	O	O
,	O	O	O
it	O	O	O
should	O	O	O
be	O	O	O
-considered	O	O	O
in	O	O	O
differential	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
the	O	O	O
upper	O	O	B-Entity
-extremity	O	O	I-Entity
trauma	O	O	I-Entity
and	O	O	O
its	O	O	O
associated	O	O	O
injuries	O	O	B-Entity
should	O	O	O
be	O	O	O
addressed	O	O	O
properly	O	O	O
.	O	O	O

-DOCSTART- (27683416)

Prolyl-4-hydroxylase	O	O	B-Entity
2	O	O	I-Entity
and	O	O	O
3	O	O	B-Entity
coregulate	O	O	O
murine	O	O	B-Entity
erythropoietin	O	O	B-Entity
in	O	O	O
brain	O	O	B-Entity
pericytes	O	O	O

A	O	O	O
classic	O	O	O
response	O	O	B-Entity
to	O	O	O
systemic	O	O	B-Entity
hypoxia	O	O	B-Entity
is	O	O	O
the	O	O	O
increased	O	O	B-Entity
production	O	O	B-Entity
of	O	O	I-Entity
red	O	O	I-Entity
blood	O	O	I-Entity
cells	O	O	I-Entity
due	O	O	O
to	O	O	O
hypoxia-inducible	O	O	B-Entity
factor	O	O	I-Entity
(HIF)-mediated	O	O	O
induction	O	O	B-Entity
of	O	O	O
erythropoietin	O	O	B-Entity
(	O	O	O
EPO	O	O	B-Entity
)	O	O	O
.	O	O	O

EPO	O	O	B-Entity
is	O	O	O
a	O	O	O
glycoprotein	O	O	B-Entity
hormone	O	O	I-Entity
that	O	O	O
is	O	O	O
essential	O	O	O
for	O	O	O
normal	O	O	B-Entity
erythropoiesis	O	O	I-Entity
and	O	O	O
is	O	O	O
predominantly	O	O	O
synthesized	O	O	O
by	O	O	O
peritubular	O	O	B-Entity
renal	O	O	B-Entity
interstitial	O	O	I-Entity
fibroblast-like	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
which	O	O	O
express	O	O	O
cellular	O	O	B-Entity
markers	O	O	I-Entity
characteristic	O	O	O
of	O	O	O
neuronal	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
pericytes	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
synthesize	O	O	O
EPO	O	O	B-Entity
is	O	O	O
a	O	O	O
general	O	O	O
functional	O	O	B-Entity
feature	O	O	B-Entity
of	O	O	O
pericytes	O	O	B-Entity
,	O	O	O
we	O	O	O
used	O	O	O
conditional	O	O	O
gene	O	O	B-Entity
targeting	O	O	I-Entity
to	O	O	O
examine	O	O	O
the	O	O	O
von	O	O	B-Entity
Hippel-Lindau	O	O	I-Entity
/	O	O	O
prolyl-4-hydroxylase	O	O	B-Entity
domain	O	O	I-Entity
(PHD)/HIF	O	O	I-Entity
axis	O	O	O
in	O	O	O
cell	O	O	B-Entity
-	O	O	O
expressing	O	O	B-Entity
neural	O	O	B-Entity
glial	O	O	I-Entity
antigen	O	O	I-Entity
2	O	O	I-Entity
,	O	O	O
a	O	O	O
known	O	O	O
molecular	O	O	B-Entity
marker	O	O	I-Entity
of	O	O	O
pericytes	O	O	O
in	O	O	O
multiple	O	O	B-Entity
organs	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
pericytes	O	O	B-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
synthesized	O	O	O
EPO	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
with	O	O	O
genetic	O	O	B-Entity
HIF	O	O	B-Entity
activation	O	O	B-Entity
and	O	O	O
were	O	O	O
capable	O	O	O
of	O	O	O
responding	O	O	O
to	O	O	O
systemic	O	O	B-Entity
hypoxia	O	O	B-Entity
with	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
Epo	O	O	B-Entity
.	O	O	O

Using	O	O	O
high-resolution	O	O	B-Entity
multiplex	O	O	O
in	O	O	B-Entity
situ	O	O	I-Entity
hybridization	O	O	I-Entity
,	O	O	O
we	O	O	O
determined	O	O	O
that	O	O	O
brain	O	O	B-Entity
pericytes	O	O	B-Entity
represent	O	O	O
an	O	O	O
important	O	O	O
cellular	O	O	B-Entity
source	O	O	I-Entity
of	O	O	O
Epo	O	O	B-Entity
in	O	O	O
the	O	O	O
hypoxic	O	O	B-Entity
brain	O	O	O
(	O	O	O
up	O	O	O
to	O	O	O
70	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
Epo	O	O	O
-	O	O	O
expressing	O	O	B-Entity
cells	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
furthermore	O	O	O
determined	O	O	O
that	O	O	O
Epo	O	O	B-Entity
transcription	O	O	B-Entity
in	O	O	O
brain	O	O	B-Entity
pericytes	O	O	B-Entity
was	O	O	O
HIF-2	O	O	B-Entity
dependent	O	O	O
and	O	O	O
cocontrolled	O	O	O
by	O	O	O
PHD2	O	O	B-Entity
and	O	O	O
PHD3	O	O	B-Entity
,	O	O	O
oxygen	O	O	B-Entity
-	O	O	O
and	O	O	O
2-oxoglutarate	O	O	B-Entity
-dependent	O	O	O
prolyl-4-hydroxylases	O	O	B-Entity
that	O	O	O
regulate	O	O	O
HIF	O	O	B-Entity
activity	O	O	B-Entity
.	O	O	O

In	O	O	O
summary	O	O	O
,	O	O	O
our	O	O	O
studies	O	O	O
provide	O	O	O
experimental	O	O	B-Entity
evidence	O	O	B-Entity
that	O	O	O
pericytes	O	O	B-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
have	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
function	O	O	O
as	O	O	O
oxygen	O	O	B-Entity
sensors	O	O	I-Entity
and	O	O	O
respond	O	O	O
to	O	O	O
hypoxia	O	O	B-Entity
with	O	O	O
EPO	O	O	B-Entity
synthesis	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
furthermore	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
synthesize	O	O	O
EPO	O	O	B-Entity
may	O	O	O
represent	O	O	O
a	O	O	O
functional	O	O	B-Entity
feature	O	O	B-Entity
of	O	O	O
pericytes	O	O	B-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
and	O	O	O
kidney	O	O	B-Entity
.	O	O	O

-DOCSTART- (27686752)

Patient	O	O	B-Entity
Satisfaction	O	O	I-Entity
with	O	O	O
Pharmacist	O	O	B-Entity
-Led	O	O	O
Collaborative	O	O	B-Entity
Follow-Up	O	O	B-Entity
Care	O	O	I-Entity
in	O	O	O
an	O	O	O
Ambulatory	O	O	B-Entity
Rheumatology	O	O	O
Clinic	O	O	O

Patient	O	O	B-Entity
satisfaction	O	O	I-Entity
is	O	O	O
known	O	O	O
to	O	O	O
increase	O	O	O
with	O	O	O
pharmacist	O	O	B-Entity
intervention	O	O	B-Entity
in	O	O	O
general	O	O	B-Entity
outpatient	O	O	I-Entity
clinics	O	O	I-Entity
and	O	O	O
with	O	O	O
nurse-led	O	O	B-Entity
care	O	O	I-Entity
in	O	O	O
rheumatology	O	O	B-Entity
clinics	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
describe	O	O	O
and	O	O	O
compare	O	O	O
patient	O	O	B-Entity
satisfaction	O	O	I-Entity
with	O	O	O
two	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
care	O	O	B-Entity
:	O	O	O
a	O	O	O
pharmacist	O	O	B-Entity
physician	O	O	B-Entity
collaborative	O	O	B-Entity
model	O	O	I-Entity
and	O	O	O
a	O	O	O
traditional	O	O	B-Entity
physician	O	O	I-Entity
model	O	O	I-Entity
in	O	O	O
a	O	O	O
rheumatology	O	O	B-Entity
clinic	O	O	I-Entity
setting	O	O	O
.	O	O	O

A	O	O	O
cross-sectional	O	O	B-Entity
survey	O	O	I-Entity
of	O	O	O
inflammatory	O	O	B-Entity
arthritis	O	O	I-Entity
patients	O	O	B-Entity
seen	O	O	O
during	O	O	O
a	O	O	O
follow-up	O	O	B-Entity
visit	O	O	I-Entity
in	O	O	O
Edmonton	O	O	B-Entity
,	O	O	O
Alberta	O	O	B-Entity
,	O	O	O
Canada	O	O	B-Entity
,	O	O	O
was	O	O	O
conducted	O	O	O
over	O	O	O
a	O	O	O
ten-week	O	O	B-Entity
period	O	O	I-Entity
.	O	O	O

Patient	O	O	B-Entity
satisfaction	O	O	B-Entity
was	O	O	O
measured	O	O	O
using	O	O	O
a	O	O	O
modified	O	O	O
version	O	O	O
of	O	O	O
the	O	O	O
validated	O	O	O
Leeds	O	O	B-Entity
Satisfaction	O	O	I-Entity
Questionnaire	O	O	I-Entity
,	O	O	O
which	O	O	O
uses	O	O	O
a	O	O	O
five-point	O	O	O
Likert	O	O	B-Entity
scale	O	O	I-Entity
to	O	O	O
measure	O	O	O
six	O	O	B-Entity
dimensions	O	O	I-Entity
of	O	O	O
satisfaction	O	O	O
,	O	O	O
and	O	O	O
compared	O	O	O
between	O	O	O
the	O	O	O
collaborative	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
traditional	O	O	B-Entity
physician	O	O	I-Entity
models	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
62	O	O	O
patients	O	O	B-Entity
completed	O	O	O
the	O	O	O
questionnaire	O	O	B-Entity
(	O	O	O
21	O	O	O
collaborative	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
41	O	O	O
traditional	O	O	B-Entity
physician	O	O	I-Entity
model	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
age	O	O	O
of	O	O	O
respondents	O	O	B-Entity
was	O	O	O
52	O	O	O
years	O	O	O
and	O	O	O
the	O	O	O
majority	O	O	O
were	O	O	O
female	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
score	O	O	I-Entity
for	O	O	I-Entity
satisfaction	O	O	I-Entity
across	O	O	O
the	O	O	O
six	O	O	B-Entity
dimensions	O	O	I-Entity
was	O	O	O
4.56	O	O	O
in	O	O	O
the	O	O	O
collaborative	O	O	B-Entity
care	O	O	I-Entity
group	O	O	I-Entity
and	O	O	O
4.30	O	O	O
in	O	O	O
the	O	O	O
traditional	O	O	B-Entity
physician	O	O	I-Entity
group	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
.	O	O	O

Patient	O	O	B-Entity
satisfaction	O	O	I-Entity
in	O	O	O
the	O	O	O
collaborative	O	O	B-Entity
care	O	O	I-Entity
group	O	O	I-Entity
was	O	O	O
consistently	O	O	O
higher	O	O	O
across	O	O	O
all	O	O	O
dimensions	O	O	O
.	O	O	O

No	O	O	B-Entity
difference	O	O	I-Entity
was	O	O	O
noted	O	O	O
between	O	O	O
participants	O	O	B-Entity
seen	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
compared	O	O	O
with	O	O	O
those	O	O	O
seen	O	O	O
two	O	O	O
or	O	O	O
more	O	O	O
times	O	O	O
by	O	O	O
the	O	O	O
pharmacist	O	O	B-Entity
.	O	O	O

A	O	O	O
collaborative	O	O	B-Entity
care	O	O	I-Entity
model	O	O	I-Entity
can	O	O	O
exceed	O	O	O
the	O	O	O
already	O	O	O
high	O	O	B-Entity
expectations	O	O	I-Entity
for	O	O	O
care	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
with	O	O	O
inflammatory	O	O	B-Entity
arthritis	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	O
support	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
pharmacists	O	O	B-Entity
using	O	O	O
a	O	O	O
collaborative	O	O	B-Entity
care	O	O	I-Entity
approach	O	O	O
to	O	O	O
care	O	O	B-Entity
for	O	O	I-Entity
patients	O	O	I-Entity
in	O	O	O
rheumatology	O	O	B-Entity
clinics	O	O	I-Entity
.	O	O	O

-DOCSTART- (27690050)

Ontology	O	O	B-Entity
-Based	O	O	O
High	O	O	B-Entity
-	O	O	O
Level	O	O	B-Entity
Context	O	O	B-Entity
Inference	O	O	B-Entity
for	O	O	O
Human	O	O	B-Entity
Behavior	O	O	I-Entity
Identification	O	O	O

Recent	O	O	O
years	O	O	O
have	O	O	O
witnessed	O	O	O
a	O	O	O
huge	O	O	O
progress	O	O	B-Entity
in	O	O	O
the	O	O	O
automatic	O	O	B-Entity
identification	O	O	B-Entity
of	O	O	O
individual	O	O	B-Entity
primitives	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
behavior	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
activities	O	O	B-Entity
or	O	O	O
locations	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
complex	O	O	B-Entity
nature	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
behavior	O	O	I-Entity
demands	O	O	O
more	O	O	O
abstract	O	O	O
contextual	O	O	B-Entity
information	O	O	B-Entity
for	O	O	O
its	O	O	O
analysis	O	O	O
.	O	O	O

This	O	O	O
work	O	O	O
presents	O	O	O
an	O	O	O
ontology	O	O	B-Entity
-based	O	O	O
method	O	O	B-Entity
that	O	O	O
combines	O	O	O
low	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
primitives	O	O	B-Entity
of	O	O	O
behavior	O	O	B-Entity
,	O	O	O
namely	O	O	O
activity	O	O	B-Entity
,	O	O	O
locations	O	O	B-Entity
and	O	O	O
emotions	O	O	B-Entity
,	O	O	O
unprecedented	O	O	B-Entity
to	O	O	O
date	O	O	B-Entity
,	O	O	O
to	O	O	O
intelligently	O	O	O
derive	O	O	O
more	O	O	O
meaningful	O	O	O
high	O	O	B-Entity
-	O	O	O
level	O	O	O
context	O	O	B-Entity
information	O	O	B-Entity
.	O	O	O

The	O	O	O
paper	O	O	O
contributes	O	O	B-Entity
with	O	O	O
a	O	O	O
new	O	O	O
open	O	O	O
ontology	O	O	B-Entity
describing	O	O	O
both	O	O	O
low	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
and	O	O	O
high	O	O	B-Entity
-	O	O	O
level	O	O	O
context	O	O	B-Entity
information	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
their	O	O	O
relationships	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
framework	O	O	B-Entity
building	O	O	O
on	O	O	O
the	O	O	O
developed	O	O	O
ontology	O	O	B-Entity
and	O	O	O
reasoning	O	O	O
models	O	O	B-Entity
is	O	O	O
presented	O	O	O
and	O	O	O
evaluated	O	O	O
.	O	O	O

The	O	O	O
proposed	O	O	O
method	O	O	O
proves	O	O	O
to	O	O	O
be	O	O	O
robust	O	O	O
while	O	O	O
identifying	O	O	O
high	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
contexts	O	O	B-Entity
even	O	O	O
in	O	O	O
the	O	O	O
event	O	O	B-Entity
of	O	O	O
erroneously	O	O	B-Entity
-	O	O	O
detected	O	O	B-Entity
low	O	O	B-Entity
-l	O	O	O
evel	O	O	B-Entity
context	O	O	B-Entity
s.	O	O	O
Despite	O	O	O
reasonable	O	O	O
inference	O	O	B-Entity
times	O	O	O
being	O	O	O
obtained	O	O	O
for	O	O	O
a	O	O	O
relevant	O	O	B-Entity
set	O	O	B-Entity
of	O	O	O
users	O	O	B-Entity
and	O	O	O
instances	O	O	B-Entity
,	O	O	O
additional	O	O	O
work	O	O	O
is	O	O	O
required	O	O	O
to	O	O	O
scale	O	O	O
to	O	O	O
long-term	O	O	O
scenarios	O	O	B-Entity
with	O	O	O
a	O	O	O
large	O	O	O
number	O	O	O
of	O	O	O
users	O	O	O
.	O	O	O

-DOCSTART- (27692572)

Characterization	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
in	O	O	O
epidemiological	O	O	B-Entity
studies	O	O	I-Entity
on	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
from	O	O	O
biodegradable	O	O	B-Entity
wastes	O	O	B-Entity
:	O	O	O
Misclassification	O	O	B-Entity
and	O	O	O
comparison	O	O	B-Entity
of	O	O	O
exposure	O	O	O
assessment	O	O	B-Entity
strategies	O	O	O

The	O	O	O
assignment	O	O	O
of	O	O	O
exposure	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
main	O	O	O
challenges	O	O	O
faced	O	O	O
by	O	O	O
environmental	O	O	B-Entity
epidemiologists	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
misclassification	O	O	B-Entity
of	O	O	O
exposures	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
explored	O	O	O
in	O	O	O
population	O	O	B-Entity
epidemiological	O	O	B-Entity
studies	O	O	I-Entity
on	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
from	O	O	O
biodegradable	O	O	B-Entity
wastes	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
use	O	O	O
of	O	O	O
different	O	O	O
approaches	O	O	O
for	O	O	O
assessing	O	O	O
exposure	O	O	B-Entity
to	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
from	O	O	O
biodegradable	O	O	B-Entity
wastes	O	O	B-Entity
by	O	O	O
analyzing	O	O	B-Entity
(	O	O	O
1	O	O	O
)	O	O	O
the	O	O	O
misclassification	O	O	B-Entity
of	O	O	O
exposure	O	O	O
that	O	O	O
is	O	O	O
committed	O	O	O
by	O	O	O
using	O	O	O
these	O	O	O
surrogates	O	O	B-Entity
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
the	O	O	O
existence	O	O	O
of	O	O	O
differentia	O	O	B-Entity
l	O	O	O
misclassification	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
the	O	O	O
effects	O	O	B-Entity
that	O	O	O
misclassification	O	O	O
may	O	O	O
have	O	O	O
on	O	O	O
health	O	O	B-Entity
effect	O	O	B-Entity
estimates	O	O	B-Entity
and	O	O	O
the	O	O	O
interpretation	O	O	B-Entity
of	O	O	O
epidemiological	O	O	B-Entity
results	O	O	B-Entity
,	O	O	O
and	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
the	O	O	O
ability	O	O	O
of	O	O	O
the	O	O	O
exposure	O	O	O
measures	O	O	O
to	O	O	O
predict	O	O	O
health	O	O	B-Entity
outcomes	O	O	I-Entity
using	O	O	O
10-fold	O	O	O
cross	O	O	B-Entity
validation	O	O	I-Entity
.	O	O	O

Four	O	O	O
different	O	O	O
exposure	O	O	B-Entity
assessment	O	O	B-Entity
approaches	O	O	O
were	O	O	O
studied	O	O	B-Entity
:	O	O	O
ammonia	O	O	B-Entity
concentrations	O	O	B-Entity
at	O	O	O
the	O	O	O
residence	O	O	B-Entity
(	O	O	O
Metric	O	O	B-Entity
I	O	O	I-Entity
)	O	O	O
,	O	O	O
distance	O	O	B-Entity
to	O	O	O
the	O	O	O
closest	O	O	O
source	O	O	B-Entity
(	O	O	O
Metric	O	O	B-Entity
II	O	O	I-Entity
)	O	O	O
,	O	O	O
number	O	O	O
of	O	O	O
sources	O	O	B-Entity
within	O	O	O
certain	O	O	O
distances	O	O	B-Entity
from	O	O	O
the	O	O	O
residence	O	O	O
(	O	O	O
Metric	O	O	B-Entity
IIIa	O	O	I-Entity
,	O	O	O
b	O	O	B-Entity
)	O	O	O
and	O	O	O
location	O	O	B-Entity
in	O	O	O
a	O	O	O
specific	O	O	O
region	O	O	B-Entity
(	O	O	O
Metric	O	O	B-Entity
IV	O	O	I-Entity
)	O	O	O
.	O	O	O

Exposure-response	O	O	B-Entity
models	O	O	I-Entity
based	O	O	O
on	O	O	O
Metric	O	O	B-Entity
I	O	O	I-Entity
provided	O	O	O
the	O	O	O
highest	O	O	O
predictive	O	O	O
ability	O	O	O
(	O	O	O
72.3	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
goodness-of-fit	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
IV	O	O	B-Entity
,	O	O	O
III	O	O	B-Entity
and	O	O	O
II	O	O	B-Entity
.	O	O	O

When	O	O	O
compared	O	O	O
to	O	O	O
Metric	O	O	B-Entity
I	O	O	I-Entity
,	O	O	O
Metric	O	O	B-Entity
IV	O	O	I-Entity
yielded	O	O	O
the	O	O	O
best	O	O	O
results	O	O	B-Entity
for	O	O	O
exposure	O	O	B-Entity
misclassification	O	O	B-Entity
analysis	O	O	B-Entity
and	O	O	O
interpretation	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
effect	O	O	B-Entity
estimates	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
Metric	O	O	B-Entity
IIIb	O	O	I-Entity
,	O	O	O
IIIa	O	O	B-Entity
and	O	O	O
II	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
showed	O	O	O
that	O	O	O
modelled	O	O	O
NH3	O	O	B-Entity
concentrations	O	O	B-Entity
provide	O	O	O
more	O	O	O
accurate	O	O	O
estimations	O	O	B-Entity
of	O	O	O
true	O	O	O
exposure	O	O	B-Entity
than	O	O	O
distances-based	O	O	O
surrogates	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
distance-based	O	O	O
surrogates	O	O	O
(	O	O	O
especially	O	O	O
those	O	O	O
based	O	O	O
on	O	O	O
distance	O	O	B-Entity
to	O	O	O
the	O	O	O
closest	O	O	O
point	O	O	O
source	O	O	B-Entity
)	O	O	O
are	O	O	O
imprecise	O	O	O
methods	O	O	O
to	O	O	O
identify	O	O	O
exposed	O	O	O
populations	O	O	B-Entity
,	O	O	O
although	O	O	O
they	O	O	O
may	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
initial	O	O	O
studies	O	O	B-Entity
.	O	O	O

-DOCSTART- (27692696)

De	O	O	B-Entity
Ritis	O	O	I-Entity
Ratio	O	O	I-Entity
(	O	O	I-Entity
AST/ALT	O	O	I-Entity
)	O	O	I-Entity
as	O	O	O
a	O	O	O
Significant	O	O	B-Entity
Prognostic	O	O	I-Entity
Factor	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
With	O	O	O
Upper	O	O	B-Entity
Tract	O	O	I-Entity
Urothelial	O	O	I-Entity
Cancer	O	O	I-Entity
Treated	O	O	B-Entity
With	O	O	O
Surgery	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
prognostic	O	O	I-Entity
value	O	O	I-Entity
of	O	O	O
preoperative	O	O	B-Entity
De	O	O	B-Entity
Ritis	O	O	I-Entity
ratio	O	O	I-Entity
(	O	O	I-Entity
aspartate	O	O	I-Entity
aminotransferase	O	O	I-Entity
[AST]/alanine	O	O	I-Entity
aminotransferase	O	O	I-Entity
[	O	O	I-Entity
ALT	O	O	I-Entity
]	O	O	I-Entity
)	O	O	I-Entity
on	O	O	O
postsurgical	O	O	B-Entity
survival	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
upper	O	O	B-Entity
tract	O	O	I-Entity
urothelial	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
UTUC	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
analyzed	O	O	I-Entity
the	O	O	O
data	O	O	B-Entity
of	O	O	O
623	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
radical	O	O	B-Entity
nephrouretectomy	O	O	I-Entity
for	O	O	O
UTUC	O	O	B-Entity
.	O	O	O

Multivariate	O	O	B-Entity
regression	O	O	I-Entity
tests	O	O	B-Entity
were	O	O	O
performed	O	O	O
to	O	O	O
identify	O	O	O
possible	O	O	B-Entity
associations	O	O	I-Entity
between	O	O	O
adverse	O	O	B-Entity
pathologic	O	O	I-Entity
events	O	O	I-Entity
and	O	O	O
AST/ALT	O	O	B-Entity
.	O	O	O

The	O	O	O
risk	O	O	O
of	O	O	O
postoperative	O	O	B-Entity
progression	O	O	B-Entity
and	O	O	O
survival	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
using	O	O	O
Kaplan-Meier	O	O	B-Entity
analyses	O	O	I-Entity
and	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
models	O	O	I-Entity
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
receiver	O	O	B-Entity
operator	O	O	I-Entity
characteristic	O	O	I-Entity
curve	O	O	I-Entity
of	O	O	O
AST/ALT	O	O	B-Entity
for	O	O	O
cancer-specific	O	O	B-Entity
mortality	O	O	I-Entity
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
AST/ALT	O	O	O
value	O	O	O
≥1.5	O	O	O
were	O	O	O
regarded	O	O	O
as	O	O	O
the	O	O	O
high	O	O	O
AST/ALT	O	O	O
group	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
remaining	O	O	O
patients	O	O	O
formed	O	O	O
the	O	O	O
low	O	O	O
AST/ALT	O	O	O
group	O	O	O
.	O	O	O

In	O	O	O
Kaplan-Meier	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
the	O	O	O
high	O	O	O
AST/ALT	O	O	B-Entity
group	O	O	O
showed	O	O	O
worse	O	O	O
progression-free	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
PFS	O	O	B-Entity
)	O	O	O
,	O	O	O
cancer-specific	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
CSS	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
all	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

Elevated	O	O	O
AST/ALT	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
higher	O	O	O
T	O	O	B-Entity
stage	O	O	I-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
HR	O	O	B-Entity
]	O	O	O
,	O	O	O
1.577	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
,	O	O	O
1.077	O	O	O
-	O	O	O
2.311	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.033	O	O	O
)	O	O	O
and	O	O	O
higher	O	O	B-Entity
cellular	O	O	I-Entity
grade	O	O	I-Entity
(	O	O	O
HR	O	O	O
,	O	O	O
1.538	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.034	O	O	O
-	O	O	O
2.287	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.041	O	O	O
)	O	O	O
in	O	O	O
multivariate	O	O	B-Entity
regression	O	O	I-Entity
tests	O	O	B-Entity
.	O	O	O

In	O	O	O
multivariate	O	O	B-Entity
Cox	O	O	I-Entity
analyses	O	O	I-Entity
,	O	O	O
high	O	O	O
AST/ALT	O	O	B-Entity
was	O	O	O
revealed	O	O	O
as	O	O	O
an	O	O	O
independent	O	O	B-Entity
predictor	O	O	I-Entity
of	O	O	O
PFS	O	O	B-Entity
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
2.335	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
1.633	O	O	O
-	O	O	O
3.340	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
,	O	O	O
CSS	O	O	B-Entity
(	O	O	O
HR	O	O	O
,	O	O	O
2.550	O	O	O
;	O	O	O
1.689	O	O	O
-	O	O	O
3.851	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
HR	O	O	O
,	O	O	O
2.069	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.409	O	O	O
-	O	O	O
3.038	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

Elevated	O	O	O
preoperative	O	O	B-Entity
AST/ALT	O	O	B-Entity
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
predictor	O	O	I-Entity
of	O	O	O
worse	O	O	B-Entity
postoperative	O	O	B-Entity
survival	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
surgically	O	O	B-Entity
treated	O	O	I-Entity
for	O	O	O
UTUC	O	O	B-Entity
.	O	O	O

Further	O	O	O
large	O	O	O
prospective	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
needed	O	O	O
for	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
prognostic	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
preoperative	O	O	B-Entity
AST/ALT	O	O	B-Entity
.	O	O	O

-DOCSTART- (27693948)

Molecular	O	O	B-Entity
simulation	O	O	I-Entity
study	O	O	B-Entity
on	O	O	O
concentration	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
rofecoxib	O	O	B-Entity
with	O	O	O
POPC	O	O	B-Entity
bilayer	O	O	O

The	O	O	O
interactions	O	O	B-Entity
between	O	O	O
rofecoxib	O	O	B-Entity
and	O	O	O
POPC	O	O	B-Entity
(	O	O	B-Entity
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine	O	O	I-Entity
)	O	O	I-Entity
bilayer	O	O	B-Entity
were	O	O	O
studied	O	O	B-Entity
using	O	O	B-Entity
all-atom	O	O	B-Entity
molecular	O	O	I-Entity
dynamics	O	O	I-Entity
simulation	O	O	I-Entity
method	O	O	B-Entity
.	O	O	O

Four	O	O	O
POPC	O	O	B-Entity
bilayer	O	O	B-Entity
systems	O	O	B-Entity
with	O	O	O
different	O	O	B-Entity
number	O	O	B-Entity
of	O	O	O
rofecoxib	O	O	B-Entity
molecules	O	O	B-Entity
were	O	O	O
constructed	O	O	B-Entity
to	O	O	O
simulate	O	O	B-Entity
different	O	O	O
drug	O	O	B-Entity
concentration	O	O	B-Entity
.	O	O	O

The	O	O	O
free	O	O	B-Entity
energy	O	O	I-Entity
of	O	O	O
rofecoxib	O	O	B-Entity
passing	O	O	B-Entity
across	O	O	O
pure	O	O	B-Entity
POPC	O	O	B-Entity
bilayer	O	O	B-Entity
has	O	O	O
two	O	O	O
minima	O	O	B-Entity
(	O	O	O
at	O	O	O
z	O	O	O
∼1.2	O	O	O
nm	O	O	O
or	O	O	O
1.6	O	O	O
nm	O	O	O
)	O	O	O
.	O	O	O

As	O	O	O
for	O	O	O
the	O	O	O
high	O	O	B-Entity
concentration	O	O	B-Entity
model	O	O	B-Entity
,	O	O	O
the	O	O	O
minimum	O	O	B-Entity
of	O	O	O
the	O	O	O
free	O	O	B-Entity
energy	O	O	I-Entity
profile	O	O	O
slightly	O	O	O
shifts	O	O	O
to	O	O	O
the	O	O	O
bilayer	O	O	B-Entity
center	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
energy	O	O	B-Entity
change	O	O	I-Entity
from	O	O	O
bulk	O	O	B-Entity
water	O	O	I-Entity
to	O	O	O
POPC	O	O	B-Entity
bilayer	O	O	B-Entity
increases	O	O	B-Entity
while	O	O	O
the	O	O	O
central	O	O	B-Entity
barrier	O	O	B-Entity
to	O	O	O
cross	O	O	B-Entity
the	O	O	O
hydrophobic	O	O	B-Entity
core	O	O	I-Entity
of	O	O	O
bilayer	O	O	O
slightly	O	O	B-Entity
decreases	O	O	B-Entity
,	O	O	O
suggesting	O	O	B-Entity
that	O	O	O
increasing	O	O	B-Entity
drug	O	O	B-Entity
concentration	O	O	B-Entity
makes	O	O	O
it	O	O	O
favorable	O	O	B-Entity
for	O	O	O
rofecoxib	O	O	B-Entity
to	O	O	O
partition	O	O	B-Entity
into	O	O	O
the	O	O	O
bilayer	O	O	O
and	O	O	O
easier	O	O	O
to	O	O	O
pass	O	O	B-Entity
across	O	O	O
bialyer	O	O	B-Entity
center	O	O	B-Entity
.	O	O	O

Energy	O	O	B-Entity
analysis	O	O	B-Entity
show	O	O	O
that	O	O	O
the	O	O	O
stabilization	O	O	B-Entity
between	O	O	O
the	O	O	O
selected	O	O	B-Entity
rofecoxib	O	O	B-Entity
and	O	O	O
other	O	O	O
pre-inserted	O	O	B-Entity
rofecoxib	O	O	O
molecule	O	O	B-Entity
is	O	O	O
mainly	O	O	O
due	O	O	O
to	O	O	O
van	O	O	B-Entity
der	O	O	I-Entity
Waals	O	O	I-Entity
interaction	O	O	I-Entity
energy	O	O	B-Entity
.	O	O	O

The	O	O	O
predicted	O	O	B-Entity
permeability	O	O	B-Entity
of	O	O	O
rofecoxib	O	O	B-Entity
in	O	O	O
high	O	O	B-Entity
concentration	O	O	B-Entity
model	O	O	B-Entity
slightly	O	O	O
weakens	O	O	B-Entity
as	O	O	O
compared	O	O	B-Entity
with	O	O	O
low	O	O	B-Entity
concentration	O	O	O
model	O	O	O
.	O	O	O

-DOCSTART- (27694392)

Short-term	O	O	B-Entity
Variability	O	O	I-Entity
of	O	O	O
Vitamin	O	O	B-Entity
D	O	O	I-Entity
-Related	O	O	O
Biomarkers	O	O	O

Quantifying	O	O	B-Entity
the	O	O	O
variability	O	O	B-Entity
of	O	O	O
biomarkers	O	O	B-Entity
is	O	O	O
important	O	O	B-Entity
,	O	O	O
as	O	O	O
high	O	O	O
within-person	O	O	O
variability	O	O	O
can	O	O	O
lead	O	O	O
to	O	O	O
misclassification	O	O	B-Entity
of	O	O	O
individuals	O	O	B-Entity
.	O	O	O

Short-term	O	O	O
variability	O	O	B-Entity
of	O	O	O
important	O	O	B-Entity
markers	O	O	B-Entity
of	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
metabolism	O	O	I-Entity
is	O	O	O
relatively	O	O	O
unknown	O	O	O
.	O	O	O

A	O	O	O
repeatability	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
160	O	O	O
Atherosclerosis	O	O	B-Entity
Risk	O	O	B-Entity
in	O	O	O
Communities	O	O	B-Entity
study	O	O	I-Entity
participants	O	O	I-Entity
(	O	O	O
60	O	O	O
%	O	O	O
female	O	O	B-Entity
,	O	O	O
28	O	O	O
%	O	O	O
black	O	O	B-Entity
,	O	O	O
mean	O	O	O
age	O	O	B-Entity
76	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Fasting	O	O	B-Entity
serum	O	O	B-Entity
was	O	O	O
drawn	O	O	O
at	O	O	O
2	O	O	O
time	O	O	O
points	O	O	O
,	O	O	O
a	O	O	O
median	O	O	O
of	O	O	O
6	O	O	O
(	O	O	O
range	O	O	O
3	O	O	O
-	O	O	O
13	O	O	O
)	O	O	O
weeks	O	O	B-Entity
apart	O	O	O
.	O	O	O

Vitamin	O	O	B-Entity
D	O	O	I-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
VDBP	O	O	B-Entity
)	O	O	O
and	O	O	O
25-hydroxyvitamin	O	O	B-Entity
D	O	O	I-Entity
[	O	O	O
25(OH)D	O	O	B-Entity
]	O	O	O
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
LC-MS	O	O	B-Entity
,	O	O	O
fibroblast	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
FGF23	O	O	B-Entity
)	O	O	O
and	O	O	O
parathyroid	O	O	B-Entity
hormone	O	O	I-Entity
(	O	O	O
PTH	O	O	B-Entity
)	O	O	O
by	O	O	O
enzyme-linked	O	O	B-Entity
immunoassay	O	O	I-Entity
,	O	O	O
and	O	O	O
calcium	O	O	B-Entity
and	O	O	O
phosphorus	O	O	B-Entity
by	O	O	O
Roche	O	O	B-Entity
Cobas	O	O	I-Entity
6000	O	O	I-Entity
.	O	O	O

Free	O	O	B-Entity
and	O	O	O
bioavailable	O	O	B-Entity
25(OH)D	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
.	O	O	O

We	O	O	O
calculated	O	O	B-Entity
the	O	O	O
within-person	O	O	B-Entity
CV	O	O	I-Entity
(	O	O	O
CVW	O	O	B-Entity
)	O	O	O
,	O	O	O
intraclass	O	O	B-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
(	O	O	O
ICC	O	O	B-Entity
)	O	O	O
,	O	O	O
Spearman	O	O	B-Entity
rank	O	O	I-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
(	O	O	O
r	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
percent	O	O	B-Entity
reclassified	O	O	B-Entity
.	O	O	O

The	O	O	O
CVW	O	O	B-Entity
was	O	O	O
lowest	O	O	B-Entity
for	O	O	O
calcium	O	O	B-Entity
(	O	O	O
2.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
albumin	O	O	B-Entity
(	O	O	O
3.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
25(OH)D	O	O	B-Entity
(	O	O	O
6.9	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
VDBP	O	O	B-Entity
(	O	O	O
7.0	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
phosphorus	O	O	B-Entity
(	O	O	O
7.6	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
intermediate	O	O	B-Entity
for	O	O	O
free	O	O	B-Entity
25(OH)D	O	O	O
(	O	O	O
9.0	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
bioavailable	O	O	B-Entity
25(OH)D	O	O	O
(	O	O	O
9.9	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
and	O	O	O
highest	O	O	B-Entity
for	O	O	O
PTH	O	O	B-Entity
(	O	O	O
16.7	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
FGF23	O	O	B-Entity
(	O	O	O
17.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Reclassification	O	O	B-Entity
was	O	O	O
highest	O	O	B-Entity
for	O	O	O
PTH	O	O	B-Entity
,	O	O	O
VDBP	O	O	B-Entity
,	O	O	O
and	O	O	O
phosphorus	O	O	B-Entity
(	O	O	O
all	O	O	O
7.5	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
ICC	O	O	B-Entity
and	O	O	O
r	O	O	B-Entity
were	O	O	O
highest	O	O	B-Entity
(	O	O	O
≥0.80	O	O	O
)	O	O	O
for	O	O	O
25(OH)D	O	O	B-Entity
,	O	O	O
free	O	O	B-Entity
25(OH)D	O	O	O
,	O	O	O
bioavailable	O	O	B-Entity
25(OH)D	O	O	O
and	O	O	O
PTH	O	O	B-Entity
,	O	O	O
but	O	O	O
somewhat	O	O	O
lower	O	O	B-Entity
(	O	O	O
approximately	O	O	B-Entity
0.60	O	O	O
-	O	O	O
0.75	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
other	O	O	O
biomarkers	O	O	B-Entity
.	O	O	O

Six-	O	O	O
week	O	O	B-Entity
short-term	O	O	B-Entity
variability	O	O	I-Entity
,	O	O	O
as	O	O	O
assessed	O	O	B-Entity
by	O	O	O
CVW	O	O	B-Entity
,	O	O	O
was	O	O	O
quite	O	O	B-Entity
low	O	O	I-Entity
for	O	O	O
VDBP	O	O	B-Entity
,	O	O	O
calcium	O	O	B-Entity
and	O	O	O
phosphorus	O	O	B-Entity
,	O	O	O
but	O	O	O
fairly	O	O	B-Entity
high	O	O	I-Entity
for	O	O	O
FGF23	O	O	B-Entity
and	O	O	O
PTH	O	O	B-Entity
.	O	O	O

As	O	O	O
such	O	O	O
,	O	O	O
multiple	O	O	B-Entity
measurements	O	O	I-Entity
of	O	O	O
FGF23	O	O	B-Entity
and	O	O	O
PTH	O	O	B-Entity
may	O	O	O
be	O	O	O
needed	O	O	O
to	O	O	O
minimize	O	O	B-Entity
misclassification	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
provide	O	O	O
insight	O	O	B-Entity
into	O	O	O
the	O	O	O
extent	O	O	O
of	O	O	O
potential	O	O	B-Entity
misclassification	O	O	B-Entity
of	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
markers	O	O	B-Entity
in	O	O	O
research	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
settings	O	O	I-Entity
.	O	O	O

-DOCSTART- (27695327)

Fabrication	O	O	B-Entity
of	O	O	O
gelatin	O	O	B-Entity
methacrylate	O	O	I-Entity
/	O	O	O
nanohydroxyapatite	O	O	B-Entity
microgel	O	O	B-Entity
arrays	O	O	B-Entity
for	O	O	O
periodontal	O	O	O
tissue	O	O	O
regeneration	O	O	O

Periodontitis	O	O	B-Entity
is	O	O	O
a	O	O	O
chronic	O	O	B-Entity
infectious	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
is	O	O	O
the	O	O	O
major	O	O	B-Entity
cause	O	O	I-Entity
of	O	O	O
tooth	O	O	B-Entity
loss	O	O	I-Entity
and	O	O	O
other	O	O	O
oral	O	O	B-Entity
health	O	O	I-Entity
issues	O	O	B-Entity
around	O	O	O
the	O	O	O
world	O	O	B-Entity
.	O	O	O

Periodontal	O	O	B-Entity
tissue	O	O	I-Entity
regeneration	O	O	I-Entity
has	O	O	O
therefore	O	O	O
always	O	O	O
been	O	O	O
the	O	O	O
ultimate	O	O	B-Entity
goal	O	O	I-Entity
of	O	O	O
dentists	O	O	B-Entity
and	O	O	O
researchers	O	O	B-Entity
.	O	O	O

Existing	O	O	O
fabrication	O	O	B-Entity
methods	O	O	B-Entity
mainly	O	O	O
focused	O	O	B-Entity
on	O	O	O
a	O	O	O
top-down	O	O	B-Entity
tissue	O	O	I-Entity
engineering	O	O	I-Entity
strategy	O	O	B-Entity
in	O	O	O
which	O	O	O
several	O	O	O
drawbacks	O	O	B-Entity
remain	O	O	B-Entity
,	O	O	O
including	O	O	O
low	O	O	B-Entity
throughput	O	O	I-Entity
and	O	O	O
limited	O	O	O
diffusion	O	O	B-Entity
properties	O	O	B-Entity
resulting	O	O	B-Entity
from	O	O	O
a	O	O	O
large	O	O	B-Entity
sample	O	O	I-Entity
size	O	O	I-Entity
.	O	O	O

Gelatin	O	O	B-Entity
methacrylate	O	O	I-Entity
(	O	O	O
GelMA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
kind	O	O	O
of	O	O	O
photocrosslinkable	O	O	B-Entity
and	O	O	O
biocompatible	O	O	B-Entity
hydrogel	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
capacities	O	O	B-Entity
of	O	O	O
enabling	O	O	B-Entity
cell	O	O	B-Entity
encapsulation	O	O	I-Entity
and	O	O	O
regeneration	O	O	B-Entity
of	O	O	I-Entity
functional	O	O	I-Entity
tissues	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	O
a	O	O	O
novel	O	O	B-Entity
method	O	O	B-Entity
to	O	O	O
fabricate	O	O	B-Entity
GelMA	O	O	B-Entity
/	O	O	O
nanohydroxylapatite	O	O	B-Entity
(	O	O	O
nHA	O	O	B-Entity
)	O	O	O
microgel	O	O	B-Entity
arrays	O	O	B-Entity
using	O	O	O
a	O	O	O
photocrosslinkable	O	O	B-Entity
strategy	O	O	B-Entity
.	O	O	O

The	O	O	O
viability	O	O	B-Entity
,	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
and	O	O	O
osteogenic	O	O	B-Entity
differentiation	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
osteogenesis	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
periodontal	O	O	B-Entity
ligament	O	O	I-Entity
stem	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
hPDLSCs	O	O	B-Entity
)	O	O	O
encapsulated	O	O	B-Entity
in	O	O	O
microgels	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
suggested	O	O	B-Entity
that	O	O	O
such	O	O	O
microgels	O	O	B-Entity
provide	O	O	B-Entity
great	O	O	O
potential	O	O	B-Entity
for	O	O	O
periodontal	O	O	B-Entity
tissue	O	O	I-Entity
repair	O	O	I-Entity
and	O	O	I-Entity
regeneration	O	O	I-Entity
.	O	O	O

Microgel	O	O	B-Entity
arrays	O	O	B-Entity
were	O	O	O
fabricated	O	O	B-Entity
by	O	O	O
blending	O	O	B-Entity
different	O	O	B-Entity
weight	O	O	B-Entity
ratios	O	O	I-Entity
of	O	O	O
GelMA	O	O	B-Entity
and	O	O	O
nHA	O	O	B-Entity
.	O	O	O

hPDLSCs	O	O	B-Entity
were	O	O	O
encapsulated	O	O	B-Entity
in	O	O	O
GelMA	O	O	B-Entity
/	O	O	O
nHA	O	O	B-Entity
microgels	O	O	B-Entity
of	O	O	O
various	O	O	O
ratios	O	O	B-Entity
for	O	O	O
a	O	O	O
systematic	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
viability	O	O	I-Entity
,	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
and	O	O	O
osteogenic	O	O	B-Entity
differentiation	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
osteogenesis	O	O	B-Entity
in	O	O	O
nude	O	O	B-Entity
mice	O	O	I-Entity
was	O	O	O
also	O	O	O
studied	O	O	O
.	O	O	O

The	O	O	O
GelMA	O	O	B-Entity
/	O	O	O
nHA	O	O	B-Entity
microgels	O	O	B-Entity
exhibited	O	O	O
appropriate	O	O	B-Entity
microarchitecture	O	O	B-Entity
,	O	O	O
mechanical	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
and	O	O	O
surface	O	O	B-Entity
roughness	O	O	B-Entity
,	O	O	O
thus	O	O	O
enabling	O	O	O
cell	O	O	B-Entity
adhesion	O	O	I-Entity
and	O	O	O
proliferation	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
the	O	O	O
GelMA	O	O	B-Entity
/	O	O	O
nHA	O	O	B-Entity
microgels	O	O	B-Entity
(	O	O	O
10%/2	O	O	O
%	O	O	O
w/v	O	O	O
)	O	O	O
enhanced	O	O	B-Entity
the	O	O	O
osteogenic	O	O	B-Entity
differentiation	O	O	I-Entity
of	O	O	O
hPDLSCs	O	O	B-Entity
by	O	O	O
elevating	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
osteogenic	O	O	B-Entity
biomarker	O	O	I-Entity
genes	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
ALP	O	O	B-Entity
,	O	O	O
BSP	O	O	B-Entity
,	O	O	O
OCN	O	O	B-Entity
,	O	O	O
and	O	O	O
RUNX2	O	O	B-Entity
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
ectopic	O	O	B-Entity
transplantation	O	O	B-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
GelMA	O	O	B-Entity
/	O	O	O
nHA	O	O	B-Entity
microgels	O	O	B-Entity
(	O	O	O
10%/2	O	O	O
%	O	O	O
w/v	O	O	O
)	O	O	O
increased	O	O	B-Entity
mineralized	O	O	B-Entity
tissue	O	O	I-Entity
formation	O	O	B-Entity
with	O	O	O
abundant	O	O	B-Entity
vascularization	O	O	B-Entity
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
1	O	O	O
%	O	O	O
,	O	O	O
3	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
pure	O	O	O
GelMA	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
GelMA	O	O	B-Entity
/	O	O	O
nHA	O	O	B-Entity
microgels	O	O	B-Entity
(	O	O	O
10%/2	O	O	O
%	O	O	O
w/v	O	O	O
)	O	O	O
facilitated	O	O	O
hPDLSCs	O	O	B-Entity
viability	O	O	B-Entity
,	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
and	O	O	O
osteogenic	O	O	B-Entity
differentiation	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
further	O	O	B-Entity
promoted	O	O	B-Entity
new	O	O	B-Entity
bone	O	O	B-Entity
formation	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
GelMA	O	O	O
/	O	O	O
nHA	O	O	O
microgels	O	O	O
(	O	O	O
10%/2	O	O	O
%	O	O	O
w/v	O	O	O
)	O	O	O
provide	O	O	B-Entity
great	O	O	O
potential	O	O	B-Entity
for	O	O	O
periodontal	O	O	B-Entity
tissue	O	O	I-Entity
regeneration	O	O	I-Entity
.	O	O	O

-DOCSTART- (27698544)

Esomeprazole	O	O	B-Entity
-	O	O	O
or	O	O	O
rabeprazole	O	O	B-Entity
-based	O	O	O
triple	O	O	B-Entity
therapy	O	O	B-Entity
eradicated	O	O	O
Helicobacter	O	O	B-Entity
pylori	O	O	I-Entity
comparably	O	O	O
regardless	O	O	B-Entity
of	O	O	O
clarithromycin	O	O	B-Entity
susceptibility	O	O	B-Entity
and	O	O	O
CYP2C19	O	O	B-Entity
genotypes	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
esomeprazole	O	O	B-Entity
-based	O	O	O
triple	O	O	B-Entity
therapy	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
rabeprazole	O	O	B-Entity
-based	O	O	O
triple	O	O	O
therapy	O	O	O
according	O	O	O
to	O	O	O
CYP2C19	O	O	B-Entity
genotype	O	O	B-Entity
and	O	O	O
clarithromycin	O	O	B-Entity
susceptibility	O	O	B-Entity
status	O	O	B-Entity
for	O	O	O
first-line	O	O	O
eradication	O	O	B-Entity
therapy	O	O	I-Entity
of	O	O	I-Entity
Helicobacter	O	O	I-Entity
pylori	O	O	I-Entity
(	O	O	O
H.	O	O	B-Entity
pylori	O	O	I-Entity
)	O	O	O
in	O	O	O
Japan	O	O	B-Entity
.	O	O	O

We	O	O	O
enrolled	O	O	O
219	O	O	O
H.	O	O	B-Entity
pylori	O	O	I-Entity
-	O	O	O
infected	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
randomly	O	O	B-Entity
allocated	O	O	B-Entity
patients	O	O	O
to	O	O	O
the	O	O	O
EAC	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
esomeprazole	O	O	B-Entity
20	O	O	O
mg	O	O	O
,	O	O	O
clarithromycin	O	O	B-Entity
200	O	O	O
mg	O	O	O
,	O	O	O
amoxicillin	O	O	B-Entity
750	O	O	O
mg	O	O	O
for	O	O	O
one	O	O	O
week	O	O	B-Entity
,	O	O	O
with	O	O	O
all	O	O	O
drugs	O	O	B-Entity
given	O	O	B-Entity
twice	O	O	B-Entity
daily	O	O	I-Entity
)	O	O	O
or	O	O	O
RAC	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
rabeprazole	O	O	B-Entity
10	O	O	O
mg	O	O	O
,	O	O	O
clarithromycin	O	O	O
200	O	O	O
mg	O	O	O
,	O	O	O
amoxicillin	O	O	O
750	O	O	O
mg	O	O	O
for	O	O	O
one	O	O	O
week	O	O	O
,	O	O	O
with	O	O	O
all	O	O	O
drugs	O	O	O
given	O	O	O
twice	O	O	O
daily	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
H.	O	O	B-Entity
pylori	O	O	I-Entity
eradication	O	O	B-Entity
rate	O	O	I-Entity
according	O	O	O
to	O	O	O
the	O	O	O
PP	O	O	B-Entity
analyses	O	O	I-Entity
was	O	O	O
75.0	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
65.2	O	O	O
-	O	O	O
82.8	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
EAC	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
71.4	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
61.4	O	O	O
-	O	O	O
79.1	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
RAC	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
statistically	O	O	O
significant	O	O	O
differences	O	O	B-Entity
.	O	O	O

The	O	O	O
eradication	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
the	O	O	O
clarithromycin	O	O	B-Entity
-resistant	O	O	O
/-	O	O	O

sensitive	O	O	B-Entity
strains	O	O	B-Entity
were	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
45.0	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
30.7	O	O	O
-	O	O	O
60.2%)/98.0	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
88.7	O	O	O
-	O	O	O
100	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
EAC	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
39.5	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
25.6	O	O	O
-	O	O	O
55.3%)/93.5	O	O	O
%	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
81.9	O	O	O
-	O	O	O
98.4	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
RAC	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
eradication	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
the	O	O	O
clarithromycin	O	O	B-Entity
-	O	O	O
sensitive	O	O	B-Entity
strains	O	O	B-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	B-Entity
than	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
resistant	O	O	B-Entity
strains	O	O	I-Entity
in	O	O	O
both	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
EAC	O	O	B-Entity
and	O	O	O
RAC	O	O	B-Entity
therapies	O	O	B-Entity
show	O	O	O
a	O	O	O
comparable	O	O	O
efficacy	O	O	B-Entity
regardless	O	O	B-Entity
of	O	O	O
the	O	O	O
CYP2C19	O	O	B-Entity
genotype	O	O	B-Entity
and	O	O	O
clarithromycin	O	O	B-Entity
susceptibility	O	O	B-Entity
status	O	O	B-Entity
in	O	O	O
Japan	O	O	B-Entity
.	O	O	O

-DOCSTART- (27698942)

Optimization	O	O	O
of	O	O	O
Early	O	O	B-Entity
Response	O	O	B-Entity
Monitoring	O	O	I-Entity
and	O	O	O
Prediction	O	O	O
of	O	O	O
Cancer	O	O	B-Entity
Antiangiogenesis	O	O	B-Entity
Therapy	O	O	I-Entity
via	O	O	O
Noninvasive	O	O	B-Entity
PET	O	O	B-Entity
Molecular	O	O	I-Entity
Imaging	O	O	I-Entity
Strategies	O	O	O
of	O	O	O
Multifactorial	O	O	B-Entity
Bioparameters	O	O	O

Objective	O	O	O
:	O	O	O
Antiangiogenesis	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
AAT	O	O	B-Entity
)	O	O	O
has	O	O	O
provided	O	O	O
substantial	O	O	O
benefits	O	O	O
regarding	O	O	O
improved	O	O	O
outcomes	O	O	O
and	O	O	O
survival	O	O	B-Entity
for	O	O	O
suitable	O	O	O
patients	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
settings	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
early	O	O	B-Entity
definition	O	O	O
of	O	O	O
therapeutic	O	O	B-Entity
effects	O	O	I-Entity
is	O	O	O
urgently	O	O	O
needed	O	O	O
to	O	O	O
guide	O	O	O
cancer	O	O	B-Entity
AAT	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
optimize	O	O	O
the	O	O	O
early	O	O	B-Entity
response	O	O	B-Entity
monitoring	O	O	I-Entity
and	O	O	O
prediction	O	O	O
of	O	O	O
AAT	O	O	B-Entity
efficacy	O	O	B-Entity
,	O	O	O
as	O	O	O
indicated	O	O	O
by	O	O	O
the	O	O	O
multi-targeted	O	O	O
anti-angiogenic	O	O	B-Entity
drug	O	O	I-Entity
sunitinib	O	O	B-Entity
in	O	O	O
U87MG	O	O	B-Entity
tumors	O	O	I-Entity
,	O	O	O
using	O	O	O
noninvasive	O	O	B-Entity
positron	O	O	B-Entity
emission	O	O	I-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	I-Entity
PET	O	O	I-Entity
)	O	O	I-Entity
molecular	O	O	I-Entity
imaging	O	O	I-Entity
strategies	O	O	O
of	O	O	O
multifactorial	O	O	B-Entity
bioparameters	O	O	B-Entity
.	O	O	O

Methods	O	O	O
:	O	O	O
U87MG	O	O	B-Entity
tumor	O	O	I-Entity
mice	O	O	B-Entity
were	O	O	O
treated	O	O	O
via	O	O	O
intragastric	O	O	B-Entity
injections	O	O	B-Entity
of	O	O	O
sunitinib	O	O	B-Entity
(	O	O	O
80	O	O	O
mg/kg	O	O	O
)	O	O	O
or	O	O	O
vehicle	O	O	B-Entity
for	O	O	O
7	O	O	O
consecutive	O	O	O
days	O	O	O
.	O	O	O

Longitudinal	O	O	B-Entity
MicroPET/CT	O	O	B-Entity
scans	O	O	I-Entity
with	O	O	O
(18)F-FDG	O	O	B-Entity
,	O	O	O
(18)F-FMISO	O	O	B-Entity
,	O	O	I-Entity
(18)F-ML-10	O	O	B-Entity
and	O	O	O
(18)F-Alfatide	O	O	B-Entity
II	O	O	I-Entity
were	O	O	O
acquired	O	O	O
to	O	O	O
quantitatively	O	O	O
measure	O	O	O
metabolism	O	O	B-Entity
,	O	O	O
hypoxia	O	O	B-Entity
,	O	O	O
apoptosis	O	O	B-Entity
and	O	O	O
angiogenesis	O	O	B-Entity
on	O	O	O
days	O	O	O
0	O	O	O
,	O	O	O
1	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
7	O	O	O
and	O	O	O
13	O	O	O
following	O	O	O
therapy	O	O	B-Entity
initiation	O	O	O
.	O	O	O

Tumor	O	O	B-Entity
tissues	O	O	I-Entity
from	O	O	O
a	O	O	O
dedicated	O	O	O
group	O	O	O
of	O	O	O
mice	O	O	B-Entity
were	O	O	O
collected	O	O	O
for	O	O	O
immunohistochemical	O	O	B-Entity
(	O	O	O
IHC	O	O	B-Entity
)	O	O	O
analysis	O	O	O
of	O	O	O
key	O	O	O
biomarkers	O	O	B-Entity
(	O	O	O
Glut-1	O	O	B-Entity
,	O	O	O
CA-IX	O	O	B-Entity
,	O	O	O
TUNEL	O	O	B-Entity
,	O	O	O
ανβ3	O	O	B-Entity
and	O	O	O
CD31	O	O	B-Entity
)	O	O	O
at	O	O	O
the	O	O	O
time	O	O	O
points	O	O	O
of	O	O	O
PET	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

The	O	O	O
tumor	O	O	B-Entity
sizes	O	O	I-Entity
and	O	O	O
mouse	O	O	B-Entity
weights	O	O	B-Entity
were	O	O	O
measured	O	O	O
throughout	O	O	O
the	O	O	O
study	O	O	O
.	O	O	O

The	O	O	O
tumor	O	O	B-Entity
uptake	O	O	B-Entity
(	O	O	O
ID%/gmax	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
ratios	O	O	B-Entity
of	O	O	O
the	O	O	O
tumor	O	O	O
/	O	O	O
muscle	O	O	B-Entity
(	O	O	O
T	O	O	B-Entity
/	O	O	O
M	O	O	B-Entity
)	O	O	O
for	O	O	O
each	O	O	O
probe	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
ratios	O	O	O
(	O	O	O
TGR	O	O	B-Entity
)	O	O	O
were	O	O	O
calculated	O	O	O
and	O	O	O
used	O	O	O
for	O	O	O
statistical	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
the	O	O	O
differences	O	O	O
and	O	O	O
correlations	O	O	O
.	O	O	O

Results	O	O	O
:	O	O	O
Sunitinib	O	O	B-Entity
successfully	O	O	O
inhibited	O	O	O
U87MG	O	O	B-Entity
tumor	O	O	I-Entity
growth	O	O	I-Entity
with	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
tumor	O	O	B-Entity
size	O	O	I-Entity
from	O	O	O
day	O	O	O
9	O	O	O
after	O	O	O
sunitinib	O	O	B-Entity
treatment	O	O	B-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
uptakes	O	O	B-Entity
of	O	O	O
(18)F-FMISO	O	O	B-Entity
(	O	O	O
reduced	O	O	O
hypoxia	O	O	B-Entity
)	O	O	O
,	O	O	O
(18)F-ML-10	O	O	B-Entity
(	O	O	O
increased	O	O	O
apoptosis	O	O	B-Entity
)	O	O	O
and	O	O	O
(18)F-Alfatide	O	O	B-Entity
II	O	O	I-Entity
(	O	O	O
decreased	O	O	O
angiogenesis	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
tumor	O	O	B-Entity
lesions	O	O	B-Entity
significantly	O	O	O
changed	O	O	O
during	O	O	O
the	O	O	O
early	O	O	B-Entity
stage	O	O	O
(	O	O	O
days	O	O	O
1	O	O	O
to	O	O	O
3	O	O	O
)	O	O	O
of	O	O	O
sunitinib	O	O	B-Entity
treatment	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
uptake	O	O	B-Entity
of	O	O	O
(18)F-FDG	O	O	B-Entity
(	O	O	O
increased	O	O	O
glucose	O	O	B-Entity
metabolism	O	O	I-Entity
)	O	O	O
was	O	O	O
significantly	O	O	O
different	O	O	O
during	O	O	O
the	O	O	O
late	O	O	B-Entity
stage	O	O	I-Entity
.	O	O	O

The	O	O	O
PET	O	O	B-Entity
imaging	O	O	I-Entity
data	O	O	O
of	O	O	O
each	O	O	O
probe	O	O	O
were	O	O	O
all	O	O	O
confirmed	O	O	O
via	O	O	O
ex	O	O	B-Entity
vivo	O	O	I-Entity
IHC	O	O	B-Entity
of	O	O	O
the	O	O	O
relevant	O	O	O
biomarkers	O	O	B-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
the	O	O	O
PET	O	O	B-Entity
imaging	O	O	I-Entity
of	O	O	O
(18)F-Alfatide	O	O	B-Entity
II	O	O	I-Entity
and	O	O	O
(18)F-FMISO	O	O	B-Entity
was	O	O	O
significantly	O	O	O
correlated	O	O	O
(	O	O	O
all	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
with	O	O	O
TGR	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
imaging	O	O	O
of	O	O	O
(18)F-FDG	O	O	B-Entity
and	O	O	O
(18)F-ML-10	O	O	B-Entity
was	O	O	O
not	O	O	O
significantly	O	O	O
correlated	O	O	O
with	O	O	O
TGR	O	O	O
.	O	O	O

Conclusion	O	O	O
:	O	O	O
Based	O	O	O
on	O	O	O
the	O	O	O
tumor	O	O	B-Entity
uptake	O	O	B-Entity
of	O	O	O
the	O	O	O
PET	O	O	B-Entity
probes	O	O	O
and	O	O	O
their	O	O	O
correlations	O	O	O
with	O	O	O
MVD	O	O	B-Entity
and	O	O	O
TGR	O	O	B-Entity
,	O	O	O
(18)F-Alfatide	O	O	B-Entity
II	O	O	I-Entity
PET	O	O	O
may	O	O	O
not	O	O	O
only	O	O	O
monitor	O	O	O
the	O	O	O
early	O	O	B-Entity
response	O	O	B-Entity
but	O	O	O
also	O	O	O
precisely	O	O	O
predict	O	O	O
the	O	O	O
therapeutic	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
the	O	O	O
multi-targeted	O	O	O
,	O	O	O
anti-angiogenic	O	O	B-Entity
drug	O	O	I-Entity
sunitinib	O	O	B-Entity
in	O	O	O
U87MG	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
feasible	O	O	O
to	O	O	O
optimize	O	O	O
the	O	O	O
early	O	O	B-Entity
response	O	O	B-Entity
monitoring	O	O	I-Entity
and	O	O	O
efficacy	O	O	B-Entity
prediction	O	O	O
of	O	O	O
cancer	O	O	B-Entity
AAT	O	O	B-Entity
using	O	O	O
noninvasive	O	O	B-Entity
PET	O	O	B-Entity
molecular	O	O	I-Entity
imaging	O	O	B-Entity
strategies	O	O	O
of	O	O	O
multifactorial	O	O	B-Entity
bioparameters	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
angiogenesis	O	O	B-Entity
imaging	O	O	O
with	O	O	O
(18)F-Alfatide	O	O	B-Entity
II	O	O	I-Entity
,	O	O	O
which	O	O	O
represents	O	O	O
an	O	O	O
RGD	O	O	B-Entity
-based	O	O	O
probe	O	O	O
.	O	O	O

-DOCSTART- (27704589)

Identifying	O	O	O
research	O	O	B-Entity
priorities	O	O	I-Entity
with	O	O	O
nurses	O	O	B-Entity
at	O	O	O
a	O	O	O
tertiary	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
hospital	O	O	B-Entity
in	O	O	O
the	O	O	O
United	O	O	O
Kingdom	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
undertake	O	O	O
a	O	O	O
research	O	O	B-Entity
priority	O	O	I-Entity
setting	O	O	O
exercise	O	O	O
with	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
maximizing	O	O	O
efficiency	O	O	B-Entity
and	O	O	O
impact	O	O	B-Entity
in	O	O	O
research	O	O	B-Entity
activity	O	O	I-Entity
undertaken	O	O	O
by	O	O	O
nurses	O	O	B-Entity
at	O	O	O
one	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
tertiary	O	O	O
healthcare	O	O	B-Entity
institution	O	O	I-Entity
by	O	O	O
ensuring	O	O	O
the	O	O	O
clinical	O	O	B-Entity
staff	O	O	I-Entity
directly	O	O	O
shaped	O	O	O
a	O	O	O
coherent	O	O	B-Entity
,	O	O	O
transparent	O	O	B-Entity
and	O	O	O
consensus	O	O	B-Entity
driven	O	O	O
nurse-led	O	O	B-Entity
research	O	O	I-Entity
agenda	O	O	I-Entity
.	O	O	O

In	O	O	O
Round	O	O	O
1	O	O	O
,	O	O	O
the	O	O	O
research	O	O	B-Entity
topics	O	O	I-Entity
of	O	O	O
147	O	O	O
nurses	O	O	B-Entity
were	O	O	O
elicited	O	O	O
using	O	O	O
a	O	O	O
modified	O	O	B-Entity
nominal	O	O	I-Entity
group	O	O	I-Entity
technique	O	O	I-Entity
as	O	O	O
the	O	O	O
consensus	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
participants	O	O	B-Entity
in	O	O	O
the	O	O	O
24	O	O	O
separate	O	O	O
discussions	O	O	O
ranged	O	O	O
from	O	O	O
3	O	O	O
to	O	O	O
21	O	O	O
,	O	O	O
generating	O	O	O
lists	O	O	O
of	O	O	O
between	O	O	O
6	O	O	O
and	O	O	O
23	O	O	O
topics	O	O	O
.	O	O	O

In	O	O	O
Round	O	O	O
2	O	O	O
,	O	O	O
nurses	O	O	B-Entity
from	O	O	O
the	O	O	O
clinical	O	O	B-Entity
areas	O	O	I-Entity
ranked	O	O	B-Entity
topics	O	O	O
of	O	O	O
importance	O	O	O
resulting	O	O	O
in	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
four	O	O	O
to	O	O	O
five	O	O	O
priorities	O	O	B-Entity
.	O	O	O

In	O	O	O
Round	O	O	O
3	O	O	O
,	O	O	O
the	O	O	O
divisional	O	O	B-Entity
heads	O	O	I-Entity
of	O	O	O
nursing	O	O	B-Entity
consulted	O	O	O
with	O	O	O
staff	O	O	B-Entity
in	O	O	O
all	O	O	O
of	O	O	O
their	O	O	O
clinical	O	O	B-Entity
areas	O	O	I-Entity
to	O	O	O
each	O	O	O
finalize	O	O	O
their	O	O	O
five	O	O	O
divisional	O	O	B-Entity
priorities	O	O	I-Entity
.	O	O	O

The	O	O	O
Nursing	O	O	B-Entity
Research	O	O	I-Entity
Working	O	O	I-Entity
Group	O	O	I-Entity
discussed	O	O	O
and	O	O	O
refined	O	O	O
the	O	O	O
divisions	O	O	B-Entity
'	O	O	I-Entity
priorities	O	O	I-Entity
and	O	O	O
voted	O	O	B-Entity
on	O	O	O
the	O	O	O
final	O	O	O
list	O	O	O
to	O	O	O
agree	O	O	O
the	O	O	O
top	O	O	O
five	O	O	O
research	O	O	B-Entity
priorities	O	O	I-Entity
for	O	O	O
the	O	O	O
organization	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
269	O	O	O
research	O	O	B-Entity
topics	O	O	I-Entity
were	O	O	O
initially	O	O	O
generated	O	O	O
.	O	O	O

Following	O	O	O
three	O	O	O
rounds	O	O	O
of	O	O	O
ranking	O	O	B-Entity
and	O	O	O
prioritizing	O	O	O
,	O	O	O
five	O	O	O
priorities	O	O	B-Entity
were	O	O	O
agreed	O	O	O
at	O	O	O
Divisional	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
and	O	O	O
from	O	O	O
these	O	O	O
,	O	O	O
the	O	O	O
five	O	O	O
top	O	O	O
organizational	O	O	B-Entity
priorities	O	O	I-Entity
were	O	O	O
selected	O	O	O
.	O	O	O

These	O	O	O
were	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
understanding	O	O	O
and	O	O	O
improving	O	O	O
all	O	O	O
aspects	O	O	O
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
journey	O	O	O
through	O	O	O
the	O	O	O
hospital	O	O	B-Entity
system	O	O	I-Entity
;	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
play	O	O	B-Entity
;	O	O	O
(	O	O	O
iii	O	O	O
)	O	O	O
staff	O	O	B-Entity
wellbeing	O	O	I-Entity
,	O	O	O
patient	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
productivity	O	O	B-Entity
;	O	O	O
(	O	O	O
iv	O	O	O
)	O	O	O
team	O	O	B-Entity
work	O	O	I-Entity
-	O	O	O
linking	O	O	O
to	O	O	O
a	O	O	O
more	O	O	O
efficient	O	O	O
service	O	O	B-Entity
;	O	O	O
and	O	O	O
(	O	O	O
v	O	O	O
)	O	O	O
supporting	O	O	B-Entity
parents	O	O	I-Entity
/	O	O	O
parent	O	O	B-Entity
pathway	O	O	O
.	O	O	O

Divisional	O	O	O
priorities	O	O	B-Entity
have	O	O	O
been	O	O	O
disseminated	O	O	O
widely	O	O	O
to	O	O	O
clinical	O	O	B-Entity
teams	O	O	I-Entity
to	O	O	O
inform	O	O	O
a	O	O	O
patient-specific	O	O	B-Entity
nurse-led	O	O	I-Entity
research	O	O	I-Entity
agenda	O	O	I-Entity
.	O	O	O

Organizational	O	O	B-Entity
priorities	O	O	I-Entity
agreed	O	O	O
upon	O	O	O
have	O	O	O
been	O	O	O
disseminated	O	O	O
through	O	O	O
management	O	O	B-Entity
structures	O	O	I-Entity
and	O	O	O
processes	O	O	O
to	O	O	O
ensure	O	O	O
engagement	O	O	O
at	O	O	O
all	O	O	O
levels	O	O	O
.	O	O	O

A	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
the	O	O	O
Nursing	O	O	B-Entity
Research	O	O	I-Entity
Working	O	O	I-Entity
Group	O	O	I-Entity
has	O	O	O
been	O	O	O
delegated	O	O	O
to	O	O	O
take	O	O	O
this	O	O	O
work	O	O	O
forward	O	O	O
so	O	O	O
that	O	O	O
the	O	O	O
agreed	O	O	O
priorities	O	O	B-Entity
continue	O	O	O
to	O	O	O
contribute	O	O	O
towards	O	O	O
shaping	O	O	O
nurse-led	O	O	B-Entity
research	O	O	I-Entity
activity	O	O	I-Entity
,	O	O	O
thereby	O	O	O
going	O	O	O
some	O	O	O
way	O	O	O
to	O	O	O
inform	O	O	O
and	O	O	O
embed	O	O	O
an	O	O	O
evidence-based	O	O	O
culture	O	O	O
of	O	O	O
inquiry	O	O	B-Entity
.	O	O	O

-DOCSTART- (27705854)

Accurate	O	O	B-Entity
Lungs	O	O	B-Entity
Segmentation	O	O	B-Entity
on	O	O	O
CT	O	O	B-Entity
Chest	O	O	B-Entity
Images	O	O	B-Entity
by	O	O	O
Adaptive	O	O	O
Appearance-Guided	O	O	O
Shape	O	O	O
Modeling	O	O	O

To	O	O	O
accurately	O	O	B-Entity
segment	O	O	B-Entity
pathological	O	O	B-Entity
and	O	O	O
healthy	O	O	B-Entity
lungs	O	O	B-Entity
for	O	O	O
reliable	O	O	B-Entity
computer-aided	O	O	B-Entity
disease	O	O	I-Entity
diagnostics	O	O	I-Entity
,	O	O	O
a	O	O	O
stack	O	O	B-Entity
of	O	O	O
chest	O	O	B-Entity
CT	O	O	B-Entity
scans	O	O	B-Entity
is	O	O	O
modeled	O	O	B-Entity
as	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
a	O	O	O
spatially	O	O	B-Entity
inhomogeneous	O	O	I-Entity
joint	O	O	B-Entity
3D	O	O	I-Entity
Markov-Gibbs	O	O	I-Entity
random	O	O	I-Entity
field	O	O	I-Entity
(	O	O	O
MGRF	O	O	B-Entity
)	O	O	O
of	O	O	O
voxel-wise	O	O	B-Entity
lung	O	O	B-Entity
and	O	O	O
chest	O	O	O
CT	O	O	O
image	O	O	B-Entity
signals	O	O	B-Entity
(	O	O	O
intensities	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
proposed	O	O	B-Entity
learnable	O	O	O
MGRF	O	O	B-Entity
integrates	O	O	B-Entity
two	O	O	O
visual	O	O	B-Entity
appearance	O	O	B-Entity
sub-models	O	O	B-Entity
with	O	O	O
an	O	O	O
adaptive	O	O	O
lung	O	O	B-Entity
shape	O	O	O
submodel	O	O	B-Entity
.	O	O	O

The	O	O	O
first-order	O	O	O
appearance	O	O	B-Entity
submodel	O	O	B-Entity
accounts	O	O	O
for	O	O	O
both	O	O	O
the	O	O	O
original	O	O	B-Entity
CT	O	O	B-Entity
image	O	O	B-Entity
and	O	O	O
its	O	O	O
Gaussian	O	O	B-Entity
scale	O	O	I-Entity
space	O	O	I-Entity
(	O	O	I-Entity
GSS	O	O	I-Entity
)	O	O	I-Entity
filtered	O	O	I-Entity
version	O	O	I-Entity
to	O	O	O
specify	O	O	O
local	O	O	O
and	O	O	O
global	O	O	O
signal	O	O	B-Entity
properties	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Each	O	O	O
empirical	O	O	B-Entity
marginal	O	O	B-Entity
probability	O	O	B-Entity
distribution	O	O	I-Entity
of	O	O	O
signals	O	O	B-Entity
is	O	O	O
closely	O	O	O
approximated	O	O	O
with	O	O	O
a	O	O	O
linear	O	O	B-Entity
combination	O	O	I-Entity
of	O	O	I-Entity
discrete	O	O	I-Entity
Gaussians	O	O	I-Entity
(	O	O	O
LCDG	O	O	B-Entity
)	O	O	O
,	O	O	O
containing	O	O	O
two	O	O	O
positive	O	O	B-Entity
dominant	O	O	I-Entity
and	O	O	I-Entity
multiple	O	O	I-Entity
sign-alternate	O	O	I-Entity
subordinate	O	O	I-Entity
DGs	O	O	I-Entity
.	O	O	O

The	O	O	O
approximation	O	O	O
is	O	O	O
separated	O	O	O
into	O	O	O
two	O	O	O
LCDGs	O	O	B-Entity
to	O	O	O
describe	O	O	O
individually	O	O	O
the	O	O	O
lungs	O	O	B-Entity
and	O	O	O
their	O	O	O
background	O	O	O
,	O	O	O
i.e.	O	O	O
,	O	O	O
all	O	O	O
other	O	O	O
chest	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

The	O	O	O
second-order	O	O	O
appearance	O	O	B-Entity
submodel	O	O	B-Entity
quantifies	O	O	B-Entity
conditional	O	O	B-Entity
pairwise	O	O	B-Entity
intensity	O	O	B-Entity
dependencies	O	O	B-Entity
in	O	O	O
the	O	O	O
nearest	O	O	O
voxel	O	O	O
26-neighborhood	O	O	O
in	O	O	O
both	O	O	O
the	O	O	O
original	O	O	B-Entity
and	O	O	O
GSS-filtered	O	O	B-Entity
images	O	O	B-Entity
.	O	O	O

The	O	O	O
shape	O	O	O
submodel	O	O	B-Entity
is	O	O	O
built	O	O	O
for	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
training	O	O	B-Entity
data	O	O	I-Entity
and	O	O	O
is	O	O	O
adapted	O	O	O
during	O	O	O
segmentation	O	O	B-Entity
using	O	O	O
both	O	O	O
the	O	O	O
lung	O	O	B-Entity
and	O	O	O
chest	O	O	B-Entity
appearances	O	O	B-Entity
.	O	O	O

The	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
the	O	O	O
proposed	O	O	B-Entity
segmentation	O	O	B-Entity
framework	O	O	O
is	O	O	O
quantitatively	O	O	B-Entity
assessed	O	O	B-Entity
using	O	O	O
two	O	O	O
public	O	O	O
databases	O	O	B-Entity
(	O	O	O
ISBI	O	O	B-Entity
VESSEL12	O	O	I-Entity
challenge	O	O	I-Entity
and	O	O	O
MICCAI	O	O	B-Entity
LOLA11	O	O	I-Entity
challenge	O	O	I-Entity
)	O	O	O
and	O	O	O
our	O	O	O
own	O	O	O
database	O	O	B-Entity
with	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
20	O	O	O
,	O	O	O
55	O	O	O
,	O	O	O
and	O	O	O
30	O	O	O
CT	O	O	B-Entity
images	O	O	B-Entity
of	O	O	O
various	O	O	O
lung	O	O	B-Entity
pathologies	O	O	B-Entity
acquired	O	O	O
with	O	O	O
different	O	O	O
scanners	O	O	B-Entity
and	O	O	O
protocols	O	O	B-Entity
.	O	O	O

Quantitative	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
our	O	O	O
framework	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
Dice	O	O	B-Entity
similarity	O	O	I-Entity
coefficients	O	O	I-Entity
,	O	O	O
95-percentile	O	O	B-Entity
bidirectional	O	O	I-Entity
Hausdorff	O	O	I-Entity
distances	O	O	I-Entity
,	O	O	O
and	O	O	O
percentage	O	O	B-Entity
volume	O	O	I-Entity
differences	O	O	I-Entity
confirms	O	O	O
the	O	O	O
high	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
our	O	O	O
model	O	O	B-Entity
on	O	O	O
both	O	O	O
our	O	O	O
database	O	O	B-Entity
(	O	O	O
98.4±1.0	O	O	O
%	O	O	O
,	O	O	O
2.2±1.0	O	O	O
mm	O	O	O
,	O	O	O
0.42±0.10	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
VESSEL12	O	O	B-Entity
database	O	O	I-Entity
(	O	O	O
99.0±0.5	O	O	O
%	O	O	O
,	O	O	O
2.1±1.6	O	O	O
mm	O	O	O
,	O	O	O
0.39±0.20	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Similarly	O	O	O
,	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
our	O	O	O
approach	O	O	B-Entity
is	O	O	O
further	O	O	O
verified	O	O	B-Entity
via	O	O	O
a	O	O	O
blind	O	O	B-Entity
evaluation	O	O	B-Entity
by	O	O	O
the	O	O	O
organizers	O	O	O
of	O	O	O
the	O	O	O
LOLA11	O	O	B-Entity
competition	O	O	B-Entity
,	O	O	O
where	O	O	O
an	O	O	O
average	O	O	B-Entity
overlap	O	O	O
of	O	O	O
98.0	O	O	O
%	O	O	O
with	O	O	O
the	O	O	O
expert	O	O	O
's	O	O	O
segmentation	O	O	B-Entity
is	O	O	O
yielded	O	O	O
on	O	O	O
all	O	O	O
55	O	O	O
subjects	O	O	O
with	O	O	O
our	O	O	O
framework	O	O	O
being	O	O	O
ranked	O	O	O
first	O	O	O
among	O	O	O
all	O	O	O
the	O	O	O
state-of-the-art	O	O	B-Entity
techniques	O	O	B-Entity
compared	O	O	B-Entity
.	O	O	O

-DOCSTART- (27706190)

Influence	O	O	B-Entity
of	O	O	O
Different	O	O	B-Entity
Levels	O	O	B-Entity
of	O	O	O
Lipoic	O	O	B-Entity
Acid	O	O	I-Entity
Synthase	O	O	I-Entity
Gene	O	O	B-Entity
Expression	O	O	I-Entity
on	O	O	O
Diabetic	O	O	O
Nephropathy	O	O	O

Oxidative	O	O	B-Entity
stress	O	O	I-Entity
is	O	O	O
implicated	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
(	O	O	O
DN	O	O	B-Entity
)	O	O	O
but	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
many	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
are	O	O	O
controversial	O	O	O
.	O	O	O

To	O	O	O
define	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
antioxidants	O	O	B-Entity
in	O	O	O
kidney	O	O	B-Entity
protection	O	O	O
during	O	O	B-Entity
the	O	O	O
development	O	O	B-Entity
of	O	O	O
diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
,	O	O	O
we	O	O	O
have	O	O	O
generated	O	O	B-Entity
a	O	O	O
novel	O	O	B-Entity
genetic	O	O	B-Entity
antioxidant	O	O	I-Entity
mouse	O	O	I-Entity
model	O	O	I-Entity
with	O	O	O
over-	O	O	B-Entity
or	O	O	I-Entity
under-expression	O	O	I-Entity
of	O	O	O
lipoic	O	O	B-Entity
acid	O	O	I-Entity
synthase	O	O	I-Entity
gene	O	O	I-Entity
(	O	O	O
Lias	O	O	B-Entity
)	O	O	O
.	O	O	O

These	O	O	O
models	O	O	B-Entity
have	O	O	O
been	O	O	O
mated	O	O	B-Entity
with	O	O	O
Ins2Akita/+	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
a	O	O	O
type	O	O	B-Entity
I	O	O	I-Entity
diabetic	O	O	I-Entity
mouse	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

We	O	O	O
compare	O	O	B-Entity
the	O	O	O
major	O	O	B-Entity
pathologic	O	O	B-Entity
changes	O	O	I-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
status	O	O	B-Entity
in	O	O	O
two	O	O	O
new	O	O	O
strains	O	O	O
of	O	O	O
the	O	O	O
mice	O	O	B-Entity
with	O	O	O
controls	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
show	O	O	O
that	O	O	O
Ins2Akita/+	O	O	B-Entity
mice	O	O	I-Entity
with	O	O	O
under-expressed	O	O	B-Entity
Lias	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
exhibit	O	O	O
higher	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
more	O	O	B-Entity
severe	O	O	B-Entity
DN	O	O	B-Entity
features	O	O	B-Entity
(	O	O	O
albuminuria	O	O	B-Entity
,	O	O	O
glomerular	O	O	B-Entity
basement	O	O	I-Entity
membrane	O	O	I-Entity
thickening	O	O	I-Entity
and	O	O	O
mesangial	O	O	B-Entity
matrix	O	O	I-Entity
expansion	O	O	I-Entity
)	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
Ins2Akita/+	O	O	B-Entity
mice	O	O	I-Entity
with	O	O	O
highly	O	O	B-Entity
-	O	O	O
expressed	O	O	B-Entity
Lias	O	O	B-Entity
gene	O	O	I-Entity
display	O	O	B-Entity
lower	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
less	O	O	B-Entity
DN	O	O	B-Entity
pathologic	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
demonstrates	O	O	B-Entity
that	O	O	O
strengthening	O	O	O
endogenous	O	O	B-Entity
antioxidant	O	O	B-Entity
capacity	O	O	B-Entity
could	O	O	O
be	O	O	O
an	O	O	O
effective	O	O	B-Entity
strategy	O	O	I-Entity
for	O	O	I-Entity
prevention	O	O	I-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
DN	O	O	B-Entity
.	O	O	O

-DOCSTART- (27706588)

Assessment	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
relationship	O	O	B-Entity
among	O	O	O
Rhododendron	O	O	B-Entity
cultivars	O	O	B-Entity
using	O	O	O
amplified	O	O	B-Entity
fragment	O	O	I-Entity
length	O	O	I-Entity
polymorphism	O	O	I-Entity
and	O	O	O
inter-simple	O	O	B-Entity
sequence	O	O	I-Entity
repeat	O	O	I-Entity
markers	O	O	O

Genetic	O	O	B-Entity
relationships	O	O	B-Entity
of	O	O	O
17	O	O	O
Rhododendron	O	O	B-Entity
cultivars	O	O	B-Entity
,	O	O	O
China	O	O	B-Entity
,	O	O	O
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
inter-simple	O	O	B-Entity
sequence	O	O	I-Entity
repeat	O	O	I-Entity
(	O	O	O
ISSR	O	O	B-Entity
)	O	O	O
and	O	O	O
amplified	O	O	B-Entity
fragment	O	O	I-Entity
length	O	O	I-Entity
polymorphism	O	O	I-Entity
(	O	O	O
AFLP	O	O	B-Entity
)	O	O	O
markers	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
133	O	O	O
bands	O	O	O
were	O	O	O
obtained	O	O	O
using	O	O	O
nine	O	O	O
selected	O	O	O
ISSR	O	O	B-Entity
primers	O	O	B-Entity
,	O	O	O
129	O	O	O
(	O	O	O
96.99	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
which	O	O	O
were	O	O	O
polymorphic	O	O	B-Entity
;	O	O	O
267	O	O	O
bands	O	O	O
were	O	O	O
amplified	O	O	O
by	O	O	O
four	O	O	O
AFLP	O	O	B-Entity
primer	O	O	B-Entity
pairs	O	O	I-Entity
,	O	O	O
251	O	O	O
(	O	O	O
94.01	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
which	O	O	O
exhibited	O	O	O
polymorphism	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
these	O	O	O
polymorphic	O	O	B-Entity
products	O	O	B-Entity
,	O	O	O
a	O	O	O
cluster	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
similarities	O	O	B-Entity
between	O	O	O
the	O	O	O
results	O	O	B-Entity
of	O	O	O
the	O	O	O
ISSR	O	O	B-Entity
and	O	O	O
AFLP	O	O	B-Entity
.	O	O	O

All	O	O	O
of	O	O	O
the	O	O	O
cultivars	O	O	B-Entity
were	O	O	O
clustered	O	O	B-Entity
into	O	O	O
two	O	O	O
major	O	O	O
branches	O	O	B-Entity
;	O	O	O
one	O	O	O
branch	O	O	B-Entity
contained	O	O	O
the	O	O	O
same	O	O	O
four	O	O	O
cultivars	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
other	O	O	O
cultivars	O	O	O
were	O	O	O
separated	O	O	O
into	O	O	O
different	O	O	O
groups	O	O	B-Entity
in	O	O	O
the	O	O	O
other	O	O	O
branch	O	O	O
.	O	O	O

The	O	O	O
cluster	O	O	B-Entity
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
genetic	O	O	B-Entity
relationships	O	O	B-Entity
of	O	O	O
the	O	O	O
17	O	O	O
cultivars	O	O	B-Entity
were	O	O	O
partly	O	O	O
related	O	O	B-Entity
to	O	O	O
their	O	O	O
morphological	O	O	B-Entity
characteristics	O	O	B-Entity
,	O	O	O
particularly	O	O	O
the	O	O	O
flowering	O	O	B-Entity
phase	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
results	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
support	O	O	O
the	O	O	O
classification	O	O	B-Entity
of	O	O	O
Rhododendron	O	O	B-Entity
cultivars	O	O	B-Entity
according	O	O	O
to	O	O	O
flowering	O	O	B-Entity
phase	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
cluster	O	O	B-Entity
results	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
select	O	O	B-Entity
suitable	O	O	O
parents	O	O	O
for	O	O	O
breeding	O	O	B-Entity
.	O	O	O

-DOCSTART- (27707812)

Spontaneous	O	O	B-Entity
activity	O	O	I-Entity
is	O	O	O
correlated	O	O	B-Entity
with	O	O	O
coding	O	O	B-Entity
density	O	O	B-Entity
in	O	O	O
primary	O	O	O
auditory	O	O	O
cortex	O	O	O

Sensory	O	O	B-Entity
neurons	O	O	I-Entity
across	O	O	O
sensory	O	O	B-Entity
modalities	O	O	I-Entity
and	O	O	O
specific	O	O	O
processing	O	O	B-Entity
areas	O	O	O
have	O	O	O
diverse	O	O	O
levels	O	O	O
of	O	O	O
spontaneous	O	O	B-Entity
firing	O	O	I-Entity
rates	O	O	I-Entity
(	O	O	O
SFRs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
sensory	O	O	B-Entity
stimuli	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
functional	O	O	B-Entity
significance	O	O	B-Entity
of	O	O	O
this	O	O	O
spontaneous	O	O	B-Entity
activity	O	O	I-Entity
is	O	O	O
not	O	O	O
well-understood	O	O	O
.	O	O	O

Previous	O	O	O
studies	O	O	B-Entity
in	O	O	O
the	O	O	O
auditory	O	O	B-Entity
system	O	O	I-Entity
have	O	O	O
demonstrated	O	O	O
that	O	O	O
different	O	O	O
levels	O	O	O
of	O	O	O
spontaneous	O	O	B-Entity
activity	O	O	I-Entity
are	O	O	O
correlated	O	O	B-Entity
with	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
physiological	O	O	B-Entity
and	O	O	O
anatomic	O	O	B-Entity
properties	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
neurons	O	O	B-Entity
with	O	O	O
differing	O	O	O
SFRs	O	O	B-Entity
make	O	O	O
unique	O	O	O
contributions	O	O	O
to	O	O	O
the	O	O	O
encoding	O	O	B-Entity
of	O	O	O
auditory	O	O	B-Entity
stimuli	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
altered	O	O	O
SFRs	O	O	B-Entity
are	O	O	O
a	O	O	O
correlate	O	O	O
of	O	O	O
tinnitus	O	O	B-Entity
,	O	O	O
arising	O	O	O
in	O	O	O
several	O	O	O
auditory	O	O	B-Entity
areas	O	O	I-Entity
after	O	O	O
exposure	O	O	O
to	O	O	O
ototoxic	O	O	B-Entity
substances	O	O	B-Entity
and	O	O	O
noise	O	O	B-Entity
trauma	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
recorded	O	O	B-Entity
single-unit	O	O	I-Entity
activity	O	O	I-Entity
from	O	O	O
primary	O	O	B-Entity
auditory	O	O	I-Entity
cortex	O	O	I-Entity
of	O	O	O
awake	O	O	O
marmoset	O	O	B-Entity
monkeys	O	O	B-Entity
while	O	O	O
delivering	O	O	O
wide-band	O	O	B-Entity
random-spectrum	O	O	I-Entity
stimuli	O	O	I-Entity
and	O	O	O
white	O	O	B-Entity
Gaussian	O	O	I-Entity
noise	O	O	I-Entity
(	O	O	O
WGN	O	O	B-Entity
)	O	O	O
to	O	O	O
examine	O	O	O
any	O	O	O
divergences	O	O	B-Entity
in	O	O	O
stimulus	O	O	B-Entity
encoding	O	O	B-Entity
properties	O	O	O
across	O	O	O
SFR	O	O	O
classes	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
higher	O	O	O
levels	O	O	O
of	O	O	O
spontaneous	O	O	B-Entity
activity	O	O	I-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
both	O	O	O
higher	O	O	O
levels	O	O	O
of	O	O	O
activation	O	O	B-Entity
relative	O	O	O
to	O	O	O
suppression	O	O	B-Entity
across	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
wide-band	O	O	B-Entity
stimuli	O	O	I-Entity
and	O	O	O
higher	O	O	O
driven	O	O	O
rates	O	O	O
in	O	O	O
response	O	O	B-Entity
to	O	O	O
WGN	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
response	O	O	B-Entity
latencies	O	O	I-Entity
to	O	O	O
WGN	O	O	B-Entity
were	O	O	O
negatively	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
level	O	O	O
of	O	O	O
activation	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
both	O	O	O
stimulus	O	O	B-Entity
types	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
are	O	O	O
consistent	O	O	O
with	O	O	O
a	O	O	O
novel	O	O	O
view	O	O	O
of	O	O	O
the	O	O	O
role	O	O	O
spontaneous	O	O	B-Entity
spiking	O	O	I-Entity
may	O	O	O
play	O	O	O
during	O	O	O
normal	O	O	O
stimulus	O	O	B-Entity
processing	O	O	B-Entity
in	O	O	O
primary	O	O	B-Entity
auditory	O	O	I-Entity
cortex	O	O	I-Entity
and	O	O	O
how	O	O	O
it	O	O	O
may	O	O	O
malfunction	O	O	B-Entity
in	O	O	O
cases	O	O	O
of	O	O	O
tinnitus	O	O	B-Entity
.	O	O	O

-DOCSTART- (27708057)

Systematic	O	O	B-Entity
mapping	O	O	I-Entity
of	O	O	O
functional	O	O	B-Entity
enhancer	O	O	B-Entity
-	O	O	O
promoter	O	O	B-Entity
connections	O	O	B-Entity
with	O	O	O
CRISPR	O	O	B-Entity
interference	O	O	O

Gene	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
mammals	O	O	B-Entity
is	O	O	O
regulated	O	O	B-Entity
by	O	O	O
noncoding	O	O	B-Entity
elements	O	O	I-Entity
that	O	O	O
can	O	O	O
affect	O	O	O
physiology	O	O	B-Entity
and	O	O	O
disease	O	O	B-Entity
,	O	O	O
yet	O	O	O
the	O	O	O
functions	O	O	B-Entity
and	O	O	O
target	O	O	B-Entity
genes	O	O	I-Entity
of	O	O	O
most	O	O	O
noncoding	O	O	O
elements	O	O	O
remain	O	O	O
unknown	O	O	B-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
high-throughput	O	O	B-Entity
approach	O	O	I-Entity
that	O	O	O
uses	O	O	O
clustered	O	O	B-Entity
regularly	O	O	I-Entity
interspaced	O	O	I-Entity
short	O	O	I-Entity
palindromic	O	O	I-Entity
repeats	O	O	I-Entity
(	O	O	I-Entity
CRISPR	O	O	B-Entity
)	O	O	I-Entity
interference	O	O	I-Entity
(	O	O	O
CRISPRi	O	O	B-Entity
)	O	O	O
to	O	O	O
discover	O	O	O
regulatory	O	O	B-Entity
elements	O	O	I-Entity
and	O	O	O
identify	O	O	O
their	O	O	O
target	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

We	O	O	O
assess	O	O	B-Entity
>	O	O	O
1	O	O	O
megabase	O	O	B-Entity
of	O	O	O
sequence	O	O	B-Entity
in	O	O	O
the	O	O	O
vicinity	O	O	O
of	O	O	O
two	O	O	O
essential	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
MYC	O	O	B-Entity
and	O	O	O
GATA1	O	O	B-Entity
,	O	O	O
and	O	O	O
identify	O	O	O
nine	O	O	O
distal	O	O	B-Entity
enhancers	O	O	B-Entity
that	O	O	O
control	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
cellular	O	O	B-Entity
proliferation	O	O	I-Entity
.	O	O	O

Quantitative	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
chromatin	O	O	B-Entity
state	O	O	B-Entity
and	O	O	O
chromosome	O	O	B-Entity
conformation	O	O	B-Entity
distinguish	O	O	O
the	O	O	O
seven	O	O	O
enhancers	O	O	B-Entity
that	O	O	O
regulate	O	O	O
MYC	O	O	B-Entity
from	O	O	O
other	O	O	O
elements	O	O	B-Entity
that	O	O	O
do	O	O	O
not	O	O	O
,	O	O	O
suggesting	O	O	O
a	O	O	O
strategy	O	O	B-Entity
for	O	O	O
predicting	O	O	O
enhancer	O	O	B-Entity
-	O	O	O
promoter	O	O	B-Entity
connectivity	O	O	B-Entity
.	O	O	O

This	O	O	O
CRISPRi	O	O	B-Entity
-based	O	O	O
approach	O	O	B-Entity
can	O	O	O
be	O	O	O
applied	O	O	O
to	O	O	O
dissect	O	O	B-Entity
transcriptional	O	O	B-Entity
networks	O	O	I-Entity
and	O	O	O
interpret	O	O	B-Entity
the	O	O	O
contributions	O	O	B-Entity
of	O	O	O
noncoding	O	O	B-Entity
genetic	O	O	I-Entity
variation	O	O	I-Entity
to	O	O	O
human	O	O	B-Entity
disease	O	O	B-Entity
.	O	O	O

-DOCSTART- (27710899)

Proliferation	O	O	B-Entity
-enhancing	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
gastrodin	O	O	B-Entity
on	O	O	O
RSC96	O	O	B-Entity
Schwann	O	O	I-Entity
cells	O	O	I-Entity
by	O	O	O
regulating	O	O	B-Entity
ERK1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
and	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
signaling	O	O	O
pathways	O	O	O

The	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
migration	O	O	B-Entity
of	O	O	O
Schwann	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
SCs	O	O	B-Entity
)	O	O	O
are	O	O	O
essential	O	O	O
in	O	O	O
the	O	O	O
process	O	O	B-Entity
of	O	O	O
peripheral	O	O	B-Entity
nerve	O	O	I-Entity
repair	O	O	I-Entity
.	O	O	O

A	O	O	O
large	O	O	O
amount	O	O	O
of	O	O	O
studies	O	O	O
focused	O	O	O
on	O	O	O
the	O	O	O
promotion	O	O	B-Entity
of	O	O	O
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
SCs	O	O	B-Entity
for	O	O	O
cell	O	O	B-Entity
based	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

Gastrodin	O	O	B-Entity
(	O	O	O
GAS	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
main	O	O	O
constituent	O	O	O
of	O	O	O
a	O	O	O
Chinese	O	O	B-Entity
traditional	O	O	I-Entity
herbal	O	O	B-Entity
medicine	O	O	I-Entity
named	O	O	O
Gastrodia	O	O	B-Entity
elata	O	O	I-Entity
Blume	O	O	I-Entity
,	O	O	O
has	O	O	O
been	O	O	O
reported	O	O	B-Entity
to	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
neuroprotective	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
GAS	O	O	B-Entity
activated	O	O	B-Entity
MAPK	O	O	B-Entity
and	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
signaling	O	O	B-Entity
pathways	O	O	I-Entity
which	O	O	O
are	O	O	O
often	O	O	O
involved	O	O	O
in	O	O	O
growth	O	O	B-Entity
of	O	O	O
nerve	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
also	O	O	O
reported	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
GAS	O	O	B-Entity
may	O	O	O
have	O	O	O
an	O	O	O
effect	O	O	O
on	O	O	O
SCs	O	O	B-Entity
growth	O	O	B-Entity
,	O	O	O
we	O	O	O
studied	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
GAS	O	O	O
on	O	O	O
rat	O	O	B-Entity
RSC96	O	O	B-Entity
Schwann	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
SCs	O	O	O
)	O	O	O
and	O	O	O
further	O	O	O
explored	O	O	O
the	O	O	O
underlying	O	O	O
mechanism	O	O	B-Entity
.	O	O	O

Various	O	O	O
concentration	O	O	B-Entity
of	O	O	O
GAS	O	O	B-Entity
(	O	O	O
0μM	O	O	O
,	O	O	O
50μM	O	O	O
,	O	O	O
100μM	O	O	O
,	O	O	O
and	O	O	O
200μM	O	O	O
)	O	O	O
was	O	O	O
used	O	O	O
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
RSC96	O	O	B-Entity
SCs	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
cell	O	O	B-Entity
proliferation	O	O	I-Entity
and	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
several	O	O	O
neurotrophic	O	O	B-Entity
factors	O	O	I-Entity
to	O	O	O
be	O	O	O
detected	O	O	O
.	O	O	O

Regulation	O	O	B-Entity
of	O	O	I-Entity
MAPK	O	O	B-Entity
and	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
signaling	O	O	B-Entity
pathways	O	O	I-Entity
were	O	O	O
assayed	O	O	O
by	O	O	O
detecting	O	O	O
phosphorylation	O	O	B-Entity
of	O	O	O
ERK1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
and	O	O	O
Akt	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
showed	O	O	O
that	O	O	O
GAS	O	O	B-Entity
could	O	O	O
effectively	O	O	O
promote	O	O	B-Entity
proliferation	O	O	B-Entity
of	O	O	O
RSC96	O	O	B-Entity
SCs	O	O	I-Entity
in	O	O	O
a	O	O	O
dose	O	O	B-Entity
-	O	O	O
and	O	O	O
time	O	O	B-Entity
-dependent	O	O	O
manner	O	O	O
.	O	O	O

The	O	O	O
best	O	O	O
performance	O	O	O
was	O	O	O
obtained	O	O	O
at	O	O	O
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
200μM.	O	O	O
Exploration	O	O	B-Entity
of	O	O	O
the	O	O	O
underlying	O	O	O
mechanism	O	O	B-Entity
showed	O	O	O
that	O	O	O
GAS	O	O	B-Entity
probably	O	O	O
affects	O	O	O
SCs	O	O	B-Entity
metabolism	O	O	B-Entity
through	O	O	O
inhibiting	O	O	B-Entity
ERK1	O	O	B-Entity
/	O	O	O
2	O	O	B-Entity
phosphorylation	O	O	B-Entity
and	O	O	O
activating	O	O	B-Entity
Akt	O	O	B-Entity
phosphorylation	O	O	O
in	O	O	O
RSC96	O	O	B-Entity
SCs	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
may	O	O	O
provide	O	O	O
reference	O	O	O
for	O	O	O
its	O	O	O
application	O	O	O
in	O	O	O
treatment	O	O	B-Entity
of	O	O	O
peripheral	O	O	B-Entity
nerve	O	O	I-Entity
injuries	O	O	I-Entity
.	O	O	O

-DOCSTART- (27713074)

An	O	O	O
influenza	O	O	B-Entity
A	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	I-Entity
H7N9	O	O	I-Entity
)	O	O	I-Entity
anti-neuraminidase	O	O	B-Entity
monoclonal	O	O	B-Entity
antibody	O	O	I-Entity
with	O	O	O
prophylactic	O	O	B-Entity
and	O	O	I-Entity
therapeutic	O	O	I-Entity
activity	O	O	I-Entity
in	O	O	O
vivo	O	O	O

Zoonotic	O	O	B-Entity
A(H7N9	O	O	B-Entity
)	O	O	I-Entity
avian	O	O	I-Entity
influenza	O	O	I-Entity
viruses	O	O	I-Entity
emerged	O	O	O
in	O	O	O
China	O	O	B-Entity
in	O	O	O
2013	O	O	O
and	O	O	O
continue	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
threat	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
public	O	O	B-Entity
health	O	O	I-Entity
,	O	O	O
having	O	O	O
infected	O	O	B-Entity
over	O	O	O
800	O	O	O
individuals	O	O	B-Entity
with	O	O	O
a	O	O	O
mortality	O	O	B-Entity
rate	O	O	I-Entity
approaching	O	O	O
40	O	O	O
%	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
options	O	O	I-Entity
for	O	O	O
people	O	O	O
infected	O	O	B-Entity
with	O	O	O
A(H7N9	O	O	B-Entity
)	O	O	I-Entity
include	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
neuraminidase	O	O	B-Entity
(	O	O	I-Entity
NA	O	O	I-Entity
)	O	O	I-Entity
inhibitors	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
like	O	O	O
other	O	O	O
influenza	O	O	B-Entity
viruses	O	O	I-Entity
,	O	O	O
A(H7N9	O	O	B-Entity
)	O	O	I-Entity
can	O	O	O
become	O	O	O
resistant	O	O	B-Entity
to	O	O	O
these	O	O	O
drugs	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
monoclonal	O	O	B-Entity
antibodies	O	O	I-Entity
is	O	O	O
a	O	O	O
rapidly	O	O	O
developing	O	O	O
strategy	O	O	B-Entity
for	O	O	O
controlling	O	O	O
influenza	O	O	B-Entity
virus	O	O	I-Entity
infection	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
generated	O	O	O
a	O	O	O
murine	O	O	B-Entity
monoclonal	O	O	B-Entity
antibody	O	O	I-Entity
(	O	O	O
3c10	O	O	B-Entity
-	O	O	I-Entity
3	O	O	I-Entity
)	O	O	O
directed	O	O	O
against	O	O	O
the	O	O	O
NA	O	O	B-Entity
of	O	O	O
A(H7N9	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
show	O	O	O
that	O	O	O
prophylactic	O	O	B-Entity
systemic	O	O	B-Entity
administration	O	O	I-Entity
of	O	O	O
3c10	O	O	O
-	O	O	O
3	O	O	O
fully	O	O	O
protected	O	O	O
mice	O	O	O
from	O	O	O
lethal	O	O	O
challenge	O	O	O
with	O	O	O
wild-type	O	O	B-Entity
A/Anhui/1/2013	O	O	B-Entity
(	O	O	O
H7N9	O	O	B-Entity
)	O	O	O
.	O	O	O

Further	O	O	O
,	O	O	O
post-	O	O	O
infection	O	O	B-Entity
treatment	O	O	B-Entity
with	O	O	O
a	O	O	O
single	O	O	O
systemic	O	O	B-Entity
dose	O	O	B-Entity
of	O	O	O
3c10	O	O	B-Entity
-	O	O	I-Entity
3	O	O	I-Entity
at	O	O	O
either	O	O	O
24	O	O	O
,	O	O	O
48	O	O	O
or	O	O	O
72	O	O	O
h	O	O	O
post	O	O	O
A(H7N9	O	O	B-Entity
)	O	O	I-Entity
challenge	O	O	O
resulted	O	O	O
in	O	O	O
both	O	O	O
dose	O	O	O
-	O	O	O
and	O	O	O
time	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
protection	O	O	B-Entity
of	O	O	O
up	O	O	O
to	O	O	O
100	O	O	O
%	O	O	O
of	O	O	O
mice	O	O	B-Entity
,	O	O	O
demonstrating	O	O	O
therapeutic	O	O	B-Entity
potential	O	O	B-Entity
for	O	O	O
3c10	O	O	O
-	O	O	O
3	O	O	O
.	O	O	O

Epitope	O	O	B-Entity
mapping	O	O	I-Entity
revealed	O	O	O
that	O	O	O
3c10	O	O	B-Entity
-	O	O	I-Entity
3	O	O	I-Entity
binds	O	O	B-Entity
near	O	O	O
the	O	O	O
enzyme	O	O	B-Entity
active	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
NA	O	O	B-Entity
,	O	O	O
and	O	O	O
functional	O	O	B-Entity
characterization	O	O	O
showed	O	O	O
that	O	O	O
3c10	O	O	O
-	O	O	O
3	O	O	O
inhibits	O	O	O
the	O	O	O
enzyme	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
NA	O	O	O
and	O	O	O
restricts	O	O	O
the	O	O	O
cell	O	O	O
-to-	O	O	O
cell	O	O	O
spread	O	O	B-Entity
of	O	O	O
the	O	O	O
virus	O	O	B-Entity
in	O	O	O
cultured	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Affinity	O	O	B-Entity
analysis	O	O	B-Entity
also	O	O	O
revealed	O	O	O
that	O	O	O
3c10	O	O	B-Entity
-	O	O	I-Entity
3	O	O	I-Entity
binds	O	O	B-Entity
equally	O	O	O
well	O	O	O
to	O	O	O
recombinant	O	O	B-Entity
NA	O	O	B-Entity
of	O	O	O
wild-type	O	O	B-Entity
A/Anhui/1/2013	O	O	B-Entity
and	O	O	O
to	O	O	O
a	O	O	O
variant	O	O	B-Entity
NA	O	O	O
carrying	O	O	O
a	O	O	O
R289	O	O	O
K	O	O	O
mutation	O	O	B-Entity
known	O	O	O
to	O	O	O
infer	O	O	O
NAI	O	O	B-Entity
resistance	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
3c10	O	O	B-Entity
-	O	O	I-Entity
3	O	O	I-Entity
has	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
to	O	O	O
treat	O	O	O
A(H7N9	O	O	B-Entity
)	O	O	I-Entity
infections	O	O	B-Entity
either	O	O	O
as	O	O	O
an	O	O	O
alternative	O	O	B-Entity
to	O	O	O
,	O	O	O
or	O	O	O
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
,	O	O	O
current	O	O	O
NA	O	O	B-Entity
antiviral	O	O	B-Entity
inhibitors	O	O	I-Entity
.	O	O	O

-DOCSTART- (27714497)

Mechanisms	O	O	B-Entity
of	O	O	O
ear	O	O	B-Entity
trauma	O	O	B-Entity
and	O	O	O
reconstructive	O	O	B-Entity
techniques	O	O	B-Entity
in	O	O	O
105	O	O	O
consecutive	O	O	B-Entity
patients	O	O	O

Acquired	O	O	B-Entity
auricular	O	O	B-Entity
deformities	O	O	B-Entity
may	O	O	O
diminish	O	O	B-Entity
facial	O	O	B-Entity
esthetics	O	O	I-Entity
and	O	O	O
cause	O	O	O
psychological	O	O	B-Entity
distress	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
article	O	O	O
is	O	O	O
to	O	O	O
provide	O	O	O
an	O	O	O
overview	O	O	O
of	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
injuries	O	O	B-Entity
and	O	O	O
applied	O	O	B-Entity
reconstructive	O	O	I-Entity
techniques	O	O	B-Entity
in	O	O	O
a	O	O	O
large	O	O	O
academic	O	O	B-Entity
hospital	O	O	I-Entity
in	O	O	O
The	O	O	O
Netherlands	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
chart	O	O	B-Entity
review	O	O	I-Entity
was	O	O	O
conducted	O	O	O
for	O	O	O
the	O	O	O
last	O	O	O
105	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
auricular	O	O	B-Entity
reconstruction	O	O	B-Entity
for	O	O	O
an	O	O	O
acquired	O	O	B-Entity
deformity	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
concerning	O	O	O
gender	O	O	B-Entity
,	O	O	O
affected	O	O	B-Entity
side	O	O	I-Entity
,	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
anatomical	O	O	B-Entity
region	O	O	I-Entity
,	O	O	O
the	O	O	O
previous	O	O	O
and	O	O	O
further	O	O	O
surgeries	O	O	B-Entity
,	O	O	O
type	O	O	O
of	O	O	O
cartilage	O	O	B-Entity
,	O	O	O
and	O	O	O
skin	O	O	B-Entity
cover	O	O	I-Entity
used	O	O	I-Entity
were	O	O	O
collected	O	O	O
and	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

105	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Acquired	O	O	B-Entity
auricular	O	O	B-Entity
deformities	O	O	B-Entity
were	O	O	O
mainly	O	O	O
caused	O	O	O
by	O	O	O
bite	O	O	B-Entity
injuries	O	O	I-Entity
(	O	O	O
22	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
traffic	O	O	B-Entity
accidents	O	O	I-Entity
(	O	O	O
17	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
burns	O	O	B-Entity
(	O	O	O
9.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
post-otoplasty	O	O	B-Entity
complications	O	O	B-Entity
(	O	O	O
9.5	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
upper	O	O	B-Entity
third	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
auricle	O	O	I-Entity
was	O	O	O
most	O	O	O
often	O	O	O
injured	O	O	B-Entity
(	O	O	O
41	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
entire	O	O	B-Entity
auricle	O	O	I-Entity
(	O	O	O
19	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

70	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	B-Entity
required	O	O	O
reconstruction	O	O	B-Entity
with	O	O	O
costal	O	O	B-Entity
cartilage	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
form	O	O	O
of	O	O	O
cutaneous	O	O	B-Entity
cover	O	O	I-Entity
was	O	O	O
a	O	O	O
postauricular	O	O	B-Entity
skin	O	O	I-Entity
flap	O	O	I-Entity
(	O	O	O
40	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
gives	O	O	O
a	O	O	O
complete	O	O	O
overview	O	O	O
of	O	O	O
causes	O	O	O
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
acquired	O	O	B-Entity
auricular	O	O	B-Entity
deformities	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
are	O	O	O
comparable	O	O	O
with	O	O	O
the	O	O	O
results	O	O	O
of	O	O	O
similar	O	O	O
studies	O	O	B-Entity
found	O	O	O
in	O	O	O
literature	O	O	B-Entity
.	O	O	O

Bite	O	O	B-Entity
wounds	O	O	I-Entity
are	O	O	O
the	O	O	O
leading	O	O	O
cause	O	O	O
of	O	O	O
acquired	O	O	B-Entity
auricular	O	O	B-Entity
injuries	O	O	B-Entity
.	O	O	O

The	O	O	O
upper	O	O	B-Entity
third	O	O	I-Entity
is	O	O	O
most	O	O	O
commonly	O	O	O
affected	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
largest	O	O	O
percentage	O	O	O
of	O	O	O
reconstructions	O	O	B-Entity
,	O	O	O
costal	O	O	B-Entity
cartilage	O	O	I-Entity
and	O	O	O
a	O	O	O
postauricular	O	O	B-Entity
flap	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
correct	O	O	O
the	O	O	O
deformity	O	O	B-Entity
.	O	O	O

-DOCSTART- (27714730)

Anatomic	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
left	O	O	B-Entity
main	O	O	I-Entity
bifurcation	O	O	I-Entity
and	O	O	O
dynamic	O	O	B-Entity
bifurcation	O	O	I-Entity
angles	O	O	I-Entity
using	O	O	O
computed	O	O	O
tomography	O	O	O
angiography	O	O	O

An	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
left	O	O	B-Entity
main	O	O	I-Entity
coronary	O	O	I-Entity
artery	O	O	I-Entity
(	O	O	O
LMCA	O	O	B-Entity
)	O	O	O
anatomy	O	O	B-Entity
is	O	O	O
important	O	O	O
for	O	O	O
accurate	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
therapeutic	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
LMCA	O	O	B-Entity
anatomy	O	O	B-Entity
via	O	O	O
128-multisliced	O	O	B-Entity
coronary	O	O	I-Entity
computed-tomography-angiography	O	O	I-Entity
(	O	O	O
CCTA	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
normal	O	O	O
LMCA	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
201	O	O	O
CCTA	O	O	B-Entity
studies	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Anatomical	O	O	B-Entity
features	O	O	I-Entity
of	O	O	O
LMCA	O	O	B-Entity
including	O	O	O
cross-sectional	O	O	B-Entity
areas	O	O	I-Entity
of	O	O	O
the	O	O	O
LMCA	O	O	O
ostial	O	O	B-Entity
,	O	O	O
LMCA	O	O	O
distal	O	O	B-Entity
,	O	O	O
LAD	O	O	B-Entity
ostial	O	O	I-Entity
and	O	O	O
LCX	O	O	B-Entity
ostial	O	O	O
,	O	O	O
and	O	O	O
degree	O	O	O
of	O	O	O
tapering	O	O	O
and	O	O	O
LMCA	O	O	O
bifurcation	O	O	B-Entity
angles	O	O	I-Entity
(	O	O	O
BA	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
LMCA	O	O	O
-	O	O	O
LCX	O	O	O
BA	O	O	O
,	O	O	O
LMCA	O	O	O
-	O	O	O
LAD	O	O	O
BA	O	O	O
,	O	O	O
LAD	O	O	O
-	O	O	O
LCX	O	O	O
BA	O	O	O
at	O	O	O
end-diastole	O	O	B-Entity
and	O	O	O
end-systole	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
age	O	O	B-Entity
was	O	O	O
55	O	O	O
±	O	O	O
11	O	O	O
with	O	O	O
55.7	O	O	O
%	O	O	O
males	O	O	B-Entity
.	O	O	O

RCA	O	O	B-Entity
was	O	O	O
dominant	O	O	B-Entity
in	O	O	O
173	O	O	O
(	O	O	O
86.1	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
.	O	O	O

Mean	O	O	O
LMCA	O	O	B-Entity
length	O	O	B-Entity
was	O	O	O
10.0±4.5	O	O	O
mm	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
values	O	O	O
of	O	O	O
LMCA	O	O	B-Entity
ostial	O	O	B-Entity
,	O	O	O
LMCA	O	O	O
distal	O	O	B-Entity
,	O	O	O
LAD	O	O	B-Entity
ostial	O	O	I-Entity
and	O	O	O
LCX	O	O	B-Entity
ostial	O	O	O
areas	O	O	B-Entity
were	O	O	O
18.2±5.1	O	O	O
mm²	O	O	O
,	O	O	O
13.2±4.0	O	O	O
,	O	O	O
9.0±3.2	O	O	O
mm²	O	O	O
and	O	O	O
7.6±2.8	O	O	O
mm²	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

LMCA	O	O	B-Entity
ostial	O	O	B-Entity
-	O	O	O
distal	O	O	B-Entity
area	O	O	B-Entity
,	O	O	O
LMCA	O	O	O
distal	O	O	O
-	O	O	O
LAD	O	O	B-Entity
ostial	O	O	I-Entity
area	O	O	O
and	O	O	O
LMCA	O	O	O
distal	O	O	O
-	O	O	O
LCX	O	O	B-Entity
ostial	O	O	O
area	O	O	B-Entity
ratios	O	O	I-Entity
were	O	O	O
≥1.44	O	O	O
-	O	O	O
<	O	O	O
1.69	O	O	O
in	O	O	O
47	O	O	O
(	O	O	O
23.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
53	O	O	O
(	O	O	O
26.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
47	O	O	O
(	O	O	O
23.4	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
and	O	O	O
were	O	O	O
≥1.69-<1.96	O	O	O
in	O	O	O
19	O	O	O
(	O	O	O
9.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
24(11.9	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
40(19.9	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	O
respectively	O	O	O
.	O	O	O

Systolic	O	O	B-Entity
motion	O	O	I-Entity
modifies	O	O	O
LMCA	O	O	B-Entity
BAs	O	O	B-Entity
;	O	O	O
systolic	O	O	B-Entity
motion	O	O	I-Entity
begets	O	O	O
an	O	O	O
increment	O	O	O
of	O	O	O
LMCA	O	O	O
-	O	O	O
LAD	O	O	B-Entity
angle	O	O	O
in	O	O	O
72.6	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
and	O	O	O
decrement	O	O	O
of	O	O	O
LAD	O	O	O
-	O	O	O
LCX	O	O	B-Entity
angle	O	O	O
in	O	O	O
75.6	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
T-shaped	O	O	O
LAD	O	O	B-Entity
-	O	O	O
LCX	O	O	B-Entity
BA	O	O	B-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
have	O	O	O
significantly	O	O	O
longer	O	O	O
LMCA	O	O	B-Entity
,	O	O	O
larger	O	O	O
LAD	O	O	B-Entity
ostial	O	O	B-Entity
area	O	O	B-Entity
,	O	O	O
larger	O	O	O
LCX	O	O	O
ostial	O	O	O
area	O	O	O
and	O	O	O
higher	O	O	O
diastolic-to-systolic	O	O	B-Entity
range	O	O	I-Entity
(	O	O	O
DSR	O	O	B-Entity
)	O	O	O
of	O	O	O
LAD	O	O	O
-	O	O	O
LCX	O	O	O
BA	O	O	O
compared	O	O	O
to	O	O	O
patients	O	O	B-Entity
with	O	O	O
Y-shaped	O	O	O
LAD	O	O	O
-	O	O	O
LCX	O	O	O
BA	O	O	O
.	O	O	O

LMCA	O	O	B-Entity
with	O	O	O
T-shaped	O	O	B-Entity
distal	O	O	B-Entity
BA	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
significantly	O	O	O
longer	O	O	O
LMCA	O	O	O
,	O	O	O
larger	O	O	O
LAD	O	O	B-Entity
ostial	O	O	B-Entity
area	O	O	B-Entity
,	O	O	O
larger	O	O	O
LCX	O	O	B-Entity
ostial	O	O	O
area	O	O	O
and	O	O	O
higher	O	O	O
DSR	O	O	B-Entity
of	O	O	O
distal	O	O	O
BA	O	O	O
compared	O	O	O
to	O	O	O
patients	O	O	B-Entity
with	O	O	O
Y-shaped	O	O	B-Entity
distal	O	O	I-Entity
BA	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
may	O	O	O
provide	O	O	O
useful	O	O	O
information	O	O	O
for	O	O	O
LMCA	O	O	B-Entity
bifurcation	O	O	B-Entity
stenting	O	O	I-Entity
or	O	O	O
designing	O	O	O
dedicated	O	O	O
stents	O	O	B-Entity
for	O	O	O
LMCA	O	O	O
.	O	O	O

-DOCSTART- (27716187)

A	O	O	O
three	O	O	B-Entity
perspective	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
the	O	O	O
sense	O	O	O
of	O	O	O
home	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
home	O	O	I-Entity
residents	O	O	B-Entity
:	O	O	O
the	O	O	O
views	O	O	O
of	O	O	O
residents	O	O	O
,	O	O	O
care	O	O	B-Entity
professionals	O	O	I-Entity
and	O	O	O
relatives	O	O	O

The	O	O	O
sense	O	O	O
of	O	O	O
home	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
home	O	O	I-Entity
residents	O	O	I-Entity
is	O	O	O
a	O	O	O
multifactorial	O	O	B-Entity
phenomenon	O	O	B-Entity
which	O	O	O
is	O	O	O
important	O	O	B-Entity
for	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
living	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
factors	O	O	B-Entity
influencing	O	O	B-Entity
the	O	O	O
sense	O	O	O
of	O	O	O
home	O	O	B-Entity
of	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
residing	O	O	B-Entity
in	O	O	O
the	O	O	O
nursing	O	O	B-Entity
home	O	O	I-Entity
from	O	O	O
the	O	O	O
perspective	O	O	O
of	O	O	O
residents	O	O	B-Entity
,	O	O	O
relatives	O	O	B-Entity
and	O	O	O
care	O	O	B-Entity
professionals	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
78	O	O	O
participants	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
24	O	O	O
residents	O	O	B-Entity
,	O	O	O
n	O	O	O
=	O	O	O
18	O	O	O
relatives	O	O	B-Entity
and	O	O	O
n	O	O	O
=	O	O	O
26	O	O	O
care	O	O	B-Entity
professionals	O	O	I-Entity
)	O	O	O
from	O	O	O
4	O	O	O
nursing	O	O	B-Entity
homes	O	O	I-Entity
in	O	O	O
the	O	O	O
Netherlands	O	O	B-Entity
engaged	O	O	O
in	O	O	O
a	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
photography	O	O	O
was	O	O	O
as	O	O	O
a	O	O	O
supportive	O	O	O
tool	O	O	O
for	O	O	O
subsequent	O	O	B-Entity
interviews	O	O	B-Entity
and	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
based	O	O	O
on	O	O	O
open	O	O	B-Entity
ended	O	O	I-Entity
coding	O	O	I-Entity
,	O	O	O
axial	O	O	B-Entity
coding	O	O	I-Entity
and	O	O	O
selective	O	O	B-Entity
coding	O	O	I-Entity
.	O	O	O

The	O	O	O
sense	O	O	O
of	O	O	O
home	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
home	O	O	I-Entity
residents	O	O	I-Entity
is	O	O	O
influenced	O	O	B-Entity
by	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
jointly	O	O	O
identified	O	O	O
factors	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
building	O	O	B-Entity
and	O	O	O
interior	O	O	B-Entity
design	O	O	I-Entity
;	O	O	O
eating	O	O	B-Entity
and	O	O	O
drinking	O	O	B-Entity
;	O	O	O
autonomy	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
;	O	O	O
involvement	O	O	B-Entity
of	O	O	O
relatives	O	O	B-Entity
;	O	O	O
engagement	O	O	O
with	O	O	O
others	O	O	O
and	O	O	O
activities	O	O	B-Entity
;	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
care	O	O	I-Entity
are	O	O	O
shared	O	O	O
themes	O	O	O
.	O	O	O

Residents	O	O	B-Entity
and	O	O	O
relatives	O	O	B-Entity
stressed	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
having	O	O	O
a	O	O	O
connection	O	O	O
with	O	O	O
nature	O	O	B-Entity
and	O	O	O
the	O	O	O
outdoors	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
coping	O	O	B-Entity
strategies	O	O	I-Entity
.	O	O	O

Relatives	O	O	B-Entity
and	O	O	O
care	O	O	B-Entity
professionals	O	O	I-Entity
emphasized	O	O	O
the	O	O	O
role	O	O	O
the	O	O	O
organization	O	O	B-Entity
of	O	O	O
facilitation	O	O	B-Entity
of	O	O	O
care	O	O	O
played	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
making	O	O	O
residents	O	O	B-Entity
feel	O	O	O
like	O	O	O
they	O	O	O
still	O	O	O
matter	O	O	O
.	O	O	O

The	O	O	O
sense	O	O	O
of	O	O	O
home	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
home	O	O	I-Entity
residents	O	O	B-Entity
is	O	O	O
influenced	O	O	B-Entity
by	O	O	O
a	O	O	O
multitude	O	O	B-Entity
of	O	O	O
factors	O	O	B-Entity
related	O	O	O
to	O	O	O
the	O	O	O
psychology	O	O	B-Entity
of	O	O	O
the	O	O	O
residents	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
social	O	O	B-Entity
and	O	O	I-Entity
built	O	O	I-Entity
environmental	O	O	I-Entity
contexts	O	O	I-Entity
.	O	O	O

A	O	O	O
holistic	O	O	B-Entity
understanding	O	O	O
of	O	O	O
which	O	O	O
factors	O	O	B-Entity
influence	O	O	B-Entity
the	O	O	O
sense	O	O	O
of	O	O	O
home	O	O	B-Entity
of	O	O	O
residents	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
strategies	O	O	O
to	O	O	O
optimize	O	O	B-Entity
this	O	O	O
sense	O	O	O
of	O	O	O
home	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
also	O	O	O
indicated	O	O	O
that	O	O	O
the	O	O	O
nursing	O	O	B-Entity
home	O	O	I-Entity
has	O	O	O
a	O	O	O
dual	O	O	O
nature	O	O	B-Entity
as	O	O	O
a	O	O	O
place	O	O	B-Entity
of	O	O	O
residence	O	O	B-Entity
and	O	O	O
a	O	O	O
place	O	O	O
where	O	O	O
people	O	O	B-Entity
are	O	O	O
supported	O	O	O
through	O	O	O
numerous	O	O	B-Entity
care	O	O	O
strategies	O	O	O
.	O	O	O

-DOCSTART- (27716352)

Integrating	O	O	O
one	O	O	B-Entity
health	O	O	I-Entity
in	O	O	O
national	O	O	B-Entity
health	O	O	I-Entity
policies	O	O	I-Entity
of	O	O	O
developing	O	O	B-Entity
countries	O	O	I-Entity
:	O	O	O
India	O	O	B-Entity
's	O	O	I-Entity
lost	O	O	O
opportunities	O	O	O

Globally	O	O	B-Entity
,	O	O	O
the	O	O	O
threat	O	O	B-Entity
of	O	O	O
infectious	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
particularly	O	O	O
emerging	O	O	B-Entity
infectious	O	O	I-Entity
diseases	O	O	I-Entity
,	O	O	O
originating	O	O	B-Entity
at	O	O	O
the	O	O	O
human	O	O	B-Entity
-	O	O	O
animal	O	O	B-Entity
-	O	O	O
environment	O	O	B-Entity
interface	O	O	B-Entity
,	O	O	O
has	O	O	O
caught	O	O	O
health	O	O	B-Entity
systems	O	O	I-Entity
off	O	O	O
guard	O	O	O
.	O	O	O

With	O	O	O
forecasts	O	O	O
that	O	O	O
future	O	O	O
pathogen	O	O	B-Entity
emergence	O	O	B-Entity
will	O	O	O
be	O	O	O
centred	O	O	O
in	O	O	O
hotspots	O	O	O
in	O	O	O
Asia	O	O	B-Entity
,	O	O	O
Africa	O	O	B-Entity
,	O	O	O
and	O	O	O
Latin	O	O	B-Entity
America	O	O	I-Entity
,	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
prepare	O	O	O
policy	O	O	B-Entity
frameworks	O	O	I-Entity
that	O	O	O
can	O	O	O
combat	O	O	O
this	O	O	O
threat	O	O	B-Entity
is	O	O	O
urgent	O	O	B-Entity
.	O	O	O

Emergence	O	O	B-Entity
of	O	O	I-Entity
diseases	O	O	I-Entity
such	O	O	O
as	O	O	O
avian	O	O	B-Entity
influenza	O	O	I-Entity
and	O	O	O
Ebola	O	O	B-Entity
virus	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
which	O	O	O
threatened	O	O	B-Entity
social	O	O	B-Entity
disruption	O	O	B-Entity
,	O	O	O
have	O	O	O
established	O	O	B-Entity
the	O	O	O
need	O	O	O
for	O	O	O
intersectoral	O	O	B-Entity
coordination/collaboration	O	O	I-Entity
.	O	O	O

These	O	O	O
events	O	O	B-Entity
led	O	O	O
to	O	O	O
the	O	O	O
initiation	O	O	B-Entity
of	O	O	O
establishing	O	O	B-Entity
institutionalised	O	O	B-Entity
collaborative	O	O	B-Entity
frameworks	O	O	I-Entity
in	O	O	O
India	O	O	B-Entity
to	O	O	O
adopt	O	O	O
a	O	O	O
One	O	O	B-Entity
Health	O	O	I-Entity
approach	O	O	I-Entity
to	O	O	O
disease	O	O	B-Entity
prevention	O	O	I-Entity
and	O	O	I-Entity
control	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
gains	O	O	B-Entity
made	O	O	O
in	O	O	O
influenza	O	O	B-Entity
control	O	O	B-Entity
could	O	O	O
not	O	O	O
be	O	O	O
adapted	O	O	O
to	O	O	O
other	O	O	O
infectious	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Intersectoral	O	O	B-Entity
coordination	O	O	I-Entity
was	O	O	O
briefly	O	O	O
carried	O	O	O
out	O	O	O
,	O	O	O
more	O	O	O
as	O	O	O
a	O	O	O
reactive	O	O	B-Entity
response	O	O	O
to	O	O	O
threats	O	O	B-Entity
.	O	O	O

The	O	O	O
systemic	O	O	B-Entity
failure	O	O	B-Entity
to	O	O	O
sustain	O	O	B-Entity
such	O	O	O
efforts	O	O	O
have	O	O	O
therefore	O	O	O
,	O	O	O
only	O	O	O
undermined	O	O	O
a	O	O	O
coordinated	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

The	O	O	O
recent	O	O	O
draft	O	O	B-Entity
National	O	O	B-Entity
Health	O	O	I-Entity
Policy	O	O	I-Entity
,	O	O	O
2015	O	O	O
,	O	O	O
has	O	O	O
also	O	O	O
failed	O	O	B-Entity
to	O	O	O
establish	O	O	B-Entity
the	O	O	O
need	O	O	O
for	O	O	O
intersectoral	O	O	B-Entity
coordination	O	O	I-Entity
in	O	O	O
disease	O	O	B-Entity
control	O	O	I-Entity
approaches	O	O	I-Entity
.	O	O	O

Neglecting	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
endorse	O	O	O
linkages	O	O	B-Entity
between	O	O	O
human	O	O	B-Entity
health	O	O	B-Entity
,	O	O	O
animal	O	O	B-Entity
health	O	O	O
and	O	O	O
husbandry	O	O	B-Entity
,	O	O	O
agriculture	O	O	B-Entity
,	O	O	O
and	O	O	O
environmental	O	O	B-Entity
sectors	O	O	B-Entity
,	O	O	O
has	O	O	O
led	O	O	O
to	O	O	O
duplicative	O	O	B-Entity
and	O	O	O
weak	O	O	B-Entity
response	O	O	I-Entity
systems	O	O	I-Entity
.	O	O	O

The	O	O	O
absence	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
impact	O	O	I-Entity
assessment	O	O	I-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
the	O	O	O
development	O	O	B-Entity
agenda	O	O	B-Entity
in	O	O	O
policies	O	O	B-Entity
,	O	O	O
has	O	O	O
cast	O	O	O
negative	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
the	O	O	O
health	O	O	O
and	O	O	O
wellbeing	O	O	B-Entity
of	O	O	I-Entity
man	O	O	I-Entity
,	O	O	O
animal	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
environment	O	O	B-Entity
.	O	O	O

Lack	O	O	B-Entity
of	O	O	I-Entity
attention	O	O	I-Entity
to	O	O	O
building	O	O	O
core	O	O	O
capacity	O	O	B-Entity
in	O	O	O
these	O	O	O
critical	O	O	B-Entity
sectors	O	O	B-Entity
has	O	O	O
further	O	O	O
raised	O	O	B-Entity
challenges	O	O	B-Entity
in	O	O	O
designing	O	O	O
and	O	O	O
deploying	O	O	B-Entity
mitigation	O	O	B-Entity
strategies	O	O	B-Entity
.	O	O	O

With	O	O	O
developing	O	O	B-Entity
countries	O	O	I-Entity
like	O	O	O
India	O	O	B-Entity
being	O	O	O
home	O	O	O
to	O	O	O
a	O	O	O
major	O	O	O
portion	O	O	B-Entity
of	O	O	O
the	O	O	O
world	O	O	B-Entity
's	O	O	I-Entity
poorest	O	O	B-Entity
livestock	O	O	B-Entity
farmers	O	O	I-Entity
,	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
a	O	O	O
policy	O	O	B-Entity
discourse	O	O	B-Entity
that	O	O	O
endorses	O	O	O
the	O	O	O
One	O	O	B-Entity
Health	O	O	I-Entity
approach	O	O	I-Entity
in	O	O	O
development	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
policies	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
hurdle	O	O	B-Entity
in	O	O	O
eliminating	O	O	B-Entity
poverty	O	O	B-Entity
and	O	O	O
poverty	O	O	O
-	O	O	O
related	O	O	B-Entity
diseases	O	O	B-Entity
.	O	O	O

The	O	O	O
adoption	O	O	B-Entity
of	O	O	O
One	O	O	B-Entity
Health	O	O	I-Entity
approaches	O	O	I-Entity
in	O	O	O
health	O	O	B-Entity
and	O	O	O
related	O	O	O
sectoral	O	O	B-Entity
policies	O	O	B-Entity
is	O	O	O
a	O	O	O
critical	O	O	B-Entity
policy	O	O	B-Entity
requirement	O	O	O
for	O	O	O
India	O	O	B-Entity
and	O	O	O
other	O	O	O
developing	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

The	O	O	O
goal	O	O	O
should	O	O	O
be	O	O	O
to	O	O	O
not	O	O	O
just	O	O	O
establish	O	O	B-Entity
preparedness	O	O	B-Entity
plans	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
to	O	O	O
encourage	O	O	B-Entity
a	O	O	O
policy	O	O	B-Entity
environment	O	O	I-Entity
where	O	O	O
assessment	O	O	B-Entity
and	O	O	O
mitigation	O	O	B-Entity
of	O	O	O
downstream	O	O	B-Entity
impacts	O	O	B-Entity
of	O	O	O
different	O	O	O
agenda	O	O	B-Entity
are	O	O	O
incorporated	O	O	B-Entity
.	O	O	O

-DOCSTART- (27717972)

Assessment	O	O	B-Entity
of	O	O	O
demographic	O	O	B-Entity
and	O	O	O
pathoanatomic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
in	O	O	O
recurrent	O	O	B-Entity
patellofemoral	O	O	B-Entity
instability	O	O	O

The	O	O	O
WARPS/STAID	O	O	B-Entity
classification	O	O	I-Entity
employs	O	O	O
clinical	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
presenting	O	O	O
features	O	O	B-Entity
and	O	O	O
anatomic	O	O	B-Entity
characteristics	O	O	B-Entity
to	O	O	O
identify	O	O	O
two	O	O	O
distinct	O	O	O
subsets	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
within	O	O	O
the	O	O	O
patellofemoral	O	O	B-Entity
instability	O	O	I-Entity
population	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	I-Entity
this	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
further	O	O	O
define	O	O	O
the	O	O	O
specific	O	O	O
demographics	O	O	B-Entity
and	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
risky	O	O	B-Entity
pathoanatomies	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
classified	O	O	O
as	O	O	O
either	O	O	O
WARPS	O	O	B-Entity
or	O	O	O
STAID	O	O	B-Entity
presenting	O	O	O
with	O	O	O
recurrent	O	O	B-Entity
patellofemoral	O	O	B-Entity
instability	O	O	B-Entity
.	O	O	O

A	O	O	O
secondary	O	O	O
purpose	O	O	O
was	O	O	O
to	O	O	O
further	O	O	O
validate	O	O	O
the	O	O	O
WARPS/STAID	O	O	B-Entity
classification	O	O	I-Entity
with	O	O	O
the	O	O	O
Banff	O	O	B-Entity
Patella	O	O	I-Entity
Instability	O	O	I-Entity
Instrument	O	O	I-Entity
(	O	O	O
BPII	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
Marx	O	O	B-Entity
activity	O	O	I-Entity
scale	O	O	I-Entity
and	O	O	O
the	O	O	O
Patellar	O	O	B-Entity
Instability	O	O	B-Entity
Severity	O	O	I-Entity
Score	O	O	I-Entity
(	O	O	O
ISS	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
convenience	O	O	O
sample	O	O	O
of	O	O	O
50	O	O	O
patients	O	O	B-Entity
with	O	O	O
recurrent	O	O	B-Entity
patellofemoral	O	O	B-Entity
instability	O	O	B-Entity
,	O	O	O
including	O	O	O
25	O	O	O
WARPS	O	O	B-Entity
and	O	O	O
25	O	O	O
STAID	O	O	B-Entity
subtype	O	O	I-Entity
patients	O	O	O
,	O	O	O
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Clinical	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
collected	O	O	O
including	O	O	O
assessment	O	O	B-Entity
of	O	O	O
demographic	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
(	O	O	O
sex	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
,	O	O	O
bilaterality	O	O	B-Entity
of	O	O	O
symptoms	O	O	B-Entity
,	O	O	O
affected	O	O	B-Entity
limb	O	O	B-Entity
side	O	O	I-Entity
and	O	O	O
age	O	O	B-Entity
at	O	O	O
first	O	O	O
dislocation	O	O	B-Entity
)	O	O	O
and	O	O	O
pathoanatomic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
(	O	O	O
TT-TG	O	O	B-Entity
distance	O	O	I-Entity
,	O	O	O
patella	O	O	B-Entity
height	O	O	B-Entity
,	O	O	O
patellar	O	O	O
tilt	O	O	O
,	O	O	O
grade	O	O	B-Entity
of	O	O	O
trochlear	O	O	B-Entity
dysplasia	O	O	I-Entity
,	O	O	O
Beighton	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
rotational	O	O	B-Entity
abnormalities	O	O	I-Entity
of	O	O	O
the	O	O	O
tibia	O	O	B-Entity
or	O	O	O
femur	O	O	B-Entity
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
completed	O	O	O
the	O	O	O
BPII	O	O	B-Entity
and	O	O	O
the	O	O	O
Marx	O	O	B-Entity
activity	O	O	I-Entity
scale	O	O	I-Entity
.	O	O	O

The	O	O	O
ISS	O	O	B-Entity
was	O	O	O
calculated	O	O	B-Entity
from	O	O	O
the	O	O	O
clinical	O	O	B-Entity
assessment	O	O	I-Entity
data	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
stratified	O	O	O
into	O	O	O
the	O	O	O
WARPS	O	O	B-Entity
or	O	O	O
STAID	O	O	B-Entity
subtypes	O	O	I-Entity
for	O	O	O
comparative	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

An	O	O	O
independent	O	O	O
t	O	O	B-Entity
test	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
compare	O	O	O
demographics	O	O	B-Entity
,	O	O	O
the	O	O	O
pathoanatomic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
and	O	O	O
subjective	O	O	O
measures	O	O	O
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
.	O	O	O

Convergent	O	O	B-Entity
validity	O	O	I-Entity
was	O	O	O
tested	O	O	O
with	O	O	O
a	O	O	O
Pearson	O	O	B-Entity
r	O	O	I-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
between	O	O	O
the	O	O	O
WARPS/STAID	O	O	B-Entity
and	O	O	O
ISS	O	O	B-Entity
scores	O	O	I-Entity
.	O	O	O

Demographic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
statistically	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
WARPS	O	O	B-Entity
subtype	O	O	I-Entity
included	O	O	O
female	O	O	B-Entity
sex	O	O	I-Entity
,	O	O	O
age	O	O	B-Entity
at	O	O	O
first	O	O	O
dislocation	O	O	B-Entity
and	O	O	O
bilaterality	O	O	B-Entity
.	O	O	O

Pathoanatomic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
statistically	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
WARPS	O	O	B-Entity
subtype	O	O	I-Entity
included	O	O	O
trochlear	O	O	B-Entity
dysplasia	O	O	I-Entity
,	O	O	O
TT-TG	O	O	B-Entity
distance	O	O	I-Entity
,	O	O	O
generalized	O	O	O
ligamentous	O	O	B-Entity
laxity	O	O	I-Entity
,	O	O	O
patellar	O	O	O
tilt	O	O	O
and	O	O	O
rotational	O	O	B-Entity
abnormalities	O	O	I-Entity
.	O	O	O

The	O	O	O
independent	O	O	O
t	O	O	B-Entity
test	O	O	I-Entity
revealed	O	O	O
a	O	O	O
significant	O	O	O
difference	O	O	O
between	O	O	O
the	O	O	O
ISS	O	O	B-Entity
scores	O	O	O
:	O	O	O
WARPS	O	O	B-Entity
subtype	O	O	I-Entity
(	O	O	O
M	O	O	O
=	O	O	O
4.4	O	O	O
,	O	O	O
SD	O	O	O
=	O	O	O
1.1	O	O	O
)	O	O	O
and	O	O	O
STAID	O	O	B-Entity
subtype	O	O	I-Entity
(	O	O	O
M	O	O	O
=	O	O	O
2.5	O	O	O
,	O	O	O
SD	O	O	O
=	O	O	O
1.5	O	O	O
)	O	O	O
;	O	O	O
t(48	O	O	O
)	O	O	O
=	O	O	O
5.2	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
.	O	O	O

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
WARPS/STAID	O	O	B-Entity
and	O	O	O
the	O	O	O
ISS	O	O	B-Entity
scores	O	O	I-Entity
,	O	O	O
measured	O	O	O
using	O	O	O
a	O	O	O
Pearson	O	O	B-Entity
r	O	O	I-Entity
correlation	O	O	I-Entity
coefficient	O	O	I-Entity
,	O	O	O
demonstrated	O	O	O
a	O	O	O
strong	O	O	O
relationship	O	O	O
:	O	O	O
r	O	O	O
=	O	O	O
-0.61	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
50	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
has	O	O	O
demonstrated	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
evidence	O	O	B-Entity
that	O	O	O
certain	O	O	O
demographics	O	O	B-Entity
and	O	O	O
pathoanatomies	O	O	B-Entity
are	O	O	O
more	O	O	O
prevalent	O	O	O
in	O	O	O
each	O	O	O
of	O	O	O
the	O	O	O
WARPS	O	O	B-Entity
and	O	O	O
STAID	O	O	B-Entity
patellofemoral	O	O	B-Entity
instability	O	O	B-Entity
subtypes	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
difference	O	O	O
in	O	O	O
quality-of-life	O	O	B-Entity
or	O	O	O
activity	O	O	B-Entity
level	O	O	I-Entity
between	O	O	O
the	O	O	O
subtypes	O	O	B-Entity
.	O	O	O

The	O	O	O
WARPS/STAID	O	O	B-Entity
score	O	O	I-Entity
demonstrated	O	O	O
convergent	O	O	B-Entity
validity	O	O	I-Entity
to	O	O	O
the	O	O	O
ISS	O	O	B-Entity
and	O	O	O
divergent	O	O	B-Entity
validity	O	O	I-Entity
to	O	O	O
the	O	O	O
BPII	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
the	O	O	O
Marx	O	O	B-Entity
activity	O	O	I-Entity
scale	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
has	O	O	O
further	O	O	O
validated	O	O	O
both	O	O	O
the	O	O	O
WARPS/STAID	O	O	B-Entity
classification	O	O	I-Entity
and	O	O	O
the	O	O	O
ISS	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
that	O	O	O
present	O	O	O
with	O	O	O
recurrent	O	O	B-Entity
patellofemoral	O	O	B-Entity
instability	O	O	B-Entity
.	O	O	O

III	O	O	O
.	O	O	O

-DOCSTART- (27718023)

Expression	O	O	B-Entity
of	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
in	O	O	O
ovarian	O	O	B-Entity
follicle	O	O	I-Entity
cells	O	O	B-Entity
of	O	O	O
the	O	O	O
lizard	O	O	B-Entity
Podarcis	O	O	O
sicula	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O

our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
plays	O	O	O
a	O	O	O
role	O	O	O
,	O	O	O
during	O	O	O
previtellogenesis	O	O	B-Entity
,	O	O	O
in	O	O	O
the	O	O	O
ovarian	O	O	B-Entity
follicular	O	O	B-Entity
epithelium	O	O	I-Entity
of	O	O	O
the	O	O	O
lizard	O	O	B-Entity
Podarcis	O	O	B-Entity
sicula	O	O	I-Entity
.	O	O	O

We	O	O	O
investigated	O	O	O
the	O	O	O
presence	O	O	O
and	O	O	O
localization	O	O	B-Entity
of	O	O	O
proform	O	O	O
and	O	O	O
active	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
by	O	O	O
enzyme	O	O	B-Entity
assay	O	O	I-Entity
,	O	O	O
Western	O	O	B-Entity
blotting	O	O	I-Entity
and	O	O	O
immunocytochemistry	O	O	B-Entity
.	O	O	O

In	O	O	O
parallel	O	O	O
,	O	O	O
a	O	O	O
fragment	O	O	B-Entity
of	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
was	O	O	O
cloned	O	O	B-Entity
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
in	O	O	O
this	O	O	O
species	O	O	B-Entity
,	O	O	O
sequenced	O	O	B-Entity
and	O	O	O
used	O	O	O
for	O	O	O
in	O	O	B-Entity
situ	O	O	I-Entity
hybridization	O	O	I-Entity
to	O	O	O
localize	O	O	B-Entity
messengers	O	O	B-Entity
and	O	O	O
analysed	O	O	O
by	O	O	O
a	O	O	O
phylogenetic	O	O	B-Entity
survey	O	O	I-Entity
to	O	O	O
shed	O	O	O
light	O	O	O
on	O	O	O
its	O	O	O
homology	O	O	B-Entity
with	O	O	O
reptilian	O	O	B-Entity
caspases	O	O	B-Entity
.	O	O	O

Results	O	O	O
demonstrated	O	O	O
that	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
the	O	O	O
follicle	O	O	B-Entity
cells	O	O	B-Entity
expressed	O	O	B-Entity
a	O	O	O
caspase	O	O	B-Entity
of	O	O	O
the	O	O	O
3/7	O	O	O
group	O	O	O
and	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
for	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
was	O	O	O
transcribed	O	O	B-Entity
in	O	O	O
the	O	O	O
stem	O	O	B-Entity
phase	O	O	I-Entity
and	O	O	O
was	O	O	O
completely	O	O	O
translated	O	O	B-Entity
during	O	O	O
cell	O	O	B-Entity
differentiation	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
the	O	O	O
proform	O	O	B-Entity
protein	O	O	I-Entity
was	O	O	O
stored	O	O	O
during	O	O	O
the	O	O	O
differentiated	O	O	B-Entity
(	O	O	I-Entity
nurse	O	O	I-Entity
)	O	O	I-Entity
stage	O	O	I-Entity
and	O	O	O
activated	O	O	B-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
previtellogenesis	O	O	B-Entity
provoking	O	O	O
the	O	O	O
degeneration	O	O	B-Entity
of	O	O	I-Entity
cells	O	O	I-Entity
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
the	O	O	O
predicted	O	O	O
protein	O	O	B-Entity
sequence	O	O	I-Entity
,	O	O	O
although	O	O	O
partial	O	O	O
,	O	O	O
had	O	O	O
a	O	O	O
strong	O	O	O
similarity	O	O	O
with	O	O	O
the	O	O	O
known	O	O	O
reptilian	O	O	B-Entity
caspases	O	O	B-Entity
3	O	O	I-Entity
.	O	O	O

The	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
of	O	O	O
the	O	O	O
ovarian	O	O	B-Entity
follicle	O	O	I-Entity
,	O	O	O
therefore	O	O	O
,	O	O	O
do	O	O	O
not	O	O	O
employ	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
during	O	O	O
the	O	O	O
nurse	O	O	B-Entity
stage	O	O	I-Entity
but	O	O	O
,	O	O	O
instead	O	O	O
,	O	O	O
prepare	O	O	O
for	O	O	O
apoptosis	O	O	B-Entity
long	O	O	O
before	O	O	O
the	O	O	O
process	O	O	O
actually	O	O	O
begins	O	O	O
.	O	O	O

The	O	O	O
relevance	O	O	O
of	O	O	O
this	O	O	O
strategy	O	O	O
is	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (27720129)

Increased	O	O	B-Entity
acute	O	O	B-Entity
mortality	O	O	B-Entity
with	O	O	O
chemoradiotherapy	O	O	B-Entity
for	O	O	O
locally	O	O	B-Entity
advanced	O	O	I-Entity
head	O	O	I-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
cancer	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
≥70	O	O	O
years	O	O	O

Concurrent	O	O	B-Entity
chemoradiotherapy	O	O	I-Entity
(	O	O	O
CRT	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
standard	O	O	B-Entity
of	O	O	I-Entity
care	O	O	I-Entity
for	O	O	O
many	O	O	O
sites	O	O	B-Entity
of	O	O	O
locally	O	O	B-Entity
advanced	O	O	I-Entity
head	O	O	I-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinomas	O	O	I-Entity
(	O	O	O
LAHNC	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
on	O	O	O
meta-analysis	O	O	B-Entity
,	O	O	O
the	O	O	O
addition	O	O	O
of	O	O	O
chemotherapy	O	O	B-Entity
did	O	O	O
not	O	O	O
improve	O	O	O
survival	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
>	O	O	O
70	O	O	O
years	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
CRT	O	O	B-Entity
would	O	O	O
have	O	O	O
increased	O	O	B-Entity
toxicity	O	O	B-Entity
without	O	O	O
similar	O	O	O
improvements	O	O	B-Entity
in	O	O	O
survival	O	O	B-Entity
.	O	O	O

A	O	O	O
single-institution	O	O	B-Entity
,	O	O	O
IRB-approved	O	O	B-Entity
retrospective	O	O	B-Entity
study	O	O	I-Entity
took	O	O	O
place	O	O	O
from	O	O	O
2005	O	O	O
to	O	O	O
2012	O	O	O
including	O	O	O
369	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
CRT	O	O	B-Entity
for	O	O	O
LAHNC	O	O	B-Entity
.	O	O	O

Multivariate	O	O	B-Entity
models	O	O	I-Entity
for	O	O	O
death	O	O	B-Entity
at	O	O	O
3	O	O	O
months	O	O	B-Entity
and	O	O	O
death	O	O	O
over	O	O	O
time	O	O	B-Entity
were	O	O	O
developed	O	O	O
using	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
and	O	O	O
Cox	O	O	B-Entity
modeling	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Patients	O	O	B-Entity
≥70	O	O	O
years	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
less	O	O	O
often	O	O	O
with	O	O	O
concurrent	O	O	B-Entity
cisplatin	O	O	B-Entity
dosed	O	O	O
every	O	O	O
3	O	O	O
weeks	O	O	B-Entity
(	O	O	O
25.5	O	O	O
%	O	O	O
vs.	O	O	O
71.4	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
and	O	O	O
more	O	O	O
often	O	O	O
with	O	O	O
weekly	O	O	B-Entity
carboplatin	O	O	B-Entity
(	O	O	O
31.9	O	O	O
%	O	O	O
vs.	O	O	O
3.4	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
patients	O	O	B-Entity
<	O	O	O
70	O	O	O
years	O	O	O
(	O	O	O
n=322	O	O	O
;	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
≥70	O	O	O
years	O	O	B-Entity
experienced	O	O	O
increased	O	O	B-Entity
toxicity	O	O	B-Entity
during	O	O	O
treatment	O	O	B-Entity
with	O	O	O
more	O	O	O
frequently	O	O	O
hospitalizations	O	O	B-Entity
(	O	O	O
36.2	O	O	O
%	O	O	O
vs.	O	O	O
21.1	O	O	O
%	O	O	O
;	O	O	O
p=0.02	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
lower	O	O	O
rate	O	O	O
of	O	O	O
PEG	O	O	B-Entity
removal	O	O	I-Entity
at	O	O	O
last	O	O	O
follow-up	O	O	B-Entity
or	O	O	O
death	O	O	B-Entity
(	O	O	O
77.1	O	O	O
%	O	O	O
vs.	O	O	O
92.9	O	O	O
%	O	O	O
;	O	O	O
p=0.004	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
higher	O	O	O
proportion	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
≥70	O	O	O
years	O	O	B-Entity
died	O	O	O
within	O	O	O
3	O	O	O
months	O	O	B-Entity
(	O	O	O
12.8	O	O	O
%	O	O	O
vs.	O	O	O
2.8	O	O	O
%	O	O	O
;	O	O	O
p=0.001	O	O	O
)	O	O	O
following	O	O	O
CRT	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
≥70	O	O	O
had	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
death	O	O	B-Entity
at	O	O	O
3	O	O	O
months	O	O	B-Entity
following	O	O	O
CRT	O	O	B-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
5.19	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
1.64	O	O	O
-	O	O	O
16.41	O	O	O
;	O	O	O
p=0.005	O	O	O
)	O	O	O
and	O	O	O
worse	O	O	O
survival	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
2.30	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.34	O	O	O
-	O	O	O
3.93	O	O	O
;	O	O	O
p=0.002	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
≥70	O	O	O
years	O	O	B-Entity
were	O	O	O
more	O	O	O
often	O	O	O
treated	O	O	B-Entity
with	O	O	O
less	O	O	O
toxic	O	O	B-Entity
chemotherapy	O	O	B-Entity
,	O	O	O
yet	O	O	O
experienced	O	O	O
higher	O	O	O
rates	O	O	B-Entity
of	O	O	O
hospitalization	O	O	B-Entity
during	O	O	O
treatment	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
rates	O	O	O
of	O	O	O
acute	O	O	B-Entity
mortality	O	O	B-Entity
following	O	O	O
CRT	O	O	B-Entity
.	O	O	O

The	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
chemoradiotherapy	O	O	B-Entity
for	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
should	O	O	O
be	O	O	O
evaluated	O	O	O
in	O	O	O
a	O	O	O
prospective	O	O	B-Entity
setting	O	O	I-Entity
.	O	O	O

-DOCSTART- (27733749)

Food	O	O	B-Entity
security	O	O	I-Entity
and	O	O	O
the	O	O	O
nutritional	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
children	O	O	B-Entity
in	O	O	O
foster	O	O	B-Entity
care	O	O	I-Entity
:	O	O	O
new	O	O	O
horizons	O	O	O
in	O	O	O
the	O	O	O
protection	O	O	O
of	O	O	O
a	O	O	O
fragile	O	O	O
population	O	O	O

The	O	O	O
nutritional	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
foster	O	O	B-Entity
children	O	O	I-Entity
,	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
daily	O	O	B-Entity
menus	O	O	I-Entity
in	O	O	O
group	O	O	B-Entity
homes	O	O	I-Entity
and	O	O	O
the	O	O	O
Food	O	O	B-Entity
Security	O	O	I-Entity
inside	O	O	O
these	O	O	O
organizations	O	O	B-Entity
have	O	O	O
been	O	O	O
poorly	O	O	O
studied	O	O	O
and	O	O	O
this	O	O	O
study	O	O	B-Entity
means	O	O	O
to	O	O	O
investigate	O	O	O
them	O	O	O
.	O	O	O

A	O	O	O
sample	O	O	O
of	O	O	O
125	O	O	O
children	O	O	B-Entity
,	O	O	O
ranging	O	O	O
in	O	O	O
age	O	O	O
from	O	O	O
0	O	O	O
-	O	O	O
17	O	O	O
years	O	O	O
,	O	O	O
among	O	O	O
seven	O	O	O
group	O	O	B-Entity
homes	O	O	I-Entity
(	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
)	O	O	O
was	O	O	O
compared	O	O	O
with	O	O	O
121	O	O	O
children	O	O	O
of	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
we	O	O	O
(	O	O	O
group	O	O	B-Entity
B	O	O	I-Entity
)	O	O	O
.	O	O	O

To	O	O	O
evaluate	O	O	O
nutritional	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
BMI	O	O	B-Entity
percentiles	O	O	I-Entity
were	O	O	O
used	O	O	O
.	O	O	O

Mean	O	O	B-Entity
percentiles	O	O	B-Entity
of	O	O	O
both	O	O	O
groups	O	O	B-Entity
were	O	O	O
compared	O	O	O
through	O	O	O
statistical	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Both	O	O	O
nutritional	O	O	B-Entity
and	O	O	O
caloric	O	O	B-Entity
daily	O	O	I-Entity
distributions	O	O	I-Entity
in	O	O	O
each	O	O	O
organization	O	O	B-Entity
were	O	O	O
obtained	O	O	O
using	O	O	O
the	O	O	O
24-hour	O	O	O
recall	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

A	O	O	O
specific	O	O	O
questionnaire	O	O	B-Entity
was	O	O	O
administered	O	O	O
to	O	O	O
evaluate	O	O	O
Food	O	O	B-Entity
Security	O	O	I-Entity
.	O	O	O

From	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
mean	O	O	B-Entity
BMI	O	O	B-Entity
-for-	O	O	O
age	O	O	B-Entity
(	O	O	O
or	O	O	O
height-for-length	O	O	O
)	O	O	O
percentiles	O	O	B-Entity
,	O	O	O
did	O	O	O
not	O	O	O
observe	O	O	O
statistically	O	O	O
significant	O	O	O
differences	O	O	B-Entity
between	O	O	O
group	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
group	O	O	O
B.	O	O	O
The	O	O	O
average	O	O	B-Entity
daily	O	O	B-Entity
nutrient	O	O	B-Entity
and	O	O	O
calorie	O	O	B-Entity
distribution	O	O	I-Entity
in	O	O	O
group	O	O	B-Entity
homes	O	O	I-Entity
proves	O	O	O
to	O	O	O
be	O	O	O
nearly	O	O	B-Entity
optimal	O	O	I-Entity
with	O	O	O
the	O	O	O
exception	O	O	O
of	O	O	O
a	O	O	O
slight	O	O	O
excess	O	O	B-Entity
in	O	O	O
proteins	O	O	B-Entity
and	O	O	O
a	O	O	O
slight	O	O	O
deficiency	O	O	B-Entity
in	O	O	O
PUFAs	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
a	O	O	O
low	O	O	B-Entity
intake	O	O	I-Entity
of	O	O	O
iron	O	O	B-Entity
and	O	O	O
calcium	O	O	B-Entity
was	O	O	O
revealed	O	O	O
.	O	O	O

All	O	O	O
organizations	O	O	B-Entity
obtained	O	O	O
a	O	O	O
"	O	O	O
High	O	O	B-Entity
Food	O	O	I-Entity
Security	O	O	I-Entity
"	O	O	O
profile	O	O	O
.	O	O	O

Nutritional	O	O	B-Entity
conditions	O	O	I-Entity
of	O	O	O
foster	O	O	B-Entity
children	O	O	B-Entity
are	O	O	O
no	O	O	O
worse	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
children	O	O	O
of	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

Foster	O	O	B-Entity
care	O	O	I-Entity
provides	O	O	O
the	O	O	O
necessary	O	O	B-Entity
conditions	O	O	I-Entity
to	O	O	O
support	O	O	O
their	O	O	O
growth	O	O	B-Entity
.	O	O	O

-DOCSTART- (27734729)

Incontinence	O	O	B-Entity
-associated	O	O	O
dermatitis	O	O	B-Entity
:	O	O	O
reducing	O	O	B-Entity
adverse	O	O	O
events	O	O	O

Incontinence	O	O	B-Entity
-associated	O	O	O
dermatitis	O	O	B-Entity
(	O	O	O
IAD	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
common	O	O	O
problem	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
faecal	O	O	B-Entity
and/or	O	O	O
urinary	O	O	B-Entity
incontinence	O	O	I-Entity
.	O	O	O

Urine	O	O	B-Entity
alters	O	O	O
the	O	O	O
normal	O	O	O
skin	O	O	B-Entity
flora	O	O	B-Entity
and	O	O	O
increases	O	O	O
permeability	O	O	B-Entity
of	O	O	O
the	O	O	O
stratum	O	O	B-Entity
corneum	O	O	I-Entity
and	O	O	O
faecal	O	O	B-Entity
enzymes	O	O	B-Entity
on	O	O	O
the	O	O	O
skin	O	O	O
contribute	O	O	O
to	O	O	O
skin	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

Faecal	O	O	B-Entity
bacteria	O	O	B-Entity
can	O	O	O
then	O	O	O
penetrate	O	O	B-Entity
the	O	O	O
skin	O	O	B-Entity
,	O	O	O
increasing	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
secondary	O	O	B-Entity
infection	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
IAD	O	O	B-Entity
can	O	O	O
be	O	O	O
prevented	O	O	B-Entity
and	O	O	O
healed	O	O	B-Entity
with	O	O	O
timely	O	O	O
and	O	O	O
appropriate	O	O	B-Entity
skin	O	O	B-Entity
cleansing	O	O	I-Entity
and	O	O	O
skin	O	O	B-Entity
protection	O	O	I-Entity
.	O	O	O

This	O	O	O
includes	O	O	O
appropriate	O	O	B-Entity
use	O	O	O
of	O	O	O
containment	O	O	B-Entity
devices	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	O
also	O	O	O
looks	O	O	O
at	O	O	O
HARTMANN	O	O	B-Entity
incontinence	O	O	I-Entity
pads	O	O	I-Entity
that	O	O	O
have	O	O	O
been	O	O	O
developed	O	O	O
to	O	O	O
absorb	O	O	O
the	O	O	O
fluids	O	O	B-Entity
that	O	O	O
cause	O	O	O
IAD	O	O	B-Entity
and	O	O	O
maintain	O	O	O
the	O	O	O
skin	O	O	B-Entity
's	O	O	I-Entity
acidic	O	O	O
pH.	O	O	O
The	O	O	O
acidic	O	O	B-Entity
pH	O	O	I-Entity
of	O	O	O
the	O	O	O
skin	O	O	O
contributes	O	O	O
to	O	O	O
its	O	O	O
barrier	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
defence	O	O	O
against	O	O	O
infection	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
maintaining	O	O	O
an	O	O	O
acidic	O	O	B-Entity
pH	O	O	I-Entity
will	O	O	O
help	O	O	O
protect	O	O	O
the	O	O	O
skin	O	O	B-Entity
from	O	O	O
damage	O	O	B-Entity
.	O	O	O

-DOCSTART- (27740919)

Feasibility	O	O	B-Entity
of	O	O	O
a	O	O	O
transition	O	O	B-Entity
intervention	O	O	B-Entity
aimed	O	O	B-Entity
at	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
chronic	O	O	O
illness	O	O	O

International	O	O	B-Entity
guidelines	O	O	B-Entity
recommend	O	O	O
planned	O	O	O
and	O	O	O
structured	O	O	O
transition	O	O	B-Entity
programmes	O	O	B-Entity
for	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
illness	O	O	I-Entity
because	O	O	O
inadequate	O	O	B-Entity
transition	O	O	O
may	O	O	O
lead	O	O	O
to	O	O	O
poor	O	O	B-Entity
disease	O	O	I-Entity
control	O	O	I-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
lacking	O	O	B-Entity
outpatient	O	O	B-Entity
follow-up	O	O	I-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
a	O	O	O
transition	O	O	B-Entity
intervention	O	O	B-Entity
aimed	O	O	B-Entity
at	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
illness	O	O	I-Entity
focusing	O	O	B-Entity
on	O	O	O
declines	O	O	B-Entity
,	O	O	O
drop-outs	O	O	B-Entity
,	O	O	O
no-shows	O	O	B-Entity
and	O	O	O
advantages	O	O	B-Entity
and	O	O	O
disadvantages	O	O	B-Entity
of	O	O	O
participating	O	O	B-Entity
.	O	O	O

We	O	O	O
invited	O	O	O
236	O	O	O
adolescents	O	O	B-Entity
(	O	O	O
12	O	O	O
-	O	O	O
20	O	O	O
years	O	O	O
)	O	O	O
with	O	O	O
juvenile	O	O	B-Entity
idiopathic	O	O	I-Entity
arthritis	O	O	I-Entity
(	O	O	O
JIA	O	O	B-Entity
)	O	O	O
to	O	O	O
participate	O	O	B-Entity
in	O	O	O
a	O	O	O
randomised	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
(	O	O	O
RCT	O	O	B-Entity
)	O	O	O
transition	O	O	B-Entity
intervention	O	O	B-Entity
.	O	O	O

Reasons	O	O	B-Entity
for	O	O	O
decline	O	O	B-Entity
and	O	O	O
drop-outs	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
.	O	O	O

Adolescents	O	O	B-Entity
'	O	O	O
experiences	O	O	B-Entity
of	O	O	O
advantages	O	O	B-Entity
and	O	O	O
disadvantages	O	O	B-Entity
of	O	O	O
participating	O	O	B-Entity
and	O	O	O
reasons	O	O	B-Entity
for	O	O	O
no-shows	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
through	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
telephone	O	O	B-Entity
interviews	O	O	I-Entity
,	O	O	O
which	O	O	O
were	O	O	O
analysed	O	O	B-Entity
using	O	O	O
thematic	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
and	O	O	O
twenty	O	O	O
of	O	O	O
the	O	O	O
236	O	O	O
eligible	O	O	O
patients	O	O	B-Entity
declined	O	O	B-Entity
to	O	O	I-Entity
participate	O	O	I-Entity
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
and	O	O	O
20	O	O	O
%	O	O	O
dropped	O	O	B-Entity
out	O	O	I-Entity
during	O	O	O
the	O	O	O
intervention	O	O	O
.	O	O	O

Unspecified	O	O	B-Entity
declines	O	O	B-Entity
and	O	O	O
practical	O	O	B-Entity
issues	O	O	I-Entity
were	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
reason	O	O	B-Entity
to	O	O	O
decline	O	O	B-Entity
,	O	O	O
and	O	O	O
'	O	O	O
do	O	O	B-Entity
not	O	O	I-Entity
wish	O	O	I-Entity
to	O	O	I-Entity
continue	O	O	I-Entity
'	O	O	O
was	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
reason	O	O	O
to	O	O	O
drop-out	O	O	B-Entity
.	O	O	O

Reasons	O	O	B-Entity
for	O	O	O
no-shows	O	O	B-Entity
were	O	O	O
forgetting	O	O	B-Entity
and	O	O	O
being	O	O	O
too	O	O	O
busy	O	O	O
.	O	O	O

Advantages	O	O	B-Entity
of	O	O	O
participating	O	O	B-Entity
were	O	O	O
stated	O	O	O
as	O	O	O
'	O	O	O
participating	O	O	O
without	O	O	B-Entity
parents	O	O	B-Entity
'	O	O	O
,	O	O	O
'	O	O	O
trust	O	O	B-Entity
and	O	O	O
confidentiality	O	O	B-Entity
'	O	O	O
,	O	O	O
'	O	O	O
being	O	O	O
able	O	O	O
to	O	O	O
set	O	O	O
the	O	O	O
agenda	O	O	B-Entity
'	O	O	O
and	O	O	O
'	O	O	O
responsiveness	O	O	B-Entity
'	O	O	O
.	O	O	O

Disadvantages	O	O	B-Entity
were	O	O	O
'	O	O	O
unclear	O	O	B-Entity
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
study	O	O	B-Entity
'	O	O	O
,	O	O	O
'	O	O	O
meeting	O	O	O
others	O	O	O
with	O	O	O
JIA	O	O	B-Entity
'	O	O	O
,	O	O	O
'	O	O	O
too	O	O	O
few	O	O	O
conversations	O	O	B-Entity
'	O	O	O
and	O	O	O
'	O	O	O
transport	O	O	B-Entity
issues	O	O	B-Entity
'	O	O	O
.	O	O	O

Many	O	O	O
adolescents	O	O	B-Entity
had	O	O	O
difficulties	O	O	B-Entity
understanding	O	O	B-Entity
the	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
most	O	O	O
participants	O	O	B-Entity
appreciated	O	O	O
the	O	O	O
conversations	O	O	B-Entity
about	O	O	O
identity	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
trust	O	O	B-Entity
and	O	O	O
confidentiality	O	O	B-Entity
in	O	O	O
the	O	O	O
communication	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
future	O	O	O
,	O	O	O
adolescents	O	O	B-Entity
should	O	O	O
be	O	O	O
offered	O	O	O
more	O	O	O
individually	O	O	O
organised	O	O	O
programmes	O	O	B-Entity
according	O	O	O
to	O	O	O
their	O	O	O
preferences	O	O	B-Entity
and	O	O	O
needs	O	O	O
in	O	O	O
cooperation	O	O	B-Entity
with	O	O	O
parents	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
providers	O	O	I-Entity
.	O	O	O

-DOCSTART- (27743356)

High-Throughput	O	O	B-Entity
Analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
IgG	O	O	B-Entity
N-Glycome	O	O	I-Entity
by	O	O	O
UPLC	O	O	B-Entity
-	O	O	O
FLR	O	O	O

As	O	O	O
biological	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
relevance	O	O	B-Entity
of	O	O	O
glycosylation	O	O	B-Entity
is	O	O	O
becoming	O	O	O
more	O	O	O
apparent	O	O	B-Entity
,	O	O	O
interest	O	O	O
in	O	O	O
large	O	O	B-Entity
scale	O	O	I-Entity
studies	O	O	I-Entity
of	O	O	O
the	O	O	O
glycome	O	O	B-Entity
is	O	O	O
growing	O	O	O
.	O	O	O

Glycans	O	O	B-Entity
attached	O	O	O
to	O	O	O
immunoglobulin	O	O	B-Entity
G	O	O	I-Entity
(	O	O	O
IgG	O	O	B-Entity
)	O	O	O
were	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
essential	O	O	B-Entity
for	O	O	O
its	O	O	O
function	O	O	B-Entity
and	O	O	O
IgG	O	O	O
glycosylation	O	O	B-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
change	O	O	B-Entity
with	O	O	O
various	O	O	O
processes	O	O	B-Entity
,	O	O	O
making	O	O	O
IgG	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
studied	O	O	O
glycoproteins	O	O	B-Entity
.	O	O	O

Many	O	O	O
approaches	O	O	B-Entity
including	O	O	O
liquid	O	O	B-Entity
chromatography	O	O	I-Entity
,	O	O	O
capillary	O	O	B-Entity
gel	O	O	I-Entity
electrophoresis	O	O	I-Entity
,	O	O	O
and	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
were	O	O	O
developed	O	O	O
to	O	O	O
study	O	O	B-Entity
IgG	O	O	B-Entity
glycosylation	O	O	B-Entity
.	O	O	O

Generation	O	O	B-Entity
of	O	O	O
high-quality	O	O	B-Entity
glycomics	O	O	B-Entity
data	O	O	B-Entity
in	O	O	O
a	O	O	O
high-throughput	O	O	B-Entity
fashion	O	O	O
requires	O	O	O
reproducible	O	O	B-Entity
and	O	O	O
robust	O	O	B-Entity
sample	O	O	B-Entity
preparation	O	O	I-Entity
and	O	O	O
accurate	O	O	B-Entity
and	O	O	O
reliable	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

This	O	O	O
chapter	O	O	B-Entity
presents	O	O	O
a	O	O	O
protocol	O	O	B-Entity
for	O	O	O
an	O	O	O
optimized	O	O	O
and	O	O	O
high-throughput	O	O	B-Entity
IgG	O	O	B-Entity
N-glycan	O	O	I-Entity
release	O	O	B-Entity
,	O	O	O
fluorescent	O	O	B-Entity
labeling	O	O	I-Entity
and	O	O	O
cleanup	O	O	B-Entity
,	O	O	O
and	O	O	O
analysis	O	O	B-Entity
of	O	O	O
fluorescently	O	O	B-Entity
labeled	O	O	I-Entity
IgG	O	O	B-Entity
N-glycans	O	O	I-Entity
by	O	O	O
hydrophilic	O	O	B-Entity
interaction	O	O	I-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
(	O	O	O
HILIC	O	O	B-Entity
)	O	O	O
on	O	O	O
an	O	O	O
ultra	O	O	B-Entity
performance	O	O	I-Entity
liquid	O	O	I-Entity
chromatography	O	O	I-Entity
(	O	O	O
UPLC	O	O	B-Entity
)	O	O	O
system	O	O	O
with	O	O	O
fluorescence	O	O	B-Entity
(	O	O	O
FLR	O	O	B-Entity
)	O	O	O
detection	O	O	B-Entity
.	O	O	O

-DOCSTART- (27744219)

Biomimetic	O	O	B-Entity
whitlockite	O	O	B-Entity
inorganic	O	O	B-Entity
nanoparticles	O	O	B-Entity
-mediated	O	O	O
in	O	O	B-Entity
situ	O	O	I-Entity
remodeling	O	O	B-Entity
and	O	O	O
rapid	O	O	O
bone	O	O	O
regeneration	O	O	O

Bone	O	O	B-Entity
remodeling	O	O	I-Entity
process	O	O	O
relies	O	O	O
on	O	O	O
complex	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
between	O	O	O
osteoblasts	O	O	B-Entity
and	O	O	O
osteoclasts	O	O	B-Entity
and	O	O	O
control	O	O	O
mechanisms	O	O	B-Entity
to	O	O	O
achieve	O	O	O
homeostasis	O	O	B-Entity
of	O	O	O
their	O	O	O
growth	O	O	B-Entity
and	O	O	O
differentiation	O	O	B-Entity
.	O	O	O

Despite	O	O	O
previous	O	O	O
achievements	O	O	O
in	O	O	O
understanding	O	O	O
complicated	O	O	O
signaling	O	O	B-Entity
pathways	O	O	I-Entity
between	O	O	O
cells	O	O	B-Entity
and	O	O	O
bone	O	O	B-Entity
extracellular	O	O	B-Entity
matrices	O	O	I-Entity
during	O	O	O
bone	O	O	B-Entity
remodeling	O	O	I-Entity
process	O	O	O
,	O	O	O
a	O	O	O
role	O	O	O
of	O	O	O
local	O	O	O
ionic	O	O	B-Entity
concentration	O	O	B-Entity
remains	O	O	O
to	O	O	O
be	O	O	O
elucidated	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
synthetic	O	O	B-Entity
whitlockite	O	O	B-Entity
(	O	O	O
WH	O	O	B-Entity
:	O	O	I-Entity
Ca18Mg2(HPO4)2(PO4)12	O	O	I-Entity
)	O	O	I-Entity
nanoparticles	O	O	B-Entity
can	O	O	O
recapitulate	O	O	B-Entity
early-stage	O	O	O
of	O	O	O
bone	O	O	B-Entity
regeneration	O	O	I-Entity
through	O	O	O
stimulating	O	O	B-Entity
osteogenic	O	O	B-Entity
differentiation	O	O	I-Entity
,	O	O	O
prohibiting	O	O	B-Entity
osteoclastic	O	O	B-Entity
activity	O	O	B-Entity
,	O	O	O
and	O	O	O
transforming	O	O	B-Entity
into	O	O	O
mechanically	O	O	O
enhanced	O	O	O
hydroxyapatite	O	O	B-Entity
(HAP)-	O	O	O
neo	O	O	B-Entity
bone	O	O	I-Entity
tissues	O	O	I-Entity
by	O	O	O
continuous	O	O	O
supply	O	O	O
of	O	O	O
PO4(3-	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
Mg(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
under	O	O	O
physiological	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
their	O	O	O
structural	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
the	O	O	O
dynamic	O	O	O
phase	O	O	B-Entity
transformation	O	O	B-Entity
from	O	O	O
WH	O	O	B-Entity
into	O	O	O
HAP	O	O	B-Entity
contributed	O	O	O
as	O	O	O
a	O	O	O
key	O	O	O
factor	O	O	B-Entity
for	O	O	O
rapid	O	O	O
bone	O	O	B-Entity
regeneration	O	O	I-Entity
with	O	O	O
denser	O	O	B-Entity
hierarchical	O	O	B-Entity
neo-bone	O	O	B-Entity
structure	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
a	O	O	O
groundbreaking	O	O	O
concept	O	O	O
of	O	O	O
'	O	O	O
living	O	O	B-Entity
bone	O	O	B-Entity
minerals	O	O	B-Entity
'	O	O	O
that	O	O	O
actively	O	O	B-Entity
communicate	O	O	B-Entity
with	O	O	O
the	O	O	O
surrounding	O	O	O
system	O	O	O
to	O	O	O
induce	O	O	B-Entity
self-healing	O	O	B-Entity
,	O	O	O
while	O	O	O
previous	O	O	O
notions	O	O	O
about	O	O	O
bone	O	O	O
minerals	O	O	O
have	O	O	O
been	O	O	O
limited	O	O	O
to	O	O	O
passive	O	O	B-Entity
products	O	O	O
of	O	O	O
cellular	O	O	B-Entity
mineralization	O	O	B-Entity
.	O	O	O

-DOCSTART- (27745773)

Is	O	O	O
the	O	O	O
inactivation	O	O	B-Entity
of	O	O	O
dentin	O	O	B-Entity
proteases	O	O	B-Entity
by	O	O	O
crosslinkers	O	O	B-Entity
reversible	O	O	B-Entity
?	O	O	O

Inactivation	O	O	B-Entity
of	O	O	O
dentin	O	O	B-Entity
proteases	O	O	B-Entity
by	O	O	O
crosslinkers	O	O	B-Entity
has	O	O	O
been	O	O	O
suggested	O	O	B-Entity
as	O	O	O
a	O	O	O
way	O	O	O
to	O	O	O
prevent	O	O	B-Entity
the	O	O	O
degradation	O	O	B-Entity
of	O	O	O
dentin	O	O	O
collagen	O	O	B-Entity
in	O	O	O
the	O	O	O
hybrid	O	O	B-Entity
layer	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
not	O	O	B-Entity
known	O	O	I-Entity
if	O	O	O
the	O	O	O
inhibition	O	O	B-Entity
is	O	O	O
reversible	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
inactivation	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
various	O	O	O
crosslinkers	O	O	B-Entity
on	O	O	O
dentin	O	O	B-Entity
protease	O	O	B-Entity
activity	O	O	B-Entity
over	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	O
6	O	O	O
months	O	O	O
.	O	O	O

Demineralized	O	O	B-Entity
dentin	O	O	I-Entity
beams	O	O	I-Entity
(	O	O	O
1	O	O	O
×	O	O	O
2	O	O	O
×	O	O	O
6	O	O	O
mm	O	O	O
,	O	O	O
n=10/group	O	O	O
)	O	O	O
were	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
(	O	O	O
1	O	O	O
)	O	O	O
1	O	O	O
%	O	O	O
glutaraldehyde	O	O	B-Entity
(	O	O	O
GA1	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
5	O	O	O
%	O	O	O
glutaraldehyde	O	O	O
(	O	O	O
GA5	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
1	O	O	O
%	O	O	O
grape	O	O	B-Entity
seed	O	O	I-Entity
extract	O	O	I-Entity
(	O	O	O
GS1	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
5	O	O	O
%	O	O	O
grape	O	O	O
seed	O	O	O
extract	O	O	O
(	O	O	O
GS5	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
5	O	O	O
)	O	O	O
10	O	O	O
%	O	O	O
sumac	O	O	B-Entity
berry	O	O	I-Entity
extract	O	O	I-Entity
(	O	O	O
S	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
6	O	O	O
)	O	O	O
20μM	O	O	B-Entity
curcumin	O	O	B-Entity
(	O	O	O
CR20	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
(	O	O	O
7	O	O	O
)	O	O	O
200μM	O	O	O
curcumin	O	O	O
(	O	O	O
CR200	O	O	B-Entity
)	O	O	O
for	O	O	O
5min	O	O	O
.	O	O	O

Untreated	O	O	B-Entity
beams	O	O	B-Entity
served	O	O	O
as	O	O	O
control	O	O	B-Entity
.	O	O	O

The	O	O	O
beams	O	O	B-Entity
were	O	O	O
incubated	O	O	B-Entity
up	O	O	O
to	O	O	O
6	O	O	O
months	O	O	O
and	O	O	O
incubation	O	O	B-Entity
media	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
analyze	O	O	B-Entity
solubilized	O	O	B-Entity
telopeptide	O	O	B-Entity
(	O	O	O
ICTP	O	O	B-Entity
and	O	O	O
CTX	O	O	B-Entity
)	O	O	O
fragments	O	O	B-Entity
as	O	O	O
indicators	O	O	B-Entity
of	O	O	O
MMP	O	O	B-Entity
-	O	O	O
and	O	O	O
cathepsin	O	O	B-Entity
K	O	O	I-Entity
-mediated	O	O	O
degradation	O	O	B-Entity
after	O	O	O
1	O	O	O
,	O	O	O
3	O	O	O
and	O	O	O
6	O	O	O
months	O	O	O
of	O	O	O
incubation	O	O	O
.	O	O	O

The	O	O	O
relative	O	O	B-Entity
MMP	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
dentin	O	O	B-Entity
beams	O	O	I-Entity
was	O	O	O
tested	O	O	O
using	O	O	O
a	O	O	O
generic	O	O	B-Entity
MMP	O	O	O
assay	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
repeated-measures	O	O	B-Entity
ANOVA	O	O	B-Entity
,	O	O	O
α=0.05	O	O	O
.	O	O	O

All	O	O	O
treated	O	O	B-Entity
groups	O	O	B-Entity
showed	O	O	O
significant	O	O	B-Entity
decrease	O	O	B-Entity
in	O	O	O
CTX	O	O	B-Entity
release	O	O	O
(	O	O	O
32.2	O	O	O
-	O	O	O
469.5pg/mg	O	O	O
dentin	O	O	B-Entity
)	O	O	O
and	O	O	O
ICTP	O	O	B-Entity
(	O	O	O
1.8	O	O	O
-	O	O	O
47.6ng/mg	O	O	O
dentin	O	O	O
)	O	O	O
fragments	O	O	B-Entity
during	O	O	O
the	O	O	O
first	O	O	O
month	O	O	O
of	O	O	O
incubation	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
(	O	O	O
1159pg/mg	O	O	O
and	O	O	O
72.9ng/mg	O	O	O
dentin	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

GA5	O	O	B-Entity
,	O	O	O
GS5	O	O	B-Entity
and	O	O	O
CR200	O	O	B-Entity
maintained	O	O	B-Entity
their	O	O	O
inhibitory	O	O	B-Entity
effect	O	O	B-Entity
during	O	O	O
6-month	O	O	O
incubation	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
were	O	O	O
confirmed	O	O	O
by	O	O	O
dry	O	O	B-Entity
mass	O	O	I-Entity
loss	O	O	I-Entity
and	O	O	O
relative	O	O	B-Entity
MMP	O	O	B-Entity
activity	O	O	B-Entity
following	O	O	O
6	O	O	O
months	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
indicate	O	O	O
that	O	O	O
the	O	O	O
long-term	O	O	B-Entity
effect	O	O	I-Entity
is	O	O	O
both	O	O	O
crosslinker	O	O	B-Entity
and	O	O	O
dose	O	O	B-Entity
dependent	O	O	I-Entity
.	O	O	O

-DOCSTART- (27752082)

Inhibition	O	O	B-Entity
of	O	O	O
STEP61	O	O	B-Entity
ameliorates	O	O	B-Entity
deficits	O	O	B-Entity
in	O	O	O
mouse	O	O	B-Entity
and	O	O	O
hiPSC	O	O	B-Entity
-based	O	O	O
schizophrenia	O	O	B-Entity
models	O	O	O

The	O	O	O
brain	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
tyrosine	O	O	B-Entity
phosphatase	O	O	I-Entity
,	O	O	O
STEP	O	O	B-Entity
(	O	O	O
STriatal-Enriched	O	O	B-Entity
protein	O	O	I-Entity
tyrosine	O	O	I-Entity
Phosphatase	O	O	I-Entity
)	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
regulator	O	O	B-Entity
of	O	O	O
synaptic	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

STEP	O	O	B-Entity
normally	O	O	O
opposes	O	O	O
synaptic	O	O	B-Entity
strengthening	O	O	B-Entity
by	O	O	O
increasing	O	O	B-Entity
N-methyl	O	O	B-Entity
D-aspartate	O	O	I-Entity
glutamate	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	O
NMDAR	O	O	B-Entity
)	O	O	O
internalization	O	O	B-Entity
through	O	O	O
dephosphorylation	O	O	B-Entity
of	O	O	O
GluN2B	O	O	B-Entity
and	O	O	O
inactivation	O	O	B-Entity
of	O	O	O
the	O	O	O
kinases	O	O	B-Entity
extracellular	O	O	B-Entity
signal-regulated	O	O	I-Entity
kinase	O	O	I-Entity
1	O	O	I-Entity
/	O	O	O
2	O	O	B-Entity
and	O	O	O
Fyn	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
STEP61	O	O	B-Entity
is	O	O	O
elevated	O	O	B-Entity
in	O	O	O
the	O	O	O
cortex	O	O	B-Entity
in	O	O	O
the	O	O	O
Nrg1(+/-	O	O	B-Entity
)	O	O	I-Entity
knockout	O	O	B-Entity
mouse	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
schizophrenia	O	O	B-Entity
(	O	O	O
SZ	O	O	B-Entity
)	O	O	O
.	O	O	O

Genetic	O	O	B-Entity
reduction	O	O	B-Entity
or	O	O	O
pharmacological	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
STEP	O	O	B-Entity
prevents	O	O	B-Entity
the	O	O	O
loss	O	O	O
of	O	O	O
NMDARs	O	O	B-Entity
from	O	O	O
synaptic	O	O	B-Entity
membranes	O	O	I-Entity
and	O	O	O
reverses	O	O	O
behavioral	O	O	B-Entity
deficits	O	O	I-Entity
in	O	O	O
Nrg1(+/-	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	B-Entity
.	O	O	O

STEP61	O	O	B-Entity
protein	O	O	I-Entity
is	O	O	O
also	O	O	O
increased	O	O	B-Entity
in	O	O	O
cortical	O	O	B-Entity
lysates	O	O	B-Entity
from	O	O	O
the	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
-	O	O	O
specific	O	O	B-Entity
ErbB2	O	O	B-Entity
/	O	O	O
4	O	O	B-Entity
mouse	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
SZ	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
human	O	O	B-Entity
induced	O	O	B-Entity
pluripotent	O	O	I-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
(hiPSC)-derived	O	O	O
forebrain	O	O	B-Entity
neurons	O	O	B-Entity
and	O	O	O
Ngn2	O	O	B-Entity
-	O	O	O
induced	O	O	O
excitatory	O	O	B-Entity
neurons	O	O	I-Entity
,	O	O	O
from	O	O	O
two	O	O	O
independent	O	O	B-Entity
SZ	O	O	O
patient	O	O	B-Entity
cohorts	O	O	B-Entity
.	O	O	O

In	O	O	O
these	O	O	O
selected	O	O	B-Entity
SZ	O	O	B-Entity
models	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
STEP61	O	O	B-Entity
protein	O	O	B-Entity
levels	O	O	I-Entity
likely	O	O	O
reflect	O	O	O
reduced	O	O	B-Entity
ubiquitination	O	O	B-Entity
and	O	O	O
degradation	O	O	B-Entity
.	O	O	O

These	O	O	O
convergent	O	O	B-Entity
findings	O	O	B-Entity
from	O	O	O
mouse	O	O	B-Entity
and	O	O	O
hiPSC	O	O	B-Entity
SZ	O	O	B-Entity
models	O	O	B-Entity
provide	O	O	B-Entity
evidence	O	O	B-Entity
for	O	O	O
STEP61	O	O	B-Entity
dysfunction	O	O	B-Entity
in	O	O	O
SZ	O	O	O
.Molecular	O	O	O
Psychiatry	O	O	O
advance	O	O	O
online	O	O	O
publication	O	O	O
,	O	O	O
18	O	O	O
October	O	O	O
2016	O	O	O
;	O	O	O
doi:10.1038/mp.2016.163	O	O	O
.	O	O	O

-DOCSTART- (27752744)

Incident	O	O	B-Entity
fracture	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
even	O	O	O
after	O	O	O
adjusting	O	O	O
for	O	O	O
frailty	O	O	B-Entity
status	O	O	B-Entity
in	O	O	O
elderly	O	O	B-Entity
Japanese	O	O	B-Entity
men	O	O	B-Entity
:	O	O	O
the	O	O	O
Fujiwara-kyo	O	O	O
Osteoporosis	O	O	O
Risk	O	O	O
in	O	O	O
Men	O	O	O
(	O	O	O
FORMEN	O	O	O
)	O	O	O
Cohort	O	O	O
Study	O	O	O

Frail	O	O	B-Entity
elderly	O	O	B-Entity
individuals	O	O	B-Entity
have	O	O	O
elevated	O	O	B-Entity
risks	O	O	B-Entity
of	O	O	O
both	O	O	O
fracture	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
incident	O	O	B-Entity
fractures	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
death	O	O	B-Entity
even	O	O	O
after	O	O	O
adjusting	O	O	O
for	O	O	O
pre-fracture	O	O	B-Entity
frailty	O	O	B-Entity
status	O	O	B-Entity
as	O	O	O
represented	O	O	O
by	O	O	O
physical	O	O	B-Entity
performance	O	O	I-Entity
tests	O	O	I-Entity
and	O	O	O
laboratory	O	O	B-Entity
tests	O	O	I-Entity
for	O	O	O
common	O	O	O
geriatric	O	O	B-Entity
diseases	O	O	B-Entity
in	O	O	O
community-dwelling	O	O	B-Entity
elderly	O	O	B-Entity
Japanese	O	O	B-Entity
men	O	O	B-Entity
.	O	O	O

While	O	O	O
fractures	O	O	B-Entity
reportedly	O	O	O
increase	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
mortality	O	O	B-Entity
,	O	O	O
frailty	O	O	B-Entity
may	O	O	O
complicate	O	O	B-Entity
this	O	O	O
association	O	O	B-Entity
,	O	O	O
generating	O	O	O
a	O	O	O
false-positive	O	O	B-Entity
result	O	O	I-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
this	O	O	O
association	O	O	B-Entity
after	O	O	O
adjusting	O	O	O
for	O	O	O
pre-fracture	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
frailty	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	B-Entity
1998	O	O	O
community-dwelling	O	O	B-Entity
ambulatory	O	O	B-Entity
men	O	O	B-Entity
aged	O	O	B-Entity
≥65	O	O	O
years	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
in	O	O	O
the	O	O	O
Fujiwara-kyo	O	O	B-Entity
Osteoporosis	O	O	I-Entity
Risk	O	O	I-Entity
in	O	O	I-Entity
Men	O	O	I-Entity
Study	O	O	I-Entity
for	O	O	O
frailty	O	O	B-Entity
status	O	O	B-Entity
as	O	O	O
represented	O	O	O
by	O	O	O
activities	O	O	B-Entity
of	O	O	I-Entity
daily	O	O	I-Entity
living	O	O	I-Entity
(	O	O	O
ADL	O	O	B-Entity
)	O	O	O
,	O	O	O
physical	O	O	B-Entity
performance	O	O	I-Entity
tests	O	O	I-Entity
(	O	O	O
grip	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
one-foot	O	O	B-Entity
standing	O	O	I-Entity
balance	O	O	I-Entity
with	O	O	I-Entity
eyes	O	O	I-Entity
open	O	O	I-Entity
,	O	O	O
timed	O	O	B-Entity
10-m	O	O	I-Entity
walk	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
laboratory	O	O	B-Entity
sera	O	O	B-Entity
tests	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
then	O	O	O
followed	O	O	O
for	O	O	O
5	O	O	O
years	O	O	B-Entity
for	O	O	O
incident	O	O	B-Entity
clinical	O	O	B-Entity
fractures	O	O	B-Entity
and	O	O	O
death	O	O	B-Entity
.	O	O	O

Effects	O	O	B-Entity
of	O	O	I-Entity
incident	O	O	B-Entity
fracture	O	O	B-Entity
on	O	O	O
death	O	O	B-Entity
were	O	O	O
determined	O	O	O
by	O	O	O
Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazards	O	O	I-Entity
model	O	O	I-Entity
with	O	O	O
the	O	O	O
first	O	O	O
fracture	O	O	O
during	O	O	O
follow-up	O	O	B-Entity
as	O	O	O
a	O	O	O
time-dependent	O	O	B-Entity
predictor	O	O	I-Entity
and	O	O	O
with	O	O	O
frailty	O	O	B-Entity
status	O	O	I-Entity
indices	O	O	I-Entity
as	O	O	O
covariates	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
111	O	O	O
fractures	O	O	B-Entity
in	O	O	O
99	O	O	O
men	O	O	B-Entity
and	O	O	O
138	O	O	O
deaths	O	O	B-Entity
during	O	O	O
the	O	O	O
follow-up	O	O	B-Entity
period	O	O	B-Entity
(	O	O	O
median	O	O	B-Entity
follow-up	O	O	O
,	O	O	O
4.5	O	O	O
years	O	O	B-Entity
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
with	O	O	O
incident	O	O	B-Entity
fractures	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
have	O	O	I-Entity
significantly	O	O	B-Entity
worse	O	O	I-Entity
frailty	O	O	B-Entity
statuses	O	O	B-Entity
,	O	O	O
but	O	O	O
did	O	O	O
show	O	O	O
a	O	O	O
significantly	O	O	O
higher	O	O	B-Entity
cumulative	O	O	B-Entity
mortality	O	O	B-Entity
rate	O	O	I-Entity
than	O	O	O
those	O	O	O
without	O	O	O
fractures	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.0047	O	O	O
)	O	O	O
.	O	O	O

Age-adjusted	O	O	B-Entity
hazard	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
)	O	O	O
of	O	O	O
death	O	O	B-Entity
for	O	O	O
incident	O	O	B-Entity
fracture	O	O	B-Entity
was	O	O	O
3.57	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
:	O	O	O
2.05	O	O	O
,	O	O	O
6.24	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
adjusted	O	O	O
for	O	O	O
physical	O	O	B-Entity
performance	O	O	I-Entity
,	O	O	O
this	O	O	O
decreased	O	O	B-Entity
to	O	O	O
2.77	O	O	O
(	O	O	O
1.51	O	O	O
,	O	O	O
5.06	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
remained	O	O	O
significant	O	O	B-Entity
.	O	O	O

The	O	O	O
HR	O	O	B-Entity
showed	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
change	O	O	I-Entity
when	O	O	O
adjusted	O	O	O
for	O	O	O
laboratory	O	O	B-Entity
test	O	O	I-Entity
results	O	O	I-Entity
(	O	O	O
3.96	O	O	O
(	O	O	O
2.26	O	O	O
,	O	O	O
6.94	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

Exclusion	O	O	B-Entity
of	O	O	O
deaths	O	O	B-Entity
within	O	O	O
the	O	O	O
first	O	O	O
24	O	O	O
months	O	O	B-Entity
of	O	O	O
follow-up	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
alter	O	O	I-Entity
these	O	O	O
results	O	O	B-Entity
.	O	O	O

Incident	O	O	B-Entity
clinical	O	O	B-Entity
fracture	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
elevated	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
death	O	O	B-Entity
independently	O	O	B-Entity
of	O	O	O
pre-fracture	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
frailty	O	O	B-Entity
in	O	O	O
community-dwelling	O	O	B-Entity
elderly	O	O	B-Entity
men	O	O	B-Entity
.	O	O	O

-DOCSTART- (27754397)

Total	O	O	B-Entity
Energy	O	O	I-Entity
Expenditure	O	O	I-Entity
in	O	O	O
Obese	O	O	B-Entity
Kuwaiti	O	O	B-Entity
Primary	O	O	I-Entity
School	O	O	I-Entity
Children	O	O	B-Entity
Assessed	O	O	B-Entity
by	O	O	O
the	O	O	O
Doubly-Labeled	O	O	O
Water	O	O	O
Technique	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
assess	O	O	B-Entity
body	O	O	O
composition	O	O	O
and	O	O	O
total	O	O	B-Entity
energy	O	O	I-Entity
expenditure	O	O	I-Entity
(	O	O	O
TEE	O	O	B-Entity
)	O	O	O
in	O	O	O
35	O	O	O
obese	O	O	B-Entity
7	O	O	O
-	O	O	O
9	O	O	O
years	O	O	B-Entity
old	O	O	O
Kuwaiti	O	O	B-Entity
children	O	O	B-Entity
(	O	O	O
18	O	O	O
girls	O	O	B-Entity
and	O	O	O
17	O	O	O
boys	O	O	B-Entity
)	O	O	O
.	O	O	O

Total	O	O	B-Entity
body	O	O	I-Entity
water	O	O	I-Entity
(	O	O	O
TBW	O	O	B-Entity
)	O	O	O
and	O	O	O
TEE	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
by	O	O	O
doubly-labeled	O	O	B-Entity
water	O	O	I-Entity
technique	O	O	I-Entity
.	O	O	O

TBW	O	O	B-Entity
was	O	O	O
derived	O	O	O
from	O	O	O
the	O	O	O
intercept	O	O	B-Entity
of	O	O	O
the	O	O	O
elimination	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
deuterium	O	O	B-Entity
and	O	O	O
TEE	O	O	B-Entity
from	O	O	O
the	O	O	O
difference	O	O	B-Entity
in	O	O	O
elimination	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
(18)O	O	O	B-Entity
and	O	O	O
deuterium	O	O	O
.	O	O	O

TBW	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	B-Entity
fat-free	O	O	B-Entity
mass	O	O	I-Entity
(	O	O	O
FFM	O	O	B-Entity
)	O	O	O
,	O	O	O
using	O	O	O
hydration	O	O	B-Entity
factors	O	O	B-Entity
for	O	O	O
different	O	O	O
ages	O	O	B-Entity
and	O	O	O
gender	O	O	B-Entity
.	O	O	O

Fat	O	O	B-Entity
mass	O	O	I-Entity
(	O	O	O
FM	O	O	B-Entity
)	O	O	O
was	O	O	O
calculated	O	O	B-Entity
as	O	O	O
the	O	O	O
difference	O	O	B-Entity
between	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
FFM	O	O	B-Entity
.	O	O	O

Body	O	O	B-Entity
weight	O	O	I-Entity
was	O	O	O
not	O	O	O
statistically	O	O	B-Entity
different	O	O	I-Entity
but	O	O	O
TBW	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.018	O	O	O
)	O	O	O
in	O	O	O
boys	O	O	B-Entity
(	O	O	O
44.9	O	O	O
%	O	O	O
±	O	O	O
3.3	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
girls	O	O	B-Entity
(	O	O	O
42.4	O	O	O
%	O	O	O
±	O	O	O
3.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
girls	O	O	O
had	O	O	O
significantly	O	O	O
higher	O	O	O
estimated	O	O	B-Entity
FM	O	O	B-Entity
(	O	O	O
45.2	O	O	O
±	O	O	O
3.9	O	O	O
weight	O	O	O
%	O	O	O
versus	O	O	O
41.6	O	O	O
%	O	O	O
±	O	O	O
4.3	O	O	O
%	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.014	O	O	O
)	O	O	O
.	O	O	O

TEE	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
boys	O	O	B-Entity
(	O	O	O
2395	O	O	O
±	O	O	O
349	O	O	O
kcal/day	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
girls	O	O	B-Entity
(	O	O	O
1978	O	O	O
±	O	O	O
169	O	O	O
kcal/day	O	O	O
)	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
.	O	O	O

Estimated	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
level	O	O	I-Entity
(	O	O	O
PAL	O	O	B-Entity
)	O	O	O
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
boys	O	O	B-Entity
;	O	O	O
1.61	O	O	O
±	O	O	O
0.167	O	O	O
versus	O	O	O
1.51	O	O	O
±	O	O	O
0.870	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.034	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
provide	O	O	O
the	O	O	O
first	O	O	O
dataset	O	O	B-Entity
of	O	O	O
TEE	O	O	B-Entity
in	O	O	O
7	O	O	O
-	O	O	O
9	O	O	O
years	O	O	B-Entity
old	O	O	O
obese	O	O	B-Entity
Kuwaiti	O	O	B-Entity
children	O	O	B-Entity
and	O	O	O
highlight	O	O	O
important	O	O	O
gender	O	O	B-Entity
differences	O	O	I-Entity
to	O	O	O
be	O	O	O
considered	O	O	O
during	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
school	O	O	B-Entity
based	O	O	I-Entity
interventions	O	O	I-Entity
targeted	O	O	O
to	O	O	O
combat	O	O	O
childhood	O	O	B-Entity
obesity	O	O	I-Entity
.	O	O	O

-DOCSTART- (27755168)

Mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
clinical	O	O	B-Entity
kidney	O	O	B-Entity
transplantation	O	O	I-Entity
:	O	O	O
how	O	O	O
tolerant	O	O	B-Entity
can	O	O	O
it	O	O	O
be	O	O	O
?	O	O	O

Progress	O	O	B-Entity
in	O	O	O
the	O	O	O
improvement	O	O	B-Entity
of	O	O	O
short-term	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
outcomes	O	O	B-Entity
of	O	O	O
kidney	O	O	B-Entity
transplantation	O	O	I-Entity
seems	O	O	O
to	O	O	O
have	O	O	O
reached	O	O	O
a	O	O	O
plateau	O	O	B-Entity
,	O	O	O
partially	O	O	O
due	O	O	O
to	O	O	O
consequences	O	O	B-Entity
of	O	O	I-Entity
very	O	O	O
efficient	O	O	B-Entity
,	O	O	O
but	O	O	O
nonspecific	O	O	B-Entity
immunosuppressive	O	O	B-Entity
drugs	O	O	I-Entity
.	O	O	O

In	O	O	O
recent	O	O	O
years	O	O	O
,	O	O	O
various	O	O	O
forms	O	O	O
of	O	O	O
cell	O	O	B-Entity
therapy	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
have	O	O	O
been	O	O	O
put	O	O	O
forward	O	O	O
as	O	O	O
an	O	O	O
alternative	O	O	B-Entity
strategy	O	O	B-Entity
for	O	O	O
more	O	O	O
defined	O	O	O
therapy	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
thought	O	O	O
that	O	O	O
these	O	O	O
therapies	O	O	B-Entity
will	O	O	O
not	O	O	O
only	O	O	O
allow	O	O	O
controlled	O	O	B-Entity
tapering	O	O	B-Entity
of	O	O	O
immunosuppressive	O	O	B-Entity
medication	O	O	I-Entity
,	O	O	O
but	O	O	O
might	O	O	O
bring	O	O	O
us	O	O	O
also	O	O	O
closer	O	O	O
to	O	O	O
the	O	O	O
ambition	O	O	B-Entity
of	O	O	O
generating	O	O	B-Entity
donor	O	O	B-Entity
-specific	O	O	O
immune	O	O	B-Entity
regulation	O	O	I-Entity
and	O	O	O
tolerance	O	O	B-Entity
.	O	O	O

Different	O	O	O
forms	O	O	O
of	O	O	O
alloimmunity	O	O	B-Entity
,	O	O	O
including	O	O	O
direct	O	O	B-Entity
,	O	O	O
indirect	O	O	B-Entity
and	O	O	O
semi-direct	O	O	B-Entity
alloantigen	O	O	B-Entity
presentation	O	O	O
have	O	O	O
to	O	O	O
be	O	O	O
controlled	O	O	O
before	O	O	O
donor	O	O	B-Entity
-specific	O	O	O
immune	O	O	B-Entity
regulation	O	O	I-Entity
can	O	O	O
be	O	O	O
reached	O	O	O
.	O	O	O

Several	O	O	O
mechanisms	O	O	B-Entity
have	O	O	O
been	O	O	O
described	O	O	O
how	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
can	O	O	O
affect	O	O	O
alloimmunity	O	O	B-Entity
.	O	O	O

Especially	O	O	O
,	O	O	O
the	O	O	O
interaction	O	O	B-Entity
with	O	O	O
professional	O	O	O
antigen	O	O	B-Entity
presenting	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
like	O	O	O
dendritic	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
is	O	O	O
of	O	O	O
critical	O	O	B-Entity
importance	O	O	B-Entity
.	O	O	O

This	O	O	O
review	O	O	O
will	O	O	O
discuss	O	O	O
the	O	O	O
current	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
ongoing	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
with	O	O	O
mesenchymal	O	O	B-Entity
stromal	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
kidney	O	O	B-Entity
transplantation	O	O	I-Entity
and	O	O	O
specifically	O	O	O
concentrate	O	O	O
on	O	O	O
the	O	O	O
possibilities	O	O	O
and	O	O	O
impossibilities	O	O	O
of	O	O	O
how	O	O	O
these	O	O	O
therapeutic	O	O	B-Entity
strategies	O	O	I-Entity
can	O	O	O
contribute	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
of	O	O	O
the	O	O	O
different	O	O	O
forms	O	O	O
of	O	O	O
alloreactivity	O	O	B-Entity
operation	O	O	O
in	O	O	O
organ	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

-DOCSTART- (27760552)

Facilitating	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
barriers	O	O	B-Entity
to	O	O	O
malaria	O	O	B-Entity
research	O	O	B-Entity
utilization	O	O	B-Entity
for	O	O	O
policy	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
Malawi	O	O	O

Research	O	O	B-Entity
on	O	O	O
various	O	O	O
determinants	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
is	O	O	O
key	O	O	O
in	O	O	O
providing	O	O	B-Entity
evidence	O	O	B-Entity
for	O	O	O
policy	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
thereby	O	O	O
leading	O	O	O
to	O	O	O
successful	O	O	B-Entity
interventions	O	O	O
.	O	O	O

Utilization	O	O	B-Entity
of	O	O	O
research	O	O	B-Entity
is	O	O	O
an	O	O	O
intricate	O	O	B-Entity
process	O	O	B-Entity
requiring	O	O	O
an	O	O	O
understanding	O	O	O
of	O	O	O
contextual	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	O
was	O	O	O
conducted	O	O	O
to	O	O	O
assess	O	O	O
enhancing	O	O	B-Entity
factors	O	O	B-Entity
and	O	O	O
barriers	O	O	B-Entity
of	O	O	O
research	O	O	B-Entity
utilization	O	O	B-Entity
for	O	O	O
malaria	O	O	B-Entity
policy	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
Malawi	O	O	B-Entity
.	O	O	O

Qualitative	O	O	B-Entity
research	O	O	B-Entity
approach	O	O	O
was	O	O	O
used	O	O	O
through	O	O	O
in-depth	O	O	O
interviews	O	O	B-Entity
with	O	O	O
39	O	O	O
key	O	O	O
informants	O	O	B-Entity
that	O	O	O
included	O	O	O
malaria	O	O	B-Entity
researchers	O	O	B-Entity
,	O	O	O
policy	O	O	B-Entity
makers	O	O	I-Entity
,	O	O	O
programme	O	O	B-Entity
managers	O	O	B-Entity
,	O	O	O
and	O	O	O
key	O	O	B-Entity
stakeholders	O	O	I-Entity
.	O	O	O

Purposive	O	O	B-Entity
sampling	O	O	I-Entity
and	O	O	O
snowballing	O	O	B-Entity
techniques	O	O	I-Entity
were	O	O	O
used	O	O	O
in	O	O	O
identifying	O	O	B-Entity
key	O	O	O
informants	O	O	B-Entity
.	O	O	O

Interview	O	O	B-Entity
transcripts	O	O	B-Entity
were	O	O	O
entered	O	O	B-Entity
in	O	O	O
QSR	O	O	B-Entity
Nvivo	O	O	I-Entity
11	O	O	I-Entity
software	O	O	I-Entity
for	O	O	O
coding	O	O	O
and	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Respondents	O	O	B-Entity
identified	O	O	B-Entity
global	O	O	B-Entity
efforts	O	O	B-Entity
as	O	O	O
key	O	O	O
in	O	O	O
advancing	O	O	O
knowledge	O	O	B-Entity
translation	O	O	I-Entity
,	O	O	O
while	O	O	O
local	O	O	B-Entity
political	O	O	B-Entity
will	O	O	I-Entity
has	O	O	O
been	O	O	O
conducive	O	O	B-Entity
for	O	O	O
research	O	O	B-Entity
utilization	O	O	B-Entity
.	O	O	O

Other	O	O	O
factors	O	O	B-Entity
were	O	O	O
availability	O	O	B-Entity
of	O	O	I-Entity
research	O	O	B-Entity
,	O	O	O
availability	O	O	O
of	O	O	O
diverse	O	O	O
local	O	O	B-Entity
researchers	O	O	B-Entity
and	O	O	O
stakeholders	O	O	B-Entity
supporting	O	O	B-Entity
knowledge	O	O	B-Entity
translation	O	O	I-Entity
.	O	O	O

While	O	O	O
barriers	O	O	B-Entity
included	O	O	O
:	O	O	O
lack	O	O	B-Entity
of	O	O	O
platforms	O	O	O
for	O	O	O
researcher	O	O	B-Entity
-	O	O	O
public	O	O	B-Entity
engagement	O	O	B-Entity
,	O	O	O
politics	O	O	B-Entity
,	O	O	O
researchers	O	O	B-Entity
'	O	O	I-Entity
lack	O	O	O
of	O	O	O
communication	O	O	B-Entity
skills	O	O	I-Entity
,	O	O	O
lack	O	O	O
of	O	O	O
research	O	O	B-Entity
collaborations	O	O	B-Entity
,	O	O	O
funder	O	O	B-Entity
driven	O	O	I-Entity
research	O	O	I-Entity
,	O	O	O
unknown	O	O	B-Entity
World	O	O	B-Entity
Health	O	O	I-Entity
Organization	O	O	I-Entity
policy	O	O	B-Entity
position	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
lack	O	O	O
of	O	O	O
a	O	O	O
malaria	O	O	B-Entity
research	O	O	O
repository	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
the	O	O	O
study	O	O	O
identified	O	O	B-Entity
facilitating	O	O	B-Entity
factors	O	O	I-Entity
to	O	O	O
malaria	O	O	B-Entity
research	O	O	B-Entity
utilization	O	O	B-Entity
for	O	O	O
policy	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
Malawi	O	O	B-Entity
.	O	O	O

These	O	O	O
factors	O	O	B-Entity
need	O	O	O
to	O	O	O
be	O	O	O
systematically	O	O	B-Entity
coordinated	O	O	B-Entity
to	O	O	O
address	O	O	O
the	O	O	O
identified	O	O	B-Entity
barriers	O	O	B-Entity
and	O	O	O
improve	O	O	B-Entity
on	O	O	O
malaria	O	O	B-Entity
research	O	O	B-Entity
utilization	O	O	B-Entity
in	O	O	O
policy	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

Malaria	O	O	B-Entity
research	O	O	B-Entity
can	O	O	O
be	O	O	O
key	O	O	O
in	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
evidence-based	O	O	B-Entity
interventions	O	O	O
to	O	O	O
reduce	O	O	B-Entity
the	O	O	O
malaria	O	O	B-Entity
burden	O	O	B-Entity
and	O	O	O
assist	O	O	O
in	O	O	O
the	O	O	O
paradigm	O	O	B-Entity
shift	O	O	I-Entity
from	O	O	O
malaria	O	O	O
control	O	O	B-Entity
to	O	O	O
elimination	O	O	B-Entity
in	O	O	O
Malawi	O	O	B-Entity
.	O	O	O

-DOCSTART- (27760700)

Altered	O	O	B-Entity
interregional	O	O	B-Entity
correlations	O	O	B-Entity
between	O	O	O
serotonin	O	O	B-Entity
transporter	O	O	I-Entity
availability	O	O	B-Entity
and	O	O	O
cerebral	O	O	B-Entity
glucose	O	O	B-Entity
metabolism	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
:	O	O	O
A	O	O	O
high-resolution	O	O	B-Entity
PET	O	O	I-Entity
study	O	O	O
using	O	O	O
[(11)C]DASB	O	O	B-Entity
and	O	O	O
[(18)F]FDG	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
patterns	O	O	O
of	O	O	O
interregional	O	O	B-Entity
correlations	O	O	B-Entity
of	O	O	O
serotonin	O	O	B-Entity
transporter	O	O	I-Entity
(	O	O	O
SERT	O	O	B-Entity
)	O	O	O
availability	O	O	B-Entity
with	O	O	O
glucose	O	O	B-Entity
metabolism	O	O	I-Entity
using	O	O	O
7-Tesla	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
and	O	O	O
high-resolution	O	O	B-Entity
positron	O	O	I-Entity
emission	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
PET	O	O	B-Entity
)	O	O	O
with	O	O	O
(11)C-3-amino-4-(2-dimethylaminomethylphenylthio)benzonitrile	O	O	B-Entity
(	O	O	O
[(11)C]DASB	O	O	B-Entity
)	O	O	O
and	O	O	O
[(18)F]fluorodeoxyglucose	O	O	B-Entity
(	O	O	O
[(18)F]FDG	O	O	B-Entity
)	O	O	O
in	O	O	O
antipsychotic-free	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
shed	O	O	O
new	O	O	O
light	O	O	O
on	O	O	O
the	O	O	O
disrupted	O	O	B-Entity
functional	O	O	B-Entity
connectivity	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	O
.	O	O	O

Nineteen	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
and	O	O	O
18	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
underwent	O	O	O
high-resolution	O	O	B-Entity
PET	O	O	I-Entity
and	O	O	O
MRI	O	O	B-Entity
.	O	O	O

The	O	O	O
binding	O	O	B-Entity
potential	O	O	I-Entity
(	O	O	O
BPND	O	O	B-Entity
)	O	O	O
of	O	O	O
[(11)C]DASB	O	O	B-Entity
and	O	O	O
standardized	O	O	B-Entity
uptake	O	O	I-Entity
value	O	O	I-Entity
ratio	O	O	I-Entity
(	O	O	O
SUVR	O	O	B-Entity
)	O	O	O
of	O	O	O
[(18)F]FDG	O	O	B-Entity
were	O	O	O
obtained	O	O	O
.	O	O	O

In	O	O	O
SERT	O	O	B-Entity
availability	O	O	B-Entity
,	O	O	O
the	O	O	O
region	O	O	B-Entity
of	O	O	I-Entity
interest	O	O	I-Entity
(ROI)-based	O	O	O
analyses	O	O	B-Entity
showed	O	O	O
no	O	O	O
significant	O	O	O
group	O	O	O
differences	O	O	O
in	O	O	O
any	O	O	O
region	O	O	O
,	O	O	O
except	O	O	O
for	O	O	O
the	O	O	O
anterior	O	O	B-Entity
hippocampus	O	O	B-Entity
where	O	O	O
the	O	O	O
SERT	O	O	O
availability	O	O	O
was	O	O	O
lower	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
than	O	O	O
in	O	O	O
controls	O	O	B-Entity
.	O	O	O

The	O	O	O
ROI	O	O	B-Entity
-	O	O	O
and	O	O	O
voxel	O	O	B-Entity
-based	O	O	O
analyses	O	O	B-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
[(18)F]FDG	O	O	B-Entity
SUVR	O	O	B-Entity
values	O	O	I-Entity
were	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
patients	O	O	B-Entity
than	O	O	O
in	O	O	O
controls	O	O	B-Entity
in	O	O	O
the	O	O	O
right	O	O	B-Entity
superior	O	O	I-Entity
frontal	O	O	I-Entity
gyrus	O	O	I-Entity
and	O	O	O
medial	O	O	B-Entity
part	O	O	I-Entity
of	O	O	O
the	O	O	O
left	O	O	B-Entity
superior	O	O	I-Entity
frontal	O	O	I-Entity
gyrus	O	O	I-Entity
.	O	O	O

Regarding	O	O	O
the	O	O	O
interregional	O	O	B-Entity
correlations	O	O	B-Entity
of	O	O	O
[(11)C]DASB	O	O	B-Entity
BPND	O	O	B-Entity
with	O	O	O
[(18)F]FDG	O	O	B-Entity
SUVR	O	O	B-Entity
,	O	O	O
more	O	O	O
widespread	O	O	O
positive	O	O	B-Entity
correlations	O	O	O
across	O	O	O
the	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
control	O	O	B-Entity
subjects	O	O	I-Entity
than	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
the	O	O	O
patients	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
subjects	O	O	I-Entity
showed	O	O	O
statistically	O	O	O
significant	O	O	O
differences	O	O	O
in	O	O	O
correlations	O	O	B-Entity
between	O	O	O
the	O	O	O
SERT	O	O	B-Entity
availability	O	O	B-Entity
in	O	O	O
the	O	O	O
parietal	O	O	B-Entity
and	O	O	O
temporal	O	O	B-Entity
cortices	O	O	I-Entity
and	O	O	O
the	O	O	O
glucose	O	O	B-Entity
metabolism	O	O	I-Entity
in	O	O	O
the	O	O	O
posterior	O	O	B-Entity
cingulate	O	O	I-Entity
cortex	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
abnormal	O	O	B-Entity
functional	O	O	B-Entity
connectivity	O	O	I-Entity
between	O	O	O
the	O	O	O
higher-order	O	O	B-Entity
cortical	O	O	I-Entity
regions	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
and	O	O	O
a	O	O	O
possible	O	O	O
important	O	O	O
role	O	O	B-Entity
of	O	O	O
the	O	O	O
posterior	O	O	B-Entity
cingulate	O	O	I-Entity
gyrus	O	O	I-Entity
and	O	O	O
its	O	O	O
related	O	O	O
circuitry	O	O	B-Entity
in	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
of	O	O	O
schizophrenia	O	O	O
.	O	O	O

-DOCSTART- (27761922)

Urticarial	O	O	B-Entity
exanthema	O	O	B-Entity
due	O	O	O
to	O	O	O
hepatitis	O	O	B-Entity
B	O	O	I-Entity
in	O	O	O
a	O	O	O
pregnant	O	O	B-Entity
woman	O	O	I-Entity
,	O	O	O
mimicking	O	O	O
a	O	O	O
polymorphic	O	O	B-Entity
eruption	O	O	I-Entity
of	O	O	O
pregnancy	O	O	O

Hepatitis	O	O	B-Entity
B	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	I-Entity
HBV	O	O	I-Entity
)	O	O	I-Entity
infection	O	O	I-Entity
in	O	O	I-Entity
pregnant	O	O	I-Entity
women	O	O	I-Entity
is	O	O	O
very	O	O	O
rare	O	O	O
in	O	O	O
western	O	O	B-Entity
countries	O	O	I-Entity
,	O	O	O
thus	O	O	O
,	O	O	O
cutaneous	O	O	B-Entity
manifestation	O	O	B-Entity
of	O	O	I-Entity
HBV	O	O	B-Entity
infection	O	O	I-Entity
may	O	O	O
be	O	O	O
confused	O	O	O
with	O	O	O
a	O	O	O
dermatosis	O	O	B-Entity
specific	O	O	O
of	O	O	O
pregnancy	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	O
a	O	O	O
39-year-old	O	O	O
woman	O	O	B-Entity
who	O	O	O
presented	O	O	O
in	O	O	O
her	O	O	O
20th	O	O	O
week	O	O	O
of	O	O	O
pregnancy	O	O	B-Entity
with	O	O	O
a	O	O	O
pruritic	O	O	B-Entity
rash	O	O	I-Entity
,	O	O	O
which	O	O	O
consisted	O	O	O
of	O	O	O
generalized	O	O	O
erythematous	O	O	B-Entity
plaques	O	O	I-Entity
,	O	O	O
some	O	O	O
of	O	O	O
them	O	O	O
with	O	O	O
a	O	O	O
purple	O	O	B-Entity
centre	O	O	I-Entity
.	O	O	O

Serology	O	O	B-Entity
testing	O	O	I-Entity
showed	O	O	O
acute	O	O	B-Entity
HBV	O	O	I-Entity
infection	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
biopsy	O	O	B-Entity
revealed	O	O	O
a	O	O	O
superficial	O	O	B-Entity
and	O	O	O
interstitial	O	O	B-Entity
perivascular	O	O	I-Entity
inflammatory	O	O	I-Entity
infiltrate	O	O	I-Entity
of	O	O	O
lymphocytes	O	O	B-Entity
and	O	O	O
eosinophils	O	O	B-Entity
.	O	O	O

A	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
exanthema	O	O	B-Entity
due	O	O	O
to	O	O	O
acute	O	O	B-Entity
hepatitis	O	O	I-Entity
B	O	O	I-Entity
infection	O	O	I-Entity
was	O	O	O
established	O	O	O
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
delivered	O	O	B-Entity
a	O	O	O
clinically	O	O	B-Entity
healthy	O	O	I-Entity
boy	O	O	I-Entity
,	O	O	O
who	O	O	O
was	O	O	O
given	O	O	O
the	O	O	O
first	O	O	B-Entity
dose	O	O	I-Entity
of	O	O	O
the	O	O	O
HBV	O	O	B-Entity
vaccine	O	O	I-Entity
and	O	O	O
intravenous	O	O	B-Entity
specific	O	O	I-Entity
immunoglobulin	O	O	I-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
second	O	O	B-Entity
dose	O	O	I-Entity
2	O	O	O
months	O	O	O
later	O	O	O
,	O	O	O
and	O	O	O
did	O	O	O
not	O	O	O
get	O	O	O
infected	O	O	B-Entity
with	O	O	O
HBV	O	O	O
.	O	O	O

To	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
this	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
case	O	O	O
describing	O	O	O
HBV	O	O	B-Entity
exanthema	O	O	B-Entity
in	O	O	O
a	O	O	O
pregnant	O	O	B-Entity
woman	O	O	I-Entity
,	O	O	O
which	O	O	O
led	O	O	O
to	O	O	O
early	O	O	O
action	O	O	O
for	O	O	O
the	O	O	O
newborn	O	O	B-Entity
,	O	O	O
avoiding	O	O	O
vertical	O	O	B-Entity
transmission	O	O	I-Entity
and	O	O	O
its	O	O	O
high	O	O	O
prevalence	O	O	O
of	O	O	O
cirrhosis	O	O	B-Entity
and	O	O	O
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
.	O	O	O

-DOCSTART- (27764829)

Determination	O	O	O
of	O	O	O
the	O	O	O
Mutant	O	O	B-Entity
Prevention	O	O	I-Entity
Concentration	O	O	I-Entity
and	O	O	O
the	O	O	O
Mutant	O	O	B-Entity
Selection	O	O	I-Entity
Window	O	O	I-Entity
of	O	O	O
Topical	O	O	B-Entity
Antimicrobial	O	O	I-Entity
Agents	O	O	I-Entity
against	O	O	O
Propionibacterium	O	O	O
acnes	O	O	O

Determination	O	O	O
of	O	O	O
the	O	O	O
mutant	O	O	B-Entity
prevention	O	O	I-Entity
concentration	O	O	I-Entity
(	O	O	O
MPC	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
mutant	O	O	B-Entity
selection	O	O	I-Entity
window	O	O	I-Entity
(	O	O	O
MSW	O	O	B-Entity
)	O	O	O
of	O	O	O
antimicrobial	O	O	B-Entity
agents	O	O	I-Entity
used	O	O	O
to	O	O	O
treat	O	O	O
pathogenic	O	O	B-Entity
bacteria	O	O	B-Entity
is	O	O	O
important	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
apply	O	O	O
effective	O	O	O
antimicrobial	O	O	O
therapies	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
determined	O	O	O
the	O	O	O
MPCs	O	O	B-Entity
of	O	O	O
the	O	O	O
major	O	O	O
topical	O	O	B-Entity
antimicrobial	O	O	I-Entity
agents	O	O	I-Entity
against	O	O	O
Propionibacterium	O	O	B-Entity
acnes	O	O	I-Entity
and	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
which	O	O	O
cause	O	O	O
skin	O	O	B-Entity
infections	O	O	I-Entity
and	O	O	O
compared	O	O	O
their	O	O	O
MSWs	O	O	B-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
MPCs	O	O	B-Entity
of	O	O	O
nadifloxacin	O	O	B-Entity
and	O	O	O
clindamycin	O	O	B-Entity
,	O	O	O
the	O	O	O
clindamycin	O	O	O
MPC	O	O	B-Entity
was	O	O	O
determined	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
lowest	O	O	B-Entity
against	O	O	O
P.	O	O	B-Entity
acnes	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
the	O	O	O
nadifloxacin	O	O	B-Entity
MPC	O	O	B-Entity
was	O	O	O
the	O	O	O
lowest	O	O	B-Entity
against	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
.	O	O	O

Calculations	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
minimum	O	O	B-Entity
inhibitory	O	O	I-Entity
concentrations	O	O	I-Entity
and	O	O	O
MPCs	O	O	B-Entity
showed	O	O	O
that	O	O	O
clindamycin	O	O	B-Entity
has	O	O	O
the	O	O	O
lowest	O	O	B-Entity
MSW	O	O	B-Entity
against	O	O	O
both	O	O	O
P.	O	O	B-Entity
acnes	O	O	I-Entity
and	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
.	O	O	O

Nadifloxacin	O	O	B-Entity
MSWs	O	O	B-Entity
were	O	O	O
4-fold	O	O	O
higher	O	O	B-Entity
against	O	O	O
P.	O	O	B-Entity
acnes	O	O	I-Entity
than	O	O	O
against	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
more	O	O	O
likely	O	O	O
for	O	O	O
P.	O	O	B-Entity
acnes	O	O	I-Entity
to	O	O	O
acquire	O	O	O
resistance	O	O	B-Entity
to	O	O	O
fluoroquinolones	O	O	B-Entity
than	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
topical	O	O	B-Entity
application	O	O	I-Entity
of	O	O	O
clindamycin	O	O	B-Entity
contributes	O	O	O
very	O	O	O
little	O	O	O
to	O	O	O
the	O	O	O
emergence	O	O	O
of	O	O	O
resistant	O	O	B-Entity
P.	O	O	B-Entity
acnes	O	O	I-Entity
and	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
strains	O	O	O
.	O	O	O

-DOCSTART- (27765805)

Total	O	O	O
colectomy	O	O	B-Entity
for	O	O	O
colon	O	O	B-Entity
perforation	O	O	I-Entity
after	O	O	O
kayexalate	O	O	B-Entity
administration	O	O	B-Entity
:	O	O	O
a	O	O	O
case	O	O	O
report	O	O	O
and	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
a	O	O	O
rare	O	O	B-Entity
complication	O	O	O

Kayexalate	O	O	B-Entity
is	O	O	O
an	O	O	O
ion	O	O	B-Entity
exchange	O	O	I-Entity
resin	O	O	I-Entity
that	O	O	O
is	O	O	O
commonly	O	O	O
used	O	O	O
to	O	O	O
acutely	O	O	O
treat	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
hyperkalemia	O	O	B-Entity
.	O	O	O

Bowel	O	O	B-Entity
ulceration	O	O	I-Entity
and	O	O	O
necrosis	O	O	B-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
and	O	O	O
uncommonly	O	O	O
recognized	O	O	O
complication	O	O	B-Entity
of	O	O	O
kayexalate	O	O	B-Entity
administration	O	O	B-Entity
.	O	O	O

More	O	O	O
often	O	O	O
,	O	O	O
concomitant	O	O	B-Entity
administration	O	O	B-Entity
with	O	O	O
sorbitol	O	O	B-Entity
is	O	O	O
reported	O	O	O
to	O	O	O
damage	O	O	B-Entity
the	O	O	O
bowel	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
reports	O	O	O
of	O	O	O
kayexalate	O	O	B-Entity
administration	O	O	O
causing	O	O	O
bowel	O	O	B-Entity
necrosis	O	O	I-Entity
without	O	O	O
sorbitol	O	O	O
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
critically	O	O	B-Entity
ill	O	O	I-Entity
patient	O	O	B-Entity
who	O	O	O
underwent	O	O	O
total	O	O	O
colectomy	O	O	B-Entity
for	O	O	O
colonic	O	O	B-Entity
necrosis	O	O	I-Entity
secondary	O	O	O
to	O	O	O
oral	O	O	B-Entity
kayexalate	O	O	B-Entity
administration	O	O	B-Entity
that	O	O	O
was	O	O	O
not	O	O	O
recognized	O	O	O
until	O	O	O
late	O	O	O
in	O	O	O
the	O	O	O
pathologic	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
review	O	O	B-Entity
the	O	O	I-Entity
literature	O	O	I-Entity
to	O	O	O
further	O	O	O
investigate	O	O	O
this	O	O	O
progression	O	O	B-Entity
.	O	O	O

-DOCSTART- (27766178)

Total	O	O	B-Entity
Arsenic	O	O	B-Entity
,	O	O	O
Cadmium	O	O	B-Entity
,	O	O	O
and	O	O	O
Lead	O	O	B-Entity
Determination	O	O	B-Entity
in	O	O	O
Brazilian	O	O	B-Entity
Rice	O	O	I-Entity
Samples	O	O	B-Entity
Using	O	O	O
ICP-MS	O	O	O

This	O	O	O
study	O	O	B-Entity
is	O	O	O
aimed	O	O	O
at	O	O	O
investigating	O	O	B-Entity
a	O	O	O
suitable	O	O	O
method	O	O	B-Entity
for	O	O	O
rice	O	O	B-Entity
sample	O	O	B-Entity
preparation	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
validating	O	O	B-Entity
and	O	O	O
applying	O	O	B-Entity
the	O	O	O
method	O	O	O
for	O	O	O
monitoring	O	O	B-Entity
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
total	O	O	B-Entity
arsenic	O	O	B-Entity
,	O	O	O
cadmium	O	O	B-Entity
,	O	O	O
and	O	O	O
lead	O	O	B-Entity
in	O	O	O
rice	O	O	O
by	O	O	O
using	O	O	O
Inductively	O	O	B-Entity
Coupled	O	O	I-Entity
Plasma	O	O	I-Entity
Mass	O	O	I-Entity
Spectrometry	O	O	I-Entity
(	O	O	O
ICP-MS	O	O	B-Entity
)	O	O	O
.	O	O	O

Various	O	O	O
rice	O	O	B-Entity
sample	O	O	B-Entity
preparation	O	O	B-Entity
procedures	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
.	O	O	O

The	O	O	O
analytical	O	O	B-Entity
method	O	O	I-Entity
was	O	O	O
validated	O	O	B-Entity
by	O	O	O
measuring	O	O	B-Entity
several	O	O	O
parameters	O	O	B-Entity
including	O	O	O
limit	O	O	B-Entity
of	O	O	I-Entity
detection	O	O	I-Entity
(	O	O	O
LOD	O	O	B-Entity
)	O	O	O
,	O	O	O
limit	O	O	B-Entity
of	O	O	I-Entity
quantification	O	O	I-Entity
(	O	O	O
LOQ	O	O	B-Entity
)	O	O	O
,	O	O	O
linearity	O	O	B-Entity
,	O	O	O
relative	O	O	B-Entity
bias	O	O	I-Entity
,	O	O	O
and	O	O	O
repeatability	O	O	B-Entity
.	O	O	O

Regarding	O	O	O
the	O	O	O
sample	O	O	B-Entity
preparation	O	O	B-Entity
,	O	O	O
recoveries	O	O	B-Entity
of	O	O	O
spiked	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
within	O	O	O
the	O	O	O
acceptable	O	O	B-Entity
range	O	O	I-Entity
from	O	O	O
89.3	O	O	O
to	O	O	O
98.2	O	O	O
%	O	O	O
for	O	O	O
muffle	O	O	B-Entity
furnace	O	O	I-Entity
,	O	O	O
94.2	O	O	O
to	O	O	O
103.3	O	O	O
%	O	O	O
for	O	O	O
heating	O	O	B-Entity
block	O	O	I-Entity
,	O	O	O
81.0	O	O	O
to	O	O	O
115.0	O	O	O
%	O	O	O
for	O	O	O
hot	O	O	B-Entity
plate	O	O	I-Entity
,	O	O	O
and	O	O	O
92.8	O	O	O
to	O	O	O
108.2	O	O	O
%	O	O	O
for	O	O	O
microwave	O	O	B-Entity
.	O	O	O

Validation	O	O	B-Entity
parameters	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
method	O	O	B-Entity
fits	O	O	O
for	O	O	O
its	O	O	O
purpose	O	O	O
,	O	O	O
being	O	O	O
the	O	O	O
total	O	O	B-Entity
arsenic	O	O	B-Entity
,	O	O	O
cadmium	O	O	B-Entity
,	O	O	O
and	O	O	O
lead	O	O	B-Entity
within	O	O	O
the	O	O	O
Brazilian	O	O	O
Legislation	O	O	O
limits	O	O	O
.	O	O	O

The	O	O	O
method	O	O	B-Entity
was	O	O	O
applied	O	O	O
for	O	O	O
analyzing	O	O	B-Entity
37	O	O	O
rice	O	O	B-Entity
samples	O	O	B-Entity
(	O	O	O
including	O	O	O
polished	O	O	B-Entity
,	O	O	O
brown	O	O	B-Entity
,	O	O	O
and	O	O	O
parboiled	O	O	B-Entity
)	O	O	O
,	O	O	O
consumed	O	O	O
by	O	O	O
the	O	O	O
Brazilian	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

The	O	O	O
total	O	O	B-Entity
arsenic	O	O	B-Entity
,	O	O	O
cadmium	O	O	B-Entity
,	O	O	O
and	O	O	O
lead	O	O	B-Entity
contents	O	O	B-Entity
were	O	O	O
lower	O	O	O
than	O	O	O
the	O	O	O
established	O	O	O
legislative	O	O	B-Entity
values	O	O	B-Entity
,	O	O	O
except	O	O	O
for	O	O	O
total	O	O	O
arsenic	O	O	O
in	O	O	O
one	O	O	O
brown	O	O	B-Entity
rice	O	O	I-Entity
sample	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
indicated	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
establish	O	O	O
monitoring	O	O	B-Entity
programs	O	O	B-Entity
for	O	O	O
emphasizing	O	O	O
the	O	O	O
study	O	O	O
on	O	O	O
this	O	O	O
type	O	O	B-Entity
of	O	O	O
cereal	O	O	B-Entity
,	O	O	O
aiming	O	O	O
at	O	O	O
promoting	O	O	O
the	O	O	O
Public	O	O	B-Entity
Health	O	O	I-Entity
.	O	O	O

-DOCSTART- (27768063)

Safety	O	O	B-Entity
Precautions	O	O	I-Entity
and	O	O	O
Operating	O	O	B-Entity
Procedures	O	O	I-Entity
in	O	O	O
an	O	O	O
(	O	O	O
A	O	O	O
)	O	O	O
BSL-4	O	O	B-Entity
Laboratory	O	O	B-Entity
:	O	O	O
1	O	O	O
.	O	O	O
Biosafety	O	O	B-Entity
Level	O	O	I-Entity
4	O	O	I-Entity
Suit	O	O	B-Entity
Laboratory	O	O	I-Entity
Suite	O	O	O
Entry	O	O	O
and	O	O	O
Exit	O	O	O
Procedures	O	O	O

Biosafety	O	O	B-Entity
level	O	O	I-Entity
4	O	O	I-Entity
(	O	O	O
BSL-4	O	O	B-Entity
)	O	O	O
suit	O	O	B-Entity
laboratories	O	O	I-Entity
are	O	O	O
specifically	O	O	O
designed	O	O	B-Entity
to	O	O	O
study	O	O	B-Entity
high-consequence	O	O	B-Entity
pathogens	O	O	I-Entity
for	O	O	O
which	O	O	O
neither	O	O	O
infection	O	O	B-Entity
prophylaxes	O	O	B-Entity
nor	O	O	O
treatment	O	O	B-Entity
options	O	O	O
exist	O	O	O
.	O	O	O

The	O	O	O
hallmarks	O	O	O
of	O	O	O
these	O	O	O
laboratories	O	O	B-Entity
are	O	O	O
:	O	O	O
custom-designed	O	O	B-Entity
airtight	O	O	B-Entity
doors	O	O	I-Entity
,	O	O	O
dedicated	O	O	O
supply	O	O	B-Entity
and	O	O	O
exhaust	O	O	B-Entity
airflow	O	O	I-Entity
systems	O	O	I-Entity
,	O	O	O
a	O	O	O
negative-pressure	O	O	B-Entity
environment	O	O	I-Entity
,	O	O	O
and	O	O	O
mandatory	O	O	O
use	O	O	O
of	O	O	O
positive-pressure	O	O	B-Entity
(	O	O	I-Entity
"	O	O	I-Entity
space	O	O	I-Entity
"	O	O	I-Entity
)	O	O	I-Entity
suits	O	O	I-Entity
.	O	O	O

The	O	O	O
risk	O	O	O
for	O	O	O
laboratory	O	O	B-Entity
specialists	O	O	B-Entity
working	O	O	O
with	O	O	O
highly	O	O	O
pathogenic	O	O	B-Entity
agents	O	O	I-Entity
is	O	O	O
minimized	O	O	O
through	O	O	O
rigorous	O	O	O
training	O	O	B-Entity
and	O	O	O
adherence	O	O	O
to	O	O	O
stringent	O	O	O
safety	O	O	B-Entity
protocols	O	O	I-Entity
and	O	O	O
standard	O	O	B-Entity
operating	O	O	I-Entity
procedures	O	O	I-Entity
.	O	O	O

Researchers	O	O	B-Entity
perform	O	O	O
the	O	O	O
majority	O	O	B-Entity
of	O	O	O
their	O	O	O
work	O	O	B-Entity
in	O	O	O
BSL-2	O	O	B-Entity
laboratories	O	O	B-Entity
and	O	O	O
switch	O	O	O
to	O	O	O
BSL-4	O	O	B-Entity
suit	O	O	B-Entity
laboratories	O	O	I-Entity
when	O	O	O
work	O	O	O
with	O	O	O
a	O	O	O
high-consequence	O	O	B-Entity
pathogen	O	O	I-Entity
is	O	O	O
required	O	O	O
.	O	O	O

Collaborators	O	O	B-Entity
and	O	O	O
scientists	O	O	B-Entity
considering	O	O	O
BSL-4	O	O	B-Entity
projects	O	O	B-Entity
should	O	O	O
be	O	O	O
aware	O	O	O
of	O	O	O
the	O	O	O
challenges	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
BSL-4	O	O	O
research	O	O	B-Entity
both	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
experimental	O	O	B-Entity
technical	O	O	B-Entity
limitations	O	O	B-Entity
in	O	O	O
BSL-4	O	O	O
laboratory	O	O	B-Entity
space	O	O	B-Entity
and	O	O	O
the	O	O	O
increased	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	O
such	O	O	O
experiments	O	O	B-Entity
.	O	O	O

Tasks	O	O	O
such	O	O	O
as	O	O	O
entering	O	O	B-Entity
and	O	O	O
exiting	O	O	B-Entity
the	O	O	O
BSL-4	O	O	B-Entity
suit	O	O	B-Entity
laboratories	O	O	B-Entity
are	O	O	O
considerably	O	O	O
more	O	O	O
complex	O	O	B-Entity
and	O	O	O
time-consuming	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
BSL-2	O	O	B-Entity
and	O	O	O
BSL-3	O	O	B-Entity
laboratories	O	O	O
.	O	O	O

The	O	O	O
focus	O	O	O
of	O	O	O
this	O	O	O
particular	O	O	O
article	O	O	B-Entity
is	O	O	O
to	O	O	O
address	O	O	B-Entity
basic	O	O	O
biosafety	O	O	B-Entity
concerns	O	O	B-Entity
and	O	O	O
describe	O	O	O
the	O	O	O
entrance	O	O	B-Entity
and	O	O	I-Entity
exit	O	O	I-Entity
procedures	O	O	I-Entity
for	O	O	O
the	O	O	O
BSL-4	O	O	B-Entity
laboratory	O	O	B-Entity
at	O	O	O
the	O	O	O
NIH	O	O	B-Entity
/	O	O	O
NIAID	O	O	B-Entity
Integrated	O	O	B-Entity
Research	O	O	I-Entity
Facility	O	O	I-Entity
at	O	O	O
Fort	O	O	O
Detrick	O	O	O
.	O	O	O

Such	O	O	O
procedures	O	O	B-Entity
include	O	O	O
checking	O	O	O
external	O	O	O
systems	O	O	O
that	O	O	O
support	O	O	O
the	O	O	O
BSL-4	O	O	B-Entity
laboratory	O	O	B-Entity
,	O	O	O
and	O	O	O
inspecting	O	O	O
and	O	O	O
donning	O	O	O
positive-pressure	O	O	B-Entity
suits	O	O	I-Entity
,	O	O	O
entering	O	O	O
the	O	O	O
laboratory	O	O	O
,	O	O	O
moving	O	O	O
through	O	O	O
air	O	O	B-Entity
pressure	O	O	I-Entity
-	O	O	O
resistant	O	O	B-Entity
doors	O	O	B-Entity
,	O	O	O
and	O	O	O
connecting	O	O	O
to	O	O	O
air-supply	O	O	B-Entity
hoses	O	O	I-Entity
.	O	O	O

We	O	O	O
will	O	O	O
also	O	O	O
discuss	O	O	O
moving	O	O	B-Entity
within	O	O	O
and	O	O	O
exiting	O	O	B-Entity
the	O	O	O
BSL-4	O	O	B-Entity
suit	O	O	B-Entity
laboratories	O	O	I-Entity
,	O	O	O
including	O	O	O
using	O	O	O
the	O	O	O
chemical	O	O	B-Entity
shower	O	O	B-Entity
and	O	O	O
removing	O	O	B-Entity
and	O	O	O
storing	O	O	B-Entity
positive-pressure	O	O	B-Entity
suits	O	O	I-Entity
.	O	O	O

-DOCSTART- (27768522)

Masters	O	O	B-Entity
Athletes	O	O	I-Entity
:	O	O	O
Exemplars	O	O	O
of	O	O	O
Successful	O	O	B-Entity
Aging	O	O	I-Entity
?	O	O	O

Global	O	O	B-Entity
population	O	O	I-Entity
aging	O	O	B-Entity
has	O	O	O
raised	O	O	B-Entity
academic	O	O	I-Entity
interest	O	O	I-Entity
in	O	O	O
successful	O	O	B-Entity
aging	O	O	I-Entity
to	O	O	O
a	O	O	O
public	O	O	B-Entity
policy	O	O	I-Entity
priority	O	O	O
.	O	O	O

Currently	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
consensus	O	O	B-Entity
regarding	O	O	O
the	O	O	O
definition	O	O	O
of	O	O	O
successful	O	O	B-Entity
aging	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
synthesis	O	O	O
of	O	O	O
research	O	O	O
shows	O	O	O
successful	O	O	B-Entity
aging	O	O	I-Entity
can	O	O	O
be	O	O	O
defined	O	O	O
as	O	O	O
a	O	O	O
late-life	O	O	B-Entity
process	O	O	I-Entity
of	O	O	I-Entity
change	O	O	I-Entity
characterized	O	O	O
by	O	O	O
high	O	O	B-Entity
physical	O	O	I-Entity
,	O	O	O
psychological	O	O	B-Entity
,	O	O	O
cognitive	O	O	B-Entity
,	O	O	O
and	O	O	O
social	O	O	B-Entity
functioning	O	O	I-Entity
.	O	O	O

Masters	O	O	B-Entity
athletes	O	O	I-Entity
systematically	O	O	B-Entity
train	O	O	I-Entity
for	O	O	O
,	O	O	O
and	O	O	O
compete	O	O	B-Entity
in	O	O	I-Entity
,	O	O	O
organized	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	I-Entity
team	O	O	I-Entity
and	O	O	O
individual	O	O	B-Entity
sport	O	O	I-Entity
specifically	O	O	O
designed	O	O	O
for	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Masters	O	O	B-Entity
athletes	O	O	I-Entity
are	O	O	O
often	O	O	O
proposed	O	O	O
as	O	O	O
exemplars	O	O	O
of	O	O	O
successful	O	O	B-Entity
aging	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
their	O	O	O
aging	O	O	B-Entity
status	O	O	I-Entity
has	O	O	O
never	O	O	O
been	O	O	O
examined	O	O	O
using	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
multidimensional	O	O	B-Entity
successful	O	O	B-Entity
aging	O	O	I-Entity
definition	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
examine	O	O	O
the	O	O	O
successful	O	O	B-Entity
aging	O	O	I-Entity
literature	O	O	B-Entity
,	O	O	O
propose	O	O	O
a	O	O	O
successful	O	O	O
aging	O	O	O
definition	O	O	O
based	O	O	O
on	O	O	O
this	O	O	O
literature	O	O	O
,	O	O	O
present	O	O	O
evidence	O	O	O
which	O	O	O
suggests	O	O	O
masters	O	O	B-Entity
athletes	O	O	I-Entity
could	O	O	O
be	O	O	O
considered	O	O	O
exemplars	O	O	O
of	O	O	O
successful	O	O	O
aging	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
proposed	O	O	O
definition	O	O	O
,	O	O	O
and	O	O	O
list	O	O	O
future	O	O	O
experimental	O	O	B-Entity
research	O	O	I-Entity
directions	O	O	O
.	O	O	O

-DOCSTART- (27768814)

Non-specific	O	O	O
transient	O	O	O
mutualism	O	O	B-Entity
between	O	O	O
the	O	O	O
plant	O	O	B-Entity
parasitic	O	O	I-Entity
nematode	O	O	I-Entity
,	O	O	O
Bursaphelenchus	O	O	B-Entity
xylophilus	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
opportunistic	O	O	O
bacterium	O	O	B-Entity
Serratia	O	O	B-Entity
quinivorans	O	O	I-Entity
BXF1	O	O	I-Entity
,	O	O	O
a	O	O	O
plant-growth	O	O	B-Entity
promoting	O	O	O
pine	O	O	B-Entity
endophyte	O	O	B-Entity
with	O	O	O
antagonistic	O	O	B-Entity
effects	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
biological	O	O	O
role	O	O	O
of	O	O	O
Serratia	O	O	B-Entity
quinivorans	O	O	I-Entity
BXF1	O	O	I-Entity
,	O	O	O
a	O	O	O
bacterium	O	O	B-Entity
commonly	O	O	O
found	O	O	O
associated	O	O	O
with	O	O	O
Bursaphelenchus	O	O	B-Entity
xylophilus	O	O	I-Entity
,	O	O	O
the	O	O	O
plant	O	O	B-Entity
parasitic	O	O	I-Entity
nematode	O	O	I-Entity
responsible	O	O	O
for	O	O	O
pine	O	O	B-Entity
wilt	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
studied	O	O	O
strain	O	O	B-Entity
BXF1	O	O	I-Entity
effect	O	O	O
in	O	O	O
pine	O	O	B-Entity
wilt	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
strain	O	O	B-Entity
BXF1	O	O	I-Entity
promoted	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
nematode	O	O	B-Entity
reproduction	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
bacteria	O	O	B-Entity
led	O	O	O
to	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
nematode	O	O	B-Entity
chitinase	O	O	B-Entity
gene	O	O	I-Entity
(	O	O	I-Entity
Bxcht-1	O	O	I-Entity
)	O	O	I-Entity
expression	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
an	O	O	O
effect	O	O	O
for	O	O	O
bacterial	O	O	B-Entity
chitinase	O	O	O
in	O	O	O
nematode	O	O	O
reproduction	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
strain	O	O	B-Entity
BXF1	O	O	I-Entity
was	O	O	O
unable	O	O	O
to	O	O	O
colonize	O	O	B-Entity
the	O	O	O
nematode	O	O	B-Entity
interior	O	O	O
,	O	O	O
bind	O	O	O
to	O	O	O
its	O	O	O
cuticle	O	O	B-Entity
with	O	O	O
high	O	O	O
affinity	O	O	O
or	O	O	O
protect	O	O	O
the	O	O	O
nematode	O	O	O
from	O	O	O
xenobiotic	O	O	B-Entity
stress	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
strain	O	O	B-Entity
BXF1	O	O	I-Entity
was	O	O	O
able	O	O	O
to	O	O	O
promote	O	O	O
tomato	O	O	B-Entity
and	O	O	O
pine	O	O	B-Entity
plant-growth	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
to	O	O	O
colonize	O	O	B-Entity
its	O	O	O
interior	O	O	O
,	O	O	O
thus	O	O	O
,	O	O	O
acting	O	O	O
like	O	O	O
a	O	O	O
plant-growth	O	O	O
promoting	O	O	O
endophyte	O	O	B-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
strain	O	O	B-Entity
BXF1	O	O	I-Entity
failed	O	O	O
to	O	O	O
induce	O	O	O
wilting	O	O	B-Entity
symptoms	O	O	I-Entity
when	O	O	O
inoculated	O	O	O
in	O	O	O
pine	O	O	B-Entity
shoot	O	O	B-Entity
artificial	O	O	B-Entity
incisions	O	O	I-Entity
.	O	O	O

This	O	O	O
bacterium	O	O	B-Entity
also	O	O	O
presented	O	O	O
strong	O	O	O
antagonistic	O	O	B-Entity
activities	O	O	B-Entity
against	O	O	O
fungi	O	O	B-Entity
and	O	O	O
bacteria	O	O	B-Entity
isolated	O	O	O
from	O	O	O
Pinus	O	O	B-Entity
pinaster	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
B.	O	O	B-Entity
xylophilus	O	O	I-Entity
does	O	O	O
not	O	O	O
possess	O	O	O
a	O	O	O
strict	O	O	O
symbiotic	O	O	B-Entity
community	O	O	I-Entity
capable	O	O	O
of	O	O	O
inducing	O	O	O
pine	O	O	B-Entity
wilt	O	O	B-Entity
disease	O	O	I-Entity
symptoms	O	O	B-Entity
as	O	O	O
previously	O	O	O
hypothesized	O	O	O
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
bacteria	O	O	B-Entity
like	O	O	O
BXF1	O	O	B-Entity
,	O	O	O
which	O	O	O
possess	O	O	O
plant-growth	O	O	B-Entity
promoting	O	O	O
and	O	O	O
antagonistic	O	O	B-Entity
effects	O	O	B-Entity
,	O	O	O
may	O	O	O
be	O	O	O
opportunistically	O	O	O
associated	O	O	O
with	O	O	O
B.	O	O	B-Entity
xylophilus	O	O	I-Entity
,	O	O	O
possibly	O	O	O
acquired	O	O	O
from	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
endophytic	O	O	B-Entity
community	O	O	I-Entity
of	O	O	O
the	O	O	O
host	O	O	B-Entity
pine	O	O	B-Entity
.	O	O	O

-DOCSTART- (27771865)

Habitual	O	O	B-Entity
physical	O	O	I-Entity
activity	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
improved	O	O	O
anthropometric	O	O	B-Entity
and	O	O	O
androgenic	O	O	B-Entity
profile	O	O	B-Entity
in	O	O	O
PCOS	O	O	B-Entity
:	O	O	O
a	O	O	O
cross-sectional	O	O	O
study	O	O	O

To	O	O	O
examine	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
habitual	O	O	B-Entity
physical	O	O	I-Entity
activity	O	O	I-Entity
(	O	O	O
PA	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
and	O	O	O
hormonal	O	O	B-Entity
profiles	O	O	I-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
polycystic	O	O	B-Entity
ovary	O	O	I-Entity
syndrome	O	O	I-Entity
.	O	O	O

Anthropometric	O	O	B-Entity
,	O	O	O
metabolic	O	O	B-Entity
and	O	O	O
hormonal	O	O	B-Entity
assessment	O	O	I-Entity
and	O	O	O
determination	O	O	O
of	O	O	O
habitual	O	O	B-Entity
PA	O	O	I-Entity
levels	O	O	O
with	O	O	O
a	O	O	O
digital	O	O	B-Entity
pedometer	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
in	O	O	O
84	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
and	O	O	O
67	O	O	O
age-	O	O	O
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(BMI)-matched	O	O	O
controls	O	O	B-Entity
.	O	O	O

PA	O	O	B-Entity
status	O	O	O
was	O	O	O
defined	O	O	O
according	O	O	O
to	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
steps	O	O	I-Entity
(	O	O	O
≥7500	O	O	O
steps	O	O	O
,	O	O	O
active	O	O	O
,	O	O	O
or	O	O	O
<	O	O	O
7500	O	O	O
steps	O	O	O
,	O	O	O
sedentary	O	O	B-Entity
)	O	O	O
.	O	O	O

BMI	O	O	B-Entity
was	O	O	O
lower	O	O	O
in	O	O	O
active	O	O	O
women	O	O	B-Entity
from	O	O	O
both	O	O	O
groups	O	O	O
.	O	O	O

Active	O	O	O
PCOS	O	O	B-Entity
women	O	O	B-Entity
presented	O	O	O
lower	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
WC	O	O	B-Entity
)	O	O	O
and	O	O	O
lipid	O	O	B-Entity
accumulation	O	O	I-Entity
product	O	O	I-Entity
(	O	O	O
LAP	O	O	B-Entity
)	O	O	O
values	O	O	O
versus	O	O	O
sedentary	O	O	B-Entity
PCOS	O	O	O
women	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
active	O	O	O
women	O	O	B-Entity
also	O	O	O
had	O	O	O
lower	O	O	O
WC	O	O	B-Entity
,	O	O	O
lower	O	O	O
values	O	O	O
for	O	O	O
fasting	O	O	O
and	O	O	O
120-min	O	O	O
insulin	O	O	B-Entity
,	O	O	O
and	O	O	O
lower	O	O	O
LAP	O	O	B-Entity
than	O	O	O
sedentary	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
PCOS	O	O	B-Entity
group	O	O	O
,	O	O	O
androgen	O	O	B-Entity
levels	O	O	O
were	O	O	O
lower	O	O	O
in	O	O	O
active	O	O	O
versus	O	O	O
sedentary	O	O	B-Entity
women	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
free	O	O	B-Entity
androgen	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
FAI	O	O	B-Entity
)	O	O	O
was	O	O	O
also	O	O	O
lower	O	O	O
in	O	O	O
active	O	O	O
versus	O	O	O
sedentary	O	O	B-Entity
women	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.018	O	O	O
)	O	O	O
.	O	O	O

Homeostasis	O	O	B-Entity
model	O	O	I-Entity
assessment	O	O	I-Entity
of	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
2000	O	O	O
daily	O	O	O
step	O	O	O
increments	O	O	O
were	O	O	O
independent	O	O	O
predictors	O	O	B-Entity
of	O	O	O
FAI	O	O	B-Entity
.	O	O	O

Each	O	O	O
2000	O	O	O
daily	O	O	O
step	O	O	O
increment	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
decrease	O	O	O
of	O	O	O
1.07	O	O	O
in	O	O	O
FAI	O	O	B-Entity
.	O	O	O

Habitual	O	O	B-Entity
PA	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
better	O	O	O
anthropometric	O	O	B-Entity
and	O	O	O
androgenic	O	O	B-Entity
profile	O	O	B-Entity
in	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

-DOCSTART- (27772674)

Geolocalization	O	O	B-Entity
of	O	O	O
Influenza	O	O	B-Entity
Outbreak	O	O	B-Entity
Within	O	O	O
an	O	O	O
Acute	O	O	B-Entity
Care	O	O	I-Entity
Population	O	O	B-Entity
:	O	O	O
A	O	O	O
Layered-Surveillance	O	O	B-Entity
Approach	O	O	O

We	O	O	O
seek	O	O	O
to	O	O	O
use	O	O	O
a	O	O	O
novel	O	O	O
layered-surveillance	O	O	B-Entity
approach	O	O	B-Entity
to	O	O	O
localize	O	O	B-Entity
influenza	O	O	B-Entity
clusters	O	O	B-Entity
within	O	O	O
an	O	O	O
acute	O	O	B-Entity
care	O	O	I-Entity
population	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	O
layer	O	O	O
of	O	O	O
this	O	O	O
system	O	O	B-Entity
is	O	O	O
a	O	O	O
syndromic	O	O	B-Entity
surveillance	O	O	B-Entity
screen	O	O	I-Entity
to	O	O	O
guide	O	O	O
rapid	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
testing	O	O	I-Entity
.	O	O	O

The	O	O	O
second	O	O	B-Entity
layer	O	O	O
is	O	O	O
geolocalization	O	O	B-Entity
and	O	O	O
cluster	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

We	O	O	O
posit	O	O	O
that	O	O	O
any	O	O	O
identified	O	O	B-Entity
clusters	O	O	B-Entity
could	O	O	O
represent	O	O	O
at-risk	O	O	B-Entity
populations	O	O	I-Entity
who	O	O	O
could	O	O	O
serve	O	O	O
as	O	O	O
high-yield	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
preventive	O	O	B-Entity
medical	O	O	I-Entity
interventions	O	O	I-Entity
.	O	O	O

This	O	O	O
was	O	O	O
a	O	O	O
prospective	O	O	B-Entity
observational	O	O	I-Entity
surveillance	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
screened	O	O	B-Entity
with	O	O	O
a	O	O	O
previously	O	O	O
derived	O	O	O
clinical	O	O	B-Entity
decision	O	O	I-Entity
guideline	O	O	I-Entity
that	O	O	O
has	O	O	O
a	O	O	O
90	O	O	O
%	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
30	O	O	O
%	O	O	O
specificity	O	O	B-Entity
for	O	O	O
influenza	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
received	O	O	O
points	O	O	B-Entity
for	O	O	O
the	O	O	O
following	O	O	O
signs	O	O	B-Entity
and	O	O	I-Entity
symptoms	O	O	I-Entity
within	O	O	O
the	O	O	O
past	O	O	B-Entity
7	O	O	O
days	O	O	B-Entity
:	O	O	O
cough	O	O	B-Entity
(	O	O	O
2	O	O	O
points	O	O	O
)	O	O	O
,	O	O	O
headache	O	O	B-Entity
(	O	O	O
1	O	O	O
point	O	O	O
)	O	O	O
,	O	O	O
subjective	O	O	B-Entity
fever	O	O	I-Entity
(	O	O	O
1	O	O	O
point	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
documented	O	O	B-Entity
fever	O	O	I-Entity
at	O	O	O
triage	O	O	B-Entity
(	O	O	O
temperature	O	O	B-Entity
>	O	O	O
38	O	O	O
°	O	O	O
C	O	O	O
[	O	O	O
100.4	O	O	O
°	O	O	O
F	O	O	O
]	O	O	O
)	O	O	O
(	O	O	O
1	O	O	O
point	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
scoring	O	O	B-Entity
3	O	O	O
points	O	O	O
or	O	O	O
higher	O	O	O
were	O	O	O
indicated	O	O	B-Entity
for	O	O	O
influenza	O	O	B-Entity
testing	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
with	O	O	O
Xpert	O	O	B-Entity
Flu	O	O	I-Entity
(	O	O	O
Cepheid	O	O	B-Entity
,	O	O	O
Sunnyvale	O	O	B-Entity
,	O	O	O
CA	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
rapid	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Positive	O	O	B-Entity
results	O	O	B-Entity
were	O	O	O
mapped	O	O	B-Entity
with	O	O	O
ArcGIS	O	O	B-Entity
(	O	O	O
ESRI	O	O	B-Entity
,	O	O	O
Redlands	O	O	B-Entity
,	O	O	O
CA	O	O	B-Entity
)	O	O	O
and	O	O	O
analyzed	O	O	B-Entity
with	O	O	O
kernel	O	O	B-Entity
density	O	O	I-Entity
estimation	O	O	I-Entity
to	O	O	O
create	O	O	O
heat	O	O	B-Entity
maps	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
1,360	O	O	O
patients	O	O	B-Entity
tested	O	O	B-Entity
with	O	O	O
Xpert	O	O	B-Entity
Flu	O	O	I-Entity
with	O	O	O
retrievable	O	O	B-Entity
addresses	O	O	B-Entity
within	O	O	O
the	O	O	O
greater	O	O	O
Phoenix	O	O	B-Entity
metro	O	O	I-Entity
area	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
sixty-seven	O	O	O
(	O	O	O
12	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
them	O	O	O
tested	O	O	B-Entity
positive	O	O	B-Entity
for	O	O	I-Entity
influenza	O	O	I-Entity
A	O	O	I-Entity
and	O	O	O
23	O	O	O
(	O	O	O
2	O	O	O
%	O	O	O
)	O	O	O
tested	O	O	O
positive	O	O	O
for	O	O	O
influenza	O	O	O
B.	O	O	O
The	O	O	O
influenza	O	O	B-Entity
A	O	O	I-Entity
virus	O	O	I-Entity
exhibited	O	O	O
a	O	O	O
clear	O	O	B-Entity
cluster	O	O	I-Entity
pattern	O	O	B-Entity
within	O	O	O
this	O	O	O
patient	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

The	O	O	O
densest	O	O	B-Entity
cluster	O	O	I-Entity
was	O	O	O
located	O	O	B-Entity
in	O	O	O
an	O	O	O
approximately	O	O	O
1-	O	O	O
square-mile	O	O	B-Entity
region	O	O	B-Entity
southeast	O	O	B-Entity
of	O	O	O
our	O	O	O
hospital	O	O	B-Entity
.	O	O	O

Our	O	O	O
layered-surveillance	O	O	B-Entity
approach	O	O	B-Entity
was	O	O	O
effective	O	O	B-Entity
in	O	O	O
localizing	O	O	B-Entity
a	O	O	O
cluster	O	O	B-Entity
of	O	O	O
influenza	O	O	B-Entity
A	O	O	I-Entity
outbreak	O	O	B-Entity
.	O	O	O

This	O	O	O
region	O	O	B-Entity
may	O	O	O
house	O	O	B-Entity
a	O	O	O
high-yield	O	O	B-Entity
target	O	O	B-Entity
population	O	O	B-Entity
for	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
intervention	O	O	I-Entity
.	O	O	O

Further	O	O	O
collaborative	O	O	B-Entity
efforts	O	O	O
will	O	O	O
be	O	O	O
made	O	O	O
between	O	O	O
our	O	O	O
hospital	O	O	B-Entity
and	O	O	O
the	O	O	O
Maricopa	O	O	B-Entity
County	O	O	I-Entity
Department	O	O	B-Entity
of	O	O	I-Entity
Public	O	O	I-Entity
Health	O	O	I-Entity
to	O	O	O
perform	O	O	B-Entity
a	O	O	O
series	O	O	O
of	O	O	O
community	O	O	B-Entity
vaccination	O	O	B-Entity
events	O	O	B-Entity
before	O	O	O
the	O	O	O
next	O	O	O
influenza	O	O	B-Entity
season	O	O	B-Entity
.	O	O	O

We	O	O	O
hope	O	O	O
these	O	O	O
efforts	O	O	O
will	O	O	O
ultimately	O	O	O
serve	O	O	O
to	O	O	O
reduce	O	O	B-Entity
the	O	O	O
burden	O	O	B-Entity
of	O	O	O
this	O	O	O
disease	O	O	B-Entity
on	O	O	O
our	O	O	O
patient	O	O	B-Entity
population	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
this	O	O	O
system	O	O	B-Entity
will	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
framework	O	O	O
for	O	O	O
future	O	O	B-Entity
investigations	O	O	B-Entity
locating	O	O	O
at-risk	O	O	B-Entity
populations	O	O	I-Entity
.	O	O	O

-DOCSTART- (27773678)

Heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
:	O	O	O
Pre-deployment	O	O	B-Entity
predictor	O	O	B-Entity
of	O	O	O
post-deployment	O	O	B-Entity
PTSD	O	O	B-Entity
symptoms	O	O	O

Heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
is	O	O	O
a	O	O	O
physiological	O	O	O
measure	O	O	O
associated	O	O	O
with	O	O	O
autonomic	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
activity	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
hypothesized	O	O	O
that	O	O	O
lower	O	O	O
pre-deployment	O	O	B-Entity
HRV	O	O	B-Entity
would	O	O	O
be	O	O	O
associated	O	O	O
with	O	O	O
higher	O	O	O
post-deployment	O	O	B-Entity
post-traumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
PTSD	O	O	B-Entity
)	O	O	O
symptoms	O	O	B-Entity
.	O	O	O

Three-hundred-forty-three	O	O	O
Army	O	O	B-Entity
National	O	O	I-Entity
Guard	O	O	I-Entity
soldiers	O	O	I-Entity
enrolled	O	O	O
in	O	O	O
the	O	O	O
Warriors	O	O	B-Entity
Achieving	O	O	I-Entity
Resilience	O	O	I-Entity
(	O	O	I-Entity
WAR	O	O	I-Entity
)	O	O	I-Entity
study	O	O	I-Entity
were	O	O	O
analyzed	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	O
outcome	O	O	B-Entity
was	O	O	O
PTSD	O	O	B-Entity
symptom	O	O	B-Entity
severity	O	O	B-Entity
using	O	O	O
the	O	O	O
PTSD	O	O	O
Checklist	O	O	B-Entity
-	O	O	O
Military	O	O	B-Entity
version	O	O	B-Entity
(	O	O	O
PCL	O	O	B-Entity
)	O	O	O
measured	O	O	O
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
3-	O	O	O
and	O	O	O
12-	O	O	O
month	O	O	B-Entity
post-deployment	O	O	B-Entity
.	O	O	O

Heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
predictor	O	O	B-Entity
variables	O	O	B-Entity
included	O	O	O
:	O	O	O
high	O	O	B-Entity
frequency	O	O	I-Entity
power	O	O	I-Entity
(	O	O	O
HF	O	O	B-Entity
)	O	O	O
and	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
of	O	O	O
the	O	O	O
normal	O	O	O
cardiac	O	O	B-Entity
inter-beat	O	O	I-Entity
interval	O	O	B-Entity
(	O	O	O
SDNN	O	O	B-Entity
)	O	O	O
.	O	O	O

Generalized	O	O	O
linear	O	O	B-Entity
mixed	O	O	I-Entity
models	O	O	I-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
pre-deployment	O	O	B-Entity
PCL	O	O	B-Entity
*	O	O	O
ln(HF	O	O	B-Entity
)	O	O	I-Entity
interaction	O	O	I-Entity
term	O	O	O
was	O	O	O
significant	O	O	O
(	O	O	O
p<0.0001	O	O	O
)	O	O	O
.	O	O	O

Pre-deployment	O	O	B-Entity
SDNN	O	O	B-Entity
was	O	O	O
not	O	O	O
a	O	O	O
significant	O	O	O
predictor	O	O	B-Entity
of	O	O	O
post-deployment	O	O	B-Entity
PCL	O	O	B-Entity
.	O	O	O

Covariates	O	O	B-Entity
included	O	O	O
age	O	O	B-Entity
,	O	O	O
pre-deployment	O	O	B-Entity
PCL	O	O	B-Entity
,	O	O	O
race	O	O	B-Entity
/	O	O	O
ethnicity	O	O	B-Entity
,	O	O	O
marital	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
tobacco	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
childhood	O	O	B-Entity
abuse	O	O	I-Entity
,	O	O	O
pre-deployment	O	O	O
traumatic	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
and	O	O	O
previous	O	O	O
combat	O	O	B-Entity
zone	O	O	I-Entity
deployment	O	O	B-Entity
.	O	O	O

Pre-deployment	O	O	B-Entity
heart	O	O	B-Entity
rate	O	O	I-Entity
variability	O	O	B-Entity
predicts	O	O	O
post-deployment	O	O	B-Entity
PTSD	O	O	B-Entity
symptoms	O	O	B-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
higher	O	O	O
pre-deployment	O	O	B-Entity
PCL	O	O	B-Entity
scores	O	O	B-Entity
.	O	O	O

-DOCSTART- (27775720)

A	O	O	O
neuronal	O	O	B-Entity
PI(3,4,5)P3	O	O	B-Entity
-dependent	O	O	O
program	O	O	B-Entity
of	O	O	O
oligodendrocyte	O	O	B-Entity
precursor	O	O	B-Entity
recruitment	O	O	B-Entity
and	O	O	O
myelination	O	O	O

The	O	O	O
molecular	O	O	B-Entity
trigger	O	O	I-Entity
of	O	O	O
CNS	O	O	B-Entity
myelination	O	O	B-Entity
is	O	O	O
unknown	O	O	B-Entity
.	O	O	O

By	O	O	O
targeting	O	O	B-Entity
Pten	O	O	B-Entity
in	O	O	O
cerebellar	O	O	B-Entity
granule	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
activating	O	O	B-Entity
the	O	O	O
AKT1	O	O	B-Entity
-	O	O	O
mTOR	O	O	B-Entity
pathway	O	O	B-Entity
,	O	O	O
we	O	O	O
increased	O	O	B-Entity
the	O	O	O
caliber	O	O	O
of	O	O	O
normally	O	O	B-Entity
unmyelinated	O	O	B-Entity
axons	O	O	I-Entity
and	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
numerous	O	O	B-Entity
genes	O	O	B-Entity
encoding	O	O	B-Entity
regulatory	O	O	B-Entity
proteins	O	O	I-Entity
.	O	O	O

This	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
expansion	O	O	B-Entity
of	O	O	O
genetically	O	O	B-Entity
wild-type	O	O	I-Entity
oligodendrocyte	O	O	B-Entity
progenitor	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
oligodendrocyte	O	O	O
differentiation	O	O	B-Entity
and	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
myelination	O	O	B-Entity
of	O	O	O
parallel	O	O	B-Entity
fibers	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
a	O	O	O
neuronal	O	O	B-Entity
program	O	O	B-Entity
dependent	O	O	O
on	O	O	O
the	O	O	O
phosphoinositide	O	O	B-Entity
PI(3,4,5)P3	O	O	B-Entity
is	O	O	O
sufficient	O	O	O
to	O	O	O
trigger	O	O	B-Entity
all	O	O	O
steps	O	O	B-Entity
of	O	O	O
myelination	O	O	B-Entity
.	O	O	O

-DOCSTART- (27777102)

Atypical	O	O	O
microglial	O	O	B-Entity
response	O	O	B-Entity
to	O	O	O
biodiesel	O	O	B-Entity
exhaust	O	O	I-Entity
in	O	O	O
healthy	O	O	B-Entity
and	O	O	O
hypertensive	O	O	B-Entity
rats	O	O	O

Accumulating	O	O	O
evidence	O	O	B-Entity
suggests	O	O	B-Entity
a	O	O	O
deleterious	O	O	B-Entity
role	O	O	B-Entity
for	O	O	O
urban	O	O	B-Entity
air	O	O	B-Entity
pollution	O	O	I-Entity
in	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
(	O	O	I-Entity
CNS	O	O	I-Entity
)	O	O	I-Entity
diseases	O	O	I-Entity
and	O	O	O
neurodevelopmental	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Microglia	O	O	B-Entity
,	O	O	O
the	O	O	O
resident	O	O	O
innate	O	O	B-Entity
immune	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
sentinels	O	O	B-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
,	O	O	O
are	O	O	O
a	O	O	O
common	O	O	B-Entity
source	O	O	B-Entity
of	O	O	O
neuroinflammation	O	O	B-Entity
and	O	O	O
are	O	O	O
implicated	O	O	O
in	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
CNS	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

While	O	O	O
renewable	O	O	B-Entity
energy	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
soy-based	O	O	B-Entity
biofuel	O	O	I-Entity
,	O	O	O
is	O	O	O
of	O	O	O
increasing	O	O	B-Entity
public	O	O	B-Entity
interest	O	O	B-Entity
,	O	O	O
there	O	O	O
is	O	O	O
little	O	O	B-Entity
information	O	O	B-Entity
on	O	O	O
how	O	O	O
soy	O	O	B-Entity
biofuel	O	O	I-Entity
may	O	O	O
affect	O	O	B-Entity
the	O	O	O
brain	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
people	O	O	B-Entity
with	O	O	O
preexisting	O	O	B-Entity
disease	O	O	I-Entity
conditions	O	O	I-Entity
.	O	O	O

To	O	O	O
address	O	O	O
this	O	O	O
,	O	O	O
male	O	O	B-Entity
spontaneously	O	O	B-Entity
hypertensive	O	O	I-Entity
rats	O	O	I-Entity
(	O	O	O
SHR	O	O	B-Entity
)	O	O	O
and	O	O	O
normotensive	O	O	B-Entity
Wistar	O	O	B-Entity
Kyoto	O	O	I-Entity
(	O	O	I-Entity
WKY	O	O	I-Entity
)	O	O	I-Entity
rats	O	O	I-Entity
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
100	O	O	B-Entity
%	O	O	I-Entity
Soy-based	O	O	I-Entity
Biodiesel	O	O	I-Entity
Exhaust	O	O	I-Entity
(	O	O	O
100SBDE	O	O	B-Entity
;	O	O	O
0	O	O	O
,	O	O	O
50	O	O	O
,	O	O	O
150	O	O	O
and	O	O	O
500μg/m(3	O	O	O
)	O	O	O
)	O	O	O
by	O	O	O
inhalation	O	O	B-Entity
,	O	O	O
4h/	O	O	O
day	O	O	B-Entity
for	O	O	O
4	O	O	O
weeks	O	O	B-Entity
(	O	O	O
5	O	O	O
days	O	O	B-Entity
/	O	O	O
week	O	O	B-Entity
)	O	O	O
.	O	O	O

Ionized	O	O	B-Entity
calcium-binding	O	O	I-Entity
adapter	O	O	I-Entity
molecule-1	O	O	I-Entity
(	O	O	O
IBA-1	O	O	B-Entity
)	O	O	O
staining	O	O	B-Entity
of	O	O	O
microglia	O	O	B-Entity
in	O	O	O
the	O	O	O
substantia	O	O	B-Entity
nigra	O	O	I-Entity
revealed	O	O	B-Entity
significant	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
morphology	O	O	B-Entity
with	O	O	O
100SBDE	O	O	B-Entity
exposure	O	O	B-Entity
in	O	O	O
rats	O	O	B-Entity
from	O	O	O
both	O	O	B-Entity
genotypes	O	O	B-Entity
,	O	O	O
where	O	O	O
SHR	O	O	B-Entity
were	O	O	O
less	O	O	B-Entity
sensitive	O	O	B-Entity
.	O	O	O

Aconitase	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
inhibited	O	O	B-Entity
in	O	O	O
the	O	O	O
frontal	O	O	B-Entity
cortex	O	O	I-Entity
and	O	O	O
cerebellum	O	O	B-Entity
of	O	O	O
WKY	O	O	B-Entity
rats	O	O	I-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
100SBDE	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
consistent	O	O	B-Entity
changes	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
pro-inflammatory	O	O	B-Entity
cytokine	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
nitrated	O	O	B-Entity
protein	O	O	I-Entity
,	O	O	O
or	O	O	O
arginase1	O	O	B-Entity
expression	O	O	O
in	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
from	O	O	O
either	O	O	O
rat	O	O	B-Entity
strain	O	O	I-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
100SBDE	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
while	O	O	O
IBA-1	O	O	B-Entity
mRNA	O	O	B-Entity
expression	O	O	I-Entity
was	O	O	O
not	O	O	B-Entity
modified	O	O	B-Entity
,	O	O	O
CX3CR1	O	O	B-Entity
mRNA	O	O	O
expression	O	O	O
was	O	O	O
lower	O	O	B-Entity
in	O	O	O
the	O	O	O
striatum	O	O	B-Entity
of	O	O	O
100SBDE	O	O	B-Entity
exposed	O	O	B-Entity
rats	O	O	I-Entity
regardless	O	O	B-Entity
of	O	O	O
genotype	O	O	B-Entity
,	O	O	O
suggesting	O	O	B-Entity
a	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
the	O	O	O
fractalkine	O	O	B-Entity
receptor	O	O	I-Entity
on	O	O	O
microglia	O	O	B-Entity
in	O	O	O
this	O	O	O
brain	O	O	B-Entity
region	O	O	I-Entity
.	O	O	O

Together	O	O	O
,	O	O	O
these	O	O	O
data	O	O	B-Entity
indicate	O	O	B-Entity
that	O	O	O
while	O	O	O
microglia	O	O	B-Entity
are	O	O	O
detecting	O	O	B-Entity
and	O	O	O
responding	O	O	B-Entity
to	O	O	O
100SBDE	O	O	B-Entity
exposure	O	O	B-Entity
with	O	O	O
changes	O	O	B-Entity
in	O	O	O
morphology	O	O	B-Entity
,	O	O	O
there	O	O	O
is	O	O	O
reduced	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
CX3CR1	O	O	B-Entity
regardless	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
background	O	O	I-Entity
and	O	O	O
the	O	O	O
activation	O	O	B-Entity
response	O	O	B-Entity
is	O	O	O
atypical	O	O	B-Entity
without	O	O	O
traditional	O	O	B-Entity
inflammatory	O	O	B-Entity
markers	O	O	I-Entity
of	O	O	O
M1	O	O	B-Entity
or	O	O	O
M2	O	O	B-Entity
activation	O	O	O
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
.	O	O	O

-DOCSTART- (27777558)

Pre-Activation	O	O	B-Entity
Negativity	O	O	I-Entity
(	O	O	O
PrAN	O	O	B-Entity
)	O	O	O
in	O	O	O
Brain	O	O	B-Entity
Potentials	O	O	B-Entity
to	O	O	O
Unfolding	O	O	O
Words	O	O	O

We	O	O	O
describe	O	O	O
an	O	O	O
event-related	O	O	B-Entity
potential	O	O	I-Entity
(	O	O	O
ERP	O	O	B-Entity
)	O	O	O
effect	O	O	B-Entity
termed	O	O	O
the	O	O	O
"	O	O	O
pre-activation	O	O	B-Entity
negativity	O	O	I-Entity
"	O	O	O
(	O	O	O
PrAN	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
proposed	O	O	O
to	O	O	O
index	O	O	B-Entity
the	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
pre-activation	O	O	I-Entity
of	O	O	O
upcoming	O	O	O
word	O	O	B-Entity
-	O	O	O
internal	O	O	B-Entity
morphemes	O	O	B-Entity
in	O	O	O
speech	O	O	B-Entity
processing	O	O	B-Entity
.	O	O	O

Using	O	O	O
lexical	O	O	B-Entity
competition	O	O	I-Entity
measures	O	O	B-Entity
based	O	O	O
on	O	O	O
word-initial	O	O	B-Entity
speech	O	O	I-Entity
fragments	O	O	I-Entity
(	O	O	O
WIFs	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
statistical	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
ERP	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
three	O	O	O
experiments	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
PrAN	O	O	B-Entity
is	O	O	O
sensitive	O	O	O
to	O	O	O
lexical	O	O	O
competition	O	O	O
and	O	O	O
that	O	O	O
it	O	O	O
reflects	O	O	O
the	O	O	O
degree	O	O	B-Entity
of	O	O	O
predictive	O	O	B-Entity
certainty	O	O	B-Entity
:	O	O	O
the	O	O	O
negativity	O	O	B-Entity
is	O	O	O
larger	O	O	B-Entity
when	O	O	O
there	O	O	O
are	O	O	O
fewer	O	O	B-Entity
upcoming	O	O	O
lexical	O	O	O
competitors	O	O	B-Entity
.	O	O	O

-DOCSTART- (27777603)

Angiotensin-converting	O	O	B-Entity
enzyme	O	O	I-Entity
insertion/deletion	O	O	I-Entity
polymorphism	O	O	I-Entity
association	O	O	B-Entity
with	O	O	I-Entity
obesity	O	O	B-Entity
and	O	O	O
some	O	O	O
related	O	O	O
disorders	O	O	B-Entity
in	O	O	O
Egyptian	O	O	B-Entity
females	O	O	B-Entity
:	O	O	O
a	O	O	O
case-control	O	O	O
observational	O	O	O
study	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
WHO	O	O	B-Entity
report	O	O	B-Entity
in	O	O	O
2015	O	O	O
,	O	O	O
obesity	O	O	B-Entity
is	O	O	O
the	O	O	O
fifth	O	O	O
leading	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
worldwide	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
Egyptian	O	O	B-Entity
female	O	O	B-Entity
obesity	O	O	O
is	O	O	O
37.5	O	O	O
%	O	O	O
.	O	O	O

Since	O	O	O
obesity	O	O	B-Entity
is	O	O	O
highly	O	O	O
influenced	O	O	B-Entity
by	O	O	O
genetics	O	O	B-Entity
,	O	O	O
and	O	O	O
adipose	O	O	B-Entity
tissue	O	O	I-Entity
renin-angiotensin	O	O	B-Entity
system	O	O	I-Entity
is	O	O	O
over-activated	O	O	B-Entity
in	O	O	O
obesity	O	O	O
,	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
angiotensin-converting	O	O	B-Entity
enzyme	O	O	I-Entity
(	O	O	I-Entity
ACE	O	O	I-Entity
)	O	O	I-Entity
insertion/deletion	O	O	I-Entity
(	O	O	I-Entity
I/D	O	O	I-Entity
)	O	O	I-Entity
polymorphism	O	O	I-Entity
on	O	O	O
obesity	O	O	O
and	O	O	O
related	O	O	O
disorders	O	O	B-Entity
was	O	O	O
studied	O	O	O
in	O	O	O
several	O	O	O
populations	O	O	B-Entity
,	O	O	O
because	O	O	O
of	O	O	O
its	O	O	O
effect	O	O	O
on	O	O	O
ACE	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Our	O	O	O
objective	O	O	B-Entity
was	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
of	O	O	O
ACE	O	O	B-Entity
I/D	O	O	I-Entity
polymorphism	O	O	I-Entity
with	O	O	O
obesity	O	O	B-Entity
and	O	O	O
certain	O	O	O
related	O	O	O
disorders	O	O	B-Entity
,	O	O	O
namely	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
,	O	O	O
in	O	O	O
Egyptian	O	O	B-Entity
females	O	O	B-Entity
.	O	O	O

Eighty	O	O	B-Entity
female	O	O	B-Entity
volunteers	O	O	B-Entity
were	O	O	O
recruited	O	O	O
,	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
and	O	O	O
body	O	O	B-Entity
measurements	O	O	I-Entity
were	O	O	O
recorded	O	O	B-Entity
and	O	O	O
a	O	O	O
fasting	O	O	B-Entity
blood	O	O	B-Entity
sample	O	O	I-Entity
was	O	O	O
obtained	O	O	O
for	O	O	O
the	O	O	O
quantitation	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
,	O	O	O
lipid	O	O	B-Entity
profile	O	O	I-Entity
,	O	O	O
insulin	O	O	B-Entity
,	O	O	I-Entity
leptin	O	O	B-Entity
and	O	O	O
identification	O	O	B-Entity
of	O	O	O
ACE	O	O	B-Entity
I/D	O	O	I-Entity
polymorphs	O	O	I-Entity
.	O	O	O

Subjects	O	O	B-Entity
were	O	O	O
grouped	O	O	O
based	O	O	O
on	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
obesity	O	O	B-Entity
states	O	O	I-Entity
.	O	O	O

Comparisons	O	O	B-Entity
of	O	O	O
continuous	O	O	B-Entity
parameters	O	O	B-Entity
were	O	O	O
made	O	O	O
with	O	O	O
independent	O	O	B-Entity
sample	O	O	B-Entity
t-test	O	O	I-Entity
between	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
frequencies	O	O	B-Entity
of	O	O	O
ACE	O	O	B-Entity
genotypes	O	O	B-Entity
and	O	O	O
alleles	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
gene	O	O	B-Entity
polymorphism	O	O	I-Entity
and	O	O	O
metabolic	O	O	B-Entity
parameters	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
chi-square	O	O	B-Entity
or	O	O	O
Fisher	O	O	B-Entity
's	O	O	I-Entity
exact	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

Genotype	O	O	B-Entity
frequencies	O	O	B-Entity
were	O	O	O
in	O	O	O
Hardy-Weinberg	O	O	B-Entity
equilibrium	O	O	I-Entity
for	O	O	O
all	O	O	O
groups	O	O	B-Entity
.	O	O	O

Genotype	O	O	B-Entity
distribution	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
significantly	O	O	O
between	O	O	O
controls	O	O	B-Entity
and	O	O	O
cases	O	O	B-Entity
of	O	O	O
all	O	O	O
the	O	O	O
studied	O	O	O
disorders	O	O	B-Entity
.	O	O	O

Although	O	O	O
DD	O	O	B-Entity
carriers	O	O	I-Entity
had	O	O	O
apparently	O	O	O
higher	O	O	B-Entity
parameters	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
,	O	O	O
lipid	O	O	B-Entity
profile	O	O	I-Entity
and	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
only	O	O	O
diastolic	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
was	O	O	O
almost	O	O	O
significant	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.057	O	O	O
)	O	O	O
.	O	O	O

I-carriers	O	O	B-Entity
were	O	O	O
significantly	O	O	O
less	O	O	O
susceptible	O	O	B-Entity
to	O	O	O
hypertension	O	O	B-Entity
than	O	O	O
DD	O	O	B-Entity
carriers	O	O	I-Entity
having	O	O	O
normal	O	O	B-Entity
waist/hip	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.007	O	O	O
,	O	O	O
OR	O	O	B-Entity
=	O	O	O
17.29	O	O	O
,	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.81	O	O	O
-	O	O	O
164.96	O	O	O
)	O	O	O
and	O	O	O
normal	O	O	O
conicity	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.024	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
7.00	O	O	O
,	O	O	O
CI	O	O	O
=	O	O	O
1.36	O	O	O
-	O	O	O
35.93	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
DD	O	O	B-Entity
genotype	O	O	I-Entity
carriers	O	O	I-Entity
,	O	O	O
a	O	O	O
significant	O	O	B-Entity
association	O	O	B-Entity
was	O	O	O
found	O	O	O
between	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
high	O	O	B-Entity
body	O	O	I-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.004	O	O	O
,	O	O	O
OR	O	O	B-Entity
=	O	O	O
8.89	O	O	O
,	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.94	O	O	O
-	O	O	O
40.71	O	O	O
)	O	O	O
,	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.003	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
9.63	O	O	O
,	O	O	O
CI	O	O	O
=	O	O	O
2.14	O	O	O
-	O	O	O
43.36	O	O	O
)	O	O	O
and	O	O	O
waist/height	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.034	O	O	O
,	O	O	O
OR	O	O	O
=	O	O	O
6.86	O	O	O
,	O	O	O
CI	O	O	O
=	O	O	O
1.25	O	O	O
-	O	O	O
37.61	O	O	O
)	O	O	O
,	O	O	O
although	O	O	O
the	O	O	O
variations	O	O	B-Entity
in	O	O	O
percentages	O	O	B-Entity
between	O	O	O
DD	O	O	O
and	O	O	O
I-carriers	O	O	B-Entity
were	O	O	O
not	O	O	O
high	O	O	O
enough	O	O	O
to	O	O	O
conclude	O	O	O
an	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
ACE	O	O	B-Entity
I/D	O	O	I-Entity
on	O	O	O
such	O	O	O
an	O	O	O
association	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
sample	O	O	B-Entity
of	O	O	O
Egyptian	O	O	B-Entity
females	O	O	B-Entity
,	O	O	O
ACE	O	O	B-Entity
I/D	O	O	I-Entity
polymorphism	O	O	I-Entity
was	O	O	O
not	O	O	B-Entity
significantly	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
obesity	O	O	B-Entity
nor	O	O	O
with	O	O	O
any	O	O	O
of	O	O	O
its	O	O	O
related	O	O	O
disorders	O	O	B-Entity
studied	O	O	O
.	O	O	O

The	O	O	O
I	O	O	B-Entity
allele	O	O	I-Entity
seemed	O	O	O
protective	O	O	O
against	O	O	O
hypertension	O	O	B-Entity
in	O	O	O
subjects	O	O	B-Entity
with	O	O	O
normal	O	O	B-Entity
,	O	O	O
not	O	O	O
high	O	O	O
,	O	O	O
waist/hip	O	O	B-Entity
ratio	O	O	I-Entity
and	O	O	O
conicity	O	O	B-Entity
index	O	O	I-Entity
compared	O	O	O
to	O	O	O
DD	O	O	B-Entity
genotype	O	O	I-Entity
carriers	O	O	I-Entity
.	O	O	O

-DOCSTART- (27781291)

Expressed	O	O	B-Entity
microRNA	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
high	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
egg	O	O	B-Entity
production	O	O	I-Entity
in	O	O	O
chicken	O	O	B-Entity
ovarian	O	O	O
follicles	O	O	O

MicroRNA	O	O	B-Entity
(	O	O	O
miRNA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
highly	O	O	O
conserved	O	O	O
class	O	O	O
of	O	O	O
small	O	O	O
noncoding	O	O	B-Entity
RNA	O	O	I-Entity
about	O	O	O
19	O	O	O
-	O	O	O
24	O	O	O
nucleotides	O	O	B-Entity
in	O	O	O
length	O	O	B-Entity
that	O	O	O
function	O	O	B-Entity
in	O	O	O
a	O	O	O
specific	O	O	O
manner	O	O	O
to	O	O	O
post-transcriptionally	O	O	B-Entity
regulate	O	O	I-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
in	O	O	O
organisms	O	O	B-Entity
.	O	O	O

Tissue	O	O	B-Entity
miRNA	O	O	B-Entity
expression	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
discovered	O	O	O
a	O	O	O
myriad	O	O	O
of	O	O	O
functions	O	O	B-Entity
for	O	O	O
miRNAs	O	O	B-Entity
in	O	O	O
various	O	O	O
aspects	O	O	O
,	O	O	O
but	O	O	O
a	O	O	O
role	O	O	O
for	O	O	O
miRNAs	O	O	O
in	O	O	O
chicken	O	O	B-Entity
ovarian	O	O	B-Entity
tissue	O	O	I-Entity
at	O	O	O
300	O	O	O
days	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
has	O	O	O
not	O	O	O
hitherto	O	O	O
been	O	O	O
reported	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
performed	O	O	O
the	O	O	O
first	O	O	O
miRNA	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
ovarian	O	O	B-Entity
tissues	O	O	I-Entity
in	O	O	O
chickens	O	O	B-Entity
with	O	O	O
low	O	O	B-Entity
and	O	O	O
high	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
egg	O	O	B-Entity
production	O	O	I-Entity
using	O	O	O
high-throughput	O	O	B-Entity
sequencing	O	O	I-Entity
.	O	O	O

By	O	O	O
comparing	O	O	O
low	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
egg	O	O	B-Entity
production	O	O	I-Entity
chickens	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
rate	O	O	O
of	O	O	O
egg	O	O	O
production	O	O	O
chickens	O	O	O
,	O	O	O
17	O	O	O
significantly	O	O	O
differentially	O	O	O
expressed	O	O	B-Entity
miRNAs	O	O	B-Entity
were	O	O	O
found	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
including	O	O	O
11	O	O	O
known	O	O	O
and	O	O	O
six	O	O	O
novel	O	O	O
miRNAs	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
all	O	O	O
11	O	O	O
known	O	O	O
miRNAs	O	O	B-Entity
were	O	O	O
involved	O	O	O
mainly	O	O	O
in	O	O	O
pathways	O	O	B-Entity
of	O	O	O
reproduction	O	O	B-Entity
regulation	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
steroid	O	O	B-Entity
hormone	O	O	I-Entity
biosynthesis	O	O	I-Entity
and	O	O	O
dopaminergic	O	O	B-Entity
synapse	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
expression	O	O	B-Entity
profiling	O	O	O
of	O	O	O
six	O	O	O
randomly	O	O	O
selected	O	O	O
differentially	O	O	O
regulated	O	O	B-Entity
miRNAs	O	O	B-Entity
were	O	O	O
validated	O	O	O
by	O	O	O
quantitative	O	O	B-Entity
real-time	O	O	I-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
RT-qPCR	O	O	B-Entity
)	O	O	O
.	O	O	O

Some	O	O	O
miRNAs	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
gga-miR-34b	O	O	B-Entity
,	O	O	O
gga-miR-34c	O	O	B-Entity
and	O	O	O
gga-miR-216b	O	O	B-Entity
,	O	O	O
were	O	O	O
reported	O	O	O
to	O	O	O
regulate	O	O	B-Entity
processes	O	O	O
such	O	O	O
as	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
,	O	O	O
apoptosis	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
and	O	O	O
were	O	O	O
expressed	O	O	B-Entity
differentially	O	O	O
in	O	O	O
ovaries	O	O	B-Entity
of	O	O	O
chickens	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
egg	O	O	B-Entity
production	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
these	O	O	O
miRNAs	O	O	O
have	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
ovary	O	O	B-Entity
development	O	O	B-Entity
and	O	O	O
reproductive	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
chicken	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
uncovered	O	O	O
that	O	O	O
a	O	O	O
significantly	O	O	O
up-regulated	O	O	B-Entity
miRNA	O	O	B-Entity
-	O	O	O
gga-miR-200a-3p	O	O	B-Entity
-is	O	O	O
ubiquitous	O	O	O
in	O	O	O
reproduction	O	O	B-Entity
-	O	O	O
regulation	O	O	B-Entity
-related	O	O	O
pathways	O	O	B-Entity
.	O	O	O

This	O	O	O
miRNA	O	O	B-Entity
may	O	O	O
play	O	O	O
a	O	O	O
special	O	O	O
central	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
reproductive	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
chicken	O	O	B-Entity
,	O	O	O
and	O	O	O
needs	O	O	O
to	O	O	O
be	O	O	O
further	O	O	O
studied	O	O	O
for	O	O	O
confirmation	O	O	O
.	O	O	O

-DOCSTART- (27784277)

Air	O	O	B-Entity
pollution	O	O	I-Entity
,	O	O	O
neighbourhood	O	O	B-Entity
and	O	O	O
maternal	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
factors	O	O	B-Entity
modify	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
smoking	O	O	B-Entity
on	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
:	O	O	O
a	O	O	O
multilevel	O	O	B-Entity
analysis	O	O	I-Entity
in	O	O	O
British	O	O	B-Entity
Columbia	O	O	I-Entity
,	O	O	O
Canada	O	O	O

Maternal	O	O	B-Entity
smoking	O	O	B-Entity
during	O	O	O
pregnancy	O	O	B-Entity
negatively	O	O	B-Entity
impacts	O	O	B-Entity
fetal	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
effect	O	O	B-Entity
is	O	O	O
not	O	O	O
homogenous	O	O	B-Entity
across	O	O	O
the	O	O	O
population	O	O	B-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
determine	O	O	O
how	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
cigarette	O	O	B-Entity
use	O	O	I-Entity
and	O	O	O
fetal	O	O	B-Entity
growth	O	O	I-Entity
is	O	O	O
modified	O	O	B-Entity
by	O	O	O
the	O	O	O
social	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
environment	O	O	I-Entity
.	O	O	O

Birth	O	O	B-Entity
records	O	O	I-Entity
with	O	O	O
covariates	O	O	O
were	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
BC	O	O	B-Entity
Perinatal	O	O	I-Entity
Database	O	O	I-Entity
Registry	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
232,291	O	O	O
)	O	O	O
.	O	O	O

Maternal	O	O	B-Entity
smoking	O	O	B-Entity
status	O	O	I-Entity
was	O	O	O
self-reported	O	O	B-Entity
as	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
cigarettes	O	O	B-Entity
smoked	O	O	B-Entity
per	O	O	B-Entity
day	O	O	I-Entity
usually	O	O	O
at	O	O	O
the	O	O	O
first	O	O	B-Entity
prenatal	O	O	I-Entity
care	O	O	I-Entity
visit	O	O	I-Entity
.	O	O	O

Census	O	O	B-Entity
dissemination	O	O	B-Entity
areas	O	O	B-Entity
(	O	O	O
DAs	O	O	B-Entity
)	O	O	O
were	O	O	O
used	O	O	O
as	O	O	O
neighbourhood	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
units	O	O	B-Entity
and	O	O	O
linked	O	O	O
to	O	O	O
individual	O	O	B-Entity
births	O	O	B-Entity
using	O	O	O
residential	O	O	B-Entity
postal	O	O	I-Entity
codes	O	O	I-Entity
to	O	O	O
assign	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	I-Entity
particulate	O	O	B-Entity
air	O	O	B-Entity
pollution	O	O	I-Entity
(	O	O	O
PM2.5	O	O	O
)	O	O	O
and	O	O	O
neighbourhood	O	O	O
-	O	O	O
level	O	O	O
attributes	O	O	B-Entity
such	O	O	O
as	O	O	O
socioeconomic	O	O	B-Entity
status	O	O	I-Entity
(	O	O	O
SES	O	O	B-Entity
)	O	O	O
,	O	O	O
proportion	O	O	B-Entity
of	O	O	O
post-secondary	O	O	B-Entity
education	O	O	I-Entity
,	O	O	O
immigrant	O	O	B-Entity
density	O	O	B-Entity
and	O	O	O
living	O	O	B-Entity
in	O	O	O
a	O	O	O
rural	O	O	B-Entity
place	O	O	I-Entity
.	O	O	O

Random	O	O	B-Entity
coefficient	O	O	B-Entity
models	O	O	B-Entity
were	O	O	O
used	O	O	O
with	O	O	O
cigarettes	O	O	B-Entity
/day	O	O	B-Entity
modeled	O	O	B-Entity
with	O	O	O
a	O	O	O
random	O	O	B-Entity
slope	O	O	B-Entity
to	O	O	O
estimate	O	O	B-Entity
its	O	O	O
between-	O	O	O
DA	O	O	B-Entity
variability	O	O	B-Entity
and	O	O	O
test	O	O	B-Entity
cross-level	O	O	B-Entity
interactions	O	O	B-Entity
with	O	O	O
the	O	O	O
neighbourhood	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
variables	O	O	B-Entity
on	O	O	O
continuous	O	O	B-Entity
birth	O	O	B-Entity
weight	O	O	I-Entity
.	O	O	O

A	O	O	O
significant	O	O	B-Entity
negative	O	O	B-Entity
and	O	O	O
non-linear	O	O	O
association	O	O	B-Entity
was	O	O	O
found	O	O	O
between	O	O	O
maternal	O	O	B-Entity
smoking	O	O	B-Entity
and	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
significant	O	O	B-Entity
between-	O	O	O
DA	O	O	B-Entity
intercept	O	O	B-Entity
variability	O	O	B-Entity
in	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
between-	O	O	O
DA	O	O	O
slope	O	O	B-Entity
variability	O	O	O
of	O	O	O
maternal	O	O	B-Entity
smoking	O	O	B-Entity
on	O	O	O
birth	O	O	O
weight	O	O	O
of	O	O	O
which	O	O	O
68	O	O	O
and	O	O	O
30	O	O	O
%	O	O	O
respectively	O	O	O
was	O	O	O
explained	O	O	O
with	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
of	O	O	O
DA	O	O	O
-	O	O	O
level	O	O	B-Entity
variables	O	O	B-Entity
and	O	O	O
their	O	O	O
cross-level	O	O	B-Entity
interactions	O	O	B-Entity
.	O	O	O

High	O	O	B-Entity
DA	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
SES	O	O	B-Entity
had	O	O	O
a	O	O	O
strong	O	O	B-Entity
positive	O	O	B-Entity
association	O	O	B-Entity
with	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
but	O	O	O
the	O	O	O
effect	O	O	B-Entity
was	O	O	O
moderated	O	O	B-Entity
with	O	O	O
increased	O	O	B-Entity
cigarettes	O	O	B-Entity
/day	O	O	B-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
heavy	O	O	B-Entity
smokers	O	O	I-Entity
showed	O	O	O
the	O	O	O
largest	O	O	B-Entity
increases	O	O	B-Entity
in	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
with	O	O	O
rising	O	O	B-Entity
neighbourhood	O	O	B-Entity
education	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

Increased	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
PM2.5	O	O	B-Entity
and	O	O	O
immigrant	O	O	B-Entity
density	O	O	B-Entity
were	O	O	O
negatively	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
birth	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
but	O	O	O
showed	O	O	O
positive	O	O	B-Entity
interactions	O	O	B-Entity
with	O	O	O
increased	O	O	B-Entity
levels	O	O	O
of	O	O	O
smoking	O	O	B-Entity
.	O	O	O

Older	O	O	O
maternal	O	O	B-Entity
age	O	O	I-Entity
and	O	O	O
suspected	O	O	B-Entity
drug	O	O	B-Entity
or	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
both	O	O	O
had	O	O	O
negative	O	O	B-Entity
interactions	O	O	B-Entity
with	O	O	O
increased	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
maternal	O	O	O
smoking	O	O	B-Entity
.	O	O	O

Maternal	O	O	B-Entity
smoking	O	O	B-Entity
had	O	O	O
a	O	O	O
negative	O	O	B-Entity
and	O	O	O
non-linear	O	O	O
dose-response	O	O	B-Entity
association	O	O	I-Entity
with	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
which	O	O	O
was	O	O	O
highly	O	O	B-Entity
variable	O	O	B-Entity
between	O	O	O
neighbourhood	O	O	B-Entity
s	O	O	O
and	O	O	O
evidence	O	O	B-Entity
of	O	O	O
effect	O	O	B-Entity
modification	O	O	B-Entity
with	O	O	O
neighbourhood	O	O	O
-	O	O	O
level	O	O	B-Entity
factors	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
focusing	O	O	O
exclusively	O	O	O
on	O	O	O
individual	O	O	B-Entity
behaviours	O	O	B-Entity
may	O	O	O
have	O	O	O
limited	O	O	B-Entity
success	O	O	B-Entity
in	O	O	O
improving	O	O	B-Entity
outcomes	O	O	B-Entity
without	O	O	B-Entity
addressing	O	O	O
the	O	O	O
contextual	O	O	B-Entity
influences	O	O	B-Entity
at	O	O	O
the	O	O	O
neighbourhood	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
.	O	O	O

Further	O	O	O
studies	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
corroborate	O	O	B-Entity
our	O	O	O
findings	O	O	B-Entity
and	O	O	O
to	O	O	O
understand	O	O	B-Entity
how	O	O	O
neighbourhood	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
attributes	O	O	B-Entity
interact	O	O	B-Entity
with	O	O	O
smoking	O	O	B-Entity
to	O	O	O
affect	O	O	B-Entity
birth	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27786590)

Individual	O	O	B-Entity
Leg	O	O	B-Entity
Muscle	O	O	I-Entity
Contributions	O	O	B-Entity
to	O	O	O
the	O	O	O
Cost	O	O	O
of	O	O	O
Walking	O	O	B-Entity
:	O	O	O
Effects	O	O	B-Entity
of	O	O	O
Age	O	O	B-Entity
and	O	O	O
Walking	O	O	O
Speed	O	O	O

This	O	O	O
study	O	O	B-Entity
examined	O	O	B-Entity
the	O	O	O
contributions	O	O	B-Entity
of	O	O	O
individual	O	O	B-Entity
muscles	O	O	B-Entity
to	O	O	O
changes	O	O	O
in	O	O	O
energetic	O	O	O
cost	O	O	B-Entity
of	O	O	I-Entity
transport	O	O	I-Entity
(	O	O	O
COT	O	O	B-Entity
)	O	O	O
over	O	O	O
seven	O	O	O
walking	O	O	B-Entity
speeds	O	O	I-Entity
,	O	O	O
and	O	O	O
compared	O	O	O
results	O	O	O
between	O	O	O
healthy	O	O	B-Entity
young	O	O	I-Entity
and	O	O	O
elderly	O	O	B-Entity
subjects	O	O	I-Entity
.	O	O	O

Twenty	O	O	O
six	O	O	O
participants	O	O	B-Entity
(	O	O	O
13	O	O	O
young	O	O	B-Entity
aged	O	O	I-Entity
18	O	O	O
-	O	O	O
30	O	O	O
;	O	O	O
13	O	O	O
old	O	O	B-Entity
aged	O	O	I-Entity
70	O	O	O
-	O	O	O
80	O	O	O
)	O	O	O
were	O	O	O
recruited	O	O	O
.	O	O	O

COT	O	O	B-Entity
(	O	O	O
O2/kg	O	O	O
body	O	O	O
mass/km	O	O	O
)	O	O	O
was	O	O	O
calculated	O	O	O
by	O	O	O
standardizing	O	O	O
the	O	O	O
mean	O	O	B-Entity
oxygen	O	O	I-Entity
consumption	O	O	I-Entity
recorded	O	O	O
during	O	O	O
steady	O	O	B-Entity
state	O	O	I-Entity
walking	O	O	I-Entity
.	O	O	O

Electromyography	O	O	B-Entity
signals	O	O	B-Entity
from	O	O	O
10	O	O	O
leg	O	O	B-Entity
muscles	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
calculate	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
activity	O	O	I-Entity
required	O	O	I-Entity
to	O	O	I-Entity
traverse	O	O	I-Entity
a	O	O	I-Entity
unit	O	O	I-Entity
of	O	O	I-Entity
distance	O	O	I-Entity
(	O	O	O
CMAPD	O	O	B-Entity
)	O	O	O
for	O	O	O
each	O	O	O
muscle	O	O	B-Entity
at	O	O	O
each	O	O	O
speed	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
old	O	O	B-Entity
group	O	O	I-Entity
CMAPD	O	O	B-Entity
was	O	O	O
correlated	O	O	B-Entity
with	O	O	O
COT	O	O	B-Entity
,	O	O	O
presented	O	O	O
higher	O	O	O
and	O	O	O
more	O	O	O
variable	O	O	O
values	O	O	O
,	O	O	O
and	O	O	O
showed	O	O	O
greater	O	O	O
increases	O	O	O
around	O	O	O
optimal	O	O	B-Entity
speed	O	O	I-Entity
for	O	O	O
all	O	O	O
studied	O	O	O
muscles	O	O	B-Entity
.	O	O	O

Soleus	O	O	B-Entity
CMAPD	O	O	B-Entity
was	O	O	O
independent	O	O	O
of	O	O	O
speed	O	O	B-Entity
in	O	O	O
the	O	O	O
young	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
but	O	O	O
this	O	O	O
was	O	O	O
not	O	O	O
evident	O	O	O
with	O	O	O
aging	O	O	B-Entity
.	O	O	O

Greater	O	O	B-Entity
energy	O	O	B-Entity
cost	O	O	I-Entity
of	O	O	O
walking	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
individuals	O	O	B-Entity
seems	O	O	O
to	O	O	O
be	O	O	O
attributable	O	O	O
to	O	O	O
increased	O	O	O
energy	O	O	O
cost	O	O	O
of	O	O	O
all	O	O	O
lower	O	O	B-Entity
limb	O	O	I-Entity
muscles	O	O	I-Entity
.	O	O	O

-DOCSTART- (27790487)

Glycated	O	O	B-Entity
Hemoglobin	O	O	I-Entity
(	O	O	O
HbA1c	O	O	B-Entity
)	O	O	O
Correlation	O	O	B-Entity
with	O	O	O
Severity	O	O	B-Entity
of	O	O	O
Coronary	O	O	B-Entity
Artery	O	O	I-Entity
Disease	O	O	I-Entity
in	O	O	O
Non-diabetic	O	O	B-Entity
Patients	O	O	B-Entity
-	O	O	O
A	O	O	O
Hospital	O	O	B-Entity
based	O	O	I-Entity
Study	O	O	B-Entity
from	O	O	O
North-Eastern	O	O	O
India	O	O	O

Glycated	O	O	B-Entity
Hemoglobin	O	O	I-Entity
(	O	O	I-Entity
HbA1c	O	O	B-Entity
)	O	O	I-Entity
levels	O	O	I-Entity
are	O	O	O
predictive	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
mortality	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
,	O	O	O
however	O	O	O
,	O	O	O
association	O	O	O
of	O	O	O
HbA1c	O	O	O
with	O	O	O
Coronary	O	O	B-Entity
Artery	O	O	I-Entity
Disease	O	O	I-Entity
(	O	O	O
CAD	O	O	B-Entity
)	O	O	O
in	O	O	O
non-diabetics	O	O	B-Entity
is	O	O	O
inconsistent	O	O	B-Entity
.	O	O	O

To	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
correlation	O	O	B-Entity
between	O	O	O
HbA1c	O	O	B-Entity
level	O	O	I-Entity
and	O	O	O
severity	O	O	B-Entity
of	O	O	O
CAD	O	O	B-Entity
in	O	O	O
non-diabetic	O	O	B-Entity
patients	O	O	I-Entity
using	O	O	O
SYNTAX	O	O	B-Entity
score	O	O	I-Entity
in	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
proven	O	O	O
CAD	O	O	O
on	O	O	O
angiography	O	O	B-Entity
at	O	O	O
Gauhati	O	O	B-Entity
Medical	O	O	I-Entity
College	O	O	I-Entity
,	O	O	O
Guwahati	O	O	B-Entity
,	O	O	I-Entity
Assam	O	O	I-Entity
,	O	O	O
India	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
major	O	O	O
tertiary	O	O	B-Entity
care	O	O	I-Entity
hospital	O	O	I-Entity
of	O	O	O
North-Eastern	O	O	B-Entity
India	O	O	I-Entity
.	O	O	O

We	O	O	O
prospectively	O	O	O
collected	O	O	O
data	O	O	B-Entity
of	O	O	O
non-diabetic	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
proven	O	O	O
CAD	O	O	B-Entity
on	O	O	O
angiography	O	O	B-Entity
from	O	O	O
June	O	O	O
2014	O	O	O
to	O	O	O
June	O	O	O
2015	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
four	O	O	O
groups	O	O	B-Entity
(	O	O	O
interquartiles	O	O	B-Entity
)	O	O	O
according	O	O	O
to	O	O	O
HbA1c	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
less	O	O	O
than	O	O	O
4.8	O	O	O
%	O	O	O
,	O	O	O
4.8	O	O	O
%	O	O	O
to	O	O	O
5.1	O	O	O
%	O	O	O
,	O	O	O
5.1	O	O	O
%	O	O	O
to	O	O	O
5.6	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
5.6	O	O	O
%	O	O	O
to	O	O	O
6.5	O	O	O
%	O	O	O
.	O	O	O

Severity	O	O	B-Entity
of	O	O	O
CAD	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
SYNTAX	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
coronary	O	O	I-Entity
vessels	O	O	I-Entity
diseased	O	O	I-Entity
.	O	O	O

We	O	O	O
compared	O	O	O
different	O	O	O
quartiles	O	O	B-Entity
of	O	O	O
HbA1c	O	O	B-Entity
with	O	O	O
regard	O	O	O
to	O	O	O
SYNTAX	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
number	O	O	O
of	O	O	O
diseased	O	O	B-Entity
vessels	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
346	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

Mean	O	O	O
age	O	O	B-Entity
was	O	O	O
58.1±10.4	O	O	O
years	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
total	O	O	O
91.9	O	O	O
%	O	O	O
(	O	O	O
318	O	O	O
)	O	O	O
were	O	O	O
males	O	O	B-Entity
,	O	O	O
44.8	O	O	O
%	O	O	O
(	O	O	O
155	O	O	O
)	O	O	O
were	O	O	O
hypertensives	O	O	B-Entity
,	O	O	O
29.2	O	O	O
%	O	O	O
(	O	O	O
101	O	O	O
)	O	O	O
were	O	O	O
smokers	O	O	B-Entity
and	O	O	O
34.7	O	O	O
%	O	O	O
(	O	O	O
120	O	O	O
)	O	O	O
were	O	O	O
dyslipidemic	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
CAD	O	O	B-Entity
severity	O	O	B-Entity
by	O	O	O
SYNTAX	O	O	B-Entity
score	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
number	O	O	O
of	O	O	O
vessels	O	O	B-Entity
involved	O	O	O
was	O	O	O
significantly	O	O	O
different	O	O	O
among	O	O	O
quartiles	O	O	B-Entity
(	O	O	O
p-values	O	O	B-Entity
<	O	O	O
0.001	O	O	O
and	O	O	O
<	O	O	O
0.001	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Increase	O	O	B-Entity
in	O	O	O
HbA1c	O	O	B-Entity
level	O	O	I-Entity
was	O	O	O
strongly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
disease	O	O	B-Entity
severity	O	O	I-Entity
and	O	O	O
higher	O	O	O
SYNTAX	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

A	O	O	O
significant	O	O	O
increase	O	O	B-Entity
was	O	O	O
noted	O	O	O
in	O	O	O
the	O	O	O
mean	O	O	O
number	O	O	O
of	O	O	O
diseased	O	O	B-Entity
vessels	O	O	I-Entity
(	O	O	O
p-value	O	O	B-Entity
<	O	O	O
0.001	O	O	O
)	O	O	O
as	O	O	O
HbA1c	O	O	B-Entity
level	O	O	I-Entity
increases	O	O	B-Entity
.	O	O	O

Age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
dyslipidemia	O	O	B-Entity
did	O	O	O
not	O	O	O
show	O	O	O
significant	O	O	O
difference	O	O	O
among	O	O	O
quartiles	O	O	B-Entity
however	O	O	O
smoking	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
independent	O	O	O
predictor	O	O	B-Entity
of	O	O	O
severity	O	O	B-Entity
of	O	O	O
CAD	O	O	B-Entity
by	O	O	O
SYNTAX	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

From	O	O	O
this	O	O	O
clinical	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
we	O	O	O
can	O	O	O
conclude	O	O	O
that	O	O	O
a	O	O	O
significant	O	O	O
correlation	O	O	B-Entity
exists	O	O	O
between	O	O	O
HbA1c	O	O	B-Entity
and	O	O	O
severity	O	O	B-Entity
of	O	O	O
CAD	O	O	B-Entity
by	O	O	O
SYNTAX	O	O	B-Entity
score	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
number	O	O	O
of	O	O	O
vessels	O	O	B-Entity
involved	O	O	O
in	O	O	O
non-	O	O	B-Entity
diabetes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27792780)

On	O	O	O
the	O	O	O
Relation	O	O	B-Entity
between	O	O	O
Face	O	O	B-Entity
and	O	O	O
Object	O	O	B-Entity
Recognition	O	O	I-Entity
in	O	O	O
Developmental	O	O	B-Entity
Prosopagnosia	O	O	I-Entity
:	O	O	O
No	O	O	O
Dissociation	O	O	B-Entity
but	O	O	O
a	O	O	O
Systematic	O	O	B-Entity
Association	O	O	O

There	O	O	O
is	O	O	O
an	O	O	O
ongoing	O	O	O
debate	O	O	B-Entity
about	O	O	O
whether	O	O	O
face	O	O	B-Entity
recognition	O	O	I-Entity
and	O	O	O
object	O	O	B-Entity
recognition	O	O	I-Entity
constitute	O	O	O
separate	O	O	B-Entity
domains	O	O	B-Entity
.	O	O	O

Clarification	O	O	B-Entity
of	O	O	O
this	O	O	O
issue	O	O	B-Entity
can	O	O	O
have	O	O	O
important	O	O	B-Entity
theoretical	O	O	B-Entity
implications	O	O	B-Entity
as	O	O	O
face	O	O	B-Entity
recognition	O	O	I-Entity
is	O	O	O
often	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
prime	O	O	O
example	O	O	B-Entity
of	O	O	O
domain	O	O	B-Entity
-	O	O	O
specificity	O	O	B-Entity
in	O	O	O
mind	O	O	B-Entity
and	O	O	O
brain	O	O	B-Entity
.	O	O	O

An	O	O	O
important	O	O	B-Entity
source	O	O	B-Entity
of	O	O	O
input	O	O	B-Entity
to	O	O	O
this	O	O	O
debate	O	O	B-Entity
comes	O	O	O
from	O	O	O
studies	O	O	O
of	O	O	O
individuals	O	O	B-Entity
with	O	O	O
developmental	O	O	B-Entity
prosopagnosia	O	O	I-Entity
,	O	O	O
suggesting	O	O	B-Entity
that	O	O	O
face	O	O	B-Entity
recognition	O	O	I-Entity
can	O	O	O
be	O	O	O
selectively	O	O	B-Entity
impaired	O	O	I-Entity
.	O	O	O

We	O	O	O
put	O	O	O
the	O	O	O
selectivity	O	O	B-Entity
hypothesis	O	O	B-Entity
to	O	O	O
test	O	O	B-Entity
by	O	O	O
assessing	O	O	O
the	O	O	O
performance	O	O	B-Entity
of	O	O	O
10	O	O	O
individuals	O	O	B-Entity
with	O	O	O
developmental	O	O	B-Entity
prosopagnosia	O	O	I-Entity
on	O	O	O
demanding	O	O	O
tests	O	O	O
of	O	O	O
visual	O	O	B-Entity
object	O	O	I-Entity
processing	O	O	I-Entity
involving	O	O	B-Entity
both	O	O	O
regular	O	O	B-Entity
and	O	O	O
degraded	O	O	B-Entity
drawings	O	O	B-Entity
.	O	O	O

None	O	O	O
of	O	O	O
the	O	O	O
individuals	O	O	B-Entity
exhibited	O	O	O
a	O	O	O
clear	O	O	O
dissociation	O	O	B-Entity
between	O	O	O
face	O	O	B-Entity
and	O	O	O
object	O	O	B-Entity
recognition	O	O	I-Entity
,	O	O	O
and	O	O	O
as	O	O	O
a	O	O	O
group	O	O	B-Entity
they	O	O	O
were	O	O	O
significantly	O	O	B-Entity
more	O	O	O
affected	O	O	B-Entity
by	O	O	O
degradation	O	O	B-Entity
of	O	O	O
objects	O	O	B-Entity
than	O	O	O
control	O	O	B-Entity
participants	O	O	B-Entity
.	O	O	O

Importantly	O	O	O
,	O	O	O
we	O	O	O
also	O	O	O
find	O	O	O
positive	O	O	B-Entity
correlations	O	O	B-Entity
between	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
the	O	O	O
face	O	O	B-Entity
recognition	O	O	I-Entity
impairment	O	O	B-Entity
and	O	O	O
the	O	O	O
degree	O	O	B-Entity
of	O	O	O
impaired	O	O	B-Entity
performance	O	O	B-Entity
with	O	O	O
degraded	O	O	B-Entity
objects	O	O	B-Entity
.	O	O	O

This	O	O	O
suggests	O	O	O
that	O	O	O
the	O	O	O
face	O	O	B-Entity
and	O	O	O
object	O	O	B-Entity
deficits	O	O	B-Entity
are	O	O	O
systematically	O	O	O
related	O	O	B-Entity
rather	O	O	O
than	O	O	O
coincidental	O	O	B-Entity
.	O	O	O

We	O	O	O
conclude	O	O	O
that	O	O	O
at	O	O	O
present	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
strong	O	O	O
evidence	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
on	O	O	O
developmental	O	O	B-Entity
prosopagnosia	O	O	I-Entity
supporting	O	O	O
domain	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
accounts	O	O	O
of	O	O	O
face	O	O	B-Entity
recognition	O	O	I-Entity
.	O	O	O

-DOCSTART- (27794081)

Reduced	O	O	B-Entity
Chest	O	O	I-Entity
and	O	O	O
Abdominal	O	O	B-Entity
Wall	O	O	I-Entity
Mobility	O	O	B-Entity
and	O	O	O
Their	O	O	O
Relationship	O	O	B-Entity
to	O	O	O
Lung	O	O	B-Entity
Function	O	O	I-Entity
,	O	O	O
Respiratory	O	O	B-Entity
Muscle	O	O	B-Entity
Strength	O	O	I-Entity
,	O	O	O
and	O	O	O
Exercise	O	O	B-Entity
Tolerance	O	O	I-Entity
in	O	O	O
Subjects	O	O	B-Entity
With	O	O	O
COPD	O	O	O

Advanced	O	O	O
air-flow	O	O	B-Entity
limitation	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
COPD	O	O	B-Entity
leads	O	O	O
to	O	O	O
a	O	O	O
reduction	O	O	B-Entity
in	O	O	O
vital	O	O	B-Entity
capacity	O	O	I-Entity
,	O	O	O
respiratory	O	O	B-Entity
muscle	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
and	O	O	O
exercise	O	O	B-Entity
capacity	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
impact	O	O	O
on	O	O	O
chest	O	O	B-Entity
and	O	O	O
abdominal	O	O	B-Entity
wall	O	O	I-Entity
mobility	O	O	B-Entity
is	O	O	O
unknown	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
ascertain	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
COPD	O	O	B-Entity
with	O	O	O
reduced	O	O	B-Entity
chest	O	O	I-Entity
and	O	O	O
abdominal	O	O	B-Entity
wall	O	O	I-Entity
mobility	O	O	B-Entity
and	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
reduced	O	O	O
chest	O	O	O
and	O	O	O
abdominal	O	O	O
wall	O	O	O
mobility	O	O	O
on	O	O	O
pulmonary	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
respiratory	O	O	B-Entity
muscle	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
and	O	O	O
exercise	O	O	B-Entity
capacity	O	O	I-Entity
.	O	O	O

In	O	O	O
51	O	O	O
elderly	O	O	B-Entity
male	O	O	B-Entity
subjects	O	O	B-Entity
with	O	O	O
COPD	O	O	B-Entity
,	O	O	O
chest	O	O	B-Entity
and	O	O	O
abdominal	O	O	B-Entity
wall	O	O	I-Entity
mobility	O	O	B-Entity
,	O	O	O
FVC	O	O	B-Entity
,	O	O	O
FEV1	O	O	B-Entity
,	O	O	O
FEV1/FVC	O	O	B-Entity
,	O	O	O
maximal	O	O	B-Entity
inspiratory	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
PImax	O	O	B-Entity
)	O	O	O
,	O	O	O
maximal	O	O	B-Entity
expiratory	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
PEmax	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
6-min	O	O	B-Entity
walk	O	O	I-Entity
distance	O	O	I-Entity
(	O	O	O
6MWD	O	O	B-Entity
)	O	O	O
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Chest	O	O	B-Entity
and	O	O	O
abdominal	O	O	B-Entity
wall	O	O	I-Entity
mobility	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
using	O	O	O
the	O	O	O
breathing	O	O	B-Entity
movement	O	O	B-Entity
scale	O	O	I-Entity
(	O	O	O
0	O	O	O
-	O	O	O
8)	O	O	O
at	O	O	O
the	O	O	O
3	O	O	O
regions	O	O	B-Entity
(	O	O	O
upper	O	O	B-Entity
chest	O	O	I-Entity
,	O	O	O
lower	O	O	B-Entity
chest	O	O	I-Entity
,	O	O	O
and	O	O	O
abdomen	O	O	B-Entity
)	O	O	O
.	O	O	O

Reduced	O	O	B-Entity
mobility	O	O	I-Entity
was	O	O	O
defined	O	O	O
as	O	O	O
a	O	O	O
value	O	O	B-Entity
lower	O	O	B-Entity
than	O	O	O
the	O	O	O
lower	O	O	B-Entity
limit	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
normal	O	O	I-Entity
scale	O	O	I-Entity
.	O	O	O

The	O	O	O
unpaired	O	O	B-Entity
t	O	O	I-Entity
test	O	O	I-Entity
,	O	O	O
Mann-Whitney	O	O	B-Entity
test	O	O	I-Entity
,	O	O	O
and	O	O	O
multiple	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
were	O	O	O
performed	O	O	B-Entity
.	O	O	O

The	O	O	O
percentages	O	O	B-Entity
of	O	O	O
subjects	O	O	B-Entity
with	O	O	O
reduced	O	O	B-Entity
mobility	O	O	I-Entity
were	O	O	O
78	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
upper	O	O	B-Entity
chest	O	O	I-Entity
,	O	O	O
76	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
lower	O	O	B-Entity
chest	O	O	I-Entity
,	O	O	O
and	O	O	O
53	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
abdomen	O	O	B-Entity
.	O	O	O

The	O	O	O
subjects	O	O	B-Entity
with	O	O	O
reduced	O	O	B-Entity
mobility	O	O	B-Entity
had	O	O	O
significantly	O	O	B-Entity
low	O	O	I-Entity
FVC	O	O	B-Entity
,	O	O	O
FEV1	O	O	B-Entity
,	O	O	O
and	O	O	O
6MWD	O	O	B-Entity
in	O	O	O
each	O	O	O
region	O	O	B-Entity
and	O	O	O
significantly	O	O	O
low	O	O	O
FEV1/FVC	O	O	B-Entity
,	O	O	O
PImax	O	O	B-Entity
,	O	O	O
and	O	O	O
PEmax	O	O	B-Entity
in	O	O	O
the	O	O	O
abdominal	O	O	B-Entity
region	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
those	O	O	O
with	O	O	O
nonreduced	O	O	O
mobility	O	O	O
.	O	O	O

FVC	O	O	B-Entity
and	O	O	O
6MWD	O	O	B-Entity
were	O	O	O
independently	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
scale	O	O	B-Entity
values	O	O	I-Entity
in	O	O	O
each	O	O	O
region	O	O	B-Entity
and	O	O	O
with	O	O	O
the	O	O	O
abdominal	O	O	B-Entity
scale	O	O	B-Entity
value	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
subjects	O	O	B-Entity
with	O	O	O
COPD	O	O	B-Entity
had	O	O	O
reduced	O	O	B-Entity
chest	O	O	I-Entity
and	O	O	O
abdominal	O	O	B-Entity
wall	O	O	I-Entity
mobility	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
independently	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
FVC	O	O	B-Entity
.	O	O	O

Even	O	O	O
though	O	O	O
abdominal	O	O	B-Entity
wall	O	O	I-Entity
mobility	O	O	B-Entity
was	O	O	O
relatively	O	O	O
preserved	O	O	O
compared	O	O	B-Entity
with	O	O	O
chest	O	O	B-Entity
wall	O	O	I-Entity
mobility	O	O	O
,	O	O	O
it	O	O	O
was	O	O	O
also	O	O	O
independently	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
6MWD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27794108)

FGF21	O	O	B-Entity
is	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
mitochondrial	O	O	B-Entity
translation	O	O	I-Entity
and	O	O	O
mtDNA	O	O	B-Entity
maintenance	O	O	B-Entity
disorders	O	O	O

To	O	O	O
validate	O	O	O
new	O	O	O
mitochondrial	O	O	B-Entity
myopathy	O	O	I-Entity
serum	O	O	B-Entity
biomarkers	O	O	B-Entity
for	O	O	O
diagnostic	O	O	B-Entity
use	O	O	I-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
serum	O	O	B-Entity
FGF21	O	O	B-Entity
(	O	O	O
S-FGF21	O	O	B-Entity
)	O	O	O
and	O	O	O
GDF15	O	O	B-Entity
from	O	O	O
patients	O	O	B-Entity
with	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
mitochondrial	O	O	B-Entity
diseases	O	O	I-Entity
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
nonmitochondrial	O	O	B-Entity
disorders	O	O	I-Entity
partially	O	O	B-Entity
overlapping	O	O	B-Entity
with	O	O	O
mitochondrial	O	O	B-Entity
disorder	O	O	I-Entity
phenotypes	O	O	B-Entity
.	O	O	O

We	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
did	O	O	O
a	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
S-FGF21	O	O	B-Entity
in	O	O	O
mitochondrial	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
analyzed	O	O	B-Entity
S-Fgf21	O	O	B-Entity
and	O	O	O
skeletal	O	O	B-Entity
muscle	O	O	B-Entity
Fgf21	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
6	O	O	O
mouse	O	O	B-Entity
models	O	O	B-Entity
with	O	O	O
different	O	O	B-Entity
muscle	O	O	O
-	O	O	O
manifesting	O	O	B-Entity
mitochondrial	O	O	B-Entity
dysfunctions	O	O	I-Entity
.	O	O	O

We	O	O	O
report	O	O	O
that	O	O	O
S-FGF21	O	O	B-Entity
consistently	O	O	O
increases	O	O	B-Entity
in	O	O	O
primary	O	O	B-Entity
mitochondrial	O	O	B-Entity
myopathy	O	O	I-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
mitochondrial	O	O	B-Entity
translation	O	O	I-Entity
defects	O	O	B-Entity
or	O	O	O
mitochondrial	O	O	B-Entity
DNA	O	O	I-Entity
(	O	O	I-Entity
mtDNA	O	O	I-Entity
)	O	O	I-Entity
deletions	O	O	I-Entity
(	O	O	O
675	O	O	O
and	O	O	O
347	O	O	O
pg/mL	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
controls	O	O	B-Entity
:	O	O	O
66	O	O	O
pg/mL	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
for	O	O	O
both	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
corroborated	O	O	O
in	O	O	O
mice	O	O	B-Entity
(	O	O	O
mtDNA	O	O	B-Entity
deletions	O	O	I-Entity
1,163	O	O	O
vs	O	O	O
379	O	O	O
pg/mL	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
patients	O	O	B-Entity
and	O	O	O
mice	O	O	B-Entity
with	O	O	O
structural	O	O	B-Entity
respiratory	O	O	I-Entity
chain	O	O	I-Entity
subunit	O	O	I-Entity
or	O	O	I-Entity
assembly	O	O	I-Entity
factor	O	O	I-Entity
defects	O	O	I-Entity
showed	O	O	O
low	O	O	B-Entity
induction	O	O	B-Entity
(	O	O	O
human	O	O	B-Entity
335	O	O	O
pg/mL	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
;	O	O	O
mice	O	O	O
335	O	O	O
pg/mL	O	O	O
,	O	O	O
not	O	O	B-Entity
significant	O	O	I-Entity
)	O	O	O
.	O	O	O

Overall	O	O	B-Entity
specificities	O	O	B-Entity
of	O	O	O
FGF21	O	O	B-Entity
and	O	O	O
GDF15	O	O	B-Entity
to	O	O	O
find	O	O	O
patients	O	O	B-Entity
with	O	O	O
mitochondrial	O	O	B-Entity
myopathy	O	O	I-Entity
were	O	O	O
89.3	O	O	O
%	O	O	O
vs	O	O	O
86.4	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
sensitivities	O	O	B-Entity
67.3	O	O	O
%	O	O	O
and	O	O	O
76.0	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
GDF15	O	O	B-Entity
was	O	O	O
increased	O	O	B-Entity
also	O	O	O
in	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
nonmitochondrial	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

S-FGF21	O	O	B-Entity
is	O	O	O
a	O	O	O
specific	O	O	B-Entity
biomarker	O	O	B-Entity
for	O	O	O
muscle	O	O	B-Entity
-	O	O	O
manifesting	O	O	B-Entity
defects	O	O	B-Entity
of	O	O	O
mitochondrial	O	O	B-Entity
translation	O	O	I-Entity
,	O	O	O
including	O	O	O
mitochondrial	O	O	O
transfer-RNA	O	O	B-Entity
mutations	O	O	B-Entity
and	O	O	O
primary	O	O	B-Entity
and	O	O	O
secondary	O	O	B-Entity
mtDNA	O	O	B-Entity
deletions	O	O	I-Entity
,	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
causes	O	O	B-Entity
of	O	O	O
mitochondrial	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
normal	O	O	B-Entity
S-FGF21	O	O	B-Entity
does	O	O	O
not	O	O	B-Entity
exclude	O	O	B-Entity
structural	O	O	B-Entity
respiratory	O	O	I-Entity
chain	O	O	I-Entity
complex	O	O	I-Entity
or	O	O	I-Entity
assembly	O	O	I-Entity
factor	O	O	I-Entity
defects	O	O	I-Entity
,	O	O	O
important	O	O	O
to	O	O	O
acknowledge	O	O	O
in	O	O	O
diagnostics	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
provides	O	O	O
Class	O	O	B-Entity
III	O	O	I-Entity
evidence	O	O	B-Entity
that	O	O	O
elevated	O	O	B-Entity
S-FGF21	O	O	B-Entity
accurately	O	O	O
distinguishes	O	O	O
patients	O	O	B-Entity
with	O	O	O
mitochondrial	O	O	B-Entity
myopathies	O	O	B-Entity
from	O	O	O
patients	O	O	O
with	O	O	O
other	O	O	O
conditions	O	O	B-Entity
,	O	O	O
and	O	O	O
FGF21	O	O	B-Entity
and	O	O	O
GDF15	O	O	B-Entity
mitochondrial	O	O	B-Entity
myopathy	O	O	I-Entity
from	O	O	O
other	O	O	O
myopathies	O	O	O
.	O	O	O

-DOCSTART- (27794490)

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
captopril	O	O	B-Entity
on	O	O	O
lipopolysaccharide	O	O	B-Entity
induced	O	O	B-Entity
learning	O	O	B-Entity
and	O	O	O
memory	O	O	B-Entity
impairments	O	O	I-Entity
and	O	O	O
the	O	O	O
brain	O	O	B-Entity
cytokine	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
damage	O	O	B-Entity
in	O	O	O
rats	O	O	O

Renin-angiotensin	O	O	B-Entity
system	O	O	I-Entity
has	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
also	O	O	O
involves	O	O	O
in	O	O	O
learning	O	O	B-Entity
and	O	O	O
memory	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
captopril	O	O	B-Entity
on	O	O	O
lipopolysaccharide	O	O	B-Entity
(	O	O	O
LPS	O	O	B-Entity
)	O	O	O
induced	O	O	B-Entity
learning	O	O	B-Entity
and	O	O	O
memory	O	O	B-Entity
impairments	O	O	I-Entity
,	O	O	O
hippocampal	O	O	B-Entity
cytokine	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
brain	O	O	B-Entity
tissues	O	O	I-Entity
oxidative	O	O	B-Entity
damage	O	O	B-Entity
was	O	O	O
investigated	O	O	B-Entity
.	O	O	O

The	O	O	O
rats	O	O	B-Entity
were	O	O	O
divided	O	O	O
and	O	O	O
treated	O	O	O
:	O	O	O
[	O	O	O
1	O	O	O
]	O	O	O
saline	O	O	B-Entity
(	O	O	O
Control	O	O	B-Entity
)	O	O	O
,	O	O	O
[	O	O	O
2	O	O	O
]	O	O	O
LPS	O	O	B-Entity
(	O	O	O
1mg/kg	O	O	O
)	O	O	O
,	O	O	O
[	O	O	O
3	O	O	O
-	O	O	O
5	O	O	O
]	O	O	O
10	O	O	O
,	O	O	O
50	O	O	O
or	O	O	O
100mg/kg	O	O	O
captopril	O	O	B-Entity
30min	O	O	O
before	O	O	O
LPS	O	O	O
.	O	O	O

The	O	O	O
treatment	O	O	B-Entity
was	O	O	O
started	O	O	O
since	O	O	O
six	O	O	O
days	O	O	B-Entity
before	O	O	O
the	O	O	O
behavioral	O	O	B-Entity
experiments	O	O	I-Entity
and	O	O	O
continued	O	O	O
during	O	O	O
the	O	O	O
behavioral	O	O	B-Entity
tests	O	O	I-Entity
(	O	O	O
LPS	O	O	B-Entity
injection	O	O	B-Entity
two	O	O	O
h	O	O	O
before	O	O	O
each	O	O	O
behavioral	O	O	B-Entity
experiment	O	O	I-Entity
)	O	O	O
.	O	O	O

Administration	O	O	B-Entity
of	O	O	O
LPS	O	O	B-Entity
prolonged	O	O	B-Entity
the	O	O	O
escape	O	O	O
latency	O	O	B-Entity
and	O	O	O
traveled	O	O	O
path	O	O	O
to	O	O	O
find	O	O	O
the	O	O	O
platform	O	O	O
in	O	O	O
Morris	O	O	B-Entity
water	O	O	I-Entity
maze	O	O	I-Entity
(	O	O	I-Entity
MWM	O	O	I-Entity
)	O	O	I-Entity
test	O	O	B-Entity
(	O	O	O
P<0.01-P<0.001	O	O	O
)	O	O	O
while	O	O	O
,	O	O	O
shortened	O	O	O
the	O	O	O
latency	O	O	O
to	O	O	O
enter	O	O	O
the	O	O	O
dark	O	O	B-Entity
compartment	O	O	I-Entity
in	O	O	O
passive	O	O	B-Entity
avoidance	O	O	I-Entity
(	O	O	O
PA	O	O	B-Entity
)	O	O	O
test	O	O	O
(	O	O	O
P<0.001	O	O	O
)	O	O	O
.	O	O	O

Pretreatment	O	O	B-Entity
by	O	O	O
all	O	O	O
doses	O	O	B-Entity
of	O	O	O
captopril	O	O	B-Entity
improved	O	O	B-Entity
performances	O	O	B-Entity
of	O	O	O
the	O	O	O
rats	O	O	B-Entity
in	O	O	O
MWM	O	O	B-Entity
(	O	O	O
P<0.05-P<0.001	O	O	O
)	O	O	O
and	O	O	O
also	O	O	O
prolonged	O	O	B-Entity
the	O	O	O
latency	O	O	B-Entity
to	O	O	O
enter	O	O	O
the	O	O	O
dark	O	O	B-Entity
in	O	O	O
PA	O	O	B-Entity
test	O	O	B-Entity
(	O	O	O
P<0.001	O	O	O
)	O	O	O
.	O	O	O

LPS	O	O	B-Entity
also	O	O	O
increased	O	O	B-Entity
IL-6	O	O	B-Entity
,	O	O	O
TNF-α	O	O	B-Entity
,	O	O	O
malondialdehyde	O	O	B-Entity
(	O	O	O
MDA	O	O	B-Entity
)	O	O	O
and	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
NO	O	O	B-Entity
)	O	O	O
metabolites	O	O	B-Entity
in	O	O	O
the	O	O	O
hippocampal	O	O	B-Entity
tissues	O	O	B-Entity
(	O	O	O
P<0.05-P<0.001	O	O	O
)	O	O	O
which	O	O	O
were	O	O	O
prevented	O	O	B-Entity
by	O	O	O
captopril	O	O	B-Entity
(	O	O	O
P<0.05-P<0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
thiol	O	O	B-Entity
,	O	O	O
superoxide	O	O	B-Entity
dismutase	O	O	I-Entity
(	O	O	O
SOD	O	O	B-Entity
)	O	O	O
and	O	O	O
catalase	O	O	B-Entity
(	O	O	O
CAT	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
of	O	O	O
LPS	O	O	B-Entity
group	O	O	B-Entity
were	O	O	O
lower	O	O	O
than	O	O	O
the	O	O	O
control	O	O	B-Entity
(	O	O	O
P<0.001	O	O	O
)	O	O	O
while	O	O	O
,	O	O	O
they	O	O	O
were	O	O	O
enhanced	O	O	B-Entity
when	O	O	O
the	O	O	O
aniamls	O	O	B-Entity
were	O	O	O
pretreated	O	O	B-Entity
by	O	O	O
captopril	O	O	B-Entity
(	O	O	O
P<0.01-P<0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
present	O	O	O
study	O	O	O
showed	O	O	O
that	O	O	O
captopril	O	O	B-Entity
improved	O	O	B-Entity
the	O	O	O
LPS	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
learning	O	O	B-Entity
and	O	O	O
memory	O	O	B-Entity
impairments	O	O	I-Entity
in	O	O	O
rats	O	O	B-Entity
which	O	O	O
were	O	O	O
accompanied	O	O	O
with	O	O	O
attenuating	O	O	B-Entity
hippocampal	O	O	B-Entity
cytokine	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
improving	O	O	B-Entity
the	O	O	O
brain	O	O	B-Entity
tissues	O	O	I-Entity
oxidative	O	O	B-Entity
damage	O	O	B-Entity
criteria	O	O	B-Entity
.	O	O	O

-DOCSTART- (27795701)

Targeted	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
gastric	O	O	O
cancer	O	O	O

Gastric	O	O	B-Entity
cancer	O	O	B-Entity
is	O	O	O
the	O	O	O
fourth	O	O	O
most	O	O	O
common	O	O	O
cancer	O	O	O
worldwide	O	O	O
.	O	O	O

Surgery	O	O	B-Entity
in	O	O	O
combination	O	O	O
with	O	O	O
multimodal	O	O	B-Entity
therapy	O	O	I-Entity
provides	O	O	O
the	O	O	O
only	O	O	O
curative	O	O	B-Entity
therapy	O	O	I-Entity
until	O	O	O
now	O	O	O
.	O	O	O

The	O	O	O
importance	O	O	O
of	O	O	O
targeted	O	O	B-Entity
therapy	O	O	I-Entity
became	O	O	O
clear	O	O	O
over	O	O	O
the	O	O	O
last	O	O	O
few	O	O	O
years	O	O	B-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
implication	O	O	B-Entity
of	O	O	O
HER2	O	O	B-Entity
and	O	O	O
angiogenesis	O	O	B-Entity
-directed	O	O	O
targeted	O	O	B-Entity
therapies	O	O	I-Entity
major	O	O	O
advances	O	O	O
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
could	O	O	O
be	O	O	O
reached	O	O	O
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
benefits	O	O	O
in	O	O	O
survival	O	O	O
remain	O	O	O
unsatisfactory	O	O	O
and	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
resistance	O	O	B-Entity
to	O	O	O
monoclonal	O	O	B-Entity
antibodies	O	O	I-Entity
is	O	O	O
arising	O	O	O
.	O	O	O

A	O	O	O
comprehensive	O	O	B-Entity
and	O	O	O
comparative	O	O	B-Entity
literature	O	O	B-Entity
research	O	O	B-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
status	O	O	O
of	O	O	O
HER2	O	O	B-Entity
and	O	O	O
angiogenesis	O	O	B-Entity
-directed	O	O	O
targeted	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Up	O	O	O
to	O	O	O
now	O	O	O
,	O	O	O
trastuzumab	O	O	B-Entity
and	O	O	O
ramucirumab	O	O	B-Entity
are	O	O	O
the	O	O	O
only	O	O	O
agents	O	O	B-Entity
showing	O	O	O
remarkable	O	O	O
benefits	O	O	O
in	O	O	O
the	O	O	O
therapy	O	O	B-Entity
for	O	O	O
the	O	O	O
patients	O	O	B-Entity
suffering	O	O	O
from	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
limitations	O	O	O
of	O	O	O
targeted	O	O	B-Entity
therapies	O	O	I-Entity
in	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
are	O	O	O
mainly	O	O	O
associated	O	O	O
with	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
secondary	O	O	O
resistance	O	O	B-Entity
.	O	O	O

Addition	O	O	O
of	O	O	O
targeted	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
second-line	O	O	B-Entity
treatment	O	O	I-Entity
is	O	O	O
beneficial	O	O	O
when	O	O	O
compared	O	O	O
with	O	O	O
chemotherapy	O	O	B-Entity
alone	O	O	O
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
results	O	O	B-Entity
in	O	O	O
first-line	O	O	B-Entity
treatment	O	O	I-Entity
remain	O	O	O
modest	O	O	O
.	O	O	O

Therefore	O	O	O
,	O	O	O
new	O	O	O
therapeutic	O	O	B-Entity
agents	O	O	I-Entity
and	O	O	O
combinations	O	O	B-Entity
in	O	O	O
the	O	O	O
first-line	O	O	B-Entity
treatment	O	O	I-Entity
of	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
are	O	O	O
urgently	O	O	O
needed	O	O	O
and	O	O	O
remain	O	O	O
to	O	O	O
be	O	O	O
validated	O	O	O
in	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
.	O	O	O

-DOCSTART- (27795726)

Serum	O	O	B-Entity
C-Reactive	O	O	I-Entity
Protein	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
with	O	O	O
Liver	O	O	B-Entity
Disease	O	O	I-Entity
and	O	O	O
Ascites	O	O	O

The	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
peritonitis	O	O	B-Entity
as	O	O	O
a	O	O	O
complication	O	O	B-Entity
of	O	O	O
cirrhosis	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	O
clinical	O	O	O
problem	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
serum	O	O	B-Entity
C-reactive	O	O	I-Entity
protein	O	O	I-Entity
levels	O	O	I-Entity
as	O	O	O
a	O	O	O
diagnostic	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
spontaneous	O	O	B-Entity
bacterial	O	O	I-Entity
peritonitis	O	O	I-Entity
(	O	O	O
SBP	O	O	B-Entity
)	O	O	O
in	O	O	O
child	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
liver	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
150	O	O	O
children	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
liver	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
ascites	O	O	B-Entity
upon	O	O	O
admission	O	O	B-Entity
to	O	O	O
Nemazee	O	O	B-Entity
Teaching	O	O	I-Entity
Hospital	O	O	I-Entity
(	O	O	O
Shiraz	O	O	B-Entity
,	O	O	O
Iran	O	O	B-Entity
)	O	O	O
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
spontaneous	O	O	B-Entity
bacterial	O	O	I-Entity
peritonitis	O	O	I-Entity
and	O	O	O
sterile	O	O	B-Entity
ascetic	O	O	I-Entity
fluid	O	O	I-Entity
groups	O	O	I-Entity
according	O	O	O
to	O	O	O
the	O	O	O
PMN	O	O	B-Entity
count	O	O	I-Entity
≥	O	O	O
250/mm(3	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
ascetic	O	O	B-Entity
fluids	O	O	I-Entity
.	O	O	O

Routine	O	O	B-Entity
laboratory	O	O	I-Entity
tests	O	O	I-Entity
were	O	O	O
conducted	O	O	O
and	O	O	O
quantitative	O	O	O
C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	I-Entity
CRP	O	O	I-Entity
)	O	O	I-Entity
levels	O	O	I-Entity
were	O	O	O
measured	O	O	O
for	O	O	O
all	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
.	O	O	O

Accuracy	O	O	B-Entity
,	O	O	O
sensitivity	O	O	B-Entity
,	O	O	I-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
of	O	O	O
CRP	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
for	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
SBP	O	O	B-Entity
.	O	O	O

Of	O	O	O
150	O	O	O
cirrhotic	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
109	O	O	O
patients	O	O	O
presented	O	O	O
without	O	O	O
SBP	O	O	B-Entity
(	O	O	O
52.29	O	O	O
%	O	O	O
male	O	O	B-Entity
,	O	O	O
mean	O	O	B-Entity
age	O	O	I-Entity
:	O	O	O
5.02	O	O	O
±	O	O	O
4.49	O	O	O
years	O	O	B-Entity
)	O	O	O
and	O	O	O
41	O	O	O
patients	O	O	O
presented	O	O	O
with	O	O	O
SBP	O	O	O
(	O	O	O
51.21	O	O	O
%	O	O	O
male	O	O	O
,	O	O	O
mean	O	O	O
age	O	O	O
:	O	O	O
4.71	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Cell	O	O	B-Entity
counts	O	O	I-Entity
,	O	O	O
protein	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
albumin	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
and	O	O	O
lactate	O	O	B-Entity
dehydrogenize	O	O	I-Entity
(	O	O	I-Entity
LDH	O	O	I-Entity
)	O	O	I-Entity
levels	O	O	I-Entity
of	O	O	O
the	O	O	O
ascetic	O	O	B-Entity
fluid	O	O	I-Entity
and	O	O	O
serum	O	O	B-Entity
samples	O	O	I-Entity
in	O	O	O
the	O	O	O
SBP	O	O	B-Entity
group	O	O	O
were	O	O	O
higher	O	O	O
than	O	O	O
the	O	O	O
rates	O	O	O
for	O	O	O
those	O	O	O
without	O	O	O
SBP	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
(	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
±	O	O	O
SD	O	O	O
of	O	O	O
CRP	O	O	B-Entity
in	O	O	O
the	O	O	O
SBP	O	O	B-Entity
group	O	O	O
(	O	O	O
36.89	O	O	O
±	O	O	O
23.43	O	O	O
)	O	O	O
increased	O	O	O
significantly	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
rate	O	O	O
among	O	O	O
those	O	O	O
without	O	O	O
SBP	O	O	O
(	O	O	O
21.59	O	O	O
±	O	O	O
15.43	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
percentages	O	O	O
for	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
of	O	O	O
CRP	O	O	B-Entity
,	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
SBP	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
PMN	O	O	B-Entity
count	O	O	I-Entity
≥	O	O	O
250/mm(3	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
cultured	O	O	B-Entity
ascites	O	O	I-Entity
were	O	O	O
69.23	O	O	O
%	O	O	O
,	O	O	O
90.25	O	O	O
%	O	O	O
,	O	O	O
88.43	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
84.32	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
areas	O	O	O
under	O	O	O
the	O	O	O
curve	O	O	O
of	O	O	O
CRP	O	O	B-Entity
for	O	O	O
SBP	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
PMN	O	O	B-Entity
count	O	O	I-Entity
≥	O	O	O
250/mm(3	O	O	O
)	O	O	O
and	O	O	O
cultured	O	O	B-Entity
ascites	O	O	I-Entity
was	O	O	O
0.94	O	O	O
(	O	O	O
CI	O	O	O
95	O	O	O
%	O	O	O
:	O	O	O
0.90	O	O	O
to	O	O	O
0.96	O	O	O
)	O	O	O
and	O	O	O
0.85	O	O	O
(	O	O	O
CI	O	O	O
95	O	O	O
%	O	O	O
:	O	O	O
0.84	O	O	O
to	O	O	O
0.92	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
showed	O	O	O
that	O	O	O
CRP	O	O	B-Entity
is	O	O	O
a	O	O	O
marker	O	O	O
with	O	O	O
high	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
for	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
SBP	O	O	B-Entity
in	O	O	O
cirrhotic	O	O	B-Entity
children	O	O	B-Entity
.	O	O	O

-DOCSTART- (27796364)

Structure	O	O	O
of	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
plant	O	O	B-Entity
-	O	O	O
ferredoxin	O	O	B-Entity
receptor	O	O	B-Entity
FusA	O	O	O

Iron	O	O	B-Entity
is	O	O	O
a	O	O	O
limiting	O	O	O
nutrient	O	O	B-Entity
in	O	O	O
bacterial	O	O	B-Entity
infection	O	O	I-Entity
putting	O	O	O
it	O	O	O
at	O	O	O
the	O	O	O
centre	O	O	O
of	O	O	O
an	O	O	O
evolutionary	O	O	O
arms	O	O	O
race	O	O	O
between	O	O	O
host	O	O	B-Entity
and	O	O	O
pathogen	O	O	B-Entity
.	O	O	O

Gram-negative	O	O	B-Entity
bacteria	O	O	I-Entity
utilize	O	O	O
TonB	O	O	B-Entity
-dependent	O	O	O
outer	O	O	B-Entity
membrane	O	O	I-Entity
receptors	O	O	B-Entity
to	O	O	O
obtain	O	O	O
iron	O	O	B-Entity
during	O	O	O
infection	O	O	B-Entity
.	O	O	O

These	O	O	O
receptors	O	O	B-Entity
acquire	O	O	O
iron	O	O	B-Entity
either	O	O	O
in	O	O	O
concert	O	O	O
with	O	O	O
soluble	O	O	O
iron-scavenging	O	O	B-Entity
siderophores	O	O	I-Entity
or	O	O	O
through	O	O	O
direct	O	O	B-Entity
interaction	O	O	I-Entity
and	O	O	O
extraction	O	O	B-Entity
from	O	O	O
host	O	O	B-Entity
proteins	O	O	B-Entity
.	O	O	O

Characterization	O	O	B-Entity
of	O	O	O
these	O	O	O
receptors	O	O	B-Entity
provides	O	O	O
invaluable	O	O	O
insight	O	O	O
into	O	O	O
pathogenesis	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
only	O	O	O
a	O	O	O
subset	O	O	O
of	O	O	O
virulence	O	O	B-Entity
-related	O	O	O
TonB	O	O	B-Entity
-dependent	O	O	O
receptors	O	O	B-Entity
have	O	O	O
been	O	O	O
currently	O	O	O
described	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	O
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
FusA	O	O	B-Entity
,	O	O	O
a	O	O	O
new	O	O	O
class	O	O	O
of	O	O	O
TonB	O	O	B-Entity
-dependent	O	O	O
receptor	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
utilized	O	O	O
by	O	O	O
phytopathogenic	O	O	O
Pectobacterium	O	O	O
spp	O	O	O
.	O	O	O

to	O	O	O
obtain	O	O	O
iron	O	O	B-Entity
from	O	O	O
plant	O	O	B-Entity
ferredoxin	O	O	B-Entity
.	O	O	O

Through	O	O	O
the	O	O	O
crystal	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
FusA	O	O	B-Entity
we	O	O	O
show	O	O	O
that	O	O	O
binding	O	O	B-Entity
of	O	O	O
ferredoxin	O	O	B-Entity
occurs	O	O	O
through	O	O	O
specialized	O	O	O
extracellular	O	O	B-Entity
loops	O	O	I-Entity
that	O	O	O
form	O	O	O
extensive	O	O	B-Entity
interactions	O	O	B-Entity
with	O	O	O
ferredoxin	O	O	O
.	O	O	O

The	O	O	O
function	O	O	B-Entity
of	O	O	O
FusA	O	O	B-Entity
and	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
homologues	O	O	B-Entity
in	O	O	O
clinically	O	O	B-Entity
important	O	O	I-Entity
pathogens	O	O	B-Entity
suggests	O	O	O
that	O	O	O
small	O	O	O
iron-containing	O	O	B-Entity
proteins	O	O	I-Entity
represent	O	O	O
an	O	O	O
iron	O	O	B-Entity
source	O	O	B-Entity
for	O	O	O
bacterial	O	O	B-Entity
pathogens	O	O	O
.	O	O	O

-DOCSTART- (27798289)

Antigen	O	O	B-Entity
Masking	O	O	B-Entity
During	O	O	O
Fixation	O	O	B-Entity
and	O	O	O
Embedding	O	O	B-Entity
,	O	O	O
Dissected	O	O	O

Antigen	O	O	B-Entity
masking	O	O	B-Entity
in	O	O	O
routinely	O	O	O
processed	O	O	B-Entity
tissue	O	O	B-Entity
is	O	O	O
a	O	O	O
poorly	O	O	O
understood	O	O	O
process	O	O	O
caused	O	O	O
by	O	O	O
multiple	O	O	B-Entity
factors	O	O	B-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
dissect	O	O	B-Entity
the	O	O	O
effect	O	O	O
on	O	O	O
antigenicity	O	O	B-Entity
of	O	O	O
each	O	O	O
step	O	O	B-Entity
of	O	O	O
processing	O	O	B-Entity
by	O	O	O
using	O	O	O
frozen	O	O	B-Entity
sections	O	O	I-Entity
as	O	O	O
proxies	O	O	B-Entity
of	O	O	O
the	O	O	O
whole	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

An	O	O	O
equivalent	O	O	O
extent	O	O	O
of	O	O	O
antigen	O	O	B-Entity
masking	O	O	B-Entity
occurs	O	O	O
across	O	O	O
variable	O	O	O
fixation	O	O	B-Entity
times	O	O	B-Entity
at	O	O	O
room	O	O	B-Entity
temperature	O	O	I-Entity
.	O	O	O

Most	O	O	O
antigens	O	O	B-Entity
benefit	O	O	O
from	O	O	O
longer	O	O	O
fixation	O	O	B-Entity
times	O	O	B-Entity
(	O	O	O
>	O	O	O
24	O	O	O
hr	O	O	O
)	O	O	O
for	O	O	O
optimal	O	O	O
detection	O	O	B-Entity
after	O	O	O
antigen	O	O	B-Entity
retrieval	O	O	B-Entity
(	O	O	O
AR	O	O	B-Entity
;	O	O	O
for	O	O	O
example	O	O	O
,	O	O	O
Ki-67	O	O	B-Entity
,	O	O	O
bcl-2	O	O	B-Entity
,	O	O	O
ER	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
transfer	O	O	B-Entity
to	O	O	O
a	O	O	O
graded	O	O	B-Entity
alcohol	O	O	I-Entity
series	O	O	B-Entity
results	O	O	O
in	O	O	O
an	O	O	O
enhanced	O	O	O
staining	O	O	B-Entity
effect	O	O	I-Entity
,	O	O	O
reproduced	O	O	O
by	O	O	O
treating	O	O	B-Entity
the	O	O	O
sections	O	O	B-Entity
with	O	O	O
detergents	O	O	B-Entity
,	O	O	O
possibly	O	O	O
because	O	O	O
of	O	O	O
a	O	O	O
better	O	O	O
access	O	O	O
of	O	O	O
the	O	O	O
polymeric	O	O	B-Entity
immunohistochemical	O	O	B-Entity
detection	O	O	B-Entity
system	O	O	B-Entity
to	O	O	O
tissue	O	O	B-Entity
structures	O	O	B-Entity
.	O	O	O

A	O	O	O
second	O	O	O
round	O	O	O
of	O	O	O
masking	O	O	B-Entity
occurs	O	O	O
upon	O	O	O
entering	O	O	O
the	O	O	O
clearing	O	O	B-Entity
agent	O	O	I-Entity
,	O	O	O
mostly	O	O	O
at	O	O	O
the	O	O	O
paraffin	O	O	B-Entity
embedding	O	O	B-Entity
step	O	O	B-Entity
.	O	O	O

This	O	O	O
may	O	O	O
depend	O	O	O
on	O	O	O
the	O	O	O
non-freezable	O	O	B-Entity
water	O	O	B-Entity
removal	O	O	B-Entity
.	O	O	O

AR	O	O	B-Entity
fully	O	O	O
reverses	O	O	O
the	O	O	O
masking	O	O	B-Entity
due	O	O	O
both	O	O	O
to	O	O	O
the	O	O	O
fixation	O	O	B-Entity
time	O	O	B-Entity
and	O	O	O
the	O	O	O
paraffin	O	O	B-Entity
embedding	O	O	B-Entity
.	O	O	O

AR	O	O	B-Entity
itself	O	O	O
destroys	O	O	B-Entity
some	O	O	O
epitopes	O	O	B-Entity
which	O	O	O
do	O	O	O
not	O	O	O
survive	O	O	O
routine	O	O	B-Entity
processing	O	O	B-Entity
.	O	O	O

Processed	O	O	B-Entity
frozen	O	O	B-Entity
sections	O	O	I-Entity
are	O	O	O
a	O	O	O
tool	O	O	O
to	O	O	O
investigate	O	O	B-Entity
fixation	O	O	B-Entity
and	O	O	O
processing	O	O	B-Entity
requirements	O	O	B-Entity
for	O	O	O
antigens	O	O	B-Entity
in	O	O	O
routine	O	O	B-Entity
specimens	O	O	B-Entity
.	O	O	O

-DOCSTART- (27798823)

Synthesis	O	O	B-Entity
of	O	O	O
1,2-Dioxetanes	O	O	B-Entity
as	O	O	O
Thermochemiluminescent	O	O	B-Entity
Labels	O	O	I-Entity
for	O	O	O
Ultrasensitive	O	O	B-Entity
Bioassays	O	O	I-Entity
:	O	O	O
Rational	O	O	B-Entity
Prediction	O	O	I-Entity
of	O	O	O
Olefin	O	O	B-Entity
Photooxygenation	O	O	B-Entity
Outcome	O	O	B-Entity
by	O	O	O
Using	O	O	O
a	O	O	O
Chemometric	O	O	O
Approach	O	O	O

Great	O	O	O
interest	O	O	O
in	O	O	O
new	O	O	O
thermochemiluminescent	O	O	B-Entity
(	O	O	I-Entity
TCL	O	O	I-Entity
)	O	O	I-Entity
molecules	O	O	I-Entity
,	O	O	O
for	O	O	O
example	O	O	O
,	O	O	O
in	O	O	O
bioanalytical	O	O	B-Entity
assays	O	O	I-Entity
,	O	O	O
has	O	O	O
prompted	O	O	O
the	O	O	O
design	O	O	B-Entity
and	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
a	O	O	O
small	O	O	O
library	O	O	B-Entity
of	O	O	O
more	O	O	O
than	O	O	O
30	O	O	O
olefins	O	O	B-Entity
to	O	O	O
be	O	O	O
subjected	O	O	O
to	O	O	O
photooxygenation	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
obtaining	O	O	O
new	O	O	O
1,2-dioxetane-based	O	O	B-Entity
TCL	O	O	B-Entity
labels	O	O	I-Entity
with	O	O	O
optimized	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Fluorine	O	O	B-Entity
atoms	O	O	O
on	O	O	O
the	O	O	O
acridan	O	O	B-Entity
system	O	O	O
remarkably	O	O	O
stabilize	O	O	O
1,2-dioxetanes	O	O	B-Entity
when	O	O	O
they	O	O	O
are	O	O	O
located	O	O	O
in	O	O	O
the	O	O	O
3-	O	O	B-Entity
and/or	O	O	I-Entity
6-position	O	O	I-Entity
(	O	O	O
4	O	O	O
h	O	O	O
and	O	O	O
4	O	O	O
i	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
2,7-difluorinated	O	O	B-Entity
acridan	O	O	I-Entity
dioxetane	O	O	I-Entity
(	O	O	O
4	O	O	O
j	O	O	O
)	O	O	O
showed	O	O	O
a	O	O	O
significantly	O	O	O
enhanced	O	O	O
fluorescence	O	O	B-Entity
quantum	O	O	I-Entity
yield	O	O	I-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
the	O	O	O
unsubstituted	O	O	B-Entity
dioxetane	O	O	I-Entity
(	O	O	O
4	O	O	O
a	O	O	O
)	O	O	O
.	O	O	O

Some	O	O	O
of	O	O	O
the	O	O	O
synthesized	O	O	B-Entity
olefins	O	O	B-Entity
did	O	O	O
not	O	O	O
undergo	O	O	O
singlet	O	O	B-Entity
oxygen	O	O	I-Entity
addition	O	O	I-Entity
and	O	O	O
a	O	O	O
rationale	O	O	B-Entity
was	O	O	O
sought	O	O	O
to	O	O	O
ease	O	O	O
the	O	O	O
photooxygenation	O	O	B-Entity
step	O	O	O
,	O	O	O
leading	O	O	O
to	O	O	O
the	O	O	O
TCL	O	O	B-Entity
dioxetanes	O	O	I-Entity
.	O	O	O

A	O	O	O
chemometric	O	O	B-Entity
approach	O	O	I-Entity
has	O	O	O
been	O	O	O
adopted	O	O	O
to	O	O	O
exploit	O	O	O
principal	O	O	B-Entity
component	O	O	I-Entity
analysis	O	O	I-Entity
and	O	O	O
linear	O	O	B-Entity
discriminant	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
structural	O	O	B-Entity
and	O	O	O
electronic	O	O	B-Entity
molecular	O	O	I-Entity
descriptors	O	O	I-Entity
obtained	O	O	O
by	O	O	O
DFT	O	O	B-Entity
optimizations	O	O	I-Entity
of	O	O	O
olefins	O	O	B-Entity
3	O	O	O
.	O	O	O

This	O	O	O
approach	O	O	B-Entity
allows	O	O	O
the	O	O	O
steric	O	O	B-Entity
and	O	O	I-Entity
electronic	O	O	I-Entity
parameters	O	O	I-Entity
that	O	O	O
govern	O	O	O
dioxetane	O	O	B-Entity
formation	O	O	B-Entity
to	O	O	O
be	O	O	O
revealed	O	O	B-Entity
.	O	O	O

-DOCSTART- (27799048)

Prostate	O	O	B-Entity
external	O	O	I-Entity
beam	O	O	I-Entity
radiotherapy	O	O	I-Entity
combined	O	O	B-Entity
with	O	O	O
high-dose-rate	O	O	B-Entity
brachytherapy	O	O	I-Entity
:	O	O	O
dose	O	O	B-Entity
-	O	O	O
volume	O	O	B-Entity
parameters	O	O	B-Entity
from	O	O	O
deformably-registered	O	O	B-Entity
plans	O	O	I-Entity
correlate	O	O	B-Entity
with	O	O	O
late	O	O	B-Entity
gastrointestinal	O	O	O
complications	O	O	O

Derivation	O	O	B-Entity
of	O	O	O
dose	O	O	B-Entity
-	O	O	O
volume	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
toxicity	O	O	B-Entity
for	O	O	O
multi-modal	O	O	B-Entity
treatments	O	O	I-Entity
can	O	O	O
be	O	O	O
difficult	O	O	B-Entity
due	O	O	O
to	O	O	O
the	O	O	O
perceived	O	O	O
need	O	O	O
for	O	O	O
voxel-by-voxel	O	O	B-Entity
dose	O	O	I-Entity
accumulation	O	O	I-Entity
.	O	O	O

With	O	O	O
data	O	O	B-Entity
available	O	O	O
for	O	O	O
a	O	O	O
single	O	O	B-Entity
-	O	O	O
institution	O	O	B-Entity
cohort	O	O	B-Entity
with	O	O	O
long	O	O	B-Entity
follow-up	O	O	B-Entity
,	O	O	O
an	O	O	O
investigation	O	O	B-Entity
was	O	O	O
undertaken	O	O	O
into	O	O	O
rectal	O	O	B-Entity
dose	O	O	B-Entity
-	O	O	O
volume	O	O	B-Entity
effects	O	O	B-Entity
for	O	O	O
gastrointestinal	O	O	B-Entity
toxicities	O	O	I-Entity
after	O	O	O
deformably-registering	O	O	O
each	O	O	O
phase	O	O	B-Entity
of	O	O	O
a	O	O	O
combined	O	O	B-Entity
external	O	O	B-Entity
beam	O	O	I-Entity
radiotherapy	O	O	I-Entity
(EBRT)/	O	O	O
high-dose-rate	O	O	B-Entity
(	O	O	I-Entity
HDR	O	O	I-Entity
)	O	O	I-Entity
brachytherapy	O	O	I-Entity
prostate	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
and	O	O	O
eighteen	O	O	O
patients	O	O	B-Entity
received	O	O	O
EBRT	O	O	B-Entity
in	O	O	O
23	O	O	O
fractions	O	O	B-Entity
of	O	O	O
2	O	O	O
Gy	O	O	B-Entity
and	O	O	O
HDR	O	O	B-Entity
(	O	O	O
TG43	O	O	B-Entity
algorithm	O	O	I-Entity
)	O	O	O
in	O	O	O
3	O	O	O
fractions	O	O	O
of	O	O	O
6.5	O	O	O
Gy	O	O	O
.	O	O	O

Results	O	O	B-Entity
for	O	O	O
the	O	O	O
Late	O	O	B-Entity
Effects	O	O	I-Entity
of	O	O	I-Entity
Normal	O	O	I-Entity
Tissues	O	O	I-Entity
-	O	O	I-Entity
Subjective	O	O	I-Entity
,	O	O	I-Entity
Objective	O	O	I-Entity
,	O	O	I-Entity
Management	O	O	I-Entity
and	O	O	I-Entity
Analytic	O	O	I-Entity
toxicity	O	O	I-Entity
assessments	O	O	I-Entity
were	O	O	O
available	O	O	O
with	O	O	O
a	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
of	O	O	O
72	O	O	O
months	O	O	B-Entity
.	O	O	O

The	O	O	O
HDR	O	O	B-Entity
CT	O	O	B-Entity
was	O	O	O
deformably-registered	O	O	O
to	O	O	O
the	O	O	O
EBRT	O	O	B-Entity
CT	O	O	O
.	O	O	O

Doses	O	O	B-Entity
were	O	O	O
corrected	O	O	B-Entity
for	O	O	O
dose	O	O	B-Entity
fractionation	O	O	I-Entity
.	O	O	O

Rectum	O	O	B-Entity
dose-volume	O	O	B-Entity
histogram	O	O	I-Entity
(	O	O	O
DVH	O	O	B-Entity
)	O	O	O
parameters	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
in	O	O	O
two	O	O	O
ways	O	O	O
.	O	O	O

(	O	O	O
1	O	O	O
)	O	O	O
Distribution-adding	O	O	B-Entity
:	O	O	O
parameters	O	O	B-Entity
were	O	O	O
calculated	O	O	B-Entity
after	O	O	O
the	O	O	O
EBRT	O	O	B-Entity
dose	O	O	B-Entity
distribution	O	O	B-Entity
was	O	O	O
3D-summed	O	O	O
with	O	O	O
the	O	O	O
registered	O	O	O
HDR	O	O	B-Entity
dose	O	O	O
distribution	O	O	O
.	O	O	O

(	O	O	O
2	O	O	O
)	O	O	O
Parameter-adding	O	O	B-Entity
:	O	O	O
the	O	O	O
EBRT	O	O	B-Entity
DVH	O	O	B-Entity
parameters	O	O	B-Entity
were	O	O	O
added	O	O	B-Entity
to	O	O	O
HDR	O	O	B-Entity
DVH	O	O	O
parameters	O	O	O
.	O	O	O

Logistic	O	O	B-Entity
regressions	O	O	I-Entity
and	O	O	O
Mann-Whitney	O	O	B-Entity
U-tests	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
correlate	O	O	B-Entity
parameters	O	O	B-Entity
with	O	O	O
late	O	O	B-Entity
peak	O	O	B-Entity
toxicity	O	O	B-Entity
(	O	O	O
dichotomised	O	O	B-Entity
at	O	O	O
grade	O	O	B-Entity
1	O	O	O
or	O	O	O
2	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
48	O	O	O
-	O	O	O
80	O	O	O
,	O	O	O
40	O	O	O
-	O	O	O
63	O	O	O
and	O	O	O
49	O	O	O
-	O	O	O
55	O	O	O
Gy	O	O	B-Entity
dose	O	O	B-Entity
regions	O	O	B-Entity
from	O	O	O
distribution-adding	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
rectal	O	O	B-Entity
bleeding	O	O	I-Entity
,	O	O	O
urgency	O	O	B-Entity
/	O	O	O
tenesmus	O	O	B-Entity
and	O	O	O
stool	O	O	B-Entity
frequency	O	O	I-Entity
respectively	O	O	O
.	O	O	O

Additionally	O	O	B-Entity
,	O	O	O
urgency	O	O	B-Entity
/	O	O	O
tenesmus	O	O	B-Entity
and	O	O	O
anorectal	O	O	B-Entity
pain	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
25	O	O	O
-	O	O	O
26	O	O	O
Gy	O	O	B-Entity
and	O	O	O
44	O	O	O
-	O	O	O
48	O	O	O
Gy	O	O	O
dose	O	O	B-Entity
regions	O	O	B-Entity
from	O	O	O
distribution-adding	O	O	B-Entity
respectively	O	O	O
.	O	O	O

Parameter-adding	O	O	B-Entity
also	O	O	O
indicated	O	O	O
the	O	O	O
low	O	O	B-Entity
-	O	O	O
mid	O	O	B-Entity
dose	O	O	B-Entity
region	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
stool	O	O	B-Entity
frequency	O	O	I-Entity
and	O	O	O
proctitis	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
confirms	O	O	B-Entity
significant	O	O	B-Entity
dose-histogram	O	O	B-Entity
effects	O	O	B-Entity
for	O	O	O
gastrointestinal	O	O	B-Entity
toxicities	O	O	I-Entity
after	O	O	O
including	O	O	B-Entity
deformable	O	O	B-Entity
registration	O	O	I-Entity
to	O	O	O
combine	O	O	B-Entity
phases	O	O	B-Entity
of	O	O	O
EBRT	O	O	B-Entity
/	O	O	O
HDR	O	O	B-Entity
prostate	O	O	B-Entity
cancer	O	O	I-Entity
treatment	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
from	O	O	O
distribution-adding	O	O	B-Entity
were	O	O	O
in	O	O	O
most	O	O	O
cases	O	O	B-Entity
consistent	O	O	B-Entity
with	O	O	I-Entity
those	O	O	O
from	O	O	O
parameter-adding	O	O	B-Entity
.	O	O	O

The	O	O	O
mid	O	O	B-Entity
-	O	O	O
high	O	O	B-Entity
dose	O	O	B-Entity
range	O	O	B-Entity
and	O	O	O
near	O	O	B-Entity
maximum	O	O	B-Entity
doses	O	O	B-Entity
were	O	O	O
important	O	O	B-Entity
for	O	O	O
rectal	O	O	B-Entity
bleeding	O	O	I-Entity
.	O	O	O

The	O	O	O
distribution-adding	O	O	B-Entity
mid	O	O	B-Entity
-	O	O	O
high	O	O	B-Entity
dose	O	O	B-Entity
range	O	O	B-Entity
was	O	O	O
also	O	O	O
important	O	O	B-Entity
for	O	O	O
stool	O	O	B-Entity
frequency	O	O	I-Entity
and	O	O	O
urgency	O	O	B-Entity
/	O	O	O
tenesmus	O	O	B-Entity
.	O	O	O

We	O	O	O
encourage	O	O	O
additional	O	O	B-Entity
studies	O	O	B-Entity
in	O	O	O
a	O	O	O
variety	O	O	B-Entity
of	O	O	O
institutions	O	O	B-Entity
using	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
dose	O	O	B-Entity
accumulation	O	O	I-Entity
methods	O	O	I-Entity
with	O	O	O
appropriate	O	O	O
inter-fraction	O	O	B-Entity
motion	O	O	I-Entity
management	O	O	I-Entity
.	O	O	O

NCT	O	O	O
NCT00193856	O	O	O
.	O	O	O

Retrospectively	O	O	O
registered	O	O	O
12	O	O	O
September	O	O	O
2005	O	O	O
.	O	O	O

-DOCSTART- (27799763)

Prescription	O	O	B-Entity
of	O	O	O
opioids	O	O	B-Entity
for	O	O	O
breathlessness	O	O	B-Entity
in	O	O	O
end-stage	O	O	B-Entity
COPD	O	O	B-Entity
:	O	O	O
a	O	O	O
national	O	O	O
population-based	O	O	O
study	O	O	O

Low-dose	O	O	B-Entity
opioids	O	O	B-Entity
can	O	O	O
relieve	O	O	B-Entity
breathlessness	O	O	B-Entity
but	O	O	O
may	O	O	O
be	O	O	O
underused	O	O	O
in	O	O	O
late-stage	O	O	B-Entity
COPD	O	O	B-Entity
due	O	O	O
to	O	O	O
fear	O	O	B-Entity
of	O	O	O
complications	O	O	B-Entity
,	O	O	O
contributing	O	O	O
to	O	O	O
poor	O	O	O
symptom	O	O	B-Entity
control	O	O	I-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
period	O	O	B-Entity
prevalence	O	O	O
and	O	O	O
indications	O	O	B-Entity
of	O	O	O
opioids	O	O	B-Entity
actually	O	O	O
prescribed	O	O	B-Entity
in	O	O	O
people	O	O	B-Entity
with	O	O	O
end-stage	O	O	B-Entity
COPD	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
was	O	O	O
a	O	O	O
longitudinal	O	O	B-Entity
,	O	O	O
population-based	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
starting	O	O	O
long-term	O	O	B-Entity
oxygen	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
LTOT	O	O	B-Entity
)	O	O	O
for	O	O	O
COPD	O	O	B-Entity
between	O	O	O
October	O	O	O
1	O	O	O
,	O	O	O
2005	O	O	O
and	O	O	O
June	O	O	O
30	O	O	O
,	O	O	O
2009	O	O	O
in	O	O	O
Sweden	O	O	B-Entity
.	O	O	O

A	O	O	O
random	O	O	O
sample	O	O	O
(	O	O	O
n=2,000	O	O	O
)	O	O	O
of	O	O	O
their	O	O	O
dispensed	O	O	B-Entity
opioid	O	O	B-Entity
prescriptions	O	O	B-Entity
was	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
national	O	O	B-Entity
Prescribed	O	O	I-Entity
Drugs	O	O	I-Entity
Register	O	O	I-Entity
from	O	O	O
91	O	O	O
days	O	O	B-Entity
before	O	O	O
starting	O	O	O
LTOT	O	O	B-Entity
until	O	O	O
the	O	O	O
first	O	O	O
of	O	O	O
LTOT	O	O	O
withdrawal	O	O	B-Entity
,	O	O	O
death	O	O	B-Entity
,	O	O	O
or	O	O	O
study	O	O	B-Entity
end	O	O	I-Entity
(	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2009	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
analyzed	O	O	O
medication	O	O	O
type	O	O	O
,	O	O	O
dispensed	O	O	B-Entity
quantity	O	O	I-Entity
,	O	O	O
date	O	O	B-Entity
of	O	O	I-Entity
dispensing	O	O	I-Entity
,	O	O	O
and	O	O	O
indications	O	O	B-Entity
categorized	O	O	O
as	O	O	O
pain	O	O	B-Entity
,	O	O	O
breathlessness	O	O	B-Entity
,	O	O	O
other	O	O	O
,	O	O	O
or	O	O	O
unknown	O	O	O
.	O	O	O

In	O	O	O
total	O	O	O
,	O	O	O
2,249	O	O	O
COPD	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
59	O	O	O
%	O	O	O
women	O	O	B-Entity
)	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

During	O	O	O
a	O	O	O
median	O	O	O
follow-up	O	O	B-Entity
of	O	O	O
1.1	O	O	O
(	O	O	O
interquartile	O	O	B-Entity
range	O	O	I-Entity
0.6	O	O	O
-	O	O	O
2.0	O	O	O
)	O	O	O
years	O	O	B-Entity
,	O	O	O
1,034	O	O	O
patients	O	O	B-Entity
(	O	O	O
46	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
dispensed	O	O	B-Entity
≥1	O	O	O
opioid	O	O	B-Entity
prescription	O	O	B-Entity
(	O	O	O
N=13,722	O	O	O
prescriptions	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
frequently	O	O	O
prescribed	O	O	B-Entity
opioids	O	O	B-Entity
were	O	O	O
tramadol	O	O	B-Entity
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
oxycodone	O	O	B-Entity
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
morphine	O	O	B-Entity
(	O	O	O
16	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
codeine	O	O	B-Entity
(	O	O	O
16	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Average	O	O	O
dispensed	O	O	B-Entity
quantity	O	O	I-Entity
was	O	O	O
9.3	O	O	O
(	O	O	O
interquartile	O	O	B-Entity
range	O	O	I-Entity
3.7	O	O	O
-	O	O	O
16.7	O	O	O
)	O	O	O
defined	O	O	O
daily	O	O	B-Entity
doses	O	O	I-Entity
per	O	O	O
prescription	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
random	O	O	O
sample	O	O	B-Entity
,	O	O	O
the	O	O	O
most	O	O	O
commonly	O	O	O
stated	O	O	O
indication	O	O	B-Entity
was	O	O	O
pain	O	O	B-Entity
(	O	O	O
97	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
only	O	O	O
2	O	O	O
%	O	O	O
for	O	O	O
breathlessness	O	O	B-Entity
and	O	O	O
1	O	O	O
%	O	O	O
for	O	O	O
other	O	O	O
reasons	O	O	O
.	O	O	O

Despite	O	O	O
evidence	O	O	O
that	O	O	O
supported	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
opioids	O	O	B-Entity
for	O	O	O
the	O	O	O
relief	O	O	B-Entity
of	O	O	O
breathlessness	O	O	B-Entity
predating	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
opioids	O	O	O
are	O	O	O
rarely	O	O	O
prescribed	O	O	B-Entity
to	O	O	O
relieve	O	O	B-Entity
breathlessness	O	O	O
in	O	O	O
oxygen-dependent	O	O	B-Entity
COPD	O	O	B-Entity
,	O	O	O
potentially	O	O	O
contributing	O	O	O
to	O	O	O
less-than-optimal	O	O	O
symptom	O	O	B-Entity
control	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
creates	O	O	O
a	O	O	O
baseline	O	O	B-Entity
against	O	O	O
which	O	O	O
to	O	O	O
compare	O	O	O
future	O	O	O
changes	O	O	O
in	O	O	O
morphine	O	O	B-Entity
prescribing	O	O	O
in	O	O	O
this	O	O	O
setting	O	O	O
.	O	O	O

-DOCSTART- (27802488)

In	O	O	B-Entity
Vivo	O	O	I-Entity
3-Dimensional	O	O	B-Entity
Strain	O	O	B-Entity
Mapping	O	O	I-Entity
Confirms	O	O	B-Entity
Large	O	O	B-Entity
Optic	O	O	B-Entity
Nerve	O	O	I-Entity
Head	O	O	I-Entity
Deformations	O	O	B-Entity
Following	O	O	B-Entity
Horizontal	O	O	O
Eye	O	O	O
Movements	O	O	O

To	O	O	O
measure	O	O	B-Entity
lamina	O	O	B-Entity
cribrosa	O	O	I-Entity
(	O	O	O
LC	O	O	B-Entity
)	O	O	O
strains	O	O	B-Entity
(	O	O	O
deformations	O	O	B-Entity
)	O	O	O
following	O	O	B-Entity
abduction	O	O	B-Entity
and	O	O	O
adduction	O	O	B-Entity
in	O	O	O
healthy	O	O	B-Entity
subjects	O	O	I-Entity
and	O	O	O
to	O	O	O
compare	O	O	B-Entity
them	O	O	O
with	O	O	O
those	O	O	O
resulting	O	O	B-Entity
from	O	O	O
a	O	O	O
relatively	O	O	B-Entity
high	O	O	B-Entity
acute	O	O	B-Entity
intraocular	O	O	B-Entity
pressure	O	O	I-Entity
(	O	O	O
IOP	O	O	B-Entity
)	O	O	O
elevation	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
16	O	O	O
eyes	O	O	B-Entity
from	O	O	O
8	O	O	O
healthy	O	O	B-Entity
subjects	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
16	O	O	O
eyes	O	O	B-Entity
,	O	O	O
11	O	O	O
had	O	O	O
peripapillary	O	O	B-Entity
atrophy	O	O	I-Entity
(	O	O	O
PPA	O	O	B-Entity
)	O	O	O
.	O	O	O

For	O	O	O
each	O	O	B-Entity
subject	O	O	B-Entity
,	O	O	O
both	O	O	O
optic	O	O	B-Entity
nerve	O	O	I-Entity
heads	O	O	I-Entity
(	O	O	O
ONHs	O	O	B-Entity
)	O	O	O
were	O	O	O
imaged	O	O	B-Entity
using	O	O	O
optical	O	O	B-Entity
coherence	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
OCT	O	O	B-Entity
)	O	O	O
at	O	O	O
baseline	O	O	B-Entity
(	O	O	O
twice	O	O	B-Entity
)	O	O	O
,	O	O	O
in	O	O	O
different	O	O	B-Entity
gaze	O	O	B-Entity
positions	O	O	B-Entity
(	O	O	O
adduction	O	O	B-Entity
and	O	O	O
abduction	O	O	B-Entity
of	O	O	O
20	O	O	O
°	O	O	O
)	O	O	O
and	O	O	O
following	O	O	B-Entity
an	O	O	O
acute	O	O	B-Entity
IOP	O	O	B-Entity
elevation	O	O	B-Entity
of	O	O	O
approximately	O	O	B-Entity
20	O	O	O
mm	O	O	O
Hg	O	O	B-Entity
from	O	O	O
baseline	O	O	O
(	O	O	O
via	O	O	O
ophthalmodynamometry	O	O	B-Entity
)	O	O	O
.	O	O	O

Strains	O	O	B-Entity
of	O	O	O
LC	O	O	B-Entity
for	O	O	O
all	O	O	O
loading	O	O	B-Entity
scenarios	O	O	I-Entity
were	O	O	O
mapped	O	O	B-Entity
using	O	O	O
a	O	O	O
three-dimensional	O	O	B-Entity
tracking	O	O	B-Entity
algorithm	O	O	B-Entity
.	O	O	O

In	O	O	O
all	O	O	O
16	O	O	O
eyes	O	O	B-Entity
,	O	O	O
LC	O	O	B-Entity
strains	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
adduction	O	O	B-Entity
and	O	O	O
abduction	O	O	B-Entity
were	O	O	O
5.83	O	O	O
%	O	O	O
±	O	O	O
3.78	O	O	O
%	O	O	O
and	O	O	O
3.93	O	O	O
%	O	O	O
±	O	O	O
2.57	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
and	O	O	O
both	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
the	O	O	O
control	O	O	B-Entity
strains	O	O	O
measured	O	O	B-Entity
from	O	O	O
the	O	O	O
repeated	O	O	B-Entity
baseline	O	O	B-Entity
acquisitions	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Strains	O	O	B-Entity
of	O	O	O
LC	O	O	B-Entity
in	O	O	O
adduction	O	O	B-Entity
were	O	O	O
on	O	O	O
average	O	O	B-Entity
higher	O	O	B-Entity
than	O	O	O
those	O	O	O
in	O	O	O
abduction	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
difference	O	O	B-Entity
was	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.07	O	O	O
)	O	O	O
.	O	O	O

Strains	O	O	B-Entity
of	O	O	O
LC	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
IOP	O	O	B-Entity
elevations	O	O	B-Entity
(	O	O	O
on	O	O	O
average	O	O	B-Entity
21.13	O	O	O
±	O	O	O
7.61	O	O	O
mm	O	O	O
Hg	O	O	B-Entity
)	O	O	O
were	O	O	O
6.41	O	O	O
%	O	O	O
±	O	O	O
3.21	O	O	O
%	O	O	O
and	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
the	O	O	O
control	O	O	B-Entity
strains	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.0005	O	O	O
)	O	O	O
.	O	O	O

Gaze	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
LC	O	O	B-Entity
strains	O	O	B-Entity
in	O	O	O
the	O	O	O
PPA	O	O	B-Entity
group	O	O	B-Entity
were	O	O	O
on	O	O	O
average	O	O	B-Entity
larger	O	O	B-Entity
than	O	O	O
those	O	O	O
in	O	O	O
the	O	O	O
non-PPA	O	O	B-Entity
group	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
relationship	O	O	B-Entity
was	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
confirm	O	O	B-Entity
that	O	O	O
horizontal	O	O	B-Entity
eye	O	O	I-Entity
movements	O	O	I-Entity
generate	O	O	B-Entity
significant	O	O	B-Entity
ONH	O	O	B-Entity
strains	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
our	O	O	O
previous	O	O	B-Entity
estimations	O	O	B-Entity
using	O	O	O
finite	O	O	B-Entity
element	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

Further	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
explore	O	O	O
a	O	O	O
possible	O	O	B-Entity
link	O	O	O
between	O	O	O
ONH	O	O	B-Entity
strains	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
eye	O	O	B-Entity
movements	O	O	I-Entity
and	O	O	O
axonal	O	O	B-Entity
loss	O	O	I-Entity
in	O	O	O
optic	O	O	B-Entity
neuropathies	O	O	I-Entity
.	O	O	O

-DOCSTART- (27804215)

Simultaneously	O	O	B-Entity
Targeting	O	O	B-Entity
Myofibroblast	O	O	B-Entity
Contractility	O	O	I-Entity
and	O	O	O
Extracellular	O	O	B-Entity
Matrix	O	O	I-Entity
Cross-Linking	O	O	B-Entity
as	O	O	O
a	O	O	O
Therapeutic	O	O	B-Entity
Concept	O	O	I-Entity
in	O	O	O
Airway	O	O	B-Entity
Fibrosis	O	O	O

Fibrosis	O	O	B-Entity
after	O	O	O
solid	O	O	B-Entity
organ	O	O	I-Entity
transplantation	O	O	I-Entity
is	O	O	O
considered	O	O	O
an	O	O	O
irreversible	O	O	B-Entity
process	O	O	B-Entity
and	O	O	O
remains	O	O	O
the	O	O	O
major	O	O	B-Entity
cause	O	O	O
of	O	O	O
graft	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
death	O	O	B-Entity
with	O	O	O
limited	O	O	B-Entity
therapies	O	O	B-Entity
.	O	O	O

This	O	O	O
remodeling	O	O	B-Entity
is	O	O	O
characterized	O	O	B-Entity
by	O	O	O
aberrant	O	O	B-Entity
accumulation	O	O	B-Entity
of	O	O	O
contractile	O	O	B-Entity
myofibroblasts	O	O	I-Entity
that	O	O	O
deposit	O	O	B-Entity
excessive	O	O	B-Entity
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
(	O	O	O
ECM	O	O	B-Entity
)	O	O	O
and	O	O	O
increase	O	O	B-Entity
tissue	O	O	B-Entity
stiffness	O	O	I-Entity
.	O	O	O

Studies	O	O	B-Entity
demonstrate	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
that	O	O	O
a	O	O	O
stiff	O	O	B-Entity
ECM	O	O	B-Entity
itself	O	O	O
promotes	O	O	B-Entity
fibroblast	O	O	B-Entity
-to-	O	O	O
myofibroblast	O	O	B-Entity
differentiation	O	O	B-Entity
,	O	O	O
stimulating	O	O	B-Entity
further	O	O	O
ECM	O	O	O
production	O	O	B-Entity
.	O	O	O

This	O	O	O
creates	O	O	O
a	O	O	O
positive	O	O	B-Entity
feedback	O	O	I-Entity
loop	O	O	I-Entity
that	O	O	O
perpetuates	O	O	B-Entity
fibrosis	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	B-Entity
that	O	O	O
simultaneously	O	O	B-Entity
targeting	O	O	B-Entity
myofibroblast	O	O	B-Entity
contractility	O	O	I-Entity
with	O	O	O
relaxin	O	O	B-Entity
and	O	O	O
ECM	O	O	B-Entity
stiffness	O	O	B-Entity
with	O	O	O
lysyl	O	O	B-Entity
oxidase	O	O	I-Entity
inhibitors	O	O	B-Entity
could	O	O	O
break	O	O	O
the	O	O	O
feedback	O	O	B-Entity
loop	O	O	I-Entity
,	O	O	O
reversing	O	O	B-Entity
established	O	O	B-Entity
fibrosis	O	O	B-Entity
.	O	O	O

To	O	O	O
test	O	O	B-Entity
this	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
the	O	O	O
orthotopic	O	O	B-Entity
tracheal	O	O	I-Entity
transplantation	O	O	I-Entity
(	O	O	O
OTT	O	O	B-Entity
)	O	O	O
mouse	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
which	O	O	O
develops	O	O	O
robust	O	O	B-Entity
fibrotic	O	O	B-Entity
airway	O	O	B-Entity
remodeling	O	O	B-Entity
.	O	O	O

Mice	O	O	B-Entity
with	O	O	O
established	O	O	B-Entity
fibrosis	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
saline	O	O	B-Entity
,	O	O	O
mono-	O	O	B-Entity
,	O	O	O
or	O	O	O
combination	O	O	B-Entity
therapies	O	O	I-Entity
.	O	O	O

Although	O	O	O
monotherapies	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
,	O	O	O
combining	O	O	B-Entity
these	O	O	I-Entity
agents	O	O	I-Entity
decreased	O	O	B-Entity
collagen	O	O	B-Entity
deposition	O	O	B-Entity
and	O	O	O
promoted	O	O	B-Entity
re-epithelialization	O	O	B-Entity
of	O	O	O
remodeled	O	O	B-Entity
airways	O	O	I-Entity
.	O	O	O

Relaxin	O	O	B-Entity
inhibited	O	O	B-Entity
myofibroblast	O	O	B-Entity
differentiation	O	O	B-Entity
and	O	O	O
contraction	O	O	B-Entity
in	O	O	O
a	O	O	O
matrix	O	O	B-Entity
-	O	O	O
stiffness	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
manner	O	O	O
through	O	O	O
prostaglandin	O	O	B-Entity
E2	O	O	I-Entity
(	O	O	O
PGE2	O	O	B-Entity
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
combination	O	O	B-Entity
therapy	O	O	I-Entity
was	O	O	O
lost	O	O	O
in	O	O	O
PGE2	O	O	B-Entity
receptor	O	O	I-Entity
knockout	O	O	B-Entity
and	O	O	O
PGE2	O	O	O
-	O	O	O
inhibited	O	O	B-Entity
OTT	O	O	B-Entity
mice	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
revealed	O	O	B-Entity
the	O	O	O
important	O	O	O
synergistic	O	O	B-Entity
roles	O	O	B-Entity
of	O	O	O
cellular	O	O	B-Entity
contractility	O	O	I-Entity
and	O	O	O
tissue	O	O	B-Entity
stiffness	O	O	I-Entity
in	O	O	O
the	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
fibrotic	O	O	B-Entity
tissue	O	O	O
and	O	O	O
suggests	O	O	O
a	O	O	O
new	O	O	O
therapeutic	O	O	B-Entity
principle	O	O	B-Entity
for	O	O	O
fibrosis	O	O	B-Entity
.	O	O	O

-DOCSTART- (27804311)

Systemic	O	O	B-Entity
matrix	O	O	I-Entity
metalloproteinase-8	O	O	I-Entity
response	O	O	B-Entity
in	O	O	O
chronic	O	O	O
tonsillitis	O	O	O

The	O	O	O
development	O	O	B-Entity
of	O	O	O
several	O	O	O
life-long	O	O	O
diseases	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
coronary	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
is	O	O	O
affected	O	O	O
by	O	O	O
low-grade	O	O	B-Entity
systemic	O	O	B-Entity
inflammation	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
the	O	O	O
potential	O	O	B-Entity
long-term	O	O	B-Entity
health	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
tonsillitis	O	O	I-Entity
are	O	O	O
limited	O	O	O
.	O	O	O

Many	O	O	O
inflammatory	O	O	B-Entity
conditions	O	O	B-Entity
present	O	O	O
with	O	O	O
enhanced	O	O	O
systemic	O	O	B-Entity
matrix	O	O	I-Entity
metalloproteinase	O	O	I-Entity
(MMP)-8	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

In	O	O	O
head	O	O	B-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
cancer	O	O	I-Entity
,	O	O	O
high	O	O	B-Entity
plasma	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
tissue	O	O	B-Entity
inhibitor	O	O	I-Entity
of	O	O	I-Entity
metalloproteinase	O	O	I-Entity
(TIMP)-1	O	O	B-Entity
predicts	O	O	B-Entity
poor	O	O	B-Entity
prognosis	O	O	I-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	O
S-MMP-8	O	O	B-Entity
with	O	O	O
immunofluorometric	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
S-TIMP-1	O	O	B-Entity
with	O	O	O
an	O	O	O
immunosorbent	O	O	B-Entity
assay	O	O	I-Entity
in	O	O	O
175	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
undergoing	O	O	O
tonsillectomy	O	O	B-Entity
for	O	O	O
benign	O	O	B-Entity
tonsillar	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
33	O	O	O
control	O	O	B-Entity
patients	O	O	O
with	O	O	O
tonsillar	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
.	O	O	O

Tonsillar	O	O	B-Entity
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(	O	O	O
HPV	O	O	B-Entity
)	O	O	O
status	O	O	O
was	O	O	O
determined	O	O	O
by	O	O	O
PCR	O	O	B-Entity
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
benign	O	O	B-Entity
tonsillar	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
chronic	O	O	B-Entity
tonsillitis	O	O	I-Entity
without	O	O	O
hypertrophy	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
enhanced	O	O	O
systemic	O	O	B-Entity
MMP-8	O	O	I-Entity
response	O	O	B-Entity
.	O	O	O

Compared	O	O	O
to	O	O	O
patients	O	O	B-Entity
with	O	O	O
benign	O	O	B-Entity
tonsillar	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
patients	O	O	O
with	O	O	O
tonsillar	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
had	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
concentrations	O	O	B-Entity
of	O	O	O
S-MMP-8	O	O	B-Entity
and	O	O	O
S-TIMP-1	O	O	B-Entity
.	O	O	O

Neither	O	O	O
S-MMP-8	O	O	B-Entity
nor	O	O	O
S-TIMP-1	O	O	B-Entity
correlated	O	O	O
with	O	O	O
tonsillar	O	O	B-Entity
HPV	O	O	B-Entity
positivity	O	O	B-Entity
.	O	O	O

-DOCSTART- (27805500)

Addressing	O	O	B-Entity
holistic	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
work	O	O	B-Entity
empowerment	O	O	B-Entity
through	O	O	B-Entity
a	O	O	O
body-mind-spirit	O	O	B-Entity
intervention	O	O	I-Entity
program	O	O	I-Entity
among	O	O	O
helping	O	O	B-Entity
professionals	O	O	B-Entity
in	O	O	O
continuous	O	O	B-Entity
education	O	O	B-Entity
:	O	O	O
A	O	O	O
pilot	O	O	O
study	O	O	O

To	O	O	O
examine	O	O	O
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
a	O	O	O
body-mind-spirit	O	O	B-Entity
(	O	O	I-Entity
BMS	O	O	I-Entity
)	O	O	I-Entity
intervention	O	O	I-Entity
program	O	O	I-Entity
in	O	O	O
improving	O	O	B-Entity
the	O	O	O
holistic	O	O	B-Entity
well-being	O	O	I-Entity
and	O	O	O
work	O	O	B-Entity
empowerment	O	O	B-Entity
among	O	O	O
helping	O	O	B-Entity
professionals	O	O	B-Entity
in	O	O	O
continuous	O	O	B-Entity
education	O	O	B-Entity
.	O	O	O

Forty-four	O	O	O
helping	O	O	B-Entity
professionals	O	O	B-Entity
,	O	O	O
who	O	O	O
were	O	O	O
in	O	O	O
their	O	O	O
first-year	O	O	O
part-time	O	O	O
postgraduate	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
participated	O	O	O
in	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
.	O	O	O

All	O	O	O
participants	O	O	B-Entity
attended	O	O	B-Entity
a	O	O	O
3-day	O	O	O
BMS	O	O	B-Entity
intervention	O	O	I-Entity
program	O	O	I-Entity
which	O	O	O
emphasized	O	O	O
a	O	O	O
holistic	O	O	B-Entity
approach	O	O	I-Entity
to	O	O	O
health	O	O	B-Entity
and	O	O	O
well-being	O	O	B-Entity
.	O	O	O

Ratings	O	O	O
on	O	O	O
their	O	O	O
levels	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
distress	O	O	I-Entity
,	O	O	O
daily	O	O	B-Entity
functioning	O	O	I-Entity
,	O	O	O
affect	O	O	B-Entity
,	O	O	O
spirituality	O	O	B-Entity
,	O	O	O
and	O	O	O
psychologica	O	O	B-Entity
l	O	O	O
empowerment	O	O	B-Entity
at	O	O	O
work	O	O	B-Entity
were	O	O	O
compared	O	O	O
before	O	O	O
and	O	O	O
immediately	O	O	O
after	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
reported	O	O	O
significantly	O	O	O
lower	O	O	O
levels	O	O	B-Entity
of	O	O	O
negative	O	O	B-Entity
affect	O	O	I-Entity
and	O	O	O
physical	O	O	B-Entity
distress	O	O	I-Entity
,	O	O	O
and	O	O	O
were	O	O	O
less	O	O	O
spiritually	O	O	B-Entity
disoriented	O	O	I-Entity
after	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

Enhanced	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
daily	O	O	B-Entity
functioning	O	O	I-Entity
,	O	O	O
positive	O	O	B-Entity
affect	O	O	I-Entity
,	O	O	O
spiritual	O	O	B-Entity
resilience	O	O	I-Entity
,	O	O	O
and	O	O	O
tranquility	O	O	B-Entity
were	O	O	O
also	O	O	O
reported	O	O	O
.	O	O	O

Results	O	O	O
also	O	O	O
suggested	O	O	O
that	O	O	O
participants	O	O	B-Entity
were	O	O	O
empowered	O	O	B-Entity
at	O	O	O
work	O	O	B-Entity
,	O	O	O
and	O	O	O
specifically	O	O	O
felt	O	O	O
more	O	O	O
able	O	O	O
to	O	O	O
make	O	O	O
an	O	O	O
impact	O	O	O
on	O	O	O
work	O	O	O
outcomes	O	O	O
.	O	O	O

The	O	O	O
3-day	O	O	O
BMS	O	O	B-Entity
intervention	O	O	I-Entity
program	O	O	I-Entity
produced	O	O	O
a	O	O	O
positive	O	O	B-Entity
and	O	O	O
measurable	O	O	B-Entity
effec	O	O	B-Entity
t	O	O	O
on	O	O	O
participants	O	O	B-Entity
'	O	O	O
holistic	O	O	B-Entity
well-being	O	O	I-Entity
and	O	O	O
empowerment	O	O	B-Entity
at	O	O	O
work	O	O	B-Entity
.	O	O	O

Educators	O	O	B-Entity
in	O	O	O
related	O	O	O
fields	O	O	B-Entity
could	O	O	O
incorporate	O	O	O
holistic	O	O	B-Entity
practices	O	O	B-Entity
into	O	O	O
the	O	O	O
curriculum	O	O	B-Entity
to	O	O	O
better	O	O	O
prepare	O	O	O
the	O	O	O
future	O	O	O
practitioners	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
better	O	O	O
outcomes	O	O	O
both	O	O	O
to	O	O	O
the	O	O	O
professionals	O	O	B-Entity
themselves	O	O	O
and	O	O	O
their	O	O	O
clients	O	O	B-Entity
or	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27805887)

Successful	O	O	B-Entity
Restoration	O	O	I-Entity
of	O	O	O
Severely	O	O	O
Mutilated	O	O	B-Entity
Primary	O	O	B-Entity
Incisors	O	O	I-Entity
Using	O	O	O
a	O	O	O
Novel	O	O	O
Method	O	O	O
to	O	O	O
Retain	O	O	O
Zirconia	O	O	B-Entity
Crowns	O	O	B-Entity
-	O	O	O
Two	O	O	B-Entity
Year	O	O	I-Entity
Results	O	O	O

This	O	O	O
manuscript	O	O	B-Entity
describes	O	O	O
a	O	O	O
simple	O	O	O
reliable	O	O	B-Entity
technique	O	O	I-Entity
for	O	O	O
restoring	O	O	B-Entity
severely	O	O	O
mutilated	O	O	B-Entity
primary	O	O	B-Entity
anterior	O	O	I-Entity
teeth	O	O	I-Entity
.	O	O	O

A	O	O	O
rigid	O	O	O
glass	O	O	B-Entity
ionomer	O	O	I-Entity
post	O	O	I-Entity
is	O	O	O
created	O	O	O
over	O	O	O
which	O	O	O
zirconia	O	O	B-Entity
crowns	O	O	B-Entity
can	O	O	O
be	O	O	O
fitted	O	O	O
to	O	O	O
achieve	O	O	O
a	O	O	O
long-term	O	O	B-Entity
stable	O	O	O
esthetic	O	O	B-Entity
restoration	O	O	B-Entity
for	O	O	O
primary	O	O	B-Entity
anterior	O	O	I-Entity
teeth	O	O	I-Entity
.	O	O	O

Children	O	O	B-Entity
aged	O	O	O
2	O	O	O
-	O	O	O
5	O	O	O
years	O	O	B-Entity
with	O	O	O
two	O	O	O
up	O	O	O
to	O	O	O
six	O	O	O
extensively	O	O	O
decayed	O	O	B-Entity
upper	O	O	B-Entity
primary	O	O	I-Entity
incisors	O	O	I-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Fuji	O	O	B-Entity
IX	O	O	I-Entity
was	O	O	O
condensed	O	O	O
into	O	O	O
an	O	O	O
intracanal	O	O	B-Entity
space	O	O	I-Entity
created	O	O	O
to	O	O	O
a	O	O	O
depth	O	O	B-Entity
of	O	O	O
3	O	O	O
mm	O	O	O
,	O	O	O
to	O	O	O
provide	O	O	O
a	O	O	O
core	O	O	B-Entity
which	O	O	O
also	O	O	O
extended	O	O	O
3	O	O	O
mm	O	O	O
supragingivally	O	O	B-Entity
.	O	O	O

Crown	O	O	B-Entity
preparations	O	O	I-Entity
were	O	O	O
completed	O	O	O
upon	O	O	O
these	O	O	O
cores	O	O	B-Entity
.	O	O	O

Zirconia	O	O	B-Entity
crowns	O	O	B-Entity
(	O	O	O
Nusmile	O	O	B-Entity
,	O	O	O
Houston	O	O	B-Entity
Texas	O	O	I-Entity
USA	O	O	B-Entity
)	O	O	O
were	O	O	O
fitted	O	O	B-Entity
and	O	O	O
cemented	O	O	B-Entity
over	O	O	O
the	O	O	O
prepared	O	O	O
cores	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
were	O	O	O
recalled	O	O	B-Entity
at	O	O	O
regular	O	O	B-Entity
intervals	O	O	I-Entity
.	O	O	O

Twenty-three	O	O	O
healthy	O	O	O
children	O	O	B-Entity
with	O	O	O
86	O	O	O
restorations	O	O	B-Entity
participated	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
of	O	O	O
the	O	O	O
restorations	O	O	B-Entity
was	O	O	O
95.3	O	O	O
%	O	O	O
after	O	O	O
12	O	O	O
months	O	O	B-Entity
and	O	O	O
80.2	O	O	O
%	O	O	O
after	O	O	O
24	O	O	O
months	O	O	O
.	O	O	O

According	O	O	O
to	O	O	O
Kaplan-Meier	O	O	B-Entity
survival	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
the	O	O	O
median	O	O	B-Entity
survival	O	O	I-Entity
time	O	O	I-Entity
was	O	O	O
not	O	O	O
reached	O	O	O
while	O	O	O
the	O	O	O
estimated	O	O	O
mean	O	O	B-Entity
survival	O	O	I-Entity
time	O	O	I-Entity
was	O	O	O
22.9	O	O	O
months	O	O	B-Entity
.	O	O	O

This	O	O	O
newly	O	O	O
described	O	O	O
clinical	O	O	B-Entity
technique	O	O	I-Entity
is	O	O	O
simple	O	O	O
and	O	O	O
reliable	O	O	B-Entity
to	O	O	O
use	O	O	O
for	O	O	O
restoration	O	O	B-Entity
of	O	O	O
extensively	O	O	O
decayed	O	O	B-Entity
primary	O	O	B-Entity
incisors	O	O	I-Entity
.	O	O	O

Use	O	O	O
of	O	O	O
zirconia	O	O	B-Entity
crowns	O	O	B-Entity
retained	O	O	O
using	O	O	O
this	O	O	O
technique	O	O	B-Entity
offers	O	O	O
superior	O	O	B-Entity
esthetic	O	O	I-Entity
,	O	O	O
durable	O	O	O
restorations	O	O	B-Entity
with	O	O	O
remarkable	O	O	O
gingival	O	O	B-Entity
response	O	O	I-Entity
up	O	O	O
to	O	O	O
24	O	O	O
months	O	O	B-Entity
.	O	O	O

-DOCSTART- (27806385)

Reimbursement	O	O	B-Entity
Based	O	O	O
on	O	O	O
Value	O	O	O
in	O	O	O
Knee	O	O	B-Entity
Surgery	O	O	I-Entity
:	O	O	O
What	O	O	O
You	O	O	O
Need	O	O	O
to	O	O	O
Know	O	O	O
about	O	O	O
the	O	O	O
Medicare	O	O	O
Access	O	O	O
and	O	O	O
Children	O	O	O
's	O	O	O
Health	O	O	O
Insurance	O	O	O
Program	O	O	O
Reauthorization	O	O	O
Act	O	O	O
of	O	O	O
2015	O	O	O

Health	O	O	B-Entity
care	O	O	I-Entity
cost	O	O	I-Entity
is	O	O	O
consuming	O	O	O
a	O	O	O
large	O	O	O
portion	O	O	O
of	O	O	O
the	O	O	O
nation	O	O	B-Entity
's	O	O	I-Entity
gross	O	O	B-Entity
domestic	O	O	I-Entity
product	O	O	I-Entity
while	O	O	O
placing	O	O	O
added	O	O	O
economic	O	O	B-Entity
burdens	O	O	I-Entity
on	O	O	O
physicians	O	O	B-Entity
and	O	O	O
their	O	O	O
patients	O	O	B-Entity
.	O	O	O

With	O	O	O
total	O	O	B-Entity
joint	O	O	I-Entity
replacement	O	O	I-Entity
being	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
early-targeted	O	O	O
procedures	O	O	B-Entity
in	O	O	O
the	O	O	O
evolving	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
environment	O	O	I-Entity
,	O	O	O
knee	O	O	B-Entity
surgeons	O	O	I-Entity
will	O	O	O
benefit	O	O	O
from	O	O	O
developing	O	O	O
a	O	O	O
critical	O	O	O
knowledge	O	O	O
on	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
reforms	O	O	I-Entity
and	O	O	O
their	O	O	O
financial	O	O	O
implications	O	O	O
.	O	O	O

The	O	O	O
Medicare	O	O	B-Entity
Access	O	O	I-Entity
and	O	O	I-Entity
Children	O	O	I-Entity
's	O	O	I-Entity
Health	O	O	I-Entity
Insurance	O	O	I-Entity
Program	O	O	I-Entity
Reauthorization	O	O	I-Entity
Act	O	O	I-Entity
represents	O	O	O
a	O	O	O
cohesive	O	O	O
movement	O	O	O
toward	O	O	O
value-based	O	O	B-Entity
payment	O	O	I-Entity
reform	O	O	I-Entity
and	O	O	O
contains	O	O	O
several	O	O	O
unchartered	O	O	O
rulings	O	O	O
that	O	O	O
require	O	O	O
detailed	O	O	O
attention	O	O	O
by	O	O	O
knee	O	O	B-Entity
surgeons	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
article	O	O	O
,	O	O	O
we	O	O	O
provide	O	O	O
a	O	O	O
contextual	O	O	B-Entity
framework	O	O	I-Entity
of	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
legislation	O	O	I-Entity
that	O	O	O
has	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
formation	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
health	O	O	B-Entity
policy	O	O	I-Entity
,	O	O	O
and	O	O	O
present	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
summary	O	O	B-Entity
and	O	O	O
update	O	O	O
on	O	O	O
the	O	O	O
Merit-Based	O	O	B-Entity
Incentive	O	O	I-Entity
Payment	O	O	I-Entity
Systems	O	O	I-Entity
and	O	O	O
Alternative	O	O	B-Entity
Payment	O	O	I-Entity
Models	O	O	I-Entity
reimbursement	O	O	I-Entity
models	O	O	I-Entity
.	O	O	O

-DOCSTART- (27806641)

Empty	O	O	B-Entity
Capsids	O	O	B-Entity
and	O	O	O
Macrophage	O	O	B-Entity
Inhibition	O	O	B-Entity
/	O	O	O
Depletion	O	O	B-Entity
Increase	O	O	B-Entity
rAAV	O	O	B-Entity
Transgene	O	O	B-Entity
Expression	O	O	B-Entity
in	O	O	O
Joints	O	O	B-Entity
of	O	O	O
Both	O	O	O
Healthy	O	O	B-Entity
and	O	O	O
Arthritic	O	O	B-Entity
Mice	O	O	O

Gene	O	O	B-Entity
therapy	O	O	I-Entity
has	O	O	O
potential	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
rheumatic	O	O	B-Entity
diseases	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
macrophages	O	O	B-Entity
in	O	O	O
the	O	O	O
joint	O	O	B-Entity
might	O	O	O
hamper	O	O	O
adeno-associated	O	O	B-Entity
viral	O	O	I-Entity
vector	O	O	B-Entity
-mediated	O	O	O
gene	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
in	O	O	O
arthritic	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
in	O	O	O
healthy	O	O	B-Entity
,	O	O	O
mice	O	O	B-Entity
administration	O	O	B-Entity
of	O	O	I-Entity
agents	O	O	I-Entity
that	O	O	O
influence	O	O	B-Entity
macrophage	O	O	B-Entity
activity	O	O	B-Entity
/	O	O	O
number	O	O	B-Entity
and/or	O	O	O
addition	O	O	B-Entity
of	O	O	O
empty	O	O	B-Entity
decoy	O	O	B-Entity
capsids	O	O	I-Entity
substantially	O	O	O
improve	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
recombinant	O	O	B-Entity
adeno-associated	O	O	B-Entity
viral	O	O	I-Entity
vector	O	O	B-Entity
5	O	O	O
transgene	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
the	O	O	O
joint	O	O	B-Entity
.	O	O	O

Pretreatment	O	O	B-Entity
with	O	O	O
triamcinolone	O	O	B-Entity
or	O	O	O
clodronate	O	O	B-Entity
liposomes	O	O	B-Entity
improved	O	O	B-Entity
luciferase	O	O	B-Entity
expression	O	O	B-Entity
over	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	O
4	O	O	O
weeks	O	O	B-Entity
.	O	O	O

Similar	O	O	B-Entity
results	O	O	B-Entity
were	O	O	O
seen	O	O	O
when	O	O	O
empty	O	O	B-Entity
decoy	O	O	B-Entity
capsids	O	O	B-Entity
were	O	O	O
added	O	O	B-Entity
to	O	O	O
full	O	O	B-Entity
genome	O	O	B-Entity
containing	O	O	O
capsids	O	O	O
in	O	O	O
a	O	O	O
5:1	O	O	O
ratio	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
study	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
duration	O	O	B-Entity
of	O	O	O
expression	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
combination	O	O	B-Entity
of	O	O	O
these	O	O	O
two	O	O	O
approaches	O	O	B-Entity
,	O	O	O
we	O	O	O
observed	O	O	B-Entity
a	O	O	O
synergistic	O	O	B-Entity
enhancement	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
sustained	O	O	B-Entity
for	O	O	O
at	O	O	O
least	O	O	O
12	O	O	O
weeks	O	O	B-Entity
.	O	O	O

The	O	O	O
enhancement	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
was	O	O	O
independent	O	O	O
of	O	O	O
the	O	O	O
route	O	O	B-Entity
of	O	O	I-Entity
administration	O	O	I-Entity
of	O	O	O
triamcinolone	O	O	B-Entity
(	O	O	O
intra-articular	O	O	B-Entity
or	O	O	O
intramuscular	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
healthy	O	O	B-Entity
mice	O	O	B-Entity
it	O	O	O
was	O	O	O
demonstrated	O	O	O
that	O	O	O
the	O	O	O
combination	O	O	B-Entity
improved	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
transgene	O	O	B-Entity
significantly	O	O	O
,	O	O	O
in	O	O	O
a	O	O	O
serotype	O	O	B-Entity
independent	O	O	O
manner	O	O	O
.	O	O	O

These	O	O	O
data	O	O	B-Entity
have	O	O	O
implications	O	O	O
for	O	O	O
future	O	O	O
applications	O	O	O
of	O	O	O
gene	O	O	B-Entity
therapy	O	O	I-Entity
to	O	O	O
the	O	O	O
joint	O	O	B-Entity
and	O	O	O
for	O	O	O
other	O	O	O
tissues	O	O	B-Entity
with	O	O	O
an	O	O	O
abundance	O	O	B-Entity
of	O	O	O
macrophages	O	O	B-Entity
.	O	O	O

-DOCSTART- (27807162)

An	O	O	O
Inhibitory	O	O	B-Entity
Septum	O	O	B-Entity
to	O	O	O
Lateral	O	O	B-Entity
Hypothalamus	O	O	I-Entity
Circuit	O	O	B-Entity
That	O	O	O
Suppresses	O	O	B-Entity
Feeding	O	O	O

Feeding	O	O	B-Entity
behavior	O	O	I-Entity
is	O	O	O
orchestrated	O	O	B-Entity
by	O	O	O
neural	O	O	B-Entity
circuits	O	O	I-Entity
primarily	O	O	O
residing	O	O	O
in	O	O	O
the	O	O	O
hypothalamus	O	O	B-Entity
and	O	O	O
hindbrain	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
relative	O	O	B-Entity
influence	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
brain	O	O	B-Entity
circuits	O	O	I-Entity
to	O	O	O
the	O	O	O
feeding	O	O	B-Entity
circuitry	O	O	B-Entity
in	O	O	O
the	O	O	O
hypothalamus	O	O	B-Entity
and	O	O	O
hindbrain	O	O	B-Entity
remains	O	O	O
unclear	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
using	O	O	B-Entity
the	O	O	O
cell-type	O	O	B-Entity
selectivity	O	O	O
of	O	O	O
genetic	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
circuit	O	O	B-Entity
mapping	O	O	I-Entity
,	O	O	O
and	O	O	O
behavior	O	O	B-Entity
assays	O	O	B-Entity
,	O	O	O
we	O	O	O
sought	O	O	O
to	O	O	O
decipher	O	O	O
neural	O	O	B-Entity
circuits	O	O	I-Entity
emanating	O	O	O
from	O	O	O
the	O	O	O
septal	O	O	B-Entity
nucleus	O	O	I-Entity
to	O	O	O
the	O	O	O
lateral	O	O	B-Entity
hypothalamus	O	O	I-Entity
(	O	O	O
LH	O	O	B-Entity
)	O	O	O
that	O	O	O
contribute	O	O	O
to	O	O	O
neural	O	O	B-Entity
regulation	O	O	I-Entity
of	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
chemogenetic	O	O	B-Entity
and	O	O	O
optogenetic	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
septal	O	O	B-Entity
vesicular	O	O	B-Entity
GABA	O	O	I-Entity
transporter	O	O	I-Entity
(vGAT)-	O	O	O
containing	O	O	B-Entity
neurons	O	O	B-Entity
or	O	O	O
their	O	O	O
projections	O	O	O
in	O	O	O
the	O	O	O
LH	O	O	B-Entity
reduced	O	O	B-Entity
food	O	O	B-Entity
intake	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

Consistently	O	O	O
,	O	O	O
chemogenetic	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
septal	O	O	B-Entity
vGAT	O	O	B-Entity
neurons	O	O	B-Entity
increased	O	O	B-Entity
food	O	O	B-Entity
intake	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
a	O	O	O
previously	O	O	O
unknown	O	O	B-Entity
neural	O	O	B-Entity
circuit	O	O	I-Entity
originating	O	O	B-Entity
from	O	O	O
septal	O	O	B-Entity
vGAT	O	O	B-Entity
neurons	O	O	B-Entity
to	O	O	O
a	O	O	O
subset	O	O	B-Entity
of	O	O	O
vGAT	O	O	O
neurons	O	O	O
in	O	O	O
the	O	O	O
LH	O	O	B-Entity
,	O	O	O
an	O	O	O
area	O	O	B-Entity
involved	O	O	B-Entity
in	O	O	O
homeostatic	O	O	B-Entity
and	O	O	O
hedonic	O	O	B-Entity
control	O	O	B-Entity
of	O	O	O
energy	O	O	B-Entity
states	O	O	I-Entity
.	O	O	O

Collectively	O	O	O
,	O	O	O
our	O	O	O
data	O	O	B-Entity
reveal	O	O	B-Entity
an	O	O	O
inhibitory	O	O	B-Entity
septohypothalamic	O	O	B-Entity
feeding	O	O	B-Entity
circuit	O	O	I-Entity
that	O	O	O
might	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
eating	O	O	B-Entity
disorders	O	O	I-Entity
such	O	O	O
as	O	O	O
anorexia	O	O	B-Entity
nervosa	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
demonstrate	O	O	O
that	O	O	O
top-down	O	O	O
projections	O	O	O
from	O	O	O
the	O	O	O
septum	O	O	B-Entity
to	O	O	O
the	O	O	O
hypothalamus	O	O	B-Entity
control	O	O	B-Entity
food	O	O	B-Entity
intake	O	O	I-Entity
negatively	O	O	B-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
known	O	O	O
role	O	O	O
for	O	O	O
both	O	O	O
of	O	O	O
these	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
in	O	O	O
the	O	O	O
control	O	O	B-Entity
of	O	O	O
feeding	O	O	B-Entity
and	O	O	O
emotion	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
behaviors	O	O	B-Entity
,	O	O	O
these	O	O	O
findings	O	O	B-Entity
reveal	O	O	B-Entity
previously	O	O	O
unknown	O	O	B-Entity
neural	O	O	B-Entity
circuitry	O	O	I-Entity
that	O	O	O
is	O	O	O
likely	O	O	O
implicated	O	O	O
in	O	O	O
emotional	O	O	B-Entity
aspects	O	O	I-Entity
of	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
and	O	O	O
provide	O	O	B-Entity
new	O	O	O
insights	O	O	B-Entity
into	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
therapeutic	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
eating	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

-DOCSTART- (27807796)

Human	O	O	B-Entity
Umbilical	O	O	B-Entity
Cord	O	O	I-Entity
Blood	O	O	I-Entity
-	O	O	O
Derived	O	O	B-Entity
Neural	O	O	B-Entity
Stem	O	O	I-Entity
Cell	O	O	I-Entity
Line	O	O	I-Entity
as	O	O	O
a	O	O	O
Screening	O	O	B-Entity
Model	O	O	B-Entity
for	O	O	O
Toxicity	O	O	O

The	O	O	O
aim	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
a	O	O	O
human	O	O	B-Entity
neural	O	O	B-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
(	O	O	O
NSC	O	O	B-Entity
)	O	O	O
line	O	O	B-Entity
derived	O	O	B-Entity
from	O	O	O
human	O	O	O
umbilical	O	O	B-Entity
cord	O	O	I-Entity
blood	O	O	I-Entity
(	O	O	O
hUCB	O	O	B-Entity
)	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
toxicity	O	O	B-Entity
study	O	O	B-Entity
.	O	O	O

Toxicity	O	O	B-Entity
of	O	O	O
both	O	O	O
neurotoxic	O	O	B-Entity
environmental	O	O	B-Entity
xenobiotics	O	O	B-Entity
,	O	O	O
methyl	O	O	B-Entity
mercury	O	O	I-Entity
chloride	O	O	I-Entity
(	O	O	O
CH3HgCl	O	O	B-Entity
)	O	O	O
,	O	O	O
lead	O	O	B-Entity
acetate	O	O	I-Entity
(	O	O	O
CH3COOPb	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
chlorpyrifos	O	O	B-Entity
(	O	O	O
CP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
non-neurotoxic	O	O	B-Entity
insecticide	O	O	B-Entity
,	O	O	O
dichlorvos	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
non-neurotoxic	O	O	O
drugs	O	O	B-Entity
,	O	O	O
theophylline	O	O	B-Entity
and	O	O	O
acetaminophen	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
differentiation	O	O	B-Entity
of	O	O	O
neuronal	O	O	B-Entity
and	O	O	O
glial	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
derived	O	O	B-Entity
from	O	O	O
hUCB	O	O	B-Entity
was	O	O	O
elucidated	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
observed	O	O	B-Entity
that	O	O	O
CH3HgCl	O	O	B-Entity
was	O	O	O
more	O	O	O
toxic	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
NSCs	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
CH3COOPb	O	O	B-Entity
and	O	O	O
CP	O	O	B-Entity
.	O	O	O

The	O	O	O
minimum	O	O	B-Entity
inhibitory	O	O	I-Entity
concentration	O	O	I-Entity
(	O	O	I-Entity
MIC	O	O	I-Entity
)	O	O	I-Entity
value	O	O	I-Entity
against	O	O	O
NSCs	O	O	B-Entity
was	O	O	O
3	O	O	O
,	O	O	O
10	O	O	O
,	O	O	O
and	O	O	O
300	O	O	O
mg/L	O	O	O
,	O	O	O
in	O	O	O
each	O	O	O
staining	O	O	B-Entity
process	O	O	I-Entity
,	O	O	O
acridine	O	O	B-Entity
orange	O	O	I-Entity
/	O	O	O
ethidium	O	O	B-Entity
bromide	O	O	I-Entity
(	O	O	O
AO	O	O	B-Entity
/	O	O	O
EB	O	O	B-Entity
)	O	O	O
staining	O	O	O
,	O	O	O
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl	O	O	B-Entity
tetrazolium	O	O	I-Entity
bromide	O	O	I-Entity
(	O	O	O
MTT	O	O	B-Entity
)	O	O	O
assay	O	O	B-Entity
,	O	O	O
and	O	O	O
Hoechst	O	O	B-Entity
staining	O	O	I-Entity
,	O	O	O
for	O	O	O
CH3HgCl	O	O	B-Entity
,	O	O	O
CP	O	O	B-Entity
,	O	O	O
and	O	O	O
CH3COOPb	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

CH3HgCl	O	O	B-Entity
had	O	O	O
the	O	O	O
LC25	O	O	B-Entity
value	O	O	B-Entity
as	O	O	O
10.0	O	O	O
,	O	O	O
14.4	O	O	O
,	O	O	O
and	O	O	O
12.7	O	O	O
mg/L	O	O	O
,	O	O	O
by	O	O	O
staining	O	O	B-Entity
method	O	O	I-Entity
mentioned	O	O	O
in	O	O	O
succession	O	O	O
.	O	O	O

CP	O	O	B-Entity
had	O	O	O
the	O	O	O
LC25	O	O	B-Entity
value	O	O	B-Entity
as	O	O	O
21.9	O	O	O
,	O	O	O
23.7	O	O	O
,	O	O	O
and	O	O	O
18.4	O	O	O
mg/L	O	O	O
;	O	O	O
similarly	O	O	O
,	O	O	O
CH3COOPb	O	O	B-Entity
had	O	O	O
LC25	O	O	O
values	O	O	B-Entity
,	O	O	O
successively	O	O	O
as	O	O	O
616.9	O	O	O
,	O	O	O
719.2	O	O	O
,	O	O	O
and	O	O	O
890.3	O	O	O
mg/L.	O	O	O
LC50	O	O	B-Entity
values	O	O	O
ranged	O	O	B-Entity
from	O	O	O
18.2	O	O	O
to	O	O	O
21.7	O	O	O
mg/L	O	O	O
for	O	O	O
CH3HgCl	O	O	B-Entity
,	O	O	O
56.4	O	O	O
to	O	O	O
60.2	O	O	O
mg/L	O	O	O
for	O	O	O
CP	O	O	O
,	O	O	O
and	O	O	O
1000	O	O	O
to	O	O	O
1460.1	O	O	O
for	O	O	O
CH3COOPb	O	O	O
.	O	O	O

Theophylline	O	O	B-Entity
,	O	O	O
acetaminophen	O	O	B-Entity
,	O	O	O
and	O	O	O
dichlorvos	O	O	B-Entity
had	O	O	O
no	O	O	O
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
viability	O	O	B-Entity
of	O	O	O
NSCs	O	O	B-Entity
.	O	O	O

This	O	O	O
work	O	O	O
justified	O	O	O
that	O	O	O
hUCB	O	O	B-Entity
-	O	O	O
NSC	O	O	B-Entity
model	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
toxicity	O	O	B-Entity
study	O	O	B-Entity
.	O	O	O

-DOCSTART- (27809747)

MiR	O	O	B-Entity
221	O	O	I-Entity
/	O	O	O
222	O	O	B-Entity
as	O	O	O
new	O	O	O
players	O	O	O
in	O	O	O
tamoxifen	O	O	B-Entity
resistance	O	O	O

Breast	O	O	B-Entity
cancer	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	O
frequent	O	O	O
cancer	O	O	O
in	O	O	O
women	O	O	B-Entity
.	O	O	O

Despite	O	O	O
advances	O	O	O
in	O	O	O
early	O	O	B-Entity
detection	O	O	I-Entity
and	O	O	O
treatment	O	O	B-Entity
,	O	O	O
it	O	O	O
has	O	O	O
the	O	O	O
second	O	O	O
highest	O	O	O
mortality	O	O	B-Entity
rate	O	O	I-Entity
after	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Around	O	O	O
85	O	O	O
%	O	O	O
of	O	O	O
breast	O	O	B-Entity
carcinomas	O	O	I-Entity
are	O	O	O
ER+	O	O	B-Entity
;	O	O	O
thus	O	O	O
,	O	O	O
antiestrogens	O	O	B-Entity
like	O	O	O
tamoxifen	O	O	B-Entity
are	O	O	O
beneficial	O	O	O
.	O	O	O

Although	O	O	O
,	O	O	O
tamoxifen	O	O	B-Entity
is	O	O	O
useful	O	O	O
for	O	O	O
many	O	O	O
patients	O	O	B-Entity
,	O	O	O
plenty	O	O	O
of	O	O	O
patients	O	O	O
respond	O	O	B-Entity
poorly	O	O	I-Entity
to	O	O	O
initial	O	O	O
therapy	O	O	B-Entity
or	O	O	O
recurrence	O	O	B-Entity
occurs	O	O	O
in	O	O	O
about	O	O	O
30	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	O
,	O	O	O
because	O	O	O
tamoxifen	O	O	O
resistance	O	O	B-Entity
happens	O	O	O
.	O	O	O

Drug	O	O	B-Entity
resistance	O	O	B-Entity
remains	O	O	O
a	O	O	O
major	O	O	O
clinical	O	O	B-Entity
obstacle	O	O	O
to	O	O	O
successful	O	O	B-Entity
treatment	O	O	I-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
more	O	O	O
than	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
unsuccessful	O	O	B-Entity
treatments	O	O	I-Entity
are	O	O	O
because	O	O	O
of	O	O	O
acquired	O	O	B-Entity
resistance	O	O	O
and	O	O	O
MultiDrug	O	O	B-Entity
Resistance	O	O	I-Entity
(	O	O	B-Entity
MDR	O	O	I-Entity
)	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
contributor	O	O	O
.	O	O	O

MicroRNAs	O	O	B-Entity
are	O	O	O
members	O	O	O
of	O	O	O
a	O	O	O
novel	O	O	O
class	O	O	O
of	O	O	O
short	O	O	O
noncoding	O	O	B-Entity
RNAs	O	O	I-Entity
.	O	O	O

Besides	O	O	O
to	O	O	O
their	O	O	O
various	O	O	O
roles	O	O	O
in	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
miRNAs	O	O	B-Entity
are	O	O	O
considered	O	O	O
as	O	O	O
important	O	O	O
cancer	O	O	B-Entity
therapeutic	O	O	B-Entity
targets	O	O	I-Entity
and	O	O	O
biomarkers	O	O	B-Entity
.	O	O	O

Since	O	O	O
2005	O	O	O
,	O	O	O
when	O	O	O
miRNA	O	O	B-Entity
deregulation	O	O	B-Entity
was	O	O	O
first	O	O	O
reported	O	O	O
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
more	O	O	O
than	O	O	O
1000	O	O	O
reports	O	O	B-Entity
have	O	O	O
been	O	O	O
published	O	O	O
about	O	O	O
miRNAs	O	O	B-Entity
.	O	O	O

Increasing	O	O	O
number	O	O	O
of	O	O	O
studies	O	O	B-Entity
showed	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
miRNAs	O	O	B-Entity
in	O	O	O
antiestrogen	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
especially	O	O	O
on	O	O	O
tamoxifen	O	O	B-Entity
;	O	O	O
thus	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
not	O	O	O
surprising	O	O	O
that	O	O	O
these	O	O	O
tiny	O	O	O
molecules	O	O	B-Entity
are	O	O	O
involved	O	O	O
in	O	O	O
drug	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
pivotal	O	O	O
role	O	O	O
of	O	O	O
these	O	O	O
known	O	O	O
RNA	O	O	B-Entity
molecules	O	O	I-Entity
,	O	O	O
in	O	O	O
this	O	O	O
review	O	O	O
,	O	O	O
we	O	O	O
tried	O	O	O
to	O	O	O
illustrate	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
the	O	O	O
miRNAs	O	O	B-Entity
as	O	O	O
a	O	O	O
new	O	O	O
player	O	O	O
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
pathogenesis	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
also	O	O	O
focused	O	O	O
on	O	O	O
cancer	O	O	B-Entity
drug	O	O	B-Entity
resistance	O	O	I-Entity
mechanisms	O	O	B-Entity
highlighting	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
important	O	O	O
oncomirs	O	O	B-Entity
,	O	O	O
miR	O	O	B-Entity
221	O	O	I-Entity
/	O	O	O
222	O	O	B-Entity
,	O	O	O
involved	O	O	O
in	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
deregulation	O	O	I-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
relationship	O	O	O
between	O	O	O
these	O	O	O
oncomiRs	O	O	B-Entity
with	O	O	O
resistance	O	O	B-Entity
to	O	O	O
tamoxifen	O	O	B-Entity
is	O	O	O
also	O	O	O
emphasized	O	O	B-Entity
.	O	O	O

-DOCSTART- (27812000)

Ultra-low	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	O
a	O	O	O
common	O	O	O
radioisotope	O	O	B-Entity
for	O	O	O
permission	O	O	B-Entity
-free	O	O	O
tracking	O	O	B-Entity
of	O	O	O
a	O	O	O
drosophilid	O	O	B-Entity
fly	O	O	I-Entity
in	O	O	O
its	O	O	O
natural	O	O	O
habitat	O	O	O

Knowledge	O	O	O
of	O	O	O
a	O	O	O
species	O	O	B-Entity
'	O	O	O
ecology	O	O	B-Entity
,	O	O	O
including	O	O	O
its	O	O	O
movement	O	O	B-Entity
in	O	O	O
time	O	O	B-Entity
and	O	O	O
space	O	O	B-Entity
,	O	O	O
is	O	O	O
key	O	O	O
for	O	O	O
many	O	O	O
questions	O	O	O
in	O	O	O
biology	O	O	B-Entity
and	O	O	O
conservation	O	O	B-Entity
.	O	O	O

While	O	O	O
numerous	O	O	O
tools	O	O	B-Entity
for	O	O	O
tracking	O	O	B-Entity
larger	O	O	O
animals	O	O	B-Entity
are	O	O	O
available	O	O	O
,	O	O	O
millimetre-sized	O	O	B-Entity
insects	O	O	I-Entity
are	O	O	O
averse	O	O	O
to	O	O	O
standard	O	O	O
tracking	O	O	O
and	O	O	O
labelling	O	O	B-Entity
procedures	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
evaluated	O	O	O
the	O	O	O
applicability	O	O	O
of	O	O	O
ultra-low	O	O	B-Entity
,	O	O	O
permission	O	O	B-Entity
-	O	O	O
exempt	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	O
the	O	O	O
metastable	O	O	B-Entity
isomer	O	O	I-Entity
of	O	O	O
the	O	O	O
radionuclide	O	O	B-Entity
Technetium-99	O	O	B-Entity
for	O	O	O
labelling	O	O	B-Entity
and	O	O	O
field	O	O	B-Entity
detection	O	O	I-Entity
of	O	O	O
the	O	O	O
mountain	O	O	B-Entity
fly	O	O	B-Entity
Drosophila	O	O	B-Entity
nigrosparsa	O	O	I-Entity
.	O	O	O

We	O	O	O
demonstrate	O	O	O
that	O	O	O
an	O	O	O
activity	O	O	B-Entity
of	O	O	O
less	O	O	O
than	O	O	O
10	O	O	O
MBq	O	O	O
is	O	O	O
sufficient	O	O	O
to	O	O	O
label	O	O	B-Entity
dozens	O	O	O
of	O	O	O
flies	O	O	B-Entity
and	O	O	O
detect	O	O	B-Entity
single	O	O	I-Entity
individuals	O	O	I-Entity
using	O	O	O
standard	O	O	O
radiation	O	O	B-Entity
protection	O	O	I-Entity
monitors	O	O	B-Entity
.	O	O	O

The	O	O	O
methodology	O	O	B-Entity
presented	O	O	O
here	O	O	O
is	O	O	O
applicable	O	O	O
to	O	O	O
many	O	O	O
small-sized	O	O	B-Entity
,	O	O	O
low-mobility	O	O	B-Entity
animals	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
independent	O	O	O
from	O	O	O
light	O	O	B-Entity
and	O	O	O
weather	O	O	B-Entity
conditions	O	O	B-Entity
and	O	O	O
visual	O	O	B-Entity
contact	O	O	I-Entity
with	O	O	O
the	O	O	O
target	O	O	B-Entity
organism	O	O	B-Entity
.	O	O	O

-DOCSTART- (27813390)

Injury	O	O	B-Entity
surveillance	O	O	I-Entity
of	O	O	O
female	O	O	B-Entity
adult	O	O	B-Entity
Zumba	O	O	B-Entity
®	O	O	O
dancers	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
patterns	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
and	O	O	O
to	O	O	O
establish	O	O	O
the	O	O	O
injury	O	O	O
incidence	O	O	B-Entity
rates	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	O
Zumba	O	O	B-Entity
®	O	O	O
.	O	O	O

Zumba	O	O	B-Entity
®	O	O	O
dancers	O	O	B-Entity
were	O	O	O
invited	O	O	O
to	O	O	O
complete	O	O	O
an	O	O	O
anonymous	O	O	O
web-based	O	O	B-Entity
survey	O	O	B-Entity
containing	O	O	O
13	O	O	O
demographic	O	O	B-Entity
background	O	O	B-Entity
and	O	O	O
14	O	O	O
(	O	O	O
1	O	O	O
yr	O	O	B-Entity
retrospective	O	O	B-Entity
)	O	O	O
injury	O	O	B-Entity
history	O	O	B-Entity
questions	O	O	B-Entity
.	O	O	O

Inclusion	O	O	B-Entity
criteria	O	O	B-Entity
stated	O	O	O
that	O	O	O
the	O	O	O
respondents	O	O	B-Entity
had	O	O	O
to	O	O	O
be	O	O	O
aged	O	O	B-Entity
18	O	O	O
-	O	O	O
64	O	O	O
yr	O	O	B-Entity
and	O	O	O
currently	O	O	O
involved	O	O	O
in	O	O	O
group	O	O	B-Entity
-based	O	O	O
classes	O	O	B-Entity
of	O	O	O
Zumba	O	O	B-Entity
®	O	O	O
,	O	O	O
either	O	O	O
as	O	O	O
a	O	O	O
registered	O	O	B-Entity
instructor	O	O	I-Entity
or	O	O	O
class	O	O	B-Entity
participant	O	O	B-Entity
.	O	O	O

Binomial	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
predict	O	O	O
the	O	O	O
odds	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
during	O	O	O
Zumba	O	O	B-Entity
®	O	O	O
and	O	O	O
Mann-Whitney	O	O	B-Entity
tests	O	O	I-Entity
were	O	O	O
employed	O	O	O
to	O	O	O
ascertain	O	O	O
differences	O	O	O
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
survey	O	O	B-Entity
response	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
74	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
final	O	O	O
sample	O	O	O
of	O	O	O
respondents	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
138	O	O	O
;	O	O	O
female	O	O	B-Entity
=	O	O	O
100	O	O	O
%	O	O	O
)	O	O	O
included	O	O	O
19	O	O	O
registered	O	O	B-Entity
instructors	O	O	I-Entity
and	O	O	O
119	O	O	O
class	O	O	B-Entity
participants	O	O	B-Entity
,	O	O	O
of	O	O	O
which	O	O	O
58	O	O	O
%	O	O	O
and	O	O	O
16	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
sustained	O	O	B-Entity
≥	O	O	O
1	O	O	O
injury	O	O	B-Entity
during	O	O	O
Zumba	O	O	B-Entity
®	O	O	O
in	O	O	O
the	O	O	O
past	O	O	O
year	O	O	B-Entity
.	O	O	O

The	O	O	O
odds	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
was	O	O	O
7	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
2	O	O	O
-	O	O	O
19	O	O	O
)	O	O	O
times	O	O	O
greater	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
for	O	O	O
registered	O	O	B-Entity
instructors	O	O	I-Entity
than	O	O	O
for	O	O	O
class	O	O	B-Entity
participants	O	O	B-Entity
.	O	O	O

Zumba	O	O	B-Entity
®	O	O	O
dancers	O	O	B-Entity
had	O	O	O
a	O	O	O
17	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
7	O	O	O
-	O	O	O
28	O	O	O
)	O	O	O
%	O	O	O
greater	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
odds	O	O	B-Entity
of	O	O	O
injury	O	O	B-Entity
for	O	O	O
every	O	O	O
1	O	O	O
h	O	O	B-Entity
of	O	O	O
non-	O	O	O
Zumba	O	O	O
®	O	O	O
-	O	O	O
related	O	O	O
moderate	O	O	B-Entity
to	O	O	I-Entity
vigorous	O	O	I-Entity
physical	O	O	I-Entity
activity	O	O	I-Entity
(	O	O	O
MVPA	O	O	B-Entity
)	O	O	O
engagement	O	O	O
per	O	O	O
week	O	O	B-Entity
.	O	O	O

The	O	O	O
injury	O	O	B-Entity
incidence	O	O	B-Entity
rate	O	O	I-Entity
for	O	O	O
registered	O	O	B-Entity
instructors	O	O	I-Entity
and	O	O	O
class	O	O	B-Entity
participants	O	O	B-Entity
was	O	O	O
5.7	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
3.1	O	O	O
-	O	O	O
8.2	O	O	O
)	O	O	O
and	O	O	O
3.9	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
2.5	O	O	O
-	O	O	O
5.3	O	O	O
)	O	O	O
injuries	O	O	B-Entity
per	O	O	O
1000	O	O	O
h	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Zumba	O	O	B-Entity
®	O	O	O
presents	O	O	O
a	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
injury	O	O	B-Entity
;	O	O	O
for	O	O	O
registered	O	O	B-Entity
instructors	O	O	I-Entity
,	O	O	O
the	O	O	O
increased	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
injury	O	O	O
is	O	O	O
likely	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
high	O	O	O
total	O	O	O
volume	O	O	O
of	O	O	O
MVPA	O	O	B-Entity
participated	O	O	B-Entity
in	O	O	O
weekly	O	O	B-Entity
.	O	O	O

-DOCSTART- (27818328)

Clinical	O	O	B-Entity
Features	O	O	B-Entity
of	O	O	O
Smokers	O	O	B-Entity
With	O	O	O
Radiological	O	O	B-Entity
Emphysema	O	O	B-Entity
But	O	O	O
Without	O	O	O
Airway	O	O	B-Entity
Limitation	O	O	O

The	O	O	O
clinical	O	O	B-Entity
characteristics	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
emphysema	O	O	B-Entity
but	O	O	O
without	O	O	O
airway	O	O	B-Entity
limitations	O	O	B-Entity
remain	O	O	O
unknown	O	O	B-Entity
.	O	O	O

The	O	O	O
goal	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
current	O	O	B-Entity
and	O	O	O
former	O	O	B-Entity
smokers	O	O	I-Entity
without	O	O	O
airflow	O	O	B-Entity
limitation	O	O	B-Entity
who	O	O	O
have	O	O	O
radiologic	O	O	B-Entity
emphysema	O	O	B-Entity
on	O	O	O
chest	O	O	B-Entity
CT	O	O	I-Entity
scans	O	O	I-Entity
vs	O	O	O
a	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
of	O	O	O
current	O	O	O
and	O	O	O
ex-smokers	O	O	B-Entity
without	O	O	O
emphysema	O	O	O
.	O	O	O

Subjects	O	O	B-Entity
enrolled	O	O	O
had	O	O	O
anthropometric	O	O	B-Entity
characteristics	O	O	I-Entity
recorded	O	O	O
,	O	O	O
provided	O	O	B-Entity
a	O	O	O
medical	O	O	B-Entity
history	O	O	I-Entity
,	O	O	O
and	O	O	O
underwent	O	O	O
low-dose	O	O	B-Entity
chest	O	O	B-Entity
CT	O	O	I-Entity
scanning	O	O	I-Entity
.	O	O	O

The	O	O	O
following	O	O	O
parameters	O	O	B-Entity
were	O	O	O
also	O	O	O
evaluated	O	O	O
:	O	O	O
pulmonary	O	O	B-Entity
function	O	O	I-Entity
tests	O	O	I-Entity
including	O	O	O
diffusion	O	O	B-Entity
capacity	O	O	I-Entity
for	O	O	I-Entity
carbon	O	O	I-Entity
monoxide	O	O	I-Entity
(	O	O	O
Dlco	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
modified	O	O	O
Medical	O	O	B-Entity
Research	O	O	I-Entity
Council	O	O	I-Entity
dyspnea	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
COPD	O	O	B-Entity
assessment	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
CAT	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
6-min	O	O	B-Entity
walk	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
6MWT	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
comparison	O	O	B-Entity
was	O	O	O
conducted	O	O	O
between	O	O	O
those	O	O	O
with	O	O	O
and	O	O	O
without	O	O	O
CT	O	O	B-Entity
-	O	O	O
confirmed	O	O	B-Entity
emphysema	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
203	O	O	O
subjects	O	O	B-Entity
,	O	O	O
154	O	O	O
had	O	O	O
emphysema	O	O	B-Entity
,	O	O	O
and	O	O	O
49	O	O	O
did	O	O	O
not	O	O	O
.	O	O	O

Adjusted	O	O	O
group	O	O	B-Entity
comparisons	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
a	O	O	O
higher	O	O	O
proportion	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
emphysema	O	O	B-Entity
according	O	O	O
to	O	O	O
low-dose	O	O	B-Entity
chest	O	O	B-Entity
CT	O	O	I-Entity
scanning	O	O	I-Entity
had	O	O	O
an	O	O	O
abnormal	O	O	B-Entity
Dlco	O	O	I-Entity
value	O	O	B-Entity
(	O	O	O
<	O	O	O
80	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
46	O	O	O
%	O	O	O
vs	O	O	O
19	O	O	O
%	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.02	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
decrease	O	O	B-Entity
in	O	O	O
percentage	O	O	B-Entity
of	O	O	O
oxygen	O	O	B-Entity
saturation	O	O	I-Entity
>	O	O	O
4	O	O	O
%	O	O	O
during	O	O	O
the	O	O	O
6MWT	O	O	B-Entity
(	O	O	O
8.5	O	O	O
%	O	O	O
vs	O	O	O
0	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.04	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
an	O	O	O
altered	O	O	B-Entity
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
CAT	O	O	B-Entity
score	O	O	B-Entity
≥	O	O	O
10	O	O	O
)	O	O	O
(	O	O	O
32	O	O	O
%	O	O	O
vs	O	O	O
14	O	O	O
%	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.01	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
detailed	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
CAT	O	O	B-Entity
questionnaire	O	O	I-Entity
items	O	O	O
revealed	O	O	B-Entity
that	O	O	O
more	O	O	O
patients	O	O	B-Entity
with	O	O	O
emphysema	O	O	B-Entity
had	O	O	O
a	O	O	O
score	O	O	B-Entity
≥	O	O	O
1	O	O	O
in	O	O	O
the	O	O	O
"	O	O	O
chest	O	O	B-Entity
tightness	O	O	I-Entity
"	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
.05	O	O	O
)	O	O	O
and	O	O	O
"	O	O	O
limitation	O	O	B-Entity
when	O	O	O
doing	O	O	O
activities	O	O	B-Entity
at	O	O	O
home	O	O	B-Entity
"	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
items	O	O	O
compared	O	O	B-Entity
with	O	O	O
those	O	O	O
with	O	O	O
no	O	O	B-Entity
emphysema	O	O	I-Entity
.	O	O	O

They	O	O	O
also	O	O	O
experienced	O	O	O
significantly	O	O	O
more	O	O	O
exacerbations	O	O	B-Entity
in	O	O	O
the	O	O	O
previous	O	O	O
year	O	O	B-Entity
(	O	O	O
0.19	O	O	O
vs	O	O	O
0.04	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.02	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
significant	O	O	B-Entity
proportion	O	O	B-Entity
of	O	O	O
smokers	O	O	B-Entity
with	O	O	O
emphysema	O	O	B-Entity
according	O	O	O
to	O	O	O
low-dose	O	O	B-Entity
chest	O	O	B-Entity
CT	O	O	I-Entity
scanning	O	O	I-Entity
but	O	O	O
without	O	O	O
airway	O	O	B-Entity
limitation	O	O	B-Entity
had	O	O	O
alterations	O	O	B-Entity
in	O	O	O
their	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
,	O	O	O
number	O	O	O
of	O	O	O
exacerbations	O	O	B-Entity
,	O	O	O
Dlco	O	O	B-Entity
values	O	O	B-Entity
,	O	O	O
and	O	O	O
oxygen	O	O	B-Entity
saturation	O	O	I-Entity
during	O	O	O
the	O	O	O
6MWT	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

-DOCSTART- (27819344)

Anti-tumor	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
SL4	O	O	B-Entity
against	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
:	O	O	O
induction	O	O	B-Entity
of	O	O	O
G2/M	O	O	B-Entity
arrest	O	O	I-Entity
through	O	O	O
modulation	O	O	B-Entity
of	O	O	O
the	O	O	O
MAPK	O	O	B-Entity
-dependent	O	O	O
p21	O	O	B-Entity
signaling	O	O	O
pathway	O	O	O

SL4	O	O	B-Entity
,	O	O	O
a	O	O	O
chalcone	O	O	B-Entity
-based	O	O	O
compound	O	O	B-Entity
,	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
retard	O	O	B-Entity
tumor	O	O	B-Entity
invasion	O	O	I-Entity
and	O	O	O
angiogenesis	O	O	B-Entity
by	O	O	O
suppressing	O	O	B-Entity
HIF1	O	O	B-Entity
activity	O	O	B-Entity
and	O	O	O
to	O	O	O
induce	O	O	B-Entity
apoptosis	O	O	B-Entity
by	O	O	O
promoting	O	O	B-Entity
ROS	O	O	B-Entity
release	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	B-Entity
that	O	O	O
SL4	O	O	B-Entity
is	O	O	O
able	O	O	O
to	O	O	O
inhibit	O	O	B-Entity
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
different	O	O	B-Entity
types	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
by	O	O	O
inducing	O	O	B-Entity
G2/M	O	O	B-Entity
cell	O	O	I-Entity
cycle	O	O	I-Entity
arrest	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
SL4	O	O	B-Entity
exhibited	O	O	B-Entity
strong	O	O	B-Entity
anti-proliferative	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	O
several	O	O	O
human	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
with	O	O	O
IC50	O	O	B-Entity
values	O	O	I-Entity
lower	O	O	B-Entity
than	O	O	O
1.3	O	O	O
μM.	O	O	O
Further	O	O	O
studies	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
SL4	O	O	O
induced	O	O	B-Entity
G2/M	O	O	B-Entity
arrest	O	O	I-Entity
in	O	O	O
these	O	O	O
cell	O	O	O
lines	O	O	O
.	O	O	O

Mechanistically	O	O	B-Entity
,	O	O	O
SL4	O	O	B-Entity
reduces	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
cyclin	O	O	B-Entity
A2	O	O	I-Entity
and	O	O	O
cdc25C	O	O	B-Entity
and	O	O	O
decreases	O	O	B-Entity
the	O	O	O
activity	O	O	B-Entity
of	O	O	O
the	O	O	O
cdc2	O	O	B-Entity
/	O	O	O
cyclin	O	O	B-Entity
B1	O	O	I-Entity
complex	O	O	B-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
SL4	O	O	B-Entity
treatment	O	O	B-Entity
resulted	O	O	B-Entity
in	O	O	I-Entity
an	O	O	O
obvious	O	O	O
increase	O	O	B-Entity
in	O	O	O
p21	O	O	B-Entity
mRNA	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
levels	O	O	B-Entity
through	O	O	O
activation	O	O	B-Entity
of	O	O	O
MAPK	O	O	B-Entity
signaling	O	O	I-Entity
pathways	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
the	O	O	O
TGF-β	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

SP600125	O	O	B-Entity
and	O	O	O
PD98059	O	O	B-Entity
,	O	O	O
specific	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
JNK	O	O	B-Entity
kinase	O	O	I-Entity
and	O	O	O
ERK	O	O	B-Entity
kinase	O	O	I-Entity
,	O	O	O
significantly	O	O	B-Entity
blocked	O	O	B-Entity
the	O	O	O
SL4	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
G2/M	O	O	B-Entity
phase	O	O	I-Entity
arrest	O	O	I-Entity
and	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
p21	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
SL4	O	O	B-Entity
suppressed	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
established	O	O	B-Entity
breast	O	O	B-Entity
tumors	O	O	I-Entity
in	O	O	O
nude	O	O	B-Entity
mice	O	O	I-Entity
through	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
p21	O	O	B-Entity
and	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
cdc25C	O	O	B-Entity
,	O	O	O
and	O	O	O
displayed	O	O	B-Entity
a	O	O	O
good	O	O	O
safety	O	O	B-Entity
profile	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	B-Entity
demonstrate	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
value	O	O	B-Entity
of	O	O	O
SL4	O	O	B-Entity
as	O	O	O
a	O	O	O
novel	O	O	O
multi-target	O	O	B-Entity
anti-tumor	O	O	I-Entity
drug	O	O	I-Entity
candidate	O	O	I-Entity
.	O	O	O

-DOCSTART- (27820857)

Identification	O	O	B-Entity
of	O	O	O
In-Chain-Functionalized	O	O	B-Entity
Compounds	O	O	I-Entity
and	O	O	O
Methyl-Branched	O	O	B-Entity
Alkanes	O	O	I-Entity
in	O	O	O
Cuticular	O	O	B-Entity
Waxes	O	O	B-Entity
of	O	O	O
Triticum	O	O	O
aestivum	O	O	O
cv	O	O	O
.	O	O	O
Bethlehem	O	O	O

Bethlehem	O	O	O
In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
cuticular	O	O	B-Entity
waxes	O	O	B-Entity
from	O	O	O
flag	O	O	B-Entity
leaf	O	O	I-Entity
blades	O	O	B-Entity
and	O	O	O
peduncles	O	O	B-Entity
of	O	O	O
Triticum	O	O	O
aestivum	O	O	O
cv	O	O	O
.	O	O	O

Bethlehem	O	O	O
were	O	O	O
investigated	O	O	B-Entity
in	O	O	O
search	O	O	O
for	O	O	O
novel	O	O	B-Entity
wax	O	O	B-Entity
compounds	O	O	I-Entity
.	O	O	O

Seven	O	O	O
wax	O	O	B-Entity
compound	O	O	I-Entity
classes	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
that	O	O	O
had	O	O	O
previously	O	O	O
not	O	O	O
been	O	O	O
reported	O	O	O
,	O	O	O
and	O	O	O
their	O	O	O
structures	O	O	B-Entity
were	O	O	O
elucidated	O	O	O
using	O	O	O
gas	O	O	B-Entity
chromatography-mass	O	O	I-Entity
spectrometry	O	O	I-Entity
of	O	O	O
various	O	O	O
derivatives	O	O	B-Entity
.	O	O	O

Six	O	O	O
of	O	O	O
the	O	O	O
classes	O	O	O
were	O	O	O
identified	O	O	O
as	O	O	O
series	O	O	B-Entity
of	O	O	I-Entity
homologs	O	O	I-Entity
differing	O	O	B-Entity
by	O	O	O
two	O	O	B-Entity
methylene	O	O	I-Entity
units	O	O	I-Entity
,	O	O	O
while	O	O	O
the	O	O	O
seventh	O	O	O
was	O	O	O
a	O	O	O
homologous	O	O	B-Entity
series	O	O	I-Entity
with	O	O	O
homologs	O	O	B-Entity
with	O	O	I-Entity
single	O	O	I-Entity
methylene	O	O	I-Entity
unit	O	O	I-Entity
differences	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
waxes	O	O	B-Entity
of	O	O	O
flag	O	O	B-Entity
leaf	O	O	I-Entity
blades	O	O	B-Entity
,	O	O	O
secondary	O	O	B-Entity
alcohols	O	O	I-Entity
(	O	O	O
predominantly	O	O	B-Entity
C27	O	O	B-Entity
and	O	O	O
C33	O	O	B-Entity
)	O	O	O
,	O	O	O
primary	O	O	B-Entity
/	O	O	O
secondary	O	O	B-Entity
diols	O	O	I-Entity
(	O	O	O
predominantly	O	O	O
C28	O	O	B-Entity
)	O	O	O
and	O	O	O
esters	O	O	B-Entity
of	O	O	I-Entity
primary	O	O	I-Entity
/	O	O	O
secondary	O	O	O
diols	O	O	O
(	O	O	O
predominantly	O	O	O
C50	O	O	B-Entity
,	O	O	O
combining	O	O	O
C28	O	O	B-Entity
diol	O	O	I-Entity
with	O	O	O
C22	O	O	B-Entity
acid	O	O	I-Entity
)	O	O	O
were	O	O	O
found	O	O	O
,	O	O	O
all	O	O	O
sharing	O	O	O
similar	O	O	O
secondary	O	O	B-Entity
hydroxyl	O	O	I-Entity
group	O	O	I-Entity
positions	O	O	I-Entity
at	O	O	O
and	O	O	O
around	O	O	O
C-12	O	O	O
or	O	O	O
ω-12	O	O	O
.	O	O	O

7-	O	O	B-Entity
and	O	O	O
8-hydroxy-2-alkanol	O	O	B-Entity
esters	O	O	I-Entity
(	O	O	O
predominantly	O	O	B-Entity
C35	O	O	B-Entity
)	O	O	O
,	O	O	O
7-	O	O	O
and	O	O	O
8-oxo-2-alkanol	O	O	B-Entity
esters	O	O	I-Entity
(	O	O	O
predominantly	O	O	O
C35	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
4-alkylbutan-4-olides	O	O	B-Entity
(	O	O	O
predominantly	O	O	O
C28	O	O	B-Entity
)	O	O	O
were	O	O	O
found	O	O	O
both	O	O	O
in	O	O	O
flag	O	O	B-Entity
leaf	O	O	I-Entity
and	O	O	O
peduncle	O	O	B-Entity
wax	O	O	B-Entity
mixtures	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
a	O	O	O
series	O	O	B-Entity
of	O	O	O
even	O	O	B-Entity
-	O	O	O
and	O	O	O
odd-numbered	O	O	B-Entity
alkane	O	O	I-Entity
homologs	O	O	I-Entity
was	O	O	O
identified	O	O	O
in	O	O	O
both	O	O	O
leaf	O	O	B-Entity
and	O	O	O
peduncle	O	O	B-Entity
waxes	O	O	B-Entity
,	O	O	O
with	O	O	O
an	O	O	O
internal	O	O	B-Entity
methyl	O	O	I-Entity
branch	O	O	I-Entity
preferentially	O	O	O
on	O	O	O
C-11	O	O	B-Entity
and	O	O	O
C-13	O	O	B-Entity
of	O	O	I-Entity
homologs	O	O	I-Entity
with	O	O	I-Entity
even	O	O	I-Entity
total	O	O	I-Entity
carbon	O	O	I-Entity
number	O	O	I-Entity
and	O	O	O
on	O	O	O
C-12	O	O	B-Entity
of	O	O	I-Entity
odd-numbered	O	O	I-Entity
homologs	O	O	I-Entity
.	O	O	O

Biosynthetic	O	O	B-Entity
pathways	O	O	I-Entity
are	O	O	O
suggested	O	O	O
for	O	O	O
all	O	O	O
compounds	O	O	B-Entity
,	O	O	O
based	O	O	O
on	O	O	O
common	O	O	O
structural	O	O	B-Entity
features	O	O	B-Entity
and	O	O	O
matching	O	O	O
chain	O	O	B-Entity
length	O	O	I-Entity
profiles	O	O	B-Entity
with	O	O	O
other	O	O	O
wheat	O	O	B-Entity
wax	O	O	B-Entity
compound	O	O	I-Entity
classes	O	O	O
.	O	O	O

-DOCSTART- (27821359)

Pupillary	O	O	B-Entity
response	O	O	I-Entity
abnormalities	O	O	B-Entity
in	O	O	O
depressive	O	O	O
disorders	O	O	O

Depressive	O	O	B-Entity
disorders	O	O	I-Entity
lack	O	O	B-Entity
objective	O	O	B-Entity
physiological	O	O	B-Entity
measurements	O	O	B-Entity
to	O	O	O
characterize	O	O	B-Entity
the	O	O	O
affected	O	O	B-Entity
population	O	O	I-Entity
and	O	O	O
facilitate	O	O	O
study	O	O	B-Entity
of	O	O	O
relevant	O	O	B-Entity
mechanisms	O	O	B-Entity
.	O	O	O

The	O	O	O
melanopsin	O	O	B-Entity
-	O	O	O
mediated	O	O	B-Entity
light	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
may	O	O	O
contribute	O	O	O
to	O	O	O
seasonal	O	O	B-Entity
variation	O	O	I-Entity
and	O	O	O
can	O	O	O
be	O	O	O
measured	O	O	B-Entity
non-invasively	O	O	O
by	O	O	O
pupillometry	O	O	B-Entity
.	O	O	O

We	O	O	O
prospectively	O	O	B-Entity
studied	O	O	I-Entity
changes	O	O	O
in	O	O	O
melanopsin	O	O	B-Entity
-	O	O	O
mediated	O	O	B-Entity
pupillary	O	O	B-Entity
constriction	O	O	I-Entity
in	O	O	O
19	O	O	O
participants	O	O	B-Entity
with	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
MDD	O	O	B-Entity
)	O	O	O
and	O	O	O
10	O	O	O
control	O	O	B-Entity
across	O	O	O
the	O	O	O
summer	O	O	B-Entity
and	O	O	I-Entity
winter	O	O	I-Entity
solstices	O	O	I-Entity
.	O	O	O

The	O	O	O
melanopsin	O	O	B-Entity
-	O	O	O
mediated	O	O	B-Entity
response	O	O	I-Entity
,	O	O	O
as	O	O	O
measured	O	O	B-Entity
by	O	O	O
the	O	O	O
pupil	O	O	B-Entity
's	O	O	I-Entity
sustained	O	O	I-Entity
constriction	O	O	I-Entity
six	O	O	O
s	O	O	O
after	O	O	O
a	O	O	O
high	O	O	B-Entity
intensity	O	O	I-Entity
blue	O	O	B-Entity
light	O	O	I-Entity
stimulus	O	O	B-Entity
,	O	O	O
was	O	O	O
marginally	O	O	O
attenuated	O	O	B-Entity
in	O	O	O
those	O	O	O
with	O	O	O
MDD	O	O	B-Entity
relative	O	O	O
to	O	O	O
controls	O	O	B-Entity
(	O	O	O
p	O	O	B-Entity
=	O	O	O
0.071	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
participants	O	O	B-Entity
with	O	O	O
MDD	O	O	B-Entity
unexpectedly	O	O	O
showed	O	O	O
a	O	O	O
significantly	O	O	B-Entity
reduced	O	O	B-Entity
transient	O	O	B-Entity
pupillary	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
low	O	O	B-Entity
intensity	O	O	I-Entity
red	O	O	B-Entity
(	O	O	O
p	O	O	B-Entity
=	O	O	O
0.011	O	O	O
)	O	O	O
and	O	O	O
blue	O	O	B-Entity
light	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.013	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
high	O	O	B-Entity
intensity	O	O	I-Entity
red	O	O	O
and	O	O	O
blue	O	O	O
light	O	O	O
.	O	O	O

Sustained	O	O	O
pupillary	O	O	B-Entity
constriction	O	O	I-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
high	O	O	B-Entity
intensity	O	O	I-Entity
blue	O	O	B-Entity
light	O	O	I-Entity
was	O	O	O
more	O	O	O
pronounced	O	O	O
with	O	O	O
increasing	O	O	B-Entity
daylight	O	O	B-Entity
hours	O	O	B-Entity
(	O	O	O
p	O	O	B-Entity
=	O	O	O
0.037	O	O	O
)	O	O	O
and	O	O	O
was	O	O	O
more	O	O	O
strongly	O	O	O
related	O	O	O
to	O	O	O
objectively	O	O	B-Entity
measured	O	O	B-Entity
versus	O	O	O
estimated	O	O	B-Entity
light	O	O	B-Entity
exposure	O	O	I-Entity
.	O	O	O

Melanopsin	O	O	B-Entity
-	O	O	O
mediated	O	O	B-Entity
impairments	O	O	B-Entity
in	O	O	O
pupil	O	O	B-Entity
response	O	O	I-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
biological	O	O	B-Entity
marker	O	O	I-Entity
for	O	O	O
vulnerability	O	O	B-Entity
to	O	O	O
depression	O	O	B-Entity
in	O	O	O
low	O	O	B-Entity
light	O	O	I-Entity
conditions	O	O	B-Entity
.	O	O	O

Assessment	O	O	B-Entity
of	O	O	O
these	O	O	O
and	O	O	O
other	O	O	O
responses	O	O	B-Entity
to	O	O	O
light	O	O	B-Entity
stimuli	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
response	O	O	B-Entity
to	O	O	O
low	O	O	B-Entity
intensity	O	O	I-Entity
light	O	O	I-Entity
,	O	O	O
may	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
the	O	O	O
study	O	O	B-Entity
of	O	O	O
the	O	O	O
neurobiology	O	O	B-Entity
of	O	O	O
MDD	O	O	B-Entity
and	O	O	O
related	O	O	O
mood	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

-DOCSTART- (27821419)

Long	O	O	B-Entity
Noncoding	O	O	I-Entity
RNAs	O	O	I-Entity
in	O	O	O
Cardiovascular	O	O	B-Entity
Pathology	O	O	I-Entity
,	O	O	O
Diagnosis	O	O	B-Entity
,	O	O	O
and	O	O	O
Therapy	O	O	O

Vast	O	O	O
parts	O	O	O
of	O	O	O
mammalian	O	O	B-Entity
genomes	O	O	B-Entity
encode	O	O	B-Entity
for	O	O	O
transcripts	O	O	B-Entity
that	O	O	O
are	O	O	O
not	O	O	O
further	O	O	O
translated	O	O	B-Entity
into	O	O	I-Entity
proteins	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
the	O	O	O
majority	O	O	B-Entity
of	O	O	O
such	O	O	O
noncoding	O	O	B-Entity
ribonucleic	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	B-Entity
RNAs	O	O	I-Entity
)	O	O	I-Entity
remained	O	O	O
paradoxical	O	O	B-Entity
for	O	O	O
a	O	O	O
long	O	O	O
time	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
growing	O	O	B-Entity
body	O	O	O
of	O	O	O
evidence	O	O	B-Entity
demonstrates	O	O	B-Entity
that	O	O	O
long	O	O	B-Entity
noncoding	O	O	I-Entity
RNAs	O	O	I-Entity
are	O	O	O
dynamically	O	O	B-Entity
expressed	O	O	B-Entity
in	O	O	O
different	O	O	B-Entity
cell	O	O	B-Entity
types	O	O	I-Entity
,	O	O	O
diseases	O	O	B-Entity
,	O	O	O
or	O	O	O
developmental	O	O	B-Entity
stages	O	O	I-Entity
to	O	O	O
execute	O	O	B-Entity
a	O	O	O
wide	O	O	B-Entity
variety	O	O	I-Entity
of	O	O	O
regulatory	O	O	B-Entity
roles	O	O	I-Entity
at	O	O	O
virtually	O	O	B-Entity
every	O	O	O
step	O	O	B-Entity
of	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
translation	O	O	B-Entity
.	O	O	O

Indeed	O	O	O
,	O	O	O
long	O	O	B-Entity
noncoding	O	O	I-Entity
RNAs	O	O	I-Entity
influence	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
via	O	O	O
epigenetic	O	O	B-Entity
modulations	O	O	I-Entity
,	O	O	O
through	O	O	O
regulating	O	O	B-Entity
alternative	O	O	B-Entity
splicing	O	O	I-Entity
,	O	O	O
or	O	O	O
by	O	O	O
acting	O	O	O
as	O	O	O
molecular	O	O	B-Entity
sponges	O	O	I-Entity
.	O	O	O

The	O	O	O
abundance	O	O	B-Entity
of	O	O	O
long	O	O	B-Entity
noncoding	O	O	I-Entity
RNAs	O	O	I-Entity
in	O	O	O
the	O	O	O
cardiovascular	O	O	B-Entity
system	O	O	I-Entity
indicates	O	O	O
that	O	O	O
they	O	O	O
may	O	O	O
be	O	O	O
part	O	O	O
of	O	O	O
a	O	O	O
complex	O	O	B-Entity
regulatory	O	O	B-Entity
network	O	O	I-Entity
governing	O	O	B-Entity
physiology	O	O	B-Entity
and	O	O	O
pathology	O	O	B-Entity
of	O	O	O
the	O	O	O
heart	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
review	O	O	O
,	O	O	O
we	O	O	O
discuss	O	O	O
the	O	O	O
multifaceted	O	O	B-Entity
functions	O	O	B-Entity
of	O	O	O
long	O	O	B-Entity
noncoding	O	O	I-Entity
RNAs	O	O	I-Entity
and	O	O	O
highlight	O	O	O
the	O	O	O
current	O	O	B-Entity
literature	O	O	I-Entity
with	O	O	O
an	O	O	O
emphasis	O	O	O
on	O	O	O
cardiac	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
disease	O	O	B-Entity
.	O	O	O

Furthermore	O	O	B-Entity
,	O	O	O
as	O	O	O
the	O	O	O
enormous	O	O	B-Entity
spectrum	O	O	O
of	O	O	O
long	O	O	B-Entity
noncoding	O	O	I-Entity
RNAs	O	O	I-Entity
potentially	O	O	B-Entity
opens	O	O	O
up	O	O	O
new	O	O	O
avenues	O	O	B-Entity
for	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
prevention	O	O	B-Entity
of	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
we	O	O	O
ultimately	O	O	O
evaluate	O	O	O
the	O	O	O
futuristic	O	O	B-Entity
prospects	O	O	I-Entity
of	O	O	O
long	O	O	O
noncoding	O	O	O
RNAs	O	O	O
as	O	O	O
biomarkers	O	O	B-Entity
,	O	O	O
and	O	O	O
therapeutic	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
.	O	O	O

-DOCSTART- (27822189)

Flexible	O	O	B-Entity
Coordination	O	O	B-Entity
of	O	O	O
Stationary	O	O	B-Entity
and	O	O	O
Mobile	O	O	B-Entity
Conversations	O	O	B-Entity
with	O	O	O
Gaze	O	O	B-Entity
:	O	O	O
Resource	O	O	B-Entity
Allocation	O	O	I-Entity
among	O	O	O
Multiple	O	O	O
Joint	O	O	O
Activities	O	O	O

Gaze	O	O	B-Entity
is	O	O	O
instrumental	O	O	O
in	O	O	O
coordinating	O	O	B-Entity
face-to-face	O	O	B-Entity
social	O	O	B-Entity
interactions	O	O	I-Entity
.	O	O	O

But	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
gaze	O	O	B-Entity
use	O	O	O
when	O	O	O
social	O	O	B-Entity
interactions	O	O	I-Entity
co-occur	O	O	B-Entity
with	O	O	O
other	O	O	O
joint	O	O	B-Entity
activities	O	O	I-Entity
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
case	O	O	O
of	O	O	O
walking	O	O	B-Entity
while	O	O	O
talking	O	O	B-Entity
.	O	O	O

We	O	O	O
assessed	O	O	B-Entity
how	O	O	O
gaze	O	O	B-Entity
gets	O	O	O
allocated	O	O	B-Entity
among	O	O	O
various	O	O	O
targets	O	O	B-Entity
in	O	O	O
mobile	O	O	B-Entity
conversations	O	O	B-Entity
,	O	O	O
whether	O	O	O
allocation	O	O	B-Entity
of	O	O	O
gaze	O	O	O
to	O	O	O
other	O	O	O
targets	O	O	O
affects	O	O	B-Entity
conversational	O	O	B-Entity
coordination	O	O	B-Entity
,	O	O	O
and	O	O	O
whether	O	O	O
reduced	O	O	B-Entity
availability	O	O	B-Entity
of	O	O	I-Entity
gaze	O	O	O
for	O	O	O
conversational	O	O	O
coordination	O	O	O
affects	O	O	O
conversational	O	O	O
performance	O	O	B-Entity
and	O	O	O
content	O	O	B-Entity
.	O	O	O

In	O	O	O
an	O	O	O
experimental	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
pairs	O	O	O
were	O	O	O
videotaped	O	O	B-Entity
in	O	O	O
four	O	O	O
conditions	O	O	B-Entity
of	O	O	O
mobility	O	O	B-Entity
(	O	O	O
standing	O	O	B-Entity
still	O	O	I-Entity
,	O	O	O
talking	O	O	B-Entity
while	O	O	O
walking	O	O	B-Entity
along	O	O	I-Entity
a	O	O	I-Entity
straight-line	O	O	I-Entity
itinerary	O	O	I-Entity
,	O	O	O
talking	O	O	O
while	O	O	O
walking	O	O	O
along	O	O	O
a	O	O	O
complex	O	O	B-Entity
itinerary	O	O	I-Entity
,	O	O	O
or	O	O	O
walking	O	O	O
along	O	O	O
a	O	O	O
complex	O	O	O
itinerary	O	O	O
with	O	O	O
no	O	O	B-Entity
conversational	O	O	I-Entity
task	O	O	B-Entity
)	O	O	O
.	O	O	O

Gaze	O	O	B-Entity
to	O	O	O
partners	O	O	B-Entity
was	O	O	O
substantially	O	O	B-Entity
reduced	O	O	I-Entity
in	O	O	O
mobile	O	O	B-Entity
conversations	O	O	B-Entity
,	O	O	O
but	O	O	O
gaze	O	O	B-Entity
was	O	O	O
still	O	O	O
used	O	O	O
to	O	O	O
coordinate	O	O	B-Entity
conversation	O	O	B-Entity
via	O	O	O
displays	O	O	B-Entity
of	O	O	O
mutual	O	O	B-Entity
orientation	O	O	B-Entity
,	O	O	O
and	O	O	O
conversational	O	O	B-Entity
performance	O	O	B-Entity
and	O	O	O
content	O	O	B-Entity
was	O	O	O
not	O	O	O
different	O	O	B-Entity
between	O	O	O
stationary	O	O	B-Entity
and	O	O	O
mobile	O	O	O
conditions	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
expand	O	O	O
the	O	O	O
phenomena	O	O	B-Entity
of	O	O	O
multitasking	O	O	O
to	O	O	O
joint	O	O	B-Entity
activities	O	O	I-Entity
.	O	O	O

-DOCSTART- (27823893)

Sepsis	O	O	B-Entity
Clinical	O	O	B-Entity
Criteria	O	O	I-Entity
in	O	O	O
Emergency	O	O	B-Entity
Department	O	O	I-Entity
Patients	O	O	B-Entity
Admitted	O	O	B-Entity
to	O	O	O
an	O	O	O
Intensive	O	O	B-Entity
Care	O	O	I-Entity
Unit	O	O	I-Entity
:	O	O	O
An	O	O	O
External	O	O	B-Entity
Validation	O	O	I-Entity
Study	O	O	I-Entity
of	O	O	O
Quick	O	O	O
Sequential	O	O	O
Organ	O	O	O
Failure	O	O	O
Assessment	O	O	O

Quick	O	O	B-Entity
Sequential	O	O	I-Entity
Organ	O	O	I-Entity
Failure	O	O	I-Entity
Assessment	O	O	I-Entity
(	O	O	O
qSOFA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
prognostic	O	O	B-Entity
score	O	O	I-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
sepsis	O	O	B-Entity
.	O	O	O

Our	O	O	O
aim	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	O
the	O	O	O
area	O	O	B-Entity
under	O	O	I-Entity
the	O	O	I-Entity
receiver	O	O	I-Entity
operating	O	O	I-Entity
curve	O	O	I-Entity
(	O	O	O
AUROC	O	O	B-Entity
)	O	O	O
,	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
specificity	O	O	B-Entity
,	O	O	O
and	O	O	O
likelihood	O	O	B-Entity
ratios	O	O	I-Entity
of	O	O	O
qSOFA	O	O	B-Entity
vs.	O	O	O
systemic	O	O	B-Entity
inflammation	O	O	I-Entity
response	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
SIRS	O	O	B-Entity
)	O	O	O
in	O	O	O
predicting	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
among	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
(	O	O	O
ED	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
with	O	O	O
suspected	O	O	B-Entity
infection	O	O	I-Entity
admitted	O	O	B-Entity
to	O	O	O
intensive	O	O	B-Entity
care	O	O	I-Entity
units	O	O	I-Entity
(	O	O	O
ICUs	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
chart	O	O	I-Entity
review	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
ED	O	O	B-Entity
patients	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	O
an	O	O	O
ICU	O	O	B-Entity
with	O	O	O
suspected	O	O	B-Entity
infection	O	O	I-Entity
from	O	O	O
August	O	O	B-Entity
1	O	O	O
,	O	O	O
2012	O	O	O
to	O	O	O
February	O	O	B-Entity
28	O	O	O
,	O	O	O
2015	O	O	O
.	O	O	O

We	O	O	O
included	O	O	O
all	O	O	O
patients	O	O	B-Entity
with	O	O	O
body	O	O	B-Entity
fluid	O	O	I-Entity
cultures	O	O	I-Entity
sampled	O	O	I-Entity
either	O	O	O
during	O	O	O
their	O	O	O
ED	O	O	B-Entity
stay	O	O	O
without	O	O	O
antibiotic	O	O	B-Entity
administration	O	O	I-Entity
or	O	O	O
within	O	O	O
24	O	O	O
h	O	O	O
of	O	O	O
antibiotics	O	O	B-Entity
administered	O	O	I-Entity
in	O	O	O
the	O	O	O
ED	O	O	O
.	O	O	O

Trained	O	O	B-Entity
chart	O	O	I-Entity
abstractors	O	O	I-Entity
blinded	O	O	O
to	O	O	O
the	O	O	O
study	O	O	B-Entity
hypothesis	O	O	O
double-entered	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
each	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
electronic	O	O	B-Entity
medical	O	O	I-Entity
record	O	O	I-Entity
including	O	O	O
demographic	O	O	B-Entity
characteristics	O	O	I-Entity
,	O	O	O
vital	O	O	B-Entity
signs	O	O	I-Entity
,	O	O	O
laboratory	O	O	B-Entity
study	O	O	I-Entity
results	O	O	I-Entity
,	O	O	O
physical	O	O	B-Entity
examination	O	O	I-Entity
findings	O	O	B-Entity
,	O	O	O
and	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
.	O	O	O

We	O	O	O
then	O	O	O
calculated	O	O	O
the	O	O	O
AUROC	O	O	B-Entity
,	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
specificity	O	O	B-Entity
,	O	O	O
and	O	O	O
likelihood	O	O	B-Entity
ratios	O	O	I-Entity
for	O	O	O
qSOFA	O	O	B-Entity
and	O	O	O
SIRS	O	O	B-Entity
for	O	O	O
predicting	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
.	O	O	O

Of	O	O	O
214	O	O	O
patients	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	O
an	O	O	O
ICU	O	O	B-Entity
with	O	O	O
presumed	O	O	B-Entity
sepsis	O	O	I-Entity
,	O	O	O
39	O	O	O
(	O	O	O
18.2	O	O	O
%	O	O	O
)	O	O	O
died	O	O	B-Entity
during	O	O	I-Entity
hospitalization	O	O	I-Entity
.	O	O	O

The	O	O	O
AUROC	O	O	B-Entity
value	O	O	O
was	O	O	O
0.65	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
0.56	O	O	O
-	O	O	O
0.74	O	O	O
)	O	O	O
for	O	O	O
SIRS	O	O	B-Entity
vs.	O	O	O
0.66	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.57	O	O	O
-	O	O	O
0.76	O	O	O
)	O	O	O
for	O	O	O
qSOFA	O	O	B-Entity
;	O	O	O
2	O	O	O
+	O	O	O
qSOFA	O	O	O
criteria	O	O	O
predicted	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
with	O	O	O
89.7	O	O	O
%	O	O	O
sensitivity	O	O	B-Entity
,	O	O	O
27.4	O	O	O
%	O	O	O
specificity	O	O	B-Entity
,	O	O	O
1.2	O	O	O
positive	O	O	B-Entity
likelihood	O	O	I-Entity
ratio	O	O	I-Entity
,	O	O	O
and	O	O	O
0.4	O	O	O
negative	O	O	B-Entity
likelihood	O	O	I-Entity
ratio	O	O	I-Entity
.	O	O	O

Among	O	O	O
ED	O	O	B-Entity
patients	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	O
an	O	O	O
ICU	O	O	B-Entity
,	O	O	O
the	O	O	O
SIRS	O	O	B-Entity
and	O	O	O
qSOFA	O	O	B-Entity
criteria	O	O	O
had	O	O	O
comparable	O	O	O
prognostic	O	O	B-Entity
value	O	O	I-Entity
for	O	O	O
predicting	O	O	O
in-hospital	O	O	B-Entity
mortality	O	O	I-Entity
.	O	O	O

These	O	O	O
prognostic	O	O	B-Entity
values	O	O	I-Entity
are	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
reported	O	O	O
by	O	O	O
the	O	O	O
Sepsis-3	O	O	B-Entity
guidelines	O	O	I-Entity
for	O	O	O
ICU	O	O	B-Entity
encounters	O	O	B-Entity
.	O	O	O

-DOCSTART- (27823981)

Repetitive	O	O	B-Entity
transcranial	O	O	I-Entity
magnetic	O	O	I-Entity
stimulation	O	O	I-Entity
improves	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
patients	O	O	O

Repetitive	O	O	B-Entity
transcranial	O	O	I-Entity
magnetic	O	O	I-Entity
stimulation	O	O	I-Entity
(	O	O	O
rTMS	O	O	B-Entity
)	O	O	O
acts	O	O	O
as	O	O	O
a	O	O	O
kind	O	O	O
of	O	O	O
widely-applied	O	O	O
and	O	O	O
non-invasive	O	O	O
method	O	O	O
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
of	O	O	O
some	O	O	O
neurological	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

This	O	O	O
prospective	O	O	B-Entity
,	O	O	O
randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	B-Entity
trial	O	O	I-Entity
investigates	O	O	B-Entity
the	O	O	O
effect	O	O	O
of	O	O	O
rTMS	O	O	B-Entity
on	O	O	O
30	O	O	O
cases	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
participants	O	O	B-Entity
,	O	O	O
who	O	O	O
were	O	O	O
classified	O	O	O
into	O	O	O
mild	O	O	B-Entity
and	O	O	O
moderate	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

Neuropsychological	O	O	B-Entity
tests	O	O	I-Entity
were	O	O	O
carried	O	O	O
out	O	O	O
using	O	O	O
the	O	O	O
AD	O	O	B-Entity
Assessment	O	O	I-Entity
Scale	O	O	I-Entity
-	O	O	O
cognitive	O	O	B-Entity
subscale	O	O	I-Entity
(	O	O	O
ADAS	O	O	B-Entity
-	O	O	O
cog	O	O	B-Entity
)	O	O	O
,	O	O	O
Mini-Mental	O	O	B-Entity
State	O	O	I-Entity
Examination	O	O	I-Entity
(	O	O	O
MMSE	O	O	B-Entity
)	O	O	O
,	O	O	O
Montreal	O	O	B-Entity
Cognitive	O	O	I-Entity
Assessment	O	O	I-Entity
(	O	O	O
MoCA	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
World	O	O	B-Entity
Health	O	O	I-Entity
Organization	O	O	I-Entity
University	O	O	I-Entity
of	O	O	I-Entity
California-Los	O	O	I-Entity
Angeles	O	O	I-Entity
,	O	O	I-Entity
Auditory	O	O	I-Entity
Verbal	O	O	I-Entity
Learning	O	O	I-Entity
Test	O	O	I-Entity
(	O	O	O
WHO-UCLA	O	O	B-Entity
AVLT	O	O	I-Entity
)	O	O	O
before	O	O	O
,	O	O	O
immediately	O	O	O
after	O	O	O
,	O	O	O
and	O	O	O
6	O	O	O
weeks	O	O	B-Entity
after	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
data	O	O	B-Entity
from	O	O	O
30	O	O	O
AD	O	O	B-Entity
patients	O	O	B-Entity
revealed	O	O	O
that	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
obvious	O	O	O
interaction	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
time-by-group	O	O	O
.	O	O	O

The	O	O	O
ADAS	O	O	B-Entity
-	O	O	O
cog	O	O	B-Entity
,	O	O	O
MMSE	O	O	B-Entity
and	O	O	O
WHO-UCLA	O	O	B-Entity
AVLT	O	O	I-Entity
score	O	O	B-Entity
in	O	O	O
the	O	O	O
rTMS	O	O	B-Entity
group	O	O	B-Entity
was	O	O	O
significantly	O	O	O
improved	O	O	O
compared	O	O	B-Entity
with	O	O	O
baselines	O	O	B-Entity
at	O	O	O
6	O	O	O
weeks	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
(	O	O	O
all	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
MoCA	O	O	B-Entity
scores	O	O	B-Entity
were	O	O	O
also	O	O	O
obviously	O	O	O
ameliorated	O	O	B-Entity
in	O	O	O
the	O	O	O
mild	O	O	B-Entity
AD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
rTMS	O	O	B-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
subgroup	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
effect	O	O	O
of	O	O	O
rTMS	O	O	B-Entity
on	O	O	O
the	O	O	O
memory	O	O	B-Entity
and	O	O	O
language	O	O	B-Entity
of	O	O	O
mild	O	O	B-Entity
AD	O	O	B-Entity
patients	O	O	B-Entity
was	O	O	O
superior	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
moderate	O	O	B-Entity
AD	O	O	O
patients	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
findings	O	O	B-Entity
suggested	O	O	O
that	O	O	O
repetitive	O	O	B-Entity
transcranial	O	O	I-Entity
magnetic	O	O	I-Entity
stimulation	O	O	I-Entity
improves	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
memory	O	O	B-Entity
and	O	O	O
language	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
AD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
mild	O	O	B-Entity
stage	O	O	B-Entity
of	O	O	O
AD	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
rTMS	O	O	B-Entity
can	O	O	O
be	O	O	O
recommended	O	O	O
as	O	O	O
a	O	O	O
promising	O	O	O
adjuvant	O	O	B-Entity
therapy	O	O	I-Entity
combined	O	O	O
with	O	O	O
cholinesterase	O	O	B-Entity
inhibitors	O	O	I-Entity
at	O	O	O
the	O	O	O
mild	O	O	B-Entity
stage	O	O	B-Entity
of	O	O	O
AD	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27824066)

A	O	O	O
Novel	O	O	B-Entity
Insulin/Glucose	O	O	B-Entity
Model	O	O	B-Entity
after	O	O	O
a	O	O	O
Mixed-Meal	O	O	B-Entity
Test	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Type	O	O	B-Entity
1	O	O	I-Entity
Diabetes	O	O	I-Entity
on	O	O	O
Insulin	O	O	B-Entity
Pump	O	O	I-Entity
Therapy	O	O	O

Current	O	O	B-Entity
closed-loop	O	O	B-Entity
insulin	O	O	I-Entity
delivery	O	O	I-Entity
methods	O	O	I-Entity
stem	O	O	O
from	O	O	O
sophisticated	O	O	O
models	O	O	O
of	O	O	O
the	O	O	O
glucose-insulin	O	O	B-Entity
(	O	O	I-Entity
G/I	O	O	I-Entity
)	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
mostly	O	O	B-Entity
based	O	O	O
on	O	O	O
complex	O	O	B-Entity
studies	O	O	B-Entity
employing	O	O	B-Entity
glucose	O	O	B-Entity
tracer	O	O	I-Entity
technology	O	O	I-Entity
.	O	O	O

We	O	O	O
tested	O	O	B-Entity
the	O	O	O
performance	O	O	B-Entity
of	O	O	O
a	O	O	O
new	O	O	O
minimal	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
GLUKINSLOOP	O	O	B-Entity
2.0	O	O	I-Entity
)	O	O	O
of	O	O	O
the	O	O	O
G/I	O	O	B-Entity
system	O	O	I-Entity
to	O	O	O
characterize	O	O	B-Entity
the	O	O	O
glucose	O	O	B-Entity
and	O	O	I-Entity
insulin	O	O	I-Entity
dynamics	O	O	B-Entity
during	O	O	O
multiple	O	O	B-Entity
mixed	O	O	B-Entity
meal	O	O	I-Entity
tests	O	O	I-Entity
(	O	O	O
MMT	O	O	B-Entity
)	O	O	O
of	O	O	O
different	O	O	B-Entity
sizes	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
(	O	O	O
T1D	O	O	B-Entity
)	O	O	O
on	O	O	O
insulin	O	O	B-Entity
pump	O	O	I-Entity
therapy	O	O	B-Entity
(	O	O	O
continuous	O	O	B-Entity
subcutaneous	O	O	I-Entity
insulin	O	O	I-Entity
infusion	O	O	I-Entity
,	O	O	O
CSII	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
GLUKINSLOOP	O	O	B-Entity
2.0	O	O	I-Entity
identified	O	O	B-Entity
the	O	O	O
G/I	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
provided	O	O	B-Entity
a	O	O	O
close	O	O	O
fit	O	O	O
of	O	O	O
the	O	O	O
G/I	O	O	O
time-courses	O	O	B-Entity
and	O	O	O
showed	O	O	O
acceptable	O	O	B-Entity
reproducibility	O	O	B-Entity
of	O	O	O
the	O	O	O
G/I	O	O	B-Entity
system	O	O	I-Entity
parameters	O	O	B-Entity
in	O	O	O
repeated	O	O	B-Entity
studies	O	O	B-Entity
of	O	O	O
identical	O	O	B-Entity
and	O	O	O
double-sized	O	O	B-Entity
MMTs	O	O	B-Entity
.	O	O	O

This	O	O	O
model	O	O	B-Entity
can	O	O	O
provide	O	O	B-Entity
a	O	O	O
fairly	O	O	O
good	O	O	O
and	O	O	O
reproducible	O	O	O
description	O	O	B-Entity
of	O	O	O
the	O	O	O
G/I	O	O	B-Entity
system	O	O	I-Entity
in	O	O	O
T1D	O	O	B-Entity
patients	O	O	B-Entity
on	O	O	O
CSII	O	O	B-Entity
,	O	O	O
and	O	O	O
it	O	O	O
may	O	O	O
be	O	O	O
applied	O	O	B-Entity
to	O	O	O
create	O	O	O
a	O	O	O
bank	O	O	O
of	O	O	O
"	O	O	B-Entity
virtual	O	O	I-Entity
"	O	O	I-Entity
patients	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
might	O	O	O
be	O	O	O
relevant	O	O	B-Entity
at	O	O	O
improving	O	O	B-Entity
the	O	O	O
architecture	O	O	O
of	O	O	O
upcoming	O	O	O
closed-loop	O	O	B-Entity
CSII	O	O	B-Entity
systems	O	O	O
.	O	O	O

-DOCSTART- (27824925)

Impact	O	O	B-Entity
of	O	O	O
Strategically	O	O	O
Located	O	O	O
White	O	O	B-Entity
Matter	O	O	I-Entity
Hyperintensities	O	O	I-Entity
on	O	O	O
Cognition	O	O	B-Entity
in	O	O	O
Memory	O	O	B-Entity
Clinic	O	O	I-Entity
Patients	O	O	B-Entity
with	O	O	O
Small	O	O	O
Vessel	O	O	O
Disease	O	O	O

Studies	O	O	O
on	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
small	O	O	B-Entity
vessel	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
SVD	O	O	B-Entity
)	O	O	O
on	O	O	O
cognition	O	O	B-Entity
generally	O	O	O
focus	O	O	B-Entity
on	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
hyperintensity	O	O	I-Entity
(	O	O	O
WMH	O	O	B-Entity
)	O	O	O
volume	O	O	B-Entity
.	O	O	O

The	O	O	O
extent	O	O	B-Entity
to	O	O	O
which	O	O	O
WMH	O	O	B-Entity
location	O	O	B-Entity
relates	O	O	B-Entity
to	O	O	O
cognitive	O	O	B-Entity
performance	O	O	I-Entity
has	O	O	O
received	O	O	B-Entity
less	O	O	B-Entity
attention	O	O	B-Entity
,	O	O	O
but	O	O	O
is	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
functionally	O	O	B-Entity
important	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
the	O	O	O
relation	O	O	B-Entity
between	O	O	O
WMH	O	O	B-Entity
location	O	O	B-Entity
and	O	O	O
cognition	O	O	B-Entity
in	O	O	O
a	O	O	O
memory	O	O	B-Entity
clinic	O	O	I-Entity
cohort	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
sporadic	O	O	B-Entity
SVD	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
167	O	O	O
patients	O	O	B-Entity
with	O	O	O
SVD	O	O	B-Entity
were	O	O	O
recruited	O	O	O
from	O	O	O
memory	O	O	B-Entity
clinics	O	O	I-Entity
.	O	O	O

Assumption-free	O	O	B-Entity
region	O	O	I-Entity
of	O	O	I-Entity
interest-based	O	O	I-Entity
analyses	O	O	B-Entity
based	O	O	B-Entity
on	O	O	O
major	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
tracts	O	O	B-Entity
and	O	O	O
voxel	O	O	B-Entity
-	O	O	O
wise	O	O	B-Entity
analyses	O	O	O
were	O	O	O
used	O	O	B-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
WMH	O	O	B-Entity
location	O	O	B-Entity
and	O	O	O
executive	O	O	B-Entity
functioning	O	O	I-Entity
,	O	O	O
visuomotor	O	O	B-Entity
speed	O	O	I-Entity
and	O	O	O
memory	O	O	B-Entity
.	O	O	O

Region	O	O	B-Entity
of	O	O	I-Entity
interest-based	O	O	I-Entity
analyses	O	O	I-Entity
showed	O	O	O
that	O	O	O
WMHs	O	O	B-Entity
located	O	O	B-Entity
particularly	O	O	O
within	O	O	B-Entity
the	O	O	O
anterior	O	O	B-Entity
thalamic	O	O	I-Entity
radiation	O	O	I-Entity
and	O	O	O
forceps	O	O	B-Entity
minor	O	O	I-Entity
were	O	O	O
inversely	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
both	O	O	O
executive	O	O	B-Entity
functioning	O	O	I-Entity
and	O	O	O
visuomotor	O	O	B-Entity
speed	O	O	I-Entity
,	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
total	O	O	B-Entity
WMH	O	O	B-Entity
volume	O	O	B-Entity
.	O	O	O

Memory	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
WMH	O	O	B-Entity
volume	O	O	B-Entity
in	O	O	O
the	O	O	O
forceps	O	O	B-Entity
minor	O	O	I-Entity
,	O	O	O
independent	O	O	B-Entity
of	O	O	I-Entity
total	O	O	B-Entity
WMH	O	O	O
volume	O	O	O
.	O	O	O

An	O	O	O
independent	O	O	B-Entity
assumption-free	O	O	I-Entity
voxel-wise	O	O	I-Entity
analysis	O	O	I-Entity
identified	O	O	B-Entity
strategic	O	O	O
voxels	O	O	B-Entity
in	O	O	O
these	O	O	O
same	O	O	B-Entity
tracts	O	O	B-Entity
.	O	O	O

Region	O	O	B-Entity
of	O	O	I-Entity
interest-based	O	O	I-Entity
analyses	O	O	I-Entity
showed	O	O	O
that	O	O	O
WMH	O	O	B-Entity
volume	O	O	B-Entity
within	O	O	B-Entity
the	O	O	O
anterior	O	O	B-Entity
thalamic	O	O	I-Entity
radiation	O	O	I-Entity
explained	O	O	O
6.8	O	O	O
%	O	O	O
of	O	O	O
variance	O	O	B-Entity
in	O	O	O
executive	O	O	B-Entity
functioning	O	O	I-Entity
,	O	O	O
compared	O	O	B-Entity
to	O	O	O
3.9	O	O	O
%	O	O	O
for	O	O	O
total	O	O	B-Entity
WMH	O	O	O
volume	O	O	O
;	O	O	O
WMH	O	O	O
volume	O	O	O
within	O	O	O
the	O	O	O
forceps	O	O	B-Entity
minor	O	O	I-Entity
explained	O	O	O
4.6	O	O	O
%	O	O	O
of	O	O	O
variance	O	O	O
in	O	O	O
visuomotor	O	O	B-Entity
speed	O	O	I-Entity
and	O	O	O
4.2	O	O	O
%	O	O	O
of	O	O	O
variance	O	O	O
in	O	O	O
memory	O	O	B-Entity
,	O	O	O
compared	O	O	O
to	O	O	O
1.8	O	O	O
%	O	O	O
and	O	O	O
1.3	O	O	O
%	O	O	O
respectively	O	O	O
for	O	O	O
total	O	O	O
WMH	O	O	O
volume	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
identify	O	O	B-Entity
the	O	O	O
anterior	O	O	B-Entity
thalamic	O	O	I-Entity
radiation	O	O	I-Entity
and	O	O	O
forceps	O	O	B-Entity
minor	O	O	I-Entity
as	O	O	O
strategic	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
tracts	O	O	B-Entity
in	O	O	O
which	O	O	O
WMHs	O	O	B-Entity
are	O	O	O
most	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
in	O	O	O
memory	O	O	B-Entity
clinic	O	O	I-Entity
patients	O	O	B-Entity
with	O	O	O
SVD	O	O	B-Entity
.	O	O	O

WMH	O	O	B-Entity
volumes	O	O	B-Entity
in	O	O	O
individual	O	O	O
tracts	O	O	B-Entity
explained	O	O	O
more	O	O	O
variance	O	O	B-Entity
in	O	O	O
cognition	O	O	B-Entity
than	O	O	O
total	O	O	B-Entity
WMH	O	O	O
burden	O	O	O
,	O	O	O
emphasizing	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
lesion	O	O	B-Entity
location	O	O	I-Entity
when	O	O	O
addressing	O	O	O
the	O	O	O
functional	O	O	B-Entity
consequences	O	O	B-Entity
of	O	O	I-Entity
WMHs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27825443)

Natural	O	O	B-Entity
competence	O	O	B-Entity
for	O	O	O
transformation	O	O	O

While	O	O	O
most	O	O	O
molecular	O	O	B-Entity
biologists	O	O	I-Entity
are	O	O	O
familiar	O	O	O
with	O	O	O
the	O	O	O
artificial	O	O	B-Entity
transformation	O	O	B-Entity
of	O	O	I-Entity
bacteria	O	O	I-Entity
in	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
laboratory	O	O	B-Entity
cloning	O	O	B-Entity
experiments	O	O	B-Entity
,	O	O	O
natural	O	O	B-Entity
competence	O	O	B-Entity
for	O	O	O
transformation	O	O	O
refers	O	O	O
to	O	O	O
a	O	O	O
specific	O	O	B-Entity
physiological	O	O	B-Entity
state	O	O	B-Entity
in	O	O	O
which	O	O	O
prokaryotes	O	O	B-Entity
are	O	O	O
able	O	O	O
to	O	O	O
take	O	O	O
up	O	O	O
genetic	O	O	B-Entity
material	O	O	I-Entity
from	O	O	O
their	O	O	O
surroundings	O	O	B-Entity
.	O	O	O

Occasionally	O	O	O
,	O	O	O
such	O	O	O
absorbed	O	O	B-Entity
DNA	O	O	B-Entity
is	O	O	O
recombined	O	O	B-Entity
into	O	O	O
the	O	O	O
organism	O	O	B-Entity
's	O	O	I-Entity
own	O	O	O
genome	O	O	B-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
natural	O	O	B-Entity
transformation	O	O	B-Entity
(	O	O	O
Figure	O	O	O
1	O	O	O
)	O	O	O
.	O	O	O

As	O	O	O
a	O	O	O
consequence	O	O	B-Entity
,	O	O	O
natural	O	O	B-Entity
competence	O	O	B-Entity
for	O	O	O
transformation	O	O	B-Entity
is	O	O	O
considered	O	O	O
a	O	O	O
primary	O	O	B-Entity
mode	O	O	B-Entity
of	O	O	O
horizontal	O	O	B-Entity
gene	O	O	I-Entity
transfer	O	O	B-Entity
(	O	O	O
HGT	O	O	B-Entity
)	O	O	O
in	O	O	O
prokaryotes	O	O	B-Entity
,	O	O	O
together	O	O	O
with	O	O	O
conjugation	O	O	B-Entity
(	O	O	O
direct	O	O	B-Entity
cell	O	O	B-Entity
to	O	O	O
cell	O	O	O
transfer	O	O	O
of	O	O	O
DNA	O	O	B-Entity
via	O	O	O
a	O	O	O
specialized	O	O	B-Entity
conjugal	O	O	B-Entity
pilus	O	O	I-Entity
)	O	O	O
and	O	O	O
phage	O	O	B-Entity
transduction	O	O	B-Entity
(	O	O	O
DNA	O	O	O
transfer	O	O	O
mediated	O	O	O
by	O	O	O
viruses	O	O	B-Entity
)	O	O	O
.	O	O	O

HGT	O	O	B-Entity
plays	O	O	O
a	O	O	O
major	O	O	O
role	O	O	O
in	O	O	O
bacterial	O	O	B-Entity
evolution	O	O	B-Entity
,	O	O	O
and	O	O	O
past	O	O	B-Entity
research	O	O	B-Entity
has	O	O	O
demonstrated	O	O	O
that	O	O	O
HGT	O	O	O
,	O	O	O
including	O	O	O
natural	O	O	B-Entity
competence	O	O	B-Entity
for	O	O	O
transformation	O	O	B-Entity
,	O	O	O
contributes	O	O	B-Entity
to	O	O	O
the	O	O	O
emergence	O	O	O
of	O	O	O
pathogens	O	O	B-Entity
and	O	O	O
the	O	O	O
spread	O	O	B-Entity
of	O	O	O
virulence	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Indeed	O	O	O
,	O	O	O
Frederick	O	O	O
Griffith	O	O	O
discovered	O	O	O
natural	O	O	B-Entity
competence	O	O	B-Entity
for	O	O	O
transformation	O	O	B-Entity
in	O	O	O
1928	O	O	O
while	O	O	O
he	O	O	O
was	O	O	O
investigating	O	O	B-Entity
the	O	O	O
exchange	O	O	B-Entity
of	O	O	O
pathogenic	O	O	B-Entity
traits	O	O	B-Entity
in	O	O	O
pneumococci	O	O	B-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
abundance	O	O	B-Entity
and	O	O	O
spread	O	O	B-Entity
of	O	O	O
multidrug-resistant	O	O	B-Entity
microbes	O	O	I-Entity
,	O	O	O
research	O	O	B-Entity
on	O	O	O
HGT	O	O	B-Entity
is	O	O	O
even	O	O	O
more	O	O	O
important	O	O	O
today	O	O	O
than	O	O	O
ever	O	O	O
before	O	O	O
.	O	O	O

-DOCSTART- (27826087)

Three-dimensional	O	O	B-Entity
constructive	O	O	I-Entity
interference	O	O	I-Entity
in	O	O	I-Entity
steady-state	O	O	I-Entity
(	O	O	I-Entity
3D-CISS	O	O	I-Entity
)	O	O	I-Entity
sequences	O	O	I-Entity
and	O	O	O
Phase-contrast	O	O	B-Entity
MRI	O	O	I-Entity
of	O	O	O
arrested	O	O	O
hydrocephalus	O	O	O

to	O	O	O
evaluate	O	O	O
role	O	O	O
of	O	O	O
three-dimensional	O	O	B-Entity
constructive	O	O	I-Entity
interference	O	O	I-Entity
in	O	O	I-Entity
steady-state	O	O	I-Entity
(	O	O	I-Entity
3D-CISS	O	O	I-Entity
)	O	O	I-Entity
sequences	O	O	I-Entity
and	O	O	O
phase-contrast	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
PC-MRI	O	O	B-Entity
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
arrested	O	O	B-Entity
hydrocephalus	O	O	I-Entity
.	O	O	O

Prospective	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
on	O	O	O
20	O	O	O
patients	O	O	B-Entity
with	O	O	O
arrested	O	O	B-Entity
hydrocephalus	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
underwent	O	O	O
PC-MRI	O	O	B-Entity
and	O	O	O
3D-CISS	O	O	B-Entity
for	O	O	O
assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
aqueduct	O	O	B-Entity
.	O	O	O

Axial	O	O	B-Entity
(	O	O	O
through-plane	O	O	B-Entity
)	O	O	O
,	O	O	O
sagittal	O	O	B-Entity
(	O	O	O
in-plane	O	O	B-Entity
)	O	O	O
PC-MRI	O	O	B-Entity
and	O	O	O
sagittal	O	O	O
3D-CISS	O	O	B-Entity
were	O	O	O
applied	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
cerebral	O	O	B-Entity
aqueduct	O	O	I-Entity
and	O	O	O
the	O	O	O
spontaneous	O	O	B-Entity
third	O	O	B-Entity
ventriculostomy	O	O	I-Entity
if	O	O	O
present	O	O	O
.	O	O	O

Aqueductal	O	O	B-Entity
patency	O	O	B-Entity
was	O	O	O
graded	O	O	B-Entity
using	O	O	O
3D-CISS	O	O	B-Entity
and	O	O	O
PC-MRI	O	O	B-Entity
.	O	O	O

Quantitative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
flow	O	O	O
through	O	O	O
the	O	O	O
aqueduct	O	O	B-Entity
was	O	O	O
done	O	O	O
using	O	O	O
PC-MRI	O	O	B-Entity
.	O	O	O

The	O	O	O
causes	O	O	O
of	O	O	O
obstruction	O	O	B-Entity
were	O	O	O
aqueductal	O	O	B-Entity
obstruction	O	O	O
in	O	O	O
75	O	O	O
%	O	O	O
(	O	O	O
n=15	O	O	O
)	O	O	O
,	O	O	O
3rd	O	O	O
ventricular	O	O	B-Entity
obstruction	O	O	I-Entity
in	O	O	O
5	O	O	O
%	O	O	O
(	O	O	O
n=1	O	O	O
)	O	O	O
and	O	O	O
4th	O	O	O
ventricular	O	O	O
obstruction	O	O	O
in	O	O	O
20	O	O	O
%	O	O	O
(	O	O	O
n=4	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
cause	O	O	O
of	O	O	O
arrest	O	O	B-Entity
of	O	O	O
hydrocephalus	O	O	B-Entity
was	O	O	O
spontaneous	O	O	B-Entity
third	O	O	B-Entity
ventriculostomy	O	O	I-Entity
in	O	O	O
65	O	O	O
%	O	O	O
(	O	O	O
n=13	O	O	O
)	O	O	O
,	O	O	O
endoscopic	O	O	B-Entity
third	O	O	I-Entity
ventriculostomy	O	O	I-Entity
in	O	O	O
10	O	O	O
%	O	O	O
(	O	O	O
n=2	O	O	O
)	O	O	O
,	O	O	O
ventriculo-peritoneal	O	O	B-Entity
shunt	O	O	I-Entity
in	O	O	O
5	O	O	O
%	O	O	O
(	O	O	O
n=1	O	O	O
)	O	O	O
and	O	O	O
no	O	O	O
cause	O	O	O
could	O	O	O
be	O	O	O
detected	O	O	B-Entity
in	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
(	O	O	O
n=4	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
positive	O	O	B-Entity
correlation	O	O	B-Entity
(	O	O	O
r=	O	O	O
0.80	O	O	O
)	O	O	O
and	O	O	O
moderate	O	O	B-Entity
agreement	O	O	B-Entity
(	O	O	O
κ=	O	O	O
0.509	O	O	O
)	O	O	O
of	O	O	O
grading	O	O	B-Entity
with	O	O	O
PC-MRI	O	O	B-Entity
and	O	O	O
3D-CISS	O	O	B-Entity
sequences	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
peak	O	O	I-Entity
systolic	O	O	I-Entity
velocity	O	O	I-Entity
of	O	O	O
CSF	O	O	B-Entity
was	O	O	O
1.86	O	O	O
±	O	O	O
2.48	O	O	O
cm/sec	O	O	O
,	O	O	O
the	O	O	O
stroke	O	O	B-Entity
volume	O	O	I-Entity
was	O	O	O
6.43	O	O	O
±	O	O	O
13.81μl/cycle	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
mean	O	O	B-Entity
flow	O	O	I-Entity
was	O	O	O
0.21	O	O	O
±	O	O	O
0.32	O	O	O
ml/min	O	O	O
.	O	O	O

We	O	O	O
concluded	O	O	O
that	O	O	O
3D-CISS	O	O	B-Entity
and	O	O	O
PC-MRI	O	O	B-Entity
are	O	O	O
non-invasive	O	O	B-Entity
sequences	O	O	O
for	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
the	O	O	O
level	O	O	O
and	O	O	O
cause	O	O	B-Entity
of	O	O	O
arrested	O	O	B-Entity
hydrocephalus	O	O	I-Entity
.	O	O	O

-DOCSTART- (27828958)

Historical	O	O	B-Entity
Environment	O	O	B-Entity
Is	O	O	O
Reflected	O	O	O
in	O	O	O
Modern	O	O	B-Entity
Population	O	O	I-Entity
Genetics	O	O	I-Entity
and	O	O	O
Biogeography	O	O	B-Entity
of	O	O	O
an	O	O	O
Island	O	O	B-Entity
Endemic	O	O	B-Entity
Lizard	O	O	B-Entity
(	O	O	O
Xantusia	O	O	B-Entity
riversiana	O	O	I-Entity
reticulata	O	O	I-Entity
)	O	O	O

The	O	O	O
restricted	O	O	B-Entity
distribution	O	O	I-Entity
and	O	O	O
isolation	O	O	B-Entity
of	O	O	O
island	O	O	B-Entity
endemics	O	O	B-Entity
often	O	O	O
produces	O	O	O
unique	O	O	O
genetic	O	O	B-Entity
and	O	O	O
phenotypic	O	O	B-Entity
diversity	O	O	B-Entity
of	O	O	O
conservation	O	O	B-Entity
interest	O	O	O
to	O	O	O
management	O	O	B-Entity
agencies	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
these	O	O	O
isolated	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
especially	O	O	O
those	O	O	O
with	O	O	O
sensitive	O	O	B-Entity
life	O	O	B-Entity
history	O	O	I-Entity
traits	O	O	B-Entity
,	O	O	O
are	O	O	O
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
for	O	O	O
the	O	O	O
adverse	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
genetic	O	O	B-Entity
drift	O	O	I-Entity
and	O	O	O
habitat	O	O	B-Entity
degradation	O	O	B-Entity
by	O	O	O
non-native	O	O	B-Entity
wildlife	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
study	O	O	B-Entity
the	O	O	O
population	O	O	B-Entity
genetic	O	O	B-Entity
diversity	O	O	I-Entity
,	O	O	O
structure	O	O	B-Entity
,	O	O	O
and	O	O	O
stability	O	O	B-Entity
of	O	O	O
a	O	O	O
classic	O	O	O
"	O	O	O
island	O	O	B-Entity
giant	O	O	I-Entity
"	O	O	O
(	O	O	O
Xantusia	O	O	B-Entity
riversiana	O	O	I-Entity
,	O	O	O
the	O	O	O
Island	O	O	B-Entity
Night	O	O	I-Entity
Lizard	O	O	I-Entity
)	O	O	O
on	O	O	O
San	O	O	B-Entity
Clemente	O	O	I-Entity
Island	O	O	I-Entity
,	O	O	O
California	O	O	B-Entity
following	O	O	O
the	O	O	O
removal	O	O	B-Entity
of	O	O	O
feral	O	O	B-Entity
goats	O	O	I-Entity
.	O	O	O

Using	O	O	O
DNA	O	O	B-Entity
microsatellites	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
this	O	O	O
population	O	O	B-Entity
is	O	O	O
reasonably	O	O	O
genetically	O	O	B-Entity
robust	O	O	B-Entity
despite	O	O	O
historical	O	O	B-Entity
grazing	O	O	B-Entity
,	O	O	O
with	O	O	O
similar	O	O	O
effective	O	O	O
population	O	O	B-Entity
sizes	O	O	I-Entity
and	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
metrics	O	O	O
across	O	O	O
all	O	O	O
sampling	O	O	B-Entity
locations	O	O	B-Entity
irrespective	O	O	O
of	O	O	O
habitat	O	O	B-Entity
type	O	O	O
and	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
degradation	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
we	O	O	O
also	O	O	O
found	O	O	O
strong	O	O	O
site-specific	O	O	B-Entity
patterns	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
variation	O	O	I-Entity
and	O	O	O
low	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
compared	O	O	O
to	O	O	O
mainland	O	O	B-Entity
congeners	O	O	I-Entity
,	O	O	O
warranting	O	O	O
continued	O	O	O
special	O	O	O
management	O	O	B-Entity
as	O	O	O
an	O	O	O
island	O	O	B-Entity
endemic	O	O	B-Entity
.	O	O	O

We	O	O	O
identify	O	O	O
both	O	O	O
high	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
elevation	O	O	B-Entity
areas	O	O	I-Entity
that	O	O	O
remain	O	O	O
valuable	O	O	O
repositories	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
and	O	O	O
provide	O	O	O
a	O	O	O
case	O	O	B-Entity
study	O	O	I-Entity
for	O	O	O
other	O	O	O
low-dispersal	O	O	B-Entity
coastal	O	O	B-Entity
organisms	O	O	B-Entity
in	O	O	O
the	O	O	O
face	O	O	O
of	O	O	O
future	O	O	B-Entity
climate	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

-DOCSTART- (27829026)

Cross-Species	O	O	O
Rhesus	O	O	B-Entity
Cytomegalovirus	O	O	B-Entity
Infection	O	O	I-Entity
of	O	O	O
Cynomolgus	O	O	O
Macaques	O	O	O

Cytomegaloviruses	O	O	B-Entity
(	O	O	O
CMV	O	O	B-Entity
)	O	O	O
are	O	O	O
highly	O	O	O
species-specific	O	O	O
due	O	O	O
to	O	O	O
millennia	O	O	O
of	O	O	O
co-evolution	O	O	B-Entity
and	O	O	O
adaptation	O	O	B-Entity
to	O	O	O
their	O	O	O
host	O	O	B-Entity
,	O	O	O
with	O	O	O
no	O	O	O
successful	O	O	O
experimental	O	O	O
cross-	O	O	O
species	O	O	B-Entity
infection	O	O	B-Entity
in	O	O	O
primates	O	O	B-Entity
reported	O	O	O
to	O	O	O
date	O	O	O
.	O	O	O

Accordingly	O	O	O
,	O	O	O
full	O	O	O
genome	O	O	B-Entity
phylogenetic	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
multiple	O	O	O
new	O	O	O
CMV	O	O	B-Entity
field	O	O	O
isolates	O	O	B-Entity
derived	O	O	O
from	O	O	O
two	O	O	O
closely	O	O	O
related	O	O	O
nonhuman	O	O	B-Entity
primate	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
Indian-origin	O	O	B-Entity
rhesus	O	O	B-Entity
macaques	O	O	I-Entity
(	O	O	O
RM	O	O	B-Entity
)	O	O	O
and	O	O	O
Mauritian	O	O	B-Entity
-origin	O	O	O
cynomolgus	O	O	B-Entity
macaques	O	O	I-Entity
(	O	O	O
MCM	O	O	B-Entity
)	O	O	O
,	O	O	O
revealed	O	O	O
distinct	O	O	O
and	O	O	O
tight	O	O	O
lineage	O	O	B-Entity
clustering	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
species	O	O	B-Entity
of	O	O	I-Entity
origin	O	O	I-Entity
,	O	O	O
with	O	O	O
MCM	O	O	O
CMV	O	O	O
isolates	O	O	O
mirroring	O	O	O
the	O	O	O
limited	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
of	O	O	O
their	O	O	O
primate	O	O	O
host	O	O	B-Entity
that	O	O	O
underwent	O	O	O
a	O	O	O
population	O	O	O
bottleneck	O	O	O
400	O	O	O
years	O	O	O
ago	O	O	O
.	O	O	O

Despite	O	O	O
the	O	O	O
ability	O	O	B-Entity
of	O	O	O
Rhesus	O	O	B-Entity
CMV	O	O	B-Entity
(	O	O	O
RhCMV	O	O	B-Entity
)	O	O	O
laboratory	O	O	B-Entity
strain	O	O	I-Entity
68	O	O	O
-	O	O	O
1	O	O	O
to	O	O	O
replicate	O	O	B-Entity
efficiently	O	O	O
in	O	O	O
MCM	O	O	B-Entity
fibroblasts	O	O	B-Entity
and	O	O	O
potently	O	O	O
inhibit	O	O	B-Entity
antigen	O	O	I-Entity
presentation	O	O	I-Entity
to	O	O	O
MCM	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
RhCMV	O	O	O
68	O	O	O
-	O	O	O
1	O	O	O
failed	O	O	O
to	O	O	O
productively	O	O	O
infect	O	O	B-Entity
MCM	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
,	O	O	O
even	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
host	O	O	B-Entity
CD8	O	O	B-Entity
+	O	O	I-Entity
T	O	O	I-Entity
and	O	O	O
NK	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
RhCMV	O	O	B-Entity
clone	O	O	B-Entity
68	O	O	O
-	O	O	O
1.2	O	O	O
,	O	O	O
genetically	O	O	B-Entity
repaired	O	O	B-Entity
to	O	O	O
express	O	O	B-Entity
the	O	O	O
homologues	O	O	B-Entity
of	O	O	O
the	O	O	O
HCMV	O	O	B-Entity
anti-apoptosis	O	O	B-Entity
gene	O	O	B-Entity
UL36	O	O	I-Entity
and	O	O	O
epithelial	O	O	B-Entity
cell	O	O	I-Entity
tropism	O	O	I-Entity
genes	O	O	B-Entity
UL128	O	O	I-Entity
and	O	O	O
UL130	O	O	B-Entity
absent	O	O	O
in	O	O	O
68	O	O	O
-	O	O	O
1	O	O	O
,	O	O	O
efficiently	O	O	O
infected	O	O	B-Entity
MCM	O	O	B-Entity
as	O	O	O
evidenced	O	O	O
by	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
transgene	O	O	B-Entity
-specific	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
virus	O	O	B-Entity
shedding	O	O	I-Entity
.	O	O	O

Recombinant	O	O	B-Entity
variants	O	O	I-Entity
of	O	O	O
RhCMV	O	O	B-Entity
68	O	O	O
-	O	O	O
1	O	O	O
and	O	O	O
68	O	O	O
-	O	O	O
1.2	O	O	O
revealed	O	O	O
that	O	O	O
expression	O	O	B-Entity
of	O	O	O
either	O	O	O
UL36	O	O	B-Entity
or	O	O	O
UL128	O	O	B-Entity
together	O	O	O
with	O	O	O
UL130	O	O	B-Entity
enabled	O	O	O
productive	O	O	O
MCM	O	O	B-Entity
infection	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
multiple	O	O	O
layers	O	O	O
of	O	O	O
cross-	O	O	O
species	O	O	B-Entity
restriction	O	O	B-Entity
operate	O	O	O
even	O	O	O
between	O	O	O
closely	O	O	O
related	O	O	O
hosts	O	O	B-Entity
.	O	O	O

Cumulatively	O	O	O
,	O	O	O
these	O	O	O
results	O	O	O
implicate	O	O	O
cell	O	O	B-Entity
tropism	O	O	I-Entity
and	O	O	O
evasion	O	O	O
of	O	O	O
apoptosis	O	O	B-Entity
as	O	O	O
critical	O	O	O
determinants	O	O	B-Entity
of	O	O	O
CMV	O	O	B-Entity
transmission	O	O	B-Entity
across	O	O	O
primate	O	O	B-Entity
species	O	O	B-Entity
barriers	O	O	O
,	O	O	O
and	O	O	O
extend	O	O	O
the	O	O	O
macaque	O	O	B-Entity
model	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
CMV	O	O	O
infection	O	O	B-Entity
and	O	O	O
immunology	O	O	B-Entity
to	O	O	O
MCM	O	O	B-Entity
,	O	O	O
a	O	O	O
nonhuman	O	O	B-Entity
primate	O	O	I-Entity
species	O	O	O
with	O	O	O
uniquely	O	O	O
simplified	O	O	O
host	O	O	B-Entity
immunogenetics	O	O	B-Entity
.	O	O	O

-DOCSTART- (27829875)

Mildly	O	O	B-Entity
raised	O	O	B-Entity
tricuspid	O	O	B-Entity
regurgitant	O	O	I-Entity
velocity	O	O	I-Entity
2.5	O	O	O
-	O	O	O
3.0	O	O	O
m/s	O	O	O
in	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
disease	O	O	I-Entity
is	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
poor	O	O	B-Entity
obstetric	O	O	B-Entity
outcome	O	O	B-Entity
-	O	O	O
An	O	O	O
observational	O	O	O
cross-sectional	O	O	O
study	O	O	O

Pulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
36	O	O	O
%	O	O	O
mortality	O	O	B-Entity
in	O	O	O
pregnancy	O	O	B-Entity
,	O	O	O
and	O	O	O
6	O	O	O
-	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
disease	O	O	I-Entity
have	O	O	O
pulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
.	O	O	O

Tricuspid	O	O	B-Entity
regurgitant	O	O	I-Entity
velocity	O	O	I-Entity
≥2.5	O	O	O
m/s	O	O	O
on	O	O	O
echocardiography	O	O	B-Entity
is	O	O	O
a	O	O	O
well	O	O	O
validated	O	O	O
means	O	O	O
of	O	O	O
screening	O	O	B-Entity
for	O	O	O
pulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
in	O	O	O
the	O	O	O
non-pregnant	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
to	O	O	O
determine	O	O	O
if	O	O	O
this	O	O	O
is	O	O	O
a	O	O	O
useful	O	O	O
non-invasive	O	O	B-Entity
screening	O	O	B-Entity
test	O	O	I-Entity
for	O	O	O
pulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
in	O	O	O
pregnancy	O	O	B-Entity
,	O	O	O
and	O	O	O
whether	O	O	O
raised	O	O	O
tricuspid	O	O	B-Entity
regurgitant	O	O	I-Entity
velocity	O	O	I-Entity
≥2.5	O	O	O
m/s	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
poor	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
over	O	O	O
a	O	O	O
five-year	O	O	O
period	O	O	O
in	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
referral	O	O	I-Entity
centre	O	O	I-Entity
with	O	O	O
a	O	O	O
specialised	O	O	O
multidisciplinary	O	O	B-Entity
clinic	O	O	I-Entity
for	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

Women	O	O	B-Entity
with	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
no	O	O	O
prior	O	O	O
pulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
and	O	O	O
singleton	O	O	B-Entity
pregnancies	O	O	B-Entity
who	O	O	O
had	O	O	O
echocardiography	O	O	B-Entity
with	O	O	O
a	O	O	O
measurable	O	O	O
tricuspid	O	O	B-Entity
regurgitant	O	O	I-Entity
velocity	O	O	I-Entity
in	O	O	O
pregnancy	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
34	O	O	O
pregnancies	O	O	B-Entity
,	O	O	O
of	O	O	O
which	O	O	O
eight	O	O	O
had	O	O	O
tricuspid	O	O	B-Entity
regurgitant	O	O	I-Entity
velocity	O	O	I-Entity
≥2.5	O	O	O
m/s	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	O
in	O	O	O
their	O	O	O
characteristics	O	O	B-Entity
,	O	O	O
sickle	O	O	B-Entity
cell	O	O	I-Entity
-related	O	O	O
complications	O	O	B-Entity
or	O	O	O
medical	O	O	B-Entity
co-morbidities	O	O	B-Entity
.	O	O	O

The	O	O	O
women	O	O	B-Entity
with	O	O	O
tricuspid	O	O	B-Entity
regurgitant	O	O	I-Entity
velocity	O	O	I-Entity
≥2.5	O	O	O
m/s	O	O	O
had	O	O	O
similar	O	O	O
obstetric	O	O	B-Entity
and	O	O	O
perinatal	O	O	B-Entity
outcomes	O	O	B-Entity
as	O	O	O
those	O	O	O
with	O	O	O
a	O	O	O
tricuspid	O	O	O
regurgitant	O	O	O
velocity	O	O	O
<	O	O	O
2.5	O	O	O
m/s	O	O	O
.	O	O	O

-DOCSTART- (27831503)

A	O	O	O
randomized	O	O	B-Entity
trial	O	O	I-Entity
of	O	O	O
TLR-2	O	O	B-Entity
agonist	O	O	B-Entity
CADI-05	O	O	B-Entity
targeting	O	O	B-Entity
desmocollin-3	O	O	B-Entity
for	O	O	O
advanced	O	O	B-Entity
non-small-cell	O	O	O
lung	O	O	O
cancer	O	O	O

Randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
to	O	O	O
evaluate	O	O	B-Entity
synergy	O	O	B-Entity
between	O	O	O
taxane	O	O	B-Entity
plus	O	O	O
platinum	O	O	B-Entity
chemotherapy	O	O	B-Entity
and	O	O	O
CADI-05	O	O	B-Entity
,	O	O	O
a	O	O	O
Toll	O	O	B-Entity
like	O	O	I-Entity
receptor-2	O	O	I-Entity
agonist	O	O	B-Entity
targeting	O	O	B-Entity
desmocollin-3	O	O	B-Entity
as	O	O	O
a	O	O	O
first-line	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
advanced	O	O	B-Entity
non-small-cell	O	O	B-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
NSCLC	O	O	B-Entity
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
advanced	O	O	B-Entity
NSCLC	O	O	B-Entity
(	O	O	O
stage	O	O	O
IIIB	O	O	O
or	O	O	O
IV	O	O	O
)	O	O	O
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
cisplatin-paclitaxel	O	O	B-Entity
(	O	O	O
chemotherapy	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
N	O	O	O
=	O	O	O
112	O	O	O
)	O	O	O
or	O	O	O
cisplatin-paclitaxel	O	O	O
plus	O	O	O
CADI-05	O	O	B-Entity
(	O	O	O
chemoimmunotherapy	O	O	B-Entity
group	O	O	O
,	O	O	O
N	O	O	O
=	O	O	O
109	O	O	O
)	O	O	O
.	O	O	O

CADI-05	O	O	B-Entity
was	O	O	O
administered	O	O	B-Entity
a	O	O	O
week	O	O	B-Entity
before	O	O	O
chemotherapy	O	O	B-Entity
and	O	O	O
on	O	O	O
days	O	O	B-Entity
8	O	O	O
and	O	O	O
15	O	O	O
of	O	O	O
each	O	O	O
cycle	O	O	B-Entity
and	O	O	O
every	O	O	O
month	O	O	B-Entity
subsequently	O	O	O
for	O	O	O
12	O	O	O
months	O	O	B-Entity
or	O	O	O
disease	O	O	B-Entity
progression	O	O	I-Entity
.	O	O	O

Overall	O	O	B-Entity
survival	O	O	I-Entity
was	O	O	O
compared	O	O	O
using	O	O	O
a	O	O	O
log-rank	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Computed	O	O	B-Entity
tomography	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
end	O	O	O
of	O	O	O
two	O	O	O
cycles	O	O	B-Entity
and	O	O	O
four	O	O	O
cycles	O	O	O
.	O	O	O

Response	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
using	O	O	O
Response	O	O	B-Entity
Evaluation	O	O	I-Entity
Criteria	O	O	I-Entity
in	O	O	I-Entity
Solid	O	O	I-Entity
Tumors	O	O	I-Entity
criteria	O	O	B-Entity
by	O	O	O
an	O	O	O
independent	O	O	B-Entity
radiologist	O	O	I-Entity
.	O	O	O

As	O	O	O
per	O	O	O
intention-to-treat	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
no	O	O	O
survival	O	O	B-Entity
benefit	O	O	B-Entity
was	O	O	O
observed	O	O	O
between	O	O	O
two	O	O	O
groups	O	O	B-Entity
[	O	O	O
208	O	O	O
versus	O	O	O
196	O	O	O
days	O	O	B-Entity
;	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
0.86	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	O
)	O	O	O
0.63	O	O	O
-	O	O	O
1.19	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.3804	O	O	O
]	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
subgroup	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
improvement	O	O	B-Entity
in	O	O	O
median	O	O	B-Entity
survival	O	O	I-Entity
by	O	O	O
127	O	O	O
days	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
squamous	O	O	B-Entity
NSCC	O	O	I-Entity
with	O	O	O
chemoimmunotherapy	O	O	B-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
0.55	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.32	O	O	O
-	O	O	O
0.95	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.046	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
receiving	O	O	O
planned	O	O	O
four	O	O	O
cycles	O	O	B-Entity
of	O	O	O
chemotherapy	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
improved	O	O	B-Entity
median	O	O	B-Entity
overall	O	O	B-Entity
survival	O	O	I-Entity
by	O	O	O
66	O	O	O
days	O	O	B-Entity
(	O	O	O
299	O	O	O
versus	O	O	O
233	O	O	O
days	O	O	O
;	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
0.64	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.41	O	O	O
to	O	O	O
0.98	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.04	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
chemoimmunotherapy	O	O	B-Entity
group	O	O	B-Entity
compared	O	O	O
with	O	O	O
the	O	O	O
chemotherapy	O	O	O
group	O	O	O
.	O	O	O

This	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
improved	O	O	B-Entity
survival	O	O	B-Entity
by	O	O	O
17.48	O	O	O
%	O	O	O
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
1	O	O	O
year	O	O	B-Entity
,	O	O	O
in	O	O	O
the	O	O	O
chemoimmunotherapy	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

Systemic	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
were	O	O	O
identical	O	O	B-Entity
in	O	O	O
both	O	O	O
the	O	O	O
group	O	O	B-Entity
s.	O	O	O
There	O	O	O
was	O	O	O
no	O	O	O
survival	O	O	B-Entity
benefit	O	O	B-Entity
with	O	O	O
the	O	O	O
addition	O	O	B-Entity
of	O	O	O
CADI-05	O	O	B-Entity
to	O	O	O
the	O	O	O
combination	O	O	B-Entity
of	O	O	O
cisplatin-paclitaxel	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
advanced	O	O	B-Entity
NSCLC	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
squamous	O	O	B-Entity
cell	O	O	I-Entity
subset	O	O	I-Entity
did	O	O	O
demonstrate	O	O	O
a	O	O	O
survival	O	O	O
advantage	O	O	O
.	O	O	O

-DOCSTART- (27831992)

Sex	O	O	B-Entity
Life	O	O	I-Entity
and	O	O	O
Impact	O	O	B-Entity
of	O	O	O
Operative	O	O	B-Entity
Intervention	O	O	B-Entity
on	O	O	O
Sex	O	O	B-Entity
Life-related	O	O	I-Entity
Pain	O	O	I-Entity
in	O	O	O
Degenerative	O	O	B-Entity
Spinal	O	O	B-Entity
Conditions	O	O	O
:	O	O	O
An	O	O	O
Analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
SPORT	O	O	O
Study	O	O	O

This	O	O	O
study	O	O	B-Entity
is	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
retrospective	O	O	I-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
OBJECTIVES	O	O	O
.	O	O	O
:	O	O	O
This	O	O	O
study	O	O	O
aims	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
is	O	O	O
relevant	O	O	O
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
spinal	O	O	B-Entity
stenosis	O	O	I-Entity
(	O	O	O
SPS	O	O	B-Entity
)	O	O	O
and	O	O	O
degenerative	O	O	B-Entity
spondylolisthesis	O	O	I-Entity
(	O	O	O
DS	O	O	B-Entity
)	O	O	O
and	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
operative	O	O	B-Entity
inter	O	O	O
vqAvention	O	O	O
on	O	O	O
sexual	O	O	O
function	O	O	O
for	O	O	O
these	O	O	O
patients	O	O	O
.	O	O	O

The	O	O	O
benefits	O	O	O
of	O	O	O
nonoperative	O	O	B-Entity
versus	O	O	O
operative	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
SPS	O	O	B-Entity
and	O	O	O
DS	O	O	B-Entity
with	O	O	O
regards	O	O	O
to	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
are	O	O	O
unknown	O	O	O
.	O	O	O

Demographic	O	O	B-Entity
,	O	O	O
treatment	O	O	B-Entity
,	O	O	O
and	O	O	O
follow-up	O	O	B-Entity
data	O	O	B-Entity
,	O	O	O
including	O	O	O
the	O	O	O
Oswestry	O	O	O
Disability	O	O	O
Index	O	O	O
(	O	O	O
ODI	O	O	O
)	O	O	O
,	O	O	O
were	O	O	O
obtained	O	O	O
on	O	O	O
patients	O	O	B-Entity
enrolled	O	O	O
in	O	O	O
the	O	O	O
SPORT	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
response	O	O	O
to	O	O	O
question	O	O	O
#	O	O	O
9	O	O	O
in	O	O	O
the	O	O	O
ODI	O	O	O
,	O	O	O
patients	O	O	B-Entity
were	O	O	O
classified	O	O	O
into	O	O	O
a	O	O	O
sexual	O	O	B-Entity
life	O	O	I-Entity
relevant	O	O	I-Entity
(	O	O	O
SLR	O	O	B-Entity
)	O	O	O
or	O	O	O
sexual	O	O	B-Entity
life	O	O	I-Entity
not	O	O	I-Entity
relevant	O	O	I-Entity
(	O	O	I-Entity
NR	O	O	I-Entity
)	O	O	I-Entity
group	O	O	I-Entity
.	O	O	O

Univariate	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
patient	O	O	B-Entity
characteristics	O	O	B-Entity
comparing	O	O	O
the	O	O	O
NR	O	O	B-Entity
and	O	O	O
SLR	O	O	B-Entity
group	O	O	I-Entity
were	O	O	O
performed	O	O	O
.	O	O	O

Operative	O	O	B-Entity
treatment	O	O	B-Entity
groups	O	O	B-Entity
were	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
nonoperative	O	O	B-Entity
group	O	O	B-Entity
with	O	O	O
regards	O	O	O
to	O	O	O
response	O	O	O
to	O	O	O
ODI	O	O	O
question	O	O	O
#	O	O	O
9	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
on	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
1235	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
to	O	O	O
determine	O	O	O
relevance	O	O	O
of	O	O	O
sex	O	O	B-Entity
life	O	O	I-Entity
.	O	O	O

Three	O	O	O
hundred	O	O	O
sixty-six	O	O	O
patients	O	O	B-Entity
(	O	O	O
29	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
NR	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Eight	O	O	O
hundred	O	O	O
sixty-nine	O	O	O
patients	O	O	B-Entity
(	O	O	O
71	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
SLR	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
that	O	O	O
were	O	O	O
older	O	O	B-Entity
,	O	O	O
female	O	O	B-Entity
,	O	O	O
unmarried	O	O	B-Entity
,	O	O	O
had	O	O	O
three	O	O	O
or	O	O	O
more	O	O	O
stenotic	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
and	O	O	O
had	O	O	O
central	O	O	B-Entity
stenosis	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
in	O	O	O
the	O	O	O
NR	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Eight	O	O	O
hundred	O	O	O
twenty-five	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
analysis	O	O	B-Entity
comparing	O	O	O
operative	O	O	B-Entity
versus	O	O	O
nonoperative	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

At	O	O	O
all	O	O	O
follow-up	O	O	B-Entity
time	O	O	O
points	O	O	O
,	O	O	O
the	O	O	O
operative	O	O	B-Entity
groups	O	O	B-Entity
had	O	O	O
a	O	O	O
lower	O	O	O
percentage	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
reporting	O	O	O
pain	O	O	B-Entity
with	O	O	O
their	O	O	O
sex	O	O	B-Entity
life	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
nonoperative	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
at	O	O	O
all	O	O	O
time	O	O	O
points	O	O	O
except	O	O	O
between	O	O	O
more	O	O	O
than	O	O	O
one	O	O	O
level	O	O	O
fusion	O	O	O
and	O	O	O
nonoperative	O	O	O
at	O	O	O
4	O	O	O
years	O	O	B-Entity
'	O	O	O
follow-up	O	O	O
)	O	O	O
.	O	O	O

Sex	O	O	B-Entity
life	O	O	I-Entity
is	O	O	O
a	O	O	O
relevant	O	O	O
consideration	O	O	O
for	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
DS	O	O	B-Entity
and	O	O	O
SPS	O	O	B-Entity
;	O	O	O
operative	O	O	B-Entity
treatment	O	O	B-Entity
leads	O	O	O
to	O	O	O
improved	O	O	B-Entity
sex	O	O	B-Entity
life-related	O	O	I-Entity
pain	O	O	I-Entity
.	O	O	O

3	O	O	O
.	O	O	O

-DOCSTART- (27835851)

Functional	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
OcRhS1	O	O	B-Entity
and	O	O	O
OcUER1	O	O	B-Entity
involved	O	O	O
in	O	O	O
UDP-L-rhamnose	O	O	B-Entity
biosynthesis	O	O	B-Entity
in	O	O	O
Ornithogalum	O	O	O
caudatum	O	O	O

UDP-L-rhamnose	O	O	B-Entity
(	O	O	O
UDP-Rha	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
sugar	O	O	B-Entity
donor	O	O	I-Entity
for	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
rhamnose	O	O	B-Entity
-containing	O	O	O
compounds	O	O	B-Entity
in	O	O	O
plants	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
only	O	O	O
a	O	O	O
few	O	O	O
enzymes	O	O	B-Entity
and	O	O	O
their	O	O	O
encoding	O	O	B-Entity
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
UDP-Rha	O	O	B-Entity
biosynthesis	O	O	B-Entity
are	O	O	O
available	O	O	O
in	O	O	O
plants	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
two	O	O	O
genes	O	O	B-Entity
encoding	O	O	B-Entity
rhamnose	O	O	B-Entity
synthase	O	O	I-Entity
(	O	O	O
RhS	O	O	B-Entity
)	O	O	O
and	O	O	O
bi-functional	O	O	B-Entity
UDP-4-keto-6-deoxy-D-glucose	O	O	B-Entity
(	O	O	O
UDP-4K6DG	O	O	B-Entity
)	O	O	O
3	O	O	B-Entity
,	O	O	I-Entity
5-epimerase/UDP-4-keto-L-rhamnose	O	O	I-Entity
(	O	O	O
UDP-4KR	O	O	B-Entity
)	O	O	O
4-keto-reductase	O	O	B-Entity
(	O	O	O
UER	O	O	B-Entity
)	O	O	O
were	O	O	O
isolated	O	O	O
from	O	O	O
Ornithogalum	O	O	B-Entity
caudatum	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
RNA	O	O	B-Entity
-	O	O	O
Seq	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

The	O	O	O
OcRhS1	O	O	B-Entity
gene	O	O	I-Entity
has	O	O	O
an	O	O	O
ORF	O	O	B-Entity
(	O	O	O
open	O	O	B-Entity
reading	O	O	I-Entity
frame	O	O	I-Entity
)	O	O	O
of	O	O	O
2019	O	O	O
bp	O	O	O
encoding	O	O	B-Entity
a	O	O	O
tri-functional	O	O	B-Entity
RhS	O	O	I-Entity
enzyme	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
vitro	O	O	I-Entity
enzymatic	O	O	B-Entity
assays	O	O	I-Entity
revealed	O	O	B-Entity
OcRhS1	O	O	B-Entity
can	O	O	O
really	O	O	O
convert	O	O	O
UDP-D-glucose	O	O	B-Entity
(	O	O	O
UDP-Glc	O	O	B-Entity
)	O	O	O
into	O	O	O
UDP-Rha	O	O	B-Entity
via	O	O	O
three	O	O	O
consecutive	O	O	B-Entity
reactions	O	O	B-Entity
.	O	O	O

Biochemical	O	O	B-Entity
evidences	O	O	B-Entity
indicated	O	O	O
that	O	O	O
the	O	O	O
recombinant	O	O	B-Entity
OcRhS1	O	O	I-Entity
was	O	O	O
active	O	O	O
in	O	O	O
the	O	O	O
pH	O	O	O
range	O	O	O
of	O	O	O
5	O	O	O
-	O	O	O
11	O	O	O
and	O	O	O
over	O	O	O
the	O	O	O
temperature	O	O	B-Entity
range	O	O	I-Entity
of	O	O	O
0	O	O	O
-	O	O	O
60	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

The	O	O	O
Km	O	O	B-Entity
value	O	O	B-Entity
of	O	O	O
OcRhS1	O	O	B-Entity
for	O	O	O
UDP-Glc	O	O	B-Entity
was	O	O	O
determined	O	O	O
to	O	O	O
be	O	O	O
1.52	O	O	O
×	O	O	O
10(-4	O	O	O
)	O	O	O
M.	O	O	O
OcRhS1	O	O	O
is	O	O	O
a	O	O	O
multi-domain	O	O	B-Entity
protein	O	O	I-Entity
with	O	O	O
two	O	O	O
sets	O	O	O
of	O	O	O
cofactor-binding	O	O	B-Entity
motifs	O	O	I-Entity
.	O	O	O

The	O	O	O
cofactors	O	O	B-Entity
dependent	O	O	O
properties	O	O	O
of	O	O	O
OcRhS1	O	O	B-Entity
were	O	O	O
thus	O	O	O
characterized	O	O	O
in	O	O	O
this	O	O	O
research	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
N-terminal	O	O	B-Entity
portion	O	O	I-Entity
of	O	O	I-Entity
OcRhS1	O	O	I-Entity
(	O	O	O
OcRhS1-N	O	O	B-Entity
)	O	O	O
was	O	O	O
observed	O	O	O
to	O	O	O
metabolize	O	O	B-Entity
UDP-Glc	O	O	B-Entity
to	O	O	O
form	O	O	O
intermediate	O	O	O
UDP-4K6DG	O	O	B-Entity
.	O	O	O

OcUER1	O	O	B-Entity
contains	O	O	O
an	O	O	O
ORF	O	O	B-Entity
of	O	O	O
906	O	O	O
bp	O	O	O
encoding	O	O	B-Entity
a	O	O	O
polypeptide	O	O	B-Entity
of	O	O	O
301	O	O	O
aa	O	O	B-Entity
.	O	O	O

OcUER1	O	O	B-Entity
shared	O	O	O
high	O	O	O
similarity	O	O	O
with	O	O	O
the	O	O	O
carboxy-terminal	O	O	B-Entity
domain	O	O	I-Entity
of	O	O	I-Entity
OcRhS1	O	O	I-Entity
(	O	O	O
OcRhS1-C	O	O	B-Entity
)	O	O	O
,	O	O	O
suggesting	O	O	O
its	O	O	O
intrinsic	O	O	O
ability	O	O	O
of	O	O	O
converting	O	O	O
UDP-4K6DG	O	O	B-Entity
into	O	O	O
UDP-Rha	O	O	B-Entity
.	O	O	O

It	O	O	O
was	O	O	O
thus	O	O	O
reasonably	O	O	O
inferred	O	O	O
that	O	O	O
UDP-Glc	O	O	B-Entity
could	O	O	O
be	O	O	O
bio-transformed	O	O	B-Entity
into	O	O	O
UDP-Rha	O	O	B-Entity
under	O	O	O
the	O	O	O
collaborating	O	O	O
action	O	O	O
of	O	O	O
OcRhS1-N	O	O	B-Entity
and	O	O	O
OcUER1	O	O	B-Entity
.	O	O	O

The	O	O	O
subsequently	O	O	O
biochemical	O	O	B-Entity
assay	O	O	I-Entity
verified	O	O	O
this	O	O	O
notion	O	O	O
.	O	O	O

Importantly	O	O	O
,	O	O	O
expression	O	O	B-Entity
profiles	O	O	I-Entity
of	O	O	O
OcRhS1	O	O	B-Entity
and	O	O	O
OcUER1	O	O	B-Entity
revealed	O	O	B-Entity
their	O	O	O
possible	O	O	O
involvement	O	O	O
in	O	O	O
the	O	O	O
biosynthesis	O	O	B-Entity
of	O	O	O
rhamnose	O	O	B-Entity
-containing	O	O	O
polysaccharides	O	O	B-Entity
in	O	O	O
O.	O	O	B-Entity
caudatum	O	O	I-Entity
.	O	O	O

-DOCSTART- (27837017)

Differing	O	O	O
rates	O	O	O
of	O	O	O
antibody	O	O	B-Entity
acquisition	O	O	B-Entity
to	O	O	O
merozoite	O	O	B-Entity
antigens	O	O	B-Entity
in	O	O	O
malaria	O	O	B-Entity
:	O	O	O
implications	O	O	O
for	O	O	O
immunity	O	O	B-Entity
and	O	O	O
surveillance	O	O	O

Antibodies	O	O	B-Entity
play	O	O	O
a	O	O	O
key	O	O	O
role	O	O	O
in	O	O	O
acquired	O	O	B-Entity
human	O	O	I-Entity
immunity	O	O	I-Entity
to	O	O	O
Plasmodium	O	O	B-Entity
falciparum	O	O	I-Entity
(	O	O	I-Entity
Pf	O	O	I-Entity
)	O	O	I-Entity
malaria	O	O	I-Entity
and	O	O	O
target	O	O	O
merozoites	O	O	B-Entity
to	O	O	O
reduce	O	O	O
or	O	O	O
prevent	O	O	O
blood	O	O	B-Entity
-stage	O	O	O
replication	O	O	B-Entity
and	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
disease	O	O	B-Entity
.	O	O	O

Merozoites	O	O	B-Entity
present	O	O	O
a	O	O	O
complex	O	O	O
array	O	O	O
of	O	O	O
antigens	O	O	B-Entity
to	O	O	O
the	O	O	O
immune	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
and	O	O	O
currently	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
only	O	O	O
a	O	O	O
partial	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
targets	O	O	O
of	O	O	O
protective	O	O	O
antibodies	O	O	B-Entity
and	O	O	O
how	O	O	O
responses	O	O	B-Entity
to	O	O	O
different	O	O	O
antigens	O	O	O
are	O	O	O
acquired	O	O	B-Entity
and	O	O	O
boosted	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
there	O	O	O
would	O	O	O
be	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
acquisition	O	O	B-Entity
of	O	O	O
antibodies	O	O	B-Entity
to	O	O	O
different	O	O	O
antigens	O	O	B-Entity
and	O	O	O
how	O	O	O
well	O	O	O
they	O	O	O
are	O	O	O
boosted	O	O	O
by	O	O	O
infection	O	O	B-Entity
,	O	O	O
which	O	O	O
impacts	O	O	O
the	O	O	O
acquisition	O	O	O
of	O	O	O
immunity	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
responses	O	O	B-Entity
to	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
merozoite	O	O	B-Entity
antigens	O	O	B-Entity
in	O	O	O
2	O	O	O
different	O	O	O
cohorts	O	O	O
of	O	O	O
children	O	O	B-Entity
and	O	O	O
adults	O	O	B-Entity
with	O	O	O
different	O	O	O
age	O	O	B-Entity
structures	O	O	O
and	O	O	O
levels	O	O	O
of	O	O	O
malaria	O	O	B-Entity
exposure	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
antibodies	O	O	B-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
age	O	O	B-Entity
,	O	O	O
exposure	O	O	O
,	O	O	O
and	O	O	O
active	O	O	O
infection	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
repertoire	O	O	O
of	O	O	O
responses	O	O	B-Entity
increased	O	O	O
with	O	O	O
age	O	O	O
and	O	O	O
active	O	O	O
infection	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
rates	O	O	O
of	O	O	O
antibody	O	O	B-Entity
acquisition	O	O	B-Entity
varied	O	O	O
between	O	O	O
antigens	O	O	B-Entity
and	O	O	O
different	O	O	O
regions	O	O	O
within	O	O	O
an	O	O	O
antigen	O	O	B-Entity
following	O	O	O
exposure	O	O	O
to	O	O	O
malaria	O	O	B-Entity
,	O	O	O
supporting	O	O	O
our	O	O	O
hypothesis	O	O	B-Entity
.	O	O	O

Antigen	O	O	B-Entity
-specific	O	O	O
responses	O	O	B-Entity
could	O	O	O
be	O	O	O
broadly	O	O	O
classified	O	O	O
into	O	O	O
early	O	O	O
response	O	O	B-Entity
types	O	O	O
in	O	O	O
which	O	O	O
antibodies	O	O	B-Entity
were	O	O	O
acquired	O	O	B-Entity
early	O	O	O
in	O	O	O
childhood	O	O	B-Entity
exposure	O	O	O
and	O	O	O
late	O	O	B-Entity
response	O	O	I-Entity
types	O	O	O
that	O	O	O
appear	O	O	O
to	O	O	O
require	O	O	O
substantially	O	O	O
more	O	O	O
exposure	O	O	O
for	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
substantial	O	O	O
levels	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	O
antigen	O	O	B-Entity
-specific	O	O	O
responses	O	O	B-Entity
that	O	O	O
were	O	O	O
effectively	O	O	O
boosted	O	O	O
after	O	O	O
recent	O	O	O
infection	O	O	B-Entity
,	O	O	O
whereas	O	O	O
other	O	O	O
responses	O	O	O
were	O	O	O
not	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
advance	O	O	O
our	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
acquisition	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
immunity	O	O	B-Entity
to	O	O	O
malaria	O	O	B-Entity
and	O	O	O
are	O	O	O
relevant	O	O	O
to	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
malaria	O	O	B-Entity
vaccines	O	O	I-Entity
targeting	O	O	O
merozoite	O	O	B-Entity
antigens	O	O	B-Entity
and	O	O	O
the	O	O	O
selection	O	O	O
of	O	O	O
antigens	O	O	O
for	O	O	O
use	O	O	O
in	O	O	O
malaria	O	O	O
surveillance	O	O	B-Entity
.	O	O	O

-DOCSTART- (27837093)

Variety	O	O	B-Entity
of	O	O	O
DNA	O	O	B-Entity
Replication	O	O	I-Entity
Activity	O	O	I-Entity
Among	O	O	O
Cyanobacteria	O	O	B-Entity
Correlates	O	O	B-Entity
with	O	O	O
Distinct	O	O	O
Respiration	O	O	B-Entity
Activity	O	O	I-Entity
in	O	O	O
the	O	O	O
Dark	O	O	O

Cyanobacteria	O	O	B-Entity
exhibit	O	O	O
light	O	O	B-Entity
-dependent	O	O	O
cell	O	O	B-Entity
growth	O	O	I-Entity
since	O	O	O
most	O	O	O
of	O	O	O
their	O	O	O
cellular	O	O	B-Entity
energy	O	O	B-Entity
is	O	O	O
obtained	O	O	O
by	O	O	O
photosynthesis	O	O	B-Entity
.	O	O	O

In	O	O	O
Synechococcus	O	O	B-Entity
elongatus	O	O	I-Entity
PCC	O	O	I-Entity
7942	O	O	I-Entity
,	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
model	O	O	O
cyanobacteria	O	O	B-Entity
,	O	O	O
DNA	O	O	B-Entity
replication	O	O	I-Entity
depends	O	O	O
on	O	O	O
photosynthetic	O	O	B-Entity
electron	O	O	I-Entity
transport	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
critical	O	O	B-Entity
signal	O	O	I-Entity
for	O	O	O
the	O	O	O
regulatory	O	O	B-Entity
mechanism	O	O	B-Entity
of	O	O	O
DNA	O	O	B-Entity
replication	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
identified	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
conservation	O	O	B-Entity
of	O	O	O
this	O	O	O
regulatory	O	O	B-Entity
mechanism	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
investigated	O	O	B-Entity
among	O	O	O
cyanobacteria	O	O	B-Entity
.	O	O	O

To	O	O	O
understand	O	O	O
this	O	O	O
regulatory	O	O	B-Entity
signal	O	O	B-Entity
and	O	O	O
its	O	O	O
dependence	O	O	O
on	O	O	O
light	O	O	B-Entity
,	O	O	O
we	O	O	O
examined	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
DNA	O	O	B-Entity
replication	O	O	I-Entity
under	O	O	O
both	O	O	O
light	O	O	O
and	O	O	O
dark	O	O	B-Entity
conditions	O	O	O
among	O	O	O
three	O	O	O
model	O	O	B-Entity
cyanobacteria	O	O	B-Entity
,	O	O	O
S.	O	O	B-Entity
elongatus	O	O	I-Entity
PCC	O	O	I-Entity
7942	O	O	I-Entity
,	O	O	O
Synechocystis	O	O	B-Entity
sp.	O	O	I-Entity
PCC	O	O	I-Entity
6803	O	O	I-Entity
and	O	O	O
Anabaena	O	O	B-Entity
sp.	O	O	I-Entity
PCC	O	O	I-Entity
7120	O	O	I-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
DNA	O	O	B-Entity
replication	O	O	I-Entity
activity	O	O	I-Entity
in	O	O	O
Synechocystis	O	O	B-Entity
and	O	O	O
Anabaena	O	O	B-Entity
was	O	O	O
retained	O	O	B-Entity
when	O	O	O
cells	O	O	B-Entity
were	O	O	O
transferred	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
dark	O	O	B-Entity
,	O	O	O
although	O	O	O
it	O	O	O
was	O	O	O
drastically	O	O	O
decreased	O	O	B-Entity
in	O	O	O
S.	O	O	B-Entity
elongatus	O	O	I-Entity
.	O	O	O

Glycogen	O	O	B-Entity
metabolism	O	O	I-Entity
and	O	O	O
respiration	O	O	B-Entity
were	O	O	O
higher	O	O	O
in	O	O	O
Synechocystis	O	O	B-Entity
and	O	O	O
Anabaena	O	O	B-Entity
than	O	O	O
in	O	O	O
S.	O	O	B-Entity
elongatus	O	O	I-Entity
in	O	O	O
the	O	O	O
dark	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
DNA	O	O	B-Entity
replication	O	O	I-Entity
activity	O	O	I-Entity
in	O	O	O
Synechocystis	O	O	B-Entity
and	O	O	O
Anabaena	O	O	B-Entity
was	O	O	O
reduced	O	O	B-Entity
to	O	O	O
the	O	O	O
same	O	O	O
level	O	O	O
as	O	O	O
that	O	O	O
in	O	O	O
S.	O	O	B-Entity
elongatus	O	O	I-Entity
by	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
respiratory	O	O	B-Entity
electron	O	O	B-Entity
transport	O	O	I-Entity
after	O	O	O
transfer	O	O	O
to	O	O	O
the	O	O	O
dark	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
demonstrate	O	O	O
that	O	O	O
there	O	O	O
is	O	O	O
disparity	O	O	B-Entity
in	O	O	O
DNA	O	O	B-Entity
replication	O	O	I-Entity
occurring	O	O	O
in	O	O	O
the	O	O	O
dark	O	O	B-Entity
among	O	O	O
cyanobacteria	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
caused	O	O	O
by	O	O	O
the	O	O	O
difference	O	O	B-Entity
in	O	O	O
activity	O	O	B-Entity
of	O	O	O
respiratory	O	O	B-Entity
electron	O	O	B-Entity
transport	O	O	I-Entity
.	O	O	O

-DOCSTART- (27838149)

Radiosensitization	O	O	B-Entity
of	O	O	O
non-small-cell	O	O	B-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
and	O	O	O
xenografts	O	O	B-Entity
by	O	O	O
the	O	O	O
interactive	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
pemetrexed	O	O	B-Entity
and	O	O	O
methoxyamine	O	O	O

The	O	O	O
anti-folate	O	O	B-Entity
pemetrexed	O	O	B-Entity
is	O	O	O
a	O	O	O
radiosensitizer	O	O	B-Entity
.	O	O	O

In	O	O	O
pre-clinical	O	O	B-Entity
models	O	O	I-Entity
,	O	O	O
pemetrexed	O	O	B-Entity
is	O	O	O
more	O	O	O
effective	O	O	B-Entity
along	O	O	O
with	O	O	O
the	O	O	O
base-excision-repair	O	O	B-Entity
inhibitor	O	O	B-Entity
methoxyamine	O	O	B-Entity
.	O	O	O

We	O	O	O
tested	O	O	B-Entity
whether	O	O	O
methoxyamine	O	O	B-Entity
enhances	O	O	B-Entity
pemetrexed	O	O	B-Entity
-mediated	O	O	O
radiosensitization	O	O	B-Entity
of	O	O	O
lung	O	O	B-Entity
adenocarcinoma	O	O	I-Entity
cells	O	O	O
and	O	O	O
xenografts	O	O	B-Entity
.	O	O	O

A549	O	O	B-Entity
and	O	O	O
H1299	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
for	O	O	O
cell	O	O	B-Entity
cycle	O	O	I-Entity
distribution	O	O	B-Entity
by	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
,	O	O	O
radiosensitization	O	O	B-Entity
by	O	O	O
clonogenic	O	O	B-Entity
assay	O	O	I-Entity
,	O	O	O
and	O	O	O
DNA	O	O	B-Entity
repair	O	O	I-Entity
by	O	O	O
neutral	O	O	B-Entity
comet	O	O	I-Entity
assay	O	O	I-Entity
and	O	O	O
repair	O	O	B-Entity
protein	O	O	I-Entity
activation	O	O	B-Entity
.	O	O	O

H460	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
included	O	O	O
in	O	O	O
some	O	O	O
studies	O	O	O
.	O	O	O

Xenografts	O	O	B-Entity
in	O	O	O
nude	O	O	B-Entity
mice	O	O	I-Entity
received	O	O	B-Entity
drug	O	O	I-Entity
(	O	O	O
s	O	O	O
)	O	O	O
and/or	O	O	O
radiation	O	O	B-Entity
,	O	O	O
and	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
was	O	O	O
monitored	O	O	O
by	O	O	O
caliper	O	O	B-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
toxicity	O	O	B-Entity
by	O	O	O
animal	O	O	B-Entity
weight	O	O	I-Entity
.	O	O	O

Exposure	O	O	B-Entity
to	O	O	I-Entity
pemetrexed	O	O	B-Entity
/	O	O	O
methoxyamine	O	O	B-Entity
for	O	O	O
24	O	O	O
(	O	O	O
H1299	O	O	B-Entity
,	O	O	O
H460	O	O	B-Entity
)	O	O	O
or	O	O	O
48	O	O	O
(A549)hours	O	O	O
before	O	O	O
irradiation	O	O	B-Entity
resulted	O	O	O
in	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
cells	O	O	B-Entity
near	O	O	O
the	O	O	O
radiosensitive	O	O	B-Entity
G1/S	O	O	I-Entity
border	O	O	I-Entity
;	O	O	O
dose	O	O	B-Entity
-	O	O	O
enhancement	O	O	B-Entity
factors	O	O	B-Entity
of	O	O	O
1.62±0.19	O	O	O
,	O	O	O
1.97±0.25	O	O	O
,	O	O	O
and	O	O	O
1.67±0.30	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
reduction	O	O	O
of	O	O	O
mean	O	O	O
inactivation	O	O	B-Entity
dose	O	O	O
by	O	O	O
32	O	O	O
%	O	O	O
,	O	O	O
30	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
46	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
and	O	O	O
significant	O	O	O
reductions	O	O	O
of	O	O	O
SF2	O	O	O
and	O	O	O
SF4	O	O	O
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Radiosensitization	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
rapid	O	O	O
DNA	O	O	B-Entity
double-strand-break	O	O	I-Entity
rejoining	O	O	I-Entity
and	O	O	O
increased	O	O	O
levels	O	O	O
of	O	O	O
DNA-PKcs	O	O	B-Entity
.	O	O	O

Both	O	O	O
tumor-growth	O	O	B-Entity
rate	O	O	B-Entity
and	O	O	O
tumor-growth	O	O	O
delay	O	O	B-Entity
were	O	O	O
significantly	O	O	O
improved	O	O	O
by	O	O	O
adding	O	O	O
methoxyamine	O	O	B-Entity
to	O	O	O
pemetrexed	O	O	B-Entity
pre-irradiation	O	O	B-Entity
(	O	O	O
p<0.0001	O	O	O
)	O	O	O
;	O	O	O
no	O	O	O
mice	O	O	B-Entity
lost	O	O	O
weight	O	O	O
during	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Addition	O	O	O
of	O	O	O
methoxyamine	O	O	B-Entity
to	O	O	O
pemetrexed	O	O	B-Entity
and	O	O	O
fractionated	O	O	O
radiotherapy	O	O	O
may	O	O	O
improve	O	O	O
outcome	O	O	O
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
locally	O	O	O
advanced	O	O	O
non-squamous	O	O	B-Entity
non-small-cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (27842269)

Using	O	O	O
language	O	O	B-Entity
for	O	O	O
social	O	O	B-Entity
interaction	O	O	I-Entity
:	O	O	O
Communication	O	O	B-Entity
mechanisms	O	O	O
promote	O	O	O
recovery	O	O	O
from	O	O	O
chronic	O	O	B-Entity
non-fluent	O	O	O
aphasia	O	O	O

Clinical	O	O	B-Entity
research	O	O	I-Entity
highlights	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
massed	O	O	B-Entity
practice	O	O	I-Entity
in	O	O	O
the	O	O	O
rehabilitation	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
post-stroke	O	O	B-Entity
aphasia	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
while	O	O	O
necessary	O	O	O
,	O	O	O
massed	O	O	B-Entity
practice	O	O	I-Entity
may	O	O	O
not	O	O	O
be	O	O	O
sufficient	O	O	O
for	O	O	O
ensuring	O	O	O
progress	O	O	B-Entity
in	O	O	O
speech-language	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Motivated	O	O	O
by	O	O	O
recent	O	O	O
advances	O	O	O
in	O	O	O
neuroscience	O	O	B-Entity
,	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
claimed	O	O	O
that	O	O	O
using	O	O	O
language	O	O	B-Entity
as	O	O	O
a	O	O	O
tool	O	O	O
for	O	O	O
communication	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
interaction	O	O	I-Entity
leads	O	O	O
to	O	O	O
synergistic	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
left	O	O	B-Entity
perisylvian	O	O	I-Entity
eloquent	O	O	I-Entity
areas	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
conducted	O	O	O
a	O	O	O
crossover	O	O	O
randomized	O	O	O
controlled	O	O	O
trial	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
influence	O	O	O
of	O	O	O
communicative	O	O	B-Entity
language	O	O	B-Entity
function	O	O	I-Entity
on	O	O	O
the	O	O	O
outcome	O	O	B-Entity
of	O	O	O
intensive	O	O	B-Entity
aphasia	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

Eighteen	O	O	O
individuals	O	O	B-Entity
with	O	O	O
left-hemisphere	O	O	B-Entity
lesions	O	O	I-Entity
and	O	O	O
chronic	O	O	B-Entity
non-fluent	O	O	B-Entity
aphasia	O	O	I-Entity
each	O	O	O
received	O	O	O
two	O	O	O
types	O	O	O
of	O	O	O
training	O	O	B-Entity
in	O	O	O
counterbalanced	O	O	B-Entity
order	O	O	I-Entity
:	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
Intensive	O	O	B-Entity
Language-Action	O	O	I-Entity
Therapy	O	O	I-Entity
(	O	O	O
ILAT	O	O	B-Entity
,	O	O	O
an	O	O	O
extended	O	O	O
form	O	O	O
of	O	O	O
Constraint-Induced	O	O	B-Entity
Aphasia	O	O	I-Entity
Therapy	O	O	I-Entity
)	O	O	O
embedding	O	O	O
verbal	O	O	B-Entity
utterances	O	O	I-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
communication	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
interaction	O	O	I-Entity
,	O	O	O
and	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
Naming	O	O	B-Entity
Therapy	O	O	I-Entity
focusing	O	O	O
on	O	O	O
speech	O	O	B-Entity
production	O	O	I-Entity
per	O	O	I-Entity
se	O	O	I-Entity
.	O	O	O

Both	O	O	O
types	O	O	O
of	O	O	O
training	O	O	B-Entity
were	O	O	O
delivered	O	O	O
with	O	O	O
the	O	O	O
same	O	O	O
high	O	O	O
intensity	O	O	O
(	O	O	O
3.5	O	O	O
h	O	O	O
per	O	O	O
session	O	O	O
)	O	O	O
and	O	O	O
duration	O	O	B-Entity
(	O	O	O
six	O	O	O
consecutive	O	O	O
working	O	O	O
days	O	O	B-Entity
)	O	O	O
,	O	O	O
with	O	O	O
therapy	O	O	B-Entity
materials	O	O	B-Entity
and	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
utterances	O	O	I-Entity
matched	O	O	O
between	O	O	O
treatment	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

A	O	O	O
standardized	O	O	O
aphasia	O	O	B-Entity
test	O	O	B-Entity
battery	O	O	I-Entity
revealed	O	O	O
significantly	O	O	O
improved	O	O	O
language	O	O	B-Entity
performance	O	O	B-Entity
with	O	O	O
ILAT	O	O	B-Entity
,	O	O	O
independent	O	O	O
of	O	O	O
when	O	O	O
this	O	O	O
method	O	O	B-Entity
was	O	O	O
administered	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
Naming	O	O	B-Entity
Therapy	O	O	I-Entity
tended	O	O	O
to	O	O	O
benefit	O	O	O
language	O	O	B-Entity
performance	O	O	O
only	O	O	O
when	O	O	O
given	O	O	O
at	O	O	O
the	O	O	O
onset	O	O	O
of	O	O	O
the	O	O	O
treatment	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
when	O	O	O
applied	O	O	O
after	O	O	O
previous	O	O	O
intensive	O	O	O
training	O	O	B-Entity
.	O	O	O

The	O	O	O
current	O	O	O
results	O	O	O
challenge	O	O	O
the	O	O	O
notion	O	O	O
that	O	O	O
massed	O	O	B-Entity
practice	O	O	I-Entity
alone	O	O	O
promotes	O	O	O
recovery	O	O	O
from	O	O	O
chronic	O	O	B-Entity
post-stroke	O	O	B-Entity
aphasia	O	O	B-Entity
.	O	O	O

Instead	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
demonstrate	O	O	O
that	O	O	O
using	O	O	O
language	O	O	B-Entity
for	O	O	O
communication	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
interaction	O	O	I-Entity
increases	O	O	O
the	O	O	O
efficacy	O	O	O
of	O	O	O
intensive	O	O	B-Entity
aphasia	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27844448)

miR-27b	O	O	B-Entity
inhibits	O	O	B-Entity
gastric	O	O	B-Entity
cancer	O	O	I-Entity
metastasis	O	O	B-Entity
by	O	O	O
targeting	O	O	B-Entity
NR2F2	O	O	O

Increasing	O	O	B-Entity
attention	O	O	B-Entity
is	O	O	O
focused	O	O	O
on	O	O	O
the	O	O	O
down-regulation	O	O	B-Entity
of	O	O	O
miRNAs	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

Nuclear	O	O	B-Entity
receptor	O	O	I-Entity
subfamily	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
NR2F2	O	O	B-Entity
,	O	O	O
also	O	O	O
known	O	O	O
as	O	O	O
COUP-TFII	O	O	B-Entity
)	O	O	O
is	O	O	O
involved	O	O	B-Entity
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
many	O	O	O
types	O	O	B-Entity
of	O	O	O
cancers	O	O	B-Entity
,	O	O	O
but	O	O	O
its	O	O	O
role	O	O	B-Entity
in	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
remains	O	O	O
elusive	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
experiment	O	O	B-Entity
,	O	O	O
oncomine	O	O	B-Entity
and	O	O	O
Kaplan-meier	O	O	B-Entity
database	O	O	I-Entity
revealed	O	O	B-Entity
that	O	O	O
NR2F2	O	O	B-Entity
was	O	O	O
up-regulated	O	O	B-Entity
in	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
that	O	O	O
the	O	O	O
high	O	O	B-Entity
NR2F2	O	O	O
expression	O	O	B-Entity
contributed	O	O	B-Entity
to	O	O	O
poor	O	O	B-Entity
survival	O	O	B-Entity
.	O	O	O

MicroRNA-27b	O	O	B-Entity
was	O	O	O
targeted	O	O	B-Entity
and	O	O	O
down-regulated	O	O	B-Entity
by	O	O	O
NR2F2	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
gastric	O	O	B-Entity
cancer	O	O	I-Entity
tissues	O	O	B-Entity
and	O	O	O
cells	O	O	B-Entity
.	O	O	O

The	O	O	O
ectopic	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
miR-27b	O	O	B-Entity
inhibited	O	O	B-Entity
gastric	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	B-Entity
proliferation	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Assays	O	O	B-Entity
suggested	O	O	B-Entity
that	O	O	O
the	O	O	O
overexpression	O	O	B-Entity
of	O	O	O
miR-27b	O	O	B-Entity
could	O	O	O
promote	O	O	B-Entity
MGC-803	O	O	B-Entity
cells	O	O	I-Entity
'	O	O	O
migration	O	O	B-Entity
and	O	O	O
invasion	O	O	B-Entity
and	O	O	O
retard	O	O	B-Entity
their	O	O	O
metastasis	O	O	B-Entity
to	O	O	O
the	O	O	O
liver	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
down-regulation	O	O	B-Entity
of	O	O	O
miR-27b	O	O	B-Entity
enhanced	O	O	O
GES-1	O	O	B-Entity
cells	O	O	I-Entity
'	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
reveal	O	O	B-Entity
that	O	O	O
miR-27b	O	O	B-Entity
is	O	O	O
a	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
in	O	O	O
gastric	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
improving	O	O	B-Entity
patients	O	O	B-Entity
'	O	O	O
survival	O	O	B-Entity
.	O	O	O

-DOCSTART- (27845744)

Promoting	O	O	B-Entity
Healthy	O	O	B-Entity
Growth	O	O	B-Entity
or	O	O	O
Feeding	O	O	B-Entity
Obesity	O	O	B-Entity
?	O	O	O
The	O	O	O
Need	O	O	B-Entity
for	O	O	O
Evidence	O	O	B-Entity
-Based	O	O	O
Oversight	O	O	O
of	O	O	O
Infant	O	O	B-Entity
Nutritional	O	O	B-Entity
Supplement	O	O	I-Entity
Claims	O	O	O

The	O	O	O
Need	O	O	B-Entity
for	O	O	O
Evidence	O	O	B-Entity
-Based	O	O	O
Oversight	O	O	O
of	O	O	O
Infant	O	O	B-Entity
Nutritional	O	O	B-Entity
Supplement	O	O	I-Entity
Claims	O	O	O
The	O	O	O
Developmental	O	O	B-Entity
Origins	O	O	I-Entity
of	O	O	I-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Disease	O	O	I-Entity
(	O	O	O
DOHaD	O	O	B-Entity
)	O	O	O
model	O	O	O
recognizes	O	O	O
growth	O	O	B-Entity
in	O	O	O
infancy	O	O	B-Entity
and	O	O	O
childhood	O	O	B-Entity
as	O	O	O
a	O	O	O
fundamental	O	O	O
determinant	O	O	O
of	O	O	O
lifespan	O	O	B-Entity
health	O	O	B-Entity
.	O	O	O

Evidence	O	O	B-Entity
of	O	O	I-Entity
long-term	O	O	B-Entity
health	O	O	B-Entity
risks	O	O	B-Entity
among	O	O	O
small	O	O	B-Entity
neonates	O	O	B-Entity
who	O	O	O
subsequently	O	O	O
grow	O	O	B-Entity
rapidly	O	O	B-Entity
poses	O	O	O
a	O	O	O
challenge	O	O	O
for	O	O	O
interventions	O	O	B-Entity
aiming	O	O	O
to	O	O	O
support	O	O	O
healthy	O	O	B-Entity
growth	O	O	B-Entity
,	O	O	O
not	O	O	O
merely	O	O	O
drive	O	O	O
weight	O	O	B-Entity
gain	O	O	I-Entity
.	O	O	O

Defining	O	O	O
healthy	O	O	B-Entity
growth	O	O	B-Entity
beyond	O	O	O
"	O	O	O
getting	O	O	O
bigger	O	O	O
"	O	O	O
is	O	O	O
essential	O	O	B-Entity
as	O	O	O
infant	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
child	O	O	B-Entity
feeding	O	O	B-Entity
industries	O	O	B-Entity
expand	O	O	O
.	O	O	O

Liquid	O	O	B-Entity
-based	O	O	O
nutritional	O	O	B-Entity
supplements	O	O	I-Entity
,	O	O	O
originally	O	O	O
formulated	O	O	B-Entity
for	O	O	O
undernourished	O	O	B-Entity
children	O	O	B-Entity
,	O	O	O
are	O	O	O
increasingly	O	O	B-Entity
marketed	O	O	B-Entity
for	O	O	O
and	O	O	O
consumed	O	O	B-Entity
by	O	O	O
children	O	O	O
generally	O	O	O
.	O	O	O

Clarifying	O	O	B-Entity
the	O	O	O
nature	O	O	O
of	O	O	O
the	O	O	O
evidentiary	O	O	O
base	O	O	O
on	O	O	O
which	O	O	O
structure/function	O	O	O
claims	O	O	O
promoting	O	O	B-Entity
"	O	O	O
healthy	O	O	B-Entity
growth	O	O	B-Entity
"	O	O	O
are	O	O	O
constructed	O	O	O
is	O	O	O
important	O	O	B-Entity
to	O	O	O
curb	O	O	O
invalid	O	O	O
generalizations	O	O	O
.	O	O	O

Evidence	O	O	B-Entity
points	O	O	O
to	O	O	O
changing	O	O	O
social	O	O	B-Entity
beliefs	O	O	B-Entity
and	O	O	O
cultural	O	O	B-Entity
practices	O	O	B-Entity
surrounding	O	O	O
supplementary	O	O	B-Entity
feeding	O	O	B-Entity
,	O	O	O
raising	O	O	O
specific	O	O	B-Entity
concerns	O	O	B-Entity
about	O	O	O
the	O	O	O
long-term	O	O	B-Entity
health	O	O	B-Entity
consequences	O	O	B-Entity
of	O	O	I-Entity
an	O	O	O
associated	O	O	B-Entity
altered	O	O	B-Entity
feeding	O	O	O
culture	O	O	B-Entity
,	O	O	O
including	O	O	O
reduced	O	O	B-Entity
dietary	O	O	B-Entity
variety	O	O	B-Entity
and	O	O	O
weight	O	O	B-Entity
gain	O	O	I-Entity
.	O	O	O

Reassessing	O	O	B-Entity
the	O	O	O
evidence	O	O	B-Entity
for	O	O	I-Entity
and	O	O	O
relevance	O	O	B-Entity
of	O	O	O
dietary	O	O	B-Entity
supplements	O	O	I-Entity
'	O	O	I-Entity
"	O	O	O
promoting	O	O	B-Entity
healthy	O	O	B-Entity
growth	O	O	B-Entity
"	O	O	O
claims	O	O	O
for	O	O	O
otherwise	O	O	O
healthy	O	O	O
children	O	O	B-Entity
is	O	O	O
both	O	O	O
needed	O	O	B-Entity
in	O	O	O
a	O	O	O
time	O	O	O
of	O	O	O
global	O	O	B-Entity
obesity	O	O	B-Entity
and	O	O	O
an	O	O	O
opportunity	O	O	B-Entity
to	O	O	O
refine	O	O	O
intervention	O	O	B-Entity
approaches	O	O	I-Entity
among	O	O	O
small	O	O	B-Entity
children	O	O	O
for	O	O	O
whom	O	O	O
rapid	O	O	B-Entity
subsequent	O	O	O
growth	O	O	O
in	O	O	O
early	O	O	O
life	O	O	O
augments	O	O	O
risk	O	O	B-Entity
for	O	O	O
chronic	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

Scientific	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
partnerships	O	O	B-Entity
are	O	O	O
needed	O	O	B-Entity
to	O	O	O
consider	O	O	O
current	O	O	O
governmental	O	O	B-Entity
oversight	O	O	O
shortfalls	O	O	O
in	O	O	O
protecting	O	O	O
vulnerable	O	O	O
populations	O	O	B-Entity
from	O	O	O
overconsumption	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
important	O	O	B-Entity
because	O	O	O
we	O	O	O
may	O	O	O
be	O	O	O
doing	O	O	O
more	O	O	O
harm	O	O	O
than	O	O	O
good	O	O	O
.	O	O	O

-DOCSTART- (27845854)

On-Site	O	O	B-Entity
Fertility	O	O	B-Entity
Preservation	O	O	I-Entity
Services	O	O	I-Entity
for	O	O	O
Adolescents	O	O	B-Entity
and	O	O	O
Young	O	O	B-Entity
Adults	O	O	I-Entity
in	O	O	O
a	O	O	O
Comprehensive	O	O	O
Cancer	O	O	O
Center	O	O	O

Adolescents	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
(	O	O	O
AYAs	O	O	B-Entity
)	O	O	O
receiving	O	O	O
cancer	O	O	B-Entity
treatments	O	O	I-Entity
that	O	O	O
may	O	O	O
impair	O	O	B-Entity
fertility	O	O	I-Entity
should	O	O	O
receive	O	O	O
counseling	O	O	B-Entity
about	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
infertility	O	O	I-Entity
and	O	O	O
options	O	O	O
for	O	O	O
fertility	O	O	B-Entity
preservation	O	O	I-Entity
(	O	O	O
FP	O	O	B-Entity
)	O	O	O
before	O	O	O
treatment	O	O	B-Entity
and/or	O	O	O
during	O	O	O
survivorship	O	O	B-Entity
.	O	O	O

Our	O	O	O
objective	O	O	B-Entity
was	O	O	O
to	O	O	O
define	O	O	O
the	O	O	O
AYA	O	O	B-Entity
patient	O	O	B-Entity
population	O	O	B-Entity
referred	O	O	O
to	O	O	O
an	O	O	O
on-site	O	O	B-Entity
fertility	O	O	I-Entity
consultation	O	O	I-Entity
service	O	O	I-Entity
within	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
cancer	O	O	I-Entity
center	O	O	I-Entity
and	O	O	O
determine	O	O	O
factors	O	O	B-Entity
associated	O	O	O
with	O	O	O
patients	O	O	B-Entity
proceeding	O	O	O
with	O	O	O
FP	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
chart	O	O	I-Entity
review	O	O	I-Entity
of	O	O	O
AYA	O	O	B-Entity
women	O	O	B-Entity
who	O	O	O
completed	O	O	O
a	O	O	O
consultation	O	O	B-Entity
at	O	O	O
the	O	O	O
MD	O	O	B-Entity
Anderson	O	O	I-Entity
Fertility	O	O	I-Entity
Preservation	O	O	I-Entity
and	O	O	I-Entity
Family	O	O	I-Entity
Building	O	O	I-Entity
Service	O	O	I-Entity
during	O	O	O
the	O	O	O
first	O	O	O
year	O	O	O
of	O	O	O
service	O	O	B-Entity
.	O	O	O

Records	O	O	B-Entity
of	O	O	O
154	O	O	O
referred	O	O	O
AYA	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
reviewed	O	O	B-Entity
for	O	O	O
age	O	O	B-Entity
,	O	O	O
ethnicity	O	O	B-Entity
,	O	O	O
cancer	O	O	B-Entity
type	O	O	I-Entity
gravidity	O	O	B-Entity
and	O	O	O
parity	O	O	B-Entity
,	O	O	O
survivorship	O	O	B-Entity
status	O	O	B-Entity
,	O	O	O
and	O	O	O
decision	O	O	O
to	O	O	O
pursue	O	O	O
FP	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
(	O	O	O
mean	O	O	O
age	O	O	O
29.7	O	O	O
)	O	O	O
were	O	O	O
Caucasian	O	O	B-Entity
(	O	O	O
55	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
Hispanic	O	O	B-Entity
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
African	O	O	B-Entity
American	O	O	I-Entity
(	O	O	O
10	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
women	O	O	B-Entity
(	O	O	O
67	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
seen	O	O	O
for	O	O	O
FP	O	O	B-Entity
before	O	O	O
cancer	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
the	O	O	O
remaining	O	O	O
sought	O	O	O
options	O	O	B-Entity
for	O	O	O
family	O	O	B-Entity
building	O	O	I-Entity
while	O	O	O
in	O	O	O
survivorship	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
cancer	O	O	B-Entity
types	O	O	I-Entity
were	O	O	O
hematologic	O	O	B-Entity
(	O	O	O
29	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
breast	O	O	B-Entity
(	O	O	O
25	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
gynecologic	O	O	B-Entity
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
referred	O	O	O
to	O	O	O
an	O	O	O
on-site	O	O	B-Entity
fertility	O	O	I-Entity
consultation	O	O	I-Entity
service	O	O	I-Entity
were	O	O	O
medically	O	O	O
and	O	O	O
ethnically	O	O	B-Entity
diverse	O	O	B-Entity
.	O	O	O

Interest	O	O	O
in	O	O	O
fertility	O	O	B-Entity
counseling	O	O	I-Entity
and	O	O	O
treatment	O	O	B-Entity
was	O	O	O
apparent	O	O	O
in	O	O	O
both	O	O	O
survivorship	O	O	B-Entity
pre-	O	O	B-Entity
and	O	O	I-Entity
postcancer	O	O	I-Entity
treatment	O	O	I-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
referral	O	O	B-Entity
group	O	O	B-Entity
was	O	O	O
ethnically	O	O	B-Entity
diverse	O	O	B-Entity
,	O	O	O
Caucasian	O	O	B-Entity
women	O	O	B-Entity
were	O	O	O
most	O	O	O
likely	O	O	O
to	O	O	O
pursue	O	O	O
FP	O	O	B-Entity
treatment	O	O	I-Entity
compared	O	O	O
to	O	O	O
women	O	O	O
of	O	O	O
other	O	O	O
ethnicities	O	O	B-Entity
.	O	O	O

-DOCSTART- (27847549)

Results	O	O	B-Entity
of	O	O	O
a	O	O	O
Multicenter	O	O	B-Entity
,	O	O	O
Randomized	O	O	B-Entity
,	O	O	O
Controlled	O	O	B-Entity
Trial	O	O	I-Entity
of	O	O	O
a	O	O	O
Hydrogen	O	O	B-Entity
Peroxide	O	O	I-Entity
-based	O	O	O
Kit	O	O	B-Entity
versus	O	O	O
a	O	O	O
Benzoyl	O	O	B-Entity
Peroxide	O	O	I-Entity
-based	O	O	O
Kit	O	O	O
in	O	O	O
Mild-to-moderate	O	O	B-Entity
Acne	O	O	O

Objective	O	O	O
:	O	O	O
To	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
tolerability	O	O	B-Entity
of	O	O	O
a	O	O	O
novel	O	O	O
hydrogen	O	O	B-Entity
peroxide	O	O	I-Entity
-based	O	O	O
regimen	O	O	B-Entity
versus	O	O	O
a	O	O	O
benzoyl	O	O	B-Entity
peroxide	O	O	I-Entity
-based	O	O	O
regimen	O	O	O
in	O	O	O
mild-to-moderate	O	O	B-Entity
acne	O	O	B-Entity
.	O	O	O

Methods	O	O	B-Entity
:	O	O	O
In	O	O	O
this	O	O	O
eight-	O	O	O
week	O	O	B-Entity
multicenter	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
patients	O	O	B-Entity
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
either	O	O	O
a	O	O	O
hydrogen	O	O	B-Entity
peroxide	O	O	I-Entity
-based	O	O	O
or	O	O	O
a	O	O	O
benzoyl	O	O	B-Entity
peroxide	O	O	I-Entity
-based	O	O	O
regimen	O	O	B-Entity
.The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
measure	O	O	I-Entity
of	O	O	O
clinical	O	O	B-Entity
response	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Global	O	O	B-Entity
Acne	O	O	I-Entity
Grading	O	O	I-Entity
System	O	O	I-Entity
(	O	O	O
GAGS	O	O	B-Entity
)	O	O	O
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
four	O	O	O
weeks	O	O	B-Entity
,	O	O	O
and	O	O	O
eight	O	O	O
weeks	O	O	O
.	O	O	O

At	O	O	O
Week	O	O	B-Entity
8	O	O	O
,	O	O	O
a	O	O	O
patient	O	O	B-Entity
self-satisfaction	O	O	B-Entity
questionnaire	O	O	I-Entity
was	O	O	O
administered	O	O	B-Entity
.	O	O	O

Investigators	O	O	B-Entity
were	O	O	O
also	O	O	O
queried	O	O	B-Entity
at	O	O	O
that	O	O	O
time	O	O	O
regarding	O	O	O
assessment	O	O	B-Entity
of	O	O	O
tolerability	O	O	B-Entity
and	O	O	O
cosmetic	O	O	B-Entity
acceptability	O	O	B-Entity
.	O	O	O

Tolerability	O	O	B-Entity
was	O	O	O
also	O	O	O
measured	O	O	B-Entity
at	O	O	O
each	O	O	O
visit	O	O	B-Entity
.	O	O	O

Results	O	O	O
:	O	O	O
Both	O	O	O
treatment	O	O	B-Entity
regimens	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
improvement	O	O	B-Entity
of	O	O	O
GAGS	O	O	B-Entity
score	O	O	I-Entity
at	O	O	O
Week	O	O	B-Entity
8	O	O	O
compared	O	O	B-Entity
to	O	O	O
baseline	O	O	B-Entity
(	O	O	O
p<0.0001	O	O	O
)	O	O	O
.	O	O	O

GAGS	O	O	B-Entity
score	O	O	I-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
significantly	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
regimens	O	O	B-Entity
over	O	O	O
the	O	O	O
same	O	O	O
period	O	O	B-Entity
(	O	O	O
p=0.7765	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
were	O	O	O
reported	O	O	B-Entity
or	O	O	O
observed	O	O	B-Entity
in	O	O	O
either	O	O	O
treatment	O	O	B-Entity
arm	O	O	I-Entity
.	O	O	O

Both	O	O	O
patients	O	O	B-Entity
and	O	O	O
investigators	O	O	B-Entity
found	O	O	O
both	O	O	O
regimens	O	O	B-Entity
to	O	O	O
be	O	O	O
similarly	O	O	O
effective	O	O	B-Entity
and	O	O	O
cosmetically	O	O	B-Entity
acceptable	O	O	B-Entity
.	O	O	O

Conclusion	O	O	O
:	O	O	O
A	O	O	O
novel	O	O	O
hydrogen	O	O	B-Entity
peroxide	O	O	I-Entity
-based	O	O	O
regimen	O	O	B-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
comparable	O	O	B-Entity
in	O	O	O
efficacy	O	O	B-Entity
,	O	O	O
safety	O	O	B-Entity
,	O	O	O
and	O	O	O
cosmetic	O	O	B-Entity
acceptability	O	O	B-Entity
to	O	O	O
a	O	O	O
benzoyl	O	O	B-Entity
peroxide	O	O	I-Entity
-based	O	O	O
regimen	O	O	O
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
mild-to-moderate	O	O	B-Entity
acne	O	O	B-Entity
.	O	O	O

-DOCSTART- (27847822)

Multisensory	O	O	B-Entity
Integration	O	O	I-Entity
in	O	O	O
the	O	O	O
Virtual	O	O	B-Entity
Hand	O	O	I-Entity
Illusion	O	O	I-Entity
with	O	O	O
Active	O	O	O
Movement	O	O	O

Improving	O	O	O
the	O	O	O
sense	O	O	B-Entity
of	O	O	I-Entity
immersion	O	O	O
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
core	O	O	O
issues	O	O	O
in	O	O	O
virtual	O	O	B-Entity
reality	O	O	I-Entity
.	O	O	O

Perceptual	O	O	B-Entity
illusions	O	O	I-Entity
of	O	O	O
ownership	O	O	O
can	O	O	O
be	O	O	O
perceived	O	O	B-Entity
over	O	O	O
a	O	O	O
virtual	O	O	B-Entity
body	O	O	I-Entity
in	O	O	O
a	O	O	O
multisensory	O	O	B-Entity
virtual	O	O	B-Entity
reality	O	O	I-Entity
environment	O	O	O
.	O	O	O

Rubber	O	O	B-Entity
Hand	O	O	I-Entity
and	O	O	O
Virtual	O	O	B-Entity
Hand	O	O	I-Entity
Illusions	O	O	I-Entity
showed	O	O	O
that	O	O	O
body	O	O	O
ownership	O	O	O
can	O	O	O
be	O	O	O
manipulated	O	O	O
by	O	O	O
applying	O	O	O
suitable	O	O	O
visual	O	O	B-Entity
and	O	O	O
tactile	O	O	B-Entity
stimulation	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
investigate	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
multisensory	O	O	B-Entity
integration	O	O	I-Entity
in	O	O	O
the	O	O	O
Virtual	O	O	B-Entity
Hand	O	O	I-Entity
Illusion	O	O	I-Entity
with	O	O	O
active	O	O	B-Entity
movement	O	O	I-Entity
.	O	O	O

A	O	O	O
virtual	O	O	B-Entity
xylophone	O	O	I-Entity
playing	O	O	I-Entity
system	O	O	O
which	O	O	O
can	O	O	O
interactively	O	O	O
provide	O	O	O
synchronous	O	O	B-Entity
visual	O	O	B-Entity
,	O	O	O
tactile	O	O	B-Entity
,	O	O	O
and	O	O	O
auditory	O	O	B-Entity
stimulation	O	O	I-Entity
was	O	O	O
constructed	O	O	O
.	O	O	O

We	O	O	O
conducted	O	O	O
two	O	O	O
experiments	O	O	O
regarding	O	O	O
different	O	O	O
movement	O	O	O
conditions	O	O	O
and	O	O	O
different	O	O	O
sensory	O	O	B-Entity
stimulations	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
demonstrate	O	O	O
that	O	O	O
multisensory	O	O	B-Entity
integration	O	O	I-Entity
with	O	O	O
free	O	O	O
active	O	O	B-Entity
movement	O	O	I-Entity
can	O	O	O
improve	O	O	O
the	O	O	O
sense	O	O	B-Entity
of	O	O	I-Entity
immersion	O	O	B-Entity
in	O	O	I-Entity
virtual	O	O	I-Entity
reality	O	O	I-Entity
.	O	O	O

-DOCSTART- (27847836)

Obstructive	O	O	B-Entity
Acute	O	O	B-Entity
Pancreatitis	O	O	I-Entity
Secondary	O	O	O
to	O	O	O
PEG	O	O	B-Entity
Tube	O	O	I-Entity
Migration	O	O	O

Percutaneous	O	O	B-Entity
gastrostomy	O	O	I-Entity
is	O	O	O
a	O	O	O
well-established	O	O	O
method	O	O	B-Entity
of	O	O	O
providing	O	O	O
enteral	O	O	B-Entity
nutrition	O	O	I-Entity
to	O	O	O
patients	O	O	B-Entity
incapable	O	O	B-Entity
of	O	O	O
oral	O	O	B-Entity
intake	O	O	I-Entity
,	O	O	O
or	O	O	O
for	O	O	O
whom	O	O	O
oral	O	O	O
intake	O	O	O
is	O	O	O
insufficient	O	O	B-Entity
to	O	O	O
meet	O	O	O
metabolic	O	O	B-Entity
needs	O	O	B-Entity
.	O	O	O

In	O	O	O
comparison	O	O	O
to	O	O	O
total	O	O	B-Entity
parenteral	O	O	I-Entity
nutrition	O	O	I-Entity
,	O	O	O
enteral	O	O	B-Entity
feeding	O	O	I-Entity
is	O	O	O
advantageous	O	O	O
in	O	O	O
that	O	O	O
it	O	O	O
helps	O	O	O
maintain	O	O	O
gut	O	O	B-Entity
mucosal	O	O	B-Entity
integrity	O	O	B-Entity
,	O	O	O
which	O	O	O
decreases	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
bacterial	O	O	B-Entity
translocation	O	O	I-Entity
through	O	O	O
the	O	O	O
gastrointestinal	O	O	B-Entity
tract	O	O	I-Entity
.	O	O	O

Complications	O	O	B-Entity
include	O	O	O
bleeding	O	O	B-Entity
,	O	O	O
aspiration	O	O	B-Entity
,	O	O	O
internal	O	O	B-Entity
organ	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
perforation	O	O	B-Entity
,	O	O	O
periostomal	O	O	B-Entity
leaks	O	O	I-Entity
,	O	O	O
tube	O	O	B-Entity
dislodgement	O	O	I-Entity
,	O	O	O
and	O	O	O
occlusion	O	O	B-Entity
.	O	O	O

Acute	O	O	B-Entity
pancreatitis	O	O	I-Entity
secondary	O	O	O
to	O	O	O
percutaneous	O	O	B-Entity
gastrostomy	O	O	I-Entity
tube	O	O	I-Entity
migration	O	O	B-Entity
is	O	O	O
rare	O	O	O
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
acute	O	O	B-Entity
obstructive	O	O	B-Entity
pancreatitis	O	O	B-Entity
secondary	O	O	O
to	O	O	O
percutaneous	O	O	B-Entity
gastrostomy	O	O	I-Entity
tube	O	O	I-Entity
migration	O	O	B-Entity
.	O	O	O

-DOCSTART- (27848238)

A	O	O	O
Tractable	O	O	B-Entity
Method	O	O	B-Entity
for	O	O	O
Measuring	O	O	B-Entity
Nanomaterial	O	O	B-Entity
Risk	O	O	B-Entity
Using	O	O	O
Bayesian	O	O	O
Networks	O	O	O

While	O	O	O
control	O	O	O
banding	O	O	B-Entity
has	O	O	O
been	O	O	O
identified	O	O	O
as	O	O	O
a	O	O	O
suitable	O	O	O
framework	O	O	O
for	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
and	O	O	O
the	O	O	O
determination	O	O	O
of	O	O	O
potential	O	O	B-Entity
human	O	O	B-Entity
health	O	O	B-Entity
risks	O	O	I-Entity
associated	O	O	O
with	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
nanomaterials	O	O	B-Entity
(	O	O	O
NMs	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
approach	O	O	O
currently	O	O	O
lacks	O	O	O
any	O	O	O
implementation	O	O	B-Entity
that	O	O	O
enjoys	O	O	O
widespread	O	O	O
support	O	O	O
.	O	O	O

Large	O	O	O
inconsistencies	O	O	O
in	O	O	O
characterisation	O	O	O
data	O	O	B-Entity
,	O	O	O
toxicological	O	O	B-Entity
measurements	O	O	B-Entity
and	O	O	O
exposure	O	O	O
scenarios	O	O	O
make	O	O	O
it	O	O	O
difficult	O	O	O
to	O	O	O
map	O	O	O
and	O	O	O
compare	O	O	O
the	O	O	O
risk	O	O	B-Entity
associated	O	O	O
with	O	O	O
NMs	O	O	B-Entity
based	O	O	O
on	O	O	O
physicochemical	O	O	B-Entity
data	O	O	O
,	O	O	O
concentration	O	O	B-Entity
and	O	O	O
exposure	O	O	B-Entity
route	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
demonstrate	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
Bayesian	O	O	B-Entity
networks	O	O	I-Entity
as	O	O	O
a	O	O	O
reliable	O	O	O
tool	O	O	B-Entity
for	O	O	O
NM	O	O	B-Entity
risk	O	O	B-Entity
estimation	O	O	O
.	O	O	O

This	O	O	O
tool	O	O	B-Entity
is	O	O	O
tractable	O	O	B-Entity
,	O	O	O
accessible	O	O	B-Entity
and	O	O	O
scalable	O	O	B-Entity
.	O	O	O

Most	O	O	O
importantly	O	O	O
,	O	O	O
it	O	O	O
captures	O	O	O
a	O	O	O
broad	O	O	O
span	O	O	O
of	O	O	O
data	O	O	B-Entity
types	O	O	O
,	O	O	O
from	O	O	O
complete	O	O	O
,	O	O	O
high	O	O	O
quality	O	O	B-Entity
data	O	O	B-Entity
sets	O	O	I-Entity
through	O	O	O
to	O	O	O
data	O	O	O
sets	O	O	O
with	O	O	O
missing	O	O	O
data	O	O	O
and/or	O	O	O
values	O	O	B-Entity
with	O	O	O
a	O	O	O
relatively	O	O	O
high	O	O	O
spread	O	O	O
of	O	O	O
probability	O	O	B-Entity
distribution	O	O	I-Entity
.	O	O	O

The	O	O	O
tool	O	O	B-Entity
is	O	O	O
able	O	O	O
to	O	O	O
learn	O	O	O
iteratively	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
further	O	O	O
refine	O	O	O
forecasts	O	O	O
as	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
data	O	O	B-Entity
available	O	O	O
improves	O	O	O
.	O	O	O

We	O	O	O
demonstrate	O	O	O
how	O	O	O
this	O	O	O
risk	O	O	B-Entity
measurement	O	O	B-Entity
approach	O	O	O
works	O	O	O
on	O	O	O
NMs	O	O	B-Entity
with	O	O	O
varying	O	O	O
degrees	O	O	O
of	O	O	O
risk	O	O	O
potential	O	O	B-Entity
,	O	O	O
namely	O	O	O
,	O	O	O
carbon	O	O	B-Entity
nanotubes	O	O	I-Entity
,	O	O	O
silver	O	O	B-Entity
and	O	O	O
titanium	O	O	B-Entity
dioxide	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
afford	O	O	O
even	O	O	O
non-experts	O	O	B-Entity
an	O	O	O
accurate	O	O	O
picture	O	O	O
of	O	O	O
the	O	O	O
occupational	O	O	O
risk	O	O	B-Entity
probabilities	O	O	O
associated	O	O	O
with	O	O	O
these	O	O	O
NMs	O	O	B-Entity
and	O	O	O
,	O	O	O
in	O	O	O
doing	O	O	O
so	O	O	O
,	O	O	O
demonstrated	O	O	O
how	O	O	O
NM	O	O	B-Entity
risk	O	O	O
can	O	O	O
be	O	O	O
evaluated	O	O	B-Entity
into	O	O	O
a	O	O	O
tractable	O	O	B-Entity
,	O	O	O
quantitative	O	O	B-Entity
risk	O	O	O
comparator	O	O	O
.	O	O	O

-DOCSTART- (27849409)

Gender	O	O	B-Entity
and	O	O	O
Direction	O	O	B-Entity
of	O	O	O
Effect	O	O	B-Entity
of	O	O	O
Alcohol	O	O	B-Entity
Problems	O	O	I-Entity
and	O	O	O
Internalizing	O	O	B-Entity
Symptoms	O	O	I-Entity
in	O	O	O
a	O	O	O
Longitudinal	O	O	B-Entity
Sample	O	O	I-Entity
of	O	O	O
College	O	O	O
Students	O	O	O

Alcohol	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
are	O	O	O
consistently	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
associated	O	O	B-Entity
but	O	O	O
how	O	O	O
they	O	O	O
relate	O	O	B-Entity
to	O	O	O
each	O	O	O
other	O	O	O
is	O	O	O
unclear	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
address	O	O	O
limitations	O	O	B-Entity
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
of	O	O	O
comorbidity	O	O	B-Entity
of	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
by	O	O	O
investigating	O	O	B-Entity
the	O	O	O
direction	O	O	B-Entity
of	O	O	O
effect	O	O	B-Entity
between	O	O	O
the	O	O	O
phenotypes	O	O	B-Entity
and	O	O	O
possible	O	O	O
gender	O	O	B-Entity
differences	O	O	I-Entity
in	O	O	O
college	O	O	B-Entity
students	O	O	I-Entity
.	O	O	O

We	O	O	O
utilized	O	O	O
data	O	O	B-Entity
from	O	O	O
a	O	O	O
large	O	O	O
longitudinal	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
college	O	O	B-Entity
students	O	O	I-Entity
from	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
2607	O	O	O
)	O	O	O
.	O	O	O

Three	O	O	O
waves	O	O	O
of	O	O	O
questionnaire-based	O	O	B-Entity
data	O	O	B-Entity
were	O	O	O
collected	O	O	O
over	O	O	O
the	O	O	O
first	O	O	O
two	O	O	O
years	O	O	B-Entity
of	O	O	O
college	O	O	B-Entity
(	O	O	O
in	O	O	O
2011	O	O	O
-	O	O	O
2013	O	O	O
)	O	O	O
.	O	O	O

Cross-lagged	O	O	B-Entity
models	O	O	I-Entity
were	O	O	O
applied	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
possible	O	O	O
direction	O	O	B-Entity
of	O	O	O
effect	O	O	B-Entity
of	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
and	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
.	O	O	O

Possible	O	O	O
effects	O	O	B-Entity
of	O	O	O
gender	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
using	O	O	O
multigroup	O	O	B-Entity
modeling	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
significant	O	O	B-Entity
correlations	O	O	B-Entity
between	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
.	O	O	O

A	O	O	O
direction	O	O	B-Entity
of	O	O	O
effect	O	O	B-Entity
was	O	O	O
found	O	O	O
between	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
but	O	O	O
differed	O	O	O
between	O	O	O
genders	O	O	B-Entity
.	O	O	O

A	O	O	O
unidirectional	O	O	O
relationship	O	O	B-Entity
varying	O	O	O
with	O	O	O
age	O	O	B-Entity
was	O	O	O
identified	O	O	O
for	O	O	O
males	O	O	B-Entity
where	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
initially	O	O	O
predicted	O	O	B-Entity
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
followed	O	O	O
by	O	O	O
internalizing	O	O	O
symptoms	O	O	O
predicting	O	O	O
alcohol	O	O	O
problems	O	O	O
.	O	O	O

For	O	O	O
females	O	O	B-Entity
,	O	O	O
a	O	O	O
unidirectional	O	O	O
relationship	O	O	B-Entity
existed	O	O	O
wherein	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
predicted	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
.	O	O	O

Conclusions/Importance	O	O	O
:	O	O	O
We	O	O	O
conclude	O	O	O
that	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
is	O	O	O
complex	O	O	B-Entity
and	O	O	O
differ	O	O	O
between	O	O	O
genders	O	O	B-Entity
.	O	O	O

In	O	O	O
males	O	O	B-Entity
,	O	O	O
both	O	O	O
phenotypes	O	O	B-Entity
are	O	O	O
predictive	O	O	B-Entity
of	O	O	O
each	O	O	O
other	O	O	O
,	O	O	O
while	O	O	O
in	O	O	O
females	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
is	O	O	O
driven	O	O	O
by	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
.	O	O	O

Importantly	O	O	O
,	O	O	O
our	O	O	O
study	O	O	B-Entity
examines	O	O	O
a	O	O	O
population-based	O	O	B-Entity
sample	O	O	I-Entity
,	O	O	O
revealing	O	O	O
that	O	O	O
the	O	O	O
observed	O	O	O
relationships	O	O	B-Entity
between	O	O	O
alcohol	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
are	O	O	O
not	O	O	O
limited	O	O	O
to	O	O	O
individuals	O	O	B-Entity
with	O	O	O
clinically	O	O	B-Entity
diagnosed	O	O	I-Entity
mental	O	O	B-Entity
health	O	O	I-Entity
or	O	O	O
substance	O	O	B-Entity
use	O	O	I-Entity
problems	O	O	I-Entity
.	O	O	O

-DOCSTART- (27853757)

Real-time	O	O	B-Entity
monitoring	O	O	B-Entity
of	O	O	O
vesicle	O	O	B-Entity
pH	O	O	B-Entity
in	O	O	O
an	O	O	O
endocytic	O	O	B-Entity
pathway	O	O	B-Entity
using	O	O	O
an	O	O	O
EGF	O	O	B-Entity
-	O	O	O
conjugated	O	O	O
two-photon	O	O	O
probe	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	O
a	O	O	O
ratiometric	O	O	B-Entity
two-photon	O	O	I-Entity
probe	O	O	I-Entity
(	O	O	O
BHS3	O	O	B-Entity
-	O	O	O
EGF	O	O	B-Entity
)	O	O	O
,	O	O	O
derived	O	O	O
from	O	O	O
a	O	O	O
pH	O	O	B-Entity
sensitive	O	O	B-Entity
dye	O	O	O
and	O	O	O
epidermal	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
EGF	O	O	O
)	O	O	O
,	O	O	O
for	O	O	O
real-time	O	O	B-Entity
monitoring	O	O	B-Entity
and	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
acidic	O	O	B-Entity
luminal	O	O	I-Entity
pH	O	O	O
values	O	O	B-Entity
during	O	O	O
endocytic	O	O	B-Entity
pathway	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Two-photon	O	O	B-Entity
microscopy	O	O	I-Entity
imaging	O	O	I-Entity
with	O	O	O
BHS3	O	O	B-Entity
-	O	O	O
EGF	O	O	B-Entity
allows	O	O	O
the	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
pH	O	O	B-Entity
distributions	O	O	B-Entity
of	O	O	O
single	O	O	O
vesicles	O	O	B-Entity
and	O	O	O
their	O	O	O
dynamics	O	O	B-Entity
in	O	O	O
receptor-mediated	O	O	B-Entity
endocytosis	O	O	I-Entity
in	O	O	O
real-time	O	O	B-Entity
.	O	O	O

-DOCSTART- (27856018)

Body	O	O	B-Entity
burden	O	O	I-Entity
of	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
among	O	O	O
HIV	O	O	B-Entity
high	O	O	B-Entity
risk	O	O	I-Entity
population	O	O	I-Entity
in	O	O	O
USA	O	O	O

HIV	O	O	B-Entity
high	O	O	B-Entity
risk	O	O	I-Entity
population	O	O	I-Entity
may	O	O	O
face	O	O	O
not	O	O	O
only	O	O	O
the	O	O	O
threat	O	O	B-Entity
of	O	O	O
HIV	O	O	B-Entity
infection	O	O	I-Entity
but	O	O	O
also	O	O	O
a	O	O	O
higher	O	O	B-Entity
chance	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
environmental	O	O	I-Entity
contaminants	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
previous	O	O	O
studies	O	O	B-Entity
have	O	O	O
examined	O	O	B-Entity
the	O	O	O
body	O	O	B-Entity
burden	O	O	I-Entity
of	O	O	O
environmental	O	O	B-Entity
pollutants	O	O	I-Entity
including	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
among	O	O	O
HIV	O	O	B-Entity
high	O	O	B-Entity
risk	O	O	I-Entity
populations	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	O
whether	O	O	O
adults	O	O	B-Entity
aged	O	O	I-Entity
20	O	O	O
-	O	O	O
59	O	O	O
years	O	O	O
old	O	O	O
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
HIV	O	O	B-Entity
infection	O	O	I-Entity
have	O	O	O
higher	O	O	B-Entity
blood	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	I-Entity
heavy	O	O	I-Entity
metals	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
with	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
HIV	O	O	O
infection	O	O	O
in	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
the	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Survey	O	O	I-Entity
(	O	O	O
NHANES	O	O	B-Entity
)	O	O	O
1999	O	O	O
-	O	O	O
2010	O	O	O
to	O	O	O
compare	O	O	B-Entity
exposures	O	O	B-Entity
to	O	O	I-Entity
heavy	O	O	B-Entity
metals	O	O	I-Entity
including	O	O	O
cadmium	O	O	B-Entity
,	O	O	O
lead	O	O	B-Entity
,	O	O	O
and	O	O	O
total	O	O	O
mercury	O	O	B-Entity
by	O	O	O
HIV	O	O	B-Entity
risk	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
showed	O	O	O
that	O	O	O
people	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
HIV	O	O	B-Entity
had	O	O	O
higher	O	O	B-Entity
blood	O	O	B-Entity
concentrations	O	O	I-Entity
of	O	O	O
all	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
their	O	O	O
counterparts	O	O	O
with	O	O	O
lower	O	O	B-Entity
HIV	O	O	B-Entity
risks	O	O	I-Entity
.	O	O	O

In	O	O	O
multivariate	O	O	B-Entity
linear	O	O	I-Entity
regression	O	O	I-Entity
models	O	O	B-Entity
,	O	O	O
HIV	O	O	B-Entity
risk	O	O	I-Entity
status	O	O	O
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
blood	O	O	B-Entity
cadmium	O	O	I-Entity
,	O	O	O
lead	O	O	B-Entity
,	O	O	O
and	O	O	O
total	O	O	B-Entity
mercury	O	O	I-Entity
after	O	O	O
adjusting	O	O	B-Entity
for	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
race	O	O	B-Entity
,	O	O	O
education	O	O	B-Entity
,	O	O	O
and	O	O	O
poverty	O	O	B-Entity
income	O	O	B-Entity
ratio	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
suggests	O	O	O
that	O	O	O
people	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
HIV	O	O	B-Entity
have	O	O	O
significantly	O	O	O
higher	O	O	B-Entity
body	O	O	B-Entity
burden	O	O	I-Entity
of	O	O	O
heavy	O	O	B-Entity
metals	O	O	I-Entity
including	O	O	O
cadmium	O	O	B-Entity
,	O	O	O
lead	O	O	B-Entity
,	O	O	O
and	O	O	O
mercury	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
with	O	O	O
low	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	O
HIV	O	O	O
.	O	O	O

Further	O	O	O
longitudinal	O	O	B-Entity
study	O	O	I-Entity
collecting	O	O	O
more	O	O	B-Entity
pollutants	O	O	B-Entity
are	O	O	O
warranted	O	O	B-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
potential	O	O	B-Entity
health	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
these	O	O	O
elevated	O	O	B-Entity
pollutants	O	O	O
on	O	O	O
both	O	O	O
HIV-infected	O	O	B-Entity
and	O	O	O
HIV	O	O	B-Entity
high-risk	O	O	B-Entity
populations	O	O	I-Entity
.	O	O	O

-DOCSTART- (27857155)

Fluorescence-	O	O	B-Entity
and	O	O	O
magnetic-activated	O	O	B-Entity
cell	O	O	I-Entity
sorting	O	O	I-Entity
strategies	O	O	B-Entity
to	O	O	O
separate	O	O	B-Entity
spermatozoa	O	O	B-Entity
involving	O	O	O
plural	O	O	B-Entity
contributors	O	O	B-Entity
from	O	O	O
biological	O	O	B-Entity
mixtures	O	O	I-Entity
for	O	O	O
human	O	O	O
identification	O	O	O

No	O	O	O
effective	O	O	O
method	O	O	B-Entity
has	O	O	O
been	O	O	O
developed	O	O	O
to	O	O	O
distinguish	O	O	B-Entity
sperm	O	O	B-Entity
cells	O	O	I-Entity
originating	O	O	O
from	O	O	O
different	O	O	O
men	O	O	B-Entity
in	O	O	O
multi-suspect	O	O	B-Entity
sexual	O	O	B-Entity
assault	O	O	I-Entity
cases	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
combined	O	O	O
MACS	O	O	B-Entity
and	O	O	O
FACS	O	O	B-Entity
to	O	O	O
isolate	O	O	B-Entity
single	O	O	B-Entity
donor	O	O	B-Entity
sperm	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
forensic	O	O	B-Entity
mixture	O	O	I-Entity
samples	O	O	I-Entity
including	O	O	O
female	O	O	B-Entity
vaginal	O	O	B-Entity
epithelial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
sperm	O	O	O
cells	O	O	O
from	O	O	O
multiple	O	O	B-Entity
contributors	O	O	B-Entity
.	O	O	O

Sperms	O	O	B-Entity
from	O	O	O
vaginal	O	O	B-Entity
swab	O	O	I-Entity
were	O	O	O
isolated	O	O	B-Entity
by	O	O	O
MACS	O	O	B-Entity
using	O	O	O
FITC	O	O	B-Entity
-conjugated	O	O	O
A	O	O	B-Entity
kinase	O	O	I-Entity
anchor	O	O	I-Entity
protein	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
AKAP3	O	O	B-Entity
)	O	O	O
antibody	O	O	B-Entity
;	O	O	O
target	O	O	B-Entity
individual	O	O	I-Entity
sperm	O	O	B-Entity
cells	O	O	I-Entity
involving	O	O	O
two	O	O	O
or	O	O	O
three	O	O	O
donors	O	O	B-Entity
were	O	O	O
separated	O	O	B-Entity
by	O	O	O
FACS	O	O	B-Entity
using	O	O	O
FITC	O	O	O
-labeled	O	O	O
blood	O	O	B-Entity
group	O	O	I-Entity
A/B	O	O	I-Entity
antigen	O	O	I-Entity
antibody	O	O	O
.	O	O	O

This	O	O	O
procedure	O	O	B-Entity
was	O	O	O
further	O	O	O
tested	O	O	B-Entity
in	O	O	O
two	O	O	O
mock	O	O	B-Entity
multi-suspect	O	O	B-Entity
sexual	O	O	B-Entity
assault	O	O	I-Entity
samples	O	O	B-Entity
and	O	O	O
one	O	O	O
practical	O	O	B-Entity
casework	O	O	I-Entity
sample	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
showed	O	O	O
that	O	O	O
complete	O	O	B-Entity
single	O	O	B-Entity
donor	O	O	B-Entity
STR	O	O	B-Entity
profiles	O	O	I-Entity
could	O	O	O
be	O	O	O
successfully	O	O	O
obtained	O	O	O
from	O	O	O
sperm	O	O	B-Entity
/	O	O	O
epithelial	O	O	B-Entity
cell	O	O	I-Entity
and	O	O	O
sperm	O	O	O
mixtures	O	O	B-Entity
from	O	O	O
two	O	O	O
contributors	O	O	B-Entity
.	O	O	O

For	O	O	O
unbalanced	O	O	O
sperm	O	O	B-Entity
/	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
sperm	O	O	B-Entity
cells	O	O	I-Entity
mixtures	O	O	B-Entity
,	O	O	O
sensitivity	O	O	B-Entity
results	O	O	O
revealed	O	O	O
that	O	O	O
target	O	O	B-Entity
cells	O	O	I-Entity
could	O	O	O
be	O	O	O
detected	O	O	B-Entity
at	O	O	O
as	O	O	O
low	O	O	O
as	O	O	O
1:32	O	O	O
and	O	O	O
1:8	O	O	O
mixed	O	O	O
ratios	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Although	O	O	O
highly	O	O	O
relies	O	O	O
on	O	O	O
cell	O	O	B-Entity
number	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
types	O	O	I-Entity
or	O	O	O
secretor	O	O	O
status	O	O	O
of	O	O	O
the	O	O	O
individuals	O	O	B-Entity
,	O	O	O
this	O	O	O
procedure	O	O	B-Entity
would	O	O	O
still	O	O	O
be	O	O	O
useful	O	O	O
tools	O	O	O
for	O	O	O
forensic	O	O	B-Entity
DNA	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
multi-suspect	O	O	B-Entity
sexual	O	O	B-Entity
assault	O	O	I-Entity
cases	O	O	B-Entity
by	O	O	O
the	O	O	O
combined	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
FACS	O	O	B-Entity
and	O	O	O
MACS	O	O	B-Entity
based	O	O	O
on	O	O	O
sperm	O	O	B-Entity
-specific	O	O	O
AKAP3	O	O	B-Entity
antigen	O	O	B-Entity
and	O	O	O
human	O	O	B-Entity
blood	O	O	B-Entity
type	O	O	I-Entity
antigen	O	O	I-Entity
.	O	O	O

-DOCSTART- (27857815)

The	O	O	O
Role	O	O	O
of	O	O	O
the	O	O	O
Iron	O	O	B-Entity
Stain	O	O	I-Entity
in	O	O	O
Assessing	O	O	B-Entity
Intracranial	O	O	O
Hemorrhage	O	O	O

The	O	O	O
timing	O	O	B-Entity
of	O	O	O
the	O	O	O
breakdown	O	O	O
of	O	O	O
red	O	O	B-Entity
blood	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
organization	O	O	B-Entity
of	O	O	O
hemorrhage	O	O	B-Entity
has	O	O	O
significance	O	O	B-Entity
in	O	O	O
the	O	O	O
catabolism	O	O	B-Entity
of	O	O	O
heme	O	O	B-Entity
and	O	O	O
the	O	O	O
processing	O	O	B-Entity
of	O	O	O
iron	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
has	O	O	O
a	O	O	O
practical	O	O	O
application	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
assigning	O	O	B-Entity
,	O	O	O
or	O	O	O
attempting	O	O	B-Entity
to	O	O	O
assign	O	O	B-Entity
,	O	O	O
a	O	O	O
time	O	O	B-Entity
course	O	O	I-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
traumatic	O	O	B-Entity
events	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
contusions	O	O	B-Entity
and	O	O	O
hemorrhages	O	O	B-Entity
)	O	O	O
.	O	O	O

Attempts	O	O	B-Entity
to	O	O	O
date	O	O	B-Entity
contusions	O	O	I-Entity
,	O	O	O
however	O	O	O
,	O	O	O
have	O	O	O
generally	O	O	O
been	O	O	O
unsuccessful	O	O	B-Entity
by	O	O	O
macroscopic	O	O	B-Entity
observation	O	O	I-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
microscopic	O	O	B-Entity
observations	O	O	I-Entity
provide	O	O	O
broad	O	O	O
data	O	O	B-Entity
but	O	O	O
are	O	O	O
also	O	O	O
anatomically	O	O	B-Entity
imprecise	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
time	O	O	B-Entity
.	O	O	O

Intracranial	O	O	B-Entity
lesions	O	O	I-Entity
are	O	O	O
of	O	O	O
particular	O	O	O
significance	O	O	B-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
the	O	O	O
timing	O	O	B-Entity
of	O	O	O
organizing	O	O	B-Entity
hemorrhage	O	O	B-Entity
given	O	O	O
the	O	O	O
acute	O	O	B-Entity
,	O	O	O
and	O	O	O
often	O	O	O
life-threatening	O	O	B-Entity
nature	O	O	B-Entity
of	O	O	O
the	O	O	O
hemorrhages	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
medicolegal	O	O	B-Entity
investigation	O	O	I-Entity
into	O	O	O
potential	O	O	B-Entity
crimes	O	O	B-Entity
.	O	O	O

Of	O	O	O
concern	O	O	O
is	O	O	O
that	O	O	O
the	O	O	O
Prussian	O	O	B-Entity
Blue	O	O	I-Entity
reaction	O	O	B-Entity
for	O	O	O
iron	O	O	B-Entity
,	O	O	O
a	O	O	O
relatively	O	O	O
straightforward	O	O	O
histochemical	O	O	B-Entity
reaction	O	O	O
that	O	O	O
has	O	O	O
been	O	O	O
in	O	O	O
use	O	O	O
for	O	O	O
over	O	O	O
150	O	O	O
years	O	O	B-Entity
,	O	O	O
is	O	O	O
sometimes	O	O	O
suggested	O	O	O
as	O	O	O
a	O	O	O
diagnostic	O	O	B-Entity
test	O	O	I-Entity
for	O	O	O
chronicity	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
this	O	O	O
study	O	O	B-Entity
examined	O	O	B-Entity
the	O	O	O
utility	O	O	O
of	O	O	O
the	O	O	O
Prussian	O	O	B-Entity
Blue	O	O	I-Entity
iron	O	O	I-Entity
stain	O	O	I-Entity
in	O	O	O
living	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
intracranial	O	O	B-Entity
hemorrhages	O	O	I-Entity
and	O	O	O
well-defined	O	O	O
symptom	O	O	B-Entity
onset	O	O	I-Entity
,	O	O	O
to	O	O	O
test	O	O	O
whether	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
Prussian	O	O	O
Blue	O	O	O
reactivity	O	O	B-Entity
could	O	O	O
be	O	O	O
correlated	O	O	B-Entity
with	O	O	O
chronicity	O	O	B-Entity
.	O	O	O

It	O	O	O
was	O	O	O
found	O	O	B-Entity
that	O	O	O
out	O	O	O
of	O	O	O
12	O	O	O
cases	O	O	B-Entity
with	O	O	O
intracranial	O	O	B-Entity
hemorrhage	O	O	I-Entity
,	O	O	O
eight	O	O	O
cases	O	O	O
showed	O	O	O
at	O	O	O
least	O	O	O
focal	O	O	B-Entity
iron	O	O	I-Entity
reactivity	O	O	B-Entity
.	O	O	O

The	O	O	O
duration	O	O	B-Entity
from	O	O	O
symptom	O	O	B-Entity
onset	O	O	I-Entity
to	O	O	O
surgery	O	O	B-Entity
in	O	O	O
those	O	O	O
eight	O	O	O
cases	O	O	B-Entity
ranged	O	O	B-Entity
from	O	O	O
<	O	O	O
24	O	O	O
hours	O	O	B-Entity
to	O	O	O
more	O	O	O
than	O	O	O
3	O	O	O
days	O	O	B-Entity
.	O	O	O

Of	O	O	O
those	O	O	O
cases	O	O	B-Entity
with	O	O	O
no	O	O	B-Entity
iron	O	O	I-Entity
reactivity	O	O	I-Entity
,	O	O	O
the	O	O	O
duration	O	O	B-Entity
from	O	O	O
symptom	O	O	B-Entity
onset	O	O	I-Entity
to	O	O	O
surgery	O	O	B-Entity
ranged	O	O	O
from	O	O	O
<	O	O	O
24	O	O	O
hours	O	O	B-Entity
to	O	O	O
six	O	O	O
days	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
Prussian	O	O	B-Entity
Blue	O	O	I-Entity
reaction	O	O	I-Entity
was	O	O	O
unreliable	O	O	B-Entity
as	O	O	O
an	O	O	O
indicator	O	O	B-Entity
of	O	O	O
timing	O	O	B-Entity
in	O	O	O
intracranial	O	O	B-Entity
hemorrhage	O	O	I-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
the	O	O	O
Prussian	O	O	B-Entity
blue	O	O	I-Entity
reaction	O	O	I-Entity
as	O	O	O
an	O	O	O
independent	O	O	B-Entity
indicator	O	O	I-Entity
of	O	O	O
chronicity	O	O	B-Entity
is	O	O	O
therefore	O	O	O
not	O	O	O
valid	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
misleading	O	O	O
.	O	O	O

Caution	O	O	O
is	O	O	O
indicated	O	O	B-Entity
when	O	O	O
employing	O	O	O
iron	O	O	B-Entity
staining	O	O	I-Entity
for	O	O	O
timing	O	O	B-Entity
purposes	O	O	O
,	O	O	O
as	O	O	O
its	O	O	O
only	O	O	O
use	O	O	O
is	O	O	O
to	O	O	O
highlight	O	O	O
,	O	O	O
as	O	O	O
opposed	O	O	O
to	O	O	O
identify	O	O	O
,	O	O	O
pre-existing	O	O	B-Entity
lesions	O	O	B-Entity
.	O	O	O

With	O	O	O
respect	O	O	O
to	O	O	O
brain	O	O	B-Entity
lesions	O	O	I-Entity
,	O	O	O
the	O	O	O
Prussian	O	O	B-Entity
blue	O	O	I-Entity
reaction	O	O	I-Entity
should	O	O	O
not	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
place	O	O	O
of	O	O	O
the	O	O	O
clinical	O	O	B-Entity
timing	O	O	B-Entity
of	O	O	O
the	O	O	O
neurologic	O	O	B-Entity
decline	O	O	I-Entity
,	O	O	O
or	O	O	O
clinical	O	O	B-Entity
data	O	O	I-Entity
that	O	O	O
is	O	O	O
otherwise	O	O	O
more	O	O	O
accurate	O	O	B-Entity
and	O	O	O
less	O	O	O
susceptible	O	O	B-Entity
to	O	O	O
false	O	O	B-Entity
positive	O	O	I-Entity
results	O	O	I-Entity
.	O	O	O

-DOCSTART- (27860542)

Successful	O	O	B-Entity
Fetal	O	O	B-Entity
Tele-Echo	O	O	I-Entity
at	O	O	O
a	O	O	O
Small	O	O	O
Regional	O	O	O
Hospital	O	O	O

Prenatal	O	O	B-Entity
diagnosis	O	O	I-Entity
of	O	O	O
complex	O	O	B-Entity
congenital	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CHD	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
improve	O	O	B-Entity
newborn	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

The	O	O	O
rate	O	O	O
of	O	O	O
prenatal	O	O	B-Entity
diagnosis	O	O	I-Entity
and	O	O	O
access	O	O	B-Entity
to	O	O	O
fetal	O	O	B-Entity
echocardiography	O	O	I-Entity
vary	O	O	O
widely	O	O	O
across	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
.	O	O	O

A	O	O	O
clinical	O	O	B-Entity
fetal	O	O	I-Entity
tele-echo	O	O	I-Entity
service	O	O	O
was	O	O	O
established	O	O	O
at	O	O	O
King	O	O	B-Entity
's	O	O	I-Entity
Daughters	O	O	I-Entity
Medical	O	O	I-Entity
Center	O	O	I-Entity
(	O	O	O
KDMC	O	O	B-Entity
)	O	O	O
in	O	O	O
Ashland	O	O	B-Entity
,	O	O	O
KY	O	O	B-Entity
,	O	O	O
a	O	O	O
region	O	O	O
in	O	O	O
eastern	O	O	B-Entity
Kentucky	O	O	I-Entity
that	O	O	O
is	O	O	O
3	O	O	O
h	O	O	O
from	O	O	O
the	O	O	O
nearest	O	O	O
congenital	O	O	B-Entity
heart	O	O	I-Entity
surgeon	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
fetal	O	O	B-Entity
tele-echo	O	O	I-Entity
utilizing	O	O	O
local	O	O	B-Entity
sonographers	O	O	I-Entity
at	O	O	O
a	O	O	O
small	O	O	B-Entity
regional	O	O	I-Entity
hospital	O	O	I-Entity
can	O	O	O
accurately	O	O	B-Entity
and	O	O	O
efficiently	O	O	B-Entity
identify	O	O	O
fetuses	O	O	B-Entity
with	O	O	O
complex	O	O	B-Entity
CHD	O	O	B-Entity
.	O	O	O

Medical	O	O	B-Entity
records	O	O	I-Entity
were	O	O	O
reviewed	O	O	B-Entity
for	O	O	O
all	O	O	O
mother-infant	O	O	B-Entity
pairs	O	O	I-Entity
who	O	O	O
had	O	O	O
fetal	O	O	B-Entity
tele-echoes	O	O	I-Entity
performed	O	O	B-Entity
at	O	O	O
KDMC	O	O	B-Entity
and	O	O	O
interpreted	O	O	B-Entity
by	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Louisville	O	O	I-Entity
pediatric	O	O	I-Entity
cardiology	O	O	I-Entity
between	O	O	O
March	O	O	O
2011	O	O	O
and	O	O	O
December	O	O	O
2013	O	O	O
.	O	O	O

Findings	O	O	B-Entity
on	O	O	O
fetal	O	O	B-Entity
tele-echo	O	O	I-Entity
were	O	O	O
compared	O	O	O
to	O	O	O
newborn	O	O	B-Entity
echo	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
course	O	O	I-Entity
,	O	O	O
and	O	O	O
divided	O	O	O
into	O	O	O
four	O	O	O
groups	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
Correct	O	O	B-Entity
-	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
between	O	O	O
fetal	O	O	O
tele-echo	O	O	O
and	O	O	O
newborn	O	O	O
echo	O	O	O
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
Likely	O	O	O
Correct-normal	O	O	O
fetal	O	O	O
tele-echo	O	O	O
and	O	O	O
benign	O	O	O
newborn	O	O	O
course	O	O	O
,	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
Major	O	O	B-Entity
Difference	O	O	I-Entity
-one	O	O	O
that	O	O	O
affected	O	O	B-Entity
newborn	O	O	O
clinical	O	O	O
course	O	O	O
,	O	O	O
and	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
Minor	O	O	B-Entity
Difference	O	O	I-Entity
-did	O	O	O
not	O	O	O
affect	O	O	O
clinical	O	O	O
course	O	O	O
.	O	O	O

Seventy-five	O	O	O
mother-infant	O	O	B-Entity
pairs	O	O	I-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Fetal	O	O	B-Entity
tele-echoes	O	O	I-Entity
were	O	O	O
Correct	O	O	B-Entity
in	O	O	O
21	O	O	O
%	O	O	O
,	O	O	O
Likely	O	O	O
Correct	O	O	O
in	O	O	O
56	O	O	O
%	O	O	O
,	O	O	O
showed	O	O	O
Major	O	O	B-Entity
Differences	O	O	I-Entity
in	O	O	O
0	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
showed	O	O	O
Minor	O	O	B-Entity
Differences	O	O	I-Entity
in	O	O	O
23	O	O	O
%	O	O	O
.	O	O	O

For	O	O	O
identifying	O	O	O
complex	O	O	B-Entity
CHD	O	O	B-Entity
,	O	O	O
fetal	O	O	B-Entity
tele-echo	O	O	I-Entity
had	O	O	O
a	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
of	O	O	O
100	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
average	O	O	O
number	O	O	O
of	O	O	O
fetal	O	O	B-Entity
echocardiograms	O	O	I-Entity
per	O	O	O
mother-infant	O	O	B-Entity
pair	O	O	I-Entity
was	O	O	O
1.1	O	O	O
.	O	O	O

Fetal	O	O	B-Entity
tele-echocardiography	O	O	I-Entity
performed	O	O	B-Entity
by	O	O	O
local	O	O	B-Entity
sonographers	O	O	I-Entity
at	O	O	O
a	O	O	O
small	O	O	B-Entity
regional	O	O	I-Entity
hospital	O	O	I-Entity
can	O	O	O
accurately	O	O	B-Entity
and	O	O	O
efficiently	O	O	B-Entity
identify	O	O	O
fetuses	O	O	B-Entity
with	O	O	O
complex	O	O	B-Entity
CHD	O	O	B-Entity
.	O	O	O

-DOCSTART- (27861731)

Identification	O	O	B-Entity
of	O	O	O
mineral	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
peptides	O	O	B-Entity
that	O	O	O
discriminate	O	O	B-Entity
between	O	O	O
chalcopyrite	O	O	B-Entity
and	O	O	O
enargite	O	O	O

Innovative	O	O	O
approaches	O	O	O
to	O	O	O
the	O	O	O
separation	O	O	B-Entity
of	O	O	O
minerals	O	O	B-Entity
and	O	O	O
subsequent	O	O	B-Entity
extraction	O	O	B-Entity
of	O	O	O
metals	O	O	B-Entity
are	O	O	O
imperative	O	O	B-Entity
owing	O	O	O
to	O	O	O
the	O	O	O
increasing	O	O	B-Entity
mineralogical	O	O	B-Entity
complexity	O	O	B-Entity
of	O	O	O
ore	O	O	B-Entity
deposits	O	O	I-Entity
that	O	O	O
are	O	O	O
difficult	O	O	B-Entity
or	O	O	O
even	O	O	O
impossible	O	O	B-Entity
to	O	O	O
separate	O	O	B-Entity
into	O	O	O
slurries	O	O	B-Entity
or	O	O	O
solutions	O	O	B-Entity
containing	O	O	B-Entity
only	O	O	O
the	O	O	O
minerals	O	O	O
or	O	O	O
metals	O	O	O
of	O	O	O
interest	O	O	O
.	O	O	O

Low	O	O	B-Entity
recovery	O	O	B-Entity
of	O	O	O
metal	O	O	B-Entity
is	O	O	O
typical	O	O	B-Entity
for	O	O	O
these	O	O	O
complex	O	O	B-Entity
deposits	O	O	B-Entity
leading	O	O	O
to	O	O	O
significant	O	O	B-Entity
losses	O	O	B-Entity
to	O	O	O
tailings	O	O	B-Entity
.	O	O	O

In	O	O	B-Entity
addition	O	O	I-Entity
,	O	O	O
the	O	O	O
minerals	O	O	B-Entity
often	O	O	O
contain	O	O	O
impurities	O	O	B-Entity
,	O	O	O
some	O	O	O
toxic	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
difficult	O	O	B-Entity
and	O	O	O
costly	O	O	B-Entity
to	O	O	O
control	O	O	B-Entity
or	O	O	O
manage	O	O	O
during	O	O	O
the	O	O	O
processing	O	O	B-Entity
of	O	O	O
a	O	O	O
concentrate	O	O	B-Entity
or	O	O	O
other	O	O	O
mineral	O	O	B-Entity
product	O	O	B-Entity
.	O	O	O

One	O	O	O
example	O	O	B-Entity
of	O	O	O
this	O	O	O
complex	O	O	B-Entity
situation	O	O	O
is	O	O	O
the	O	O	O
significant	O	O	B-Entity
economic	O	O	B-Entity
and	O	O	O
environmental	O	O	B-Entity
costs	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
diluting	O	O	B-Entity
and	O	O	O
processing	O	O	B-Entity
copper	O	O	B-Entity
concentrates	O	O	B-Entity
containing	O	O	B-Entity
arsenic	O	O	B-Entity
(	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
the	O	O	O
mineral	O	O	B-Entity
enargite	O	O	I-Entity
,	O	O	O
Cu3	O	O	B-Entity
AsS4	O	O	I-Entity
)	O	O	O
in	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
pure	O	O	B-Entity
copper	O	O	O
.	O	O	O

To	O	O	O
overcome	O	O	O
these	O	O	O
separation	O	O	B-Entity
problems	O	O	B-Entity
,	O	O	O
we	O	O	O
have	O	O	O
utilized	O	O	O
phage	O	O	B-Entity
display	O	O	I-Entity
to	O	O	O
identify	O	O	B-Entity
peptides	O	O	B-Entity
that	O	O	O
demonstrate	O	O	O
selective	O	O	B-Entity
recognition	O	O	B-Entity
of	O	O	O
enargite	O	O	B-Entity
and	O	O	O
the	O	O	O
arsenic	O	O	B-Entity
-	O	O	O
free	O	O	B-Entity
copper	O	O	B-Entity
sulfide	O	O	I-Entity
,	O	O	O
chalcopyrite	O	O	B-Entity
.	O	O	O

Screening	O	O	O
of	O	O	O
two	O	O	O
random	O	O	B-Entity
peptide	O	O	B-Entity
phage	O	O	I-Entity
display	O	O	I-Entity
libraries	O	O	I-Entity
resulted	O	O	O
in	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
an	O	O	O
enargite	O	O	B-Entity
-	O	O	O
selective	O	O	B-Entity
peptide	O	O	O
with	O	O	O
the	O	O	O
sequence	O	O	B-Entity
MHKPTVHIKGPT	O	O	I-Entity
and	O	O	O
a	O	O	O
chalcopyrite	O	O	B-Entity
-	O	O	O
selective	O	O	O
peptide	O	O	O
with	O	O	O
the	O	O	O
sequence	O	O	B-Entity
RKKKCKGNCCYTPQ	O	O	I-Entity
.	O	O	O

Mineral	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
selectivity	O	O	B-Entity
was	O	O	O
demonstrated	O	O	O
by	O	O	O
binding	O	O	O
studies	O	O	B-Entity
,	O	O	O
zeta	O	O	B-Entity
potential	O	O	I-Entity
determination	O	O	B-Entity
and	O	O	O
immunochemistry	O	O	B-Entity
.	O	O	O

Peptides	O	O	B-Entity
that	O	O	O
have	O	O	O
the	O	O	O
ability	O	O	B-Entity
to	O	O	O
discriminate	O	O	B-Entity
between	O	O	O
enargite	O	O	B-Entity
and	O	O	O
chalcopyrite	O	O	B-Entity
provide	O	O	O
a	O	O	O
greener	O	O	O
option	O	O	B-Entity
for	O	O	O
the	O	O	O
separation	O	O	B-Entity
of	O	O	O
arsenic	O	O	B-Entity
containing	O	O	B-Entity
contaminants	O	O	B-Entity
from	O	O	O
copper	O	O	B-Entity
concentrates	O	O	B-Entity
.	O	O	O

This	O	O	O
represents	O	O	O
the	O	O	O
first	O	O	O
step	O	O	O
towards	O	O	O
a	O	O	O
major	O	O	B-Entity
advance	O	O	B-Entity
in	O	O	O
the	O	O	O
replacement	O	O	B-Entity
or	O	O	O
reduction	O	O	B-Entity
of	O	O	O
toxic	O	O	B-Entity
collectors	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
reducing	O	O	B-Entity
the	O	O	O
level	O	O	B-Entity
of	O	O	O
arsenic	O	O	B-Entity
-	O	O	O
bearing	O	O	B-Entity
minerals	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
mineral	O	O	B-Entity
processing	O	O	B-Entity
.	O	O	O

Biotechnol	O	O	O
.	O	O	O

Bioeng	O	O	O
.	O	O	O

2016;9999	O	O	O
:	O	O	O
1	O	O	O
-	O	O	O
8	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O

-DOCSTART- (27861771)

High-density	O	O	B-Entity
lipoprotein	O	O	I-Entity
-associated	O	O	O
sphingosine-1-phosphate	O	O	B-Entity
activity	O	O	O
in	O	O	O
heterozygous	O	O	O
familial	O	O	O
hypercholesterolaemia	O	O	O

Patients	O	O	B-Entity
with	O	O	O
heterozygous	O	O	B-Entity
familial	O	O	I-Entity
hypercholesterolaemia	O	O	I-Entity
(	O	O	O
FH	O	O	B-Entity
)	O	O	O
suffer	O	O	B-Entity
from	O	O	O
high	O	O	B-Entity
plasma	O	O	I-Entity
cholesterol	O	O	I-Entity
and	O	O	O
an	O	O	O
environment	O	O	B-Entity
of	O	O	O
increased	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
its	O	O	O
potential	O	O	O
effects	O	O	O
on	O	O	O
high-density	O	O	B-Entity
lipoprotein	O	O	I-Entity
(HDL)-associated	O	O	O
sphingosine-1-phosphate	O	O	B-Entity
(	O	O	O
S1P	O	O	B-Entity
)	O	O	O
content	O	O	O
(	O	O	O
HDL	O	O	B-Entity
-	O	O	O
S1P	O	O	O
)	O	O	O
and	O	O	O
HDL	O	O	O
-mediated	O	O	O
protection	O	O	B-Entity
against	O	O	I-Entity
oxidative	O	O	I-Entity
stress	O	O	I-Entity
,	O	O	O
both	O	O	O
with	O	O	O
and	O	O	O
without	O	O	O
statin	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
case-control	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
HDL	O	O	B-Entity
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
12	O	O	O
FH	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
statin	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
from	O	O	O
12	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

The	O	O	O
HDL	O	O	B-Entity
-	O	O	O
S1P	O	O	B-Entity
content	O	O	O
and	O	O	O
the	O	O	O
capacity	O	O	O
of	O	O	O
HDL	O	O	O
to	O	O	O
protect	O	O	B-Entity
cardiomyocytes	O	O	B-Entity
against	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
were	O	O	O
measured	O	O	O
.	O	O	O

HDL	O	O	B-Entity
-associated	O	O	O
S1P	O	O	B-Entity
was	O	O	O
significantly	O	O	O
correlated	O	O	O
with	O	O	O
cell	O	O	B-Entity
protection	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
with	O	O	O
HDL-cholesterol	O	O	B-Entity
or	O	O	O
apolipoprotein	O	O	B-Entity
AI	O	O	I-Entity
.	O	O	O

The	O	O	O
latter	O	O	O
did	O	O	O
not	O	O	O
correlate	O	O	O
with	O	O	O
HDL	O	O	B-Entity
-mediated	O	O	O
cell	O	O	B-Entity
protection	O	O	I-Entity
.	O	O	O

Neither	O	O	O
the	O	O	O
HDL	O	O	B-Entity
-	O	O	O
S1P	O	O	B-Entity
content	O	O	O
nor	O	O	O
HDL	O	O	O
protective	O	O	O
capacity	O	O	O
differed	O	O	O
between	O	O	O
nontreated	O	O	O
FH	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
controls	O	O	O
.	O	O	O

The	O	O	O
relative	O	O	O
amounts	O	O	O
of	O	O	O
apolipoprotein	O	O	B-Entity
AI	O	O	I-Entity
and	O	O	O
apolipoprotein	O	O	B-Entity
M	O	O	I-Entity
were	O	O	O
similar	O	O	O
between	O	O	O
controls	O	O	O
and	O	O	O
FH	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Statin	O	O	B-Entity
treatment	O	O	I-Entity
had	O	O	O
no	O	O	O
effect	O	O	O
on	O	O	O
any	O	O	O
of	O	O	O
these	O	O	O
measures	O	O	O
.	O	O	O

The	O	O	O
FH	O	O	B-Entity
environment	O	O	B-Entity
is	O	O	O
not	O	O	O
detrimental	O	O	O
to	O	O	O
HDL	O	O	B-Entity
-	O	O	O
S1P	O	O	B-Entity
content	O	O	O
or	O	O	O
HDL	O	O	O
-	O	O	O
S1P	O	O	O
-mediated	O	O	O
cell	O	O	B-Entity
protection	O	O	I-Entity
.	O	O	O

Statin	O	O	B-Entity
treatment	O	O	I-Entity
does	O	O	O
not	O	O	O
modulate	O	O	O
HDL	O	O	B-Entity
function	O	O	O
in	O	O	O
this	O	O	O
regard	O	O	O
.	O	O	O

-DOCSTART- (27863736)

Moberg	O	O	B-Entity
Picking-Up	O	O	I-Entity
Test	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
hand	O	O	O
osteoarthritis	O	O	O

Clinical	O	O	B-Entity
measurement	O	O	I-Entity
.	O	O	O

The	O	O	O
Moberg	O	O	B-Entity
Pick-up	O	O	I-Entity
Test	O	O	I-Entity
(	O	O	O
MPUT	O	O	B-Entity
)	O	O	O
was	O	O	O
previously	O	O	O
used	O	O	O
to	O	O	O
evaluate	O	O	O
functional	O	O	B-Entity
performance	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
hand	O	O	B-Entity
inflammatory	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	O
using	O	O	O
the	O	O	O
MPUT	O	O	B-Entity
in	O	O	O
hand	O	O	B-Entity
osteoarthritis	O	O	I-Entity
(	O	O	O
OA	O	O	B-Entity
)	O	O	O
.	O	O	O

Compare	O	O	O
the	O	O	O
functional	O	O	B-Entity
performance	O	O	I-Entity
(	O	O	O
MPUT	O	O	B-Entity
)	O	O	O
in	O	O	O
hand	O	O	B-Entity
OA	O	O	I-Entity
patients	O	O	B-Entity
and	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Fifty	O	O	O
hand	O	O	B-Entity
OA	O	O	I-Entity
patients	O	O	B-Entity
and	O	O	O
50	O	O	O
controls	O	O	B-Entity
were	O	O	O
assessed	O	O	O
using	O	O	O
the	O	O	O
MPUT	O	O	B-Entity
,	O	O	O
AUSCAN	O	O	B-Entity
and	O	O	O
Cochin	O	O	B-Entity
questionnaires	O	O	I-Entity
,	O	O	O
grip	O	O	B-Entity
and	O	O	O
pinch	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
pain	O	O	B-Entity
using	O	O	O
a	O	O	O
visual	O	O	B-Entity
analog	O	O	I-Entity
scale	O	O	I-Entity
and	O	O	O
a	O	O	O
Likert	O	O	B-Entity
scale	O	O	I-Entity
regarding	O	O	O
difficulty	O	O	O
to	O	O	O
perform	O	O	O
MPUT	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
MPUT	O	O	B-Entity
evaluation	O	O	B-Entity
,	O	O	O
the	O	O	O
OA	O	O	B-Entity
group	O	O	O
presented	O	O	O
a	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	O
from	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
OA	O	O	B-Entity
group	O	O	O
spent	O	O	O
more	O	O	B-Entity
time	O	O	B-Entity
executing	O	O	O
test	O	O	B-Entity
.	O	O	O

The	O	O	O
grip	O	O	B-Entity
and	O	O	O
pinch	O	O	B-Entity
strength	O	O	I-Entity
measurements	O	O	I-Entity
showed	O	O	O
higher	O	O	O
values	O	O	O
for	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
OA	O	O	B-Entity
group	O	O	O
reported	O	O	O
a	O	O	O
greater	O	O	O
difficulty	O	O	B-Entity
than	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
in	O	O	O
performing	O	O	O
the	O	O	O
test	O	O	B-Entity
.	O	O	O

The	O	O	O
MPUT	O	O	B-Entity
is	O	O	O
a	O	O	O
short	O	O	O
and	O	O	O
easy	O	O	O
to	O	O	O
apply	O	O	O
test	O	O	B-Entity
,	O	O	O
which	O	O	O
can	O	O	O
be	O	O	O
safely	O	O	O
used	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
functional	O	O	B-Entity
performance	O	O	I-Entity
of	O	O	O
the	O	O	O
hand	O	O	B-Entity
OA	O	O	I-Entity
.	O	O	O

II	O	O	O
.	O	O	O

-DOCSTART- (27867770)

Soymilk	O	O	B-Entity
residue	O	O	B-Entity
(	O	O	O
okara	O	O	B-Entity
)	O	O	O
as	O	O	O
a	O	O	O
natural	O	O	B-Entity
immobilization	O	O	B-Entity
carrier	O	O	I-Entity
for	O	O	O
Lactobacillus	O	O	B-Entity
plantarum	O	O	I-Entity
cells	O	O	B-Entity
enhances	O	O	B-Entity
soymilk	O	O	B-Entity
fermentation	O	O	B-Entity
,	O	O	O
glucosidic	O	O	B-Entity
isoflavone	O	O	I-Entity
bioconversion	O	O	B-Entity
,	O	O	O
and	O	O	O
cell	O	O	B-Entity
survival	O	O	I-Entity
under	O	O	O
simulated	O	O	B-Entity
gastric	O	O	I-Entity
and	O	O	O
intestinal	O	O	B-Entity
conditions	O	O	O

Cell	O	O	B-Entity
immobilization	O	O	I-Entity
is	O	O	O
an	O	O	O
alternative	O	O	B-Entity
to	O	O	O
microencapsulation	O	O	B-Entity
for	O	O	O
the	O	O	O
maintenance	O	O	O
of	O	O	O
cells	O	O	B-Entity
in	O	O	O
a	O	O	O
liquid	O	O	B-Entity
medium	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
artificial	O	O	B-Entity
immobilization	O	O	B-Entity
carriers	O	O	I-Entity
are	O	O	O
expensive	O	O	O
and	O	O	O
pose	O	O	O
a	O	O	O
high	O	O	O
safety	O	O	B-Entity
risk	O	O	B-Entity
.	O	O	O

Okara	O	O	B-Entity
,	O	O	O
a	O	O	O
food-grade	O	O	B-Entity
byproduct	O	O	B-Entity
from	O	O	O
soymilk	O	O	B-Entity
production	O	O	B-Entity
,	O	O	O
is	O	O	O
rich	O	O	O
in	O	O	O
prebiotics	O	O	B-Entity
.	O	O	O

Lactobacilli	O	O	B-Entity
could	O	O	O
provide	O	O	O
health	O	O	B-Entity
enhancing	O	O	B-Entity
effects	O	O	B-Entity
to	O	O	O
the	O	O	O
host	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
potential	O	O	O
of	O	O	O
okara	O	O	B-Entity
as	O	O	O
a	O	O	O
natural	O	O	O
immobilizer	O	O	O
for	O	O	O
L.	O	O	B-Entity
plantarum	O	O	I-Entity
70810	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
study	O	O	O
also	O	O	O
aimed	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
okara-immobilized	O	O	B-Entity
L.	O	O	B-Entity
plantarum	O	O	I-Entity
70810	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
IL	O	O	B-Entity
)	O	O	O
on	O	O	O
soymilk	O	O	B-Entity
fermentation	O	O	B-Entity
,	O	O	O
glucosidic	O	O	B-Entity
isoflavone	O	O	I-Entity
bioconversion	O	O	B-Entity
,	O	O	O
and	O	O	O
cell	O	O	B-Entity
resistance	O	O	B-Entity
to	O	O	O
simulated	O	O	B-Entity
gastric	O	O	I-Entity
and	O	O	O
intestinal	O	O	B-Entity
stresses	O	O	B-Entity
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
SEM	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
show	O	O	O
cells	O	O	B-Entity
adherence	O	O	B-Entity
to	O	O	O
the	O	O	O
surface	O	O	B-Entity
of	O	O	O
okara	O	O	B-Entity
.	O	O	O

Lactic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
acetic	O	O	B-Entity
acid	O	O	I-Entity
and	O	O	O
isoflavone	O	O	B-Entity
analyses	O	O	B-Entity
in	O	O	O
unfermented	O	O	O
and	O	O	O
fermented	O	O	B-Entity
soymilk	O	O	B-Entity
were	O	O	O
performed	O	O	B-Entity
by	O	O	O
HPLC	O	O	B-Entity
with	O	O	I-Entity
UV	O	O	I-Entity
detection	O	O	I-Entity
.	O	O	O

Viability	O	O	B-Entity
and	O	O	O
growth	O	O	O
kinetics	O	O	O
of	O	O	O
immobilized	O	O	B-Entity
and	O	O	O
free	O	O	B-Entity
L.	O	O	I-Entity
plantarum	O	O	I-Entity
70810	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
FL	O	O	B-Entity
)	O	O	O
were	O	O	O
followed	O	O	O
during	O	O	O
soymilk	O	O	B-Entity
fermentation	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
changes	O	O	B-Entity
in	O	O	O
pH	O	O	B-Entity
,	O	O	O
titrable	O	O	B-Entity
acidity	O	O	I-Entity
and	O	O	O
viscosity	O	O	B-Entity
were	O	O	O
measured	O	O	B-Entity
by	O	O	O
conventional	O	O	B-Entity
methods	O	O	I-Entity
.	O	O	O

For	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
testing	O	O	B-Entity
of	O	O	O
simulated	O	O	O
gastrointestinal	O	O	B-Entity
resistance	O	O	B-Entity
,	O	O	O
fermented	O	O	B-Entity
soymilk	O	O	B-Entity
was	O	O	O
inoculated	O	O	B-Entity
with	O	O	O
FL	O	O	B-Entity
or	O	O	O
IL	O	O	B-Entity
and	O	O	O
an	O	O	O
aliquot	O	O	B-Entity
incubated	O	O	B-Entity
into	O	O	O
acidic	O	O	B-Entity
MRS	O	O	I-Entity
broth	O	O	I-Entity
which	O	O	O
was	O	O	O
conveniently	O	O	O
prepared	O	O	O
to	O	O	O
simulate	O	O	O
gastric	O	O	B-Entity
,	O	O	O
pancreatic	O	O	B-Entity
juices	O	O	I-Entity
and	O	O	O
bile	O	O	B-Entity
salts	O	O	I-Entity
.	O	O	O

Survival	O	O	O
to	O	O	O
simulated	O	O	B-Entity
gastric	O	O	I-Entity
and	O	O	O
intestinal	O	O	B-Entity
stresses	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
by	O	O	O
plate	O	O	B-Entity
count	O	O	I-Entity
of	O	O	I-Entity
colony	O	O	I-Entity
forming	O	O	I-Entity
units	O	O	I-Entity
on	O	O	O
MRS	O	O	B-Entity
agar	O	O	I-Entity
.	O	O	O

SEM	O	O	B-Entity
revealed	O	O	O
that	O	O	O

the	O	O	O
lactobacilli	O	O	B-Entity
cells	O	O	B-Entity
attached	O	O	B-Entity
and	O	O	O
bound	O	O	O
to	O	O	O
the	O	O	O
surface	O	O	B-Entity
of	O	O	O
okara	O	O	B-Entity
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
FL	O	O	B-Entity
,	O	O	O
IL	O	O	B-Entity
exhibited	O	O	O
a	O	O	O
significantly	O	O	O
higher	O	O	B-Entity
specific	O	O	B-Entity
growth	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
shorter	O	O	B-Entity
lag	O	O	B-Entity
phase	O	O	I-Entity
of	O	O	O
growth	O	O	O
,	O	O	O
higher	O	O	O
productions	O	O	O
of	O	O	O
lactic	O	O	B-Entity
and	O	O	O
acetic	O	O	B-Entity
acids	O	O	I-Entity
,	O	O	O
a	O	O	O
faster	O	O	B-Entity
decrease	O	O	B-Entity
in	O	O	O
pH	O	O	B-Entity
and	O	O	O
increase	O	O	B-Entity
in	O	O	O
titrable	O	O	B-Entity
acidity	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
higher	O	O	O
soymilk	O	O	B-Entity
viscosity	O	O	B-Entity
.	O	O	O

Similarly	O	O	O
,	O	O	O
IL	O	O	B-Entity
in	O	O	O
soymilk	O	O	B-Entity
showed	O	O	O
higher	O	O	O
productions	O	O	O
of	O	O	O
daizein	O	O	B-Entity
and	O	O	O
genistein	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
control	O	O	B-Entity
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
FL	O	O	B-Entity
,	O	O	O
IL	O	O	B-Entity
showed	O	O	O
reinforced	O	O	O
resistance	O	O	O
to	O	O	O
simulatedgastric	O	O	B-Entity
and	O	O	O
intestinal	O	O	B-Entity
stresses	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
that	O	O	O
included	O	O	O
low	O	O	B-Entity
pH	O	O	I-Entity
,	O	O	O
low	O	O	B-Entity
pH	O	O	I-Entity
plus	O	O	I-Entity
pepsin	O	O	B-Entity
,	O	O	O
pancreatin	O	O	B-Entity
,	O	O	O
and	O	O	O
bile	O	O	B-Entity
salt	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
okara	O	O	B-Entity
is	O	O	O
a	O	O	O
new	O	O	O
potential	O	O	O
immobilization	O	O	B-Entity
carrier	O	O	I-Entity
to	O	O	O
enhance	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
and	O	O	O
glucosidic	O	O	B-Entity
isoflavone	O	O	I-Entity
bioconversion	O	O	B-Entity
activities	O	O	B-Entity
of	O	O	O
L.	O	O	B-Entity
plantarum	O	O	I-Entity
in	O	O	O
soymilk	O	O	B-Entity
and	O	O	O
improve	O	O	B-Entity
cell	O	O	B-Entity
survivability	O	O	I-Entity
following	O	O	O
simulated	O	O	B-Entity
gastric	O	O	I-Entity
and	O	O	O
intestinal	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27871600)

Comparison	O	O	O
of	O	O	O
a	O	O	O
new	O	O	O
visual	O	O	B-Entity
stylet	O	O	I-Entity
(Discopo)-guided	O	O	I-Entity
laryngeal	O	O	B-Entity
mask	O	O	I-Entity
airway	O	O	I-Entity
placement	O	O	I-Entity
vs	O	O	O
conventional	O	O	B-Entity
blind	O	O	I-Entity
technique	O	O	I-Entity
:	O	O	O
a	O	O	O
prospective	O	O	O
randomized	O	O	B-Entity
study	O	O	O

To	O	O	O
compare	O	O	O
the	O	O	O
ease	O	O	O
of	O	O	O
laryngeal	O	O	B-Entity
mask	O	O	I-Entity
airway	O	O	I-Entity
(	O	O	I-Entity
LMA	O	O	B-Entity
)	O	O	I-Entity
insertion	O	O	I-Entity
and	O	O	O
fiberoptic	O	O	B-Entity
view	O	O	I-Entity
of	O	O	O
LMA	O	O	O
after	O	O	O
placement	O	O	B-Entity
using	O	O	O
the	O	O	O
Discopo	O	O	B-Entity
visual	O	O	I-Entity
stylet-guided	O	O	I-Entity
insertion	O	O	I-Entity
and	O	O	O
conventional	O	O	B-Entity
blind	O	O	I-Entity
technique	O	O	I-Entity
.	O	O	O

Prospective	O	O	O
,	O	O	O
randomized	O	O	B-Entity
controlled	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Operating	O	O	B-Entity
room	O	O	I-Entity
in	O	O	O
a	O	O	O
university	O	O	B-Entity
hospital	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
scheduled	O	O	O
for	O	O	O
elective	O	O	B-Entity
surgery	O	O	I-Entity
under	O	O	O
LMA	O	O	B-Entity
general	O	O	B-Entity
anesthesia	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
allocated	O	O	O
to	O	O	O
2	O	O	O
groups	O	O	B-Entity
:	O	O	O
GLMA	O	O	B-Entity
group	O	O	I-Entity
using	O	O	O
a	O	O	O
visual	O	O	B-Entity
stylet-guided	O	O	I-Entity
technique	O	O	I-Entity
(	O	O	O
n=50	O	O	O
)	O	O	O
and	O	O	O
BLMA	O	O	B-Entity
group	O	O	I-Entity
using	O	O	O
standard	O	O	O
blind	O	O	B-Entity
technique	O	O	I-Entity
(	O	O	O
n=50	O	O	O
)	O	O	O
.	O	O	O

Correct	O	O	O
placement	O	O	B-Entity
of	O	O	O
the	O	O	O
LMA	O	O	B-Entity
was	O	O	O
confirmed	O	O	O
using	O	O	O
clinical	O	O	B-Entity
test	O	O	I-Entity
along	O	O	O
with	O	O	O
fiberoptic	O	O	B-Entity
assessment	O	O	B-Entity
.	O	O	O

Unblinded	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
collected	O	O	O
about	O	O	O
the	O	O	O
insertion	O	O	B-Entity
time	O	O	O
,	O	O	O
the	O	O	O
first	O	O	O
attempt	O	O	O
success	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
the	O	O	O
LMA	O	O	B-Entity
position	O	O	B-Entity
adjustment	O	O	O
rate	O	O	O
,	O	O	O
fiberoptic	O	O	B-Entity
view	O	O	I-Entity
of	O	O	O
LMA	O	O	O
anatomical	O	O	B-Entity
position	O	O	I-Entity
,	O	O	O
hemodynamic	O	O	B-Entity
responses	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
adverse	O	O	B-Entity
insertion	O	O	O
responses	O	O	O
(	O	O	O
bucking	O	O	B-Entity
,	O	O	O
breathholding	O	O	B-Entity
,	O	O	O
and	O	O	O
laryngospasm	O	O	B-Entity
)	O	O	O
.	O	O	O

Blinded	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
recorded	O	O	O
about	O	O	O
postoperative	O	O	B-Entity
airway	O	O	B-Entity
morbidity	O	O	I-Entity
(	O	O	O
visible	O	O	O
blood	O	O	B-Entity
staining	O	O	I-Entity
on	O	O	O
LMA	O	O	B-Entity
at	O	O	O
removal	O	O	O
,	O	O	O
sore	O	O	B-Entity
throat	O	O	I-Entity
,	O	O	O
and	O	O	O
hoarseness	O	O	B-Entity
)	O	O	O
.	O	O	O

Insertion	O	O	B-Entity
was	O	O	O
more	O	O	O
frequently	O	O	O
successful	O	O	O
at	O	O	O
the	O	O	O
first	O	O	O
attempt	O	O	O
in	O	O	O
GLMA	O	O	B-Entity
than	O	O	O
that	O	O	O
in	O	O	O
BLMA	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
100	O	O	O
%	O	O	O
vs	O	O	O
92	O	O	O
%	O	O	O
;	O	O	O
P=.041	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
time	O	O	O
taken	O	O	O
for	O	O	O
establishing	O	O	O
effective	O	O	O
airway	O	O	O
was	O	O	O
shorter	O	O	O
in	O	O	O
GLMA	O	O	B-Entity
than	O	O	O
that	O	O	O
in	O	O	O
BLMA	O	O	B-Entity
(	O	O	O
54.8	O	O	O
vs	O	O	O
62.9	O	O	O
seconds	O	O	O
;	O	O	O
P=.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
in	O	O	O
BLMA	O	O	B-Entity
group	O	O	I-Entity
required	O	O	O
more	O	O	O
readjustment	O	O	O
and	O	O	O
reinsertion	O	O	B-Entity
than	O	O	O
those	O	O	O
in	O	O	O
GLMA	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
38	O	O	O
%	O	O	O
vs	O	O	O
0	O	O	O
%	O	O	O
;	O	O	O
P=.000	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
fiberoptic	O	O	B-Entity
view	O	O	I-Entity
was	O	O	O
significantly	O	O	O
better	O	O	O
in	O	O	O
GLMA	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
P<.001	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
difference	O	O	O
between	O	O	O
the	O	O	O
2	O	O	O
groups	O	O	B-Entity
existed	O	O	O
regarding	O	O	O
hemodynamic	O	O	B-Entity
stress	O	O	I-Entity
responses	O	O	I-Entity
,	O	O	O
incidences	O	O	B-Entity
of	O	O	O
adverse	O	O	B-Entity
insertion	O	O	B-Entity
responses	O	O	O
,	O	O	O
and	O	O	O
postoperative	O	O	B-Entity
airway	O	O	B-Entity
morbidity	O	O	I-Entity
.	O	O	O

By	O	O	O
direct	O	O	O
visualizing	O	O	O
the	O	O	O
whole	O	O	O
process	O	O	O
of	O	O	O
LMA	O	O	B-Entity
insertion	O	O	B-Entity
,	O	O	O
the	O	O	O
Discopo	O	O	B-Entity
visual	O	O	I-Entity
stylet	O	O	I-Entity
increases	O	O	O
the	O	O	O
success	O	O	B-Entity
rate	O	O	I-Entity
and	O	O	O
accuracy	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
LMA	O	O	O
placement	O	O	B-Entity
without	O	O	O
increasing	O	O	O
hemodynamic	O	O	B-Entity
stress	O	O	I-Entity
response	O	O	I-Entity
or	O	O	O
incidences	O	O	B-Entity
of	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

-DOCSTART- (27871881)

Targeting	O	O	B-Entity
brain	O	O	B-Entity
and	O	O	O
peripheral	O	O	B-Entity
plasticity	O	O	I-Entity
of	O	O	O
the	O	O	O
lipidome	O	O	B-Entity
in	O	O	O
acute	O	O	B-Entity
kainic	O	O	B-Entity
acid	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
epileptic	O	O	B-Entity
seizures	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
via	O	O	O
quantitative	O	O	O
mass	O	O	O
spectrometry	O	O	O

Epilepsy	O	O	B-Entity
is	O	O	O
a	O	O	O
highly	O	O	O
common	O	O	O
chronic	O	O	B-Entity
neurological	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
manifested	O	O	B-Entity
in	O	O	O
many	O	O	O
different	O	O	O
types	O	O	B-Entity
,	O	O	O
affecting	O	O	O
~1	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
worldwide	O	O	O
human	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

The	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	I-Entity
of	O	O	O
epileptogenesis	O	O	B-Entity
have	O	O	O
not	O	O	O
yet	O	O	O
been	O	O	O
clarified	O	O	O
,	O	O	O
and	O	O	O
pharmacoresistance	O	O	B-Entity
exhibited	O	O	O
by	O	O	O
30	O	O	O
-	O	O	O
40	O	O	O
%	O	O	O
of	O	O	O
epilepsy	O	O	B-Entity
patients	O	O	B-Entity
remains	O	O	O
a	O	O	O
major	O	O	O
obstacle	O	O	O
in	O	O	O
medical	O	O	B-Entity
care	O	O	B-Entity
.	O	O	O

Growing	O	O	O
evidence	O	O	B-Entity
indicates	O	O	O
a	O	O	O
role	O	O	O
of	O	O	O
lipid	O	O	B-Entity
signalling	O	O	B-Entity
pathways	O	O	I-Entity
in	O	O	O
epileptogenesis	O	O	B-Entity
,	O	O	O
thus	O	O	O
lipid	O	O	O
signals	O	O	B-Entity
emerge	O	O	O
as	O	O	O
potential	O	O	B-Entity
biomarkers	O	O	B-Entity
for	O	O	O
the	O	O	O
onset	O	O	O
and	O	O	O
evolving	O	O	O
course	O	O	O
of	O	O	O
the	O	O	O
epileptic	O	O	B-Entity
disorder	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
potential	O	O	O
therapeutic	O	O	B-Entity
agents	O	O	I-Entity
and	O	O	O
targets	O	O	B-Entity
.	O	O	O

For	O	O	O
this	O	O	O
purpose	O	O	O
,	O	O	O
we	O	O	O
applied	O	O	O
a	O	O	O
lipidomic	O	O	B-Entity
strategy	O	O	B-Entity
to	O	O	O
unravel	O	O	O
lipid	O	O	B-Entity
alterations	O	O	O
in	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
,	O	O	O
periphery	O	O	B-Entity
tissues	O	O	I-Entity
and	O	O	O
plasma	O	O	B-Entity
that	O	O	O
are	O	O	O
specific	O	O	B-Entity
for	O	O	O
acute	O	O	B-Entity
epileptic	O	O	B-Entity
seizures	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
at	O	O	O
1h	O	O	O
after	O	O	O
seizure	O	O	B-Entity
induction	O	O	B-Entity
by	O	O	O
systemic	O	O	B-Entity
kainic	O	O	B-Entity
acid	O	O	I-Entity
injection	O	O	B-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
vehicle	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
levels	O	O	B-Entity
of	O	O	O
(	O	O	O
i	O	O	O
)	O	O	O
selected	O	O	O
phospholipids	O	O	B-Entity
and	O	O	O
sphingomyelins	O	O	B-Entity
,	O	O	O
(	O	O	O
ii	O	O	O
)	O	O	O
the	O	O	O
endocannabinoids	O	O	B-Entity
anandamide	O	O	B-Entity
(	O	O	O
AEA	O	O	B-Entity
)	O	O	O
and	O	O	O
2-arachidonoyl	O	O	B-Entity
glycerol	O	O	I-Entity
(	O	O	O
2-AG	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
endocannabinoid	O	O	B-Entity
-related	O	O	O
compounds	O	O	B-Entity
oleoylethanolamide	O	O	B-Entity
(	O	O	O
OEA	O	O	B-Entity
)	O	O	O
and	O	O	O
palmitoylethanolamide	O	O	B-Entity
(	O	O	O
PEA	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
iii	O	O	O
)	O	O	O
arachidonic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
AA	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
iv	O	O	O
)	O	O	O
selected	O	O	O
eicosanoids	O	O	B-Entity
,	O	O	O
and	O	O	O
(	O	O	O
v	O	O	O
)	O	O	O
fatty	O	O	B-Entity
acyl	O	O	I-Entity
content	O	O	O
of	O	O	O
lipidome	O	O	B-Entity
were	O	O	O
determined	O	O	O
in	O	O	O
pulverized	O	O	B-Entity
tissues	O	O	B-Entity
from	O	O	O
six	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
of	O	O	O
kainic	O	O	B-Entity
acid	O	O	I-Entity
induced	O	O	B-Entity
epileptic	O	O	B-Entity
seizure	O	O	I-Entity
models	O	O	B-Entity
and	O	O	O
vehicle	O	O	B-Entity
controls	O	O	I-Entity
:	O	O	O
hypothalamus	O	O	B-Entity
,	O	O	O
hippocampus	O	O	B-Entity
,	O	O	O
thalamus	O	O	B-Entity
,	O	O	O
striatum	O	O	B-Entity
,	O	O	O
cerebellum	O	O	B-Entity
and	O	O	O
cerebral	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
and	O	O	O
from	O	O	O
peripheral	O	O	B-Entity
organs	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
heart	O	O	B-Entity
and	O	O	O
lungs	O	O	B-Entity
,	O	O	O
and	O	O	O
in	O	O	O
plasma	O	O	B-Entity
.	O	O	O

Alterations	O	O	O
in	O	O	O
lipid	O	O	B-Entity
levels	O	O	O
after	O	O	O
acute	O	O	B-Entity
epileptic	O	O	B-Entity
seizures	O	O	I-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
non-seizure	O	O	B-Entity
controls	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
brain	O	O	B-Entity
region	O	O	I-Entity
-	O	O	O
and	O	O	O
periphery	O	O	B-Entity
tissue	O	O	I-Entity
-	O	O	O
specific	O	O	B-Entity
,	O	O	O
including	O	O	O
specific	O	O	O
plasma	O	O	B-Entity
lipid	O	O	O
correlates	O	O	O
,	O	O	O
highlighting	O	O	O
their	O	O	O
value	O	O	O
as	O	O	O
marker	O	O	B-Entity
candidates	O	O	I-Entity
in	O	O	O
translational	O	O	O
research	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
and/or	O	O	O
drug	O	O	B-Entity
discovery	O	O	I-Entity
and	O	O	O
response	O	O	B-Entity
monitoring	O	O	I-Entity
.	O	O	O

-DOCSTART- (27872609)

Panitumumab	O	O	B-Entity
-Associated	O	O	O
Encephalopathy	O	O	B-Entity
after	O	O	O
Accidental	O	O	O
Intra-arterial	O	O	B-Entity
Application	O	O	B-Entity
through	O	O	O
Dislocated	O	O	O
Central	O	O	O
Venous	O	O	O
Access	O	O	O
Device	O	O	O

Acute	O	O	B-Entity
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
CNS	O	O	B-Entity
)	O	O	O
toxicity	O	O	B-Entity
and	O	O	O
immune	O	O	B-Entity
-related	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
are	O	O	O
increasingly	O	O	O
recognized	O	O	O
with	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
monoclonal	O	O	B-Entity
antibodies	O	O	I-Entity
for	O	O	O
cancer	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
patient	O	O	B-Entity
who	O	O	O
developed	O	O	O
of	O	O	O
acute-onset	O	O	B-Entity
encephalopathy	O	O	I-Entity
and	O	O	O
coma	O	O	B-Entity
,	O	O	O
which	O	O	O
began	O	O	O
shortly	O	O	O
after	O	O	O
administration	O	O	B-Entity
of	O	O	O
panitumumab	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
metastatic	O	O	B-Entity
colorectal	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

Echocardiography	O	O	B-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
drug	O	O	B-Entity
had	O	O	O
been	O	O	O
infused	O	O	O
into	O	O	O
the	O	O	O
left	O	O	B-Entity
cardiac	O	O	I-Entity
ventricle	O	O	I-Entity
via	O	O	O
a	O	O	O
dislocated	O	O	B-Entity
central	O	O	I-Entity
venous	O	O	I-Entity
line	O	O	I-Entity
.	O	O	O

Diffusion-weighted	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
disclosed	O	O	O
multiple	O	O	O
cortical	O	O	B-Entity
hyperintensities	O	O	I-Entity
,	O	O	O
which	O	O	O
were	O	O	O
preferentially	O	O	O
located	O	O	O
in	O	O	O
the	O	O	O
frontal	O	O	B-Entity
lobes	O	O	I-Entity
.	O	O	O

While	O	O	O
the	O	O	O
neurological	O	O	B-Entity
condition	O	O	I-Entity
improved	O	O	O
within	O	O	O
a	O	O	O
few	O	O	O
days	O	O	B-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
died	O	O	B-Entity
4	O	O	O
weeks	O	O	B-Entity
later	O	O	O
.	O	O	O

It	O	O	O
seems	O	O	O
likely	O	O	O
that	O	O	O
the	O	O	O
administration	O	O	B-Entity
of	O	O	O
the	O	O	O
antibody	O	O	B-Entity
via	O	O	O
the	O	O	O
intra-arterial	O	O	B-Entity
route	O	O	I-Entity
contributed	O	O	O
to	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
this	O	O	O
condition	O	O	B-Entity
.	O	O	O

Toxic	O	O	B-Entity
encephalopathy	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
hitherto	O	O	B-Entity
unrecognized	O	O	O
complication	O	O	B-Entity
of	O	O	O
panitumumab	O	O	B-Entity
treatment	O	O	B-Entity
and	O	O	O
should	O	O	O
be	O	O	O
taken	O	O	O
into	O	O	O
consideration	O	O	O
in	O	O	O
patients	O	O	B-Entity
developing	O	O	O
CNS	O	O	B-Entity
symptoms	O	O	B-Entity
undergoing	O	O	O
this	O	O	O
therapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (27874309)

Abundance	O	O	B-Entity
and	O	O	O
Characterization	O	O	B-Entity
of	O	O	O
Perfect	O	O	O
Microsatellites	O	O	B-Entity
on	O	O	O
the	O	O	O
Cattle	O	O	B-Entity
Y	O	O	O
Chromosome	O	O	O

Microsatellites	O	O	B-Entity
or	O	O	O
simple	O	O	B-Entity
sequence	O	O	I-Entity
repeats	O	O	I-Entity
(	O	O	O
SSRs	O	O	B-Entity
)	O	O	O
are	O	O	O
found	O	O	O
in	O	O	O
most	O	O	O
organisms	O	O	B-Entity
and	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
genomic	O	O	B-Entity
organization	O	O	I-Entity
and	O	O	O
function	O	O	B-Entity
.	O	O	O

To	O	O	O
characterize	O	O	B-Entity
the	O	O	O
abundance	O	O	B-Entity
of	O	O	O
SSRs	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
6	O	O	O
base-pairs	O	O	B-Entity
[	O	O	O
bp	O	O	B-Entity
]	O	O	O
)	O	O	O
on	O	O	O
the	O	O	O
cattle	O	O	B-Entity
Y	O	O	B-Entity
chromsome	O	O	I-Entity
,	O	O	O
the	O	O	O
relative	O	O	O
frequency	O	O	B-Entity
and	O	O	O
density	O	O	B-Entity
of	O	O	O
perfect	O	O	O
or	O	O	O
uninterrupted	O	O	O
SSRs	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
published	O	O	O
Y	O	O	B-Entity
chromosome	O	O	I-Entity
sequence	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
17,273	O	O	O
perfect	O	O	O
SSRs	O	O	B-Entity
were	O	O	O
found	O	O	O
,	O	O	O
with	O	O	O
total	O	O	O
length	O	O	B-Entity
of	O	O	O
324.78	O	O	O
kb	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
approximately	O	O	O
0.75	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
cattle	O	O	B-Entity
Y	O	O	B-Entity
chromosome	O	O	I-Entity
sequence	O	O	B-Entity
(	O	O	O
43.30	O	O	O
Mb	O	O	O
)	O	O	O
comprises	O	O	O
perfect	O	O	O
SSRs	O	O	O
,	O	O	O
with	O	O	O
an	O	O	O
average	O	O	O
length	O	O	O
of	O	O	O
18.80	O	O	O
bp	O	O	B-Entity
.	O	O	O

The	O	O	O
relative	O	O	O
frequency	O	O	B-Entity
and	O	O	O
density	O	O	B-Entity
were	O	O	O
398.92	O	O	O
loci/Mb	O	O	O
and	O	O	O
7500.62	O	O	O
bp	O	O	B-Entity
/Mb	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
proportions	O	O	O
of	O	O	O
the	O	O	O
six	O	O	O
classes	O	O	O
of	O	O	O
perfect	O	O	O
SSRs	O	O	B-Entity
were	O	O	O
highly	O	O	O
variable	O	O	O
on	O	O	O
the	O	O	O
cattle	O	O	B-Entity
Y	O	O	B-Entity
chromosome	O	O	I-Entity
.	O	O	O

Mononucleotide	O	O	B-Entity
repeats	O	O	I-Entity
had	O	O	O
a	O	O	O
total	O	O	O
number	O	O	O
of	O	O	O
8073	O	O	O
(	O	O	O
46.74	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
an	O	O	O
average	O	O	O
length	O	O	B-Entity
of	O	O	O
15.45	O	O	O
bp	O	O	B-Entity
,	O	O	O
and	O	O	O
were	O	O	O
the	O	O	O
most	O	O	O
abundant	O	O	O
SSRs	O	O	B-Entity
class	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
percentages	O	O	O
of	O	O	O
di-	O	O	B-Entity
,	O	O	O
tetra-	O	O	B-Entity
,	O	O	O
tri-	O	O	B-Entity
,	O	O	O
penta-	O	O	B-Entity
,	O	O	O
and	O	O	O
hexa-nucleotide	O	O	B-Entity
repeats	O	O	I-Entity
were	O	O	O
22.86	O	O	O
%	O	O	O
,	O	O	O
11.98	O	O	O
%	O	O	O
,	O	O	O
11.58	O	O	O
%	O	O	O
,	O	O	O
6.65	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
0.19	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Different	O	O	O
classes	O	O	O
of	O	O	O
SSRs	O	O	B-Entity
varied	O	O	O
in	O	O	O
their	O	O	O
repeat	O	O	O
number	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
highest	O	O	O
being	O	O	O
42	O	O	O
for	O	O	O
dinucleotides	O	O	B-Entity
.	O	O	O

Results	O	O	O
reveal	O	O	O
that	O	O	O
repeat	O	O	O
categories	O	O	O
A	O	O	B-Entity
,	O	O	O
AC	O	O	B-Entity
,	O	O	O
AT	O	O	B-Entity
,	O	O	O
AAC	O	O	B-Entity
,	O	O	O
AGC	O	O	B-Entity
,	O	O	O
GTTT	O	O	B-Entity
,	O	O	O
CTTT	O	O	B-Entity
,	O	O	O
ATTT	O	O	B-Entity
,	O	O	O
and	O	O	O
AACTG	O	O	B-Entity
predominate	O	O	O
on	O	O	O
the	O	O	O
Y	O	O	B-Entity
chromosome	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
provides	O	O	O
insight	O	O	O
into	O	O	O
the	O	O	O
organization	O	O	O
of	O	O	O
cattle	O	O	B-Entity
Y	O	O	B-Entity
chromosome	O	O	I-Entity
repetitive	O	O	O
DNA	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
information	O	O	O
useful	O	O	O
for	O	O	O
developing	O	O	O
more	O	O	O
polymorphic	O	O	B-Entity
cattle	O	O	O
Y-chromosome	O	O	B-Entity
-specific	O	O	O
SSRs	O	O	B-Entity
.	O	O	O

-DOCSTART- (27875058)

Antenatal	O	O	B-Entity
Stressful	O	O	B-Entity
Life	O	O	I-Entity
Events	O	O	I-Entity
and	O	O	O
Postpartum	O	O	B-Entity
Depressive	O	O	B-Entity
Symptoms	O	O	I-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
:	O	O	O
The	O	O	O
Role	O	O	O
of	O	O	O
Women	O	O	B-Entity
's	O	O	I-Entity
Socioeconomic	O	O	B-Entity
Status	O	O	I-Entity
Indices	O	O	B-Entity
at	O	O	O
the	O	O	O
State	O	O	O
Level	O	O	O

Approximately	O	O	O
10%-20	O	O	O
%	O	O	O
of	O	O	O
women	O	O	B-Entity
suffer	O	O	B-Entity
from	O	O	O
postpartum	O	O	B-Entity
depression	O	O	I-Entity
(	O	O	O
PPD	O	O	B-Entity
)	O	O	O
,	O	O	O
important	O	O	O
predictors	O	O	B-Entity
of	O	O	O
which	O	O	O
are	O	O	O
antenatal	O	O	B-Entity
stressful	O	O	B-Entity
life	O	O	I-Entity
event	O	O	I-Entity
(	O	O	O
SLE	O	O	B-Entity
)	O	O	O
experiences	O	O	B-Entity
.	O	O	O

The	O	O	O
association	O	O	B-Entity
between	O	O	O
women	O	O	B-Entity
's	O	O	I-Entity
state-level	O	O	B-Entity
socioeconomic	O	O	B-Entity
status	O	O	I-Entity
(	O	O	O
SES	O	O	B-Entity
)	O	O	O
and	O	O	O
PPD	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
explored	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
examine	O	O	O
whether	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
antenatal	O	O	B-Entity
SLE	O	O	B-Entity
and	O	O	O
PPD	O	O	B-Entity
symptoms	O	O	B-Entity
was	O	O	O
moderated	O	O	B-Entity
by	O	O	O
women	O	O	B-Entity
's	O	O	I-Entity
state-level	O	O	B-Entity
SES	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
the	O	O	O
2009	O	O	O
-	O	O	O
2011	O	O	O
Pregnancy	O	O	B-Entity
Risk	O	O	I-Entity
Assessment	O	O	I-Entity
Monitoring	O	O	I-Entity
System	O	O	I-Entity
(	O	O	O
PRAMS	O	O	B-Entity
)	O	O	O
were	O	O	O
used	O	O	O
.	O	O	O

State-level	O	O	B-Entity
women	O	O	B-Entity
's	O	O	I-Entity
employment	O	O	B-Entity
/	O	O	O
earnings	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
/	O	O	O
economic	O	O	B-Entity
autonomy	O	O	B-Entity
indices	O	O	B-Entity
were	O	O	O
computed	O	O	O
from	O	O	O
indicators	O	O	B-Entity
published	O	O	O
by	O	O	O
the	O	O	O
Institute	O	O	B-Entity
of	O	O	I-Entity
Women	O	O	I-Entity
's	O	O	I-Entity
Policy	O	O	I-Entity
Research	O	O	I-Entity
(	O	O	O
IWPR	O	O	B-Entity
)	O	O	O
.	O	O	O

Multilevel	O	O	B-Entity
multivariable	O	O	I-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
were	O	O	O
performed	O	O	O
.	O	O	O

Among	O	O	O
91,253	O	O	O
women	O	O	B-Entity
with	O	O	O
valid	O	O	B-Entity
responses	O	O	B-Entity
,	O	O	O
11.3	O	O	O
%	O	O	O
had	O	O	O
PPD	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
prevalence	O	O	B-Entity
ranging	O	O	O
from	O	O	O
7.1	O	O	O
%	O	O	O
in	O	O	O
Illinois	O	O	B-Entity
to	O	O	O
17.1	O	O	O
%	O	O	O
in	O	O	O
Arkansas	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
who	O	O	O
experienced	O	O	O
all	O	O	O
four	O	O	O
stressor	O	O	B-Entity
categories	O	O	B-Entity
,	O	O	O
including	O	O	O
partner	O	O	B-Entity
related	O	O	B-Entity
,	O	O	O
traumatic	O	O	B-Entity
,	O	O	O
emotional	O	O	B-Entity
,	O	O	O
and	O	O	O
financial	O	O	B-Entity
,	O	O	O
had	O	O	O
the	O	O	O
highest	O	O	O
odds	O	O	B-Entity
(	O	O	O
adjusted	O	O	B-Entity
odds	O	O	I-Entity
ratio	O	O	I-Entity
[	O	O	O
aOR	O	O	B-Entity
]	O	O	O
:	O	O	O
5.43	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
[	O	O	O
CI	O	O	B-Entity
]	O	O	O
:	O	O	O
5.36	O	O	O
-	O	O	O
5.51	O	O	O
)	O	O	O
of	O	O	O
PPD	O	O	B-Entity
symptoms	O	O	B-Entity
.	O	O	O

The	O	O	O
odds	O	O	B-Entity
of	O	O	O
experiencing	O	O	O
PPD	O	O	B-Entity
symptoms	O	O	B-Entity
decreased	O	O	B-Entity
with	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
state-level	O	O	B-Entity
social	O	O	B-Entity
/	O	O	O
economic	O	O	B-Entity
autonomy	O	O	B-Entity
index	O	O	B-Entity
(	O	O	O
aOR	O	O	B-Entity
:	O	O	O
0.75	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.64	O	O	O
-	O	O	O
0.88	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
significant	O	O	O
cross-level	O	O	B-Entity
interaction	O	O	I-Entity
between	O	O	O
number	O	O	O
of	O	O	O
stressor	O	O	B-Entity
categories	O	O	B-Entity
experienced	O	O	O
and	O	O	O
state-level	O	O	B-Entity
index	O	O	B-Entity
.	O	O	O

Screening	O	O	B-Entity
for	O	O	O
antenatal	O	O	B-Entity
SLEs	O	O	B-Entity
can	O	O	O
help	O	O	O
identify	O	O	O
women	O	O	B-Entity
at	O	O	B-Entity
risk	O	O	I-Entity
for	O	O	O
PPD	O	O	B-Entity
symptoms	O	O	B-Entity
.	O	O	O

That	O	O	O
the	O	O	O
odds	O	O	B-Entity
of	O	O	O
having	O	O	O
PPD	O	O	B-Entity
symptoms	O	O	B-Entity
decreased	O	O	B-Entity
with	O	O	O
increasing	O	O	B-Entity
state-level	O	O	B-Entity
social	O	O	B-Entity
/	O	O	O
economic	O	O	B-Entity
autonomy	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
residing	O	O	O
in	O	O	O
states	O	O	B-Entity
with	O	O	O
lower	O	O	O
indices	O	O	B-Entity
were	O	O	O
more	O	O	B-Entity
vulnerable	O	O	I-Entity
to	O	O	O
the	O	O	O
impacts	O	O	O
of	O	O	O
antenatal	O	O	B-Entity
stressors	O	O	B-Entity
,	O	O	O
could	O	O	O
have	O	O	O
policy	O	O	B-Entity
implications	O	O	I-Entity
related	O	O	O
to	O	O	O
improving	O	O	O
the	O	O	O
SES	O	O	B-Entity
of	O	O	O
women	O	O	O
in	O	O	O
these	O	O	O
states	O	O	O
.	O	O	O

-DOCSTART- (27876369)

Multi-component	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
intramural	O	O	O
hematoma	O	O	O

A	O	O	O
novel	O	O	O
multi-component	O	O	B-Entity
model	O	O	I-Entity
is	O	O	O
introduced	O	O	O
for	O	O	O
studying	O	O	B-Entity
interaction	O	O	B-Entity
between	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
and	O	O	O
deforming	O	O	B-Entity
aortic	O	O	B-Entity
wall	O	O	I-Entity
with	O	O	O
intramural	O	O	B-Entity
hematoma	O	O	I-Entity
(	O	O	O
IMH	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
aortic	O	O	B-Entity
wall	O	O	I-Entity
is	O	O	O
simulated	O	O	B-Entity
by	O	O	O
a	O	O	O
composite	O	O	B-Entity
structure	O	O	I-Entity
submodel	O	O	I-Entity
representing	O	O	O
material	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
the	O	O	O
three	O	O	O
main	O	O	O
wall	O	O	B-Entity
layers	O	O	I-Entity
.	O	O	O

The	O	O	O
IMH	O	O	B-Entity
is	O	O	O
described	O	O	O
by	O	O	O
a	O	O	O
poroelasticity	O	O	B-Entity
submodel	O	O	I-Entity
which	O	O	O
takes	O	O	O
into	O	O	O
account	O	O	O
both	O	O	O
the	O	O	O
pressure	O	O	B-Entity
inside	O	O	O
hematoma	O	O	B-Entity
and	O	O	O
its	O	O	O
deformation	O	O	B-Entity
.	O	O	O

The	O	O	O
submodel	O	O	B-Entity
of	O	O	O
the	O	O	O
hematoma	O	O	B-Entity
is	O	O	O
fully	O	O	O
coupled	O	O	O
with	O	O	O
the	O	O	O
aortic	O	O	B-Entity
submodel	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
with	O	O	O
the	O	O	O
submodel	O	O	O
of	O	O	O
the	O	O	O
pulsatile	O	O	B-Entity
blood	O	O	I-Entity
flow	O	O	I-Entity
.	O	O	O

Model	O	O	B-Entity
simulations	O	O	I-Entity
are	O	O	O
used	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
relation	O	O	O
between	O	O	O
the	O	O	O
peak	O	O	O
wall	O	O	O
stress	O	O	O
,	O	O	O
hematoma	O	O	B-Entity
thickness	O	O	O
and	O	O	O
permeability	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
of	O	O	O
different	O	O	O
age	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
hematoma	O	O	B-Entity
thickness	O	O	O
leads	O	O	O
to	O	O	O
larger	O	O	O
wall	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
in	O	O	O
agreement	O	O	O
with	O	O	O
clinical	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

Further	O	O	O
simulations	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
a	O	O	O
hematoma	O	O	B-Entity
with	O	O	O
smaller	O	O	O
permeability	O	O	B-Entity
results	O	O	O
in	O	O	O
larger	O	O	O
wall	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
blood	O	O	B-Entity
coagulation	O	O	I-Entity
in	O	O	O
hematoma	O	O	O
might	O	O	O
increase	O	O	O
its	O	O	O
mechanical	O	O	B-Entity
stability	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
in	O	O	O
agreement	O	O	O
with	O	O	O
previous	O	O	O
experimental	O	O	B-Entity
observations	O	O	B-Entity
of	O	O	O
coagulation	O	O	B-Entity
having	O	O	O
a	O	O	O
beneficial	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
the	O	O	O
condition	O	O	O
of	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
the	O	O	O
IMH	O	O	B-Entity
.	O	O	O

-DOCSTART- (27877221)

The	O	O	O
Impact	O	O	B-Entity
of	O	O	I-Entity
Diabetes	O	O	B-Entity
on	O	O	O
the	O	O	O
Risk	O	O	B-Entity
of	O	O	O
Prostate	O	O	B-Entity
Cancer	O	O	I-Entity
Development	O	O	B-Entity
according	O	O	O
to	O	O	O
Body	O	O	B-Entity
Mass	O	O	I-Entity
Index	O	O	I-Entity
:	O	O	O
A	O	O	O
10-year	O	O	O
Nationwide	O	O	O
Cohort	O	O	O
Study	O	O	O

Purpose	O	O	O
:	O	O	O
We	O	O	O
examined	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
obesity	O	O	B-Entity
and	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
both	O	O	O
with	O	O	O
and	O	O	O
without	O	O	B-Entity
diabetic	O	O	B-Entity
patients	O	O	B-Entity
included	O	O	O
in	O	O	O
the	O	O	O
analysis	O	O	O
using	O	O	O
nationally	O	O	O
representative	O	O	O
data	O	O	B-Entity
of	O	O	O
the	O	O	O
Korean	O	O	B-Entity
population	O	O	I-Entity
from	O	O	O
the	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
Insurance	O	O	I-Entity
System	O	O	I-Entity
(	O	O	O
NHIS	O	O	B-Entity
)	O	O	O
.	O	O	O

Materials	O	O	O
and	O	O	O
Methods	O	O	O
:	O	O	O
Of	O	O	O
the	O	O	O
424,712	O	O	O
participants	O	O	B-Entity
who	O	O	O
underwent	O	O	O
health	O	O	B-Entity
examinations	O	O	I-Entity
in	O	O	O
2002	O	O	O
-	O	O	O
2008	O	O	O
,	O	O	O
139,519	O	O	O
men	O	O	B-Entity
≥40	O	O	I-Entity
years	O	O	I-Entity
old	O	O	I-Entity
and	O	O	O
without	O	O	B-Entity
prostate	O	O	B-Entity
cancer	O	O	I-Entity
were	O	O	O
followed	O	O	O
from	O	O	O
the	O	O	O
beginning	O	O	O
of	O	O	O
2002	O	O	O
to	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
2012	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
adjusted	O	O	I-Entity
Cox	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
)	O	O	O
and	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
both	O	O	O
with	O	O	O
and	O	O	O
without	O	O	B-Entity
diabetes	O	O	B-Entity
.	O	O	O

Results	O	O	O
:	O	O	O
The	O	O	O
HR	O	O	B-Entity
for	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
according	O	O	O
to	O	O	O
the	O	O	O
existence	O	O	O
of	O	O	O
diabetes	O	O	B-Entity
was	O	O	O
stratified	O	O	B-Entity
by	O	O	O
BMI	O	O	B-Entity
in	O	O	O
both	O	O	O
age	O	O	B-Entity
-	O	O	O
and	O	O	O
multivariable-adjusted	O	O	B-Entity
models	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
population	O	O	B-Entity
without	O	O	B-Entity
diabetes	O	O	B-Entity
,	O	O	O
the	O	O	O
HR	O	O	B-Entity
for	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
significantly	O	O	B-Entity
increased	O	O	I-Entity
as	O	O	O
BMI	O	O	B-Entity
increased	O	O	O
beyond	O	O	O
the	O	O	O
reference	O	O	O
range	O	O	O
in	O	O	O
a	O	O	O
model	O	O	B-Entity
adjusted	O	O	I-Entity
for	O	O	I-Entity
age	O	O	I-Entity
and	O	O	I-Entity
multiple	O	O	I-Entity
variables	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
increase	O	O	O
in	O	O	O
the	O	O	O
HR	O	O	O
was	O	O	O
small	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
population	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
the	O	O	O
HR	O	O	B-Entity
for	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
significantly	O	O	B-Entity
increased	O	O	I-Entity
as	O	O	O
BMI	O	O	B-Entity
increased	O	O	O
from	O	O	O
<	O	O	O
18.5	O	O	O
kg/m(2	O	O	O
)	O	O	O
to	O	O	O
within	O	O	O
the	O	O	O
reference	O	O	O
range	O	O	O
(	O	O	O
18.5	O	O	O
to	O	O	O
22.9	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
multivariable-adjusted	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
a	O	O	O
marked	O	O	B-Entity
decrease	O	O	I-Entity
in	O	O	O
HR	O	O	B-Entity
in	O	O	O
the	O	O	O
population	O	O	B-Entity
with	O	O	O
BMI	O	O	B-Entity
of	O	O	O
<	O	O	O
18.5	O	O	O
kg/m(2	O	O	O
)	O	O	O
was	O	O	O
seen	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
reference	O	O	O
or	O	O	O
higher	O	O	O
BMI	O	O	O
population	O	O	O
.	O	O	O

Conclusion	O	O	O
:	O	O	O
This	O	O	O
population	O	O	B-Entity
-based	O	O	O
study	O	O	O
shows	O	O	O
the	O	O	O
evidence	O	O	O
of	O	O	O
association	O	O	O
between	O	O	O
obesity	O	O	B-Entity
and	O	O	O
development	O	O	B-Entity
of	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
risk	O	O	B-Entity
increases	O	O	I-Entity
vary	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
change	O	O	O
of	O	O	O
BMI	O	O	B-Entity
category	O	O	O
and	O	O	O
the	O	O	O
existence	O	O	O
of	O	O	O
diabetes	O	O	B-Entity
.	O	O	O

-DOCSTART- (27882066)

Bioinformatic	O	O	B-Entity
Analysis	O	O	B-Entity
of	O	O	O
Codon	O	O	B-Entity
Usage	O	O	B-Entity
and	O	O	O
Phylogenetic	O	O	B-Entity
Relationships	O	O	I-Entity
in	O	O	O
Different	O	O	O
Genotypes	O	O	B-Entity
of	O	O	O
the	O	O	O
Hepatitis	O	O	O
C	O	O	O
Virus	O	O	O

The	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
HCV	O	O	B-Entity
)	O	O	O
has	O	O	O
six	O	O	O
major	O	O	O
genotypes	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
phylogenetically	O	O	B-Entity
investigate	O	O	I-Entity
the	O	O	O
differences	O	O	O
between	O	O	O
the	O	O	O
genotypes	O	O	B-Entity
of	O	O	O
HCV	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
types	O	O	O
of	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
codon	O	O	B-Entity
usage	O	O	B-Entity
in	O	O	O
the	O	O	O
structure	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
virus	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
discover	O	O	O
new	O	O	O
methods	O	O	O
for	O	O	O
treatment	O	O	B-Entity
regimes	O	O	I-Entity
.	O	O	O

The	O	O	O
codon	O	O	B-Entity
usage	O	O	B-Entity
of	O	O	O
the	O	O	O
six	O	O	O
genotypes	O	O	B-Entity
of	O	O	O
the	O	O	O
HCV	O	O	B-Entity
nucleotide	O	O	B-Entity
sequence	O	O	I-Entity
was	O	O	O
investigated	O	O	B-Entity
through	O	O	O
the	O	O	O
online	O	O	O
application	O	O	O
available	O	O	O
on	O	O	O
the	O	O	O
website	O	O	B-Entity
Gene	O	O	I-Entity
Infinity	O	O	I-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
phylogenetic	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
the	O	O	O
evolutionary	O	O	B-Entity
relationship	O	O	I-Entity
of	O	O	O
HCV	O	O	B-Entity
genotypes	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
with	O	O	O
MEGA	O	O	B-Entity
7	O	O	I-Entity
software	O	O	I-Entity
.	O	O	O

The	O	O	O
six	O	O	O
genotypes	O	O	B-Entity
of	O	O	O
HCV	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
based	O	O	O
on	O	O	O
their	O	O	O
codon	O	O	B-Entity
usage	O	O	B-Entity
properties	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
first	O	O	O
group	O	O	B-Entity
,	O	O	O
genotypes	O	O	B-Entity
1	O	O	I-Entity
and	O	O	I-Entity
5	O	O	I-Entity
(	O	O	O
74.02	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
the	O	O	O
second	O	O	O
group	O	O	O
,	O	O	O
genotypes	O	O	B-Entity
2	O	O	I-Entity
and	O	O	I-Entity
6	O	O	I-Entity
(	O	O	O
72.43	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
shown	O	O	O
to	O	O	O
have	O	O	O
the	O	O	O
most	O	O	O
similarity	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
codon	O	O	B-Entity
usage	O	O	B-Entity
.	O	O	O

Unlike	O	O	O
the	O	O	O
results	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
determining	O	O	O
the	O	O	O
similarity	O	O	B-Entity
of	O	O	O
codon	O	O	B-Entity
usage	O	O	B-Entity
,	O	O	O
the	O	O	O
phylogenetic	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
the	O	O	O
closest	O	O	O
resemblance	O	O	B-Entity
and	O	O	O
correlation	O	O	B-Entity
between	O	O	O
genotypes	O	O	B-Entity
1	O	O	I-Entity
and	O	O	I-Entity
4	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	O
also	O	O	O
showed	O	O	O
that	O	O	O
HCV	O	O	B-Entity
has	O	O	O
a	O	O	O
GC	O	O	B-Entity
(	O	O	O
guanine	O	O	B-Entity
-	O	O	I-Entity
cytosine	O	O	B-Entity
)	O	O	O
abundant	O	O	O
genome	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	O
prefers	O	O	O
codons	O	O	B-Entity
with	O	O	O
GC	O	O	O
for	O	O	O
translation	O	O	B-Entity
.	O	O	O

Genotypes	O	O	B-Entity
1	O	O	I-Entity
and	O	O	I-Entity
4	O	O	I-Entity
demonstrated	O	O	O
remarkable	O	O	O
similarity	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
genome	O	O	B-Entity
sequences	O	O	I-Entity
and	O	O	O
proteins	O	O	B-Entity
,	O	O	O
but	O	O	O
surprisingly	O	O	O
,	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
the	O	O	O
preferred	O	O	O
codons	O	O	B-Entity
for	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
they	O	O	O
showed	O	O	O
the	O	O	O
greatest	O	O	O
difference	O	O	O
.	O	O	O

More	O	O	O
studies	O	O	B-Entity
are	O	O	O
therefore	O	O	O
needed	O	O	O
to	O	O	O
confirm	O	O	O
the	O	O	O
results	O	O	O
and	O	O	O
select	O	O	O
the	O	O	O
best	O	O	O
approach	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
of	O	O	O
these	O	O	O
genotypes	O	O	B-Entity
based	O	O	O
on	O	O	O
their	O	O	O
codon	O	O	B-Entity
usage	O	O	B-Entity
properties	O	O	B-Entity
.	O	O	O

-DOCSTART- (27884163)

Chronic	O	O	B-Entity
adiponectin	O	O	B-Entity
deficiency	O	O	I-Entity
leads	O	O	O
to	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
-like	O	O	O
cognitive	O	O	B-Entity
impairments	O	O	I-Entity
and	O	O	O
pathologies	O	O	B-Entity
through	O	O	O
AMPK	O	O	B-Entity
inactivation	O	O	O
and	O	O	O
cerebral	O	O	B-Entity
insulin	O	O	B-Entity
resistance	O	O	I-Entity
in	O	O	O
aged	O	O	B-Entity
mice	O	O	O

Insulin	O	O	B-Entity
resistance	O	O	I-Entity
is	O	O	O
the	O	O	O
major	O	O	O
pathogenesis	O	O	B-Entity
underlying	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
mellitus	O	O	I-Entity
(	O	O	O
T2DM	O	O	B-Entity
)	O	O	O
and	O	O	O
these	O	O	O
patients	O	O	B-Entity
have	O	O	O
doubled	O	O	O
risk	O	O	B-Entity
of	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
.	O	O	O

Increasing	O	O	O
evidence	O	O	O
suggests	O	O	O
that	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
AD	O	O	O
pathogenesis	O	O	B-Entity
,	O	O	O
possibly	O	O	O
due	O	O	O
to	O	O	O
abnormal	O	O	O
GSK3β	O	O	B-Entity
activation	O	O	B-Entity
,	O	O	O
causing	O	O	O
intra-	O	O	B-Entity
and	O	O	O
extracellular	O	O	B-Entity
amyloid-beta	O	O	B-Entity
(	O	O	O
Aβ	O	O	B-Entity
)	O	O	O
accumulation	O	O	O
.	O	O	O

Adiponectin	O	O	B-Entity
(	O	O	O
APN	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
adipokine	O	O	B-Entity
with	O	O	O
insulin-sensitizing	O	O	O
and	O	O	O
anti-inflammatory	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

Reduced	O	O	O
circulatory	O	O	O
APN	O	O	B-Entity
level	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
T2DM	O	O	B-Entity
.	O	O	O

The	O	O	O
role	O	O	O
of	O	O	O
APN	O	O	B-Entity
in	O	O	O
AD	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
elucidated	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
aim	O	O	O
to	O	O	O
examine	O	O	O
if	O	O	O
adiponectin	O	O	B-Entity
deficiency	O	O	I-Entity
would	O	O	O
lead	O	O	O
to	O	O	O
cerebral	O	O	B-Entity
insulin	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
cognitive	O	O	B-Entity
decline	O	O	I-Entity
and	O	O	O
Alzheimer's-like	O	O	B-Entity
pathology	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

To	O	O	O
study	O	O	B-Entity
the	O	O	O
role	O	O	O
of	O	O	O
adiponectin	O	O	B-Entity
in	O	O	O
cognitive	O	O	B-Entity
functions	O	O	I-Entity
,	O	O	O
we	O	O	O
employed	O	O	O
adiponectin-knockout	O	O	B-Entity
(	O	O	B-Entity
APN-KO	O	O	I-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
and	O	O	O
demonstrated	O	O	O
chronic	O	O	B-Entity
APN	O	O	B-Entity
deficiency	O	O	I-Entity
in	O	O	O
their	O	O	O
CNS	O	O	B-Entity
.	O	O	O

Behavioral	O	O	B-Entity
tests	O	O	I-Entity
were	O	O	O
performed	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
cognitions	O	O	B-Entity
of	O	O	O
male	O	O	B-Entity
APN-KO	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Brains	O	O	B-Entity
and	O	O	O
tissue	O	O	B-Entity
lysates	O	O	B-Entity
were	O	O	O
collected	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
pathophysiological	O	O	O
and	O	O	O
molecular	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
of	O	O	O
APN-KO	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

SH-SY5Y	O	O	B-Entity
neuroblastoma	O	O	I-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
study	O	O	B-Entity
the	O	O	O
molecular	O	O	B-Entity
mechanism	O	O	I-Entity
upon	O	O	O
APN	O	O	B-Entity
and	O	O	O
insulin	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Aged	O	O	B-Entity
APN	O	O	B-Entity
-deficient	O	O	O
mice	O	O	B-Entity
displayed	O	O	O
spatial	O	O	B-Entity
memory	O	O	I-Entity
and	O	O	O
learning	O	O	B-Entity
impairments	O	O	B-Entity
,	O	O	O
fear-conditioned	O	O	B-Entity
memory	O	O	B-Entity
deficit	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
anxiety	O	O	B-Entity
.	O	O	O

These	O	O	O
mice	O	O	B-Entity
also	O	O	O
developed	O	O	O
AD	O	O	B-Entity
pathologies	O	O	B-Entity
including	O	O	O
increased	O	O	O
cerebral	O	O	B-Entity
Aβ42	O	O	B-Entity
level	O	O	O
,	O	O	O
Aβ	O	O	B-Entity
deposition	O	O	O
,	O	O	O
hyperphosphorylated	O	O	B-Entity
Tau	O	O	I-Entity
proteins	O	O	I-Entity
,	O	O	O
microgliosis	O	O	B-Entity
and	O	O	O
astrogliosis	O	O	B-Entity
with	O	O	O
increased	O	O	O
cerebral	O	O	O
IL-1β	O	O	B-Entity
and	O	O	O
TNFα	O	O	B-Entity
levels	O	O	O
that	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	O
neuronal	O	O	B-Entity
apoptosis	O	O	I-Entity
and	O	O	O
reduced	O	O	O
synaptic	O	O	B-Entity
proteins	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
APN	O	O	B-Entity
deficiency	O	O	I-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
neuronal	O	O	O
and	O	O	O
synaptic	O	O	O
loss	O	O	O
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
.	O	O	O

AD	O	O	B-Entity
pathologies	O	O	B-Entity
-associated	O	O	O
APN	O	O	B-Entity
-	O	O	O
KO	O	O	B-Entity
mice	O	O	I-Entity
displayed	O	O	O
attenuated	O	O	O
AMPK	O	O	B-Entity
phosphorylation	O	O	B-Entity
and	O	O	O
impaired	O	O	O
insulin	O	O	B-Entity
signaling	O	O	I-Entity
including	O	O	O
decreased	O	O	O
Akt	O	O	B-Entity
induction	O	O	O
and	O	O	O
increased	O	O	O
GSK3β	O	O	B-Entity
activation	O	O	B-Entity
in	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
and	O	O	O
frontal	O	O	B-Entity
cortex	O	O	I-Entity
.	O	O	O

Aged	O	O	B-Entity
APN	O	O	B-Entity
-KO	O	O	O
mice	O	O	B-Entity
developed	O	O	O
hippocampal	O	O	B-Entity
insulin	O	O	B-Entity
resistance	O	O	I-Entity
with	O	O	O
reduced	O	O	O
pAkt	O	O	B-Entity
induction	O	O	O
upon	O	O	O
intracerebral	O	O	O
insulin	O	O	B-Entity
injection	O	O	I-Entity
.	O	O	O

Consistently	O	O	O
,	O	O	O
APN	O	O	B-Entity
treatment	O	O	B-Entity
in	O	O	O
SH-SY5Y	O	O	B-Entity
cells	O	O	I-Entity
with	O	O	O
insulin	O	O	B-Entity
resistance	O	O	I-Entity
and	O	O	O
overexpressing	O	O	B-Entity
Aβ	O	O	B-Entity
induce	O	O	O
higher	O	O	O
pAkt	O	O	B-Entity
levels	O	O	O
through	O	O	O
AdipoR1	O	O	B-Entity
upon	O	O	O
insulin	O	O	B-Entity
treatment	O	O	I-Entity
whereas	O	O	O
the	O	O	O
induction	O	O	O
was	O	O	O
blocked	O	O	B-Entity
by	O	O	O
compound	O	O	B-Entity
C	O	O	I-Entity
,	O	O	O
indicating	O	O	O
APN	O	O	O
can	O	O	O
enhance	O	O	O
neuronal	O	O	B-Entity
insulin	O	O	B-Entity
sensitivity	O	O	I-Entity
through	O	O	O
AMPK	O	O	B-Entity
activation	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
indicated	O	O	O
that	O	O	O
chronic	O	O	B-Entity
APN	O	O	B-Entity
deficiency	O	O	I-Entity
inactivated	O	O	O
AMPK	O	O	B-Entity
causing	O	O	O
insulin	O	O	O
desensitization	O	O	O
and	O	O	O
elicited	O	O	O
AD-like	O	O	B-Entity
pathogenesis	O	O	I-Entity
in	O	O	O
aged	O	O	B-Entity
mice	O	O	B-Entity
which	O	O	O
also	O	O	O
developed	O	O	O
significant	O	O	O
cognitive	O	O	B-Entity
impairments	O	O	I-Entity
and	O	O	O
psychiatric	O	O	B-Entity
symptoms	O	O	I-Entity
.	O	O	O

-DOCSTART- (27884960)

Can	O	O	O
inorganic	O	O	B-Entity
phosphate	O	O	I-Entity
explain	O	O	O
sag	O	O	B-Entity
during	O	O	O
unfused	O	O	B-Entity
tetanic	O	O	B-Entity
contractions	O	O	I-Entity
of	O	O	O
skeletal	O	O	B-Entity
muscle	O	O	I-Entity
?	O	O	O

We	O	O	O
test	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
cytosolic	O	O	B-Entity
inorganic	O	O	B-Entity
phosphate	O	O	I-Entity
(	O	O	O
Pi	O	O	B-Entity
)	O	O	O
can	O	O	O
account	O	O	O
for	O	O	O
the	O	O	O
contraction	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
reductions	O	O	B-Entity
in	O	O	O
twitch	O	O	B-Entity
duration	O	O	B-Entity
which	O	O	O
impair	O	O	B-Entity
summation	O	O	O
and	O	O	O
cause	O	O	O
force	O	O	B-Entity
to	O	O	O
decline	O	O	B-Entity
(	O	O	O
sag	O	O	B-Entity
)	O	O	O
during	O	O	O
unfused	O	O	B-Entity
tetanic	O	O	B-Entity
contractions	O	O	I-Entity
of	O	O	O
fast-twitch	O	O	B-Entity
muscle	O	O	I-Entity
.	O	O	O

A	O	O	O
five-state	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
crossbridge	O	O	B-Entity
cycling	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
simulate	O	O	B-Entity
twitch	O	O	B-Entity
and	O	O	O
unfused	O	O	B-Entity
tetanic	O	O	B-Entity
contractions	O	O	I-Entity
.	O	O	O

As	O	O	O
Pi	O	O	B-Entity
concentration	O	O	B-Entity
(	O	O	O
[	O	O	O
Pi	O	O	O
]	O	O	O
)	O	O	O
was	O	O	O
increased	O	O	B-Entity
from	O	O	O
0	O	O	O
to	O	O	O
30	O	O	O
mmol·L(-1	O	O	O
)	O	O	O
,	O	O	O
twitch	O	O	B-Entity
duration	O	O	B-Entity
decreased	O	O	B-Entity
,	O	O	O
with	O	O	O
progressive	O	O	B-Entity
reductions	O	O	B-Entity
in	O	O	O
sensitivity	O	O	B-Entity
to	O	O	O
Pi	O	O	O
as	O	O	O
[	O	O	O
Pi	O	O	O
]	O	O	O
was	O	O	O
increased	O	O	O
.	O	O	O

When	O	O	O
unfused	O	O	B-Entity
tetani	O	O	O
were	O	O	O
simulated	O	O	B-Entity
with	O	O	O
rising	O	O	O
[	O	O	O
Pi	O	O	B-Entity
]	O	O	O
,	O	O	O
sag	O	O	B-Entity
was	O	O	O
most	O	O	O
pronounced	O	O	B-Entity
when	O	O	O
initial	O	O	B-Entity
[	O	O	O
Pi	O	O	O
]	O	O	O
was	O	O	O
low	O	O	B-Entity
,	O	O	O
and	O	O	O
when	O	O	O
the	O	O	O
magnitude	O	O	B-Entity
of	O	O	O
[	O	O	O
Pi	O	O	O
]	O	O	O
increase	O	O	B-Entity
was	O	O	O
large	O	O	B-Entity
.	O	O	O

Fast-twitch	O	O	B-Entity
extensor	O	O	B-Entity
digitorum	O	O	I-Entity
longus	O	O	I-Entity
(	O	O	I-Entity
EDL	O	O	I-Entity
)	O	O	I-Entity
muscles	O	O	I-Entity
(	O	O	O
sag-prone	O	O	B-Entity
,	O	O	O
typically	O	O	O
low	O	O	O
basal	O	O	O
[	O	O	O
Pi	O	O	B-Entity
]	O	O	O
)	O	O	O
and	O	O	O
slow-twitch	O	O	B-Entity
soleus	O	O	B-Entity
muscles	O	O	I-Entity
(	O	O	O
sag	O	O	B-Entity
-	O	O	O
resistant	O	O	B-Entity
,	O	O	O
typically	O	O	O
high	O	O	O
basal	O	O	O
[	O	O	O
Pi	O	O	O
]	O	O	O
)	O	O	O
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
14	O	O	O
female	O	O	B-Entity
C57BL/6	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Muscles	O	O	B-Entity
were	O	O	O
sequentially	O	O	O
incubated	O	O	B-Entity
in	O	O	O
solutions	O	O	B-Entity
containing	O	O	O
either	O	O	O
glucose	O	O	B-Entity
or	O	O	O
pyruvate	O	O	B-Entity
to	O	O	O
create	O	O	O
typical	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
Pi	O	O	B-Entity
environments	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Twitch	O	O	B-Entity
duration	O	O	B-Entity
was	O	O	O
greater	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
in	O	O	O
pyruvate	O	O	B-Entity
than	O	O	O
glucose	O	O	B-Entity
in	O	O	O
both	O	O	O
muscles	O	O	B-Entity
.	O	O	O

Stimuli	O	O	B-Entity
applied	O	O	B-Entity
at	O	O	O
intervals	O	O	B-Entity
approximately	O	O	O
three	O	O	O
times	O	O	O
the	O	O	O
time	O	O	O
to	O	O	O
peak	O	O	B-Entity
twitch	O	O	B-Entity
tension	O	O	B-Entity
resulted	O	O	O
in	O	O	O
sag	O	O	B-Entity
of	O	O	O
35.0	O	O	O
±	O	O	O
3.7	O	O	O
%	O	O	O
in	O	O	O
glucose	O	O	B-Entity
and	O	O	O
50.5	O	O	O
±	O	O	O
1.4	O	O	O
%	O	O	O
in	O	O	O
pyruvate	O	O	B-Entity
in	O	O	O
the	O	O	O
EDL	O	O	B-Entity
(	O	O	O
pyruvate	O	O	O
>	O	O	O
glucose	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
3.9	O	O	O
±	O	O	O
0.3	O	O	O
%	O	O	O
in	O	O	O
glucose	O	O	O
and	O	O	O
37.8	O	O	O
±	O	O	O
2.7	O	O	O
%	O	O	O
in	O	O	O
pyruvate	O	O	O
in	O	O	O
the	O	O	O
soleus	O	O	B-Entity
(	O	O	O
pyruvate	O	O	O
>	O	O	O
glucose	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
influence	O	O	O
of	O	O	O
Pi	O	O	B-Entity
on	O	O	O
crossbridge	O	O	B-Entity
cycling	O	O	I-Entity
provides	O	O	O
a	O	O	O
tenable	O	O	B-Entity
mechanism	O	O	I-Entity
for	O	O	O
sag	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
low	O	O	B-Entity
basal	O	O	I-Entity
[	O	O	O
Pi	O	O	B-Entity
]	O	O	O
in	O	O	O
fast-twitch	O	O	B-Entity
relative	O	O	O
to	O	O	O
slow-twitch	O	O	B-Entity
muscle	O	O	I-Entity
has	O	O	O
promise	O	O	O
as	O	O	O
an	O	O	O
explanation	O	O	B-Entity
for	O	O	O
the	O	O	O
fiber-type	O	O	B-Entity
dependency	O	O	O
of	O	O	O
sag	O	O	B-Entity
.	O	O	O

-DOCSTART- (27885308)

Pancreatic	O	O	B-Entity
Cancer	O	O	I-Entity
:	O	O	O
A	O	O	O
Survival	O	O	B-Entity
Analysis	O	O	I-Entity
Study	O	O	B-Entity
in	O	O	O
Oklahoma	O	O	O

Pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
among	O	O	O
the	O	O	O
most	O	O	O
deadly	O	O	B-Entity
cancers	O	O	I-Entity
.	O	O	O

Risk	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
disease	O	O	B-Entity
include	O	O	O
age	O	O	B-Entity
,	O	O	O
race	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
smoking	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
and	O	O	O
diabetes	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
prospective	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
survival	O	O	I-Entity
among	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	I-Entity
living	O	O	O
in	O	O	O
Oklahoma	O	O	B-Entity
between	O	O	O
1997	O	O	O
and	O	O	O
2012	O	O	O
(	O	O	O
n=6,291	O	O	O
)	O	O	O
.	O	O	O

Kaplan-Meier	O	O	B-Entity
survival	O	O	I-Entity
curves	O	O	I-Entity
were	O	O	O
created	O	O	B-Entity
followed	O	O	O
by	O	O	O
the	O	O	O
log-rank	O	O	B-Entity
test	O	O	I-Entity
to	O	O	O
compare	O	O	O
difference	O	O	B-Entity
in	O	O	O
the	O	O	O
survival	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

Cox	O	O	B-Entity
proportional	O	O	I-Entity
hazard	O	O	I-Entity
regression	O	O	I-Entity
models	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
strength	O	O	B-Entity
of	O	O	I-Entity
association	O	O	I-Entity
through	O	O	O
the	O	O	O
estimated	O	O	B-Entity
hazard	O	O	B-Entity
ratios	O	O	I-Entity
.	O	O	O

The	O	O	O
median	O	O	B-Entity
survival	O	O	I-Entity
time	O	O	I-Entity
of	O	O	O
the	O	O	O
cohort	O	O	B-Entity
was	O	O	O
three	O	O	O
months	O	O	B-Entity
.	O	O	O

Significant	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
reduced	O	O	B-Entity
survival	O	O	B-Entity
times	O	O	I-Entity
included	O	O	O
age	O	O	B-Entity
,	O	O	O
stage	O	O	B-Entity
at	O	O	I-Entity
diagnosis	O	O	I-Entity
,	O	O	O
and	O	O	O
year	O	O	B-Entity
of	O	O	I-Entity
diagnosis	O	O	I-Entity
.	O	O	O

Results	O	O	B-Entity
are	O	O	O
in	O	O	O
agreement	O	O	O
with	O	O	O
previous	O	O	O
research	O	O	B-Entity
findings	O	O	I-Entity
.	O	O	O

There	O	O	O
have	O	O	O
been	O	O	O
small	O	O	O
but	O	O	O
noteworthy	O	O	B-Entity
improvements	O	O	I-Entity
in	O	O	O
survival	O	O	B-Entity
times	O	O	I-Entity
for	O	O	O
pancreatic	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	I-Entity
in	O	O	O
Oklahoma	O	O	B-Entity
.	O	O	O

Length	O	O	B-Entity
of	O	O	I-Entity
survival	O	O	I-Entity
during	O	O	O
the	O	O	O
study	O	O	B-Entity
period	O	O	I-Entity
was	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
known	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
such	O	O	O
as	O	O	O
age	O	O	B-Entity
and	O	O	O
stage	O	O	B-Entity
of	O	O	I-Entity
diagnosis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27887661)

Biochemical	O	O	B-Entity
and	O	O	O
proteomic	O	O	B-Entity
analyses	O	O	B-Entity
of	O	O	O
the	O	O	O
physiological	O	O	B-Entity
response	O	O	I-Entity
induced	O	O	O
by	O	O	O
individual	O	O	O
housing	O	O	B-Entity
in	O	O	O
gilts	O	O	B-Entity
provide	O	O	O
new	O	O	O
potential	O	O	B-Entity
stress	O	O	B-Entity
markers	O	O	O

The	O	O	O
objective	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
animal	O	O	B-Entity
stress	O	O	B-Entity
and	O	O	O
welfare	O	O	O
requires	O	O	O
proper	O	O	O
laboratory	O	O	B-Entity
biomarkers	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
analyzed	O	O	O
the	O	O	O
changes	O	O	O
in	O	O	O
serum	O	O	B-Entity
composition	O	O	B-Entity
in	O	O	O
gilts	O	O	B-Entity
after	O	O	O
switching	O	O	O
their	O	O	O
housing	O	O	B-Entity
,	O	O	O
from	O	O	O
pen	O	O	O
to	O	O	O
individual	O	O	O
stalls	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
generally	O	O	O
accepted	O	O	O
to	O	O	O
cause	O	O	O
animal	O	O	B-Entity
discomfort	O	O	B-Entity
.	O	O	O

Blood	O	O	B-Entity
and	O	O	O
saliva	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
collected	O	O	O
a	O	O	O
day	O	O	O
before	O	O	O
and	O	O	O
up	O	O	O
to	O	O	O
four	O	O	O
days	O	O	O
after	O	O	O
changing	O	O	O
the	O	O	O
housing	O	O	B-Entity
system	O	O	O
.	O	O	O

Biochemical	O	O	B-Entity
analyses	O	O	B-Entity
showed	O	O	O
adaptive	O	O	B-Entity
changes	O	O	O
in	O	O	O
lipid	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
metabolism	O	O	I-Entity
after	O	O	O
the	O	O	O
housing	O	O	B-Entity
switch	O	O	O
,	O	O	O
whereas	O	O	O
cortisol	O	O	B-Entity
and	O	O	O
muscular	O	O	B-Entity
markers	O	O	B-Entity
showed	O	O	O
a	O	O	O
large	O	O	O
variability	O	O	B-Entity
between	O	O	O
animals	O	O	B-Entity
.	O	O	O

2D-DIGE	O	O	B-Entity
and	O	O	O
iTRAQ	O	O	B-Entity
proteomic	O	O	B-Entity
approaches	O	O	B-Entity
revealed	O	O	O
variations	O	O	O
in	O	O	O
serum	O	O	B-Entity
protein	O	O	I-Entity
composition	O	O	B-Entity
after	O	O	O
changing	O	O	O
housing	O	O	B-Entity
and	O	O	O
diet	O	O	O
of	O	O	O
gilts	O	O	B-Entity
.	O	O	O

Both	O	O	O
techniques	O	O	B-Entity
showed	O	O	O
alterations	O	O	B-Entity
in	O	O	O
two	O	O	O
main	O	O	O
homeostatic	O	O	B-Entity
mechanisms	O	O	I-Entity
:	O	O	O
the	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
and	O	O	O
redox	O	O	B-Entity
systems	O	O	O
.	O	O	O

The	O	O	O
acute	O	O	B-Entity
phase	O	O	I-Entity
proteins	O	O	I-Entity
haptoglobin	O	O	B-Entity
,	O	O	O
apolipoprotein	O	O	B-Entity
A-I	O	O	I-Entity
and	O	O	O
α1-antichymotrypsin	O	O	O
3	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
antioxidant	O	O	B-Entity
enzyme	O	O	O
peroxiredoxin	O	O	B-Entity
2	O	O	I-Entity
were	O	O	O
found	O	O	O
differentially	O	O	O
expressed	O	O	O
by	O	O	O
2D-DIGE	O	O	B-Entity
.	O	O	O

Other	O	O	O
proteins	O	O	B-Entity
related	O	O	O
to	O	O	O
the	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
including	O	O	O
lactotransferrin	O	O	B-Entity
,	O	O	O
protegrin	O	O	B-Entity
3	O	O	I-Entity
and	O	O	O
galectin	O	O	B-Entity
1	O	O	I-Entity
were	O	O	O
also	O	O	O
identified	O	O	O
by	O	O	O
iTRAQ	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
enzymes	O	O	B-Entity
such	O	O	O
as	O	O	O
peroxiredoxin	O	O	B-Entity
2	O	O	I-Entity
and	O	O	O
glutathione	O	O	B-Entity
peroxidase	O	O	I-Entity
3	O	O	I-Entity
.	O	O	O

Proteomics	O	O	B-Entity
also	O	O	O
revealed	O	O	O
the	O	O	O
decrease	O	O	B-Entity
of	O	O	O
apolipoproteins	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
intracellular	O	O	B-Entity
proteins	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
,	O	O	O
which	O	O	O
may	O	O	O
indicate	O	O	O
physical	O	O	B-Entity
injury	O	O	I-Entity
to	O	O	O
tissues	O	O	B-Entity
.	O	O	O

Housing	O	O	B-Entity
of	O	O	O
gilts	O	O	B-Entity
in	O	O	O
individual	O	O	O
stalls	O	O	B-Entity
and	O	O	O
diet	O	O	O
change	O	O	O
increase	O	O	O
lipid	O	O	B-Entity
and	O	O	O
protein	O	O	B-Entity
catabolism	O	O	I-Entity
,	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
activate	O	O	O
the	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
system	O	O	I-Entity
and	O	O	O
cause	O	O	O
a	O	O	O
certain	O	O	O
degree	O	O	O
of	O	O	O
tissue	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

We	O	O	O
propose	O	O	O
that	O	O	O
valuable	O	O	O
assays	O	O	O
for	O	O	O
stress	O	O	B-Entity
assessment	O	O	I-Entity
in	O	O	O
gilts	O	O	B-Entity
may	O	O	O
be	O	O	O
based	O	O	O
on	O	O	O
a	O	O	O
score	O	O	B-Entity
composed	O	O	O
by	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
salivary	O	O	O
cortisol	O	O	O
,	O	O	O
lipid	O	O	B-Entity
metabolites	O	O	B-Entity
,	O	O	O
innate	O	O	B-Entity
immunity	O	O	I-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
markers	O	O	B-Entity
and	O	O	O
intracellular	O	O	B-Entity
proteins	O	O	B-Entity
.	O	O	O

-DOCSTART- (27887778)

Cultivation	O	O	B-Entity
of	O	O	O
four	O	O	O
microalgae	O	O	B-Entity
species	O	O	B-Entity
in	O	O	O
the	O	O	O
effluent	O	O	B-Entity
of	O	O	O
anaerobic	O	O	B-Entity
digester	O	O	I-Entity
for	O	O	O
biodiesel	O	O	B-Entity
production	O	O	O

This	O	O	O
study	O	O	B-Entity
investigated	O	O	B-Entity
if	O	O	O
an	O	O	O
effluent	O	O	B-Entity
from	O	O	O
anaerobic	O	O	B-Entity
digestion	O	O	I-Entity
(	O	O	I-Entity
AD	O	O	I-Entity
)	O	O	I-Entity
system	O	O	I-Entity
can	O	O	O
be	O	O	O
used	O	O	B-Entity
as	O	O	O
a	O	O	O
nutrients	O	O	B-Entity
source	O	O	B-Entity
for	O	O	O
the	O	O	O
microalgae	O	O	B-Entity
cultivation	O	O	B-Entity
,	O	O	O
and	O	O	O
in	O	O	O
so	O	O	O
doing	O	O	O
,	O	O	O
if	O	O	O
the	O	O	O
effluent	O	O	O
can	O	O	O
be	O	O	O
properly	O	O	O
treated	O	O	B-Entity
.	O	O	O

Nitrogen	O	O	B-Entity
and	O	O	O
phosphorus	O	O	B-Entity
in	O	O	O
the	O	O	O
AD	O	O	B-Entity
effluent	O	O	B-Entity
well	O	O	O
supported	O	O	O
microalgal	O	O	B-Entity
growth	O	O	B-Entity
,	O	O	O
and	O	O	O
their	O	O	O
removal	O	O	B-Entity
efficiency	O	O	B-Entity
reached	O	O	O
>	O	O	O
97.9	O	O	O
%	O	O	O
and	O	O	O
99.2	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Among	O	O	O
four	O	O	O
different	O	O	B-Entity
algal	O	O	B-Entity
species	O	O	B-Entity
tested	O	O	B-Entity
,	O	O	O
Micractinium	O	O	B-Entity
inermum	O	O	I-Entity
particularly	O	O	O
stood	O	O	B-Entity
out	O	O	I-Entity
,	O	O	O
showing	O	O	O
the	O	O	O
highest	O	O	B-Entity
biomass	O	O	B-Entity
and	O	O	O
FAME	O	O	B-Entity
productivity	O	O	B-Entity
:	O	O	O
0.16gL(-1)d(-1	O	O	O
)	O	O	O
with	O	O	O
3.23gL(-1	O	O	O
)	O	O	O
of	O	O	O
dry	O	O	B-Entity
cell	O	O	B-Entity
weight	O	O	B-Entity
,	O	O	O
and	O	O	O
0.04gL(-1)d(-1	O	O	O
)	O	O	O
with	O	O	O
27.54	O	O	O
%	O	O	O
(	O	O	O
w/w	O	O	O
)	O	O	O
of	O	O	O
FAME	O	O	O
contents	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

As	O	O	O
the	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
the	O	O	O
nutrients	O	O	B-Entity
decreased	O	O	B-Entity
over	O	O	B-Entity
time	O	O	B-Entity
,	O	O	O
the	O	O	O
FAME	O	O	B-Entity
contents	O	O	B-Entity
were	O	O	O
increased	O	O	B-Entity
and	O	O	O
its	O	O	O
quality	O	O	B-Entity
as	O	O	O
well	O	O	B-Entity
,	O	O	O
satisfying	O	O	O
several	O	O	B-Entity
biodiesel	O	O	B-Entity
quality	O	O	O
standards	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
supports	O	O	O
that	O	O	O
the	O	O	O
AD	O	O	B-Entity
effluent	O	O	B-Entity
can	O	O	O
indeed	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
cheap	O	O	B-Entity
and	O	O	O
nutrient	O	O	B-Entity
-	O	O	O
rich	O	O	B-Entity
medium	O	O	B-Entity
for	O	O	O
microalgae	O	O	B-Entity
cultivation	O	O	B-Entity
,	O	O	O
and	O	O	O
equally	O	O	B-Entity
importantly	O	O	B-Entity
,	O	O	O
microalgae	O	O	O
can	O	O	O
be	O	O	O
a	O	O	O
workable	O	O	O
treatment	O	O	B-Entity
option	O	O	B-Entity
for	O	O	O
it	O	O	O
.	O	O	O

-DOCSTART- (27889529)

Antiviral	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	O
selected	O	O	O
antimalarials	O	O	B-Entity
against	O	O	B-Entity
dengue	O	O	B-Entity
virus	O	O	I-Entity
type	O	O	I-Entity
2	O	O	I-Entity
and	O	O	O
Zika	O	O	O
virus	O	O	O

In	O	O	O
a	O	O	O
previous	O	O	B-Entity
study	O	O	B-Entity
,	O	O	I-Entity
twelve	O	O	O
antimalarial	O	O	B-Entity
compounds	O	O	I-Entity
,	O	O	O
amodiaquine	O	O	B-Entity
(	O	O	O
AQ	O	O	B-Entity
)	O	O	O
and	O	O	O
derivatives	O	O	B-Entity
,	O	O	O
were	O	O	O
shown	O	O	O
to	O	O	O
have	O	O	O
potent	O	O	B-Entity
anti-dengue	O	O	B-Entity
viral	O	O	I-Entity
(	O	O	I-Entity
DENV	O	O	I-Entity
)	O	O	I-Entity
activity	O	O	I-Entity
by	O	O	O
using	O	O	O
the	O	O	O
stable	O	O	B-Entity
DENV2	O	O	B-Entity
Renilla	O	O	B-Entity
luciferase	O	O	I-Entity
reporter	O	O	B-Entity
replicon	O	O	B-Entity
expressing	O	O	B-Entity
BHK-21	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
infectivity	O	O	B-Entity
(	O	O	O
plaque	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
qRT-PCR	O	O	B-Entity
assays	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
performed	O	O	B-Entity
molecular	O	O	B-Entity
modeling	O	O	I-Entity
on	O	O	O
these	O	O	O
compounds	O	O	B-Entity
to	O	O	O
determine	O	O	O
their	O	O	O
stereo-electronic	O	O	B-Entity
properties	O	O	I-Entity
required	O	O	O
for	O	O	O
optimal	O	O	B-Entity
antiviral	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
the	O	O	O
similarity	O	O	B-Entity
of	O	O	O
calculated	O	O	O
stereo-electronic	O	O	B-Entity
profiles	O	O	I-Entity
,	O	O	O
specifically	O	O	O
the	O	O	O
electrostatic	O	O	B-Entity
potential	O	O	I-Entity
profiles	O	O	I-Entity
of	O	O	O
the	O	O	O
compounds	O	O	B-Entity
,	O	O	O
and	O	O	O
in	O	O	B-Entity
silico	O	O	I-Entity
screening	O	O	I-Entity
of	O	O	O
related	O	O	O
compounds	O	O	O
from	O	O	O
literature	O	O	B-Entity
,	O	O	O
we	O	O	O
identified	O	O	B-Entity
three	O	O	O
additional	O	O	B-Entity
compounds	O	O	O
,	O	O	O
Quinacrine	O	O	B-Entity
(	O	O	O
QC	O	O	B-Entity
)	O	O	O
,	O	O	O
Mefloquine	O	O	B-Entity
(	O	O	O
MQ	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
GSK369796	O	O	B-Entity
.	O	O	O

Analysis	O	O	O
of	O	O	O
their	O	O	O
antiviral	O	O	B-Entity
activities	O	O	I-Entity
indicated	O	O	O
that	O	O	O
all	O	O	O
three	O	O	B-Entity
compounds	O	O	I-Entity
have	O	O	O
high	O	O	B-Entity
anti-DENV	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
the	O	O	O
DENV2	O	O	B-Entity
replicon	O	O	B-Entity
expressing	O	O	B-Entity
cells	O	O	B-Entity
with	O	O	O
EC50	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
5.30	O	O	O
±	O	O	O
1.31	O	O	O
μM	O	O	O
(	O	O	O
QC	O	O	B-Entity
)	O	O	O
,	O	O	O
3.22	O	O	O
±	O	O	O
0.37	O	O	O
μM	O	O	O
(	O	O	O
MQ	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
5.06	O	O	O
±	O	O	O
0.86	O	O	O
μM	O	O	O
(	O	O	O
GSK369796	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
infectivity	O	O	B-Entity
assays	O	O	I-Entity
revealed	O	O	B-Entity
the	O	O	O
EC50	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
7.09	O	O	O
±	O	O	O
1.67	O	O	O
μM	O	O	O
(	O	O	O
QC	O	O	B-Entity
)	O	O	O
,	O	O	O
4.36	O	O	O
±	O	O	O
0.31	O	O	O
μM	O	O	O
(	O	O	O
MQ	O	O	B-Entity
)	O	O	O
and	O	O	O
3.03	O	O	O
±	O	O	O
0.35	O	O	O
μM	O	O	O
(	O	O	O
GSK369796	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
mode	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
of	O	O	O
these	O	O	O
compounds	O	O	B-Entity
is	O	O	O
through	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
autophagy	O	O	B-Entity
,	O	O	O
thereby	O	O	O
affecting	O	O	B-Entity
DENV2	O	O	B-Entity
replication	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
these	O	O	O
compounds	O	O	B-Entity
also	O	O	O
showed	O	O	O
antiviral	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	B-Entity
the	O	O	O
rapidly	O	O	O
emerging	O	O	O
Zika	O	O	B-Entity
virus	O	O	I-Entity
(	O	O	O
ZIKV	O	O	B-Entity
)	O	O	O
with	O	O	O
EC50	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
2.27	O	O	O
±	O	O	O
0.14	O	O	O
μM	O	O	O
(	O	O	O
QC	O	O	B-Entity
)	O	O	O
,	O	O	O
3.95	O	O	O
±	O	O	O
0.21	O	O	O
μM	O	O	O
(	O	O	O
MQ	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
2.57	O	O	O
±	O	O	O
0.09	O	O	O
μM	O	O	O
(	O	O	O
GSK369796	O	O	B-Entity
)	O	O	O
.	O	O	O

-DOCSTART- (27892236)

1	O	O	O
in	O	O	O
100	O	O	O
babies	O	O	B-Entity
:	O	O	O
the	O	O	O
fetal	O	O	B-Entity
alcohol	O	O	I-Entity
spectrum	O	O	I-Entity
disorder	O	O	I-Entity
pathway	O	O	O

Alcohol	O	O	B-Entity
consumed	O	O	B-Entity
during	O	O	O
pregnancy	O	O	B-Entity
is	O	O	O
the	O	O	O
nation	O	O	B-Entity
's	O	O	I-Entity
leading	O	O	O
preventable	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	O
developmental	O	O	B-Entity
disabilities	O	O	I-Entity
and	O	O	O
birth	O	O	B-Entity
defects	O	O	I-Entity
.	O	O	O

One	O	O	O
in	O	O	O
100	O	O	O
babies	O	O	B-Entity
is	O	O	O
estimated	O	O	O
to	O	O	O
be	O	O	O
born	O	O	B-Entity
with	O	O	O
alcohol-related	O	O	B-Entity
damage	O	O	I-Entity
,	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
World	O	O	B-Entity
Health	O	O	I-Entity
Organization	O	O	I-Entity
.	O	O	O

Fetal	O	O	B-Entity
alcohol	O	O	I-Entity
spectrum	O	O	I-Entity
disorders	O	O	I-Entity
(	O	O	O
FASDs	O	O	B-Entity
)	O	O	O
are	O	O	O
more	O	O	O
common	O	O	O
than	O	O	O
autism	O	O	B-Entity
but	O	O	O
are	O	O	O
under-	O	O	O
diagnosed	O	O	B-Entity
.	O	O	O

-DOCSTART- (27892857)

Genotyping	O	O	B-Entity
of	O	O	O
German	O	O	B-Entity
and	O	O	O
Austrian	O	O	B-Entity
Taylorella	O	O	B-Entity
equigenitalis	O	O	I-Entity
isolates	O	O	B-Entity
using	O	O	O
repetitive	O	O	B-Entity
extragenic	O	O	I-Entity
palindromic	O	O	I-Entity
(	O	O	I-Entity
REP	O	O	I-Entity
)	O	O	I-Entity
PCR	O	O	I-Entity
and	O	O	O
pulsed-field	O	O	B-Entity
gel	O	O	I-Entity
electrophoresis	O	O	I-Entity
(	O	O	O
PFGE	O	O	B-Entity
)	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
124	O	O	O
Taylorella	O	O	B-Entity
(	O	O	I-Entity
T.	O	O	I-Entity
)	O	O	I-Entity
equigenitalis	O	O	I-Entity
and	O	O	O
five	O	O	O
T.	O	O	B-Entity
asinigenitalis	O	O	I-Entity
field	O	O	B-Entity
isolates	O	O	B-Entity
collected	O	O	B-Entity
between	O	O	O
2002	O	O	O
and	O	O	O
2014	O	O	O
were	O	O	O
available	O	O	B-Entity
for	O	O	O
genotyping	O	O	B-Entity
using	O	O	O
REP-	O	O	B-Entity
(	O	O	I-Entity
repetitive	O	O	I-Entity
extragenic	O	O	I-Entity
palindromic	O	O	I-Entity
)	O	O	I-Entity
PCR	O	O	I-Entity
and	O	O	O
PFGE	O	O	B-Entity
(	O	O	O
pulsed-field	O	O	B-Entity
gel	O	O	I-Entity
electrophoresis	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
comprised	O	O	O
79	O	O	O
T.	O	O	B-Entity
equigenitalis	O	O	I-Entity
field	O	O	B-Entity
isolates	O	O	B-Entity
originating	O	O	O
from	O	O	O
ten	O	O	O
defined	O	O	O
breeds	O	O	B-Entity
of	O	O	O
German	O	O	B-Entity
horses	O	O	I-Entity
and	O	O	O
revealed	O	O	B-Entity
a	O	O	O
spectrum	O	O	B-Entity
of	O	O	O
five	O	O	O
REP	O	O	B-Entity
(	O	O	O
rep-E1-E4	O	O	B-Entity
,	O	O	O
rep-E3a	O	O	B-Entity
)	O	O	O
and	O	O	O
15	O	O	O
PFGE	O	O	B-Entity
(	O	O	O
TE-A1-A9	O	O	B-Entity
,	O	O	O
TE-B1-B3	O	O	B-Entity
,	O	O	O
TE-C	O	O	B-Entity
,	O	O	O
TE-E1	O	O	B-Entity
,	O	O	O
and	O	O	O
TE-E2	O	O	B-Entity
)	O	O	O
genotypes	O	O	B-Entity
.	O	O	O

T.	O	O	B-Entity
equigenitalis	O	O	I-Entity
field	O	O	B-Entity
isolates	O	O	B-Entity
(	O	O	O
n=40	O	O	O
)	O	O	O
obtained	O	O	B-Entity
from	O	O	O
Austrian	O	O	B-Entity
Lipizzaner	O	O	I-Entity
horses	O	O	I-Entity
were	O	O	O
differentiated	O	O	B-Entity
into	O	O	O
three	O	O	O
REP	O	O	B-Entity
(	O	O	O
rep-E1	O	O	B-Entity
,	O	O	O
rep-E3a	O	O	B-Entity
,	O	O	O
and	O	O	O
rep-E4	O	O	B-Entity
)	O	O	O
and	O	O	O
three	O	O	O
PFGE	O	O	B-Entity
genotypes	O	O	B-Entity
(	O	O	O
TE-A2	O	O	B-Entity
,	O	O	O
TE-A5	O	O	B-Entity
,	O	O	O
and	O	O	O
TE-D	O	O	B-Entity
)	O	O	O
;	O	O	O
those	O	O	O
isolated	O	O	B-Entity
from	O	O	O
four	O	O	O
Austrian	O	O	B-Entity
Trotters	O	O	I-Entity
belonged	O	O	O
to	O	O	O
the	O	O	O
REP	O	O	O
/	O	O	O
PFGE	O	O	O
genotype	O	O	B-Entity
rep-E2/TE-A1	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
a	O	O	O
T.	O	O	B-Entity
equigenitalis	O	O	I-Entity
isolate	O	O	B-Entity
recovered	O	O	B-Entity
from	O	O	I-Entity
a	O	O	O
Holsteiner	O	O	B-Entity
stallion	O	O	I-Entity
living	O	O	B-Entity
in	O	O	O
South	O	O	B-Entity
Africa	O	O	I-Entity
revealed	O	O	B-Entity
the	O	O	O
REP	O	O	B-Entity
/	O	O	O
PFGE	O	O	B-Entity
genotype	O	O	B-Entity
rep-E1/TE-A5	O	O	B-Entity
which	O	O	O
was	O	O	O
otherwise	O	O	O
exclusively	O	O	B-Entity
present	O	O	B-Entity
in	O	O	O
the	O	O	O
majority	O	O	B-Entity
of	O	O	O
Austrian	O	O	B-Entity
Lipizzaner	O	O	I-Entity
horses	O	O	I-Entity
in	O	O	O
our	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
type	O	O	O
strain	O	O	B-Entity
included	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
revealed	O	O	B-Entity
the	O	O	O
genotype	O	O	B-Entity
REP	O	O	B-Entity
/	O	O	O
PFGE	O	O	B-Entity
rep-E1/TE-F.	O	O	O
Six	O	O	O
strains	O	O	B-Entity
of	O	O	O
T.	O	O	B-Entity
asinigenitalis	O	O	I-Entity
including	O	O	O
the	O	O	O
type	O	O	O
strain	O	O	O
were	O	O	O
separated	O	O	B-Entity
into	O	O	O
three	O	O	O
REP	O	O	O
(	O	O	O
rep-A1-A3	O	O	B-Entity
)	O	O	O
and	O	O	O
six	O	O	O
PFGE	O	O	O
genotypes	O	O	B-Entity
(	O	O	O
TA-A1	O	O	B-Entity
,	O	O	O
TA-A2	O	O	B-Entity
,	O	O	O
TA-A3	O	O	B-Entity
,	O	O	O
TA-B	O	O	B-Entity
,	O	O	O
TA-C	O	O	B-Entity
,	O	O	O
TA-D	O	O	B-Entity
)	O	O	O
.	O	O	O

Overall	O	O	B-Entity
,	O	O	I-Entity
the	O	O	O
generated	O	O	B-Entity
REP	O	O	B-Entity
and	O	O	O
PFGE	O	O	B-Entity
genotypes	O	O	B-Entity
showed	O	O	O
a	O	O	O
good	O	O	B-Entity
correlation	O	O	B-Entity
,	O	O	O
whereas	O	O	O
REP-PCR	O	O	B-Entity
proved	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
suitable	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
molecular	O	O	B-Entity
epidemiological	O	O	I-Entity
screening	O	O	I-Entity
of	O	O	O
T.	O	O	B-Entity
equigenitalis	O	O	I-Entity
and	O	O	O
T.	O	O	B-Entity
asinigenitalis	O	O	I-Entity
isolates	O	O	B-Entity
that	O	O	O
should	O	O	O
be	O	O	O
differentiated	O	O	B-Entity
in	O	O	O
detail	O	O	B-Entity
by	O	O	O
genotyping	O	O	B-Entity
using	O	O	O
PFGE	O	O	O
.	O	O	O

-DOCSTART- (27896225)

The	O	O	O
Urokinase	O	O	B-Entity
/	O	O	O
Urokinase	O	O	B-Entity
Receptor	O	O	I-Entity
System	O	O	O
in	O	O	O
Mast	O	O	B-Entity
Cells	O	O	I-Entity
:	O	O	O
Effects	O	O	B-Entity
of	O	O	O
its	O	O	O
Functional	O	O	B-Entity
Interaction	O	O	B-Entity
with	O	O	O
fMLF	O	O	O
Receptors	O	O	O

Mast	O	O	B-Entity
cell	O	O	I-Entity
and	O	O	O
basophils	O	O	B-Entity
express	O	O	B-Entity
the	O	O	O
high	O	O	B-Entity
affinity	O	O	I-Entity
receptor	O	O	I-Entity
for	O	O	O
IgE	O	O	B-Entity
(	O	O	O
FcɛRI	O	O	B-Entity
)	O	O	O
and	O	O	O
are	O	O	O
primary	O	O	B-Entity
effector	O	O	I-Entity
cells	O	O	I-Entity
of	O	O	O
allergic	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

The	O	O	O
urokinase	O	O	B-Entity
(uPA)-mediated	O	O	O
plasminogen	O	O	B-Entity
activation	O	O	I-Entity
system	O	O	I-Entity
is	O	O	O
involved	O	O	O
in	O	O	O
physiological	O	O	B-Entity
and	O	O	O
pathological	O	O	B-Entity
events	O	O	I-Entity
based	O	O	O
on	O	O	O
cell	O	O	B-Entity
migration	O	O	I-Entity
and	O	O	O
tissue	O	O	B-Entity
remodelling	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
,	O	O	O
angiogenesis	O	O	B-Entity
and	O	O	O
metastasis	O	O	B-Entity
.	O	O	O

uPA	O	O	B-Entity
is	O	O	O
a	O	O	O
serine	O	O	B-Entity
protease	O	O	I-Entity
that	O	O	O
binds	O	O	O
uPAR	O	O	B-Entity
,	O	O	O
a	O	O	O
high	O	O	B-Entity
affinity	O	O	I-Entity
glycosyl-phosphatidyl-inositol	O	O	I-Entity
(GPI)-anchored	O	O	I-Entity
receptor	O	O	B-Entity
.	O	O	O

uPAR	O	O	B-Entity
focuses	O	O	O
uPA	O	O	B-Entity
activity	O	O	B-Entity
at	O	O	O
the	O	O	O
cell	O	O	B-Entity
surface	O	O	I-Entity
and	O	O	O
activates	O	O	B-Entity
intracellular	O	O	I-Entity
signaling	O	O	I-Entity
through	O	O	O
lateral	O	O	O
interactions	O	O	B-Entity
with	O	O	O
integrins	O	O	B-Entity
,	O	O	O
receptor	O	O	B-Entity
tyrosine	O	O	I-Entity
kinases	O	O	I-Entity
and	O	O	O
the	O	O	O
G-protein-coupled	O	O	B-Entity
family	O	O	I-Entity
of	O	O	O
fMLF	O	O	B-Entity
chemotaxis	O	O	I-Entity
receptors	O	O	I-Entity
(	O	O	O
FPRs	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
uPA	O	O	B-Entity
-	O	O	O
uPAR	O	O	B-Entity
system	O	O	O
and	O	O	O
its	O	O	O
functional	O	O	B-Entity
interaction	O	O	B-Entity
with	O	O	O
FPRs	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
mast	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
MCs	O	O	B-Entity
)	O	O	O
.	O	O	O

Differently	O	O	O
from	O	O	O
basophils	O	O	B-Entity
,	O	O	O
MCs	O	O	B-Entity
produced	O	O	O
uPA	O	O	B-Entity
that	O	O	O
was	O	O	O
able	O	O	O
to	O	O	O
induce	O	O	O
their	O	O	O
chemotaxis	O	O	B-Entity
.	O	O	O

Indeed	O	O	O
,	O	O	O
MCs	O	O	B-Entity
also	O	O	O
expressed	O	O	O
uPAR	O	O	B-Entity
,	O	O	O
both	O	O	O
in	O	O	O
the	O	O	O
intact	O	O	O
and	O	O	O
in	O	O	O
a	O	O	O
cleaved	O	O	O
form	O	O	O
(	O	O	O
DII-DIII-uPAR	O	O	B-Entity
)	O	O	O
that	O	O	O
can	O	O	O
expose	O	O	O
,	O	O	O
at	O	O	O
the	O	O	O
N-terminus	O	O	O
,	O	O	O
the	O	O	O
SRSRY	O	O	B-Entity
sequence	O	O	I-Entity
,	O	O	O
able	O	O	O
to	O	O	O
interact	O	O	O
with	O	O	O
FPRs	O	O	B-Entity
and	O	O	O
to	O	O	O
mediate	O	O	O
cell	O	O	B-Entity
chemotaxis	O	O	I-Entity
.	O	O	O

MCs	O	O	B-Entity
also	O	O	O
expressed	O	O	O
mRNAs	O	O	B-Entity
for	O	O	O
FPRs	O	O	B-Entity
that	O	O	O
were	O	O	O
functionally	O	O	O
active	O	O	O
;	O	O	O
indeed	O	O	O
,	O	O	O
uPA	O	O	B-Entity
and	O	O	O
a	O	O	O
soluble	O	O	B-Entity
peptide	O	O	I-Entity
(	O	O	O
uPAR84	O	O	B-Entity
-	O	O	I-Entity
95	O	O	I-Entity
)	O	O	O
,	O	O	O
containing	O	O	O
the	O	O	O
SRSRY	O	O	B-Entity
chemotactic	O	O	I-Entity
sequence	O	O	I-Entity
of	O	O	O
uPAR	O	O	B-Entity
and	O	O	O
able	O	O	O
to	O	O	O
interact	O	O	O
with	O	O	O
FPRs	O	O	O
,	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
induce	O	O	O
MCs	O	O	O
chemotaxis	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
uPA	O	O	B-Entity
is	O	O	O
a	O	O	O
potent	O	O	O
chemoattractant	O	O	B-Entity
for	O	O	O
MCs	O	O	B-Entity
acting	O	O	O
through	O	O	O
the	O	O	O
exposure	O	O	B-Entity
of	O	O	O
the	O	O	O
chemotactic	O	O	B-Entity
epitope	O	O	B-Entity
of	O	O	O
uPAR	O	O	B-Entity
,	O	O	O
that	O	O	O
is	O	O	O
an	O	O	O
endogenous	O	O	B-Entity
ligand	O	O	B-Entity
for	O	O	O
FPRs	O	O	B-Entity
.	O	O	O

The	O	O	O
same	O	O	O
mechanism	O	O	B-Entity
could	O	O	O
be	O	O	O
involved	O	O	O
in	O	O	O
VEGF-A	O	O	B-Entity
secretion	O	O	B-Entity
by	O	O	O
human	O	O	B-Entity
MCs	O	O	B-Entity
,	O	O	O
also	O	O	O
induced	O	O	B-Entity
by	O	O	O
uPA	O	O	B-Entity
and	O	O	O
uPAR84	O	O	B-Entity
-	O	O	I-Entity
95	O	O	I-Entity
stimulation	O	O	O
.	O	O	O

-DOCSTART- (27898362)

Psychogenic	O	O	B-Entity
non-epileptic	O	O	I-Entity
seizure	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
intellectual	O	O	B-Entity
disability	O	O	I-Entity
with	O	O	O
special	O	O	O
focus	O	O	O
on	O	O	O
choice	O	O	B-Entity
of	O	O	O
therapeutic	O	O	O
intervention	O	O	O

There	O	O	O
have	O	O	O
been	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
studies	O	O	B-Entity
exploring	O	O	O
treatments	O	O	B-Entity
for	O	O	O
psychogenic	O	O	B-Entity
non-epileptic	O	O	I-Entity
seizure	O	O	I-Entity
(	O	O	O
PNES	O	O	B-Entity
)	O	O	O
but	O	O	O
largely	O	O	O
neglecting	O	O	B-Entity
the	O	O	O
sizable	O	O	O
subgroup	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
intellectual	O	O	B-Entity
disability	O	O	I-Entity
(	O	O	O
ID	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
,	O	O	O
we	O	O	O
attempted	O	O	B-Entity
to	O	O	O
demonstrate	O	O	B-Entity
effects	O	O	B-Entity
and	O	O	O
preferred	O	O	B-Entity
modes	O	O	O
of	O	O	O
therapeutic	O	O	B-Entity
intervention	O	O	I-Entity
in	O	O	O
PNES	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
ID	O	O	B-Entity
being	O	O	O
treated	O	O	B-Entity
at	O	O	O
a	O	O	O
Japanese	O	O	B-Entity
municipal	O	O	I-Entity
center	O	O	I-Entity
with	O	O	O
a	O	O	O
short	O	O	B-Entity
referral	O	O	B-Entity
chain	O	O	I-Entity
.	O	O	O

We	O	O	O
examined	O	O	B-Entity
46	O	O	O
PNES	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
ID	O	O	B-Entity
(	O	O	O
ID	O	O	O
group	O	O	B-Entity
)	O	O	O
and	O	O	O
106	O	O	O
PNES	O	O	O
patients	O	O	O
without	O	O	O
ID	O	O	O
(	O	O	O
non-ID	O	O	B-Entity
group	O	O	O
)	O	O	O
retrospectively	O	O	B-Entity
in	O	O	O
case	O	O	B-Entity
charts	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
addition	O	O	I-Entity
to	O	O	I-Entity
examining	O	O	B-Entity
basic	O	O	O
demographic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
data	O	O	I-Entity
,	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
different	O	O	B-Entity
therapeutic	O	O	B-Entity
intervention	O	O	I-Entity
were	O	O	O
examined	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
decrease	O	O	B-Entity
or	O	O	O
disappearance	O	O	B-Entity
of	O	O	O
PNES	O	O	B-Entity
attacks	O	O	O
in	O	O	O
the	O	O	O
ID	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

Age	O	O	B-Entity
at	O	O	O
the	O	O	O
first	O	O	O
visit	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
PNES	O	O	B-Entity
onset	O	O	B-Entity
was	O	O	O
younger	O	O	B-Entity
in	O	O	O
the	O	O	O
ID	O	O	B-Entity
than	O	O	O
in	O	O	O
the	O	O	O
non-ID	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
t=2.651	O	O	O
,	O	O	O
p=0.009	O	O	O
;	O	O	O
t=3.528	O	O	O
,	O	O	O
p=0.001	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

PNES	O	O	B-Entity
-free	O	O	O
ratio	O	O	B-Entity
at	O	O	O
the	O	O	O
last	O	O	O
visit	O	O	B-Entity
tended	O	O	O
to	O	O	O
be	O	O	O
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
non-ID	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
chi	O	O	B-Entity
square	O	O	I-Entity
=	O	O	O
3.455	O	O	O
;	O	O	O
p=0.063	O	O	O
)	O	O	O
.	O	O	O

Psychosis	O	O	B-Entity
was	O	O	O
more	O	O	O
often	O	O	O
encountered	O	O	O
in	O	O	O
the	O	O	O
ID	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
chi	O	O	B-Entity
square	O	O	I-Entity
=	O	O	O
13.443	O	O	O
;	O	O	O
p=0.001	O	O	O
)	O	O	O
.	O	O	O

Although	O	O	O
cognitive	O	O	B-Entity
therapy	O	O	I-Entity
and	O	O	O
pharmaco-therapeutic	O	O	B-Entity
approaches	O	O	O
were	O	O	O
quite	O	O	O
similarly	O	O	B-Entity
distributed	O	O	B-Entity
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
,	O	O	O
environmental	O	O	B-Entity
adjustment	O	O	B-Entity
was	O	O	O
often	O	O	O
introduced	O	O	B-Entity
in	O	O	O
the	O	O	O
ID	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
44	O	O	O
%	O	O	O
)	O	O	O
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
non-ID	O	O	B-Entity
group	O	O	O
(	O	O	O
15	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
chi	O	O	B-Entity
square	O	O	I-Entity
=	O	O	O
14.299	O	O	O
;	O	O	O
p=0.001	O	O	O
)	O	O	O
.	O	O	O

Brief	O	O	B-Entity
weekly	O	O	B-Entity
visit	O	O	B-Entity
service	O	O	I-Entity
is	O	O	O
also	O	O	O
more	O	O	O
often	O	O	O
utilized	O	O	B-Entity
by	O	O	O
the	O	O	O
patients	O	O	B-Entity
with	O	O	O
ID	O	O	B-Entity
(	O	O	O
54	O	O	O
%	O	O	O
)	O	O	O
than	O	O	O
by	O	O	O
those	O	O	O
without	O	O	O
ID	O	O	O
(	O	O	O
35	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
chi	O	O	B-Entity
square	O	O	I-Entity
=	O	O	O
5.021	O	O	O
,	O	O	O
p=0.025	O	O	O
)	O	O	O
.	O	O	O

Optimal	O	O	B-Entity
treatment	O	O	B-Entity
approaches	O	O	O
in	O	O	O
this	O	O	O
sizable	O	O	O
patient	O	O	B-Entity
subgroup	O	O	B-Entity
should	O	O	O
be	O	O	O
the	O	O	O
subject	O	O	B-Entity
of	O	O	O
future	O	O	B-Entity
prospective	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

-DOCSTART- (27900080)

Effect	O	O	B-Entity
of	O	O	I-Entity
an	O	O	O
immunomodulatory	O	O	B-Entity
regimen	O	O	I-Entity
for	O	O	O
cancer	O	O	B-Entity
prevention	O	O	I-Entity
:	O	O	O
A	O	O	O
case	O	O	O
report	O	O	O

In	O	O	O
the	O	O	O
present	O	O	B-Entity
case	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
an	O	O	O
immunomodulatory	O	O	B-Entity
regimen	O	O	I-Entity
for	O	O	O
cancer	O	O	B-Entity
prevention	O	O	I-Entity
is	O	O	O
reported	O	O	B-Entity
.	O	O	O

A	O	O	O
patient	O	O	B-Entity
with	O	O	O
an	O	O	O
abnormally	O	O	B-Entity
high	O	O	I-Entity
level	O	O	B-Entity
of	O	O	O
the	O	O	O
tumor	O	O	B-Entity
markers	O	O	I-Entity
,	O	O	O
carbohydrate	O	O	B-Entity
antigen-724	O	O	I-Entity
(	O	O	O
CA724	O	O	B-Entity
)	O	O	O
,	O	O	O
CA19	O	O	B-Entity
-	O	O	I-Entity
9	O	O	I-Entity
and	O	O	O
carcinoembryonic	O	O	B-Entity
antigen	O	O	I-Entity
(	O	O	O
CEA	O	O	B-Entity
)	O	O	O
,	O	O	O
although	O	O	O
without	O	O	B-Entity
any	O	O	O
detectable	O	O	B-Entity
tumor	O	O	O
,	O	O	O
was	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
immunomodulatory	O	O	B-Entity
therapy	O	O	I-Entity
featuring	O	O	O
an	O	O	O
infusion	O	O	B-Entity
of	O	O	O
cytokine-induced	O	O	B-Entity
autologous	O	O	I-Entity
killer	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
CIKs	O	O	B-Entity
)	O	O	O
at	O	O	O
the	O	O	O
request	O	O	B-Entity
of	O	O	O
the	O	O	O
patient	O	O	O
.	O	O	O

Following	O	O	O
the	O	O	O
therapy	O	O	B-Entity
,	O	O	O
the	O	O	O
three	O	O	O
tumor	O	O	B-Entity
markers	O	O	I-Entity
rapidly	O	O	B-Entity
decreased	O	O	B-Entity
to	O	O	O
below	O	O	O
the	O	O	O
normal	O	O	B-Entity
reference	O	O	I-Entity
level	O	O	I-Entity
,	O	O	O
although	O	O	O
there	O	O	O
still	O	O	O
were	O	O	O
slight	O	O	B-Entity
fluctuations	O	O	B-Entity
within	O	O	O
a	O	O	O
narrow	O	O	B-Entity
range	O	O	B-Entity
frequently	O	O	B-Entity
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
was	O	O	O
monitored	O	O	B-Entity
for	O	O	O
21	O	O	O
months	O	O	B-Entity
to	O	O	O
the	O	O	O
present	O	O	B-Entity
day	O	O	B-Entity
and	O	O	O
no	O	O	B-Entity
abnormality	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
indicated	O	O	O
that	O	O	O
this	O	O	O
therapy	O	O	B-Entity
may	O	O	O
be	O	O	O
applied	O	O	O
as	O	O	O
a	O	O	O
novel	O	O	B-Entity
strategy	O	O	O
that	O	O	O
is	O	O	O
effective	O	O	B-Entity
and	O	O	O
reliable	O	O	B-Entity
for	O	O	O
cancer	O	O	B-Entity
prevention	O	O	I-Entity
.	O	O	O

As	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
promising	O	O	O
regimen	O	O	B-Entity
for	O	O	O
the	O	O	O
prevention	O	O	B-Entity
of	O	O	I-Entity
malignancies	O	O	I-Entity
to	O	O	O
date	O	O	O
,	O	O	O
such	O	O	O
a	O	O	O
treatment	O	O	B-Entity
may	O	O	O
become	O	O	O
a	O	O	O
major	O	O	B-Entity
cancer	O	O	B-Entity
prophylactic	O	O	B-Entity
regimen	O	O	I-Entity
,	O	O	O
particularly	O	O	O
for	O	O	O
patients	O	O	B-Entity
who	O	O	O
are	O	O	O
at	O	O	O
a	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
cancer	O	O	O
.	O	O	O

-DOCSTART- (27900133)

The	O	O	O
relationships	O	O	B-Entity
between	O	O	O
rugby	O	O	B-Entity
players	O	O	B-Entity
'	O	O	I-Entity
tackle	O	O	B-Entity
training	O	O	B-Entity
attitudes	O	O	B-Entity
and	O	O	O
behaviour	O	O	B-Entity
and	O	O	O
their	O	O	O
match	O	O	B-Entity
tackle	O	O	I-Entity
attitudes	O	O	I-Entity
and	O	O	O
behaviour	O	O	O

The	O	O	O
tackle	O	O	B-Entity
event	O	O	O
in	O	O	O
rugby	O	O	B-Entity
is	O	O	O
a	O	O	O
technical	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
contest	O	O	B-Entity
between	O	O	O
opposing	O	O	O
players	O	O	B-Entity
.	O	O	O

A	O	O	O
player	O	O	B-Entity
's	O	O	I-Entity
ability	O	O	O
to	O	O	O
tolerate	O	O	B-Entity
and	O	O	O
contest	O	O	B-Entity
during	O	O	O
a	O	O	O
tackle	O	O	B-Entity
is	O	O	O
a	O	O	O
prerequisite	O	O	B-Entity
for	O	O	O
safe	O	O	B-Entity
participation	O	O	B-Entity
and	O	O	O
success	O	O	B-Entity
in	O	O	O
rugby	O	O	B-Entity
.	O	O	O

Little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
tackle	O	O	B-Entity
training	O	O	I-Entity
and	O	O	O
tackling	O	O	B-Entity
in	O	O	O
matches	O	O	B-Entity
in	O	O	O
rugby	O	O	B-Entity
union	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
players	O	O	B-Entity
'	O	O	I-Entity
training	O	O	B-Entity
attitudes	O	O	I-Entity
and	O	O	O
behaviour	O	O	B-Entity
and	O	O	O
their	O	O	O
match	O	O	B-Entity
attitudes	O	O	I-Entity
and	O	O	O
behaviour	O	O	O
for	O	O	O
tackling	O	O	B-Entity
in	O	O	O
rugby	O	O	B-Entity
union	O	O	I-Entity
.	O	O	O

A	O	O	O
questionnaire	O	O	B-Entity
was	O	O	O
designed	O	O	O
to	O	O	O
assess	O	O	B-Entity
attitude	O	O	B-Entity
(	O	O	O
importance	O	O	O
)	O	O	O
and	O	O	O
behaviours	O	O	B-Entity
(	O	O	O
frequency	O	O	B-Entity
and	O	O	O
quantity	O	O	B-Entity
)	O	O	O
among	O	O	O
junior	O	O	B-Entity
(	O	O	O
under	O	O	O
19	O	O	O
)	O	O	O
players	O	O	B-Entity
on	O	O	O
a	O	O	O
5-point	O	O	B-Entity
Likert	O	O	I-Entity
Scale	O	O	I-Entity
.	O	O	O

Questionnaires	O	O	B-Entity
were	O	O	O
handed	O	O	O
out	O	O	O
to	O	O	O
220	O	O	O
players	O	O	B-Entity
(	O	O	O
10	O	O	O
schools	O	O	B-Entity
)	O	O	O
at	O	O	O
a	O	O	O
tournament	O	O	B-Entity
and	O	O	O
75	O	O	O
%	O	O	O
(	O	O	O
9	O	O	O
schools	O	O	O
,	O	O	O
n=164	O	O	O
)	O	O	O
were	O	O	O
returned	O	O	O
for	O	O	O
analysis	O	O	B-Entity
.	O	O	O

Associations	O	O	B-Entity
between	O	O	O
training	O	O	B-Entity
attitudes	O	O	I-Entity
and	O	O	O
behaviours	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
using	O	O	O
the	O	O	O
χ(2	O	O	B-Entity
)	O	O	I-Entity
test	O	O	I-Entity
,	O	O	I-Entity
Cramer	O	O	I-Entity
's	O	O	I-Entity
V	O	O	I-Entity
and	O	O	I-Entity
τ-b	O	O	I-Entity
.	O	O	O

The	O	O	O
more	O	O	O
time	O	O	O
spent	O	O	O
on	O	O	O
emphasising	O	O	O
proper	O	O	O
technique	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
injuries	O	O	B-Entity
in	O	O	O
training	O	O	B-Entity
,	O	O	O
the	O	O	O
more	O	O	O
important	O	O	O
players	O	O	B-Entity
rated	O	O	O
'	O	O	O
own	O	O	O
safety	O	O	O
'	O	O	O
(	O	O	O
τ-b=0.21	O	O	O
,	O	O	O
moderate	O	O	B-Entity
,	O	O	O
z=3.1	O	O	O
,	O	O	O
p<0.01	O	O	O
)	O	O	O
,	O	O	O
'	O	O	O
going	O	O	O
for	O	O	O
the	O	O	O
ball	O	O	B-Entity
only	O	O	O
'	O	O	O
(	O	O	O
τ-b=0.27	O	O	O
,	O	O	O
moderate	O	O	O
,	O	O	O
z=4.6	O	O	O
,	O	O	O
p<0.001	O	O	O
)	O	O	O
and	O	O	O
'	O	O	O
staying	O	O	O
on	O	O	O
feet	O	O	O
'	O	O	O
(	O	O	O
τ-b=0.23	O	O	O
,	O	O	O
moderate	O	O	O
,	O	O	O
z=3.6	O	O	O
,	O	O	O
p<0.001	O	O	O
)	O	O	O
in	O	O	O
match	O	O	B-Entity
play	O	O	I-Entity
.	O	O	O

The	O	O	O
more	O	O	O
time	O	O	O
spent	O	O	O
on	O	O	O
emphasising	O	O	O
proper	O	O	O
technique	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
performance	O	O	B-Entity
in	O	O	O
training	O	O	B-Entity
,	O	O	O
the	O	O	O
more	O	O	O
important	O	O	O
players	O	O	B-Entity
rated	O	O	O
actions	O	O	O
'	O	O	O
going	O	O	O
for	O	O	O
ball	O	O	B-Entity
only	O	O	O
'	O	O	O
(	O	O	O
τ-b=0.23	O	O	O
,	O	O	O
moderate	O	O	B-Entity
,	O	O	O
z=3.7	O	O	O
,	O	O	O
p<0.001	O	O	O
)	O	O	O
and	O	O	O
'	O	O	O
preventing	O	O	B-Entity
the	O	O	O
ball	O	O	O
carrier	O	O	O
from	O	O	O
retaining	O	O	B-Entity
position	O	O	B-Entity
'	O	O	O
(	O	O	O
τ-b=0.20	O	O	O
,	O	O	O
moderate	O	O	O
,	O	O	O
z=3.1	O	O	O
,	O	O	O
p<0.01	O	O	O
)	O	O	O
in	O	O	O
match	O	O	B-Entity
play	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	B-Entity
to	O	O	O
report	O	O	O
on	O	O	O
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
players	O	O	B-Entity
'	O	O	O
training	O	O	B-Entity
attitudes	O	O	I-Entity
and	O	O	O
behaviour	O	O	B-Entity
and	O	O	O
their	O	O	O
match	O	O	B-Entity
attitudes	O	O	I-Entity
and	O	O	O
behaviour	O	O	O
s	O	O	O
for	O	O	O
tackling	O	O	B-Entity
in	O	O	O
rugby	O	O	B-Entity
union	O	O	I-Entity
.	O	O	O

The	O	O	O
importance	O	O	O
of	O	O	O
tackle	O	O	B-Entity
training	O	O	B-Entity
to	O	O	O
prevent	O	O	B-Entity
injury	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
amount	O	O	O
of	O	O	O
time	O	O	O
spent	O	O	O
on	O	O	O
technique	O	O	B-Entity
to	O	O	O
prevent	O	O	O
injuries	O	O	B-Entity
,	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
behaviours	O	O	B-Entity
that	O	O	O
reduce	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
injury	O	O	I-Entity
in	O	O	O
matches	O	O	B-Entity
.	O	O	O

-DOCSTART- (27903991)

Role	O	O	B-Entity
of	O	O	O
Oxidative	O	O	B-Entity
Stress	O	O	I-Entity
and	O	O	O
Inflammatory	O	O	B-Entity
Factors	O	O	B-Entity
in	O	O	O
Diabetic	O	O	O
Kidney	O	O	O
Disease	O	O	O

Diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
(	O	O	O
DN	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
serious	O	O	B-Entity
complication	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
,	O	O	O
and	O	O	O
its	O	O	O
prevalence	O	O	B-Entity
has	O	O	O
been	O	O	O
increasing	O	O	B-Entity
in	O	O	O
developed	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

Diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
has	O	O	O
become	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
single	O	O	B-Entity
cause	O	O	O
of	O	O	O
end-stage	O	O	B-Entity
renal	O	O	I-Entity
disease	O	O	I-Entity
worldwide	O	O	B-Entity
.	O	O	O

Oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
inflammation	O	O	B-Entity
factors	O	O	B-Entity
are	O	O	O
hypothesized	O	O	B-Entity
to	O	O	O
play	O	O	B-Entity
a	O	O	I-Entity
role	O	O	I-Entity
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
late	O	O	B-Entity
diabetes	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

Chronic	O	O	B-Entity
hyperglycemia	O	O	I-Entity
increases	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
significantly	O	O	B-Entity
modifies	O	O	I-Entity
the	O	O	O
structure	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
of	O	O	O
proteins	O	O	B-Entity
and	O	O	O
lipids	O	O	B-Entity
,	O	O	O
and	O	O	O
induces	O	O	B-Entity
glycoxidation	O	O	B-Entity
and	O	O	O
peroxidation	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
hyperglycemia	O	O	B-Entity
causes	O	O	O
auto-oxidation	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
,	O	O	O
glycation	O	O	B-Entity
of	O	O	O
proteins	O	O	B-Entity
,	O	O	O
and	O	O	O
activation	O	O	B-Entity
of	O	O	O
polyol	O	O	B-Entity
mechanism	O	O	I-Entity
.	O	O	O

Overproduction	O	O	B-Entity
of	O	O	O
intracellular	O	O	B-Entity
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
contributes	O	O	B-Entity
to	O	O	O
several	O	O	B-Entity
microvascular	O	O	B-Entity
and	O	O	O
macrovascular	O	O	B-Entity
complications	O	O	B-Entity
of	O	O	O
DN	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
modulates	O	O	B-Entity
signaling	O	O	B-Entity
cascade	O	O	I-Entity
of	O	O	O
immune	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

An	O	O	O
increase	O	O	B-Entity
in	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
can	O	O	O
increase	O	O	O
the	O	O	O
production	O	O	B-Entity
of	O	O	O
inflammatory	O	O	B-Entity
cytokines	O	O	B-Entity
,	O	O	O
and	O	O	O
likewise	O	O	O
,	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
inflammatory	O	O	O
cytokines	O	O	O
can	O	O	O
stimulate	O	O	B-Entity
the	O	O	O
production	O	O	O
of	O	O	O
free	O	O	B-Entity
radicals	O	O	I-Entity
.	O	O	O

Some	O	O	O
studies	O	O	B-Entity
have	O	O	O
shown	O	O	O
that	O	O	O
kidney	O	O	B-Entity
inflammation	O	O	I-Entity
is	O	O	O
serious	O	O	B-Entity
in	O	O	O
promoting	O	O	B-Entity
the	O	O	O
development	O	O	B-Entity
and	O	O	O
progression	O	O	B-Entity
of	O	O	O
DN	O	O	B-Entity
.	O	O	O

Inflammatory	O	O	B-Entity
factors	O	O	B-Entity
which	O	O	O
are	O	O	O
activated	O	O	B-Entity
by	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
,	O	O	O
biochemical	O	O	B-Entity
,	O	O	O
and	O	O	O
hemodynamic	O	O	B-Entity
derangements	O	O	O
are	O	O	O
known	O	O	O
to	O	O	O
exist	O	O	B-Entity
in	O	O	O
the	O	O	O
diabetic	O	O	B-Entity
kidney	O	O	I-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
discusses	O	O	O
facts	O	O	O
for	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
inflammatory	O	O	B-Entity
factors	O	O	B-Entity
in	O	O	O
DN	O	O	B-Entity
and	O	O	O
encompasses	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
immune	O	O	B-Entity
and	O	O	O
inflammatory	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
inflammatory	O	O	O
cytokines	O	O	B-Entity
,	O	O	O
and	O	O	O
stress	O	O	B-Entity
oxidative	O	O	I-Entity
factors	O	O	O
.	O	O	O

-DOCSTART- (27908503)

Cobalt-60	O	O	B-Entity
Machines	O	O	I-Entity
and	O	O	O
Medical	O	O	B-Entity
Linear	O	O	I-Entity
Accelerators	O	O	I-Entity
:	O	O	O
Competing	O	O	B-Entity
Technologies	O	O	I-Entity
for	O	O	O
External	O	O	O
Beam	O	O	O
Radiotherapy	O	O	O

Medical	O	O	B-Entity
linear	O	O	I-Entity
accelerators	O	O	I-Entity
(	O	O	O
linacs	O	O	B-Entity
)	O	O	O
and	O	O	O
cobalt-60	O	O	B-Entity
machines	O	O	I-Entity
are	O	O	O
both	O	O	O
mature	O	O	O
technologies	O	O	B-Entity
for	O	O	O
external	O	O	B-Entity
beam	O	O	I-Entity
radiotherapy	O	O	I-Entity
.	O	O	O

A	O	O	O
comparison	O	O	B-Entity
is	O	O	O
made	O	O	O
between	O	O	O
these	O	O	O
two	O	O	O
technologies	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
infrastructure	O	O	B-Entity
and	O	O	O
maintenance	O	O	B-Entity
,	O	O	O
dosimetry	O	O	B-Entity
,	O	O	O
shielding	O	O	B-Entity
requirements	O	O	B-Entity
,	O	O	O
staffing	O	O	B-Entity
,	O	O	O
costs	O	O	B-Entity
,	O	O	O
security	O	O	B-Entity
,	O	O	O
patient	O	O	B-Entity
throughput	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
use	O	O	I-Entity
.	O	O	O

Infrastructure	O	O	B-Entity
and	O	O	O
maintenance	O	O	B-Entity
are	O	O	O
more	O	O	O
demanding	O	O	B-Entity
for	O	O	O
linacs	O	O	B-Entity
due	O	O	O
to	O	O	O
the	O	O	O
complex	O	O	B-Entity
electric	O	O	I-Entity
componentry	O	O	I-Entity
.	O	O	O

In	O	O	O
dosimetry	O	O	B-Entity
,	O	O	O
a	O	O	O
higher	O	O	B-Entity
beam	O	O	B-Entity
energy	O	O	I-Entity
,	O	O	O
modulated	O	O	B-Entity
dose	O	O	B-Entity
rate	O	O	I-Entity
and	O	O	O
smaller	O	O	B-Entity
focal	O	O	B-Entity
spot	O	O	I-Entity
size	O	O	I-Entity
mean	O	O	O
that	O	O	O
it	O	O	O
is	O	O	O
easier	O	O	B-Entity
to	O	O	O
create	O	O	B-Entity
an	O	O	O
optimised	O	O	B-Entity
treatment	O	O	B-Entity
with	O	O	O
a	O	O	O
linac	O	O	B-Entity
for	O	O	O
conformal	O	O	O
dose	O	O	O
coverage	O	O	B-Entity
of	O	O	O
the	O	O	O
tumour	O	O	B-Entity
while	O	O	O
sparing	O	O	O
healthy	O	O	B-Entity
organs	O	O	I-Entity
at	O	O	O
risk	O	O	B-Entity
.	O	O	O

In	O	O	O
shielding	O	O	B-Entity
,	O	O	O
the	O	O	O
requirements	O	O	B-Entity
for	O	O	O
a	O	O	O
concrete	O	O	B-Entity
bunker	O	O	I-Entity
are	O	O	O
similar	O	O	O
for	O	O	O
cobalt-60	O	O	B-Entity
machines	O	O	I-Entity
and	O	O	O
linacs	O	O	B-Entity
but	O	O	O
extra	O	O	O
shielding	O	O	O
and	O	O	O
protection	O	O	B-Entity
from	O	O	O
neutrons	O	O	B-Entity
are	O	O	O
required	O	O	O
for	O	O	O
linacs	O	O	O
.	O	O	O

Staffing	O	O	B-Entity
levels	O	O	I-Entity
can	O	O	O
be	O	O	O
higher	O	O	B-Entity
for	O	O	O
linacs	O	O	B-Entity
and	O	O	O
more	O	O	O
staff	O	O	B-Entity
training	O	O	I-Entity
is	O	O	O
required	O	O	O
for	O	O	O
linacs	O	O	O
.	O	O	O

Life	O	O	B-Entity
cycle	O	O	I-Entity
costs	O	O	I-Entity
are	O	O	O
higher	O	O	B-Entity
for	O	O	O
linacs	O	O	B-Entity
,	O	O	O
especially	O	O	O
multi-energy	O	O	B-Entity
linacs	O	O	I-Entity
.	O	O	O

Security	O	O	B-Entity
is	O	O	O
more	O	O	O
complex	O	O	B-Entity
for	O	O	O
cobalt-60	O	O	B-Entity
machines	O	O	I-Entity
because	O	O	O
of	O	O	O
the	O	O	O
high	O	O	B-Entity
activity	O	O	B-Entity
radioactive	O	O	B-Entity
source	O	O	I-Entity
.	O	O	O

Patient	O	O	B-Entity
throughput	O	O	B-Entity
can	O	O	O
be	O	O	O
affected	O	O	B-Entity
by	O	O	O
source	O	O	B-Entity
decay	O	O	B-Entity
for	O	O	O
cobalt-60	O	O	B-Entity
machines	O	O	I-Entity
but	O	O	O
poor	O	O	B-Entity
maintenance	O	O	B-Entity
and	O	O	O
breakdowns	O	O	B-Entity
can	O	O	O
severely	O	O	O
affect	O	O	B-Entity
patient	O	O	B-Entity
throughput	O	O	O
for	O	O	O
linacs	O	O	B-Entity
.	O	O	O

In	O	O	O
clinical	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
more	O	O	O
complex	O	O	B-Entity
treatment	O	O	B-Entity
techniques	O	O	B-Entity
are	O	O	O
easier	O	O	B-Entity
to	O	O	O
achieve	O	O	O
with	O	O	O
linacs	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
availability	O	O	B-Entity
of	O	O	I-Entity
electron	O	O	B-Entity
beams	O	O	I-Entity
on	O	O	O
high	O	O	B-Entity
-	O	O	O
energy	O	O	B-Entity
linacs	O	O	O
can	O	O	O
be	O	O	O
useful	O	O	O
for	O	O	O
certain	O	O	O
treatments	O	O	B-Entity
.	O	O	O

In	O	O	O
summary	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
simple	O	O	O
answer	O	O	O
to	O	O	O
the	O	O	O
question	O	O	O
of	O	O	O
the	O	O	O
choice	O	O	O
of	O	O	O
either	O	O	O
cobalt-60	O	O	B-Entity
machines	O	O	I-Entity
or	O	O	O
linacs	O	O	B-Entity
for	O	O	O
radiotherapy	O	O	B-Entity
in	O	O	O
low-	O	O	B-Entity
and	O	O	O
middle-income	O	O	B-Entity
countries	O	O	B-Entity
.	O	O	O

In	O	O	O
fact	O	O	O
a	O	O	O
radiotherapy	O	O	B-Entity
department	O	O	I-Entity
with	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
technologies	O	O	B-Entity
,	O	O	O
including	O	O	O
orthovoltage	O	O	B-Entity
X-ray	O	O	I-Entity
units	O	O	I-Entity
,	O	O	O
may	O	O	O
be	O	O	O
an	O	O	O
option	O	O	B-Entity
.	O	O	O

Local	O	O	B-Entity
needs	O	O	B-Entity
,	O	O	O
conditions	O	O	B-Entity
and	O	O	O
resources	O	O	B-Entity
will	O	O	O
have	O	O	O
to	O	O	O
be	O	O	O
factored	O	O	O
into	O	O	O
any	O	O	O
decision	O	O	B-Entity
on	O	O	O
technology	O	O	B-Entity
taking	O	O	O
into	O	O	O
account	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
both	O	O	O
forms	O	O	O
of	O	O	O
teletherapy	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
primary	O	O	O
goal	O	O	B-Entity
being	O	O	O
the	O	O	O
sustainability	O	O	B-Entity
of	O	O	O
the	O	O	O
radiotherapy	O	O	B-Entity
service	O	O	I-Entity
over	O	O	O
the	O	O	O
useful	O	O	O
lifetime	O	O	B-Entity
of	O	O	O
the	O	O	O
equipment	O	O	B-Entity
.	O	O	O

-DOCSTART- (27908539)

Design	O	O	B-Entity
,	O	O	O
synthesis	O	O	B-Entity
,	O	O	O
molecular	O	O	B-Entity
docking	O	O	I-Entity
,	O	O	O
anti-Proteus	O	O	B-Entity
mirabilis	O	O	I-Entity
and	O	O	O
urease	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
new	O	O	O
fluoroquinolone	O	O	O
carboxylic	O	O	O
acid	O	O	O
derivatives	O	O	O

New	O	O	O
hydroxamic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
hydrazide	O	O	B-Entity
and	O	O	O
amide	O	O	B-Entity
derivatives	O	O	I-Entity
of	O	O	O
ciprofloxacin	O	O	B-Entity
in	O	O	O
addition	O	O	O
to	O	O	O
their	O	O	O
analogues	O	O	B-Entity
of	O	O	O
levofloxacin	O	O	B-Entity
were	O	O	O
prepared	O	O	O
and	O	O	O
identified	O	O	O
by	O	O	O
different	O	O	O
spectroscopic	O	O	B-Entity
techniques	O	O	I-Entity
.	O	O	O

Some	O	O	O
of	O	O	O
the	O	O	O
prepared	O	O	O
compounds	O	O	B-Entity
revealed	O	O	O
good	O	O	O
activity	O	O	B-Entity
against	O	O	O
the	O	O	O
urease	O	O	B-Entity
splitting	O	O	O
bacteria	O	O	B-Entity
,	O	O	O
Proteus	O	O	B-Entity
mirabilis	O	O	I-Entity
.	O	O	O

The	O	O	O
urease	O	O	B-Entity
inhibitory	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
investigated	O	O	O
using	O	O	O
indophenol	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
tested	O	O	B-Entity
compounds	O	O	B-Entity
showed	O	O	O
better	O	O	O
activity	O	O	B-Entity
than	O	O	O
the	O	O	O
reference	O	O	O
acetohydroxamic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
AHA	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
ciprofloxacin	O	O	B-Entity
hydrazide	O	O	I-Entity
derivative	O	O	I-Entity
3a	O	O	I-Entity
and	O	O	O
levofloxacin	O	O	B-Entity
hydroxamic	O	O	I-Entity
acid	O	O	I-Entity
7	O	O	I-Entity
experienced	O	O	O
the	O	O	O
highest	O	O	O
activity	O	O	B-Entity
(	O	O	O
IC50	O	O	B-Entity
=	O	O	O
1.22μM	O	O	O
and	O	O	O
2.20μM	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Molecular	O	O	B-Entity
docking	O	O	I-Entity
study	O	O	I-Entity
revealed	O	O	O
high	O	O	O
spontaneous	O	O	O
binding	O	O	B-Entity
ability	O	O	I-Entity
of	O	O	O
the	O	O	O
tested	O	O	B-Entity
compounds	O	O	B-Entity
to	O	O	O
the	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
urease	O	O	B-Entity
.	O	O	O

-DOCSTART- (27909143)

Interobserver	O	O	B-Entity
and	O	O	O
Intraobserver	O	O	B-Entity
Reliability	O	O	B-Entity
of	O	O	O
Clinical	O	O	B-Entity
Assessments	O	O	I-Entity
in	O	O	O
Knee	O	O	O
Osteoarthritis	O	O	O

Clinical	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	O
the	O	O	O
knee	O	O	B-Entity
is	O	O	O
subject	O	O	O
to	O	O	O
measurement	O	O	B-Entity
error	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
analysis	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	O
interobserver	O	O	B-Entity
and	O	O	O
intraobserver	O	O	B-Entity
reliability	O	O	B-Entity
of	O	O	O
commonly	O	O	O
used	O	O	O
clinical	O	O	O
tests	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
knee	O	O	B-Entity
osteoarthritis	O	O	I-Entity
(	O	O	O
OA	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
studied	O	O	O
subjects	O	O	B-Entity
with	O	O	O
symptomatic	O	O	B-Entity
knee	O	O	B-Entity
OA	O	O	I-Entity
who	O	O	O
were	O	O	O
participants	O	O	B-Entity
in	O	O	O
an	O	O	O
open-label	O	O	B-Entity
clinical	O	O	I-Entity
trial	O	O	I-Entity
of	O	O	O
intraarticular	O	O	B-Entity
steroid	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

Following	O	O	O
standardization	O	O	B-Entity
of	O	O	O
the	O	O	O
clinical	O	O	B-Entity
test	O	O	I-Entity
procedures	O	O	I-Entity
,	O	O	O
2	O	O	O
clinicians	O	O	B-Entity
assessed	O	O	B-Entity
25	O	O	O
subjects	O	O	B-Entity
independently	O	O	O
at	O	O	O
the	O	O	O
same	O	O	O
visit	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
same	O	O	O
clinician	O	O	B-Entity
assessed	O	O	O
88	O	O	O
subjects	O	O	O
over	O	O	O
an	O	O	O
interval	O	O	B-Entity
period	O	O	I-Entity
of	O	O	O
2	O	O	O
-	O	O	O
10	O	O	O
weeks	O	O	O
;	O	O	O
in	O	O	O
both	O	O	O
cases	O	O	O
prior	O	O	O
to	O	O	O
the	O	O	O
steroid	O	O	B-Entity
intervention	O	O	B-Entity
.	O	O	O

Clinical	O	O	B-Entity
examination	O	O	I-Entity
included	O	O	B-Entity
assessment	O	O	B-Entity
of	O	O	O
bony	O	O	B-Entity
enlargement	O	O	I-Entity
,	O	O	O
crepitus	O	O	B-Entity
,	O	O	O
quadriceps	O	O	B-Entity
wasting	O	O	I-Entity
,	O	O	O
knee	O	O	B-Entity
effusion	O	O	I-Entity
,	O	O	O
joint-line	O	O	B-Entity
and	O	O	O
anserine	O	O	B-Entity
tenderness	O	O	B-Entity
,	O	O	O
and	O	O	O
knee	O	O	B-Entity
range	O	O	I-Entity
of	O	O	I-Entity
movement	O	O	I-Entity
(	O	O	O
ROM	O	O	B-Entity
)	O	O	O
.	O	O	O

Intraclass	O	O	B-Entity
correlation	O	O	I-Entity
coefficients	O	O	I-Entity
(	O	O	O
ICC	O	O	B-Entity
)	O	O	O
,	O	O	O
estimated	O	O	B-Entity
kappa	O	O	I-Entity
(	O	O	O
κ	O	O	B-Entity
)	O	O	O
,	O	O	O
weighted	O	O	B-Entity
kappa	O	O	I-Entity
(	O	O	O
κω	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
Bland-Altman	O	O	B-Entity
plots	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
determine	O	O	O
interobserver	O	O	B-Entity
and	O	O	O
intraobserver	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
agreement	O	O	B-Entity
.	O	O	O

Using	O	O	O
Landis	O	O	B-Entity
and	O	O	I-Entity
Koch	O	O	I-Entity
criteria	O	O	I-Entity
,	O	O	O
interobserver	O	O	B-Entity
κ	O	O	B-Entity
scores	O	O	I-Entity
were	O	O	O
moderate	O	O	B-Entity
for	O	O	O
patellofemoral	O	O	B-Entity
joint	O	O	I-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.53	O	O	O
)	O	O	O
and	O	O	O
anserine	O	O	B-Entity
tenderness	O	O	B-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.48	O	O	O
)	O	O	O
;	O	O	O
good	O	O	B-Entity
for	O	O	O
bony	O	O	B-Entity
enlargement	O	O	I-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.66	O	O	O
)	O	O	O
,	O	O	O
quadriceps	O	O	B-Entity
wasting	O	O	I-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.78	O	O	O
)	O	O	O
,	O	O	O
crepitus	O	O	B-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.78	O	O	O
)	O	O	O
,	O	O	O
medial	O	O	B-Entity
tibiofemoral	O	O	B-Entity
joint	O	O	I-Entity
tenderness	O	O	O
(	O	O	O
κ	O	O	O
=	O	O	O
0.76	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
effusion	O	O	B-Entity
assessed	O	O	O
by	O	O	O
ballottement	O	O	B-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.73	O	O	O
)	O	O	O
and	O	O	O
bulge	O	O	B-Entity
sign	O	O	I-Entity
(	O	O	O
κω	O	O	B-Entity
=	O	O	O
0.78	O	O	O
)	O	O	O
;	O	O	O
and	O	O	O
excellent	O	O	B-Entity
for	O	O	O
lateral	O	O	B-Entity
tibiofemoral	O	O	O
joint	O	O	O
tenderness	O	O	O
(	O	O	O
κ	O	O	O
=	O	O	O
1.00	O	O	O
)	O	O	O
,	O	O	O
flexion	O	O	B-Entity
(	O	O	O
ICC	O	O	B-Entity
=	O	O	O
0.97	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
extension	O	O	B-Entity
(	O	O	O
ICC	O	O	O
=	O	O	O
0.87	O	O	O
)	O	O	O
ROM	O	O	B-Entity
.	O	O	O

Intraobserver	O	O	B-Entity
κ	O	O	B-Entity
scores	O	O	I-Entity
were	O	O	O
moderate	O	O	B-Entity
for	O	O	O
lateral	O	O	B-Entity
tibiofemoral	O	O	B-Entity
joint	O	O	I-Entity
tenderness	O	O	B-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.60	O	O	O
)	O	O	O
;	O	O	O
good	O	O	O
for	O	O	O
crepitus	O	O	O
(	O	O	O
κ	O	O	O
=	O	O	O
0.78	O	O	O
)	O	O	O
,	O	O	O
effusion	O	O	B-Entity
assessed	O	O	O
by	O	O	O
ballottement	O	O	B-Entity
test	O	O	I-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.77	O	O	O
)	O	O	O
,	O	O	O
patellofemoral	O	O	B-Entity
joint	O	O	I-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.66	O	O	O
)	O	O	O
,	O	O	O
medial	O	O	B-Entity
tibiofemoral	O	O	O
joint	O	O	O
(	O	O	O
κ	O	O	O
=	O	O	O
0.64	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
anserine	O	O	B-Entity
tenderness	O	O	O
(	O	O	O
κ	O	O	O
=	O	O	O
0.73	O	O	O
)	O	O	O
;	O	O	O
and	O	O	O
excellent	O	O	B-Entity
for	O	O	O
effusion	O	O	O
assessed	O	O	O
by	O	O	O
bulge	O	O	B-Entity
sign	O	O	I-Entity
(	O	O	O
κω	O	O	B-Entity
=	O	O	O
0.83	O	O	O
)	O	O	O
,	O	O	O
bony	O	O	B-Entity
enlargement	O	O	I-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.98	O	O	O
)	O	O	O
,	O	O	O
quadriceps	O	O	B-Entity
wasting	O	O	I-Entity
(	O	O	O
κ	O	O	O
=	O	O	O
0.83	O	O	O
)	O	O	O
,	O	O	O
flexion	O	O	B-Entity
(	O	O	O
ICC	O	O	B-Entity
=	O	O	O
0.99	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
extension	O	O	B-Entity
(	O	O	O
ICC	O	O	O
=	O	O	O
0.96	O	O	O
)	O	O	O
ROM	O	O	B-Entity
.	O	O	O

Among	O	O	O
individuals	O	O	B-Entity
with	O	O	O
symptomatic	O	O	B-Entity
knee	O	O	B-Entity
OA	O	O	I-Entity
,	O	O	O
the	O	O	O
reliability	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	O
the	O	O	O
knee	O	O	O
was	O	O	O
at	O	O	O
least	O	O	O
good	O	O	O
for	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
clinical	O	O	B-Entity
signs	O	O	I-Entity
of	O	O	O
knee	O	O	B-Entity
OA	O	O	I-Entity
.	O	O	O

-DOCSTART- (27913319)

Assessing	O	O	O
the	O	O	O
benefits	O	O	B-Entity
of	O	O	O
targeted	O	O	B-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
by	O	O	O
nanocarriers	O	O	B-Entity
:	O	O	O
A	O	O	O
partico/pharmacokinetic	O	O	O
framework	O	O	O

An	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
kinetic	O	O	B-Entity
framework	O	O	I-Entity
is	O	O	O
introduced	O	O	O
to	O	O	O
analyze	O	O	B-Entity
and	O	O	O
predict	O	O	O
the	O	O	O
quantitative	O	O	B-Entity
advantage	O	O	O
of	O	O	O
using	O	O	O
nanocarriers	O	O	B-Entity
to	O	O	O
deliver	O	O	B-Entity
drugs	O	O	B-Entity
,	O	O	O
especially	O	O	O
anticancer	O	O	B-Entity
agents	O	O	I-Entity
,	O	O	O
compared	O	O	B-Entity
to	O	O	O
administering	O	O	B-Entity
the	O	O	O
same	O	O	O
drugs	O	O	O
in	O	O	O
their	O	O	O
free	O	O	O
form	O	O	O
.	O	O	O

This	O	O	O
framework	O	O	B-Entity
recognizes	O	O	O
three	O	O	O
levels	O	O	B-Entity
of	O	O	O
kinetics	O	O	B-Entity
.	O	O	O

First	O	O	O
is	O	O	O
the	O	O	O
particokinetics	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
deposition	O	O	B-Entity
of	O	O	O
nanocarriers	O	O	B-Entity
into	O	O	O
tissues	O	O	B-Entity
associated	O	O	O
with	O	O	O
drug	O	O	B-Entity
effect	O	O	I-Entity
and	O	O	O
toxicity	O	O	B-Entity
,	O	O	O
their	O	O	O
residence	O	O	B-Entity
inside	O	O	O
those	O	O	O
tissues	O	O	O
,	O	O	O
and	O	O	O
elimination	O	O	B-Entity
of	O	O	O
the	O	O	O
nanocarriers	O	O	O
from	O	O	O
the	O	O	O
body	O	O	B-Entity
.	O	O	O

Second	O	O	O
is	O	O	O
the	O	O	O
release	O	O	B-Entity
pattern	O	O	I-Entity
in	O	O	O
time	O	O	O
of	O	O	O
free	O	O	B-Entity
drug	O	O	I-Entity
from	O	O	O
the	O	O	O
nanocarriers	O	O	B-Entity
.	O	O	O

Third	O	O	O
is	O	O	O
the	O	O	O
pharmacokinetics	O	O	B-Entity
of	O	O	O
free	O	O	B-Entity
drug	O	O	I-Entity
,	O	O	O
as	O	O	O
it	O	O	O
relates	O	O	O
to	O	O	O
deposition	O	O	B-Entity
and	O	O	O
elimination	O	O	B-Entity
processes	O	O	I-Entity
in	O	O	O
the	O	O	O
target	O	O	B-Entity
and	O	O	O
toxicity	O	O	B-Entity
associated	O	O	B-Entity
tissues	O	O	B-Entity
,	O	O	O
and	O	O	O
total	O	O	B-Entity
body	O	O	I-Entity
clearance	O	O	I-Entity
.	O	O	O

A	O	O	O
figure	O	O	O
of	O	O	O
merit	O	O	O
,	O	O	O
the	O	O	O
drug	O	O	B-Entity
targeting	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
DTI	O	O	B-Entity
)	O	O	O
,	O	O	O
is	O	O	O
used	O	O	O
to	O	O	O
quantitate	O	O	B-Entity
the	O	O	O
benefit	O	O	O
of	O	O	O
nanocarrier	O	O	B-Entity
based	O	O	O
drug	O	O	B-Entity
delivery	O	O	I-Entity
by	O	O	O
considering	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
preferential	O	O	O
deposition	O	O	B-Entity
of	O	O	O
nanoparticles	O	O	B-Entity
into	O	O	O
target	O	O	B-Entity
tissues	O	O	B-Entity
and	O	O	O
relative	O	O	O
avoidance	O	O	O
of	O	O	O
tissues	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
drug	O	O	B-Entity
toxicity	O	O	I-Entity
,	O	O	O
compared	O	O	B-Entity
to	O	O	O
drug	O	O	O
that	O	O	O
is	O	O	O
administered	O	O	B-Entity
in	O	O	O
its	O	O	O
free	O	O	O
form	O	O	O
.	O	O	O

General	O	O	O
methods	O	O	B-Entity
are	O	O	O
derived	O	O	O
for	O	O	O
calculating	O	O	B-Entity
DTI	O	O	B-Entity
when	O	O	O
appropriate	O	O	O
particokinetic	O	O	B-Entity
,	O	O	O
pharmacokinetic	O	O	B-Entity
,	O	O	O
and	O	O	O
drug	O	O	B-Entity
release	O	O	I-Entity
rate	O	O	I-Entity
information	O	O	O
is	O	O	O
available	O	O	O
,	O	O	O
and	O	O	O
it	O	O	O
is	O	O	O
shown	O	O	O
that	O	O	O
relatively	O	O	O
simple	O	O	O
algebraic	O	O	O
forms	O	O	O
result	O	O	B-Entity
when	O	O	O
some	O	O	O
common	O	O	O
assumptions	O	O	O
are	O	O	O
made	O	O	O
.	O	O	O

This	O	O	O
approach	O	O	O
may	O	O	O
find	O	O	O
use	O	O	O
in	O	O	O
developing	O	O	B-Entity
and	O	O	O
selecting	O	O	O
nanocarrier	O	O	B-Entity
formulations	O	O	B-Entity
,	O	O	O
either	O	O	O
for	O	O	O
populations	O	O	B-Entity
or	O	O	O
for	O	O	O
individuals	O	O	B-Entity
.	O	O	O

-DOCSTART- (27914462)

Recombinant	O	O	B-Entity
MHC	O	O	B-Entity
Tetramers	O	O	I-Entity
for	O	O	O
Isolation	O	O	B-Entity
of	O	O	O
Virus	O	O	B-Entity
-	O	O	O
Specific	O	O	B-Entity
CD8(+	O	O	B-Entity
)	O	O	I-Entity
Cells	O	O	I-Entity
from	O	O	O
Healthy	O	O	B-Entity
Donors	O	O	I-Entity
:	O	O	O
Potential	O	O	B-Entity
Approach	O	O	O
for	O	O	O
Cell	O	O	B-Entity
Therapy	O	O	I-Entity
of	O	O	O
Posttransplant	O	O	O
Cytomegalovirus	O	O	O
Infection	O	O	O

Patients	O	O	B-Entity
undergoing	O	O	O
allogeneic	O	O	B-Entity
hematopoietic	O	O	B-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
transplantation	O	O	I-Entity
have	O	O	O
a	O	O	O
high	O	O	O
risk	O	O	O
of	O	O	O
cytomegalovirus	O	O	B-Entity
reactivation	O	O	I-Entity
,	O	O	O
which	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
T-cell	O	O	B-Entity
immunity	O	O	I-Entity
can	O	O	O
result	O	O	O
in	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
an	O	O	O
acute	O	O	B-Entity
inflammatory	O	O	I-Entity
reaction	O	O	I-Entity
and	O	O	O
damage	O	O	B-Entity
of	O	O	I-Entity
internal	O	O	I-Entity
organs	O	O	I-Entity
.	O	O	O

Transfusion	O	O	B-Entity
of	O	O	O
the	O	O	O
virus-specific	O	O	B-Entity
donor	O	O	B-Entity
T-lymphocytes	O	O	I-Entity
represents	O	O	O
an	O	O	O
alternative	O	O	O
to	O	O	O
a	O	O	O
highly	O	O	B-Entity
toxic	O	O	I-Entity
and	O	O	O
often	O	O	O
ineffective	O	O	B-Entity
antiviral	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

Potentially	O	O	B-Entity
promising	O	O	O
cell	O	O	B-Entity
therapy	O	O	I-Entity
approach	O	O	O
comprises	O	O	O
transfusion	O	O	B-Entity
of	O	O	O
cytotoxic	O	O	B-Entity
T-lymphocytes	O	O	I-Entity
,	O	O	O
specific	O	O	B-Entity
to	O	O	O
the	O	O	O
viral	O	O	B-Entity
antigens	O	O	I-Entity
,	O	O	O
immediately	O	O	O
after	O	O	O
their	O	O	O
isolation	O	O	B-Entity
from	O	O	O
the	O	O	O
donor	O	O	B-Entity
's	O	O	I-Entity
blood	O	O	I-Entity
circulation	O	O	I-Entity
without	O	O	O
any	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
expansion	O	O	I-Entity
.	O	O	O

Specific	O	O	B-Entity
T-cells	O	O	B-Entity
could	O	O	O
be	O	O	O
separated	O	O	O
from	O	O	O
potentially	O	O	B-Entity
alloreactive	O	O	B-Entity
lymphocytes	O	O	I-Entity
using	O	O	O
recombinant	O	O	B-Entity
major	O	O	B-Entity
histocompatibility	O	O	I-Entity
complex	O	O	I-Entity
(	O	O	O
MHC	O	O	B-Entity
)	O	O	O
multimers	O	O	B-Entity
,	O	O	O
carrying	O	O	O
synthetic	O	O	B-Entity
viral	O	O	I-Entity
peptides	O	O	I-Entity
.	O	O	O

Rapid	O	O	O
transfusion	O	O	B-Entity
of	O	O	O
virus	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
T-cells	O	O	B-Entity
to	O	O	O
patients	O	O	B-Entity
has	O	O	O
several	O	O	O
crucial	O	O	O
advantages	O	O	O
in	O	O	O
comparison	O	O	O
with	O	O	O
methods	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
expansion	O	O	I-Entity
of	O	O	O
the	O	O	O
cells	O	O	B-Entity
.	O	O	O

About	O	O	O
30	O	O	O
%	O	O	O
of	O	O	O
hematopoietic	O	O	B-Entity
stem	O	O	B-Entity
cell	O	O	I-Entity
donors	O	O	I-Entity
and	O	O	O
46	O	O	O
%	O	O	O
of	O	O	O
transplant	O	O	B-Entity
recipients	O	O	I-Entity
at	O	O	O
the	O	O	O
National	O	O	B-Entity
Research	O	O	I-Entity
Center	O	O	I-Entity
for	O	O	I-Entity
Hematology	O	O	I-Entity
were	O	O	O
carriers	O	O	O
of	O	O	O
the	O	O	O
HLA-A*02	O	O	B-Entity
allele	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
94	O	O	O
%	O	O	O
of	O	O	O
Russian	O	O	B-Entity
donors	O	O	B-Entity
have	O	O	O
an	O	O	O
immune	O	O	B-Entity
response	O	O	I-Entity
against	O	O	O
the	O	O	O
cytomegalovirus	O	O	B-Entity
(	O	O	O
CMV	O	O	B-Entity
)	O	O	O
.	O	O	O

Using	O	O	O
recombinant	O	O	B-Entity
HLA-A*02	O	O	B-Entity
multimers	O	O	B-Entity
carrying	O	O	O
an	O	O	O
immunodominant	O	O	B-Entity
cytomegalovirus	O	O	B-Entity
peptide	O	O	I-Entity
(	O	O	O
NLV	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
healthy	O	O	B-Entity
donors	O	O	I-Entity
have	O	O	O
pronounced	O	O	O
T-cell	O	O	B-Entity
immunity	O	O	I-Entity
against	O	O	O
this	O	O	O
antigen	O	O	B-Entity
,	O	O	O
whereas	O	O	O
shortly	O	O	O
after	O	O	O
the	O	O	O
transplantation	O	O	B-Entity
the	O	O	O
patients	O	O	B-Entity
do	O	O	O
not	O	O	O
have	O	O	O
specific	O	O	B-Entity
T-lymphocytes	O	O	B-Entity
.	O	O	O

The	O	O	O
donor	O	O	B-Entity
cells	O	O	I-Entity
have	O	O	O
the	O	O	O
immune	O	O	B-Entity
phenotype	O	O	I-Entity
of	O	O	O
memory	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
can	O	O	O
be	O	O	O
activated	O	O	B-Entity
and	O	O	O
proliferate	O	O	B-Entity
after	O	O	O
stimulation	O	O	O
with	O	O	O
the	O	O	O
specific	O	O	B-Entity
antigen	O	O	B-Entity
.	O	O	O

Donor	O	O	B-Entity
lymphocytes	O	O	I-Entity
can	O	O	O
be	O	O	O
substantially	O	O	O
enriched	O	O	B-Entity
to	O	O	O
significant	O	O	O
purity	O	O	B-Entity
by	O	O	O
magnetic	O	O	B-Entity
separation	O	O	I-Entity
with	O	O	O
recombinant	O	O	B-Entity
MHC	O	O	B-Entity
multimers	O	O	B-Entity
and	O	O	O
are	O	O	O
not	O	O	O
activated	O	O	B-Entity
upon	O	O	O
cocultivation	O	O	B-Entity
with	O	O	O
the	O	O	O
antigen	O	O	B-Entity
-presenting	O	O	O
cells	O	O	B-Entity
from	O	O	O
HLA	O	O	B-Entity
-	O	O	O
incompatible	O	O	B-Entity
donors	O	O	I-Entity
without	O	O	O
addition	O	O	O
of	O	O	O
the	O	O	O
specific	O	O	B-Entity
antigen	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
strong	O	O	O
immune	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
CMV	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
donors	O	O	I-Entity
and	O	O	O
prevalence	O	O	O
of	O	O	O
HLA-A*02	O	O	B-Entity
allele	O	O	I-Entity
in	O	O	O
the	O	O	O
Russian	O	O	B-Entity
population	O	O	I-Entity
make	O	O	O
it	O	O	O
possible	O	O	O
to	O	O	O
isolate	O	O	O
a	O	O	O
significant	O	O	O
number	O	O	O
of	O	O	O
virus-specific	O	O	B-Entity
cells	O	O	B-Entity
using	O	O	O
HLA-A*02-NLV	O	O	B-Entity
multimers	O	O	B-Entity
.	O	O	O

After	O	O	O
the	O	O	O
transfusion	O	O	B-Entity
,	O	O	O
these	O	O	O
cells	O	O	B-Entity
should	O	O	O
protect	O	O	O
patients	O	O	B-Entity
from	O	O	O
CMV	O	O	B-Entity
without	O	O	O
development	O	O	O
of	O	O	O
allogeneic	O	O	B-Entity
immune	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

-DOCSTART- (27914587)

Outcomes	O	O	B-Entity
of	O	O	O
chest	O	O	B-Entity
wall	O	O	I-Entity
resections	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
sarcoma	O	O	B-Entity
patients	O	O	O

Chest	O	O	B-Entity
wall	O	O	I-Entity
tumors	O	O	I-Entity
in	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
are	O	O	O
rare	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluates	O	O	O
outcomes	O	O	B-Entity
in	O	O	O
pediatric	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
have	O	O	O
undergone	O	O	O
chest	O	O	B-Entity
wall	O	O	I-Entity
resections	O	O	I-Entity
secondary	O	O	O
to	O	O	O
sarcomas	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
review	O	O	I-Entity
was	O	O	O
performed	O	O	O
for	O	O	O
patients	O	O	B-Entity
<	O	O	O
19years	O	O	O
old	O	O	O
who	O	O	O
underwent	O	O	O
chest	O	O	B-Entity
wall	O	O	I-Entity
resections	O	O	I-Entity
for	O	O	O
sarcoma	O	O	B-Entity
1999	O	O	O
-	O	O	O
2014	O	O	O
at	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Texas	O	O	I-Entity
MD	O	O	I-Entity
Anderson	O	O	I-Entity
Cancer	O	O	I-Entity
Center	O	O	I-Entity
.	O	O	O

Of	O	O	O
44	O	O	O
patients	O	O	B-Entity
,	O	O	O
Ewing	O	O	B-Entity
's	O	O	I-Entity
sarcoma	O	O	I-Entity
(	O	O	O
n=18	O	O	O
)	O	O	O
and	O	O	O
osteosarcoma	O	O	B-Entity
(	O	O	O
n=16	O	O	O
)	O	O	O
were	O	O	O
most	O	O	O
common	O	O	O
.	O	O	O

Other	O	O	O
sarcomas	O	O	B-Entity
included	O	O	O
synovial	O	O	B-Entity
sarcoma	O	O	I-Entity
,	O	O	O
chondrosarcoma	O	O	B-Entity
,	O	O	O
and	O	O	O
rhabdomyosarcoma	O	O	B-Entity
.	O	O	O

Gore-Tex	O	O	B-Entity
®	O	O	O
or	O	O	O
a	O	O	O
Marlex	O	O	B-Entity
™	O	O	I-Entity
mesh	O	O	I-Entity
and	O	O	O
methyl	O	O	B-Entity
methacrylate	O	O	I-Entity
sandwich	O	O	I-Entity
was	O	O	O
used	O	O	O
in	O	O	O
22	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
9	O	O	O
children	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
require	O	O	I-Entity
reconstruction	O	O	I-Entity
.	O	O	O

Twenty-four	O	O	O
(	O	O	O
54.5	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
had	O	O	O
normal	O	O	B-Entity
activity	O	O	B-Entity
,	O	O	O
3	O	O	O
(	O	O	O
6.8	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
occasional	O	O	B-Entity
discomfort	O	O	I-Entity
,	O	O	O
2	O	O	O
(	O	O	O
4.5	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
pain	O	O	B-Entity
impairing	O	O	I-Entity
function	O	O	I-Entity
,	O	O	O
7	O	O	O
(	O	O	O
15.9	O	O	O
%	O	O	O
)	O	O	O
required	O	O	O
medication	O	O	B-Entity
or	O	O	O
physical	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
impairment	O	O	B-Entity
,	O	O	O
and	O	O	O
8	O	O	O
(	O	O	O
18.2	O	O	O
%	O	O	O
)	O	O	O
needed	O	O	O
additional	O	O	O
surgery	O	O	B-Entity
.	O	O	O

Five	O	O	O
children	O	O	B-Entity
(	O	O	O
11.4	O	O	O
%	O	O	O
)	O	O	O
developed	O	O	O
scoliosis	O	O	B-Entity
,	O	O	O
and	O	O	O
all	O	O	O
of	O	O	O
these	O	O	O
patients	O	O	B-Entity
had	O	O	O
posterior	O	O	B-Entity
rib	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

Median	O	O	B-Entity
overall	O	O	I-Entity
survival	O	O	I-Entity
for	O	O	O
the	O	O	O
entire	O	O	B-Entity
cohort	O	O	I-Entity
was	O	O	O
41.9±11.82	O	O	O
months	O	O	B-Entity
.	O	O	O

Histology	O	O	B-Entity
(	O	O	O
p=0.003	O	O	O
)	O	O	O
,	O	O	O
location	O	O	B-Entity
of	O	O	O
tumor	O	O	B-Entity
on	O	O	O
the	O	O	O
ribs	O	O	B-Entity
(	O	O	O
p=0.007	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
surgical	O	O	B-Entity
margins	O	O	I-Entity
(	O	O	O
p=0.011	O	O	O
)	O	O	O
were	O	O	O
significantly	O	O	B-Entity
associated	O	O	I-Entity
with	O	O	I-Entity
overall	O	O	B-Entity
survival	O	O	I-Entity
.	O	O	O

Tumors	O	O	B-Entity
on	O	O	O
the	O	O	O
middle	O	O	O
and	O	O	O
posterior	O	O	B-Entity
(	O	O	O
p=0.003	O	O	O
)	O	O	O
portions	O	O	O
of	O	O	O
the	O	O	O
ribs	O	O	B-Entity
had	O	O	O
a	O	O	O
lower	O	O	O
chance	O	O	O
of	O	O	O
death	O	O	B-Entity
.	O	O	O

Scoliosis	O	O	B-Entity
is	O	O	O
more	O	O	O
common	O	O	O
in	O	O	O
posterior	O	O	B-Entity
rib	O	O	B-Entity
resections	O	O	I-Entity
.	O	O	O

Histology	O	O	B-Entity
,	O	O	O
location	O	O	B-Entity
of	O	O	O
the	O	O	O
tumor	O	O	B-Entity
,	O	O	O
and	O	O	O
surgical	O	O	B-Entity
margins	O	O	I-Entity
impact	O	O	O
survival	O	O	B-Entity
,	O	O	O
but	O	O	O
,	O	O	O
type	O	O	O
of	O	O	O
reconstruction	O	O	O
does	O	O	O
not	O	O	O
.	O	O	O

III	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
Study	O	O	I-Entity
.	O	O	O

-DOCSTART- (27914987)

Tetrabromobisphenol	O	O	B-Entity
A	O	O	I-Entity
activates	O	O	B-Entity
the	O	O	O
hepatic	O	O	B-Entity
interferon	O	O	B-Entity
pathway	O	O	I-Entity
in	O	O	O
rats	O	O	O

Tetrabromobisphenol	O	O	B-Entity
A	O	O	I-Entity
(	O	O	O
TBBPA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
widely	O	O	O
used	O	O	O
flame	O	O	B-Entity
retardant	O	O	I-Entity
in	O	O	O
printed	O	O	B-Entity
circuit	O	O	I-Entity
boards	O	O	I-Entity
,	O	O	O
paper	O	O	B-Entity
,	O	O	O
and	O	O	O
textiles	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
two-year	O	O	B-Entity
study	O	O	B-Entity
,	O	O	O
TBBPA	O	O	B-Entity
showed	O	O	O
evidence	O	O	O
of	O	O	O
uterine	O	O	B-Entity
tumors	O	O	I-Entity
in	O	O	O
female	O	O	B-Entity
Wistar-Han	O	O	B-Entity
rats	O	O	I-Entity
and	O	O	O
liver	O	O	B-Entity
and	O	O	O
colon	O	O	B-Entity
tumors	O	O	I-Entity
in	O	O	O
B6C3F1	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
gain	O	O	O
further	O	O	O
insight	O	O	O
into	O	O	O
early	O	O	O
gene	O	O	B-Entity
and	O	O	O
pathway	O	O	B-Entity
changes	O	O	O
leading	O	O	O
to	O	O	O
cancer	O	O	B-Entity
,	O	O	O
we	O	O	O
exposed	O	O	O
female	O	O	B-Entity
Wistar	O	O	B-Entity
Han	O	O	I-Entity
rats	O	O	I-Entity
to	O	O	O
TBBPA	O	O	B-Entity
at	O	O	O
0	O	O	O
,	O	O	O
25	O	O	O
,	O	O	O
250	O	O	O
,	O	O	O
or	O	O	O
1000mg/kg	O	O	O
(	O	O	O
oral	O	O	B-Entity
gavage	O	O	I-Entity
in	O	O	O
corn	O	O	B-Entity
oil	O	O	I-Entity
,	O	O	O
5	O	O	O
×	O	O	O
/	O	O	O
week	O	O	B-Entity
)	O	O	O
for	O	O	O
13	O	O	O
weeks	O	O	B-Entity
.	O	O	O

Because	O	O	O
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
TBBPA	O	O	B-Entity
exposure	O	O	B-Entity
period	O	O	O
,	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
treatment-related	O	O	O
effects	O	O	O
on	O	O	O
body	O	O	B-Entity
weights	O	O	B-Entity
,	O	O	O
liver	O	O	B-Entity
or	O	O	O
uterus	O	O	B-Entity
lesions	O	O	I-Entity
,	O	O	O
and	O	O	O
liver	O	O	O
and	O	O	O
uterine	O	O	B-Entity
organ	O	O	I-Entity
weights	O	O	O
were	O	O	O
within	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
controls	O	O	B-Entity
,	O	O	O
only	O	O	O
the	O	O	O
high	O	O	O
dose	O	O	B-Entity
animals	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
hepatic	O	O	B-Entity
and	O	O	O
uterine	O	O	B-Entity
transcriptomes	O	O	B-Entity
showed	O	O	O
TBBPA	O	O	B-Entity
-induced	O	O	O
changes	O	O	O
primarily	O	O	O
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
(	O	O	O
1000mg/kg	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
159	O	O	O
transcripts	O	O	B-Entity
corresponding	O	O	O
to	O	O	O
132	O	O	O
genes	O	O	B-Entity
differentially	O	O	O
expressed	O	O	B-Entity
compared	O	O	O
to	O	O	O
controls	O	O	B-Entity
(	O	O	O
FDR=0.05	O	O	O
)	O	O	O
.	O	O	O

Pathway	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
activation	O	O	B-Entity
of	O	O	O
interferon	O	O	B-Entity
(	O	O	O
IFN	O	O	B-Entity
)	O	O	O
and	O	O	O
metabolic	O	O	B-Entity
networks	O	O	I-Entity
.	O	O	O

TBBPA	O	O	B-Entity
induced	O	O	O
few	O	O	O
molecular	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
uterus	O	O	B-Entity
.	O	O	O

Activation	O	O	B-Entity
of	O	O	O
the	O	O	O
interferon	O	O	B-Entity
pathway	O	O	I-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
occurred	O	O	O
after	O	O	O
13-weeks	O	O	B-Entity
of	O	O	O
TBBPA	O	O	B-Entity
exposure	O	O	B-Entity
,	O	O	O
and	O	O	O
with	O	O	O
longer	O	O	O
term	O	O	O
TBBPA	O	O	O
exposure	O	O	O
this	O	O	O
may	O	O	O
lead	O	O	O
to	O	O	O
immunomodulatory	O	O	B-Entity
changes	O	O	B-Entity
that	O	O	O
contribute	O	O	O
to	O	O	O
carcinogenic	O	O	B-Entity
processes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27916672)

Famous	O	O	B-Entity
faces	O	O	I-Entity
and	O	O	O
voices	O	O	B-Entity
:	O	O	O
Differential	O	O	B-Entity
profiles	O	O	B-Entity
in	O	O	O
early	O	O	B-Entity
right	O	O	B-Entity
and	O	O	O
left	O	O	B-Entity
semantic	O	O	B-Entity
dementia	O	O	I-Entity
and	O	O	O
in	O	O	O
Alzheimer	O	O	O
's	O	O	O
disease	O	O	O

Famous	O	O	B-Entity
face	O	O	I-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
is	O	O	O
reported	O	O	O
to	O	O	O
be	O	O	O
impaired	O	O	B-Entity
both	O	O	O
in	O	O	O
semantic	O	O	B-Entity
dementia	O	O	I-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
and	O	O	O
in	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
,	O	O	O

although	O	O	O
more	O	O	O
severely	O	O	B-Entity
in	O	O	O
the	O	O	O
former	O	O	O
.	O	O	O

In	O	O	O
AD	O	O	B-Entity
a	O	O	O
coexistence	O	O	O
of	O	O	O
perceptual	O	O	B-Entity
impairment	O	O	B-Entity
in	O	O	O
face	O	O	B-Entity
and	O	O	O
voice	O	O	B-Entity
processing	O	O	B-Entity
has	O	O	O
also	O	O	O
been	O	O	O
reported	O	O	O
and	O	O	O
this	O	O	O
could	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
altered	O	O	O
performance	O	O	B-Entity
in	O	O	O
complex	O	O	B-Entity
semantic	O	O	B-Entity
tasks	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
in	O	O	O
SD	O	O	B-Entity
both	O	O	O
face	O	O	B-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
disorders	O	O	B-Entity
could	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
atrophy	O	O	B-Entity
in	O	O	O
the	O	O	O
right	O	O	B-Entity
temporal	O	O	I-Entity
lobe	O	O	I-Entity
(	O	O	O
RTL	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
twofold	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
to	O	O	O
investigate	O	O	B-Entity
famous	O	O	B-Entity
faces	O	O	I-Entity
and	O	O	O
voices	O	O	B-Entity
recognition	O	O	I-Entity
in	O	O	O
SD	O	O	B-Entity
and	O	O	O
AD	O	O	B-Entity
to	O	O	O
verify	O	O	O
if	O	O	O
the	O	O	O
two	O	O	O
diseases	O	O	B-Entity
show	O	O	O
a	O	O	O
differential	O	O	B-Entity
pattern	O	O	B-Entity
of	O	O	O
impairment	O	O	B-Entity
,	O	O	O
resulting	O	O	O
from	O	O	O
disruption	O	O	B-Entity
of	O	O	O
different	O	O	O
cognitive	O	O	B-Entity
mechanisms	O	O	B-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
to	O	O	O
check	O	O	O
if	O	O	O
face	O	O	B-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
disorders	O	O	B-Entity
prevail	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
atrophy	O	O	B-Entity
mainly	O	O	O
affecting	O	O	O
the	O	O	O
RTL	O	O	B-Entity
.	O	O	O

To	O	O	O
avoid	O	O	O
the	O	O	O
potential	O	O	B-Entity
influence	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
perceptual	O	O	B-Entity
problems	O	O	B-Entity
in	O	O	O
face	O	O	B-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
,	O	O	O
a	O	O	O
pool	O	O	O
of	O	O	O
patients	O	O	B-Entity
suffering	O	O	O
from	O	O	O
early	O	O	B-Entity
SD	O	O	B-Entity
and	O	O	O
AD	O	O	B-Entity
were	O	O	O
administered	O	O	B-Entity
a	O	O	O
detailed	O	O	O
set	O	O	O
of	O	O	O
tests	O	O	B-Entity
exploring	O	O	O
face	O	O	O
and	O	O	O
voice	O	O	O
perception	O	O	B-Entity
.	O	O	O

Thirteen	O	O	O
SD	O	O	B-Entity
(	O	O	O
8	O	O	O
with	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
right	O	O	B-Entity
and	O	O	O
5	O	O	O
with	O	O	O
prevalence	O	O	O
of	O	O	O
left	O	O	B-Entity
temporal	O	O	I-Entity
atrophy	O	O	B-Entity
)	O	O	O
and	O	O	O
25	O	O	O
CE	O	O	O
patients	O	O	B-Entity
,	O	O	O
who	O	O	O
did	O	O	O
not	O	O	O
show	O	O	O
visual	O	O	B-Entity
and	O	O	O
auditory	O	O	B-Entity
perceptual	O	O	B-Entity
impairment	O	O	B-Entity
,	O	O	O
were	O	O	O
finally	O	O	O
selected	O	O	O
and	O	O	O
were	O	O	O
administered	O	O	B-Entity
an	O	O	O
experimental	O	O	B-Entity
battery	O	O	B-Entity
exploring	O	O	O
famous	O	O	B-Entity
face	O	O	I-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
and	O	O	O
naming	O	O	B-Entity
.	O	O	O

Twelve	O	O	O
SD	O	O	B-Entity
patients	O	O	B-Entity
underwent	O	O	O
cerebral	O	O	B-Entity
PET	O	O	B-Entity
imaging	O	O	I-Entity
and	O	O	O
were	O	O	O
classified	O	O	O
in	O	O	O
right	O	O	B-Entity
and	O	O	O
left	O	O	B-Entity
SD	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
onset	O	O	O
modality	O	O	B-Entity
and	O	O	O
to	O	O	O
the	O	O	O
prevalent	O	O	O
decrease	O	O	B-Entity
in	O	O	O
FDG	O	O	B-Entity
uptake	O	O	I-Entity
in	O	O	O
right	O	O	O
or	O	O	O
left	O	O	B-Entity
temporal	O	O	I-Entity
lobe	O	O	I-Entity
respectively	O	O	O
.	O	O	O

Correlation	O	O	B-Entity
of	O	O	O
PET	O	O	B-Entity
imaging	O	O	I-Entity
and	O	O	O
famous	O	O	B-Entity
face	O	O	I-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

Results	O	O	B-Entity
showed	O	O	O
a	O	O	O
differential	O	O	B-Entity
performance	O	O	B-Entity
profile	O	O	B-Entity
in	O	O	O
the	O	O	O
two	O	O	O
diseases	O	O	B-Entity
,	O	O	O
because	O	O	O
AD	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
significantly	O	O	O
impaired	O	O	B-Entity
in	O	O	O
the	O	O	O
naming	O	O	B-Entity
tests	O	O	I-Entity
,	O	O	O
but	O	O	O
showed	O	O	O
preserved	O	O	O
recognition	O	O	B-Entity
,	O	O	O
whereas	O	O	O
SD	O	O	B-Entity
patients	O	O	O
were	O	O	O
profoundly	O	O	O
impaired	O	O	O
both	O	O	O
in	O	O	O
naming	O	O	O
and	O	O	O
in	O	O	O
recognition	O	O	B-Entity
of	O	O	I-Entity
famous	O	O	I-Entity
faces	O	O	I-Entity
and	O	O	O
voices	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
face	O	O	B-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
disorders	O	O	B-Entity
prevailed	O	O	O
in	O	O	O
SD	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
RTL	O	O	B-Entity
atrophy	O	O	B-Entity
,	O	O	O
who	O	O	O
also	O	O	O
showed	O	O	O
a	O	O	O
conceptual	O	O	B-Entity
impairment	O	O	B-Entity
on	O	O	O
the	O	O	O
Pyramids	O	O	B-Entity
and	O	O	I-Entity
Palm	O	O	I-Entity
Trees	O	O	I-Entity
test	O	O	I-Entity
more	O	O	O
important	O	O	O
in	O	O	O
the	O	O	O
pictorial	O	O	O
than	O	O	O
in	O	O	O
the	O	O	O
verbal	O	O	B-Entity
modality	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
in	O	O	O
12	O	O	O
SD	O	O	B-Entity
patients	O	O	B-Entity
in	O	O	O
whom	O	O	O
PET	O	O	B-Entity
was	O	O	O
available	O	O	O
,	O	O	O
a	O	O	O
strong	O	O	O
correlation	O	O	B-Entity
between	O	O	O
FDG	O	O	B-Entity
uptake	O	O	I-Entity
and	O	O	O
face-to-name	O	O	B-Entity
and	O	O	O
voice-to-name	O	O	B-Entity
matching	O	O	I-Entity
data	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
right	O	O	B-Entity
but	O	O	O
not	O	O	O
in	O	O	O
the	O	O	O
left	O	O	B-Entity
temporal	O	O	I-Entity
lobe	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
support	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
of	O	O	O
a	O	O	O
different	O	O	O
cognitive	O	O	B-Entity
basis	O	O	O
for	O	O	O
impairment	O	O	B-Entity
of	O	O	O
face	O	O	B-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
in	O	O	O
the	O	O	O
two	O	O	O
dementias	O	O	B-Entity
and	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
pattern	O	O	B-Entity
of	O	O	O
impairment	O	O	O
in	O	O	O
SD	O	O	B-Entity
may	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
a	O	O	O
loss	O	O	O
of	O	O	O
semantic	O	O	B-Entity
representations	O	O	B-Entity
,	O	O	O
while	O	O	O
a	O	O	O
defect	O	O	O
of	O	O	O
semantic	O	O	O
control	O	O	B-Entity
,	O	O	O
with	O	O	O
impaired	O	O	B-Entity
naming	O	O	B-Entity
and	O	O	O
preserved	O	O	B-Entity
recognition	O	O	I-Entity
might	O	O	O
be	O	O	O
hypothesized	O	O	O
in	O	O	O
AD	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
correlation	O	O	B-Entity
between	O	O	O
face	O	O	B-Entity
and	O	O	O
voice	O	O	B-Entity
recognition	O	O	I-Entity
disorders	O	O	B-Entity
and	O	O	O
RTL	O	O	B-Entity
damage	O	O	B-Entity
are	O	O	O
consistent	O	O	O
with	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
assuming	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
RTL	O	O	O
person	O	O	B-Entity
-specific	O	O	O
knowledge	O	O	B-Entity
may	O	O	O
be	O	O	O
mainly	O	O	O
based	O	O	O
upon	O	O	O
non-verbal	O	O	B-Entity
representations	O	O	I-Entity
.	O	O	O

-DOCSTART- (27917468)

Dry	O	O	B-Entity
skin	O	O	I-Entity
conditions	O	O	O
are	O	O	O
related	O	O	B-Entity
to	O	O	O
the	O	O	O
recovery	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
skin	O	O	B-Entity
temperature	O	O	I-Entity
after	O	O	O
cold	O	O	B-Entity
stress	O	O	B-Entity
rather	O	O	O
than	O	O	O
to	O	O	O
blood	O	O	O
flow	O	O	O

Cutaneous	O	O	B-Entity
blood	O	O	B-Entity
flow	O	O	I-Entity
plays	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	O
in	O	O	O
the	O	O	O
thermoregulation	O	O	B-Entity
,	O	O	O
oxygen	O	O	B-Entity
supply	O	O	I-Entity
,	O	O	O
and	O	O	O
nutritional	O	O	B-Entity
support	O	O	I-Entity
necessary	O	O	O
to	O	O	O
maintain	O	O	B-Entity
the	O	O	O
skin	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
little	O	O	O
evidence	O	O	B-Entity
for	O	O	O
a	O	O	O
link	O	O	O
between	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
and	O	O	O
skin	O	O	B-Entity
physiology	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
conducted	O	O	O
surveys	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
volunteers	O	O	I-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
relationship	O	O	B-Entity
(	O	O	O
s	O	O	O
)	O	O	O
between	O	O	O
dry	O	O	B-Entity
skin	O	O	I-Entity
properties	O	O	O
and	O	O	O
cutaneous	O	O	B-Entity
vascular	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

Water	O	O	O
content	O	O	O
of	O	O	O
the	O	O	O
stratum	O	O	B-Entity
corneum	O	O	I-Entity
,	O	O	O
transepidermal	O	O	B-Entity
water	O	O	I-Entity
loss	O	O	I-Entity
,	O	O	O
and	O	O	O
visual	O	O	B-Entity
dryness	O	O	I-Entity
score	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
as	O	O	O
dry	O	O	B-Entity
skin	O	O	I-Entity
parameters	O	O	B-Entity
.	O	O	O

Cutaneous	O	O	B-Entity
blood	O	O	B-Entity
flow	O	O	I-Entity
in	O	O	O
the	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
,	O	O	O
the	O	O	O
recovery	O	O	B-Entity
rate	O	O	I-Entity
(	O	O	O
RR	O	O	B-Entity
)	O	O	O
of	O	O	O
skin	O	O	B-Entity
temperature	O	O	I-Entity
on	O	O	O
the	O	O	O
hand	O	O	B-Entity
after	O	O	O
a	O	O	O
cold-stress	O	O	B-Entity
test	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
responsiveness	O	O	B-Entity
of	O	O	O
facial	O	O	B-Entity
skin	O	O	I-Entity
blood	O	O	O
flow	O	O	O
to	O	O	O
local	O	O	B-Entity
cooling	O	O	I-Entity
were	O	O	O
examined	O	O	B-Entity
as	O	O	O
indices	O	O	B-Entity
of	O	O	O
cutaneous	O	O	B-Entity
vascular	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

The	O	O	O
relationships	O	O	B-Entity
between	O	O	O
dry	O	O	B-Entity
skin	O	O	I-Entity
parameters	O	O	B-Entity
and	O	O	O
cutaneous	O	O	B-Entity
vascular	O	O	B-Entity
functions	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

The	O	O	O
RR	O	O	B-Entity
correlated	O	O	B-Entity
negatively	O	O	O
with	O	O	O
the	O	O	O
visual	O	O	B-Entity
dryness	O	O	I-Entity
score	O	O	I-Entity
of	O	O	O
skin	O	O	B-Entity
on	O	O	O
the	O	O	O
leg	O	O	B-Entity
but	O	O	O
correlated	O	O	O
positively	O	O	O
with	O	O	O
water	O	O	O
content	O	O	O
of	O	O	O
the	O	O	O
stratum	O	O	B-Entity
corneum	O	O	I-Entity
on	O	O	O
the	O	O	O
arm	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	O
correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
of	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
and	O	O	O
dry	O	O	B-Entity
skin	O	O	I-Entity
parameters	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
.	O	O	O

In	O	O	O
both	O	O	O
the	O	O	O
face	O	O	B-Entity
and	O	O	O
the	O	O	O
body	O	O	B-Entity
,	O	O	O
deterioration	O	O	B-Entity
in	O	O	O
skin	O	O	B-Entity
dryness	O	O	I-Entity
from	O	O	O
summer	O	O	B-Entity
to	O	O	O
winter	O	O	B-Entity
was	O	O	O
significant	O	O	B-Entity
in	O	O	O
subjects	O	O	O
with	O	O	O
low	O	O	O
RR	O	O	B-Entity
.	O	O	O

The	O	O	O
RR	O	O	B-Entity
correlated	O	O	B-Entity
well	O	O	O
with	O	O	O
the	O	O	O
responsiveness	O	O	B-Entity
of	O	O	O
facial	O	O	B-Entity
skin	O	O	I-Entity
blood	O	O	B-Entity
flow	O	O	I-Entity
to	O	O	O
local	O	O	B-Entity
cooling	O	O	I-Entity
,	O	O	O
indicating	O	O	B-Entity
that	O	O	O
the	O	O	O
RR	O	O	O
affects	O	O	O
systemic	O	O	O
dry	O	O	B-Entity
skin	O	O	I-Entity
conditions	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
RR	O	O	B-Entity
but	O	O	O
not	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
at	O	O	O
the	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
dry	O	O	B-Entity
skin	O	O	I-Entity
conditions	O	O	O
and	O	O	O
is	O	O	O
involved	O	O	O
in	O	O	O
skin	O	O	O
homeostasis	O	O	B-Entity
during	O	O	O
seasonal	O	O	B-Entity
environmental	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27919226)

Molar	O	O	B-Entity
loss	O	O	I-Entity
and	O	O	O
powder	O	O	B-Entity
diet	O	O	I-Entity
leads	O	O	O
to	O	O	O
memory	O	O	B-Entity
deficit	O	O	I-Entity
and	O	O	O
modifies	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
brain-derived	O	O	B-Entity
neurotrophic	O	O	I-Entity
factor	O	O	I-Entity
in	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
mice	O	O	O

It	O	O	O
is	O	O	O
known	O	O	O
that	O	O	O
tooth	O	O	B-Entity
loss	O	O	I-Entity
is	O	O	O
known	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
soft	O	O	B-Entity
diet	O	O	I-Entity
feeding	O	O	B-Entity
induces	O	O	O
memory	O	O	B-Entity
impairment	O	O	I-Entity
.	O	O	O

Recent	O	O	O
studies	O	O	O
have	O	O	O
shown	O	O	O
that	O	O	O
brain-derived	O	O	B-Entity
neurotrophic	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
BDNF	O	O	B-Entity
)	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
tooth	O	O	B-Entity
loss	O	O	I-Entity
or	O	O	O
soft	O	O	B-Entity
diet	O	O	I-Entity
in	O	O	O
young	O	O	O
animal	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
and	O	O	O
that	O	O	O
BDNF	O	O	O
expression	O	O	B-Entity
is	O	O	O
decreased	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
single	O	O	O
or	O	O	O
combined	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
tooth	O	O	B-Entity
loss	O	O	I-Entity
and/or	O	O	O
soft	O	O	B-Entity
diet	O	O	I-Entity
on	O	O	O
brain	O	O	B-Entity
function	O	O	I-Entity
has	O	O	O
not	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
examined	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
molar	O	O	B-Entity
loss	O	O	I-Entity
and	O	O	O
powder	O	O	B-Entity
diet	O	O	I-Entity
on	O	O	O
memory	O	O	B-Entity
ability	O	O	I-Entity
and	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
BDNF	O	O	B-Entity
mRNA	O	O	I-Entity
in	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
C57BL/6J	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Twenty	O	O	O
eight-weeks-old	O	O	O
C57BL/6J	O	O	B-Entity
mice	O	O	I-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
intact	O	O	O
molar	O	O	O
group	O	O	O
and	O	O	O
extracted	O	O	O
molar	O	O	O
group	O	O	O
.	O	O	O

They	O	O	O
were	O	O	O
randomly	O	O	B-Entity
divided	O	O	O
into	O	O	O
the	O	O	O
I/S	O	O	O
group	O	O	O
(	O	O	O
Intact	O	O	O
upper	O	O	B-Entity
molar	O	O	I-Entity
teeth	O	O	I-Entity
/	O	O	O
Solid	O	O	B-Entity
diet	O	O	I-Entity
feeding	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
E/S	O	O	O
group	O	O	O
(	O	O	O
Extracted	O	O	B-Entity
upper	O	O	O
molar	O	O	O
teeth	O	O	O
/	O	O	O
Solid	O	O	O
diet	O	O	O
feeding	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
I/P	O	O	O
group	O	O	O
(	O	O	O
Intact	O	O	O
upper	O	O	O
molar	O	O	O
teeth	O	O	O
/	O	O	O
Powder	O	O	B-Entity
diet	O	O	I-Entity
feeding	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
E/P	O	O	O
group	O	O	O
(	O	O	O
Extracted	O	O	O
upper	O	O	O
molar	O	O	O
teeth	O	O	O
/	O	O	O
Powder	O	O	O
diet	O	O	O
feeding	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
observation	O	O	O
periods	O	O	O
were	O	O	O
4	O	O	O
and	O	O	O
16-week	O	O	O
.	O	O	O

To	O	O	O
analyze	O	O	B-Entity
the	O	O	O
memory	O	O	B-Entity
ability	O	O	I-Entity
,	O	O	O
the	O	O	O
step-through	O	O	O
passive	O	O	B-Entity
avoidance	O	O	I-Entity
test	O	O	O
was	O	O	O
conducted	O	O	O
.	O	O	O

BDNF-related	O	O	B-Entity
mRNA	O	O	I-Entity
in	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
was	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
real-time	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
RT-PCR	O	O	B-Entity
)	O	O	O
.	O	O	O

At	O	O	O
4	O	O	O
weeks	O	O	O
later	O	O	O
,	O	O	O
we	O	O	O
performed	O	O	O
memory	O	O	B-Entity
test	O	O	I-Entity
and	O	O	O
isolated	O	O	O
brains	O	O	B-Entity
to	O	O	O
analyze	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
differences	O	O	I-Entity
in	O	O	O
memory	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
BDNF	O	O	B-Entity
mRNA	O	O	I-Entity
level	O	O	O
between	O	O	O
these	O	O	O
four	O	O	O
groups	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
at	O	O	O
16	O	O	O
weeks	O	O	O
later	O	O	O
,	O	O	O
E/S	O	O	O
and	O	O	O
E/P	O	O	O
group	O	O	O
showed	O	O	O
memory	O	O	B-Entity
impairment	O	O	I-Entity
,	O	O	O
and	O	O	O
decreased	O	O	O
level	O	O	O
of	O	O	O
BDNF	O	O	B-Entity
mRNA	O	O	I-Entity
.	O	O	O

Whereas	O	O	O
,	O	O	O
the	O	O	O
powder	O	O	B-Entity
diet	O	O	I-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
memory	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
BDNF	O	O	B-Entity
mRNA	O	O	I-Entity
level	O	O	O
even	O	O	O
at	O	O	O
16	O	O	O
weeks	O	O	O
later	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
molar	O	O	B-Entity
loss	O	O	I-Entity
and	O	O	O
powder	O	O	B-Entity
diet	O	O	I-Entity
on	O	O	O
memory	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
BDNF	O	O	B-Entity
mRNA	O	O	I-Entity
levels	O	O	O
were	O	O	O
different	O	O	O
,	O	O	O
molar	O	O	O
loss	O	O	O
may	O	O	O
have	O	O	O
a	O	O	O
greater	O	O	O
long-term	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
memory	O	O	B-Entity
ability	O	O	I-Entity
than	O	O	O
powder	O	O	O
diet	O	O	O
does	O	O	O
.	O	O	O

-DOCSTART- (27920607)

Description	O	O	O
of	O	O	O
the	O	O	O
first	O	O	O
species	O	O	B-Entity
of	O	O	O
Fiorianteon	O	O	B-Entity
Olmi	O	O	I-Entity
(	O	O	O
Hymenoptera	O	O	B-Entity
,	O	O	O
Dryinidae	O	O	B-Entity
)	O	O	O
from	O	O	O
the	O	O	O
Afrotropical	O	O	O
region	O	O	O

Fiorianteon	O	O	B-Entity
sulcatumsp	O	O	I-Entity
.	O	O	O

n.	O	O	O
is	O	O	O
described	O	O	O
from	O	O	O
Fianarantsoa	O	O	B-Entity
Province	O	O	I-Entity
(	O	O	O
Madagascar	O	O	B-Entity
)	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
species	O	O	B-Entity
of	O	O	O
Fiorianteon	O	O	B-Entity
found	O	O	O
in	O	O	O
the	O	O	O
Afrotropical	O	O	B-Entity
region	O	O	I-Entity
.	O	O	O

The	O	O	O
genus	O	O	B-Entity
Fiorianteon	O	O	B-Entity
can	O	O	O
be	O	O	O
distinguished	O	O	O
from	O	O	O
the	O	O	O
closely	O	O	O
related	O	O	O
genus	O	O	O
Conganteon	O	O	B-Entity
by	O	O	O
the	O	O	O
distal	O	O	B-Entity
part	O	O	O
of	O	O	O
the	O	O	O
stigmal	O	O	B-Entity
vein	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
as	O	O	O
long	O	O	B-Entity
as	O	O	O
,	O	O	O
or	O	O	O
shorter	O	O	B-Entity
than	O	O	O
the	O	O	O
proximal	O	O	B-Entity
part	O	O	O
of	O	O	O
the	O	O	O
stigmal	O	O	O
vein	O	O	O
(	O	O	O
longer	O	O	O
than	O	O	O
the	O	O	O
proximal	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
vein	O	O	O
in	O	O	O
Conganteon	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (27920947)

The	O	O	B-Entity
Daniel	O	O	I-Entity
K.	O	O	I-Entity
Inouye	O	O	I-Entity
College	O	O	I-Entity
of	O	O	I-Entity
Pharmacy	O	O	I-Entity
Scripts	O	O	I-Entity
:	O	O	O
Poha	O	O	B-Entity
Berry	O	O	I-Entity
(	O	O	O
Physalis	O	O	B-Entity
peruviana	O	O	I-Entity
)	O	O	O
with	O	O	O
Potential	O	O	B-Entity
Anti-inflammatory	O	O	B-Entity
and	O	O	O
Cancer	O	O	B-Entity
Prevention	O	O	I-Entity
Activities	O	O	O

The	O	O	B-Entity
Daniel	O	O	I-Entity
K.	O	O	I-Entity
Inouye	O	O	I-Entity
College	O	O	I-Entity
of	O	O	I-Entity
Pharmacy	O	O	I-Entity
,	O	O	O
during	O	O	O
a	O	O	O
historic	O	O	B-Entity
event	O	O	I-Entity
in	O	O	O
Spring	O	O	B-Entity
2016	O	O	O
,	O	O	O
graduated	O	O	B-Entity
the	O	O	O
first	O	O	O
two	O	O	O
students	O	O	B-Entity
in	O	O	O
the	O	O	O
Pacific	O	O	B-Entity
region	O	O	I-Entity
to	O	O	O
earn	O	O	O
a	O	O	O
PhD	O	O	B-Entity
in	O	O	O
pharmaceutical	O	O	B-Entity
sciences	O	O	I-Entity
at	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Hawai'i	O	O	I-Entity
at	O	O	O
Hilo	O	O	B-Entity
.	O	O	O

The	O	O	O
college	O	O	B-Entity
offers	O	O	O
PhD	O	O	B-Entity
programs	O	O	B-Entity
in	O	O	O
these	O	O	O
five	O	O	O
disciplines	O	O	B-Entity
:	O	O	O
Cancer	O	O	B-Entity
Biology	O	O	I-Entity
,	O	O	O
Medicinal	O	O	B-Entity
Chemistry	O	O	I-Entity
,	O	O	O
Pharmaceutics	O	O	B-Entity
,	O	O	O
Pharmacognosy	O	O	B-Entity
,	O	O	O
and	O	O	O
Pharmacology	O	O	B-Entity
.	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
Pharmacognosy	O	O	B-Entity
dissertations	O	O	B-Entity
focused	O	O	O
on	O	O	O
plant-derived	O	O	B-Entity
natural	O	O	B-Entity
products	O	O	I-Entity
with	O	O	O
potential	O	O	B-Entity
anti-inflammatory	O	O	B-Entity
and	O	O	O
cancer	O	O	B-Entity
chemopreventive	O	O	B-Entity
activities	O	O	B-Entity
.	O	O	O

Physalis	O	O	B-Entity
peruviana	O	O	I-Entity
(	O	O	O
Pp	O	O	B-Entity
)	O	O	O
L.	O	O	O
originated	O	O	O
in	O	O	O
tropical	O	O	O
South	O	O	B-Entity
America	O	O	I-Entity
.	O	O	O

It	O	O	O
has	O	O	O
become	O	O	O
naturalized	O	O	B-Entity
and	O	O	O
is	O	O	O
found	O	O	O
readily	O	O	O
on	O	O	O
the	O	O	O
Island	O	O	B-Entity
of	O	O	I-Entity
Hawai'i	O	O	I-Entity
.	O	O	O

The	O	O	O
edible	O	O	B-Entity
fruits	O	O	B-Entity
are	O	O	O
commonly	O	O	O
known	O	O	O
as	O	O	O
cape	O	O	B-Entity
gooseberry	O	O	I-Entity
or	O	O	O
poha	O	O	B-Entity
in	O	O	O
Hawai'i	O	O	B-Entity
.	O	O	O

In	O	O	O
part	O	O	O
of	O	O	O
our	O	O	O
study	O	O	O
,	O	O	O
three	O	O	O
new	O	O	O
withanolides	O	O	B-Entity
,	O	O	O
physaperuvin	O	O	B-Entity
G	O	O	I-Entity
(	O	O	O
1	O	O	O
)	O	O	O
,	O	O	O
physaperuvins	O	O	B-Entity
I-J	O	O	I-Entity
(	O	O	O
2	O	O	O
-	O	O	O
3	O	O	O
)	O	O	O
,	O	O	O
along	O	O	O
with	O	O	O
four	O	O	O
known	O	O	O
withanolides	O	O	O
,	O	O	O
namely	O	O	O
,	O	O	O
4β-hydroxywithanolide	O	O	B-Entity
E	O	O	I-Entity
(	O	O	O
4	O	O	O
)	O	O	O
,	O	O	O
withaperuvin	O	O	B-Entity
C	O	O	I-Entity
(	O	O	O
5	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
physalactone	O	O	B-Entity
(	O	O	O
6	O	O	O
)	O	O	O
,	O	O	O
coagulin	O	O	B-Entity
(	O	O	O
7	O	O	O
)	O	O	O
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
aerial	O	O	B-Entity
parts	O	O	I-Entity
of	O	O	O
P.	O	O	B-Entity
peruviana	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
two	O	O	O
known	O	O	O
compounds	O	O	B-Entity
,	O	O	O
phyperunolide	O	O	B-Entity
F	O	O	I-Entity
(	O	O	O
8)	O	O	O
,	O	O	O
and	O	O	O
withanolide	O	O	B-Entity
S	O	O	I-Entity
(	O	O	O
9	O	O	O
)	O	O	O
,	O	O	O
were	O	O	O
isolated	O	O	B-Entity
and	O	O	O
identified	O	O	O
from	O	O	O
the	O	O	O
poha	O	O	B-Entity
berry	O	O	I-Entity
fruits	O	O	I-Entity
.	O	O	O

The	O	O	O
structures	O	O	B-Entity
and	O	O	O
absolute	O	O	B-Entity
stereochemistry	O	O	I-Entity
of	O	O	O
new	O	O	O
compounds	O	O	O
from	O	O	O
poha	O	O	B-Entity
were	O	O	O
elucidated	O	O	O
by	O	O	O
several	O	O	O
spectroscopy	O	O	B-Entity
methods	O	O	I-Entity
:	O	O	O
Nuclear	O	O	B-Entity
Magnetic	O	O	I-Entity
Resonance	O	O	I-Entity
(	O	O	I-Entity
NMR	O	O	I-Entity
)	O	O	I-Entity
spectroscopy	O	O	I-Entity
,	O	O	O
X-ray	O	O	B-Entity
diffraction	O	O	I-Entity
,	O	O	O
and	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
analyses	O	O	B-Entity
.	O	O	O

All	O	O	O
isolated	O	O	B-Entity
poha	O	O	B-Entity
compounds	O	O	B-Entity
(	O	O	O
aerial	O	O	B-Entity
parts	O	O	I-Entity
and	O	O	O
fruits	O	O	B-Entity
)	O	O	O
were	O	O	O
evaluated	O	O	O
for	O	O	O
their	O	O	O
anti-inflammatory	O	O	B-Entity
activity	O	O	I-Entity
with	O	O	O
lipopolysaccharide	O	O	B-Entity
(LPS)-activated	O	O	O
murine	O	O	B-Entity
macrophage	O	O	B-Entity
RAW	O	O	I-Entity
264.7	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
tumor	O	O	B-Entity
necrosis	O	O	I-Entity
factor	O	O	I-Entity
alpha	O	O	I-Entity
(TNF-α)-activated	O	O	O
nuclear	O	O	B-Entity
factor-kappa	O	O	I-Entity
B	O	O	I-Entity
(	O	O	O
NF-κB	O	O	B-Entity
)	O	O	O
with	O	O	O
transfected	O	O	O
human	O	O	B-Entity
embryonic	O	O	I-Entity
kidney	O	O	I-Entity
cells	O	O	I-Entity
293	O	O	I-Entity
.	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
isolated	O	O	B-Entity
natural	O	O	B-Entity
compounds	O	O	I-Entity
showed	O	O	O
activity	O	O	B-Entity
with	O	O	O
these	O	O	O
assays	O	O	B-Entity
.	O	O	O

Additional	O	O	O
studies	O	O	O
were	O	O	O
performed	O	O	O
with	O	O	O
models	O	O	B-Entity
of	O	O	O
colon	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
4β-hydroxywithanolide	O	O	B-Entity
E	O	O	I-Entity
(	O	O	O
4HWE	O	O	B-Entity
)	O	O	O
inhibited	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
colon	O	O	B-Entity
cancer	O	O	I-Entity
monolayer	O	O	B-Entity
and	O	O	O
spheroid	O	O	B-Entity
cultures	O	O	B-Entity
.	O	O	O

The	O	O	O
compound	O	O	B-Entity
induced	O	O	B-Entity
cell	O	O	B-Entity
cycle	O	O	I-Entity
arrest	O	O	I-Entity
at	O	O	O
low	O	O	B-Entity
concentrations	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
at	O	O	O
higher	O	O	B-Entity
concentrations	O	O	I-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
suggest	O	O	O
the	O	O	O
ingestion	O	O	B-Entity
of	O	O	O
poha	O	O	B-Entity
berries	O	O	I-Entity
may	O	O	O
have	O	O	O
some	O	O	O
effect	O	O	O
on	O	O	O
the	O	O	O
prevalence	O	O	O
of	O	O	O
colon	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
poha	O	O	B-Entity
isolates	O	O	B-Entity
compounds	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
for	O	O	O
their	O	O	O
growth	O	O	B-Entity
inhibitory	O	O	I-Entity
effects	O	O	I-Entity
with	O	O	O
U251MG	O	O	B-Entity
glioblastoma	O	O	I-Entity
and	O	O	O
MDA-MB-231	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
that	O	O	O
harbor	O	O	O
aberrantly-active	O	O	O
signal	O	O	B-Entity
transducer	O	O	I-Entity
and	O	O	I-Entity
activation	O	O	I-Entity
of	O	O	I-Entity
transcription	O	O	I-Entity
3	O	O	I-Entity
(	O	O	I-Entity
STAT3	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
compared	O	O	O
to	O	O	O
normal	O	O	O
NIH-3T3	O	O	B-Entity
mouse	O	O	I-Entity
fibroblasts	O	O	I-Entity
.	O	O	O

This	O	O	O
work	O	O	O
has	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
filing	O	O	O
of	O	O	O
three	O	O	O
provisional	O	O	B-Entity
patents	O	O	I-Entity
with	O	O	O
the	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Hawai'i	O	O	I-Entity
Office	O	O	I-Entity
of	O	O	I-Entity
Technology	O	O	I-Entity
Transfer	O	O	I-Entity
and	O	O	I-Entity
Economic	O	O	I-Entity
Development	O	O	I-Entity
.	O	O	O

-DOCSTART- (27922526)

Air	O	O	B-Entity
Pollutant	O	O	I-Entity
Exposure	O	O	B-Entity
Within	O	O	O
a	O	O	O
Few	O	O	O
Days	O	O	O
of	O	O	O
Delivery	O	O	B-Entity
and	O	O	O
Placental	O	O	B-Entity
Abruption	O	O	I-Entity
in	O	O	O
Japan	O	O	O

Placental	O	O	B-Entity
abruption	O	O	I-Entity
is	O	O	O
an	O	O	O
emergency	O	O	B-Entity
obstetric	O	O	I-Entity
complication	O	O	I-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
etiology	O	O	B-Entity
of	O	O	O
abruption	O	O	B-Entity
is	O	O	O
not	O	O	O
fully	O	O	O
understood	O	O	O
,	O	O	O
acute	O	O	B-Entity
stimuli	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
ischemia	O	O	B-Entity
and/or	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
rupture	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
decidual	O	O	I-Entity
artery	O	O	I-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
placental	O	O	B-Entity
separation	O	O	I-Entity
.	O	O	O

Ischemia	O	O	B-Entity
and	O	O	O
inflammation	O	O	B-Entity
are	O	O	O
acute	O	O	B-Entity
biologic	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
pollution	O	O	I-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
case-crossover	O	O	B-Entity
design	O	O	I-Entity
,	O	O	O
we	O	O	O
tested	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
a	O	O	O
short-term	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
exposure	O	O	B-Entity
to	O	O	O
air	O	O	B-Entity
pollutants	O	O	I-Entity
is	O	O	O
a	O	O	O
potential	O	O	B-Entity
trigger	O	O	B-Entity
of	O	O	O
placental	O	O	B-Entity
abruption	O	O	I-Entity
.	O	O	O

We	O	O	O
received	O	O	O
data	O	O	B-Entity
for	O	O	O
western	O	O	B-Entity
Japan	O	O	I-Entity
(	O	O	O
Kyushu-Okinawa	O	O	B-Entity
Districts	O	O	I-Entity
)	O	O	O
from	O	O	O
the	O	O	O
Japan	O	O	B-Entity
Perinatal	O	O	I-Entity
Registry	O	O	I-Entity
Network	O	O	I-Entity
database	O	O	I-Entity
.	O	O	O

From	O	O	O
2005	O	O	O
to	O	O	O
2010	O	O	O
,	O	O	O
821	O	O	O
singleton	O	O	B-Entity
pregnant	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
placental	O	O	B-Entity
abruption	O	O	I-Entity
were	O	O	O
identified	O	O	O
.	O	O	O

We	O	O	O
assigned	O	O	O
daily	O	O	B-Entity
concentrations	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
pollutants	O	O	I-Entity
,	O	O	O
including	O	O	O
nitrogen	O	O	B-Entity
dioxide	O	O	I-Entity
(	O	O	O
NO2	O	O	B-Entity
)	O	O	O
,	O	O	O
suspended	O	O	B-Entity
particulate	O	O	I-Entity
matter	O	O	I-Entity
,	O	O	O
ozone	O	O	B-Entity
,	O	O	O
and	O	O	O
sulfur	O	O	B-Entity
dioxide	O	O	I-Entity
(	O	O	O
SO2	O	O	B-Entity
)	O	O	O
,	O	O	O
from	O	O	O
the	O	O	O
nearest	O	O	O
monitoring	O	O	B-Entity
station	O	O	I-Entity
to	O	O	O
the	O	O	O
respective	O	O	O
delivery	O	O	B-Entity
hospital	O	O	B-Entity
of	O	O	O
each	O	O	O
woman	O	O	B-Entity
.	O	O	O

Because	O	O	O
information	O	O	B-Entity
on	O	O	O
the	O	O	O
onset	O	O	B-Entity
day	O	O	B-Entity
of	O	O	O
abruption	O	O	B-Entity
was	O	O	O
not	O	O	O
obtained	O	O	O
,	O	O	O
we	O	O	O
assumed	O	O	O
the	O	O	O
case	O	O	B-Entity
day	O	O	O
to	O	O	O
be	O	O	O
1	O	O	O
day	O	O	O
before	O	O	O
the	O	O	O
day	O	O	O
of	O	O	O
delivery	O	O	B-Entity
.	O	O	O

Exposure	O	O	B-Entity
to	O	O	O
NO2	O	O	B-Entity
at	O	O	O
2	O	O	O
days	O	O	O
'	O	O	O
lag	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
placental	O	O	B-Entity
abruption	O	O	I-Entity
(	O	O	O
temperature	O	O	B-Entity
adjusted	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
per	O	O	O
10	O	O	O
ppb	O	O	O
increase	O	O	B-Entity
=	O	O	O
1.4	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
=	O	O	O
1.1	O	O	O
,	O	O	O
1.8	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
association	O	O	B-Entity
patterns	O	O	O
were	O	O	O
similar	O	O	O
,	O	O	O
when	O	O	O
we	O	O	O
restricted	O	O	O
to	O	O	O
participants	O	O	B-Entity
who	O	O	O
delivered	O	O	B-Entity
by	O	O	O
emergency	O	O	B-Entity
cesarean	O	O	I-Entity
(	O	O	O
1.4	O	O	O
,	O	O	O
1.1	O	O	O
,	O	O	O
1.9	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
who	O	O	O
delivered	O	O	O
after	O	O	O
35	O	O	B-Entity
weeks	O	O	I-Entity
of	O	O	I-Entity
gestation	O	O	I-Entity
(	O	O	O
1.4	O	O	O
,	O	O	O
1.0	O	O	O
,	O	O	O
2.0	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
association	O	O	I-Entity
with	O	O	O
suspended	O	O	B-Entity
particulate	O	O	I-Entity
matter	O	O	I-Entity
,	O	O	O
ozone	O	O	B-Entity
,	O	O	O
or	O	O	O
SO2	O	O	B-Entity
.	O	O	O

We	O	O	O
observed	O	O	O
an	O	O	O
association	O	O	B-Entity
between	O	O	O
NO2	O	O	B-Entity
exposure	O	O	B-Entity
at	O	O	O
2	O	O	O
days	O	O	B-Entity
before	O	O	O
the	O	O	O
day	O	O	B-Entity
of	O	O	O
delivery	O	O	B-Entity
and	O	O	O
placental	O	O	B-Entity
abruption	O	O	I-Entity
in	O	O	O
pregnant	O	O	B-Entity
Japanese	O	O	I-Entity
women	O	O	I-Entity
.	O	O	O

-DOCSTART- (27922994)

The	O	O	O
2016	O	O	O
Infusion	O	O	B-Entity
Therapy	O	O	I-Entity
Standards	O	O	B-Entity
of	O	O	O
Practice	O	O	O

Approximately	O	O	O
every	O	O	O
5	O	O	O
years	O	O	O
,	O	O	O
the	O	O	O
Infusion	O	O	B-Entity
Nurses	O	O	I-Entity
Society	O	O	I-Entity
publishes	O	O	B-Entity
evidence-based	O	O	B-Entity
practice	O	O	I-Entity
standards	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	B-Entity
provides	O	O	B-Entity
an	O	O	O
overview	O	O	O
of	O	O	O
the	O	O	O
process	O	O	B-Entity
used	O	O	B-Entity
in	O	O	O
standards	O	O	B-Entity
development	O	O	B-Entity
,	O	O	O
describes	O	O	O
the	O	O	O
format	O	O	B-Entity
of	O	O	O
the	O	O	O
standards	O	O	O
,	O	O	O
and	O	O	O
provides	O	O	O
a	O	O	O
short	O	O	O
summary	O	O	B-Entity
of	O	O	O
selected	O	O	B-Entity
standards	O	O	O
as	O	O	O
applied	O	O	B-Entity
to	O	O	O
home	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

The	O	O	O
Standards	O	O	B-Entity
are	O	O	O
an	O	O	O
important	O	O	B-Entity
document	O	O	B-Entity
that	O	O	O
should	O	O	O
be	O	O	O
available	O	O	B-Entity
to	O	O	O
every	O	O	B-Entity
home	O	O	B-Entity
care	O	O	I-Entity
organization	O	O	B-Entity
that	O	O	O
provides	O	O	B-Entity
home	O	O	B-Entity
infusion	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (27924297)

Datasets	O	O	B-Entity
for	O	O	O
the	O	O	O
validation	O	O	B-Entity
of	O	O	O
the	O	O	O
"	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
"	O	O	O
siRNA	O	O	B-Entity
-	O	O	O
silencing	O	O	B-Entity
of	O	O	O
CD40	O	O	B-Entity
and	O	O	O
for	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
new	O	O	O
markers	O	O	B-Entity
of	O	O	O
atherosclerosis	O	O	B-Entity
progression	O	O	B-Entity
in	O	O	O
ApoE	O	O	B-Entity
-	O	O	O
deficient	O	O	B-Entity
mice	O	O	O

Data	O	O	B-Entity
presented	O	O	O
in	O	O	O
this	O	O	O
Data	O	O	O
in	O	O	O
Brief	O	O	O
article	O	O	O
correspond	O	O	O
to	O	O	O
the	O	O	O
article	O	O	O
"	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
"	O	O	O
silencing	O	O	B-Entity
of	O	O	O
CD40	O	O	B-Entity
reduces	O	O	O
progression	O	O	B-Entity
of	O	O	O
experimental	O	O	B-Entity
atherogenesis	O	O	B-Entity
through	O	O	O
a	O	O	O
NFκB	O	O	B-Entity
/	O	O	O
miR-125b	O	O	B-Entity
axis	O	O	O
and	O	O	O
reveals	O	O	O
new	O	O	O
potential	O	O	B-Entity
mediators	O	O	B-Entity
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
atherosclerosis	O	O	B-Entity
"	O	O	O
(	O	O	O
M.	O	O	B-Entity
Hueso	O	O	I-Entity
,	O	O	O
L.	O	O	B-Entity
De	O	O	I-Entity
Ramon	O	O	I-Entity
,	O	O	O
E.	O	O	B-Entity
Navarro	O	O	I-Entity
,	O	O	O
E.	O	O	B-Entity
Ripoll	O	O	I-Entity
,	O	O	O
J.M.	O	O	B-Entity
Cruzado	O	O	I-Entity
,	O	O	O
J.M.	O	O	B-Entity
Grinyo	O	O	I-Entity
,	O	O	O
J.	O	O	B-Entity
Torras	O	O	I-Entity
,	O	O	O
2016	O	O	O
)	O	O	O
[	O	O	O
1	O	O	O
]	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
validation	O	O	B-Entity
of	O	O	O
the	O	O	O
silencing	O	O	B-Entity
of	O	O	O
CD40	O	O	B-Entity
expression	O	O	B-Entity
with	O	O	O
a	O	O	O
specific	O	O	O
siRNA	O	O	B-Entity
in	O	O	O
ApoE(-/-	O	O	B-Entity
)	O	O	I-Entity
mouse	O	O	B-Entity
aortas	O	O	B-Entity
,	O	O	O
and	O	O	O
its	O	O	O
systemic	O	O	O
effects	O	O	O
on	O	O	O
splenic	O	O	B-Entity
lymphocytic	O	O	B-Entity
subpopulations	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
on	O	O	O
the	O	O	O
infiltration	O	O	B-Entity
of	O	O	O
aortic	O	O	B-Entity
intima	O	O	I-Entity
by	O	O	O
F4/80(+	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
galectin-3(+	O	O	B-Entity
)	O	O	I-Entity
macrophages	O	O	I-Entity
or	O	O	O
by	O	O	O
NF-κB(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
show	O	O	O
the	O	O	O
output	O	O	O
of	O	O	O
a	O	O	O
Gene	O	O	B-Entity
Ontology	O	O	I-Entity
and	O	O	O
TLDA	O	O	B-Entity
analysis	O	O	I-Entity
which	O	O	O
allowed	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
potential	O	O	B-Entity
mediators	O	O	B-Entity
of	O	O	O
atherosclerosis	O	O	B-Entity
progression	O	O	B-Entity
.	O	O	O

We	O	O	O
provide	O	O	O
the	O	O	O
scientific	O	O	O
community	O	O	O
with	O	O	O
a	O	O	O
set	O	O	O
of	O	O	O
genes	O	O	B-Entity
whose	O	O	O
expression	O	O	B-Entity
is	O	O	O
increased	O	O	B-Entity
during	O	O	O
atherosclerosis	O	O	B-Entity
progression	O	O	B-Entity
but	O	O	O
downregulated	O	O	B-Entity
upon	O	O	O
CD40	O	O	B-Entity
silencing	O	O	B-Entity
.	O	O	O

-DOCSTART- (27927071)

Investigation	O	O	B-Entity
on	O	O	O
evaluation	O	O	B-Entity
criteria	O	O	B-Entity
of	O	O	O
backwashing	O	O	B-Entity
effects	O	O	B-Entity
for	O	O	O
a	O	O	O
pilot-scale	O	O	B-Entity
BAF	O	O	B-Entity
treating	O	O	B-Entity
petrochemical	O	O	B-Entity
wastewater	O	O	O

Parameters	O	O	B-Entity
for	O	O	O
evaluation	O	O	B-Entity
criteria	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
-	O	O	O
water	O	O	B-Entity
backwashing	O	O	B-Entity
effect	O	O	B-Entity
s	O	O	O
of	O	O	O
a	O	O	O
pilot-scale	O	O	B-Entity
biological	O	O	B-Entity
aerated	O	O	I-Entity
filter	O	O	I-Entity
(	O	O	O
BAF	O	O	B-Entity
)	O	O	O
treating	O	O	B-Entity
petrochemical	O	O	B-Entity
wastewater	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
.	O	O	O

The	O	O	O
parameters	O	O	B-Entity
included	O	O	O
the	O	O	O
suspended	O	O	B-Entity
solids	O	O	B-Entity
(	O	O	O
SS	O	O	B-Entity
)	O	O	O
and	O	O	O
specific	O	O	B-Entity
oxygen	O	O	I-Entity
uptake	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
SOUR	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
backwashing	O	O	B-Entity
effluent	O	O	B-Entity
,	O	O	O
recovery	O	O	B-Entity
of	O	O	O
the	O	O	O
BAF	O	O	B-Entity
after	O	O	O
backwashing	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
removal	O	O	B-Entity
of	O	O	O
the	O	O	O
biomass	O	O	B-Entity
/	O	O	O
bioactivity	O	O	B-Entity
attached	O	O	B-Entity
on	O	O	O
the	O	O	O
filter	O	O	B-Entity
media	O	O	B-Entity
after	O	O	O
backwashing	O	O	O
.	O	O	O

Results	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
weight	O	O	B-Entity
of	O	O	O
the	O	O	O
total	O	O	B-Entity
sludge	O	O	B-Entity
produced	O	O	O
in	O	O	O
the	O	O	O
backwashing	O	O	B-Entity
effluent	O	O	B-Entity
increased	O	O	B-Entity
with	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
water	O	O	B-Entity
-	O	O	O
backwashing	O	O	O
intensity	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
total	O	O	O
SOUR	O	O	B-Entity
of	O	O	O
backwashing	O	O	O
effluent	O	O	O
rose	O	O	O
notably	O	O	B-Entity
with	O	O	O
the	O	O	O
increase	O	O	O
of	O	O	O
air	O	O	B-Entity
-	O	O	O
backwashing	O	O	O
intensity	O	O	O
.	O	O	O

The	O	O	O
optimal	O	O	B-Entity
backwashing	O	O	B-Entity
intensity	O	O	B-Entity
of	O	O	O
14	O	O	O
L/(m(2)·s	O	O	O
)	O	O	O
for	O	O	O
air	O	O	B-Entity
and	O	O	O
4	O	O	O
L/(m(2)·s	O	O	O
)	O	O	O
for	O	O	O
water	O	O	B-Entity
were	O	O	O
obtained	O	O	B-Entity
.	O	O	O

When	O	O	O
the	O	O	O
BAF	O	O	B-Entity
was	O	O	O
backwashed	O	O	B-Entity
on	O	O	O
this	O	O	O
condition	O	O	O
,	O	O	O
the	O	O	O
BAF	O	O	O
recovered	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
average	O	O	B-Entity
removal	O	O	B-Entity
of	O	O	O
chemical	O	O	B-Entity
oxygen	O	O	I-Entity
demand	O	O	I-Entity
(	O	O	O
COD	O	O	B-Entity
)	O	O	O
and	O	O	O
ammonia	O	O	B-Entity
nitrogen	O	O	I-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
of	O	O	O
14.3	O	O	O
%	O	O	O
and	O	O	O
50.3	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

High	O	O	B-Entity
amount	O	O	B-Entity
of	O	O	O
biomass	O	O	B-Entity
removal	O	O	B-Entity
at	O	O	O
15.8	O	O	O
%	O	O	O
and	O	O	O
low	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
bioactivity	O	O	B-Entity
removal	O	O	O
at	O	O	O
8.8	O	O	O
%	O	O	O
attached	O	O	B-Entity
on	O	O	O
the	O	O	O
filter	O	O	B-Entity
media	O	O	B-Entity
were	O	O	O
also	O	O	O
found	O	O	O
.	O	O	O

Concentrations	O	O	B-Entity
of	O	O	O
the	O	O	O
benzene	O	O	B-Entity
,	O	O	O
toluene	O	O	B-Entity
,	O	O	O
ethylbenzene	O	O	B-Entity
and	O	O	O
(	O	O	B-Entity
o-	O	O	I-Entity
,	O	O	I-Entity
m-	O	O	I-Entity
,	O	O	I-Entity
p-	O	O	I-Entity
)	O	O	I-Entity
xylenes	O	O	I-Entity
(	O	O	O
BTEX	O	O	B-Entity
)	O	O	O
and	O	O	O
phenol	O	O	B-Entity
in	O	O	O
the	O	O	O
backwashed	O	O	B-Entity
sludge	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
,	O	O	O
showing	O	O	O
that	O	O	O
the	O	O	O
backwashing	O	O	B-Entity
was	O	O	O
essential	O	O	B-Entity
to	O	O	O
remove	O	O	B-Entity
some	O	O	O
aromatic	O	O	B-Entity
compounds	O	O	I-Entity
adsorbed	O	O	B-Entity
in	O	O	O
the	O	O	O
microorganisms	O	O	B-Entity
.	O	O	O

-DOCSTART- (27928742)

Implementation	O	O	B-Entity
of	O	O	O
infrared	O	O	B-Entity
and	O	O	O
Raman	O	O	B-Entity
modalities	O	O	B-Entity
for	O	O	O
glycosaminoglycan	O	O	B-Entity
characterization	O	O	B-Entity
in	O	O	O
complex	O	O	B-Entity
systems	O	O	O

Glycosaminoglycans	O	O	B-Entity
(	O	O	O
GAGs	O	O	B-Entity
)	O	O	O
are	O	O	O
natural	O	O	B-Entity
,	O	O	O
linear	O	O	B-Entity
and	O	O	O
negatively	O	O	B-Entity
charged	O	O	I-Entity
heteropolysaccharides	O	O	B-Entity
which	O	O	O
are	O	O	O
incident	O	O	B-Entity
in	O	O	O
every	O	O	O
mammalian	O	O	B-Entity
tissue	O	O	B-Entity
.	O	O	O

They	O	O	O
consist	O	O	O
of	O	O	O
repeating	O	O	O
disaccharide	O	O	B-Entity
units	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
composed	O	O	O
of	O	O	O
either	O	O	O
sulfated	O	O	B-Entity
or	O	O	O
non-sulfated	O	O	B-Entity
monosaccharides	O	O	I-Entity
.	O	O	O

Depending	O	O	O
on	O	O	O
tissue	O	O	B-Entity
types	O	O	B-Entity
,	O	O	O
GAGs	O	O	B-Entity
exhibit	O	O	O
structural	O	O	B-Entity
heterogeneity	O	O	B-Entity
such	O	O	O
as	O	O	O
the	O	O	O
position	O	O	B-Entity
and	O	O	O
degree	O	O	B-Entity
of	O	O	O
sulfation	O	O	B-Entity
or	O	O	O
within	O	O	O
their	O	O	O
disaccharide	O	O	B-Entity
units	O	O	B-Entity
composition	O	O	B-Entity
being	O	O	O
heparin	O	O	B-Entity
,	O	O	O
heparan	O	O	B-Entity
sulfate	O	O	I-Entity
,	O	O	O
chondroitine	O	O	B-Entity
sulfate	O	O	I-Entity
,	O	O	O
dermatan	O	O	B-Entity
sulfate	O	O	I-Entity
,	O	O	O
keratan	O	O	B-Entity
sulfate	O	O	I-Entity
,	O	O	O
and	O	O	O
hyaluronic	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

They	O	O	O
are	O	O	O
covalently	O	O	B-Entity
linked	O	O	I-Entity
to	O	O	O
a	O	O	O
core	O	O	B-Entity
protein	O	O	B-Entity
(	O	O	O
proteoglycans	O	O	B-Entity
)	O	O	O
or	O	O	O
as	O	O	O
free	O	O	B-Entity
chains	O	O	B-Entity
(	O	O	O
hyaluronan	O	O	B-Entity
)	O	O	O
.	O	O	O

GAGs	O	O	B-Entity
affect	O	O	O
cell	O	O	B-Entity
properties	O	O	B-Entity
and	O	O	O
functions	O	O	B-Entity
either	O	O	O
by	O	O	O
direct	O	O	B-Entity
interaction	O	O	B-Entity
with	O	O	O
cell	O	O	B-Entity
receptors	O	O	I-Entity
or	O	O	O
by	O	O	O
sequestration	O	O	B-Entity
of	O	O	O
growth	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

These	O	O	O
evidences	O	O	B-Entity
of	O	O	I-Entity
divert	O	O	B-Entity
biological	O	O	B-Entity
roles	O	O	B-Entity
of	O	O	O
GAGs	O	O	B-Entity
make	O	O	O
their	O	O	O
characterization	O	O	B-Entity
at	O	O	O
cell	O	O	B-Entity
and	O	O	O
tissue	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
importance	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
non-invasive	O	O	B-Entity
techniques	O	O	B-Entity
are	O	O	O
interesting	O	O	O
to	O	O	O
investigate	O	O	B-Entity
,	O	O	O
to	O	O	O
qualitatively	O	O	B-Entity
and	O	O	O
quantitatively	O	O	B-Entity
characterize	O	O	O
GAGs	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
use	O	O	O
them	O	O	O
as	O	O	O
diagnostic	O	O	B-Entity
biomarkers	O	O	B-Entity
and/or	O	O	O
as	O	O	O
therapeutic	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	O
several	O	O	O
human	O	O	B-Entity
diseases	O	O	B-Entity
including	O	O	O
cancer	O	O	B-Entity
.	O	O	O

Infrared	O	O	B-Entity
and	O	O	O
Raman	O	O	B-Entity
microspectroscopies	O	O	I-Entity
and	O	O	O
imaging	O	O	B-Entity
are	O	O	O
sensitive	O	O	B-Entity
enough	O	O	O
to	O	O	O
differentiate	O	O	O
and	O	O	O
classify	O	O	B-Entity
GAG	O	O	B-Entity
types	O	O	B-Entity
and	O	O	O
subtypes	O	O	B-Entity
in	O	O	O
spite	O	O	O
of	O	O	O
their	O	O	O
close	O	O	O
molecular	O	O	B-Entity
structures	O	O	I-Entity
.	O	O	O

Spectroscopic	O	O	B-Entity
markers	O	O	B-Entity
characteristic	O	O	O
of	O	O	O
reference	O	O	O
GAG	O	O	B-Entity
molecules	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

Beyond	O	O	O
these	O	O	O
investigations	O	O	B-Entity
of	O	O	O
the	O	O	O
standard	O	O	O
GAG	O	O	B-Entity
spectral	O	O	O
signature	O	O	O
,	O	O	O
infrared	O	O	B-Entity
and	O	O	O
Raman	O	O	B-Entity
spectral	O	O	O
signatures	O	O	O
of	O	O	O
GAG	O	O	O
were	O	O	O
searched	O	O	O
in	O	O	O
complex	O	O	B-Entity
biological	O	O	B-Entity
systems	O	O	B-Entity
like	O	O	O
cells	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
review	O	O	O
is	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
implementation	O	O	B-Entity
of	O	O	O
these	O	O	O
complementary	O	O	O
vibrational	O	O	B-Entity
spectroscopy	O	O	I-Entity
techniques	O	O	I-Entity
,	O	O	O
and	O	O	O
to	O	O	O
discuss	O	O	O
their	O	O	O
potentials	O	O	O
,	O	O	O
advantages	O	O	O
and	O	O	O
disadvantages	O	O	O
for	O	O	O
GAG	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
this	O	O	O
review	O	O	O
presents	O	O	O
new	O	O	O
data	O	O	O
as	O	O	O
we	O	O	O
show	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
GAG	O	O	B-Entity
infrared	O	O	B-Entity
and	O	O	O
Raman	O	O	B-Entity
spectral	O	O	O
signatures	O	O	O
from	O	O	O
conditioned	O	O	B-Entity
media	O	O	I-Entity
and	O	O	O
live	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

-DOCSTART- (27932568)

Targeting	O	O	B-Entity
HIF2	O	O	B-Entity
in	O	O	O
Clear	O	O	O
Cell	O	O	O
Renal	O	O	O
Cell	O	O	O
Carcinoma	O	O	O

Inactivation	O	O	O
of	O	O	O
the	O	O	O
von	O	O	B-Entity
Hippel-Lindau	O	O	I-Entity
tumor-suppressor	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
pVHL	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
signature	O	O	B-Entity
"	O	O	I-Entity
truncal	O	O	I-Entity
"	O	O	I-Entity
event	O	O	I-Entity
in	O	O	O
clear	O	O	B-Entity
cell	O	O	I-Entity
renal	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
form	O	O	O
of	O	O	O
kidney	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

pVHL	O	O	B-Entity
is	O	O	O
part	O	O	O
of	O	O	O
a	O	O	O
ubiquitin	O	O	B-Entity
ligase	O	O	I-Entity
the	O	O	O
targets	O	O	B-Entity
the	O	O	O
α	O	O	B-Entity
subunit	O	O	I-Entity
of	O	O	O
the	O	O	O
hypoxia-inducible	O	O	B-Entity
factor	O	O	I-Entity
(	O	O	I-Entity
HIF	O	O	I-Entity
)	O	O	I-Entity
transcription	O	O	I-Entity
factor	O	O	I-Entity
for	O	O	O
destruction	O	O	B-Entity
when	O	O	O
oxygen	O	O	O
is	O	O	O
available	O	O	O
.	O	O	O

Preclinical	O	O	B-Entity
studies	O	O	B-Entity
strongly	O	O	O
suggest	O	O	O
that	O	O	O
deregulation	O	O	B-Entity
of	O	O	O
HIF	O	O	B-Entity
,	O	O	O
and	O	O	O
particularly	O	O	O
HIF2	O	O	B-Entity
,	O	O	O
drives	O	O	O
pVHL	O	O	B-Entity
-defective	O	O	O
renal	O	O	B-Entity
carcinogenesis	O	O	I-Entity
.	O	O	O

Although	O	O	O
HIF2α	O	O	B-Entity
was	O	O	O
classically	O	O	O
considered	O	O	O
undruggable	O	O	B-Entity
,	O	O	O
structural	O	O	O
and	O	O	O
chemical	O	O	O
work	O	O	O
by	O	O	O
Rick	O	O	B-Entity
Bruick	O	O	I-Entity
and	O	O	O
Kevin	O	O	B-Entity
Gardner	O	O	I-Entity
at	O	O	O
University	O	O	B-Entity
of	O	O	I-Entity
Texas	O	O	I-Entity
Southwestern	O	O	I-Entity
laid	O	O	O
the	O	O	O
foundation	O	O	O
for	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
small	O	O	B-Entity
molecule	O	O	I-Entity
direct	O	O	O
HIF2α	O	O	B-Entity
antagonists	O	O	I-Entity
(	O	O	O
PT2385	O	O	B-Entity
and	O	O	O
the	O	O	O
related	O	O	O
tool	O	O	O
compound	O	O	O
PT2399	O	O	B-Entity
)	O	O	O
by	O	O	O
Peloton	O	O	B-Entity
Therapeutics	O	O	I-Entity
that	O	O	O
block	O	O	B-Entity
the	O	O	O
dimerization	O	O	B-Entity
of	O	O	O
HIF2α	O	O	O
with	O	O	O
its	O	O	O
partner	O	O	O
protein	O	O	B-Entity
ARNT1	O	O	I-Entity
.	O	O	O

These	O	O	O
compounds	O	O	O
inhibit	O	O	B-Entity
clear	O	O	I-Entity
cell	O	O	I-Entity
renal	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
growth	O	O	I-Entity
in	O	O	O
preclinical	O	O	B-Entity
models	O	O	I-Entity
,	O	O	O
and	O	O	O
PT2385	O	O	B-Entity
has	O	O	O
now	O	O	O
entered	O	O	O
the	O	O	O
clinic	O	O	B-Entity
.	O	O	O

Nonetheless	O	O	O
,	O	O	O
the	O	O	O
availability	O	O	O
of	O	O	O
such	O	O	B-Entity
compounds	O	O	I-Entity
,	O	O	O
together	O	O	O
with	O	O	O
clustered	O	O	B-Entity
regularly	O	O	I-Entity
interspaced	O	O	I-Entity
short	O	O	I-Entity
palindromic	O	O	I-Entity
repeat	O	O	I-Entity
(CRISPR)-based	O	O	O
gene	O	O	B-Entity
editing	O	O	I-Entity
approaches	O	O	I-Entity
,	O	O	O
has	O	O	O
revealed	O	O	O
a	O	O	O
previously	O	O	O
unappreciated	O	O	B-Entity
heterogeneity	O	O	I-Entity
among	O	O	O
clear	O	O	B-Entity
cell	O	O	I-Entity
renal	O	O	I-Entity
carcinomas	O	O	I-Entity
and	O	O	O
patient	O	O	B-Entity
-derived	O	O	O
xenografts	O	O	B-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
HIF2	O	O	B-Entity
dependence	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
predictive	O	O	B-Entity
biomarkers	O	O	I-Entity
will	O	O	O
be	O	O	O
needed	O	O	O
to	O	O	O
optimize	O	O	B-Entity
the	O	O	O
use	O	O	O
of	O	O	O
such	O	O	B-Entity
agents	O	O	I-Entity
in	O	O	O
the	O	O	O
clinic	O	O	B-Entity
.	O	O	O

-DOCSTART- (27935120)

Prevalence	O	O	B-Entity
of	O	O	O
high-risk	O	O	B-Entity
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
infection	O	O	I-Entity
among	O	O	O
women	O	O	B-Entity
in	O	O	O
Shaanxi	O	O	B-Entity
province	O	O	B-Entity
of	O	O	O
China	O	O	B-Entity
:	O	O	O
A	O	O	O
hospital	O	O	B-Entity
-based	O	O	O
investigation	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
female	O	O	B-Entity
high-risk	O	O	B-Entity
human	O	O	I-Entity
papillomavirus	O	O	I-Entity
(	O	O	I-Entity
HR-HPV	O	O	I-Entity
)	O	O	I-Entity
infection	O	O	I-Entity
in	O	O	O
Shaanxi	O	O	B-Entity
province	O	O	B-Entity
of	O	O	O
China	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
14	O	O	O
111	O	O	O
women	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
for	O	O	O
HPV	O	O	B-Entity
genotyping	O	O	B-Entity
test	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
cytology	O	O	B-Entity
,	O	O	O
and/or	O	O	O
cervix	O	O	B-Entity
biopsy	O	O	I-Entity
were	O	O	O
performed	O	O	O
in	O	O	O
partial	O	O	O
women	O	O	O
.	O	O	O

Of	O	O	O
these	O	O	O
women	O	O	B-Entity
,	O	O	O
the	O	O	O
HPV	O	O	B-Entity
infection	O	O	I-Entity
rate	O	O	B-Entity
was	O	O	O
30.21	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
26.73	O	O	O
%	O	O	O
were	O	O	O
caused	O	O	O
by	O	O	O
HR-HPV	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
HR-HPV	O	O	B-Entity
genotypes	O	O	B-Entity
were	O	O	O
HPV-16	O	O	B-Entity
,	O	O	O
HPV-58	O	O	B-Entity
,	O	O	O
HPV-52	O	O	B-Entity
,	O	O	O
HPV-18	O	O	B-Entity
,	O	O	O
and	O	O	O
HPV-31	O	O	B-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
HR-HPV	O	O	B-Entity
among	O	O	O
women	O	O	B-Entity
older	O	O	O
than	O	O	O
50	O	O	O
years	O	O	O
was	O	O	O
significantly	O	O	O
higher	O	O	O
than	O	O	O
the	O	O	O
other	O	O	O
groups	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
carcinogenic	O	O	B-Entity
genotypes	O	O	B-Entity
were	O	O	O
HPV-16	O	O	B-Entity
,	O	O	O
HPV-18	O	O	B-Entity
,	O	O	O
HPV-58	O	O	B-Entity
,	O	O	O
HPV-52	O	O	B-Entity
,	O	O	O
and	O	O	O
HPV-31	O	O	B-Entity
.	O	O	O

HPV-16	O	O	B-Entity
and	O	O	O
HPV-18	O	O	B-Entity
combined	O	O	O
caused	O	O	O
80.79	O	O	O
%	O	O	O
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
cases	O	O	O
.	O	O	O

The	O	O	O
infection	O	O	B-Entity
with	O	O	O
multiple	O	O	O
HR-HPVs	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
cervical	O	O	B-Entity
lesions	O	O	I-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
HPV	O	O	B-Entity
infection	O	O	I-Entity
was	O	O	O
common	O	O	O
among	O	O	O
women	O	O	B-Entity
in	O	O	O
Shaanxi	O	O	B-Entity
province	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
older	O	O	O
than	O	O	O
50	O	O	O
years	O	O	O
were	O	O	O
a	O	O	O
high-risk	O	O	B-Entity
group	O	O	I-Entity
for	O	O	O
HR-HPV	O	O	B-Entity
infection	O	O	I-Entity
and	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

HPV-16	O	O	B-Entity
and	O	O	O
HPV-18	O	O	B-Entity
were	O	O	O
the	O	O	O
main	O	O	O
carcinogenic	O	O	B-Entity
genotypes	O	O	B-Entity
in	O	O	O
this	O	O	O
region	O	O	B-Entity
.	O	O	O

-DOCSTART- (27935944)

Novel	O	O	B-Entity
and	O	O	O
Lost	O	O	B-Entity
Forests	O	O	B-Entity
in	O	O	O
the	O	O	O
Upper	O	O	B-Entity
Midwestern	O	O	I-Entity
United	O	O	I-Entity
States	O	O	I-Entity
,	O	O	O
from	O	O	O
New	O	O	B-Entity
Estimates	O	O	B-Entity
of	O	O	O
Settlement-Era	O	O	B-Entity
Composition	O	O	O
,	O	O	O
Stem	O	O	B-Entity
Density	O	O	B-Entity
,	O	O	O
and	O	O	O
Biomass	O	O	O

EuroAmerican	O	O	B-Entity
land-use	O	O	B-Entity
and	O	O	O
its	O	O	O
legacies	O	O	B-Entity
have	O	O	O
transformed	O	O	B-Entity
forest	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	O
composition	O	O	O
across	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
(	O	O	O
US	O	O	B-Entity
)	O	O	O
.	O	O	O

More	O	O	B-Entity
accurate	O	O	B-Entity
reconstructions	O	O	B-Entity
of	O	O	O
historical	O	O	B-Entity
states	O	O	I-Entity
are	O	O	O
critical	O	O	B-Entity
to	O	O	O
understanding	O	O	O
the	O	O	O
processes	O	O	B-Entity
governing	O	O	B-Entity
past	O	O	B-Entity
,	O	O	O
current	O	O	B-Entity
,	O	O	O
and	O	O	O
future	O	O	B-Entity
forest	O	O	B-Entity
dynamics	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
present	O	O	O
new	O	O	O
gridded	O	O	O
(	O	O	O
8x8	O	O	O
km	O	O	O
)	O	O	O
reconstructions	O	O	B-Entity
of	O	O	O
pre-settlement	O	O	B-Entity
(	O	O	O
1800s	O	O	O
)	O	O	O
forest	O	O	B-Entity
composition	O	O	O
and	O	O	O
structure	O	O	O
from	O	O	O
the	O	O	O
upper	O	O	B-Entity
Midwestern	O	O	I-Entity
US	O	O	I-Entity
(	O	O	O
Minnesota	O	O	B-Entity
,	O	O	O
Wisconsin	O	O	B-Entity
,	O	O	O
and	O	O	O
most	O	O	O
of	O	O	O
Michigan	O	O	B-Entity
)	O	O	O
,	O	O	O
using	O	O	O
19th	O	O	O
Century	O	O	B-Entity
Public	O	O	I-Entity
Land	O	O	I-Entity
Survey	O	O	I-Entity
System	O	O	I-Entity
(	O	O	O
PLSS	O	O	B-Entity
)	O	O	O
,	O	O	O
with	O	O	O
estimates	O	O	B-Entity
of	O	O	O
relative	O	O	B-Entity
composition	O	O	O
,	O	O	O
above-ground	O	O	B-Entity
biomass	O	O	B-Entity
,	O	O	O
stem	O	O	B-Entity
density	O	O	B-Entity
,	O	O	O
and	O	O	O
basal	O	O	B-Entity
area	O	O	I-Entity
for	O	O	O
28	O	O	O
tree	O	O	B-Entity
types	O	O	B-Entity
.	O	O	O

This	O	O	O
mapping	O	O	B-Entity
is	O	O	O
more	O	O	O
robust	O	O	B-Entity
than	O	O	O
past	O	O	B-Entity
efforts	O	O	B-Entity
,	O	O	O
using	O	O	O
spatially	O	O	O
varying	O	O	O
correction	O	O	B-Entity
factors	O	O	I-Entity
to	O	O	O
accommodate	O	O	O
sampling	O	O	B-Entity
design	O	O	I-Entity
,	O	O	O
azimuthal	O	O	B-Entity
censoring	O	O	I-Entity
,	O	O	O
and	O	O	O
biases	O	O	B-Entity
in	O	O	O
tree	O	O	B-Entity
selection	O	O	B-Entity
.	O	O	O

We	O	O	O
compare	O	O	O
pre-settlement	O	O	B-Entity
to	O	O	O
modern	O	O	B-Entity
forests	O	O	B-Entity
using	O	O	O
US	O	O	B-Entity
Forest	O	O	B-Entity
Service	O	O	B-Entity
Forest	O	O	B-Entity
Inventory	O	O	I-Entity
and	O	O	I-Entity
Analysis	O	O	I-Entity
(	O	O	I-Entity
FIA	O	O	I-Entity
)	O	O	I-Entity
data	O	O	I-Entity
to	O	O	O
show	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
lost	O	O	B-Entity
forests	O	O	O
(	O	O	O
pre-settlement	O	O	O
forests	O	O	O
with	O	O	O
no	O	O	B-Entity
current	O	O	B-Entity
analog	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
novel	O	O	B-Entity
forests	O	O	O
(	O	O	O
modern	O	O	O
forests	O	O	O
with	O	O	O
no	O	O	O
past	O	O	B-Entity
analogs	O	O	B-Entity
)	O	O	O
.	O	O	O

Differences	O	O	O
between	O	O	O
pre-settlement	O	O	B-Entity
and	O	O	O
modern	O	O	B-Entity
forests	O	O	B-Entity
are	O	O	O
spatially	O	O	O
structured	O	O	O
owing	O	O	O
to	O	O	O
differences	O	O	O
in	O	O	O
land-use	O	O	B-Entity
impacts	O	O	B-Entity
and	O	O	O
accompanying	O	O	O
ecological	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

Modern	O	O	B-Entity
forests	O	O	B-Entity
are	O	O	O
more	O	O	O
homogeneous	O	O	B-Entity
,	O	O	O
and	O	O	O
ecotonal	O	O	B-Entity
gradients	O	O	B-Entity
are	O	O	O
more	O	O	O
diffuse	O	O	B-Entity
today	O	O	O
than	O	O	O
in	O	O	B-Entity
the	O	O	I-Entity
past	O	O	I-Entity
.	O	O	O

Novel	O	O	B-Entity
forest	O	O	B-Entity
assemblages	O	O	B-Entity
represent	O	O	O
28	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
FIA	O	O	B-Entity
cells	O	O	O
,	O	O	O
and	O	O	O
28	O	O	O
%	O	O	O
of	O	O	O
pre-settlement	O	O	B-Entity
forests	O	O	B-Entity
no	O	O	B-Entity
longer	O	O	I-Entity
exist	O	O	B-Entity
in	O	O	O
a	O	O	O
modern	O	O	B-Entity
context	O	O	B-Entity
.	O	O	O

Lost	O	O	B-Entity
forests	O	O	B-Entity
include	O	O	O
tamarack	O	O	B-Entity
forests	O	O	O
in	O	O	O
northeastern	O	O	B-Entity
Minnesota	O	O	B-Entity
,	O	O	O
hemlock	O	O	B-Entity
and	O	O	O
cedar	O	O	B-Entity
dominated	O	O	O
forests	O	O	O
in	O	O	O
north-central	O	O	B-Entity
Wisconsin	O	O	B-Entity
and	O	O	O
along	O	O	O
the	O	O	O
Upper	O	O	B-Entity
Peninsula	O	O	I-Entity
of	O	O	I-Entity
Michigan	O	O	I-Entity
,	O	O	O
and	O	O	O
elm	O	O	B-Entity
,	O	O	O
oak	O	O	B-Entity
,	O	O	O
basswood	O	O	B-Entity
and	O	O	O
ironwood	O	O	B-Entity
forests	O	O	O
along	O	O	O
the	O	O	O
forest	O	O	B-Entity
-	O	O	O
prairie	O	O	B-Entity
boundary	O	O	I-Entity
in	O	O	O
south	O	O	B-Entity
central	O	O	I-Entity
Minnesota	O	O	I-Entity
and	O	O	O
eastern	O	O	B-Entity
Wisconsin	O	O	O
.	O	O	O

Novel	O	O	B-Entity
FIA	O	O	B-Entity
forest	O	O	B-Entity
assemblages	O	O	B-Entity
are	O	O	O
distributed	O	O	O
evenly	O	O	O
across	O	O	O
the	O	O	O
region	O	O	B-Entity
,	O	O	O
but	O	O	O
novelty	O	O	B-Entity
shows	O	O	O
a	O	O	O
strong	O	O	B-Entity
relationship	O	O	B-Entity
to	O	O	O
spatial	O	O	B-Entity
distance	O	O	I-Entity
from	O	O	O
remnant	O	O	B-Entity
forests	O	O	B-Entity
in	O	O	O
the	O	O	O
upper	O	O	B-Entity
Midwest	O	O	I-Entity
,	O	O	O
with	O	O	O
novelty	O	O	O
predicted	O	O	B-Entity
at	O	O	O
between	O	O	O
20	O	O	O
to	O	O	O
60	O	O	O
km	O	O	O
from	O	O	O
remnants	O	O	B-Entity
,	O	O	O
depending	O	O	O
on	O	O	O
historical	O	O	B-Entity
forest	O	O	B-Entity
type	O	O	I-Entity
.	O	O	O

The	O	O	O
spatial	O	O	B-Entity
relationships	O	O	B-Entity
between	O	O	O
remnant	O	O	B-Entity
and	O	O	O
novel	O	O	B-Entity
forests	O	O	B-Entity
,	O	O	O
shifts	O	O	B-Entity
in	O	O	O
ecotone	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	O
the	O	O	O
loss	O	O	B-Entity
of	O	O	O
historic	O	O	B-Entity
forest	O	O	B-Entity
types	O	O	I-Entity
point	O	O	O
to	O	O	O
significant	O	O	B-Entity
challenges	O	O	O
for	O	O	O
land	O	O	B-Entity
managers	O	O	B-Entity
if	O	O	O
landscape	O	O	B-Entity
restoration	O	O	O
is	O	O	O
a	O	O	O
priority	O	O	B-Entity
.	O	O	O

The	O	O	O
spatial	O	O	O
signals	O	O	O
of	O	O	O
novelty	O	O	B-Entity
and	O	O	O
ecological	O	O	B-Entity
change	O	O	B-Entity
also	O	O	O
point	O	O	O
to	O	O	O
potential	O	O	B-Entity
challenges	O	O	O
in	O	O	O
using	O	O	O
modern	O	O	B-Entity
spatial	O	O	B-Entity
distributions	O	O	I-Entity
of	O	O	O
species	O	O	B-Entity
and	O	O	O
communities	O	O	B-Entity
and	O	O	O
their	O	O	O
relationship	O	O	B-Entity
to	O	O	O
underlying	O	O	O
geophysical	O	O	B-Entity
and	O	O	O
climatic	O	O	B-Entity
attributes	O	O	I-Entity
in	O	O	O
understanding	O	O	O
potential	O	O	O
responses	O	O	O
to	O	O	O
changing	O	O	B-Entity
climate	O	O	B-Entity
.	O	O	O

The	O	O	O
signal	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
settlement	O	O	B-Entity
on	O	O	O
modern	O	O	B-Entity
forests	O	O	B-Entity
is	O	O	O
broad	O	O	B-Entity
,	O	O	O
spatially	O	O	O
varying	O	O	O
and	O	O	O
acts	O	O	O
to	O	O	O
homogenize	O	O	B-Entity
modern	O	O	O
forests	O	O	O
relative	O	O	B-Entity
to	O	O	O
their	O	O	O
historic	O	O	B-Entity
counterparts	O	O	O
,	O	O	O
with	O	O	O
significant	O	O	B-Entity
implications	O	O	O
for	O	O	O
future	O	O	B-Entity
management	O	O	B-Entity
.	O	O	O

-DOCSTART- (27936362)

Prevalence	O	O	B-Entity
of	O	O	O
Self-Reported	O	O	B-Entity
Prescription	O	O	B-Entity
Drug	O	O	I-Entity
Use	O	O	B-Entity
in	O	O	O
a	O	O	O
National	O	O	B-Entity
Sample	O	O	B-Entity
of	O	O	O
U.S.	O	O	O
Drivers	O	O	O

Drug	O	O	B-Entity
-involved	O	O	O
driving	O	O	B-Entity
has	O	O	O
become	O	O	O
an	O	O	O
increasing	O	O	B-Entity
concern	O	O	B-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
focus	O	O	O
has	O	O	O
been	O	O	O
on	O	O	O
illegal	O	O	B-Entity
drugs	O	O	I-Entity
,	O	O	O
there	O	O	O
is	O	O	O
evidence	O	O	B-Entity
that	O	O	O
prescribed	O	O	B-Entity
medications	O	O	I-Entity
can	O	O	O
impair	O	O	B-Entity
driving	O	O	I-Entity
ability	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	B-Entity
the	O	O	O
self-reported	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
prescription	O	O	B-Entity
drug	O	O	I-Entity
use	O	O	B-Entity
,	O	O	O
including	O	O	O
medical	O	O	B-Entity
and	O	O	O
nonmedical	O	O	B-Entity
use	O	O	O
,	O	O	O
among	O	O	O
a	O	O	O
nationally	O	O	B-Entity
representative	O	O	B-Entity
sample	O	O	B-Entity
of	O	O	O
drivers	O	O	B-Entity
and	O	O	O
to	O	O	O
report	O	O	O
related	O	O	O
driver	O	O	B-Entity
characteristics	O	O	B-Entity
.	O	O	O

As	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
2013	O	O	O
-	O	O	O
2014	O	O	O
National	O	O	B-Entity
Roadside	O	O	I-Entity
Survey	O	O	I-Entity
,	O	O	O
drivers	O	O	B-Entity
from	O	O	O
60	O	O	O
sites	O	O	O
were	O	O	O
randomly	O	O	B-Entity
recruited	O	O	O
and	O	O	O
asked	O	O	O
to	O	O	O
complete	O	O	B-Entity
a	O	O	O
survey	O	O	B-Entity
on	O	O	O
prescription	O	O	B-Entity
drug	O	O	I-Entity
use	O	O	B-Entity
.	O	O	O

Almost	O	O	O
20	O	O	O
%	O	O	O
of	O	O	O
drivers	O	O	B-Entity
reported	O	O	O
using	O	O	O
a	O	O	O
prescription	O	O	B-Entity
drug	O	O	I-Entity
within	O	O	O
the	O	O	O
past	O	O	B-Entity
2	O	O	O
days	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
drug	O	O	I-Entity
class	O	O	I-Entity
being	O	O	O
sedatives	O	O	B-Entity
(	O	O	O
8.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
antidepressants	O	O	B-Entity
(	O	O	O
7.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
narcotics	O	O	B-Entity
(	O	O	O
7.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
stimulants	O	O	B-Entity
(	O	O	O
3.9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Drivers	O	O	B-Entity
who	O	O	O
reported	O	O	O
prescription	O	O	B-Entity
drug	O	O	I-Entity
use	O	O	B-Entity
were	O	O	O
significantly	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
female	O	O	B-Entity
,	O	O	O
older	O	O	B-Entity
,	O	O	O
non-Hispanic	O	O	B-Entity
White	O	O	I-Entity
,	O	O	O
and	O	O	O
report	O	O	O
disability	O	O	B-Entity
.	O	O	O

Three	O	O	O
of	O	O	O
four	O	O	O
drivers	O	O	B-Entity
who	O	O	O
reported	O	O	O
medication	O	O	B-Entity
use	O	O	B-Entity
(	O	O	O
78.2	O	O	O
%	O	O	O
)	O	O	O
said	O	O	O
the	O	O	O
drug	O	O	B-Entity
was	O	O	O
prescribed	O	O	B-Entity
for	O	O	O
their	O	O	O
use	O	O	O
;	O	O	O
the	O	O	O
odds	O	O	O
of	O	O	O
using	O	O	O
without	O	O	O
a	O	O	O
prescription	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
for	O	O	O
males	O	O	B-Entity
,	O	O	O
Black/African	O	O	B-Entity
American	O	O	I-Entity
,	O	O	O
and	O	O	O
Hispanic	O	O	B-Entity
drivers	O	O	O
,	O	O	O
and	O	O	O
lower	O	O	O
for	O	O	O
older	O	O	B-Entity
drivers	O	O	O
.	O	O	O

Among	O	O	O
those	O	O	O
with	O	O	O
a	O	O	O
prescription	O	O	B-Entity
,	O	O	O
taking	O	O	O
more	O	O	O
than	O	O	O
prescribed	O	O	B-Entity
was	O	O	O
most	O	O	O
common	O	O	O
for	O	O	O
narcotics	O	O	B-Entity
(	O	O	O
6.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
followed	O	O	O
by	O	O	O
sedatives	O	O	B-Entity
(	O	O	O
4.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
stimulants	O	O	B-Entity
(	O	O	O
3.8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
antidepressants	O	O	B-Entity
(	O	O	O
1.5	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
help	O	O	O
to	O	O	O
identify	O	O	O
drivers	O	O	B-Entity
using	O	O	O
potentially	O	O	B-Entity
impairing	O	O	I-Entity
prescription	O	O	B-Entity
drugs	O	O	I-Entity
,	O	O	O
both	O	O	O
medically	O	O	B-Entity
and	O	O	O
nonmedically	O	O	B-Entity
,	O	O	O
and	O	O	O
may	O	O	O
inform	O	O	O
the	O	O	O
targeting	O	O	B-Entity
of	O	O	O
interventions	O	O	B-Entity
to	O	O	O
reduce	O	O	O
impaired	O	O	B-Entity
driving	O	O	I-Entity
related	O	O	O
to	O	O	O
medications	O	O	B-Entity
.	O	O	O

-DOCSTART- (27938482)

Repetitive	O	O	B-Entity
and	O	O	O
Prolonged	O	O	B-Entity
Omega-3	O	O	B-Entity
Fatty	O	O	I-Entity
Acid	O	O	I-Entity
Treatment	O	O	B-Entity
After	O	O	B-Entity
Traumatic	O	O	B-Entity
Brain	O	O	I-Entity
Injury	O	O	I-Entity
Enhances	O	O	B-Entity
Long-Term	O	O	B-Entity
Tissue	O	O	B-Entity
Restoration	O	O	B-Entity
and	O	O	O
Cognitive	O	O	O
Recovery	O	O	O

Traumatic	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
TBI	O	O	B-Entity
)	O	O	O
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
disabling	O	O	B-Entity
clinical	O	O	I-Entity
conditions	O	O	I-Entity
that	O	O	O
could	O	O	O
lead	O	O	B-Entity
to	O	O	O
neurocognitive	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
survivors	O	O	B-Entity
.	O	O	O

Our	O	O	O
group	O	O	B-Entity
and	O	O	O
others	O	O	B-Entity
previously	O	O	O
reported	O	O	B-Entity
that	O	O	O
prophylactic	O	O	B-Entity
enrichment	O	O	I-Entity
of	O	O	O
dietary	O	O	B-Entity
omega-3	O	O	B-Entity
polyunsaturated	O	O	I-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	O
n-3	O	O	B-Entity
PUFAs	O	O	I-Entity
)	O	O	O
markedly	O	O	O
ameliorate	O	O	B-Entity
cognitive	O	O	B-Entity
deficits	O	O	I-Entity
after	O	O	B-Entity
TBI	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
remains	O	O	O
unclear	O	O	B-Entity
whether	O	O	O
a	O	O	O
clinically	O	O	B-Entity
relevant	O	O	B-Entity
therapeutic	O	O	B-Entity
regimen	O	O	I-Entity
with	O	O	O
n-3	O	O	B-Entity
PUFAs	O	O	I-Entity
administered	O	O	B-Entity
after	O	O	B-Entity
TBI	O	O	B-Entity
would	O	O	O
still	O	O	O
offer	O	O	O
significant	O	O	O
improvement	O	O	B-Entity
of	O	O	O
long-term	O	O	B-Entity
cognitive	O	O	B-Entity
recovery	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
employed	O	O	O
the	O	O	O
decline	O	O	B-Entity
of	O	O	O
spatial	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
as	O	O	O
a	O	O	O
main	O	O	B-Entity
outcome	O	O	B-Entity
after	O	O	B-Entity
TBI	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
therapeutic	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
post	O	O	B-Entity
-	O	O	O
TBI	O	O	O
n-3	O	O	B-Entity
PUFA	O	O	I-Entity
treatment	O	O	B-Entity
and	O	O	O
the	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
.	O	O	O

Mice	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
sham	O	O	B-Entity
operation	O	O	I-Entity
or	O	O	O
controlled	O	O	B-Entity
cortical	O	O	B-Entity
impact	O	O	B-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
random	O	O	B-Entity
assignment	O	O	I-Entity
to	O	O	O
receive	O	O	B-Entity
the	O	O	O
following	O	O	O
four	O	O	B-Entity
treatments	O	O	B-Entity
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
vehicle	O	O	B-Entity
control	O	O	B-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
daily	O	O	B-Entity
intraperitoneal	O	O	B-Entity
injections	O	O	I-Entity
of	O	O	O
n-3	O	O	B-Entity
PUFAs	O	O	I-Entity
for	O	O	O
2	O	O	O
weeks	O	O	B-Entity
,	O	O	O
beginning	O	O	B-Entity
2	O	O	O
h	O	O	B-Entity
after	O	O	B-Entity
TBI	O	O	B-Entity
;	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
fish	O	O	B-Entity
oil	O	O	I-Entity
dietary	O	O	I-Entity
supplementation	O	O	B-Entity
throughout	O	O	O
the	O	O	O
study	O	O	B-Entity
,	O	O	O
beginning	O	O	O
1	O	O	O
day	O	O	B-Entity
after	O	O	O
TBI	O	O	O
;	O	O	O
or	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
combination	O	O	B-Entity
of	O	O	O
treatments	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
and	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
.	O	O	O

Spatial	O	O	O
cognitive	O	O	O
deficits	O	O	O
and	O	O	O
chronic	O	O	B-Entity
brain	O	O	B-Entity
tissue	O	O	I-Entity
loss	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
endogenous	O	O	B-Entity
brain	O	O	B-Entity
repair	O	O	I-Entity
processes	O	O	I-Entity
such	O	O	O
as	O	O	O
neurogenesis	O	O	B-Entity
,	O	O	O
angiogenesis	O	O	B-Entity
,	O	O	O
and	O	O	O
oligodendrogenesis	O	O	B-Entity
,	O	O	O
were	O	O	O
evaluated	O	O	O
up	O	O	O
to	O	O	O
35	O	O	O
days	O	O	B-Entity
after	O	O	B-Entity
TBI	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
revealed	O	O	B-Entity
prominent	O	O	O
spatial	O	O	O
cognitive	O	O	B-Entity
deficits	O	O	I-Entity
and	O	O	O
massive	O	O	B-Entity
tissue	O	O	B-Entity
loss	O	O	B-Entity
caused	O	O	O
by	O	O	O
TBI	O	O	B-Entity
.	O	O	O

Among	O	O	O
all	O	O	O
mice	O	O	B-Entity
receiving	O	O	B-Entity
post-TBI	O	O	B-Entity
n-3	O	O	B-Entity
PUFA	O	O	I-Entity
treatments	O	O	B-Entity
,	O	O	O
the	O	O	O
combined	O	O	B-Entity
treatment	O	O	B-Entity
of	O	O	O
fish	O	O	B-Entity
oil	O	O	I-Entity
dietary	O	O	I-Entity
supplement	O	O	B-Entity
and	O	O	O
n-3	O	O	O
PUFA	O	O	O
injections	O	O	B-Entity
demonstrated	O	O	B-Entity
a	O	O	O
reproducible	O	O	B-Entity
beneficial	O	O	I-Entity
effect	O	O	I-Entity
in	O	O	O
attenuating	O	O	O
cognitive	O	O	B-Entity
deficits	O	O	I-Entity
although	O	O	O
without	O	O	O
reducing	O	O	B-Entity
gross	O	O	B-Entity
tissue	O	O	B-Entity
loss	O	O	B-Entity
.	O	O	O

Mechanistically	O	O	O
,	O	O	O
the	O	O	O
combined	O	O	O
treatment	O	O	B-Entity
promoted	O	O	B-Entity
post-TBI	O	O	B-Entity
restorative	O	O	B-Entity
processes	O	O	I-Entity
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
,	O	O	O
including	O	O	B-Entity
generation	O	O	O
of	O	O	O
immature	O	O	B-Entity
neurons	O	O	I-Entity
,	O	O	O
microvessels	O	O	B-Entity
,	O	O	O
and	O	O	O
oligodendrocytes	O	O	B-Entity
,	O	O	O
each	O	O	O
of	O	O	O
which	O	O	O
was	O	O	O
significantly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
the	O	O	O
improved	O	O	B-Entity
cognitive	O	O	B-Entity
recovery	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
repetitive	O	O	B-Entity
and	O	O	O
prolonged	O	O	B-Entity
n-3	O	O	B-Entity
PUFA	O	O	I-Entity
treatments	O	O	B-Entity
after	O	O	B-Entity
TBI	O	O	B-Entity
are	O	O	O
capable	O	O	O
of	O	O	O
enhancing	O	O	B-Entity
brain	O	O	B-Entity
remodeling	O	O	B-Entity
and	O	O	O
could	O	O	O
be	O	O	O
developed	O	O	O
as	O	O	O
a	O	O	O
potential	O	O	B-Entity
therapy	O	O	B-Entity
to	O	O	O
treat	O	O	O
TBI	O	O	O
victims	O	O	B-Entity
in	O	O	O
the	O	O	O
clinic	O	O	B-Entity
.	O	O	O

-DOCSTART- (27939139)

Influence	O	O	B-Entity
of	O	O	O
yeast	O	O	B-Entity
and	O	O	O
lactic	O	O	B-Entity
acid	O	O	I-Entity
bacterium	O	O	I-Entity
on	O	O	O
the	O	O	O
constituent	O	O	B-Entity
profile	O	O	B-Entity
of	O	O	O
soy	O	O	B-Entity
sauce	O	O	I-Entity
during	O	O	B-Entity
fermentation	O	O	O

Soy	O	O	B-Entity
sauce	O	O	I-Entity
is	O	O	O
a	O	O	O
Japanese	O	O	B-Entity
traditional	O	O	B-Entity
seasoning	O	O	B-Entity
composed	O	O	B-Entity
of	O	O	O
various	O	O	B-Entity
constituents	O	O	B-Entity
that	O	O	O
are	O	O	O
produced	O	O	B-Entity
by	O	O	O
various	O	O	O
microbes	O	O	B-Entity
during	O	O	B-Entity
a	O	O	O
long-term	O	O	B-Entity
fermentation	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

Due	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
complexity	O	O	B-Entity
of	O	O	O
the	O	O	O
process	O	O	B-Entity
,	O	O	O
the	O	O	O
investigation	O	O	B-Entity
of	O	O	O
the	O	O	O
constituent	O	O	B-Entity
profile	O	O	B-Entity
during	O	O	B-Entity
fermentation	O	O	B-Entity
is	O	O	O
difficult	O	O	B-Entity
.	O	O	O

Metabolomics	O	O	B-Entity
,	O	O	O
the	O	O	O
comprehensive	O	O	B-Entity
study	O	O	B-Entity
of	O	O	O
low	O	O	B-Entity
molecular	O	O	B-Entity
weight	O	O	I-Entity
compounds	O	O	B-Entity
in	O	O	O
biological	O	O	B-Entity
samples	O	O	B-Entity
,	O	O	O
is	O	O	O
thought	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
promising	O	O	O
strategy	O	O	O
for	O	O	O
deep	O	O	O
understanding	O	O	B-Entity
of	O	O	O
the	O	O	O
constituent	O	O	B-Entity
contribution	O	O	B-Entity
to	O	O	O
food	O	O	B-Entity
flavor	O	O	I-Entity
characteristics	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
metabolomics	O	O	B-Entity
is	O	O	O
suitable	O	O	B-Entity
for	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
soy	O	O	B-Entity
sauce	O	O	I-Entity
fermentation	O	O	B-Entity
.	O	O	O

Unfortunately	O	O	O
,	O	O	O
only	O	O	O
few	O	O	O
and	O	O	O
unrefined	O	O	O
studies	O	O	B-Entity
of	O	O	O
soy	O	O	B-Entity
sauce	O	O	I-Entity
fermentation	O	O	B-Entity
using	O	O	B-Entity
metabolomics	O	O	B-Entity
approach	O	O	B-Entity
have	O	O	O
been	O	O	O
reported	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
low	O	O	B-Entity
molecular	O	O	B-Entity
weight	O	O	I-Entity
hydrophilic	O	O	B-Entity
and	O	O	O
volatile	O	O	B-Entity
compounds	O	O	I-Entity
of	O	O	O
soy	O	O	B-Entity
sauce	O	O	I-Entity
using	O	O	O
gas	O	O	B-Entity
chromatography/mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(GC/MS)-	O	O	O
based	O	O	B-Entity
non-targeted	O	O	B-Entity
metabolic	O	O	B-Entity
profiling	O	O	I-Entity
.	O	O	O

The	O	O	O
data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
statistical	O	O	B-Entity
analysis	O	O	I-Entity
to	O	O	O
evaluate	O	O	O
influences	O	O	B-Entity
of	O	O	O
yeast	O	O	B-Entity
and	O	O	O
lactic	O	O	B-Entity
acid	O	O	I-Entity
bacterium	O	O	I-Entity
on	O	O	O
the	O	O	O
constituent	O	O	B-Entity
profile	O	O	B-Entity
.	O	O	O

Consequently	O	O	O
,	O	O	O
our	O	O	O
results	O	O	B-Entity
suggested	O	O	B-Entity
a	O	O	O
novel	O	O	B-Entity
finding	O	O	B-Entity
that	O	O	O
lactic	O	O	B-Entity
acid	O	O	I-Entity
bacterium	O	O	I-Entity
affected	O	O	B-Entity
the	O	O	O
production	O	O	B-Entity
of	O	O	O
several	O	O	B-Entity
constituents	O	O	B-Entity
such	O	O	O
as	O	O	O
cyclotene	O	O	B-Entity
,	O	O	O
furfural	O	O	B-Entity
,	O	O	O
furfuryl	O	O	B-Entity
alcohol	O	O	I-Entity
and	O	O	O
methional	O	O	B-Entity
in	O	O	O
the	O	O	O
soy	O	O	B-Entity
sauce	O	O	I-Entity
fermentation	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

-DOCSTART- (27941491)

Low	O	O	B-Entity
intensity	O	O	B-Entity
sprint	O	O	B-Entity
training	O	O	I-Entity
with	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
restriction	O	O	I-Entity
improves	O	O	O
100	O	O	O
m	O	O	O
dash	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
practical	O	O	B-Entity
blood	O	O	I-Entity
flow	O	O	I-Entity
restriction	O	O	I-Entity
(	O	O	O
pBFR	O	O	B-Entity
)	O	O	O
of	O	O	O
leg	O	O	B-Entity
muscles	O	O	I-Entity
during	O	O	O
sprint	O	O	B-Entity
training	O	O	I-Entity
on	O	O	O
the	O	O	O
100	O	O	O
m	O	O	O
dash	O	O	O
time	O	O	B-Entity
in	O	O	O
well-trained	O	O	B-Entity
sport	O	O	I-Entity
students	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
performed	O	O	O
6x100	O	O	O
m	O	O	O
sprints	O	O	B-Entity
at	O	O	O
60	O	O	O
-	O	O	O
70	O	O	O
%	O	O	O
of	O	O	O
their	O	O	O
maximal	O	O	O
100	O	O	O
m	O	O	O
sprinting	O	O	B-Entity
speed	O	O	I-Entity
twice	O	O	B-Entity
a	O	O	I-Entity
week	O	O	I-Entity
for	O	O	O
6	O	O	O
weeks	O	O	B-Entity
,	O	O	O
either	O	O	O
with	O	O	O
(	O	O	O
IG	O	O	B-Entity
;	O	O	O
n=12	O	O	O
)	O	O	O
or	O	O	O
without	O	O	O
pBFR	O	O	B-Entity
(	O	O	O
CG	O	O	B-Entity
;	O	O	O
n=12	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
100	O	O	O
m	O	O	O
dash	O	O	O
time	O	O	B-Entity
significantly	O	O	O
decreased	O	O	B-Entity
more	O	O	O
in	O	O	O
the	O	O	O
IG	O	O	B-Entity
(	O	O	O
-0.38±0.24	O	O	O
s	O	O	O
)	O	O	O
than	O	O	O
in	O	O	O
the	O	O	O
CG	O	O	B-Entity
(	O	O	O
-0.16±0.17	O	O	O
s	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
muscle	O	O	B-Entity
thickness	O	O	B-Entity
of	O	O	O
the	O	O	O
rectus	O	O	B-Entity
femoris	O	O	I-Entity
increased	O	O	B-Entity
only	O	O	O
in	O	O	O
the	O	O	O
IG	O	O	B-Entity
,	O	O	O
while	O	O	O
no	O	O	O
group	O	O	B-Entity
by	O	O	O
time	O	O	B-Entity
interactions	O	O	B-Entity
were	O	O	O
found	O	O	O
for	O	O	O
the	O	O	O
muscle	O	O	O
thickness	O	O	O
of	O	O	O
the	O	O	O
biceps	O	O	B-Entity
femoris	O	O	I-Entity
and	O	O	O
the	O	O	O
biceps	O	O	B-Entity
brachii	O	O	I-Entity
.	O	O	O

The	O	O	O
maximal	O	O	B-Entity
isometric	O	O	I-Entity
force	O	O	I-Entity
,	O	O	O
measured	O	O	O
using	O	O	O
a	O	O	O
leg	O	O	B-Entity
press	O	O	I-Entity
,	O	O	O
did	O	O	O
not	O	O	B-Entity
change	O	O	I-Entity
in	O	O	O
either	O	O	O
group	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	I-Entity
force	O	O	I-Entity
development	O	O	I-Entity
improved	O	O	O
in	O	O	O
the	O	O	O
IG	O	O	B-Entity
.	O	O	O

Growth	O	O	B-Entity
hormone	O	O	I-Entity
,	O	O	O
testosterone	O	O	B-Entity
,	O	O	O
insulin-like	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
1	O	O	I-Entity
,	O	O	O
and	O	O	O
cortisol	O	O	B-Entity
concentrations	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
significantly	O	O	I-Entity
differ	O	O	I-Entity
between	O	O	O
both	O	O	O
groups	O	O	B-Entity
at	O	O	O
any	O	O	O
measurement	O	O	B-Entity
time	O	O	B-Entity
point	O	O	I-Entity
(	O	O	O
pre	O	O	O
,	O	O	O
1	O	O	O
min	O	O	O
,	O	O	O
20	O	O	O
min	O	O	O
,	O	O	O
120	O	O	O
min	O	O	O
,	O	O	O
and	O	O	O
24	O	O	O
h	O	O	O
after	O	O	O
the	O	O	O
six	O	O	O
all-out	O	O	O
sprints	O	O	B-Entity
of	O	O	O
the	O	O	O
first	O	O	O
training	O	O	B-Entity
session	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
muscle	O	O	B-Entity
damage	O	O	I-Entity
marker	O	O	B-Entity
h-FABP	O	O	B-Entity
increased	O	O	B-Entity
significantly	O	O	O
more	O	O	O
in	O	O	O
the	O	O	O
CG	O	O	B-Entity
than	O	O	O
in	O	O	O
the	O	O	O
IG	O	O	B-Entity
.	O	O	O

The	O	O	O
pBFR	O	O	B-Entity
improved	O	O	O
the	O	O	O
100	O	O	O
m	O	O	O
dash	O	O	O
time	O	O	B-Entity
significantly	O	O	O
more	O	O	O
than	O	O	O
low	O	O	B-Entity
-	O	O	O
intensity	O	O	B-Entity
sprint	O	O	B-Entity
interval	O	O	I-Entity
training	O	O	I-Entity
alone	O	O	O
.	O	O	O

Other	O	O	O
noted	O	O	O
benefits	O	O	B-Entity
of	O	O	O
training	O	O	B-Entity
with	O	O	O
pBFR	O	O	B-Entity
were	O	O	O
a	O	O	O
decreased	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
muscle	O	O	B-Entity
damage	O	O	I-Entity
,	O	O	O
a	O	O	O
greater	O	O	O
increase	O	O	B-Entity
of	O	O	O
the	O	O	O
rectus	O	O	B-Entity
femoris	O	O	I-Entity
muscle	O	O	I-Entity
thickness	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
higher	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	I-Entity
force	O	O	I-Entity
development	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
tested	O	O	B-Entity
hormones	O	O	B-Entity
were	O	O	O
unable	O	O	O
to	O	O	O
explain	O	O	O
the	O	O	O
additional	O	O	O
beneficial	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

-DOCSTART- (27941576)

Sedation	O	O	B-Entity
of	O	O	O
Patients	O	O	B-Entity
With	O	O	O
Disorders	O	O	B-Entity
of	O	O	I-Entity
Consciousness	O	O	I-Entity
During	O	O	O
Neuroimaging	O	O	B-Entity
:	O	O	O
Effects	O	O	O
on	O	O	O
Resting	O	O	O
State	O	O	O
Functional	O	O	O
Brain	O	O	O
Connectivity	O	O	O

To	O	O	O
reduce	O	O	O
head	O	O	B-Entity
movement	O	O	I-Entity
during	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
functional	O	O	I-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
,	O	O	O
post-coma	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
disorders	O	O	B-Entity
of	O	O	I-Entity
consciousness	O	O	I-Entity
(	O	O	O
DOC	O	O	B-Entity
)	O	O	O
are	O	O	O
frequently	O	O	O
sedated	O	O	B-Entity
with	O	O	O
propofol	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
this	O	O	O
sedation	O	O	B-Entity
on	O	O	O
the	O	O	O
brain	O	O	B-Entity
connectivity	O	O	I-Entity
patterns	O	O	I-Entity
in	O	O	O
the	O	O	O
damaged	O	O	B-Entity
brain	O	O	I-Entity
essential	O	O	O
for	O	O	O
differential	O	O	B-Entity
diagnosis	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
assess	O	O	B-Entity
these	O	O	O
effects	O	O	O
.	O	O	O

Using	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
functional	O	O	I-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
3	O	O	O
T	O	O	O
data	O	O	O
obtained	O	O	O
over	O	O	O
several	O	O	O
years	O	O	O
of	O	O	O
scanning	O	O	B-Entity
patients	O	O	B-Entity
for	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
research	O	O	B-Entity
purposes	O	O	B-Entity
,	O	O	O
we	O	O	O
employed	O	O	O
a	O	O	O
seed-based	O	O	O
approach	O	O	O
to	O	O	O
examine	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
connectivity	O	O	B-Entity
in	O	O	O
higher-order	O	O	O
(	O	O	O
default	O	O	O
mode	O	O	O
,	O	O	O
bilateral	O	O	B-Entity
external	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
and	O	O	O
salience	O	O	O
)	O	O	O
and	O	O	O
lower-order	O	O	O
(	O	O	O
auditory	O	O	B-Entity
,	O	O	O
sensorimotor	O	O	B-Entity
,	O	O	O
and	O	O	O
visual	O	O	B-Entity
)	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
networks	O	O	I-Entity
and	O	O	O
connectivity	O	O	O
with	O	O	O
the	O	O	O
thalamus	O	O	B-Entity
,	O	O	O
in	O	O	O
20	O	O	O
healthy	O	O	B-Entity
unsedated	O	O	B-Entity
controls	O	O	B-Entity
,	O	O	O
8	O	O	O
unsedated	O	O	O
patients	O	O	O
with	O	O	O
DOC	O	O	B-Entity
,	O	O	O
and	O	O	O
8	O	O	O
patients	O	O	O
with	O	O	O
DOC	O	O	O
sedated	O	O	B-Entity
with	O	O	O
propofol	O	O	B-Entity
.	O	O	O

The	O	O	O
DOC	O	O	B-Entity
groups	O	O	O
were	O	O	O
matched	O	O	O
for	O	O	O
age	O	O	B-Entity
at	O	O	I-Entity
onset	O	O	I-Entity
,	O	O	O
etiology	O	O	B-Entity
,	O	O	O
time	O	O	B-Entity
spent	O	O	I-Entity
in	O	O	O
DOC	O	O	O
,	O	O	O
diagnosis	O	O	B-Entity
,	O	O	O
standardized	O	O	B-Entity
behavioral	O	O	I-Entity
assessment	O	O	I-Entity
scores	O	O	I-Entity
,	O	O	O
movement	O	O	B-Entity
intensities	O	O	B-Entity
,	O	O	O
and	O	O	O
pattern	O	O	O
of	O	O	O
structural	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
as	O	O	O
assessed	O	O	O
with	O	O	O
T1-based	O	O	B-Entity
voxel-based	O	O	I-Entity
morphometry	O	O	I-Entity
)	O	O	O
.	O	O	O

DOC	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
severely	O	O	O
impaired	O	O	O
resting	O	O	B-Entity
state	O	O	I-Entity
network	O	O	B-Entity
connectivity	O	O	I-Entity
in	O	O	O
all	O	O	O
but	O	O	O
the	O	O	O
visual	O	O	B-Entity
network	O	O	O
.	O	O	O

Thalamic	O	O	B-Entity
connectivity	O	O	B-Entity
to	O	O	O
higher-order	O	O	O
network	O	O	O
regions	O	O	O
was	O	O	O
also	O	O	O
reduced	O	O	B-Entity
.	O	O	O

Propofol	O	O	B-Entity
administration	O	O	B-Entity
to	O	O	O
patients	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
minor	O	O	O
further	O	O	O
decreases	O	O	B-Entity
in	O	O	O
thalamic	O	O	B-Entity
and	O	O	O
insular	O	O	B-Entity
connectivity	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
indicate	O	O	O
that	O	O	O
connectivity	O	O	B-Entity
decreases	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
propofol	O	O	B-Entity
sedation	O	O	B-Entity
,	O	O	O
involving	O	O	O
the	O	O	O
thalamus	O	O	B-Entity
and	O	O	O
insula	O	O	B-Entity
,	O	O	O
are	O	O	O
relatively	O	O	O
small	O	O	O
compared	O	O	O
with	O	O	O
those	O	O	O
already	O	O	O
caused	O	O	O
by	O	O	O
DOC	O	O	B-Entity
-associated	O	O	O
structural	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
.	O	O	O

Nonetheless	O	O	O
,	O	O	O
given	O	O	O
the	O	O	O
known	O	O	O
importance	O	O	O
of	O	O	O
the	O	O	O
thalamus	O	O	B-Entity
in	O	O	O
brain	O	O	B-Entity
arousal	O	O	I-Entity
,	O	O	O
its	O	O	O
disruption	O	O	B-Entity
could	O	O	O
well	O	O	O
reflect	O	O	O
the	O	O	O
diminished	O	O	B-Entity
movement	O	O	B-Entity
obtained	O	O	O
in	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
more	O	O	O
research	O	O	B-Entity
is	O	O	O
needed	O	O	O
on	O	O	O
this	O	O	O
topic	O	O	O
to	O	O	O
fully	O	O	O
address	O	O	O
the	O	O	O
research	O	O	B-Entity
question	O	O	I-Entity
.	O	O	O

-DOCSTART- (27942049)

Potassium	O	O	B-Entity
depletion	O	O	I-Entity
stimulates	O	O	B-Entity
Na-Cl	O	O	B-Entity
cotransporter	O	O	I-Entity
via	O	O	O
phosphorylation	O	O	B-Entity
and	O	O	O
inactivation	O	O	B-Entity
of	O	O	O
the	O	O	O
ubiquitin	O	O	B-Entity
ligase	O	O	I-Entity
Kelch-like	O	O	O
3	O	O	O

Kelch-like	O	O	B-Entity
3	O	O	I-Entity
(	O	O	O
KLHL3	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
component	O	O	B-Entity
of	O	O	O
an	O	O	O
E3	O	O	B-Entity
ubiquitin	O	O	I-Entity
ligase	O	O	I-Entity
complex	O	O	I-Entity
that	O	O	O
regulates	O	O	B-Entity
blood	O	O	B-Entity
pressure	O	O	I-Entity
by	O	O	O
targeting	O	O	B-Entity
With-No-Lysine	O	O	B-Entity
(	O	O	I-Entity
WNK	O	O	I-Entity
)	O	O	I-Entity
kinases	O	O	I-Entity
for	O	O	O
degradation	O	O	B-Entity
.	O	O	O

Mutations	O	O	B-Entity
in	O	O	O
KLHL3	O	O	B-Entity
cause	O	O	O
constitutively	O	O	O
increased	O	O	B-Entity
renal	O	O	I-Entity
salt	O	O	I-Entity
reabsorption	O	O	I-Entity
and	O	O	O
impaired	O	O	B-Entity
K(+	O	O	B-Entity
)	O	O	I-Entity
secretion	O	O	B-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
hypertension	O	O	B-Entity
and	O	O	O
hyperkalemia	O	O	B-Entity
.	O	O	O

Although	O	O	O
clinical	O	O	B-Entity
studies	O	O	I-Entity
have	O	O	O
shown	O	O	O
that	O	O	O
dietary	O	O	B-Entity
K(+	O	O	I-Entity
)	O	O	I-Entity
intake	O	O	B-Entity
affects	O	O	B-Entity
blood	O	O	B-Entity
pressure	O	O	I-Entity
,	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
have	O	O	O
been	O	O	O
obscure	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
the	O	O	O
KLHL3	O	O	B-Entity
ubiquitin	O	O	B-Entity
ligase	O	O	I-Entity
complex	O	O	B-Entity
is	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
low-	O	O	O
K(+	O	O	B-Entity
)	O	O	I-Entity
-mediated	O	O	O
activation	O	O	B-Entity
of	O	O	O
Na-Cl	O	O	B-Entity
cotransporter	O	O	I-Entity
(	O	O	O
NCC	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
kidney	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
distal	O	O	B-Entity
convoluted	O	O	I-Entity
tubules	O	O	I-Entity
of	O	O	O
mice	O	O	B-Entity
eating	O	O	B-Entity
a	O	O	O
low-K(+	O	O	B-Entity
)	O	O	I-Entity
diet	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
increased	O	O	O
KLHL3	O	O	B-Entity
phosphorylation	O	O	B-Entity
at	O	O	O
S433	O	O	B-Entity
(	O	O	B-Entity
KLHL3(S433-P	O	O	I-Entity
)	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
a	O	O	O
modification	O	O	B-Entity
that	O	O	O
impairs	O	O	B-Entity
WNK	O	O	B-Entity
binding	O	O	B-Entity
,	O	O	O
and	O	O	O
also	O	O	O
reduced	O	O	O
total	O	O	O
KLHL3	O	O	O
levels	O	O	B-Entity
.	O	O	O

These	O	O	O
changes	O	O	O
are	O	O	O
accompanied	O	O	O
by	O	O	O
the	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
the	O	O	O
target	O	O	B-Entity
substrate	O	O	B-Entity
WNK4	O	O	B-Entity
,	O	O	O
and	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
downstream	O	O	B-Entity
kinases	O	O	B-Entity
SPAK	O	O	I-Entity
(	O	O	O
STE20	O	O	B-Entity
/	O	O	O
SPS1	O	O	B-Entity
-related	O	O	O
proline-alanine-rich	O	O	B-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
)	O	O	O
and	O	O	O
OSR1	O	O	B-Entity
(	O	O	O
oxidative	O	O	B-Entity
stress-responsive	O	O	I-Entity
1	O	O	I-Entity
)	O	O	O
,	O	O	O
resulting	O	O	O
in	O	O	O
NCC	O	O	B-Entity
phosphorylation	O	O	B-Entity
and	O	O	O
its	O	O	O
accumulation	O	O	O
at	O	O	O
the	O	O	O
plasma	O	O	B-Entity
membrane	O	O	I-Entity
.	O	O	O

Increased	O	O	O
phosphorylation	O	O	B-Entity
of	O	O	O
S433	O	O	B-Entity
was	O	O	O
explained	O	O	O
by	O	O	O
increased	O	O	O
levels	O	O	B-Entity
of	O	O	O
active	O	O	B-Entity
,	O	O	O
phosphorylated	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
C	O	O	I-Entity
(	O	O	O
but	O	O	O
not	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
A	O	O	I-Entity
)	O	O	O
,	O	O	O
which	O	O	O
directly	O	O	O
phosphorylates	O	O	B-Entity
S433	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
in	O	O	O
HEK	O	O	B-Entity
cells	O	O	I-Entity
expressing	O	O	B-Entity
KLHL3	O	O	B-Entity
and	O	O	O
WNK4	O	O	B-Entity
,	O	O	O
we	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
C	O	O	I-Entity
by	O	O	O
phorbol	O	O	B-Entity
12-myristate	O	O	I-Entity
13-acetate	O	O	I-Entity
induces	O	O	B-Entity
KLHL3(S433-P	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
increases	O	O	O
WNK4	O	O	O
levels	O	O	B-Entity
by	O	O	O
abrogating	O	O	O
its	O	O	O
ubiquitination	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
demonstrate	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
KLHL3	O	O	B-Entity
in	O	O	O
low-	O	O	O
K(+	O	O	B-Entity
)	O	O	I-Entity
-mediated	O	O	O
induction	O	O	B-Entity
of	O	O	O
NCC	O	O	B-Entity
;	O	O	O
this	O	O	O
physiologic	O	O	B-Entity
adaptation	O	O	I-Entity
reduces	O	O	O
distal	O	O	B-Entity
electrogenic	O	O	B-Entity
Na(+	O	O	B-Entity
)	O	O	I-Entity
reabsorption	O	O	I-Entity
,	O	O	O
preventing	O	O	B-Entity
further	O	O	O
renal	O	O	B-Entity
K(+	O	O	O
)	O	O	O
loss	O	O	B-Entity
but	O	O	O
promoting	O	O	B-Entity
increased	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
.	O	O	O

-DOCSTART- (27942150)

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
thoracic	O	O	B-Entity
configuration	O	O	B-Entity
and	O	O	O
changes	O	O	B-Entity
in	O	O	O
volumes	O	O	B-Entity
of	O	O	O
hemithoraces	O	O	B-Entity
in	O	O	O
upright	O	O	O
sitting	O	O	O

[	O	O	O
Purpose	O	O	O
]	O	O	O
Some	O	O	O
patients	O	O	B-Entity
with	O	O	O
respiratory	O	O	B-Entity
disease	O	O	I-Entity
exhibit	O	O	O
asymmetrical	O	O	B-Entity
movement	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
thorax	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
of	O	O	O
thoracic	O	O	B-Entity
configuration	O	O	B-Entity
with	O	O	O
changes	O	O	B-Entity
in	O	O	O
thoracic	O	O	B-Entity
volume	O	O	I-Entity
in	O	O	O
13	O	O	O
sedentary	O	O	B-Entity
healthy	O	O	B-Entity
men	O	O	B-Entity
.	O	O	O

[	O	O	O
Subjects	O	O	O
and	O	O	O
Methods	O	O	O
]	O	O	O
In	O	O	O
upright	O	O	B-Entity
sitting	O	O	I-Entity
,	O	O	O
84	O	O	O
reflective	O	O	B-Entity
markers	O	O	I-Entity
were	O	O	O
placed	O	O	O
on	O	O	O
the	O	O	O
anterior	O	O	B-Entity
and	O	O	O
posterior	O	O	B-Entity
aspects	O	O	B-Entity
of	O	O	O
the	O	O	O
trunk	O	O	B-Entity
to	O	O	O
record	O	O	O
thoracic	O	O	B-Entity
volume	O	O	I-Entity
during	O	O	O
quiet	O	O	B-Entity
and	O	O	O
volitional	O	O	B-Entity
deep	O	O	B-Entity
breathing	O	O	I-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
three-dimensional	O	O	B-Entity
motion	O	O	I-Entity
analyzer	O	O	I-Entity
,	O	O	O
the	O	O	O
difference	O	O	B-Entity
in	O	O	O
volume	O	O	B-Entity
within	O	O	O
the	O	O	O
upper	O	O	B-Entity
and	O	O	O
lower	O	O	B-Entity
hemithoraces	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
.	O	O	O

For	O	O	O
calculation	O	O	B-Entity
of	O	O	O
the	O	O	O
thoracic	O	O	B-Entity
volume	O	O	I-Entity
six	O	O	O
imaginary	O	O	B-Entity
hexahedra	O	O	I-Entity
were	O	O	O
visualized	O	O	O
for	O	O	O
the	O	O	O
upper	O	O	B-Entity
and	O	O	O
lower	O	O	B-Entity
thorax	O	O	B-Entity
using	O	O	O
four	O	O	O
reflective	O	O	B-Entity
markers	O	O	I-Entity
for	O	O	O
each	O	O	O
on	O	O	O
the	O	O	O
anterior	O	O	B-Entity
and	O	O	O
posterior	O	O	B-Entity
aspects	O	O	B-Entity
of	O	O	O
the	O	O	O
thorax	O	O	O
.	O	O	O

Each	O	O	O
hexahedron	O	O	B-Entity
was	O	O	O
then	O	O	O
divided	O	O	O
into	O	O	O
three	O	O	O
imaginary	O	O	B-Entity
triangular	O	O	I-Entity
pyramids	O	O	I-Entity
to	O	O	O
calculate	O	O	B-Entity
positional	O	O	B-Entity
vectors	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
volume	O	O	B-Entity
for	O	O	O
both	O	O	O
the	O	O	O
hexahedra	O	O	B-Entity
and	O	O	O
triangular	O	O	B-Entity
pyramids	O	O	I-Entity
was	O	O	O
calculated	O	O	B-Entity
.	O	O	O

Four	O	O	O
thoracic	O	O	B-Entity
volumes	O	O	I-Entity
were	O	O	O
obtained	O	O	O
.	O	O	O

[	O	O	O
Results	O	O	O
]	O	O	O

The	O	O	O
findings	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
left	O	O	B-Entity
upper	O	O	B-Entity
and	O	O	O
right	O	O	B-Entity
lower	O	O	B-Entity
hemithorax	O	O	B-Entity
yielded	O	O	O
significantly	O	O	O
larger	O	O	B-Entity
thoracic	O	O	B-Entity
volumes	O	O	I-Entity
.	O	O	O

[	O	O	O
Conclusion	O	O	O
]	O	O	O
In	O	O	O
conclusion	O	O	B-Entity
the	O	O	O
left	O	O	B-Entity
upper	O	O	B-Entity
and	O	O	O
right	O	O	B-Entity
lower	O	O	B-Entity
hemithoraces	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
expand	O	O	B-Entity
more	O	O	O
than	O	O	O
their	O	O	O
corresponding	O	O	O
sides	O	O	B-Entity
.	O	O	O

Understanding	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
thoracic	O	O	B-Entity
excursion	O	O	B-Entity
during	O	O	O
quiet	O	O	B-Entity
and	O	O	O
volitional	O	O	B-Entity
deep	O	O	B-Entity
breathing	O	O	I-Entity
could	O	O	O
be	O	O	O
of	O	O	O
value	O	O	B-Entity
in	O	O	O
assessment	O	O	B-Entity
and	O	O	O
instruction	O	O	B-Entity
of	O	O	O
breathing	O	O	B-Entity
techniques	O	O	I-Entity
to	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27951480)

Development	O	O	B-Entity
of	O	O	O
the	O	O	O
four-item	O	O	B-Entity
Letter	O	O	I-Entity
and	O	O	I-Entity
Shape	O	O	I-Entity
Drawing	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
LSD-4	O	O	B-Entity
):	O	O	O
A	O	O	O
brief	O	O	O
bedside	O	O	B-Entity
test	O	O	I-Entity
of	O	O	O
visuospatial	O	O	O
function	O	O	O

Conventional	O	O	B-Entity
bedside	O	O	B-Entity
tests	O	O	I-Entity
of	O	O	O
visuospatial	O	O	B-Entity
function	O	O	I-Entity
such	O	O	O
as	O	O	O
the	O	O	O
Clock	O	O	B-Entity
Drawing	O	O	I-Entity
(	O	O	O
CDT	O	O	B-Entity
)	O	O	O
and	O	O	O
Intersecting	O	O	B-Entity
Pentagons	O	O	I-Entity
(	O	O	O
IPT	O	O	B-Entity
)	O	O	O
lack	O	O	B-Entity
consistency	O	O	B-Entity
in	O	O	O
delivery	O	O	O
and	O	O	O
interpretation	O	O	B-Entity
.	O	O	O

We	O	O	O
compared	O	O	B-Entity
performance	O	O	B-Entity
on	O	O	O
a	O	O	O
novel	O	O	O
test	O	O	O
of	O	O	O
visuospatial	O	O	B-Entity
ability	O	O	I-Entity
-	O	O	O
the	O	O	O
LSD	O	O	B-Entity
-	O	O	O
with	O	O	O
the	O	O	O
IPT	O	O	B-Entity
,	O	O	O
CDT	O	O	B-Entity
and	O	O	O
MMSE	O	O	B-Entity
in	O	O	O
180	O	O	O
acute	O	O	B-Entity
elderly	O	O	B-Entity
medical	O	O	B-Entity
inpatients	O	O	B-Entity
[	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
79.7±7.1	O	O	O
(	O	O	O
range	O	O	B-Entity
62	O	O	O
-	O	O	O
96	O	O	O
)	O	O	O
;	O	O	O
91	O	O	O
females	O	O	B-Entity
(	O	O	O
50.6	O	O	O
%	O	O	O
)	O	O	O
]	O	O	O
.	O	O	O

124	O	O	O
(	O	O	O
69	O	O	O
%	O	O	O
)	O	O	O
scored	O	O	B-Entity
≤23	O	O	O
on	O	O	O
the	O	O	O
MMSE	O	O	B-Entity
;	O	O	O
60	O	O	O
with	O	O	O
mild	O	O	B-Entity
(	O	O	O
score	O	O	B-Entity
18	O	O	O
-	O	O	O
23	O	O	O
)	O	O	O
and	O	O	O
64	O	O	O
with	O	O	O
severe	O	O	B-Entity
(	O	O	O
score	O	O	O
≤17	O	O	O
)	O	O	O
impairment	O	O	B-Entity
.	O	O	O

78	O	O	O
(	O	O	O
43	O	O	O
%	O	O	O
)	O	O	O
scored	O	O	B-Entity
≥6	O	O	O
on	O	O	O
the	O	O	O
CDT	O	O	B-Entity
,	O	O	O
while	O	O	O
for	O	O	O
the	O	O	O
IPT	O	O	B-Entity
,	O	O	O
87	O	O	O
(	O	O	O
47	O	O	O
%	O	O	O
)	O	O	O
scored	O	O	O
≥4	O	O	O
.	O	O	O

The	O	O	O
CDT	O	O	B-Entity
and	O	O	O
IPT	O	O	B-Entity
agreed	O	O	B-Entity
on	O	O	O
the	O	O	O
classification	O	O	B-Entity
of	O	O	O
138	O	O	O
patients	O	O	B-Entity
(	O	O	O
77	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
modest-	O	O	O
strong	O	O	B-Entity
agreement	O	O	O
with	O	O	O
the	O	O	O
MMSE	O	O	B-Entity
categories	O	O	B-Entity
.	O	O	O

Correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
LSD	O	O	B-Entity
and	O	O	O
visuospatial	O	O	B-Entity
tests	O	O	I-Entity
was	O	O	O
high	O	O	B-Entity
.	O	O	O

A	O	O	O
four-item	O	O	B-Entity
version	O	O	I-Entity
of	O	O	O
the	O	O	O
LSD	O	O	B-Entity
incorporating	O	O	O
items	O	O	B-Entity
1,10,12,15	O	O	O
had	O	O	O
high	O	O	B-Entity
correlation	O	O	B-Entity
with	O	O	O
the	O	O	O
LSD-15	O	O	B-Entity
and	O	O	O
strong	O	O	B-Entity
association	O	O	B-Entity
with	O	O	I-Entity
MMSE	O	O	B-Entity
categories	O	O	B-Entity
.	O	O	O

The	O	O	O
LSD-4	O	O	B-Entity
provides	O	O	O
a	O	O	O
brief	O	O	O
and	O	O	O
easily	O	O	B-Entity
interpreted	O	O	B-Entity
bedside	O	O	B-Entity
test	O	O	I-Entity
of	O	O	O
visuospatial	O	O	B-Entity
function	O	O	I-Entity
that	O	O	O
has	O	O	O
high	O	O	B-Entity
coverage	O	O	B-Entity
of	O	O	O
elderly	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
neurocognitive	O	O	B-Entity
impairment	O	O	I-Entity
,	O	O	O
good	O	O	O
agreement	O	O	O
with	O	O	O
conventional	O	O	B-Entity
tests	O	O	O
of	O	O	O
visuospatial	O	O	B-Entity
ability	O	O	I-Entity
and	O	O	O
favourable	O	O	O
ability	O	O	O
to	O	O	O
identify	O	O	B-Entity
significant	O	O	B-Entity
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
.	O	O	O

[	O	O	O
181	O	O	O
words	O	O	O
]	O	O	O
.	O	O	O

-DOCSTART- (27956431)

Salvage	O	O	B-Entity
Therapy	O	O	I-Entity
with	O	O	O
Ceftolozane-Tazobactam	O	O	B-Entity
for	O	O	O
Multidrug-Resistant	O	O	B-Entity
Pseudomonas	O	O	I-Entity
aeruginosa	O	O	I-Entity
Infections	O	O	O

Infections	O	O	B-Entity
caused	O	O	O
by	O	O	O
multidrug-resistant	O	O	B-Entity
Pseudomonas	O	O	I-Entity
aeruginosa	O	O	I-Entity
(	O	O	O
MDRPA	O	O	B-Entity
)	O	O	O
present	O	O	O
a	O	O	O
major	O	O	O
problem	O	O	O
for	O	O	O
therapeutic	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

We	O	O	O
report	O	O	O
here	O	O	O
our	O	O	O
experience	O	O	O
with	O	O	O
12	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
severe	O	O	O
MDRPA	O	O	B-Entity
infection	O	O	B-Entity
(	O	O	O
6	O	O	O
of	O	O	O
which	O	O	O
were	O	O	O
pneumonia	O	O	B-Entity
)	O	O	O
who	O	O	O
received	O	O	O
salvage	O	O	B-Entity
therapy	O	O	I-Entity
with	O	O	O
ceftolozane-tazobactam	O	O	B-Entity
after	O	O	O
inappropriate	O	O	O
empirical	O	O	B-Entity
treatment	O	O	B-Entity
and/or	O	O	O
suboptimal	O	O	B-Entity
targeted	O	O	O
treatment	O	O	O
.	O	O	O

Although	O	O	O
10	O	O	O
of	O	O	O
the	O	O	O
12	O	O	O
patients	O	O	B-Entity
(	O	O	O
83.3	O	O	O
%	O	O	O
)	O	O	O
experienced	O	O	O
septic	O	O	B-Entity
shock	O	O	I-Entity
,	O	O	O
only	O	O	O
3	O	O	O
patients	O	O	O
(	O	O	O
25	O	O	O
%	O	O	O
)	O	O	O
died	O	O	B-Entity
during	O	O	O
the	O	O	O
follow-up	O	O	B-Entity
period	O	O	O
.	O	O	O

Microbiological	O	O	B-Entity
cure	O	O	B-Entity
in	O	O	O
7	O	O	O
patients	O	O	B-Entity
(	O	O	O
58.3	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
observed	O	O	O
.	O	O	O

-DOCSTART- (27960292)

Ankaflavin	O	O	B-Entity
and	O	O	O
Monascin	O	O	B-Entity
Induce	O	O	B-Entity
Apoptosis	O	O	B-Entity
in	O	O	O
Activated	O	O	B-Entity
Hepatic	O	O	B-Entity
Stellate	O	O	I-Entity
Cells	O	O	I-Entity
through	O	O	O
Suppression	O	O	B-Entity
of	O	O	O
the	O	O	O
Akt	O	O	B-Entity
/	O	O	O
NF-κB	O	O	B-Entity
/	O	O	O
p38	O	O	B-Entity
Signaling	O	O	O
Pathway	O	O	O

The	O	O	O
increased	O	O	B-Entity
proliferation	O	O	B-Entity
of	O	O	O
activated	O	O	B-Entity
hepatic	O	O	B-Entity
stellate	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
HSCs	O	O	B-Entity
)	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
hepatic	O	O	B-Entity
fibrosis	O	O	I-Entity
and	O	O	O
excessive	O	O	B-Entity
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
(ECM)-	O	O	O
protein	O	O	B-Entity
production	O	O	O
.	O	O	O

We	O	O	O
examined	O	O	O
the	O	O	O
inhibitory	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
Monascus	O	O	B-Entity
purpureus	O	O	I-Entity
-fermented	O	O	O
metabolites	O	O	B-Entity
,	O	O	O
ankaflavin	O	O	B-Entity
and	O	O	O
monascin	O	O	B-Entity
(	O	O	O
15	O	O	O
and	O	O	O
30	O	O	O
μM	O	O	O
)	O	O	O
,	O	O	O
on	O	O	O
the	O	O	O
Akt	O	O	B-Entity
/	O	O	O
nuclear	O	O	B-Entity
factor	O	O	I-Entity
(NF)-κB	O	O	I-Entity
and	O	O	O
p38	O	O	B-Entity
mitogen-activated	O	O	I-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
(	O	O	O
MAPK	O	O	B-Entity
)	O	O	O
signaling	O	O	B-Entity
pathways	O	O	I-Entity
in	O	O	O
HSC-T6	O	O	B-Entity
(	O	O	O
activated	O	O	B-Entity
hepatic	O	O	I-Entity
stellate	O	O	I-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
)	O	O	O
.	O	O	O

Ankaflavin	O	O	B-Entity
and	O	O	O
monascin	O	O	B-Entity
(	O	O	O
30	O	O	O
μM	O	O	O
)	O	O	O
induced	O	O	B-Entity
apoptosis	O	O	B-Entity
and	O	O	O
significantly	O	O	B-Entity
inhibited	O	O	B-Entity
cell	O	O	B-Entity
growth	O	O	I-Entity
(	O	O	O
cell	O	O	B-Entity
viabilities	O	O	I-Entity
:	O	O	O
80.2	O	O	O
±	O	O	O
5.43	O	O	O
%	O	O	O
and	O	O	O
62.8	O	O	O
±	O	O	O
8.20	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
versus	O	O	O
control	O	O	B-Entity
cells	O	O	I-Entity
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Apoptosis	O	O	B-Entity
and	O	O	O
G1	O	O	B-Entity
phase	O	O	I-Entity
arrest	O	O	I-Entity
(	O	O	O
G1	O	O	O
phase	O	O	O
percentages	O	O	B-Entity
:	O	O	O
76.1	O	O	O
±	O	O	O
2.85	O	O	O
%	O	O	O
and	O	O	O
79.9	O	O	O
±	O	O	O
1.80	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
versus	O	O	O
control	O	O	B-Entity
cells	O	O	I-Entity
65.9	O	O	O
±	O	O	O
4.94	O	O	O
%	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
correlated	O	O	B-Entity
with	O	O	O
increased	O	O	B-Entity
p53	O	O	B-Entity
and	O	O	O
p21	O	O	B-Entity
levels	O	O	B-Entity
and	O	O	O
caspase	O	O	B-Entity
3	O	O	I-Entity
activity	O	O	I-Entity
and	O	O	O
decreased	O	O	B-Entity
cyclin	O	O	B-Entity
D1	O	O	I-Entity
and	O	O	O
Bcl-2-family	O	O	B-Entity
protein	O	O	I-Entity
levels	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
,	O	O	O
all	O	O	O
cases	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
apoptotic	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
ankaflavin	O	O	B-Entity
and	O	O	O
monascin	O	O	B-Entity
were	O	O	O
HSC-T6	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
their	O	O	O
potential	O	O	B-Entity
in	O	O	O
treating	O	O	B-Entity
liver	O	O	B-Entity
fibrosis	O	O	I-Entity
.	O	O	O

-DOCSTART- (27965132)

Low-Volume	O	O	B-Entity
vs	O	O	O
High-Volume	O	O	B-Entity
Centers	O	O	I-Entity
and	O	O	O
Management	O	O	B-Entity
of	O	O	I-Entity
Fournier	O	O	B-Entity
's	O	O	I-Entity
Gangrene	O	O	I-Entity
in	O	O	O
Washington	O	O	O
State	O	O	O

Fournier	O	O	B-Entity
's	O	O	I-Entity
gangrene	O	O	I-Entity
(	O	O	O
FG	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
life-threatening	O	O	B-Entity
infection	O	O	I-Entity
affecting	O	O	B-Entity
the	O	O	O
perineum	O	O	B-Entity
and	O	O	O
genitals	O	O	B-Entity
.	O	O	O

Complex	O	O	B-Entity
patient	O	O	B-Entity
management	O	O	I-Entity
often	O	O	O
necessitates	O	O	O
transfer	O	O	O
to	O	O	O
tertiary	O	O	B-Entity
centers	O	O	I-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
characterize	O	O	O
hospital	O	O	B-Entity
transfer	O	O	I-Entity
patterns	O	O	B-Entity
and	O	O	O
assess	O	O	O
morbidity	O	O	B-Entity
among	O	O	O
patients	O	O	B-Entity
with	O	O	O
FG	O	O	B-Entity
in	O	O	O
Washington	O	O	B-Entity
State	O	O	I-Entity
.	O	O	O

The	O	O	O
Washington	O	O	B-Entity
State	O	O	I-Entity
Comprehensive	O	O	B-Entity
Hospital	O	O	O
Abstract	O	O	B-Entity
Reporting	O	O	I-Entity
System	O	O	O
includes	O	O	O
claims	O	O	O
from	O	O	O
all	O	O	O
hospital	O	O	B-Entity
discharges	O	O	I-Entity
in	O	O	O
Washington	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	O
patients	O	O	B-Entity
with	O	O	O
FG	O	O	B-Entity
between	O	O	O
2007	O	O	O
and	O	O	O
2013	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
diagnosis	O	O	B-Entity
and	O	O	I-Entity
treatment	O	O	I-Entity
codes	O	O	I-Entity
.	O	O	O

Analyses	O	O	O
were	O	O	O
stratified	O	O	B-Entity
by	O	O	O
center	O	O	O
volume	O	O	O
(	O	O	O
low-volume	O	O	B-Entity
centers	O	O	I-Entity
[	O	O	O
LVCs	O	O	B-Entity
]	O	O	O
or	O	O	O
high-volume	O	O	B-Entity
centers	O	O	I-Entity
[	O	O	O
HVCs	O	O	B-Entity
]	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
transfer	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

Variables	O	O	O
of	O	O	O
interest	O	O	O
included	O	O	O
number	O	O	O
of	O	O	O
debridements	O	O	B-Entity
,	O	O	O
septic	O	O	B-Entity
shock	O	O	I-Entity
,	O	O	O
acute	O	O	B-Entity
renal	O	O	I-Entity
failure	O	O	I-Entity
,	O	O	O
acute	O	O	B-Entity
respiratory	O	O	I-Entity
failure	O	O	I-Entity
,	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
hospitalization	O	O	I-Entity
,	O	O	O
and	O	O	O
death	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	O
165	O	O	O
FG	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Only	O	O	O
1	O	O	O
HVC	O	O	B-Entity
treated	O	O	B-Entity
more	O	O	O
than	O	O	O
2	O	O	O
FG	O	O	B-Entity
patients	O	O	B-Entity
per	O	O	O
year	O	O	O
.	O	O	O

Overall	O	O	B-Entity
mortality	O	O	I-Entity
was	O	O	O
6.7	O	O	O
%	O	O	O
.	O	O	O

Most	O	O	O
patients	O	O	B-Entity
(	O	O	O
57	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
treated	O	O	B-Entity
entirely	O	O	O
at	O	O	O
LVCs	O	O	B-Entity
;	O	O	O
87	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	O
treated	O	O	O
at	O	O	O
the	O	O	O
HVC	O	O	B-Entity
were	O	O	O
transferred	O	O	O
from	O	O	O
an	O	O	O
LVC	O	O	B-Entity
.	O	O	O

High-volume	O	O	B-Entity
center	O	O	I-Entity
-treated	O	O	O
patients	O	O	B-Entity
had	O	O	O
similar	O	O	O
baseline	O	O	O
comorbidities	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.77	O	O	O
)	O	O	O
and	O	O	O
similar	O	O	O
mortality	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.87	O	O	O
)	O	O	O
,	O	O	O
despite	O	O	O
higher	O	O	O
rates	O	O	O
of	O	O	O
septic	O	O	B-Entity
shock	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
respiratory	O	O	B-Entity
failure	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.01	O	O	O
)	O	O	O
compared	O	O	O
with	O	O	O
LVC	O	O	B-Entity
patients	O	O	O
.	O	O	O

Among	O	O	O
HVC	O	O	B-Entity
-	O	O	O
transferred	O	O	B-Entity
patients	O	O	I-Entity
,	O	O	O
immediate	O	O	B-Entity
compared	O	O	O
with	O	O	O
delayed	O	O	B-Entity
transfer	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
fewer	O	O	O
debridements	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
,	O	O	O
lower	O	O	O
rates	O	O	O
of	O	O	O
septic	O	O	B-Entity
shock	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
acute	O	O	B-Entity
renal	O	O	I-Entity
failure	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.04	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
treated	O	O	B-Entity
at	O	O	O
the	O	O	O
HVC	O	O	B-Entity
were	O	O	O
more	O	O	O
acutely	O	O	B-Entity
ill	O	O	I-Entity
,	O	O	O
yet	O	O	O
mortality	O	O	B-Entity
was	O	O	O
similar	O	O	O
compared	O	O	O
with	O	O	O
patients	O	O	B-Entity
treated	O	O	O
solely	O	O	O
at	O	O	O
LVCs	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
a	O	O	O
benefit	O	O	O
to	O	O	O
transfer	O	O	O
of	O	O	O
high	O	O	O
acuity	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

Immediate	O	O	B-Entity
vs	O	O	O
delayed	O	O	B-Entity
transfer	O	O	O
may	O	O	O
benefit	O	O	O
FG	O	O	B-Entity
health	O	O	B-Entity
outcomes	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
this	O	O	O
may	O	O	O
also	O	O	O
reflect	O	O	O
greater	O	O	O
disease	O	O	B-Entity
acuity	O	O	B-Entity
of	O	O	I-Entity
patients	O	O	I-Entity
with	O	O	O
delayed	O	O	O
transfer	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

-DOCSTART- (27965450)

Functional	O	O	O
Characterization	O	O	O
of	O	O	O
Pneumocystis	O	O	B-Entity
carinii	O	O	I-Entity
Inositol	O	O	O
Transporter	O	O	O
1	O	O	O

Fungi	O	O	B-Entity
in	O	O	O
the	O	O	O
genus	O	O	B-Entity
Pneumocystis	O	O	I-Entity
live	O	O	O
in	O	O	O
the	O	O	O
lungs	O	O	B-Entity
of	O	O	O
mammals	O	O	B-Entity
,	O	O	O
where	O	O	O
they	O	O	O
can	O	O	O
cause	O	O	O
a	O	O	O
fatal	O	O	B-Entity
pneumonia	O	O	B-Entity
(	O	O	O
PCP	O	O	B-Entity
[	O	O	O
Pneumocystis	O	O	B-Entity
pneumonia	O	O	I-Entity
]	O	O	O
)	O	O	O
in	O	O	O
hosts	O	O	B-Entity
with	O	O	O
compromised	O	O	O
immune	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

The	O	O	O
absence	O	O	O
of	O	O	O
a	O	O	O
continuous	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
culture	O	O	B-Entity
system	O	O	I-Entity
for	O	O	O
any	O	O	O
species	O	O	B-Entity
of	O	O	O
Pneumocystis	O	O	B-Entity
has	O	O	O
led	O	O	O
to	O	O	O
limited	O	O	O
understanding	O	O	O
of	O	O	O
these	O	O	O
fungi	O	O	B-Entity
,	O	O	O
especially	O	O	O
for	O	O	O
the	O	O	O
discovery	O	O	B-Entity
of	O	O	O
new	O	O	O
therapies	O	O	B-Entity
.	O	O	O

We	O	O	O
recently	O	O	O
reported	O	O	O
that	O	O	O
Pneumocystis	O	O	B-Entity
carinii	O	O	I-Entity
,	O	O	O
Pneumocystis	O	O	B-Entity
murina	O	O	I-Entity
,	O	O	O
and	O	O	O
most	O	O	O
significantly	O	O	O
,	O	O	O
Pneumocystis	O	O	B-Entity
jirovecii	O	O	I-Entity
lack	O	O	O
both	O	O	O
enzymes	O	O	B-Entity
necessary	O	O	O
for	O	O	O
myo-inositol	O	O	B-Entity
biosynthesis	O	O	I-Entity
but	O	O	O
contain	O	O	O
genes	O	O	B-Entity
with	O	O	I-Entity
homologies	O	O	I-Entity
to	O	O	O
fungal	O	O	B-Entity
myo-inositol	O	O	O
transporters	O	O	B-Entity
.	O	O	O

Since	O	O	O
myo-inositol	O	O	B-Entity
is	O	O	O
essential	O	O	O
for	O	O	O
eukaryotic	O	O	B-Entity
viability	O	O	B-Entity
,	O	O	O
the	O	O	O
primary	O	O	O
transporter	O	O	B-Entity
,	O	O	O
ITR1	O	O	B-Entity
,	O	O	O
was	O	O	O
functionally	O	O	B-Entity
and	O	O	O
structurally	O	O	B-Entity
characterized	O	O	O
in	O	O	O
P.	O	O	B-Entity
carinii	O	O	I-Entity
The	O	O	O
predicted	O	O	O
structure	O	O	B-Entity
of	O	O	O
P.	O	O	O
carinii	O	O	O
ITR1	O	O	O
(	O	O	O
PcITR1	O	O	B-Entity
)	O	O	O
contained	O	O	O
12	O	O	O
transmembrane	O	O	B-Entity
alpha-helices	O	O	B-Entity
with	O	O	O
intracellular	O	O	B-Entity
C	O	O	B-Entity
and	O	O	O
N	O	O	B-Entity
termini	O	O	I-Entity
,	O	O	O
consistent	O	O	O
with	O	O	O
other	O	O	O
inositol	O	O	B-Entity
transporters	O	O	B-Entity
.	O	O	O

The	O	O	O
apparent	O	O	O
Km	O	O	O
was	O	O	O
0.94	O	O	O
±	O	O	O
0.08	O	O	O
(	O	O	O
mean	O	O	O
±	O	O	O
standard	O	O	O
deviation	O	O	O
)	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
myo-inositol	O	O	B-Entity
transport	O	O	I-Entity
in	O	O	O
P.	O	O	B-Entity
carinii	O	O	I-Entity
is	O	O	O
likely	O	O	O
through	O	O	O
a	O	O	O
low-affinity	O	O	O
,	O	O	O
highly	O	O	O
selective	O	O	O
transport	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
as	O	O	O
no	O	O	O
other	O	O	O
sugars	O	O	B-Entity
or	O	O	O
inositol	O	O	B-Entity
stereoisomers	O	O	B-Entity
were	O	O	O
significant	O	O	O
competitive	O	O	B-Entity
inhibitors	O	O	B-Entity
.	O	O	O

Glucose	O	O	B-Entity
transport	O	O	B-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
use	O	O	O
a	O	O	O
different	O	O	O
transport	O	O	O
system	O	O	O
.	O	O	O

The	O	O	O
myo-inositol	O	O	B-Entity
transport	O	O	I-Entity
was	O	O	O
distinct	O	O	O
from	O	O	O
mammalian	O	O	B-Entity
transporters	O	O	B-Entity
,	O	O	O
as	O	O	O
it	O	O	O
was	O	O	O
not	O	O	O
sodium	O	O	B-Entity
dependent	O	O	I-Entity
and	O	O	O
was	O	O	O
cytochalasin	O	O	B-Entity
B	O	O	I-Entity
resistant	O	O	B-Entity
.	O	O	O

Inositol	O	O	B-Entity
transport	O	O	B-Entity
in	O	O	O
these	O	O	O
fungi	O	O	B-Entity
offers	O	O	O
an	O	O	O
attractive	O	O	B-Entity
new	O	O	O
drug	O	O	B-Entity
target	O	O	B-Entity
because	O	O	O
of	O	O	O
the	O	O	O
reliance	O	O	O
of	O	O	O
the	O	O	O
fungi	O	O	O
on	O	O	O
its	O	O	O
transport	O	O	O
,	O	O	O
clear	O	O	O
differences	O	O	O
between	O	O	O
the	O	O	O
mammalian	O	O	B-Entity
and	O	O	O
fungal	O	O	B-Entity
transporters	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
ability	O	O	O
of	O	O	O
the	O	O	O
host	O	O	B-Entity
to	O	O	O
both	O	O	O
synthesize	O	O	O
and	O	O	O
transport	O	O	O
this	O	O	O
critical	O	O	B-Entity
nutrient	O	O	B-Entity
,	O	O	O
predicting	O	O	O
low	O	O	B-Entity
toxicity	O	O	B-Entity
of	O	O	O
potential	O	O	B-Entity
inhibitors	O	O	B-Entity
to	O	O	O
the	O	O	O
fungal	O	O	O
transporter	O	O	B-Entity
.	O	O	O

myo-Inositol	O	O	B-Entity
is	O	O	O
a	O	O	O
sugarlike	O	O	B-Entity
nutrient	O	O	B-Entity
that	O	O	O
is	O	O	O
essential	O	O	B-Entity
for	O	O	O
life	O	O	B-Entity
in	O	O	O
most	O	O	O
organisms	O	O	B-Entity
.	O	O	O

Humans	O	O	B-Entity
and	O	O	O
microbes	O	O	B-Entity
alike	O	O	O
can	O	O	O
obtain	O	O	O
it	O	O	O
by	O	O	O
making	O	O	O
it	O	O	O
,	O	O	O
which	O	O	O
involves	O	O	O
only	O	O	O
2	O	O	O
enzymes	O	O	B-Entity
,	O	O	O
by	O	O	O
taking	O	O	O
it	O	O	O
from	O	O	O
the	O	O	O
environment	O	O	B-Entity
by	O	O	O
a	O	O	O
transport	O	O	B-Entity
process	O	O	I-Entity
,	O	O	O
or	O	O	O
by	O	O	O
recycling	O	O	O
it	O	O	O
from	O	O	O
other	O	O	O
cellular	O	O	B-Entity
constituents	O	O	B-Entity
.	O	O	O

Inspection	O	O	O
of	O	O	O
the	O	O	O
genomes	O	O	B-Entity
of	O	O	O
the	O	O	O
pathogenic	O	O	B-Entity
fungi	O	O	I-Entity
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
Pneumocystis	O	O	I-Entity
showed	O	O	O
that	O	O	O
these	O	O	O
pneumonia	O	O	B-Entity
-	O	O	O
causing	O	O	B-Entity
parasites	O	O	B-Entity
could	O	O	O
not	O	O	O
make	O	O	O
myo-inositol	O	O	B-Entity
,	O	O	O
as	O	O	O
they	O	O	O
lacked	O	O	O
the	O	O	O
2	O	O	O
enzymes	O	O	B-Entity
.	O	O	O

Instead	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
evidence	O	O	O
of	O	O	O
inositol	O	O	B-Entity
transporters	O	O	B-Entity
,	O	O	O
which	O	O	O
would	O	O	O
import	O	O	O
the	O	O	O
sugar	O	O	B-Entity
from	O	O	O
the	O	O	O
lungs	O	O	B-Entity
where	O	O	O
the	O	O	O
fungi	O	O	B-Entity
reside	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
report	O	O	O
,	O	O	O
we	O	O	O
characterized	O	O	O
the	O	O	O
transport	O	O	B-Entity
of	O	O	O
myo-inositol	O	O	B-Entity
in	O	O	O
the	O	O	O
fungus	O	O	B-Entity
and	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
transporter	O	O	B-Entity
was	O	O	O
highly	O	O	O
selective	O	O	O
for	O	O	O
myo-inositol	O	O	O
and	O	O	O
did	O	O	O
not	O	O	O
transport	O	O	O
any	O	O	O
other	O	O	O
molecules	O	O	B-Entity
.	O	O	O

The	O	O	O
transport	O	O	B-Entity
was	O	O	O
distinct	O	O	O
from	O	O	O
that	O	O	O
in	O	O	O
mammalian	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
since	O	O	O
mammals	O	O	B-Entity
can	O	O	O
both	O	O	O
make	O	O	O
and	O	O	O
transport	O	O	O
myo-inositol	O	O	B-Entity
,	O	O	O
while	O	O	O
Pneumocystis	O	O	B-Entity
fungi	O	O	I-Entity
must	O	O	O
transport	O	O	O
it	O	O	O
,	O	O	O
this	O	O	O
process	O	O	O
offers	O	O	O
a	O	O	O
potential	O	O	B-Entity
new	O	O	O
drug	O	O	B-Entity
target	O	O	B-Entity
.	O	O	O

-DOCSTART- (27976878)

Worldwide	O	O	B-Entity
Occurrence	O	O	B-Entity
of	O	O	O
Mycotoxins	O	O	B-Entity
in	O	O	O
Cereals	O	O	B-Entity
and	O	O	O
Cereal	O	O	B-Entity
-	O	O	O
Derived	O	O	B-Entity
Food	O	O	B-Entity
Products	O	O	I-Entity
:	O	O	O
Public	O	O	B-Entity
Health	O	O	B-Entity
Perspectives	O	O	B-Entity
of	O	O	O
Their	O	O	O
Co-occurrence	O	O	O

Cereal	O	O	B-Entity
grains	O	O	I-Entity
and	O	O	O
their	O	O	O
processed	O	O	B-Entity
food	O	O	B-Entity
products	O	O	I-Entity
are	O	O	O
frequently	O	O	O
contaminated	O	O	B-Entity
with	O	O	O
mycotoxins	O	O	B-Entity
.	O	O	O

Among	O	O	O
many	O	O	O
,	O	O	O
five	O	O	B-Entity
major	O	O	B-Entity
mycotoxins	O	O	B-Entity
of	O	O	O
aflatoxins	O	O	B-Entity
,	O	O	O
ochratoxins	O	O	B-Entity
,	O	O	O
fumonisins	O	O	B-Entity
,	O	O	O
deoxynivalenol	O	O	B-Entity
,	O	O	O
and	O	O	O
zearalenone	O	O	B-Entity
are	O	O	O
of	O	O	O
significant	O	O	O
public	O	O	B-Entity
health	O	O	B-Entity
concern	O	O	B-Entity
as	O	O	O
they	O	O	O
can	O	O	O
cause	O	O	B-Entity
adverse	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

Being	O	O	O
airborne	O	O	B-Entity
or	O	O	O
soilborne	O	O	B-Entity
,	O	O	O
the	O	O	O
cosmopolitan	O	O	O
nature	O	O	B-Entity
of	O	O	O
mycotoxigenic	O	O	B-Entity
fungi	O	O	I-Entity
contribute	O	O	O
to	O	O	O
the	O	O	O
worldwide	O	O	B-Entity
occurrence	O	O	B-Entity
of	O	O	O
mycotoxins	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	B-Entity
of	O	O	O
the	O	O	O
global	O	O	B-Entity
occurrence	O	O	B-Entity
data	O	O	B-Entity
reported	O	O	B-Entity
during	O	O	O
the	O	O	O
past	O	O	O
10	O	O	O
years	O	O	O
,	O	O	O
the	O	O	O
incidences	O	O	B-Entity
and	O	O	O
maximum	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
raw	O	O	B-Entity
cereal	O	O	B-Entity
grains	O	O	I-Entity
were	O	O	O
55	O	O	O
%	O	O	O
and	O	O	O
1642	O	O	O
μg/kg	O	O	O
for	O	O	O
aflatoxins	O	O	B-Entity
,	O	O	O
29	O	O	O
%	O	O	O
and	O	O	O
1164	O	O	O
μg/kg	O	O	O
for	O	O	O
ochratoxin	O	O	B-Entity
A	O	O	I-Entity
,	O	O	O
61	O	O	O
%	O	O	O
and	O	O	O
71,121	O	O	O
μg/kg	O	O	O
for	O	O	O
fumonisins	O	O	B-Entity
,	O	O	O
58	O	O	O
%	O	O	O
and	O	O	O
41,157	O	O	O
μg/kg	O	O	O
,	O	O	O
for	O	O	O
deoxynivalenol	O	O	B-Entity
,	O	O	O
and	O	O	O
46	O	O	O
%	O	O	O
and	O	O	O
3049	O	O	O
μg/kg	O	O	O
for	O	O	O
zearalenone	O	O	B-Entity
.	O	O	O

The	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
mycotoxins	O	O	B-Entity
tend	O	O	O
to	O	O	O
be	O	O	O
lower	O	O	B-Entity
in	O	O	O
processed	O	O	B-Entity
food	O	O	B-Entity
products	O	O	I-Entity
;	O	O	O
the	O	O	O
incidences	O	O	B-Entity
varied	O	O	O
depending	O	O	O
on	O	O	O
the	O	O	O
individual	O	O	O
mycotoxins	O	O	O
,	O	O	O
possibly	O	O	O
due	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
varying	O	O	B-Entity
stability	O	O	B-Entity
during	O	O	B-Entity
processing	O	O	B-Entity
and	O	O	O
distribution	O	O	B-Entity
of	O	O	O
mycotoxins	O	O	O
.	O	O	O

It	O	O	O
should	O	O	O
be	O	O	O
noted	O	O	O
that	O	O	O
more	O	O	O
than	O	O	O
one	O	O	O
mycotoxin	O	O	B-Entity
,	O	O	O
produced	O	O	B-Entity
by	O	O	O
a	O	O	O
single	O	O	B-Entity
or	O	O	O
several	O	O	B-Entity
fungal	O	O	B-Entity
species	O	O	B-Entity
,	O	O	O
may	O	O	O
occur	O	O	O
in	O	O	O
various	O	O	B-Entity
combinations	O	O	B-Entity
in	O	O	O
a	O	O	O
given	O	O	O
sample	O	O	B-Entity
or	O	O	O
food	O	O	B-Entity
.	O	O	O

Most	O	O	O
studies	O	O	B-Entity
reported	O	O	B-Entity
additive	O	O	B-Entity
or	O	O	O
synergistic	O	O	B-Entity
effects	O	O	B-Entity
,	O	O	O
suggesting	O	O	B-Entity
that	O	O	O
these	O	O	O
mixtures	O	O	B-Entity
may	O	O	O
pose	O	O	O
a	O	O	O
significant	O	O	B-Entity
threat	O	O	B-Entity
to	O	O	O
public	O	O	B-Entity
health	O	O	B-Entity
,	O	O	O
particularly	O	O	O
to	O	O	O
infants	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
children	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
information	O	O	B-Entity
on	O	O	O
the	O	O	O
co-occurrence	O	O	O
of	O	O	O
mycotoxins	O	O	B-Entity
and	O	O	O
their	O	O	O
interactive	O	O	B-Entity
toxicity	O	O	B-Entity
is	O	O	O
summarized	O	O	B-Entity
in	O	O	O
this	O	O	O
paper	O	O	O
.	O	O	O

-DOCSTART- (27979320)

Locating	O	O	O
the	O	O	O
Seventh	O	O	B-Entity
Cervical	O	O	I-Entity
Spinous	O	O	I-Entity
Process	O	O	I-Entity
:	O	O	O
Development	O	O	O
and	O	O	O
Validation	O	O	O
of	O	O	O
a	O	O	O
Multivariate	O	O	B-Entity
Model	O	O	I-Entity
Using	O	O	O
Palpation	O	O	B-Entity
and	O	O	O
Personal	O	O	O
Information	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
develop	O	O	O
and	O	O	O
validate	O	O	O
a	O	O	O
multivariate	O	O	B-Entity
prediction	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
guided	O	O	O
by	O	O	O
palpation	O	O	B-Entity
and	O	O	O
personal	O	O	B-Entity
information	O	O	I-Entity
,	O	O	O
for	O	O	O
locating	O	O	O
the	O	O	O
seventh	O	O	B-Entity
cervical	O	O	I-Entity
spinous	O	O	I-Entity
process	O	O	I-Entity
(	O	O	O
C7SP	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
single-blinded	O	O	B-Entity
,	O	O	I-Entity
cross-sectional	O	O	I-Entity
study	O	O	I-Entity
at	O	O	O
a	O	O	O
primary	O	O	B-Entity
to	O	O	I-Entity
tertiary	O	O	I-Entity
health	O	O	I-Entity
care	O	O	I-Entity
center	O	O	I-Entity
was	O	O	O
conducted	O	O	O
for	O	O	O
model	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
temporal	O	O	B-Entity
validation	O	O	I-Entity
.	O	O	O

One-hundred	O	O	O
sixty	O	O	O
participants	O	O	B-Entity
were	O	O	O
prospectively	O	O	O
included	O	O	O
for	O	O	O
model	O	O	B-Entity
development	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
80	O	O	O
)	O	O	O
and	O	O	O
time-split	O	O	B-Entity
validation	O	O	I-Entity
stages	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
80	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
C7SP	O	O	B-Entity
was	O	O	O
located	O	O	O
using	O	O	O
the	O	O	O
thorax-rib	O	O	B-Entity
static	O	O	I-Entity
method	O	O	I-Entity
(	O	O	O
TRSM	O	O	B-Entity
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
underwent	O	O	O
chest	O	O	B-Entity
radiography	O	O	I-Entity
for	O	O	O
assessment	O	O	O
of	O	O	O
the	O	O	O
inner	O	O	B-Entity
body	O	O	B-Entity
structure	O	O	I-Entity
located	O	O	O
with	O	O	O
TRSM	O	O	B-Entity
and	O	O	O
using	O	O	O
radio-opaque	O	O	B-Entity
markers	O	O	I-Entity
placed	O	O	O
over	O	O	O
the	O	O	O
skin	O	O	B-Entity
.	O	O	O

Age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
height	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
,	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
,	O	O	O
and	O	O	O
vertex-marker	O	O	B-Entity
distanc	O	O	I-Entity
e	O	O	O
(	O	O	O
DV-M	O	O	B-Entity
)	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
predict	O	O	O
the	O	O	O
distance	O	O	B-Entity
from	O	O	O
the	O	O	O
C7SP	O	O	B-Entity
to	O	O	O
the	O	O	O
vertex	O	O	B-Entity
(	O	O	O
DV-C7	O	O	B-Entity
)	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
linear	O	O	I-Entity
regression	O	O	I-Entity
modeling	O	O	I-Entity
,	O	O	O
limits	O	O	O
of	O	O	O
agreement	O	O	O
plot	O	O	O
,	O	O	O
histogram	O	O	B-Entity
of	O	O	I-Entity
residues	O	O	I-Entity
,	O	O	O
receiver	O	O	B-Entity
operating	O	O	I-Entity
characteristic	O	O	I-Entity
curves	O	O	I-Entity
,	O	O	O
and	O	O	O
confusion	O	O	B-Entity
tables	O	O	I-Entity
were	O	O	O
analyzed	O	O	O
.	O	O	O

The	O	O	O
multivariate	O	O	B-Entity
linear	O	O	I-Entity
prediction	O	O	I-Entity
model	O	O	I-Entity
for	O	O	O
DV-C7	O	O	B-Entity
(	O	O	O
in	O	O	O
centimeters	O	O	O
)	O	O	O
was	O	O	O
DV-C7	O	O	O
=	O	O	O
0.986DV-M	O	O	O
+	O	O	O
0.018(mass	O	O	O
)	O	O	O
+	O	O	O
0.014(age	O	O	O
)	O	O	O
-	O	O	O
1.008	O	O	O
.	O	O	O

Receiver	O	O	B-Entity
operating	O	O	I-Entity
characteristic	O	O	I-Entity
curves	O	O	I-Entity
had	O	O	O
better	O	O	O
discrimination	O	O	O
of	O	O	O
DV-C7	O	O	B-Entity
(	O	O	O
area	O	O	O
under	O	O	O
the	O	O	O
curve	O	O	O
=	O	O	O
0.661	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
=	O	O	O
0.541	O	O	O
-	O	O	O
0.782	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.015	O	O	O
)	O	O	O
than	O	O	O
DV-M	O	O	B-Entity
(	O	O	O
area	O	O	O
under	O	O	O
the	O	O	O
curve	O	O	O
=	O	O	O
0.480	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	O
interval	O	O	O
=	O	O	O
0.345	O	O	O
-	O	O	O
0.614	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.761	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
respective	O	O	O
cutoff	O	O	O
points	O	O	O
at	O	O	O
23.40	O	O	O
cm	O	O	O
(	O	O	O
sensitivity	O	O	B-Entity
=	O	O	O
41	O	O	O
%	O	O	O
,	O	O	O
specificity	O	O	B-Entity
=	O	O	O
63	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
24.75	O	O	O
cm	O	O	O
(	O	O	O
sensitivity	O	O	O
=	O	O	O
69	O	O	O
%	O	O	O
,	O	O	O
specificity	O	O	O
=	O	O	O
52	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
C7SP	O	O	B-Entity
was	O	O	O
correctly	O	O	O
located	O	O	O
more	O	O	O
often	O	O	O
when	O	O	O
using	O	O	O
predicted	O	O	O
DV-C7	O	O	B-Entity
in	O	O	O
the	O	O	O
validation	O	O	O
sample	O	O	O
than	O	O	O
when	O	O	O
using	O	O	O
the	O	O	O
TRSM	O	O	B-Entity
in	O	O	O
the	O	O	O
development	O	O	O
sample	O	O	O
:	O	O	O
n	O	O	O
=	O	O	O
53	O	O	O
(	O	O	O
66	O	O	O
%	O	O	O
)	O	O	O
vs	O	O	O
n	O	O	O
=	O	O	O
32	O	O	O
(	O	O	O
40	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
.	O	O	O

Better	O	O	O
accuracy	O	O	O
was	O	O	O
obtained	O	O	O
when	O	O	O
locating	O	O	O
the	O	O	O
C7SP	O	O	B-Entity
by	O	O	O
use	O	O	O
of	O	O	O
a	O	O	O
multivariate	O	O	B-Entity
model	O	O	I-Entity
that	O	O	O
incorporates	O	O	O
palpation	O	O	B-Entity
and	O	O	O
personal	O	O	B-Entity
information	O	O	I-Entity
.	O	O	O

-DOCSTART- (27983510)

Comparison	O	O	B-Entity
of	O	O	O
Leishmania	O	O	B-Entity
typing	O	O	B-Entity
results	O	O	B-Entity
obtained	O	O	B-Entity
from	O	O	O
16	O	O	O
European	O	O	B-Entity
clinical	O	O	B-Entity
laboratories	O	O	I-Entity
in	O	O	O
2014	O	O	O

Leishmaniasis	O	O	B-Entity
is	O	O	O
endemic	O	O	B-Entity
in	O	O	O
southern	O	O	B-Entity
Europe	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
other	O	O	O
European	O	O	B-Entity
countries	O	O	B-Entity
cases	O	O	B-Entity
are	O	O	O
diagnosed	O	O	B-Entity
in	O	O	O
travellers	O	O	B-Entity
who	O	O	O
have	O	O	O
visited	O	O	O
affected	O	O	B-Entity
areas	O	O	I-Entity
both	O	O	O
within	O	O	B-Entity
the	O	O	O
continent	O	O	B-Entity
and	O	O	O
beyond	O	O	O
.	O	O	O

Prompt	O	O	B-Entity
and	O	O	O
accurate	O	O	B-Entity
diagnosis	O	O	B-Entity
poses	O	O	O
a	O	O	O
challenge	O	O	O
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
in	O	O	O
Europe	O	O	B-Entity
.	O	O	O

Different	O	O	B-Entity
methods	O	O	B-Entity
exist	O	O	B-Entity
for	O	O	O
identification	O	O	B-Entity
of	O	O	O
the	O	O	O
infecting	O	O	B-Entity
Leishmania	O	O	B-Entity
species	O	O	B-Entity
.	O	O	O

Sixteen	O	O	O
clinical	O	O	B-Entity
laboratories	O	O	I-Entity
in	O	O	O
10	O	O	O
European	O	O	B-Entity
countries	O	O	B-Entity
,	O	O	O
plus	O	O	O
Israel	O	O	B-Entity
and	O	O	O
Turkey	O	O	B-Entity
,	O	O	O
conducted	O	O	O
a	O	O	O
study	O	O	B-Entity
to	O	O	O
assess	O	O	O
their	O	O	O
genotyping	O	O	B-Entity
performance	O	O	B-Entity
.	O	O	O

DNA	O	O	B-Entity
from	O	O	O
21	O	O	O
promastigote	O	O	B-Entity
cultures	O	O	I-Entity
of	O	O	O
13	O	O	O
species	O	O	B-Entity
was	O	O	O
analysed	O	O	B-Entity
blindly	O	O	B-Entity
by	O	O	O
the	O	O	O
routinely	O	O	B-Entity
used	O	O	O
typing	O	O	B-Entity
method	O	O	B-Entity
.	O	O	O

Five	O	O	O
different	O	O	B-Entity
molecular	O	O	B-Entity
targets	O	O	I-Entity
were	O	O	O
used	O	O	O
,	O	O	O
which	O	O	O
were	O	O	O
analysed	O	O	B-Entity
with	O	O	O
PCR-based	O	O	B-Entity
methods	O	O	B-Entity
.	O	O	O

Different	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
identification	O	O	B-Entity
were	O	O	O
achieved	O	O	B-Entity
,	O	O	O
and	O	O	O
either	O	O	O
the	O	O	O
Leishmania	O	O	B-Entity
subgenus	O	O	B-Entity
,	O	O	O
species	O	O	B-Entity
complex	O	O	O
,	O	O	O
or	O	O	O
actual	O	O	O
species	O	O	O
were	O	O	O
reported	O	O	B-Entity
.	O	O	O

The	O	O	O
overall	O	O	B-Entity
error	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
strains	O	O	B-Entity
placed	O	O	O
in	O	O	O
the	O	O	O
wrong	O	O	B-Entity
complex	O	O	O
or	O	O	O
species	O	O	B-Entity
was	O	O	O
8.5	O	O	O
%	O	O	O
.	O	O	O

Various	O	O	O
reasons	O	O	B-Entity
for	O	O	O
incorrect	O	O	B-Entity
typing	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
shows	O	O	O
there	O	O	O
is	O	O	O
considerable	O	O	B-Entity
room	O	O	O
for	O	O	O
improvement	O	O	B-Entity
and	O	O	O
standardisation	O	O	B-Entity
of	O	O	O
Leishmania	O	O	B-Entity
typing	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
well	O	O	O
validated	O	O	B-Entity
standard	O	O	B-Entity
operating	O	O	I-Entity
procedures	O	O	I-Entity
is	O	O	O
recommended	O	O	B-Entity
,	O	O	O
covering	O	O	O
testing	O	O	B-Entity
,	O	O	O
interpretation	O	O	B-Entity
,	O	O	O
and	O	O	O
reporting	O	O	B-Entity
guidelines	O	O	B-Entity
.	O	O	O

Application	O	O	O
of	O	O	O
the	O	O	O
internal	O	O	B-Entity
transcribed	O	O	B-Entity
spacer	O	O	B-Entity
1	O	O	I-Entity
of	O	O	O
the	O	O	O
rDNA	O	O	B-Entity
array	O	O	B-Entity
should	O	O	O
be	O	O	O
restricted	O	O	B-Entity
to	O	O	O
Old	O	O	B-Entity
World	O	O	I-Entity
samples	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
heat-shock	O	O	B-Entity
protein	O	O	I-Entity
70	O	O	I-Entity
gene	O	O	I-Entity
and	O	O	O
the	O	O	O
mini-exon	O	O	B-Entity
can	O	O	O
be	O	O	O
applied	O	O	B-Entity
globally	O	O	B-Entity
.	O	O	O

-DOCSTART- (27983636)

Scoparone	O	O	B-Entity
Inhibits	O	O	O
LPS	O	O	B-Entity
-	O	O	O
Simulated	O	O	B-Entity
Inflammatory	O	O	B-Entity
Response	O	O	I-Entity
by	O	O	O
Suppressing	O	O	B-Entity
IRF3	O	O	B-Entity
and	O	O	O
ERK	O	O	B-Entity
in	O	O	O
BV-2	O	O	O
Microglial	O	O	O
Cells	O	O	O

Microglia	O	O	B-Entity
activation	O	O	B-Entity
and	O	O	O
the	O	O	O
release	O	O	O
of	O	O	O
various	O	O	O
inflammatory	O	O	B-Entity
cytokines	O	O	B-Entity
are	O	O	O
largely	O	O	O
related	O	O	O
to	O	O	O
neurological	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
including	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
,	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
,	O	O	O
and	O	O	O
other	O	O	B-Entity
brain	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

The	O	O	O
suppression	O	O	O
of	O	O	O
microglial	O	O	B-Entity
cells	O	O	I-Entity
using	O	O	O
natural	O	O	B-Entity
bioactive	O	O	B-Entity
compounds	O	O	I-Entity
has	O	O	O
become	O	O	O
increasingly	O	O	B-Entity
important	O	O	B-Entity
for	O	O	O
brain	O	O	B-Entity
therapy	O	O	I-Entity
owing	O	O	O
to	O	O	O
the	O	O	O
expected	O	O	O
beneficial	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
lower	O	O	B-Entity
toxicity	O	O	B-Entity
.	O	O	O

Scoparone	O	O	B-Entity
(	O	O	O
6,7-dimethoxycoumarin	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
major	O	O	O
bioactive	O	O	B-Entity
compound	O	O	I-Entity
found	O	O	B-Entity
in	O	O	O
various	O	O	O
plant	O	O	B-Entity
parts	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
inner	O	O	O
shell	O	O	B-Entity
of	O	O	O
chestnut	O	O	B-Entity
(	O	O	O
Castanea	O	O	B-Entity
crenata	O	O	I-Entity
)	O	O	O
,	O	O	O
was	O	O	O
evaluated	O	O	O
on	O	O	O
lipopolysaccharide	O	O	B-Entity
(LPS)-	O	O	O
activated	O	O	B-Entity
BV-2	O	O	B-Entity
microglia	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
scoparone	O	O	B-Entity
suppresses	O	O	B-Entity
the	O	O	O
LPS	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
increase	O	O	B-Entity
of	O	O	O
neuroinflammatory	O	O	B-Entity
responses	O	O	I-Entity
and	O	O	O
inhibited	O	O	B-Entity
the	O	O	O
pro-inflammatory	O	O	B-Entity
cytokine	O	O	B-Entity
production	O	O	O
in	O	O	O
the	O	O	O
BV-2	O	O	B-Entity
microglial	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

A	O	O	O
mechanistic	O	O	B-Entity
study	O	O	I-Entity
showed	O	O	O
that	O	O	O
scoparone	O	O	B-Entity
specifically	O	O	O
inhibited	O	O	B-Entity
the	O	O	O
LPS	O	O	B-Entity
-	O	O	O
stimulated	O	O	B-Entity
activation	O	O	B-Entity
via	O	O	O
a	O	O	O
major	O	O	O
regulation	O	O	B-Entity
of	O	O	O
IRF-3	O	O	B-Entity
and	O	O	O
a	O	O	O
regulation	O	O	O
of	O	O	O
ERK	O	O	B-Entity
,	O	O	O
whereby	O	O	O
the	O	O	O
phosphorylation	O	O	B-Entity
in	O	O	O
the	O	O	O
BV-2	O	O	B-Entity
microglial	O	O	I-Entity
cells	O	O	I-Entity
is	O	O	O
blocked	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
scoparone	O	O	B-Entity
has	O	O	O
anti-neuroinflammatory	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
LPS	O	O	B-Entity
-	O	O	O
activated	O	O	B-Entity
BV-2	O	O	B-Entity
microglial	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
could	O	O	O
possibly	O	O	O
be	O	O	O
used	O	O	B-Entity
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
novel	O	O	B-Entity
drugs	O	O	B-Entity
for	O	O	O
the	O	O	O
prevention	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
neuroinflammatory	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

-DOCSTART- (27987038)

Efficient	O	O	O
genome	O	O	B-Entity
editing	O	O	I-Entity
of	O	O	O
differentiated	O	O	B-Entity
renal	O	O	B-Entity
epithelial	O	O	O
cells	O	O	O

Recent	O	O	O
advances	O	O	O
in	O	O	O
genome	O	O	B-Entity
editing	O	O	I-Entity
technologies	O	O	I-Entity
have	O	O	O
enabled	O	O	O
the	O	O	O
rapid	O	O	O
and	O	O	O
precise	O	O	O
manipulation	O	O	B-Entity
of	O	O	I-Entity
genomes	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
targeted	O	O	B-Entity
introduction	O	O	I-Entity
,	O	O	O
alteration	O	O	B-Entity
,	O	O	O
and	O	O	O
removal	O	O	B-Entity
of	O	O	I-Entity
genomic	O	O	I-Entity
sequences	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
respective	O	O	O
methods	O	O	B-Entity
have	O	O	O
been	O	O	O
described	O	O	O
mainly	O	O	O
in	O	O	O
non-differentiated	O	O	B-Entity
or	O	O	O
haploid	O	O	B-Entity
cell	O	O	B-Entity
types	O	O	I-Entity
.	O	O	O

Genome	O	O	B-Entity
editing	O	O	I-Entity
of	O	O	O
well-differentiated	O	O	B-Entity
renal	O	O	B-Entity
epithelial	O	O	B-Entity
cells	O	O	I-Entity
has	O	O	O
been	O	O	O
hampered	O	O	O
by	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
technological	O	O	B-Entity
issues	O	O	I-Entity
,	O	O	O
including	O	O	O
optimal	O	O	B-Entity
design	O	O	B-Entity
,	O	O	O
efficient	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	I-Entity
multiple	O	O	I-Entity
genome	O	O	I-Entity
editing	O	O	I-Entity
constructs	O	O	I-Entity
,	O	O	O
attainable	O	O	B-Entity
mutation	O	O	B-Entity
rates	O	O	I-Entity
,	O	O	O
and	O	O	O
best	O	O	O
screening	O	O	B-Entity
strategies	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
an	O	O	O
easily	O	O	O
implementable	O	O	O
workflow	O	O	B-Entity
for	O	O	O
the	O	O	O
rapid	O	O	B-Entity
generation	O	O	B-Entity
of	O	O	I-Entity
targeted	O	O	I-Entity
heterozygous	O	O	I-Entity
and	O	O	I-Entity
homozygous	O	O	I-Entity
genomic	O	O	I-Entity
sequence	O	O	I-Entity
alterations	O	O	I-Entity
in	O	O	O
renal	O	O	B-Entity
cells	O	O	B-Entity
using	O	O	O
transcription	O	O	B-Entity
activator-like	O	O	I-Entity
effector	O	O	I-Entity
nucleases	O	O	I-Entity
(	O	O	O
TALENs	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
clustered	O	O	B-Entity
regularly	O	O	I-Entity
interspaced	O	O	I-Entity
short	O	O	I-Entity
palindromic	O	O	I-Entity
repeat	O	O	I-Entity
(	O	O	I-Entity
CRISPR	O	O	I-Entity
)	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

We	O	O	O
demonstrate	O	O	O
the	O	O	O
versatility	O	O	O
of	O	O	O
established	O	O	O
protocols	O	O	B-Entity
by	O	O	O
generating	O	O	B-Entity
novel	O	O	B-Entity
cellular	O	O	B-Entity
models	O	O	I-Entity
for	O	O	O
studying	O	O	B-Entity
autosomal	O	O	B-Entity
dominant	O	O	I-Entity
polycystic	O	O	I-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
ADPKD	O	O	B-Entity
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
cell	O	O	B-Entity
culture-validated	O	O	I-Entity
genetic	O	O	I-Entity
modifications	O	O	I-Entity
can	O	O	O
be	O	O	O
readily	O	O	O
applied	O	O	O
to	O	O	O
mouse	O	O	B-Entity
embryonic	O	O	I-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
mESCs	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
generation	O	O	B-Entity
of	O	O	O
corresponding	O	O	O
mouse	O	O	O
models	O	O	B-Entity
.	O	O	O

The	O	O	O
described	O	O	O
procedure	O	O	B-Entity
for	O	O	O
efficient	O	O	O
genome	O	O	B-Entity
editing	O	O	I-Entity
can	O	O	O
be	O	O	O
applied	O	O	O
to	O	O	O
any	O	O	O
cell	O	O	B-Entity
type	O	O	I-Entity
to	O	O	O
study	O	O	B-Entity
physiological	O	O	B-Entity
and	O	O	O
pathophysiological	O	O	B-Entity
functions	O	O	I-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
precisely	O	O	O
engineered	O	O	B-Entity
genotypes	O	O	I-Entity
.	O	O	O

-DOCSTART- (27988278)

Right	O	O	B-Entity
Ventricular	O	O	I-Entity
Response	O	O	B-Entity
During	O	O	B-Entity
Exercise	O	O	B-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Chronic	O	O	O
Obstructive	O	O	O
Pulmonary	O	O	O
Disease	O	O	O

Right	O	O	B-Entity
ventricular	O	O	I-Entity
(	O	O	O
RV	O	O	B-Entity
)	O	O	O
pump	O	O	B-Entity
function	O	O	I-Entity
is	O	O	O
of	O	O	O
essential	O	O	B-Entity
clinical	O	O	B-Entity
and	O	O	O
prognostic	O	O	B-Entity
importance	O	O	B-Entity
in	O	O	O
a	O	O	O
variety	O	O	B-Entity
of	O	O	O
heart	O	O	B-Entity
and	O	O	O
lung	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

While	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
RV	O	O	B-Entity
performance	O	O	B-Entity
at	O	O	O
rest	O	O	B-Entity
has	O	O	O
been	O	O	O
implemented	O	O	O
in	O	O	O
the	O	O	O
clinical	O	O	B-Entity
setting	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
unknown	O	O	O
whether	O	O	O
this	O	O	O
assessment	O	O	B-Entity
during	O	O	B-Entity
exercise	O	O	B-Entity
may	O	O	O
provide	O	O	O
additional	O	O	B-Entity
benefit	O	O	B-Entity
.	O	O	O

With	O	O	O
this	O	O	O
aim	O	O	B-Entity
,	O	O	O
we	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
pulmonary	O	O	B-Entity
arterial	O	O	I-Entity
systolic	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
PASP	O	O	B-Entity
)	O	O	O
increase	O	O	B-Entity
during	O	O	B-Entity
exercise	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
chronic	O	O	B-Entity
obstructive	O	O	I-Entity
pulmonary	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
COPD	O	O	B-Entity
)	O	O	O
as	O	O	O
an	O	O	O
expression	O	O	O
of	O	O	O
RV	O	O	B-Entity
contractile	O	O	B-Entity
reserve	O	O	I-Entity
.	O	O	O

Cardiopulmonary	O	O	B-Entity
exercise	O	O	I-Entity
testing	O	O	I-Entity
(	O	O	O
CPET	O	O	B-Entity
)	O	O	O
with	O	O	O
synchronic	O	O	B-Entity
echocardiography	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
in	O	O	O
81	O	O	O
patients	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
classified	O	O	B-Entity
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
according	O	O	O
to	O	O	O
an	O	O	O
exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PASP	O	O	B-Entity
increase	O	O	B-Entity
above	O	O	O
30mmHg	O	O	O
(	O	O	O
High	O	O	B-Entity
PSAP	O	O	B-Entity
)	O	O	O
or	O	O	O
below	O	O	O
30mmHg	O	O	O
(	O	O	O
Low	O	O	B-Entity
PSAP	O	O	O
)	O	O	O
during	O	O	B-Entity
maximal	O	O	B-Entity
exercise	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
then	O	O	O
followed	O	O	B-Entity
for	O	O	O
three	O	O	O
years	O	O	B-Entity
.	O	O	O

Sixteen	O	O	O
patients	O	O	B-Entity
(	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
low	O	O	B-Entity
PSAP	O	O	B-Entity
and	O	O	O
65	O	O	O
(	O	O	O
80	O	O	O
%	O	O	O
)	O	O	O
showed	O	O	O
high	O	O	B-Entity
PSAP	O	O	O
.	O	O	O

These	O	O	O
were	O	O	O
not	O	O	B-Entity
significant	O	O	I-Entity
clinical	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
differences	O	O	B-Entity
.	O	O	O

Low	O	O	B-Entity
PSAP	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
peak	O	O	B-Entity
VO2	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
,	O	O	O
35	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
%	O	O	O
predicted	O	O	B-Entity
)	O	O	O
compared	O	O	B-Entity
to	O	O	O
high	O	O	B-Entity
PSAP	O	O	O
response	O	O	B-Entity
(	O	O	O
peak	O	O	O
VO2	O	O	O
45	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
%	O	O	O
predicted	O	O	O
)	O	O	O
,	O	O	O
p=0.045	O	O	O
.	O	O	O

Factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
mortality	O	O	B-Entity
were	O	O	O
age	O	O	B-Entity
and	O	O	O
exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PASP	O	O	B-Entity
.	O	O	O

Seventeen	O	O	O
patients	O	O	B-Entity
died	O	O	O
during	O	O	B-Entity
the	O	O	O
three	O	O	O
years	O	O	B-Entity
of	O	O	O
follow-up	O	O	B-Entity
(	O	O	O
7	O	O	O
(	O	O	O
39	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
low	O	O	B-Entity
PSAP	O	O	B-Entity
group	O	O	B-Entity
and	O	O	O
only	O	O	O
10	O	O	O
(	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
high	O	O	B-Entity
PSAP	O	O	O
group	O	O	O
,	O	O	O
p=0.041	O	O	O
)	O	O	O
.	O	O	O

Cardiopulmonary	O	O	B-Entity
exercise	O	O	I-Entity
testing	O	O	I-Entity
with	O	O	O
a	O	O	O
synchronic	O	O	B-Entity
echocardiography	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	O
tool	O	O	O
for	O	O	O
the	O	O	O
assessment	O	O	B-Entity
of	O	O	O
RV	O	O	B-Entity
contractile	O	O	B-Entity
reserve	O	O	I-Entity
in	O	O	O
severe	O	O	B-Entity
COPD	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Exercise	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PSAP	O	O	B-Entity
emerges	O	O	O
as	O	O	O
a	O	O	O
possible	O	O	O
prognostic	O	O	B-Entity
factor	O	O	I-Entity
in	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (27989992)

Adverse	O	O	B-Entity
outcomes	O	O	I-Entity
in	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
attending	O	O	B-Entity
emergency	O	O	B-Entity
departments	O	O	I-Entity
:	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
Identification	O	O	O
of	O	O	O
Seniors	O	O	O
At	O	O	O
Risk	O	O	O
(	O	O	O
ISAR	O	O	O
)	O	O	O
screening	O	O	O
tool	O	O	O

older	O	O	B-Entity
adults	O	O	I-Entity
are	O	O	O
frequent	O	O	B-Entity
users	O	O	O
of	O	O	O
emergency	O	O	B-Entity
services	O	O	I-Entity
and	O	O	O
demonstrate	O	O	O
high	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
adverse	O	O	B-Entity
outcomes	O	O	I-Entity
following	O	O	O
emergency	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

to	O	O	O
perform	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
and	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
Identification	O	O	B-Entity
of	O	O	I-Entity
Seniors	O	O	I-Entity
At	O	O	I-Entity
Risk	O	O	I-Entity
(	O	O	I-Entity
ISAR	O	O	I-Entity
)	O	O	I-Entity
screening	O	O	I-Entity
tool	O	O	I-Entity
,	O	O	O
to	O	O	O
determine	O	O	O
its	O	O	O
predictive	O	O	B-Entity
value	O	O	I-Entity
in	O	O	O
identifying	O	O	O
adults	O	O	B-Entity
≥65	O	O	O
years	O	O	B-Entity
at	O	O	O
risk	O	O	B-Entity
of	O	O	O
functional	O	O	B-Entity
decline	O	O	I-Entity
,	O	O	O
unplanned	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
(	O	O	I-Entity
ED	O	O	I-Entity
)	O	O	I-Entity
readmission	O	O	I-Entity
,	O	O	O
emergency	O	O	O
hospitalisation	O	O	B-Entity
or	O	O	O
death	O	O	B-Entity
within	O	O	O
180	O	O	O
days	O	O	B-Entity
after	O	O	O
index	O	O	O
ED	O	O	B-Entity
visit	O	O	I-Entity
/	O	O	O
hospitalisation	O	O	O
.	O	O	O
a	O	O	O
systematic	O	O	O
literature	O	O	B-Entity
search	O	O	B-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
PubMed	O	O	B-Entity
,	O	O	O
EMBASE	O	O	B-Entity
,	O	O	O
CINAHL	O	O	B-Entity
,	O	O	O
EBSCO	O	O	B-Entity
and	O	O	O
the	O	O	O
Cochrane	O	O	B-Entity
Library	O	O	I-Entity
to	O	O	O
identify	O	O	O
validation	O	O	B-Entity
and	O	O	O
impact	O	O	B-Entity
analysis	O	O	B-Entity
studies	O	O	O
of	O	O	O
the	O	O	O
ISAR	O	O	B-Entity
tool	O	O	I-Entity
.	O	O	O

A	O	O	O
pre-specified	O	O	B-Entity
ISAR	O	O	B-Entity
score	O	O	B-Entity
of	O	O	O
≥2	O	O	O
(	O	O	O
maximum	O	O	O
score	O	O	O
6	O	O	O
points	O	O	O
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
identify	O	O	O
patients	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
adverse	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

A	O	O	O
bivariate	O	O	B-Entity
random	O	O	I-Entity
effects	O	O	I-Entity
model	O	O	I-Entity
generated	O	O	O
pooled	O	O	B-Entity
estimates	O	O	B-Entity
of	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
.	O	O	O

Statistical	O	O	B-Entity
heterogeneity	O	O	I-Entity
was	O	O	O
explored	O	O	O
and	O	O	O
methodological	O	O	B-Entity
quality	O	O	I-Entity
was	O	O	O
assessed	O	O	O
using	O	O	O
validated	O	O	B-Entity
criteria	O	O	I-Entity
.	O	O	O

thirty-two	O	O	O
validation	O	O	B-Entity
studies	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
12,939	O	O	O
)	O	O	O
are	O	O	O
included	O	O	B-Entity
.	O	O	O

At	O	O	O
≥2	O	O	O
,	O	O	O
the	O	O	O
pooled	O	O	B-Entity
sensitivity	O	O	B-Entity
of	O	O	O
the	O	O	O
ISAR	O	O	B-Entity
for	O	O	O
predicting	O	O	O
ED	O	O	B-Entity
return	O	O	B-Entity
,	O	O	O
emergency	O	O	B-Entity
hospitalisation	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
at	O	O	O
6	O	O	O
months	O	O	B-Entity
is	O	O	O
0.80	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
0.70	O	O	O
-	O	O	O
0.87	O	O	O
)	O	O	O
,	O	O	O
0.82	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.74	O	O	O
-	O	O	O
0.88	O	O	O
)	O	O	O
and	O	O	O
0.87	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.75	O	O	O
-	O	O	O
0.94	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
a	O	O	O
pooled	O	O	O
specificity	O	O	B-Entity
of	O	O	O
0.31	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.24	O	O	O
-	O	O	O
0.38	O	O	O
)	O	O	O
,	O	O	O
0.32	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.24	O	O	O
-	O	O	O
0.41	O	O	O
)	O	O	O
and	O	O	O
0.35	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.26	O	O	O
-	O	O	O
0.44	O	O	O
)	O	O	O
.	O	O	O

Similar	O	O	O
values	O	O	B-Entity
are	O	O	O
demonstrated	O	O	O
at	O	O	O
30	O	O	O
and	O	O	O
90	O	O	O
days	O	O	B-Entity
.	O	O	O

Three	O	O	O
heterogeneous	O	O	B-Entity
impact	O	O	B-Entity
analysis	O	O	B-Entity
studies	O	O	O
examined	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
implementation	O	O	B-Entity
of	O	O	O
the	O	O	O
ISAR	O	O	B-Entity
and	O	O	O
reported	O	O	O
mixed	O	O	B-Entity
findings	O	O	I-Entity
across	O	O	O
patient	O	O	B-Entity
and	O	O	O
process	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

the	O	O	O
ISAR	O	O	B-Entity
has	O	O	O
modest	O	O	O
predictive	O	O	B-Entity
accuracy	O	O	B-Entity
and	O	O	O
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
decision-making	O	O	B-Entity
adjunct	O	O	B-Entity
when	O	O	O
determining	O	O	O
which	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
can	O	O	O
be	O	O	O
safely	O	O	O
discharged	O	O	B-Entity
.	O	O	O

-DOCSTART- (27991947)

Ecohydrological	O	O	B-Entity
modeling	O	O	I-Entity
and	O	O	O
environmental	O	O	B-Entity
flow	O	O	B-Entity
regime	O	O	B-Entity
in	O	O	O
the	O	O	O
Formoso	O	O	B-Entity
River	O	O	I-Entity
,	O	O	O
Minas	O	O	B-Entity
Gerais	O	O	I-Entity
State	O	O	I-Entity
,	O	O	O
Brazil	O	O	O

This	O	O	O
paper	O	O	B-Entity
aimed	O	O	O
at	O	O	O
determining	O	O	B-Entity
the	O	O	O
environmental	O	O	B-Entity
flow	O	O	B-Entity
regime	O	O	O
in	O	O	O
a	O	O	O
1	O	O	B-Entity
km	O	O	I-Entity
stretch	O	O	B-Entity
of	O	O	O
the	O	O	O
Formoso	O	O	B-Entity
River	O	O	I-Entity
,	O	O	O
MG	O	O	B-Entity
,	O	O	O
using	O	O	O
River2D	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

To	O	O	O
carry	O	O	O
out	O	O	O
the	O	O	O
ecohydrological	O	O	B-Entity
modeling	O	O	I-Entity
,	O	O	O
the	O	O	O
following	O	O	B-Entity
information	O	O	B-Entity
was	O	O	O
used	O	O	O
:	O	O	O
bathymetry	O	O	B-Entity
,	O	O	O
physical	O	O	B-Entity
and	O	O	O
hydraulic	O	O	B-Entity
features	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
Habitat	O	O	B-Entity
Suitability	O	O	B-Entity
Index	O	O	I-Entity
for	O	O	O
species	O	O	B-Entity
of	O	O	O
the	O	O	O
Hypostomus	O	O	B-Entity
auroguttatus	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
River2D	O	O	B-Entity
,	O	O	O
the	O	O	O
Weighted	O	O	B-Entity
Usable	O	O	B-Entity
Areas	O	O	B-Entity
were	O	O	O
determined	O	O	B-Entity
from	O	O	O
the	O	O	O
average	O	O	B-Entity
long-term	O	O	B-Entity
streamflows	O	O	B-Entity
with	O	O	O
percentage	O	O	B-Entity
from	O	O	O
10	O	O	O
%	O	O	O
to	O	O	O
100	O	O	O
%	O	O	O
.	O	O	O

Those	O	O	O
streamflows	O	O	B-Entity
were	O	O	O
simulated	O	O	O
for	O	O	O
the	O	O	O
later	O	O	B-Entity
construction	O	O	B-Entity
of	O	O	O
optimization	O	O	B-Entity
matrices	O	O	B-Entity
that	O	O	O
maximize	O	O	B-Entity
the	O	O	O
habitat	O	O	B-Entity
area	O	O	B-Entity
throughout	O	O	B-Entity
the	O	O	O
year	O	O	B-Entity
.	O	O	O

For	O	O	O
H.	O	O	B-Entity
auroguttatus	O	O	I-Entity
Juvenile	O	O	B-Entity
,	O	O	O
higher	O	O	B-Entity
values	O	O	B-Entity
of	O	O	O
Weighted	O	O	B-Entity
Usable	O	O	B-Entity
Area	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
60	O	O	O
%	O	O	O
and	O	O	O
70	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
average	O	O	B-Entity
long-term	O	O	B-Entity
streamflows	O	O	B-Entity
in	O	O	O
October	O	O	B-Entity
and	O	O	O
September	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

For	O	O	O
H.	O	O	B-Entity
auroguttatus	O	O	I-Entity
Adult	O	O	B-Entity
,	O	O	O
the	O	O	O
highest	O	O	B-Entity
value	O	O	B-Entity
of	O	O	O
Weighted	O	O	B-Entity
Usable	O	O	B-Entity
Area	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
100	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
average	O	O	B-Entity
long-term	O	O	B-Entity
streamflow	O	O	B-Entity
in	O	O	O
September	O	O	B-Entity
.	O	O	O

The	O	O	O
environmental	O	O	B-Entity
flows	O	O	B-Entity
found	O	O	B-Entity
for	O	O	O
this	O	O	O
stretch	O	O	B-Entity
of	O	O	O
the	O	O	O
Formoso	O	O	B-Entity
River	O	O	I-Entity
varied	O	O	B-Entity
over	O	O	B-Entity
the	O	O	O
year	O	O	B-Entity
.	O	O	O

The	O	O	O
lowest	O	O	B-Entity
environmental	O	O	B-Entity
flow	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
in	O	O	O
December	O	O	B-Entity
(	O	O	O
2.85	O	O	O
m3	O	O	O
s-1	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
highest	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
May	O	O	B-Entity
(	O	O	O
4.13	O	O	O
m3	O	O	O
s-1	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
paper	O	O	B-Entity
shows	O	O	O
the	O	O	O
importance	O	O	B-Entity
of	O	O	O
ecohydrological	O	O	B-Entity
studies	O	O	I-Entity
in	O	O	O
forming	O	O	B-Entity
a	O	O	O
basis	O	O	B-Entity
for	O	O	O
water	O	O	B-Entity
resources	O	O	I-Entity
management	O	O	B-Entity
actions	O	O	B-Entity
.	O	O	O

-DOCSTART- (27992983)

Risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
infection	O	O	I-Entity
in	O	O	O
the	O	O	O
Colombian	O	O	B-Entity
Caribbean	O	O	B-Entity
coast	O	O	I-Entity
:	O	O	O
A	O	O	O
case-control	O	O	O
study	O	O	O

An	O	O	O
estimated	O	O	O
6.8	O	O	O
-	O	O	O
8.9	O	O	O
million	O	O	B-Entity
people	O	O	B-Entity
are	O	O	O
infected	O	O	B-Entity
with	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
in	O	O	O
Latin	O	O	B-Entity
America	O	O	I-Entity
,	O	O	O
of	O	O	O
which	O	O	O
less	O	O	B-Entity
than	O	O	I-Entity
1	O	O	O
%	O	O	O
receives	O	O	O
antiviral	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Studies	O	O	B-Entity
so	O	O	O
far	O	O	O
in	O	O	O
Colombia	O	O	B-Entity
have	O	O	O
attempted	O	O	B-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
in	O	O	O
some	O	O	O
risk	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
thus	O	O	O
preventing	O	O	B-Entity
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
other	O	O	O
factors	O	O	B-Entity
potentially	O	O	B-Entity
involved	O	O	O
in	O	O	O
the	O	O	O
spread	O	O	O
of	O	O	O
the	O	O	O
infection	O	O	B-Entity
.	O	O	O

To	O	O	O
identify	O	O	B-Entity
traditional	O	O	O
and	O	O	O
non-traditional	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
chronic	O	O	B-Entity
hepatitis	O	O	I-Entity
C	O	O	I-Entity
in	O	O	O
the	O	O	O
Colombian	O	O	B-Entity
Caribbean	O	O	B-Entity
coast	O	O	I-Entity
.	O	O	O

This	O	O	O
was	O	O	O
a	O	O	O
case-control	O	O	B-Entity
study	O	O	I-Entity
(	O	O	O
1:3	O	O	O
)	O	O	O
matched	O	O	O
by	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
provider	O	O	I-Entity
and	O	O	O
age	O	O	B-Entity
(	O	O	O
±	O	O	O
10	O	O	O
years	O	O	B-Entity
)	O	O	O
conducted	O	O	O
at	O	O	O
the	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
level	O	O	I-Entity
of	O	O	O
gastroenterology	O	O	B-Entity
and	O	O	O
hepatology	O	O	B-Entity
outpatient	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
positive	O	O	B-Entity
ELISA	O	O	B-Entity
underwent	O	O	O
a	O	O	O
confirmatory	O	O	B-Entity
viral	O	O	B-Entity
load	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

A	O	O	O
multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
identified	O	O	B-Entity
the	O	O	O
independent	O	O	B-Entity
predictors	O	O	I-Entity
of	O	O	O
infection	O	O	B-Entity
.	O	O	O

Blood	O	O	B-Entity
transfusion	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
159.2	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
35.4	O	O	O
-	O	O	O
715	O	O	O
;	O	O	O
p<0.001	O	O	O
)	O	O	O
and	O	O	O
history	O	O	B-Entity
of	O	O	I-Entity
hospitalization	O	O	I-Entity
before	O	O	O
1994	O	O	O
(	O	O	O
OR	O	O	O
=	O	O	O
4.7	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.3	O	O	O
-	O	O	O
17.1	O	O	O
;	O	O	O
p=0.018	O	O	O
)	O	O	O
were	O	O	O
identified	O	O	B-Entity
as	O	O	O
the	O	O	O
only	O	O	O
two	O	O	O
independent	O	O	B-Entity
predictors	O	O	I-Entity
of	O	O	O
infection	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
necessary	O	O	O
to	O	O	O
check	O	O	O
the	O	O	O
reproducibility	O	O	B-Entity
of	O	O	I-Entity
these	O	O	I-Entity
results	O	O	I-Entity
and	O	O	O
to	O	O	O
conduct	O	O	O
cost-effectiveness	O	O	B-Entity
studies	O	O	B-Entity
before	O	O	O
recommending	O	O	B-Entity
their	O	O	O
use	O	O	B-Entity
in	O	O	O
the	O	O	O
design	O	O	B-Entity
of	O	O	O
new	O	O	B-Entity
screening	O	O	I-Entity
strategies	O	O	I-Entity
.	O	O	O

-DOCSTART- (27993519)

Quo	O	O	O
vadis	O	O	O
G	O	O	B-Entity
protein-coupled	O	O	I-Entity
receptor	O	O	I-Entity
ligands	O	O	I-Entity
?	O	O	O
A	O	O	O
tool	O	O	O
for	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
emergence	O	O	B-Entity
of	O	O	O
new	O	O	O
groups	O	O	B-Entity
of	O	O	O
compounds	O	O	B-Entity
over	O	O	O
time	O	O	O

A	O	O	O
tool	O	O	O
for	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
emergence	O	O	B-Entity
of	O	O	O
new	O	O	O
groups	O	O	B-Entity
of	O	O	O
compounds	O	O	B-Entity
over	O	O	B-Entity
time	O	O	I-Entity
Exponential	O	O	B-Entity
growth	O	O	B-Entity
in	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
compounds	O	O	O
with	O	O	O
experimentally	O	O	B-Entity
verified	O	O	B-Entity
activity	O	O	B-Entity
towards	O	O	O
particular	O	O	O
target	O	O	B-Entity
has	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
emergence	O	O	O
of	O	O	O
various	O	O	O
databases	O	O	B-Entity
gathering	O	O	O
data	O	O	B-Entity
on	O	O	O
biological	O	O	B-Entity
activity	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
ligands	O	O	B-Entity
of	O	O	O
family	O	O	B-Entity
A	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
G	O	O	I-Entity
Protein-Coupled	O	O	I-Entity
Receptors	O	O	I-Entity
that	O	O	O
are	O	O	O
collected	O	O	B-Entity
in	O	O	O
the	O	O	O
ChEMBL	O	O	B-Entity
database	O	O	I-Entity
were	O	O	O
examined	O	O	B-Entity
,	O	O	O
and	O	O	O
special	O	O	O
attention	O	O	O
was	O	O	O
given	O	O	O
to	O	O	O
serotonin	O	O	B-Entity
receptors	O	O	I-Entity
.	O	O	O

Sets	O	O	B-Entity
of	O	O	O
compounds	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
their	O	O	O
appearance	O	O	B-Entity
over	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
they	O	O	O
were	O	O	O
mapped	O	O	B-Entity
to	O	O	O
the	O	O	O
chemical	O	O	B-Entity
space	O	O	I-Entity
of	O	O	O
drugs	O	O	B-Entity
deposited	O	O	O
in	O	O	O
DrugBank	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
emergence	O	O	B-Entity
of	O	O	O
structurally	O	O	B-Entity
new	O	O	I-Entity
clusters	O	O	I-Entity
of	O	O	I-Entity
compounds	O	O	I-Entity
was	O	O	O
indicated	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
a	O	O	O
tool	O	O	O
for	O	O	O
detailed	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
obtained	O	O	B-Entity
visualizations	O	O	B-Entity
was	O	O	O
prepared	O	O	B-Entity
and	O	O	O
made	O	O	O
available	O	O	B-Entity
online	O	O	B-Entity
at	O	O	O
http://chem.gmum.net/vischem	O	O	B-Entity
,	O	O	O
which	O	O	O
enables	O	O	O
the	O	O	O
investigation	O	O	B-Entity
of	O	O	O
chemical	O	O	B-Entity
structures	O	O	I-Entity
while	O	O	O
referring	O	O	B-Entity
to	O	O	O
particular	O	O	O
data	O	O	B-Entity
points	O	O	I-Entity
depicted	O	O	O
in	O	O	O
the	O	O	O
figures	O	O	B-Entity
and	O	O	O
changes	O	O	B-Entity
in	O	O	O
compounds	O	O	B-Entity
datasets	O	O	B-Entity
over	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

-DOCSTART- (27995352)

Diabetes	O	O	B-Entity
and	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
in	O	O	O
Black	O	O	O
women	O	O	O

Breast	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
is	O	O	O
higher	O	O	O
in	O	O	O
Black	O	O	B-Entity
women	O	O	I-Entity
than	O	O	O
in	O	O	O
White	O	O	B-Entity
women	O	O	I-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
is	O	O	O
also	O	O	O
higher	O	O	O
,	O	O	O
yet	O	O	O
data	O	O	B-Entity
on	O	O	O
whether	O	O	O
diabetes	O	O	O
affects	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
are	O	O	O
lacking	O	O	B-Entity
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
relation	O	O	O
of	O	O	O
diabetes	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
diagnosis	O	O	B-Entity
to	O	O	O
breast	O	O	O
cancer	O	O	O
mortality	O	O	B-Entity
in	O	O	O
the	O	O	O
Black	O	O	B-Entity
Women	O	O	I-Entity
's	O	O	I-Entity
Health	O	O	B-Entity
Study	O	O	B-Entity
,	O	O	O
a	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

1,621	O	O	O
Black	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
invasive	O	O	B-Entity
breast	O	O	B-Entity
cancer	O	O	I-Entity
diagnosed	O	O	B-Entity
in	O	O	O
1995	O	O	O
-	O	O	O
2013	O	O	O
were	O	O	O
followed	O	O	B-Entity
by	O	O	I-Entity
mailed	O	O	O
questionnaires	O	O	B-Entity
and	O	O	O
searches	O	O	O
of	O	O	O
the	O	O	O
National	O	O	B-Entity
Death	O	O	I-Entity
Index	O	O	I-Entity
.	O	O	O

Multivariable	O	O	B-Entity
Cox	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
compute	O	O	O
hazard	O	O	B-Entity
ratios	O	O	I-Entity
(	O	O	O
HRs	O	O	B-Entity
)	O	O	O
for	O	O	O
diabetes	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
and	O	O	O
all-cause	O	O	O
mortality	O	O	O
,	O	O	O
with	O	O	O
adjustment	O	O	O
for	O	O	O
age	O	O	B-Entity
,	O	O	O
stage	O	O	B-Entity
,	O	O	O
treatment	O	O	B-Entity
modality	O	O	I-Entity
,	O	O	O
estrogen	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
ER	O	O	B-Entity
)	O	O	O
status	O	O	B-Entity
,	O	O	O
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
368	O	O	O
deaths	O	O	B-Entity
during	O	O	O
follow-up	O	O	B-Entity
,	O	O	O
of	O	O	O
which	O	O	O
273	O	O	O
were	O	O	O
due	O	O	O
to	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Breast	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
increased	O	O	I-Entity
in	O	O	O
women	O	O	B-Entity
who	O	O	O
had	O	O	O
been	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
at	O	O	O
least	O	O	O
5	O	O	O
years	O	O	O
before	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
occurrence	O	O	B-Entity
,	O	O	O
HR	O	O	B-Entity
1.86	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.20	O	O	O
-	O	O	O
2.89	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
elevations	O	O	B-Entity
observed	O	O	B-Entity
for	O	O	O
both	O	O	O
ER+	O	O	B-Entity
and	O	O	O
ER-	O	O	B-Entity
breast	O	O	O
cancer	O	O	O
.	O	O	O

All-cause	O	O	O
mortality	O	O	B-Entity
was	O	O	O
also	O	O	O
higher	O	O	O
in	O	O	O
diabetics	O	O	B-Entity
,	O	O	O
with	O	O	O
HRs	O	O	B-Entity
of	O	O	O
1.54	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.12	O	O	O
-	O	O	O
2.07	O	O	O
)	O	O	O
overall	O	O	B-Entity
and	O	O	O
2.26	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.62	O	O	O
-	O	O	O
3.15	O	O	O
)	O	O	O
for	O	O	O
≥5-year	O	O	O
duration	O	O	O
of	O	O	O
diabetes	O	O	B-Entity
relative	O	O	B-Entity
to	O	O	O
non-diabetics	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
present	O	O	B-Entity
the	O	O	O
first	O	O	O
solid	O	O	O
evidence	O	O	B-Entity
of	O	O	O
a	O	O	O
positive	O	O	B-Entity
association	O	O	O
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
with	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
in	O	O	O
Black	O	O	B-Entity
women	O	O	I-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
higher	O	O	O
prevalence	O	O	B-Entity
and	O	O	O
earlier	O	O	B-Entity
onset	O	O	I-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	B-Entity
in	O	O	O
Black	O	O	B-Entity
women	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
likely	O	O	O
that	O	O	O
diabetes	O	O	O
contributes	O	O	B-Entity
to	O	O	O
racial	O	O	B-Entity
disparities	O	O	B-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
.	O	O	O

-DOCSTART- (27998307)

Neuro-Behcet	O	O	B-Entity
disease	O	O	I-Entity
presenting	O	O	B-Entity
as	O	O	O
a	O	O	O
solitary	O	O	O
cerebellar	O	O	B-Entity
hemorrhagic	O	O	I-Entity
lesion	O	O	B-Entity
:	O	O	O
a	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
and	O	O	O
review	O	O	O
of	O	O	O
the	O	O	O
literature	O	O	O

Behcet	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
is	O	O	O
a	O	O	O
heterogeneous	O	O	B-Entity
,	O	O	O
multisystem	O	O	B-Entity
,	O	O	O
inflammatory	O	O	B-Entity
disorder	O	O	I-Entity
of	O	O	O
unknown	O	O	B-Entity
etiology	O	O	I-Entity
.	O	O	O

The	O	O	O
classic	O	O	O
triad	O	O	O
of	O	O	O
oral	O	O	B-Entity
and	O	O	O
genital	O	O	B-Entity
ulcerations	O	O	I-Entity
in	O	O	O
conjunction	O	O	B-Entity
with	O	O	O
uveitis	O	O	B-Entity
was	O	O	O
originally	O	O	O
described	O	O	B-Entity
by	O	O	O
the	O	O	O
Turkish	O	O	B-Entity
dermatologist	O	O	B-Entity
Hulusi	O	O	O
Behcet	O	O	O
in	O	O	O
1937	O	O	O
,	O	O	O
but	O	O	O
associated	O	O	B-Entity
symptoms	O	O	I-Entity
of	O	O	O
the	O	O	O
cardiovascular	O	O	B-Entity
,	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
,	O	O	O
pulmonary	O	O	B-Entity
,	O	O	O
and	O	O	O
gastrointestinal	O	O	B-Entity
systems	O	O	I-Entity
were	O	O	O
later	O	O	O
identified	O	O	B-Entity
.	O	O	O

In	O	O	O
fact	O	O	O
,	O	O	O
Behcet	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
with	O	O	O
neurological	O	O	B-Entity
involvement	O	O	I-Entity
(	O	O	O
neuro-Behcet	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
)	O	O	O
is	O	O	O
not	O	O	O
uncommon	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
neuro-Behcet	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
typically	O	O	O
exhibit	O	O	O
a	O	O	O
diverse	O	O	O
array	O	O	O
of	O	O	O
symptoms	O	O	B-Entity
,	O	O	O
most	O	O	B-Entity
commonly	O	O	B-Entity
in	O	O	O
the	O	O	O
brainstem	O	O	B-Entity
and	O	O	O
diencephalic	O	O	B-Entity
regions	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
report	O	O	B-Entity
an	O	O	O
unusual	O	O	B-Entity
case	O	O	B-Entity
of	O	O	O
neuro-Behcet	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
who	O	O	O
presented	O	O	B-Entity
with	O	O	O
a	O	O	O
solitary	O	O	O
cerebellar	O	O	B-Entity
hemorrhage	O	O	I-Entity
.	O	O	O

A	O	O	O
39-year-old	O	O	B-Entity
Asian	O	O	B-Entity
woman	O	O	B-Entity
was	O	O	O
admitted	O	O	B-Entity
to	O	O	O
our	O	O	O
hospital	O	O	B-Entity
with	O	O	O
complaints	O	O	B-Entity
of	O	O	O
a	O	O	O
sudden	O	O	B-Entity
speech	O	O	B-Entity
difficulty	O	O	I-Entity
that	O	O	O
had	O	O	O
manifested	O	O	B-Entity
the	O	O	O
same	O	O	B-Entity
morning	O	O	B-Entity
,	O	O	O
and	O	O	O
dizziness	O	O	B-Entity
and	O	O	O
mild	O	O	B-Entity
vomiting	O	O	B-Entity
experienced	O	O	O
over	O	O	B-Entity
the	O	O	O
previous	O	O	B-Entity
3	O	O	O
days	O	O	B-Entity
.	O	O	O

Magnetic	O	O	B-Entity
resonance	O	O	I-Entity
images	O	O	I-Entity
revealed	O	O	B-Entity
target-like	O	O	O
hemorrhagic	O	O	B-Entity
lesions	O	O	B-Entity
in	O	O	O
the	O	O	O
right	O	O	B-Entity
hemisphere	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
cerebellum	O	O	I-Entity
.	O	O	O

Risk	O	O	B-Entity
factors	O	O	I-Entity
that	O	O	O
may	O	O	O
result	O	O	B-Entity
in	O	O	O
cerebellar	O	O	B-Entity
hemorrhage	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
high	O	O	B-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
or	O	O	O
bleeding	O	O	B-Entity
diathesis	O	O	I-Entity
,	O	O	O
were	O	O	O
ruled	O	O	B-Entity
out	O	O	I-Entity
,	O	O	O
and	O	O	O
subsequent	O	O	B-Entity
brain	O	O	B-Entity
angiograms	O	O	B-Entity
were	O	O	O
normal	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
cerebellar	O	O	B-Entity
hemorrhage	O	O	I-Entity
could	O	O	O
have	O	O	O
been	O	O	O
due	O	O	B-Entity
to	O	O	I-Entity
intracranial	O	O	B-Entity
vasculitis	O	O	B-Entity
in	O	O	O
a	O	O	O
rare	O	O	B-Entity
,	O	O	O
if	O	O	O
not	O	O	O
unique	O	O	O
,	O	O	O
complication	O	O	B-Entity
of	O	O	O
neuro-Behcet	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

-DOCSTART- (27999011)

Intrinsic	O	O	B-Entity
rifamycin	O	O	B-Entity
resistance	O	O	B-Entity
of	O	O	O
Mycobacterium	O	O	B-Entity
abscessus	O	O	I-Entity
is	O	O	O
mediated	O	O	O
by	O	O	O
ADP-ribosyltransferase	O	O	B-Entity
MAB_0591	O	O	O

Rifampicin	O	O	B-Entity
,	O	O	O
a	O	O	O
potent	O	O	O
first-line	O	O	O
TB	O	O	B-Entity
drug	O	O	I-Entity
of	O	O	O
the	O	O	O
rifamycin	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
shows	O	O	O
only	O	O	O
little	O	O	O
activity	O	O	B-Entity
against	O	O	O
the	O	O	O
emerging	O	O	O
pathogen	O	O	B-Entity
Mycobacterium	O	O	B-Entity
abscessus	O	O	I-Entity
.	O	O	O

Reportedly	O	O	O
,	O	O	O
bacterial	O	O	B-Entity
resistance	O	O	I-Entity
to	O	O	O
rifampicin	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
polymorphisms	O	O	B-Entity
in	O	O	O
the	O	O	O
target	O	O	O
gene	O	O	B-Entity
rpoB	O	O	I-Entity
or	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
enzymes	O	O	B-Entity
that	O	O	O
modify	O	O	O
and	O	O	O
thereby	O	O	O
inactivate	O	O	O
rifampicin	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
MAB_0591	O	O	B-Entity
(arrMab)-encoded	O	O	O
rifampicin	O	O	B-Entity
ADP-ribosyltransferase	O	O	B-Entity
(	O	O	O
Arr_Mab	O	O	B-Entity
)	O	O	O
in	O	O	O
innate	O	O	O
high-level	O	O	O
rifampicin	O	O	O
resistance	O	O	B-Entity
in	O	O	O
M.	O	O	B-Entity
abscessus	O	O	I-Entity
.	O	O	O

Recombinant	O	O	B-Entity
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
and	O	O	O
Mycobacterium	O	O	B-Entity
tuberculosis	O	O	I-Entity
strains	O	O	B-Entity
expressing	O	O	B-Entity
MAB_0591	O	O	B-Entity
were	O	O	O
generated	O	O	O
,	O	O	O
as	O	O	O
was	O	O	O
an	O	O	O
M.	O	O	B-Entity
abscessus	O	O	I-Entity
deletion	O	O	B-Entity
mutant	O	O	I-Entity
deficient	O	O	B-Entity
for	O	O	O
MAB_0591	O	O	O
.	O	O	O

MIC	O	O	B-Entity
assays	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
study	O	O	O
susceptibility	O	O	B-Entity
to	O	O	O
rifampicin	O	O	B-Entity
and	O	O	O
C25	O	O	B-Entity
carbamate	O	O	I-Entity
-modified	O	O	O
rifamycin	O	O	B-Entity
derivatives	O	O	I-Entity
.	O	O	O

Heterologous	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
MAB_0591	O	O	B-Entity
conferred	O	O	O
rifampicin	O	O	B-Entity
resistance	O	O	B-Entity
to	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
and	O	O	O
M.	O	O	B-Entity
tuberculosis	O	O	I-Entity
Rifamycin	O	O	B-Entity
MIC	O	O	B-Entity
values	O	O	I-Entity
were	O	O	O
consistently	O	O	O
lower	O	O	O
for	O	O	O
the	O	O	O
M.	O	O	B-Entity
abscessus	O	O	I-Entity
ΔarrMab	O	O	B-Entity
mutant	O	O	I-Entity
as	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
M.	O	O	B-Entity
abscessus	O	O	I-Entity
ATCC	O	O	I-Entity
19977	O	O	I-Entity
parental	O	O	B-Entity
type	O	O	I-Entity
strain	O	O	I-Entity
.	O	O	O

The	O	O	O
rifamycin	O	O	B-Entity
WT	O	O	B-Entity
phenotype	O	O	B-Entity
was	O	O	O
restored	O	O	O
after	O	O	O
complementation	O	O	B-Entity
of	O	O	O
the	O	O	O
M.	O	O	B-Entity
abscessus	O	O	I-Entity
ΔarrMab	O	O	B-Entity
mutant	O	O	I-Entity
with	O	O	O
arrMab	O	O	B-Entity
Further	O	O	O
MIC	O	O	B-Entity
data	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
a	O	O	O
C25	O	O	B-Entity
modification	O	O	B-Entity
increases	O	O	O
rifamycin	O	O	O
activity	O	O	B-Entity
in	O	O	O
WT	O	O	O
M.	O	O	O
abscessus	O	O	O
However	O	O	O
,	O	O	O
MIC	O	O	B-Entity
studies	O	O	I-Entity
in	O	O	O
the	O	O	O
M.	O	O	O
abscessus	O	O	O
ΔarrMab	O	O	O
mutant	O	O	O
suggest	O	O	O
that	O	O	O
C25	O	O	O
modified	O	O	O
rifamycins	O	O	B-Entity
are	O	O	O
still	O	O	O
subject	O	O	O
to	O	O	O
modification	O	O	O
by	O	O	O
Arr_Mab	O	O	B-Entity
CONCLUSIONS	O	O	O
:	O	O	O
Our	O	O	O
findings	O	O	O
identify	O	O	O
Arr_Mab	O	O	O
as	O	O	O
the	O	O	O
major	O	O	O
innate	O	O	O
rifamycin	O	O	O
resistance	O	O	B-Entity
determinant	O	O	O
of	O	O	O
M.	O	O	O
abscessus	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	O
also	O	O	O
indicate	O	O	O
that	O	O	O
Arr_Mab	O	O	B-Entity
-mediated	O	O	O
rifamycin	O	O	B-Entity
resistance	O	O	B-Entity
in	O	O	O
M.	O	O	B-Entity
abscessus	O	O	I-Entity
can	O	O	O
only	O	O	O
in	O	O	O
part	O	O	O
be	O	O	O
overcome	O	O	O
by	O	O	O
C25	O	O	B-Entity
carbamate	O	O	I-Entity
modification	O	O	B-Entity
.	O	O	O

-DOCSTART- (28002691)

The	O	O	O
Silorane-based	O	O	B-Entity
Resin	O	O	I-Entity
Composites	O	O	I-Entity
:	O	O	O
A	O	O	O
Review	O	O	O

This	O	O	O
article	O	O	B-Entity
aims	O	O	O
to	O	O	O
review	O	O	B-Entity
the	O	O	O
research	O	O	B-Entity
done	O	O	O
on	O	O	O
the	O	O	O
silorane-based	O	O	B-Entity
resin	O	O	I-Entity
composites	O	O	I-Entity
(	O	O	O
SBRC	O	O	B-Entity
)	O	O	O
regarding	O	O	O
polymerization	O	O	B-Entity
shrinkage	O	O	B-Entity
and	O	O	O
contraction	O	O	B-Entity
stresses	O	O	I-Entity
and	O	O	O
their	O	O	O
ability	O	O	O
to	O	O	O
improve	O	O	O
the	O	O	O
shortcomings	O	O	O
of	O	O	O
the	O	O	O
methacrylate-based	O	O	B-Entity
resin	O	O	I-Entity
composites	O	O	I-Entity
(	O	O	O
MRBC	O	O	B-Entity
)	O	O	O
.	O	O	O

Special	O	O	O
attention	O	O	O
is	O	O	O
given	O	O	O
to	O	O	O
their	O	O	O
physical	O	O	B-Entity
and	O	O	O
mechanical	O	O	B-Entity
properties	O	O	I-Entity
,	O	O	O
bond	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
marginal	O	O	B-Entity
adaptation	O	O	I-Entity
,	O	O	O
and	O	O	O
cusp	O	O	B-Entity
deflection	O	O	I-Entity
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
significance	O	O	I-Entity
of	O	O	O
this	O	O	O
material	O	O	B-Entity
is	O	O	O
critically	O	O	O
appraised	O	O	O
with	O	O	O
a	O	O	O
focus	O	O	O
on	O	O	O
the	O	O	O
ability	O	O	O
of	O	O	O
SBRC	O	O	B-Entity
to	O	O	O
strengthen	O	O	O
the	O	O	O
tooth	O	O	B-Entity
structure	O	O	I-Entity
as	O	O	O
a	O	O	O
direct	O	O	B-Entity
restorative	O	O	I-Entity
material	O	O	I-Entity
.	O	O	O

A	O	O	O
search	O	O	O
of	O	O	O
English	O	O	B-Entity
peer-reviewed	O	O	B-Entity
dental	O	O	I-Entity
literature	O	O	I-Entity
(	O	O	O
2003	O	O	O
-	O	O	O
2015	O	O	O
)	O	O	O
from	O	O	O
PubMed	O	O	B-Entity
and	O	O	O
MEDLINE	O	O	B-Entity
databases	O	O	B-Entity
was	O	O	O
conducted	O	O	O
with	O	O	O
the	O	O	O
terms	O	O	O
"	O	O	O
low	O	O	B-Entity
shrinkage	O	O	B-Entity
"	O	O	O
and	O	O	O
"	O	O	O
silorane	O	O	B-Entity
composites	O	O	I-Entity
.	O	O	O
"	O	O	O
The	O	O	O
list	O	O	O
was	O	O	O
screened	O	O	O
,	O	O	O
and	O	O	O
70	O	O	O
articles	O	O	B-Entity
that	O	O	O
were	O	O	O
relevant	O	O	O
to	O	O	O
the	O	O	O
objectives	O	O	B-Entity
of	O	O	O
this	O	O	O
work	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

-DOCSTART- (28003168)

Endoscopic	O	O	B-Entity
endonasal	O	O	B-Entity
surgery	O	O	B-Entity
for	O	O	O
remission	O	O	B-Entity
of	O	O	O
Cushing	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
caused	O	O	O
by	O	O	O
ectopic	O	O	B-Entity
intracavernous	O	O	B-Entity
macroadenoma	O	O	B-Entity
:	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
and	O	O	O
literature	O	O	O
review	O	O	O

Complete	O	O	O
surgical	O	O	B-Entity
resection	O	O	I-Entity
of	O	O	O
an	O	O	O
ACTH-secreting	O	O	B-Entity
pituitary	O	O	I-Entity
adenoma	O	O	I-Entity
is	O	O	O
the	O	O	O
gold	O	O	B-Entity
standard	O	O	I-Entity
of	O	O	O
treatment	O	O	B-Entity
of	O	O	O
Cushing	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
.	O	O	O

Ectopic	O	O	B-Entity
location	O	O	B-Entity
of	O	O	O
these	O	O	O
adenomas	O	O	B-Entity
is	O	O	O
an	O	O	O
extremely	O	O	O
rare	O	O	B-Entity
condition	O	O	O
that	O	O	O
may	O	O	O
compromise	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
surgical	O	O	B-Entity
success	O	O	B-Entity
.	O	O	O

We	O	O	O
present	O	O	O
the	O	O	O
first	O	O	O
case	O	O	O
of	O	O	O
an	O	O	O
ectopic	O	O	B-Entity
intracavernous	O	O	B-Entity
ACTH-secreting	O	O	B-Entity
macroadenoma	O	O	I-Entity
totally	O	O	O
resected	O	O	O
with	O	O	O
endoscopic	O	O	B-Entity
endonasal	O	O	B-Entity
surgery	O	O	B-Entity
(	O	O	O
EES	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
36	O	O	O
year	O	O	O
old	O	O	O
female	O	O	B-Entity
presented	O	O	O
with	O	O	O
Cushing	O	O	B-Entity
syndrome	O	O	I-Entity
.	O	O	O

Increased	O	O	B-Entity
ACTH	O	O	B-Entity
,	O	O	O
serum	O	O	B-Entity
cortisol	O	O	I-Entity
and	O	O	O
free	O	O	B-Entity
urine	O	O	I-Entity
cortisol	O	O	I-Entity
levels	O	O	B-Entity
were	O	O	O
identified	O	O	O
,	O	O	O
however	O	O	O
the	O	O	O
pituitary	O	O	B-Entity
MRI	O	O	I-Entity
failed	O	O	O
to	O	O	O
reveal	O	O	O
a	O	O	O
pituitary	O	O	B-Entity
tumor	O	O	I-Entity
;	O	O	O
instead	O	O	O
,	O	O	O
a	O	O	O
parasellar	O	O	B-Entity
lesion	O	O	I-Entity
in	O	O	O
the	O	O	O
left	O	O	O
cavernous	O	O	B-Entity
sinus	O	O	I-Entity
(	O	O	O
CS	O	O	B-Entity
)	O	O	O
was	O	O	O
noticed	O	O	O
.	O	O	O

Inferior	O	O	B-Entity
petrosal	O	O	I-Entity
sinus	O	O	I-Entity
sampling	O	O	I-Entity
demonstrated	O	O	O
a	O	O	O
significant	O	O	O
central	O	O	B-Entity
-to-	O	O	O
peripheral	O	O	B-Entity
and	O	O	O
lateralized	O	O	O
left-sided	O	O	O
ACTH	O	O	B-Entity
gradient	O	O	O
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
underwent	O	O	O
EES	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
tumor	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
sella	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
left	O	O	O
CS	O	O	B-Entity
was	O	O	O
widely	O	O	O
explored	O	O	O
and	O	O	O
a	O	O	O
tumor	O	O	O
was	O	O	O
found	O	O	O
lateral	O	O	B-Entity
to	O	O	O
the	O	O	O
paraclival	O	O	O
segment	O	O	O
of	O	O	O
the	O	O	O
carotid	O	O	B-Entity
artery	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
complications	O	O	B-Entity
following	O	O	O
EES	O	O	B-Entity
.	O	O	O

Pathology	O	O	B-Entity
confirmed	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
an	O	O	O
ACTH-secreting	O	O	B-Entity
adenoma	O	O	I-Entity
.	O	O	O

During	O	O	O
the	O	O	O
immediately	O	O	O
postoperative	O	O	B-Entity
course	O	O	O
serum	O	O	B-Entity
cortisol	O	O	I-Entity
levels	O	O	B-Entity
dropped	O	O	O
below	O	O	O
5	O	O	O
mcg/dl	O	O	O
.	O	O	O

Postoperative	O	O	B-Entity
MRI	O	O	B-Entity
demonstrated	O	O	O
complete	O	O	O
tumor	O	O	B-Entity
resection	O	O	I-Entity
.	O	O	O

At	O	O	O
20	O	O	O
months	O	O	O
follow-up	O	O	B-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
remains	O	O	O
in	O	O	O
clinical	O	O	B-Entity
and	O	O	O
biochemical	O	O	B-Entity
remission	O	O	B-Entity
of	O	O	O
Cushing	O	O	B-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
.	O	O	O

Only	O	O	O
12	O	O	O
cases	O	O	O
of	O	O	O
ectopic	O	O	B-Entity
intracavernous	O	O	B-Entity
ACTH-secreting	O	O	B-Entity
adenomas	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
date	O	O	O
and	O	O	O
all	O	O	O
were	O	O	O
microadenomas	O	O	B-Entity
.	O	O	O

The	O	O	O
presence	O	O	O
of	O	O	O
an	O	O	O
ectopic	O	O	B-Entity
ACTH-secreting	O	O	B-Entity
macroadenoma	O	O	I-Entity
in	O	O	O
the	O	O	O
CS	O	O	B-Entity
represents	O	O	O
a	O	O	O
surgical	O	O	B-Entity
challenge	O	O	O
.	O	O	O

EES	O	O	B-Entity
is	O	O	O
the	O	O	O
ideal	O	O	O
approach	O	O	O
for	O	O	O
complete	O	O	O
resection	O	O	B-Entity
of	O	O	O
ectopic	O	O	B-Entity
intracavernous	O	O	B-Entity
adenomas	O	O	B-Entity
allowing	O	O	O
for	O	O	O
a	O	O	O
wide	O	O	O
exploration	O	O	B-Entity
of	O	O	O
the	O	O	O
CS	O	O	B-Entity
with	O	O	O
no	O	O	B-Entity
surgical	O	O	B-Entity
complications	O	O	B-Entity
.	O	O	O

-DOCSTART- (28005403)

Preliminary	O	O	O
Randomized	O	O	B-Entity
Controlled	O	O	I-Entity
Trial	O	O	I-Entity
of	O	O	O
Habit	O	O	B-Entity
Reversal	O	O	I-Entity
Training	O	O	I-Entity
for	O	O	O
Treatment	O	O	B-Entity
of	O	O	O
Hair	O	O	B-Entity
Pulling	O	O	I-Entity
in	O	O	O
Youth	O	O	O

This	O	O	O
study	O	O	B-Entity
evaluated	O	O	B-Entity
the	O	O	O
treatment	O	O	B-Entity
efficacy	O	O	B-Entity
of	O	O	O
habit	O	O	B-Entity
reversal	O	O	I-Entity
training	O	O	I-Entity
(	O	O	O
HRT	O	O	B-Entity
)	O	O	O
relative	O	O	O
to	O	O	O
treatment	O	O	B-Entity
as	O	O	I-Entity
usual	O	O	I-Entity
(	O	O	O
TAU	O	O	B-Entity
)	O	O	O
for	O	O	O
children	O	O	B-Entity
and	O	O	O
adolescents	O	O	B-Entity
aged	O	O	B-Entity
7	O	O	O
-	O	O	O
17	O	O	O
years	O	O	B-Entity
with	O	O	O
a	O	O	O
primary	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
trichotillomania	O	O	B-Entity
(	O	O	O
TTM	O	O	B-Entity
)	O	O	O
.	O	O	O

An	O	O	O
initial	O	O	O
assessment	O	O	B-Entity
consisting	O	O	O
of	O	O	O
semistructured	O	O	O
interviews	O	O	B-Entity
and	O	O	O
rating	O	O	B-Entity
scales	O	O	I-Entity
was	O	O	O
conducted	O	O	O
.	O	O	O

Participants	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
40	O	O	O
,	O	O	O
85	O	O	O
%	O	O	O
female	O	O	B-Entity
)	O	O	O
meeting	O	O	O
diagnostic	O	O	B-Entity
criteria	O	O	I-Entity
for	O	O	O
TTM	O	O	B-Entity
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
either	O	O	O
8	O	O	O
weekly	O	O	B-Entity
sessions	O	O	O
of	O	O	O
HRT	O	O	B-Entity
by	O	O	O
trained	O	O	O
therapists	O	O	B-Entity
or	O	O	O
8	O	O	O
weeks	O	O	B-Entity
of	O	O	O
TAU	O	O	B-Entity
.	O	O	O

One	O	O	O
week	O	O	B-Entity
after	O	O	O
the	O	O	O
final	O	O	O
HRT	O	O	B-Entity
session	O	O	O
or	O	O	O
final	O	O	O
TAU	O	O	B-Entity
week	O	O	O
,	O	O	O
patients	O	O	B-Entity
completed	O	O	O
a	O	O	O
posttreatment	O	O	B-Entity
assessment	O	O	I-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
1-	O	O	O
and	O	O	O
3-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
assessments	O	O	B-Entity
.	O	O	O

All	O	O	O
assessments	O	O	B-Entity
were	O	O	O
conducted	O	O	O
by	O	O	O
a	O	O	O
trained	O	O	O
rater	O	O	B-Entity
who	O	O	O
was	O	O	O
blinded	O	O	B-Entity
to	O	O	O
treatment	O	O	B-Entity
condition	O	O	B-Entity
.	O	O	O

The	O	O	O
group	O	O	O
by	O	O	O
time	O	O	O
analysis	O	O	B-Entity
of	O	O	I-Entity
variance	O	O	I-Entity
yielded	O	O	O
a	O	O	O
significant	O	O	B-Entity
interaction	O	O	O
on	O	O	O
the	O	O	O
National	O	O	B-Entity
Institute	O	O	I-Entity
of	O	O	I-Entity
Mental	O	O	I-Entity
Health	O	O	I-Entity
-	O	O	O
Trichotillomania	O	O	B-Entity
Severity	O	O	I-Entity
Scale	O	O	I-Entity
Total	O	O	I-Entity
Score	O	O	I-Entity
(	O	O	O
F1,38	O	O	O
=	O	O	O
16.47	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
,	O	O	O
η(2)p	O	O	O
=	O	O	O
0.30	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
score	O	O	I-Entity
decreased	O	O	O
from	O	O	O
12.67	O	O	O
±	O	O	O
4.60	O	O	O
at	O	O	O
baseline	O	O	B-Entity
to	O	O	O
5.62	O	O	O
±	O	O	O
4.38	O	O	O
at	O	O	O
posttreatment	O	O	B-Entity
in	O	O	O
the	O	O	O
HRT	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
t20	O	O	O
=	O	O	O
5.99	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
,	O	O	O
d	O	O	O
=	O	O	O
1.31	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
TAU	O	O	B-Entity
group	O	O	O
changed	O	O	O
from	O	O	O
10.42	O	O	O
±	O	O	O
4.35	O	O	O
to	O	O	O
9.32	O	O	O
±	O	O	O
4.11	O	O	O
(	O	O	O
t18	O	O	O
=	O	O	O
1.34	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.20	O	O	O
,	O	O	O
d	O	O	O
=	O	O	O
0.31	O	O	O
)	O	O	O
.	O	O	O

The	O	O	B-Entity
Massachusetts	O	O	I-Entity
General	O	O	I-Entity
Hospital-Hair	O	O	I-Entity
Pulling	O	O	I-Entity
Scale	O	O	I-Entity
Total	O	O	I-Entity
Score	O	O	I-Entity
decreased	O	O	O
from	O	O	O
15.14	O	O	O
±	O	O	O
3.86	O	O	O
at	O	O	O
baseline	O	O	B-Entity
to	O	O	O
7.14	O	O	O
±	O	O	O
5.54	O	O	O
at	O	O	O
posttreatment	O	O	B-Entity
in	O	O	O
the	O	O	O
HRT	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
t20	O	O	O
=	O	O	O
6.16	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
,	O	O	O
d	O	O	O
=	O	O	O
1.34	O	O	O
)	O	O	O
;	O	O	O
the	O	O	O
TAU	O	O	B-Entity
group	O	O	O
changed	O	O	O
from	O	O	O
14.16	O	O	O
±	O	O	O
4.51	O	O	O
to	O	O	O
12.26	O	O	O
±	O	O	O
4.34	O	O	O
(	O	O	O
t18	O	O	O
=	O	O	O
1.50	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.15	O	O	O
,	O	O	O
d	O	O	O
=	O	O	O
0.34	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
Clinical	O	O	B-Entity
Global	O	O	I-Entity
Impressions-Improvement	O	O	I-Entity
,	O	O	O
16/21	O	O	O
participants	O	O	B-Entity
(	O	O	O
76	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
rated	O	O	O
as	O	O	O
treatment	O	O	B-Entity
responders	O	O	B-Entity
in	O	O	O
the	O	O	O
HRT	O	O	B-Entity
group	O	O	B-Entity
versus	O	O	O
4/19	O	O	O
(	O	O	O
21	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
TAU	O	O	B-Entity
group	O	O	O
(	O	O	O
χ(2	O	O	O
)	O	O	O
=	O	O	O
12.13	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
,	O	O	O
V	O	O	O
=	O	O	O
0.55	O	O	O
)	O	O	O
.	O	O	O

At	O	O	O
1-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
,	O	O	O
10	O	O	O
-	O	O	O
12	O	O	O
treatment	O	O	B-Entity
responders	O	O	B-Entity
who	O	O	O
completed	O	O	O
the	O	O	O
assessment	O	O	B-Entity
maintained	O	O	O
improvement	O	O	B-Entity
.	O	O	O

At	O	O	O
3-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
,	O	O	O
six	O	O	O
of	O	O	O
eight	O	O	O
maintained	O	O	O
improvement	O	O	B-Entity
.	O	O	O

HRT	O	O	B-Entity
can	O	O	O
be	O	O	O
an	O	O	O
effective	O	O	O
treatment	O	O	B-Entity
for	O	O	O
TTM	O	O	B-Entity
in	O	O	O
youth	O	O	B-Entity
.	O	O	O

-DOCSTART- (28005775)

Fully	O	O	B-Entity
Endoscope	O	O	B-Entity
-	O	O	O
Controlled	O	O	B-Entity
Clipping	O	O	B-Entity
Bilateral	O	O	B-Entity
Middle	O	O	I-Entity
Cerebral	O	O	I-Entity
Artery	O	O	I-Entity
Aneurysm	O	O	I-Entity
Via	O	O	O
Unilateral	O	O	O
Supraorbital	O	O	O
Keyhole	O	O	O
Approach	O	O	O

Clipping	O	O	B-Entity
bilateral	O	O	B-Entity
middle	O	O	I-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
(	O	O	I-Entity
bMCA	O	O	I-Entity
)	O	O	I-Entity
aneurysms	O	O	I-Entity
via	O	O	O
unilateral	O	O	B-Entity
approach	O	O	I-Entity
in	O	O	O
a	O	O	O
single-stage	O	O	B-Entity
operation	O	O	I-Entity
is	O	O	O
considered	O	O	O
as	O	O	O
a	O	O	O
challenge	O	O	O
procedure	O	O	O
.	O	O	O

To	O	O	O
our	O	O	O
knowledge	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
study	O	O	O
in	O	O	O
surgical	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
bMCA	O	O	B-Entity
aneurysms	O	O	I-Entity
by	O	O	O
fully	O	O	O
endoscope	O	O	B-Entity
-	O	O	O
controlled	O	O	B-Entity
techniques	O	O	B-Entity
.	O	O	O

The	O	O	O
author	O	O	O
reported	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
bMCA	O	O	B-Entity
aneurysms	O	O	I-Entity
who	O	O	O
underwent	O	O	O
aneurysms	O	O	B-Entity
clipping	O	O	I-Entity
via	O	O	O
a	O	O	O
unilateral	O	O	B-Entity
supraorbital	O	O	I-Entity
keyhole	O	O	I-Entity
approach	O	O	I-Entity
by	O	O	O
endoscope	O	O	B-Entity
-	O	O	O
controlled	O	O	B-Entity
microneurosurgery	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
patient	O	O	O
had	O	O	O
an	O	O	O
uneventful	O	O	O
postoperative	O	O	B-Entity
course	O	O	I-Entity
without	O	O	B-Entity
neurologic	O	O	B-Entity
impairment	O	O	B-Entity
and	O	O	O
complication	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
author	O	O	O
discussed	O	O	O
the	O	O	O
advantages	O	O	O
and	O	O	O
adaptation	O	O	B-Entity
of	O	O	O
endoscope	O	O	B-Entity
-	O	O	O
controlled	O	O	B-Entity
clipping	O	O	B-Entity
bMCA	O	O	B-Entity
aneurysms	O	O	I-Entity
via	O	O	O
unilateral	O	O	B-Entity
supraorbital	O	O	I-Entity
keyhole	O	O	I-Entity
approach	O	O	I-Entity
.	O	O	O

-DOCSTART- (28007859)

Novel	O	O	B-Entity
Observations	O	O	B-Entity
in	O	O	O
11	O	O	O
Heteroresistant	O	O	B-Entity
Vancomycin-Intermediate	O	O	B-Entity
Methicillin-Resistant	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
Strains	O	O	I-Entity
from	O	O	O
South	O	O	O
India	O	O	O

We	O	O	O
report	O	O	O
here	O	O	O
the	O	O	O
draft	O	O	O
genome	O	O	B-Entity
sequences	O	O	I-Entity
of	O	O	O
11	O	O	O
heteroresistant	O	O	B-Entity
vancomycin-intermediate	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
(	O	O	I-Entity
hVISA	O	O	I-Entity
)	O	O	I-Entity
strains	O	O	I-Entity
from	O	O	O
bloodstream	O	O	B-Entity
infection	O	O	I-Entity
.	O	O	O

All	O	O	O
strains	O	O	B-Entity
harbor	O	O	O
mutations	O	O	B-Entity
in	O	O	O
vraSR	O	O	B-Entity
,	O	O	O
graSR	O	O	B-Entity
,	O	O	O
walKR	O	O	B-Entity
,	O	O	O
and/or	O	O	O
tcaRAB	O	O	B-Entity
and	O	O	O
are	O	O	O
often	O	O	O
implicated	O	O	O
as	O	O	O
the	O	O	O
frequently	O	O	O
mutated	O	O	B-Entity
candidate	O	O	O
genes	O	O	B-Entity
in	O	O	O
hVISA	O	O	B-Entity
phenotypes	O	O	B-Entity
.	O	O	O

-DOCSTART- (28008561)

Endpoints	O	O	B-Entity
for	O	O	O
screening	O	O	B-Entity
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
in	O	O	O
the	O	O	O
Republic	O	O	B-Entity
of	O	O	I-Entity
Korea	O	O	I-Entity
:	O	O	O
thyroid	O	O	O
specialists	O	O	B-Entity
'	O	O	O
perspectives	O	O	O

Cancer	O	O	B-Entity
screening	O	O	I-Entity
is	O	O	O
aimed	O	O	O
primarily	O	O	O
at	O	O	O
reducing	O	O	B-Entity
deaths	O	O	B-Entity
from	O	O	O
the	O	O	O
specific	O	O	O
cancer	O	O	B-Entity
.	O	O	O

Thyroid-specific	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
may	O	O	O
be	O	O	O
the	O	O	O
most	O	O	O
ambitious	O	O	O
endpoint	O	O	B-Entity
for	O	O	O
obtaining	O	O	O
estimates	O	O	B-Entity
of	O	O	O
screening	O	O	B-Entity
effect	O	O	B-Entity
.	O	O	O

Numerous	O	O	B-Entity
observations	O	O	B-Entity
have	O	O	O
accumulated	O	O	B-Entity
over	O	O	O
the	O	O	O
years	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
mortality	O	O	B-Entity
endpoint	O	O	B-Entity
has	O	O	O
been	O	O	O
difficult	O	O	B-Entity
to	O	O	O
study	O	O	O
and	O	O	O
is	O	O	O
confounded	O	O	O
by	O	O	O
population	O	O	B-Entity
heterogeneity	O	O	I-Entity
,	O	O	O
provision	O	O	B-Entity
of	O	O	O
randomization	O	O	B-Entity
,	O	O	O
and	O	O	O
requirement	O	O	B-Entity
of	O	O	O
large	O	O	O
cohorts	O	O	B-Entity
with	O	O	O
sufficiently	O	O	O
long	O	O	B-Entity
follow-up	O	O	I-Entity
due	O	O	O
to	O	O	O
the	O	O	O
excellent	O	O	B-Entity
prognosis	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

Accordingly	O	O	O
,	O	O	O
it	O	O	O
may	O	O	O
be	O	O	O
important	O	O	B-Entity
to	O	O	O
reconsider	O	O	O
how	O	O	O
to	O	O	O
best	O	O	O
measure	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
screening	O	O	B-Entity
efficacy	O	O	B-Entity
.	O	O	O

Recommendations	O	O	B-Entity
against	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	B-Entity
screening	O	O	B-Entity
should	O	O	O
be	O	O	O
based	O	O	O
upon	O	O	O
trials	O	O	O
designed	O	O	O
to	O	O	O
evaluate	O	O	O
its	O	O	O
effectiveness	O	O	B-Entity
not	O	O	O
only	O	O	O
in	O	O	O
significant	O	O	B-Entity
reduction	O	O	I-Entity
in	O	O	O
cancer	O	O	O
mortality	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
of	O	O	O
other	O	O	O
distinct	O	O	O
endpoint	O	O	B-Entity
s.	O	O	O
It	O	O	O
is	O	O	O
desirable	O	O	O
to	O	O	O
evaluate	O	O	O
derivative	O	O	O
endpoints	O	O	B-Entity
that	O	O	O
can	O	O	O
reliably	O	O	O
predict	O	O	O
reductions	O	O	B-Entity
in	O	O	I-Entity
mortality	O	O	I-Entity
.	O	O	O

The	O	O	O
term	O	O	O
"	O	O	O
derivative	O	O	O
"	O	O	O
means	O	O	O
a	O	O	O
variable	O	O	O
that	O	O	O
is	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
true	O	O	O
endpoint	O	O	B-Entity
and	O	O	O
is	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
observable	O	O	O
before	O	O	O
the	O	O	O
primary	O	O	O
endpoint	O	O	O
.	O	O	O

Derivative	O	O	O
endpoints	O	O	B-Entity
may	O	O	O
include	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
incidence	O	O	B-Entity
,	O	O	O
the	O	O	O
proportion	O	O	B-Entity
of	O	O	O
early-stage	O	O	B-Entity
tumors	O	O	B-Entity
detected	O	O	B-Entity
,	O	O	O
more	O	O	O
treatable	O	O	B-Entity
stage	O	O	I-Entity
,	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
small	O	O	B-Entity
tumors	O	O	I-Entity
(	O	O	O
to	O	O	O
maintain	O	O	O
in	O	O	O
observation	O	O	O
)	O	O	O
,	O	O	O
decrease	O	O	B-Entity
in	O	O	I-Entity
the	O	O	I-Entity
number	O	O	I-Entity
of	O	O	I-Entity
people	O	O	I-Entity
who	O	O	O
develop	O	O	O
metastatic	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
the	O	O	O
increased	O	O	B-Entity
chance	O	O	O
of	O	O	O
lesser	O	O	O
extent	O	O	O
surgery	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
approaches	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
no	O	O	O
need	O	O	O
for	O	O	O
lifelong	O	O	B-Entity
thyroid	O	O	B-Entity
replacement	O	O	I-Entity
therapy	O	O	I-Entity
,	O	O	O
a	O	O	O
consistent	O	O	B-Entity
follow-up	O	O	B-Entity
,	O	O	O
low-dose	O	O	B-Entity
or	O	O	O
no	O	O	O
RAI	O	O	B-Entity
administration	O	O	I-Entity
and	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
assessments	O	O	I-Entity
where	O	O	O
case	O	O	B-Entity
findings	O	O	I-Entity
should	O	O	O
be	O	O	O
continuous	O	O	B-Entity
.	O	O	O

The	O	O	O
Korean	O	O	B-Entity
guidelines	O	O	O
for	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
national-level	O	O	B-Entity
screening	O	O	B-Entity
were	O	O	O
published	O	O	O
by	O	O	O
a	O	O	O
relevant	O	O	O
group	O	O	O
of	O	O	O
multidisciplinary	O	O	B-Entity
thyroid	O	O	I-Entity
experts	O	O	I-Entity
.	O	O	O

It	O	O	O
was	O	O	O
concluded	O	O	O
that	O	O	O
the	O	O	O
evidence	O	O	B-Entity
is	O	O	I-Entity
insufficient	O	O	I-Entity
to	O	O	O
balance	O	O	O
the	O	O	O
benefits	O	O	B-Entity
and	O	O	O
harms	O	O	O
of	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
screening	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
paper	O	O	O
seems	O	O	O
to	O	O	O
raise	O	O	O
the	O	O	O
necessary	O	O	O
investments	O	O	O
in	O	O	O
future	O	O	O
research	O	O	B-Entity
and	O	O	O
demand	O	O	O
a	O	O	O
complete	O	O	B-Entity
analysis	O	O	B-Entity
for	O	O	O
derivative	O	O	O
endpoints	O	O	B-Entity
,	O	O	O
and	O	O	O
offer	O	O	O
screening	O	O	B-Entity
participants	O	O	B-Entity
with	O	O	O
complete	O	O	O
information	O	O	B-Entity
necessary	O	O	O
to	O	O	B-Entity
make	O	O	I-Entity
decisions	O	O	I-Entity
that	O	O	O
will	O	O	O
provide	O	O	O
them	O	O	O
with	O	O	O
the	O	O	O
most	O	O	O
value	O	O	O
when	O	O	O
a	O	O	O
small	O	O	O
thyroid	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
screen-	O	O	O
identified	O	O	B-Entity
.	O	O	O

-DOCSTART- (28009049)

Zebrafish	O	O	B-Entity
adult	O	O	B-Entity
pigment	O	O	I-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
are	O	O	O
multipotent	O	O	B-Entity
and	O	O	O
form	O	O	B-Entity
pigment	O	O	I-Entity
cells	O	O	I-Entity
by	O	O	O
a	O	O	O
progressive	O	O	B-Entity
fate	O	O	B-Entity
restriction	O	O	I-Entity
process	O	O	I-Entity
:	O	O	O
Clonal	O	O	B-Entity
analysis	O	O	I-Entity
identifies	O	O	B-Entity
shared	O	O	O
origin	O	O	O
of	O	O	O
all	O	O	O
pigment	O	O	O
cell	O	O	O
types	O	O	O

Skin	O	O	B-Entity
pigment	O	O	I-Entity
pattern	O	O	B-Entity
formation	O	O	I-Entity
is	O	O	O
a	O	O	O
paradigmatic	O	O	B-Entity
example	O	O	O
of	O	O	O
pattern	O	O	O
formation	O	O	O
.	O	O	O

In	O	O	O
zebrafish	O	O	B-Entity
,	O	O	O
the	O	O	O
adult	O	O	B-Entity
body	O	O	B-Entity
stripes	O	O	I-Entity
are	O	O	O
generated	O	O	B-Entity
by	O	O	O
coordinated	O	O	B-Entity
rearrangement	O	O	B-Entity
of	O	O	O
three	O	O	B-Entity
distinct	O	O	O
pigment	O	O	B-Entity
cell-types	O	O	I-Entity
,	O	O	O
black	O	O	B-Entity
melanocytes	O	O	B-Entity
,	O	O	O
shiny	O	O	B-Entity
iridophores	O	O	B-Entity
and	O	O	O
yellow	O	O	B-Entity
xanthophores	O	O	B-Entity
.	O	O	O

A	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
origin	O	O	I-Entity
of	O	O	O
melanocytes	O	O	B-Entity
and	O	O	O
iridophores	O	O	B-Entity
has	O	O	O
been	O	O	O
proposed	O	O	O
although	O	O	O
the	O	O	O
potency	O	O	B-Entity
of	O	O	O
those	O	O	O
stem	O	O	B-Entity
cells	O	O	I-Entity
has	O	O	O
remained	O	O	B-Entity
unclear	O	O	B-Entity
.	O	O	O

Xanthophores	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
seemed	O	O	O
to	O	O	O
originate	O	O	O
predominantly	O	O	B-Entity
from	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
embryonic	O	O	B-Entity
xanthophores	O	O	B-Entity
.	O	O	O

Now	O	O	O
,	O	O	O
data	O	O	B-Entity
from	O	O	O
Singh	O	O	O
et	O	O	O
al.	O	O	O
shows	O	O	O
that	O	O	O
all	O	O	O
three	O	O	B-Entity
cell-types	O	O	B-Entity
derive	O	O	B-Entity
from	O	O	O
shared	O	O	O
stem	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
and	O	O	O
that	O	O	O
these	O	O	O
cells	O	O	O
generate	O	O	B-Entity
peripheral	O	O	B-Entity
neural	O	O	B-Entity
cell-types	O	O	I-Entity
too	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
clonal	O	O	B-Entity
compositions	O	O	B-Entity
are	O	O	O
best	O	O	O
explained	O	O	O
by	O	O	O
a	O	O	O
progressive	O	O	B-Entity
fate	O	O	B-Entity
restriction	O	O	I-Entity
model	O	O	I-Entity
generating	O	O	B-Entity
the	O	O	O
individual	O	O	B-Entity
cell-types	O	O	B-Entity
.	O	O	O

The	O	O	O
numbers	O	O	B-Entity
of	O	O	O
adult	O	O	B-Entity
pigment	O	O	I-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
dorsal	O	O	B-Entity
root	O	O	I-Entity
ganglia	O	O	I-Entity
remain	O	O	B-Entity
low	O	O	B-Entity
,	O	O	O
but	O	O	O
progenitor	O	O	B-Entity
numbers	O	O	O
increase	O	O	B-Entity
significantly	O	O	O
during	O	O	B-Entity
larval	O	O	B-Entity
development	O	O	I-Entity
up	O	O	O
to	O	O	O
metamorphosis	O	O	B-Entity
,	O	O	O
likely	O	O	O
via	O	O	O
production	O	O	O
of	O	O	O
partially	O	O	B-Entity
restricted	O	O	B-Entity
progenitors	O	O	B-Entity
on	O	O	O
the	O	O	O
spinal	O	O	B-Entity
nerves	O	O	I-Entity
.	O	O	O

-DOCSTART- (28010062)

Covalent	O	O	B-Entity
Modulators	O	O	I-Entity
of	O	O	O
the	O	O	O
Vacuolar	O	O	O
ATPase	O	O	O

The	O	O	O
vacuolar	O	O	B-Entity
H(+	O	O	I-Entity
)	O	O	I-Entity
ATPase	O	O	I-Entity
(	O	O	O
V-ATPase	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
complex	O	O	B-Entity
multisubunit	O	O	O
machine	O	O	B-Entity
that	O	O	O
regulates	O	O	B-Entity
important	O	O	O
cellular	O	O	B-Entity
processes	O	O	I-Entity
through	O	O	O
controlling	O	O	B-Entity
acidity	O	O	B-Entity
of	O	O	O
intracellular	O	O	B-Entity
compartments	O	O	B-Entity
in	O	O	O
eukaryotes	O	O	B-Entity
.	O	O	O

Existing	O	O	O
small-molecule	O	O	B-Entity
modulators	O	O	B-Entity
of	O	O	O
V-ATPase	O	O	B-Entity
either	O	O	O
are	O	O	O
restricted	O	O	B-Entity
to	O	O	O
targeting	O	O	B-Entity
one	O	O	O
membranous	O	O	B-Entity
subunit	O	O	B-Entity
of	O	O	O
V-ATPase	O	O	O
or	O	O	O
have	O	O	O
poorly	O	O	O
understood	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
action	O	O	O
.	O	O	O

Small	O	O	B-Entity
molecules	O	O	I-Entity
with	O	O	O
novel	O	O	B-Entity
and	O	O	O
defined	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
inhibition	O	O	B-Entity
are	O	O	O
thus	O	O	O
needed	O	O	B-Entity
to	O	O	O
functionally	O	O	B-Entity
characterize	O	O	B-Entity
V-ATPase	O	O	B-Entity
and	O	O	O
to	O	O	O
fully	O	O	O
evaluate	O	O	O
the	O	O	O
therapeutic	O	O	B-Entity
relevance	O	O	B-Entity
of	O	O	O
V-ATPase	O	O	O
in	O	O	O
human	O	O	B-Entity
diseases	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
discovered	O	O	O
electrophilic	O	O	B-Entity
quinazolines	O	O	B-Entity
that	O	O	O
covalently	O	O	B-Entity
modify	O	O	I-Entity
a	O	O	O
soluble	O	O	B-Entity
catalytic	O	O	B-Entity
subunit	O	O	I-Entity
of	O	O	O
V-ATPase	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
potency	O	O	B-Entity
and	O	O	O
exquisite	O	O	O
proteomic	O	O	B-Entity
selectivity	O	O	I-Entity
as	O	O	O
revealed	O	O	B-Entity
by	O	O	O
fluorescence	O	O	B-Entity
imaging	O	O	I-Entity
and	O	O	O
chemical	O	O	B-Entity
proteomic	O	O	I-Entity
activity-based	O	O	I-Entity
profiling	O	O	I-Entity
.	O	O	O

The	O	O	O
site	O	O	B-Entity
of	O	O	O
covalent	O	O	O
modification	O	O	B-Entity
was	O	O	O
mapped	O	O	B-Entity
to	O	O	O
a	O	O	O
cysteine	O	O	B-Entity
residue	O	O	B-Entity
located	O	O	B-Entity
in	O	O	I-Entity
a	O	O	O
region	O	O	B-Entity
of	O	O	O
V-ATPase	O	O	B-Entity
subunit	O	O	B-Entity
A	O	O	I-Entity
that	O	O	O
is	O	O	O
thought	O	O	B-Entity
to	O	O	O
regulate	O	O	B-Entity
the	O	O	O
dissociation	O	O	B-Entity
of	O	O	O
V-ATPase	O	O	O
.	O	O	O

We	O	O	O
further	O	O	O
demonstrate	O	O	O
that	O	O	O
a	O	O	O
previously	O	O	O
reported	O	O	O
V-ATPase	O	O	B-Entity
inhibitor	O	O	I-Entity
,	O	O	O
3-bromopyruvate	O	O	B-Entity
,	O	O	O
also	O	O	O
targets	O	O	B-Entity
the	O	O	O
same	O	O	B-Entity
cysteine	O	O	B-Entity
residue	O	O	B-Entity
and	O	O	O
that	O	O	O
our	O	O	O
electrophilic	O	O	B-Entity
quinazolines	O	O	B-Entity
modulate	O	O	B-Entity
the	O	O	O
function	O	O	B-Entity
of	O	O	O
V-ATPase	O	O	O
in	O	O	O
cells	O	O	B-Entity
.	O	O	O

With	O	O	O
their	O	O	O
well-defined	O	O	B-Entity
mechanism	O	O	B-Entity
of	O	O	O
action	O	O	B-Entity
and	O	O	O
high	O	O	B-Entity
proteomic	O	O	B-Entity
specificity	O	O	I-Entity
,	O	O	O
the	O	O	O
described	O	O	O
quinazolines	O	O	B-Entity
offer	O	O	O
a	O	O	O
powerful	O	O	B-Entity
set	O	O	B-Entity
of	O	O	O
chemical	O	O	B-Entity
probes	O	O	I-Entity
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
physiological	O	O	B-Entity
and	O	O	O
pathological	O	O	B-Entity
roles	O	O	B-Entity
of	O	O	O
V-ATPase	O	O	B-Entity
.	O	O	O

-DOCSTART- (28011044)

Association	O	O	B-Entity
of	O	O	O
Radiomics	O	O	O
and	O	O	O
Metabolic	O	O	B-Entity
Tumor	O	O	B-Entity
Volumes	O	O	I-Entity
in	O	O	O
Radiation	O	O	B-Entity
Treatment	O	O	I-Entity
of	O	O	O
Glioblastoma	O	O	O
Multiforme	O	O	O

To	O	O	O
build	O	O	O
a	O	O	O
framework	O	O	O
for	O	O	O
investigation	O	O	B-Entity
of	O	O	O
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
imaging	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
target	O	O	I-Entity
volumes	O	O	B-Entity
(	O	O	O
CTVs	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
metabolic	O	O	B-Entity
tumor	O	O	B-Entity
volumes	O	O	I-Entity
(	O	O	O
MTVs	O	O	B-Entity
)	O	O	O
features	O	O	B-Entity
for	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
underlying	O	O	O
information	O	O	B-Entity
in	O	O	O
the	O	O	O
CTVs	O	O	O
and	O	O	O
dependencies	O	O	O
between	O	O	O
these	O	O	O
volumes	O	O	O
.	O	O	O

High-throughput	O	O	B-Entity
extraction	O	O	I-Entity
of	O	O	O
imaging	O	O	B-Entity
and	O	O	O
metabolomic	O	O	B-Entity
quantitative	O	O	B-Entity
features	O	O	B-Entity
from	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
and	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
spectroscopic	O	O	I-Entity
imaging	O	O	I-Entity
of	O	O	O
glioblastoma	O	O	B-Entity
multiforme	O	O	I-Entity
(	O	O	O
GBM	O	O	B-Entity
)	O	O	O
results	O	O	O
in	O	O	O
tens	O	O	O
of	O	O	O
variables	O	O	O
per	O	O	O
patient	O	O	B-Entity
.	O	O	O

In	O	O	O
radiation	O	O	B-Entity
therapy	O	O	I-Entity
of	O	O	O
GBM	O	O	B-Entity
the	O	O	O
relevant	O	O	B-Entity
metabolic	O	O	B-Entity
tumor	O	O	B-Entity
volumes	O	O	I-Entity
(	O	O	O
MTVs	O	O	B-Entity
)	O	O	O
are	O	O	O
related	O	O	O
to	O	O	O
aberrant	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
N-acetyl	O	O	B-Entity
aspartate	O	O	I-Entity
(	O	O	O
NAA	O	O	B-Entity
)	O	O	O
and	O	O	O
choline	O	O	B-Entity
(	O	O	O
Cho	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
corresponding	O	O	O
clinical	O	O	B-Entity
target	O	O	I-Entity
volumes	O	O	I-Entity
(	O	O	O
CTVs	O	O	B-Entity
)	O	O	O
for	O	O	O
radiation	O	O	B-Entity
therapy	O	O	I-Entity
are	O	O	O
based	O	O	O
on	O	O	O
contrast-enhanced	O	O	B-Entity
T1-weighted	O	O	I-Entity
(	O	O	O
CE-T1w	O	O	B-Entity
)	O	O	O
and	O	O	O
T2-weighted	O	O	B-Entity
(T2w)/fluid-attenuated	O	O	I-Entity
inversion	O	O	I-Entity
recovery	O	O	I-Entity
MRI	O	O	I-Entity
.	O	O	O

Necrotic	O	O	B-Entity
portions	O	O	I-Entity
,	O	O	O
enhancing	O	O	B-Entity
lesion	O	O	I-Entity
,	O	O	O
and	O	O	O
edema	O	O	B-Entity
were	O	O	O
manually	O	O	O
contoured	O	O	O
on	O	O	O
CE-T1w	O	O	B-Entity
/	O	O	O
T2w	O	O	B-Entity
images	O	O	I-Entity
for	O	O	O
17	O	O	O
GBM	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Clinical	O	O	B-Entity
target	O	O	I-Entity
volumes	O	O	I-Entity
and	O	O	O
MTVs	O	O	B-Entity
for	O	O	O
NAA	O	O	B-Entity
(	O	O	O
MTVNAA	O	O	B-Entity
)	O	O	O
and	O	O	O
Cho	O	O	B-Entity
(	O	O	O
MTVCho	O	O	B-Entity
)	O	O	O
were	O	O	O
constructed	O	O	O
.	O	O	O

Imaging	O	O	B-Entity
and	O	O	O
metabolic	O	O	B-Entity
features	O	O	I-Entity
related	O	O	O
to	O	O	O
size	O	O	B-Entity
,	O	O	O
shape	O	O	B-Entity
,	O	O	O
and	O	O	O
signal	O	O	B-Entity
intensities	O	O	I-Entity
of	O	O	O
the	O	O	O
volumes	O	O	B-Entity
were	O	O	O
extracted	O	O	O
.	O	O	O

Tumors	O	O	B-Entity
were	O	O	O
also	O	O	O
scored	O	O	O
categorically	O	O	O
for	O	O	O
10	O	O	O
semantic	O	O	B-Entity
imaging	O	O	B-Entity
traits	O	O	I-Entity
by	O	O	O
a	O	O	O
neuroradiologist	O	O	B-Entity
.	O	O	O

All	O	O	O
features	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
for	O	O	O
redundancy	O	O	B-Entity
.	O	O	O

Two-way	O	O	B-Entity
correlations	O	O	I-Entity
between	O	O	O
imaging	O	O	B-Entity
and	O	O	O
CTVs	O	O	B-Entity
/	O	O	O
MTVs	O	O	B-Entity
features	O	O	O
were	O	O	O
visualized	O	O	O
as	O	O	O
heatmaps	O	O	B-Entity
.	O	O	O

Associations	O	O	B-Entity
between	O	O	O
MTVNAA	O	O	B-Entity
and	O	O	O
MTVCho	O	O	B-Entity
and	O	O	O
imaging	O	O	B-Entity
features	O	O	I-Entity
were	O	O	O
studied	O	O	O
using	O	O	O
Spearman	O	O	B-Entity
correlation	O	O	I-Entity
.	O	O	O

Forty-eight	O	O	O
imaging	O	O	B-Entity
features	O	O	I-Entity
were	O	O	O
extracted	O	O	O
per	O	O	O
patient	O	O	B-Entity
.	O	O	O

Half	O	O	B-Entity
of	O	O	O
the	O	O	O
imaging	O	O	B-Entity
traits	O	O	I-Entity
were	O	O	O
replaced	O	O	B-Entity
with	O	O	O
automatically	O	O	O
extracted	O	O	O
continuous	O	O	B-Entity
variables	O	O	I-Entity
.	O	O	O

Twenty	O	O	O
features	O	O	B-Entity
were	O	O	O
extracted	O	O	O
from	O	O	O
CTVs	O	O	B-Entity
and	O	O	O
MTVs	O	O	B-Entity
.	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
semantic	O	O	B-Entity
imaging	O	O	B-Entity
traits	O	O	I-Entity
were	O	O	O
replaced	O	O	B-Entity
with	O	O	O
automatically	O	O	O
extracted	O	O	O
continuous	O	O	B-Entity
variables	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
multiple	O	O	O
(	O	O	O
22	O	O	O
)	O	O	O
significant	O	O	O
correlations	O	O	B-Entity
of	O	O	O
imaging	O	O	B-Entity
measures	O	O	I-Entity
with	O	O	O
CTVs	O	O	B-Entity
/	O	O	O
MTVNAA	O	O	B-Entity
,	O	O	O
whereas	O	O	O
there	O	O	O
were	O	O	O
only	O	O	O
6	O	O	O
with	O	O	O
CTVs	O	O	O
/	O	O	O
MTVCho	O	O	B-Entity
.	O	O	O

A	O	O	O
framework	O	O	O
for	O	O	O
investigation	O	O	O
of	O	O	O
codependencies	O	O	O
between	O	O	O
MRI	O	O	B-Entity
and	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
spectroscopic	O	O	I-Entity
imaging	O	O	I-Entity
radiomic	O	O	O
features	O	O	B-Entity
and	O	O	O
CTVs	O	O	B-Entity
/	O	O	O
MTVs	O	O	B-Entity
has	O	O	O
been	O	O	O
established	O	O	O
.	O	O	O

The	O	O	O
MTV	O	O	B-Entity
for	O	O	O
NAA	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
closely	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
MRI	O	O	B-Entity
volumes	O	O	B-Entity
,	O	O	O
whereas	O	O	O
very	O	O	O
few	O	O	O
imaging	O	O	B-Entity
features	O	O	I-Entity
were	O	O	O
related	O	O	O
to	O	O	O
MTVCho	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
Cho	O	O	B-Entity
provides	O	O	O
additional	O	O	B-Entity
information	O	O	I-Entity
to	O	O	O
imaging	O	O	O
.	O	O	O

-DOCSTART- (28011408)

Measurement	O	O	B-Entity
of	O	O	O
fidgeting	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
anorexia	O	O	B-Entity
nervosa	O	O	I-Entity
using	O	O	O
a	O	O	O
novel	O	O	O
shoe	O	O	B-Entity
-based	O	O	O
monitor	O	O	O

To	O	O	O
objectively	O	O	O
assess	O	O	O
seated	O	O	B-Entity
non-exercise	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
anorexia	O	O	B-Entity
nervosa	O	O	I-Entity
(	O	O	O
AN	O	O	B-Entity
)	O	O	O
relative	O	O	O
to	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
(	O	O	O
HCs	O	O	B-Entity
)	O	O	O
and	O	O	O
examine	O	O	O
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
this	O	O	O
physical	O	O	O
activity	O	O	O
,	O	O	O
eating	O	O	B-Entity
disorder	O	O	I-Entity
pathology	O	O	B-Entity
,	O	O	O
and	O	O	O
levels	O	O	B-Entity
of	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
depression	O	O	B-Entity
.	O	O	O

Eleven	O	O	O
inpatients	O	O	B-Entity
with	O	O	O
AN	O	O	B-Entity
and	O	O	O
10	O	O	O
HCs	O	O	B-Entity
wore	O	O	O
a	O	O	O
shoe	O	O	B-Entity
-based	O	O	O
accelerometer	O	O	B-Entity
(	O	O	O
SmartShoe	O	O	B-Entity
)	O	O	O
at	O	O	O
three	O	O	O
time	O	O	B-Entity
points	O	O	I-Entity
:	O	O	O
a	O	O	O
)	O	O	O
while	O	O	B-Entity
eating	O	O	I-Entity
lunch	O	O	I-Entity
,	O	O	O
b	O	O	O
)	O	O	O
filling	O	O	B-Entity
out	O	O	I-Entity
questionnaires	O	O	I-Entity
,	O	O	O
and	O	O	O
c	O	O	O
)	O	O	O
watching	O	O	B-Entity
television	O	O	I-Entity
for	O	O	I-Entity
1h	O	O	I-Entity
.	O	O	O

Across	O	O	O
all	O	O	O
three	O	O	O
tasks	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
AN	O	O	B-Entity
were	O	O	O
significantly	O	O	O
more	O	O	B-Entity
active	O	O	I-Entity
than	O	O	O
HCs	O	O	B-Entity
,	O	O	O
thereby	O	O	O
engaging	O	O	O
in	O	O	O
a	O	O	O
greater	O	O	B-Entity
degree	O	O	I-Entity
of	O	O	O
restless	O	O	B-Entity
or	O	O	O
fidgeting	O	O	B-Entity
behavior	O	O	B-Entity
.	O	O	O

Degree	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
positively	O	O	B-Entity
correlated	O	O	I-Entity
with	O	O	O
eating	O	O	B-Entity
disorder	O	O	I-Entity
psychopathology	O	O	B-Entity
in	O	O	O
the	O	O	O
sample	O	O	O
with	O	O	O
AN	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
trend	O	O	O
towards	O	O	O
a	O	O	O
positive	O	O	B-Entity
association	O	O	I-Entity
between	O	O	O
physical	O	O	O
activity	O	O	O
and	O	O	O
levels	O	O	B-Entity
of	O	O	O
depression	O	O	B-Entity
and	O	O	O
anxiety	O	O	B-Entity
was	O	O	O
also	O	O	O
found	O	O	O
in	O	O	O
this	O	O	O
sample	O	O	O
.	O	O	O

Among	O	O	O
individuals	O	O	B-Entity
with	O	O	O
AN	O	O	B-Entity
,	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
not	O	O	B-Entity
significantly	O	O	O
correlated	O	O	B-Entity
with	O	O	O
BMI	O	O	B-Entity
,	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
illness	O	O	I-Entity
,	O	O	O
or	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
days	O	O	I-Entity
since	O	O	O
hospital	O	O	B-Entity
admission	O	O	I-Entity
.	O	O	O

Use	O	O	O
of	O	O	O
a	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
,	O	O	O
shoe	O	O	B-Entity
-based	O	O	O
monitor	O	O	B-Entity
revealed	O	O	O
patients	O	O	B-Entity
with	O	O	O
AN	O	O	B-Entity
engaged	O	O	O
in	O	O	O
a	O	O	O
greater	O	O	B-Entity
degree	O	O	I-Entity
of	O	O	O
fidgeting	O	O	B-Entity
relative	O	O	O
to	O	O	O
HCs	O	O	B-Entity
during	O	O	O
quiet	O	O	O
,	O	O	O
seated	O	O	B-Entity
tasks	O	O	B-Entity
and	O	O	O
this	O	O	O
heightened	O	O	O
activity	O	O	B-Entity
was	O	O	O
related	O	O	O
to	O	O	O
measures	O	O	B-Entity
of	O	O	O
pathology	O	O	B-Entity
.	O	O	O

Non-exercise	O	O	B-Entity
physical	O	O	I-Entity
activity	O	O	I-Entity
,	O	O	O
including	O	O	O
fidgeting	O	O	B-Entity
,	O	O	O
may	O	O	O
warrant	O	O	O
further	O	O	O
clinical	O	O	B-Entity
attention	O	O	O
in	O	O	O
this	O	O	O
patient	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

-DOCSTART- (28013377)

Hospital	O	O	B-Entity
clowning	O	O	I-Entity
:	O	O	O
a	O	O	O
paediatrician	O	O	B-Entity
's	O	O	I-Entity
view	O	O	O

This	O	O	O
study	O	O	B-Entity
investigates	O	O	B-Entity
the	O	O	O
current	O	O	B-Entity
position	O	O	O
of	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
from	O	O	O
the	O	O	O
perspective	O	O	B-Entity
of	O	O	O
paediatricians	O	O	B-Entity
and	O	O	O
paediatric	O	O	B-Entity
residents	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
14	O	O	O
attending	O	O	B-Entity
paediatricians	O	O	I-Entity
and	O	O	O
paediatric	O	O	B-Entity
residents	O	O	I-Entity
participated	O	O	B-Entity
in	O	O	O
two	O	O	O
focus	O	O	B-Entity
group	O	O	I-Entity
sessions	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
using	O	O	O
Atlas.ti	O	O	B-Entity
5.0	O	O	I-Entity
.	O	O	O

In	O	O	O
general	O	O	B-Entity
,	O	O	O
physicians	O	O	B-Entity
reported	O	O	B-Entity
positive	O	O	B-Entity
experiences	O	O	B-Entity
regarding	O	O	O
the	O	O	O
interaction	O	O	B-Entity
between	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
and	O	O	O
paediatric	O	O	B-Entity
patients	O	O	I-Entity
on	O	O	O
the	O	O	O
ward	O	O	B-Entity
.	O	O	O

Physicians	O	O	B-Entity
were	O	O	O
more	O	O	O
interested	O	O	B-Entity
in	O	O	O
research	O	O	B-Entity
on	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
perception	O	O	I-Entity
of	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
than	O	O	O
in	O	O	O
research	O	O	O
on	O	O	O
the	O	O	O
clinical	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
hospital	O	O	B-Entity
clowning	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
direct	O	O	I-Entity
collaboration	O	O	B-Entity
between	O	O	O
physicians	O	O	B-Entity
and	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
was	O	O	O
reported	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
physicians	O	O	B-Entity
proposed	O	O	B-Entity
conditions	O	O	B-Entity
which	O	O	O
may	O	O	O
streamline	O	O	B-Entity
their	O	O	O
encounters	O	O	B-Entity
with	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
such	O	O	O
as	O	O	O
clear	O	O	B-Entity
communication	O	O	I-Entity
prior	O	O	B-Entity
to	O	O	O
hospital	O	O	B-Entity
clown	O	O	I-Entity
visits	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
condition	O	O	B-Entity
that	O	O	O
visits	O	O	O
do	O	O	O
not	O	O	O
impede	O	O	B-Entity
medical	O	O	B-Entity
interventions	O	O	I-Entity
.	O	O	O

Overall	O	O	B-Entity
,	O	O	O
paediatricians	O	O	B-Entity
and	O	O	O
paediatric	O	O	B-Entity
residents	O	O	I-Entity
view	O	O	B-Entity
the	O	O	O
positive	O	O	B-Entity
impact	O	O	B-Entity
on	O	O	O
paediatric	O	O	B-Entity
patients	O	O	I-Entity
as	O	O	O
the	O	O	O
most	O	O	O
important	O	O	B-Entity
aspect	O	O	B-Entity
of	O	O	O
hospital	O	O	B-Entity
clown	O	O	I-Entity
visits	O	O	B-Entity
,	O	O	O
rather	O	O	O
than	O	O	O
the	O	O	O
clinical	O	O	B-Entity
efficacy	O	O	I-Entity
of	O	O	O
hospital	O	O	B-Entity
clowning	O	O	I-Entity
.	O	O	O

In	O	O	O
light	O	O	O
of	O	O	O
the	O	O	O
growing	O	O	O
number	O	O	O
of	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
worldwide	O	O	B-Entity
,	O	O	O
this	O	O	O
article	O	O	B-Entity
provides	O	O	O
recommendations	O	O	B-Entity
for	O	O	O
arranging	O	O	O
their	O	O	O
encounters	O	O	B-Entity
with	O	O	O
paediatricians	O	O	B-Entity
and	O	O	O
paediatric	O	O	B-Entity
residents	O	O	I-Entity
to	O	O	O
maintain	O	O	B-Entity
optimal	O	O	B-Entity
health	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O
What	O	O	O
is	O	O	O
known	O	O	O
:	O	O	O
•	O	O	O
Previous	O	O	B-Entity
studies	O	O	B-Entity
show	O	O	O
a	O	O	O
clinically	O	O	B-Entity
significant	O	O	I-Entity
pain	O	O	B-Entity
-	O	O	O
and	O	O	O
anxiety	O	O	B-Entity
-	O	O	O
reducing	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
hospital	O	O	B-Entity
clowning	O	O	I-Entity
in	O	O	O
paediatric	O	O	B-Entity
patients	O	O	I-Entity
admitted	O	O	B-Entity
to	O	O	I-Entity
hospitals	O	O	I-Entity
or	O	O	O
undergoing	O	O	B-Entity
(	O	O	O
invasive	O	O	B-Entity
)	O	O	O
medical	O	O	B-Entity
procedures	O	O	I-Entity
.	O	O	O

•	O	O	O
In	O	O	O
general	O	O	O
,	O	O	O
paediatricians	O	O	B-Entity
have	O	O	O
positive	O	O	B-Entity
ideas	O	O	B-Entity
about	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
,	O	O	O
aside	O	O	O
from	O	O	O
personal	O	O	B-Entity
prejudices	O	O	I-Entity
.	O	O	O

What	O	O	O
is	O	O	O
new	O	O	O
:	O	O	O
•	O	O	O
This	O	O	O
novel	O	O	B-Entity
study	O	O	B-Entity
gives	O	O	O
deeper	O	O	O
insight	O	O	B-Entity
into	O	O	O
day-to-day	O	O	B-Entity
interaction	O	O	B-Entity
between	O	O	O
paediatricians	O	O	B-Entity
and	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
on	O	O	O
the	O	O	O
ward	O	O	B-Entity
.	O	O	O

•	O	O	O
This	O	O	O
study	O	O	B-Entity
provides	O	O	O
recommendations	O	O	B-Entity
for	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
to	O	O	O
arrange	O	O	O
encounters	O	O	B-Entity
between	O	O	O
physicians	O	O	B-Entity
and	O	O	O
hospital	O	O	B-Entity
clowns	O	O	I-Entity
during	O	O	O
hospital	O	O	B-Entity
clown	O	O	I-Entity
visits	O	O	B-Entity
.	O	O	O

-DOCSTART- (28019021)

Multiparametric	O	O	B-Entity
estimation	O	O	I-Entity
of	O	O	O
brain	O	O	B-Entity
hemodynamics	O	O	I-Entity
with	O	O	O
MR	O	O	O
fingerprinting	O	O	O
ASL	O	O	O

Assessment	O	O	B-Entity
of	O	O	O
brain	O	O	B-Entity
hemodynamics	O	O	I-Entity
without	O	O	O
exogenous	O	O	B-Entity
contrast	O	O	B-Entity
agents	O	O	I-Entity
is	O	O	O
of	O	O	O
increasing	O	O	B-Entity
importance	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aims	O	O	O
to	O	O	O
develop	O	O	O
an	O	O	O
MR	O	O	B-Entity
perfusion	O	O	I-Entity
technique	O	O	I-Entity
that	O	O	O
can	O	O	O
provide	O	O	O
noncontrast	O	O	B-Entity
and	O	O	O
multiparametric	O	O	B-Entity
estimation	O	O	I-Entity
of	O	O	O
hemodynamic	O	O	B-Entity
markers	O	O	B-Entity
.	O	O	O

We	O	O	O
devised	O	O	O
an	O	O	O
arterial	O	O	B-Entity
spin	O	O	I-Entity
labeling	O	O	I-Entity
(	O	O	O
ASL	O	O	B-Entity
)	O	O	O
method	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
principle	O	O	O
of	O	O	O
MR	O	O	B-Entity
fingerprinting	O	O	I-Entity
(	O	O	O
MRF	O	O	B-Entity
)	O	O	O
,	O	O	O
referred	O	O	B-Entity
to	O	O	O
as	O	O	O
MRF-ASL	O	O	B-Entity
.	O	O	O

By	O	O	O
taking	O	O	O
advantage	O	O	O
of	O	O	O
the	O	O	O
rich	O	O	O
information	O	O	B-Entity
contained	O	O	O
in	O	O	O
MRF	O	O	B-Entity
sequence	O	O	I-Entity
,	O	O	O
up	O	O	O
to	O	O	O
seven	O	O	O
hemodynamic	O	O	B-Entity
parameters	O	O	B-Entity
can	O	O	O
be	O	O	O
estimated	O	O	B-Entity
concomitantly	O	O	B-Entity
.	O	O	O

Feasibility	O	O	B-Entity
demonstration	O	O	I-Entity
,	O	O	O
flip	O	O	B-Entity
angle	O	O	I-Entity
optimization	O	O	B-Entity
,	O	O	O
comparison	O	O	B-Entity
with	O	O	O
Look-Locker	O	O	B-Entity
ASL	O	O	I-Entity
,	O	O	O
reproducibility	O	O	B-Entity
test	O	O	I-Entity
,	O	O	O
sensitivity	O	O	B-Entity
to	O	O	O
hypercapnia	O	O	B-Entity
challenge	O	O	I-Entity
,	O	O	O
and	O	O	O
initial	O	O	O
clinical	O	O	B-Entity
application	O	O	I-Entity
in	O	O	O
an	O	O	O
intracranial	O	O	B-Entity
steno-occlusive	O	O	I-Entity
process	O	O	I-Entity
,	O	O	O
Moyamoya	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
were	O	O	O
performed	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
this	O	O	O
technique	O	O	B-Entity
.	O	O	O

Magnetic	O	O	B-Entity
resonance	O	O	I-Entity
fingerprinting	O	O	I-Entity
ASL	O	O	I-Entity
provided	O	O	B-Entity
estimation	O	O	O
of	O	O	O
up	O	O	O
to	O	O	O
seven	O	O	O
parameters	O	O	B-Entity
,	O	O	O
including	O	O	O
B1	O	O	B-Entity
+	O	O	I-Entity
,	O	O	O
tissue	O	O	B-Entity
T1	O	O	B-Entity
,	O	O	O
cerebral	O	O	B-Entity
blood	O	O	I-Entity
flow	O	O	I-Entity
(	O	O	O
CBF	O	O	B-Entity
)	O	O	O
,	O	O	O
tissue	O	O	O
bolus	O	O	B-Entity
arrival	O	O	I-Entity
time	O	O	I-Entity
(	O	O	O
BAT	O	O	B-Entity
)	O	O	O
,	O	O	O
pass-through	O	O	O
arterial	O	O	B-Entity
BAT	O	O	O
,	O	O	O
pass-through	O	O	O
blood	O	O	B-Entity
volume	O	O	I-Entity
,	O	O	O
and	O	O	O
pass-through	O	O	O
blood	O	O	B-Entity
travel	O	O	I-Entity
time	O	O	I-Entity
.	O	O	O

Coefficients	O	O	B-Entity
of	O	O	O
variation	O	O	B-Entity
of	O	O	O
the	O	O	O
estimated	O	O	B-Entity
parameters	O	O	B-Entity
ranged	O	O	O
from	O	O	O
0.2	O	O	O
to	O	O	O
9.6	O	O	O
%	O	O	O
.	O	O	O

Hypercapnia	O	O	B-Entity
resulted	O	O	O
in	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
CBF	O	O	B-Entity
by	O	O	O
57.7	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
decrease	O	O	B-Entity
in	O	O	O
BAT	O	O	B-Entity
by	O	O	O
13.7	O	O	O
and	O	O	O
24.8	O	O	O
%	O	O	O
in	O	O	O
tissue	O	O	B-Entity
and	O	O	O
vessels	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
Moyamoya	O	O	B-Entity
disease	O	O	I-Entity
showed	O	O	O
diminished	O	O	B-Entity
CBF	O	O	B-Entity
and	O	O	O
lengthened	O	O	B-Entity
BAT	O	O	B-Entity
that	O	O	O
could	O	O	B-Entity
not	O	O	I-Entity
be	O	O	I-Entity
detected	O	O	I-Entity
with	O	O	O
regular	O	O	B-Entity
ASL	O	O	B-Entity
.	O	O	O

Magnetic	O	O	B-Entity
resonance	O	O	I-Entity
fingerprinting	O	O	I-Entity
ASL	O	O	I-Entity
is	O	O	O
a	O	O	O
promising	O	O	O
technique	O	O	B-Entity
for	O	O	O
noncontrast	O	O	B-Entity
,	O	O	O
multiparametric	O	O	B-Entity
perfusion	O	O	B-Entity
assessment	O	O	I-Entity
.	O	O	O

Magn	O	O	O
Reson	O	O	O
Med	O	O	O
,	O	O	O
2016	O	O	O
.	O	O	O

©	O	O	O
2016	O	O	O
International	O	O	B-Entity
Society	O	O	I-Entity
for	O	O	I-Entity
Magnetic	O	O	I-Entity
Resonance	O	O	I-Entity
in	O	O	I-Entity
Medicine	O	O	I-Entity
.	O	O	O

-DOCSTART- (28019706)

Acute	O	O	B-Entity
sensitivity	O	O	B-Entity
of	O	O	O
the	O	O	O
vernal	O	O	B-Entity
pool	O	O	I-Entity
fairy	O	O	I-Entity
shrimp	O	O	I-Entity
,	O	O	O
Branchinecta	O	O	B-Entity
lynchi	O	O	I-Entity
(	O	O	O
Anostraca	O	O	B-Entity
;	O	O	O
Branchinectidae	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
surrogate	O	O	B-Entity
species	O	O	B-Entity
to	O	O	O
10	O	O	O
chemicals	O	O	O

Vernal	O	O	B-Entity
pool	O	O	I-Entity
fairy	O	O	B-Entity
shrimp	O	O	I-Entity
,	O	O	O
Branchinecta	O	O	B-Entity
lynchi	O	O	I-Entity
,	O	O	O
(	O	O	O
Branchiopoda	O	O	B-Entity
;	O	O	O
Anostraca	O	O	B-Entity
)	O	O	O
and	O	O	O
other	O	O	O
fairy	O	O	O
shrimp	O	O	O
species	O	O	B-Entity
have	O	O	O
been	O	O	O
listed	O	O	O
as	O	O	O
threatened	O	O	B-Entity
or	O	O	O
endangered	O	O	B-Entity
under	O	O	O
the	O	O	O
US	O	O	O
Endangered	O	O	O
Species	O	O	O
Act	O	O	O
.	O	O	O

Because	O	O	O
few	O	O	O
data	O	O	B-Entity
exist	O	O	O
about	O	O	O
the	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
Branchinecta	O	O	B-Entity
spp	O	O	O
.	O	O	O

to	O	O	O
toxic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
contaminants	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
difficult	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
they	O	O	O
are	O	O	O
adequately	O	O	B-Entity
protected	O	O	I-Entity
by	O	O	O
water	O	O	B-Entity
quality	O	O	I-Entity
criteria	O	O	B-Entity
.	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
acute	O	O	B-Entity
(	O	O	I-Entity
24-h	O	O	I-Entity
)	O	O	I-Entity
lethality/immobilization	O	O	I-Entity
tests	O	O	I-Entity
was	O	O	O
conducted	O	O	O
with	O	O	O
3	O	O	O
species	O	O	B-Entity
of	O	O	O
fairy	O	O	B-Entity
shrimp	O	O	I-Entity
(	O	O	O
B.	O	O	B-Entity
lynchi	O	O	I-Entity
,	O	O	O
Branchinecta	O	O	B-Entity
lindahli	O	O	I-Entity
,	O	O	O
and	O	O	O
Thamnocephalus	O	O	B-Entity
platyurus	O	O	I-Entity
)	O	O	O
and	O	O	O
10	O	O	O
chemicals	O	O	B-Entity
with	O	O	O
varying	O	O	O
modes	O	O	O
of	O	O	O
toxic	O	O	B-Entity
action	O	O	I-Entity
:	O	O	O
ammonia	O	O	B-Entity
,	O	O	O
potassium	O	O	B-Entity
,	O	O	O
chloride	O	O	B-Entity
,	O	O	O
sulfate	O	O	B-Entity
,	O	O	O
chromium(VI	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
copper	O	O	B-Entity
,	O	O	O
nickel	O	O	B-Entity
,	O	O	O
zinc	O	O	B-Entity
,	O	O	O
alachlor	O	O	B-Entity
,	O	O	O
and	O	O	O
metolachlor	O	O	B-Entity
.	O	O	O

The	O	O	O
same	O	O	O
chemicals	O	O	B-Entity
were	O	O	O
tested	O	O	O
in	O	O	O
48-	O	O	O
h	O	O	B-Entity
tests	O	O	B-Entity
with	O	O	O
other	O	O	O
branchiopods	O	O	B-Entity
(	O	O	O
the	O	O	O
cladocerans	O	O	B-Entity
Daphnia	O	O	B-Entity
magna	O	O	I-Entity
and	O	O	O
Ceriodaphnia	O	O	B-Entity
dubia	O	O	I-Entity
)	O	O	O
and	O	O	O
an	O	O	O
amphipod	O	O	B-Entity
(	O	O	O
Hyalella	O	O	B-Entity
azteca	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
96-	O	O	O
h	O	O	O
tests	O	O	O
with	O	O	O
snails	O	O	B-Entity
(	O	O	O
Physa	O	O	B-Entity
gyrina	O	O	I-Entity
and	O	O	O
Lymnaea	O	O	B-Entity
stagnalis	O	O	I-Entity
)	O	O	O
.	O	O	O

Median	O	O	O
effect	O	O	B-Entity
concentrations	O	O	I-Entity
(	O	O	O
EC50s	O	O	B-Entity
)	O	O	O
for	O	O	O
B.	O	O	B-Entity
lynchi	O	O	I-Entity
were	O	O	O
strongly	O	O	O
correlated	O	O	B-Entity
(	O	O	O
r(2	O	O	O
)	O	O	O
=	O	O	O
0.975	O	O	O
)	O	O	O
with	O	O	O
EC50s	O	O	O
for	O	O	O
the	O	O	O
commercially	O	O	O
available	O	O	O
fairy	O	O	B-Entity
shrimp	O	O	I-Entity
species	O	O	B-Entity
T.	O	O	B-Entity
platyurus	O	O	I-Entity
for	O	O	O
most	O	O	O
chemicals	O	O	B-Entity
tested	O	O	O
.	O	O	O

Comparison	O	O	B-Entity
of	O	O	O
EC50s	O	O	B-Entity
for	O	O	O
fairy	O	O	B-Entity
shrimp	O	O	I-Entity
and	O	O	O
EC50s	O	O	O
for	O	O	O
invertebrate	O	O	B-Entity
taxa	O	O	I-Entity
tested	O	O	O
concurrently	O	O	O
and	O	O	O
with	O	O	O
other	O	O	O
published	O	O	O
toxicity	O	O	B-Entity
data	O	O	B-Entity
indicated	O	O	O
that	O	O	O
fairy	O	O	O
shrimp	O	O	O
were	O	O	O
relatively	O	O	O
sensitive	O	O	B-Entity
to	O	O	O
potassium	O	O	B-Entity
and	O	O	O
several	O	O	O
trace	O	O	B-Entity
metals	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
other	O	O	O
invertebrate	O	O	O
taxa	O	O	O
,	O	O	O
although	O	O	O
cladocerans	O	O	B-Entity
,	O	O	O
amphipods	O	O	B-Entity
,	O	O	O
and	O	O	O
mussels	O	O	B-Entity
had	O	O	O
similar	O	O	O
broad	O	O	O
toxicant	O	O	B-Entity
sensitivity	O	O	B-Entity
.	O	O	O

Interspecies	O	O	B-Entity
correlation	O	O	I-Entity
estimation	O	O	I-Entity
models	O	O	B-Entity
for	O	O	O
predicting	O	O	O
toxicity	O	O	B-Entity
to	O	O	O
fairy	O	O	B-Entity
shrimp	O	O	I-Entity
from	O	O	O
surrogate	O	O	B-Entity
species	O	O	B-Entity
indicated	O	O	O
that	O	O	O
models	O	O	O
with	O	O	O
cladocerans	O	O	B-Entity
and	O	O	O
freshwater	O	O	B-Entity
mussels	O	O	I-Entity
as	O	O	O
surrogates	O	O	B-Entity
produced	O	O	O
the	O	O	O
best	O	O	O
predictions	O	O	O
of	O	O	O
the	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
fairy	O	O	O
shrimp	O	O	O
to	O	O	O
contaminants	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
of	O	O	O
these	O	O	O
studies	O	O	B-Entity
indicate	O	O	O
that	O	O	O
fairy	O	O	B-Entity
shrimp	O	O	I-Entity
are	O	O	O
relatively	O	O	O
sensitive	O	O	B-Entity
to	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
toxicants	O	O	B-Entity
,	O	O	O
but	O	O	O
Endangered	O	O	O
Species	O	O	O
Act	O	O	O
-listed	O	O	O
fairy	O	O	O
shrimp	O	O	O
of	O	O	O
the	O	O	O
genus	O	O	B-Entity
Branchinecta	O	O	I-Entity
were	O	O	O
not	O	O	O
consistently	O	O	O
more	O	O	O
sensitive	O	O	O
than	O	O	O
other	O	O	O
fairy	O	O	B-Entity
shrimp	O	O	I-Entity
taxa	O	O	I-Entity
.	O	O	O

Environ	O	O	O
Toxicol	O	O	O
Chem	O	O	O
2016;9999:1	O	O	O
-	O	O	O
10	O	O	O
.	O	O	O

Published	O	O	O
2016	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
Inc.	O	O	O
on	O	O	O
behalf	O	O	O
of	O	O	O
SETAC	O	O	O
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
a	O	O	O
US	O	O	O
government	O	O	O
work	O	O	O
and	O	O	O
,	O	O	O
as	O	O	O
such	O	O	O
,	O	O	O
is	O	O	O
in	O	O	O
the	O	O	O
public	O	O	O
domain	O	O	O
in	O	O	O
the	O	O	O
United	O	O	O
States	O	O	O
of	O	O	O
America	O	O	O
.	O	O	O

-DOCSTART- (28024592)

Bi-layered	O	O	B-Entity
constructs	O	O	I-Entity
of	O	O	O
poly(glycerol-sebacate	O	O	B-Entity
)	O	O	I-Entity
-	O	O	O
β-tricalcium	O	O	B-Entity
phosphate	O	O	I-Entity
for	O	O	O
bone-soft	O	O	B-Entity
tissue	O	O	I-Entity
interface	O	O	O
applications	O	O	O

This	O	O	O
study	O	O	B-Entity
aims	O	O	O
to	O	O	O
establish	O	O	O
a	O	O	O
facile	O	O	O
protocol	O	O	B-Entity
for	O	O	O
the	O	O	O
preparation	O	O	B-Entity
of	O	O	O
a	O	O	O
bi-layered	O	O	B-Entity
poly(glycerol-sebacate	O	O	B-Entity
)	O	O	I-Entity
(PGS)/	O	O	O
β-tricalcium	O	O	B-Entity
phosphate	O	O	I-Entity
(	O	O	O
β-TCP	O	O	B-Entity
)	O	O	O
construct	O	O	B-Entity
and	O	O	O
to	O	O	O
investigate	O	O	B-Entity
its	O	O	O
potential	O	O	O
for	O	O	O
bone-soft	O	O	B-Entity
tissue	O	O	I-Entity
engineering	O	O	B-Entity
applications	O	O	B-Entity
.	O	O	O

The	O	O	O
layered	O	O	B-Entity
structure	O	O	I-Entity
was	O	O	O
prepared	O	O	O
by	O	O	O
distributing	O	O	B-Entity
the	O	O	O
ceramic	O	O	B-Entity
particles	O	O	B-Entity
within	O	O	O
a	O	O	O
prepolymer	O	O	B-Entity
synthesized	O	O	B-Entity
in	O	O	O
a	O	O	O
microwave	O	O	B-Entity
reactor	O	O	I-Entity
followed	O	O	O
by	O	O	O
a	O	O	O
cross-linking	O	O	B-Entity
of	O	O	O
the	O	O	O
final	O	O	O
construct	O	O	B-Entity
in	O	O	O
vacuum	O	O	B-Entity
(	O	O	O
<	O	O	O
10	O	O	O
mbar	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
vacuum	O	O	B-Entity
stage	O	O	B-Entity
led	O	O	O
to	O	O	O
the	O	O	O
separation	O	O	B-Entity
of	O	O	O
cross-linked	O	O	B-Entity
elastomer	O	O	B-Entity
(	O	O	O
top	O	O	B-Entity
)	O	O	O
and	O	O	O
ceramic	O	O	B-Entity
(	O	O	O
bottom	O	O	B-Entity
)	O	O	O
phases	O	O	B-Entity
.	O	O	O

Results	O	O	O
showed	O	O	O
that	O	O	O
addition	O	O	O
of	O	O	O
β-TCP	O	O	B-Entity
particles	O	O	B-Entity
to	O	O	O
the	O	O	O
elastomer	O	O	B-Entity
matrix	O	O	I-Entity
after	O	O	O
the	O	O	O
polymerization	O	O	B-Entity
led	O	O	O
to	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
compression	O	O	B-Entity
strength	O	O	I-Entity
(	O	O	O
up	O	O	O
to	O	O	O
14±2.3MPa	O	O	O
)	O	O	O
.	O	O	O

Tensile	O	O	B-Entity
strength	O	O	I-Entity
(	O	O	O
σ	O	O	O
)	O	O	O
,	O	O	O
Young	O	O	B-Entity
's	O	O	I-Entity
modulus	O	O	I-Entity
(	O	O	O
E	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
elongation	O	O	B-Entity
at	O	O	I-Entity
break	O	O	I-Entity
(	O	O	O
%	O	O	O
)	O	O	O
values	O	O	O
were	O	O	O
calculated	O	O	O
as	O	O	O
0.29±0.03MPa	O	O	O
and	O	O	O
0.21±0.03	O	O	O
;	O	O	O
0.38±0.02	O	O	O
and	O	O	O
1.95±0.4	O	O	O
;	O	O	O
and	O	O	O
240±50	O	O	O
%	O	O	O
and	O	O	O
24±2	O	O	O
%	O	O	O
for	O	O	O
PGS	O	O	B-Entity
and	O	O	O
PGS	O	O	O
/	O	O	O
β-TCP	O	O	B-Entity
bi-layered	O	O	B-Entity
constructs	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Morphology	O	O	B-Entity
was	O	O	O
characterized	O	O	O
by	O	O	O
using	O	O	O
Scanning	O	O	B-Entity
Electron	O	O	I-Entity
Microscopy	O	O	I-Entity
(	O	O	O
SEM	O	O	B-Entity
)	O	O	O
and	O	O	O
micro-computed	O	O	B-Entity
tomography	O	O	I-Entity
(	O	O	O
μ-CT	O	O	B-Entity
)	O	O	O
.	O	O	O

Tomography	O	O	B-Entity
data	O	O	B-Entity
revealed	O	O	O
an	O	O	O
open	O	O	B-Entity
porosity	O	O	I-Entity
of	O	O	O
35	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
construct	O	O	B-Entity
,	O	O	O
mostly	O	O	O
contributed	O	O	O
from	O	O	O
the	O	O	O
ceramic	O	O	B-Entity
phase	O	O	I-Entity
since	O	O	O
the	O	O	O
elastomer	O	O	B-Entity
side	O	O	B-Entity
has	O	O	O
no	O	O	O
pore	O	O	B-Entity
.	O	O	O

Homogeneous	O	O	B-Entity
β-TCP	O	O	B-Entity
distribution	O	O	B-Entity
within	O	O	O
the	O	O	O
elastomeric	O	O	B-Entity
structure	O	O	I-Entity
was	O	O	O
observed	O	O	O
.	O	O	O

Cell	O	O	B-Entity
culture	O	O	I-Entity
studies	O	O	I-Entity
confirmed	O	O	O
biocompatibility	O	O	B-Entity
with	O	O	O
poor	O	O	O
elastomer	O	O	B-Entity
-	O	O	O
side	O	O	B-Entity
and	O	O	O
good	O	O	O
bone	O	O	B-Entity
-	O	O	O
side	O	O	O
cell	O	O	B-Entity
attachment	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
further	O	O	O
study	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
osteogenic	O	O	B-Entity
properties	O	O	B-Entity
,	O	O	O
the	O	O	O
construct	O	O	B-Entity
were	O	O	O
loaded	O	O	O
with	O	O	O
BMP-2	O	O	B-Entity
and/or	O	O	O
TGF-β1	O	O	B-Entity
.	O	O	O

The	O	O	O
PGS	O	O	B-Entity
/	O	O	O
β-TCP	O	O	B-Entity
bi-layered	O	O	B-Entity
constructs	O	O	I-Entity
with	O	O	O
improved	O	O	O
mechanical	O	O	B-Entity
and	O	O	O
biological	O	O	B-Entity
properties	O	O	B-Entity
have	O	O	O
the	O	O	O
potential	O	O	O
to	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
bone-soft	O	O	B-Entity
tissue	O	O	I-Entity
interface	O	O	B-Entity
applications	O	O	I-Entity
where	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
penetration	O	O	B-Entity
is	O	O	O
a	O	O	O
problem	O	O	B-Entity
.	O	O	O

-DOCSTART- (28024987)

Effects	O	O	B-Entity
of	O	O	I-Entity
high-intensity	O	O	B-Entity
training	O	O	I-Entity
on	O	O	O
cardiovascular	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
in	O	O	O
premenopausal	O	O	B-Entity
and	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	O

Menopause	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
risk	O	O	O
of	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
the	O	O	O
causal	O	O	O
factors	O	O	B-Entity
have	O	O	O
been	O	O	O
proposed	O	O	O
to	O	O	O
be	O	O	O
the	O	O	O
loss	O	O	B-Entity
of	O	O	O
estrogen	O	O	B-Entity
and	O	O	O
the	O	O	O
subsequent	O	O	O
alterations	O	O	O
of	O	O	O
the	O	O	O
hormonal	O	O	B-Entity
milieu	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
which	O	O	O
factors	O	O	B-Entity
contribute	O	O	B-Entity
to	O	O	O
the	O	O	O
deterioration	O	O	B-Entity
of	O	O	O
cardiometabolic	O	O	B-Entity
health	O	O	I-Entity
in	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
is	O	O	O
debated	O	O	O
as	O	O	O
the	O	O	O
menopausal	O	O	B-Entity
transition	O	O	B-Entity
is	O	O	O
also	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
age	O	O	B-Entity
and	O	O	O
fat	O	O	B-Entity
mass	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
indications	O	O	B-Entity
of	O	O	O
reduced	O	O	B-Entity
cardiometabolic	O	O	B-Entity
adaptations	O	O	B-Entity
to	O	O	O
exercise	O	O	B-Entity
in	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
add	O	O	O
to	O	O	O
the	O	O	O
adverse	O	O	B-Entity
health	O	O	B-Entity
profile	O	O	I-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
and	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
late	O	O	B-Entity
premenopausal	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
,	O	O	O
matched	O	O	O
by	O	O	O
age	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
and	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effect	O	O	O
of	O	O	O
high-intensity	O	O	B-Entity
training	O	O	I-Entity
.	O	O	O

A	O	O	O
3-month	O	O	O
high-intensity	O	O	B-Entity
aerobic	O	O	I-Entity
training	O	O	I-Entity
intervention	O	O	B-Entity
,	O	O	O
involving	O	O	O
healthy	O	O	B-Entity
,	O	O	O
nonobese	O	O	B-Entity
,	O	O	O
late	O	O	B-Entity
premenopausal	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
40	O	O	O
)	O	O	O
and	O	O	O
early	O	O	B-Entity
postmenopausal	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
39	O	O	O
)	O	O	O
women	O	O	B-Entity
was	O	O	O
conducted	O	O	O
and	O	O	O
anthropometrics	O	O	B-Entity
,	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
,	O	O	O
lipid	O	O	B-Entity
profile	O	O	I-Entity
,	O	O	O
glucose	O	O	B-Entity
tolerance	O	O	I-Entity
,	O	O	O
and	O	O	O
maximal	O	O	B-Entity
oxygen	O	O	I-Entity
consumption	O	O	I-Entity
were	O	O	O
determined	O	O	O
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
after	O	O	O
the	O	O	O
intervention	O	O	O
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
,	O	O	O
the	O	O	O
groups	O	O	B-Entity
matched	O	O	O
in	O	O	O
anthropometrics	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
and	O	O	O
only	O	O	O
differed	O	O	O
by	O	O	O
4.2	O	O	O
years	O	O	O
in	O	O	O
age	O	O	B-Entity
(	O	O	O
mean	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
limits	O	O	I-Entity
]	O	O	O
49.2	O	O	O
[	O	O	O
48.5	O	O	O
-	O	O	O
49.9	O	O	O
]	O	O	O
vs	O	O	O
53.4	O	O	O
[	O	O	O
52.4	O	O	O
-	O	O	O
54.4	O	O	O
]	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Time	O	O	O
since	O	O	O
last	O	O	O
menstrual	O	O	B-Entity
period	O	O	I-Entity
for	O	O	O
the	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
was	O	O	O
(	O	O	O
mean	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
confidecnce	O	O	B-Entity
limits	O	O	I-Entity
]	O	O	O
3.1	O	O	O
[	O	O	O
2.6	O	O	O
-	O	O	O
3.7	O	O	O
]	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Hormonal	O	O	B-Entity
levels	O	O	I-Entity
(	O	O	O
estrogen	O	O	B-Entity
,	O	O	O
follicle	O	O	B-Entity
stimulation	O	O	I-Entity
hormone	O	O	I-Entity
,	O	O	O
luteinizing	O	O	B-Entity
hormone	O	O	I-Entity
)	O	O	O
confirmed	O	O	O
menopausal	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

At	O	O	O
baseline	O	O	B-Entity
the	O	O	O
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
had	O	O	O
higher	O	O	O
total	O	O	B-Entity
cholesterol	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
,	O	O	O
low-density	O	O	B-Entity
lipoprotein-cholesterol	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
high-density	O	O	B-Entity
lipoprotein-cholesterol	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
than	O	O	O
the	O	O	O
premenopausal	O	O	B-Entity
women	O	O	O
.	O	O	O

The	O	O	O
training	O	O	O
intervention	O	O	B-Entity
reduced	O	O	B-Entity
body	O	O	B-Entity
weight	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
,	O	O	O
waist	O	O	B-Entity
circumference	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
improved	O	O	B-Entity
body	O	O	B-Entity
composition	O	O	I-Entity
by	O	O	O
increasing	O	O	B-Entity
lean	O	O	B-Entity
body	O	O	I-Entity
mass	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
and	O	O	O
decreasing	O	O	B-Entity
fat	O	O	B-Entity
mass	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
similarly	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
training	O	O	O
resulted	O	O	O
in	O	O	O
lower	O	O	B-Entity
diastolic	O	O	I-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
,	O	O	O
resting	O	O	B-Entity
heart	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
,	O	O	O
total	O	O	B-Entity
cholesterol	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
,	O	O	O
low-density	O	O	B-Entity
lipoprotein-cholesterol	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
,	O	O	O
total	O	O	O
cholesterol	O	O	O
/	O	O	O
high-density	O	O	B-Entity
lipoprotein-cholesterol	O	O	I-Entity
index	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
improved	O	O	B-Entity
plasma	O	O	B-Entity
insulin	O	O	I-Entity
concentration	O	O	I-Entity
during	O	O	O
the	O	O	O
oral	O	O	B-Entity
glucose	O	O	I-Entity
tolerance	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	B-Entity
.	O	O	O

Cardiovascular	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
are	O	O	O
similar	O	O	O
in	O	O	O
late	O	O	B-Entity
premenopausal	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
,	O	O	O
matched	O	O	O
by	O	O	O
age	O	O	B-Entity
and	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
exception	O	O	O
that	O	O	O
postmenopausal	O	O	O
women	O	O	O
have	O	O	O
higher	O	O	O
high-	O	O	B-Entity
and	O	O	O
low-density	O	O	B-Entity
lipoprotein-cholesterol	O	O	I-Entity
levels	O	O	I-Entity
.	O	O	O

A	O	O	O
3-month	O	O	O
intervention	O	O	B-Entity
of	O	O	O
high-intensity	O	O	B-Entity
aerobic	O	O	I-Entity
training	O	O	I-Entity
reduces	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
.diabetes	O	O	I-Entity
and	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
to	O	O	O
a	O	O	O
similar	O	O	O
extent	O	O	O
in	O	O	O
late	O	O	B-Entity
premenopausal	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
postmenopausal	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

-DOCSTART- (28025023)

Correlation	O	O	B-Entity
between	O	O	O
preoperative	O	O	B-Entity
physical	O	O	B-Entity
signs	O	O	I-Entity
and	O	O	O
functional	O	O	B-Entity
outcomes	O	O	B-Entity
after	O	O	O
laminoplasty	O	O	B-Entity
for	O	O	O
ossification	O	O	O
of	O	O	O
the	O	O	O
posterior	O	O	O
longitudinal	O	O	O
ligament	O	O	O

Ossification	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
posterior	O	O	I-Entity
longitudinal	O	O	I-Entity
ligament	O	O	I-Entity
(	O	O	O
OPLL	O	O	B-Entity
)	O	O	O
can	O	O	O
cause	O	O	O
myelopathy	O	O	B-Entity
that	O	O	O
is	O	O	O
often	O	O	B-Entity
managed	O	O	B-Entity
surgically	O	O	B-Entity
.	O	O	O

Knowledge	O	O	B-Entity
of	O	O	O
predictors	O	O	B-Entity
of	O	O	O
surgical	O	O	B-Entity
outcomes	O	O	B-Entity
can	O	O	O
provide	O	O	B-Entity
decision	O	O	B-Entity
support	O	O	I-Entity
to	O	O	O
surgeons	O	O	B-Entity
.	O	O	O

The	O	O	O
aims	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
preoperative	O	O	B-Entity
physical	O	O	B-Entity
signs	O	O	I-Entity
and	O	O	O
postoperative	O	O	B-Entity
functional	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
OPLL	O	O	B-Entity
and	O	O	O
to	O	O	O
clarify	O	O	B-Entity
whether	O	O	O
physical	O	O	O
signs	O	O	O
could	O	O	O
predict	O	O	B-Entity
functional	O	O	O
outcomes	O	O	O
.	O	O	O

Fifty-five	O	O	O
patients	O	O	B-Entity
with	O	O	O
OPLL	O	O	B-Entity
who	O	O	O
had	O	O	O
undergone	O	O	O
cervical	O	O	B-Entity
laminoplasty	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Six	O	O	O
physical	O	O	B-Entity
signs	O	O	I-Entity
including	O	O	O
hyperreflexia	O	O	B-Entity
,	O	O	O
Babinski	O	O	B-Entity
sign	O	O	I-Entity
,	O	O	O
sensory	O	O	B-Entity
disturbance	O	O	I-Entity
,	O	O	O
grip	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
10-s	O	O	B-Entity
grip	O	O	I-Entity
and	O	O	I-Entity
release	O	O	I-Entity
test	O	O	I-Entity
,	O	O	O
and	O	O	O
bladder	O	O	B-Entity
dysfunction	O	O	I-Entity
,	O	O	O
and	O	O	O
four	O	O	O
other	O	O	O
factors	O	O	B-Entity
including	O	O	O
age	O	O	B-Entity
,	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
symptoms	O	O	I-Entity
,	O	O	O
history	O	O	O
of	O	O	O
minor	O	O	B-Entity
trauma	O	O	I-Entity
and	O	O	O
preoperative	O	O	B-Entity
Japanese	O	O	B-Entity
Orthopaedic	O	O	I-Entity
Association	O	O	I-Entity
(	O	O	I-Entity
JOA	O	O	I-Entity
)	O	O	I-Entity
score	O	O	I-Entity
were	O	O	O
investigated	O	O	B-Entity
as	O	O	O
potential	O	O	B-Entity
predictive	O	O	B-Entity
prognostic	O	O	B-Entity
factors	O	O	I-Entity
using	O	O	O
both	O	O	O
univariate	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
analyses	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
recovery	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
JOA	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
62.5	O	O	O
±	O	O	O
32.5	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
neurological	O	O	B-Entity
recovery	O	O	B-Entity
rate	O	O	I-Entity
was	O	O	O
negatively	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
age	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
duration	O	O	B-Entity
of	O	O	I-Entity
symptoms	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
and	O	O	O
Babinski	O	O	B-Entity
sign	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.007	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
it	O	O	O
was	O	O	O
positively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
grip	O	O	B-Entity
strength	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.011	O	O	O
)	O	O	O
.	O	O	O

Multiple	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
revealed	O	O	B-Entity
that	O	O	O
age	O	O	B-Entity
(	O	O	O
Odds	O	O	B-Entity
ratio	O	O	I-Entity
:	O	O	O
0.89	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.81	O	O	O
-	O	O	O
0.99	O	O	O
)	O	O	O
and	O	O	O
Babinski	O	O	B-Entity
sign	O	O	I-Entity
(	O	O	O
Odds	O	O	O
ratio	O	O	O
:	O	O	O
0.18	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.04	O	O	O
-	O	O	O
0.89	O	O	O
)	O	O	O
were	O	O	O
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
functional	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

Satisfactory	O	O	B-Entity
functional	O	O	B-Entity
outcomes	O	O	B-Entity
could	O	O	O
be	O	O	O
expected	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
who	O	O	O
are	O	O	O
young	O	O	B-Entity
and	O	O	O
do	O	O	O
not	O	O	O
exhibit	O	O	O
the	O	O	O
Babinski	O	O	B-Entity
sign	O	O	I-Entity
,	O	O	O
showing	O	O	O
that	O	O	O
the	O	O	O
Babinski	O	O	O
sign	O	O	O
could	O	O	O
be	O	O	O
useful	O	O	B-Entity
as	O	O	O
an	O	O	O
indicator	O	O	B-Entity
of	O	O	O
the	O	O	O
window	O	O	B-Entity
of	O	O	I-Entity
opportunity	O	O	I-Entity
for	O	O	O
achieving	O	O	B-Entity
satisfactory	O	O	B-Entity
functional	O	O	O
outcomes	O	O	O
.	O	O	O

-DOCSTART- (28025224)

Bacteria	O	O	B-Entity
and	O	O	O
Hoverflies	O	O	B-Entity
(	O	O	O
Diptera	O	O	B-Entity
:	O	O	O
Syrphidae	O	O	B-Entity
)	O	O	O
in	O	O	O
Tree	O	O	B-Entity
Hollows	O	O	I-Entity
From	O	O	O
the	O	O	O
Iberian	O	O	O
Mediterranean	O	O	O
Forest	O	O	O

Saproxylic	O	O	B-Entity
insect	O	O	I-Entity
communities	O	O	I-Entity
inhabiting	O	O	B-Entity
tree	O	O	B-Entity
hollows	O	O	I-Entity
in	O	O	O
Mediterranean	O	O	B-Entity
forests	O	O	I-Entity
depend	O	O	O
on	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
physical	O	O	B-Entity
characteristics	O	O	I-Entity
and	O	O	O
interactions	O	O	B-Entity
occurring	O	O	O
between	O	O	O
community	O	O	B-Entity
member	O	O	I-Entity
species	O	O	I-Entity
.	O	O	O

Despite	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
preserve	O	O	O
these	O	O	O
organisms	O	O	B-Entity
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
their	O	O	O
interrelationships	O	O	B-Entity
,	O	O	O
in	O	O	O
particular	O	O	O
those	O	O	O
relationships	O	O	B-Entity
between	O	O	O
saproxylic	O	O	B-Entity
insects	O	O	I-Entity
and	O	O	O
microbiota	O	O	B-Entity
occurring	O	O	O
in	O	O	O
these	O	O	O
microhabitats	O	O	B-Entity
.	O	O	O

In	O	O	O
tree	O	O	B-Entity
hollows	O	O	I-Entity
of	O	O	O
Quercus	O	O	B-Entity
rotundifolia	O	O	I-Entity
Lamark	O	O	I-Entity
that	O	O	O
hold	O	O	B-Entity
water	O	O	I-Entity
and	O	O	O
contain	O	O	O
dead	O	O	B-Entity
leaves	O	O	I-Entity
,	O	O	O
abundant	O	O	B-Entity
microbial	O	O	I-Entity
populations	O	O	I-Entity
can	O	O	O
be	O	O	O
found	O	O	O
.	O	O	O

Developing	O	O	O
on	O	O	O
them	O	O	O
are	O	O	O
the	O	O	O
larvae	O	O	B-Entity
of	O	O	O
Mallota	O	O	B-Entity
dusmeti	O	O	I-Entity
Andréu	O	O	O
,	O	O	O
1926	O	O	O
(	O	O	O
Diptera	O	O	B-Entity
:	O	O	O
Syrphidae	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
vulnerable	O	O	B-Entity
species	O	O	I-Entity
(	O	O	O
IUCN	O	O	B-Entity
category	O	O	I-Entity
:	O	O	O
Marcos-García	O	O	B-Entity
and	O	O	O
Quinto	O	O	B-Entity
2011	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
provides	O	O	O
the	O	O	O
first	O	O	O
data	O	O	O
on	O	O	O
the	O	O	O
microbiota	O	O	B-Entity
living	O	O	B-Entity
inside	O	O	I-Entity
the	O	O	O
gut	O	O	B-Entity
of	O	O	O
the	O	O	O
larvae	O	O	B-Entity
of	O	O	O
M.	O	O	B-Entity
dusmeti	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
microbiota	O	O	O
in	O	O	O
the	O	O	O
hollow	O	O	B-Entity
where	O	O	O
these	O	O	O
larvae	O	O	O
develop	O	O	B-Entity
.	O	O	O

Bacteria	O	O	B-Entity
were	O	O	O
identified	O	O	O
by	O	O	O
amplification	O	O	B-Entity
and	O	O	I-Entity
partial	O	O	I-Entity
sequencing	O	O	I-Entity
of	O	O	O
the	O	O	O
V1-V3	O	O	B-Entity
regions	O	O	I-Entity
and	O	O	O
the	O	O	O
complete	O	O	O
nucleotide	O	O	B-Entity
sequence	O	O	I-Entity
of	O	O	O
16S	O	O	B-Entity
rRNA	O	O	I-Entity
genes	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
eight	O	O	O
species	O	O	B-Entity
of	O	O	I-Entity
bacteria	O	O	B-Entity
living	O	O	B-Entity
in	O	O	I-Entity
tree	O	O	B-Entity
hollows	O	O	I-Entity
and	O	O	O
three	O	O	O
species	O	O	O
in	O	O	B-Entity
the	O	O	I-Entity
gut	O	O	I-Entity
of	O	O	O
M.	O	O	B-Entity
dusmeti	O	O	I-Entity
larvae	O	O	B-Entity
:	O	O	O
Bacillus	O	O	B-Entity
cereus	O	O	I-Entity
,	O	O	O
Bacillus	O	O	B-Entity
toyonensis	O	O	I-Entity
,	O	O	O
and	O	O	O
Lysinibacillus	O	O	B-Entity
sphaericus	O	O	I-Entity
The	O	O	O
filter-feeding	O	O	B-Entity
mechanism	O	O	I-Entity
characteristic	O	O	I-Entity
of	O	O	O
M.	O	O	O
dusmeti	O	O	O
larvae	O	O	O
is	O	O	O
selective	O	O	O
in	O	O	O
enabling	O	O	O
ingestion	O	O	B-Entity
of	O	O	O
bacteria	O	O	O
only	O	O	O
above	O	O	O
2.1	O	O	O
µm	O	O	O
in	O	O	O
diameter	O	O	O
.	O	O	O

-DOCSTART- (28026207)

Impact	O	O	B-Entity
sports	O	O	I-Entity
and	O	O	O
bone	O	O	B-Entity
fractures	O	O	I-Entity
among	O	O	O
adolescents	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
different	O	O	B-Entity
sports	O	O	B-Entity
on	O	O	O
stress	O	O	B-Entity
fractures	O	O	I-Entity
among	O	O	O
adolescents	O	O	B-Entity
during	O	O	O
a	O	O	O
9-	O	O	O
month	O	O	B-Entity
follow-up	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

The	O	O	O
sample	O	O	B-Entity
was	O	O	O
composed	O	O	O
of	O	O	O
184	O	O	O
adolescents	O	O	B-Entity
divided	O	O	O
into	O	O	O
three	O	O	O
groups	O	O	B-Entity
(	O	O	O
impact	O	O	B-Entity
sports	O	O	I-Entity
[	O	O	O
n	O	O	O
=	O	O	O
102	O	O	O
]	O	O	O
;	O	O	O
swimming	O	O	B-Entity
[	O	O	O
n	O	O	O
=	O	O	O
35	O	O	O
]	O	O	O
;	O	O	O
non-sports	O	O	B-Entity
[	O	O	O
n	O	O	O
=	O	O	O
47	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
stress	O	O	B-Entity
fracture	O	O	I-Entity
was	O	O	O
reported	O	O	O
by	O	O	O
participants	O	O	B-Entity
and	O	O	O
coaches	O	O	B-Entity
.	O	O	O

As	O	O	O
potential	O	O	O
confounders	O	O	B-Entity
we	O	O	O
considered	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
resistance	O	O	B-Entity
training	O	O	I-Entity
,	O	O	O
body	O	O	B-Entity
composition	O	O	I-Entity
variables	O	O	B-Entity
and	O	O	O
age	O	O	O
at	O	O	O
peak	O	O	B-Entity
of	O	O	O
height	O	O	B-Entity
velocity	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
13	O	O	O
adolescents	O	O	B-Entity
who	O	O	O
reported	O	O	O
fractures	O	O	B-Entity
during	O	O	O
the	O	O	O
9-	O	O	O
month	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Bone	O	O	B-Entity
mineral	O	O	I-Entity
density	O	O	I-Entity
values	O	O	B-Entity
were	O	O	O
higher	O	O	O
in	O	O	O
adolescents	O	O	B-Entity
engaged	O	O	O
in	O	O	O
impact	O	O	B-Entity
sports	O	O	I-Entity
(	O	O	O
P-value	O	O	B-Entity
=	O	O	O
0.002	O	O	O
)	O	O	O
.	O	O	O

Independently	O	O	O
of	O	O	O
confounders	O	O	B-Entity
,	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
stress	O	O	B-Entity
fracture	O	O	B-Entity
was	O	O	O
lower	O	O	O
in	O	O	O
adolescents	O	O	B-Entity
engaged	O	O	O
in	O	O	O
impact	O	O	B-Entity
sports	O	O	I-Entity
than	O	O	O
in	O	O	O
non-active	O	O	B-Entity
adolescents	O	O	I-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
HR	O	O	B-Entity
]	O	O	O
=	O	O	O
0.23	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
=	O	O	O
0.05	O	O	O
to	O	O	O
0.98	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
swimming	O	O	B-Entity
practice	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	O
to	O	O	O
lower	O	O	O
risk	O	O	O
of	O	O	O
fracture	O	O	O
(	O	O	O
HR	O	O	O
=	O	O	O
0.49	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0.09	O	O	O
to	O	O	O
2.55	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
findings	O	O	B-Entity
from	O	O	O
this	O	O	O
study	O	O	B-Entity
indicate	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
sports	O	O	B-Entity
participation	O	O	B-Entity
among	O	O	O
adolescents	O	O	B-Entity
in	O	O	O
the	O	O	O
reduction	O	O	B-Entity
of	O	O	O
stress	O	O	B-Entity
fracture	O	O	I-Entity
risk	O	O	B-Entity
,	O	O	O
especially	O	O	O
with	O	O	O
impact	O	O	B-Entity
sports	O	O	I-Entity
.	O	O	O

More	O	O	O
importantly	O	O	O
,	O	O	O
these	O	O	O
results	O	O	B-Entity
could	O	O	O
be	O	O	O
relevant	O	O	B-Entity
for	O	O	O
recognising	O	O	O
adolescents	O	O	B-Entity
in	O	O	O
danger	O	O	O
of	O	O	O
not	O	O	O
reaching	O	O	O
their	O	O	O
potential	O	O	O
for	O	O	O
peak	O	O	B-Entity
bone	O	O	B-Entity
mass	O	O	I-Entity
and	O	O	O
later	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
fractures	O	O	B-Entity
.	O	O	O

-DOCSTART- (28027163)

The	O	O	O
Business	O	O	B-Entity
of	O	O	O
Health	O	O	B-Entity
Physics	O	O	I-Entity
-	O	O	O
Jobs	O	O	B-Entity
In	O	O	O
A	O	O	O
Changing	O	O	O
Market	O	O	O

The	O	O	O
health	O	O	B-Entity
physics	O	O	I-Entity
profession	O	O	B-Entity
was	O	O	O
born	O	O	O
abruptly	O	O	O
when	O	O	O
once	O	O	O
rare	O	O	O
and	O	O	O
precious	O	O	O
radioactive	O	O	B-Entity
materials	O	O	I-Entity
became	O	O	O
commonplace	O	O	B-Entity
.	O	O	O

The	O	O	O
technological	O	O	B-Entity
advancements	O	O	I-Entity
that	O	O	O
triggered	O	O	O
an	O	O	O
industrial	O	O	B-Entity
complex	O	O	I-Entity
and	O	O	O
ended	O	O	O
World	O	O	B-Entity
War	O	O	I-Entity
II	O	O	I-Entity
demanded	O	O	O
radiation	O	O	B-Entity
safety	O	O	I-Entity
on	O	O	O
an	O	O	O
unprecedented	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

Until	O	O	O
then	O	O	O
,	O	O	O
protective	O	O	B-Entity
measures	O	O	I-Entity
against	O	O	I-Entity
radiation	O	O	I-Entity
were	O	O	O
largely	O	O	O
absent	O	O	O
in	O	O	O
laboratories	O	O	B-Entity
.	O	O	O

Over	O	O	O
the	O	O	O
subsequent	O	O	O
decades	O	O	O
,	O	O	O
health	O	O	B-Entity
physicists	O	O	I-Entity
began	O	O	O
protecting	O	O	B-Entity
people	O	O	I-Entity
and	O	O	O
the	O	O	O
environment	O	O	B-Entity
in	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
settings	O	O	O
including	O	O	O
medical	O	O	B-Entity
,	O	O	O
research	O	O	B-Entity
,	O	O	O
and	O	O	O
industrial	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
radioactive	O	O	I-Entity
materials	O	O	I-Entity
and	O	O	O
radiation-generating	O	O	B-Entity
devices	O	O	I-Entity
is	O	O	O
prevalent	O	O	B-Entity
today	O	O	I-Entity
.	O	O	O

Radiation	O	O	B-Entity
doses	O	O	I-Entity
occur	O	O	O
continuously	O	O	O
including	O	O	O
during	O	O	O
airline	O	O	B-Entity
flights	O	O	I-Entity
,	O	O	O
in	O	O	O
our	O	O	O
homes	O	O	O
,	O	O	O
during	O	O	O
medical	O	O	B-Entity
procedures	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
energy	O	O	O
production	O	O	O
.	O	O	O

Radiation	O	O	B-Entity
is	O	O	O
integral	O	O	B-Entity
to	O	O	I-Entity
numerous	O	O	I-Entity
applications	O	O	I-Entity
including	O	O	O
those	O	O	O
in	O	O	O
medicine	O	O	B-Entity
,	O	O	O
dentistry	O	O	B-Entity
,	O	O	O
manufacturing	O	O	B-Entity
,	O	O	O
construction	O	O	O
,	O	O	O
scientific	O	O	B-Entity
research	O	O	I-Entity
,	O	O	O
nuclear	O	O	B-Entity
electric	O	O	I-Entity
power	O	O	I-Entity
generation	O	O	I-Entity
,	O	O	O
and	O	O	O
oil	O	O	B-Entity
and	O	O	I-Entity
gas	O	O	I-Entity
exploration	O	O	I-Entity
.	O	O	O

Activities	O	O	O
that	O	O	O
were	O	O	O
once	O	O	O
groundbreaking	O	O	O
have	O	O	O
now	O	O	O
become	O	O	O
routine	O	O	B-Entity
and	O	O	O
scripted	O	O	B-Entity
.	O	O	O

At	O	O	O
higher	O	O	B-Entity
doses	O	O	I-Entity
,	O	O	O
health	O	O	B-Entity
effects	O	O	I-Entity
are	O	O	O
understood	O	O	B-Entity
and	O	O	I-Entity
avoided	O	O	I-Entity
.	O	O	O

Instruments	O	O	B-Entity
for	O	O	I-Entity
the	O	O	I-Entity
detection	O	O	I-Entity
and	O	O	I-Entity
measurement	O	O	I-Entity
of	O	O	I-Entity
radiation	O	O	I-Entity
are	O	O	O
at	O	O	O
times	O	O	O
smarter	O	O	O
than	O	O	O
their	O	O	O
users	O	O	O
.	O	O	O

Ironically	O	O	O
,	O	O	O
the	O	O	O
same	O	O	O
health	O	O	B-Entity
physics	O	O	I-Entity
community	O	O	O
that	O	O	O
has	O	O	O
been	O	O	O
successful	O	O	O
in	O	O	O
demonstrating	O	O	O
that	O	O	O
exposures	O	O	B-Entity
to	O	O	I-Entity
radiation	O	O	I-Entity
and	O	O	O
to	O	O	O
radioactive	O	O	B-Entity
materials	O	O	I-Entity
can	O	O	O
be	O	O	O
effectively	O	O	B-Entity
managed	O	O	I-Entity
is	O	O	O
shrinking	O	O	O
at	O	O	O
an	O	O	O
increasingly	O	O	O
rapid	O	O	B-Entity
rate	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
highlights	O	O	O
the	O	O	O
creation	O	O	B-Entity
of	O	O	O
past	O	O	O
and	O	O	O
current	O	O	O
jobs	O	O	B-Entity
,	O	O	O
predicts	O	O	O
the	O	O	O
future	O	O	O
opportunities	O	O	B-Entity
in	O	O	I-Entity
the	O	O	I-Entity
profession	O	O	I-Entity
,	O	O	O
and	O	O	O
makes	O	O	O
recommendations	O	O	B-Entity
necessary	O	O	O
to	O	O	O
protect	O	O	O
the	O	O	O
disappearing	O	O	B-Entity
specialties	O	O	I-Entity
.	O	O	O

-DOCSTART- (28032366)

Permanence	O	O	B-Entity
can	O	O	O
be	O	O	O
Defended	O	O	O

In	O	O	O
donation	O	O	B-Entity
after	O	O	O
the	O	O	O
circulatory-respiratory	O	O	B-Entity
determination	O	O	I-Entity
of	O	O	I-Entity
death	O	O	I-Entity
(	O	O	O
DCDD	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
dead	O	O	B-Entity
donor	O	O	B-Entity
rule	O	O	B-Entity
requires	O	O	B-Entity
that	O	O	O
the	O	O	O
donor	O	O	O
be	O	O	O
dead	O	O	O
before	O	O	B-Entity
organ	O	O	B-Entity
procurement	O	O	I-Entity
can	O	O	O
proceed	O	O	O
.	O	O	O

Under	O	O	O
the	O	O	O
relevant	O	O	B-Entity
limb	O	O	I-Entity
of	O	O	O
the	O	O	O
Uniform	O	O	B-Entity
Determination	O	O	I-Entity
of	O	O	I-Entity
Death	O	O	I-Entity
Act	O	O	I-Entity
1981	O	O	I-Entity
(	O	O	I-Entity
USA	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
a	O	O	O
person	O	O	B-Entity
is	O	O	O
dead	O	O	B-Entity
when	O	O	O
the	O	O	O
cessation	O	O	B-Entity
of	O	O	O
circulatory-respiratory	O	O	B-Entity
function	O	O	I-Entity
is	O	O	O
'	O	O	O
irreversible	O	O	B-Entity
'	O	O	O
.	O	O	O

Critics	O	O	B-Entity
of	O	O	O
current	O	O	B-Entity
practice	O	O	B-Entity
in	O	O	O
DCDD	O	O	B-Entity
have	O	O	O
argued	O	O	B-Entity
that	O	O	O
the	O	O	O
donor	O	O	B-Entity
is	O	O	O
not	O	O	O
dead	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
organs	O	O	B-Entity
are	O	O	O
procured	O	O	B-Entity
,	O	O	O
and	O	O	O
so	O	O	O
the	O	O	O
procurement	O	O	B-Entity
of	O	O	I-Entity
organs	O	O	I-Entity
from	O	O	O
these	O	O	O
donors	O	O	B-Entity
violates	O	O	O
the	O	O	O
dead	O	O	O
donor	O	O	O
rule	O	O	B-Entity
.	O	O	O

We	O	O	O
offer	O	O	B-Entity
a	O	O	O
new	O	O	B-Entity
argument	O	O	B-Entity
here	O	O	O
in	O	O	O
defence	O	O	B-Entity
of	O	O	O
current	O	O	B-Entity
DCDD	O	O	B-Entity
practice	O	O	B-Entity
,	O	O	O
and	O	O	O
,	O	O	O
in	O	O	O
particular	O	O	O
,	O	O	O
of	O	O	O
the	O	O	O
interpretation	O	O	B-Entity
of	O	O	O
the	O	O	O
requirement	O	O	B-Entity
of	O	O	O
'	O	O	O
irreversibility	O	O	B-Entity
'	O	O	O
as	O	O	O
permanence	O	O	B-Entity
.	O	O	O

-DOCSTART- (28033725)

Untypeable	O	O	B-Entity
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
subtypes	O	O	B-Entity
in	O	O	O
Pakistan	O	O	B-Entity
:	O	O	O
A	O	O	O
neglected	O	O	O
section	O	O	O

Diagnostically	O	O	B-Entity
untypeable	O	O	B-Entity
subtypes	O	O	B-Entity
contribute	O	O	O
a	O	O	O
considerable	O	O	O
percent	O	O	O
of	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
(	O	O	O
HCV	O	O	B-Entity
)	O	O	O
subtypes	O	O	O
in	O	O	O
Pakistan	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
chronically	O	O	B-Entity
infected	O	O	I-Entity
HCV	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
known	O	O	O
viremia	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
HCV	O	O	O
genotyping	O	O	B-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
total	O	O	O
retrieved	O	O	O
samples	O	O	B-Entity
,	O	O	O
92.7	O	O	O
%	O	O	O
(	O	O	O
64/69	O	O	O
)	O	O	O
were	O	O	O
found	O	O	O
typeable	O	O	B-Entity
while	O	O	O
7.24	O	O	O
%	O	O	O
(	O	O	O
5/69	O	O	O
)	O	O	O
were	O	O	O
diagnostically	O	O	B-Entity
untypeable	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
large	O	O	O
number	O	O	O
of	O	O	O
untypeable	O	O	B-Entity
HCV	O	O	B-Entity
subtypes	O	O	B-Entity
emphasizes	O	O	O
the	O	O	O
need	O	O	O
of	O	O	O
an	O	O	O
updated	O	O	O
type	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
genotyping	O	O	B-Entity
assay	O	O	B-Entity
and	O	O	O
consideration	O	O	O
of	O	O	O
primers	O	O	B-Entity
for	O	O	O
proportionally	O	O	O
rare	O	O	B-Entity
subtypes	O	O	O
to	O	O	O
minimize	O	O	B-Entity
the	O	O	O
number	O	O	O
of	O	O	O
untypeable	O	O	O
HCV	O	O	O
subtypes	O	O	O
.	O	O	O

-DOCSTART- (28036301)

ITPR3	O	O	B-Entity
gene	O	O	I-Entity
haplotype	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
cervical	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
risk	O	O	B-Entity
in	O	O	O
Taiwanese	O	O	B-Entity
women	O	O	O

Host	O	O	B-Entity
immunogenetic	O	O	I-Entity
background	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(	O	O	I-Entity
HPV	O	O	I-Entity
)	O	O	I-Entity
infection	O	O	I-Entity
and	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
development	O	O	I-Entity
.	O	O	O

Inositol	O	O	B-Entity
1,4,5-triphosphate	O	O	I-Entity
receptor	O	O	I-Entity
type	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
ITPR3	O	O	B-Entity
)	O	O	O
is	O	O	O
essential	O	O	O
for	O	O	O
both	O	O	O
immune	O	O	B-Entity
activation	O	O	I-Entity
and	O	O	O
cancer	O	O	B-Entity
pathogenesis	O	O	B-Entity
.	O	O	O

We	O	O	O
aim	O	O	O
to	O	O	O
investigate	O	O	O
if	O	O	O
ITPR3	O	O	B-Entity
genetic	O	O	B-Entity
polymorphisms	O	O	I-Entity
are	O	O	O
associated	O	O	O
with	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
cervical	O	O	I-Entity
cancer	O	O	I-Entity
in	O	O	O
Taiwanese	O	O	B-Entity
women	O	O	B-Entity
.	O	O	O

ITPR3	O	O	B-Entity
rs3748079	O	O	B-Entity
A/G	O	O	I-Entity
and	O	O	O
rs2229634	O	O	B-Entity
C/T	O	O	I-Entity
polymorphisms	O	O	I-Entity
were	O	O	O
genotyped	O	O	B-Entity
in	O	O	O
a	O	O	O
hospital-based	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
462	O	O	O
women	O	O	B-Entity
with	O	O	O
cervical	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
CSCC	O	O	B-Entity
)	O	O	O
and	O	O	O
921	O	O	O
age-matched	O	O	O
healthy	O	O	B-Entity
control	O	O	I-Entity
women	O	O	O
.	O	O	O

The	O	O	O
presence	O	O	O
and	O	O	O
genotypes	O	O	B-Entity
of	O	O	O
HPV	O	O	B-Entity
in	O	O	O
CSCC	O	O	B-Entity
was	O	O	O
determined	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	O
association	O	O	O
of	O	O	O
individual	O	O	O
ITPR3	O	O	B-Entity
variants	O	O	B-Entity
were	O	O	O
found	O	O	O
among	O	O	O
controls	O	O	O
,	O	O	O
CSCC	O	O	B-Entity
,	O	O	O
and	O	O	O
HPV-16	O	O	B-Entity
positive	O	O	I-Entity
CSCC	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	O
of	O	O	O
haplotype	O	O	B-Entity
AT	O	O	I-Entity
between	O	O	O
CSCC	O	O	B-Entity
and	O	O	O
controls	O	O	O
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
2.28	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
1.31	O	O	O
-	O	O	O
3.97	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
2.83	O	O	O
×	O	O	O
10	O	O	O
-	O	O	O
3	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
OR	O	O	O
increased	O	O	O
further	O	O	O
in	O	O	O
CSCC	O	O	O
patients	O	O	B-Entity
infected	O	O	I-Entity
with	O	O	O
HPV-16	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
2.89	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.55	O	O	O
-	O	O	O
5.37	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
4.54	O	O	O
×	O	O	O
10	O	O	O
-	O	O	O
4	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
linkage	O	O	B-Entity
disequilibrium	O	O	I-Entity
analysis	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
ITPR3	O	O	B-Entity
association	O	O	B-Entity
with	O	O	O
CSCC	O	O	B-Entity
was	O	O	O
independent	O	O	O
of	O	O	O
HLA-DRB1	O	O	B-Entity
alleles	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
AT	O	O	B-Entity
haplotype	O	O	I-Entity
in	O	O	O
the	O	O	O
ITPR3	O	O	B-Entity
gene	O	O	I-Entity
may	O	O	O
serve	O	O	O
as	O	O	O
a	O	O	O
potential	O	O	B-Entity
marker	O	O	I-Entity
for	O	O	O
genetic	O	O	B-Entity
susceptibility	O	O	I-Entity
to	O	O	O
CSCC	O	O	B-Entity
.	O	O	O

-DOCSTART- (28039284)

Defining	O	O	O
categories	O	O	B-Entity
of	O	O	O
actionability	O	O	B-Entity
for	O	O	O
secondary	O	O	B-Entity
findings	O	O	B-Entity
in	O	O	O
next-generation	O	O	O
sequencing	O	O	O

Next-generation	O	O	B-Entity
sequencing	O	O	I-Entity
is	O	O	O
increasingly	O	O	O
used	O	O	O
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
for	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
Mendelian	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Because	O	O	O
of	O	O	O
the	O	O	O
high	O	O	O
likelihood	O	O	O
of	O	O	O
secondary	O	O	B-Entity
findings	O	O	B-Entity
associated	O	O	O
with	O	O	O
this	O	O	O
technique	O	O	B-Entity
,	O	O	O
the	O	O	O
process	O	O	O
of	O	O	O
informing	O	O	B-Entity
patients	O	O	I-Entity
is	O	O	O
beset	O	O	O
with	O	O	O
new	O	O	O
challenges	O	O	O
.	O	O	O

One	O	O	O
of	O	O	O
them	O	O	O
is	O	O	O
regarding	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
secondary	O	O	B-Entity
findings	O	O	B-Entity
that	O	O	O
ought	O	O	O
to	O	O	O
be	O	O	O
disclosed	O	O	O
to	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
research	O	O	B-Entity
is	O	O	O
to	O	O	O
propose	O	O	O
a	O	O	O
practical	O	O	O
implementation	O	O	B-Entity
of	O	O	O
the	O	O	O
notion	O	O	O
of	O	O	O
actionability	O	O	B-Entity
,	O	O	O
a	O	O	O
common	O	O	O
criteria	O	O	O
justifying	O	O	O
the	O	O	O
disclosure	O	O	B-Entity
of	O	O	O
secondary	O	O	B-Entity
findings	O	O	B-Entity
but	O	O	O
whose	O	O	O
interpretation	O	O	B-Entity
varies	O	O	O
greatly	O	O	O
among	O	O	O
professionals	O	O	B-Entity
.	O	O	O

We	O	O	O
distinguish	O	O	O
three	O	O	O
types	O	O	O
of	O	O	O
actionability	O	O	B-Entity
corresponding	O	O	O
to	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
well-established	O	O	O
medical	O	O	B-Entity
actions	O	O	B-Entity
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
patient	O	O	B-Entity
-initiated	O	O	O
health-related	O	O	B-Entity
actions	O	O	I-Entity
and	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
life-plan	O	O	B-Entity
decisions	O	O	I-Entity
.	O	O	O

We	O	O	O
argue	O	O	O
that	O	O	O
actionability	O	O	B-Entity
depends	O	O	O
on	O	O	O
the	O	O	O
characteristics	O	O	O
of	O	O	O
the	O	O	O
mutation	O	O	B-Entity
or	O	O	O
gene	O	O	B-Entity
and	O	O	O
on	O	O	O
the	O	O	O
values	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

In	O	O	O
discussing	O	O	O
the	O	O	O
return	O	O	O
of	O	O	O
secondary	O	O	B-Entity
findings	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
important	O	O	O
that	O	O	O
the	O	O	O
physician	O	O	B-Entity
tries	O	O	O
to	O	O	O
get	O	O	O
an	O	O	O
impression	O	O	B-Entity
of	O	O	O
the	O	O	O
specific	O	O	O
situation	O	O	O
and	O	O	O
values	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

Regarding	O	O	O
variants	O	O	B-Entity
of	O	O	O
uncertain	O	O	O
clinical	O	O	B-Entity
significance	O	O	I-Entity
in	O	O	O
actionable	O	O	O
genes	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
different	O	O	O
understandings	O	O	O
of	O	O	O
autonomy	O	O	B-Entity
lead	O	O	O
to	O	O	O
different	O	O	O
conclusions	O	O	B-Entity
and	O	O	O
that	O	O	O
,	O	O	O
for	O	O	O
some	O	O	O
of	O	O	O
them	O	O	O
,	O	O	O
it	O	O	O
may	O	O	O
be	O	O	O
legitimate	O	O	O
to	O	O	O
refrain	O	O	O
from	O	O	O
returning	O	O	O
uncertain	O	O	O
information	O	O	B-Entity
.	O	O	O

-DOCSTART- (28039304)

Allergen	O	O	B-Entity
Valency	O	O	B-Entity
,	O	O	O
Dose	O	O	B-Entity
,	O	O	O
and	O	O	O
FcεRI	O	O	B-Entity
Occupancy	O	O	B-Entity
Set	O	O	O
Thresholds	O	O	B-Entity
for	O	O	O
Secretory	O	O	B-Entity
Responses	O	O	I-Entity
to	O	O	O
Pen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
and	O	O	O
Motivate	O	O	O
Design	O	O	B-Entity
of	O	O	O
Hypoallergens	O	O	O

Ag	O	O	B-Entity
-mediated	O	O	O
crosslinking	O	O	B-Entity
of	O	O	O
IgE	O	O	B-Entity
-	O	O	O
FcεRI	O	O	B-Entity
complexes	O	O	B-Entity
activates	O	O	O
mast	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
basophils	O	O	B-Entity
,	O	O	O
initiating	O	O	O
the	O	O	O
allergic	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

Of	O	O	O
34	O	O	O
donors	O	O	O
recruited	O	O	O
having	O	O	O
self-reported	O	O	B-Entity
shrimp	O	O	B-Entity
allergy	O	O	I-Entity
,	O	O	O
only	O	O	O
35	O	O	O
%	O	O	O
had	O	O	O
significant	O	O	O
levels	O	O	O
of	O	O	O
shrimp-specific	O	O	B-Entity
IgE	O	O	I-Entity
in	O	O	O
serum	O	O	B-Entity
and	O	O	O
measurable	O	O	O
basophil	O	O	B-Entity
secretory	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
rPen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
shrimp	O	O	O
tropomyosin	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
report	O	O	O
that	O	O	O
degranulation	O	O	O
is	O	O	O
linked	O	O	O
to	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
FcεRI	O	O	B-Entity
occupied	O	O	O
with	O	O	O
allergen-specific	O	O	B-Entity
IgE	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
dose	O	O	B-Entity
and	O	O	O
valency	O	O	B-Entity
of	O	O	O
Pen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
.	O	O	O

Using	O	O	O
clustered	O	O	B-Entity
regularly	O	O	I-Entity
interspaced	O	O	I-Entity
palindromic	O	O	I-Entity
repeat-based	O	O	I-Entity
gene	O	O	I-Entity
editing	O	O	I-Entity
,	O	O	O
human	O	O	O
RBL(rαKO	O	O	O
)	O	O	O
cells	O	O	O
were	O	O	O
created	O	O	O
that	O	O	O
exclusively	O	O	O
express	O	O	O
the	O	O	O
human	O	O	O
FcεRIα	O	O	B-Entity
subunit	O	O	O
.	O	O	O

Pen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
-	O	O	O
specific	O	O	B-Entity
IgE	O	O	I-Entity
was	O	O	O
affinity	O	O	O
purified	O	O	O
from	O	O	O
shrimp	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
plasma	O	O	B-Entity
.	O	O	O

Cells	O	O	O
primed	O	O	O
with	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
Pen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
-	O	O	O
specific	O	O	B-Entity
IgE	O	O	I-Entity
and	O	O	O
challenged	O	O	O
with	O	O	O
Pen	O	O	O
a	O	O	O
1	O	O	O
showed	O	O	O
a	O	O	O
bell-shaped	O	O	O
dose	O	O	B-Entity
response	O	O	B-Entity
for	O	O	I-Entity
secretion	O	O	I-Entity
,	O	O	O
with	O	O	O
optimal	O	O	O
Pen	O	O	O
a	O	O	O
1	O	O	O
doses	O	O	B-Entity
of	O	O	O
0.1	O	O	O
-	O	O	O
10	O	O	O
ng/ml	O	O	O
.	O	O	O

Mathematical	O	O	B-Entity
modeling	O	O	I-Entity
provided	O	O	O
estimates	O	O	O
of	O	O	O
receptor	O	O	B-Entity
aggregation	O	O	I-Entity
kinetics	O	O	B-Entity
based	O	O	O
on	O	O	O
FcεRI	O	O	B-Entity
occupancy	O	O	O
with	O	O	O
IgE	O	O	B-Entity
and	O	O	O
allergen	O	O	B-Entity
dose	O	O	B-Entity
.	O	O	O

Maximal	O	O	O
degranulation	O	O	O
was	O	O	O
elicited	O	O	O
when	O	O	O
∼2700	O	O	O
I	O	O	O
gE	O	O	B-Entity
-	O	O	O
FcεRI	O	O	B-Entity
complexes	O	O	B-Entity
were	O	O	O
occupied	O	O	O
with	O	O	O
specific	O	O	B-Entity
IgE	O	O	B-Entity
and	O	O	O
challenged	O	O	O
with	O	O	O
Pen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
IgE	O	O	O
epitope	O	O	B-Entity
valency	O	O	B-Entity
of	O	O	O
≥8	O	O	O
)	O	O	O
,	O	O	O
although	O	O	O
measurable	O	O	O
responses	O	O	O
were	O	O	O
achieved	O	O	O
when	O	O	O
only	O	O	O
a	O	O	O
few	O	O	O
hundred	O	O	O
FcεRI	O	O	O
were	O	O	O
occupied	O	O	O
.	O	O	O

Prolonged	O	O	O
periods	O	O	O
of	O	O	O
pepsin	O	O	B-Entity
-mediated	O	O	O
Pen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
proteolysis	O	O	B-Entity
,	O	O	O
which	O	O	O
simulates	O	O	O
gastric	O	O	B-Entity
digestion	O	O	B-Entity
,	O	O	O
were	O	O	O
required	O	O	O
to	O	O	O
diminish	O	O	O
secretory	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

Recombinant	O	O	B-Entity
fragments	O	O	I-Entity
(	O	O	O
60	O	O	O
-	O	O	O
79	O	O	O
aa	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
together	O	O	O
span	O	O	O
the	O	O	O
entire	O	O	O
length	O	O	O
of	O	O	O
tropomyosin	O	O	B-Entity
,	O	O	O
were	O	O	O
weak	O	O	O
secretagogues	O	O	O
.	O	O	O

These	O	O	O
fragments	O	O	O
have	O	O	O
reduced	O	O	O
dimerization	O	O	B-Entity
capacity	O	O	B-Entity
,	O	O	O
compete	O	O	O
with	O	O	O
intact	O	O	O
Pen	O	O	B-Entity
a	O	O	I-Entity
1	O	O	I-Entity
for	O	O	O
binding	O	O	O
to	O	O	O
IgE	O	O	B-Entity
-	O	O	O
FcεRI	O	O	B-Entity
complexes	O	O	B-Entity
,	O	O	O
and	O	O	O
represent	O	O	O
a	O	O	O
starting	O	O	O
point	O	O	O
for	O	O	O
the	O	O	O
design	O	O	O
of	O	O	O
promising	O	O	O
hypoallergens	O	O	B-Entity
for	O	O	O
immunotherapy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28043654)

Selected	O	O	B-Entity
flavonoid	O	O	B-Entity
compounds	O	O	I-Entity
as	O	O	O
promising	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
CK2α	O	O	B-Entity
and	O	O	O
CK2α	O	O	B-Entity
'	O	O	I-Entity
,	O	O	O
the	O	O	O
catalytic	O	O	B-Entity
subunits	O	O	I-Entity
of	O	O	O
CK2	O	O	O

CK2	O	O	B-Entity
is	O	O	O
a	O	O	O
ubiquitous	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
involved	O	O	O
in	O	O	O
many	O	O	O
cell	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

During	O	O	O
the	O	O	O
last	O	O	O
years	O	O	B-Entity
it	O	O	O
became	O	O	O
an	O	O	O
interesting	O	O	O
target	O	O	B-Entity
in	O	O	O
cancer	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
flavonoid	O	O	B-Entity
compounds	O	O	I-Entity
was	O	O	O
tested	O	O	B-Entity
as	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
kinase	O	O	I-Entity
CK2	O	O	B-Entity
.	O	O	O

Several	O	O	O
substances	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
highly	O	O	B-Entity
active	O	O	B-Entity
against	O	O	I-Entity
both	O	O	O
catalytic	O	O	B-Entity
subunits	O	O	I-Entity
with	O	O	O
IC50	O	O	B-Entity
values	O	O	B-Entity
below	O	O	O
1	O	O	O
μM	O	O	O
in	O	O	O
case	O	O	O
of	O	O	O
CK2α	O	O	B-Entity
'	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
promising	O	O	O
inhibitor	O	O	B-Entity
we	O	O	O
identified	O	O	B-Entity
is	O	O	O
chrysoeriol	O	O	B-Entity
with	O	O	O
IC50	O	O	B-Entity
values	O	O	B-Entity
of	O	O	O
250	O	O	O
and	O	O	O
34	O	O	O
nM	O	O	O
for	O	O	O
CK2α	O	O	B-Entity
and	O	O	O
CK2α	O	O	B-Entity
'	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

-DOCSTART- (28044140)

Fibrinogen	O	O	B-Entity
:	O	O	O
A	O	O	O
Marker	O	O	B-Entity
in	O	O	O
Predicting	O	O	O
Diabetic	O	O	B-Entity
Foot	O	O	I-Entity
Ulcer	O	O	I-Entity
Severity	O	O	O

Aims	O	O	O
.	O	O	O

To	O	O	O
examine	O	O	B-Entity
whether	O	O	O
fibrinogen	O	O	B-Entity
levels	O	O	I-Entity
are	O	O	O
a	O	O	O
valuable	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
assessing	O	O	B-Entity
disease	O	O	B-Entity
severity	O	O	I-Entity
and	O	O	O
monitoring	O	O	B-Entity
disease	O	O	B-Entity
progression	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
diabetic	O	O	B-Entity
foot	O	O	I-Entity
ulcer	O	O	I-Entity
(	O	O	O
DFU	O	O	B-Entity
)	O	O	O
.	O	O	O

Methods	O	O	O
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
designed	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
fibrinogen	O	O	B-Entity
in	O	O	O
estimating	O	O	O
disease	O	O	B-Entity
severity	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
DFU	O	O	B-Entity
admitted	O	O	B-Entity
to	O	O	O
our	O	O	O
hospital	O	O	B-Entity
between	O	O	O
January	O	O	B-Entity
2015	O	O	O
and	O	O	O
January	O	O	O
2016	O	O	O
.	O	O	O

In	O	O	O
total	O	O	O
,	O	O	O
152	O	O	O
patients	O	O	B-Entity
with	O	O	O
DFU	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
and	O	O	O
52	O	O	O
age	O	O	O
and	O	O	O
gender	O	O	B-Entity
matched	O	O	O
people	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
but	O	O	O
no	O	O	O
DFU	O	O	O
were	O	O	O
included	O	O	O
as	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

DFU	O	O	B-Entity
severity	O	O	B-Entity
was	O	O	O
assessed	O	O	O
using	O	O	O
Wagner	O	O	O
criteria	O	O	O
.	O	O	O

Results	O	O	O
.	O	O	O

Patients	O	O	B-Entity
with	O	O	O
DFU	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
2	O	O	O
subgroups	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
Wagner	O	O	O
criteria	O	O	O
.	O	O	O

Mean	O	O	O
fibrinogen	O	O	B-Entity
values	O	O	I-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
DFU	O	O	B-Entity
grade	O	O	B-Entity
≧	O	O	O
3	O	O	O
compared	O	O	O
to	O	O	O
those	O	O	O
with	O	O	O
DFU	O	O	O
grades	O	O	B-Entity
1	O	O	O
-	O	O	O
2	O	O	O
(	O	O	O
5.23	O	O	O
±	O	O	O
1.37	O	O	O
g/L	O	O	O
versus	O	O	O
3.61	O	O	O
±	O	O	O
1.04	O	O	O
g/L	O	O	O
)	O	O	O
.	O	O	O

Using	O	O	O
ROC	O	O	B-Entity
statistic	O	O	I-Entity
,	O	O	O
a	O	O	O
cut-off	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
5.13	O	O	O
g/L	O	O	O
indicated	O	O	O
the	O	O	O
possible	O	O	O
amputation	O	O	B-Entity
with	O	O	O
a	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
81.8	O	O	O
%	O	O	O
and	O	O	O
a	O	O	O
specificity	O	O	B-Entity
of	O	O	O
78.9	O	O	O
%	O	O	O
(	O	O	O
positive	O	O	B-Entity
predictive	O	O	I-Entity
value	O	O	I-Entity
[	O	O	O
PPV	O	O	B-Entity
]	O	O	O
78.6	O	O	O
%	O	O	O
,	O	O	O
negative	O	O	B-Entity
predictive	O	O	I-Entity
value	O	O	I-Entity
[	O	O	O
89.0	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
.	O	O	O

Fibrinogen	O	O	B-Entity
values	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
correlated	O	O	O
with	O	O	O
CRP	O	O	B-Entity
levels	O	O	I-Entity
,	O	O	O
neutrophil	O	O	B-Entity
,	O	O	O
and	O	O	O
WBC	O	O	B-Entity
count	O	O	I-Entity
.	O	O	O

Conclusions	O	O	O
.	O	O	O

Fibrinogen	O	O	B-Entity
levels	O	O	I-Entity
might	O	O	O
be	O	O	O
a	O	O	O
valuable	O	O	O
tool	O	O	O
for	O	O	O
assessing	O	O	B-Entity
the	O	O	O
disease	O	O	B-Entity
severity	O	O	I-Entity
and	O	O	O
monitoring	O	O	B-Entity
the	O	O	O
disease	O	O	B-Entity
progression	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
DFU	O	O	B-Entity
.	O	O	O

-DOCSTART- (28046142)

Nitrogen	O	O	B-Entity
utilization	O	O	I-Entity
efficiency	O	O	B-Entity
and	O	O	O
prediction	O	O	B-Entity
of	O	O	O
nitrogen	O	O	B-Entity
excretion	O	O	B-Entity
in	O	O	O
sheep	O	O	B-Entity
offered	O	O	B-Entity
fresh	O	O	B-Entity
perennial	O	O	I-Entity
ryegrass	O	O	I-Entity
(	O	O	O
)	O	O	O

Nitrogen	O	O	B-Entity
excretion	O	O	B-Entity
from	O	O	O
sheep	O	O	B-Entity
production	O	O	B-Entity
systems	O	O	I-Entity
is	O	O	O
an	O	O	O
important	O	O	O
source	O	O	O
of	O	O	O
nitrate	O	O	B-Entity
,	O	O	O
ammonia	O	O	B-Entity
,	O	O	O
and	O	O	O
nitrous	O	O	B-Entity
oxide	O	O	I-Entity
responsible	O	O	O
for	O	O	O
groundwater	O	O	B-Entity
pollution	O	O	B-Entity
and	O	O	O
global	O	O	B-Entity
warming	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
identify	O	O	B-Entity
key	O	O	B-Entity
parameters	O	O	I-Entity
influencing	O	O	O
N	O	O	B-Entity
utilization	O	O	I-Entity
efficiency	O	O	B-Entity
and	O	O	O
develop	O	O	O
prediction	O	O	B-Entity
equations	O	O	B-Entity
for	O	O	O
manure	O	O	B-Entity
N	O	O	O
,	O	O	O
feces	O	O	B-Entity
N	O	O	O
,	O	O	O
and	O	O	O
urine	O	O	B-Entity
N	O	O	O
outputs	O	O	B-Entity
in	O	O	O
sheep	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
used	O	O	O
were	O	O	O
collected	O	O	O
from	O	O	O
82	O	O	O
sheep	O	O	B-Entity
offered	O	O	B-Entity
fresh	O	O	B-Entity
perennial	O	O	I-Entity
ryegrass	O	O	I-Entity
(	O	O	O
)	O	O	O
as	O	O	O
the	O	O	O
sole	O	O	B-Entity
diet	O	O	I-Entity
in	O	O	O
6	O	O	O
metabolism	O	O	B-Entity
experiments	O	O	B-Entity
(	O	O	O
data	O	O	B-Entity
from	O	O	O
non-grass-only	O	O	B-Entity
diets	O	O	I-Entity
were	O	O	O
not	O	O	B-Entity
used	O	O	I-Entity
)	O	O	O
.	O	O	O

Sheep	O	O	B-Entity
were	O	O	O
from	O	O	O
breeds	O	O	B-Entity
of	O	O	O
Highlander	O	O	B-Entity
,	O	O	O
Texel	O	O	B-Entity
,	O	O	O
Scottish	O	O	B-Entity
Blackface	O	O	I-Entity
,	O	O	O
and	O	O	O
Swaledale	O	O	B-Entity
at	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
5	O	O	O
to	O	O	O
18	O	O	O
mo	O	O	B-Entity
and	O	O	O
weighing	O	O	O
from	O	O	O
24.5	O	O	O
to	O	O	O
62.7	O	O	O
kg	O	O	O
.	O	O	O

Herbage	O	O	B-Entity
was	O	O	O
harvested	O	O	B-Entity
daily	O	O	B-Entity
from	O	O	O
6	O	O	O
swards	O	O	B-Entity
of	O	O	O
contrasting	O	O	O
harvest	O	O	B-Entity
dates	O	O	B-Entity
(	O	O	O
May	O	O	O
to	O	O	O
December	O	O	O
)	O	O	O
,	O	O	O
offering	O	O	B-Entity
wide	O	O	O
variation	O	O	B-Entity
in	O	O	O
feed	O	O	O
value	O	O	O
to	O	O	O
cover	O	O	O
the	O	O	O
range	O	O	B-Entity
that	O	O	O
would	O	O	O
be	O	O	O
offered	O	O	B-Entity
in	O	O	O
most	O	O	O
practical	O	O	O
farm	O	O	B-Entity
situations	O	O	I-Entity
.	O	O	O

Before	O	O	O
the	O	O	O
commencement	O	O	O
of	O	O	O
each	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
experimental	O	O	B-Entity
sward	O	O	B-Entity
was	O	O	O
harvested	O	O	B-Entity
at	O	O	O
a	O	O	O
residual	O	O	B-Entity
height	O	O	B-Entity
of	O	O	O
4	O	O	O
cm	O	O	O
and	O	O	O
allowed	O	O	O
to	O	O	O
grow	O	O	B-Entity
for	O	O	O
2	O	O	O
to	O	O	O
4	O	O	O
wk	O	O	B-Entity
to	O	O	O
target	O	O	B-Entity
an	O	O	O
average	O	O	O
pregrazing	O	O	O
sward	O	O	O
height	O	O	O
in	O	O	O
a	O	O	O
range	O	O	B-Entity
of	O	O	O
8	O	O	O
to	O	O	O
15	O	O	O
cm	O	O	O
depending	O	O	B-Entity
on	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
year	O	O	I-Entity
.	O	O	O

Sheep	O	O	B-Entity
were	O	O	O
housed	O	O	B-Entity
in	O	O	O
individual	O	O	O
pens	O	O	O
for	O	O	O
14	O	O	O
d	O	O	B-Entity
and	O	O	O
then	O	O	O
transferred	O	O	B-Entity
to	O	O	I-Entity
individual	O	O	O
metabolism	O	O	B-Entity
crates	O	O	O
for	O	O	O
4	O	O	O
d	O	O	O
with	O	O	O
feed	O	O	B-Entity
intake	O	O	B-Entity
and	O	O	O
feces	O	O	B-Entity
and	O	O	O
urine	O	O	B-Entity
outputs	O	O	B-Entity
measured	O	O	O
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
the	O	O	O
linear	O	O	B-Entity
mixed	O	O	I-Entity
model	O	O	I-Entity
procedure	O	O	I-Entity
to	O	O	O
develop	O	O	O
prediction	O	O	B-Entity
equations	O	O	B-Entity
for	O	O	O
feces	O	O	B-Entity
N	O	O	B-Entity
,	O	O	O
urine	O	O	B-Entity
N	O	O	O
,	O	O	O
and	O	O	O
manure	O	O	B-Entity
N	O	O	O
outputs	O	O	B-Entity
using	O	O	O
N	O	O	B-Entity
intake	O	O	I-Entity
,	O	O	O
herbage	O	O	B-Entity
chemical	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
and	O	O	O
digestibility	O	O	B-Entity
with	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
sex	O	O	B-Entity
,	O	O	O
breed	O	O	B-Entity
,	O	O	O
and	O	O	O
experimental	O	O	O
periods	O	O	B-Entity
removed	O	O	B-Entity
.	O	O	O

Nitrogen	O	O	B-Entity
intake	O	O	B-Entity
was	O	O	O
the	O	O	O
best	O	O	B-Entity
single	O	O	B-Entity
predictor	O	O	I-Entity
for	O	O	O
N	O	O	B-Entity
output	O	O	B-Entity
in	O	O	O
feces	O	O	B-Entity
,	O	O	O
urine	O	O	B-Entity
,	O	O	O
and	O	O	O
manure	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
value	O	O	O
for	O	O	O
prediction	O	O	B-Entity
of	O	O	O
manure	O	O	O
N	O	O	O
output	O	O	O
was	O	O	O
greater	O	O	B-Entity
than	O	O	O
those	O	O	O
for	O	O	O
feces	O	O	O
N	O	O	O
and	O	O	O
urine	O	O	O
N	O	O	O
(	O	O	O
0.86	O	O	O
vs.	O	O	O
0.70	O	O	O
and	O	O	O
0.77	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Animal	O	O	B-Entity
BW	O	O	B-Entity
and	O	O	O
herbage	O	O	B-Entity
DM	O	O	B-Entity
,	O	O	O
ether	O	O	B-Entity
extract	O	O	I-Entity
,	O	O	O
NDF	O	O	B-Entity
,	O	O	O
ADF	O	O	B-Entity
,	O	O	O
water	O	O	B-Entity
soluble	O	O	I-Entity
carbohydrate	O	O	I-Entity
,	O	O	O
and	O	O	O
DE	O	O	O
concentrations	O	O	O
and	O	O	O
N	O	O	B-Entity
digestibility	O	O	B-Entity
were	O	O	O
also	O	O	O
used	O	O	O
to	O	O	O
predict	O	O	B-Entity
N	O	O	O
outputs	O	O	B-Entity
because	O	O	O
N	O	O	O
intake	O	O	B-Entity
may	O	O	O
not	O	O	B-Entity
be	O	O	I-Entity
available	O	O	I-Entity
in	O	O	O
commercial	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

The	O	O	O
prediction	O	O	B-Entity
equations	O	O	B-Entity
for	O	O	O
N	O	O	B-Entity
utilizatio	O	O	I-Entity
n	O	O	O
efficiency	O	O	B-Entity
indicated	O	O	O
that	O	O	O
increasing	O	O	B-Entity
feeding	O	O	B-Entity
level	O	O	B-Entity
and	O	O	O
ME	O	O	B-Entity
concentration	O	O	B-Entity
and	O	O	O
reducing	O	O	B-Entity
N	O	O	B-Entity
concentration	O	O	I-Entity
could	O	O	O
improve	O	O	B-Entity
N	O	O	B-Entity
utilization	O	O	I-Entity
efficiency	O	O	O
and	O	O	O
shift	O	O	O
N	O	O	O
excretion	O	O	B-Entity
into	O	O	O
feces	O	O	B-Entity
rather	O	O	B-Entity
than	O	O	I-Entity
urine	O	O	B-Entity
(	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
equations	O	O	B-Entity
developed	O	O	O
in	O	O	O
the	O	O	O
current	O	O	O
study	O	O	B-Entity
provide	O	O	O
an	O	O	O
approach	O	O	B-Entity
for	O	O	O
sheep	O	O	B-Entity
producers	O	O	B-Entity
to	O	O	O
quantify	O	O	B-Entity
N	O	O	B-Entity
excretion	O	O	B-Entity
against	O	O	O
production	O	O	B-Entity
and	O	O	O
,	O	O	O
consequently	O	O	O
,	O	O	O
to	O	O	O
develop	O	O	O
their	O	O	O
own	O	O	O
mitigation	O	O	B-Entity
strategies	O	O	I-Entity
to	O	O	O
reduce	O	O	B-Entity
the	O	O	O
environmental	O	O	B-Entity
impact	O	O	I-Entity
of	O	O	O
sheep	O	O	O
production	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

-DOCSTART- (28049415)

Improving	O	O	B-Entity
protein	O	O	B-Entity
complex	O	O	I-Entity
prediction	O	O	B-Entity
by	O	O	O
reconstructing	O	O	B-Entity
a	O	O	O
high-confidence	O	O	B-Entity
protein-protein	O	O	B-Entity
interaction	O	O	I-Entity
network	O	O	I-Entity
of	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
from	O	O	O
different	O	O	O
physical	O	O	B-Entity
interaction	O	O	I-Entity
data	O	O	O
sources	O	O	O

Although	O	O	O
different	O	O	O
protein-protein	O	O	B-Entity
physical	O	O	I-Entity
interaction	O	O	I-Entity
(	O	O	O
PPI	O	O	B-Entity
)	O	O	O
datasets	O	O	B-Entity
exist	O	O	O
for	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
,	O	O	O
no	O	O	O
common	O	O	O
methodology	O	O	B-Entity
exists	O	O	O
to	O	O	O
integrate	O	O	B-Entity
these	O	O	O
datasets	O	O	O
and	O	O	O
extract	O	O	O
reliable	O	O	O
modules	O	O	B-Entity
reflecting	O	O	O
the	O	O	O
existing	O	O	O
biological	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
protein	O	O	B-Entity
complexes	O	O	I-Entity
.	O	O	O

Naïve	O	O	B-Entity
Bayesian	O	O	I-Entity
formula	O	O	I-Entity
is	O	O	O
the	O	O	O
highly	O	O	O
accepted	O	O	O
method	O	O	O
to	O	O	O
integrate	O	O	B-Entity
different	O	O	O
PPI	O	O	B-Entity
datasets	O	O	B-Entity
into	O	O	O
a	O	O	O
single	O	O	O
weighted	O	O	B-Entity
PPI	O	O	B-Entity
network	O	O	B-Entity
,	O	O	O
but	O	O	O
detecting	O	O	O
proper	O	O	O
weights	O	O	B-Entity
in	O	O	O
such	O	O	O
network	O	O	O
is	O	O	O
still	O	O	O
a	O	O	O
major	O	O	O
problem	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
proposed	O	O	O
a	O	O	O
new	O	O	O
methodology	O	O	B-Entity
to	O	O	O
integrate	O	O	B-Entity
various	O	O	O
physical	O	O	B-Entity
PPI	O	O	I-Entity
datasets	O	O	B-Entity
into	O	O	O
a	O	O	O
single	O	O	O
weighted	O	O	B-Entity
PPI	O	O	B-Entity
network	O	O	I-Entity
in	O	O	O
a	O	O	O
way	O	O	O
that	O	O	O
the	O	O	O
detected	O	O	B-Entity
modules	O	O	B-Entity
in	O	O	O
PPI	O	O	O
network	O	O	O
exhibit	O	O	O
the	O	O	O
highest	O	O	O
similarity	O	O	O
to	O	O	O
available	O	O	O
functional	O	O	B-Entity
modules	O	O	O
.	O	O	O

We	O	O	O
used	O	O	O
the	O	O	O
co-expression	O	O	B-Entity
modules	O	O	B-Entity
as	O	O	O
functional	O	O	B-Entity
modules	O	O	O
,	O	O	O
and	O	O	O
we	O	O	O
shown	O	O	O
that	O	O	O
direct	O	O	O
functional	O	O	O
modules	O	O	O
detected	O	O	B-Entity
from	O	O	O
Gene	O	O	B-Entity
Ontology	O	O	I-Entity
terms	O	O	B-Entity
could	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
an	O	O	O
alternative	O	O	O
dataset	O	O	B-Entity
.	O	O	O

After	O	O	O
running	O	O	O
this	O	O	O
integrating	O	O	B-Entity
methodology	O	O	B-Entity
over	O	O	O
six	O	O	O
different	O	O	O
physical	O	O	B-Entity
PPI	O	O	B-Entity
datasets	O	O	B-Entity
,	O	O	O
orthologous	O	O	B-Entity
high-confidence	O	O	B-Entity
interactions	O	O	B-Entity
from	O	O	O
a	O	O	O
related	O	O	O
organism	O	O	B-Entity
and	O	O	O
two	O	O	O
AP-MS	O	O	B-Entity
PPI	O	O	O
datasets	O	O	O
gained	O	O	B-Entity
high	O	O	I-Entity
weights	O	O	B-Entity
in	O	O	O
the	O	O	O
integrated	O	O	B-Entity
networks	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
weights	O	O	O
for	O	O	O
one	O	O	O
AP-MS	O	O	O
PPI	O	O	O
dataset	O	O	B-Entity
and	O	O	O
two	O	O	O
other	O	O	O
datasets	O	O	O
derived	O	O	O
from	O	O	O
public	O	O	B-Entity
databases	O	O	I-Entity
have	O	O	O
converged	O	O	O
to	O	O	O
zero	O	O	O
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
detected	O	O	B-Entity
modules	O	O	B-Entity
shaped	O	O	O
around	O	O	O
one	O	O	O
or	O	O	O
few	O	O	O
hub	O	O	B-Entity
protein(s	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Still	O	O	O
,	O	O	O
a	O	O	O
large	O	O	O
number	O	O	O
of	O	O	O
highly	O	O	O
interacting	O	O	O
protein	O	O	B-Entity
modules	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
which	O	O	O
are	O	O	O
functionally	O	O	B-Entity
relevant	O	O	B-Entity
and	O	O	O
are	O	O	O
likely	O	O	O
to	O	O	O
construct	O	O	B-Entity
protein	O	O	B-Entity
complexes	O	O	I-Entity
.	O	O	O

We	O	O	O
provided	O	O	O
a	O	O	O
new	O	O	O
high	O	O	B-Entity
confidence	O	O	I-Entity
protein	O	O	B-Entity
complex	O	O	I-Entity
prediction	O	O	B-Entity
method	O	O	O
supported	O	O	O
by	O	O	O
functional	O	O	B-Entity
studies	O	O	O
and	O	O	O
literature	O	O	B-Entity
mining	O	O	O
.	O	O	O

-DOCSTART- (28053186)

AAV9	O	O	B-Entity
-	O	O	O
NPC1	O	O	B-Entity
significantly	O	O	B-Entity
ameliorates	O	O	B-Entity
Purkinje	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	B-Entity
and	O	O	O
behavioral	O	O	B-Entity
abnormalities	O	O	I-Entity
in	O	O	O
mouse	O	O	B-Entity
NPC	O	O	O
disease	O	O	O

Niemann-Pick	O	O	B-Entity
type	O	O	I-Entity
C	O	O	I-Entity
(	O	O	I-Entity
NPC	O	O	I-Entity
)	O	O	I-Entity
disease	O	O	I-Entity
is	O	O	O
a	O	O	O
fatal	O	O	B-Entity
inherited	O	O	B-Entity
neurodegenerative	O	O	B-Entity
disorder	O	O	I-Entity
caused	O	O	O
by	O	O	O
loss-of-function	O	O	B-Entity
mutations	O	O	B-Entity
in	O	O	O
the	O	O	O
NPC1	O	O	B-Entity
or	O	O	O
NPC2	O	O	B-Entity
gene	O	O	I-Entity
.	O	O	O

There	O	O	O
is	O	O	O
no	O	O	O
effective	O	O	O
way	O	O	O
to	O	O	O
treat	O	O	B-Entity
NPC	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
used	O	O	O
adeno-associated	O	O	B-Entity
virus	O	O	I-Entity
(	O	O	O
AAV	O	O	B-Entity
)	O	O	O
serotype	O	O	B-Entity
9	O	O	I-Entity
(	O	O	O
AAV9	O	O	B-Entity
)	O	O	O
to	O	O	O
deliver	O	O	O
a	O	O	O
functional	O	O	B-Entity
NPC1	O	O	B-Entity
gene	O	O	I-Entity
systemically	O	O	B-Entity
into	O	O	O
NPC1(-/-	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	B-Entity
at	O	O	O
postnatal	O	O	B-Entity
day	O	O	I-Entity
4	O	O	I-Entity
.	O	O	O

One	O	O	O
single	O	O	B-Entity
AAV9-NPC1	O	O	B-Entity
injection	O	O	I-Entity
resulted	O	O	O
in	O	O	O
robust	O	O	B-Entity
NPC1	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
various	O	O	O
tissues	O	O	B-Entity
,	O	O	O
including	O	O	O
brain	O	O	B-Entity
,	O	O	O
heart	O	O	B-Entity
,	O	O	O
and	O	O	O
lung	O	O	B-Entity
.	O	O	O

Strikingly	O	O	O
,	O	O	O
AAV9-mediated	O	O	B-Entity
NPC1	O	O	B-Entity
delivery	O	O	I-Entity
significantly	O	O	B-Entity
promoted	O	O	B-Entity
Purkinje	O	O	B-Entity
cell	O	O	I-Entity
survival	O	O	B-Entity
,	O	O	O
restored	O	O	O
locomotor	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
coordination	O	O	B-Entity
,	O	O	O
and	O	O	O
increased	O	O	B-Entity
the	O	O	O
lifespan	O	O	B-Entity
of	O	O	O
NPC1(-/-	O	O	B-Entity
)	O	O	I-Entity
mice	O	O	B-Entity
.	O	O	O

Our	O	O	O
work	O	O	O
suggests	O	O	O
that	O	O	O
AAV-based	O	O	B-Entity
gene	O	O	I-Entity
therapy	O	O	I-Entity
is	O	O	O
a	O	O	O
promising	O	O	O
means	O	O	O
to	O	O	O
treat	O	O	B-Entity
NPC	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

-DOCSTART- (28055142)

Executive	O	O	B-Entity
functions	O	O	I-Entity
deficits	O	O	B-Entity
impair	O	O	B-Entity
extinction	O	O	B-Entity
of	O	O	O
generalization	O	O	B-Entity
of	O	O	O
fear	O	O	B-Entity
of	O	O	O
movement-related	O	O	O
pain	O	O	O

Generalization	O	O	B-Entity
of	O	O	O
fear	O	O	B-Entity
of	O	O	O
movement-related	O	O	B-Entity
pain	O	O	B-Entity
across	O	O	O
novel	O	O	O
but	O	O	O
similar	O	O	O
movements	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
fear	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
movements	O	O	O
that	O	O	O
are	O	O	O
actually	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
pain	O	O	O
.	O	O	O

The	O	O	O
peak-shift	O	O	B-Entity
effect	O	O	I-Entity
describes	O	O	O
a	O	O	O
phenomenon	O	O	B-Entity
whereby	O	O	O
particular	O	O	O
novel	O	O	O
movements	O	O	B-Entity
elicit	O	O	B-Entity
even	O	O	O
greater	O	O	O
fear	O	O	B-Entity
responses	O	O	I-Entity
than	O	O	O
the	O	O	O
original	O	O	O
pain-provoking	O	O	B-Entity
movement	O	O	B-Entity
(	O	O	O
CS+	O	O	B-Entity
)	O	O	O
,	O	O	O
because	O	O	O
they	O	O	O
represent	O	O	O
a	O	O	O
more	O	O	O
extreme	O	O	O
version	O	O	O
of	O	O	O
the	O	O	O
CS+	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
great	O	O	O
variance	O	O	B-Entity
in	O	O	O
the	O	O	O
propensity	O	O	O
to	O	O	O
generalize	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
speed	O	O	O
of	O	O	O
extinction	O	O	B-Entity
learning	O	O	I-Entity
when	O	O	O
these	O	O	O
novel	O	O	O
movements	O	O	B-Entity
are	O	O	O
not	O	O	O
followed	O	O	O
by	O	O	O
pain	O	O	B-Entity
.	O	O	O

It	O	O	O
can	O	O	O
be	O	O	O
argued	O	O	O
that	O	O	O
this	O	O	O
variance	O	O	B-Entity
may	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
executive	O	O	B-Entity
function	O	O	I-Entity
capacity	O	O	I-Entity
,	O	O	O
as	O	O	O
individuals	O	O	B-Entity
may	O	O	O
be	O	O	O
unable	O	O	O
to	O	O	O
intentionally	O	O	O
inhibit	O	O	B-Entity
fear	O	O	I-Entity
responses	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
examined	O	O	B-Entity
whether	O	O	O
executive	O	O	B-Entity
function	O	O	I-Entity
capacity	O	O	I-Entity
contributes	O	O	O
to	O	O	O
generalization	O	O	B-Entity
and	O	O	O
extinction	O	O	B-Entity
of	O	O	O
generalization	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
peak-shift	O	O	B-Entity
of	O	O	O
conditioned	O	O	B-Entity
fear	O	O	I-Entity
of	O	O	O
movement-related	O	O	B-Entity
pain	O	O	I-Entity
and	O	O	O
expectancy	O	O	B-Entity
.	O	O	O

Healthy	O	O	B-Entity
participants	O	O	I-Entity
performed	O	O	O
a	O	O	O
proprioceptive	O	O	B-Entity
fear	O	O	B-Entity
conditioning	O	O	I-Entity
task	O	O	I-Entity
.	O	O	O

Executive	O	O	B-Entity
function	O	O	I-Entity
tests	O	O	I-Entity
assessing	O	O	O
updating	O	O	B-Entity
,	O	O	O
switching	O	O	O
,	O	O	O
and	O	O	O
inhibition	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
predict	O	O	O
changes	O	O	O
in	O	O	O
(	O	O	O
extinction	O	O	B-Entity
of	O	O	O
)	O	O	O
fear	O	O	B-Entity
of	O	O	O
movement-related	O	O	B-Entity
pain	O	O	B-Entity
and	O	O	O
pain	O	O	O
expectancy	O	O	B-Entity
generalization	O	O	B-Entity
.	O	O	O

Low	O	O	B-Entity
inhibitory	O	O	I-Entity
capacity	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
slower	O	O	O
extinction	O	O	B-Entity
of	O	O	O
generalized	O	O	B-Entity
fear	O	O	I-Entity
of	O	O	O
movement-related	O	O	B-Entity
pain	O	O	B-Entity
and	O	O	O
pain	O	O	O
expectancy	O	O	B-Entity
.	O	O	O

Evidence	O	O	O
was	O	O	O
found	O	O	O
in	O	O	O
favor	O	O	O
of	O	O	O
an	O	O	O
area-shift	O	O	B-Entity
,	O	O	O
rather	O	O	O
than	O	O	O
a	O	O	O
peak-shift	O	O	B-Entity
effect	O	O	I-Entity
,	O	O	O
which	O	O	O
implies	O	O	O
that	O	O	O
the	O	O	O
peak	O	O	B-Entity
conditioned	O	O	B-Entity
fear	O	O	I-Entity
response	O	O	I-Entity
extended	O	O	O
to	O	O	O
,	O	O	O
but	O	O	O
did	O	O	O
not	O	O	O
shift	O	O	O
to	O	O	O
a	O	O	O
novel	O	O	O
stimulus	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
with	O	O	O
low	O	O	O
inhibitory	O	O	B-Entity
capacity	O	O	I-Entity
may	O	O	O
have	O	O	O
difficulties	O	O	O
withholding	O	O	O
fear	O	O	B-Entity
responses	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
a	O	O	O
slower	O	O	O
decrease	O	O	O
of	O	O	O
generalized	O	O	B-Entity
fear	O	O	I-Entity
over	O	O	O
time	O	O	B-Entity
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
may	O	O	O
be	O	O	O
relevant	O	O	O
to	O	O	O
inform	O	O	O
treatments	O	O	B-Entity
.	O	O	O

Low	O	O	B-Entity
inhibitory	O	O	I-Entity
capacity	O	O	I-Entity
is	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
slower	O	O	O
generalization	O	O	B-Entity
,	O	O	O
but	O	O	O
extinction	O	O	B-Entity
of	O	O	O
fear	O	O	B-Entity
generalization	O	O	O
.	O	O	O

Fear	O	O	B-Entity
elicited	O	O	B-Entity
by	O	O	I-Entity
a	O	O	O
novel	O	O	O
safe	O	O	O
movement	O	O	B-Entity
,	O	O	O
situated	O	O	O
outside	O	O	O
the	O	O	O
CS+/-	O	O	B-Entity
continuum	O	O	O
on	O	O	O
the	O	O	O
CS+	O	O	B-Entity
side	O	O	O
,	O	O	O
can	O	O	O
be	O	O	O
as	O	O	O
strong	O	O	O
as	O	O	O
to	O	O	O
the	O	O	O
original	O	O	O
stimulus	O	O	B-Entity
predicting	O	O	O
the	O	O	O
pain-onset	O	O	B-Entity
.	O	O	O

-DOCSTART- (28055920)

Robust	O	O	B-Entity
DLPP	O	O	B-Entity
With	O	O	O
Nongreedy	O	O	B-Entity
ℓ₁$-Norm	O	O	I-Entity
Minimization	O	O	I-Entity
and	O	O	O
Maximization	O	O	O

Recently	O	O	O
,	O	O	O
discriminant	O	O	B-Entity
locality	O	O	I-Entity
preserving	O	O	I-Entity
projection	O	O	I-Entity
based	O	O	I-Entity
on	O	O	I-Entity
L1-norm	O	O	I-Entity
(	O	O	O
DLPP-L1	O	O	B-Entity
)	O	O	O
was	O	O	O
developed	O	O	O
for	O	O	O
robust	O	O	B-Entity
subspace	O	O	B-Entity
learning	O	O	I-Entity
and	O	O	O
image	O	O	B-Entity
classification	O	O	B-Entity
.	O	O	O

It	O	O	O
obtains	O	O	O
projection	O	O	B-Entity
vectors	O	O	B-Entity
by	O	O	O
greedy	O	O	B-Entity
strategy	O	O	I-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
all	O	O	O
projection	O	O	O
vectors	O	O	O
are	O	O	O
optimized	O	O	O
individually	O	O	O
through	O	O	O
maximizing	O	O	B-Entity
the	O	O	O
objective	O	O	B-Entity
function	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
obtained	O	O	O
solution	O	O	B-Entity
does	O	O	O
not	O	O	O
necessarily	O	O	O
best	O	O	O
optimize	O	O	O
the	O	O	O
corresponding	O	O	O
trace	O	O	B-Entity
ratio	O	O	I-Entity
optimization	O	O	I-Entity
algorithm	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
the	O	O	O
essential	O	O	O
objective	O	O	B-Entity
function	O	O	B-Entity
for	O	O	O
general	O	O	O
dimensionality	O	O	B-Entity
reduction	O	O	I-Entity
.	O	O	O

It	O	O	O
results	O	O	O
in	O	O	O
insufficient	O	O	O
recognition	O	O	B-Entity
accuracy	O	O	B-Entity
.	O	O	O

To	O	O	O
tackle	O	O	O
this	O	O	O
problem	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
a	O	O	O
nongreedy	O	O	B-Entity
algorithm	O	O	I-Entity
to	O	O	O
solve	O	O	O
the	O	O	O
trace	O	O	B-Entity
ratio	O	O	I-Entity
formula	O	O	I-Entity
of	O	O	O
DLPP-L1	O	O	B-Entity
,	O	O	O
and	O	O	O
analyze	O	O	O
its	O	O	O
convergence	O	O	B-Entity
.	O	O	O

Experimental	O	O	O
results	O	O	O
on	O	O	O
three	O	O	O
databases	O	O	B-Entity
illustrate	O	O	O
the	O	O	O
effectiveness	O	O	O
of	O	O	O
our	O	O	O
proposed	O	O	O
algorithm	O	O	B-Entity
.	O	O	O

-DOCSTART- (28056024)

A	O	O	O
Double-Blind	O	O	B-Entity
Randomized	O	O	B-Entity
Controlled	O	O	I-Entity
Trial	O	O	I-Entity
of	O	O	O
Maternal	O	O	B-Entity
Postpartum	O	O	I-Entity
Deworming	O	O	B-Entity
to	O	O	O
Improve	O	O	O
Infant	O	O	B-Entity
Weight	O	O	B-Entity
Gain	O	O	I-Entity
in	O	O	O
the	O	O	O
Peruvian	O	O	B-Entity
Amazon	O	O	O

Nutritional	O	O	B-Entity
interventions	O	O	I-Entity
targeting	O	O	O
the	O	O	O
critical	O	O	B-Entity
growth	O	O	B-Entity
and	O	O	I-Entity
development	O	O	I-Entity
period	O	O	I-Entity
before	O	O	O
two	O	O	O
years	O	O	O
of	O	O	O
age	O	O	B-Entity
can	O	O	O
have	O	O	O
the	O	O	O
greatest	O	O	O
impact	O	O	O
on	O	O	O
health	O	O	B-Entity
trajectories	O	O	B-Entity
over	O	O	O
the	O	O	O
life	O	O	B-Entity
course	O	O	I-Entity
.	O	O	O

Compelling	O	O	O
evidence	O	O	B-Entity
has	O	O	O
demonstrated	O	O	O
that	O	O	O
interventions	O	O	B-Entity
investing	O	O	O
in	O	O	O
maternal	O	O	B-Entity
health	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
1000	O	O	O
days	O	O	B-Entity
of	O	O	O
life	O	O	B-Entity
are	O	O	O
beneficial	O	O	O
for	O	O	O
both	O	O	O
mothers	O	O	B-Entity
and	O	O	O
their	O	O	O
children	O	O	B-Entity
.	O	O	O

One	O	O	O
such	O	O	O
potential	O	O	O
intervention	O	O	B-Entity
is	O	O	O
deworming	O	O	B-Entity
integrated	O	O	O
into	O	O	O
maternal	O	O	B-Entity
postpartum	O	O	I-Entity
care	O	O	I-Entity
in	O	O	O
areas	O	O	B-Entity
where	O	O	O
soil	O	O	B-Entity
-	O	O	O
transmitted	O	O	B-Entity
helminth	O	O	B-Entity
(	O	O	O
STH	O	O	B-Entity
)	O	O	O
infections	O	O	B-Entity
are	O	O	O
endemic	O	O	B-Entity
.	O	O	O

From	O	O	O
February	O	O	B-Entity
to	O	O	O
August	O	O	B-Entity
2014	O	O	O
,	O	O	O
1010	O	O	O
mother	O	O	B-Entity
-	O	O	O
infant	O	O	B-Entity
pairs	O	O	O
were	O	O	O
recruited	O	O	O
into	O	O	O
a	O	O	O
trial	O	O	B-Entity
aimed	O	O	O
at	O	O	O
assessing	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
maternal	O	O	B-Entity
postpartum	O	O	I-Entity
deworming	O	O	B-Entity
on	O	O	O
infant	O	O	O
and	O	O	O
maternal	O	O	B-Entity
health	O	O	I-Entity
outcomes	O	O	B-Entity
.	O	O	O

Following	O	O	B-Entity
delivery	O	O	B-Entity
,	O	O	O
mothers	O	O	B-Entity
were	O	O	O
randomly	O	O	O
assigned	O	O	O
to	O	O	O
receive	O	O	O
either	O	O	O
single-	O	O	O
dose	O	O	B-Entity
400	O	O	O
mg	O	O	O
albendazole	O	O	B-Entity
or	O	O	O
placebo	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
followed-up	O	O	B-Entity
at	O	O	O
1	O	O	B-Entity
and	O	O	O
6	O	O	B-Entity
months	O	O	I-Entity
postpartum	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
statistically	O	O	I-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
in	O	O	O
mean	O	O	O
weight	O	O	B-Entity
gain	O	O	I-Entity
between	O	O	O
infants	O	O	B-Entity
in	O	O	O
the	O	O	O
experimental	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
groups	O	O	I-Entity
(	O	O	O
mean	O	O	B-Entity
difference	O	O	I-Entity
:	O	O	O
-0.02	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
-0.1	O	O	O
,	O	O	O
0.08	O	O	O
)	O	O	O
at	O	O	O
6	O	O	B-Entity
months	O	O	I-Entity
of	O	O	O
age	O	O	B-Entity
.	O	O	O

Further	O	O	O
,	O	O	O
deworming	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
measured	O	O	O
infant	O	O	B-Entity
morbidity	O	O	I-Entity
indicators	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
ad	O	O	B-Entity
hoc	O	O	I-Entity
analyses	O	O	I-Entity
restricted	O	O	O
to	O	O	O
mothers	O	O	B-Entity
who	O	O	O
tested	O	O	O
positive	O	O	B-Entity
for	O	O	O
STHs	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
suggest	O	O	O
that	O	O	O
infants	O	O	B-Entity
of	O	O	O
mothers	O	O	O
in	O	O	O
the	O	O	O
experimental	O	O	O
group	O	O	O
had	O	O	O
greater	O	O	O
mean	O	O	O
length	O	O	B-Entity
gain	O	O	B-Entity
in	O	O	O
cm	O	O	O
(	O	O	O
mean	O	O	B-Entity
difference	O	O	I-Entity
:	O	O	O
0.8	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.1	O	O	O
,	O	O	O
1.4	O	O	O
)	O	O	O
and	O	O	O
length-for-age	O	O	B-Entity
z-score	O	O	I-Entity
(	O	O	O
mean	O	O	O
difference	O	O	O
:	O	O	O
0.5	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.2	O	O	O
,	O	O	O
0.8	O	O	O
)	O	O	O
at	O	O	O
6	O	O	B-Entity
months	O	O	I-Entity
of	O	O	O
age	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
study	O	O	B-Entity
population	O	O	I-Entity
composed	O	O	O
of	O	O	O
both	O	O	O
STH-infected	O	O	B-Entity
and	O	O	O
uninfected	O	O	B-Entity
mothers	O	O	B-Entity
,	O	O	O
maternal	O	O	B-Entity
postpartum	O	O	B-Entity
deworming	O	O	B-Entity
was	O	O	O
insufficient	O	O	B-Entity
to	O	O	O
impact	O	O	O
infant	O	O	B-Entity
growth	O	O	B-Entity
and	O	O	O
morbidity	O	O	B-Entity
indicators	O	O	B-Entity
up	O	O	O
to	O	O	O
6	O	O	B-Entity
months	O	O	I-Entity
postpartum	O	O	O
.	O	O	O

Among	O	O	O
STH-infected	O	O	B-Entity
mothers	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
important	O	O	O
improvements	O	O	O
in	O	O	O
infant	O	O	B-Entity
length	O	O	O
gain	O	O	O
and	O	O	O
length-for-age	O	O	B-Entity
were	O	O	O
observed	O	O	O
.	O	O	O

The	O	O	O
benefits	O	O	O
of	O	O	O
maternal	O	O	B-Entity
postpartum	O	O	I-Entity
deworming	O	O	B-Entity
should	O	O	O
be	O	O	O
further	O	O	O
investigated	O	O	O
in	O	O	O
study	O	O	B-Entity
populations	O	O	I-Entity
having	O	O	O
higher	O	O	O
overall	O	O	O
prevalences	O	O	B-Entity
and	O	O	O
intensities	O	O	B-Entity
of	O	O	O
STH	O	O	B-Entity
infections	O	O	I-Entity
and	O	O	O
,	O	O	O
in	O	O	O
particular	O	O	O
,	O	O	O
where	O	O	O
whipworm	O	O	B-Entity
and	O	O	O
hookworm	O	O	B-Entity
infections	O	O	I-Entity
are	O	O	O
of	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
concern	O	O	I-Entity
.	O	O	O

ClinicalTrials.gov	O	O	O
(	O	O	O
NCT01748929	O	O	O
)	O	O	O
.	O	O	O

-DOCSTART- (28056376)

Technical	O	O	O
note	O	O	O
:	O	O	O
A	O	O	O
preliminary	O	O	B-Entity
comparative	O	O	B-Entity
study	O	O	I-Entity
between	O	O	O
classical	O	O	B-Entity
and	O	O	O
interventional	O	O	B-Entity
radiological	O	O	I-Entity
approaches	O	O	I-Entity
for	O	O	O
multi-phase	O	O	B-Entity
post-mortem	O	O	B-Entity
CT	O	O	I-Entity
angiography	O	O	O

Multi-phase	O	O	B-Entity
post-mortem	O	O	B-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
angiography	O	O	I-Entity
(	O	O	O
MPMCTA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
new	O	O	B-Entity
diagnostic	O	O	B-Entity
tool	O	O	I-Entity
,	O	O	O
used	O	O	O
in	O	O	O
forensic	O	O	B-Entity
pathology	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
one	O	O	O
hand	O	O	O
,	O	O	O
this	O	O	O
technique	O	O	B-Entity
allows	O	O	O
a	O	O	O
better	O	O	O
and	O	O	O
direct	O	O	B-Entity
visualization	O	O	I-Entity
of	O	O	O
vascular	O	O	B-Entity
and	O	O	O
solid	O	O	B-Entity
organ	O	O	I-Entity
lesions	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
the	O	O	O
invasiveness	O	O	B-Entity
of	O	O	O
the	O	O	O
procedure	O	O	B-Entity
-which	O	O	O
requires	O	O	O
surgical	O	O	B-Entity
denudation	O	O	I-Entity
(	O	O	O
inguinal	O	O	B-Entity
and/or	O	O	O
cervical	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
insertion	O	O	B-Entity
of	O	O	O
surgical	O	O	B-Entity
cannulas	O	O	I-Entity
-leads	O	O	O
to	O	O	O
many	O	O	O
relatives	O	O	B-Entity
refusing	O	O	B-Entity
scientific	O	O	B-Entity
autopsies	O	O	I-Entity
.	O	O	O

Our	O	O	O
hypothesis	O	O	B-Entity
states	O	O	O
that	O	O	O
a	O	O	O
minimally-invasive	O	O	B-Entity
procedure	O	O	I-Entity
combining	O	O	O
interventional	O	O	B-Entity
radiological	O	O	I-Entity
techniques	O	O	I-Entity
with	O	O	O
MPMCTA	O	O	B-Entity
(	O	O	O
replacement	O	O	B-Entity
of	O	O	O
surgical	O	O	B-Entity
cannulas	O	O	I-Entity
by	O	O	O
radiological	O	O	B-Entity
catheters	O	O	I-Entity
)	O	O	O
will	O	O	O
improve	O	O	B-Entity
the	O	O	O
approval	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
scientific	O	O	B-Entity
autopsies	O	O	I-Entity
by	O	O	O
families	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
the	O	O	O
minimally-invasive	O	O	B-Entity
MPMCTA	O	O	B-Entity
approach	O	O	O
and	O	O	O
to	O	O	O
compare	O	O	B-Entity
its	O	O	O
performance	O	O	B-Entity
to	O	O	O
the	O	O	O
current	O	O	B-Entity
reference-standard	O	O	B-Entity
(	O	O	O
the	O	O	O
conventional	O	O	O
approach	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
included	O	O	O
consecutively	O	O	B-Entity
16	O	O	O
corpses	O	O	B-Entity
divided	O	O	O
in	O	O	O
two	O	O	O
groups	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
contrast	O	O	B-Entity
enhancement	O	O	B-Entity
approach	O	O	O
:	O	O	O
radiological	O	O	B-Entity
catheters	O	O	I-Entity
(	O	O	O
n=8	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
surgical	O	O	B-Entity
cannulas	O	O	I-Entity
(	O	O	O
n=8	O	O	O
)	O	O	O
.	O	O	O

Corpses	O	O	B-Entity
were	O	O	O
chosen	O	O	O
and	O	O	O
assigned	O	O	O
randomly	O	O	O
from	O	O	O
our	O	O	O
local	O	O	O
data	O	O	B-Entity
.	O	O	O

The	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
imaging	O	O	B-Entity
procedure	O	O	I-Entity
was	O	O	O
compared	O	O	B-Entity
according	O	O	O
to	O	O	O
four	O	O	O
items	O	O	O
:	O	O	O
global	O	O	B-Entity
vascular	O	O	I-Entity
opacification	O	O	B-Entity
,	O	O	O
cerebral	O	O	B-Entity
venous	O	O	B-Entity
opacification	O	O	I-Entity
,	O	O	O
and	O	O	O
lower	O	O	B-Entity
limbs	O	O	I-Entity
opacification	O	O	O
(	O	O	O
arterial	O	O	B-Entity
and	O	O	O
venous	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
minimally-invasive	O	O	B-Entity
approach	O	O	I-Entity
for	O	O	O
scientific	O	O	B-Entity
autopsies	O	O	I-Entity
is	O	O	O
feasible	O	O	O
through	O	O	O
a	O	O	O
radiological	O	O	B-Entity
catheter	O	O	I-Entity
.	O	O	O

Vascular	O	O	B-Entity
opacification	O	O	B-Entity
was	O	O	O
optimal	O	O	B-Entity
in	O	O	O
8	O	O	O
out	O	O	O
of	O	O	O
8	O	O	O
cases	O	O	O
and	O	O	O
was	O	O	O
no	O	O	O
less	O	O	O
effective	O	O	B-Entity
than	O	O	O
the	O	O	O
control	O	O	B-Entity
reference	O	O	I-Entity
group	O	O	I-Entity
using	O	O	O
surgical	O	O	B-Entity
cannula	O	O	I-Entity
incision	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
their	O	O	O
non-occlusive	O	O	B-Entity
aspects	O	O	I-Entity
.	O	O	O

-DOCSTART- (28056892)

Correlations	O	O	B-Entity
between	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
neurocognitive	O	O	B-Entity
domain	O	O	I-Entity
functions	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
:	O	O	O
a	O	O	O
cross-sectional	O	O	O
study	O	O	O

Neurocognitive	O	O	B-Entity
dysfunction	O	O	I-Entity
is	O	O	O
a	O	O	O
critical	O	O	O
target	O	O	O
symptom	O	O	B-Entity
of	O	O	O
schizophrenia	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

A	O	O	O
positive	O	O	O
correlation	O	O	B-Entity
between	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
level	O	O	O
and	O	O	O
neurocognitive	O	O	B-Entity
function	O	O	I-Entity
has	O	O	O
been	O	O	O
reported	O	O	O
in	O	O	O
healthy	O	O	B-Entity
individuals	O	O	I-Entity
,	O	O	O
but	O	O	O
it	O	O	O
is	O	O	O
unclear	O	O	O
whether	O	O	O
such	O	O	O
a	O	O	O
correlation	O	O	O
exists	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
and	O	O	O
whether	O	O	O
the	O	O	O
relationship	O	O	B-Entity
is	O	O	O
different	O	O	O
according	O	O	O
to	O	O	O
inpatients	O	O	B-Entity
or	O	O	O
outpatients	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
examine	O	O	B-Entity
the	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
correlations	O	O	B-Entity
between	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
multiple	O	O	O
neurocognitive	O	O	B-Entity
domains	O	O	I-Entity
in	O	O	O
inpatients	O	O	B-Entity
and	O	O	O
outpatients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
and	O	O	O
obtain	O	O	O
suggestions	O	O	B-Entity
for	O	O	O
further	O	O	O
study	O	O	O
to	O	O	O
facilitate	O	O	O
this	O	O	O
field	O	O	O
.	O	O	O

Twenty-nine	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
were	O	O	O
examined	O	O	B-Entity
(	O	O	O
16	O	O	O
inpatients	O	O	B-Entity
and	O	O	O
13	O	O	O
outpatients	O	O	B-Entity
,	O	O	O
56.0	O	O	O
±	O	O	O
11.4	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
)	O	O	O
.	O	O	O

Current	O	O	O
symptoms	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Positive	O	O	B-Entity
and	O	O	O
Negative	O	O	B-Entity
Symptom	O	O	B-Entity
Scale	O	O	I-Entity
and	O	O	O
neurocognitive	O	O	B-Entity
functions	O	O	I-Entity
using	O	O	O
Cognitrax	O	O	B-Entity
,	O	O	O
which	O	O	O
yields	O	O	O
a	O	O	O
composite	O	O	O
neurocognitive	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
NCI	O	O	B-Entity
)	O	O	O
and	O	O	O
11	O	O	O
domain	O	O	O
scores	O	O	B-Entity
.	O	O	O

After	O	O	O
testing	O	O	O
,	O	O	O
participants	O	O	B-Entity
wore	O	O	O
an	O	O	O
HJA-750C	O	O	B-Entity
accelerometer	O	O	I-Entity
for	O	O	O
one	O	O	B-Entity
week	O	O	I-Entity
to	O	O	O
measure	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
levels	O	O	O
and	O	O	O
durations	O	O	B-Entity
.	O	O	O

Partial	O	O	B-Entity
correlation	O	O	I-Entity
analyses	O	O	I-Entity
were	O	O	O
performed	O	O	O
between	O	O	O
exercise	O	O	B-Entity
and	O	O	O
cognitive	O	O	B-Entity
parameters	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
outpatient	O	O	B-Entity
group	O	O	O
,	O	O	O
higher	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
faster	O	O	O
Motor	O	O	B-Entity
and	O	O	O
Psychomotor	O	O	B-Entity
Speeds	O	O	B-Entity
in	O	O	O
outpatients	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
higher	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
lower	O	O	B-Entity
overall	O	O	O
NCI	O	O	B-Entity
,	O	O	O
Attention	O	O	B-Entity
score	O	O	B-Entity
,	O	O	O
and	O	O	O
Memory	O	O	B-Entity
scores	O	O	B-Entity
in	O	O	O
inpatients	O	O	B-Entity
.	O	O	O

Although	O	O	O
higher	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
better	O	O	O
neurocognitive	O	O	B-Entity
functions	O	O	I-Entity
of	O	O	O
outpatients	O	O	B-Entity
,	O	O	O
in	O	O	O
inpatients	O	O	B-Entity
with	O	O	O
non-remitted	O	O	O
schizophrenia	O	O	B-Entity
,	O	O	O
higher	O	O	O
physical	O	O	O
activity	O	O	O
was	O	O	O
associated	O	O	O
with	O	O	O
worsening	O	O	O
of	O	O	O
several	O	O	O
cognitive	O	O	B-Entity
domains	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
future	O	O	O
study	O	O	B-Entity
examining	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
neurocognitive	O	O	B-Entity
function	O	O	I-Entity
for	O	O	O
facilitating	O	O	O
this	O	O	O
research	O	O	O
field	O	O	O
,	O	O	O
separation	O	O	O
between	O	O	O
inpatients	O	O	B-Entity
and	O	O	O
outpatients	O	O	B-Entity
are	O	O	O
needed	O	O	O
because	O	O	O
the	O	O	O
relationship	O	O	O
is	O	O	O
different	O	O	O
between	O	O	O
inpatients	O	O	O
and	O	O	O
outpatients	O	O	O
.	O	O	O

-DOCSTART- (28057994)

A	O	O	O
completely	O	O	B-Entity
calcified	O	O	B-Entity
prostate	O	O	O

Prostatic	O	O	B-Entity
calcification	O	O	I-Entity
and	O	O	O
prostatic	O	O	B-Entity
calculus	O	O	I-Entity
formation	O	O	B-Entity
is	O	O	O
commonly	O	O	O
seen	O	O	O
in	O	O	O
adult	O	O	B-Entity
population	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
prostatitis	O	O	I-Entity
,	O	O	O
however	O	O	O
,	O	O	O
gross	O	O	O
prostatic	O	O	B-Entity
calcification	O	O	I-Entity
which	O	O	O
involves	O	O	O
more	O	O	O
than	O	O	O
3	O	O	O
cm(2	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
gland	O	O	B-Entity
is	O	O	O
quite	O	O	O
rare	O	O	B-Entity
.	O	O	O

We	O	O	O
are	O	O	O
presenting	O	O	B-Entity
here	O	O	O
one	O	O	O
such	O	O	O
case	O	O	B-Entity
in	O	O	O
which	O	O	O
almost	O	O	O
whole	O	O	O
glandular	O	O	B-Entity
prostate	O	O	I-Entity
was	O	O	O
converted	O	O	B-Entity
into	O	O	O
stone	O	O	B-Entity
which	O	O	O
is	O	O	O
never	O	O	O
reported	O	O	O
so	O	O	O
far	O	O	O
.	O	O	O

-DOCSTART- (28058375)

A	O	O	O
rare	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	O
gastric	O	O	B-Entity
obstruction	O	O	I-Entity
:	O	O	O
Lighters	O	O	B-Entity
swallowing	O	O	O

The	O	O	O
majority	O	O	B-Entity
of	O	O	O
swallowed	O	O	B-Entity
foreign	O	O	I-Entity
bodies	O	O	I-Entity
are	O	O	O
thrown	O	O	B-Entity
spontaneously	O	O	B-Entity
without	O	O	B-Entity
causing	O	O	B-Entity
complications	O	O	B-Entity
in	O	O	O
the	O	O	O
digestive	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

Multiple	O	O	B-Entity
number	O	O	B-Entity
of	O	O	O
foreign	O	O	B-Entity
bodies	O	O	I-Entity
may	O	O	O
be	O	O	O
swallowed	O	O	B-Entity
by	O	O	O
psychiatric	O	O	B-Entity
patients	O	O	I-Entity
which	O	O	O
delay	O	O	B-Entity
diagnosis	O	O	I-Entity
and	O	O	O
increase	O	O	B-Entity
the	O	O	O
complication	O	O	B-Entity
rate	O	O	B-Entity
.	O	O	O

Long	O	O	B-Entity
and	O	O	O
hard	O	O	B-Entity
objects	O	O	B-Entity
can	O	O	O
not	O	O	O
pass	O	O	O
through	O	O	O
the	O	O	O
pylorus	O	O	B-Entity
,	O	O	O
and	O	O	O
may	O	O	O
cause	O	O	B-Entity
obstruction	O	O	B-Entity
,	O	O	O
ulceration	O	O	B-Entity
,	O	O	O
bleeding	O	O	B-Entity
and	O	O	O
perforation	O	O	B-Entity
.	O	O	O

Endoscopy	O	O	B-Entity
is	O	O	O
used	O	O	B-Entity
as	O	O	O
an	O	O	O
effective	O	O	B-Entity
method	O	O	B-Entity
in	O	O	O
such	O	O	O
cases	O	O	B-Entity
.	O	O	O

An	O	O	O
exploratory	O	O	B-Entity
laparatomy	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
after	O	O	O
unsuccessful	O	O	B-Entity
endoscopic	O	O	B-Entity
foreign	O	O	B-Entity
object	O	O	I-Entity
removal	O	O	B-Entity
in	O	O	O
a	O	O	O
28-year-old	O	O	O
schizophrenic	O	O	B-Entity
patient	O	O	B-Entity
with	O	O	O
gastric	O	O	B-Entity
outlet	O	O	I-Entity
obstruction	O	O	I-Entity
due	O	O	B-Entity
to	O	O	I-Entity
multiple	O	O	B-Entity
cigarette	O	O	B-Entity
lighter	O	O	I-Entity
swallowing	O	O	B-Entity
.	O	O	O

Ten	O	O	O
lighters	O	O	B-Entity
were	O	O	O
removed	O	O	B-Entity
from	O	O	O
the	O	O	O
stomach	O	O	B-Entity
through	O	O	B-Entity
gastrotomy	O	O	B-Entity
and	O	O	O
one	O	O	O
more	O	O	O
lighter	O	O	B-Entity
was	O	O	O
removed	O	O	O
from	O	O	O
the	O	O	O
descending	O	O	B-Entity
colon	O	O	I-Entity
by	O	O	O
milking	O	O	B-Entity
through	O	O	O
the	O	O	O
anus	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
paper	O	O	O
is	O	O	O
to	O	O	O
discuss	O	O	O
encountered	O	O	O
difficulties	O	O	B-Entity
in	O	O	O
psychiatric	O	O	B-Entity
patients	O	O	I-Entity
who	O	O	O
underwent	O	O	O
surgery	O	O	B-Entity
due	O	O	B-Entity
to	O	O	I-Entity
intake	O	O	B-Entity
of	O	O	O
foreign	O	O	B-Entity
bodies	O	O	I-Entity
.	O	O	O

-DOCSTART- (28058593)

Ceftaroline	O	O	B-Entity
fosamil	O	O	I-Entity
for	O	O	O
community-acquired	O	O	B-Entity
pneumonia	O	O	I-Entity
and	O	O	O
skin	O	O	B-Entity
and	O	O	O
skin	O	O	B-Entity
structure	O	O	I-Entity
infections	O	O	I-Entity
:	O	O	O
a	O	O	O
systematic	O	O	O
review	O	O	O

Background	O	O	O
Ceftaroline	O	O	B-Entity
is	O	O	O
a	O	O	O
parentally	O	O	O
administered	O	O	B-Entity
cephalosporin	O	O	B-Entity
that	O	O	O
has	O	O	O
an	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
expanded	O	O	B-Entity
spectrum	O	O	O
of	O	O	O
activity	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
other	O	O	O
cephalosporins	O	O	B-Entity
yet	O	O	O
data	O	O	B-Entity
is	O	O	O
conflicting	O	O	O
regarding	O	O	O
its	O	O	O
place	O	O	O
in	O	O	O
therapy	O	O	B-Entity
.	O	O	O

Aim	O	O	O
of	O	O	O
the	O	O	O
Review	O	O	B-Entity
To	O	O	O
compare	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
ceftaroline	O	O	B-Entity
against	O	O	O
standard	O	O	O
antibiotic	O	O	B-Entity
regimens	O	O	B-Entity
for	O	O	O
community-acquired	O	O	B-Entity
pneumonia	O	O	I-Entity
(	O	O	O
CAP	O	O	B-Entity
)	O	O	O
and	O	O	O
complicated	O	O	B-Entity
skin	O	O	I-Entity
and	O	O	I-Entity
skin	O	O	I-Entity
structure	O	O	I-Entity
infections	O	O	I-Entity
(	O	O	O
cSSSIs	O	O	B-Entity
)	O	O	O
.	O	O	O

Method	O	O	O
The	O	O	O
databases	O	O	B-Entity
of	O	O	O
MEDLINE	O	O	B-Entity
,	O	O	O
EBSCO	O	O	B-Entity
,	O	O	O
and	O	O	O
Embase	O	O	B-Entity
were	O	O	O
searched	O	O	O
up	O	O	O
to	O	O	O
June	O	O	O
2016	O	O	O
.	O	O	O

Manual	O	O	B-Entity
review	O	O	I-Entity
of	O	O	I-Entity
references	O	O	I-Entity
was	O	O	I-Entity
completed	O	O	I-Entity
and	O	O	O
experts	O	O	B-Entity
in	O	O	O
the	O	O	O
field	O	O	O
were	O	O	O
contacted	O	O	O
for	O	O	O
unpublished	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

Randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
of	O	O	O
ceftaroline	O	O	B-Entity
in	O	O	O
CAP	O	O	B-Entity
or	O	O	O
cSSSI	O	O	B-Entity
populations	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Outcomes	O	O	B-Entity
included	O	O	O
clinical	O	O	B-Entity
cure	O	O	I-Entity
,	O	O	O
mortality	O	O	B-Entity
,	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
serious	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
,	O	O	O
and	O	O	O
discontinuation	O	O	B-Entity
due	O	O	O
to	O	O	O
adverse	O	O	O
events	O	O	O
.	O	O	O

Meta-analysis	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
pool	O	O	O
results	O	O	O
for	O	O	O
these	O	O	O
outcomes	O	O	B-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
subgroup	O	O	B-Entity
analyses	O	O	B-Entity
for	O	O	O
gram	O	O	B-Entity
positive	O	O	I-Entity
infections	O	O	B-Entity
in	O	O	O
CAP	O	O	B-Entity
and	O	O	O
infections	O	O	O
caused	O	O	O
by	O	O	O
methicillin-resistant	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
in	O	O	O
cSSSIs	O	O	B-Entity
.	O	O	O

Risk	O	O	B-Entity
of	O	O	O
bias	O	O	B-Entity
was	O	O	O
assessed	O	O	O
for	O	O	O
all	O	O	O
studies	O	O	B-Entity
.	O	O	O

Results	O	O	O
Six	O	O	O
trials	O	O	B-Entity
(	O	O	O
three	O	O	O
for	O	O	O
each	O	O	O
indication	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
,	O	O	O
each	O	O	O
of	O	O	O
which	O	O	O
had	O	O	O
an	O	O	O
unclear	O	O	O
or	O	O	O
high	O	O	O
risk	O	O	B-Entity
of	O	O	O
bias	O	O	B-Entity
in	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
domain	O	O	O
.	O	O	O

For	O	O	O
CAP	O	O	B-Entity
,	O	O	O
ceftaroline	O	O	B-Entity
was	O	O	O
significantly	O	O	O
more	O	O	O
efficacious	O	O	B-Entity
in	O	O	O
achieving	O	O	O
clinical	O	O	B-Entity
cure	O	O	I-Entity
than	O	O	O
ceftriaxone	O	O	B-Entity
[	O	O	O
risk	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
RR	O	O	B-Entity
)	O	O	O
1.11	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
1.04	O	O	O
-	O	O	O
1.19	O	O	O
;	O	O	O
I(2	O	O	O
)	O	O	O
=	O	O	O
47	O	O	O
%	O	O	O
]	O	O	O
.	O	O	O

For	O	O	O
cSSSIs	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
clinical	O	O	B-Entity
cure	O	O	I-Entity
between	O	O	O
ceftaroline	O	O	B-Entity
and	O	O	O
vancomycin	O	O	B-Entity
plus	O	O	O
aztreonam	O	O	B-Entity
(	O	O	O
RR	O	O	B-Entity
1.01	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
0.97	O	O	O
-	O	O	O
1.05	O	O	O
;	O	O	O
I(2	O	O	O
)	O	O	O
=	O	O	O
0	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
differences	O	O	O
were	O	O	O
found	O	O	O
for	O	O	O
overall	O	O	O
mortality	O	O	B-Entity
,	O	O	O
serious	O	O	B-Entity
adverse	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
discontinuation	O	O	B-Entity
due	O	O	O
to	O	O	O
adverse	O	O	O
events	O	O	O
,	O	O	O
and	O	O	O
overall	O	O	O
adverse	O	O	O
events	O	O	O
.	O	O	O

Conclusion	O	O	O
Ceftaroline	O	O	B-Entity
is	O	O	O
a	O	O	O
viable	O	O	O
therapeutic	O	O	B-Entity
alternative	O	O	I-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
CAP	O	O	B-Entity
and	O	O	O
cSSSIs	O	O	B-Entity
,	O	O	O
yet	O	O	O
identified	O	O	O
risks	O	O	B-Entity
of	O	O	O
bias	O	O	B-Entity
and	O	O	O
poor	O	O	B-Entity
external	O	O	I-Entity
validity	O	O	I-Entity
preclude	O	O	O
it	O	O	O
from	O	O	O
being	O	O	O
recommended	O	O	O
as	O	O	O
a	O	O	O
first-line	O	O	B-Entity
agent	O	O	I-Entity
.	O	O	O

-DOCSTART- (28062192)

Direct	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
glucose	O	O	B-Entity
,	O	O	O
insulin	O	O	B-Entity
,	O	O	O
GLP-1	O	O	B-Entity
,	O	O	O
and	O	O	O
GIP	O	O	B-Entity
on	O	O	O
bulbospinal	O	O	B-Entity
neurons	O	O	B-Entity
in	O	O	O
the	O	O	O
rostral	O	O	B-Entity
ventrolateral	O	O	I-Entity
medulla	O	O	I-Entity
in	O	O	O
neonatal	O	O	B-Entity
wistar	O	O	O
rats	O	O	O

Although	O	O	O
patients	O	O	B-Entity
with	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
(	O	O	O
DM	O	O	B-Entity
)	O	O	O
often	O	O	O
exhibit	O	O	O
hypertension	O	O	B-Entity
,	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
responsible	O	O	O
for	O	O	O
this	O	O	O
correlation	O	O	B-Entity
are	O	O	O
not	O	O	O
well	O	O	O
known	O	O	O
.	O	O	O

We	O	O	O
hypothesized	O	O	O
that	O	O	O
the	O	O	O
bulbospinal	O	O	B-Entity
neurons	O	O	B-Entity
in	O	O	O
the	O	O	O
rostral	O	O	B-Entity
ventrolateral	O	O	I-Entity
medulla	O	O	I-Entity
(	O	O	O
RVLM	O	O	B-Entity
)	O	O	O
are	O	O	O
affected	O	O	B-Entity
by	O	O	O
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
,	O	O	O
insulin	O	O	B-Entity
,	O	O	O
or	O	O	O
incretins	O	O	B-Entity
(	O	O	O
glucagon	O	O	B-Entity
like	O	O	I-Entity
peptide-1	O	O	I-Entity
[	O	O	O
GLP-1	O	O	B-Entity
]	O	O	O
or	O	O	O
glucose-dependent	O	O	B-Entity
insulinotropic	O	O	I-Entity
peptide	O	O	I-Entity
[	O	O	O
GIP	O	O	B-Entity
]	O	O	O
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
DM	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
are	O	O	O
activated	O	O	B-Entity
by	O	O	O
glucose	O	O	B-Entity
,	O	O	O
insulin	O	O	B-Entity
,	O	O	O
GLP-1	O	O	B-Entity
,	O	O	O
or	O	O	O
GIP	O	O	B-Entity
,	O	O	O
we	O	O	O
examined	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
membrane	O	O	B-Entity
potentials	O	O	I-Entity
of	O	O	O
bulbospinal	O	O	B-Entity
RVLM	O	O	O
neurons	O	O	O
using	O	O	O
whole-cell	O	O	B-Entity
patch-clamp	O	O	B-Entity
technique	O	O	I-Entity
during	O	O	O
superfusion	O	O	B-Entity
with	O	O	O
various	O	O	O
levels	O	O	B-Entity
of	O	O	O
glucose	O	O	O
or	O	O	O
these	O	O	O
hormones	O	O	B-Entity
in	O	O	O
neonatal	O	O	B-Entity
Wistar	O	O	B-Entity
rats	O	O	I-Entity
.	O	O	O

A	O	O	O
brainstem	O	O	B-Entity
-	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
preparation	O	O	B-Entity
was	O	O	O
used	O	O	O
for	O	O	O
the	O	O	O
experiments	O	O	B-Entity
.	O	O	O

A	O	O	O
low	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
stimulated	O	O	O
bulbospinal	O	O	B-Entity
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

During	O	O	O
insulin	O	O	B-Entity
superfusion	O	O	B-Entity
,	O	O	O
almost	O	O	O
all	O	O	O
the	O	O	O
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
were	O	O	O
depolarized	O	O	B-Entity
,	O	O	O
while	O	O	O
during	O	O	O
GLP-1	O	O	B-Entity
or	O	O	O
GIP	O	O	B-Entity
superfusion	O	O	O
,	O	O	O
almost	O	O	O
all	O	O	O
the	O	O	O
RVLM	O	O	O
neurons	O	O	O
were	O	O	O
hyperpolarized	O	O	B-Entity
.	O	O	O

Next	O	O	O
,	O	O	O
histological	O	O	B-Entity
examinations	O	O	I-Entity
were	O	O	O
performed	O	O	O
to	O	O	O
examine	O	O	O
transporters	O	O	B-Entity
for	O	O	I-Entity
glucose	O	O	I-Entity
and	O	O	O
receptors	O	O	B-Entity
for	O	O	O
insulin	O	O	B-Entity
,	O	O	O
GLP-1	O	O	B-Entity
,	O	O	O
and	O	O	O
GIP	O	O	B-Entity
on	O	O	O
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

Low	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
glucose	O	O	B-Entity
-	O	O	O
depolarized	O	O	B-Entity
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
exhibited	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
transporter	O	O	I-Entity
3	O	O	I-Entity
(	O	O	O
GLUT3	O	O	B-Entity
)	O	O	O
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
insulin	O	O	B-Entity
-	O	O	O
depolarized	O	O	B-Entity
,	O	O	O
GLP-1	O	O	B-Entity
-	O	O	O
hyperpolarized	O	O	B-Entity
,	O	O	O
and	O	O	O
GIP	O	O	B-Entity
-	O	O	O
hyperpolarized	O	O	O
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
showed	O	O	O
each	O	O	O
of	O	O	O
the	O	O	O
respective	O	O	O
specific	O	O	B-Entity
receptor	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
a	O	O	O
low	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
stimulates	O	O	B-Entity
bulbospinal	O	O	B-Entity
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
via	O	O	O
specific	O	O	B-Entity
transporters	O	O	B-Entity
on	O	O	O
these	O	O	O
neurons	O	O	O
,	O	O	O
inducing	O	O	B-Entity
hypertension	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
insulin	O	O	B-Entity
or	O	O	O
a	O	O	O
reduction	O	O	B-Entity
in	O	O	O
incretins	O	O	B-Entity
may	O	O	O
also	O	O	O
activate	O	O	B-Entity
the	O	O	O
sympathetic	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
and	O	O	O
induce	O	O	B-Entity
hypertension	O	O	B-Entity
by	O	O	O
activating	O	O	B-Entity
RVLM	O	O	B-Entity
neurons	O	O	B-Entity
via	O	O	O
their	O	O	O
own	O	O	O
receptors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28063273)

Mechanisms	O	O	B-Entity
of	O	O	O
compensation	O	O	B-Entity
in	O	O	O
the	O	O	O
gait	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
drop	O	O	O
foot	O	O	O

Drop	O	O	B-Entity
foot	O	O	I-Entity
is	O	O	O
a	O	O	O
complex	O	O	O
syndrome	O	O	B-Entity
,	O	O	O
with	O	O	O
multiple	O	O	B-Entity
interactions	O	O	B-Entity
between	O	O	O
joints	O	O	B-Entity
and	O	O	O
muscles	O	O	B-Entity
.	O	O	O

Abnormalities	O	O	B-Entity
in	O	O	O
movement	O	O	B-Entity
patterns	O	O	I-Entity
can	O	O	O
be	O	O	O
measured	O	O	O
using	O	O	O
motion	O	O	B-Entity
capture	O	O	I-Entity
techniques	O	O	I-Entity
,	O	O	O
but	O	O	O
identifying	O	O	O
compensation	O	O	B-Entity
mechanisms	O	O	B-Entity
remains	O	O	O
challenging	O	O	O
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
identify	O	O	O
compensatory	O	O	B-Entity
mechanisms	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
drop	O	O	B-Entity
foot	O	O	I-Entity
,	O	O	O
this	O	O	O
study	O	O	B-Entity
evaluated	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
15	O	O	O
such	O	O	O
patients	O	O	O
using	O	O	O
a	O	O	O
computerized	O	O	B-Entity
gait	O	O	B-Entity
analysis	O	O	I-Entity
system	O	O	I-Entity
,	O	O	O
as	O	O	O
compared	O	O	O
to	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
15	O	O	O
healthy	O	O	B-Entity
subjects	O	O	I-Entity
.	O	O	O

Four	O	O	O
classes	O	O	O
of	O	O	O
parameters	O	O	O
were	O	O	O
distinguished	O	O	O
,	O	O	O
falling	O	O	B-Entity
in	O	O	O
differing	O	O	O
intervals	O	O	B-Entity
of	O	O	O
percentage	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
first	O	O	O
class	O	O	O
comprised	O	O	O
two	O	O	O
kinematic	O	O	B-Entity
parameters	O	O	I-Entity
for	O	O	O
which	O	O	O
the	O	O	O
values	O	O	O
of	O	O	O
percentage	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
were	O	O	O
more	O	O	O
than	O	O	O
100	O	O	O
%	O	O	O
greater	O	O	O
than	O	O	O
for	O	O	O
the	O	O	O
patient	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
second	O	O	O
class	O	O	O
comprised	O	O	O
two	O	O	O
kinetic	O	O	B-Entity
parameters	O	O	I-Entity
falling	O	O	B-Entity
in	O	O	O
the	O	O	O
interval	O	O	B-Entity
of	O	O	O
100	O	O	O
-	O	O	O
49	O	O	O
%	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
third	O	O	O
class	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
49	O	O	O
-	O	O	O
20	O	O	O
%	O	O	O
interval	O	O	B-Entity
the	O	O	O
main	O	O	O
differences	O	O	O
were	O	O	O
observed	O	O	O
for	O	O	O
spatiotemporal	O	O	B-Entity
parameters	O	O	I-Entity
,	O	O	O
whereas	O	O	O
in	O	O	O
the	O	O	O
20	O	O	O
-	O	O	O
4	O	O	O
%	O	O	O
interval	O	O	O
the	O	O	O
differences	O	O	O
were	O	O	O
distributed	O	O	O
similarly	O	O	O
for	O	O	O
kinematic	O	O	B-Entity
,	O	O	O
kinetic	O	O	B-Entity
and	O	O	O
spatiotemporal	O	O	O
parameters	O	O	O
.	O	O	O

These	O	O	O
differences	O	O	O
in	O	O	O
gait	O	O	B-Entity
pattern	O	O	I-Entity
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
may	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
both	O	O	O
primary	O	O	O
motor	O	O	B-Entity
deficits	O	O	I-Entity
and	O	O	O
secondary	O	O	O
compensatory	O	O	B-Entity
mechanisms	O	O	B-Entity
.	O	O	O

Generally	O	O	O
,	O	O	O
we	O	O	O
conclude	O	O	O
that	O	O	O
drop	O	O	B-Entity
foot	O	O	I-Entity
affects	O	O	O
the	O	O	O
patients	O	O	B-Entity
'	O	O	O
overall	O	O	O
kinematic	O	O	B-Entity
and	O	O	O
kinetic	O	O	B-Entity
gait	O	O	B-Entity
parameters	O	O	O
,	O	O	O
with	O	O	O
compensation	O	O	B-Entity
seen	O	O	O
as	O	O	O
a	O	O	O
chain	O	O	O
originating	O	O	O
from	O	O	O
a	O	O	O
change	O	O	B-Entity
of	O	O	O
movement	O	O	B-Entity
within	O	O	O
the	O	O	O
ankle	O	O	B-Entity
joint	O	O	I-Entity
.	O	O	O

-DOCSTART- (28063305)

Inhibitory	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
Lactobacillus	O	O	B-Entity
rhamnosus	O	O	I-Entity
and	O	O	O
Lactobacillus	O	O	B-Entity
casei	O	O	I-Entity
on	O	O	O
Candida	O	O	B-Entity
biofilm	O	O	B-Entity
of	O	O	O
denture	O	O	O
surface	O	O	O

Candida	O	O	B-Entity
albicans	O	O	I-Entity
biofilm	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
denture-related	O	O	B-Entity
stomatitis	O	O	I-Entity
and	O	O	O
oral	O	O	B-Entity
candidiasis	O	O	I-Entity
of	O	O	O
elderly	O	O	B-Entity
.	O	O	O

Probiotics	O	O	B-Entity
are	O	O	O
beneficial	O	O	O
bacteria	O	O	B-Entity
and	O	O	O
have	O	O	O
antibacterial	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
pathogenic	O	O	B-Entity
bacteria	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
antifungal	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
various	O	O	O
probiotics	O	O	B-Entity
against	O	O	O
C.	O	O	B-Entity
albicans	O	O	I-Entity
and	O	O	O
the	O	O	O
inhibitory	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
probiotics	O	O	O
on	O	O	O
Candida	O	O	B-Entity
biofilm	O	O	B-Entity
on	O	O	O
the	O	O	O
denture	O	O	B-Entity
surface	O	O	I-Entity
.	O	O	O

The	O	O	O
spent	O	O	B-Entity
culture	O	O	I-Entity
media	O	O	I-Entity
of	O	O	O
various	O	O	O
probiotics	O	O	B-Entity
were	O	O	O
investigated	O	O	O
the	O	O	O
antifungal	O	O	B-Entity
efficacy	O	O	I-Entity
against	O	O	O
C.	O	O	B-Entity
albicans	O	O	I-Entity
.	O	O	O

Candida	O	O	B-Entity
biofilm	O	O	B-Entity
was	O	O	O
formed	O	O	O
on	O	O	O
a	O	O	O
denture	O	O	B-Entity
base	O	O	I-Entity
resin	O	O	I-Entity
and	O	O	O
was	O	O	O
then	O	O	O
treated	O	O	B-Entity
with	O	O	O
Lactobacillus	O	O	B-Entity
rhamnosus	O	O	I-Entity
and	O	O	O
Lactobacillus	O	O	B-Entity
casei	O	O	I-Entity
.	O	O	O

Also	O	O	O
,	O	O	O
the	O	O	O
biofilm	O	O	B-Entity
s	O	O	O
of	O	O	O
L.	O	O	B-Entity
rhamnosus	O	O	I-Entity
and	O	O	O
L.	O	O	B-Entity
casei	O	O	I-Entity
were	O	O	O
formed	O	O	O
and	O	O	O
were	O	O	O
sequentially	O	O	O
treated	O	O	B-Entity
with	O	O	O
C.	O	O	B-Entity
albicans	O	O	I-Entity
.	O	O	O

Colony-forming	O	O	B-Entity
units	O	O	I-Entity
of	O	O	O
C.	O	O	B-Entity
albicans	O	O	I-Entity
on	O	O	O
the	O	O	O
denture	O	O	B-Entity
surface	O	O	I-Entity
were	O	O	O
counted	O	O	O
after	O	O	O
spreading	O	O	B-Entity
on	O	O	O
agar	O	O	B-Entity
plate	O	O	B-Entity
.	O	O	O

The	O	O	O
denture	O	O	B-Entity
base	O	O	I-Entity
resin	O	O	I-Entity
was	O	O	O
treated	O	O	B-Entity
with	O	O	O
the	O	O	O
spent	O	O	B-Entity
culture	O	O	I-Entity
media	O	O	I-Entity
for	O	O	O
30	O	O	O
days	O	O	B-Entity
,	O	O	O
after	O	O	O
which	O	O	O
the	O	O	O
denture	O	O	B-Entity
surface	O	O	I-Entity
roughness	O	O	B-Entity
was	O	O	O
analyzed	O	O	O
with	O	O	O
an	O	O	O
atomic	O	O	B-Entity
force	O	O	I-Entity
microscope	O	O	I-Entity
.	O	O	O

L.	O	O	B-Entity
rhamnosus	O	O	I-Entity
and	O	O	O
L.	O	O	B-Entity
casei	O	O	I-Entity
exhibited	O	O	O
stronger	O	O	O
antifungal	O	O	B-Entity
activity	O	O	I-Entity
than	O	O	O
other	O	O	O
probiotics	O	O	B-Entity
.	O	O	O

The	O	O	O
spent	O	O	B-Entity
culture	O	O	I-Entity
medium	O	O	I-Entity
of	O	O	O
L.	O	O	B-Entity
rhamnosus	O	O	I-Entity
and	O	O	O
L.	O	O	B-Entity
casei	O	O	I-Entity
exhibited	O	O	O
the	O	O	O
antifungal	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
blastoconidia	O	O	B-Entity
and	O	O	O
biofilm	O	O	B-Entity
of	O	O	O
C.	O	O	B-Entity
albicans	O	O	I-Entity
.	O	O	O

L.	O	O	B-Entity
rhamnosus	O	O	I-Entity
and	O	O	O
L.	O	O	B-Entity
casei	O	O	I-Entity
showed	O	O	O
the	O	O	O
antifungal	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
Candida	O	O	B-Entity
biofilm	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
biofilm	O	O	O
of	O	O	O
L.	O	O	O
rhamnosus	O	O	O
and	O	O	O
L.	O	O	O
casei	O	O	O
inhibited	O	O	B-Entity
formation	O	O	B-Entity
of	O	O	O
Candida	O	O	O
biofilm	O	O	O
on	O	O	O
denture	O	O	B-Entity
surface	O	O	I-Entity
.	O	O	O

Neither	O	O	O
of	O	O	O
the	O	O	O
probiotics	O	O	B-Entity
affected	O	O	O
the	O	O	O
surface	O	O	B-Entity
roughness	O	O	I-Entity
of	O	O	O
the	O	O	O
denture	O	O	B-Entity
base	O	O	I-Entity
resin	O	O	I-Entity
.	O	O	O

L.	O	O	B-Entity
rhamnosus	O	O	I-Entity
and	O	O	O
L.	O	O	B-Entity
casei	O	O	I-Entity
may	O	O	O
be	O	O	O
the	O	O	O
ideal	O	O	O
probiotics	O	O	B-Entity
for	O	O	O
the	O	O	O
prevention	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
denture-related	O	O	B-Entity
stomatitis	O	O	I-Entity
.	O	O	O

-DOCSTART- (28063657)

Persistent	O	O	B-Entity
Organic	O	O	I-Entity
Pollutants	O	O	I-Entity
(	O	O	O
POPs	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
atmosphere	O	O	B-Entity
of	O	O	O
three	O	O	O
Chilean	O	O	B-Entity
cities	O	O	B-Entity
using	O	O	O
passive	O	O	B-Entity
air	O	O	O
samplers	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
passive	O	O	B-Entity
air	O	O	B-Entity
samplers	O	O	I-Entity
containing	O	O	O
polyurethane	O	O	B-Entity
foam	O	O	I-Entity
(	O	O	O
PUF	O	O	B-Entity
)	O	O	O
disks	O	O	B-Entity
were	O	O	O
deployed	O	O	B-Entity
in	O	O	O
three	O	O	O
cities	O	O	B-Entity
across	O	O	O
Chile	O	O	B-Entity
;	O	O	O
Santiago	O	O	B-Entity
(	O	O	O
STG	O	O	B-Entity
)	O	O	O
(	O	O	O
n=5	O	O	O
,	O	O	O
sampling	O	O	B-Entity
sites	O	O	I-Entity
)	O	O	O
,	O	O	O
Concepciόn	O	O	B-Entity
(	O	O	O
CON	O	O	B-Entity
)	O	O	O
(	O	O	O
n=6	O	O	O
)	O	O	O
and	O	O	O
Temuco	O	O	B-Entity
(	O	O	O
TEM	O	O	B-Entity
)	O	O	O
(	O	O	O
n=6	O	O	O
)	O	O	O
from	O	O	O
2008	O	O	O
to	O	O	O
2009	O	O	O
.	O	O	O

Polychlorinated	O	O	B-Entity
biphenyls	O	O	I-Entity
(	O	O	O
PCBs	O	O	B-Entity
)	O	O	O
(	O	O	O
7	O	O	O
indicator	O	O	B-Entity
congeners	O	O	B-Entity
)	O	O	O
,	O	O	O
chlorinated	O	O	B-Entity
pesticides	O	O	I-Entity
hexachlorocyclohexanes	O	O	B-Entity
(	O	O	O
HCHs	O	O	B-Entity
)	O	O	O
,	O	O	O
dichlorodiphenyl	O	O	B-Entity
trichloroethanes	O	O	I-Entity
(	O	O	O
DDTs	O	O	B-Entity
)	O	O	O
and	O	O	O
flame	O	O	B-Entity
retardants	O	O	I-Entity
such	O	O	O
as	O	O	O
polybrominated	O	O	B-Entity
diphenyl	O	O	I-Entity
ethers	O	O	I-Entity
(	O	O	O
PBDEs	O	O	B-Entity
)	O	O	O
were	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
gas	O	O	B-Entity
chromatography	O	O	I-Entity
coupled	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
GC/MS	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
sampling	O	O	B-Entity
rate	O	O	B-Entity
(	O	O	O
R	O	O	B-Entity
)	O	O	O
typical	O	O	O
of	O	O	O
urban	O	O	B-Entity
sites	O	O	I-Entity
(	O	O	O
4m(3)/day	O	O	O
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
atmospheric	O	O	B-Entity
concentrations	O	O	B-Entity
of	O	O	O
individual	O	O	B-Entity
compounds	O	O	B-Entity
.	O	O	O

PCB	O	O	B-Entity
concentrations	O	O	B-Entity
in	O	O	O
the	O	O	O
air	O	O	B-Entity
(	O	O	O
pg/m(3	O	O	O
)	O	O	O
)	O	O	O
ranged	O	O	B-Entity
from	O	O	O
~1	O	O	O
-	O	O	O
10	O	O	O
(	O	O	O
TEM	O	O	B-Entity
)	O	O	O
,	O	O	O
~1	O	O	O
-	O	O	O
40	O	O	O
(	O	O	O
STG	O	O	B-Entity
)	O	O	O
and	O	O	O
4	O	O	O
-	O	O	O
30	O	O	O
(	O	O	O
CON	O	O	B-Entity
)	O	O	O
.	O	O	O

Higher	O	O	B-Entity
molecular	O	O	I-Entity
weight	O	O	I-Entity
PCBs	O	O	B-Entity
(	O	O	O
PCB	O	O	B-Entity
-153	O	O	O
,	O	O	O
-180	O	O	O
)	O	O	O
were	O	O	O
detected	O	O	B-Entity
at	O	O	O
industrial	O	O	B-Entity
sites	O	O	I-Entity
(	O	O	O
in	O	O	O
Concepción	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
HCHs	O	O	B-Entity
showed	O	O	O
a	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
γ-HCH	O	O	B-Entity
across	O	O	O
all	O	O	O
sites	O	O	B-Entity
,	O	O	O
indicative	O	O	B-Entity
of	O	O	O
inputs	O	O	B-Entity
from	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
lindane	O	O	B-Entity
but	O	O	O
a	O	O	O
limited	O	O	B-Entity
use	O	O	O
of	O	O	O
technical	O	O	B-Entity
HCHs	O	O	O
in	O	O	O
Chile	O	O	B-Entity
.	O	O	O

DDTs	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
with	O	O	O
a	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
p	O	O	B-Entity
,	O	O	I-Entity
p'-DDE	O	O	I-Entity
accounting	O	O	B-Entity
for	O	O	O
~50	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
total	O	O	O
DDTs	O	O	O
.	O	O	O

PBDE	O	O	B-Entity
concentrations	O	O	B-Entity
in	O	O	O
air	O	O	B-Entity
(	O	O	O
pg/m(3	O	O	O
)	O	O	O
)	O	O	O
ranged	O	O	B-Entity
from	O	O	O
1	O	O	O
to	O	O	O
55	O	O	O
(	O	O	O
STG	O	O	B-Entity
)	O	O	O
,	O	O	O
0.5	O	O	O
to	O	O	O
20	O	O	O
(	O	O	O
CON	O	O	B-Entity
)	O	O	O
and	O	O	O
from	O	O	O
0.4	O	O	O
to	O	O	O
10	O	O	O
(	O	O	O
TEM	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
were	O	O	O
generally	O	O	O
similar	O	O	B-Entity
to	O	O	O
those	O	O	O
reported	O	O	B-Entity
for	O	O	O
many	O	O	O
other	O	O	O
urban	O	O	B-Entity
areas	O	O	I-Entity
globally	O	O	B-Entity
.	O	O	O

The	O	O	O
pattern	O	O	B-Entity
of	O	O	O
PBDEs	O	O	B-Entity
was	O	O	O
different	O	O	O
among	O	O	O
the	O	O	O
three	O	O	O
cities	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
PBDE	O	O	B-Entity
-209	O	O	O
was	O	O	O
dominant	O	O	B-Entity
at	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
sites	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
represent	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
few	O	O	O
assessments	O	O	B-Entity
of	O	O	O
air	O	O	B-Entity
concentrations	O	O	B-Entity
of	O	O	O
POPs	O	O	B-Entity
across	O	O	O
different	O	O	O
urban	O	O	B-Entity
areas	O	O	I-Entity
within	O	O	O
the	O	O	O
same	O	O	O
country	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
will	O	O	O
support	O	O	B-Entity
Chilean	O	O	B-Entity
commitments	O	O	B-Entity
as	O	O	O
a	O	O	O
signatory	O	O	B-Entity
to	O	O	O
the	O	O	O
Stockholm	O	O	B-Entity
Convention	O	O	I-Entity
on	O	O	O
POPs	O	O	B-Entity
and	O	O	O
for	O	O	O
reporting	O	O	B-Entity
as	O	O	O
a	O	O	O
member	O	O	B-Entity
country	O	O	B-Entity
of	O	O	O
the	O	O	O
Group	O	O	B-Entity
of	O	O	I-Entity
Latin	O	O	I-Entity
America	O	O	I-Entity
and	O	O	I-Entity
Caribbean	O	O	I-Entity
Countries	O	O	I-Entity
(	O	O	I-Entity
GRULAC	O	O	I-Entity
)	O	O	I-Entity
region	O	O	I-Entity
.	O	O	O

-DOCSTART- (28067693)

Intraoperative	O	O	B-Entity
ketamine	O	O	B-Entity
reduces	O	O	B-Entity
immediate	O	O	B-Entity
postoperative	O	O	B-Entity
opioid	O	O	B-Entity
consumption	O	O	B-Entity
after	O	O	O
spinal	O	O	B-Entity
fusion	O	O	I-Entity
surgery	O	O	I-Entity
in	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
patients	O	O	B-Entity
with	O	O	O
opioid	O	O	O
dependency	O	O	B-Entity
:	O	O	O
a	O	O	O
randomized	O	O	B-Entity
,	O	O	O
blinded	O	O	O
trial	O	O	O

Perioperative	O	O	B-Entity
handling	O	O	B-Entity
of	O	O	O
surgical	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
opioid	O	O	B-Entity
dependency	O	O	B-Entity
represents	O	O	O
an	O	O	O
important	O	O	B-Entity
clinical	O	O	B-Entity
problem	O	O	B-Entity
.	O	O	O

Animal	O	O	B-Entity
studies	O	O	I-Entity
suggest	O	O	O
that	O	O	O
ketamine	O	O	B-Entity
attenuates	O	O	B-Entity
central	O	O	B-Entity
sensitization	O	O	I-Entity
and	O	O	O
hyperalgesia	O	O	B-Entity
and	O	O	O
thereby	O	O	O
reduces	O	O	B-Entity
postoperative	O	O	B-Entity
opioid	O	O	B-Entity
tolerance	O	O	O
.	O	O	O

We	O	O	O
hypothesized	O	O	B-Entity
that	O	O	O
intraoperative	O	O	B-Entity
ketamine	O	O	B-Entity
would	O	O	O
reduce	O	O	B-Entity
immediate	O	O	B-Entity
postoperative	O	O	B-Entity
opioid	O	O	B-Entity
consumption	O	O	B-Entity
compared	O	O	O
with	O	O	O
placebo	O	O	B-Entity
in	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
patients	O	O	B-Entity
with	O	O	O
opioid	O	O	O
dependency	O	O	B-Entity
undergoing	O	O	O
lumbar	O	O	B-Entity
spinal	O	O	I-Entity
fusion	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

Primary	O	O	B-Entity
outcome	O	O	I-Entity
was	O	O	O
morphine	O	O	B-Entity
consumption	O	O	B-Entity
0	O	O	B-Entity
to	O	O	I-Entity
24	O	O	I-Entity
hours	O	O	I-Entity
postoperatively	O	O	B-Entity
.	O	O	O

Secondary	O	O	B-Entity
outcomes	O	O	I-Entity
were	O	O	O
acute	O	O	B-Entity
pain	O	O	B-Entity
at	O	O	I-Entity
rest	O	O	I-Entity
and	O	O	O
during	O	O	O
mobilization	O	O	B-Entity
2	O	O	B-Entity
to	O	O	I-Entity
24	O	O	I-Entity
hours	O	O	I-Entity
postoperatively	O	O	B-Entity
(	O	O	O
visual	O	O	B-Entity
analogue	O	O	I-Entity
scale	O	O	I-Entity
)	O	O	O
,	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
and	O	O	O
persistent	O	O	B-Entity
pain	O	O	O
6	O	O	O
months	O	O	O
postoperatively	O	O	O
.	O	O	O

One	O	O	O
hundred	O	O	O
fifty	O	O	O
patients	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
assigned	O	O	I-Entity
to	O	O	O
intraoperative	O	O	B-Entity
S-ketamine	O	O	B-Entity
bolus	O	O	B-Entity
0.5	O	O	I-Entity
mg/kg	O	O	I-Entity
and	O	O	I-Entity
infusion	O	O	I-Entity
0.25	O	O	O
mg·kg·h	O	O	O
or	O	O	O
placebo	O	O	B-Entity
.	O	O	O

Postoperatively	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
received	O	O	O
their	O	O	O
usual	O	O	O
opioids	O	O	B-Entity
,	O	O	O
paracetamol	O	O	B-Entity
and	O	O	O
IV	O	O	O
patient-controlled	O	O	B-Entity
analgesia	O	O	I-Entity
with	O	O	O
morphine	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
final	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
147	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

Patient-controlled	O	O	B-Entity
analgesia	O	O	I-Entity
IV	O	O	O
morphine	O	O	B-Entity
consumption	O	O	B-Entity
0	O	O	O
to	O	O	O
24	O	O	O
hours	O	O	O
postoperatively	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
reduced	O	O	B-Entity
in	O	O	O
the	O	O	O
ketamine	O	O	B-Entity
group	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
placebo	O	O	B-Entity
group	O	O	O
:	O	O	O
79	O	O	O
(	O	O	O
47	O	O	O
)	O	O	O
vs	O	O	O
121	O	O	O
(	O	O	O
53	O	O	O
)	O	O	O
mg	O	O	O
IV	O	O	O
,	O	O	O
mean	O	O	B-Entity
difference	O	O	B-Entity
42	O	O	O
mg	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
-59	O	O	O
to	O	O	O
-25	O	O	O
)	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
.	O	O	O

Sedation	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
reduced	O	O	B-Entity
in	O	O	O
the	O	O	O
ketamine	O	O	B-Entity
group	O	O	O
6	O	O	O
and	O	O	O
24	O	O	O
hours	O	O	O
postoperatively	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
regarding	O	O	O
acute	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
nausea	O	O	B-Entity
,	O	O	O
vomiting	O	O	B-Entity
,	O	O	O
hallucinations	O	O	B-Entity
,	O	O	O
or	O	O	O
nightmares	O	O	B-Entity
.	O	O	O

Back	O	O	B-Entity
pain	O	O	B-Entity
at	O	O	O
6	O	O	O
months	O	O	O
postoperatively	O	O	B-Entity
compared	O	O	O
with	O	O	O
preoperative	O	O	B-Entity
pain	O	O	O
was	O	O	O
significantly	O	O	B-Entity
more	O	O	O
improved	O	O	B-Entity
in	O	O	O
the	O	O	O
ketamine	O	O	B-Entity
group	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
placebo	O	O	B-Entity
group	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.005	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
intraoperative	O	O	B-Entity
ketamine	O	O	B-Entity
significantly	O	O	B-Entity
reduced	O	O	B-Entity
morphine	O	O	B-Entity
consumption	O	O	B-Entity
0	O	O	B-Entity
to	O	O	I-Entity
24	O	O	I-Entity
hours	O	O	I-Entity
after	O	O	O
lumbar	O	O	B-Entity
fusion	O	O	I-Entity
surgery	O	O	I-Entity
in	O	O	O
opioid	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
trend	O	O	B-Entity
regarding	O	O	O
less	O	O	O
persistent	O	O	B-Entity
pain	O	O	B-Entity
6	O	O	O
months	O	O	O
postoperatively	O	O	B-Entity
needs	O	O	O
further	O	O	B-Entity
investigation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28068639)

Effects	O	O	B-Entity
of	O	O	I-Entity
argan	O	O	B-Entity
oil	O	O	I-Entity
on	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
antioxidant	O	O	B-Entity
system	O	O	I-Entity
and	O	O	O
the	O	O	O
activity	O	O	B-Entity
of	O	O	O
NADPH	O	O	B-Entity
-	O	O	O
generating	O	O	B-Entity
enzymes	O	O	B-Entity
in	O	O	O
acrylamide	O	O	B-Entity
treated	O	O	B-Entity
rat	O	O	B-Entity
brain	O	O	O

Argan	O	O	B-Entity
oil	O	O	I-Entity
(	O	O	O
AO	O	O	B-Entity
)	O	O	O
is	O	O	O
rich	O	O	O
in	O	O	O
minor	O	O	O
compounds	O	O	B-Entity
such	O	O	O
as	O	O	O
polyphenols	O	O	B-Entity
and	O	O	O
tocopherols	O	O	B-Entity
which	O	O	O
are	O	O	O
powerful	O	O	O
antioxidants	O	O	B-Entity
.	O	O	O

Acrylamide	O	O	B-Entity
(	O	O	O
ACR	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
classified	O	O	B-Entity
as	O	O	O
a	O	O	O
neurotoxic	O	O	B-Entity
agent	O	O	I-Entity
in	O	O	O
animals	O	O	B-Entity
and	O	O	O
humans	O	O	B-Entity
.	O	O	O

Mitochondrial	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
dysfunction	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
probable	O	O	B-Entity
molecular	O	O	B-Entity
mechanisms	O	O	I-Entity
of	O	O	O
neurodegenerative	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Female	O	O	B-Entity
Sprague	O	O	B-Entity
Dawley	O	O	I-Entity
rats	O	O	I-Entity
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
ACR	O	O	B-Entity
(	O	O	O
50mg/kg	O	O	O
i.p	O	O	O
.	O	O	O

three	O	O	O
times	O	O	O
a	O	O	O
week	O	O	O
)	O	O	O
,	O	O	O
AO	O	O	B-Entity
(	O	O	O
6ml/kg	O	O	O
,	O	O	O
o.p	O	O	O
,	O	O	O
per	O	O	O
day	O	O	O
)	O	O	O
or	O	O	O
together	O	O	O
for	O	O	O
30days	O	O	O
.	O	O	O

The	O	O	O
activities	O	O	B-Entity
of	O	O	O
cytosolic	O	O	B-Entity
enzymes	O	O	B-Entity
such	O	O	O
as	O	O	O
xanthine	O	O	B-Entity
oxidase	O	O	I-Entity
(	O	O	O
XO	O	O	B-Entity
)	O	O	O
,	O	O	O
glucose	O	O	B-Entity
6-phosphate	O	O	I-Entity
dehydrogenase	O	O	I-Entity
(	O	O	O
G6PDH	O	O	B-Entity
)	O	O	O
,	O	O	O
glutathione-S-transferase	O	O	B-Entity
(	O	O	O
GST	O	O	B-Entity
)	O	O	O
,	O	O	O
mitochondrial	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
oxidative	O	O	B-Entity
phosphorylation	O	O	I-Entity
(	O	O	O
OXPHOS	O	O	B-Entity
)	O	O	O
and	O	O	O
tricarboxylic	O	O	B-Entity
acid	O	O	I-Entity
cycle	O	O	I-Entity
(	O	O	O
TCA	O	O	B-Entity
)	O	O	O
enzymes	O	O	O
,	O	O	O
mitochondrial	O	O	O
metabolic	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
adenosine	O	O	B-Entity
triphosphate	O	O	I-Entity
(	O	O	O
ATP	O	O	B-Entity
)	O	O	O
level	O	O	B-Entity
and	O	O	O
acetylcholinesterase	O	O	B-Entity
(	O	O	I-Entity
AChE	O	O	I-Entity
)	O	O	I-Entity
activity	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
brain	O	O	B-Entity
.	O	O	O

Cytosolic	O	O	B-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
antioxidant	O	O	B-Entity
enzymes	O	O	I-Entity
were	O	O	O
significantly	O	O	B-Entity
diminished	O	O	B-Entity
in	O	O	O
the	O	O	O
brains	O	O	B-Entity
of	O	O	O
rats	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
ACR	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
those	O	O	O
in	O	O	O
control	O	O	B-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
ACR	O	O	B-Entity
treatment	O	O	B-Entity
resulted	O	O	B-Entity
in	O	O	O
a	O	O	O
significant	O	O	B-Entity
reduction	O	O	B-Entity
in	O	O	O
brain	O	O	B-Entity
ATP	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
mitochondrial	O	O	B-Entity
metabolic	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
OXPHOS	O	O	B-Entity
and	O	O	O
TCA	O	O	B-Entity
enzymes	O	O	B-Entity
.	O	O	O

Administration	O	O	B-Entity
of	O	O	O
AO	O	O	B-Entity
restored	O	O	O
both	O	O	O
the	O	O	O
cytosolic	O	O	B-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
by	O	O	O
normalizing	O	O	B-Entity
nicotinamide	O	O	B-Entity
adenine	O	O	I-Entity
dinucleotide	O	O	I-Entity
phosphate	O	O	I-Entity
(	O	O	O
NADPH	O	O	B-Entity
)	O	O	O
generating	O	O	B-Entity
enzymes	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
improved	O	O	B-Entity
mitochondrial	O	O	B-Entity
function	O	O	I-Entity
primarily	O	O	O
enhancing	O	O	B-Entity
nicotinamide	O	O	B-Entity
adenine	O	O	I-Entity
dinucleotide	O	O	I-Entity
(	O	O	O
NADH	O	O	B-Entity
)	O	O	O
generated	O	O	B-Entity
enzymes	O	O	B-Entity
activities	O	O	I-Entity
and	O	O	O
ATP	O	O	B-Entity
level	O	O	B-Entity
in	O	O	O
the	O	O	O
mitochondria	O	O	B-Entity
.	O	O	O

The	O	O	O
reason	O	O	B-Entity
for	O	O	O
AO	O	O	B-Entity
's	O	O	I-Entity
obvious	O	O	O
beneficial	O	O	B-Entity
effects	O	O	I-Entity
in	O	O	O
this	O	O	O
study	O	O	B-Entity
may	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
synergistic	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
its	O	O	O
different	O	O	B-Entity
bioactive	O	O	B-Entity
compounds	O	O	I-Entity
which	O	O	O
is	O	O	O
especially	O	O	O
effective	O	O	B-Entity
on	O	O	O
mitochondria	O	O	B-Entity
.	O	O	O

Modulation	O	O	B-Entity
of	O	O	O
the	O	O	O
brain	O	O	B-Entity
mitochondrial	O	O	B-Entity
functions	O	O	I-Entity
and	O	O	O
antioxidant	O	O	B-Entity
systems	O	O	I-Entity
by	O	O	O
AO	O	O	B-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
new	O	O	O
mitochondria	O	O	B-Entity
-	O	O	O
targeted	O	O	B-Entity
antioxidants	O	O	B-Entity
in	O	O	O
the	O	O	O
future	O	O	B-Entity
.	O	O	O

-DOCSTART- (28070811)

Encaged	O	O	B-Entity
Chironomus	O	O	B-Entity
riparius	O	O	I-Entity
larvae	O	O	B-Entity
in	O	O	O
assessment	O	O	B-Entity
of	O	O	O
trace	O	O	B-Entity
metal	O	O	I-Entity
bioavailability	O	O	B-Entity
and	O	O	O
transfer	O	O	B-Entity
in	O	O	O
a	O	O	O
landfill	O	O	B-Entity
leachate	O	O	I-Entity
collection	O	O	B-Entity
pond	O	O	O

Household	O	O	B-Entity
wastes	O	O	B-Entity
may	O	O	O
constitute	O	O	B-Entity
a	O	O	O
vector	O	O	B-Entity
of	O	O	O
environmental	O	O	B-Entity
contamination	O	O	I-Entity
when	O	O	O
buried	O	O	B-Entity
,	O	O	O
in	O	O	O
particular	O	O	O
through	O	O	O
degradation	O	O	B-Entity
and	O	O	O
production	O	O	O
of	O	O	O
leachates	O	O	B-Entity
containing	O	O	B-Entity
significant	O	O	B-Entity
trace	O	O	B-Entity
metal	O	O	I-Entity
(	O	O	O
TM	O	O	B-Entity
)	O	O	O
concentrations	O	O	B-Entity
that	O	O	O
may	O	O	O
constitute	O	O	O
a	O	O	O
serious	O	O	O
risk	O	O	B-Entity
to	O	O	O
biota	O	O	B-Entity
.	O	O	O

The	O	O	O
objectives	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
bioavailability	O	O	B-Entity
and	O	O	O
transfer	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
various	O	O	O
TMs	O	O	B-Entity
present	O	O	B-Entity
in	O	O	O
water	O	O	B-Entity
and	O	O	O
sediments	O	O	B-Entity
in	O	O	O
a	O	O	O
reservoir	O	O	B-Entity
receiving	O	O	B-Entity
landfill	O	O	B-Entity
leachates	O	O	I-Entity
.	O	O	O

An	O	O	O
active	O	O	B-Entity
biomonitoring	O	O	B-Entity
approach	O	O	O
was	O	O	O
adopted	O	O	O
consisting	O	O	O
of	O	O	O
exposing	O	O	B-Entity
naive	O	O	O
laboratory	O	O	B-Entity
organisms	O	O	I-Entity
in	O	O	O
cages	O	O	B-Entity
deployed	O	O	B-Entity
in	O	O	B-Entity
the	O	O	I-Entity
field	O	O	I-Entity
.	O	O	O

Aquatic	O	O	B-Entity
insects	O	O	I-Entity
such	O	O	O
as	O	O	O
Chironomus	O	O	B-Entity
riparius	O	O	I-Entity
larvae	O	O	B-Entity
are	O	O	O
good	O	O	O
candidates	O	O	O
since	O	O	O
they	O	O	O
represent	O	O	B-Entity
key	O	O	O
organisms	O	O	B-Entity
in	O	O	O
the	O	O	O
trophic	O	O	B-Entity
functioning	O	O	B-Entity
of	O	O	O
aquatic	O	O	B-Entity
ecosystems	O	O	I-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
show	O	O	O
that	O	O	O
water	O	O	B-Entity
,	O	O	O
suspended	O	O	B-Entity
particles	O	O	B-Entity
,	O	O	O
and	O	O	O
sediments	O	O	B-Entity
were	O	O	O
significant	O	O	B-Entity
ly	O	O	O
contaminated	O	O	B-Entity
by	O	O	O
various	O	O	O
TMs	O	O	B-Entity
(	O	O	O
As	O	O	B-Entity
,	O	O	O
Cd	O	O	B-Entity
,	O	O	O
Cu	O	O	B-Entity
,	O	O	O
Ni	O	O	B-Entity
,	O	O	O
Pb	O	O	B-Entity
,	O	O	O
and	O	O	O
Zn	O	O	B-Entity
)	O	O	O
.	O	O	O

Their	O	O	O
contribution	O	O	B-Entity
to	O	O	O
the	O	O	O
transfer	O	O	B-Entity
of	O	O	O
TMs	O	O	B-Entity
depends	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
on	O	O	O
the	O	O	O
specific	O	O	B-Entity
element	O	O	B-Entity
considered	O	O	B-Entity
,	O	O	O
e.g.	O	O	O
,	O	O	O
Cd	O	O	B-Entity
in	O	O	O
sediments	O	O	B-Entity
or	O	O	O
Pb	O	O	B-Entity
in	O	O	O
both	O	O	O
suspended	O	O	B-Entity
particles	O	O	B-Entity
and	O	O	O
sediments	O	O	O
.	O	O	O

The	O	O	O
internal	O	O	O
fate	O	O	O
of	O	O	O
TMs	O	O	B-Entity
was	O	O	O
investigated	O	O	B-Entity
according	O	O	O
to	O	O	O
their	O	O	O
fractionation	O	O	B-Entity
between	O	O	O
an	O	O	O
insoluble	O	O	B-Entity
and	O	O	O
a	O	O	O
cytosolic	O	O	B-Entity
fraction	O	O	B-Entity
.	O	O	O

This	O	O	O
approach	O	O	O
revealed	O	O	B-Entity
different	O	O	O
detoxification	O	O	B-Entity
strategies	O	O	B-Entity
capable	O	O	O
of	O	O	O
preventing	O	O	B-Entity
the	O	O	O
induction	O	O	B-Entity
of	O	O	O
deleterious	O	O	B-Entity
effects	O	O	I-Entity
at	O	O	O
the	O	O	O
individual	O	O	B-Entity
scale	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
accumulation	O	O	B-Entity
of	O	O	O
several	O	O	O
TMs	O	O	B-Entity
in	O	O	O
C.	O	O	B-Entity
riparius	O	O	I-Entity
larvae	O	O	B-Entity
tissues	O	O	B-Entity
may	O	O	O
also	O	O	O
represent	O	O	B-Entity
a	O	O	O
significant	O	O	B-Entity
load	O	O	O
potentially	O	O	B-Entity
transferable	O	O	B-Entity
to	O	O	O
higher	O	O	B-Entity
trophic	O	O	B-Entity
levels	O	O	B-Entity
.	O	O	O

-DOCSTART- (28072457)

Effects	O	O	O
of	O	O	O
Binge-Like	O	O	B-Entity
Ethanol	O	O	B-Entity
Exposure	O	O	I-Entity
During	O	O	O
Adolescence	O	O	B-Entity
on	O	O	O
the	O	O	O
Febrile	O	O	B-Entity
Response	O	O	B-Entity
in	O	O	O
Rats	O	O	O

Ethanol	O	O	B-Entity
(	O	O	I-Entity
EtOH	O	O	I-Entity
)	O	O	I-Entity
exposure	O	O	I-Entity
during	O	O	O
different	O	O	O
phases	O	O	B-Entity
of	O	O	O
life	O	O	B-Entity
may	O	O	O
increase	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	I-Entity
infections	O	O	I-Entity
and	O	O	O
cause	O	O	O
alterations	O	O	B-Entity
in	O	O	O
the	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
binge-like	O	O	B-Entity
EtOH	O	O	B-Entity
exposure	O	O	I-Entity
in	O	O	O
adolescent	O	O	B-Entity
rats	O	O	B-Entity
on	O	O	O
the	O	O	O
febrile	O	O	B-Entity
response	O	O	B-Entity
that	O	O	O
was	O	O	O
induced	O	O	O
by	O	O	O
lipopolysaccharide	O	O	B-Entity
(	O	O	O
LPS	O	O	B-Entity
)	O	O	O
and	O	O	O
interleukin-1β	O	O	B-Entity
(	O	O	O
IL-1β	O	O	B-Entity
)	O	O	O
.	O	O	O

Male	O	O	O
rats	O	O	B-Entity
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
EtOH	O	O	I-Entity
from	O	O	O
postnatal	O	O	B-Entity
days	O	O	I-Entity
25	O	O	O
to	O	O	O
38	O	O	O
in	O	O	O
a	O	O	O
binge-like	O	O	B-Entity
pattern	O	O	O
.	O	O	O

Fever	O	O	B-Entity
was	O	O	O
induced	O	O	O
by	O	O	O
LPS	O	O	B-Entity
(	O	O	O
5	O	O	O
and	O	O	O
50	O	O	O
μg/kg	O	O	O
,	O	O	O
intraperitoneally	O	O	B-Entity
)	O	O	O
and	O	O	O
evaluated	O	O	O
on	O	O	O
postnatal	O	O	B-Entity
days	O	O	I-Entity
51	O	O	O
and	O	O	O
63	O	O	O
,	O	O	O
or	O	O	O
by	O	O	O
IL-β	O	O	B-Entity
(	O	O	O
3	O	O	O
ng	O	O	O
)	O	O	O
and	O	O	O
evaluated	O	O	O
on	O	O	O
postnatal	O	O	B-Entity
day	O	O	I-Entity
51	O	O	O
.	O	O	O

Hematological	O	O	B-Entity
parameters	O	O	O
,	O	O	O
the	O	O	O
status	O	O	O
of	O	O	O
peritoneal	O	O	B-Entity
macrophages	O	O	I-Entity
,	O	O	O
and	O	O	O
plasma	O	O	B-Entity
and	O	O	O
cerebrospinal	O	O	B-Entity
IL-1β	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
also	O	O	O
evaluated	O	O	O
on	O	O	O
postnatal	O	O	B-Entity
day	O	O	I-Entity
51	O	O	O
.	O	O	O

EtOH	O	O	B-Entity
exposure	O	O	I-Entity
during	O	O	O
adolescence	O	O	B-Entity
did	O	O	O
not	O	O	O
alter	O	O	O
normal	O	O	B-Entity
body	O	O	I-Entity
temperature	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
significant	O	O	O
reduction	O	O	O
in	O	O	O
the	O	O	O
febrile	O	O	B-Entity
response	O	O	B-Entity
that	O	O	O
was	O	O	O
induced	O	O	O
by	O	O	O
LPS	O	O	B-Entity
at	O	O	O
both	O	O	O
doses	O	O	O
was	O	O	O
observed	O	O	O
on	O	O	O
postnatal	O	O	B-Entity
day	O	O	O
51	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
febrile	O	O	B-Entity
response	O	O	B-Entity
were	O	O	O
observed	O	O	O
on	O	O	O
postnatal	O	O	B-Entity
day	O	O	I-Entity
63	O	O	O
in	O	O	O
EtOH-exposed	O	O	B-Entity
animals	O	O	B-Entity
.	O	O	O

The	O	O	O
febrile	O	O	B-Entity
response	O	O	B-Entity
that	O	O	O
was	O	O	O
induced	O	O	O
by	O	O	O
intracerebroventricular	O	O	B-Entity
IL-1β	O	O	B-Entity
also	O	O	O
significantly	O	O	O
decreased	O	O	O
in	O	O	O
animals	O	O	B-Entity
that	O	O	O
received	O	O	O
binge-like	O	O	B-Entity
EtOH	O	O	B-Entity
exposure	O	O	I-Entity
during	O	O	O
adolescence	O	O	B-Entity
.	O	O	O

Acute	O	O	B-Entity
oral	O	O	I-Entity
treatment	O	O	I-Entity
with	O	O	O
EtOH	O	O	B-Entity
24	O	O	O
h	O	O	O
prior	O	O	O
to	O	O	O
LPS	O	O	B-Entity
administration	O	O	B-Entity
did	O	O	O
not	O	O	O
alter	O	O	O
the	O	O	O
febrile	O	O	B-Entity
response	O	O	B-Entity
that	O	O	O
was	O	O	O
induced	O	O	O
by	O	O	O
LPS	O	O	O
.	O	O	O

Binge-like	O	O	B-Entity
EtOH	O	O	B-Entity
exposure	O	O	I-Entity
during	O	O	O
adolescence	O	O	B-Entity
did	O	O	O
not	O	O	O
alter	O	O	O
hematological	O	O	B-Entity
parameters	O	O	O
or	O	O	O
the	O	O	O
number	O	O	O
or	O	O	O
viability	O	O	B-Entity
of	O	O	O
peritoneal	O	O	B-Entity
macrophages	O	O	I-Entity
.	O	O	O

Binge-like	O	O	B-Entity
EtOH	O	O	B-Entity
exposure	O	O	I-Entity
did	O	O	O
not	O	O	O
alter	O	O	O
plasma	O	O	B-Entity
IL-1β	O	O	B-Entity
levels	O	O	B-Entity
but	O	O	O
reduced	O	O	O
the	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
levels	O	O	O
of	O	O	O
this	O	O	O
cytokine	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
binge-like	O	O	B-Entity
EtOH	O	O	B-Entity
exposure	O	O	I-Entity
during	O	O	O
adolescence	O	O	B-Entity
causes	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
that	O	O	O
can	O	O	O
impair	O	O	O
the	O	O	O
febrile	O	O	B-Entity
response	O	O	B-Entity
that	O	O	O
can	O	O	O
be	O	O	O
observed	O	O	O
after	O	O	O
the	O	O	O
cessation	O	O	B-Entity
of	O	O	O
EtOH	O	O	O
exposure	O	O	O
.	O	O	O

These	O	O	O
changes	O	O	O
were	O	O	O
reversible	O	O	O
and	O	O	O
appeared	O	O	O
to	O	O	O
involve	O	O	O
the	O	O	O
LPS	O	O	B-Entity
/	O	O	O
IL-1β	O	O	B-Entity
system	O	O	O
.	O	O	O

-DOCSTART- (28072668)

Genital	O	O	B-Entity
and	O	O	O
Extragenital	O	O	B-Entity
Gonorrhea	O	O	I-Entity
and	O	O	O
Chlamydia	O	O	B-Entity
in	O	O	O
Children	O	O	B-Entity
and	O	O	O
Adolescents	O	O	B-Entity
Evaluated	O	O	B-Entity
for	O	O	O
Sexual	O	O	O
Abuse	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
a	O	O	O
nucleic	O	O	B-Entity
acid	O	O	I-Entity
amplification	O	O	I-Entity
test	O	O	I-Entity
in	O	O	O
detecting	O	O	B-Entity
genital	O	O	B-Entity
and	O	O	O
extragenital	O	O	B-Entity
Neisseria	O	O	I-Entity
gonorrhoeae	O	O	I-Entity
(	O	O	O
NG	O	O	B-Entity
)	O	O	O
and	O	O	O
Chlamydia	O	O	B-Entity
trachomatis	O	O	I-Entity
(	O	O	O
CT	O	O	B-Entity
)	O	O	O
in	O	O	O
children	O	O	B-Entity
and	O	O	O
adolescents	O	O	B-Entity
assessed	O	O	B-Entity
for	O	O	O
sexual	O	O	B-Entity
abuse	O	O	I-Entity
/	O	O	O
assault	O	O	B-Entity
.	O	O	O

The	O	O	O
charts	O	O	O
of	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
0	O	O	O
to	O	O	O
17	O	O	O
years	O	O	B-Entity
,	O	O	O
consecutively	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
sexual	O	O	B-Entity
victimization	O	O	I-Entity
,	O	O	O
in	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
and	O	O	O
outpatient	O	O	B-Entity
settings	O	O	I-Entity
were	O	O	O
reviewed	O	O	O
.	O	O	O

Data	O	O	B-Entity
extracted	O	O	O
included	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
type	O	O	O
of	O	O	O
sexual	O	O	B-Entity
contact	O	O	I-Entity
,	O	O	O
anogenital	O	O	B-Entity
findings	O	O	B-Entity
,	O	O	O
previous	O	O	B-Entity
sexual	O	O	O
contact	O	O	O
,	O	O	O
toxicology	O	O	B-Entity
results	O	O	I-Entity
,	O	O	O
and	O	O	O
sites	O	O	B-Entity
tested	O	O	B-Entity
for	O	O	O
NG	O	O	B-Entity
and	O	O	O
CT	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
1319	O	O	O
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
tested	O	O	B-Entity
,	O	O	O
579	O	O	O
were	O	O	O
tested	O	O	O
at	O	O	O
more	O	O	O
than	O	O	O
1	O	O	O
site	O	O	B-Entity
,	O	O	O
and	O	O	O
120	O	O	O
had	O	O	O
at	O	O	O
least	O	O	O
1	O	O	O
infected	O	O	B-Entity
site	O	O	O
.	O	O	O

Chlamydia	O	O	B-Entity
trachomatis	O	O	I-Entity
was	O	O	O
identified	O	O	O
in	O	O	O
104	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
NG	O	O	B-Entity
was	O	O	O
found	O	O	O
in	O	O	O
33	O	O	O
.	O	O	O

In	O	O	O
bivariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
a	O	O	O
positive	O	O	O
test	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
female	O	O	B-Entity
sex	O	O	I-Entity
,	O	O	O
age	O	O	B-Entity
older	O	O	O
than	O	O	O
11	O	O	O
years	O	O	B-Entity
,	O	O	O
previous	O	O	B-Entity
sexual	O	O	B-Entity
contact	O	O	I-Entity
,	O	O	O
acute	O	O	O
or	O	O	O
healed	O	O	B-Entity
genital	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
drug/alcohol	O	O	B-Entity
intoxication	O	O	I-Entity
,	O	O	O
and	O	O	O
examination	O	O	B-Entity
within	O	O	O
72	O	O	O
hours	O	O	B-Entity
of	O	O	O
sexual	O	O	O
contact	O	O	O
.	O	O	O

Fifty-one	O	O	O
patients	O	O	B-Entity
had	O	O	O
positive	O	O	B-Entity
anal	O	O	B-Entity
tests	O	O	B-Entity
,	O	O	O
and	O	O	O
24	O	O	O
had	O	O	O
positive	O	O	O
oral	O	O	B-Entity
tests	O	O	O
.	O	O	O

More	O	O	O
than	O	O	O
75	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
positive	O	O	B-Entity
extragenital	O	O	B-Entity
tests	O	O	B-Entity
had	O	O	O
additional	O	O	O
positive	O	O	O
tests	O	O	O
or	O	O	O
anogenital	O	O	B-Entity
injury	O	O	B-Entity
.	O	O	O

Most	O	O	O
with	O	O	O
a	O	O	O
positive	O	O	B-Entity
anal	O	O	B-Entity
(	O	O	O
59	O	O	O
%	O	O	O
)	O	O	O
or	O	O	O
oral	O	O	B-Entity
(	O	O	O
77	O	O	O
%	O	O	O
)	O	O	O
test	O	O	B-Entity
did	O	O	O
not	O	O	O
report	O	O	O
that	O	O	O
the	O	O	O
assailant	O	O	O
's	O	O	O
genitals	O	O	B-Entity
came	O	O	O
into	O	O	O
contact	O	O	O
with	O	O	O
that	O	O	O
site	O	O	B-Entity
.	O	O	O

Positive	O	O	B-Entity
tests	O	O	B-Entity
for	O	O	O
NG	O	O	B-Entity
and	O	O	O
CT	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
evaluated	O	O	B-Entity
for	O	O	O
sexual	O	O	B-Entity
victimization	O	O	I-Entity
may	O	O	O
represent	O	O	O
infection	O	O	B-Entity
from	O	O	O
sexual	O	O	B-Entity
contact	O	O	I-Entity
,	O	O	O
contiguous	O	O	B-Entity
spread	O	O	I-Entity
of	O	O	O
infection	O	O	O
,	O	O	O
or	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
infected	O	O	B-Entity
assailant	O	O	I-Entity
secretions	O	O	I-Entity
.	O	O	O

Relying	O	O	O
on	O	O	O
patient	O	O	B-Entity
reports	O	O	O
of	O	O	O
symptoms	O	O	B-Entity
,	O	O	O
or	O	O	O
types	O	O	O
of	O	O	O
sexual	O	O	B-Entity
contact	O	O	I-Entity
,	O	O	O
to	O	O	O
determine	O	O	O
need	O	O	O
for	O	O	O
testing	O	O	O
may	O	O	O
miss	O	O	O
NG	O	O	B-Entity
and	O	O	O
CT	O	O	B-Entity
infections	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
evaluated	O	O	B-Entity
for	O	O	O
sexual	O	O	B-Entity
victimization	O	O	I-Entity
.	O	O	O

-DOCSTART- (28074357)

The	O	O	O
Longitudinal	O	O	B-Entity
Effects	O	O	B-Entity
of	O	O	I-Entity
Parenting	O	O	B-Entity
on	O	O	O
Adaptive	O	O	B-Entity
Behavior	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
with	O	O	O
Fragile	O	O	O
X	O	O	O
Syndrome	O	O	O

Several	O	O	O
studies	O	O	B-Entity
have	O	O	O
reported	O	O	O
declines	O	O	B-Entity
in	O	O	O
adaptive	O	O	B-Entity
behavior	O	O	I-Entity
amongst	O	O	O
children	O	O	B-Entity
with	O	O	O
fragile	O	O	B-Entity
X	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
FXS	O	O	B-Entity
)	O	O	O
starting	O	O	O
in	O	O	O
middle	O	O	B-Entity
childhood	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
maternal	O	O	B-Entity
responsivity	O	O	B-Entity
on	O	O	O
adaptive	O	O	B-Entity
behavior	O	O	I-Entity
in	O	O	O
55	O	O	O
children	O	O	B-Entity
with	O	O	O
FXS	O	O	B-Entity
visited	O	O	O
5	O	O	O
-	O	O	O
6	O	O	O
times	O	O	O
in	O	O	O
their	O	O	O
homes	O	O	B-Entity
from	O	O	O
early	O	O	O
through	O	O	O
middle	O	O	B-Entity
childhood	O	O	B-Entity
.	O	O	O

Our	O	O	O
analyses	O	O	B-Entity
indicated	O	O	O
that	O	O	O
sustained	O	O	B-Entity
maternal	O	O	B-Entity
responsivity	O	O	B-Entity
had	O	O	O
a	O	O	O
significant	O	O	B-Entity
positive	O	O	B-Entity
impact	O	O	I-Entity
on	O	O	O
the	O	O	O
trajectories	O	O	B-Entity
of	O	O	O
communication	O	O	B-Entity
and	O	O	O
to	O	O	O
a	O	O	O
lesser	O	O	O
extent	O	O	O
other	O	O	O
adaptive	O	O	B-Entity
behavior	O	O	I-Entity
domains	O	O	B-Entity
through	O	O	O
middle	O	O	B-Entity
childhood	O	O	B-Entity
with	O	O	O
many	O	O	O
effects	O	O	B-Entity
remaining	O	O	O
significant	O	O	O
after	O	O	O
controlling	O	O	B-Entity
for	O	O	O
autism	O	O	B-Entity
symptoms	O	O	I-Entity
and	O	O	O
developmental	O	O	B-Entity
level	O	O	I-Entity
.	O	O	O

For	O	O	O
children	O	O	B-Entity
who	O	O	O
showed	O	O	O
declines	O	O	B-Entity
in	O	O	O
adaptive	O	O	B-Entity
behavior	O	O	I-Entity
during	O	O	O
middle	O	O	B-Entity
childhood	O	O	B-Entity
,	O	O	O
sustained	O	O	B-Entity
high	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
maternal	O	O	B-Entity
responsivity	O	O	B-Entity
minimized	O	O	B-Entity
the	O	O	O
amount	O	O	O
of	O	O	O
decline	O	O	B-Entity
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
communication	O	O	B-Entity
,	O	O	O
socialization	O	O	B-Entity
,	O	O	O
and	O	O	O
daily	O	O	B-Entity
living	O	O	I-Entity
domains	O	O	I-Entity
.	O	O	O

-DOCSTART- (28076405)

Development	O	O	B-Entity
and	O	O	O
Validation	O	O	B-Entity
of	O	O	O
a	O	O	O
New	O	O	O
Reliable	O	O	O
Method	O	O	B-Entity
for	O	O	O
the	O	O	O
Diagnosis	O	O	B-Entity
of	O	O	O
Avian	O	O	B-Entity
Botulism	O	O	O

Liver	O	O	B-Entity
is	O	O	O
a	O	O	O
reliable	O	O	O
matrix	O	O	B-Entity
for	O	O	O
laboratory	O	O	B-Entity
confirmation	O	O	B-Entity
of	O	O	I-Entity
avian	O	O	B-Entity
botulism	O	O	B-Entity
using	O	O	O
real-time	O	O	B-Entity
PCR	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	B-Entity
,	O	O	O
optimized	O	O	B-Entity
,	O	O	O
and	O	O	O
validated	O	O	B-Entity
the	O	O	O
analytical	O	O	B-Entity
steps	O	O	B-Entity
preceding	O	O	B-Entity
PCR	O	O	B-Entity
to	O	O	O
maximize	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
Clostridium	O	O	B-Entity
botulinum	O	O	I-Entity
group	O	O	I-Entity
III	O	O	I-Entity
in	O	O	O
avian	O	O	B-Entity
liver	O	O	B-Entity
.	O	O	O

These	O	O	O
pre	O	O	B-Entity
-	O	O	O
PCR	O	O	B-Entity
steps	O	O	B-Entity
included	O	O	O
enrichment	O	O	B-Entity
incubation	O	O	B-Entity
of	O	O	O
the	O	O	O
whole	O	O	O
liver	O	O	B-Entity
(	O	O	O
maximum	O	O	O
25	O	O	O
g	O	O	O
)	O	O	O
at	O	O	O
37	O	O	B-Entity
°	O	O	I-Entity
C	O	O	I-Entity
for	O	O	O
at	O	O	O
least	O	O	O
24	O	O	O
h	O	O	B-Entity
in	O	O	O
an	O	O	O
anaerobic	O	O	B-Entity
chamber	O	O	I-Entity
and	O	O	O
DNA	O	O	B-Entity
extraction	O	O	I-Entity
using	O	O	O
an	O	O	O
enzymatic	O	O	B-Entity
digestion	O	O	I-Entity
step	O	O	O
followed	O	O	O
by	O	O	O
a	O	O	O
DNA	O	O	B-Entity
purification	O	O	I-Entity
step	O	O	O
.	O	O	O

Conditions	O	O	O
of	O	O	O
sample	O	O	B-Entity
storage	O	O	B-Entity
before	O	O	O
analysis	O	O	B-Entity
appear	O	O	O
to	O	O	O
have	O	O	O
a	O	O	O
strong	O	O	O
effect	O	O	B-Entity
on	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
group	O	O	B-Entity
III	O	O	I-Entity
C.	O	O	I-Entity
botulinum	O	O	I-Entity
strains	O	O	I-Entity
and	O	O	O
our	O	O	O
results	O	O	B-Entity
recommend	O	O	O
storage	O	O	O
at	O	O	O
temperatures	O	O	B-Entity
below	O	O	O
-18	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Short-term	O	O	B-Entity
storage	O	O	B-Entity
at	O	O	O
5	O	O	O
°	O	O	O
C	O	O	O
is	O	O	O
possible	O	O	O
for	O	O	O
up	O	O	O
to	O	O	O
24	O	O	O
h	O	O	B-Entity
,	O	O	O
but	O	O	O
a	O	O	O
decrease	O	O	B-Entity
in	O	O	O
sensitivity	O	O	B-Entity
was	O	O	O
observed	O	O	O
at	O	O	O
48	O	O	O
h	O	O	O
of	O	O	O
storage	O	O	O
at	O	O	O
this	O	O	O
temperature	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
whole	O	O	O
livers	O	O	B-Entity
(	O	O	O
maximum	O	O	O
25	O	O	O
g	O	O	O
)	O	O	O
is	O	O	O
required	O	O	O
and	O	O	O
pooling	O	O	B-Entity
samples	O	O	B-Entity
before	O	O	O
enrichment	O	O	B-Entity
culturing	O	O	I-Entity
must	O	O	O
be	O	O	O
avoided	O	O	O
.	O	O	O

Pooling	O	O	B-Entity
is	O	O	O
however	O	O	O
possible	O	O	O
before	O	O	O
or	O	O	O
after	O	O	O
DNA	O	O	B-Entity
extraction	O	O	I-Entity
under	O	O	O
certain	O	O	O
conditions	O	O	O
.	O	O	O

Whole	O	O	O
livers	O	O	B-Entity
should	O	O	O
be	O	O	O
10-fold	O	O	O
diluted	O	O	O
in	O	O	O
enrichment	O	O	B-Entity
medium	O	O	I-Entity
and	O	O	O
homogenized	O	O	O
using	O	O	O
a	O	O	O
Pulsifier	O	O	B-Entity
®	O	O	I-Entity
blender	O	O	I-Entity
(	O	O	O
Microgen	O	O	O
,	O	O	O
Surrey	O	O	B-Entity
,	O	O	O
UK	O	O	B-Entity
)	O	O	O
instead	O	O	O
of	O	O	O
a	O	O	O
conventional	O	O	O
paddle	O	O	B-Entity
blender	O	O	I-Entity
.	O	O	O

Spiked	O	O	B-Entity
liver	O	O	B-Entity
samples	O	O	B-Entity
showed	O	O	O
a	O	O	O
limit	O	O	O
of	O	O	O
detection	O	O	B-Entity
of	O	O	O
5	O	O	O
spores	O	O	B-Entity
/g	O	O	O
liver	O	O	O
for	O	O	O
types	O	O	B-Entity
C	O	O	I-Entity
and	O	O	O
D	O	O	B-Entity
and	O	O	O
250	O	O	O
spores	O	O	O
/g	O	O	O
for	O	O	O
type	O	O	O
E.	O	O	O
Using	O	O	O
the	O	O	O
method	O	O	B-Entity
developed	O	O	B-Entity
here	O	O	O
,	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
268	O	O	O
samples	O	O	O
from	O	O	O
73	O	O	O
suspected	O	O	O
outbreaks	O	O	B-Entity
showed	O	O	O
100	O	O	O
%	O	O	O
specificity	O	O	B-Entity
and	O	O	O
95.35	O	O	O
%	O	O	O
sensitivity	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
other	O	O	O
PCR	O	O	B-Entity
-based	O	O	O
methods	O	O	B-Entity
considered	O	O	O
as	O	O	O
reference	O	O	O
.	O	O	O

The	O	O	O
mosaic	O	O	B-Entity
type	O	O	I-Entity
C	O	O	I-Entity
/	O	O	O
D	O	O	B-Entity
was	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
neurotoxin	O	O	B-Entity
type	O	O	O
found	O	O	O
in	O	O	O
examined	O	O	O
samples	O	O	B-Entity
,	O	O	O
which	O	O	O
included	O	O	O
both	O	O	O
wild	O	O	B-Entity
and	O	O	O
domestic	O	O	B-Entity
birds	O	O	I-Entity
.	O	O	O

-DOCSTART- (28077898)

Quality	O	O	B-Entity
Improvement	O	O	I-Entity
of	O	O	O
Liver	O	O	B-Entity
Ultrasound	O	O	B-Entity
Images	O	O	B-Entity
Using	O	O	O
Fuzzy	O	O	B-Entity
Techniques	O	O	O

Liver	O	O	B-Entity
ultrasound	O	O	B-Entity
images	O	O	B-Entity
are	O	O	O
so	O	O	O
common	O	O	O
and	O	O	O
are	O	O	O
applied	O	O	O
so	O	O	O
often	O	O	O
to	O	O	O
diagnose	O	O	B-Entity
diffuse	O	O	B-Entity
liver	O	O	I-Entity
diseases	O	O	I-Entity
like	O	O	O
fatty	O	O	B-Entity
liver	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
low	O	O	B-Entity
quality	O	O	B-Entity
of	O	O	O
such	O	O	O
images	O	O	B-Entity
makes	O	O	O
it	O	O	O
difficult	O	O	O
to	O	O	O
analyze	O	O	B-Entity
them	O	O	O
and	O	O	O
diagnose	O	O	B-Entity
diseases	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
therefore	O	O	O
,	O	O	O
is	O	O	O
to	O	O	O
improve	O	O	O
the	O	O	O
contrast	O	O	B-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	O
liver	O	O	B-Entity
ultrasound	O	O	B-Entity
images	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
image	O	O	B-Entity
contrast	O	O	B-Entity
enhancement	O	O	B-Entity
algorithms	O	O	B-Entity
which	O	O	O
are	O	O	O
based	O	O	O
on	O	O	O
fuzzy	O	O	B-Entity
logic	O	O	I-Entity
were	O	O	O
applied	O	O	O
to	O	O	O
liver	O	O	B-Entity
ultrasound	O	O	B-Entity
images	O	O	B-Entity
-	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
view	O	O	O
of	O	O	O
kidney	O	O	B-Entity
is	O	O	O
observable	O	O	O
-	O	O	O
using	O	O	O
Matlab2013b	O	O	B-Entity
to	O	O	O
improve	O	O	O
the	O	O	O
image	O	O	O
contrast	O	O	O
and	O	O	O
quality	O	O	B-Entity
which	O	O	O
has	O	O	O
a	O	O	O
fuzzy	O	O	O
definition	O	O	B-Entity
;	O	O	O
just	O	O	O
like	O	O	O
image	O	O	O
contrast	O	O	O
improvement	O	O	B-Entity
algorithms	O	O	O
using	O	O	O
a	O	O	O
fuzzy	O	O	O
intensification	O	O	B-Entity
operator	O	O	I-Entity
,	O	O	O
contrast	O	O	O
improvement	O	O	O
algorithms	O	O	O
applying	O	O	O
fuzzy	O	O	O
image	O	O	O
histogram	O	O	B-Entity
hyperbolization	O	O	I-Entity
,	O	O	O
and	O	O	O
contrast	O	O	O
improvement	O	O	O
algorithms	O	O	O
by	O	O	O
fuzzy	O	O	O
IF-THEN	O	O	B-Entity
rules	O	O	I-Entity
.	O	O	O

With	O	O	O
the	O	O	O
measurement	O	O	B-Entity
of	O	O	O
Mean	O	O	B-Entity
Squared	O	O	I-Entity
Error	O	O	I-Entity
and	O	O	O
Peak	O	O	B-Entity
Signal	O	O	B-Entity
to	O	O	I-Entity
Noise	O	O	I-Entity
Ratio	O	O	I-Entity
obtained	O	O	O
from	O	O	O
different	O	O	O
images	O	O	B-Entity
,	O	O	O
fuzzy	O	O	B-Entity
methods	O	O	B-Entity
provided	O	O	O
better	O	O	O
results	O	O	B-Entity
,	O	O	O
and	O	O	O
their	O	O	O
implementation	O	O	B-Entity
-	O	O	O
compared	O	O	B-Entity
with	O	O	O
histogram	O	O	B-Entity
equalization	O	O	I-Entity
method	O	O	I-Entity
-	O	O	O
led	O	O	O
both	O	O	O
to	O	O	O
the	O	O	O
improvement	O	O	B-Entity
of	O	O	O
contrast	O	O	B-Entity
and	O	O	O
visual	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	O
images	O	O	O
and	O	O	O
to	O	O	O
the	O	O	O
improvement	O	O	O
of	O	O	O
liver	O	O	B-Entity
segmentation	O	O	B-Entity
algorithms	O	O	I-Entity
results	O	O	O
in	O	O	O
images	O	O	O
.	O	O	O

Comparison	O	O	B-Entity
of	O	O	O
the	O	O	O
four	O	O	O
algorithms	O	O	B-Entity
revealed	O	O	O
the	O	O	O
power	O	O	O
of	O	O	O
fuzzy	O	O	B-Entity
logic	O	O	I-Entity
in	O	O	O
improving	O	O	O
image	O	O	B-Entity
contrast	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
traditional	O	O	O
image	O	O	B-Entity
processing	O	O	I-Entity
algorithms	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
contrast	O	O	B-Entity
improvement	O	O	B-Entity
algorithm	O	O	B-Entity
based	O	O	O
on	O	O	O
a	O	O	O
fuzzy	O	O	B-Entity
intensification	O	O	B-Entity
operator	O	O	I-Entity
was	O	O	O
selected	O	O	O
as	O	O	O
the	O	O	O
strongest	O	O	O
algorithm	O	O	O
considering	O	O	O
the	O	O	O
measured	O	O	O
indicators	O	O	O
.	O	O	O

This	O	O	O
method	O	O	B-Entity
can	O	O	O
also	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
future	O	O	O
studies	O	O	B-Entity
on	O	O	O
other	O	O	O
ultrasound	O	O	B-Entity
images	O	O	B-Entity
for	O	O	O
quality	O	O	B-Entity
improvement	O	O	I-Entity
and	O	O	O
other	O	O	O
image	O	O	B-Entity
processing	O	O	I-Entity
and	O	O	O
analysis	O	O	B-Entity
applications	O	O	B-Entity
.	O	O	O

-DOCSTART- (28078640)

Development	O	O	B-Entity
of	O	O	O
the	O	O	O
pediatric	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
inventory	O	O	I-Entity
neurofibromatosis	O	O	B-Entity
type	O	O	I-Entity
1	O	O	I-Entity
module	O	O	B-Entity
items	O	O	B-Entity
for	O	O	O
children	O	O	B-Entity
,	O	O	O
adolescents	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
:	O	O	O
qualitative	O	O	O
methods	O	O	O

Health-related	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
HRQOL	O	O	B-Entity
)	O	O	O
is	O	O	O
arguably	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
important	O	O	B-Entity
measures	O	O	B-Entity
in	O	O	O
evaluating	O	O	B-Entity
effectiveness	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
treatments	O	O	I-Entity
.	O	O	O

At	O	O	O
present	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
disease	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
outcome	O	O	B-Entity
measure	O	O	I-Entity
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
HRQOL	O	O	B-Entity
of	O	O	O
children	O	O	B-Entity
,	O	O	O
adolescents	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
with	O	O	O
Neurofibromatosis	O	O	B-Entity
Type	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
NF1	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
develop	O	O	O
the	O	O	O
items	O	O	B-Entity
and	O	O	O
support	O	O	O
the	O	O	O
content	O	O	B-Entity
validity	O	O	I-Entity
for	O	O	O
the	O	O	O
Pediatric	O	O	B-Entity
Quality	O	O	I-Entity
of	O	O	I-Entity
Life	O	O	I-Entity
Inventory	O	O	I-Entity
™	O	O	I-Entity
(	O	O	O
PedsQL	O	O	B-Entity
™	O	O	I-Entity
)	O	O	O
NF1	O	O	B-Entity
Module	O	O	B-Entity
for	O	O	O
children	O	O	B-Entity
,	O	O	O
adolescents	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

The	O	O	O
iterative	O	O	B-Entity
process	O	O	B-Entity
included	O	O	O
multiphase	O	O	B-Entity
qualitative	O	O	I-Entity
methods	O	O	I-Entity
including	O	O	O
a	O	O	O
literature	O	O	B-Entity
review	O	O	I-Entity
,	O	O	O
survey	O	O	B-Entity
of	O	O	O
expert	O	O	B-Entity
opinions	O	O	I-Entity
,	O	O	O
semi-structured	O	O	B-Entity
interviews	O	O	B-Entity
,	O	O	O
cognitive	O	O	B-Entity
interviews	O	O	O
and	O	O	O
pilot	O	O	B-Entity
testing	O	O	I-Entity
.	O	O	O

Fifteen	O	O	O
domains	O	O	B-Entity
were	O	O	O
derived	O	O	O
from	O	O	O
the	O	O	O
qualitative	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
with	O	O	O
content	O	O	B-Entity
saturation	O	O	O
achieved	O	O	O
,	O	O	O
resulting	O	O	O
in	O	O	O
115	O	O	O
items	O	O	B-Entity
.	O	O	O

The	O	O	O
domains	O	O	B-Entity
include	O	O	O
skin	O	O	B-Entity
,	O	O	O
pain	O	O	B-Entity
,	O	O	O
pain	O	O	O
impact	O	O	B-Entity
,	O	O	O
pain	O	O	B-Entity
management	O	O	I-Entity
,	O	O	O
cognitive	O	O	B-Entity
functioning	O	O	I-Entity
,	O	O	O
speech	O	O	B-Entity
,	O	O	O
fine	O	O	B-Entity
motor	O	O	I-Entity
,	O	O	O
balance	O	O	B-Entity
,	O	O	O
vision	O	O	B-Entity
,	O	O	O
perceived	O	O	B-Entity
physical	O	O	B-Entity
appearance	O	O	I-Entity
,	O	O	O
communication	O	O	B-Entity
,	O	O	O
worry	O	O	B-Entity
,	O	O	O
treatment	O	O	B-Entity
,	O	O	O
medicines	O	O	B-Entity
and	O	O	O
gastrointestinal	O	O	B-Entity
symptoms	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
is	O	O	O
limited	O	O	B-Entity
because	O	O	O
all	O	O	O
participants	O	O	B-Entity
are	O	O	O
recruited	O	O	O
from	O	O	O
a	O	O	O
single	O	O	B-Entity
-	O	O	O
site	O	O	B-Entity
.	O	O	O

Qualitative	O	O	B-Entity
methods	O	O	I-Entity
support	O	O	O
the	O	O	O
content	O	O	B-Entity
validity	O	O	I-Entity
for	O	O	O
the	O	O	O
PedsQL	O	O	B-Entity
™	O	O	I-Entity
NF1	O	O	B-Entity
Module	O	O	B-Entity
for	O	O	O
children	O	O	B-Entity
,	O	O	O
adolescents	O	O	B-Entity
and	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

The	O	O	O
PedsQL	O	O	B-Entity
™	O	O	I-Entity
NF1	O	O	B-Entity
Module	O	O	B-Entity
is	O	O	O
now	O	O	O
undergoing	O	O	O
national	O	O	B-Entity
multisite	O	O	I-Entity
field	O	O	I-Entity
testing	O	O	I-Entity
for	O	O	O
the	O	O	O
psychometric	O	O	B-Entity
validation	O	O	B-Entity
of	O	O	O
the	O	O	O
instrument	O	O	B-Entity
development	O	O	B-Entity
.	O	O	O

-DOCSTART- (28079476)

Mimiviruses	O	O	B-Entity
and	O	O	O
the	O	O	O
Human	O	O	B-Entity
Interferon	O	O	B-Entity
System	O	O	B-Entity
:	O	O	O
Viral	O	O	B-Entity
Evasion	O	O	I-Entity
of	O	O	O
Classical	O	O	B-Entity
Antiviral	O	O	B-Entity
Activities	O	O	I-Entity
,	O	O	O
But	O	O	O
Inhibition	O	O	B-Entity
By	O	O	O
a	O	O	O
Novel	O	O	O
Interferon-β	O	O	B-Entity
Regulated	O	O	B-Entity
Immunomodulatory	O	O	B-Entity
Pathway	O	O	O

In	O	O	O
this	O	O	O
review	O	O	B-Entity
we	O	O	O
discuss	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
mimiviruses	O	O	B-Entity
as	O	O	O
potential	O	O	B-Entity
human	O	O	B-Entity
pathogens	O	O	B-Entity
focusing	O	O	O
on	O	O	O
clinical	O	O	B-Entity
and	O	O	O
evolutionary	O	O	B-Entity
evidence	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
propose	O	O	B-Entity
a	O	O	O
novel	O	O	O
antiviral	O	O	B-Entity
immunomodulatory	O	O	B-Entity
pathway	O	O	B-Entity
controlled	O	O	B-Entity
by	O	O	O
interferon-β	O	O	B-Entity
(	O	O	O
IFN-β	O	O	B-Entity
)	O	O	O
and	O	O	O
mediated	O	O	O
by	O	O	O
immune-responsive	O	O	B-Entity
gene	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
IRG1	O	O	B-Entity
)	O	O	O
and	O	O	O
itaconic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
its	O	O	O
product	O	O	B-Entity
.	O	O	O

Acanthamoeba	O	O	B-Entity
polyphaga	O	O	I-Entity
Mimivirus	O	O	I-Entity
(	O	O	O
APMV	O	O	B-Entity
)	O	O	O
was	O	O	O
isolated	O	O	B-Entity
from	O	O	O
amoebae	O	O	B-Entity
in	O	O	O
a	O	O	O
hospital	O	O	B-Entity
while	O	O	O
investigating	O	O	B-Entity
a	O	O	O
pneumonia	O	O	B-Entity
outbreak	O	O	B-Entity
.	O	O	O

Mimivirus	O	O	B-Entity
ubiquity	O	O	B-Entity
and	O	O	O
role	O	O	B-Entity
as	O	O	O
protist	O	O	B-Entity
pathogens	O	O	B-Entity
are	O	O	O
well	O	O	O
understood	O	O	O
,	O	O	O
and	O	O	O
its	O	O	O
putative	O	O	B-Entity
status	O	O	B-Entity
as	O	O	O
a	O	O	O
human	O	O	B-Entity
pathogen	O	O	B-Entity
has	O	O	O
been	O	O	O
gaining	O	O	B-Entity
strength	O	O	B-Entity
as	O	O	O
more	O	O	O
evidence	O	O	B-Entity
is	O	O	O
being	O	O	O
found	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
of	O	O	O
APMV	O	O	B-Entity
and	O	O	O
human	O	O	B-Entity
cells	O	O	B-Entity
interaction	O	O	B-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
virus	O	O	B-Entity
is	O	O	O
able	O	O	O
to	O	O	O
evade	O	O	B-Entity
the	O	O	O
IFN	O	O	B-Entity
system	O	O	B-Entity
by	O	O	O
inhibiting	O	O	B-Entity
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
interferon	O	O	B-Entity
-stimulated	O	O	O
genes	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
the	O	O	O
virus	O	O	O
and	O	O	O
humans	O	O	B-Entity
have	O	O	O
had	O	O	O
host-pathogen	O	O	B-Entity
interactions	O	O	I-Entity
.	O	O	O

It	O	O	O
also	O	O	O
has	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
virus	O	O	B-Entity
is	O	O	O
capable	O	O	B-Entity
of	O	O	O
growing	O	O	O
on	O	O	O
IFN-α2	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
on	O	O	O
IFN-β	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
hinting	O	O	O
at	O	O	O
an	O	O	O
exclusive	O	O	B-Entity
IFN-β	O	O	O
antiviral	O	O	B-Entity
pathway	O	O	B-Entity
.	O	O	O

Our	O	O	O
hypothesis	O	O	B-Entity
based	O	O	B-Entity
on	O	O	O
preliminary	O	O	B-Entity
data	O	O	I-Entity
and	O	O	O
published	O	O	B-Entity
articles	O	O	I-Entity
is	O	O	O
that	O	O	O
IFN-β	O	O	B-Entity
preferentially	O	O	B-Entity
upregulates	O	O	B-Entity
IRG1	O	O	B-Entity
in	O	O	I-Entity
human	O	O	I-Entity
macrophagic	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
produces	O	O	O
itaconic	O	O	B-Entity
acid	O	O	I-Entity
.	O	O	O

This	O	O	O
metabolite	O	O	B-Entity
links	O	O	O
metabolism	O	O	B-Entity
to	O	O	O
antiviral	O	O	B-Entity
activity	O	O	I-Entity
by	O	O	O
inactivating	O	O	B-Entity
the	O	O	O
virus	O	O	B-Entity
,	O	O	O
in	O	O	O
a	O	O	O
novel	O	O	O
immunomodulatory	O	O	B-Entity
pathway	O	O	B-Entity
relevant	O	O	B-Entity
for	O	O	O
APMV	O	O	B-Entity
infections	O	O	B-Entity
and	O	O	O
probably	O	O	O
to	O	O	O
other	O	O	O
infectious	O	O	B-Entity
diseases	O	O	I-Entity
as	O	O	O
well	O	O	O
.	O	O	O

-DOCSTART- (28080032)

Heteroprotein	O	O	B-Entity
Complex	O	O	B-Entity
Formation	O	O	O
of	O	O	O
Bovine	O	O	B-Entity
Lactoferrin	O	O	I-Entity
and	O	O	O
Pea	O	O	B-Entity
Protein	O	O	I-Entity
Isolate	O	O	B-Entity
:	O	O	O
A	O	O	O
Multiscale	O	O	O
Structural	O	O	O
Analysis	O	O	O

Associative	O	O	B-Entity
electrostatic	O	O	B-Entity
interactions	O	O	I-Entity
between	O	O	O
two	O	O	O
oppositely	O	O	B-Entity
charged	O	O	B-Entity
globular	O	O	B-Entity
proteins	O	O	I-Entity
,	O	O	O
lactoferrin	O	O	B-Entity
(	O	O	O
LF	O	O	B-Entity
)	O	O	O
and	O	O	O
pea	O	O	B-Entity
protein	O	O	I-Entity
isolate	O	O	B-Entity
(	O	O	O
PPI	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
latter	O	O	O
being	O	O	O
a	O	O	O
mixture	O	O	B-Entity
of	O	O	O
vicilin	O	O	B-Entity
,	O	O	O
legumin	O	O	B-Entity
,	O	O	O
and	O	O	O
convicilin	O	O	B-Entity
,	O	O	O
was	O	O	O
studied	O	O	B-Entity
with	O	O	O
a	O	O	O
specific	O	O	B-Entity
PPI	O	O	O
/	O	O	O
LF	O	O	O
molar	O	O	B-Entity
ratio	O	O	I-Entity
at	O	O	O
room	O	O	B-Entity
temperature	O	O	I-Entity
.	O	O	O

Structural	O	O	B-Entity
aspects	O	O	B-Entity
of	O	O	O
the	O	O	O
electrostatic	O	O	B-Entity
complexes	O	O	B-Entity
probed	O	O	O
at	O	O	O
different	O	O	B-Entity
length	O	O	B-Entity
scales	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
pH	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
different	O	O	O
complementary	O	O	B-Entity
techniques	O	O	I-Entity
,	O	O	O
namely	O	O	O
,	O	O	O
with	O	O	O
dynamic	O	O	B-Entity
light	O	O	I-Entity
scattering	O	O	I-Entity
,	O	O	O
small-angle	O	O	B-Entity
X-ray	O	O	I-Entity
scattering	O	O	I-Entity
(	O	O	O
SAXS	O	O	B-Entity
)	O	O	O
,	O	O	O
turbidity	O	O	B-Entity
measurements	O	O	I-Entity
,	O	O	O
and	O	O	O
atomic	O	O	B-Entity
force	O	O	I-Entity
microscopy	O	O	I-Entity
(	O	O	O
AFM	O	O	B-Entity
)	O	O	O
.	O	O	O

Irrespective	O	O	O
of	O	O	O
the	O	O	O
applied	O	O	O
techniques	O	O	B-Entity
,	O	O	O
the	O	O	O
results	O	O	B-Entity
consistently	O	O	B-Entity
displayed	O	O	B-Entity
that	O	O	O
complexation	O	O	B-Entity
between	O	O	O
LF	O	O	B-Entity
and	O	O	O
PPI	O	O	B-Entity
did	O	O	O
occur	O	O	B-Entity
.	O	O	O

In	O	O	O
an	O	O	O
optimum	O	O	B-Entity
narrow	O	O	B-Entity
range	O	O	B-Entity
of	O	O	O
pH	O	O	B-Entity
5.0	O	O	O
-	O	O	O
5.8	O	O	O
,	O	O	O
a	O	O	O
viscous	O	O	B-Entity
liquid	O	O	B-Entity
phase	O	O	B-Entity
of	O	O	O
complex	O	O	B-Entity
coacervate	O	O	B-Entity
was	O	O	O
obtained	O	O	B-Entity
upon	O	O	O
mild	O	O	O
centrifugation	O	O	B-Entity
of	O	O	O
the	O	O	O
turbid	O	O	B-Entity
LF	O	O	B-Entity
-	O	O	O
PPI	O	O	B-Entity
mixture	O	O	B-Entity
with	O	O	O
a	O	O	O
maximum	O	O	B-Entity
Rh	O	O	O
,	O	O	O
turbidity	O	O	B-Entity
and	O	O	O
the	O	O	O
ζ-potential	O	O	B-Entity
being	O	O	O
close	O	O	O
to	O	O	O
zero	O	O	O
observed	O	O	B-Entity
at	O	O	O
pH	O	O	O
5.4	O	O	O
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
SAXS	O	O	B-Entity
data	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
the	O	O	O
coacervates	O	O	B-Entity
were	O	O	O
densely	O	O	B-Entity
assembled	O	O	B-Entity
with	O	O	O
a	O	O	O
roughly	O	O	B-Entity
spherical	O	O	B-Entity
size	O	O	B-Entity
distribution	O	O	B-Entity
exhibiting	O	O	O
a	O	O	O
maximum	O	O	B-Entity
extension	O	O	B-Entity
of	O	O	O
∼80	O	O	O
nm	O	O	O
at	O	O	O
pH	O	O	B-Entity
5.4	O	O	O
.	O	O	O

Equally	O	O	O
,	O	O	O
AFM	O	O	B-Entity
image	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
size	O	O	B-Entity
distributions	O	O	B-Entity
containing	O	O	B-Entity
most	O	O	O
frequent	O	O	B-Entity
cluster	O	O	B-Entity
sizes	O	O	B-Entity
around	O	O	O
40	O	O	O
-	O	O	O
80	O	O	O
nm	O	O	O
with	O	O	O
spherical	O	O	B-Entity
to	O	O	O
elliptical	O	O	B-Entity
shapes	O	O	I-Entity
(	O	O	O
axis	O	O	O
aspect	O	O	O
ratio	O	O	O
≤	O	O	O
2	O	O	O
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
less	O	O	O
frequent	O	O	O
elongated	O	O	O
to	O	O	O
chainlike	O	O	B-Entity
structures	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
frequently	O	O	B-Entity
observed	O	O	B-Entity
compact	O	O	O
complexes	O	O	B-Entity
,	O	O	O
we	O	O	O
identify	O	O	O
as	O	O	O
mainly	O	O	O
leading	O	O	O
to	O	O	O
LF	O	O	B-Entity
-	O	O	O
PPI	O	O	B-Entity
coacervation	O	O	B-Entity
,	O	O	O
whereas	O	O	O
for	O	O	O
the	O	O	O
less	O	O	O
frequent	O	O	B-Entity
chain-like	O	O	B-Entity
aggregates	O	O	I-Entity
,	O	O	O
we	O	O	O
hypothesize	O	O	O
that	O	O	O
additionally	O	O	O
PPI	O	O	O
-	O	O	O
PPI	O	O	O
facilitated	O	O	O
complexes	O	O	O
exist	O	O	O
.	O	O	O

-DOCSTART- (28084862)

Visual	O	O	B-Entity
outcome	O	O	B-Entity
,	O	O	O
endocrine	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
control	O	O	B-Entity
after	O	O	O
fractionated	O	O	B-Entity
stereotactic	O	O	I-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
of	O	O	O
craniopharyngiomas	O	O	B-Entity
in	O	O	I-Entity
adults	O	O	I-Entity
:	O	O	O
findings	O	O	O
in	O	O	O
a	O	O	O
prospective	O	O	O
cohort	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
examine	O	O	B-Entity
visual	O	O	B-Entity
outcome	O	O	B-Entity
,	O	O	O
endocrine	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
control	O	O	B-Entity
in	O	O	O
a	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
of	O	O	O
craniopharyngioma	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
fractionated	O	O	B-Entity
stereotactic	O	O	I-Entity
radiation	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
FSRT	O	O	B-Entity
)	O	O	O
.	O	O	O

Sixteen	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
craniopharyngiomas	O	O	B-Entity
were	O	O	O
eligible	O	O	B-Entity
for	O	O	O
analysis	O	O	B-Entity
.	O	O	O

They	O	O	O
were	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
linear	O	O	B-Entity
accelerator-based	O	O	I-Entity
FSRT	O	O	B-Entity
during	O	O	O
1999	O	O	O
-	O	O	O
2015	O	O	O
.	O	O	O

In	O	O	O
all	O	O	O
cases	O	O	B-Entity
,	O	O	O
diagnosis	O	O	B-Entity
was	O	O	O
confirmed	O	O	O
by	O	O	O
histological	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
prescription	O	O	B-Entity
dose	O	O	B-Entity
to	O	O	O
the	O	O	O
tumor	O	O	B-Entity
was	O	O	O
54	O	O	O
Gy	O	O	B-Entity
(	O	O	O
median	O	O	B-Entity
,	O	O	O
range	O	O	B-Entity
48	O	O	O
-	O	O	O
54	O	O	O
)	O	O	O
in	O	O	O
1.8	O	O	O
or	O	O	O
2.0	O	O	O
Gy	O	O	O
per	O	O	O
fraction	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
maximum	O	O	O
radiation	O	O	B-Entity
dose	O	O	I-Entity
to	O	O	O
the	O	O	O
optic	O	O	B-Entity
nerves	O	O	I-Entity
and	O	O	O
chiasm	O	O	B-Entity
was	O	O	O
54.2	O	O	O
Gy	O	O	O
(	O	O	O
median	O	O	O
,	O	O	O
range	O	O	O
48.6	O	O	O
-	O	O	O
60.0	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
cohort	O	O	B-Entity
.	O	O	O

Serial	O	O	O
ophthalmological	O	O	B-Entity
and	O	O	O
endocrine	O	O	B-Entity
evaluations	O	O	I-Entity
and	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MRI	O	O	B-Entity
)	O	O	O
scans	O	O	B-Entity
were	O	O	O
performed	O	O	O
at	O	O	O
regular	O	O	O
intervals	O	O	O
.	O	O	O

Median	O	O	B-Entity
follow-up	O	O	B-Entity
was	O	O	O
3.3	O	O	O
years	O	O	B-Entity
(	O	O	O
range	O	O	B-Entity
1.1	O	O	O
-	O	O	O
14.1	O	O	O
)	O	O	O
,	O	O	O
3.7	O	O	O
years	O	O	O
(	O	O	O
range	O	O	O
0.8	O	O	O
-	O	O	O
15.2	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
3.6	O	O	O
years	O	O	O
(	O	O	O
range	O	O	O
0.7	O	O	O
-	O	O	O
13.1	O	O	O
)	O	O	O
for	O	O	O
visual	O	O	B-Entity
outcome	O	O	B-Entity
,	O	O	O
endocrine	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
and	O	O	O
tumor	O	O	B-Entity
control	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Visual	O	O	B-Entity
acuity	O	O	I-Entity
impairment	O	O	B-Entity
was	O	O	O
present	O	O	O
in	O	O	O
10	O	O	O
patients	O	O	B-Entity
(	O	O	O
62.5	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
visual	O	O	B-Entity
field	O	O	I-Entity
defects	O	O	I-Entity
were	O	O	O
present	O	O	O
in	O	O	O
12	O	O	O
patients	O	O	O
(	O	O	O
75	O	O	O
%	O	O	O
)	O	O	O
before	O	O	O
FSRT	O	O	B-Entity
.	O	O	O

One	O	O	O
patient	O	O	B-Entity
developed	O	O	O
radiation-induced	O	O	B-Entity
optic	O	O	I-Entity
neuropathy	O	O	I-Entity
at	O	O	O
seven	O	O	O
years	O	O	B-Entity
after	O	O	O
FSRT	O	O	B-Entity
.	O	O	O

Thirteen	O	O	O
of	O	O	O
16	O	O	O
patients	O	O	B-Entity
(	O	O	O
81.3	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
pituitary	O	O	B-Entity
deficiency	O	O	I-Entity
before	O	O	O
FSRT	O	O	B-Entity
,	O	O	O
and	O	O	O
did	O	O	O
not	O	O	O
develop	O	O	O
further	O	O	O
pituitary	O	O	O
deficiency	O	O	O
after	O	O	O
FSRT	O	O	O
.	O	O	O

Mean	O	O	B-Entity
tumor	O	O	B-Entity
volume	O	O	I-Entity
pre-	O	O	O
FSRT	O	O	B-Entity
was	O	O	O
2.72	O	O	O
cm(3	O	O	O
)	O	O	O
(	O	O	O
range	O	O	B-Entity
0.20	O	O	O
-	O	O	O
9.90	O	O	O
)	O	O	O
and	O	O	O
post-	O	O	O
FSRT	O	O	O
1.2	O	O	O
cm(3	O	O	O
)	O	O	O
(	O	O	O
range	O	O	O
0.00	O	O	O
-	O	O	O
13.10	O	O	O
)	O	O	O
.	O	O	O

Tumor	O	O	B-Entity
control	O	O	B-Entity
rate	O	O	B-Entity
was	O	O	O
81.3	O	O	O
%	O	O	O
at	O	O	O
two	O	O	O
,	O	O	O
five	O	O	O
,	O	O	O
and	O	O	O
10	O	O	O
years	O	O	B-Entity
after	O	O	O
FSRT	O	O	B-Entity
.	O	O	O

FSRT	O	O	B-Entity
was	O	O	O
relatively	O	O	O
safe	O	O	O
in	O	O	O
this	O	O	O
prospective	O	O	O
cohort	O	O	B-Entity
of	O	O	O
craniopharyngiomas	O	O	B-Entity
,	O	O	O
with	O	O	O
only	O	O	O
one	O	O	O
case	O	O	B-Entity
of	O	O	O
radiation-induced	O	O	B-Entity
optic	O	O	I-Entity
neuropathy	O	O	I-Entity
and	O	O	O
no	O	O	O
case	O	O	O
of	O	O	O
new	O	O	O
endocrinopathy	O	O	B-Entity
.	O	O	O

Tumor	O	O	B-Entity
control	O	O	B-Entity
rate	O	O	B-Entity
was	O	O	O
acceptable	O	O	O
.	O	O	O

-DOCSTART- (28086772)

Scutellaria	O	O	B-Entity
barbata	O	O	I-Entity
D.	O	O	I-Entity
Don	O	O	I-Entity
extract	O	O	I-Entity
inhibits	O	O	B-Entity
the	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
through	O	O	O
down-regulating	O	O	B-Entity
of	O	O	O
Treg	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
manipulating	O	O	B-Entity
Th1	O	O	B-Entity
/	O	O	O
Th17	O	O	B-Entity
immune	O	O	I-Entity
response	O	O	I-Entity
in	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	O

Previous	O	O	O
studies	O	O	O
showed	O	O	O
Scutellaria	O	O	B-Entity
barbata	O	O	I-Entity
D.	O	O	I-Entity
Don	O	O	I-Entity
extract	O	O	I-Entity
(	O	O	O
SBE	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
potent	O	O	O
inhibitor	O	O	B-Entity
in	O	O	O
hepatoma	O	O	B-Entity
and	O	O	O
could	O	O	O
improve	O	O	O
immune	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
immunomodulatory	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
SBE	O	O	B-Entity
on	O	O	O
the	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
of	O	O	O
hepatoma	O	O	B-Entity
remains	O	O	O
unclear	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
anti-tumor	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
SBE	O	O	B-Entity
on	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	B-Entity
and	O	O	O
explore	O	O	O
the	O	O	O
underlying	O	O	O
immunomodulatory	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

The	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
by	O	O	O
SBE	O	O	B-Entity
for	O	O	O
30	O	O	O
days	O	O	B-Entity
.	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
SBE	O	O	B-Entity
on	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
the	O	O	O
growth	O	O	B-Entity
of	O	O	I-Entity
transplanted	O	O	I-Entity
tumor	O	O	I-Entity
,	O	O	O
the	O	O	O
cytotoxicity	O	O	B-Entity
of	O	O	I-Entity
natural	O	O	I-Entity
killer	O	O	I-Entity
(	O	O	I-Entity
NK	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
spleen	O	O	B-Entity
,	O	O	O
the	O	O	O
amount	O	O	B-Entity
of	O	O	O
CD4(+)CD25(+)Foxp3(+	O	O	B-Entity
)	O	O	I-Entity
Treg	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
Th17	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
tumor	O	O	B-Entity
tissue	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
IL-10	O	O	B-Entity
,	O	O	O
TGF-β	O	O	B-Entity
,	O	O	O
IL-17A	O	O	B-Entity
,	O	O	O
IL-2	O	O	B-Entity
,	O	O	O
and	O	O	O
IFN-γ	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
of	O	O	O
the	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	B-Entity
was	O	O	O
observered	O	O	O
.	O	O	O

IL-17A	O	O	B-Entity
was	O	O	O
injected	O	O	B-Entity
to	O	O	O
the	O	O	O
SBE	O	O	B-Entity
treated	O	O	B-Entity
mice	O	O	B-Entity
from	O	O	O
day	O	O	B-Entity
9	O	O	O
post	O	O	B-Entity
H22	O	O	B-Entity
inoculation	O	O	B-Entity
to	O	O	O
examine	O	O	O
its	O	O	O
effect	O	O	B-Entity
on	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

SBE	O	O	B-Entity
treatment	O	O	B-Entity
inhibited	O	O	B-Entity
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
with	O	O	O
a	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	I-Entity
and	O	O	O
significantly	O	O	O
suppressed	O	O	B-Entity
the	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
of	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
it	O	O	O
increased	O	O	B-Entity
NK	O	O	B-Entity
cells	O	O	I-Entity
'	O	O	I-Entity
cytotoxicity	O	O	I-Entity
in	O	O	O
spleen	O	O	B-Entity
,	O	O	O
down-regulated	O	O	B-Entity
the	O	O	O
amount	O	O	B-Entity
of	O	O	O
CD4(+)CD25(+)Foxp3(+	O	O	B-Entity
)	O	O	I-Entity
Treg	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
Th17	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
tumor	O	O	B-Entity
tissue	O	O	I-Entity
,	O	O	O
and	O	O	O
decreased	O	O	B-Entity
IL-10	O	O	B-Entity
,	O	O	O
TGF-β	O	O	B-Entity
,	O	O	O
and	O	O	O
IL-17A	O	O	B-Entity
levels	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
whereas	O	O	O
increased	O	O	O
IL-2	O	O	B-Entity
and	O	O	O
IFN-γ	O	O	B-Entity
levels	O	O	O
(	O	O	O
P	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
serum	O	O	B-Entity
of	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
administration	O	O	B-Entity
of	O	O	O
recombinant	O	O	B-Entity
mouse	O	O	I-Entity
IL-17A	O	O	B-Entity
reversed	O	O	B-Entity
the	O	O	O
anti-tumor	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
SBE	O	O	B-Entity
.	O	O	O

SBE	O	O	B-Entity
could	O	O	O
inhibit	O	O	B-Entity
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
SBE	O	O	B-Entity
also	O	O	O
could	O	O	O
inhibit	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
H22	O	O	B-Entity
implanted	O	O	B-Entity
tumor	O	O	I-Entity
in	O	O	O
hepatoma	O	O	B-Entity
H22	O	O	I-Entity
-bearing	O	O	O
mice	O	O	B-Entity
,	O	O	O
and	O	O	O
this	O	O	O
function	O	O	B-Entity
might	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
immunomodulatory	O	O	B-Entity
activity	O	O	I-Entity
through	O	O	O
down-regulating	O	O	B-Entity
of	O	O	O
Treg	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
manipulating	O	O	B-Entity
Th1	O	O	B-Entity
/	O	O	O
Th17	O	O	B-Entity
immune	O	O	I-Entity
response	O	O	I-Entity
.	O	O	O

-DOCSTART- (28086838)

Clinical	O	O	B-Entity
characteristics	O	O	I-Entity
of	O	O	O
genital	O	O	B-Entity
chlamydia	O	O	I-Entity
infection	O	O	I-Entity
in	O	O	O
pelvic	O	O	O
inflammatory	O	O	O
disease	O	O	O

Chlamydia	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
acute	O	O	B-Entity
pelvic	O	O	I-Entity
inflammatory	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PID	O	O	B-Entity
)	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
serious	O	O	O
complications	O	O	B-Entity
including	O	O	O
ectopic	O	O	B-Entity
pregnancy	O	O	I-Entity
,	O	O	O
tubal	O	O	B-Entity
infertility	O	O	I-Entity
,	O	O	O
Fitz-Hugh-Curtis	O	O	B-Entity
syndrome	O	O	I-Entity
and	O	O	O
tubo-ovarian	O	O	B-Entity
abscess	O	O	I-Entity
(	O	O	O
TOA	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
compared	O	O	O
clinical	O	O	B-Entity
and	O	O	O
laboratory	O	O	B-Entity
data	O	O	I-Entity
between	O	O	O
PID	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
chlamydia	O	O	B-Entity
infection	O	O	I-Entity
.	O	O	O

The	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
497	O	O	O
women	O	O	B-Entity
who	O	O	O
were	O	O	O
admitted	O	O	O
with	O	O	O
PID	O	O	B-Entity
between	O	O	O
2002	O	O	O
and	O	O	O
2011	O	O	O
were	O	O	O
reviewed	O	O	O
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
(	O	O	O
PID	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
chlamydia	O	O	B-Entity
infection	O	O	I-Entity
)	O	O	O
,	O	O	O
which	O	O	O
were	O	O	O
compared	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
'	O	O	I-Entity
characteristics	O	O	I-Entity
,	O	O	O
clinical	O	O	B-Entity
presentation	O	O	I-Entity
,	O	O	O
and	O	O	O
laboratory	O	O	B-Entity
findings	O	O	I-Entity
,	O	O	O
including	O	O	O
inflammatory	O	O	B-Entity
markers	O	O	B-Entity
.	O	O	O

The	O	O	O
chlamydia	O	O	B-Entity
and	O	O	O
non-chlamydia	O	O	B-Entity
groups	O	O	I-Entity
comprised	O	O	O
175	O	O	O
and	O	O	O
322	O	O	O
women	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
chlamydia	O	O	B-Entity
group	O	O	I-Entity
were	O	O	O
younger	O	O	B-Entity
and	O	O	O
had	O	O	O
a	O	O	O
higher	O	O	O
rate	O	O	O
of	O	O	O
TOA	O	O	B-Entity
,	O	O	O
a	O	O	O
longer	O	O	O
mean	O	O	B-Entity
hospital	O	O	B-Entity
stay	O	O	I-Entity
,	O	O	O
and	O	O	O
had	O	O	O
undergone	O	O	O
more	O	O	O
surgeries	O	O	B-Entity
than	O	O	O
the	O	O	O
patients	O	O	O
in	O	O	O
the	O	O	O
non-	O	O	B-Entity
chlamydia	O	O	I-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
erythrocyte	O	O	B-Entity
sedimentation	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
ESR	O	O	B-Entity
)	O	O	O
,	O	O	O
C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
CRP	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
CA-125	O	O	B-Entity
level	O	O	B-Entity
were	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
chlamydia	O	O	B-Entity
group	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
non-chlamydia	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
but	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	B-Entity
difference	O	O	O
in	O	O	O
the	O	O	O
white	O	O	B-Entity
blood	O	O	I-Entity
cell	O	O	I-Entity
count	O	O	I-Entity
between	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
CA-125	O	O	B-Entity
level	O	O	B-Entity
was	O	O	O
the	O	O	O
strongest	O	O	O
predictor	O	O	B-Entity
of	O	O	O
chlamydia	O	O	B-Entity
infection	O	O	I-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
the	O	O	O
ESR	O	O	B-Entity
and	O	O	O
CRP	O	O	B-Entity
level	O	O	O
.	O	O	O

The	O	O	O
area	O	O	B-Entity
under	O	O	O
the	O	O	O
receiving	O	O	B-Entity
operating	O	O	I-Entity
curve	O	O	I-Entity
for	O	O	O
CA-125	O	O	B-Entity
,	O	O	O
ESR	O	O	B-Entity
,	O	O	O
and	O	O	O
CRP	O	O	B-Entity
was	O	O	O
0.804	O	O	O
,	O	O	O
0.755	O	O	O
,	O	O	O
and	O	O	O
0.663	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Chlamydia	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
acute	O	O	B-Entity
PID	O	O	I-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	O
level	O	O	B-Entity
of	O	O	O
inflammatory	O	O	B-Entity
markers	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
CA-125	O	O	B-Entity
,	O	O	O
ESR	O	O	B-Entity
and	O	O	O
CRP	O	O	B-Entity
,	O	O	O
incidence	O	O	O
of	O	O	O
TOA	O	O	B-Entity
,	O	O	O
operation	O	O	B-Entity
risk	O	O	B-Entity
,	O	O	O
and	O	O	O
longer	O	O	O
hospitalization	O	O	B-Entity
.	O	O	O

-DOCSTART- (28087131)

Incidence	O	O	B-Entity
and	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
variant	O	O	B-Entity
histology	O	O	B-Entity
on	O	O	O
oncological	O	O	B-Entity
outcomes	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
bladder	O	O	B-Entity
cancer	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
radical	O	O	O
cystectomy	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
describe	O	O	O
incidence	O	O	B-Entity
of	O	O	O
histological	O	O	B-Entity
variants	O	O	B-Entity
after	O	O	O
radical	O	O	B-Entity
cystectomy	O	O	I-Entity
(	O	O	O
RC	O	O	B-Entity
)	O	O	O
due	O	O	O
to	O	O	O
bladder	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
BCa	O	O	B-Entity
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	O
survival	O	O	B-Entity
outcomes	O	O	B-Entity
accounting	O	O	O
for	O	O	O
this	O	O	O
parameter	O	O	O
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
evaluated	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
1,067	O	O	O
patients	O	O	B-Entity
with	O	O	O
BCa	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
RC	O	O	B-Entity
between	O	O	O
1990	O	O	O
and	O	O	O
2013	O	O	O
at	O	O	O
a	O	O	O
single	O	O	B-Entity
tertiary	O	O	I-Entity
care	O	O	I-Entity
referral	O	O	I-Entity
center	O	O	I-Entity
.	O	O	O

All	O	O	O
specimen	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
dedicated	O	O	O
uropathologists	O	O	B-Entity
.	O	O	O

Univariable	O	O	B-Entity
and	O	O	I-Entity
multivariable	O	O	I-Entity
Cox	O	O	I-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
tested	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
different	O	O	O
histopathological	O	O	B-Entity
variant	O	O	B-Entity
on	O	O	O
recurrence	O	O	B-Entity
,	O	O	O
cancer-specific	O	O	B-Entity
mortality	O	O	I-Entity
(	O	O	O
CSM	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
overall	O	O	B-Entity
mortality	O	O	I-Entity
(	O	O	O
OM	O	O	B-Entity
)	O	O	O
after	O	O	O
accounting	O	O	O
for	O	O	O
all	O	O	O
available	O	O	O
confounders	O	O	B-Entity
.	O	O	O

Of	O	O	O
1,067	O	O	O
patients	O	O	B-Entity
,	O	O	O
729	O	O	O
(	O	O	O
68.3	O	O	O
%	O	O	O
)	O	O	O
harbored	O	O	O
pure	O	O	B-Entity
urothelial	O	O	I-Entity
BCa	O	O	I-Entity
while	O	O	O
338	O	O	O
(	O	O	O
31.7	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
a	O	O	O
variant	O	O	B-Entity
.	O	O	O

Considering	O	O	O
uncommon	O	O	O
variants	O	O	B-Entity
,	O	O	O
21	O	O	O
(	O	O	O
2.0	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
sarcomatoid	O	O	B-Entity
,	O	O	O
10	O	O	O
(	O	O	O
0.9	O	O	O
%	O	O	O
)	O	O	O
lymphoepitelial	O	O	B-Entity
,	O	O	O
19	O	O	O
(	O	O	O
1.8	O	O	O
%	O	O	O
)	O	O	O
small	O	O	B-Entity
cell	O	O	I-Entity
,	O	O	O
109	O	O	O
(	O	O	O
10.2	O	O	O
%	O	O	O
)	O	O	O
squamous	O	O	B-Entity
,	O	O	O
89	O	O	O
(	O	O	O
8.3	O	O	O
%	O	O	O
)	O	O	O
micropapillary	O	O	B-Entity
,	O	O	O
23	O	O	O
(	O	O	O
2.2	O	O	O
%	O	O	O
)	O	O	O
glandular	O	O	B-Entity
,	O	O	O
34	O	O	O
(	O	O	O
3.2	O	O	O
%	O	O	O
)	O	O	O
mixed	O	O	O
variants	O	O	O
,	O	O	O
and	O	O	O
33	O	O	O
(	O	O	O
3.1	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
found	O	O	O
with	O	O	O
other	O	O	O
types	O	O	O
of	O	O	O
variants	O	O	O
.	O	O	O

With	O	O	O
a	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
of	O	O	O
6.2	O	O	O
years	O	O	B-Entity
,	O	O	O
343	O	O	O
recurrence	O	O	B-Entity
,	O	O	O
365	O	O	O
CSM	O	O	B-Entity
,	O	O	O
and	O	O	O
451	O	O	O
OM	O	O	B-Entity
were	O	O	O
recorded	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

At	O	O	O
multivariable	O	O	B-Entity
Cox	O	O	I-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
,	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
small	O	O	B-Entity
cell	O	O	I-Entity
variant	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
higher	O	O	O
recurrence	O	O	B-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
[	O	O	O
HR	O	O	B-Entity
]	O	O	O
=	O	O	O
3.47	O	O	O
,	O	O	O
P<0.001	O	O	O
)	O	O	O
,	O	O	O
CSM	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
3.30	O	O	O
,	O	O	O
P<0.04	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
OM	O	O	B-Entity
(	O	O	O
HR	O	O	O
=	O	O	O
2.97	O	O	O
,	O	O	O
P<0.003	O	O	O
)	O	O	O
as	O	O	O
compared	O	O	O
with	O	O	O
pure	O	O	O
urothelial	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
no	O	O	B-Entity
survival	O	O	I-Entity
differences	O	O	I-Entity
were	O	O	O
recorded	O	O	O
considering	O	O	O
other	O	O	O
histological	O	O	B-Entity
variants	O	O	B-Entity
(	O	O	O
all	O	O	O
P	O	O	O
>	O	O	O
0.1	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
confirms	O	O	O
that	O	O	O
histological	O	O	B-Entity
variant	O	O	B-Entity
is	O	O	O
not	O	O	O
an	O	O	O
infrequent	O	O	O
event	O	O	O
at	O	O	O
RC	O	O	B-Entity
specimen	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
our	O	O	O
single-center	O	O	B-Entity
series	O	O	I-Entity
,	O	O	O
only	O	O	O
patients	O	O	B-Entity
found	O	O	O
with	O	O	O
small	O	O	B-Entity
cell	O	O	I-Entity
variant	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
negative	O	O	B-Entity
effect	O	O	B-Entity
on	O	O	O
survival	O	O	B-Entity
after	O	O	O
RC	O	O	B-Entity
.	O	O	O

-DOCSTART- (28087217)

Psychometric	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
the	O	O	O
Japanese	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
short	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	O
the	O	O	O
Pain	O	O	B-Entity
Catastrophizing	O	O	I-Entity
Scale	O	O	I-Entity
in	O	O	O
participants	O	O	B-Entity
with	O	O	O
musculoskeletal	O	O	B-Entity
pain	O	O	I-Entity
:	O	O	O
A	O	O	O
cross-sectional	O	O	O
study	O	O	O

The	O	O	O
Pain	O	O	B-Entity
Catastrophizing	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
PCS	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
commonly	O	O	O
used	O	O	O
as	O	O	O
measure	O	O	B-Entity
of	O	O	O
pain	O	O	B-Entity
catastrophizing	O	O	I-Entity
.	O	O	O

The	O	O	O
scale	O	O	B-Entity
comprises	O	O	O
13	O	O	O
items	O	O	B-Entity
related	O	O	O
to	O	O	O
magnification	O	O	B-Entity
,	O	O	O
rumination	O	O	B-Entity
,	O	O	O
and	O	O	O
helplessness	O	O	B-Entity
.	O	O	O

To	O	O	O
facilitate	O	O	O
quick	O	O	O
screening	O	O	B-Entity
and	O	O	O
to	O	O	O
reduce	O	O	B-Entity
participant	O	O	B-Entity
's	O	O	I-Entity
burden	O	O	B-Entity
,	O	O	O
the	O	O	O
four-	O	O	O
item	O	O	B-Entity
and	O	O	O
six-	O	O	O
item	O	O	O
short	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	O
the	O	O	O
English	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
the	O	O	O
PCS	O	O	B-Entity
were	O	O	O
developed	O	O	O
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
psychometric	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
a	O	O	O
Japanese	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
the	O	O	O
short	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	O
PCS	O	O	B-Entity
using	O	O	O
a	O	O	O
contemporary	O	O	O
approach	O	O	B-Entity
called	O	O	O
Rasch	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
216	O	O	O
patients	O	O	B-Entity
with	O	O	O
musculoskeletal	O	O	B-Entity
disorders	O	O	I-Entity
were	O	O	O
recruited	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
completed	O	O	O
study	O	O	B-Entity
measures	O	O	B-Entity
,	O	O	O
which	O	O	O
included	O	O	O
the	O	O	O
pain	O	O	B-Entity
intensity	O	O	I-Entity
,	O	O	O
the	O	O	O
Pain	O	O	B-Entity
Catastrophizing	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
PCS	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
Tampa	O	O	B-Entity
Scale	O	O	I-Entity
of	O	O	I-Entity
Kinesiophobia	O	O	I-Entity
(	O	O	O
TSK	O	O	B-Entity
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
four-	O	O	O
item	O	O	B-Entity
(	O	O	O
items	O	O	B-Entity
3	O	O	O
,	O	O	O
6	O	O	O
,	O	O	O
8	O	O	O
,	O	O	O
and	O	O	O
11	O	O	O
)	O	O	O
and	O	O	O
six-	O	O	O
item	O	O	O
(	O	O	O
items	O	O	O
4	O	O	O
,	O	O	O
5	O	O	O
,	O	O	O
6	O	O	O
,	O	O	O
10	O	O	O
,	O	O	O
11	O	O	O
,	O	O	O
and	O	O	O
13	O	O	O
)	O	O	O
short	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	O
the	O	O	O
Japanese	O	O	B-Entity
version	O	O	B-Entity
of	O	O	O
PCS	O	O	B-Entity
were	O	O	O
measured	O	O	O
.	O	O	O

We	O	O	O
used	O	O	O
Rasch	O	O	B-Entity
analysis	O	O	I-Entity
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
psychometric	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
the	O	O	O
original	O	O	O
,	O	O	O
four-	O	O	O
item	O	O	B-Entity
,	O	O	O
and	O	O	O
six-	O	O	O
item	O	O	O
short	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	O
PCS	O	O	B-Entity
.	O	O	O

Rasch	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
both	O	O	O
short	O	O	B-Entity
forms	O	O	I-Entity
of	O	O	O
PCS	O	O	B-Entity
had	O	O	O
acceptable	O	O	O
internal	O	O	O
consistency	O	O	B-Entity
,	O	O	O
unidimensionality	O	O	B-Entity
,	O	O	O
and	O	O	O
no	O	O	O
notable	O	O	O
DIF	O	O	O
and	O	O	O
were	O	O	O
functional	O	O	B-Entity
on	O	O	O
the	O	O	O
category	O	O	B-Entity
rating	O	O	I-Entity
scale	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
four-	O	O	O
item	O	O	B-Entity
short	O	O	B-Entity
form	O	O	I-Entity
of	O	O	O
PCS	O	O	B-Entity
had	O	O	O
two	O	O	O
misfit	O	O	O
items	O	O	B-Entity
.	O	O	O

Six-	O	O	O
item	O	O	B-Entity
short	O	O	B-Entity
form	O	O	I-Entity
of	O	O	O
PCS	O	O	B-Entity
has	O	O	O
acceptable	O	O	O
psychometric	O	O	B-Entity
properties	O	O	B-Entity
and	O	O	O
is	O	O	O
suitable	O	O	O
for	O	O	O
use	O	O	O
in	O	O	O
participants	O	O	B-Entity
with	O	O	O
musculoskeletal	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
six-	O	O	O
item	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
brief	O	O	O
instruments	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
pain	O	O	B-Entity
catastrophizing	O	O	I-Entity
.	O	O	O

-DOCSTART- (28088177)

A	O	O	O
novel	O	O	O
quantitative	O	O	B-Entity
PCR	O	O	I-Entity
detects	O	O	O
Babesia	O	O	B-Entity
infection	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
not	O	O	O
identified	O	O	O
by	O	O	O
currently	O	O	O
available	O	O	O
non-nucleic	O	O	O
acid	O	O	O
amplification	O	O	O
tests	O	O	O

Ticks	O	O	B-Entity
transmit	O	O	B-Entity
Babesia	O	O	B-Entity
microti	O	O	I-Entity
,	O	O	O
the	O	O	O
causative	O	O	B-Entity
agents	O	O	I-Entity
of	O	O	O
babesiosis	O	O	B-Entity
in	O	O	O
North	O	O	B-Entity
America	O	O	I-Entity
and	O	O	O
Europe	O	O	B-Entity
.	O	O	O

Babesiosis	O	O	B-Entity
is	O	O	O
now	O	O	O
endemic	O	O	B-Entity
in	O	O	O
Northeastern	O	O	B-Entity
USA	O	O	B-Entity
and	O	O	O
affects	O	O	O
people	O	O	B-Entity
of	O	O	O
all	O	O	O
ages	O	O	B-Entity
.	O	O	O

Babesia	O	O	B-Entity
species	O	O	I-Entity
infect	O	O	O
erythrocytes	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
transmitted	O	O	B-Entity
through	O	O	O
blood	O	O	B-Entity
transfusion	O	O	I-Entity
.	O	O	O

Whole	O	O	B-Entity
blood	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
products	O	O	I-Entity
,	O	O	O
which	O	O	O
are	O	O	O
not	O	O	O
tested	O	O	O
for	O	O	O
Babesia	O	O	B-Entity
,	O	O	O
can	O	O	O
cause	O	O	O
transfusion	O	O	B-Entity
-	O	O	O
transmitted	O	O	B-Entity
babesiosis	O	O	B-Entity
(	O	O	O
TTB	O	O	B-Entity
)	O	O	O
resulting	O	O	O
in	O	O	O
severe	O	O	B-Entity
consequences	O	O	B-Entity
in	O	O	O
the	O	O	O
immuno-compromised	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
epidemiological	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
babesiosis	O	O	B-Entity
in	O	O	O
a	O	O	O
tick-infested	O	O	B-Entity
state	O	O	I-Entity
.	O	O	O

We	O	O	O
examined	O	O	B-Entity
blood	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
192	O	O	O
patients	O	O	B-Entity
who	O	O	O
visited	O	O	O
clinics	O	O	B-Entity
during	O	O	O
the	O	O	O
active	O	O	O
tick-borne	O	O	B-Entity
diseases	O	O	I-Entity
season	O	O	B-Entity
,	O	O	O
using	O	O	O
a	O	O	O
newly	O	O	O
developed	O	O	O
qPCR	O	O	B-Entity
assay	O	O	I-Entity
that	O	O	O
uses	O	O	O
the	O	O	O
specific	O	O	O
molecular	O	O	B-Entity
beacon	O	O	I-Entity
probe	O	O	I-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
clear	O	O	O
symptomology	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
laboratories	O	O	I-Entity
did	O	O	O
not	O	O	O
test	O	O	O
131	O	O	O
samples	O	O	B-Entity
by	O	O	O
IFA	O	O	B-Entity
,	O	O	O
FISH	O	O	B-Entity
or	O	O	O
microscopic	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	O
Giemsa-stained	O	O	B-Entity
blood	O	O	B-Entity
smears	O	O	I-Entity
.	O	O	O

Babesia	O	O	B-Entity
infection	O	O	B-Entity
was	O	O	O
detected	O	O	O
in	O	O	O
all	O	O	O
age	O	O	B-Entity
groups	O	O	I-Entity
by	O	O	O
FISH	O	O	B-Entity
and	O	O	O
microscopy	O	O	B-Entity
;	O	O	O
notably	O	O	O
patients	O	O	B-Entity
>	O	O	O
40	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	O
represented	O	O	O
64	O	O	O
%	O	O	O
of	O	O	O
tested	O	O	O
samples	O	O	B-Entity
and	O	O	O
13	O	O	O
%	O	O	O
were	O	O	O
younger	O	O	B-Entity
patients	O	O	O
.	O	O	O

We	O	O	O
tested	O	O	O
all	O	O	O
samples	O	O	B-Entity
using	O	O	O
qPCR	O	O	B-Entity
and	O	O	O
found	O	O	O
that	O	O	O
38	O	O	O
%	O	O	O
were	O	O	O
positive	O	O	B-Entity
for	O	O	O
Babesia	O	O	B-Entity
.	O	O	O

Of	O	O	O
28	O	O	O
samples	O	O	B-Entity
that	O	O	O
were	O	O	O
positive	O	O	B-Entity
by	O	O	O
FISH	O	O	B-Entity
,	O	O	O
27	O	O	O
(	O	O	O
96	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
also	O	O	O
positive	O	O	O
by	O	O	O
qPCR	O	O	B-Entity
indicating	O	O	O
high	O	O	O
congruency	O	O	O
between	O	O	O
nucleic	O	O	B-Entity
acid	O	O	I-Entity
based	O	O	I-Entity
tests	O	O	I-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
of	O	O	O
78	O	O	O
asymptomatic	O	O	B-Entity
samples	O	O	B-Entity
not	O	O	O
tested	O	O	O
by	O	O	O
FISH	O	O	B-Entity
,	O	O	O
22	O	O	O
were	O	O	O
positive	O	O	B-Entity
by	O	O	O
our	O	O	O
qPCR	O	O	B-Entity
.	O	O	O

Direct	O	O	O
detection	O	O	B-Entity
of	O	O	O
Babesia	O	O	B-Entity
relies	O	O	O
upon	O	O	O
microscopic	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	O
patient	O	O	B-Entity
blood	O	O	B-Entity
smears	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
labor	O	O	O
intensive	O	O	O
,	O	O	O
difficult	O	O	O
to	O	O	O
scale	O	O	O
up	O	O	O
,	O	O	O
requires	O	O	O
specific	O	O	O
expertise	O	O	O
and	O	O	O
is	O	O	O
hence	O	O	O
,	O	O	O
often	O	O	O
not	O	O	O
performed	O	O	O
.	O	O	O

In	O	O	O
fact	O	O	O
,	O	O	O
a	O	O	O
clinical	O	O	B-Entity
laboratory	O	O	I-Entity
examined	O	O	B-Entity
only	O	O	O
23	O	O	O
of	O	O	O
86	O	O	O
blood	O	O	B-Entity
samples	O	O	I-Entity
obtained	O	O	O
from	O	O	O
two	O	O	O
different	O	O	O
counties	O	O	B-Entity
by	O	O	O
microscopy	O	O	B-Entity
.	O	O	O

By	O	O	O
considering	O	O	O
individuals	O	O	B-Entity
positive	O	O	B-Entity
for	O	O	O
Babesia	O	O	B-Entity
infection	O	O	B-Entity
when	O	O	O
results	O	O	O
from	O	O	O
currently	O	O	O
available	O	O	O
microscopy	O	O	B-Entity
,	O	O	O
FISH	O	O	B-Entity
or	O	O	O
serological	O	O	B-Entity
tests	O	O	I-Entity
were	O	O	O
positive	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
our	O	O	O
qPCR	O	O	B-Entity
is	O	O	O
highly	O	O	O
sensitive	O	O	B-Entity
(	O	O	O
96.2	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
showed	O	O	O
a	O	O	O
specificity	O	O	B-Entity
of	O	O	O
70.5	O	O	O
%	O	O	O
for	O	O	O
Babesia	O	O	O
.	O	O	O

Robust	O	O	O
qPCR	O	O	B-Entity
using	O	O	O
specific	O	O	O
probes	O	O	B-Entity
can	O	O	O
be	O	O	O
highly	O	O	O
useful	O	O	O
for	O	O	O
efficient	O	O	O
and	O	O	O
appropriate	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
babesiosis	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
in	O	O	O
conjunction	O	O	O
with	O	O	O
conventional	O	O	O
diagnostics	O	O	B-Entity
,	O	O	O
or	O	O	O
as	O	O	O
a	O	O	O
stand-alone	O	O	O
test	O	O	O
,	O	O	O
especially	O	O	O
for	O	O	O
donated	O	O	O
blood	O	O	B-Entity
screening	O	O	I-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
a	O	O	O
nucleic	O	O	B-Entity
acid	O	O	I-Entity
amplification	O	O	I-Entity
test	O	O	I-Entity
based	O	O	O
screening	O	O	B-Entity
of	O	O	I-Entity
blood	O	O	I-Entity
and	O	O	O
blood	O	O	B-Entity
products	O	O	I-Entity
could	O	O	O
prevent	O	O	O
TTB	O	O	B-Entity
.	O	O	O

-DOCSTART- (28088402)

Historical	O	O	B-Entity
relationships	O	O	I-Entity
of	O	O	O
three	O	O	O
enigmatic	O	O	B-Entity
phasianid	O	O	B-Entity
genera	O	O	I-Entity
(	O	O	O
Aves	O	O	B-Entity
:	O	O	O
Galliformes	O	O	B-Entity
)	O	O	O
inferred	O	O	O
using	O	O	O
phylogenomic	O	O	O
and	O	O	O
mitogenomic	O	O	O
data	O	O	O

The	O	O	O
phylogeny	O	O	B-Entity
of	O	O	O
the	O	O	O
Phasianidae	O	O	B-Entity
(	O	O	O
pheasants	O	O	B-Entity
,	O	O	O
partridges	O	O	B-Entity
,	O	O	O
and	O	O	O
allies	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
studied	O	O	O
extensively	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
these	O	O	O
studies	O	O	O
have	O	O	O
largely	O	O	O
ignored	O	O	O
three	O	O	O
enigmatic	O	O	B-Entity
genera	O	O	I-Entity
because	O	O	O
of	O	O	O
scarce	O	O	B-Entity
DNA	O	O	B-Entity
source	O	O	B-Entity
material	O	O	I-Entity
and	O	O	O
limited	O	O	O
overlapping	O	O	O
phylogenetic	O	O	B-Entity
data	O	O	I-Entity
:	O	O	O
blood	O	O	B-Entity
pheasants	O	O	I-Entity
(	O	O	O
Ithaginis	O	O	B-Entity
)	O	O	O
,	O	O	O
snow	O	O	B-Entity
partridges	O	O	I-Entity
(	O	O	O
Lerwa	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
long-billed	O	O	B-Entity
partridges	O	O	I-Entity
(	O	O	O
Rhizothera	O	O	B-Entity
)	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
phylogenetic	O	O	B-Entity
positions	O	O	I-Entity
of	O	O	O
these	O	O	O
three	O	O	O
genera	O	O	O
remain	O	O	O
uncertain	O	O	O
in	O	O	O
what	O	O	O
is	O	O	O
otherwise	O	O	O
a	O	O	O
well-resolved	O	O	O
phylogeny	O	O	B-Entity
.	O	O	O

Previous	O	O	O
studies	O	O	O
using	O	O	O
different	O	O	O
data	O	O	B-Entity
types	O	O	O
place	O	O	O
Lerwa	O	O	B-Entity
and	O	O	O
Ithaginis	O	O	B-Entity
in	O	O	O
similar	O	O	O
positions	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
overlapping	O	O	B-Entity
data	O	O	I-Entity
means	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
them	O	O	O
could	O	O	O
not	O	O	O
be	O	O	O
inferred	O	O	O
.	O	O	O

Rhizothera	O	O	B-Entity
was	O	O	O
originally	O	O	O
described	O	O	O
in	O	O	O
the	O	O	O
genus	O	O	O
Perdix	O	O	B-Entity
(	O	O	O
true	O	O	B-Entity
partridges	O	O	I-Entity
)	O	O	O
,	O	O	O
although	O	O	O
a	O	O	O
partial	O	O	O
cytochrome	O	O	B-Entity
b	O	O	I-Entity
(	O	O	O
CYB	O	O	B-Entity
)	O	O	O
sequence	O	O	O
suggests	O	O	O
it	O	O	O
is	O	O	O
sister	O	O	B-Entity
to	O	O	O
Pucrasia	O	O	B-Entity
(	O	O	O
koklass	O	O	B-Entity
pheasant	O	O	I-Entity
)	O	O	O
.	O	O	O

To	O	O	O
identify	O	O	O
robust	O	O	O
relationships	O	O	B-Entity
among	O	O	O
Ithaginis	O	O	B-Entity
,	O	O	O
Lerwa	O	O	B-Entity
,	O	O	O
Rhizothera	O	O	B-Entity
,	O	O	O
and	O	O	O
their	O	O	O
phasianid	O	O	B-Entity
relatives	O	O	B-Entity
,	O	O	O
we	O	O	O
used	O	O	O
3692	O	O	O
ultra-conserved	O	O	B-Entity
element	O	O	I-Entity
(	O	O	I-Entity
UCE	O	O	I-Entity
)	O	O	I-Entity
loci	O	O	I-Entity
and	O	O	O
complete	O	O	O
mitogenomes	O	O	B-Entity
from	O	O	O
19	O	O	O
species	O	O	B-Entity
including	O	O	O
previously	O	O	O
hypothesized	O	O	B-Entity
relatives	O	O	O
of	O	O	O
the	O	O	O
three	O	O	O
focal	O	O	O
genera	O	O	O
and	O	O	O
representatives	O	O	O
from	O	O	O
all	O	O	O
major	O	O	O
phasianid	O	O	B-Entity
clades	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
DNA	O	O	B-Entity
extracted	O	O	I-Entity
from	O	O	O
historical	O	O	O
specimen	O	O	B-Entity
toepads	O	O	I-Entity
for	O	O	O
species	O	O	O
that	O	O	O
lacked	O	O	B-Entity
fresh	O	O	I-Entity
tissue	O	O	I-Entity
in	O	O	O
museum	O	O	B-Entity
collections	O	O	I-Entity
.	O	O	O

Maximum	O	O	O
likelihood	O	O	O
and	O	O	O
multispecies	O	O	B-Entity
coalescent	O	O	I-Entity
UCE	O	O	I-Entity
analyses	O	O	I-Entity
strongly	O	O	O
supported	O	O	O
Lerwa	O	O	B-Entity
sister	O	O	B-Entity
to	O	O	O
a	O	O	O
large	O	O	B-Entity
clade	O	O	I-Entity
which	O	O	O
included	O	O	O
Ithaginis	O	O	B-Entity
at	O	O	O
its	O	O	O
base	O	O	O
,	O	O	O
and	O	O	O
also	O	O	O
including	O	O	O
turkey	O	O	B-Entity
,	O	O	O
grouse	O	O	B-Entity
,	O	O	O
typical	O	O	O
pheasants	O	O	B-Entity
,	O	O	O
tragopans	O	O	B-Entity
,	O	O	O
Pucrasia	O	O	B-Entity
,	O	O	O
and	O	O	O
Perdix	O	O	B-Entity
.	O	O	O

Rhizothera	O	O	B-Entity
was	O	O	O
also	O	O	O
in	O	O	O
this	O	O	O
clade	O	O	B-Entity
,	O	O	O
sister	O	O	B-Entity
to	O	O	O
a	O	O	O
diverse	O	O	O
group	O	O	O
comprising	O	O	O
Perdix	O	O	B-Entity
,	O	O	O
typical	O	O	O
pheasants	O	O	B-Entity
,	O	O	O
Pucrasia	O	O	B-Entity
,	O	O	O
turkey	O	O	B-Entity
and	O	O	O
grouse	O	O	B-Entity
.	O	O	O

Mitogenomic	O	O	B-Entity
genealogies	O	O	I-Entity
differed	O	O	O
from	O	O	O
UCEs	O	O	B-Entity
topologies	O	O	I-Entity
,	O	O	O
supporting	O	O	O
a	O	O	O
sister	O	O	B-Entity
relationship	O	O	I-Entity
between	O	O	O
Ithaginis	O	O	B-Entity
and	O	O	O
Lerwa	O	O	B-Entity
rather	O	O	O
than	O	O	O
a	O	O	O
grade	O	O	O
.	O	O	O

The	O	O	O
position	O	O	O
of	O	O	O
Rhizothera	O	O	B-Entity
using	O	O	O
mitogenomes	O	O	B-Entity
depended	O	O	O
on	O	O	O
analytical	O	O	B-Entity
choices	O	O	I-Entity
.	O	O	O

Unpartitioned	O	O	O
and	O	O	O
codon-based	O	O	B-Entity
analyses	O	O	I-Entity
placed	O	O	O
Rhizothera	O	O	B-Entity
sister	O	O	B-Entity
to	O	O	O
a	O	O	O
tragopan	O	O	B-Entity
clade	O	O	I-Entity
,	O	O	O
whereas	O	O	O
a	O	O	O
partitioned	O	O	O
DNA	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
the	O	O	O
mitogenome	O	O	B-Entity
was	O	O	O
congruent	O	O	B-Entity
with	O	O	O
UCE	O	O	B-Entity
results	O	O	I-Entity
.	O	O	O

In	O	O	O
all	O	O	O
mitogenome	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
Pucrasia	O	O	B-Entity
was	O	O	O
sister	O	O	B-Entity
to	O	O	O
a	O	O	O
clade	O	O	B-Entity
including	O	O	O
Perdix	O	O	B-Entity
and	O	O	O
the	O	O	O
typical	O	O	O
pheasants	O	O	B-Entity
with	O	O	O
high	O	O	O
support	O	O	O
,	O	O	O
in	O	O	O
contrast	O	O	O
to	O	O	O
UCEs	O	O	O
and	O	O	O
published	O	O	B-Entity
nuclear	O	O	I-Entity
intron	O	O	I-Entity
data	O	O	I-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
the	O	O	O
strong	O	O	O
support	O	O	O
and	O	O	O
consistent	O	O	O
topology	O	O	B-Entity
provided	O	O	O
by	O	O	O
all	O	O	O
UCE	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
we	O	O	O
have	O	O	O
identified	O	O	O
phylogenetic	O	O	B-Entity
relationships	O	O	B-Entity
of	O	O	O
these	O	O	O
three	O	O	O
enigmatic	O	O	B-Entity
,	O	O	O
poorly-studied	O	O	O
,	O	O	O
phasianid	O	O	B-Entity
taxa	O	O	I-Entity
.	O	O	O

-DOCSTART- (28091848)

A	O	O	O
novel	O	O	B-Entity
combination	O	O	O
treatment	O	O	B-Entity
to	O	O	O
stimulate	O	O	B-Entity
bone	O	O	B-Entity
healing	O	O	I-Entity
and	O	O	O
regeneration	O	O	B-Entity
under	O	O	O
hypoxic	O	O	B-Entity
conditions	O	O	I-Entity
:	O	O	O
photobiomodulation	O	O	B-Entity
and	O	O	O
melatonin	O	O	O

Melatonin	O	O	B-Entity
has	O	O	O
anabolic	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
the	O	O	O
bone	O	O	B-Entity
,	O	O	O
even	O	O	O
under	O	O	O
hypoxia	O	O	B-Entity
,	O	O	O
and	O	O	O
laser	O	O	B-Entity
irradiation	O	O	I-Entity
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
improve	O	O	O
osteoblastic	O	O	B-Entity
differentiation	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
laser	O	O	B-Entity
irradiation	O	O	I-Entity
and	O	O	O
melatonin	O	O	B-Entity
would	O	O	O
have	O	O	O
synergistic	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
osteoblastic	O	O	B-Entity
differentiation	O	O	I-Entity
and	O	O	O
mineralization	O	O	B-Entity
under	O	O	O
hypoxic	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

MC3T3-E1	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
exposed	O	O	O
to	O	O	O
1	O	O	O
%	O	O	O
oxygen	O	O	B-Entity
tension	O	O	I-Entity
for	O	O	O
the	O	O	O
hypoxia	O	O	B-Entity
condition	O	O	I-Entity
.	O	O	O

The	O	O	O
cells	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
four	O	O	O
groups	O	O	B-Entity
:	O	O	O
G1	O	O	B-Entity
-	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
medium	O	O	B-Entity
only	O	O	O
(	O	O	O
as	O	O	O
the	O	O	O
hypoxic	O	O	B-Entity
condition	O	O	I-Entity
)	O	O	O
,	O	O	O
G2	O	O	B-Entity
-	O	O	O
treatment	O	O	B-Entity
with	O	O	O
50	O	O	O
μM	O	O	O
melatonin	O	O	B-Entity
only	O	O	O
,	O	O	O
G3	O	O	B-Entity
-	O	O	O
laser	O	O	B-Entity
irradiation	O	O	I-Entity
(	O	O	O
808	O	O	O
nm	O	O	O
,	O	O	O
80	O	O	O
mW	O	O	O
,	O	O	O
GaAlAs	O	O	B-Entity
diode	O	O	I-Entity
)	O	O	O
only	O	O	O
,	O	O	O
and	O	O	O
G4	O	O	B-Entity
-	O	O	O
treatment	O	O	O
with	O	O	O
50	O	O	O
μM	O	O	O
melatonin	O	O	O
and	O	O	O
laser	O	O	O
irradiation	O	O	O
(	O	O	O
808	O	O	O
nm	O	O	O
,	O	O	O
80	O	O	O
mW	O	O	O
,	O	O	O
GaAlAs	O	O	O
diode	O	O	O
)	O	O	O
.	O	O	O

Immunoblotting	O	O	B-Entity
showed	O	O	O
that	O	O	O
osterix	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
markedly	O	O	O
increased	O	O	B-Entity
in	O	O	O
the	O	O	O
melatonin	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
and	O	O	O
laser-irradiated	O	O	B-Entity
cells	O	O	B-Entity
at	O	O	O
48	O	O	O
and	O	O	O
72	O	O	O
h.	O	O	O
In	O	O	O
addition	O	O	O
,	O	O	O
alkaline	O	O	B-Entity
phosphatase	O	O	I-Entity
activity	O	O	B-Entity
significantly	O	O	O
increased	O	O	O
and	O	O	O
continued	O	O	B-Entity
to	O	O	O
rise	O	O	O
throughout	O	O	O
the	O	O	O
experiment	O	O	B-Entity
.	O	O	O

Alizarin	O	O	B-Entity
Red	O	O	I-Entity
staining	O	O	I-Entity
showed	O	O	O
markedly	O	O	O
increased	O	O	B-Entity
mineralized	O	O	B-Entity
nodules	O	O	B-Entity
as	O	O	O
compared	O	O	O
with	O	O	O
only	O	O	O
melatonin	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
or	O	O	O
laser-irradiated	O	O	B-Entity
cells	O	O	B-Entity
at	O	O	O
day	O	O	O
7	O	O	O
,	O	O	O
which	O	O	O
significantly	O	O	O
increased	O	O	O
by	O	O	O
day	O	O	O
14	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
when	O	O	O
melatonin	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
cells	O	O	B-Entity
were	O	O	O
laser-irradiated	O	O	B-Entity
,	O	O	O
the	O	O	O
differentiation	O	O	B-Entity
and	O	O	O
mineralization	O	O	B-Entity
of	O	O	O
cells	O	O	O
were	O	O	O
found	O	O	O
to	O	O	O
involve	O	O	O
p38	O	O	B-Entity
MAPK	O	O	I-Entity
and	O	O	O
PRKD1	O	O	B-Entity
signaling	O	O	B-Entity
mechanisms	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
enhanced	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
laser	O	O	B-Entity
irradiation	O	O	I-Entity
with	O	O	O
melatonin	O	O	B-Entity
were	O	O	O
markedly	O	O	O
inhibited	O	O	B-Entity
when	O	O	O
the	O	O	O
cells	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
luzindole	O	O	B-Entity
,	O	O	O
a	O	O	O
selective	O	O	O
melatonin	O	O	B-Entity
receptor	O	O	I-Entity
antagonist	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
concluded	O	O	O
that	O	O	O
laser	O	O	B-Entity
irradiation	O	O	I-Entity
could	O	O	O
promote	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
melatonin	O	O	B-Entity
on	O	O	O
the	O	O	O
differentiation	O	O	B-Entity
and	O	O	O
mineralization	O	O	B-Entity
of	O	O	O
MC3T3-E1	O	O	B-Entity
cells	O	O	I-Entity
under	O	O	O
hypoxic	O	O	B-Entity
conditions	O	O	I-Entity
,	O	O	O
and	O	O	O
that	O	O	O
this	O	O	O
process	O	O	O
is	O	O	O
mediated	O	O	O
through	O	O	O
melatonin	O	O	B-Entity
1/2	O	O	I-Entity
receptors	O	O	I-Entity
and	O	O	O
PKRD	O	O	B-Entity
/	O	O	O
p38	O	O	B-Entity
signaling	O	O	B-Entity
pathways	O	O	I-Entity
.	O	O	O

-DOCSTART- (28092112)

Aquaporin-2	O	O	B-Entity
excretion	O	O	B-Entity
in	O	O	O
hospitalized	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
cirrhosis	O	O	B-Entity
:	O	O	O
Relation	O	O	O
to	O	O	O
development	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
insufficiency	O	O	I-Entity
and	O	O	O
mortality	O	O	O

Urinary	O	O	B-Entity
aquaporin-2	O	O	B-Entity
(	O	O	O
AQP2	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
parameter	O	O	O
of	O	O	O
water	O	O	B-Entity
transport	O	O	I-Entity
in	O	O	O
the	O	O	O
principal	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
the	O	O	O
distal	O	O	B-Entity
part	O	O	I-Entity
of	O	O	O
the	O	O	O
nephron	O	O	B-Entity
and	O	O	O
involved	O	O	O
in	O	O	O
water	O	O	B-Entity
retention	O	O	I-Entity
in	O	O	O
cirrhosis	O	O	B-Entity
and	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
AQP2	O	O	B-Entity
as	O	O	O
a	O	O	O
predictor	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
insufficiency	O	O	I-Entity
and	O	O	O
death	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
cirrhosis	O	O	B-Entity
.	O	O	O

Urine	O	O	B-Entity
samples	O	O	I-Entity
from	O	O	O
199	O	O	O
patients	O	O	B-Entity
(	O	O	O
90	O	O	O
patients	O	O	O
without	O	O	O
organ	O	O	B-Entity
failure	O	O	I-Entity
[	O	O	O
Group	O	O	B-Entity
1	O	O	I-Entity
]	O	O	O
,	O	O	O
58	O	O	O
patients	O	O	O
with	O	O	O
organ	O	O	O
failure	O	O	O
excluding	O	O	O
renal	O	O	B-Entity
failure	O	O	I-Entity
[	O	O	O
Group	O	O	B-Entity
2	O	O	I-Entity
]	O	O	O
,	O	O	O
and	O	O	O
51	O	O	O
patients	O	O	O
with	O	O	O
organ	O	O	O
failure	O	O	O
including	O	O	O
renal	O	O	O
failure	O	O	O
[	O	O	O
Group	O	O	B-Entity
3	O	O	I-Entity
]	O	O	O
)	O	O	O
from	O	O	O
the	O	O	O
CANONIC	O	O	B-Entity
study	O	O	I-Entity
were	O	O	O
analyzed	O	O	O
for	O	O	O
urine	O	O	B-Entity
AQP2	O	O	B-Entity
and	O	O	O
urine	O	O	B-Entity
osmolality	O	O	I-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
AQP2	O	O	B-Entity
between	O	O	O
the	O	O	O
three	O	O	O
groups	O	O	B-Entity
.	O	O	O

Urine	O	O	B-Entity
osmolality	O	O	I-Entity
was	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
in	O	O	O
Group	O	O	B-Entity
3	O	O	I-Entity
versus	O	O	O
Group	O	O	B-Entity
1	O	O	I-Entity
and	O	O	O
Group	O	O	B-Entity
2	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.0004	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
relation	O	O	I-Entity
was	O	O	O
found	O	O	O
between	O	O	O
AQP2	O	O	B-Entity
and	O	O	O
glomerular	O	O	B-Entity
filtration	O	O	I-Entity
rate	O	O	I-Entity
or	O	O	O
creatinine	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
AQP2	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	O
predictor	O	O	B-Entity
of	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
insufficiency	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.0485	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
AQP2	O	O	B-Entity
was	O	O	O
a	O	O	O
significant	O	O	O
predictor	O	O	B-Entity
of	O	O	O
14	O	O	O
and	O	O	O
28-day	O	O	O
survival	O	O	B-Entity
,	O	O	O
but	O	O	O
this	O	O	O
was	O	O	O
not	O	O	O
confirmed	O	O	O
in	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Aquaporin-2	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
disease	O	O	B-Entity
severity	O	O	I-Entity
or	O	O	O
markers	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
but	O	O	O
was	O	O	O
a	O	O	O
predictor	O	O	B-Entity
for	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
insufficiency	O	O	I-Entity
and	O	O	O
death	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
its	O	O	O
future	O	O	O
use	O	O	O
as	O	O	O
marker	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
insufficiency	O	O	I-Entity
could	O	O	O
be	O	O	O
promising	O	O	O
,	O	O	O
but	O	O	O
further	O	O	O
research	O	O	B-Entity
is	O	O	O
needed	O	O	O
before	O	O	O
it	O	O	O
can	O	O	O
be	O	O	O
considered	O	O	O
a	O	O	O
clinical	O	O	B-Entity
useful	O	O	O
tool	O	O	O
.	O	O	O

-DOCSTART- (28092340)

Decompression	O	O	B-Entity
Surgery	O	O	I-Entity
Alone	O	O	O
Versus	O	O	O
Decompression	O	O	O
Plus	O	O	O
Fusion	O	O	B-Entity
in	O	O	O
Symptomatic	O	O	B-Entity
Lumbar	O	O	B-Entity
Spinal	O	O	I-Entity
Stenosis	O	O	I-Entity
:	O	O	O
A	O	O	O
Swiss	O	O	B-Entity
Prospective	O	O	B-Entity
Multi-center	O	O	I-Entity
Cohort	O	O	I-Entity
Study	O	O	I-Entity
with	O	O	O
3	O	O	O
Years	O	O	B-Entity
of	O	O	O
Follow-up	O	O	O

Retrospective	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
a	O	O	O
prospective	O	O	B-Entity
,	O	O	I-Entity
multicenter	O	O	I-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

To	O	O	O
estimate	O	O	O
the	O	O	O
added	O	O	O
effect	O	O	B-Entity
of	O	O	O
surgical	O	O	B-Entity
fusion	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
decompression	O	O	B-Entity
surgery	O	O	I-Entity
alone	O	O	O
in	O	O	O
symptomatic	O	O	B-Entity
lumbar	O	O	B-Entity
spinal	O	O	I-Entity
stenosis	O	O	I-Entity
patients	O	O	B-Entity
with	O	O	O
spondylolisthesis	O	O	B-Entity
.	O	O	O

The	O	O	O
optimal	O	O	B-Entity
surgical	O	O	I-Entity
management	O	O	I-Entity
of	O	O	O
lumbar	O	O	B-Entity
spinal	O	O	I-Entity
stenosis	O	O	I-Entity
patients	O	O	B-Entity
with	O	O	O
spondylolisthesis	O	O	B-Entity
remains	O	O	O
controversial	O	O	O
.	O	O	O

Patients	O	O	B-Entity
of	O	O	O
the	O	O	O
LSOS	O	O	B-Entity
with	O	O	O
confirmed	O	O	O
DLSS	O	O	B-Entity
and	O	O	O
spondylolisthesis	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
Spinal	O	O	B-Entity
Stenosis	O	O	I-Entity
Measure	O	O	O
(	O	O	O
SSM	O	O	B-Entity
)	O	O	O
symptoms	O	O	B-Entity
(	O	O	O
score	O	O	B-Entity
range	O	O	I-Entity
1	O	O	O
-	O	O	O
5	O	O	O
,	O	O	O
best-worst	O	O	O
)	O	O	O
and	O	O	O
function	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
4	O	O	O
)	O	O	O
over	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
measured	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
6	O	O	O
,	O	O	O
12	O	O	O
,	O	O	O
24	O	O	O
and	O	O	O
36	O	O	O
months	O	O	B-Entity
follow-up	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
quantify	O	O	B-Entity
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
fusion	O	O	B-Entity
surgery	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
decompression	O	O	B-Entity
alone	O	O	O
and	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
decompressed	O	O	I-Entity
levels	O	O	I-Entity
,	O	O	O
we	O	O	O
used	O	O	O
mixed	O	O	O
effects	O	O	B-Entity
models	O	O	B-Entity
and	O	O	O
accounted	O	O	O
for	O	O	O
the	O	O	O
repeated	O	O	B-Entity
observations	O	O	I-Entity
in	O	O	O
main	O	O	O
outcomes	O	O	B-Entity
(	O	O	O
SSM	O	O	B-Entity
symptoms	O	O	B-Entity
and	O	O	O
SSM	O	O	O
function	O	O	B-Entity
)	O	O	O
over	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
individual	O	O	O
patients	O	O	B-Entity
'	O	O	O
random	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
we	O	O	O
also	O	O	O
fitted	O	O	B-Entity
random	O	O	I-Entity
slopes	O	O	I-Entity
for	O	O	O
follow-up	O	O	B-Entity
time	O	O	B-Entity
points	O	O	I-Entity
and	O	O	O
compared	O	O	O
these	O	O	O
two	O	O	O
approaches	O	O	B-Entity
with	O	O	O
Akaike	O	O	B-Entity
's	O	O	I-Entity
Information	O	O	I-Entity
Criterion	O	O	I-Entity
(	O	O	O
AIC	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
chi-squared	O	O	B-Entity
test	O	O	I-Entity
.	O	O	O

Confounders	O	O	B-Entity
were	O	O	O
adjusted	O	O	O
with	O	O	O
fixed	O	O	B-Entity
effects	O	O	I-Entity
for	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
,	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
CIRS	O	O	B-Entity
musculoskeletal	O	O	B-Entity
disorders	O	O	I-Entity
and	O	O	O
duration	O	O	B-Entity
of	O	O	O
symptoms	O	O	B-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
and	O	O	O
thirty-one	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
decompression	O	O	B-Entity
surgery	O	O	I-Entity
alone	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
85	O	O	O
)	O	O	O
or	O	O	O
decompression	O	O	O
plus	O	O	O
fusion	O	O	B-Entity
surgery	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
46	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
multiple	O	O	B-Entity
mixed	O	O	I-Entity
effects	O	O	I-Entity
model	O	O	B-Entity
the	O	O	O
adjusted	O	O	O
effect	O	O	B-Entity
of	O	O	O
fusion	O	O	B-Entity
versus	O	O	O
decompression	O	O	B-Entity
alone	O	O	I-Entity
surgery	O	O	I-Entity
on	O	O	O
SSM	O	O	B-Entity
symptoms	O	O	B-Entity
was	O	O	O
0.06	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
,	O	O	O
CI	O	O	B-Entity
:	O	O	O
-0.16	O	O	O
to	O	O	O
0.27	O	O	O
)	O	O	O
and	O	O	O
-0.07	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
-0.25	O	O	O
to	O	O	O
0.10	O	O	O
)	O	O	O
on	O	O	O
SSM	O	O	O
function	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Among	O	O	O
the	O	O	O
patients	O	O	B-Entity
with	O	O	O
degenerative	O	O	B-Entity
lumbar	O	O	I-Entity
spinal	O	O	I-Entity
stenosis	O	O	I-Entity
and	O	O	O
spondylolisthesis	O	O	B-Entity
our	O	O	O
study	O	O	B-Entity
confirms	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
,	O	O	O
decompression	O	O	B-Entity
alone	O	O	O
and	O	O	O
decompression	O	O	O
plus	O	O	O
fusion	O	O	B-Entity
,	O	O	O
patients	O	O	O
distinctively	O	O	O
benefited	O	O	O
from	O	O	O
surgical	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

When	O	O	O
adjusted	O	O	O
for	O	O	O
confounders	O	O	B-Entity
,	O	O	O
fusion	O	O	B-Entity
surgery	O	O	I-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
more	O	O	O
favorable	O	O	O
outcome	O	O	B-Entity
in	O	O	O
both	O	O	O
SSM	O	O	B-Entity
scores	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
decompression	O	O	B-Entity
alone	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

3	O	O	O
.	O	O	O

-DOCSTART- (28097208)

Muscle	O	O	B-Entity
synergies	O	O	B-Entity
after	O	O	O
stroke	O	O	B-Entity
are	O	O	O
correlated	O	O	O
with	O	O	O
perilesional	O	O	B-Entity
high	O	O	O
gamma	O	O	O

Movements	O	O	B-Entity
can	O	O	O
be	O	O	O
factored	O	O	O
into	O	O	O
modules	O	O	B-Entity
termed	O	O	O
"	O	O	O
muscle	O	O	B-Entity
synergies	O	O	B-Entity
"	O	O	O
.	O	O	O

After	O	O	O
stroke	O	O	B-Entity
,	O	O	O
abnormal	O	O	B-Entity
synergies	O	O	B-Entity
are	O	O	O
linked	O	O	O
to	O	O	O
impaired	O	O	B-Entity
movements	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
their	O	O	O
neural	O	O	B-Entity
basis	O	O	B-Entity
is	O	O	O
not	O	O	O
understood	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
single	O	O	O
subject	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
how	O	O	O
electrocorticography	O	O	B-Entity
signals	O	O	I-Entity
from	O	O	O
the	O	O	O
perilesional	O	O	B-Entity
cortex	O	O	B-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
synergies	O	O	B-Entity
.	O	O	O

The	O	O	O
measured	O	O	O
synergies	O	O	B-Entity
contained	O	O	B-Entity
a	O	O	O
mix	O	O	O
of	O	O	O
both	O	O	O
normal	O	O	B-Entity
and	O	O	O
abnormal	O	O	B-Entity
patterns	O	O	B-Entity
and	O	O	O
were	O	O	O
remarkably	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
described	O	O	O
in	O	O	O
past	O	O	O
work	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
both	O	O	O
normal	O	O	B-Entity
and	O	O	O
abnormal	O	O	B-Entity
synergies	O	O	B-Entity
were	O	O	O
correlated	O	O	O
with	O	O	O
perilesional	O	O	B-Entity
high	O	O	B-Entity
gamma	O	O	I-Entity
.	O	O	O

Given	O	O	O
the	O	O	O
link	O	O	O
between	O	O	O
high	O	O	B-Entity
gamma	O	O	I-Entity
and	O	O	O
cortical	O	O	B-Entity
spiking	O	O	I-Entity
,	O	O	O
our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
perilesional	O	O	B-Entity
spiking	O	O	I-Entity
may	O	O	O
organize	O	O	O
synergies	O	O	B-Entity
after	O	O	O
stroke	O	O	B-Entity
.	O	O	O

-DOCSTART- (28097611)

Assessing	O	O	B-Entity
nitrous	O	O	B-Entity
oxide	O	O	I-Entity
effect	O	O	B-Entity
using	O	O	O
electroencephalographically	O	O	B-Entity
-based	O	O	O
depth	O	O	B-Entity
of	O	O	I-Entity
anesthesia	O	O	I-Entity
measures	O	O	B-Entity
cortical	O	O	B-Entity
state	O	O	B-Entity
and	O	O	O
cortical	O	O	O
input	O	O	O

Existing	O	O	O
electroencephalography	O	O	B-Entity
(	O	O	O
EEG	O	O	B-Entity
)	O	O	O
based	O	O	O
depth	O	O	B-Entity
of	O	O	I-Entity
anesthesia	O	O	B-Entity
monitors	O	O	B-Entity
can	O	O	O
not	O	O	O
reliably	O	O	O
track	O	O	O
sedative	O	O	B-Entity
or	O	O	O
anesthetic	O	O	B-Entity
states	O	O	B-Entity
during	O	O	O
n-methyl-D-aspartate	O	O	B-Entity
(	O	O	I-Entity
NMDA	O	O	I-Entity
)	O	O	I-Entity
receptor	O	O	I-Entity
antagonist	O	O	I-Entity
based	O	O	O
anesthesia	O	O	O
with	O	O	O
ketamine	O	O	B-Entity
or	O	O	O
nitrous	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
N2O	O	O	B-Entity
)	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
a	O	O	O
physiologically	O	O	B-Entity
-motivated	O	O	O
depth	O	O	B-Entity
of	O	O	I-Entity
anesthesia	O	O	I-Entity
monitoring	O	O	B-Entity
algorithm	O	O	B-Entity
based	O	O	O
on	O	O	O
autoregressive-moving-average	O	O	B-Entity
(	O	O	I-Entity
ARMA	O	O	I-Entity
)	O	O	I-Entity
modeling	O	O	I-Entity
and	O	O	O
derivative	O	O	O
measures	O	O	O
of	O	O	O
interest	O	O	O
,	O	O	O
Cortical	O	O	B-Entity
State	O	O	B-Entity
(	O	O	O
CS	O	O	B-Entity
)	O	O	O
and	O	O	O
Cortical	O	O	O
Input	O	O	B-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
,	O	O	O
is	O	O	O
retrospectively	O	O	B-Entity
applied	O	O	O
in	O	O	O
an	O	O	O
exploratory	O	O	B-Entity
manner	O	O	O
to	O	O	O
the	O	O	O
NMDA	O	O	B-Entity
receptor	O	O	I-Entity
antagonist	O	O	I-Entity
N2O	O	O	B-Entity
,	O	O	O
an	O	O	O
adjuvant	O	O	B-Entity
anesthetic	O	O	I-Entity
gas	O	O	I-Entity
used	O	O	O
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

Composite	O	O	B-Entity
Cortical	O	O	I-Entity
State	O	O	I-Entity
(	O	O	O
CCS	O	O	B-Entity
)	O	O	O
and	O	O	O
Composite	O	O	B-Entity
Cortical	O	O	I-Entity
State	O	O	I-Entity
distance	O	O	I-Entity
(	O	O	O
CCSd	O	O	B-Entity
)	O	O	O
,	O	O	O
two	O	O	O
new	O	O	O
modifications	O	O	B-Entity
of	O	O	O
CS	O	O	B-Entity
,	O	O	O
along	O	O	O
with	O	O	O
CS	O	O	O
and	O	O	O
CI	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
on	O	O	O
electroencephalographic	O	O	B-Entity
(	O	O	O
EEG	O	O	B-Entity
)	O	O	O
data	O	O	B-Entity
of	O	O	O
healthy	O	O	B-Entity
control	O	O	I-Entity
individuals	O	O	I-Entity
undergoing	O	O	O
N2O	O	O	B-Entity
inhalation	O	O	B-Entity
up	O	O	O
to	O	O	O
equilibrated	O	O	B-Entity
peak	O	O	B-Entity
gas	O	O	I-Entity
concentrations	O	O	I-Entity
of	O	O	O
20	O	O	O
,	O	O	O
40	O	O	O
or	O	O	O
60	O	O	O
%	O	O	O
N2O	O	O	O
/	O	O	O
O2	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
CCSd	O	O	B-Entity
has	O	O	O
been	O	O	O
devised	O	O	O
to	O	O	O
vary	O	O	O
consistently	O	O	O
for	O	O	O
increasing	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
anesthetic	O	O	B-Entity
concentration	O	O	I-Entity
independent	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
anesthetic	O	O	B-Entity
's	O	O	I-Entity
microscopic	O	O	B-Entity
mode	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
for	O	O	O
both	O	O	O
N2O	O	O	B-Entity
and	O	O	O
propofol	O	O	B-Entity
.	O	O	O

The	O	O	O
strongest	O	O	O
effects	O	O	B-Entity
were	O	O	O
observed	O	O	O
for	O	O	O
the	O	O	O
60	O	O	O
%	O	O	O
peak	O	O	B-Entity
gas	O	O	I-Entity
concentration	O	O	I-Entity
group	O	O	B-Entity
.	O	O	O

For	O	O	O
the	O	O	O
50	O	O	O
-	O	O	O
60	O	O	O
%	O	O	O
peak	O	O	B-Entity
gas	O	O	I-Entity
levels	O	O	I-Entity
,	O	O	O
individuals	O	O	B-Entity
showed	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
reductions	O	O	B-Entity
in	O	O	O
responsiveness	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
rest	O	O	B-Entity
,	O	O	O
and	O	O	O
across	O	O	O
the	O	O	O
group	O	O	B-Entity
CS	O	O	B-Entity
and	O	O	O
CCS	O	O	B-Entity
increased	O	O	B-Entity
by	O	O	O
39	O	O	O
and	O	O	O
42	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
while	O	O	O
CCSd	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
decrease	O	O	B-Entity
by	O	O	O
398	O	O	O
%	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
a	O	O	O
clear	O	O	O
conclusion	O	O	B-Entity
regarding	O	O	O
the	O	O	O
changes	O	O	O
in	O	O	O
CI	O	O	B-Entity
could	O	O	O
not	O	O	O
be	O	O	O
reached	O	O	O
.	O	O	O

These	O	O	O
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
,	O	O	O
contrary	O	O	B-Entity
to	O	O	O
previous	O	O	O
depth	O	O	B-Entity
of	O	O	I-Entity
anesthesia	O	O	I-Entity
monitoring	O	O	B-Entity
measures	O	O	B-Entity
,	O	O	O
the	O	O	O
CS	O	O	B-Entity
,	O	O	O
CCS	O	O	B-Entity
,	O	O	O
and	O	O	O
especially	O	O	O
CCSd	O	O	B-Entity
measures	O	O	O
derived	O	O	B-Entity
from	O	O	O
frontal	O	O	B-Entity
EEG	O	O	B-Entity
are	O	O	O
potentially	O	O	B-Entity
useful	O	O	O
for	O	O	O
differentiating	O	O	O
gas	O	O	B-Entity
concentration	O	O	I-Entity
and	O	O	O
responsiveness	O	O	B-Entity
levels	O	O	I-Entity
in	O	O	O
people	O	O	B-Entity
under	O	O	O
N2O	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
determining	O	O	O
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
CI	O	O	B-Entity
in	O	O	O
this	O	O	O
regard	O	O	O
will	O	O	O
require	O	O	O
larger	O	O	B-Entity
sample	O	O	B-Entity
sizes	O	O	I-Entity
and	O	O	O
potentially	O	O	B-Entity
higher	O	O	B-Entity
gas	O	O	B-Entity
concentrations	O	O	I-Entity
.	O	O	O

Future	O	O	O
work	O	O	O
will	O	O	O
assess	O	O	B-Entity
the	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
CS	O	O	B-Entity
-based	O	O	O
and	O	O	O
CI	O	O	B-Entity
measures	O	O	B-Entity
to	O	O	O
other	O	O	O
anesthetics	O	O	B-Entity
and	O	O	O
their	O	O	O
utility	O	O	B-Entity
in	O	O	O
a	O	O	O
clinical	O	O	B-Entity
environment	O	O	B-Entity
.	O	O	O

-DOCSTART- (28098510)

DT	O	O	B-Entity
MRI	O	O	I-Entity
microstructural	O	O	B-Entity
cortical	O	O	B-Entity
lesion	O	O	B-Entity
damage	O	O	B-Entity
does	O	O	O
not	O	O	O
explain	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
in	O	O	O
MS	O	O	O

We	O	O	O
combined	O	O	O
double	O	O	B-Entity
inversion	O	O	I-Entity
recovery	O	O	I-Entity
(	O	O	O
DIR	O	O	B-Entity
)	O	O	O
and	O	O	O
diffusion	O	O	B-Entity
tensor	O	O	I-Entity
(	O	O	I-Entity
DT	O	O	I-Entity
)	O	O	I-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	I-Entity
MRI	O	O	I-Entity
)	O	O	I-Entity
to	O	O	O
quantify	O	O	B-Entity
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
cortical	O	O	B-Entity
lesion	O	O	B-Entity
(	O	O	O
CL	O	O	B-Entity
)	O	O	O
microstructural	O	O	B-Entity
tissue	O	O	B-Entity
abnormalities	O	O	B-Entity
in	O	O	O
a	O	O	O
large	O	O	B-Entity
cohort	O	O	B-Entity
of	O	O	O
relapse	O	O	B-Entity
-	O	O	O
onset	O	O	B-Entity
multiple	O	O	B-Entity
sclerosis	O	O	I-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
and	O	O	O
its	O	O	O
contribution	O	O	B-Entity
to	O	O	O
cognitive	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

DIR	O	O	B-Entity
,	O	O	O
DT	O	O	B-Entity
,	O	O	O
dual-echo	O	O	B-Entity
,	O	O	O
and	O	O	O
three-dimensional	O	O	B-Entity
(	O	O	O
3D	O	O	B-Entity
)	O	O	O
T1-weighted	O	O	B-Entity
scans	O	O	I-Entity
were	O	O	O
acquired	O	O	O
from	O	O	O
149	O	O	O
MS	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
40	O	O	O
controls	O	O	B-Entity
.	O	O	O

Cognitively	O	O	B-Entity
impaired	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
patients	O	O	B-Entity
had	O	O	O
⩾2	O	O	O
abnormal	O	O	B-Entity
neuropsychological	O	O	B-Entity
tests	O	O	I-Entity
.	O	O	O

Diffusivity	O	O	B-Entity
values	O	O	I-Entity
in	O	O	O
CLs	O	O	B-Entity
,	O	O	O
cortex	O	O	B-Entity
,	O	O	O
white	O	O	B-Entity
matter	O	O	I-Entity
(	O	O	I-Entity
WM	O	O	I-Entity
)	O	O	I-Entity
lesions	O	O	I-Entity
,	O	O	O
and	O	O	O
normal-appearing	O	O	B-Entity
(	O	O	I-Entity
NA	O	O	I-Entity
)	O	O	I-Entity
WM	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Predictors	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
using	O	O	O
a	O	O	O
random	O	O	B-Entity
forest	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

Compared	O	O	O
to	O	O	O
controls	O	O	B-Entity
,	O	O	O
MS	O	O	B-Entity
patients	O	O	B-Entity
had	O	O	O
lower	O	O	B-Entity
normalized	O	O	B-Entity
brain	O	O	I-Entity
volume	O	O	I-Entity
(	O	O	O
NBV	O	O	B-Entity
)	O	O	O
,	O	O	O
gray	O	O	B-Entity
matter	O	O	I-Entity
volume	O	O	I-Entity
(	O	O	O
GMV	O	O	B-Entity
)	O	O	O
,	O	O	O
WM	O	O	B-Entity
volume	O	O	I-Entity
,	O	O	O
lower	O	O	O
fractional	O	O	B-Entity
anisotropy	O	O	I-Entity
(	O	O	O
FA	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
higher	O	O	B-Entity
mean	O	O	B-Entity
diffusivity	O	O	I-Entity
in	O	O	O
cortex	O	O	B-Entity
and	O	O	O
normal-appearing	O	O	B-Entity
white	O	O	I-Entity
matter	O	O	I-Entity
(	O	O	O
NAWM	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
44	O	O	O
(	O	O	O
29.5	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
were	O	O	O
CI	O	O	B-Entity
.	O	O	O

Compared	O	O	O
to	O	O	O
cognitively	O	O	B-Entity
preserved	O	O	I-Entity
(	O	O	O
CP	O	O	B-Entity
)	O	O	O
,	O	O	O
CI	O	O	B-Entity
patients	O	O	B-Entity
had	O	O	O
higher	O	O	B-Entity
T2	O	O	B-Entity
WM	O	O	I-Entity
lesion	O	O	I-Entity
volume	O	O	I-Entity
(	O	O	O
LV	O	O	B-Entity
)	O	O	O
,	O	O	O
lower	O	O	B-Entity
NBV	O	O	B-Entity
and	O	O	O
GMV	O	O	B-Entity
,	O	O	O
and	O	O	O
more	O	O	O
severe	O	O	B-Entity
diffusivity	O	O	B-Entity
abnormalities	O	O	B-Entity
in	O	O	O
WM	O	O	B-Entity
lesions	O	O	I-Entity
,	O	O	O
cortex	O	O	B-Entity
,	O	O	O
and	O	O	O
NAWM	O	O	B-Entity
.	O	O	O

CL	O	O	B-Entity
measures	O	O	B-Entity
did	O	O	O
not	O	O	B-Entity
differ	O	O	I-Entity
between	O	O	O
CI	O	O	B-Entity
and	O	O	O
CP	O	O	B-Entity
patients	O	O	I-Entity
.	O	O	O

Cortex	O	O	B-Entity
FA	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
,	O	O	O
disease	O	O	B-Entity
duration	O	O	I-Entity
,	O	O	O
T2	O	O	B-Entity
WM	O	O	I-Entity
LV	O	O	I-Entity
,	O	O	O
and	O	O	O
GMV	O	O	B-Entity
best	O	O	O
predicted	O	O	O
MS	O	O	B-Entity
-related	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
(	O	O	O
C-statistic	O	O	O
=	O	O	O
0.88	O	O	O
)	O	O	O
.	O	O	O

"	O	O	O
Diffuse	O	O	B-Entity
"	O	O	O
GM	O	O	B-Entity
and	O	O	O
NAWM	O	O	B-Entity
damage	O	O	B-Entity
and	O	O	O
WM	O	O	B-Entity
lesions	O	O	I-Entity
,	O	O	O
rather	O	O	O
than	O	O	O
intrinsic	O	O	B-Entity
CL	O	O	B-Entity
damage	O	O	O
,	O	O	O
contribute	O	O	O
to	O	O	O
cognitive	O	O	B-Entity
impairment	O	O	I-Entity
in	O	O	O
MS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28099597)

Correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
histopathology	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
urticaria	O	O	I-Entity
and	O	O	O
its	O	O	O
clinical	O	O	O
picture	O	O	O

Chronic	O	O	B-Entity
urticaria	O	O	I-Entity
is	O	O	O
characterized	O	O	O
by	O	O	O
transient	O	O	B-Entity
,	O	O	O
pruritic	O	O	B-Entity
lesions	O	O	I-Entity
of	O	O	O
varying	O	O	O
sizes	O	O	B-Entity
,	O	O	O
with	O	O	O
central	O	O	B-Entity
pallor	O	O	B-Entity
and	O	O	O
well-defined	O	O	O
edges	O	O	O
,	O	O	O
with	O	O	O
disease	O	O	B-Entity
duration	O	O	O
longer	O	O	O
than	O	O	O
six	O	O	O
weeks	O	O	B-Entity
.	O	O	O

Its	O	O	O
cellular	O	O	B-Entity
infiltrate	O	O	I-Entity
consists	O	O	O
of	O	O	O
neutrophils	O	O	B-Entity
,	O	O	O
lymphocytes	O	O	B-Entity
and	O	O	O
eosinophils	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
subgroup	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
eosinophilic	O	O	B-Entity
or	O	O	O
neutrophilic	O	O	B-Entity
urticaria	O	O	I-Entity
,	O	O	O
resistant	O	O	O
to	O	O	O
the	O	O	O
treatment	O	O	B-Entity
with	O	O	O
antihistamines	O	O	B-Entity
,	O	O	O
but	O	O	O
that	O	O	O
respond	O	O	O
to	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
antihistamine	O	O	B-Entity
with	O	O	O
other	O	O	O
drugs	O	O	B-Entity
.	O	O	O

To	O	O	O
evaluate	O	O	O
the	O	O	O
present	O	O	O
infiltration	O	O	B-Entity
in	O	O	O
chronic	O	O	B-Entity
urticaria	O	O	I-Entity
biopsies	O	O	B-Entity
and	O	O	O
correlate	O	O	O
it	O	O	O
with	O	O	O
the	O	O	O
clinical	O	O	B-Entity
disease	O	O	I-Entity
activity	O	O	I-Entity
and	O	O	O
response	O	O	B-Entity
to	O	O	I-Entity
treatment	O	O	I-Entity
.	O	O	O

Forty-one	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
urticaria	O	O	I-Entity
were	O	O	O
classified	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
score	O	O	B-Entity
of	O	O	I-Entity
severity	O	O	I-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
,	O	O	O
response	O	O	B-Entity
to	O	O	I-Entity
treatment	O	O	I-Entity
and	O	O	O
type	O	O	O
of	O	O	O
perivascular	O	O	B-Entity
infiltrate	O	O	I-Entity
.	O	O	O

Inflammatory	O	O	B-Entity
infiltrates	O	O	I-Entity
were	O	O	O
divided	O	O	O
in	O	O	O
eosinophilic	O	O	B-Entity
(	O	O	O
46.30	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
neutrophilic	O	O	B-Entity
and	O	O	O
mixed	O	O	O
.	O	O	O

An	O	O	O
association	O	O	B-Entity
was	O	O	O
found	O	O	O
between	O	O	O
the	O	O	O
eosinophilic	O	O	B-Entity
infiltrate	O	O	I-Entity
and	O	O	O
clinical	O	O	B-Entity
scores	O	O	I-Entity
of	O	O	O
greater	O	O	O
severity	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
association	O	O	B-Entity
shows	O	O	O
that	O	O	O
the	O	O	O
eosinophilic	O	O	B-Entity
inflammatory	O	O	I-Entity
infiltrates	O	O	I-Entity
denote	O	O	O
high	O	O	O
clinical	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
which	O	O	O
means	O	O	O
more	O	O	O
severe	O	O	B-Entity
and	O	O	O
exuberant	O	O	O
clinical	O	O	B-Entity
pictures	O	O	I-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
.	O	O	O

-DOCSTART- (28100136)

Barriers	O	O	B-Entity
to	O	O	O
access	O	O	B-Entity
and	O	O	I-Entity
uptake	O	O	I-Entity
of	O	O	O
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
among	O	O	O
HIV-positive	O	O	B-Entity
men	O	O	B-Entity
who	O	O	I-Entity
have	O	O	I-Entity
sex	O	O	I-Entity
with	O	O	I-Entity
men	O	O	I-Entity
in	O	O	O
Hanoi	O	O	B-Entity
,	O	O	O
Vietnam	O	O	B-Entity
:	O	O	O
from	O	O	O
HIV	O	O	B-Entity
testing	O	O	I-Entity
to	O	O	O
treatment	O	O	O

Little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
experiences	O	O	B-Entity
of	O	O	O
Vietnamese	O	O	B-Entity
men	O	O	B-Entity
who	O	O	I-Entity
have	O	O	I-Entity
sex	O	O	I-Entity
with	O	O	I-Entity
men	O	O	I-Entity
in	O	O	O
accessing	O	O	B-Entity
HIV	O	O	B-Entity
testing	O	O	I-Entity
and	O	O	O
treatment	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
explore	O	O	O
barriers	O	O	B-Entity
to	O	O	O
access	O	O	B-Entity
and	O	O	I-Entity
uptake	O	O	I-Entity
of	O	O	O
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
ART	O	O	B-Entity
)	O	O	O
among	O	O	O
HIV-positive	O	O	B-Entity
men	O	O	B-Entity
who	O	O	I-Entity
have	O	O	I-Entity
sex	O	O	I-Entity
with	O	O	I-Entity
men	O	O	I-Entity
in	O	O	O
Hanoi	O	O	B-Entity
.	O	O	O

During	O	O	O
2015	O	O	O
,	O	O	O
we	O	O	O
conducted	O	O	O
qualitative	O	O	B-Entity
interviews	O	O	B-Entity
with	O	O	O
35	O	O	O
participants	O	O	B-Entity
recruited	O	O	O
using	O	O	O
snowball	O	O	B-Entity
sampling	O	O	I-Entity
based	O	O	O
on	O	O	O
previous	O	O	O
research	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
networks	O	O	I-Entity
.	O	O	O

Key	O	O	O
individual	O	O	O
impediments	O	O	O
to	O	O	O
ART	O	O	B-Entity
uptake	O	O	O
included	O	O	O
inadequate	O	O	B-Entity
preparation	O	O	B-Entity
for	O	O	O
a	O	O	O
positive	O	O	B-Entity
diagnosis	O	O	B-Entity
and	O	O	O
the	O	O	O
dual	O	O	O
stigmatisation	O	O	B-Entity
of	O	O	O
homosexuality	O	O	B-Entity
and	O	O	O
HIV	O	O	B-Entity
and	O	O	O
its	O	O	O
consequences	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
fear	O	O	B-Entity
of	O	O	O
disclosure	O	O	B-Entity
of	O	O	O
HIV	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

Health	O	O	B-Entity
system	O	O	I-Entity
barriers	O	O	B-Entity
included	O	O	O
lack	O	O	O
of	O	O	O
clarity	O	O	O
and	O	O	O
consistency	O	O	B-Entity
about	O	O	O
how	O	O	O
to	O	O	O
register	O	O	O
for	O	O	O
and	O	O	O
access	O	O	B-Entity
ART	O	O	B-Entity
,	O	O	O
failure	O	O	O
to	O	O	O
protect	O	O	O
patient	O	O	B-Entity
confidentiality	O	O	B-Entity
and	O	O	O
a	O	O	O
reticence	O	O	O
by	O	O	O
providers	O	O	B-Entity
to	O	O	O
discuss	O	O	O
sexual	O	O	B-Entity
identity	O	O	I-Entity
and	O	O	O
same-sex	O	O	B-Entity
issues	O	O	I-Entity
.	O	O	O

Results	O	O	O
suggest	O	O	O
fundamental	O	O	O
problems	O	O	O
in	O	O	O
the	O	O	O
way	O	O	O
HIV	O	O	B-Entity
testing	O	O	I-Entity
is	O	O	O
currently	O	O	O
delivered	O	O	O
in	O	O	O
Hanoi	O	O	B-Entity
,	O	O	O
including	O	O	O
a	O	O	O
lack	O	O	O
of	O	O	O
client-centred	O	O	O
counselling	O	O	B-Entity
,	O	O	O
peer	O	O	B-Entity
support	O	O	I-Entity
and	O	O	O
clear	O	O	B-Entity
referral	O	O	I-Entity
pathways	O	O	O
.	O	O	O

Overcoming	O	O	O
these	O	O	O
barriers	O	O	B-Entity
will	O	O	O
require	O	O	O
educating	O	O	O
men	O	O	B-Entity
who	O	O	I-Entity
have	O	O	I-Entity
sex	O	O	I-Entity
with	O	O	I-Entity
men	O	O	I-Entity
about	O	O	O
the	O	O	O
benefits	O	O	B-Entity
of	O	O	O
routine	O	O	B-Entity
testing	O	O	I-Entity
,	O	O	O
improving	O	O	B-Entity
access	O	O	B-Entity
to	O	O	O
quality	O	O	O
diagnostic	O	O	B-Entity
services	O	O	I-Entity
and	O	O	O
building	O	O	O
a	O	O	O
safe	O	O	O
,	O	O	O
confidential	O	O	B-Entity
treatment	O	O	B-Entity
environment	O	O	B-Entity
for	O	O	O
HIV-positive	O	O	B-Entity
men	O	O	O
to	O	O	O
access	O	O	O
,	O	O	O
receive	O	O	B-Entity
and	O	O	I-Entity
remain	O	O	I-Entity
in	O	O	I-Entity
care	O	O	I-Entity
.	O	O	O

-DOCSTART- (28100698)

Cdc45	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
loading	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
RPA	O	O	I-Entity
onto	O	O	O
single-stranded	O	O	O
DNA	O	O	O

Cell	O	O	B-Entity
division	O	O	I-Entity
cycle	O	O	I-Entity
protein	O	O	I-Entity
45	O	O	I-Entity
(	O	O	O
Cdc45	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
essential	O	O	O
component	O	O	O
of	O	O	O
the	O	O	O
eukaryotic	O	O	B-Entity
replicative	O	O	B-Entity
DNA	O	O	B-Entity
helicase	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
human	O	O	B-Entity
Cdc45	O	O	I-Entity
forms	O	O	O
a	O	O	O
complex	O	O	B-Entity
with	O	O	O
the	O	O	O
single-stranded	O	O	B-Entity
DNA	O	O	I-Entity
(	O	O	I-Entity
ssDNA	O	O	I-Entity
)	O	O	I-Entity
binding	O	O	I-Entity
protein	O	O	I-Entity
RPA	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
it	O	O	O
actively	O	O	O
loads	O	O	B-Entity
RPA	O	O	B-Entity
onto	O	O	O
nascent	O	O	O
ssDNA	O	O	B-Entity
.	O	O	O

Pull-down	O	O	B-Entity
assays	O	O	I-Entity
and	O	O	O
surface	O	O	B-Entity
plasmon	O	O	I-Entity
resonance	O	O	I-Entity
studies	O	O	I-Entity
revealed	O	O	O
that	O	O	O
Cdc45	O	O	B-Entity
-	O	O	O
bound	O	O	B-Entity
RPA	O	O	B-Entity
complexed	O	O	B-Entity
with	O	O	O
ssDNA	O	O	B-Entity
in	O	O	O
the	O	O	O
8	O	O	O
-	O	O	O
10	O	O	O
nucleotide	O	O	B-Entity
binding	O	O	I-Entity
mode	O	O	O
,	O	O	O
but	O	O	O
dissociated	O	O	B-Entity
when	O	O	O
RPA	O	O	O
covered	O	O	O
a	O	O	O
30-mer	O	O	B-Entity
.	O	O	O

Real-time	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
RPA	O	O	B-Entity
-	O	O	O
ssDNA	O	O	B-Entity
binding	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
Cdc45	O	O	B-Entity
catalytically	O	O	O
loaded	O	O	B-Entity
RPA	O	O	O
onto	O	O	O
ssDNA	O	O	O
.	O	O	O

This	O	O	O
placement	O	O	B-Entity
reaction	O	O	B-Entity
required	O	O	O
physical	O	O	B-Entity
contacts	O	O	I-Entity
of	O	O	O
Cdc45	O	O	B-Entity
with	O	O	O
the	O	O	O
RPA70A	O	O	B-Entity
subdomain	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
imply	O	O	O
that	O	O	O
Cdc45	O	O	B-Entity
controlled	O	O	O
stabilization	O	O	B-Entity
of	O	O	O
the	O	O	O
8-	O	O	O
nt	O	O	B-Entity
RPA	O	O	B-Entity
binding	O	O	B-Entity
mode	O	O	B-Entity
,	O	O	O
the	O	O	O
subsequent	O	O	O
RPA	O	O	O
transition	O	O	O
into	O	O	O
30-mer	O	O	B-Entity
mode	O	O	O
and	O	O	O
facilitated	O	O	O
an	O	O	O
ordered	O	O	O
binding	O	O	O
to	O	O	O
ssDNA	O	O	B-Entity
.	O	O	O

We	O	O	O
propose	O	O	O
that	O	O	O
a	O	O	O
Cdc45	O	O	B-Entity
-mediated	O	O	O
loading	O	O	B-Entity
guarantees	O	O	O
a	O	O	O
seamless	O	O	O
deposition	O	O	B-Entity
of	O	O	O
RPA	O	O	B-Entity
on	O	O	O
newly	O	O	O
emerging	O	O	O
ssDNA	O	O	B-Entity
at	O	O	O
the	O	O	O
nascent	O	O	O
replication	O	O	B-Entity
fork	O	O	I-Entity
.	O	O	O

-DOCSTART- (28101782)

The	O	O	O
antineoplastic	O	O	B-Entity
drug	O	O	I-Entity
,	O	O	O
trastuzumab	O	O	B-Entity
,	O	O	O
dysregulates	O	O	B-Entity
metabolism	O	O	B-Entity
in	O	O	O
iPSC	O	O	B-Entity
-derived	O	O	O
cardiomyocytes	O	O	O

The	O	O	O
targeted	O	O	B-Entity
ERBB2	O	O	I-Entity
therapy	O	O	I-Entity
,	O	O	O
trastuzumab	O	O	B-Entity
,	O	O	O
has	O	O	O
had	O	O	O
a	O	O	O
tremendous	O	O	O
impact	O	O	B-Entity
on	O	O	O
management	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
HER2	O	O	B-Entity
+	O	O	I-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
development	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
use	O	O	O
of	O	O	O
further	O	O	O
HER2	O	O	O
targeted	O	O	B-Entity
therapies	O	O	I-Entity
.	O	O	O

The	O	O	O
major	O	O	O
clinical	O	O	B-Entity
side	O	O	B-Entity
effect	O	O	I-Entity
is	O	O	O
cardiotoxicity	O	O	B-Entity
but	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
is	O	O	O
largely	O	O	O
unknown	O	O	O
.	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	O
that	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
is	O	O	O
known	O	O	O
to	O	O	O
be	O	O	O
altered	O	O	B-Entity
in	O	O	O
multiple	O	O	B-Entity
models	O	O	B-Entity
of	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
we	O	O	O
examined	O	O	O
differential	O	O	B-Entity
gene	O	O	I-Entity
expression	O	O	I-Entity
of	O	O	O
iPSC	O	O	B-Entity
-derived	O	O	O
cardiomyocytes	O	O	B-Entity
treated	O	O	B-Entity
at	O	O	O
day	O	O	B-Entity
11	O	O	O
with	O	O	O
the	O	O	O
ERBB2	O	O	B-Entity
targeted	O	O	O
monoclonal	O	O	B-Entity
antibody	O	O	I-Entity
,	O	O	O
trastuzumab	O	O	B-Entity
for	O	O	O
48	O	O	O
h	O	O	O
and	O	O	O
the	O	O	O
small	O	O	B-Entity
molecule	O	O	I-Entity
tyrosine	O	O	I-Entity
kinase	O	O	I-Entity
inhibitor	O	O	I-Entity
of	O	O	O
EGFR	O	O	B-Entity
and	O	O	O
ERBB2	O	O	O
.	O	O	O

Transcriptome	O	O	B-Entity
sequencing	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
on	O	O	O
four	O	O	O
replicates	O	O	B-Entity
from	O	O	O
each	O	O	O
group	O	O	B-Entity
(	O	O	O
48	O	O	O
h	O	O	O
untreated	O	O	O
,	O	O	O
48	O	O	O
h	O	O	O
trastuzumab	O	O	B-Entity
and	O	O	O
48	O	O	O
h	O	O	O
lapatinib	O	O	B-Entity
)	O	O	O
and	O	O	O
differential	O	O	B-Entity
gene	O	O	I-Entity
expression	O	O	I-Entity
analyses	O	O	B-Entity
were	O	O	O
performed	O	O	O
on	O	O	O
each	O	O	O
treatment	O	O	B-Entity
group	O	O	O
relative	O	O	O
to	O	O	O
untreated	O	O	O
cardiomyocytes	O	O	B-Entity
.	O	O	O

517	O	O	O
and	O	O	O
1358	O	O	O
genes	O	O	B-Entity
were	O	O	O
differentially	O	O	B-Entity
expressed	O	O	I-Entity
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
,	O	O	O
respectively	O	O	O
in	O	O	O
cardiomyocytes	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
trastuzumab	O	O	B-Entity
and	O	O	O
lapatinib	O	O	B-Entity
.	O	O	O

Gene	O	O	B-Entity
ontology	O	O	I-Entity
analyses	O	O	B-Entity
revealed	O	O	O
in	O	O	O
cardiomyocytes	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
trastuzumab	O	O	B-Entity
,	O	O	O
significant	O	O	B-Entity
down-regulation	O	O	B-Entity
of	O	O	O
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
small	O	O	B-Entity
molecule	O	O	I-Entity
metabolism	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
3.22	O	O	O
�	O	O	O
—	O	O	O
10(-9	O	O	O
)	O	O	O
)	O	O	O
and	O	O	O
cholesterol	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.01	O	O	O
)	O	O	O
and	O	O	O
sterol	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.03	O	O	O
)	O	O	O
processing	O	O	O
.	O	O	O

We	O	O	O
next	O	O	O
measured	O	O	B-Entity
glucose	O	O	B-Entity
uptake	O	O	I-Entity
and	O	O	O
lactate	O	O	B-Entity
production	O	O	B-Entity
in	O	O	O
iPSC	O	O	B-Entity
-derived	O	O	O
cardiomyocytes	O	O	B-Entity
13	O	O	O
days	O	O	B-Entity
post-plating	O	O	O
,	O	O	O
treated	O	O	B-Entity
with	O	O	O
trastuzumab	O	O	B-Entity
up	O	O	O
to	O	O	O
96	O	O	O
h.	O	O	O
We	O	O	O
observed	O	O	B-Entity
significantly	O	O	B-Entity
decreased	O	O	B-Entity
glucose	O	O	O
uptake	O	O	O
from	O	O	O
the	O	O	O
media	O	O	B-Entity
of	O	O	O
iPSC	O	O	O
-derived	O	O	O
cardiomyocytes	O	O	O
treated	O	O	O
with	O	O	O
trastuzumab	O	O	O
as	O	O	O
early	O	O	O
as	O	O	O
24	O	O	O
h	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
consistently	O	O	B-Entity
up	O	O	O
to	O	O	O
96	O	O	O
h	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.03	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
suggests	O	O	O
dysregulation	O	O	B-Entity
of	O	O	O
cardiac	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
metabolism	O	O	B-Entity
as	O	O	O
key	O	O	O
elements	O	O	O
of	O	O	O
ERBB2	O	O	B-Entity
signaling	O	O	B-Entity
that	O	O	O
could	O	O	O
potentially	O	O	B-Entity
be	O	O	O
early	O	O	O
biomarkers	O	O	B-Entity
of	O	O	O
cardiotoxicity	O	O	B-Entity
.	O	O	O

-DOCSTART- (28102508)

Simvastatin	O	O	B-Entity
Promotes	O	O	O
Hematoma	O	O	B-Entity
Absorption	O	O	B-Entity
and	O	O	O
Reduces	O	O	O
Hydrocephalus	O	O	B-Entity
Following	O	O	O
Intraventricular	O	O	B-Entity
Hemorrhage	O	O	I-Entity
in	O	O	O
Part	O	O	O
by	O	O	O
Upregulating	O	O	B-Entity
CD36	O	O	O

We	O	O	O
previously	O	O	O
found	O	O	O
that	O	O	O
hematoma	O	O	B-Entity
worsens	O	O	B-Entity
hydrocephalus	O	O	B-Entity
after	O	O	O
intraventricular	O	O	B-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
IVH	O	O	B-Entity
)	O	O	O
via	O	O	O
increasing	O	O	B-Entity
iron	O	O	B-Entity
deposition	O	O	I-Entity
and	O	O	O
aggravating	O	O	O
ependymal	O	O	B-Entity
cilia	O	O	B-Entity
injury	O	O	B-Entity
;	O	O	O
therefore	O	O	O
,	O	O	O
promoting	O	O	O
hematoma	O	O	O
absorption	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
promising	O	O	O
strategy	O	O	O
for	O	O	O
IVH	O	O	O
.	O	O	O

Recently	O	O	O
,	O	O	O
some	O	O	O
investigations	O	O	O
imply	O	O	O
that	O	O	O
simvastatin	O	O	B-Entity
has	O	O	O
the	O	O	O
ability	O	O	O
of	O	O	O
accelerating	O	O	O
hematoma	O	O	B-Entity
absorption	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
designed	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
simvastatin	O	O	B-Entity
for	O	O	O
IVH	O	O	B-Entity
in	O	O	O
rats	O	O	B-Entity
.	O	O	O

Intracerebral	O	O	B-Entity
hemorrhage	O	O	I-Entity
with	O	O	O
ventricular	O	O	O
extension	O	O	O
was	O	O	O
induced	O	O	O
in	O	O	O
adult	O	O	B-Entity
male	O	O	I-Entity
Sprague-Dawley	O	O	B-Entity
rats	O	O	I-Entity
after	O	O	O
autologous	O	O	B-Entity
blood	O	O	I-Entity
injection	O	O	I-Entity
.	O	O	O

Simvastatin	O	O	B-Entity
or	O	O	O
vehicle	O	O	B-Entity
was	O	O	O
administered	O	O	B-Entity
orally	O	O	I-Entity
at	O	O	O
1	O	O	O
day	O	O	O
after	O	O	O
IVH	O	O	B-Entity
and	O	O	O
then	O	O	O
daily	O	O	O
for	O	O	O
1	O	O	O
week	O	O	O
.	O	O	O

MRI	O	O	B-Entity
studies	O	O	I-Entity
were	O	O	O
performed	O	O	O
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
volumes	O	O	B-Entity
of	O	O	O
intracranial	O	O	B-Entity
hematoma	O	O	B-Entity
and	O	O	O
lateral	O	O	B-Entity
ventricle	O	O	I-Entity
at	O	O	O
days	O	O	O
1	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
7	O	O	O
,	O	O	O
14	O	O	O
,	O	O	O
and	O	O	O
28	O	O	O
after	O	O	O
IVH	O	O	B-Entity
.	O	O	O

Motor	O	O	B-Entity
and	O	O	O
neurocognitive	O	O	B-Entity
functions	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
at	O	O	O
days	O	O	O
1	O	O	O
to	O	O	O
7	O	O	O
and	O	O	O
23	O	O	O
to	O	O	O
28	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Iron	O	O	B-Entity
deposition	O	O	I-Entity
,	O	O	O
iron	O	O	B-Entity
-related	O	O	O
protein	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
ependymal	O	O	B-Entity
damage	O	O	I-Entity
,	O	O	O
and	O	O	O
histology	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
at	O	O	O
day	O	O	O
28	O	O	O
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
CD36	O	O	B-Entity
scavenger	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
facilitating	O	O	O
phagocytosis	O	O	B-Entity
)	O	O	O
was	O	O	O
examined	O	O	B-Entity
at	O	O	O
day	O	O	O
3	O	O	O
after	O	O	O
IVH	O	O	B-Entity
using	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
and	O	O	O
immunofluorescence	O	O	B-Entity
.	O	O	O

Simvastatin	O	O	B-Entity
significantly	O	O	O
increased	O	O	B-Entity
hematoma	O	O	B-Entity
absorption	O	O	B-Entity
ratio	O	O	B-Entity
,	O	O	O
reduced	O	O	B-Entity
ventricular	O	O	B-Entity
volume	O	O	I-Entity
,	O	O	O
and	O	O	O
attenuated	O	O	B-Entity
neurological	O	O	I-Entity
dysfunction	O	O	I-Entity
post-	O	O	O
IVH	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
less	O	O	B-Entity
iron	O	O	I-Entity
accumulation	O	O	I-Entity
and	O	O	O
more	O	O	O
cilia	O	O	B-Entity
survival	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
simvastatin	O	O	B-Entity
group	O	O	O
when	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
control	O	O	B-Entity
.	O	O	O

What	O	O	O
's	O	O	O
more	O	O	O
,	O	O	O
higher	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
CD36	O	O	B-Entity
was	O	O	O
detected	O	O	B-Entity
around	O	O	O
the	O	O	O
hematoma	O	O	B-Entity
after	O	O	O
simvastatin	O	O	B-Entity
administration	O	O	B-Entity
.	O	O	O

Simvastatin	O	O	B-Entity
significantly	O	O	O
enhanced	O	O	O
brain	O	O	B-Entity
hematoma	O	O	B-Entity
absorption	O	O	B-Entity
,	O	O	O
alleviated	O	O	B-Entity
hydrocephalus	O	O	I-Entity
,	O	O	O
and	O	O	O
improved	O	O	B-Entity
neurological	O	O	B-Entity
recovery	O	O	B-Entity
after	O	O	O
experimental	O	O	B-Entity
IVH	O	O	B-Entity
,	O	O	O
which	O	O	O
may	O	O	O
in	O	O	O
part	O	O	O
by	O	O	O
upregulating	O	O	B-Entity
CD36	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
early	O	O	O
simvastatin	O	O	B-Entity
use	O	O	O
may	O	O	O
be	O	O	O
a	O	O	O
novel	O	O	B-Entity
therapy	O	O	B-Entity
for	O	O	O
IVH	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28103582)

AMPK	O	O	B-Entity
-	O	O	O
autophagy	O	O	B-Entity
inhibition	O	O	B-Entity
sensitizes	O	O	O
icaritin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
anti-colorectal	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	O
activity	O	O	O

The	O	O	O
current	O	O	B-Entity
research	O	O	B-Entity
studied	O	O	O
the	O	O	O
potential	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
autophagy	O	O	B-Entity
on	O	O	O
icaritin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
anti-colorectal	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
CRC	O	O	B-Entity
)	O	O	O
cell	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

Treatment	O	O	B-Entity
of	O	O	O
icaritin	O	O	B-Entity
in	O	O	O
both	O	O	O
primary	O	O	B-Entity
and	O	O	O
established	O	O	B-Entity
(	O	O	O
HT-29	O	O	B-Entity
)	O	O	O
CRC	O	O	B-Entity
cells	O	O	B-Entity
induced	O	O	B-Entity
feedback	O	O	B-Entity
activation	O	O	I-Entity
of	O	O	O
autophagy	O	O	B-Entity
,	O	O	O
evidenced	O	O	O
by	O	O	O
p62	O	O	B-Entity
degradation	O	O	B-Entity
,	O	O	O
Beclin-1	O	O	B-Entity
and	O	O	O
autophagy-related	O	O	B-Entity
gene-5	O	O	I-Entity
(	O	O	O
ATG-5	O	O	B-Entity
)	O	O	O
upregulation	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
light	O	O	B-Entity
chain	O	O	I-Entity
3B	O	O	I-Entity
(LC3B)-	O	O	O
GFP	O	O	B-Entity
puncta	O	O	O
formation	O	O	B-Entity
.	O	O	O

Pharmacological	O	O	B-Entity
inhibiting	O	O	B-Entity
of	O	O	O
autophagy	O	O	B-Entity
dramatically	O	O	O
potentiated	O	O	O
icaritin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
CRC	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
shRNA	O	O	B-Entity
-mediated	O	O	O
knockdown	O	O	B-Entity
of	O	O	O
Beclin-1	O	O	B-Entity
or	O	O	O
ATG-5	O	O	B-Entity
also	O	O	O
sensitized	O	O	O
icaritin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
CRC	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
.	O	O	O

Icaritin	O	O	B-Entity
activated	O	O	B-Entity
AMP-activated	O	O	B-Entity
protein	O	O	I-Entity
kinase	O	O	I-Entity
(	O	O	O
AMPK	O	O	B-Entity
)	O	O	O
signaling	O	O	B-Entity
in	O	O	O
CRC	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
functioning	O	O	B-Entity
as	O	O	O
the	O	O	O
upstream	O	O	O
signaling	O	O	O
for	O	O	O
autophagy	O	O	B-Entity
activation	O	O	B-Entity
.	O	O	O

shRNA	O	O	B-Entity
/	O	O	O
siRNA	O	O	B-Entity
-mediated	O	O	O
knockdown	O	O	B-Entity
of	O	O	O
AMPKα1	O	O	B-Entity
inhibited	O	O	B-Entity
icaritin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
autophagy	O	O	B-Entity
activation	O	O	B-Entity
,	O	O	O
but	O	O	O
exacerbated	O	O	B-Entity
CRC	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
the	O	O	O
AMPK	O	O	B-Entity
activator	O	O	O
compound	O	O	B-Entity
13	O	O	I-Entity
(	O	O	O
C13	O	O	B-Entity
)	O	O	O
or	O	O	O
the	O	O	O
autophagy	O	O	B-Entity
activator	O	O	O
MHY1485	O	O	B-Entity
attenuated	O	O	B-Entity
icaritin	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
cytotoxicity	O	O	B-Entity
.	O	O	O

In	O	O	O
nude	O	O	B-Entity
mice	O	O	I-Entity
,	O	O	O
icaritin	O	O	B-Entity
(	O	O	O
oral	O	O	O
administration)-	O	O	O
induced	O	O	B-Entity
HT-29	O	O	B-Entity
tumor	O	O	B-Entity
growth	O	O	I-Entity
inhibition	O	O	B-Entity
was	O	O	O
potentiated	O	O	O
when	O	O	O
combined	O	O	O
with	O	O	O
AMPKα1	O	O	B-Entity
shRNA	O	O	B-Entity
knockdown	O	O	B-Entity
in	O	O	O
tumors	O	O	B-Entity
.	O	O	O

We	O	O	O
conclude	O	O	O
that	O	O	O
feedback	O	O	B-Entity
activation	O	O	I-Entity
of	O	O	O
AMPK	O	O	B-Entity
-	O	O	O
autophagy	O	O	B-Entity
pathway	O	O	B-Entity
could	O	O	O
be	O	O	O
a	O	O	O
primary	O	O	O
resistance	O	O	B-Entity
factor	O	O	B-Entity
of	O	O	O
icaritin	O	O	B-Entity
.	O	O	O

-DOCSTART- (28105970)

Classification	O	O	B-Entity
of	O	O	O
Edible	O	O	B-Entity
Oils	O	O	I-Entity
Based	O	O	O
on	O	O	O
ATR-FTIR	O	O	B-Entity
Spectral	O	O	B-Entity
Information	O	O	I-Entity
During	O	O	O
a	O	O	O
Long	O	O	O
Heating	O	O	O
Treatment	O	O	O

Identification	O	O	B-Entity
of	O	O	O
oil	O	O	B-Entity
type	O	O	B-Entity
and	O	O	O
its	O	O	O
QC	O	O	B-Entity
are	O	O	O
important	O	O	O
concerns	O	O	O
in	O	O	O
food	O	O	B-Entity
control	O	O	I-Entity
laboratories	O	O	I-Entity
.	O	O	O

Classifying	O	O	B-Entity
edible	O	O	B-Entity
oils	O	O	I-Entity
that	O	O	O
have	O	O	O
not	O	O	O
been	O	O	O
used	O	O	O
(	O	O	O
i.e.	O	O	O
,	O	O	O
unheated	O	O	B-Entity
)	O	O	O
with	O	O	O
the	O	O	O
aid	O	O	O
of	O	O	O
vibrational	O	O	B-Entity
spectroscopy	O	O	I-Entity
has	O	O	O
previously	O	O	O
been	O	O	O
reported	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
classification	O	O	B-Entity
of	O	O	O
used	O	O	O
(	O	O	O
i.e.	O	O	O
,	O	O	O
heat-treated	O	O	B-Entity
)	O	O	O
oils	O	O	B-Entity
needs	O	O	O
special	O	O	O
attention	O	O	O
.	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	O
long	O	O	B-Entity
heating	O	O	I-Entity
times	O	O	I-Entity
on	O	O	O
the	O	O	O
classification	O	O	B-Entity
of	O	O	O
four	O	O	O
kinds	O	O	O
of	O	O	O
edible	O	O	B-Entity
oils	O	O	I-Entity
(	O	O	O
canola	O	O	B-Entity
,	O	O	O
corn	O	O	B-Entity
,	O	O	O
frying	O	O	B-Entity
,	O	O	O
and	O	O	O
sunflower	O	O	B-Entity
)	O	O	O
based	O	O	O
on	O	O	O
attenuated	O	O	B-Entity
total	O	O	I-Entity
reflectance	O	O	I-Entity
(ATR)-FTIR	O	O	I-Entity
spectra	O	O	I-Entity
was	O	O	O
surveyed	O	O	B-Entity
.	O	O	O

The	O	O	O
sampling	O	O	B-Entity
was	O	O	O
done	O	O	O
on	O	O	O
the	O	O	O
oils	O	O	B-Entity
during	O	O	O
a	O	O	O
36	O	O	O
h	O	O	O
heating	O	O	B-Entity
process	O	O	I-Entity
(	O	O	O
at	O	O	O
170	O	O	O
°	O	O	O
C	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
ATR-FTIR	O	O	B-Entity
spectra	O	O	I-Entity
of	O	O	O
the	O	O	O
samples	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
in	O	O	O
the	O	O	O
range	O	O	O
of	O	O	O
4000	O	O	O
-	O	O	O
550	O	O	O
cm-1	O	O	O
.	O	O	O

Interval	O	O	B-Entity
extended	O	O	I-Entity
canonical	O	O	I-Entity
variates	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
ECVA	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
a	O	O	O
variable	O	O	B-Entity
selection	O	O	I-Entity
and	O	O	O
classification	O	O	B-Entity
tool	O	O	O
,	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
best	O	O	O
intervals	O	O	B-Entity
during	O	O	O
the	O	O	O
heating	O	O	B-Entity
procedure	O	O	I-Entity
for	O	O	O
classification	O	O	O
.	O	O	O

Principal	O	O	B-Entity
component	O	O	I-Entity
analysis	O	O	I-Entity
discriminate	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
partial	O	O	B-Entity
least-squares	O	O	I-Entity
discriminate	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
and	O	O	O
ECVA	O	O	B-Entity
were	O	O	O
performed	O	O	O
on	O	O	O
the	O	O	O
selected	O	O	O
intervals	O	O	B-Entity
and	O	O	O
on	O	O	O
the	O	O	O
total	O	O	B-Entity
heating	O	O	I-Entity
time	O	O	I-Entity
.	O	O	O

The	O	O	O
effect	O	O	O
of	O	O	O
autoscaling	O	O	B-Entity
and	O	O	O
mean-centering	O	O	B-Entity
,	O	O	O
as	O	O	O
data	O	O	B-Entity
preprocessing	O	O	I-Entity
methods	O	O	I-Entity
,	O	O	O
was	O	O	O
also	O	O	O
investigated	O	O	B-Entity
.	O	O	O

The	O	O	O
ECVA	O	O	B-Entity
method	O	O	I-Entity
resulted	O	O	O
in	O	O	O
the	O	O	O
best	O	O	O
performances	O	O	O
for	O	O	O
classification	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
94	O	O	O
%	O	O	O
cross-validated	O	O	B-Entity
nonerror	O	O	I-Entity
rate	O	O	I-Entity
(	O	O	O
one	O	O	O
misclassification	O	O	O
)	O	O	O
for	O	O	O
the	O	O	O
heating	O	O	B-Entity
process	O	O	I-Entity
times	O	O	B-Entity
of	O	O	O
24	O	O	O
-	O	O	O
27	O	O	O
and	O	O	O
33	O	O	O
-	O	O	O
36	O	O	O
h.	O	O	O

-DOCSTART- (28106239)

Intravitreal	O	O	B-Entity
chemotherapy	O	O	B-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
vitreous	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
retinoblastoma	O	O	O

To	O	O	O
evaluate	O	O	O
the	O	O	O
therapeutic	O	O	B-Entity
outcome	O	O	I-Entity
of	O	O	O
intravitreal	O	O	B-Entity
melphalan	O	O	B-Entity
injection	O	O	B-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
vitreous	O	O	B-Entity
disease	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
retinoblastoma	O	O	B-Entity
.	O	O	O

We	O	O	O
particularly	O	O	O
aimed	O	O	O
to	O	O	O
assess	O	O	O
whether	O	O	O
higher	O	O	B-Entity
melphalan	O	O	B-Entity
dose	O	O	B-Entity
with	O	O	O
lower	O	O	B-Entity
number	O	O	B-Entity
of	O	O	O
injections	O	O	B-Entity
was	O	O	O
more	O	O	O
effective	O	O	B-Entity
and	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
fewer	O	O	B-Entity
side	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

This	O	O	O
retrospective	O	O	B-Entity
,	O	O	O
interventional	O	O	B-Entity
,	O	O	O
noncomparative	O	O	B-Entity
,	O	O	O
and	O	O	O
nonrandomized	O	O	B-Entity
study	O	O	I-Entity
included	O	O	O
39	O	O	O
eyes	O	O	B-Entity
of	O	O	O
37	O	O	O
patients	O	O	B-Entity
.	O	O	O

Vitreous	O	O	B-Entity
seeds	O	O	I-Entity
were	O	O	O
classified	O	O	B-Entity
as	O	O	O
dust	O	O	B-Entity
,	O	O	O
sphere	O	O	B-Entity
,	O	O	O
and	O	O	O
cloud	O	O	B-Entity
types	O	O	I-Entity
.	O	O	O

Intravitreal	O	O	B-Entity
injections	O	O	B-Entity
were	O	O	O
performed	O	O	B-Entity
through	O	O	B-Entity
pars	O	O	B-Entity
plana	O	O	I-Entity
free	O	O	O
of	O	O	O
any	O	O	O
visible	O	O	B-Entity
tumor	O	O	B-Entity
using	O	O	B-Entity
30-G	O	O	B-Entity
needle	O	O	I-Entity
.	O	O	O

Response	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
seeds	O	O	I-Entity
(	O	O	O
disappearance	O	O	B-Entity
,	O	O	O
conversion	O	O	B-Entity
into	O	O	O
inactive	O	O	B-Entity
debris	O	O	I-Entity
,	O	O	O
or	O	O	O
progression	O	O	B-Entity
)	O	O	O
and	O	O	O
enucleation	O	O	B-Entity
rate	O	O	B-Entity
were	O	O	O
determined	O	O	O
as	O	O	O
outcome	O	O	B-Entity
measures	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
previously	O	O	O
received	O	O	B-Entity
systemic	O	O	B-Entity
or	O	O	O
intra-arterial	O	O	B-Entity
chemotherapy	O	O	I-Entity
.	O	O	O

Vitreous	O	O	B-Entity
seeding	O	O	I-Entity
was	O	O	O
primary	O	O	B-Entity
in	O	O	O
54	O	O	O
%	O	O	O
of	O	O	O
eyes	O	O	B-Entity
and	O	O	O
secondary	O	O	B-Entity
in	O	O	O
46	O	O	O
%	O	O	O
of	O	O	O
eyes	O	O	O
.	O	O	O

Vitreous	O	O	B-Entity
seeds	O	O	I-Entity
were	O	O	O
classified	O	O	B-Entity
as	O	O	O
dust	O	O	B-Entity
in	O	O	O
9	O	O	O
(	O	O	O
23.1	O	O	O
%	O	O	O
)	O	O	O
eyes	O	O	B-Entity
,	O	O	O
sphere	O	O	B-Entity
in	O	O	O
24	O	O	O
(	O	O	O
61.5	O	O	O
%	O	O	O
)	O	O	O
eyes	O	O	O
,	O	O	O
and	O	O	O
cloud	O	O	B-Entity
in	O	O	O
6	O	O	O
(	O	O	O
15.4	O	O	O
%	O	O	O
)	O	O	O
eyes	O	O	O
.	O	O	O

Melphalan	O	O	B-Entity
dose	O	O	B-Entity
varied	O	O	O
between	O	O	O
20	O	O	O
and	O	O	O
40	O	O	O
µg	O	O	O
and	O	O	O
20	O	O	O
(	O	O	O
51.3	O	O	O
%	O	O	O
)	O	O	O
eyes	O	O	B-Entity
received	O	O	B-Entity
>	O	O	O
30	O	O	O
µg	O	O	O
.	O	O	O

The	O	O	O
total	O	O	B-Entity
number	O	O	I-Entity
of	O	O	O
injections	O	O	B-Entity
was	O	O	O
70	O	O	O
(	O	O	O
range	O	O	O
1	O	O	O
-	O	O	O
5	O	O	O
,	O	O	O
mean	O	O	B-Entity
1.8	O	O	O
per	O	O	O
eye	O	O	B-Entity
)	O	O	O
.	O	O	O

Various	O	O	B-Entity
types	O	O	B-Entity
of	O	O	O
regression	O	O	B-Entity
were	O	O	O
obtained	O	O	B-Entity
in	O	O	O
27	O	O	O
(	O	O	O
69.2	O	O	O
%	O	O	O
)	O	O	O
eyes	O	O	B-Entity
.	O	O	O

Sphere-type	O	O	B-Entity
seeds	O	O	I-Entity
were	O	O	O
the	O	O	O
most	O	O	B-Entity
responsive	O	O	B-Entity
to	O	O	O
melphalan	O	O	B-Entity
.	O	O	O

Nonresponse	O	O	B-Entity
and	O	O	O
disease	O	O	B-Entity
progression	O	O	I-Entity
were	O	O	O
noted	O	O	B-Entity
in	O	O	O
12	O	O	O
(	O	O	O
30.8	O	O	O
%	O	O	O
)	O	O	O
eyes	O	O	B-Entity
.	O	O	O

After	O	O	O
a	O	O	O
mean	O	O	B-Entity
follow-up	O	O	B-Entity
of	O	O	O
11.8	O	O	O
months	O	O	B-Entity
,	O	O	O
17	O	O	O
(	O	O	O
44	O	O	O
%	O	O	O
)	O	O	O
eyes	O	O	B-Entity
were	O	O	O
enucleated	O	O	B-Entity
.	O	O	O

Vitreous	O	O	B-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
18	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
retinal	O	O	B-Entity
pigment	O	O	I-Entity
epithelial	O	O	I-Entity
alterations	O	O	B-Entity
(	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
the	O	O	O
most	O	O	B-Entity
common	O	O	B-Entity
side	O	O	B-Entity
effects	O	O	I-Entity
.	O	O	O

Intravitreal	O	O	B-Entity
melphalan	O	O	B-Entity
at	O	O	O
30	O	O	O
-	O	O	O
40	O	O	O
µg	O	O	O
in	O	O	O
1	O	O	O
or	O	O	O
2	O	O	O
injections	O	O	B-Entity
proved	O	O	O
effective	O	O	B-Entity
in	O	O	O
69.2	O	O	O
%	O	O	O
of	O	O	O
eyes	O	O	B-Entity
with	O	O	O
vitreous	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

-DOCSTART- (28108399)

Fine	O	O	B-Entity
structure	O	O	I-Entity
of	O	O	O
the	O	O	O
anterior	O	O	B-Entity
median	O	O	I-Entity
eyes	O	O	I-Entity
of	O	O	O
the	O	O	O
funnel	O	O	B-Entity
-	O	O	O
web	O	O	B-Entity
spider	O	O	I-Entity
Agelena	O	O	B-Entity
labyrinthica	O	O	I-Entity
(	O	O	O
Araneae	O	O	B-Entity
:	O	O	O
Agelenidae	O	O	B-Entity
)	O	O	O

Only	O	O	O
few	O	O	O
electron	O	O	B-Entity
microscopic	O	O	I-Entity
studies	O	O	I-Entity
exist	O	O	O
on	O	O	O
the	O	O	O
structure	O	O	B-Entity
of	O	O	O
the	O	O	O
main	O	O	O
eyes	O	O	B-Entity
(	O	O	O
anterior	O	O	B-Entity
median	O	O	I-Entity
eyes	O	O	I-Entity
,	O	O	O
AME	O	O	B-Entity
)	O	O	O
of	O	O	O
web	O	O	B-Entity
spiders	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
paper	O	O	O
provides	O	O	O
details	O	O	O
on	O	O	O
the	O	O	O
anatomy	O	O	B-Entity
of	O	O	O
the	O	O	O
AME	O	O	B-Entity
in	O	O	O
the	O	O	O
funnel-web	O	O	O
spider	O	O	B-Entity
Agelena	O	O	B-Entity
labyrinthica	O	O	I-Entity
.	O	O	O

The	O	O	O
retina	O	O	B-Entity
consists	O	O	O
of	O	O	O
two	O	O	O
separate	O	O	O
regions	O	O	B-Entity
with	O	O	O
differently	O	O	O
arranged	O	O	O
photoreceptor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Its	O	O	O
central	O	O	B-Entity
part	O	O	I-Entity
has	O	O	O
sensory	O	O	B-Entity
cells	O	O	I-Entity
with	O	O	O
rhabdomeres	O	O	B-Entity
on	O	O	O
2	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
or	O	O	O
4	O	O	O
sides	O	O	O
,	O	O	O
whereas	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
ventral	O	O	B-Entity
retina	O	O	B-Entity
have	O	O	O
only	O	O	O
two	O	O	O
rhabdomeres	O	O	O
on	O	O	O
opposite	O	O	O
sides	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
rhabdomeres	O	O	B-Entity
of	O	O	O
the	O	O	O
ventral	O	O	B-Entity
retina	O	O	B-Entity
are	O	O	O
arranged	O	O	O
in	O	O	O
a	O	O	O
specific	O	O	O
way	O	O	O
:	O	O	O
Whereas	O	O	O
in	O	O	O
the	O	O	O
most	O	O	O
ventral	O	O	O
part	O	O	O
they	O	O	O
form	O	O	O
long	O	O	B-Entity
tangential	O	O	I-Entity
rows	O	O	I-Entity
,	O	O	O
those	O	O	O
towards	O	O	O
the	O	O	O
center	O	O	B-Entity
are	O	O	O
detached	O	O	O
and	O	O	O
are	O	O	O
arranged	O	O	O
radially	O	O	O
.	O	O	O

All	O	O	O
sensory	O	O	B-Entity
cells	O	O	I-Entity
are	O	O	O
wrapped	O	O	O
by	O	O	O
unpigmented	O	O	B-Entity
pigment	O	O	B-Entity
cell	O	O	I-Entity
processes	O	O	B-Entity
.	O	O	O

In	O	O	O
agelenid	O	O	B-Entity
spiders	O	O	B-Entity
the	O	O	O
axons	O	O	B-Entity
of	O	O	O
the	O	O	O
sensory	O	O	B-Entity
cells	O	O	I-Entity
exit	O	O	O
from	O	O	O
the	O	O	O
middle	O	O	O
of	O	O	O
the	O	O	O
cell	O	O	B-Entity
body	O	O	I-Entity
;	O	O	O
their	O	O	O
fine	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	O
course	O	O	O
through	O	O	O
the	O	O	O
eye	O	O	B-Entity
cup	O	O	I-Entity
is	O	O	O
described	O	O	O
in	O	O	O
detail	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
central	O	O	B-Entity
part	O	O	I-Entity
of	O	O	O
the	O	O	O
retina	O	O	B-Entity
efferent	O	O	O
nerve	O	O	B-Entity
fibres	O	O	I-Entity
were	O	O	O
found	O	O	O
forming	O	O	O
synapses	O	O	B-Entity
along	O	O	O
the	O	O	O
distal	O	O	B-Entity
region	O	O	I-Entity
of	O	O	O
the	O	O	O
receptor	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

A	O	O	O
muscle	O	O	B-Entity
is	O	O	O
attached	O	O	O
laterally	O	O	O
to	O	O	O
each	O	O	O
eye	O	O	B-Entity
cup	O	O	I-Entity
that	O	O	O
allows	O	O	O
mainly	O	O	O
rotational	O	O	B-Entity
movements	O	O	B-Entity
of	O	O	O
the	O	O	O
eyes	O	O	B-Entity
.	O	O	O

The	O	O	O
optical	O	O	B-Entity
performance	O	O	I-Entity
(	O	O	O
image	O	O	B-Entity
resolution	O	O	I-Entity
)	O	O	O
of	O	O	O
these	O	O	O
main	O	O	O
eyes	O	O	B-Entity
with	O	O	O
relatively	O	O	O
few	O	O	O
visual	O	O	B-Entity
cells	O	O	I-Entity
is	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (28111379)

Knocking	O	O	B-Entity
down	O	O	I-Entity
TCF8	O	O	B-Entity
inhibits	O	O	O
high	O	O	B-Entity
glucose	O	O	I-Entity
-	O	O	O
and	O	O	O
angiotensin	O	O	B-Entity
II	O	O	I-Entity
-	O	O	O
induced	O	O	B-Entity
epithelial	O	O	B-Entity
to	O	O	I-Entity
mesenchymal	O	O	I-Entity
transition	O	O	I-Entity
in	O	O	O
podocytes	O	O	O

Epithelial	O	O	B-Entity
to	O	O	I-Entity
mesenchymal	O	O	I-Entity
transition	O	O	I-Entity
(	O	O	O
EMT	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
physiological	O	O	B-Entity
phenomenon	O	O	I-Entity
in	O	O	O
mammalian	O	O	B-Entity
embryogenesis	O	O	B-Entity
by	O	O	O
which	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
become	O	O	O
mesenchymal	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Studies	O	O	O
have	O	O	O
indicated	O	O	O
that	O	O	O
an	O	O	O
inappropriate	O	O	O
EMT	O	O	B-Entity
plays	O	O	O
a	O	O	O
key	O	O	O
role	O	O	O
in	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
pathogenic	O	O	B-Entity
processes	O	O	B-Entity
such	O	O	O
as	O	O	O
embryonic	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
metastasis	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
recent	O	O	O
studies	O	O	O
have	O	O	O
indicated	O	O	O
EMT	O	O	B-Entity
also	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
renal	O	O	B-Entity
fibrosis	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
study	O	O	O
,	O	O	O
glucose	O	O	B-Entity
and	O	O	O
angiotensin	O	O	B-Entity
II	O	O	I-Entity
promoted	O	O	O
EMT	O	O	B-Entity
in	O	O	O
podocytes	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
changes	O	O	O
in	O	O	O
the	O	O	O
cellular	O	O	B-Entity
morphology	O	O	I-Entity
of	O	O	O
podocytes	O	O	O
.	O	O	O

A	O	O	O
high	O	O	B-Entity
concentration	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
and	O	O	O
angiotensin	O	O	B-Entity
II	O	O	I-Entity
also	O	O	O
promoted	O	O	O
podocyte	O	O	B-Entity
movement	O	O	B-Entity
and	O	O	O
migration	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
a	O	O	O
high	O	O	B-Entity
concentration	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
and	O	O	O
angiotensin	O	O	B-Entity
II	O	O	I-Entity
promoted	O	O	O
TCF8	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

Inhibiting	O	O	B-Entity
TCF8	O	O	B-Entity
expression	O	O	B-Entity
with	O	O	O
siRNA	O	O	B-Entity
reversed	O	O	O
EMT	O	O	B-Entity
in	O	O	O
podocytes	O	O	B-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
high	O	O	B-Entity
concentration	O	O	B-Entity
of	O	O	O
glucose	O	O	B-Entity
and	O	O	O
angiotensin	O	O	B-Entity
.	O	O	O

Inhibiting	O	O	B-Entity
TCF8	O	O	B-Entity
expression	O	O	B-Entity
also	O	O	O
reversed	O	O	O
changes	O	O	O
in	O	O	O
cellular	O	O	B-Entity
morphology	O	O	I-Entity
and	O	O	O
podocyte	O	O	B-Entity
movement	O	O	B-Entity
and	O	O	O
migration	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
glucose	O	O	B-Entity
and	O	O	O
angiotensin	O	O	B-Entity
II	O	O	I-Entity
may	O	O	O
promote	O	O	O
EMT	O	O	B-Entity
in	O	O	O
podocytes	O	O	B-Entity
via	O	O	O
TCF8	O	O	B-Entity
.	O	O	O

-DOCSTART- (28113047)

Temporal	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
host	O	O	B-Entity
surface	O	O	I-Entity
receptors	O	O	I-Entity
provides	O	O	O
a	O	O	O
window	O	O	O
of	O	O	O
opportunity	O	O	O
for	O	O	O
bacterial	O	O	B-Entity
adhesion	O	O	I-Entity
and	O	O	O
disease	O	O	O

Host	O	O	B-Entity
surface	O	O	I-Entity
receptors	O	O	I-Entity
provide	O	O	O
bacteria	O	O	B-Entity
with	O	O	O
a	O	O	O
foothold	O	O	O
from	O	O	O
which	O	O	O
to	O	O	O
attach	O	O	B-Entity
,	O	O	O
colonize	O	O	O
and	O	O	O
,	O	O	O
in	O	O	O
some	O	O	O
cases	O	O	O
,	O	O	O
invade	O	O	O
tissue	O	O	B-Entity
and	O	O	O
elicit	O	O	O
human	O	O	B-Entity
disease	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
review	O	O	O
,	O	O	O
we	O	O	O
discuss	O	O	O
several	O	O	O
key	O	O	O
host	O	O	B-Entity
receptors	O	O	I-Entity
and	O	O	O
cognate	O	O	B-Entity
adhesins	O	O	I-Entity
that	O	O	O
function	O	O	O
in	O	O	O
bacterial	O	O	B-Entity
pathogenesis	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
we	O	O	O
examine	O	O	O
the	O	O	O
elevated	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
host	O	O	B-Entity
surface	O	O	I-Entity
receptors	O	O	I-Entity
such	O	O	O
as	O	O	O
CEACAM-1	O	O	B-Entity
,	O	O	O
CEACAM-6	O	O	B-Entity
,	O	O	O
ICAM-1	O	O	B-Entity
and	O	O	O
PAFR	O	O	B-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	I-Entity
specific	O	O	I-Entity
stimuli	O	O	I-Entity
.	O	O	O

We	O	O	O
explore	O	O	O
how	O	O	O
upregulated	O	O	B-Entity
receptors	O	O	I-Entity
,	O	O	O
in	O	O	O
turn	O	O	O
,	O	O	O
expose	O	O	O
the	O	O	O
host	O	O	B-Entity
to	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
bacterial	O	O	B-Entity
infections	O	O	I-Entity
in	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
tract	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
apparent	O	O	O
that	O	O	O
exploitation	O	O	O
of	O	O	O
receptor	O	O	B-Entity
induction	O	O	B-Entity
for	O	O	O
bacterial	O	O	B-Entity
adherence	O	O	I-Entity
is	O	O	O
not	O	O	O
unique	O	O	O
to	O	O	O
one	O	O	O
body	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
but	O	O	O
is	O	O	O
also	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
,	O	O	O
gastrointestinal	O	O	B-Entity
and	O	O	O
urogenital	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

Prokaryotic	O	O	B-Entity
pathogens	O	O	B-Entity
which	O	O	O
utilize	O	O	O
this	O	O	O
mechanism	O	O	O
for	O	O	O
their	O	O	O
infectivity	O	O	B-Entity
include	O	O	O
Streptococcus	O	O	B-Entity
pneumoniae	O	O	I-Entity
,	O	O	O
Haemophilus	O	O	B-Entity
influenzae	O	O	I-Entity
,	O	O	O
Neisseria	O	O	B-Entity
meningitidis	O	O	I-Entity
and	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
.	O	O	O

A	O	O	O
number	O	O	O
of	O	O	O
approaches	O	O	O
have	O	O	O
been	O	O	O
used	O	O	O
,	O	O	O
in	O	O	O
both	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
experimental	O	O	I-Entity
models	O	O	I-Entity
,	O	O	O
to	O	O	O
inhibit	O	O	O
bacterial	O	O	B-Entity
attachment	O	O	I-Entity
to	O	O	O
temporally	O	O	O
expressed	O	O	B-Entity
host	O	O	B-Entity
receptors	O	O	I-Entity
.	O	O	O

Some	O	O	O
of	O	O	O
these	O	O	O
novel	O	O	O
strategies	O	O	O
may	O	O	O
advance	O	O	O
future	O	O	O
targeted	O	O	B-Entity
interventions	O	O	B-Entity
for	O	O	O
the	O	O	O
prevention	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
of	O	O	O
bacterial	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

-DOCSTART- (28115057)

Optogenetic	O	O	B-Entity
Demonstration	O	O	B-Entity
of	O	O	O
Functional	O	O	B-Entity
Innervation	O	O	B-Entity
of	O	O	O
Mouse	O	O	B-Entity
Colon	O	O	B-Entity
by	O	O	O
Neurons	O	O	B-Entity
Derived	O	O	O
From	O	O	O
Transplanted	O	O	B-Entity
Neural	O	O	O
Cells	O	O	O

Cell	O	O	B-Entity
therapy	O	O	I-Entity
offers	O	O	O
the	O	O	O
potential	O	O	O
to	O	O	O
treat	O	O	B-Entity
gastrointestinal	O	O	B-Entity
motility	O	O	I-Entity
disorders	O	O	I-Entity
caused	O	O	O
by	O	O	O
diseased	O	O	B-Entity
or	O	O	O
absent	O	O	B-Entity
enteric	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
whether	O	O	O
neurons	O	O	B-Entity
generated	O	O	O
from	O	O	O
transplanted	O	O	B-Entity
enteric	O	O	B-Entity
neural	O	O	B-Entity
cells	O	O	I-Entity
provide	O	O	O
a	O	O	O
functional	O	O	B-Entity
innervation	O	O	B-Entity
of	O	O	O
bowel	O	O	B-Entity
smooth	O	O	B-Entity
muscle	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
.	O	O	O

Enteric	O	O	B-Entity
neural	O	O	B-Entity
cells	O	O	I-Entity
expressing	O	O	O
the	O	O	O
light-sensitive	O	O	B-Entity
ion	O	O	I-Entity
channel	O	O	I-Entity
,	O	O	O
channelrhodopsin	O	O	B-Entity
,	O	O	O
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
fetal	O	O	B-Entity
or	O	O	O
postnatal	O	O	B-Entity
mouse	O	O	B-Entity
bowel	O	O	B-Entity
and	O	O	O
transplanted	O	O	B-Entity
into	O	O	O
the	O	O	O
distal	O	O	B-Entity
colon	O	O	I-Entity
of	O	O	O
3-	O	O	O
to	O	O	O
4-	O	O	O
week	O	O	B-Entity
-old	O	O	O
wild-type	O	O	B-Entity
recipient	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Intracellular	O	O	B-Entity
electrophysiological	O	O	B-Entity
recordings	O	O	I-Entity
of	O	O	O
responses	O	O	B-Entity
to	O	O	O
light	O	O	B-Entity
stimulation	O	O	I-Entity
of	O	O	O
the	O	O	O
transplanted	O	O	B-Entity
cells	O	O	B-Entity
were	O	O	O
made	O	O	O
from	O	O	O
colonic	O	O	B-Entity
smooth	O	O	B-Entity
muscle	O	O	I-Entity
cells	O	O	I-Entity
in	O	O	O
recipient	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Electrical	O	O	B-Entity
stimulation	O	O	I-Entity
of	O	O	O
endogenous	O	O	B-Entity
enteric	O	O	B-Entity
neurons	O	O	B-Entity
was	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
control	O	O	B-Entity
.	O	O	O

The	O	O	O
axons	O	O	B-Entity
of	O	O	O
graft	O	O	B-Entity
-derived	O	O	O
neurons	O	O	B-Entity
formed	O	O	O
a	O	O	O
plexus	O	O	B-Entity
in	O	O	O
the	O	O	O
circular	O	O	B-Entity
muscle	O	O	I-Entity
layer	O	O	I-Entity
.	O	O	O

Selective	O	O	B-Entity
stimulation	O	O	I-Entity
of	O	O	O
graft	O	O	B-Entity
-derived	O	O	O
cells	O	O	B-Entity
by	O	O	O
light	O	O	B-Entity
resulted	O	O	O
in	O	O	O
excitatory	O	O	B-Entity
and	O	O	O
inhibitory	O	O	B-Entity
junction	O	O	I-Entity
potentials	O	O	I-Entity
,	O	O	O
the	O	O	O
electrical	O	O	B-Entity
events	O	O	B-Entity
underlying	O	O	O
contraction	O	O	B-Entity
and	O	O	O
relaxation	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
in	O	O	O
colonic	O	O	B-Entity
muscle	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Graft	O	O	B-Entity
-derived	O	O	O
excitatory	O	O	B-Entity
and	O	O	O
inhibitory	O	O	B-Entity
motor	O	O	B-Entity
neurons	O	O	I-Entity
released	O	O	O
the	O	O	O
same	O	O	O
neurotransmitters	O	O	B-Entity
as	O	O	O
endogenous	O	O	B-Entity
motor	O	O	O
neurons	O	O	O
-	O	O	O
acetylcholine	O	O	B-Entity
and	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
adenosine	O	O	B-Entity
triphosphate	O	O	I-Entity
and	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Graft	O	O	B-Entity
-derived	O	O	O
neurons	O	O	B-Entity
also	O	O	O
included	O	O	O
interneurons	O	O	B-Entity
that	O	O	O
provided	O	O	O
synaptic	O	O	O
inputs	O	O	O
to	O	O	O
motor	O	O	O
neurons	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
pharmacologic	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
interneurons	O	O	O
varied	O	O	O
with	O	O	O
the	O	O	O
age	O	O	B-Entity
of	O	O	O
the	O	O	O
donors	O	O	B-Entity
from	O	O	O
which	O	O	O
enteric	O	O	B-Entity
neural	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
obtained	O	O	O
.	O	O	O

Enteric	O	O	B-Entity
neural	O	O	B-Entity
cells	O	O	I-Entity
transplanted	O	O	B-Entity
into	O	O	O
the	O	O	O
bowel	O	O	B-Entity
give	O	O	O
rise	O	O	O
to	O	O	O
multiple	O	O	B-Entity
functional	O	O	B-Entity
types	O	O	B-Entity
of	O	O	O
neurons	O	O	B-Entity
that	O	O	O
integrate	O	O	O
and	O	O	O
provide	O	O	O
a	O	O	O
functional	O	O	O
innervation	O	O	B-Entity
of	O	O	O
the	O	O	O
smooth	O	O	B-Entity
muscle	O	O	I-Entity
of	O	O	O
the	O	O	O
bowel	O	O	B-Entity
wall	O	O	I-Entity
.	O	O	O

Circuits	O	O	B-Entity
composed	O	O	O
of	O	O	O
both	O	O	O
motor	O	O	B-Entity
neurons	O	O	I-Entity
and	O	O	O
interneurons	O	O	B-Entity
were	O	O	O
established	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
age	O	O	B-Entity
at	O	O	O
which	O	O	O
cells	O	O	B-Entity
are	O	O	O
isolated	O	O	O
influences	O	O	O
the	O	O	O
neurotransmitter	O	O	B-Entity
phenotype	O	O	B-Entity
of	O	O	O
interneurons	O	O	O
that	O	O	O
are	O	O	O
generated	O	O	O
.	O	O	O

-DOCSTART- (28117211)

Assessment	O	O	B-Entity
of	O	O	O
Vascular	O	O	B-Entity
Stent	O	O	I-Entity
Heating	O	O	B-Entity
with	O	O	O
Repetitive	O	O	O
Transcranial	O	O	O
Magnetic	O	O	O
Stimulation	O	O	O

A	O	O	O
high	O	O	O
proportion	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
stroke	O	O	B-Entity
do	O	O	O
not	O	O	O
qualify	O	O	O
for	O	O	O
repetitive	O	O	B-Entity
transcranial	O	O	I-Entity
magnetic	O	O	I-Entity
stimulation	O	O	I-Entity
(	O	O	O
rTMS	O	O	B-Entity
)	O	O	O
clinical	O	O	B-Entity
studies	O	O	I-Entity
due	O	O	O
to	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
metallic	O	O	B-Entity
stents	O	O	I-Entity
.	O	O	O

The	O	O	O
ultimate	O	O	O
concern	O	O	O
is	O	O	O
that	O	O	O
any	O	O	O
metal	O	O	B-Entity
could	O	O	O
become	O	O	O
heated	O	O	B-Entity
due	O	O	O
to	O	O	O
eddy	O	O	B-Entity
currents	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
to	O	O	O
date	O	O	O
,	O	O	O
no	O	O	O
clinical	O	O	B-Entity
safety	O	O	I-Entity
data	O	O	I-Entity
are	O	O	O
available	O	O	O
regarding	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
metallic	O	O	B-Entity
stents	O	O	I-Entity
heating	O	O	B-Entity
with	O	O	O
rTMS	O	O	B-Entity
.	O	O	O

We	O	O	O
tested	O	O	B-Entity
the	O	O	O
safety	O	O	B-Entity
of	O	O	O
common	O	O	O
rTMS	O	O	B-Entity
protocols	O	O	B-Entity
(	O	O	O
1	O	O	O
Hz	O	O	O
and	O	O	O
10	O	O	O
Hz	O	O	O
)	O	O	O
with	O	O	O
stents	O	O	B-Entity
used	O	O	O
commonly	O	O	O
in	O	O	O
stroke	O	O	B-Entity
,	O	O	O
nitinol	O	O	B-Entity
and	O	O	O
elgiloy	O	O	B-Entity
.	O	O	O

In	O	O	O
our	O	O	O
method	O	O	O
,	O	O	O
stents	O	O	B-Entity
were	O	O	O
tested	O	O	B-Entity
in	O	O	O
gelled	O	O	B-Entity
saline	O	O	B-Entity
at	O	O	O
2	O	O	O
different	O	O	O
locations	O	O	B-Entity
:	O	O	O
at	O	O	B-Entity
the	O	O	I-Entity
center	O	O	I-Entity
and	O	O	O
at	O	O	O
the	O	O	O
lobe	O	O	B-Entity
of	O	O	O
the	O	O	O
coil	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
at	O	O	O
each	O	O	O
location	O	O	B-Entity
,	O	O	O
stent	O	O	B-Entity
heating	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
in	O	O	O
3	O	O	O
different	O	O	O
orientations	O	O	B-Entity
:	O	O	O
parallel	O	O	B-Entity
to	O	O	O
the	O	O	O
long	O	O	B-Entity
axis	O	O	I-Entity
of	O	O	O
coil	O	O	B-Entity
,	O	O	O
parallel	O	O	O
to	O	O	O
the	O	O	O
short	O	O	B-Entity
axis	O	O	I-Entity
of	O	O	O
the	O	O	O
coil	O	O	O
,	O	O	O
and	O	O	O
perpendicular	O	O	B-Entity
to	O	O	O
the	O	O	O
plane	O	O	O
of	O	O	O
the	O	O	O
coil	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
stents	O	O	B-Entity
did	O	O	O
not	O	O	O
heat	O	O	B-Entity
to	O	O	O
more	O	O	O
than	O	O	O
1	O	O	O
°	O	O	O
C	O	O	O
with	O	O	O
either	O	O	O
1	O	O	O
Hz	O	O	O
rTMS	O	O	B-Entity
or	O	O	O
10	O	O	O
Hz	O	O	O
rTMS	O	O	O
in	O	O	O
any	O	O	O
configuration	O	O	O
or	O	O	O
orientation	O	O	B-Entity
.	O	O	O

Heating	O	O	B-Entity
in	O	O	O
general	O	O	O
was	O	O	O
greater	O	O	B-Entity
at	O	O	O
the	O	O	O
lobe	O	O	B-Entity
when	O	O	O
the	O	O	O
stent	O	O	B-Entity
was	O	O	O
oriented	O	O	B-Entity
perpendicularly	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
represents	O	O	O
a	O	O	O
new	O	O	O
method	O	O	O
for	O	O	O
ex	O	O	B-Entity
vivo	O	O	I-Entity
quantification	O	O	B-Entity
of	O	O	O
stent	O	O	B-Entity
heating	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
found	O	O	O
that	O	O	O
heating	O	O	B-Entity
of	O	O	O
stents	O	O	B-Entity
was	O	O	O
well	O	O	O
below	O	O	O
the	O	O	O
Food	O	O	B-Entity
and	O	O	I-Entity
Drug	O	O	I-Entity
Administration	O	O	I-Entity
standards	O	O	B-Entity
of	O	O	O
2	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
our	O	O	O
study	O	O	O
paves	O	O	O
the	O	O	O
way	O	O	O
for	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
testing	O	O	B-Entity
of	O	O	O
rTMS	O	O	B-Entity
(	O	O	O
≤10	O	O	O
Hz	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
implanted	O	O	B-Entity
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
-	O	O	O
compatible	O	O	B-Entity
stents	O	O	B-Entity
in	O	O	O
animal	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

When	O	O	O
planning	O	O	O
human	O	O	B-Entity
safety	O	O	B-Entity
studies	O	O	I-Entity
though	O	O	O
,	O	O	O
geometry	O	O	B-Entity
,	O	O	O
orientation	O	O	B-Entity
,	O	O	O
and	O	O	O
location	O	O	B-Entity
relative	O	O	O
to	O	O	O
the	O	O	O
coil	O	O	B-Entity
would	O	O	O
be	O	O	O
important	O	O	O
to	O	O	O
consider	O	O	O
as	O	O	O
well	O	O	O
.	O	O	O

-DOCSTART- (28118200)

Clinical	O	O	B-Entity
Observation	O	O	I-Entity
of	O	O	O
Treatment	O	O	B-Entity
of	O	O	O
Chronic	O	O	B-Entity
Subdural	O	O	I-Entity
Hematoma	O	O	I-Entity
With	O	O	O
Novel	O	O	O
Double	O	O	O
Needle	O	O	O
Minimally	O	O	O
Invasive	O	O	O
Aspiration	O	O	O
Technology	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
clinical	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
prevention	O	O	O
of	O	O	O
complications	O	O	B-Entity
,	O	O	O
of	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
subdural	O	O	I-Entity
hematoma	O	O	I-Entity
with	O	O	O
double	O	O	B-Entity
needle	O	O	I-Entity
aspiration	O	O	I-Entity
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
data	O	O	I-Entity
of	O	O	O
31	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
subdural	O	O	I-Entity
hematoma	O	O	I-Entity
treated	O	O	B-Entity
by	O	O	O
double	O	O	B-Entity
YL-1	O	O	I-Entity
needle	O	O	I-Entity
double	O	O	O
skull	O	O	B-Entity
drilling	O	O	B-Entity
and	O	O	O
31	O	O	O
controls	O	O	O
treated	O	O	O
by	O	O	O
traditional	O	O	O
drilling	O	O	O
and	O	O	O
drainage	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
retrospectively	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
YL-1	O	O	B-Entity
needle	O	O	I-Entity
group	O	O	B-Entity
,	O	O	O
only	O	O	O
1	O	O	O
patient	O	O	B-Entity
was	O	O	O
with	O	O	O
hematoma	O	O	B-Entity
recurrence	O	O	B-Entity
,	O	O	O
1	O	O	O
patient	O	O	O
was	O	O	O
with	O	O	O
intracranial	O	O	B-Entity
pneumocephalus	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
remaining	O	O	O
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
followed	O	O	O
up	O	O	O
for	O	O	O
3	O	O	O
months	O	O	B-Entity
achieved	O	O	O
a	O	O	O
clinical	O	O	B-Entity
cure	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
traditional	O	O	B-Entity
drilling	O	O	I-Entity
and	O	O	O
drainage	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
13	O	O	O
patients	O	O	B-Entity
were	O	O	O
with	O	O	O
hematoma	O	O	B-Entity
recurrence	O	O	B-Entity
within	O	O	O
3	O	O	O
months	O	O	B-Entity
after	O	O	O
the	O	O	O
operation	O	O	B-Entity
and	O	O	O
7	O	O	O
patients	O	O	O
were	O	O	O
with	O	O	O
postoperative	O	O	B-Entity
intracranial	O	O	B-Entity
pneumocephalus	O	O	I-Entity
.	O	O	O

The	O	O	O
method	O	O	B-Entity
of	O	O	O
double	O	O	B-Entity
YL-1	O	O	I-Entity
needle	O	O	I-Entity
is	O	O	O
better	O	O	O
than	O	O	O
the	O	O	O
traditional	O	O	B-Entity
drilling	O	O	I-Entity
and	O	O	O
drainage	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
subdural	O	O	I-Entity
hematoma	O	O	I-Entity
because	O	O	O
it	O	O	O
reduces	O	O	O
the	O	O	O
postoperative	O	O	B-Entity
recurrence	O	O	B-Entity
rate	O	O	O
and	O	O	O
complications	O	O	B-Entity
.	O	O	O

-DOCSTART- (28118752)

The	O	O	O
impact	O	O	B-Entity
of	O	O	O
adjunctive	O	O	B-Entity
guanfacine	O	O	B-Entity
extended	O	O	B-Entity
release	O	O	I-Entity
on	O	O	O
stimulant	O	O	B-Entity
adherence	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
/	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
attention-deficit	O	O	B-Entity
/	O	O	O
hyperactivity	O	O	O
disorder	O	O	O

To	O	O	O
assess	O	O	O
stimulant	O	O	B-Entity
adherence	O	O	B-Entity
among	O	O	O
children	O	O	B-Entity
/	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
attention-deficit	O	O	B-Entity
/	O	O	O
hyperactivity	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	O
ADHD	O	O	B-Entity
)	O	O	O
augmenting	O	O	B-Entity
stimulants	O	O	B-Entity
with	O	O	O
guanfacine	O	O	B-Entity
extended-release	O	O	I-Entity
(	O	O	O
GXR	O	O	B-Entity
)	O	O	O
.	O	O	O

Inclusion	O	O	B-Entity
criteria	O	O	I-Entity
:	O	O	O
6	O	O	O
-	O	O	O
17	O	O	O
years	O	O	B-Entity
,	O	O	O
≥1	O	O	O
ADHD	O	O	B-Entity
diagnosis	O	O	B-Entity
,	O	O	O
≥1	O	O	O
long-acting	O	O	B-Entity
and/or	O	O	O
short-acting	O	O	B-Entity
stimulant	O	O	I-Entity
with	O	O	O
GXR	O	O	B-Entity
augmentation	O	O	B-Entity
.	O	O	O

Modified	O	O	B-Entity
medication	O	O	B-Entity
possession	O	O	I-Entity
ratio	O	O	I-Entity
(	O	O	O
mMPR	O	O	B-Entity
;	O	O	O
days	O	O	B-Entity
medication	O	O	O
available	O	O	B-Entity
/	O	O	O
days	O	O	O
in	O	O	O
period	O	O	B-Entity
,	O	O	O
excluding	O	O	B-Entity
medication	O	O	O
holidays	O	O	B-Entity
)	O	O	O
was	O	O	O
assessed	O	O	O
;	O	O	O
mMPR	O	O	O
<	O	O	O
0.80	O	O	O
nonadherent	O	O	B-Entity
.	O	O	O

Regression	O	O	B-Entity
models	O	O	B-Entity
assessed	O	O	B-Entity
change	O	O	B-Entity
in	O	O	O
mMPR	O	O	B-Entity
adjusting	O	O	B-Entity
for	O	O	O
demographic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

Among	O	O	O
patients	O	O	B-Entity
nonadherent	O	O	B-Entity
to	O	O	O
stimulants	O	O	B-Entity
pre	O	O	B-Entity
-	O	O	O
augmentation	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
165	O	O	O
)	O	O	O
,	O	O	O
unadjusted	O	O	B-Entity
mean	O	O	O
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
pre	O	O	O
-	O	O	O
and	O	O	O
post	O	O	B-Entity
-	O	O	O
stimulant	O	O	B-Entity
mMPRs	O	O	B-Entity
were	O	O	O
0.68	O	O	O
(	O	O	O
0.11	O	O	O
)	O	O	O
and	O	O	O
0.87	O	O	O
(	O	O	O
0.16	O	O	O
)	O	O	O
.	O	O	O

Adjusted	O	O	B-Entity
mean	O	O	O
change	O	O	B-Entity
in	O	O	O
mMPR	O	O	B-Entity
was	O	O	O
0.20	O	O	O
for	O	O	O
long-acting	O	O	B-Entity
versus	O	O	O
0.18	O	O	O
for	O	O	O
short-acting	O	O	B-Entity
stimulants	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.34	O	O	O
)	O	O	O
.	O	O	O

Among	O	O	O
patients	O	O	B-Entity
nonadherent	O	O	B-Entity
to	O	O	O
stimulants	O	O	B-Entity
,	O	O	O
GXR	O	O	B-Entity
augmentation	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
stimulant	O	O	B-Entity
adherence	O	O	B-Entity
.	O	O	O

-DOCSTART- (28118814)

Bxb1	O	O	B-Entity
phage	O	O	I-Entity
recombinase	O	O	B-Entity
assists	O	O	O
genome	O	O	B-Entity
engineering	O	O	I-Entity
in	O	O	O
Drosophila	O	O	O
melanogaster	O	O	O

Rapid	O	O	B-Entity
and	O	O	O
reliable	O	O	B-Entity
genome	O	O	B-Entity
modifications	O	O	I-Entity
provide	O	O	O
the	O	O	O
basis	O	O	O
for	O	O	O
detailed	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
functional	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
any	O	O	O
genomic	O	O	B-Entity
entity	O	O	I-Entity
(	O	O	O
gene	O	O	B-Entity
,	O	O	O
regulatory	O	O	B-Entity
DNA	O	O	I-Entity
,	O	O	O
non-coding	O	O	B-Entity
RNA	O	O	I-Entity
,	O	O	O
etc	O	O	O
)	O	O	O
.	O	O	O

With	O	O	O
the	O	O	O
advent	O	O	O
of	O	O	O
CRISPR	O	O	B-Entity
/	O	O	O
Cas9	O	O	B-Entity
genome	O	O	I-Entity
editing	O	O	I-Entity
technology	O	O	I-Entity
,	O	O	O
manipulation	O	O	B-Entity
of	O	O	O
a	O	O	O
particular	O	O	O
genomic	O	O	B-Entity
locus	O	O	I-Entity
has	O	O	O
become	O	O	O
a	O	O	O
routine	O	O	O
undertaking	O	O	O
in	O	O	O
variety	O	O	O
of	O	O	O
model	O	O	B-Entity
organisms	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
fruit	O	O	B-Entity
fly	O	O	I-Entity
Drosophila	O	O	I-Entity
melanogaster	O	O	I-Entity
.	O	O	O

To	O	O	O
further	O	O	O
diversify	O	O	O
the	O	O	O
available	O	O	O
tools	O	O	O
for	O	O	O
genome	O	O	B-Entity
engineering	O	O	I-Entity
,	O	O	O
we	O	O	O
successfully	O	O	O
harnessed	O	O	O
the	O	O	O
phage	O	O	B-Entity
recombinase	O	O	B-Entity
Bxb1	O	O	I-Entity
to	O	O	O
perform	O	O	O
recombinase-mediated	O	O	O
cassette	O	O	O
exchange	O	O	O
(	O	O	O
RMCE	O	O	O
)	O	O	O
in	O	O	O
D.	O	O	B-Entity
melanogaster	O	O	I-Entity
.	O	O	O

We	O	O	O
demonstrate	O	O	O
that	O	O	O
Bxb1	O	O	B-Entity
possesses	O	O	O
highly	O	O	O
efficient	O	O	O
recombinase	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
could	O	O	O
be	O	O	O
used	O	O	O
alone	O	O	O
or	O	O	O
in	O	O	O
conjunction	O	O	O
with	O	O	O
other	O	O	O
currently	O	O	O
available	O	O	O
recombinases	O	O	B-Entity
for	O	O	O
creating	O	O	O
platforms	O	O	O
for	O	O	O
cassette	O	O	O
exchange	O	O	O
of	O	O	O
targeted	O	O	B-Entity
loci	O	O	I-Entity
.	O	O	O

-DOCSTART- (28119222)

Tailor-made	O	O	B-Entity
drug	O	O	I-Entity
carrier	O	O	I-Entity
:	O	O	O
Comparison	O	O	B-Entity
of	O	O	O
formation-dependent	O	O	O
physicochemical	O	O	B-Entity
properties	O	O	I-Entity
within	O	O	O
self-assembled	O	O	B-Entity
aggregates	O	O	B-Entity
for	O	O	O
an	O	O	O
optimal	O	O	B-Entity
drug	O	O	O
carrier	O	O	O

Self-assembled	O	O	B-Entity
surfactant	O	O	B-Entity
aggregates	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
micelles	O	O	B-Entity
and	O	O	O
vesicles	O	O	B-Entity
,	O	O	O
have	O	O	O
been	O	O	O
investigated	O	O	O
for	O	O	O
their	O	O	O
application	O	O	B-Entity
as	O	O	O
drug	O	O	B-Entity
carriers	O	O	I-Entity
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
various	O	O	O
diseases	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
that	O	O	O
decide	O	O	O
which	O	O	O
aggregate	O	O	B-Entity
is	O	O	O
the	O	O	O
best	O	O	B-Entity
drug	O	O	B-Entity
carrier	O	O	I-Entity
for	O	O	O
each	O	O	O
disease	O	O	B-Entity
have	O	O	O
not	O	O	O
yet	O	O	O
been	O	O	O
clarified	O	O	O
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
design	O	O	B-Entity
an	O	O	O
optimal	O	O	B-Entity
drug	O	O	B-Entity
carrier	O	O	I-Entity
for	O	O	O
each	O	O	O
disease	O	O	B-Entity
,	O	O	O
various	O	O	O
kinds	O	O	O
of	O	O	O
self-assembled	O	O	B-Entity
aggregates	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
spherical	O	O	B-Entity
micelles	O	O	I-Entity
,	O	O	O
lens-like	O	O	B-Entity
vesicles	O	O	I-Entity
,	O	O	O
and	O	O	O
tube-like	O	O	B-Entity
vesicles	O	O	I-Entity
,	O	O	O
were	O	O	O
evaluated	O	O	O
by	O	O	O
"	O	O	O
multiple	O	O	B-Entity
techniques	O	O	I-Entity
"	O	O	O
including	O	O	O
dynamic	O	O	B-Entity
light	O	O	I-Entity
scattering	O	O	I-Entity
,	O	O	O
differential	O	O	B-Entity
scanning	O	O	I-Entity
calorimetry	O	O	I-Entity
,	O	O	O
nuclear	O	O	B-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
spectroscopy	O	O	I-Entity
,	O	O	O
and	O	O	O
fluorescence	O	O	B-Entity
measurement	O	O	I-Entity
using	O	O	O
the	O	O	O
Laurdan	O	O	B-Entity
probe	O	O	B-Entity
.	O	O	O

These	O	O	O
studies	O	O	B-Entity
led	O	O	O
to	O	O	O
the	O	O	O
compilation	O	O	O
of	O	O	O
a	O	O	O
database	O	O	B-Entity
on	O	O	O
the	O	O	O
formation-dependent	O	O	O
properties	O	O	O
of	O	O	O
self-assembled	O	O	B-Entity
aggregates	O	O	B-Entity
.	O	O	O

As	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
physicochemical	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
self-assembled	O	O	B-Entity
aggregates	O	O	B-Entity
and	O	O	O
their	O	O	O
functions	O	O	B-Entity
as	O	O	O
drug	O	O	B-Entity
carriers	O	O	I-Entity
have	O	O	O
been	O	O	O
extensively	O	O	O
reported	O	O	O
,	O	O	O
this	O	O	O
database	O	O	B-Entity
can	O	O	O
be	O	O	O
utilized	O	O	O
for	O	O	O
designing	O	O	O
an	O	O	O
optimal	O	O	B-Entity
drug	O	O	B-Entity
carrier	O	O	I-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
a	O	O	O
tailor-made	O	O	B-Entity
drug	O	O	I-Entity
carrier	O	O	I-Entity
.	O	O	O

-DOCSTART- (28122499)

Uridine	O	O	B-Entity
stimulate	O	O	O
laxative	O	O	B-Entity
effect	O	O	B-Entity
in	O	O	O
the	O	O	O
loperamide	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
constipation	O	O	B-Entity
of	O	O	O
SD	O	O	B-Entity
rats	O	O	I-Entity
through	O	O	O
regulation	O	O	B-Entity
of	O	O	O
the	O	O	O
mAChRs	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
and	O	O	O
mucin	O	O	B-Entity
secretion	O	O	O

Uridine	O	O	B-Entity
(	O	O	O
Urd	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
has	O	O	O
been	O	O	O
reported	O	O	B-Entity
as	O	O	O
a	O	O	O
major	O	O	B-Entity
component	O	O	O
of	O	O	O
RNA	O	O	B-Entity
,	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	B-Entity
in	O	O	O
various	O	O	O
biological	O	O	B-Entity
process	O	O	I-Entity
including	O	O	O
neuroprotection	O	O	B-Entity
,	O	O	O
biochemical	O	O	B-Entity
modulation	O	O	I-Entity
and	O	O	O
glycolysis	O	O	B-Entity
,	O	O	O
although	O	O	O
its	O	O	O
role	O	O	O
in	O	O	O
constipation	O	O	B-Entity
has	O	O	O
yet	O	O	O
to	O	O	O
be	O	O	O
established	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
laxative	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
Urd	O	O	B-Entity
on	O	O	O
chronic	O	O	B-Entity
constipation	O	O	B-Entity
.	O	O	O

The	O	O	O
constipation	O	O	B-Entity
phenotypes	O	O	B-Entity
and	O	O	O
their	O	O	O
related	O	O	O
mechanisms	O	O	B-Entity
were	O	O	O
investigated	O	O	B-Entity
in	O	O	O
the	O	O	O
transverse	O	O	B-Entity
colons	O	O	I-Entity
of	O	O	O
SD	O	O	B-Entity
rats	O	O	I-Entity
with	O	O	O
loperamide	O	O	B-Entity
(Lop)-	O	O	O
induced	O	O	B-Entity
constipation	O	O	O
after	O	O	O
treatment	O	O	B-Entity
with	O	O	O
100	O	O	O
mg/kg	O	O	O
of	O	O	O
Urd	O	O	B-Entity
.	O	O	O

The	O	O	O
number	O	O	B-Entity
,	O	O	O
weight	O	O	B-Entity
and	O	O	O
water	O	O	B-Entity
contents	O	O	B-Entity
of	O	O	O
stools	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
Lop	O	O	B-Entity
+	O	O	O
Urd	O	O	B-Entity
treated	O	O	B-Entity
group	O	O	B-Entity
than	O	O	O
the	O	O	O
Lop	O	O	O
+	O	O	O
Vehicle	O	O	B-Entity
treated	O	O	O
group	O	O	O
,	O	O	O
while	O	O	O
food	O	O	B-Entity
intake	O	O	I-Entity
and	O	O	O
water	O	O	B-Entity
consumption	O	O	I-Entity
of	O	O	O
the	O	O	O
same	O	O	O
group	O	O	O
were	O	O	O
maintained	O	O	O
at	O	O	O
a	O	O	O
constant	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

The	O	O	O
thickness	O	O	B-Entity
of	O	O	O
the	O	O	O
mucosa	O	O	B-Entity
layer	O	O	I-Entity
,	O	O	O
muscle	O	O	B-Entity
and	O	O	O
flat	O	O	B-Entity
luminal	O	O	I-Entity
surface	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
goblet	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
paneth	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
lipid	O	O	B-Entity
droplets	O	O	I-Entity
were	O	O	O
enhanced	O	O	B-Entity
in	O	O	O
the	O	O	O
Lop	O	O	B-Entity
+	O	O	O
Urd	O	O	B-Entity
treated	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
muscarinic	O	O	B-Entity
acetylcholine	O	O	I-Entity
receptors	O	O	I-Entity
M2	O	O	I-Entity
and	O	O	O
M3	O	O	B-Entity
(	O	O	O
mAChR	O	O	B-Entity
M2	O	O	I-Entity
and	O	O	O
M3	O	O	O
)	O	O	O
at	O	O	O
the	O	O	O
transcriptional	O	O	B-Entity
and	O	O	O
translational	O	O	B-Entity
level	O	O	B-Entity
was	O	O	O
recovered	O	O	B-Entity
in	O	O	O
the	O	O	O
Lop	O	O	B-Entity
+	O	O	O
Urd	O	O	B-Entity
treated	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
while	O	O	O
some	O	O	O
markers	O	O	B-Entity
such	O	O	O
as	O	O	O
Gα	O	O	B-Entity
and	O	O	O
inositol	O	O	B-Entity
triphosphate	O	O	I-Entity
(	O	O	O
IP3	O	O	B-Entity
)	O	O	O
in	O	O	O
their	O	O	O
downstream	O	O	B-Entity
signaling	O	O	B-Entity
pathway	O	O	I-Entity
were	O	O	O
completely	O	O	O
recovered	O	O	O
by	O	O	O
Urd	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
ability	O	O	O
for	O	O	O
mucin	O	O	B-Entity
secretion	O	O	B-Entity
and	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
membrane	O	O	B-Entity
water	O	O	I-Entity
channel	O	O	I-Entity
(	O	O	O
aquaporine	O	O	B-Entity
8	O	O	I-Entity
,	O	O	O
AQP8	O	O	B-Entity
)	O	O	O
were	O	O	O
increased	O	O	B-Entity
significantly	O	O	B-Entity
in	O	O	O
the	O	O	O
Lop	O	O	B-Entity
+	O	O	O
Urd	O	O	B-Entity
treated	O	O	B-Entity
group	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
Lop	O	O	O
+	O	O	O
Vehicle	O	O	B-Entity
treated	O	O	O
group	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
activity	O	O	B-Entity
of	O	O	O
Urd	O	O	B-Entity
was	O	O	O
confirmed	O	O	O
in	O	O	O
primary	O	O	B-Entity
smooth	O	O	I-Entity
muscle	O	O	I-Entity
of	O	O	O
rat	O	O	B-Entity
intestine	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
pRISMC	O	O	B-Entity
)	O	O	O
based	O	O	O
on	O	O	O
Gα	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
IP3	O	O	B-Entity
concentration	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
provide	O	O	O
the	O	O	O
first	O	O	O
strong	O	O	B-Entity
evidence	O	O	B-Entity
that	O	O	O
Urd	O	O	B-Entity
can	O	O	O
be	O	O	O
considered	O	O	O
an	O	O	O
important	O	O	B-Entity
candidate	O	O	O
for	O	O	O
improving	O	O	B-Entity
chronic	O	O	B-Entity
constipation	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
Lop	O	O	B-Entity
treatment	O	O	B-Entity
in	O	O	O
animal	O	O	B-Entity
models	O	O	I-Entity
.	O	O	O

-DOCSTART- (28123107)

Characterization	O	O	B-Entity
of	O	O	O
Phytochrome	O	O	B-Entity
Interacting	O	O	I-Entity
Factors	O	O	I-Entity
from	O	O	O
the	O	O	O
Moss	O	O	B-Entity
Physcomitrella	O	O	B-Entity
patens	O	O	I-Entity
Illustrates	O	O	O
Conservation	O	O	B-Entity
of	O	O	O
Phytochrome	O	O	B-Entity
Signaling	O	O	I-Entity
Modules	O	O	I-Entity
in	O	O	O
Land	O	O	O
Plants	O	O	O

Across	O	O	O
the	O	O	O
plant	O	O	B-Entity
kingdom	O	O	I-Entity
,	O	O	O
phytochrome	O	O	B-Entity
(	O	O	O
PHY	O	O	B-Entity
)	O	O	O
photoreceptors	O	O	B-Entity
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
during	O	O	O
adaptive	O	O	B-Entity
and	O	O	O
developmental	O	O	O
responses	O	O	B-Entity
to	O	O	I-Entity
light	O	O	I-Entity
.	O	O	O

In	O	O	O
Arabidopsis	O	O	B-Entity
thaliana	O	O	I-Entity
,	O	O	O
light-activated	O	O	O
PHYs	O	O	B-Entity
accumulate	O	O	O
in	O	O	O
the	O	O	O
nucleus	O	O	B-Entity
,	O	O	O
where	O	O	O
they	O	O	O
regulate	O	O	O
downstream	O	O	B-Entity
signaling	O	O	I-Entity
components	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
phytochrome	O	O	B-Entity
interacting	O	O	I-Entity
factors	O	O	I-Entity
(	O	O	O
PIFs	O	O	B-Entity
)	O	O	O
.	O	O	O

PIFs	O	O	B-Entity
are	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
that	O	O	O
act	O	O	O
as	O	O	O
repressors	O	O	B-Entity
of	O	O	O
photomorphogenesis	O	O	B-Entity
;	O	O	O
their	O	O	O
inhibition	O	O	B-Entity
by	O	O	O
PHYs	O	O	B-Entity
leads	O	O	O
to	O	O	O
substantial	O	O	O
changes	O	O	O
in	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
.	O	O	O

The	O	O	O
nuclear	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
PHYs	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
has	O	O	O
so	O	O	O
far	O	O	O
been	O	O	O
investigated	O	O	O
in	O	O	O
only	O	O	O
a	O	O	O
few	O	O	O
non-seed	O	O	B-Entity
plants	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	O
putative	O	O	O
target	O	O	O
genes	O	O	B-Entity
of	O	O	O
PHY	O	O	B-Entity
signaling	O	O	B-Entity
in	O	O	O
the	O	O	O
moss	O	O	B-Entity
Physcomitrella	O	O	B-Entity
patens	O	O	I-Entity
and	O	O	O
found	O	O	O
light-regulated	O	O	B-Entity
genes	O	O	I-Entity
that	O	O	O
are	O	O	O
putative	O	O	O
orthologs	O	O	B-Entity
of	O	O	O
PIF-controlled	O	O	B-Entity
genes	O	O	I-Entity
in	O	O	O
Arabidopsis	O	O	B-Entity
.	O	O	O

Phylogenetic	O	O	B-Entity
analyses	O	O	I-Entity
revealed	O	O	O
that	O	O	O
an	O	O	O
ancestral	O	O	O
PIF-like	O	O	B-Entity
gene	O	O	I-Entity
was	O	O	O
already	O	O	O
present	O	O	O
in	O	O	O
streptophyte	O	O	B-Entity
algae	O	O	I-Entity
,	O	O	O
i.e.	O	O	O
,	O	O	O
before	O	O	O
the	O	O	O
water-to-land	O	O	B-Entity
transition	O	O	I-Entity
of	O	O	O
plants	O	O	B-Entity
.	O	O	O

The	O	O	O
PIF	O	O	B-Entity
homologs	O	O	I-Entity
in	O	O	O
the	O	O	O
genome	O	O	B-Entity
of	O	O	O
P.	O	O	B-Entity
patens	O	O	I-Entity
resemble	O	O	O
Arabidopsis	O	O	B-Entity
PIFs	O	O	B-Entity
in	O	O	O
their	O	O	O
protein	O	O	B-Entity
domain	O	O	I-Entity
structure	O	O	I-Entity
,	O	O	O
molecular	O	O	B-Entity
properties	O	O	I-Entity
,	O	O	O
and	O	O	O
physiological	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
albeit	O	O	O
with	O	O	O
notable	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
motif-dependent	O	O	O
PHY	O	O	B-Entity
interaction	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
P.	O	O	B-Entity
patens	O	O	I-Entity
PIFs	O	O	B-Entity
are	O	O	O
involved	O	O	O
in	O	O	O
PHY	O	O	B-Entity
signaling	O	O	B-Entity
.	O	O	O

The	O	O	O
PHY-PIF	O	O	B-Entity
signaling	O	O	I-Entity
node	O	O	I-Entity
that	O	O	O
relays	O	O	O
light	O	O	B-Entity
signals	O	O	I-Entity
to	O	O	O
target	O	O	O
genes	O	O	B-Entity
has	O	O	O
been	O	O	O
largely	O	O	O
conserved	O	O	O
during	O	O	O
land	O	O	B-Entity
plant	O	O	I-Entity
evolution	O	O	B-Entity
,	O	O	O
with	O	O	O
evidence	O	O	O
of	O	O	O
lineage-specific	O	O	B-Entity
diversification	O	O	I-Entity
.	O	O	O

-DOCSTART- (28125105)

Conditional	O	O	B-Entity
reprogramming	O	O	I-Entity
and	O	O	O
long-term	O	O	B-Entity
expansion	O	O	B-Entity
of	O	O	O
normal	O	O	B-Entity
and	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
from	O	O	O
human	O	O	B-Entity
biospecimens	O	O	O

Historically	O	O	O
,	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
difficult	O	O	O
to	O	O	O
propagate	O	O	B-Entity
cells	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
that	O	O	O
are	O	O	O
derived	O	O	O
directly	O	O	O
from	O	O	O
human	O	O	B-Entity
tumors	O	O	B-Entity
or	O	O	O
healthy	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
preclinical	O	O	B-Entity
models	O	O	I-Entity
are	O	O	O
essential	O	O	O
tools	O	O	O
for	O	O	O
both	O	O	O
the	O	O	O
study	O	O	B-Entity
of	O	O	I-Entity
basic	O	O	I-Entity
cancer	O	O	I-Entity
biology	O	O	I-Entity
and	O	O	O
the	O	O	O
promotion	O	O	O
of	O	O	O
translational	O	O	B-Entity
research	O	O	I-Entity
,	O	O	O
including	O	O	O
drug	O	O	B-Entity
discovery	O	O	I-Entity
and	O	O	O
drug	O	O	B-Entity
target	O	O	I-Entity
identification	O	O	I-Entity
.	O	O	O

This	O	O	O
protocol	O	O	B-Entity
describes	O	O	O
conditional	O	O	B-Entity
reprogramming	O	O	I-Entity
(	O	O	O
CR	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
involves	O	O	O
coculture	O	O	B-Entity
of	O	O	O
irradiated	O	O	O
mouse	O	O	B-Entity
fibroblast	O	O	B-Entity
feeder	O	O	I-Entity
cells	O	O	I-Entity
with	O	O	O
normal	O	O	B-Entity
and	O	O	O
tumor	O	O	B-Entity
human	O	O	B-Entity
epithelial	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
Rho	O	O	B-Entity
kinase	O	O	I-Entity
inhibitor	O	O	B-Entity
(	O	O	O
Y-27632	O	O	B-Entity
)	O	O	O
.	O	O	O

CR	O	O	B-Entity
cells	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
various	O	O	O
applications	O	O	O
,	O	O	O
including	O	O	O
regenerative	O	O	B-Entity
medicine	O	O	I-Entity
,	O	O	O
drug	O	O	B-Entity
sensitivity	O	O	I-Entity
testing	O	O	I-Entity
,	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
profiling	O	O	I-Entity
and	O	O	O
xenograft	O	O	B-Entity
studies	O	O	I-Entity
.	O	O	O

The	O	O	O
method	O	O	B-Entity
requires	O	O	O
a	O	O	O
pathologist	O	O	B-Entity
to	O	O	O
differentiate	O	O	O
healthy	O	O	B-Entity
tissue	O	O	I-Entity
from	O	O	O
tumor	O	O	B-Entity
tissue	O	O	I-Entity
,	O	O	O
and	O	O	O
basic	O	O	B-Entity
tissue	O	O	I-Entity
culture	O	O	I-Entity
skills	O	O	O
.	O	O	O

The	O	O	O
protocol	O	O	B-Entity
can	O	O	O
be	O	O	O
used	O	O	O
with	O	O	O
cells	O	O	B-Entity
derived	O	O	O
from	O	O	O
both	O	O	O
fresh	O	O	B-Entity
and	O	O	O
cryopreserved	O	O	B-Entity
tissue	O	O	I-Entity
samples	O	O	I-Entity
.	O	O	O

As	O	O	O
approximately	O	O	O
1	O	O	O
million	O	O	O
cells	O	O	B-Entity
can	O	O	O
be	O	O	O
generated	O	O	B-Entity
in	O	O	O
7	O	O	O
d	O	O	O
,	O	O	O
the	O	O	O
technique	O	O	B-Entity
is	O	O	O
directly	O	O	O
applicable	O	O	O
to	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
predictive	O	O	B-Entity
medicine	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
can	O	O	O
be	O	O	O
propagated	O	O	B-Entity
indefinitely	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
yet	O	O	O
retain	O	O	O
the	O	O	O
capacity	O	O	B-Entity
to	O	O	O
become	O	O	O
fully	O	O	O
differentiated	O	O	B-Entity
when	O	O	O
placed	O	O	O
into	O	O	O
conditions	O	O	B-Entity
that	O	O	O
mimic	O	O	O
their	O	O	O
natural	O	O	B-Entity
environment	O	O	I-Entity
.	O	O	O

-DOCSTART- (28125454)

Types	O	O	O
of	O	O	O
internal	O	O	B-Entity
facilitation	O	O	I-Entity
activities	O	O	B-Entity
in	O	O	O
hospitals	O	O	B-Entity
implementing	O	O	O
evidence-based	O	O	O
interventions	O	O	O

Implementation	O	O	B-Entity
models	O	O	B-Entity
,	O	O	O
frameworks	O	O	B-Entity
,	O	O	O
and	O	O	O
theories	O	O	B-Entity
recognize	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
activities	O	O	B-Entity
that	O	O	O
facilitate	O	O	O
implementation	O	O	B-Entity
success	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
internal	O	O	B-Entity
facilitation	O	O	I-Entity
activities	O	O	B-Entity
that	O	O	O
hospital	O	O	B-Entity
personnel	O	O	I-Entity
engage	O	O	B-Entity
in	O	O	O
during	O	O	O
implementation	O	O	B-Entity
efforts	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
examine	O	O	O
internal	O	O	B-Entity
facilitation	O	O	B-Entity
activities	O	O	B-Entity
at	O	O	O
10	O	O	O
critical	O	O	B-Entity
access	O	O	I-Entity
hospitals	O	O	I-Entity
in	O	O	O
rural	O	O	B-Entity
Iowa	O	O	I-Entity
during	O	O	O
their	O	O	O
implementation	O	O	B-Entity
of	O	O	O
TeamSTEPPS	O	O	B-Entity
,	O	O	O
a	O	O	O
patient	O	O	B-Entity
safety	O	O	I-Entity
intervention	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
identify	O	O	O
characteristics	O	O	B-Entity
that	O	O	O
distinguish	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
facilitation	O	O	O
activities	O	O	O
.	O	O	O

We	O	O	O
followed	O	O	O
10	O	O	O
critical	O	O	B-Entity
access	O	O	I-Entity
hospitals	O	O	I-Entity
for	O	O	O
2	O	O	O
years	O	O	B-Entity
after	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
implementation	O	O	B-Entity
,	O	O	O
conducting	O	O	O
quarterly	O	O	B-Entity
interviews	O	O	B-Entity
with	O	O	O
key	O	O	B-Entity
informants	O	O	I-Entity
.	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
transcripts	O	O	B-Entity
from	O	O	O
the	O	O	O
first	O	O	O
two	O	O	O
quarters	O	O	B-Entity
,	O	O	O
a	O	O	O
coding	O	O	B-Entity
template	O	O	I-Entity
was	O	O	O
developed	O	O	O
using	O	O	O
inductive	O	O	B-Entity
analyses	O	O	I-Entity
.	O	O	O

The	O	O	O
template	O	O	B-Entity
was	O	O	O
then	O	O	O
applied	O	O	O
deductively	O	O	B-Entity
to	O	O	O
code	O	O	O
all	O	O	O
interview	O	O	B-Entity
transcripts	O	O	B-Entity
.	O	O	O

Using	O	O	O
comparative	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
we	O	O	O
examined	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
that	O	O	O
distinguish	O	O	O
between	O	O	O
the	O	O	O
facilitation	O	O	B-Entity
types	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	O
four	O	O	O
types	O	O	O
of	O	O	O
facilitation	O	O	B-Entity
activities	O	O	B-Entity
-	O	O	O
Leadership	O	O	B-Entity
,	O	O	O
Buy-in	O	O	O
,	O	O	O
Customization	O	O	B-Entity
,	O	O	O
and	O	O	O
Accountability	O	O	B-Entity
.	O	O	O

Individuals	O	O	B-Entity
and	O	O	O
teams	O	O	B-Entity
engaged	O	O	B-Entity
in	O	O	O
different	O	O	O
types	O	O	O
of	O	O	O
facilitation	O	O	B-Entity
activities	O	O	B-Entity
,	O	O	O
both	O	O	O
in	O	O	O
a	O	O	O
planned	O	O	O
and	O	O	O
an	O	O	O
ad	O	O	B-Entity
hoc	O	O	I-Entity
manner	O	O	I-Entity
.	O	O	O

These	O	O	O
activities	O	O	B-Entity
targeted	O	O	O
at	O	O	O
both	O	O	O
people	O	O	B-Entity
and	O	O	O
practices	O	O	B-Entity
and	O	O	O
exhibited	O	O	O
varying	O	O	O
temporal	O	O	B-Entity
patterns	O	O	I-Entity
(	O	O	O
start	O	O	B-Entity
and	O	O	O
peak	O	O	B-Entity
time	O	O	I-Entity
)	O	O	O
.	O	O	O

There	O	O	O
are	O	O	O
four	O	O	O
types	O	O	O
of	O	O	O
facilitation	O	O	B-Entity
activities	O	O	B-Entity
that	O	O	O
hospitals	O	O	B-Entity
engage	O	O	B-Entity
in	O	O	O
while	O	O	O
implementing	O	O	B-Entity
evidence-based	O	O	B-Entity
practices	O	O	I-Entity
,	O	O	O
offering	O	O	O
a	O	O	O
parsimonious	O	O	B-Entity
way	O	O	O
to	O	O	O
characterize	O	O	O
facilitation	O	O	O
activities	O	O	O
.	O	O	O

New	O	O	O
theoretical	O	O	B-Entity
and	O	O	O
empirical	O	O	B-Entity
research	O	O	B-Entity
opportunities	O	O	I-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

Understanding	O	O	O
the	O	O	O
types	O	O	O
of	O	O	O
facilitation	O	O	B-Entity
activities	O	O	B-Entity
and	O	O	O
their	O	O	O
distinguishing	O	O	O
characteristics	O	O	B-Entity
can	O	O	O
assist	O	O	O
managers	O	O	B-Entity
in	O	O	O
planning	O	O	B-Entity
and	O	O	O
executing	O	O	B-Entity
implementations	O	O	B-Entity
of	O	O	O
evidence-based	O	O	B-Entity
interventions	O	O	I-Entity
.	O	O	O

-DOCSTART- (28129043)

Directing	O	O	B-Entity
traffic	O	O	I-Entity
on	O	O	I-Entity
DNA	O	O	I-Entity
-How	O	O	O
transcription	O	O	B-Entity
factors	O	O	I-Entity
relieve	O	O	B-Entity
or	O	O	O
induce	O	O	B-Entity
transcriptional	O	O	O
interference	O	O	O

Transcriptional	O	O	B-Entity
interference	O	O	I-Entity
(	O	O	O
TI	O	O	B-Entity
)	O	O	O
is	O	O	O
increasingly	O	O	O
recognized	O	O	O
as	O	O	O
a	O	O	O
widespread	O	O	B-Entity
mechanism	O	O	O
of	O	O	O
gene	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
particularly	O	O	O
given	O	O	O
the	O	O	O
pervasive	O	O	B-Entity
nature	O	O	I-Entity
of	O	O	O
transcription	O	O	B-Entity
,	O	O	O
both	O	O	O
sense	O	O	B-Entity
and	O	O	O
antisense	O	O	B-Entity
,	O	O	O
across	O	O	O
all	O	O	O
kingdoms	O	O	B-Entity
of	O	O	O
life	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
discuss	O	O	O
how	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
binding	O	O	B-Entity
kinetics	O	O	I-Entity
strongly	O	O	O
influence	O	O	B-Entity
the	O	O	O
ability	O	O	B-Entity
of	O	O	O
a	O	O	O
transcription	O	O	O
factor	O	O	O
to	O	O	O
relieve	O	O	B-Entity
or	O	O	O
induce	O	O	B-Entity
TI	O	O	B-Entity
.	O	O	O

-DOCSTART- (28131759)

Acoustic	O	O	B-Entity
startle	O	O	I-Entity
response	O	O	I-Entity
in	O	O	O
rats	O	O	B-Entity
predicts	O	O	O
inter-individual	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
fear	O	O	B-Entity
extinction	O	O	O

Although	O	O	O
a	O	O	O
large	O	O	O
portion	O	O	O
of	O	O	O
the	O	O	O
population	O	O	B-Entity
is	O	O	O
exposed	O	O	O
to	O	O	O
a	O	O	O
traumatic	O	O	B-Entity
event	O	O	B-Entity
at	O	O	O
some	O	O	O
point	O	O	O
,	O	O	O
only	O	O	O
a	O	O	O
small	O	O	O
percentage	O	O	B-Entity
of	O	O	O
the	O	O	O
population	O	O	O
develops	O	O	O
post-traumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
PTSD	O	O	B-Entity
)	O	O	O
,	O	O	O
suggesting	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
predisposing	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Abnormal	O	O	B-Entity
acoustic	O	O	B-Entity
startle	O	O	I-Entity
response	O	O	I-Entity
(	O	O	O
ASR	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
associated	O	O	O
with	O	O	O
PTSD	O	O	B-Entity
,	O	O	O
implicating	O	O	O
it	O	O	O
as	O	O	O
a	O	O	O
potential	O	O	B-Entity
predictor	O	O	B-Entity
of	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
PTSD	O	O	O
-like	O	O	O
behavior	O	O	B-Entity
.	O	O	O

Since	O	O	O
poor	O	O	O
extinction	O	O	B-Entity
and	O	O	O
retention	O	O	O
of	O	O	O
extinction	O	O	B-Entity
learning	O	O	I-Entity
are	O	O	O
characteristic	O	O	O
of	O	O	O
PTSD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
of	O	O	O
interest	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
abnormal	O	O	B-Entity
ASR	O	O	B-Entity
is	O	O	O
predictive	O	O	O
of	O	O	O
development	O	O	B-Entity
of	O	O	O
such	O	O	O
deficits	O	O	B-Entity
.	O	O	O

To	O	O	O
determine	O	O	O
whether	O	O	O
baseline	O	O	B-Entity
ASR	O	O	B-Entity
has	O	O	O
utility	O	O	O
in	O	O	O
predicting	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
PTSD	O	O	B-Entity
-like	O	O	O
behavior	O	O	B-Entity
,	O	O	O
the	O	O	O
relationship	O	O	O
between	O	O	O
baseline	O	O	O
ASR	O	O	O
and	O	O	O
freezing	O	O	B-Entity
behavior	O	O	I-Entity
following	O	O	O
Pavlovian	O	O	B-Entity
fear	O	O	I-Entity
conditioning	O	O	I-Entity
was	O	O	O
examined	O	O	O
in	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
adult	O	O	B-Entity
,	O	O	O
male	O	O	B-Entity
Sprague-Dawley	O	O	B-Entity
rats	O	O	I-Entity
.	O	O	O

Baseline	O	O	B-Entity
acoustic	O	O	B-Entity
startle	O	O	I-Entity
response	O	O	I-Entity
(	O	O	O
ASR	O	O	B-Entity
)	O	O	O
was	O	O	O
assessed	O	O	O
preceding	O	O	O
exposure	O	O	O
to	O	O	O
a	O	O	O
Pavlovian	O	O	B-Entity
fear	O	O	B-Entity
conditioning	O	O	I-Entity
paradigm	O	O	I-Entity
where	O	O	O
freezing	O	O	B-Entity
behavior	O	O	I-Entity
was	O	O	O
measured	O	O	O
during	O	O	O
fear	O	O	O
conditioning	O	O	O
,	O	O	O
extinction	O	O	B-Entity
training	O	O	B-Entity
,	O	O	O
and	O	O	O
extinction	O	O	O
testing	O	O	B-Entity
.	O	O	O

Although	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
relationship	O	O	O
between	O	O	O
baseline	O	O	B-Entity
ASR	O	O	B-Entity
and	O	O	O
fear	O	O	B-Entity
memory	O	O	B-Entity
following	O	O	O
conditioning	O	O	B-Entity
,	O	O	O
rats	O	O	B-Entity
with	O	O	O
low	O	O	O
baseline	O	O	O
ASR	O	O	O
had	O	O	O
significantly	O	O	O
lower	O	O	O
magnitude	O	O	O
of	O	O	O
retention	O	O	B-Entity
of	O	O	O
the	O	O	O
extinction	O	O	B-Entity
memory	O	O	O
than	O	O	O
rats	O	O	O
with	O	O	O
high	O	O	O
baseline	O	O	O
ASR	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
baseline	O	O	B-Entity
ASR	O	O	B-Entity
has	O	O	O
value	O	O	O
as	O	O	O
a	O	O	O
predictive	O	O	B-Entity
index	O	O	B-Entity
of	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
a	O	O	O
PTSD	O	O	B-Entity
-like	O	O	O
phenotype	O	O	B-Entity
.	O	O	O

-DOCSTART- (28132082)

High	O	O	O
tacrolimus	O	O	B-Entity
blood	O	O	B-Entity
concentrations	O	O	I-Entity
early	O	O	O
after	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
and	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
kidney	O	O	O
injury	O	O	O

Lung	O	O	B-Entity
transplant	O	O	B-Entity
recipients	O	O	I-Entity
often	O	O	O
develop	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
AKI	O	O	B-Entity
)	O	O	O
evolving	O	O	O
into	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CKD	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
immunosuppressant	O	O	B-Entity
tacrolimus	O	O	B-Entity
might	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
emergence	O	O	O
of	O	O	O
AKI	O	O	B-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	O
the	O	O	O
development	O	O	B-Entity
and	O	O	O
recovery	O	O	B-Entity
of	O	O	O
kidney	O	O	B-Entity
injury	O	O	I-Entity
after	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
and	O	O	O
related	O	O	O
AKI	O	O	B-Entity
to	O	O	O
whole-blood	O	O	B-Entity
tacrolimus	O	O	B-Entity
trough	O	O	B-Entity
concentrations	O	O	I-Entity
and	O	O	O
other	O	O	O
factors	O	O	O
causing	O	O	O
kidney	O	O	O
injury	O	O	O
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
studied	O	O	I-Entity
kidney	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
186	O	O	O
lung-transplantation	O	O	B-Entity
patients	O	O	B-Entity
at	O	O	O
the	O	O	O
UMC	O	O	B-Entity
Utrecht	O	O	I-Entity
between	O	O	O
2001	O	O	O
and	O	O	O
2011	O	O	O
.	O	O	O

Kidney	O	O	B-Entity
function	O	O	I-Entity
and	O	O	O
whole-blood	O	O	B-Entity
tacrolimus	O	O	B-Entity
trough	O	O	B-Entity
concentrations	O	O	I-Entity
were	O	O	O
determined	O	O	O
from	O	O	O
day	O	O	B-Entity
1	O	O	O
to	O	O	O
14	O	O	O
and	O	O	O
at	O	O	O
1	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
6	O	O	O
,	O	O	O
and	O	O	O
12	O	O	O
months	O	O	B-Entity
postoperative	O	O	B-Entity
.	O	O	O

Systemic	O	O	B-Entity
inflammatory	O	O	I-Entity
response	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
SIRS	O	O	B-Entity
)	O	O	O
,	O	O	O
septic	O	O	B-Entity
shock	O	O	I-Entity
,	O	O	O
and	O	O	O
nephrotoxic	O	O	B-Entity
medications	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
as	O	O	O
covariates	O	O	B-Entity
for	O	O	O
AKI	O	O	B-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	O
liver	O	O	B-Entity
injury	O	O	I-Entity
and	O	O	O
drug-drug	O	O	B-Entity
interactions	O	O	I-Entity
.	O	O	O

AKI	O	O	B-Entity
was	O	O	O
present	O	O	B-Entity
in	O	O	O
85	O	O	O
(	O	O	O
46	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
.	O	O	O

Tacrolimus	O	O	B-Entity
concentrations	O	O	B-Entity
were	O	O	O
supra-therapeutic	O	O	B-Entity
in	O	O	O
135	O	O	O
of	O	O	O
186	O	O	O
patients	O	O	B-Entity
(	O	O	O
73	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

AKI	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	O
week	O	O	B-Entity
after	O	O	O
transplantation	O	O	B-Entity
was	O	O	O
related	O	O	O
to	O	O	O
supra-therapeutic	O	O	B-Entity
tacrolimus	O	O	B-Entity
concentrations	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
1.55	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
1.06	O	O	O
-	O	O	O
2.27	O	O	O
)	O	O	O
,	O	O	O
≥3	O	O	O
other	O	O	O
nephrotoxic	O	O	B-Entity
drugs	O	O	I-Entity
(	O	O	O
OR	O	O	O
1.96	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.02	O	O	O
-	O	O	O
3.77	O	O	O
)	O	O	O
,	O	O	O
infection	O	O	B-Entity
(	O	O	O
OR	O	O	O
2.48	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.31	O	O	O
-	O	O	O
4.70	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
cystic	O	O	B-Entity
fibrosis	O	O	I-Entity
(	O	O	O
OR	O	O	O
2.17	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.16	O	O	O
-	O	O	O
4.06	O	O	O
)	O	O	O
.	O	O	O

Recovery	O	O	B-Entity
rate	O	O	I-Entity
of	O	O	O
AKI	O	O	B-Entity
was	O	O	O
lower	O	O	O
than	O	O	O
expected	O	O	O
(	O	O	O
19	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
cumulative	O	O	O
incidence	O	O	B-Entity
of	O	O	O
severe	O	O	O
CKD	O	O	B-Entity
at	O	O	O
1	O	O	O
year	O	O	B-Entity
was	O	O	O
15	O	O	O
%	O	O	O
.	O	O	O

After	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
,	O	O	O
AKI	O	O	B-Entity
is	O	O	O
common	O	O	O
and	O	O	O
often	O	O	O
evolves	O	O	O
into	O	O	O
severe	O	O	B-Entity
CKD	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
known	O	O	O
cause	O	O	O
of	O	O	O
morbidity	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Supra-therapeutic	O	O	B-Entity
whole-blood	O	O	B-Entity
tacrolimus	O	O	B-Entity
trough	O	O	B-Entity
concentrations	O	O	I-Entity
are	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
early	O	O	O
onset	O	O	O
of	O	O	O
AKI	O	O	B-Entity
.	O	O	O

Conscientious	O	O	B-Entity
targeting	O	O	B-Entity
tacrolimus	O	O	B-Entity
blood	O	O	B-Entity
concentrations	O	O	I-Entity
might	O	O	O
be	O	O	O
vital	O	O	B-Entity
in	O	O	O
the	O	O	O
early	O	O	B-Entity
phase	O	O	I-Entity
after	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

What	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
this	O	O	O
subject	O	O	O
?	O	O	O

•	O	O	O
Lung	O	O	B-Entity
transplant	O	O	B-Entity
recipients	O	O	I-Entity
often	O	O	O
develop	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
evolving	O	O	O
into	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
increasing	O	O	O
both	O	O	O
morbidity	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
.	O	O	O

•	O	O	O
To	O	O	O
date	O	O	O
,	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
of	O	O	O
kidney	O	O	B-Entity
injury	O	O	I-Entity
after	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
fully	O	O	O
elucidated	O	O	O
.	O	O	O

•	O	O	O
The	O	O	O
immunosuppressant	O	O	B-Entity
tacrolimus	O	O	B-Entity
is	O	O	O
difficult	O	O	O
to	O	O	O
dose	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
the	O	O	O
unstable	O	O	B-Entity
clinical	O	O	B-Entity
setting	O	O	I-Entity
,	O	O	O
and	O	O	O
is	O	O	O
nephrotoxic	O	O	B-Entity
.	O	O	O

•	O	O	O
For	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
supra-therapeutic	O	O	B-Entity
whole-blood	O	O	B-Entity
tacrolimus	O	O	B-Entity
trough	O	O	B-Entity
concentrations	O	O	I-Entity
are	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
emergence	O	O	O
of	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
days	O	O	B-Entity
after	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

•	O	O	O
Supra-therapeutic	O	O	B-Entity
whole-blood	O	O	B-Entity
tacrolimus	O	O	B-Entity
trough	O	O	B-Entity
concentrations	O	O	I-Entity
often	O	O	O
occur	O	O	O
early	O	O	O
after	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
.	O	O	O

•	O	O	O
AKI	O	O	B-Entity
after	O	O	O
lung	O	O	B-Entity
transplantation	O	O	I-Entity
shows	O	O	O
low	O	O	B-Entity
recovery	O	O	B-Entity
rates	O	O	B-Entity
.	O	O	O

-DOCSTART- (28132765)

Zebrafish	O	O	B-Entity
akt2	O	O	B-Entity
is	O	O	O
essential	O	O	B-Entity
for	O	O	O
survival	O	O	B-Entity
,	O	O	O
growth	O	O	B-Entity
,	O	O	O
bone	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
and	O	O	O
glucose	O	O	O
homeostasis	O	O	O

As	O	O	O
one	O	O	O
of	O	O	O
three	O	O	O
akt	O	O	B-Entity
isoforms	O	O	B-Entity
,	O	O	O
akt2	O	O	B-Entity
plays	O	O	O
a	O	O	O
key	O	O	O
role	O	O	B-Entity
in	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
widely	O	O	O
divergent	O	O	O
cellular	O	O	B-Entity
processes	O	O	I-Entity
in	O	O	O
mammals	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
role	O	O	B-Entity
and	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
in	O	O	O
zebrafish	O	O	B-Entity
remain	O	O	O
largely	O	O	O
unknown	O	O	B-Entity
.	O	O	O

To	O	O	O
elucidate	O	O	O
the	O	O	O
function	O	O	B-Entity
of	O	O	O
akt2	O	O	B-Entity
in	O	O	O
zebrafish	O	O	B-Entity
,	O	O	O
we	O	O	O
generated	O	O	B-Entity
zebrafish	O	O	O
lacking	O	O	B-Entity
akt2	O	O	B-Entity
gene	O	O	I-Entity
via	O	O	O
CRISPR/Cas9	O	O	B-Entity
technology	O	O	B-Entity
.	O	O	O

Akt2	O	O	B-Entity
-	O	O	O
null	O	O	B-Entity
zebrafish	O	O	B-Entity
exhibit	O	O	O
partial	O	O	O
lethality	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
growth	O	O	B-Entity
deficiency	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
different	O	O	O
from	O	O	O
those	O	O	O
observed	O	O	O
in	O	O	O
akt2	O	O	B-Entity
-	O	O	O
null	O	O	O
mice	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
akt2	O	O	B-Entity
-	O	O	O
null	O	O	B-Entity
zebrafish	O	O	B-Entity
display	O	O	B-Entity
deficiency	O	O	B-Entity
in	O	O	O
fin	O	O	B-Entity
ray	O	O	I-Entity
development	O	O	I-Entity
,	O	O	O
but	O	O	O
their	O	O	O
cartilage	O	O	B-Entity
is	O	O	O
not	O	O	B-Entity
affected	O	O	I-Entity
.	O	O	O

Similar	O	O	O
to	O	O	O
observations	O	O	B-Entity
in	O	O	O
akt2	O	O	B-Entity
-	O	O	O
null	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
akt2	O	O	O
-	O	O	O
null	O	O	O
zebrafish	O	O	B-Entity
display	O	O	B-Entity
impaired	O	O	B-Entity
glucose	O	O	B-Entity
homeostasis	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
contrast	O	O	O
to	O	O	O
that	O	O	O
in	O	O	O
akt2	O	O	B-Entity
-	O	O	O
null	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
insulin	O	O	B-Entity
level	O	O	I-Entity
is	O	O	O
lower	O	O	B-Entity
in	O	O	O
akt2	O	O	O
-	O	O	O
null	O	O	O
zebrafish	O	O	B-Entity
,	O	O	O
implicating	O	O	O
the	O	O	O
symptoms	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
I	O	O	I-Entity
diabetes	O	O	I-Entity
exhibited	O	O	O
in	O	O	O
akt2	O	O	O
-	O	O	O
null	O	O	O
zebrafish	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
transcriptome	O	O	B-Entity
analysis	O	O	I-Entity
reveals	O	O	B-Entity
that	O	O	O
the	O	O	O
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
metabolism	O	O	B-Entity
and	O	O	O
osteogenesis	O	O	B-Entity
are	O	O	O
disturbed	O	O	O
in	O	O	O
akt2	O	O	B-Entity
-	O	O	O
null	O	O	B-Entity
zebrafish	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
these	O	O	O
data	O	O	B-Entity
not	O	O	O
only	O	O	O
support	O	O	O
an	O	O	O
important	O	O	O
role	O	O	B-Entity
of	O	O	O
akt2	O	O	B-Entity
in	O	O	O
zebrafish	O	O	B-Entity
survival	O	O	B-Entity
,	O	O	O
growth	O	O	B-Entity
,	O	O	O
bone	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
glucose	O	O	B-Entity
homeostasis	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
suggest	O	O	O
that	O	O	O
akt2	O	O	O
has	O	O	O
divergent	O	O	O
functions	O	O	B-Entity
between	O	O	O
mice	O	O	B-Entity
and	O	O	O
zebrafish	O	O	O
,	O	O	O
even	O	O	O
though	O	O	O
they	O	O	O
are	O	O	O
evolutionarily	O	O	B-Entity
conserved	O	O	B-Entity
.	O	O	O

-DOCSTART- (28132824)

Physiological	O	O	B-Entity
Properties	O	O	B-Entity
and	O	O	O
Behavioral	O	O	B-Entity
Correlates	O	O	B-Entity
of	O	O	O
Hippocampal	O	O	B-Entity
Granule	O	O	B-Entity
Cells	O	O	I-Entity
and	O	O	O
Mossy	O	O	O
Cells	O	O	O

The	O	O	O
hippocampal	O	O	B-Entity
dentate	O	O	B-Entity
gyrus	O	O	I-Entity
is	O	O	O
often	O	O	O
viewed	O	O	O
as	O	O	O
a	O	O	O
segregator	O	O	B-Entity
of	O	O	O
upstream	O	O	B-Entity
information	O	O	I-Entity
.	O	O	O

Physiological	O	O	B-Entity
support	O	O	I-Entity
for	O	O	O
such	O	O	O
function	O	O	B-Entity
has	O	O	O
been	O	O	O
hampered	O	O	O
by	O	O	O
a	O	O	O
lack	O	O	B-Entity
of	O	O	O
well-defined	O	O	B-Entity
characteristics	O	O	B-Entity
that	O	O	O
can	O	O	O
identify	O	O	O
granule	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
mossy	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
developed	O	O	O
an	O	O	O
electrophysiology	O	O	B-Entity
-based	O	O	O
classification	O	O	B-Entity
of	O	O	O
dentate	O	O	B-Entity
granule	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
mossy	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
that	O	O	O
we	O	O	O
validated	O	O	O
by	O	O	O
optogenetic	O	O	B-Entity
tagging	O	O	I-Entity
of	O	O	O
mossy	O	O	O
cells	O	O	O
.	O	O	O

Granule	O	O	B-Entity
cells	O	O	I-Entity
exhibited	O	O	O
sparse	O	O	O
firing	O	O	B-Entity
,	O	O	O
had	O	O	O
a	O	O	O
single	O	O	B-Entity
place	O	O	B-Entity
field	O	O	I-Entity
,	O	O	O
and	O	O	O
showed	O	O	O
only	O	O	O
modest	O	O	O
changes	O	O	B-Entity
when	O	O	O
the	O	O	O
mouse	O	O	B-Entity
was	O	O	O
tested	O	O	B-Entity
in	O	O	O
different	O	O	O
mazes	O	O	B-Entity
in	O	O	O
the	O	O	O
same	O	O	O
room	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
mossy	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
more	O	O	O
active	O	O	B-Entity
,	O	O	O
had	O	O	O
multiple	O	O	B-Entity
place	O	O	B-Entity
fields	O	O	I-Entity
and	O	O	O
showed	O	O	O
stronger	O	O	O
remapping	O	O	O
of	O	O	O
place	O	O	O
fields	O	O	O
under	O	O	O
the	O	O	O
same	O	O	O
conditions	O	O	B-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
granule	O	O	B-Entity
cell	O	O	I-Entity
-	O	O	O
mossy	O	O	B-Entity
cell	O	O	I-Entity
synapse	O	O	B-Entity
was	O	O	O
strong	O	O	O
and	O	O	O
facilitating	O	O	O
,	O	O	O
mossy	O	O	B-Entity
cells	O	O	I-Entity
rarely	O	O	O
"	O	O	O
inherited	O	O	O
"	O	O	O
place	O	O	B-Entity
fields	O	O	I-Entity
from	O	O	O
single	O	O	B-Entity
granule	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
granule	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
mossy	O	O	B-Entity
cells	O	O	I-Entity
could	O	O	O
be	O	O	O
modulated	O	O	B-Entity
separately	O	O	O
and	O	O	O
their	O	O	O
joint	O	O	O
action	O	O	B-Entity
may	O	O	O
be	O	O	O
critical	O	O	O
for	O	O	O
pattern	O	O	B-Entity
separation	O	O	I-Entity
.	O	O	O

-DOCSTART- (28134415)

A	O	O	O
primer	O	O	O
on	O	O	O
intraosseous	O	O	B-Entity
access	O	O	I-Entity
:	O	O	O
History	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
considerations	O	O	I-Entity
,	O	O	O
and	O	O	O
current	O	O	O
devices	O	O	O

Intraosseous	O	O	B-Entity
(	O	O	I-Entity
IO	O	O	I-Entity
)	O	O	I-Entity
access	O	O	I-Entity
is	O	O	O
a	O	O	O
method	O	O	B-Entity
recommended	O	O	O
by	O	O	O
the	O	O	O
American	O	O	B-Entity
Heart	O	O	I-Entity
Association	O	O	I-Entity
and	O	O	O
the	O	O	O
European	O	O	B-Entity
Resuscitation	O	O	I-Entity
Council	O	O	I-Entity
to	O	O	O
administer	O	O	B-Entity
resuscitative	O	O	B-Entity
drugs	O	O	I-Entity
and	O	O	O
fluids	O	O	B-Entity
when	O	O	O
intravenous	O	O	B-Entity
(	O	O	I-Entity
IV	O	O	I-Entity
)	O	O	I-Entity
access	O	O	I-Entity
can	O	O	O
not	O	O	O
be	O	O	O
rapidly	O	O	O
or	O	O	O
easily	O	O	O
obtained	O	O	O
.	O	O	O

Many	O	O	O
clinicians	O	O	B-Entity
have	O	O	O
limited	O	O	B-Entity
knowledge	O	O	I-Entity
or	O	O	O
experience	O	O	B-Entity
with	O	O	O
the	O	O	O
IO	O	O	B-Entity
route	O	O	I-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
review	O	O	B-Entity
was	O	O	O
to	O	O	O
provide	O	O	O
the	O	O	O
reader	O	O	O
with	O	O	O
a	O	O	O
succinct	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
the	O	O	O
history	O	O	B-Entity
,	O	O	O
clinical	O	O	B-Entity
considerations	O	O	I-Entity
,	O	O	O
and	O	O	O
devices	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
IO	O	O	B-Entity
access	O	O	I-Entity
.	O	O	O

Narrative	O	O	O
review	O	O	O
.	O	O	O

University-based	O	O	O
academic	O	O	O
research	O	O	O
cell	O	O	O
.	O	O	O

Not	O	O	O
applicable	O	O	O
.	O	O	O

Not	O	O	O
applicable	O	O	O
.	O	O	O

IO	O	O	B-Entity
access	O	O	I-Entity
is	O	O	O
a	O	O	O
lifesaving	O	O	B-Entity
bridge	O	O	I-Entity
to	O	O	O
definitive	O	O	B-Entity
vascular	O	O	I-Entity
access	O	O	I-Entity
that	O	O	O
may	O	O	O
be	O	O	O
considered	O	O	O
when	O	O	O
an	O	O	O
IV	O	O	B-Entity
can	O	O	O
not	O	O	O
be	O	O	O
rapidly	O	O	O
attained	O	O	O
and	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
outcome	O	O	I-Entity
may	O	O	O
be	O	O	O
negatively	O	O	B-Entity
affected	O	O	I-Entity
without	O	O	O
prompt	O	O	B-Entity
circulatory	O	O	I-Entity
access	O	O	I-Entity
.	O	O	O

The	O	O	O
IO	O	O	B-Entity
route	O	O	I-Entity
has	O	O	O
few	O	O	O
contraindications	O	O	B-Entity
for	O	O	O
use	O	O	O
and	O	O	O
a	O	O	O
low	O	O	O
rate	O	O	O
of	O	O	O
serious	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

Multiple	O	O	O
manual	O	O	B-Entity
and	O	O	O
powered	O	O	B-Entity
devices	O	O	I-Entity
that	O	O	O
may	O	O	O
be	O	O	O
placed	O	O	O
in	O	O	O
several	O	O	B-Entity
anatomic	O	O	I-Entity
sites	O	O	I-Entity
are	O	O	O
commercially	O	O	O
available	O	O	O
.	O	O	O

All	O	O	O
clinicians	O	O	B-Entity
who	O	O	O
provide	O	O	O
acute	O	O	B-Entity
care	O	O	I-Entity
or	O	O	O
respond	O	O	O
to	O	O	O
cardiovascular	O	O	B-Entity
emergencies	O	O	B-Entity
should	O	O	O
obtain	O	O	O
training	O	O	B-Entity
and	O	O	O
maintain	O	O	O
proficiency	O	O	B-Entity
in	O	O	O
placing	O	O	O
and	O	O	O
using	O	O	O
IO	O	O	B-Entity
devices	O	O	B-Entity
as	O	O	O
the	O	O	O
IO	O	O	B-Entity
route	O	O	I-Entity
is	O	O	O
recommended	O	O	O
by	O	O	O
the	O	O	O
major	O	O	O
resuscitation	O	O	B-Entity
organizations	O	O	I-Entity
as	O	O	O
the	O	O	O
preferred	O	O	B-Entity
route	O	O	I-Entity
of	O	O	I-Entity
infusion	O	O	I-Entity
when	O	O	O
rapid	O	O	O
,	O	O	O
reliable	O	O	O
IV	O	O	B-Entity
access	O	O	I-Entity
is	O	O	O
unavailable	O	O	O
.	O	O	O

-DOCSTART- (28135569)

C-5a-substituted	O	O	B-Entity
validamine	O	O	I-Entity
type	O	O	I-Entity
glycosidase	O	O	O
inhibitors	O	O	O

A	O	O	O
series	O	O	O
of	O	O	O
N-alkyl	O	O	B-Entity
derivatives	O	O	I-Entity
of	O	O	O
the	O	O	O
D-galactosidase	O	O	B-Entity
inhibitor	O	O	B-Entity
1,4-di-epi-validamine	O	O	B-Entity
featuring	O	O	O
lipophilic	O	O	B-Entity
substituents	O	O	B-Entity
at	O	O	I-Entity
position	O	O	I-Entity
C-5a	O	O	I-Entity
was	O	O	O
prepared	O	O	O
and	O	O	O
screened	O	O	B-Entity
for	O	O	O
their	O	O	O
glycosidase	O	O	B-Entity
inhibitory	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Products	O	O	B-Entity
turned	O	O	O
out	O	O	O
selective	O	O	O
for	O	O	O
β-galactosidases	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
β-glucosidases	O	O	B-Entity
.	O	O	O

-DOCSTART- (28135997)

Exposure	O	O	B-Entity
to	O	O	I-Entity
suicidal	O	O	I-Entity
behaviors	O	O	I-Entity
:	O	O	O
A	O	O	O
common	O	O	O
suicide	O	O	B-Entity
risk	O	O	B-Entity
factor	O	O	I-Entity
or	O	O	O
a	O	O	O
personal	O	O	B-Entity
negative	O	O	B-Entity
life	O	O	I-Entity
event	O	O	I-Entity
?	O	O	O

Numerous	O	O	B-Entity
suicide	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
have	O	O	O
been	O	O	O
proposed	O	O	O
but	O	O	O
not	O	O	O
adequately	O	O	O
validated	O	O	B-Entity
for	O	O	I-Entity
epidemiology	O	O	I-Entity
,	O	O	O
treatment	O	O	B-Entity
and	O	O	O
prevention	O	O	B-Entity
efforts	O	O	I-Entity
.	O	O	O

Exposures	O	O	B-Entity
to	O	O	I-Entity
suicidal	O	O	B-Entity
behaviors	O	O	I-Entity
(	O	O	O
ESB	O	O	B-Entity
)	O	O	O
,	O	O	O
from	O	O	O
family	O	O	B-Entity
and	O	O	O
friend	O	O	B-Entity
suicide	O	O	B-Entity
attempts	O	O	I-Entity
and	O	O	O
completions	O	O	B-Entity
,	O	O	O
were	O	O	O
tested	O	O	O
for	O	O	O
validity	O	O	B-Entity
as	O	O	O
a	O	O	O
suicidal	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
and	O	O	O
also	O	O	O
for	O	O	O
measurement	O	O	B-Entity
and	O	O	O
construct	O	O	O
adequacy	O	O	B-Entity
.	O	O	O

An	O	O	O
anonymous	O	O	B-Entity
online	O	O	B-Entity
survey	O	O	B-Entity
yielded	O	O	O
713	O	O	O
participants	O	O	B-Entity
(	O	O	O
aged	O	O	B-Entity
18	O	O	O
-	O	O	O
71	O	O	O
)	O	O	O
,	O	O	O
who	O	O	O
reported	O	O	O
ESB	O	O	B-Entity
,	O	O	O
completed	O	O	O
the	O	O	O
Suicidal	O	O	B-Entity
Affect-Behavior-Cognition	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
SABCS	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
comprised	O	O	O
a	O	O	O
broad	O	O	O
spectrum	O	O	O
on	O	O	O
those	O	O	O
variables	O	O	B-Entity
.	O	O	O

Tests	O	O	B-Entity
of	O	O	O
dimensionality	O	O	B-Entity
and	O	O	O
internal	O	O	B-Entity
consistency	O	O	I-Entity
showed	O	O	O
the	O	O	O
four	O	O	O
ESB	O	O	B-Entity
variables	O	O	B-Entity
(	O	O	O
attempts	O	O	B-Entity
/	O	O	O
completions	O	O	B-Entity
through	O	O	O
family	O	O	B-Entity
/	O	O	O
friends	O	O	B-Entity
)	O	O	O
were	O	O	O
independent	O	O	B-Entity
and	O	O	O
did	O	O	O
not	O	O	O
form	O	O	O
a	O	O	O
common	O	O	O
factor	O	O	O
or	O	O	O
an	O	O	O
identifiable	O	O	O
ESB	O	O	O
latent	O	O	B-Entity
trait	O	O	B-Entity
.	O	O	O

ESB	O	O	B-Entity
variables	O	O	B-Entity
were	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
associated	O	O	O
with	O	O	O
demographic	O	O	B-Entity
and	O	O	O
psychiatric	O	O	B-Entity
histories	O	O	I-Entity
.	O	O	O

A	O	O	O
battery	O	O	O
of	O	O	O
tests	O	O	B-Entity
revealed	O	O	O
no	O	O	O
meaningful	O	O	O
associations	O	O	B-Entity
between	O	O	O
ESB	O	O	B-Entity
and	O	O	O
total	O	O	O
suicidality	O	O	B-Entity
or	O	O	O
suicide	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
(	O	O	O
social	O	O	B-Entity
support	O	O	I-Entity
,	O	O	O
depression	O	O	B-Entity
,	O	O	O
anxiety	O	O	B-Entity
,	O	O	O
stress	O	O	B-Entity
,	O	O	O
satisfaction	O	O	B-Entity
with	O	O	I-Entity
life	O	O	I-Entity
and	O	O	O
emotional	O	O	B-Entity
stability	O	O	I-Entity
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
in	O	O	O
contrast	O	O	O
to	O	O	O
previous	O	O	O
reports	O	O	B-Entity
,	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
200	O	O	O
;	O	O	O
aged	O	O	B-Entity
18	O	O	O
-	O	O	O
20	O	O	O
)	O	O	O
showed	O	O	O
no	O	O	O
increased	O	O	B-Entity
suicidality	O	O	B-Entity
due	O	O	O
to	O	O	O
ESB	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
showed	O	O	O
no	O	O	O
validity	O	O	B-Entity
for	O	O	O
ESB	O	O	B-Entity
as	O	O	O
a	O	O	O
common	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
suicidality	O	O	B-Entity
or	O	O	O
other	O	O	O
psychopathology	O	O	B-Entity
,	O	O	O
or	O	O	O
as	O	O	O
a	O	O	O
latent	O	O	B-Entity
trait	O	O	B-Entity
.	O	O	O

ESB	O	O	B-Entity
showed	O	O	O
evidence	O	O	B-Entity
as	O	O	O
a	O	O	O
personal	O	O	B-Entity
negative	O	O	B-Entity
life	O	O	I-Entity
event	O	O	I-Entity
with	O	O	O
individual	O	O	B-Entity
effects	O	O	B-Entity
and	O	O	O
interpretations	O	O	B-Entity
.	O	O	O

-DOCSTART- (28137262)

Direct	O	O	B-Entity
anterior	O	O	I-Entity
approach	O	O	I-Entity
for	O	O	O
total	O	O	B-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
with	O	O	O
a	O	O	O
novel	O	O	O
mobile	O	O	B-Entity
traction	O	O	I-Entity
table	O	O	I-Entity
-a	O	O	O
prospective	O	O	O
cohort	O	O	O
study	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
clarify	O	O	O
the	O	O	O
safety	O	O	O
and	O	O	O
efficacy	O	O	O
of	O	O	O
total	O	O	B-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
via	O	O	O
the	O	O	O
direct	O	O	B-Entity
anterior	O	O	I-Entity
approach	O	O	I-Entity
in	O	O	O
the	O	O	O
supine	O	O	B-Entity
position	O	O	I-Entity
with	O	O	O
a	O	O	O
novel	O	O	O
mobile	O	O	B-Entity
traction	O	O	I-Entity
table	O	O	I-Entity
.	O	O	O

The	O	O	O
first	O	O	O
experience	O	O	O
of	O	O	O
consecutive	O	O	B-Entity
surgeries	O	O	I-Entity
by	O	O	O
a	O	O	O
single	O	O	B-Entity
surgeon	O	O	I-Entity
using	O	O	O
the	O	O	O
direct	O	O	B-Entity
anterior	O	O	I-Entity
approach	O	O	I-Entity
with	O	O	O
a	O	O	O
traction	O	O	B-Entity
table	O	O	I-Entity
is	O	O	O
described	O	O	O
with	O	O	O
a	O	O	O
two-year	O	O	O
follow-up	O	O	B-Entity
period	O	O	O
.	O	O	O

Of	O	O	O
121	O	O	O
patients	O	O	B-Entity
,	O	O	O
100	O	O	O
patients	O	O	O
without	O	O	O
previous	O	O	B-Entity
hip	O	O	I-Entity
surgeries	O	O	I-Entity
,	O	O	O
severe	O	O	B-Entity
deformity	O	O	I-Entity
,	O	O	O
or	O	O	O
cemented	O	O	B-Entity
implants	O	O	I-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
comprising	O	O	O
the	O	O	O
first	O	O	O
50	O	O	O
patients	O	O	O
and	O	O	O
the	O	O	O
second	O	O	O
50	O	O	O
patients	O	O	O
.	O	O	O

The	O	O	O
implant	O	O	B-Entity
survival	O	O	I-Entity
rate	O	O	I-Entity
was	O	O	O
99	O	O	O
%	O	O	O
at	O	O	O
the	O	O	O
two-year	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Revision	O	O	B-Entity
surgery	O	O	I-Entity
was	O	O	O
required	O	O	O
for	O	O	O
periprosthetic	O	O	B-Entity
femoral	O	O	B-Entity
fracture	O	O	I-Entity
in	O	O	O
one	O	O	O
patient	O	O	B-Entity
.	O	O	O

The	O	O	O
complication	O	O	B-Entity
rate	O	O	B-Entity
possibly	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
traction	O	O	B-Entity
table	O	O	I-Entity
was	O	O	O
5	O	O	O
%	O	O	O
(	O	O	O
5	O	O	O
patients	O	O	B-Entity
):	O	O	O
three	O	O	O
anterior	O	O	B-Entity
dislocations	O	O	I-Entity
,	O	O	O
one	O	O	O
periprosthetic	O	O	B-Entity
femoral	O	O	B-Entity
fracture	O	O	I-Entity
,	O	O	O
and	O	O	O
one	O	O	O
intraoperative	O	O	B-Entity
perforation	O	O	I-Entity
caused	O	O	O
by	O	O	O
femoral	O	O	B-Entity
rasping	O	O	I-Entity
.	O	O	O

The	O	O	O
complication	O	O	B-Entity
rate	O	O	B-Entity
tended	O	O	O
to	O	O	O
decrease	O	O	B-Entity
in	O	O	O
the	O	O	O
second	O	O	O
group	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
first	O	O	O
group	O	O	O
(	O	O	O
4	O	O	O
%	O	O	O
versus	O	O	O
6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Mean	O	O	B-Entity
surgical	O	O	I-Entity
time	O	O	I-Entity
(	O	O	O
72.0	O	O	O
minutes	O	O	O
versus	O	O	O
82.5	O	O	O
min	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.027	O	O	O
)	O	O	O
,	O	O	O
rate	O	O	B-Entity
of	O	O	O
allogeneic	O	O	B-Entity
blood	O	O	I-Entity
transfusion	O	O	I-Entity
(	O	O	O
2	O	O	O
%	O	O	O
versus	O	O	O
24	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
cup	O	O	B-Entity
alignment	O	O	I-Entity
in	O	O	O
the	O	O	O
safe	O	O	B-Entity
zone	O	O	I-Entity
(	O	O	O
100	O	O	O
%	O	O	O
versus	O	O	O
88	O	O	O
%	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.027	O	O	O
)	O	O	O
were	O	O	O
significantly	O	O	O
improved	O	O	O
in	O	O	O
the	O	O	O
second	O	O	O
group	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
first	O	O	O
group	O	O	O
.	O	O	O

The	O	O	O
direct	O	O	B-Entity
anterior	O	O	I-Entity
approach	O	O	I-Entity
with	O	O	O
a	O	O	O
novel	O	O	O
mobile	O	O	B-Entity
traction	O	O	I-Entity
table	O	O	I-Entity
showed	O	O	O
a	O	O	O
positive	O	O	B-Entity
learning	O	O	I-Entity
curve	O	O	I-Entity
for	O	O	O
surgical	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
rate	O	O	B-Entity
of	O	O	O
allogeneic	O	O	B-Entity
blood	O	O	I-Entity
transfusion	O	O	I-Entity
,	O	O	O
and	O	O	O
cup	O	O	B-Entity
alignment	O	O	I-Entity
in	O	O	O
the	O	O	O
safe	O	O	B-Entity
zone	O	O	I-Entity
.	O	O	O

-DOCSTART- (28137449)

The	O	O	O
binding	O	O	B-Entity
orientations	O	O	B-Entity
of	O	O	O
structurally	O	O	B-Entity
-related	O	O	O
ligands	O	O	B-Entity
can	O	O	O
differ	O	O	B-Entity
;	O	O	O
A	O	O	O
cautionary	O	O	O
note	O	O	O

Crystal	O	O	B-Entity
structures	O	O	I-Entity
can	O	O	O
identify	O	O	O
ligand-receptor	O	O	B-Entity
interactions	O	O	I-Entity
and	O	O	O
assist	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
novel	O	O	O
therapeutics	O	O	B-Entity
,	O	O	O
but	O	O	O
experimental	O	O	B-Entity
challenges	O	O	O
sometimes	O	O	O
necessitate	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
homologous	O	O	B-Entity
proteins	O	O	I-Entity
.	O	O	O

Tropisetron	O	O	B-Entity
is	O	O	O
an	O	O	O
orthosteric	O	O	B-Entity
ligand	O	O	I-Entity
at	O	O	O
both	O	O	O
5-HT3	O	O	B-Entity
and	O	O	O
α7	O	O	B-Entity
nACh	O	O	I-Entity
receptors	O	O	I-Entity
and	O	O	O
its	O	O	O
binding	O	O	B-Entity
orientation	O	O	B-Entity
has	O	O	O
been	O	O	O
determined	O	O	O
in	O	O	O
the	O	O	O
structural	O	O	B-Entity
homologue	O	O	I-Entity
AChBP	O	O	B-Entity
(	O	O	O
pdbid	O	O	O
:	O	O	O
2WNC	O	O	O
)	O	O	O
.	O	O	O

Co-crystallisation	O	O	B-Entity
with	O	O	O
a	O	O	O
structurally	O	O	B-Entity
-related	O	O	O
ligand	O	O	B-Entity
,	O	O	O
granisetron	O	O	B-Entity
,	O	O	O
reveals	O	O	O
an	O	O	O
almost	O	O	O
identical	O	O	B-Entity
orientation	O	O	B-Entity
(	O	O	O
pdbid	O	O	O
;	O	O	O
2YME	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
>	O	O	O
1000-fold	O	O	O
difference	O	O	B-Entity
in	O	O	O
the	O	O	O
affinity	O	O	B-Entity
of	O	O	O
tropisetron	O	O	B-Entity
at	O	O	O
5-HT3	O	O	B-Entity
versus	O	O	O
α7	O	O	B-Entity
nACh	O	O	I-Entity
receptors	O	O	I-Entity
,	O	O	O
and	O	O	O
α7	O	O	O
nACh	O	O	O
receptors	O	O	O
do	O	O	O
not	O	O	B-Entity
bind	O	O	B-Entity
granisetron	O	O	B-Entity
.	O	O	O

These	O	O	O
striking	O	O	O
pharmacological	O	O	B-Entity
differences	O	O	B-Entity
prompt	O	O	O
questions	O	O	O
about	O	O	O
which	O	O	O
receptor	O	O	B-Entity
the	O	O	O
crystal	O	O	B-Entity
structures	O	O	I-Entity
most	O	O	O
closely	O	O	O
represent	O	O	O
and	O	O	O
whether	O	O	O
the	O	O	O
ligand	O	O	B-Entity
orientations	O	O	B-Entity
are	O	O	O
correct	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
probe	O	O	O
the	O	O	O
binding	O	O	B-Entity
orientation	O	O	B-Entity
of	O	O	O
tropisetron	O	O	B-Entity
and	O	O	O
granisetron	O	O	B-Entity
at	O	O	O
5-HT3	O	O	B-Entity
receptors	O	O	I-Entity
by	O	O	O
in	O	O	B-Entity
silico	O	O	I-Entity
modelling	O	O	B-Entity
and	O	O	O
docking	O	O	B-Entity
,	O	O	O
radioligand	O	O	B-Entity
binding	O	O	I-Entity
on	O	O	O
cysteine	O	O	B-Entity
-	O	O	O
substituted	O	O	B-Entity
5-HT3	O	O	B-Entity
receptor	O	O	I-Entity
mutants	O	O	B-Entity
transiently	O	O	O
expressed	O	O	B-Entity
in	O	O	O
HEK	O	O	B-Entity
293	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
and	O	O	O
synthetic	O	O	B-Entity
modification	O	O	I-Entity
of	O	O	O
the	O	O	O
ligands	O	O	B-Entity
.	O	O	O

For	O	O	O
15	O	O	O
of	O	O	O
the	O	O	O
23	O	O	O
cysteine	O	O	B-Entity
substitutions	O	O	B-Entity
,	O	O	O
the	O	O	O
effects	O	O	B-Entity
on	O	O	O
tropisetron	O	O	B-Entity
and	O	O	O
granisetron	O	O	B-Entity
were	O	O	O
different	O	O	O
.	O	O	O

Structure-activity	O	O	B-Entity
relationships	O	O	I-Entity
on	O	O	O
synthesised	O	O	O
derivatives	O	O	O
of	O	O	O
both	O	O	O
ligands	O	O	B-Entity
were	O	O	O
also	O	O	O
consistent	O	O	O
with	O	O	O
different	O	O	B-Entity
orientations	O	O	B-Entity
,	O	O	O
revealing	O	O	B-Entity
that	O	O	O
contrary	O	O	O
to	O	O	O
the	O	O	O
crystallographic	O	O	B-Entity
evidence	O	O	B-Entity
from	O	O	O
AChBP	O	O	B-Entity
,	O	O	O
the	O	O	O
two	O	O	O
ligands	O	O	O
adopt	O	O	O
different	O	O	O
orientations	O	O	O
in	O	O	O
the	O	O	O
5-HT3	O	O	B-Entity
receptor	O	O	I-Entity
binding	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
show	O	O	O
that	O	O	O
even	O	O	O
quite	O	O	O
structurally	O	O	B-Entity
similar	O	O	O
molecules	O	O	B-Entity
can	O	O	O
adopt	O	O	O
different	O	O	O
orientations	O	O	B-Entity
in	O	O	O
the	O	O	O
same	O	O	O
binding	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
and	O	O	O
that	O	O	O
caution	O	O	O
may	O	O	O
be	O	O	O
needed	O	O	O
when	O	O	O
using	O	O	O
homologous	O	O	B-Entity
proteins	O	O	I-Entity
to	O	O	O
predict	O	O	O
ligand	O	O	B-Entity
binding	O	O	I-Entity
.	O	O	O

-DOCSTART- (28138631)

Pancreatic	O	O	B-Entity
neuroendocrine	O	O	B-Entity
cancer	O	O	I-Entity
with	O	O	O
liver	O	O	B-Entity
metastases	O	O	I-Entity
and	O	O	O
multiple	O	O	B-Entity
peritoneal	O	O	I-Entity
metastases	O	O	I-Entity
:	O	O	O
report	O	O	O
of	O	O	O
one	O	O	O
case	O	O	O

Pancreatic	O	O	B-Entity
neuroendocrine	O	O	B-Entity
tumor	O	O	I-Entity
(	O	O	O
pNET	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	O
pancreatic	O	O	B-Entity
tumor	O	O	I-Entity
,	O	O	O
with	O	O	O
its	O	O	O
incidence	O	O	O
showing	O	O	O
a	O	O	O
rising	O	O	O
trend	O	O	O
in	O	O	O
recent	O	O	O
years	O	O	O
.	O	O	O

Most	O	O	O
of	O	O	O
its	O	O	O
distant	O	O	B-Entity
metastases	O	O	I-Entity
are	O	O	O
found	O	O	B-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	O
describes	O	O	O
a	O	O	O
59-year-old	O	O	O
male	O	O	B-Entity
patient	O	O	I-Entity
with	O	O	O
pNET	O	O	B-Entity
with	O	O	O
liver	O	O	B-Entity
metastasis	O	O	I-Entity
and	O	O	O
multiple	O	O	B-Entity
abdominal	O	O	I-Entity
metastases	O	O	I-Entity
,	O	O	O
focusing	O	O	O
on	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
this	O	O	O
tumor	O	O	B-Entity
in	O	O	O
its	O	O	O
advanced	O	O	B-Entity
stage	O	O	I-Entity
.	O	O	O

-DOCSTART- (28139296)

Lignans	O	O	B-Entity
from	O	O	O
the	O	O	O
fruits	O	O	B-Entity
of	O	O	O
Schisandra	O	O	B-Entity
chinensis	O	O	I-Entity
(	O	O	I-Entity
Turcz	O	O	I-Entity
.	O	O	I-Entity
)	O	O	I-Entity
Baill	O	O	I-Entity
inhibit	O	O	B-Entity
proprotein	O	O	B-Entity
convertase	O	O	I-Entity
subtilisin/kexin	O	O	I-Entity
type	O	O	I-Entity
9	O	O	I-Entity
expression	O	O	O

Bioactivity-guided	O	O	B-Entity
fractionation	O	O	I-Entity
of	O	O	O
the	O	O	O
fruits	O	O	B-Entity
of	O	O	O
Schisandra	O	O	B-Entity
chinensis	O	O	I-Entity
,	O	O	O
using	O	O	O
the	O	O	O
proprotein	O	O	B-Entity
convertase	O	O	I-Entity
subtilisin-kexin	O	O	I-Entity
type	O	O	I-Entity
9	O	O	I-Entity
(	O	O	O
PCSK9	O	O	B-Entity
)	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
screening	O	O	B-Entity
assay	O	O	I-Entity
,	O	O	O
led	O	O	O
to	O	O	O
isolation	O	O	B-Entity
of	O	O	O
two	O	O	B-Entity
previously	O	O	B-Entity
unknown	O	O	I-Entity
lignans	O	O	B-Entity
,	O	O	O
14-tigloylschinlignan	O	O	B-Entity
D	O	O	I-Entity
and	O	O	O
rel-(7R	O	O	B-Entity
,	O	O	I-Entity
8R	O	O	I-Entity
,	O	O	I-Entity
7'R	O	O	I-Entity
,	O	O	I-Entity
8'R)-manglisin	O	O	I-Entity
E	O	O	I-Entity
,	O	O	O
along	O	O	O
with	O	O	O
28	O	O	O
known	O	O	O
compounds	O	O	O
.	O	O	O

All	O	O	O
structures	O	O	B-Entity
were	O	O	O
established	O	O	B-Entity
by	O	O	O
NMR	O	O	B-Entity
spectroscopic	O	O	I-Entity
data	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
CD	O	O	B-Entity
and	O	O	O
MS	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

All	O	O	O
isolates	O	O	O
were	O	O	O
tested	O	O	B-Entity
for	O	O	O
their	O	O	O
inhibitory	O	O	B-Entity
activities	O	O	B-Entity
on	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
PCSK9	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
tested	O	O	B-Entity
compounds	O	O	O
,	O	O	O
four	O	O	B-Entity
of	O	O	O
the	O	O	O
compounds	O	O	O
rel-(7R	O	O	B-Entity
,	O	O	I-Entity
8R	O	O	I-Entity
,	O	O	I-Entity
7'R	O	O	I-Entity
,	O	O	I-Entity
8'R)-manglisin	O	O	I-Entity
E	O	O	I-Entity
,	O	O	O
(-)-schisandrin	O	O	B-Entity
C	O	O	I-Entity
,	O	O	O
schinlignan	O	O	B-Entity
D	O	O	I-Entity
,	O	O	O
and	O	O	O
(+)-schisandrol	O	O	B-Entity
B	O	O	I-Entity
potently	O	O	O
inhibited	O	O	B-Entity
PCSK9	O	O	B-Entity
mRNA	O	O	B-Entity
expression	O	O	I-Entity
with	O	O	O
IC50	O	O	B-Entity
values	O	O	O
of	O	O	O
3.15	O	O	O
,	O	O	O
3.85	O	O	O
,	O	O	O
0.36	O	O	O
,	O	O	O
and	O	O	O
1.10	O	O	O
μM	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
schinlignan	O	O	B-Entity
D	O	O	I-Entity
and	O	O	O
(+)-schisandrol	O	O	B-Entity
B	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
suppress	O	O	B-Entity
PCSK9	O	O	B-Entity
protein	O	O	B-Entity
expressions	O	O	I-Entity
and	O	O	O
schinlignan	O	O	O
D	O	O	O
deemed	O	O	O
to	O	O	O
increase	O	O	O
low	O	O	B-Entity
density	O	O	I-Entity
lipoprotein	O	O	I-Entity
receptor	O	O	I-Entity
expression	O	O	B-Entity
.	O	O	O

-DOCSTART- (28139371)

A	O	O	O
comparison	O	O	O
of	O	O	O
outcomes	O	O	B-Entity
in	O	O	O
morbidly	O	O	B-Entity
obese	O	O	B-Entity
,	O	O	O
obese	O	O	O
and	O	O	O
non-obese	O	O	B-Entity
patients	O	O	B-Entity
undergoing	O	O	O
primary	O	O	B-Entity
total	O	O	I-Entity
knee	O	O	I-Entity
and	O	O	O
total	O	O	O
hip	O	O	O
arthroplasty	O	O	O

Obesity	O	O	B-Entity
is	O	O	O
a	O	O	O
growing	O	O	O
public	O	O	B-Entity
health	O	O	B-Entity
issue	O	O	I-Entity
with	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
morbid	O	O	B-Entity
obesity	O	O	I-Entity
,	O	O	I-Entity
(	O	O	I-Entity
Body	O	O	I-Entity
Mass	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	I-Entity
BMI	O	O	I-Entity
)	O	O	I-Entity
≥	O	O	I-Entity
40	O	O	I-Entity
kg/m(2	O	O	I-Entity
)	O	O	I-Entity
)	O	O	I-Entity
increasing	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
some	O	O	O
evidence	O	O	B-Entity
these	O	O	O
patients	O	O	B-Entity
have	O	O	O
more	O	O	O
peri-	O	O	B-Entity
and	O	O	I-Entity
post-operative	O	O	I-Entity
complications	O	O	I-Entity
and	O	O	O
poorer	O	O	B-Entity
outcomes	O	O	I-Entity
when	O	O	O
undergoing	O	O	O
arthroplasty	O	O	B-Entity
procedures	O	O	I-Entity
.	O	O	O

This	O	O	O
audit	O	O	O
aimed	O	O	O
to	O	O	O
determine	O	O	O
and	O	O	O
compare	O	O	O
the	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
non-obese	O	O	B-Entity
,	O	O	O
obese	O	O	B-Entity
and	O	O	O
morbidly	O	O	B-Entity
obese	O	O	I-Entity
patients	O	O	B-Entity
undergoing	O	O	O
arthroplasty	O	O	B-Entity
at	O	O	O
our	O	O	O
institution	O	O	B-Entity
.	O	O	O

This	O	O	O
was	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
audit	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
from	O	O	O
our	O	O	O
institution	O	O	B-Entity
who	O	O	O
had	O	O	O
undergone	O	O	O
total	O	O	B-Entity
knee	O	O	I-Entity
(	O	O	O
TKA	O	O	B-Entity
)	O	O	O
or	O	O	O
total	O	O	B-Entity
hip	O	O	I-Entity
arthroplasty	O	O	I-Entity
(	O	O	O
THA	O	O	B-Entity
)	O	O	O
in	O	O	O
2009	O	O	O
.	O	O	O

Data	O	O	B-Entity
collected	O	O	B-Entity
were	O	O	O
:	O	O	O
age	O	O	B-Entity
,	O	O	O
gender	O	O	B-Entity
,	O	O	O
BMI	O	O	B-Entity
,	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
(	O	O	O
LOS	O	O	B-Entity
)	O	O	O
,	O	O	O
Oxford	O	O	B-Entity
knee	O	O	I-Entity
or	O	O	O
hip	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
OKS	O	O	B-Entity
/	O	O	O
OHS	O	O	B-Entity
)	O	O	O
,	O	O	O
satisfaction	O	O	B-Entity
and	O	O	O
complications	O	O	B-Entity
up	O	O	O
to	O	O	O
two	O	O	O
years	O	O	B-Entity
post	O	O	B-Entity
operation	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
three	O	O	O
groups	O	O	B-Entity
:	O	O	O
BMI	O	O	B-Entity
<	O	O	I-Entity
30	O	O	I-Entity
,	O	O	O
BMI	O	O	B-Entity
30	O	O	I-Entity
-	O	O	I-Entity
40	O	O	I-Entity
and	O	O	O
BMI	O	O	B-Entity
>	O	O	I-Entity
40	O	O	I-Entity
.	O	O	O

Outcomes	O	O	B-Entity
for	O	O	O
each	O	O	O
BMI	O	O	B-Entity
group	O	O	B-Entity
were	O	O	O
compared	O	O	O
.	O	O	O

1014	O	O	O
TKA	O	O	B-Entity
and	O	O	O
906	O	O	O
THA	O	O	B-Entity
operations	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

When	O	O	O
compared	O	O	O
to	O	O	O
obese	O	O	B-Entity
and	O	O	O
non-obese	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
morbidly	O	O	B-Entity
obese	O	O	I-Entity
patients	O	O	O
undergoing	O	O	O
TKA	O	O	B-Entity
had	O	O	O
a	O	O	O
mean	O	O	O
LOS	O	O	B-Entity
one	O	O	O
day	O	O	B-Entity
longer	O	O	O
,	O	O	O
a	O	O	O
mean	O	O	B-Entity
OKS	O	O	I-Entity
four	O	O	O
points	O	O	O
lower	O	O	O
and	O	O	O
higher	O	O	O
rates	O	O	O
of	O	O	O
postoperative	O	O	B-Entity
problems	O	O	I-Entity
,	O	O	O
37	O	O	O
%	O	O	O
vs.	O	O	O
21	O	O	O
%	O	O	O
.	O	O	O

For	O	O	O
THA	O	O	B-Entity
patients	O	O	B-Entity
there	O	O	O
was	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
LOS	O	O	B-Entity
,	O	O	O
OHS	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
two	O	O	O
points	O	O	O
lower	O	O	O
for	O	O	O
each	O	O	O
increasing	O	O	B-Entity
BMI	O	O	B-Entity
category	O	O	B-Entity
and	O	O	O
postoperative	O	O	B-Entity
problems	O	O	I-Entity
increase	O	O	B-Entity
from	O	O	O
25	O	O	O
%	O	O	O
for	O	O	O
non-obese	O	O	B-Entity
to	O	O	O
31	O	O	O
%	O	O	O
for	O	O	O
obese	O	O	B-Entity
and	O	O	O
38	O	O	O
%	O	O	O
for	O	O	O
morbidly	O	O	B-Entity
obese	O	O	I-Entity
patients	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
will	O	O	O
be	O	O	O
useful	O	O	O
in	O	O	O
informing	O	O	O
obese	O	O	B-Entity
patients	O	O	B-Entity
of	O	O	O
their	O	O	O
potential	O	O	O
outcomes	O	O	B-Entity
following	O	O	O
TKA	O	O	B-Entity
or	O	O	O
THA	O	O	B-Entity
.	O	O	O

These	O	O	O
patients	O	O	B-Entity
can	O	O	O
then	O	O	O
make	O	O	O
a	O	O	O
more	O	O	O
informed	O	O	O
choice	O	O	O
before	O	O	O
proceeding	O	O	O
with	O	O	O
arthroplasty	O	O	B-Entity
.	O	O	O

-DOCSTART- (28139665)

Vitamin	O	O	B-Entity
D	O	O	I-Entity
Receptor	O	O	I-Entity
Activator	O	O	I-Entity
Use	O	O	O
and	O	O	O
Cause-specific	O	O	B-Entity
Death	O	O	I-Entity
among	O	O	O
dialysis	O	O	B-Entity
Patients	O	O	B-Entity
:	O	O	O
a	O	O	O
Nationwide	O	O	B-Entity
Cohort	O	O	I-Entity
Study	O	O	I-Entity
using	O	O	O
Coarsened	O	O	O
Exact	O	O	O
Matching	O	O	O

Vitamin	O	O	B-Entity
D	O	O	I-Entity
receptor	O	O	I-Entity
activators	O	O	I-Entity
(	O	O	O
VDRA	O	O	B-Entity
)	O	O	O
may	O	O	O
exert	O	O	O
pleiotropic	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
malignancy	O	O	B-Entity
,	O	O	O
and	O	O	O
infections	O	O	B-Entity
among	O	O	O
dialysis	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
but	O	O	O
recent	O	O	O
studies	O	O	O
have	O	O	O
mainly	O	O	O
focused	O	O	O
on	O	O	O
cardiovascular	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

Among	O	O	O
8,675	O	O	O
patients	O	O	B-Entity
who	O	O	O
started	O	O	O
dialysis	O	O	B-Entity
in	O	O	O
2007	O	O	O
and	O	O	O
who	O	O	B-Entity
survived	O	O	I-Entity
until	O	O	O
January	O	O	O
1	O	O	O
,	O	O	O
2010	O	O	O
,	O	O	O
listed	O	O	O
in	O	O	O
the	O	O	O
Renal	O	O	B-Entity
Data	O	O	I-Entity
Registry	O	O	I-Entity
of	O	O	O
the	O	O	O
Japanese	O	O	B-Entity
Society	O	O	I-Entity
for	O	O	O
Dialysis	O	O	B-Entity
Therapy	O	O	I-Entity
,	O	O	O
5,365	O	O	O
VDRA	O	O	B-Entity
users	O	O	O
were	O	O	O
matched	O	O	O
to	O	O	O
3,203	O	O	O
non-users	O	O	O
based	O	O	O
on	O	O	O
clinically	O	O	B-Entity
relevant	O	O	I-Entity
variables	O	O	I-Entity
at	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
2009	O	O	O
using	O	O	O
the	O	O	O
coarsened	O	O	B-Entity
exact	O	O	I-Entity
matching	O	O	I-Entity
procedure	O	O	I-Entity
.	O	O	O

Until	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2011	O	O	O
,	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
1,128	O	O	O
deaths	O	O	B-Entity
occurred	O	O	O
,	O	O	O
of	O	O	O
which	O	O	O
468	O	O	O
(	O	O	O
42	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
cardiovascular	O	O	B-Entity
deaths	O	O	I-Entity
,	O	O	O
229	O	O	O
(	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
infection-related	O	O	B-Entity
deaths	O	O	I-Entity
,	O	O	O
and	O	O	O
141	O	O	O
(	O	O	O
12	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
malignancy-related	O	O	B-Entity
deaths	O	O	I-Entity
.	O	O	O

Multivariable	O	O	B-Entity
survival	O	O	I-Entity
analyses	O	O	I-Entity
accounting	O	O	O
for	O	O	O
intra-region	O	O	B-Entity
correlation	O	O	I-Entity
revealed	O	O	O
that	O	O	O
VDRA	O	O	B-Entity
use	O	O	O
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
lower	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
infection	O	O	B-Entity
-	O	O	O
and	O	O	O
malignancy	O	O	B-Entity
-related	O	O	O
deaths	O	O	B-Entity
[	O	O	O
subhazard	O	O	B-Entity
ratio	O	O	I-Entity
0.62	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.52	O	O	O
-	O	O	O
0.73	O	O	O
)	O	O	O
and	O	O	O
0.70	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.50	O	O	O
-	O	O	O
0.97	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
]	O	O	O
but	O	O	O
not	O	O	O
with	O	O	O
cardiovascular	O	O	B-Entity
death	O	O	I-Entity
[	O	O	O
subhazard	O	O	O
ratio	O	O	O
0.86	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.72	O	O	O
-	O	O	O
1.04	O	O	O
)	O	O	O
]	O	O	O
.	O	O	O

Future	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trials	O	O	I-Entity
with	O	O	O
a	O	O	O
sufficient	O	O	O
sample	O	O	B-Entity
size	O	O	I-Entity
and	O	O	O
an	O	O	O
adequate	O	O	O
follow-up	O	O	B-Entity
period	O	O	O
are	O	O	O
warranted	O	O	O
to	O	O	O
test	O	O	O
the	O	O	O
clinical	O	O	B-Entity
effectiveness	O	O	I-Entity
of	O	O	O
VDRA	O	O	B-Entity
on	O	O	O
infection	O	O	B-Entity
and	O	O	O
malignancy	O	O	B-Entity
,	O	O	O
rather	O	O	O
than	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
among	O	O	O
dialysis	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28144096)

Burden	O	O	B-Entity
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
and	O	O	O
role	O	O	O
of	O	O	O
screening	O	O	B-Entity
in	O	O	O
India	O	O	O

Cervical	O	O	B-Entity
cancer	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
cause	O	O	O
of	O	O	O
cancer	O	O	B-Entity
mortality	O	O	I-Entity
in	O	O	O
women	O	O	B-Entity
and	O	O	O
more	O	O	O
than	O	O	O
a	O	O	O
quarter	O	O	B-Entity
of	O	O	O
its	O	O	O
global	O	O	B-Entity
burden	O	O	B-Entity
is	O	O	O
contributed	O	O	B-Entity
by	O	O	O
developing	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

In	O	O	O
India	O	O	B-Entity
,	O	O	O
in	O	O	O
spite	O	O	O
of	O	O	O
alarmingly	O	O	O
high	O	O	O
figures	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
nationwide	O	O	O
government-sponsored	O	O	B-Entity
screening	O	O	I-Entity
program	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
conducted	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
burden	O	O	B-Entity
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
in	O	O	O
India	O	O	B-Entity
and	O	O	O
review	O	O	B-Entity
the	O	O	O
performance	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
available	O	O	O
cervical	O	O	O
cancer	O	O	O
screening	O	O	B-Entity
tools	O	O	O
,	O	O	O
so	O	O	O
as	O	O	O
to	O	O	O
provide	O	O	B-Entity
evidence	O	O	B-Entity
-based	O	O	O
recommendations	O	O	B-Entity
for	O	O	O
application	O	O	O
of	O	O	O
most	O	O	O
practically	O	O	O
suited	O	O	O
screening	O	O	B-Entity
test	O	O	I-Entity
to	O	O	O
be	O	O	O
used	O	O	O
in	O	O	O
resource	O	O	B-Entity
-poor	O	O	O
field	O	O	O
settings	O	O	O
.	O	O	O

MEDLINE	O	O	B-Entity
and	O	O	O
Web	O	O	B-Entity
of	O	O	I-Entity
Science	O	O	I-Entity
electronic	O	O	I-Entity
database	O	O	I-Entity
were	O	O	O
searched	O	O	B-Entity
from	O	O	O
January	O	O	B-Entity
1990	O	O	O
to	O	O	O
December	O	O	B-Entity
2015	O	O	O
,	O	O	O
using	O	O	O
the	O	O	O
keywords	O	O	B-Entity
such	O	O	O
as	O	O	O
"	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
"	O	O	O
,	O	O	O
"	O	O	O
screening	O	O	B-Entity
"	O	O	O
,	O	O	O
"	O	O	O
early	O	O	B-Entity
detection	O	O	I-Entity
"	O	O	O
,	O	O	O
"	O	O	O
cervical	O	O	B-Entity
cytology	O	O	I-Entity
"	O	O	O
and	O	O	O
"	O	O	O
visual	O	O	B-Entity
inspection	O	O	I-Entity
"	O	O	O
,	O	O	O
and	O	O	O
their	O	O	O
corresponding	O	O	O
MeSH	O	O	B-Entity
terms	O	O	I-Entity
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
Boolean	O	O	B-Entity
operators	O	O	I-Entity
"	O	O	O
OR	O	O	O
,	O	O	O
AND	O	O	O
.	O	O	O
"	O	O	O
Two	O	O	O
authors	O	O	B-Entity
independently	O	O	O
selected	O	O	B-Entity
studies	O	O	B-Entity
that	O	O	O
are	O	O	O
published	O	O	B-Entity
in	O	O	O
English	O	O	B-Entity
and	O	O	O
conducted	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
11	O	O	O
studies	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
to	O	O	O
be	O	O	O
relevant	O	O	B-Entity
and	O	O	O
eligible	O	O	B-Entity
to	O	O	O
be	O	O	O
included	O	O	B-Entity
in	O	O	O
the	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
.	O	O	O

In	O	O	O
India	O	O	B-Entity
,	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
contributes	O	O	B-Entity
to	O	O	O
approximately	O	O	B-Entity
6	O	O	O
-	O	O	O
29	O	O	O
%	O	O	O
of	O	O	O
all	O	O	O
cancers	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
.	O	O	O

The	O	O	O
age-adjusted	O	O	B-Entity
incidence	O	O	I-Entity
rate	O	O	I-Entity
of	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
varies	O	O	O
widely	O	O	O
among	O	O	O
registries	O	O	B-Entity
;	O	O	O
highest	O	O	B-Entity
is	O	O	O
23.07/100,000	O	O	O
in	O	O	O
Mizoram	O	O	B-Entity
state	O	O	I-Entity
and	O	O	O
the	O	O	O
lowest	O	O	B-Entity
is	O	O	O
4.91/100,000	O	O	O
in	O	O	O
Dibrugarh	O	O	B-Entity
district	O	O	I-Entity
.	O	O	O

The	O	O	O
pooled	O	O	O
estimates	O	O	B-Entity
of	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
specificity	O	O	B-Entity
of	O	O	O
visual	O	O	B-Entity
inspection	O	O	I-Entity
with	O	O	I-Entity
acetic	O	O	I-Entity
acid	O	O	I-Entity
(	O	O	O
VIA	O	O	B-Entity
)	O	O	O
,	O	O	O
magnified	O	O	B-Entity
VIA	O	O	I-Entity
,	O	O	O
visual	O	O	B-Entity
inspection	O	O	I-Entity
with	O	O	I-Entity
Lugol	O	O	I-Entity
's	O	O	I-Entity
iodine	O	O	I-Entity
(	O	O	O
VILI	O	O	B-Entity
)	O	O	O
,	O	O	O
cytology	O	O	B-Entity
(	O	O	O
Pap	O	O	B-Entity
smear	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
DNA	O	O	I-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
67.65	O	O	O
%	O	O	O
and	O	O	O
84.32	O	O	O
%	O	O	O
,	O	O	O
65.36	O	O	O
%	O	O	O
and	O	O	O
85.76	O	O	O
%	O	O	O
,	O	O	O
78.27	O	O	O
%	O	O	O
and	O	O	O
87.10	O	O	O
%	O	O	O
,	O	O	O
62.11	O	O	O
%	O	O	O
and	O	O	O
93.51	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
77.81	O	O	O
%	O	O	O
and	O	O	O
91.54	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
developing	O	O	B-Entity
countries	O	O	I-Entity
because	O	O	O
of	O	O	O
lack	O	O	B-Entity
of	O	O	O
necessary	O	O	O
infrastructure	O	O	B-Entity
and	O	O	O
quality	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
high-quality	O	O	B-Entity
cytology	O	O	B-Entity
screening	O	O	I-Entity
may	O	O	O
not	O	O	O
be	O	O	O
feasible	O	O	O
for	O	O	O
wide-scale	O	O	O
implementation	O	O	B-Entity
.	O	O	O

Hence	O	O	O
,	O	O	O
cervical	O	O	B-Entity
cancer	O	O	I-Entity
screening	O	O	B-Entity
program	O	O	B-Entity
based	O	O	O
on	O	O	O
visual	O	O	B-Entity
screening	O	O	I-Entity
test	O	O	I-Entity
such	O	O	O
as	O	O	O
VIA	O	O	B-Entity
/	O	O	O
VILI	O	O	B-Entity
should	O	O	O
be	O	O	O
adopted	O	O	O
as	O	O	O
an	O	O	O
integral	O	O	O
part	O	O	O
of	O	O	O
primary	O	O	O
health-care	O	O	B-Entity
setup	O	O	I-Entity
in	O	O	O
resource	O	O	B-Entity
-	O	O	O
poor	O	O	B-Entity
countries	O	O	B-Entity
like	O	O	O
India	O	O	B-Entity
.	O	O	O

-DOCSTART- (28144564)

Structural	O	O	B-Entity
and	O	O	I-Entity
tribometric	O	O	I-Entity
characterization	O	O	I-Entity
of	O	O	O
biomimetically	O	O	O
inspired	O	O	O
synthetic	O	O	O
"	O	O	O
insect	O	O	B-Entity
adhesives	O	O	B-Entity
"	O	O	O

Background	O	O	O
:	O	O	O
Based	O	O	O
on	O	O	O
previous	O	O	O
chemical	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
insect	O	O	B-Entity
tarsal	O	O	B-Entity
adhesives	O	O	B-Entity
,	O	O	O
we	O	O	O
prepared	O	O	O
12	O	O	O
heterogeneous	O	O	B-Entity
synthetic	O	O	B-Entity
emulsions	O	O	B-Entity
mimicking	O	O	O
the	O	O	O
polar/non-polar	O	O	B-Entity
principle	O	O	I-Entity
,	O	O	O
analysed	O	O	O
their	O	O	O
microscopical	O	O	B-Entity
structure	O	O	I-Entity
and	O	O	O
tested	O	O	O
their	O	O	O
adhesive	O	O	B-Entity
,	O	O	O
frictional	O	O	B-Entity
,	O	O	O
and	O	O	O
rheological	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Results	O	O	O
:	O	O	O
The	O	O	O
prepared	O	O	B-Entity
emulsions	O	O	B-Entity
varied	O	O	O
in	O	O	O
their	O	O	O
consistency	O	O	B-Entity
from	O	O	O
solid	O	O	B-Entity
rubber-like	O	O	B-Entity
,	O	O	O
over	O	O	O
soft	O	O	B-Entity
elastic	O	O	B-Entity
,	O	O	O
to	O	O	O
fluid	O	O	B-Entity
(	O	O	O
watery	O	O	B-Entity
or	O	O	O
oily	O	O	B-Entity
)	O	O	O
.	O	O	O

With	O	O	O
droplet	O	O	B-Entity
sizes	O	O	I-Entity
>	O	O	O
100	O	O	O
nm	O	O	O
,	O	O	O
all	O	O	O
the	O	O	O
emulsions	O	O	B-Entity
belonged	O	O	O
to	O	O	O
the	O	O	O
common	O	O	O
type	O	O	O
of	O	O	O
macroemulsions	O	O	B-Entity
.	O	O	O

The	O	O	O
emulsions	O	O	B-Entity
of	O	O	O
the	O	O	O
first	O	O	B-Entity
generation	O	O	I-Entity
generally	O	O	O
showed	O	O	O
broader	O	O	O
droplet-size	O	O	B-Entity
ranges	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
second	O	O	B-Entity
generation	O	O	I-Entity
,	O	O	O
especially	O	O	O
when	O	O	O
less	O	O	O
defined	O	O	O
components	O	O	B-Entity
such	O	O	O
as	O	O	O
petrolatum	O	O	B-Entity
or	O	O	O
waxes	O	O	B-Entity
were	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
lipophilic	O	O	B-Entity
fraction	O	O	B-Entity
of	O	O	O
the	O	O	O
first	O	O	O
generation	O	O	O
of	O	O	O
emulsions	O	O	O
.	O	O	O

Some	O	O	O
of	O	O	O
the	O	O	O
prepared	O	O	B-Entity
emulsions	O	O	B-Entity
showed	O	O	O
a	O	O	O
yield	O	O	B-Entity
point	O	O	I-Entity
and	O	O	O
were	O	O	O
Bingham	O	O	B-Entity
fluids	O	O	I-Entity
.	O	O	O

Tribometric	O	O	B-Entity
adhesion	O	O	I-Entity
was	O	O	O
tested	O	O	O
via	O	O	O
probe	O	O	B-Entity
tack	O	O	I-Entity
tests	O	O	I-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
the	O	O	O
"	O	O	O
second	O	O	B-Entity
generation	O	O	I-Entity
"	O	O	O
(	O	O	O
containing	O	O	O
less	O	O	O
viscous	O	O	B-Entity
components	O	O	B-Entity
)	O	O	O
,	O	O	O
the	O	O	O
"	O	O	O
first	O	O	B-Entity
generation	O	O	I-Entity
"	O	O	O
emulsions	O	O	B-Entity
were	O	O	O
much	O	O	O
more	O	O	B-Entity
adhesive	O	O	I-Entity
(	O	O	O
31	O	O	O
-	O	O	O
93	O	O	O
mN	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
finding	O	O	O
attributable	O	O	O
to	O	O	O
their	O	O	O
highly	O	O	O
viscous	O	O	O
components	O	O	O
,	O	O	O
i.e.	O	O	O
,	O	O	O
wax	O	O	B-Entity
,	O	O	O
petrolatum	O	O	B-Entity
,	O	O	O
gelatin	O	O	B-Entity
and	O	O	O
poly(vinyl	O	O	B-Entity
alcohol	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
second	O	O	B-Entity
generation	O	O	I-Entity
emulsions	O	O	B-Entity
,	O	O	O
we	O	O	O
attained	O	O	O
much	O	O	O
lower	O	O	O
adhesivenesses	O	O	B-Entity
,	O	O	O
ranging	O	O	O
between	O	O	O
1	O	O	O
-	O	O	O
18	O	O	O
mN.	O	O	O
The	O	O	O
adhesive	O	O	B-Entity
performance	O	O	B-Entity
was	O	O	O
drastically	O	O	O
reduced	O	O	B-Entity
in	O	O	O
the	O	O	O
emulsions	O	O	O
that	O	O	O
contained	O	O	O
albumin	O	O	B-Entity
as	O	O	O
the	O	O	O
protein	O	O	B-Entity
component	O	O	I-Entity
or	O	O	O
that	O	O	O
lacked	O	O	O
protein	O	O	O
.	O	O	O

Tribometric	O	O	B-Entity
shear	O	O	I-Entity
tests	O	O	I-Entity
were	O	O	O
performed	O	O	O
at	O	O	O
moderate	O	O	O
normal	O	O	B-Entity
loads	O	O	I-Entity
.	O	O	O

Our	O	O	O
measured	O	O	O
friction	O	O	B-Entity
forces	O	O	I-Entity
(	O	O	O
4	O	O	O
-	O	O	O
93	O	O	O
mN	O	O	O
in	O	O	O
the	O	O	O
first	O	O	O
and	O	O	O
0.1	O	O	O
-	O	O	O
5.8	O	O	O
mN	O	O	O
in	O	O	O
the	O	O	O
second	O	O	B-Entity
generation	O	O	I-Entity
emulsions	O	O	B-Entity
)	O	O	O
were	O	O	O
comparatively	O	O	O
low	O	O	O
.	O	O	O

Differences	O	O	B-Entity
in	O	O	O
shear	O	O	B-Entity
performance	O	O	B-Entity
were	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
chemical	O	O	B-Entity
composition	O	O	I-Entity
and	O	O	O
emulsion	O	O	B-Entity
structure	O	O	B-Entity
.	O	O	O

Conclusion	O	O	O
:	O	O	O
By	O	O	O
varying	O	O	O
their	O	O	O
chemical	O	O	B-Entity
composition	O	O	I-Entity
,	O	O	O
synthetic	O	O	O
heterogeneous	O	O	B-Entity
adhesive	O	O	B-Entity
emulsions	O	O	B-Entity
can	O	O	O
be	O	O	O
adjusted	O	O	O
to	O	O	O
have	O	O	O
diverse	O	O	O
consistencies	O	O	B-Entity
and	O	O	O
are	O	O	O
able	O	O	O
to	O	O	O
mimic	O	O	O
certain	O	O	O
rheological	O	O	B-Entity
and	O	O	O
tribological	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
natural	O	O	B-Entity
tarsal	O	O	B-Entity
insect	O	O	B-Entity
adhesives	O	O	B-Entity
.	O	O	O

-DOCSTART- (28149973)

Opioids	O	O	B-Entity
for	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
:	O	O	O
The	O	O	O
CDC	O	O	B-Entity
's	O	O	I-Entity
12	O	O	O
recommendations	O	O	O

The	O	O	O
Centers	O	O	B-Entity
for	O	O	I-Entity
Disease	O	O	I-Entity
Control	O	O	I-Entity
and	O	O	I-Entity
Prevention	O	O	I-Entity
has	O	O	O
issued	O	O	O
12	O	O	O
recommendations	O	O	B-Entity
to	O	O	O
help	O	O	O
clinicians	O	O	B-Entity
prescribe	O	O	B-Entity
an	O	O	O
optimal	O	O	B-Entity
and	O	O	O
safe	O	O	O
course	O	O	O
of	O	O	O
treatment	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28150322)

Three-Dimensional	O	O	B-Entity
HyCoSy	O	O	B-Entity
With	O	O	O
Perfluoropropane-Albumin	O	O	B-Entity
Microspheres	O	O	I-Entity
as	O	O	O
Contrast	O	O	B-Entity
Agents	O	O	I-Entity
and	O	O	O
Normal	O	O	O
Saline	O	O	B-Entity
Injections	O	O	B-Entity
Into	O	O	O
the	O	O	O
Pelvic	O	O	B-Entity
Cavity	O	O	I-Entity
for	O	O	O
Morphological	O	O	B-Entity
Assessment	O	O	B-Entity
of	O	O	O
the	O	O	O
Fallopian	O	O	B-Entity
Tube	O	O	I-Entity
in	O	O	O
Infertile	O	O	B-Entity
Women	O	O	O

To	O	O	O
apply	O	O	O
the	O	O	O
three-dimensional	O	O	B-Entity
(	O	O	O
3D	O	O	B-Entity
)	O	O	O
hysterosalpingo-contrast	O	O	B-Entity
sonography	O	O	I-Entity
(	O	O	O
HyCoSy	O	O	B-Entity
)	O	O	O
with	O	O	O
perfluoropropane-albumin	O	O	B-Entity
microspheres	O	O	I-Entity
as	O	O	O
contrast	O	O	B-Entity
agents	O	O	I-Entity
and	O	O	O
normal	O	O	O
saline	O	O	B-Entity
injections	O	O	B-Entity
into	O	O	O
the	O	O	O
pelvic	O	O	B-Entity
cavity	O	O	I-Entity
for	O	O	O
assessment	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
tubal	O	O	I-Entity
patency	O	O	I-Entity
and	O	O	O
adhesions	O	O	B-Entity
of	O	O	I-Entity
fimbrial	O	O	I-Entity
parts	O	O	I-Entity
.	O	O	O

Fifty-five	O	O	O
infertile	O	O	B-Entity
female	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
recruited	O	O	O
to	O	O	O
undergo	O	O	O
3D	O	O	B-Entity
HyCoSy	O	O	B-Entity
with	O	O	O
normal	O	O	O
saline	O	O	B-Entity
injected	O	O	B-Entity
into	O	O	O
the	O	O	O
pelvic	O	O	B-Entity
cavity	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
the	O	O	O
tubal	O	O	O
patency	O	O	O
was	O	O	O
observed	O	O	O
by	O	O	O
visualizing	O	O	O
the	O	O	O
spillage	O	O	O
of	O	O	O
contrast	O	O	B-Entity
agents	O	O	I-Entity
from	O	O	O
the	O	O	O
fimbriae	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
fimbrial	O	O	B-Entity
adhesion	O	O	I-Entity
was	O	O	O
confirmed	O	O	O
by	O	O	O
the	O	O	O
finger-like	O	O	B-Entity
projections	O	O	I-Entity
of	O	O	O
the	O	O	O
fimbriae	O	O	O
and	O	O	O
their	O	O	O
floating	O	O	B-Entity
and	O	O	O
moving	O	O	B-Entity
status	O	O	I-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
55	O	O	O
patients	O	O	B-Entity
,	O	O	O
bilateral	O	O	B-Entity
tubal	O	O	I-Entity
patency	O	O	I-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
44	O	O	O
(	O	O	O
80.0	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
unilateral	O	O	B-Entity
tubal	O	O	I-Entity
patency	O	O	I-Entity
and	O	O	O
the	O	O	O
other	O	O	O
partial	O	O	B-Entity
occlusion	O	O	I-Entity
in	O	O	O
7	O	O	O
(	O	O	O
12.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
unilateral	O	O	O
partial	O	O	O
occlusion	O	O	O
and	O	O	O
the	O	O	O
other	O	O	O
complete	O	O	B-Entity
occlusion	O	O	I-Entity
in	O	O	O
3	O	O	O
(	O	O	O
5.4	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
bilateral	O	O	O
complete	O	O	O
occlusion	O	O	O
in	O	O	O
1	O	O	O
(	O	O	O
1.8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
fimbrial	O	O	B-Entity
parts	O	O	I-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
105	O	O	O
fallopian	O	O	B-Entity
tubes	O	O	I-Entity
,	O	O	O
among	O	O	O
which	O	O	O
101	O	O	O
were	O	O	O
seen	O	O	O
with	O	O	O
the	O	O	O
finger-like	O	O	B-Entity
fimbriae	O	O	B-Entity
floated	O	O	B-Entity
and	O	O	O
moved	O	O	B-Entity
in	O	O	O
the	O	O	O
pelvic	O	O	B-Entity
cavity	O	O	I-Entity
,	O	O	O
whereas	O	O	O
4	O	O	O
tubes	O	O	O
were	O	O	O
not	O	O	O
because	O	O	O
of	O	O	O
adhesion	O	O	B-Entity
to	O	O	O
the	O	O	O
pelvic	O	O	O
cavity	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
3	O	O	O
)	O	O	O
or	O	O	O
the	O	O	O
ovary	O	O	B-Entity
and	O	O	O
intestine	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1	O	O	O
)	O	O	O
.	O	O	O

More	O	O	O
than	O	O	O
three	O	O	O
visible	O	O	O
,	O	O	O
quite	O	O	O
long	O	O	O
,	O	O	O
and	O	O	O
distributed	O	O	O
evenly	O	O	O
finger-like	O	O	B-Entity
projection	O	O	I-Entity
s	O	O	O
were	O	O	O
present	O	O	O
for	O	O	O
the	O	O	O
patent	O	O	B-Entity
fimbrial	O	O	B-Entity
parts	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
fewer	O	O	B-Entity
,	O	O	O
flat	O	O	B-Entity
,	O	O	O
and	O	O	O
not	O	O	O
evenly	O	O	O
distributed	O	O	O
finger-like	O	O	O
projection	O	O	O
s	O	O	O
were	O	O	O
present	O	O	O
for	O	O	O
the	O	O	O
adhesive	O	O	B-Entity
tubes	O	O	I-Entity
.	O	O	O

No	O	O	O
serious	O	O	O
complications	O	O	B-Entity
occurred	O	O	O
during	O	O	O
or	O	O	O
after	O	O	O
this	O	O	O
procedure	O	O	B-Entity
.	O	O	O

Combination	O	O	B-Entity
of	O	O	O
3D	O	O	B-Entity
HyCoSy	O	O	B-Entity
with	O	O	O
normal	O	O	O
saline	O	O	B-Entity
injected	O	O	B-Entity
into	O	O	O
the	O	O	O
pelvic	O	O	B-Entity
cavity	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
feasible	O	O	O
and	O	O	O
safe	O	O	O
procedure	O	O	B-Entity
to	O	O	O
assess	O	O	O
tubal	O	O	O
patency	O	O	O
and	O	O	O
adhesions	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
fimbrial	O	O	I-Entity
parts	O	O	I-Entity
.	O	O	O

-DOCSTART- (28150378)

Challenging	O	O	B-Entity
some	O	O	O
assumptions	O	O	O
about	O	O	O
empathy	O	O	O

In	O	O	O
New	O	O	B-Entity
Zealand	O	O	I-Entity
little	O	O	O
nursing	O	O	B-Entity
or	O	O	O
medical	O	O	B-Entity
curricula	O	O	I-Entity
time	O	O	B-Entity
,	O	O	O
if	O	O	O
any	O	O	O
,	O	O	O
is	O	O	O
specifically	O	O	O
devoted	O	O	O
to	O	O	O
the	O	O	O
enhancement	O	O	B-Entity
of	O	O	O
empathy	O	O	B-Entity
.	O	O	O

If	O	O	O
being	O	O	O
empathic	O	O	B-Entity
is	O	O	O
important	O	O	B-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
patient	O	O	B-Entity
care	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
a	O	O	O
quality	O	O	O
that	O	O	O
is	O	O	O
already	O	O	O
present	O	O	O
in	O	O	O
students	O	O	B-Entity
or	O	O	O
is	O	O	O
learned	O	O	O
by	O	O	O
students	O	O	O
during	O	O	O
their	O	O	O
practicum	O	O	B-Entity
in	O	O	O
the	O	O	O
company	O	O	O
of	O	O	O
experienced	O	O	B-Entity
clinicians	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
compare	O	O	B-Entity
self-reported	O	O	B-Entity
empathy	O	O	B-Entity
ratings	O	O	O
between	O	O	O
different	O	O	O
groups	O	O	B-Entity
of	O	O	O
medical	O	O	B-Entity
students	O	O	I-Entity
and	O	O	O
one	O	O	O
cohort	O	O	B-Entity
of	O	O	O
nursing	O	O	B-Entity
students	O	O	I-Entity
who	O	O	O
were	O	O	O
either	O	O	O
exposed	O	O	O
or	O	O	O
not	O	O	O
exposed	O	O	O
to	O	O	O
explicit	O	O	O
empathy	O	O	O
training	O	O	B-Entity
or	O	O	O
learning	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
settings	O	O	I-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
Jefferson	O	O	B-Entity
Scale	O	O	I-Entity
of	O	O	I-Entity
Physician	O	O	I-Entity
Empathy	O	O	I-Entity
(	O	O	O
JSPE	O	O	B-Entity
)	O	O	O
was	O	O	O
completed	O	O	O
before	O	O	O
and	O	O	O
after	O	O	O
groups	O	O	O
of	O	O	O
medical	O	O	B-Entity
and	O	O	O
nursing	O	O	B-Entity
students	O	O	I-Entity
had	O	O	O
been	O	O	O
exposed	O	O	O
to	O	O	O
various	O	O	O
extended	O	O	B-Entity
periods	O	O	B-Entity
of	O	O	O
practicum	O	O	B-Entity
.	O	O	O

Some	O	O	O
medical	O	O	B-Entity
student	O	O	I-Entity
cohorts	O	O	B-Entity
undertook	O	O	O
brief	O	O	B-Entity
empathy	O	O	B-Entity
training	O	O	B-Entity
,	O	O	O
whereas	O	O	O
others	O	O	O
had	O	O	O
no	O	O	O
exposure	O	O	O
.	O	O	O

The	O	O	O
nursing	O	O	B-Entity
student	O	O	I-Entity
cohort	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
formal	O	O	I-Entity
,	O	O	O
explicit	O	O	O
empathy	O	O	B-Entity
training	O	O	B-Entity
.	O	O	O

Irrespective	O	O	O
of	O	O	O
profession	O	O	B-Entity
,	O	O	O
length	O	O	B-Entity
of	O	O	O
practicum	O	O	B-Entity
or	O	O	O
exposure	O	O	O
to	O	O	O
specific	O	O	O
empathy	O	O	B-Entity
training	O	O	B-Entity
,	O	O	O
there	O	O	O
were	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
in	O	O	O
the	O	O	O
self-reported	O	O	B-Entity
JSPE	O	O	B-Entity
scores	O	O	I-Entity
across	O	O	O
the	O	O	O
seven	O	O	O
different	O	O	O
cohorts	O	O	B-Entity
of	O	O	O
students	O	O	B-Entity
.	O	O	O

Empathy	O	O	B-Entity
is	O	O	O
a	O	O	O
quality	O	O	B-Entity
that	O	O	O
is	O	O	O
already	O	O	O
present	O	O	B-Entity
in	O	O	O
students	O	O	B-Entity
or	O	O	O
is	O	O	O
learned	O	O	B-Entity
by	O	O	I-Entity
students	O	O	O
during	O	O	O
their	O	O	O
practicum	O	O	B-Entity
DISCUSSION	O	O	B-Entity
:	O	O	O
If	O	O	O
empathy	O	O	B-Entity
is	O	O	O
caught	O	O	B-Entity
rather	O	O	O
than	O	O	O
taught	O	O	B-Entity
,	O	O	O
then	O	O	O
brief	O	O	O
efforts	O	O	O
to	O	O	O
enhance	O	O	B-Entity
empathy	O	O	O
may	O	O	O
be	O	O	O
futile	O	O	B-Entity
.	O	O	O

To	O	O	O
optimise	O	O	O
the	O	O	O
inherent	O	O	B-Entity
empathic	O	O	I-Entity
qualities	O	O	I-Entity
of	O	O	O
aspirant	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
,	O	O	O
explicit	O	O	O
consideration	O	O	B-Entity
should	O	O	O
be	O	O	O
given	O	O	O
to	O	O	O
how	O	O	O
empathy	O	O	B-Entity
is	O	O	O
influenced	O	O	B-Entity
by	O	O	O
the	O	O	O
practicum	O	O	B-Entity
experience	O	O	B-Entity
.	O	O	O

-DOCSTART- (28155918)

Surface	O	O	B-Entity
mediated	O	O	O
cooperative	O	O	O
interactions	O	O	B-Entity
of	O	O	I-Entity
drugs	O	O	I-Entity
enhance	O	O	B-Entity
mechanical	O	O	B-Entity
forces	O	O	I-Entity
for	O	O	O
antibiotic	O	O	B-Entity
action	O	O	O

The	O	O	O
alarming	O	O	B-Entity
increase	O	O	I-Entity
of	O	O	O
pathogenic	O	O	B-Entity
bacteria	O	O	I-Entity
that	O	O	O
are	O	O	O
resistant	O	O	B-Entity
to	O	O	I-Entity
multiple	O	O	I-Entity
antibiotics	O	O	I-Entity
is	O	O	O
now	O	O	O
recognized	O	O	O
as	O	O	O
a	O	O	O
major	O	O	B-Entity
health	O	O	I-Entity
issue	O	O	I-Entity
fuelling	O	O	O
demand	O	O	B-Entity
for	O	O	O
new	O	O	O
drugs	O	O	B-Entity
.	O	O	O

Bacterial	O	O	B-Entity
resistance	O	O	I-Entity
is	O	O	O
often	O	O	O
caused	O	O	O
by	O	O	O
molecular	O	O	B-Entity
changes	O	O	I-Entity
at	O	O	O
the	O	O	O
bacterial	O	O	B-Entity
surface	O	O	I-Entity
,	O	O	O
which	O	O	O
alter	O	O	O
the	O	O	O
nature	O	O	O
of	O	O	O
specific	O	O	O
drug-target	O	O	B-Entity
interactions	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
identify	O	O	O
a	O	O	O
novel	O	O	O
mechanism	O	O	B-Entity
by	O	O	O
which	O	O	O
drug-target	O	O	B-Entity
interactions	O	O	I-Entity
in	O	O	O
resistant	O	O	B-Entity
bacteria	O	O	I-Entity
can	O	O	O
be	O	O	O
enhanced	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
the	O	O	O
surface	O	O	B-Entity
forces	O	O	B-Entity
generated	O	O	O
by	O	O	O
four	O	O	O
antibiotics	O	O	B-Entity
;	O	O	O
vancomycin	O	O	B-Entity
,	O	O	O
ristomycin	O	O	B-Entity
,	O	O	O
chloroeremomycin	O	O	B-Entity
and	O	O	O
oritavancin	O	O	B-Entity
against	O	O	O
drug-susceptible	O	O	B-Entity
and	O	O	O
drug-resistant	O	O	B-Entity
targets	O	O	I-Entity
on	O	O	O
a	O	O	O
cantilever	O	O	O
and	O	O	O
demonstrated	O	O	O
significant	O	O	B-Entity
differences	O	O	O
in	O	O	O
mechanical	O	O	B-Entity
response	O	O	B-Entity
when	O	O	O
drug-resistant	O	O	O
targets	O	O	O
are	O	O	O
challenged	O	O	O
with	O	O	O
different	O	O	O
antibiotics	O	O	O
although	O	O	O
no	O	O	O
significant	O	O	O
differences	O	O	O
were	O	O	O
observed	O	O	B-Entity
when	O	O	O
using	O	O	O
susceptible	O	O	B-Entity
targets	O	O	I-Entity
.	O	O	O

Remarkably	O	O	O
,	O	O	O
the	O	O	O
binding	O	O	B-Entity
affinity	O	O	I-Entity
for	O	O	O
oritavancin	O	O	B-Entity
against	O	O	O
drug-resistant	O	O	B-Entity
targets	O	O	I-Entity
(	O	O	O
70	O	O	O
nM	O	O	O
)	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
11,000	O	O	O
times	O	O	O
stronger	O	O	O
than	O	O	O
for	O	O	O
vancomycin	O	O	B-Entity
(	O	O	O
800	O	O	O
μM	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
powerful	O	O	O
antibiotic	O	O	B-Entity
used	O	O	O
as	O	O	O
the	O	O	O
last	O	O	O
resort	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
streptococcal	O	O	B-Entity
and	O	O	O
staphylococcal	O	O	B-Entity
bacteria	O	O	I-Entity
including	O	O	O
methicillin-resistant	O	O	B-Entity
Staphylococcus	O	O	I-Entity
aureus	O	O	I-Entity
(	O	O	O
MRSA	O	O	B-Entity
)	O	O	O
.	O	O	O

Using	O	O	O
an	O	O	O
exactly	O	O	B-Entity
solvable	O	O	I-Entity
model	O	O	I-Entity
,	O	O	O
which	O	O	O
takes	O	O	O
into	O	O	O
account	O	O	O
the	O	O	O
solvent	O	O	B-Entity
and	O	O	O
membrane	O	O	B-Entity
effects	O	O	B-Entity
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
drug-target	O	O	B-Entity
interactions	O	O	I-Entity
are	O	O	O
strengthened	O	O	O
by	O	O	O
pronounced	O	O	B-Entity
polyvalent	O	O	I-Entity
interactions	O	O	I-Entity
catalyzed	O	O	B-Entity
by	O	O	O
the	O	O	O
surface	O	O	B-Entity
itself	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
further	O	O	O
enhance	O	O	B-Entity
our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
antibiotic	O	O	B-Entity
mode	O	O	I-Entity
of	O	O	I-Entity
action	O	O	I-Entity
and	O	O	O
will	O	O	O
enable	O	O	O
development	O	O	B-Entity
of	O	O	O
more	O	O	O
effective	O	O	O
therapies	O	O	B-Entity
.	O	O	O

-DOCSTART- (28162781)

Intra-articular	O	O	B-Entity
corticosteroids	O	O	B-Entity
versus	O	O	O
intra-articular	O	O	B-Entity
corticosteroids	O	O	O
plus	O	O	B-Entity
methotrexate	O	O	B-Entity
in	O	O	O
oligoarticular	O	O	B-Entity
juvenile	O	O	I-Entity
idiopathic	O	O	I-Entity
arthritis	O	O	I-Entity
:	O	O	O
a	O	O	O
multicentre	O	O	B-Entity
,	O	O	O
prospective	O	O	B-Entity
,	O	O	O
randomised	O	O	B-Entity
,	O	O	O
open-label	O	O	O
trial	O	O	O

Little	O	O	O
evidence-based	O	O	O
information	O	O	O
is	O	O	O
available	O	O	O
to	O	O	O
guide	O	O	B-Entity
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
oligoarticular	O	O	B-Entity
juvenile	O	O	I-Entity
idiopathic	O	O	I-Entity
arthritis	O	O	I-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
oral	O	O	B-Entity
methotrexate	O	O	I-Entity
increases	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
intra-articular	O	O	B-Entity
corticosteroid	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

We	O	O	O
did	O	O	O
this	O	O	O
prospective	O	O	B-Entity
,	O	O	O
open-label	O	O	B-Entity
,	O	O	O
randomised	O	O	B-Entity
trial	O	O	I-Entity
at	O	O	O
ten	O	O	O
hospitals	O	O	B-Entity
in	O	O	O
Italy	O	O	B-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
concealed	O	O	B-Entity
computer-generated	O	O	B-Entity
list	O	O	I-Entity
,	O	O	O
children	O	O	B-Entity
younger	O	O	B-Entity
than	O	O	I-Entity
18	O	O	O
years	O	O	B-Entity
with	O	O	O
oligoarticular	O	O	B-Entity
-	O	O	O
onset	O	O	B-Entity
disease	O	O	I-Entity
were	O	O	O
randomly	O	O	B-Entity
assigned	O	O	B-Entity
(	O	O	O
1:1	O	O	O
)	O	O	O
to	O	O	O
intra-articular	O	O	B-Entity
corticosteroids	O	O	B-Entity
alone	O	O	B-Entity
or	O	O	O
in	O	O	B-Entity
combination	O	O	I-Entity
with	O	O	I-Entity
oral	O	O	B-Entity
methotrexate	O	O	I-Entity
(	O	O	O
15	O	O	O
mg/m(2	O	O	O
)	O	O	O
;	O	O	O
maximum	O	O	B-Entity
20	O	O	O
mg	O	O	O
)	O	O	O
.	O	O	O

Corticosteroids	O	O	B-Entity
used	O	O	O
were	O	O	O
triamcinolone	O	O	B-Entity
hexacetonide	O	O	I-Entity
(	O	O	O
shoulder	O	O	B-Entity
,	O	O	O
elbow	O	O	B-Entity
,	O	O	O
wrist	O	O	B-Entity
,	O	O	O
knee	O	O	B-Entity
,	O	O	O
and	O	O	O
tibiotalar	O	O	B-Entity
joints	O	O	I-Entity
)	O	O	O
or	O	O	O
methylprednisolone	O	O	B-Entity
acetate	O	O	I-Entity
(	O	O	O
ie	O	O	O
,	O	O	O
subtalar	O	O	B-Entity
and	O	O	O
tarsal	O	O	B-Entity
joints	O	O	I-Entity
)	O	O	O
.	O	O	O

We	O	O	O
did	O	O	O
not	O	O	O
mask	O	O	O
patients	O	O	B-Entity
or	O	O	O
investigators	O	O	B-Entity
to	O	O	O
treatment	O	O	B-Entity
assignments	O	O	B-Entity
.	O	O	O

Our	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
was	O	O	O
the	O	O	O
proportion	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
intention-to-treat	O	O	B-Entity
population	O	O	B-Entity
who	O	O	O
had	O	O	O
remission	O	O	B-Entity
of	O	O	O
arthritis	O	O	B-Entity
in	O	O	O
all	O	O	O
injected	O	O	B-Entity
joints	O	O	B-Entity
at	O	O	O
12	O	O	O
months	O	O	B-Entity
.	O	O	O

This	O	O	O
trial	O	O	B-Entity
is	O	O	O
registered	O	O	B-Entity
with	O	O	O
European	O	O	B-Entity
Union	O	O	I-Entity
Clinical	O	O	I-Entity
Trials	O	O	I-Entity
Register	O	O	I-Entity
,	O	O	O
EudraCT	O	O	B-Entity
number	O	O	I-Entity
2008	O	O	O
-	O	O	O
006741	O	O	O
-	O	O	O
70	O	O	O
.	O	O	O

Between	O	O	O
July	O	O	B-Entity
7	O	O	O
,	O	O	O
2009	O	O	O
,	O	O	O
and	O	O	O
March	O	O	B-Entity
31	O	O	O
,	O	O	O
2013	O	O	O
,	O	O	O
we	O	O	O
screened	O	O	B-Entity
226	O	O	O
participants	O	O	B-Entity
and	O	O	O
randomly	O	O	B-Entity
assigned	O	O	B-Entity
102	O	O	O
to	O	O	O
intra-articular	O	O	B-Entity
corticosteroids	O	O	B-Entity
alone	O	O	B-Entity
and	O	O	O
105	O	O	O
to	O	O	O
intra-articular	O	O	O
corticosteroids	O	O	O
plus	O	O	B-Entity
methotrexate	O	O	B-Entity
.	O	O	O

33	O	O	O
(	O	O	O
32	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
assigned	O	O	B-Entity
to	O	O	O
intra-articular	O	O	B-Entity
corticosteroids	O	O	B-Entity
alone	O	O	B-Entity
and	O	O	O
39	O	O	O
(	O	O	O
37	O	O	O
%	O	O	O
)	O	O	O
assigned	O	O	O
to	O	O	O
intra-articular	O	O	O
corticosteroids	O	O	O
and	O	O	O
methotrexate	O	O	B-Entity
therapy	O	O	B-Entity
had	O	O	O
remission	O	O	B-Entity
of	O	O	O
arthritis	O	O	B-Entity
in	O	O	O
all	O	O	O
injected	O	O	B-Entity
joints	O	O	B-Entity
(	O	O	O
p=0·48	O	O	O
)	O	O	O
.	O	O	O

Adverse	O	O	B-Entity
events	O	O	I-Entity
were	O	O	O
recorded	O	O	O
for	O	O	O
20	O	O	O
(	O	O	O
17	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
methotrexate	O	O	B-Entity
,	O	O	O
which	O	O	O
led	O	O	O
to	O	O	O
permanent	O	O	B-Entity
treatment	O	O	B-Entity
discontinuation	O	O	B-Entity
in	O	O	O
two	O	O	O
patients	O	O	O
(	O	O	O
one	O	O	O
due	O	O	O
to	O	O	O
increased	O	O	B-Entity
liver	O	O	I-Entity
transaminases	O	O	I-Entity
and	O	O	O
one	O	O	O
due	O	O	O
to	O	O	O
gastrointestinal	O	O	B-Entity
discomfort	O	O	I-Entity
)	O	O	O
.	O	O	O

No	O	O	B-Entity
patient	O	O	B-Entity
had	O	O	O
a	O	O	O
serious	O	O	B-Entity
adverse	O	O	B-Entity
event	O	O	I-Entity
.	O	O	O

Concomitant	O	O	B-Entity
administration	O	O	I-Entity
of	O	O	O
methotrexate	O	O	B-Entity
did	O	O	O
not	O	O	O
augment	O	O	B-Entity
the	O	O	O
effectiveness	O	O	B-Entity
of	O	O	O
intra-articular	O	O	B-Entity
corticosteroid	O	O	I-Entity
therapy	O	O	I-Entity
.	O	O	O

Future	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
define	O	O	O
the	O	O	O
optimal	O	O	B-Entity
therapeutic	O	O	B-Entity
strategies	O	O	I-Entity
for	O	O	O
oligoarticular	O	O	B-Entity
juvenile	O	O	I-Entity
idiopathic	O	O	I-Entity
arthritis	O	O	I-Entity
.	O	O	O

Italian	O	O	B-Entity
Agency	O	O	I-Entity
of	O	O	I-Entity
Drug	O	O	I-Entity
Evaluation	O	O	I-Entity
.	O	O	O

-DOCSTART- (28164568)

Methylation	O	O	B-Entity
Analysis	O	O	I-Entity
of	O	O	O
BRCA1	O	O	B-Entity
and	O	O	O
APC	O	O	B-Entity
in	O	O	O
Breast	O	O	B-Entity
Cancer	O	O	I-Entity
and	O	O	O
It	O	O	O
's	O	O	O
Relationship	O	O	B-Entity
to	O	O	O
Clinicopathological	O	O	B-Entity
Features	O	O	O

Promoter	O	O	B-Entity
methylation	O	O	I-Entity
of	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
genes	O	O	I-Entity
is	O	O	O
an	O	O	O
important	O	O	O
epigenetic	O	O	B-Entity
alteration	O	O	I-Entity
that	O	O	O
occurs	O	O	O
in	O	O	O
the	O	O	O
primary	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
tumors	O	O	B-Entity
,	O	O	O
including	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Identification	O	O	O
of	O	O	O
methylated	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
their	O	O	O
relationship	O	O	B-Entity
to	O	O	O
clinical	O	O	B-Entity
features	O	O	B-Entity
can	O	O	O
contribute	O	O	O
to	O	O	O
the	O	O	O
prognosis	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
detection	O	O	I-Entity
of	O	O	O
tumors	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
explored	O	O	O
the	O	O	O
methylation	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
APC	O	O	B-Entity
and	O	O	O
BRCA1	O	O	B-Entity
genes	O	O	I-Entity
and	O	O	O
their	O	O	O
relationship	O	O	B-Entity
to	O	O	O
clinical	O	O	B-Entity
factors	O	O	B-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

BRCA1	O	O	B-Entity
and	O	O	O
APC	O	O	B-Entity
promoter	O	O	B-Entity
methylation	O	O	B-Entity
was	O	O	O
examined	O	O	O
by	O	O	O
methylation	O	O	O
-	O	O	O
specific	O	O	B-Entity
multiplex	O	O	I-Entity
ligation-dependent	O	O	I-Entity
probe	O	O	I-Entity
amplification	O	O	I-Entity
(	O	O	O
MS-MLPA	O	O	B-Entity
)	O	O	O
assay	O	O	B-Entity
in	O	O	O
formalin-fixed	O	O	B-Entity
paraffin	O	O	I-Entity
embedded	O	O	I-Entity
(	O	O	I-Entity
FFPE	O	O	I-Entity
)	O	O	I-Entity
breast	O	O	I-Entity
tissue	O	O	I-Entity
from	O	O	O
75	O	O	O
patients	O	O	B-Entity
.	O	O	O

APC	O	O	B-Entity
promoter	O	O	B-Entity
methylation	O	O	I-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
30.67	O	O	O
%	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
tissues	O	O	B-Entity
and	O	O	O
BRCA1	O	O	B-Entity
was	O	O	O
methylated	O	O	B-Entity
in	O	O	O
9.33	O	O	O
%	O	O	O
of	O	O	O
breast	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

Methylation	O	O	B-Entity
of	O	O	O
APC	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
low	O	O	O
histological	O	O	B-Entity
grade	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.006	O	O	O
)	O	O	O
and	O	O	O
methylation	O	O	B-Entity
of	O	O	O
BRCA1	O	O	B-Entity
was	O	O	O
related	O	O	O
with	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.017	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
methylation	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
APC	O	O	B-Entity
and	O	O	O
BRCA1	O	O	B-Entity
can	O	O	O
be	O	O	O
a	O	O	O
predictive	O	O	B-Entity
marker	O	O	I-Entity
for	O	O	O
early	O	O	B-Entity
detection	O	O	I-Entity
and	O	O	O
better	O	O	O
management	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28166607)

Recombinant	O	O	B-Entity
fibrinogen	O	O	B-Entity
reveals	O	O	O
the	O	O	O
differential	O	O	B-Entity
roles	O	O	O
of	O	O	O
α-	O	O	B-Entity
and	O	O	O
γ-chain	O	O	B-Entity
cross-linking	O	O	B-Entity
and	O	O	O
molecular	O	O	B-Entity
heterogeneity	O	O	B-Entity
in	O	O	O
fibrin	O	O	B-Entity
clot	O	O	I-Entity
strain-stiffening	O	O	O

Essentials	O	O	O
Fibrinogen	O	O	B-Entity
circulates	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
plasma	O	O	B-Entity
as	O	O	O
a	O	O	O
complex	O	O	B-Entity
mixture	O	O	B-Entity
of	O	O	O
heterogeneous	O	O	B-Entity
molecular	O	O	B-Entity
variants	O	O	B-Entity
.	O	O	O

We	O	O	O
measured	O	O	B-Entity
strain-stiffening	O	O	B-Entity
of	O	O	O
recombinantly	O	O	B-Entity
produced	O	O	O
fibrinogen	O	O	B-Entity
upon	O	O	O
clotting	O	O	B-Entity
.	O	O	O

Factor	O	O	B-Entity
XIII	O	O	I-Entity
and	O	O	O
molecular	O	O	B-Entity
heterogeneity	O	O	B-Entity
alter	O	O	O
clot	O	O	B-Entity
elasticity	O	O	B-Entity
at	O	O	O
the	O	O	O
protofibril	O	O	B-Entity
and	O	O	O
fiber	O	O	B-Entity
level	O	O	O
.	O	O	O

This	O	O	O
highlights	O	O	O
the	O	O	O
hitherto	O	O	O
unknown	O	O	O
role	O	O	O
of	O	O	O
molecular	O	O	B-Entity
composition	O	O	B-Entity
in	O	O	O
fibrin	O	O	B-Entity
clot	O	O	I-Entity
mechanics	O	O	B-Entity
.	O	O	O

Background	O	O	O
Fibrin	O	O	B-Entity
plays	O	O	O
a	O	O	O
crucial	O	O	O
role	O	O	O
in	O	O	O
haemostasis	O	O	B-Entity
and	O	O	O
wound	O	O	B-Entity
healing	O	O	I-Entity
by	O	O	O
forming	O	O	O
strain-stiffening	O	O	B-Entity
fibrous	O	O	B-Entity
networks	O	O	I-Entity
that	O	O	O
reinforce	O	O	O
blood	O	O	B-Entity
clots	O	O	I-Entity
.	O	O	O

The	O	O	O
molecular	O	O	B-Entity
origin	O	O	O
of	O	O	O
fibrin	O	O	B-Entity
's	O	O	I-Entity
strain-stiffening	O	O	B-Entity
behavior	O	O	O
remains	O	O	O
poorly	O	O	O
understood	O	O	O
,	O	O	O
primarily	O	O	O
because	O	O	O
plasma	O	O	B-Entity
fibrinogen	O	O	B-Entity
is	O	O	O
a	O	O	O
complex	O	O	B-Entity
mixture	O	O	B-Entity
of	O	O	O
heterogeneous	O	O	B-Entity
molecular	O	O	O
variants	O	O	B-Entity
and	O	O	O
is	O	O	O
often	O	O	O
contaminated	O	O	O
by	O	O	O
plasma	O	O	B-Entity
factors	O	O	I-Entity
that	O	O	O
affect	O	O	O
clot	O	O	B-Entity
properties	O	O	B-Entity
.	O	O	O

Objectives	O	O	O
and	O	O	O
methods	O	O	O
To	O	O	O
facilitate	O	O	O
mechanistic	O	O	B-Entity
dissection	O	O	I-Entity
of	O	O	O
fibrin	O	O	B-Entity
nonlinear	O	O	B-Entity
elasticity	O	O	I-Entity
,	O	O	O
we	O	O	O
produced	O	O	O
a	O	O	O
homogeneous	O	O	B-Entity
recombinant	O	O	B-Entity
fibrinogen	O	O	B-Entity
corresponding	O	O	O
to	O	O	O
the	O	O	O
main	O	O	O
variant	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
plasma	O	O	B-Entity
,	O	O	O
termed	O	O	O
rFib610	O	O	B-Entity
.	O	O	O

We	O	O	O
characterized	O	O	O
the	O	O	O
structure	O	O	B-Entity
of	O	O	O
rFib610	O	O	B-Entity
clots	O	O	B-Entity
using	O	O	O
turbidimetry	O	O	B-Entity
,	O	O	O
microscopy	O	O	B-Entity
and	O	O	O
X-ray	O	O	B-Entity
scattering	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
rheology	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
the	O	O	O
strain-stiffening	O	O	B-Entity
behavior	O	O	O
of	O	O	O
the	O	O	O
clots	O	O	B-Entity
and	O	O	O
determined	O	O	O
the	O	O	O
fiber	O	O	B-Entity
properties	O	O	B-Entity
by	O	O	O
modeling	O	O	B-Entity
the	O	O	O
clots	O	O	O
as	O	O	O
semi-flexible	O	O	B-Entity
polymer	O	O	I-Entity
networks	O	O	I-Entity
.	O	O	O

Results	O	O	O
We	O	O	O
show	O	O	O
that	O	O	O
addition	O	O	O
of	O	O	O
FXIII	O	O	B-Entity
to	O	O	O
rFib610	O	O	B-Entity
clots	O	O	B-Entity
causes	O	O	O
a	O	O	O
dose-dependent	O	O	B-Entity
stiffness	O	O	I-Entity
increase	O	O	O
at	O	O	O
small	O	O	O
deformations	O	O	B-Entity
and	O	O	O
renders	O	O	O
the	O	O	O
strain-stiffening	O	O	B-Entity
response	O	O	O
reversible	O	O	O
.	O	O	O

We	O	O	O
find	O	O	O
that	O	O	O
γ-chain	O	O	B-Entity
cross-linking	O	O	B-Entity
contributes	O	O	O
to	O	O	O
clot	O	O	B-Entity
elasticity	O	O	B-Entity
by	O	O	O
changing	O	O	O
the	O	O	O
force-extension	O	O	B-Entity
behavior	O	O	I-Entity
of	O	O	O
the	O	O	O
protofibrils	O	O	B-Entity
,	O	O	O
whereas	O	O	O
α-chain	O	O	B-Entity
cross-linking	O	O	O
stiffens	O	O	O
the	O	O	O
fibers	O	O	B-Entity
,	O	O	O
as	O	O	O
a	O	O	O
consequence	O	O	O
of	O	O	O
tighter	O	O	B-Entity
coupling	O	O	I-Entity
between	O	O	O
the	O	O	O
constituent	O	O	O
protofibrils	O	O	O
.	O	O	O

Interestingly	O	O	O
,	O	O	O
rFib610	O	O	B-Entity
protofibrils	O	O	B-Entity
have	O	O	O
a	O	O	O
25	O	O	O
%	O	O	O
larger	O	O	O
bending	O	O	B-Entity
rigidity	O	O	I-Entity
than	O	O	O
plasma	O	O	B-Entity
-purified	O	O	O
fibrin	O	O	B-Entity
protofibrils	O	O	O
and	O	O	O
a	O	O	O
delayed	O	O	O
strain-stiffening	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
molecular	O	O	B-Entity
heterogeneity	O	O	B-Entity
influences	O	O	B-Entity
clot	O	O	B-Entity
mechanics	O	O	B-Entity
at	O	O	O
the	O	O	O
protofibril	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

Conclusions	O	O	O
Fibrinogen	O	O	B-Entity
molecular	O	O	B-Entity
heterogeneity	O	O	B-Entity
and	O	O	O
FXIII	O	O	B-Entity
affect	O	O	O
the	O	O	O
mechanical	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
fibrin	O	O	B-Entity
clots	O	O	I-Entity
by	O	O	O
altering	O	O	O
the	O	O	O
nonlinear	O	O	B-Entity
viscoelastic	O	O	I-Entity
properties	O	O	I-Entity
at	O	O	O
the	O	O	O
protofibril	O	O	B-Entity
and	O	O	O
fiber	O	O	B-Entity
scale	O	O	I-Entity
.	O	O	O

This	O	O	O
work	O	O	O
provides	O	O	O
a	O	O	O
starting	O	O	O
point	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
role	O	O	O
of	O	O	O
molecular	O	O	B-Entity
heterogeneity	O	O	B-Entity
of	O	O	O
plasma	O	O	B-Entity
fibrinogen	O	O	B-Entity
in	O	O	O
fibrin	O	O	B-Entity
clot	O	O	I-Entity
mechanics	O	O	B-Entity
and	O	O	O
haemostasis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28166877)

Effects	O	O	O
of	O	O	O
display	O	O	B-Entity
curvature	O	O	B-Entity
,	O	O	O
display	O	O	O
zone	O	O	B-Entity
,	O	O	O
and	O	O	O
task	O	O	B-Entity
duration	O	O	B-Entity
on	O	O	O
legibility	O	O	B-Entity
and	O	O	O
visual	O	O	B-Entity
fatigue	O	O	I-Entity
during	O	O	O
visual	O	O	O
search	O	O	O
task	O	O	O

This	O	O	O
study	O	O	O
examined	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
display	O	O	B-Entity
curvature	O	O	B-Entity
(	O	O	O
400	O	O	O
,	O	O	O
600	O	O	O
,	O	O	O
1200	O	O	O
mm	O	O	O
,	O	O	O
and	O	O	O
flat	O	O	B-Entity
)	O	O	O
,	O	O	O
display	O	O	O
zone	O	O	B-Entity
(	O	O	O
5	O	O	O
zones	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
task	O	O	B-Entity
duration	O	O	B-Entity
(	O	O	O
15	O	O	O
and	O	O	O
30	O	O	O
min	O	O	O
)	O	O	O
on	O	O	O
legibility	O	O	B-Entity
and	O	O	O
visual	O	O	B-Entity
fatigue	O	O	I-Entity
.	O	O	O

Each	O	O	O
participant	O	O	B-Entity
completed	O	O	O
two	O	O	O
15-min	O	O	O
visual	O	O	B-Entity
search	O	O	I-Entity
task	O	O	I-Entity
sets	O	O	O
at	O	O	O
each	O	O	O
curvature	O	O	B-Entity
setting	O	O	B-Entity
.	O	O	O

The	O	O	O
600-mm	O	O	O
and	O	O	O
1200-mm	O	O	O
settings	O	O	B-Entity
yielded	O	O	O
better	O	O	O
results	O	O	O
than	O	O	O
the	O	O	O
flat	O	O	B-Entity
setting	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
legibility	O	O	B-Entity
and	O	O	O
perceived	O	O	O
visual	O	O	B-Entity
fatigue	O	O	I-Entity
.	O	O	O

Relative	O	O	O
to	O	O	O
the	O	O	O
corresponding	O	O	O
centre	O	O	B-Entity
zone	O	O	B-Entity
,	O	O	O
the	O	O	O
outermost	O	O	O
zones	O	O	B-Entity
of	O	O	O
the	O	O	O
1200-mm	O	O	O
and	O	O	O
flat	O	O	B-Entity
settings	O	O	B-Entity
showed	O	O	O
a	O	O	O
decrease	O	O	O
of	O	O	O
8%-37	O	O	O
%	O	O	O
in	O	O	O
legibility	O	O	B-Entity
,	O	O	O
whereas	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
flat	O	O	O
setting	O	O	B-Entity
showed	O	O	O
an	O	O	O
increase	O	O	B-Entity
of	O	O	O
26%-45	O	O	O
%	O	O	O
in	O	O	O
perceived	O	O	B-Entity
visual	O	O	B-Entity
fatigue	O	O	I-Entity
.	O	O	O

Across	O	O	O
curvature	O	O	B-Entity
s	O	O	O
,	O	O	O
legibility	O	O	B-Entity
decreased	O	O	B-Entity
by	O	O	O
2%-8	O	O	O
%	O	O	O
,	O	O	O
whereas	O	O	O
perceived	O	O	B-Entity
visual	O	O	B-Entity
fatigue	O	O	I-Entity
increased	O	O	B-Entity
by	O	O	O
22	O	O	O
%	O	O	O
during	O	O	O
the	O	O	O
second	O	O	O
task	O	O	B-Entity
set	O	O	I-Entity
.	O	O	O

The	O	O	O
two	O	O	O
task	O	O	B-Entity
sets	O	O	I-Entity
induced	O	O	O
an	O	O	O
increase	O	O	B-Entity
of	O	O	O
102	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
eye	O	O	B-Entity
complaint	O	O	I-Entity
score	O	O	I-Entity
and	O	O	O
a	O	O	O
decrease	O	O	O
of	O	O	O
0.3	O	O	O
Hz	O	O	O
in	O	O	O
the	O	O	O
critical	O	O	B-Entity
fusion	O	O	I-Entity
frequency	O	O	I-Entity
,	O	O	O
both	O	O	O
of	O	O	O
which	O	O	O
indicated	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
visual	O	O	B-Entity
fatigue	O	O	I-Entity
.	O	O	O

In	O	O	O
summary	O	O	O
,	O	O	O
a	O	O	O
curvature	O	O	B-Entity
of	O	O	O
around	O	O	O
600	O	O	O
mm	O	O	O
,	O	O	O
central	O	O	B-Entity
display	O	O	B-Entity
zones	O	O	B-Entity
,	O	O	O
and	O	O	O
frequent	O	O	O
breaks	O	O	B-Entity
are	O	O	O
recommended	O	O	O
to	O	O	O
improve	O	O	B-Entity
legibility	O	O	B-Entity
and	O	O	O
reduce	O	O	O
visual	O	O	B-Entity
fatigue	O	O	I-Entity
.	O	O	O

-DOCSTART- (28171696)

Predicting	O	O	O
changes	O	O	O
in	O	O	O
adaptive	O	O	B-Entity
functioning	O	O	B-Entity
and	O	O	O
behavioral	O	O	B-Entity
adjustment	O	O	B-Entity
following	O	O	O
treatment	O	O	B-Entity
for	O	O	O
a	O	O	O
pediatric	O	O	B-Entity
brain	O	O	I-Entity
tumor	O	O	I-Entity
:	O	O	O
A	O	O	O
report	O	O	B-Entity
from	O	O	O
the	O	O	O
Brain	O	O	B-Entity
Radiation	O	O	O
Investigative	O	O	O
Study	O	O	O
Consortium	O	O	O

Children	O	O	B-Entity
are	O	O	O
at	O	O	O
risk	O	O	B-Entity
for	O	O	O
behavioral	O	O	B-Entity
and	O	O	O
adaptive	O	O	B-Entity
difficulties	O	O	B-Entity
following	O	O	O
pediatric	O	O	B-Entity
brain	O	O	I-Entity
tumor	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
explored	O	O	O
whether	O	O	O
familial	O	O	B-Entity
/	O	O	O
demographic	O	O	B-Entity
,	O	O	O
developmental	O	O	B-Entity
,	O	O	O
diagnostic	O	O	B-Entity
,	O	O	O
or	O	O	O
treatment	O	O	B-Entity
-related	O	O	O
variables	O	O	B-Entity
best	O	O	O
predict	O	O	O
posttreatment	O	O	B-Entity
behavioral	O	O	B-Entity
and	O	O	O
adaptive	O	O	B-Entity
functioning	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
included	O	O	O
40	O	O	O
children	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
=	O	O	O
12.76	O	O	O
years	O	O	O
,	O	O	O
SD	O	O	B-Entity
=	O	O	O
4.01	O	O	O
)	O	O	O
posttreatment	O	O	B-Entity
(	O	O	O
mean	O	O	O
time	O	O	B-Entity
since	O	O	O
diagnosis	O	O	B-Entity
=	O	O	O
1.99	O	O	O
years	O	O	O
,	O	O	O
SD	O	O	O
=	O	O	O
0.21	O	O	O
)	O	O	O
for	O	O	O
pediatric	O	O	B-Entity
brain	O	O	I-Entity
tumor	O	O	I-Entity
.	O	O	O

Parents	O	O	B-Entity
rated	O	O	O
children	O	O	B-Entity
's	O	O	O
behavioral	O	O	B-Entity
adjustment	O	O	B-Entity
and	O	O	O
adaptive	O	O	B-Entity
functioning	O	O	B-Entity
and	O	O	O
provided	O	O	O
demographic	O	O	B-Entity
and	O	O	O
developmental	O	O	B-Entity
histories	O	O	B-Entity
.	O	O	O

Diagnostic	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
-related	O	O	O
information	O	O	B-Entity
was	O	O	O
abstracted	O	O	O
from	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
.	O	O	O

Ratings	O	O	B-Entity
of	O	O	O
adaptive	O	O	B-Entity
and	O	O	O
behavioral	O	O	B-Entity
functioning	O	O	B-Entity
approximately	O	O	O
2	O	O	O
years	O	O	O
postdiagnosis	O	O	B-Entity
were	O	O	O
within	O	O	O
the	O	O	O
average	O	O	B-Entity
range	O	O	B-Entity
,	O	O	O
although	O	O	O
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
children	O	O	B-Entity
exceeding	O	O	O
clinical	O	O	B-Entity
cutoffs	O	O	B-Entity
for	O	O	O
impairment	O	O	B-Entity
in	O	O	O
adaptive	O	O	O
skills	O	O	B-Entity
exceeded	O	O	O
expectation	O	O	B-Entity
,	O	O	O
particularly	O	O	O
practical	O	O	O
skills	O	O	O
.	O	O	O

Premorbid	O	O	B-Entity
behavior	O	O	I-Entity
problems	O	O	B-Entity
and	O	O	O
tumor	O	O	B-Entity
size	O	O	I-Entity
predicted	O	O	O
posttreatment	O	O	B-Entity
adaptive	O	O	B-Entity
functioning	O	O	B-Entity
.	O	O	O

After	O	O	O
accounting	O	O	O
for	O	O	O
adaptive	O	O	B-Entity
functioning	O	O	B-Entity
near	O	O	O
diagnosis	O	O	B-Entity
,	O	O	O
premorbid	O	O	B-Entity
behavior	O	O	I-Entity
problems	O	O	B-Entity
predicted	O	O	O
declines	O	O	O
in	O	O	O
adaptive	O	O	O
functioning	O	O	O
2	O	O	O
years	O	O	O
postdiagnosis	O	O	B-Entity
.	O	O	O

After	O	O	O
accounting	O	O	O
for	O	O	O
adjustment	O	O	B-Entity
near	O	O	O
diagnosis	O	O	B-Entity
,	O	O	O
no	O	O	O
variables	O	O	B-Entity
predicted	O	O	O
declines	O	O	O
in	O	O	O
behavioral	O	O	B-Entity
adjustment	O	O	O
.	O	O	O

Children	O	O	B-Entity
may	O	O	O
be	O	O	O
vulnerable	O	O	B-Entity
to	O	O	O
reduced	O	O	O
adaptive	O	O	B-Entity
functioning	O	O	B-Entity
following	O	O	O
pediatric	O	O	B-Entity
brain	O	O	I-Entity
tumor	O	O	I-Entity
treatment	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
practical	O	O	O
skills	O	O	O
.	O	O	O

Assessing	O	O	O
prediagnosis	O	O	B-Entity
functioning	O	O	B-Entity
and	O	O	O
diagnostic	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
-related	O	O	O
variables	O	O	B-Entity
may	O	O	O
improve	O	O	B-Entity
our	O	O	O
ability	O	O	B-Entity
to	O	O	O
predict	O	O	O
those	O	O	O
at	O	O	O
greatest	O	O	O
risk	O	O	B-Entity
,	O	O	O
although	O	O	O
those	O	O	O
factors	O	O	B-Entity
may	O	O	O
be	O	O	O
less	O	O	O
helpful	O	O	B-Entity
in	O	O	O
identifying	O	O	B-Entity
children	O	O	B-Entity
likely	O	O	O
to	O	O	O
develop	O	O	O
behavioral	O	O	B-Entity
difficulties	O	O	B-Entity
.	O	O	O

Screening	O	O	B-Entity
of	O	O	O
these	O	O	O
factors	O	O	B-Entity
in	O	O	O
tertiary	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
long-term	O	O	B-Entity
follow-up	O	O	B-Entity
settings	O	O	O
may	O	O	O
improve	O	O	B-Entity
identification	O	O	B-Entity
of	O	O	O
those	O	O	O
at	O	O	O
greatest	O	O	O
need	O	O	B-Entity
for	O	O	O
support	O	O	B-Entity
services	O	O	I-Entity
.	O	O	O

-DOCSTART- (28175980)

Spine	O	O	B-Entity
fracture	O	O	I-Entity
prevalence	O	O	B-Entity
in	O	O	O
a	O	O	O
nationally	O	O	B-Entity
representative	O	O	I-Entity
sample	O	O	O
of	O	O	O
US	O	O	B-Entity
women	O	O	B-Entity
and	O	O	O
men	O	O	B-Entity
aged	O	O	B-Entity
≥40	O	O	O
years	O	O	O
:	O	O	O
results	O	O	O
from	O	O	O
the	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
and	O	O	I-Entity
Nutrition	O	O	I-Entity
Examination	O	O	I-Entity
Survey	O	O	I-Entity
(	O	O	O
NHANES	O	O	B-Entity
)	O	O	O
2013	O	O	O
-	O	O	O
2014	O	O	O

Spine	O	O	B-Entity
fracture	O	O	I-Entity
prevalence	O	O	B-Entity
is	O	O	O
similar	O	O	O
in	O	O	O
men	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
,	O	O	O
increasing	O	O	O
from	O	O	O
<	O	O	O
5	O	O	O
%	O	O	O
in	O	O	O
those	O	O	O
<	O	O	O
60	O	O	O
to	O	O	O
11	O	O	O
%	O	O	O
in	O	O	O
those	O	O	O
70	O	O	O
-	O	O	O
79	O	O	O
and	O	O	O
18	O	O	O
%	O	O	O
in	O	O	O
those	O	O	O
≥80	O	O	O
years	O	O	O
.	O	O	O

Prevalence	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
with	O	O	O
age	O	O	B-Entity
,	O	O	O
lower	O	O	B-Entity
bone	O	O	B-Entity
mineral	O	O	I-Entity
density	O	O	I-Entity
(	O	O	O
BMD	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
in	O	O	O
those	O	O	O
meeting	O	O	O
criteria	O	O	B-Entity
for	O	O	O
spine	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

Most	O	O	O
subjects	O	O	B-Entity
with	O	O	O
spine	O	O	B-Entity
fractures	O	O	I-Entity
were	O	O	O
unaware	O	O	B-Entity
of	O	O	O
them	O	O	O
.	O	O	O

Spine	O	O	B-Entity
fractures	O	O	I-Entity
have	O	O	O
substantial	O	O	O
medical	O	O	B-Entity
significance	O	O	O
but	O	O	O
are	O	O	O
seldom	O	O	B-Entity
recognized	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
collected	O	O	O
contemporary	O	O	O
nationally	O	O	B-Entity
representative	O	O	I-Entity
spine	O	O	B-Entity
fracture	O	O	I-Entity
prevalence	O	O	B-Entity
data	O	O	O
.	O	O	O

Cross-sectional	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
3330	O	O	O
US	O	O	B-Entity
adults	O	O	B-Entity
aged	O	O	B-Entity
≥40	O	O	O
years	O	O	O
participating	O	O	O
in	O	O	O
NHANES	O	O	B-Entity
2013	O	O	O
-	O	O	O
2014	O	O	O
with	O	O	O
evaluable	O	O	O
Vertebral	O	O	B-Entity
Fracture	O	O	I-Entity
Assessment	O	O	O
(	O	O	O
VFA	O	O	B-Entity
)	O	O	O
.	O	O	O

VFA	O	O	B-Entity
was	O	O	O
graded	O	O	O
by	O	O	O
semiquantitative	O	O	O
measurement	O	O	O
.	O	O	O

BMD	O	O	B-Entity
and	O	O	O
an	O	O	O
osteoporosis	O	O	B-Entity
questionnaire	O	O	B-Entity
were	O	O	O
collected	O	O	O
.	O	O	O

Overall	O	O	O
spine	O	O	B-Entity
fracture	O	O	I-Entity
prevalence	O	O	B-Entity
was	O	O	O
5.4	O	O	O
%	O	O	O
and	O	O	O
similar	O	O	O
in	O	O	O
men	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
.	O	O	O

Prevalence	O	O	B-Entity
increased	O	O	O
with	O	O	O
age	O	O	B-Entity
from	O	O	O
<	O	O	O
5	O	O	O
%	O	O	O
in	O	O	O
those	O	O	O
<	O	O	O
60	O	O	O
to	O	O	O
11	O	O	O
%	O	O	O
in	O	O	O
those	O	O	O
70	O	O	O
-	O	O	O
79	O	O	O
and	O	O	O
18	O	O	O
%	O	O	O
in	O	O	O
those	O	O	O
≥80	O	O	O
years	O	O	O
.	O	O	O

Fractures	O	O	B-Entity
were	O	O	O
more	O	O	O
common	O	O	O
in	O	O	O
non-Hispanic	O	O	B-Entity
whites	O	O	I-Entity
and	O	O	O
in	O	O	O
people	O	O	O
with	O	O	O
lower	O	O	B-Entity
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
and	O	O	O
BMD	O	O	B-Entity
.	O	O	O

Among	O	O	O
subjects	O	O	B-Entity
with	O	O	O
spine	O	O	B-Entity
fracture	O	O	I-Entity
,	O	O	O
26	O	O	O
%	O	O	O
met	O	O	O
BMD	O	O	B-Entity
criteria	O	O	B-Entity
for	O	O	O
osteoporosis	O	O	B-Entity
.	O	O	O

Prevalence	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
in	O	O	O
subjects	O	O	B-Entity
who	O	O	O
met	O	O	O
National	O	O	B-Entity
Osteoporosis	O	O	I-Entity
Foundation	O	O	I-Entity
(	O	O	O
NOF	O	O	B-Entity
)	O	O	O
criteria	O	O	B-Entity
for	O	O	O
spine	O	O	B-Entity
imaging	O	O	I-Entity
(	O	O	O
14	O	O	O
vs	O	O	O
4.7	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Only	O	O	O
8	O	O	O
%	O	O	O
of	O	O	O
people	O	O	O
with	O	O	O
a	O	O	O
spine	O	O	B-Entity
fracture	O	O	B-Entity
diagnosed	O	O	B-Entity
by	O	O	O
VFA	O	O	B-Entity
had	O	O	O
a	O	O	O
self-reported	O	O	B-Entity
fracture	O	O	O
,	O	O	O
and	O	O	O
among	O	O	O
those	O	O	O
who	O	O	O
self-reported	O	O	O
a	O	O	O
spine	O	O	O
fracture	O	O	O
,	O	O	O
only	O	O	O
21	O	O	O
%	O	O	O
were	O	O	O
diagnosed	O	O	O
with	O	O	O
fracture	O	O	O
by	O	O	O
VFA	O	O	O
.	O	O	O

Spine	O	O	B-Entity
fracture	O	O	I-Entity
prevalence	O	O	B-Entity
is	O	O	O
similar	O	O	O
in	O	O	O
women	O	O	B-Entity
and	O	O	O
men	O	O	B-Entity
and	O	O	O
increases	O	O	O
with	O	O	O
age	O	O	B-Entity
and	O	O	O
lower	O	O	B-Entity
BMD	O	O	B-Entity
,	O	O	O
although	O	O	O
most	O	O	O
subjects	O	O	B-Entity
with	O	O	O
spine	O	O	B-Entity
fracture	O	O	I-Entity
do	O	O	O
not	O	O	O
meet	O	O	O
BMD	O	O	O
criteria	O	O	O
for	O	O	O
osteoporosis	O	O	B-Entity
.	O	O	O

Since	O	O	O
most	O	O	O
(	O	O	O
>	O	O	O
90	O	O	O
%	O	O	O
)	O	O	O
individuals	O	O	B-Entity
were	O	O	O
unaware	O	O	B-Entity
of	O	O	O
their	O	O	O
spine	O	O	B-Entity
fractures	O	O	I-Entity
,	O	O	O
lateral	O	O	B-Entity
spine	O	O	B-Entity
imaging	O	O	I-Entity
is	O	O	O
needed	O	O	O
to	O	O	O
identify	O	O	O
these	O	O	O
women	O	O	B-Entity
and	O	O	O
men	O	O	B-Entity
.	O	O	O

Spine	O	O	B-Entity
fracture	O	O	I-Entity
prevalence	O	O	B-Entity
was	O	O	O
threefold	O	O	O
higher	O	O	B-Entity
in	O	O	O
individuals	O	O	B-Entity
meeting	O	O	O
NOF	O	O	B-Entity
criteria	O	O	B-Entity
for	O	O	O
spine	O	O	B-Entity
imaging	O	O	I-Entity
(	O	O	O
∼1	O	O	O
in	O	O	O
7	O	O	O
undergoing	O	O	O
VFA	O	O	B-Entity
)	O	O	O
.	O	O	O

Identifying	O	O	O
spine	O	O	B-Entity
fractures	O	O	I-Entity
as	O	O	O
part	O	O	O
of	O	O	O
comprehensive	O	O	B-Entity
risk	O	O	B-Entity
assessment	O	O	I-Entity
may	O	O	O
improve	O	O	B-Entity
clinical	O	O	B-Entity
decision	O	O	I-Entity
making	O	O	I-Entity
.	O	O	O

-DOCSTART- (28179308)

Renieramycin	O	O	B-Entity
M	O	O	I-Entity
Attenuates	O	O	O
Cancer	O	O	B-Entity
Stem	O	O	I-Entity
Cell	O	O	I-Entity
-like	O	O	O
Phenotypes	O	O	B-Entity
in	O	O	O
H460	O	O	B-Entity
Lung	O	O	B-Entity
Cancer	O	O	O
Cells	O	O	O

Cancer	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
CSCs	O	O	B-Entity
)	O	O	O
are	O	O	O
a	O	O	O
subpopulation	O	O	O
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
that	O	O	O
possess	O	O	O
self-renewal	O	O	B-Entity
and	O	O	O
differentiation	O	O	B-Entity
capacities	O	O	O
.	O	O	O

CSCs	O	O	B-Entity
contribute	O	O	O
to	O	O	O
drug-resistance	O	O	B-Entity
,	O	O	O
cancer	O	O	B-Entity
recurrence	O	O	I-Entity
and	O	O	O
metastasis	O	O	B-Entity
,	O	O	O
thus	O	O	O
development	O	O	B-Entity
of	O	O	O
CSC	O	O	B-Entity
-targeted	O	O	O
therapeutic	O	O	B-Entity
strategies	O	O	I-Entity
has	O	O	O
recently	O	O	O
received	O	O	O
significant	O	O	O
attention	O	O	O
in	O	O	O
cancer	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
potential	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
renieramycin	O	O	B-Entity
M	O	O	I-Entity
(	O	O	O
RM	O	O	B-Entity
)	O	O	O
isolated	O	O	O
from	O	O	O
the	O	O	O
sponge	O	O	B-Entity
Xestospongia	O	O	B-Entity
species	O	O	I-Entity
,	O	O	O
was	O	O	O
examined	O	O	B-Entity
against	O	O	O
lung	O	O	B-Entity
CSCs	O	O	B-Entity
.	O	O	O

Colony	O	O	B-Entity
and	O	O	I-Entity
spheroid	O	O	I-Entity
formation	O	O	I-Entity
assays	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
lung	O	O	B-Entity
CSC	O	O	B-Entity
protein	O	O	B-Entity
markers	O	O	B-Entity
were	O	O	O
employed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
CSC	O	O	O
-like	O	O	O
phenotypes	O	O	B-Entity
of	O	O	O
H460	O	O	B-Entity
lung	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
after	O	O	O
treatment	O	O	B-Entity
with	O	O	O
RM	O	O	B-Entity
at	O	O	O
non-toxic	O	O	B-Entity
concentrations	O	O	I-Entity
.	O	O	O

RM	O	O	B-Entity
treatment	O	O	B-Entity
reduced	O	O	O
significantly	O	O	O
colony	O	O	B-Entity
and	O	O	I-Entity
spheroid	O	O	I-Entity
formation	O	O	I-Entity
of	O	O	O
H460	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
CSC	O	O	B-Entity
markers	O	O	B-Entity
CD133	O	O	B-Entity
,	O	O	O
CD44	O	O	B-Entity
and	O	O	O
ALDH1A1	O	O	B-Entity
of	O	O	O
CSC	O	O	O
-enriched	O	O	O
H460	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
reduced	O	O	O
significantly	O	O	O
following	O	O	O
RM	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

RM	O	O	B-Entity
could	O	O	O
be	O	O	O
a	O	O	O
potent	O	O	O
anti-metastatic	O	O	B-Entity
agent	O	O	I-Entity
by	O	O	O
suppressing	O	O	O
lung	O	O	B-Entity
CSC	O	O	B-Entity
-like	O	O	O
phenotypes	O	O	B-Entity
in	O	O	O
H460	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (28181464)

Physicochemical	O	O	O
characterization	O	O	O
of	O	O	O
chitosan	O	O	B-Entity
-	O	O	O
hyaluronan	O	O	B-Entity
-coated	O	O	O
solid	O	O	O
lipid	O	O	B-Entity
nanoparticles	O	O	I-Entity
for	O	O	O
the	O	O	O
targeted	O	O	O
delivery	O	O	B-Entity
of	O	O	O
paclitaxel	O	O	B-Entity
:	O	O	O
a	O	O	O
proof-of-concept	O	O	B-Entity
study	O	O	I-Entity
in	O	O	O
breast	O	O	O
cancer	O	O	O
cells	O	O	O

To	O	O	O
investigate	O	O	O
the	O	O	O
potential	O	O	O
of	O	O	O
modified	O	O	O
solid	O	O	B-Entity
lipid	O	O	I-Entity
nanoparticles	O	O	I-Entity
(	O	O	O
SLN	O	O	B-Entity
)	O	O	O
for	O	O	O
the	O	O	O
delivery	O	O	O
of	O	O	O
paclitaxel	O	O	B-Entity
(	O	O	O
PAX	O	O	B-Entity
)	O	O	O
.	O	O	O

SLN	O	O	B-Entity
loaded	O	O	I-Entity
with	O	O	I-Entity
PAX	O	O	I-Entity
were	O	O	O
prepared	O	O	O
via	O	O	O
modified	O	O	O
high-pressure	O	O	B-Entity
hot	O	O	I-Entity
homogenization	O	O	I-Entity
.	O	O	O

Formulation	O	O	B-Entity
parameters	O	O	I-Entity
were	O	O	O
optimized	O	O	O
to	O	O	O
obtain	O	O	O
a	O	O	O
high-quality	O	O	B-Entity
delivery	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

SLN	O	O	B-Entity
cores	O	O	O
were	O	O	O
coated	O	O	B-Entity
,	O	O	I-Entity
layer-by-layer	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
chitosan	O	O	B-Entity
and	O	O	O
hyaluronan	O	O	B-Entity
(	O	O	O
HA	O	O	B-Entity
)	O	O	O
shell	O	O	O
.	O	O	O

Selectivity	O	O	O
toward	O	O	O
HA	O	O	B-Entity
receptors	O	O	B-Entity
was	O	O	O
tested	O	O	O
in	O	O	O
a	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
,	O	O	O
MCF-7	O	O	B-Entity
.	O	O	O

Stable	O	O	B-Entity
and	O	O	I-Entity
reproducible	O	O	I-Entity
nano-sized	O	O	B-Entity
and	O	O	O
negatively	O	O	B-Entity
charged	O	O	I-Entity
nanoparticles	O	O	I-Entity
resulted	O	O	O
.	O	O	O

Findings	O	O	O
reveal	O	O	O
that	O	O	O
chitosan	O	O	B-Entity
-	O	O	O
HA	O	O	B-Entity
-coated	O	O	O
SLN	O	O	B-Entity
facilitated	O	O	O
the	O	O	O
targeting	O	O	B-Entity
,	O	O	O
cellular	O	O	B-Entity
uptake	O	O	I-Entity
and	O	O	O
the	O	O	O
time-/dose-controlled	O	O	B-Entity
delivery	O	O	I-Entity
and	O	O	I-Entity
release	O	O	I-Entity
of	O	O	O
PAX	O	O	B-Entity
,	O	O	O
enhancing	O	O	O
intrinsic	O	O	B-Entity
chemotherapeutic	O	O	I-Entity
activities	O	O	I-Entity
.	O	O	O

SLN	O	O	B-Entity
are	O	O	O
suitable	O	O	O
carrier	O	O	B-Entity
candidates	O	O	I-Entity
for	O	O	O
nano-oncology	O	O	B-Entity
given	O	O	O
their	O	O	O
localized	O	O	O
,	O	O	O
and	O	O	O
potent	O	O	O
cytotoxic	O	O	B-Entity
potential	O	O	I-Entity
overcoming	O	O	B-Entity
multidrug-resistant	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (28181538)

Epigenetic	O	O	B-Entity
Editing	O	O	I-Entity
of	O	O	O
Ascl1	O	O	B-Entity
Gene	O	O	I-Entity
in	O	O	O
Neural	O	O	B-Entity
Stem	O	O	I-Entity
Cells	O	O	I-Entity
by	O	O	O
Optogenetics	O	O	O

Enzymes	O	O	B-Entity
involved	O	O	O
in	O	O	O
epigenetic	O	O	B-Entity
processes	O	O	I-Entity
such	O	O	O
as	O	O	O
methyltransferases	O	O	B-Entity
or	O	O	O
demethylases	O	O	B-Entity
are	O	O	O
becoming	O	O	O
highly	O	O	B-Entity
utilized	O	O	B-Entity
for	O	O	O
their	O	O	O
persistent	O	O	B-Entity
DNA	O	O	I-Entity
or	O	O	O
histone	O	O	B-Entity
modifying	O	O	I-Entity
efficacy	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
developed	O	O	O
an	O	O	O
optogenetic	O	O	B-Entity
toolbox	O	O	B-Entity
fused	O	O	O
to	O	O	O
the	O	O	O
catalytic	O	O	B-Entity
domain	O	O	I-Entity
(	O	O	O
CD	O	O	B-Entity
)	O	O	O
of	O	O	O
DNA-methyltransferase3A	O	O	B-Entity
(	O	O	O
DNMT3A	O	O	B-Entity
-	O	O	O
CD	O	O	O
)	O	O	O
or	O	O	O
Ten-Eleven	O	O	B-Entity
Dioxygenase-1	O	O	I-Entity
(	O	O	O
TET1	O	O	B-Entity
-	O	O	O
CD	O	O	O
)	O	O	O
for	O	O	O
loci	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
alteration	O	O	B-Entity
of	O	O	O
the	O	O	O
methylation	O	O	B-Entity
state	O	O	B-Entity
at	O	O	O
the	O	O	O
promoter	O	O	B-Entity
of	O	O	O
Ascl1	O	O	B-Entity
(	O	O	O
Mash1	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
candidate	O	O	B-Entity
proneuron	O	O	I-Entity
gene	O	O	I-Entity
.	O	O	O

Optogenetical	O	O	B-Entity
protein	O	O	I-Entity
pairs	O	O	I-Entity
,	O	O	O
CRY2	O	O	B-Entity
linked	O	O	O
to	O	O	O
DNMT3A	O	O	B-Entity
-	O	O	O
CD	O	O	B-Entity
or	O	O	O
TET1	O	O	B-Entity
-	O	O	O
CD	O	O	O
and	O	O	O
CIB1	O	O	B-Entity
fused	O	O	B-Entity
to	O	O	O
a	O	O	O
Transcription	O	O	B-Entity
Activator-Like	O	O	I-Entity
Element	O	O	I-Entity
(	O	O	O
TALE	O	O	B-Entity
)	O	O	O
locating	O	O	O
an	O	O	O
Ascl1	O	O	B-Entity
promoter	O	O	B-Entity
region	O	O	I-Entity
,	O	O	O
were	O	O	O
designed	O	O	O
for	O	O	O
site	O	O	B-Entity
specific	O	O	I-Entity
epigenetic	O	O	B-Entity
editing	O	O	I-Entity
.	O	O	O

A	O	O	O
differentially	O	O	B-Entity
methylated	O	O	B-Entity
region	O	O	I-Entity
at	O	O	O
the	O	O	O
Ascl1	O	O	B-Entity
promoter	O	O	B-Entity
,	O	O	O
isolated	O	O	B-Entity
from	O	O	O
murine	O	O	B-Entity
dorsal	O	O	B-Entity
root	O	O	I-Entity
ganglion	O	O	I-Entity
(	O	O	O
hypermethylated	O	O	B-Entity
)	O	O	O
and	O	O	O
striated	O	O	B-Entity
cells	O	O	B-Entity
(	O	O	O
hypomethylated	O	O	B-Entity
)	O	O	O
,	O	O	O
was	O	O	O
targeted	O	O	B-Entity
with	O	O	O
these	O	O	O
optogenetic-epigenetic	O	O	B-Entity
constructs	O	O	I-Entity
.	O	O	O

Optimized	O	O	O
blue-light	O	O	B-Entity
illumination	O	O	B-Entity
triggered	O	O	B-Entity
the	O	O	O
co-localization	O	O	B-Entity
of	O	O	O
TALE	O	O	B-Entity
constructs	O	O	I-Entity
with	O	O	O
DNMT3A	O	O	B-Entity
-	O	O	O
CD	O	O	B-Entity
or	O	O	O
TET1	O	O	B-Entity
-	O	O	O
CD	O	O	O
fusion	O	O	B-Entity
proteins	O	O	I-Entity
at	O	O	O
the	O	O	O
targeted	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
the	O	O	O
Ascl1	O	O	B-Entity
promoter	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
this	O	O	O
spatiotemporal	O	O	B-Entity
association	O	O	O
of	O	O	O
the	O	O	O
fusion	O	O	B-Entity
proteins	O	O	I-Entity
selectively	O	O	O
alters	O	O	B-Entity
the	O	O	O
methylation	O	O	B-Entity
state	O	O	B-Entity
and	O	O	O
also	O	O	O
regulates	O	O	B-Entity
gene	O	O	B-Entity
activity	O	O	I-Entity
.	O	O	O

This	O	O	O
proof	O	O	O
of	O	O	O
concept	O	O	B-Entity
developed	O	O	O
herein	O	O	O
holds	O	O	O
immense	O	O	B-Entity
promise	O	O	B-Entity
for	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
regulate	O	O	B-Entity
gene	O	O	B-Entity
activity	O	O	I-Entity
via	O	O	O
epigenetic	O	O	B-Entity
modulation	O	O	I-Entity
with	O	O	O
spatiotemporal	O	O	B-Entity
precision	O	O	B-Entity
.	O	O	O

-DOCSTART- (28182076)

Vaginal	O	O	B-Entity
Infections	O	O	I-Entity
of	O	O	O
Albanian	O	O	B-Entity
women	O	O	B-Entity
Infected	O	O	B-Entity
with	O	O	O
HPV	O	O	B-Entity
and	O	O	O
their	O	O	O
impact	O	O	O
in	O	O	O
intraepithelial	O	O	B-Entity
cervical	O	O	I-Entity
lesions	O	O	I-Entity
evidenced	O	O	O
by	O	O	O
Pap	O	O	O
test	O	O	O

Cervical	O	O	B-Entity
cytology	O	O	I-Entity
is	O	O	O
the	O	O	O
best	O	O	O
single	O	O	O
method	O	O	O
for	O	O	O
large	O	O	O
screening	O	O	B-Entity
of	O	O	O
the	O	O	O
population	O	O	O
in	O	O	O
identifying	O	O	O
precancerous	O	O	B-Entity
lesions	O	O	I-Entity
of	O	O	O
the	O	O	O
uterine	O	O	B-Entity
cervix	O	O	I-Entity
.	O	O	O

To	O	O	O
estimate	O	O	O
the	O	O	O
frequency	O	O	O
of	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(	O	O	I-Entity
HPV	O	O	B-Entity
)	O	O	I-Entity
positivity	O	O	I-Entity
in	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
Albanian	O	O	B-Entity
women	O	O	B-Entity
,	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
vaginal	O	O	B-Entity
coinfections	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
relationship	O	O	O
of	O	O	O
coinfections	O	O	O
with	O	O	O
HPV	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
their	O	O	O
role	O	O	O
in	O	O	O
metaplasia	O	O	B-Entity
or	O	O	O
cervical	O	O	B-Entity
intraepithelial	O	O	I-Entity
lesions	O	O	I-Entity
(	O	O	O
CIN	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
2075	O	O	O
vaginal	O	O	B-Entity
smears	O	O	I-Entity
were	O	O	O
examined	O	O	O
.	O	O	O

The	O	O	O
Papanicolaou	O	O	B-Entity
stain	O	O	I-Entity
was	O	O	O
used	O	O	O
for	O	O	O
all	O	O	O
slides	O	O	O
.	O	O	O

The	O	O	O
New	O	O	B-Entity
Bethesda	O	O	I-Entity
System	O	O	I-Entity
2001	O	O	O
was	O	O	O
used	O	O	O
for	O	O	O
the	O	O	O
interpretations	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
smears	O	O	I-Entity
.	O	O	O

Data	O	O	O
analysis	O	O	O
was	O	O	O
completed	O	O	O
using	O	O	O
the	O	O	O
Statistical	O	O	B-Entity
Package	O	O	I-Entity
for	O	O	I-Entity
the	O	O	I-Entity
Social	O	O	I-Entity
Sciences	O	O	I-Entity
version	O	O	I-Entity
19.0	O	O	O
.	O	O	O

Prevalence	O	O	B-Entity
of	O	O	O
HPV	O	O	B-Entity
positivity	O	O	I-Entity
was	O	O	O
43.9	O	O	O
%	O	O	O
with	O	O	O
an	O	O	O
average	O	O	O
age	O	O	O
of	O	O	O
35.48	O	O	O
±	O	O	O
9.27	O	O	O
years	O	O	O
.	O	O	O

Candida	O	O	B-Entity
coinfection	O	O	I-Entity
resulted	O	O	O
in	O	O	O
57.8	O	O	O
%	O	O	O
of	O	O	O
HPV	O	O	B-Entity
positive	O	O	I-Entity
women	O	O	B-Entity
with	O	O	O
a	O	O	O
significant	O	O	O
relationship	O	O	O
between	O	O	O
them	O	O	O
.	O	O	O

Gardnerella	O	O	B-Entity
coinfection	O	O	I-Entity
resulted	O	O	O
in	O	O	O
36	O	O	O
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
mixed	O	O	B-Entity
flora	O	O	I-Entity
in	O	O	O
34	O	O	O
(	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
Trichomonas	O	O	B-Entity
vaginalis	O	O	I-Entity
in	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
HPV	O	O	B-Entity
positive	O	O	I-Entity
woman	O	O	B-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
women	O	O	B-Entity
with	O	O	O
positive	O	O	B-Entity
HPV	O	O	B-Entity
,	O	O	O
19	O	O	O
%	O	O	O
had	O	O	O
CIN	O	O	B-Entity
,	O	O	O
8	O	O	O
%	O	O	O
had	O	O	O
metaplasia	O	O	B-Entity
,	O	O	O
and	O	O	O
1	O	O	O
%	O	O	O
had	O	O	O
metaplasia	O	O	O
and	O	O	O
CIN	O	O	O
;	O	O	O
9	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
women	O	O	O
with	O	O	O
HPV	O	O	O
had	O	O	O
CIN1	O	O	B-Entity
and	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
coinfections	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
strong	O	O	O
relationship	O	O	O
between	O	O	O
CIN1	O	O	B-Entity
and	O	O	O
HPV	O	O	B-Entity
positivity	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
between	O	O	O
CIN1	O	O	O
and	O	O	O
coinfections	O	O	B-Entity
.	O	O	O

HPV	O	O	B-Entity
infection	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
factor	O	O	O
contributing	O	O	O
to	O	O	O
metaplasia	O	O	B-Entity
,	O	O	O
and	O	O	O
bacterial	O	O	B-Entity
coinfections	O	O	I-Entity
in	O	O	O
HPV	O	O	B-Entity
positive	O	O	I-Entity
women	O	O	B-Entity
have	O	O	O
a	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
impact	O	O	O
in	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
metaplasia	O	O	O
.	O	O	O

-DOCSTART- (28182129)

A	O	O	O
Case	O	O	O
of	O	O	O
Acute	O	O	B-Entity
Hepatitis	O	O	B-Entity
E	O	O	I-Entity
Infection	O	O	I-Entity
in	O	O	O
a	O	O	O
Patient	O	O	B-Entity
with	O	O	O
Non-Hodgkin	O	O	B-Entity
Lymphoma	O	O	I-Entity
Treated	O	O	B-Entity
Successfully	O	O	O
with	O	O	O
Ribavirin	O	O	O

We	O	O	O
present	O	O	O
the	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
man	O	O	B-Entity
who	O	O	O
,	O	O	O
following	O	O	O
immunosuppressive	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
non-Hodgkin	O	O	B-Entity
lymphoma	O	O	I-Entity
,	O	O	O
became	O	O	O
infected	O	O	B-Entity
with	O	O	O
viral	O	O	O
hepatitis	O	O	O
E.	O	O	O
Acute	O	O	B-Entity
hepatitis	O	O	B-Entity
E	O	O	I-Entity
virus	O	O	I-Entity
infection	O	O	I-Entity
should	O	O	O
be	O	O	O
considered	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
deranged	O	O	B-Entity
liver	O	O	B-Entity
function	O	O	I-Entity
on	O	O	O
a	O	O	O
background	O	O	O
of	O	O	O
haematological	O	O	B-Entity
malignancies	O	O	I-Entity
or	O	O	O
immunosuppression	O	O	B-Entity
,	O	O	O
even	O	O	O
without	O	O	O
travel	O	O	O
to	O	O	O
endemic	O	O	B-Entity
regions	O	O	I-Entity
.	O	O	O

Whilst	O	O	O
clearance	O	O	O
is	O	O	O
usually	O	O	O
spontaneous	O	O	O
in	O	O	O
immune	O	O	B-Entity
-	O	O	O
competent	O	O	B-Entity
individuals	O	O	B-Entity
,	O	O	O
these	O	O	O
at-risk	O	O	B-Entity
groups	O	O	I-Entity
may	O	O	O
develop	O	O	O
a	O	O	O
more	O	O	O
complicated	O	O	O
and	O	O	O
protracted	O	O	B-Entity
disease	O	O	I-Entity
course	O	O	I-Entity
.	O	O	O

Thus	O	O	O
awareness	O	O	O
is	O	O	O
important	O	O	O
as	O	O	O
additional	O	O	O
treatment	O	O	B-Entity
with	O	O	O
ribavirin	O	O	B-Entity
or	O	O	O
pegylated	O	O	B-Entity
interferon	O	O	I-Entity
may	O	O	O
be	O	O	O
required	O	O	O
,	O	O	O
as	O	O	O
in	O	O	O
this	O	O	O
case	O	O	O
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
help	O	O	O
achieve	O	O	O
eradication	O	O	B-Entity
.	O	O	O

-DOCSTART- (28183806)

Commissioning	O	O	B-Entity
through	O	O	O
competition	O	O	B-Entity
and	O	O	O
cooperation	O	O	B-Entity
in	O	O	O
the	O	O	O
English	O	O	B-Entity
NHS	O	O	B-Entity
under	O	O	O
the	O	O	O
Health	O	O	B-Entity
and	O	O	I-Entity
Social	O	O	I-Entity
Care	O	O	I-Entity
Act	O	O	I-Entity
2012	O	O	I-Entity
:	O	O	O
evidence	O	O	O
from	O	O	O
a	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
four	O	O	O
clinical	O	O	O
commissioning	O	O	O
groups	O	O	O

The	O	O	O
Health	O	O	B-Entity
and	O	O	I-Entity
Social	O	O	I-Entity
Care	O	O	I-Entity
Act	O	O	I-Entity
2012	O	O	I-Entity
(	O	O	O
'	O	O	O
HSCA	O	O	B-Entity
2012	O	O	I-Entity
'	O	O	O
)	O	O	O
introduced	O	O	O
a	O	O	O
new	O	O	O
,	O	O	O
statutory	O	O	O
,	O	O	O
form	O	O	O
of	O	O	O
regulation	O	O	B-Entity
of	O	O	O
competition	O	O	B-Entity
into	O	O	O
the	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
Service	O	O	I-Entity
(	O	O	O
NHS	O	O	B-Entity
)	O	O	O
,	O	O	O
while	O	O	O
at	O	O	O
the	O	O	O
same	O	O	O
time	O	O	O
recognising	O	O	O
that	O	O	O
cooperation	O	O	B-Entity
was	O	O	O
necessary	O	O	O
.	O	O	O

NHS	O	O	B-Entity
England	O	O	B-Entity
's	O	O	I-Entity
policy	O	O	I-Entity
document	O	O	I-Entity
,	O	O	O
The	O	O	O
Five	O	O	B-Entity
Year	O	O	I-Entity
Forward	O	O	I-Entity
View	O	O	I-Entity
(	O	O	O
'	O	O	O
5YFV	O	O	B-Entity
'	O	O	O
)	O	O	O
of	O	O	O
2014	O	O	O
placed	O	O	O
less	O	O	O
emphasis	O	O	O
on	O	O	O
competition	O	O	B-Entity
without	O	O	O
altering	O	O	O
the	O	O	O
legislation	O	O	B-Entity
.	O	O	O

We	O	O	O
explored	O	O	O
how	O	O	O
commissioners	O	O	B-Entity
and	O	O	O
providers	O	O	B-Entity
understand	O	O	O
the	O	O	O
complex	O	O	B-Entity
regulatory	O	O	B-Entity
framework	O	O	I-Entity
,	O	O	O
and	O	O	O
how	O	O	O
they	O	O	O
behave	O	O	O
in	O	O	O
relation	O	O	O
to	O	O	O
competition	O	O	B-Entity
and	O	O	O
cooperation	O	O	B-Entity
.	O	O	O

We	O	O	O
carried	O	O	O
out	O	O	O
detailed	O	O	O
case	O	O	B-Entity
studies	O	O	I-Entity
in	O	O	O
four	O	O	O
clinical	O	O	B-Entity
commissioning	O	O	I-Entity
groups	O	O	I-Entity
,	O	O	O
using	O	O	O
interviews	O	O	B-Entity
and	O	O	O
documentary	O	O	B-Entity
analysis	O	O	I-Entity
to	O	O	O
explore	O	O	O
the	O	O	O
commissioners	O	O	B-Entity
'	O	O	O
and	O	O	O
providers	O	O	B-Entity
'	O	O	O
understanding	O	O	O
and	O	O	O
experience	O	O	O
of	O	O	O
competition	O	O	B-Entity
and	O	O	O
cooperation	O	O	B-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
42	O	O	O
interviews	O	O	B-Entity
with	O	O	O
senior	O	O	B-Entity
managers	O	O	I-Entity
in	O	O	O
commissioning	O	O	B-Entity
organisations	O	O	B-Entity
and	O	O	O
senior	O	O	O
managers	O	O	O
in	O	O	O
NHS	O	O	B-Entity
and	O	O	O
independent	O	O	B-Entity
provider	O	O	I-Entity
organisations	O	O	I-Entity
(	O	O	O
acute	O	O	B-Entity
and	O	O	I-Entity
community	O	O	I-Entity
services	O	O	I-Entity
)	O	O	O
.	O	O	O

Neither	O	O	O
commissioners	O	O	B-Entity
nor	O	O	O
providers	O	O	B-Entity
fully	O	O	O
understand	O	O	O
the	O	O	O
regulatory	O	O	B-Entity
regime	O	O	I-Entity
in	O	O	O
respect	O	O	O
of	O	O	O
competition	O	O	B-Entity
in	O	O	O
the	O	O	O
NHS	O	O	B-Entity
,	O	O	O
and	O	O	O
have	O	O	O
not	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
regulatory	O	O	B-Entity
authorities	O	O	I-Entity
have	O	O	O
provided	O	O	O
adequate	O	O	O
guidance	O	O	B-Entity
.	O	O	O

Despite	O	O	O
the	O	O	O
HSCA	O	O	B-Entity
2012	O	O	I-Entity
promoting	O	O	B-Entity
competition	O	O	B-Entity
,	O	O	O
commissioners	O	O	B-Entity
chose	O	O	O
mainly	O	O	O
to	O	O	O
use	O	O	O
collaborative	O	O	B-Entity
strategies	O	O	I-Entity
to	O	O	O
effect	O	O	O
major	O	O	O
service	O	O	B-Entity
reconfigurations	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
endorsed	O	O	O
as	O	O	O
a	O	O	O
suitable	O	O	O
approach	O	O	O
by	O	O	O
providers	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
commissioners	O	O	B-Entity
are	O	O	O
using	O	O	O
competitive	O	O	B-Entity
tendering	O	O	O
in	O	O	O
respect	O	O	O
of	O	O	O
more	O	O	O
peripheral	O	O	B-Entity
services	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
improve	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
care	O	O	I-Entity
and	O	O	O
value	O	O	B-Entity
for	O	O	I-Entity
money	O	O	I-Entity
.	O	O	O

Commissioners	O	O	B-Entity
regard	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
competition	O	O	B-Entity
and	O	O	O
cooperation	O	O	B-Entity
as	O	O	O
appropriate	O	O	O
in	O	O	O
the	O	O	O
NHS	O	O	B-Entity
currently	O	O	O
,	O	O	O
although	O	O	O
collaborative	O	O	B-Entity
strategies	O	O	I-Entity
appear	O	O	O
more	O	O	O
helpful	O	O	O
in	O	O	O
respect	O	O	O
of	O	O	O
large-scale	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
current	O	O	O
regulatory	O	O	B-Entity
framework	O	O	I-Entity
contained	O	O	O
in	O	O	O
the	O	O	O
HSCA	O	O	B-Entity
2012	O	O	I-Entity
,	O	O	O
particularly	O	O	O
since	O	O	O
the	O	O	O
publication	O	O	B-Entity
of	O	O	O
the	O	O	O
5YFV	O	O	B-Entity
,	O	O	O
is	O	O	O
not	O	O	O
clear	O	O	O
.	O	O	O

Better	O	O	O
guidance	O	O	B-Entity
should	O	O	O
be	O	O	O
issued	O	O	O
by	O	O	O
the	O	O	O
regulatory	O	O	B-Entity
authorities	O	O	I-Entity
.	O	O	O

-DOCSTART- (28187247)

Prevalence	O	O	B-Entity
and	O	O	O
correlates	O	O	B-Entity
of	O	O	O
antibiotic	O	O	B-Entity
sharing	O	O	B-Entity
in	O	O	O
the	O	O	O
Philippines	O	O	B-Entity
:	O	O	O
antibiotic	O	O	O
misconceptions	O	O	B-Entity
and	O	O	O
community	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
access	O	O	O
to	O	O	O
non-medical	O	O	B-Entity
sources	O	O	B-Entity
of	O	O	O
antibiotics	O	O	O

To	O	O	O
identify	O	O	O
sociodemographic	O	O	B-Entity
,	O	O	O
knowledge	O	O	B-Entity
and	O	O	O
attitudinal	O	O	B-Entity
correlates	O	O	B-Entity
to	O	O	O
antibiotic	O	O	B-Entity
sharing	O	O	B-Entity
among	O	O	O
a	O	O	O
community-based	O	O	B-Entity
sample	O	O	I-Entity
of	O	O	O
adults	O	O	B-Entity
(	O	O	O
age	O	O	O
18	O	O	O
and	O	O	O
older	O	O	O
)	O	O	O
in	O	O	O
a	O	O	O
low-income	O	O	B-Entity
setting	O	O	I-Entity
of	O	O	O
the	O	O	O
Philippines	O	O	B-Entity
and	O	O	O
to	O	O	O
explore	O	O	O
community	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
data	O	O	B-Entity
on	O	O	O
informal	O	O	B-Entity
antibiotic	O	O	O
distribution	O	O	B-Entity
in	O	O	O
roadside	O	O	B-Entity
stands	O	O	I-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
sari-sari	O	O	B-Entity
stands	O	O	I-Entity
)	O	O	O
.	O	O	O

Participants	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
307	O	O	O
)	O	O	O
completed	O	O	B-Entity
self-administered	O	O	B-Entity
surveys	O	O	B-Entity
.	O	O	O

Correlates	O	O	B-Entity
to	O	O	O
antibiotic	O	O	B-Entity
sharing	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
with	O	O	O
Firth	O	O	B-Entity
's	O	O	I-Entity
bias-adjusted	O	O	I-Entity
estimate	O	O	I-Entity
s.	O	O	O
Study	O	O	O
staff	O	O	B-Entity
also	O	O	O
visited	O	O	O
106	O	O	O
roadside	O	O	B-Entity
stands	O	O	B-Entity
and	O	O	O
collected	O	O	B-Entity
data	O	O	I-Entity
on	O	O	O
availability	O	O	B-Entity
and	O	O	O
characteristics	O	O	O
of	O	O	O
antibiotics	O	O	B-Entity
in	O	O	O
the	O	O	O
stands	O	O	O
.	O	O	O

78	O	O	O
%	O	O	O
had	O	O	O
shared	O	O	B-Entity
antibiotics	O	O	B-Entity
in	O	O	O
their	O	O	O
lifetime	O	O	B-Entity
,	O	O	O
most	O	O	O
often	O	O	B-Entity
with	O	O	O
family	O	O	B-Entity
members	O	O	I-Entity
.	O	O	O

In	O	O	O
multivariable	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
agreement	O	O	B-Entity
with	O	O	O
the	O	O	O
belief	O	O	B-Entity
that	O	O	O
it	O	O	O
is	O	O	O
safe	O	O	O
to	O	O	O
prematurely	O	O	B-Entity
stop	O	O	B-Entity
an	O	O	O
antibiotic	O	O	B-Entity
course	O	O	B-Entity
(	O	O	O
OR	O	O	B-Entity
:	O	O	O
2.8	O	O	O
,	O	O	O
CI	O	O	O
:	O	O	O
1.3	O	O	O
-	O	O	O
5.8	O	O	O
)	O	O	O
and	O	O	O
concerns	O	O	B-Entity
about	O	O	O
antibiotic	O	O	B-Entity
side	O	O	I-Entity
effects	O	O	I-Entity
(	O	O	O
OR	O	O	O
:	O	O	O
2.1	O	O	O
,	O	O	O
CI	O	O	O
:	O	O	O
1.1	O	O	O
-	O	O	O
4.4	O	O	O
)	O	O	O
were	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
increased	O	O	B-Entity
odds	O	O	O
of	O	O	O
reported	O	O	O
antibiotic	O	O	O
sharing	O	O	B-Entity
.	O	O	O

Antibiotic	O	O	B-Entity
sharing	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
sociodemographic	O	O	B-Entity
characteristics	O	O	I-Entity
or	O	O	O
antibiotic	O	O	B-Entity
knowledge	O	O	B-Entity
.	O	O	O

Antibiotics	O	O	B-Entity
were	O	O	O
widely	O	O	O
available	O	O	B-Entity
in	O	O	O
60	O	O	O
%	O	O	O
of	O	O	O
sampled	O	O	O
sari-sari	O	O	B-Entity
stands	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
59	O	O	O
%	O	O	O
of	O	O	O
antibiotics	O	O	B-Entity
were	O	O	O
missing	O	O	B-Entity
expiration	O	O	I-Entity
dates	O	O	I-Entity
.	O	O	O

Amoxicillin	O	O	B-Entity
and	O	O	O
cephalexin	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
commonly	O	O	B-Entity
available	O	O	B-Entity
antibiotics	O	O	B-Entity
for	O	O	O
sale	O	O	O
at	O	O	O
the	O	O	O
stands	O	O	B-Entity
(	O	O	O
60	O	O	O
%	O	O	O
and	O	O	O
21	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Antibiotic	O	O	B-Entity
sharing	O	O	B-Entity
was	O	O	O
common	O	O	B-Entity
and	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
misconceptions	O	O	B-Entity
about	O	O	O
proper	O	O	O
antibiotic	O	O	B-Entity
use	O	O	O
.	O	O	O

Antibiotics	O	O	B-Entity
were	O	O	O
widely	O	O	O
available	O	O	B-Entity
in	O	O	O
sari-sari	O	O	B-Entity
stands	O	O	I-Entity
,	O	O	O
and	O	O	O
usually	O	O	O
without	O	O	B-Entity
expiration	O	O	B-Entity
information	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
suggests	O	O	O
that	O	O	O
multipronged	O	O	O
and	O	O	O
locally	O	O	O
tailored	O	O	O
approaches	O	O	O
to	O	O	O
curbing	O	O	B-Entity
informal	O	O	B-Entity
antibiotic	O	O	B-Entity
access	O	O	O
are	O	O	O
needed	O	O	O
in	O	O	O
the	O	O	O
Philippines	O	O	B-Entity
and	O	O	O
similar	O	O	O
Southeast-Asian	O	O	B-Entity
countries	O	O	I-Entity
.	O	O	O

-DOCSTART- (28187885)

Automated	O	O	B-Entity
characterization	O	O	B-Entity
and	O	O	O
counting	O	O	B-Entity
of	O	O	O
Ki-67	O	O	B-Entity
protein	O	O	I-Entity
for	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
prognosis	O	O	B-Entity
:	O	O	O
A	O	O	O
quantitative	O	O	B-Entity
immunohistochemistry	O	O	B-Entity
approach	O	O	O

Ki-67	O	O	B-Entity
protein	O	O	I-Entity
expression	O	O	B-Entity
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
predicting	O	O	O
the	O	O	O
proliferative	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
tumour	O	O	B-Entity
cell	O	O	I-Entity
s	O	O	O
and	O	O	O
deciding	O	O	O
the	O	O	O
future	O	O	B-Entity
course	O	O	B-Entity
of	O	O	O
therapy	O	O	B-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Immunohistochemical	O	O	B-Entity
(	O	O	I-Entity
IHC	O	O	I-Entity
)	O	O	I-Entity
determination	O	O	I-Entity
of	O	O	O
Ki-67	O	O	B-Entity
score	O	O	I-Entity
or	O	O	O
labelling	O	O	B-Entity
index	O	O	I-Entity
,	O	O	O
by	O	O	O
estimating	O	O	O
the	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
Ki67	O	O	B-Entity
positively	O	O	B-Entity
stained	O	O	B-Entity
tumour	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
is	O	O	O
the	O	O	O
most	O	O	O
widely	O	O	O
practiced	O	O	O
method	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
tumour	O	O	O
proliferation	O	O	B-Entity
(	O	O	O
Dowsett	O	O	O
et	O	O	O
al.	O	O	O
2011	O	O	O
)	O	O	O
.	O	O	O

Accurate	O	O	B-Entity
manual	O	O	B-Entity
counting	O	O	I-Entity
of	O	O	O
these	O	O	O
cells	O	O	B-Entity
(	O	O	O
specifically	O	O	B-Entity
nuclei	O	O	B-Entity
)	O	O	O
due	O	O	O
to	O	O	O
complex	O	O	B-Entity
and	O	O	O
dense	O	O	B-Entity
distribution	O	O	B-Entity
of	O	O	O
cells	O	O	O
,	O	O	O
therefore	O	O	O
,	O	O	O
becomes	O	O	O
critical	O	O	B-Entity
and	O	O	O
presents	O	O	B-Entity
a	O	O	O
major	O	O	B-Entity
challenge	O	O	O
to	O	O	O
pathologists	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
suggest	O	O	O
a	O	O	O
hybrid	O	O	B-Entity
clustering	O	O	I-Entity
algorithm	O	O	I-Entity
to	O	O	O
quantify	O	O	B-Entity
the	O	O	O
proliferative	O	O	B-Entity
index	O	O	I-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
based	O	O	O
on	O	O	O
automated	O	O	B-Entity
counting	O	O	I-Entity
of	O	O	O
Ki-67	O	O	B-Entity
nuclei	O	O	B-Entity
.	O	O	O

The	O	O	O
proposed	O	O	O
methodology	O	O	B-Entity
initially	O	O	B-Entity
pre-processes	O	O	B-Entity
the	O	O	O
IHC	O	O	B-Entity
images	O	O	B-Entity
of	O	O	O
Ki-67	O	O	B-Entity
stained	O	O	B-Entity
slides	O	O	B-Entity
of	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
RGB	O	O	O
images	O	O	O
are	O	O	O
converted	O	O	O
to	O	O	O
grey	O	O	B-Entity
,	O	O	O
L*a*b	O	O	O
*	O	O	O
,	O	O	O
HSI	O	O	O
,	O	O	O
YCbCr	O	O	O
,	O	O	O
YIQ	O	O	O
and	O	O	O
XYZ	O	O	O
colour	O	O	B-Entity
space	O	O	I-Entity
.	O	O	O

All	O	O	O
the	O	O	O
stained	O	O	B-Entity
cells	O	O	B-Entity
are	O	O	O
then	O	O	O
characterized	O	O	B-Entity
by	O	O	O
two	O	O	B-Entity
stage	O	O	I-Entity
segmentation	O	O	I-Entity
process	O	O	I-Entity
.	O	O	O

Fuzzy	O	O	B-Entity
C-means	O	O	I-Entity
quantifies	O	O	B-Entity
all	O	O	O
the	O	O	O
stained	O	O	B-Entity
cells	O	O	B-Entity
as	O	O	O
one	O	O	O
cluster	O	O	B-Entity
.	O	O	O

The	O	O	O
blue	O	O	B-Entity
channel	O	O	B-Entity
of	O	O	O
the	O	O	O
first	O	O	B-Entity
stage	O	O	I-Entity
output	O	O	B-Entity
is	O	O	O
given	O	O	O
as	O	O	O
input	O	O	O
to	O	O	O
k-means	O	O	B-Entity
algorithm	O	O	I-Entity
,	O	O	O
which	O	O	O
provides	O	O	O
separate	O	O	B-Entity
cluster	O	O	B-Entity
for	O	O	O
Ki-67	O	O	B-Entity
positive	O	O	B-Entity
and	O	O	I-Entity
negative	O	O	I-Entity
cells	O	O	B-Entity
.	O	O	O

The	O	O	O
count	O	O	B-Entity
of	O	O	O
positive	O	O	B-Entity
and	O	O	I-Entity
negative	O	O	I-Entity
nuclei	O	O	B-Entity
is	O	O	O
used	O	O	O
to	O	O	O
calculate	O	O	B-Entity
the	O	O	O
F-measure	O	O	B-Entity
for	O	O	O
each	O	O	O
colour	O	O	B-Entity
space	O	O	I-Entity
.	O	O	O

A	O	O	O
comparative	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
our	O	O	O
work	O	O	O
with	O	O	O
the	O	O	O
expert	O	O	B-Entity
opinion	O	O	I-Entity
is	O	O	O
studied	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
error	O	O	B-Entity
rate	O	O	B-Entity
.	O	O	O

The	O	O	O
positive	O	O	B-Entity
and	O	O	I-Entity
negative	O	O	I-Entity
nuclei	O	O	B-Entity
detection	O	O	B-Entity
results	O	O	B-Entity
for	O	O	O
all	O	O	O
colour	O	O	B-Entity
space	O	O	I-Entity
s	O	O	O
are	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
ground	O	O	O
truth	O	O	O
for	O	O	O
validation	O	O	O
and	O	O	O
F-measure	O	O	B-Entity
is	O	O	O
calculated	O	O	B-Entity
.	O	O	O

The	O	O	O
F-measure	O	O	B-Entity
for	O	O	O
L*a*b	O	O	O
*	O	O	O
colour	O	O	B-Entity
space	O	O	I-Entity
(	O	O	O
0.8847	O	O	O
)	O	O	O
provides	O	O	O
the	O	O	O
best	O	O	O
statistical	O	O	B-Entity
result	O	O	B-Entity
as	O	O	O
compared	O	O	B-Entity
to	O	O	O
grey	O	O	B-Entity
,	O	O	O
HSI	O	O	O
,	O	O	O
YCbCr	O	O	O
,	O	O	O
YIQ	O	O	O
and	O	O	O
XYZ	O	O	O
colour	O	O	O
space	O	O	O
.	O	O	O

Further	O	O	O
,	O	O	O
a	O	O	O
study	O	O	B-Entity
is	O	O	O
carried	O	O	O
out	O	O	O
to	O	O	O
count	O	O	B-Entity
nuclei	O	O	B-Entity
manually	O	O	B-Entity
and	O	O	O
automatically	O	O	B-Entity
from	O	O	O
the	O	O	O
proposed	O	O	O
algorithm	O	O	B-Entity
with	O	O	O
an	O	O	O
average	O	O	B-Entity
error	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
6.84	O	O	O
%	O	O	O
which	O	O	O
is	O	O	O
significant	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
provides	O	O	O
an	O	O	O
automated	O	O	B-Entity
count	O	O	B-Entity
of	O	O	O
positive	O	O	B-Entity
and	O	O	I-Entity
negative	O	O	I-Entity
nuclei	O	O	B-Entity
using	O	O	O
L*a*b	O	O	O
*	O	O	O
colour	O	O	B-Entity
space	O	O	I-Entity
and	O	O	O
hybrid	O	O	B-Entity
segmentation	O	O	I-Entity
technique	O	O	I-Entity
.	O	O	O

Computerized	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
proliferation	O	O	B-Entity
index	O	O	I-Entity
can	O	O	O
aid	O	O	O
pathologist	O	O	B-Entity
in	O	O	O
assessing	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
severity	O	O	B-Entity
.	O	O	O

The	O	O	O
proposed	O	O	O
methodology	O	O	B-Entity
,	O	O	O
further	O	O	O
,	O	O	O
has	O	O	O
the	O	O	O
potential	O	O	B-Entity
advantage	O	O	O
of	O	O	O
saving	O	O	O
time	O	O	O
and	O	O	O
assisting	O	O	B-Entity
in	O	O	O
decision	O	O	O
making	O	O	O
over	O	O	O
the	O	O	O
present	O	O	O
manual	O	O	B-Entity
procedure	O	O	I-Entity
and	O	O	O
could	O	O	O
evolve	O	O	O
as	O	O	O
an	O	O	O
assistive	O	O	O
pathological	O	O	B-Entity
decision	O	O	B-Entity
support	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

-DOCSTART- (28189069)

Multitarget	O	O	B-Entity
sensing	O	O	B-Entity
of	O	O	I-Entity
glucose	O	O	I-Entity
and	O	O	O
cholesterol	O	O	B-Entity
based	O	O	O
on	O	O	O
Janus	O	O	O
hydrogel	O	O	O
microparticles	O	O	O

A	O	O	O
visualized	O	O	B-Entity
sensing	O	O	B-Entity
method	O	O	I-Entity
for	O	O	I-Entity
glucose	O	O	I-Entity
and	O	O	O
cholesterol	O	O	B-Entity
was	O	O	O
developed	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
hemispheres	O	O	O
of	O	O	O
the	O	O	O
same	O	O	O
Janus	O	O	B-Entity
hydrogel	O	O	I-Entity
microparticles	O	O	I-Entity
.	O	O	O

Single-phase	O	O	O
and	O	O	O
Janus	O	O	B-Entity
hydrogel	O	O	I-Entity
microparticles	O	O	I-Entity
were	O	O	O
both	O	O	O
generated	O	O	O
using	O	O	O
a	O	O	O
centrifugal	O	O	B-Entity
microfluidic	O	O	B-Entity
chip	O	O	I-Entity
.	O	O	O

For	O	O	O
glucose	O	O	B-Entity
sensing	O	O	I-Entity
,	O	O	O
concanavalin	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
fluorescein	O	O	B-Entity
labeled	O	O	I-Entity
dextran	O	O	I-Entity
used	O	O	O
for	O	O	O
competitive	O	O	B-Entity
binding	O	O	I-Entity
assay	O	O	I-Entity
were	O	O	O
encapsulated	O	O	B-Entity
in	O	O	O
alginate	O	O	B-Entity
microparticles	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
fluorescence	O	O	B-Entity
of	O	O	O
the	O	O	O
microparticles	O	O	O
was	O	O	O
positively	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
glucose	O	O	O
concentration	O	O	B-Entity
.	O	O	O

For	O	O	O
cholesterol	O	O	B-Entity
sensing	O	O	I-Entity
,	O	O	O
the	O	O	O
microparticles	O	O	B-Entity
embedded	O	O	O
with	O	O	O
γ-Fe2O3	O	O	B-Entity
nanoparticles	O	O	I-Entity
were	O	O	O
used	O	O	O
as	O	O	O
catalyst	O	O	B-Entity
for	O	O	O
the	O	O	O
oxidation	O	O	B-Entity
of	O	O	O
3,3',5,5'-Tetramethylbenzidine	O	O	B-Entity
by	O	O	O
H2O2	O	O	B-Entity
,	O	O	O
an	O	O	O
enzymatic	O	O	B-Entity
hydrolysis	O	O	B-Entity
product	O	O	B-Entity
of	O	O	O
cholesterol	O	O	O
.	O	O	O

And	O	O	O
the	O	O	O
color	O	O	B-Entity
transition	O	O	B-Entity
was	O	O	O
more	O	O	O
sensitive	O	O	B-Entity
in	O	O	O
the	O	O	O
microparticles	O	O	B-Entity
than	O	O	O
in	O	O	O
solutions	O	O	B-Entity
,	O	O	O
indicating	O	O	O
the	O	O	O
microparticles	O	O	O
are	O	O	O
more	O	O	O
applicable	O	O	B-Entity
for	O	O	O
visualized	O	O	B-Entity
determination	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
Janus	O	O	B-Entity
microparticles	O	O	B-Entity
were	O	O	O
employed	O	O	B-Entity
for	O	O	O
multitarget	O	O	B-Entity
sensing	O	O	B-Entity
in	O	O	O
the	O	O	O
two	O	O	O
hemespheres	O	O	O
,	O	O	O
and	O	O	O
glucose	O	O	B-Entity
and	O	O	O
cholesterol	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
within	O	O	O
the	O	O	O
same	O	O	O
microparticles	O	O	O
without	O	O	O
obvious	O	O	O
interference	O	O	B-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
the	O	O	O
particles	O	O	B-Entity
could	O	O	O
be	O	O	O
manipulated	O	O	O
by	O	O	O
an	O	O	O
external	O	O	B-Entity
magnetic	O	O	B-Entity
field	O	O	I-Entity
.	O	O	O

The	O	O	O
glucose	O	O	B-Entity
and	O	O	O
cholesterol	O	O	B-Entity
levels	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
serum	O	O	B-Entity
utilizing	O	O	O
the	O	O	O
microparticles	O	O	B-Entity
,	O	O	O
which	O	O	O
confirmed	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
application	O	O	O
of	O	O	O
the	O	O	O
microparticles	O	O	O
in	O	O	O
real	O	O	O
sample	O	O	B-Entity
detection	O	O	B-Entity
.	O	O	O

-DOCSTART- (28190392)

PI3	O	O	B-Entity
K	O	O	I-Entity
/	O	O	O
Akt	O	O	B-Entity
pathway	O	O	B-Entity
:	O	O	O
a	O	O	O
potential	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
chronic	O	O	O
pain	O	O	O

Chronic	O	O	B-Entity
pain	O	O	I-Entity
is	O	O	O
among	O	O	O
the	O	O	O
most	O	O	O
disabling	O	O	B-Entity
and	O	O	O
costly	O	O	O
disorders	O	O	B-Entity
,	O	O	O
with	O	O	O
prevalence	O	O	B-Entity
ranging	O	O	B-Entity
from	O	O	O
10	O	O	O
%	O	O	O
to	O	O	O
55	O	O	O
%	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
current	O	O	O
therapeutic	O	O	B-Entity
strategies	O	O	O
for	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
are	O	O	O
unsatisfactory	O	O	B-Entity
due	O	O	O
to	O	O	O
our	O	O	O
poor	O	O	B-Entity
understanding	O	O	B-Entity
of	O	O	O
its	O	O	O
mechanisms	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
novel	O	O	O
therapeutic	O	O	B-Entity
targets	O	O	B-Entity
need	O	O	O
to	O	O	O
be	O	O	O
found	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
improve	O	O	B-Entity
these	O	O	O
patients	O	O	B-Entity
'	O	O	I-Entity
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

PI3	O	O	B-Entity
K	O	O	I-Entity
and	O	O	O
its	O	O	O
downstream	O	O	B-Entity
Akt	O	O	B-Entity
are	O	O	O
widely	O	O	O
expressed	O	O	B-Entity
in	O	O	O
the	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
the	O	O	O
laminae	O	O	B-Entity
I-IV	O	O	I-Entity
of	O	O	O
the	O	O	O
dorsal	O	O	B-Entity
horn	O	O	I-Entity
,	O	O	O
where	O	O	O
nociceptive	O	O	B-Entity
C	O	O	I-Entity
and	O	O	O
Aδ	O	O	B-Entity
fibers	O	O	I-Entity
of	O	O	O
primary	O	O	B-Entity
afferents	O	O	B-Entity
principally	O	O	O
terminate	O	O	B-Entity
.	O	O	O

Recent	O	O	O
studies	O	O	B-Entity
have	O	O	O
demonstrated	O	O	O
their	O	O	O
critical	O	O	B-Entity
roles	O	O	B-Entity
in	O	O	O
the	O	O	O
development	O	O	B-Entity
and	O	O	O
maintenance	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
review	O	O	B-Entity
,	O	O	O
we	O	O	O
summarized	O	O	O
the	O	O	O
roles	O	O	B-Entity
and	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
/	O	O	O
Akt	O	O	B-Entity
pathway	O	O	B-Entity
in	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
through	O	O	O
sciatic	O	O	B-Entity
nerve	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
diabetic	O	O	B-Entity
neuropathy	O	O	I-Entity
,	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
bone	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
opioid	O	O	B-Entity
tolerance	O	O	I-Entity
,	O	O	O
or	O	O	O
opioid	O	O	O
-	O	O	O
induced	O	O	B-Entity
hyperalgesia	O	O	B-Entity
.	O	O	O

-DOCSTART- (28190791)

No	O	O	O
free	O	O	B-Entity
bed	O	O	I-Entity
with	O	O	O
ventilator	O	O	B-Entity
:	O	O	O
experience	O	O	O
of	O	O	O
a	O	O	O
public	O	O	O
health	O	O	O
specialist	O	O	O

While	O	O	O
the	O	O	O
author	O	O	B-Entity
was	O	O	O
dealing	O	O	O
with	O	O	O
a	O	O	O
poor	O	O	B-Entity
elderly	O	O	B-Entity
father	O	O	I-Entity
struggling	O	O	O
to	O	O	O
shift	O	O	O
his	O	O	O
gravely	O	O	B-Entity
injured	O	O	I-Entity
young	O	O	B-Entity
son	O	O	B-Entity
to	O	O	O
a	O	O	O
government	O	O	B-Entity
hospital	O	O	I-Entity
due	O	O	O
to	O	O	O
the	O	O	O
high	O	O	O
cost	O	O	O
of	O	O	O
intensive	O	O	B-Entity
care	O	O	I-Entity
,	O	O	O
her	O	O	O
friends	O	O	B-Entity
across	O	O	O
the	O	O	O
globe	O	O	B-Entity
were	O	O	O
discussing	O	O	O
euthanasia	O	O	B-Entity
in	O	O	O
the	O	O	O
social	O	O	B-Entity
media	O	O	I-Entity
.	O	O	O

While	O	O	O
marginalised	O	O	B-Entity
groups	O	O	B-Entity
of	O	O	I-Entity
people	O	O	B-Entity
are	O	O	O
struggling	O	O	O
to	O	O	O
access	O	O	B-Entity
care	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
,	O	O	O
friends	O	O	B-Entity
who	O	O	O
have	O	O	O
moved	O	O	O
to	O	O	O
developed	O	O	B-Entity
parts	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
world	O	O	I-Entity
were	O	O	O
discussing	O	O	O
one	O	O	O
's	O	O	O
choice	O	O	B-Entity
to	O	O	O
live	O	O	B-Entity
or	O	O	O
die	O	O	B-Entity
!	O	O	O
The	O	O	O
poor	O	O	B-Entity
father	O	O	B-Entity
,	O	O	O
after	O	O	O
battling	O	O	B-Entity
to	O	O	O
save	O	O	B-Entity
his	O	O	O
son	O	O	B-Entity
and	O	O	O
reaching	O	O	O
out	O	O	O
to	O	O	O
many	O	O	O
people	O	O	O
for	O	O	O
help	O	O	B-Entity
,	O	O	O
could	O	O	O
not	O	O	O
save	O	O	O
him	O	O	O
.	O	O	O

Early	O	O	B-Entity
treatment	O	O	I-Entity
might	O	O	O
have	O	O	O
helped	O	O	B-Entity
the	O	O	O
young	O	O	B-Entity
boy	O	O	B-Entity
.	O	O	O

The	O	O	O
incident	O	O	B-Entity
left	O	O	O
the	O	O	O
author	O	O	B-Entity
thinking	O	O	O
about	O	O	O
how	O	O	O
the	O	O	O
poor	O	O	B-Entity
are	O	O	O
denied	O	O	B-Entity
care	O	O	B-Entity
simply	O	O	O
because	O	O	O
they	O	O	O
can	O	O	O
not	O	O	O
afford	O	O	O
it	O	O	O
.	O	O	O

Others	O	O	O
debate	O	O	B-Entity
when	O	O	O
to	O	O	O
pull	O	O	B-Entity
the	O	O	I-Entity
plug	O	O	I-Entity
on	O	O	O
the	O	O	O
patient	O	O	B-Entity
.	O	O	O

…	O	O	O
How	O	O	O
many	O	O	O
families	O	O	B-Entity
can	O	O	O
afford	O	O	O
such	O	O	O
care	O	O	B-Entity
in	O	O	O
India	O	O	B-Entity
?	O	O	O
When	O	O	O
nearly	O	O	O
71	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
people	O	O	B-Entity
are	O	O	O
paying	O	O	B-Entity
out	O	O	I-Entity
of	O	O	I-Entity
pocket	O	O	I-Entity
for	O	O	O
healthcare	O	O	B-Entity
and	O	O	O
16	O	O	O
%	O	O	O
are	O	O	O
pushed	O	O	O
below	O	O	B-Entity
the	O	O	I-Entity
poverty	O	O	I-Entity
line	O	O	I-Entity
every	O	O	B-Entity
year	O	O	I-Entity
,	O	O	O
can	O	O	O
we	O	O	O
even	O	O	O
think	O	O	B-Entity
of	O	O	O
universal	O	O	B-Entity
health	O	O	B-Entity
coverage	O	O	I-Entity
?	O	O	O

It	O	O	O
just	O	O	O
sounds	O	O	O
like	O	O	O
a	O	O	O
fancy	O	O	B-Entity
term	O	O	I-Entity
to	O	O	O
be	O	O	O
used	O	O	O
at	O	O	O
conferences	O	O	B-Entity
and	O	O	I-Entity
meetings	O	O	I-Entity
because	O	O	O
the	O	O	O
ground	O	O	B-Entity
reality	O	O	I-Entity
is	O	O	O
completely	O	O	B-Entity
different	O	O	I-Entity
.	O	O	O

-DOCSTART- (28192718)

Quantitative	O	O	B-Entity
determination	O	O	B-Entity
of	O	O	O
five	O	O	O
metabolites	O	O	B-Entity
of	O	O	O
aspirin	O	O	B-Entity
by	O	O	O
UHPLC-MS	O	O	B-Entity
/	O	O	O
MS	O	O	B-Entity
coupled	O	O	B-Entity
with	O	O	O
enzymatic	O	O	B-Entity
reaction	O	O	I-Entity
and	O	O	O
its	O	O	O
application	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
aspirin	O	O	O
dosage	O	O	B-Entity
on	O	O	O
the	O	O	O
metabolic	O	O	O
profile	O	O	O

Acetylsalicylic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
Aspirin	O	O	B-Entity
,	O	O	O
ASA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
famous	O	O	O
drug	O	O	B-Entity
for	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
in	O	O	O
recent	O	O	O
years	O	O	B-Entity
.	O	O	O

Effects	O	O	O
of	O	O	O
ASA	O	O	B-Entity
dosage	O	O	B-Entity
on	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
profile	O	O	I-Entity
have	O	O	O
not	O	O	O
been	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
our	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
establish	O	O	O
a	O	O	O
rapid	O	O	B-Entity
and	O	O	O
reliable	O	O	B-Entity
method	O	O	B-Entity
to	O	O	O
quantify	O	O	B-Entity
ASA	O	O	B-Entity
metabolites	O	O	B-Entity
in	O	O	O
biological	O	O	B-Entity
matrices	O	O	I-Entity
,	O	O	O
especially	O	O	O
for	O	O	O
glucuronide	O	O	B-Entity
metabolites	O	O	O
whose	O	O	O
standards	O	O	O
are	O	O	O
not	O	O	O
commercially	O	O	O
available	O	O	O
.	O	O	O

Then	O	O	O
we	O	O	O
applied	O	O	O
this	O	O	O
method	O	O	B-Entity
to	O	O	O
evaluate	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
ASA	O	O	B-Entity
dosage	O	O	B-Entity
on	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
and	O	O	O
excretion	O	O	B-Entity
profile	O	O	B-Entity
of	O	O	O
ASA	O	O	O
metabolites	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
urine	O	O	B-Entity
.	O	O	O

Salicylic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
SA	O	O	B-Entity
)	O	O	O
,	O	O	O
gentisic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
GA	O	O	B-Entity
)	O	O	O
and	O	O	O
salicyluric	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
SUA	O	O	B-Entity
)	O	O	O
were	O	O	O
determined	O	O	O
directly	O	O	O
by	O	O	O
UHPLC-MS	O	O	B-Entity
/	O	O	O
MS	O	O	B-Entity
,	O	O	O
while	O	O	O
salicyl	O	O	B-Entity
phenolic	O	O	I-Entity
glucuronide	O	O	I-Entity
(	O	O	O
SAPG	O	O	B-Entity
)	O	O	O
and	O	O	O
salicyluric	O	O	B-Entity
acid	O	O	I-Entity
phenolic	O	O	I-Entity
glucuronide	O	O	I-Entity
(	O	O	O
SUAPG	O	O	B-Entity
)	O	O	O
were	O	O	O
quantified	O	O	B-Entity
indirectly	O	O	O
by	O	O	O
measuring	O	O	O
the	O	O	O
released	O	O	O
SA	O	O	O
and	O	O	O
SUA	O	O	O
from	O	O	O
SAPG	O	O	O
and	O	O	O
SUAPG	O	O	O
after	O	O	O
β-glucuronidase	O	O	B-Entity
digestion	O	O	B-Entity
.	O	O	O

SUA	O	O	B-Entity
and	O	O	O
SUAPG	O	O	B-Entity
were	O	O	O
the	O	O	O
major	O	O	O
metabolites	O	O	B-Entity
of	O	O	O
ASA	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
urine	O	O	B-Entity
24	O	O	O
h	O	O	B-Entity
after	O	O	O
ASA	O	O	O
administration	O	O	B-Entity
,	O	O	O
which	O	O	O
accounted	O	O	O
for	O	O	O
50	O	O	O
%	O	O	O
(	O	O	O
SUA	O	O	O
)	O	O	O
and	O	O	O
26	O	O	O
%	O	O	O
(	O	O	O
SUAPG	O	O	O
)	O	O	O
.	O	O	O

When	O	O	O
ASA	O	O	B-Entity
dosage	O	O	B-Entity
was	O	O	O
increased	O	O	B-Entity
,	O	O	O
the	O	O	O
contributions	O	O	O
dropped	O	O	O
to	O	O	O
32	O	O	O
%	O	O	O
and	O	O	O
18	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
excretion	O	O	B-Entity
of	O	O	O
other	O	O	O
three	O	O	O
metabolites	O	O	B-Entity
(	O	O	O
GA	O	O	B-Entity
,	O	O	O
SA	O	O	B-Entity
and	O	O	O
SAPG	O	O	B-Entity
)	O	O	O
however	O	O	O
showed	O	O	O
remarkable	O	O	O
increases	O	O	O
by	O	O	O
16	O	O	O
%	O	O	O
,	O	O	O
6	O	O	O
%	O	O	O
and	O	O	O
4	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
SUA	O	O	B-Entity
and	O	O	O
SUAPG	O	O	B-Entity
were	O	O	O
mainly	O	O	O
excreted	O	O	B-Entity
in	O	O	O
the	O	O	O
time	O	O	B-Entity
period	O	O	I-Entity
of	O	O	O
12	O	O	O
-	O	O	O
24	O	O	O
h	O	O	B-Entity
,	O	O	O
while	O	O	O
GA	O	O	B-Entity
was	O	O	O
excreted	O	O	O
in	O	O	O
the	O	O	O
earlier	O	O	O
time	O	O	B-Entity
periods	O	O	I-Entity
(	O	O	O
0	O	O	O
-	O	O	O
4	O	O	O
h	O	O	O
and	O	O	O
4	O	O	O
-	O	O	O
8	O	O	O
h	O	O	O
)	O	O	O
.	O	O	O

SA	O	O	B-Entity
was	O	O	O
mainly	O	O	O
excreted	O	O	B-Entity
in	O	O	O
the	O	O	O
time	O	O	B-Entity
period	O	O	I-Entity
of	O	O	O
0	O	O	O
-	O	O	O
4	O	O	O
h	O	O	B-Entity
and	O	O	O
12	O	O	O
-	O	O	O
24	O	O	O
h.	O	O	O
And	O	O	O
the	O	O	O
excretion	O	O	B-Entity
of	O	O	O
SAPG	O	O	B-Entity
was	O	O	O
equally	O	O	O
distributed	O	O	O
in	O	O	O
the	O	O	O
four	O	O	O
time	O	O	B-Entity
periods	O	O	I-Entity
.	O	O	O

We	O	O	O
went	O	O	O
further	O	O	O
to	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
excretion	O	O	B-Entity
of	O	O	O
five	O	O	O
metabolites	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
urine	O	O	B-Entity
was	O	O	O
delayed	O	O	O
when	O	O	O
ASA	O	O	B-Entity
dosage	O	O	B-Entity
was	O	O	O
increased	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
developed	O	O	O
a	O	O	O
rapid	O	O	B-Entity
and	O	O	O
sensitive	O	O	B-Entity
method	O	O	B-Entity
to	O	O	O
determine	O	O	O
the	O	O	O
five	O	O	O
ASA	O	O	B-Entity
metabolites	O	O	B-Entity
(	O	O	O
SA	O	O	B-Entity
,	O	O	O
GA	O	O	B-Entity
,	O	O	O
SUA	O	O	B-Entity
,	O	O	O
SAPG	O	O	B-Entity
and	O	O	O
SUAPG	O	O	B-Entity
)	O	O	O
in	O	O	O
rat	O	O	B-Entity
urine	O	O	B-Entity
.	O	O	O

We	O	O	O
showed	O	O	O
that	O	O	O
ASA	O	O	B-Entity
dosage	O	O	B-Entity
could	O	O	O
significantly	O	O	O
influence	O	O	B-Entity
the	O	O	O
metabolic	O	O	B-Entity
and	O	O	O
excretion	O	O	B-Entity
profile	O	O	B-Entity
of	O	O	O
ASA	O	O	O
metabolites	O	O	B-Entity
in	O	O	O
rat	O	O	B-Entity
urine	O	O	B-Entity
.	O	O	O

-DOCSTART- (28193730)

Mismatch	O	O	B-Entity
Repair	O	O	I-Entity
Incompatibilities	O	O	B-Entity
in	O	O	O
Diverse	O	O	B-Entity
Yeast	O	O	B-Entity
Populations	O	O	O

An	O	O	O
elevated	O	O	B-Entity
mutation	O	O	B-Entity
rate	O	O	I-Entity
can	O	O	O
provide	O	O	O
cells	O	O	B-Entity
with	O	O	O
a	O	O	O
source	O	O	B-Entity
of	O	O	O
mutations	O	O	B-Entity
to	O	O	O
adapt	O	O	O
to	O	O	O
changing	O	O	B-Entity
environments	O	O	B-Entity
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
a	O	O	O
negative	O	O	B-Entity
epistatic	O	O	B-Entity
interaction	O	O	I-Entity
involving	O	O	B-Entity
naturally	O	O	O
occurring	O	O	O
variants	O	O	B-Entity
in	O	O	O
the	O	O	O
MLH1	O	O	B-Entity
and	O	O	O
PMS1	O	O	B-Entity
mismatch	O	O	B-Entity
repair	O	O	I-Entity
(	O	O	O
MMR	O	O	B-Entity
)	O	O	O
genes	O	O	B-Entity
of	O	O	O
Saccharomyces	O	O	B-Entity
cerevisiae	O	O	I-Entity
We	O	O	O
hypothesized	O	O	O
that	O	O	O
this	O	O	O
MMR	O	O	O
incompatibility	O	O	B-Entity
,	O	O	O
created	O	O	O
through	O	O	O
mating	O	O	B-Entity
between	O	O	O
divergent	O	O	O
S.	O	O	B-Entity
cerevisiae	O	O	I-Entity
,	O	O	O
yields	O	O	O
mutator	O	O	O
progeny	O	O	B-Entity
that	O	O	O
can	O	O	O
rapidly	O	O	B-Entity
but	O	O	O
transiently	O	O	O
adapt	O	O	O
to	O	O	O
an	O	O	O
environmental	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
MLH1	O	O	B-Entity
and	O	O	O
PMS1	O	O	B-Entity
genes	O	O	I-Entity
across	O	O	O
1010	O	O	O
S.	O	O	B-Entity
cerevisiae	O	O	I-Entity
natural	O	O	B-Entity
isolates	O	O	B-Entity
spanning	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	B-Entity
of	O	O	O
ecological	O	O	B-Entity
sources	O	O	B-Entity
(	O	O	O
tree	O	O	B-Entity
exudates	O	O	B-Entity
,	O	O	O
Drosophila	O	O	B-Entity
,	O	O	O
fruits	O	O	B-Entity
,	O	O	O
and	O	O	O
various	O	O	O
fermentation	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
isolates	O	O	O
)	O	O	O
and	O	O	O
geographical	O	O	B-Entity
sources	O	O	O
(	O	O	O
Europe	O	O	B-Entity
,	O	O	O
America	O	O	B-Entity
,	O	O	O
Africa	O	O	B-Entity
,	O	O	O
and	O	O	O
Asia	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
identified	O	O	B-Entity
one	O	O	O
homozygous	O	O	B-Entity
clinical	O	O	B-Entity
isolate	O	O	B-Entity
and	O	O	O
18	O	O	O
heterozygous	O	O	B-Entity
isolates	O	O	B-Entity
containing	O	O	B-Entity
the	O	O	O
incompatible	O	O	O
MMR	O	O	B-Entity
genotype	O	O	B-Entity
.	O	O	O

The	O	O	O
MLH1	O	O	B-Entity
-	O	O	O
PMS1	O	O	B-Entity
gene	O	O	I-Entity
combination	O	O	B-Entity
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
homozygous	O	O	B-Entity
clinical	O	O	B-Entity
isolate	O	O	B-Entity
conferred	O	O	O
a	O	O	O
mutator	O	O	O
phenotype	O	O	B-Entity
when	O	O	O
expressed	O	O	B-Entity
in	O	O	O
the	O	O	O
S288c	O	O	O
laboratory	O	O	B-Entity
background	O	O	B-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
novel	O	O	O
reporter	O	O	B-Entity
to	O	O	O
measure	O	O	B-Entity
mutation	O	O	B-Entity
rates	O	O	I-Entity
,	O	O	O
we	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
overall	O	O	B-Entity
mutation	O	O	B-Entity
rate	O	O	I-Entity
in	O	O	O
the	O	O	O
homozygous	O	O	B-Entity
incompatible	O	O	O
background	O	O	B-Entity
was	O	O	O
similar	O	O	O
to	O	O	O
that	O	O	O
seen	O	O	O
in	O	O	O
compatible	O	O	B-Entity
strains	O	O	B-Entity
,	O	O	O
indicating	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
suppressor	O	O	B-Entity
mutations	O	O	I-Entity
in	O	O	O
the	O	O	O
clinical	O	O	B-Entity
isolate	O	O	B-Entity
that	O	O	O
lowered	O	O	O
its	O	O	O
mutation	O	O	O
rate	O	O	O
.	O	O	O

This	O	O	O
observation	O	O	B-Entity
and	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
18	O	O	O
heterozygous	O	O	B-Entity
isolates	O	O	B-Entity
,	O	O	O
which	O	O	O
can	O	O	O
lead	O	O	O
to	O	O	O
MMR	O	O	B-Entity
incompatible	O	O	O
genotypes	O	O	B-Entity
in	O	O	O
the	O	O	O
offspring	O	O	B-Entity
,	O	O	O
are	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
elevated	O	O	B-Entity
mutation	O	O	B-Entity
rate	O	O	I-Entity
rapidly	O	O	O
but	O	O	O
transiently	O	O	O
facilitating	O	O	O
adaptation	O	O	B-Entity
.	O	O	O

To	O	O	O
avoid	O	O	O
long-term	O	O	B-Entity
fitness	O	O	B-Entity
costs	O	O	B-Entity
,	O	O	O
the	O	O	O
incompatibility	O	O	B-Entity
is	O	O	O
apparently	O	O	O
buffered	O	O	B-Entity
by	O	O	O
mating	O	O	B-Entity
or	O	O	O
by	O	O	O
acquiring	O	O	O
suppressors	O	O	B-Entity
.	O	O	O

These	O	O	O
observations	O	O	B-Entity
highlight	O	O	O
effective	O	O	B-Entity
strategies	O	O	O
in	O	O	O
eukaryotes	O	O	B-Entity
to	O	O	O
avoid	O	O	O
long-term	O	O	B-Entity
fitness	O	O	B-Entity
costs	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
elevated	O	O	B-Entity
mutation	O	O	B-Entity
rates	O	O	I-Entity
.	O	O	O

-DOCSTART- (28203094)

Mapping	O	O	B-Entity
circulating	O	O	B-Entity
serum	O	O	B-Entity
miRNAs	O	O	B-Entity
to	O	O	O
their	O	O	O
immune	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
target	O	O	B-Entity
mRNAs	O	O	O

Evidence	O	O	B-Entity
suggests	O	O	B-Entity
that	O	O	O
circulating	O	O	B-Entity
serum	O	O	B-Entity
microRNAs	O	O	B-Entity
(	O	O	O
miRNAs	O	O	B-Entity
)	O	O	O
might	O	O	O
preferentially	O	O	O
target	O	O	B-Entity
immune	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
mRNAs	O	O	B-Entity
.	O	O	O

If	O	O	O
this	O	O	O
were	O	O	O
the	O	O	O
case	O	O	O
,	O	O	O
we	O	O	O
hypothesized	O	O	O
that	O	O	O
immune	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
mRNAs	O	O	B-Entity
would	O	O	O
have	O	O	O
more	O	O	O
predicted	O	O	B-Entity
serum	O	O	B-Entity
miRNA	O	O	B-Entity
binding	O	O	I-Entity
sites	O	O	B-Entity
than	O	O	O
other	O	O	O
mRNAs	O	O	O
and	O	O	O
,	O	O	O
reciprocally	O	O	B-Entity
,	O	O	O
that	O	O	O
serum	O	O	O
miRNAs	O	O	B-Entity
would	O	O	O
have	O	O	O
more	O	O	O
immune	O	O	O
-	O	O	O
related	O	O	O
mRNA	O	O	B-Entity
targets	O	O	B-Entity
than	O	O	O
non	O	O	B-Entity
-	O	O	O
serum	O	O	O
miRNAs	O	O	O
.	O	O	O

We	O	O	O
developed	O	O	B-Entity
a	O	O	O
consensus	O	O	O
target	O	O	B-Entity
predictor	O	O	O
using	O	O	O
the	O	O	O
random	O	O	B-Entity
forest	O	O	I-Entity
framework	O	O	I-Entity
and	O	O	O
calculated	O	O	B-Entity
the	O	O	O
number	O	O	O
of	O	O	O
predicted	O	O	B-Entity
miRNA	O	O	B-Entity
-	O	O	O
mRNA	O	O	B-Entity
interactions	O	O	B-Entity
in	O	O	O
various	O	O	O
subsets	O	O	B-Entity
of	O	O	O
miRNAs	O	O	B-Entity
(	O	O	O
serum	O	O	B-Entity
,	O	O	O
non	O	O	B-Entity
-	O	O	O
serum	O	O	O
)	O	O	O
and	O	O	O
mRNAs	O	O	B-Entity
(	O	O	O
immune	O	O	B-Entity
related	O	O	B-Entity
,	O	O	O
nonimmune	O	O	B-Entity
related	O	O	I-Entity
)	O	O	O
.	O	O	O

Immune	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
mRNAs	O	O	B-Entity
were	O	O	O
predicted	O	O	B-Entity
to	O	O	O
be	O	O	O
targeted	O	O	B-Entity
by	O	O	O
serum	O	O	B-Entity
miRNA	O	O	B-Entity
more	O	O	O
than	O	O	O
other	O	O	O
mRNAs	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
serum	O	O	B-Entity
miRNAs	O	O	B-Entity
were	O	O	O
predicted	O	O	B-Entity
to	O	O	O
target	O	O	B-Entity
many	O	O	O
more	O	O	O
immune	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
mRNA	O	O	B-Entity
targets	O	O	B-Entity
than	O	O	O
non	O	O	B-Entity
-	O	O	O
serum	O	O	O
miRNAs	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
these	O	O	O
two	O	O	O
biases	O	O	B-Entity
in	O	O	O
immune	O	O	O
-	O	O	O
related	O	O	O
mRNAs	O	O	B-Entity
and	O	O	O
serum	O	O	O
miRNAs	O	O	O
appear	O	O	O
to	O	O	O
be	O	O	O
completely	O	O	B-Entity
independent	O	O	B-Entity
.	O	O	O

Immune	O	O	B-Entity
-	O	O	O
related	O	O	B-Entity
mRNAs	O	O	B-Entity
have	O	O	O
more	O	O	O
miRNA	O	O	B-Entity
binding	O	O	I-Entity
sites	O	O	B-Entity
in	O	O	O
general	O	O	O
,	O	O	O
not	O	O	O
just	O	O	O
for	O	O	O
serum	O	O	B-Entity
miRNAs	O	O	B-Entity
;	O	O	O
likewise	O	O	O
,	O	O	O
serum	O	O	O
miRNAs	O	O	O
target	O	O	B-Entity
many	O	O	O
more	O	O	O
mRNAs	O	O	O
than	O	O	O
non	O	O	B-Entity
-	O	O	O
serum	O	O	O
miRNAs	O	O	O
overall	O	O	O
,	O	O	O
regardless	O	O	B-Entity
of	O	O	O
whether	O	O	O
they	O	O	O
are	O	O	O
immune	O	O	B-Entity
related	O	O	O
or	O	O	O
not	O	O	O
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
these	O	O	O
two	O	O	O
independent	O	O	B-Entity
phenomena	O	O	B-Entity
result	O	O	B-Entity
in	O	O	O
a	O	O	O
significantly	O	O	O
larger	O	O	O
number	O	O	O
of	O	O	O
predicted	O	O	B-Entity
serum	O	O	B-Entity
miRNA	O	O	B-Entity
-	O	O	O
immune	O	O	B-Entity
mRNA	O	O	B-Entity
interactions	O	O	B-Entity
than	O	O	O
would	O	O	O
be	O	O	O
expected	O	O	O
by	O	O	O
chance	O	O	O
.	O	O	O

-DOCSTART- (28205317)

Oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
immunosenescence	O	O	B-Entity
in	O	O	O
spleen	O	O	B-Entity
of	O	O	O
obese	O	O	B-Entity
mice	O	O	I-Entity
can	O	O	O
be	O	O	O
reversed	O	O	O
by	O	O	O
2-hydroxyoleic	O	O	O
acid	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
obesity	O	O	B-Entity
on	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
leukocyte	O	O	B-Entity
function	O	O	B-Entity
in	O	O	O
spleen	O	O	B-Entity
of	O	O	O
mice	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
assess	O	O	O
whether	O	O	O
supplementation	O	O	B-Entity
with	O	O	O
2-hydroxyoleic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
2-OHOA	O	O	B-Entity
)	O	O	O
or	O	O	O
n-3	O	O	B-Entity
polyunsaturated	O	O	I-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	O
PUFA	O	O	B-Entity
)	O	O	O
could	O	O	O
reverse	O	O	O
those	O	O	O
effects	O	O	O
.	O	O	O

Female	O	O	B-Entity
ICR/CD1	O	O	B-Entity
mice	O	O	I-Entity
(	O	O	O
8	O	O	O
weeks	O	O	B-Entity
old	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
24	O	O	O
)	O	O	O
received	O	O	O
an	O	O	O
obesogenic	O	O	B-Entity
diet	O	O	I-Entity
(	O	O	O
22	O	O	O
%	O	O	O
fat	O	O	B-Entity
for	O	O	O
4	O	O	O
weeks	O	O	O
and	O	O	O
60	O	O	O
%	O	O	O
fat	O	O	O
for	O	O	O
14	O	O	O
weeks	O	O	O
)	O	O	O
.	O	O	O

After	O	O	O
6	O	O	O
weeks	O	O	B-Entity
,	O	O	O
mice	O	O	B-Entity
were	O	O	O
split	O	O	O
in	O	O	O
three	O	O	O
groups	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
8/	O	O	O
group	O	O	B-Entity
):	O	O	O
no	O	O	B-Entity
supplementation	O	O	I-Entity
,	O	O	O
2-OHOA	O	O	B-Entity
supplementation	O	O	I-Entity
(	O	O	O
1500	O	O	O
mg	O	O	O
kg(-1	O	O	O
)	O	O	O
)	O	O	O
and	O	O	O
n-3	O	O	B-Entity
PUFA	O	O	I-Entity
supplementation	O	O	I-Entity
(	O	O	O
EPA	O	O	B-Entity
+	O	O	O
DHA	O	O	B-Entity
,	O	O	O
3000	O	O	O
mg	O	O	O
kg(-1	O	O	O
)	O	O	O
diet	O	O	O
)	O	O	O
.	O	O	O

Eight	O	O	O
mice	O	O	B-Entity
were	O	O	O
fed	O	O	O
standard	O	O	O
diet	O	O	B-Entity
for	O	O	O
the	O	O	O
whole	O	O	O
duration	O	O	B-Entity
of	O	O	O
the	O	O	O
study	O	O	B-Entity
(	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
)	O	O	O
.	O	O	O

At	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
the	O	O	O
experiment	O	O	B-Entity
,	O	O	O
the	O	O	O
following	O	O	O
variables	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
in	O	O	O
spleens	O	O	B-Entity
:	O	O	O
levels	O	O	B-Entity
of	O	O	O
reduced	O	O	B-Entity
(	O	O	O
GSH	O	O	B-Entity
)	O	O	O
and	O	O	O
oxidized	O	O	B-Entity
(	O	O	I-Entity
GSSG	O	O	B-Entity
)	O	O	I-Entity
glutathione	O	O	I-Entity
,	O	O	O
GSH	O	O	O
/	O	O	O
GSSG	O	O	O
,	O	O	O
xanthine	O	O	B-Entity
oxidase	O	O	I-Entity
(	O	O	I-Entity
XO	O	O	I-Entity
)	O	O	I-Entity
activity	O	O	I-Entity
,	O	O	O
lipid	O	O	B-Entity
peroxidation	O	O	I-Entity
,	O	O	O
lymphocyte	O	O	B-Entity
chemotaxis	O	O	I-Entity
,	O	O	O
natural	O	O	B-Entity
killer	O	O	I-Entity
(	O	O	I-Entity
NK	O	O	I-Entity
)	O	O	I-Entity
activity	O	O	I-Entity
and	O	O	O
mitogen	O	O	B-Entity
(	O	O	O
ConA	O	O	B-Entity
and	O	O	O
LPS)-induced	O	O	O
lymphocyte	O	O	B-Entity
proliferation	O	O	I-Entity
.	O	O	O

Obese	O	O	B-Entity
animals	O	O	B-Entity
presented	O	O	O
higher	O	O	B-Entity
GSSG	O	O	B-Entity
levels	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.003	O	O	O
)	O	O	O
,	O	O	O
GSSG	O	O	O
/	O	O	O
GSH	O	O	B-Entity
ratio	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.013	O	O	O
)	O	O	O
,	O	O	O
lipid	O	O	B-Entity
peroxidation	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.004	O	O	O
)	O	O	O
,	O	O	O
XO	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.015	O	O	O
)	O	O	O
and	O	O	O
lymphocyte	O	O	B-Entity
chemotaxis	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
lower	O	O	O
NK	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.003	O	O	O
)	O	O	O
and	O	O	O
proliferation	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
ConA	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
than	O	O	O
controls	O	O	B-Entity
.	O	O	O

2-OHOA	O	O	B-Entity
reversed	O	O	O
totally	O	O	O
or	O	O	O
partially	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
changes	O	O	B-Entity
(	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
fat	O	O	O
content	O	O	O
,	O	O	O
GSSG	O	O	B-Entity
levels	O	O	B-Entity
,	O	O	O
GSH	O	O	B-Entity
/	O	O	O
GSSG	O	O	O
,	O	O	O
lipid	O	O	B-Entity
peroxidation	O	O	I-Entity
,	O	O	O
chemotaxis	O	O	B-Entity
and	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
all	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
n-3	O	O	B-Entity
PUFA	O	O	I-Entity
reversed	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
XO	O	O	B-Entity
activity	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.032	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
2-OHOA	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
a	O	O	O
lesser	O	O	O
extent	O	O	O
n-3	O	O	B-Entity
PUFA	O	O	I-Entity
,	O	O	O
could	O	O	O
ameliorate	O	O	O
the	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
alteration	O	O	B-Entity
of	O	O	O
leukocyte	O	O	B-Entity
function	O	O	B-Entity
in	O	O	O
spleen	O	O	B-Entity
of	O	O	O
obese	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
support	O	O	O
a	O	O	O
link	O	O	O
between	O	O	O
obesity	O	O	B-Entity
and	O	O	O
immunosenescence	O	O	B-Entity
and	O	O	O
suggest	O	O	O
a	O	O	O
potential	O	O	O
therapeutic	O	O	B-Entity
tool	O	O	I-Entity
for	O	O	O
obesity	O	O	O
-related	O	O	O
immune	O	O	B-Entity
dysfunction	O	O	I-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (28207180)

Assembly	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
outermost	O	O	I-Entity
spore	O	O	I-Entity
layer	O	O	I-Entity
:	O	O	O
pieces	O	O	O
of	O	O	O
the	O	O	O
puzzle	O	O	O
are	O	O	O
coming	O	O	O
together	O	O	O

Certain	O	O	O
endospore-forming	O	O	B-Entity
soil	O	O	I-Entity
dwelling	O	O	I-Entity
bacteria	O	O	I-Entity
are	O	O	O
important	O	O	O
human	O	O	B-Entity
,	O	O	O
animal	O	O	B-Entity
or	O	O	O
insect	O	O	B-Entity
pathogens	O	O	B-Entity
.	O	O	O

These	O	O	O
organisms	O	O	B-Entity
produce	O	O	O
spores	O	O	B-Entity
containing	O	O	O
an	O	O	O
outer	O	O	B-Entity
layer	O	O	I-Entity
,	O	O	O
the	O	O	O
exosporium	O	O	B-Entity
.	O	O	O

The	O	O	O
exosporium	O	O	B-Entity
is	O	O	O
the	O	O	O
site	O	O	B-Entity
of	O	O	I-Entity
interactions	O	O	B-Entity
between	O	O	O
the	O	O	O
spore	O	O	B-Entity
and	O	O	O
the	O	O	O
soil	O	O	B-Entity
environment	O	O	B-Entity
and	O	O	O
between	O	O	O
the	O	O	O
spore	O	O	O
and	O	O	O
the	O	O	O
infected	O	O	B-Entity
host	O	O	B-Entity
during	O	O	O
the	O	O	O
initial	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
infection	O	O	B-Entity
.	O	O	O

The	O	O	O
composition	O	O	B-Entity
and	O	O	O
assembly	O	O	B-Entity
process	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
exosporium	O	O	I-Entity
are	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
partly	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
extreme	O	O	O
stability	O	O	B-Entity
of	O	O	O
the	O	O	O
exosporium	O	O	B-Entity
that	O	O	O
has	O	O	O
proven	O	O	O
to	O	O	O
be	O	O	O
refractive	O	O	O
to	O	O	O
existing	O	O	O
methods	O	O	B-Entity
to	O	O	O
deconstruct	O	O	O
the	O	O	O
intact	O	O	B-Entity
structure	O	O	B-Entity
into	O	O	O
its	O	O	O
component	O	O	B-Entity
parts	O	O	B-Entity
.	O	O	O

Although	O	O	O
more	O	O	O
than	O	O	O
20	O	O	O
proteins	O	O	B-Entity
have	O	O	O
been	O	O	O
identified	O	O	B-Entity
as	O	O	O
exosporium	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
,	O	O	O
their	O	O	O
abundance	O	O	B-Entity
,	O	O	O
relationship	O	O	B-Entity
to	O	O	O
other	O	O	O
proteins	O	O	O
and	O	O	O
the	O	O	O
processes	O	O	B-Entity
by	O	O	O
which	O	O	O
they	O	O	O
are	O	O	O
assembled	O	O	B-Entity
to	O	O	I-Entity
create	O	O	I-Entity
the	O	O	I-Entity
exosporium	O	O	I-Entity
are	O	O	O
largely	O	O	O
unknown	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
issue	O	O	O
of	O	O	O
Molecular	O	O	B-Entity
Microbiology	O	O	I-Entity
,	O	O	O
Terry	O	O	O
,	O	O	O
Jiang	O	O	O
,	O	O	O
and	O	O	O
colleagues	O	O	O
in	O	O	O
Per	O	O	O
Bullough	O	O	O
's	O	O	O
laboratory	O	O	B-Entity
show	O	O	O
that	O	O	O
the	O	O	O
ExsY	O	O	B-Entity
protein	O	O	I-Entity
is	O	O	O
a	O	O	O
major	O	O	O
structural	O	O	B-Entity
protein	O	O	I-Entity
of	O	O	O
the	O	O	O
exosporium	O	O	B-Entity
basal	O	O	I-Entity
layer	O	O	I-Entity
of	O	O	O
B.	O	O	B-Entity
cereus	O	O	I-Entity
family	O	O	I-Entity
spores	O	O	B-Entity
and	O	O	O
that	O	O	O
it	O	O	O
can	O	O	O
self-assemble	O	O	B-Entity
into	O	O	O
complex	O	O	B-Entity
structures	O	O	B-Entity
that	O	O	O
possess	O	O	O
many	O	O	O
of	O	O	O
the	O	O	O
structural	O	O	O
features	O	O	B-Entity
characteristic	O	O	B-Entity
of	O	O	O
the	O	O	O
exosporium	O	O	O
basal	O	O	O
layer	O	O	O
.	O	O	O

The	O	O	O
authors	O	O	B-Entity
refined	O	O	O
a	O	O	O
model	O	O	B-Entity
for	O	O	O
exosporium	O	O	B-Entity
assembly	O	O	I-Entity
.	O	O	O

Their	O	O	O
findings	O	O	B-Entity
may	O	O	O
have	O	O	O
implications	O	O	O
for	O	O	O
exosporium	O	O	B-Entity
formation	O	O	B-Entity
in	O	O	O
other	O	O	O
spore	O	O	B-Entity
forming	O	O	I-Entity
bacteria	O	O	I-Entity
,	O	O	O
including	O	O	O
Clostridium	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

-DOCSTART- (28207880)

Skeletal	O	O	B-Entity
muscle	O	O	I-Entity
metabolic	O	O	O
adaptations	O	O	B-Entity
to	O	O	O
endurance	O	O	B-Entity
exercise	O	O	B-Entity
training	O	O	I-Entity
are	O	O	O
attainable	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
with	O	O	O
simvastatin	O	O	B-Entity
treatment	O	O	O

We	O	O	O
tested	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
a	O	O	O
6-week	O	O	O
regimen	O	O	B-Entity
of	O	O	O
simvastatin	O	O	B-Entity
would	O	O	O
attenuate	O	O	B-Entity
skeletal	O	O	B-Entity
muscle	O	O	I-Entity
adaptation	O	O	B-Entity
to	O	O	O
low-intensity	O	O	B-Entity
exercise	O	O	I-Entity
.	O	O	O

Male	O	O	B-Entity
C57BL/6J	O	O	B-Entity
wildtype	O	O	I-Entity
mice	O	O	I-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
6-weeks	O	O	O
of	O	O	O
voluntary	O	O	B-Entity
wheel	O	O	I-Entity
running	O	O	I-Entity
or	O	O	O
normal	O	O	O
cage	O	O	B-Entity
activities	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
simvastatin	O	O	B-Entity
treatment	O	O	B-Entity
(	O	O	O
20	O	O	O
mg/kg/d	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
7	O	O	O
-	O	O	O
8	O	O	O
per	O	O	O
group	O	O	O
)	O	O	O
.	O	O	O

Adaptations	O	O	B-Entity
in	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
fatigue	O	O	B-Entity
resistance	O	O	B-Entity
were	O	O	O
determined	O	O	O
by	O	O	O
a	O	O	O
treadmill	O	O	B-Entity
running	O	O	I-Entity
test	O	O	I-Entity
,	O	O	O
and	O	O	O
by	O	O	O
ankle	O	O	B-Entity
plantarflexor	O	O	I-Entity
contractile	O	O	B-Entity
assessment	O	O	O
.	O	O	O

The	O	O	O
tibialis	O	O	B-Entity
anterior	O	O	I-Entity
,	O	O	O
gastrocnemius	O	O	B-Entity
,	O	O	O
and	O	O	O
plantaris	O	O	B-Entity
muscles	O	O	I-Entity
were	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
exercised	O	O	B-Entity
-induced	O	O	O
mitochondrial	O	O	B-Entity
adaptations	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
biogenesis	O	O	B-Entity
,	O	O	O
function	O	O	B-Entity
,	O	O	O
autophagy	O	O	B-Entity
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
weekly	O	O	O
wheel	O	O	B-Entity
running	O	O	I-Entity
distance	O	O	I-Entity
between	O	O	O
control	O	O	O
and	O	O	O
simvastatin	O	O	B-Entity
-	O	O	O
treated	O	O	B-Entity
mice	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.51	O	O	O
)	O	O	O
.	O	O	O

Trained	O	O	B-Entity
mice	O	O	B-Entity
had	O	O	O
greater	O	O	O
treadmill	O	O	B-Entity
running	O	O	I-Entity
distance	O	O	B-Entity
(	O	O	O
296	O	O	O
%	O	O	O
,	O	O	O
P<0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
ankle	O	O	B-Entity
plantarflexor	O	O	I-Entity
contractile	O	O	B-Entity
fatigue	O	O	B-Entity
resistance	O	O	B-Entity
(	O	O	O
9	O	O	O
%	O	O	O
,	O	O	O
P<0.05	O	O	O
)	O	O	O
compared	O	O	O
to	O	O	O
sedentary	O	O	O
mice	O	O	O
,	O	O	O
independent	O	O	O
of	O	O	O
simvastatin	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
cellular	O	O	B-Entity
level	O	O	I-Entity
,	O	O	O
trained	O	O	B-Entity
mice	O	O	B-Entity
had	O	O	O
greater	O	O	O
mitochondrial	O	O	B-Entity
biogenesis	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
~2-fold	O	O	O
greater	O	O	O
PGC1α	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
P<0.05	O	O	O
)	O	O	O
and	O	O	O
mitochondrial	O	O	O
content	O	O	O
(	O	O	O
e.g.	O	O	O
,	O	O	O
25	O	O	O
%	O	O	O
greater	O	O	O
citrate	O	O	B-Entity
synthase	O	O	I-Entity
activity	O	O	B-Entity
,	O	O	O
P<0.05	O	O	O
)	O	O	O
,	O	O	O
independent	O	O	O
of	O	O	O
simvastatin	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

Mitochondrial	O	O	B-Entity
autophagy	O	O	B-Entity
-related	O	O	O
protein	O	O	B-Entity
contents	O	O	O
were	O	O	O
greater	O	O	O
in	O	O	O
trained	O	O	B-Entity
mice	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
40	O	O	O
%	O	O	O
greater	O	O	O
Bnip3	O	O	B-Entity
,	O	O	O
P<0.05	O	O	O
)	O	O	O
,	O	O	O
independent	O	O	O
of	O	O	O
simvastatin	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
Drp1	O	O	B-Entity
,	O	O	O
a	O	O	O
marker	O	O	B-Entity
of	O	O	O
mitochondrial	O	O	B-Entity
fission	O	O	I-Entity
,	O	O	O
was	O	O	O
less	O	O	O
in	O	O	O
simvastatin	O	O	B-Entity
treated	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
independent	O	O	O
of	O	O	O
exercise	O	O	B-Entity
training	O	O	B-Entity
,	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	O
interaction	O	O	B-Entity
between	O	O	O
training	O	O	O
and	O	O	O
statin	O	O	O
treatment	O	O	B-Entity
(	O	O	O
P<0.022	O	O	O
)	O	O	O
for	O	O	O
LC3-II	O	O	B-Entity
protein	O	O	I-Entity
content	O	O	B-Entity
,	O	O	O
a	O	O	O
marker	O	O	O
of	O	O	O
autophagy	O	O	B-Entity
flux	O	O	O
.	O	O	O

These	O	O	O
data	O	O	O
indicate	O	O	O
that	O	O	O
whole	O	O	B-Entity
body	O	O	I-Entity
and	O	O	O
skeletal	O	O	B-Entity
muscle	O	O	B-Entity
adaptations	O	O	B-Entity
to	O	O	O
endurance	O	O	B-Entity
exercise	O	O	B-Entity
training	O	O	I-Entity
are	O	O	O
attainable	O	O	B-Entity
with	O	O	O
simvastatin	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
but	O	O	O
simvastatin	O	O	O
may	O	O	O
have	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
muscle	O	O	O
mitochondrial	O	O	B-Entity
maintenance	O	O	O
via	O	O	O
autophagy	O	O	B-Entity
,	O	O	O
which	O	O	O
could	O	O	O
have	O	O	O
long-term	O	O	B-Entity
implications	O	O	O
on	O	O	O
muscle	O	O	O
health	O	O	B-Entity
.	O	O	O

-DOCSTART- (28210010)

Evaluation	O	O	B-Entity
and	O	O	O
Treatment	O	O	B-Entity
of	O	O	O
Anemia	O	O	B-Entity
in	O	O	O
Premature	O	O	O
Infants	O	O	O

Anemia	O	O	B-Entity
in	O	O	O
preterm	O	O	B-Entity
infants	O	O	B-Entity
is	O	O	O
the	O	O	O
pathophysiological	O	O	B-Entity
process	O	O	B-Entity
with	O	O	O
greater	O	O	O
and	O	O	O
more	O	O	O
rapid	O	O	O
decline	O	O	B-Entity
in	O	O	O
hemoglobin	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	O
the	O	O	O
physiological	O	O	B-Entity
anemia	O	O	B-Entity
in	O	O	O
infants	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
transfusions	O	O	B-Entity
and	O	O	O
administration	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
recombinant	O	O	I-Entity
erythropoietin	O	O	I-Entity
.	O	O	O

To	O	O	O
determine	O	O	B-Entity
the	O	O	O
frequency	O	O	B-Entity
of	O	O	O
anemia	O	O	B-Entity
in	O	O	O
premature	O	O	B-Entity
infants	O	O	I-Entity
at	O	O	O
the	O	O	O
Pediatric	O	O	B-Entity
Clinic	O	O	I-Entity
,	O	O	I-Entity
University	O	O	I-Entity
Clinical	O	O	I-Entity
Center	O	O	I-Entity
Sarajevo	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
parameter	O	O	B-Entity
values	O	O	I-Entity
in	O	O	O
the	O	O	O
blood	O	O	B-Entity
count	O	O	I-Entity
of	O	O	O
premature	O	O	O
infants	O	O	O
and	O	O	O
to	O	O	O
explore	O	O	O
a	O	O	O
relationship	O	O	B-Entity
between	O	O	O
blood	O	O	B-Entity
transfusions	O	O	I-Entity
with	O	O	O
the	O	O	O
advent	O	O	O
of	O	O	O
intraventricular	O	O	B-Entity
hemorrhage	O	O	I-Entity
(	O	O	O
determine	O	O	O
treatment	O	O	B-Entity
outcome	O	O	O
in	O	O	O
preterm	O	O	B-Entity
infants	O	O	I-Entity
)	O	O	O
.	O	O	O

Research	O	O	B-Entity
is	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
it	O	O	O
included	O	O	O
the	O	O	O
period	O	O	B-Entity
of	O	O	O
six	O	O	O
months	O	O	B-Entity
in	O	O	O
year	O	O	B-Entity
2014	O	O	O
.	O	O	O

Research	O	O	B-Entity
included	O	O	O
100	O	O	O
patients	O	O	B-Entity
,	O	O	O
gestational	O	O	B-Entity
age	O	O	I-Entity
<	O	O	O
37	O	O	O
weeks	O	O	B-Entity
(	O	O	O
premature	O	O	B-Entity
infants	O	O	I-Entity
)	O	O	O
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
by	O	O	O
examining	O	O	B-Entity
the	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
at	O	O	O
the	O	O	O
Pediatric	O	O	B-Entity
Clinic	O	O	I-Entity
,	O	O	I-Entity
UCCS	O	O	I-Entity
.	O	O	O

The	O	O	O
first	O	O	B-Entity
group	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
were	O	O	O
premature	O	O	B-Entity
infants	O	O	I-Entity
of	O	O	O
gestational	O	O	B-Entity
age	O	O	I-Entity
≤	O	O	O
32	O	O	O
weeks	O	O	B-Entity
(	O	O	O
62/100	O	O	O
)	O	O	O
and	O	O	O
the	O	O	O
second	O	O	B-Entity
group	O	O	O
were	O	O	O
premature	O	O	O
infants	O	O	O
of	O	O	O
gestational	O	O	O
age	O	O	O
33	O	O	O
-	O	O	O
37	O	O	O
weeks	O	O	O
(	O	O	O
38/100	O	O	O
)	O	O	O
.	O	O	O

Among	O	O	O
the	O	O	O
patients	O	O	B-Entity
,	O	O	O
5	O	O	O
%	O	O	O
were	O	O	O
boys	O	O	B-Entity
and	O	O	O
46	O	O	O
%	O	O	O
girls	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
significant	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
birth	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
APGAR	O	O	B-Entity
score	O	O	I-Entity
among	O	O	O
the	O	O	O
groups	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
first	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
there	O	O	O
were	O	O	O
27.42	O	O	O
%	O	O	O
of	O	O	O
deaths	O	O	B-Entity
,	O	O	O
while	O	O	O
in	O	O	O
the	O	O	O
second	O	O	B-Entity
group	O	O	O
,	O	O	O
there	O	O	O
were	O	O	O
only	O	O	O
10.53	O	O	O
%	O	O	O
of	O	O	O
deaths	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
the	O	O	O
length	O	O	O
of	O	O	O
treatment	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
in	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
transfusion	O	O	B-Entity
among	O	O	O
the	O	O	O
groups	O	O	B-Entity
.	O	O	O

18	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	B-Entity
group	O	O	B-Entity
required	O	O	O
a	O	O	O
transfusion	O	O	B-Entity
,	O	O	O
while	O	O	O
in	O	O	O
the	O	O	O
second	O	O	B-Entity
group	O	O	O
only	O	O	O
3	O	O	O
patients	O	O	O
.	O	O	O

Preterm	O	O	B-Entity
infants	O	O	I-Entity
of	O	O	O
gestational	O	O	B-Entity
age	O	O	I-Entity
≤	O	O	O
32	O	O	O
weeks	O	O	B-Entity
are	O	O	O
likely	O	O	O
candidates	O	O	B-Entity
for	O	O	O
blood	O	O	B-Entity
transfusion	O	O	I-Entity
during	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Preterm	O	O	B-Entity
infants	O	O	I-Entity
of	O	O	O
gestational	O	O	B-Entity
age	O	O	I-Entity
≤	O	O	O
32	O	O	O
weeks	O	O	B-Entity
have	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
intracranial	O	O	B-Entity
bleeding	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
application	O	O	B-Entity
of	O	O	O
blood	O	O	B-Entity
transfusion	O	O	I-Entity
in	O	O	O
the	O	O	O
first	O	O	O
week	O	O	B-Entity
of	O	O	O
life	O	O	B-Entity
.	O	O	O

-DOCSTART- (28210659)

Medial	O	O	B-Entity
Patellofemoral	O	O	I-Entity
Ligament	O	O	I-Entity
Reconstruction	O	O	B-Entity
Femoral	O	O	B-Entity
Tunnel	O	O	B-Entity
Accuracy	O	O	B-Entity
:	O	O	O
Relationship	O	O	O
to	O	O	O
Disease	O	O	B-Entity
-	O	O	O
Specific	O	O	B-Entity
Quality	O	O	O
of	O	O	O
Life	O	O	O

Medial	O	O	B-Entity
patellofemoral	O	O	I-Entity
ligament	O	O	I-Entity
(	O	O	O
MPFL	O	O	B-Entity
)	O	O	O
reconstruction	O	O	B-Entity
is	O	O	O
a	O	O	O
procedure	O	O	O
aimed	O	O	O
to	O	O	O
reestablish	O	O	O
the	O	O	O
checkrein	O	O	O
to	O	O	O
lateral	O	O	B-Entity
patellar	O	O	I-Entity
translation	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
symptomatic	O	O	B-Entity
patellofemoral	O	O	I-Entity
instability	O	O	I-Entity
.	O	O	O

Correct	O	O	O
femoral	O	O	B-Entity
tunnel	O	O	B-Entity
position	O	O	B-Entity
is	O	O	O
thought	O	O	O
to	O	O	O
be	O	O	O
crucial	O	O	O
to	O	O	O
successful	O	O	O
MPFL	O	O	B-Entity
reconstruction	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
this	O	O	O
statement	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
patient	O	O	B-Entity
outcomes	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
tested	O	O	O
.	O	O	O

To	O	O	O
assess	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
femoral	O	O	B-Entity
tunnel	O	O	B-Entity
placement	O	O	B-Entity
in	O	O	O
an	O	O	O
MPFL	O	O	B-Entity
reconstruction	O	O	B-Entity
cohort	O	O	B-Entity
and	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
correlation	O	O	B-Entity
between	O	O	O
tunnel	O	O	O
accuracy	O	O	O
and	O	O	O
a	O	O	O
validated	O	O	B-Entity
disease	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
,	O	O	O
patient	O	O	B-Entity
-reported	O	O	O
quality-of-life	O	O	B-Entity
outcome	O	O	B-Entity
measure	O	O	I-Entity
.	O	O	O

Case	O	O	O
series	O	O	O
;	O	O	O
Level	O	O	O
of	O	O	O
evidence	O	O	O
,	O	O	O
4	O	O	O
.	O	O	O

Between	O	O	O
June	O	O	B-Entity
2008	O	O	O
and	O	O	O
February	O	O	B-Entity
2014	O	O	O
,	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
206	O	O	O
subjects	O	O	B-Entity
underwent	O	O	O
an	O	O	O
MPFL	O	O	B-Entity
reconstruction	O	O	B-Entity
.	O	O	O

Lateral	O	O	B-Entity
radiographs	O	O	B-Entity
were	O	O	O
measured	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
the	O	O	O
femoral	O	O	B-Entity
tunnel	O	O	B-Entity
by	O	O	O
measuring	O	O	O
the	O	O	O
distance	O	O	O
from	O	O	O
the	O	O	O
center	O	O	O
of	O	O	O
the	O	O	O
femoral	O	O	O
tunnel	O	O	O
to	O	O	O
the	O	O	O
Schöttle	O	O	B-Entity
point	O	O	I-Entity
.	O	O	O

Banff	O	O	B-Entity
Patella	O	O	I-Entity
Instability	O	O	I-Entity
Instrument	O	O	I-Entity
(	O	O	I-Entity
BPII	O	O	I-Entity
)	O	O	I-Entity
scores	O	O	I-Entity
were	O	O	O
collected	O	O	O
a	O	O	O
mean	O	O	B-Entity
24	O	O	O
months	O	O	B-Entity
postoperatively	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
155	O	O	O
(	O	O	O
79.5	O	O	O
%	O	O	O
)	O	O	O
subjects	O	O	O
had	O	O	O
adequate	O	O	O
postoperative	O	O	B-Entity
lateral	O	O	B-Entity
radiographs	O	O	B-Entity
and	O	O	O
complete	O	O	O
BPII	O	O	B-Entity
scores	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	O
follow-up	O	O	B-Entity
(	O	O	O
±	O	O	O
SD	O	O	B-Entity
)	O	O	O
was	O	O	O
24.4	O	O	O
±	O	O	O
8.2	O	O	O
months	O	O	B-Entity
(	O	O	O
range	O	O	O
,	O	O	O
12	O	O	O
-	O	O	O
74	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

Measurement	O	O	B-Entity
from	O	O	O
the	O	O	O
center	O	O	B-Entity
of	O	O	O
the	O	O	O
femoral	O	O	B-Entity
tunnel	O	O	B-Entity
to	O	O	O
the	O	O	O
Schöttle	O	O	B-Entity
point	O	O	I-Entity
resulted	O	O	O
in	O	O	O
143	O	O	O
(	O	O	O
92.3	O	O	O
%	O	O	O
)	O	O	O
tunnel	O	O	O
s	O	O	O
being	O	O	O
categorized	O	O	O
as	O	O	O
"	O	O	O
good	O	O	B-Entity
"	O	O	O
or	O	O	O
"	O	O	O
ideal	O	O	B-Entity
.	O	O	O
"	O	O	O
There	O	O	O
were	O	O	O
8	O	O	O
failures	O	O	B-Entity
in	O	O	O
the	O	O	O
cohort	O	O	B-Entity
,	O	O	O
none	O	O	O
of	O	O	O
which	O	O	O
occurred	O	O	O
in	O	O	O
malpositioned	O	O	B-Entity
tunnels	O	O	B-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
distance	O	O	O
from	O	O	O
the	O	O	O
center	O	O	B-Entity
of	O	O	O
the	O	O	O
MPFL	O	O	B-Entity
tunnel	O	O	B-Entity
to	O	O	O
the	O	O	O
center	O	O	O
of	O	O	O
the	O	O	O
Schöttle	O	O	B-Entity
point	O	O	I-Entity
was	O	O	O
5.9	O	O	O
±	O	O	O
4.2	O	O	O
mm	O	O	O
(	O	O	O
range	O	O	O
,	O	O	O
0.5	O	O	O
-	O	O	O
25.9	O	O	O
mm	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
postoperative	O	O	B-Entity
BPII	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
65.2	O	O	O
±	O	O	O
22.5	O	O	O
(	O	O	O
range	O	O	O
,	O	O	O
9.2	O	O	O
-	O	O	O
100	O	O	O
)	O	O	O
.	O	O	O

Pearson	O	O	B-Entity
r	O	O	I-Entity
correlation	O	O	I-Entity
demonstrated	O	O	O
no	O	O	B-Entity
statistically	O	O	I-Entity
significant	O	O	I-Entity
relationship	O	O	B-Entity
between	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
femoral	O	O	B-Entity
tunnel	O	O	B-Entity
position	O	O	B-Entity
and	O	O	O
BPII	O	O	B-Entity
score	O	O	I-Entity
(	O	O	O
r	O	O	O
=	O	O	O
-0.08	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
-0.24	O	O	O
to	O	O	O
0.08	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
evidence	O	O	I-Entity
of	O	O	I-Entity
a	O	O	O
correlation	O	O	B-Entity
between	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
MPFL	O	O	B-Entity
reconstruction	O	O	B-Entity
femoral	O	O	B-Entity
tunnel	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
the	O	O	O
Schöttle	O	O	B-Entity
point	O	O	I-Entity
and	O	O	O
disease	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
quality-of-life	O	O	B-Entity
scores	O	O	I-Entity
.	O	O	O

Graft	O	O	B-Entity
failure	O	O	I-Entity
was	O	O	O
not	O	O	O
related	O	O	O
to	O	O	O
femoral	O	O	B-Entity
tunnel	O	O	B-Entity
placement	O	O	B-Entity
.	O	O	O

The	O	O	O
patellofemoral	O	O	B-Entity
instability	O	O	I-Entity
population	O	O	O
is	O	O	O
complex	O	O	O
,	O	O	O
and	O	O	O
patients	O	O	B-Entity
present	O	O	O
with	O	O	O
multiple	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
that	O	O	O
,	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
femoral	O	O	O
tunnel	O	O	B-Entity
position	O	O	B-Entity
,	O	O	O
contribute	O	O	O
to	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
and	O	O	O
warrant	O	O	O
further	O	O	O
investigation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28210819)

Evidence	O	O	O
for	O	O	O
instructions	O	O	B-Entity
-based	O	O	O
updating	O	O	O
of	O	O	O
task-set	O	O	B-Entity
representations	O	O	I-Entity
:	O	O	O
the	O	O	O
informed	O	O	B-Entity
fadeout	O	O	O
effect	O	O	O

The	O	O	O
cognitive	O	O	B-Entity
system	O	O	I-Entity
can	O	O	O
be	O	O	O
updated	O	O	O
rapidly	O	O	O
and	O	O	O
efficiently	O	O	O
to	O	O	O
maximize	O	O	O
performance	O	O	B-Entity
in	O	O	O
cognitive	O	O	B-Entity
tasks	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	O
used	O	O	O
a	O	O	O
task	O	O	B-Entity
-	O	O	O
switching	O	O	B-Entity
task	O	O	O
to	O	O	O
explore	O	O	O
updating	O	O	O
at	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
the	O	O	O
plausible	O	O	O
task	O	O	O
-sets	O	O	O
held	O	O	O
for	O	O	O
future	O	O	O
performance	O	O	B-Entity
.	O	O	O

Previous	O	O	O
research	O	O	B-Entity
suggested	O	O	O
a	O	O	O
"	O	O	O
fadeout	O	O	B-Entity
effect	O	O	I-Entity
"	O	O	O
,	O	O	O
performance	O	O	B-Entity
improvement	O	O	B-Entity
when	O	O	O
moving	O	O	O
from	O	O	O
task	O	O	B-Entity
-	O	O	O
switching	O	O	B-Entity
context	O	O	O
to	O	O	O
single-task	O	O	B-Entity
context	O	O	O
,	O	O	O
yet	O	O	O
this	O	O	O
effect	O	O	O
could	O	O	O
reflect	O	O	O
passive	O	O	B-Entity
learning	O	O	B-Entity
rather	O	O	O
than	O	O	O
intentional	O	O	B-Entity
control	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
novel	O	O	O
"	O	O	O
informed	O	O	B-Entity
fadeout	O	O	B-Entity
paradigm	O	O	B-Entity
"	O	O	O
,	O	O	O
one	O	O	O
of	O	O	O
two	O	O	O
tasks	O	O	B-Entity
was	O	O	O
canceled	O	O	O
for	O	O	O
a	O	O	O
certain	O	O	O
number	O	O	O
of	O	O	O
trials	O	O	B-Entity
and	O	O	O
participants	O	O	B-Entity
were	O	O	O
informed	O	O	O
or	O	O	O
uninformed	O	O	B-Entity
regarding	O	O	O
task	O	O	B-Entity
cancelation	O	O	B-Entity
.	O	O	O

The	O	O	O
"	O	O	O
informed	O	O	B-Entity
fadeout	O	O	B-Entity
effect	O	O	I-Entity
"	O	O	O
indicates	O	O	O
better	O	O	O
performance	O	O	B-Entity
in	O	O	O
the	O	O	O
informed	O	O	O
than	O	O	O
uninformed	O	O	B-Entity
fadeout	O	O	O
after	O	O	O
one	O	O	O
informed	O	O	O
trial	O	O	B-Entity
had	O	O	O
been	O	O	O
executed	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
results	O	O	O
regarding	O	O	O
the	O	O	O
first	O	O	O
trial	O	O	B-Entity
were	O	O	O
inconclusive	O	O	O
.	O	O	O

Possible	O	O	O
underlying	O	O	O
mechanisms	O	O	B-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

-DOCSTART- (28217198)

Metacarpophalangeal	O	O	B-Entity
Joint	O	O	I-Entity
Arthrodesis	O	O	I-Entity
of	O	O	O
the	O	O	O
Thumb	O	O	B-Entity
-	O	O	O
Minimum	O	O	O
of	O	O	O
Eight	O	O	O
Months	O	O	B-Entity
Follow-up	O	O	O

Disorders	O	O	B-Entity
of	O	O	O
the	O	O	O
thumb	O	O	B-Entity
metacarpophalangeal	O	O	I-Entity
(	O	O	I-Entity
MCP	O	O	I-Entity
)	O	O	I-Entity
joint	O	O	I-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
significant	O	O	O
loss	O	O	B-Entity
of	O	O	O
function	O	O	B-Entity
and	O	O	O
pain	O	O	B-Entity
.	O	O	O

Thumb	O	O	B-Entity
MCP	O	O	I-Entity
arthrodesis	O	O	B-Entity
following	O	O	O
traumatic	O	O	B-Entity
injuries	O	O	I-Entity
is	O	O	O
inadequately	O	O	O
described	O	O	B-Entity
and	O	O	O
recent	O	O	O
studies	O	O	B-Entity
have	O	O	O
questioned	O	O	O
the	O	O	O
outcome	O	O	B-Entity
of	O	O	O
this	O	O	O
treatment	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
report	O	O	B-Entity
outcome	O	O	B-Entity
and	O	O	O
disability	O	O	B-Entity
following	O	O	O
thumb	O	O	B-Entity
MCP	O	O	I-Entity
joint	O	O	I-Entity
arthrodesis	O	O	B-Entity
in	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
instability	O	O	I-Entity
after	O	O	O
traumatic	O	O	B-Entity
injuries	O	O	I-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
review	O	O	B-Entity
of	O	O	O
26	O	O	O
patients	O	O	B-Entity
operated	O	O	B-Entity
on	O	O	O
with	O	O	O
MCP	O	O	B-Entity
joint	O	O	I-Entity
arthrodesis	O	O	B-Entity
,	O	O	O
median	O	O	O
follow-up	O	O	B-Entity
42	O	O	O
months	O	O	B-Entity
(	O	O	O
8	O	O	O
-	O	O	O
104	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

Subjective	O	O	O
outcome	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
disabilities	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
Arm	O	O	I-Entity
,	O	O	I-Entity
Shoulder	O	O	I-Entity
,	O	O	I-Entity
and	O	O	I-Entity
Hand-questionnaire	O	O	I-Entity
(	O	O	O
DASH	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
patient	O	O	B-Entity
satisfaction	O	O	I-Entity
,	O	O	O
pain	O	O	B-Entity
,	O	O	O
stiffness	O	O	B-Entity
,	O	O	O
and	O	O	O
impairment	O	O	B-Entity
of	O	O	O
activities	O	O	B-Entity
of	O	O	I-Entity
daily	O	O	I-Entity
living	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
on	O	O	O
a	O	O	O
Visual	O	O	B-Entity
Analogue	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
VAS	O	O	B-Entity
)	O	O	O
followed	O	O	O
by	O	O	O
a	O	O	O
question	O	O	O
stating	O	O	O
whether	O	O	O
they	O	O	O
would	O	O	O
undergo	O	O	O
the	O	O	O
same	O	O	O
procedure	O	O	B-Entity
again	O	O	O
.	O	O	O

Two	O	O	O
patients	O	O	B-Entity
(	O	O	O
7.7	O	O	O
%	O	O	O
)	O	O	O
needed	O	O	O
re-operation	O	O	B-Entity
due	O	O	O
to	O	O	O
nonunion	O	O	B-Entity
.	O	O	O

Four	O	O	O
patients	O	O	B-Entity
(	O	O	O
15.4	O	O	O
%	O	O	O
)	O	O	O
needed	O	O	O
hardware	O	O	B-Entity
removal	O	O	I-Entity
.	O	O	O

Median	O	O	B-Entity
DASH	O	O	B-Entity
-	O	O	O
score	O	O	B-Entity
was	O	O	O
18	O	O	O
(	O	O	O
25	O	O	O
-	O	O	O
75	O	O	O
%	O	O	O
range	O	O	B-Entity
6	O	O	O
-	O	O	O
47	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
lower	O	O	O
DASH	O	O	O
score	O	O	B-Entity
s	O	O	I-Entity
being	O	O	O
better	O	O	O
.	O	O	O

Score	O	O	B-Entity
s	O	O	I-Entity
were	O	O	O
significantly	O	O	O
worse	O	O	O
in	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
matched	O	O	O
individuals	O	O	B-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Median	O	O	B-Entity
VAS	O	O	B-Entity
for	O	O	O
pain	O	O	B-Entity
was	O	O	O
3.7	O	O	O
(	O	O	O
range	O	O	B-Entity
0	O	O	O
-	O	O	O
8)	O	O	O
.	O	O	O

More	O	O	O
than	O	O	O
50	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
reported	O	O	O
mild	O	O	B-Entity
,	O	O	O
moderate	O	O	B-Entity
or	O	O	O
severe	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
but	O	O	O
all	O	O	O
patients	O	O	O
reported	O	O	O
that	O	O	O
they	O	O	O
were	O	O	O
willing	O	O	O
to	O	O	O
undergo	O	O	O
the	O	O	O
same	O	O	O
procedure	O	O	B-Entity
again	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
suggest	O	O	O
,	O	O	O
that	O	O	O
patients	O	O	B-Entity
with	O	O	O
post-traumatic	O	O	B-Entity
thumb	O	O	B-Entity
injuries	O	O	I-Entity
managed	O	O	O
with	O	O	O
thumb	O	O	B-Entity
MCP	O	O	I-Entity
joint	O	O	I-Entity
arthrodesis	O	O	B-Entity
perform	O	O	O
worse	O	O	O
than	O	O	O
gender	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
matched	O	O	O
individuals	O	O	B-Entity
.	O	O	O

Many	O	O	O
lived	O	O	O
with	O	O	O
pain	O	O	B-Entity
,	O	O	O
but	O	O	O
all	O	O	O
reported	O	O	O
that	O	O	O
they	O	O	O
were	O	O	O
willing	O	O	O
to	O	O	O
undergo	O	O	O
the	O	O	O
same	O	O	O
procedure	O	O	B-Entity
again	O	O	O
.	O	O	O

We	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
disability	O	O	B-Entity
scale	O	O	I-Entity
by	O	O	O
the	O	O	O
National	O	O	B-Entity
Board	O	O	I-Entity
of	O	O	I-Entity
Industrial	O	O	I-Entity
Injuries	O	O	I-Entity
should	O	O	O
be	O	O	O
reconsidered	O	O	O
for	O	O	O
patients	O	O	B-Entity
operated	O	O	B-Entity
on	O	O	O
with	O	O	O
thumb	O	O	B-Entity
MCP	O	O	I-Entity
arthrodesis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28217611)

Pyoderma	O	O	B-Entity
gangrenosum	O	O	I-Entity
:	O	O	O
A	O	O	O
clinician	O	O	B-Entity
's	O	O	I-Entity
nightmare	O	O	O

Pyoderma	O	O	B-Entity
gangrenosum	O	O	I-Entity
(	O	O	O
PG	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
and	O	O	O
that	O	O	O
affecting	O	O	O
specifically	O	O	O
the	O	O	O
sole	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
foot	O	O	I-Entity
,	O	O	O
is	O	O	O
even	O	O	O
rarer	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	B-Entity
the	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
54-year-	O	O	O
old	O	O	B-Entity
female	O	O	B-Entity
admitted	O	O	B-Entity
with	O	O	O
a	O	O	O
painful	O	O	B-Entity
ulcer	O	O	B-Entity
on	O	O	O
the	O	O	O
sole	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
right	O	O	I-Entity
foot	O	O	I-Entity
which	O	O	O
was	O	O	O
initially	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
empirical	O	O	O
antibiotics	O	O	B-Entity
and	O	O	O
debridement	O	O	B-Entity
.	O	O	O

The	O	O	O
disease	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
spread	O	O	O
rapidly	O	O	B-Entity
after	O	O	O
each	O	O	O
debridement	O	O	B-Entity
.	O	O	O

The	O	O	O
culture	O	O	B-Entity
reports	O	O	I-Entity
were	O	O	O
negative	O	O	B-Entity
;	O	O	O
rheumatology	O	O	B-Entity
workup	O	O	B-Entity
and	O	O	O
Doppler	O	O	B-Entity
study	O	O	I-Entity
were	O	O	O
within	O	O	O
normal	O	O	B-Entity
limits	O	O	I-Entity
.	O	O	O

A	O	O	O
clinical	O	O	B-Entity
suspicion	O	O	B-Entity
of	O	O	O
PG	O	O	B-Entity
was	O	O	O
made	O	O	O
and	O	O	O
was	O	O	O
confirmed	O	O	O
with	O	O	O
tissue	O	O	B-Entity
biopsy	O	O	I-Entity
.	O	O	O

She	O	O	O
was	O	O	O
started	O	O	B-Entity
on	O	O	I-Entity
oral	O	O	I-Entity
steroids	O	O	I-Entity
following	O	O	O
which	O	O	O
she	O	O	O
dramatically	O	O	O
improved	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
when	O	O	O
a	O	O	O
patient	O	O	B-Entity
presents	O	O	O
with	O	O	O
a	O	O	O
rapidly	O	O	B-Entity
expanding	O	O	O
painful	O	O	B-Entity
ulcer	O	O	B-Entity
in	O	O	O
a	O	O	O
vascular	O	O	B-Entity
limb	O	O	I-Entity
that	O	O	O
is	O	O	O
refractory	O	O	B-Entity
to	O	O	O
antibiotic	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
exacerbating	O	O	B-Entity
on	O	O	O
debridement	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
imperative	O	O	O
to	O	O	O
consider	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
PG	O	O	B-Entity
.	O	O	O

-DOCSTART- (28217766)

Visualization	O	O	B-Entity
for	O	O	O
Understanding	O	O	O
Uncertainty	O	O	B-Entity
in	O	O	O
Activation	O	O	B-Entity
Volumes	O	O	B-Entity
for	O	O	O
Deep	O	O	O
Brain	O	O	O
Stimulation	O	O	O

We	O	O	O
have	O	O	O
created	O	O	O
the	O	O	O
Neurostimulation	O	O	B-Entity
Uncertainty	O	O	I-Entity
Viewer	O	O	I-Entity
(	O	O	I-Entity
nuView	O	O	I-Entity
or	O	O	I-Entity
νView	O	O	I-Entity
)	O	O	I-Entity
tool	O	O	I-Entity
for	O	O	O
exploring	O	O	O
data	O	O	B-Entity
arising	O	O	O
from	O	O	O
deep	O	O	B-Entity
brain	O	O	I-Entity
stimulation	O	O	I-Entity
(	O	O	O
DBS	O	O	B-Entity
)	O	O	O
.	O	O	O

Simulated	O	O	B-Entity
volume	O	O	B-Entity
of	O	O	I-Entity
tissue	O	O	I-Entity
activated	O	O	I-Entity
(	O	O	O
VTA	O	O	B-Entity
)	O	O	O
,	O	O	O
using	O	O	O
clinical	O	O	B-Entity
electrode	O	O	I-Entity
placements	O	O	I-Entity
,	O	O	O
are	O	O	O
recorded	O	O	B-Entity
along	O	O	O
with	O	O	O
patient	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
the	O	O	O
Unified	O	O	B-Entity
Parkinson	O	O	I-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
rating	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
UPDRS	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
is	O	O	O
volumetric	O	O	B-Entity
and	O	O	O
sparse	O	O	B-Entity
,	O	O	O
with	O	O	O
multi-value	O	O	B-Entity
patient	O	O	B-Entity
results	O	O	B-Entity
for	O	O	O
each	O	O	O
activated	O	O	B-Entity
voxel	O	O	B-Entity
in	O	O	O
the	O	O	O
simulation	O	O	B-Entity
.	O	O	O

νView	O	O	B-Entity
provides	O	O	O
a	O	O	O
collection	O	O	B-Entity
of	O	O	O
visual	O	O	B-Entity
methods	O	O	I-Entity
to	O	O	O
explore	O	O	O
the	O	O	O
activated	O	O	B-Entity
tissue	O	O	B-Entity
to	O	O	O
enhance	O	O	O
understanding	O	O	O
of	O	O	O
electrode	O	O	B-Entity
usage	O	O	B-Entity
for	O	O	O
improved	O	O	O
therapy	O	O	B-Entity
with	O	O	O
DBS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28217770)

Post-synthetic	O	O	O
conversion	O	O	B-Entity
of	O	O	O
5-pivaloyloxymethyluridine	O	O	B-Entity
present	O	O	B-Entity
in	O	O	O
a	O	O	O
support-bound	O	O	O
RNA	O	O	B-Entity
oligomer	O	O	B-Entity
into	O	O	O
biologically	O	O	B-Entity
relevant	O	O	B-Entity
derivatives	O	O	B-Entity
of	O	O	O
5-methyluridine	O	O	O

A	O	O	O
post-synthetic	O	O	O
reaction	O	O	B-Entity
of	O	O	O
5-pivaloyloxymethyluridine	O	O	B-Entity
(	O	O	O
present	O	O	B-Entity
in	O	O	O
a	O	O	O
support-bound	O	O	O
RNA	O	O	B-Entity
oligomer	O	O	B-Entity
)	O	O	O
with	O	O	O
various	O	O	O
nucleophilic	O	O	B-Entity
reagents	O	O	I-Entity
furnished	O	O	O
efficiently	O	O	O
the	O	O	O
corresponding	O	O	O
products	O	O	B-Entity
bearing	O	O	O
one	O	O	O
aof	O	O	O
the	O	O	O
tRNA	O	O	B-Entity
wobble	O	O	I-Entity
5-methyluridines	O	O	B-Entity
(	O	O	O
mnm(5)U	O	O	B-Entity
,	O	O	O
cmnm(5)U	O	O	B-Entity
,	O	O	O
τm(5)U	O	O	B-Entity
,	O	O	O
nm(5)U	O	O	B-Entity
,	O	O	O
inm(5)U	O	O	B-Entity
or	O	O	O
cnm(5)U	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
syntheses	O	O	B-Entity
of	O	O	O
oligoribonucleotides	O	O	B-Entity
modified	O	O	B-Entity
with	O	O	O
inm(5)U	O	O	B-Entity
and	O	O	O
cnm(5)U	O	O	B-Entity
are	O	O	O
reported	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
.	O	O	O

-DOCSTART- (28219657)

Non-pharmacological	O	O	B-Entity
treatments	O	O	B-Entity
for	O	O	O
pain	O	O	B-Entity
relief	O	O	I-Entity
:	O	O	O
TENS	O	O	B-Entity
and	O	O	O
acupuncture	O	O	O

Acupuncture	O	O	B-Entity
and	O	O	O
transcutaneous	O	O	B-Entity
electrical	O	O	I-Entity
nerve	O	O	I-Entity
stimulation	O	O	I-Entity
(	O	O	O
TENS	O	O	B-Entity
)	O	O	O
are	O	O	O
non-pharmacological	O	O	B-Entity
methods	O	O	B-Entity
that	O	O	O
have	O	O	O
been	O	O	O
used	O	O	O
for	O	O	O
millennia	O	O	B-Entity
to	O	O	O
relieve	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

As	O	O	O
with	O	O	O
all	O	O	O
complementary	O	O	B-Entity
treatments	O	O	I-Entity
,	O	O	O
efficacy	O	O	B-Entity
evaluations	O	O	B-Entity
face	O	O	O
two	O	O	O
hurdles	O	O	O
:	O	O	O
the	O	O	O
non-feasibility	O	O	O
of	O	O	O
double-blinding	O	O	B-Entity
and	O	O	O
the	O	O	O
difficulty	O	O	O
in	O	O	O
identifying	O	O	O
the	O	O	O
optimal	O	O	B-Entity
control	O	O	I-Entity
population	O	O	I-Entity
or	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
recent	O	O	O
studies	O	O	O
of	O	O	O
good	O	O	B-Entity
methodological	O	O	B-Entity
quality	O	O	I-Entity
have	O	O	O
demonstrated	O	O	O
benefits	O	O	B-Entity
in	O	O	O
many	O	O	O
types	O	O	O
of	O	O	O
pain	O	O	B-Entity
compared	O	O	O
to	O	O	O
conventional	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

The	O	O	O
mechanisms	O	O	B-Entity
of	O	O	I-Entity
action	O	O	I-Entity
of	O	O	O
acupuncture	O	O	B-Entity
and	O	O	O
TENS	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
increasingly	O	O	B-Entity
well	O	O	O
understood	O	O	O
,	O	O	O
involve	O	O	O
endogenous	O	O	B-Entity
pain	O	O	B-Entity
control	O	O	I-Entity
systems	O	O	I-Entity
,	O	O	O
cerebral	O	O	B-Entity
plasticity	O	O	I-Entity
,	O	O	O
and	O	O	O
nonspecific	O	O	O
effects	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
,	O	O	O
expectations	O	O	B-Entity
and	O	O	O
placebo	O	O	B-Entity
effect	O	O	I-Entity
)	O	O	O
.	O	O	O

No	O	O	O
serious	O	O	O
adverse	O	O	B-Entity
effects	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
.	O	O	O

These	O	O	O
data	O	O	B-Entity
support	O	O	O
the	O	O	O
more	O	O	O
widespread	O	O	O
use	O	O	O
of	O	O	O
non-pharmacological	O	O	B-Entity
pain	O	O	B-Entity
management	O	O	I-Entity
,	O	O	O
most	O	O	O
notably	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
inadequately	O	O	O
relieved	O	O	B-Entity
by	O	O	I-Entity
medications	O	O	B-Entity
alone	O	O	O
.	O	O	O

-DOCSTART- (28220082)

Synaptic	O	O	B-Entity
and	O	O	O
Neuronal	O	O	B-Entity
Autoantibody	O	O	B-Entity
-	O	O	O
Associated	O	O	B-Entity
Psychiatric	O	O	B-Entity
Syndromes	O	O	I-Entity
:	O	O	O
Controversies	O	O	B-Entity
and	O	O	O
Hypotheses	O	O	O

Autoimmune	O	O	B-Entity
encephalitis	O	O	I-Entity
(	O	O	O
AE	O	O	B-Entity
)	O	O	O
mediated	O	O	O
by	O	O	O
antibodies	O	O	B-Entity
against	O	O	O
synaptic	O	O	B-Entity
and	O	O	O
neuronal	O	O	B-Entity
surface	O	O	B-Entity
targets	O	O	B-Entity
frequently	O	O	B-Entity
presents	O	O	B-Entity
with	O	O	O
a	O	O	O
psychiatric	O	O	B-Entity
syndrome	O	O	I-Entity
.	O	O	O

In	O	O	O
these	O	O	O
patients	O	O	B-Entity
,	O	O	O
removal	O	O	B-Entity
of	O	O	I-Entity
autoantibodies	O	O	B-Entity
treats	O	O	B-Entity
the	O	O	O
disease	O	O	B-Entity
and	O	O	O
outcomes	O	O	B-Entity
are	O	O	O
closely	O	O	O
linked	O	O	O
to	O	O	O
early	O	O	O
intervention	O	O	B-Entity
.	O	O	O

The	O	O	O
discovery	O	O	B-Entity
of	O	O	O
these	O	O	O
autoantibodies	O	O	B-Entity
in	O	O	O
isolated	O	O	B-Entity
psychiatric	O	O	B-Entity
syndromes	O	O	I-Entity
has	O	O	O
raised	O	O	B-Entity
the	O	O	O
possibility	O	O	O
that	O	O	O
these	O	O	O
patients	O	O	B-Entity
may	O	O	O
derive	O	O	O
similar	O	O	O
benefits	O	O	B-Entity
from	O	O	O
immunotherapy	O	O	B-Entity
,	O	O	O
a	O	O	O
potentially	O	O	B-Entity
transformational	O	O	O
approach	O	O	B-Entity
to	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
mental	O	O	B-Entity
illness	O	O	I-Entity
.	O	O	O

Although	O	O	O
open-label	O	O	B-Entity
case	O	O	I-Entity
series	O	O	I-Entity
suggest	O	O	O
impressive	O	O	O
therapeutic	O	O	B-Entity
outcomes	O	O	I-Entity
,	O	O	O
the	O	O	O
pathological	O	O	B-Entity
relevance	O	O	B-Entity
of	O	O	O
these	O	O	O
autoantibodies	O	O	B-Entity
outside	O	O	O
of	O	O	O
canonical	O	O	B-Entity
presentations	O	O	I-Entity
is	O	O	O
debated	O	O	O
.	O	O	O

The	O	O	O
advent	O	O	O
of	O	O	O
diagnostic	O	O	B-Entity
criteria	O	O	I-Entity
for	O	O	O
AE	O	O	B-Entity
attempts	O	O	B-Entity
to	O	O	O
facilitate	O	O	O
its	O	O	O
prompt	O	O	O
identification	O	O	B-Entity
but	O	O	O
risks	O	O	B-Entity
prematurely	O	O	O
neglecting	O	O	O
the	O	O	O
potential	O	O	B-Entity
scientific	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
significance	O	O	I-Entity
of	O	O	O
isolated	O	O	B-Entity
syndromes	O	O	B-Entity
that	O	O	O
do	O	O	O
not	O	O	O
satisfy	O	O	O
these	O	O	O
criteria	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
using	O	O	O
a	O	O	O
syndrome	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
taxonomy	O	O	B-Entity
that	O	O	O
has	O	O	O
occasional	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
necessary	O	O	O
,	O	O	O
overlap	O	O	B-Entity
with	O	O	O
AE	O	O	B-Entity
:	O	O	O
synaptic	O	O	B-Entity
and	O	O	O
neuronal	O	O	B-Entity
autoantibody	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
psychiatric	O	O	B-Entity
syndromes	O	O	I-Entity
or	O	O	O
"	O	O	O
SNAps	O	O	B-Entity
"	O	O	O
.	O	O	O

This	O	O	O
will	O	O	O
prevent	O	O	B-Entity
confusion	O	O	O
with	O	O	O
AE	O	O	B-Entity
and	O	O	O
act	O	O	B-Entity
heuristically	O	O	I-Entity
to	O	O	O
promote	O	O	B-Entity
active	O	O	B-Entity
investigation	O	O	B-Entity
into	O	O	O
this	O	O	O
rare	O	O	B-Entity
example	O	O	B-Entity
of	O	O	O
psychopathology	O	O	B-Entity
defined	O	O	B-Entity
on	O	O	O
a	O	O	O
molecular	O	O	B-Entity
level	O	O	I-Entity
.	O	O	O

We	O	O	O
suggest	O	O	O
that	O	O	O
this	O	O	O
concept	O	O	B-Entity
would	O	O	O
have	O	O	O
application	O	O	O
in	O	O	O
other	O	O	O
autoantibody	O	O	B-Entity
-	O	O	O
associated	O	O	B-Entity
syndromes	O	O	B-Entity
including	O	O	B-Entity
seizure	O	O	B-Entity
,	O	O	O
cognitive	O	O	B-Entity
,	O	O	O
and	O	O	O
movement	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
similar	O	O	B-Entity
issues	O	O	B-Entity
arise	O	O	O
.	O	O	O

We	O	O	O
review	O	O	B-Entity
putative	O	O	O
direct	O	O	B-Entity
and	O	O	O
indirect	O	O	B-Entity
mechanisms	O	O	B-Entity
and	O	O	O
outline	O	O	O
experimentally	O	O	B-Entity
testable	O	O	O
hypotheses	O	O	B-Entity
that	O	O	O
would	O	O	O
help	O	O	O
to	O	O	O
determine	O	O	O
prospectively	O	O	B-Entity
in	O	O	O
whom	O	O	O
autoantibody	O	O	B-Entity
detection	O	O	B-Entity
is	O	O	O
relevant	O	O	B-Entity
,	O	O	O
and	O	O	O
as	O	O	O
important	O	O	B-Entity
,	O	O	O
in	O	O	O
whom	O	O	O
it	O	O	O
is	O	O	O
not	O	O	O
.	O	O	O

We	O	O	O
summarize	O	O	O
a	O	O	O
pragmatic	O	O	B-Entity
approach	O	O	O
to	O	O	O
autoantibody	O	O	B-Entity
testing	O	O	B-Entity
and	O	O	O
management	O	O	B-Entity
in	O	O	O
severe	O	O	B-Entity
mental	O	O	B-Entity
illness	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
promptly	O	O	O
diagnose	O	O	B-Entity
AE	O	O	B-Entity
and	O	O	O
advocate	O	O	O
a	O	O	O
research	O	O	B-Entity
-	O	O	O
orientated	O	O	B-Entity
experimental	O	O	B-Entity
medicine	O	O	B-Entity
paradigm	O	O	B-Entity
for	O	O	O
SNAps	O	O	B-Entity
,	O	O	O
where	O	O	O
there	O	O	O
is	O	O	O
greater	O	O	B-Entity
equipoise	O	O	B-Entity
.	O	O	O

We	O	O	O
conclude	O	O	O
that	O	O	O
SNAps	O	O	B-Entity
remains	O	O	O
a	O	O	O
nascent	O	O	O
area	O	O	O
of	O	O	O
clinical	O	O	B-Entity
neuroscience	O	O	B-Entity
with	O	O	O
great	O	O	O
potential	O	O	B-Entity
and	O	O	O
in	O	O	O
ongoing	O	O	B-Entity
need	O	O	B-Entity
of	O	O	O
psychiatry	O	O	B-Entity
-led	O	O	O
basic	O	O	O
and	O	O	O
clinical	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

-DOCSTART- (28220122)

NF-κB	O	O	B-Entity
Links	O	O	O
TLR2	O	O	B-Entity
and	O	O	O
PAR1	O	O	B-Entity
to	O	O	O
Soluble	O	O	B-Entity
Immunomodulator	O	O	B-Entity
Factor	O	O	I-Entity
Secretion	O	O	B-Entity
in	O	O	O
Human	O	O	B-Entity
Platelets	O	O	O

The	O	O	O
primary	O	O	B-Entity
toll-like	O	O	B-Entity
receptor	O	O	I-Entity
(TLR)-mediated	O	O	O
immune	O	O	B-Entity
cell	O	O	I-Entity
response	O	O	I-Entity
pathway	O	O	I-Entity
common	O	O	O
for	O	O	O
all	O	O	O
TLRs	O	O	B-Entity
is	O	O	O
MyD88	O	O	B-Entity
-dependent	O	O	O
activation	O	O	B-Entity
of	O	O	O
NF-κB	O	O	B-Entity
,	O	O	O
a	O	O	O
seminal	O	O	B-Entity
transcription	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
many	O	O	O
chemokines	O	O	B-Entity
and	O	O	O
cytokines	O	O	B-Entity
.	O	O	O

Remarkably	O	O	O
,	O	O	O
anucleate	O	O	B-Entity
platelets	O	O	B-Entity
express	O	O	O
the	O	O	O
NF-κB	O	O	B-Entity
machinery	O	O	O
,	O	O	O
whose	O	O	O
role	O	O	O
in	O	O	O
platelets	O	O	O
remains	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
contribution	O	O	B-Entity
of	O	O	O
NF-κB	O	O	B-Entity
in	O	O	O
the	O	O	O
release	O	O	B-Entity
of	O	O	O
cytokines	O	O	B-Entity
and	O	O	O
serotonin	O	O	B-Entity
by	O	O	O
human	O	O	B-Entity
platelets	O	O	B-Entity
,	O	O	O
following	O	O	B-Entity
selective	O	O	O
stimulation	O	O	O
of	O	O	O
TLR2	O	O	B-Entity
and	O	O	O
protease	O	O	B-Entity
activated	O	O	I-Entity
receptor	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
PAR1	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
classical	O	O	O
and	O	O	O
non-classical	O	O	O
pattern-recognition	O	O	B-Entity
receptor	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
able	O	O	O
to	O	O	O
participate	O	O	O
to	O	O	O
the	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

We	O	O	O
discovered	O	O	O
that	O	O	O
platelet	O	O	B-Entity
PAR1	O	O	B-Entity
activation	O	O	B-Entity
drives	O	O	O
the	O	O	O
process	O	O	O
of	O	O	O
NF-κB	O	O	B-Entity
phosphorylation	O	O	B-Entity
,	O	O	O
in	O	O	O
contrast	O	O	O
to	O	O	O
TLR2	O	O	B-Entity
activation	O	O	O
,	O	O	O
which	O	O	O
induces	O	O	B-Entity
a	O	O	O
slower	O	O	O
phosphorylation	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
platelet	O	O	B-Entity
PAR1	O	O	B-Entity
and	O	O	O
TLR2	O	O	B-Entity
activation	O	O	B-Entity
induces	O	O	B-Entity
similar	O	O	O
ERK1/2	O	O	B-Entity
,	O	O	O
p38	O	O	B-Entity
,	O	O	O
and	O	O	O
AKT	O	O	B-Entity
phosphorylation	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
engagement	O	O	O
of	O	O	O
platelet	O	O	B-Entity
TLR2	O	O	B-Entity
with	O	O	O
its	O	O	O
ligand	O	O	B-Entity
,	O	O	O
Pam3CSK4	O	O	B-Entity
,	O	O	O
significantly	O	O	B-Entity
increases	O	O	I-Entity
the	O	O	O
release	O	O	B-Entity
of	O	O	O
sCD62P	O	O	B-Entity
,	O	O	O
RANTES	O	O	B-Entity
,	O	O	O
and	O	O	O
sCD40L	O	O	B-Entity
;	O	O	O
this	O	O	O
effect	O	O	B-Entity
was	O	O	O
attenuated	O	O	B-Entity
by	O	O	I-Entity
incubating	O	O	B-Entity
platelets	O	O	B-Entity
with	O	O	O
a	O	O	O
blocking	O	O	B-Entity
anti-TLR2	O	O	B-Entity
antibody	O	O	I-Entity
.	O	O	O

This	O	O	O
effect	O	O	B-Entity
appeared	O	O	I-Entity
selective	O	O	O
since	O	O	O
no	O	O	O
modulation	O	O	B-Entity
of	O	O	O
serotonin	O	O	B-Entity
secretion	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
following	O	O	B-Entity
platelet	O	O	B-Entity
TLR2	O	O	B-Entity
activation	O	O	B-Entity
.	O	O	O

Platelet	O	O	B-Entity
release	O	O	B-Entity
of	O	O	O
sCD62P	O	O	B-Entity
,	O	O	O
RANTES	O	O	B-Entity
,	O	O	O
and	O	O	O
sCD40L	O	O	B-Entity
following	O	O	B-Entity
TLR2	O	O	B-Entity
or	O	O	O
PAR1	O	O	B-Entity
triggering	O	O	O
was	O	O	O
abolished	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
the	O	O	O
NF-κB	O	O	B-Entity
inhibitor	O	O	B-Entity
Bay11	O	O	B-Entity
-	O	O	I-Entity
7082	O	O	I-Entity
,	O	O	O
while	O	O	O
serotonin	O	O	B-Entity
release	O	O	I-Entity
following	O	O	O
PAR1	O	O	O
activation	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
decreased	O	O	I-Entity
.	O	O	O

These	O	O	O
new	O	O	B-Entity
findings	O	O	B-Entity
support	O	O	O
the	O	O	O
concept	O	O	O
that	O	O	O
NF-κB	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	O
player	O	O	O
in	O	O	O
platelet	O	O	B-Entity
immunoregulations	O	O	B-Entity
and	O	O	O
functions	O	O	B-Entity
.	O	O	O

-DOCSTART- (28222010)

Optical	O	O	B-Entity
tweezers	O	O	I-Entity
studies	O	O	B-Entity
of	O	O	O
transcription	O	O	B-Entity
by	O	O	O
eukaryotic	O	O	B-Entity
RNA	O	O	O
polymerases	O	O	O

Transcription	O	O	B-Entity
is	O	O	O
the	O	O	O
first	O	O	B-Entity
step	O	O	I-Entity
in	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
information	O	O	B-Entity
and	O	O	O
it	O	O	O
is	O	O	O
carried	O	O	B-Entity
out	O	O	O
by	O	O	O
large	O	O	O
macromolecular	O	O	B-Entity
enzymes	O	O	B-Entity
called	O	O	O
RNA	O	O	B-Entity
polymerases	O	O	I-Entity
.	O	O	O

Transcription	O	O	B-Entity
has	O	O	O
been	O	O	O
studied	O	O	B-Entity
for	O	O	O
many	O	O	O
years	O	O	O
and	O	O	O
with	O	O	O
a	O	O	O
myriad	O	O	B-Entity
of	O	O	O
experimental	O	O	B-Entity
techniques	O	O	B-Entity
,	O	O	O
ranging	O	O	B-Entity
from	O	O	O
bulk	O	O	O
studies	O	O	B-Entity
to	O	O	O
high-resolution	O	O	B-Entity
transcript	O	O	I-Entity
sequencing	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
review	O	O	B-Entity
,	O	O	O
we	O	O	O
emphasise	O	O	O
the	O	O	O
advantages	O	O	O
of	O	O	O
using	O	O	O
single-molecule	O	O	B-Entity
techniques	O	O	B-Entity
,	O	O	O
particularly	O	O	O
optical	O	O	B-Entity
tweezers	O	O	I-Entity
,	O	O	O
to	O	O	O
study	O	O	B-Entity
transcription	O	O	B-Entity
dynamics	O	O	B-Entity
.	O	O	O

We	O	O	O
give	O	O	O
an	O	O	O
overview	O	O	B-Entity
of	O	O	O
the	O	O	O
latest	O	O	O
results	O	O	B-Entity
in	O	O	O
the	O	O	O
single-molecule	O	O	B-Entity
transcription	O	O	B-Entity
field	O	O	B-Entity
,	O	O	O
focusing	O	O	O
on	O	O	O
transcription	O	O	O
by	O	O	O
eukaryotic	O	O	B-Entity
RNA	O	O	B-Entity
polymerases	O	O	I-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
evaluate	O	O	O
recent	O	O	O
quantitative	O	O	B-Entity
models	O	O	B-Entity
that	O	O	O
describe	O	O	B-Entity
the	O	O	O
biophysics	O	O	B-Entity
of	O	O	O
RNA	O	O	B-Entity
polymerase	O	O	I-Entity
translocation	O	O	B-Entity
and	O	O	O
backtracking	O	O	O
dynamics	O	O	B-Entity
.	O	O	O

-DOCSTART- (28222462)

Decreased	O	O	B-Entity
Frequencies	O	O	I-Entity
of	O	O	O
Peripheral	O	O	B-Entity
Blood	O	O	I-Entity
CD4+CD25+CD127-Foxp3	O	O	B-Entity
+	O	O	I-Entity
in	O	O	O
Patients	O	O	B-Entity
with	O	O	O
Graves	O	O	B-Entity
'	O	O	I-Entity
Disease	O	O	I-Entity
and	O	O	O
Graves	O	O	B-Entity
'	O	O	I-Entity
Orbitopathy	O	O	I-Entity
:	O	O	O
Enhancing	O	O	B-Entity
Effect	O	O	I-Entity
of	O	O	O
Insulin	O	O	B-Entity
Growth	O	O	I-Entity
Factor-1	O	O	I-Entity
on	O	O	O
Treg	O	O	O
Cells	O	O	O

Graves	O	O	B-Entity
'	O	O	I-Entity
orbitopathy	O	O	I-Entity
(	O	O	O
GO	O	O	B-Entity
)	O	O	O
is	O	O	O
characterized	O	O	B-Entity
by	O	O	O
orbital	O	O	B-Entity
T	O	O	I-Entity
cell	O	O	I-Entity
infiltration	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
regulatory	O	O	B-Entity
T	O	O	I-Entity
(	O	O	I-Entity
Treg	O	O	I-Entity
)	O	O	I-Entity
cell	O	O	I-Entity
fractions	O	O	B-Entity
induced	O	O	B-Entity
with	O	O	O
IGF-1	O	O	B-Entity
in	O	O	O
Graves	O	O	B-Entity
'	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
GD	O	O	B-Entity
)	O	O	O
with	O	O	O
and	O	O	O
without	O	O	O
GO	O	O	B-Entity
.	O	O	O

Peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
PBMCs	O	O	B-Entity
)	O	O	O
were	O	O	O
obtained	O	O	O
from	O	O	O
13	O	O	O
patients	O	O	B-Entity
with	O	O	O
GD	O	O	B-Entity
without	O	O	O
eye	O	O	B-Entity
manifestations	O	O	I-Entity
;	O	O	O
10	O	O	O
patients	O	O	O
with	O	O	O
active	O	O	B-Entity
GO	O	O	B-Entity
;	O	O	O
and	O	O	O
12	O	O	O
patients	O	O	O
with	O	O	O
nodular	O	O	B-Entity
goiter	O	O	I-Entity
(	O	O	O
NG	O	O	B-Entity
)	O	O	O
.	O	O	O

All	O	O	O
the	O	O	O
patients	O	O	B-Entity
from	O	O	O
GD	O	O	B-Entity
,	O	O	O
GO	O	O	B-Entity
,	O	O	O
and	O	O	O
NG	O	O	B-Entity
were	O	O	O
subclinical	O	O	B-Entity
hyperthyroid	O	O	I-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
expression	O	O	B-Entity
of	O	O	I-Entity
Treg	O	O	I-Entity
cell	O	O	I-Entity
markers	O	O	I-Entity
(	O	O	O
CD4	O	O	B-Entity
,	O	O	O
CD25	O	O	B-Entity
,	O	O	O
CD127(-	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
Foxp3	O	O	B-Entity
)	O	O	O
on	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
their	O	O	O
ability	O	O	O
to	O	O	O
respond	O	O	B-Entity
to	O	O	I-Entity
IGF-1	O	O	B-Entity
stimulation	O	O	B-Entity
.	O	O	O

In	O	O	O
patients	O	O	B-Entity
with	O	O	O
GD	O	O	B-Entity
without	O	O	O
GO	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
lowered	O	O	B-Entity
percentages	O	O	I-Entity
of	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
Foxp3(+	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
as	O	O	O
compared	O	O	O
to	O	O	O
nodular	O	O	B-Entity
goiter	O	O	I-Entity
1.77	O	O	O
vs.	O	O	O
5.42	O	O	O
%	O	O	O
(	O	O	O
p=0.0276	O	O	O
)	O	O	O
.	O	O	O

Similarly	O	O	O
,	O	O	O
significantly	O	O	B-Entity
reduced	O	O	I-Entity
frequencies	O	O	I-Entity
of	O	O	O
CD4(+)CD25(+)CD127(-)Foxp3(+	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
CD4(+)CD25(+)CD127(-	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
were	O	O	O
observed	O	O	B-Entity
in	O	O	O
GD	O	O	B-Entity
patients	O	O	B-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
nodular	O	O	B-Entity
goiter	O	O	I-Entity
patients	O	O	O
with	O	O	O
hyperthyreosis	O	O	B-Entity
,	O	O	O
(	O	O	O
0.7	O	O	O
vs.	O	O	O
1.48	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
p=0.0071	O	O	O
)	O	O	O
and	O	O	O
(	O	O	O
14.5	O	O	O
vs.	O	O	O
37.2	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
p=0.0051	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
GO	O	O	B-Entity
with	O	O	O
active	O	O	B-Entity
GO	O	O	O
,	O	O	O
only	O	O	O
the	O	O	O
percentage	O	O	B-Entity
of	O	O	O
CD4(+)CD25(+)CD127(-	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
decreased	O	O	B-Entity
versus	O	O	O
nodular	O	O	B-Entity
goiter	O	O	I-Entity
(	O	O	O
9.35	O	O	O
vs.	O	O	O
37.2	O	O	O
)	O	O	O
(	O	O	O
p=0.0275	O	O	O
)	O	O	O
.	O	O	O

Stimulation	O	O	B-Entity
of	O	O	O
PBMC	O	O	B-Entity
derived	O	O	O
from	O	O	O
GO	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
IGF-1	O	O	B-Entity
resulted	O	O	O
in	O	O	O
significant	O	O	B-Entity
increase	O	O	I-Entity
of	O	O	I-Entity
frequency	O	O	I-Entity
of	O	O	O
both	O	O	O
CD4(+	O	O	B-Entity
)	O	O	I-Entity
Foxp3(+	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
CD4(+)CD25(+)CD127(-	O	O	B-Entity
)	O	O	I-Entity
Foxp3	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Decreased	O	O	B-Entity
frequencies	O	O	I-Entity
of	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
CD4(+)CD25(+)CD127(-)Foxp3(+	O	O	B-Entity
)	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
GD	O	O	B-Entity
and	O	O	O
GO	O	O	B-Entity
could	O	O	O
be	O	O	O
an	O	O	O
useful	O	O	B-Entity
marker	O	O	I-Entity
of	O	O	O
autoimmune	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
perhaps	O	O	O
a	O	O	O
possible	O	O	O
target	O	O	O
for	O	O	O
future	O	O	B-Entity
therapies	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	B-Entity
demonstrating	O	O	O
Treg	O	O	B-Entity
-	O	O	O
enhancing	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
IGF-1	O	O	B-Entity
.	O	O	O

Thus	O	O	O
IGF-1	O	O	B-Entity
can	O	O	O
be	O	O	O
accounted	O	O	O
for	O	O	O
modulating	O	O	B-Entity
Treg	O	O	B-Entity
cell	O	O	I-Entity
-related	O	O	O
action	O	O	B-Entity
in	O	O	O
GO	O	O	B-Entity
.	O	O	O

-DOCSTART- (28228227)

γ-Butenolide	O	O	B-Entity
and	O	O	O
furanone	O	O	B-Entity
derivatives	O	O	I-Entity
from	O	O	O
the	O	O	O
soil	O	O	B-Entity
-derived	O	O	O
fungus	O	O	B-Entity
Aspergillus	O	O	B-Entity
sclerotiorum	O	O	I-Entity
PSU-RSPG178	O	O	O

Chromatographic	O	O	B-Entity
separation	O	O	I-Entity
of	O	O	O
the	O	O	O
broth	O	O	B-Entity
extract	O	O	B-Entity
of	O	O	O
the	O	O	O
soil	O	O	B-Entity
-derived	O	O	O
fungus	O	O	B-Entity
Aspergillus	O	O	B-Entity
sclerotiorum	O	O	I-Entity
PSU-RSPG178	O	O	B-Entity
resulted	O	O	O
in	O	O	O
isolation	O	O	B-Entity
of	O	O	O
four	O	O	O
γ-butenolide-furanone	O	O	B-Entity
dimers	O	O	I-Entity
,	O	O	O
aspersclerotiorones	O	O	B-Entity
A-D	O	O	I-Entity
,	O	O	O
a	O	O	O
furanone	O	O	B-Entity
derivative	O	O	I-Entity
,	O	O	O
aspersclerotiorone	O	O	B-Entity
E	O	O	I-Entity
,	O	O	O
and	O	O	O
two	O	O	O
γ-butenolide	O	O	B-Entity
derivatives	O	O	I-Entity
,	O	O	O
aspersclerotiorones	O	O	B-Entity
F	O	O	I-Entity
and	O	O	O
G	O	O	B-Entity
,	O	O	O
together	O	O	O
with	O	O	O
six	O	O	O
known	O	O	O
compounds	O	O	O
,	O	O	O
penicillic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
dihydropenicillic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
5,6-dihydro-6-hydroxypenicillic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
6-methoxy-5,6-dihydropenicillic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
coculnol	O	O	B-Entity
and	O	O	O
(4R,5R)-4,5-dihydroxy-3-methoxy-5-methylcyclohex-2-en-1-one	O	O	B-Entity
.	O	O	O

Their	O	O	O
structures	O	O	B-Entity
were	O	O	O
determined	O	O	O
by	O	O	O
spectroscopic	O	O	B-Entity
evidence	O	O	I-Entity
.	O	O	O

For	O	O	O
aspersclerotiorones	O	O	B-Entity
A	O	O	I-Entity
and	O	O	O
B	O	O	B-Entity
,	O	O	O
the	O	O	O
structures	O	O	B-Entity
were	O	O	O
confirmed	O	O	O
by	O	O	O
single-crystal	O	O	B-Entity
X-ray	O	O	I-Entity
diffraction	O	O	I-Entity
crystallography	O	O	I-Entity
.	O	O	O

Penicillic	O	O	O
acid	O	O	O
displayed	O	O	O
weak	O	O	O
antibacterial	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
and	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
with	O	O	O
equal	O	O	O
MIC	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
128	O	O	O
μg/mL	O	O	O
,	O	O	O
and	O	O	O
it	O	O	O
was	O	O	O
noncytotoxic	O	O	B-Entity
towards	O	O	O
African	O	O	B-Entity
green	O	O	I-Entity
monkey	O	O	I-Entity
kidney	O	O	B-Entity
fibroblast	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (28228265)

E3	O	O	B-Entity
Ligase	O	O	I-Entity
RNF126	O	O	B-Entity
Directly	O	O	O
Ubiquitinates	O	O	B-Entity
Frataxin	O	O	B-Entity
,	O	O	O
Promoting	O	O	B-Entity
Its	O	O	O
Degradation	O	O	B-Entity
:	O	O	O
Identification	O	O	B-Entity
of	O	O	O
a	O	O	O
Potential	O	O	O
Therapeutic	O	O	B-Entity
Target	O	O	B-Entity
for	O	O	O
Friedreich	O	O	O
Ataxia	O	O	O

Friedreich	O	O	B-Entity
ataxia	O	O	I-Entity
(	O	O	O
FRDA	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
severe	O	O	O
genetic	O	O	B-Entity
neurodegenerative	O	O	B-Entity
disease	O	O	I-Entity
caused	O	O	O
by	O	O	O
reduced	O	O	O
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
protein	O	O	I-Entity
frataxin	O	O	B-Entity
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
therapy	O	O	B-Entity
to	O	O	O
treat	O	O	B-Entity
this	O	O	O
condition	O	O	B-Entity
.	O	O	O

The	O	O	O
amount	O	O	O
of	O	O	O
residual	O	O	B-Entity
frataxin	O	O	B-Entity
critically	O	O	O
affects	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
;	O	O	O
thus	O	O	O
,	O	O	O
attempts	O	O	O
to	O	O	O
restore	O	O	O
physiological	O	O	B-Entity
frataxin	O	O	O
levels	O	O	B-Entity
are	O	O	O
considered	O	O	O
therapeutically	O	O	B-Entity
relevant	O	O	B-Entity
.	O	O	O

Frataxin	O	O	B-Entity
levels	O	O	B-Entity
are	O	O	O
controlled	O	O	B-Entity
by	O	O	I-Entity
the	O	O	O
ubiquitin-proteasome	O	O	B-Entity
system	O	O	I-Entity
;	O	O	O
therefore	O	O	O
,	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
the	O	O	O
frataxin	O	O	B-Entity
E3	O	O	B-Entity
ligase	O	O	I-Entity
may	O	O	O
represent	O	O	O
a	O	O	O
strategy	O	O	B-Entity
to	O	O	O
achieve	O	O	O
an	O	O	O
increase	O	O	O
in	O	O	O
frataxin	O	O	O
levels	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
the	O	O	O
RING	O	O	B-Entity
E3	O	O	I-Entity
ligase	O	O	I-Entity
RNF126	O	O	B-Entity
as	O	O	O
the	O	O	O
enzyme	O	O	B-Entity
that	O	O	O
specifically	O	O	O
mediates	O	O	O
frataxin	O	O	B-Entity
ubiquitination	O	O	B-Entity
and	O	O	O
targets	O	O	O
it	O	O	O
for	O	O	O
degradation	O	O	B-Entity
.	O	O	O

RNF126	O	O	B-Entity
interacts	O	O	B-Entity
with	O	O	O
frataxin	O	O	B-Entity
and	O	O	O
promotes	O	O	B-Entity
its	O	O	O
ubiquitination	O	O	B-Entity
in	O	O	O
a	O	O	O
catalytic	O	O	B-Entity
activity	O	O	I-Entity
-	O	O	O
dependent	O	O	B-Entity
manner	O	O	O
,	O	O	O
both	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

Most	O	O	O
importantly	O	O	O
,	O	O	O
RNF126	O	O	B-Entity
depletion	O	O	B-Entity
results	O	O	O
in	O	O	O
frataxin	O	O	B-Entity
accumulation	O	O	B-Entity
in	O	O	O
cells	O	O	B-Entity
derived	O	O	O
from	O	O	O
FRDA	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
highlighting	O	O	O
the	O	O	O
relevance	O	O	B-Entity
of	O	O	O
RNF126	O	O	O
as	O	O	O
a	O	O	O
new	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
for	O	O	O
Friedreich	O	O	B-Entity
ataxia	O	O	I-Entity
.	O	O	O

-DOCSTART- (28228370)

Enhancing	O	O	O
Doctors	O	O	B-Entity
'	O	O	I-Entity
Competencies	O	O	B-Entity
in	O	O	O
Communication	O	O	B-Entity
With	O	O	O
and	O	O	O
Activation	O	O	B-Entity
of	O	O	O
Older	O	O	B-Entity
Patients	O	O	B-Entity
:	O	O	O
The	O	O	O
Promoting	O	O	B-Entity
Active	O	O	B-Entity
Aging	O	O	B-Entity
(	O	O	O
PRACTA	O	O	B-Entity
)	O	O	O
Computer-Based	O	O	O
Intervention	O	O	O
Study	O	O	O

Demographic	O	O	B-Entity
changes	O	O	B-Entity
over	O	O	O
the	O	O	O
past	O	O	O
decades	O	O	B-Entity
call	O	O	O
for	O	O	O
the	O	O	O
promotion	O	O	B-Entity
of	O	O	I-Entity
health	O	O	I-Entity
and	O	O	I-Entity
disease	O	O	I-Entity
prevention	O	O	I-Entity
for	O	O	O
older	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
strategies	O	O	O
to	O	O	O
enhance	O	O	O
their	O	O	O
independence	O	O	B-Entity
,	O	O	O
productivity	O	O	B-Entity
,	O	O	O
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

Our	O	O	O
objective	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
a	O	O	O
computer-based	O	O	B-Entity
educational	O	O	I-Entity
intervention	O	O	I-Entity
designed	O	O	O
for	O	O	O
general	O	O	B-Entity
practitioners	O	O	I-Entity
(	O	O	O
GPs	O	O	B-Entity
)	O	O	O
to	O	O	O
promote	O	O	O
active	O	O	B-Entity
aging	O	O	B-Entity
.	O	O	O

The	O	O	O
Promoting	O	O	B-Entity
Active	O	O	O
Aging	O	O	B-Entity
(	O	O	O
PRACTA	O	O	B-Entity
)	O	O	O
study	O	O	O
consisted	O	O	O
of	O	O	O
a	O	O	O
baseline	O	O	B-Entity
questionnaire	O	O	I-Entity
,	O	O	O
implementation	O	O	B-Entity
of	O	O	O
an	O	O	O
intervention	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
follow-up	O	O	B-Entity
questionnaire	O	O	I-Entity
that	O	O	O
was	O	O	O
administered	O	O	B-Entity
1	O	O	O
month	O	O	O
after	O	O	O
the	O	O	O
intervention	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
151	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
facilities	O	O	I-Entity
(	O	O	O
response	O	O	B-Entity
rate	O	O	I-Entity
151/767	O	O	O
,	O	O	O
19.7	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
503	O	O	O
GPs	O	O	B-Entity
(	O	O	O
response	O	O	O
rate	O	O	O
503/996	O	O	O
,	O	O	O
50.5	O	O	O
%	O	O	O
)	O	O	O
agreed	O	O	O
to	O	O	O
participate	O	O	B-Entity
in	O	O	O
the	O	O	O
baseline	O	O	B-Entity
assessment	O	O	I-Entity
.	O	O	O

At	O	O	O
the	O	O	O
follow-up	O	O	B-Entity
,	O	O	O
393	O	O	O
GPs	O	O	B-Entity
filled	O	O	O
in	O	O	O
the	O	O	O
questionnaires	O	O	B-Entity
(	O	O	O
response	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
393/503	O	O	O
,	O	O	O
78.1	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
all	O	O	O
of	O	O	O
them	O	O	O
took	O	O	O
part	O	O	O
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
.	O	O	O

The	O	O	O
final	O	O	O
study	O	O	B-Entity
group	O	O	I-Entity
of	O	O	O
225	O	O	O
GPs	O	O	B-Entity
participated	O	O	O
in	O	O	O
3	O	O	O
study	O	O	O
conditions	O	O	O
:	O	O	O
e-learning	O	O	B-Entity
(	O	O	O
knowledge	O	O	B-Entity
plus	O	O	O
skills	O	O	B-Entity
modelling	O	O	B-Entity
,	O	O	O
n=42	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
pdf	O	O	B-Entity
article	O	O	I-Entity
(	O	O	O
knowledge	O	O	O
only	O	O	O
,	O	O	O
n=89	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
control	O	O	B-Entity
(	O	O	O
no	O	O	B-Entity
intervention	O	O	B-Entity
,	O	O	O
n=94	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
measured	O	O	O
the	O	O	O
outcome	O	O	O
as	O	O	O
scores	O	O	B-Entity
on	O	O	O
the	O	O	O
Patients	O	O	B-Entity
Expectations	O	O	B-Entity
Scale	O	O	I-Entity
,	O	O	O
Communication	O	O	B-Entity
Scale	O	O	I-Entity
,	O	O	O
Attitude	O	O	B-Entity
Toward	O	O	I-Entity
Treatment	O	O	I-Entity
and	O	O	I-Entity
Health	O	O	I-Entity
Scale	O	O	I-Entity
,	O	O	O
and	O	O	O
Self-Efficacy	O	O	B-Entity
Scale	O	O	I-Entity
.	O	O	O

GPs	O	O	B-Entity
participating	O	O	O
in	O	O	O
e-learning	O	O	B-Entity
demonstrated	O	O	O
a	O	O	O
significant	O	O	B-Entity
rise	O	O	O
in	O	O	O
their	O	O	O
perception	O	O	B-Entity
of	O	O	O
older	O	O	B-Entity
patients	O	O	B-Entity
'	O	O	O
expectations	O	O	B-Entity
for	O	O	O
disease	O	O	B-Entity
explanation	O	O	I-Entity
(	O	O	O
Wald	O	O	O
χ(2)=19.7	O	O	O
,	O	O	O
P<.001	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
perception	O	O	O
of	O	O	O
motivational	O	O	B-Entity
aspect	O	O	O
of	O	O	O
older	O	O	O
patients	O	O	O
'	O	O	O
attitude	O	O	O
toward	O	O	O
treatment	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
(	O	O	O
Wald	O	O	O
χ(2)=8.9	O	O	O
,	O	O	O
P=.03	O	O	O
)	O	O	O
in	O	O	O
comparison	O	O	O
with	O	O	O
both	O	O	O
the	O	O	O
control	O	O	B-Entity
and	O	O	O
pdf	O	O	B-Entity
article	O	O	I-Entity
groups	O	O	I-Entity
.	O	O	O

We	O	O	O
observed	O	O	O
additional	O	O	O
between-	O	O	O
group	O	O	B-Entity
differences	O	O	O
at	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
statistical	O	O	B-Entity
trend	O	O	O
.	O	O	O

GPs	O	O	B-Entity
participating	O	O	O
in	O	O	O
the	O	O	O
pdf	O	O	B-Entity
article	O	O	I-Entity
intervention	O	O	B-Entity
demonstrated	O	O	O
a	O	O	O
decline	O	O	O
in	O	O	O
self-assessed	O	O	O
communication	O	O	B-Entity
,	O	O	O
both	O	O	O
at	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
global	O	O	B-Entity
scoring	O	O	I-Entity
(	O	O	O
Wald	O	O	O
χ(2)=34.5	O	O	O
,	O	O	O
P<.001	O	O	O
)	O	O	O
and	O	O	O
at	O	O	O
the	O	O	O
level	O	O	O
of	O	O	O
20	O	O	O
of	O	O	O
26	O	O	O
specific	O	O	B-Entity
behaviors	O	O	I-Entity
(	O	O	O
all	O	O	O
P<.05	O	O	O
)	O	O	O
.	O	O	O

Factors	O	O	O
moderating	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
intervention	O	O	B-Entity
were	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
patients	O	O	B-Entity
per	O	O	O
GP	O	O	B-Entity
and	O	O	O
the	O	O	O
facility	O	O	O
's	O	O	O
organizational	O	O	B-Entity
structure	O	O	I-Entity
.	O	O	O

Both	O	O	O
methods	O	O	O
were	O	O	O
suitable	O	O	O
,	O	O	O
but	O	O	O
in	O	O	O
different	O	O	O
areas	O	O	B-Entity
and	O	O	O
under	O	O	O
different	O	O	O
conditions	O	O	B-Entity
.	O	O	O

The	O	O	O
key	O	O	O
benefit	O	O	O
of	O	O	O
the	O	O	O
pdf	O	O	B-Entity
article	O	O	I-Entity
intervention	O	O	B-Entity
was	O	O	O
raising	O	O	O
doctors	O	O	B-Entity
'	O	O	O
reflection	O	O	O
on	O	O	O
limitations	O	O	B-Entity
in	O	O	O
their	O	O	O
communication	O	O	B-Entity
skills	O	O	I-Entity
,	O	O	O
whereas	O	O	O
e-learning	O	O	B-Entity
was	O	O	O
more	O	O	O
effective	O	O	B-Entity
in	O	O	O
changing	O	O	O
their	O	O	O
perception	O	O	O
of	O	O	O
older	O	O	B-Entity
patients	O	O	B-Entity
'	O	O	O
proactive	O	O	O
attitude	O	O	O
,	O	O	O
especially	O	O	O
among	O	O	O
GPs	O	O	B-Entity
working	O	O	O
in	O	O	O
privately	O	O	B-Entity
owned	O	O	I-Entity
facilities	O	O	I-Entity
and	O	O	O
having	O	O	O
a	O	O	O
greater	O	O	O
number	O	O	O
of	O	O	O
assigned	O	O	B-Entity
patients	O	O	O
.	O	O	O

Although	O	O	O
we	O	O	O
did	O	O	O
not	O	O	O
achieve	O	O	O
all	O	O	O
expected	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
PRACTA	O	O	B-Entity
intervention	O	O	I-Entity
,	O	O	O
both	O	O	O
its	O	O	O
forms	O	O	O
seem	O	O	O
promising	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
enhancing	O	O	O
the	O	O	O
competencies	O	O	B-Entity
of	O	O	O
doctors	O	O	B-Entity
in	O	O	O
communication	O	O	B-Entity
with	O	O	O
and	O	O	O
activation	O	O	O
of	O	O	O
older	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28229178)

The	O	O	O
consummatory	O	O	B-Entity
and	O	O	O
motivational	O	O	B-Entity
behaviors	O	O	B-Entity
for	O	O	O
natural	O	O	B-Entity
rewards	O	O	B-Entity
following	O	O	O
long-term	O	O	O
withdrawal	O	O	B-Entity
from	O	O	O
morphine	O	O	B-Entity
:	O	O	O
no	O	O	O
anhedonia	O	O	B-Entity
but	O	O	O
persistent	O	O	O
maladaptive	O	O	B-Entity
behaviors	O	O	I-Entity
for	O	O	O
high-value	O	O	O
rewards	O	O	O

The	O	O	O
negative	O	O	O
affective	O	O	O
state	O	O	O
,	O	O	O
e.g.	O	O	O
,	O	O	O
anhedonia	O	O	B-Entity
,	O	O	O
emerges	O	O	O
after	O	O	O
abstinence	O	O	B-Entity
from	O	O	O
abused	O	O	B-Entity
drugs	O	O	I-Entity
may	O	O	O
be	O	O	O
linked	O	O	O
to	O	O	O
the	O	O	O
motivational	O	O	B-Entity
processes	O	O	B-Entity
of	O	O	O
drug	O	O	B-Entity
craving	O	O	I-Entity
and	O	O	O
relapse	O	O	B-Entity
.	O	O	O

Although	O	O	O
anhedonia	O	O	B-Entity
diminishes	O	O	O
over	O	O	O
time	O	O	O
with	O	O	O
drug	O	O	B-Entity
abstinence	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
not	O	O	O
yet	O	O	O
rather	O	O	O
explicit	O	O	O
whether	O	O	O
anhedonia	O	O	O
exists	O	O	O
or	O	O	O
not	O	O	O
following	O	O	O
protracted	O	O	O
withdrawal	O	O	B-Entity
.	O	O	O

The	O	O	O
behavioral	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
natural	O	O	B-Entity
rewards	O	O	B-Entity
were	O	O	O
examined	O	O	O
after	O	O	O
2	O	O	O
to	O	O	O
3	O	O	O
weeks	O	O	B-Entity
withdrawal	O	O	B-Entity
from	O	O	O
morphine	O	O	B-Entity
.	O	O	O

Male	O	O	B-Entity
rats	O	O	B-Entity
were	O	O	O
pretreated	O	O	O
with	O	O	O
either	O	O	O
a	O	O	O
binge-like	O	O	O
morphine	O	O	B-Entity
paradigm	O	O	B-Entity
or	O	O	O
daily	O	O	B-Entity
saline	O	O	B-Entity
injection	O	O	I-Entity
for	O	O	O
5	O	O	O
days	O	O	B-Entity
.	O	O	O

The	O	O	O
consummatory	O	O	B-Entity
and	O	O	O
motivational	O	O	B-Entity
behaviors	O	O	B-Entity
for	O	O	O
three	O	O	O
natural	O	O	B-Entity
rewards	O	O	B-Entity
(	O	O	O
sucrose	O	O	B-Entity
solutions	O	O	I-Entity
4	O	O	O
,	O	O	O
15	O	O	O
,	O	O	O
and	O	O	O
60	O	O	O
%	O	O	O
,	O	O	O
social	O	O	B-Entity
stimulus	O	O	B-Entity
:	O	O	O
male	O	O	B-Entity
rat	O	O	B-Entity
,	O	O	O
and	O	O	O
sexual	O	O	B-Entity
stimulus	O	O	O
:	O	O	O
estrous	O	O	B-Entity
female	O	O	B-Entity
rat	O	O	O
)	O	O	O
were	O	O	O
examined	O	O	O
under	O	O	O
varied	O	O	O
testing	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

The	O	O	O
morphine	O	O	B-Entity
-	O	O	O
withdrawn	O	O	B-Entity
rats	O	O	B-Entity
significantly	O	O	O
increased	O	O	O
their	O	O	O
intake	O	O	O
of	O	O	O
15	O	O	O
%	O	O	O
sucrose	O	O	B-Entity
solution	O	O	I-Entity
during	O	O	O
the	O	O	O
1-h	O	O	O
consumption	O	O	B-Entity
test	O	O	I-Entity
and	O	O	O
their	O	O	O
operant	O	O	B-Entity
responding	O	O	I-Entity
for	O	O	O
15	O	O	O
%	O	O	O
sucrose	O	O	O
solution	O	O	O
under	O	O	O
a	O	O	O
progressive	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	I-Entity
PR	O	O	I-Entity
)	O	O	I-Entity
schedule	O	O	I-Entity
of	O	O	I-Entity
reinforcement	O	O	I-Entity
.	O	O	O

When	O	O	O
obtaining	O	O	O
a	O	O	O
reinforcer	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
a	O	O	O
0.5	O	O	O
mA	O	O	O
foot	O	O	B-Entity
shock	O	O	B-Entity
under	O	O	O
a	O	O	O
PR-punishment	O	O	B-Entity
schedule	O	O	I-Entity
,	O	O	O
the	O	O	O
morphine	O	O	B-Entity
-	O	O	O
withdrawn	O	O	B-Entity
rats	O	O	B-Entity
showed	O	O	O
a	O	O	O
higher	O	O	O
performance	O	O	O
for	O	O	O
60	O	O	O
%	O	O	O
sucrose	O	O	B-Entity
solution	O	O	I-Entity
.	O	O	O

Meanwhile	O	O	O
,	O	O	O
the	O	O	O
morphine	O	O	B-Entity
-	O	O	O
withdrawn	O	O	B-Entity
rats	O	O	B-Entity
displayed	O	O	O
a	O	O	O
higher	O	O	O
motivation	O	O	B-Entity
to	O	O	O
sexual	O	O	B-Entity
stimulus	O	O	B-Entity
during	O	O	O
the	O	O	O
free-approach	O	O	B-Entity
test	O	O	I-Entity
and	O	O	O
more	O	O	O
approaching	O	O	O
behaviors	O	O	B-Entity
towards	O	O	O
sexual	O	O	O
stimulus	O	O	O
in	O	O	O
a	O	O	O
conflict-based	O	O	B-Entity
approach	O	O	I-Entity
test	O	O	I-Entity
(	O	O	O
concurrent	O	O	O
presence	O	O	O
of	O	O	O
reward	O	O	B-Entity
and	O	O	O
aversive	O	O	B-Entity
stimulus	O	O	I-Entity
)	O	O	O
.	O	O	O

No	O	O	B-Entity
anhedonia	O	O	B-Entity
-like	O	O	O
behavior	O	O	B-Entity
but	O	O	O
sensitized	O	O	B-Entity
behaviors	O	O	B-Entity
for	O	O	O
natural	O	O	B-Entity
rewards	O	O	B-Entity
were	O	O	O
found	O	O	O
after	O	O	O
long-term	O	O	O
morphine	O	O	B-Entity
withdrawal	O	O	B-Entity
.	O	O	O

Notably	O	O	O
,	O	O	O
the	O	O	O
morphine	O	O	B-Entity
-	O	O	O
withdrawn	O	O	B-Entity
rats	O	O	B-Entity
displayed	O	O	O
persistent	O	O	O
motivated	O	O	B-Entity
behaviors	O	O	B-Entity
for	O	O	O
high-value	O	O	O
rewards	O	O	B-Entity
(	O	O	O
60	O	O	O
%	O	O	O
sucrose	O	O	B-Entity
and	O	O	O
sexual	O	O	B-Entity
stimulus	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
conflict	O	O	B-Entity
tests	O	O	I-Entity
suggesting	O	O	O
impairments	O	O	O
in	O	O	O
inhibitory	O	O	O
control	O	O	O
in	O	O	O
morphine	O	O	O
-	O	O	O
treated	O	O	B-Entity
rats	O	O	O
.	O	O	O

-DOCSTART- (28230977)

Extracellular	O	O	B-Entity
Self-Assembly	O	O	B-Entity
of	O	O	O
Functional	O	O	B-Entity
and	O	O	O
Tunable	O	O	B-Entity
Protein	O	O	I-Entity
Conjugates	O	O	I-Entity
from	O	O	O
Bacillus	O	O	O
subtilis	O	O	O

The	O	O	O
ability	O	O	O
to	O	O	O
stably	O	O	B-Entity
and	O	O	O
specifically	O	O	O
conjugate	O	O	B-Entity
recombinant	O	O	B-Entity
proteins	O	O	I-Entity
to	O	O	O
one	O	O	O
another	O	O	O
is	O	O	O
a	O	O	O
powerful	O	O	O
approach	O	O	O
for	O	O	O
engineering	O	O	B-Entity
multifunctional	O	O	B-Entity
enzymes	O	O	B-Entity
,	O	O	O
protein	O	O	B-Entity
therapeutics	O	O	I-Entity
,	O	O	O
and	O	O	O
novel	O	O	B-Entity
biological	O	O	B-Entity
materials	O	O	I-Entity
.	O	O	O

While	O	O	O
many	O	O	O
of	O	O	O
these	O	O	O
applications	O	O	B-Entity
have	O	O	O
been	O	O	O
illustrated	O	O	O
through	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
intracellular	O	O	B-Entity
protein	O	O	B-Entity
conjugation	O	O	I-Entity
methods	O	O	O
,	O	O	O
extracellular	O	O	B-Entity
self-assembly	O	O	B-Entity
of	O	O	O
protein	O	O	B-Entity
conjugates	O	O	I-Entity
offers	O	O	O
unique	O	O	O
advantages	O	O	O
:	O	O	O
simplifying	O	O	O
purification	O	O	B-Entity
,	O	O	O
reducing	O	O	B-Entity
toxicity	O	O	B-Entity
and	O	O	O
burden	O	O	B-Entity
,	O	O	O
and	O	O	O
enabling	O	O	O
tunability	O	O	B-Entity
.	O	O	O

Exploiting	O	O	O
the	O	O	O
recently	O	O	O
described	O	O	O
SpyTag-SpyCatcher	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
we	O	O	O
describe	O	O	O
here	O	O	O
how	O	O	O
enzymes	O	O	B-Entity
and	O	O	O
structural	O	O	B-Entity
proteins	O	O	I-Entity
can	O	O	O
be	O	O	O
genetically	O	O	B-Entity
encoded	O	O	I-Entity
to	O	O	O
covalently	O	O	B-Entity
conjugate	O	O	B-Entity
in	O	O	O
culture	O	O	B-Entity
media	O	O	I-Entity
following	O	O	O
programmable	O	O	B-Entity
secretion	O	O	I-Entity
from	O	O	O
Bacillus	O	O	B-Entity
subtilis	O	O	I-Entity
.	O	O	O

Using	O	O	O
this	O	O	O
approach	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
how	O	O	O
self-conjugation	O	O	B-Entity
of	O	O	O
a	O	O	O
secreted	O	O	B-Entity
industrial	O	O	O
enzyme	O	O	B-Entity
,	O	O	O
XynA	O	O	B-Entity
,	O	O	O
dramatically	O	O	O
increases	O	O	B-Entity
its	O	O	O
resilience	O	O	B-Entity
to	O	O	O
boiling	O	O	B-Entity
,	O	O	O
and	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
cellular	O	O	B-Entity
consortia	O	O	I-Entity
can	O	O	O
be	O	O	O
engineered	O	O	B-Entity
to	O	O	O
self-assemble	O	O	B-Entity
functional	O	O	B-Entity
protein-protein	O	O	B-Entity
conjugates	O	O	I-Entity
with	O	O	O
tunable	O	O	O
composition	O	O	O
.	O	O	O

This	O	O	O
novel	O	O	B-Entity
genetically	O	O	B-Entity
encoded	O	O	I-Entity
modular	O	O	B-Entity
system	O	O	I-Entity
provides	O	O	O
a	O	O	O
flexible	O	O	B-Entity
strategy	O	O	I-Entity
for	O	O	O
protein	O	O	B-Entity
conjugation	O	O	I-Entity
harnessing	O	O	O
the	O	O	O
substantial	O	O	O
advantages	O	O	O
of	O	O	O
extracellular	O	O	B-Entity
self-assembly	O	O	B-Entity
.	O	O	O

-DOCSTART- (28234672)

Vascular	O	O	B-Entity
smooth	O	O	I-Entity
muscle	O	O	I-Entity
cell	O	O	I-Entity
peroxisome	O	O	B-Entity
proliferator-activated	O	O	I-Entity
receptor	O	O	I-Entity
γ	O	O	I-Entity
protects	O	O	O
against	O	O	O
endothelin-1	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
inflammation	O	O	O

Peroxisome	O	O	B-Entity
proliferator-activated	O	O	I-Entity
receptor	O	O	I-Entity
γ	O	O	I-Entity
(	O	O	O
PPARγ	O	O	B-Entity
)	O	O	O
agonists	O	O	B-Entity
reduce	O	O	B-Entity
blood	O	O	B-Entity
pressure	O	O	I-Entity
and	O	O	O
vascular	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
hypertensive	O	O	B-Entity
rodents	O	O	B-Entity
.	O	O	O

Pparγ	O	O	B-Entity
inactivation	O	O	B-Entity
in	O	O	O
vascular	O	O	B-Entity
smooth	O	O	I-Entity
muscle	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
VSMC	O	O	B-Entity
)	O	O	O
enhances	O	O	B-Entity
vascular	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

Transgenic	O	O	B-Entity
mice	O	O	I-Entity
overexpressing	O	O	B-Entity
endothelin	O	O	B-Entity
(ET)-1	O	O	I-Entity
selectively	O	O	O
in	O	O	O
the	O	O	O
endothelium	O	O	B-Entity
(	O	O	B-Entity
eET-1	O	O	I-Entity
)	O	O	I-Entity
exhibit	O	O	O
endothelial	O	O	B-Entity
dysfunction	O	O	I-Entity
,	O	O	O
increased	O	O	B-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
inflammation	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	B-Entity
that	O	O	O
inactivation	O	O	B-Entity
of	O	O	O
the	O	O	O
Pparγ	O	O	B-Entity
gene	O	O	I-Entity
in	O	O	O
VSMC	O	O	B-Entity
(	O	O	O
smPparγ	O	O	B-Entity
)	O	O	O
would	O	O	O
exaggerate	O	O	B-Entity
ET-1	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
vascular	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

eET-1	O	O	B-Entity
,	O	O	O
smPparγ	O	O	B-Entity
and	O	O	O
eET-1	O	O	O
/	O	O	O
smPparγ	O	O	O
mice	O	O	B-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
tamoxifen	O	O	B-Entity
for	O	O	O
5	O	O	O
days	O	O	O
and	O	O	O
studied	O	O	B-Entity
4	O	O	O
weeks	O	O	O
later	O	O	O
.	O	O	O

SBP	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
in	O	O	O
eET-1	O	O	B-Entity
and	O	O	O
unaffected	O	O	B-Entity
by	O	O	O
smPparγ	O	O	B-Entity
inactivation	O	O	B-Entity
.	O	O	O

Mesenteric	O	O	B-Entity
artery	O	O	I-Entity
vasodilatory	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
acetylcholine	O	O	B-Entity
were	O	O	O
impaired	O	O	B-Entity
only	O	O	O
in	O	O	O
smPparγ	O	O	B-Entity
.	O	O	O

N-Nitro-L-arginine	O	O	B-Entity
methyl	O	O	I-Entity
ester	O	O	I-Entity
abrogated	O	O	B-Entity
relaxation	O	O	B-Entity
responses	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
Ednra	O	O	B-Entity
/	O	O	O
Ednrb	O	O	B-Entity
mRNA	O	O	B-Entity
ratio	O	O	B-Entity
was	O	O	O
decreased	O	O	B-Entity
in	O	O	O
eET-1	O	O	B-Entity
/	O	O	O
smPparγ	O	O	B-Entity
,	O	O	O
which	O	O	O
could	O	O	O
indicate	O	O	B-Entity
that	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
production	O	O	B-Entity
was	O	O	O
enhanced	O	O	B-Entity
by	O	O	O
ET-1	O	O	B-Entity
stimulation	O	O	B-Entity
of	O	O	O
endothelin	O	O	B-Entity
type	O	O	I-Entity
B	O	O	I-Entity
receptors	O	O	I-Entity
.	O	O	O

Mesenteric	O	O	B-Entity
artery	O	O	I-Entity
media	O	O	B-Entity
/	O	O	O
lumen	O	O	B-Entity
was	O	O	O
greater	O	O	B-Entity
only	O	O	O
in	O	O	O
eET-1	O	O	B-Entity
/	O	O	O
smPparγ	O	O	B-Entity
.	O	O	O

Mesenteric	O	O	B-Entity
artery	O	O	I-Entity
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
increased	O	O	B-Entity
in	O	O	O
smPparγ	O	O	B-Entity
and	O	O	O
were	O	O	O
further	O	O	O
enhanced	O	O	B-Entity
in	O	O	O
eET-1	O	O	B-Entity
/	O	O	O
smPparγ	O	O	O
.	O	O	O

Perivascular	O	O	B-Entity
fat	O	O	B-Entity
monocyte	O	O	I-Entity
/	O	O	O
macrophage	O	O	B-Entity
infiltration	O	O	B-Entity
was	O	O	O
higher	O	O	B-Entity
in	O	O	O
eET-1	O	O	B-Entity
and	O	O	O
smPparγ	O	O	B-Entity
and	O	O	O
increased	O	O	B-Entity
further	O	O	O
in	O	O	O
eET-1	O	O	O
/	O	O	O
smPparγ	O	O	O
.	O	O	O

Spleen	O	O	B-Entity
CD11b	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
increased	O	O	B-Entity
in	O	O	O
smPparγ	O	O	B-Entity
and	O	O	O
further	O	O	O
enhance	O	O	B-Entity
d	O	O	O
in	O	O	O
eET-1	O	O	B-Entity
/	O	O	O
smPparγ	O	O	O
,	O	O	O
whereas	O	O	O
Ly-6C	O	O	B-Entity
monocytes	O	O	I-Entity
increased	O	O	O
in	O	O	O
eET-1	O	O	O
and	O	O	O
smPparγ	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
eET-1	O	O	O
/	O	O	O
smPparγ	O	O	O
.	O	O	O

Spleen	O	O	B-Entity
T	O	O	B-Entity
regulatory	O	O	I-Entity
lymphocytes	O	O	I-Entity
increased	O	O	B-Entity
in	O	O	O
smPparγ	O	O	B-Entity
and	O	O	O
decreased	O	O	B-Entity
in	O	O	O
eET-1	O	O	B-Entity
,	O	O	O
and	O	O	O
decreased	O	O	O
further	O	O	O
in	O	O	O
eET-1	O	O	O
/	O	O	O
smPparγ	O	O	O
.	O	O	O

VSMC	O	O	B-Entity
Pparγ	O	O	B-Entity
inactivation	O	O	B-Entity
exaggerates	O	O	B-Entity
ET-1	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
vascular	O	O	B-Entity
injury	O	O	I-Entity
,	O	O	O
supporting	O	O	O
a	O	O	O
protective	O	O	O
role	O	O	B-Entity
for	O	O	O
PPARγ	O	O	B-Entity
in	O	O	O
hypertension	O	O	B-Entity
through	O	O	O
modulation	O	O	B-Entity
of	O	O	O
pro-oxidant	O	O	B-Entity
and	O	O	O
proinflammatory	O	O	B-Entity
pathways	O	O	B-Entity
.	O	O	O

Paradoxically	O	O	O
,	O	O	O
ET-1	O	O	B-Entity
overexpression	O	O	B-Entity
preserved	O	O	O
endothelial	O	O	B-Entity
function	O	O	B-Entity
in	O	O	O
smPparγ	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
presumably	O	O	O
by	O	O	O
enhancing	O	O	B-Entity
nitric	O	O	B-Entity
oxide	O	O	I-Entity
through	O	O	O
stimulation	O	O	B-Entity
of	O	O	O
endothelin	O	O	B-Entity
type	O	O	I-Entity
B	O	O	I-Entity
receptors	O	O	I-Entity
.	O	O	O

-DOCSTART- (28235120)

Prospective	O	O	O
Evaluation	O	O	B-Entity
of	O	O	O
Opioid	O	O	B-Entity
Consumption	O	O	I-Entity
After	O	O	O
Distal	O	O	B-Entity
Radius	O	O	I-Entity
Fracture	O	O	I-Entity
Repair	O	O	O
Surgery	O	O	O

Pain	O	O	B-Entity
management	O	O	I-Entity
and	O	O	O
opioid	O	O	B-Entity
consumption	O	O	I-Entity
after	O	O	O
distal	O	O	B-Entity
radius	O	O	I-Entity
fracture	O	O	I-Entity
(	O	O	O
DRF	O	O	B-Entity
)	O	O	O
open	O	O	B-Entity
reduction	O	O	I-Entity
and	O	O	I-Entity
internal	O	O	I-Entity
fixation	O	O	I-Entity
(	O	O	I-Entity
ORIF	O	O	I-Entity
)	O	O	I-Entity
are	O	O	O
highly	O	O	O
variable	O	O	O
and	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

To	O	O	O
optimize	O	O	B-Entity
postoperative	O	O	B-Entity
opioid	O	O	B-Entity
dosage	O	O	B-Entity
and	O	O	O
better	O	O	O
understand	O	O	O
opioid	O	O	B-Entity
consumption	O	O	I-Entity
patterns	O	O	O
after	O	O	O
DRF	O	O	B-Entity
-	O	O	O
ORIF	O	O	B-Entity
,	O	O	O
we	O	O	O
conducted	O	O	O
a	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
with	O	O	O
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
opioid	O	O	O
consumption	O	O	O
would	O	O	O
increase	O	O	B-Entity
with	O	O	O
worsening	O	O	B-Entity
fracture	O	O	B-Entity
classification	O	O	B-Entity
and	O	O	O
various	O	O	O
patient	O	O	B-Entity
demographics	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
DRF	O	O	B-Entity
-	O	O	O
ORIF	O	O	B-Entity
were	O	O	O
consecutively	O	O	O
enrolled	O	O	O
over	O	O	O
a	O	O	O
6-month	O	O	B-Entity
period	O	O	I-Entity
.	O	O	O

Information	O	O	O
collected	O	O	O
included	O	O	O
patient	O	O	B-Entity
demographics	O	O	I-Entity
,	O	O	O
fracture	O	O	B-Entity
type	O	O	B-Entity
,	O	O	O
anesthesia	O	O	B-Entity
type	O	O	I-Entity
,	O	O	O
amount	O	O	B-Entity
and	O	O	O
type	O	O	O
of	O	O	O
opioid	O	O	B-Entity
prescribed	O	O	B-Entity
,	O	O	O
number	O	O	B-Entity
of	O	O	O
pills	O	O	B-Entity
taken	O	O	B-Entity
,	O	O	O
reason	O	O	B-Entity
for	O	O	O
stopping	O	O	B-Entity
,	O	O	O
and	O	O	O
adverse	O	O	B-Entity
events	O	O	I-Entity
.	O	O	O

Statistical	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	O
.	O	O	O

Ninety-eight	O	O	O
patients	O	O	B-Entity
(	O	O	O
79	O	O	O
female	O	O	B-Entity
,	O	O	O
19	O	O	O
male	O	O	B-Entity
)	O	O	O
were	O	O	O
eligible	O	O	O
for	O	O	O
the	O	O	O
study	O	O	O
.	O	O	O

Mean	O	O	O
age	O	O	O
was	O	O	O
58	O	O	O
years	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
98	O	O	O
patients	O	O	B-Entity
,	O	O	O
45	O	O	O
received	O	O	O
general	O	O	B-Entity
anesthesia	O	O	I-Entity
,	O	O	O
and	O	O	O
53	O	O	O
received	O	O	O
regional	O	O	B-Entity
anesthesia	O	O	I-Entity
with	O	O	O
a	O	O	O
single-shot	O	O	O
peripheral	O	O	B-Entity
nerve	O	O	I-Entity
block	O	O	I-Entity
.	O	O	O

Mean	O	O	O
opioid	O	O	B-Entity
consumption	O	O	I-Entity
(	O	O	O
morphine	O	O	B-Entity
equivalence	O	O	B-Entity
)	O	O	O
over	O	O	O
a	O	O	O
mean	O	O	O
of	O	O	O
4.8	O	O	O
postoperative	O	O	B-Entity
days	O	O	I-Entity
(	O	O	O
range	O	O	O
,	O	O	O
0	O	O	O
-	O	O	O
16	O	O	O
days	O	O	O
)	O	O	O
was	O	O	O
58.5	O	O	O
mg	O	O	O
(	O	O	O
range	O	O	O
,	O	O	O
0	O	O	O
-	O	O	O
280	O	O	O
mg	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	O
in	O	O	O
opioid	O	O	B-Entity
consumption	O	O	I-Entity
between	O	O	O
the	O	O	O
general	O	O	B-Entity
and	O	O	O
regional	O	O	B-Entity
anesthesia	O	O	I-Entity
groups	O	O	O
.	O	O	O

Mean	O	O	O
opioid	O	O	B-Entity
consumption	O	O	I-Entity
for	O	O	O
the	O	O	O
3	O	O	O
fracture-type	O	O	B-Entity
groups	O	O	O
(	O	O	O
AO/OTA	O	O	B-Entity
[	O	O	I-Entity
Arbeitsgemeinschaft	O	O	I-Entity
für	O	O	I-Entity
Osteosynthesefragen/Orthopaedic	O	O	I-Entity
Trauma	O	O	I-Entity
Association	O	O	I-Entity
]	O	O	I-Entity
classification	O	O	I-Entity
)	O	O	O
was	O	O	O
57.7	O	O	O
mg	O	O	O
(	O	O	O
class	O	O	B-Entity
A	O	O	I-Entity
)	O	O	O
,	O	O	O
60.3	O	O	O
mg	O	O	O
(	O	O	O
class	O	O	B-Entity
B	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
62.0	O	O	O
mg	O	O	O
(	O	O	O
class	O	O	B-Entity
C	O	O	I-Entity
)	O	O	O
.	O	O	O

Demographic	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
an	O	O	O
inverse	O	O	B-Entity
relationship	O	O	B-Entity
between	O	O	O
age	O	O	B-Entity
and	O	O	O
opioid	O	O	B-Entity
use	O	O	I-Entity
.	O	O	O

Similarly	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
trend	O	O	O
toward	O	O	O
more	O	O	O
opioid	O	O	B-Entity
consumption	O	O	I-Entity
among	O	O	O
self-pay	O	O	B-Entity
and	O	O	O
Medicaid	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Opioid	O	O	B-Entity
consumption	O	O	I-Entity
after	O	O	O
DRF	O	O	B-Entity
-	O	O	O
ORIF	O	O	B-Entity
was	O	O	O
equivalent	O	O	B-Entity
for	O	O	O
general	O	O	B-Entity
and	O	O	O
regional	O	O	B-Entity
anesthesia	O	O	I-Entity
.	O	O	O

A	O	O	O
significant	O	O	O
relationship	O	O	B-Entity
was	O	O	O
found	O	O	O
between	O	O	O
increasing	O	O	B-Entity
age	O	O	I-Entity
and	O	O	O
decreasing	O	O	B-Entity
opioid	O	O	B-Entity
consumption	O	O	I-Entity
.	O	O	O

Worsening	O	O	B-Entity
fracture	O	O	B-Entity
classification	O	O	I-Entity
and	O	O	O
self-payment	O	O	B-Entity
/	O	O	O
Medicaid	O	O	B-Entity
payment	O	O	I-Entity
trended	O	O	O
toward	O	O	O
increasing	O	O	B-Entity
opioid	O	O	B-Entity
consumption	O	O	I-Entity
.	O	O	O

Mean	O	O	O
overall	O	O	O
opioid	O	O	B-Entity
consumption	O	O	I-Entity
(	O	O	O
morphine	O	O	B-Entity
equivalence	O	O	B-Entity
)	O	O	O
was	O	O	O
58.5	O	O	O
mg	O	O	O
,	O	O	O
or	O	O	O
14.6	O	O	O
pills	O	O	B-Entity
of	O	O	O
oxycodone/acetaminophen	O	O	B-Entity
5/325	O	O	O
mg	O	O	O
.	O	O	O

Surgeons	O	O	B-Entity
should	O	O	O
take	O	O	O
these	O	O	O
findings	O	O	O
into	O	O	O
account	O	O	O
when	O	O	O
optimizing	O	O	B-Entity
opioid	O	O	B-Entity
prescribing	O	O	O
after	O	O	O
DRF	O	O	B-Entity
repair	O	O	B-Entity
.	O	O	O

-DOCSTART- (28236130)

Entrapment	O	O	B-Entity
of	O	O	O
the	O	O	O
posterior	O	O	B-Entity
femoral	O	O	I-Entity
cutaneous	O	O	I-Entity
nerve	O	O	I-Entity
and	O	O	O
its	O	O	O
inferior	O	O	B-Entity
cluneal	O	O	I-Entity
branches	O	O	I-Entity
:	O	O	O
anatomical	O	O	B-Entity
basis	O	O	I-Entity
of	O	O	O
surgery	O	O	B-Entity
for	O	O	O
inferior	O	O	O
cluneal	O	O	O
neuralgia	O	O	O

The	O	O	O
apparent	O	O	O
failure	O	O	O
of	O	O	O
pudendal	O	O	B-Entity
nerve	O	O	I-Entity
surgery	O	O	B-Entity
in	O	O	O
some	O	O	O
patients	O	O	B-Entity
has	O	O	O
led	O	O	O
us	O	O	O
to	O	O	O
suggest	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
entrapment	O	O	B-Entity
of	O	O	O
other	O	O	O
adjacent	O	O	B-Entity
nerve	O	O	I-Entity
structures	O	O	I-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
the	O	O	O
concept	O	O	O
of	O	O	O
inferior	O	O	B-Entity
cluneal	O	O	I-Entity
neuralgia	O	O	I-Entity
.	O	O	O

Via	O	O	O
its	O	O	O
numerous	O	O	O
collateral	O	O	B-Entity
branches	O	O	I-Entity
,	O	O	O
the	O	O	O
posterior	O	O	B-Entity
femoral	O	O	I-Entity
cutaneous	O	O	I-Entity
nerve	O	O	I-Entity
innervates	O	O	O
a	O	O	O
very	O	O	O
extensive	O	O	O
territory	O	O	O
including	O	O	O
the	O	O	O
posterior	O	O	B-Entity
surface	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
thigh	O	O	I-Entity
,	O	O	O
the	O	O	O
infragluteal	O	O	B-Entity
fold	O	O	I-Entity
,	O	O	O
the	O	O	O
skin	O	O	B-Entity
over	O	O	O
the	O	O	O
ischial	O	O	B-Entity
tuberosity	O	O	I-Entity
,	O	O	O
but	O	O	O
also	O	O	O
the	O	O	O
lateral	O	O	B-Entity
anal	O	O	I-Entity
region	O	O	I-Entity
,	O	O	O
scrotum	O	O	B-Entity
or	O	O	O
labium	O	O	B-Entity
majus	O	O	I-Entity
via	O	O	O
its	O	O	O
perineal	O	O	B-Entity
branch	O	O	I-Entity
.	O	O	O

We	O	O	O
described	O	O	O
the	O	O	O
pathophysiological	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
cluneal	O	O	B-Entity
neuralgia	O	O	I-Entity
,	O	O	O
the	O	O	O
surgical	O	O	B-Entity
technique	O	O	I-Entity
and	O	O	O
our	O	O	O
preliminary	O	O	B-Entity
results	O	O	I-Entity
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
transmuscular	O	O	B-Entity
approach	O	O	I-Entity
leading	O	O	O
to	O	O	O
the	O	O	O
fat	O	O	B-Entity
of	O	O	O
the	O	O	O
deep	O	O	O
gluteal	O	O	B-Entity
region	O	O	I-Entity
.	O	O	O

Exploration	O	O	B-Entity
was	O	O	O
continued	O	O	O
cranially	O	O	O
underneath	O	O	O
the	O	O	O
piriformis	O	O	B-Entity
,	O	O	O
looking	O	O	O
for	O	O	O
potential	O	O	O
entrapments	O	O	B-Entity
affecting	O	O	O
the	O	O	O
posterior	O	O	B-Entity
femoral	O	O	I-Entity
cutaneous	O	O	I-Entity
nerve	O	O	I-Entity
and	O	O	O
the	O	O	O
sciatic	O	O	B-Entity
nerve	O	O	I-Entity
.	O	O	O

Nerve	O	O	B-Entity
decompression	O	O	I-Entity
on	O	O	O
the	O	O	O
lateral	O	O	B-Entity
surface	O	O	I-Entity
of	O	O	O
the	O	O	O
ischial	O	O	B-Entity
tuberosity	O	O	I-Entity
was	O	O	O
then	O	O	O
performed	O	O	O
.	O	O	O

A	O	O	O
constant	O	O	O
anatomical	O	O	B-Entity
finding	O	O	I-Entity
must	O	O	O
be	O	O	O
highlighted	O	O	O
:	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
a	O	O	O
lateral	O	O	B-Entity
fibrous	O	O	I-Entity
expansion	O	O	B-Entity
from	O	O	O
the	O	O	O
ischium	O	O	B-Entity
passing	O	O	O
behind	O	O	O
the	O	O	O
nerves	O	O	B-Entity
and	O	O	O
vessels	O	O	B-Entity
,	O	O	O
especially	O	O	O
the	O	O	O
posterior	O	O	B-Entity
femoral	O	O	I-Entity
cutaneous	O	O	I-Entity
nerve	O	O	I-Entity
and	O	O	O
its	O	O	O
perineal	O	O	B-Entity
branches	O	O	I-Entity
.	O	O	O

In	O	O	O
our	O	O	O
patients	O	O	B-Entity
,	O	O	O
release	O	O	O
of	O	O	O
this	O	O	O
expansion	O	O	B-Entity
allowed	O	O	O
decompression	O	O	B-Entity
of	O	O	O
the	O	O	O
nerve	O	O	B-Entity
trapped	O	O	I-Entity
by	O	O	O
this	O	O	O
expansion	O	O	O
.	O	O	O

Cluneal	O	O	B-Entity
neuralgia	O	O	I-Entity
constitutes	O	O	O
a	O	O	O
distinct	O	O	O
entity	O	O	O
of	O	O	O
perineal	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
which	O	O	O
must	O	O	O
be	O	O	O
identified	O	O	O
and	O	O	O
distinguished	O	O	O
from	O	O	O
pudendal	O	O	B-Entity
neuralgia	O	O	I-Entity
.	O	O	O

Surgery	O	O	B-Entity
should	O	O	O
be	O	O	O
performed	O	O	O
via	O	O	O
a	O	O	O
transgluteal	O	O	B-Entity
approach	O	O	I-Entity
.	O	O	O

A	O	O	O
lateral	O	O	B-Entity
ischial	O	O	I-Entity
obstacle	O	O	O
must	O	O	O
be	O	O	O
investigated	O	O	B-Entity
,	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
a	O	O	O
constant	O	O	O
fibrous	O	O	B-Entity
expansion	O	O	B-Entity
,	O	O	O
which	O	O	O
,	O	O	O
like	O	O	O
a	O	O	O
retinaculum	O	O	B-Entity
,	O	O	O
can	O	O	O
cause	O	O	O
nerve	O	O	B-Entity
entrapment	O	O	I-Entity
.	O	O	O

-DOCSTART- (28237116)

Methods	O	O	B-Entity
to	O	O	O
Study	O	O	B-Entity
Autophagy	O	O	B-Entity
in	O	O	O
Zebrafish	O	O	O

Autophagy	O	O	B-Entity
(	O	O	O
cellular	O	O	B-Entity
self-eating	O	O	I-Entity
)	O	O	O
is	O	O	O
a	O	O	O
highly	O	O	O
regulated	O	O	O
degradation	O	O	B-Entity
process	O	O	I-Entity
of	O	O	O
the	O	O	O
eukaryotic	O	O	B-Entity
cell	O	O	I-Entity
during	O	O	O
which	O	O	O
parts	O	O	O
of	O	O	O
the	O	O	O
cytoplasm	O	O	B-Entity
are	O	O	O
delivered	O	O	B-Entity
into	O	O	O
,	O	O	O
and	O	O	O
broken	O	O	B-Entity
down	O	O	I-Entity
within	O	O	O
,	O	O	O
the	O	O	O
lysosomal	O	O	B-Entity
compartment	O	O	I-Entity
.	O	O	O

The	O	O	O
process	O	O	O
serves	O	O	O
as	O	O	O
a	O	O	O
main	O	O	O
route	O	O	O
for	O	O	O
the	O	O	O
elimination	O	O	B-Entity
of	O	O	O
superfluous	O	O	O
and	O	O	O
damaged	O	O	O
cellular	O	O	B-Entity
constituents	O	O	I-Entity
,	O	O	O
thereby	O	O	O
mediating	O	O	O
macromolecular	O	O	B-Entity
and	O	O	O
organellar	O	O	B-Entity
turnover	O	O	I-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
to	O	O	O
maintaining	O	O	O
cellular	O	O	B-Entity
homeostasis	O	O	I-Entity
,	O	O	O
autophagy	O	O	B-Entity
is	O	O	O
involved	O	O	O
in	O	O	O
various	O	O	O
other	O	O	O
cellular	O	O	O
and	O	O	O
developmental	O	O	B-Entity
processes	O	O	I-Entity
by	O	O	O
degrading	O	O	B-Entity
specific	O	O	O
regulatory	O	O	B-Entity
proteins	O	O	I-Entity
,	O	O	O
and	O	O	O
contributing	O	O	O
to	O	O	O
the	O	O	O
clearance	O	O	O
of	O	O	O
intracellular	O	O	B-Entity
pathogens	O	O	B-Entity
.	O	O	O

The	O	O	O
physiological	O	O	B-Entity
roles	O	O	I-Entity
and	O	O	O
pathological	O	O	B-Entity
involvement	O	O	O
of	O	O	O
autophagy	O	O	B-Entity
can	O	O	O
be	O	O	O
effectively	O	O	O
studied	O	O	O
in	O	O	O
divergent	O	O	O
eukaryotic	O	O	B-Entity
model	O	O	B-Entity
systems	O	O	I-Entity
ranging	O	O	O
from	O	O	O
yeast	O	O	B-Entity
to	O	O	O
mice	O	O	B-Entity
.	O	O	O

Such	O	O	O
a	O	O	O
tractable	O	O	O
animal	O	O	B-Entity
model	O	O	I-Entity
applied	O	O	O
only	O	O	O
recently	O	O	O
for	O	O	O
autophagy	O	O	B-Entity
researchis	O	O	O
the	O	O	O
zebrafish	O	O	B-Entity
Danio	O	O	B-Entity
rerio	O	O	I-Entity
,	O	O	O
which	O	O	O
also	O	O	O
facilitates	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
more	O	O	O
specific	O	O	O
biological	O	O	B-Entity
processes	O	O	I-Entity
such	O	O	O
as	O	O	O
tissue	O	O	B-Entity
regeneration	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
chapter	O	O	O
,	O	O	O
we	O	O	O
overview	O	O	O
the	O	O	O
main	O	O	O
methods	O	O	B-Entity
and	O	O	I-Entity
tools	O	O	I-Entity
that	O	O	O
are	O	O	O
used	O	O	O
to	O	O	O
monitor	O	O	O
autophagic	O	O	B-Entity
structures	O	O	I-Entity
and	O	O	O
to	O	O	O
assay	O	O	B-Entity
autophagic	O	O	B-Entity
responses	O	O	I-Entity
in	O	O	O
this	O	O	O
vertebrate	O	O	B-Entity
organism	O	O	I-Entity
.	O	O	O

We	O	O	O
place	O	O	O
emphasis	O	O	O
on	O	O	O
genetic	O	O	B-Entity
(	O	O	I-Entity
functional	O	O	I-Entity
)	O	O	I-Entity
approaches	O	O	I-Entity
applied	O	O	O
for	O	O	O
exploring	O	O	O
novel	O	O	O
cellular	O	O	B-Entity
and	O	O	O
developmental	O	O	B-Entity
roles	O	O	I-Entity
of	O	O	O
the	O	O	O
autophagic	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

-DOCSTART- (28237961)

Healthcare	O	O	B-Entity
usage	O	O	B-Entity
and	O	O	O
economic	O	O	B-Entity
impact	O	O	I-Entity
of	O	O	O
non-treated	O	O	B-Entity
obesity	O	O	B-Entity
in	O	O	O
Italy	O	O	B-Entity
:	O	O	O
findings	O	O	B-Entity
from	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
administrative	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
database	O	O	I-Entity
analysis	O	O	O

Investigate	O	O	B-Entity
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
in	O	O	O
Italy	O	O	B-Entity
and	O	O	O
examine	O	O	O
its	O	O	O
resource	O	O	B-Entity
consumption	O	O	B-Entity
and	O	O	O
economic	O	O	B-Entity
impact	O	O	I-Entity
on	O	O	O
the	O	O	O
Italian	O	O	B-Entity
national	O	O	B-Entity
healthcare	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
NHS	O	O	B-Entity
)	O	O	O
.	O	O	O

Retrospective	O	O	B-Entity
,	O	O	O
observational	O	O	B-Entity
and	O	O	O
real-life	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
three	O	O	O
health	O	O	B-Entity
units	O	O	I-Entity
from	O	O	O
Northern	O	O	B-Entity
(	O	O	O
Bergamo	O	O	B-Entity
,	O	O	O
Lombardy	O	O	B-Entity
)	O	O	O
,	O	O	O
Central	O	O	B-Entity
(	O	O	O
Grosseto	O	O	B-Entity
,	O	O	O
Tuscany	O	O	B-Entity
)	O	O	O
and	O	O	O
Southern	O	O	B-Entity
(	O	O	O
Naples	O	O	B-Entity
,	O	O	O
Campania	O	O	B-Entity
)	O	O	O
Italy	O	O	B-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
aged	O	O	B-Entity
≥18	O	O	B-Entity
years	O	O	I-Entity
with	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
recorded	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
measurement	O	O	B-Entity
between	O	O	O
1	O	O	O
January	O	O	O
2009	O	O	O
and	O	O	O
31	O	O	O
December	O	O	O
2012	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

Information	O	O	B-Entity
retrieved	O	O	O
from	O	O	O
the	O	O	O
databases	O	O	B-Entity
included	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
data	O	O	I-Entity
,	O	O	O
medical	O	O	B-Entity
prescriptions	O	O	I-Entity
,	O	O	O
specialist	O	O	B-Entity
consultations	O	O	I-Entity
and	O	O	O
hospital	O	O	B-Entity
discharge	O	O	I-Entity
records	O	O	I-Entity
from	O	O	O
2009	O	O	O
-	O	O	O
2013	O	O	O
.	O	O	O

Costs	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
these	O	O	O
data	O	O	B-Entity
were	O	O	O
also	O	O	O
calculated	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
are	O	O	O
presented	O	O	O
for	O	O	O
two	O	O	O
time	O	O	B-Entity
periods	O	O	I-Entity
(	O	O	O
1	O	O	B-Entity
year	O	O	I-Entity
after	O	O	O
BMI	O	O	B-Entity
measurement	O	O	B-Entity
and	O	O	O
study	O	O	O
end	O	O	O
)	O	O	O
.	O	O	O

Primary	O	O	B-Entity
-to	O	O	O
estimate	O	O	B-Entity
health	O	O	B-Entity
resources	O	O	I-Entity
consumption	O	O	B-Entity
and	O	O	O
the	O	O	O
associated	O	O	O
economic	O	O	B-Entity
impact	O	O	I-Entity
on	O	O	O
the	O	O	O
Italian	O	O	B-Entity
NHS	O	O	B-Entity
.	O	O	O

Secondary	O	O	B-Entity
-the	O	O	O
prevalence	O	O	B-Entity
and	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
subjects	O	O	B-Entity
by	O	O	O
BMI	O	O	B-Entity
category	O	O	B-Entity
.	O	O	O

20	O	O	O
159	O	O	O
adult	O	O	B-Entity
subjects	O	O	B-Entity
with	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
documented	O	O	B-Entity
BMI	O	O	I-Entity
measurement	O	O	B-Entity
.	O	O	O

Subjects	O	O	B-Entity
with	O	O	O
BMI	O	O	B-Entity
≥30	O	O	O
kg/m(2	O	O	O
)	O	O	O
were	O	O	O
defined	O	O	O
as	O	O	O
obese	O	O	B-Entity
.	O	O	O

The	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
was	O	O	O
22.2	O	O	O
%	O	O	O
(	O	O	O
N=4471	O	O	O
)	O	O	O
and	O	O	O
increased	O	O	B-Entity
with	O	O	O
age	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
1-year	O	O	B-Entity
observation	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
obese	O	O	B-Entity
subjects	O	O	B-Entity
who	O	O	O
did	O	O	O
not	O	O	O
receive	O	O	O
treatment	O	O	B-Entity
for	O	O	O
their	O	O	O
obesity	O	O	B-Entity
experienced	O	O	O
longer	O	O	B-Entity
durations	O	O	I-Entity
of	O	O	O
hospitalisation	O	O	B-Entity
(	O	O	O
median	O	O	O
length	O	O	O
:	O	O	O
5	O	O	B-Entity
days	O	O	I-Entity
vs	O	O	O
3	O	O	B-Entity
days	O	O	I-Entity
)	O	O	O
,	O	O	O
used	O	O	O
more	O	O	O
prescription	O	O	B-Entity
drugs	O	O	I-Entity
(	O	O	O
75.0	O	O	O
%	O	O	O
vs	O	O	O
57.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
required	O	O	O
more	O	O	O
specialised	O	O	B-Entity
outpatient	O	O	B-Entity
healthcare	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
number	O	O	I-Entity
:	O	O	O
5.3	O	O	O
vs	O	O	O
4.4	O	O	O
)	O	O	O
and	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
greater	O	O	B-Entity
costs	O	O	I-Entity
,	O	O	O
primarily	O	O	O
owing	O	O	O
to	O	O	O
prescription	O	O	O
drugs	O	O	O
and	O	O	O
hospital	O	O	B-Entity
admissions	O	O	I-Entity
(	O	O	O
mean	O	O	B-Entity
annual	O	O	I-Entity
cost	O	O	I-Entity
per	O	O	O
year	O	O	B-Entity
per	O	O	O
patient	O	O	B-Entity
:	O	O	O
€	O	O	O
460.6	O	O	O
vs	O	O	O
€	O	O	O
288.0	O	O	O
for	O	O	O
drug	O	O	B-Entity
prescriptions	O	O	I-Entity
,	O	O	O
€	O	O	O
422.7	O	O	O
vs	O	O	O
€	O	O	O
279.2	O	O	O
for	O	O	O
hospitalisations	O	O	B-Entity
and	O	O	O
€	O	O	O
283.2	O	O	O
vs	O	O	O
€	O	O	O
251.7	O	O	O
for	O	O	O
outpatient	O	O	B-Entity
care	O	O	I-Entity
)	O	O	O
,	O	O	O
compared	O	O	O
with	O	O	O
normal	O	O	B-Entity
weight	O	O	I-Entity
subjects	O	O	O
.	O	O	O

Similar	O	O	O
findings	O	O	B-Entity
were	O	O	O
observed	O	O	O
for	O	O	O
the	O	O	O
period	O	O	B-Entity
up	O	O	O
to	O	O	O
data	O	O	B-Entity
cut-off	O	O	O
(	O	O	O
mean	O	O	O
follow-up	O	O	B-Entity
of	O	O	O
2.7	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

Untreated	O	O	B-Entity
obesity	O	O	B-Entity
has	O	O	O
a	O	O	O
significant	O	O	O
economic	O	O	B-Entity
impact	O	O	I-Entity
on	O	O	O
the	O	O	O
Italian	O	O	B-Entity
healthcare	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
highlighting	O	O	O
the	O	O	O
need	O	O	O
to	O	O	O
raise	O	O	O
awareness	O	O	B-Entity
and	O	O	O
proactively	O	O	O
treat	O	O	B-Entity
obese	O	O	O
subjects	O	O	B-Entity
.	O	O	O

-DOCSTART- (28239032)

Effects	O	O	B-Entity
of	O	O	I-Entity
heat	O	O	B-Entity
treatment	O	O	B-Entity
on	O	O	O
conformation	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
growth	O	O	I-Entity
activity	O	O	O
of	O	O	O
alpha-	O	O	B-Entity
lactalbumin	O	O	I-Entity
and	O	O	O
beta-lactoglobulin	O	O	B-Entity
from	O	O	O
market	O	O	B-Entity
milk	O	O	O

Heat	O	O	B-Entity
processes	O	O	B-Entity
,	O	O	O
low	O	O	B-Entity
temperature	O	O	B-Entity
for	O	O	O
long	O	O	B-Entity
time	O	O	B-Entity
(	O	O	O
LTLT	O	O	B-Entity
)	O	O	O
pasteurization	O	O	B-Entity
and	O	O	O
ultra-heat	O	O	B-Entity
treatment	O	O	I-Entity
(	O	O	I-Entity
UHT	O	O	I-Entity
)	O	O	I-Entity
sterilization	O	O	I-Entity
,	O	O	O
are	O	O	O
essential	O	O	O
for	O	O	O
commercial	O	O	O
market	O	O	B-Entity
milk	O	O	B-Entity
to	O	O	O
improve	O	O	O
the	O	O	O
shelf	O	O	B-Entity
life	O	O	I-Entity
of	O	O	O
raw	O	O	B-Entity
milk	O	O	I-Entity
and	O	O	O
ensure	O	O	O
microbial	O	O	B-Entity
safety	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
heat	O	O	B-Entity
experience	O	O	O
on	O	O	O
the	O	O	O
molecular	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
α-lactalbumin	O	O	B-Entity
(	O	O	O
α-LA	O	O	B-Entity
)	O	O	O
and	O	O	O
β-lactoglobulin	O	O	B-Entity
(	O	O	O
β-LG	O	O	B-Entity
)	O	O	O
isolated	O	O	O
from	O	O	O
four	O	O	O
types	O	O	O
of	O	O	O
market	O	O	B-Entity
milk	O	O	B-Entity
such	O	O	O
as	O	O	O
LTLT-A	O	O	B-Entity
(	O	O	O
66	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
30	O	O	O
min	O	O	O
)	O	O	O
,	O	O	O
LTLT-B	O	O	B-Entity
(	O	O	O
65	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
30	O	O	O
min	O	O	O
)	O	O	O
,	O	O	O
UHT-I	O	O	B-Entity
(	O	O	O
130	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
2	O	O	O
s	O	O	O
,	O	O	O
indirect	O	O	B-Entity
heating	O	O	B-Entity
)	O	O	O
and	O	O	O
UHT-D	O	O	B-Entity
(	O	O	O
135	O	O	O
°	O	O	O
C	O	O	O
for	O	O	O
2	O	O	O
s	O	O	O
,	O	O	O
direct	O	O	B-Entity
heating	O	O	O
)	O	O	O
samples	O	O	O
.	O	O	O

We	O	O	O
examined	O	O	O
molecular	O	O	B-Entity
conformations	O	O	I-Entity
using	O	O	O
circular	O	O	B-Entity
dichroism	O	O	I-Entity
spectrum	O	O	I-Entity
measurement	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
growth	O	O	I-Entity
activity	O	O	O
using	O	O	O
the	O	O	O
WST-1	O	O	B-Entity
method	O	O	I-Entity
for	O	O	O
the	O	O	O
proteins	O	O	B-Entity
.	O	O	O

α-LA	O	O	B-Entity
isolated	O	O	O
from	O	O	O
each	O	O	O
of	O	O	O
these	O	O	O
four	O	O	O
types	O	O	O
of	O	O	O
market	O	O	B-Entity
milk	O	O	B-Entity
displayed	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
structural	O	O	B-Entity
difference	O	O	B-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
raw	O	O	B-Entity
milk	O	O	I-Entity
α-LA	O	O	O
,	O	O	O
while	O	O	O
α-LA	O	O	O
of	O	O	O
UHT-I	O	O	B-Entity
only	O	O	O
inhibited	O	O	B-Entity
cell	O	O	B-Entity
growth	O	O	I-Entity
of	O	O	O
an	O	O	O
intestinal	O	O	B-Entity
epithelial	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
more	O	O	O
potently	O	O	O
than	O	O	O
raw	O	O	O
milk	O	O	O
α-LA	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
case	O	O	O
of	O	O	O
β-LG	O	O	B-Entity
,	O	O	O
only	O	O	O
the	O	O	O
UHT-I	O	O	B-Entity
sample	O	O	O
demonstrated	O	O	O
a	O	O	O
drastic	O	O	O
change	O	O	B-Entity
in	O	O	O
structure	O	O	B-Entity
,	O	O	O
while	O	O	O
it	O	O	O
did	O	O	B-Entity
not	O	O	I-Entity
exhibit	O	O	I-Entity
any	O	O	O
cytotoxicity	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
cell	O	O	B-Entity
viability	O	O	I-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
α-LA	O	O	B-Entity
and	O	O	O
β-LG	O	O	B-Entity
are	O	O	O
attributable	O	O	O
to	O	O	O
the	O	O	O
type	O	O	O
of	O	O	O
UHT	O	O	B-Entity
;	O	O	O
indirect	O	O	B-Entity
and	O	O	O
direct	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
indicate	O	O	O
that	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
heat	O	O	B-Entity
treatment	O	O	B-Entity
on	O	O	O
whey	O	O	B-Entity
proteins	O	O	I-Entity
should	O	O	O
carefully	O	O	O
be	O	O	O
investigated	O	O	B-Entity
further	O	O	O
.	O	O	O

-DOCSTART- (28240640)

Comparison	O	O	B-Entity
of	O	O	O
270	O	O	B-Entity
Versus	O	O	O
320	O	O	B-Entity
mg	O	O	I-Entity
I/mL	O	O	I-Entity
of	O	O	I-Entity
Iodixanol	O	O	I-Entity
in	O	O	O
1	O	O	O
Image	O	O	B-Entity
Assessment	O	O	I-Entity
of	O	O	O
Both	O	O	O
Renal	O	O	B-Entity
Arteries	O	O	I-Entity
and	O	O	O
Veins	O	O	B-Entity
With	O	O	O
Dual-Energy	O	O	B-Entity
Spectral	O	O	I-Entity
CT	O	O	I-Entity
Imaging	O	O	I-Entity
in	O	O	O
Late	O	O	B-Entity
Arterial	O	O	I-Entity
Phase	O	O	I-Entity
and	O	O	O
Their	O	O	O
Influence	O	O	B-Entity
on	O	O	O
Renal	O	O	O
Function	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
image	O	O	B-Entity
quality	O	O	I-Entity
of	O	O	O
renal	O	O	B-Entity
arteries	O	O	I-Entity
and	O	O	O
veins	O	O	B-Entity
with	O	O	O
dual-energy	O	O	B-Entity
spectral	O	O	I-Entity
computed	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	I-Entity
CT	O	O	I-Entity
)	O	O	I-Entity
imaging	O	O	I-Entity
in	O	O	O
late	O	O	B-Entity
arterial	O	O	I-Entity
phase	O	O	I-Entity
using	O	O	O
270	O	O	B-Entity
and	O	O	O
320	O	O	B-Entity
mg	O	O	I-Entity
I/mL	O	O	I-Entity
of	O	O	I-Entity
iodixanol	O	O	I-Entity
and	O	O	O
their	O	O	O
influence	O	O	B-Entity
on	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
1062	O	O	O
patients	O	O	B-Entity
underwent	O	O	O
renal	O	O	B-Entity
CT	O	O	I-Entity
angiography	O	O	I-Entity
with	O	O	O
270	O	O	B-Entity
or	O	O	O
320	O	O	B-Entity
mg	O	O	I-Entity
I/mL	O	O	I-Entity
of	O	O	I-Entity
iodixanol	O	O	I-Entity
with	O	O	O
dual-energy	O	O	B-Entity
spectral	O	O	I-Entity
CT	O	O	I-Entity
imaging	O	O	I-Entity
in	O	O	O
late	O	O	B-Entity
arterial	O	O	I-Entity
phase	O	O	I-Entity
.	O	O	O

Image	O	O	B-Entity
quality	O	O	I-Entity
and	O	O	O
their	O	O	O
influence	O	O	B-Entity
on	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
were	O	O	O
compared	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
significant	O	O	O
differences	O	O	O
of	O	O	O
CT	O	O	B-Entity
value	O	O	I-Entity
,	O	O	O
signal-to-noise	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
contrast-to-noise	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
and	O	O	O
subjective	O	O	O
score	O	O	B-Entity
of	O	O	O
renal	O	O	B-Entity
vessels	O	O	I-Entity
between	O	O	O
2	O	O	O
groups	O	O	O
(	O	O	O
all	O	O	O
P	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
contrast-induced	O	O	B-Entity
nephropathy	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
abnormal	O	O	B-Entity
renal	O	O	I-Entity
function	O	O	I-Entity
using	O	O	O
320	O	O	B-Entity
mg	O	O	I-Entity
I/mL	O	O	I-Entity
of	O	O	I-Entity
iodixanol	O	O	I-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	O
than	O	O	O
using	O	O	O
270	O	O	B-Entity
mg	O	O	I-Entity
I/mL	O	O	I-Entity
of	O	O	I-Entity
iodixanol	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.043	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
renal	O	O	B-Entity
arteries	O	O	I-Entity
and	O	O	O
veins	O	O	B-Entity
can	O	O	O
be	O	O	O
fully	O	O	O
assessed	O	O	O
in	O	O	O
late	O	O	B-Entity
arterial	O	O	I-Entity
phase	O	O	I-Entity
with	O	O	O
270	O	O	B-Entity
mg	O	O	I-Entity
I/mL	O	O	I-Entity
of	O	O	I-Entity
iodixanol	O	O	I-Entity
using	O	O	O
dual-energy	O	O	B-Entity
spectral	O	O	I-Entity
CT	O	O	I-Entity
scan	O	O	I-Entity
with	O	O	O
better	O	O	O
preserved	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

-DOCSTART- (28241991)

Effect	O	O	O
of	O	O	O
magnesium	O	O	B-Entity
supplementation	O	O	I-Entity
on	O	O	O
depression	O	O	B-Entity
status	O	O	B-Entity
in	O	O	O
depressed	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
magnesium	O	O	B-Entity
deficiency	O	O	I-Entity
:	O	O	O
A	O	O	O
randomized	O	O	B-Entity
,	O	O	O
double-blind	O	O	B-Entity
,	O	O	O
placebo-controlled	O	O	O
trial	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
magnesium	O	O	B-Entity
supplementation	O	O	I-Entity
on	O	O	O
the	O	O	O
depression	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
depressed	O	O	B-Entity
patients	O	O	B-Entity
suffering	O	O	B-Entity
from	O	O	O
magnesium	O	O	B-Entity
deficiency	O	O	I-Entity
.	O	O	O

Sixty	O	O	B-Entity
depressed	O	O	I-Entity
people	O	O	I-Entity
suffering	O	O	B-Entity
from	O	O	O
hypomagnesemia	O	O	B-Entity
participated	O	O	O
in	O	O	O
this	O	O	B-Entity
trial	O	O	I-Entity
.	O	O	O

The	O	O	O
individuals	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
categorized	O	O	I-Entity
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
of	O	O	O
30	O	O	O
members	O	O	O
;	O	O	O
one	O	O	O
receiving	O	O	O
two	O	O	O
250-mg	O	O	O
tablets	O	O	B-Entity
of	O	O	I-Entity
magnesium	O	O	I-Entity
oxide	O	O	I-Entity
(	O	O	O
MG	O	O	B-Entity
)	O	O	O
daily	O	O	O
and	O	O	O
the	O	O	O
other	O	O	O
receiving	O	O	O
placebo	O	O	B-Entity
(	O	O	O
PG	O	O	B-Entity
)	O	O	O
for	O	O	O
8	O	O	O
wk	O	O	O
.	O	O	O

The	O	O	O
Beck	O	O	B-Entity
Depression	O	O	I-Entity
Inventory-II	O	O	I-Entity
was	O	O	O
conducted	O	O	O
and	O	O	O
the	O	O	O
concentration	O	O	O
of	O	O	O
serum	O	O	B-Entity
magnesium	O	O	I-Entity
was	O	O	I-Entity
measured	O	O	I-Entity
.	O	O	O

At	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
intervention	O	O	O
,	O	O	O
88.5	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
MG	O	O	B-Entity
and	O	O	O
48.1	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
PG	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
had	O	O	O
a	O	O	O
normal	O	O	B-Entity
level	O	O	I-Entity
of	O	O	I-Entity
magnesium	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	O
changes	O	O	B-Entity
of	O	O	I-Entity
serum	O	O	I-Entity
magnesium	O	O	I-Entity
were	O	O	O
significantly	O	O	O
different	O	O	O
across	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

After	O	O	O
the	O	O	O
intervention	O	O	O
,	O	O	O
the	O	O	O
mean	O	O	B-Entity
Beck	O	O	I-Entity
score	O	O	I-Entity
significantly	O	O	B-Entity
declined	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
MG	O	O	B-Entity
,	O	O	O
this	O	O	O
reduction	O	O	O
was	O	O	O
more	O	O	B-Entity
significant	O	O	I-Entity
than	O	O	O
in	O	O	O
the	O	O	O
PG	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.02	O	O	O
)	O	O	O
,	O	O	O
so	O	O	O
that	O	O	O
the	O	O	O
mean	O	O	O
changes	O	O	O
in	O	O	O
this	O	O	O
group	O	O	B-Entity
experienced	O	O	O
15.65	O	O	O
±	O	O	O
8.9	O	O	O
reduction	O	O	O
,	O	O	O
but	O	O	O
in	O	O	O
the	O	O	O
PG	O	O	O
,	O	O	O
it	O	O	O
declined	O	O	O
by	O	O	O
10.40	O	O	O
±	O	O	O
7.9	O	O	O
.	O	O	O

Daily	O	O	B-Entity
consumption	O	O	I-Entity
of	O	O	O
500	O	O	O
mg	O	O	O
magnesium	O	O	B-Entity
oxide	O	O	I-Entity
tablets	O	O	I-Entity
for	O	O	O
≥8	O	O	O
wk	O	O	O
by	O	O	O
depressed	O	O	B-Entity
patients	O	O	B-Entity
suffering	O	O	B-Entity
from	O	O	O
magnesium	O	O	B-Entity
deficiency	O	O	I-Entity
leads	O	O	O
to	O	O	O
improvements	O	O	O
in	O	O	O
depression	O	O	B-Entity
status	O	O	B-Entity
and	O	O	O
magnesium	O	O	B-Entity
levels	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
assessment	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
magnesium	O	O	I-Entity
serum	O	O	I-Entity
and	O	O	O
resolving	O	O	O
this	O	O	O
deficiency	O	O	B-Entity
positively	O	O	O
influence	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
depressed	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28243780)

The	O	O	O
influence	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
load	O	O	I-Entity
on	O	O	O
metabolic	O	O	B-Entity
cost	O	O	B-Entity
of	O	O	O
transport	O	O	B-Entity
during	O	O	O
overground	O	O	B-Entity
walking	O	O	I-Entity
in	O	O	O
healthy	O	O	B-Entity
,	O	O	O
young	O	O	O
adults	O	O	O

Our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	O
whether	O	O	O
cognitive	O	O	B-Entity
processing	O	O	I-Entity
during	O	O	O
walking	O	O	B-Entity
increases	O	O	B-Entity
the	O	O	O
metabolic	O	O	B-Entity
cost	O	O	B-Entity
of	O	O	O
transport	O	O	B-Entity
in	O	O	O
healthy	O	O	B-Entity
young	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Twenty	O	O	O
healthy	O	O	B-Entity
,	O	O	O
young	O	O	B-Entity
adults	O	O	I-Entity
completed	O	O	O
five	O	O	O
conditions	O	O	B-Entity
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
walking	O	O	B-Entity
at	O	O	O
a	O	O	O
self	O	O	B-Entity
-	O	O	O
selected	O	O	B-Entity
speed	O	O	B-Entity
(	O	O	O
spontaneous	O	O	B-Entity
single-task	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
seated	O	O	B-Entity
resting	O	O	B-Entity
(	O	O	O
baseline	O	O	B-Entity
)	O	O	O
,	O	O	O
(	O	O	O
3	O	O	O
)	O	O	O
performing	O	O	B-Entity
cognitive	O	O	B-Entity
task	O	O	B-Entity
while	O	O	O
seated	O	O	O
(	O	O	O
cognitive	O	O	O
single-task	O	O	O
)	O	O	O
,	O	O	O
(	O	O	O
4	O	O	O
)	O	O	O
walking	O	O	O
while	O	O	O
simultaneously	O	O	B-Entity
performing	O	O	O
the	O	O	O
cognitive	O	O	O
task	O	O	O
(	O	O	O
dual-task	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
(	O	O	O
5	O	O	O
)	O	O	O
single-task	O	O	O
walking	O	O	O
at	O	O	O
a	O	O	O
speed	O	O	O
that	O	O	O
matched	O	O	B-Entity
the	O	O	O
participant	O	O	B-Entity
's	O	O	I-Entity
dual-task	O	O	O
gait	O	O	B-Entity
speed	O	O	I-Entity
(	O	O	O
matched	O	O	O
single-task	O	O	O
)	O	O	O
.	O	O	O

Rate	O	O	B-Entity
of	O	O	I-Entity
oxygen	O	O	I-Entity
consumption	O	O	I-Entity
(	O	O	O
V̇O2	O	O	B-Entity
)	O	O	O
was	O	O	O
recorded	O	O	O
during	O	O	O
all	O	O	O
conditions	O	O	B-Entity
.	O	O	O

Gait	O	O	B-Entity
speed	O	O	I-Entity
and	O	O	O
cost	O	O	B-Entity
of	O	O	O
walking	O	O	B-Entity
(	O	O	O
Cw	O	O	B-Entity
;	O	O	O
oxygen	O	O	B-Entity
consumed	O	O	I-Entity
per	O	O	I-Entity
distance	O	O	I-Entity
traveled	O	O	I-Entity
)	O	O	O
were	O	O	O
recorded	O	O	O
during	O	O	O
all	O	O	O
walking	O	O	O
conditions	O	O	B-Entity
.	O	O	O

Reaction	O	O	B-Entity
time	O	O	I-Entity
and	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
responses	O	O	B-Entity
in	O	O	O
the	O	O	O
cognitive	O	O	B-Entity
task	O	O	B-Entity
were	O	O	O
recorded	O	O	O
during	O	O	O
all	O	O	O
cognitive	O	O	O
task	O	O	O
conditions	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
from	O	O	O
the	O	O	O
fifth	O	O	O
minute	O	O	B-Entity
of	O	O	O
each	O	O	O
5-	O	O	O
min	O	O	B-Entity
condition	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
difference	O	O	O
in	O	O	O
V̇O2	O	O	B-Entity
between	O	O	O
the	O	O	O
dual-task	O	O	B-Entity
and	O	O	O
matched	O	O	B-Entity
single-task	O	O	B-Entity
walking	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

V̇O2	O	O	B-Entity
in	O	O	O
the	O	O	O
seated	O	O	B-Entity
cognitive	O	O	B-Entity
condition	O	O	B-Entity
was	O	O	O
significantly	O	O	O
smaller	O	O	O
than	O	O	O
both	O	O	O
walking	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
but	O	O	O
was	O	O	O
not	O	O	O
significantly	O	O	O
different	O	O	O
than	O	O	O
zero	O	O	O
.	O	O	O

Cw	O	O	B-Entity
was	O	O	O
significantly	O	O	O
greater	O	O	O
during	O	O	O
the	O	O	O
matched	O	O	B-Entity
single-task	O	O	B-Entity
walking	O	O	B-Entity
condition	O	O	B-Entity
than	O	O	O
during	O	O	O
the	O	O	O
dual-task	O	O	B-Entity
walking	O	O	O
condition	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
difference	O	O	O
in	O	O	O
Cw	O	O	B-Entity
was	O	O	O
so	O	O	O
small	O	O	O
that	O	O	O
it	O	O	O
is	O	O	O
unlikely	O	O	O
to	O	O	O
be	O	O	O
clinically	O	O	B-Entity
significant	O	O	B-Entity
(	O	O	O
0.008	O	O	O
mLO2/kg/m	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
0.002	O	O	O
-	O	O	O
0.014	O	O	O
)	O	O	O
.	O	O	O

Cognitive	O	O	B-Entity
processing	O	O	I-Entity
while	O	O	O
walking	O	O	B-Entity
may	O	O	O
not	O	O	O
increase	O	O	B-Entity
energy	O	O	B-Entity
demands	O	O	O
of	O	O	O
walking	O	O	O
in	O	O	O
healthy	O	O	B-Entity
young	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Maintaining	O	O	O
non-preferred	O	O	O
gait	O	O	B-Entity
speed	O	O	B-Entity
(	O	O	O
matched	O	O	B-Entity
speed	O	O	O
)	O	O	O
overground	O	O	O
continuously	O	O	O
for	O	O	O
5	O	O	O
min	O	O	B-Entity
may	O	O	O
require	O	O	O
attentional	O	O	B-Entity
resources	O	O	B-Entity
,	O	O	O
and	O	O	O
thereby	O	O	O
increase	O	O	B-Entity
metabolic	O	O	B-Entity
costs	O	O	B-Entity
relative	O	O	O
to	O	O	O
walking	O	O	B-Entity
at	O	O	O
habitual	O	O	B-Entity
speed	O	O	O
.	O	O	O

-DOCSTART- (28245193)

Problem-based	O	O	B-Entity
learning	O	O	I-Entity
using	O	O	O
patient	O	O	B-Entity
-simulated	O	O	I-Entity
videos	O	O	I-Entity
showing	O	O	O
daily	O	O	B-Entity
life	O	O	B-Entity
for	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
clinical	O	O	B-Entity
approach	O	O	O

We	O	O	O
examined	O	O	O
whether	O	O	O
problem-based	O	O	B-Entity
learning	O	O	B-Entity
tutorials	O	O	B-Entity
using	O	O	O
patient	O	O	B-Entity
-simulated	O	O	I-Entity
videos	O	O	I-Entity
showing	O	O	O
daily	O	O	B-Entity
life	O	O	B-Entity
are	O	O	O
more	O	O	O
practical	O	O	O
for	O	O	O
clinical	O	O	B-Entity
learning	O	O	O
,	O	O	O
compared	O	O	O
with	O	O	O
traditional	O	O	O
paper-based	O	O	B-Entity
problem-based	O	O	I-Entity
learning	O	O	I-Entity
,	O	O	O
for	O	O	O
the	O	O	O
consideration	O	O	O
rate	O	O	B-Entity
of	O	O	I-Entity
psychosocial	O	O	I-Entity
issues	O	O	I-Entity
and	O	O	O
the	O	O	O
recall	O	O	B-Entity
rate	O	O	I-Entity
for	O	O	O
experienced	O	O	B-Entity
learning	O	O	I-Entity
.	O	O	O

Twenty-two	O	O	O
groups	O	O	B-Entity
with	O	O	O
120	O	O	O
fifth-	O	O	O
year	O	O	B-Entity
students	O	O	B-Entity
were	O	O	O
each	O	O	O
assigned	O	O	O
paper-based	O	O	B-Entity
problem-based	O	O	I-Entity
learning	O	O	I-Entity
and	O	O	O
video	O	O	B-Entity
-based	O	O	I-Entity
problem-based	O	O	I-Entity
learning	O	O	I-Entity
using	O	O	O
patient	O	O	B-Entity
-simulated	O	O	I-Entity
videos	O	O	I-Entity
.	O	O	O

We	O	O	O
compared	O	O	O
target	O	O	B-Entity
achievement	O	O	B-Entity
rates	O	O	I-Entity
in	O	O	O
questionnaires	O	O	B-Entity
using	O	O	O
the	O	O	O
Wilcoxon	O	O	B-Entity
signed-rank	O	O	I-Entity
test	O	O	I-Entity
and	O	O	O
discussion	O	O	B-Entity
contents	O	O	B-Entity
diversity	O	O	B-Entity
using	O	O	O
the	O	O	O
Mann-Whitney	O	O	B-Entity
U	O	O	I-Entity
test	O	O	I-Entity
.	O	O	O

A	O	O	O
follow-up	O	O	B-Entity
survey	O	O	B-Entity
used	O	O	O
a	O	O	O
chi-square	O	O	B-Entity
test	O	O	I-Entity
to	O	O	O
measure	O	O	O
students	O	O	B-Entity
'	O	O	O
recall	O	O	O
of	O	O	O
cases	O	O	O
in	O	O	O
three	O	O	O
categories	O	O	B-Entity
:	O	O	O
video	O	O	B-Entity
,	O	O	O
paper	O	O	B-Entity
,	O	O	O
and	O	O	O
non-experienced	O	O	B-Entity
.	O	O	O

Video	O	O	B-Entity
-based	O	O	I-Entity
problem-based	O	O	I-Entity
learning	O	O	I-Entity
displayed	O	O	O
significantly	O	O	O
higher	O	O	O
achievement	O	O	B-Entity
rates	O	O	I-Entity
for	O	O	O
imagining	O	O	O
authentic	O	O	B-Entity
patients	O	O	I-Entity
(	O	O	O
p=0.001	O	O	O
)	O	O	O
,	O	O	O
incorporating	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
approach	O	O	B-Entity
including	O	O	O
psychosocial	O	O	B-Entity
aspects	O	O	I-Entity
(	O	O	O
p<0.001	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
satisfaction	O	O	O
with	O	O	O
sessions	O	O	B-Entity
(	O	O	O
p=0.001	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	I-Entity
existed	O	O	O
in	O	O	O
the	O	O	O
discussion	O	O	B-Entity
contents	O	O	B-Entity
diversity	O	O	B-Entity
regarding	O	O	O
the	O	O	O
International	O	O	B-Entity
Classification	O	O	I-Entity
of	O	O	I-Entity
Primary	O	O	I-Entity
Care	O	O	I-Entity
Second	O	O	I-Entity
Edition	O	O	I-Entity
codes	O	O	I-Entity
and	O	O	I-Entity
chapter	O	O	I-Entity
types	O	O	I-Entity
or	O	O	O
in	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	I-Entity
psychological	O	O	I-Entity
codes	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
follow-up	O	O	B-Entity
survey	O	O	B-Entity
comparing	O	O	O
video	O	O	B-Entity
and	O	O	O
paper	O	O	B-Entity
groups	O	O	B-Entity
to	O	O	O
non-experienced	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
the	O	O	O
rates	O	O	B-Entity
were	O	O	O
higher	O	O	O
for	O	O	O
video	O	O	O
(	O	O	O
χ(2)=24.319	O	O	O
,	O	O	O
p<0.001	O	O	O
)	O	O	O
and	O	O	O
paper	O	O	O
(	O	O	O
χ(2)=11.134	O	O	O
,	O	O	O
p=0.001	O	O	O
)	O	O	O
.	O	O	O

Although	O	O	O
the	O	O	O
video	O	O	B-Entity
rate	O	O	B-Entity
tended	O	O	O
to	O	O	O
be	O	O	O
higher	O	O	O
than	O	O	O
the	O	O	O
paper	O	O	B-Entity
rate	O	O	O
,	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
was	O	O	O
found	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
.	O	O	O

Patient	O	O	B-Entity
-simulated	O	O	I-Entity
videos	O	O	I-Entity
showing	O	O	O
daily	O	O	B-Entity
life	O	O	B-Entity
facilitate	O	O	O
imagining	O	O	O
true	O	O	O
patients	O	O	B-Entity
and	O	O	O
support	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
approach	O	O	B-Entity
that	O	O	O
fosters	O	O	B-Entity
better	O	O	O
memory	O	O	B-Entity
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
patient	O	O	B-Entity
-simulated	O	O	I-Entity
video	O	O	I-Entity
method	O	O	B-Entity
is	O	O	O
more	O	O	O
practical	O	O	O
and	O	O	O
clinical	O	O	O
problem-based	O	O	B-Entity
tutorials	O	O	I-Entity
can	O	O	O
be	O	O	O
implemented	O	O	O
if	O	O	O
we	O	O	O
create	O	O	O
patient	O	O	B-Entity
-simulated	O	O	I-Entity
videos	O	O	I-Entity
for	O	O	O
each	O	O	O
symptom	O	O	B-Entity
as	O	O	O
teaching	O	O	B-Entity
materials	O	O	I-Entity
.	O	O	O

-DOCSTART- (28246934)

Forensic	O	O	B-Entity
characteristics	O	O	I-Entity
and	O	O	O
phylogenetic	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
the	O	O	O
Chinese	O	O	B-Entity
Yi	O	O	B-Entity
population	O	O	I-Entity
via	O	O	O
19	O	O	O
X-chromosomal	O	O	B-Entity
STR	O	O	B-Entity
loci	O	O	O

The	O	O	O
demographic	O	O	B-Entity
characteristics	O	O	I-Entity
and	O	O	O
genetic	O	O	B-Entity
polymorphism	O	O	I-Entity
data	O	O	B-Entity
of	O	O	O
56	O	O	O
Chinese	O	O	B-Entity
nationalities	O	O	B-Entity
or	O	O	O
31	O	O	O
administrative	O	O	B-Entity
divisions	O	O	I-Entity
in	O	O	O
Chinese	O	O	B-Entity
mainland	O	O	I-Entity
have	O	O	O
repeatedly	O	O	O
been	O	O	O
the	O	O	O
genetic	O	O	B-Entity
research	O	O	I-Entity
hotspots	O	O	B-Entity
.	O	O	O

While	O	O	O
most	O	O	O
genetic	O	O	B-Entity
studies	O	O	I-Entity
focused	O	O	O
on	O	O	O
some	O	O	O
particular	O	O	O
Chinese	O	O	B-Entity
populations	O	O	B-Entity
based	O	O	O
on	O	O	O
autosomal	O	O	B-Entity
or	O	O	O
Y-chromosomal	O	O	B-Entity
genetic	O	O	B-Entity
markers	O	O	I-Entity
,	O	O	O
the	O	O	O
forensic	O	O	B-Entity
characteristics	O	O	I-Entity
and	O	O	O
phylogenetic	O	O	B-Entity
analyses	O	O	I-Entity
of	O	O	O
the	O	O	O
seventh	O	O	O
largest	O	O	O
Chinese	O	O	O
population	O	O	B-Entity
(	O	O	O
Yi	O	O	B-Entity
ethnicity	O	O	I-Entity
)	O	O	O
on	O	O	O
the	O	O	O
X-chromosomal	O	O	B-Entity
genetic	O	O	O
markers	O	O	O
are	O	O	O
scarce	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
allele	O	O	B-Entity
frequencies	O	O	I-Entity
and	O	O	O
forensic	O	O	B-Entity
statistical	O	O	I-Entity
parameters	O	O	I-Entity
for	O	O	O
19	O	O	O
X-chromosomal	O	O	B-Entity
short	O	O	B-Entity
tandem	O	O	I-Entity
repeat	O	O	I-Entity
loci	O	O	B-Entity
(	O	O	O
DXS7424-DXS101	O	O	B-Entity
,	O	O	O
DXS6789-DXS6809	O	O	B-Entity
,	O	O	O
DXS7423-DXS10134	O	O	B-Entity
,	O	O	O
DXS10103-HPRTB-DXS10101	O	O	B-Entity
,	O	O	O
DXS10159-DXS10162-DXS10164	O	O	B-Entity
,	O	O	O
DXS10148-DXS10135-DXS8378	O	O	B-Entity
,	O	O	O
and	O	O	O
DXS7132-DXS10079-DXS10074-DXS10075	O	O	B-Entity
)	O	O	O
of	O	O	O
331	O	O	O
Chinese	O	O	B-Entity
Yi	O	O	B-Entity
individuals	O	O	I-Entity
were	O	O	O
obtained	O	O	O
.	O	O	O

All	O	O	O
19	O	O	O
X-chromosomal	O	O	B-Entity
short	O	O	B-Entity
tandem	O	O	I-Entity
repeat	O	O	I-Entity
(	O	O	O
STR	O	O	B-Entity
)	O	O	O
loci	O	O	B-Entity
in	O	O	O
females	O	O	B-Entity
were	O	O	O
consistent	O	O	O
with	O	O	O
the	O	O	O
Hardy-Weinberg	O	O	O
equilibrium	O	O	O
test	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
214	O	O	O
alleles	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
with	O	O	O
the	O	O	O
corresponding	O	O	O
allele	O	O	B-Entity
frequencies	O	O	I-Entity
spanned	O	O	O
from	O	O	O
0.0019	O	O	O
to	O	O	O
0.6106	O	O	O
.	O	O	O

The	O	O	O
combined	O	O	O
PE	O	O	B-Entity
,	O	O	O
PDF	O	O	B-Entity
,	O	O	O
and	O	O	O
PDM	O	O	B-Entity
were	O	O	O
0.9999999214	O	O	O
,	O	O	O
0.9999999999999999999993	O	O	O
,	O	O	O
and	O	O	O
0.9999999999998	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
high	O	O	O
combined	O	O	O
MECKrüger	O	O	B-Entity
,	O	O	O
MECKishida	O	O	B-Entity
,	O	O	O
MECDesmarais	O	O	B-Entity
,	O	O	O
and	O	O	O
MECDesmarais	O	O	B-Entity
Duo	O	O	I-Entity
were	O	O	O
achieved	O	O	O
as	O	O	O
0.9999999617638	O	O	O
,	O	O	O
0.9999999999971	O	O	O
,	O	O	O
0.9999999999971	O	O	O
,	O	O	O
and	O	O	O
0.9999999931538	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	B-Entity
suggested	O	O	O
that	O	O	O
the	O	O	O
panel	O	O	B-Entity
of	O	O	O
19	O	O	O
X-STR	O	O	B-Entity
loci	O	O	B-Entity
is	O	O	O
highly	O	O	O
polymorphic	O	O	B-Entity
and	O	O	O
informative	O	O	B-Entity
in	O	O	O
the	O	O	O
Yi	O	O	B-Entity
ethnic	O	O	I-Entity
population	O	O	I-Entity
and	O	O	O
can	O	O	O
be	O	O	O
considered	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
powerful	O	O	O
tool	O	O	B-Entity
in	O	O	O
forensic	O	O	B-Entity
complex	O	O	I-Entity
kinship	O	O	I-Entity
identification	O	O	I-Entity
.	O	O	O

Population	O	O	B-Entity
differentiation	O	O	I-Entity
analyses	O	O	I-Entity
among	O	O	O
12	O	O	O
populations	O	O	B-Entity
indicated	O	O	O
that	O	O	O
significant	O	O	O
differences	O	O	B-Entity
in	O	O	O
genetic	O	O	B-Entity
structure	O	O	I-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
between	O	O	O
the	O	O	O
Yi	O	O	B-Entity
ethnicity	O	O	I-Entity
and	O	O	O
the	O	O	O
Chinese	O	O	B-Entity
Uyghur	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
Kazakh	O	O	B-Entity
,	O	O	O
and	O	O	O
genetic	O	O	B-Entity
homogeneity	O	O	I-Entity
existed	O	O	O
in	O	O	O
similar	O	O	O
ethno-origin	O	O	B-Entity
or	O	O	O
geographic	O	O	B-Entity
origin	O	O	I-Entity
populations	O	O	I-Entity
.	O	O	O

-DOCSTART- (28249160)

Loss	O	O	B-Entity
of	O	O	O
Snf5	O	O	B-Entity
Induces	O	O	B-Entity
Formation	O	O	B-Entity
of	O	O	O
an	O	O	O
Aberrant	O	O	B-Entity
SWI/SNF	O	O	O
Complex	O	O	O

The	O	O	O
SWI/SNF	O	O	B-Entity
chromatin	O	O	B-Entity
remodeling	O	O	I-Entity
complex	O	O	I-Entity
is	O	O	O
highly	O	O	O
conserved	O	O	O
from	O	O	O
yeast	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
,	O	O	O
and	O	O	O
aberrant	O	O	B-Entity
SWI/SNF	O	O	B-Entity
complexes	O	O	I-Entity
contribute	O	O	O
to	O	O	O
human	O	O	O
disease	O	O	B-Entity
.	O	O	O

The	O	O	O
Snf5/SMARCB1/INI1	O	O	B-Entity
subunit	O	O	B-Entity
of	O	O	O
SWI/SNF	O	O	B-Entity
is	O	O	O
a	O	O	O
tumor	O	O	B-Entity
suppressor	O	O	I-Entity
frequently	O	O	O
lost	O	O	B-Entity
in	O	O	O
pediatric	O	O	B-Entity
rhabdoid	O	O	B-Entity
cancers	O	O	I-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
Snf5	O	O	B-Entity
loss	O	O	B-Entity
on	O	O	O
the	O	O	O
composition	O	O	B-Entity
,	O	O	O
nucleosome	O	O	B-Entity
binding	O	O	I-Entity
,	O	O	O
recruitment	O	O	O
,	O	O	O
and	O	O	O
remodeling	O	O	O
activities	O	O	O
of	O	O	O
yeast	O	O	B-Entity
SWI/SNF	O	O	B-Entity
.	O	O	O

The	O	O	O
Snf5	O	O	B-Entity
subunit	O	O	B-Entity
is	O	O	O
shown	O	O	O
by	O	O	O
crosslinking-mass	O	O	B-Entity
spectrometry	O	O	I-Entity
(	O	O	O
CX-MS	O	O	B-Entity
)	O	O	O
and	O	O	O
subunit	O	O	O
deletion	O	O	B-Entity
analysis	O	O	I-Entity
to	O	O	O
interact	O	O	O
with	O	O	O
the	O	O	O
ATPase	O	O	B-Entity
domain	O	O	I-Entity
of	O	O	O
Snf2	O	O	B-Entity
and	O	O	O
to	O	O	O
form	O	O	O
a	O	O	O
submodule	O	O	B-Entity
consisting	O	O	O
of	O	O	O
Snf5	O	O	O
,	O	O	O
Swp82	O	O	B-Entity
,	O	O	O
and	O	O	O
Taf14	O	O	B-Entity
.	O	O	O

Snf5	O	O	B-Entity
promotes	O	O	O
binding	O	O	B-Entity
of	O	O	O
the	O	O	O
Snf2	O	O	B-Entity
ATPase	O	O	B-Entity
domain	O	O	I-Entity
to	O	O	O
nucleosomal	O	O	B-Entity
DNA	O	O	I-Entity
and	O	O	O
enhances	O	O	O
the	O	O	O
catalytic	O	O	O
and	O	O	O
nucleosome	O	O	O
remodeling	O	O	O
activities	O	O	O
of	O	O	O
SWI/SNF	O	O	B-Entity
.	O	O	O

Snf5	O	O	B-Entity
is	O	O	O
also	O	O	O
required	O	O	O
for	O	O	O
SWI/SNF	O	O	B-Entity
recruitment	O	O	O
by	O	O	O
acidic	O	O	B-Entity
transcription	O	O	I-Entity
factors	O	O	I-Entity
.	O	O	O

RNA-seq	O	O	B-Entity
analysis	O	O	I-Entity
suggests	O	O	O
that	O	O	O
both	O	O	O
the	O	O	O
recruitment	O	O	O
and	O	O	O
remodeling	O	O	O
functions	O	O	O
of	O	O	O
Snf5	O	O	B-Entity
are	O	O	O
required	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
for	O	O	O
SWI/SNF	O	O	B-Entity
regulation	O	O	B-Entity
of	O	O	I-Entity
gene	O	O	I-Entity
expression	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
loss	O	O	B-Entity
of	O	O	O
SNF5	O	O	B-Entity
alters	O	O	O
the	O	O	O
structure	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
of	O	O	O
SWI/SNF	O	O	B-Entity
.	O	O	O

-DOCSTART- (28249785)

Identifying	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
using	O	O	O
low-frequency	O	O	B-Entity
fluctuations	O	O	B-Entity
in	O	O	O
BOLD	O	O	O
signals	O	O	O

Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
chronic	O	O	B-Entity
,	O	O	O
progressive	O	O	B-Entity
,	O	O	O
and	O	O	O
degenerative	O	O	B-Entity
neurological	O	O	B-Entity
disorder	O	O	I-Entity
that	O	O	O
is	O	O	O
characterized	O	O	B-Entity
by	O	O	O
the	O	O	O
degeneration	O	O	B-Entity
of	O	O	O
dopamine	O	O	B-Entity
neurons	O	O	I-Entity
in	O	O	O
the	O	O	O
substantia	O	O	B-Entity
nigra	O	O	I-Entity
and	O	O	O
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
intracellular	O	O	B-Entity
Lewy	O	O	B-Entity
inclusion	O	O	I-Entity
bodies	O	O	I-Entity
.	O	O	O

Resting-state	O	O	B-Entity
functional	O	O	I-Entity
magnetic	O	O	I-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
RS-fMRI	O	O	B-Entity
)	O	O	O
has	O	O	O
demonstrated	O	O	O
evidence	O	O	B-Entity
of	O	O	O
changes	O	O	O
in	O	O	O
metabolic	O	O	B-Entity
patterns	O	O	B-Entity
in	O	O	O
individuals	O	O	B-Entity
with	O	O	O
PD	O	O	B-Entity
.	O	O	O

The	O	O	O
purpose	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
PD	O	O	B-Entity
could	O	O	O
be	O	O	O
"	O	O	O
predicted	O	O	B-Entity
"	O	O	O
based	O	O	O
on	O	O	O
resting	O	O	O
fluctuations	O	O	B-Entity
in	O	O	O
the	O	O	O
blood	O	O	B-Entity
oxygenation	O	O	I-Entity
level	O	O	I-Entity
dependent	O	O	I-Entity
signal	O	O	I-Entity
.	O	O	O

We	O	O	O
utilized	O	O	O
RS-fMRI	O	O	B-Entity
to	O	O	O
measure	O	O	O
the	O	O	O
amplitude	O	O	B-Entity
of	O	O	O
low-frequency	O	O	B-Entity
fluctuation	O	O	B-Entity
(	O	O	O
ALFF	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
fractional	O	O	O
ALFF	O	O	O
(	O	O	O
fALFF	O	O	B-Entity
)	O	O	O
in	O	O	O
51	O	O	O
patients	O	O	B-Entity
with	O	O	O
PD	O	O	B-Entity
and	O	O	O
50	O	O	O
age	O	O	B-Entity
-	O	O	O
and	O	O	O
sex	O	O	B-Entity
-matched	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Compared	O	O	O
with	O	O	O
the	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
,	O	O	O
the	O	O	O
individuals	O	O	B-Entity
with	O	O	O
PD	O	O	B-Entity
exhibited	O	O	O
altered	O	O	O
ALFFs	O	O	B-Entity
in	O	O	O
the	O	O	O
bilateral	O	O	B-Entity
lingual	O	O	B-Entity
gyrus	O	O	I-Entity
and	O	O	O
left	O	O	B-Entity
putamen	O	O	I-Entity
and	O	O	O
an	O	O	O
altered	O	O	O
fALFF	O	O	B-Entity
in	O	O	O
the	O	O	O
right	O	O	B-Entity
cerebellum	O	O	I-Entity
posterior	O	O	I-Entity
lobe	O	O	I-Entity
.	O	O	O

Support	O	O	B-Entity
vector	O	O	I-Entity
machines	O	O	I-Entity
(	O	O	O
SVMs	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
comprise	O	O	O
a	O	O	O
supervised	O	O	O
pattern	O	O	B-Entity
recognition	O	O	I-Entity
method	O	O	B-Entity
that	O	O	O
enables	O	O	O
predictions	O	O	B-Entity
at	O	O	O
the	O	O	O
individual	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
were	O	O	O
trained	O	O	O
to	O	O	O
separate	O	O	O
individuals	O	O	B-Entity
with	O	O	O
PD	O	O	B-Entity
from	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
ALFF	O	O	B-Entity
and	O	O	O
fALFF	O	O	B-Entity
.	O	O	O

Using	O	O	O
the	O	O	O
leave-one-out	O	O	O
cross-validation	O	O	B-Entity
method	O	O	I-Entity
to	O	O	O
analyze	O	O	B-Entity
our	O	O	O
sample	O	O	B-Entity
,	O	O	O
we	O	O	O
reliably	O	O	O
distinguished	O	O	O
the	O	O	O
participants	O	O	B-Entity
with	O	O	O
PD	O	O	B-Entity
from	O	O	O
the	O	O	O
controls	O	O	B-Entity
with	O	O	O
92	O	O	O
%	O	O	O
sensitivity	O	O	B-Entity
and	O	O	O
87	O	O	O
%	O	O	O
specificity	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
SVM	O	O	B-Entity
-	O	O	O
neuroimaging	O	O	B-Entity
approach	O	O	O
may	O	O	O
be	O	O	O
of	O	O	O
particular	O	O	O
clinical	O	O	B-Entity
value	O	O	O
because	O	O	O
it	O	O	O
enables	O	O	O
the	O	O	O
accurate	O	O	O
identification	O	O	O
of	O	O	O
PD	O	O	B-Entity
at	O	O	O
the	O	O	O
individual	O	O	B-Entity
level	O	O	B-Entity
.	O	O	O

RS-fMRI	O	O	B-Entity
should	O	O	O
be	O	O	O
considered	O	O	O
for	O	O	O
development	O	O	B-Entity
as	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
and	O	O	O
an	O	O	O
analytical	O	O	O
tool	O	O	O
for	O	O	O
the	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
PD	O	O	B-Entity
.	O	O	O

-DOCSTART- (28250235)

Methylation	O	O	B-Entity
dynamics	O	O	B-Entity
during	O	O	O
folliculogenesis	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
embryo	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
sheep	O	O	O

Genome	O	O	B-Entity
-wide	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
reprogramming	O	O	O
occurs	O	O	O
during	O	O	O
mammalian	O	O	B-Entity
gametogenesis	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
embryogenesis	O	O	B-Entity
.	O	O	O

Post	O	O	B-Entity
-	O	O	O
fertilization	O	O	B-Entity
demethylation	O	O	B-Entity
of	O	O	O
paternal	O	O	B-Entity
and	O	O	O
maternal	O	O	B-Entity
genomes	O	O	B-Entity
is	O	O	O
considered	O	O	O
to	O	O	O
occur	O	O	O
by	O	O	O
an	O	O	O
active	O	O	O
and	O	O	O
passive	O	O	O
mechanism	O	O	O
respectively	O	O	O
,	O	O	O
in	O	O	O
most	O	O	O
mammals	O	O	B-Entity
but	O	O	O
sheep	O	O	B-Entity
;	O	O	O
in	O	O	O
this	O	O	O
species	O	O	O
no	O	O	O
loss	O	O	O
of	O	O	O
methylation	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
either	O	O	O
pronucleus	O	O	B-Entity
.	O	O	O

Post	O	O	B-Entity
-	O	O	O
fertilization	O	O	B-Entity
reprogramming	O	O	O
relies	O	O	O
on	O	O	O
methylating	O	O	B-Entity
and	O	O	O
demethylating	O	O	B-Entity
enzymes	O	O	I-Entity
and	O	O	O
co-factors	O	O	O
that	O	O	O
are	O	O	O
stored	O	O	O
during	O	O	O
oocyte	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
concurrently	O	O	O
with	O	O	O
the	O	O	O
re-methylation	O	O	B-Entity
of	O	O	O
the	O	O	O
oocyte	O	O	O
itself	O	O	O
.	O	O	O

The	O	O	O
crucial	O	O	O
remodelling	O	O	O
of	O	O	O
the	O	O	O
oocyte	O	O	B-Entity
epigenetic	O	O	O
baggage	O	O	O
often	O	O	O
overlaps	O	O	O
with	O	O	O
potential	O	O	O
interfering	O	O	O
events	O	O	O
such	O	O	O
as	O	O	O
exposure	O	O	O
to	O	O	O
assisted	O	O	O
reproduction	O	O	B-Entity
technologies	O	O	I-Entity
or	O	O	O
environmental	O	O	B-Entity
changes	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
temporal	O	O	O
analysis	O	O	O
of	O	O	O
methylation	O	O	B-Entity
dynamics	O	O	B-Entity
during	O	O	O
folliculogenesis	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
embryo	O	O	B-Entity
development	O	O	I-Entity
in	O	O	O
sheep	O	O	B-Entity
.	O	O	O

We	O	O	O
characterized	O	O	O
global	O	O	O
DNA	O	O	B-Entity
methylation	O	O	I-Entity
and	O	O	O
hydroxymethylation	O	O	B-Entity
by	O	O	O
immunofluorescence	O	O	B-Entity
and	O	O	O
relatively	O	O	O
quantified	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
enzymes	O	O	B-Entity
and	O	O	O
co-factors	O	O	O
mainly	O	O	O
responsible	O	O	O
for	O	O	O
their	O	O	O
remodelling	O	O	O
(	O	O	O
DNA	O	O	B-Entity
methyltransferases	O	O	I-Entity
(	O	O	O
DNMTs	O	O	B-Entity
)	O	O	O
,	O	O	O
ten-eleven	O	O	B-Entity
translocation	O	O	I-Entity
(	O	O	I-Entity
TET	O	O	I-Entity
)	O	O	I-Entity
proteins	O	O	B-Entity
and	O	O	O
methyl-CpG-binding	O	O	B-Entity
domain	O	O	I-Entity
(	O	O	O
MBD	O	O	B-Entity
)	O	O	O
proteins	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
illustrate	O	O	O
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
the	O	O	O
patterns	O	O	O
of	O	O	O
hydroxymethylation	O	O	B-Entity
during	O	O	O
oocyte	O	O	B-Entity
growth	O	O	I-Entity
.	O	O	O

We	O	O	O
observed	O	O	O
different	O	O	O
patterns	O	O	O
of	O	O	O
methylation	O	O	B-Entity
and	O	O	O
hydroxymethylation	O	O	B-Entity
between	O	O	O
the	O	O	O
two	O	O	O
parental	O	O	B-Entity
pronuclei	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
male	O	O	B-Entity
pronucleus	O	O	I-Entity
undergoes	O	O	O
active	O	O	O
demethylation	O	O	B-Entity
also	O	O	O
in	O	O	O
sheep	O	O	B-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
gene	O	O	B-Entity
-specific	O	O	O
accumulation	O	O	O
dynamics	O	O	B-Entity
for	O	O	O
methylating	O	O	B-Entity
and	O	O	O
demethylating	O	O	B-Entity
enzymes	O	O	I-Entity
during	O	O	O
oocyte	O	O	B-Entity
growth	O	O	I-Entity
and	O	O	O
observe	O	O	O
patterns	O	O	O
of	O	O	O
expression	O	O	B-Entity
associated	O	O	O
with	O	O	O
developmental	O	O	B-Entity
competence	O	O	B-Entity
in	O	O	O
a	O	O	O
differential	O	O	O
model	O	O	O
of	O	O	O
oocyte	O	O	O
potential	O	O	O
.	O	O	O

Our	O	O	O
work	O	O	O
contributes	O	O	O
to	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
methylation	O	O	B-Entity
dynamics	O	O	B-Entity
during	O	O	O
folliculogenesis	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
embryo	O	O	B-Entity
development	O	O	I-Entity
and	O	O	O
improves	O	O	O
the	O	O	O
overall	O	O	O
picture	O	O	O
of	O	O	O
early	O	O	O
rearrangements	O	O	O
that	O	O	O
will	O	O	O
originate	O	O	O
the	O	O	O
embryo	O	O	O
epigenome	O	O	B-Entity
.	O	O	O

-DOCSTART- (28250430)

Network	O	O	B-Entity
analysis	O	O	B-Entity
reveals	O	O	B-Entity
why	O	O	O
Xylella	O	O	B-Entity
fastidiosa	O	O	I-Entity
will	O	O	O
persist	O	O	O
in	O	O	O
Europe	O	O	O

The	O	O	O
insect	O	O	B-Entity
vector	O	O	I-Entity
borne	O	O	O
bacterium	O	O	B-Entity
Xylella	O	O	B-Entity
fastidiosa	O	O	I-Entity
was	O	O	O
first	O	O	O
detected	O	O	O
in	O	O	O
olive	O	O	B-Entity
trees	O	O	I-Entity
in	O	O	O
Southern	O	O	B-Entity
Italy	O	O	I-Entity
in	O	O	O
2013	O	O	O
,	O	O	O
and	O	O	O
identified	O	O	O
as	O	O	O
the	O	O	O
main	O	O	O
culprit	O	O	O
behind	O	O	O
the	O	O	O
'	O	O	O
olive	O	O	B-Entity
quick	O	O	I-Entity
decline	O	O	I-Entity
syndrome	O	O	I-Entity
'	O	O	O
.	O	O	O

Since	O	O	O
then	O	O	O
,	O	O	O
the	O	O	O
disease	O	O	B-Entity
has	O	O	O
spread	O	O	O
rapidly	O	O	O
through	O	O	O
Italy	O	O	B-Entity
's	O	O	I-Entity
main	O	O	O
olive	O	O	B-Entity
oil	O	O	I-Entity
producing	O	O	O
region	O	O	B-Entity
.	O	O	O

The	O	O	O
epidemiology	O	O	B-Entity
of	O	O	O
the	O	O	O
outbreak	O	O	B-Entity
is	O	O	O
largely	O	O	O
unstudied	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
list	O	O	O
of	O	O	O
X.	O	O	B-Entity
fastidiosa	O	O	I-Entity
hosts	O	O	B-Entity
and	O	O	O
vectors	O	O	B-Entity
in	O	O	O
Europe	O	O	B-Entity
likely	O	O	O
incomplete	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
role	O	O	O
humans	O	O	B-Entity
play	O	O	O
in	O	O	O
dispersal	O	O	B-Entity
unknown	O	O	B-Entity
.	O	O	O

These	O	O	O
knowledge	O	O	B-Entity
gaps	O	O	B-Entity
have	O	O	O
led	O	O	O
to	O	O	O
management	O	O	B-Entity
strategies	O	O	I-Entity
based	O	O	O
on	O	O	O
general	O	O	O
assumptions	O	O	O
that	O	O	O
require	O	O	O
,	O	O	O
among	O	O	O
others	O	O	O
,	O	O	O
local	O	O	O
vector	O	O	B-Entity
control	O	O	I-Entity
and	O	O	O
,	O	O	O
in	O	O	O
certain	O	O	O
areas	O	O	B-Entity
,	O	O	O
the	O	O	O
destruction	O	O	B-Entity
of	O	O	O
infected	O	O	B-Entity
plants	O	O	I-Entity
and	O	O	O
healthy	O	O	B-Entity
ones	O	O	O
around	O	O	O
them	O	O	O
in	O	O	O
an	O	O	O
attempt	O	O	O
to	O	O	O
eradicate	O	O	B-Entity
or	O	O	O
halt	O	O	B-Entity
the	O	O	O
spreading	O	O	B-Entity
pest	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
,	O	O	O
regardless	O	O	O
of	O	O	O
epidemiological	O	O	B-Entity
uncertainties	O	O	B-Entity
,	O	O	O
the	O	O	O
mere	O	O	O
distribution	O	O	O
of	O	O	O
olive	O	O	B-Entity
orchards	O	O	O
in	O	O	O
Southern	O	O	B-Entity
Italy	O	O	I-Entity
makes	O	O	O
the	O	O	O
chances	O	O	O
of	O	O	O
eradicating	O	O	B-Entity
X.	O	O	B-Entity
fastidiosa	O	O	I-Entity
from	O	O	O
the	O	O	O
region	O	O	B-Entity
extremely	O	O	O
slim	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
imply	O	O	O
that	O	O	O
Southern	O	O	B-Entity
Italy	O	O	I-Entity
is	O	O	O
becoming	O	O	O
a	O	O	O
reservoir	O	O	B-Entity
for	O	O	O
X.	O	O	B-Entity
fastidiosa	O	O	I-Entity
.	O	O	O

As	O	O	O
a	O	O	O
consequence	O	O	O
,	O	O	O
management	O	O	B-Entity
strategies	O	O	I-Entity
should	O	O	O
keep	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
X.	O	O	B-Entity
fastidiosa	O	O	I-Entity
in	O	O	O
the	O	O	O
region	O	O	B-Entity
as	O	O	O
low	O	O	O
as	O	O	O
possible	O	O	O
,	O	O	O
primarily	O	O	O
through	O	O	O
vector	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
lest	O	O	B-Entity
the	O	O	O
pathogen	O	O	B-Entity
,	O	O	O
that	O	O	O
has	O	O	O
also	O	O	O
been	O	O	O
detected	O	O	O
in	O	O	O
southern	O	O	B-Entity
France	O	O	I-Entity
and	O	O	O
the	O	O	O
island	O	O	B-Entity
of	O	O	I-Entity
Mallorca	O	O	I-Entity
(	O	O	O
Spain	O	O	B-Entity
)	O	O	O
,	O	O	O
continues	O	O	O
spreading	O	O	B-Entity
through	O	O	O
Italy	O	O	B-Entity
and	O	O	O
Europe	O	O	B-Entity
.	O	O	O

-DOCSTART- (28251086)

Novel	O	O	O
biomarkers	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
idiopathic	O	O	B-Entity
acute	O	O	B-Entity
anterior	O	O	I-Entity
uveitis	O	O	I-Entity
:	O	O	O
neutrophil	O	O	B-Entity
to	O	O	O
lymphocyte	O	O	B-Entity
ratio	O	O	B-Entity
and	O	O	O
platelet	O	O	B-Entity
to	O	O	O
lymphocyte	O	O	O
ratio	O	O	O

To	O	O	O
assess	O	O	B-Entity
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
the	O	O	O
neutrophil	O	O	B-Entity
to	O	O	O
lymphocyte	O	O	B-Entity
ratio	O	O	B-Entity
(	O	O	O
N	O	O	B-Entity
/	O	O	O
L	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
platelet	O	O	B-Entity
to	O	O	O
lymphocyte	O	O	O
ratio	O	O	O
(	O	O	O
P	O	O	B-Entity
/	O	O	O
L	O	O	O
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
idiopathic	O	O	B-Entity
acute	O	O	B-Entity
anterior	O	O	I-Entity
uveitis	O	O	I-Entity
(	O	O	O
AAU	O	O	B-Entity
)	O	O	O
and	O	O	O
to	O	O	O
compare	O	O	B-Entity
with	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Thirty-six	O	O	O
male	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
idiopathic	O	O	B-Entity
AAU	O	O	B-Entity
and	O	O	O
36	O	O	O
male	O	O	O
healthy	O	O	B-Entity
subjects	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
in	O	O	O
this	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

Complete	O	O	B-Entity
ophthalmological	O	O	B-Entity
examination	O	O	I-Entity
and	O	O	O
complete	O	O	O
blood	O	O	B-Entity
count	O	O	I-Entity
measurements	O	O	I-Entity
results	O	O	B-Entity
of	O	O	O
all	O	O	O
subjects	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
difference	O	O	O
in	O	O	O
N	O	O	B-Entity
/	O	O	O
L	O	O	B-Entity
and	O	O	O
P	O	O	B-Entity
/	O	O	O
L	O	O	O
between	O	O	O
idiopathic	O	O	B-Entity
AAU	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
groups	O	O	I-Entity
(	O	O	O
P=0.006	O	O	O
,	O	O	O
P=0.022	O	O	O
)	O	O	O
.	O	O	O

Also	O	O	O
,	O	O	O
correlation	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
a	O	O	O
significant	O	O	B-Entity
correlation	O	O	O
between	O	O	O
C-reactive	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
CRP	O	O	B-Entity
)	O	O	O
and	O	O	O
N	O	O	B-Entity
/	O	O	O
L	O	O	B-Entity
(	O	O	O
P=0.002	O	O	O
;	O	O	O
r=0.461	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
for	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
provides	O	O	O
evidence	O	O	B-Entity
of	O	O	I-Entity
N	O	O	B-Entity
/	O	O	O
L	O	O	B-Entity
and	O	O	O
P	O	O	B-Entity
/	O	O	O
L	O	O	O
may	O	O	O
be	O	O	O
useful	O	O	B-Entity
biomarkers	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
idiopathic	O	O	B-Entity
AAU	O	O	B-Entity
.	O	O	O

N	O	O	B-Entity
/	O	O	O
L	O	O	B-Entity
is	O	O	O
correlated	O	O	B-Entity
with	O	O	O
CRP	O	O	B-Entity
,	O	O	O
so	O	O	O
it	O	O	O
can	O	O	O
be	O	O	O
a	O	O	O
useful	O	O	B-Entity
biomarker	O	O	B-Entity
to	O	O	O
predict	O	O	O
the	O	O	O
prognosis	O	O	B-Entity
in	O	O	O
idiopathic	O	O	B-Entity
AAU	O	O	B-Entity
.	O	O	O

-DOCSTART- (28251780)

Comparison	O	O	B-Entity
between	O	O	O
magnetic	O	O	B-Entity
resonance	O	O	I-Entity
imaging	O	O	I-Entity
and	O	O	O
B-mode	O	O	B-Entity
ultrasound	O	O	I-Entity
in	O	O	O
detecting	O	O	B-Entity
and	O	O	O
estimating	O	O	B-Entity
the	O	O	O
extent	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
carotid	O	O	O
atherosclerosis	O	O	O

In	O	O	O
MRI	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
carotid	O	O	B-Entity
plaques	O	O	B-Entity
,	O	O	O
ultrasound	O	O	B-Entity
is	O	O	O
used	O	O	O
to	O	O	O
find	O	O	B-Entity
plaques	O	O	O
,	O	O	O
which	O	O	O
are	O	O	O
later	O	O	O
imaged	O	O	B-Entity
using	O	O	O
MRI	O	O	O
.	O	O	O

The	O	O	O
performance	O	O	B-Entity
in	O	O	O
plaque	O	O	B-Entity
detection	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
compared	O	O	B-Entity
between	O	O	O
the	O	O	O
modalities	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
performance	O	O	B-Entity
of	O	O	O
MRI	O	O	B-Entity
and	O	O	O
ultrasound	O	O	B-Entity
in	O	O	O
detecting	O	O	B-Entity
carotid	O	O	B-Entity
artery	O	O	I-Entity
plaques	O	O	I-Entity
and	O	O	O
measuring	O	O	B-Entity
extent	O	O	B-Entity
of	O	O	O
atherosclerosis	O	O	B-Entity
.	O	O	O

Subjects	O	O	B-Entity
with	O	O	O
at	O	O	O
least	O	O	O
one	O	O	O
plaque	O	O	B-Entity
(	O	O	O
height	O	O	B-Entity
≥2·5	O	O	O
mm	O	O	O
)	O	O	O
on	O	O	O
ultrasound	O	O	B-Entity
were	O	O	O
imaged	O	O	B-Entity
using	O	O	O
MRI	O	O	B-Entity
.	O	O	O

The	O	O	O
number	O	O	B-Entity
of	O	O	O
plaques	O	O	B-Entity
and	O	O	O
their	O	O	O
height	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
in	O	O	O
both	O	O	O
modalities	O	O	B-Entity
;	O	O	O
plaque	O	O	B-Entity
area	O	O	B-Entity
and	O	O	O
volume	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
on	O	O	O
ultrasound	O	O	B-Entity
and	O	O	O
MRI	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Thirty-eight	O	O	B-Entity
subjects	O	O	B-Entity
were	O	O	O
included	O	O	B-Entity
.	O	O	O

MRI	O	O	B-Entity
detected	O	O	B-Entity
plaques	O	O	B-Entity
in	O	O	O
95	O	O	O
%	O	O	O
of	O	O	O
carotid	O	O	B-Entity
arteries	O	O	I-Entity
with	O	O	O
a	O	O	O
plaque	O	O	B-Entity
height	O	O	B-Entity
of	O	O	O
≥2·5	O	O	O
mm	O	O	O
on	O	O	O
ultrasound	O	O	B-Entity
and	O	O	O
in	O	O	O
all	O	O	O
carotid	O	O	O
arteries	O	O	O
with	O	O	O
a	O	O	O
plaque	O	O	O
exceeding	O	O	O
2·5	O	O	O
mm	O	O	O
.	O	O	O

MRI	O	O	B-Entity
detected	O	O	B-Entity
53	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
plaques	O	O	B-Entity
with	O	O	O
a	O	O	O
height	O	O	B-Entity
below	O	O	O
2·5	O	O	O
mm	O	O	O
.	O	O	O

The	O	O	O
plaque	O	O	B-Entity
height	O	O	B-Entity
measured	O	O	B-Entity
with	O	O	O
both	O	O	O
techniques	O	O	B-Entity
correlated	O	O	B-Entity
significantly	O	O	O
,	O	O	O
0·59	O	O	O
,	O	O	O
P<0·0001	O	O	O
.	O	O	O

Ultrasound	O	O	B-Entity
-derived	O	O	O
plaque	O	O	B-Entity
height	O	O	B-Entity
and	O	O	O
plaque	O	O	O
area	O	O	B-Entity
correlated	O	O	B-Entity
similarly	O	O	B-Entity
to	O	O	O
MRI	O	O	B-Entity
-derived	O	O	O
plaque	O	O	O
volume	O	O	B-Entity
,	O	O	O
r	O	O	O
=	O	O	O
0·52	O	O	O
;	O	O	O
P<0·0001	O	O	O
and	O	O	O
r	O	O	O
=	O	O	O
0·47	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0·001	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

We	O	O	O
conclude	O	O	O
that	O	O	O
MRI	O	O	B-Entity
has	O	O	O
a	O	O	O
similar	O	O	B-Entity
sensitivity	O	O	B-Entity
to	O	O	O
ultrasound	O	O	B-Entity
in	O	O	O
finding	O	O	B-Entity
carotid	O	O	B-Entity
artery	O	O	I-Entity
plaques	O	O	I-Entity
that	O	O	O
are	O	O	O
2·5	O	O	O
mm	O	O	O
or	O	O	O
higher	O	O	B-Entity
.	O	O	O

In	O	O	O
smaller	O	O	B-Entity
plaques	O	O	B-Entity
,	O	O	O
MRI	O	O	B-Entity
detects	O	O	B-Entity
fewer	O	O	B-Entity
plaques	O	O	O
.	O	O	O

Multiple	O	O	B-Entity
carotid	O	O	I-Entity
plaques	O	O	I-Entity
seen	O	O	O
on	O	O	O
ultrasound	O	O	B-Entity
most	O	O	O
often	O	O	O
are	O	O	O
a	O	O	O
misinterpretation	O	O	O
of	O	O	O
the	O	O	O
anatomy	O	O	B-Entity
and	O	O	O
correspond	O	O	O
to	O	O	O
a	O	O	O
single	O	O	B-Entity
plaque	O	O	I-Entity
.	O	O	O

Plaque	O	O	B-Entity
height	O	O	B-Entity
on	O	O	O
ultrasound	O	O	B-Entity
is	O	O	O
comparable	O	O	O
to	O	O	O
plaque	O	O	B-Entity
height	O	O	O
on	O	O	O
MRI	O	O	B-Entity
and	O	O	O
correlates	O	O	B-Entity
fairly	O	O	O
well	O	O	O
with	O	O	O
plaque	O	O	O
volume	O	O	B-Entity
on	O	O	O
MRI	O	O	O
making	O	O	O
it	O	O	O
an	O	O	O
interesting	O	O	O
proxy	O	O	O
for	O	O	O
plaque	O	O	O
burden	O	O	B-Entity
.	O	O	O

-DOCSTART- (28252933)

Lightweight	O	O	O
Open-Cell	O	O	B-Entity
Scaffolds	O	O	I-Entity
from	O	O	O
Sea	O	O	B-Entity
Urchin	O	O	I-Entity
Spines	O	O	B-Entity
with	O	O	O
Superior	O	O	O
Material	O	O	B-Entity
Properties	O	O	B-Entity
for	O	O	O
Bone	O	O	O
Defect	O	O	O
Repair	O	O	O

Sea	O	O	B-Entity
urchin	O	O	I-Entity
spines	O	O	B-Entity
(	O	O	O
Heterocentrotus	O	O	B-Entity
mammillatus	O	O	I-Entity
)	O	O	O
,	O	O	O
with	O	O	O
a	O	O	O
hierarchical	O	O	O
open-cell	O	O	B-Entity
structure	O	O	I-Entity
similar	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
human	O	O	B-Entity
trabecular	O	O	B-Entity
bone	O	O	I-Entity
and	O	O	O
superior	O	O	O
mechanical	O	O	B-Entity
property	O	O	I-Entity
(	O	O	O
compressive	O	O	B-Entity
strength	O	O	I-Entity
∼43.4	O	O	O
MPa	O	O	O
)	O	O	O
suitable	O	O	B-Entity
for	O	O	O
machining	O	O	B-Entity
to	O	O	O
shape	O	O	B-Entity
,	O	O	O
were	O	O	O
explored	O	O	O
for	O	O	O
potential	O	O	B-Entity
applications	O	O	B-Entity
of	O	O	O
bone	O	O	B-Entity
defect	O	O	I-Entity
repair	O	O	I-Entity
.	O	O	O

Finite	O	O	B-Entity
element	O	O	I-Entity
analyses	O	O	I-Entity
reveal	O	O	O
that	O	O	O
the	O	O	O
compressive	O	O	O
stress	O	O	B-Entity
concentrates	O	O	B-Entity
along	O	O	O
the	O	O	O
dense	O	O	B-Entity
growth	O	O	B-Entity
rings	O	O	I-Entity
and	O	O	O
dissipates	O	O	B-Entity
through	O	O	O
strut	O	O	O
structures	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
stereoms	O	O	I-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
the	O	O	O
exquisite	O	O	O
mesostructures	O	O	B-Entity
play	O	O	O
an	O	O	O
important	O	O	B-Entity
role	O	O	O
in	O	O	O
high	O	O	O
strength	O	O	B-Entity
-to-	O	O	O
weight	O	O	B-Entity
ratios	O	O	B-Entity
.	O	O	O

The	O	O	O
fracture	O	O	B-Entity
strength	O	O	B-Entity
of	O	O	O
magnesium	O	O	B-Entity
-	O	O	O
substituted	O	O	B-Entity
tricalcium	O	O	I-Entity
phosphate	O	O	I-Entity
(	O	O	B-Entity
β-TCMP	O	O	I-Entity
)	O	O	I-Entity
scaffolds	O	O	I-Entity
produced	O	O	O
by	O	O	O
hydrothermal	O	O	B-Entity
conversion	O	O	B-Entity
of	O	O	O
urchin	O	O	B-Entity
spines	O	O	B-Entity
is	O	O	O
about	O	O	O
9.3	O	O	O
MPa	O	O	O
,	O	O	O
comparable	O	O	B-Entity
to	O	O	O
that	O	O	O
of	O	O	O
human	O	O	B-Entity
trabecular	O	O	B-Entity
bone	O	O	I-Entity
.	O	O	O

New	O	O	O
bone	O	O	B-Entity
forms	O	O	B-Entity
along	O	O	O
outer	O	O	O
surfaces	O	O	B-Entity
of	O	O	O
β-TCMP	O	O	B-Entity
scaffolds	O	O	I-Entity
after	O	O	O
implantation	O	O	B-Entity
in	O	O	O
rabbit	O	O	B-Entity
femoral	O	O	B-Entity
defects	O	O	I-Entity
for	O	O	O
one	O	O	O
month	O	O	B-Entity
and	O	O	O
grows	O	O	B-Entity
into	O	O	O
the	O	O	O
majority	O	O	O
of	O	O	O
the	O	O	O
inner	O	O	O
open-cell	O	O	B-Entity
spaces	O	O	I-Entity
postoperation	O	O	B-Entity
in	O	O	O
three	O	O	O
month	O	O	O
s	O	O	O
,	O	O	O
showing	O	O	O
tight	O	O	B-Entity
interface	O	O	I-Entity
between	O	O	O
the	O	O	O
scaffold	O	O	B-Entity
and	O	O	O
regenerative	O	O	B-Entity
bone	O	O	I-Entity
tissue	O	O	I-Entity
.	O	O	O

Fusion	O	O	B-Entity
of	O	O	O
beagle	O	O	B-Entity
lumbar	O	O	B-Entity
facet	O	O	I-Entity
joints	O	O	I-Entity
using	O	O	O
a	O	O	O
Ti-6Al-4V	O	O	B-Entity
cage	O	O	I-Entity
and	O	O	O
β-TCMP	O	O	B-Entity
scaffold	O	O	I-Entity
can	O	O	O
be	O	O	O
completed	O	O	B-Entity
within	O	O	O
seven	O	O	O
months	O	O	B-Entity
with	O	O	O
obvious	O	O	O
biodegradation	O	O	B-Entity
of	O	O	O
the	O	O	O
β-TCMP	O	O	O
scaffold	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
nearly	O	O	O
completely	O	O	B-Entity
degraded	O	O	B-Entity
and	O	O	O
replaced	O	O	B-Entity
by	O	O	I-Entity
newly	O	O	O
formed	O	O	B-Entity
bone	O	O	B-Entity
ten	O	O	O
months	O	O	O
after	O	O	O
implantation	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
sea	O	O	B-Entity
urchin	O	O	I-Entity
spines	O	O	B-Entity
suitable	O	O	O
for	O	O	O
machining	O	O	B-Entity
to	O	O	O
shape	O	O	B-Entity
have	O	O	O
advantages	O	O	O
for	O	O	O
production	O	O	O
of	O	O	O
biodegradable	O	O	B-Entity
artificial	O	O	B-Entity
grafts	O	O	I-Entity
for	O	O	O
bone	O	O	B-Entity
defect	O	O	I-Entity
repair	O	O	I-Entity
.	O	O	O

-DOCSTART- (28254544)

Melatonin	O	O	B-Entity
and	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
regulate	O	O	B-Entity
sunflower	O	O	B-Entity
seedling	O	O	B-Entity
growth	O	O	I-Entity
under	O	O	O
salt	O	O	B-Entity
stress	O	O	I-Entity
accompanying	O	O	O
differential	O	O	O
expression	O	O	B-Entity
of	O	O	O
Cu/Zn	O	O	B-Entity
SOD	O	O	I-Entity
and	O	O	O
Mn	O	O	O
SOD	O	O	O

Salinity	O	O	B-Entity
results	O	O	I-Entity
in	O	O	O
significant	O	O	B-Entity
reduction	O	O	I-Entity
in	O	O	O
sunflower	O	O	B-Entity
(	O	O	O
Helianthus	O	O	B-Entity
annuus	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
seedling	O	O	B-Entity
growth	O	O	I-Entity
and	O	O	O
excessive	O	O	O
generation	O	O	O
of	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
.	O	O	O

Present	O	O	O
work	O	O	O
highlights	O	O	O
the	O	O	O
possible	O	O	O
role	O	O	O
of	O	O	O
melatonin	O	O	B-Entity
as	O	O	O
an	O	O	O
antioxidant	O	O	B-Entity
through	O	O	O
its	O	O	O
interaction	O	O	O
with	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
NO	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
as	O	O	O
an	O	O	O
early	O	O	O
and	O	O	O
long	O	O	O
distance	O	O	O
NaCl-stress	O	O	B-Entity
sensing	O	O	O
signaling	O	O	B-Entity
molecule	O	O	I-Entity
in	O	O	O
seedling	O	O	B-Entity
cotyledons	O	O	B-Entity
.	O	O	O

Exogenous	O	O	B-Entity
melatonin	O	O	B-Entity
(15µM)±	O	O	O
NaCl	O	O	B-Entity
(	O	O	O
120mM	O	O	O
)	O	O	O
inhibit	O	O	B-Entity
seedling	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
also	O	O	O
correlated	O	O	O
with	O	O	O
NO	O	O	B-Entity
availability	O	O	O
,	O	O	O
accumulation	O	O	O
of	O	O	O
potential	O	O	B-Entity
superoxide	O	O	I-Entity
anion	O	O	I-Entity
(	O	O	O
O2(•-	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
and	O	O	O
peroxynitrite	O	O	B-Entity
anion	O	O	I-Entity
(	O	O	O
ONOO(-	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
,	O	O	O
extent	O	O	O
of	O	O	O
tyrosine-nitration	O	O	B-Entity
of	O	O	O
proteins	O	O	B-Entity
,	O	O	O
spatial	O	O	B-Entity
localization	O	O	I-Entity
and	O	O	O
activity	O	O	B-Entity
of	O	O	I-Entity
superoxide	O	O	I-Entity
dismutase	O	O	I-Entity
(	O	O	O
SOD	O	O	B-Entity
)	O	O	O
isoforms	O	O	B-Entity
.	O	O	O

NO	O	O	B-Entity
acts	O	O	O
as	O	O	O
a	O	O	O
positive	O	O	O
modulator	O	O	O
of	O	O	O
melatonin	O	O	B-Entity
accumulation	O	O	O
in	O	O	O
seedling	O	O	B-Entity
cotyledons	O	O	B-Entity
as	O	O	O
a	O	O	O
long-distance	O	O	B-Entity
signaling	O	O	I-Entity
response	O	O	I-Entity
.	O	O	O

Modulation	O	O	B-Entity
of	O	O	I-Entity
superoxide	O	O	I-Entity
anion	O	O	I-Entity
and	O	O	O
peroxynitrite	O	O	B-Entity
anion	O	O	I-Entity
content	O	O	O
by	O	O	O
melatonin	O	O	B-Entity
highlights	O	O	O
its	O	O	O
crucial	O	O	O
role	O	O	O
in	O	O	O
combating	O	O	O
deleterious	O	O	O
effects	O	O	O
of	O	O	O
ROS	O	O	B-Entity
and	O	O	O
reactive	O	O	B-Entity
nitrogen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
RNS	O	O	O
)	O	O	O
.	O	O	O

Present	O	O	O
findings	O	O	O
provide	O	O	O
evidence	O	O	O
for	O	O	O
an	O	O	O
interaction	O	O	O
between	O	O	O
melatonin	O	O	B-Entity
and	O	O	O
NO	O	O	B-Entity
in	O	O	O
their	O	O	O
effect	O	O	O
on	O	O	O
seedling	O	O	B-Entity
growth	O	O	I-Entity
under	O	O	O
salt	O	O	B-Entity
stress	O	O	I-Entity
accompanying	O	O	I-Entity
differential	O	O	O
modulation	O	O	O
of	O	O	O
two	O	O	O
SOD	O	O	B-Entity
isoforms	O	O	B-Entity
,	O	O	O
i.e.	O	O	O
Cu/Zn	O	O	B-Entity
SOD	O	O	I-Entity
and	O	O	O
Mn	O	O	B-Entity
SOD	O	O	I-Entity
.	O	O	O

-DOCSTART- (28258572)

The	O	O	O
Physiological	O	O	B-Entity
Role	O	O	O
and	O	O	O
Regulation	O	O	B-Entity
of	O	O	O
Aquaporins	O	O	B-Entity
in	O	O	O
Teleost	O	O	B-Entity
Germ	O	O	O
Cells	O	O	O

The	O	O	O
unicellular	O	O	O
germ	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
gametes	O	O	B-Entity
of	O	O	O
oviparous	O	O	B-Entity
teleosts	O	O	B-Entity
lack	O	O	O
the	O	O	O
osmoregulatory	O	O	B-Entity
organs	O	O	B-Entity
present	O	O	O
in	O	O	O
juveniles	O	O	B-Entity
and	O	O	O
adults	O	O	B-Entity
,	O	O	O
yet	O	O	O
during	O	O	O
development	O	O	B-Entity
and	O	O	O
particularly	O	O	O
at	O	O	O
spawning	O	O	B-Entity
,	O	O	O
they	O	O	O
face	O	O	O
tremendous	O	O	O
osmotic	O	O	B-Entity
challenges	O	O	B-Entity
when	O	O	O
released	O	O	O
into	O	O	O
the	O	O	O
external	O	O	B-Entity
aquatic	O	O	B-Entity
environment	O	O	I-Entity
.	O	O	O

Increasing	O	O	O
evidence	O	O	O
suggests	O	O	O
that	O	O	O
transmembrane	O	O	B-Entity
water	O	O	I-Entity
channels	O	O	I-Entity
(	O	O	O
aquaporins	O	O	B-Entity
)	O	O	O
evolved	O	O	O
to	O	O	O
play	O	O	O
vital	O	O	O
adaptive	O	O	O
roles	O	O	O
that	O	O	O
mitigate	O	O	B-Entity
the	O	O	O
osmotic	O	O	B-Entity
and	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
problems	O	O	B-Entity
of	O	O	O
the	O	O	O
developing	O	O	B-Entity
oocytes	O	O	B-Entity
,	O	O	O
embryos	O	O	B-Entity
and	O	O	O
spermatozoa	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
chapter	O	O	O
,	O	O	O
we	O	O	O
provide	O	O	O
a	O	O	O
short	O	O	O
overview	O	O	O
of	O	O	O
the	O	O	O
diversity	O	O	B-Entity
of	O	O	O
the	O	O	O
aquaporin	O	O	B-Entity
superfamily	O	O	O
in	O	O	O
teleosts	O	O	B-Entity
,	O	O	O
and	O	O	O
summarize	O	O	O
the	O	O	O
findings	O	O	O
that	O	O	O
uncovered	O	O	O
a	O	O	O
highly	O	O	O
specific	O	O	O
molecular	O	O	B-Entity
regulation	O	O	I-Entity
of	O	O	O
aquaporins	O	O	B-Entity
during	O	O	O
oogenesis	O	O	B-Entity
and	O	O	O
spermatogenesis	O	O	B-Entity
.	O	O	O

We	O	O	O
further	O	O	O
review	O	O	O
the	O	O	O
multiple	O	O	O
functions	O	O	O
that	O	O	O
these	O	O	O
channels	O	O	B-Entity
play	O	O	O
during	O	O	O
the	O	O	O
establishment	O	O	O
of	O	O	O
egg	O	O	B-Entity
buoyancy	O	O	B-Entity
and	O	O	O
the	O	O	O
activation	O	O	B-Entity
and	O	O	O
detoxification	O	O	B-Entity
of	O	O	O
spermatozoa	O	O	B-Entity
in	O	O	O
the	O	O	O
marine	O	O	B-Entity
environment	O	O	B-Entity
.	O	O	O

-DOCSTART- (28261447)

Caribbean	O	O	B-Entity
massive	O	O	B-Entity
corals	O	O	I-Entity
not	O	O	B-Entity
recovering	O	O	I-Entity
from	O	O	I-Entity
repeated	O	O	O
thermal	O	O	B-Entity
stress	O	O	I-Entity
events	O	O	B-Entity
during	O	O	O
2005	O	O	O
-	O	O	O
2013	O	O	O

Massive	O	O	B-Entity
coral	O	O	I-Entity
bleaching	O	O	B-Entity
events	O	O	B-Entity
associated	O	O	O
with	O	O	O
high	O	O	O
sea	O	O	B-Entity
surface	O	O	B-Entity
temperatures	O	O	B-Entity
are	O	O	O
forecast	O	O	O
to	O	O	O
become	O	O	O
more	O	O	O
frequent	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
in	O	O	O
the	O	O	O
future	O	O	O
due	O	O	O
to	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

Monitoring	O	O	B-Entity
colony	O	O	B-Entity
recovery	O	O	B-Entity
from	O	O	O
bleaching	O	O	B-Entity
disturbances	O	O	O
over	O	O	O
multiyear	O	O	B-Entity
time	O	O	I-Entity
frames	O	O	I-Entity
is	O	O	O
important	O	O	O
for	O	O	O
improving	O	O	O
predictions	O	O	O
of	O	O	O
future	O	O	O
coral	O	O	B-Entity
community	O	O	B-Entity
changes	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
currently	O	O	O
few	O	O	O
multiyear	O	O	B-Entity
studies	O	O	I-Entity
describing	O	O	O
long-term	O	O	B-Entity
outcomes	O	O	B-Entity
for	O	O	O
coral	O	O	B-Entity
colonies	O	O	B-Entity
following	O	O	O
acute	O	O	B-Entity
bleaching	O	O	I-Entity
events	O	O	B-Entity
.	O	O	O

We	O	O	O
recorded	O	O	O
colony	O	O	B-Entity
pigmentation	O	O	B-Entity
and	O	O	O
size	O	O	B-Entity
for	O	O	O
bleached	O	O	B-Entity
and	O	O	O
unbleached	O	O	B-Entity
groups	O	O	I-Entity
of	O	O	O
co-located	O	O	O
conspecifics	O	O	O
of	O	O	O
three	O	O	O
major	O	O	O
reef-building	O	O	B-Entity
scleractinian	O	O	I-Entity
corals	O	O	B-Entity
(	O	O	O
Orbicella	O	O	B-Entity
franksi	O	O	I-Entity
,	O	O	O
Siderastrea	O	O	B-Entity
siderea	O	O	I-Entity
,	O	O	O
and	O	O	O
Stephanocoenia	O	O	B-Entity
michelini	O	O	I-Entity
;	O	O	O
n	O	O	O
=	O	O	O
198	O	O	O
total	O	O	O
)	O	O	O
in	O	O	O
Bocas	O	O	B-Entity
del	O	O	I-Entity
Toro	O	O	I-Entity
,	O	O	O
Panama	O	O	B-Entity
,	O	O	O
during	O	O	O
the	O	O	O
major	O	O	O
2005	O	O	O
bleaching	O	O	B-Entity
event	O	O	B-Entity
and	O	O	O
then	O	O	O
monitored	O	O	B-Entity
pigmentation	O	O	O
status	O	O	B-Entity
and	O	O	O
changes	O	O	O
live	O	O	B-Entity
tissue	O	O	I-Entity
colony	O	O	O
size	O	O	O
for	O	O	O
8	O	O	O
years	O	O	B-Entity
(	O	O	O
2005	O	O	O
-	O	O	O
2013	O	O	O
)	O	O	O
.	O	O	O

Corals	O	O	B-Entity
that	O	O	O
were	O	O	O
bleached	O	O	B-Entity
in	O	O	O
2005	O	O	O
demonstrated	O	O	O
markedly	O	O	O
different	O	O	O
response	O	O	O
trajectories	O	O	O
compared	O	O	O
to	O	O	O
unbleached	O	O	O
colony	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
with	O	O	O
extensive	O	O	O
live	O	O	B-Entity
tissue	O	O	I-Entity
loss	O	O	B-Entity
for	O	O	O
bleached	O	O	O
corals	O	O	B-Entity
of	O	O	O
all	O	O	O
species	O	O	B-Entity
following	O	O	O
bleaching	O	O	B-Entity
,	O	O	O
with	O	O	O
mean	O	O	O
live	O	O	O
tissue	O	O	O
losses	O	O	B-Entity
per	O	O	O
colony	O	O	O
9	O	O	O
months	O	O	B-Entity
postbleaching	O	O	B-Entity
of	O	O	O
26.2	O	O	O
%	O	O	O
(	O	O	O
±5.4	O	O	O
SE	O	O	O
)	O	O	O
for	O	O	O
O.	O	O	B-Entity
franksi	O	O	I-Entity
,	O	O	O
35.7	O	O	O
%	O	O	O
(	O	O	O
±4.7	O	O	O
SE	O	O	O
)	O	O	O
for	O	O	O
S.	O	O	B-Entity
michelini	O	O	I-Entity
,	O	O	O
and	O	O	O
11.2	O	O	O
%	O	O	O
(	O	O	O
±3.9	O	O	O
SE	O	O	O
)	O	O	O
for	O	O	O
S.	O	O	B-Entity
siderea	O	O	I-Entity
.	O	O	O

Two	O	O	O
species	O	O	B-Entity
,	O	O	O
O.	O	O	B-Entity
franksi	O	O	I-Entity
and	O	O	O
S.	O	O	B-Entity
michelini	O	O	I-Entity
,	O	O	O
later	O	O	O
recovered	O	O	O
to	O	O	O
net	O	O	O
positive	O	O	B-Entity
growth	O	O	B-Entity
,	O	O	O
which	O	O	O
continued	O	O	O
until	O	O	O
a	O	O	O
second	O	O	O
thermal	O	O	B-Entity
stress	O	O	I-Entity
event	O	O	B-Entity
in	O	O	O
2010	O	O	O
.	O	O	O

Following	O	O	O
this	O	O	O
event	O	O	B-Entity
,	O	O	O
all	O	O	O
species	O	O	B-Entity
again	O	O	O
lost	O	O	B-Entity
tissue	O	O	B-Entity
,	O	O	O
with	O	O	O
previously	O	O	O
unbleached	O	O	O
colony	O	O	B-Entity
species	O	O	O
groups	O	O	B-Entity
experiencing	O	O	O
greater	O	O	O
declines	O	O	O
than	O	O	O
conspecific	O	O	O
sample	O	O	O
groups	O	O	O
,	O	O	O
which	O	O	O
were	O	O	O
previously	O	O	O
bleached	O	O	B-Entity
,	O	O	O
indicating	O	O	O
a	O	O	O
possible	O	O	O
positive	O	O	O
acclimative	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
despite	O	O	O
this	O	O	O
beneficial	O	O	O
effect	O	O	O
for	O	O	O
previously	O	O	O
bleached	O	O	B-Entity
corals	O	O	B-Entity
,	O	O	O
all	O	O	O
groups	O	O	B-Entity
experienced	O	O	O
substantial	O	O	O
net	O	O	O
tissue	O	O	B-Entity
loss	O	O	B-Entity
between	O	O	O
2005	O	O	O
and	O	O	O
2013	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
many	O	O	O
important	O	O	O
Caribbean	O	O	B-Entity
reef-building	O	O	B-Entity
corals	O	O	I-Entity
will	O	O	O
likely	O	O	O
suffer	O	O	O
continued	O	O	O
tissue	O	O	O
loss	O	O	O
and	O	O	O
may	O	O	O
be	O	O	O
unable	O	O	O
to	O	O	O
maintain	O	O	O
current	O	O	O
benthic	O	O	B-Entity
coverage	O	O	I-Entity
when	O	O	O
faced	O	O	O
with	O	O	O
future	O	O	O
thermal	O	O	B-Entity
stress	O	O	I-Entity
forecast	O	O	O
for	O	O	O
the	O	O	O
region	O	O	B-Entity
,	O	O	O
even	O	O	O
with	O	O	O
potential	O	O	O
benefits	O	O	O
from	O	O	O
bleaching	O	O	B-Entity
-related	O	O	O
acclimation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28263833)

Preparation	O	O	B-Entity
and	O	O	O
characterization	O	O	B-Entity
of	O	O	O
gastrointestinal	O	O	B-Entity
wafer	O	O	B-Entity
formulations	O	O	O

Many	O	O	O
active	O	O	B-Entity
pharmaceutical	O	O	I-Entity
ingredients	O	O	I-Entity
(	O	O	O
API	O	O	B-Entity
)	O	O	O
have	O	O	O
a	O	O	O
very	O	O	O
poor	O	O	O
or	O	O	O
highly	O	O	O
variable	O	O	B-Entity
bioavailability	O	O	B-Entity
after	O	O	O
oral	O	O	B-Entity
administration	O	O	I-Entity
.	O	O	O

One	O	O	O
possibility	O	O	O
to	O	O	O
overcome	O	O	B-Entity
this	O	O	O
problem	O	O	O
might	O	O	O
be	O	O	O
found	O	O	O
in	O	O	O
the	O	O	O
application	O	O	O
of	O	O	O
mucoadhesive	O	O	B-Entity
dosage	O	O	I-Entity
forms	O	O	I-Entity
like	O	O	O
gastrointestinal	O	O	B-Entity
wafers	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
currently	O	O	B-Entity
unsolved	O	O	B-Entity
challenge	O	O	O
is	O	O	O
the	O	O	O
control	O	O	B-Entity
of	O	O	O
the	O	O	O
adhesion	O	O	B-Entity
of	O	O	O
the	O	O	O
wafer	O	O	B-Entity
to	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
mucus	O	O	I-Entity
.	O	O	O

One	O	O	O
suggested	O	O	O
solution	O	O	O
might	O	O	O
be	O	O	O
the	O	O	O
combination	O	O	B-Entity
of	O	O	O
gastrointestinal	O	O	B-Entity
wafers	O	O	B-Entity
and	O	O	O
expanding	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

Such	O	O	O
a	O	O	O
combination	O	O	B-Entity
requires	O	O	O
thin	O	O	B-Entity
and	O	O	I-Entity
elastic	O	O	I-Entity
wafers	O	O	I-Entity
which	O	O	O
are	O	O	O
further	O	O	O
characterized	O	O	B-Entity
by	O	O	O
an	O	O	O
unidirectional	O	O	B-Entity
drug	O	O	I-Entity
release	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
gastrointestinal	O	O	B-Entity
,	O	O	O
twolayered	O	O	B-Entity
wafers	O	O	I-Entity
containing	O	O	O
a	O	O	O
water-insoluble	O	O	B-Entity
backing	O	O	I-Entity
layer	O	O	I-Entity
and	O	O	O
a	O	O	O
drug-loaded	O	O	B-Entity
,	O	O	O
mucoadhesive	O	O	B-Entity
layer	O	O	I-Entity
were	O	O	O
fabricated	O	O	O
by	O	O	O
casting	O	O	B-Entity
solvent	O	O	I-Entity
technique	O	O	I-Entity
.	O	O	O

The	O	O	O
backing	O	O	B-Entity
layer	O	O	I-Entity
consists	O	O	O
of	O	O	O
Ethocel	O	O	B-Entity
™	O	O	I-Entity
Standard	O	O	I-Entity
10	O	O	I-Entity
Premium	O	O	I-Entity
and	O	O	O
the	O	O	O
mucoadhesive	O	O	B-Entity
layer	O	O	I-Entity
was	O	O	O
prepared	O	O	O
using	O	O	O
a	O	O	O
mixture	O	O	B-Entity
of	O	O	O
Methocel	O	O	B-Entity
™	O	O	I-Entity
E15	O	O	I-Entity
Premium	O	O	I-Entity
LV	O	O	I-Entity
,	O	O	O
polyvinyl	O	O	B-Entity
alcohol	O	O	I-Entity
and	O	O	O
Macrogol	O	O	B-Entity
400	O	O	I-Entity
.	O	O	O

The	O	O	O
wafers	O	O	B-Entity
were	O	O	O
characterized	O	O	B-Entity
regarding	O	O	O
their	O	O	O
appearance	O	O	B-Entity
,	O	O	O
mechanical	O	O	B-Entity
properties	O	O	I-Entity
and	O	O	O
dissolution	O	O	B-Entity
profiles	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
backing	O	O	B-Entity
layer	O	O	I-Entity
thickness	O	O	B-Entity
on	O	O	O
drug	O	O	B-Entity
transfer	O	O	I-Entity
and	O	O	O
their	O	O	O
ability	O	O	O
of	O	O	O
unidirectional	O	O	B-Entity
drug	O	O	I-Entity
release	O	O	I-Entity
.	O	O	O

The	O	O	O
wafers	O	O	B-Entity
with	O	O	O
backing	O	O	B-Entity
layer	O	O	I-Entity
thickness	O	O	B-Entity
of	O	O	O
500μg	O	O	B-Entity
Ethocel	O	O	I-Entity
™	O	O	O
/cm(2	O	O	O
)	O	O	O
presented	O	O	O
adequate	O	O	B-Entity
mechanical	O	O	B-Entity
properties	O	O	I-Entity
,	O	O	O
a	O	O	O
drug	O	O	B-Entity
transfer	O	O	I-Entity
about	O	O	O
73	O	O	O
%	O	O	O
and	O	O	O
unidirectional	O	O	B-Entity
drug	O	O	I-Entity
release	O	O	I-Entity
.	O	O	O

-DOCSTART- (28264394)

Discovery	O	O	B-Entity
of	O	O	O
<	O	O	B-Entity
i	O	O	I-Entity
>	O	O	I-Entity
Neopanorpa	O	O	I-Entity
chillcotti</i	O	O	I-Entity
>	O	O	I-Entity
Byers	O	O	I-Entity
(	O	O	O
Mecoptera	O	O	B-Entity
:	O	O	O
Panorpidae	O	O	B-Entity
)	O	O	O
from	O	O	O
Tibet	O	O	B-Entity
,	O	O	O
China	O	O	B-Entity
,	O	O	O
with	O	O	O
discussion	O	O	O
of	O	O	O
its	O	O	O
generic	O	O	O
status	O	O	O

Neopanorpa	O	O	B-Entity
chillcotti	O	O	I-Entity
Byers	O	O	I-Entity
,	O	O	O
1971	O	O	O
was	O	O	O
originally	O	O	O
described	O	O	O
from	O	O	O
Kathmandu	O	O	B-Entity
in	O	O	O
Nepal	O	O	B-Entity
and	O	O	O
is	O	O	O
now	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
distributed	O	O	O
in	O	O	O
Gyirong	O	O	B-Entity
,	O	O	O
Tibet	O	O	B-Entity
in	O	O	O
China	O	O	B-Entity
.	O	O	O

The	O	O	O
species	O	O	O
is	O	O	O
redescribed	O	O	O
and	O	O	O
illustrated	O	O	O
based	O	O	O
on	O	O	O
new	O	O	B-Entity
material	O	O	I-Entity
from	O	O	O
China	O	O	B-Entity
and	O	O	O
Nepal	O	O	B-Entity
.	O	O	O

The	O	O	O
generic	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
this	O	O	O
species	O	O	B-Entity
is	O	O	O
briefly	O	O	O
discussed	O	O	B-Entity
.	O	O	O

-DOCSTART- (28264678)

Passive	O	O	B-Entity
case	O	O	I-Entity
detection	O	O	I-Entity
of	O	O	O
malaria	O	O	B-Entity
in	O	O	O
Ratanakiri	O	O	B-Entity
Province	O	O	I-Entity
(	O	O	O
Cambodia	O	O	B-Entity
)	O	O	O
to	O	O	O
detect	O	O	B-Entity
villages	O	O	B-Entity
at	O	O	B-Entity
higher	O	O	I-Entity
risk	O	O	I-Entity
for	O	O	O
malaria	O	O	O

Cambodia	O	O	B-Entity
reduced	O	O	B-Entity
malaria	O	O	B-Entity
incidence	O	O	B-Entity
by	O	O	O
more	O	O	O
than	O	O	O
75	O	O	O
%	O	O	O
between	O	O	O
2000	O	O	O
and	O	O	O
2015	O	O	O
,	O	O	O
a	O	O	O
target	O	O	B-Entity
of	O	O	O
the	O	O	O
Millennium	O	O	B-Entity
Development	O	O	I-Entity
Goal	O	O	I-Entity
6	O	O	I-Entity
.	O	O	O

The	O	O	O
Cambodian	O	O	B-Entity
Government	O	O	B-Entity
aims	O	O	B-Entity
to	O	O	O
eliminate	O	O	B-Entity
all	O	O	O
forms	O	O	O
of	O	O	O
malaria	O	O	B-Entity
by	O	O	O
2025	O	O	O
.	O	O	O

The	O	O	O
country	O	O	B-Entity
's	O	O	I-Entity
malaria	O	O	B-Entity
incidence	O	O	B-Entity
is	O	O	O
highly	O	O	B-Entity
variable	O	O	B-Entity
at	O	O	O
provincial	O	O	B-Entity
level	O	O	B-Entity
,	O	O	O
but	O	O	O
less	O	O	O
is	O	O	O
known	O	O	O
at	O	O	O
village	O	O	B-Entity
level	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
used	O	O	O
passive	O	O	B-Entity
case	O	O	I-Entity
detection	O	O	I-Entity
(	O	O	O
PCD	O	O	B-Entity
)	O	O	O
data	O	O	O
at	O	O	O
village	O	O	B-Entity
level	O	O	B-Entity
in	O	O	O
Ratanakiri	O	O	B-Entity
Province	O	O	I-Entity
from	O	O	O
2010	O	O	O
to	O	O	O
2014	O	O	O
to	O	O	O
describe	O	O	O
incidence	O	O	B-Entity
trends	O	O	B-Entity
and	O	O	O
identify	O	O	B-Entity
high-risk	O	O	B-Entity
areas	O	O	I-Entity
of	O	O	I-Entity
malaria	O	O	B-Entity
to	O	O	O
be	O	O	O
primarily	O	O	B-Entity
targeted	O	O	B-Entity
towards	O	O	O
malaria	O	O	O
elimination	O	O	B-Entity
.	O	O	O

In	O	O	O
2010	O	O	O
,	O	O	O
the	O	O	O
Cambodian	O	O	B-Entity
malaria	O	O	B-Entity
programme	O	O	B-Entity
created	O	O	O
a	O	O	O
Malaria	O	O	B-Entity
Information	O	O	I-Entity
System	O	O	I-Entity
(	O	O	O
MIS	O	O	B-Entity
)	O	O	O
to	O	O	O
capture	O	O	O
malaria	O	O	O
information	O	O	B-Entity
at	O	O	O
village	O	O	B-Entity
level	O	O	B-Entity
through	O	O	O
PCD	O	O	B-Entity
by	O	O	O
village	O	O	O
malaria	O	O	B-Entity
workers	O	O	I-Entity
and	O	O	O
health	O	O	B-Entity
facilities	O	O	I-Entity
.	O	O	O

The	O	O	O
MIS	O	O	B-Entity
data	O	O	B-Entity
of	O	O	O
Ratanakiri	O	O	B-Entity
Province	O	O	I-Entity
2010	O	O	O
-	O	O	O
2014	O	O	O
were	O	O	O
used	O	O	O
to	O	O	O
calculate	O	O	B-Entity
annual	O	O	B-Entity
incidence	O	O	B-Entity
rates	O	O	I-Entity
by	O	O	O
Plasmodium	O	O	B-Entity
species	O	O	I-Entity
at	O	O	O
province	O	O	B-Entity
and	O	O	O
commune	O	O	B-Entity
levels	O	O	B-Entity
.	O	O	O

For	O	O	O
estimating	O	O	B-Entity
the	O	O	O
trend	O	O	B-Entity
at	O	O	O
provincial	O	O	B-Entity
level	O	O	B-Entity
only	O	O	O
villages	O	O	B-Entity
reporting	O	O	B-Entity
each	O	O	O
year	O	O	B-Entity
were	O	O	O
selected	O	O	O
.	O	O	O

The	O	O	O
communal	O	O	B-Entity
incidences	O	O	B-Entity
and	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
cases	O	O	B-Entity
per	O	O	B-Entity
village	O	O	B-Entity
were	O	O	O
visualized	O	O	O
on	O	O	O
a	O	O	O
map	O	O	B-Entity
per	O	O	O
Plasmodium	O	O	B-Entity
species	O	O	I-Entity
and	O	O	O
per	O	O	B-Entity
year	O	O	I-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	I-Entity
spatial	O	O	I-Entity
clustering	O	O	I-Entity
of	O	O	O
village	O	O	B-Entity
malaria	O	O	B-Entity
cases	O	O	B-Entity
by	O	O	O
Plasmodium	O	O	B-Entity
species	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
by	O	O	O
year	O	O	B-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
malaria	O	O	B-Entity
annual	O	O	B-Entity
incidence	O	O	B-Entity
rates	O	O	I-Entity
per	O	O	O
1000	O	O	O
inhabitants	O	O	B-Entity
decreased	O	O	B-Entity
from	O	O	O
86	O	O	O
(	O	O	O
2010	O	O	O
)	O	O	O
to	O	O	O
30	O	O	O
(	O	O	O
2014	O	O	O
)	O	O	O
.	O	O	O

Falciparum	O	O	B-Entity
incidence	O	O	B-Entity
decreased	O	O	B-Entity
(	O	O	O
by	O	O	O
79	O	O	O
%	O	O	O
in	O	O	O
2014	O	O	O
compared	O	O	B-Entity
to	O	O	O
2010	O	O	O
;	O	O	O
CI	O	O	B-Entity
95	O	O	O
%	O	O	O
76	O	O	O
-	O	O	O
82	O	O	O
%	O	O	O
)	O	O	O
more	O	O	O
rapidly	O	O	B-Entity
than	O	O	O
vivax	O	O	B-Entity
incidence	O	O	O
(	O	O	O
by	O	O	O
19	O	O	O
%	O	O	O
in	O	O	O
2014	O	O	O
compared	O	O	O
to	O	O	O
2010	O	O	O
;	O	O	O
CI	O	O	O
95	O	O	O
%	O	O	O
5	O	O	O
-	O	O	O
32	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
were	O	O	O
ten	O	O	O
to	O	O	O
16	O	O	O
significant	O	O	B-Entity
spatial	O	O	B-Entity
clusters	O	O	I-Entity
each	O	O	O
year	O	O	B-Entity
.	O	O	O

Big	O	O	B-Entity
clusters	O	O	I-Entity
tended	O	O	O
to	O	O	O
extend	O	O	B-Entity
along	O	O	O
the	O	O	O
Cambodian-Vietnamese	O	O	B-Entity
border	O	O	I-Entity
and	O	O	O
along	O	O	O
the	O	O	O
Sesan	O	O	B-Entity
River	O	O	I-Entity
.	O	O	O

Three	O	O	O
clusters	O	O	B-Entity
appeared	O	O	O
throughout	O	O	O
all	O	O	O
years	O	O	B-Entity
(	O	O	O
2010	O	O	O
-	O	O	O
2014	O	O	O
):	O	O	O
one	O	O	O
with	O	O	O
21	O	O	O
villages	O	O	B-Entity
appeared	O	O	O
each	O	O	O
year	O	O	B-Entity
,	O	O	O
the	O	O	O
second	O	O	O
shrunk	O	O	B-Entity
progressively	O	O	B-Entity
from	O	O	O
2012	O	O	O
to	O	O	O
2014	O	O	O
and	O	O	O
the	O	O	O
third	O	O	O
was	O	O	O
split	O	O	B-Entity
into	O	O	O
two	O	O	O
smaller	O	O	O
clusters	O	O	O
in	O	O	O
2013	O	O	O
and	O	O	O
2014	O	O	O
.	O	O	O

The	O	O	O
decline	O	O	B-Entity
of	O	O	O
malaria	O	O	B-Entity
burden	O	O	B-Entity
can	O	O	O
be	O	O	O
attributed	O	O	O
to	O	O	O
intensive	O	O	B-Entity
malaria	O	O	B-Entity
control	O	O	I-Entity
activities	O	O	I-Entity
implemented	O	O	B-Entity
in	O	O	O
the	O	O	O
areas	O	O	B-Entity
:	O	O	O
distribution	O	O	B-Entity
of	O	O	O
a	O	O	O
long-lasting	O	O	B-Entity
insecticidal	O	O	B-Entity
net	O	O	I-Entity
per	O	O	O
person	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
diagnosis	O	O	I-Entity
and	O	O	O
prompt	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

Dihydro-artemisinin	O	O	B-Entity
piperaquine	O	O	B-Entity
was	O	O	O
the	O	O	O
only	O	O	O
first-line	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
all	O	O	O
malaria	O	O	B-Entity
cases	O	O	B-Entity
.	O	O	O

No	O	O	O
radical	O	O	B-Entity
treatment	O	O	B-Entity
with	O	O	O
primaquine	O	O	B-Entity
was	O	O	O
provided	O	O	O
for	O	O	O
Plasmodium	O	O	B-Entity
vivax	O	O	I-Entity
cases	O	O	B-Entity
,	O	O	O
which	O	O	O
could	O	O	O
explain	O	O	O
the	O	O	O
slow	O	O	B-Entity
decrease	O	O	B-Entity
of	O	O	O
P.	O	O	B-Entity
vivax	O	O	I-Entity
due	O	O	O
to	O	O	O
relapses	O	O	B-Entity
.	O	O	O

To	O	O	O
achieve	O	O	B-Entity
malaria	O	O	B-Entity
elimination	O	O	B-Entity
by	O	O	O
2025	O	O	O
,	O	O	O
priority	O	O	B-Entity
should	O	O	O
be	O	O	O
given	O	O	O
to	O	O	O
the	O	O	O
control	O	O	O
of	O	O	O
stable	O	O	B-Entity
malaria	O	O	B-Entity
clusters	O	O	I-Entity
appearing	O	O	O
over	O	O	O
time	O	O	O
.	O	O	O

-DOCSTART- (28266114)

Interaction	O	O	B-Entity
of	O	O	I-Entity
lifestyle	O	O	I-Entity
,	O	O	O
behaviour	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
diseases	O	O	I-Entity
with	O	O	O
dental	O	O	B-Entity
caries	O	O	B-Entity
and	O	O	O
periodontal	O	O	B-Entity
diseases	O	O	I-Entity
:	O	O	O
consensus	O	O	B-Entity
report	O	O	I-Entity
of	O	O	I-Entity
group	O	O	I-Entity
2	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
joint	O	O	I-Entity
EFP/ORCA	O	O	I-Entity
workshop	O	O	I-Entity
on	O	O	O
the	O	O	O
boundaries	O	O	O
between	O	O	O
caries	O	O	O
and	O	O	O
periodontal	O	O	O
diseases	O	O	O

Periodontal	O	O	B-Entity
diseases	O	O	I-Entity
and	O	O	O
dental	O	O	B-Entity
caries	O	O	I-Entity
are	O	O	O
the	O	O	O
most	O	O	O
common	O	O	B-Entity
diseases	O	O	I-Entity
of	O	O	O
humans	O	O	O
and	O	O	O
the	O	O	O
main	O	O	O
cause	O	O	O
of	O	O	O
tooth	O	O	B-Entity
loss	O	O	I-Entity
.	O	O	O

Both	O	O	O
diseases	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
nutritional	O	O	B-Entity
compromise	O	O	I-Entity
and	O	O	O
negative	O	O	O
impacts	O	O	O
upon	O	O	O
self-esteem	O	O	B-Entity
and	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

As	O	O	O
complex	O	O	B-Entity
chronic	O	O	I-Entity
diseases	O	O	I-Entity
,	O	O	O
they	O	O	O
share	O	O	O
common	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
a	O	O	O
requirement	O	O	O
for	O	O	O
a	O	O	O
pathogenic	O	O	B-Entity
plaque	O	O	I-Entity
biofilm	O	O	I-Entity
,	O	O	O
yet	O	O	O
they	O	O	O
exhibit	O	O	O
distinct	O	O	B-Entity
pathophysiologies	O	O	I-Entity
.	O	O	O

Multiple	O	O	B-Entity
exposures	O	O	I-Entity
contribute	O	O	O
to	O	O	O
their	O	O	O
causal	O	O	O
pathways	O	O	O
,	O	O	O
and	O	O	O
susceptibility	O	O	B-Entity
involves	O	O	I-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
that	O	O	O
are	O	O	O
inherited	O	O	B-Entity
(	O	O	O
e.g.	O	O	O
genetic	O	O	B-Entity
variants	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
those	O	O	O
that	O	O	O
are	O	O	O
acquired	O	O	O
(	O	O	O
e.g.	O	O	O
socio-economic	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
biofilm	O	O	B-Entity
load	O	O	O
or	O	O	O
composition	O	O	O
,	O	O	O
smoking	O	O	B-Entity
,	O	O	O
carbohydrate	O	O	B-Entity
intake	O	O	I-Entity
)	O	O	O
.	O	O	O

Identification	O	O	O
of	O	O	O
these	O	O	O
factors	O	O	O
is	O	O	O
crucial	O	O	O
in	O	O	O
the	O	O	O
prevention	O	O	B-Entity
of	O	O	I-Entity
both	O	O	I-Entity
diseases	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
their	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

To	O	O	O
systematically	O	O	O
appraise	O	O	O
the	O	O	O
scientific	O	O	B-Entity
literature	O	O	I-Entity
to	O	O	O
identify	O	O	O
potential	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
for	O	O	O
caries	O	O	B-Entity
and	O	O	O
periodontal	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

One	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
(	O	O	O
genetic	O	O	B-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
)	O	O	O
,	O	O	O
one	O	O	O
narrative	O	O	B-Entity
review	O	O	I-Entity
(	O	O	O
role	O	O	B-Entity
of	O	O	I-Entity
diet	O	O	I-Entity
and	O	O	I-Entity
nutrition	O	O	I-Entity
)	O	O	O
and	O	O	O
reference	O	O	B-Entity
documentation	O	O	I-Entity
for	O	O	O
modifiable	O	O	B-Entity
acquired	O	O	I-Entity
risk	O	O	I-Entity
factors	O	O	I-Entity
common	O	O	O
to	O	O	O
both	O	O	O
disease	O	O	O
groups	O	O	O
,	O	O	O
formed	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
the	O	O	O
report	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
moderately	O	O	O
strong	O	O	O
evidence	O	O	O
for	O	O	O
a	O	O	O
genetic	O	O	B-Entity
contribution	O	O	I-Entity
to	O	O	O
periodontal	O	O	B-Entity
diseases	O	O	I-Entity
and	O	O	O
caries	O	O	B-Entity
susceptibility	O	O	I-Entity
,	O	O	O
with	O	O	O
an	O	O	O
attributable	O	O	B-Entity
risk	O	O	I-Entity
estimated	O	O	O
to	O	O	O
be	O	O	O
up	O	O	O
to	O	O	O
50	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
genetics	O	O	B-Entity
literature	O	O	I-Entity
for	O	O	O
periodontal	O	O	B-Entity
disease	O	O	I-Entity
is	O	O	O
more	O	O	O
substantial	O	O	O
than	O	O	O
for	O	O	O
caries	O	O	B-Entity
and	O	O	O
genes	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
chronic	O	O	B-Entity
periodontitis	O	O	I-Entity
are	O	O	O
the	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
receptor	O	O	I-Entity
(	O	O	O
VDR	O	O	B-Entity
)	O	O	O
,	O	O	O
Fc	O	O	B-Entity
gamma	O	O	I-Entity
receptor	O	O	I-Entity
IIA	O	O	I-Entity
(	O	O	O
Fc-γRIIA	O	O	B-Entity
)	O	O	O
and	O	O	O
Interleukin	O	O	B-Entity
10	O	O	I-Entity
(	O	O	I-Entity
IL10	O	O	B-Entity
)	O	O	I-Entity
genes	O	O	I-Entity
.	O	O	O

For	O	O	O
caries	O	O	B-Entity
,	O	O	O
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
enamel	O	O	B-Entity
formation	O	O	I-Entity
(	O	O	O
AMELX	O	O	B-Entity
,	O	O	O
AMBN	O	O	B-Entity
,	O	O	O
ENAM	O	O	B-Entity
,	O	O	O
TUFT	O	O	B-Entity
,	O	O	O
MMP20	O	O	B-Entity
,	O	O	O
and	O	O	O
KLK4	O	O	B-Entity
)	O	O	O
,	O	O	O
salivary	O	O	B-Entity
characteristics	O	O	I-Entity
(	O	O	O
AQP5	O	O	B-Entity
)	O	O	O
,	O	O	O
immune	O	O	B-Entity
regulation	O	O	I-Entity
and	O	O	O
dietary	O	O	B-Entity
preferences	O	O	I-Entity
had	O	O	O
the	O	O	O
largest	O	O	B-Entity
impact	O	O	I-Entity
.	O	O	O

No	O	O	O
common	O	O	O
genetic	O	O	O
variants	O	O	O
were	O	O	O
found	O	O	O
.	O	O	O

Fermentable	O	O	B-Entity
carbohydrates	O	O	I-Entity
(	O	O	O
sugars	O	O	B-Entity
and	O	O	I-Entity
starches	O	O	I-Entity
)	O	O	O
were	O	O	O
the	O	O	O
most	O	O	O
relevant	O	O	O
common	O	O	O
dietary	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	I-Entity
both	O	O	I-Entity
diseases	O	O	I-Entity
,	O	O	O
but	O	O	O
associated	O	O	O
mechanisms	O	O	O
differed	O	O	O
.	O	O	O

In	O	O	O
caries	O	O	B-Entity
,	O	O	O
the	O	O	O
fermentation	O	O	B-Entity
process	O	O	I-Entity
leads	O	O	O
to	O	O	O
acid	O	O	O
production	O	O	O
and	O	O	O
the	O	O	O
generation	O	O	B-Entity
of	O	O	I-Entity
biofilm	O	O	I-Entity
components	O	O	O
such	O	O	O
as	O	O	O
Glucans	O	O	B-Entity
.	O	O	O

In	O	O	O
periodontitis	O	O	B-Entity
,	O	O	O
glycaemia	O	O	B-Entity
drives	O	O	I-Entity
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
advanced	O	O	B-Entity
glycation	O	O	I-Entity
end-products	O	O	O
may	O	O	O
also	O	O	O
trigger	O	O	O
a	O	O	O
hyper	O	O	B-Entity
inflammatory	O	O	I-Entity
state	O	O	O
.	O	O	O

Micronutrient	O	O	B-Entity
deficiencies	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
for	O	O	O
vitamin	O	O	B-Entity
C	O	O	I-Entity
,	O	O	O
vitamin	O	O	B-Entity
D	O	O	I-Entity
or	O	O	O
vitamin	O	O	B-Entity
B12	O	O	I-Entity
,	O	O	O
may	O	O	O
be	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
onset	O	O	B-Entity
and	O	O	O
progression	O	O	B-Entity
of	O	O	I-Entity
both	O	O	I-Entity
diseases	O	O	I-Entity
.	O	O	O

Functional	O	O	B-Entity
foods	O	O	I-Entity
or	O	O	O
probiotics	O	O	B-Entity
could	O	O	O
be	O	O	O
helpful	O	O	O
in	O	O	O
caries	O	O	B-Entity
prevention	O	O	I-Entity
and	O	O	O
periodontal	O	O	B-Entity
disease	O	O	I-Entity
management	O	O	B-Entity
,	O	O	O
although	O	O	O
evidence	O	O	O
is	O	O	O
limited	O	O	O
and	O	O	O
biological	O	O	B-Entity
mechanisms	O	O	I-Entity
not	O	O	O
fully	O	O	O
elucidated	O	O	O
.	O	O	O

Hyposalivation	O	O	B-Entity
,	O	O	O
rheumatoid	O	O	B-Entity
arthritis	O	O	I-Entity
,	O	O	O
smoking/tobacco	O	O	B-Entity
use	O	O	I-Entity
,	O	O	O
undiagnosed	O	O	B-Entity
or	O	O	O
sub-optimally	O	O	B-Entity
controlled	O	O	I-Entity
diabetes	O	O	B-Entity
and	O	O	O
obesity	O	O	B-Entity
are	O	O	O
common	O	O	O
acquired	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
both	O	O	O
caries	O	O	B-Entity
and	O	O	O
periodontal	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

-DOCSTART- (28266884)

Intestinal	O	O	B-Entity
micropatches	O	O	B-Entity
for	O	O	O
oral	O	O	B-Entity
insulin	O	O	O
delivery	O	O	O

Diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
has	O	O	O
become	O	O	O
a	O	O	O
major	O	O	O
public	O	O	B-Entity
health	O	O	I-Entity
issue	O	O	I-Entity
that	O	O	O
has	O	O	O
almost	O	O	O
reached	O	O	O
epidemic	O	O	B-Entity
proportions	O	O	I-Entity
worldwide	O	O	O
.	O	O	O

Injectable	O	O	B-Entity
insulin	O	O	I-Entity
has	O	O	O
been	O	O	O
typically	O	O	O
utilized	O	O	O
for	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
this	O	O	O
chronic	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
patient	O	O	I-Entity
compliance	O	O	I-Entity
with	O	O	O
injectable	O	O	B-Entity
formulations	O	O	B-Entity
has	O	O	O
spurred	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
oral	O	O	B-Entity
insulin	O	O	B-Entity
formulations	O	O	O
,	O	O	O
which	O	O	O
although	O	O	O
appealing	O	O	O
,	O	O	O
face	O	O	O
several	O	O	O
delivery	O	O	B-Entity
challenges	O	O	B-Entity
.	O	O	O

We	O	O	O
have	O	O	O
developed	O	O	O
novel	O	O	O
mucoadhesive	O	O	B-Entity
intestinal	O	O	B-Entity
patches	O	O	B-Entity
,	O	O	O
several	O	O	O
hundred	O	O	O
micrometers	O	O	B-Entity
in	O	O	O
dimension	O	O	B-Entity
(	O	O	O
micropatches	O	O	B-Entity
)	O	O	O
that	O	O	O
address	O	O	O
the	O	O	O
challenges	O	O	B-Entity
of	O	O	O
oral	O	O	B-Entity
insulin	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

The	O	O	O
micropatches	O	O	B-Entity
adhere	O	O	B-Entity
to	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
mucosa	O	O	I-Entity
,	O	O	O
release	O	O	O
their	O	O	O
drug	O	O	B-Entity
load	O	O	O
rapidly	O	O	B-Entity
within	O	O	O
30	O	O	O
min	O	O	O
and	O	O	O
are	O	O	O
effective	O	O	B-Entity
in	O	O	O
lowering	O	O	B-Entity
blood	O	O	I-Entity
glucose	O	O	I-Entity
levels	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

When	O	O	O
insulin	O	O	B-Entity
-loaded	O	O	O
micropatches	O	O	B-Entity
were	O	O	O
administered	O	O	B-Entity
with	O	O	O
a	O	O	O
permeation	O	O	B-Entity
enhancer	O	O	I-Entity
and	O	O	O
protease	O	O	B-Entity
inhibitor	O	O	I-Entity
,	O	O	O
a	O	O	O
peak	O	O	B-Entity
efficacy	O	O	B-Entity
of	O	O	O
34	O	O	O
%	O	O	O
drop	O	O	B-Entity
in	O	O	I-Entity
blood	O	O	I-Entity
glucose	O	O	I-Entity
levels	O	O	I-Entity
was	O	O	O
observed	O	O	O
within	O	O	O
3	O	O	O
h.	O	O	O
Efficacy	O	O	B-Entity
further	O	O	O
improved	O	O	O
to	O	O	O
41	O	O	O
%	O	O	O
when	O	O	O
micropatches	O	O	O
were	O	O	O
administered	O	O	O
in	O	O	O
multiple	O	O	B-Entity
doses	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
design	O	O	O
of	O	O	O
micropatches	O	O	B-Entity
as	O	O	O
an	O	O	O
oral	O	O	B-Entity
insulin	O	O	B-Entity
formulation	O	O	B-Entity
and	O	O	O
report	O	O	O
their	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
efficacy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28269523)

Hybrid	O	O	B-Entity
automata	O	O	I-Entity
models	O	O	I-Entity
of	O	O	O
cardiac	O	O	B-Entity
ventricular	O	O	I-Entity
electrophysiology	O	O	B-Entity
for	O	O	O
real-time	O	O	B-Entity
computational	O	O	O
applications	O	O	O

Virtual	O	O	O
heart	O	O	B-Entity
models	O	O	I-Entity
have	O	O	O
been	O	O	O
proposed	O	O	O
for	O	O	O
closed	O	O	B-Entity
loop	O	O	I-Entity
validation	O	O	B-Entity
of	O	O	O
safety	O	O	B-Entity
-	O	O	O
critical	O	O	B-Entity
embedded	O	O	O
medical	O	O	B-Entity
devices	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
pacemakers	O	O	B-Entity
.	O	O	O

These	O	O	O
models	O	O	B-Entity
must	O	O	O
react	O	O	O
in	O	O	O
real-time	O	O	B-Entity
to	O	O	O
off-the-shelf	O	O	O
medical	O	O	B-Entity
devices	O	O	I-Entity
.	O	O	O

Real-time	O	O	B-Entity
performance	O	O	B-Entity
can	O	O	O
be	O	O	O
obtained	O	O	B-Entity
by	O	O	O
implementing	O	O	O
models	O	O	B-Entity
in	O	O	O
computer	O	O	B-Entity
hardware	O	O	I-Entity
,	O	O	O
and	O	O	O
methods	O	O	B-Entity
of	O	O	O
compiling	O	O	O
classes	O	O	O
of	O	O	O
Hybrid	O	O	B-Entity
Automata	O	O	I-Entity
(	O	O	O
HA	O	O	B-Entity
)	O	O	O
onto	O	O	O
FPGA	O	O	B-Entity
have	O	O	O
been	O	O	O
developed	O	O	O
.	O	O	O

Models	O	O	B-Entity
of	O	O	O
ventricular	O	O	B-Entity
cardiac	O	O	I-Entity
cell	O	O	I-Entity
electrophysiology	O	O	B-Entity
have	O	O	O
been	O	O	O
described	O	O	B-Entity
using	O	O	O
HA	O	O	B-Entity
which	O	O	O
capture	O	O	B-Entity
the	O	O	O
complex	O	O	O
nonlinear	O	O	O
behavior	O	O	B-Entity
of	O	O	O
biological	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
many	O	O	O
models	O	O	B-Entity
that	O	O	O
have	O	O	O
been	O	O	O
used	O	O	O
for	O	O	O
closed-loop	O	O	B-Entity
validation	O	O	B-Entity
of	O	O	O
pacemakers	O	O	B-Entity
are	O	O	O
highly	O	O	O
abstract	O	O	B-Entity
and	O	O	O
do	O	O	O
not	O	O	O
capture	O	O	B-Entity
important	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
the	O	O	O
dynamic	O	O	B-Entity
rate	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

We	O	O	O
developed	O	O	O
a	O	O	O
new	O	O	O
HA	O	O	B-Entity
model	O	O	B-Entity
of	O	O	O
cardiac	O	O	B-Entity
cells	O	O	I-Entity
which	O	O	O
captures	O	O	B-Entity
dynamic	O	O	B-Entity
behavior	O	O	B-Entity
and	O	O	O
we	O	O	O
implemented	O	O	O
the	O	O	O
model	O	O	O
in	O	O	O
hardware	O	O	B-Entity
.	O	O	O

This	O	O	O
potentially	O	O	B-Entity
enables	O	O	O
modeling	O	O	B-Entity
the	O	O	O
heart	O	O	B-Entity
with	O	O	O
over	O	O	O
1	O	O	O
million	O	O	B-Entity
dynamic	O	O	B-Entity
cells	O	O	B-Entity
,	O	O	O
making	O	O	O
the	O	O	O
approach	O	O	O
ideal	O	O	B-Entity
for	O	O	O
closed	O	O	B-Entity
loop	O	O	I-Entity
testing	O	O	B-Entity
of	O	O	O
medical	O	O	B-Entity
devices	O	O	I-Entity
.	O	O	O

-DOCSTART- (28269731)

Comparison	O	O	B-Entity
of	O	O	O
pulse	O	O	B-Entity
wave	O	O	I-Entity
velocity	O	O	I-Entity
derived	O	O	O
from	O	O	O
accelerometer	O	O	B-Entity
and	O	O	O
reflective	O	O	B-Entity
photo-plethysmography	O	O	I-Entity
signals	O	O	I-Entity
placed	O	O	O
at	O	O	O
the	O	O	O
carotid	O	O	B-Entity
and	O	O	O
femoral	O	O	O
artery	O	O	O

Carotid	O	O	B-Entity
-	O	O	O
femoral	O	O	B-Entity
pulse	O	O	B-Entity
wave	O	O	I-Entity
velocity	O	O	I-Entity
is	O	O	O
an	O	O	O
established	O	O	B-Entity
measure	O	O	I-Entity
to	O	O	O
assess	O	O	B-Entity
cardiovascular	O	O	B-Entity
risk	O	O	I-Entity
and	O	O	O
an	O	O	O
interesting	O	O	O
surrogate	O	O	B-Entity
parameter	O	O	I-Entity
towards	O	O	O
non-invasive	O	O	B-Entity
continuous	O	O	I-Entity
blood	O	O	I-Entity
pressure	O	O	I-Entity
inference	O	O	I-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
progress	O	O	B-Entity
in	O	O	O
sensing	O	O	O
technologies	O	O	O
for	O	O	O
wearable	O	O	B-Entity
wrist	O	O	I-Entity
worn	O	O	I-Entity
sensors	O	O	I-Entity
,	O	O	O
there	O	O	O
are	O	O	O
low	O	O	O
cost	O	O	O
sensor	O	O	O
combinations	O	O	O
of	O	O	O
photo-plethysmography	O	O	B-Entity
and	O	O	O
high	O	O	B-Entity
fidelity	O	O	I-Entity
accelerometer	O	O	I-Entity
s	O	O	I-Entity
available	O	O	O
offering	O	O	O
access	O	O	O
to	O	O	O
pulse	O	O	B-Entity
information	O	O	I-Entity
from	O	O	O
larger	O	O	B-Entity
arteries	O	O	I-Entity
complemented	O	O	O
by	O	O	O
blood	O	O	B-Entity
volume	O	O	I-Entity
changes	O	O	O
in	O	O	O
the	O	O	O
superficial	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
we	O	O	O
compare	O	O	O
pulse	O	O	B-Entity
wave	O	O	I-Entity
velocities	O	O	I-Entity
derived	O	O	O
from	O	O	O
accelerometer	O	O	B-Entity
and	O	O	O
reflective	O	O	B-Entity
photo-plethysmography	O	O	I-Entity
signals	O	O	I-Entity
placed	O	O	O
at	O	O	O
the	O	O	O
carotid	O	O	B-Entity
and	O	O	O
femoral	O	O	B-Entity
artery	O	O	I-Entity
.	O	O	O

We	O	O	O
discuss	O	O	O
the	O	O	O
different	O	O	O
underlying	O	O	O
physiological	O	O	B-Entity
processes	O	O	I-Entity
for	O	O	O
the	O	O	O
two	O	O	O
sensing	O	O	B-Entity
principles	O	O	I-Entity
and	O	O	O
present	O	O	O
experimental	O	O	B-Entity
results	O	O	I-Entity
obtained	O	O	O
in	O	O	O
a	O	O	O
study	O	O	B-Entity
with	O	O	O
healthy	O	O	B-Entity
subjects	O	O	I-Entity
.	O	O	O

-DOCSTART- (28270328)

Constructive	O	O	B-Entity
and	O	O	I-Entity
Unproductive	O	O	I-Entity
Processing	O	O	I-Entity
of	O	O	O
Traumatic	O	O	B-Entity
Experiences	O	O	I-Entity
in	O	O	O
Trauma-Focused	O	O	B-Entity
Cognitive-Behavioral	O	O	I-Entity
Therapy	O	O	I-Entity
for	O	O	O
Youth	O	O	O

Although	O	O	O
there	O	O	O
is	O	O	O
substantial	O	O	O
evidence	O	O	B-Entity
to	O	O	O
support	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
cognitive-behavioral	O	O	B-Entity
treatments	O	O	B-Entity
(	O	O	O
CBT	O	O	B-Entity
)	O	O	O
for	O	O	O
posttraumatic	O	O	B-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
PTSD	O	O	B-Entity
)	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
some	O	O	O
debate	O	O	O
about	O	O	O
how	O	O	O
these	O	O	O
treatments	O	O	O
have	O	O	O
their	O	O	O
effects	O	O	O
.	O	O	O

Modern	O	O	O
learning	O	O	B-Entity
theory	O	O	I-Entity
and	O	O	O
cognitive	O	O	B-Entity
and	O	O	I-Entity
emotional	O	O	I-Entity
processing	O	O	I-Entity
theories	O	O	I-Entity
highlight	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
reducing	O	O	O
avoidance	O	O	B-Entity
,	O	O	O
facilitating	O	O	O
the	O	O	O
constructive	O	O	B-Entity
processing	O	O	I-Entity
of	O	O	I-Entity
feared	O	O	I-Entity
experiences	O	O	I-Entity
,	O	O	O
and	O	O	O
strengthening	O	O	O
new	O	O	O
inhibitory	O	O	B-Entity
learning	O	O	I-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
variables	O	O	O
thought	O	O	O
to	O	O	O
be	O	O	O
associated	O	O	O
with	O	O	O
unproductive	O	O	B-Entity
and	O	O	I-Entity
constructive	O	O	I-Entity
processing	O	O	I-Entity
of	O	O	O
traumatic	O	O	B-Entity
experiences	O	O	I-Entity
in	O	O	O
a	O	O	O
sample	O	O	O
of	O	O	O
81	O	O	O
youth	O	O	O
with	O	O	O
elevated	O	O	O
PTSD	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
who	O	O	O
received	O	O	O
Trauma-Focused	O	O	B-Entity
Cognitive	O	O	I-Entity
Behavioral	O	O	I-Entity
Therapy	O	O	I-Entity
(	O	O	O
TF-CBT	O	O	B-Entity
)	O	O	O
for	O	O	O
abuse	O	O	B-Entity
or	O	O	O
traumatic	O	O	O
interpersonal	O	O	B-Entity
loss	O	O	I-Entity
.	O	O	O

Sessions	O	O	B-Entity
during	O	O	O
the	O	O	O
trauma	O	O	B-Entity
narrative	O	O	I-Entity
phase	O	O	I-Entity
of	O	O	O
TF-CBT	O	O	B-Entity
were	O	O	O
coded	O	O	O
for	O	O	O
indicators	O	O	O
of	O	O	O
unproductive	O	O	B-Entity
processing	O	O	I-Entity
(	O	O	O
overgeneralization	O	O	B-Entity
,	O	O	O
rumination	O	O	B-Entity
,	O	O	O
avoidance	O	O	B-Entity
)	O	O	O
and	O	O	O
constructive	O	O	B-Entity
processing	O	O	I-Entity
(	O	O	O
decentering	O	O	B-Entity
,	O	O	O
accommodation	O	O	B-Entity
of	O	O	I-Entity
corrective	O	O	I-Entity
information	O	O	I-Entity
)	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
levels	O	O	B-Entity
of	O	O	I-Entity
negative	O	O	I-Entity
emotion	O	O	I-Entity
.	O	O	O

In	O	O	O
previous	O	O	B-Entity
analyses	O	O	O
of	O	O	O
this	O	O	O
trial	O	O	O
(	O	O	O
Ready	O	O	O
et	O	O	O
al.	O	O	O
,	O	O	O
2015	O	O	O
)	O	O	O
,	O	O	O
more	O	O	O
overgeneralization	O	O	B-Entity
during	O	O	O
the	O	O	O
narrative	O	O	B-Entity
phase	O	O	I-Entity
predicted	O	O	O
less	O	O	O
improvement	O	O	O
in	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
at	O	O	O
posttreatment	O	O	B-Entity
and	O	O	O
a	O	O	O
worsening	O	O	B-Entity
of	O	O	O
externalizing	O	O	B-Entity
symptoms	O	O	I-Entity
over	O	O	O
the	O	O	O
12-month	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
more	O	O	O
accommodation	O	O	B-Entity
predicted	O	O	I-Entity
improvement	O	O	I-Entity
in	O	O	O
internalizing	O	O	B-Entity
symptoms	O	O	I-Entity
and	O	O	O
also	O	O	O
moderated	O	O	B-Entity
the	O	O	O
negative	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
overgeneralization	O	O	B-Entity
on	O	O	O
internalizing	O	O	B-Entity
and	O	O	I-Entity
externalizing	O	O	I-Entity
symptoms	O	O	I-Entity
.	O	O	O

The	O	O	O
current	O	O	O
study	O	O	O
examined	O	O	O
correlates	O	O	O
of	O	O	O
overgeneralization	O	O	B-Entity
and	O	O	O
accommodation	O	O	B-Entity
.	O	O	O

Overgeneralization	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
more	O	O	O
rumination	O	O	B-Entity
,	O	O	O
less	O	O	O
decentering	O	O	O
,	O	O	O
and	O	O	O
more	O	O	O
negative	O	O	B-Entity
emotion	O	O	I-Entity
,	O	O	O
suggesting	O	O	B-Entity
immersion	O	O	B-Entity
in	O	O	O
trauma	O	O	B-Entity
-related	O	O	O
material	O	O	O
.	O	O	O

Accommodation	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
less	O	O	O
avoidance	O	O	B-Entity
and	O	O	O
more	O	O	O
decentering	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
a	O	O	O
healthy	O	O	B-Entity
distance	O	O	O
from	O	O	O
trauma	O	O	B-Entity
-related	O	O	O
material	O	O	O
that	O	O	O
might	O	O	O
allow	O	O	O
for	O	O	O
processing	O	O	O
and	O	O	O
cognitive	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

Decentering	O	O	O
also	O	O	O
predicted	O	O	B-Entity
improvement	O	O	B-Entity
in	O	O	O
externalizing	O	O	B-Entity
symptoms	O	O	I-Entity
at	O	O	O
posttreatment	O	O	B-Entity
.	O	O	O

Rumination	O	O	B-Entity
and	O	O	O
avoidance	O	O	B-Entity
showed	O	O	O
important	O	O	O
associations	O	O	O
with	O	O	O
overgeneralization	O	O	B-Entity
and	O	O	O
accommodation	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
but	O	O	O
did	O	O	O
not	O	O	O
predict	O	O	O
treatment	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
identifies	O	O	O
correlates	O	O	O
of	O	O	O
overgeneralization	O	O	B-Entity
and	O	O	O
accommodation	O	O	B-Entity
that	O	O	O
might	O	O	O
shed	O	O	O
light	O	O	O
on	O	O	O
how	O	O	O
these	O	O	O
variables	O	O	O
relate	O	O	O
to	O	O	O
unproductive	O	O	B-Entity
and	O	O	I-Entity
constructive	O	O	I-Entity
processing	O	O	I-Entity
of	O	O	O
traumatic	O	O	B-Entity
experiences	O	O	I-Entity
.	O	O	O

-DOCSTART- (28273985)

Giant	O	O	B-Entity
Antrochoanal	O	O	B-Entity
Polyp	O	O	I-Entity
-A	O	O	O
Rare	O	O	B-Entity
Presentation	O	O	O

Antrochoanal	O	O	B-Entity
polyp	O	O	I-Entity
(	O	O	O
ACP	O	O	B-Entity
)	O	O	O
,	O	O	O
also	O	O	O
called	O	O	O
as	O	O	O
Killian	O	O	B-Entity
polyp	O	O	I-Entity
,	O	O	O
is	O	O	O
an	O	O	O
infrequent	O	O	O
,	O	O	O
benign	O	O	B-Entity
lesion	O	O	I-Entity
of	O	O	O
maxillary	O	O	B-Entity
origin	O	O	O
in	O	O	O
non-atopic	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
antrochoanal	O	O	B-Entity
polyp	O	O	I-Entity
is	O	O	O
shaped	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
anatomical	O	O	B-Entity
constraints	O	O	O
of	O	O	O
the	O	O	O
lateral	O	O	B-Entity
nasal	O	O	I-Entity
wall	O	O	I-Entity
,	O	O	O
particularly	O	O	O
the	O	O	O
middle	O	O	B-Entity
meatus	O	O	I-Entity
and	O	O	O
antrum	O	O	B-Entity
,	O	O	O
resembling	O	O	O
typically	O	O	O
a	O	O	O
dumbbell	O	O	B-Entity
.	O	O	O

Here	O	O	O
presenting	O	O	O
a	O	O	O
common	O	O	O
problem	O	O	B-Entity
with	O	O	O
unusual	O	O	B-Entity
presentation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28274612)

Effects	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
on	O	O	O
IL-33	O	O	B-Entity
/	O	O	O
ST2	O	O	B-Entity
system	O	O	B-Entity
in	O	O	O
heart	O	O	B-Entity
,	O	O	O
adipose	O	O	B-Entity
tissue	O	O	I-Entity
and	O	O	O
liver	O	O	B-Entity
:	O	O	O
study	O	O	B-Entity
in	O	O	O
the	O	O	O
experimental	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
Zucker	O	O	O
rats	O	O	O

Suppression	O	O	B-Entity
of	O	O	I-Entity
tumorigenicity	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
ST2	O	O	B-Entity
)	O	O	O
mediates	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
Interleukin-33	O	O	B-Entity
(	O	O	O
IL-33	O	O	B-Entity
)	O	O	O
.	O	O	O

Few	O	O	O
data	O	O	O
are	O	O	O
reported	O	O	O
on	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
IL-33	O	O	B-Entity
/	O	O	O
ST2	O	O	B-Entity
and	O	O	O
obesity	O	O	B-Entity
.	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	O
effects	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
on	O	O	O
IL-33	O	O	B-Entity
/	O	O	O
ST2	O	O	B-Entity
system	O	O	B-Entity
in	O	O	O
heart	O	O	B-Entity
,	O	O	O
adipose	O	O	B-Entity
tissue	O	O	I-Entity
and	O	O	O
liver	O	O	B-Entity
in	O	O	O
a	O	O	O
rodent	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
obesity	O	O	O
.	O	O	O

The	O	O	O
relationship	O	O	B-Entity
of	O	O	O
cardiac	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
IL-33	O	O	B-Entity
/	O	O	O
ST2	O	O	B-Entity
system	O	O	B-Entity
with	O	O	O
natriuretic	O	O	B-Entity
peptides	O	O	I-Entity
(	O	O	O
NPs	O	O	B-Entity
)	O	O	O
system	O	O	O
and	O	O	O
inflammatory	O	O	B-Entity
mediators	O	O	I-Entity
was	O	O	O
also	O	O	O
studied	O	O	O
.	O	O	O

mRNA	O	O	B-Entity
expression	O	O	I-Entity
of	O	O	O
IL-33	O	O	B-Entity
/	O	O	O
ST2	O	O	B-Entity
system	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
in	O	O	O
cardiac	O	O	B-Entity
,	O	O	O
adipose	O	O	B-Entity
and	O	O	O
hepatic	O	O	B-Entity
biopsies	O	O	I-Entity
from	O	O	O
obese	O	O	B-Entity
Zucker	O	O	I-Entity
rats	O	O	I-Entity
(	O	O	O
O	O	O	B-Entity
)	O	O	O
and	O	O	O
controls	O	O	B-Entity
(	O	O	O
CO	O	O	B-Entity
)	O	O	O
.	O	O	O

Expression	O	O	B-Entity
levels	O	O	O
of	O	O	O
sST2	O	O	B-Entity
was	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
O	O	O	B-Entity
rats	O	O	I-Entity
compared	O	O	O
with	O	O	O
CO	O	O	B-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
in	O	O	O
all	O	O	O
tissues	O	O	B-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
the	O	O	O
mRNA	O	O	B-Entity
levels	O	O	O
of	O	O	O
IL-33	O	O	B-Entity
decreased	O	O	O
significant	O	O	O
in	O	O	O
fat	O	O	O
of	O	O	O
O	O	O	B-Entity
respect	O	O	O
to	O	O	O
CO	O	O	B-Entity
,	O	O	O
while	O	O	O
,	O	O	O
expression	O	O	B-Entity
levels	O	O	O
of	O	O	O
ST2L	O	O	B-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	O
in	O	O	O
liver	O	O	B-Entity
of	O	O	O
CO	O	O	O
than	O	O	O
in	O	O	O
O.	O	O	O
A	O	O	O
strong	O	O	O
relationship	O	O	B-Entity
of	O	O	O
IL-33	O	O	O
/	O	O	O
ST2	O	O	B-Entity
with	O	O	O
NPs	O	O	B-Entity
and	O	O	O
classical	O	O	O
inflammatory	O	O	B-Entity
mediators	O	O	I-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
cardiac	O	O	B-Entity
tissue	O	O	I-Entity
.	O	O	O

Expression	O	O	B-Entity
of	O	O	O
sST2	O	O	B-Entity
in	O	O	O
cardiac	O	O	B-Entity
,	O	O	O
adipose	O	O	B-Entity
and	O	O	O
liver	O	O	B-Entity
tissue	O	O	I-Entity
decreased	O	O	O
in	O	O	O
O	O	O	B-Entity
compared	O	O	O
with	O	O	O
controls	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
an	O	O	O
involvement	O	O	O
for	O	O	O
IL-33	O	O	B-Entity
/	O	O	O
ST2	O	O	B-Entity
system	O	O	B-Entity
in	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	I-Entity
of	O	O	O
obesity	O	O	B-Entity
.	O	O	O

The	O	O	O
strong	O	O	O
relationships	O	O	B-Entity
with	O	O	O
NP	O	O	B-Entity
systems	O	O	B-Entity
and	O	O	O
inflammatory	O	O	B-Entity
mediators	O	O	I-Entity
could	O	O	O
suggest	O	O	O
an	O	O	O
involvement	O	O	O
for	O	O	O
IL-33	O	O	B-Entity
/	O	O	O
ST2	O	O	B-Entity
in	O	O	O
molecular	O	O	B-Entity
pathways	O	O	I-Entity
leading	O	O	O
to	O	O	O
cardiac	O	O	B-Entity
dysfunction	O	O	I-Entity
and	O	O	O
inflammation	O	O	B-Entity
associated	O	O	O
with	O	O	O
obesity	O	O	B-Entity
.	O	O	O

-DOCSTART- (28277316)

CXCL14	O	O	B-Entity
-	O	O	O
CXCR4	O	O	B-Entity
and	O	O	O
CXCL12	O	O	B-Entity
-	O	O	O
CXCR4	O	O	O
Axes	O	O	O
May	O	O	O
Play	O	O	O
Important	O	O	O
Roles	O	O	O
in	O	O	O
the	O	O	O
Unique	O	O	O
Invasion	O	O	B-Entity
Process	O	O	B-Entity
of	O	O	O
Endometrioid	O	O	B-Entity
Carcinoma	O	O	I-Entity
With	O	O	O
MELF-Pattern	O	O	B-Entity
Myoinvasion	O	O	O

The	O	O	O
term	O	O	O
"	O	O	O
MELF-pattern	O	O	B-Entity
myometrial	O	O	B-Entity
invasion	O	O	B-Entity
"	O	O	O
(	O	O	O
MELF	O	O	B-Entity
pattern	O	O	I-Entity
)	O	O	O
denotes	O	O	O
an	O	O	O
unusual	O	O	B-Entity
morphology	O	O	B-Entity
of	O	O	O
myometrial	O	O	O
invasion	O	O	O
in	O	O	O
endometrioid	O	O	B-Entity
carcinomas	O	O	I-Entity
,	O	O	O
and	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
frequent	O	O	O
lymphovascular	O	O	B-Entity
invasion	O	O	I-Entity
and	O	O	O
lymph	O	O	B-Entity
node	O	O	I-Entity
metastasis	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
tumor	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
directly	O	O	O
collected	O	O	B-Entity
from	O	O	O
a	O	O	O
MELF	O	O	B-Entity
pattern	O	O	I-Entity
site	O	O	O
,	O	O	O
using	O	O	O
laser	O	O	B-Entity
microdissection	O	O	I-Entity
.	O	O	O

Comprehensive	O	O	B-Entity
microarray	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
genes	O	O	B-Entity
was	O	O	O
conducted	O	O	O
,	O	O	O
and	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
results	O	O	O
,	O	O	O
expression	O	O	B-Entity
of	O	O	O
a	O	O	O
metastasis	O	O	B-Entity
progression	O	O	I-Entity
gene	O	O	I-Entity
,	O	O	I-Entity
CXCR4	O	O	I-Entity
,	O	O	O
and	O	O	O
its	O	O	O
ligands	O	O	B-Entity
CXCL14	O	O	B-Entity
and	O	O	O
CXCL12	O	O	B-Entity
,	O	O	O
was	O	O	O
further	O	O	O
investigated	O	O	B-Entity
.	O	O	O

In	O	O	B-Entity
vitro	O	O	I-Entity
studies	O	O	I-Entity
of	O	O	O
endometrioid	O	O	B-Entity
carcinoma	O	O	I-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
revealed	O	O	O
elevated	O	O	B-Entity
invasion	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	O
a	O	O	O
manner	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
CXCL14	O	O	B-Entity
-	O	O	O
CXCR4	O	O	B-Entity
or	O	O	O
CXCL12	O	O	B-Entity
-	O	O	O
CXCR4	O	O	O
axis	O	O	O
.	O	O	O

Immunohistochemical	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
93	O	O	O
(	O	O	O
MELF	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
46	O	O	O
;	O	O	O
non-MELF	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
47	O	O	O
)	O	O	O
cases	O	O	O
illustrated	O	O	O
CXCR4	O	O	B-Entity
was	O	O	O
expressed	O	O	B-Entity
in	O	O	O
all	O	O	O
endometrioid	O	O	B-Entity
carcinomas	O	O	I-Entity
,	O	O	O
while	O	O	O
based	O	O	O
on	O	O	O
CXCL14	O	O	B-Entity
and	O	O	O
CXCL12	O	O	B-Entity
expression	O	O	B-Entity
score	O	O	B-Entity
,	O	O	O
high	O	O	B-Entity
proportions	O	O	I-Entity
of	O	O	O
cells	O	O	B-Entity
were	O	O	O
positive	O	O	B-Entity
at	O	O	O
the	O	O	O
sites	O	O	B-Entity
of	O	O	O
the	O	O	O
MELF	O	O	B-Entity
pattern	O	O	I-Entity
(	O	O	O
P<0.01	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
in	O	O	O
progression-free	O	O	B-Entity
survival	O	O	I-Entity
or	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
between	O	O	O
MELF	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
non-MELF	O	O	B-Entity
group	O	O	I-Entity
by	O	O	O
Kaplan-Meier	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
suggest	O	O	O
a	O	O	O
possibility	O	O	O
that	O	O	O
cells	O	O	B-Entity
at	O	O	O
the	O	O	O
sites	O	O	B-Entity
of	O	O	O
MELF	O	O	B-Entity
pattern	O	O	I-Entity
had	O	O	O
acquired	O	O	O
increased	O	O	B-Entity
invasiveness	O	O	B-Entity
through	O	O	O
the	O	O	O
function	O	O	B-Entity
of	O	O	O
the	O	O	O
CXCL14	O	O	B-Entity
-	O	O	O
CXCR4	O	O	B-Entity
and	O	O	O
CXCL12	O	O	B-Entity
-	O	O	O
CXCR4	O	O	O
axes	O	O	O
.	O	O	O

-DOCSTART- (28277879)

Crude	O	O	B-Entity
4-methylcyclohexanemethanol	O	O	B-Entity
(	O	O	O
MCHM	O	O	B-Entity
)	O	O	O
did	O	O	O
not	O	O	O
cause	O	O	B-Entity
skin	O	O	B-Entity
irritation	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
in	O	O	O
48-h	O	O	B-Entity
patch	O	O	O
test	O	O	O

Crude	O	O	B-Entity
4-methylcyclohexanemethanol	O	O	B-Entity
(	O	O	O
MCHM	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
industrial	O	O	B-Entity
chemical	O	O	B-Entity
used	O	O	O
to	O	O	O
wash	O	O	B-Entity
and	O	O	O
clean	O	O	B-Entity
coal	O	O	B-Entity
.	O	O	O

On	O	O	O
January	O	O	O
9th	O	O	O
,	O	O	O
2014	O	O	O
approximately	O	O	O
10,000	O	O	B-Entity
gallons	O	O	I-Entity
of	O	O	O
a	O	O	O
mixture	O	O	B-Entity
containing	O	O	O
crude	O	O	B-Entity
MCHM	O	O	B-Entity
were	O	O	O
released	O	O	O
into	O	O	O
the	O	O	O
Elk	O	O	B-Entity
River	O	O	I-Entity
near	O	O	O
Charleston	O	O	B-Entity
,	O	O	O
West	O	O	B-Entity
Virginia	O	O	I-Entity
,	O	O	O
contaminating	O	O	B-Entity
the	O	O	O
local	O	O	B-Entity
water	O	O	B-Entity
supply	O	O	I-Entity
.	O	O	O

Following	O	O	O
the	O	O	O
spill	O	O	B-Entity
,	O	O	O
residents	O	O	B-Entity
reported	O	O	B-Entity
numerous	O	O	B-Entity
health	O	O	B-Entity
complaints	O	O	I-Entity
,	O	O	O
and	O	O	O
sought	O	O	O
medical	O	O	B-Entity
attention	O	O	I-Entity
for	O	O	O
ailments	O	O	B-Entity
including	O	O	O
rashes	O	O	B-Entity
and	O	O	O
itching	O	O	B-Entity
.	O	O	O

The	O	O	O
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
complaints	O	O	B-Entity
and	O	O	O
the	O	O	O
spill	O	O	B-Entity
were	O	O	O
unknown	O	O	O
,	O	O	O
as	O	O	O
such	O	O	O
symptoms	O	O	B-Entity
are	O	O	O
reported	O	O	B-Entity
frequently	O	O	B-Entity
in	O	O	O
the	O	O	O
background	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
the	O	O	O
primary	O	O	B-Entity
irritation	O	O	B-Entity
potential	O	O	B-Entity
of	O	O	O
crude	O	O	B-Entity
MCHM	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
in	O	O	O
206	O	O	O
individuals	O	O	B-Entity
who	O	O	O
underwent	O	O	O
48	O	O	B-Entity
hour	O	O	I-Entity
semi-occluded	O	O	B-Entity
patch	O	O	B-Entity
testing	O	O	I-Entity
.	O	O	O

MCHM	O	O	B-Entity
concentrations	O	O	B-Entity
assessed	O	O	O
in	O	O	O
this	O	O	O
study	O	O	B-Entity
were	O	O	O
1	O	O	O
,	O	O	O
5	O	O	O
,	O	O	O
15	O	O	O
,	O	O	O
and	O	O	O
100	O	O	O
ppm	O	O	O
.	O	O	O

No	O	O	O
appreciable	O	O	O
skin	O	O	B-Entity
reactions	O	O	I-Entity
were	O	O	O
observed	O	O	O
in	O	O	O
individuals	O	O	B-Entity
at	O	O	O
any	O	O	O
concentration	O	O	B-Entity
.	O	O	O

Three	O	O	O
of	O	O	O
the	O	O	O
five	O	O	O
concentrations	O	O	B-Entity
evaluated	O	O	B-Entity
were	O	O	O
above	O	O	O
the	O	O	O
highest	O	O	O
measured	O	O	B-Entity
concentration	O	O	I-Entity
of	O	O	O
MCHM	O	O	B-Entity
in	O	O	O
the	O	O	O
tap	O	O	B-Entity
water	O	O	I-Entity
of	O	O	O
residents	O	O	B-Entity
in	O	O	O
West	O	O	B-Entity
Virginia	O	O	I-Entity
(	O	O	O
3.7	O	O	O
ppm	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
results	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
suggest	O	O	O
that	O	O	O
crude	O	O	B-Entity
MCHM	O	O	B-Entity
would	O	O	O
not	O	O	O
be	O	O	O
a	O	O	O
dermal	O	O	B-Entity
irritant	O	O	B-Entity
for	O	O	O
the	O	O	O
vast	O	O	O
majority	O	O	O
,	O	O	O
if	O	O	O
not	O	O	O
all	O	O	O
,	O	O	O
potentially	O	O	O
exposed	O	O	O
persons	O	O	B-Entity
at	O	O	O
the	O	O	O
concentrations	O	O	B-Entity
in	O	O	O
the	O	O	O
water	O	O	B-Entity
reported	O	O	B-Entity
after	O	O	O
the	O	O	O
spill	O	O	B-Entity
.	O	O	O

-DOCSTART- (28278674)

New	O	O	B-Entity
metabolites	O	O	B-Entity
from	O	O	O
the	O	O	O
sponge	O	O	B-Entity
-derived	O	O	O
fungus	O	O	B-Entity
Aspergillus	O	O	O
sydowii	O	O	O
J05B-7F-4	O	O	O

Two	O	O	O
new	O	O	B-Entity
metabolites	O	O	B-Entity
,	O	O	O
diorcinolic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
1	O	O	O
)	O	O	O
and	O	O	O
β-d-glucopyranosyl	O	O	B-Entity
aspergillusene	O	O	I-Entity
A	O	O	I-Entity
(	O	O	O
8)	O	O	O
,	O	O	O
together	O	O	O
with	O	O	O
six	O	O	O
diphenylethers	O	O	B-Entity
(	O	O	O
2	O	O	O
-	O	O	O
7	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
diketopiperazine	O	O	B-Entity
(	O	O	O
9	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
chromone	O	O	B-Entity
(	O	O	O
10	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
xanthone	O	O	B-Entity
(	O	O	O
11	O	O	O
)	O	O	O
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
fungus	O	O	B-Entity
Aspergillus	O	O	B-Entity
sydowii	O	O	I-Entity
derived	O	O	O
from	O	O	O
the	O	O	O
marine	O	O	B-Entity
sponge	O	O	I-Entity
Stelletta	O	O	O
sp.	O	O	O
The	O	O	O
planar	O	O	O
structures	O	O	O
and	O	O	O
their	O	O	O
relative	O	O	O
configurations	O	O	B-Entity
were	O	O	O
elucidated	O	O	O
by	O	O	O
analysing	O	O	O
1D	O	O	B-Entity
,	O	O	I-Entity
2D	O	O	I-Entity
NMR	O	O	I-Entity
and	O	O	O
HRESIMS	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

Compound	O	O	B-Entity
8	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
glycoside	O	O	B-Entity
of	O	O	O
phenolic	O	O	B-Entity
bisabolane	O	O	B-Entity
sesquiterpenes	O	O	I-Entity
.	O	O	O

Compounds	O	O	B-Entity
1	O	O	I-Entity
and	O	O	I-Entity
8	O	O	I-Entity
exhibited	O	O	O
mild	O	O	B-Entity
cytotoxicity	O	O	B-Entity
against	O	O	O
KB	O	O	B-Entity
(	O	O	O
human	O	O	B-Entity
nasopharyngeal	O	O	I-Entity
carcinoma	O	O	I-Entity
cells	O	O	I-Entity
)	O	O	O
,	O	O	O
HepG2	O	O	B-Entity
(	O	O	O
human	O	O	B-Entity
liver	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
)	O	O	O
and	O	O	O
HCT	O	O	B-Entity
116	O	O	I-Entity
(	O	O	O
human	O	O	B-Entity
colon	O	O	I-Entity
cancer	O	O	I-Entity
cells	O	O	I-Entity
)	O	O	O
.	O	O	O

All	O	O	O
compounds	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
antibacterial	O	O	B-Entity
activity	O	O	I-Entity
and	O	O	O
their	O	O	O
abilities	O	O	O
to	O	O	O
suppress	O	O	B-Entity
LPS	O	O	B-Entity
-induced	O	O	O
nitric	O	O	B-Entity
oxide	O	O	I-Entity
(	O	O	O
NO	O	O	B-Entity
)	O	O	O
production	O	O	O
.	O	O	O

Compounds	O	O	B-Entity
2	O	O	I-Entity
and	O	O	I-Entity
4	O	O	I-Entity
-	O	O	I-Entity
7	O	O	I-Entity
showed	O	O	O
mild	O	O	B-Entity
antibacterial	O	O	B-Entity
activity	O	O	I-Entity
against	O	O	O
human	O	O	B-Entity
pathogen	O	O	B-Entity
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
and	O	O	O
fish	O	O	B-Entity
pathogens	O	O	B-Entity
Streptococcus	O	O	B-Entity
iniae	O	O	I-Entity
and	O	O	O
Vibrio	O	O	B-Entity
ichthyoenteri	O	O	I-Entity
,	O	O	O
and	O	O	O
compounds	O	O	B-Entity
4	O	O	I-Entity
and	O	O	I-Entity
7	O	O	I-Entity
weakly	O	O	O
suppressed	O	O	B-Entity
NO	O	O	B-Entity
production	O	O	O
.	O	O	O

-DOCSTART- (28279706)

The	O	O	O
neural	O	O	B-Entity
legacy	O	O	B-Entity
of	O	O	O
a	O	O	O
single	O	O	O
concussion	O	O	O

It	O	O	O
has	O	O	O
been	O	O	O
hypothesized	O	O	B-Entity
that	O	O	O
concussions	O	O	B-Entity
impart	O	O	B-Entity
lasting	O	O	B-Entity
brain	O	O	B-Entity
damage	O	O	I-Entity
,	O	O	O
even	O	O	O
after	O	O	O
a	O	O	O
patient	O	O	B-Entity
has	O	O	O
ostensibly	O	O	O
recovered	O	O	B-Entity
.	O	O	O

This	O	O	O
hypothesis	O	O	B-Entity
is	O	O	O
based	O	O	O
largely	O	O	B-Entity
upon	O	O	O
neuropathological	O	O	B-Entity
studies	O	O	B-Entity
in	O	O	O
deceased	O	O	B-Entity
athletes	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
leaving	O	O	O
open	O	O	O
the	O	O	O
question	O	O	O
of	O	O	O
whether	O	O	O
it	O	O	O
can	O	O	O
be	O	O	O
detected	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

We	O	O	O
measured	O	O	B-Entity
neural	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
speech	O	O	B-Entity
in	O	O	O
collegiate	O	O	B-Entity
student	O	O	I-Entity
-	O	O	O
athletes	O	O	B-Entity
with	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
a	O	O	O
single	O	O	O
concussion	O	O	B-Entity
from	O	O	O
which	O	O	O
they	O	O	O
had	O	O	O
recovered	O	O	B-Entity
.	O	O	O

These	O	O	O
student	O	O	B-Entity
-	O	O	O
athletes	O	O	B-Entity
had	O	O	O
weaker	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
speech	O	O	B-Entity
than	O	O	O
age	O	O	B-Entity
-	O	O	O
and	O	O	O
position	O	O	B-Entity
-	O	O	O
matched	O	O	B-Entity
peers	O	O	B-Entity
.	O	O	O

This	O	O	O
group	O	O	B-Entity
difference	O	O	B-Entity
suggests	O	O	B-Entity
that	O	O	O
concussions	O	O	B-Entity
engender	O	O	B-Entity
small	O	O	B-Entity
,	O	O	O
but	O	O	O
detectable	O	O	B-Entity
,	O	O	O
changes	O	O	B-Entity
in	O	O	O
brain	O	O	B-Entity
function	O	O	I-Entity
prior	O	O	B-Entity
to	O	O	O
the	O	O	O
emergence	O	O	B-Entity
of	O	O	O
frank	O	O	B-Entity
behavioral	O	O	B-Entity
indications	O	O	I-Entity
.	O	O	O

-DOCSTART- (28281265)

Enhanced	O	O	O
Performance	O	O	B-Entity
of	O	O	O
Colorimetric	O	O	B-Entity
Biosensing	O	O	B-Entity
on	O	O	O
Paper	O	O	B-Entity
Microfluidic	O	O	B-Entity
Platforms	O	O	I-Entity
Through	O	O	O
Chemical	O	O	B-Entity
Modification	O	O	I-Entity
and	O	O	O
Incorporation	O	O	B-Entity
of	O	O	O
Nanoparticles	O	O	O

This	O	O	O
chapter	O	O	O
describes	O	O	O
two	O	O	O
different	O	O	O
methodologies	O	O	B-Entity
used	O	O	O
to	O	O	O
improve	O	O	O
the	O	O	O
analytical	O	O	B-Entity
performance	O	O	I-Entity
of	O	O	O
colorimetric	O	O	B-Entity
paper	O	O	B-Entity
-based	O	O	O
biosensors	O	O	B-Entity
.	O	O	O

Microfluidic	O	O	B-Entity
paper-based	O	O	I-Entity
analytical	O	O	I-Entity
devices	O	O	I-Entity
(	O	O	O
μPADs	O	O	B-Entity
)	O	O	O
have	O	O	O
been	O	O	O
produced	O	O	O
by	O	O	O
a	O	O	O
stamping	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
CO2	O	O	B-Entity
laser	O	O	B-Entity
ablation	O	O	I-Entity
and	O	O	O
modified	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
through	O	O	O
an	O	O	O
oxidation	O	O	B-Entity
step	O	O	B-Entity
and	O	O	O
incorporation	O	O	O
of	O	O	O
silica	O	O	B-Entity
nanoparticles	O	O	B-Entity
on	O	O	O
the	O	O	O
paper	O	O	B-Entity
structure	O	O	I-Entity
.	O	O	O

Both	O	O	O
methods	O	O	B-Entity
are	O	O	O
employed	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
overcome	O	O	O
the	O	O	O
largest	O	O	O
problem	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
colorimetric	O	O	B-Entity
detection	O	O	I-Entity
,	O	O	O
the	O	O	O
heterogeneity	O	O	B-Entity
of	O	O	O
the	O	O	O
color	O	O	B-Entity
distribution	O	O	B-Entity
in	O	O	O
the	O	O	O
detection	O	O	B-Entity
zones	O	O	I-Entity
.	O	O	O

The	O	O	O
modification	O	O	B-Entity
steps	O	O	B-Entity
are	O	O	O
necessary	O	O	O
to	O	O	O
improve	O	O	O
the	O	O	O
interaction	O	O	B-Entity
between	O	O	O
the	O	O	O
paper	O	O	B-Entity
surface	O	O	B-Entity
and	O	O	O
the	O	O	O
selected	O	O	O
enzymes	O	O	B-Entity
.	O	O	O

The	O	O	O
enhanced	O	O	O
performance	O	O	B-Entity
has	O	O	O
ensured	O	O	O
reliability	O	O	B-Entity
for	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
clinically	O	O	B-Entity
relevant	O	O	O
compounds	O	O	B-Entity
.	O	O	O

-DOCSTART- (28282510)

CXCR4	O	O	B-Entity
(	O	O	O
CD184	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
on	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
harvest	O	O	I-Entity
and	O	O	O
CD34(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	B-Entity
post-transplant	O	O	O

CXCR4	O	O	B-Entity
is	O	O	O
a	O	O	O
receptor	O	O	B-Entity
for	O	O	O
stromal-derived	O	O	B-Entity
factor-1	O	O	I-Entity
(	O	O	O
SDF-1	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
molecule	O	O	B-Entity
that	O	O	O
has	O	O	O
a	O	O	O
chemotactic	O	O	B-Entity
activity	O	O	B-Entity
for	O	O	O
lymphocytes	O	O	B-Entity
and	O	O	O
is	O	O	O
important	O	O	O
in	O	O	O
homing	O	O	B-Entity
of	O	O	O
hematopoietic	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
their	O	O	O
adult	O	O	B-Entity
marrow	O	O	I-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
CXCR4	O	O	B-Entity
(	O	O	O
CD184	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
in	O	O	O
the	O	O	O
harvest	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
in	O	O	O
the	O	O	O
post-transplant	O	O	B-Entity
bone	O	O	B-Entity
marrow	O	O	I-Entity
(	O	O	O
BM	O	O	B-Entity
)	O	O	O
and	O	O	O
its	O	O	O
relation	O	O	B-Entity
to	O	O	O
engraftment	O	O	B-Entity
,	O	O	O
as	O	O	O
determined	O	O	O
by	O	O	O
the	O	O	O
consensus	O	O	B-Entity
criteria	O	O	I-Entity
and	O	O	O
chimerism	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
a	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
which	O	O	O
included	O	O	O
30	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
hematopoietic	O	O	B-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
transplantation	O	O	I-Entity
;	O	O	O
15	O	O	O
patients	O	O	O
received	O	O	B-Entity
autograft	O	O	B-Entity
and	O	O	O
15	O	O	O
patients	O	O	O
received	O	O	O
allograft	O	O	B-Entity
on	O	O	O
dates	O	O	O
between	O	O	O
January	O	O	O
2012	O	O	O
and	O	O	O
May	O	O	O
2014	O	O	O
.	O	O	O

We	O	O	O
assessed	O	O	B-Entity
CD184	O	O	B-Entity
(	O	O	O
CXCR4	O	O	B-Entity
)	O	O	O
using	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
in	O	O	O
the	O	O	O
harvest	O	O	B-Entity
cells	O	O	B-Entity
together	O	O	O
with	O	O	O
post-transplant	O	O	B-Entity
BM	O	O	B-Entity
assessment	O	O	B-Entity
on	O	O	O
Day	O	O	O
28	O	O	O
and	O	O	O
Day	O	O	O
90	O	O	O
for	O	O	O
complete	O	O	B-Entity
morphologic	O	O	B-Entity
,	O	O	O
molecular	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
and	O	O	O
detection	O	O	B-Entity
of	O	O	O
CD184	O	O	O
expression	O	O	B-Entity
on	O	O	O
CD34(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	O
with	O	O	O
chimerism	O	O	B-Entity
studies	O	O	O
on	O	O	O
total	O	O	B-Entity
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Diagnoses	O	O	B-Entity
of	O	O	O
the	O	O	O
enrolled	O	O	O
patients	O	O	B-Entity
were	O	O	O
as	O	O	O
follows	O	O	O
:	O	O	O
seven	O	O	O
(	O	O	O
24.1	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
acute	O	O	B-Entity
myeloid	O	O	I-Entity
leukemia	O	O	I-Entity
,	O	O	O
eight	O	O	O
(	O	O	O
27.6	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
multiple	O	O	B-Entity
myeloma	O	O	I-Entity
,	O	O	O
four	O	O	O
(	O	O	O
13.8	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
acute	O	O	B-Entity
lymphoblastic	O	O	I-Entity
leukemia	O	O	I-Entity
,	O	O	O
three	O	O	O
(	O	O	O
10.3	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
non-Hodgkin	O	O	B-Entity
lymphoma	O	O	I-Entity
,	O	O	O
two	O	O	O
(	O	O	O
6.9	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
myelodysplastic	O	O	B-Entity
syndromes	O	O	I-Entity
,	O	O	O
two	O	O	O
(	O	O	O
6.9	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
aplastic	O	O	B-Entity
anemia	O	O	I-Entity
,	O	O	O
two	O	O	O
(	O	O	O
6.9	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
chronic	O	O	B-Entity
myeloid	O	O	I-Entity
leukemia	O	O	I-Entity
,	O	O	O
one	O	O	O
(	O	O	O
3.4	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
Hodgkin	O	O	B-Entity
lymphoma	O	O	I-Entity
,	O	O	O
and	O	O	O
one	O	O	O
(	O	O	O
3.4	O	O	O
%	O	O	O
)	O	O	O
with	O	O	O
plasmacytomas	O	O	B-Entity
.	O	O	O

One	O	O	O
patient	O	O	B-Entity
died	O	O	B-Entity
and	O	O	O
was	O	O	O
excluded	O	O	B-Entity
from	O	O	O
the	O	O	O
study	O	O	B-Entity
because	O	O	O
there	O	O	O
were	O	O	O
not	O	O	O
enough	O	O	O
data	O	O	O
about	O	O	O
engraftment	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
statistical	O	O	B-Entity
significance	O	O	I-Entity
between	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
CD184	O	O	B-Entity
in	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
harvest	O	O	I-Entity
and	O	O	O
the	O	O	O
prediction	O	O	B-Entity
of	O	O	O
successful	O	O	B-Entity
engraftment	O	O	B-Entity
(	O	O	O
p>0.05	O	O	O
)	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
Day	O	O	O
28	O	O	O
BM	O	O	B-Entity
sample	O	O	I-Entity
(	O	O	O
p>0.05	O	O	O
)	O	O	O
,	O	O	O
whereas	O	O	O
there	O	O	O
was	O	O	O
a	O	O	O
statistical	O	O	O
significance	O	O	O
between	O	O	O
the	O	O	O
level	O	O	O
of	O	O	O
CD184	O	O	O
in	O	O	O
Day	O	O	O
90	O	O	O
BM	O	O	O
sample	O	O	O
and	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
successful	O	O	O
engraftment	O	O	O
(	O	O	O
p=0.002	O	O	O
)	O	O	O
.	O	O	O

SDF-1	O	O	B-Entity
/	O	O	O
CXCR4	O	O	B-Entity
axis	O	O	O
plays	O	O	O
a	O	O	O
crucial	O	O	O
role	O	O	O
in	O	O	O
engraftment	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
more	O	O	O
studies	O	O	O
are	O	O	O
warranted	O	O	O
to	O	O	O
assess	O	O	B-Entity
their	O	O	O
expression	O	O	B-Entity
post-transplant	O	O	B-Entity
.	O	O	O

Evaluating	O	O	O
the	O	O	O
ligand	O	O	O
(	O	O	O
chemokine	O	O	B-Entity
,	O	O	O
SDF-1	O	O	B-Entity
)	O	O	O
or	O	O	O
its	O	O	O
receptor	O	O	B-Entity
(	O	O	O
CXCR4	O	O	B-Entity
)	O	O	O
may	O	O	O
serve	O	O	O
as	O	O	O
potential	O	O	B-Entity
surrogate	O	O	B-Entity
markers	O	O	I-Entity
for	O	O	O
assessment	O	O	B-Entity
of	O	O	O
engraftment	O	O	B-Entity
.	O	O	O

-DOCSTART- (28284223)

Genetic	O	O	B-Entity
diversity	O	O	I-Entity
of	O	O	O
Taenia	O	O	B-Entity
saginata	O	O	I-Entity
(	O	O	O
Cestoda	O	O	B-Entity
:	O	O	O
Cyclophyllidea	O	O	B-Entity
)	O	O	O
from	O	O	O
Lao	O	O	B-Entity
People	O	O	I-Entity
's	O	O	I-Entity
Democratic	O	O	I-Entity
Republic	O	O	I-Entity
and	O	O	O
northeastern	O	O	B-Entity
Thailand	O	O	B-Entity
based	O	O	O
on	O	O	O
mitochondrial	O	O	O
DNA	O	O	O

Taenia	O	O	B-Entity
saginata	O	O	I-Entity
is	O	O	O
a	O	O	O
tapeworm	O	O	B-Entity
found	O	O	O
in	O	O	O
cattle	O	O	B-Entity
worldwide	O	O	O
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
in	O	O	O
different	O	O	O
geographical	O	O	B-Entity
populations	O	O	I-Entity
of	O	O	O
T.	O	O	B-Entity
saginata	O	O	I-Entity
not	O	O	O
only	O	O	O
helps	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
origin	O	O	B-Entity
,	O	O	O
transmission	O	O	B-Entity
and	O	O	O
spread	O	O	B-Entity
of	O	O	O
this	O	O	O
organism	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
selection	O	O	O
pressures	O	O	O
acting	O	O	O
on	O	O	O
T.	O	O	O
saginata	O	O	O
and	O	O	O
how	O	O	O
it	O	O	O
is	O	O	O
responding	O	O	O
to	O	O	O
them	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
are	O	O	O
few	O	O	O
reports	O	O	O
of	O	O	O
the	O	O	O
genetic	O	O	B-Entity
variability	O	O	I-Entity
of	O	O	O
T.	O	O	B-Entity
saginata	O	O	I-Entity
populations	O	O	I-Entity
in	O	O	O
different	O	O	O
regions	O	O	B-Entity
of	O	O	O
the	O	O	O
world	O	O	B-Entity
,	O	O	O
including	O	O	O
Lao	O	O	B-Entity
PDR	O	O	I-Entity
and	O	O	O
Thailand	O	O	B-Entity
.	O	O	O

We	O	O	O
report	O	O	O
the	O	O	O
genetic	O	O	B-Entity
diversity	O	O	I-Entity
of	O	O	O
T.	O	O	B-Entity
saginata	O	O	I-Entity
populations	O	O	I-Entity
in	O	O	O
Lao	O	O	B-Entity
PDR	O	O	I-Entity
and	O	O	O
northeastern	O	O	B-Entity
Thailand	O	O	B-Entity
together	O	O	O
with	O	O	O
sequences	O	O	B-Entity
of	O	O	O
T.	O	O	O
saginata	O	O	O
from	O	O	O
other	O	O	O
countries	O	O	B-Entity
deposited	O	O	O
in	O	O	O
GenBank	O	O	B-Entity
.	O	O	O

Mitochondrial	O	O	B-Entity
cox1	O	O	I-Entity
sequence	O	O	B-Entity
analysis	O	O	I-Entity
revealed	O	O	O
that	O	O	O
15	O	O	O
and	O	O	O
8	O	O	O
haplotypes	O	O	B-Entity
were	O	O	O
identified	O	O	O
in	O	O	O
30	O	O	O
and	O	O	O
21	O	O	O
T.	O	O	B-Entity
saginata	O	O	I-Entity
isolates	O	O	O
from	O	O	O
Lao	O	O	B-Entity
PDR	O	O	I-Entity
and	O	O	O
northeastern	O	O	B-Entity
Thailand	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Fifty-three	O	O	O
haplotypes	O	O	B-Entity
were	O	O	O
identified	O	O	O
from	O	O	O
98	O	O	O
sequences	O	O	B-Entity
.	O	O	O

Phylogenetic	O	O	B-Entity
tree	O	O	I-Entity
and	O	O	O
haplotype	O	O	B-Entity
network	O	O	I-Entity
analyses	O	O	I-Entity
revealed	O	O	O
that	O	O	O
global	O	O	B-Entity
isolates	O	O	O
of	O	O	O
T.	O	O	B-Entity
saginata	O	O	I-Entity
were	O	O	O
genetically	O	O	O
divided	O	O	O
into	O	O	O
five	O	O	O
groups	O	O	B-Entity
(	O	O	O
A	O	O	B-Entity
,	O	O	O
B	O	O	B-Entity
,	O	O	O
C1	O	O	B-Entity
,	O	O	O
C2	O	O	B-Entity
and	O	O	O
D	O	O	B-Entity
)	O	O	O
.	O	O	O

Taenia	O	O	B-Entity
saginata	O	O	I-Entity
isolates	O	O	O
from	O	O	O
Lao	O	O	B-Entity
PDR	O	O	I-Entity
and	O	O	O
northeastern	O	O	B-Entity
Thailand	O	O	B-Entity
belonged	O	O	O
to	O	O	O
either	O	O	O
Group	O	O	B-Entity
A	O	O	I-Entity
or	O	O	O
B.	O	O	O
Taenia	O	O	O
saginata	O	O	O
from	O	O	O
western	O	O	B-Entity
Thailand	O	O	O
clustered	O	O	O
in	O	O	O
groups	O	O	B-Entity
C1	O	O	I-Entity
,	O	O	O
C2	O	O	B-Entity
and	O	O	O
D	O	O	B-Entity
,	O	O	O
and	O	O	O
populations	O	O	B-Entity
from	O	O	O
the	O	O	O
northeast	O	O	B-Entity
and	O	O	O
western	O	O	O
Thailand	O	O	O
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
genetically	O	O	O
distinct	O	O	O
.	O	O	O

Taenia	O	O	B-Entity
saginata	O	O	I-Entity
isolates	O	O	O
in	O	O	O
Lao	O	O	B-Entity
PDR	O	O	I-Entity
and	O	O	O
Thailand	O	O	B-Entity
were	O	O	O
also	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
genetically	O	O	B-Entity
diverse	O	O	I-Entity
but	O	O	O
the	O	O	O
degree	O	O	O
of	O	O	O
genetic	O	O	B-Entity
differentiation	O	O	I-Entity
was	O	O	O
low	O	O	O
.	O	O	O

Taenia	O	O	B-Entity
saginata	O	O	I-Entity
populations	O	O	I-Entity
from	O	O	O
Lao	O	O	B-Entity
PDR	O	O	I-Entity
and	O	O	O
northeastern	O	O	B-Entity
Thailand	O	O	B-Entity
are	O	O	O
genetically	O	O	O
distinct	O	O	O
from	O	O	O
the	O	O	O
population	O	O	B-Entity
in	O	O	O
western	O	O	B-Entity
Thailand	O	O	O
and	O	O	O
it	O	O	O
is	O	O	O
proposed	O	O	O
that	O	O	O
T.	O	O	B-Entity
saginata	O	O	I-Entity
has	O	O	O
been	O	O	O
dispersed	O	O	O
by	O	O	O
different	O	O	O
transmission	O	O	B-Entity
routes	O	O	I-Entity
in	O	O	O
Southeast	O	O	B-Entity
Asia	O	O	I-Entity
.	O	O	O

-DOCSTART- (28284864)

Development	O	O	O
of	O	O	O
a	O	O	O
novel	O	O	B-Entity
near-infrared	O	O	B-Entity
fluorescent	O	O	B-Entity
theranostic	O	O	B-Entity
combretastain	O	O	B-Entity
A-4	O	O	I-Entity
analogue	O	O	B-Entity
,	O	O	O
YK-5	O	O	B-Entity
-	O	O	I-Entity
252	O	O	I-Entity
,	O	O	O
to	O	O	O
target	O	O	O
triple	O	O	O
negative	O	O	O
breast	O	O	O
cancer	O	O	O

The	O	O	O
treatment	O	O	B-Entity
of	O	O	O
triple	O	O	B-Entity
negative	O	O	I-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
TNBC	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
significant	O	O	O
challenge	O	O	O
to	O	O	O
cancer	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

The	O	O	O
lack	O	O	O
of	O	O	O
hormone	O	O	B-Entity
receptors	O	O	I-Entity
limits	O	O	O
the	O	O	O
treatment	O	O	B-Entity
options	O	O	O
available	O	O	O
to	O	O	O
patients	O	O	B-Entity
with	O	O	O
this	O	O	O
diagnosis	O	O	B-Entity
,	O	O	O
forcing	O	O	O
them	O	O	O
to	O	O	O
endure	O	O	O
prolonged	O	O	O
radiation	O	O	B-Entity
and	O	O	O
chemotherapy	O	O	B-Entity
.	O	O	O

Anti-angiogenesis	O	O	B-Entity
is	O	O	O
a	O	O	O
chemotherapeutic	O	O	O
strategy	O	O	O
that	O	O	O
targets	O	O	O
the	O	O	O
vasculature	O	O	B-Entity
of	O	O	O
tumors	O	O	B-Entity
.	O	O	O

Combretastatin	O	O	B-Entity
A-4	O	O	I-Entity
(	O	O	O
CA-4	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
well-known	O	O	O
vasculature	O	O	B-Entity
-	O	O	O
disrupting	O	O	O
agent	O	O	O
,	O	O	O
which	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
effectively	O	O	O
kill	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
cancers	O	O	B-Entity
through	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
tubulin	O	O	B-Entity
polymerization	O	O	B-Entity
.	O	O	O

Due	O	O	O
to	O	O	O
its	O	O	O
toxicity	O	O	B-Entity
,	O	O	O
small	O	O	O
molecule	O	O	O
analogues	O	O	B-Entity
of	O	O	O
CA-4	O	O	B-Entity
have	O	O	O
been	O	O	O
sought	O	O	O
out	O	O	O
.	O	O	O

We	O	O	O
have	O	O	O
designed	O	O	O
a	O	O	O
novel	O	O	B-Entity
dual	O	O	O
action	O	O	O
CA-4	O	O	B-Entity
prodrug	O	O	B-Entity
,	O	O	O
YK-5	O	O	B-Entity
-	O	O	I-Entity
252	O	O	I-Entity
,	O	O	O
which	O	O	O
releases	O	O	O
the	O	O	O
drug	O	O	B-Entity
through	O	O	O
a	O	O	O
disulfide	O	O	B-Entity
bond	O	O	I-Entity
cleavage	O	O	B-Entity
mechanism	O	O	B-Entity
and	O	O	O
contains	O	O	O
a	O	O	O
near-infrared	O	O	B-Entity
(	O	O	O
NIR	O	O	B-Entity
)	O	O	O
fluorophore	O	O	B-Entity
,	O	O	O
which	O	O	O
allows	O	O	O
fluorescence	O	O	B-Entity
monitoring	O	O	O
of	O	O	O
cleavage	O	O	O
.	O	O	O

This	O	O	O
disulfide	O	O	B-Entity
linkage	O	O	I-Entity
causes	O	O	O
CA-4	O	O	B-Entity
to	O	O	O
become	O	O	O
effective	O	O	O
only	O	O	O
when	O	O	O
released	O	O	O
by	O	O	O
glutathione	O	O	B-Entity
(	O	O	O
GSH	O	O	B-Entity
)	O	O	O
reducing	O	O	O
the	O	O	O
toxicity	O	O	B-Entity
of	O	O	O
the	O	O	O
drug	O	O	B-Entity
while	O	O	O
simultaneously	O	O	O
releasing	O	O	O
the	O	O	O
NIR	O	O	B-Entity
fluorophore	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
the	O	O	O
prodrug	O	O	B-Entity
,	O	O	O
YK-5	O	O	B-Entity
-	O	O	I-Entity
252	O	O	I-Entity
,	O	O	O
represents	O	O	O
a	O	O	O
novel	O	O	B-Entity
CA-4	O	O	B-Entity
analogue	O	O	B-Entity
which	O	O	O
has	O	O	O
reduced	O	O	O
toxicity	O	O	B-Entity
and	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
for	O	O	O
theranostics	O	O	B-Entity
imaging	O	O	B-Entity
.	O	O	O

-DOCSTART- (28288758)

Epidemiological	O	O	B-Entity
patterns	O	O	B-Entity
of	O	O	O
bovine	O	O	B-Entity
besnoitiosis	O	O	B-Entity
in	O	O	O
an	O	O	O
endemic	O	O	B-Entity
beef	O	O	B-Entity
cattle	O	O	I-Entity
herd	O	O	B-Entity
reared	O	O	B-Entity
under	O	O	O
extensive	O	O	O
conditions	O	O	O

Bovine	O	O	B-Entity
besnoitiosis	O	O	B-Entity
is	O	O	O
a	O	O	O
parasitic	O	O	B-Entity
disease	O	O	I-Entity
caused	O	O	O
by	O	O	O
the	O	O	O
protozoan	O	O	B-Entity
Besnoitia	O	O	B-Entity
besnoiti	O	O	I-Entity
.	O	O	O

Described	O	O	O
many	O	O	O
decades	O	O	O
ago	O	O	O
,	O	O	O
recent	O	O	O
epidemiological	O	O	B-Entity
studies	O	O	I-Entity
reveal	O	O	O
its	O	O	O
important	O	O	O
spread	O	O	O
within	O	O	O
Europe	O	O	B-Entity
in	O	O	O
the	O	O	O
last	O	O	O
years	O	O	B-Entity
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
many	O	O	O
epidemiological	O	O	B-Entity
aspects	O	O	B-Entity
related	O	O	O
to	O	O	O
life	O	O	O
cycle	O	O	O
,	O	O	O
routes	O	O	O
of	O	O	O
transmission	O	O	B-Entity
,	O	O	O
incidence	O	O	B-Entity
rates	O	O	I-Entity
and	O	O	O
associated	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
are	O	O	O
lacking	O	O	B-Entity
;	O	O	O
hence	O	O	O
,	O	O	O
the	O	O	O
establishment	O	O	O
of	O	O	O
appropriate	O	O	B-Entity
disease	O	O	I-Entity
control	O	O	I-Entity
programmes	O	O	B-Entity
poses	O	O	O
an	O	O	O
important	O	O	O
challenge	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
epidemiological	O	O	B-Entity
pattern	O	O	B-Entity
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
in	O	O	O
an	O	O	O
endemic	O	O	B-Entity
herd	O	O	B-Entity
reared	O	O	B-Entity
under	O	O	O
extensive	O	O	O
conditions	O	O	O
(	O	O	O
Spanish	O	O	B-Entity
Pyrenees	O	O	B-Entity
)	O	O	O
by	O	O	O
identifying	O	O	O
main	O	O	O
factors	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
infection	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
disease	O	O	I-Entity
dynamics	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
population	O	O	I-Entity
consisted	O	O	O
of	O	O	O
276	O	O	O
Brown	O	O	B-Entity
Swiss	O	O	I-Entity
and	O	O	O
Pirenaica	O	O	B-Entity
adult	O	O	B-Entity
animals	O	O	I-Entity
and	O	O	O
145	O	O	O
calves	O	O	B-Entity
born	O	O	B-Entity
and	O	O	O
weaned	O	O	B-Entity
at	O	O	O
the	O	O	O
farm	O	O	B-Entity
during	O	O	O
the	O	O	O
study	O	O	O
.	O	O	O

Three	O	O	O
sampling	O	O	B-Entity
time	O	O	B-Entity
frames	O	O	I-Entity
were	O	O	O
used	O	O	O
:	O	O	O
January	O	O	O
2010	O	O	O
,	O	O	O
September	O	O	O
2010	O	O	O
and	O	O	O
February	O	O	O
2011	O	O	O
,	O	O	O
which	O	O	O
allowed	O	O	O
us	O	O	O
to	O	O	O
differentiate	O	O	O
two	O	O	O
periods	O	O	B-Entity
designated	O	O	O
as	O	O	O
mountain	O	O	B-Entity
and	O	O	O
valley	O	O	B-Entity
periods	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
related	O	O	O
to	O	O	O
animals	O	O	B-Entity
(	O	O	O
breed	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
and	O	O	O
age	O	O	B-Entity
)	O	O	O
and	O	O	O
herd	O	O	B-Entity
management	O	O	B-Entity
(	O	O	O
animal	O	O	B-Entity
grouping	O	O	I-Entity
and	O	O	O
time	O	O	B-Entity
in	O	O	O
housing	O	O	B-Entity
)	O	O	O
were	O	O	O
recorded	O	O	O
.	O	O	O

The	O	O	O
data	O	O	B-Entity
collection	O	O	I-Entity
methodology	O	O	B-Entity
was	O	O	O
mainly	O	O	O
based	O	O	O
on	O	O	O
clinical	O	O	B-Entity
examinations	O	O	I-Entity
and	O	O	O
defining	O	O	O
the	O	O	O
serological	O	O	B-Entity
status	O	O	B-Entity
against	O	O	O
bovine	O	O	B-Entity
besnoitiosis	O	O	B-Entity
by	O	O	O
the	O	O	O
immunofluorescent	O	O	B-Entity
antibody	O	O	I-Entity
testing	O	O	I-Entity
of	O	O	O
blood	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

The	O	O	O
total	O	O	O
prevalence	O	O	B-Entity
among	O	O	O
adult	O	O	B-Entity
animals	O	O	B-Entity
was	O	O	O
38.34	O	O	O
%	O	O	O
(	O	O	O
CI	O	O	B-Entity
95	O	O	O
%	O	O	O
:	O	O	O
34.53	O	O	O
-	O	O	O
42.07	O	O	O
)	O	O	O
,	O	O	O
with	O	O	O
18.54	O	O	O
%	O	O	O
of	O	O	O
seropositive	O	O	B-Entity
animals	O	O	O
showing	O	O	O
clinical	O	O	O
signs	O	O	O
.	O	O	O

In	O	O	O
regard	O	O	O
to	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
incidence	O	O	I-Entity
,	O	O	O
34.57	O	O	O
%	O	O	O
of	O	O	O
new	O	O	B-Entity
infections	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
during	O	O	O
the	O	O	O
mountain	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
in	O	O	O
contrast	O	O	O
to	O	O	O
the	O	O	O
24.59	O	O	O
%	O	O	O
observed	O	O	O
in	O	O	O
the	O	O	O
valley	O	O	B-Entity
period	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
density	O	O	I-Entity
was	O	O	O
0.058	O	O	O
and	O	O	O
0.061	O	O	O
new	O	O	B-Entity
infections	O	O	B-Entity
per	O	O	O
animal	O	O	B-Entity
-	O	O	O
month	O	O	B-Entity
for	O	O	O
the	O	O	O
mountain	O	O	B-Entity
and	O	O	O
valley	O	O	B-Entity
periods	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
seroepidemiological	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
the	O	O	O
seroconversion	O	O	B-Entity
probability	O	O	B-Entity
of	O	O	O
B.	O	O	B-Entity
besnoiti	O	O	I-Entity
infection	O	O	B-Entity
was	O	O	O
directly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
number	O	O	B-Entity
of	O	O	O
seropositive	O	O	B-Entity
cows	O	O	B-Entity
with	O	O	O
whom	O	O	O
an	O	O	O
animal	O	O	B-Entity
had	O	O	O
been	O	O	O
stabled	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
housing	O	O	B-Entity
period	O	O	B-Entity
duration	O	O	B-Entity
,	O	O	O
supporting	O	O	O
horizontal	O	O	B-Entity
transmission	O	O	I-Entity
by	O	O	O
close	O	O	O
contact	O	O	O
as	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
important	O	O	O
methods	O	O	O
of	O	O	O
disease	O	O	B-Entity
spread	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
developing	O	O	O
the	O	O	O
clinical	O	O	B-Entity
course	O	O	I-Entity
increased	O	O	B-Entity
with	O	O	O
age	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
signs	O	O	I-Entity
was	O	O	O
related	O	O	O
to	O	O	O
higher	O	O	B-Entity
antibody	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

Among	O	O	O
calves	O	O	B-Entity
(	O	O	O
from	O	O	O
3.1	O	O	O
to	O	O	O
7.1	O	O	O
months	O	O	B-Entity
old	O	O	B-Entity
)	O	O	O
sampled	O	O	O
once	O	O	O
at	O	O	O
weaning	O	O	B-Entity
,	O	O	O
the	O	O	O
total	O	O	O
seroprevalence	O	O	B-Entity
was	O	O	O
15.17	O	O	O
%	O	O	O
(	O	O	O
CI	O	O	B-Entity
95	O	O	O
%	O	O	O
:	O	O	O
9.36	O	O	O
-	O	O	O
21.04	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
chronic	O	O	B-Entity
stage	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
three	O	O	O
animals	O	O	B-Entity
,	O	O	O
supporting	O	O	O
the	O	O	O
ability	O	O	O
of	O	O	O
B.	O	O	B-Entity
besnoiti	O	O	I-Entity
to	O	O	O
infect	O	O	B-Entity
and	O	O	O
even	O	O	O
cause	O	O	B-Entity
disease	O	O	B-Entity
in	O	O	O
animals	O	O	O
less	O	O	O
than	O	O	O
6	O	O	O
months	O	O	O
old	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
calf	O	O	B-Entity
seroconversion	O	O	B-Entity
was	O	O	O
positively	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
serological	O	O	B-Entity
status	O	O	B-Entity
of	O	O	O
the	O	O	O
cows	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
postnatal	O	O	B-Entity
transmission	O	O	B-Entity
between	O	O	O
dams	O	O	B-Entity
and	O	O	O
offspring	O	O	B-Entity
by	O	O	O
contact	O	O	O
during	O	O	O
the	O	O	O
suckling	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

-DOCSTART- (28295177)

A	O	O	O
fast	O	O	B-Entity
small-sample	O	O	I-Entity
kernel	O	O	I-Entity
independence	O	O	I-Entity
test	O	O	I-Entity
for	O	O	O
microbiome	O	O	B-Entity
community	O	O	B-Entity
-	O	O	O
level	O	O	O
association	O	O	O
analysis	O	O	O

To	O	O	O
fully	O	O	O
understand	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
microbiome	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
health	O	O	B-Entity
and	O	O	O
diseases	O	O	B-Entity
,	O	O	O
researchers	O	O	B-Entity
are	O	O	O
increasingly	O	O	O
interested	O	O	O
in	O	O	O
assessing	O	O	B-Entity
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
microbiome	O	O	B-Entity
composition	O	O	I-Entity
and	O	O	O
host	O	O	B-Entity
genomic	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

The	O	O	O
dimensionality	O	O	B-Entity
of	O	O	O
the	O	O	O
data	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
complex	O	O	B-Entity
relationships	O	O	B-Entity
between	O	O	O
microbiota	O	O	B-Entity
and	O	O	O
host	O	O	B-Entity
genomics	O	O	B-Entity
pose	O	O	O
considerable	O	O	O
challenges	O	O	B-Entity
for	O	O	O
analysis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
article	O	O	O
,	O	O	O
we	O	O	O
apply	O	O	O
a	O	O	O
kernel	O	O	B-Entity
RV	O	O	I-Entity
coefficient	O	O	I-Entity
(	O	O	I-Entity
KRV	O	O	I-Entity
)	O	O	I-Entity
test	O	O	I-Entity
to	O	O	O
evaluate	O	O	O
the	O	O	O
overall	O	O	B-Entity
association	O	O	B-Entity
between	O	O	O
host	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
microbiome	O	O	B-Entity
composition	O	O	I-Entity
.	O	O	O

The	O	O	O
KRV	O	O	B-Entity
statistic	O	O	I-Entity
can	O	O	O
capture	O	O	O
nonlinear	O	O	B-Entity
correlations	O	O	I-Entity
and	O	O	O
complex	O	O	B-Entity
relationships	O	O	B-Entity
among	O	O	O
the	O	O	O
individual	O	O	O
data	O	O	B-Entity
types	O	O	I-Entity
and	O	O	O
between	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
and	O	O	O
microbiome	O	O	B-Entity
composition	O	O	I-Entity
through	O	O	O
measuring	O	O	O
general	O	O	O
dependency	O	O	B-Entity
.	O	O	O

Testing	O	O	B-Entity
proceeds	O	O	O
via	O	O	O
a	O	O	O
similar	O	O	O
route	O	O	O
as	O	O	O
existing	O	O	O
tests	O	O	B-Entity
of	O	O	O
the	O	O	O
generalized	O	O	O
RV	O	O	B-Entity
coefficients	O	O	I-Entity
and	O	O	O
allows	O	O	O
for	O	O	O
rapid	O	O	O
p-value	O	O	B-Entity
calculation	O	O	B-Entity
.	O	O	O

Strategies	O	O	B-Entity
to	O	O	O
allow	O	O	O
adjustment	O	O	O
for	O	O	O
confounding	O	O	B-Entity
effects	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
crucial	O	O	O
for	O	O	O
avoiding	O	O	O
misleading	O	O	O
results	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
alleviate	O	O	O
the	O	O	O
problem	O	O	B-Entity
of	O	O	O
selecting	O	O	O
the	O	O	O
most	O	O	O
favorable	O	O	O
kernel	O	O	B-Entity
are	O	O	O
considered	O	O	O
.	O	O	O

Simulation	O	O	B-Entity
studies	O	O	I-Entity
show	O	O	O
that	O	O	O
KRV	O	O	B-Entity
is	O	O	O
useful	O	O	O
in	O	O	O
testing	O	O	B-Entity
statistical	O	O	B-Entity
independence	O	O	I-Entity
with	O	O	O
finite	O	O	O
samples	O	O	O
given	O	O	O
the	O	O	O
kernels	O	O	B-Entity
are	O	O	O
appropriately	O	O	O
chosen	O	O	O
,	O	O	O
and	O	O	O
can	O	O	O
powerfully	O	O	O
identify	O	O	O
existing	O	O	O
associations	O	O	B-Entity
between	O	O	O
microbiome	O	O	B-Entity
composition	O	O	I-Entity
and	O	O	O
host	O	O	B-Entity
genomic	O	O	B-Entity
data	O	O	B-Entity
while	O	O	O
protecting	O	O	O
type	O	O	B-Entity
I	O	O	I-Entity
error	O	O	B-Entity
.	O	O	O

We	O	O	O
apply	O	O	O
the	O	O	O
KRV	O	O	B-Entity
to	O	O	O
a	O	O	O
microbiome	O	O	B-Entity
study	O	O	B-Entity
examining	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
host	O	O	B-Entity
transcriptome	O	O	B-Entity
and	O	O	O
microbiome	O	O	B-Entity
composition	O	O	I-Entity
within	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
inflammatory	O	O	B-Entity
bowel	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
are	O	O	O
able	O	O	O
to	O	O	O
derive	O	O	O
new	O	O	O
biological	O	O	O
insights	O	O	O
and	O	O	O
provide	O	O	O
formal	O	O	O
inference	O	O	O
on	O	O	O
prior	O	O	O
qualitative	O	O	B-Entity
observations	O	O	I-Entity
.	O	O	O

-DOCSTART- (28295357)

An	O	O	O
Analysis	O	O	B-Entity
of	O	O	O
Systematic	O	O	B-Entity
Elemental	O	O	B-Entity
Changes	O	O	B-Entity
in	O	O	O
Decomposing	O	O	O
Bone	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
compositional	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
bone	O	O	B-Entity
during	O	O	O
decomposition	O	O	B-Entity
.	O	O	O

Elemental	O	O	B-Entity
concentrations	O	O	B-Entity
of	O	O	O
barium	O	O	B-Entity
,	O	O	O
calcium	O	O	B-Entity
,	O	O	O
iron	O	O	B-Entity
,	O	O	O
potassium	O	O	B-Entity
,	O	O	O
magnesium	O	O	B-Entity
,	O	O	O
zinc	O	O	B-Entity
and	O	O	O
phosphorus	O	O	B-Entity
in	O	O	O
porcine	O	O	B-Entity
bone	O	O	B-Entity
(	O	O	O
as	O	O	O
an	O	O	O
experimental	O	O	B-Entity
analog	O	O	B-Entity
for	O	O	O
human	O	O	B-Entity
bone	O	O	O
)	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
by	O	O	O
inductively	O	O	B-Entity
coupled	O	O	I-Entity
plasma	O	O	I-Entity
optical	O	O	I-Entity
emission	O	O	I-Entity
spectroscopy	O	O	I-Entity
(	O	O	O
ICP-OES	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
samples	O	O	B-Entity
were	O	O	O
taken	O	O	O
from	O	O	O
porcine	O	O	B-Entity
bone	O	O	B-Entity
subjected	O	O	B-Entity
to	O	O	O
shallow	O	O	B-Entity
burial	O	O	I-Entity
and	O	O	O
surface	O	O	B-Entity
depositions	O	O	B-Entity
at	O	O	O
28-	O	O	O
day	O	O	B-Entity
intervals	O	O	B-Entity
for	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	O
140	O	O	O
days	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
indicated	O	O	B-Entity
that	O	O	O
ICP-OES	O	O	B-Entity
elemental	O	O	B-Entity
profiling	O	O	B-Entity
has	O	O	O
potential	O	O	B-Entity
to	O	O	O
be	O	O	O
developed	O	O	B-Entity
as	O	O	O
a	O	O	O
forensic	O	O	B-Entity
test	O	O	I-Entity
for	O	O	O
determining	O	O	B-Entity
whether	O	O	O
a	O	O	O
bone	O	O	B-Entity
sample	O	O	I-Entity
originates	O	O	O
from	O	O	O
the	O	O	O
early	O	O	B-Entity
stages	O	O	B-Entity
of	O	O	O
soft	O	O	B-Entity
tissue	O	O	I-Entity
putrefaction	O	O	B-Entity
.	O	O	O

Significant	O	O	B-Entity
changes	O	O	I-Entity
in	O	O	O
iron	O	O	B-Entity
,	O	O	O
sodium	O	O	B-Entity
and	O	O	O
potassium	O	O	B-Entity
concentrations	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
over	O	O	B-Entity
140	O	O	O
days	O	O	B-Entity
.	O	O	O

These	O	O	O
elements	O	O	B-Entity
are	O	O	O
known	O	O	B-Entity
to	O	O	O
be	O	O	O
primarily	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
proteins	O	O	B-Entity
and/or	O	O	O
tissue	O	O	B-Entity
fluids	O	O	I-Entity
within	O	O	O
the	O	O	O
bone	O	O	B-Entity
.	O	O	O

Changes	O	O	B-Entity
in	O	O	O
their	O	O	O
respective	O	O	O
concentrations	O	O	B-Entity
may	O	O	O
therefore	O	O	O
be	O	O	O
linked	O	O	O
to	O	O	O
dehydration	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
and	O	O	O
in	O	O	O
turn	O	O	O
may	O	O	O
be	O	O	O
indicative	O	O	O
of	O	O	O
time	O	O	O
since	O	O	B-Entity
deposition	O	O	B-Entity
.	O	O	O

-DOCSTART- (28295838)

Chasing	O	O	O
ghosts	O	O	O
:	O	O	O
allopolyploid	O	O	O
origin	O	O	O
of	O	O	O
Oxyria	O	O	B-Entity
sinensis	O	O	I-Entity
(	O	O	O
Polygonaceae	O	O	B-Entity
)	O	O	O
from	O	O	O
its	O	O	O
only	O	O	O
diploid	O	O	B-Entity
congener	O	O	B-Entity
and	O	O	O
an	O	O	O
unknown	O	O	O
ancestor	O	O	O

Reconstructing	O	O	O
the	O	O	O
origin	O	O	B-Entity
of	O	O	O
a	O	O	O
polyploid	O	O	B-Entity
species	O	O	B-Entity
is	O	O	O
particularly	O	O	O
challenging	O	O	O
when	O	O	O
an	O	O	O
ancestor	O	O	B-Entity
has	O	O	O
become	O	O	O
extinct	O	O	B-Entity
.	O	O	O

Under	O	O	O
such	O	O	O
circumstances	O	O	O
,	O	O	O
the	O	O	O
extinct	O	O	B-Entity
donor	O	O	O
of	O	O	O
a	O	O	O
genome	O	O	B-Entity
found	O	O	O
in	O	O	O
the	O	O	O
polyploid	O	O	B-Entity
may	O	O	O
be	O	O	O
treated	O	O	O
as	O	O	O
a	O	O	O
'	O	O	O
ghost	O	O	O
'	O	O	O
species	O	O	B-Entity
in	O	O	O
that	O	O	O
its	O	O	O
prior	O	O	O
existence	O	O	B-Entity
is	O	O	O
recognized	O	O	O
through	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
its	O	O	O
genome	O	O	O
in	O	O	O
the	O	O	O
polyploid	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
polyploid	O	O	B-Entity
origin	O	O	B-Entity
of	O	O	O
Oxyria	O	O	B-Entity
sinensis	O	O	I-Entity
(	O	O	O
2n	O	O	O
=	O	O	O
40	O	O	O
)	O	O	O
for	O	O	O
which	O	O	O
only	O	O	O
one	O	O	O
congeneric	O	O	B-Entity
species	O	O	B-Entity
is	O	O	O
known	O	O	O
,	O	O	O
that	O	O	O
is	O	O	O
diploid	O	O	B-Entity
O.	O	O	B-Entity
digyna	O	O	I-Entity
(	O	O	O
2n	O	O	O
=	O	O	O
14	O	O	O
)	O	O	O
.	O	O	O

Genomic	O	O	B-Entity
in	O	O	I-Entity
situ	O	O	I-Entity
hybridization	O	O	I-Entity
(	O	O	O
GISH	O	O	B-Entity
)	O	O	O
,	O	O	O
transcriptome	O	O	B-Entity
,	O	O	O
phylogenetic	O	O	B-Entity
and	O	O	O
demographic	O	O	B-Entity
analyses	O	O	I-Entity
,	O	O	O
and	O	O	O
ecological	O	O	B-Entity
niche	O	O	I-Entity
modelling	O	O	I-Entity
were	O	O	O
conducted	O	O	O
for	O	O	O
this	O	O	O
purpose	O	O	O
.	O	O	O

GISH	O	O	B-Entity
revealed	O	O	O
that	O	O	O
O.	O	O	B-Entity
sinensis	O	O	I-Entity
comprised	O	O	O
14	O	O	O
chromosomes	O	O	B-Entity
from	O	O	O
O.	O	O	B-Entity
digyna	O	O	I-Entity
and	O	O	O
26	O	O	O
chromosomes	O	O	O
from	O	O	O
an	O	O	O
unknown	O	O	O
ancestor	O	O	B-Entity
.	O	O	O

Transcriptome	O	O	B-Entity
analysis	O	O	I-Entity
indicated	O	O	O
that	O	O	O
following	O	O	O
divergence	O	O	B-Entity
from	O	O	O
O.	O	O	B-Entity
digyna	O	O	I-Entity
,	O	O	O
involving	O	O	O
genome	O	O	B-Entity
duplication	O	O	I-Entity
around	O	O	O
12	O	O	O
million	O	O	O
years	O	O	O
ago	O	O	O
(	O	O	O
Ma	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
second	O	O	O
genome	O	O	O
duplication	O	O	O
occurred	O	O	O
approximately	O	O	O
6	O	O	O
Ma	O	O	O
to	O	O	O
give	O	O	O
rise	O	O	O
to	O	O	O
O.	O	O	B-Entity
sinensis	O	O	I-Entity
.	O	O	O

Oxyria	O	O	B-Entity
sinensis	O	O	I-Entity
was	O	O	O
shown	O	O	O
to	O	O	O
contain	O	O	O
homologous	O	O	B-Entity
gene	O	O	I-Entity
sequences	O	O	I-Entity
divergent	O	O	B-Entity
from	O	O	O
those	O	O	O
present	O	O	O
in	O	O	O
O.	O	O	B-Entity
digyna	O	O	I-Entity
in	O	O	O
addition	O	O	O
to	O	O	O
a	O	O	O
set	O	O	O
that	O	O	O
clustered	O	O	B-Entity
with	O	O	O
those	O	O	O
in	O	O	O
O.	O	O	O
digyna	O	O	O
.	O	O	O

Coalescent	O	O	B-Entity
simulations	O	O	I-Entity
indicated	O	O	O
that	O	O	O
O.	O	O	B-Entity
sinensis	O	O	I-Entity
expanded	O	O	O
its	O	O	O
distribution	O	O	B-Entity
approximately	O	O	O
6	O	O	O
-	O	O	O
7	O	O	O
Ma	O	O	O
,	O	O	O
possibly	O	O	O
following	O	O	O
the	O	O	O
second	O	O	O
polyploidization	O	O	B-Entity
event	O	O	I-Entity
,	O	O	O
whereas	O	O	O
O.	O	O	B-Entity
digyna	O	O	I-Entity
expanded	O	O	O
its	O	O	O
range	O	O	O
much	O	O	O
later	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
also	O	O	O
indicated	O	O	O
that	O	O	O
the	O	O	O
distributions	O	O	B-Entity
of	O	O	O
both	O	O	O
species	O	O	B-Entity
contracted	O	O	B-Entity
and	O	O	I-Entity
re-expanded	O	O	I-Entity
during	O	O	O
the	O	O	O
Pleistocene	O	O	B-Entity
climatic	O	O	I-Entity
oscillations	O	O	I-Entity
.	O	O	O

Ecological	O	O	B-Entity
niche	O	O	I-Entity
modelling	O	O	I-Entity
similarly	O	O	O
suggested	O	O	O
that	O	O	O
both	O	O	O
species	O	O	B-Entity
experienced	O	O	O
changes	O	O	O
in	O	O	O
their	O	O	O
distributional	O	O	B-Entity
ranges	O	O	O
in	O	O	O
response	O	O	O
to	O	O	O
Quaternary	O	O	B-Entity
climatic	O	O	I-Entity
changes	O	O	I-Entity
.	O	O	O

The	O	O	O
extinction	O	O	B-Entity
of	O	O	O
the	O	O	O
unknown	O	O	O
'	O	O	O
ghost	O	O	O
'	O	O	O
tetraploid	O	O	B-Entity
species	O	O	B-Entity
implicated	O	O	O
in	O	O	O
the	O	O	O
origin	O	O	B-Entity
of	O	O	O
O.	O	O	B-Entity
sinensis	O	O	I-Entity
could	O	O	O
have	O	O	O
resulted	O	O	O
from	O	O	O
superior	O	O	O
adaptation	O	O	B-Entity
of	O	O	O
O.	O	O	O
sinensis	O	O	O
to	O	O	O
repeated	O	O	B-Entity
climatic	O	O	I-Entity
changes	O	O	I-Entity
in	O	O	O
the	O	O	O
region	O	O	O
where	O	O	O
it	O	O	O
now	O	O	O
occurs	O	O	O
.	O	O	O

-DOCSTART- (28296680)

Primitive	O	O	B-Entity
Neuroectodermal	O	O	I-Entity
Tumors	O	O	I-Entity
of	O	O	O
the	O	O	O
Female	O	O	B-Entity
Genital	O	O	I-Entity
Tract	O	O	I-Entity
:	O	O	O
A	O	O	O
Morphologic	O	O	B-Entity
,	O	O	O
Immunohistochemical	O	O	B-Entity
,	O	O	O
and	O	O	O
Molecular	O	O	B-Entity
Study	O	O	B-Entity
of	O	O	O
19	O	O	O
Cases	O	O	O

Primary	O	O	B-Entity
primitive	O	O	I-Entity
neuroectodermal	O	O	I-Entity
tumor	O	O	I-Entity
(	O	O	O
PNET	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
female	O	O	B-Entity
genital	O	O	I-Entity
tract	O	O	I-Entity
is	O	O	O
rare	O	O	O
,	O	O	O
and	O	O	O
its	O	O	O
proper	O	O	O
classification	O	O	B-Entity
remains	O	O	O
unclear	O	O	O
.	O	O	O

The	O	O	O
clinical	O	O	B-Entity
,	O	O	O
histologic	O	O	B-Entity
,	O	O	O
and	O	O	O
immunophenotypic	O	O	B-Entity
features	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
EWSR1	O	O	B-Entity
rearrangement	O	O	B-Entity
status	O	O	O
of	O	O	O
19	O	O	O
gynecologic	O	O	B-Entity
PNETs	O	O	B-Entity
,	O	O	O
including	O	O	O
10	O	O	O
ovarian	O	O	B-Entity
,	O	O	O
8	O	O	O
uterine	O	O	B-Entity
,	O	O	O
and	O	O	O
1	O	O	O
vulvar	O	O	B-Entity
tumors	O	O	B-Entity
,	O	O	O
are	O	O	O
herein	O	O	O
reported	O	O	B-Entity
.	O	O	O

Patient	O	O	B-Entity
age	O	O	B-Entity
ranged	O	O	B-Entity
from	O	O	O
12	O	O	O
to	O	O	O
68	O	O	O
years	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
median	O	O	O
age	O	O	O
of	O	O	O
20	O	O	O
and	O	O	O
51	O	O	O
years	O	O	O
among	O	O	O
those	O	O	O
with	O	O	O
ovarian	O	O	B-Entity
and	O	O	O
uterine	O	O	B-Entity
PNETs	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

Morphologic	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
central	O	O	B-Entity
nervous	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
CNS	O	O	B-Entity
)	O	O	O
tumors	O	O	B-Entity
were	O	O	O
seen	O	O	O
in	O	O	O
15	O	O	O
PNETs	O	O	B-Entity
,	O	O	O
including	O	O	O
9	O	O	O
medulloblastomas	O	O	B-Entity
,	O	O	O
3	O	O	O
ependymomas	O	O	B-Entity
,	O	O	O
2	O	O	O
medulloepitheliomas	O	O	B-Entity
,	O	O	O
and	O	O	O
1	O	O	O
glioblastoma	O	O	B-Entity
,	O	O	O
consistent	O	O	O
with	O	O	O
central	O	O	B-Entity
PNET	O	O	I-Entity
.	O	O	O

The	O	O	O
remaining	O	O	O
4	O	O	O
PNETs	O	O	B-Entity
were	O	O	O
composed	O	O	O
entirely	O	O	O
of	O	O	O
undifferentiated	O	O	B-Entity
small	O	O	B-Entity
round	O	O	I-Entity
blue	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
were	O	O	O
classified	O	O	O
as	O	O	O
Ewing	O	O	B-Entity
sarcoma/peripheral	O	O	I-Entity
PNET	O	O	I-Entity
.	O	O	O

Eight	O	O	O
PNETs	O	O	B-Entity
were	O	O	O
associated	O	O	O
with	O	O	O
another	O	O	O
tumor	O	O	B-Entity
type	O	O	O
,	O	O	O
including	O	O	O
5	O	O	O
ovarian	O	O	B-Entity
mature	O	O	B-Entity
cystic	O	O	I-Entity
teratomas	O	O	I-Entity
,	O	O	O
2	O	O	O
endometrial	O	O	B-Entity
low-grade	O	O	I-Entity
endometrioid	O	O	B-Entity
carcinomas	O	O	I-Entity
,	O	O	O
and	O	O	O
a	O	O	O
uterine	O	O	B-Entity
carcinosarcoma	O	O	I-Entity
.	O	O	O

By	O	O	O
immunohistochemistry	O	O	B-Entity
,	O	O	O
17	O	O	O
PNETs	O	O	B-Entity
expressed	O	O	O
at	O	O	O
least	O	O	O
1	O	O	O
marker	O	O	B-Entity
of	O	O	O
neuronal	O	O	B-Entity
differentiation	O	O	I-Entity
,	O	O	O
including	O	O	O
synaptophysin	O	O	B-Entity
,	O	O	O
NSE	O	O	B-Entity
,	O	O	O
CD56	O	O	B-Entity
,	O	O	O
S100	O	O	B-Entity
,	O	O	O
and	O	O	O
chromogranin	O	O	B-Entity
in	O	O	O
10	O	O	O
,	O	O	O
8	O	O	O
,	O	O	O
14	O	O	O
,	O	O	O
8	O	O	O
,	O	O	O
and	O	O	O
1	O	O	O
tumors	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

GFAP	O	O	B-Entity
was	O	O	O
positive	O	O	O
in	O	O	O
4	O	O	O
PNETs	O	O	B-Entity
,	O	O	O
all	O	O	O
of	O	O	O
which	O	O	O
were	O	O	O
of	O	O	O
central	O	O	O
type	O	O	O
.	O	O	O

Membranous	O	O	B-Entity
CD99	O	O	B-Entity
and	O	O	O
nuclear	O	O	B-Entity
Fli-1	O	O	B-Entity
staining	O	O	B-Entity
was	O	O	O
seen	O	O	O
in	O	O	O
10	O	O	O
and	O	O	O
16	O	O	O
tumors	O	O	B-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
and	O	O	O
concurrent	O	O	O
expression	O	O	B-Entity
of	O	O	O
both	O	O	O
markers	O	O	B-Entity
was	O	O	O
seen	O	O	O
in	O	O	O
both	O	O	O
central	O	O	B-Entity
and	O	O	O
Ewing	O	O	B-Entity
sarcoma/peripheral	O	O	I-Entity
PNET	O	O	I-Entity
s.	O	O	O
All	O	O	O
tumors	O	O	O
expressed	O	O	B-Entity
vimentin	O	O	B-Entity
,	O	O	O
whereas	O	O	O
keratin	O	O	B-Entity
cocktail	O	O	O
(	O	O	O
CAM5.2	O	O	B-Entity
,	O	O	O
AE1/AE3	O	O	B-Entity
)	O	O	O
staining	O	O	O
was	O	O	O
only	O	O	O
focally	O	O	O
present	O	O	O
in	O	O	O
4	O	O	O
PNETs	O	O	B-Entity
.	O	O	O

Fluorescence	O	O	B-Entity
in	O	O	I-Entity
situ	O	O	I-Entity
hybridization	O	O	I-Entity
was	O	O	O
successful	O	O	O
in	O	O	O
all	O	O	O
cases	O	O	B-Entity
and	O	O	O
confirmed	O	O	O
EWSR1	O	O	B-Entity
rearrangement	O	O	B-Entity
in	O	O	O
2	O	O	O
of	O	O	O
4	O	O	O
tumors	O	O	B-Entity
demonstrating	O	O	O
morphologic	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
Ewing	O	O	B-Entity
sarcoma/peripheral	O	O	I-Entity
PNET	O	O	I-Entity
and	O	O	O
concurrent	O	O	O
CD99	O	O	B-Entity
and	O	O	O
Fli-1	O	O	B-Entity
expression	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
central	O	O	B-Entity
and	O	O	O
Ewing	O	O	B-Entity
sarcoma/peripheral	O	O	I-Entity
PNETs	O	O	I-Entity
may	O	O	O
be	O	O	O
encountered	O	O	O
in	O	O	O
the	O	O	O
female	O	O	B-Entity
genital	O	O	I-Entity
tract	O	O	I-Entity
with	O	O	O
central	O	O	B-Entity
PNETs	O	O	I-Entity
being	O	O	O
more	O	O	O
common	O	O	O
.	O	O	O

Central	O	O	B-Entity
PNETs	O	O	I-Entity
show	O	O	O
a	O	O	O
spectrum	O	O	B-Entity
of	O	O	O
morphologic	O	O	B-Entity
features	O	O	B-Entity
that	O	O	O
overlaps	O	O	O
with	O	O	O
CNS	O	O	B-Entity
tumors	O	O	B-Entity
but	O	O	O
lack	O	O	O
EWSR1	O	O	B-Entity
rearrangement	O	O	B-Entity
s.	O	O	O
GFAP	O	O	B-Entity
expression	O	O	B-Entity
supports	O	O	O
a	O	O	O
morphologic	O	O	O
impression	O	O	O
of	O	O	O
central	O	O	B-Entity
PNET	O	O	I-Entity
and	O	O	O
is	O	O	O
absent	O	O	O
in	O	O	O
Ewing	O	O	O
sarcoma/peripheral	O	O	B-Entity
PNET	O	O	I-Entity
.	O	O	O

Ewing	O	O	B-Entity
sarcoma/peripheral	O	O	I-Entity
PNETs	O	O	I-Entity
lack	O	O	O
morphologic	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
CNS	O	O	B-Entity
tumors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28297577)

Surgical	O	O	B-Entity
Excision	O	O	I-Entity
of	O	O	O
Heterotopic	O	O	B-Entity
Ossification	O	O	I-Entity
Leads	O	O	O
to	O	O	O
Re-Emergence	O	O	B-Entity
of	O	O	O
Mesenchymal	O	O	B-Entity
Stem	O	O	I-Entity
Cell	O	O	I-Entity
Populations	O	O	I-Entity
Responsible	O	O	O
for	O	O	O
Recurrence	O	O	O

Trauma-induced	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
(	O	O	O
HO	O	O	B-Entity
)	O	O	O
occurs	O	O	O
after	O	O	O
severe	O	O	B-Entity
musculoskeletal	O	O	B-Entity
injuries	O	O	I-Entity
and	O	O	O
burns	O	O	B-Entity
,	O	O	O
and	O	O	O
presents	O	O	O
a	O	O	O
significant	O	O	B-Entity
barrier	O	O	O
to	O	O	O
patient	O	O	B-Entity
rehabilitation	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
HO	O	O	B-Entity
significantly	O	O	O
increases	O	O	B-Entity
with	O	O	O
repeated	O	O	B-Entity
operations	O	O	I-Entity
and	O	O	O
after	O	O	O
resection	O	O	B-Entity
of	O	O	O
previous	O	O	O
HO	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
of	O	O	O
established	O	O	O
heterotopic	O	O	B-Entity
ossification	O	O	I-Entity
is	O	O	O
challenging	O	O	O
because	O	O	O
surgical	O	O	B-Entity
excision	O	O	I-Entity
is	O	O	O
often	O	O	O
incomplete	O	O	B-Entity
,	O	O	O
with	O	O	O
evidence	O	O	B-Entity
of	O	O	I-Entity
persistent	O	O	B-Entity
heterotopic	O	O	B-Entity
bone	O	O	I-Entity
.	O	O	O

As	O	O	O
a	O	O	O
result	O	O	O
,	O	O	O
patients	O	O	B-Entity
may	O	O	O
continue	O	O	B-Entity
to	O	O	O
report	O	O	O
the	O	O	O
signs	O	O	B-Entity
or	O	O	I-Entity
symptoms	O	O	I-Entity
of	O	O	O
HO	O	O	B-Entity
,	O	O	O
including	O	O	O
chronic	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
nonhealing	O	O	B-Entity
wounds	O	O	B-Entity
,	O	O	O
and	O	O	O
joint	O	O	B-Entity
restriction	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
designed	O	O	O
a	O	O	O
model	O	O	B-Entity
of	O	O	O
recurrent	O	O	B-Entity
HO	O	O	B-Entity
that	O	O	O
occurs	O	O	O
after	O	O	O
surgical	O	O	B-Entity
excision	O	O	I-Entity
of	O	O	O
mature	O	O	B-Entity
HO	O	O	O
in	O	O	O
a	O	O	O
mouse	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
hind-limb	O	O	B-Entity
Achilles	O	O	I-Entity
'	O	O	I-Entity
tendon	O	O	I-Entity
transection	O	O	B-Entity
with	O	O	O
dorsal	O	O	B-Entity
burn	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

We	O	O	O
first	O	O	O
demonstrated	O	O	O
that	O	O	O
key	O	O	B-Entity
signaling	O	O	B-Entity
mediators	O	O	B-Entity
of	O	O	O
HO	O	O	B-Entity
,	O	O	O
including	O	O	O
bone	O	O	B-Entity
morphogenetic	O	O	I-Entity
protein	O	O	I-Entity
signaling	O	O	I-Entity
,	O	O	O
are	O	O	O
diminished	O	O	O
in	O	O	O
mature	O	O	B-Entity
bone	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
upon	O	O	O
surgical	O	O	B-Entity
excision	O	O	I-Entity
,	O	O	O
we	O	O	O
have	O	O	O
noted	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
downstream	O	O	B-Entity
mediators	O	O	B-Entity
of	O	O	O
osteogenic	O	O	B-Entity
differentiation	O	O	B-Entity
,	O	O	O
including	O	O	O
pSMAD	O	O	B-Entity
1	O	O	I-Entity
/	O	O	O
5	O	O	B-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
surgical	O	O	B-Entity
excision	O	O	I-Entity
resulted	O	O	O
in	O	O	O
re-emergence	O	O	B-Entity
of	O	O	O
a	O	O	O
mesenchymal	O	O	B-Entity
cell	O	O	I-Entity
population	O	O	I-Entity
marked	O	O	O
by	O	O	O
expression	O	O	B-Entity
of	O	O	O
platelet-derived	O	O	B-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
receptor-α	O	O	I-Entity
(	O	O	O
PDGFRα	O	O	B-Entity
)	O	O	O
and	O	O	O
present	O	O	B-Entity
in	O	O	O
the	O	O	O
initial	O	O	B-Entity
developing	O	O	O
HO	O	O	B-Entity
lesion	O	O	B-Entity
but	O	O	O
absent	O	O	B-Entity
in	O	O	O
mature	O	O	B-Entity
HO	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
recurrent	O	O	B-Entity
lesion	O	O	B-Entity
,	O	O	O
these	O	O	O
PDGFRα	O	O	B-Entity
+	O	O	O
mesenchymal	O	O	B-Entity
cells	O	O	I-Entity
are	O	O	O
also	O	O	O
highly	O	O	O
proliferative	O	O	B-Entity
,	O	O	O
similar	O	O	O
to	O	O	O
the	O	O	O
initial	O	O	B-Entity
developing	O	O	O
HO	O	O	B-Entity
lesion	O	O	O
.	O	O	O

These	O	O	O
findings	O	O	O
indicate	O	O	O
that	O	O	O
surgical	O	O	B-Entity
excision	O	O	I-Entity
of	O	O	O
HO	O	O	B-Entity
results	O	O	B-Entity
in	O	O	O
recurrence	O	O	B-Entity
through	O	O	O
similar	O	O	O
mesenchymal	O	O	B-Entity
cell	O	O	I-Entity
populations	O	O	I-Entity
and	O	O	O
signaling	O	O	B-Entity
mechanisms	O	O	B-Entity
that	O	O	O
are	O	O	O
present	O	O	B-Entity
in	O	O	O
the	O	O	O
initial	O	O	B-Entity
developing	O	O	O
HO	O	O	O
lesion	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
are	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
findings	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
that	O	O	O
new	O	O	O
foci	O	O	B-Entity
of	O	O	O
ectopic	O	O	B-Entity
bone	O	O	B-Entity
can	O	O	O
develop	O	O	O
in	O	O	O
excision	O	O	B-Entity
sites	O	O	B-Entity
and	O	O	O
are	O	O	O
likely	O	O	O
related	O	O	O
to	O	O	O
de	O	O	B-Entity
novo	O	O	I-Entity
formation	O	O	B-Entity
rather	O	O	O
than	O	O	O
extension	O	O	B-Entity
of	O	O	O
unresected	O	O	B-Entity
bone	O	O	O
.	O	O	O

Stem	O	O	O
Cells	O	O	O
Translational	O	O	O
Medicine	O	O	O
2017;6:799	O	O	O
-	O	O	O
806	O	O	O
.	O	O	O

-DOCSTART- (28298171)

Extended	O	O	B-Entity
release	O	O	I-Entity
of	O	O	O
flurbiprofen	O	O	B-Entity
from	O	O	O
tromethamine	O	O	B-Entity
-	O	O	O
buffered	O	O	B-Entity
HPMC	O	O	B-Entity
hydrophilic	O	O	B-Entity
matrix	O	O	O
tablets	O	O	O

The	O	O	O
pH	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
solubility	O	O	B-Entity
of	O	O	O
a	O	O	O
drug	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
pH	O	O	O
-	O	O	O
dependent	O	O	O
drug	O	O	B-Entity
release	O	O	I-Entity
from	O	O	O
hydrophilic	O	O	B-Entity
matrix	O	O	B-Entity
tablets	O	O	I-Entity
.	O	O	O

Adding	O	O	O
buffer	O	O	B-Entity
salts	O	O	I-Entity
to	O	O	O
the	O	O	O
formulation	O	O	B-Entity
to	O	O	O
attempt	O	O	B-Entity
to	O	O	O
mitigate	O	O	B-Entity
this	O	O	O
can	O	O	O
impair	O	O	B-Entity
matrix	O	O	B-Entity
hydration	O	O	I-Entity
and	O	O	O
negatively	O	O	B-Entity
impact	O	O	B-Entity
drug	O	O	B-Entity
release	O	O	I-Entity
.	O	O	O

An	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
buffering	O	O	B-Entity
of	O	O	O
hydrophilic	O	O	B-Entity
matrix	O	O	B-Entity
tablets	O	O	I-Entity
containing	O	O	O
a	O	O	O
pH	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
solubility	O	O	B-Entity
weak	O	O	B-Entity
acid	O	O	I-Entity
drug	O	O	I-Entity
(	O	O	O
flurbiprofen	O	O	B-Entity
)	O	O	O
,	O	O	O
identified	O	O	B-Entity
as	O	O	O
possessing	O	O	B-Entity
a	O	O	O
deleterious	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
hydroxypropyl	O	O	B-Entity
methylcellulose	O	O	I-Entity
(	O	O	O
HPMC	O	O	B-Entity
)	O	O	O
solubility	O	O	O
,	O	O	O
swelling	O	O	B-Entity
and	O	O	O
gelation	O	O	B-Entity
,	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
drug	O	O	B-Entity
dissolution	O	O	I-Entity
and	O	O	O
the	O	O	O
characteristics	O	O	B-Entity
of	O	O	O
the	O	O	O
hydrophilic	O	O	O
matrix	O	O	B-Entity
gel	O	O	I-Entity
layer	O	O	I-Entity
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
tromethamine	O	O	B-Entity
as	O	O	O
a	O	O	O
buffer	O	O	B-Entity
was	O	O	O
undertaken	O	O	O
.	O	O	O

The	O	O	O
inclusion	O	O	B-Entity
of	O	O	O
tromethamine	O	O	B-Entity
as	O	O	O
an	O	O	O
alkalizing	O	O	B-Entity
agent	O	O	I-Entity
afforded	O	O	O
pH	O	O	B-Entity
-	O	O	O
independent	O	O	B-Entity
flurbiprofen	O	O	B-Entity
release	O	O	B-Entity
from	O	O	O
matrices	O	O	B-Entity
based	O	O	O
on	O	O	O
both	O	O	O
HPMC	O	O	B-Entity
2910	O	O	I-Entity
(	O	O	I-Entity
E	O	O	I-Entity
series	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
2208	O	O	B-Entity
(	O	O	I-Entity
K	O	O	I-Entity
series	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
while	O	O	O
concomitantly	O	O	B-Entity
decreasing	O	O	B-Entity
the	O	O	O
apparent	O	O	O
critical	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
dissolution	O	O	B-Entity
mediated	O	O	B-Entity
by	O	O	O
this	O	O	O
drug	O	O	B-Entity
with	O	O	O
respect	O	O	O
to	O	O	O
the	O	O	O
early	O	O	O
pseudo-gel	O	O	B-Entity
layer	O	O	I-Entity
formation	O	O	I-Entity
and	O	O	O
functionality	O	O	B-Entity
.	O	O	O

Drug	O	O	B-Entity
release	O	O	I-Entity
profiles	O	O	I-Entity
were	O	O	O
unaffected	O	O	B-Entity
by	O	O	O
matrix	O	O	B-Entity
pH-changes	O	O	B-Entity
resulting	O	O	O
from	O	O	O
loss	O	O	B-Entity
of	O	O	O
tromethamine	O	O	B-Entity
over	O	O	B-Entity
time	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
HPMC	O	O	B-Entity
inhibited	O	O	B-Entity
precipitation	O	O	B-Entity
of	O	O	O
drug	O	O	B-Entity
from	O	O	O
supersaturated	O	O	B-Entity
solution	O	O	I-Entity
in	O	O	O
the	O	O	O
hydrated	O	O	B-Entity
matrix	O	O	I-Entity
.	O	O	O

We	O	O	O
propose	O	O	O
that	O	O	O
facilitation	O	O	B-Entity
of	O	O	O
diffusion-based	O	O	B-Entity
release	O	O	B-Entity
of	O	O	O
potentially	O	O	O
deleterious	O	O	B-Entity
drugs	O	O	I-Entity
in	O	O	O
hydrophilic	O	O	B-Entity
matrices	O	O	B-Entity
may	O	O	O
be	O	O	O
achieved	O	O	O
through	O	O	O
judicious	O	O	O
selection	O	O	O
of	O	O	O
a	O	O	O
buffering	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

-DOCSTART- (28299515)

The	O	O	O
influence	O	O	B-Entity
of	O	O	O
slope	O	O	B-Entity
on	O	O	O
Spartium	O	O	B-Entity
junceum	O	O	I-Entity
root	O	O	B-Entity
system	O	O	I-Entity
:	O	O	O
morphological	O	O	B-Entity
,	O	O	O
anatomical	O	O	B-Entity
and	O	O	O
biomechanical	O	O	B-Entity
adaptation	O	O	O

Root	O	O	B-Entity
systems	O	O	I-Entity
have	O	O	O
a	O	O	O
pivotal	O	O	O
role	O	O	B-Entity
in	O	O	O
plant	O	O	B-Entity
anchorage	O	O	B-Entity
and	O	O	O
their	O	O	O
mechanical	O	O	B-Entity
interactions	O	O	I-Entity
with	O	O	O
the	O	O	O
soil	O	O	B-Entity
may	O	O	O
contribute	O	O	O
to	O	O	O
soil	O	O	O
reinforcement	O	O	B-Entity
and	O	O	O
stabilization	O	O	B-Entity
of	O	O	O
slide-prone	O	O	B-Entity
slopes	O	O	I-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
responses	O	O	B-Entity
of	O	O	O
root	O	O	B-Entity
system	O	O	I-Entity
to	O	O	O
mechanical	O	O	B-Entity
stress	O	O	I-Entity
induced	O	O	B-Entity
by	O	O	O
slope	O	O	B-Entity
,	O	O	O
samples	O	O	B-Entity
of	O	O	O
Spartium	O	O	B-Entity
junceum	O	O	I-Entity
L.	O	O	I-Entity
,	O	O	O
growing	O	O	B-Entity
in	O	O	O
slope	O	O	O
and	O	O	O
in	O	O	O
plane	O	O	B-Entity
natural	O	O	B-Entity
conditions	O	O	I-Entity
,	O	O	O
were	O	O	O
compared	O	O	O
in	O	O	O
their	O	O	O
morphology	O	O	B-Entity
,	O	O	O
biomechanical	O	O	B-Entity
properties	O	O	I-Entity
and	O	O	O
anatomical	O	O	B-Entity
features	O	O	I-Entity
.	O	O	O

Soils	O	O	B-Entity
sampled	O	O	B-Entity
in	O	O	O
slope	O	O	B-Entity
and	O	O	O
plane	O	O	B-Entity
revealed	O	O	O
similar	O	O	O
characteristics	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
exception	O	O	B-Entity
of	O	O	O
organic	O	O	B-Entity
matter	O	O	I-Entity
content	O	O	B-Entity
and	O	O	O
penetrometer	O	O	B-Entity
resistance	O	O	I-Entity
,	O	O	O
both	O	O	O
higher	O	O	O
in	O	O	O
slope	O	O	O
.	O	O	O

Slope	O	O	B-Entity
significantly	O	O	O
influenced	O	O	B-Entity
root	O	O	B-Entity
morphology	O	O	B-Entity
and	O	O	O
in	O	O	O
particular	O	O	O
the	O	O	O
distribution	O	O	B-Entity
of	O	O	O
lateral	O	O	B-Entity
roots	O	O	B-Entity
along	O	O	O
the	O	O	O
soil	O	O	B-Entity
depth	O	O	B-Entity
.	O	O	O

Indeed	O	O	O
,	O	O	O
first-order	O	O	B-Entity
lateral	O	O	B-Entity
roots	O	O	B-Entity
of	O	O	O
plants	O	O	B-Entity
growing	O	O	B-Entity
on	O	O	O
slope	O	O	B-Entity
condition	O	O	B-Entity
showed	O	O	O
an	O	O	O
asymmetric	O	O	B-Entity
distribution	O	O	B-Entity
between	O	O	O
up-	O	O	B-Entity
and	O	O	O
down-slope	O	O	B-Entity
.	O	O	O

Contrarily	O	O	O
,	O	O	O
this	O	O	O
asymmetric	O	O	B-Entity
distribution	O	O	B-Entity
was	O	O	O
not	O	O	O
observed	O	O	O
in	O	O	O
plants	O	O	B-Entity
growing	O	O	B-Entity
in	O	O	O
plane	O	O	B-Entity
.	O	O	O

The	O	O	O
tensile	O	O	B-Entity
strength	O	O	I-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
lateral	O	O	B-Entity
roots	O	O	B-Entity
growing	O	O	B-Entity
up-slope	O	O	B-Entity
and	O	O	O
in	O	O	O
plane	O	O	B-Entity
conditions	O	O	B-Entity
than	O	O	O
in	O	O	O
those	O	O	O
growing	O	O	O
down-slope	O	O	B-Entity
.	O	O	O

Anatomical	O	O	B-Entity
investigations	O	O	I-Entity
revealed	O	O	O
that	O	O	O
,	O	O	O
while	O	O	O
roots	O	O	B-Entity
grown	O	O	O
up-slope	O	O	B-Entity
had	O	O	O
higher	O	O	O
area	O	O	B-Entity
covered	O	O	O
by	O	O	O
xylem	O	O	B-Entity
fibers	O	O	I-Entity
,	O	O	O
the	O	O	O
ratio	O	O	B-Entity
of	O	O	O
xylem	O	O	O
and	O	O	O
phloem	O	O	B-Entity
fibers	O	O	I-Entity
to	O	O	O
root	O	O	B-Entity
diameter	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
among	O	O	O
the	O	O	O
three	O	O	O
conditions	O	O	B-Entity
,	O	O	O
as	O	O	O
also	O	O	O
,	O	O	O
no	O	O	B-Entity
differences	O	O	I-Entity
were	O	O	O
found	O	O	O
for	O	O	O
xylem	O	O	B-Entity
fiber	O	O	I-Entity
cell	O	O	B-Entity
wall	O	O	I-Entity
thickness	O	O	B-Entity
.	O	O	O

Roots	O	O	B-Entity
growing	O	O	B-Entity
up-slope	O	O	B-Entity
were	O	O	O
the	O	O	O
main	O	O	O
contributors	O	O	O
to	O	O	O
anchorage	O	O	B-Entity
properties	O	O	B-Entity
,	O	O	O
which	O	O	O
included	O	O	O
higher	O	O	O
strength	O	O	B-Entity
and	O	O	O
higher	O	O	O
number	O	O	O
of	O	O	O
fibers	O	O	B-Entity
in	O	O	O
the	O	O	O
xylematic	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

Results	O	O	O
suggested	O	O	O
that	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
root	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
morphological	O	O	B-Entity
,	O	O	O
anatomical	O	O	B-Entity
and	O	O	O
biomechanical	O	O	B-Entity
traits	O	O	B-Entity
,	O	O	O
determines	O	O	O
anchorage	O	O	B-Entity
functions	O	O	B-Entity
in	O	O	O
slope	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

-DOCSTART- (28299817)

Altered	O	O	O
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
Olr59	O	O	B-Entity
,	O	O	O
Ethe1	O	O	B-Entity
,	O	O	O
and	O	O	O
Slc10a2	O	O	B-Entity
genes	O	O	I-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
of	O	O	O
F344	O	O	B-Entity
rats	O	O	I-Entity
by	O	O	O
neonatal	O	O	B-Entity
thyroid	O	O	O
hormone	O	O	O
disruption	O	O	O

Many	O	O	O
concerns	O	O	O
have	O	O	O
been	O	O	O
expressed	O	O	O
regarding	O	O	O
the	O	O	O
possible	O	O	O
adverse	O	O	O
effects	O	O	O
of	O	O	O
thyroid	O	O	B-Entity
hormone-disrupting	O	O	I-Entity
chemicals	O	O	B-Entity
in	O	O	O
the	O	O	O
environment	O	O	B-Entity
.	O	O	O

The	O	O	O
disruption	O	O	B-Entity
of	O	O	I-Entity
thyroid	O	O	B-Entity
hormones	O	O	I-Entity
in	O	O	O
the	O	O	O
neonatal	O	O	B-Entity
period	O	O	I-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
permanent	O	O	B-Entity
effects	O	O	I-Entity
on	O	O	O
thyroid	O	O	B-Entity
hormone	O	O	I-Entity
homeostasis	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
related	O	O	O
developmental	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
as	O	O	O
thyroid	O	O	O
hormones	O	O	O
are	O	O	O
essential	O	O	O
for	O	O	O
regulating	O	O	B-Entity
the	O	O	I-Entity
growth	O	O	I-Entity
and	O	O	O
differentiation	O	O	B-Entity
of	O	O	I-Entity
many	O	O	I-Entity
tissues	O	O	I-Entity
.	O	O	O

To	O	O	O
understand	O	O	O
the	O	O	O
long-term	O	O	O
alteration	O	O	O
in	O	O	O
gene	O	O	B-Entity
expressions	O	O	I-Entity
by	O	O	O
neonatal	O	O	B-Entity
administration	O	O	B-Entity
of	O	O	I-Entity
thyroid	O	O	B-Entity
hormone	O	O	I-Entity
-like	O	O	O
chemicals	O	O	O
in	O	O	O
general	O	O	O
,	O	O	O
we	O	O	O
identified	O	O	O
genes	O	O	B-Entity
whose	O	O	I-Entity
expression	O	O	I-Entity
was	O	O	O
altered	O	O	B-Entity
in	O	O	O
the	O	O	O
liver	O	O	B-Entity
,	O	O	O
an	O	O	O
important	O	O	O
component	O	O	O
of	O	O	O
the	O	O	O
thyroid	O	O	O
hormone	O	O	O
axis	O	O	O
,	O	O	O
by	O	O	O
neonatal	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
triiodothyronine	O	O	B-Entity
(	O	O	O
T3	O	O	B-Entity
)	O	O	O
.	O	O	O

T3	O	O	B-Entity
was	O	O	O
administered	O	O	B-Entity
to	O	O	O
male	O	O	B-Entity
F344	O	O	I-Entity
rats	O	O	I-Entity
on	O	O	O
postnatal	O	O	B-Entity
days	O	O	I-Entity
1	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
and	O	O	O
5	O	O	O
(	O	O	O
week	O	O	O
0	O	O	O
)	O	O	O
.	O	O	O

At	O	O	O
8	O	O	O
weeks	O	O	O
of	O	O	O
age	O	O	O
,	O	O	O
cDNA	O	O	B-Entity
microarray	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
identify	O	O	O
hepatic	O	O	B-Entity
genes	O	O	B-Entity
whose	O	O	O
expression	O	O	B-Entity
was	O	O	O
altered	O	O	O
by	O	O	O
neonatal	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	I-Entity
T3	O	O	B-Entity
.	O	O	O

Among	O	O	O
the	O	O	O
up-regulated	O	O	B-Entity
genes	O	O	I-Entity
that	O	O	O
were	O	O	O
identified	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
Olr59	O	O	B-Entity
,	O	O	O
Ethe1	O	O	B-Entity
,	O	O	O
and	O	O	O
Slc10a2	O	O	B-Entity
increased	O	O	O
specifically	O	O	O
in	O	O	O
rats	O	O	B-Entity
neonatally	O	O	B-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
T3	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
altered	O	O	O
hepatic	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	I-Entity
these	O	O	I-Entity
genes	O	O	I-Entity
indeed	O	O	O
increased	O	O	O
when	O	O	O
a	O	O	O
hydroxylated	O	O	B-Entity
polybrominated	O	O	I-Entity
diphenyl	O	O	I-Entity
ether	O	O	I-Entity
(	O	O	O
PBDE	O	O	B-Entity
)	O	O	O
,	O	O	O
OH-BDE42	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
capable	O	O	O
of	O	O	O
binding	O	O	B-Entity
to	O	O	I-Entity
the	O	O	I-Entity
TR	O	O	I-Entity
,	O	O	O
was	O	O	O
given	O	O	O
neonatally	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	O
demonstrated	O	O	O
that	O	O	O
neonatal	O	O	B-Entity
exposure	O	O	O
to	O	O	O
thyroid	O	O	B-Entity
hormones	O	O	I-Entity
could	O	O	O
affect	O	O	O
the	O	O	O
long-term	O	O	O
expression	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
genes	O	O	I-Entity
,	O	O	O
which	O	O	O
could	O	O	O
be	O	O	O
useful	O	O	O
markers	O	O	O
for	O	O	O
neonatal	O	O	B-Entity
effects	O	O	I-Entity
by	O	O	O
thyroid	O	O	B-Entity
hormone	O	O	I-Entity
-	O	O	O
disrupting	O	O	B-Entity
chemicals	O	O	I-Entity
.	O	O	O

Copyright	O	O	O
©	O	O	O
2017	O	O	O
John	O	O	O
Wiley	O	O	O
&	O	O	O
Sons	O	O	O
,	O	O	O
Ltd.	O	O	O

-DOCSTART- (28300431)

The	O	O	O
Psychometric	O	O	B-Entity
Costs	O	O	I-Entity
of	O	O	O
Applicants	O	O	B-Entity
'	O	O	O
Faking	O	O	B-Entity
:	O	O	O
Examining	O	O	O
Measurement	O	O	B-Entity
Invariance	O	O	O
and	O	O	O
Retest	O	O	B-Entity
Correlations	O	O	I-Entity
Across	O	O	O
Response	O	O	O
Conditions	O	O	O

This	O	O	O
study	O	O	O
examines	O	O	B-Entity
the	O	O	I-Entity
stability	O	O	I-Entity
of	O	O	O
the	O	O	O
response	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
the	O	O	O
rank-order	O	O	B-Entity
of	O	O	O
respondents	O	O	B-Entity
responding	O	O	B-Entity
to	O	O	O
3	O	O	O
personality	O	O	B-Entity
scales	O	O	I-Entity
in	O	O	O
4	O	O	O
different	O	O	O
response	O	O	B-Entity
conditions	O	O	I-Entity
.	O	O	O

Applicants	O	O	B-Entity
to	O	O	O
the	O	O	O
University	O	O	B-Entity
College	O	O	I-Entity
of	O	O	I-Entity
Teacher	O	O	I-Entity
Education	O	O	I-Entity
Styria	O	O	B-Entity
(	O	O	O
N	O	O	O
=	O	O	O
243	O	O	O
)	O	O	O
completed	O	O	O
personality	O	O	B-Entity
scales	O	O	I-Entity
as	O	O	O
part	O	O	O
of	O	O	O
their	O	O	O
college	O	O	B-Entity
admission	O	O	I-Entity
process	O	O	I-Entity
.	O	O	O

Half	O	O	O
a	O	O	O
year	O	O	O
later	O	O	O
,	O	O	O
they	O	O	O
retook	O	O	O
the	O	O	O
same	O	O	O
personality	O	O	B-Entity
scales	O	O	I-Entity
in	O	O	O
1	O	O	O
of	O	O	O
3	O	O	O
randomly	O	O	B-Entity
assigned	O	O	I-Entity
experimental	O	O	O
response	O	O	B-Entity
conditions	O	O	I-Entity
:	O	O	O
honest	O	O	B-Entity
,	O	O	O
faking-good	O	O	B-Entity
,	O	O	O
or	O	O	O
reproduce	O	O	O
.	O	O	O

Longitudinal	O	O	B-Entity
means	O	O	I-Entity
and	O	O	O
covariance	O	O	B-Entity
structure	O	O	I-Entity
analyses	O	O	I-Entity
showed	O	O	O
that	O	O	O
applicants	O	O	B-Entity
'	O	O	O
response	O	O	B-Entity
processes	O	O	I-Entity
could	O	O	O
be	O	O	O
partially	O	O	O
reproduced	O	O	O
after	O	O	O
half	O	O	O
a	O	O	O
year	O	O	O
,	O	O	O
and	O	O	O
respondents	O	O	B-Entity
seemed	O	O	O
to	O	O	O
rely	O	O	O
on	O	O	O
an	O	O	O
honest	O	O	B-Entity
response	O	O	B-Entity
behavior	O	O	I-Entity
as	O	O	O
a	O	O	O
frame	O	O	B-Entity
of	O	O	I-Entity
reference	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
applicants	O	O	B-Entity
'	O	O	O
faking	O	O	B-Entity
behavior	O	O	I-Entity
and	O	O	O
instructed	O	O	O
faking	O	O	O
(	O	O	O
faking-good	O	O	B-Entity
)	O	O	O
caused	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
latent	O	O	B-Entity
retest	O	O	B-Entity
correlations	O	O	I-Entity
and	O	O	O
consistently	O	O	O
affected	O	O	O
measurement	O	O	B-Entity
properties	O	O	O
.	O	O	O

The	O	O	O
varying	O	O	O
latent	O	O	B-Entity
retest	O	O	B-Entity
correlations	O	O	I-Entity
indicated	O	O	B-Entity
that	O	O	O
faking	O	O	B-Entity
can	O	O	O
distort	O	O	B-Entity
respondents	O	O	B-Entity
'	O	O	O
rank-order	O	O	B-Entity
and	O	O	O
thus	O	O	O
the	O	O	O
fairness	O	O	B-Entity
of	O	O	O
subsequent	O	O	O
selection	O	O	B-Entity
decisions	O	O	I-Entity
,	O	O	O
depending	O	O	O
on	O	O	O
the	O	O	O
kind	O	O	O
of	O	O	O
faking	O	O	B-Entity
behavior	O	O	I-Entity
.	O	O	O

Instructed	O	O	O
faking	O	O	B-Entity
(	O	O	O
faking-good	O	O	B-Entity
)	O	O	O
even	O	O	O
affected	O	O	O
weak	O	O	O
measurement	O	O	B-Entity
invariance	O	O	O
,	O	O	O
whereas	O	O	O
applicants	O	O	B-Entity
'	O	O	O
faking	O	O	B-Entity
behavior	O	O	I-Entity
did	O	O	O
not	O	O	O
.	O	O	O

Consequently	O	O	O
,	O	O	O
correlations	O	O	B-Entity
with	O	O	O
personality	O	O	B-Entity
scales	O	O	I-Entity
-which	O	O	O
can	O	O	O
be	O	O	O
utilized	O	O	O
for	O	O	O
predictive	O	O	B-Entity
validity	O	O	I-Entity
-may	O	O	O
be	O	O	O
readily	O	O	O
interpreted	O	O	B-Entity
for	O	O	O
applicants	O	O	B-Entity
.	O	O	O

Faking	O	O	B-Entity
behavior	O	O	I-Entity
also	O	O	O
introduced	O	O	O
a	O	O	O
uniform	O	O	B-Entity
bias	O	O	I-Entity
,	O	O	O
implying	O	O	O
that	O	O	O
the	O	O	O
classically	O	O	O
observed	O	O	O
mean	O	O	B-Entity
raw	O	O	I-Entity
score	O	O	I-Entity
differences	O	O	O
may	O	O	O
not	O	O	O
be	O	O	O
readily	O	O	O
interpreted	O	O	B-Entity
.	O	O	O

-DOCSTART- (28303067)

Intraspinal	O	O	B-Entity
meningioma	O	O	I-Entity
with	O	O	O
malignant	O	O	B-Entity
transformation	O	O	I-Entity
and	O	O	O
distant	O	O	O
metastasis	O	O	O

Meningioma	O	O	B-Entity
is	O	O	O
typically	O	O	O
considered	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
benign	O	O	B-Entity
tumor	O	O	I-Entity
.	O	O	O

Malignant	O	O	B-Entity
transformation	O	O	I-Entity
and	O	O	O
metastasis	O	O	B-Entity
of	O	O	O
meningiomas	O	O	B-Entity
are	O	O	O
rare	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
most	O	O	O
meningiomas	O	O	B-Entity
are	O	O	O
intracranial	O	O	B-Entity
,	O	O	O
and	O	O	O
there	O	O	O
are	O	O	O
few	O	O	O
reports	O	O	B-Entity
on	O	O	O
intraspinal	O	O	B-Entity
meningiomas	O	O	I-Entity
.	O	O	O

This	O	O	O
report	O	O	B-Entity
aimed	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
clinical	O	O	B-Entity
features	O	O	I-Entity
and	O	O	O
pathological	O	O	B-Entity
findings	O	O	B-Entity
of	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
malignant	O	O	B-Entity
transformation	O	O	I-Entity
and	O	O	O
distant	O	O	B-Entity
metastasis	O	O	I-Entity
of	O	O	O
intraspinal	O	O	B-Entity
meningioma	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
review	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
literature	O	O	B-Entity
.	O	O	O

A	O	O	O
44-year-old	O	O	O
man	O	O	B-Entity
with	O	O	O
a	O	O	O
bilateral	O	O	B-Entity
lower	O	O	B-Entity
limb	O	O	I-Entity
paresis	O	O	I-Entity
was	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
an	O	O	O
intradural	O	O	B-Entity
extramedullary	O	O	I-Entity
tumor	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
thoracic	O	O	I-Entity
spine	O	O	I-Entity
.	O	O	O

Primary	O	O	B-Entity
tumor	O	O	B-Entity
resection	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
histological	O	O	B-Entity
findings	O	O	I-Entity
revealed	O	O	O
atypical	O	O	B-Entity
meningioma	O	O	I-Entity
.	O	O	O

The	O	O	O
meningioma	O	O	B-Entity
recurred	O	O	B-Entity
2	O	O	O
years	O	O	B-Entity
after	O	O	O
the	O	O	O
primary	O	O	B-Entity
surgery	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
second	O	O	B-Entity
resection	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
,	O	O	O
but	O	O	O
only	O	O	O
partial	O	O	B-Entity
resection	O	O	O
was	O	O	O
possible	O	O	O
because	O	O	O
of	O	O	O
decreased	O	O	B-Entity
motor	O	O	B-Entity
evoked	O	O	I-Entity
potential	O	O	I-Entity
.	O	O	O

At	O	O	O
age	O	O	B-Entity
48	O	O	O
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
lower	O	O	B-Entity
limb	O	O	I-Entity
weakness	O	O	I-Entity
returned	O	O	B-Entity
,	O	O	O
and	O	O	O
a	O	O	O
third	O	O	B-Entity
resection	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
histological	O	O	B-Entity
finding	O	O	I-Entity
remained	O	O	O
atypical	O	O	B-Entity
meningioma	O	O	I-Entity
.	O	O	O

At	O	O	O
age	O	O	B-Entity
54	O	O	O
,	O	O	O
the	O	O	O
tumor	O	O	B-Entity
increased	O	O	B-Entity
and	O	O	O
stereotactic	O	O	B-Entity
irradiation	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
.	O	O	O

At	O	O	O
age	O	O	B-Entity
60	O	O	O
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
was	O	O	O
diagnosed	O	O	B-Entity
with	O	O	O
metastatic	O	O	B-Entity
tumors	O	O	I-Entity
of	O	O	O
the	O	O	O
rib	O	O	B-Entity
,	O	O	O
lumbar	O	O	B-Entity
vertebra	O	O	I-Entity
,	O	O	O
cervical	O	O	B-Entity
spine	O	O	I-Entity
,	O	O	O
and	O	O	O
sacrum	O	O	B-Entity
.	O	O	O

Biopsy	O	O	B-Entity
of	O	O	O
the	O	O	O
rib	O	O	B-Entity
metastatic	O	O	B-Entity
tumor	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
histological	O	O	B-Entity
findings	O	O	I-Entity
revealed	O	O	O
anaplastic	O	O	B-Entity
meningioma	O	O	I-Entity
.	O	O	O

This	O	O	O
case	O	O	B-Entity
is	O	O	O
the	O	O	O
first	O	O	O
report	O	O	B-Entity
of	O	O	O
an	O	O	O
intraspinal	O	O	B-Entity
meningioma	O	O	I-Entity
that	O	O	O
transformed	O	O	B-Entity
from	O	O	O
atypical	O	O	B-Entity
to	O	O	O
anaplastic	O	O	B-Entity
meningioma	O	O	I-Entity
with	O	O	O
distant	O	O	B-Entity
hematogenous	O	O	B-Entity
metastasis	O	O	I-Entity
.	O	O	O

-DOCSTART- (28303341)

Epidemiology	O	O	B-Entity
and	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
surgical	O	O	B-Entity
site	O	O	I-Entity
infection	O	O	I-Entity
after	O	O	O
different	O	O	O
types	O	O	B-Entity
of	O	O	O
hepatobiliary	O	O	O
and	O	O	O
pancreatic	O	O	O
surgery	O	O	O

Surgical	O	O	B-Entity
site	O	O	I-Entity
infection	O	O	I-Entity
(	O	O	O
SSI	O	O	B-Entity
)	O	O	O
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
healthcare-associated	O	O	B-Entity
infections	O	O	I-Entity
(	O	O	O
HAIs	O	O	B-Entity
)	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
SSI	O	O	O
after	O	O	O
hepatobiliary	O	O	B-Entity
and	O	O	I-Entity
pancreatic	O	O	I-Entity
surgery	O	O	I-Entity
(	O	O	O
HBPS	O	O	B-Entity
)	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
well	O	O	O
investigated	O	O	B-Entity
in	O	O	O
a	O	O	O
large	O	O	B-Entity
cohort	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
analyzed	O	O	O
the	O	O	O
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
SSI	O	O	B-Entity
following	O	O	O
HBPS	O	O	B-Entity
in	O	O	O
Japan	O	O	B-Entity
,	O	O	O
using	O	O	O
a	O	O	O
Japanese	O	O	B-Entity
national	O	O	I-Entity
database	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
HBPS	O	O	B-Entity
performed	O	O	B-Entity
between	O	O	O
2012	O	O	O
and	O	O	O
2014	O	O	O
were	O	O	O
extracted	O	O	B-Entity
from	O	O	O
a	O	O	O
national	O	O	B-Entity
monitoring	O	O	I-Entity
system	O	O	I-Entity
for	O	O	O
HAI	O	O	B-Entity
:	O	O	O
The	O	O	O
Japan	O	O	B-Entity
Nosocomial	O	O	I-Entity
Infections	O	O	I-Entity
Surveillance	O	O	I-Entity
.	O	O	O

Using	O	O	O
multivariate	O	O	B-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
,	O	O	O
I	O	O	O
assessed	O	O	B-Entity
the	O	O	O
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
SSI	O	O	B-Entity
.	O	O	O

The	O	O	O
cumulative	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
SSI	O	O	B-Entity
following	O	O	O
HBPS	O	O	B-Entity
was	O	O	O
15.6	O	O	O
%	O	O	O
(	O	O	O
2873/18,398	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
SSI	O	O	B-Entity
after	O	O	O
pancreatoduodenectomy	O	O	B-Entity
was	O	O	O
28.0	O	O	O
%	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
that	O	O	O
after	O	O	O
liver	O	O	B-Entity
resection	O	O	I-Entity
and	O	O	O
other	O	O	O
types	O	O	B-Entity
of	O	O	O
HBPS	O	O	B-Entity
(	O	O	O
8.8	O	O	O
and	O	O	O
15.5	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Among	O	O	O
the	O	O	O
four	O	O	O
traditional	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
the	O	O	O
American	O	O	B-Entity
Society	O	O	I-Entity
of	O	O	I-Entity
Anesthesiologists	O	O	I-Entity
score	O	O	B-Entity
was	O	O	O
ineffective	O	O	B-Entity
for	O	O	O
predicting	O	O	B-Entity
SSI	O	O	B-Entity
in	O	O	O
the	O	O	O
final	O	O	O
model	O	O	B-Entity
of	O	O	O
all	O	O	O
three	O	O	O
types	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
.	O	O	O

Additional	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
,	O	O	O
including	O	O	O
age	O	O	B-Entity
and	O	O	O
male	O	O	B-Entity
gender	O	O	I-Entity
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
and	O	O	O
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
SSI	O	O	B-Entity
after	O	O	O
the	O	O	O
three	O	O	O
types	O	O	B-Entity
of	O	O	O
HBPS	O	O	B-Entity
analyzed	O	O	O
differed	O	O	O
significantly	O	O	O
.	O	O	O

To	O	O	O
accurately	O	O	B-Entity
compare	O	O	B-Entity
hospital	O	O	B-Entity
performance	O	O	B-Entity
in	O	O	O
relation	O	O	B-Entity
to	O	O	O
SSI	O	O	B-Entity
following	O	O	O
HBPS	O	O	B-Entity
,	O	O	O
the	O	O	O
operative	O	O	B-Entity
procedure	O	O	I-Entity
category	O	O	B-Entity
in	O	O	O
the	O	O	O
surveillance	O	O	B-Entity
system	O	O	I-Entity
must	O	O	O
be	O	O	O
divided	O	O	B-Entity
into	O	O	O
three	O	O	O
types	O	O	B-Entity
.	O	O	O

-DOCSTART- (28303942)

Signature	O	O	B-Entity
of	O	O	O
an	O	O	O
aggregation	O	O	B-Entity
-	O	O	O
prone	O	O	B-Entity
conformation	O	O	O
of	O	O	O
tau	O	O	O

The	O	O	O
self-assembly	O	O	B-Entity
of	O	O	O
the	O	O	O
microtubule	O	O	B-Entity
associated	O	O	B-Entity
tau	O	O	B-Entity
protein	O	O	I-Entity
into	O	O	O
fibrillar	O	O	B-Entity
cell	O	O	I-Entity
inclusions	O	O	I-Entity
is	O	O	O
linked	O	O	B-Entity
to	O	O	O
a	O	O	O
number	O	O	B-Entity
of	O	O	O
devastating	O	O	O
neurodegenerative	O	O	B-Entity
disorders	O	O	I-Entity
collectively	O	O	O
known	O	O	O
as	O	O	O
tauopathies	O	O	B-Entity
.	O	O	O

The	O	O	O
mechanism	O	O	B-Entity
by	O	O	O
which	O	O	O
tau	O	O	B-Entity
self-assembles	O	O	B-Entity
into	O	O	O
pathological	O	O	B-Entity
entities	O	O	B-Entity
is	O	O	O
a	O	O	O
matter	O	O	O
of	O	O	O
much	O	O	O
debate	O	O	B-Entity
,	O	O	O
largely	O	O	B-Entity
due	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
lack	O	O	O
of	O	O	O
direct	O	O	B-Entity
experimental	O	O	B-Entity
insights	O	O	B-Entity
into	O	O	O
the	O	O	O
earliest	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
aggregation	O	O	B-Entity
.	O	O	O

We	O	O	O
present	O	O	O
pulsed	O	O	B-Entity
double	O	O	I-Entity
electron-electron	O	O	I-Entity
resonance	O	O	I-Entity
measurements	O	O	B-Entity
of	O	O	O
two	O	O	O
key	O	O	O
fibril	O	O	B-Entity
-	O	O	O
forming	O	O	B-Entity
regions	O	O	B-Entity
of	O	O	O
tau	O	O	B-Entity
,	O	O	O
PHF6	O	O	B-Entity
and	O	O	O
PHF6	O	O	B-Entity
*	O	O	I-Entity
,	O	O	O
in	O	O	O
transient	O	O	B-Entity
as	O	O	O
aggregation	O	O	B-Entity
happens	O	O	O
.	O	O	O

By	O	O	O
monitoring	O	O	O
the	O	O	O
end-to-end	O	O	B-Entity
distance	O	O	I-Entity
distribution	O	O	B-Entity
of	O	O	O
these	O	O	O
segments	O	O	O
as	O	O	O
a	O	O	O
function	O	O	B-Entity
of	O	O	O
aggregation	O	O	B-Entity
time	O	O	B-Entity
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
PHF6	O	O	B-Entity
(	O	O	I-Entity
(	O	O	I-Entity
*	O	O	I-Entity
)	O	O	I-Entity
)	O	O	I-Entity
regions	O	O	B-Entity
dramatically	O	O	O
extend	O	O	B-Entity
to	O	O	O
distances	O	O	B-Entity
commensurate	O	O	B-Entity
with	O	O	O
extended	O	O	B-Entity
β-strand	O	O	B-Entity
structures	O	O	I-Entity
within	O	O	O
the	O	O	O
earliest	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
aggregation	O	O	O
,	O	O	O
well	O	O	O
before	O	O	O
fibril	O	O	B-Entity
formation	O	O	B-Entity
.	O	O	O

Combined	O	O	B-Entity
with	O	O	O
simulations	O	O	B-Entity
,	O	O	O
our	O	O	O
experiments	O	O	B-Entity
show	O	O	O
that	O	O	O
the	O	O	O
extended	O	O	B-Entity
β-strand	O	O	B-Entity
conformational	O	O	I-Entity
state	O	O	B-Entity
of	O	O	O
PHF6	O	O	B-Entity
(	O	O	I-Entity
(	O	O	I-Entity
*	O	O	I-Entity
)	O	O	I-Entity
)	O	O	I-Entity
is	O	O	O
readily	O	O	O
populated	O	O	O
under	O	O	O
aggregating	O	O	B-Entity
conditions	O	O	B-Entity
,	O	O	O
constituting	O	O	O
a	O	O	O
defining	O	O	O
signature	O	O	B-Entity
of	O	O	O
aggregation	O	O	B-Entity
-	O	O	O
prone	O	O	B-Entity
tau	O	O	B-Entity
,	O	O	O
and	O	O	O
as	O	O	O
such	O	O	O
,	O	O	O
a	O	O	O
possible	O	O	O
target	O	O	B-Entity
for	O	O	O
therapeutic	O	O	B-Entity
interventions	O	O	I-Entity
.	O	O	O

-DOCSTART- (28304102)

Design	O	O	B-Entity
,	O	O	O
Synthesis	O	O	B-Entity
,	O	O	O
and	O	O	O
Cytotoxic	O	O	B-Entity
Evaluation	O	O	B-Entity
of	O	O	O
Certain	O	O	O
7-Chloro-4-(piperazin-1-yl)quinoline	O	O	B-Entity
Derivatives	O	O	B-Entity
as	O	O	O
VEGFR-II	O	O	B-Entity
Inhibitors	O	O	O

Signaling	O	O	B-Entity
pathway	O	O	I-Entity
inhibition	O	O	B-Entity
of	O	O	O
VEGFR-II	O	O	B-Entity
is	O	O	O
visualized	O	O	O
as	O	O	O
valuable	O	O	O
tool	O	O	O
in	O	O	O
cancer	O	O	B-Entity
management	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	B-Entity
study	O	O	I-Entity
,	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
novel	O	O	B-Entity
1	O	O	B-Entity
-	O	O	I-Entity
4-(7-chloroquinolin-4-yl)piperazin-1-yl)-2-(N-substituted-amino)-ethanone	O	O	I-Entity
derivatives	O	O	B-Entity
(	O	O	O
4a-t	O	O	B-Entity
)	O	O	O
was	O	O	O
achieved	O	O	O
through	O	O	O
the	O	O	O
amination	O	O	B-Entity
of	O	O	O
2-chloro-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone	O	O	B-Entity
(	O	O	I-Entity
3	O	O	I-Entity
)	O	O	I-Entity
with	O	O	O
different	O	O	O
secondary	O	O	O
amines	O	O	O
.	O	O	O

The	O	O	O
structures	O	O	B-Entity
of	O	O	O
the	O	O	O
target	O	O	B-Entity
compounds	O	O	B-Entity
were	O	O	O
confirmed	O	O	B-Entity
by	O	O	I-Entity
IR	O	O	B-Entity
,	O	O	O
(	O	O	B-Entity
1	O	O	I-Entity
)	O	O	I-Entity
H-NMR	O	O	I-Entity
,	O	O	O
(	O	O	B-Entity
13	O	O	I-Entity
)	O	O	I-Entity
C-NMR	O	O	I-Entity
,	O	O	O
HRMS	O	O	B-Entity
,	O	O	O
and	O	O	O
microanalysis	O	O	B-Entity
.	O	O	O

Compounds	O	O	B-Entity
4a-t	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
anticancer	O	O	B-Entity
screening	O	O	B-Entity
against	O	O	O
human	O	O	B-Entity
breast	O	O	I-Entity
cancer	O	O	I-Entity
(	O	O	O
MCF-7	O	O	B-Entity
)	O	O	O
and	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
PC3	O	O	B-Entity
)	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

The	O	O	O
highest	O	O	O
cytotoxicty	O	O	B-Entity
against	O	O	O
both	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
was	O	O	O
displayed	O	O	O
by	O	O	O
2-(4-(4-bromobenzyl)piperazin-1-yl)-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone	O	O	B-Entity
(	O	O	I-Entity
4q	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
with	O	O	O
IC50	O	O	B-Entity
values	O	O	I-Entity
of	O	O	O
6.502	O	O	O
and	O	O	O
11.751	O	O	O
μM	O	O	O
against	O	O	O
MCF-7	O	O	B-Entity
and	O	O	O
PC3	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
respectively	O	O	O
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
standard	O	O	B-Entity
drug	O	O	I-Entity
doxorubicin	O	O	B-Entity
(	O	O	O
MCF-7	O	O	O
:	O	O	O
6.774	O	O	O
μM	O	O	O
,	O	O	O
PC3	O	O	O
:	O	O	O
7.7316	O	O	O
μM	O	O	O
)	O	O	O
.	O	O	O

Due	O	O	O
to	O	O	O
its	O	O	O
notable	O	O	O
activity	O	O	B-Entity
toward	O	O	O
MCF-7	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
4q	O	O	B-Entity
was	O	O	O
further	O	O	O
evaluated	O	O	O
as	O	O	O
VEGFR-II	O	O	B-Entity
inhibitor	O	O	B-Entity
,	O	O	O
showing	O	O	O
an	O	O	O
IC50	O	O	B-Entity
of	O	O	O
1.38	O	O	O
μM	O	O	O
compared	O	O	O
to	O	O	O
sorafenib	O	O	B-Entity
(	O	O	O
0.33	O	O	O
μM	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
docking	O	O	B-Entity
study	O	O	O
proved	O	O	O
that	O	O	O
4q	O	O	B-Entity
has	O	O	O
a	O	O	O
binding	O	O	B-Entity
mode	O	O	I-Entity
akin	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
VEGFR-II	O	O	B-Entity
inhibitors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28304405)

The	O	O	O
ErbB3	O	O	B-Entity
receptor	O	O	I-Entity
tyrosine	O	O	I-Entity
kinase	O	O	I-Entity
negatively	O	O	O
regulates	O	O	B-Entity
Paneth	O	O	B-Entity
cells	O	O	I-Entity
by	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
-	O	O	O
dependent	O	O	B-Entity
suppression	O	O	B-Entity
of	O	O	O
Atoh1	O	O	O

Paneth	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
PCs	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
secretory	O	O	B-Entity
population	O	O	I-Entity
located	O	O	O
at	O	O	O
the	O	O	O
base	O	O	O
of	O	O	O
the	O	O	O
intestinal	O	O	B-Entity
crypt	O	O	I-Entity
,	O	O	O
support	O	O	O
the	O	O	O
intestinal	O	O	O
stem	O	O	B-Entity
cells	O	O	I-Entity
(	O	O	O
ISC	O	O	B-Entity
)	O	O	O
with	O	O	O
growth	O	O	B-Entity
factors	O	O	I-Entity
and	O	O	O
participate	O	O	O
in	O	O	O
innate	O	O	B-Entity
immunity	O	O	I-Entity
by	O	O	O
releasing	O	O	O
antimicrobial	O	O	B-Entity
peptides	O	O	I-Entity
,	O	O	O
including	O	O	O
lysozyme	O	O	B-Entity
and	O	O	O
defensins	O	O	B-Entity
.	O	O	O

PC	O	O	B-Entity
dysfunction	O	O	B-Entity
is	O	O	O
associated	O	O	O
with	O	O	O
disorders	O	O	B-Entity
such	O	O	O
as	O	O	O
Crohn	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
and	O	O	O
necrotizing	O	O	B-Entity
enterocolitis	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
specific	O	O	O
pathways	O	O	B-Entity
regulating	O	O	B-Entity
PC	O	O	O
development	O	O	B-Entity
and	O	O	O
function	O	O	B-Entity
are	O	O	O
not	O	O	O
fully	O	O	O
understood	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
tested	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
neuregulin	O	O	B-Entity
receptor	O	O	I-Entity
ErbB3	O	O	I-Entity
in	O	O	O
control	O	O	O
of	O	O	O
PC	O	O	B-Entity
differentiation	O	O	B-Entity
and	O	O	O
the	O	O	O
ISC	O	O	B-Entity
niche	O	O	I-Entity
.	O	O	O

Intestinal	O	O	B-Entity
epithelial	O	O	B-Entity
ErbB3	O	O	B-Entity
knockout	O	O	B-Entity
caused	O	O	O
precocious	O	O	B-Entity
appearance	O	O	B-Entity
of	O	O	O
PCs	O	O	B-Entity
as	O	O	O
early	O	O	O
as	O	O	O
postnatal	O	O	B-Entity
day	O	O	B-Entity
7	O	O	I-Entity
,	O	O	O
and	O	O	O
substantially	O	O	O
increased	O	O	B-Entity
the	O	O	O
number	O	O	O
of	O	O	O
mature	O	O	B-Entity
PCs	O	O	O
in	O	O	O
adult	O	O	B-Entity
mouse	O	O	I-Entity
ileum	O	O	B-Entity
.	O	O	O

ErbB3	O	O	B-Entity
loss	O	O	O
had	O	O	O
no	O	O	O
effect	O	O	O
on	O	O	O
other	O	O	O
secretory	O	O	B-Entity
lineages	O	O	I-Entity
,	O	O	O
but	O	O	O
increased	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
the	O	O	O
ISC	O	O	B-Entity
marker	O	O	O
Lgr5	O	O	B-Entity
.	O	O	O

ErbB3	O	O	B-Entity
-null	O	O	O
intestines	O	O	B-Entity
had	O	O	O
elevated	O	O	O
levels	O	O	O
of	O	O	O
the	O	O	O
Atoh1	O	O	B-Entity
transcription	O	O	B-Entity
factor	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
required	O	O	O
for	O	O	O
secretory	O	O	O
fate	O	O	O
determination	O	O	O
,	O	O	O
while	O	O	O
Atoh1(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	B-Entity
had	O	O	O
reduced	O	O	O
ErbB3	O	O	O
,	O	O	O
suggesting	O	O	O
reciprocal	O	O	B-Entity
negative	O	O	B-Entity
regulation	O	O	B-Entity
.	O	O	O

ErbB3	O	O	B-Entity
-null	O	O	O
intestinal	O	O	B-Entity
progenitor	O	O	I-Entity
cells	O	O	I-Entity
showed	O	O	O
reduced	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
PI3K-Akt	O	O	B-Entity
and	O	O	O
ERK	O	O	B-Entity
MAPK	O	O	I-Entity
pathways	O	O	I-Entity
.	O	O	O

Inhibiting	O	O	O
these	O	O	O
pathways	O	O	B-Entity
in	O	O	O
HT29	O	O	B-Entity
cells	O	O	I-Entity
increased	O	O	B-Entity
levels	O	O	O
of	O	O	O
ATOH1	O	O	B-Entity
and	O	O	O
the	O	O	O
PC	O	O	B-Entity
marker	O	O	O
LYZ	O	O	B-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
ErbB3	O	O	B-Entity
activation	O	O	O
suppressed	O	O	B-Entity
LYZ	O	O	B-Entity
and	O	O	O
ATOH1	O	O	B-Entity
in	O	O	O
a	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
-	O	O	O
dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

Expansion	O	O	O
of	O	O	O
the	O	O	O
PC	O	O	B-Entity
compartment	O	O	O
in	O	O	O
ErbB3	O	O	B-Entity
-null	O	O	O
intestines	O	O	B-Entity
was	O	O	O
accompanied	O	O	O
with	O	O	O
elevated	O	O	O
ER	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
inflammation	O	O	B-Entity
markers	O	O	B-Entity
,	O	O	O
raising	O	O	O
the	O	O	O
possibility	O	O	O
that	O	O	O
negative	O	O	B-Entity
regulation	O	O	B-Entity
of	O	O	O
PCs	O	O	B-Entity
by	O	O	O
ErbB3	O	O	O
is	O	O	O
necessary	O	O	O
to	O	O	O
maintain	O	O	O
homeostasis	O	O	B-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
our	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
ErbB3	O	O	B-Entity
restricts	O	O	O
PC	O	O	B-Entity
numbers	O	O	O
through	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
-mediated	O	O	O
suppression	O	O	B-Entity
of	O	O	O
Atoh1	O	O	B-Entity
levels	O	O	O
leading	O	O	O
to	O	O	O
inhibition	O	O	O
of	O	O	O
PC	O	O	O
differentiation	O	O	B-Entity
,	O	O	O
with	O	O	O
important	O	O	O
implications	O	O	O
for	O	O	O
regulation	O	O	B-Entity
of	O	O	O
the	O	O	O
ISC	O	O	B-Entity
niche	O	O	I-Entity
.	O	O	O

-DOCSTART- (28306155)

CDF	O	O	B-Entity
-	O	O	O
quantile	O	O	B-Entity
distributions	O	O	B-Entity
for	O	O	O
modelling	O	O	B-Entity
random	O	O	B-Entity
variables	O	O	I-Entity
on	O	O	O
the	O	O	O
unit	O	O	O
interval	O	O	O

This	O	O	O
paper	O	O	O
introduces	O	O	O
a	O	O	O
two-parameter	O	O	B-Entity
family	O	O	O
of	O	O	O
distributions	O	O	B-Entity
for	O	O	O
modelling	O	O	B-Entity
random	O	O	B-Entity
variables	O	O	I-Entity
on	O	O	O
the	O	O	O
(	O	O	O
0,1	O	O	O
)	O	O	O
interval	O	O	B-Entity
by	O	O	O
applying	O	O	O
the	O	O	O
cumulative	O	O	B-Entity
distribution	O	O	I-Entity
function	O	O	B-Entity
of	O	O	O
one	O	O	O
'	O	O	O
parent	O	O	B-Entity
'	O	O	I-Entity
distribution	O	O	I-Entity
to	O	O	O
the	O	O	O
quantile	O	O	B-Entity
function	O	O	O
of	O	O	O
another	O	O	O
.	O	O	O

Family	O	O	O
members	O	O	O
have	O	O	O
explicit	O	O	O
probability	O	O	B-Entity
density	O	O	I-Entity
functions	O	O	B-Entity
,	O	O	O
cumulative	O	O	B-Entity
distribution	O	O	I-Entity
functions	O	O	I-Entity
and	O	O	O
quantile	O	O	B-Entity
s	O	O	O
in	O	O	O
a	O	O	O
location	O	O	B-Entity
parameter	O	O	B-Entity
and	O	O	O
a	O	O	O
dispersion	O	O	B-Entity
parameter	O	O	O
.	O	O	O

They	O	O	O
capture	O	O	O
a	O	O	O
wide	O	O	O
variety	O	O	B-Entity
of	O	O	O
shapes	O	O	B-Entity
that	O	O	O
the	O	O	O
beta	O	O	B-Entity
and	O	O	O
Kumaraswamy	O	O	B-Entity
distributions	O	O	I-Entity
can	O	O	B-Entity
not	O	O	I-Entity
.	O	O	O

They	O	O	O
are	O	O	O
amenable	O	O	B-Entity
to	O	O	O
likelihood	O	O	B-Entity
inference	O	O	I-Entity
,	O	O	O
and	O	O	O
enable	O	O	O
a	O	O	O
wide	O	O	O
variety	O	O	B-Entity
of	O	O	O
quantile	O	O	B-Entity
regression	O	O	B-Entity
models	O	O	I-Entity
,	O	O	O
with	O	O	O
predictors	O	O	B-Entity
for	O	O	O
both	O	O	O
the	O	O	O
location	O	O	B-Entity
and	O	O	O
dispersion	O	O	B-Entity
parameters	O	O	B-Entity
.	O	O	O

We	O	O	O
demonstrate	O	O	O
their	O	O	O
applicability	O	O	O
to	O	O	O
psychological	O	O	B-Entity
research	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
their	O	O	O
utility	O	O	B-Entity
in	O	O	O
modelling	O	O	B-Entity
real	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

-DOCSTART- (28314676)

First	O	O	B-Entity
and	O	O	O
second	O	O	B-Entity
generation	O	O	B-Entity
DESs	O	O	B-Entity
reduce	O	O	B-Entity
diabetes	O	O	B-Entity
adverse	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
mortality	O	O	B-Entity
and	O	O	O
re-intervention	O	O	B-Entity
in	O	O	O
multivessel	O	O	B-Entity
coronary	O	O	B-Entity
disease	O	O	I-Entity
:	O	O	O
9-	O	O	O
Year	O	O	B-Entity
analysis	O	O	O

Diabetes	O	O	B-Entity
portends	O	O	B-Entity
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
adverse	O	O	B-Entity
early	O	O	B-Entity
and	O	O	O
late	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
undergoing	O	O	O
PCI	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
if	O	O	O
the	O	O	O
adverse	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
(	O	O	O
DM	O	O	B-Entity
)	O	O	O
on	O	O	O
early	O	O	B-Entity
and	O	O	O
late	O	O	B-Entity
PCI	O	O	B-Entity
outcomes	O	O	B-Entity
is	O	O	O
reduced	O	O	B-Entity
with	O	O	O
drug-eluting	O	O	B-Entity
(	O	O	O
DES	O	O	B-Entity
)	O	O	O
compared	O	O	O
to	O	O	O
bare-metal	O	O	B-Entity
(	O	O	I-Entity
BMS	O	O	I-Entity
)	O	O	I-Entity
stents	O	O	I-Entity
.	O	O	O

We	O	O	O
reviewed	O	O	B-Entity
the	O	O	O
Mount	O	O	B-Entity
Sinai	O	O	I-Entity
Beth	O	O	I-Entity
Israel	O	O	I-Entity
Hospital	O	O	I-Entity
first	O	O	B-Entity
PCI	O	O	B-Entity
experience	O	O	O
for	O	O	O
multivessel	O	O	B-Entity
coronary	O	O	B-Entity
artery	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CAD	O	O	B-Entity
,	O	O	O
1998	O	O	O
-	O	O	O
2009	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
excluded	O	O	B-Entity
if	O	O	O
they	O	O	O
had	O	O	O
single-vessel	O	O	B-Entity
CAD	O	O	I-Entity
,	O	O	O
emergency	O	O	B-Entity
,	O	O	O
no	O	O	B-Entity
stent	O	O	B-Entity
,	O	O	O
prior	O	O	B-Entity
bypass	O	O	B-Entity
graft	O	O	I-Entity
or	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
<	O	O	O
24h	O	O	O
.	O	O	O

Diabetes	O	O	B-Entity
-	O	O	O
effect	O	O	B-Entity
was	O	O	O
derived	O	O	O
from	O	O	O
9-	O	O	O
year	O	O	B-Entity
all-cause	O	O	O
mortality	O	O	B-Entity
and	O	O	O
re-intervention	O	O	B-Entity
risk-adjusted	O	O	B-Entity
hazard	O	O	I-Entity
ratios	O	O	I-Entity
[	O	O	O
AHR	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
intervals	O	O	I-Entity
)	O	O	O
]	O	O	O
for	O	O	O
DES	O	O	B-Entity
(	O	O	O
N=2679	O	O	O
;	O	O	O
48	O	O	O
%	O	O	O
three-vessel	O	O	B-Entity
;	O	O	O
39	O	O	O
%	O	O	O
DM	O	O	B-Entity
)	O	O	O
and	O	O	O
BMS	O	O	B-Entity
(	O	O	O
N=2651	O	O	O
;	O	O	O
40	O	O	O
%	O	O	O
three-vessel	O	O	O
;	O	O	O
33	O	O	O
%	O	O	O
DM	O	O	O
)	O	O	O
and	O	O	O
then	O	O	O
stratified	O	O	O
based	O	O	O
on	O	O	O
stent	O	O	B-Entity
(	O	O	O
DES	O	O	O
/	O	O	O
BMS	O	O	O
)	O	O	O
and	O	O	O
vessel	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
two	O	O	B-Entity
/	O	O	O
three	O	O	B-Entity
)	O	O	O
.	O	O	O

Diabetes	O	O	B-Entity
-	O	O	O
effect	O	O	B-Entity
on	O	O	O
mortality	O	O	B-Entity
was	O	O	O
lower	O	O	B-Entity
for	O	O	O
DES	O	O	B-Entity
(	O	O	O
AHRDM/NoDM	O	O	B-Entity
=	O	O	O
1.41	O	O	O
[	O	O	O
1.14	O	O	O
-	O	O	O
1.74	O	O	O
]	O	O	O
)	O	O	O
versus	O	O	O
BMS	O	O	B-Entity
(	O	O	O
AHRDM/NoDM	O	O	O
=	O	O	O
1.71	O	O	O
[	O	O	O
1.50	O	O	O
-	O	O	O
2.01	O	O	O
]	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
this	O	O	O
was	O	O	O
predominantly	O	O	B-Entity
driven	O	O	O
by	O	O	O
two-vessel	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
diabetes	O	O	B-Entity
effect	O	O	B-Entity
was	O	O	O
similar	O	O	O
for	O	O	O
first	O	O	B-Entity
(	O	O	O
DES1	O	O	B-Entity
:	O	O	O
AHRDM/NoDM	O	O	B-Entity
=	O	O	O
1.43	O	O	O
[	O	O	O
1.14	O	O	O
-	O	O	O
1.79	O	O	O
]	O	O	O
)	O	O	O
and	O	O	O
second	O	O	B-Entity
(	O	O	O
DES2	O	O	B-Entity
:	O	O	O
AHRDM/NoDM	O	O	O
=	O	O	O
1.53	O	O	O
[	O	O	O
0.77	O	O	O
-	O	O	O
3.07	O	O	O
]	O	O	O
)	O	O	O
generation	O	O	B-Entity
DES	O	O	B-Entity
.	O	O	O

Re-intervention	O	O	B-Entity
comparisons	O	O	B-Entity
were	O	O	O
similarly	O	O	O
increased	O	O	B-Entity
by	O	O	O
diabetes	O	O	B-Entity
in	O	O	O
all	O	O	O
sub-cohorts	O	O	B-Entity
.	O	O	O

Our	O	O	O
analysis	O	O	B-Entity
of	O	O	O
a	O	O	O
large	O	O	O
real-world	O	O	O
PCI	O	O	B-Entity
series	O	O	O
indicates	O	O	O
that	O	O	O
diabetes	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
worse	O	O	B-Entity
9-	O	O	O
year	O	O	B-Entity
mortality	O	O	B-Entity
irrespective	O	O	B-Entity
of	O	O	O
stent	O	O	B-Entity
type	O	O	B-Entity
,	O	O	O
albeit	O	O	O
this	O	O	O
is	O	O	O
mitigated	O	O	O
to	O	O	O
varying	O	O	O
degrees	O	O	O
with	O	O	O
DES	O	O	B-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
DES2	O	O	B-Entity
and	O	O	O
in	O	O	O
case	O	O	O
of	O	O	O
2-vessel	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

A	O	O	O
complementary	O	O	B-Entity
stent	O	O	B-Entity
-	O	O	O
effect	O	O	B-Entity
analysis	O	O	B-Entity
confirmed	O	O	B-Entity
DES	O	O	B-Entity
-to-	O	O	O
BMS	O	O	B-Entity
and	O	O	O
DES2	O	O	B-Entity
-to-	O	O	O
DES1	O	O	B-Entity
superiority	O	O	B-Entity
in	O	O	O
both	O	O	O
diabetics	O	O	B-Entity
and	O	O	O
non-diabetics	O	O	B-Entity
.	O	O	O

-DOCSTART- (28318092)

Lycopene	O	O	B-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
:	O	O	O
A	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
observational	O	O	O
studies	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
current	O	O	O
meta-analysis	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
relation	O	O	O
between	O	O	O
lycopene	O	O	B-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
(	O	O	O
CVD	O	O	B-Entity
)	O	O	O
.	O	O	O

Studies	O	O	B-Entity
concerning	O	O	O
about	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
lycopene	O	O	B-Entity
and	O	O	O
risk	O	O	B-Entity
of	O	O	O
CVD	O	O	B-Entity
were	O	O	O
searched	O	O	O
on	O	O	O
Pubmed	O	O	B-Entity
,	O	O	O
Embase	O	O	B-Entity
,	O	O	O
and	O	O	O
Web	O	O	B-Entity
of	O	O	I-Entity
Science	O	O	I-Entity
from	O	O	O
inception	O	O	O
to	O	O	O
October	O	O	O
2016	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
14	O	O	O
eligible	O	O	B-Entity
studies	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

A	O	O	O
significantly	O	O	O
inverse	O	O	B-Entity
association	O	O	I-Entity
with	O	O	O
a	O	O	O
pooled	O	O	O
risk	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
RR	O	O	B-Entity
)	O	O	O
of	O	O	O
0.83	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.76	O	O	O
-	O	O	O
0.90	O	O	O
)	O	O	O
was	O	O	O
shown	O	O	O
between	O	O	O
lycopene	O	O	B-Entity
exposure	O	O	B-Entity
and	O	O	O
risk	O	O	O
of	O	O	O
CVD	O	O	B-Entity
.	O	O	O

Findings	O	O	B-Entity
were	O	O	O
similar	O	O	O
restricting	O	O	O
to	O	O	O
dietary	O	O	B-Entity
studies	O	O	B-Entity
(	O	O	O
RR	O	O	B-Entity
=	O	O	O
0.87	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
0.79	O	O	O
-	O	O	O
0.96	O	O	O
)	O	O	O
and	O	O	O
biomarker	O	O	B-Entity
studies	O	O	O
(	O	O	O
RR	O	O	O
=	O	O	O
0.74	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
0	O	O	O
.	O	O	O
62	O	O	O
-	O	O	O
0.87	O	O	O
)	O	O	O
.	O	O	O

Dietary	O	O	B-Entity
lycopene	O	O	B-Entity
intake	O	O	B-Entity
was	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
for	O	O	O
coronary	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CHD	O	O	B-Entity
)	O	O	O
(	O	O	O
RR	O	O	B-Entity
:	O	O	O
0.87	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.76	O	O	O
-	O	O	O
0.98	O	O	O
)	O	O	O
and	O	O	O
stroke	O	O	B-Entity
(	O	O	O
RR	O	O	O
:	O	O	O
0.83	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.69	O	O	O
-	O	O	O
0.96).The	O	O	O
pooled	O	O	O
risk	O	O	B-Entity
estimate	O	O	I-Entity
was	O	O	O
generally	O	O	O
similar	O	O	O
for	O	O	O
lycopene	O	O	O
biomarker	O	O	B-Entity
concentrations	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
association	O	O	O
was	O	O	O
only	O	O	O
statistically	O	O	O
significant	O	O	O
for	O	O	O
stroke	O	O	O
(	O	O	O
RR	O	O	O
:	O	O	O
0.65	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.42	O	O	O
-	O	O	O
0.87	O	O	O
)	O	O	O
.	O	O	O

Subgroup	O	O	B-Entity
analyses	O	O	B-Entity
showed	O	O	O
that	O	O	O
retrospective	O	O	B-Entity
and	O	O	O
low	O	O	O
quality	O	O	O
studies	O	O	B-Entity
were	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
sources	O	O	O
of	O	O	O
heterogeneity	O	O	B-Entity
.	O	O	O

Higher	O	O	O
lycopene	O	O	B-Entity
exposure	O	O	B-Entity
is	O	O	O
inversely	O	O	B-Entity
associated	O	O	I-Entity
with	O	O	O
a	O	O	O
lower	O	O	O
risk	O	O	B-Entity
of	O	O	O
CVD	O	O	B-Entity
.	O	O	O

Further	O	O	O
well-designed	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trials	O	O	I-Entity
are	O	O	O
required	O	O	O
to	O	O	O
assess	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
lycopene	O	O	B-Entity
on	O	O	O
CVD	O	O	B-Entity
.	O	O	O

-DOCSTART- (28318300)

Bacteria	O	O	B-Entity
from	O	O	O
Wheat	O	O	B-Entity
and	O	O	O
Cucurbit	O	O	B-Entity
Plant	O	O	B-Entity
Roots	O	O	I-Entity
Metabolize	O	O	B-Entity
PAHs	O	O	B-Entity
and	O	O	O
Aromatic	O	O	B-Entity
Root	O	O	B-Entity
Exudates	O	O	B-Entity
:	O	O	O
Implications	O	O	B-Entity
for	O	O	O
Rhizodegradation	O	O	O

The	O	O	O
chemical	O	O	B-Entity
interaction	O	O	I-Entity
between	O	O	O
plants	O	O	B-Entity
and	O	O	O
bacteria	O	O	B-Entity
in	O	O	O
the	O	O	O
root	O	O	B-Entity
zone	O	O	B-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
soil	O	O	B-Entity
decontamination	O	O	B-Entity
.	O	O	O

Bacteria	O	O	B-Entity
which	O	O	O
degrade	O	O	B-Entity
PAHs	O	O	B-Entity
have	O	O	O
been	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
rhizospheres	O	O	B-Entity
of	O	O	O
plant	O	O	B-Entity
species	O	O	B-Entity
with	O	O	O
varied	O	O	O
biological	O	O	B-Entity
traits	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
not	O	O	O
known	O	O	O
what	O	O	O
phytochemicals	O	O	B-Entity
promote	O	O	O
contaminant	O	O	B-Entity
degradation	O	O	B-Entity
.	O	O	O

One	O	O	O
monocot	O	O	B-Entity
and	O	O	O
two	O	O	O
dicotyledon	O	O	B-Entity
plants	O	O	I-Entity
were	O	O	O
grown	O	O	B-Entity
in	O	O	O
PAH	O	O	B-Entity
-	O	O	O
contaminated	O	O	B-Entity
soil	O	O	B-Entity
from	O	O	O
a	O	O	O
manufactured	O	O	B-Entity
gas	O	O	I-Entity
plant	O	O	I-Entity
(	O	O	O
MGP	O	O	B-Entity
)	O	O	O
site	O	O	B-Entity
.	O	O	O

A	O	O	O
phytotoxicity	O	O	B-Entity
assay	O	O	I-Entity
confirmed	O	O	O
greater	O	O	O
soil	O	O	B-Entity
decontamination	O	O	B-Entity
in	O	O	O
rhizospheres	O	O	B-Entity
when	O	O	O
compared	O	O	B-Entity
to	O	O	O
bulk	O	O	O
soil	O	O	O
controls	O	O	B-Entity
.	O	O	O

Bacteria	O	O	B-Entity
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
plant	O	O	B-Entity
roots	O	O	I-Entity
(	O	O	O
rhizobacteria	O	O	B-Entity
)	O	O	O
and	O	O	O
selected	O	O	B-Entity
for	O	O	O
growth	O	O	B-Entity
on	O	O	O
anthracene	O	O	B-Entity
and	O	O	O
chrysene	O	O	B-Entity
on	O	O	O
PAH	O	O	B-Entity
-	O	O	O
amended	O	O	B-Entity
plates	O	O	B-Entity
.	O	O	O

Rhizosphere	O	O	B-Entity
isolates	O	O	B-Entity
metabolized	O	O	B-Entity
3-	O	O	O
and	O	O	O
4-ring	O	O	O
PAHs	O	O	B-Entity
and	O	O	O
PAH	O	O	B-Entity
catabolic	O	O	B-Entity
intermediates	O	O	O
in	O	O	O
liquid	O	O	B-Entity
incubations	O	O	I-Entity
.	O	O	O

Aromatic	O	O	B-Entity
root	O	O	B-Entity
exudate	O	O	B-Entity
compounds	O	O	I-Entity
,	O	O	O
namely	O	O	O
flavonoids	O	O	B-Entity
and	O	O	O
simple	O	O	B-Entity
phenols	O	O	I-Entity
,	O	O	O
were	O	O	O
also	O	O	O
substrates	O	O	B-Entity
for	O	O	O
isolated	O	O	B-Entity
rhizobacteria	O	O	B-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
phenolic	O	O	B-Entity
compounds	O	O	I-Entity
-	O	O	O
morin	O	O	B-Entity
,	O	O	O
caffeic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
and	O	O	O
protocatechuic	O	O	B-Entity
acid	O	O	I-Entity
-	O	O	O
appear	O	O	O
to	O	O	O
be	O	O	O
linked	O	O	O
to	O	O	O
bacterial	O	O	B-Entity
degradation	O	O	B-Entity
of	O	O	O
3-	O	O	O
and	O	O	O
4-	O	O	O
ring	O	O	O
PAHs	O	O	B-Entity
in	O	O	O
the	O	O	O
rhizosphere	O	O	B-Entity
.	O	O	O

-DOCSTART- (28319455)

Joint	O	O	B-Entity
model	O	O	I-Entity
imputation	O	O	I-Entity
to	O	O	O
estimate	O	O	B-Entity
the	O	O	O
treatment	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
long-term	O	O	B-Entity
survival	O	O	B-Entity
using	O	O	O
auxiliary	O	O	O
events	O	O	O

Clinical	O	O	B-Entity
trial	O	O	I-Entity
duration	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
concern	O	O	O
in	O	O	O
clinical	O	O	B-Entity
research	O	O	I-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
cancer	O	O	B-Entity
trials	O	O	I-Entity
where	O	O	O
the	O	O	O
endpoint	O	O	B-Entity
is	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
.	O	O	O

A	O	O	O
surrogate	O	O	B-Entity
endpoint	O	O	I-Entity
can	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
an	O	O	O
auxiliary	O	O	B-Entity
variable	O	O	I-Entity
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
treatment	O	O	B-Entity
effect	O	O	I-Entity
earlier	O	O	O
.	O	O	O

At	O	O	O
an	O	O	O
early	O	O	O
time	O	O	O
point	O	O	O
,	O	O	O
the	O	O	O
high	O	O	O
number	O	O	O
of	O	O	O
censored	O	O	B-Entity
observations	O	O	B-Entity
can	O	O	O
be	O	O	O
compensated	O	O	B-Entity
by	O	O	O
the	O	O	O
imputation	O	O	B-Entity
of	O	O	O
the	O	O	O
unobserved	O	O	B-Entity
deaths	O	O	B-Entity
times	O	O	O
.	O	O	O

We	O	O	O
propose	O	O	O
to	O	O	O
use	O	O	O
predictions	O	O	B-Entity
of	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
death	O	O	B-Entity
from	O	O	O
a	O	O	O
joint	O	O	B-Entity
model	O	O	I-Entity
for	O	O	O
a	O	O	O
recurrent	O	O	B-Entity
event	O	O	B-Entity
and	O	O	O
a	O	O	O
terminal	O	O	B-Entity
event	O	O	O
,	O	O	O
which	O	O	O
account	O	O	O
for	O	O	O
disease	O	O	B-Entity
relapse	O	O	I-Entity
information	O	O	B-Entity
.	O	O	O

Two	O	O	O
imputation	O	O	B-Entity
methods	O	O	I-Entity
were	O	O	O
compared	O	O	B-Entity
:	O	O	O
sampling	O	O	B-Entity
from	O	O	O
the	O	O	O
estimated	O	O	B-Entity
parametric	O	O	I-Entity
distribution	O	O	I-Entity
of	O	O	O
the	O	O	O
survival	O	O	B-Entity
time	O	O	I-Entity
and	O	O	O
sampling	O	O	O
using	O	O	O
its	O	O	O
nonparametric	O	O	B-Entity
estimation	O	O	I-Entity
.	O	O	O

The	O	O	O
treatment	O	O	B-Entity
effect	O	O	I-Entity
and	O	O	O
its	O	O	O
standard	O	O	B-Entity
error	O	O	I-Entity
were	O	O	O
estimated	O	O	B-Entity
via	O	O	O
multiple	O	O	B-Entity
imputations	O	O	I-Entity
.	O	O	O

The	O	O	O
performances	O	O	B-Entity
of	O	O	O
the	O	O	O
two	O	O	O
methods	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
bias	O	O	B-Entity
in	O	O	O
the	O	O	O
estimates	O	O	B-Entity
,	O	O	O
standard	O	O	B-Entity
errors	O	O	I-Entity
,	O	O	O
and	O	O	O
coverage	O	O	B-Entity
probability	O	O	B-Entity
.	O	O	O

Both	O	O	O
methods	O	O	B-Entity
were	O	O	O
then	O	O	O
retrospectively	O	O	B-Entity
applied	O	O	B-Entity
to	O	O	O
two	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trials	O	O	I-Entity
studying	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
adjuvant	O	O	B-Entity
chemotherapy	O	O	B-Entity
in	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

-DOCSTART- (28319640)

The	O	O	O
Corneal	O	O	B-Entity
Epithelial	O	O	I-Entity
Barrier	O	O	B-Entity
and	O	O	O
Its	O	O	O
Developmental	O	O	B-Entity
Role	O	O	O
in	O	O	O
Isolating	O	O	B-Entity
Corneal	O	O	O
Epithelial	O	O	O
and	O	O	O
Conjunctival	O	O	B-Entity
Cells	O	O	I-Entity
From	O	O	O
One	O	O	O
Another	O	O	O

During	O	O	O
development	O	O	B-Entity
,	O	O	O
the	O	O	O
corneal	O	O	B-Entity
epithelium	O	O	I-Entity
(	O	O	O
CE	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
conjunctiva	O	O	B-Entity
are	O	O	O
derived	O	O	O
from	O	O	O
the	O	O	O
surface	O	O	B-Entity
ectoderm	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
have	O	O	O
examined	O	O	B-Entity
how	O	O	O
,	O	O	O
during	O	O	O
development	O	O	B-Entity
,	O	O	O
the	O	O	O
cells	O	O	B-Entity
of	O	O	O
these	O	O	O
two	O	O	O
issues	O	O	O
become	O	O	O
isolated	O	O	B-Entity
from	O	O	O
each	O	O	O
other	O	O	O
.	O	O	O

Epithelia	O	O	B-Entity
from	O	O	O
the	O	O	O
anterior	O	O	B-Entity
eyes	O	O	I-Entity
of	O	O	O
chicken	O	O	B-Entity
embryos	O	O	I-Entity
were	O	O	O
labeled	O	O	B-Entity
with	O	O	O
the	O	O	O
fluorescent	O	O	B-Entity
,	O	O	O
lipophilic	O	O	B-Entity
dye	O	O	I-Entity
,	O	O	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine	O	O	B-Entity
perchlorate	O	O	I-Entity
(	O	O	O
DiI	O	O	B-Entity
)	O	O	O
.	O	O	O

DiI	O	O	B-Entity
was	O	O	O
placed	O	O	O
on	O	O	O
the	O	O	O
epithelial	O	O	B-Entity
surface	O	O	I-Entity
of	O	O	O
the	O	O	O
developing	O	O	O
anterior	O	O	B-Entity
eye	O	O	I-Entity
and	O	O	O
its	O	O	O
diffusion	O	O	B-Entity
was	O	O	O
monitored	O	O	O
by	O	O	O
fluorescence	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

Concomitant	O	O	O
morphologic	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
surface	O	O	B-Entity
cells	O	O	I-Entity
of	O	O	I-Entity
these	O	O	I-Entity
epithelial	O	O	I-Entity
were	O	O	O
examined	O	O	B-Entity
by	O	O	O
scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
.	O	O	O

Immunofluorescence	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
analyze	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
cytokeratin	O	O	B-Entity
K3	O	O	I-Entity
,	O	O	O
ZO-1	O	O	B-Entity
,	O	O	O
N-cadherin	O	O	B-Entity
and	O	O	O
Connexin-43	O	O	B-Entity
and	O	O	O
the	O	O	O
function	O	O	B-Entity
of	O	O	O
gap	O	O	B-Entity
junctions	O	O	I-Entity
was	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
a	O	O	O
cut-loading	O	O	B-Entity
with	O	O	O
the	O	O	O
fluorescent	O	O	B-Entity
dye	O	O	I-Entity
rhodamine-dextran	O	O	B-Entity
.	O	O	O

Prior	O	O	O
to	O	O	O
embryonic	O	O	B-Entity
day	O	O	B-Entity
8	O	O	O
(	O	O	O
E	O	O	B-Entity
8)	O	O	O
,	O	O	O
DiI	O	O	B-Entity
placed	O	O	O
on	O	O	O
the	O	O	O
surface	O	O	B-Entity
of	O	O	O
the	O	O	O
CE	O	O	B-Entity
spreads	O	O	B-Entity
throughout	O	O	O
all	O	O	O
the	O	O	O
epithelial	O	O	B-Entity
cells	O	O	I-Entity
of	O	O	O
the	O	O	O
anterior	O	O	B-Entity
eye	O	O	I-Entity
.	O	O	O

When	O	O	O
older	O	O	B-Entity
eyes	O	O	I-Entity
were	O	O	O
similarly	O	O	O
labeled	O	O	B-Entity
,	O	O	O
dye	O	O	B-Entity
diffusion	O	O	B-Entity
was	O	O	O
restricted	O	O	B-Entity
to	O	O	O
the	O	O	O
CE	O	O	B-Entity
.	O	O	O

Similarly	O	O	O
,	O	O	O
diffusion	O	O	B-Entity
of	O	O	O
DiI	O	O	B-Entity
placed	O	O	O
on	O	O	O
the	O	O	O
conjunctival	O	O	B-Entity
surface	O	O	B-Entity
after	O	O	O
E	O	O	B-Entity
8	O	O	O
was	O	O	O
restricted	O	O	B-Entity
to	O	O	O
the	O	O	O
conjunctiva	O	O	B-Entity
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
showed	O	O	O
that	O	O	O
developmentally	O	O	B-Entity
(	O	O	O
1	O	O	O
)	O	O	O
physical	O	O	B-Entity
separations	O	O	B-Entity
progressively	O	O	B-Entity
form	O	O	O
between	O	O	O
the	O	O	O
cells	O	O	B-Entity
of	O	O	O
the	O	O	O
CE	O	O	B-Entity
and	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
conjunctiva	O	O	B-Entity
,	O	O	O
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
by	O	O	O
E	O	O	B-Entity
8	O	O	O
these	O	O	O
separations	O	O	O
form	O	O	O
a	O	O	O
ring	O	O	B-Entity
that	O	O	O
completely	O	O	O
encompasses	O	O	O
the	O	O	O
cornea	O	O	B-Entity
.	O	O	O

The	O	O	O
functional	O	O	B-Entity
restriction	O	O	B-Entity
of	O	O	O
gap	O	O	B-Entity
junctions	O	O	I-Entity
between	O	O	O
these	O	O	O
tissues	O	O	B-Entity
did	O	O	O
not	O	O	O
occur	O	O	B-Entity
until	O	O	O
E	O	O	B-Entity
14	O	O	O
.	O	O	O

During	O	O	O
ocular	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
a	O	O	O
barrier	O	O	B-Entity
to	O	O	O
the	O	O	O
diffusion	O	O	B-Entity
of	O	O	O
DiI	O	O	B-Entity
forms	O	O	O
between	O	O	O
the	O	O	O
contiguous	O	O	B-Entity
CE	O	O	B-Entity
and	O	O	O
conjunctiva	O	O	B-Entity
prior	O	O	O
to	O	O	O
the	O	O	O
differential	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
gap	O	O	B-Entity
junctions	O	O	I-Entity
within	O	O	O
these	O	O	O
tissues	O	O	B-Entity
.	O	O	O

-DOCSTART- (28321789)

Longitudinal	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
bovine	O	O	B-Entity
rotavirus	O	O	B-Entity
group	O	O	I-Entity
A	O	O	I-Entity
in	O	O	O
newborn	O	O	B-Entity
calves	O	O	B-Entity
from	O	O	O
vaccinated	O	O	B-Entity
and	O	O	O
unvaccinated	O	O	B-Entity
dairy	O	O	O
herds	O	O	O

Reports	O	O	O
of	O	O	O
rotavirus	O	O	B-Entity
excretion	O	O	B-Entity
in	O	O	O
calves	O	O	B-Entity
usually	O	O	O
result	O	O	O
from	O	O	O
cross-sectional	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
and	O	O	O
in	O	O	O
face	O	O	O
of	O	O	O
the	O	O	O
conflicting	O	O	O
results	O	O	O
regarding	O	O	O
protection	O	O	B-Entity
of	O	O	O
calves	O	O	O
born	O	O	B-Entity
to	O	O	O
vaccinated	O	O	B-Entity
dams	O	O	B-Entity
against	O	O	O
diarrhea	O	O	B-Entity
,	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
evaluate	O	O	O
rotavirus	O	O	O
excretion	O	O	O
in	O	O	O
dairy	O	O	B-Entity
calves	O	O	I-Entity
born	O	O	O
to	O	O	O
vaccinated	O	O	O
or	O	O	O
unvaccinated	O	O	B-Entity
dams	O	O	O
,	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
genotypes	O	O	B-Entity
of	O	O	O
bovine	O	O	B-Entity
rotavirus	O	O	B-Entity
group	O	O	I-Entity
A	O	O	I-Entity
(	O	O	O
RVA	O	O	B-Entity
)	O	O	O
strains	O	O	B-Entity
isolated	O	O	O
from	O	O	O
these	O	O	O
animals	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
to	O	O	O
investigate	O	O	O
characteristics	O	O	O
of	O	O	O
the	O	O	O
disease	O	O	B-Entity
in	O	O	O
naturally	O	O	B-Entity
occurring	O	O	B-Entity
circumstances	O	O	O
throughout	O	O	O
the	O	O	O
first	O	O	B-Entity
month	O	O	I-Entity
of	O	O	I-Entity
life	O	O	I-Entity
.	O	O	O

Five	O	O	O
hundred	O	O	O
fifty-two	O	O	O
fecal	O	O	B-Entity
samples	O	O	B-Entity
were	O	O	O
taken	O	O	O
from	O	O	O
56	O	O	O
calves	O	O	B-Entity
,	O	O	O
28	O	O	O
from	O	O	O
each	O	O	O
farm	O	O	B-Entity
and	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
vaccinated	O	O	B-Entity
herd	O	O	B-Entity
,	O	O	O
11/281	O	O	O
samples	O	O	O
(	O	O	O
3.91	O	O	O
%	O	O	O
)	O	O	O
taken	O	O	O
from	O	O	O
six	O	O	O
different	O	O	O
calves	O	O	O
tested	O	O	B-Entity
positive	O	O	I-Entity
for	O	O	O
RVA	O	O	B-Entity
while	O	O	O
in	O	O	O
the	O	O	O
unvaccinated	O	O	B-Entity
herd	O	O	O
,	O	O	O
3/271	O	O	O
samples	O	O	O
(	O	O	O
1.11	O	O	O
%	O	O	O
)	O	O	O
taken	O	O	O
from	O	O	O
3	O	O	O
different	O	O	O
calves	O	O	O
tested	O	O	O
positive	O	O	O
.	O	O	O

The	O	O	O
genotyping	O	O	B-Entity
of	O	O	O
the	O	O	O
VP7	O	O	B-Entity
genes	O	O	I-Entity
showed	O	O	O
91.2	O	O	O
%	O	O	O
nucleotide	O	O	B-Entity
sequence	O	O	I-Entity
identity	O	O	O
to	O	O	O
G6	O	O	B-Entity
genotype	O	O	I-Entity
(	O	O	O
NCDV	O	O	B-Entity
strain	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
for	O	O	O
the	O	O	O
VP4	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
strains	O	O	B-Entity
from	O	O	O
the	O	O	O
vaccinated	O	O	B-Entity
herd	O	O	B-Entity
were	O	O	O
96.6	O	O	O
%	O	O	O
related	O	O	O
to	O	O	O
B223	O	O	B-Entity
strain	O	O	I-Entity
,	O	O	O
while	O	O	O
strains	O	O	O
from	O	O	O
the	O	O	O
unvaccinated	O	O	B-Entity
herd	O	O	O
were	O	O	O
88	O	O	O
%	O	O	O
related	O	O	O
to	O	O	O
P[5	O	O	B-Entity
]	O	O	I-Entity
genotype	O	O	I-Entity
(	O	O	O
UK	O	O	B-Entity
strain	O	O	I-Entity
)	O	O	O
.	O	O	O

Genotypes	O	O	B-Entity
found	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
were	O	O	O
G6P[11	O	O	B-Entity
]	O	O	I-Entity
in	O	O	O
the	O	O	O
vaccinated	O	O	B-Entity
herd	O	O	B-Entity
and	O	O	O
G6P[5	O	O	B-Entity
]	O	O	I-Entity
in	O	O	O
the	O	O	O
unvaccinated	O	O	B-Entity
herd	O	O	O
.	O	O	O

All	O	O	O
calves	O	O	B-Entity
infected	O	O	B-Entity
with	O	O	O
rotavirus	O	O	B-Entity
presented	O	O	O
an	O	O	O
episode	O	O	O
of	O	O	O
diarrhea	O	O	B-Entity
in	O	O	O
the	O	O	O
first	O	O	O
month	O	O	O
of	O	O	O
life	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
discrepancy	O	O	O
between	O	O	O
the	O	O	O
genotypes	O	O	B-Entity
found	O	O	O
in	O	O	O
the	O	O	O
commercial	O	O	B-Entity
vaccine	O	O	I-Entity
(	O	O	O
G6P[1	O	O	B-Entity
]	O	O	I-Entity
and	O	O	O
G10P[11	O	O	B-Entity
]	O	O	I-Entity
)	O	O	O
and	O	O	O
the	O	O	O
rotavirus	O	O	O
strains	O	O	B-Entity
circulating	O	O	O
in	O	O	O
both	O	O	O
vaccinated	O	O	B-Entity
and	O	O	O
unvaccinated	O	O	B-Entity
herds	O	O	B-Entity
show	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
keeping	O	O	O
constant	O	O	B-Entity
surveillance	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
avoid	O	O	O
potential	O	O	B-Entity
causes	O	O	B-Entity
of	O	O	O
vaccination	O	O	B-Entity
failure	O	O	B-Entity
.	O	O	O

-DOCSTART- (28322352)

Gene	O	O	B-Entity
-based	O	O	O
genome-wide	O	O	B-Entity
association	O	O	I-Entity
study	O	O	I-Entity
identified	O	O	B-Entity
19p13.3	O	O	B-Entity
for	O	O	O
lean	O	O	O
body	O	O	O
mass	O	O	O

Lean	O	O	B-Entity
body	O	O	I-Entity
mass	O	O	I-Entity
(	O	O	O
LBM	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
complex	O	O	O
trait	O	O	B-Entity
for	O	O	O
human	O	O	B-Entity
health	O	O	B-Entity
.	O	O	O

To	O	O	O
identify	O	O	O
genomic	O	O	B-Entity
loci	O	O	I-Entity
underlying	O	O	O
LBM	O	O	B-Entity
,	O	O	O
we	O	O	O
performed	O	O	O
a	O	O	O
gene	O	O	B-Entity
-based	O	O	O
genome-wide	O	O	B-Entity
association	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
lean	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
LMI	O	O	B-Entity
)	O	O	O
in	O	O	O
1000	O	O	O
unrelated	O	O	B-Entity
Caucasian	O	O	B-Entity
subjects	O	O	B-Entity
,	O	O	O
and	O	O	O
replicated	O	O	B-Entity
in	O	O	O
2283	O	O	O
unrelated	O	O	O
Caucasians	O	O	B-Entity
subjects	O	O	O
.	O	O	O

Gene	O	O	B-Entity
-based	O	O	O
association	O	O	B-Entity
analyses	O	O	I-Entity
highlighted	O	O	O
the	O	O	O
significant	O	O	O
associations	O	O	B-Entity
of	O	O	O
three	O	O	O
genes	O	O	B-Entity
UQCR	O	O	B-Entity
,	O	O	O
TCF3	O	O	B-Entity
and	O	O	O
MBD3	O	O	B-Entity
in	O	O	O
one	O	O	O
single	O	O	B-Entity
locus	O	O	B-Entity
19p13.3	O	O	B-Entity
(	O	O	O
discovery	O	O	B-Entity
p	O	O	O
=	O	O	O
6.10	O	O	O
×	O	O	O
10(-5	O	O	O
)	O	O	O
,	O	O	O
1.65	O	O	O
×	O	O	O
10(-4	O	O	O
)	O	O	O
and	O	O	O
1.10	O	O	O
×	O	O	O
10(-4	O	O	O
)	O	O	O
;	O	O	O
replication	O	O	B-Entity
p	O	O	O
=	O	O	O
2.21	O	O	O
×	O	O	O
10(-3	O	O	O
)	O	O	O
,	O	O	O
1.84	O	O	O
×	O	O	O
10(-3	O	O	O
)	O	O	O
and	O	O	O
6.95	O	O	O
×	O	O	O
10(-3	O	O	O
)	O	O	O
;	O	O	O
combined	O	O	O
p	O	O	O
=	O	O	O
2.26	O	O	O
×	O	O	O
10(-6	O	O	O
)	O	O	O
,	O	O	O
4.86	O	O	O
×	O	O	O
10(-6	O	O	O
)	O	O	O
and	O	O	O
1.15	O	O	O
×	O	O	O
10(-5	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

These	O	O	O
results	O	O	O
,	O	O	O
together	O	O	O
with	O	O	O
the	O	O	O
known	O	O	O
functional	O	O	B-Entity
relevance	O	O	B-Entity
of	O	O	O
the	O	O	O
three	O	O	O
genes	O	O	B-Entity
to	O	O	O
LMI	O	O	B-Entity
,	O	O	O
suggested	O	O	O
that	O	O	O
the	O	O	O
19p13.3	O	O	B-Entity
region	O	O	B-Entity
containing	O	O	O
UQCR	O	O	B-Entity
,	O	O	O
TCF3	O	O	B-Entity
and	O	O	O
MBD3	O	O	B-Entity
genes	O	O	I-Entity
was	O	O	O
a	O	O	O
novel	O	O	O
locus	O	O	B-Entity
underlying	O	O	O
lean	O	O	B-Entity
mass	O	O	I-Entity
variation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28322744)

Basal	O	O	B-Entity
ryanodine	O	O	B-Entity
receptor	O	O	I-Entity
activity	O	O	I-Entity
suppresses	O	O	B-Entity
autophagic	O	O	B-Entity
flux	O	O	O

The	O	O	O
inositol	O	O	B-Entity
1,4,5-trisphosphate	O	O	I-Entity
receptors	O	O	I-Entity
(	O	O	O
IP3Rs	O	O	B-Entity
)	O	O	O
and	O	O	O
intracellular	O	O	B-Entity
Ca(2	O	O	I-Entity
+	O	O	I-Entity
)	O	O	I-Entity
signaling	O	O	I-Entity
are	O	O	O
critically	O	O	B-Entity
involved	O	O	B-Entity
in	O	O	O
regulating	O	O	B-Entity
different	O	O	B-Entity
steps	O	O	B-Entity
of	O	O	O
autophagy	O	O	B-Entity
,	O	O	O
a	O	O	O
lysosomal	O	O	B-Entity
degradation	O	O	B-Entity
pathway	O	O	I-Entity
.	O	O	O

The	O	O	O
ryanodine	O	O	B-Entity
receptors	O	O	I-Entity
(	O	O	O
RyR	O	O	B-Entity
)	O	O	O
,	O	O	O
intracellular	O	O	B-Entity
Ca(2+)-release	O	O	I-Entity
channels	O	O	I-Entity
mainly	O	O	O
expressed	O	O	B-Entity
in	O	O	O
excitable	O	O	B-Entity
cell	O	O	B-Entity
types	O	O	I-Entity
including	O	O	B-Entity
muscle	O	O	B-Entity
and	O	O	O
neurons	O	O	B-Entity
,	O	O	O
have	O	O	O
however	O	O	O
not	O	O	O
yet	O	O	O
been	O	O	O
extensively	O	O	B-Entity
studied	O	O	B-Entity
in	O	O	O
relation	O	O	O
to	O	O	O
autophagy	O	O	B-Entity
.	O	O	O

Yet	O	O	O
,	O	O	O
aberrant	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
excessive	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
RyRs	O	O	B-Entity
in	O	O	O
these	O	O	O
tissues	O	O	B-Entity
has	O	O	O
been	O	O	O
implicated	O	O	B-Entity
in	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
several	O	O	B-Entity
diseases	O	O	B-Entity
including	O	O	B-Entity
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
,	O	O	O
where	O	O	O
impaired	O	O	B-Entity
autophagy	O	O	B-Entity
regulation	O	O	B-Entity
contributes	O	O	B-Entity
to	O	O	O
the	O	O	O
pathology	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
determined	O	O	B-Entity
whether	O	O	O
pharmacological	O	O	B-Entity
RyR	O	O	B-Entity
inhibition	O	O	B-Entity
could	O	O	O
modulate	O	O	B-Entity
autophagic	O	O	B-Entity
flux	O	O	B-Entity
in	O	O	O
ectopic	O	O	B-Entity
RyR	O	O	O
-	O	O	O
expressing	O	O	B-Entity
models	O	O	B-Entity
,	O	O	O
like	O	O	O
HEK293	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
in	O	O	O
cell	O	O	B-Entity
types	O	O	I-Entity
that	O	O	O
endogenously	O	O	B-Entity
express	O	O	B-Entity
RyR	O	O	O
s	O	O	O
,	O	O	O
like	O	O	O
C2C12	O	O	B-Entity
myoblasts	O	O	I-Entity
and	O	O	O
primary	O	O	B-Entity
hippocampal	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

Importantly	O	O	B-Entity
,	O	O	O
RyR3	O	O	B-Entity
overexpression	O	O	B-Entity
in	O	O	O
HEK293	O	O	B-Entity
cells	O	O	I-Entity
impaired	O	O	B-Entity
the	O	O	O
autophagic	O	O	B-Entity
flux	O	O	B-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
in	O	O	O
all	O	O	O
cell	O	O	B-Entity
models	O	O	B-Entity
tested	O	O	B-Entity
,	O	O	O
pharmacological	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
endogenous	O	O	B-Entity
or	O	O	O
ectopically	O	O	B-Entity
expressed	O	O	B-Entity
RyRs	O	O	B-Entity
,	O	O	O
using	O	O	O
dantrolene	O	O	B-Entity
or	O	O	O
ryanodine	O	O	B-Entity
,	O	O	O
augmented	O	O	B-Entity
autophagic	O	O	B-Entity
flux	O	O	B-Entity
by	O	O	O
increasing	O	O	B-Entity
lysosomal	O	O	B-Entity
turn-over	O	O	B-Entity
(	O	O	O
number	O	O	B-Entity
of	O	O	O
autophagosomes	O	O	B-Entity
and	O	O	O
autolysosomes	O	O	B-Entity
measured	O	O	B-Entity
as	O	O	O
mCherry	O	O	B-Entity
-	O	O	O
LC3	O	O	B-Entity
punctae	O	O	I-Entity
/	O	O	O
cell	O	O	O
increased	O	O	B-Entity
from	O	O	O
70.37±7.81	O	O	O
in	O	O	O
control	O	O	B-Entity
HEK	O	O	B-Entity
RyR3	O	O	I-Entity
cells	O	O	I-Entity
to	O	O	O
111.18±7.72	O	O	O
and	O	O	O
98.14±7.31	O	O	O
after	O	O	O
dantrolene	O	O	O
and	O	O	O
ryanodine	O	O	O
treatments	O	O	B-Entity
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
in	O	O	O
differentiated	O	O	B-Entity
C2C12	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
transmission	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
demonstrated	O	O	B-Entity
that	O	O	O
dantrolene	O	O	B-Entity
treatment	O	O	B-Entity
decreased	O	O	B-Entity
the	O	O	O
number	O	O	B-Entity
of	O	O	O
early	O	O	O
autophagic	O	O	B-Entity
vacuoles	O	O	B-Entity
from	O	O	O
5.9±2.97	O	O	O
to	O	O	O
1.8±1.03	O	O	O
per	O	O	O
cellular	O	O	B-Entity
cross	O	O	B-Entity
section	O	O	I-Entity
.	O	O	O

The	O	O	O
modulation	O	O	B-Entity
of	O	O	O
the	O	O	O
autophagic	O	O	B-Entity
flux	O	O	B-Entity
could	O	O	O
be	O	O	O
linked	O	O	O
to	O	O	O
the	O	O	O
functional	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
RyR	O	O	B-Entity
channels	O	O	I-Entity
as	O	O	O
both	O	O	O
RyR	O	O	O
inhibitors	O	O	B-Entity
efficiently	O	O	B-Entity
diminished	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
cells	O	O	B-Entity
showing	O	O	O
spontaneous	O	O	B-Entity
RyR3	O	O	B-Entity
activity	O	O	B-Entity
in	O	O	O
the	O	O	O
HEK293	O	O	B-Entity
cell	O	O	I-Entity
model	O	O	B-Entity
(	O	O	O
from	O	O	O
41.14%±2.12	O	O	O
in	O	O	O
control	O	O	B-Entity
cells	O	O	O
to	O	O	O
18.70%±2.25	O	O	O
and	O	O	O
9.74%±2.67	O	O	O
after	O	O	O
dantrolene	O	O	B-Entity
and	O	O	O
ryanodine	O	O	B-Entity
treatments	O	O	B-Entity
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
basal	O	O	B-Entity
RyR	O	O	B-Entity
-mediated	O	O	O
Ca(2+)-release	O	O	B-Entity
events	O	O	I-Entity
suppress	O	O	B-Entity
autophagic	O	O	B-Entity
flux	O	O	B-Entity
at	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
the	O	O	O
lysosomes	O	O	B-Entity
.	O	O	O

-DOCSTART- (28322885)

Fluoride	O	O	B-Entity
concentration	O	O	B-Entity
in	O	O	O
saliva	O	O	B-Entity
and	O	O	O
biofilm	O	O	B-Entity
fluid	O	O	I-Entity
following	O	O	O
the	O	O	O
application	O	O	B-Entity
of	O	O	O
three	O	O	O
fluoride	O	O	O
varnishes	O	O	O

Most	O	O	O
of	O	O	O
the	O	O	O
commercially	O	O	O
available	O	O	O
fluoride	O	O	B-Entity
varnishes	O	O	I-Entity
(	O	O	O
FV	O	O	B-Entity
)	O	O	O
have	O	O	O
not	O	O	O
been	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
their	O	O	O
cariostatic	O	O	B-Entity
properties	O	O	I-Entity
.	O	O	O

Consequently	O	O	B-Entity
,	O	O	O
the	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
intra	O	O	B-Entity
-	O	O	O
oral	O	O	B-Entity
fluoride	O	O	B-Entity
retention	O	O	B-Entity
and	O	O	O
clearance	O	O	B-Entity
patterns	O	O	I-Entity
from	O	O	O
three	O	O	O
different	O	O	O
FV	O	O	B-Entity
.	O	O	O

Eighteen	O	O	O
subjects	O	O	B-Entity
(	O	O	O
7	O	O	O
-	O	O	O
11	O	O	O
years	O	O	B-Entity
)	O	O	O
participated	O	O	O
in	O	O	O
a	O	O	O
laboratory	O	O	B-Entity
analyst	O	O	B-Entity
-	O	O	O
blinded	O	O	B-Entity
,	O	O	O
randomized	O	O	B-Entity
,	O	O	O
crossover	O	O	B-Entity
study	O	O	I-Entity
comparing	O	O	B-Entity
the	O	O	O
ability	O	O	B-Entity
of	O	O	O
5	O	O	O
%	O	O	O
sodium	O	O	B-Entity
fluoride	O	O	B-Entity
varnishes	O	O	I-Entity
(	O	O	O
CavityShield-CS	O	O	B-Entity
,	O	O	O
Enamel	O	O	B-Entity
Pro-EP	O	O	I-Entity
,	O	O	O
Vanish-V	O	O	B-Entity
)	O	O	O
to	O	O	O
enhance	O	O	B-Entity
fluoride	O	O	O
concentrations	O	O	B-Entity
in	O	O	O
biofilm	O	O	B-Entity
fluid	O	O	I-Entity
,	O	O	O
centrifuged	O	O	B-Entity
and	O	O	O
whole	O	O	B-Entity
saliva	O	O	B-Entity
over	O	O	O
a	O	O	O
period	O	O	B-Entity
of	O	O	O
48h	O	O	O
after	O	O	O
a	O	O	O
single	O	O	O
FV	O	O	B-Entity
application	O	O	O
.	O	O	O

Similar	O	O	O
fluoride	O	O	B-Entity
concentration	O	O	B-Entity
×	O	O	O
time	O	O	B-Entity
patterns	O	O	I-Entity
were	O	O	O
noted	O	O	B-Entity
for	O	O	O
all	O	O	O
investigated	O	O	B-Entity
FV	O	O	B-Entity
and	O	O	O
studied	O	O	B-Entity
variables	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
highest	O	O	B-Entity
fluoride	O	O	O
concentrations	O	O	B-Entity
observed	O	O	B-Entity
for	O	O	O
the	O	O	O
first	O	O	O
biological	O	O	B-Entity
sample	O	O	I-Entity
collected	O	O	B-Entity
after	O	O	O
FV	O	O	O
application	O	O	O
(	O	O	O
30min	O	O	O
)	O	O	O
.	O	O	O

Mean±SE	O	O	B-Entity
(	O	O	O
area	O	O	B-Entity
under	O	O	I-Entity
fluoride	O	O	I-Entity
clearance	O	O	I-Entity
curve	O	O	I-Entity
)	O	O	O
values	O	O	B-Entity
were	O	O	O
(	O	O	O
μg	O	O	O
F/g	O	O	O
or	O	O	O
ml	O	O	O
×	O	O	O
min	O	O	O
):	O	O	O
biofilm	O	O	B-Entity
fluid	O	O	I-Entity
-	O	O	O
CS	O	O	B-Entity
(	O	O	O
472±191	O	O	O
)	O	O	O
,	O	O	O
EP	O	O	B-Entity
(	O	O	O
423±75	O	O	O
)	O	O	O
,	O	O	O
V	O	O	B-Entity
(	O	O	O
1264±279	O	O	O
)	O	O	O
;	O	O	O
centrifuged	O	O	B-Entity
saliva	O	O	B-Entity
-	O	O	O
CS	O	O	O
(	O	O	O
42±7	O	O	O
)	O	O	O
,	O	O	O
EP	O	O	O
(	O	O	O
19±3	O	O	O
)	O	O	O
,	O	O	O
V	O	O	O
(	O	O	O
41±8	O	O	O
)	O	O	O
;	O	O	O
whole	O	O	B-Entity
saliva	O	O	O
-	O	O	O
CS	O	O	O
(	O	O	O
68±11	O	O	O
)	O	O	O
,	O	O	O
EP	O	O	O
(	O	O	O
64±10	O	O	O
)	O	O	O
,	O	O	O
V	O	O	O
(	O	O	O
60±7	O	O	O
)	O	O	O
.	O	O	O

V	O	O	B-Entity
delivered	O	O	O
more	O	O	O
fluoride	O	O	B-Entity
to	O	O	O
biofilm	O	O	B-Entity
fluid	O	O	I-Entity
than	O	O	O
CS	O	O	B-Entity
(	O	O	O
p=0.0116	O	O	O
)	O	O	O
and	O	O	O
EP	O	O	B-Entity
(	O	O	O
p=0.0065	O	O	O
)	O	O	O
,	O	O	O
which	O	O	O
did	O	O	O
not	O	O	O
differ	O	O	O
(	O	O	O
p=0.27	O	O	O
)	O	O	O
.	O	O	O

For	O	O	O
centrifuged	O	O	B-Entity
saliva	O	O	B-Entity
,	O	O	O
CS	O	O	B-Entity
and	O	O	O
V	O	O	B-Entity
were	O	O	O
not	O	O	O
significantly	O	O	B-Entity
different	O	O	O
(	O	O	O
p=0.86	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
resulted	O	O	B-Entity
in	O	O	O
higher	O	O	B-Entity
fluoride	O	O	B-Entity
retention	O	O	B-Entity
than	O	O	O
EP	O	O	B-Entity
(	O	O	O
p<0.0008	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	B-Entity
differences	O	O	O
among	O	O	O
FV	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
for	O	O	O
whole	O	O	B-Entity
saliva	O	O	B-Entity
(	O	O	O
p=0.79	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
present	O	O	B-Entity
study	O	O	B-Entity
has	O	O	O
shown	O	O	O
that	O	O	O
FV	O	O	B-Entity
vary	O	O	O
in	O	O	O
their	O	O	O
ability	O	O	B-Entity
to	O	O	O
deliver	O	O	O
fluoride	O	O	B-Entity
intra	O	O	B-Entity
-	O	O	O
orally	O	O	B-Entity
potentially	O	O	B-Entity
related	O	O	B-Entity
to	O	O	O
formulation	O	O	O
differences	O	O	B-Entity
.	O	O	O

To	O	O	O
what	O	O	O
extent	O	O	B-Entity
the	O	O	O
present	O	O	B-Entity
findings	O	O	B-Entity
relate	O	O	B-Entity
to	O	O	O
clinical	O	O	B-Entity
efficacy	O	O	I-Entity
remains	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
to	O	O	O
be	O	O	O
determined	O	O	B-Entity
.	O	O	O

Clinical	O	O	B-Entity
research	O	O	I-Entity
that	O	O	O
investigates	O	O	B-Entity
fluoride	O	O	B-Entity
release	O	O	B-Entity
patterns	O	O	B-Entity
into	O	O	O
saliva	O	O	B-Entity
and	O	O	O
biofilm	O	O	B-Entity
fluid	O	O	I-Entity
from	O	O	O
different	O	O	O
FV	O	O	B-Entity
products	O	O	I-Entity
is	O	O	O
insufficient	O	O	B-Entity
.	O	O	O

More	O	O	O
research	O	O	B-Entity
is	O	O	O
needed	O	O	O
to	O	O	O
investigate	O	O	B-Entity
different	O	O	O
FV	O	O	B-Entity
formulations	O	O	I-Entity
for	O	O	O
their	O	O	O
efficacy	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
help	O	O	O
clinicians	O	O	B-Entity
make	O	O	O
better	O	O	B-Entity
evidence	O	O	B-Entity
based	O	O	O
treatment	O	O	B-Entity
choices	O	O	O
.	O	O	O

-DOCSTART- (28323338)

The	O	O	O
prognostic	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
extranodal	O	O	B-Entity
extension	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
-associated	O	O	O
oropharyngeal	O	O	O
squamous	O	O	O
cell	O	O	O
carcinoma	O	O	O

Extranodal	O	O	B-Entity
(	O	O	I-Entity
or	O	O	I-Entity
extracapsular	O	O	I-Entity
)	O	O	I-Entity
extension	O	O	I-Entity
(	O	O	O
ENE	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
adverse	O	O	B-Entity
prognostic	O	O	I-Entity
factor	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
head	O	O	B-Entity
and	O	O	I-Entity
neck	O	O	I-Entity
cancers	O	O	I-Entity
who	O	O	O
undergo	O	O	O
primary	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
significance	O	O	O
of	O	O	O
ENE	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
papillomavirus	O	O	I-Entity
(HPV)-positive	O	O	I-Entity
oropharyngeal	O	O	I-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	I-Entity
OPSCC	O	O	I-Entity
)	O	O	I-Entity
is	O	O	O
not	O	O	O
well	O	O	O
established	O	O	O
,	O	O	O
and	O	O	O
single-institution	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
not	O	O	B-Entity
established	O	O	I-Entity
that	O	O	O
ENE	O	O	O
predicts	O	O	B-Entity
inferior	O	O	B-Entity
outcome	O	O	B-Entity
.	O	O	O

The	O	O	O
authors	O	O	O
investigated	O	O	O
the	O	O	O
prognostic	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
ENE	O	O	B-Entity
in	O	O	O
HPV	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
primary	O	O	B-Entity
surgery	O	O	I-Entity
and	O	O	O
whether	O	O	O
adjuvant	O	O	B-Entity
chemoradiation	O	O	I-Entity
improved	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
OS	O	O	B-Entity
)	O	O	O
compared	O	O	B-Entity
with	O	O	O
radiation	O	O	B-Entity
alone	O	O	I-Entity
in	O	O	O
ENE	O	O	O
-	O	O	O
positive	O	O	O
patients	O	O	O
.	O	O	O

Patients	O	O	B-Entity
who	O	O	O
underwent	O	O	O
primary	O	O	B-Entity
surgery	O	O	I-Entity
for	O	O	O
pathologic	O	O	B-Entity
T1	O	O	I-Entity
(	O	O	O
pT1	O	O	B-Entity
)	O	O	O
through	O	O	O
pT4	O	O	B-Entity
tumors	O	O	I-Entity
,	O	O	O
pathologic	O	O	B-Entity
N1	O	O	I-Entity
(	O	O	O
pN1	O	O	B-Entity
)	O	O	O
through	O	O	O
pN3	O	O	B-Entity
lymph	O	O	I-Entity
node	O	O	I-Entity
status	O	O	B-Entity
,	O	O	O
HPV-positive	O	O	B-Entity
OPSCC	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
the	O	O	O
National	O	O	B-Entity
Cancer	O	O	I-Entity
Data	O	O	I-Entity
Base	O	O	I-Entity
from	O	O	O
2010	O	O	O
through	O	O	O
2012	O	O	O
.	O	O	O

Features	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
ENE	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Univariable	O	O	B-Entity
and	O	O	I-Entity
multivariable	O	O	I-Entity
Cox	O	O	I-Entity
regression	O	O	I-Entity
analyses	O	O	I-Entity
identified	O	O	B-Entity
predictors	O	O	B-Entity
of	O	O	O
OS	O	O	B-Entity
.	O	O	O

The	O	O	O
effect	O	O	B-Entity
of	O	O	O
adjuvant	O	O	B-Entity
treatment	O	O	I-Entity
on	O	O	O
OS	O	O	B-Entity
in	O	O	O
ENE	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
cohort	O	O	B-Entity
was	O	O	O
also	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

In	O	O	O
total	O	O	O
,	O	O	O
1043	O	O	O
patients	O	O	B-Entity
met	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	I-Entity
,	O	O	O
among	O	O	O
whom	O	O	O
43.5	O	O	O
%	O	O	O
were	O	O	O
ENE	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
ENE	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
treatment	O	O	B-Entity
details	O	O	O
available	O	O	O
,	O	O	O
72	O	O	O
%	O	O	O
received	O	O	B-Entity
concurrent	O	O	B-Entity
chemoradiotherapy	O	O	I-Entity
,	O	O	O
16	O	O	O
%	O	O	O
received	O	O	O
radiotherapy	O	O	B-Entity
,	O	O	O
and	O	O	O
12	O	O	O
%	O	O	O
received	O	O	O
no	O	O	B-Entity
adjuvant	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

After	O	O	O
a	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
of	O	O	O
28.4	O	O	O
months	O	O	B-Entity
,	O	O	O
ENE	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
worse	O	O	B-Entity
3-	O	O	O
year	O	O	B-Entity
OS	O	O	B-Entity
(	O	O	O
89.3	O	O	O
%	O	O	O
vs	O	O	O
93.6	O	O	O
%	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.01	O	O	O
)	O	O	O
.	O	O	O

On	O	O	O
multivariable	O	O	B-Entity
analysis	O	O	I-Entity
that	O	O	O
included	O	O	B-Entity
involved	O	O	O
lymph	O	O	B-Entity
nodes	O	O	I-Entity
,	O	O	O
only	O	O	O
ENE	O	O	B-Entity
,	O	O	O
lymphovascular	O	O	B-Entity
invasion	O	O	I-Entity
,	O	O	O
pT3/pT4	O	O	B-Entity
tumors	O	O	I-Entity
,	O	O	O
and	O	O	O
Charlson-Deyo	O	O	B-Entity
score	O	O	I-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
worse	O	O	B-Entity
OS	O	O	B-Entity
.	O	O	O

Among	O	O	O
ENE	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
3-	O	O	O
year	O	O	B-Entity
OS	O	O	B-Entity
between	O	O	O
those	O	O	O
who	O	O	O
received	O	O	B-Entity
adjuvant	O	O	B-Entity
concurrent	O	O	I-Entity
chemoradiotherapy	O	O	I-Entity
versus	O	O	O
radiotherapy	O	O	B-Entity
alone	O	O	I-Entity
(	O	O	O
89.6	O	O	O
%	O	O	O
vs	O	O	O
89.3	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.55	O	O	O
)	O	O	O
.	O	O	O

Propensity	O	O	B-Entity
score	O	O	I-Entity
-	O	O	O
matched	O	O	B-Entity
comparison	O	O	I-Entity
revealed	O	O	B-Entity
similar	O	O	O
results	O	O	B-Entity
.	O	O	O

ENE	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
inferior	O	O	B-Entity
OS	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
HPV-positive	O	O	B-Entity
OPSCC	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
OS	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
better	O	O	I-Entity
with	O	O	O
adjuvant	O	O	B-Entity
chemoradiotherapy	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
radiotherapy	O	O	B-Entity
alone	O	O	I-Entity
in	O	O	O
ENE	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
current	O	O	B-Entity
findings	O	O	I-Entity
support	O	O	I-Entity
the	O	O	O
need	O	O	O
for	O	O	O
prospective	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
adjuvant	O	O	B-Entity
chemoradiation	O	O	I-Entity
in	O	O	O
HPV	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
ENE	O	O	B-Entity
.	O	O	O

Cancer	O	O	O
2017	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
American	O	O	O
Cancer	O	O	O
Society	O	O	O
.	O	O	O

-DOCSTART- (28323926)

Psychological	O	O	B-Entity
Distress	O	O	I-Entity
Is	O	O	O
More	O	O	O
Prevalent	O	O	O
in	O	O	O
Fertile	O	O	B-Entity
Age	O	O	B-Entity
and	O	O	O
Premenopausal	O	O	B-Entity
Women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
Symptoms	O	O	B-Entity
-15-yr	O	O	O
Follow-up	O	O	O

Polycystic	O	O	B-Entity
ovary	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
PCOS	O	O	B-Entity
)	O	O	O
is	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	O
psychological	O	O	B-Entity
distress	O	O	I-Entity
;	O	O	O
obesity	O	O	B-Entity
and	O	O	O
hyperandrogenism	O	O	B-Entity
being	O	O	O
suggested	O	O	O
as	O	O	O
key	O	O	O
promoters	O	O	B-Entity
.	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
anxiety	O	O	B-Entity
/	O	O	O
depression	O	O	B-Entity
and	O	O	O
their	O	O	O
coexistence	O	O	O
in	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
/	O	O	O
PCOS	O	O	O
symptoms	O	O	B-Entity
at	O	O	O
age	O	O	B-Entity
s	O	O	O
31	O	O	O
and	O	O	O
46	O	O	O
.	O	O	O

The	O	O	O
roles	O	O	O
of	O	O	O
obesity	O	O	B-Entity
,	O	O	O
hyperandrogenism	O	O	B-Entity
and	O	O	O
awareness	O	O	B-Entity
of	O	O	O
PCOS	O	O	B-Entity
on	O	O	O
psychological	O	O	B-Entity
distress	O	O	I-Entity
were	O	O	O
also	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Population	O	O	B-Entity
based	O	O	I-Entity
follow-up	O	O	I-Entity
.	O	O	O

Northern	O	O	B-Entity
Finland	O	O	I-Entity
Birth	O	O	B-Entity
Cohort	O	O	I-Entity
1966	O	O	O
with	O	O	O
15-	O	O	O
year	O	O	B-Entity
follow-up	O	O	B-Entity
.	O	O	O

At	O	O	O
age	O	O	B-Entity
31	O	O	O
a	O	O	O
questionnaire-based	O	O	B-Entity
screening	O	O	I-Entity
for	O	O	O
oligoamenorrhea	O	O	B-Entity
(	O	O	O
OA	O	O	B-Entity
)	O	O	O
and	O	O	O
hirsutism	O	O	B-Entity
(	O	O	O
H	O	O	B-Entity
):	O	O	O
2188	O	O	O
asymptomatic	O	O	B-Entity
(	O	O	O
controls	O	O	B-Entity
)	O	O	O
,	O	O	O
331	O	O	O
OA	O	O	O
,	O	O	O
323	O	O	O
H	O	O	O
,	O	O	O
125	O	O	O
OA	O	O	O
+	O	O	O
H	O	O	O
(	O	O	O
PCOS	O	O	B-Entity
)	O	O	O
.	O	O	O

46	O	O	O
year	O	O	B-Entity
old	O	O	O
follow-up	O	O	B-Entity
:	O	O	O
1576	O	O	O
controls	O	O	B-Entity
,	O	O	O
239	O	O	O
OA	O	O	B-Entity
,	O	O	O
231	O	O	O
H	O	O	B-Entity
and	O	O	O
85	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

Questionnaire-based	O	O	B-Entity
screening	O	O	I-Entity
for	O	O	O
anxiety	O	O	B-Entity
and	O	O	O
depression	O	O	B-Entity
symptoms	O	O	I-Entity
(	O	O	O
Hopkins	O	O	B-Entity
Symptom	O	O	I-Entity
Checklist-25	O	O	I-Entity
)	O	O	O
and	O	O	O
previously	O	O	O
diagnosed	O	O	B-Entity
/	O	O	O
treated	O	O	B-Entity
depression	O	O	O
at	O	O	O
age	O	O	B-Entity
31	O	O	O
and	O	O	O
46	O	O	O
.	O	O	O

BMI	O	O	B-Entity
,	O	O	O
serum	O	O	B-Entity
testosterone	O	O	I-Entity
/	O	O	O
free	O	O	B-Entity
androgen	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
FAI	O	O	B-Entity
)	O	O	O
and	O	O	O
awareness	O	O	B-Entity
of	O	O	O
polycystic	O	O	B-Entity
ovaries	O	O	I-Entity
/	O	O	O
PCOS	O	O	B-Entity
on	O	O	O
psychological	O	O	B-Entity
distress	O	O	I-Entity
were	O	O	O
also	O	O	O
assessed	O	O	B-Entity
.	O	O	O

Population-based	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
anxiety	O	O	B-Entity
and/or	O	O	O
depression	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
/	O	O	O
PCOS	O	O	O
symptoms	O	O	B-Entity
at	O	O	O
age	O	O	B-Entity
s	O	O	O
31	O	O	O
and	O	O	O
46	O	O	O
.	O	O	O

Anxiety	O	O	B-Entity
and/or	O	O	O
depression	O	O	B-Entity
symptoms	O	O	I-Entity
,	O	O	O
their	O	O	O
coexistence	O	O	O
and	O	O	O
rate	O	O	O
of	O	O	O
depression	O	O	O
were	O	O	O
increased	O	O	O
at	O	O	O
age	O	O	B-Entity
31	O	O	O
and	O	O	O
46	O	O	O
in	O	O	O
women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
or	O	O	O
isolated	O	O	O
H	O	O	B-Entity
compared	O	O	O
with	O	O	O
controls	O	O	B-Entity
.	O	O	O

High	O	O	O
BMI	O	O	B-Entity
or	O	O	O
hyperandrogenism	O	O	B-Entity
did	O	O	O
not	O	O	O
associate	O	O	O
with	O	O	O
increased	O	O	O
anxiety	O	O	B-Entity
or	O	O	O
depression	O	O	B-Entity
symptoms	O	O	I-Entity
.	O	O	O

The	O	O	O
awareness	O	O	B-Entity
of	O	O	O
PCOS	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
increased	O	O	O
anxiety	O	O	B-Entity
.	O	O	O

Women	O	O	B-Entity
with	O	O	O
PCOS	O	O	B-Entity
or	O	O	O
isolated	O	O	O
H	O	O	B-Entity
present	O	O	O
more	O	O	O
often	O	O	O
with	O	O	O
anxiety	O	O	B-Entity
and/or	O	O	O
depression	O	O	B-Entity
symptoms	O	O	I-Entity
and	O	O	O
their	O	O	O
coexistence	O	O	O
compared	O	O	O
with	O	O	O
controls	O	O	B-Entity
.	O	O	O

High	O	O	O
BMI	O	O	B-Entity
or	O	O	O
hyperandrogenism	O	O	B-Entity
did	O	O	O
not	O	O	O
provoke	O	O	O
psychological	O	O	B-Entity
distress	O	O	I-Entity
in	O	O	O
PCOS	O	O	B-Entity
.	O	O	O

The	O	O	O
awareness	O	O	B-Entity
of	O	O	O
PCOS	O	O	B-Entity
increased	O	O	O
anxiety	O	O	B-Entity
but	O	O	O
did	O	O	O
not	O	O	O
associate	O	O	O
with	O	O	O
severe	O	O	O
anxiety	O	O	O
or	O	O	O
depression	O	O	B-Entity
.	O	O	O

-DOCSTART- (28327913)

The	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
Oxford	O	O	B-Entity
Nanopore	O	O	I-Entity
native	O	O	B-Entity
barcoding	O	O	B-Entity
for	O	O	O
complete	O	O	B-Entity
genome	O	O	O
assembly	O	O	O

The	O	O	O
Oxford	O	O	B-Entity
Nanopore	O	O	I-Entity
Technologies	O	O	I-Entity
MinION(TM	O	O	B-Entity
)	O	O	I-Entity
is	O	O	O
a	O	O	O
mobile	O	O	B-Entity
DNA	O	O	O
sequencer	O	O	O
that	O	O	O
can	O	O	O
produce	O	O	O
long	O	O	B-Entity
read	O	O	I-Entity
sequences	O	O	I-Entity
with	O	O	O
a	O	O	O
short	O	O	O
turn-around	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	B-Entity
the	O	O	O
first	O	O	O
demonstration	O	O	O
of	O	O	O
single	O	O	B-Entity
contig	O	O	I-Entity
genome	O	O	I-Entity
assembly	O	O	I-Entity
using	O	O	B-Entity
Oxford	O	O	B-Entity
Nanopore	O	O	I-Entity
native	O	O	B-Entity
barcoding	O	O	B-Entity
when	O	O	O
applied	O	O	B-Entity
to	O	O	O
a	O	O	O
multiplexed	O	O	B-Entity
library	O	O	I-Entity
of	O	O	O
12	O	O	O
samples	O	O	B-Entity
and	O	O	O
combined	O	O	B-Entity
with	O	O	O
existing	O	O	B-Entity
Illumina	O	O	O
short-read	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

This	O	O	O
paves	O	O	O
the	O	O	O
way	O	O	O
for	O	O	O
the	O	O	O
closure	O	O	B-Entity
of	O	O	O
multiple	O	O	B-Entity
bacterial	O	O	B-Entity
genomes	O	O	I-Entity
from	O	O	O
a	O	O	O
single	O	O	B-Entity
MinION(TM	O	O	B-Entity
)	O	O	I-Entity
sequencing	O	O	B-Entity
run	O	O	B-Entity
,	O	O	O
given	O	O	O
the	O	O	O
availability	O	O	B-Entity
of	O	O	I-Entity
existing	O	O	B-Entity
short-read	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

The	O	O	O
strain	O	O	B-Entity
we	O	O	O
used	O	O	B-Entity
,	O	O	O
MHO_001	O	O	B-Entity
,	O	O	O
represents	O	O	O
the	O	O	O
important	O	O	O
community-acquired	O	O	O
methicillin	O	O	B-Entity
resistant	O	O	I-Entity
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
lineage	O	O	O
USA300	O	O	B-Entity
.	O	O	O

Using	O	O	B-Entity
a	O	O	O
hybrid	O	O	O
assembly	O	O	B-Entity
of	O	O	O
existing	O	O	B-Entity
short	O	O	B-Entity
read	O	O	I-Entity
and	O	O	O
barcoded	O	O	B-Entity
long	O	O	I-Entity
read	O	O	I-Entity
sequences	O	O	I-Entity
from	O	O	O
multiplexed	O	O	B-Entity
data	O	O	I-Entity
,	O	O	O
we	O	O	O
completed	O	O	O
a	O	O	O
genome	O	O	B-Entity
of	O	O	O
the	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
USA300	O	O	B-Entity
strain	O	O	I-Entity
MHO_001	O	O	I-Entity
.	O	O	O

The	O	O	O
long-read	O	O	B-Entity
data	O	O	I-Entity
represented	O	O	O
only	O	O	O
~5	O	O	O
-	O	O	O
10	O	O	O
%	O	O	O
of	O	O	O
an	O	O	O
average	O	O	B-Entity
MinION(TM	O	O	B-Entity
)	O	O	I-Entity
run	O	O	B-Entity
(	O	O	O
~7x	O	O	O
genomic	O	O	B-Entity
coverage	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
,	O	O	O
using	O	O	B-Entity
standard	O	O	B-Entity
tools	O	O	B-Entity
,	O	O	O
this	O	O	O
was	O	O	O
sufficient	O	O	B-Entity
to	O	O	O
complete	O	O	B-Entity
the	O	O	O
circular	O	O	B-Entity
chromosome	O	O	I-Entity
of	O	O	O
S.	O	O	B-Entity
aureus	O	O	I-Entity
strain	O	O	B-Entity
MHO_001	O	O	I-Entity
(	O	O	O
2.86	O	O	O
Mb	O	O	O
)	O	O	O
and	O	O	O
two	O	O	O
complete	O	O	O
plasmids	O	O	B-Entity
(	O	O	O
27	O	O	O
Kb	O	O	O
and	O	O	O
3	O	O	O
Kb	O	O	O
)	O	O	O
.	O	O	O

Minor	O	O	B-Entity
differences	O	O	B-Entity
were	O	O	O
noted	O	O	B-Entity
when	O	O	O
compared	O	O	B-Entity
to	O	O	O
USA300	O	O	B-Entity
reference	O	O	O
genome	O	O	B-Entity
,	O	O	O
USA300_FPR3757	O	O	B-Entity
,	O	O	O
including	O	O	B-Entity
the	O	O	O
translocation	O	O	B-Entity
,	O	O	O
loss	O	O	B-Entity
and	O	O	O
gain	O	O	B-Entity
of	O	O	O
mobile	O	O	B-Entity
genetic	O	O	I-Entity
elements	O	O	I-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
MinION(TM	O	O	B-Entity
)	O	O	I-Entity
reads	O	O	B-Entity
,	O	O	O
multiplexed	O	O	B-Entity
using	O	O	B-Entity
native	O	O	B-Entity
barcoding	O	O	B-Entity
,	O	O	O
can	O	O	O
be	O	O	O
used	O	O	B-Entity
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
short-read	O	O	B-Entity
data	O	O	I-Entity
,	O	O	O
to	O	O	O
fully	O	O	O
complete	O	O	B-Entity
a	O	O	O
bacterial	O	O	B-Entity
genome	O	O	I-Entity
.	O	O	O

The	O	O	O
ability	O	O	O
to	O	O	O
complete	O	O	B-Entity
multiple	O	O	B-Entity
genomes	O	O	B-Entity
,	O	O	O
for	O	O	O
which	O	O	O
short-read	O	O	B-Entity
data	O	O	I-Entity
is	O	O	O
already	O	O	O
available	O	O	B-Entity
,	O	O	O
from	O	O	O
a	O	O	O
single	O	O	B-Entity
MinION(TM	O	O	B-Entity
)	O	O	I-Entity
run	O	O	B-Entity
is	O	O	O
set	O	O	O
to	O	O	O
impact	O	O	B-Entity
on	O	O	O
our	O	O	O
understanding	O	O	B-Entity
of	O	O	O
accessory	O	O	B-Entity
genome	O	O	B-Entity
content	O	O	I-Entity
,	O	O	O
plasmid	O	O	B-Entity
diversity	O	O	B-Entity
and	O	O	O
genome	O	O	O
rearrangements	O	O	B-Entity
.	O	O	O

-DOCSTART- (28329872)

Doxorubicin	O	O	B-Entity
Has	O	O	O
Dose-Dependent	O	O	B-Entity
Toxicity	O	O	B-Entity
on	O	O	O
Mouse	O	O	B-Entity
Ovarian	O	O	B-Entity
Follicle	O	O	I-Entity
Development	O	O	B-Entity
,	O	O	O
Hormone	O	O	B-Entity
Secretion	O	O	I-Entity
,	O	O	O
and	O	O	O
Oocyte	O	O	O
Maturation	O	O	O

Doxorubicin	O	O	B-Entity
(	O	O	O
DOX	O	O	B-Entity
)	O	O	O
,	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
commonly	O	O	B-Entity
used	O	O	O
anticancer	O	O	B-Entity
medications	O	O	I-Entity
,	O	O	O
has	O	O	O
been	O	O	O
reported	O	O	O
to	O	O	O
affect	O	O	O
fertility	O	O	B-Entity
by	O	O	O
damaging	O	O	B-Entity
ovarian	O	O	B-Entity
follicles	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
the	O	O	O
dose-dependent	O	O	B-Entity
toxicity	O	O	B-Entity
of	O	O	O
DOX	O	O	O
on	O	O	O
the	O	O	O
dynamic	O	O	B-Entity
follicle	O	O	B-Entity
development	O	O	B-Entity
and	O	O	O
oocyte	O	O	B-Entity
maturation	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
well-defined	O	O	O
.	O	O	O

Our	O	O	O
objective	O	O	B-Entity
is	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
human	O	O	B-Entity
-	O	O	O
relevant	O	O	B-Entity
exposure	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
DOX	O	O	B-Entity
on	O	O	O
follicular	O	O	B-Entity
functions	O	O	B-Entity
across	O	O	O
developmental	O	O	B-Entity
time	O	O	B-Entity
.	O	O	O

In	O	O	B-Entity
vitro	O	O	I-Entity
cultured	O	O	B-Entity
multilayered	O	O	B-Entity
secondary	O	O	I-Entity
mouse	O	O	I-Entity
follicles	O	O	I-Entity
were	O	O	O
treated	O	O	B-Entity
with	O	O	O
DOX	O	O	B-Entity
at	O	O	O
0	O	O	O
,	O	O	O
2	O	O	O
,	O	O	O
20	O	O	O
,	O	O	O
100	O	O	O
,	O	O	O
and	O	O	O
200	O	O	O
nM	O	O	O
for	O	O	O
24	O	O	O
h	O	O	O
,	O	O	O
and	O	O	O
follicle	O	O	B-Entity
development	O	O	B-Entity
,	O	O	O
hormone	O	O	B-Entity
secretion	O	O	I-Entity
,	O	O	O
and	O	O	O
oocyte	O	O	B-Entity
maturation	O	O	I-Entity
were	O	O	O
analyzed	O	O	O
.	O	O	O

DOX	O	O	B-Entity
caused	O	O	O
dose-dependent	O	O	B-Entity
toxicity	O	O	B-Entity
on	O	O	O
follicle	O	O	B-Entity
growth	O	O	I-Entity
,	O	O	O
survival	O	O	B-Entity
,	O	O	O
and	O	O	O
secretion	O	O	B-Entity
of	O	O	O
17β-estradiol	O	O	B-Entity
(	O	O	O
E2	O	O	B-Entity
)	O	O	O
.	O	O	O

At	O	O	O
200	O	O	O
nM	O	O	O
,	O	O	O
DOX	O	O	B-Entity
induced	O	O	B-Entity
DNA	O	O	B-Entity
damage	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
in	O	O	O
follicle	O	O	B-Entity
somatic	O	O	B-Entity
cells	O	O	I-Entity
first	O	O	O
and	O	O	O
then	O	O	O
in	O	O	O
oocytes	O	O	B-Entity
,	O	O	O
which	O	O	O
was	O	O	O
correlated	O	O	O
with	O	O	O
the	O	O	O
uptake	O	O	B-Entity
of	O	O	O
DOX	O	O	O
first	O	O	O
to	O	O	O
the	O	O	O
somatic	O	O	O
cells	O	O	O
followed	O	O	O
by	O	O	O
germ	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Follicles	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
DOX	O	O	B-Entity
at	O	O	O
0	O	O	O
,	O	O	O
2	O	O	O
,	O	O	O
and	O	O	O
20	O	O	O
nM	O	O	O
showed	O	O	O
similar	O	O	O
oocyte	O	O	B-Entity
metaphase	O	O	B-Entity
II	O	O	I-Entity
(	O	O	O
MII	O	O	B-Entity
)	O	O	O
percentages	O	O	B-Entity
after	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
oocyte	O	O	B-Entity
maturation	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
20	O	O	O
nM	O	O	O
DOX	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
the	O	O	O
number	O	O	O
of	O	O	O
MII	O	O	O
oocytes	O	O	B-Entity
with	O	O	O
abnormal	O	O	B-Entity
spindle	O	O	B-Entity
morphology	O	O	B-Entity
and	O	O	O
chromosome	O	O	B-Entity
misalignment	O	O	B-Entity
.	O	O	O

In	O	O	O
an	O	O	O
effort	O	O	O
to	O	O	O
harmonize	O	O	O
the	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
study	O	O	I-Entity
to	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
treatment	O	O	B-Entity
,	O	O	O
dose-dependent	O	O	B-Entity
toxicity	O	O	B-Entity
on	O	O	O
oocyte	O	O	B-Entity
meiotic	O	O	I-Entity
maturation	O	O	I-Entity
was	O	O	O
found	O	O	O
in	O	O	O
16-day-old	O	O	O
CD-1	O	O	B-Entity
mice	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
DOX	O	O	B-Entity
at	O	O	O
0	O	O	O
,	O	O	O
0.4	O	O	O
,	O	O	O
2	O	O	O
,	O	O	O
and	O	O	O
10	O	O	O
mg/kg	O	O	O
,	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
in	O	O	O
vitro	O	O	O
oocyte	O	O	B-Entity
maturation	O	O	I-Entity
outcomes	O	O	B-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
demonstrates	O	O	O
that	O	O	O
DOX	O	O	B-Entity
has	O	O	O
dose-dependent	O	O	B-Entity
toxicity	O	O	B-Entity
on	O	O	O
ovarian	O	O	B-Entity
follicle	O	O	I-Entity
development	O	O	B-Entity
,	O	O	O
hormone	O	O	B-Entity
secretion	O	O	I-Entity
,	O	O	O
and	O	O	O
oocyte	O	O	B-Entity
maturation	O	O	I-Entity
,	O	O	O
which	O	O	O
are	O	O	O
three	O	O	O
key	O	O	O
factors	O	O	B-Entity
to	O	O	O
support	O	O	O
the	O	O	O
female	O	O	B-Entity
reproductive	O	O	I-Entity
and	O	O	O
endocrine	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

-DOCSTART- (28330470)

Involvement	O	O	O
of	O	O	O
apoptotic	O	O	B-Entity
pathways	O	O	I-Entity
in	O	O	O
docosahexaenoic	O	O	B-Entity
acid	O	O	I-Entity
-induced	O	O	O
benefit	O	O	O
in	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
:	O	O	O
Pathway-focused	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
analysis	O	O	I-Entity
using	O	O	O
RT(2	O	O	O
)	O	O	O
Profile	O	O	O
PCR	O	O	O
Array	O	O	O
System	O	O	O

Present	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
better	O	O	O
understand	O	O	O
the	O	O	O
potential	O	O	O
apoptotic	O	O	B-Entity
pathways	O	O	I-Entity
that	O	O	O
involved	O	O	O
in	O	O	O
docosahexaenoic	O	O	B-Entity
acid	O	O	I-Entity
(DHA)-induced	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
cells	O	O	B-Entity
.	O	O	O

Human	O	O	B-Entity
prostate	O	O	B-Entity
cancer	O	O	I-Entity
DU145	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
treated	O	O	O
with	O	O	O
different	O	O	O
concentrations	O	O	O
of	O	O	O
fish	O	O	B-Entity
oil	O	O	I-Entity
,	O	O	O
omega-3	O	O	B-Entity
PUFA	O	O	I-Entity
(	O	O	O
DHA	O	O	B-Entity
,	O	O	O
and	O	O	O
Eicosapentaenoic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
EPA	O	O	B-Entity
)	O	O	O
,	O	O	O
or	O	O	O
omega-6	O	O	B-Entity
PUFA	O	O	I-Entity
(	O	O	O
Arachidonic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
AA	O	O	B-Entity
)	O	O	O
.	O	O	O

Cell	O	O	B-Entity
viability	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
were	O	O	O
evaluated	O	O	O
by	O	O	O
MTT	O	O	B-Entity
assay	O	O	I-Entity
and	O	O	O
Hoechst	O	O	B-Entity
staining	O	O	I-Entity
.	O	O	O

Pathway-focused	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
profiling	O	O	I-Entity
of	O	O	O
DU145	O	O	B-Entity
cells	O	O	I-Entity
was	O	O	O
analyzed	O	O	O
with	O	O	O
the	O	O	O
RT(2	O	O	O
)	O	O	O
Profile	O	O	O
PCR	O	O	O
Array	O	O	O
System	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
were	O	O	O
verified	O	O	O
by	O	O	O
real	O	O	B-Entity
time	O	O	I-Entity
quantitative	O	O	I-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
RT-qPCR	O	O	B-Entity
)	O	O	O
.	O	O	O

AA	O	O	B-Entity
exposure	O	O	O
showed	O	O	O
no	O	O	O
obvious	O	O	O
effect	O	O	O
on	O	O	O
viability	O	O	B-Entity
of	O	O	O
DU145	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
exposure	O	O	O
with	O	O	O
fish	O	O	B-Entity
oil	O	O	I-Entity
,	O	O	O
EPA	O	O	B-Entity
,	O	O	O
or	O	O	O
DHA	O	O	B-Entity
for	O	O	O
24	O	O	O
h	O	O	O
significantly	O	O	O
affected	O	O	O
cell	O	O	B-Entity
viability	O	O	I-Entity
.	O	O	O

The	O	O	O
growth	O	O	B-Entity
inhibition	O	O	I-Entity
of	O	O	O
DHA	O	O	B-Entity
was	O	O	O
more	O	O	O
pronounced	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
EPA	O	O	B-Entity
and	O	O	O
showed	O	O	O
a	O	O	O
time-dependent	O	O	O
increase	O	O	O
.	O	O	O

DHA	O	O	B-Entity
exposure	O	O	O
caused	O	O	O
typical	O	O	O
apoptotic	O	O	B-Entity
characteristics	O	O	O
.	O	O	O

Ten	O	O	O
genes	O	O	B-Entity
were	O	O	O
more	O	O	O
expressed	O	O	O
,	O	O	O
while	O	O	O
5	O	O	O
genes	O	O	O
were	O	O	O
less	O	O	O
expressed	O	O	O
following	O	O	O
DHA	O	O	B-Entity
exposure	O	O	O
.	O	O	O

RT-qPCR	O	O	B-Entity
confirmed	O	O	O
the	O	O	O
time	O	O	O
dependent	O	O	O
effect	O	O	O
of	O	O	O
DHA	O	O	B-Entity
on	O	O	O
the	O	O	O
expression	O	O	O
of	O	O	O
these	O	O	O
differentially	O	O	O
expressed	O	O	O
genes	O	O	B-Entity
.	O	O	O

KEGG	O	O	O
pathway	O	O	O
analysis	O	O	O
showed	O	O	O
that	O	O	O
DHA	O	O	B-Entity
may	O	O	O
induce	O	O	O
the	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
preferentially	O	O	O
through	O	O	O
mediating	O	O	O
P53	O	O	B-Entity
,	O	O	O
MAPK	O	O	B-Entity
,	O	O	O
TNF	O	O	B-Entity
,	O	O	O
PI3K/AKT	O	O	B-Entity
,	O	O	O
and	O	O	O
NF-κB	O	O	B-Entity
signaling	O	O	I-Entity
pathways	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	O
demonstrated	O	O	O
the	O	O	O
beneficial	O	O	O
action	O	O	O
of	O	O	O
DHA	O	O	B-Entity
on	O	O	O
human	O	O	B-Entity
prostate	O	O	B-Entity
carcinoma	O	O	I-Entity
cell	O	O	B-Entity
line	O	O	I-Entity
DU145	O	O	I-Entity
.	O	O	O

The	O	O	O
pro-apoptotic	O	O	O
effect	O	O	O
of	O	O	O
DHA	O	O	B-Entity
on	O	O	O
DU145	O	O	B-Entity
cells	O	O	I-Entity
may	O	O	O
involve	O	O	O
mediation	O	O	O
various	O	O	O
pathways	O	O	B-Entity
,	O	O	O
especially	O	O	O
P53	O	O	B-Entity
,	O	O	O
MAPK	O	O	B-Entity
,	O	O	O
TNF	O	O	B-Entity
,	O	O	O
PI3K/AKT	O	O	B-Entity
,	O	O	O
and	O	O	O
NF-κB	O	O	B-Entity
signaling	O	O	I-Entity
pathways	O	O	I-Entity
.	O	O	O

Molecular	O	O	B-Entity
mechanisms	O	O	I-Entity
of	O	O	O
DHA	O	O	B-Entity
on	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
still	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
further	O	O	O
clarified	O	O	O
.	O	O	O

-DOCSTART- (28333697)

Medication	O	O	B-Entity
Reconciliation	O	O	I-Entity
During	O	O	O
Hospitalization	O	O	B-Entity
and	O	O	O
in	O	O	O
Hospital-Home	O	O	B-Entity
Interface	O	O	I-Entity
:	O	O	O
An	O	O	O
Observational	O	O	O
Retrospective	O	O	O
Study	O	O	O

Medication	O	O	B-Entity
errors	O	O	I-Entity
are	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
leading	O	O	O
causes	O	O	O
of	O	O	O
patient	O	O	B-Entity
harms	O	O	I-Entity
.	O	O	O

Medication	O	O	B-Entity
reconciliation	O	O	I-Entity
is	O	O	O
a	O	O	O
fundamental	O	O	O
process	O	O	O
that	O	O	O
to	O	O	O
be	O	O	O
effective	O	O	O
,	O	O	O
it	O	O	O
should	O	O	O
be	O	O	O
embraced	O	O	O
during	O	O	O
each	O	O	O
single	O	O	O
care	O	O	B-Entity
transition	O	O	I-Entity
.	O	O	O

Our	O	O	O
objectives	O	O	O
were	O	O	O
to	O	O	O
investigate	O	O	B-Entity
current	O	O	O
medication	O	O	B-Entity
reconciliation	O	O	I-Entity
practices	O	O	O
in	O	O	O
the	O	O	O
2	O	O	O
Fondazione	O	O	B-Entity
Toscana	O	O	I-Entity
Gabriele	O	O	I-Entity
Monasterio	O	O	I-Entity
hospitals	O	O	I-Entity
and	O	O	O
comprehensively	O	O	O
assess	O	O	B-Entity
the	O	O	I-Entity
quality	O	O	I-Entity
of	O	O	O
medication	O	O	O
reconciliation	O	O	O
practices	O	O	O
between	O	O	O
inpatient	O	O	B-Entity
and	O	O	O
outpatient	O	O	B-Entity
care	O	O	B-Entity
by	O	O	O
analyzing	O	O	B-Entity
the	O	O	O
medication	O	O	B-Entity
patterns	O	O	I-Entity
6	O	O	O
months	O	O	B-Entity
before	O	O	O
admission	O	O	B-Entity
,	O	O	O
during	O	O	O
hospitalization	O	O	B-Entity
,	O	O	O
and	O	O	O
9	O	O	O
months	O	O	O
after	O	O	O
discharge	O	O	B-Entity
for	O	O	O
a	O	O	O
selected	O	O	O
group	O	O	O
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
cardiovascular	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
observational	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
the	O	O	O
Cardiothoracic	O	O	B-Entity
Department	O	O	I-Entity
of	O	O	O
the	O	O	O
Fondazione	O	O	B-Entity
Toscana	O	O	I-Entity
Gabriele	O	O	I-Entity
Monasterio	O	O	I-Entity
hospitals	O	O	I-Entity
.	O	O	O

Medication	O	O	B-Entity
history	O	O	I-Entity
was	O	O	O
reviewed	O	O	B-Entity
for	O	O	O
all	O	O	O
the	O	O	O
patients	O	O	B-Entity
admitted	O	O	B-Entity
from	O	O	O
and	O	O	O
discharged	O	O	B-Entity
to	O	O	O
the	O	O	O
community	O	O	B-Entity
,	O	O	O
from	O	O	O
January	O	O	O
to	O	O	O
March	O	O	O
2013	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
excluded	O	O	O
if	O	O	O
they	O	O	O
had	O	O	O
less	O	O	O
than	O	O	O
4	O	O	O
drugs	O	O	B-Entity
or	O	O	O
less	O	O	O
than	O	O	O
2	O	O	O
drugs	O	O	O
for	O	O	O
cardiovascular	O	O	B-Entity
system	O	O	I-Entity
in	O	O	O
their	O	O	O
prescription	O	O	B-Entity
list	O	O	I-Entity
at	O	O	O
admission	O	O	B-Entity
or	O	O	O
if	O	O	O
they	O	O	O
died	O	O	B-Entity
during	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

We	O	O	O
selected	O	O	O
714	O	O	O
patients	O	O	B-Entity
,	O	O	O
and	O	O	O
we	O	O	O
obtained	O	O	O
the	O	O	O
clinical	O	O	B-Entity
charts	O	O	I-Entity
and	O	O	O
all	O	O	O
drug	O	O	B-Entity
prescriptions	O	O	I-Entity
collected	O	O	O
during	O	O	O
patients	O	O	O
'	O	O	O
hospitalization	O	O	B-Entity
by	O	O	O
the	O	O	O
electronic	O	O	B-Entity
clinical	O	O	I-Entity
recording	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
analyzed	O	O	B-Entity
the	O	O	O
list	O	O	B-Entity
of	O	O	I-Entity
prescriptions	O	O	I-Entity
of	O	O	O
this	O	O	O
sample	O	O	O
of	O	O	O
patients	O	O	B-Entity
,	O	O	O
from	O	O	O
6	O	O	O
months	O	O	B-Entity
before	O	O	O
admission	O	O	B-Entity
to	O	O	O
9	O	O	O
months	O	O	O
after	O	O	O
discharge	O	O	B-Entity
,	O	O	O
extracted	O	O	O
from	O	O	O
the	O	O	O
regional	O	O	B-Entity
prescription	O	O	I-Entity
registry	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
resulting	O	O	O
sample	O	O	O
,	O	O	O
prescriptions	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
to	O	O	O
assess	O	O	O
unintentional	O	O	B-Entity
discrepancies	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
included	O	O	O
298	O	O	O
patients	O	O	B-Entity
(	O	O	O
mean	O	O	O
age	O	O	B-Entity
,	O	O	O
71.2	O	O	O
years	O	O	B-Entity
)	O	O	O
,	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
and	O	O	I-Entity
exclusion	O	O	I-Entity
criteria	O	O	I-Entity
.	O	O	O

Among	O	O	O
14,573	O	O	O
prescriptions	O	O	B-Entity
analyzed	O	O	B-Entity
,	O	O	O
we	O	O	O
found	O	O	O
4363	O	O	O
discrepancies	O	O	B-Entity
(	O	O	O
14.6	O	O	O
discrepancies	O	O	O
per	O	O	O
patient	O	O	B-Entity
)	O	O	O
.	O	O	O

Among	O	O	O
these	O	O	O
discrepancies	O	O	B-Entity
,	O	O	O
1310	O	O	O
were	O	O	O
classified	O	O	O
as	O	O	O
unintentional	O	O	B-Entity
(	O	O	O
4.4	O	O	O
discrepancies	O	O	O
per	O	O	O
patient	O	O	B-Entity
)	O	O	O
.	O	O	O

Among	O	O	O
unintentional	O	O	B-Entity
discrepancies	O	O	B-Entity
,	O	O	O
only	O	O	O
63	O	O	O
(	O	O	O
4.8	O	O	O
%	O	O	O
)	O	O	O
took	O	O	O
place	O	O	O
during	O	O	O
hospitalization	O	O	B-Entity
.	O	O	O

Although	O	O	O
at	O	O	O
the	O	O	O
hospital-home	O	O	B-Entity
interface	O	O	I-Entity
,	O	O	O
33.1	O	O	O
%	O	O	O
of	O	O	O
unintentional	O	O	B-Entity
discrepancies	O	O	B-Entity
were	O	O	O
detected	O	O	O
through	O	O	O
the	O	O	O
comparison	O	O	B-Entity
between	O	O	O
the	O	O	O
patients	O	O	B-Entity
'	O	O	O
declared	O	O	O
therapy	O	O	B-Entity
and	O	O	O
the	O	O	O
previous	O	O	O
medication	O	O	B-Entity
consumption	O	O	I-Entity
and	O	O	O
62.1	O	O	O
%	O	O	O
were	O	O	O
identified	O	O	O
in	O	O	O
the	O	O	O
comparison	O	O	O
between	O	O	O
the	O	O	O
prescription	O	O	B-Entity
at	O	O	O
the	O	O	O
discharge	O	O	B-Entity
and	O	O	O
the	O	O	O
following	O	O	O
medication	O	O	B-Entity
pattern	O	O	I-Entity
at	O	O	O
home	O	O	B-Entity
.	O	O	O

Medication	O	O	B-Entity
errors	O	O	I-Entity
have	O	O	O
important	O	O	O
implications	O	O	O
for	O	O	O
patient	O	O	B-Entity
safety	O	O	I-Entity
,	O	O	O
and	O	O	O
their	O	O	O
identification	O	O	O
is	O	O	O
a	O	O	O
main	O	O	O
target	O	O	O
for	O	O	O
improving	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

The	O	O	O
comparison	O	O	B-Entity
between	O	O	O
the	O	O	O
medication	O	O	B-Entity
patterns	O	O	I-Entity
acquired	O	O	O
through	O	O	O
the	O	O	O
regional	O	O	B-Entity
prescription	O	O	I-Entity
registry	O	O	I-Entity
before	O	O	O
and	O	O	O
after	O	O	O
hospitalization	O	O	B-Entity
outlined	O	O	O
critical	O	O	O
touchpoint	O	O	O
in	O	O	O
the	O	O	O
current	O	O	O
medication	O	O	B-Entity
reconciliation	O	O	I-Entity
process	O	O	O
,	O	O	O
calling	O	O	O
for	O	O	O
the	O	O	O
definition	O	O	O
of	O	O	O
shared	O	O	O
medication	O	O	O
reconciliation	O	O	O
standards	O	O	O
between	O	O	O
hospitals	O	O	B-Entity
and	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
services	O	O	I-Entity
to	O	O	O
minimize	O	O	O
medication	O	O	B-Entity
discrepancies	O	O	I-Entity
and	O	O	O
enhance	O	O	O
patient	O	O	B-Entity
safety	O	O	I-Entity
.	O	O	O

-DOCSTART- (28334327)

Autologous	O	O	B-Entity
vs	O	O	O
Irradiated	O	O	B-Entity
Homologous	O	O	I-Entity
Costal	O	O	I-Entity
Cartilage	O	O	I-Entity
as	O	O	O
Graft	O	O	B-Entity
Material	O	O	I-Entity
in	O	O	O
Rhinoplasty	O	O	O

Studies	O	O	O
comparing	O	O	O
surgical	O	O	O
results	O	O	O
of	O	O	O
rhinoplasty	O	O	B-Entity
using	O	O	O
autologous	O	O	B-Entity
costal	O	O	I-Entity
cartilage	O	O	I-Entity
(	O	O	O
ACC	O	O	B-Entity
)	O	O	O
and	O	O	O
irradiated	O	O	B-Entity
homologous	O	O	I-Entity
costal	O	O	I-Entity
cartilage	O	O	I-Entity
(	O	O	O
IHCC	O	O	B-Entity
)	O	O	O
are	O	O	O
rare	O	O	O
.	O	O	O

To	O	O	O
compare	O	O	O
the	O	O	O
clinical	O	O	B-Entity
results	O	O	I-Entity
of	O	O	O
major	O	O	O
augmentation	O	O	B-Entity
rhinoplasty	O	O	I-Entity
using	O	O	O
ACC	O	O	B-Entity
vs	O	O	O
IHCC	O	O	B-Entity
and	O	O	O
analyze	O	O	O
the	O	O	O
histologic	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
both	O	O	O
types	O	O	O
of	O	O	O
cartilage	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
clinical	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
among	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
undergone	O	O	O
rhinoseptoplasty	O	O	B-Entity
using	O	O	O
ACC	O	O	B-Entity
or	O	O	O
IHCC	O	O	B-Entity
from	O	O	O
January	O	O	O
1	O	O	O
,	O	O	O
2009	O	O	O
,	O	O	O
to	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2014	O	O	O
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
followed	O	O	B-Entity
up	O	O	I-Entity
for	O	O	O
more	O	O	O
than	O	O	O
1	O	O	O
year	O	O	O
after	O	O	O
surgery	O	O	B-Entity
and	O	O	O
the	O	O	O
histologic	O	O	B-Entity
characteristics	O	O	I-Entity
of	O	O	O
ACC	O	O	B-Entity
and	O	O	O
IHCC	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
.	O	O	O

The	O	O	O
details	O	O	O
of	O	O	O
the	O	O	O
surgical	O	O	B-Entity
procedures	O	O	I-Entity
and	O	O	O
complications	O	O	B-Entity
,	O	O	O
including	O	O	O
warping	O	O	B-Entity
,	O	O	O
infection	O	O	B-Entity
,	O	O	O
resorption	O	O	B-Entity
,	O	O	O
and/or	O	O	O
donor-site	O	O	B-Entity
morbidity	O	O	B-Entity
,	O	O	O
were	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
reviewing	O	O	O
medical	O	O	B-Entity
records	O	O	I-Entity
and	O	O	O
facial	O	O	B-Entity
photographs	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
'	O	O	O
subjective	O	O	B-Entity
satisfaction	O	O	B-Entity
with	O	O	O
aesthetic	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
results	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
using	O	O	O
a	O	O	O
questionnaire	O	O	B-Entity
.	O	O	O

The	O	O	O
details	O	O	O
of	O	O	O
the	O	O	O
surgical	O	O	B-Entity
procedures	O	O	I-Entity
and	O	O	O
complications	O	O	B-Entity
,	O	O	O
including	O	O	O
warping	O	O	B-Entity
,	O	O	O
infection	O	O	B-Entity
,	O	O	O
resorption	O	O	B-Entity
,	O	O	O
and/or	O	O	O
donor-site	O	O	B-Entity
morbidity	O	O	B-Entity
;	O	O	O
patients	O	O	B-Entity
'	O	O	O
subjective	O	O	B-Entity
satisfaction	O	O	B-Entity
with	O	O	O
aesthetic	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
results	O	O	B-Entity
'	O	O	O
objective	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
surgical	O	O	O
outcomes	O	O	B-Entity
,	O	O	O
including	O	O	O
symmetry	O	O	B-Entity
,	O	O	O
dorsal	O	O	B-Entity
height	O	O	B-Entity
,	O	O	O
dorsal	O	O	O
length	O	O	B-Entity
,	O	O	O
dorsal	O	O	O
width	O	O	B-Entity
,	O	O	O
tip	O	O	B-Entity
projection	O	O	I-Entity
,	O	O	O
tip	O	O	B-Entity
rotation	O	O	I-Entity
,	O	O	O
tip	O	O	B-Entity
width	O	O	I-Entity
,	O	O	O
and	O	O	O
overall	O	O	B-Entity
result	O	O	B-Entity
;	O	O	O
and	O	O	O
histologic	O	O	B-Entity
structures	O	O	B-Entity
.	O	O	O

Objective	O	O	B-Entity
evaluation	O	O	B-Entity
of	O	O	O
surgical	O	O	B-Entity
outcomes	O	O	B-Entity
was	O	O	O
graded	O	O	O
using	O	O	O
the	O	O	O
Objective	O	O	O
Rhinoplasty	O	O	B-Entity
Outcome	O	O	B-Entity
Score	O	O	I-Entity
,	O	O	O
which	O	O	O
assessed	O	O	O
symmetry	O	O	B-Entity
,	O	O	O
dorsal	O	O	B-Entity
height	O	O	B-Entity
,	O	O	O
dorsal	O	O	O
length	O	O	B-Entity
,	O	O	O
dorsal	O	O	O
width	O	O	B-Entity
,	O	O	O
tip	O	O	B-Entity
projection	O	O	I-Entity
,	O	O	O
tip	O	O	B-Entity
rotation	O	O	I-Entity
,	O	O	O
tip	O	O	B-Entity
width	O	O	I-Entity
,	O	O	O
and	O	O	O
overall	O	O	B-Entity
result	O	O	B-Entity
.	O	O	O

Histologic	O	O	B-Entity
structures	O	O	I-Entity
were	O	O	O
evaluated	O	O	B-Entity
using	O	O	O
hematoxylin	O	O	B-Entity
and	O	O	I-Entity
eosin	O	O	I-Entity
,	O	O	O
Masson	O	O	B-Entity
trichrome	O	O	I-Entity
,	O	O	O
Alcian	O	O	B-Entity
blue	O	O	I-Entity
,	O	O	O
and	O	O	O
Verhoeff	O	O	B-Entity
elastic	O	O	I-Entity
stains	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
63	O	O	O
patients	O	O	B-Entity
(	O	O	O
27	O	O	O
males	O	O	B-Entity
and	O	O	O
36	O	O	O
females	O	O	B-Entity
;	O	O	O
mean	O	O	O
[	O	O	O
SD	O	O	O
]	O	O	O
age	O	O	O
,	O	O	O
30.6	O	O	O
[	O	O	O
9.5	O	O	O
]	O	O	O
years	O	O	O
)	O	O	O
had	O	O	O
rhinoseptoplasty	O	O	B-Entity
using	O	O	O
ACC	O	O	B-Entity
and	O	O	O
20	O	O	O
(	O	O	O
9	O	O	O
males	O	O	O
and	O	O	O
11	O	O	O
females	O	O	O
;	O	O	O
mean	O	O	O
[	O	O	O
SD	O	O	O
]	O	O	O
age	O	O	O
,	O	O	O
35.4	O	O	O
[	O	O	O
15.4	O	O	O
]	O	O	O
years	O	O	O
)	O	O	O
had	O	O	O
rhinoseptoplasty	O	O	O
using	O	O	O
IHCC	O	O	B-Entity
.	O	O	O

Among	O	O	O
observed	O	O	B-Entity
complications	O	O	B-Entity
,	O	O	O
only	O	O	O
notable	O	O	B-Entity
resorption	O	O	B-Entity
occurred	O	O	B-Entity
more	O	O	O
frequently	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
using	O	O	O
IHCC	O	O	B-Entity
(	O	O	O
6	O	O	O
[	O	O	O
30	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
than	O	O	O
with	O	O	O
ACC	O	O	B-Entity
(	O	O	O
2	O	O	O
[	O	O	O
3	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
.002	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
subjective	O	O	B-Entity
evaluations	O	O	B-Entity
of	O	O	O
aesthetic	O	O	B-Entity
satisfaction	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
who	O	O	O
received	O	O	B-Entity
ACC	O	O	B-Entity
showed	O	O	O
significantly	O	O	B-Entity
greater	O	O	B-Entity
satisfaction	O	O	O
(	O	O	O
37	O	O	O
of	O	O	O
51	O	O	O
patients	O	O	O
[	O	O	O
73	O	O	O
%	O	O	O
]	O	O	O
were	O	O	O
very	O	O	B-Entity
satisfied	O	O	I-Entity
)	O	O	O
than	O	O	O
did	O	O	O
those	O	O	O
who	O	O	O
received	O	O	O
IHCC	O	O	B-Entity
(	O	O	O
6	O	O	O
of	O	O	O
20	O	O	O
[	O	O	O
30	O	O	O
%	O	O	O
]	O	O	O
)	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
.001	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
no	O	O	O
between-group	O	O	O
difference	O	O	O
in	O	O	O
subjective	O	O	B-Entity
functional	O	O	B-Entity
outcomes	O	O	B-Entity
:	O	O	O
4	O	O	O
of	O	O	O
51	O	O	O
patients	O	O	B-Entity
receiving	O	O	B-Entity
ACC	O	O	B-Entity
(	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
5	O	O	O
of	O	O	O
20	O	O	O
receiving	O	O	O
IHCC	O	O	B-Entity
(	O	O	O
25	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
satisfied	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.50	O	O	O
)	O	O	O
and	O	O	O
45	O	O	O
of	O	O	O
51	O	O	O
receiving	O	O	O
ACC	O	O	O
(	O	O	O
88	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
15	O	O	O
of	O	O	O
20	O	O	O
receiving	O	O	O
IHCC	O	O	O
(	O	O	O
75	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
very	O	O	B-Entity
satisfied	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.15	O	O	O
)	O	O	O
.	O	O	O

Regarding	O	O	O
objective	O	O	B-Entity
aesthetic	O	O	B-Entity
outcomes	O	O	B-Entity
,	O	O	O
all	O	O	O
scores	O	O	B-Entity
for	O	O	O
both	O	O	O
ACC	O	O	B-Entity
and	O	O	O
IHCC	O	O	B-Entity
were	O	O	O
more	O	O	O
than	O	O	O
3.1	O	O	O
(	O	O	O
between	O	O	O
good	O	O	B-Entity
and	O	O	O
excellent	O	O	B-Entity
)	O	O	O
.	O	O	O

Histologic	O	O	B-Entity
analyses	O	O	I-Entity
showed	O	O	O
larger	O	O	B-Entity
,	O	O	O
more	O	O	O
evenly	O	O	O
distributed	O	O	O
,	O	O	O
uniform	O	O	B-Entity
chondrocytes	O	O	B-Entity
and	O	O	O
more	O	O	O
collagens	O	O	B-Entity
and	O	O	O
proteoglycan	O	O	B-Entity
contents	O	O	B-Entity
in	O	O	O
ACC	O	O	B-Entity
than	O	O	O
in	O	O	O
IHCC	O	O	B-Entity
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
patients	O	O	B-Entity
receiving	O	O	B-Entity
IHCC	O	O	B-Entity
,	O	O	O
those	O	O	O
receiving	O	O	O
ACC	O	O	B-Entity
for	O	O	O
rhinoseptoplasty	O	O	B-Entity
showed	O	O	O
superior	O	O	B-Entity
aesthetic	O	O	B-Entity
satisfaction	O	O	B-Entity
;	O	O	O
ACC	O	O	O
also	O	O	O
had	O	O	O
less	O	O	B-Entity
frequent	O	O	B-Entity
notable	O	O	B-Entity
resorption	O	O	B-Entity
.	O	O	O

Autologous	O	O	B-Entity
costal	O	O	I-Entity
cartilage	O	O	I-Entity
also	O	O	O
had	O	O	O
better	O	O	B-Entity
histologic	O	O	B-Entity
properties	O	O	I-Entity
than	O	O	O
IHCC	O	O	B-Entity
did	O	O	O
,	O	O	O
suggesting	O	O	O
it	O	O	O
as	O	O	O
an	O	O	O
ideal	O	O	B-Entity
graft	O	O	B-Entity
material	O	O	I-Entity
with	O	O	O
less	O	O	B-Entity
chance	O	O	B-Entity
of	O	O	O
long-term	O	O	B-Entity
resorption	O	O	B-Entity
.	O	O	O

3	O	O	O
.	O	O	O

-DOCSTART- (28334784)

Testing	O	O	O
the	O	O	O
Ret	O	O	B-Entity
and	O	O	O
Sema3d	O	O	B-Entity
genetic	O	O	B-Entity
interaction	O	O	I-Entity
in	O	O	O
mouse	O	O	B-Entity
enteric	O	O	O
nervous	O	O	O
system	O	O	O
development	O	O	O

For	O	O	O
most	O	O	O
multigenic	O	O	B-Entity
disorders	O	O	I-Entity
,	O	O	O
clinical	O	O	B-Entity
manifestation	O	O	I-Entity
(	O	O	O
penetrance	O	O	B-Entity
)	O	O	O
and	O	O	O
presentation	O	O	B-Entity
(	O	O	O
expressivity	O	O	B-Entity
)	O	O	O
are	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
outcome	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
interaction	O	O	I-Entity
between	O	O	O
multiple	O	O	O
susceptibility	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
using	O	O	O
gene	O	O	B-Entity
knockouts	O	O	I-Entity
in	O	O	O
mice	O	O	B-Entity
we	O	O	O
evaluated	O	O	O
genetic	O	O	B-Entity
interaction	O	O	I-Entity
between	O	O	O
loss	O	O	O
of	O	O	O
Ret	O	O	B-Entity
and	O	O	O
loss	O	O	O
of	O	O	O
Sema3d	O	O	B-Entity
,	O	O	O
two	O	O	O
Hirschsprung	O	O	B-Entity
disease	O	O	I-Entity
susceptibility	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

We	O	O	O
intercrossed	O	O	O
Ret	O	O	B-Entity
and	O	O	O
Sema3d	O	O	B-Entity
double	O	O	O
null	O	O	O
heterozygotes	O	O	O
to	O	O	O
generate	O	O	B-Entity
mice	O	O	I-Entity
with	O	O	O
the	O	O	O
nine	O	O	O
possible	O	O	O
genotypes	O	O	B-Entity
and	O	O	O
assessed	O	O	B-Entity
survival	O	O	I-Entity
by	O	O	O
counting	O	O	B-Entity
various	O	O	I-Entity
genotypes	O	O	I-Entity
,	O	O	O
myenteric	O	O	B-Entity
plexus	O	O	I-Entity
presence	O	O	O
by	O	O	O
acetylcholinesterase	O	O	B-Entity
staining	O	O	I-Entity
and	O	O	O
embryonic	O	O	B-Entity
day	O	O	I-Entity
12.5	O	O	I-Entity
(	O	O	O
E12.5	O	O	B-Entity
)	O	O	O
intestine	O	O	B-Entity
transcriptome	O	O	I-Entity
by	O	O	O
RNA-sequencing	O	O	B-Entity
.	O	O	O

Survival	O	O	B-Entity
rates	O	O	I-Entity
of	O	O	O
Ret	O	O	B-Entity
wildtype	O	O	B-Entity
,	O	O	O
null	O	O	O
heterozygote	O	O	O
and	O	O	O
null	O	O	O
homozygote	O	O	O
mice	O	O	B-Entity
at	O	O	O
E12.5	O	O	B-Entity
,	O	O	O
birth	O	O	B-Entity
and	O	O	O
weaning	O	O	B-Entity
were	O	O	O
not	O	O	O
influenced	O	O	O
by	O	O	O
the	O	O	O
genotypes	O	O	B-Entity
at	O	O	O
Sema3d	O	O	B-Entity
locus	O	O	B-Entity
and	O	O	O
vice-versa	O	O	O
.	O	O	O

Loss	O	O	O
of	O	O	O
myenteric	O	O	B-Entity
plexus	O	O	I-Entity
was	O	O	O
observed	O	O	O
only	O	O	O
in	O	O	O
all	O	O	O
Ret	O	O	B-Entity
null	O	O	O
homozygotes	O	O	O
,	O	O	O
irrespective	O	O	O
of	O	O	O
the	O	O	O
genotypes	O	O	B-Entity
at	O	O	O
Sema3d	O	O	B-Entity
locus	O	O	B-Entity
,	O	O	O
and	O	O	O
Sema3d	O	O	O
null	O	O	O
heterozygote	O	O	B-Entity
and	O	O	O
homozygote	O	O	B-Entity
mice	O	O	I-Entity
had	O	O	O
normal	O	O	O
intestinal	O	O	B-Entity
innervation	O	O	I-Entity
.	O	O	O

As	O	O	O
compared	O	O	O
to	O	O	O
wildtype	O	O	B-Entity
mice	O	O	I-Entity
intestinal	O	O	I-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
loss	O	O	O
of	O	O	O
Ret	O	O	B-Entity
in	O	O	O
null	O	O	O
homozygotes	O	O	O
led	O	O	O
to	O	O	O
differential	O	O	O
expression	O	O	B-Entity
of	O	O	I-Entity
∼300	O	O	I-Entity
genes	O	O	I-Entity
,	O	O	I-Entity
whereas	O	O	O
loss	O	O	O
of	O	O	O
Sema3d	O	O	B-Entity
in	O	O	O
null	O	O	O
homozygotes	O	O	O
had	O	O	O
no	O	O	O
major	O	O	O
consequence	O	O	O
and	O	O	O
there	O	O	O
was	O	O	O
no	O	O	B-Entity
evidence	O	O	I-Entity
supporting	O	O	O
major	O	O	O
interaction	O	O	B-Entity
between	O	O	I-Entity
the	O	O	I-Entity
two	O	O	I-Entity
genes	O	O	I-Entity
influencing	O	O	O
intestine	O	O	B-Entity
transcriptome	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
given	O	O	O
the	O	O	O
null	O	O	B-Entity
alleles	O	O	I-Entity
and	O	O	O
phenotypic	O	O	B-Entity
assays	O	O	I-Entity
used	O	O	O
,	O	O	O
we	O	O	O
did	O	O	O
not	O	O	B-Entity
find	O	O	I-Entity
evidence	O	O	I-Entity
for	O	O	O
genetic	O	O	B-Entity
interaction	O	O	I-Entity
between	O	O	O
Ret	O	O	B-Entity
and	O	O	O
Sema3d	O	O	B-Entity
affecting	O	O	O
survival	O	O	O
,	O	O	O
presence	O	O	O
of	O	O	O
myenteric	O	O	B-Entity
plexus	O	O	I-Entity
or	O	O	O
intestine	O	O	B-Entity
transcriptome	O	O	I-Entity
.	O	O	O

-DOCSTART- (28338376)

Pembrolizumab	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
non-small	O	O	O
cell	O	O	O
lung	O	O	O
cancer	O	O	O

In	O	O	O
the	O	O	O
last	O	O	O
years	O	O	O
,	O	O	O
a	O	O	O
spectacular	O	O	O
development	O	O	B-Entity
of	O	O	O
immunotherapeutic	O	O	B-Entity
agents	O	O	I-Entity
aimed	O	O	O
at	O	O	O
the	O	O	O
PD-1	O	O	B-Entity
/	O	O	O
PD-L1	O	O	B-Entity
axis	O	O	O
has	O	O	O
taken	O	O	O
place	O	O	O
.	O	O	O

This	O	O	O
development	O	O	B-Entity
of	O	O	O
these	O	O	O
checkpoint	O	O	B-Entity
inhibitors	O	O	I-Entity
has	O	O	O
greatly	O	O	O
influenced	O	O	O
our	O	O	O
approach	O	O	O
to	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
lung	O	O	B-Entity
cancer	O	O	I-Entity
in	O	O	O
first	O	O	B-Entity
and	O	O	O
second	O	O	B-Entity
line	O	O	I-Entity
.	O	O	O

The	O	O	O
limited	O	O	B-Entity
toxicity	O	O	B-Entity
profile	O	O	O
and	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
treat	O	O	B-Entity
for	O	O	O
prolonged	O	O	B-Entity
periods	O	O	B-Entity
,	O	O	O
even	O	O	O
in	O	O	O
smokers	O	O	B-Entity
,	O	O	O
is	O	O	O
a	O	O	O
welcome	O	O	O
expansion	O	O	O
of	O	O	O
the	O	O	O
therapeutic	O	O	O
arsenal	O	O	O
of	O	O	O
the	O	O	O
oncologist	O	O	B-Entity
.	O	O	O

Areas	O	O	O
covered	O	O	O
:	O	O	O
This	O	O	O
review	O	O	B-Entity
highlights	O	O	O
the	O	O	O
results	O	O	B-Entity
of	O	O	O
recent	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
on	O	O	O
pembrolizumab	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
non-small	O	O	B-Entity
cell	O	O	I-Entity
lung	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

The	O	O	O
authors	O	O	B-Entity
discuss	O	O	O
both	O	O	O
first	O	O	B-Entity
and	O	O	O
second	O	O	B-Entity
line	O	O	I-Entity
treatment	O	O	I-Entity
with	O	O	O
pembrolizumab	O	O	B-Entity
as	O	O	O
monotherapy	O	O	B-Entity
and	O	O	O
in	O	O	O
combination	O	O	B-Entity
therapies	O	O	I-Entity
.	O	O	O

Additionally	O	O	O
,	O	O	O
implications	O	O	O
of	O	O	O
the	O	O	O
PD-L1	O	O	B-Entity
immunohistochemistry	O	O	B-Entity
assay	O	O	I-Entity
with	O	O	O
the	O	O	O
22C3	O	O	B-Entity
antibody	O	O	I-Entity
and	O	O	O
its	O	O	O
use	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
and	O	O	O
trials	O	O	B-Entity
is	O	O	O
discussed	O	O	O
.	O	O	O

Expert	O	O	O
commentary	O	O	O
:	O	O	O
A	O	O	O
higher	O	O	B-Entity
overall	O	O	B-Entity
response	O	O	I-Entity
,	O	O	O
overall	O	O	B-Entity
survival	O	O	I-Entity
and	O	O	O
a	O	O	O
moderate	O	O	B-Entity
toxicity	O	O	B-Entity
profile	O	O	O
is	O	O	O
observed	O	O	O
with	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	O
pembrolizumab	O	O	B-Entity
,	O	O	O
compared	O	O	O
to	O	O	O
chemotherapy	O	O	B-Entity
,	O	O	O
in	O	O	O
both	O	O	O
first	O	O	B-Entity
and	O	O	O
second	O	O	B-Entity
line	O	O	I-Entity
.	O	O	O

These	O	O	O
promising	O	O	O
results	O	O	B-Entity
have	O	O	O
already	O	O	O
translated	O	O	O
into	O	O	O
the	O	O	O
registration	O	O	B-Entity
of	O	O	O
pembrolizumab	O	O	B-Entity
in	O	O	O
first	O	O	B-Entity
and	O	O	O
second	O	O	B-Entity
line	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
high	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
PD-L1	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
as	O	O	O
PD-L1	O	O	B-Entity
staining	O	O	B-Entity
does	O	O	O
not	O	O	O
sufficiently	O	O	O
discriminate	O	O	O
responders	O	O	B-Entity
from	O	O	O
non-responders	O	O	B-Entity
for	O	O	O
all	O	O	O
checkpoint	O	O	B-Entity
inhibitors	O	O	I-Entity
,	O	O	O
there	O	O	O
still	O	O	O
is	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
a	O	O	O
better	O	O	O
predictive	O	O	B-Entity
biomarker	O	O	B-Entity
.	O	O	O

-DOCSTART- (28338976)

Synchronisms	O	O	B-Entity
between	O	O	O
bud	O	O	B-Entity
and	O	O	O
cambium	O	O	B-Entity
phenology	O	O	B-Entity
in	O	O	O
black	O	O	B-Entity
spruce	O	O	I-Entity
:	O	O	O
early	O	O	B-Entity
-	O	O	O
flushing	O	O	B-Entity
provenances	O	O	B-Entity
exhibit	O	O	O
early	O	O	O
xylem	O	O	B-Entity
formation	O	O	O

Bud	O	O	B-Entity
and	O	O	O
cambial	O	O	B-Entity
phenology	O	O	B-Entity
represent	O	O	B-Entity
the	O	O	O
adaptation	O	O	B-Entity
of	O	O	O
species	O	O	B-Entity
to	O	O	O
the	O	O	O
local	O	O	B-Entity
environment	O	O	B-Entity
that	O	O	O
allows	O	O	O
the	O	O	O
growing	O	O	B-Entity
season	O	O	I-Entity
to	O	O	O
be	O	O	O
maximized	O	O	B-Entity
while	O	O	O
minimizing	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
frost	O	O	B-Entity
for	O	O	O
the	O	O	O
developing	O	O	B-Entity
tissues	O	O	B-Entity
.	O	O	O

The	O	O	O
temporal	O	O	B-Entity
relationship	O	O	B-Entity
between	O	O	O
the	O	O	O
apical	O	O	B-Entity
and	O	O	O
radial	O	O	B-Entity
meristems	O	O	B-Entity
can	O	O	O
help	O	O	O
in	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
tree	O	O	B-Entity
growth	O	O	B-Entity
as	O	O	O
a	O	O	O
whole	O	O	B-Entity
process	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
compare	O	O	B-Entity
cambial	O	O	B-Entity
phenology	O	O	B-Entity
in	O	O	O
black	O	O	B-Entity
spruce	O	O	I-Entity
(	O	O	O
Picea	O	O	B-Entity
mariana	O	O	I-Entity
(	O	O	O
Mill	O	O	O
.	O	O	O
)	O	O	O
B.S.P.	O	O	O
)	O	O	O
provenances	O	O	B-Entity
classified	O	O	B-Entity
as	O	O	O
early	O	O	B-Entity
and	O	O	O
late	O	O	B-Entity
bud	O	O	B-Entity
flushing	O	O	B-Entity
.	O	O	O

The	O	O	O
different	O	O	B-Entity
phases	O	O	B-Entity
of	O	O	O
cambial	O	O	B-Entity
phenology	O	O	B-Entity
were	O	O	O
assessed	O	O	B-Entity
on	O	O	O
wood	O	O	B-Entity
microcores	O	O	B-Entity
sampled	O	O	B-Entity
weekly	O	O	B-Entity
from	O	O	O
April	O	O	O
to	O	O	O
October	O	O	O
in	O	O	O
2014	O	O	O
and	O	O	O
2015	O	O	O
from	O	O	O
61	O	O	O
trees	O	O	B-Entity
growing	O	O	B-Entity
in	O	O	O
a	O	O	O
provenance	O	O	B-Entity
trial	O	O	I-Entity
in	O	O	O
Quebec	O	O	B-Entity
,	O	O	O
Canada	O	O	B-Entity
.	O	O	O

Trees	O	O	B-Entity
showing	O	O	O
an	O	O	O
early	O	O	B-Entity
bud	O	O	B-Entity
flush	O	O	B-Entity
also	O	O	O
exhibited	O	O	O
early	O	O	O
reactivation	O	O	B-Entity
of	O	O	O
xylem	O	O	B-Entity
differentiation	O	O	B-Entity
,	O	O	O
although	O	O	O
an	O	O	O
average	O	O	B-Entity
difference	O	O	B-Entity
of	O	O	O
12	O	O	O
days	O	O	B-Entity
for	O	O	O
buds	O	O	B-Entity
corresponded	O	O	O
to	O	O	O
small	O	O	B-Entity
although	O	O	O
significant	O	O	B-Entity
differences	O	O	B-Entity
of	O	O	O
4	O	O	O
days	O	O	O
for	O	O	O
xylem	O	O	O
.	O	O	O

Provenances	O	O	B-Entity
with	O	O	O
early	O	O	B-Entity
bud	O	O	B-Entity
flush	O	O	B-Entity
had	O	O	O
an	O	O	O
early	O	O	O
bud	O	O	O
set	O	O	O
and	O	O	O
completed	O	O	B-Entity
xylem	O	O	B-Entity
formation	O	O	B-Entity
earlier	O	O	B-Entity
than	O	O	O
late	O	O	B-Entity
bud	O	O	O
flush	O	O	O
provenances	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
in	O	O	O
the	O	O	O
period	O	O	B-Entity
of	O	O	O
xylem	O	O	B-Entity
formation	O	O	B-Entity
and	O	O	O
total	O	O	B-Entity
growth	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
between	O	O	O
the	O	O	O
flushing	O	O	B-Entity
classes	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
demonstrate	O	O	O
that	O	O	O
the	O	O	O
ecotype	O	O	B-Entity
differentiation	O	O	B-Entity
of	O	O	O
black	O	O	B-Entity
spruce	O	O	I-Entity
provenances	O	O	B-Entity
represented	O	O	O
by	O	O	O
the	O	O	O
phenological	O	O	B-Entity
adaptation	O	O	B-Entity
of	O	O	O
buds	O	O	B-Entity
to	O	O	O
the	O	O	O
local	O	O	B-Entity
climate	O	O	B-Entity
corresponds	O	O	O
to	O	O	O
specific	O	O	B-Entity
growth	O	O	B-Entity
dynamics	O	O	B-Entity
of	O	O	O
the	O	O	O
xylem	O	O	B-Entity
.	O	O	O

-DOCSTART- (28340485)

An	O	O	O
approach	O	O	O
for	O	O	O
liposome	O	O	B-Entity
immobilization	O	O	B-Entity
using	O	O	O
sterically	O	O	B-Entity
stabilized	O	O	I-Entity
micelles	O	O	B-Entity
(	O	O	O
SSMs	O	O	B-Entity
)	O	O	O
as	O	O	O
a	O	O	O
precursor	O	O	B-Entity
for	O	O	O
bio-layer	O	O	B-Entity
interferometry	O	O	I-Entity
-	O	O	O
based	O	O	B-Entity
interaction	O	O	B-Entity
studies	O	O	O

Non-fluidic	O	O	B-Entity
bio-layer	O	O	B-Entity
interferometry	O	O	I-Entity
(	O	O	O
BLI	O	O	B-Entity
)	O	O	O
has	O	O	O
rapidly	O	O	B-Entity
become	O	O	O
a	O	O	O
standard	O	O	B-Entity
tool	O	O	O
for	O	O	O
monitoring	O	O	B-Entity
almost	O	O	O
all	O	O	O
biomolecular	O	O	B-Entity
interactions	O	O	B-Entity
in	O	O	O
a	O	O	O
label-free	O	O	B-Entity
,	O	O	O
real-time	O	O	B-Entity
and	O	O	O
high-throughput	O	O	B-Entity
manner	O	O	O
.	O	O	O

High	O	O	B-Entity
-	O	O	O
efficiency	O	O	B-Entity
screening	O	O	B-Entity
methods	O	O	I-Entity
which	O	O	O
measure	O	O	B-Entity
the	O	O	O
kinetics	O	O	B-Entity
of	O	O	O
liposomes	O	O	B-Entity
with	O	O	O
a	O	O	O
variety	O	O	B-Entity
of	O	O	O
compounds	O	O	B-Entity
require	O	O	O
the	O	O	O
immobilization	O	O	B-Entity
of	O	O	O
liposomes	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
work	O	O	O
,	O	O	O
a	O	O	O
method	O	O	B-Entity
is	O	O	O
described	O	O	B-Entity
for	O	O	O
immobilizing	O	O	B-Entity
liposomes	O	O	B-Entity
for	O	O	O
interaction	O	O	B-Entity
studies	O	O	B-Entity
,	O	O	O
based	O	O	B-Entity
on	O	O	O
the	O	O	O
biophysical	O	O	B-Entity
principles	O	O	I-Entity
of	O	O	O
this	O	O	O
biosensor	O	O	B-Entity
platform	O	O	B-Entity
.	O	O	O

The	O	O	O
immobilization	O	O	B-Entity
approach	O	O	O
includes	O	O	B-Entity
the	O	O	O
loading	O	O	B-Entity
of	O	O	O
DSPE-PEG(2000	O	O	B-Entity
)	O	O	I-Entity
-	O	O	O
biotin	O	O	B-Entity
containing	O	O	O
sterically	O	O	B-Entity
stabilized	O	O	I-Entity
micelles	O	O	B-Entity
(	O	O	O
SSMs	O	O	B-Entity
)	O	O	O
which	O	O	O
are	O	O	O
restructured	O	O	B-Entity
in	O	O	O
a	O	O	O
buffer	O	O	B-Entity
change	O	O	I-Entity
step	O	O	O
,	O	O	O
resulting	O	O	B-Entity
in	O	O	I-Entity
an	O	O	O
accessible	O	O	O
substrate	O	O	B-Entity
for	O	O	O
liposome	O	O	B-Entity
immobilization	O	O	O
.	O	O	O

Liposomes	O	O	B-Entity
in	O	O	O
a	O	O	O
concentration	O	O	B-Entity
of	O	O	O
5mM	O	O	O
of	O	O	O
varying	O	O	O
composition	O	O	B-Entity
and	O	O	O
fluidity	O	O	B-Entity
were	O	O	O
immobilized	O	O	B-Entity
on	O	O	O
the	O	O	O
sensor	O	O	B-Entity
surface	O	O	B-Entity
by	O	O	O
inserting	O	O	O
the	O	O	O
hydrophobic	O	O	B-Entity
residues	O	O	B-Entity
of	O	O	O
the	O	O	O
former	O	O	B-Entity
loaded	O	O	O
SSMs	O	O	B-Entity
.	O	O	O

This	O	O	O
proof	O	O	O
of	O	O	O
principle	O	O	O
was	O	O	O
carried	O	O	O
out	O	O	O
using	O	O	O
Cytochrome	O	O	B-Entity
C	O	O	I-Entity
as	O	O	O
a	O	O	O
membrane-interacting	O	O	B-Entity
model	O	O	O
protein	O	O	B-Entity
.	O	O	O

The	O	O	O
binding	O	O	B-Entity
of	O	O	O
Cytochrome	O	O	B-Entity
C	O	O	I-Entity
to	O	O	O
the	O	O	O
immobilized	O	O	B-Entity
liposomes	O	O	B-Entity
was	O	O	O
demonstrated	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
derived	O	O	O
kinetic	O	O	B-Entity
and	O	O	O
affinity	O	O	B-Entity
constants	O	O	B-Entity
were	O	O	O
similar	O	O	B-Entity
to	O	O	O
values	O	O	B-Entity
given	O	O	O
in	O	O	O
the	O	O	O
literature	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
obtain	O	O	O
a	O	O	O
detailed	O	O	B-Entity
understanding	O	O	B-Entity
of	O	O	O
this	O	O	O
surface	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
show	O	O	O
the	O	O	O
integrity	O	O	B-Entity
of	O	O	O
the	O	O	O
liposomes	O	O	B-Entity
,	O	O	O
confocal	O	O	B-Entity
fluorescence	O	O	I-Entity
microscopy	O	O	I-Entity
was	O	O	O
used	O	O	O
.	O	O	O

Images	O	O	O
of	O	O	O
immobilized	O	O	B-Entity
liposomes	O	O	B-Entity
containing	O	O	B-Entity
calcein	O	O	B-Entity
in	O	O	O
the	O	O	O
aqueous	O	O	B-Entity
core	O	O	B-Entity
indicated	O	O	B-Entity
intact	O	O	B-Entity
vesicles	O	O	B-Entity
.	O	O	O

A	O	O	O
combination	O	O	B-Entity
of	O	O	O
this	O	O	O
simple	O	O	O
liposome	O	O	B-Entity
immobilization	O	O	B-Entity
approach	O	O	O
,	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
automation	O	O	B-Entity
on	O	O	O
BLI	O	O	B-Entity
systems	O	O	B-Entity
with	O	O	O
high	O	O	B-Entity
throughput	O	O	I-Entity
within	O	O	O
an	O	O	O
acceptable	O	O	B-Entity
timescale	O	O	O
and	O	O	O
excellent	O	O	B-Entity
reproducibility	O	O	B-Entity
makes	O	O	O
this	O	O	O
assay	O	O	B-Entity
suitable	O	O	B-Entity
for	O	O	O
basic	O	O	O
research	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
for	O	O	O
industrial	O	O	B-Entity
and	O	O	O
regulatory	O	O	B-Entity
applications	O	O	I-Entity
.	O	O	O

-DOCSTART- (28341903)

Exercise	O	O	B-Entity
increases	O	O	B-Entity
lactoferrin	O	O	B-Entity
,	O	O	O
but	O	O	O
decreases	O	O	B-Entity
lysozyme	O	O	B-Entity
in	O	O	O
salivary	O	O	B-Entity
granulocytes	O	O	O

Intracellular	O	O	B-Entity
lactoferrin	O	O	I-Entity
(	O	O	O
Lac	O	O	B-Entity
)	O	O	O
and	O	O	O
lysozyme	O	O	B-Entity
(	O	O	O
Lys	O	O	B-Entity
)	O	O	O
content	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
regulating	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
promoting	O	O	B-Entity
host	O	O	B-Entity
protection	O	O	I-Entity
.	O	O	O

While	O	O	O
exercise	O	O	B-Entity
has	O	O	O
demonstrated	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
Lac	O	O	B-Entity
and	O	O	O
Lys	O	O	B-Entity
concentration	O	O	B-Entity
in	O	O	O
exocrine	O	O	B-Entity
solutions	O	O	I-Entity
,	O	O	O
little	O	O	O
is	O	O	O
known	O	O	O
regarding	O	O	O
intracellular	O	O	B-Entity
concentration	O	O	I-Entity
changes	O	O	I-Entity
in	O	O	O
response	O	O	O
to	O	O	O
exercise	O	O	O
.	O	O	O

To	O	O	O
quantify	O	O	B-Entity
intracellular	O	O	O
Lac	O	O	B-Entity
and	O	O	O
Lys	O	O	B-Entity
concentration	O	O	B-Entity
before	O	O	O
and	O	O	O
after	O	O	O
exercise	O	O	B-Entity
in	O	O	O
salivary	O	O	B-Entity
CD45(+)CD15(+	O	O	B-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

11	O	O	O
males	O	O	B-Entity
(	O	O	O
20.3	O	O	O
±	O	O	O
0.8	O	O	O
years	O	O	B-Entity
,	O	O	O
57.2	O	O	O
±	O	O	O
7.6	O	O	O
mL/kg/min	O	O	O
V̇O2pk	O	O	B-Entity
,	O	O	O
11.1	O	O	O
±	O	O	O
3.9	O	O	O
%	O	O	O
body	O	O	B-Entity
fat	O	O	I-Entity
)	O	O	O
ran	O	O	B-Entity
for	O	O	O
45	O	O	O
min	O	O	B-Entity
at	O	O	O
75	O	O	O
%	O	O	O
of	O	O	O
VO2pk	O	O	B-Entity
.	O	O	O

12	O	O	O
mL	O	O	O
of	O	O	O
stimulated	O	O	B-Entity
saliva	O	O	I-Entity
were	O	O	O
collected	O	O	B-Entity
pre	O	O	B-Entity
and	O	O	O
immediately	O	O	O
post	O	O	B-Entity
exercise	O	O	I-Entity
.	O	O	O

Saliva	O	O	B-Entity
was	O	O	O
filtered	O	O	O
through	O	O	O
a	O	O	O
30-µm	O	O	O
filter	O	O	O
before	O	O	O
analysis	O	O	O
of	O	O	O
leukocytes	O	O	B-Entity
(	O	O	O
CD45(+	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
and	O	O	O
granulocytes	O	O	B-Entity
(	O	O	O
CD45(+)CD15(+	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
using	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

Median	O	O	B-Entity
fluorescent	O	O	I-Entity
intensity	O	O	I-Entity
(	O	O	O
MFI	O	O	B-Entity
)	O	O	O
of	O	O	O
Lac	O	O	B-Entity
increased	O	O	B-Entity
from	O	O	O
pre	O	O	B-Entity
(	O	O	O
64,268	O	O	O
±	O	O	O
46,036	O	O	O
MFI	O	O	O
)	O	O	O
to	O	O	O
post	O	O	B-Entity
(	O	O	O
117,134	O	O	O
±	O	O	O
88,115	O	O	O
MFI	O	O	O
)	O	O	O
exercise	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Lys	O	O	B-Entity
MFI	O	O	B-Entity
decreased	O	O	B-Entity
with	O	O	O
exercise	O	O	B-Entity
(	O	O	O
pre	O	O	B-Entity
:	O	O	O
16,933	O	O	O
±	O	O	O
8249	O	O	O
;	O	O	O
post	O	O	B-Entity
:	O	O	O
11,616	O	O	O
±	O	O	O
6875	O	O	O
)	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Acute	O	O	B-Entity
running	O	O	I-Entity
resulted	O	O	O
in	O	O	O
an	O	O	O
increased	O	O	B-Entity
Lac	O	O	B-Entity
concentration	O	O	B-Entity
which	O	O	O
could	O	O	O
lead	O	O	O
to	O	O	O
a	O	O	O
decrease	O	O	B-Entity
in	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
adding	O	O	O
further	O	O	O
evidence	O	O	O
of	O	O	O
the	O	O	O
anti-inflammatory	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
exercise	O	O	B-Entity
.	O	O	O

Conversely	O	O	O
,	O	O	O
the	O	O	O
exercise	O	O	B-Entity
-associated	O	O	O
decrease	O	O	B-Entity
of	O	O	O
intracellular	O	O	B-Entity
Lys	O	O	B-Entity
content	O	O	O
could	O	O	O
be	O	O	O
the	O	O	O
cause	O	O	B-Entity
of	O	O	O
increased	O	O	B-Entity
Lys	O	O	O
in	O	O	O
exocrine	O	O	B-Entity
solutions	O	O	I-Entity
.	O	O	O

-DOCSTART- (28345005)

Chronic	O	O	B-Entity
Enzyme	O	O	I-Entity
Replacement	O	O	I-Entity
to	O	O	O
the	O	O	O
Brain	O	O	B-Entity
of	O	O	O
a	O	O	O
Late	O	O	B-Entity
Infantile	O	O	I-Entity
Neuronal	O	O	I-Entity
Ceroid	O	O	I-Entity
Lipofuscinosis	O	O	I-Entity
Mouse	O	O	B-Entity
Has	O	O	O
Differential	O	O	O
Effects	O	O	B-Entity
on	O	O	O
Phenotypes	O	O	B-Entity
of	O	O	O
Disease	O	O	O

Late	O	O	B-Entity
infantile	O	O	I-Entity
neuronal	O	O	I-Entity
ceroid	O	O	I-Entity
lipofuscinosis	O	O	I-Entity
(	O	O	O
LINCL	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
fatal	O	O	B-Entity
inherited	O	O	O
neurodegenerative	O	O	B-Entity
disease	O	O	I-Entity
caused	O	O	O
by	O	O	O
loss	O	O	O
of	O	O	O
lysosomal	O	O	B-Entity
protease	O	O	I-Entity
tripeptidyl	O	O	I-Entity
peptidase	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
TPP1	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
have	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
intrathecal	O	O	I-Entity
(	O	O	I-Entity
IT	O	O	I-Entity
)	O	O	I-Entity
administration	O	O	I-Entity
using	O	O	O
enzyme	O	O	B-Entity
replacement	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
ERT	O	O	B-Entity
)	O	O	O
to	O	O	O
the	O	O	O
brain	O	O	B-Entity
of	O	O	O
an	O	O	O
LINCL	O	O	B-Entity
mouse	O	O	B-Entity
model	O	O	I-Entity
,	O	O	O
in	O	O	O
which	O	O	O
locomotor	O	O	B-Entity
function	O	O	I-Entity
declines	O	O	O
dramatically	O	O	O
prior	O	O	O
to	O	O	O
early	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

Median	O	O	O
lifespan	O	O	B-Entity
was	O	O	O
significantly	O	O	O
extended	O	O	O
from	O	O	O
126	O	O	O
days	O	O	B-Entity
to	O	O	O
>	O	O	O
259	O	O	O
days	O	O	O
when	O	O	O
chronic	O	O	B-Entity
IT	O	O	I-Entity
treatment	O	O	I-Entity
was	O	O	O
initiated	O	O	O
before	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	O
disease	O	O	B-Entity
.	O	O	O

While	O	O	O
treated	O	O	O
animals	O	O	B-Entity
lived	O	O	O
longer	O	O	O
and	O	O	O
showed	O	O	O
little	O	O	O
sign	O	O	O
of	O	O	O
locomotor	O	O	B-Entity
dysfunction	O	O	I-Entity
as	O	O	O
measured	O	O	O
by	O	O	O
stride	O	O	O
length	O	O	O
,	O	O	O
some	O	O	O
or	O	O	O
all	O	O	O
(	O	O	O
depending	O	O	O
on	O	O	O
regimen	O	O	O
)	O	O	O
still	O	O	O
died	O	O	B-Entity
prematurely	O	O	O
.	O	O	O

One	O	O	O
explanation	O	O	O
is	O	O	O
that	O	O	O
cerebrospinal	O	O	B-Entity
fluid	O	O	I-Entity
(CSF)-mediated	O	O	O
delivery	O	O	B-Entity
may	O	O	O
not	O	O	O
deliver	O	O	B-Entity
TPP1	O	O	B-Entity
to	O	O	O
all	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
.	O	O	O

Morphological	O	O	B-Entity
studies	O	O	B-Entity
support	O	O	O
this	O	O	O
,	O	O	O
showing	O	O	O
delivery	O	O	B-Entity
of	O	O	O
TPP1	O	O	B-Entity
to	O	O	O
ventral	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
deeper	O	O	O
and	O	O	O
dorsal	O	O	B-Entity
regions	O	O	I-Entity
.	O	O	O

When	O	O	O
IT	O	O	B-Entity
treatment	O	O	I-Entity
is	O	O	O
initiated	O	O	O
in	O	O	O
severely	O	O	B-Entity
affected	O	O	B-Entity
LINCL	O	O	B-Entity
mice	O	O	B-Entity
,	O	O	O
lifespan	O	O	B-Entity
was	O	O	O
extended	O	O	O
modestly	O	O	O
in	O	O	O
most	O	O	O
but	O	O	O
dramatically	O	O	O
extended	O	O	O
in	O	O	O
approximately	O	O	O
one-third	O	O	O
of	O	O	O
the	O	O	O
cohort	O	O	B-Entity
.	O	O	O

Treatment	O	O	B-Entity
improved	O	O	O
locomotor	O	O	B-Entity
function	O	O	I-Entity
in	O	O	O
these	O	O	O
severely	O	O	O
compromised	O	O	O
animals	O	O	B-Entity
after	O	O	O
it	O	O	O
had	O	O	O
declined	O	O	O
to	O	O	O
the	O	O	O
point	O	O	O
at	O	O	O
which	O	O	O
animals	O	O	O
normally	O	O	O
die	O	O	B-Entity
.	O	O	O

This	O	O	O
indicates	O	O	O
that	O	O	O
some	O	O	O
pathology	O	O	B-Entity
in	O	O	O
LINCL	O	O	B-Entity
is	O	O	O
reversible	O	O	B-Entity
and	O	O	O
does	O	O	O
not	O	O	O
simply	O	O	O
reflect	O	O	O
neuronal	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

-DOCSTART- (28346872)

5-Bromo-2-aryl	O	O	B-Entity
benzimidazole	O	O	I-Entity
derivatives	O	O	I-Entity
as	O	O	O
non-cytotoxic	O	O	B-Entity
potential	O	O	B-Entity
dual	O	O	O
inhibitors	O	O	B-Entity
of	O	O	O
α-glucosidase	O	O	B-Entity
and	O	O	O
urease	O	O	O
enzymes	O	O	O

On	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
previous	O	O	O
report	O	O	B-Entity
on	O	O	O
promising	O	O	O
α-glucosidase	O	O	B-Entity
inhibitory	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
5-bromo-2-aryl	O	O	B-Entity
benzimidazole	O	O	I-Entity
derivatives	O	O	I-Entity
,	O	O	O
these	O	O	O
derivatives	O	O	O
were	O	O	O
further	O	O	O
screened	O	O	B-Entity
for	O	O	O
urease	O	O	B-Entity
inhibitory	O	O	O
and	O	O	O
cytotoxicity	O	O	B-Entity
activity	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
get	O	O	O
more	O	O	B-Entity
potent	O	O	I-Entity
and	O	O	O
non-cytotoxic	O	O	B-Entity
potential	O	O	B-Entity
dual	O	O	O
inhibitor	O	O	B-Entity
for	O	O	O
the	O	O	O
patients	O	O	B-Entity
suffering	O	O	O
from	O	O	O
diabetes	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
peptic	O	O	B-Entity
ulcer	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
all	O	O	O
compounds	O	O	B-Entity
showed	O	O	O
varying	O	O	O
degree	O	O	B-Entity
of	O	O	I-Entity
potency	O	O	I-Entity
in	O	O	O
the	O	O	O
range	O	O	O
of	O	O	O
(	O	O	O
IC50	O	O	B-Entity
=	O	O	O
8.15±0.03	O	O	O
-	O	O	O
354.67±0.19μM	O	O	O
)	O	O	O
as	O	O	O
compared	O	O	O
to	O	O	O
standard	O	O	B-Entity
thiourea	O	O	B-Entity
(	O	O	O
IC50	O	O	O
=	O	O	O
21.25±0.15μM	O	O	O
)	O	O	O
.	O	O	O

It	O	O	O
is	O	O	O
worth	O	O	O
mentioning	O	O	O
that	O	O	O
derivatives	O	O	B-Entity
7	O	O	I-Entity
(	O	O	O
IC50	O	O	B-Entity
=	O	O	O
12.07±0.05μM	O	O	O
)	O	O	O
,	O	O	O
8	O	O	B-Entity
(	O	O	O
IC50	O	O	O
=	O	O	O
10.57±0.12μM	O	O	O
)	O	O	O
,	O	O	O
11	O	O	B-Entity
(	O	O	O
IC50	O	O	O
=	O	O	O
13.76±0.02μM	O	O	O
)	O	O	O
,	O	O	O
14	O	O	B-Entity
(	O	O	O
IC50	O	O	O
=	O	O	O
15.70±0.12μM	O	O	O
)	O	O	O
and	O	O	O
22	O	O	B-Entity
(	O	O	O
IC50	O	O	O
=	O	O	O
8.15±0.03μM	O	O	O
)	O	O	O
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
potent	O	O	B-Entity
inhibitors	O	O	I-Entity
than	O	O	O
standard	O	O	B-Entity
.	O	O	O

All	O	O	O
compounds	O	O	B-Entity
were	O	O	O
also	O	O	O
evaluated	O	O	O
for	O	O	O
cytotoxicity	O	O	B-Entity
towards	O	O	O
3T3	O	O	B-Entity
mouse	O	O	B-Entity
fibroblast	O	O	I-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
and	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
completely	O	O	O
non-toxic	O	O	B-Entity
.	O	O	O

Previously	O	O	O
benzimidazole	O	O	B-Entity
1	O	O	I-Entity
-	O	O	I-Entity
25	O	O	I-Entity
were	O	O	O
also	O	O	O
showed	O	O	O
α-glucosidase	O	O	B-Entity
inhibitory	O	O	B-Entity
potential	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
silico	O	O	I-Entity
studies	O	O	B-Entity
were	O	O	O
performed	O	O	O
on	O	O	O
the	O	O	O
lead	O	O	B-Entity
molecules	O	O	I-Entity
i.e.	O	O	O
2	O	O	B-Entity
,	O	O	O
7	O	O	B-Entity
,	O	O	O
8	O	O	B-Entity
,	O	O	O
11	O	O	B-Entity
,	O	O	O
14	O	O	B-Entity
,	O	O	O
and	O	O	O
22	O	O	B-Entity
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
rationalize	O	O	O
the	O	O	O
binding	O	O	B-Entity
interaction	O	O	I-Entity
of	O	O	O
compounds	O	O	B-Entity
with	O	O	O
the	O	O	O
active	O	O	B-Entity
site	O	O	I-Entity
of	O	O	O
urease	O	O	B-Entity
enzyme	O	O	I-Entity
.	O	O	O

-DOCSTART- (28347978)

Intra-articular	O	O	B-Entity
implantation	O	O	B-Entity
of	O	O	O
collagen	O	O	B-Entity
scaffold	O	O	B-Entity
carriers	O	O	B-Entity
is	O	O	O
safe	O	O	B-Entity
in	O	O	O
both	O	O	O
native	O	O	B-Entity
and	O	O	O
arthrofibrotic	O	O	B-Entity
rabbit	O	O	B-Entity
knee	O	O	O
joints	O	O	O

Sustained	O	O	B-Entity
intra-articular	O	O	B-Entity
delivery	O	O	B-Entity
of	O	O	I-Entity
pharmacological	O	O	I-Entity
agents	O	O	I-Entity
is	O	O	O
an	O	O	O
attractive	O	O	B-Entity
modality	O	O	B-Entity
but	O	O	O
requires	O	O	O
use	O	O	B-Entity
of	O	O	O
a	O	O	O
safe	O	O	B-Entity
carrier	O	O	B-Entity
that	O	O	O
would	O	O	O
not	O	O	O
induce	O	O	B-Entity
cartilage	O	O	B-Entity
damage	O	O	I-Entity
or	O	O	O
fibrosis	O	O	B-Entity
.	O	O	O

Collagen	O	O	B-Entity
scaffolds	O	O	B-Entity
are	O	O	O
widely	O	O	O
available	O	O	B-Entity
and	O	O	O
could	O	O	O
be	O	O	O
used	O	O	O
intra-articularly	O	O	B-Entity
,	O	O	O
but	O	O	O
no	O	O	O
investigation	O	O	B-Entity
has	O	O	O
looked	O	O	O
at	O	O	O
the	O	O	O
safety	O	O	B-Entity
of	O	O	O
collagen	O	O	B-Entity
scaffolds	O	O	O
within	O	O	O
synovial	O	O	B-Entity
joints	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
determine	O	O	B-Entity
the	O	O	O
safety	O	O	B-Entity
of	O	O	O
collagen	O	O	B-Entity
scaffold	O	O	B-Entity
implantation	O	O	B-Entity
in	O	O	O
a	O	O	O
validated	O	O	B-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
animal	O	O	B-Entity
model	O	O	O
of	O	O	O
knee	O	O	B-Entity
arthrofibrosis	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
96	O	O	O
rabbits	O	O	B-Entity
were	O	O	O
randomly	O	O	B-Entity
and	O	O	O
equally	O	O	B-Entity
assigned	O	O	B-Entity
to	O	O	O
four	O	O	O
different	O	O	B-Entity
groups	O	O	B-Entity
:	O	O	O
arthrotomy	O	O	B-Entity
alone	O	O	O
;	O	O	O
arthrotomy	O	O	O
and	O	O	O
collagen	O	O	B-Entity
scaffold	O	O	B-Entity
placement	O	O	B-Entity
;	O	O	O
contracture	O	O	B-Entity
surgery	O	O	B-Entity
;	O	O	O
and	O	O	O
contracture	O	O	O
surgery	O	O	O
and	O	O	O
collagen	O	O	O
scaffold	O	O	O
placement	O	O	O
.	O	O	O

Animals	O	O	B-Entity
were	O	O	O
killed	O	O	B-Entity
in	O	O	O
equal	O	O	B-Entity
numbers	O	O	O
at	O	O	O
72	O	O	O
hours	O	O	B-Entity
,	O	O	O
two	O	O	O
weeks	O	O	B-Entity
,	O	O	O
eight	O	O	O
weeks	O	O	O
,	O	O	O
and	O	O	O
24	O	O	O
weeks	O	O	O
.	O	O	O

Joint	O	O	B-Entity
contracture	O	O	I-Entity
was	O	O	O
measured	O	O	B-Entity
,	O	O	O
and	O	O	O
cartilage	O	O	B-Entity
and	O	O	O
synovial	O	O	B-Entity
samples	O	O	B-Entity
underwent	O	O	O
histological	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Animals	O	O	B-Entity
that	O	O	O
underwent	O	O	O
arthrotomy	O	O	B-Entity
had	O	O	O
equivalent	O	O	B-Entity
joint	O	O	B-Entity
contractures	O	O	I-Entity
regardless	O	O	O
of	O	O	O
scaffold	O	O	B-Entity
implantation	O	O	B-Entity
(	O	O	O
-13.9	O	O	O
°	O	O	O
versus	O	O	O
-10.9	O	O	O
°	O	O	O
,	O	O	O
equivalence	O	O	O
limit	O	O	O
15	O	O	O
°	O	O	O
)	O	O	O
.	O	O	O

Animals	O	O	B-Entity
that	O	O	O
underwent	O	O	O
surgery	O	O	B-Entity
to	O	O	O
induce	O	O	B-Entity
contracture	O	O	B-Entity
did	O	O	O
not	O	O	O
demonstrate	O	O	O
equivalent	O	O	B-Entity
joint	O	O	B-Entity
contracture	O	O	I-Entity
s	O	O	O
with	O	O	O
(	O	O	O
41.8	O	O	O
°	O	O	O
)	O	O	O
or	O	O	O
without	O	O	O
(	O	O	O
53.9	O	O	O
°	O	O	O
)	O	O	O
collagen	O	O	B-Entity
scaffold	O	O	B-Entity
implantation	O	O	B-Entity
.	O	O	O

Chondral	O	O	B-Entity
damage	O	O	B-Entity
occurred	O	O	B-Entity
in	O	O	O
similar	O	O	O
rates	O	O	B-Entity
with	O	O	O
(	O	O	O
11	O	O	O
of	O	O	O
48	O	O	O
)	O	O	O
and	O	O	O
without	O	O	O
(	O	O	O
nine	O	O	O
of	O	O	O
48	O	O	O
)	O	O	O
scaffold	O	O	B-Entity
implantation	O	O	B-Entity
.	O	O	O

No	O	O	O
significant	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
synovitis	O	O	B-Entity
was	O	O	O
noted	O	O	O
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

Absorption	O	O	B-Entity
of	O	O	O
the	O	O	O
collagen	O	O	B-Entity
scaffold	O	O	B-Entity
occurred	O	O	B-Entity
within	O	O	O
eight	O	O	O
weeks	O	O	B-Entity
in	O	O	O
all	O	O	O
animals	O	O	B-Entity
CONCLUSION	O	O	O
:	O	O	O
Our	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
intra-articular	O	O	B-Entity
implantation	O	O	B-Entity
of	O	O	O
a	O	O	O
collagen	O	O	O
sponge	O	O	B-Entity
does	O	O	O
not	O	O	O
induce	O	O	B-Entity
synovitis	O	O	B-Entity
or	O	O	O
cartilage	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

Implantation	O	O	B-Entity
in	O	O	O
a	O	O	O
native	O	O	B-Entity
joint	O	O	B-Entity
does	O	O	O
not	O	O	O
seem	O	O	O
to	O	O	O
induce	O	O	B-Entity
contracture	O	O	B-Entity
.	O	O	O

Implantation	O	O	B-Entity
of	O	O	O
the	O	O	O
collagen	O	O	B-Entity
sponge	O	O	B-Entity
in	O	O	O
a	O	O	O
rabbit	O	O	B-Entity
knee	O	O	O
model	O	O	O
of	O	O	O
contracture	O	O	B-Entity
may	O	O	O
decrease	O	O	B-Entity
the	O	O	O
severity	O	O	B-Entity
of	O	O	O
the	O	O	O
contracture	O	O	O
.Cite	O	O	O
this	O	O	O
article	O	O	O
:	O	O	O
J.	O	O	O
A.	O	O	O
Walker	O	O	O
,	O	O	O
T.	O	O	O
J.	O	O	O
Ewald	O	O	O
,	O	O	O
E.	O	O	O
Lewallen	O	O	O
,	O	O	O
A.	O	O	O
Van	O	O	O
Wijnen	O	O	O
,	O	O	O
A.	O	O	O
D.	O	O	O
Hanssen	O	O	O
,	O	O	O
B.	O	O	O
F.	O	O	O
Morrey	O	O	O
,	O	O	O
M.	O	O	O
E.	O	O	O
Morrey	O	O	O
,	O	O	O
M.	O	O	O
P.	O	O	O
Abdel	O	O	O
,	O	O	O
J.	O	O	O
Sanchez-Sotelo	O	O	O
.	O	O	O

Intra-articular	O	O	O
implantation	O	O	O
of	O	O	O
collagen	O	O	O
scaffold	O	O	O
carriers	O	O	O
is	O	O	O
safe	O	O	O
in	O	O	O
both	O	O	O
native	O	O	O
and	O	O	O
arthrofibrotic	O	O	O
rabbit	O	O	O
knee	O	O	O
joints	O	O	O
.	O	O	O

Bone	O	O	O
Joint	O	O	O
Res	O	O	O
2016;6:162	O	O	O
-	O	O	O
171	O	O	O
.	O	O	O

DOI	O	O	O
:	O	O	O
10.1302/2046	O	O	O
-	O	O	O
3758.63.BJR-2016	O	O	O
-	O	O	O
0193	O	O	O
.	O	O	O

-DOCSTART- (28348057)

HOST	O	O	B-Entity
IMMUNE	O	O	B-Entity
RECOGNITION	O	O	I-Entity
OF	O	O	O
THE	O	O	O
EPIDEMIC	O	O	B-Entity
CYSTIC	O	O	B-Entity
FIBROSIS	O	O	I-Entity
PATHOGEN	O	O	B-Entity
BURKHOLDERIA	O	O	O
DOLOSA	O	O	O

Burkholderia	O	O	B-Entity
dolosa	O	O	I-Entity
caused	O	O	O
an	O	O	O
outbreak	O	O	O
in	O	O	O
the	O	O	O
cystic	O	O	B-Entity
fibrosis	O	O	I-Entity
(	O	O	O
CF	O	O	B-Entity
)	O	O	O
clinic	O	O	O
at	O	O	O
Boston	O	O	B-Entity
Children	O	O	I-Entity
's	O	O	I-Entity
Hospital	O	O	I-Entity
from	O	O	O
1998	O	O	O
to	O	O	O
2005	O	O	O
and	O	O	O
led	O	O	O
to	O	O	O
the	O	O	O
infection	O	O	B-Entity
of	O	O	O
over	O	O	O
40	O	O	O
patients	O	O	B-Entity
,	O	O	O
many	O	O	O
of	O	O	O
whom	O	O	O
died	O	O	B-Entity
due	O	O	O
to	O	O	O
complications	O	O	B-Entity
from	O	O	O
infection	O	O	O
by	O	O	O
this	O	O	O
organism	O	O	B-Entity
.	O	O	O

To	O	O	O
assess	O	O	O
whether	O	O	O
B.	O	O	B-Entity
dolosa	O	O	I-Entity
significantly	O	O	O
contributes	O	O	O
to	O	O	O
disease	O	O	B-Entity
or	O	O	O
is	O	O	O
recognized	O	O	O
by	O	O	O
the	O	O	O
host	O	O	B-Entity
immune	O	O	B-Entity
response	O	O	I-Entity
,	O	O	O
mice	O	O	B-Entity
were	O	O	O
infected	O	O	B-Entity
with	O	O	O
a	O	O	O
sequenced	O	O	O
outbreak	O	O	O
B.	O	O	B-Entity
dolosa	O	O	I-Entity
strain	O	O	I-Entity
,	O	O	O
AU0158	O	O	B-Entity
,	O	O	O
and	O	O	O
responses	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
well-studied	O	O	O
CF	O	O	B-Entity
pathogen	O	O	B-Entity
,	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
In	O	O	O
parallel	O	O	O
,	O	O	O
mice	O	O	O
were	O	O	O
also	O	O	O
infected	O	O	O
with	O	O	O
a	O	O	O
polar	O	O	O
flagellin	O	O	B-Entity
mutant	O	O	B-Entity
of	O	O	O
B.	O	O	O
dolosa	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
flagella	O	O	B-Entity
in	O	O	O
B.	O	O	O
dolosa	O	O	O
lung	O	O	B-Entity
colonization	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
showed	O	O	O
a	O	O	O
higher	O	O	B-Entity
persistence	O	O	B-Entity
in	O	O	O
the	O	O	O
host	O	O	B-Entity
by	O	O	O
B.	O	O	B-Entity
dolosa	O	O	I-Entity
strains	O	O	I-Entity
and	O	O	O
yet	O	O	O
neutrophil	O	O	B-Entity
recruitment	O	O	O
and	O	O	O
cytokine	O	O	B-Entity
production	O	O	B-Entity
were	O	O	O
lower	O	O	O
compared	O	O	O
to	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
The	O	O	O
ability	O	O	O
of	O	O	O
host	O	O	O
immune	O	O	B-Entity
cells	O	O	I-Entity
to	O	O	O
recognize	O	O	O
B.	O	O	O
dolosa	O	O	O
was	O	O	O
then	O	O	O
assessed	O	O	O
and	O	O	O
B.	O	O	O
dolosa	O	O	O
induced	O	O	O
a	O	O	O
robust	O	O	O
cytokine	O	O	O
response	O	O	O
in	O	O	O
cultured	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
this	O	O	O
effect	O	O	O
was	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
flagella	O	O	B-Entity
only	O	O	O
when	O	O	O
bacteria	O	O	B-Entity
were	O	O	O
dead	O	O	B-Entity
.	O	O	O

Together	O	O	O
,	O	O	O
these	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
B.	O	O	B-Entity
dolosa	O	O	I-Entity
can	O	O	O
be	O	O	O
recognized	O	O	O
by	O	O	O
host	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
but	O	O	O
may	O	O	O
avoid	O	O	O
or	O	O	O
suppress	O	O	B-Entity
the	O	O	O
host	O	O	O
immune	O	O	B-Entity
response	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
through	O	O	O
unknown	O	O	O
mechanisms	O	O	O
.	O	O	O

B.	O	O	B-Entity
dolosa	O	O	I-Entity
was	O	O	O
then	O	O	O
compared	O	O	O
to	O	O	O
other	O	O	O
Burkholderia	O	O	B-Entity
species	O	O	I-Entity
and	O	O	O
found	O	O	O
to	O	O	O
induce	O	O	O
similar	O	O	O
levels	O	O	O
of	O	O	O
cytokine	O	O	B-Entity
production	O	O	B-Entity
despite	O	O	O
being	O	O	O
internalized	O	O	O
by	O	O	O
macrophages	O	O	B-Entity
more	O	O	O
than	O	O	O
B.	O	O	B-Entity
cenocepacia	O	O	I-Entity
strains	O	O	I-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
suggest	O	O	O
that	O	O	O
B.	O	O	B-Entity
dolosa	O	O	I-Entity
AU0158	O	O	I-Entity
may	O	O	O
act	O	O	O
differently	O	O	O
with	O	O	O
host	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
is	O	O	O
it	O	O	O
recognized	O	O	O
differently	O	O	O
by	O	O	O
immune	O	O	B-Entity
systems	O	O	I-Entity
compared	O	O	O
other	O	O	O
Burkholderia	O	O	B-Entity
strains	O	O	I-Entity
or	O	O	O
species	O	O	B-Entity
.	O	O	O

-DOCSTART- (28355176)

Visualization	O	O	B-Entity
and	O	O	O
targeting	O	O	B-Entity
of	O	O	O
LGR5(+	O	O	B-Entity
)	O	O	I-Entity
human	O	O	B-Entity
colon	O	O	B-Entity
cancer	O	O	O
stem	O	O	O
cells	O	O	O

The	O	O	O
cancer	O	O	B-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
(	O	O	O
CSC	O	O	B-Entity
)	O	O	O
theory	O	O	B-Entity
highlights	O	O	O
a	O	O	O
self-renewing	O	O	B-Entity
subpopulation	O	O	B-Entity
of	O	O	O
cancer	O	O	B-Entity
cells	O	O	I-Entity
that	O	O	O
fuels	O	O	O
tumour	O	O	O
growth	O	O	O
.	O	O	O

The	O	O	O
existence	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
CSCs	O	O	B-Entity
is	O	O	O
mainly	O	O	O
supported	O	O	O
by	O	O	O
xenotransplantation	O	O	B-Entity
of	O	O	O
prospectively	O	O	O
isolated	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
but	O	O	O
their	O	O	O
clonal	O	O	B-Entity
dynamics	O	O	B-Entity
and	O	O	O
plasticity	O	O	B-Entity
remain	O	O	O
unclear	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
human	O	O	B-Entity
LGR5(+	O	O	B-Entity
)	O	O	I-Entity
colorectal	O	O	B-Entity
cancer	O	O	B-Entity
cells	O	O	I-Entity
serve	O	O	O
as	O	O	O
CSCs	O	O	B-Entity
in	O	O	O
growing	O	O	O
cancer	O	O	O
tissues	O	O	B-Entity
.	O	O	O

Lineage	O	O	B-Entity
-	O	O	O
tracing	O	O	B-Entity
experiments	O	O	I-Entity
with	O	O	O
a	O	O	O
tamoxifen	O	O	B-Entity
-inducible	O	O	O
Cre	O	O	B-Entity
knock-in	O	O	B-Entity
allele	O	O	B-Entity
of	O	O	O
LGR5	O	O	B-Entity
reveal	O	O	O
the	O	O	O
self-renewal	O	O	B-Entity
and	O	O	O
differentiation	O	O	B-Entity
capacity	O	O	B-Entity
of	O	O	O
LGR5(+	O	O	B-Entity
)	O	O	I-Entity
tumour	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Selective	O	O	O
ablation	O	O	B-Entity
of	O	O	O
LGR5(+	O	O	B-Entity
)	O	O	I-Entity
CSCs	O	O	B-Entity
in	O	O	O
LGR5	O	O	B-Entity
-i	O	O	O
Caspase9	O	O	B-Entity
knock-in	O	O	B-Entity
organoids	O	O	B-Entity
leads	O	O	O
to	O	O	O
tumour	O	O	B-Entity
regression	O	O	I-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
tumour	O	O	B-Entity
regrowth	O	O	I-Entity
driven	O	O	O
by	O	O	O
re-emerging	O	O	O
LGR5(+	O	O	O
)	O	O	O
CSCs	O	O	O
.	O	O	O

KRT20	O	O	B-Entity
knock-in	O	O	B-Entity
reporter	O	O	B-Entity
marks	O	O	O
differentiated	O	O	B-Entity
cancer	O	O	B-Entity
cells	O	O	I-Entity
that	O	O	O
constantly	O	O	O
diminish	O	O	O
in	O	O	O
tumour	O	O	B-Entity
tissues	O	O	I-Entity
,	O	O	O
while	O	O	O
reverting	O	O	O
to	O	O	O
LGR5(+	O	O	B-Entity
)	O	O	I-Entity
CSCs	O	O	B-Entity
and	O	O	O
contributing	O	O	O
to	O	O	O
tumour	O	O	B-Entity
regrowth	O	O	I-Entity
after	O	O	O
LGR5(+	O	O	O
)	O	O	O
CSC	O	O	B-Entity
ablation	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
show	O	O	O
that	O	O	O
combined	O	O	O
chemotherapy	O	O	B-Entity
potentiates	O	O	O
targeting	O	O	B-Entity
of	O	O	O
LGR5(+	O	O	B-Entity
)	O	O	I-Entity
CSCs	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	B-Entity
provide	O	O	O
insights	O	O	O
into	O	O	O
the	O	O	O
plasticity	O	O	B-Entity
of	O	O	O
CSCs	O	O	B-Entity
and	O	O	O
their	O	O	O
potential	O	O	B-Entity
as	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
target	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (28355605)

The	O	O	O
Use	O	O	O
of	O	O	O
a	O	O	O
Software	O	O	B-Entity
-	O	O	O
Assisted	O	O	B-Entity
Method	O	O	B-Entity
to	O	O	O
Estimate	O	O	B-Entity
Fetal	O	O	B-Entity
Weight	O	O	I-Entity
at	O	O	O
and	O	O	O
Near	O	O	O
Term	O	O	B-Entity
Using	O	O	O
Magnetic	O	O	O
Resonance	O	O	O
Imaging	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
apply	O	O	O
a	O	O	O
semi-automated	O	O	B-Entity
calculation	O	O	B-Entity
method	O	O	B-Entity
of	O	O	O
fetal	O	O	B-Entity
body	O	O	B-Entity
volume	O	O	I-Entity
and	O	O	O
,	O	O	O
thus	O	O	O
,	O	O	O
of	O	O	O
magnetic	O	O	B-Entity
resonance-estimated	O	O	I-Entity
fetal	O	O	I-Entity
weight	O	O	I-Entity
(	O	O	O
MR-EFW	O	O	B-Entity
)	O	O	O
prior	O	O	O
to	O	O	O
planned	O	O	B-Entity
delivery	O	O	B-Entity
and	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
whether	O	O	O
the	O	O	O
technique	O	O	B-Entity
of	O	O	O
measurement	O	O	B-Entity
could	O	O	O
be	O	O	O
simplified	O	O	B-Entity
while	O	O	O
remaining	O	O	B-Entity
accurate	O	O	B-Entity
.	O	O	O

MR-EFW	O	O	B-Entity
was	O	O	O
calculated	O	O	B-Entity
using	O	O	O
a	O	O	O
semi-automated	O	O	B-Entity
method	O	O	B-Entity
at	O	O	O
38.6	O	O	O
weeks	O	O	B-Entity
of	O	O	O
gestation	O	O	B-Entity
in	O	O	O
36	O	O	O
patients	O	O	B-Entity
and	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
picture	O	O	B-Entity
archiving	O	O	I-Entity
and	O	O	I-Entity
communication	O	O	I-Entity
system	O	O	I-Entity
(	O	O	O
PACS	O	O	B-Entity
)	O	O	O
.	O	O	O

Per	O	O	O
patient	O	O	B-Entity
,	O	O	O
8	O	O	O
sequences	O	O	B-Entity
were	O	O	O
acquired	O	O	B-Entity
with	O	O	O
a	O	O	O
slice	O	O	B-Entity
thickness	O	O	I-Entity
of	O	O	O
4	O	O	O
-	O	O	O
8	O	O	O
mm	O	O	O
and	O	O	O
an	O	O	O
intersection	O	O	B-Entity
gap	O	O	I-Entity
of	O	O	O
0	O	O	O
,	O	O	O
4	O	O	O
,	O	O	O
8	O	O	O
,	O	O	O
12	O	O	O
,	O	O	O
16	O	O	O
,	O	O	O
or	O	O	O
20	O	O	O
mm	O	O	O
.	O	O	O

The	O	O	O
median	O	O	B-Entity
absolute	O	O	B-Entity
relative	O	O	B-Entity
errors	O	O	I-Entity
for	O	O	O
MR-EFW	O	O	B-Entity
and	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	O
planimetric	O	O	B-Entity
measurements	O	O	I-Entity
were	O	O	O
calculated	O	O	B-Entity
for	O	O	O
all	O	O	O
8	O	O	O
sequences	O	O	B-Entity
and	O	O	O
for	O	O	O
each	O	O	O
method	O	O	B-Entity
(	O	O	O
assisted	O	O	B-Entity
vs.	O	O	O
PACS	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
difference	O	O	O
between	O	O	O
the	O	O	O
methods	O	O	B-Entity
was	O	O	O
calculated	O	O	O
.	O	O	O

The	O	O	O
median	O	O	B-Entity
delivery	O	O	O
weight	O	O	O
was	O	O	O
3,280	O	O	O
g.	O	O	O
The	O	O	O
overall	O	O	O
median	O	O	O
relative	O	O	B-Entity
error	O	O	I-Entity
for	O	O	O
all	O	O	O
288	O	O	O
MR-EFW	O	O	B-Entity
calculations	O	O	B-Entity
was	O	O	O
2.4	O	O	O
%	O	O	O
using	O	O	O
the	O	O	O
semi-automated	O	O	B-Entity
method	O	O	B-Entity
and	O	O	O
2.2	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
PACS	O	O	B-Entity
method	O	O	O
.	O	O	O

Measurements	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
between	O	O	O
the	O	O	O
8	O	O	O
sequences	O	O	B-Entity
using	O	O	O
the	O	O	O
assisted	O	O	B-Entity
method	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.313	O	O	O
)	O	O	O
or	O	O	O
the	O	O	O
PACS	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.118	O	O	O
)	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	O
planimetric	O	O	B-Entity
measurement	O	O	I-Entity
decreased	O	O	B-Entity
significantly	O	O	O
with	O	O	O
a	O	O	O
larger	O	O	O
gap	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
in	O	O	O
the	O	O	O
assisted	O	O	O
method	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
PACS	O	O	O
method	O	O	O
(	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
simplified	O	O	B-Entity
MR-EFW	O	O	B-Entity
measurement	O	O	B-Entity
showed	O	O	O
a	O	O	O
dramatic	O	O	B-Entity
decrease	O	O	B-Entity
in	O	O	O
time	O	O	B-Entity
of	O	O	O
planimetric	O	O	B-Entity
measurement	O	O	I-Entity
without	O	O	O
a	O	O	O
decrease	O	O	O
in	O	O	O
the	O	O	O
accuracy	O	O	B-Entity
of	O	O	O
weight	O	O	B-Entity
estimates	O	O	B-Entity
.	O	O	O

-DOCSTART- (28355968)

Abiraterone	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
rhabdomyolysis	O	O	B-Entity
resulting	O	O	O
in	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
:	O	O	O
A	O	O	O
case	O	O	B-Entity
report	O	O	I-Entity
and	O	O	O
review	O	O	O
of	O	O	O
the	O	O	O
literature	O	O	O

Abiraterone	O	O	B-Entity
,	O	O	O
a	O	O	O
CYP17	O	O	B-Entity
inhibitor	O	O	I-Entity
,	O	O	O
blocks	O	O	O
androgen	O	O	B-Entity
biosynthesis	O	O	I-Entity
in	O	O	O
multiple	O	O	O
tissue	O	O	B-Entity
types	O	O	O
.	O	O	O

In	O	O	O
combination	O	O	O
with	O	O	O
prednisone	O	O	B-Entity
,	O	O	O
it	O	O	O
is	O	O	O
approved	O	O	O
as	O	O	O
a	O	O	O
first-line	O	O	B-Entity
treatment	O	O	I-Entity
for	O	O	O
metastatic	O	O	B-Entity
castration-resistant	O	O	B-Entity
prostate	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
rhabdomyolysis	O	O	B-Entity
associated	O	O	O
with	O	O	O
abiraterone	O	O	B-Entity
therapy	O	O	B-Entity
resulting	O	O	O
in	O	O	O
acute	O	O	B-Entity
on	O	O	O
chronic	O	O	B-Entity
kidney	O	O	B-Entity
injury	O	O	I-Entity
in	O	O	O
a	O	O	O
patient	O	O	B-Entity
with	O	O	O
metastatic	O	O	B-Entity
castration-resistant	O	O	B-Entity
prostate	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

Strict	O	O	O
monitoring	O	O	B-Entity
should	O	O	O
be	O	O	O
employed	O	O	O
in	O	O	O
patients	O	O	B-Entity
started	O	O	O
on	O	O	O
abiraterone	O	O	B-Entity
who	O	O	O
have	O	O	O
additional	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
developing	O	O	O
rhabdomyolysis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28356949)

Association	O	O	B-Entity
between	O	O	O
XRCC1	O	O	B-Entity
and	O	O	O
ERCC1	O	O	B-Entity
single-nucleotide	O	O	B-Entity
polymorphisms	O	O	I-Entity
and	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
concurrent	O	O	B-Entity
radiochemotherapy	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
esophageal	O	O	O
squamous	O	O	O
cell	O	O	O
carcinoma	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
between	O	O	O
single-nucleotide	O	O	B-Entity
polymorphisms	O	O	I-Entity
(	O	O	O
SNPs	O	O	B-Entity
)	O	O	O
in	O	O	O
X-ray	O	O	B-Entity
repair	O	O	I-Entity
cross-complementing	O	O	I-Entity
1	O	O	I-Entity
-	O	O	I-Entity
399	O	O	I-Entity
(	O	O	O
XRCC1	O	O	B-Entity
-	O	O	I-Entity
399	O	O	I-Entity
)	O	O	O
or	O	O	O
excision	O	O	B-Entity
repair	O	O	I-Entity
cross-complementation	O	O	I-Entity
group	O	O	I-Entity
1	O	O	I-Entity
-	O	O	I-Entity
118	O	O	I-Entity
(	O	O	O
ERCC1	O	O	B-Entity
-	O	O	I-Entity
118	O	O	I-Entity
)	O	O	O
and	O	O	O
the	O	O	O
short-term	O	O	B-Entity
efficacy	O	O	B-Entity
of	O	O	O
radiochemotherapy	O	O	B-Entity
,	O	O	O
tumor	O	O	B-Entity
metastasis	O	O	I-Entity
and	O	O	O
relapse	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
survival	O	O	B-Entity
time	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
esophageal	O	O	B-Entity
squamous	O	O	I-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
(	O	O	O
ESCC	O	O	B-Entity
)	O	O	O
.	O	O	O

TaqMan	O	O	B-Entity
probe-based	O	O	I-Entity
quantitative	O	O	I-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
qPCR	O	O	B-Entity
)	O	O	O
was	O	O	O
conducted	O	O	O
to	O	O	O
examine	O	O	B-Entity
the	O	O	O
levels	O	O	B-Entity
of	O	O	O
XRCC1	O	O	B-Entity
-	O	O	I-Entity
399	O	O	I-Entity
and	O	O	O
ERCC1	O	O	B-Entity
-	O	O	I-Entity
118	O	O	I-Entity
SNPs	O	O	B-Entity
in	O	O	O
the	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
of	O	O	O
50	O	O	O
patients	O	O	B-Entity
with	O	O	O
pathologically	O	O	B-Entity
confirmed	O	O	B-Entity
ESCC	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
associations	O	O	B-Entity
between	O	O	O
different	O	O	B-Entity
genotypes	O	O	B-Entity
and	O	O	O
short-term	O	O	B-Entity
therapeutic	O	O	B-Entity
efficacy	O	O	I-Entity
[	O	O	O
the	O	O	O
complete	O	O	B-Entity
remission	O	O	I-Entity
(	O	O	O
CR	O	O	B-Entity
)	O	O	O
rate	O	O	B-Entity
]	O	O	O
,	O	O	O
tumor	O	O	B-Entity
metastasis	O	O	I-Entity
and	O	O	O
relapse	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
survival	O	O	B-Entity
time	O	O	I-Entity
following	O	O	O
concurrent	O	O	B-Entity
radiochemotherapy	O	O	I-Entity
,	O	O	O
were	O	O	O
determined	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
50	O	O	O
ESCC	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
concurrent	O	O	B-Entity
radiochemotherapy	O	O	I-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

It	O	O	O
was	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
short-term	O	O	B-Entity
therapeutic	O	O	B-Entity
efficacy	O	O	I-Entity
(	O	O	O
CR	O	O	B-Entity
rate	O	O	B-Entity
)	O	O	O
was	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
group	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
carrying	O	O	O
the	O	O	O
homozygous	O	O	B-Entity
mutation	O	O	B-Entity
of	O	O	O
XRCC1	O	O	B-Entity
-	O	O	I-Entity
399	O	O	I-Entity
(	O	O	O
A	O	O	B-Entity
/	O	O	O
A	O	O	O
genotype	O	O	B-Entity
)	O	O	O
than	O	O	O
in	O	O	O
the	O	O	O
group	O	O	O
of	O	O	O
patients	O	O	O
without	O	O	O
the	O	O	O
XRCC1	O	O	O
-	O	O	O
399	O	O	O
mutation	O	O	O
(	O	O	O
G	O	O	B-Entity
/	O	O	O
G	O	O	O
genotype	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
CR	O	O	B-Entity
rate	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
increased	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
carrying	O	O	O
one	O	O	O
or	O	O	O
two	O	O	O
ERCC1	O	O	B-Entity
-	O	O	I-Entity
118	O	O	I-Entity
C	O	O	B-Entity
alleles	O	O	B-Entity
(	O	O	O
C	O	O	O
/	O	O	O
C	O	O	O
or	O	O	O
C	O	O	O
/	O	O	O
T	O	O	B-Entity
genotype	O	O	B-Entity
)	O	O	O
compared	O	O	B-Entity
with	O	O	O
patients	O	O	O
lacking	O	O	O
the	O	O	O
C	O	O	O
allele	O	O	B-Entity
(	O	O	O
T	O	O	O
/	O	O	O
T	O	O	O
genotype	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
differences	O	O	O
were	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
(	O	O	O
A	O	O	B-Entity
/	O	O	O
A	O	O	O
vs.	O	O	O
G	O	O	B-Entity
/	O	O	O
G	O	O	O
,	O	O	O
P=0.014	O	O	O
;	O	O	O
T	O	O	B-Entity
T	O	O	O
vs.	O	O	O
C	O	O	B-Entity
/	O	O	O
T	O	O	O
+	O	O	O
C	O	O	O
/	O	O	O
C	O	O	O
,	O	O	O
P=0.040	O	O	O
)	O	O	O
.	O	O	O

During	O	O	O
the	O	O	O
follow-up	O	O	B-Entity
period	O	O	I-Entity
,	O	O	O
the	O	O	O
group	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
carrying	O	O	O
the	O	O	O
homozygous	O	O	B-Entity
mutation	O	O	I-Entity
of	O	O	O
XRCC1	O	O	B-Entity
-	O	O	I-Entity
399	O	O	I-Entity
(	O	O	O
A	O	O	B-Entity
/	O	O	O
A	O	O	O
genotype	O	O	B-Entity
)	O	O	O
exhibited	O	O	O
a	O	O	O
markedly	O	O	B-Entity
reduced	O	O	I-Entity
risk	O	O	B-Entity
of	O	O	O
metastasis	O	O	B-Entity
and	O	O	O
relapse	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
group	O	O	O
of	O	O	O
patients	O	O	O
carrying	O	O	O
non-mutated	O	O	O
XRCC1	O	O	O
-	O	O	O
399	O	O	O
(	O	O	O
G	O	O	B-Entity
/	O	O	O
G	O	O	O
genotype	O	O	O
;	O	O	O
P=0.031	O	O	O
)	O	O	O
.	O	O	O

By	O	O	O
contrast	O	O	O
,	O	O	O
ERCC1	O	O	B-Entity
-	O	O	I-Entity
118	O	O	I-Entity
SNP	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
metastasis	O	O	B-Entity
and	O	O	O
recurrence	O	O	B-Entity
(	O	O	O
P>0.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
combined	O	O	O
results	O	O	O
of	O	O	O
univariate	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
Cox	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
SNP	O	O	B-Entity
in	O	O	O
ERCC1	O	O	B-Entity
-	O	O	I-Entity
118	O	O	I-Entity
was	O	O	O
closely	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
survival	O	O	B-Entity
time	O	O	I-Entity
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
survival	O	O	I-Entity
time	O	O	I-Entity
was	O	O	O
significantly	O	O	B-Entity
prolonged	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
carrying	O	O	O
1	O	O	O
or	O	O	O
2	O	O	O
C	O	O	B-Entity
alleles	O	O	B-Entity
(	O	O	O
C	O	O	O
/	O	O	O
C	O	O	O
or	O	O	O
C	O	O	O
/	O	O	O
T	O	O	B-Entity
genotype	O	O	B-Entity
)	O	O	O
compared	O	O	B-Entity
with	O	O	O
patients	O	O	O
lacking	O	O	O
the	O	O	O
C	O	O	O
allele	O	O	B-Entity
(	O	O	O
T	O	O	O
/	O	O	O
T	O	O	O
genotype	O	O	O
)	O	O	O
[	O	O	O
T	O	O	O
/	O	O	O
T	O	O	O
vs.	O	O	O
C	O	O	O
/	O	O	O
C	O	O	O
,	O	O	O
HR	O	O	B-Entity
=	O	O	O
12.96	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(CI)=3.08	O	O	O
-	O	O	O
54.61	O	O	O
,	O	O	O
P<0.001	O	O	O
;	O	O	O
T	O	O	O
T	O	O	O
vs.	O	O	O
C	O	O	O
/	O	O	O
T	O	O	O
+	O	O	O
C	O	O	O
/	O	O	O
C	O	O	O
,	O	O	O
HR	O	O	O
=	O	O	O
11.71	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
3.06	O	O	O
-	O	O	O
44.83	O	O	O
,	O	O	O
P<0.001	O	O	O
]	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
XRCC1	O	O	B-Entity
-	O	O	I-Entity
399	O	O	I-Entity
SNP	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
on	O	O	O
survival	O	O	B-Entity
time	O	O	I-Entity
(	O	O	O
P>0.05	O	O	O
)	O	O	O
.	O	O	O

XRCCl-399	O	O	B-Entity
SNP	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
short-term	O	O	B-Entity
therapeutic	O	O	B-Entity
efficacy	O	O	I-Entity
(	O	O	O
the	O	O	O
CR	O	O	B-Entity
rate	O	O	B-Entity
)	O	O	O
and	O	O	O
tumor	O	O	B-Entity
metastasis	O	O	I-Entity
/	O	O	O
relapse	O	O	B-Entity
in	O	O	O
ESCC	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
the	O	O	O
docetaxel	O	O	B-Entity
plus	O	O	I-Entity
cisplatin	O	O	I-Entity
(	O	O	I-Entity
TP	O	O	I-Entity
)	O	O	I-Entity
regimen	O	O	I-Entity
-based	O	O	O
concurrent	O	O	B-Entity
radiochemotherapy	O	O	I-Entity
.	O	O	O

By	O	O	O
contrast	O	O	O
,	O	O	O
ERCC1	O	O	B-Entity
-	O	O	I-Entity
118	O	O	I-Entity
SNP	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
short-term	O	O	B-Entity
therapeutic	O	O	B-Entity
efficacy	O	O	I-Entity
(	O	O	O
the	O	O	O
CR	O	O	B-Entity
rate	O	O	B-Entity
)	O	O	O
and	O	O	O
survival	O	O	B-Entity
time	O	O	I-Entity
in	O	O	O
ESCC	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
TP	O	O	B-Entity
regimen	O	O	I-Entity
-based	O	O	O
concurrent	O	O	B-Entity
radiochemotherapy	O	O	I-Entity
.	O	O	O

-DOCSTART- (28357725)

Ventricular	O	O	B-Entity
pacing	O	O	I-Entity
site	O	O	B-Entity
separation	O	O	I-Entity
by	O	O	O
cardiac	O	O	B-Entity
computed	O	O	B-Entity
tomography	O	O	I-Entity
:	O	O	O
validation	O	O	B-Entity
for	O	O	O
the	O	O	O
prediction	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
cardiac	O	O	O
resynchronization	O	O	O
therapy	O	O	O

Cardiac	O	O	B-Entity
Resynchronization	O	O	I-Entity
Therapy	O	O	I-Entity
(	O	O	O
CRT	O	O	B-Entity
)	O	O	O
fails	O	O	O
to	O	O	O
provide	O	O	B-Entity
benefit	O	O	B-Entity
in	O	O	O
up	O	O	O
to	O	O	O
one-third	O	O	O
of	O	O	O
patients	O	O	B-Entity
.	O	O	O

Maximizing	O	O	O
the	O	O	O
geographic	O	O	B-Entity
separation	O	O	I-Entity
of	O	O	O
right	O	O	B-Entity
and	O	O	O
left	O	O	B-Entity
ventricular	O	O	B-Entity
pacing	O	O	I-Entity
lead	O	O	B-Entity
sites	O	O	I-Entity
has	O	O	O
been	O	O	O
suggested	O	O	B-Entity
as	O	O	O
one	O	O	O
way	O	O	O
to	O	O	O
improve	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

Cardiac	O	O	B-Entity
CT	O	O	I-Entity
provides	O	O	B-Entity
an	O	O	O
opportunity	O	O	B-Entity
to	O	O	O
explore	O	O	O
3-dimensional	O	O	B-Entity
inter-lead	O	O	B-Entity
distance	O	O	I-Entity
(	O	O	O
ILD	O	O	B-Entity
)	O	O	O
measures	O	O	B-Entity
for	O	O	O
the	O	O	O
prediction	O	O	B-Entity
of	O	O	O
CRT	O	O	B-Entity
response	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
associations	O	O	B-Entity
between	O	O	O
standardized	O	O	B-Entity
measures	O	O	B-Entity
of	O	O	O
ILD	O	O	B-Entity
by	O	O	O
cardiac	O	O	B-Entity
CT	O	O	I-Entity
and	O	O	O
echocardiographic	O	O	B-Entity
response	O	O	B-Entity
to	O	O	O
CRT	O	O	B-Entity
.	O	O	O

Forty-two	O	O	O
consecutive	O	O	B-Entity
patients	O	O	B-Entity
undergoing	O	O	O
CRT	O	O	B-Entity
had	O	O	O
serial	O	O	O
clinical	O	O	B-Entity
and	O	O	O
echocardiographic	O	O	B-Entity
evaluations	O	O	B-Entity
performed	O	O	B-Entity
in	O	O	B-Entity
addition	O	O	I-Entity
to	O	O	I-Entity
a	O	O	O
post-procedural	O	O	B-Entity
cardiac	O	O	B-Entity
-gated	O	O	O
CT	O	O	B-Entity
with	O	O	O
blinded	O	O	B-Entity
measurement	O	O	B-Entity
of	O	O	O
direct	O	O	B-Entity
and	O	O	O
circumferential	O	O	B-Entity
(	O	O	O
via	O	O	O
the	O	O	O
myocardium	O	O	B-Entity
)	O	O	O
ILD	O	O	B-Entity
measures	O	O	B-Entity
.	O	O	O

Clinical	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
CRT	O	O	B-Entity
,	O	O	O
the	O	O	O
primary	O	O	B-Entity
clinical	O	O	I-Entity
outcome	O	O	I-Entity
,	O	O	O
was	O	O	O
defined	O	O	O
as	O	O	O
a	O	O	O
≥15	O	O	O
%	O	O	O
reduction	O	O	B-Entity
in	O	O	O
LVESV	O	O	B-Entity
using	O	O	O
echocardiography	O	O	B-Entity
at	O	O	O
6-months	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
age	O	O	I-Entity
and	O	O	O
ejection	O	O	B-Entity
fraction	O	O	I-Entity
was	O	O	O
63.6	O	O	O
±	O	O	O
8.9	O	O	O
years	O	O	O
and	O	O	O
25.2	O	O	O
±	O	O	O
7.8	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
occurred	O	O	B-Entity
in	O	O	O
35	O	O	O
of	O	O	O
42	O	O	O
patients	O	O	B-Entity
(	O	O	O
83	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Both	O	O	O
direct	O	O	B-Entity
and	O	O	O
circumferential	O	O	B-Entity
CT	O	O	B-Entity
-based	O	O	O
ILD	O	O	B-Entity
measures	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
by	O	O	O
univariate	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Receiver	O	O	B-Entity
Operator	O	O	I-Entity
Characteristic	O	O	I-Entity
analysis	O	O	B-Entity
identified	O	O	O
Circumferential	O	O	B-Entity
ILD	O	O	B-Entity
to	O	O	O
have	O	O	O
the	O	O	O
strongest	O	O	O
predictive	O	O	B-Entity
accuracy	O	O	B-Entity
(	O	O	O
AUC	O	O	O
0.78	O	O	O
)	O	O	O
.	O	O	O

Inter-	O	O	B-Entity
and	O	O	O
intra-observer	O	O	B-Entity
reproducibility	O	O	B-Entity
of	O	O	O
CT	O	O	B-Entity
-derived	O	O	O
ILD	O	O	B-Entity
measures	O	O	B-Entity
was	O	O	O
excellent	O	O	B-Entity
.	O	O	O

Circumferential	O	O	B-Entity
ILD	O	O	B-Entity
measures	O	O	B-Entity
on	O	O	O
cardiac	O	O	B-Entity
CT	O	O	I-Entity
are	O	O	O
predictive	O	O	B-Entity
of	O	O	O
clinical	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
CRT	O	O	B-Entity
.	O	O	O

Incorporation	O	O	B-Entity
of	O	O	O
these	O	O	O
measures	O	O	B-Entity
into	O	O	O
the	O	O	O
selection	O	O	B-Entity
of	O	O	O
optimal	O	O	B-Entity
pacing	O	O	B-Entity
targets	O	O	B-Entity
,	O	O	O
particularly	O	O	O
from	O	O	O
pre-procedural	O	O	B-Entity
CT	O	O	B-Entity
coronary	O	O	B-Entity
vein	O	O	I-Entity
imaging	O	O	B-Entity
may	O	O	O
be	O	O	O
of	O	O	O
therapeutic	O	O	B-Entity
benefit	O	O	B-Entity
and	O	O	O
warrants	O	O	O
further	O	O	O
investigation	O	O	B-Entity
.	O	O	O

-DOCSTART- (28358234)

Iodine	O	O	B-Entity
Storage	O	O	I-Entity
and	O	O	O
Metabolism	O	O	B-Entity
of	O	O	O
Mild	O	O	B-Entity
to	O	O	I-Entity
Moderate	O	O	I-Entity
Iodine-Deficient	O	O	B-Entity
Pregnant	O	O	B-Entity
Rats	O	O	O

Severe	O	O	B-Entity
iodine	O	O	I-Entity
deficiency	O	O	I-Entity
during	O	O	B-Entity
pregnancy	O	O	I-Entity
results	O	O	I-Entity
in	O	O	O
neurodevelopmental	O	O	B-Entity
disorders	O	O	I-Entity
in	O	O	O
children	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
consequences	O	O	B-Entity
of	O	O	I-Entity
mild	O	O	B-Entity
to	O	O	I-Entity
moderate	O	O	I-Entity
iodine	O	O	I-Entity
deficiency	O	O	I-Entity
(	O	O	O
MMID	O	O	B-Entity
)	O	O	O
are	O	O	O
uncertain	O	O	B-Entity
.	O	O	O

The	O	O	O
concentration	O	O	B-Entity
of	O	O	I-Entity
iodine	O	O	I-Entity
in	O	O	O
the	O	O	O
thyroid	O	O	B-Entity
is	O	O	O
the	O	O	O
most	O	O	O
accurate	O	O	O
indicator	O	O	O
of	O	O	O
iodine	O	O	B-Entity
nutrition	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aimed	O	O	O
to	O	O	O
evaluate	O	O	O
whether	O	O	O
the	O	O	O
iodine	O	O	B-Entity
stores	O	O	I-Entity
in	O	O	O
the	O	O	O
thyroid	O	O	B-Entity
cover	O	O	I-Entity
the	O	O	O
needs	O	O	O
of	O	O	O
the	O	O	O
mother	O	O	B-Entity
and	O	O	I-Entity
the	O	O	I-Entity
fetus	O	O	I-Entity
in	O	O	O
iodine	O	O	O
-	O	O	O
sufficient	O	O	B-Entity
and	O	O	O
MMID	O	O	B-Entity
conditions	O	O	O
by	O	O	O
inductively	O	O	B-Entity
coupled	O	O	I-Entity
plasma-mass	O	O	I-Entity
spectrometry	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
four-week-old	O	O	O
female	O	O	B-Entity
Wistar	O	O	I-Entity
rats	O	O	I-Entity
were	O	O	O
randomly	O	O	O
divided	O	O	O
into	O	O	O
MMID	O	O	B-Entity
(	O	O	O
low	O	O	B-Entity
iodine	O	O	I-Entity
intake	O	O	I-Entity
[	O	O	O
L	O	O	O
]	O	O	O
)	O	O	O
and	O	O	O
normal	O	O	B-Entity
(	O	O	O
normal	O	O	B-Entity
iodine	O	O	I-Entity
intake	O	O	I-Entity
[	O	O	O
N	O	O	O
]	O	O	O
)	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
rats	O	O	B-Entity
were	O	O	O
fed	O	O	B-Entity
for	O	O	I-Entity
the	O	O	I-Entity
next	O	O	I-Entity
three	O	O	I-Entity
months	O	O	I-Entity
,	O	O	O
and	O	O	O
after	O	O	B-Entity
pregnancy	O	O	B-Entity
they	O	O	O
were	O	O	O
further	O	O	O
divided	O	O	B-Entity
into	O	O	I-Entity
two	O	O	I-Entity
subgroups	O	O	I-Entity
,	O	O	O
respectively	O	O	O
:	O	O	O
low	O	O	B-Entity
iodine	O	O	I-Entity
pregnancy	O	O	O
(	O	O	O
LP	O	O	B-Entity
)	O	O	O
and	O	O	O
low	O	O	O
iodine	O	O	O
pregnancy	O	O	O
with	O	O	O
iodine	O	O	B-Entity
supplement	O	O	I-Entity
(	O	O	O
LP+	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
normal	O	O	B-Entity
iodine	O	O	I-Entity
intake	O	O	I-Entity
pregnancy	O	O	O
(	O	O	O
NP	O	O	B-Entity
)	O	O	O
and	O	O	O
normal	O	O	O
iodine	O	O	O
intake	O	O	O
pregnancy	O	O	O
with	O	O	O
iodine	O	O	O
supplement	O	O	O
(	O	O	O
NP+	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
iodine	O	O	B-Entity
intake	O	O	I-Entity
of	O	O	O
pregnant	O	O	B-Entity
rats	O	O	B-Entity
in	O	O	O
the	O	O	O
NP+	O	O	B-Entity
and	O	O	O
LP+	O	O	B-Entity
groups	O	O	I-Entity
was	O	O	O
twice	O	O	O
as	O	O	O
much	O	O	O
as	O	O	O
in	O	O	O
the	O	O	O
NP	O	O	B-Entity
and	O	O	O
LP	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
rats	O	O	B-Entity
were	O	O	O
sacrificed	O	O	O
on	O	O	O
gestational	O	O	B-Entity
day	O	O	I-Entity
15	O	O	O
and	O	O	O
postnatal	O	O	B-Entity
day	O	O	I-Entity
7	O	O	O
.	O	O	O

The	O	O	O
iodine	O	O	B-Entity
concentration	O	O	I-Entity
in	O	O	O
the	O	O	O
thyroid	O	O	B-Entity
of	O	O	O
the	O	O	O
maternal	O	O	B-Entity
and	O	O	O
newborn	O	O	B-Entity
rats	O	O	B-Entity
,	O	O	O
maternal	O	O	B-Entity
serum	O	O	I-Entity
,	O	O	O
placenta	O	O	B-Entity
,	O	O	O
and	O	O	O
amniotic	O	O	B-Entity
fluid	O	O	I-Entity
were	O	O	O
determined	O	O	O
by	O	O	O
inductively	O	O	B-Entity
coupled	O	O	I-Entity
plasma-mass	O	O	I-Entity
spectrometry	O	O	I-Entity
.	O	O	O

The	O	O	O
concentration	O	O	B-Entity
of	O	O	I-Entity
iodine	O	O	I-Entity
in	O	O	O
the	O	O	O
thyroid	O	O	B-Entity
of	O	O	O
the	O	O	O
N	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
than	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
L	O	O	B-Entity
group	O	O	I-Entity
before	O	O	B-Entity
pregnancy	O	O	I-Entity
.	O	O	O

The	O	O	O
concentration	O	O	B-Entity
of	O	O	I-Entity
iodine	O	O	I-Entity
in	O	O	O
the	O	O	O
maternal	O	O	B-Entity
thyroids	O	O	I-Entity
of	O	O	O
the	O	O	O
LP	O	O	B-Entity
group	O	O	I-Entity
decreased	O	O	O
during	O	O	B-Entity
pregnancy	O	O	I-Entity
,	O	O	O
whereas	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
NP	O	O	B-Entity
group	O	O	I-Entity
did	O	O	O
not	O	O	O
change	O	O	O
significantly	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
the	O	O	O
iodine	O	O	B-Entity
concentration	O	O	I-Entity
in	O	O	O
the	O	O	O
thyroid	O	O	B-Entity
of	O	O	O
mothers	O	O	B-Entity
and	O	O	O
offspring	O	O	B-Entity
between	O	O	O
the	O	O	O
NP	O	O	B-Entity
and	O	O	O
NP+	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
but	O	O	O
it	O	O	O
was	O	O	O
significant	O	O	O
between	O	O	O
LP	O	O	B-Entity
and	O	O	O
LP+	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

The	O	O	O
concentration	O	O	B-Entity
of	O	O	I-Entity
iodine	O	O	I-Entity
in	O	O	O
amniotic	O	O	B-Entity
fluid	O	O	I-Entity
was	O	O	O
significantly	O	O	O
different	O	O	O
between	O	O	O
the	O	O	O
four	O	O	O
groups	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
sufficient	O	O	O
iodine	O	O	B-Entity
storage	O	O	I-Entity
in	O	O	O
the	O	O	O
thyroid	O	O	B-Entity
of	O	O	O
maternal	O	O	B-Entity
rats	O	O	B-Entity
with	O	O	O
normal	O	O	B-Entity
iodine	O	O	I-Entity
intake	O	O	I-Entity
during	O	O	B-Entity
pregnancy	O	O	I-Entity
,	O	O	O
and	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
need	O	O	O
for	O	O	O
iodine	O	O	B-Entity
supplementation	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
iodine	O	O	B-Entity
stores	O	O	I-Entity
are	O	O	O
insufficient	O	O	O
in	O	O	O
rats	O	O	B-Entity
with	O	O	O
MMID	O	O	B-Entity
.	O	O	O

Iodine	O	O	B-Entity
supplementation	O	O	I-Entity
can	O	O	O
increase	O	O	O
the	O	O	O
iodine	O	O	B-Entity
concentration	O	O	I-Entity
in	O	O	O
the	O	O	O
thyroid	O	O	B-Entity
of	O	O	O
maternal	O	O	B-Entity
rats	O	O	B-Entity
with	O	O	O
MMID	O	O	B-Entity
and	O	O	O
their	O	O	O
offspring	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
the	O	O	O
amniotic	O	O	B-Entity
fluid	O	O	I-Entity
during	O	O	B-Entity
pregnancy	O	O	I-Entity
.	O	O	O

-DOCSTART- (28359664)

Omega	O	O	B-Entity
3	O	O	I-Entity
Fatty	O	O	I-Entity
Acids	O	O	I-Entity
Reduce	O	O	B-Entity
Bone	O	O	B-Entity
Resorption	O	O	I-Entity
While	O	O	O
Promoting	O	O	B-Entity
Bone	O	O	I-Entity
Generation	O	O	I-Entity
in	O	O	O
Rat	O	O	B-Entity
Apical	O	O	O
Periodontitis	O	O	O

This	O	O	O
study	O	O	O
evaluated	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
dietary	O	O	B-Entity
supplement	O	O	I-Entity
omega	O	O	B-Entity
3	O	O	I-Entity
polyunsaturated	O	O	I-Entity
fatty	O	O	I-Entity
acids	O	O	I-Entity
(	O	O	O
ω-3	O	O	B-Entity
PUFAs	O	O	I-Entity
)	O	O	O
on	O	O	O
pulp	O	O	B-Entity
exposure	O	O	I-Entity
-induced	O	O	O
apical	O	O	B-Entity
periodontitis	O	O	I-Entity
(	O	O	O
AP	O	O	B-Entity
)	O	O	O
in	O	O	O
rats	O	O	B-Entity
.	O	O	O

Twenty-eight	O	O	O
male	O	O	B-Entity
rats	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
groups	O	O	B-Entity
:	O	O	O
control	O	O	O
untreated	O	O	B-Entity
rats	O	O	O
(	O	O	O
C	O	O	O
)	O	O	O
,	O	O	O
control	O	O	O
rats	O	O	O
treated	O	O	B-Entity
with	O	O	I-Entity
ω-3	O	O	B-Entity
PUFAs	O	O	I-Entity
alone	O	O	O
(	O	O	O
C-O	O	O	O
)	O	O	O
,	O	O	O
rats	O	O	O
with	O	O	O
pulp	O	O	B-Entity
exposure	O	O	I-Entity
-induced	O	O	O
AP	O	O	B-Entity
,	O	O	O
and	O	O	O
rats	O	O	O
with	O	O	O
pulp	O	O	O
exposure	O	O	O
-induced	O	O	O
AP	O	O	O
treated	O	O	O
with	O	O	O
ω-3	O	O	O
PUFAs	O	O	O
(	O	O	O
AP	O	O	O
-O	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
ω-3	O	O	B-Entity
PUFAs	O	O	I-Entity
were	O	O	O
administered	O	O	B-Entity
orally	O	O	I-Entity
,	O	O	O
once	O	O	O
a	O	O	O
day	O	O	O
,	O	O	O
for	O	O	O
15	O	O	O
days	O	O	O
before	O	O	O
pulp	O	O	B-Entity
exposure	O	O	I-Entity
and	O	O	O
,	O	O	O
subsequently	O	O	O
,	O	O	O
30	O	O	O
days	O	O	O
after	O	O	O
pulp	O	O	O
exposure	O	O	O
.	O	O	O

Rats	O	O	B-Entity
were	O	O	O
killed	O	O	B-Entity
30	O	O	O
days	O	O	O
after	O	O	O
pulp	O	O	B-Entity
exposure	O	O	I-Entity
,	O	O	O
and	O	O	O
jaws	O	O	B-Entity
were	O	O	O
subjected	O	O	O
to	O	O	O
histologic	O	O	B-Entity
and	O	O	O
immunohistochemical	O	O	B-Entity
analyses	O	O	B-Entity
.	O	O	O

Immunohistochemical	O	O	B-Entity
analyses	O	O	B-Entity
were	O	O	O
performed	O	O	O
to	O	O	O
detect	O	O	O
tartrate-resistant	O	O	B-Entity
acid	O	O	I-Entity
phosphatase	O	O	I-Entity
-	O	O	O
positive	O	O	B-Entity
osteoclasts	O	O	B-Entity
and	O	O	O
osteocalcin	O	O	B-Entity
-	O	O	O
positive	O	O	O
osteoblasts	O	O	B-Entity
on	O	O	O
the	O	O	O
bone	O	O	B-Entity
surface	O	O	I-Entity
of	O	O	O
periapical	O	O	B-Entity
area	O	O	I-Entity
.	O	O	O

Results	O	O	O
were	O	O	O
statistically	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
using	O	O	O
analysis	O	O	B-Entity
of	O	O	I-Entity
variance	O	O	I-Entity
and	O	O	O
Tukey	O	O	B-Entity
honestly	O	O	I-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
,	O	O	O
and	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
was	O	O	O
considered	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
.	O	O	O

The	O	O	O
bone	O	O	B-Entity
resorption	O	O	I-Entity
lesion	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
larger	O	O	I-Entity
in	O	O	O
the	O	O	O
AP	O	O	B-Entity
group	O	O	O
compared	O	O	O
with	O	O	O
AP	O	O	O
-O	O	O	O
,	O	O	O
C	O	O	O
,	O	O	O
and	O	O	O
C-O	O	O	O
groups	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
level	O	O	B-Entity
of	O	O	O
inflammatory	O	O	B-Entity
cell	O	O	I-Entity
infiltration	O	O	I-Entity
was	O	O	O
significantly	O	O	O
elevated	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
tartrate-resistant	O	O	B-Entity
acid	O	O	I-Entity
phosphatase	O	O	I-Entity
-	O	O	O
positive	O	O	B-Entity
osteoclasts	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
in	O	O	O
the	O	O	O
periapical	O	O	B-Entity
lesions	O	O	B-Entity
of	O	O	O
the	O	O	O
AP	O	O	B-Entity
group	O	O	O
compared	O	O	O
with	O	O	O
AP	O	O	O
-O	O	O	O
,	O	O	O
C	O	O	O
,	O	O	O
and	O	O	O
C-O	O	O	O
groups	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
number	O	O	O
of	O	O	O
osteocalcin	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
osteoblasts	O	O	B-Entity
was	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
the	O	O	O
AP	O	O	B-Entity
-O	O	O	O
group	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
AP	O	O	O
group	O	O	O
(	O	O	O
P	O	O	O
>	O	O	O
.05	O	O	O
)	O	O	O
.	O	O	O

Supplementation	O	O	B-Entity
with	O	O	O
ω-3	O	O	B-Entity
PUFAs	O	O	I-Entity
not	O	O	O
only	O	O	O
suppresses	O	O	B-Entity
bone	O	O	B-Entity
resorption	O	O	I-Entity
but	O	O	O
also	O	O	O
promotes	O	O	B-Entity
new	O	O	I-Entity
bone	O	O	I-Entity
formation	O	O	I-Entity
in	O	O	O
the	O	O	O
periapical	O	O	B-Entity
area	O	O	I-Entity
of	O	O	O
rats	O	O	B-Entity
with	O	O	O
AP	O	O	B-Entity
in	O	O	O
conjunction	O	O	B-Entity
with	O	O	O
downregulation	O	O	B-Entity
of	O	O	O
inflammatory	O	O	B-Entity
cell	O	O	I-Entity
infiltration	O	O	I-Entity
into	O	O	O
the	O	O	O
lesion	O	O	B-Entity
.	O	O	O

-DOCSTART- (28360843)

MagR	O	O	B-Entity
Alone	O	O	O
Is	O	O	O
Insufficient	O	O	B-Entity
to	O	O	O
Confer	O	O	O
Cellular	O	O	B-Entity
Calcium	O	O	I-Entity
Responses	O	O	I-Entity
to	O	O	O
Magnetic	O	O	B-Entity
Stimulation	O	O	O

Magnetic	O	O	B-Entity
manipulation	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
activity	O	O	I-Entity
offers	O	O	O
advantages	O	O	B-Entity
over	O	O	O
optical	O	O	B-Entity
manipulation	O	O	I-Entity
but	O	O	O
an	O	O	O
ideal	O	O	O
tool	O	O	O
remains	O	O	O
elusive	O	O	O
.	O	O	O

The	O	O	O
MagR	O	O	B-Entity
protein	O	O	B-Entity
was	O	O	O
found	O	O	O
through	O	O	O
its	O	O	O
interaction	O	O	B-Entity
with	O	O	O
cryptochrome	O	O	B-Entity
(	O	O	O
Cry	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
protein	O	O	O
in	O	O	O
solution	O	O	B-Entity
appeared	O	O	O
to	O	O	O
respond	O	O	B-Entity
to	O	O	O
magnetic	O	O	B-Entity
stimulation	O	O	B-Entity
(	O	O	O
MS	O	O	B-Entity
)	O	O	O
.	O	O	O

After	O	O	O
we	O	O	O
initiated	O	O	O
an	O	O	O
investigation	O	O	B-Entity
on	O	O	O
the	O	O	O
specific	O	O	O
role	O	O	B-Entity
of	O	O	O
MagR	O	O	B-Entity
in	O	O	O
cellular	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
MS	O	O	B-Entity
,	O	O	O
a	O	O	O
subsequent	O	O	O
study	O	O	B-Entity
claimed	O	O	O
that	O	O	O
MagR	O	O	O
expression	O	O	B-Entity
alone	O	O	O
could	O	O	O
achieve	O	O	O
cellular	O	O	B-Entity
activation	O	O	I-Entity
by	O	O	O
MS	O	O	O
.	O	O	O

Here	O	O	O
we	O	O	O
report	O	O	O
that	O	O	O
despite	O	O	O
systematically	O	O	B-Entity
testing	O	O	B-Entity
different	O	O	O
ways	O	O	O
of	O	O	O
measuring	O	O	B-Entity
intracellular	O	O	B-Entity
calcium	O	O	B-Entity
and	O	O	O
different	O	O	O
MS	O	O	B-Entity
protocols	O	O	B-Entity
,	O	O	O
it	O	O	O
was	O	O	O
not	O	O	O
possible	O	O	O
to	O	O	O
detect	O	O	B-Entity
any	O	O	O
cellular	O	O	B-Entity
or	O	O	O
neuronal	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
MS	O	O	O
in	O	O	O
MagR	O	O	B-Entity
-	O	O	O
expressing	O	O	B-Entity
HEK	O	O	B-Entity
cells	O	O	I-Entity
or	O	O	O
primary	O	O	B-Entity
neurons	O	O	B-Entity
from	O	O	O
the	O	O	O
dorsal	O	O	B-Entity
root	O	O	B-Entity
ganglion	O	O	I-Entity
and	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
.	O	O	O

By	O	O	O
contrast	O	O	O
,	O	O	O
in	O	O	O
neurons	O	O	B-Entity
co-expressing	O	O	B-Entity
MagR	O	O	B-Entity
and	O	O	O
channelrhodopin	O	O	B-Entity
,	O	O	O
optical	O	O	B-Entity
but	O	O	O
not	O	O	O
MS	O	O	B-Entity
increased	O	O	B-Entity
calcium	O	O	B-Entity
influx	O	O	I-Entity
in	O	O	O
hippocampal	O	O	B-Entity
neurons	O	O	O
.	O	O	O

Our	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
MagR	O	O	B-Entity
alone	O	O	O
is	O	O	O
not	O	O	B-Entity
sufficient	O	O	I-Entity
to	O	O	O
confer	O	O	O
cellular	O	O	B-Entity
magnetic	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

-DOCSTART- (28361230)

Acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
and	O	O	O
fluid	O	O	B-Entity
overload	O	O	I-Entity
in	O	O	O
infants	O	O	B-Entity
and	O	O	O
children	O	O	B-Entity
after	O	O	O
cardiac	O	O	O
surgery	O	O	O

Acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
is	O	O	O
a	O	O	O
common	O	O	O
and	O	O	O
serious	O	O	B-Entity
complication	O	O	B-Entity
after	O	O	O
congenital	O	O	B-Entity
heart	O	O	I-Entity
surgery	O	O	I-Entity
,	O	O	O
particularly	O	O	O
among	O	O	O
infants	O	O	B-Entity
.	O	O	O

This	O	O	O
comorbidity	O	O	B-Entity
has	O	O	O
been	O	O	O
independently	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
adverse	O	O	B-Entity
outcomes	O	O	I-Entity
including	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
mortality	O	O	B-Entity
.	O	O	O

Postoperative	O	O	B-Entity
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
has	O	O	O
a	O	O	O
complex	O	O	O
pathophysiology	O	O	B-Entity
with	O	O	O
many	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
and	O	O	O
therefore	O	O	O
no	O	O	B-Entity
single	O	O	I-Entity
medication	O	O	I-Entity
or	O	O	O
therapy	O	O	B-Entity
has	O	O	O
been	O	O	O
demonstrated	O	O	O
to	O	O	O
be	O	O	O
effective	O	O	B-Entity
for	O	O	O
treatment	O	O	B-Entity
or	O	O	O
prevention	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
established	O	O	O
that	O	O	O
the	O	O	O
associated	O	O	O
fluid	O	O	B-Entity
overload	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
major	O	O	O
determinants	O	O	B-Entity
of	O	O	O
morbidity	O	O	B-Entity
,	O	O	O
particularly	O	O	O
in	O	O	O
infants	O	O	B-Entity
after	O	O	O
cardiac	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
an	O	O	O
intervention	O	O	B-Entity
to	O	O	O
prevent	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
,	O	O	O
much	O	O	O
of	O	O	O
the	O	O	O
effort	O	O	O
to	O	O	O
improve	O	O	B-Entity
outcomes	O	O	B-Entity
has	O	O	O
focused	O	O	O
on	O	O	O
treating	O	O	B-Entity
and	O	O	O
preventing	O	O	B-Entity
fluid	O	O	B-Entity
overload	O	O	I-Entity
.	O	O	O

Early	O	O	B-Entity
renal	O	O	B-Entity
replacement	O	O	I-Entity
therapy	O	O	I-Entity
,	O	O	O
often	O	O	O
in	O	O	O
the	O	O	O
form	O	O	O
of	O	O	O
peritoneal	O	O	B-Entity
dialysis	O	O	I-Entity
,	O	O	O
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
safe	O	O	B-Entity
and	O	O	O
beneficial	O	O	B-Entity
in	O	O	O
infants	O	O	B-Entity
with	O	O	O
oliguria	O	O	B-Entity
after	O	O	O
heart	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

As	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
of	O	O	O
acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
and	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
confidently	O	O	O
diagnose	O	O	B-Entity
it	O	O	O
earlier	O	O	O
continues	O	O	O
to	O	O	O
evolve	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
likely	O	O	O
that	O	O	O
novel	O	O	O
preventative	O	O	B-Entity
and	O	O	O
therapeutic	O	O	B-Entity
interventions	O	O	I-Entity
will	O	O	O
be	O	O	O
available	O	O	O
in	O	O	O
the	O	O	O
future	O	O	O
.	O	O	O

-DOCSTART- (28362102)

Systems	O	O	B-Entity
Toxicology	O	O	B-Entity
:	O	O	O
Real	O	O	O
World	O	O	B-Entity
Applications	O	O	B-Entity
and	O	O	O
Opportunities	O	O	O

Systems	O	O	B-Entity
Toxicology	O	O	B-Entity
aims	O	O	O
to	O	O	O
change	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
how	O	O	O
adverse	O	O	B-Entity
biological	O	O	I-Entity
effects	O	O	I-Entity
of	O	O	O
xenobiotics	O	O	B-Entity
are	O	O	O
characterized	O	O	B-Entity
from	O	O	O
empirical	O	O	B-Entity
end	O	O	B-Entity
points	O	O	I-Entity
to	O	O	O
describing	O	O	O
modes	O	O	B-Entity
of	O	O	O
action	O	O	B-Entity
as	O	O	O
adverse	O	O	O
outcome	O	O	B-Entity
pathways	O	O	B-Entity
and	O	O	O
perturbed	O	O	B-Entity
networks	O	O	I-Entity
.	O	O	O

Toward	O	O	O
this	O	O	O
aim	O	O	O
,	O	O	O
Systems	O	O	B-Entity
Toxicology	O	O	B-Entity
entails	O	O	O
the	O	O	O
integration	O	O	B-Entity
of	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
toxicity	O	O	B-Entity
data	O	O	B-Entity
with	O	O	O
computational	O	O	B-Entity
modeling	O	O	I-Entity
.	O	O	O

This	O	O	O
evolving	O	O	O
approach	O	O	B-Entity
depends	O	O	O
critically	O	O	O
on	O	O	O
data	O	O	B-Entity
reliability	O	O	B-Entity
and	O	O	O
relevance	O	O	B-Entity
,	O	O	O
which	O	O	O
in	O	O	O
turn	O	O	O
depends	O	O	O
on	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
experimental	O	O	B-Entity
models	O	O	I-Entity
and	O	O	O
bioanalysis	O	O	B-Entity
techniques	O	O	I-Entity
used	O	O	O
to	O	O	O
generate	O	O	O
toxicological	O	O	B-Entity
data	O	O	O
.	O	O	O

Systems	O	O	B-Entity
Toxicology	O	O	B-Entity
involves	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
large-scale	O	O	O
data	O	O	B-Entity
streams	O	O	I-Entity
(	O	O	O
"	O	O	O
big	O	O	O
data	O	O	O
"	O	O	O
)	O	O	O
,	O	O	O
such	O	O	O
as	O	O	O
those	O	O	O
derived	O	O	O
from	O	O	O
omics	O	O	B-Entity
measurements	O	O	I-Entity
that	O	O	O
require	O	O	O
computational	O	O	B-Entity
means	O	O	O
for	O	O	O
obtaining	O	O	O
informative	O	O	B-Entity
results	O	O	B-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
integrative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
multiple	O	O	B-Entity
molecular	O	O	B-Entity
measurements	O	O	I-Entity
,	O	O	O
particularly	O	O	O
acquired	O	O	O
by	O	O	O
omics	O	O	B-Entity
strategies	O	O	I-Entity
,	O	O	O
is	O	O	O
a	O	O	O
key	O	O	O
approach	O	O	B-Entity
in	O	O	O
Systems	O	O	B-Entity
Toxicology	O	O	B-Entity
.	O	O	O

In	O	O	O
recent	O	O	O
years	O	O	O
,	O	O	O
there	O	O	O
have	O	O	O
been	O	O	O
significant	O	O	O
advances	O	O	O
centered	O	O	O
on	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
test	O	O	O
systems	O	O	O
and	O	O	O
bioanalytical	O	O	B-Entity
strategies	O	O	I-Entity
,	O	O	O
yet	O	O	O
a	O	O	O
frontier	O	O	O
challenge	O	O	O
concerns	O	O	O
linking	O	O	B-Entity
observed	O	O	O
network	O	O	B-Entity
perturbations	O	O	B-Entity
to	O	O	O
phenotypes	O	O	B-Entity
,	O	O	O
which	O	O	O
will	O	O	O
require	O	O	O
understanding	O	O	O
pathways	O	O	B-Entity
and	O	O	O
networks	O	O	B-Entity
that	O	O	O
give	O	O	O
rise	O	O	O
to	O	O	O
adverse	O	O	B-Entity
responses	O	O	I-Entity
.	O	O	O

This	O	O	O
summary	O	O	B-Entity
perspective	O	O	O
from	O	O	O
a	O	O	O
2016	O	O	O
Systems	O	O	B-Entity
Toxicology	O	O	B-Entity
meeting	O	O	B-Entity
,	O	O	O
an	O	O	O
international	O	O	B-Entity
conference	O	O	I-Entity
held	O	O	O
in	O	O	O
the	O	O	O
Alps	O	O	B-Entity
of	O	O	O
Switzerland	O	O	B-Entity
,	O	O	O
describes	O	O	O
the	O	O	O
limitations	O	O	B-Entity
and	O	O	O
opportunities	O	O	B-Entity
of	O	O	O
selected	O	O	O
emerging	O	O	O
applications	O	O	B-Entity
in	O	O	O
this	O	O	O
rapidly	O	O	O
advancing	O	O	O
field	O	O	O
.	O	O	O

Systems	O	O	B-Entity
Toxicology	O	O	B-Entity
aims	O	O	O
to	O	O	O
change	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
how	O	O	O
adverse	O	O	B-Entity
biological	O	O	I-Entity
effects	O	O	I-Entity
of	O	O	O
xenobiotics	O	O	B-Entity
are	O	O	O
characterized	O	O	B-Entity
,	O	O	O
from	O	O	O
empirical	O	O	B-Entity
end	O	O	B-Entity
points	O	O	I-Entity
to	O	O	O
pathways	O	O	B-Entity
of	O	O	O
toxicity	O	O	B-Entity
.	O	O	O

This	O	O	O
requires	O	O	O
the	O	O	O
integration	O	O	B-Entity
of	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
data	O	O	B-Entity
with	O	O	O
computational	O	O	B-Entity
modeling	O	O	I-Entity
.	O	O	O

Test	O	O	O
systems	O	O	O
and	O	O	O
bioanalytical	O	O	B-Entity
technologies	O	O	I-Entity
have	O	O	O
made	O	O	O
significant	O	O	O
advances	O	O	O
,	O	O	O
but	O	O	O
ensuring	O	O	O
data	O	O	B-Entity
reliability	O	O	B-Entity
and	O	O	O
relevance	O	O	B-Entity
is	O	O	O
an	O	O	O
ongoing	O	O	O
concern	O	O	O
.	O	O	O

The	O	O	O
major	O	O	O
challenge	O	O	O
facing	O	O	O
the	O	O	O
new	O	O	O
pathway	O	O	B-Entity
approach	O	O	B-Entity
is	O	O	O
determining	O	O	O
how	O	O	O
to	O	O	O
link	O	O	B-Entity
observed	O	O	O
network	O	O	B-Entity
perturbations	O	O	B-Entity
to	O	O	O
phenotypic	O	O	B-Entity
toxicity	O	O	B-Entity
.	O	O	O

-DOCSTART- (28363626)

Validating	O	O	B-Entity
Signs	O	O	B-Entity
and	O	O	I-Entity
Symptoms	O	O	I-Entity
From	O	O	O
An	O	O	O
Actual	O	O	O
Mass	O	O	B-Entity
Casualty	O	O	I-Entity
Incident	O	O	I-Entity
to	O	O	O
Characterize	O	O	B-Entity
An	O	O	O
Irritant	O	O	B-Entity
Gas	O	O	I-Entity
Syndrome	O	O	I-Entity
Agent	O	O	I-Entity
(	O	O	O
IGSA	O	O	B-Entity
)	O	O	O
Exposure	O	O	O
:	O	O	O
A	O	O	O
First	O	O	O
Step	O	O	O
in	O	O	O
The	O	O	O
Development	O	O	B-Entity
of	O	O	O
a	O	O	O
Novel	O	O	B-Entity
IGSA	O	O	O
Triage	O	O	B-Entity
Algorithm	O	O	O

Chemical	O	O	B-Entity
exposures	O	O	I-Entity
can	O	O	O
pose	O	O	O
a	O	O	O
significant	O	O	B-Entity
threat	O	O	B-Entity
to	O	O	O
life	O	O	B-Entity
.	O	O	O

Rapid	O	O	O
assessment	O	O	B-Entity
by	O	O	O
first	O	O	B-Entity
responders	O	O	I-Entity
/	O	O	O
emergency	O	O	B-Entity
nurses	O	O	I-Entity
is	O	O	O
required	O	O	B-Entity
to	O	O	O
reduce	O	O	B-Entity
death	O	O	B-Entity
and	O	O	O
disability	O	O	B-Entity
.	O	O	O

Currently	O	O	O
,	O	O	O
no	O	O	B-Entity
informatics	O	O	B-Entity
tools	O	O	I-Entity
for	O	O	O
irritant	O	O	B-Entity
gas	O	O	I-Entity
syndrome	O	O	I-Entity
agent	O	O	I-Entity
s	O	O	O
(	O	O	O
IGSA	O	O	B-Entity
)	O	O	O
exposures	O	O	B-Entity
exist	O	O	B-Entity
to	O	O	O
process	O	O	B-Entity
victims	O	O	B-Entity
efficiently	O	O	B-Entity
,	O	O	O
continuously	O	O	B-Entity
monitor	O	O	B-Entity
for	O	O	O
latent	O	O	B-Entity
signs/symptoms	O	O	B-Entity
,	O	O	O
or	O	O	O
make	O	O	O
triage	O	O	B-Entity
recommendations	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
describes	O	O	O
the	O	O	O
first	O	O	O
step	O	O	O
in	O	O	O
developing	O	O	O
ED	O	O	B-Entity
informatics	O	O	B-Entity
tools	O	O	I-Entity
for	O	O	O
chemical	O	O	B-Entity
incidents	O	O	I-Entity
:	O	O	O
validation	O	O	B-Entity
of	O	O	O
signs/symptoms	O	O	B-Entity
that	O	O	O
characterize	O	O	B-Entity
an	O	O	O
IGSA	O	O	B-Entity
syndrome	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
abstracted	O	O	I-Entity
from	O	O	O
146	O	O	O
patients	O	O	B-Entity
treated	O	O	B-Entity
for	O	O	O
chlorine	O	O	B-Entity
exposure	O	O	I-Entity
in	O	O	O
one	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
during	O	O	B-Entity
a	O	O	O
2005	O	O	O
train	O	O	B-Entity
derailment	O	O	I-Entity
and	O	O	O
152	O	O	O
patients	O	O	O
not	O	O	B-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
chlorine	O	O	I-Entity
(	O	O	O
a	O	O	O
comparison	O	O	B-Entity
group	O	O	I-Entity
)	O	O	O
were	O	O	O
mapped	O	O	B-Entity
to	O	O	O
93	O	O	O
possible	O	O	O
signs/symptoms	O	O	B-Entity
within	O	O	O
2	O	O	O
tools	O	O	B-Entity
(	O	O	O
WISER	O	O	B-Entity
and	O	O	O
CHEMM-IST	O	O	B-Entity
)	O	O	O
designed	O	O	B-Entity
to	O	O	O
assist	O	O	B-Entity
emergency	O	O	B-Entity
responders	O	O	I-Entity
/	O	O	O
emergency	O	O	B-Entity
nurses	O	O	I-Entity
with	O	O	O
managing	O	O	O
hazardous	O	O	B-Entity
material	O	O	I-Entity
exposures	O	O	B-Entity
.	O	O	O

Inferential	O	O	B-Entity
statistics	O	O	I-Entity
(	O	O	O
χ(2)/	O	O	O
Fisher	O	O	B-Entity
's	O	O	I-Entity
exact	O	O	I-Entity
test	O	O	I-Entity
)	O	O	O
and	O	O	O
diagnostics	O	O	B-Entity
tests	O	O	I-Entity
were	O	O	O
used	O	O	B-Entity
to	O	O	O
examine	O	O	O
mapped	O	O	B-Entity
signs/symptoms	O	O	B-Entity
of	O	O	O
persons	O	O	B-Entity
who	O	O	O
were	O	O	O
and	O	O	O
were	O	O	O
not	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
chlorine	O	O	I-Entity
.	O	O	O

Three	O	O	O
clusters	O	O	B-Entity
of	O	O	O
signs/symptoms	O	O	B-Entity
are	O	O	O
statistically	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
IGSA	O	O	B-Entity
syndrome	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.01	O	O	O
):	O	O	O
respiratory	O	O	B-Entity
(	O	O	O
shortness	O	O	B-Entity
of	O	O	I-Entity
breath	O	O	I-Entity
,	O	O	O
wheezing	O	O	B-Entity
,	O	O	O
coughing	O	O	B-Entity
,	O	O	O
and	O	O	O
choking	O	O	B-Entity
)	O	O	O
;	O	O	O
chest	O	O	B-Entity
discomfort	O	O	I-Entity
(	O	O	O
tightness	O	O	B-Entity
,	O	O	O
pain	O	O	B-Entity
,	O	O	O
and	O	O	O
burning	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
eye	O	O	B-Entity
,	O	O	O
nose	O	O	B-Entity
and/or	O	O	O
throat	O	O	B-Entity
(	O	O	O
pain	O	O	O
,	O	O	O
irritation	O	O	B-Entity
,	O	O	O
and	O	O	O
burning	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
syndrome	O	O	B-Entity
requires	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
signs/symptoms	O	O	B-Entity
from	O	O	O
at	O	O	O
least	O	O	O
2	O	O	O
of	O	O	O
these	O	O	O
clusters	O	O	B-Entity
.	O	O	O

The	O	O	O
latency	O	O	B-Entity
period	O	O	I-Entity
must	O	O	O
also	O	O	O
be	O	O	O
considered	O	O	B-Entity
for	O	O	O
exposed	O	O	B-Entity
/	O	O	O
potentially	O	O	B-Entity
exposed	O	O	B-Entity
persons	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
uses	O	O	B-Entity
actual	O	O	O
patient	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
a	O	O	O
chemical	O	O	B-Entity
incident	O	O	I-Entity
to	O	O	O
characterize	O	O	B-Entity
and	O	O	O
validate	O	O	B-Entity
signs/symptoms	O	O	B-Entity
of	O	O	O
an	O	O	O
IGSA	O	O	B-Entity
syndrome	O	O	B-Entity
.	O	O	O

Validating	O	O	B-Entity
signs/symptoms	O	O	B-Entity
is	O	O	O
the	O	O	O
first	O	O	O
step	O	O	O
in	O	O	O
developing	O	O	O
new	O	O	B-Entity
ED	O	O	B-Entity
informatics	O	O	B-Entity
tools	O	O	I-Entity
with	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
revolutionize	O	O	O
the	O	O	O
process	O	O	B-Entity
by	O	O	O
which	O	O	O
emergency	O	O	B-Entity
nurses	O	O	I-Entity
manage	O	O	O
triage	O	O	B-Entity
victims	O	O	B-Entity
of	O	O	O
chemical	O	O	B-Entity
incidents	O	O	I-Entity
.	O	O	O

-DOCSTART- (28363782)

Fyn	O	O	B-Entity
regulates	O	O	O
multipolar	O	O	B-Entity
-	O	O	O
bipolar	O	O	B-Entity
transition	O	O	B-Entity
and	O	O	O
neurite	O	O	B-Entity
morphogenesis	O	O	I-Entity
of	O	O	O
migrating	O	O	B-Entity
neurons	O	O	I-Entity
in	O	O	O
the	O	O	O
developing	O	O	O
neocortex	O	O	O

Fyn	O	O	B-Entity
is	O	O	O
a	O	O	O
non-receptor	O	O	B-Entity
protein	O	O	B-Entity
tyrosine	O	O	I-Entity
kinase	O	O	I-Entity
that	O	O	O
belongs	O	O	O
to	O	O	O
Src	O	O	B-Entity
family	O	O	I-Entity
kinases	O	O	I-Entity
.	O	O	O

Fyn	O	O	B-Entity
plays	O	O	O
a	O	O	O
critical	O	O	O
role	O	O	O
in	O	O	O
neuronal	O	O	B-Entity
migration	O	O	I-Entity
,	O	O	O
but	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
remains	O	O	O
unclear	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
reported	O	O	O
that	O	O	O
suppression	O	O	B-Entity
of	O	O	O
Fyn	O	O	B-Entity
expression	O	O	B-Entity
in	O	O	O
mouse	O	O	B-Entity
cerebral	O	O	I-Entity
cortex	O	O	I-Entity
led	O	O	O
to	O	O	O
migration	O	O	B-Entity
defects	O	O	I-Entity
of	O	O	O
both	O	O	O
early-born	O	O	B-Entity
and	O	O	O
late-born	O	O	B-Entity
neurons	O	O	B-Entity
.	O	O	O

Morphological	O	O	B-Entity
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
loss	O	O	O
of	O	O	O
Fyn	O	O	B-Entity
function	O	O	O
impaired	O	O	O
multipolar	O	O	B-Entity
-	O	O	O
bipolar	O	O	B-Entity
transition	O	O	B-Entity
of	O	O	O
newly	O	O	O
generated	O	O	B-Entity
neurons	O	O	B-Entity
and	O	O	O
neurite	O	O	B-Entity
formation	O	O	I-Entity
in	O	O	O
the	O	O	O
early	O	O	O
phase	O	O	B-Entity
of	O	O	O
migration	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
Fyn	O	O	B-Entity
inhibition	O	O	B-Entity
increased	O	O	O
the	O	O	O
length	O	O	O
of	O	O	O
leading	O	O	B-Entity
process	O	O	I-Entity
and	O	O	O
decreased	O	O	O
the	O	O	O
branching	O	O	B-Entity
number	O	O	O
of	O	O	O
the	O	O	O
migrating	O	O	B-Entity
cortical	O	O	I-Entity
neurons	O	O	I-Entity
.	O	O	O

Together	O	O	O
,	O	O	O
these	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
Fyn	O	O	B-Entity
controls	O	O	B-Entity
neuronal	O	O	B-Entity
migration	O	O	I-Entity
by	O	O	O
regulating	O	O	B-Entity
the	O	O	O
cytoskeletal	O	O	B-Entity
dynamics	O	O	B-Entity
and	O	O	O
multipolar	O	O	B-Entity
-	O	O	O
bipolar	O	O	B-Entity
transition	O	O	B-Entity
of	O	O	O
newly	O	O	B-Entity
generated	O	O	B-Entity
neurons	O	O	B-Entity
during	O	O	O
cortical	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

-DOCSTART- (28367636)

Closing	O	O	B-Entity
the	O	O	I-Entity
Loop	O	O	I-Entity
in	O	O	O
Adults	O	O	B-Entity
,	O	O	O
Children	O	O	B-Entity
and	O	O	O
Adolescents	O	O	B-Entity
With	O	O	O
Suboptimally	O	O	B-Entity
Controlled	O	O	I-Entity
Type	O	O	I-Entity
1	O	O	I-Entity
Diabetes	O	O	I-Entity
Under	O	O	O
Free	O	O	B-Entity
Living	O	O	B-Entity
Conditions	O	O	I-Entity
:	O	O	O
A	O	O	O
Psychosocial	O	O	B-Entity
Substudy	O	O	O

The	O	O	O
objective	O	O	O
was	O	O	O
to	O	O	O
explore	O	O	O
psychosocial	O	O	B-Entity
experiences	O	O	I-Entity
of	O	O	O
closed	O	O	B-Entity
loop	O	O	I-Entity
technology	O	O	I-Entity
for	O	O	O
adults	O	O	B-Entity
,	O	O	O
children	O	O	B-Entity
,	O	O	O
and	O	O	O
adolescents	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
and	O	O	O
their	O	O	O
parents	O	O	B-Entity
taking	O	O	O
part	O	O	O
in	O	O	O
two	O	O	O
multicenter	O	O	B-Entity
,	O	O	O
free	O	O	B-Entity
-	O	O	O
living	O	O	B-Entity
,	O	O	O
randomized	O	O	B-Entity
crossover	O	O	B-Entity
home	O	O	I-Entity
studies	O	O	I-Entity
.	O	O	O

Participants	O	O	B-Entity
using	O	O	O
insulin	O	O	B-Entity
pump	O	O	I-Entity
therapy	O	O	B-Entity
were	O	O	O
randomized	O	O	B-Entity
to	O	O	O
either	O	O	O
12	O	O	O
weeks	O	O	B-Entity
of	O	O	O
automated	O	O	B-Entity
closed-loop	O	O	B-Entity
glucose	O	O	B-Entity
control	O	O	I-Entity
,	O	O	O
then	O	O	O
12	O	O	O
weeks	O	O	O
of	O	O	O
sensor	O	O	B-Entity
augmented	O	O	B-Entity
insulin	O	O	O
pump	O	O	O
therapy	O	O	O
(	O	O	O
open	O	O	B-Entity
loop	O	O	I-Entity
)	O	O	O
,	O	O	O
or	O	O	O
vice	O	O	O
versa	O	O	O
.	O	O	O

Closed	O	O	B-Entity
loop	O	O	I-Entity
was	O	O	O
used	O	O	O
for	O	O	O
24	O	O	O
hours	O	O	B-Entity
by	O	O	O
adults	O	O	B-Entity
and	O	O	O
overnight	O	O	B-Entity
only	O	O	O
by	O	O	O
children	O	O	B-Entity
and	O	O	O
adolescents	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
completed	O	O	O
the	O	O	O
Diabetes	O	O	B-Entity
Technology	O	O	I-Entity
Questionnaire	O	O	I-Entity
(	O	O	O
DTQ	O	O	B-Entity
)	O	O	O
periodically	O	O	B-Entity
and	O	O	O
shared	O	O	O
their	O	O	O
views	O	O	B-Entity
in	O	O	O
semistructured	O	O	B-Entity
interviews	O	O	I-Entity
.	O	O	O

This	O	O	O
analysis	O	O	B-Entity
characterizes	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
the	O	O	O
technology	O	O	B-Entity
,	O	O	O
positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
aspects	O	O	O
of	O	O	O
living	O	O	B-Entity
with	O	O	O
the	O	O	O
device	O	O	B-Entity
,	O	O	O
alongside	O	O	O
participants	O	O	B-Entity
'	O	O	O
expectations	O	O	B-Entity
,	O	O	O
hopes	O	O	B-Entity
,	O	O	O
and	O	O	O
anxieties	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
32	O	O	O
adults	O	O	B-Entity
,	O	O	O
age	O	O	B-Entity
38.6	O	O	O
±	O	O	O
9.6	O	O	O
years	O	O	B-Entity
,	O	O	O
55	O	O	O
%	O	O	O
male	O	O	B-Entity
,	O	O	O
and	O	O	O
26	O	O	O
children	O	O	B-Entity
,	O	O	O
mean	O	O	O
age	O	O	O
12	O	O	O
years	O	O	O
(	O	O	O
range	O	O	O
6	O	O	O
-	O	O	O
18	O	O	O
years	O	O	O
)	O	O	O
,	O	O	O
54	O	O	O
%	O	O	O
male	O	O	O
.	O	O	O

DTQ	O	O	B-Entity
results	O	O	B-Entity
indicated	O	O	O
moderately	O	O	B-Entity
favorable	O	O	I-Entity
impact	O	O	I-Entity
of	O	O	O
,	O	O	O
and	O	O	O
satisfaction	O	O	O
with	O	O	O
,	O	O	O
both	O	O	O
open	O	O	B-Entity
and	O	O	O
closed	O	O	B-Entity
loop	O	O	I-Entity
interventions	O	O	B-Entity
,	O	O	O
but	O	O	O
little	O	O	O
evidence	O	O	B-Entity
of	O	O	O
a	O	O	O
comparative	O	O	B-Entity
advantage	O	O	I-Entity
of	O	O	O
either	O	O	O
.	O	O	O

Key	O	O	O
positive	O	O	B-Entity
themes	O	O	I-Entity
included	O	O	O
perceived	O	O	O
improved	O	O	B-Entity
blood	O	O	I-Entity
glucose	O	O	I-Entity
control	O	O	I-Entity
,	O	O	O
improved	O	O	B-Entity
general	O	O	I-Entity
well-being	O	O	I-Entity
,	O	O	O
particularly	O	O	O
on	O	O	O
waking	O	O	B-Entity
,	O	O	O
improved	O	O	B-Entity
sleep	O	O	I-Entity
,	O	O	O
reduced	O	O	B-Entity
burden	O	O	B-Entity
of	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
and	O	O	O
visibility	O	O	B-Entity
of	O	O	O
data	O	O	B-Entity
.	O	O	O

Key	O	O	O
negative	O	O	B-Entity
themes	O	O	I-Entity
included	O	O	O
having	O	O	O
to	O	O	O
carry	O	O	O
around	O	O	O
the	O	O	O
equipment	O	O	B-Entity
and	O	O	O
dislike	O	O	B-Entity
of	O	O	O
the	O	O	O
pump	O	O	B-Entity
and	O	O	O
second	O	O	O
cannula	O	O	B-Entity
(	O	O	O
ie	O	O	O
,	O	O	O
sensor	O	O	B-Entity
)	O	O	O
inserted	O	O	O
.	O	O	O

Overall	O	O	O
,	O	O	O
participants	O	O	B-Entity
reported	O	O	O
a	O	O	O
positive	O	O	B-Entity
experience	O	O	B-Entity
of	O	O	O
the	O	O	O
closed	O	O	B-Entity
loop	O	O	I-Entity
technology	O	O	I-Entity
.	O	O	O

Results	O	O	B-Entity
are	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
previous	O	O	O
research	O	O	O
with	O	O	O
size	O	O	B-Entity
of	O	O	O
equipment	O	O	B-Entity
continuing	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
problem	O	O	B-Entity
.	O	O	O

Progress	O	O	O
is	O	O	O
being	O	O	O
made	O	O	O
in	O	O	O
the	O	O	O
usability	O	O	B-Entity
of	O	O	O
the	O	O	O
closed-loop	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

-DOCSTART- (28370352)

Serum	O	O	B-Entity
levels	O	O	B-Entity
of	O	O	O
genomic	O	O	B-Entity
DNA	O	O	I-Entity
of	O	O	O
α1(I	O	O	B-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
are	O	O	O
elevated	O	O	B-Entity
in	O	O	O
scleroderma	O	O	B-Entity
patients	O	O	O

Recent	O	O	O
studies	O	O	O
have	O	O	O
indicated	O	O	O
that	O	O	O
various	O	O	O
nucleic	O	O	B-Entity
acids	O	O	I-Entity
are	O	O	O
present	O	O	O
in	O	O	O
human	O	O	B-Entity
sera	O	O	B-Entity
,	O	O	O
and	O	O	O
attracted	O	O	O
attention	O	O	O
for	O	O	O
their	O	O	O
potential	O	O	O
as	O	O	O
novel	O	O	O
disease	O	O	B-Entity
markers	O	O	I-Entity
in	O	O	O
many	O	O	O
human	O	O	O
diseases	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
tried	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
possibility	O	O	O
that	O	O	O
DNA	O	O	B-Entity
and	O	O	O
RNA	O	O	B-Entity
of	O	O	O
collagens	O	O	B-Entity
exist	O	O	O
in	O	O	O
human	O	O	B-Entity
sera	O	O	B-Entity
,	O	O	O
and	O	O	O
determined	O	O	O
whether	O	O	O
their	O	O	O
serum	O	O	B-Entity
levels	O	O	B-Entity
can	O	O	O
be	O	O	O
useful	O	O	O
biomarkers	O	O	B-Entity
in	O	O	O
scleroderma	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
RNA	O	O	B-Entity
or	O	O	O
DNA	O	O	B-Entity
of	O	O	O
collagens	O	O	B-Entity
were	O	O	O
purified	O	O	B-Entity
from	O	O	O
sera	O	O	B-Entity
,	O	O	O
and	O	O	O
detected	O	O	B-Entity
by	O	O	O
polymerase	O	O	B-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
or	O	O	O
quantitated	O	O	B-Entity
by	O	O	O
real-time	O	O	B-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
.	O	O	O

Among	O	O	O
approximately	O	O	O
18	O	O	O
360	O	O	B-Entity
bases	O	O	I-Entity
of	O	O	I-Entity
full-length	O	O	I-Entity
α1(I	O	O	I-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
DNA	O	O	B-Entity
,	O	O	O
various	O	O	O
regions	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
by	O	O	O
polymerase	O	O	B-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
sera	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
α2(I	O	O	B-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
DNA	O	O	B-Entity
,	O	O	O
α1(I	O	O	B-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
RNA	O	O	B-Entity
or	O	O	O
α2(I	O	O	O
)	O	O	O
collagen	O	O	O
RNA	O	O	O
were	O	O	O
not	O	O	B-Entity
detectable	O	O	I-Entity
.	O	O	O

α1(I	O	O	B-Entity
)	O	O	I-Entity
Collagen	O	O	I-Entity
DNA	O	O	B-Entity
in	O	O	O
sera	O	O	B-Entity
was	O	O	O
quantitative	O	O	B-Entity
using	O	O	O
our	O	O	O
method	O	O	O
.	O	O	O

The	O	O	O
levels	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
α1(I	O	O	B-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
DNA	O	O	B-Entity
were	O	O	O
significantly	O	O	O
increased	O	O	B-Entity
in	O	O	O
scleroderma	O	O	B-Entity
patients	O	O	B-Entity
compared	O	O	O
with	O	O	O
healthy	O	O	B-Entity
control	O	O	I-Entity
subjects	O	O	B-Entity
or	O	O	O
systemic	O	O	B-Entity
lupus	O	O	I-Entity
erythematosus	O	O	I-Entity
patients	O	O	O
.	O	O	O

According	O	O	O
to	O	O	O
the	O	O	O
receiver-operator	O	O	B-Entity
curve	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
serum	O	O	B-Entity
α1(I	O	O	B-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
DNA	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
effective	O	O	O
as	O	O	O
a	O	O	O
diagnostic	O	O	B-Entity
marker	O	O	I-Entity
of	O	O	O
scleroderma	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
when	O	O	O
we	O	O	O
determined	O	O	O
the	O	O	O
association	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
α1(I	O	O	B-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
DNA	O	O	B-Entity
levels	O	O	B-Entity
with	O	O	O
clinical	O	O	B-Entity
/	O	O	O
laboratory	O	O	B-Entity
features	O	O	B-Entity
in	O	O	O
scleroderma	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
those	O	O	O
with	O	O	O
elevated	O	O	B-Entity
α1(I	O	O	O
)	O	O	O
collagen	O	O	O
DNA	O	O	O
levels	O	O	O
showed	O	O	O
significantly	O	O	O
higher	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
pitting	O	O	B-Entity
scars	O	O	I-Entity
/	O	O	O
ulcers	O	O	B-Entity
.	O	O	O

In	O	O	O
summary	O	O	O
,	O	O	O
elevation	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
α1(I	O	O	B-Entity
)	O	O	I-Entity
collagen	O	O	I-Entity
DNA	O	O	B-Entity
levels	O	O	B-Entity
in	O	O	O
scleroderma	O	O	B-Entity
patients	O	O	B-Entity
may	O	O	O
be	O	O	O
useful	O	O	O
as	O	O	O
the	O	O	O
diagnostic	O	O	B-Entity
marker	O	O	I-Entity
,	O	O	O
reflecting	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
vasculopathy	O	O	B-Entity
.	O	O	O

Jou	O	O	O
rna	O	O	O

-DOCSTART- (28370605)

Metabolite	O	O	B-Entity
mapping	O	O	B-Entity
by	O	O	O
consecutive	O	O	O
nanostructure	O	O	B-Entity
and	O	O	O
silver-assisted	O	O	B-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
imaging	O	O	I-Entity
on	O	O	O
tissue	O	O	O
sections	O	O	O

Nanostructure-based	O	O	B-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
MSI	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
promising	O	O	O
technology	O	O	O
for	O	O	O
molecular	O	O	B-Entity
imaging	O	O	I-Entity
of	O	O	O
small	O	O	B-Entity
molecules	O	O	I-Entity
,	O	O	O
without	O	O	O
the	O	O	O
complex	O	O	O
chemical	O	O	O
background	O	O	O
typically	O	O	O
encountered	O	O	O
in	O	O	O
matrix-assisted	O	O	B-Entity
molecular	O	O	I-Entity
imaging	O	O	I-Entity
approaches	O	O	O
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
enhanced	O	O	O
these	O	O	O
surfaces	O	O	B-Entity
with	O	O	O
silver	O	O	B-Entity
(	O	O	O
Ag	O	O	B-Entity
)	O	O	O
to	O	O	O
provide	O	O	O
a	O	O	O
second	O	O	O
tier	O	O	O
of	O	O	O
MSI	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
a	O	O	O
single	O	O	O
sample	O	O	O
.	O	O	O

MSI	O	O	B-Entity
data	O	O	I-Entity
was	O	O	O
acquired	O	O	O
through	O	O	O
the	O	O	O
application	O	O	B-Entity
of	O	O	O
laser	O	O	B-Entity
desorption/ionization	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
to	O	O	O
biological	O	O	B-Entity
samples	O	O	I-Entity
imprinted	O	O	O
onto	O	O	O
desorption/ionization	O	O	B-Entity
on	O	O	I-Entity
silicon	O	O	I-Entity
(	O	O	O
DIOS	O	O	B-Entity
)	O	O	O
substrates	O	O	B-Entity
.	O	O	O

Following	O	O	O
initial	O	O	O
analysis	O	O	B-Entity
,	O	O	O
ultra-thin	O	O	B-Entity
Ag	O	O	I-Entity
layers	O	O	I-Entity
were	O	O	O
overlaid	O	O	O
onto	O	O	O
the	O	O	O
followed	O	O	O
by	O	O	O
MSI	O	O	B-Entity
analysis	O	O	I-Entity
(	O	O	O
Ag-DIOS	O	O	B-Entity
MSI	O	O	I-Entity
)	O	O	O
.	O	O	O

This	O	O	O
approach	O	O	O
was	O	O	O
first	O	O	O
demonstrated	O	O	O
for	O	O	O
fingermark	O	O	O
small	O	O	B-Entity
molecules	O	O	I-Entity
including	O	O	O
environmental	O	O	B-Entity
contaminants	O	O	B-Entity
and	O	O	O
sebum	O	O	B-Entity
components	O	O	O
.	O	O	O

Subsequently	O	O	O
,	O	O	O
this	O	O	O
bimodal	O	O	O
method	O	O	O
was	O	O	O
translated	O	O	O
to	O	O	O
lipids	O	O	B-Entity
and	O	O	O
metabolites	O	O	B-Entity
in	O	O	O
fore-stomach	O	O	B-Entity
sections	O	O	I-Entity
from	O	O	O
a	O	O	O
6-bromoisatin	O	O	B-Entity
chemopreventative	O	O	B-Entity
murine	O	O	B-Entity
mouse	O	O	I-Entity
model	O	O	I-Entity
.	O	O	O

DIOS	O	O	B-Entity
MSI	O	O	I-Entity
allowed	O	O	O
mapping	O	O	B-Entity
of	O	O	O
common	O	O	O
ions	O	O	B-Entity
in	O	O	O
fingermarks	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
6-bromoisatin	O	O	B-Entity
metabolites	O	O	B-Entity
and	O	O	O
lipids	O	O	B-Entity
in	O	O	O
murine	O	O	B-Entity
fore-stomach	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
DIOS	O	O	B-Entity
MSI	O	O	I-Entity
was	O	O	O
complemented	O	O	O
by	O	O	O
the	O	O	O
Ag-DIOS	O	O	B-Entity
MSI	O	O	I-Entity
of	O	O	O
Ag-adductable	O	O	B-Entity
lipids	O	O	I-Entity
such	O	O	O
as	O	O	O
wax	O	O	B-Entity
esters	O	O	I-Entity
in	O	O	O
fingermarks	O	O	O
and	O	O	O
cholesterol	O	O	B-Entity
in	O	O	O
murine	O	O	B-Entity
fore-stomach	O	O	I-Entity
.	O	O	O

Gastrointestinal	O	O	B-Entity
acid	O	O	I-Entity
condensation	O	O	B-Entity
products	O	O	B-Entity
of	O	O	O
6-bromoisatin	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
the	O	O	O
6,6'-dibromoindirubin	O	O	B-Entity
mapped	O	O	O
herein	O	O	O
,	O	O	O
are	O	O	O
very	O	O	O
challenging	O	O	O
to	O	O	O
isolate	O	O	B-Entity
and	O	O	O
characterize	O	O	B-Entity
.	O	O	O

By	O	O	O
re-analyzing	O	O	O
the	O	O	O
same	O	O	O
tissue	O	O	B-Entity
imprints	O	O	O
,	O	O	O
this	O	O	O
metabolite	O	O	B-Entity
was	O	O	O
readily	O	O	O
detected	O	O	O
by	O	O	O
DIOS	O	O	B-Entity
,	O	O	O
placed	O	O	O
in	O	O	O
a	O	O	O
tissue-specific	O	O	B-Entity
spatial	O	O	I-Entity
context	O	O	I-Entity
,	O	O	O
and	O	O	O
subsequently	O	O	O
overlaid	O	O	O
with	O	O	O
additional	O	O	O
lipid	O	O	B-Entity
distributions	O	O	I-Entity
acquired	O	O	O
using	O	O	O
Ag-DIOS	O	O	B-Entity
MSI	O	O	I-Entity
.	O	O	O

The	O	O	O
ability	O	O	O
to	O	O	O
place	O	O	O
metabolite	O	O	B-Entity
and	O	O	O
lipid	O	O	B-Entity
classes	O	O	O
in	O	O	O
a	O	O	O
tissue-specific	O	O	B-Entity
context	O	O	O
makes	O	O	O
this	O	O	O
novel	O	O	O
method	O	O	O
suited	O	O	O
to	O	O	O
MSI	O	O	B-Entity
analyses	O	O	I-Entity
where	O	O	O
the	O	O	O
collection	O	O	O
of	O	O	O
additional	O	O	O
information	O	O	O
from	O	O	O
the	O	O	O
same	O	O	O
sample	O	O	O
maximises	O	O	O
resource	O	O	O
use	O	O	O
,	O	O	O
and	O	O	O
also	O	O	O
maximises	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
annotated	O	O	O
small	O	O	B-Entity
molecules	O	O	I-Entity
,	O	O	O
in	O	O	O
particular	O	O	O
for	O	O	O
metabolites	O	O	B-Entity
that	O	O	O
are	O	O	O
typically	O	O	O
undetectable	O	O	B-Entity
with	O	O	O
traditional	O	O	O
platforms	O	O	O
.	O	O	O

Copyright	O	O	O
©	O	O	O
2017	O	O	O
John	O	O	O
Wiley	O	O	O
&	O	O	O
Sons	O	O	O
,	O	O	O
Ltd.	O	O	O

-DOCSTART- (28370728)

Towards	O	O	O
culturally	O	O	B-Entity
competent	O	O	I-Entity
paediatric	O	O	I-Entity
oncology	O	O	I-Entity
care	O	O	I-Entity
.	O	O	O
A	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
from	O	O	O
the	O	O	O
perspective	O	O	B-Entity
of	O	O	O
care	O	O	O
providers	O	O	O

A	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
from	O	O	O
the	O	O	O
perspective	O	O	B-Entity
of	O	O	O
care	O	O	B-Entity
providers	O	O	I-Entity
In	O	O	O
order	O	O	O
to	O	O	O
gain	O	O	O
more	O	O	O
insight	O	O	O
on	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
ethnic	O	O	B-Entity
diversity	O	O	B-Entity
in	O	O	O
paediatric	O	O	B-Entity
cancer	O	O	B-Entity
care	O	O	I-Entity
,	O	O	O
the	O	O	O
perspectives	O	O	B-Entity
of	O	O	O
care	O	O	O
providers	O	O	O
were	O	O	O
explored	O	O	O
.	O	O	O

Semi-structured	O	O	B-Entity
interviews	O	O	I-Entity
were	O	O	O
conducted	O	O	O
among	O	O	O
12	O	O	O
paediatric	O	O	B-Entity
oncologists	O	O	I-Entity
and	O	O	O
13	O	O	O
nurses	O	O	B-Entity
of	O	O	O
two	O	O	O
different	O	O	O
paediatric	O	O	B-Entity
oncology	O	O	I-Entity
wards	O	O	I-Entity
and	O	O	O
were	O	O	O
analysed	O	O	B-Entity
using	O	O	O
a	O	O	O
framework	O	O	B-Entity
method	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
care	O	O	B-Entity
providers	O	O	I-Entity
described	O	O	O
the	O	O	O
contact	O	O	O
with	O	O	O
Turkish	O	O	B-Entity
and	O	O	O
Moroccan	O	O	B-Entity
parents	O	O	B-Entity
as	O	O	O
more	O	O	O
difficult	O	O	O
.	O	O	O

They	O	O	O
offered	O	O	O
two	O	O	O
reasons	O	O	O
for	O	O	O
this	O	O	O
:	O	O	O
(	O	O	O
1	O	O	O
)	O	O	O
language	O	O	B-Entity
barriers	O	O	I-Entity
between	O	O	O
care	O	O	B-Entity
provider	O	O	I-Entity
and	O	O	O
parents	O	O	B-Entity
hindered	O	O	B-Entity
the	O	O	O
exchange	O	O	B-Entity
of	O	O	I-Entity
information	O	O	I-Entity
;	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
cultural	O	O	B-Entity
barriers	O	O	I-Entity
between	O	O	O
care	O	O	O
provider	O	O	O
and	O	O	O
parents	O	O	O
about	O	O	O
sharing	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
palliative	O	O	B-Entity
perspective	O	O	B-Entity
hindered	O	O	O
communication	O	O	B-Entity
.	O	O	O

Care	O	O	B-Entity
providers	O	O	I-Entity
reported	O	O	O
different	O	O	O
solutions	O	O	B-Entity
to	O	O	O
deal	O	O	O
with	O	O	O
these	O	O	O
barriers	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
using	O	O	O
an	O	O	O
interpreter	O	O	B-Entity
and	O	O	O
improving	O	O	O
their	O	O	O
cultural	O	O	B-Entity
knowledge	O	O	I-Entity
about	O	O	O
their	O	O	O
patients	O	O	B-Entity
.	O	O	O

They	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
were	O	O	O
not	O	O	O
using	O	O	O
interpreters	O	O	B-Entity
sufficiently	O	O	O
and	O	O	O
were	O	O	O
unaware	O	O	O
of	O	O	O
the	O	O	O
importance	O	O	O
of	O	O	O
eliciting	O	O	B-Entity
parents	O	O	B-Entity
'	O	O	O
perspectives	O	O	B-Entity
.	O	O	O

Communication	O	O	B-Entity
techniques	O	O	B-Entity
to	O	O	O
overcome	O	O	O
dilemmas	O	O	B-Entity
between	O	O	O
parents	O	O	B-Entity
and	O	O	O
care	O	O	B-Entity
providers	O	O	I-Entity
were	O	O	O
not	O	O	O
used	O	O	O
and	O	O	O
care	O	O	O
providers	O	O	O
were	O	O	O
unaware	O	O	O
of	O	O	O
stereotypes	O	O	B-Entity
and	O	O	O
prejudice	O	O	B-Entity
.	O	O	O

Care	O	O	B-Entity
providers	O	O	I-Entity
should	O	O	O
be	O	O	O
offered	O	O	O
insight	O	O	O
in	O	O	O
cultural	O	O	B-Entity
barriers	O	O	I-Entity
they	O	O	O
are	O	O	O
unaware	O	O	O
of	O	O	O
.	O	O	O

Training	O	O	B-Entity
in	O	O	O
cultural	O	O	B-Entity
competence	O	O	I-Entity
might	O	O	O
be	O	O	O
a	O	O	O
possibility	O	O	O
to	O	O	O
overcome	O	O	O
manifest	O	O	B-Entity
barriers	O	O	B-Entity
.	O	O	O

-DOCSTART- (28371313)

Obesogenic	O	O	B-Entity
eating	O	O	B-Entity
behaviors	O	O	I-Entity
mediate	O	O	O
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
psychological	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
BMI	O	O	B-Entity
in	O	O	O
children	O	O	O

To	O	O	O
examine	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
psychological	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
weight	O	O	B-Entity
status	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
aged	O	O	B-Entity
3.5	O	O	O
to	O	O	O
4	O	O	O
years	O	O	B-Entity
and	O	O	O
test	O	O	O
whether	O	O	O
obesogenic	O	O	B-Entity
eating	O	O	B-Entity
behaviors	O	O	I-Entity
mediate	O	O	O
this	O	O	O
relationship	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
is	O	O	O
a	O	O	O
cross-sectional	O	O	B-Entity
secondary	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	O
data	O	O	B-Entity
from	O	O	O
first-time	O	O	B-Entity
mothers	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
194	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
control	O	O	O
arm	O	O	O
of	O	O	O
the	O	O	O
NOURISH	O	O	B-Entity
randomized	O	O	I-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
.	O	O	O

At	O	O	O
child	O	O	B-Entity
age	O	O	O
3.5	O	O	O
to	O	O	O
4	O	O	O
years	O	O	O
,	O	O	O
maternal	O	O	B-Entity
-reported	O	O	O
child	O	O	O
eating	O	O	B-Entity
behaviors	O	O	I-Entity
and	O	O	O
psychological	O	O	B-Entity
problems	O	O	I-Entity
were	O	O	O
collected	O	O	O
via	O	O	O
valid	O	O	O
tools	O	O	O
,	O	O	O
and	O	O	O
child	O	O	O
weight	O	O	B-Entity
and	O	O	O
height	O	O	B-Entity
data	O	O	B-Entity
were	O	O	I-Entity
collected	O	O	I-Entity
by	O	O	O
trained	O	O	O
study	O	O	O
staff	O	O	B-Entity
.	O	O	O

Pearson	O	O	B-Entity
's	O	O	I-Entity
correlations	O	O	I-Entity
and	O	O	O
linear	O	O	B-Entity
regressions	O	O	I-Entity
examined	O	O	O
associations	O	O	B-Entity
between	O	O	O
eating	O	O	B-Entity
behaviors	O	O	I-Entity
,	O	O	O
psychological	O	O	B-Entity
problems	O	O	I-Entity
,	O	O	O
and	O	O	O
BMI	O	O	B-Entity
z	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

Multiple	O	O	B-Entity
mediation	O	O	I-Entity
models	O	O	I-Entity
were	O	O	O
tested	O	O	B-Entity
by	O	O	O
assessing	O	O	O
indirect	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
psychological	O	O	B-Entity
problems	O	O	I-Entity
on	O	O	O
BMI	O	O	B-Entity
z	O	O	B-Entity
score	O	O	I-Entity
via	O	O	O
obesogenic	O	O	B-Entity
eating	O	O	B-Entity
behaviors	O	O	I-Entity
.	O	O	O

Peer	O	O	B-Entity
problems	O	O	B-Entity
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
both	O	O	O
higher	O	O	B-Entity
food	O	O	B-Entity
responsiveness	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
overeating	O	O	I-Entity
and	O	O	O
directly	O	O	B-Entity
with	O	O	O
higher	O	O	O
BMI	O	O	B-Entity
z	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

This	O	O	O
relationship	O	O	B-Entity
was	O	O	O
partially	O	O	O
mediated	O	O	O
by	O	O	O
emotional	O	O	B-Entity
overeating	O	O	I-Entity
.	O	O	O

Both	O	O	O
emotional	O	O	B-Entity
overeating	O	O	I-Entity
and	O	O	O
food	O	O	B-Entity
responsiveness	O	O	B-Entity
fully	O	O	O
mediated	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
emotional	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
BMI	O	O	B-Entity
z	O	O	B-Entity
score	O	O	I-Entity
,	O	O	O
and	O	O	O
food	O	O	O
responsiveness	O	O	O
fully	O	O	O
mediated	O	O	O
the	O	O	O
association	O	O	O
between	O	O	O
conduct	O	O	B-Entity
problems	O	O	I-Entity
and	O	O	O
BMI	O	O	O
z	O	O	O
score	O	O	O
.	O	O	O

The	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
children	O	O	B-Entity
with	O	O	O
psychological	O	O	B-Entity
problems	O	O	I-Entity
may	O	O	O
also	O	O	O
display	O	O	O
obesogenic	O	O	B-Entity
eating	O	O	B-Entity
behaviors	O	O	I-Entity
,	O	O	O
which	O	O	O
may	O	O	O
result	O	O	O
in	O	O	O
higher	O	O	B-Entity
BMI	O	O	B-Entity
.	O	O	O

This	O	O	O
needs	O	O	O
to	O	O	O
be	O	O	O
considered	O	O	O
in	O	O	O
the	O	O	O
clinical	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
both	O	O	O
pediatric	O	O	B-Entity
overweight	O	O	B-Entity
/	O	O	O
obesity	O	O	B-Entity
and	O	O	O
psychological	O	O	B-Entity
problems	O	O	I-Entity
.	O	O	O

-DOCSTART- (28371745)

Homocysteine	O	O	B-Entity
as	O	O	O
a	O	O	O
peripheral	O	O	B-Entity
biomarker	O	O	B-Entity
in	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
:	O	O	O
A	O	O	O
meta-analysis	O	O	O

Bipolar	O	O	B-Entity
disorder	O	O	I-Entity
(	O	O	O
BD	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
psychiatric	O	O	B-Entity
disorder	O	O	I-Entity
with	O	O	O
an	O	O	O
uncertain	O	O	B-Entity
aetiology	O	O	B-Entity
.	O	O	O

Recently	O	O	O
,	O	O	O
special	O	O	O
attention	O	O	O
has	O	O	O
been	O	O	O
given	O	O	O
to	O	O	O
homocysteine	O	O	B-Entity
(	O	O	O
Hcy	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
suggested	O	O	O
that	O	O	O
alterations	O	O	B-Entity
in	O	O	O
1-carbon	O	O	B-Entity
metabolism	O	O	I-Entity
might	O	O	O
be	O	O	O
implicated	O	O	O
in	O	O	O
diverse	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
uncertainty	O	O	B-Entity
regarding	O	O	O
possible	O	O	O
alterations	O	O	B-Entity
in	O	O	O
peripheral	O	O	B-Entity
Hcy	O	O	B-Entity
levels	O	O	O
in	O	O	O
BD	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
comprises	O	O	O
a	O	O	O
meta-analysis	O	O	B-Entity
comparing	O	O	O
serum	O	O	B-Entity
and	O	O	O
plasma	O	O	B-Entity
Hcy	O	O	I-Entity
levels	O	O	I-Entity
in	O	O	O
persons	O	O	B-Entity
with	O	O	O
BD	O	O	B-Entity
and	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

We	O	O	O
conducted	O	O	O
a	O	O	O
systematic	O	O	B-Entity
search	O	O	B-Entity
for	O	O	O
all	O	O	O
eligible	O	O	B-Entity
English	O	O	O
and	O	O	O
non-English	O	O	O
peer-reviewed	O	O	B-Entity
articles	O	O	I-Entity
.	O	O	O

Nine	O	O	O
cross-sectional	O	O	B-Entity
studies	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
in	O	O	O
the	O	O	O
meta-analyses	O	O	B-Entity
,	O	O	O
providing	O	O	B-Entity
data	O	O	B-Entity
on	O	O	O
1547	O	O	O
participants	O	O	B-Entity
.	O	O	O

Random-effects	O	O	B-Entity
meta-analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
serum	O	O	B-Entity
and	O	O	O
plasma	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	I-Entity
Hcy	O	O	I-Entity
were	O	O	O
increased	O	O	B-Entity
in	O	O	O
subjects	O	O	B-Entity
with	O	O	O
BD	O	O	B-Entity
in	O	O	O
either	O	O	O
mania	O	O	B-Entity
or	O	O	O
euthymia	O	O	B-Entity
when	O	O	O
compared	O	O	B-Entity
to	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
,	O	O	O
with	O	O	O
a	O	O	O
large	O	O	O
effect	O	O	B-Entity
size	O	O	I-Entity
in	O	O	O
the	O	O	O
mania	O	O	O
group	O	O	B-Entity
(	O	O	O
g=0.98	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
:	O	O	O
0.8	O	O	O
-	O	O	O
1.17	O	O	O
,	O	O	O
P<0.001	O	O	O
,	O	O	O
n=495	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
small	O	O	O
effect	O	O	O
in	O	O	O
the	O	O	O
euthymia	O	O	O
group	O	O	O
(	O	O	O
g=0.3	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.11	O	O	O
-	O	O	O
0.48	O	O	O
,	O	O	O
P=0.002	O	O	O
,	O	O	O
n=1052	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
meta-analysis	O	O	B-Entity
provides	O	O	O
evidence	O	O	O
that	O	O	O
Hcy	O	O	B-Entity
levels	O	O	I-Entity
are	O	O	I-Entity
elevated	O	O	I-Entity
in	O	O	O
persons	O	O	B-Entity
with	O	O	O
BD	O	O	B-Entity
during	O	O	O
mania	O	O	B-Entity
and	O	O	O
euthymia	O	O	B-Entity
.	O	O	O

Peripheral	O	O	B-Entity
Hcy	O	O	B-Entity
could	O	O	O
be	O	O	O
considered	O	O	B-Entity
as	O	O	O
a	O	O	O
potential	O	O	B-Entity
biomarker	O	O	B-Entity
in	O	O	O
BD	O	O	B-Entity
,	O	O	O
both	O	O	O
of	O	O	O
trait	O	O	B-Entity
(	O	O	O
since	O	O	O
it	O	O	O
is	O	O	O
increased	O	O	B-Entity
in	O	O	O
euthymia	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
also	O	O	O
of	O	O	O
state	O	O	B-Entity
(	O	O	O
since	O	O	O
its	O	O	O
increase	O	O	B-Entity
is	O	O	O
more	O	O	O
accentuated	O	O	B-Entity
in	O	O	O
mania	O	O	B-Entity
)	O	O	O
.	O	O	O

Longitudinal	O	O	B-Entity
studies	O	O	I-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
clarify	O	O	O
the	O	O	O
relationship	O	O	B-Entity
between	O	O	O
bipolar	O	O	B-Entity
disorder	O	O	I-Entity
and	O	O	O
Hcy	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
usefulness	O	O	B-Entity
of	O	O	O
peripheral	O	O	B-Entity
Hcy	O	O	O
as	O	O	O
both	O	O	O
a	O	O	O
trait	O	O	B-Entity
and	O	O	O
state	O	O	B-Entity
biomarker	O	O	B-Entity
in	O	O	O
BD	O	O	B-Entity
.	O	O	O

-DOCSTART- (28373195)

Structural	O	O	B-Entity
Modification	O	O	I-Entity
of	O	O	O
Lipopolysaccharide	O	O	B-Entity
Conferred	O	O	O
by	O	O	O
mcr-1	O	O	B-Entity
in	O	O	O
Gram-Negative	O	O	B-Entity
ESKAPE	O	O	I-Entity
Pathogens	O	O	O

mcr-1	O	O	B-Entity
was	O	O	O
initially	O	O	O
reported	O	O	O
as	O	O	O
the	O	O	O
first	O	O	O
plasmid	O	O	B-Entity
-mediated	O	O	O
colistin	O	O	B-Entity
resistance	O	O	B-Entity
gene	O	O	I-Entity
in	O	O	O
clinical	O	O	B-Entity
isolates	O	O	I-Entity
of	O	O	O
Escherichia	O	O	B-Entity
coli	O	O	I-Entity
and	O	O	O
Klebsiella	O	O	B-Entity
pneumoniae	O	O	I-Entity
in	O	O	O
China	O	O	B-Entity
and	O	O	O
has	O	O	O
subsequently	O	O	O
been	O	O	O
identified	O	O	O
worldwide	O	O	O
in	O	O	O
various	O	O	O
species	O	O	B-Entity
of	O	O	O
the	O	O	O
family	O	O	B-Entity
Enterobacteriaceae	O	O	I-Entity
mcr-1	O	O	O
encodes	O	O	O
a	O	O	O
phosphoethanolamine	O	O	B-Entity
transferase	O	O	I-Entity
,	O	O	O
and	O	O	O
its	O	O	O
expression	O	O	B-Entity
has	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
generate	O	O	O
phosphoethanolamine	O	O	O
-modified	O	O	O
bis-phosphorylated	O	O	B-Entity
hexa-acylated	O	O	I-Entity
lipid	O	O	I-Entity
A	O	O	I-Entity
in	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
mcr-1	O	O	O
on	O	O	O
colistin	O	O	O
susceptibility	O	O	B-Entity
and	O	O	O
on	O	O	O
lipopolysaccharide	O	O	B-Entity
structures	O	O	B-Entity
in	O	O	O
laboratory	O	O	B-Entity
and	O	O	O
clinical	O	O	O
strains	O	O	B-Entity
of	O	O	O
the	O	O	O
Gram-negative	O	O	B-Entity
ESKAPE	O	O	I-Entity
(	O	O	O
Enterococcus	O	O	B-Entity
faecium	O	O	I-Entity
,	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
,	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
,	O	O	O
Acinetobacter	O	O	B-Entity
baumannii	O	O	I-Entity
,	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
,	O	O	O
and	O	O	O
Enterobacter	O	O	B-Entity
species	O	O	I-Entity
)	O	O	O
pathogens	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
often	O	O	O
treated	O	O	B-Entity
clinically	O	O	B-Entity
by	O	O	O
colistin	O	O	O
.	O	O	O

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
mcr-1	O	O	B-Entity
on	O	O	O
colistin	O	O	B-Entity
resistance	O	O	B-Entity
were	O	O	O
determined	O	O	O
using	O	O	O
MIC	O	O	B-Entity
assays	O	O	I-Entity
of	O	O	O
laboratory	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
strains	O	O	B-Entity
of	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
,	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
,	O	O	O
A.	O	O	B-Entity
baumannii	O	O	I-Entity
,	O	O	O
and	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
Lipid	O	O	B-Entity
A	O	O	I-Entity
structural	O	O	B-Entity
changes	O	O	O
resulting	O	O	O
from	O	O	O
MCR-1	O	O	B-Entity
were	O	O	O
analyzed	O	O	O
by	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
.	O	O	O

The	O	O	O
introduction	O	O	O
of	O	O	O
mcr-1	O	O	B-Entity
led	O	O	O
to	O	O	O
colistin	O	O	B-Entity
resistance	O	O	B-Entity
in	O	O	O
E.	O	O	B-Entity
coli	O	O	I-Entity
,	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
,	O	O	O
and	O	O	O
A.	O	O	B-Entity
baumannii	O	O	I-Entity
but	O	O	O
only	O	O	O
moderately	O	O	O
reduced	O	O	B-Entity
susceptibility	O	O	B-Entity
in	O	O	O
P.	O	O	B-Entity
aeruginosa	O	O	I-Entity
Phosphoethanolamine	O	O	B-Entity
modification	O	O	B-Entity
of	O	O	O
lipid	O	O	B-Entity
A	O	O	I-Entity
was	O	O	O
observed	O	O	O
consistently	O	O	O
for	O	O	O
all	O	O	O
four	O	O	O
species	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	B-Entity
highlight	O	O	O
the	O	O	O
risk	O	O	B-Entity
of	O	O	O
colistin	O	O	B-Entity
resistance	O	O	B-Entity
as	O	O	O
a	O	O	O
consequence	O	O	B-Entity
of	O	O	I-Entity
mcr-1	O	O	B-Entity
expression	O	O	B-Entity
among	O	O	O
ESKAPE	O	O	B-Entity
pathogens	O	O	B-Entity
,	O	O	O
especially	O	O	O
in	O	O	O
K.	O	O	B-Entity
pneumoniae	O	O	I-Entity
and	O	O	O
A.	O	O	B-Entity
baumannii	O	O	I-Entity
Furthermore	O	O	O
,	O	O	O
the	O	O	O
observation	O	O	O
that	O	O	O
lipid	O	O	B-Entity
A	O	O	I-Entity
structures	O	O	B-Entity
were	O	O	O
modified	O	O	O
despite	O	O	O
only	O	O	O
modest	O	O	O
increases	O	O	B-Entity
in	O	O	O
colistin	O	O	O
MICs	O	O	B-Entity
in	O	O	O
some	O	O	O
instances	O	O	O
suggests	O	O	O
more	O	O	O
sophisticated	O	O	O
surveillance	O	O	B-Entity
methods	O	O	I-Entity
may	O	O	O
need	O	O	O
to	O	O	O
be	O	O	O
developed	O	O	O
to	O	O	O
track	O	O	O
the	O	O	O
dissemination	O	O	B-Entity
of	O	O	O
mcr-1	O	O	O
or	O	O	O
plasmid	O	O	B-Entity
-mediated	O	O	O
phosphoethanolamine	O	O	B-Entity
transferases	O	O	I-Entity
in	O	O	O
general	O	O	O
.	O	O	O

-DOCSTART- (28373627)

Effects	O	O	B-Entity
of	O	O	O
Transplanted	O	O	B-Entity
Human	O	O	B-Entity
Cord	O	O	B-Entity
Blood	O	O	I-Entity
-	O	O	O
Mononuclear	O	O	B-Entity
Cells	O	O	I-Entity
on	O	O	O
Pulmonary	O	O	B-Entity
Hypertension	O	O	I-Entity
in	O	O	O
Immunodeficient	O	O	B-Entity
Mice	O	O	I-Entity
and	O	O	O
Their	O	O	O
Distribution	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
umbilical	O	O	B-Entity
cord	O	O	I-Entity
blood	O	O	I-Entity
-derived	O	O	O
mononuclear	O	O	B-Entity
cell	O	O	I-Entity
(	O	O	O
hUCB	O	O	B-Entity
-	O	O	O
MNC	O	O	B-Entity
)	O	O	O
transplantation	O	O	B-Entity
on	O	O	O
pulmonary	O	O	B-Entity
hypertension	O	O	I-Entity
(	O	O	O
PH	O	O	B-Entity
)	O	O	O
induced	O	O	B-Entity
by	O	O	O
monocrotaline	O	O	B-Entity
(	O	O	O
MCT	O	O	B-Entity
)	O	O	O
in	O	O	O
immunodeficient	O	O	B-Entity
mice	O	O	I-Entity
and	O	O	O
their	O	O	O
distribution	O	O	B-Entity
.	O	O	O

MCT	O	O	B-Entity
was	O	O	O
administered	O	O	B-Entity
to	O	O	O
BALB/c	O	O	B-Entity
Slc-nu/nu	O	O	I-Entity
mice	O	O	B-Entity
,	O	O	O
and	O	O	O
PH	O	O	B-Entity
was	O	O	O
induced	O	O	B-Entity
in	O	O	O
mice	O	O	O
4	O	O	O
weeks	O	O	O
later	O	O	O
.	O	O	O

Fresh	O	O	B-Entity
hUCB	O	O	B-Entity
-	O	O	O
MNCs	O	O	B-Entity
harvested	O	O	B-Entity
from	O	O	O
a	O	O	O
human	O	O	B-Entity
donor	O	O	B-Entity
after	O	O	O
her	O	O	O
delivery	O	O	B-Entity
were	O	O	O
injected	O	O	B-Entity
intravenously	O	O	I-Entity
into	O	O	O
those	O	O	O
PH	O	O	B-Entity
mice	O	O	B-Entity
.	O	O	O

The	O	O	O
medial	O	O	B-Entity
thickness	O	O	B-Entity
of	O	O	O
pulmonary	O	O	B-Entity
arterioles	O	O	I-Entity
,	O	O	O
ratio	O	O	B-Entity
of	O	O	O
right	O	O	B-Entity
ventricular	O	O	I-Entity
to	O	O	O
septum	O	O	B-Entity
plus	O	O	B-Entity
left	O	O	B-Entity
ventricular	O	O	I-Entity
weight	O	O	B-Entity
(	O	O	O
RV	O	O	B-Entity
/	O	O	O
S	O	O	B-Entity
+	O	O	O
LV	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
ratio	O	O	O
of	O	O	O
acceleration	O	O	B-Entity
time	O	O	I-Entity
to	O	O	O
ejection	O	O	B-Entity
time	O	O	I-Entity
of	O	O	O
pulmonary	O	O	B-Entity
blood	O	O	I-Entity
flow	O	O	I-Entity
waveform	O	O	B-Entity
(	O	O	O
AT	O	O	B-Entity
/	O	O	O
ET	O	O	B-Entity
)	O	O	O
were	O	O	O
determined	O	O	B-Entity
4	O	O	O
weeks	O	O	O
after	O	O	O
hUCB	O	O	B-Entity
-	O	O	O
MNC	O	O	B-Entity
transplantation	O	O	B-Entity
.	O	O	O

To	O	O	O
reveal	O	O	B-Entity
the	O	O	O
incorporation	O	O	B-Entity
into	O	O	O
the	O	O	O
lung	O	O	B-Entity
,	O	O	O
CMTMR	O	O	B-Entity
-	O	O	O
labeled	O	O	B-Entity
hUCB	O	O	B-Entity
-	O	O	O
MNCs	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
lung	O	O	O
by	O	O	O
fluorescent	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

DiR-labeled	O	O	B-Entity
hUCB	O	O	B-Entity
-	O	O	O
MNCs	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
the	O	O	O
lung	O	O	B-Entity
and	O	O	O
other	O	O	O
organs	O	O	B-Entity
by	O	O	O
bioluminescence	O	O	B-Entity
images	O	O	I-Entity
.	O	O	O

Medial	O	O	B-Entity
thickness	O	O	B-Entity
,	O	O	O
RV	O	O	B-Entity
/	O	O	O
S	O	O	B-Entity
+	O	O	O
LV	O	O	B-Entity
and	O	O	O
AT	O	O	B-Entity
/	O	O	O
ET	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
improved	O	O	B-Entity
4	O	O	O
weeks	O	O	O
after	O	O	O
hUCB	O	O	B-Entity
-	O	O	O
MNC	O	O	B-Entity
transplantation	O	O	B-Entity
compared	O	O	B-Entity
with	O	O	O
those	O	O	O
in	O	O	O
mice	O	O	B-Entity
without	O	O	O
hUCB	O	O	O
-	O	O	O
MNC	O	O	O
transplantation	O	O	O
.	O	O	O

CMTMR	O	O	B-Entity
-	O	O	O
positive	O	O	B-Entity
hUCB	O	O	B-Entity
-	O	O	O
MNCs	O	O	B-Entity
were	O	O	O
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
lung	O	O	B-Entity
3	O	O	O
hours	O	O	O
after	O	O	O
transplantation	O	O	B-Entity
.	O	O	O

Bioluminescence	O	O	B-Entity
signals	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
more	O	O	O
strongly	O	O	B-Entity
in	O	O	O
the	O	O	O
lung	O	O	B-Entity
than	O	O	O
in	O	O	O
other	O	O	O
organs	O	O	B-Entity
for	O	O	O
24	O	O	O
hours	O	O	O
after	O	O	O
transplantation	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	B-Entity
indicate	O	O	B-Entity
that	O	O	O
hUCB	O	O	B-Entity
-	O	O	O
MNCs	O	O	B-Entity
are	O	O	O
incorporated	O	O	B-Entity
into	O	O	O
the	O	O	O
lung	O	O	B-Entity
early	O	O	B-Entity
after	O	O	O
hUCB	O	O	O
-	O	O	O
MNC	O	O	B-Entity
transplantation	O	O	B-Entity
and	O	O	O
improve	O	O	B-Entity
MCT	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
PH	O	O	B-Entity
.	O	O	O

J.	O	O	O
Med	O	O	O
.	O	O	O

Invest	O	O	O
.	O	O	O

64	O	O	O
:	O	O	O
43	O	O	O
-	O	O	O
49	O	O	O
,	O	O	O
February	O	O	O
,	O	O	O
2017	O	O	O
.	O	O	O

-DOCSTART- (28375952)

Interprofessional	O	O	B-Entity
Barriers	O	O	I-Entity
:	O	O	O
A	O	O	O
Study	O	O	O
of	O	O	O
Quality	O	O	B-Entity
Improvement	O	O	I-Entity
Work	O	O	I-Entity
Among	O	O	O
Nurses	O	O	B-Entity
and	O	O	O
Physicians	O	O	O

This	O	O	O
article	O	O	O
studies	O	O	O
interprofessional	O	O	B-Entity
barriers	O	O	I-Entity
between	O	O	O
nurses	O	O	B-Entity
and	O	O	O
physicians	O	O	B-Entity
in	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
quality	O	O	B-Entity
improvement	O	O	I-Entity
work	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
17	O	O	O
nurses	O	O	B-Entity
and	O	O	O
10	O	O	O
physicians	O	O	B-Entity
were	O	O	O
interviewed	O	O	B-Entity
at	O	O	O
2	O	O	O
hospitals	O	O	B-Entity
in	O	O	O
Sweden	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
uncovered	O	O	I-Entity
a	O	O	O
number	O	O	B-Entity
of	O	O	I-Entity
barriers	O	O	I-Entity
relating	O	O	O
to	O	O	O
both	O	O	O
the	O	O	O
relative	O	O	O
status	O	O	O
of	O	O	O
each	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
their	O	O	O
defined	O	O	O
areas	O	O	B-Entity
of	O	O	I-Entity
responsibility	O	O	I-Entity
.	O	O	O

-DOCSTART- (28376287)

Recovery	O	O	B-Entity
from	O	O	O
alcohol	O	O	B-Entity
dependence	O	O	I-Entity
:	O	O	O
Do	O	O	O
smoking	O	O	B-Entity
indicators	O	O	B-Entity
predict	O	O	O
abstinence	O	O	B-Entity
?	O	O	O

There	O	O	O
is	O	O	O
inconsistent	O	O	B-Entity
evidence	O	O	B-Entity
about	O	O	O
the	O	O	O
potential	O	O	B-Entity
influence	O	O	B-Entity
of	O	O	O
smoking	O	O	B-Entity
on	O	O	O
recovery	O	O	B-Entity
from	O	O	O
alcohol	O	O	B-Entity
dependence	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
aimed	O	O	O
at	O	O	O
assessing	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
smoking-behavior	O	O	B-Entity
on	O	O	O
relapse	O	O	B-Entity
during	O	O	O
a	O	O	O
12	O	O	O
months	O	O	B-Entity
follow-up	O	O	B-Entity
period	O	O	B-Entity
following	O	O	O
a	O	O	O
detoxification	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
Alcohol	O	O	B-Entity
Use	O	O	I-Entity
Disorder	O	O	I-Entity
(	O	O	O
AUD	O	O	B-Entity
)	O	O	O
.	O	O	O

Three	O	O	O
hundred	O	O	O
Patients	O	O	B-Entity
with	O	O	O
AUD	O	O	B-Entity
(	O	O	O
74.9	O	O	O
%	O	O	O
smoking	O	O	B-Entity
)	O	O	O
were	O	O	O
recruited	O	O	O
from	O	O	O
two	O	O	O
inpatient	O	O	B-Entity
detoxification	O	O	B-Entity
units	O	O	I-Entity
in	O	O	O
psychiatric	O	O	B-Entity
hospitals	O	O	I-Entity
in	O	O	O
Germany	O	O	B-Entity
and	O	O	O
their	O	O	O
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
was	O	O	O
prospectively	O	O	O
followed	O	O	O
for	O	O	O
1	O	O	O
year	O	O	B-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
different	O	O	O
indicators	O	O	B-Entity
of	O	O	O
smoking	O	O	B-Entity
behavior	O	O	I-Entity
was	O	O	O
gathered	O	O	O
.	O	O	O

Cox	O	O	B-Entity
regression	O	O	I-Entity
model	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
potential	O	O	B-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
on	O	O	O
time	O	O	O
to	O	O	O
relapse	O	O	B-Entity
of	O	O	O
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
.	O	O	O

Two	O	O	O
hundred	O	O	O
seventy-nine	O	O	O
participants	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
279	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
final	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

Smoking	O	O	B-Entity
increased	O	O	B-Entity
the	O	O	O
risk	O	O	B-Entity
for	O	O	O
alcohol	O	O	B-Entity
relapse	O	O	I-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
=	O	O	O
3.962	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
1.582	O	O	O
-	O	O	O
9.921	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
this	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
is	O	O	O
slightly	O	O	O
reduced	O	O	B-Entity
with	O	O	O
higher	O	O	O
numbers	O	O	O
of	O	O	O
daily	O	O	B-Entity
consumed	O	O	B-Entity
cigarettes	O	O	I-Entity
(	O	O	O
hazard	O	O	B-Entity
ratio	O	O	I-Entity
per	O	O	B-Entity
cigarette	O	O	B-Entity
=	O	O	O
.986	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
.976-.995	O	O	O
)	O	O	O
.	O	O	O

Smoking	O	O	B-Entity
reduced	O	O	I-Entity
the	O	O	O
probability	O	O	B-Entity
of	O	O	O
maintaining	O	O	B-Entity
alcohol	O	O	B-Entity
abstinence	O	O	I-Entity
significantly	O	O	B-Entity
,	O	O	O
whereas	O	O	O
higher	O	O	B-Entity
number	O	O	O
of	O	O	O
cigarettes	O	O	B-Entity
smoked	O	O	I-Entity
daily	O	O	B-Entity
diminished	O	O	B-Entity
the	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
alcohol	O	O	B-Entity
relapse	O	O	I-Entity
in	O	O	O
alcohol-dependent	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Coordinated	O	O	B-Entity
psychiatric	O	O	B-Entity
and	O	O	O
substance	O	O	B-Entity
abuse	O	O	I-Entity
interventions	O	O	B-Entity
for	O	O	O
different	O	O	O
subgroups	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
AUD	O	O	B-Entity
in	O	O	O
the	O	O	O
post-acute	O	O	B-Entity
treatment	O	O	I-Entity
phase	O	O	I-Entity
are	O	O	O
necessary	O	O	O
.	O	O	O

Individualized	O	O	B-Entity
treatment	O	O	B-Entity
planning	O	O	O
is	O	O	O
especially	O	O	O
important	O	O	O
in	O	O	O
smoking	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
AUD	O	O	B-Entity
who	O	O	O
are	O	O	O
vulnerable	O	O	O
for	O	O	O
a	O	O	O
relapse	O	O	B-Entity
to	O	O	I-Entity
alcohol	O	O	I-Entity
drinking	O	O	I-Entity
and	O	O	O
for	O	O	O
somatic	O	O	B-Entity
complications	O	O	B-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
might	O	O	O
support	O	O	O
individualized	O	O	B-Entity
treatment	O	O	B-Entity
plans	O	O	I-Entity
.(Am	O	O	O
J	O	O	O
Addict	O	O	O
2017;XX:1	O	O	O
-	O	O	O
8)	O	O	O
.	O	O	O

-DOCSTART- (28377210)

Similar	O	O	O
patterns	O	O	B-Entity
of	O	O	O
neural	O	O	B-Entity
activity	O	O	I-Entity
predict	O	O	O
memory	O	O	B-Entity
function	O	O	I-Entity
during	O	O	O
encoding	O	O	B-Entity
and	O	O	O
retrieval	O	O	O

Neural	O	O	B-Entity
networks	O	O	I-Entity
that	O	O	O
span	O	O	B-Entity
the	O	O	O
medial	O	O	B-Entity
temporal	O	O	I-Entity
lobe	O	O	I-Entity
(	O	O	O
MTL	O	O	B-Entity
)	O	O	O
,	O	O	O
prefrontal	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
and	O	O	O
posterior	O	O	B-Entity
cortical	O	O	I-Entity
regions	O	O	I-Entity
are	O	O	O
essential	O	O	O
to	O	O	O
episodic	O	O	B-Entity
memory	O	O	I-Entity
function	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

Encoding	O	O	B-Entity
and	O	O	O
retrieval	O	O	B-Entity
are	O	O	O
supported	O	O	O
by	O	O	O
the	O	O	O
engagement	O	O	O
of	O	O	O
both	O	O	O
distinct	O	O	O
neural	O	O	B-Entity
pathways	O	O	I-Entity
across	O	O	O
the	O	O	O
cortex	O	O	B-Entity
and	O	O	O
common	O	O	O
structures	O	O	B-Entity
within	O	O	O
the	O	O	O
medial	O	O	B-Entity
temporal	O	O	I-Entity
lobes	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
degree	O	O	O
to	O	O	O
which	O	O	O
memory	O	O	B-Entity
performance	O	O	I-Entity
can	O	O	O
be	O	O	O
determined	O	O	O
by	O	O	O
neural	O	O	B-Entity
processing	O	O	I-Entity
that	O	O	O
is	O	O	O
common	O	O	O
to	O	O	O
encoding	O	O	B-Entity
and	O	O	O
retrieval	O	O	B-Entity
remains	O	O	O
to	O	O	O
be	O	O	O
determined	O	O	O
.	O	O	O

To	O	O	O
identify	O	O	O
neural	O	O	B-Entity
signatures	O	O	I-Entity
of	O	O	O
successful	O	O	O
memory	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
we	O	O	O
administered	O	O	O
a	O	O	O
delayed	O	O	O
free-recall	O	O	B-Entity
task	O	O	I-Entity
to	O	O	O
187	O	O	O
neurosurgical	O	O	B-Entity
patients	O	O	B-Entity
implanted	O	O	B-Entity
with	O	O	O
subdural	O	O	B-Entity
or	O	O	O
intraparenchymal	O	O	B-Entity
depth	O	O	B-Entity
electrodes	O	O	I-Entity
.	O	O	O

We	O	O	O
developed	O	O	O
multivariate	O	O	B-Entity
classifiers	O	O	I-Entity
to	O	O	O
identify	O	O	O
patterns	O	O	B-Entity
of	O	O	O
spectral	O	O	O
power	O	O	O
across	O	O	O
the	O	O	O
brain	O	O	B-Entity
that	O	O	O
independently	O	O	O
predicted	O	O	O
successful	O	O	O
episodic	O	O	B-Entity
encoding	O	O	I-Entity
and	O	O	O
retrieval	O	O	B-Entity
.	O	O	O

During	O	O	O
encoding	O	O	B-Entity
and	O	O	O
retrieval	O	O	B-Entity
,	O	O	O
patterns	O	O	B-Entity
of	O	O	O
increased	O	O	O
high	O	O	B-Entity
frequency	O	O	I-Entity
activity	O	O	B-Entity
in	O	O	O
prefrontal	O	O	B-Entity
,	O	O	O
MTL	O	O	B-Entity
,	O	O	O
and	O	O	O
inferior	O	O	B-Entity
parietal	O	O	I-Entity
cortices	O	O	I-Entity
,	O	O	O
accompanied	O	O	O
by	O	O	O
widespread	O	O	O
decreases	O	O	O
in	O	O	O
low	O	O	B-Entity
frequency	O	O	I-Entity
power	O	O	O
across	O	O	O
the	O	O	O
brain	O	O	B-Entity
predicted	O	O	O
successful	O	O	O
memory	O	O	B-Entity
function	O	O	I-Entity
.	O	O	O

Using	O	O	O
a	O	O	O
cross-decoding	O	O	B-Entity
approach	O	O	I-Entity
,	O	O	O
we	O	O	O
demonstrate	O	O	O
the	O	O	O
ability	O	O	O
to	O	O	O
predict	O	O	O
memory	O	O	B-Entity
function	O	O	I-Entity
across	O	O	O
distinct	O	O	O
phases	O	O	O
of	O	O	O
the	O	O	O
free-recall	O	O	B-Entity
task	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
classifiers	O	O	B-Entity
that	O	O	O
combine	O	O	O
information	O	O	O
from	O	O	O
both	O	O	O
encoding	O	O	B-Entity
and	O	O	O
retrieval	O	O	B-Entity
states	O	O	I-Entity
can	O	O	O
outperform	O	O	O
task-independent	O	O	B-Entity
models	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
engagement	O	O	O
of	O	O	O
a	O	O	O
core	O	O	O
memory	O	O	B-Entity
network	O	O	I-Entity
during	O	O	O
either	O	O	O
encoding	O	O	B-Entity
or	O	O	O
retrieval	O	O	B-Entity
shapes	O	O	B-Entity
the	O	O	O
ability	O	O	B-Entity
to	O	O	I-Entity
remember	O	O	I-Entity
the	O	O	I-Entity
past	O	O	I-Entity
,	O	O	O
despite	O	O	O
distinct	O	O	O
neural	O	O	B-Entity
interactions	O	O	I-Entity
that	O	O	O
facilitate	O	O	O
encoding	O	O	O
and	O	O	O
retrieval	O	O	O
.	O	O	O

-DOCSTART- (28378668)

Trump	O	O	B-Entity
's	O	O	I-Entity
got	O	O	O
the	O	O	O
right	O	O	O
idea	O	O	O

I	O	O	O
am	O	O	O
a	O	O	O
US	O	O	B-Entity
nursing	O	O	B-Entity
student	O	O	I-Entity
and	O	O	O
feel	O	O	B-Entity
that	O	O	O
Obamacare	O	O	B-Entity
is	O	O	O
a	O	O	O
bad	O	O	B-Entity
idea	O	O	I-Entity
.	O	O	O
I	O	O	O
'm	O	O	O
disappointed	O	O	B-Entity
that	O	O	O
President	O	O	B-Entity
Trump	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
able	O	O	I-Entity
to	O	O	I-Entity
get	O	O	I-Entity
rid	O	O	I-Entity
of	O	O	I-Entity
it	O	O	O
last	O	O	B-Entity
month	O	O	I-Entity
.	O	O	O

-DOCSTART- (28379026)

Bilirubin	O	O	B-Entity
and	O	O	O
atherosclerotic	O	O	B-Entity
diseases	O	O	O

Bilirubin	O	O	B-Entity
is	O	O	O
the	O	O	O
final	O	O	O
product	O	O	B-Entity
of	O	O	O
heme	O	O	B-Entity
catabolism	O	O	I-Entity
in	O	O	O
the	O	O	O
systemic	O	O	B-Entity
circulation	O	O	I-Entity
.	O	O	O

For	O	O	O
decades	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
serum	O	O	B-Entity
/	O	O	O
plasma	O	O	B-Entity
bilirubin	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
considered	O	O	O
an	O	O	O
ominous	O	O	O
sign	O	O	B-Entity
of	O	O	O
an	O	O	O
underlying	O	O	O
liver	O	O	B-Entity
disease	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
data	O	O	B-Entity
from	O	O	O
recent	O	O	O
years	O	O	B-Entity
convincingly	O	O	O
suggest	O	O	O
that	O	O	O
mildly	O	O	O
elevated	O	O	B-Entity
bilirubin	O	O	B-Entity
concentrations	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	O
protection	O	O	B-Entity
against	O	O	O
various	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
-mediated	O	O	O
diseases	O	O	B-Entity
,	O	O	O
atherosclerotic	O	O	B-Entity
conditions	O	O	O
being	O	O	O
the	O	O	O
most	O	O	O
clinically	O	O	B-Entity
relevant	O	O	B-Entity
.	O	O	O

Although	O	O	O
scarce	O	O	O
data	O	O	B-Entity
on	O	O	O
beneficial	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
bilirubin	O	O	B-Entity
had	O	O	O
been	O	O	O
published	O	O	B-Entity
also	O	O	O
in	O	O	O
the	O	O	O
past	O	O	O
,	O	O	O
it	O	O	O
took	O	O	O
until	O	O	O
1994	O	O	O
when	O	O	O
the	O	O	O
first	O	O	O
clinical	O	O	B-Entity
study	O	O	I-Entity
demonstrated	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
coronary	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
subjects	O	O	O
with	O	O	O
low	O	O	B-Entity
serum	O	O	B-Entity
bilirubin	O	O	O
levels	O	O	B-Entity
,	O	O	O
and	O	O	O
bilirubin	O	O	O
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
atherosclerotic	O	O	B-Entity
diseases	O	O	B-Entity
independent	O	O	O
of	O	O	O
standard	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

Consistent	O	O	O
with	O	O	O
these	O	O	O
results	O	O	B-Entity
,	O	O	O
we	O	O	O
proved	O	O	O
in	O	O	O
our	O	O	O
own	O	O	O
studies	O	O	B-Entity
,	O	O	O
that	O	O	O
subjects	O	O	O
with	O	O	O
mild	O	O	B-Entity
elevation	O	O	I-Entity
of	O	O	I-Entity
serum	O	O	I-Entity
levels	O	O	I-Entity
of	O	O	I-Entity
unconjugated	O	O	I-Entity
bilirubin	O	O	I-Entity
(	O	O	O
benign	O	O	B-Entity
hyperbilirubinemia	O	O	B-Entity
,	O	O	O
Gilbert	O	O	B-Entity
syndrome	O	O	I-Entity
)	O	O	O
have	O	O	O
much	O	O	O
lower	O	O	O
prevalence	O	O	B-Entity
/	O	O	O
incidence	O	O	B-Entity
of	O	O	O
coronary	O	O	B-Entity
heart	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
peripheral	O	O	B-Entity
vascular	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
also	O	O	O
demonstrated	O	O	O
that	O	O	O
this	O	O	O
association	O	O	B-Entity
is	O	O	O
even	O	O	O
more	O	O	O
general	O	O	O
,	O	O	O
with	O	O	O
serum	O	O	B-Entity
bilirubin	O	O	B-Entity
being	O	O	O
a	O	O	O
biomarker	O	O	B-Entity
of	O	O	O
numerous	O	O	O
other	O	O	O
diseases	O	O	B-Entity
,	O	O	O
often	O	O	O
associated	O	O	B-Entity
with	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
atherosclerosis	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
very	O	O	O
recent	O	O	O
data	O	O	B-Entity
have	O	O	O
demonstrated	O	O	O
biological	O	O	B-Entity
pathways	O	O	I-Entity
modulated	O	O	O
by	O	O	O
bilirubin	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
responsible	O	O	O
for	O	O	O
observed	O	O	O
strong	O	O	O
clinical	O	O	B-Entity
associations	O	O	B-Entity
.	O	O	O

-DOCSTART- (28379326)

An	O	O	O
Automated	O	O	B-Entity
,	O	O	O
Pharmacist	O	O	B-Entity
-Driven	O	O	O
Initiative	O	O	B-Entity
Improves	O	O	B-Entity
Quality	O	O	B-Entity
of	O	O	I-Entity
Care	O	O	I-Entity
for	O	O	O
Staphylococcus	O	O	O
aureus	O	O	O
Bacteremia	O	O	O

Infectious	O	O	B-Entity
diseases	O	O	I-Entity
(	O	O	O
ID	O	O	B-Entity
)	O	O	O
consultation	O	O	B-Entity
and	O	O	O
antimicrobial	O	O	B-Entity
stewardship	O	O	I-Entity
intervention	O	O	I-Entity
have	O	O	O
been	O	O	O
shown	O	O	O
to	O	O	O
improve	O	O	B-Entity
the	O	O	O
management	O	O	B-Entity
of	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
bacteremia	O	O	I-Entity
(	O	O	O
SAB	O	O	B-Entity
)	O	O	O
.	O	O	O

As	O	O	O
the	O	O	O
workload	O	O	B-Entity
of	O	O	O
antimicrobial	O	O	B-Entity
stewardship	O	O	I-Entity
programs	O	O	I-Entity
(	O	O	O
ASPs	O	O	B-Entity
)	O	O	O
continues	O	O	O
to	O	O	O
increase	O	O	O
,	O	O	O
ASPs	O	O	O
must	O	O	O
find	O	O	O
a	O	O	O
way	O	O	O
to	O	O	O
maximize	O	O	O
the	O	O	O
efficiency	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
program	O	O	I-Entity
while	O	O	O
optimizing	O	O	O
patient	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
incorporating	O	O	O
health	O	O	B-Entity
informatics	O	O	I-Entity
into	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
SAB	O	O	B-Entity
via	O	O	O
a	O	O	O
pharmacist	O	O	B-Entity
-driven	O	O	O
initiative	O	O	B-Entity
.	O	O	O

Retrospective	O	O	B-Entity
,	O	O	O
single-center	O	O	O
quasi-experimental	O	O	B-Entity
study	O	O	B-Entity
of	O	O	O
hospitalized	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
SAB	O	O	B-Entity
.	O	O	O

During	O	O	O
the	O	O	O
intervention	O	O	B-Entity
period	O	O	B-Entity
,	O	O	O
pharmacists	O	O	B-Entity
were	O	O	O
alerted	O	O	O
to	O	O	O
patients	O	O	B-Entity
with	O	O	O
SAB	O	O	B-Entity
via	O	O	O
a	O	O	O
patient	O	O	B-Entity
scoring	O	O	B-Entity
tool	O	O	I-Entity
integrated	O	O	O
into	O	O	O
the	O	O	O
electronic	O	O	B-Entity
medical	O	O	I-Entity
record	O	O	I-Entity
.	O	O	O

Pharmacists	O	O	B-Entity
utilized	O	O	O
the	O	O	O
scoring	O	O	B-Entity
tool	O	O	I-Entity
and	O	O	O
the	O	O	O
institution	O	O	B-Entity
's	O	O	I-Entity
evidence-based	O	O	B-Entity
practice	O	O	I-Entity
guideline	O	O	B-Entity
to	O	O	O
make	O	O	O
standardized	O	O	B-Entity
recommendations	O	O	I-Entity
to	O	O	O
promote	O	O	O
adherence	O	O	B-Entity
to	O	O	O
SAB	O	O	B-Entity
quality-of-care	O	O	B-Entity
measures	O	O	B-Entity
and	O	O	O
encourage	O	O	O
ID	O	O	B-Entity
consultation	O	O	B-Entity
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
outcome	O	O	B-Entity
was	O	O	O
overall	O	O	O
compliance	O	O	B-Entity
along	O	O	O
with	O	O	O
adherence	O	O	B-Entity
to	O	O	O
individual	O	O	B-Entity
quality-of-care	O	O	B-Entity
components	O	O	B-Entity
.	O	O	O

Secondary	O	O	B-Entity
clinical	O	O	O
outcomes	O	O	B-Entity
were	O	O	O
also	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

84	O	O	O
patients	O	O	B-Entity
were	O	O	O
identified	O	O	O
for	O	O	O
study	O	O	B-Entity
inclusion	O	O	B-Entity
,	O	O	O
45	O	O	O
in	O	O	O
the	O	O	O
pre-	O	O	O
intervention	O	O	B-Entity
and	O	O	O
39	O	O	O
in	O	O	O
the	O	O	O
intervention	O	O	O
group	O	O	B-Entity
.	O	O	O

As	O	O	O
a	O	O	O
whole	O	O	O
,	O	O	O
all	O	O	O
four	O	O	O
quality-of-care	O	O	B-Entity
components	O	O	B-Entity
for	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
SAB	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
more	O	O	O
frequently	O	O	O
adhered	O	O	O
to	O	O	O
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
68.9	O	O	O
%	O	O	O
vs.	O	O	O
92.3	O	O	O
%	O	O	O
;	O	O	O
P=0.008	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
ID	O	O	B-Entity
consult	O	O	B-Entity
improved	O	O	B-Entity
significantly	O	O	B-Entity
by	O	O	O
almost	O	O	O
20	O	O	O
%	O	O	O
in	O	O	O
the	O	O	O
intervention	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
75.6	O	O	O
%	O	O	O
vs.	O	O	O
94.9	O	O	O
%	O	O	O
,	O	O	O
P=0.015	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
in	O	O	O
duration	O	O	O
of	O	O	O
bacteremia	O	O	B-Entity
,	O	O	O
length-of-stay	O	O	B-Entity
,	O	O	O
infection	O	O	B-Entity
-related	O	O	O
length-of-stay	O	O	O
,	O	O	O
or	O	O	O
readmission	O	O	B-Entity
were	O	O	O
observed	O	O	O
between	O	O	O
the	O	O	O
groups	O	O	B-Entity
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
all-cause	O	O	O
mortality	O	O	B-Entity
was	O	O	O
6-fold	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
pre-	O	O	O
intervention	O	O	B-Entity
group	O	O	B-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
intervention	O	O	O
group	O	O	O
(	O	O	O
15.6	O	O	O
%	O	O	O
vs.	O	O	O
2.6	O	O	O
%	O	O	O
,	O	O	O
P=0.063	O	O	O
)	O	O	O
.	O	O	O

An	O	O	O
automated	O	O	B-Entity
,	O	O	O
pharmacist	O	O	B-Entity
-driven	O	O	O
intervention	O	O	B-Entity
for	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
SAB	O	O	B-Entity
demonstrated	O	O	O
a	O	O	O
significant	O	O	B-Entity
improvement	O	O	B-Entity
in	O	O	O
patients	O	O	O
receiving	O	O	O
an	O	O	O
ID	O	O	B-Entity
consult	O	O	B-Entity
,	O	O	O
targeted	O	O	B-Entity
antimicrobial	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
and	O	O	O
adherence	O	O	B-Entity
to	O	O	O
all	O	O	O
SAB	O	O	O
quality-of-care	O	O	B-Entity
measures	O	O	B-Entity
.	O	O	O

As	O	O	O
antimicrobial	O	O	B-Entity
stewardship	O	O	I-Entity
becomes	O	O	O
a	O	O	O
mandatory	O	O	B-Entity
aspect	O	O	O
of	O	O	O
healthcare	O	O	B-Entity
in	O	O	O
all	O	O	O
hospitals	O	O	B-Entity
in	O	O	O
the	O	O	O
U.S.	O	O	B-Entity
,	O	O	O
ASPs	O	O	B-Entity
will	O	O	O
be	O	O	O
forced	O	O	B-Entity
to	O	O	O
find	O	O	B-Entity
ways	O	O	O
to	O	O	O
provide	O	O	O
more	O	O	O
efficient	O	O	B-Entity
,	O	O	O
impactful	O	O	B-Entity
,	O	O	O
disease	O	O	B-Entity
state-based	O	O	O
patient	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
provides	O	O	O
the	O	O	O
framework	O	O	O
for	O	O	O
and	O	O	O
data	O	O	B-Entity
to	O	O	O
support	O	O	O
this	O	O	O
intervention	O	O	B-Entity
in	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
clinically	O	O	B-Entity
important	O	O	I-Entity
infectious	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

-DOCSTART- (28380662)

Involvement	O	O	O
of	O	O	O
intracellular	O	O	B-Entity
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
signaling	O	O	B-Entity
in	O	O	O
LTP	O	O	B-Entity
at	O	O	O
perforant	O	O	B-Entity
pathway	O	O	I-Entity
-	O	O	O
CA1	O	O	O
pyramidal	O	O	O
cell	O	O	O
synapse	O	O	O

Physiological	O	O	B-Entity
significance	O	O	O
of	O	O	O
synaptic	O	O	B-Entity
Zn(2	O	O	I-Entity
+	O	O	I-Entity
)	O	O	I-Entity
signaling	O	O	I-Entity
was	O	O	O
examined	O	O	O
at	O	O	O
perforant	O	O	B-Entity
pathway	O	O	I-Entity
-	O	O	O
CA1	O	O	B-Entity
pyramidal	O	O	I-Entity
cell	O	O	I-Entity
synapses	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
long-term	O	O	B-Entity
potentiation	O	O	I-Entity
(	O	O	O
LTP	O	O	B-Entity
)	O	O	O
at	O	O	O
perforant	O	O	B-Entity
pathway	O	O	I-Entity
-	O	O	O
CA1	O	O	B-Entity
pyramidal	O	O	I-Entity
cell	O	O	I-Entity
synapses	O	O	I-Entity
was	O	O	O
induced	O	O	O
using	O	O	O
a	O	O	O
recording	O	O	O
electrode	O	O	B-Entity
attached	O	O	O
to	O	O	O
a	O	O	O
microdialysis	O	O	B-Entity
probe	O	O	B-Entity
and	O	O	O
the	O	O	O
recording	O	O	O
region	O	O	O
was	O	O	O
locally	O	O	O
perfused	O	O	B-Entity
with	O	O	O
artificial	O	O	B-Entity
cerebrospinal	O	O	I-Entity
fluid	O	O	I-Entity
(	O	O	O
ACSF	O	O	B-Entity
)	O	O	O
via	O	O	O
the	O	O	O
microdialysis	O	O	O
probe	O	O	O
.	O	O	O

Perforant	O	O	B-Entity
pathway	O	O	I-Entity
LTP	O	O	B-Entity
was	O	O	O
not	O	O	O
attenuated	O	O	O
under	O	O	O
perfusion	O	O	B-Entity
with	O	O	O
CaEDTA	O	O	B-Entity
(	O	O	O
10	O	O	O
mM	O	O	O
)	O	O	O
,	O	O	O
an	O	O	O
extracellular	O	O	B-Entity
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
chelator	O	O	O
,	O	O	O
but	O	O	O
attenuated	O	O	O
under	O	O	O
perfusion	O	O	O
with	O	O	O
ZnAF-2DA	O	O	B-Entity
(	O	O	O
50	O	O	O
μM	O	O	O
)	O	O	O
,	O	O	O
an	O	O	O
intracellular	O	O	B-Entity
Zn(2	O	O	O
+	O	O	O
)	O	O	O
chelator	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
intracellular	O	O	O
Zn(2	O	O	O
+	O	O	O
)	O	O	O
signaling	O	O	B-Entity
is	O	O	O
required	O	O	O
for	O	O	O
perforant	O	O	B-Entity
pathway	O	O	I-Entity
LTP	O	O	O
.	O	O	O

Even	O	O	O
in	O	O	O
rat	O	O	B-Entity
brain	O	O	I-Entity
slices	O	O	I-Entity
bathed	O	O	O
in	O	O	O
CaEDTA	O	O	B-Entity
in	O	O	O
ACSF	O	O	B-Entity
,	O	O	O
intracellular	O	O	B-Entity
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
level	O	O	O
,	O	O	O
which	O	O	O
was	O	O	O
measured	O	O	O
with	O	O	O
intracellular	O	O	O
ZnAF-2	O	O	B-Entity
,	O	O	O
was	O	O	O
increased	O	O	O
in	O	O	O
the	O	O	O
stratum	O	O	B-Entity
lacunosum-moleculare	O	O	I-Entity
where	O	O	O
perforant	O	O	B-Entity
pathway	O	O	I-Entity
-	O	O	O
CA1	O	O	B-Entity
pyramidal	O	O	I-Entity
cell	O	O	I-Entity
synapses	O	O	I-Entity
were	O	O	O
contained	O	O	O
after	O	O	O
tetanic	O	O	B-Entity
stimulation	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
intracellular	O	O	B-Entity
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
signaling	O	O	B-Entity
,	O	O	O
which	O	O	O
originates	O	O	O
in	O	O	O
internal	O	O	O
stores/	O	O	O
proteins	O	O	B-Entity
,	O	O	O
is	O	O	O
involved	O	O	O
in	O	O	O
LTP	O	O	B-Entity
at	O	O	O
perforant	O	O	B-Entity
pathway	O	O	I-Entity
-	O	O	O
CA1	O	O	B-Entity
pyramidal	O	O	I-Entity
cell	O	O	I-Entity
synapses	O	O	I-Entity
.	O	O	O

Because	O	O	O
the	O	O	O
influx	O	O	B-Entity
of	O	O	O
extracellular	O	O	B-Entity
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
which	O	O	O
originates	O	O	O
in	O	O	O
presynaptic	O	O	B-Entity
Zn(2	O	O	I-Entity
+	O	O	I-Entity
)	O	O	I-Entity
release	O	O	I-Entity
,	O	O	O
is	O	O	O
involved	O	O	O
in	O	O	O
LTP	O	O	B-Entity
at	O	O	O
Schaffer	O	O	B-Entity
collateral	O	O	I-Entity
-	O	O	O
CA1	O	O	B-Entity
pyramidal	O	O	I-Entity
cell	O	O	I-Entity
synapses	O	O	I-Entity
,	O	O	O
synapse	O	O	B-Entity
-dependent	O	O	O
Zn(2	O	O	O
+	O	O	O
)	O	O	O
dynamics	O	O	O
may	O	O	O
be	O	O	O
involved	O	O	O
in	O	O	O
plasticity	O	O	B-Entity
of	O	O	O
postsynaptic	O	O	B-Entity
CA1	O	O	B-Entity
pyramidal	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

-DOCSTART- (28381880)

20S	O	O	B-Entity
immunoproteasomes	O	O	I-Entity
remove	O	O	O
formaldehyde	O	O	B-Entity
-	O	O	O
damaged	O	O	B-Entity
cytoplasmic	O	O	B-Entity
proteins	O	O	I-Entity
suppressing	O	O	B-Entity
caspase-independent	O	O	O
cell	O	O	O
death	O	O	O

Immunoproteasomes	O	O	B-Entity
are	O	O	O
known	O	O	O
for	O	O	O
their	O	O	O
involvement	O	O	B-Entity
in	O	O	O
antigen	O	O	B-Entity
presentation	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
their	O	O	O
broad	O	O	B-Entity
tissue	O	O	B-Entity
presence	O	O	B-Entity
and	O	O	O
other	O	O	O
evidence	O	O	B-Entity
are	O	O	O
indicative	O	O	B-Entity
of	O	O	I-Entity
nonimmune	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
a	O	O	O
role	O	O	O
for	O	O	O
immunoproteasomes	O	O	B-Entity
in	O	O	O
cellular	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
the	O	O	O
endogenous	O	O	B-Entity
and	O	O	O
environmental	O	O	B-Entity
carcinogen	O	O	I-Entity
formaldehyde	O	O	B-Entity
(	O	O	O
FA	O	O	B-Entity
)	O	O	O
that	O	O	O
binds	O	O	O
to	O	O	O
cytosolic	O	O	B-Entity
and	O	O	O
nuclear	O	O	B-Entity
proteins	O	O	I-Entity
producing	O	O	O
proteotoxic	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
genotoxic	O	O	B-Entity
DNA	O	O	B-Entity
-	O	O	O
histone	O	O	B-Entity
crosslinks	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
immunoproteasomes	O	O	B-Entity
were	O	O	O
important	O	O	B-Entity
for	O	O	O
suppression	O	O	B-Entity
of	O	O	O
a	O	O	O
caspase-independent	O	O	B-Entity
cell	O	O	I-Entity
death	O	O	I-Entity
and	O	O	O
the	O	O	O
long-term	O	O	B-Entity
survival	O	O	B-Entity
of	O	O	O
FA-treated	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

All	O	O	O
major	O	O	O
genotoxic	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
FA	O	O	B-Entity
,	O	O	O
including	O	O	O
replication	O	O	B-Entity
inhibition	O	O	I-Entity
and	O	O	O
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
transcription	O	O	B-Entity
factor	O	O	I-Entity
p53	O	O	I-Entity
and	O	O	O
the	O	O	O
apical	O	O	B-Entity
ATM	O	O	B-Entity
and	O	O	O
ATR	O	O	B-Entity
kinases	O	O	I-Entity
,	O	O	O
were	O	O	O
unaffected	O	O	B-Entity
by	O	O	O
immunoproteasome	O	O	B-Entity
inactivity	O	O	B-Entity
.	O	O	O

Immunoproteasome	O	O	O
inhibition	O	O	B-Entity
enhanced	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
the	O	O	O
cytosolic	O	O	B-Entity
protein	O	O	B-Entity
damage	O	O	B-Entity
sensor	O	O	B-Entity
HSF1	O	O	I-Entity
,	O	O	O
elevated	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
K48-polyubiquitinated	O	O	B-Entity
cytoplasmic	O	O	B-Entity
proteins	O	O	I-Entity
and	O	O	O
increased	O	O	B-Entity
depletion	O	O	B-Entity
of	O	O	O
unconjugated	O	O	B-Entity
ubiquitin	O	O	B-Entity
.	O	O	O

We	O	O	O
further	O	O	O
found	O	O	O
that	O	O	O
FA	O	O	B-Entity
induced	O	O	B-Entity
the	O	O	O
disassembly	O	O	B-Entity
of	O	O	O
26S	O	O	B-Entity
immunoproteasomes	O	O	I-Entity
,	O	O	O
but	O	O	O
not	O	O	O
standard	O	O	O
26S	O	O	B-Entity
proteasomes	O	O	I-Entity
,	O	O	O
releasing	O	O	O
the	O	O	O
20S	O	O	B-Entity
catalytic	O	O	I-Entity
immunoproteasome	O	O	I-Entity
.	O	O	O

FA-treated	O	O	B-Entity
cells	O	O	I-Entity
also	O	O	O
had	O	O	O
higher	O	O	B-Entity
amounts	O	O	I-Entity
of	O	O	O
small	O	O	O
activators	O	O	B-Entity
PA28αβ	O	O	I-Entity
and	O	O	O
PA28γ	O	O	B-Entity
bound	O	O	O
to	O	O	O
20S	O	O	B-Entity
particles	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	O
highlight	O	O	O
the	O	O	O
significance	O	O	B-Entity
of	O	O	O
nonnuclear	O	O	B-Entity
damage	O	O	I-Entity
in	O	O	O
FA	O	O	B-Entity
injury	O	O	O
and	O	O	O
reveal	O	O	O
a	O	O	O
major	O	O	O
role	O	O	O
for	O	O	O
immunoproteasomes	O	O	B-Entity
in	O	O	O
elimination	O	O	O
of	O	O	O
FA-damaged	O	O	B-Entity
cytoplasmic	O	O	B-Entity
proteins	O	O	I-Entity
through	O	O	O
ubiquitin	O	O	B-Entity
-	O	O	O
independent	O	O	B-Entity
proteolysis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28383311)

Musculoskeletal	O	O	B-Entity
pain	O	O	I-Entity
profile	O	O	B-Entity
of	O	O	O
obese	O	O	B-Entity
individuals	O	O	B-Entity
attending	O	O	B-Entity
a	O	O	O
multidisciplinary	O	O	O
weight	O	O	O
management	O	O	O
service	O	O	O

Obesity	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
numerous	O	O	B-Entity
chronic	O	O	B-Entity
diseases	O	O	I-Entity
,	O	O	O
including	O	O	B-Entity
musculoskeletal	O	O	B-Entity
(	O	O	I-Entity
MSK	O	O	I-Entity
)	O	O	I-Entity
pain	O	O	I-Entity
,	O	O	O
which	O	O	O
impacts	O	O	B-Entity
on	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
QoL	O	O	B-Entity
)	O	O	O
.	O	O	O

There	O	O	O
is	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
limited	O	O	O
research	O	O	O
providing	O	O	O
a	O	O	O
comprehensive	O	O	B-Entity
MSK	O	O	B-Entity
pain	O	O	I-Entity
profile	O	O	B-Entity
of	O	O	O
an	O	O	O
obese	O	O	B-Entity
cohort	O	O	B-Entity
.	O	O	O

This	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
utilized	O	O	O
a	O	O	O
patient	O	O	B-Entity
database	O	O	B-Entity
at	O	O	O
a	O	O	O
national	O	O	B-Entity
weight	O	O	I-Entity
management	O	O	I-Entity
service	O	O	I-Entity
(	O	O	O
WMS	O	O	B-Entity
)	O	O	O
.	O	O	O

Following	O	O	O
ethical	O	O	B-Entity
approval	O	O	B-Entity
,	O	O	O
anonymized	O	O	B-Entity
patient	O	O	B-Entity
data	O	O	I-Entity
were	O	O	O
statistically	O	O	B-Entity
analyzed	O	O	I-Entity
to	O	O	O
develop	O	O	O
a	O	O	O
pain	O	O	B-Entity
profile	O	O	B-Entity
,	O	O	O
investigate	O	O	B-Entity
relationships	O	O	B-Entity
between	O	O	O
pain	O	O	O
,	O	O	O
sleep	O	O	B-Entity
,	O	O	O
and	O	O	O
function	O	O	B-Entity
,	O	O	O
and	O	O	O
explore	O	O	O
variables	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
having	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
(	O	O	O
LBP	O	O	B-Entity
)	O	O	O
and	O	O	O
knee	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
915	O	O	O
individuals	O	O	B-Entity
attended	O	O	O
the	O	O	O
WMS	O	O	B-Entity
from	O	O	O
January	O	O	O
2011	O	O	O
to	O	O	O
September	O	O	O
2015	O	O	O
[	O	O	O
male	O	O	B-Entity
,	O	O	O
35	O	O	O
%	O	O	O
(	O	O	O
n=318	O	O	O
;	O	O	O
CI	O	O	B-Entity
=	O	O	O
32	O	O	O
-	O	O	O
38	O	O	O
)	O	O	O
;	O	O	O
female	O	O	B-Entity
,	O	O	O
65	O	O	O
%	O	O	O
(	O	O	O
n=597	O	O	O
;	O	O	O
CI	O	O	O
=	O	O	O
62	O	O	O
-	O	O	O
68	O	O	O
)	O	O	O
;	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
44.6	O	O	O
]	O	O	O
.	O	O	O

Mean	O	O	B-Entity
BMI	O	O	B-Entity
was	O	O	O
50.7	O	O	O
kg/m2	O	O	O
[	O	O	O
Class	O	O	O
III	O	O	O
obese	O	O	B-Entity
(	O	O	O
BMI	O	O	O
≥40	O	O	O
kg/m2	O	O	O
)	O	O	O
,	O	O	O
92	O	O	O
%	O	O	O
(	O	O	O
n=835	O	O	O
;	O	O	O
CI	O	O	B-Entity
=	O	O	O
91	O	O	O
-	O	O	O
94	O	O	O
)	O	O	O
]	O	O	O
.	O	O	O

Approximately	O	O	B-Entity
91	O	O	O
%	O	O	O
reported	O	O	O
MSK	O	O	B-Entity
pain	O	O	I-Entity
:	O	O	O
LBP	O	O	B-Entity
,	O	O	O
69	O	O	O
%	O	O	O
(	O	O	O
n=539	O	O	O
;	O	O	O
CI	O	O	B-Entity
=	O	O	O
65-	O	O	O
72	O	O	O
)	O	O	O
[	O	O	O
mean	O	O	B-Entity
NRS	O	O	O
7.4	O	O	O
]	O	O	O
;	O	O	O
knee	O	O	B-Entity
pain	O	O	I-Entity
,	O	O	O
58	O	O	O
%	O	O	O
(	O	O	O
n=447	O	O	O
;	O	O	O
CI	O	O	O
=	O	O	O
55	O	O	O
-	O	O	O
61	O	O	O
)	O	O	O
[	O	O	O
mean	O	O	O
NRS	O	O	O
6.8	O	O	O
]	O	O	O
.	O	O	O

Class	O	O	O
III	O	O	O
obese	O	O	B-Entity
and	O	O	O
multi-site	O	O	B-Entity
pain	O	O	B-Entity
patients	O	O	B-Entity
had	O	O	O
lower	O	O	B-Entity
QoL	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
levels	O	O	B-Entity
,	O	O	O
reduced	O	O	B-Entity
sleep	O	O	B-Entity
,	O	O	O
and	O	O	O
poorer	O	O	B-Entity
physical	O	O	B-Entity
function	O	O	I-Entity
than	O	O	O
less	O	O	B-Entity
obese	O	O	O
patients	O	O	O
and	O	O	O
those	O	O	O
without	O	O	B-Entity
pain	O	O	O
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Relationships	O	O	B-Entity
were	O	O	O
found	O	O	O
between	O	O	O
demographic	O	O	B-Entity
,	O	O	O
pain	O	O	B-Entity
,	O	O	O
self-report	O	O	B-Entity
,	O	O	O
psychological	O	O	B-Entity
,	O	O	O
and	O	O	O
functional	O	O	B-Entity
measures	O	O	B-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Patients	O	O	B-Entity
who	O	O	O
slept	O	O	B-Entity
fewer	O	O	I-Entity
hours	O	O	I-Entity
and	O	O	O
had	O	O	O
poorer	O	O	B-Entity
functional	O	O	B-Entity
outcomes	O	O	I-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
LBP	O	O	B-Entity
;	O	O	O
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
divorced	O	O	B-Entity
,	O	O	O
had	O	O	O
lower	O	O	B-Entity
QoL	O	O	B-Entity
,	O	O	O
and	O	O	O
more	O	O	O
frequent	O	O	B-Entity
nocturia	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
knee	O	O	B-Entity
pain	O	O	I-Entity
(	O	O	O
p<0.05	O	O	O
)	O	O	O
.	O	O	O

Multi-site	O	O	B-Entity
MSK	O	O	B-Entity
pain	O	O	I-Entity
is	O	O	O
prevalent	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
in	O	O	O
obese	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
is	O	O	O
negatively	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
most	O	O	O
self-report	O	O	O
and	O	O	O
functional	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

This	O	O	O
high	O	O	O
prevalence	O	O	B-Entity
suggests	O	O	O
pain	O	O	B-Entity
management	O	O	I-Entity
strategies	O	O	O
must	O	O	O
be	O	O	O
considered	O	O	O
when	O	O	O
treating	O	O	B-Entity
obesity	O	O	B-Entity
.	O	O	O

-DOCSTART- (28384898)

Primary	O	O	B-Entity
Management	O	O	B-Entity
and	O	O	O
Outcome	O	O	B-Entity
-	O	O	O
Open	O	O	O
Laryngotracheal	O	O	O
Trauma	O	O	O

Acute	O	O	B-Entity
external	O	O	B-Entity
injury	O	O	I-Entity
to	O	O	O
the	O	O	O
larynx	O	O	B-Entity
is	O	O	O
both	O	O	O
life	O	O	B-Entity
threatening	O	O	I-Entity
and	O	O	O
a	O	O	O
potential	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
management	O	O	B-Entity
challenge	O	O	O
.	O	O	O

As	O	O	O
Otorhinolaryngologist	O	O	B-Entity
we	O	O	O
must	O	O	O
be	O	O	O
prepared	O	O	O
and	O	O	O
well	O	O	O
versed	O	O	O
to	O	O	O
manage	O	O	O
these	O	O	O
patients	O	O	B-Entity
.	O	O	O

In	O	O	O
our	O	O	O
study	O	O	O
seven	O	O	O
patients	O	O	B-Entity
of	O	O	O
open	O	O	B-Entity
laryngeal	O	O	I-Entity
traumas	O	O	I-Entity
were	O	O	O
managed	O	O	O
by	O	O	O
primary	O	O	B-Entity
closure	O	O	I-Entity
.	O	O	O

In	O	O	O
five	O	O	O
patients	O	O	B-Entity
nature	O	O	B-Entity
of	O	O	I-Entity
injury	O	O	I-Entity
was	O	O	O
known	O	O	O
in	O	O	O
other	O	O	O
two	O	O	O
patients	O	O	O
exact	O	O	O
nature	O	O	O
of	O	O	O
injury	O	O	O
was	O	O	O
not	O	O	O
known	O	O	O
.	O	O	O

After	O	O	O
primary	O	O	B-Entity
closure	O	O	I-Entity
five	O	O	O
patients	O	O	B-Entity
with	O	O	O
known	O	O	O
injury	O	O	B-Entity
survived	O	O	B-Entity
and	O	O	O
two	O	O	O
patients	O	O	O
with	O	O	O
unknown	O	O	O
injury	O	O	O
died	O	O	B-Entity
.	O	O	O

As	O	O	O
per	O	O	O
our	O	O	O
experience	O	O	B-Entity
,	O	O	O
we	O	O	O
recommend	O	O	O
primary	O	O	B-Entity
closure	O	O	I-Entity
,	O	O	O
if	O	O	O
the	O	O	O
exact	O	O	O
nature	O	O	B-Entity
of	O	O	I-Entity
injury	O	O	I-Entity
is	O	O	O
known	O	O	O
as	O	O	O
the	O	O	O
outcome	O	O	B-Entity
is	O	O	O
definitely	O	O	O
favourable	O	O	B-Entity
.	O	O	O

-DOCSTART- (28385001)

Comparative	O	O	O
kinematic	O	O	B-Entity
gait	O	O	I-Entity
analysis	O	O	I-Entity
in	O	O	O
young	O	O	B-Entity
and	O	O	O
old	O	O	B-Entity
Beagle	O	O	O
dogs	O	O	O

Age-related	O	O	B-Entity
involution	O	O	B-Entity
in	O	O	O
dogs	O	O	B-Entity
involves	O	O	O
loss	O	O	B-Entity
of	O	O	I-Entity
muscle	O	O	I-Entity
mass	O	O	I-Entity
and	O	O	O
changes	O	O	O
in	O	O	O
connective	O	O	B-Entity
tissue	O	O	I-Entity
and	O	O	O
articular	O	O	B-Entity
cartilage	O	O	I-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
examine	O	O	B-Entity
whether	O	O	O
an	O	O	O
age-related	O	O	B-Entity
influence	O	O	O
on	O	O	O
joint	O	O	B-Entity
mobility	O	O	I-Entity
can	O	O	O
be	O	O	O
detected	O	O	B-Entity
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
diseases	O	O	B-Entity
.	O	O	O

Five	O	O	O
young	O	O	B-Entity
(	O	O	O
Ø	O	O	O
2.0	O	O	O
years	O	O	B-Entity
)	O	O	O
and	O	O	O
five	O	O	O
old	O	O	B-Entity
(	O	O	O
Ø	O	O	O
10.4	O	O	O
years	O	O	O
)	O	O	O
healthy	O	O	B-Entity
and	O	O	O
sound	O	O	B-Entity
Beagle	O	O	I-Entity
dogs	O	O	I-Entity
were	O	O	O
measured	O	O	B-Entity
during	O	O	O
locomotion	O	O	B-Entity
on	O	O	O
a	O	O	O
treadmill	O	O	B-Entity
by	O	O	O
computer-assisted	O	O	B-Entity
gait	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

Angles	O	O	B-Entity
of	O	O	O
the	O	O	O
shoulder	O	O	B-Entity
,	O	O	O
elbow	O	O	B-Entity
,	O	O	O
carpal	O	O	B-Entity
,	O	O	O
hip	O	O	B-Entity
,	O	O	O
stifle	O	O	B-Entity
and	O	O	O
tarsal	O	O	B-Entity
joints	O	O	I-Entity
were	O	O	O
analyzed	O	O	B-Entity
,	O	O	O
including	O	O	O
joint	O	O	B-Entity
angle	O	O	I-Entity
progression	O	O	I-Entity
curves	O	O	I-Entity
,	O	O	O
minimum	O	O	B-Entity
and	O	O	O
maximum	O	O	B-Entity
joint	O	O	O
angles	O	O	B-Entity
and	O	O	O
range	O	O	B-Entity
of	O	O	I-Entity
motion	O	O	I-Entity
(	O	O	O
ROM	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
old	O	O	B-Entity
group	O	O	B-Entity
showed	O	O	O
a	O	O	O
smaller	O	O	O
maximum	O	O	O
joint	O	O	B-Entity
angle	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.037	O	O	O
)	O	O	O
and	O	O	O
ROM	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.037	O	O	O
)	O	O	O
of	O	O	O
the	O	O	O
carpal	O	O	B-Entity
joint	O	O	I-Entity
and	O	O	O
similar	O	O	O
tendencies	O	O	O
in	O	O	O
the	O	O	O
shoulder	O	O	B-Entity
,	O	O	O
elbow	O	O	B-Entity
and	O	O	O
carpal	O	O	O
joint	O	O	O
.	O	O	O

The	O	O	O
descriptive	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
the	O	O	O
progression	O	O	B-Entity
curves	O	O	I-Entity
revealed	O	O	O
less	O	O	B-Entity
flexion	O	O	I-Entity
and	O	O	O
extension	O	O	B-Entity
of	O	O	O
the	O	O	O
joints	O	O	B-Entity
of	O	O	O
the	O	O	O
forelimb	O	O	B-Entity
.	O	O	O

This	O	O	O
indicates	O	O	O
restricted	O	O	B-Entity
joint	O	O	B-Entity
mobility	O	O	I-Entity
of	O	O	O
the	O	O	O
forelimb	O	O	B-Entity
but	O	O	O
primarily	O	O	O
of	O	O	O
the	O	O	O
carpal	O	O	B-Entity
joint	O	O	I-Entity
.	O	O	O

Findings	O	O	B-Entity
in	O	O	O
the	O	O	O
joints	O	O	B-Entity
of	O	O	O
the	O	O	O
hindlimb	O	O	B-Entity
were	O	O	O
not	O	O	O
consistent	O	O	B-Entity
;	O	O	O
contrasting	O	O	O
alterations	O	O	B-Entity
may	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
a	O	O	O
compensatory	O	O	B-Entity
mechanism	O	O	B-Entity
.	O	O	O

As	O	O	O
most	O	O	O
alterations	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
in	O	O	O
the	O	O	O
distal	O	O	B-Entity
joints	O	O	I-Entity
,	O	O	O
these	O	O	O
should	O	O	O
receive	O	O	O
particular	O	O	B-Entity
attention	O	O	I-Entity
when	O	O	O
examining	O	O	O
elderly	O	O	B-Entity
dogs	O	O	I-Entity
.	O	O	O

-DOCSTART- (28385075)

Propensity	O	O	B-Entity
Score	O	O	I-Entity
Matched	O	O	O
Comparison	O	O	B-Entity
of	O	O	O
Partial	O	O	B-Entity
to	O	O	O
Whole	O	O	B-Entity
Gland	O	O	B-Entity
Cryotherapy	O	O	B-Entity
for	O	O	O
Intermediate-Risk	O	O	B-Entity
Prostate	O	O	B-Entity
Cancer	O	O	I-Entity
:	O	O	O
An	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
COLD	O	O	O
registry	O	O	O
data	O	O	O

To	O	O	O
compare	O	O	O
the	O	O	O
oncological	O	O	B-Entity
and	O	O	O
functional	O	O	B-Entity
outcomes	O	O	B-Entity
of	O	O	O
partial	O	O	B-Entity
versus	O	O	O
whole	O	O	B-Entity
-	O	O	O
gland	O	O	B-Entity
cryotherapy	O	O	B-Entity
for	O	O	O
men	O	O	B-Entity
with	O	O	O
intermediate-risk	O	O	B-Entity
prostate	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

Men	O	O	B-Entity
with	O	O	O
intermediate-risk	O	O	B-Entity
prostate	O	O	B-Entity
cancer	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	I-Entity
primary	O	O	B-Entity
prostate	O	O	B-Entity
cryotherapy	O	O	I-Entity
from	O	O	O
1993	O	O	O
-	O	O	O
2013	O	O	O
were	O	O	O
selected	O	O	O
from	O	O	O
the	O	O	O
Cryo	O	O	B-Entity
On-Line	O	O	I-Entity
Data	O	O	I-Entity
Registry	O	O	I-Entity
for	O	O	O
a	O	O	O
1:1	O	O	O
matched	O	O	B-Entity
comparison	O	O	B-Entity
between	O	O	O
those	O	O	O
undergoing	O	O	O
whole	O	O	B-Entity
-	O	O	O
gland	O	O	B-Entity
and	O	O	O
partial	O	O	B-Entity
prostate	O	O	O
cryotherapy	O	O	O
(	O	O	O
targeted-ablation	O	O	B-Entity
,	O	O	O
unilateral/bilateral	O	O	B-Entity
nerve-sparing	O	O	I-Entity
ablations	O	O	I-Entity
)	O	O	O
.	O	O	O

A	O	O	O
propensity	O	O	B-Entity
score	O	O	I-Entity
was	O	O	O
developed	O	O	O
based	O	O	O
on	O	O	O
age	O	O	B-Entity
,	O	O	O
pre-biopsy	O	O	B-Entity
serum	O	O	I-Entity
PSA	O	O	B-Entity
,	O	O	O
biopsy	O	O	B-Entity
Gleason	O	O	I-Entity
score	O	O	I-Entity
,	O	O	O
clinical	O	O	B-Entity
stage	O	O	I-Entity
,	O	O	O
prostate	O	O	B-Entity
volume	O	O	I-Entity
,	O	O	O
neoadjuvant	O	O	B-Entity
androgen	O	O	I-Entity
deprivation	O	O	I-Entity
status	O	O	B-Entity
,	O	O	O
year	O	O	B-Entity
of	O	O	O
surgery	O	O	B-Entity
and	O	O	O
pre-treatment	O	O	B-Entity
potency	O	O	O
.	O	O	O

Outcomes	O	O	B-Entity
were	O	O	O
biochemical	O	O	B-Entity
progression-free	O	O	B-Entity
survival	O	O	I-Entity
(	O	O	O
BPFS	O	O	B-Entity
)	O	O	O
using	O	O	O
ASTRO	O	O	B-Entity
and	O	O	O
Phoenix	O	O	B-Entity
criteria	O	O	I-Entity
,	O	O	O
12-month	O	O	O
continence	O	O	B-Entity
(	O	O	O
strictly	O	O	O
pad-free	O	O	O
)	O	O	O
and	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
(	O	O	O
potency	O	O	O
sufficient	O	O	B-Entity
for	O	O	O
sexual	O	O	B-Entity
intercourse	O	O	I-Entity
)	O	O	O
.	O	O	O

After	O	O	O
propensity	O	O	B-Entity
score	O	O	I-Entity
-	O	O	O
matching	O	O	B-Entity
,	O	O	O
BPFS	O	O	B-Entity
was	O	O	O
compared	O	O	B-Entity
using	O	O	O
Kaplan-Meier	O	O	B-Entity
analysis	O	O	I-Entity
and	O	O	O
functional	O	O	B-Entity
outcomes	O	O	B-Entity
using	O	O	O
chi-square	O	O	B-Entity
tests	O	O	I-Entity
.	O	O	O

In	O	O	O
all	O	O	O
,	O	O	O
897	O	O	O
men	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
(	O	O	O
731	O	O	O
whole	O	O	B-Entity
-	O	O	O
gland	O	O	B-Entity
and	O	O	O
166	O	O	O
partial	O	O	B-Entity
)	O	O	O
.	O	O	O

Post-matching	O	O	B-Entity
,	O	O	O
166	O	O	O
pairs	O	O	O
of	O	O	O
men	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
(	O	O	O
mean	O	O	O
follow-up	O	O	B-Entity
31	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
2/5	O	O	O
year	O	O	O
BPFS	O	O	B-Entity
rate	O	O	B-Entity
was	O	O	O
87.2%/76.4	O	O	O
%	O	O	O
for	O	O	O
whole	O	O	B-Entity
-	O	O	O
gland	O	O	B-Entity
vs.	O	O	O
80.7%/70.0	O	O	O
%	O	O	O
for	O	O	O
partial	O	O	B-Entity
ablation	O	O	B-Entity
using	O	O	O
Phoenix	O	O	B-Entity
(	O	O	O
p=0.26	O	O	O
)	O	O	O
and	O	O	O
72.3%/69.6	O	O	O
%	O	O	O
for	O	O	O
whole	O	O	O
gland	O	O	O
vs.	O	O	O
82.1%/75.0	O	O	O
%	O	O	O
for	O	O	O
partial	O	O	O
ablation	O	O	O
using	O	O	O
ASTRO	O	O	B-Entity
criteria	O	O	O
(	O	O	O
p=0.10	O	O	O
)	O	O	O
.	O	O	O

Of	O	O	O
164	O	O	O
pairs	O	O	O
,	O	O	O
the	O	O	O
12-month	O	O	O
continence	O	O	B-Entity
rate	O	O	B-Entity
was	O	O	O
similar	O	O	B-Entity
94.1	O	O	O
%	O	O	O
vs.	O	O	O
95.1	O	O	O
%	O	O	O
(	O	O	O
p=0.803	O	O	O
)	O	O	O
.	O	O	O

Of	O	O	O
139	O	O	O
pairs	O	O	O
,	O	O	O
the	O	O	O
12-month	O	O	O
rate	O	O	O
of	O	O	O
successful	O	O	B-Entity
intercourse	O	O	B-Entity
was	O	O	O
29.5	O	O	O
%	O	O	O
for	O	O	O
whole	O	O	B-Entity
-	O	O	O
gland	O	O	B-Entity
and	O	O	O
46.8	O	O	O
%	O	O	O
for	O	O	O
partial	O	O	B-Entity
ablation	O	O	B-Entity
(	O	O	O
OR	O	O	O
2.1	O	O	O
,	O	O	O
p=0.003	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
incidence	O	O	B-Entity
of	O	O	O
post-treatment	O	O	B-Entity
urinary	O	O	B-Entity
retention	O	O	I-Entity
was	O	O	O
6.0	O	O	O
%	O	O	O
and	O	O	O
6.6	O	O	O
%	O	O	O
(	O	O	O
p=0.88	O	O	O
)	O	O	O
following	O	O	O
whole	O	O	B-Entity
-	O	O	O
gland	O	O	B-Entity
and	O	O	O
partial	O	O	B-Entity
ablation	O	O	B-Entity
respectively	O	O	O
and	O	O	O
that	O	O	O
of	O	O	O
rectourethral	O	O	B-Entity
fistula	O	O	I-Entity
was	O	O	O
1.2	O	O	O
%	O	O	O
and	O	O	O
0	O	O	O
%	O	O	O
(	O	O	O
p=0.50	O	O	O
)	O	O	O
Conclusion	O	O	O
:	O	O	O
Partial	O	O	B-Entity
ablation	O	O	O
results	O	O	B-Entity
in	O	O	O
better	O	O	B-Entity
post-treatment	O	O	O
sexual	O	O	B-Entity
function	O	O	I-Entity
compared	O	O	B-Entity
to	O	O	O
whole	O	O	O
-	O	O	O
gland	O	O	O
ablation	O	O	O
in	O	O	O
men	O	O	B-Entity
with	O	O	O
intermediate-risk	O	O	B-Entity
prostate	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

We	O	O	O
did	O	O	O
not	O	O	O
observe	O	O	O
a	O	O	O
difference	O	O	O
in	O	O	O
early	O	O	B-Entity
BPFS	O	O	B-Entity
between	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

-DOCSTART- (28386687)

Abnormal	O	O	B-Entity
metabolic	O	O	B-Entity
brain	O	O	B-Entity
network	O	O	B-Entity
associated	O	O	O
with	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
:	O	O	O
replication	O	O	B-Entity
on	O	O	O
a	O	O	O
new	O	O	O
European	O	O	B-Entity
sample	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
identify	O	O	B-Entity
the	O	O	O
specific	O	O	O
metabolic	O	O	B-Entity
brain	O	O	B-Entity
pattern	O	O	B-Entity
characteristic	O	O	B-Entity
for	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
PD	O	O	B-Entity
):	O	O	O
Parkinson	O	O	B-Entity
's	O	O	I-Entity
disease-related	O	O	I-Entity
pattern	O	O	I-Entity
(	O	O	O
PDRP	O	O	B-Entity
)	O	O	O
,	O	O	O
using	O	O	O
network	O	O	B-Entity
analysis	O	O	O
of	O	O	O
[18F]-fluorodeoxyglucose	O	O	B-Entity
positron	O	O	I-Entity
emission	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
FDG-PET	O	O	B-Entity
)	O	O	O
brain	O	O	O
images	O	O	B-Entity
in	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
Slovenian	O	O	B-Entity
PD	O	O	O
patients	O	O	B-Entity
.	O	O	O

Twenty	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
age	O	O	B-Entity
70.1	O	O	O
±	O	O	O
7.8	O	O	O
years	O	O	B-Entity
,	O	O	O
Movement	O	O	B-Entity
Disorder	O	O	I-Entity
Society	O	O	I-Entity
Unified	O	O	I-Entity
Parkinson	O	O	I-Entity
's	O	O	I-Entity
Disease	O	O	I-Entity
Motor	O	O	I-Entity
Rating	O	O	I-Entity
Scale	O	O	I-Entity
(	O	O	O
MDS-UPDRS-III	O	O	B-Entity
)	O	O	O
38.3	O	O	O
±	O	O	O
12.2	O	O	O
;	O	O	O
disease	O	O	B-Entity
duration	O	O	I-Entity
4.3	O	O	O
±	O	O	O
4.1	O	O	O
years	O	O	O
)	O	O	O
and	O	O	O
20	O	O	O
age	O	O	O
-	O	O	O
matched	O	O	B-Entity
normal	O	O	B-Entity
controls	O	O	I-Entity
(	O	O	O
NCs	O	O	B-Entity
)	O	O	O
underwent	O	O	O
FDG-PET	O	O	B-Entity
brain	O	O	B-Entity
imaging	O	O	I-Entity
.	O	O	O

An	O	O	O
automatic	O	O	B-Entity
voxel-based	O	O	I-Entity
scaled	O	O	I-Entity
subprofile	O	O	I-Entity
model	O	O	I-Entity
/	O	O	O
principal	O	O	B-Entity
component	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
SSM	O	O	B-Entity
/	O	O	O
PCA	O	O	B-Entity
)	O	O	O
was	O	O	O
applied	O	O	O
to	O	O	O
these	O	O	O
scans	O	O	B-Entity
for	O	O	O
PDRP	O	O	B-Entity
-	O	O	O
Slovenia	O	O	B-Entity
identification	O	O	B-Entity
.	O	O	O

The	O	O	O
pattern	O	O	B-Entity
was	O	O	O
characterized	O	O	B-Entity
by	O	O	O
relative	O	O	O
hypermetabolism	O	O	B-Entity
in	O	O	O
pallidum	O	O	B-Entity
,	O	O	O
putamen	O	O	B-Entity
,	O	O	O
thalamus	O	O	B-Entity
,	O	O	O
brain	O	O	B-Entity
stem	O	O	I-Entity
,	O	O	O
and	O	O	O
cerebellum	O	O	B-Entity
associated	O	O	O
with	O	O	O
hypometabolism	O	O	B-Entity
in	O	O	O
sensorimotor	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
posterior	O	O	B-Entity
parietal	O	O	I-Entity
,	O	O	O
occipital	O	O	B-Entity
,	O	O	O
and	O	O	O
frontal	O	O	B-Entity
cortices	O	O	I-Entity
.	O	O	O

The	O	O	O
expression	O	O	B-Entity
of	O	O	O
PDRP	O	O	B-Entity
-	O	O	O
Slovenia	O	O	B-Entity
discriminated	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
from	O	O	O
NCs	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.0001	O	O	O
)	O	O	O
and	O	O	O
correlated	O	O	B-Entity
positively	O	O	O
with	O	O	O
patients	O	O	O
'	O	O	O
clinical	O	O	B-Entity
score	O	O	B-Entity
(	O	O	O
MDS-UPDRS-III	O	O	B-Entity
,	O	O	O
p	O	O	O
=	O	O	O
0.03	O	O	O
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
its	O	O	O
topography	O	O	B-Entity
agrees	O	O	O
well	O	O	O
with	O	O	O
the	O	O	O
original	O	O	O
PDRP	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
identified	O	O	B-Entity
in	O	O	O
American	O	O	B-Entity
cohort	O	O	B-Entity
of	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

We	O	O	O
validated	O	O	O
the	O	O	O
PDRP	O	O	B-Entity
-	O	O	O
Slovenia	O	O	B-Entity
expression	O	O	B-Entity
on	O	O	O
additional	O	O	O
FDG-PET	O	O	B-Entity
scans	O	O	B-Entity
of	O	O	O
20	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
20	O	O	O
NCs	O	O	B-Entity
,	O	O	O
and	O	O	O
25	O	O	O
patients	O	O	O
with	O	O	O
atypical	O	O	B-Entity
parkinsonism	O	O	I-Entity
(	O	O	O
AP	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
confirmed	O	O	O
that	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
PDRP	O	O	B-Entity
-	O	O	O
Slovenia	O	O	B-Entity
manifests	O	O	O
good	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
with	O	O	O
specificity	O	O	B-Entity
and	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
85	O	O	O
-	O	O	O
90	O	O	O
%	O	O	O
at	O	O	O
optimal	O	O	O
pattern	O	O	B-Entity
expression	O	O	O
cutoff	O	O	O
for	O	O	O
discrimination	O	O	O
of	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
NCs	O	O	B-Entity
and	O	O	O
is	O	O	O
not	O	O	O
expressed	O	O	O
in	O	O	O
AP	O	O	B-Entity
.	O	O	O

PDRP	O	O	B-Entity
-	O	O	O
Slovenia	O	O	B-Entity
proves	O	O	O
to	O	O	O
be	O	O	O
a	O	O	O
robust	O	O	O
and	O	O	O
reproducible	O	O	O
functional	O	O	B-Entity
imaging	O	O	I-Entity
biomarker	O	O	B-Entity
independent	O	O	O
of	O	O	O
patient	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

It	O	O	O
accurately	O	O	O
differentiates	O	O	O
PD	O	O	B-Entity
patients	O	O	B-Entity
from	O	O	O
NCs	O	O	B-Entity
and	O	O	O
AP	O	O	B-Entity
and	O	O	O
correlates	O	O	O
well	O	O	O
with	O	O	O
the	O	O	O
clinical	O	O	B-Entity
measure	O	O	B-Entity
of	O	O	O
PD	O	O	O
progression	O	O	B-Entity
.	O	O	O

-DOCSTART- (28386942)

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
gestational	O	O	B-Entity
use	O	O	B-Entity
of	O	O	I-Entity
antidepressants	O	O	B-Entity
and	O	O	O
antipsychotics	O	O	B-Entity
on	O	O	O
neonatal	O	O	B-Entity
outcomes	O	O	B-Entity
for	O	O	O
women	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
mental	O	O	O
illness	O	O	O

Psychotropic	O	O	B-Entity
medication	O	O	I-Entity
use	O	O	B-Entity
occurs	O	O	B-Entity
in	O	O	O
8	O	O	O
%	O	O	O
of	O	O	O
pregnancies	O	O	B-Entity
,	O	O	O
with	O	O	O
rates	O	O	B-Entity
increasing	O	O	B-Entity
,	O	O	O
and	O	O	O
often	O	O	B-Entity
multiple	O	O	B-Entity
medications	O	O	B-Entity
prescribed	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
aims	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
psychotropic	O	O	B-Entity
medication	O	O	I-Entity
,	O	O	O
in	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
mental	O	O	B-Entity
illness	O	O	I-Entity
,	O	O	O
increases	O	O	B-Entity
rates	O	O	B-Entity
of	O	O	O
special	O	O	B-Entity
care	O	O	I-Entity
nursery	O	O	I-Entity
admission	O	O	B-Entity
and	O	O	O
reports	O	O	B-Entity
differences	O	O	B-Entity
between	O	O	O
antidepressant	O	O	B-Entity
and	O	O	O
antipsychotic	O	O	B-Entity
medication	O	O	I-Entity
use	O	O	O
either	O	O	O
alone	O	O	B-Entity
or	O	O	O
in	O	O	O
combination	O	O	B-Entity
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
database	O	O	I-Entity
analysis	O	O	I-Entity
from	O	O	I-Entity
a	O	O	I-Entity
cohort	O	O	I-Entity
with	O	O	O
severe	O	O	B-Entity
mental	O	O	B-Entity
illness	O	O	I-Entity
in	O	O	O
pregnancy	O	O	B-Entity
identified	O	O	B-Entity
268	O	O	O
pregnant	O	O	B-Entity
women	O	O	I-Entity
who	O	O	O
were	O	O	O
grouped	O	O	B-Entity
according	O	O	O
to	O	O	O
medication	O	O	B-Entity
type	O	O	B-Entity
.	O	O	O

Demographic	O	O	B-Entity
,	O	O	O
obstetric	O	O	B-Entity
and	O	O	O
neonatal	O	O	B-Entity
variables	O	O	B-Entity
were	O	O	O
analysed	O	O	B-Entity
using	O	O	B-Entity
t-tests	O	O	B-Entity
,	O	O	O
χ(2	O	O	O
)	O	O	O
,	O	O	O
analysis	O	O	B-Entity
of	O	O	O
variance	O	O	B-Entity
and	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
for	O	O	O
special	O	O	B-Entity
care	O	O	I-Entity
nursery	O	O	I-Entity
admission	O	O	B-Entity
.	O	O	O

The	O	O	O
medication	O	O	B-Entity
groups	O	O	I-Entity
consisted	O	O	O
of	O	O	O
:	O	O	O
women	O	O	B-Entity
taking	O	O	B-Entity
no	O	O	I-Entity
psychotropic	O	O	I-Entity
medications	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
67	O	O	O
)	O	O	O
;	O	O	O
those	O	O	B-Entity
taking	O	O	I-Entity
antipsychotics	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
87	O	O	O
)	O	O	O
;	O	O	O
those	O	O	B-Entity
taking	O	O	I-Entity
antidepressants	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
55	O	O	O
)	O	O	O
;	O	O	O
those	O	O	B-Entity
taking	O	O	I-Entity
and	O	O	I-Entity
a	O	O	I-Entity
combination	O	O	I-Entity
of	O	O	I-Entity
antidepressants/antipsychotics	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
59	O	O	O
)	O	O	O
.	O	O	O

Rates	O	O	B-Entity
of	O	O	O
special	O	O	B-Entity
care	O	O	I-Entity
nursery	O	O	I-Entity
admission	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
who	O	O	O
took	O	O	O
psychotropic	O	O	B-Entity
medication	O	O	I-Entity
(	O	O	O
41.3	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
elevated	O	O	O
compared	O	O	B-Entity
to	O	O	O
those	O	O	B-Entity
who	O	O	I-Entity
did	O	O	I-Entity
not	O	O	I-Entity
(	O	O	O
26.9	O	O	O
%	O	O	O
)	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.035	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
were	O	O	O
significantly	O	O	B-Entity
raised	O	O	B-Entity
when	O	O	O
compared	O	O	O
to	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.000	O	O	O
)	O	O	O
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	I-Entity
occurred	O	O	O
between	O	O	O
the	O	O	O
medication	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

A	O	O	O
significant	O	O	B-Entity
adjusted	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
of	O	O	O
2.79	O	O	O
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
1.286	O	O	O
-	O	O	O
6.049	O	O	O
)	O	O	O
was	O	O	O
found	O	O	B-Entity
for	O	O	O
special	O	O	B-Entity
care	O	O	I-Entity
nursery	O	O	I-Entity
and	O	O	O
psychiatric	O	O	B-Entity
admission	O	O	I-Entity
during	O	O	B-Entity
pregnancy	O	O	B-Entity
but	O	O	O
not	O	O	O
for	O	O	O
psychotropic	O	O	B-Entity
medication	O	O	I-Entity
.	O	O	O

Rates	O	O	B-Entity
of	O	O	O
special	O	O	B-Entity
care	O	O	I-Entity
nursery	O	O	I-Entity
admission	O	O	B-Entity
are	O	O	O
elevated	O	O	O
in	O	O	O
neonates	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
severe	O	O	B-Entity
mental	O	O	B-Entity
illness	O	O	I-Entity
taking	O	O	O
psychotropic	O	O	B-Entity
medication	O	O	I-Entity
,	O	O	O
but	O	O	O
were	O	O	O
not	O	O	O
different	O	O	O
for	O	O	O
monotherapy	O	O	B-Entity
or	O	O	O
polytherapy	O	O	B-Entity
when	O	O	O
prescribing	O	O	B-Entity
antidepressants	O	O	B-Entity
or	O	O	O
antipsychotic	O	O	B-Entity
medication	O	O	I-Entity
.	O	O	O

Additional	O	O	O
vulnerability	O	O	B-Entity
occurs	O	O	B-Entity
in	O	O	O
the	O	O	O
neonates	O	O	B-Entity
of	O	O	O
women	O	O	B-Entity
with	O	O	O
a	O	O	O
mental	O	O	B-Entity
illness	O	O	I-Entity
and	O	O	O
paediatric	O	O	B-Entity
presence	O	O	O
at	O	O	O
delivery	O	O	B-Entity
is	O	O	O
recommended	O	O	B-Entity
.	O	O	O

-DOCSTART- (28387851)

Does	O	O	O
Intrawound	O	O	B-Entity
Vancomycin	O	O	I-Entity
Application	O	O	B-Entity
During	O	O	O
Spine	O	O	B-Entity
Surgery	O	O	I-Entity
Create	O	O	O
Vancomycin-Resistant	O	O	B-Entity
Organism	O	O	B-Entity
?	O	O	O

Surgical	O	O	B-Entity
site	O	O	I-Entity
infection	O	O	I-Entity
(	O	O	O
SSI	O	O	B-Entity
)	O	O	O
following	O	O	O
spine	O	O	B-Entity
surgery	O	O	I-Entity
is	O	O	O
a	O	O	O
morbid	O	O	B-Entity
and	O	O	O
expensive	O	O	B-Entity
complication	O	O	I-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
is	O	O	O
emerging	O	O	O
as	O	O	O
a	O	O	O
solution	O	O	O
to	O	O	O
reduce	O	O	O
SSI	O	O	B-Entity
.	O	O	O

The	O	O	O
development	O	O	O
of	O	O	O
vancomycin-resistant	O	O	B-Entity
pathogens	O	O	B-Entity
is	O	O	O
an	O	O	O
understandable	O	O	O
concern	O	O	O
.	O	O	O

To	O	O	O
determine	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
vancomycin-resistant	O	O	B-Entity
SSI	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
and	O	O	O
without	O	O	O
use	O	O	O
of	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
undergoing	O	O	O
elective	O	O	O
spine	O	O	B-Entity
surgery	O	O	I-Entity
were	O	O	O
dichotomized	O	O	B-Entity
based	O	O	O
on	O	O	O
whether	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
was	O	O	O
applied	O	O	O
.	O	O	O

Outcome	O	O	O
was	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
SSI	O	O	B-Entity
requiring	O	O	O
return	O	O	O
to	O	O	O
the	O	O	O
operating	O	O	B-Entity
room	O	O	I-Entity
within	O	O	O
postoperative	O	O	B-Entity
90	O	O	I-Entity
days	O	O	I-Entity
.	O	O	O

The	O	O	O
intrawound	O	O	B-Entity
culture	O	O	I-Entity
and	O	O	O
vancomycin	O	O	B-Entity
minimal	O	O	B-Entity
inhibitory	O	O	I-Entity
concentrations	O	O	I-Entity
(	O	O	O
MIC	O	O	B-Entity
)	O	O	O
were	O	O	O
reviewed	O	O	O
.	O	O	O

Analyses	O	O	O
were	O	O	O
conducted	O	O	O
to	O	O	O
compare	O	O	O
the	O	O	O
pathogen	O	O	B-Entity
profile	O	O	I-Entity
and	O	O	O
MIC	O	O	B-Entity
for	O	O	O
vancomycin	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
vancomycin	O	O	O
and	O	O	O
those	O	O	O
who	O	O	O
did	O	O	O
not	O	O	O
.	O	O	O

Of	O	O	O
the	O	O	O
total	O	O	O
2802	O	O	O
patients	O	O	B-Entity
,	O	O	O
43	O	O	O
%	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
1215	O	O	O
)	O	O	O
had	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
application	O	O	O
during	O	O	B-Entity
the	O	O	I-Entity
index	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
vancomycin	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
deep	O	O	O
SSI	O	O	B-Entity
rates	O	O	B-Entity
(	O	O	O
1.6	O	O	O
%	O	O	O
[	O	O	O
n	O	O	O
=	O	O	O
20	O	O	O
]	O	O	O
vs	O	O	O
2.5	O	O	O
%	O	O	O
[	O	O	O
n	O	O	O
=	O	O	O
40	O	O	O
]	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.02	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
Staphylococcus	O	O	B-Entity
aureus	O	O	I-Entity
SSI	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
lower	O	O	I-Entity
in	O	O	O
the	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
application	O	O	B-Entity
of	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
(	O	O	O
32	O	O	O
%	O	O	O
vs	O	O	O
65	O	O	O
%	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.003	O	O	O
)	O	O	O
.	O	O	O

None	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
application	O	O	B-Entity
of	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
powder	O	O	I-Entity
,	O	O	O
and	O	O	O
subsequently	O	O	O
developed	O	O	O
an	O	O	O
S	O	O	B-Entity
aureus	O	O	I-Entity
SSI	O	O	B-Entity
,	O	O	O
demonstrated	O	O	O
pathogens	O	O	B-Entity
with	O	O	O
resistance	O	O	B-Entity
to	O	O	I-Entity
vancomycin	O	O	I-Entity
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
had	O	O	O
MIC	O	O	B-Entity
<	O	O	O
2	O	O	O
μg/mL	O	O	O
,	O	O	O
the	O	O	O
vancomycin	O	O	B-Entity
susceptibility	O	O	O
threshold	O	O	O
.	O	O	O

The	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
gram-negative	O	O	B-Entity
SSI	O	O	B-Entity
(	O	O	O
28	O	O	O
%	O	O	O
vs	O	O	O
7	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
culture	O	O	B-Entity
negative	O	O	I-Entity
fluid	O	O	I-Entity
collection	O	O	I-Entity
(	O	O	O
16	O	O	O
%	O	O	O
vs	O	O	O
5	O	O	O
%	O	O	O
)	O	O	O
was	O	O	O
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
vancomycin	O	O	B-Entity
cohort	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
during	O	O	O
the	O	O	O
index	O	O	O
spine	O	O	B-Entity
surgery	O	O	I-Entity
was	O	O	O
protective	O	O	O
against	O	O	O
SSI	O	O	B-Entity
following	O	O	O
spine	O	O	O
surgery	O	O	O
.	O	O	O

The	O	O	O
application	O	O	B-Entity
of	O	O	O
intrawound	O	O	B-Entity
vancomycin	O	O	I-Entity
during	O	O	B-Entity
index	O	O	I-Entity
surgery	O	O	I-Entity
does	O	O	O
not	O	O	O
appear	O	O	O
to	O	O	O
create	O	O	O
vancomycin-resistant	O	O	B-Entity
organisms	O	O	B-Entity
in	O	O	O
the	O	O	O
event	O	O	O
of	O	O	O
an	O	O	O
SSI	O	O	B-Entity
.	O	O	O

-DOCSTART- (28388017)

Adequacy	O	O	B-Entity
criteria	O	O	B-Entity
for	O	O	O
thyroid	O	O	B-Entity
FNA	O	O	I-Entity
evaluated	O	O	B-Entity
by	O	O	O
ThinPrep	O	O	B-Entity
slides	O	O	I-Entity
only	O	O	O

Adequacy	O	O	B-Entity
criteria	O	O	B-Entity
for	O	O	O
thyroid	O	O	B-Entity
fine-needle	O	O	I-Entity
aspiration	O	O	I-Entity
(	O	O	O
FNA	O	O	B-Entity
)	O	O	O
recommended	O	O	B-Entity
by	O	O	O
The	O	O	O
Bethesda	O	O	B-Entity
System	O	O	I-Entity
for	O	O	I-Entity
Reporting	O	O	I-Entity
Thyroid	O	O	I-Entity
Cytopathology	O	O	I-Entity
(	O	O	O
TBS	O	O	B-Entity
)	O	O	O
were	O	O	O
developed	O	O	O
with	O	O	O
smears	O	O	B-Entity
,	O	O	O
but	O	O	O
they	O	O	O
are	O	O	O
commonly	O	O	O
applied	O	O	B-Entity
to	O	O	O
ThinPreps	O	O	B-Entity
(	O	O	O
TPs	O	O	B-Entity
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	O
evaluated	O	O	B-Entity
adequacy	O	O	B-Entity
in	O	O	O
TPs	O	O	B-Entity
at	O	O	O
different	O	O	O
diagnostic	O	O	B-Entity
thresholds	O	O	B-Entity
.	O	O	O

All	O	O	O
FNA	O	O	B-Entity
procedures	O	O	I-Entity
performed	O	O	B-Entity
between	O	O	O
2010	O	O	O
and	O	O	O
2015	O	O	O
with	O	O	O
matched	O	O	B-Entity
surgical	O	O	B-Entity
specimens	O	O	I-Entity
were	O	O	O
analyzed	O	O	B-Entity
.	O	O	O

Cell	O	O	B-Entity
counts	O	O	I-Entity
and	O	O	O
cytological	O	O	B-Entity
features	O	O	B-Entity
were	O	O	O
evaluated	O	O	B-Entity
in	O	O	O
all	O	O	O
initially	O	O	O
nondiagnostic	O	O	B-Entity
(	O	O	O
ND	O	O	B-Entity
)	O	O	O
cases	O	O	B-Entity
.	O	O	O

ND	O	O	B-Entity
cases	O	O	B-Entity
were	O	O	O
reclassified	O	O	B-Entity
into	O	O	O
TBS	O	O	B-Entity
categories	O	O	B-Entity
by	O	O	O
2	O	O	O
pathologists	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
results	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
surgical	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	B-Entity
forty-six	O	O	I-Entity
of	O	O	O
the	O	O	O
151	O	O	O
cases	O	O	B-Entity
initially	O	O	O
classified	O	O	B-Entity
as	O	O	O
ND	O	O	B-Entity
were	O	O	O
available	O	O	B-Entity
for	O	O	O
review	O	O	B-Entity
,	O	O	O
and	O	O	O
they	O	O	O
had	O	O	O
a	O	O	O
mean	O	O	B-Entity
cell	O	O	B-Entity
count	O	O	I-Entity
of	O	O	O
60.5	O	O	O
(	O	O	O
standard	O	O	B-Entity
deviation	O	O	I-Entity
,	O	O	O
71.4	O	O	O
)	O	O	O
.	O	O	O

Interobserver	O	O	B-Entity
agreement	O	O	I-Entity
on	O	O	O
the	O	O	O
reclassification	O	O	B-Entity
of	O	O	O
ND	O	O	B-Entity
cases	O	O	B-Entity
was	O	O	O
moderate	O	O	B-Entity
(	O	O	O
k	O	O	O
=	O	O	O
0.57	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
consensus	O	O	B-Entity
yielded	O	O	B-Entity
48	O	O	O
ND	O	O	O
cases	O	O	O
(	O	O	O
33	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
72	O	O	O
benign	O	O	B-Entity
cases	O	O	O
(	O	O	O
49	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
24	O	O	O
cases	O	O	O
of	O	O	O
atypia	O	O	B-Entity
of	O	O	O
undetermined	O	O	B-Entity
significance	O	O	I-Entity
(	O	O	O
16	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
2	O	O	O
cases	O	O	O
suspicious	O	O	B-Entity
for	O	O	I-Entity
malignancy	O	O	I-Entity
(	O	O	O
1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Lowering	O	O	B-Entity
the	O	O	O
diagnostic	O	O	B-Entity
threshold	O	O	B-Entity
to	O	O	O
any	O	O	O
follicular	O	O	B-Entity
cells	O	O	B-Entity
yielded	O	O	B-Entity
a	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
92	O	O	O
%	O	O	O
,	O	O	O
a	O	O	O
specificity	O	O	B-Entity
of	O	O	O
60	O	O	O
%	O	O	O
,	O	O	O
a	O	O	O
positive	O	O	B-Entity
predictive	O	O	I-Entity
value	O	O	I-Entity
of	O	O	O
59	O	O	O
%	O	O	O
,	O	O	O
a	O	O	O
negative	O	O	B-Entity
predictive	O	O	I-Entity
value	O	O	I-Entity
of	O	O	O
92	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
false-negative	O	O	B-Entity
rate	O	O	B-Entity
of	O	O	O
7.7	O	O	O
%	O	O	O
,	O	O	O
whereas	O	O	O
the	O	O	O
values	O	O	O
for	O	O	O
the	O	O	O
initially	O	O	O
diagnostic	O	O	O
cases	O	O	B-Entity
were	O	O	O
93	O	O	O
%	O	O	O
,	O	O	O
58	O	O	O
%	O	O	O
,	O	O	O
59	O	O	O
%	O	O	O
,	O	O	O
93	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
7.7	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Including	O	O	O
cases	O	O	B-Entity
with	O	O	O
>	O	O	O
60	O	O	O
cells	O	O	B-Entity
but	O	O	O
lacking	O	O	B-Entity
6	O	O	O
groups	O	O	B-Entity
containing	O	O	B-Entity
at	O	O	O
least	O	O	O
10	O	O	O
cells	O	O	O
did	O	O	O
not	O	O	O
affect	O	O	O
test	O	O	B-Entity
performance	O	O	I-Entity
.	O	O	O

Nuclear	O	O	B-Entity
enlargement	O	O	I-Entity
,	O	O	O
pallor	O	O	B-Entity
,	O	O	O
grooves	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
histiocytoid	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
initially	O	O	O
ND	O	O	B-Entity
FNA	O	O	B-Entity
correlated	O	O	B-Entity
with	O	O	O
malignancy	O	O	B-Entity
.	O	O	O

In	O	O	O
thyroid	O	O	B-Entity
FNA	O	O	I-Entity
examined	O	O	B-Entity
with	O	O	O
TP	O	O	B-Entity
only	O	O	O
,	O	O	O
lowering	O	O	B-Entity
the	O	O	O
adequacy	O	O	B-Entity
threshold	O	O	B-Entity
and	O	O	O
eliminating	O	O	O
the	O	O	O
requirement	O	O	B-Entity
of	O	O	O
6	O	O	O
groups	O	O	B-Entity
of	O	O	O
at	O	O	O
least	O	O	O
10	O	O	O
cells	O	O	B-Entity
did	O	O	O
not	O	O	O
significantly	O	O	B-Entity
affect	O	O	O
test	O	O	B-Entity
performance	O	O	I-Entity
if	O	O	O
cytological	O	O	B-Entity
features	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
malignancy	O	O	B-Entity
were	O	O	O
absent	O	O	B-Entity
.	O	O	O

Cancer	O	O	O
Cytopathol	O	O	O
2017	O	O	O
.	O	O	O

©	O	O	O
2017	O	O	O
American	O	O	O
Cancer	O	O	O
Society	O	O	O
.	O	O	O

-DOCSTART- (28389368)

Silk	O	O	B-Entity
I	O	O	I-Entity
and	O	O	O
Silk	O	O	B-Entity
II	O	O	I-Entity
studied	O	O	B-Entity
by	O	O	O
fast	O	O	O
scanning	O	O	O
calorimetry	O	O	O

Using	O	O	O
fast	O	O	B-Entity
scanning	O	O	I-Entity
calorimetry	O	O	I-Entity
(	O	O	O
FSC	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
glass	O	O	B-Entity
transition	O	O	I-Entity
and	O	O	O
crystal	O	O	B-Entity
melting	O	O	B-Entity
of	O	O	O
samples	O	O	B-Entity
of	O	O	O
B.	O	O	B-Entity
mori	O	O	I-Entity
silk	O	O	B-Entity
fibroin	O	O	I-Entity
containing	O	O	O
Silk	O	O	B-Entity
I	O	O	I-Entity
and/or	O	O	O
Silk	O	O	B-Entity
II	O	O	I-Entity
crystal	O	O	O
s.	O	O	O
Due	O	O	O
to	O	O	O
the	O	O	O
very	O	O	O
short	O	O	B-Entity
residence	O	O	B-Entity
times	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
temperatures	O	O	B-Entity
during	O	O	O
such	O	O	O
measurements	O	O	B-Entity
,	O	O	O
thermal	O	O	B-Entity
decomposition	O	O	B-Entity
of	O	O	O
silk	O	O	B-Entity
protein	O	O	I-Entity
can	O	O	O
be	O	O	O
significantly	O	O	B-Entity
suppressed	O	O	B-Entity
.	O	O	O

FSC	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
at	O	O	O
2000K/s	O	O	O
using	O	O	O
the	O	O	O
Mettler	O	O	B-Entity
Flash	O	O	I-Entity
DSC1	O	O	I-Entity
on	O	O	O
fibroin	O	O	B-Entity
films	O	O	B-Entity
with	O	O	O
masses	O	O	B-Entity
around	O	O	O
130	O	O	O
-	O	O	O
270ng	O	O	O
.	O	O	O

Films	O	O	B-Entity
were	O	O	O
prepared	O	O	O
with	O	O	O
different	O	O	B-Entity
crystalline	O	O	B-Entity
fractions	O	O	B-Entity
(	O	O	O
ranging	O	O	O
from	O	O	O
0.26	O	O	O
to	O	O	O
0.50	O	O	O
)	O	O	O
and	O	O	O
with	O	O	O
different	O	O	O
crystal	O	O	B-Entity
structures	O	O	I-Entity
(	O	O	O
Silk	O	O	B-Entity
I	O	O	I-Entity
,	O	O	O
Silk	O	O	B-Entity
II	O	O	I-Entity
,	O	O	O
or	O	O	O
mixed	O	O	O
)	O	O	O
by	O	O	O
varying	O	O	O
the	O	O	O
processing	O	O	B-Entity
conditions	O	O	B-Entity
.	O	O	O

These	O	O	O
included	O	O	O
water	O	O	B-Entity
annealing	O	O	B-Entity
at	O	O	O
different	O	O	B-Entity
temperatures	O	O	B-Entity
,	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
50	O	O	O
%	O	O	O
MeOH	O	O	B-Entity
in	O	O	O
water	O	O	O
,	O	O	O
or	O	O	O
autoclaving	O	O	B-Entity
.	O	O	O

The	O	O	O
resulting	O	O	B-Entity
crystal	O	O	B-Entity
structure	O	O	I-Entity
was	O	O	O
examined	O	O	O
using	O	O	O
wide	O	O	B-Entity
angle	O	O	I-Entity
X-ray	O	O	B-Entity
scattering	O	O	I-Entity
.	O	O	O

Degree	O	O	B-Entity
of	O	O	O
crystallinity	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
from	O	O	O
Fourier	O	O	B-Entity
transform	O	O	I-Entity
infrared	O	O	I-Entity
(	O	O	I-Entity
FTIR	O	O	I-Entity
)	O	O	I-Entity
spectroscopy	O	O	I-Entity
and	O	O	O
from	O	O	O
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
heat	O	O	B-Entity
capacity	O	O	I-Entity
increment	O	O	B-Entity
at	O	O	O
the	O	O	O
glass	O	O	B-Entity
transition	O	O	I-Entity
temperature	O	O	I-Entity
.	O	O	O

Silk	O	O	B-Entity
fibroin	O	O	I-Entity
films	O	O	B-Entity
prepared	O	O	O
by	O	O	O
water	O	O	B-Entity
annealing	O	O	B-Entity
at	O	O	O
25	O	O	O
°	O	O	O
C	O	O	O
were	O	O	O
the	O	O	O
least	O	O	O
crystalline	O	O	B-Entity
and	O	O	O
had	O	O	O
Silk	O	O	B-Entity
I	O	O	I-Entity
structure	O	O	B-Entity
.	O	O	O

FTIR	O	O	B-Entity
and	O	O	O
FSC	O	O	B-Entity
studies	O	O	B-Entity
showed	O	O	O
that	O	O	O
films	O	O	B-Entity
prepared	O	O	O
by	O	O	O
autoclaving	O	O	B-Entity
or	O	O	O
50	O	O	O
%	O	O	O
MeOH	O	O	B-Entity
exposure	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	O
crystalline	O	O	B-Entity
and	O	O	O
had	O	O	O
Silk	O	O	B-Entity
II	O	O	I-Entity
structure	O	O	B-Entity
.	O	O	O

Intermediate	O	O	B-Entity
crystalline	O	O	B-Entity
fraction	O	O	B-Entity
and	O	O	O
mixed	O	O	O
Silk	O	O	B-Entity
I	O	O	I-Entity
/	O	O	O
Silk	O	O	B-Entity
II	O	O	I-Entity
structure	O	O	B-Entity
s	O	O	O
were	O	O	O
found	O	O	O
in	O	O	O
films	O	O	B-Entity
prepared	O	O	O
by	O	O	O
water	O	O	B-Entity
annealing	O	O	B-Entity
at	O	O	O
37	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

FSC	O	O	B-Entity
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
Silk	O	O	B-Entity
I	O	O	I-Entity
I	O	O	O
crystals	O	O	B-Entity
exhibit	O	O	O
endotherms	O	O	B-Entity
of	O	O	O
narrower	O	O	B-Entity
width	O	O	I-Entity
and	O	O	O
have	O	O	O
higher	O	O	B-Entity
mean	O	O	B-Entity
melting	O	O	B-Entity
temperature	O	O	I-Entity
Tm(II)=351±2.6	O	O	O
°	O	O	O
C	O	O	O
,	O	O	O
compared	O	O	B-Entity
to	O	O	O
Silk	O	O	O
I	O	O	O
crystals	O	O	O
which	O	O	O
melt	O	O	B-Entity
at	O	O	O
Tm(I)=292±3.8	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Films	O	O	B-Entity
containing	O	O	O
mixed	O	O	O
Silk	O	O	B-Entity
I	O	O	I-Entity
/	O	O	O
Silk	O	O	B-Entity
II	O	O	I-Entity
structure	O	O	B-Entity
showed	O	O	O
two	O	O	O
clearly	O	O	B-Entity
separated	O	O	B-Entity
endothermic	O	O	B-Entity
peaks	O	O	B-Entity
.	O	O	O

Evidence	O	O	B-Entity
suggests	O	O	O
that	O	O	O
the	O	O	O
two	O	O	O
types	O	O	O
of	O	O	O
crystal	O	O	B-Entity
s	O	O	O
melt	O	O	B-Entity
separately	O	O	B-Entity
and	O	O	O
do	O	O	O
not	O	O	O
thermal	O	O	B-Entity
ly	O	O	O
interconvert	O	O	B-Entity
on	O	O	O
the	O	O	O
extremely	O	O	B-Entity
short	O	O	B-Entity
time	O	O	B-Entity
scale	O	O	I-Entity
(	O	O	O
0.065s	O	O	O
between	O	O	O
onset	O	O	O
and	O	O	O
end	O	O	O
of	O	O	O
melting	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
FSC	O	O	B-Entity
experiment	O	O	I-Entity
.	O	O	O

Silkworm	O	O	B-Entity
silk	O	O	B-Entity
is	O	O	O
a	O	O	O
naturally	O	O	B-Entity
occurring	O	O	O
biomaterial	O	O	B-Entity
.	O	O	O

The	O	O	O
fibroin	O	O	B-Entity
component	O	O	I-Entity
of	O	O	O
silk	O	O	B-Entity
forms	O	O	I-Entity
two	O	O	O
types	O	O	O
of	O	O	O
crystals	O	O	B-Entity
.	O	O	O

Silk	O	O	B-Entity
properties	O	O	B-Entity
depend	O	O	O
upon	O	O	O
the	O	O	O
amount	O	O	B-Entity
and	O	O	O
type	O	O	O
of	O	O	O
crystals	O	O	B-Entity
,	O	O	O
and	O	O	O
their	O	O	O
stability	O	O	B-Entity
.	O	O	O

One	O	O	O
measure	O	O	B-Entity
of	O	O	O
stability	O	O	B-Entity
is	O	O	O
crystal	O	O	B-Entity
melting	O	O	B-Entity
temperature	O	O	I-Entity
.	O	O	O

Crystal	O	O	B-Entity
s	O	O	O
which	O	O	O
are	O	O	O
more	O	O	O
stable	O	O	B-Entity
have	O	O	O
a	O	O	O
higher	O	O	B-Entity
melting	O	O	B-Entity
temperature	O	O	I-Entity
.	O	O	O

Until	O	O	O
now	O	O	O
,	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
challenging	O	O	O
to	O	O	O
study	O	O	B-Entity
thermal	O	O	B-Entity
behavior	O	O	B-Entity
of	O	O	O
silk	O	O	B-Entity
crystal	O	O	B-Entity
s	O	O	O
because	O	O	O
they	O	O	O
degrade	O	O	B-Entity
at	O	O	O
high	O	O	B-Entity
temperature	O	O	B-Entity
.	O	O	O

To	O	O	O
avoid	O	O	O
degradation	O	O	B-Entity
,	O	O	O
and	O	O	O
study	O	O	B-Entity
the	O	O	O
melting	O	O	B-Entity
properties	O	O	B-Entity
of	O	O	O
silk	O	O	B-Entity
biomaterial	O	O	B-Entity
,	O	O	O
we	O	O	O
heated	O	O	B-Entity
silk	O	O	O
at	O	O	O
a	O	O	O
very	O	O	O
fast	O	O	O
rate	O	O	O
of	O	O	O
2000K/s	O	O	O
using	O	O	O
a	O	O	O
special	O	O	B-Entity
calorimeter	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
shown	O	O	O
that	O	O	O
the	O	O	O
two	O	O	O
crystal	O	O	B-Entity
types	O	O	O
have	O	O	O
very	O	O	O
different	O	O	B-Entity
melting	O	O	B-Entity
temperature	O	O	I-Entity
s	O	O	O
,	O	O	O
indicating	O	O	O
that	O	O	O
one	O	O	O
crystal	O	O	O
type	O	O	B-Entity
is	O	O	O
much	O	O	O
more	O	O	O
stable	O	O	B-Entity
than	O	O	O
the	O	O	O
other	O	O	O
.	O	O	O

-DOCSTART- (28389633)

Leonurine	O	O	B-Entity
Attenuates	O	O	B-Entity
Hyperalgesia	O	O	B-Entity
in	O	O	O
Mice	O	O	B-Entity
with	O	O	O
Induced	O	O	B-Entity
Adenomyosis	O	O	O

BACKGROUND	O	O	O
Adenomyosis	O	O	B-Entity
,	O	O	O
defined	O	O	O
as	O	O	O
the	O	O	O
invasion	O	O	B-Entity
of	O	O	O
endometrial	O	O	B-Entity
glands	O	O	I-Entity
and	O	O	O
stroma	O	O	B-Entity
into	O	O	O
the	O	O	O
myometrium	O	O	B-Entity
,	O	O	O
is	O	O	O
a	O	O	O
common	O	O	B-Entity
gynecological	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
we	O	O	O
report	O	O	B-Entity
on	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
leonurine	O	O	B-Entity
on	O	O	O
ICR	O	O	B-Entity
mice	O	O	I-Entity
with	O	O	O
adenomyosis	O	O	B-Entity
induced	O	O	B-Entity
by	O	O	O
neonatal	O	O	B-Entity
tamoxifen	O	O	B-Entity
.	O	O	O

MATERIAL	O	O	O
AND	O	O	O
METHODS	O	O	O
After	O	O	O
being	O	O	O
treated	O	O	B-Entity
with	O	O	O
tamoxifen	O	O	B-Entity
for	O	O	O
4	O	O	O
,	O	O	O
8	O	O	O
,	O	O	O
and	O	O	O
12	O	O	O
weeks	O	O	O
,	O	O	O
we	O	O	O
assessed	O	O	B-Entity
body	O	O	B-Entity
weight	O	O	I-Entity
and	O	O	O
pain	O	O	B-Entity
modulation	O	O	O
in	O	O	O
mice	O	O	B-Entity
in	O	O	O
hotplate	O	O	B-Entity
tests	O	O	B-Entity
.	O	O	O

The	O	O	O
mice	O	O	B-Entity
were	O	O	O
divided	O	O	B-Entity
into	O	O	O
5	O	O	O
groups	O	O	B-Entity
:	O	O	O
a	O	O	O
low-dose	O	O	B-Entity
leonurine	O	O	B-Entity
treatment	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
a	O	O	O
high-dose	O	O	B-Entity
leonurine	O	O	O
treatment	O	O	O
group	O	O	O
,	O	O	O
a	O	O	O
valproic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
VPA	O	O	B-Entity
)	O	O	O
treatment	O	O	O
group	O	O	O
,	O	O	O
a	O	O	O
vehicle	O	O	B-Entity
only	O	O	B-Entity
treatment	O	O	O
group	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
blank	O	O	B-Entity
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
body	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
pain	O	O	O
modulation	O	O	O
in	O	O	O
hotplate	O	O	B-Entity
tests	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
depth	O	O	B-Entity
of	O	O	O
myometrial	O	O	B-Entity
infiltration	O	O	B-Entity
.	O	O	O

Immunoreactivity	O	O	B-Entity
staining	O	O	B-Entity
of	O	O	O
progesterone	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
PR	O	O	B-Entity
)	O	O	O
,	O	O	O
nuclear	O	O	B-Entity
factor-κB	O	O	I-Entity
phosphorylated-p65	O	O	I-Entity
(	O	O	O
p-p65	O	O	B-Entity
)	O	O	O
,	O	O	O
cyclooxygenase-2	O	O	B-Entity
(	O	O	O
COX-2	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
oxytocin	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
OTR	O	O	B-Entity
)	O	O	O
was	O	O	O
evaluated	O	O	B-Entity
by	O	O	O
immunohistochemistry	O	O	B-Entity
.	O	O	O

RESULTS	O	O	O
The	O	O	O
measurement	O	O	B-Entity
of	O	O	O
the	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
myometrial	O	O	B-Entity
infiltration	O	O	B-Entity
,	O	O	O
and	O	O	O
pain	O	O	O
modulation	O	O	O
showed	O	O	O
that	O	O	O
neonatal	O	O	B-Entity
tamoxifen	O	O	B-Entity
treatment	O	O	B-Entity
led	O	O	O
to	O	O	O
adenomyosis	O	O	B-Entity
.	O	O	O

Leonurine	O	O	B-Entity
treatment	O	O	B-Entity
appeared	O	O	O
to	O	O	O
decrease	O	O	B-Entity
hyperalgesia	O	O	B-Entity
and	O	O	O
myometrial	O	O	B-Entity
infiltration	O	O	B-Entity
.	O	O	O

Immunoreactivity	O	O	B-Entity
staining	O	O	B-Entity
showed	O	O	O
decreased	O	O	B-Entity
p-p65	O	O	B-Entity
,	O	O	O
COX-2	O	O	B-Entity
,	O	O	O
and	O	O	O
OTR	O	O	B-Entity
protein	O	O	B-Entity
expressions	O	O	I-Entity
.	O	O	O

CONCLUSIONS	O	O	O
Our	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
leonurine	O	O	B-Entity
attenuates	O	O	B-Entity
hyperalgesia	O	O	B-Entity
in	O	O	O
mice	O	O	B-Entity
with	O	O	O
induced	O	O	B-Entity
adenomyosis	O	O	B-Entity
via	O	O	O
down-regulating	O	O	B-Entity
expressions	O	O	B-Entity
of	O	O	O
p-P65	O	O	B-Entity
,	O	O	O
COX-2	O	O	B-Entity
,	O	O	O
and	O	O	O
OTR	O	O	B-Entity
,	O	O	O
and	O	O	O
could	O	O	O
be	O	O	O
beneficial	O	O	O
for	O	O	O
treating	O	O	B-Entity
adenomyosis	O	O	O
.	O	O	O

-DOCSTART- (28394217)

A	O	O	O
Randomized	O	O	B-Entity
,	O	O	O
Head-to-Head	O	O	B-Entity
Study	O	O	B-Entity
of	O	O	O
Virtual	O	O	B-Entity
Reality	O	O	I-Entity
Exposure	O	O	I-Entity
Therapy	O	O	I-Entity
for	O	O	O
Posttraumatic	O	O	O
Stress	O	O	O
Disorder	O	O	O

Virtual	O	O	B-Entity
reality	O	O	I-Entity
exposure	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
VRET	O	O	B-Entity
)	O	O	O
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
few	O	O	O
interventions	O	O	B-Entity
supported	O	O	B-Entity
by	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
combat-related	O	O	B-Entity
posttraumatic	O	O	I-Entity
stress	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
PTSD	O	O	B-Entity
)	O	O	O
in	O	O	O
active	O	O	B-Entity
duty	O	O	I-Entity
service	O	O	I-Entity
members	O	O	B-Entity
.	O	O	O

A	O	O	O
comparative	O	O	B-Entity
effectiveness	O	O	I-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	O
to	O	O	O
determine	O	O	O
if	O	O	O
virtual	O	O	B-Entity
reality	O	O	I-Entity
technology	O	O	B-Entity
itself	O	O	O
improved	O	O	B-Entity
outcomes	O	O	B-Entity
,	O	O	O
or	O	O	O
if	O	O	O
similar	O	O	B-Entity
results	O	O	B-Entity
could	O	O	O
be	O	O	O
achieved	O	O	B-Entity
with	O	O	O
a	O	O	O
control	O	O	B-Entity
exposure	O	O	I-Entity
therapy	O	O	I-Entity
(	O	O	O
CET	O	O	B-Entity
)	O	O	O
condition	O	O	B-Entity
.	O	O	O

Service	O	O	B-Entity
members	O	O	B-Entity
with	O	O	O
combat-related	O	O	B-Entity
PTSD	O	O	I-Entity
were	O	O	O
randomly	O	O	B-Entity
selected	O	O	B-Entity
to	O	O	O
receive	O	O	B-Entity
nine	O	O	O
weeks	O	O	B-Entity
of	O	O	O
VRET	O	O	B-Entity
or	O	O	O
CET	O	O	B-Entity
.	O	O	O

Assessors	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
therapists	O	O	B-Entity
,	O	O	O
were	O	O	O
blinded	O	O	B-Entity
.	O	O	O

PTSD	O	O	B-Entity
symptom	O	O	B-Entity
improvement	O	O	B-Entity
was	O	O	O
assessed	O	O	B-Entity
one	O	O	O
week	O	O	B-Entity
and	O	O	O
3	O	O	O
months	O	O	B-Entity
after	O	O	O
the	O	O	O
conclusion	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
using	O	O	O
the	O	O	O
clinician-administered	O	O	B-Entity
PTSD	O	O	I-Entity
scale	O	O	I-Entity
(	O	O	O
CAPS	O	O	B-Entity
)	O	O	O
.	O	O	O

A	O	O	O
small	O	O	B-Entity
crossover	O	O	O
component	O	O	O
was	O	O	O
included	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
PTSD	O	O	B-Entity
symptoms	O	O	B-Entity
improved	O	O	B-Entity
with	O	O	O
both	O	O	O
treatments	O	O	B-Entity
,	O	O	O
but	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
between	O	O	O
groups	O	O	B-Entity
.	O	O	O

Dropout	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
higher	O	O	B-Entity
in	O	O	O
VRET	O	O	B-Entity
.	O	O	O

Of	O	O	O
those	O	O	O
who	O	O	O
received	O	O	B-Entity
VRET	O	O	B-Entity
,	O	O	O
13/42	O	O	O
(	O	O	O
31	O	O	O
%	O	O	O
)	O	O	O
showed	O	O	O
>	O	O	O
30	O	O	O
%	O	O	O
improvement	O	O	B-Entity
on	O	O	O
the	O	O	O
CAPS	O	O	B-Entity
,	O	O	O
versus	O	O	O
16/43	O	O	O
(	O	O	O
37	O	O	O
%	O	O	O
)	O	O	O
who	O	O	O
received	O	O	O
CET	O	O	B-Entity
.	O	O	O

Three	O	O	O
months	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
,	O	O	O
>	O	O	O
30	O	O	O
%	O	O	O
improvement	O	O	B-Entity
was	O	O	O
seen	O	O	O
in	O	O	O
10/33	O	O	O
(	O	O	O
30	O	O	O
%	O	O	O
)	O	O	O
of	O	O	O
VRET	O	O	B-Entity
participants	O	O	B-Entity
and	O	O	O
12/33	O	O	O
(	O	O	O
36	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
CET	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
who	O	O	O
crossed	O	O	B-Entity
over	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
11	O	O	O
)	O	O	O
showed	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
improvements	O	O	B-Entity
in	O	O	O
a	O	O	O
second	O	O	B-Entity
round	O	O	O
of	O	O	O
treatment	O	O	B-Entity
,	O	O	O
regardless	O	O	B-Entity
of	O	O	O
condition	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
supported	O	O	B-Entity
the	O	O	O
utility	O	O	B-Entity
of	O	O	O
exposure	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
PTSD	O	O	B-Entity
,	O	O	O
but	O	O	O
did	O	O	O
not	O	O	O
support	O	O	B-Entity
additional	O	O	B-Entity
benefit	O	O	B-Entity
by	O	O	O
the	O	O	O
inclusion	O	O	B-Entity
of	O	O	O
virtual	O	O	B-Entity
reality	O	O	I-Entity
.	O	O	O

-DOCSTART- (28394503)

Accounting	O	O	B-Entity
for	O	O	O
linkage	O	O	B-Entity
disequilibrium	O	O	I-Entity
in	O	O	O
genome	O	O	B-Entity
scans	O	O	I-Entity
for	O	O	O
selection	O	O	B-Entity
without	O	O	B-Entity
individual	O	O	B-Entity
genotypes	O	O	B-Entity
:	O	O	O
The	O	O	O
local	O	O	O
score	O	O	O
approach	O	O	O

Detecting	O	O	B-Entity
genomic	O	O	I-Entity
footprints	O	O	I-Entity
of	O	O	O
selection	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	O
step	O	O	O
in	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
evolution	O	O	B-Entity
.	O	O	O

Accounting	O	O	O
for	O	O	O
linkage	O	O	B-Entity
disequilibrium	O	O	I-Entity
in	O	O	O
genome	O	O	B-Entity
scans	O	O	I-Entity
increases	O	O	O
detection	O	O	B-Entity
power	O	O	B-Entity
,	O	O	O
but	O	O	O
haplotype	O	O	B-Entity
-based	O	O	O
methods	O	O	O
require	O	O	O
individual	O	O	B-Entity
genotypes	O	O	B-Entity
and	O	O	O
are	O	O	O
not	O	O	O
applicable	O	O	O
on	O	O	O
pool-sequenced	O	O	B-Entity
samples	O	O	I-Entity
.	O	O	O

We	O	O	O
propose	O	O	O
to	O	O	O
take	O	O	O
advantage	O	O	O
of	O	O	O
the	O	O	O
local	O	O	B-Entity
score	O	O	I-Entity
approach	O	O	I-Entity
to	O	O	O
account	O	O	O
for	O	O	O
linkage	O	O	B-Entity
disequilibrium	O	O	I-Entity
in	O	O	O
genome	O	O	B-Entity
scans	O	O	I-Entity
for	O	O	O
selection	O	O	B-Entity
,	O	O	O
cumulating	O	O	B-Entity
(	O	O	O
possibly	O	O	O
small	O	O	O
)	O	O	O
signals	O	O	B-Entity
from	O	O	O
single	O	O	O
markers	O	O	B-Entity
over	O	O	O
a	O	O	O
genomic	O	O	B-Entity
segment	O	O	I-Entity
,	O	O	O
to	O	O	O
clearly	O	O	O
pinpoint	O	O	O
a	O	O	O
selection	O	O	O
signal	O	O	B-Entity
.	O	O	O

Using	O	O	O
computer	O	O	B-Entity
simulations	O	O	I-Entity
,	O	O	O
we	O	O	O
demonstrate	O	O	O
that	O	O	O
this	O	O	O
approach	O	O	O
detects	O	O	B-Entity
selection	O	O	B-Entity
with	O	O	O
higher	O	O	O
power	O	O	O
than	O	O	O
several	O	O	O
state-of-the-art	O	O	B-Entity
single-marker	O	O	B-Entity
,	O	O	O
windowing	O	O	O
or	O	O	O
haplotype	O	O	B-Entity
-based	O	O	O
approaches	O	O	O
.	O	O	O

We	O	O	O
illustrate	O	O	O
this	O	O	O
on	O	O	O
two	O	O	O
benchmark	O	O	B-Entity
data	O	O	B-Entity
sets	O	O	I-Entity
including	O	O	O
individual	O	O	B-Entity
genotypes	O	O	B-Entity
,	O	O	O
for	O	O	O
which	O	O	O
we	O	O	O
obtain	O	O	O
similar	O	O	O
results	O	O	O
with	O	O	O
the	O	O	O
local	O	O	B-Entity
score	O	O	I-Entity
and	O	O	O
one	O	O	O
haplotype	O	O	B-Entity
-based	O	O	O
approach	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
we	O	O	O
apply	O	O	O
the	O	O	O
local	O	O	B-Entity
score	O	O	I-Entity
approach	O	O	I-Entity
to	O	O	O
Pool-Seq	O	O	B-Entity
data	O	O	I-Entity
obtained	O	O	O
from	O	O	O
a	O	O	O
divergent	O	O	B-Entity
selection	O	O	B-Entity
experiment	O	O	B-Entity
on	O	O	O
behaviour	O	O	B-Entity
in	O	O	O
quail	O	O	B-Entity
and	O	O	O
obtain	O	O	O
precise	O	O	O
and	O	O	O
biologically	O	O	B-Entity
coherent	O	O	B-Entity
selection	O	O	O
signals	O	O	B-Entity
:	O	O	O
while	O	O	O
competing	O	O	O
methods	O	O	O
fail	O	O	O
to	O	O	O
highlight	O	O	O
any	O	O	O
clear	O	O	O
selection	O	O	O
signature	O	O	O
,	O	O	O
our	O	O	O
method	O	O	O
detects	O	O	B-Entity
several	O	O	O
regions	O	O	O
involving	O	O	O
genes	O	O	B-Entity
known	O	O	O
to	O	O	O
act	O	O	O
on	O	O	O
social	O	O	B-Entity
responsiveness	O	O	B-Entity
or	O	O	O
autistic	O	O	B-Entity
traits	O	O	I-Entity
.	O	O	O

Although	O	O	O
we	O	O	O
focus	O	O	O
here	O	O	O
on	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
positive	O	O	B-Entity
selection	O	O	B-Entity
from	O	O	O
multiple	O	O	B-Entity
population	O	O	I-Entity
data	O	O	I-Entity
,	O	O	O
the	O	O	O
local	O	O	B-Entity
score	O	O	I-Entity
approach	O	O	I-Entity
is	O	O	O
general	O	O	O
and	O	O	O
can	O	O	O
be	O	O	O
applied	O	O	O
to	O	O	O
other	O	O	O
genome	O	O	B-Entity
scans	O	O	I-Entity
for	O	O	O
selection	O	O	O
or	O	O	O
other	O	O	O
genomewide	O	O	B-Entity
analyses	O	O	I-Entity
such	O	O	O
as	O	O	O
GWAS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28394602)

Is	O	O	O
UV	O	O	B-Entity
-	O	O	O
Induced	O	O	B-Entity
Electron-Driven	O	O	B-Entity
Proton	O	O	I-Entity
Transfer	O	O	I-Entity
Active	O	O	B-Entity
in	O	O	O
a	O	O	O
Chemically	O	O	B-Entity
Modified	O	O	I-Entity
A	O	O	B-Entity
·	O	O	O
T	O	O	B-Entity
DNA	O	O	B-Entity
Base	O	O	B-Entity
Pair	O	O	I-Entity
?	O	O	O

Transient	O	O	B-Entity
electronic	O	O	I-Entity
and	O	O	I-Entity
vibrational	O	O	I-Entity
absorption	O	O	I-Entity
spectroscopies	O	O	I-Entity
have	O	O	O
been	O	O	O
used	O	O	O
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
UV	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
electron-driven	O	O	B-Entity
proton	O	O	I-Entity
transfer	O	O	I-Entity
(	O	O	O
EDPT	O	O	B-Entity
)	O	O	O
mechanisms	O	O	B-Entity
are	O	O	O
active	O	O	B-Entity
in	O	O	O
a	O	O	O
chemically	O	O	B-Entity
modified	O	O	I-Entity
adenine	O	O	B-Entity
-	O	O	O
thymine	O	O	B-Entity
(	O	O	O
A	O	O	B-Entity
·	O	O	O
T	O	O	B-Entity
)	O	O	O
DNA	O	O	B-Entity
base	O	O	B-Entity
pair	O	O	I-Entity
.	O	O	O

To	O	O	O
enhance	O	O	O
the	O	O	O
fraction	O	O	B-Entity
of	O	O	I-Entity
biologically	O	O	B-Entity
relevant	O	O	I-Entity
Watson-Crick	O	O	B-Entity
(	O	O	I-Entity
WC	O	O	I-Entity
)	O	O	I-Entity
hydrogen-bonding	O	O	I-Entity
motifs	O	O	B-Entity
and	O	O	O
eliminate	O	O	O
undesired	O	O	O
Hoogsteen	O	O	B-Entity
structures	O	O	I-Entity
,	O	O	O
a	O	O	O
chemically	O	O	B-Entity
modified	O	O	I-Entity
derivative	O	O	B-Entity
of	O	O	I-Entity
A	O	O	B-Entity
was	O	O	O
synthesized	O	O	B-Entity
,	O	O	O
8-(tert-butyl)-9-ethyladenine	O	O	B-Entity
(	O	O	O
8tBA	O	O	B-Entity
)	O	O	O
.	O	O	O

Equimolar	O	O	B-Entity
solutions	O	O	I-Entity
of	O	O	O
8tBA	O	O	B-Entity
and	O	O	O
silyl-protected	O	O	B-Entity
T	O	O	I-Entity
nucleosides	O	O	B-Entity
in	O	O	O
chloroform	O	O	B-Entity
yield	O	O	B-Entity
a	O	O	O
mixture	O	O	B-Entity
of	O	O	O
WC	O	O	B-Entity
pairs	O	O	I-Entity
,	O	O	O
reverse	O	O	B-Entity
WC	O	O	I-Entity
pairs	O	O	I-Entity
,	O	O	O
and	O	O	O
residual	O	O	B-Entity
monomers	O	O	I-Entity
.	O	O	O

Unlike	O	O	O
previous	O	O	O
transient	O	O	B-Entity
absorption	O	O	I-Entity
studies	O	O	I-Entity
of	O	O	O
WC	O	O	O
guanine	O	O	B-Entity
-	O	O	O
cytosin	O	O	B-Entity
e	O	O	O
(	O	O	O
G	O	O	B-Entity
·	O	O	O
C	O	O	B-Entity
)	O	O	O
pairs	O	O	B-Entity
,	O	O	O
no	O	O	O
clear	O	O	O
spectroscopic	O	O	B-Entity
or	O	O	I-Entity
kinetic	O	O	I-Entity
evidence	O	O	I-Entity
was	O	O	O
identified	O	O	B-Entity
for	O	O	O
the	O	O	O
participation	O	O	B-Entity
of	O	O	O
EDPT	O	O	B-Entity
in	O	O	O
the	O	O	O
excited-state	O	O	B-Entity
relaxation	O	O	I-Entity
dynamics	O	O	I-Entity
of	O	O	O
8tBA	O	O	B-Entity
·	O	O	O
T	O	O	B-Entity
pairs	O	O	O
,	O	O	O
although	O	O	O
ultrafast	O	O	B-Entity
(	O	O	O
sub-100	O	O	O
fs	O	O	O
)	O	O	O
EDPT	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
discounted	O	O	O
.	O	O	O

Monomer-like	O	O	B-Entity
dynamics	O	O	I-Entity
are	O	O	O
proposed	O	O	O
to	O	O	O
dominate	O	O	O
in	O	O	O
8tBA	O	O	B-Entity
·	O	O	O
T.	O	O	O

-DOCSTART- (28395554)

Monitoring	O	O	B-Entity
proteolytic	O	O	B-Entity
processing	O	O	I-Entity
events	O	O	B-Entity
by	O	O	O
quantitative	O	O	O
mass	O	O	O
spectrometry	O	O	O

Protease	O	O	B-Entity
activity	O	O	I-Entity
plays	O	O	O
a	O	O	O
key	O	O	O
role	O	O	B-Entity
in	O	O	O
a	O	O	O
wide	O	O	O
variety	O	O	O
of	O	O	O
biological	O	O	B-Entity
processes	O	O	I-Entity
including	O	O	B-Entity
gene	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
protein	O	O	B-Entity
turnover	O	O	I-Entity
and	O	O	O
development	O	O	B-Entity
.	O	O	O

misregulation	O	O	B-Entity
of	O	O	O
these	O	O	O
proteins	O	O	B-Entity
has	O	O	O
been	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
many	O	O	O
cancer	O	O	B-Entity
types	O	O	I-Entity
such	O	O	O
as	O	O	O
prostate	O	O	B-Entity
,	O	O	O
breast	O	O	B-Entity
,	O	O	O
and	O	O	O
skin	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

thus	O	O	O
,	O	O	O
the	O	O	O
identification	O	O	B-Entity
of	O	O	O
protease	O	O	B-Entity
substrates	O	O	B-Entity
will	O	O	O
provide	O	O	B-Entity
key	O	O	O
information	O	O	B-Entity
to	O	O	O
understand	O	O	B-Entity
proteolysis	O	O	B-Entity
-related	O	O	O
pathologies	O	O	B-Entity
.	O	O	O

Areas	O	O	O
covered	O	O	B-Entity
:	O	O	O
Proteomics	O	O	B-Entity
-based	O	O	O
methods	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
proteolysis	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	I-Entity
focusing	O	O	O
on	O	O	O
substrate	O	O	B-Entity
identification	O	O	B-Entity
,	O	O	O
protease	O	O	B-Entity
specificity	O	O	B-Entity
and	O	O	O
their	O	O	O
applications	O	O	B-Entity
in	O	O	O
systems	O	O	B-Entity
biology	O	O	I-Entity
are	O	O	O
reviewed	O	O	B-Entity
.	O	O	O

Their	O	O	O
quantification	O	O	B-Entity
strategies	O	O	O
,	O	O	O
challenges	O	O	B-Entity
and	O	O	O
pitfalls	O	O	B-Entity
are	O	O	O
underlined	O	O	O
and	O	O	O
the	O	O	O
biological	O	O	B-Entity
implications	O	O	O
of	O	O	O
protease	O	O	B-Entity
malfunction	O	O	B-Entity
are	O	O	O
highlighted	O	O	O
.	O	O	O

Expert	O	O	B-Entity
commentary	O	O	I-Entity
:	O	O	O
Dysregulated	O	O	B-Entity
protease	O	O	B-Entity
activity	O	O	I-Entity
is	O	O	O
a	O	O	O
hallmark	O	O	B-Entity
for	O	O	O
some	O	O	O
disease	O	O	B-Entity
pathologies	O	O	B-Entity
such	O	O	O
as	O	O	O
cancer	O	O	B-Entity
.	O	O	O

Current	O	O	B-Entity
biochemical	O	O	B-Entity
approaches	O	O	B-Entity
are	O	O	O
low	O	O	B-Entity
throughput	O	O	B-Entity
and	O	O	O
some	O	O	O
are	O	O	O
limited	O	O	B-Entity
by	O	O	O
the	O	O	O
amount	O	O	B-Entity
of	O	O	O
sample	O	O	B-Entity
required	O	O	B-Entity
to	O	O	O
obtain	O	O	B-Entity
reliable	O	O	O
results	O	O	B-Entity
.	O	O	O

Mass	O	O	B-Entity
spectrometry	O	O	I-Entity
based	O	O	O
proteomics	O	O	B-Entity
provides	O	O	B-Entity
a	O	O	O
suitable	O	O	B-Entity
platform	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
protease	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
providing	O	O	B-Entity
information	O	O	B-Entity
about	O	O	O
substrate	O	O	B-Entity
specificity	O	O	I-Entity
and	O	O	O
mapping	O	O	B-Entity
cleavage	O	O	B-Entity
sites	O	O	I-Entity
.	O	O	O

-DOCSTART- (28396744)

Diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
as	O	O	O
the	O	O	O
cause	O	O	B-Entity
of	O	O	O
end-stage	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
reported	O	O	O
on	O	O	O
the	O	O	O
medical	O	O	B-Entity
evidence	O	O	I-Entity
form	O	O	I-Entity
CMS2728	O	O	B-Entity
at	O	O	O
a	O	O	O
single	O	O	O
center	O	O	O

Background	O	O	O
:	O	O	O
End-stage	O	O	B-Entity
renal	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
ESRD	O	O	B-Entity
)	O	O	O
incidence	O	O	B-Entity
due	O	O	O
to	O	O	O
Type	O	O	B-Entity
2	O	O	I-Entity
diabetic	O	O	B-Entity
nephropathy	O	O	I-Entity
(	O	O	O
DN	O	O	B-Entity
)	O	O	O
is	O	O	O
35	O	O	O
-	O	O	O
50	O	O	O
%	O	O	O
,	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
Renal	O	O	I-Entity
Data	O	O	I-Entity
System	O	O	I-Entity
.	O	O	O

Methods	O	O	O
:	O	O	O
A	O	O	O
single-	O	O	O
center	O	O	B-Entity
,	O	O	O
retrospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
to	O	O	O
determine	O	O	O
incidence	O	O	B-Entity
and	O	O	O
diagnostic	O	O	B-Entity
accuracy	O	O	I-Entity
for	O	O	O
Type	O	O	B-Entity
2	O	O	I-Entity
DN	O	O	B-Entity
as	O	O	O
the	O	O	O
primary	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	O
ESRD	O	O	B-Entity
(	O	O	O
Code	O	O	O
250.40	O	O	O
)	O	O	O
on	O	O	O
the	O	O	O
Center	O	O	B-Entity
for	O	O	I-Entity
Medicare	O	O	I-Entity
&	O	O	I-Entity
Medicaid	O	O	I-Entity
(	O	O	O
CMS	O	O	B-Entity
)	O	O	O
Medical	O	O	B-Entity
Evidence	O	O	I-Entity
Report	O	O	I-Entity
form	O	O	I-Entity
(	O	O	O
CMS2728	O	O	B-Entity
)	O	O	O
submitted	O	O	B-Entity
at	O	O	O
renal	O	O	B-Entity
replacement	O	O	I-Entity
therapy	O	O	I-Entity
initiation	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
≥18	O	O	O
years	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
with	O	O	O
a	O	O	O
CMS2728	O	O	B-Entity
submitted	O	O	B-Entity
between	O	O	O
1	O	O	O
March	O	O	O
2006	O	O	O
and	O	O	O
31	O	O	O
March	O	O	O
2015	O	O	O
at	O	O	O
a	O	O	O
single	O	O	O
academic	O	O	B-Entity
military	O	O	I-Entity
medical	O	O	I-Entity
center	O	O	I-Entity
(	O	O	O
ESRD	O	O	B-Entity
Network	O	O	O
5	O	O	O
)	O	O	O
were	O	O	O
included	O	O	O
.	O	O	O

Medical	O	O	B-Entity
records	O	O	I-Entity
of	O	O	O
those	O	O	O
with	O	O	O
a	O	O	O
Code	O	O	O
250.40	O	O	O
diagnosis	O	O	B-Entity
were	O	O	O
reviewed	O	O	B-Entity
to	O	O	O
determine	O	O	O
whether	O	O	O
they	O	O	O
met	O	O	O
the	O	O	O
Kidney	O	O	B-Entity
Disease	O	O	I-Entity
Outcomes	O	O	I-Entity
Quality	O	O	I-Entity
Initiative	O	O	I-Entity
(	O	O	O
KDOQI	O	O	B-Entity
)	O	O	O
2007	O	O	O
criteria	O	O	B-Entity
for	O	O	O
DN	O	O	B-Entity
.	O	O	O

Results	O	O	O
:	O	O	O
ESRD	O	O	B-Entity
incidence	O	O	B-Entity
secondary	O	O	O
to	O	O	O
Type	O	O	B-Entity
2	O	O	I-Entity
DN	O	O	B-Entity
was	O	O	O
18.7	O	O	O
%	O	O	O
(	O	O	O
56/299	O	O	O
individual	O	O	B-Entity
CMS2728	O	O	B-Entity
submissions	O	O	B-Entity
over	O	O	O
9.09	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
all	O	O	O
,	O	O	O
12/56	O	O	O
(	O	O	O
21.4	O	O	O
%	O	O	O
)	O	O	O
did	O	O	O
not	O	O	O
meet	O	O	O
KDOQI	O	O	B-Entity
criteria	O	O	I-Entity
for	O	O	O
Type	O	O	B-Entity
2	O	O	I-Entity
DN	O	O	B-Entity
.	O	O	O

Although	O	O	O
all	O	O	O
had	O	O	O
diabetes	O	O	B-Entity
,	O	O	O
those	O	O	O
not	O	O	B-Entity
meeting	O	O	I-Entity
criteria	O	O	I-Entity
had	O	O	O
shorter	O	O	O
disease	O	O	B-Entity
duration	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.007	O	O	O
)	O	O	O
,	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
active	O	O	B-Entity
urine	O	O	B-Entity
sediment	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.006	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
were	O	O	O
less	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
macroalbuminuria	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.037	O	O	O
)	O	O	O
or	O	O	O
retinopathy	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.002	O	O	O
)	O	O	O
prior	O	O	O
to	O	O	O
ESRD	O	O	B-Entity
.	O	O	O

On	O	O	O
exact	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
,	O	O	O
retinopathy	O	O	B-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
KDOQI	O	O	B-Entity
-predicted	O	O	O
DN	O	O	B-Entity
[	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
=	O	O	O
19.16	O	O	O
(	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
2.76	O	O	O
-	O	O	O
223.7	O	O	O
)	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
0.0009	O	O	O
]	O	O	O
.	O	O	O

Conclusions	O	O	B-Entity
:	O	O	O
In	O	O	O
this	O	O	O
single-	O	O	O
center	O	O	B-Entity
cohort	O	O	B-Entity
,	O	O	O
21.4	O	O	O
%	O	O	O
identified	O	O	B-Entity
as	O	O	O
having	O	O	O
Type	O	O	B-Entity
2	O	O	I-Entity
DN	O	O	B-Entity
as	O	O	O
the	O	O	O
primary	O	O	B-Entity
cause	O	O	B-Entity
of	O	O	O
ESRD	O	O	B-Entity
were	O	O	O
incorrectly	O	O	O
assigned	O	O	B-Entity
per	O	O	O
KDOQI	O	O	B-Entity
2007	O	O	O
clinical	O	O	B-Entity
criteria	O	O	B-Entity
.	O	O	O

If	O	O	O
replicated	O	O	B-Entity
in	O	O	O
larger	O	O	B-Entity
populations	O	O	B-Entity
,	O	O	O
this	O	O	O
could	O	O	O
have	O	O	O
substantial	O	O	O
implications	O	O	O
regarding	O	O	O
the	O	O	O
epidemiology	O	O	B-Entity
of	O	O	O
ESRD	O	O	B-Entity
in	O	O	O
the	O	O	O
USA	O	O	B-Entity
.	O	O	O

-DOCSTART- (28397533)

Socioeconomic	O	O	B-Entity
Predictors	O	O	B-Entity
of	O	O	O
Adherence	O	O	B-Entity
Behavior	O	O	I-Entity
Among	O	O	O
HIV-Positive	O	O	B-Entity
Patients	O	O	B-Entity
Receiving	O	O	B-Entity
Antiretroviral	O	O	B-Entity
Therapy	O	O	I-Entity
in	O	O	O
Selangor	O	O	B-Entity
,	O	O	O
Malaysia	O	O	O

Medication	O	O	B-Entity
adherence	O	O	I-Entity
remains	O	O	O
a	O	O	O
critical	O	O	B-Entity
link	O	O	O
between	O	O	O
the	O	O	O
prescribed	O	O	B-Entity
ART	O	O	B-Entity
regimen	O	O	B-Entity
and	O	O	O
treatment	O	O	B-Entity
outcome	O	O	I-Entity
.	O	O	O

Several	O	O	B-Entity
factors	O	O	B-Entity
may	O	O	O
influence	O	O	B-Entity
adherence	O	O	B-Entity
behavior	O	O	I-Entity
.	O	O	O

This	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
aimed	O	O	B-Entity
to	O	O	O
highlight	O	O	O
socioeconomic	O	O	B-Entity
predictors	O	O	B-Entity
of	O	O	O
adherence	O	O	B-Entity
behavior	O	O	I-Entity
among	O	O	O
a	O	O	O
cohort	O	O	B-Entity
of	O	O	O
242	O	O	O
adult	O	O	B-Entity
Malaysian	O	O	B-Entity
patients	O	O	B-Entity
receiving	O	O	B-Entity
antiretroviral	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
Hospital	O	O	B-Entity
Sungai	O	O	I-Entity
Buloh	O	O	I-Entity
,	O	O	O
Malaysia	O	O	B-Entity
,	O	O	O
where	O	O	O
they	O	O	O
were	O	O	O
enrolled	O	O	O
in	O	O	O
a	O	O	O
parent	O	O	O
study	O	O	O
(	O	O	O
single-blinded	O	O	B-Entity
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
)	O	O	O
between	O	O	O
January	O	O	B-Entity
and	O	O	O
December	O	O	B-Entity
2014	O	O	O
.	O	O	O

Statistical	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	O
secondary	O	O	B-Entity
data	O	O	I-Entity
on	O	O	O
adherence	O	O	B-Entity
behavior	O	O	I-Entity
and	O	O	O
sociodemographic	O	O	B-Entity
characteristics	O	O	I-Entity
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
revealed	O	O	B-Entity
mean	O	O	B-Entity
age	O	O	I-Entity
of	O	O	O
33.4	O	O	O
years	O	O	B-Entity
and	O	O	O
ranged	O	O	B-Entity
from	O	O	O
18	O	O	O
to	O	O	O
64	O	O	O
years	O	O	O
;	O	O	O
88.8	O	O	O
%	O	O	O
were	O	O	O
males	O	O	B-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
224	O	O	O
(	O	O	O
93	O	O	O
%	O	O	O
)	O	O	O
patients	O	O	B-Entity
who	O	O	O
completed	O	O	O
6	O	O	O
months	O	O	O
'	O	O	O
adherence	O	O	B-Entity
assessment	O	O	I-Entity
were	O	O	O
included	O	O	B-Entity
in	O	O	O
the	O	O	O
model	O	O	O
.	O	O	O

Of	O	O	O
these	O	O	O
,	O	O	O
135	O	O	O
(	O	O	O
60.3	O	O	O
%	O	O	O
)	O	O	O
achieved	O	O	B-Entity
optimal	O	O	B-Entity
adherence	O	O	B-Entity
.	O	O	O

Multivariate	O	O	B-Entity
binary	O	O	I-Entity
logistic	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	B-Entity
that	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
income	O	O	B-Entity
and	O	O	O
ethnicity	O	O	B-Entity
were	O	O	O
significant	O	O	B-Entity
predictors	O	O	B-Entity
of	O	O	O
adherence	O	O	B-Entity
behavior	O	O	I-Entity
.	O	O	O

This	O	O	O
may	O	O	O
be	O	O	O
valuable	O	O	O
for	O	O	O
targeted	O	O	B-Entity
programmatic	O	O	B-Entity
interventions	O	O	I-Entity
to	O	O	O
further	O	O	O
enhance	O	O	B-Entity
successful	O	O	B-Entity
treatment	O	O	I-Entity
outcomes	O	O	B-Entity
among	O	O	O
the	O	O	O
target	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

-DOCSTART- (28399372)

A	O	O	O
Tobramycin	O	O	B-Entity
Vector	O	O	I-Entity
Enhances	O	O	B-Entity
Synergy	O	O	B-Entity
and	O	O	O
Efficacy	O	O	B-Entity
of	O	O	O
Efflux	O	O	B-Entity
Pump	O	O	I-Entity
Inhibitors	O	O	I-Entity
against	O	O	B-Entity
Multidrug-Resistant	O	O	B-Entity
Gram-Negative	O	O	O
Bacteria	O	O	O

Drug	O	O	B-Entity
efflux	O	O	I-Entity
mechanisms	O	O	B-Entity
interact	O	O	B-Entity
synergistically	O	O	B-Entity
with	O	O	O
the	O	O	O
outer	O	O	B-Entity
membrane	O	O	I-Entity
permeability	O	O	B-Entity
barrier	O	O	B-Entity
of	O	O	O
Gram-negative	O	O	B-Entity
bacteria	O	O	I-Entity
,	O	O	O
leading	O	O	B-Entity
to	O	O	O
intrinsic	O	O	B-Entity
resistance	O	O	B-Entity
that	O	O	O
presents	O	O	O
a	O	O	O
major	O	O	B-Entity
challenge	O	O	B-Entity
for	O	O	O
antibiotic	O	O	B-Entity
drug	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

Efflux	O	O	B-Entity
pump	O	O	I-Entity
inhibitors	O	O	I-Entity
(	O	O	O
EPIs	O	O	B-Entity
)	O	O	O
which	O	O	O
block	O	O	B-Entity
the	O	O	O
efflux	O	O	B-Entity
of	O	O	O
antibiotics	O	O	B-Entity
synergize	O	O	B-Entity
antibiotics	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
clinical	O	O	B-Entity
development	O	O	I-Entity
of	O	O	O
EPI	O	O	B-Entity
/	O	O	O
antibiotic	O	O	B-Entity
combination	O	O	B-Entity
therapy	O	O	I-Entity
to	O	O	O
treat	O	O	B-Entity
multidrug-resistant	O	O	B-Entity
(	O	O	O
MDR	O	O	B-Entity
)	O	O	O
Gram-negative	O	O	B-Entity
infections	O	O	I-Entity
has	O	O	O
been	O	O	O
challenging	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
in	O	O	O
part	O	O	O
caused	O	O	B-Entity
by	O	O	O
the	O	O	O
inefficiency	O	O	B-Entity
of	O	O	O
current	O	O	B-Entity
EPIs	O	O	B-Entity
to	O	O	O
penetrate	O	O	B-Entity
the	O	O	O
outer	O	O	B-Entity
membrane	O	O	I-Entity
and	O	O	O
resist	O	O	B-Entity
efflux	O	O	B-Entity
.	O	O	O

We	O	O	O
demonstrate	O	O	O
that	O	O	O
conjugation	O	O	B-Entity
of	O	O	O
a	O	O	O
tobramycin	O	O	B-Entity
(	O	O	O
TOB	O	O	B-Entity
)	O	O	O
vector	O	O	O
to	O	O	O
EPIs	O	O	B-Entity
like	O	O	O
NMP	O	O	B-Entity
,	O	O	O
paroxetine	O	O	B-Entity
,	O	O	O
or	O	O	O
DBP	O	O	B-Entity
enhances	O	O	B-Entity
synergy	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
EPIs	O	O	O
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
tetracycline	O	O	B-Entity
antibiotics	O	O	I-Entity
against	O	O	O
MDR	O	O	B-Entity
Gram-negative	O	O	B-Entity
bacteria	O	O	I-Entity
including	O	O	O
Pseudomonas	O	O	B-Entity
aeruginosa	O	O	I-Entity
.	O	O	O

Besides	O	O	O
potentiating	O	O	B-Entity
tetracycline	O	O	B-Entity
antibiotics	O	O	I-Entity
,	O	O	O
TOB	O	O	B-Entity
-	O	O	O
EPI	O	O	B-Entity
conjugates	O	O	B-Entity
can	O	O	O
also	O	O	O
suppress	O	O	B-Entity
resistance	O	O	B-Entity
development	O	O	B-Entity
to	O	O	O
the	O	O	O
tetracycline	O	O	B-Entity
antibiotic	O	O	I-Entity
minocycline	O	O	B-Entity
,	O	O	O
thereby	O	O	O
providing	O	O	B-Entity
a	O	O	O
strategy	O	O	B-Entity
to	O	O	O
develop	O	O	B-Entity
more	O	O	O
effective	O	O	B-Entity
adjuvants	O	O	B-Entity
to	O	O	O
rescue	O	O	O
tetracycline	O	O	O
antibiotics	O	O	O
from	O	O	O
resistance	O	O	O
in	O	O	O
MDR	O	O	B-Entity
Gram-negative	O	O	B-Entity
bacteria	O	O	I-Entity
.	O	O	O

-DOCSTART- (28400582)

Detection	O	O	B-Entity
of	O	O	O
AMA-M2	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
saliva	O	O	B-Entity
:	O	O	O
Potentials	O	O	B-Entity
in	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
primary	O	O	O
biliary	O	O	O
cholangitis	O	O	O

Serum	O	O	B-Entity
anti-mitochondrial	O	O	B-Entity
antibody	O	O	I-Entity
type	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
AMA-M2	O	O	B-Entity
)	O	O	O
is	O	O	O
considered	O	O	O
as	O	O	O
a	O	O	O
pivotal	O	O	O
biomarker	O	O	B-Entity
for	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
primary	O	O	B-Entity
biliary	O	O	I-Entity
cholangitis	O	O	I-Entity
(	O	O	O
PBC	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
serological	O	O	B-Entity
tests	O	O	I-Entity
have	O	O	O
many	O	O	O
limitations	O	O	B-Entity
,	O	O	O
including	O	O	O
inconvenience	O	O	B-Entity
,	O	O	O
invasiveness	O	O	B-Entity
,	O	O	O
and	O	O	O
infection	O	O	B-Entity
risks	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
a	O	O	O
less	O	O	B-Entity
invasive	O	O	B-Entity
approach	O	O	B-Entity
to	O	O	O
detect	O	O	B-Entity
AMA-M2	O	O	B-Entity
titer	O	O	I-Entity
is	O	O	O
desirable	O	O	O
.	O	O	O

We	O	O	O
examined	O	O	O
salivary	O	O	B-Entity
AMA-M2	O	O	B-Entity
of	O	O	O
potential	O	O	B-Entity
PBC	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
found	O	O	O
that	O	O	O
AMA-M2	O	O	O
could	O	O	O
be	O	O	O
detected	O	O	B-Entity
only	O	O	O
in	O	O	O
saliva	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
AMA-M2-positive	O	O	B-Entity
PBC	O	O	O
patients	O	O	O
,	O	O	O
but	O	O	O
not	O	O	O
in	O	O	O
saliva	O	O	O
of	O	O	O
serum	O	O	O
AMA-M2-negative	O	O	B-Entity
PBC	O	O	O
patients	O	O	O
,	O	O	O
oral	O	O	B-Entity
lichen	O	O	I-Entity
planus	O	O	I-Entity
patients	O	O	O
(	O	O	O
OLP	O	O	B-Entity
)	O	O	O
patients	O	O	O
,	O	O	O
or	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
salivary	O	O	B-Entity
AMA-M2	O	O	B-Entity
was	O	O	O
positively	O	O	B-Entity
correlated	O	O	I-Entity
with	O	O	O
the	O	O	O
amount	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
AMA-M2	O	O	O
in	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
salivary	O	O	B-Entity
inflammatory	O	O	B-Entity
cytokines	O	O	I-Entity
were	O	O	O
increased	O	O	B-Entity
in	O	O	O
the	O	O	O
PBC	O	O	B-Entity
,	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
results	O	O	B-Entity
of	O	O	O
serum	O	O	B-Entity
test	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
indicated	O	O	O
that	O	O	O
saliva	O	O	B-Entity
might	O	O	O
be	O	O	O
a	O	O	O
less	O	O	B-Entity
invasive	O	O	B-Entity
and	O	O	O
cost-effective	O	O	B-Entity
medium	O	O	B-Entity
to	O	O	O
accurately	O	O	O
test	O	O	B-Entity
for	O	O	O
AMA-M2	O	O	B-Entity
levels	O	O	I-Entity
and	O	O	O
this	O	O	O
is	O	O	O
a	O	O	O
promising	O	O	O
development	O	O	B-Entity
for	O	O	O
the	O	O	O
diagnosis	O	O	B-Entity
and	O	O	O
monitoring	O	O	B-Entity
of	O	O	O
PBC	O	O	B-Entity
.	O	O	O

-DOCSTART- (28402002)

Mental	O	O	B-Entity
health	O	O	I-Entity
and	O	O	O
associated	O	O	B-Entity
factors	O	O	B-Entity
among	O	O	O
young	O	O	B-Entity
offenders	O	O	B-Entity
in	O	O	O
Chile	O	O	B-Entity
:	O	O	O
a	O	O	O
cross-sectional	O	O	O
study	O	O	O

Few	O	O	O
studies	O	O	O
in	O	O	O
Latin	O	O	B-Entity
America	O	O	I-Entity
have	O	O	O
explored	O	O	O
mental	O	O	B-Entity
disorder	O	O	I-Entity
among	O	O	O
young	O	O	B-Entity
offenders	O	O	B-Entity
,	O	O	O
or	O	O	O
variables	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
it	O	O	O
.	O	O	O

Our	O	O	O
aim	O	O	O
was	O	O	O
to	O	O	O
test	O	O	O
for	O	O	O
associations	O	O	B-Entity
between	O	O	O
childhood	O	O	B-Entity
adversity	O	O	B-Entity
or	O	O	O
substance	O	O	B-Entity
misuse	O	O	I-Entity
and	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
among	O	O	O
young	O	O	B-Entity
offenders	O	O	B-Entity
.	O	O	O

Sentenced	O	O	B-Entity
adolescent	O	O	B-Entity
offenders	O	O	B-Entity
were	O	O	O
recruited	O	O	B-Entity
from	O	O	O
young	O	O	B-Entity
offenders	O	O	B-Entity
'	O	O	I-Entity
institutions	O	O	B-Entity
or	O	O	O
community	O	O	B-Entity
centres	O	O	I-Entity
provided	O	O	O
by	O	O	O
the	O	O	O
Chilean	O	O	B-Entity
National	O	O	I-Entity
Service	O	O	I-Entity
for	O	O	I-Entity
Minors	O	O	I-Entity
.	O	O	O

Psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
were	O	O	O
assessed	O	O	B-Entity
using	O	O	O
the	O	O	O
Mini	O	O	B-Entity
International	O	O	I-Entity
Neuropsychiatric	O	O	I-Entity
Interview	O	O	I-Entity
,	O	O	O
conducted	O	O	O
by	O	O	O
trained	O	O	B-Entity
psychologists	O	O	I-Entity
.	O	O	O

A	O	O	O
trained	O	O	B-Entity
sociologist	O	O	I-Entity
used	O	O	O
an	O	O	O
ad	O	O	B-Entity
hoc	O	O	I-Entity
interview	O	O	I-Entity
to	O	O	O
collect	O	O	O
information	O	O	B-Entity
about	O	O	O
childhood	O	O	B-Entity
experiences	O	O	I-Entity
,	O	O	O
including	O	O	O
parenting	O	O	B-Entity
,	O	O	O
trauma	O	O	B-Entity
,	O	O	O
education	O	O	B-Entity
and	O	O	O
substance	O	O	B-Entity
misuse	O	O	I-Entity
.	O	O	O

Multivariable	O	O	B-Entity
logistic	O	O	I-Entity
regressions	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
analyse	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
prevalent	O	O	O
psychiatric	O	O	B-Entity
disorders	O	O	I-Entity
among	O	O	O
the	O	O	O
935	O	O	O
participants	O	O	B-Entity
were	O	O	O
marijuana	O	O	B-Entity
dependence	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
and	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Substance	O	O	B-Entity
use	O	O	I-Entity
disorders	O	O	I-Entity
were	O	O	O
less	O	O	O
frequent	O	O	B-Entity
among	O	O	O
young	O	O	B-Entity
offenders	O	O	B-Entity
who	O	O	O
were	O	O	O
serving	O	O	O
their	O	O	O
sentence	O	O	B-Entity
in	O	O	O
young	O	O	O
offenders	O	O	B-Entity
'	O	O	I-Entity
institutions	O	O	B-Entity
than	O	O	O
among	O	O	O
those	O	O	O
serving	O	O	O
in	O	O	O
community	O	O	B-Entity
centres	O	O	I-Entity
and	O	O	O
more	O	O	O
frequent	O	O	O
among	O	O	O
those	O	O	O
who	O	O	O
started	O	O	B-Entity
to	O	O	O
use	O	O	B-Entity
marijuana	O	O	I-Entity
at	O	O	O
an	O	O	O
earlier	O	O	B-Entity
age	O	O	I-Entity
.	O	O	O

Among	O	O	O
other	O	O	O
variables	O	O	B-Entity
,	O	O	O
childhood	O	O	B-Entity
maltreatment	O	O	I-Entity
was	O	O	O
related	O	O	O
to	O	O	O
major	O	O	B-Entity
depressive	O	O	I-Entity
disorder	O	O	I-Entity
,	O	O	O
and	O	O	O
maternal	O	O	B-Entity
death	O	O	I-Entity
to	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Higher	O	O	O
educational	O	O	B-Entity
status	O	O	I-Entity
was	O	O	O
related	O	O	O
to	O	O	O
a	O	O	O
lower	O	O	B-Entity
frequency	O	O	I-Entity
of	O	O	O
depressive	O	O	B-Entity
and	O	O	O
anxiety	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
greater	O	O	O
efforts	O	O	O
must	O	O	O
be	O	O	O
made	O	O	O
to	O	O	O
identify	O	O	B-Entity
vulnerable	O	O	B-Entity
young	O	O	B-Entity
people	O	O	B-Entity
much	O	O	O
earlier	O	O	B-Entity
.	O	O	O

Few	O	O	B-Entity
of	O	O	O
these	O	O	O
young	O	O	B-Entity
offenders	O	O	B-Entity
with	O	O	O
mental	O	O	B-Entity
health	O	O	B-Entity
problems	O	O	B-Entity
had	O	O	O
been	O	O	O
well	O	O	O
adjusted	O	O	B-Entity
in	O	O	O
health	O	O	O
,	O	O	O
education	O	O	B-Entity
or	O	O	O
socially	O	O	B-Entity
before	O	O	O
this	O	O	O
period	O	O	B-Entity
of	O	O	O
detention	O	O	B-Entity
.	O	O	O

©	O	O	O
2017	O	O	O
The	O	O	O
Authors	O	O	O
.	O	O	O

Criminal	O	O	O
Behaviour	O	O	O
and	O	O	O
Mental	O	O	O
Health	O	O	O
Published	O	O	O
by	O	O	O
John	O	O	O
Wiley	O	O	O
&	O	O	O
Sons	O	O	O
Ltd.	O	O	O

-DOCSTART- (28402055)

Effects	O	O	B-Entity
of	O	O	I-Entity
regular	O	O	B-Entity
water	O	O	B-Entity
-	O	O	O
and	O	O	O
land-based	O	O	B-Entity
exercise	O	O	I-Entity
on	O	O	O
physical	O	O	B-Entity
function	O	O	I-Entity
after	O	O	O
5	O	O	O
years	O	O	B-Entity
:	O	O	O
A	O	O	O
long-term	O	O	B-Entity
study	O	O	I-Entity
on	O	O	O
the	O	O	O
well-being	O	O	O
of	O	O	O
older	O	O	B-Entity
Japanese	O	O	I-Entity
adults	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
5	O	O	O
years	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
exercise	O	O	I-Entity
on	O	O	O
functional	O	O	B-Entity
parameters	O	O	B-Entity
among	O	O	O
older	O	O	B-Entity
Japanese	O	O	I-Entity
adults	O	O	B-Entity
who	O	O	O
carried	O	O	O
out	O	O	O
water	O	O	B-Entity
-	O	O	O
or	O	O	O
land-based	O	O	B-Entity
exercise	O	O	I-Entity
.	O	O	O

We	O	O	O
retrospectively	O	O	B-Entity
investigated	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
5707	O	O	O
medical	O	O	B-Entity
examinations	O	O	I-Entity
and	O	O	O
enrolled	O	O	B-Entity
77	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
into	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

Eligible	O	O	O
participants	O	O	B-Entity
had	O	O	O
to	O	O	O
be	O	O	O
aged	O	O	B-Entity
≥60	O	O	O
years	O	O	B-Entity
,	O	O	O
and	O	O	O
engaged	O	O	O
in	O	O	O
water-based	O	O	B-Entity
exercise	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
38	O	O	O
)	O	O	O
or	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
water	O	O	B-Entity
-	O	O	O
and	O	O	O
land-based	O	O	B-Entity
exercise	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
39	O	O	O
)	O	O	O
for	O	O	O
at	O	O	O
least	O	O	O
80	O	O	O
%	O	O	O
of	O	O	O
their	O	O	O
total	O	O	B-Entity
exercise	O	O	I-Entity
time	O	O	I-Entity
for	O	O	O
over	O	O	O
5	O	O	O
years	O	O	O
at	O	O	O
our	O	O	O
fitness	O	O	B-Entity
center	O	O	I-Entity
.	O	O	O

In	O	O	O
statistical	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
a	O	O	O
two-way	O	O	B-Entity
repeated-measures	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	I-Entity
variance	O	O	I-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
to	O	O	O
examine	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
and	O	O	O
by	O	O	O
exercise	O	O	B-Entity
type	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
changes	O	O	B-Entity
in	O	O	O
each	O	O	O
parameter	O	O	B-Entity
over	O	O	O
5	O	O	O
years	O	O	B-Entity
were	O	O	O
also	O	O	O
compared	O	O	B-Entity
between	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	B-Entity
significant	O	O	B-Entity
main	O	O	B-Entity
effects	O	O	B-Entity
and	O	O	O
an	O	O	O
interaction	O	O	B-Entity
between	O	O	O
time	O	O	B-Entity
and	O	O	O
exercise	O	O	B-Entity
type	O	O	I-Entity
for	O	O	O
gait	O	O	B-Entity
speed	O	O	I-Entity
,	O	O	O
with	O	O	O
an	O	O	O
early	O	O	B-Entity
decline	O	O	I-Entity
in	O	O	O
the	O	O	O
combined	O	O	B-Entity
exercise	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
significant	O	O	O
main	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
time	O	O	O
,	O	O	O
showing	O	O	O
a	O	O	O
functional	O	O	B-Entity
decline	O	O	I-Entity
in	O	O	O
grip	O	O	B-Entity
strength	O	O	I-Entity
,	O	O	O
one-leg	O	O	B-Entity
standing	O	O	I-Entity
time	O	O	O
and	O	O	O
step/height	O	O	B-Entity
ratio	O	O	B-Entity
in	O	O	O
both	O	O	O
exercise	O	O	B-Entity
types	O	O	I-Entity
at	O	O	O
the	O	O	O
5-	O	O	O
year	O	O	B-Entity
follow	O	O	B-Entity
up	O	O	I-Entity
.	O	O	O

The	O	O	O
5-	O	O	O
year	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
each	O	O	O
parameter	O	O	B-Entity
did	O	O	O
not	O	O	O
differ	O	O	O
between	O	O	O
the	O	O	O
two	O	O	O
groups	O	O	B-Entity
despite	O	O	O
the	O	O	O
frequency	O	O	B-Entity
of	O	O	I-Entity
exercise	O	O	I-Entity
,	O	O	O
even	O	O	O
though	O	O	O
we	O	O	O
found	O	O	B-Entity
a	O	O	O
negative	O	O	B-Entity
correlation	O	O	B-Entity
between	O	O	O
changes	O	O	O
in	O	O	O
one-leg	O	O	B-Entity
standing	O	O	I-Entity
time	O	O	B-Entity
and	O	O	O
total	O	O	B-Entity
amount	O	O	B-Entity
of	O	O	O
water-based	O	O	B-Entity
exercise	O	O	I-Entity
.	O	O	O

Contrary	O	O	O
to	O	O	O
expectations	O	O	B-Entity
,	O	O	O
these	O	O	O
results	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
regular	O	O	B-Entity
engagement	O	O	O
in	O	O	O
water-based	O	O	B-Entity
exercise	O	O	I-Entity
,	O	O	O
even	O	O	O
combined	O	O	B-Entity
with	O	O	O
land-based	O	O	B-Entity
exercise	O	O	I-Entity
,	O	O	O
might	O	O	O
have	O	O	O
poor	O	O	O
long-term	O	O	B-Entity
benefits	O	O	B-Entity
for	O	O	O
maintaining	O	O	B-Entity
physical	O	O	B-Entity
performance	O	O	I-Entity
in	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

Geriatr	O	O	O
Gerontol	O	O	O
Int	O	O	O
2017	O	O	O
;	O	O	O
••	O	O	O
:	O	O	O
••-••.	O	O	O

-DOCSTART- (28402232)

Combined	O	O	B-Entity
exposures	O	O	B-Entity
of	O	O	O
whole-body	O	O	B-Entity
vibration	O	O	I-Entity
and	O	O	O
awkward	O	O	B-Entity
posture	O	O	I-Entity
:	O	O	O
a	O	O	O
cross	O	O	B-Entity
sectional	O	O	I-Entity
investigation	O	O	I-Entity
among	O	O	O
occupational	O	O	B-Entity
drivers	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
simultaneous	O	O	B-Entity
field	O	O	O
measurements	O	O	O

Multifactorial	O	O	B-Entity
workloads	O	O	B-Entity
such	O	O	O
as	O	O	O
whole-body	O	O	B-Entity
vibration	O	O	I-Entity
(	O	O	O
WBV	O	O	B-Entity
)	O	O	O
,	O	O	O
awkward	O	O	B-Entity
posture	O	O	I-Entity
and	O	O	O
heavy	O	O	O
lifting	O	O	B-Entity
are	O	O	O
potential	O	O	B-Entity
predictors	O	O	B-Entity
for	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
(	O	O	O
LBP	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigate	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
between	O	O	O
LBP	O	O	B-Entity
and	O	O	O
these	O	O	O
exposures	O	O	B-Entity
among	O	O	O
102	O	O	O
professional	O	O	B-Entity
drivers	O	O	B-Entity
.	O	O	O

The	O	O	O
combined	O	O	B-Entity
exposures	O	O	B-Entity
of	O	O	O
WBV	O	O	B-Entity
and	O	O	O
posture	O	O	O
are	O	O	O
measured	O	O	B-Entity
at	O	O	O
different	O	O	B-Entity
workplaces	O	O	B-Entity
.	O	O	O

Health	O	O	B-Entity
and	O	O	O
personal	O	O	O
data	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
information	O	O	B-Entity
about	O	O	O
lifting	O	O	B-Entity
tasks	O	O	B-Entity
are	O	O	O
collected	O	O	B-Entity
by	O	O	O
a	O	O	O
questionnaire	O	O	B-Entity
.	O	O	O

The	O	O	O
daily	O	O	B-Entity
vibration	O	O	B-Entity
exposure	O	O	I-Entity
value	O	O	B-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
1.69	O	O	O
)	O	O	O
and	O	O	O
an	O	O	O
index	O	O	B-Entity
for	O	O	O
awkward	O	O	B-Entity
posture	O	O	I-Entity
(	O	O	O
odds	O	O	O
ratio	O	O	O
1.63	O	O	O
)	O	O	O
show	O	O	O
significant	O	O	B-Entity
association	O	O	B-Entity
with	O	O	O
the	O	O	O
occurence	O	O	B-Entity
of	O	O	O
LBP	O	O	B-Entity
.	O	O	O

Awkward	O	O	B-Entity
posture	O	O	I-Entity
and	O	O	O
heavy	O	O	O
lifting	O	O	B-Entity
appear	O	O	B-Entity
to	O	O	O
be	O	O	O
more	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
sick	O	O	B-Entity
leave	O	O	I-Entity
than	O	O	O
WBV	O	O	B-Entity
exposure	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
the	O	O	O
measurement	O	O	B-Entity
results	O	O	B-Entity
of	O	O	O
WBV	O	O	B-Entity
and	O	O	O
awkward	O	O	B-Entity
posture	O	O	I-Entity
into	O	O	O
one	O	O	O
quantity	O	O	B-Entity
also	O	O	O
shows	O	O	O
significant	O	O	B-Entity
correlation	O	O	B-Entity
to	O	O	O
LBP	O	O	B-Entity
.	O	O	O

The	O	O	O
combined	O	O	B-Entity
exposure	O	O	B-Entity
of	O	O	O
WBV	O	O	B-Entity
and	O	O	O
awkward	O	O	B-Entity
posture	O	O	I-Entity
can	O	O	O
be	O	O	O
described	O	O	B-Entity
in	O	O	O
terms	O	O	O
of	O	O	O
the	O	O	O
daily	O	O	B-Entity
vibration	O	O	B-Entity
exposure	O	O	I-Entity
and	O	O	O
the	O	O	O
index	O	O	B-Entity
for	O	O	O
awkward	O	O	O
posture	O	O	O
.	O	O	O

This	O	O	O
facilitates	O	O	O
work	O	O	B-Entity
place	O	O	I-Entity
assessments	O	O	B-Entity
and	O	O	O
future	O	O	B-Entity
research	O	O	B-Entity
in	O	O	O
this	O	O	O
area	O	O	B-Entity
.	O	O	O

Practitioner	O	O	O
Summary	O	O	O
:	O	O	O
For	O	O	O
the	O	O	O
first	O	O	O
time	O	O	O
,	O	O	O
quantitative	O	O	B-Entity
measures	O	O	B-Entity
combining	O	O	O
whole-body	O	O	B-Entity
vibration	O	O	I-Entity
and	O	O	O
awkward	O	O	B-Entity
posture	O	O	I-Entity
exposures	O	O	B-Entity
have	O	O	O
shown	O	O	O
to	O	O	O
correlate	O	O	B-Entity
with	O	O	O
the	O	O	O
occurrence	O	O	B-Entity
of	O	O	O
low	O	O	B-Entity
back	O	O	I-Entity
pain	O	O	I-Entity
significantly	O	O	O
.	O	O	O

This	O	O	O
validates	O	O	O
the	O	O	O
proposed	O	O	O
quantities	O	O	B-Entity
and	O	O	O
measurement	O	O	B-Entity
methods	O	O	B-Entity
,	O	O	O
which	O	O	O
facilitate	O	O	O
workplace	O	O	B-Entity
assessments	O	O	B-Entity
and	O	O	O
assist	O	O	B-Entity
in	O	O	O
the	O	O	O
design	O	O	B-Entity
of	O	O	O
further	O	O	B-Entity
studies	O	O	B-Entity
which	O	O	O
are	O	O	O
necessary	O	O	O
to	O	O	O
establish	O	O	B-Entity
a	O	O	O
causal	O	O	B-Entity
exposure	O	O	I-Entity
-	O	O	O
response	O	O	B-Entity
relationship	O	O	B-Entity
.	O	O	O

-DOCSTART- (28402261)

Association	O	O	B-Entity
of	O	O	O
CKIP-1	O	O	B-Entity
P21A	O	O	I-Entity
polymorphism	O	O	B-Entity
with	O	O	O
risk	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
in	O	O	O
a	O	O	O
Chinese	O	O	O
population	O	O	O

Pathological	O	O	B-Entity
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
is	O	O	O
an	O	O	O
independent	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
.	O	O	O

Casein	O	O	B-Entity
kinase-2	O	O	I-Entity
interacting	O	O	I-Entity
protein-1	O	O	I-Entity
(	O	O	O
CKIP-1	O	O	B-Entity
)	O	O	O
can	O	O	O
inhibit	O	O	O
pathological	O	O	B-Entity
cardiac	O	O	B-Entity
hypertrophy	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
whether	O	O	O
CKIP-1	O	O	B-Entity
nonsynonymous	O	O	B-Entity
polymorphism	O	O	I-Entity
rs2306235	O	O	I-Entity
(	O	O	O
Pro21Ala	O	O	B-Entity
)	O	O	O
contributes	O	O	O
to	O	O	O
risk	O	O	B-Entity
and	O	O	O
prognosis	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
in	O	O	O
a	O	O	O
Chinese	O	O	B-Entity
population	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
923	O	O	O
adult	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
and	O	O	O
1020	O	O	O
age	O	O	B-Entity
-	O	O	O
and	O	O	O
gender	O	O	B-Entity
-matched	O	O	O
healthy	O	O	B-Entity
controls	O	O	I-Entity
were	O	O	O
recruited	O	O	O
.	O	O	O

CKIP-1	O	O	B-Entity
rs2306235	O	O	I-Entity
polymorphism	O	O	B-Entity
was	O	O	O
genotyped	O	O	B-Entity
using	O	O	O
PCR	O	O	B-Entity
-	O	O	O
restriction	O	O	B-Entity
fragment	O	O	I-Entity
length	O	O	I-Entity
polymorphism	O	O	I-Entity
.	O	O	O

Additional	O	O	O
follow-up	O	O	B-Entity
data	O	O	B-Entity
for	O	O	O
140	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
patients	O	O	B-Entity
was	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

The	O	O	O
rs2306235	O	O	B-Entity
G	O	O	B-Entity
allele	O	O	I-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
=	O	O	O
1.38	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
=	O	O	O
1.09	O	O	O
-	O	O	O
1.75	O	O	O
,	O	O	O
p	O	O	B-Entity
=	O	O	O
0.007	O	O	O
)	O	O	O
,	O	O	O
especially	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
hypertension	O	O	B-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
1.45	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.09	O	O	O
-	O	O	O
1.75	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.006	O	O	O
)	O	O	O
and	O	O	O
coronary	O	O	B-Entity
heart	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
OR	O	O	O
=	O	O	O
1.41	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
=	O	O	O
1.09	O	O	O
-	O	O	O
1.83	O	O	O
,	O	O	O
p	O	O	O
=	O	O	O
0.010	O	O	O
)	O	O	O
after	O	O	O
adjustment	O	O	O
for	O	O	O
multiple	O	O	B-Entity
cardiovascular	O	O	I-Entity
risk	O	O	B-Entity
factors	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
rs2306235	O	O	B-Entity
polymorphism	O	O	B-Entity
was	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
cardiovascular	O	O	B-Entity
mortality	O	O	I-Entity
in	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.875	O	O	O
)	O	O	O
.	O	O	O

CKIP-1	O	O	B-Entity
rs2306235	O	O	I-Entity
polymorphism	O	O	B-Entity
may	O	O	O
be	O	O	O
a	O	O	O
risk	O	O	B-Entity
factor	O	O	I-Entity
for	O	O	O
chronic	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
in	O	O	O
a	O	O	O
Chinese	O	O	B-Entity
Han	O	O	I-Entity
population	O	O	I-Entity
.	O	O	O

-DOCSTART- (28403152)

Linking	O	O	O
phenological	O	O	B-Entity
events	O	O	I-Entity
in	O	O	O
migratory	O	O	B-Entity
passerines	O	O	I-Entity
with	O	O	O
a	O	O	O
changing	O	O	B-Entity
climate	O	O	I-Entity
:	O	O	O
50	O	O	O
years	O	O	B-Entity
in	O	O	O
the	O	O	O
Laurel	O	O	O
Highlands	O	O	O
of	O	O	O
Pennsylvania	O	O	O

Advanced	O	O	B-Entity
timing	O	O	I-Entity
of	O	O	O
both	O	O	O
seasonal	O	O	B-Entity
migration	O	O	O
and	O	O	O
reproduction	O	O	B-Entity
in	O	O	O
birds	O	O	B-Entity
has	O	O	O
been	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
warming	O	O	B-Entity
climate	O	O	I-Entity
for	O	O	O
many	O	O	O
bird	O	O	B-Entity
species	O	O	B-Entity
.	O	O	O

Phenological	O	O	B-Entity
responses	O	O	I-Entity
to	O	O	O
climate	O	O	B-Entity
linking	O	O	O
these	O	O	O
stages	O	O	B-Entity
may	O	O	O
ultimately	O	O	O
impact	O	O	B-Entity
fitness	O	O	B-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
five	O	O	O
decades	O	O	B-Entity
of	O	O	O
banding	O	O	B-Entity
data	O	O	I-Entity
from	O	O	O
17	O	O	O
migratory	O	O	B-Entity
bird	O	O	I-Entity
species	O	O	B-Entity
to	O	O	O
investigate	O	O	O
1	O	O	O
)	O	O	O
how	O	O	O
spring	O	O	B-Entity
arrival	O	O	B-Entity
related	O	O	O
to	O	O	O
timing	O	O	B-Entity
of	O	O	O
breeding	O	O	B-Entity
,	O	O	O
2	O	O	O
)	O	O	O
if	O	O	O
the	O	O	O
interval	O	O	B-Entity
between	O	O	O
arrival	O	O	O
and	O	O	O
breeding	O	O	O
has	O	O	O
changed	O	O	O
with	O	O	O
increasing	O	O	B-Entity
spring	O	O	O
temperatures	O	O	B-Entity
,	O	O	O
and	O	O	O
3	O	O	O
)	O	O	O
whether	O	O	O
arrival	O	O	O
timing	O	O	O
or	O	O	O
breeding	O	O	O
timing	O	O	O
best	O	O	O
predicted	O	O	O
local	O	O	B-Entity
productivity	O	O	I-Entity
.	O	O	O

Four	O	O	O
of	O	O	O
17	O	O	O
species	O	O	B-Entity
,	O	O	O
all	O	O	O
mid-	O	O	B-Entity
to	O	O	I-Entity
long-distance	O	O	I-Entity
migrants	O	O	B-Entity
,	O	O	O
hatched	O	O	B-Entity
young	O	O	O
earlier	O	O	B-Entity
in	O	O	O
years	O	O	B-Entity
when	O	O	O
migrants	O	O	O
arrived	O	O	B-Entity
earlier	O	O	O
to	O	O	O
the	O	O	O
breeding	O	O	B-Entity
grounds	O	O	I-Entity
(	O	O	O
~1:1	O	O	O
day	O	O	B-Entity
advancement	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
interval	O	O	B-Entity
between	O	O	O
arrival	O	O	B-Entity
on	O	O	O
breeding	O	O	B-Entity
grounds	O	O	I-Entity
and	O	O	O
appearance	O	O	B-Entity
of	O	O	O
juveniles	O	O	B-Entity
shortened	O	O	B-Entity
with	O	O	O
warmer	O	O	O
spring	O	O	B-Entity
temperatures	O	O	B-Entity
for	O	O	O
12	O	O	O
species	O	O	B-Entity
(	O	O	O
1	O	O	O
-	O	O	O
6	O	O	O
days	O	O	B-Entity
for	O	O	O
every	O	O	O
1	O	O	O
°	O	O	O
C	O	O	O
increase	O	O	B-Entity
)	O	O	O
and	O	O	O
over	O	O	O
time	O	O	B-Entity
for	O	O	O
seven	O	O	O
species	O	O	O
(	O	O	O
1	O	O	O
-	O	O	O
8	O	O	O
days	O	O	O
per	O	O	O
decade	O	O	B-Entity
)	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
some	O	O	O
migratory	O	O	B-Entity
passerines	O	O	I-Entity
adapt	O	O	O
to	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
by	O	O	O
laying	O	O	B-Entity
more	O	O	B-Entity
quickly	O	O	I-Entity
after	O	O	O
arrival	O	O	O
or	O	O	O
reducing	O	O	B-Entity
the	O	O	O
time	O	O	O
from	O	O	O
laying	O	O	O
to	O	O	O
fledging	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
more	O	O	O
support	O	O	O
for	O	O	O
the	O	O	O
former	O	O	B-Entity
,	O	O	O
that	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
reproductive	O	O	B-Entity
advancement	O	O	I-Entity
was	O	O	O
higher	O	O	B-Entity
than	O	O	O
that	O	O	O
for	O	O	O
arrival	O	O	B-Entity
in	O	O	O
warm	O	O	B-Entity
years	O	O	I-Entity
.	O	O	O

Timing	O	O	B-Entity
of	O	O	O
spring	O	O	B-Entity
arrival	O	O	B-Entity
and	O	O	O
breeding	O	O	B-Entity
were	O	O	O
both	O	O	O
poor	O	O	B-Entity
predictors	O	O	B-Entity
of	O	O	O
avian	O	O	B-Entity
productivity	O	O	B-Entity
for	O	O	O
most	O	O	O
migrants	O	O	B-Entity
analyzed	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
evidence	O	O	B-Entity
that	O	O	O
fitness	O	O	B-Entity
benefits	O	O	O
may	O	O	O
occur	O	O	O
from	O	O	O
shifts	O	O	B-Entity
to	O	O	O
earlier	O	O	O
spring	O	O	B-Entity
arrival	O	O	B-Entity
for	O	O	O
the	O	O	O
multi-brooded	O	O	B-Entity
Song	O	O	I-Entity
Sparrow	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
uniquely	O	O	O
demonstrate	O	O	O
that	O	O	O
co-occurring	O	O	O
avian	O	O	B-Entity
species	O	O	B-Entity
are	O	O	O
phenologically	O	O	B-Entity
plastic	O	O	I-Entity
in	O	O	O
their	O	O	O
response	O	O	B-Entity
to	O	O	O
climate	O	O	B-Entity
change	O	O	I-Entity
on	O	O	O
their	O	O	O
breeding	O	O	B-Entity
grounds	O	O	I-Entity
.	O	O	O

If	O	O	O
migrants	O	O	B-Entity
continue	O	O	O
to	O	O	O
show	O	O	O
a	O	O	O
weaker	O	O	B-Entity
response	O	O	B-Entity
to	O	O	O
temperatures	O	O	B-Entity
during	O	O	O
migration	O	O	O
than	O	O	O
breeding	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
window	O	O	B-Entity
between	O	O	O
arrival	O	O	B-Entity
and	O	O	O
optimal	O	O	B-Entity
breeding	O	O	I-Entity
shortens	O	O	B-Entity
further	O	O	O
,	O	O	O
biological	O	O	O
constraints	O	O	O
to	O	O	O
plasticity	O	O	B-Entity
may	O	O	O
limit	O	O	O
the	O	O	O
ability	O	O	B-Entity
of	O	O	O
species	O	O	B-Entity
to	O	O	O
adapt	O	O	O
successfully	O	O	O
to	O	O	O
future	O	O	B-Entity
warming	O	O	I-Entity
.	O	O	O

-DOCSTART- (28404634)

Mucosal	O	O	B-Entity
IgM	O	O	B-Entity
Antibody	O	O	I-Entity
with	O	O	O
d-Mannose	O	O	B-Entity
Affinity	O	O	B-Entity
in	O	O	O
Fugu	O	O	B-Entity
Takifugu	O	O	I-Entity
rubripes	O	O	I-Entity
Is	O	O	O
Utilized	O	O	O
by	O	O	O
a	O	O	O
Monogenean	O	O	B-Entity
Parasite	O	O	B-Entity
Heterobothrium	O	O	B-Entity
okamotoi	O	O	I-Entity
for	O	O	O
Host	O	O	O
Recognition	O	O	O

How	O	O	O
parasites	O	O	B-Entity
recognize	O	O	B-Entity
their	O	O	O
definitive	O	O	B-Entity
hosts	O	O	B-Entity
is	O	O	O
a	O	O	O
mystery	O	O	O
;	O	O	O
however	O	O	O
,	O	O	O
parasitism	O	O	B-Entity
is	O	O	O
reportedly	O	O	O
initiated	O	O	O
by	O	O	O
recognition	O	O	B-Entity
of	O	O	O
certain	O	O	O
molecules	O	O	B-Entity
on	O	O	O
host	O	O	B-Entity
surfaces	O	O	I-Entity
.	O	O	O

Fish	O	O	B-Entity
ectoparasites	O	O	B-Entity
make	O	O	O
initial	O	O	B-Entity
contact	O	O	I-Entity
with	O	O	O
their	O	O	O
hosts	O	O	B-Entity
at	O	O	O
body	O	O	B-Entity
surfaces	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
skin	O	O	B-Entity
and	O	O	O
gills	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
covered	O	O	B-Entity
with	O	O	O
mucosa	O	O	B-Entity
that	O	O	O
are	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
mammalian	O	O	B-Entity
guts	O	O	I-Entity
.	O	O	O

Fish	O	O	B-Entity
are	O	O	O
among	O	O	O
the	O	O	O
most	O	O	O
primitive	O	O	B-Entity
vertebrates	O	O	I-Entity
with	O	O	O
immune	O	O	B-Entity
systems	O	O	I-Entity
that	O	O	O
are	O	O	O
equivalent	O	O	O
to	O	O	O
those	O	O	O
in	O	O	O
mammals	O	O	B-Entity
,	O	O	O
and	O	O	O
they	O	O	O
produce	O	O	O
and	O	O	O
secrete	O	O	B-Entity
IgM	O	O	B-Entity
into	O	O	O
mucus	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
monogenean	O	O	B-Entity
parasite	O	O	B-Entity
Heterobothrium	O	O	B-Entity
okamotoi	O	O	I-Entity
utilizes	O	O	O
IgM	O	O	B-Entity
to	O	O	O
recognize	O	O	B-Entity
its	O	O	O
host	O	O	B-Entity
,	O	O	O
fugu	O	O	B-Entity
Takifugu	O	O	I-Entity
rubripes	O	O	I-Entity
Oncomiracidia	O	O	I-Entity
are	O	O	O
infective	O	O	B-Entity
larvae	O	O	I-Entity
of	O	O	O
H.	O	O	B-Entity
okamotoi	O	O	I-Entity
that	O	O	O
shed	O	O	O
their	O	O	O
cilia	O	O	B-Entity
and	O	O	O
metamorphose	O	O	B-Entity
into	O	O	O
juveniles	O	O	B-Entity
when	O	O	O
exposed	O	O	O
to	O	O	O
purified	O	O	B-Entity
d-mannose	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
fractions	O	O	B-Entity
from	O	O	O
fugu	O	O	O
mucus	O	O	B-Entity
.	O	O	O

Using	O	O	O
liquid	O	O	B-Entity
chromatography-tandem	O	O	I-Entity
mass	O	O	I-Entity
spectrometry	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
proteins	O	O	B-Entity
contained	O	O	O
in	O	O	O
the	O	O	O
fraction	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
as	O	O	O
d-mannose	O	O	B-Entity
-specific	O	O	O
IgM	O	O	B-Entity
with	O	O	O
two	O	O	O
d-mannose	O	O	B-Entity
-binding	O	O	I-Entity
lectins	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
although	O	O	O
deciliation	O	O	B-Entity
was	O	O	O
significantly	O	O	O
induced	O	O	B-Entity
by	O	O	O
IgM	O	O	B-Entity
and	O	O	O
was	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
d-mannose	O	O	B-Entity
or	O	O	O
a	O	O	O
specific	O	O	O
Ab	O	O	B-Entity
against	O	O	O
fugu	O	O	B-Entity
IgM	O	O	O
,	O	O	O
other	O	O	O
lectins	O	O	B-Entity
had	O	O	O
no	O	O	B-Entity
effect	O	O	I-Entity
,	O	O	O
and	O	O	O
IgM	O	O	O
without	O	O	O
d-mannose	O	O	O
affinity	O	O	B-Entity
induced	O	O	O
deciliation	O	O	O
to	O	O	O
a	O	O	O
limited	O	O	O
degree	O	O	O
.	O	O	O

Subsequent	O	O	O
immunofluorescent	O	O	B-Entity
staining	O	O	I-Entity
experiments	O	O	I-Entity
showed	O	O	O
that	O	O	O
fugu	O	O	B-Entity
d-mannose	O	O	B-Entity
-specific	O	O	O
IgM	O	O	B-Entity
binds	O	O	B-Entity
ciliated	O	O	B-Entity
epidermal	O	O	I-Entity
cells	O	O	I-Entity
of	O	O	O
oncomiracidium	O	O	B-Entity
.	O	O	O

These	O	O	O
observations	O	O	B-Entity
suggest	O	O	O
that	O	O	O
deciliation	O	O	B-Entity
is	O	O	O
triggered	O	O	B-Entity
by	O	O	I-Entity
binding	O	O	B-Entity
of	O	O	O
fugu	O	O	B-Entity
IgM	O	O	B-Entity
to	O	O	O
cell	O	O	B-Entity
surface	O	O	I-Entity
Ags	O	O	I-Entity
via	O	O	O
Ag	O	O	B-Entity
binding	O	O	I-Entity
sites	O	O	I-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
concentrations	O	O	B-Entity
of	O	O	O
d-mannose	O	O	B-Entity
-	O	O	O
binding	O	O	B-Entity
IgM	O	O	B-Entity
in	O	O	O
gill	O	O	B-Entity
mucus	O	O	I-Entity
were	O	O	O
sufficient	O	O	O
to	O	O	O
induce	O	O	B-Entity
deciliation	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
,	O	O	O
indicating	O	O	B-Entity
that	O	O	O
H.	O	O	B-Entity
okamotoi	O	O	I-Entity
parasites	O	O	I-Entity
initially	O	O	O
use	O	O	B-Entity
host	O	O	B-Entity
Abs	O	O	B-Entity
to	O	O	O
colonize	O	O	B-Entity
host	O	O	O
gills	O	O	B-Entity
.	O	O	O

-DOCSTART- (28404899)

BALB/c	O	O	B-Entity
mice	O	O	I-Entity
immunized	O	O	B-Entity
with	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
virus-like	O	O	B-Entity
particles	O	O	I-Entity
incorporating	O	O	O
Kaposi	O	O	B-Entity
sarcoma-associated	O	O	I-Entity
herpesvirus	O	O	I-Entity
(	O	O	O
KSHV	O	O	B-Entity
)	O	O	O
envelope	O	O	O
glycoproteins	O	O	B-Entity
gpK8.1	O	O	I-Entity
,	O	O	O
gB	O	O	B-Entity
,	O	O	O
and	O	O	O
gH	O	O	B-Entity
/	O	O	O
gL	O	O	B-Entity
induced	O	O	O
comparable	O	O	O
serum	O	O	B-Entity
neutralizing	O	O	B-Entity
antibody	O	O	I-Entity
activity	O	O	B-Entity
to	O	O	O
UV	O	O	B-Entity
-	O	O	O
inactivated	O	O	B-Entity
KSHV	O	O	O

Infection	O	O	O
with	O	O	O
Kaposi	O	O	B-Entity
sarcoma-associated	O	O	I-Entity
herpesvirus	O	O	I-Entity
(	O	O	O
KSHV	O	O	B-Entity
)	O	O	O
is	O	O	O
estimated	O	O	O
to	O	O	O
account	O	O	O
for	O	O	O
over	O	O	O
44,000	O	O	O
new	O	O	O
cases	O	O	O
of	O	O	O
Kaposi	O	O	B-Entity
sarcoma	O	O	I-Entity
annually	O	O	O
,	O	O	O
with	O	O	O
84	O	O	O
%	O	O	O
occurring	O	O	O
in	O	O	O
Africa	O	O	B-Entity
,	O	O	O
where	O	O	O
the	O	O	O
virus	O	O	B-Entity
is	O	O	O
endemic	O	O	O
.	O	O	O

To	O	O	O
date	O	O	O
,	O	O	O
there	O	O	O
is	O	O	O
no	O	O	O
prophylactic	O	O	B-Entity
vaccine	O	O	I-Entity
against	O	O	O
KSHV	O	O	B-Entity
.	O	O	O

KSHV	O	O	B-Entity
gpK8.1	O	O	B-Entity
,	O	O	O
gB	O	O	B-Entity
,	O	O	O
and	O	O	O
gH	O	O	B-Entity
/	O	O	O
gL	O	O	B-Entity
glycoproteins	O	O	I-Entity
,	O	O	O
implicated	O	O	O
in	O	O	O
the	O	O	O
virus	O	O	B-Entity
entry	O	O	O
into	O	O	O
host	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
are	O	O	O
attractive	O	O	O
vaccine	O	O	B-Entity
targets	O	O	B-Entity
for	O	O	O
eliciting	O	O	O
potent	O	O	O
neutralizing	O	O	B-Entity
antibodies	O	O	I-Entity
(	O	O	O
nAbs	O	O	B-Entity
)	O	O	O
against	O	O	O
virus	O	O	B-Entity
infection	O	O	I-Entity
.	O	O	O

We	O	O	O
incorporated	O	O	O
gpK8.1	O	O	B-Entity
,	O	O	O
gB	O	O	B-Entity
,	O	O	O
or	O	O	O
gH	O	O	B-Entity
/	O	O	O
gL	O	O	B-Entity
on	O	O	O
the	O	O	O
surface	O	O	O
of	O	O	O
virus-like	O	O	B-Entity
particles	O	O	I-Entity
(	O	O	O
VLPs	O	O	B-Entity
)	O	O	O
and	O	O	O
characterized	O	O	O
these	O	O	O
VLPs	O	O	O
for	O	O	O
their	O	O	O
composition	O	O	O
,	O	O	O
size	O	O	O
,	O	O	O
and	O	O	O
functionality	O	O	O
.	O	O	O

To	O	O	O
determine	O	O	O
which	O	O	O
viral	O	O	B-Entity
glycoprotein(s	O	O	I-Entity
)	O	O	I-Entity
elicit	O	O	O
the	O	O	O
most	O	O	O
effective	O	O	O
serum	O	O	B-Entity
-	O	O	O
nAbs	O	O	B-Entity
,	O	O	O
we	O	O	O
immunized	O	O	B-Entity
BALB/c	O	O	B-Entity
mice	O	O	I-Entity
with	O	O	O
gpK8.1	O	O	B-Entity
,	O	O	O
gB	O	O	B-Entity
,	O	O	O
or	O	O	O
gH	O	O	B-Entity
/	O	O	O
gL	O	O	B-Entity
VLPs	O	O	B-Entity
individually	O	O	O
or	O	O	O
in	O	O	O
combination	O	O	O
.	O	O	O

Neutralizing	O	O	B-Entity
antibody	O	O	I-Entity
assay	O	O	O
revealed	O	O	O
that	O	O	O
sera	O	O	O
from	O	O	O
mice	O	O	B-Entity
immunized	O	O	B-Entity
with	O	O	O
the	O	O	O
VLPs	O	O	B-Entity
inhibited	O	O	O
KSHV	O	O	B-Entity
infection	O	O	B-Entity
of	O	O	O
HEK-293	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
a	O	O	O
dose-dependent	O	O	B-Entity
manner	O	O	O
.	O	O	O

As	O	O	O
a	O	O	O
single	O	O	O
immunogen	O	O	B-Entity
,	O	O	O
gpK8.1	O	O	B-Entity
VLPs	O	O	B-Entity
stimulated	O	O	O
comparable	O	O	O
nAb	O	O	B-Entity
activity	O	O	O
to	O	O	O
that	O	O	O
of	O	O	O
UV	O	O	B-Entity
-	O	O	O
inactivated	O	O	B-Entity
KSHV	O	O	B-Entity
(	O	O	O
UV-KSHV	O	O	B-Entity
)	O	O	O
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
UV-KSHV	O	O	B-Entity
stimulated	O	O	O
higher	O	O	O
titers	O	O	O
of	O	O	O
nAb	O	O	O
compared	O	O	O
to	O	O	O
gB	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0316	O	O	O
)	O	O	O
or	O	O	O
gH	O	O	B-Entity
/	O	O	O
gL	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.0486	O	O	O
)	O	O	O
.	O	O	O

Mice	O	O	B-Entity
immunized	O	O	B-Entity
with	O	O	O
the	O	O	O
combination	O	O	O
of	O	O	O
gB	O	O	B-Entity
and	O	O	O
gH	O	O	B-Entity
/	O	O	O
gL	O	O	B-Entity
VLPs	O	O	B-Entity
had	O	O	O
a	O	O	O
better	O	O	O
nAb	O	O	O
response	O	O	O
than	O	O	O
those	O	O	O
immunized	O	O	O
with	O	O	O
either	O	O	O
gB	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.0268	O	O	O
)	O	O	O
,	O	O	O
or	O	O	O
gH	O	O	O
/gL	O	O	O
(	O	O	O
p	O	O	O
=	O	O	O
0.0397	O	O	O
)	O	O	O
as	O	O	O
single	O	O	O
VLP	O	O	B-Entity
immunogens	O	O	B-Entity
.	O	O	O

Immunization	O	O	B-Entity
with	O	O	O
any	O	O	O
VLP	O	O	B-Entity
combination	O	O	O
stimulated	O	O	O
comparable	O	O	O
nAb	O	O	B-Entity
activity	O	O	O
to	O	O	O
UV-KSHV	O	O	B-Entity
serum	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	O
provide	O	O	O
the	O	O	O
first	O	O	O
evidence	O	O	O
that	O	O	O
KSHV	O	O	B-Entity
gpK8.1	O	O	B-Entity
,	O	O	O
gB	O	O	B-Entity
,	O	O	O
and	O	O	O
gH	O	O	B-Entity
/	O	O	O
gL	O	O	B-Entity
glycoproteins	O	O	I-Entity
can	O	O	O
be	O	O	O
incorporated	O	O	O
onto	O	O	O
the	O	O	O
surface	O	O	O
of	O	O	O
VLPs	O	O	B-Entity
and	O	O	O
used	O	O	O
as	O	O	O
prophylactic	O	O	B-Entity
vaccine	O	O	I-Entity
candidates	O	O	O
,	O	O	O
with	O	O	O
potential	O	O	O
to	O	O	O
prevent	O	O	O
KSHV	O	O	O
infection	O	O	B-Entity
.	O	O	O

-DOCSTART- (28405013)

A	O	O	O
missense	O	O	B-Entity
variant	O	O	B-Entity
,	O	O	O
rs373863828-A	O	O	B-Entity
(	O	O	I-Entity
p.	O	O	I-Entity
Arg457Gln	O	O	I-Entity
)	O	O	I-Entity
,	O	O	I-Entity
of	O	O	I-Entity
CREBRF	O	O	I-Entity
and	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
in	O	O	O
Oceanic	O	O	O
populations	O	O	O

It	O	O	O
has	O	O	O
been	O	O	O
suggested	O	O	O
that	O	O	O
a	O	O	O
'	O	O	O
thrifty	O	O	O
'	O	O	O
genotype	O	O	B-Entity
hypothesis	O	O	B-Entity
can	O	O	O
account	O	O	O
for	O	O	O
high	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
obesity	O	O	B-Entity
in	O	O	O
the	O	O	O
island	O	O	B-Entity
populations	O	O	B-Entity
of	O	O	O
Oceania	O	O	B-Entity
.	O	O	O

A	O	O	O
recent	O	O	O
genome-wide	O	O	B-Entity
association	O	O	I-Entity
study	O	O	I-Entity
revealed	O	O	O
that	O	O	O
a	O	O	O
missense	O	O	B-Entity
variant	O	O	B-Entity
,	O	O	O
rs373863828-A	O	O	B-Entity
(	O	O	I-Entity
p.	O	O	I-Entity
Arg457Gln	O	O	I-Entity
)	O	O	I-Entity
,	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
CREBRF	O	O	I-Entity
gene	O	O	I-Entity
(	O	O	O
encoding	O	O	O
CREB3	O	O	B-Entity
regulatory	O	O	I-Entity
factor	O	O	I-Entity
)	O	O	O
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
an	O	O	O
excessive	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
body	O	O	B-Entity
mass	O	O	I-Entity
index	O	O	I-Entity
(	O	O	O
BMI	O	O	B-Entity
)	O	O	O
in	O	O	O
Samoans	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
the	O	O	O
association	O	O	O
of	O	O	O
rs373863828-A	O	O	B-Entity
with	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
BMI	O	O	B-Entity
was	O	O	O
examined	O	O	B-Entity
in	O	O	O
four	O	O	O
Austronesian	O	O	B-Entity
(AN)-	O	O	O
speaking	O	O	B-Entity
populations	O	O	B-Entity
in	O	O	O
Oceania	O	O	B-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
rs373863828-A	O	O	B-Entity
was	O	O	O
frequently	O	O	O
observed	O	O	O
(	O	O	O
frequency	O	O	O
of	O	O	O
0.15	O	O	O
)	O	O	O
in	O	O	O
Tongans	O	O	B-Entity
(	O	O	O
Polynesians	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
was	O	O	O
strongly	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
higher	O	O	O
BMI	O	O	B-Entity
(	O	O	O
P=6.1	O	O	O
×	O	O	O
10(-4	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

A	O	O	O
single	O	O	O
copy	O	O	O
of	O	O	O
the	O	O	O
rs373863828-A	O	O	B-Entity
allele	O	O	B-Entity
increased	O	O	B-Entity
BMI	O	O	B-Entity
by	O	O	O
3.09	O	O	O
kg	O	O	O
m(-2	O	O	O
)	O	O	O
after	O	O	O
adjustment	O	O	O
of	O	O	O
age	O	O	B-Entity
and	O	O	O
sex	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
association	O	O	B-Entity
was	O	O	O
detected	O	O	B-Entity
in	O	O	O
the	O	O	O
other	O	O	O
three	O	O	O
AN	O	O	B-Entity
-	O	O	O
speaking	O	O	B-Entity
populations	O	O	B-Entity
(	O	O	O
Melanesians	O	O	B-Entity
and	O	O	O
Micronesians	O	O	B-Entity
)	O	O	O
living	O	O	B-Entity
in	O	O	O
Solomon	O	O	B-Entity
Islands	O	O	I-Entity
.	O	O	O

This	O	O	O
was	O	O	O
probably	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
low	O	O	B-Entity
allele	O	O	B-Entity
frequency	O	O	I-Entity
(	O	O	O
0.02	O	O	O
-	O	O	O
0.06	O	O	O
)	O	O	O
of	O	O	O
rs373863828-A	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
small	O	O	O
sample	O	O	B-Entity
size	O	O	I-Entity
.	O	O	O

The	O	O	O
rs373863828-A	O	O	B-Entity
allele	O	O	B-Entity
was	O	O	O
not	O	O	O
found	O	O	O
in	O	O	O
both	O	O	O
AN	O	O	B-Entity
-	O	O	O
speaking	O	O	B-Entity
and	O	O	O
non-	O	O	O
AN	O	O	O
-	O	O	O
speaking	O	O	O
Melanesians	O	O	B-Entity
living	O	O	O
in	O	O	O
Papua	O	O	B-Entity
New	O	O	I-Entity
Guinea	O	O	I-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
rs373863828-A	O	O	B-Entity
of	O	O	I-Entity
CREBRF	O	O	I-Entity
,	O	O	O
a	O	O	O
promising	O	O	O
thrifty	O	O	O
variant	O	O	B-Entity
,	O	O	O
arose	O	O	O
in	O	O	O
recent	O	O	O
ancestors	O	O	B-Entity
of	O	O	O
AN	O	O	B-Entity
-	O	O	O
speaking	O	O	B-Entity
Polynesians	O	O	B-Entity
.Journal	O	O	O
of	O	O	O
Human	O	O	O
Genetics	O	O	O
advance	O	O	O
online	O	O	O
publication	O	O	O
,	O	O	O
13	O	O	O
April	O	O	O
2017	O	O	O
;	O	O	O
doi:10.1038/jhg.2017.44	O	O	O
.	O	O	O

-DOCSTART- (28405450)

Vaccination	O	O	B-Entity
of	O	O	O
piglets	O	O	B-Entity
at	O	O	O
2	O	O	O
and	O	O	O
3	O	O	O
weeks	O	O	O
of	O	O	O
age	O	O	O
with	O	O	O
Ingelvac	O	O	B-Entity
PRRSFLEX	O	O	I-Entity
®	O	O	I-Entity
EU	O	O	I-Entity
provides	O	O	O
protection	O	O	B-Entity
against	O	O	O
heterologous	O	O	B-Entity
field	O	O	O
challenge	O	O	O
in	O	O	O
the	O	O	O
face	O	O	O
of	O	O	O
homologous	O	O	B-Entity
maternally	O	O	O
derived	O	O	O
antibodies	O	O	O

Due	O	O	O
to	O	O	O
difficulties	O	O	O
in	O	O	O
eradicating	O	O	B-Entity
porcine	O	O	B-Entity
reproductive	O	O	I-Entity
and	O	O	I-Entity
respiratory	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
PRRS	O	O	B-Entity
)	O	O	O
linked	O	O	O
to	O	O	O
biosecurity	O	O	O
challenges	O	O	O
,	O	O	O
transmission	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
virus	O	O	I-Entity
and	O	O	O
the	O	O	O
lack	O	O	O
of	O	O	O
efficient	O	O	B-Entity
DIVA	O	O	B-Entity
vaccines	O	O	I-Entity
,	O	O	O
successful	O	O	B-Entity
control	O	O	B-Entity
of	O	O	O
PRRS	O	O	O
requires	O	O	O
a	O	O	O
combination	O	O	O
of	O	O	O
strict	O	O	O
management	O	O	B-Entity
measures	O	O	I-Entity
and	O	O	O
vaccination	O	O	B-Entity
of	O	O	O
both	O	O	O
sows	O	O	B-Entity
and	O	O	O
piglets	O	O	B-Entity
.	O	O	O

The	O	O	O
present	O	O	O
study	O	O	B-Entity
aimed	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
a	O	O	O
recently	O	O	O
developed	O	O	O
MLV	O	O	B-Entity
vaccine	O	O	I-Entity
(	O	O	O
Ingelvac	O	O	B-Entity
PRRSFLEX	O	O	I-Entity
®	O	O	I-Entity
EU	O	O	I-Entity
)	O	O	O
in	O	O	O
piglets	O	O	B-Entity
at	O	O	O
2	O	O	O
and	O	O	O
3-weeks	O	O	O
of	O	O	O
age	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
homologous	O	O	B-Entity
maternally	O	O	B-Entity
derived	O	O	I-Entity
antibodies	O	O	I-Entity
as	O	O	O
the	O	O	O
dams	O	O	O
were	O	O	O
vaccinated	O	O	B-Entity
with	O	O	O
the	O	O	O
same	O	O	O
vaccine	O	O	B-Entity
strain	O	O	I-Entity
(	O	O	O
ReproCyc	O	O	B-Entity
®	O	O	I-Entity
PRRS	O	O	I-Entity
EU	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
was	O	O	O
carried	O	O	O
out	O	O	O
on	O	O	O
a	O	O	O
Hungarian	O	O	B-Entity
farrow	O	O	I-Entity
to	O	O	O
finish	O	O	O
farm	O	O	B-Entity
naturally	O	O	B-Entity
infected	O	O	I-Entity
with	O	O	O
PRRSv	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
was	O	O	O
designed	O	O	O
as	O	O	O
a	O	O	O
blind	O	O	B-Entity
,	O	O	O
placebo	O	O	B-Entity
controlled	O	O	I-Entity
side	O	O	O
by	O	O	O
side	O	O	O
trial	O	O	O
.	O	O	O

ORF5	O	O	B-Entity
sequence	O	O	B-Entity
similarity	O	O	I-Entity
of	O	O	O
the	O	O	O
vaccine	O	O	B-Entity
strain	O	O	I-Entity
and	O	O	O
the	O	O	O
resident	O	O	B-Entity
field	O	O	I-Entity
strain	O	O	I-Entity
was	O	O	O
87.8	O	O	O
%	O	O	O
.	O	O	O

PRRS	O	O	B-Entity
specific	O	O	O
real-time	O	O	B-Entity
quantitative	O	O	I-Entity
PCR	O	O	I-Entity
was	O	O	O
performed	O	O	O
from	O	O	O
serum	O	O	B-Entity
samples	O	O	I-Entity
to	O	O	O
measure	O	O	B-Entity
both	O	O	O
the	O	O	O
viral	O	O	B-Entity
load	O	O	I-Entity
and	O	O	O
the	O	O	O
frequency	O	O	O
of	O	O	O
virus	O	O	B-Entity
positive	O	O	I-Entity
animals	O	O	B-Entity
.	O	O	O

At	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
the	O	O	O
natural	O	O	B-Entity
infection	O	O	I-Entity
observed	O	O	B-Entity
in	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
at	O	O	O
10	O	O	O
-	O	O	O
12	O	O	O
weeks	O	O	O
of	O	O	O
age	O	O	O
,	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
viraemic	O	O	B-Entity
animals	O	O	B-Entity
did	O	O	O
not	O	O	O
increase	O	O	O
significantly	O	O	O
in	O	O	O
the	O	O	O
vaccinated	O	O	B-Entity
group	O	O	O
.	O	O	O

To	O	O	O
understand	O	O	O
the	O	O	O
infection	O	O	B-Entity
dynamics	O	O	B-Entity
,	O	O	O
positive	O	O	B-Entity
PCR	O	O	B-Entity
samples	O	O	B-Entity
with	O	O	O
low	O	O	O
Ct	O	O	O
values	O	O	O
were	O	O	O
sequenced	O	O	O
(	O	O	O
ORF5	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
data	O	O	B-Entity
analysis	O	O	I-Entity
indicated	O	O	B-Entity
the	O	O	O
circulation	O	O	B-Entity
of	O	O	O
wild	O	O	O
type	O	O	O
virus	O	O	B-Entity
in	O	O	O
both	O	O	O
groups	O	O	O
,	O	O	O
however	O	O	O
wild	O	O	O
type	O	O	O
virus	O	O	O
was	O	O	O
only	O	O	O
found	O	O	O
in	O	O	O
non-vaccinated	O	O	O
animals	O	O	O
.	O	O	O

Our	O	O	O
data	O	O	B-Entity
indicate	O	O	O
that	O	O	O
piglets	O	O	B-Entity
vaccinated	O	O	B-Entity
at	O	O	O
as	O	O	O
early	O	O	O
as	O	O	O
2	O	O	O
weeks	O	O	O
of	O	O	O
age	O	O	O
with	O	O	O
Ingelvac	O	O	B-Entity
PRRSFLEX	O	O	I-Entity
®	O	O	I-Entity
EU	O	O	I-Entity
were	O	O	O
protected	O	O	O
both	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
proportion	O	O	B-Entity
of	O	O	O
viraemic	O	O	B-Entity
animals	O	O	B-Entity
and	O	O	O
viraemia	O	O	B-Entity
levels	O	O	O
.	O	O	O

It	O	O	O
has	O	O	O
to	O	O	O
be	O	O	O
highlighted	O	O	O
that	O	O	O
these	O	O	O
results	O	O	O
were	O	O	O
achieved	O	O	O
in	O	O	O
piglets	O	O	B-Entity
with	O	O	O
high	O	O	O
levels	O	O	O
of	O	O	O
homologous	O	O	B-Entity
maternally	O	O	B-Entity
derived	O	O	I-Entity
antibodies	O	O	I-Entity
(	O	O	O
MDA	O	O	B-Entity
)	O	O	O
at	O	O	O
the	O	O	O
time	O	O	O
of	O	O	O
vaccination	O	O	B-Entity
.	O	O	O

-DOCSTART- (28406413)

Lung	O	O	B-Entity
nodule	O	O	I-Entity
in	O	O	O
French	O	O	B-Entity
Guiana	O	O	I-Entity
in	O	O	O
a	O	O	O
immunocompetent	O	O	B-Entity
patient	O	O	O

We	O	O	O
report	O	O	O
the	O	O	O
case	O	O	B-Entity
of	O	O	O
an	O	O	O
immunocompetent	O	O	B-Entity
French	O	O	B-Entity
soldier	O	O	B-Entity
stationed	O	O	O
in	O	O	O
French	O	O	B-Entity
Guiana	O	O	I-Entity
,	O	O	O
who	O	O	O
developed	O	O	O
symptomatic	O	O	B-Entity
pulmonary	O	O	B-Entity
histoplasmosis	O	O	I-Entity
.	O	O	O

-DOCSTART- (28407625)

Comparison	O	O	B-Entity
of	O	O	O
Occlusive	O	O	B-Entity
and	O	O	O
Open	O	O	B-Entity
Application	O	O	B-Entity
in	O	O	O
a	O	O	O
Psoriasis	O	O	B-Entity
Plaque	O	O	I-Entity
Test	O	O	I-Entity
Design	O	O	I-Entity
,	O	O	O
Exemplarily	O	O	O
Using	O	O	O
Investigations	O	O	B-Entity
of	O	O	O
Mapracorat	O	O	B-Entity
0.1	O	O	O
%	O	O	O
Ointment	O	O	B-Entity
versus	O	O	O
Vehicle	O	O	B-Entity
and	O	O	O
Reference	O	O	B-Entity
Drugs	O	O	O

Psoriasis	O	O	B-Entity
plaque	O	O	I-Entity
tests	O	O	I-Entity
(	O	O	O
PPTs	O	O	B-Entity
)	O	O	O
are	O	O	O
important	O	O	O
tools	O	O	O
in	O	O	O
the	O	O	O
early	O	O	O
phases	O	O	O
of	O	O	O
antipsoriatic	O	O	B-Entity
drug	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

Two	O	O	O
distinct	O	O	O
PPT	O	O	B-Entity
design	O	O	I-Entity
variants	O	O	O
(	O	O	O
open	O	O	B-Entity
vs.	O	O	O
occluded	O	O	B-Entity
drug	O	O	I-Entity
application	O	O	I-Entity
)	O	O	O
are	O	O	O
commonly	O	O	O
used	O	O	O
,	O	O	O
but	O	O	O
no	O	O	O
previous	O	O	O
work	O	O	O
has	O	O	O
aimed	O	O	O
to	O	O	O
directly	O	O	O
compare	O	O	O
and	O	O	O
contrast	O	O	O
their	O	O	O
performance	O	O	O
.	O	O	O

We	O	O	O
compared	O	O	O
the	O	O	O
antipsoriatic	O	O	B-Entity
efficacy	O	O	O
of	O	O	O
mapracorat	O	O	B-Entity
0.1	O	O	O
%	O	O	O
ointment	O	O	B-Entity
and	O	O	O
reference	O	O	B-Entity
drugs	O	O	B-Entity
reported	O	O	O
in	O	O	O
2	O	O	O
separate	O	O	O
studies	O	O	B-Entity
,	O	O	O
representing	O	O	O
open	O	O	B-Entity
and	O	O	O
occluded	O	O	B-Entity
PPT	O	O	I-Entity
designs	O	O	I-Entity
.	O	O	O

The	O	O	O
drug	O	O	B-Entity
effect	O	O	I-Entity
size	O	O	O
was	O	O	O
measured	O	O	O
by	O	O	O
sonography	O	O	B-Entity
(	O	O	O
mean	O	O	O
change	O	O	O
in	O	O	O
echo-poor	O	O	O
band	O	O	O
thickness	O	O	B-Entity
)	O	O	O
,	O	O	O
chromametry	O	O	B-Entity
,	O	O	O
and	O	O	O
standardized	O	O	O
clinical	O	O	B-Entity
assessment	O	O	I-Entity
.	O	O	O

Antipsoriatic	O	O	B-Entity
effects	O	O	B-Entity
were	O	O	O
detectable	O	O	O
for	O	O	O
the	O	O	O
study	O	O	B-Entity
drugs	O	O	B-Entity
in	O	O	O
both	O	O	O
occluded	O	O	B-Entity
and	O	O	O
open	O	O	B-Entity
PPTs	O	O	I-Entity
.	O	O	O

Differences	O	O	O
between	O	O	O
the	O	O	O
potency	O	O	B-Entity
of	O	O	O
antipsoriatic	O	O	B-Entity
drugs	O	O	I-Entity
and	O	O	O
vehicle	O	O	B-Entity
were	O	O	O
observable	O	O	O
.	O	O	O

The	O	O	O
total	O	O	O
antipsoriatic	O	O	B-Entity
effect	O	O	B-Entity
size	O	O	O
appeared	O	O	O
to	O	O	O
be	O	O	O
higher	O	O	O
in	O	O	O
the	O	O	O
occluded	O	O	B-Entity
PPT	O	O	I-Entity
than	O	O	O
the	O	O	O
open	O	O	B-Entity
PPT	O	O	I-Entity
,	O	O	O
despite	O	O	O
the	O	O	O
shorter	O	O	O
treatment	O	O	B-Entity
duration	O	O	I-Entity
(	O	O	O
2	O	O	O
vs.	O	O	O
4	O	O	O
weeks	O	O	B-Entity
)	O	O	O
.	O	O	O

Effect	O	O	B-Entity
dynamics	O	O	B-Entity
over	O	O	O
time	O	O	B-Entity
revealed	O	O	O
greater	O	O	O
differences	O	O	O
between	O	O	O
some	O	O	O
study	O	O	B-Entity
drugs	O	O	B-Entity
in	O	O	O
the	O	O	O
open	O	O	B-Entity
PPT	O	O	I-Entity
compared	O	O	O
to	O	O	O
the	O	O	O
occluded	O	O	B-Entity
PPT	O	O	I-Entity
.	O	O	O

Taking	O	O	O
the	O	O	O
higher	O	O	O
technical	O	O	B-Entity
challenges	O	O	I-Entity
for	O	O	O
the	O	O	O
open	O	O	B-Entity
PPT	O	O	I-Entity
into	O	O	O
account	O	O	O
,	O	O	O
we	O	O	O
recommend	O	O	O
the	O	O	O
occluded	O	O	B-Entity
PPT	O	O	I-Entity
as	O	O	O
a	O	O	O
standard	O	O	O
screening	O	O	B-Entity
setting	O	O	O
in	O	O	O
early	O	O	B-Entity
drug	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

In	O	O	O
special	O	O	O
cases	O	O	O
,	O	O	O
considering	O	O	O
certain	O	O	O
drug	O	O	B-Entity
aspects	O	O	B-Entity
or	O	O	O
study	O	O	B-Entity
objectives	O	O	O
that	O	O	O
would	O	O	O
require	O	O	O
procedural	O	O	O
adaptations	O	O	O
,	O	O	O
an	O	O	O
open	O	O	B-Entity
PPT	O	O	I-Entity
could	O	O	O
be	O	O	O
the	O	O	O
better-suited	O	O	O
design	O	O	O
.	O	O	O

Finally	O	O	O
,	O	O	O
both	O	O	O
PPT	O	O	B-Entity
models	O	O	O
show	O	O	O
clear	O	O	O
advantages	O	O	O
:	O	O	O
classification	O	O	B-Entity
as	O	O	O
phase	O	O	B-Entity
I	O	O	I-Entity
studies	O	O	I-Entity
,	O	O	O
small	O	O	O
number	O	O	O
of	O	O	O
psoriatic	O	O	O
subjects	O	O	O
,	O	O	O
relatively	O	O	O
short	O	O	O
study	O	O	B-Entity
duration	O	O	B-Entity
,	O	O	O
excellent	O	O	O
discrimination	O	O	O
between	O	O	O
compounds	O	O	B-Entity
and	O	O	O
concentrations	O	O	B-Entity
,	O	O	O
parallel	O	O	O
measurement	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
response	O	O	I-Entity
,	O	O	O
and	O	O	O
go/no	O	O	O
go	O	O	O
decisions	O	O	O
very	O	O	O
early	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

-DOCSTART- (28407650)

Insurance	O	O	B-Entity
Coverage	O	O	I-Entity
and	O	O	O
Utilization	O	O	B-Entity
at	O	O	O
a	O	O	O
Sexually	O	O	B-Entity
Transmitted	O	O	I-Entity
Disease	O	O	I-Entity
Clinic	O	O	I-Entity
in	O	O	O
a	O	O	O
Medicaid	O	O	B-Entity
Expansion	O	O	O
State	O	O	O

In	O	O	O
Rhode	O	O	B-Entity
Island	O	O	I-Entity
,	O	O	O
the	O	O	O
Patient	O	O	B-Entity
Protection	O	O	I-Entity
and	O	O	I-Entity
Affordable	O	O	I-Entity
Care	O	O	I-Entity
Act	O	O	I-Entity
has	O	O	O
led	O	O	O
to	O	O	O
over	O	O	O
95	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
state	O	O	B-Entity
's	O	O	I-Entity
population	O	O	B-Entity
being	O	O	O
insured	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
insurance	O	O	B-Entity
coverage	O	O	I-Entity
and	O	O	O
barriers	O	O	B-Entity
to	O	O	O
insurance	O	O	O
use	O	O	O
among	O	O	O
patients	O	O	B-Entity
presenting	O	O	O
for	O	O	O
services	O	O	B-Entity
at	O	O	O
the	O	O	O
Rhode	O	O	B-Entity
Island	O	O	I-Entity
sexually	O	O	B-Entity
transmitted	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	I-Entity
STD	O	O	I-Entity
)	O	O	I-Entity
clinic	O	O	I-Entity
.	O	O	O

We	O	O	O
analyzed	O	O	B-Entity
factors	O	O	B-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
insurance	O	O	B-Entity
coverage	O	O	I-Entity
and	O	O	O
utilization	O	O	B-Entity
among	O	O	O
patients	O	O	B-Entity
presenting	O	O	O
for	O	O	O
STD	O	O	B-Entity
services	O	O	B-Entity
between	O	O	O
July	O	O	B-Entity
and	O	O	O
December	O	O	B-Entity
2015	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
692	O	O	O
patients	O	O	B-Entity
had	O	O	O
insurance	O	O	B-Entity
information	O	O	I-Entity
available	O	O	B-Entity
;	O	O	O
of	O	O	O
those	O	O	O
,	O	O	O
40	O	O	O
%	O	O	O
were	O	O	O
uninsured	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
without	O	O	B-Entity
insurance	O	O	B-Entity
were	O	O	O
more	O	O	O
likely	O	O	O
than	O	O	O
those	O	O	O
with	O	O	O
insurance	O	O	O
to	O	O	O
be	O	O	O
nonwhite	O	O	O
(	O	O	O
50	O	O	O
%	O	O	O
among	O	O	O
uninsured	O	O	B-Entity
,	O	O	O
compared	O	O	O
with	O	O	O
40	O	O	O
%	O	O	O
among	O	O	O
insured	O	O	B-Entity
;	O	O	O
P	O	O	O
=	O	O	O
0.014	O	O	O
)	O	O	O
and	O	O	O
Hispanic	O	O	B-Entity
or	O	O	O
Latino/a	O	O	B-Entity
(	O	O	O
25	O	O	O
%	O	O	O
,	O	O	O
compared	O	O	O
with	O	O	O
16	O	O	O
%	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.006	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
less	O	O	O
likely	O	O	O
to	O	O	O
be	O	O	O
men	O	O	B-Entity
who	O	O	O
have	O	O	O
sex	O	O	B-Entity
with	O	O	O
men	O	O	O
(	O	O	O
27	O	O	O
%	O	O	O
,	O	O	O
compared	O	O	O
with	O	O	O
39	O	O	O
%	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Of	O	O	O
those	O	O	O
with	O	O	O
health	O	O	B-Entity
insurance	O	O	I-Entity
,	O	O	O
26	O	O	O
%	O	O	O
obtained	O	O	O
coverage	O	O	B-Entity
as	O	O	O
a	O	O	O
result	O	O	B-Entity
of	O	O	O
the	O	O	O
Affordable	O	O	B-Entity
Care	O	O	I-Entity
Act	O	O	I-Entity
,	O	O	O
and	O	O	O
56	O	O	O
%	O	O	O
of	O	O	O
those	O	O	O
were	O	O	O
previously	O	O	O
uninsured	O	O	B-Entity
.	O	O	O

Among	O	O	O
uninsured	O	O	B-Entity
individuals	O	O	I-Entity
,	O	O	O
barriers	O	O	B-Entity
to	O	O	O
obtaining	O	O	O
health	O	O	B-Entity
insurance	O	O	I-Entity
included	O	O	O
cost	O	O	B-Entity
and	O	O	O
unemployment	O	O	B-Entity
.	O	O	O

Among	O	O	O
those	O	O	O
with	O	O	B-Entity
insurance	O	O	B-Entity
,	O	O	O
43	O	O	O
%	O	O	O
reported	O	O	O
willingness	O	O	B-Entity
to	O	O	O
use	O	O	O
insurance	O	O	O
for	O	O	O
STD	O	O	B-Entity
services	O	O	B-Entity
.	O	O	O

Barriers	O	O	B-Entity
to	O	O	O
insurance	O	O	B-Entity
use	O	O	O
included	O	O	O
concerns	O	O	O
about	O	O	O
anonymity	O	O	B-Entity
and	O	O	O
out-of-pocket	O	O	B-Entity
costs	O	O	I-Entity
.	O	O	O

Despite	O	O	O
expanded	O	O	O
insurance	O	O	B-Entity
access	O	O	B-Entity
,	O	O	O
many	O	O	O
individuals	O	O	B-Entity
presenting	O	O	O
to	O	O	O
the	O	O	O
Rhode	O	O	B-Entity
Island	O	O	I-Entity
STD	O	O	B-Entity
Clinic	O	O	I-Entity
were	O	O	O
uninsured	O	O	B-Entity
.	O	O	O

Among	O	O	O
those	O	O	O
who	O	O	O
were	O	O	O
insured	O	O	B-Entity
,	O	O	O
significant	O	O	O
barriers	O	O	B-Entity
still	O	O	O
existed	O	O	O
to	O	O	O
using	O	O	O
insurance	O	O	B-Entity
.	O	O	O

STD	O	O	B-Entity
clinics	O	O	I-Entity
continue	O	O	O
to	O	O	O
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
providing	O	O	O
safety-net	O	O	B-Entity
STD	O	O	O
services	O	O	B-Entity
in	O	O	O
states	O	O	B-Entity
with	O	O	O
low	O	O	O
uninsured	O	O	B-Entity
rates	O	O	B-Entity
.	O	O	O

Both	O	O	O
public	O	O	B-Entity
and	O	O	O
private	O	O	B-Entity
insurers	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
address	O	O	O
financial	O	O	B-Entity
barriers	O	O	I-Entity
and	O	O	O
optimize	O	O	B-Entity
payment	O	O	B-Entity
structures	O	O	B-Entity
for	O	O	O
services	O	O	B-Entity
.	O	O	O

-DOCSTART- (28410389)

Molecular	O	O	B-Entity
subtyping	O	O	I-Entity
of	O	O	O
Treponema	O	O	B-Entity
pallidum	O	O	I-Entity
and	O	O	O
associated	O	O	B-Entity
factors	O	O	I-Entity
of	O	O	O
serofast	O	O	B-Entity
status	O	O	B-Entity
in	O	O	O
early	O	O	B-Entity
syphilis	O	O	I-Entity
patients	O	O	B-Entity
:	O	O	O
Identified	O	O	B-Entity
novel	O	O	O
genotype	O	O	B-Entity
and	O	O	O
cytokine	O	O	B-Entity
marker	O	O	O

Serofast	O	O	B-Entity
,	O	O	O
a	O	O	O
persistent	O	O	B-Entity
nontreponemal	O	O	B-Entity
serological	O	O	I-Entity
response	O	O	B-Entity
observed	O	O	B-Entity
in	O	O	O
early	O	O	B-Entity
syphilis	O	O	B-Entity
patients	O	O	B-Entity
after	O	O	O
conventional	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
remains	O	O	O
a	O	O	O
concern	O	O	B-Entity
of	O	O	O
clinicians	O	O	B-Entity
and	O	O	O
syphilis	O	O	O
patients	O	O	O
.	O	O	O

No	O	O	O
consensus	O	O	O
has	O	O	O
been	O	O	O
established	O	O	O
,	O	O	O
however	O	O	O
,	O	O	O
that	O	O	O
defines	O	O	O
an	O	O	O
effective	O	O	B-Entity
treatment	O	O	B-Entity
strategy	O	O	I-Entity
and	O	O	O
clarifies	O	O	B-Entity
the	O	O	O
pathogenesis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
517	O	O	O
patients	O	O	B-Entity
with	O	O	O
early	O	O	B-Entity
syphilis	O	O	I-Entity
were	O	O	O
enrolled	O	O	B-Entity
and	O	O	O
treated	O	O	B-Entity
.	O	O	O

Twelve	O	O	O
months	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
,	O	O	O
79.3	O	O	O
%	O	O	O
(	O	O	O
410/517	O	O	O
)	O	O	O
of	O	O	O
patients	O	O	B-Entity
achieved	O	O	O
serological	O	O	B-Entity
cure	O	O	B-Entity
,	O	O	O
20.1	O	O	O
%	O	O	O
(	O	O	O
104/517	O	O	O
)	O	O	O
were	O	O	O
serofast	O	O	B-Entity
,	O	O	O
and	O	O	O
0.6	O	O	O
%	O	O	O
(	O	O	O
3/517	O	O	O
)	O	O	O
were	O	O	O
serological	O	O	O
failures	O	O	B-Entity
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
older	O	O	B-Entity
age	O	O	I-Entity
(	O	O	O
>	O	O	O
40	O	O	O
years	O	O	B-Entity
)	O	O	O
and	O	O	O
lower	O	O	O
baseline	O	O	B-Entity
RPR	O	O	B-Entity
titer	O	O	I-Entity
(	O	O	O
≤	O	O	O
1:8	O	O	O
)	O	O	O
were	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
serofast	O	O	B-Entity
status	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
identified	O	O	O
21	O	O	O
T.	O	O	B-Entity
pallidum	O	O	I-Entity
molecular	O	O	B-Entity
subtypes	O	O	I-Entity
among	O	O	O
early	O	O	B-Entity
syphilis	O	O	I-Entity
patients	O	O	B-Entity
and	O	O	O
detected	O	O	O
a	O	O	O
new	O	O	O
subtype	O	O	B-Entity
,	O	O	I-Entity
14i/a	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
proportion	O	O	O
of	O	O	O
14i/a	O	O	B-Entity
type	O	O	I-Entity
in	O	O	O
serofast	O	O	B-Entity
patients	O	O	B-Entity
was	O	O	O
significantly	O	O	O
higher	O	O	O
than	O	O	O
that	O	O	O
in	O	O	O
patients	O	O	O
with	O	O	O
serological	O	O	B-Entity
cure	O	O	B-Entity
,	O	O	O
predicting	O	O	O
an	O	O	O
increasing	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	O
serofast	O	O	O
status	O	O	B-Entity
.	O	O	O

Levels	O	O	B-Entity
of	O	O	O
chemerin	O	O	B-Entity
were	O	O	O
higher	O	O	B-Entity
in	O	O	O
the	O	O	O
serum	O	O	B-Entity
of	O	O	O
serofast	O	O	B-Entity
cases	O	O	O
than	O	O	O
serological	O	O	B-Entity
cure	O	O	B-Entity
cases	O	O	O
,	O	O	O
potentially	O	O	O
indicating	O	O	O
a	O	O	O
novel	O	O	O
cytokine	O	O	B-Entity
marker	O	O	B-Entity
for	O	O	O
serofast	O	O	O
in	O	O	O
early	O	O	B-Entity
syphilis	O	O	I-Entity
patients	O	O	B-Entity
after	O	O	O
therapy	O	O	B-Entity
.	O	O	O

We	O	O	O
hope	O	O	O
that	O	O	O
these	O	O	O
results	O	O	B-Entity
contribute	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
guidelines	O	O	B-Entity
for	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
syphilis	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
experience	O	O	O
serofast	O	O	B-Entity
.	O	O	O

-DOCSTART- (28411311)

Total	O	O	O
Fluorescence	O	O	B-Entity
Fingerprinting	O	O	B-Entity
of	O	O	O
Pesticides	O	O	B-Entity
:	O	O	O
A	O	O	O
Reliable	O	O	O
Approach	O	O	O
for	O	O	O
Continuous	O	O	B-Entity
Monitoring	O	O	O
of	O	O	O
Soils	O	O	O
and	O	O	O
Waters	O	O	O

The	O	O	O
present	O	O	O
work	O	O	O
relates	O	O	O
to	O	O	O
the	O	O	O
creation	O	O	B-Entity
/	O	O	O
extension	O	O	B-Entity
of	O	O	O
a	O	O	O
database	O	O	B-Entity
of	O	O	O
Total	O	O	B-Entity
Excitation-Emission	O	O	I-Entity
and	O	O	I-Entity
Total	O	O	I-Entity
Synchronous	O	O	I-Entity
Fluorescence	O	O	I-Entity
Matrices	O	O	I-Entity
(	O	O	O
TEEMs	O	O	B-Entity
and	O	O	I-Entity
TSFMs	O	O	I-Entity
)	O	O	O
along	O	O	O
with	O	O	O
optimal	O	O	B-Entity
Synchronous	O	O	I-Entity
Fluorescence	O	O	I-Entity
Spectra	O	O	I-Entity
(	O	O	O
SFS	O	O	B-Entity
)	O	O	O
to	O	O	O
fingerprint	O	O	B-Entity
pesticides	O	O	B-Entity
widely	O	O	O
used	O	O	O
in	O	O	O
Morocco	O	O	B-Entity
.	O	O	O

This	O	O	O
spectrometric	O	O	B-Entity
multi-component	O	O	I-Entity
fingerprinting	O	O	I-Entity
may	O	O	O
permit	O	O	O
the	O	O	O
direct	O	O	O
detection	O	O	B-Entity
of	O	O	I-Entity
pesticides	O	O	I-Entity
persisting	O	O	B-Entity
in	O	O	I-Entity
soil	O	O	I-Entity
or	O	O	O
water	O	O	B-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
investigation	O	O	O
is	O	O	O
to	O	O	O
detect	O	O	B-Entity
four	O	O	I-Entity
pesticide	O	O	I-Entity
remains	O	O	O
in	O	O	O
agricultural	O	O	B-Entity
soils	O	O	I-Entity
by	O	O	O
applying	O	O	O
the	O	O	O
spectrometric	O	O	B-Entity
fingerprinting	O	O	I-Entity
results	O	O	O
.	O	O	O

They	O	O	O
are	O	O	O
the	O	O	O
commercial	O	O	O
:	O	O	O
i	O	O	O
)	O	O	O
insecticide	O	O	B-Entity
Axlera	O	O	I-Entity
5	O	O	I-Entity
G	O	O	I-Entity
(	O	O	O
carbamate	O	O	B-Entity
)	O	O	O
,	O	O	O
ii	O	O	O
)	O	O	O
fungicide	O	O	B-Entity
Orsalis	O	O	I-Entity
5	O	O	I-Entity
%	O	O	I-Entity
SC	O	O	I-Entity
(	O	O	O
triazole	O	O	B-Entity
)	O	O	O
,	O	O	O
iii	O	O	O
)	O	O	O
insecticide	O	O	B-Entity
Force	O	O	I-Entity
0,5	O	O	I-Entity
G	O	O	I-Entity
(	O	O	O
pyrethrinoid	O	O	B-Entity
)	O	O	O
and	O	O	O
iv	O	O	O
)	O	O	O
insecticide	O	O	B-Entity
Proclaim	O	O	I-Entity
05	O	O	I-Entity
SG	O	O	I-Entity
(	O	O	O
non-assigned	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
agricultural	O	O	B-Entity
plantations	O	O	I-Entity
monitored	O	O	I-Entity
are	O	O	O
located	O	O	O
in	O	O	O
the	O	O	O
great	O	O	B-Entity
agricultural	O	O	I-Entity
Doukkala	O	O	I-Entity
region	O	O	I-Entity
at	O	O	O
the	O	O	O
western	O	O	B-Entity
Atlantic	O	O	I-Entity
side	O	O	I-Entity
of	O	O	O
Morocco	O	O	B-Entity
,	O	O	O
where	O	O	O
these	O	O	O
chemicals	O	O	B-Entity
are	O	O	O
in	O	O	O
large	O	O	O
sale	O	O	O
and	O	O	O
use	O	O	O
.	O	O	O

-DOCSTART- (28412969)

Engagement	O	O	O
of	O	O	O
cellular	O	O	B-Entity
prion	O	O	I-Entity
protein	O	O	I-Entity
with	O	O	O
the	O	O	O
co-chaperone	O	O	B-Entity
Hsp70	O	O	B-Entity
/	O	O	I-Entity
90	O	O	B-Entity
organizing	O	O	I-Entity
protein	O	O	I-Entity
regulates	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
glioblastoma	O	O	B-Entity
stem-like	O	O	O
cells	O	O	O

Glioblastoma	O	O	B-Entity
(	O	O	O
GBM	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
highly	O	O	O
aggressive	O	O	O
brain	O	O	B-Entity
tumor	O	O	B-Entity
,	O	O	O
contains	O	O	O
a	O	O	O
subpopulation	O	O	O
of	O	O	O
glioblastoma	O	O	B-Entity
stem-like	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
GSCs	O	O	B-Entity
)	O	O	O
that	O	O	O
play	O	O	O
roles	O	O	O
in	O	O	O
tumor	O	O	O
maintenance	O	O	B-Entity
,	O	O	O
invasion	O	O	B-Entity
,	O	O	O
and	O	O	O
therapeutic	O	O	B-Entity
resistance	O	O	I-Entity
.	O	O	O

GSCs	O	O	B-Entity
are	O	O	O
therefore	O	O	O
a	O	O	O
promising	O	O	O
target	O	O	B-Entity
for	O	O	O
GBM	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

Our	O	O	O
group	O	O	O
identified	O	O	O
the	O	O	O
cellular	O	O	B-Entity
prion	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
and	O	O	O
its	O	O	O
partner	O	O	O
,	O	O	O
the	O	O	O
co-chaperone	O	O	B-Entity
Hsp70	O	O	B-Entity
/	O	O	I-Entity
90	O	O	B-Entity
organizing	O	O	I-Entity
protein	O	O	I-Entity
(	O	O	O
HOP	O	O	B-Entity
)	O	O	O
,	O	O	O
as	O	O	O
potential	O	O	O
target	O	O	B-Entity
candidates	O	O	O
due	O	O	O
to	O	O	O
their	O	O	O
role	O	O	O
in	O	O	O
GBM	O	O	B-Entity
tumorigenesis	O	O	B-Entity
and	O	O	O
in	O	O	O
neural	O	O	B-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
maintenance	O	O	O
.	O	O	O

GSCs	O	O	B-Entity
expressing	O	O	O
different	O	O	O
levels	O	O	O
of	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
were	O	O	O
cultured	O	O	B-Entity
as	O	O	O
neurospheres	O	O	B-Entity
with	O	O	O
growth	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
and	O	O	O
characterized	O	O	O
with	O	O	O
stem	O	O	B-Entity
cells	O	O	I-Entity
markers	O	O	B-Entity
and	O	O	O
adhesion	O	O	B-Entity
molecules	O	O	I-Entity
markers	O	O	I-Entity
through	O	O	O
immunofluorescence	O	O	B-Entity
and	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

We	O	O	O
than	O	O	O
evaluated	O	O	O
GSC	O	O	B-Entity
self-renewal	O	O	B-Entity
and	O	O	O
proliferation	O	O	B-Entity
by	O	O	O
clonal	O	O	B-Entity
density	O	O	I-Entity
assays	O	O	I-Entity
and	O	O	O
BrdU	O	O	B-Entity
incorporation	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
in	O	O	O
front	O	O	O
of	O	O	O
recombinant	O	O	O
HOP	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
combined	O	O	O
or	O	O	O
not	O	O	O
with	O	O	O
a	O	O	O
HOP	O	O	O
peptide	O	O	B-Entity
which	O	O	O
mimics	O	O	O
the	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
binding	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

Stable	O	O	O
silencing	O	O	B-Entity
of	O	O	O
HOP	O	O	B-Entity
was	O	O	O
also	O	O	O
performed	O	O	O
in	O	O	O
parental	O	O	O
and/or	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
-depleted	O	O	O
cell	O	O	B-Entity
populations	O	O	I-Entity
,	O	O	O
and	O	O	O
proliferation	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
growth	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
were	O	O	O
evaluated	O	O	O
.	O	O	O

Migration	O	O	B-Entity
assays	O	O	I-Entity
were	O	O	O
performed	O	O	O
on	O	O	O
laminin-1	O	O	B-Entity
pre-coated	O	O	I-Entity
glass	O	O	I-Entity
.	O	O	O

We	O	O	O
observed	O	O	O
that	O	O	O
,	O	O	O
when	O	O	O
GBM	O	O	B-Entity
cells	O	O	B-Entity
are	O	O	O
cultured	O	O	B-Entity
as	O	O	O
neurospheres	O	O	B-Entity
,	O	O	O
they	O	O	O
express	O	O	O
specific	O	O	O
stemness	O	O	B-Entity
markers	O	O	I-Entity
such	O	O	O
as	O	O	O
CD133	O	O	B-Entity
,	O	O	O
CD15	O	O	B-Entity
,	O	O	O
Oct4	O	O	B-Entity
,	O	O	O
and	O	O	O
SOX2	O	O	B-Entity
;	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
is	O	O	O
upregulated	O	O	O
compared	O	O	O
to	O	O	O
monolayer	O	O	B-Entity
culture	O	O	I-Entity
and	O	O	O
co-localizes	O	O	O
with	O	O	O
CD133	O	O	O
.	O	O	O

PrP(C	O	O	B-Entity
)	O	O	I-Entity
silencing	O	O	B-Entity
downregulates	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	I-Entity
molecules	O	O	I-Entity
associated	O	O	O
with	O	O	O
cancer	O	O	B-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
upregulates	O	O	O
markers	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
differentiation	O	O	I-Entity
and	O	O	O
affects	O	O	O
GSC	O	O	B-Entity
self-renewal	O	O	B-Entity
,	O	O	O
pointing	O	O	O
to	O	O	O
a	O	O	O
pivotal	O	O	O
role	O	O	O
for	O	O	O
PrP(C	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
maintenance	O	O	O
of	O	O	O
GSCs	O	O	B-Entity
.	O	O	O

Exogenous	O	O	O
HOP	O	O	B-Entity
treatment	O	O	B-Entity
increases	O	O	O
proliferation	O	O	B-Entity
and	O	O	O
self-renewal	O	O	B-Entity
of	O	O	O
GSCs	O	O	B-Entity
in	O	O	O
a	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
-dependent	O	O	O
manner	O	O	O
while	O	O	O
HOP	O	O	O
knockdown	O	O	O
disturbs	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

In	O	O	B-Entity
vivo	O	O	I-Entity
,	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
and/or	O	O	O
HOP	O	O	B-Entity
knockdown	O	O	O
potently	O	O	O
inhibits	O	O	B-Entity
the	O	O	O
growth	O	O	B-Entity
of	O	O	O
subcutaneously	O	O	O
implanted	O	O	O
glioblastoma	O	O	B-Entity
cells	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
disruption	O	O	O
of	O	O	O
the	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
-	O	O	I-Entity
HOP	O	O	B-Entity
complex	O	O	I-Entity
by	O	O	O
a	O	O	O
HOP	O	O	O
peptide	O	O	B-Entity
,	O	O	O
which	O	O	O
mimics	O	O	O
the	O	O	O
PrP(C	O	O	O
)	O	O	O
binding	O	O	B-Entity
site	O	O	I-Entity
,	O	O	O
affects	O	O	O
GSC	O	O	B-Entity
self-renewal	O	O	B-Entity
and	O	O	O
proliferation	O	O	B-Entity
indicating	O	O	O
that	O	O	O
the	O	O	O
HOP	O	O	B-Entity
-	O	O	I-Entity
PrP(C	O	O	I-Entity
)	O	O	I-Entity
complex	O	O	I-Entity
is	O	O	O
required	O	O	O
for	O	O	O
GSC	O	O	O
stemness	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
-depleted	O	O	O
GSCs	O	O	B-Entity
downregulate	O	O	O
cell	O	O	B-Entity
adhesion-related	O	O	B-Entity
proteins	O	O	I-Entity
and	O	O	O
impair	O	O	O
cell	O	O	B-Entity
migration	O	O	I-Entity
indicating	O	O	O
a	O	O	O
putative	O	O	O
role	O	O	O
for	O	O	O
PrP(C	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
cell	O	O	B-Entity
surface	O	O	I-Entity
stability	O	O	I-Entity
of	O	O	O
cell	O	O	B-Entity
adhesion	O	O	I-Entity
molecules	O	O	I-Entity
and	O	O	O
GBM	O	O	B-Entity
cell	O	O	O
invasiveness	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
our	O	O	O
results	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
modulation	O	O	O
of	O	O	O
HOP	O	O	B-Entity
-	O	O	O
PrP(C	O	O	B-Entity
)	O	O	I-Entity
engagement	O	O	O
or	O	O	O
the	O	O	O
decrease	O	O	O
of	O	O	O
PrP(C	O	O	O
)	O	O	O
and	O	O	O
HOP	O	O	O
expression	O	O	B-Entity
may	O	O	O
represent	O	O	O
a	O	O	O
potential	O	O	O
therapeutic	O	O	B-Entity
intervention	O	O	I-Entity
in	O	O	O
GBM	O	O	B-Entity
,	O	O	O
regulating	O	O	O
glioblastoma	O	O	B-Entity
stem-like	O	O	I-Entity
cell	O	O	I-Entity
self-renewal	O	O	B-Entity
,	O	O	O
proliferation	O	O	B-Entity
,	O	O	O
and	O	O	O
migration	O	O	B-Entity
.	O	O	O

-DOCSTART- (28413179)

Cyclic	O	O	B-Entity
thrombocytopenia	O	O	B-Entity
synchronizing	O	O	B-Entity
with	O	O	O
the	O	O	O
menstrual	O	O	B-Entity
cycle	O	O	I-Entity
showing	O	O	O
periodic	O	O	B-Entity
phases	O	O	B-Entity
of	O	O	O
thrombocytopenia	O	O	O
and	O	O	O
rebound	O	O	B-Entity
thrombocytosis	O	O	O

A	O	O	O
37-	O	O	O
year	O	O	B-Entity
-old	O	O	O
woman	O	O	B-Entity
was	O	O	O
admitted	O	O	B-Entity
to	O	O	O
our	O	O	O
hospital	O	O	B-Entity
for	O	O	O
purpura	O	O	B-Entity
involving	O	O	O
the	O	O	O
extremities	O	O	B-Entity
and	O	O	O
thrombocytopenia	O	O	B-Entity
.	O	O	O

Prednisolone	O	O	B-Entity
(	O	O	O
PSL	O	O	B-Entity
)	O	O	O
was	O	O	O
administered	O	O	B-Entity
based	O	O	O
on	O	O	O
a	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
idiopathic	O	O	B-Entity
thrombocytopenic	O	O	I-Entity
purpura	O	O	I-Entity
(	O	O	O
ITP	O	O	B-Entity
)	O	O	O
,	O	O	O
but	O	O	O
was	O	O	O
not	O	O	B-Entity
effective	O	O	I-Entity
for	O	O	O
maintaining	O	O	B-Entity
her	O	O	O
platelet	O	O	B-Entity
count	O	O	I-Entity
within	O	O	O
the	O	O	O
normal	O	O	B-Entity
range	O	O	I-Entity
,	O	O	O
which	O	O	O
showed	O	O	O
cyclic	O	O	B-Entity
fluctuation	O	O	I-Entity
corresponding	O	O	O
to	O	O	O
the	O	O	O
menstrual	O	O	B-Entity
cycle	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
discontinued	O	O	B-Entity
PSL	O	O	B-Entity
,	O	O	O
and	O	O	O
cyclic	O	O	B-Entity
thrombocytopenia	O	O	I-Entity
(	O	O	O
CTP	O	O	B-Entity
)	O	O	O
was	O	O	O
diagnosed	O	O	B-Entity
.	O	O	O

CTP	O	O	B-Entity
is	O	O	O
a	O	O	O
rare	O	O	B-Entity
disease	O	O	I-Entity
which	O	O	O
is	O	O	O
usually	O	O	O
treated	O	O	B-Entity
as	O	O	O
ITP	O	O	B-Entity
but	O	O	O
with	O	O	O
no	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

Although	O	O	O
the	O	O	O
exact	O	O	O
cause	O	O	B-Entity
of	O	O	O
CTP	O	O	B-Entity
is	O	O	O
uncertain	O	O	B-Entity
,	O	O	O
in	O	O	O
our	O	O	O
case	O	O	B-Entity
,	O	O	O
a	O	O	O
hormonal	O	O	B-Entity
mechanism	O	O	I-Entity
may	O	O	O
be	O	O	O
responsible	O	O	O
for	O	O	O
fluctuating	O	O	B-Entity
platelet	O	O	B-Entity
count	O	O	I-Entity
.	O	O	O

-DOCSTART- (28413794)

Comparative	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
iodine-131	O	O	B-Entity
metaiodobenzylguanidine	O	O	I-Entity
and	O	O	O
18-fluorodeoxyglucose	O	O	B-Entity
positron	O	O	B-Entity
emission	O	O	I-Entity
tomography	O	O	I-Entity
in	O	O	O
assessing	O	O	O
neural	O	O	B-Entity
crest	O	O	I-Entity
tumors	O	O	I-Entity
:	O	O	O
Will	O	O	O
they	O	O	O
play	O	O	O
a	O	O	O
complementary	O	O	O
role	O	O	O
?	O	O	O

18-Fluorodeoxyglucose	O	O	B-Entity
positron	O	O	B-Entity
emission	O	O	I-Entity
tomography	O	O	I-Entity
(	O	O	O
FDG-PET	O	O	B-Entity
)	O	O	O
has	O	O	O
established	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
evaluation	O	O	O
of	O	O	O
several	O	O	O
malignancies	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
precise	O	O	O
clinical	O	O	B-Entity
role	O	O	I-Entity
in	O	O	O
the	O	O	O
neural	O	O	B-Entity
crest	O	O	I-Entity
cell	O	O	I-Entity
tumors	O	O	I-Entity
continues	O	O	O
to	O	O	O
evolve	O	O	O
.	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
compare	O	O	O
iodine-131	O	O	B-Entity
metaiodobenzylguanidine	O	O	I-Entity
(	O	O	O
(131)I-MIBG	O	O	B-Entity
)	O	O	O
and	O	O	O
FDG-PET	O	O	B-Entity
of	O	O	O
head	O	O	O
to	O	O	O
head	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
neural	O	O	B-Entity
crest	O	O	I-Entity
tumors	O	O	I-Entity
both	O	O	O
qualitatively	O	O	B-Entity
and	O	O	O
semiquantitatively	O	O	B-Entity
and	O	O	O
to	O	O	O
determine	O	O	O
their	O	O	O
clinical	O	O	B-Entity
utility	O	O	I-Entity
in	O	O	O
disease	O	O	B-Entity
status	O	O	I-Entity
evaluation	O	O	I-Entity
and	O	O	O
further	O	O	B-Entity
management	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
32	O	O	O
patients	O	O	B-Entity
who	O	O	O
had	O	O	O
undergone	O	O	O
(131)I-MIBG	O	O	B-Entity
and	O	O	O
FDG-PET	O	O	B-Entity
prospectively	O	O	O
were	O	O	O
evaluated	O	O	O
and	O	O	O
clinicopathologically	O	O	B-Entity
grouped	O	O	O
into	O	O	O
three	O	O	O
categories	O	O	O
:	O	O	O
neuroblastoma	O	O	B-Entity
,	O	O	O
pheochromocytoma	O	O	B-Entity
,	O	O	O
and	O	O	O
medullary	O	O	B-Entity
carcinoma	O	O	I-Entity
thyroid	O	O	I-Entity
.	O	O	O

In	O	O	O
18	O	O	O
patients	O	O	B-Entity
of	O	O	O
neuroblastoma	O	O	B-Entity
,	O	O	O
FDG	O	O	B-Entity
PET	O	O	I-Entity
and	O	O	O
(131)I-MIBG	O	O	B-Entity
showed	O	O	O
patient-specific	O	O	B-Entity
sensitivity	O	O	I-Entity
of	O	O	O
84	O	O	O
%	O	O	O
and	O	O	O
72	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
maximum	O	O	B-Entity
standardized	O	O	I-Entity
uptake	O	O	I-Entity
value	O	O	I-Entity
(	O	O	O
SUVmax	O	O	B-Entity
)	O	O	O
of	O	O	O
primary	O	O	B-Entity
lesions	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
unfavorable	O	O	B-Entity
histology	O	O	I-Entity
was	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
relatively	O	O	O
higher	O	O	O
than	O	O	O
those	O	O	O
with	O	O	O
favorable	O	O	B-Entity
histology	O	O	I-Entity
(	O	O	O
5.18	O	O	O
±	O	O	O
2.38	O	O	O
vs.	O	O	O
3.21	O	O	O
±	O	O	O
1.69	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	O
SUVmax	O	O	B-Entity
of	O	O	O
two	O	O	O
common	O	O	O
sites	O	O	O
(	O	O	O
posterior	O	O	B-Entity
superior	O	O	I-Entity
iliac	O	O	I-Entity
spine	O	O	I-Entity
[	O	O	O
PSIS	O	O	B-Entity
]	O	O	O
and	O	O	O
greater	O	O	B-Entity
trochanter	O	O	I-Entity
)	O	O	O
was	O	O	O
higher	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
involved	O	O	O
marrow	O	O	B-Entity
than	O	O	O
those	O	O	O
with	O	O	O
uninvolved	O	O	O
one	O	O	O
(	O	O	O
2.36	O	O	O
and	O	O	O
2.75	O	O	O
vs.	O	O	O
1.26	O	O	O
and	O	O	O
1.34	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
ratio	O	O	O
of	O	O	O
SUVmax	O	O	B-Entity
of	O	O	O
the	O	O	O
involved/	O	O	O
contralateral	O	O	B-Entity
normal	O	O	I-Entity
sites	O	O	I-Entity
was	O	O	O
2.16	O	O	O
±	O	O	O
1.9	O	O	O
.	O	O	O

In	O	O	O
equivocal	O	O	B-Entity
bone	O	O	B-Entity
marrow	O	O	I-Entity
results	O	O	I-Entity
,	O	O	O
the	O	O	O
uptake	O	O	O
pattern	O	O	O
with	O	O	O
SUV	O	O	B-Entity
estimation	O	O	O
can	O	O	O
depict	O	O	O
metastatic	O	O	B-Entity
involvement	O	O	I-Entity
and	O	O	O
help	O	O	O
in	O	O	O
redirecting	O	O	O
the	O	O	O
biopsy	O	O	B-Entity
site	O	O	I-Entity
.	O	O	O

Among	O	O	O
seven	O	O	O
patients	O	O	B-Entity
of	O	O	O
pheochromocytoma	O	O	B-Entity
,	O	O	O
FDG-PET	O	O	B-Entity
revealed	O	O	O
100	O	O	O
%	O	O	O
patient-specific	O	O	B-Entity
sensitivity	O	O	I-Entity
.	O	O	O

FDG-PET	O	O	B-Entity
detected	O	O	O
more	O	O	O
metastatic	O	O	B-Entity
foci	O	O	I-Entity
than	O	O	O
(131)I-MIBG	O	O	B-Entity
(	O	O	O
18	O	O	O
vs.	O	O	O
13	O	O	O
sites	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
seven	O	O	O
patients	O	O	B-Entity
of	O	O	O
medullary	O	O	B-Entity
carcinoma	O	O	I-Entity
thyroid	O	O	I-Entity
,	O	O	O
FDG-PET	O	O	B-Entity
localized	O	O	O
residual	O	O	O
,	O	O	O
recurrent	O	O	B-Entity
,	O	O	O
or	O	O	O
metastatic	O	O	B-Entity
disease	O	O	I-Entity
with	O	O	O
much	O	O	O
higher	O	O	O
sensitivity	O	O	O
(	O	O	O
32	O	O	O
metastatic	O	O	B-Entity
foci	O	O	I-Entity
with	O	O	O
72	O	O	O
%	O	O	O
patient	O	O	B-Entity
specific	O	O	I-Entity
sensitivity	O	O	I-Entity
)	O	O	O
than	O	O	O
(131)I-MIBG	O	O	B-Entity
,	O	O	O
trending	O	O	O
along	O	O	O
the	O	O	O
higher	O	O	B-Entity
serum	O	O	I-Entity
calcitonin	O	O	I-Entity
levels	O	O	I-Entity
.	O	O	O

FDG-PET	O	O	B-Entity
is	O	O	O
not	O	O	O
only	O	O	O
a	O	O	O
good	O	O	O
complementary	O	O	B-Entity
modality	O	O	I-Entity
in	O	O	O
the	O	O	O
management	O	O	O
of	O	O	O
neural	O	O	B-Entity
crest	O	O	I-Entity
cell	O	O	I-Entity
tumors	O	O	I-Entity
but	O	O	O
also	O	O	O
it	O	O	O
can	O	O	O
even	O	O	O
be	O	O	O
superior	O	O	O
,	O	O	O
especially	O	O	O
in	O	O	O
cases	O	O	O
of	O	O	O
(131)I-MIBG	O	O	B-Entity
nonavid	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

-DOCSTART- (28416410)

Progressive	O	O	B-Entity
Occlusion	O	O	I-Entity
and	O	O	O
Recanalization	O	O	B-Entity
after	O	O	O
Endovascular	O	O	B-Entity
Treatment	O	O	I-Entity
for	O	O	O
287	O	O	O
Unruptured	O	O	B-Entity
Small	O	O	I-Entity
Aneurysms	O	O	I-Entity
(	O	O	O
<	O	O	O
5	O	O	O
mm	O	O	O
):	O	O	O
A	O	O	O
Single-Center	O	O	B-Entity
6-Year	O	O	B-Entity
Experience	O	O	O

We	O	O	O
aimed	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
coiling	O	O	B-Entity
for	O	O	O
small	O	O	O
unruptured	O	O	B-Entity
intracranial	O	O	I-Entity
aneurysms	O	O	I-Entity
(UIAs)﹤5	O	O	O
mm	O	O	O
)	O	O	O
on	O	O	O
progressive	O	O	B-Entity
occlusio	O	O	I-Entity
n	O	O	O
and	O	O	O
recanalization	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
dubious	O	O	O
factors	O	O	O
related	O	O	O
to	O	O	O
progressive	O	O	B-Entity
occlusion	O	O	B-Entity
and	O	O	O
recanalization	O	O	O
among	O	O	O
UIAs	O	O	B-Entity
without	O	O	O
complete	O	O	O
occlusion	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
264	O	O	O
patients	O	O	B-Entity
with	O	O	O
287	O	O	O
small	O	O	O
UIAs	O	O	B-Entity
were	O	O	O
coiled	O	O	O
in	O	O	O
our	O	O	O
institute	O	O	B-Entity
between	O	O	O
June	O	O	O
2009	O	O	O
and	O	O	O
December	O	O	O
2014	O	O	O
.	O	O	O

All	O	O	O
UIAs	O	O	B-Entity
enrolled	O	O	O
were	O	O	O
divided	O	O	O
into	O	O	O
small	O	O	O
(	O	O	O
3	O	O	O
-	O	O	O
5	O	O	O
mm	O	O	O
)	O	O	O
and	O	O	O
very	O	O	O
small	O	O	O
(	O	O	O
<3	O	O	O
mm	O	O	O
)	O	O	O
group	O	O	B-Entity
s	O	O	O
,	O	O	O
and	O	O	O
UIAs	O	O	O
without	O	O	O
initial	O	O	O
complete	O	O	O
occlusion	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
progressive	O	O	B-Entity
,	O	O	O
stable	O	O	B-Entity
and	O	O	O
recanalization	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

Baseline	O	O	B-Entity
characteristics	O	O	B-Entity
,	O	O	O
procedure	O	O	B-Entity
-related	O	O	O
complications	O	O	B-Entity
,	O	O	O
angiographic	O	O	B-Entity
follow-up	O	O	B-Entity
results	O	O	I-Entity
,	O	O	O
and	O	O	O
clinical	O	O	B-Entity
outcomes	O	O	I-Entity
were	O	O	O
statistically	O	O	B-Entity
analyzed	O	O	I-Entity
.	O	O	O

Among	O	O	O
287	O	O	O
aneurysms	O	O	B-Entity
,	O	O	O
211	O	O	O
aneurysms	O	O	O
(	O	O	O
73.5	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
completely	O	O	O
coiled	O	O	O
,	O	O	O
three	O	O	O
(	O	O	O
1.2	O	O	O
%	O	O	O
)	O	O	O
intraoperative	O	O	B-Entity
ruptures	O	O	B-Entity
and	O	O	O
12	O	O	O
(	O	O	O
4.2	O	O	O
%	O	O	O
)	O	O	O
perioperative	O	O	B-Entity
thromboembolic	O	O	B-Entity
events	O	O	I-Entity
occurred	O	O	O
.	O	O	O

Angiographic	O	O	B-Entity
follow-up	O	O	B-Entity
was	O	O	O
available	O	O	O
for	O	O	O
174	O	O	O
patients	O	O	B-Entity
(	O	O	O
65.9	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
recanalization	O	O	B-Entity
was	O	O	O
5.7	O	O	O
%	O	O	O
.	O	O	O

Among	O	O	O
56	O	O	O
aneurysms	O	O	B-Entity
without	O	O	O
complete	O	O	O
occlusion	O	O	B-Entity
,	O	O	O
43	O	O	O
(	O	O	O
76.8	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
progressive	O	O	B-Entity
occlusion	O	O	I-Entity
and	O	O	O
6(10.7	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
recanalization	O	O	B-Entity
.	O	O	O

Anatomic	O	O	B-Entity
results	O	O	I-Entity
of	O	O	O
initial	O	O	O
and	O	O	O
follow-up	O	O	B-Entity
between	O	O	O
small	O	O	O
and	O	O	O
very	O	O	O
small	O	O	O
groups	O	O	B-Entity
were	O	O	O
similar	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	O
.	O	O	O

On	O	O	O
logistic	O	O	B-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
smaller	O	O	O
size	O	O	B-Entity
(	O	O	O
<3	O	O	O
mm	O	O	O
)	O	O	O
without	O	O	O
complete	O	O	O
occlusion	O	O	B-Entity
related	O	O	O
to	O	O	O
recanalization	O	O	B-Entity
(	O	O	O
OR	O	O	O
,	O	O	O
8.0	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
1.3	O	O	O
-	O	O	O
50.0	O	O	O
,	O	O	O
P=0.026	O	O	O
)	O	O	O
.	O	O	O

Our	O	O	O
study	O	O	B-Entity
suggested	O	O	O
that	O	O	O
coil	O	O	B-Entity
embolization	O	O	I-Entity
of	O	O	O
small	O	O	O
UIAs	O	O	B-Entity
can	O	O	O
achieve	O	O	O
a	O	O	O
high	O	O	O
rate	O	O	O
of	O	O	O
progressive	O	O	B-Entity
occlusion	O	O	I-Entity
and	O	O	O
low	O	O	O
rate	O	O	O
of	O	O	O
recanalization	O	O	B-Entity
during	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Anatomic	O	O	B-Entity
results	O	O	I-Entity
of	O	O	O
initial	O	O	O
and	O	O	O
follow-up	O	O	B-Entity
between	O	O	O
small	O	O	O
(	O	O	O
3	O	O	O
-	O	O	O
5	O	O	O
mm	O	O	O
)	O	O	O
and	O	O	O
very	O	O	O
small	O	O	O
(	O	O	O
<3	O	O	O
mm	O	O	O
)	O	O	O
groups	O	O	B-Entity
were	O	O	O
similar	O	O	O
in	O	O	O
both	O	O	O
groups	O	O	O
.	O	O	O

What	O	O	O
's	O	O	O
more	O	O	O
,	O	O	O
smaller	O	O	O
size	O	O	O
(	O	O	O
<3	O	O	O
mm	O	O	O
)	O	O	O
without	O	O	O
complete	O	O	O
occlusion	O	O	B-Entity
may	O	O	O
relate	O	O	O
to	O	O	O
recanalization	O	O	B-Entity
.	O	O	O

-DOCSTART- (28417422)

Selection	O	O	B-Entity
of	O	O	O
an	O	O	O
Artificial	O	O	B-Entity
Diet	O	O	B-Entity
for	O	O	O
Laboratory	O	O	B-Entity
Rearing	O	O	B-Entity
of	O	O	O
Opogona	O	O	B-Entity
sacchari	O	O	I-Entity
(	O	O	O
Lepidoptera	O	O	B-Entity
:	O	O	O
Tineidae	O	O	B-Entity
)	O	O	O
(	O	O	O
Bojer	O	O	O
,	O	O	O
1856	O	O	O
)	O	O	O

The	O	O	O
banana	O	O	B-Entity
moth	O	O	I-Entity
Opogona	O	O	I-Entity
sacchari	O	O	I-Entity
(	O	O	O
Bojer	O	O	B-Entity
)	O	O	O
(	O	O	O
Lepidoptera	O	O	B-Entity
:	O	O	O
Tineidae	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
polyphagous	O	O	B-Entity
pest	O	O	I-Entity
that	O	O	O
can	O	O	O
cause	O	O	O
serious	O	O	B-Entity
damage	O	O	B-Entity
,	O	O	O
in	O	O	O
particular	O	O	O
to	O	O	O
banana	O	O	O
crops	O	O	B-Entity
in	O	O	O
southern	O	O	B-Entity
Brazil	O	O	B-Entity
.	O	O	O

The	O	O	O
insect	O	O	B-Entity
is	O	O	O
a	O	O	O
quarantine	O	O	O
pest	O	O	B-Entity
in	O	O	O
several	O	O	O
countries	O	O	B-Entity
,	O	O	O
including	O	O	O
Argentina	O	O	B-Entity
,	O	O	O
the	O	O	O
main	O	O	O
consumer	O	O	B-Entity
market	O	O	B-Entity
for	O	O	O
bananas	O	O	B-Entity
from	O	O	O
southern	O	O	B-Entity
Brazil	O	O	B-Entity
.	O	O	O

Little	O	O	O
information	O	O	B-Entity
is	O	O	O
available	O	O	O
about	O	O	O
the	O	O	O
biology	O	O	B-Entity
and	O	O	O
ecology	O	O	B-Entity
of	O	O	O
this	O	O	O
moth	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
a	O	O	O
suitable	O	O	O
diet	O	O	B-Entity
for	O	O	O
laboratory	O	O	B-Entity
rearing	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
provide	O	O	O
support	O	O	O
for	O	O	O
integrated	O	O	O
pest	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
the	O	O	O
pest	O	O	O
,	O	O	O
this	O	O	O
study	O	O	B-Entity
furnished	O	O	O
data	O	O	B-Entity
for	O	O	O
selecting	O	O	O
two	O	O	O
diets	O	O	B-Entity
suitable	O	O	O
for	O	O	O
continuous	O	O	O
laboratory	O	O	B-Entity
rearing	O	O	B-Entity
of	O	O	O
O.	O	O	B-Entity
sacchari	O	O	I-Entity
,	O	O	O
one	O	O	O
based	O	O	O
on	O	O	O
dried	O	O	B-Entity
beans	O	O	B-Entity
,	O	O	O
wheat	O	O	B-Entity
germ	O	O	I-Entity
,	O	O	O
soy	O	O	B-Entity
bran	O	O	I-Entity
,	O	O	O
brewer	O	O	B-Entity
's	O	O	I-Entity
yeast	O	O	I-Entity
,	O	O	O
and	O	O	O
casein	O	O	B-Entity
and	O	O	O
another	O	O	O
diet	O	O	B-Entity
with	O	O	O
wheat	O	O	O
germ	O	O	O
and	O	O	O
casein	O	O	O
as	O	O	O
protein	O	O	B-Entity
sources	O	O	B-Entity
.	O	O	O

With	O	O	O
both	O	O	O
diets	O	O	B-Entity
,	O	O	O
the	O	O	O
viability	O	O	B-Entity
of	O	O	O
the	O	O	O
egg	O	O	B-Entity
-	O	O	O
adult	O	O	B-Entity
period	O	O	B-Entity
exceeded	O	O	O
68	O	O	O
%	O	O	O
,	O	O	O
with	O	O	O
fertility	O	O	B-Entity
over	O	O	O
338	O	O	O
eggs	O	O	B-Entity
per	O	O	O
female	O	O	B-Entity
.	O	O	O

A	O	O	O
corrected	O	O	O
biotic	O	O	B-Entity
potential	O	O	B-Entity
analysis	O	O	B-Entity
gave	O	O	O
similar	O	O	O
values	O	O	B-Entity
for	O	O	O
the	O	O	O
two	O	O	O
diets	O	O	B-Entity
.	O	O	O

-DOCSTART- (28420538)

The	O	O	O
impact	O	O	B-Entity
on	O	O	O
productivity	O	O	B-Entity
of	O	O	O
a	O	O	O
hypothetical	O	O	B-Entity
tax	O	O	I-Entity
on	O	O	O
sugar-sweetened	O	O	O
beverages	O	O	O

To	O	O	O
quantify	O	O	O
the	O	O	O
potential	O	O	B-Entity
impact	O	O	B-Entity
of	O	O	O
an	O	O	O
additional	O	O	B-Entity
20	O	O	O
%	O	O	O
tax	O	O	B-Entity
on	O	O	O
sugar-sweetened	O	O	B-Entity
beverages	O	O	I-Entity
(	O	O	O
SSBs	O	O	B-Entity
)	O	O	O
on	O	O	O
productivity	O	O	B-Entity
in	O	O	O
Australia	O	O	B-Entity
.	O	O	O

We	O	O	O
used	O	O	O
a	O	O	O
multi-state	O	O	B-Entity
lifetable	O	O	I-Entity
Markov	O	O	I-Entity
model	O	O	I-Entity
to	O	O	O
examine	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
impact	O	O	B-Entity
of	O	O	O
an	O	O	O
additional	O	O	B-Entity
20	O	O	O
%	O	O	O
tax	O	O	B-Entity
on	O	O	O
SSBs	O	O	B-Entity
on	O	O	O
total	O	O	B-Entity
lifetime	O	O	I-Entity
productivity	O	O	B-Entity
in	O	O	O
the	O	O	O
paid	O	O	B-Entity
and	O	O	I-Entity
unpaid	O	O	I-Entity
sectors	O	O	I-Entity
of	O	O	O
the	O	O	O
economy	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
population	O	O	I-Entity
consisted	O	O	O
of	O	O	O
Australians	O	O	B-Entity
aged	O	O	B-Entity
20	O	O	O
years	O	O	B-Entity
or	O	O	O
older	O	O	B-Entity
in	O	O	O
2010	O	O	O
,	O	O	O
whose	O	O	O
health	O	O	B-Entity
and	O	O	O
other	O	O	O
relevant	O	O	B-Entity
outcomes	O	O	B-Entity
were	O	O	O
modelled	O	O	B-Entity
over	O	O	O
their	O	O	O
remaining	O	O	B-Entity
lifetime	O	O	B-Entity
.	O	O	O

The	O	O	O
SSBs	O	O	B-Entity
tax	O	O	B-Entity
was	O	O	O
estimated	O	O	B-Entity
to	O	O	O
reduce	O	O	B-Entity
the	O	O	O
number	O	O	B-Entity
of	O	O	O
people	O	O	B-Entity
with	O	O	O
obesity	O	O	B-Entity
by	O	O	O
1.96	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
entire	O	O	O
population	O	O	B-Entity
(	O	O	O
437,000	O	O	O
fewer	O	O	O
persons	O	O	B-Entity
with	O	O	O
obesity	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
reduce	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
employees	O	O	B-Entity
with	O	O	O
obesity	O	O	O
by	O	O	O
317,000	O	O	O
persons	O	O	O
.	O	O	O

These	O	O	O
effects	O	O	B-Entity
translated	O	O	O
into	O	O	O
productivity	O	O	B-Entity
gains	O	O	B-Entity
in	O	O	O
the	O	O	O
paid	O	O	B-Entity
sector	O	O	I-Entity
of	O	O	O
AU$751	O	O	O
million	O	O	B-Entity
for	O	O	O
the	O	O	O
working	O	O	B-Entity
-	O	O	O
age	O	O	B-Entity
population	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
:	O	O	O
AU$565	O	O	O
million	O	O	O
to	O	O	O
AU$954	O	O	O
million	O	O	O
)	O	O	O
,	O	O	O
using	O	O	O
the	O	O	O
human	O	O	B-Entity
capital	O	O	I-Entity
approach	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
unpaid	O	O	B-Entity
sector	O	O	I-Entity
,	O	O	O
the	O	O	O
potential	O	O	B-Entity
productivity	O	O	B-Entity
gains	O	O	B-Entity
amounted	O	O	B-Entity
to	O	O	O
AU$1172	O	O	O
million	O	O	B-Entity
(	O	O	O
AU$929	O	O	O
million	O	O	O
to	O	O	O
AU$1435	O	O	O
million	O	O	O
)	O	O	O
using	O	O	O
the	O	O	O
replacement	O	O	B-Entity
cost	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

These	O	O	O
productivity	O	O	B-Entity
benefits	O	O	B-Entity
are	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
the	O	O	O
health	O	O	B-Entity
benefits	O	O	I-Entity
of	O	O	O
35,000	O	O	O
life	O	O	B-Entity
years	O	O	I-Entity
gained	O	O	B-Entity
and	O	O	O
a	O	O	O
reduction	O	O	B-Entity
in	O	O	O
healthcare	O	O	B-Entity
costs	O	O	I-Entity
of	O	O	O
AU$425	O	O	O
million	O	O	B-Entity
.	O	O	O

An	O	O	O
additional	O	O	B-Entity
20	O	O	O
%	O	O	O
tax	O	O	B-Entity
on	O	O	O
SSBs	O	O	B-Entity
not	O	O	O
only	O	O	O
improves	O	O	B-Entity
health	O	O	B-Entity
outcomes	O	O	I-Entity
and	O	O	O
reduces	O	O	B-Entity
healthcare	O	O	B-Entity
costs	O	O	I-Entity
,	O	O	O
but	O	O	O
provides	O	O	O
productivity	O	O	B-Entity
gains	O	O	B-Entity
in	O	O	O
both	O	O	O
the	O	O	O
paid	O	O	B-Entity
and	O	O	I-Entity
unpaid	O	O	I-Entity
sectors	O	O	I-Entity
of	O	O	O
the	O	O	O
economy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28421026)

Keeping	O	O	O
the	O	O	O
Spirits	O	O	O
Up	O	O	O
:	O	O	O
The	O	O	O
Effect	O	O	B-Entity
of	O	O	O
Teachers	O	O	B-Entity
'	O	O	I-Entity
and	O	O	O
Parents	O	O	B-Entity
'	O	O	I-Entity
Emotional	O	O	B-Entity
Support	O	O	I-Entity
on	O	O	O
Children	O	O	B-Entity
's	O	O	I-Entity
Working	O	O	B-Entity
Memory	O	O	I-Entity
Performance	O	O	O

Working	O	O	B-Entity
memory	O	O	I-Entity
,	O	O	O
used	O	O	O
to	O	O	O
temporarily	O	O	B-Entity
store	O	O	I-Entity
and	O	O	O
mentally	O	O	O
manipulate	O	O	O
information	O	O	B-Entity
,	O	O	O
is	O	O	O
important	O	O	O
for	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
learning	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
therefore	O	O	O
valuable	O	O	O
to	O	O	O
understand	O	O	O
which	O	O	O
(	O	O	O
contextual	O	O	O
)	O	O	O
factors	O	O	B-Entity
promote	O	O	B-Entity
or	O	O	O
hinder	O	O	B-Entity
working	O	O	B-Entity
memory	O	O	I-Entity
performance	O	O	B-Entity
.	O	O	O

Recent	O	O	O
research	O	O	B-Entity
shows	O	O	O
positive	O	O	B-Entity
associations	O	O	B-Entity
between	O	O	O
positive	O	O	O
parent-child	O	O	B-Entity
and	O	O	O
teacher-student	O	O	B-Entity
interactions	O	O	I-Entity
and	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
performance	O	O	B-Entity
and	O	O	O
development	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
no	O	O	O
study	O	O	B-Entity
has	O	O	O
yet	O	O	O
experimentally	O	O	B-Entity
investigated	O	O	I-Entity
how	O	O	O
parents	O	O	B-Entity
and	O	O	O
teachers	O	O	B-Entity
affect	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
performance	O	O	B-Entity
.	O	O	O

Based	O	O	O
on	O	O	O
attachment	O	O	B-Entity
theory	O	O	I-Entity
,	O	O	O
the	O	O	O
current	O	O	O
study	O	O	B-Entity
investigated	O	O	B-Entity
the	O	O	O
role	O	O	O
of	O	O	O
parent	O	O	B-Entity
and	O	O	O
teacher	O	O	B-Entity
emotional	O	O	B-Entity
support	O	O	I-Entity
in	O	O	O
promoting	O	O	B-Entity
working	O	O	B-Entity
memory	O	O	I-Entity
performance	O	O	B-Entity
by	O	O	O
buffering	O	O	O
the	O	O	O
negative	O	O	B-Entity
effect	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

Questionnaires	O	O	B-Entity
and	O	O	O
an	O	O	O
experimental	O	O	B-Entity
session	O	O	I-Entity
were	O	O	O
completed	O	O	O
by	O	O	O
170	O	O	O
children	O	O	B-Entity
from	O	O	O
grade	O	O	O
1	O	O	O
to	O	O	O
2	O	O	O
(	O	O	O
Mage	O	O	O
=	O	O	O
7	O	O	O
years	O	O	B-Entity
6	O	O	O
months	O	O	B-Entity
,	O	O	O
SD	O	O	O
=	O	O	O
7	O	O	O
months	O	O	O
)	O	O	O
.	O	O	O

Questionnaires	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
assess	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
perceptions	O	O	B-Entity
of	O	O	O
the	O	O	O
teacher-student	O	O	B-Entity
and	O	O	O
parent-child	O	O	B-Entity
relationship	O	O	I-Entity
.	O	O	O

During	O	O	O
an	O	O	O
experimental	O	O	B-Entity
session	O	O	I-Entity
,	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
was	O	O	O
measured	O	O	O
with	O	O	O
the	O	O	O
Corsi	O	O	B-Entity
task	O	O	I-Entity
backward	O	O	I-Entity
(	O	O	O
Milner	O	O	O
,	O	O	O
1971	O	O	O
)	O	O	O
in	O	O	O
a	O	O	O
pre-	O	O	B-Entity
and	O	O	O
post-test	O	O	B-Entity
design	O	O	I-Entity
.	O	O	O

In-between	O	O	O
the	O	O	O
tests	O	O	B-Entity
stress	O	O	B-Entity
was	O	O	O
induced	O	O	B-Entity
in	O	O	O
the	O	O	O
children	O	O	B-Entity
using	O	O	O
the	O	O	O
Cyberball	O	O	B-Entity
paradigm	O	O	I-Entity
(	O	O	O
Williams	O	O	O
et	O	O	O
al.	O	O	O
,	O	O	O
2000	O	O	O
)	O	O	O
.	O	O	O

Emotional	O	O	B-Entity
support	O	O	I-Entity
was	O	O	O
manipulated	O	O	B-Entity
(	O	O	O
between-subjects	O	O	O
)	O	O	O
through	O	O	O
an	O	O	O
audio	O	O	B-Entity
message	O	O	B-Entity
(	O	O	O
either	O	O	O
a	O	O	O
weather	O	O	B-Entity
report	O	O	B-Entity
,	O	O	O
a	O	O	O
supportive	O	O	B-Entity
message	O	O	O
of	O	O	O
a	O	O	O
stranger	O	O	B-Entity
,	O	O	O
a	O	O	O
supportive	O	O	O
message	O	O	O
of	O	O	O
a	O	O	O
parent	O	O	B-Entity
,	O	O	O
or	O	O	O
a	O	O	O
supportive	O	O	O
message	O	O	O
of	O	O	O
a	O	O	O
teacher	O	O	B-Entity
)	O	O	O
.	O	O	O

Results	O	O	B-Entity
of	O	O	O
repeated	O	O	B-Entity
measures	O	O	I-Entity
ANOVA	O	O	B-Entity
showed	O	O	O
no	O	O	O
clear	O	O	O
effect	O	O	B-Entity
of	O	O	O
the	O	O	O
stress	O	O	B-Entity
induction	O	O	B-Entity
.	O	O	O

Nevertheless	O	O	O
,	O	O	O
an	O	O	O
effect	O	O	B-Entity
of	O	O	O
parent	O	O	B-Entity
and	O	O	O
teacher	O	O	B-Entity
support	O	O	B-Entity
was	O	O	O
found	O	O	O
and	O	O	O
depended	O	O	O
on	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
parent-child	O	O	B-Entity
relationship	O	O	I-Entity
.	O	O	O

When	O	O	O
children	O	O	B-Entity
had	O	O	O
a	O	O	O
positive	O	O	B-Entity
relationship	O	O	B-Entity
with	O	O	O
their	O	O	O
parent	O	O	B-Entity
,	O	O	O
support	O	O	B-Entity
of	O	O	O
parents	O	O	B-Entity
and	O	O	O
teachers	O	O	B-Entity
had	O	O	O
little	O	O	O
effect	O	O	B-Entity
on	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
performance	O	O	B-Entity
.	O	O	O

When	O	O	O
children	O	O	B-Entity
had	O	O	O
a	O	O	O
negative	O	O	B-Entity
relationship	O	O	B-Entity
with	O	O	O
their	O	O	O
parent	O	O	B-Entity
,	O	O	O
a	O	O	O
supportive	O	O	B-Entity
message	O	O	B-Entity
of	O	O	O
that	O	O	O
parent	O	O	O
decreased	O	O	O
working	O	O	B-Entity
memory	O	O	I-Entity
performance	O	O	B-Entity
,	O	O	O
while	O	O	O
a	O	O	O
supportive	O	O	O
message	O	O	O
from	O	O	O
the	O	O	O
teacher	O	O	B-Entity
increased	O	O	O
performance	O	O	O
.	O	O	O

In	O	O	O
sum	O	O	O
,	O	O	O
the	O	O	O
current	O	O	O
study	O	O	B-Entity
suggests	O	O	O
that	O	O	O
parents	O	O	B-Entity
and	O	O	O
teachers	O	O	B-Entity
can	O	O	O
support	O	O	B-Entity
working	O	O	B-Entity
memory	O	O	I-Entity
performance	O	O	B-Entity
by	O	O	O
being	O	O	O
supportive	O	O	B-Entity
for	O	O	O
the	O	O	O
child	O	O	B-Entity
.	O	O	O

Teacher	O	O	B-Entity
support	O	O	B-Entity
is	O	O	O
most	O	O	O
effective	O	O	B-Entity
when	O	O	O
the	O	O	O
child	O	O	B-Entity
has	O	O	O
a	O	O	O
negative	O	O	B-Entity
relationship	O	O	B-Entity
with	O	O	O
the	O	O	O
parent	O	O	B-Entity
.	O	O	O

These	O	O	O
insights	O	O	O
can	O	O	O
give	O	O	O
direction	O	O	O
to	O	O	O
specific	O	O	O
measures	O	O	O
aimed	O	O	O
at	O	O	O
preventing	O	O	B-Entity
and	O	O	O
resolving	O	O	B-Entity
working	O	O	B-Entity
memory	O	O	I-Entity
problems	O	O	B-Entity
and	O	O	O
related	O	O	O
issues	O	O	B-Entity
.	O	O	O

-DOCSTART- (28424445)

Management	O	O	B-Entity
of	O	O	O
tachyarrhythmia	O	O	B-Entity
during	O	O	O
pregnancy	O	O	O

Maternal	O	O	B-Entity
tachyarrhythmia	O	O	B-Entity
is	O	O	O
a	O	O	O
common	O	O	B-Entity
complication	O	O	B-Entity
during	O	O	O
pregnancy	O	O	B-Entity
due	O	O	O
to	O	O	O
hormonal	O	O	B-Entity
changes	O	O	I-Entity
that	O	O	O
enhance	O	O	B-Entity
pre-existing	O	O	B-Entity
arrhythmias	O	O	B-Entity
or	O	O	O
induce	O	O	B-Entity
new	O	O	O
arrhythmias	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
congenital	O	O	B-Entity
heart	O	O	I-Entity
defects	O	O	I-Entity
in	O	O	O
pregnant	O	O	B-Entity
females	O	O	I-Entity
.	O	O	O

Presence	O	O	B-Entity
of	O	O	O
tachyarrhythmia	O	O	B-Entity
during	O	O	O
pregnancy	O	O	B-Entity
poses	O	O	O
risk	O	O	B-Entity
to	O	O	O
the	O	O	O
mother	O	O	B-Entity
and	O	O	O
fetus	O	O	B-Entity
,	O	O	O
calling	O	O	B-Entity
for	O	O	O
proper	O	O	B-Entity
treatment	O	O	I-Entity
with	O	O	O
medications	O	O	B-Entity
.	O	O	O

Use	O	O	O
of	O	O	O
antiarrhythmic	O	O	B-Entity
drugs	O	O	I-Entity
in	O	O	O
cases	O	O	O
of	O	O	O
maternal	O	O	B-Entity
tachyarrhythmia	O	O	B-Entity
must	O	O	O
give	O	O	O
due	O	O	O
consideration	O	O	B-Entity
of	O	O	O
potential	O	O	B-Entity
teratogenic	O	O	B-Entity
side	O	O	I-Entity
effects	O	O	I-Entity
.	O	O	O

Utilization	O	O	B-Entity
of	O	O	O
antiarrhythmic	O	O	B-Entity
drugs	O	O	I-Entity
during	O	O	O
pregnancy	O	O	B-Entity
has	O	O	O
been	O	O	O
well	O	O	O
studied	O	O	B-Entity
;	O	O	O
some	O	O	O
result	O	O	B-Entity
in	O	O	O
minimal	O	O	B-Entity
fetal	O	O	B-Entity
harm	O	O	B-Entity
or	O	O	O
none	O	O	O
at	O	O	O
all	O	O	O
.	O	O	O

New	O	O	O
techniques	O	O	B-Entity
,	O	O	O
such	O	O	O
as	O	O	O
cardiac	O	O	B-Entity
ablation	O	O	I-Entity
,	O	O	O
have	O	O	O
also	O	O	O
been	O	O	O
implemented	O	O	B-Entity
with	O	O	O
minimal	O	O	B-Entity
or	O	O	O
no	O	O	O
radiation	O	O	B-Entity
exposure	O	O	I-Entity
to	O	O	O
the	O	O	O
fetus	O	O	B-Entity
or	O	O	O
mother	O	O	B-Entity
.	O	O	O

Pregnant	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
tachyarrhythmia	O	O	B-Entity
have	O	O	O
been	O	O	O
successfully	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
little	O	O	B-Entity
to	O	O	O
no	O	O	O
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
developing	O	O	B-Entity
fetus	O	O	I-Entity
as	O	O	O
result	O	O	B-Entity
of	O	O	O
increasing	O	O	B-Entity
experience	O	O	B-Entity
with	O	O	O
antiarrhythmic	O	O	B-Entity
drugs	O	O	I-Entity
and	O	O	O
progress	O	O	B-Entity
of	O	O	O
new	O	O	O
procedural	O	O	B-Entity
techniques	O	O	B-Entity
.	O	O	O

-DOCSTART- (28424584)

Hif-1α	O	O	B-Entity
Overexpression	O	O	B-Entity
Improves	O	O	B-Entity
Transplanted	O	O	B-Entity
Bone	O	O	I-Entity
Mesenchymal	O	O	I-Entity
Stem	O	O	I-Entity
Cells	O	O	I-Entity
Survival	O	O	B-Entity
in	O	O	O
Rat	O	O	O
MCAO	O	O	O
Stroke	O	O	O
Model	O	O	O

Bone	O	O	B-Entity
mesenchymal	O	O	I-Entity
stem	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
BMSCs	O	O	B-Entity
)	O	O	O
death	O	O	B-Entity
after	O	O	O
transplantation	O	O	B-Entity
is	O	O	O
a	O	O	O
serious	O	O	O
obstacle	O	O	O
impacting	O	O	O
on	O	O	O
the	O	O	O
outcome	O	O	O
of	O	O	O
cell	O	O	B-Entity
therapy	O	O	I-Entity
for	O	O	O
cerebral	O	O	B-Entity
infarction	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
was	O	O	O
aimed	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
modification	O	O	B-Entity
of	O	O	O
BMSCs	O	O	B-Entity
with	O	O	O
hypoxia-inducible	O	O	B-Entity
factor	O	O	I-Entity
1α	O	O	I-Entity
(	O	O	O
Hif-1α	O	O	B-Entity
)	O	O	O
could	O	O	O
enhance	O	O	B-Entity
the	O	O	O
survival	O	O	B-Entity
of	O	O	O
the	O	O	O
implanted	O	O	B-Entity
BMSCs	O	O	I-Entity
.	O	O	O

BMSCs	O	O	B-Entity
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
Wistar	O	O	B-Entity
rats	O	O	I-Entity
,	O	O	O
and	O	O	O
were	O	O	O
infected	O	O	B-Entity
with	O	O	O
Hif-1α-GFP	O	O	B-Entity
lentiviral	O	O	I-Entity
vector	O	O	I-Entity
or	O	O	O
Hif-1α	O	O	B-Entity
siRNA	O	O	I-Entity
.	O	O	O

The	O	O	O
modified	O	O	B-Entity
BMSCs	O	O	B-Entity
were	O	O	O
exposed	O	O	O
to	O	O	O
oxygen-glucose	O	O	B-Entity
deprivation	O	O	I-Entity
(	O	O	I-Entity
OGD	O	O	I-Entity
)	O	O	I-Entity
condition	O	O	I-Entity
,	O	O	O
cellular	O	O	B-Entity
viability	O	O	I-Entity
and	O	O	O
apoptosis	O	O	B-Entity
were	O	O	O
then	O	O	O
assessed	O	O	B-Entity
.	O	O	O

An	O	O	O
inhibitor	O	O	B-Entity
of	O	O	O
AMPK	O	O	B-Entity
(	O	O	O
compound	O	O	B-Entity
C	O	O	I-Entity
)	O	O	O
was	O	O	O
used	O	O	O
to	O	O	O
detect	O	O	B-Entity
whether	O	O	O
AMPK	O	O	O
and	O	O	O
mTOR	O	O	B-Entity
were	O	O	O
implicated	O	O	O
in	O	O	O
the	O	O	O
functions	O	O	O
of	O	O	O
Hif-1α	O	O	B-Entity
on	O	O	O
BMSCs	O	O	B-Entity
survival	O	O	I-Entity
.	O	O	O

Besides	O	O	O
,	O	O	O
ultrastructure	O	O	O
of	O	O	O
BMSCs	O	O	B-Entity
was	O	O	O
observed	O	O	O
and	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	I-Entity
autophagy	O	O	I-Entity
markers	O	O	I-Entity
was	O	O	O
measured	O	O	O
.	O	O	O

The	O	O	O
modified	O	O	B-Entity
BMSCs	O	O	B-Entity
were	O	O	O
transplanted	O	O	B-Entity
into	O	O	O
middle	O	O	B-Entity
cerebral	O	O	I-Entity
artery	O	O	I-Entity
occlusion	O	O	I-Entity
(	O	O	O
MCAO	O	O	B-Entity
)	O	O	O
model	O	O	B-Entity
of	O	O	I-Entity
rats	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
cerebral	O	O	B-Entity
infarction	O	O	I-Entity
volume	O	O	B-Entity
and	O	O	O
neurological	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
.	O	O	O

The	O	O	O
results	O	O	O
indicated	O	O	O
that	O	O	O
Hif-1α	O	O	B-Entity
overexpression	O	O	I-Entity
protected	O	O	O
OGD	O	O	B-Entity
induced	O	O	B-Entity
injury	O	O	B-Entity
by	O	O	O
promoting	O	O	O
cellular	O	O	B-Entity
viability	O	O	I-Entity
and	O	O	O
inhibiting	O	O	B-Entity
apoptosis	O	O	B-Entity
.	O	O	O

AMPK	O	O	B-Entity
was	O	O	O
activated	O	O	O
while	O	O	O
mTOR	O	O	B-Entity
was	O	O	O
inactivated	O	O	B-Entity
by	O	O	O
Hif-1α	O	O	B-Entity
overexpression	O	O	I-Entity
,	O	O	O
and	O	O	O
that	O	O	O
might	O	O	O
be	O	O	O
through	O	O	O
which	O	O	O
Hif-1α	O	O	O
functioned	O	O	O
BMSCs	O	O	B-Entity
survival	O	O	I-Entity
.	O	O	O

Hif-1α	O	O	B-Entity
overexpression	O	O	I-Entity
promoted	O	O	O
autophagy	O	O	B-Entity
;	O	O	O
more	O	O	O
important	O	O	O
,	O	O	O
compound	O	O	B-Entity
C	O	O	I-Entity
abolished	O	O	O
the	O	O	O
induction	O	O	B-Entity
of	O	O	I-Entity
Hif-1α	O	O	I-Entity
on	O	O	O
autophagy	O	O	O
.	O	O	O

Transplantation	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
overexpressed	O	O	I-Entity
Hif-1α	O	O	I-Entity
of	O	O	I-Entity
BMSCs	O	O	I-Entity
into	O	O	O
the	O	O	O
MCAO	O	O	B-Entity
rats	O	O	I-Entity
reduced	O	O	O
brain	O	O	B-Entity
infarct	O	O	I-Entity
volume	O	O	B-Entity
and	O	O	O
improved	O	O	B-Entity
neurobehavioral	O	O	B-Entity
outcome	O	O	I-Entity
;	O	O	O
besides	O	O	O
,	O	O	O
it	O	O	O
inhibited	O	O	O
pro-inflammatory	O	O	B-Entity
cytokines	O	O	I-Entity
generation	O	O	O
while	O	O	O
promoted	O	O	O
neurotrophin	O	O	B-Entity
secretion	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
Hif-1α	O	O	B-Entity
might	O	O	O
be	O	O	O
contributed	O	O	O
in	O	O	O
the	O	O	O
survival	O	O	B-Entity
of	O	O	I-Entity
BMSCs	O	O	I-Entity
by	O	O	O
regulating	O	O	O
the	O	O	O
activation	O	O	B-Entity
of	O	O	I-Entity
AMPK	O	O	I-Entity
and	O	O	I-Entity
mTOR	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
by	O	O	O
promoting	O	O	O
autophagy	O	O	B-Entity
.	O	O	O

-DOCSTART- (28425183)

Associations	O	O	B-Entity
between	O	O	O
major	O	O	B-Entity
life	O	O	I-Entity
events	O	O	I-Entity
and	O	O	O
adherence	O	O	B-Entity
,	O	O	O
glycemic	O	O	B-Entity
control	O	O	I-Entity
,	O	O	I-Entity
and	O	O	O
psychosocial	O	O	B-Entity
characteristics	O	O	I-Entity
in	O	O	O
teens	O	O	B-Entity
with	O	O	O
type	O	O	O
1	O	O	O
diabetes	O	O	O

This	O	O	O
cross-sectional	O	O	B-Entity
study	O	O	I-Entity
assessed	O	O	B-Entity
the	O	O	O
type	O	O	O
of	O	O	O
major	O	O	B-Entity
life	O	O	I-Entity
events	O	O	I-Entity
occurring	O	O	O
in	O	O	O
a	O	O	O
contemporary	O	O	O
sample	O	O	O
of	O	O	O
teens	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
and	O	O	O
the	O	O	O
association	O	O	B-Entity
between	O	O	O
event	O	O	B-Entity
frequency	O	O	I-Entity
and	O	O	O
demographic	O	O	B-Entity
,	O	O	O
diabetes	O	O	B-Entity
management	O	O	I-Entity
,	O	O	O
and	O	O	O
psychosocial	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

Parents	O	O	B-Entity
of	O	O	O
178	O	O	O
teens	O	O	B-Entity
completed	O	O	O
the	O	O	O
Life	O	O	B-Entity
Events	O	O	I-Entity
Checklist	O	O	B-Entity
to	O	O	O
report	O	O	O
major	O	O	O
events	O	O	B-Entity
teens	O	O	O
had	O	O	O
experienced	O	O	B-Entity
in	O	O	O
the	O	O	O
last	O	O	O
year	O	O	B-Entity
:	O	O	O
42	O	O	O
%	O	O	O
experienced	O	O	O
0	O	O	O
to	O	O	O
1	O	O	O
event	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
75	O	O	O
)	O	O	O
,	O	O	O
32	O	O	O
%	O	O	O
experienced	O	O	O
2	O	O	O
to	O	O	O
3	O	O	O
events	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
57	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
26	O	O	O
%	O	O	O
experienced	O	O	O
4	O	O	O
+	O	O	O
events	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
46	O	O	O
)	O	O	O
.	O	O	O

Teens	O	O	B-Entity
and	O	O	O
parents	O	O	B-Entity
completed	O	O	O
validated	O	O	O
measures	O	O	B-Entity
of	O	O	O
treatment	O	O	B-Entity
adherence	O	O	I-Entity
,	O	O	O
diabetes	O	O	B-Entity
-specific	O	O	O
self-efficacy	O	O	B-Entity
,	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
,	O	O	O
and	O	O	O
diabetes	O	O	O
-specific	O	O	O
family	O	O	B-Entity
conflict	O	O	I-Entity
.	O	O	O

Parent-youth	O	O	B-Entity
interview	O	O	I-Entity
and	O	O	O
chart	O	O	B-Entity
review	O	O	I-Entity
provided	O	O	O
demographics	O	O	B-Entity
and	O	O	O
diabetes	O	O	B-Entity
management	O	O	I-Entity
data	O	O	O
.	O	O	O

Mean	O	O	O
number	O	O	O
of	O	O	O
events	O	O	B-Entity
/	O	O	O
teen	O	O	B-Entity
was	O	O	O
2.6	O	O	O
±	O	O	O
2.7	O	O	O
(	O	O	O
range	O	O	O
=	O	O	O
0	O	O	O
-	O	O	O
15	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
events	O	O	B-Entity
were	O	O	O
"	O	O	O
Hospitalization	O	O	B-Entity
of	O	O	O
a	O	O	O
family	O	O	B-Entity
member	O	O	I-Entity
"	O	O	O
(	O	O	O
24	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
"	O	O	O
Getting	O	O	B-Entity
a	O	O	I-Entity
bad	O	O	I-Entity
report	O	O	I-Entity
card	O	O	I-Entity
"	O	O	O
(	O	O	O
20	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
"	O	O	O
Serious	O	O	O
arguments	O	O	B-Entity
between	O	O	O
parents	O	O	B-Entity
"	O	O	O
(	O	O	O
19	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
"	O	O	O
Serious	O	O	B-Entity
illness	O	O	I-Entity
/	O	O	O
injury	O	O	B-Entity
in	O	O	O
a	O	O	O
family	O	O	O
member	O	O	O
"	O	O	O
(	O	O	O
19	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Compared	O	O	O
with	O	O	O
teens	O	O	B-Entity
experiencing	O	O	O
0	O	O	O
to	O	O	O
1	O	O	O
event	O	O	B-Entity
,	O	O	O
teens	O	O	O
experiencing	O	O	O
4	O	O	O
+	O	O	O
events	O	O	B-Entity
were	O	O	O
less	O	O	O
likely	O	O	O
to	O	O	O
have	O	O	O
married	O	O	O
parents	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.01	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
parent	O	O	B-Entity
with	O	O	O
a	O	O	O
college	O	O	B-Entity
degree	O	O	I-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.006	O	O	O
)	O	O	O
.	O	O	O

Teen	O	O	B-Entity
s	O	O	O
with	O	O	O
4	O	O	O
+	O	O	O
events	O	O	B-Entity
had	O	O	O
significantly	O	O	O
poorer	O	O	O
adherence	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.002	O	O	O
teen	O	O	B-Entity
,	O	O	O
P	O	O	O
=	O	O	O
.02	O	O	O
parent	O	O	B-Entity
)	O	O	O
,	O	O	O
lower	O	O	O
self-efficacy	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.03	O	O	O
teen	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
parent	O	O	O
)	O	O	O
,	O	O	O
poorer	O	O	O
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
teen	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
parent	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
more	O	O	O
conflict	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.006	O	O	O
teen	O	O	O
,	O	O	O
P	O	O	O
=	O	O	O
.02	O	O	O
parent	O	O	O
)	O	O	O
than	O	O	O
teens	O	O	B-Entity
with	O	O	O
fewer	O	O	O
events	O	O	O
.	O	O	O

In	O	O	O
a	O	O	O
multivariate	O	O	B-Entity
model	O	O	I-Entity
(	O	O	O
R	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
=	O	O	O
0.21	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
.0001	O	O	O
)	O	O	O
controlling	O	O	O
for	O	O	O
demographic	O	O	B-Entity
and	O	O	O
diabetes	O	O	B-Entity
management	O	O	I-Entity
characteristics	O	O	O
,	O	O	O
fewer	O	O	O
events	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
lower	O	O	O
A1c	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
.0009	O	O	O
)	O	O	O
.	O	O	O

Occurrence	O	O	O
of	O	O	O
more	O	O	O
major	O	O	B-Entity
life	O	O	I-Entity
events	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
poorer	O	O	O
diabetes	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
A1c	O	O	B-Entity
and	O	O	O
more	O	O	O
negative	O	O	O
psychosocial	O	O	B-Entity
qualities	O	O	I-Entity
in	O	O	O
teens	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
1	O	O	I-Entity
diabetes	O	O	I-Entity
.	O	O	O

-DOCSTART- (28427537)

Metabolomics	O	O	B-Entity
,	O	O	O
Nutrition	O	O	B-Entity
,	O	O	O
and	O	O	O
Potential	O	O	B-Entity
Biomarkers	O	O	B-Entity
of	O	O	O
Food	O	O	B-Entity
Quality	O	O	I-Entity
,	O	O	O
Intake	O	O	B-Entity
,	O	O	O
and	O	O	O
Health	O	O	O
Status	O	O	O

Diet	O	O	B-Entity
,	O	O	O
dietary	O	O	B-Entity
patterns	O	O	I-Entity
,	O	O	O
and	O	O	O
other	O	O	O
environmental	O	O	B-Entity
factors	O	O	I-Entity
such	O	O	O
as	O	O	O
exposure	O	O	B-Entity
to	O	O	I-Entity
toxins	O	O	B-Entity
are	O	O	O
playing	O	O	O
an	O	O	O
important	O	O	O
role	O	O	B-Entity
in	O	O	O
the	O	O	O
prevention	O	O	B-Entity
/	O	O	O
development	O	O	B-Entity
of	O	O	O
many	O	O	O
diseases	O	O	B-Entity
,	O	O	O
like	O	O	O
obesity	O	O	B-Entity
,	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
,	O	O	O
and	O	O	O
consequently	O	O	O
on	O	O	O
the	O	O	O
health	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
individuals	O	O	B-Entity
.	O	O	O

A	O	O	O
major	O	O	O
challenge	O	O	O
nowadays	O	O	O
is	O	O	O
to	O	O	O
identify	O	O	B-Entity
novel	O	O	B-Entity
biomarkers	O	O	B-Entity
to	O	O	O
detect	O	O	B-Entity
as	O	O	O
early	O	O	B-Entity
as	O	O	O
possible	O	O	O
metabolic	O	O	B-Entity
dysfunction	O	O	B-Entity
and	O	O	O
to	O	O	O
predict	O	O	B-Entity
evolution	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
status	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
refine	O	O	O
nutritional	O	O	B-Entity
advices	O	O	I-Entity
to	O	O	O
specific	O	O	O
population	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

Omics	O	O	B-Entity
technologies	O	O	I-Entity
such	O	O	O
as	O	O	O
genomics	O	O	B-Entity
,	O	O	O
transcriptomics	O	O	O
,	O	O	O
proteomics	O	O	B-Entity
,	O	O	O
and	O	O	O
metabolomics	O	O	B-Entity
coupled	O	O	B-Entity
with	O	O	O
statistical	O	O	B-Entity
and	O	O	O
bioinformatics	O	O	B-Entity
tools	O	O	I-Entity
have	O	O	O
already	O	O	O
shown	O	O	O
great	O	O	O
potential	O	O	B-Entity
in	O	O	O
this	O	O	O
research	O	O	B-Entity
field	O	O	I-Entity
even	O	O	O
if	O	O	O
so	O	O	O
far	O	O	O
only	O	O	O
few	O	O	O
biomarkers	O	O	B-Entity
have	O	O	O
been	O	O	O
validated	O	O	O
.	O	O	O

For	O	O	O
the	O	O	O
past	O	O	O
two	O	O	O
decades	O	O	B-Entity
,	O	O	O
important	O	O	O
analytical	O	O	B-Entity
techniques	O	O	I-Entity
have	O	O	O
been	O	O	O
developed	O	O	B-Entity
to	O	O	O
detect	O	O	B-Entity
as	O	O	O
many	O	O	O
metabolites	O	O	B-Entity
as	O	O	O
possible	O	O	O
in	O	O	O
human	O	O	B-Entity
biofluids	O	O	B-Entity
such	O	O	O
as	O	O	O
urine	O	O	B-Entity
,	O	O	O
blood	O	O	B-Entity
,	O	O	O
and	O	O	O
saliva	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
field	O	O	O
of	O	O	O
food	O	O	B-Entity
science	O	O	I-Entity
and	O	O	O
nutrition	O	O	B-Entity
,	O	O	O
many	O	O	O
studies	O	O	B-Entity
have	O	O	O
been	O	O	O
carried	O	O	O
out	O	O	O
for	O	O	O
food	O	O	O
authenticity	O	O	B-Entity
,	O	O	O
quality	O	O	B-Entity
,	O	O	O
and	O	O	O
safety	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
for	O	O	O
food	O	O	B-Entity
processing	O	O	I-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
metabolomic	O	O	B-Entity
investigations	O	O	B-Entity
have	O	O	O
been	O	O	O
carried	O	O	O
out	O	O	O
to	O	O	O
discover	O	O	B-Entity
new	O	O	O
early	O	O	B-Entity
biomarkers	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
dysfunction	O	O	B-Entity
and	O	O	O
predictive	O	O	B-Entity
biomarkers	O	O	O
of	O	O	O
developing	O	O	O
pathologies	O	O	B-Entity
(	O	O	O
obesity	O	O	B-Entity
,	O	O	O
metabolic	O	O	B-Entity
syndrome	O	O	I-Entity
,	O	O	O
type-2	O	O	B-Entity
diabetes	O	O	I-Entity
,	O	O	O
etc	O	O	O
.	O	O	O
)	O	O	O
.	O	O	O

Great	O	O	O
emphasis	O	O	O
is	O	O	O
also	O	O	O
placed	O	O	O
in	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
methodologies	O	O	B-Entity
to	O	O	O
identify	O	O	B-Entity
and	O	O	O
validate	O	O	O
biomarkers	O	O	B-Entity
of	O	O	O
nutrients	O	O	B-Entity
exposure	O	O	B-Entity
.	O	O	O

-DOCSTART- (28428293)

Draft	O	O	B-Entity
Genome	O	O	I-Entity
Sequence	O	O	I-Entity
of	O	O	O
Bacillus	O	O	B-Entity
cereus	O	O	I-Entity
LA2007	O	O	I-Entity
,	O	O	O
a	O	O	O
Human-Pathogenic	O	O	B-Entity
Isolate	O	O	I-Entity
Harboring	O	O	O
Anthrax	O	O	B-Entity
-Like	O	O	O
Plasmids	O	O	O

We	O	O	O
present	O	O	O
the	O	O	O
genome	O	O	B-Entity
sequence	O	O	I-Entity
of	O	O	O
Bacillus	O	O	B-Entity
cereus	O	O	I-Entity
LA2007	O	O	I-Entity
,	O	O	O
a	O	O	O
strain	O	O	B-Entity
isolated	O	O	B-Entity
in	O	O	O
2007	O	O	O
from	O	O	O
a	O	O	O
fatal	O	O	B-Entity
pneumonia	O	O	I-Entity
case	O	O	B-Entity
in	O	O	O
Louisiana	O	O	B-Entity
.	O	O	O

Sequence-based	O	O	B-Entity
genome	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	B-Entity
that	O	O	O
LA2007	O	O	B-Entity
carries	O	O	B-Entity
a	O	O	O
plasmid	O	O	B-Entity
highly	O	O	O
similar	O	O	O
to	O	O	O
Bacillus	O	O	B-Entity
anthracis	O	O	I-Entity
pXO1	O	O	I-Entity
,	O	O	O
including	O	O	O
the	O	O	O
genes	O	O	B-Entity
responsible	O	O	O
for	O	O	O
the	O	O	O
production	O	O	B-Entity
and	O	O	O
regulation	O	O	B-Entity
of	O	O	O
anthrax	O	O	B-Entity
toxin	O	O	I-Entity
.	O	O	O

-DOCSTART- (28429154)

Developing	O	O	O
elite	O	O	B-Entity
Neurospora	O	O	B-Entity
crassa	O	O	I-Entity
strains	O	O	B-Entity
for	O	O	O
cellulosic	O	O	B-Entity
ethanol	O	O	B-Entity
production	O	O	I-Entity
using	O	O	O
fungal	O	O	B-Entity
breeding	O	O	O

The	O	O	O
demand	O	O	O
for	O	O	O
renewable	O	O	B-Entity
and	O	O	O
sustainable	O	O	B-Entity
energy	O	O	I-Entity
has	O	O	O
generated	O	O	B-Entity
considerable	O	O	O
interest	O	O	B-Entity
in	O	O	O
the	O	O	O
conversion	O	O	B-Entity
of	O	O	O
cellulosic	O	O	B-Entity
biomass	O	O	B-Entity
into	O	O	O
liquid	O	O	B-Entity
fuels	O	O	B-Entity
such	O	O	O
as	O	O	O
ethanol	O	O	B-Entity
using	O	O	O
a	O	O	O
filamentous	O	O	B-Entity
fungus	O	O	I-Entity
.	O	O	O

While	O	O	O
attempts	O	O	B-Entity
have	O	O	O
been	O	O	O
made	O	O	O
to	O	O	O
study	O	O	B-Entity
cellulose	O	O	B-Entity
metabolism	O	O	I-Entity
through	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
knock-out	O	O	B-Entity
mutants	O	O	B-Entity
,	O	O	O
there	O	O	O
have	O	O	O
been	O	O	O
no	O	O	O
systematic	O	O	B-Entity
effort	O	O	O
to	O	O	O
characterize	O	O	B-Entity
natural	O	O	B-Entity
variation	O	O	B-Entity
for	O	O	O
cellulose	O	O	O
metabolism	O	O	O
in	O	O	O
ecotypes	O	O	B-Entity
adapted	O	O	B-Entity
to	O	O	O
different	O	O	B-Entity
habitats	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
characterized	O	O	B-Entity
natural	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
saccharification	O	O	B-Entity
of	O	O	O
cellulose	O	O	B-Entity
and	O	O	O
fermentation	O	O	B-Entity
in	O	O	O
73	O	O	O
ecotypes	O	O	B-Entity
and	O	O	O
89	O	O	O
laboratory	O	O	B-Entity
strains	O	O	B-Entity
of	O	O	O
the	O	O	O
model	O	O	B-Entity
fungus	O	O	B-Entity
Neurospora	O	O	B-Entity
crassa	O	O	I-Entity
.	O	O	O

We	O	O	O
observed	O	O	B-Entity
significant	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
both	O	O	O
traits	O	O	B-Entity
among	O	O	O
natural	O	O	B-Entity
and	O	O	O
laboratory	O	O	B-Entity
generated	O	O	I-Entity
populations	O	O	B-Entity
,	O	O	O
with	O	O	O
some	O	O	O
elite	O	O	B-Entity
strains	O	O	B-Entity
performing	O	O	B-Entity
better	O	O	B-Entity
than	O	O	O
the	O	O	O
reference	O	O	B-Entity
strain	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
F1	O	O	B-Entity
population	O	O	B-Entity
N345	O	O	I-Entity
,	O	O	O
15	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
population	O	O	O
outperformed	O	O	O
both	O	O	O
parents	O	O	B-Entity
with	O	O	O
the	O	O	O
top	O	O	O
performing	O	O	B-Entity
strain	O	O	B-Entity
having	O	O	O
10	O	O	O
%	O	O	O
improvement	O	O	B-Entity
in	O	O	O
ethanol	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
natural	O	O	B-Entity
alleles	O	O	B-Entity
can	O	O	O
be	O	O	O
exploited	O	O	O
through	O	O	O
fungal	O	O	B-Entity
breeding	O	O	B-Entity
for	O	O	O
developing	O	O	O
elite	O	O	B-Entity
industrial	O	O	B-Entity
strains	O	O	B-Entity
for	O	O	O
bioethanol	O	O	B-Entity
production	O	O	I-Entity
.	O	O	O

-DOCSTART- (28429354)

The	O	O	O
role	O	O	O
of	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
and	O	O	O
the	O	O	O
function	O	O	O
of	O	O	O
calcitonin	O	O	B-Entity
gene-related	O	O	I-Entity
peptide	O	O	I-Entity
in	O	O	O
the	O	O	O
mechanism	O	O	O
of	O	O	O
traumatic	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
accelerating	O	O	O
fracture-healing	O	O	O

This	O	O	O
research	O	O	O
attempts	O	O	O
to	O	O	O
identify	O	O	O
the	O	O	O
part	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
plays	O	O	O
in	O	O	O
accelerated	O	O	O
fracture-healing	O	O	B-Entity
after	O	O	O
traumatic	O	O	B-Entity
brain	O	O	I-Entity
injury	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
to	O	O	O
test	O	O	O
functions	O	O	O
of	O	O	O
calcitonin	O	O	B-Entity
gene-related	O	O	I-Entity
peptide	O	O	I-Entity
(	O	O	O
CGRP	O	O	B-Entity
)	O	O	O
during	O	O	O
this	O	O	O
process	O	O	O
.	O	O	O

Experiments	O	O	O
were	O	O	O
carried	O	O	O
out	O	O	O
on	O	O	O
Male	O	O	O
Sprague-Dawley	O	O	B-Entity
rats	O	O	I-Entity
that	O	O	O
were	O	O	O
split	O	O	O
into	O	O	O
four	O	O	O
groups	O	O	B-Entity
at	O	O	O
random	O	O	O
:	O	O	O
TBI	O	O	B-Entity
-	O	O	O
fracture	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
fracture	O	O	O
-	O	O	O
only	O	O	B-Entity
group	O	O	O
,	O	O	O
TBI	O	O	O
-	O	O	O
only	O	O	O
group	O	O	O
,	O	O	O
and	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
first	O	O	O
week	O	O	O
,	O	O	O
blood	O	O	B-Entity
specimen	O	O	I-Entity
would	O	O	O
be	O	O	O
drawn	O	O	O
from	O	O	O
rats	O	O	B-Entity
among	O	O	O
the	O	O	O
groups	O	O	B-Entity
except	O	O	O
those	O	O	O
of	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
at	O	O	O
three-time	O	O	O
points	O	O	O
(	O	O	O
24	O	O	O
,	O	O	O
72	O	O	O
and	O	O	O
168	O	O	O
hours	O	O	O
)	O	O	O
post	O	O	B-Entity
-	O	O	O
damage	O	O	B-Entity
.	O	O	O

These	O	O	O
rats	O	O	B-Entity
would	O	O	O
be	O	O	O
assessed	O	O	O
from	O	O	O
the	O	O	O
neurological	O	O	B-Entity
perspective	O	O	O
based	O	O	O
on	O	O	O
their	O	O	O
grades	O	O	O
of	O	O	O
performance	O	O	O
in	O	O	O
a	O	O	O
sequence	O	O	O
of	O	O	O
tests	O	O	O
24	O	O	O
hours	O	O	O
before	O	O	O
and	O	O	O
12	O	O	O
hours	O	O	O
after	O	O	O
brain	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

Blood	O	O	B-Entity
samples	O	O	I-Entity
were	O	O	O
also	O	O	O
taken	O	O	O
from	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
24	O	O	O
hours	O	O	O
before	O	O	O
the	O	O	O
injury	O	O	B-Entity
,	O	O	O
and	O	O	O
whole	O	O	O
brain	O	O	B-Entity
tissues	O	O	I-Entity
in	O	O	O
the	O	O	O
injured	O	O	B-Entity
groups	O	O	B-Entity
were	O	O	O
harvested	O	O	B-Entity
at	O	O	O
72	O	O	O
and	O	O	O
168	O	O	O
hours	O	O	O
post	O	O	B-Entity
-	O	O	O
injury	O	O	O
.	O	O	O

We	O	O	O
compared	O	O	O
the	O	O	O
serum	O	O	B-Entity
CGRP	O	O	B-Entity
concentration	O	O	B-Entity
,	O	O	O
the	O	O	O
distribution	O	O	O
of	O	O	O
CGRP	O	O	O
,	O	O	O
the	O	O	O
CGRP	O	O	O
expression	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
expression	O	O	O
of	O	O	O
CGRP	O	O	O
in	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
,	O	O	O
the	O	O	O
expression	O	O	O
of	O	O	O
CGRP	O	O	O
in	O	O	O
the	O	O	O
hippocampus	O	O	O
,	O	O	O
the	O	O	O
expression	O	O	O
of	O	O	O
CGRP	O	O	O
in	O	O	O
the	O	O	O
hippocampus	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
expression	O	O	O
of	O	O	O
CGRP	O	O	O
in	O	O	O
the	O	O	O
brain	O	O	B-Entity
by	O	O	O
immunohistochemistry	O	O	B-Entity
,	O	O	O
Western	O	O	B-Entity
blotting	O	O	I-Entity
,	O	O	O
RT	O	O	B-Entity
-	O	O	O
Of	O	O	O
CGRP	O	O	O
RNA	O	O	B-Entity
expression	O	O	I-Entity
levels	O	O	O
.	O	O	O

Neurological	O	O	B-Entity
examinations	O	O	I-Entity
suggested	O	O	O
that	O	O	O
the	O	O	O
functions	O	O	O
of	O	O	O
the	O	O	O
cerebral	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
cerebellum	O	O	B-Entity
,	O	O	O
and	O	O	O
brain	O	O	B-Entity
stem	O	O	I-Entity
showed	O	O	O
significant	O	O	O
differences	O	O	O
pre	O	O	B-Entity
-	O	O	O
and	O	O	O
post	O	O	B-Entity
-	O	O	O
injury	O	O	B-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

ELISA	O	O	B-Entity
analysis	O	O	I-Entity
indicated	O	O	O
a	O	O	O
great	O	O	O
density	O	O	O
of	O	O	O
CGRP	O	O	B-Entity
in	O	O	O
TBI	O	O	B-Entity
-	O	O	O
fracture	O	O	B-Entity
group	O	O	B-Entity
at	O	O	O
different	O	O	O
time	O	O	O
points	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
in	O	O	O
the	O	O	O
TBI	O	O	B-Entity
-	O	O	O
fracture	O	O	B-Entity
group	O	O	B-Entity
,	O	O	O
CGRP	O	O	B-Entity
in	O	O	O
both	O	O	O
hippocampus	O	O	B-Entity
and	O	O	O
the	O	O	O
whole	O	O	B-Entity
brain	O	O	I-Entity
showed	O	O	O
a	O	O	O
noticeable	O	O	O
augment	O	O	O
in	O	O	O
RT-PCR	O	O	B-Entity
and	O	O	O
western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	I-Entity
at	O	O	O
72	O	O	O
and	O	O	O
168	O	O	O
h	O	O	O
post	O	O	B-Entity
-	O	O	O
injury	O	O	B-Entity
,	O	O	O
and	O	O	O
only	O	O	B-Entity
in	O	O	O
this	O	O	O
group	O	O	O
,	O	O	O
immunohistochemistry	O	O	B-Entity
analysis	O	O	I-Entity
indicated	O	O	O
that	O	O	O
CGRP	O	O	O
was	O	O	O
present	O	O	O
in	O	O	O
the	O	O	O
hippocampus	O	O	O
at	O	O	O
168	O	O	O
hours	O	O	O
post	O	O	O
-	O	O	O
injury	O	O	O
.	O	O	O

We	O	O	O
observed	O	O	O
that	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
and	O	O	O
CGRP	O	O	B-Entity
were	O	O	O
responsible	O	O	O
for	O	O	O
quick	O	O	O
bone-healing	O	O	B-Entity
mechanisms	O	O	O
.	O	O	O

We	O	O	O
suggest	O	O	O
a	O	O	O
role	O	O	O
for	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
in	O	O	O
accelerated	O	O	O
fracture	O	O	B-Entity
healing	O	O	I-Entity
.	O	O	O

CGRP	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
as	O	O	O
determined	O	O	O
by	O	O	O
IHC	O	O	B-Entity
,	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
observed	O	O	O
in	O	O	O
other	O	O	O
groups	O	O	B-Entity
,	O	O	O
indicating	O	O	O
that	O	O	O
the	O	O	O
hippocampus	O	O	B-Entity
may	O	O	O
be	O	O	O
the	O	O	O
specific	O	O	O
component	O	O	O
of	O	O	O
the	O	O	O
brain	O	O	B-Entity
that	O	O	O
responds	O	O	O
to	O	O	O
"	O	O	O
big	O	O	B-Entity
stress	O	O	I-Entity
"	O	O	O
.	O	O	O

-DOCSTART- (28429412)

Bone	O	O	B-Entity
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
hydrogel	O	O	B-Entity
enhances	O	O	O
osteogenic	O	O	B-Entity
differentiation	O	O	I-Entity
of	O	O	O
C2C12	O	O	B-Entity
myoblasts	O	O	I-Entity
and	O	O	O
mouse	O	O	B-Entity
primary	O	O	O
calvarial	O	O	B-Entity
cells	O	O	O

Hydrogel	O	O	B-Entity
scaffolds	O	O	I-Entity
derived	O	O	O
from	O	O	O
the	O	O	O
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
(	O	O	O
ECM	O	O	B-Entity
)	O	O	O
of	O	O	O
mammalian	O	O	B-Entity
tissues	O	O	I-Entity
have	O	O	O
been	O	O	O
successfully	O	O	O
used	O	O	O
to	O	O	O
promote	O	O	O
tissue	O	O	B-Entity
repair	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
and	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
osteogenic	O	O	B-Entity
potential	O	O	I-Entity
of	O	O	O
ECM	O	O	B-Entity
hydrogels	O	O	B-Entity
prepared	O	O	O
from	O	O	O
demineralized	O	O	B-Entity
and	O	O	O
decellularized	O	O	B-Entity
bovine	O	O	I-Entity
bone	O	O	I-Entity
in	O	O	O
the	O	O	O
presence	O	O	O
and	O	O	O
absence	O	O	O
of	O	O	O
osteogenic	O	O	B-Entity
medium	O	O	I-Entity
.	O	O	O

Culture	O	O	B-Entity
of	O	O	O
C2C12	O	O	B-Entity
and	O	O	O
mouse	O	O	B-Entity
primary	O	O	O
calvarial	O	O	B-Entity
cells	O	O	B-Entity
(	O	O	O
mPCs	O	O	B-Entity
)	O	O	O
on	O	O	O
decellularized	O	O	B-Entity
bone	O	O	I-Entity
ECM	O	O	I-Entity
(	O	O	O
bECM	O	O	B-Entity
)	O	O	O
and	O	O	O
demineralized	O	O	B-Entity
bone	O	O	I-Entity
matrix	O	O	I-Entity
(	O	O	O
DBM	O	O	B-Entity
)	O	O	O
gels	O	O	B-Entity
resulted	O	O	O
in	O	O	O
increased	O	O	O
expression	O	O	B-Entity
of	O	O	O
osteogenic	O	O	B-Entity
gene	O	O	I-Entity
markers	O	O	I-Entity
,	O	O	O
including	O	O	O
a	O	O	O
3.6-	O	O	O
and	O	O	O
13.4-fold	O	O	O
increase	O	O	O
in	O	O	O
osteopontin	O	O	B-Entity
and	O	O	O
15.7-	O	O	O
and	O	O	O
27.1-fold	O	O	O
increase	O	O	O
in	O	O	O
osteocalcin	O	O	B-Entity
when	O	O	O
mPCs	O	O	O
were	O	O	O
cultured	O	O	B-Entity
upon	O	O	O
bECM	O	O	O
with	O	O	O
basal	O	O	B-Entity
and	O	O	O
osteogenic	O	O	B-Entity
media	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

bECM	O	O	B-Entity
hydrogels	O	O	B-Entity
stimulated	O	O	O
the	O	O	O
osteogenic	O	O	B-Entity
differentiation	O	O	I-Entity
of	O	O	O
C2C12	O	O	B-Entity
and	O	O	O
mPCs	O	O	B-Entity
even	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
osteogenic	O	O	B-Entity
medium	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	O
that	O	O	O
bECM	O	O	B-Entity
hydrogel	O	O	B-Entity
scaffolds	O	O	I-Entity
may	O	O	O
have	O	O	O
great	O	O	O
utility	O	O	O
in	O	O	O
future	O	O	O
clinical	O	O	B-Entity
applications	O	O	B-Entity
for	O	O	O
bone	O	O	B-Entity
tissue	O	O	B-Entity
engineering	O	O	I-Entity
.	O	O	O

©	O	O	O
2017	O	O	O
Wiley	O	O	O
Periodicals	O	O	O
,	O	O	O
Inc.	O	O	O
J	O	O	O
Biomed	O	O	O
Mater	O	O	O
Res	O	O	O
Part	O	O	O
B	O	O	O
:	O	O	O
Appl	O	O	O
Biomater	O	O	O
,	O	O	O
2017	O	O	O
.	O	O	O

-DOCSTART- (28430341)

Prostate-specific	O	O	B-Entity
antigen	O	O	I-Entity
increase	O	O	B-Entity
during	O	O	O
dutasteride	O	O	B-Entity
to	O	O	O
indicate	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
prostate	O	O	B-Entity
biopsy	O	O	I-Entity
:	O	O	O
influence	O	O	O
of	O	O	O
prostatic	O	O	O
inflammation	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
analyze	O	O	B-Entity
the	O	O	O
significance	O	O	O
of	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
total	O	O	B-Entity
prostate-specific	O	O	I-Entity
antigen	O	O	I-Entity
(	O	O	I-Entity
PSA	O	O	I-Entity
)	O	O	I-Entity
serum	O	O	I-Entity
levels	O	O	I-Entity
despite	O	O	O
dutasteride	O	O	B-Entity
treatment	O	O	B-Entity
as	O	O	O
a	O	O	O
predictor	O	O	B-Entity
of	O	O	O
prostate	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
PC	O	O	B-Entity
)	O	O	O
at	O	O	O
biopsy	O	O	B-Entity
.	O	O	O

We	O	O	O
focused	O	O	O
our	O	O	O
attention	O	O	O
on	O	O	O
the	O	O	O
rate	O	O	B-Entity
of	O	O	O
the	O	O	O
first	O	O	O
PSA	O	O	B-Entity
increase	O	O	B-Entity
and	O	O	O
on	O	O	O
the	O	O	O
influence	O	O	O
of	O	O	O
prostatic	O	O	B-Entity
inflammation	O	O	I-Entity
.	O	O	O

From	O	O	O
2011	O	O	O
to	O	O	O
2016	O	O	O
,	O	O	O
365	O	O	O
men	O	O	B-Entity
with	O	O	O
a	O	O	O
previous	O	O	O
negative	O	O	O
prostate	O	O	B-Entity
biopsy	O	O	I-Entity
and	O	O	O
persistent	O	O	O
elevated	O	O	B-Entity
PSA	O	O	B-Entity
levels	O	O	O
received	O	O	O
dutasteride	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

The	O	O	O
population	O	O	B-Entity
was	O	O	O
followed	O	O	O
for	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
12	O	O	O
-	O	O	O
48	O	O	O
months	O	O	O
.	O	O	O

One	O	O	O
hundred	O	O	O
twelve	O	O	O
cases	O	O	O
with	O	O	O
a	O	O	O
confirmed	O	O	O
PSA	O	O	B-Entity
increase	O	O	B-Entity
>	O	O	O
0.5	O	O	O
ng/ml	O	O	O
over	O	O	O
the	O	O	O
nadir	O	O	O
value	O	O	O
during	O	O	O
the	O	O	O
follow-up	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
Group	O	O	O
A	O	O	O
and	O	O	O
underwent	O	O	O
a	O	O	O
new	O	O	O
prostate	O	O	B-Entity
biopsy	O	O	I-Entity
.	O	O	O

In	O	O	O
Group	O	O	O
A	O	O	O
,	O	O	O
the	O	O	O
PSA	O	O	B-Entity
increase	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
PC	O	O	B-Entity
at	O	O	O
the	O	O	O
re-biopsy	O	O	B-Entity
in	O	O	O
66	O	O	O
%	O	O	O
of	O	O	O
cases	O	O	O
.	O	O	O

The	O	O	O
percentage	O	O	O
of	O	O	O
PSA	O	O	B-Entity
reduction	O	O	I-Entity
after	O	O	O
6	O	O	O
months	O	O	O
of	O	O	O
treatment	O	O	B-Entity
was	O	O	O
not	O	O	O
a	O	O	O
significant	O	O	O
indicator	O	O	B-Entity
of	O	O	O
the	O	O	O
risk	O	O	O
for	O	O	O
PC	O	O	B-Entity
.	O	O	O

The	O	O	O
distribution	O	O	O
of	O	O	O
inflammatory	O	O	B-Entity
infiltrates	O	O	I-Entity
significantly	O	O	O
(	O	O	O
p<00.01	O	O	O
)	O	O	O
varied	O	O	O
from	O	O	O
positive	O	O	O
to	O	O	O
negative	O	O	O
prostate	O	O	B-Entity
biopsies	O	O	I-Entity
.	O	O	O

The	O	O	O
relative	O	O	O
risk	O	O	O
for	O	O	O
PC	O	O	B-Entity
at	O	O	O
biopsy	O	O	B-Entity
significantly	O	O	O
increase	O	O	B-Entity
d	O	O	O
according	O	O	O
to	O	O	O
PSA	O	O	B-Entity
level	O	O	O
during	O	O	O
dutasteride	O	O	B-Entity
.	O	O	O

Treatment	O	O	B-Entity
with	O	O	O
dutasteride	O	O	B-Entity
can	O	O	O
help	O	O	O
to	O	O	O
analyze	O	O	B-Entity
PSA	O	O	B-Entity
kinetic	O	O	B-Entity
.	O	O	O

A	O	O	O
persistent	O	O	O
prostatic	O	O	B-Entity
inflammation	O	O	I-Entity
is	O	O	O
a	O	O	O
factor	O	O	O
able	O	O	O
to	O	O	O
reduce	O	O	O
the	O	O	O
performance	O	O	O
of	O	O	O
PSA	O	O	B-Entity
kinetic	O	O	B-Entity
during	O	O	O
dutasteride	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

-DOCSTART- (28433844)

Neurological	O	O	B-Entity
Decline	O	O	I-Entity
in	O	O	O
an	O	O	O
Elderly	O	O	B-Entity
with	O	O	O
Repaired	O	O	B-Entity
Myelomeningocele	O	O	B-Entity
Complicated	O	O	B-Entity
with	O	O	O
Lumbar	O	O	B-Entity
Canal	O	O	I-Entity
Stenosis	O	O	I-Entity
:	O	O	O
a	O	O	O
case	O	O	O
report	O	O	O

Tethered	O	O	B-Entity
cord	O	O	I-Entity
syndrome	O	O	I-Entity
is	O	O	O
a	O	O	O
well-known	O	O	O
complication	O	O	B-Entity
after	O	O	O
myelomeningocele	O	O	B-Entity
(	O	O	O
MMC	O	O	B-Entity
)	O	O	O
repair	O	O	B-Entity
in	O	O	O
childhood	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
late	O	O	O
complications	O	O	B-Entity
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
a	O	O	O
repaired	O	O	B-Entity
MMC	O	O	B-Entity
are	O	O	O
not	O	O	O
well	O	O	O
understood	O	O	O
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
the	O	O	O
influence	O	O	B-Entity
of	O	O	O
a	O	O	O
degenerative	O	O	B-Entity
spinal	O	O	I-Entity
deformity	O	O	I-Entity
on	O	O	O
a	O	O	O
sustained	O	O	B-Entity
tethered	O	O	B-Entity
cord	O	O	I-Entity
is	O	O	O
still	O	O	O
unclear	O	O	O
.	O	O	O

A	O	O	O
63-year-old	O	O	B-Entity
man	O	O	B-Entity
with	O	O	O
a	O	O	O
repaired	O	O	B-Entity
MMC	O	O	B-Entity
presented	O	O	O
with	O	O	O
a	O	O	O
progressive	O	O	B-Entity
gait	O	O	I-Entity
disturbance	O	O	I-Entity
and	O	O	O
numbness	O	O	B-Entity
in	O	O	O
both	O	O	O
lower	O	O	B-Entity
limbs	O	O	I-Entity
.	O	O	O

Magnetic	O	O	B-Entity
resonance	O	O	I-Entity
images	O	O	I-Entity
demonstrated	O	O	O
that	O	O	O
the	O	O	O
tethered	O	O	B-Entity
spinal	O	O	I-Entity
cord	O	O	I-Entity
was	O	O	O
compressed	O	O	B-Entity
by	O	O	O
severe	O	O	B-Entity
canal	O	O	B-Entity
stenosis	O	O	I-Entity
along	O	O	O
the	O	O	O
entire	O	O	B-Entity
lumbar	O	O	I-Entity
spine	O	O	I-Entity
.	O	O	O

After	O	O	O
a	O	O	O
multi-level	O	O	B-Entity
lumbar	O	O	I-Entity
decompression	O	O	I-Entity
surgery	O	O	B-Entity
,	O	O	O
the	O	O	O
patient	O	O	B-Entity
recovered	O	O	I-Entity
to	O	O	O
baseline	O	O	B-Entity
neurological	O	O	B-Entity
status	O	O	O
.	O	O	O

In	O	O	O
adults	O	O	B-Entity
with	O	O	O
a	O	O	O
repaired	O	O	B-Entity
MMC	O	O	B-Entity
,	O	O	O
lumbar	O	O	B-Entity
canal	O	O	I-Entity
stenosis	O	O	I-Entity
should	O	O	O
be	O	O	O
investigated	O	O	B-Entity
as	O	O	O
a	O	O	O
possible	O	O	O
cause	O	O	O
of	O	O	O
late	O	O	O
neurological	O	O	B-Entity
decline	O	O	I-Entity
.	O	O	O

Clinical	O	O	O
manifestations	O	O	O
may	O	O	O
be	O	O	O
complicated	O	O	B-Entity
by	O	O	O
the	O	O	O
coexistence	O	O	O
of	O	O	O
both	O	O	O
the	O	O	O
original	O	O	O
and	O	O	O
subsequent	O	O	O
neurological	O	O	B-Entity
disorders	O	O	I-Entity
.	O	O	O

Because	O	O	O
these	O	O	O
additional	O	O	O
disorders	O	O	B-Entity
result	O	O	O
from	O	O	O
compressive	O	O	B-Entity
myelopathy	O	O	I-Entity
,	O	O	O
early	O	O	O
surgical	O	O	B-Entity
decompression	O	O	I-Entity
is	O	O	O
indicated	O	O	O
to	O	O	O
avoid	O	O	O
irreversible	O	O	O
spinal	O	O	B-Entity
cord	O	O	I-Entity
dysfunction	O	O	I-Entity
.	O	O	O

-DOCSTART- (28434897)

Epidemiology	O	O	B-Entity
of	O	O	O
polyomavirus	O	O	B-Entity
BK	O	O	I-Entity
(	O	O	O
BKV	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
emergent	O	O	B-Entity
African	O	O	B-Entity
variant	O	O	B-Entity
in	O	O	O
kidney	O	O	B-Entity
and	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
transplant	O	O	B-Entity
recipients	O	O	I-Entity
in	O	O	O
the	O	O	O
Fundacion	O	O	B-Entity
Valle	O	O	I-Entity
del	O	O	I-Entity
Lili	O	O	I-Entity
in	O	O	I-Entity
Cali	O	O	I-Entity
,	O	O	O
Colombia	O	O	O

To	O	O	O
describe	O	O	O
the	O	O	O
epidemiology	O	O	B-Entity
of	O	O	O
BKV	O	O	B-Entity
and	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
the	O	O	O
African	O	O	B-Entity
variant	O	O	B-Entity
in	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
and	O	O	O
kidney	O	O	B-Entity
transplant	O	O	I-Entity
patients	O	O	I-Entity
who	O	O	O
have	O	O	O
suspected	O	O	B-Entity
BKV	O	O	O
reactivation	O	O	B-Entity
.	O	O	O

A	O	O	O
descriptive	O	O	B-Entity
study	O	O	I-Entity
was	O	O	O
conducted	O	O	B-Entity
,	O	O	O
using	O	O	O
institutional	O	O	B-Entity
records	O	O	I-Entity
,	O	O	O
at	O	O	O
the	O	O	O
Fundación	O	O	B-Entity
Valle	O	O	I-Entity
del	O	O	I-Entity
Lili	O	O	I-Entity
,	O	O	I-Entity
Cali	O	O	I-Entity
-	O	O	O
Colombia	O	O	B-Entity
.	O	O	O

The	O	O	O
overall	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
BKV	O	O	B-Entity
during	O	O	O
the	O	O	O
study	O	O	O
period	O	O	O
was	O	O	O
51	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
African	O	O	B-Entity
variant	O	O	B-Entity
was	O	O	O
identified	O	O	B-Entity
in	O	O	O
49.4	O	O	O
%	O	O	O
of	O	O	O
samples	O	O	B-Entity
that	O	O	O
were	O	O	O
positive	O	O	B-Entity
for	O	O	O
BKV	O	O	B-Entity
.	O	O	O

50.6	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
samples	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
have	O	O	O
the	O	O	O
wild	O	O	B-Entity
strain	O	O	B-Entity
of	O	O	O
BKV	O	O	B-Entity
.	O	O	O

Among	O	O	O
BKV	O	O	B-Entity
positive	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
57	O	O	O
%	O	O	O
were	O	O	O
kidney	O	O	B-Entity
transplant	O	O	B-Entity
recipients	O	O	I-Entity
and	O	O	O
43	O	O	O
%	O	O	O
were	O	O	O
bone	O	O	B-Entity
marrow	O	O	I-Entity
transplant	O	O	O
recipients	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
epidemiological	O	O	B-Entity
study	O	O	I-Entity
describing	O	O	O
the	O	O	O
African	O	O	B-Entity
variant	O	O	B-Entity
of	O	O	O
BKV	O	O	B-Entity
in	O	O	O
Colombia	O	O	B-Entity
.	O	O	O

-DOCSTART- (28434980)

Thaw	O	O	B-Entity
-and-use	O	O	O
target	O	O	B-Entity
cells	O	O	I-Entity
pre-labeled	O	O	B-Entity
with	O	O	O
calcein	O	O	B-Entity
AM	O	O	I-Entity
for	O	O	O
antibody-dependent	O	O	O
cell-mediated	O	O	O
cytotoxicity	O	O	O
assays	O	O	O

In	O	O	B-Entity
vitro	O	O	I-Entity
antibody-dependent	O	O	B-Entity
cell-mediated	O	O	I-Entity
cytotoxicity	O	O	I-Entity
(	O	O	I-Entity
ADCC	O	O	I-Entity
)	O	O	I-Entity
assays	O	O	I-Entity
are	O	O	O
routinely	O	O	O
performed	O	O	O
to	O	O	O
support	O	O	O
the	O	O	O
research	O	O	O
and	O	O	O
development	O	O	O
of	O	O	O
therapeutic	O	O	B-Entity
antibodies	O	O	I-Entity
.	O	O	O

In	O	O	O
ADCC	O	O	B-Entity
assays	O	O	I-Entity
,	O	O	O
target	O	O	B-Entity
cells	O	O	I-Entity
bound	O	O	O
by	O	O	O
the	O	O	O
antibodies	O	O	B-Entity
are	O	O	O
lysed	O	O	B-Entity
by	O	O	O
activated	O	O	B-Entity
effector	O	O	B-Entity
cells	O	O	I-Entity
following	O	O	O
interactions	O	O	O
between	O	O	O
the	O	O	O
Fc	O	O	B-Entity
region	O	O	I-Entity
of	O	O	O
the	O	O	O
bound	O	O	O
antibody	O	O	B-Entity
and	O	O	O
Fcγ	O	O	B-Entity
receptors	O	O	I-Entity
on	O	O	O
effector	O	O	O
cells	O	O	O
.	O	O	O

Target	O	O	B-Entity
cell	O	O	I-Entity
lysis	O	O	B-Entity
is	O	O	O
typically	O	O	O
measured	O	O	O
by	O	O	O
quantification	O	O	B-Entity
of	O	O	O
released	O	O	O
endogenous	O	O	B-Entity
enzymes	O	O	B-Entity
,	O	O	O
e.g.	O	O	O
,	O	O	O
lactate	O	O	B-Entity
dehydrogenase	O	O	I-Entity
,	O	O	O
or	O	O	O
measurement	O	O	O
of	O	O	O
released	O	O	O
exogenous	O	O	B-Entity
labels	O	O	B-Entity
,	O	O	O
e.g.	O	O	O
,	O	O	O
(51)Cr	O	O	B-Entity
,	O	O	O
europium	O	O	B-Entity
or	O	O	O
calcein	O	O	B-Entity
.	O	O	O

ADCC	O	O	B-Entity
assays	O	O	I-Entity
based	O	O	O
on	O	O	O
the	O	O	O
detection	O	O	O
of	O	O	O
exogenous	O	O	B-Entity
labels	O	O	B-Entity
released	O	O	O
from	O	O	O
lysed	O	O	B-Entity
target	O	O	B-Entity
cells	O	O	I-Entity
generally	O	O	O
show	O	O	O
higher	O	O	O
sensitivity	O	O	O
and	O	O	O
require	O	O	O
shorter	O	O	O
incubation	O	O	B-Entity
times	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
target	O	O	B-Entity
cells	O	O	I-Entity
are	O	O	O
usually	O	O	O
labeled	O	O	B-Entity
immediately	O	O	O
prior	O	O	O
to	O	O	O
assay	O	O	B-Entity
,	O	O	O
which	O	O	O
inadvertently	O	O	O
introduces	O	O	O
additional	O	O	O
assay	O	O	O
variations	O	O	B-Entity
due	O	O	O
to	O	O	O
differences	O	O	O
in	O	O	O
target	O	O	B-Entity
cell	O	O	I-Entity
conditions	O	O	O
and	O	O	O
labeling	O	O	B-Entity
/	O	O	O
handling	O	O	B-Entity
processes	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
report	O	O	O
,	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
thaw	O	O	B-Entity
-and-use	O	O	O
pre-labeled	O	O	B-Entity
target	O	O	B-Entity
cells	O	O	I-Entity
for	O	O	O
ADCC	O	O	B-Entity
assays	O	O	I-Entity
.	O	O	O

Thaw	O	O	B-Entity
-and-use	O	O	O
target	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
our	O	O	O
experiments	O	O	O
were	O	O	O
pre-labeled	O	O	B-Entity
with	O	O	O
the	O	O	O
fluorescent	O	O	B-Entity
dye	O	O	I-Entity
calcein	O	O	I-Entity
AM	O	O	I-Entity
,	O	O	O
cryopreserved	O	O	B-Entity
in	O	O	O
single-use	O	O	O
aliquots	O	O	O
and	O	O	O
used	O	O	O
directly	O	O	O
in	O	O	O
assays	O	O	B-Entity
after	O	O	O
thawing	O	O	B-Entity
.	O	O	O

Upon	O	O	O
thaw	O	O	B-Entity
,	O	O	O
the	O	O	O
pre-labeled	O	O	B-Entity
cells	O	O	B-Entity
displayed	O	O	O
viability	O	O	B-Entity
and	O	O	O
label	O	O	B-Entity
retention	O	O	B-Entity
comparable	O	O	O
to	O	O	O
freshly	O	O	O
labeled	O	O	B-Entity
cells	O	O	O
,	O	O	O
responded	O	O	O
to	O	O	O
ADCC	O	O	B-Entity
mediated	O	O	O
by	O	O	O
both	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
and	O	O	O
engineered	O	O	B-Entity
natural	O	O	I-Entity
killer	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
performed	O	O	O
stably	O	O	O
for	O	O	O
at	O	O	O
least	O	O	O
3	O	O	O
years	O	O	O
and	O	O	O
provided	O	O	O
favorable	O	O	O
precision	O	O	O
and	O	O	O
accuracy	O	O	O
to	O	O	O
ADCC	O	O	B-Entity
assays	O	O	I-Entity
.	O	O	O

Implementation	O	O	O
of	O	O	O
thaw	O	O	B-Entity
-and-use	O	O	O
pre-labeled	O	O	B-Entity
target	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
ADCC	O	O	B-Entity
assays	O	O	I-Entity
can	O	O	O
help	O	O	O
to	O	O	O
alleviate	O	O	O
both	O	O	O
cell	O	O	B-Entity
culture	O	O	I-Entity
and	O	O	O
dye	O	O	B-Entity
labeling	O	O	I-Entity
derived	O	O	O
variability	O	O	O
,	O	O	O
increase	O	O	O
the	O	O	O
flexibility	O	O	O
of	O	O	O
assay	O	O	B-Entity
scheduling	O	O	O
and	O	O	O
improve	O	O	O
assay	O	O	B-Entity
consistency	O	O	I-Entity
and	O	O	O
robustness	O	O	B-Entity
.	O	O	O

-DOCSTART- (28436433)

Pathways	O	O	B-Entity
and	O	O	O
Genes	O	O	B-Entity
Associated	O	O	B-Entity
with	O	O	I-Entity
Immune	O	O	B-Entity
Dysfunction	O	O	B-Entity
in	O	O	O
Sheep	O	O	B-Entity
Paratuberculosis	O	O	O

Multibacillary	O	O	B-Entity
and	O	O	O
paucibacillary	O	O	B-Entity
paratuberculosis	O	O	B-Entity
are	O	O	O
both	O	O	O
caused	O	O	O
by	O	O	O
Mycobacterium	O	O	B-Entity
avium	O	O	I-Entity
subspecies	O	O	I-Entity
paratuberculosis	O	O	I-Entity
.	O	O	O

Multibacillary	O	O	B-Entity
lesions	O	O	B-Entity
are	O	O	O
composed	O	O	O
largely	O	O	O
of	O	O	O
infected	O	O	B-Entity
epithelioid	O	O	B-Entity
macrophages	O	O	I-Entity
and	O	O	O
paucibacillary	O	O	B-Entity
lesions	O	O	O
contain	O	O	O
T	O	O	B-Entity
cells	O	O	I-Entity
but	O	O	O
few	O	O	O
bacteria	O	O	B-Entity
.	O	O	O

Multibacillary	O	O	B-Entity
disease	O	O	B-Entity
is	O	O	O
similar	O	O	O
to	O	O	O
human	O	O	O
lepromatous	O	O	B-Entity
leprosy	O	O	I-Entity
,	O	O	O
with	O	O	O
variable/high	O	O	O
levels	O	O	O
of	O	O	O
antibody	O	O	B-Entity
and	O	O	O
a	O	O	O
dysfunctional	O	O	B-Entity
immune	O	O	B-Entity
response	O	O	I-Entity
.	O	O	O

Animals	O	O	B-Entity
with	O	O	O
paucibacillary	O	O	B-Entity
disease	O	O	B-Entity
have	O	O	O
high	O	O	O
cell-mediated	O	O	B-Entity
immunity	O	O	I-Entity
and	O	O	O
variable	O	O	B-Entity
levels	O	O	I-Entity
of	O	O	O
antibody	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	O
aims	O	O	O
to	O	O	O
characterize	O	O	O
the	O	O	O
immunological	O	O	B-Entity
dysfunction	O	O	I-Entity
using	O	O	O
TruSeq	O	O	B-Entity
analysis	O	O	B-Entity
of	O	O	O
the	O	O	O
ileocaecal	O	O	B-Entity
lymph	O	O	B-Entity
node	O	O	I-Entity
that	O	O	O
drains	O	O	O
disease	O	O	B-Entity
lesions	O	O	B-Entity
.	O	O	O

Immune	O	O	B-Entity
dysfunction	O	O	B-Entity
is	O	O	O
highlighted	O	O	O
by	O	O	O
repression	O	O	B-Entity
of	O	O	O
TCR	O	O	B-Entity
/	O	O	O
CD3	O	O	B-Entity
genes	O	O	B-Entity
,	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
co-receptors	O	O	I-Entity
/	O	O	O
co-stimulators	O	O	B-Entity
,	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
activation	O	O	I-Entity
and	O	O	O
signal-transduction	O	O	B-Entity
genes	O	O	O
.	O	O	O

Inflammation	O	O	B-Entity
was	O	O	O
an	O	O	O
acute	O	O	B-Entity
phase	O	O	I-Entity
response	O	O	I-Entity
and	O	O	O
chronic	O	O	B-Entity
inflammation	O	O	I-Entity
,	O	O	O
with	O	O	O
little	O	O	O
evidence	O	O	O
of	O	O	O
acute	O	O	B-Entity
inflammation	O	O	I-Entity
.	O	O	O

The	O	O	O
high	O	O	O
levels	O	O	O
of	O	O	O
immunoglobulin	O	O	B-Entity
and	O	O	O
plasma	O	O	B-Entity
cell	O	O	I-Entity
transcripts	O	O	B-Entity
is	O	O	O
consistent	O	O	O
with	O	O	O
the	O	O	O
anti-MAP	O	O	B-Entity
antibody	O	O	I-Entity
responses	O	O	I-Entity
in	O	O	O
paratuberculosis	O	O	B-Entity
sheep	O	O	B-Entity
.	O	O	O

Also	O	O	O
notable	O	O	O
was	O	O	O
the	O	O	O
overwhelming	O	O	O
reduction	O	O	B-Entity
in	O	O	O
mast	O	O	B-Entity
cell	O	O	I-Entity
transcripts	O	O	B-Entity
,	O	O	O
potentially	O	O	O
affecting	O	O	B-Entity
DC	O	O	B-Entity
activation	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
immune	O	O	I-Entity
response	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
also	O	O	O
shows	O	O	O
that	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
fundamental	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
gene	O	O	B-Entity
expression	O	O	I-Entity
patterns	O	O	O
in	O	O	O
multibacillary	O	O	B-Entity
and	O	O	O
paucibacillary	O	O	B-Entity
disease	O	O	B-Entity
,	O	O	O
no	O	O	O
shift	O	O	O
in	O	O	O
T	O	O	B-Entity
cell	O	O	I-Entity
genes	O	O	B-Entity
from	O	O	O
Th1	O	O	B-Entity
to	O	O	O
Th2	O	O	B-Entity
pattern	O	O	O
but	O	O	O
rather	O	O	O
an	O	O	O
incremental	O	O	B-Entity
decline	O	O	O
into	O	O	O
immune	O	O	B-Entity
dysfunction	O	O	B-Entity
leading	O	O	O
to	O	O	O
multibacillary	O	O	O
pathology	O	O	B-Entity
.	O	O	O

-DOCSTART- (28437582)

Modified	O	O	B-Entity
frailty	O	O	B-Entity
index	O	O	I-Entity
predicts	O	O	B-Entity
postoperative	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
gastrointestinal	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	O

Frailty	O	O	B-Entity
disproportionately	O	O	B-Entity
impacts	O	O	B-Entity
older	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
gastrointestinal	O	O	B-Entity
cancer	O	O	I-Entity
,	O	O	O
rendering	O	O	B-Entity
them	O	O	O
at	O	O	O
increased	O	O	B-Entity
risk	O	O	I-Entity
for	O	O	I-Entity
poor	O	O	I-Entity
outcomes	O	O	I-Entity
.	O	O	O

A	O	O	O
frailty	O	O	B-Entity
index	O	O	I-Entity
may	O	O	O
aid	O	O	O
in	O	O	O
preoperative	O	O	B-Entity
risk	O	O	B-Entity
stratification	O	O	B-Entity
.	O	O	O

We	O	O	O
hypothesized	O	O	B-Entity
that	O	O	O
high	O	O	O
modified	O	O	B-Entity
frailty	O	O	I-Entity
index	O	O	I-Entity
(	O	O	I-Entity
mFI	O	O	I-Entity
)	O	O	I-Entity
scores	O	O	I-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
adverse	O	O	B-Entity
outcomes	O	O	I-Entity
after	O	O	O
tumor	O	O	B-Entity
resection	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
,	O	O	O
gastrointestinal	O	O	B-Entity
cancer	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
(	O	O	O
60	O	O	B-Entity
-	O	O	I-Entity
90	O	O	I-Entity
years	O	O	I-Entity
old	O	O	I-Entity
)	O	O	O
who	O	O	O
underwent	O	O	B-Entity
gastrointestinal	O	O	B-Entity
tumor	O	O	I-Entity
resection	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
the	O	O	O
2005	O	O	O
-	O	O	O
2012	O	O	O
NSQIP	O	O	B-Entity
Participant	O	O	B-Entity
Use	O	O	O
File	O	O	O
.	O	O	O

mFI	O	O	B-Entity
was	O	O	O
defined	O	O	O
by	O	O	O
11	O	O	O
previously	O	O	B-Entity
described	O	O	B-Entity
,	O	O	O
preoperative	O	O	B-Entity
variables	O	O	B-Entity
.	O	O	O

Frailty	O	O	B-Entity
was	O	O	O
defined	O	O	O
by	O	O	O
an	O	O	O
mFI	O	O	B-Entity
score	O	O	I-Entity
>	O	O	O
0.27	O	O	O
.	O	O	O

The	O	O	O
postoperative	O	O	B-Entity
course	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
using	O	O	O
univariate	O	O	B-Entity
and	O	O	O
multivariate	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

41	O	O	O
455	O	O	O
patients	O	O	B-Entity
(	O	O	O
mean	O	O	O
age	O	O	O
72.4	O	O	O
years	O	O	O
,	O	O	O
47.4	O	O	O
%	O	O	O
female	O	O	B-Entity
)	O	O	O
were	O	O	O
identified	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
prevalent	O	O	B-Entity
form	O	O	I-Entity
of	O	O	O
cancer	O	O	B-Entity
was	O	O	O
colorectal	O	O	B-Entity
(	O	O	O
69.3	O	O	O
%	O	O	O
,	O	O	O
n	O	O	O
=	O	O	O
28	O	O	O
708	O	O	O
)	O	O	O
and	O	O	O
2.8	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
were	O	O	O
frail	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
1,164	O	O	O
)	O	O	O
.	O	O	O

Frail	O	O	B-Entity
patients	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
more	O	O	B-Entity
likely	O	O	I-Entity
to	O	O	O
have	O	O	O
increased	O	O	B-Entity
length	O	O	I-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
(	O	O	O
11.7	O	O	O
vs	O	O	O
9.0	O	O	O
days	O	O	O
)	O	O	O
,	O	O	O
major	O	O	B-Entity
complications	O	O	B-Entity
(	O	O	O
29.1	O	O	O
%	O	O	O
vs	O	O	O
17.9	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
30-day	O	O	O
mortality	O	O	B-Entity
(	O	O	O
5.6	O	O	O
%	O	O	O
vs	O	O	O
2.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
(	O	O	O
all	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
analysis	O	O	I-Entity
identified	O	O	B-Entity
mFI	O	O	B-Entity
as	O	O	O
an	O	O	O
independent	O	O	B-Entity
predictor	O	O	B-Entity
of	O	O	O
major	O	O	B-Entity
complications	O	O	B-Entity
(	O	O	O
OR	O	O	O
1.52	O	O	O
,	O	O	O
95%CI	O	O	O
1.39	O	O	O
-	O	O	O
1.65	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
and	O	O	O
30-day	O	O	O
mortality	O	O	B-Entity
(	O	O	O
OR	O	O	O
1.48	O	O	O
,	O	O	O
95%CI	O	O	O
1.24	O	O	O
-	O	O	O
1.75	O	O	O
,	O	O	O
P	O	O	O
<	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

mFI	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
complications	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
surgical	O	O	B-Entity
patients	O	O	I-Entity
with	O	O	O
gastrointestinal	O	O	B-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (28440090)

Spermatocytic	O	O	B-Entity
Tumor	O	O	I-Entity
With	O	O	O
Sarcoma	O	O	B-Entity
:	O	O	O
A	O	O	O
Rare	O	O	B-Entity
Testicular	O	O	O
Neoplasm	O	O	O

Spermatocytic	O	O	B-Entity
tumor	O	O	I-Entity
,	O	O	O
formerly	O	O	O
known	O	O	O
as	O	O	O
spermatocytic	O	O	B-Entity
seminoma	O	O	B-Entity
,	O	O	O
is	O	O	O
an	O	O	O
uncommon	O	O	B-Entity
testicular	O	O	B-Entity
neoplasm	O	O	I-Entity
which	O	O	O
is	O	O	O
a	O	O	O
distinct	O	O	O
clinicopathologic	O	O	B-Entity
entity	O	O	I-Entity
from	O	O	O
classic	O	O	O
seminoma	O	O	O
.	O	O	O

These	O	O	O
tumors	O	O	B-Entity
are	O	O	O
not	O	O	O
associated	O	O	O
with	O	O	O
germ	O	O	B-Entity
cell	O	O	I-Entity
neoplasia	O	O	I-Entity
in	O	O	O
situ	O	O	O
,	O	O	O
other	O	O	O
germ	O	O	B-Entity
cell	O	O	I-Entity
tumors	O	O	I-Entity
,	O	O	O
or	O	O	O
isochromosome	O	O	B-Entity
12p	O	O	I-Entity
.	O	O	O

Although	O	O	O
typically	O	O	O
,	O	O	O
these	O	O	O
tumors	O	O	B-Entity
have	O	O	O
an	O	O	O
excellent	O	O	B-Entity
prognosis	O	O	B-Entity
occasional	O	O	B-Entity
cases	O	O	I-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
sarcoma	O	O	B-Entity
and	O	O	O
have	O	O	O
a	O	O	O
very	O	O	B-Entity
poor	O	O	I-Entity
prognosis	O	O	I-Entity
.	O	O	O

We	O	O	O
present	O	O	O
a	O	O	O
case	O	O	B-Entity
of	O	O	O
spermatocytic	O	O	B-Entity
tumor	O	O	I-Entity
with	O	O	O
sarcoma	O	O	B-Entity
showing	O	O	O
a	O	O	O
chondrosarcomatous	O	O	B-Entity
component	O	O	I-Entity
,	O	O	O
discuss	O	O	O
the	O	O	O
pathologic	O	O	B-Entity
findings	O	O	I-Entity
and	O	O	O
differential	O	O	B-Entity
diagnosis	O	O	I-Entity
and	O	O	O
provide	O	O	O
follow-up	O	O	B-Entity
information	O	O	B-Entity
.	O	O	O

-DOCSTART- (28443376)

Remote	O	O	B-Entity
Ischemic	O	O	B-Entity
Conditioning	O	O	I-Entity
and	O	O	O
Renal	O	O	B-Entity
Protection	O	O	O

Over	O	O	O
the	O	O	O
course	O	O	O
of	O	O	O
the	O	O	O
last	O	O	O
2	O	O	O
decades	O	O	O
,	O	O	O
the	O	O	O
concept	O	O	O
of	O	O	O
remote	O	O	B-Entity
ischemic	O	O	B-Entity
conditioning	O	O	I-Entity
(	O	O	O
RIC	O	O	B-Entity
)	O	O	O
has	O	O	O
attracted	O	O	O
considerable	O	O	O
research	O	O	B-Entity
interest	O	O	B-Entity
,	O	O	O
because	O	O	O
RIC	O	O	O
,	O	O	O
in	O	O	O
most	O	O	O
of	O	O	O
its	O	O	O
embodiments	O	O	O
offers	O	O	O
an	O	O	O
inexpensive	O	O	O
way	O	O	O
of	O	O	O
protecting	O	O	B-Entity
tissues	O	O	B-Entity
against	O	O	O
ischemic	O	O	O
damage	O	O	B-Entity
inflicted	O	O	O
by	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
medical	O	O	B-Entity
conditions	O	O	B-Entity
or	O	O	O
procedures	O	O	B-Entity
.	O	O	O

Acute	O	O	B-Entity
kidney	O	O	I-Entity
injury	O	O	I-Entity
(	O	O	O
AKI	O	O	B-Entity
)	O	O	O
is	O	O	O
a	O	O	O
common	O	O	O
side	O	O	B-Entity
effect	O	O	I-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
various	O	O	O
medical	O	O	B-Entity
procedures	O	O	I-Entity
,	O	O	O
and	O	O	O
RIC	O	O	B-Entity
has	O	O	O
been	O	O	O
suggested	O	O	O
as	O	O	O
a	O	O	O
means	O	O	O
of	O	O	O
reducing	O	O	O
its	O	O	O
incidence	O	O	O
.	O	O	O

Outcomes	O	O	B-Entity
regarding	O	O	O
kidney	O	O	B-Entity
function	O	O	I-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
in	O	O	O
numerous	O	O	O
studies	O	O	B-Entity
that	O	O	O
evaluated	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
RIC	O	O	B-Entity
in	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
settings	O	O	O
(	O	O	O
eg	O	O	O
,	O	O	O
cardiac	O	O	B-Entity
surgery	O	O	I-Entity
,	O	O	O
interventions	O	O	B-Entity
requiring	O	O	O
intravenous	O	O	B-Entity
administration	O	O	I-Entity
of	O	O	O
contrast	O	O	B-Entity
media	O	O	I-Entity
)	O	O	O
.	O	O	O

Although	O	O	O
several	O	O	O
individual	O	O	O
studies	O	O	B-Entity
have	O	O	O
implied	O	O	O
a	O	O	O
beneficial	O	O	O
effect	O	O	B-Entity
of	O	O	I-Entity
RIC	O	O	B-Entity
in	O	O	O
preserving	O	O	O
kidney	O	O	B-Entity
function	O	O	I-Entity
,	O	O	O
3	O	O	O
recently	O	O	O
published	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trials	O	O	I-Entity
evaluating	O	O	O
more	O	O	O
than	O	O	O
1000	O	O	O
patients	O	O	B-Entity
each	O	O	O
(	O	O	O
Effect	O	O	B-Entity
of	O	O	I-Entity
Remote	O	O	B-Entity
Ischemic	O	O	I-Entity
Preconditioning	O	O	I-Entity
in	O	O	O
the	O	O	O
Cardiac	O	O	B-Entity
Surgery	O	O	I-Entity
,	O	O	O
Remote	O	O	B-Entity
Ischaemic	O	O	I-Entity
Preconditioning	O	O	I-Entity
for	O	O	O
Heart	O	O	B-Entity
Surgery	O	O	I-Entity
,	O	O	O
and	O	O	O
E	O	O	B-Entity
RIC	O	O	I-Entity
CA	O	O	I-Entity
)	O	O	O

were	O	O	O
negative	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
AKI	O	O	B-Entity
or	O	O	O
any	O	O	O
other	O	O	O
index	O	O	O
of	O	O	O
renal	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
not	O	O	O
a	O	O	O
stand-alone	O	O	O
primary	O	O	O
end	O	O	O
point	O	O	O
in	O	O	O
any	O	O	O
of	O	O	O
these	O	O	O
trials	O	O	B-Entity
.	O	O	O

On	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
a	O	O	O
range	O	O	O
of	O	O	O
meta-analyses	O	O	B-Entity
(	O	O	O
each	O	O	O
including	O	O	O
thousands	O	O	O
of	O	O	O
participants	O	O	B-Entity
)	O	O	O
have	O	O	O
reported	O	O	O
mixed	O	O	O
results	O	O	B-Entity
,	O	O	O
with	O	O	O
the	O	O	O
most	O	O	O
recent	O	O	O
among	O	O	O
them	O	O	O
showing	O	O	O
benefit	O	O	O
from	O	O	O
RIC	O	O	B-Entity
,	O	O	O
pinpointing	O	O	O
at	O	O	O
the	O	O	O
same	O	O	O
time	O	O	O
a	O	O	O
number	O	O	O
of	O	O	O
shortcomings	O	O	O
in	O	O	O
published	O	O	B-Entity
studies	O	O	B-Entity
,	O	O	O
adversely	O	O	B-Entity
affecting	O	O	I-Entity
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
available	O	O	B-Entity
data	O	O	I-Entity
.	O	O	O

The	O	O	O
present	O	O	O
review	O	O	B-Entity
provides	O	O	O
a	O	O	O
critical	O	O	O
appraisal	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
state	O	O	O
of	O	O	O
this	O	O	O
field	O	O	O
of	O	O	O
research	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
the	O	O	O
opinion	O	O	O
of	O	O	O
the	O	O	O
authors	O	O	B-Entity
of	O	O	O
this	O	O	O
review	O	O	B-Entity
that	O	O	O
there	O	O	O
is	O	O	O
a	O	O	O
clear	O	O	O
need	O	O	O
for	O	O	O
a	O	O	O
common	O	O	O
clinical	O	O	B-Entity
trial	O	O	I-Entity
framework	O	O	O
for	O	O	O
ischemic	O	O	B-Entity
conditioning	O	O	I-Entity
studies	O	O	B-Entity
.	O	O	O

If	O	O	O
the	O	O	O
current	O	O	O
babel	O	O	O
of	O	O	O
definitions	O	O	B-Entity
,	O	O	O
procedures	O	O	B-Entity
,	O	O	O
outcomes	O	O	B-Entity
,	O	O	O
and	O	O	O
goals	O	O	B-Entity
persists	O	O	I-Entity
,	O	O	O
it	O	O	O
is	O	O	O
most	O	O	O
likely	O	O	O
that	O	O	O
soon	O	O	O
ischemic	O	O	B-Entity
conditioning	O	O	I-Entity
will	O	O	O
be	O	O	O
"	O	O	O
yesterday	O	O	O
's	O	O	O
news	O	O	O
"	O	O	O
with	O	O	O
no	O	O	O
definitive	O	O	O
conclusions	O	O	O
having	O	O	O
been	O	O	O
reached	O	O	O
in	O	O	O
terms	O	O	O
of	O	O	O
its	O	O	O
real	O	O	O
clinical	O	O	B-Entity
utility	O	O	I-Entity
.	O	O	O

-DOCSTART- (28446912)

Temporal	O	O	B-Entity
and	O	O	O
Spatial	O	O	B-Entity
Variability	O	O	B-Entity
of	O	O	O
Fungal	O	O	B-Entity
Structures	O	O	I-Entity
and	O	O	O
Host	O	O	B-Entity
Responses	O	O	I-Entity
in	O	O	O
an	O	O	O
Incompatible	O	O	O
Rust-Wheat	O	O	O
Interaction	O	O	O

Information	O	O	B-Entity
about	O	O	O
temporal	O	O	B-Entity
and	O	O	O
spatial	O	O	B-Entity
variability	O	O	B-Entity
of	O	O	O
fungal	O	O	B-Entity
structures	O	O	I-Entity
and	O	O	O
host	O	O	B-Entity
responses	O	O	I-Entity
is	O	O	O
scarce	O	O	B-Entity
in	O	O	O
comparison	O	O	B-Entity
to	O	O	O
the	O	O	O
vast	O	O	O
amount	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
,	O	O	O
biochemical	O	O	B-Entity
,	O	O	O
and	O	O	O
physiological	O	O	B-Entity
studies	O	O	B-Entity
of	O	O	O
host-pathogen	O	O	B-Entity
interactions	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
used	O	O	B-Entity
avirulent	O	O	B-Entity
wild	O	O	B-Entity
type	O	O	I-Entity
and	O	O	O
virulent	O	O	B-Entity
mutant	O	O	B-Entity
isolates	O	O	B-Entity
of	O	O	O
Puccinia	O	O	B-Entity
striiformis	O	O	I-Entity
to	O	O	O
characterize	O	O	B-Entity
the	O	O	O
interactions	O	O	B-Entity
in	O	O	O
wheat	O	O	B-Entity
carrying	O	O	B-Entity
yellow	O	O	B-Entity
rust	O	O	I-Entity
Yr2	O	O	B-Entity
resistance	O	O	B-Entity
.	O	O	O

Both	O	O	O
conventional	O	O	B-Entity
and	O	O	O
advanced	O	O	B-Entity
microscopic	O	O	B-Entity
techniques	O	O	B-Entity
were	O	O	O
used	O	O	B-Entity
for	O	O	O
a	O	O	O
detailed	O	O	B-Entity
study	O	O	B-Entity
of	O	O	O
morphology	O	O	B-Entity
and	O	O	O
growth	O	O	B-Entity
of	O	O	O
fungal	O	O	B-Entity
colonies	O	O	B-Entity
and	O	O	O
associated	O	O	B-Entity
host	O	O	B-Entity
cell	O	O	I-Entity
responses	O	O	I-Entity
.	O	O	O

The	O	O	O
growth	O	O	B-Entity
of	O	O	O
the	O	O	O
wild	O	O	B-Entity
type	O	O	I-Entity
isolates	O	O	B-Entity
was	O	O	O
highly	O	O	B-Entity
restricted	O	O	B-Entity
due	O	O	O
to	O	O	O
hypersensitive	O	O	B-Entity
response	O	O	I-Entity
(	O	O	O
HR	O	O	B-Entity
,	O	O	O
plant	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
)	O	O	O
indicated	O	O	B-Entity
by	O	O	O
autofluorescence	O	O	B-Entity
and	O	O	O
change	O	O	B-Entity
in	O	O	O
the	O	O	O
shape	O	O	B-Entity
of	O	O	O
the	O	O	O
affected	O	O	B-Entity
plant	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
host	O	O	B-Entity
response	O	O	B-Entity
appeared	O	O	B-Entity
post	O	O	B-Entity
-	O	O	O
haustorial	O	O	B-Entity
,	O	O	O
but	O	O	O
large	O	O	B-Entity
variation	O	O	B-Entity
in	O	O	O
the	O	O	O
time	O	O	B-Entity
and	O	O	O
stage	O	O	B-Entity
of	O	O	O
arrest	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
for	O	O	O
individual	O	O	B-Entity
fungal	O	O	B-Entity
colonies	O	O	B-Entity
,	O	O	O
probably	O	O	B-Entity
due	O	O	O
to	O	O	O
a	O	O	O
delay	O	O	B-Entity
between	O	O	B-Entity
detection	O	O	B-Entity
and	O	O	O
response	O	O	O
.	O	O	O

Some	O	O	O
colonies	O	O	B-Entity
were	O	O	O
stopped	O	O	B-Entity
right	O	O	B-Entity
after	O	O	I-Entity
the	O	O	O
formation	O	O	B-Entity
of	O	O	O
the	O	O	O
primary	O	O	B-Entity
infection	O	O	I-Entity
hyphae	O	O	B-Entity
whereas	O	O	O
others	O	O	O
formed	O	O	B-Entity
highly	O	O	B-Entity
branched	O	O	B-Entity
mycelia	O	O	B-Entity
.	O	O	O

HR	O	O	B-Entity
was	O	O	O
first	O	O	O
observed	O	O	B-Entity
in	O	O	O
host	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	O
direct	O	O	B-Entity
contact	O	O	B-Entity
with	O	O	O
fungal	O	O	B-Entity
structures	O	O	I-Entity
,	O	O	O
after	O	O	O
which	O	O	O
the	O	O	O
defense	O	O	B-Entity
responses	O	O	I-Entity
spread	O	O	B-Entity
to	O	O	O
adjacent	O	O	B-Entity
host	O	O	O
cells	O	O	O
,	O	O	O
and	O	O	O
eventually	O	O	O
led	O	O	O
to	O	O	O
encasement	O	O	B-Entity
of	O	O	O
the	O	O	O
fungal	O	O	O
colony	O	O	B-Entity
.	O	O	O

Several	O	O	B-Entity
cells	O	O	B-Entity
with	O	O	O
HR	O	O	B-Entity
contained	O	O	B-Entity
haustoria	O	O	B-Entity
,	O	O	O
which	O	O	O
were	O	O	O
small	O	O	B-Entity
and	O	O	O
underdeveloped	O	O	B-Entity
,	O	O	O
but	O	O	O
some	O	O	B-Entity
cells	O	O	O
contained	O	O	O
normal	O	O	B-Entity
sized	O	O	B-Entity
haustoria	O	O	O
without	O	O	O
signs	O	O	B-Entity
of	O	O	O
hypersensitivity	O	O	B-Entity
.	O	O	O

The	O	O	O
growth	O	O	B-Entity
of	O	O	O
the	O	O	O
virulent	O	O	B-Entity
mutants	O	O	B-Entity
in	O	O	O
the	O	O	O
resistant	O	O	B-Entity
plants	O	O	B-Entity
was	O	O	O
similar	O	O	B-Entity
to	O	O	O
the	O	O	O
growth	O	O	O
in	O	O	O
plants	O	O	O
without	O	O	O
Yr2	O	O	B-Entity
resistance	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
a	O	O	O
strong	O	O	B-Entity
indication	O	O	B-Entity
that	O	O	O
the	O	O	O
incompatible	O	O	B-Entity
phenotype	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	O
Yr2	O	O	O
.	O	O	O

The	O	O	O
interaction	O	O	B-Entity
between	O	O	B-Entity
P.	O	O	B-Entity
striiformis	O	O	I-Entity
and	O	O	O
wheat	O	O	B-Entity
with	O	O	O
Yr2	O	O	B-Entity
resistance	O	O	B-Entity
was	O	O	O
highly	O	O	B-Entity
variable	O	O	B-Entity
in	O	O	O
time	O	O	B-Entity
and	O	O	O
space	O	O	B-Entity
,	O	O	O
which	O	O	O
demonstrate	O	O	B-Entity
that	O	O	O
histological	O	O	B-Entity
studies	O	O	B-Entity
are	O	O	O
important	O	O	B-Entity
for	O	O	O
a	O	O	O
deeper	O	O	B-Entity
understanding	O	O	I-Entity
of	O	O	O
host-pathogen	O	O	B-Entity
interactions	O	O	I-Entity
and	O	O	O
plant	O	O	B-Entity
defense	O	O	B-Entity
mechanisms	O	O	B-Entity
in	O	O	O
general	O	O	B-Entity
.	O	O	O

-DOCSTART- (28447924)

The	O	O	O
Effects	O	O	B-Entity
of	O	O	I-Entity
Messages	O	O	B-Entity
about	O	O	O
the	O	O	O
Causes	O	O	B-Entity
of	O	O	O
Obesity	O	O	B-Entity
on	O	O	O
Disciplinary	O	O	B-Entity
Action	O	O	I-Entity
Decisions	O	O	B-Entity
for	O	O	O
Overweight	O	O	B-Entity
Employees	O	O	O

We	O	O	O
investigated	O	O	B-Entity
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
messages	O	O	B-Entity
about	O	O	O
the	O	O	O
causes	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
(	O	O	O
controllable	O	O	B-Entity
or	O	O	O
uncontrollable	O	O	B-Entity
)	O	O	O
on	O	O	O
the	O	O	O
disciplinary	O	O	B-Entity
action	O	O	I-Entity
consequences	O	O	B-Entity
selected	O	O	O
for	O	O	O
obese	O	O	B-Entity
employees	O	O	B-Entity
in	O	O	O
response	O	O	B-Entity
to	O	O	O
a	O	O	O
work-related	O	O	B-Entity
mistake	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
read	O	O	O
about	O	O	O
either	O	O	O
the	O	O	O
controllable	O	O	B-Entity
or	O	O	O
uncontrollable	O	O	B-Entity
causes	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
before	O	O	O
reviewing	O	O	B-Entity
an	O	O	O
ostensible	O	O	B-Entity
employee	O	O	B-Entity
file	O	O	B-Entity
that	O	O	O
included	O	O	O
a	O	O	O
description	O	O	O
of	O	O	O
an	O	O	O
employee	O	O	O
mistake	O	O	B-Entity
.	O	O	O

Depending	O	O	O
on	O	O	O
condition	O	O	O
,	O	O	O
the	O	O	O
file	O	O	B-Entity
contained	O	O	O
a	O	O	O
photo	O	O	B-Entity
of	O	O	O
the	O	O	O
employee	O	O	B-Entity
that	O	O	O
either	O	O	O
depicted	O	O	O
them	O	O	O
as	O	O	O
obese	O	O	B-Entity
or	O	O	O
average	O	O	B-Entity
weight	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
more	O	O	O
willing	O	O	O
to	O	O	O
withhold	O	O	B-Entity
a	O	O	O
raise	O	O	O
or	O	O	O
promotion	O	O	B-Entity
from	O	O	O
an	O	O	O
obese	O	O	B-Entity
employee	O	O	B-Entity
than	O	O	O
from	O	O	O
an	O	O	O
average	O	O	B-Entity
-	O	O	O
weight	O	O	B-Entity
employee	O	O	O
.	O	O	O

Further	O	O	O
,	O	O	O
there	O	O	O
was	O	O	O
little	O	O	O
evidence	O	O	B-Entity
that	O	O	O
the	O	O	O
messages	O	O	B-Entity
about	O	O	O
the	O	O	O
causes	O	O	B-Entity
of	O	O	O
obesity	O	O	B-Entity
affected	O	O	B-Entity
participants	O	O	B-Entity
'	O	O	O
perceived	O	O	B-Entity
control	O	O	I-Entity
and	O	O	O
self-efficacy	O	O	B-Entity
for	O	O	O
healthy	O	O	B-Entity
behaviors	O	O	B-Entity
.	O	O	O

-DOCSTART- (28447984)

Experience	O	O	B-Entity
is	O	O	O
Instrumental	O	O	B-Entity
in	O	O	O
Tuning	O	O	B-Entity
a	O	O	O
Link	O	O	B-Entity
Between	O	O	O
Language	O	O	B-Entity
and	O	O	O
Cognition	O	O	B-Entity
:	O	O	O
Evidence	O	O	B-Entity
from	O	O	O
6-	O	O	B-Entity
to	O	O	I-Entity
7-	O	O	I-Entity
Month-Old	O	O	I-Entity
Infants	O	O	B-Entity
'	O	O	O
Object	O	O	O
Categorization	O	O	O

At	O	O	B-Entity
birth	O	O	I-Entity
,	O	O	O
infants	O	O	B-Entity
not	O	O	O
only	O	O	O
prefer	O	O	O
listening	O	O	B-Entity
to	O	O	O
human	O	O	B-Entity
vocalizations	O	O	B-Entity
,	O	O	O
but	O	O	O
also	O	O	O
have	O	O	O
begun	O	O	B-Entity
to	O	O	O
link	O	O	B-Entity
these	O	O	O
vocalizations	O	O	O
to	O	O	O
cognition	O	O	B-Entity
:	O	O	O
For	O	O	O
infants	O	O	O
as	O	O	O
young	O	O	B-Entity
as	O	O	O
three	O	O	B-Entity
months	O	O	I-Entity
of	O	O	O
age	O	O	B-Entity
,	O	O	O
listening	O	O	O
to	O	O	O
human	O	O	O
language	O	O	B-Entity
supports	O	O	O
object	O	O	O
categorization	O	O	B-Entity
,	O	O	O
a	O	O	O
core	O	O	B-Entity
cognitive	O	O	B-Entity
capacity	O	O	B-Entity
.	O	O	O

This	O	O	O
precocious	O	O	B-Entity
link	O	O	B-Entity
is	O	O	O
initially	O	O	B-Entity
broad	O	O	B-Entity
:	O	O	O
At	O	O	O
3	O	O	O
and	O	O	O
4	O	O	O
months	O	O	O
,	O	O	O
vocalizations	O	O	B-Entity
of	O	O	O
both	O	O	B-Entity
humans	O	O	B-Entity
and	O	O	O
nonhuman	O	O	B-Entity
primates	O	O	I-Entity
support	O	O	O
categorization	O	O	B-Entity
.	O	O	O

But	O	O	O
by	O	O	O
6	O	O	B-Entity
months	O	O	I-Entity
,	O	O	O
infants	O	O	B-Entity
have	O	O	O
narrowed	O	O	B-Entity
the	O	O	O
link	O	O	B-Entity
:	O	O	O
Only	O	O	O
human	O	O	B-Entity
vocalizations	O	O	B-Entity
support	O	O	O
object	O	O	O
categorization	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
ask	O	O	O
what	O	O	O
guides	O	O	O
infants	O	O	B-Entity
as	O	O	O
they	O	O	O
tune	O	O	B-Entity
their	O	O	O
initially	O	O	B-Entity
broad	O	O	B-Entity
link	O	O	B-Entity
to	O	O	O
a	O	O	O
more	O	O	O
precise	O	O	B-Entity
one	O	O	O
,	O	O	O
engaged	O	O	O
only	O	O	O
by	O	O	O
the	O	O	O
vocalizations	O	O	B-Entity
of	O	O	O
our	O	O	O
species	O	O	B-Entity
.	O	O	O

Across	O	O	O
three	O	O	O
studies	O	O	B-Entity
,	O	O	O
we	O	O	O
use	O	O	O
a	O	O	O
novel	O	O	B-Entity
exposure	O	O	B-Entity
paradigm	O	O	B-Entity
to	O	O	O
examine	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	O
experience	O	O	B-Entity
.	O	O	O

We	O	O	O
document	O	O	O
that	O	O	O
merely	O	O	O
exposing	O	O	B-Entity
infants	O	O	B-Entity
to	O	O	O
nonhuman	O	O	B-Entity
primate	O	O	I-Entity
vocalizations	O	O	B-Entity
enables	O	O	B-Entity
infants	O	O	O
to	O	O	O
preserve	O	O	O
the	O	O	O
early	O	O	B-Entity
-	O	O	O
established	O	O	B-Entity
link	O	O	B-Entity
between	O	O	O
this	O	O	O
signal	O	O	B-Entity
and	O	O	O
categorization	O	O	B-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
,	O	O	O
exposing	O	O	B-Entity
infants	O	O	B-Entity
to	O	O	O
backward	O	O	B-Entity
speech	O	O	B-Entity
-	O	O	O
a	O	O	O
signal	O	O	B-Entity
that	O	O	O
fails	O	O	B-Entity
to	O	O	O
support	O	O	B-Entity
categorization	O	O	B-Entity
at	O	O	O
any	O	O	O
age	O	O	B-Entity
-	O	O	O
offers	O	O	O
no	O	O	O
such	O	O	O
advantage	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
reveal	O	O	B-Entity
the	O	O	O
power	O	O	B-Entity
of	O	O	O
early	O	O	B-Entity
experience	O	O	B-Entity
as	O	O	O
infants	O	O	B-Entity
specify	O	O	O
which	O	O	O
signals	O	O	B-Entity
,	O	O	O
from	O	O	O
an	O	O	O
initially	O	O	B-Entity
broad	O	O	B-Entity
set	O	O	O
,	O	O	O
they	O	O	O
will	O	O	O
continue	O	O	B-Entity
to	O	O	O
link	O	O	B-Entity
to	O	O	O
cognition	O	O	B-Entity
.	O	O	O

-DOCSTART- (28448089)

Bone	O	O	B-Entity
Degeneration	O	O	I-Entity
and	O	O	O
Its	O	O	O
Recovery	O	O	O
in	O	O	O
SMP30/GNL	O	O	B-Entity
-	O	O	O
Knockout	O	O	O
Mice	O	O	O

Senescence	O	O	B-Entity
marker	O	O	I-Entity
protein-30	O	O	I-Entity
(	O	O	O
SMP30	O	O	B-Entity
)	O	O	O
decreases	O	O	O
androgen	O	O	B-Entity
-independently	O	O	O
with	O	O	O
aging	O	O	B-Entity
and	O	O	O
is	O	O	O
a	O	O	O
lactone	O	O	B-Entity
-	O	O	O
hydrolyzing	O	O	B-Entity
enzyme	O	O	I-Entity
gluconolactonase	O	O	B-Entity
(	O	O	O
GNL	O	O	B-Entity
)	O	O	O
that	O	O	O
is	O	O	O
involved	O	O	O
in	O	O	O
vitamin	O	O	B-Entity
C	O	O	I-Entity
biosynthesis	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
,	O	O	O
bone	O	O	B-Entity
properties	O	O	O
of	O	O	O
SMP30/GNL	O	O	B-Entity
knockout	O	O	B-Entity
(	O	O	I-Entity
KO	O	O	I-Entity
)	O	O	I-Entity
mice	O	O	I-Entity
with	O	O	O
deficiency	O	O	B-Entity
in	O	O	O
vitamin	O	O	B-Entity
C	O	O	I-Entity
synthesis	O	O	B-Entity
were	O	O	O
investigated	O	O	O
to	O	O	O
reveal	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
SMP30/GNL	O	O	O
and	O	O	O
exogenous	O	O	B-Entity
vitamin	O	O	O
C	O	O	O
supplementation	O	O	B-Entity
on	O	O	O
bone	O	O	B-Entity
formation	O	O	I-Entity
.	O	O	O

Mineral	O	O	B-Entity
content	O	O	I-Entity
(	O	O	O
BMC	O	O	B-Entity
)	O	O	O
and	O	O	O
mineral	O	O	B-Entity
density	O	O	I-Entity
(	O	O	O
BMD	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
mandible	O	O	B-Entity
and	O	O	O
femur	O	O	B-Entity
of	O	O	O
SMP30/GNL	O	O	B-Entity
KO	O	O	B-Entity
and	O	O	O
wild-type	O	O	B-Entity
mice	O	O	I-Entity
at	O	O	O
2	O	O	O
and	O	O	O
3	O	O	O
months	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
with	O	O	O
or	O	O	O
without	O	O	O
vitamin	O	O	B-Entity
C	O	O	I-Entity
supplementation	O	O	B-Entity
were	O	O	O
measured	O	O	O
by	O	O	O
dual-energy	O	O	B-Entity
X-ray	O	O	I-Entity
absorptiometry	O	O	I-Entity
.	O	O	O

Body	O	O	B-Entity
and	O	O	O
bone	O	O	B-Entity
weight	O	O	B-Entity
of	O	O	O
both	O	O	O
age	O	O	B-Entity
groups	O	O	I-Entity
decreased	O	O	O
and	O	O	O
became	O	O	O
significantly	O	O	O
lower	O	O	O
than	O	O	O
those	O	O	O
of	O	O	O
wild-type	O	O	B-Entity
mice	O	O	I-Entity
.	O	O	O

The	O	O	O
bones	O	O	B-Entity
of	O	O	O
SMP30/GNL	O	O	B-Entity
KO	O	O	B-Entity
mice	O	O	I-Entity
were	O	O	O
rough	O	O	O
and	O	O	O
porous	O	O	O
,	O	O	O
with	O	O	O
BMC	O	O	B-Entity
and	O	O	O
BMD	O	O	B-Entity
significantly	O	O	O
below	O	O	O
wild-type	O	O	B-Entity
.	O	O	O

Oral	O	O	B-Entity
supplementation	O	O	B-Entity
with	O	O	O
vitamin	O	O	B-Entity
C	O	O	I-Entity
eliminated	O	O	O
differences	O	O	O
in	O	O	O
body	O	O	B-Entity
weight	O	O	I-Entity
,	O	O	O
bone	O	O	B-Entity
weight	O	O	O
,	O	O	O
BMC	O	O	B-Entity
,	O	O	O
and	O	O	O
BMD	O	O	B-Entity
between	O	O	O
SMP30/GNL	O	O	B-Entity
KO	O	O	B-Entity
and	O	O	O
wild-type	O	O	B-Entity
mice	O	O	I-Entity
at	O	O	O
each	O	O	O
age	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	O
indicate	O	O	O
that	O	O	O
bone	O	O	B-Entity
degeneration	O	O	I-Entity
in	O	O	O
SMP30/GNL	O	O	B-Entity
KO	O	O	B-Entity
mice	O	O	I-Entity
was	O	O	O
caused	O	O	O
by	O	O	O
lack	O	O	O
of	O	O	O
vitamin	O	O	B-Entity
C	O	O	I-Entity
,	O	O	O
and	O	O	O
that	O	O	O
this	O	O	O
mouse	O	O	B-Entity
strain	O	O	I-Entity
is	O	O	O
an	O	O	O
appropriate	O	O	O
model	O	O	B-Entity
for	O	O	O
bone	O	O	B-Entity
metabolism	O	O	I-Entity
in	O	O	O
humans	O	O	B-Entity
,	O	O	O
which	O	O	O
have	O	O	O
no	O	O	O
ability	O	O	O
to	O	O	O
synthesize	O	O	B-Entity
vitamin	O	O	O
C.	O	O	O

-DOCSTART- (28449774)

Utility	O	O	O
of	O	O	O
Post-Mortem	O	O	B-Entity
Genetic	O	O	B-Entity
Testing	O	O	I-Entity
in	O	O	O
Cases	O	O	O
of	O	O	O
Sudden	O	O	O
Arrhythmic	O	O	O
Death	O	O	O
Syndrome	O	O	O

Sudden	O	O	B-Entity
arrhythmic	O	O	I-Entity
death	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
SADS	O	O	B-Entity
)	O	O	O
describes	O	O	O
a	O	O	O
sudden	O	O	B-Entity
death	O	O	I-Entity
with	O	O	O
negative	O	O	O
autopsy	O	O	B-Entity
and	O	O	O
toxicological	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

Cardiac	O	O	B-Entity
genetic	O	O	I-Entity
disease	O	O	I-Entity
is	O	O	O
a	O	O	O
likely	O	O	O
etiology	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
investigated	O	O	B-Entity
the	O	O	O
clinical	O	O	B-Entity
utility	O	O	I-Entity
and	O	O	O
combined	O	O	O
yield	O	O	O
of	O	O	O
post-mortem	O	O	B-Entity
genetic	O	O	B-Entity
testing	O	O	I-Entity
(	O	O	O
molecular	O	O	B-Entity
autopsy	O	O	I-Entity
)	O	O	O
in	O	O	O
cases	O	O	O
of	O	O	O
SADS	O	O	B-Entity
and	O	O	O
comprehensive	O	O	B-Entity
clinical	O	O	B-Entity
evaluation	O	O	I-Entity
of	O	O	O
surviving	O	O	B-Entity
relatives	O	O	B-Entity
.	O	O	O

We	O	O	O
evaluated	O	O	B-Entity
302	O	O	O
expertly	O	O	O
validated	O	O	O
SADS	O	O	B-Entity
cases	O	O	O
with	O	O	O
suitable	O	O	O
DNA	O	O	B-Entity
(	O	O	O
median	O	O	O
age	O	O	B-Entity
:	O	O	O
24	O	O	O
years	O	O	O
;	O	O	O
65	O	O	O
%	O	O	O
males	O	O	B-Entity
)	O	O	O
who	O	O	O
underwent	O	O	O
next-generation	O	O	B-Entity
sequencing	O	O	B-Entity
using	O	O	O
an	O	O	O
extended	O	O	O
panel	O	O	B-Entity
of	O	O	O
77	O	O	O
primary	O	O	B-Entity
electrical	O	O	I-Entity
disorder	O	O	I-Entity
and	O	O	O
cardiomyopathy	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

Pathogenic	O	O	B-Entity
and	O	O	O
likely	O	O	O
pathogenic	O	O	B-Entity
variants	O	O	I-Entity
were	O	O	O
classified	O	O	O
using	O	O	O
American	O	O	B-Entity
College	O	O	I-Entity
of	O	O	I-Entity
Medical	O	O	I-Entity
Genetics	O	O	I-Entity
(	O	O	O
ACMG	O	O	B-Entity
)	O	O	O
consensus	O	O	B-Entity
guidelines	O	O	I-Entity
.	O	O	O

The	O	O	O
yield	O	O	O
of	O	O	O
combined	O	O	O
molecular	O	O	B-Entity
autopsy	O	O	I-Entity
and	O	O	O
clinical	O	O	B-Entity
evaluation	O	O	I-Entity
in	O	O	O
82	O	O	O
surviving	O	O	B-Entity
families	O	O	I-Entity
was	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

A	O	O	O
gene-level	O	O	B-Entity
rare	O	O	I-Entity
variant	O	O	I-Entity
association	O	O	I-Entity
analysis	O	O	I-Entity
was	O	O	O
conducted	O	O	O
in	O	O	O
SADS	O	O	B-Entity
cases	O	O	O
versus	O	O	O
controls	O	O	B-Entity
.	O	O	O

A	O	O	O
clinically	O	O	B-Entity
actionable	O	O	I-Entity
pathogenic	O	O	B-Entity
or	O	O	O
likely	O	O	O
pathogenic	O	O	B-Entity
variant	O	O	I-Entity
was	O	O	O
identified	O	O	O
in	O	O	O
40	O	O	O
of	O	O	O
302	O	O	O
cases	O	O	O
(	O	O	O
13	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
etiologies	O	O	B-Entity
established	O	O	O
were	O	O	O
catecholaminergic	O	O	B-Entity
polymorphic	O	O	I-Entity
ventricular	O	O	I-Entity
tachycardia	O	O	I-Entity
and	O	O	O
long	O	O	B-Entity
QT	O	O	I-Entity
syndrome	O	O	I-Entity
(	O	O	O
17	O	O	O
[	O	O	O
6	O	O	O
%	O	O	O
]	O	O	O
and	O	O	O
11	O	O	O
[	O	O	O
4	O	O	O
%	O	O	O
]	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
.	O	O	O

Gene-based	O	O	B-Entity
rare	O	O	I-Entity
variants	O	O	I-Entity
association	O	O	I-Entity
analysis	O	O	I-Entity
showed	O	O	O
enrichment	O	O	O
of	O	O	O
rare	O	O	O
predicted	O	O	O
deleterious	O	O	B-Entity
variants	O	O	I-Entity
in	O	O	O
RYR2	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
5	O	O	O
×	O	O	O
10(-5	O	O	O
)	O	O	O
)	O	O	O
.	O	O	O

Combining	O	O	O
molecular	O	O	B-Entity
autopsy	O	O	I-Entity
with	O	O	O
clinical	O	O	B-Entity
evaluation	O	O	I-Entity
in	O	O	O
surviving	O	O	B-Entity
families	O	O	I-Entity
increased	O	O	O
diagnostic	O	O	B-Entity
yield	O	O	I-Entity
from	O	O	O
26	O	O	O
%	O	O	O
to	O	O	O
39	O	O	O
%	O	O	O
.	O	O	O

Molecular	O	O	B-Entity
autopsy	O	O	I-Entity
for	O	O	O
electrical	O	O	B-Entity
disorder	O	O	I-Entity
and	O	O	O
cardiomyopathy	O	O	B-Entity
genes	O	O	I-Entity
,	O	O	O
using	O	O	O
ACMG	O	O	B-Entity
guidelines	O	O	B-Entity
for	O	O	O
variant	O	O	B-Entity
classification	O	O	I-Entity
,	O	O	O
identified	O	O	O
a	O	O	O
modest	O	O	O
but	O	O	O
realistic	O	O	O
yield	O	O	O
in	O	O	O
SADS	O	O	B-Entity
.	O	O	O

Our	O	O	O
data	O	O	O
highlighted	O	O	O
the	O	O	O
predominant	O	O	O
role	O	O	O
of	O	O	O
catecholaminergic	O	O	B-Entity
polymorphic	O	O	I-Entity
ventricular	O	O	I-Entity
tachycardia	O	O	I-Entity
and	O	O	O
long	O	O	B-Entity
QT	O	O	I-Entity
syndrome	O	O	I-Entity
,	O	O	O
especially	O	O	O
the	O	O	O
RYR2	O	O	B-Entity
gene	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
minimal	O	O	O
yield	O	O	O
from	O	O	O
other	O	O	O
genes	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
showed	O	O	O
the	O	O	O
enhanced	O	O	O
utility	O	O	O
of	O	O	O
combined	O	O	O
clinical	O	O	B-Entity
and	O	O	O
genetic	O	O	B-Entity
evaluation	O	O	I-Entity
.	O	O	O

-DOCSTART- (28450395)

Binding	O	O	B-Entity
of	O	O	O
DEAD-box	O	O	B-Entity
helicase	O	O	I-Entity
Dhh1	O	O	B-Entity
to	O	O	O
the	O	O	O
5'UTR	O	O	B-Entity
of	O	O	O
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
represses	O	O	B-Entity
localized	O	O	O
translation	O	O	B-Entity
of	O	O	O
ASH1	O	O	O
in	O	O	O
yeast	O	O	B-Entity
cells	O	O	O

Local	O	O	B-Entity
translation	O	O	I-Entity
of	O	O	O
specific	O	O	B-Entity
mRNAs	O	O	B-Entity
is	O	O	O
regulated	O	O	B-Entity
by	O	O	O
dynamic	O	O	O
changes	O	O	B-Entity
in	O	O	O
their	O	O	O
subcellular	O	O	B-Entity
localization	O	O	B-Entity
,	O	O	O
and	O	O	O
these	O	O	O
changes	O	O	O
are	O	O	O
due	O	O	O
to	O	O	O
complex	O	O	B-Entity
mechanisms	O	O	B-Entity
controlling	O	O	B-Entity
cytoplasmic	O	O	B-Entity
mRNA	O	O	B-Entity
transport	O	O	I-Entity
.	O	O	O

The	O	O	O
budding	O	O	B-Entity
yeast	O	O	I-Entity
Saccharomyces	O	O	B-Entity
cerevisiae	O	O	I-Entity
is	O	O	O
well	O	O	O
suited	O	O	O
to	O	O	O
studying	O	O	O
these	O	O	O
mechanisms	O	O	B-Entity
because	O	O	O
many	O	O	O
of	O	O	O
its	O	O	O
transcripts	O	O	B-Entity
are	O	O	O
transported	O	O	B-Entity
from	O	O	O
the	O	O	O
mother	O	O	B-Entity
cell	O	O	I-Entity
to	O	O	O
the	O	O	O
budding	O	O	O
daughter	O	O	B-Entity
cell	O	O	I-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
translational	O	O	B-Entity
control	O	O	I-Entity
of	O	O	O
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
after	O	O	O
transport	O	O	B-Entity
and	O	O	O
localization	O	O	B-Entity
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
although	O	O	O
ASH1	O	O	B-Entity
transcripts	O	O	B-Entity
were	O	O	O
translated	O	O	B-Entity
after	O	O	O
they	O	O	O
reached	O	O	O
the	O	O	O
bud-tip	O	O	B-Entity
,	O	O	O
some	O	O	O
mRNAs	O	O	B-Entity
were	O	O	O
bound	O	O	O
by	O	O	O
the	O	O	O
RNA-binding	O	O	B-Entity
protein	O	O	I-Entity
Puf6	O	O	B-Entity
and	O	O	O
were	O	O	O
non-polysomal	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
found	O	O	O
that	O	O	O

the	O	O	O
DEAD-box	O	O	B-Entity
helicase	O	O	I-Entity
Dhh1	O	O	B-Entity
complexed	O	O	B-Entity
with	O	O	O
the	O	O	O
untranslated	O	O	B-Entity
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
and	O	O	O
Puf6	O	O	B-Entity
.	O	O	O

Loss	O	O	O
of	O	O	O
Dhh1	O	O	B-Entity
affected	O	O	O
local	O	O	B-Entity
translation	O	O	I-Entity
of	O	O	O
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
and	O	O	O
resulted	O	O	O
in	O	O	O
delocalization	O	O	B-Entity
of	O	O	O
ASH1	O	O	O
transcript	O	O	B-Entity
in	O	O	O
the	O	O	O
bud	O	O	B-Entity
.	O	O	O

Forcibly	O	O	O
shifting	O	O	O
the	O	O	O
non-polysomal	O	O	B-Entity
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
into	O	O	O
polysomes	O	O	B-Entity
was	O	O	O
associated	O	O	O
with	O	O	O
Dhh1	O	O	B-Entity
dissociation	O	O	B-Entity
.	O	O	O

We	O	O	O
further	O	O	O
demonstrated	O	O	O
that	O	O	O
Dhh1	O	O	B-Entity
is	O	O	O
not	O	O	O
recruited	O	O	O
to	O	O	O
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
co-transcriptionally	O	O	B-Entity
,	O	O	O
suggesting	O	O	B-Entity
that	O	O	O
it	O	O	O
could	O	O	O
bind	O	O	O
to	O	O	O
ASH1	O	O	O
mRNA	O	O	O
within	O	O	O
the	O	O	O
cytoplasm	O	O	B-Entity
.	O	O	O

Of	O	O	O
note	O	O	O
,	O	O	O
Dhh1	O	O	B-Entity
bound	O	O	O
to	O	O	O
the	O	O	O
5	O	O	B-Entity
UTR	O	O	I-Entity
of	O	O	O
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
and	O	O	O
inhibited	O	O	B-Entity
its	O	O	O
translation	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggest	O	O	B-Entity
that	O	O	O
after	O	O	O
localization	O	O	B-Entity
to	O	O	O
the	O	O	O
bud	O	O	B-Entity
tip	O	O	I-Entity
,	O	O	I-Entity
a	O	O	O
portion	O	O	B-Entity
of	O	O	O
the	O	O	O
localized	O	O	B-Entity
ASH1	O	O	B-Entity
mRNA	O	O	B-Entity
becomes	O	O	O
translationally	O	O	B-Entity
inactive	O	O	B-Entity
,	O	O	O
because	O	O	O
of	O	O	O
binding	O	O	B-Entity
of	O	O	O
Dhh1	O	O	B-Entity
and	O	O	O
Puf6	O	O	B-Entity
to	O	O	O
the	O	O	O
5	O	O	B-Entity
'	O	O	I-Entity
and	O	O	I-Entity
3	O	O	I-Entity
'	O	O	I-Entity
UTRs	O	O	I-Entity
of	O	O	O
ASH1	O	O	O
mRNA	O	O	O
.	O	O	O

-DOCSTART- (28450855)

The	O	O	O
Abundance	O	O	B-Entity
of	O	O	O
Endofungal	O	O	B-Entity
Bacterium	O	O	I-Entity
Rhizobium	O	O	B-Entity
radiobacter	O	O	I-Entity
(	O	O	O
syn	O	O	O
.	O	O	O
Agrobacterium	O	O	B-Entity
tumefaciens	O	O	I-Entity
)	O	O	O
Increases	O	O	B-Entity
in	O	O	O
Its	O	O	O
Fungal	O	O	B-Entity
Host	O	O	B-Entity
Piriformospora	O	O	B-Entity
indica	O	O	I-Entity
during	O	O	O
the	O	O	O
Tripartite	O	O	O
Sebacinalean	O	O	B-Entity
Symbiosis	O	O	B-Entity
with	O	O	O
Higher	O	O	O
Plants	O	O	O

Agrobacterium	O	O	B-Entity
tumefaciens	O	O	I-Entity
)	O	O	O
Increases	O	O	B-Entity
in	O	O	O
Its	O	O	O
Fungal	O	O	B-Entity
Host	O	O	B-Entity
Piriformospora	O	O	B-Entity
indica	O	O	I-Entity
during	O	O	O
the	O	O	O
Tripartite	O	O	O
Sebacinalean	O	O	B-Entity
Symbiosis	O	O	B-Entity
with	O	O	O
Higher	O	O	B-Entity
Plants	O	O	I-Entity
Rhizobium	O	O	B-Entity
radiobacter	O	O	I-Entity
(	O	O	O
syn	O	O	O
.	O	O	O

Agrobacterium	O	O	B-Entity
tumefaciens	O	O	I-Entity
,	O	O	O
syn	O	O	O
.	O	O	O
"	O	O	O
Agrobacterium	O	O	B-Entity
fabrum	O	O	I-Entity
"	O	O	O
)	O	O	O
is	O	O	O
an	O	O	O
endofungal	O	O	B-Entity
bacterium	O	O	I-Entity
of	O	O	O
the	O	O	O
fungal	O	O	B-Entity
mutualist	O	O	B-Entity
Piriformospora	O	O	B-Entity
(	O	O	O
syn	O	O	O
.	O	O	O

Serendipita	O	O	B-Entity
)	O	O	O
indica	O	O	B-Entity
(	O	O	O
Basidiomycota	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
together	O	O	O
form	O	O	O
a	O	O	O
tripartite	O	O	O
Sebacinalean	O	O	B-Entity
symbiosis	O	O	B-Entity
with	O	O	O
a	O	O	O
broad	O	O	O
range	O	O	O
of	O	O	O
plants	O	O	B-Entity
.	O	O	O

R.	O	O	B-Entity
radiobacter	O	O	I-Entity
strain	O	O	B-Entity
F4	O	O	I-Entity
(	O	O	O
RrF4	O	O	B-Entity
)	O	O	O
,	O	O	O
isolated	O	O	O
from	O	O	O
P.	O	O	B-Entity
indica	O	O	I-Entity
DSM	O	O	I-Entity
11827	O	O	I-Entity
,	O	O	O
induces	O	O	B-Entity
growth	O	O	B-Entity
promotion	O	O	B-Entity
and	O	O	O
systemic	O	O	B-Entity
resistance	O	O	I-Entity
in	O	O	O
cereal	O	O	B-Entity
crops	O	O	B-Entity
,	O	O	O
including	O	O	O
barley	O	O	B-Entity
and	O	O	O
wheat	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
R.	O	O	O
radiobacter	O	O	O
contributes	O	O	O
to	O	O	O
a	O	O	O
successful	O	O	O
symbiosis	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
studied	O	O	O
the	O	O	O
impact	O	O	B-Entity
of	O	O	O
endobacteria	O	O	B-Entity
on	O	O	O
the	O	O	O
morphology	O	O	B-Entity
and	O	O	O
the	O	O	O
beneficial	O	O	O
activity	O	O	O
of	O	O	O
P.	O	O	B-Entity
indica	O	O	I-Entity
during	O	O	O
interactions	O	O	B-Entity
with	O	O	O
plants	O	O	B-Entity
.	O	O	O

Low	O	O	O
numbers	O	O	O
of	O	O	O
endobacteria	O	O	B-Entity
were	O	O	O
detected	O	O	B-Entity
in	O	O	O
the	O	O	O
axenically	O	O	B-Entity
grown	O	O	I-Entity
P.	O	O	B-Entity
indica	O	O	I-Entity
(	O	O	O
long	O	O	B-Entity
term	O	O	I-Entity
lab-cultured	O	O	B-Entity
,	O	O	O
lcPiri	O	O	B-Entity
)	O	O	O
whereas	O	O	O
mycelia	O	O	B-Entity
colonizing	O	O	B-Entity
the	O	O	O
plant	O	O	B-Entity
root	O	O	I-Entity
contained	O	O	O
increased	O	O	B-Entity
numbers	O	O	O
of	O	O	O
bacteria	O	O	B-Entity
.	O	O	O

Higher	O	O	O
numbers	O	O	O
of	O	O	O
endobacteria	O	O	B-Entity
were	O	O	O
also	O	O	O
found	O	O	O
in	O	O	O
axenic	O	O	B-Entity
cultures	O	O	I-Entity
of	O	O	O
P.	O	O	B-Entity
indica	O	O	I-Entity
that	O	O	O
was	O	O	O
freshly	O	O	O
re-isolated	O	O	B-Entity
(	O	O	O
riPiri	O	O	B-Entity
)	O	O	O
from	O	O	O
plant	O	O	B-Entity
roots	O	O	I-Entity
,	O	O	O
though	O	O	O
numbers	O	O	O
dropped	O	O	O
during	O	O	O
repeated	O	O	O
axenic	O	O	B-Entity
re-cultivation	O	O	I-Entity
.	O	O	O

Prolonged	O	O	B-Entity
treatments	O	O	B-Entity
of	O	O	O
P.	O	O	B-Entity
indica	O	O	I-Entity
cultures	O	O	B-Entity
with	O	O	O
various	O	O	O
antibiotics	O	O	B-Entity
could	O	O	O
not	O	O	O
completely	O	O	O
eliminate	O	O	O
the	O	O	O
bacterium	O	O	B-Entity
,	O	O	O
though	O	O	O
the	O	O	O
number	O	O	O
of	O	O	O
detectable	O	O	B-Entity
endobacteria	O	O	B-Entity
decreased	O	O	B-Entity
significantly	O	O	B-Entity
,	O	O	O
resulting	O	O	O
in	O	O	O
partial-cured	O	O	B-Entity
P.	O	O	O
indica	O	O	O
(	O	O	O
pcPiri	O	O	B-Entity
)	O	O	O
.	O	O	O

pcPiri	O	O	B-Entity
showed	O	O	O
reduced	O	O	B-Entity
growth	O	O	B-Entity
in	O	O	O
axenic	O	O	B-Entity
cultures	O	O	I-Entity
and	O	O	O
poor	O	O	B-Entity
sporulation	O	O	B-Entity
.	O	O	O

Consistent	O	O	B-Entity
with	O	O	I-Entity
this	O	O	O
,	O	O	O
pcPiri	O	O	B-Entity
also	O	O	O
showed	O	O	O
reduced	O	O	B-Entity
plant	O	O	B-Entity
growth	O	O	I-Entity
promotion	O	O	B-Entity
and	O	O	O
reduced	O	O	O
systemic	O	O	B-Entity
resistanc	O	O	I-Entity
e	O	O	O
against	O	O	O
powdery	O	O	B-Entity
mildew	O	O	I-Entity
infection	O	O	B-Entity
as	O	O	O
compared	O	O	O
with	O	O	O
riPiri	O	O	B-Entity
and	O	O	O
lcPiri	O	O	B-Entity
.	O	O	O

These	O	O	O
results	O	O	B-Entity
are	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
the	O	O	O
assumption	O	O	O
that	O	O	O
the	O	O	O
endobacterium	O	O	B-Entity
R.	O	O	B-Entity
radiobacter	O	O	I-Entity
improves	O	O	B-Entity
P.	O	O	B-Entity
indica	O	O	I-Entity
's	O	O	I-Entity
fitness	O	O	B-Entity
and	O	O	O
thus	O	O	O
contributes	O	O	O
to	O	O	O
the	O	O	O
success	O	O	O
of	O	O	O
the	O	O	O
tripartite	O	O	O
Sebacinalean	O	O	B-Entity
symbiosis	O	O	B-Entity
.	O	O	O

-DOCSTART- (28451446)

Stem	O	O	B-Entity
cell	O	O	I-Entity
registry	O	O	B-Entity
programme	O	O	B-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
ischemic	O	O	B-Entity
cardiomyopathy	O	O	I-Entity
undergoing	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
bypass	O	O	I-Entity
grafting	O	O	I-Entity
:	O	O	O
what	O	O	O
benefits	O	O	B-Entity
does	O	O	O
it	O	O	O
derive	O	O	O
?	O	O	O

Standardization	O	O	B-Entity
of	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
therapy	O	O	I-Entity
requires	O	O	O
application	O	O	O
of	O	O	O
appropriate	O	O	O
methods	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
safety	O	O	B-Entity
and	O	O	I-Entity
efficac	O	O	I-Entity
y	O	O	O
,	O	O	O
including	O	O	O
long-term	O	O	B-Entity
pharmacovigilance	O	O	B-Entity
.	O	O	O

To	O	O	O
accomplish	O	O	O
this	O	O	O
objective	O	O	B-Entity
,	O	O	O
a	O	O	O
long-term	O	O	B-Entity
registry	O	O	B-Entity
programme	O	O	I-Entity
was	O	O	O
installed	O	O	O
.	O	O	O

We	O	O	O
analysed	O	O	O
150	O	O	O
patients	O	O	B-Entity
with	O	O	O
ischemic	O	O	B-Entity
cardiomyopathy	O	O	I-Entity
,	O	O	O
who	O	O	O
received	O	O	B-Entity
intramyocardial	O	O	B-Entity
CD133	O	O	B-Entity
+	O	O	I-Entity
bone	O	O	I-Entity
marrow	O	O	I-Entity
mononuclear	O	O	I-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
treatment	O	O	B-Entity
combined	O	O	B-Entity
with	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
bypass	O	O	I-Entity
grafting	O	O	I-Entity
(	O	O	O
CABG	O	O	B-Entity
)	O	O	O
or	O	O	O
CABG	O	O	O
alone	O	O	B-Entity
.	O	O	O

The	O	O	O
mortality	O	O	B-Entity
rate	O	O	I-Entity
,	O	O	O
major	O	O	B-Entity
adverse	O	O	B-Entity
cerebral	O	O	I-Entity
and	O	O	O
cardiac	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
and	O	O	O
functional	O	O	O
outcome	O	O	O
parameters	O	O	O
were	O	O	O
evaluated	O	O	B-Entity
for	O	O	O
the	O	O	O
time	O	O	B-Entity
period	O	O	I-Entity
up	O	O	O
to	O	O	O
14	O	O	O
years	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

As	O	O	O
a	O	O	O
result	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
stratified	O	O	B-Entity
the	O	O	O
patient	O	O	B-Entity
population	O	O	B-Entity
(	O	O	O
96	O	O	O
patients	O	O	B-Entity
)	O	O	O
into	O	O	O
responders	O	O	B-Entity
and	O	O	O
non-responders	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
relevant	O	O	B-Entity
predictors	O	O	B-Entity
of	O	O	O
good	O	O	B-Entity
response	O	O	I-Entity
to	O	O	O
CD133	O	O	B-Entity
+	O	O	I-Entity
bone	O	O	I-Entity
marrow	O	O	I-Entity
mononuclear	O	O	I-Entity
stem	O	O	I-Entity
cell	O	O	I-Entity
treatment	O	O	B-Entity
was	O	O	O
performed	O	O	B-Entity
.	O	O	O

Several	O	O	B-Entity
positive	O	O	O
tendencies	O	O	O
related	O	O	O
to	O	O	O
stem	O	O	B-Entity
cells	O	O	I-Entity
transplantation	O	O	I-Entity
were	O	O	O
demonstrated	O	O	O
.	O	O	O

First	O	O	O
,	O	O	O
no	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
in	O	O	O
major	O	O	B-Entity
adverse	O	O	B-Entity
cardiovascular	O	O	I-Entity
and	O	O	O
cerebral	O	O	B-Entity
events	O	O	I-Entity
was	O	O	O
observed	O	O	B-Entity
between	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
and	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
up	O	O	O
to	O	O	O
14	O	O	O
years	O	O	O
follow-up	O	O	B-Entity
.	O	O	O

Second	O	O	O
,	O	O	O
an	O	O	O
improvement	O	O	B-Entity
of	O	O	O
left	O	O	B-Entity
ventricle	O	O	I-Entity
ejection	O	O	I-Entity
fraction	O	O	I-Entity
(	O	O	O
LVEF	O	O	B-Entity
)	O	O	O
in	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
group	O	O	B-Entity
retained	O	O	B-Entity
for	O	O	O
5	O	O	O
years	O	O	O
in	O	O	O
contrast	O	O	B-Entity
with	O	O	O
CABG	O	O	B-Entity
-	O	O	O
only	O	O	B-Entity
group	O	O	O
,	O	O	O
where	O	O	O
no	O	O	O
significant	O	O	O
changes	O	O	O
in	O	O	O
LVEF	O	O	O
after	O	O	O
2	O	O	O
years	O	O	O
were	O	O	O
observed	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
LVEF	O	O	B-Entity
under	O	O	O
30	O	O	O
%	O	O	O
and	O	O	O
left	O	O	B-Entity
ventricle	O	O	I-Entity
end	O	O	I-Entity
diastolic	O	O	I-Entity
diameter	O	O	I-Entity
above	O	O	O
60	O	O	O
mm	O	O	O
were	O	O	O
independent	O	O	O
predictors	O	O	B-Entity
of	O	O	O
functional	O	O	B-Entity
response	O	O	O
to	O	O	O
CD133	O	O	B-Entity
+	O	O	I-Entity
cell	O	O	I-Entity
therapy	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
with	O	O	O
overt	O	O	B-Entity
heart	O	O	I-Entity
failure	O	O	I-Entity
benefit	O	O	B-Entity
most	O	O	B-Entity
from	O	O	O
CABG	O	O	B-Entity
combined	O	O	B-Entity
with	O	O	O
intramyocardial	O	O	B-Entity
injection	O	O	B-Entity
of	O	O	O
CD133	O	O	B-Entity
+	O	O	I-Entity
bone	O	O	I-Entity
marrow	O	O	I-Entity
mononuclear	O	O	I-Entity
cell	O	O	I-Entity
within	O	O	O
the	O	O	O
group	O	O	B-Entity
.	O	O	O

An	O	O	O
improvement	O	O	B-Entity
LVEF	O	O	B-Entity
in	O	O	O
stem	O	O	B-Entity
cell	O	O	I-Entity
group	O	O	B-Entity
remained	O	O	O
for	O	O	O
5	O	O	O
years	O	O	O
in	O	O	O
contrast	O	O	B-Entity
with	O	O	O
the	O	O	O
CABG	O	O	B-Entity
-	O	O	O
only	O	O	B-Entity
group	O	O	O
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
,	O	O	O
in	O	O	O
whom	O	O	O
the	O	O	O
improvement	O	O	B-Entity
of	O	O	O
both	O	O	O
LVEF	O	O	B-Entity
and	O	O	O
LVED	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
,	O	O	O
have	O	O	O
benefited	O	O	O
by	O	O	O
increased	O	O	B-Entity
life	O	O	B-Entity
expectancy	O	O	I-Entity
.	O	O	O

-DOCSTART- (28454482)

Effects	O	O	B-Entity
of	O	O	O
Environmental	O	O	B-Entity
Factors	O	O	B-Entity
and	O	O	O
Metallic	O	O	B-Entity
Electrodes	O	O	B-Entity
on	O	O	O
AC	O	O	B-Entity
Electrical	O	O	B-Entity
Conduction	O	O	I-Entity
Through	O	O	O
DNA	O	O	O
Molecule	O	O	O

Deoxyribonucleic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	I-Entity
DNA	O	O	I-Entity
)	O	O	I-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
best	O	O	O
candidate	O	O	O
materials	O	O	O
for	O	O	O
various	O	O	O
device	O	O	B-Entity
applications	O	O	B-Entity
such	O	O	O
as	O	O	O
in	O	O	O
electrodes	O	O	B-Entity
for	O	O	O
rechargeable	O	O	B-Entity
batteries	O	O	I-Entity
,	O	O	O
biosensors	O	O	B-Entity
,	O	O	O
molecular	O	O	B-Entity
electronics	O	O	I-Entity
,	O	O	O
medical	O	O	B-Entity
-	O	O	O
and	O	O	O
biomedical	O	O	B-Entity
-	O	O	O
applications	O	O	O
etc	O	O	O
.	O	O	O

Hence	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
worthwhile	O	O	O
to	O	O	O
examine	O	O	O
the	O	O	O
mechanism	O	O	O
of	O	O	O
charge	O	O	B-Entity
transport	O	O	I-Entity
in	O	O	O
the	O	O	O
DNA	O	O	B-Entity
molecule	O	O	I-Entity
,	O	O	O
however	O	O	O
,	O	O	O
still	O	O	O
a	O	O	O
question	O	O	O
without	O	O	O
a	O	O	O
clear	O	O	O
answer	O	O	O
is	O	O	O
DNA	O	O	O
a	O	O	O
molecular	O	O	B-Entity
conducting	O	O	B-Entity
material	O	O	B-Entity
(	O	O	O
wire	O	O	B-Entity
)	O	O	O
,	O	O	O
semiconductor	O	O	B-Entity
,	O	O	O
or	O	O	O
insulator	O	O	B-Entity
?	O	O	O

The	O	O	O
answer	O	O	O
,	O	O	O
after	O	O	O
the	O	O	O
published	O	O	O
data	O	O	O
,	O	O	O
is	O	O	O
still	O	O	O
ambiguous	O	O	O
without	O	O	O
any	O	O	O
confirmed	O	O	O
and	O	O	O
clear	O	O	O
scientific	O	O	O
answer	O	O	O
.	O	O	O

DNA	O	O	B-Entity
is	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
always	O	O	O
surrounded	O	O	O
with	O	O	O
different	O	O	O
electric	O	O	B-Entity
charges	O	O	I-Entity
,	O	O	O
ions	O	O	B-Entity
,	O	O	O
and	O	O	O
dipoles	O	O	B-Entity
.	O	O	O

These	O	O	O
surrounding	O	O	O
charges	O	O	B-Entity
and	O	O	O
electric	O	O	B-Entity
barrier(s	O	O	I-Entity
)	O	O	I-Entity
due	O	O	O
to	O	O	O
metallic	O	O	B-Entity
electrodes	O	O	B-Entity
(	O	O	O
as	O	O	O
environmental	O	O	B-Entity
factors	O	O	B-Entity
(	O	O	O
EFs	O	O	B-Entity
)	O	O	O
)	O	O	O
play	O	O	O
a	O	O	O
substantial	O	O	O
role	O	O	O
when	O	O	O
measuring	O	O	B-Entity
the	O	O	O
electrical	O	O	B-Entity
conductivity	O	O	I-Entity
through	O	O	O
λ-double	O	O	B-Entity
helix	O	O	I-Entity
(	O	O	I-Entity
DNA	O	O	I-Entity
)	O	O	I-Entity
molecule	O	O	I-Entity
suspended	O	O	O
between	O	O	O
metallic	O	O	O
electrodes	O	O	O
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
strong	O	O	B-Entity
frequency	O	O	B-Entity
dependence	O	O	O
of	O	O	O
AC	O	O	B-Entity
-	O	O	O
complex	O	O	B-Entity
conductivity	O	O	B-Entity
comes	O	O	O
from	O	O	O
the	O	O	O
electrical	O	O	B-Entity
conduction	O	O	I-Entity
of	O	O	O
EFs	O	O	B-Entity
.	O	O	O

This	O	O	O
leads	O	O	O
to	O	O	O
superimposing	O	O	O
serious	O	O	O
incorrect	O	O	O
experimental	O	O	B-Entity
data	O	O	O
to	O	O	O
measured	O	O	B-Entity
ones	O	O	O
.	O	O	O

At	O	O	O
1	O	O	O
MHz	O	O	O
,	O	O	O
we	O	O	O
carried	O	O	O
out	O	O	O
a	O	O	O
first	O	O	O
control	O	O	O
experiment	O	O	B-Entity
on	O	O	O
electrical	O	O	B-Entity
conductivity	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
DNA	O	O	B-Entity
molecule	O	O	I-Entity
.	O	O	O

If	O	O	O
there	O	O	O
are	O	O	O
possible	O	O	O
electrical	O	O	B-Entity
conduction	O	O	I-Entity
due	O	O	O
to	O	O	O
stray	O	O	O
ions	O	O	B-Entity
and	O	O	O
contribution	O	O	O
of	O	O	O
substrate	O	O	O
,	O	O	O
we	O	O	O
will	O	O	O
detected	O	O	O
them	O	O	O
.	O	O	O

This	O	O	O
control	O	O	O
experiment	O	O	B-Entity
revealed	O	O	O
that	O	O	O
there	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
played	O	O	O
by	O	O	O
the	O	O	O
environmental	O	O	B-Entity
-	O	O	O
charges	O	O	B-Entity
around	O	O	O
DNA	O	O	B-Entity
molecule	O	O	I-Entity
and	O	O	O
any	O	O	O
experiment	O	O	O
should	O	O	O
consider	O	O	O
this	O	O	O
role	O	O	O
.	O	O	O

We	O	O	O
have	O	O	O
succeeded	O	O	O
to	O	O	O
measure	O	O	B-Entity
both	O	O	O
electrical	O	O	B-Entity
conductivity	O	O	I-Entity
due	O	O	O
to	O	O	O
EFs	O	O	B-Entity
(	O	O	O
σ	O	O	O
ENV	O	O	O
)	O	O	O
and	O	O	O
electrical	O	O	O
conductivity	O	O	O
due	O	O	O
to	O	O	O
DNA	O	O	B-Entity
molecule	O	O	I-Entity
(	O	O	O
σ	O	O	B-Entity
DNA	O	O	I-Entity
)	O	O	O
independently	O	O	O
by	O	O	O
carrying	O	O	O
the	O	O	O
measurements	O	O	B-Entity
at	O	O	O
different	O	O	O
DNA	O	O	O
-	O	O	O
lengths	O	O	B-Entity
and	O	O	O
subtracting	O	O	O
the	O	O	O
data	O	O	O
.	O	O	O

We	O	O	O
carried	O	O	O
out	O	O	O
measurements	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	O
of	O	O	O
frequency	O	O	B-Entity
(	O	O	I-Entity
f	O	O	I-Entity
)	O	O	I-Entity
and	O	O	O
temperature	O	O	B-Entity
(	O	O	I-Entity
T	O	O	I-Entity
)	O	O	I-Entity
in	O	O	O
the	O	O	O
ranges	O	O	O
0.1	O	O	O
Hz	O	O	O
<	O	O	O
f	O	O	O
<	O	O	O
1	O	O	O
MHz	O	O	O
and	O	O	O
288	O	O	O
K	O	O	O
<	O	O	O
T	O	O	O
<	O	O	O
343	O	O	O
K.	O	O	O
The	O	O	O
measured	O	O	B-Entity
conductivity	O	O	B-Entity
(	O	O	O
σ	O	O	O
MES	O	O	O
)	O	O	O
portrays	O	O	O
a	O	O	O
metal	O	O	B-Entity
-like	O	O	O
behavior	O	O	O
at	O	O	O
high	O	O	B-Entity
frequencies	O	O	I-Entity
near	O	O	O
1	O	O	O
MHz	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
σ	O	O	B-Entity
DNA	O	O	I-Entity
was	O	O	O
far	O	O	O
from	O	O	O
this	O	O	O
behavior	O	O	O
because	O	O	O
the	O	O	O
conduction	O	O	B-Entity
due	O	O	O
to	O	O	O
EFs	O	O	B-Entity
superimposes	O	O	O
σ	O	O	O
DNA	O	O	O
,	O	O	O
in	O	O	O
particular	O	O	O
at	O	O	O
low	O	O	B-Entity
frequencies	O	O	I-Entity
.	O	O	O

By	O	O	O
measuring	O	O	B-Entity
the	O	O	O
electrical	O	O	B-Entity
conductivity	O	O	I-Entity
at	O	O	O
different	O	O	O
lengths	O	O	B-Entity
:	O	O	O
40	O	O	O
,	O	O	O
60	O	O	O
,	O	O	O
80	O	O	O
,	O	O	O
and	O	O	O
100	O	O	O
nm	O	O	O
,	O	O	O
we	O	O	O
have	O	O	O
succeeded	O	O	O
not	O	O	O
only	O	O	O
to	O	O	O
separate	O	O	O
the	O	O	O
electrical	O	O	B-Entity
conduction	O	O	I-Entity
of	O	O	O
the	O	O	O
DNA	O	O	B-Entity
molecule	O	O	B-Entity
from	O	O	O
all	O	O	O
EFs	O	O	B-Entity
effects	O	O	O
that	O	O	O
surround	O	O	O
the	O	O	O
molecule	O	O	O
,	O	O	O
but	O	O	O
also	O	O	O
to	O	O	O
present	O	O	O
accurate	O	O	O
values	O	O	O
of	O	O	O
σ	O	O	B-Entity
DNA	O	O	I-Entity
and	O	O	O
the	O	O	O
dielectric	O	O	B-Entity
constant	O	O	I-Entity
of	O	O	O
the	O	O	O
molecule	O	O	O
ε'DNA	O	O	B-Entity
as	O	O	O
a	O	O	O
function	O	O	O
of	O	O	O
temperature	O	O	O
and	O	O	O
frequency	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
explain	O	O	O
these	O	O	O
data	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
a	O	O	O
model	O	O	O
describing	O	O	O
the	O	O	O
electrical	O	O	B-Entity
conduction	O	O	I-Entity
through	O	O	O
DNA	O	O	B-Entity
molecule	O	O	I-Entity
:	O	O	O
DNA	O	O	O
is	O	O	O
a	O	O	O
classical	O	O	O
semiconductor	O	O	B-Entity
with	O	O	O
charges	O	O	B-Entity
,	O	O	O
dipoles	O	O	B-Entity
and	O	O	O
ions	O	O	B-Entity
that	O	O	O
result	O	O	O
in	O	O	O
creation	O	O	O
of	O	O	O
localized	O	O	B-Entity
energy	O	O	B-Entity
-	O	O	O
states	O	O	B-Entity
(	O	O	O
LESs	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
extended	O	O	O
bands	O	O	O
and	O	O	O
in	O	O	O
the	O	O	O
energy	O	O	B-Entity
gap	O	O	I-Entity
of	O	O	O
the	O	O	O
DNA	O	O	B-Entity
molecule	O	O	I-Entity
.	O	O	O

This	O	O	O
model	O	O	O
explains	O	O	O
clearly	O	O	O
the	O	O	O
mechanism	O	O	O
of	O	O	O
charge	O	O	B-Entity
transfer	O	O	I-Entity
mechanism	O	O	I-Entity
in	O	O	O
the	O	O	O
DNA	O	O	B-Entity
,	O	O	O
and	O	O	O
it	O	O	O
sheds	O	O	O
light	O	O	O
on	O	O	O
why	O	O	O
the	O	O	O
charge	O	O	O
transfer	O	O	O
through	O	O	O
the	O	O	O
DNA	O	O	O
can	O	O	O
lead	O	O	O
to	O	O	O
insulating	O	O	B-Entity
,	O	O	O
semiconducting	O	O	B-Entity
,	O	O	O
or	O	O	O
metallic	O	O	B-Entity
behavior	O	O	O
on	O	O	O
the	O	O	O
same	O	O	O
time	O	O	O
.	O	O	O

The	O	O	O
model	O	O	O
considers	O	O	O
charges	O	O	B-Entity
on	O	O	O
DNA	O	O	B-Entity
,	O	O	O
in	O	O	O
the	O	O	O
extended	O	O	O
bands	O	O	O
,	O	O	O
either	O	O	O
could	O	O	O
be	O	O	O
free	O	O	O
to	O	O	O
move	O	O	O
under	O	O	O
electric	O	O	B-Entity
field	O	O	I-Entity
or	O	O	O
localized	O	O	O
in	O	O	O
potential	O	O	B-Entity
wells/hills	O	O	I-Entity
.	O	O	O

Localization	O	O	B-Entity
of	O	O	O
charges	O	O	B-Entity
in	O	O	O
DNA	O	O	B-Entity
is	O	O	O
an	O	O	O
intrinsic	O	O	B-Entity
structural	O	O	B-Entity
-	O	O	O
property	O	O	B-Entity
of	O	O	O
this	O	O	O
solitaire	O	O	O
molecule	O	O	O
.	O	O	O

At	O	O	O
all	O	O	O
temperatures	O	O	O
,	O	O	O
the	O	O	O
expected	O	O	O
increase	O	O	O
in	O	O	O
thermal	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
charge	O	O	B-Entity
is	O	O	O
attributed	O	O	O
to	O	O	O
the	O	O	O
delocalization	O	O	B-Entity
of	O	O	I-Entity
holes	O	O	I-Entity
(	O	O	O
or/and	O	O	O
electrons	O	O	B-Entity
)	O	O	O
in	O	O	O
potential	O	O	B-Entity
hills	O	O	I-Entity
(	O	O	O
or/and	O	O	O
potential	O	O	B-Entity
wells	O	O	I-Entity
)	O	O	I-Entity
which	O	O	O
accurately	O	O	O
accounts	O	O	O
for	O	O	O
the	O	O	O
total	O	O	O
electric	O	O	B-Entity
and	O	O	O
dielectric	O	O	B-Entity
behavior	O	O	I-Entity
through	O	O	O
DNA	O	O	B-Entity
molecule	O	O	I-Entity
.	O	O	O

We	O	O	O
succeeded	O	O	O
to	O	O	O
fit	O	O	O
the	O	O	O
experiment	O	O	B-Entity
al	O	O	O
data	O	O	O
to	O	O	O
the	O	O	O
proposed	O	O	O
model	O	O	O
with	O	O	O
reasonable	O	O	O
magnitudes	O	O	O
of	O	O	O
potential	O	O	B-Entity
hills/wells	O	O	I-Entity
that	O	O	O
are	O	O	O
in	O	O	O
the	O	O	O
energy	O	O	B-Entity
range	O	O	O
from	O	O	O
0.068	O	O	O
eV.	O	O	O

-DOCSTART- (28456987)

Next-Generation	O	O	B-Entity
Sequencing	O	O	I-Entity
Approaches	O	O	B-Entity
to	O	O	O
Define	O	O	O
the	O	O	O
Role	O	O	B-Entity
of	O	O	O
the	O	O	O
Autophagy	O	O	B-Entity
Lysosomal	O	O	I-Entity
Pathway	O	O	I-Entity
in	O	O	O
Human	O	O	B-Entity
Disease	O	O	B-Entity
:	O	O	O
The	O	O	O
Example	O	O	B-Entity
of	O	O	O
LysoPlex	O	O	O

Next-Generation	O	O	B-Entity
Sequencing	O	O	I-Entity
(	O	O	I-Entity
NGS	O	O	I-Entity
)	O	O	I-Entity
technologies	O	O	I-Entity
have	O	O	O
deeply	O	O	O
changed	O	O	O
the	O	O	O
throughput	O	O	B-Entity
of	O	O	O
genetic	O	O	B-Entity
testing	O	O	I-Entity
allowing	O	O	O
analyzing	O	O	O
millions	O	O	O
of	O	O	O
DNA	O	O	B-Entity
fragments	O	O	I-Entity
in	O	O	O
parallel	O	O	B-Entity
.	O	O	O

One	O	O	O
key	O	O	O
application	O	O	B-Entity
is	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
genetically	O	O	B-Entity
heterogeneous	O	O	B-Entity
and	O	O	O
complex	O	O	B-Entity
diseases	O	O	I-Entity
where	O	O	O
50	O	O	O
-	O	O	O
100	O	O	O
different	O	O	O
genes	O	O	B-Entity
may	O	O	O
converge	O	O	O
to	O	O	O
control	O	O	B-Entity
the	O	O	O
same	O	O	O
pathways	O	O	B-Entity
.	O	O	O

These	O	O	O
disorders	O	O	B-Entity
can	O	O	O
not	O	O	O
be	O	O	O
studied	O	O	O
using	O	O	O
traditional	O	O	B-Entity
approaches	O	O	B-Entity
,	O	O	O
based	O	O	O
on	O	O	O
gene-by-gene	O	O	B-Entity
Sanger	O	O	I-Entity
sequencing	O	O	I-Entity
.	O	O	O

We	O	O	O
have	O	O	O
set	O	O	O
up	O	O	O
an	O	O	O
NGS	O	O	B-Entity
protocol	O	O	B-Entity
based	O	O	O
on	O	O	O
a	O	O	O
specific	O	O	O
selection	O	O	B-Entity
of	O	O	O
DNA	O	O	B-Entity
regions	O	O	I-Entity
belonging	O	O	O
to	O	O	O
about	O	O	O
900	O	O	O
genes	O	O	B-Entity
of	O	O	O
the	O	O	O
autophagy-lysosomal	O	O	B-Entity
(	O	O	I-Entity
ALP	O	O	I-Entity
)	O	O	I-Entity
pathway	O	O	I-Entity
.	O	O	O

We	O	O	O
here	O	O	O
specify	O	O	O
all	O	O	O
the	O	O	O
technical	O	O	B-Entity
steps	O	O	I-Entity
and	O	O	O
challenges	O	O	B-Entity
of	O	O	O
our	O	O	O
protocol	O	O	B-Entity
,	O	O	O
named	O	O	O
LysoPlex	O	O	B-Entity
.	O	O	O

This	O	O	O
is	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
Haloplex	O	O	O
technology	O	O	O
and	O	O	O
together	O	O	O
with	O	O	O
high-coverage	O	O	B-Entity
sequencing	O	O	I-Entity
empowers	O	O	O
a	O	O	O
high	O	O	O
and	O	O	O
uniform	O	O	O
coverage	O	O	O
of	O	O	O
ALP	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

LysoPlex	O	O	B-Entity
outplays	O	O	O
other	O	O	O
NGS	O	O	B-Entity
applications	O	O	B-Entity
in	O	O	O
sensitivity	O	O	B-Entity
and	O	O	I-Entity
specificity	O	O	I-Entity
,	O	O	O
providing	O	O	O
an	O	O	O
accurate	O	O	O
picture	O	O	O
of	O	O	O
all	O	O	O
variations	O	O	B-Entity
in	O	O	O
ALP	O	O	B-Entity
genes	O	O	I-Entity
.	O	O	O

-DOCSTART- (28457143)

Typical	O	O	O
Skin	O	O	B-Entity
Injuries	O	O	I-Entity
in	O	O	O
Children	O	O	B-Entity
With	O	O	O
Autism	O	O	O
Spectrum	O	O	O
Disorder	O	O	O

Pediatric	O	O	B-Entity
skin	O	O	B-Entity
injuries	O	O	I-Entity
have	O	O	O
primarily	O	O	O
been	O	O	O
described	O	O	O
in	O	O	O
typically	O	O	O
developing	O	O	B-Entity
children	O	O	I-Entity
.	O	O	O

Our	O	O	O
objectives	O	O	B-Entity
were	O	O	O
to	O	O	O
describe	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
and	O	O	O
pattern	O	O	B-Entity
of	O	O	O
skin	O	O	B-Entity
injuries	O	O	I-Entity
of	O	O	O
children	O	O	B-Entity
with	O	O	O
autism	O	O	B-Entity
spectrum	O	O	I-Entity
disorder	O	O	I-Entity
(	O	O	O
ASD	O	O	B-Entity
)	O	O	O
,	O	O	O
to	O	O	O
describe	O	O	O
how	O	O	O
this	O	O	O
compared	O	O	O
with	O	O	O
previously	O	O	O
demonstrated	O	O	O
skin	O	O	B-Entity
injury	O	O	I-Entity
locations	O	O	B-Entity
in	O	O	O
typically	O	O	O
developing	O	O	B-Entity
children	O	O	I-Entity
,	O	O	O
and	O	O	O
to	O	O	O
identify	O	O	O
differences	O	O	B-Entity
in	O	O	O
skin	O	O	O
injury	O	O	O
frequency	O	O	B-Entity
and	O	O	O
locations	O	O	O
between	O	O	O
autistic	O	O	B-Entity
children	O	O	I-Entity
with	O	O	O
and	O	O	O
without	O	O	O
self-injurious	O	O	B-Entity
behaviors	O	O	I-Entity
(	O	O	O
SIBs	O	O	B-Entity
)	O	O	O
.	O	O	O

Children	O	O	B-Entity
with	O	O	O
ASD	O	O	B-Entity
were	O	O	O
recruited	O	O	O
between	O	O	O
September	O	O	B-Entity
of	O	O	O
2011	O	O	O
and	O	O	O
September	O	O	O
of	O	O	O
2014	O	O	O
.	O	O	O

Demographic	O	O	B-Entity
information	O	O	I-Entity
was	O	O	O
obtained	O	O	O
from	O	O	O
the	O	O	O
caregiver	O	O	B-Entity
.	O	O	O

All	O	O	O
skin	O	O	B-Entity
injuries	O	O	I-Entity
and	O	O	O
their	O	O	O
locations	O	O	B-Entity
were	O	O	O
documented	O	O	B-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
41	O	O	O
children	O	O	B-Entity
enrolled	O	O	O
,	O	O	O
half	O	O	O
were	O	O	O
reported	O	O	O
to	O	O	O
have	O	O	O
SIBs	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
identified	O	O	O
skin	O	O	B-Entity
injury	O	O	I-Entity
locations	O	O	B-Entity
were	O	O	O
the	O	O	O
legs	O	O	B-Entity
,	O	O	O
knees	O	O	B-Entity
,	O	O	O
and	O	O	O
back	O	O	B-Entity
.	O	O	O

Children	O	O	B-Entity
with	O	O	O
autism	O	O	B-Entity
(	O	O	O
1	O	O	O
)	O	O	O
obtain	O	O	O
skin	O	O	B-Entity
injuries	O	O	I-Entity
frequently	O	O	O
and	O	O	O
in	O	O	O
similar	O	O	O
locations	O	O	B-Entity
as	O	O	O
typically	O	O	O
developing	O	O	B-Entity
children	O	O	I-Entity
and	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
rarely	O	O	O
obtain	O	O	O
skin	O	O	O
injuries	O	O	O
to	O	O	O
locations	O	O	O
that	O	O	O
are	O	O	O
considered	O	O	O
uncommon	O	O	O
for	O	O	O
accidental	O	O	B-Entity
injuries	O	O	I-Entity
despite	O	O	O
reports	O	O	O
of	O	O	O
SIBs	O	O	B-Entity
.	O	O	O

-DOCSTART- (28459420)

Is	O	O	O
Total	O	O	B-Entity
Elbow	O	O	I-Entity
Arthroplasty	O	O	I-Entity
Safe	O	O	B-Entity
as	O	O	O
an	O	O	O
Outpatient	O	O	B-Entity
Procedure	O	O	I-Entity
?	O	O	O

Ambulatory	O	O	B-Entity
surgery	O	O	I-Entity
centers	O	O	I-Entity
are	O	O	O
the	O	O	O
preferred	O	O	B-Entity
setting	O	O	B-Entity
for	O	O	O
many	O	O	O
procedures	O	O	B-Entity
formerly	O	O	O
performed	O	O	B-Entity
in	O	O	O
a	O	O	O
hospital	O	O	B-Entity
setting	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
sought	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
outpatient	O	O	B-Entity
total	O	O	B-Entity
elbow	O	O	I-Entity
arthroplasty	O	O	I-Entity
(	O	O	O
TEA	O	O	B-Entity
)	O	O	O
is	O	O	O
as	O	O	O
safe	O	O	B-Entity
as	O	O	O
inpatient	O	O	B-Entity
TEA	O	O	O
.	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	B-Entity
of	O	O	O
inpatient	O	O	B-Entity
(	O	O	O
IP	O	O	B-Entity
)	O	O	O
versus	O	O	O
outpatient	O	O	B-Entity
(	O	O	O
OP	O	O	B-Entity
)	O	O	O
TEA	O	O	B-Entity
by	O	O	O
a	O	O	O
single	O	O	B-Entity
surgeon	O	O	B-Entity
over	O	O	O
a	O	O	O
period	O	O	O
of	O	O	O
18	O	O	O
years	O	O	B-Entity
.	O	O	O

Demographic	O	O	B-Entity
,	O	O	O
social	O	O	B-Entity
,	O	O	O
and	O	O	O
comorbidity	O	O	B-Entity
measures	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
complication	O	O	B-Entity
rates	O	O	B-Entity
were	O	O	O
analyzed	O	O	B-Entity
and	O	O	O
stratified	O	O	B-Entity
by	O	O	O
IP	O	O	B-Entity
or	O	O	O
OP	O	O	B-Entity
status	O	O	B-Entity
.	O	O	O

Bivariate	O	O	B-Entity
comparison	O	O	I-Entity
showed	O	O	O
increased	O	O	B-Entity
prevalence	O	O	B-Entity
of	O	O	O
coronary	O	O	B-Entity
artery	O	O	I-Entity
disease	O	O	I-Entity
in	O	O	O
the	O	O	O
OP	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
32	O	O	O
%	O	O	O
vs.	O	O	O
7	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
increased	O	O	O
age	O	O	B-Entity
in	O	O	O
the	O	O	O
IP	O	O	B-Entity
group	O	O	O
(	O	O	O
68	O	O	O
years	O	O	B-Entity
vs.	O	O	O
58	O	O	O
years	O	O	O
)	O	O	O
.	O	O	O

All	O	O	O
other	O	O	O
demographic	O	O	B-Entity
,	O	O	O
social	O	O	B-Entity
,	O	O	O
and	O	O	O
comorbidity	O	O	B-Entity
factors	O	O	I-Entity
were	O	O	O
comparable	O	O	B-Entity
between	O	O	O
the	O	O	O
IP	O	O	B-Entity
and	O	O	O
OP	O	O	B-Entity
groups	O	O	B-Entity
,	O	O	O
although	O	O	O
more	O	O	B-Entity
infections	O	O	B-Entity
were	O	O	O
seen	O	O	B-Entity
in	O	O	O
the	O	O	O
IP	O	O	O
group	O	O	B-Entity
.	O	O	O

The	O	O	O
surgeons	O	O	B-Entity
'	O	O	I-Entity
initial	O	O	B-Entity
learning	O	O	I-Entity
curve	O	O	I-Entity
occurred	O	O	B-Entity
mostly	O	O	O
within	O	O	O
the	O	O	O
IP	O	O	B-Entity
group	O	O	B-Entity
.	O	O	O

Most	O	O	O
important	O	O	O
,	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
complication	O	O	B-Entity
rate	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
between	O	O	O
the	O	O	O
IP	O	O	B-Entity
and	O	O	O
OP	O	O	B-Entity
groups	O	O	B-Entity
.	O	O	O

-DOCSTART- (28459654)

Developmental	O	O	B-Entity
Hypoxia	O	O	B-Entity
Has	O	O	O
Negligible	O	O	B-Entity
Effects	O	O	B-Entity
on	O	O	O
Long-Term	O	O	B-Entity
Hypoxia	O	O	O
Tolerance	O	O	B-Entity
and	O	O	O
Aerobic	O	O	B-Entity
Metabolism	O	O	I-Entity
of	O	O	O
Atlantic	O	O	B-Entity
Salmon	O	O	I-Entity
(	O	O	O
Salmo	O	O	B-Entity
salar	O	O	I-Entity
)	O	O	O

Exposure	O	O	B-Entity
to	O	O	I-Entity
developmental	O	O	B-Entity
hypoxia	O	O	B-Entity
can	O	O	O
have	O	O	O
long-term	O	O	B-Entity
impacts	O	O	B-Entity
on	O	O	O
the	O	O	O
physiological	O	O	B-Entity
performance	O	O	B-Entity
of	O	O	O
fish	O	O	B-Entity
because	O	O	O
of	O	O	O
irreversible	O	O	B-Entity
plasticity	O	O	B-Entity
.	O	O	O

Wild	O	O	B-Entity
and	O	O	O
captive-reared	O	O	B-Entity
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
(	O	O	O
Salmo	O	O	B-Entity
salar	O	O	I-Entity
)	O	O	O
can	O	O	O
be	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
hypoxic	O	O	B-Entity
conditions	O	O	B-Entity
during	O	O	O
development	O	O	B-Entity
and	O	O	O
continue	O	O	B-Entity
to	O	O	O
experience	O	O	O
fluctuating	O	O	B-Entity
oxygen	O	O	B-Entity
levels	O	O	B-Entity
as	O	O	O
juveniles	O	O	B-Entity
and	O	O	O
adults	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
examine	O	O	B-Entity
whether	O	O	O
developmental	O	O	B-Entity
hypoxia	O	O	B-Entity
impacts	O	O	B-Entity
subsequent	O	O	B-Entity
hypoxia	O	O	O
tolerance	O	O	B-Entity
and	O	O	O
aerobic	O	O	B-Entity
performance	O	O	B-Entity
of	O	O	O
Atlantic	O	O	B-Entity
salmon	O	O	I-Entity
.	O	O	O

Individuals	O	O	B-Entity
at	O	O	O
8	O	O	O
°	O	O	O
C	O	O	O
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
50	O	O	O
%	O	O	O
(	O	O	O
hypoxia	O	O	B-Entity
)	O	O	O
or	O	O	O
100	O	O	O
%	O	O	O
(	O	O	O
normoxia	O	O	B-Entity
)	O	O	O
dissolved	O	O	B-Entity
oxygen	O	O	I-Entity
(	O	O	I-Entity
DO	O	O	I-Entity
)	O	O	I-Entity
saturation	O	O	I-Entity
(	O	O	O
as	O	O	O
percent	O	O	O
of	O	O	O
air	O	O	B-Entity
saturation	O	O	I-Entity
)	O	O	O
from	O	O	O
fertilization	O	O	B-Entity
for	O	O	O
∼100	O	O	O
d	O	O	O
(	O	O	O
800	O	O	O
degree	O	O	O
days	O	O	O
)	O	O	O
and	O	O	O
then	O	O	O
raised	O	O	B-Entity
in	O	O	O
normoxic	O	O	B-Entity
conditions	O	O	B-Entity
for	O	O	O
a	O	O	O
further	O	O	O
15	O	O	O
mo	O	O	O
.	O	O	O

At	O	O	O
18	O	O	O
mo	O	O	O
after	O	O	O
fertilization	O	O	B-Entity
,	O	O	O
aerobic	O	O	B-Entity
scope	O	O	B-Entity
was	O	O	O
calculated	O	O	B-Entity
in	O	O	O
normoxia	O	O	B-Entity
(	O	O	O
100	O	O	O
%	O	O	O
DO	O	O	B-Entity
)	O	O	O
and	O	O	O
acute	O	O	B-Entity
(	O	O	O
18	O	O	O
h	O	O	O
)	O	O	O
hypoxia	O	O	B-Entity
(	O	O	O
50	O	O	O
%	O	O	O
DO	O	O	O
)	O	O	O
from	O	O	O
the	O	O	O
difference	O	O	B-Entity
between	O	O	O
the	O	O	O
minimum	O	O	B-Entity
and	O	O	O
maximum	O	O	B-Entity
oxygen	O	O	B-Entity
consumption	O	O	I-Entity
rates	O	O	B-Entity
(	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
and	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
at	O	O	O
10	O	O	O
°	O	O	O
C	O	O	O
.	O	O	O

Hypoxia	O	O	B-Entity
tolerance	O	O	B-Entity
was	O	O	O
determined	O	O	B-Entity
as	O	O	O
the	O	O	O
DO	O	O	B-Entity
at	O	O	O
which	O	O	O
loss	O	O	B-Entity
of	O	O	I-Entity
equilibrium	O	O	I-Entity
(	O	O	O
LOE	O	O	B-Entity
)	O	O	O
occurred	O	O	B-Entity
in	O	O	O
a	O	O	O
constantly	O	O	O
decreasing	O	O	B-Entity
DO	O	O	O
environment	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	B-Entity
difference	O	O	I-Entity
in	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
,	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
,	O	O	O
or	O	O	O
aerobic	O	O	B-Entity
scope	O	O	B-Entity
between	O	O	O
fish	O	O	B-Entity
raised	O	O	B-Entity
in	O	O	O
hypoxia	O	O	B-Entity
or	O	O	O
normoxia	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
some	O	O	O
evidence	O	O	B-Entity
that	O	O	O
hypoxia	O	O	B-Entity
tolerance	O	O	B-Entity
was	O	O	O
lower	O	O	B-Entity
(	O	O	O
higher	O	O	O
DO	O	O	B-Entity
at	O	O	O
LOE	O	O	B-Entity
)	O	O	O
in	O	O	O
hypoxia	O	O	O
-	O	O	O
raised	O	O	B-Entity
fish	O	O	B-Entity
compared	O	O	O
with	O	O	O
those	O	O	O
raised	O	O	O
in	O	O	O
normoxia	O	O	B-Entity
,	O	O	O
but	O	O	O
the	O	O	O
magnitude	O	O	B-Entity
of	O	O	O
the	O	O	O
effect	O	O	B-Entity
was	O	O	O
small	O	O	B-Entity
(	O	O	O
12.52	O	O	O
%	O	O	O
DO	O	O	O
vs.	O	O	O
11.73	O	O	O
%	O	O	O
DO	O	O	O
at	O	O	O
LOE	O	O	O
)	O	O	O
.	O	O	O

Acute	O	O	B-Entity
hypoxia	O	O	B-Entity
significantly	O	O	O
reduced	O	O	B-Entity
aerobic	O	O	B-Entity
scope	O	O	B-Entity
by	O	O	O
reducing	O	O	B-Entity
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
,	O	O	O
while	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
remained	O	O	O
unchanged	O	O	B-Entity
.	O	O	O

Interestingly	O	O	O
,	O	O	O
acute	O	O	B-Entity
hypoxia	O	O	B-Entity
uncovered	O	O	O
individual	O	O	B-Entity
-level	O	O	O
relationships	O	O	B-Entity
between	O	O	O
DO	O	O	B-Entity
at	O	O	O
LOE	O	O	B-Entity
and	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
,	O	O	O
[	O	O	O
Formula	O	O	O
:	O	O	O
see	O	O	O
text	O	O	O
]	O	O	O
,	O	O	O
and	O	O	O
aerobic	O	O	B-Entity
scope	O	O	B-Entity
.	O	O	O

We	O	O	O
discuss	O	O	O
our	O	O	O
findings	O	O	B-Entity
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
developmental	O	O	B-Entity
trajectories	O	O	O
and	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
aerobic	O	O	B-Entity
performance	O	O	B-Entity
in	O	O	O
hypoxia	O	O	B-Entity
tolerance	O	O	B-Entity
.	O	O	O

-DOCSTART- (28460374)

LDL	O	O	B-Entity
particle	O	O	B-Entity
number	O	O	I-Entity
and	O	O	O
size	O	O	B-Entity
and	O	O	O
cardiovascular	O	O	B-Entity
risk	O	O	B-Entity
:	O	O	O
anything	O	O	O
new	O	O	O
under	O	O	O
the	O	O	O
sun	O	O	O
?	O	O	O

We	O	O	O
provide	O	O	O
here	O	O	O
an	O	O	O
up-to-date	O	O	O
perspective	O	O	O
on	O	O	O
the	O	O	O
potential	O	O	B-Entity
use	O	O	B-Entity
of	O	O	O
LDL	O	O	B-Entity
particle	O	O	B-Entity
number	O	O	I-Entity
and	O	O	O
size	O	O	B-Entity
as	O	O	O
complementary	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
to	O	O	O
predict	O	O	O
and	O	O	O
manage	O	O	O
cardiovascular	O	O	B-Entity
disease	O	O	I-Entity
(	O	O	O
CVD	O	O	B-Entity
)	O	O	O
risk	O	O	O
in	O	O	O
the	O	O	O
clinical	O	O	B-Entity
realm	O	O	O
.	O	O	O

Studies	O	O	B-Entity
show	O	O	O
that	O	O	O
a	O	O	O
significant	O	O	B-Entity
proportion	O	O	B-Entity
of	O	O	O
the	O	O	O
population	O	O	B-Entity
has	O	O	O
discordant	O	O	B-Entity
LDL	O	O	B-Entity
particle	O	O	B-Entity
number	O	O	I-Entity
and	O	O	O
cholesterol	O	O	B-Entity
indices	O	O	B-Entity
[	O	O	O
non-HDL	O	O	B-Entity
cholesterol	O	O	I-Entity
(	O	O	O
HDL-C	O	O	B-Entity
)	O	O	O
]	O	O	O
.	O	O	O

Data	O	O	O
also	O	O	O
show	O	O	O
that	O	O	O
risk	O	O	O
prediction	O	O	O
may	O	O	O
be	O	O	O
improved	O	O	O
when	O	O	O
using	O	O	O
information	O	O	B-Entity
on	O	O	O
LDL	O	O	B-Entity
particle	O	O	B-Entity
number	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
discordant	O	O	B-Entity
particle	O	O	O
number	O	O	O
and	O	O	O
cholesterol	O	O	B-Entity
data	O	O	O
.	O	O	O

Yet	O	O	O
,	O	O	O
most	O	O	O
of	O	O	O
the	O	O	O
current	O	O	O
CVD	O	O	B-Entity
guidelines	O	O	B-Entity
conclude	O	O	O
that	O	O	O
LDL	O	O	B-Entity
particle	O	O	B-Entity
number	O	O	I-Entity
is	O	O	O
not	O	O	O
superior	O	O	O
to	O	O	O
cholesterol	O	O	B-Entity
indices	O	O	B-Entity
,	O	O	O
including	O	O	O
non-HDL-C	O	O	B-Entity
concentrations	O	O	B-Entity
,	O	O	O
in	O	O	O
predicting	O	O	O
CVD	O	O	O
risk	O	O	B-Entity
.	O	O	O

LDL	O	O	B-Entity
particle	O	O	B-Entity
size	O	O	I-Entity
,	O	O	O
on	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
,	O	O	O
has	O	O	O
not	O	O	O
been	O	O	O
independently	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
CVD	O	O	B-Entity
risk	O	O	B-Entity
after	O	O	O
adjustment	O	O	B-Entity
for	O	O	O
other	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
such	O	O	O
as	O	O	O
LDL	O	O	B-Entity
cholesterol	O	O	I-Entity
,	O	O	O
triglycerides	O	O	B-Entity
,	O	O	O
and	O	O	O
HDL-C	O	O	B-Entity
and	O	O	O
that	O	O	O
routine	O	O	O
use	O	O	O
of	O	O	O
information	O	O	B-Entity
pertaining	O	O	O
to	O	O	O
particle	O	O	O
size	O	O	O
to	O	O	O
determine	O	O	O
and	O	O	O
manage	O	O	O
patients	O	O	B-Entity
'	O	O	I-Entity
risk	O	O	O
is	O	O	O
not	O	O	O
yet	O	O	O
justified	O	O	O
.	O	O	O

Additional	O	O	B-Entity
studies	O	O	B-Entity
are	O	O	O
required	O	O	O
to	O	O	O
settle	O	O	O
the	O	O	O
debate	O	O	B-Entity
on	O	O	O
which	O	O	O
of	O	O	O
cholesterol	O	O	B-Entity
indices	O	O	B-Entity
and	O	O	O
LDL	O	O	B-Entity
particle	O	O	B-Entity
number	O	O	I-Entity
is	O	O	O
the	O	O	O
best	O	O	O
predictor	O	O	O
of	O	O	O
CVD	O	O	B-Entity
risk	O	O	B-Entity
,	O	O	O
and	O	O	O
if	O	O	O
such	O	O	O
measures	O	O	B-Entity
should	O	O	O
be	O	O	O
integrated	O	O	O
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

-DOCSTART- (28462032)

The	O	O	O
emerging	O	O	B-Entity
contribution	O	O	I-Entity
of	O	O	O
social	O	O	B-Entity
wasps	O	O	I-Entity
to	O	O	O
grape	O	O	B-Entity
rot	O	O	I-Entity
disease	O	O	I-Entity
ecology	O	O	O

Grape	O	O	B-Entity
sour	O	O	I-Entity
(	O	O	I-Entity
bunch	O	O	I-Entity
)	O	O	I-Entity
rot	O	O	I-Entity
is	O	O	O
a	O	O	O
polymicrobial	O	O	B-Entity
disease	O	O	I-Entity
of	O	O	O
vineyards	O	O	B-Entity
that	O	O	O
causes	O	O	O
millions	O	O	B-Entity
of	O	O	O
dollars	O	O	B-Entity
in	O	O	O
lost	O	O	B-Entity
revenue	O	O	I-Entity
per	O	O	B-Entity
year	O	O	I-Entity
due	O	O	O
to	O	O	O
decreased	O	O	B-Entity
quality	O	O	B-Entity
of	O	O	O
grapes	O	O	B-Entity
and	O	O	O
resultant	O	O	B-Entity
wine	O	O	I-Entity
.	O	O	O

The	O	O	O
disease	O	O	B-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
damaged	O	O	B-Entity
berries	O	O	B-Entity
infected	O	O	B-Entity
with	O	O	O
a	O	O	O
community	O	O	B-Entity
of	O	O	O
acetic	O	O	B-Entity
acid	O	O	I-Entity
bacteria	O	O	I-Entity
,	O	O	O
yeasts	O	O	B-Entity
,	O	O	O
and	O	O	O
filamentous	O	O	B-Entity
fungi	O	O	I-Entity
that	O	O	O
results	O	O	O
in	O	O	O
rotting	O	O	B-Entity
berries	O	O	O
with	O	O	O
high	O	O	B-Entity
amounts	O	O	B-Entity
of	O	O	O
undesirable	O	O	O
volatile	O	O	B-Entity
acidity	O	O	B-Entity
.	O	O	O

Many	O	O	O
insect	O	O	B-Entity
species	O	O	B-Entity
cause	O	O	O
the	O	O	O
initial	O	O	B-Entity
grape	O	O	B-Entity
berry	O	O	B-Entity
damage	O	O	B-Entity
that	O	O	O
can	O	O	O
lead	O	O	O
to	O	O	O
this	O	O	O
disease	O	O	B-Entity
,	O	O	O
but	O	O	O
most	O	O	O
studies	O	O	B-Entity
have	O	O	O
focused	O	O	B-Entity
on	O	O	O
the	O	O	O
role	O	O	B-Entity
of	O	O	O
fruit	O	O	B-Entity
flies	O	O	I-Entity
in	O	O	O
facilitating	O	O	O
symptoms	O	O	B-Entity
and	O	O	O
vectoring	O	O	B-Entity
the	O	O	O
microorganisms	O	O	B-Entity
of	O	O	O
this	O	O	O
disease	O	O	O
complex	O	O	B-Entity
.	O	O	O

Like	O	O	O
fruit	O	O	B-Entity
flies	O	O	I-Entity
,	O	O	O
social	O	O	B-Entity
wasps	O	O	I-Entity
are	O	O	O
abundant	O	O	B-Entity
in	O	O	O
vineyards	O	O	B-Entity
where	O	O	O
they	O	O	O
feed	O	O	O
on	O	O	O
ripe	O	O	B-Entity
berries	O	O	I-Entity
and	O	O	O
cause	O	O	O
significant	O	O	B-Entity
damage	O	O	B-Entity
,	O	O	O
while	O	O	O
also	O	O	O
dispersing	O	O	B-Entity
yeasts	O	O	B-Entity
involved	O	O	B-Entity
in	O	O	O
wine	O	O	B-Entity
fermentation	O	O	B-Entity
.	O	O	O

Despite	O	O	O
this	O	O	O
,	O	O	O
their	O	O	O
possible	O	O	O
role	O	O	B-Entity
in	O	O	O
disease	O	O	B-Entity
facilitation	O	O	O
and	O	O	O
dispersal	O	O	B-Entity
of	O	O	I-Entity
grape	O	O	I-Entity
rots	O	O	I-Entity
has	O	O	O
not	O	O	O
been	O	O	O
explored	O	O	O
.	O	O	O

We	O	O	O
tested	O	O	B-Entity
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
the	O	O	O
paper	O	O	B-Entity
wasp	O	O	I-Entity
Polistes	O	O	B-Entity
dominulus	O	O	I-Entity
could	O	O	O
facilitate	O	O	O
grape	O	O	B-Entity
sour	O	O	I-Entity
rot	O	O	I-Entity
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
other	O	O	O
insect	O	O	B-Entity
vectors	O	O	I-Entity
.	O	O	O

Using	O	O	O
marker	O	O	B-Entity
gene	O	O	I-Entity
sequencing	O	O	I-Entity
we	O	O	O
characterized	O	O	B-Entity
the	O	O	O
bacterial	O	O	B-Entity
and	O	O	O
fungal	O	O	B-Entity
community	O	O	B-Entity
of	O	O	O
wild-caught	O	O	B-Entity
adults	O	O	I-Entity
.	O	O	O

We	O	O	O
used	O	O	O
a	O	O	O
sterilized	O	O	O
foraging	O	O	B-Entity
arena	O	O	I-Entity
to	O	O	O
determine	O	O	O
if	O	O	O
these	O	O	O
wasps	O	O	B-Entity
transfer	O	O	O
viable	O	O	B-Entity
microorganisms	O	O	B-Entity
when	O	O	O
foraging	O	O	O
.	O	O	O

We	O	O	O
then	O	O	O
tested	O	O	B-Entity
if	O	O	O
wasps	O	O	B-Entity
harboring	O	O	O
their	O	O	O
native	O	O	B-Entity
microbial	O	O	B-Entity
community	O	O	B-Entity
,	O	O	O
or	O	O	O
those	O	O	O
inoculated	O	O	B-Entity
with	O	O	O
sour	O	O	B-Entity
rot	O	O	I-Entity
,	O	O	O
had	O	O	O
an	O	O	O
effect	O	O	B-Entity
on	O	O	O
grape	O	O	B-Entity
sour	O	O	I-Entity
rot	O	O	I-Entity
incidence	O	O	B-Entity
and	O	O	O
severity	O	O	B-Entity
using	O	O	O
a	O	O	O
laboratory	O	O	B-Entity
foraging	O	O	I-Entity
arena	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
all	O	O	O
wasps	O	O	B-Entity
harbor	O	O	O
some	O	O	O
portion	O	O	O
of	O	O	O
the	O	O	O
sour	O	O	B-Entity
rot	O	O	I-Entity
microbial	O	O	B-Entity
community	O	O	B-Entity
and	O	O	O
that	O	O	O
they	O	O	O
have	O	O	O
the	O	O	O
ability	O	O	B-Entity
to	O	O	O
transfer	O	O	O
viable	O	O	B-Entity
microorganisms	O	O	B-Entity
when	O	O	O
foraging	O	O	B-Entity
.	O	O	O

Foraging	O	O	B-Entity
by	O	O	O
inoculated	O	O	B-Entity
and	O	O	O
uninoculated	O	O	B-Entity
wasps	O	O	I-Entity
led	O	O	O
to	O	O	O
an	O	O	O
increase	O	O	B-Entity
in	O	O	O
berry	O	O	B-Entity
rot	O	O	I-Entity
disease	O	O	I-Entity
symptom	O	O	B-Entity
severity	O	O	B-Entity
and	O	O	O
incidence	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	B-Entity
indicate	O	O	O
that	O	O	O
paper	O	O	B-Entity
wasps	O	O	I-Entity
can	O	O	O
facilitate	O	O	O
sour	O	O	B-Entity
rot	O	O	I-Entity
diseases	O	O	I-Entity
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
other	O	O	B-Entity
vectors	O	O	I-Entity
and	O	O	O
that	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
this	O	O	O
facilitation	O	O	O
may	O	O	O
include	O	O	O
both	O	O	O
increasing	O	O	B-Entity
host	O	O	B-Entity
susceptibility	O	O	B-Entity
and	O	O	O
transmitting	O	O	B-Entity
these	O	O	O
microbial	O	O	B-Entity
communities	O	O	B-Entity
to	O	O	O
the	O	O	O
grapes	O	O	B-Entity
.	O	O	O

Social	O	O	B-Entity
wasps	O	O	I-Entity
are	O	O	O
understudied	O	O	O
but	O	O	O
relevant	O	O	B-Entity
players	O	O	I-Entity
in	O	O	O
the	O	O	O
sour	O	O	B-Entity
rot	O	O	I-Entity
ecology	O	O	B-Entity
of	O	O	O
vineyards	O	O	B-Entity
.	O	O	O

-DOCSTART- (28463085)

Low-intensity	O	O	B-Entity
pulsed	O	O	I-Entity
ultrasound	O	O	I-Entity
reduces	O	O	O
periodontal	O	O	B-Entity
atrophy	O	O	I-Entity
in	O	O	O
occlusal	O	O	B-Entity
hypofunctional	O	O	B-Entity
teeth	O	O	O

To	O	O	O
clarify	O	O	O
whether	O	O	O
low-intensity	O	O	B-Entity
pulsed	O	O	I-Entity
ultrasound	O	O	I-Entity
(	O	O	O
LIPUS	O	O	B-Entity
)	O	O	O
exposure	O	O	O
has	O	O	O
recovery	O	O	O
effects	O	O	O
on	O	O	O
the	O	O	O
hypofunctional	O	O	B-Entity
periodontal	O	O	B-Entity
ligament	O	O	I-Entity
(	O	O	O
PDL	O	O	B-Entity
)	O	O	O
and	O	O	O
interradicular	O	O	B-Entity
alveolar	O	O	I-Entity
bone	O	O	I-Entity
(	O	O	O
IRAB	O	O	B-Entity
)	O	O	O
.	O	O	O

Twelve-	O	O	O
week	O	O	B-Entity
-old	O	O	O
male	O	O	B-Entity
Sprague-Dawley	O	O	B-Entity
rats	O	O	I-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
three	O	O	O
groups	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
5	O	O	O
each	O	O	O
):	O	O	O
a	O	O	O
normal	O	O	B-Entity
occlusion	O	O	I-Entity
(	O	O	O
C	O	O	O
)	O	O	O
group	O	O	B-Entity
,	O	O	O
an	O	O	O
occlusal	O	O	B-Entity
hypofunction	O	O	B-Entity
(	O	O	O
H	O	O	O
)	O	O	O
group	O	O	O
,	O	O	O
and	O	O	O
an	O	O	O
occlusal	O	O	B-Entity
hypofunction	O	O	I-Entity
group	O	O	I-Entity
subjected	O	O	O
to	O	O	O
LIPUS	O	O	B-Entity
(	O	O	O
HL	O	O	O
)	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Hypofunctional	O	O	B-Entity
occlusion	O	O	B-Entity
of	O	O	O
the	O	O	O
maxillary	O	O	B-Entity
first	O	O	I-Entity
molar	O	O	I-Entity
(	O	O	O
M1	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
H	O	O	B-Entity
and	O	O	O
HL	O	O	B-Entity
groups	O	O	I-Entity
was	O	O	O
induced	O	O	O
by	O	O	O
the	O	O	O
bite-raising	O	O	B-Entity
technique	O	O	I-Entity
.	O	O	O

Only	O	O	O
the	O	O	O
HL	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
irradiated	O	O	O
with	O	O	O
LIPUS	O	O	B-Entity
for	O	O	O
5	O	O	O
days	O	O	B-Entity
.	O	O	O

The	O	O	O
IRAB	O	O	B-Entity
and	O	O	O
PDL	O	O	B-Entity
of	O	O	O
M1	O	O	B-Entity
were	O	O	O
examined	O	O	O
by	O	O	O
microcomputed	O	O	B-Entity
tomography	O	O	I-Entity
(	O	O	O
micro-CT	O	O	B-Entity
)	O	O	O
analysis	O	O	B-Entity
.	O	O	O

To	O	O	O
quantify	O	O	O
mRNA	O	O	B-Entity
expression	O	O	B-Entity
of	O	O	O
cytokines	O	O	B-Entity
involved	O	O	O
in	O	O	O
PDL	O	O	B-Entity
proliferation	O	O	B-Entity
and	O	O	O
development	O	O	B-Entity
,	O	O	O
real-time	O	O	B-Entity
reverse	O	O	I-Entity
transcription	O	O	I-Entity
quantitative	O	O	I-Entity
PCR	O	O	I-Entity
(	O	O	O
qRT-PCR	O	O	B-Entity
)	O	O	O
was	O	O	O
performed	O	O	O
for	O	O	O
twist	O	O	B-Entity
family	O	O	I-Entity
bHLH	O	O	I-Entity
transcription	O	O	I-Entity
factor	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
Twist1	O	O	B-Entity
)	O	O	O
,	O	O	O
periostin	O	O	B-Entity
,	O	O	O
and	O	O	O
connective	O	O	B-Entity
tissue	O	O	I-Entity
growth	O	O	I-Entity
factor	O	O	I-Entity
(	O	O	O
CTGF	O	O	B-Entity
)	O	O	O
in	O	O	O
the	O	O	O
PDL	O	O	O
samples	O	O	B-Entity
.	O	O	O

Micro-CT	O	O	B-Entity
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
the	O	O	O
PDL	O	O	B-Entity
volume	O	O	B-Entity
was	O	O	O
decreased	O	O	O
in	O	O	O
the	O	O	O
H	O	O	B-Entity
group	O	O	I-Entity
compared	O	O	O
with	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
C	O	O	B-Entity
and	O	O	O
HL	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

Both	O	O	O
bone	O	O	B-Entity
volume	O	O	I-Entity
per	O	O	O
tissue	O	O	B-Entity
volume	O	O	I-Entity
(	O	O	O
BV	O	O	B-Entity
/	O	O	O
TV	O	O	B-Entity
)	O	O	O
of	O	O	O
IRAB	O	O	B-Entity
was	O	O	O
decreased	O	O	O
in	O	O	O
the	O	O	O
H	O	O	B-Entity
group	O	O	I-Entity
compared	O	O	O
with	O	O	O
that	O	O	O
in	O	O	O
the	O	O	O
C	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

LIPUS	O	O	B-Entity
exposure	O	O	O
restored	O	O	O
BV	O	O	B-Entity
/	O	O	O
TV	O	O	B-Entity
in	O	O	O
the	O	O	O
IRAB	O	O	B-Entity
of	O	O	O
the	O	O	O
HL	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

qRT-PCR	O	O	B-Entity
analysis	O	O	B-Entity
showed	O	O	O
that	O	O	O
Twist1	O	O	B-Entity
,	O	O	O
periostin	O	O	B-Entity
,	O	O	O
and	O	O	O
CTGF	O	O	B-Entity
mRNA	O	O	B-Entity
levels	O	O	B-Entity
were	O	O	O
decreased	O	O	O
in	O	O	O
the	O	O	O
H	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
increased	O	O	O
in	O	O	O
the	O	O	O
HL	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

LIPUS	O	O	B-Entity
exposure	O	O	O
reduced	O	O	O
the	O	O	O
atrophic	O	O	B-Entity
changes	O	O	B-Entity
of	O	O	O
alveolar	O	O	B-Entity
bone	O	O	I-Entity
by	O	O	O
inducing	O	O	B-Entity
the	O	O	O
upregulation	O	O	B-Entity
of	O	O	O
periostin	O	O	B-Entity
and	O	O	O
CTGF	O	O	B-Entity
expression	O	O	B-Entity
to	O	O	O
promote	O	O	O
PDL	O	O	B-Entity
healing	O	O	B-Entity
after	O	O	O
induction	O	O	B-Entity
of	O	O	O
occlusal	O	O	B-Entity
hypofunction	O	O	B-Entity
.	O	O	O

-DOCSTART- (28464019)

Radiologic	O	O	B-Entity
assessment	O	O	I-Entity
of	O	O	O
quality	O	O	O
of	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
fillings	O	O	I-Entity
and	O	O	O
periapical	O	O	B-Entity
status	O	O	I-Entity
in	O	O	O
an	O	O	O
Austrian	O	O	B-Entity
subpopulation	O	O	B-Entity
-	O	O	O
An	O	O	O
observational	O	O	O
study	O	O	O

Progress	O	O	B-Entity
in	O	O	O
endodontic	O	O	B-Entity
techniques	O	O	I-Entity
and	O	O	O
methodological	O	O	O
advances	O	O	O
have	O	O	O
altered	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
therapy	O	O	I-Entity
over	O	O	O
the	O	O	O
last	O	O	O
decades	O	O	O
.	O	O	O

These	O	O	O
techniques	O	O	O
and	O	O	O
methods	O	O	O
need	O	O	O
periodical	O	O	B-Entity
documentation	O	O	B-Entity
.	O	O	O

This	O	O	O
observational	O	O	B-Entity
study	O	O	I-Entity
determined	O	O	O
the	O	O	O
current	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
endodontic	O	O	B-Entity
treatments	O	O	I-Entity
,	O	O	I-Entity
and	O	O	O
investigated	O	O	B-Entity
the	O	O	O
relationship	O	O	O
of	O	O	O
various	O	O	O
factors	O	O	O
with	O	O	O
the	O	O	O
periapical	O	O	B-Entity
status	O	O	I-Entity
in	O	O	O
a	O	O	O
Lower	O	O	O
Austrian	O	O	B-Entity
subpopulation	O	O	B-Entity
.	O	O	O

One	O	O	O
thousand	O	O	O
orthopantomograms	O	O	B-Entity
of	O	O	O
first-time	O	O	O
university	O	O	B-Entity
adult	O	O	O
patients	O	O	B-Entity
radiographed	O	O	B-Entity
at	O	O	O
an	O	O	O
outpatient	O	O	B-Entity
clinic	O	O	I-Entity
were	O	O	O
evaluated	O	O	B-Entity
.	O	O	O

For	O	O	O
each	O	O	O
tooth	O	O	B-Entity
,	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
periradicular	O	O	B-Entity
pathosis	O	O	I-Entity
and/or	O	O	O
endodontic	O	O	B-Entity
treatment	O	O	I-Entity
was	O	O	O
recorded	O	O	O
,	O	O	O
as	O	O	O
was	O	O	O
the	O	O	O
quality	O	O	O
of	O	O	O
(	O	O	O
post-	O	O	O
)	O	O	O
endodontic	O	O	O
treatment	O	O	O
(	O	O	O
homogeneity	O	O	B-Entity
and	O	O	O
length	O	O	O
of	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
fillings	O	O	I-Entity
;	O	O	O
preparation	O	O	B-Entity
failures	O	O	I-Entity
;	O	O	O
posts	O	O	B-Entity
/	O	O	O
screws	O	O	B-Entity
;	O	O	O
apicoectomies	O	O	B-Entity
;	O	O	O
coronal	O	O	B-Entity
restorations	O	O	I-Entity
)	O	O	O
.	O	O	O

Two	O	O	O
evaluators	O	O	B-Entity
,	O	O	O
blinded	O	O	B-Entity
to	O	O	O
each	O	O	O
other	O	O	O
,	O	O	O
scored	O	O	B-Entity
all	O	O	O
teeth	O	O	B-Entity
.	O	O	O

In	O	O	O
cases	O	O	O
of	O	O	O
disagreement	O	O	O
,	O	O	O
they	O	O	O
joined	O	O	O
for	O	O	O
a	O	O	O
consensus	O	O	O
score	O	O	B-Entity
.	O	O	O

In	O	O	O
all	O	O	O
,	O	O	O
22,586	O	O	O
teeth	O	O	B-Entity
were	O	O	I-Entity
counted	O	O	I-Entity
.	O	O	O

Of	O	O	O
these	O	O	O
,	O	O	O
2,907	O	O	O
teeth	O	O	B-Entity
(	O	O	O
12.9	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
periapical	O	O	B-Entity
pathosis	O	O	I-Entity
,	O	O	O
while	O	O	O
2,504	O	O	O
teeth	O	O	O
had	O	O	O
undergone	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
treatment	O	O	I-Entity
.	O	O	O

Of	O	O	O
the	O	O	O
endodontically	O	O	B-Entity
treated	O	O	I-Entity
teeth	O	O	I-Entity
,	O	O	O
52	O	O	O
%	O	O	O
showed	O	O	O
no	O	O	O
radiographic	O	O	B-Entity
signs	O	O	O
of	O	O	O
apical	O	O	B-Entity
periodontitis	O	O	I-Entity
,	O	O	O
while	O	O	O
44.9	O	O	O
%	O	O	O
had	O	O	O
overt	O	O	O
apical	O	O	B-Entity
lesions	O	O	I-Entity
,	O	O	O
and	O	O	O
3,1	O	O	O
%	O	O	O
revealed	O	O	O
widened	O	O	B-Entity
periodontal	O	O	I-Entity
ligament	O	O	I-Entity
space	O	O	I-Entity
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
the	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
fillings	O	O	I-Entity
was	O	O	O
inhomogeneous	O	O	O
(	O	O	O
70.4	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
75.4	O	O	O
%	O	O	O
were	O	O	O
rated	O	O	O
too	O	O	O
short	O	O	O
,	O	O	O
and	O	O	O
3.8	O	O	O
%	O	O	O
too	O	O	O
long	O	O	O
.	O	O	O

The	O	O	O
presence	O	O	B-Entity
of	O	O	O
apical	O	O	B-Entity
pathosis	O	O	B-Entity
was	O	O	O
significantly	O	O	B-Entity
correlated	O	O	I-Entity
(	O	O	O
odds	O	O	B-Entity
ratio	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
)	O	O	O
2.556	O	O	O
[	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
2.076	O	O	O
-	O	O	O
3.146	O	O	O
]	O	O	O
;	O	O	O
P<0.0001	O	O	O
)	O	O	O
with	O	O	O
poor	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
fillings	O	O	I-Entity
(	O	O	O
length	O	O	O
and	O	O	O
homogeneity	O	O	B-Entity
)	O	O	O
.	O	O	O

Posts	O	O	B-Entity
or	O	O	O
screws	O	O	B-Entity
positively	O	O	O
affected	O	O	O
periapical	O	O	B-Entity
status	O	O	I-Entity
(	O	O	O
OR	O	O	B-Entity
1.853	O	O	O
[	O	O	O
CI	O	O	O
1.219	O	O	O
-	O	O	O
2.819	O	O	O
]	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
0.004	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
endodontically	O	O	B-Entity
treated	O	O	I-Entity
posterior	O	O	I-Entity
teeth	O	O	I-Entity
were	O	O	O
infrequently	O	O	O
restored	O	O	B-Entity
(	O	O	O
posts	O	O	B-Entity
,	O	O	O
7.5	O	O	O
%	O	O	O
;	O	O	O
screws	O	O	O
,	O	O	O
2.7	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Best	O	O	O
results	O	O	O
were	O	O	O
found	O	O	O
for	O	O	O
teeth	O	O	B-Entity
with	O	O	O
both	O	O	O
appropriate	O	O	O
endodontic	O	O	B-Entity
treatment	O	O	I-Entity
and	O	O	O
adequate	O	O	O
coronal	O	O	B-Entity
restoration	O	O	I-Entity
.	O	O	O

A	O	O	O
high	O	O	B-Entity
prevalence	O	O	I-Entity
of	O	O	O
periradicular	O	O	B-Entity
radiolucencies	O	O	I-Entity
was	O	O	O
observed	O	O	O
with	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
filled	O	O	I-Entity
teeth	O	O	I-Entity
,	O	O	O
along	O	O	O
with	O	O	O
high	O	O	O
numbers	O	O	O
of	O	O	O
unmet	O	O	O
treatment	O	O	B-Entity
needs	O	O	O
.	O	O	O

Periapical	O	O	B-Entity
health	O	O	B-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
adequate	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
obturation	O	O	I-Entity
and	O	O	O
high-grade	O	O	O
postendodontic	O	O	B-Entity
restorations	O	O	I-Entity
,	O	O	O
and	O	O	O
quality	O	O	O
regarding	O	O	O
these	O	O	O
latter	O	O	O
aspects	O	O	O
is	O	O	O
considered	O	O	O
mandatory	O	O	O
to	O	O	O
promote	O	O	O
periapical	O	O	B-Entity
health	O	O	O
.	O	O	O

-DOCSTART- (28464071)

Chemical	O	O	B-Entity
composition	O	O	I-Entity
and	O	O	O
amino	O	O	B-Entity
acid	O	O	I-Entity
digestibility	O	O	B-Entity
of	O	O	O
soybean	O	O	B-Entity
meal	O	O	I-Entity
produced	O	O	O
in	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
,	O	O	O
China	O	O	B-Entity
,	O	O	O
Argentina	O	O	B-Entity
,	O	O	O
Brazil	O	O	B-Entity
,	O	O	O
or	O	O	O
India	O	O	O

An	O	O	O
experiment	O	O	O
was	O	O	O
conducted	O	O	O
to	O	O	O
compare	O	O	O
nutritional	O	O	B-Entity
composition	O	O	B-Entity
of	O	O	O
soybean	O	O	B-Entity
meal	O	O	I-Entity
(	O	O	O
SBM	O	O	B-Entity
)	O	O	O
produced	O	O	O
in	O	O	O
China	O	O	B-Entity
,	O	O	O
Argentina	O	O	B-Entity
,	O	O	O
Brazil	O	O	B-Entity
,	O	O	O
the	O	O	O
U.S	O	O	B-Entity
.	O	O	O
,	O	O	O
or	O	O	O
India	O	O	B-Entity
and	O	O	O
the	O	O	O
apparent	O	O	B-Entity
ileal	O	O	I-Entity
digestibility	O	O	I-Entity
(	O	O	O
AID	O	O	B-Entity
)	O	O	O
and	O	O	O
the	O	O	O
standardized	O	O	B-Entity
ileal	O	O	I-Entity
digestibility	O	O	I-Entity
(	O	O	O
SID	O	O	B-Entity
)	O	O	O
of	O	O	O
CP	O	O	B-Entity
and	O	O	O
AA	O	O	B-Entity
in	O	O	O
these	O	O	O
SBM	O	O	O
when	O	O	O
fed	O	O	O
to	O	O	O
growing	O	O	O
pigs	O	O	B-Entity
.	O	O	O

Five	O	O	O
sources	O	O	O
of	O	O	O
SBM	O	O	B-Entity
from	O	O	O
China	O	O	B-Entity
,	O	O	O
Argentina	O	O	B-Entity
,	O	O	O
Brazil	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
U.S	O	O	B-Entity
.	O	O	O
,	O	O	O
and	O	O	O
4	O	O	O
sources	O	O	O
from	O	O	O
India	O	O	B-Entity
were	O	O	O
collected	O	O	O
for	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
24	O	O	O
sources	O	O	O
of	O	O	O
SBM	O	O	O
.	O	O	O

All	O	O	O
samples	O	O	O
were	O	O	O
analyzed	O	O	O
for	O	O	O
energy	O	O	B-Entity
,	O	O	O
DM	O	O	B-Entity
,	O	O	O
and	O	O	O
nutrients	O	O	B-Entity
,	O	O	O
and	O	O	O
each	O	O	O
source	O	O	O
was	O	O	O
included	O	O	O
in	O	O	O
a	O	O	O
cornstarch	O	O	B-Entity
based	O	O	I-Entity
diet	O	O	I-Entity
in	O	O	O
which	O	O	O
SBM	O	O	B-Entity
was	O	O	O
the	O	O	O
only	O	O	O
AA	O	O	B-Entity
contributing	O	O	O
ingredient	O	O	B-Entity
.	O	O	O

An	O	O	O
N-free	O	O	B-Entity
diet	O	O	I-Entity
was	O	O	O
also	O	O	O
formulated	O	O	O
.	O	O	O

Twenty-five	O	O	O
barrows	O	O	O
(	O	O	O
initial	O	O	O
BW	O	O	O
:	O	O	O
30.53	O	O	O
±	O	O	O
1.73	O	O	O
kg	O	O	O
)	O	O	O
were	O	O	O
equipped	O	O	O
with	O	O	O
a	O	O	O
T-cannula	O	O	O
in	O	O	O
the	O	O	O
distal	O	O	B-Entity
ileum	O	O	I-Entity
and	O	O	O
randomly	O	O	O
allotted	O	O	O
to	O	O	O
a	O	O	O
25	O	O	O
×	O	O	O
8	O	O	O
Youden	O	O	B-Entity
square	O	O	I-Entity
design	O	O	I-Entity
with	O	O	O
25	O	O	O
diets	O	O	B-Entity
and	O	O	O
8	O	O	O
periods	O	O	B-Entity
.	O	O	O

Results	O	O	O
indicate	O	O	O
that	O	O	O
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
CP	O	O	B-Entity
was	O	O	O
greater	O	O	O
(	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
in	O	O	O
SBM	O	O	B-Entity
from	O	O	O
Brazil	O	O	B-Entity
and	O	O	O
India	O	O	B-Entity
(	O	O	O
49.3	O	O	O
and	O	O	O
49.5	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
than	O	O	O
in	O	O	O
SBM	O	O	O
from	O	O	O
China	O	O	B-Entity
,	O	O	O
Argentina	O	O	B-Entity
,	O	O	O
or	O	O	O
the	O	O	O
U.S.	O	O	O
(	O	O	O
45.1	O	O	O
,	O	O	O
46.7	O	O	O
,	O	O	O
and	O	O	O
47.3	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
as-fed	O	O	O
basis	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
concentration	O	O	B-Entity
of	O	O	O
most	O	O	O
indispensable	O	O	O
AA	O	O	B-Entity
followed	O	O	O
the	O	O	O
same	O	O	O
pattern	O	O	O
as	O	O	O
CP	O	O	B-Entity
with	O	O	O
the	O	O	O
exception	O	O	O
that	O	O	O
SBM	O	O	B-Entity
from	O	O	O
the	O	O	O
U.S.	O	O	O
contained	O	O	O
more	O	O	O
(	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
indispensable	O	O	O
AA	O	O	O
than	O	O	O
SBM	O	O	O
from	O	O	O
China	O	O	B-Entity
or	O	O	O
Argentina	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
SBM	O	O	B-Entity
from	O	O	O
India	O	O	B-Entity
contained	O	O	O
more	O	O	O
(	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
trypsin	O	O	B-Entity
inhibitors	O	O	I-Entity
than	O	O	O
SBM	O	O	O
from	O	O	O
the	O	O	O
other	O	O	O
countries	O	O	B-Entity
.	O	O	O

A	O	O	O
greater	O	O	O
(	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
AID	O	O	B-Entity
and	O	O	O
SID	O	O	B-Entity
of	O	O	O
CP	O	O	B-Entity
and	O	O	O
most	O	O	O
AA	O	O	B-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
SBM	O	O	B-Entity
from	O	O	O
the	O	O	O
U.S.	O	O	O
compared	O	O	O
with	O	O	O
SBM	O	O	O
from	O	O	O
Brazil	O	O	B-Entity
,	O	O	O
Argentina	O	O	B-Entity
,	O	O	O
and	O	O	O
India	O	O	B-Entity
,	O	O	O
but	O	O	O
there	O	O	O
were	O	O	O
no	O	O	O
differences	O	O	O
between	O	O	O
SBM	O	O	O
from	O	O	O
the	O	O	O
U.S.	O	O	O
and	O	O	O
SBM	O	O	O
from	O	O	O
China	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
because	O	O	O
of	O	O	O
the	O	O	O
lower	O	O	O
concentration	O	O	B-Entity
of	O	O	O
AA	O	O	B-Entity
in	O	O	O
SBM	O	O	B-Entity
from	O	O	O
China	O	O	B-Entity
,	O	O	O
the	O	O	O
concentration	O	O	O
of	O	O	O
standardized	O	O	B-Entity
ileal	O	O	I-Entity
digestible	O	O	I-Entity
AA	O	O	O
in	O	O	O
SBM	O	O	O
from	O	O	O
China	O	O	O
was	O	O	O
less	O	O	O
(	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
than	O	O	O
in	O	O	O
SBM	O	O	O
from	O	O	O
the	O	O	O
U.S.	O	O	O
Soybean	O	O	O
meal	O	O	O
from	O	O	O
the	O	O	O
U.S.	O	O	O
or	O	O	O
Brazil	O	O	B-Entity
had	O	O	O
less	O	O	O
(	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
variability	O	O	O
in	O	O	O
SID	O	O	B-Entity
values	O	O	O
than	O	O	O
SBM	O	O	O
from	O	O	O
Argentina	O	O	B-Entity
,	O	O	O
China	O	O	O
,	O	O	O
or	O	O	O
India	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	O
,	O	O	O
the	O	O	O
SID	O	O	B-Entity
of	O	O	O
CP	O	O	B-Entity
and	O	O	O
AA	O	O	B-Entity
is	O	O	O
dependent	O	O	O
on	O	O	O
the	O	O	O
country	O	O	B-Entity
where	O	O	O
the	O	O	O
SBM	O	O	B-Entity
is	O	O	O
produced	O	O	O
.	O	O	O

This	O	O	O
difference	O	O	O
and	O	O	O
the	O	O	O
variability	O	O	O
within	O	O	O
each	O	O	O
country	O	O	B-Entity
should	O	O	O
be	O	O	O
evaluated	O	O	O
when	O	O	O
formulating	O	O	B-Entity
diets	O	O	I-Entity
for	O	O	O
pigs	O	O	B-Entity
.	O	O	O

-DOCSTART- (28464291)

Developing	O	O	B-Entity
understanding	O	O	B-Entity
of	O	O	O
object	O	O	B-Entity
fall	O	O	B-Entity
:	O	O	O
Going	O	O	O
beyond	O	O	O
inhibitory	O	O	B-Entity
processes	O	O	O

A	O	O	O
study	O	O	B-Entity
is	O	O	O
reported	O	O	B-Entity
where	O	O	O
118	O	O	O
participants	O	O	B-Entity
aged	O	O	B-Entity
between	O	O	O
10	O	O	O
years	O	O	O
and	O	O	O
early	O	O	B-Entity
20s	O	O	O
drew	O	O	O
the	O	O	O
trajectories	O	O	B-Entity
they	O	O	O
expected	O	O	B-Entity
objects	O	O	B-Entity
to	O	O	O
follow	O	O	B-Entity
as	O	O	O
they	O	O	O
fell	O	O	B-Entity
.	O	O	O

The	O	O	O
younger	O	O	B-Entity
participants	O	O	B-Entity
typically	O	O	B-Entity
anticipated	O	O	B-Entity
backward	O	O	B-Entity
trajectories	O	O	B-Entity
during	O	O	O
fall	O	O	B-Entity
from	O	O	O
moving	O	O	B-Entity
carriers	O	O	B-Entity
while	O	O	O
forward	O	O	B-Entity
but	O	O	O
non-parabolic	O	O	B-Entity
trajectories	O	O	I-Entity
were	O	O	O
relatively	O	O	B-Entity
more	O	O	B-Entity
frequent	O	O	B-Entity
amongst	O	O	O
the	O	O	O
older	O	O	B-Entity
participants	O	O	I-Entity
.	O	O	O

Both	O	O	O
patterns	O	O	B-Entity
suggest	O	O	B-Entity
strong	O	O	B-Entity
sociocultural	O	O	B-Entity
influences	O	O	B-Entity
,	O	O	O
with	O	O	O
implications	O	O	B-Entity
for	O	O	O
models	O	O	B-Entity
that	O	O	O
regard	O	O	O
development	O	O	B-Entity
in	O	O	O
this	O	O	O
area	O	O	B-Entity
as	O	O	O
purely	O	O	B-Entity
the	O	O	O
inhibition	O	O	B-Entity
of	O	O	O
principles	O	O	B-Entity
established	O	O	B-Entity
in	O	O	O
infancy	O	O	B-Entity
.	O	O	O

Statement	O	O	B-Entity
of	O	O	O
contribution	O	O	B-Entity
What	O	O	O
is	O	O	O
already	O	O	O
known	O	O	B-Entity
on	O	O	O
this	O	O	O
subject	O	O	B-Entity
?	O	O	O

Research	O	O	B-Entity
with	O	O	O
infants	O	O	B-Entity
demonstrates	O	O	B-Entity
an	O	O	O
early	O	O	B-Entity
-	O	O	O
established	O	O	B-Entity
belief	O	O	B-Entity
that	O	O	O
dropped	O	O	B-Entity
objects	O	O	B-Entity
fall	O	O	B-Entity
straight	O	O	B-Entity
down	O	O	B-Entity
.	O	O	O

The	O	O	O
erroneous	O	O	B-Entity
expectations	O	O	B-Entity
that	O	O	O
pre-schoolers	O	O	B-Entity
hold	O	O	B-Entity
about	O	O	O
object	O	O	B-Entity
fall	O	O	B-Entity
are	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
failure	O	O	B-Entity
to	O	O	O
inhibit	O	O	B-Entity
the	O	O	O
presumption	O	O	B-Entity
of	O	O	O
straight	O	O	B-Entity
-	O	O	O
down	O	O	B-Entity
fall	O	O	O
,	O	O	O
in	O	O	O
contexts	O	O	B-Entity
where	O	O	O
it	O	O	O
is	O	O	O
inappropriate	O	O	B-Entity
.	O	O	O

What	O	O	O
does	O	O	O
this	O	O	O
study	O	O	B-Entity
add	O	O	O
?	O	O	O

The	O	O	O
research	O	O	B-Entity
replicates	O	O	B-Entity
and	O	O	O
extends	O	O	B-Entity
research	O	O	O
with	O	O	O
older	O	O	B-Entity
participants	O	O	I-Entity
,	O	O	O
which	O	O	O
indicates	O	O	B-Entity
errors	O	O	B-Entity
that	O	O	O
can	O	O	O
not	O	O	O
be	O	O	O
explained	O	O	B-Entity
via	O	O	O
failed	O	O	B-Entity
inhibition	O	O	B-Entity
of	O	O	O
straight	O	O	B-Entity
-	O	O	O
down	O	O	B-Entity
fall	O	O	B-Entity
.	O	O	O

It	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	B-Entity
to	O	O	O
trace	O	O	O
patterns	O	O	B-Entity
of	O	O	O
errors	O	O	B-Entity
across	O	O	O
late	O	O	B-Entity
childhood	O	O	B-Entity
,	O	O	O
adolescence	O	O	B-Entity
and	O	O	O
early	O	O	B-Entity
adulthood	O	O	B-Entity
.	O	O	O

A	O	O	O
consequence	O	O	B-Entity
of	O	O	I-Entity
the	O	O	O
findings	O	O	B-Entity
is	O	O	O
that	O	O	O
adequate	O	O	B-Entity
modelling	O	O	B-Entity
in	O	O	O
developmental	O	O	B-Entity
psychology	O	O	I-Entity
must	O	O	O
consider	O	O	B-Entity
multilayered	O	O	B-Entity
interactions	O	O	B-Entity
between	O	O	O
prior	O	O	B-Entity
representations	O	O	B-Entity
and	O	O	O
sociocultural	O	O	B-Entity
experiences	O	O	B-Entity
.	O	O	O

-DOCSTART- (28464602)

Attenuation	O	O	B-Entity
of	O	O	O
High	O	O	B-Entity
Glucose	O	O	I-Entity
-	O	O	O
Induced	O	O	B-Entity
Rat	O	O	B-Entity
Cardiomyocyte	O	O	B-Entity
Apoptosis	O	O	B-Entity
by	O	O	O
Exendin-4	O	O	B-Entity
via	O	O	O
Intervention	O	O	B-Entity
of	O	O	O
HO-1	O	O	B-Entity
/	O	O	O
Nrf-2	O	O	B-Entity
and	O	O	O
the	O	O	O
PI3K/AKT	O	O	O
Signaling	O	O	O
Pathway	O	O	O

Exendin-4	O	O	B-Entity
,	O	O	O
a	O	O	O
glucagon-like	O	O	B-Entity
peptide-1	O	O	I-Entity
receptor	O	O	I-Entity
agonist	O	O	I-Entity
,	O	O	O
demonstrated	O	O	O
cytoprotective	O	O	B-Entity
actions	O	O	I-Entity
beyond	O	O	O
glycemic	O	O	B-Entity
control	O	O	I-Entity
in	O	O	O
recent	O	O	O
studies	O	O	O
.	O	O	O

The	O	O	O
aims	O	O	B-Entity
of	O	O	O
the	O	O	O
present	O	O	O
study	O	O	B-Entity
were	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
exendin-4	O	O	B-Entity
on	O	O	O
high	O	O	B-Entity
glucose	O	O	I-Entity
(HG)-	O	O	O
induced	O	O	B-Entity
cardiomyocyte	O	O	B-Entity
apoptosis	O	O	B-Entity
and	O	O	O
the	O	O	O
possible	O	O	O
mechanisms	O	O	B-Entity
.	O	O	O

Rat	O	O	B-Entity
cardiomyocytes	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
3	O	O	O
groups	O	O	B-Entity
:	O	O	O
normal	O	O	B-Entity
glucose	O	O	I-Entity
group	O	O	B-Entity
(	O	O	O
NG	O	O	B-Entity
group	O	O	O
)	O	O	O
,	O	O	O
HG	O	O	B-Entity
group	O	O	O
and	O	O	O
HG	O	O	O
+	O	O	O
exendin-4	O	O	B-Entity
group	O	O	O
(	O	O	O
HG	O	O	O
+	O	O	O
Ex	O	O	B-Entity
Group	O	O	B-Entity
)	O	O	O
.	O	O	O

Cardiomyocyte	O	O	B-Entity
apoptosis	O	O	B-Entity
was	O	O	O
evaluated	O	O	O
by	O	O	O
double-staining	O	O	B-Entity
with	O	O	O
annexin	O	O	B-Entity
V-fluorescein	O	O	I-Entity
isothiocyanate	O	O	I-Entity
(FITC)/	O	O	O
propidium	O	O	B-Entity
iodide	O	O	I-Entity
(	O	O	O
PI	O	O	B-Entity
)	O	O	O
and	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
.	O	O	O

Intracellular	O	O	B-Entity
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	I-Entity
ROS	O	O	I-Entity
)	O	O	I-Entity
production	O	O	B-Entity
was	O	O	O
detected	O	O	B-Entity
by	O	O	O
2’,7’-dichlorodihydrofluorescein	O	O	B-Entity
diacetate	O	O	I-Entity
(	O	O	O
DCHF-DA	O	O	B-Entity
)	O	O	O
incubation	O	O	B-Entity
and	O	O	O
fluorescence	O	O	B-Entity
microscopy	O	O	I-Entity
.	O	O	O

LY294002	O	O	B-Entity
(	O	O	O
LY	O	O	B-Entity
)	O	O	O
,	O	O	O
a	O	O	O
phosphoinositide	O	O	B-Entity
3-kinase	O	O	I-Entity
(	O	O	O
PI3	O	O	B-Entity
K	O	O	I-Entity
)	O	O	O
pathway	O	O	B-Entity
inhibitor	O	O	B-Entity
,	O	O	O
was	O	O	O
added	O	O	O
to	O	O	O
the	O	O	O
medium	O	O	B-Entity
of	O	O	O
the	O	O	O
HG	O	O	B-Entity
+	O	O	O
Ex	O	O	B-Entity
+	O	O	O
LY	O	O	O
Group	O	O	B-Entity
for	O	O	O
further	O	O	O
western	O	O	B-Entity
blot	O	O	I-Entity
analysis	O	O	I-Entity
.	O	O	O

The	O	O	O
proteins	O	O	B-Entity
analyzed	O	O	B-Entity
involved	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
-	O	O	O
associated	O	O	B-Entity
proteins	O	O	I-Entity
,	O	O	O
heme	O	O	B-Entity
oxygenase-1	O	O	I-Entity
(	O	O	O
HO-1	O	O	B-Entity
)	O	O	O
and	O	O	O
nuclear	O	O	B-Entity
factor	O	O	I-Entity
E2-related	O	O	I-Entity
factor	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
Nrf-2	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
apoptosis	O	O	B-Entity
-	O	O	O
associated	O	O	O
proteins	O	O	O
,	O	O	O
caspase-3	O	O	B-Entity
,	O	O	O
Bax/B-cell	O	O	B-Entity
lymphoma	O	O	I-Entity
2	O	O	I-Entity
(	O	O	O
Bcl-2	O	O	B-Entity
)	O	O	O
and	O	O	O
p-AKT	O	O	B-Entity
/	O	O	O
AKT	O	O	B-Entity
.	O	O	O

HG	O	O	B-Entity
treatment	O	O	B-Entity
induced	O	O	B-Entity
cardiomyocyte	O	O	B-Entity
apoptosis	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.00	O	O	O
)	O	O	O
and	O	O	O
clearly	O	O	O
upregulated	O	O	B-Entity
ROS	O	O	B-Entity
production	O	O	B-Entity
(	O	O	O
P	O	O	O
=	O	O	O
0.00	O	O	O
)	O	O	O
;	O	O	O
exendin-4	O	O	B-Entity
co-incubation	O	O	B-Entity
also	O	O	O
ameliorated	O	O	O
cardiomyocyte	O	O	O
apoptosis	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.004	O	O	O
)	O	O	O
and	O	O	O
decreased	O	O	B-Entity
ROS	O	O	O
(	O	O	O
P	O	O	O
=	O	O	O
0.00	O	O	O
)	O	O	O
level	O	O	B-Entity
significantly	O	O	B-Entity
.	O	O	O

HO-1	O	O	B-Entity
and	O	O	O
Nrf-2	O	O	B-Entity
protein	O	O	B-Entity
expression	O	O	I-Entity
levels	O	O	B-Entity
decreased	O	O	B-Entity
significantly	O	O	B-Entity
in	O	O	O
the	O	O	O
HG	O	O	B-Entity
group	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
levels	O	O	O
were	O	O	O
elevated	O	O	B-Entity
by	O	O	O
exendin-4	O	O	B-Entity
intervention	O	O	B-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Furthermore	O	O	O
,	O	O	O
exendin-4	O	O	B-Entity
attenuated	O	O	B-Entity
HG	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
higher	O	O	O
protein	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
including	O	O	O
cleaved	O	O	O
caspase-3	O	O	B-Entity
and	O	O	O
Bax	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
the	O	O	O
expression	O	O	O
of	O	O	O
Bcl-2	O	O	B-Entity
protein	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
these	O	O	O
impacts	O	O	B-Entity
of	O	O	O
exendin-4	O	O	B-Entity
were	O	O	O
counteracted	O	O	O
significantly	O	O	B-Entity
by	O	O	O
co-incubation	O	O	B-Entity
with	O	O	O
LY294002	O	O	B-Entity
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
exendin-4	O	O	B-Entity
ameliorated	O	O	O
HG	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
p-AKT	O	O	B-Entity
/	O	O	O
AKT	O	O	B-Entity
lower	O	O	B-Entity
expression	O	O	I-Entity
,	O	O	O
and	O	O	O
this	O	O	O
impact	O	O	B-Entity
was	O	O	O
also	O	O	O
suppressed	O	O	B-Entity
by	O	O	O
LY294002	O	O	B-Entity
.	O	O	O

Exendin-4	O	O	B-Entity
ameliorates	O	O	O
HG	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
cardiomyocyte	O	O	B-Entity
apoptosis	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
mechanisms	O	O	B-Entity
may	O	O	O
involve	O	O	O
anti-oxidative	O	O	B-Entity
stress	O	O	I-Entity
via	O	O	O
the	O	O	O
HO-1	O	O	B-Entity
/	O	O	O
Nrf-2	O	O	B-Entity
system	O	O	O
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
intervention	O	O	B-Entity
of	O	O	O
the	O	O	O
PI3K/AKT	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
.	O	O	O

-DOCSTART- (28465793)

KMAP-O	O	O	B-Entity
framework	O	O	I-Entity
for	O	O	O
care	O	O	B-Entity
management	O	O	I-Entity
research	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	O
2	O	O	O
diabetes	O	O	O

To	O	O	O
review	O	O	B-Entity
impacts	O	O	B-Entity
of	O	O	O
interventions	O	O	B-Entity
involving	O	O	O
self-management	O	O	B-Entity
education	O	O	I-Entity
,	O	O	O
health	O	O	B-Entity
coaching	O	O	I-Entity
,	O	O	O
and	O	O	O
motivational	O	O	B-Entity
interviewing	O	O	I-Entity
for	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
.	O	O	O

A	O	O	O
thorough	O	O	O
review	O	O	B-Entity
of	O	O	O
the	O	O	O
scientific	O	O	B-Entity
literature	O	O	I-Entity
on	O	O	O
diabetes	O	O	B-Entity
care	O	O	B-Entity
and	O	O	I-Entity
management	O	O	I-Entity
was	O	O	O
executed	O	O	O
by	O	O	O
a	O	O	O
research	O	O	B-Entity
team	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	B-Entity
summarizes	O	O	O
important	O	O	O
findings	O	O	B-Entity
in	O	O	O
regard	O	O	O
to	O	O	O
the	O	O	O
validity	O	O	B-Entity
of	O	O	O
developing	O	O	B-Entity
a	O	O	O
comprehensive	O	O	B-Entity
behavioral	O	O	B-Entity
system	O	O	I-Entity
as	O	O	O
a	O	O	O
framework	O	O	B-Entity
for	O	O	O
empirical	O	O	B-Entity
investigation	O	O	B-Entity
.	O	O	O

The	O	O	O
behavioral	O	O	B-Entity
system	O	O	I-Entity
framework	O	O	B-Entity
consists	O	O	O
of	O	O	O
patients	O	O	B-Entity
'	O	O	O
knowledge	O	O	B-Entity
(	O	O	O
K	O	O	B-Entity
)	O	O	O
,	O	O	O
motivation	O	O	B-Entity
(	O	O	O
M	O	O	B-Entity
)	O	O	O
,	O	O	O
attitude	O	O	B-Entity
(	O	O	O
A	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
practice	O	O	B-Entity
(	O	O	O
P	O	O	B-Entity
)	O	O	O
as	O	O	O
predictor	O	O	B-Entity
variables	O	O	B-Entity
for	O	O	O
diabetes	O	O	B-Entity
care	O	O	B-Entity
outcomes	O	O	I-Entity
(	O	O	O
O	O	O	B-Entity
)	O	O	O
.	O	O	O

Care	O	O	B-Entity
management	O	O	I-Entity
strategies	O	O	O
or	O	O	O
health	O	O	B-Entity
education	O	O	I-Entity
programs	O	O	I-Entity
serve	O	O	O
as	O	O	O
the	O	O	O
intervention	O	O	B-Entity
variable	O	O	B-Entity
that	O	O	O
directly	O	O	O
influences	O	O	B-Entity
K	O	O	B-Entity
,	O	O	O
M	O	O	B-Entity
,	O	O	O
A	O	O	B-Entity
,	O	O	O
and	O	O	O
P	O	O	B-Entity
and	O	O	O
then	O	O	O
indirectly	O	O	O
affects	O	O	O
the	O	O	O
variability	O	O	B-Entity
in	O	O	O
patient	O	O	B-Entity
care	O	O	B-Entity
outcomes	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
.	O	O	O

This	O	O	O
review	O	O	B-Entity
contributes	O	O	O
to	O	O	O
the	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
KMAP-O	O	O	B-Entity
framework	O	O	I-Entity
and	O	O	O
how	O	O	O
it	O	O	O
can	O	O	O
guide	O	O	B-Entity
the	O	O	O
care	O	O	B-Entity
management	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
.	O	O	O

It	O	O	O
will	O	O	O
allow	O	O	O
the	O	O	O
tailoring	O	O	O
of	O	O	O
interventions	O	O	B-Entity
to	O	O	O
be	O	O	O
more	O	O	O
effective	O	O	O
through	O	O	O
knowledge	O	O	B-Entity
enhancement	O	O	B-Entity
,	O	O	O
increased	O	O	B-Entity
motivation	O	O	I-Entity
,	O	O	O
attitudinal	O	O	B-Entity
changes	O	O	B-Entity
,	O	O	O
and	O	O	O
improved	O	O	B-Entity
preventive	O	O	B-Entity
practice	O	O	I-Entity
to	O	O	O
reduce	O	O	B-Entity
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
type	O	O	B-Entity
2	O	O	I-Entity
diabetes	O	O	I-Entity
and	O	O	O
comorbidities	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
the	O	O	O
use	O	O	B-Entity
of	O	O	I-Entity
health	O	O	B-Entity
information	O	O	I-Entity
technology	O	O	I-Entity
for	O	O	O
enhancing	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
KMAP	O	O	B-Entity
and	O	O	O
communications	O	O	B-Entity
is	O	O	O
advocated	O	O	O
in	O	O	O
health	O	O	B-Entity
promotion	O	O	I-Entity
and	O	O	O
development	O	O	B-Entity
.	O	O	O

-DOCSTART- (28466379)

Bayesian	O	O	B-Entity
and	O	O	O
Phylogenic	O	O	B-Entity
Approaches	O	O	I-Entity
for	O	O	O
Studying	O	O	O
Relationships	O	O	B-Entity
among	O	O	O
Table	O	O	O
Olive	O	O	O
Cultivars	O	O	O

To	O	O	O
enhance	O	O	O
table	O	O	B-Entity
olive	O	O	I-Entity
tree	O	O	I-Entity
authentication	O	O	B-Entity
,	O	O	O
relationship	O	O	B-Entity
,	O	O	O
and	O	O	O
productivity	O	O	B-Entity
,	O	O	O
we	O	O	O
consider	O	O	O
the	O	O	O
analysis	O	O	B-Entity
of	O	O	O
18	O	O	O
worldwide	O	O	O
table	O	O	B-Entity
olive	O	O	I-Entity
cultivars	O	O	I-Entity
(	O	O	O
Olea	O	O	B-Entity
europaea	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	O
based	O	O	O
on	O	O	O
morphological	O	O	B-Entity
,	O	O	O
biological	O	O	B-Entity
,	O	O	O
and	O	O	O
physicochemical	O	O	B-Entity
markers	O	O	I-Entity
analyzed	O	O	O
by	O	O	O
bioinformatic	O	O	B-Entity
and	O	O	O
biostatistic	O	O	B-Entity
tools	O	O	I-Entity
.	O	O	O

Accordingly	O	O	O
,	O	O	O
we	O	O	O
assess	O	O	O
the	O	O	O
relationships	O	O	B-Entity
between	O	O	O
the	O	O	O
studied	O	O	O
varieties	O	O	B-Entity
,	O	O	O
on	O	O	O
the	O	O	O
one	O	O	O
hand	O	O	O
,	O	O	O
and	O	O	O
the	O	O	O
potential	O	O	O
productivity	O	O	B-Entity
-	O	O	O
quantitative	O	O	B-Entity
parameter	O	O	B-Entity
links	O	O	O
on	O	O	O
the	O	O	O
other	O	O	O
hand	O	O	O
.	O	O	O

The	O	O	O
bioinformatic	O	O	B-Entity
analysis	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
graphical	O	O	B-Entity
representation	O	O	I-Entity
of	O	O	O
the	O	O	O
matrix	O	O	B-Entity
of	O	O	I-Entity
Euclidean	O	O	I-Entity
distances	O	O	I-Entity
,	O	O	O
the	O	O	O
principal	O	O	B-Entity
components	O	O	I-Entity
analysis	O	O	I-Entity
,	O	O	O
unweighted	O	O	B-Entity
pair	O	O	I-Entity
group	O	O	I-Entity
method	O	O	I-Entity
with	O	O	O
arithmetic	O	O	B-Entity
mean	O	O	I-Entity
,	O	O	O
and	O	O	O
principal	O	O	B-Entity
coordinate	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
PCoA	O	O	B-Entity
)	O	O	O
revealed	O	O	O
three	O	O	O
major	O	O	O
clusters	O	O	B-Entity
which	O	O	O
were	O	O	O
not	O	O	O
correlated	O	O	O
with	O	O	O
the	O	O	O
geographic	O	O	B-Entity
origin	O	O	B-Entity
.	O	O	O

The	O	O	O
statistical	O	O	B-Entity
analysis	O	O	I-Entity
based	O	O	O
on	O	O	O
Kendall	O	O	O
's	O	O	O
and	O	O	O
Spearman	O	O	B-Entity
correlation	O	O	I-Entity
coefficients	O	O	I-Entity
suggests	O	O	O
two	O	O	O
highly	O	O	O
significant	O	O	O
associations	O	O	B-Entity
with	O	O	O
both	O	O	O
fruit	O	O	B-Entity
color	O	O	B-Entity
and	O	O	O
pollinization	O	O	B-Entity
and	O	O	O
the	O	O	O
productivity	O	O	B-Entity
character	O	O	O
.	O	O	O

These	O	O	O
results	O	O	B-Entity
are	O	O	O
confirmed	O	O	O
by	O	O	O
the	O	O	O
multiple	O	O	B-Entity
linear	O	O	I-Entity
regression	O	O	I-Entity
prediction	O	O	I-Entity
models	O	O	I-Entity
.	O	O	O

In	O	O	O
fact	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
the	O	O	O
coefficient	O	O	B-Entity
of	O	O	I-Entity
determination	O	O	I-Entity
(	O	O	O
R	O	O	B-Entity
(	O	O	I-Entity
2	O	O	I-Entity
)	O	O	I-Entity
)	O	O	O
value	O	O	O
,	O	O	O
the	O	O	O
best	O	O	O
model	O	O	B-Entity
demonstrated	O	O	O
the	O	O	O
power	O	O	B-Entity
of	O	O	O
the	O	O	O
pollinization	O	O	B-Entity
on	O	O	O
the	O	O	O
tree	O	O	O
productivity	O	O	B-Entity
(	O	O	O
R	O	O	O
(	O	O	O
2	O	O	O
)	O	O	O
=	O	O	O
0.846	O	O	O
)	O	O	O
.	O	O	O

Moreover	O	O	O
,	O	O	O
the	O	O	O
derived	O	O	O
directed	O	O	B-Entity
acyclic	O	O	I-Entity
graph	O	O	I-Entity
showed	O	O	O
that	O	O	O
only	O	O	O
two	O	O	O
direct	O	O	O
influences	O	O	B-Entity
are	O	O	O
detected	O	O	B-Entity
:	O	O	O
effect	O	O	B-Entity
of	O	O	O
tolerance	O	O	B-Entity
on	O	O	O
fruit	O	O	B-Entity
and	O	O	O
stone	O	O	B-Entity
symmetry	O	O	I-Entity
on	O	O	O
side	O	O	O
and	O	O	O
effect	O	O	O
of	O	O	O
tolerance	O	O	O
on	O	O	O
stone	O	O	B-Entity
form	O	O	I-Entity
and	O	O	O
oil	O	O	B-Entity
content	O	O	B-Entity
on	O	O	O
the	O	O	O
other	O	O	O
side	O	O	O
.	O	O	O

This	O	O	O
work	O	O	O
provides	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
the	O	O	O
diversity	O	O	B-Entity
available	O	O	O
in	O	O	O
worldwide	O	O	O
table	O	O	B-Entity
olive	O	O	B-Entity
cultivars	O	O	I-Entity
and	O	O	O
supplies	O	O	O
an	O	O	O
important	O	O	O
contribution	O	O	O
for	O	O	O
olive	O	O	O
breeding	O	O	B-Entity
and	O	O	O
authenticity	O	O	B-Entity
.	O	O	O

-DOCSTART- (28468175)

Wiedemann-Rautenstrauch	O	O	B-Entity
Syndrome	O	O	I-Entity
With	O	O	O
Bilateral	O	O	B-Entity
Tarsal	O	O	B-Entity
Kink	O	O	I-Entity
:	O	O	O
Three	O	O	O
Sutures	O	O	B-Entity
for	O	O	O
Correction	O	O	O

The	O	O	O
authors	O	O	O
describe	O	O	O
a	O	O	O
5-	O	O	O
month-old	O	O	B-Entity
male	O	O	B-Entity
infant	O	O	B-Entity
with	O	O	O
Wiedemann-Rautenstrauch	O	O	B-Entity
syndrome	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
an	O	O	O
extremely	O	O	O
rare	O	O	B-Entity
condition	O	O	B-Entity
.	O	O	O

He	O	O	O
had	O	O	O
tarsal	O	O	B-Entity
kink	O	O	I-Entity
in	O	O	O
upper	O	O	B-Entity
eyelids	O	O	I-Entity
in	O	O	O
both	O	O	B-Entity
eyes	O	O	I-Entity
.	O	O	O

The	O	O	O
authors	O	O	O
treated	O	O	B-Entity
bilateral	O	O	B-Entity
tarsal	O	O	B-Entity
kink	O	O	I-Entity
with	O	O	O
an	O	O	O
everting	O	O	B-Entity
suture	O	O	B-Entity
via	O	O	O
a	O	O	O
transconjunctival	O	O	B-Entity
approach	O	O	I-Entity
under	O	O	O
local	O	O	B-Entity
anesthesia	O	O	I-Entity
.	O	O	O

-DOCSTART- (28468714)

The	O	O	O
Indications	O	O	B-Entity
for	O	O	O
Laparoscopic	O	O	O
Pancreatectomy	O	O	O

Laparoscopic	O	O	B-Entity
pancreatectomy	O	O	I-Entity
is	O	O	O
not	O	O	O
yet	O	O	O
established	O	O	O
as	O	O	O
a	O	O	O
routine	O	O	B-Entity
procedure	O	O	I-Entity
everywhere	O	O	O
in	O	O	O
Germany	O	O	B-Entity
or	O	O	O
in	O	O	O
other	O	O	O
countries	O	O	B-Entity
.	O	O	O

Few	O	O	O
data	O	O	B-Entity
are	O	O	O
available	O	O	O
on	O	O	O
its	O	O	O
short-	O	O	B-Entity
and	O	O	I-Entity
long-term	O	O	I-Entity
outcomes	O	O	I-Entity
.	O	O	O

From	O	O	O
2008	O	O	O
onward	O	O	O
,	O	O	O
a	O	O	O
working	O	O	B-Entity
group	O	O	I-Entity
initiated	O	O	O
by	O	O	O
10	O	O	O
centers	O	O	B-Entity
and	O	O	O
currently	O	O	O
comprising	O	O	O
34	O	O	O
centers	O	O	O
has	O	O	O
gathered	O	O	O
data	O	O	B-Entity
on	O	O	O
all	O	O	O
cases	O	O	B-Entity
of	O	O	O
laparoscopic	O	O	B-Entity
pancreatectomy	O	O	I-Entity
.	O	O	O

Procedures	O	O	B-Entity
in	O	O	O
which	O	O	O
laparoscopy	O	O	B-Entity
was	O	O	O
converted	O	O	O
to	O	O	O
open	O	O	B-Entity
surgery	O	O	I-Entity
are	O	O	O
also	O	O	O
included	O	O	O
.	O	O	O

The	O	O	O
registry	O	O	B-Entity
now	O	O	O
contains	O	O	O
550	O	O	O
data	O	O	B-Entity
sets	O	O	O
representing	O	O	O
267	O	O	O
cases	O	O	B-Entity
of	O	O	O
benign	O	O	B-Entity
disease	O	O	I-Entity
,	O	O	O
244	O	O	O
malignancies	O	O	B-Entity
,	O	O	O
and	O	O	O
39	O	O	O
borderline	O	O	B-Entity
tumors	O	O	I-Entity
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
procedure	O	O	B-Entity
was	O	O	O
laparoscopic	O	O	B-Entity
left	O	O	I-Entity
pancreatectomy	O	O	I-Entity
,	O	O	O
followed	O	O	O
by	O	O	O
resection	O	O	B-Entity
of	O	O	O
the	O	O	O
head	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
pancreas	O	O	I-Entity
and	O	O	O
tumor	O	O	B-Entity
enucleation	O	O	B-Entity
.	O	O	O

The	O	O	O
most	O	O	O
common	O	O	O
intraoperative	O	O	B-Entity
complication	O	O	I-Entity
was	O	O	O
hemorrhage	O	O	B-Entity
,	O	O	O
with	O	O	O
a	O	O	O
frequency	O	O	O
of	O	O	O
3	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
rate	O	O	B-Entity
of	O	O	O
conversion	O	O	B-Entity
to	O	O	O
open	O	O	B-Entity
surgery	O	O	I-Entity
was	O	O	O
35	O	O	O
%	O	O	O
;	O	O	O
if	O	O	O
minilaparotomies	O	O	B-Entity
are	O	O	O
excluded	O	O	O
,	O	O	O
the	O	O	O
conversion	O	O	O
rate	O	O	O
was	O	O	O
only	O	O	O
16	O	O	O
%	O	O	O
.	O	O	O

39	O	O	O
%	O	O	O
of	O	O	O
patients	O	O	B-Entity
developed	O	O	O
a	O	O	O
pancreatic	O	O	B-Entity
fistula	O	O	I-Entity
after	O	O	O
surgery	O	O	B-Entity
(	O	O	O
usually	O	O	O
grade	O	O	O
A	O	O	O
or	O	O	O
B	O	O	O
,	O	O	O
with	O	O	O
1.5	O	O	O
%	O	O	O
grade	O	O	O
C	O	O	O
)	O	O	O
and	O	O	O
3	O	O	O
%	O	O	O
underwent	O	O	O
reoperation	O	O	B-Entity
because	O	O	O
of	O	O	O
postoperative	O	O	B-Entity
hemorrhage	O	O	I-Entity
.	O	O	O

The	O	O	O
procedure-related	O	O	B-Entity
mortality	O	O	I-Entity
was	O	O	O
1.3	O	O	O
%	O	O	O
.	O	O	O

91	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
patients	O	O	B-Entity
reported	O	O	O
only	O	O	O
very	O	O	O
mild	O	O	O
postoperative	O	O	B-Entity
pain	O	O	I-Entity
.	O	O	O

6.7	O	O	O
%	O	O	O
newly	O	O	O
developed	O	O	O
diabetes	O	O	B-Entity
mellitus	O	O	I-Entity
after	O	O	O
the	O	O	O
procedure	O	O	B-Entity
.	O	O	O

The	O	O	O
patient	O	O	B-Entity
cohort	O	O	B-Entity
in	O	O	O
the	O	O	O
registry	O	O	B-Entity
consists	O	O	O
of	O	O	O
persons	O	O	B-Entity
who	O	O	O
were	O	O	O
selected	O	O	O
to	O	O	O
undergo	O	O	O
laparoscopic	O	O	B-Entity
pancreatectomy	O	O	I-Entity
by	O	O	O
the	O	O	O
participating	O	O	O
hospital	O	O	B-Entity
teams	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
data	O	O	B-Entity
are	O	O	O
thus	O	O	O
inherently	O	O	O
affected	O	O	O
by	O	O	O
selection	O	O	B-Entity
bias	O	O	I-Entity
.	O	O	O

The	O	O	O
operative	O	O	B-Entity
procedures	O	O	I-Entity
that	O	O	O
they	O	O	O
underwent	O	O	O
reflect	O	O	O
the	O	O	O
current	O	O	O
practice	O	O	O
of	O	O	O
laparoscopic	O	O	B-Entity
pancreatectomy	O	O	I-Entity
in	O	O	O
Germany	O	O	B-Entity
.	O	O	O

The	O	O	O
complication	O	O	B-Entity
rates	O	O	B-Entity
are	O	O	O
similar	O	O	O
to	O	O	O
those	O	O	O
of	O	O	O
open	O	O	B-Entity
surgery	O	O	I-Entity
.	O	O	O

Selection	O	O	B-Entity
bias	O	O	I-Entity
can	O	O	O
be	O	O	O
avoided	O	O	O
only	O	O	O
by	O	O	O
a	O	O	O
randomized	O	O	B-Entity
trial	O	O	I-Entity
.	O	O	O

-DOCSTART- (28470106)

Associations	O	O	O
of	O	O	O
NEUROD2	O	O	B-Entity
polymorphisms	O	O	B-Entity
and	O	O	O
change	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
dysfunctions	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
and	O	O	O
schizoaffective	O	O	B-Entity
disorder	O	O	I-Entity
after	O	O	O
eight	O	O	O
weeks	O	O	B-Entity
of	O	O	O
antipsychotic	O	O	B-Entity
treatment	O	O	O

NEUROD2	O	O	B-Entity
is	O	O	O
a	O	O	O
neurospecific	O	O	B-Entity
helix-loop-helix	O	O	I-Entity
transcription	O	O	B-Entity
factor	O	O	I-Entity
which	O	O	O
has	O	O	O
an	O	O	O
impact	O	O	B-Entity
on	O	O	O
the	O	O	O
regulation	O	O	B-Entity
of	O	O	O
glutamatergic	O	O	B-Entity
and	O	O	O
GABAergic	O	O	B-Entity
genes	O	O	B-Entity
.	O	O	O

We	O	O	O
investigated	O	O	B-Entity
an	O	O	O
association	O	O	O
of	O	O	O
NEUROD2	O	O	B-Entity
with	O	O	O
neurocognitive	O	O	B-Entity
dysfunctions	O	O	I-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
and	O	O	O
schizoaffective	O	O	B-Entity
disorder	O	O	I-Entity
patients	O	O	B-Entity
before	O	O	O
and	O	O	O
during	O	O	O
treatment	O	O	B-Entity
with	O	O	O
different	O	O	O
second-generation	O	O	B-Entity
antipsychotics	O	O	I-Entity
.	O	O	O

Patients	O	O	B-Entity
were	O	O	O
genotyped	O	O	B-Entity
for	O	O	O
four	O	O	O
different	O	O	O
polymorphisms	O	O	B-Entity
of	O	O	O
the	O	O	O
NEUROD2	O	O	B-Entity
gene	O	O	B-Entity
(	O	O	O
(	O	O	O
rs9889354(A/G	O	O	B-Entity
)	O	O	O
,	O	O	O
rs1877032(C/T	O	O	B-Entity
)	O	O	I-Entity
,	O	O	O
rs12453682(C/T	O	O	B-Entity
)	O	O	I-Entity
and	O	O	O
rs11078918(C/G	O	O	B-Entity
)	O	O	I-Entity
)	O	O	O
.	O	O	O

Cognitive	O	O	B-Entity
function	O	O	I-Entity
was	O	O	O
assessed	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
week	O	O	B-Entity
8	O	O	O
.	O	O	O

Results	O	O	B-Entity
of	O	O	O
individual	O	O	O
neuropsychological	O	O	B-Entity
tests	O	O	I-Entity
were	O	O	O
assigned	O	O	O
to	O	O	O
six	O	O	O
cognitive	O	O	B-Entity
domains	O	O	I-Entity
(	O	O	B-Entity
reaction	O	O	I-Entity
time	O	O	I-Entity
and	O	O	O
quality	O	O	B-Entity
;	O	O	O
executive	O	O	B-Entity
function	O	O	I-Entity
;	O	O	O
working	O	O	B-Entity
,	O	O	O
verbal	O	O	B-Entity
and	O	O	O
visual	O	O	B-Entity
memory	O	O	I-Entity
)	O	O	O
and	O	O	O
a	O	O	O
general	O	O	O
cognitive	O	O	O
index	O	O	B-Entity
.	O	O	O

167	O	O	O
patients	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

The	O	O	O
NEUROD2	O	O	B-Entity
exonic	O	O	B-Entity
polymorphism	O	O	I-Entity
rs11078918	O	O	I-Entity
showed	O	O	O
significant	O	O	O
associations	O	O	O
with	O	O	O
verbal	O	O	B-Entity
memory	O	O	I-Entity
and	O	O	O
executive	O	O	B-Entity
functions	O	O	I-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
NEUROD2	O	O	O
polymorphism	O	O	B-Entity
rs12453682	O	O	I-Entity
was	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
working	O	O	B-Entity
and	O	O	O
verbal	O	O	O
memory	O	O	O
,	O	O	O
executive	O	O	O
functions	O	O	O
and	O	O	O
with	O	O	O
a	O	O	O
cognitive	O	O	B-Entity
index	O	O	B-Entity
.	O	O	O

Significant	O	O	O
associations	O	O	O
were	O	O	O
found	O	O	O
at	O	O	O
baseline	O	O	B-Entity
and	O	O	O
after	O	O	O
eight	O	O	O
weeks	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
significant	O	O	O
associations	O	O	O
between	O	O	O
the	O	O	O
change	O	O	B-Entity
in	O	O	O
neuropsychological	O	O	B-Entity
test	O	O	I-Entity
results	O	O	B-Entity
during	O	O	O
antipsychotic	O	O	B-Entity
treatment	O	O	B-Entity
and	O	O	O
the	O	O	O
NEUROD2	O	O	B-Entity
polymorphisms	O	O	B-Entity
rs11078918	O	O	B-Entity
and	O	O	O
rs12453682	O	O	B-Entity
were	O	O	O
observed	O	O	O
.	O	O	O

Our	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
the	O	O	O
NEUROD2	O	O	B-Entity
gene	O	O	I-Entity
could	O	O	O
play	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
the	O	O	O
pathophysiology	O	O	B-Entity
of	O	O	O
neurocognitive	O	O	B-Entity
dysfunctions	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
in	O	O	O
the	O	O	O
change	O	O	B-Entity
of	O	O	O
cognitive	O	O	B-Entity
symptoms	O	O	I-Entity
under	O	O	O
antipsychotic	O	O	B-Entity
treatment	O	O	B-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
and	O	O	O
schizoaffective	O	O	B-Entity
disorder	O	O	I-Entity
.	O	O	O

-DOCSTART- (28470482)

New	O	O	B-Entity
Diterpenoids	O	O	B-Entity
from	O	O	O
Clerodendranthus	O	O	O
spicatus	O	O	O

Two	O	O	O
new	O	O	B-Entity
diterpenoids	O	O	B-Entity
,	O	O	O
neoorthosiphonones	O	O	B-Entity
B	O	O	I-Entity
and	O	O	O
C	O	O	B-Entity
(	O	O	O
1	O	O	B-Entity
and	O	O	O
2	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
one	O	O	O
known	O	O	O
diterpenoid	O	O	B-Entity
,	O	O	O
were	O	O	O
isolated	O	O	B-Entity
from	O	O	O
the	O	O	O
aerial	O	O	B-Entity
parts	O	O	I-Entity
of	O	O	O
Clerodendranthus	O	O	B-Entity
spicatus	O	O	I-Entity
.	O	O	O

Their	O	O	O
structures	O	O	B-Entity
including	O	O	O
absolute	O	O	B-Entity
configurations	O	O	B-Entity
were	O	O	O
determined	O	O	B-Entity
by	O	O	I-Entity
comprehensive	O	O	O
spectroscopic	O	O	B-Entity
analyses	O	O	I-Entity
and	O	O	O
X-ray	O	O	B-Entity
crystallographic	O	O	I-Entity
methods	O	O	I-Entity
.	O	O	O

No	O	O	O
compound	O	O	B-Entity
was	O	O	O
found	O	O	O
to	O	O	O
inhibit	O	O	B-Entity
fibronectin	O	O	B-Entity
production	O	O	B-Entity
at	O	O	O
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
20	O	O	O
μM.	O	O	O

-DOCSTART- (28470753)

Stalk	O	O	B-Entity
versus	O	O	O
base	O	O	B-Entity
invasion	O	O	B-Entity
in	O	O	O
pT1	O	O	B-Entity
papillary	O	O	B-Entity
cancers	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
bladder	O	O	I-Entity
:	O	O	O
improved	O	O	O
substaging	O	O	O
system	O	O	O
predicting	O	O	O
risk	O	O	B-Entity
of	O	O	O
progression	O	O	O

Pathologic	O	O	B-Entity
stage	O	O	I-Entity
T1	O	O	I-Entity
(	O	O	O
pT1	O	O	B-Entity
)	O	O	O
bladder	O	O	B-Entity
cancers	O	O	I-Entity
are	O	O	O
a	O	O	O
clinically	O	O	B-Entity
heterogeneous	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
current	O	O	O
staging	O	O	B-Entity
guidelines	O	O	O
for	O	O	O
superficially	O	O	B-Entity
invasive	O	O	B-Entity
cancers	O	O	I-Entity
do	O	O	O
not	O	O	O
acknowledge	O	O	O
the	O	O	O
variability	O	O	B-Entity
in	O	O	O
type	O	O	O
and	O	O	O
extent	O	O	O
of	O	O	O
lamina	O	O	B-Entity
propria	O	O	I-Entity
invasion	O	O	I-Entity
in	O	O	O
papillary	O	O	B-Entity
urothelial	O	O	I-Entity
carcinomas	O	O	I-Entity
(	O	O	O
PUC	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
historically	O	O	O
proposed	O	O	O
substaging	O	O	O
systems	O	O	O
showed	O	O	O
either	O	O	O
high	O	O	O
inter-observer	O	O	B-Entity
variation	O	O	I-Entity
or	O	O	O
limited	O	O	B-Entity
value	O	O	I-Entity
in	O	O	O
predicting	O	O	O
patient	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

Herein	O	O	O
we	O	O	O
reappraise	O	O	B-Entity
pT1	O	O	B-Entity
PUC	O	O	B-Entity
substaging	O	O	O
,	O	O	O
aiming	O	O	B-Entity
to	O	O	O
identify	O	O	B-Entity
a	O	O	O
novel	O	O	B-Entity
scheme	O	O	B-Entity
which	O	O	O
is	O	O	O
reproducible	O	O	B-Entity
and	O	O	O
prognostically	O	O	B-Entity
meaningful	O	O	O
.	O	O	O

Stage	O	O	B-Entity
pT1	O	O	I-Entity
PUC	O	O	B-Entity
diagnosed	O	O	B-Entity
during	O	O	O
years	O	O	B-Entity
1999	O	O	O
-	O	O	O
2015	O	O	O
were	O	O	O
retrospectively	O	O	B-Entity
reviewed	O	O	I-Entity
and	O	O	O
characterized	O	O	B-Entity
as	O	O	O
focal	O	O	B-Entity
invasion	O	O	B-Entity
confined	O	O	O
to	O	O	O
papillary	O	O	B-Entity
stalk	O	O	I-Entity
,	O	O	O
focal	O	O	O
invasion	O	O	O
of	O	O	O
tumor	O	O	B-Entity
base	O	O	B-Entity
,	O	O	O
or	O	O	O
extensive	O	O	O
invasion	O	O	O
of	O	O	O
tumor	O	O	O
base	O	O	O
.	O	O	O

Cases	O	O	B-Entity
with	O	O	O
concurrent	O	O	B-Entity
flat	O	O	B-Entity
carcinoma	O	O	I-Entity
in-situ	O	O	I-Entity
,	O	O	O
angiolymphatic	O	O	B-Entity
invasion	O	O	I-Entity
,	O	O	O
absent	O	O	B-Entity
muscularis	O	O	B-Entity
propria	O	O	I-Entity
,	O	O	O
or	O	O	O
clinically	O	O	B-Entity
advanced	O	O	B-Entity
disease	O	O	I-Entity
were	O	O	O
excluded	O	O	B-Entity
.	O	O	O

We	O	O	O
calculated	O	O	O
cumulative	O	O	B-Entity
incidence	O	O	B-Entity
of	O	O	O
recurrence	O	O	B-Entity
,	O	O	O
progression	O	O	B-Entity
,	O	O	O
and	O	O	O
death	O	O	B-Entity
by	O	O	O
tumor	O	O	B-Entity
subtype	O	O	I-Entity
and	O	O	O
evaluated	O	O	B-Entity
differential	O	O	B-Entity
risks	O	O	I-Entity
using	O	O	O
log-rank	O	O	B-Entity
tests	O	O	I-Entity
and	O	O	O
Kaplan-Meier	O	O	B-Entity
curves	O	O	I-Entity
stratified	O	O	B-Entity
by	O	O	O
type	O	O	B-Entity
and	O	O	O
extent	O	O	B-Entity
of	O	O	I-Entity
invasion	O	O	I-Entity
.	O	O	O

Among	O	O	O
62	O	O	O
patients	O	O	B-Entity
satisfying	O	O	O
inclusion	O	O	B-Entity
criteria	O	O	B-Entity
,	O	O	O
22	O	O	O
of	O	O	O
29	O	O	O
patients	O	O	O
with	O	O	O
base	O	O	B-Entity
extensive	O	O	B-Entity
invasion	O	O	B-Entity
progressed	O	O	B-Entity
while	O	O	O
4	O	O	O
of	O	O	O
13	O	O	O
with	O	O	O
base	O	O	O
focal	O	O	B-Entity
and	O	O	O
0	O	O	O
of	O	O	O
20	O	O	O
with	O	O	O
stalk	O	O	B-Entity
only	O	O	O
invasion	O	O	O
progressed	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
strong	O	O	O
evidence	O	O	O
that	O	O	O
base	O	O	B-Entity
extensive	O	O	O
patients	O	O	B-Entity
had	O	O	O
higher	O	O	O
risk	O	O	B-Entity
of	O	O	O
progression	O	O	B-Entity
and	O	O	O
death	O	O	B-Entity
due	O	O	O
to	O	O	O
bladder	O	O	B-Entity
cancer	O	O	I-Entity
than	O	O	O
base	O	O	O
focal	O	O	B-Entity
or	O	O	O
stalk	O	O	B-Entity
only	O	O	O
counterparts	O	O	O
(	O	O	O
P<0.0001	O	O	O
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
tumor	O	O	B-Entity
subtype	O	O	I-Entity
was	O	O	O
not	O	O	O
significantly	O	O	O
associated	O	O	O
with	O	O	O
risk	O	O	B-Entity
of	O	O	O
recurrence	O	O	B-Entity
(	O	O	O
P=0.21	O	O	O
)	O	O	O
.	O	O	O

We	O	O	O
propose	O	O	O
an	O	O	O
innovative	O	O	O
substaging	O	O	O
approach	O	O	O
for	O	O	O
reporting	O	O	O
site	O	O	O
and	O	O	O
extent	O	O	O
of	O	O	O
lamina	O	O	B-Entity
propria	O	O	I-Entity
invasion	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
pT1	O	O	B-Entity
PUC	O	O	B-Entity
allowing	O	O	O
patient	O	O	B-Entity
stratification	O	O	B-Entity
for	O	O	O
risk	O	O	B-Entity
of	O	O	O
progression	O	O	B-Entity
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (28471941)

Basic	O	O	B-Entity
science	O	O	I-Entity
and	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
ageing	O	O	B-Entity
with	O	O	O
HIV	O	O	B-Entity
:	O	O	O
potential	O	O	O
mechanisms	O	O	B-Entity
and	O	O	O
biomarkers	O	O	O

:	O	O	O
The	O	O	O
increased	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
age	O	O	B-Entity
-related	O	O	O
comorbidities	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
is	O	O	O
worrisome	O	O	B-Entity
in	O	O	O
ageing	O	O	B-Entity
HIV-infected	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Here	O	O	O
,	O	O	O
we	O	O	O
aim	O	O	B-Entity
to	O	O	O
analyse	O	O	B-Entity
the	O	O	O
different	O	O	O
ageing	O	O	B-Entity
mechanisms	O	O	B-Entity
with	O	O	O
regard	O	O	O
to	O	O	O
HIV	O	O	B-Entity
infection	O	O	I-Entity
.	O	O	O

Ageing	O	O	B-Entity
results	O	O	O
from	O	O	O
the	O	O	O
time	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
accumulation	O	O	B-Entity
of	O	O	O
random	O	O	O
cellular	O	O	B-Entity
damage	O	O	I-Entity
.	O	O	O

Epigenetic	O	O	B-Entity
modifications	O	O	I-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
DNA	O	O	I-Entity
haplogroups	O	O	B-Entity
modulate	O	O	B-Entity
ageing	O	O	B-Entity
.	O	O	O

In	O	O	O
antiretroviral	O	O	B-Entity
treatment	O	O	I-Entity
-controlled	O	O	O
patients	O	O	B-Entity
,	O	O	O
epigenetic	O	O	B-Entity
clock	O	O	I-Entity
appears	O	O	O
to	O	O	O
be	O	O	O
advanced	O	O	O
,	O	O	O
and	O	O	O
some	O	O	O
haplogroups	O	O	B-Entity
are	O	O	O
associated	O	O	O
with	O	O	O
HIV	O	O	B-Entity
infection	O	O	I-Entity
severity	O	O	B-Entity
.	O	O	O

Telomere	O	O	B-Entity
shortening	O	O	I-Entity
is	O	O	O
enhanced	O	O	O
in	O	O	O
HIV-infected	O	O	B-Entity
patients	O	O	B-Entity
because	O	O	O
of	O	O	O
HIV	O	O	B-Entity
and	O	O	O
some	O	O	O
nucleoside	O	O	B-Entity
analogue	O	O	I-Entity
reverse	O	O	B-Entity
transcriptase	O	O	I-Entity
inhibitors	O	O	I-Entity
.	O	O	O

Mitochondria	O	O	B-Entity
-related	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
and	O	O	O
mitochondrial	O	O	B-Entity
DNA	O	O	I-Entity
mutations	O	O	B-Entity
are	O	O	O
increased	O	O	O
during	O	O	O
ageing	O	O	B-Entity
and	O	O	O
also	O	O	O
by	O	O	O
some	O	O	O
nucleoside	O	O	B-Entity
analogue	O	O	I-Entity
reverse	O	O	B-Entity
transcriptase	O	O	I-Entity
inhibitors	O	O	I-Entity
.	O	O	O

Overall	O	O	O
,	O	O	O
increased	O	O	O
inflammation	O	O	B-Entity
or	O	O	O
'	O	O	O
inflammageing	O	O	B-Entity
'	O	O	O
is	O	O	O
a	O	O	O
major	O	O	O
driver	O	O	O
of	O	O	O
ageing	O	O	B-Entity
and	O	O	O
could	O	O	O
result	O	O	O
from	O	O	O
cell	O	O	B-Entity
senescence	O	O	I-Entity
with	O	O	O
secreted	O	O	O
proinflammatory	O	O	B-Entity
mediators	O	O	I-Entity
,	O	O	O
altered	O	O	O
gut	O	O	B-Entity
microbiota	O	O	I-Entity
,	O	O	O
and	O	O	O
coinfections	O	O	B-Entity
.	O	O	O

In	O	O	O
HIV-infected	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
and	O	O	O
innate	O	O	B-Entity
immunity	O	O	I-Entity
activation	O	O	B-Entity
is	O	O	O
enhanced	O	O	O
and	O	O	O
related	O	O	O
to	O	O	O
most	O	O	O
comorbidities	O	O	B-Entity
and	O	O	O
to	O	O	O
mortality	O	O	B-Entity
.	O	O	O

This	O	O	O
status	O	O	O
could	O	O	O
result	O	O	O
,	O	O	O
in	O	O	O
addition	O	O	O
to	O	O	O
age	O	O	B-Entity
,	O	O	O
from	O	O	O
the	O	O	O
virus	O	O	B-Entity
itself	O	O	O
or	O	O	O
viral	O	O	B-Entity
protein	O	O	I-Entity
released	O	O	O
from	O	O	O
reservoirs	O	O	B-Entity
,	O	O	O
from	O	O	O
HIV	O	O	B-Entity
-enhanced	O	O	O
gut	O	O	B-Entity
permeability	O	O	B-Entity
and	O	O	O
dysbiosis	O	O	B-Entity
,	O	O	O
from	O	O	O
antiretroviral	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
from	O	O	O
frequent	O	O	O
cytomegalovirus	O	O	B-Entity
and	O	O	O
hepatitis	O	O	B-Entity
C	O	O	I-Entity
virus	O	O	I-Entity
coinfections	O	O	B-Entity
,	O	O	O
and	O	O	O
also	O	O	O
from	O	O	O
personal	O	O	O
and	O	O	O
environmental	O	O	B-Entity
factors	O	O	I-Entity
,	O	O	O
as	O	O	O
central	O	O	O
fat	O	O	B-Entity
accumulation	O	O	I-Entity
or	O	O	O
smoking	O	O	B-Entity
.	O	O	O

Adaptive	O	O	B-Entity
immune	O	O	I-Entity
activation	O	O	B-Entity
and	O	O	O
immunosenescence	O	O	B-Entity
are	O	O	O
associated	O	O	O
with	O	O	O
comorbidities	O	O	B-Entity
and	O	O	O
mortality	O	O	B-Entity
in	O	O	O
the	O	O	O
general	O	O	B-Entity
population	O	O	I-Entity
but	O	O	O
are	O	O	O
less	O	O	O
predictive	O	O	B-Entity
in	O	O	O
HIV-infected	O	O	B-Entity
patients	O	O	B-Entity
.	O	O	O

Biomarkers	O	O	B-Entity
to	O	O	O
evaluate	O	O	B-Entity
ageing	O	O	B-Entity
in	O	O	O
HIV-infected	O	O	B-Entity
patients	O	O	B-Entity
are	O	O	O
required	O	O	O
.	O	O	O

Numerous	O	O	O
systemic	O	O	B-Entity
or	O	O	O
cellular	O	O	B-Entity
inflammatory	O	O	I-Entity
,	O	O	O
immune	O	O	B-Entity
activation	O	O	B-Entity
,	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
,	O	O	O
or	O	O	O
senescence	O	O	O
markers	O	O	B-Entity
can	O	O	O
be	O	O	O
tested	O	O	B-Entity
in	O	O	O
serum	O	O	B-Entity
or	O	O	O
peripheral	O	O	B-Entity
blood	O	O	I-Entity
mononuclear	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

The	O	O	O
novel	O	O	O
European	O	O	B-Entity
Study	O	O	B-Entity
to	O	O	O
Establish	O	O	O
Biomarkers	O	O	B-Entity
of	O	O	O
Human	O	O	B-Entity
Ageing	O	O	I-Entity
MARK-AGE	O	O	I-Entity
algorithm	O	O	I-Entity
,	O	O	O
evaluating	O	O	B-Entity
the	O	O	O
biological	O	O	B-Entity
age	O	O	B-Entity
,	O	O	O
is	O	O	O
currently	O	O	O
assessed	O	O	O
in	O	O	O
HIV-infected	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
reveals	O	O	O
an	O	O	O
advanced	O	O	O
biological	O	O	O
age	O	O	O
.	O	O	O

Some	O	O	O
enhanced	O	O	O
inflammatory	O	O	B-Entity
or	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
activation	O	O	B-Entity
markers	O	O	B-Entity
are	O	O	O
interesting	O	O	O
but	O	O	O
still	O	O	O
not	O	O	O
validated	O	O	O
for	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	I-Entity
follow-up	O	O	B-Entity
.	O	O	O

To	O	O	O
be	O	O	O
able	O	O	O
to	O	O	O
assess	O	O	O
patients	O	O	B-Entity
'	O	O	O
biological	O	O	B-Entity
age	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	O
objective	O	O	O
to	O	O	O
improve	O	O	O
their	O	O	O
healthspan	O	O	B-Entity
.	O	O	O

-DOCSTART- (28473015)

MESOTHELIAL	O	O	B-Entity
CELL	O	O	I-Entity
ADHERENCE	O	O	B-Entity
TO	O	O	O
VASCULAR	O	O	B-Entity
PROSTHESES	O	O	I-Entity
AND	O	O	O
THEIR	O	O	O
SUBSEQUENT	O	O	B-Entity
GROWTH	O	O	B-Entity
IN	O	O	O
VITRO	O	O	O

Cell	O	O	B-Entity
seeding	O	O	B-Entity
may	O	O	O
decrease	O	O	B-Entity
the	O	O	O
thrombogenicity	O	O	B-Entity
of	O	O	O
implanted	O	O	B-Entity
vascular	O	O	B-Entity
grafts	O	O	I-Entity
,	O	O	O
but	O	O	O
its	O	O	O
application	O	O	O
is	O	O	O
hampered	O	O	O
by	O	O	O
the	O	O	O
limited	O	O	O
availability	O	O	B-Entity
of	O	O	I-Entity
autologous	O	O	B-Entity
endothelial	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Human	O	O	B-Entity
peritoneal	O	O	B-Entity
mesothelial	O	O	B-Entity
cells	O	O	I-Entity
have	O	O	O
blood	O	O	B-Entity
flow	O	O	I-Entity
supporting	O	O	B-Entity
qualities	O	O	I-Entity
and	O	O	O
are	O	O	O
readily	O	O	B-Entity
available	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
investigated	O	O	B-Entity
the	O	O	O
adherence	O	O	B-Entity
of	O	O	O
mesothelial	O	O	B-Entity
cells	O	O	I-Entity
to	O	O	O
vascular	O	O	B-Entity
prostheses	O	O	I-Entity
and	O	O	O
their	O	O	O
subsequent	O	O	B-Entity
growth	O	O	B-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

Circular	O	O	B-Entity
pieces	O	O	B-Entity
of	O	O	O
various	O	O	O
vascular	O	O	B-Entity
prosthetic	O	O	B-Entity
materials	O	O	I-Entity
were	O	O	O
seeded	O	O	B-Entity
with	O	O	O
51Chromium-labeled	O	O	B-Entity
mesothelial	O	O	B-Entity
and	O	O	O
endothelial	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
left	O	O	O
for	O	O	O
either	O	O	O
5	O	O	O
,	O	O	O
15	O	O	O
,	O	O	O
30	O	O	O
,	O	O	O
60	O	O	O
,	O	O	O
and	O	O	O
120	O	O	O
minutes	O	O	B-Entity
.	O	O	O

The	O	O	O
unattached	O	O	B-Entity
cells	O	O	B-Entity
were	O	O	O
removed	O	O	B-Entity
and	O	O	O
the	O	O	O
degree	O	O	B-Entity
of	O	O	O
cell	O	O	B-Entity
attachment	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
.	O	O	O

The	O	O	O
number	O	O	B-Entity
of	O	O	O
mesothelial	O	O	B-Entity
cells	O	O	I-Entity
to	O	O	O
Dacron	O	O	B-Entity
increased	O	O	B-Entity
during	O	O	O
the	O	O	O
first	O	O	O
60	O	O	O
min	O	O	B-Entity
up	O	O	O
to	O	O	O
35.2	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
seeded	O	O	B-Entity
inoculum	O	O	B-Entity
where	O	O	O
after	O	O	O
a	O	O	O
plateau	O	O	B-Entity
was	O	O	O
reached	O	O	B-Entity
.	O	O	O

Scanning	O	O	B-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
showed	O	O	O
spreaded	O	O	B-Entity
mesothelial	O	O	B-Entity
cells	O	O	I-Entity
adherent	O	O	B-Entity
to	O	O	O
the	O	O	O
Dacron	O	O	B-Entity
fibers	O	O	I-Entity
.	O	O	O

A	O	O	O
significant	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
adherence	O	O	B-Entity
was	O	O	O
observed	O	O	B-Entity
after	O	O	O
preincubation	O	O	B-Entity
of	O	O	O
Dacron	O	O	B-Entity
with	O	O	O
10	O	O	O
μg/mL	O	O	O
fibronectin	O	O	B-Entity
,	O	O	O
but	O	O	O
no	O	O	B-Entity
improvement	O	O	I-Entity
was	O	O	O
found	O	O	B-Entity
after	O	O	O
preincubation	O	O	O
with	O	O	O
human	O	O	B-Entity
serum	O	O	B-Entity
albumin	O	O	I-Entity
or	O	O	O
gelatin	O	O	B-Entity
.	O	O	O

Mesothelial	O	O	B-Entity
cells	O	O	I-Entity
adhered	O	O	B-Entity
better	O	O	O
to	O	O	O
Gelcoated	O	O	B-Entity
than	O	O	O
to	O	O	O
Gelsealed	O	O	B-Entity
or	O	O	O
plain	O	O	B-Entity
Dacron	O	O	I-Entity
.	O	O	O

The	O	O	O
adherence	O	O	B-Entity
of	O	O	O
mesothelial	O	O	B-Entity
cells	O	O	I-Entity
to	O	O	O
ePTFE	O	O	B-Entity
(	O	O	O
Teflon	O	O	B-Entity
)	O	O	O
was	O	O	O
significantly	O	O	B-Entity
poorer	O	O	B-Entity
.	O	O	O

No	O	O	B-Entity
significant	O	O	I-Entity
differences	O	O	B-Entity
in	O	O	O
adherence	O	O	B-Entity
were	O	O	O
found	O	O	B-Entity
between	O	O	O
mesothelial	O	O	B-Entity
and	O	O	O
endothelial	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Mesothelial	O	O	B-Entity
cell	O	O	I-Entity
growth	O	O	B-Entity
on	O	O	O
Dacron	O	O	B-Entity
resulted	O	O	B-Entity
in	O	O	O
a	O	O	O
modest	O	O	B-Entity
increase	O	O	I-Entity
in	O	O	O
the	O	O	O
number	O	O	B-Entity
of	O	O	O
viable	O	O	B-Entity
cells	O	O	I-Entity
during	O	O	O
27	O	O	O
days	O	O	B-Entity
,	O	O	O
which	O	O	O
implies	O	O	O
biocompatibility	O	O	B-Entity
of	O	O	O
Dacron	O	O	O
and	O	O	O
mesothelial	O	O	B-Entity
cells	O	O	I-Entity
in	O	O	B-Entity
vitro	O	O	I-Entity
.	O	O	O

-DOCSTART- (28473640)

Anterolateral	O	O	B-Entity
entorhinal	O	O	B-Entity
cortex	O	O	I-Entity
volume	O	O	B-Entity
predicted	O	O	O
by	O	O	O
altered	O	O	O
intra-item	O	O	O
configural	O	O	O
processing	O	O	O

Recent	O	O	O
functional	O	O	O
imaging	O	O	B-Entity
studies	O	O	I-Entity
have	O	O	O
proposed	O	O	O
that	O	O	O
the	O	O	O
human	O	O	B-Entity
entorhinal	O	O	B-Entity
cortex	O	O	I-Entity
is	O	O	O
subdivided	O	O	O
into	O	O	O
functionally	O	O	O
distinct	O	O	O
anterolateral	O	O	B-Entity
(	O	O	O
alERC	O	O	B-Entity
)	O	O	O
and	O	O	O
posteromedial	O	O	B-Entity
(	O	O	O
pmERC	O	O	B-Entity
)	O	O	O
subregions	O	O	B-Entity
.	O	O	O

The	O	O	O
alERC	O	O	B-Entity
overlaps	O	O	O
with	O	O	O
regions	O	O	O
that	O	O	O
are	O	O	O
affected	O	O	O
earliest	O	O	O
by	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
pathology	O	O	B-Entity
,	O	O	O
yet	O	O	O
its	O	O	O
cognitive	O	O	B-Entity
function	O	O	I-Entity
remains	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

Previous	O	O	O
human	O	O	B-Entity
fMRI	O	O	B-Entity
studies	O	O	B-Entity
have	O	O	O
focused	O	O	O
on	O	O	O
its	O	O	O
role	O	O	O
in	O	O	O
object	O	O	B-Entity
memory	O	O	B-Entity
,	O	O	O
but	O	O	O
rodent	O	O	B-Entity
studies	O	O	O
on	O	O	O
the	O	O	O
putatively	O	O	O
homologous	O	O	O
lateral	O	O	O
entorhinal	O	O	B-Entity
cortex	O	O	I-Entity
suggest	O	O	O
that	O	O	O
it	O	O	O
also	O	O	O
plays	O	O	O
an	O	O	O
important	O	O	O
role	O	O	O
in	O	O	O
representing	O	O	O
spatial	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
objects	O	O	B-Entity
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
investigate	O	O	O
the	O	O	O
cognitive	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
human	O	O	B-Entity
alERC	O	O	B-Entity
volume	O	O	B-Entity
differences	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	O
an	O	O	O
eyetracking-based	O	O	O
task	O	O	O
to	O	O	O
evaluate	O	O	B-Entity
intra-item	O	O	B-Entity
configural	O	O	I-Entity
processing	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
,	O	O	O
processing	O	O	O
the	O	O	O
arrangement	O	O	B-Entity
of	O	O	O
an	O	O	O
object	O	O	B-Entity
's	O	O	I-Entity
features	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
used	O	O	O
manual	O	O	B-Entity
segmentation	O	O	I-Entity
based	O	O	O
on	O	O	O
a	O	O	O
recently-	O	O	O
developed	O	O	B-Entity
protocol	O	O	I-Entity
to	O	O	O
delineate	O	O	O
the	O	O	O
alERC	O	O	O
/	O	O	O
pmERC	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
other	O	O	O
medial	O	O	B-Entity
temporal	O	O	I-Entity
lobe	O	O	I-Entity
(	O	O	O
MTL	O	O	B-Entity
)	O	O	O
subregions	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
older	O	O	O
adult	O	O	B-Entity
men	O	O	B-Entity
and	O	O	O
women	O	O	B-Entity
at	O	O	O
varying	O	O	O
stages	O	O	B-Entity
of	O	O	O
brain	O	O	B-Entity
atrophy	O	O	I-Entity
and	O	O	O
cognitive	O	O	B-Entity
decline	O	O	I-Entity
,	O	O	O
we	O	O	O
found	O	O	O
that	O	O	O
intra-item	O	O	B-Entity
configural	O	O	I-Entity
processing	O	O	I-Entity
-	O	O	O
regardless	O	O	O
of	O	O	O
an	O	O	O
object	O	O	B-Entity
's	O	O	I-Entity
novelty	O	O	O
-	O	O	O
was	O	O	O
strongly	O	O	O
predicted	O	O	O
by	O	O	O
alERC	O	O	B-Entity
volume	O	O	B-Entity
,	O	O	O
but	O	O	O
not	O	O	O
by	O	O	O
the	O	O	O
volume	O	O	O
of	O	O	O
any	O	O	O
other	O	O	O
MTL	O	O	B-Entity
subregion	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
provide	O	O	O
the	O	O	O
first	O	O	O
evidence	O	O	O
that	O	O	O
the	O	O	O
human	O	O	B-Entity
alERC	O	O	B-Entity
plays	O	O	O
a	O	O	O
role	O	O	O
in	O	O	O
supporting	O	O	O
a	O	O	O
distinct	O	O	O
aspect	O	O	O
of	O	O	O
object	O	O	B-Entity
processing	O	O	B-Entity
,	O	O	O
namely	O	O	O
attending	O	O	O
to	O	O	O
the	O	O	O
arrangement	O	O	B-Entity
of	O	O	O
an	O	O	O
object	O	O	B-Entity
's	O	O	I-Entity
component	O	O	O
features	O	O	O
.	O	O	O

SIGNIFICANCE	O	O	O
STATEMENT	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
pathology	O	O	B-Entity
appears	O	O	O
earliest	O	O	O
in	O	O	O
brain	O	O	B-Entity
regions	O	O	I-Entity
that	O	O	O
overlap	O	O	O
with	O	O	O
the	O	O	O
anterolateral	O	O	B-Entity
entorhinal	O	O	B-Entity
cortex	O	O	I-Entity
(	O	O	O
alERC	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
cognitive	O	O	B-Entity
role	O	O	I-Entity
of	O	O	O
the	O	O	O
alERC	O	O	B-Entity
is	O	O	O
poorly	O	O	O
understood	O	O	O
.	O	O	O

Previous	O	O	O
human	O	O	B-Entity
studies	O	O	I-Entity
treat	O	O	B-Entity
the	O	O	O
alERC	O	O	B-Entity
as	O	O	O
an	O	O	O
extension	O	O	O
of	O	O	O
the	O	O	O
neighboring	O	O	O
perirhinal	O	O	B-Entity
cortex	O	O	I-Entity
,	O	O	O
supporting	O	O	O
object	O	O	B-Entity
memory	O	O	B-Entity
.	O	O	O

Animal	O	O	B-Entity
studies	O	O	I-Entity
suggest	O	O	O
that	O	O	O
the	O	O	O
alERC	O	O	B-Entity
may	O	O	O
support	O	O	O
the	O	O	O
spatial	O	O	B-Entity
properties	O	O	I-Entity
of	O	O	O
objects	O	O	B-Entity
.	O	O	O

In	O	O	O
a	O	O	O
group	O	O	O
of	O	O	O
older	O	O	O
adult	O	O	B-Entity
humans	O	O	B-Entity
at	O	O	O
the	O	O	O
earliest	O	O	B-Entity
stages	O	O	I-Entity
of	O	O	O
cognitive	O	O	B-Entity
decline	O	O	I-Entity
,	O	O	O
we	O	O	O
show	O	O	O
that	O	O	O
alERC	O	O	B-Entity
volume	O	O	B-Entity
selectively	O	O	O
predicted	O	O	O
configural	O	O	B-Entity
processing	O	O	I-Entity
(	O	O	O
attention	O	O	B-Entity
to	O	O	O
the	O	O	O
spatial	O	O	B-Entity
arrangement	O	O	I-Entity
of	O	O	O
an	O	O	O
object	O	O	B-Entity
's	O	O	I-Entity
parts	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
first	O	O	O
study	O	O	O
to	O	O	O
demonstrate	O	O	O
a	O	O	O
cognitive	O	O	B-Entity
role	O	O	I-Entity
related	O	O	O
to	O	O	O
alERC	O	O	B-Entity
volume	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
.	O	O	O

This	O	O	O
task	O	O	O
can	O	O	O
be	O	O	O
adapted	O	O	O
to	O	O	O
serve	O	O	O
as	O	O	O
an	O	O	O
early	O	O	B-Entity
detection	O	O	I-Entity
method	O	O	I-Entity
for	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
pathology	O	O	B-Entity
.	O	O	O

-DOCSTART- (28476271)

Alcohol	O	O	B-Entity
brief	O	O	I-Entity
intervention	O	O	I-Entity
in	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
:	O	O	O
Blood	O	O	B-Entity
pressure	O	O	I-Entity
outcomes	O	O	B-Entity
in	O	O	O
hypertensive	O	O	B-Entity
patients	O	O	O

In	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
alcohol	O	O	B-Entity
brief	O	O	I-Entity
intervention	O	O	I-Entity
(	O	O	O
BI	O	O	B-Entity
)	O	O	O
in	O	O	O
adult	O	O	B-Entity
primary	O	O	B-Entity
care	O	O	I-Entity
has	O	O	O
been	O	O	O
efficacious	O	O	B-Entity
in	O	O	O
reducing	O	O	B-Entity
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
,	O	O	O
but	O	O	O
we	O	O	O
know	O	O	O
little	O	O	O
about	O	O	O
its	O	O	O
impact	O	O	B-Entity
on	O	O	O
health	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

Hypertension	O	O	B-Entity
is	O	O	O
a	O	O	O
prevalent	O	O	O
and	O	O	O
costly	O	O	O
chronic	O	O	B-Entity
condition	O	O	I-Entity
in	O	O	O
the	O	O	O
U.S.	O	O	B-Entity
and	O	O	O
worldwide	O	O	B-Entity
,	O	O	O
and	O	O	O
alcohol	O	O	B-Entity
use	O	O	I-Entity
is	O	O	O
a	O	O	O
modifiable	O	O	O
hypertension	O	O	B-Entity
risk	O	O	B-Entity
factor	O	O	I-Entity
.	O	O	O

To	O	O	O
evaluate	O	O	O
the	O	O	O
effect	O	O	B-Entity
of	O	O	O
receiving	O	O	O
BI	O	O	B-Entity
for	O	O	O
unhealthy	O	O	B-Entity
drinking	O	O	I-Entity
on	O	O	O
blood	O	O	B-Entity
pressure	O	O	I-Entity
(	O	O	I-Entity
BP	O	O	I-Entity
)	O	O	I-Entity
control	O	O	I-Entity
among	O	O	O
adult	O	O	B-Entity
hypertensive	O	O	B-Entity
patients	O	O	B-Entity
by	O	O	O
analyzing	O	O	B-Entity
secondary	O	O	I-Entity
data	O	O	I-Entity
from	O	O	O
a	O	O	O
clustered	O	O	B-Entity
,	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
on	O	O	O
alcohol	O	O	B-Entity
screening	O	O	I-Entity
,	O	O	O
brief	O	O	B-Entity
intervention	O	O	I-Entity
and	O	O	O
referral	O	O	B-Entity
to	O	O	I-Entity
treatment	O	O	I-Entity
(	O	O	O
SBIRT	O	O	B-Entity
)	O	O	O
implementation	O	O	B-Entity
by	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
physicians	O	O	I-Entity
(	O	O	O
PCP	O	O	B-Entity
intervention	O	O	I-Entity
arm	O	O	I-Entity
)	O	O	O
and	O	O	O
non-physician	O	O	B-Entity
providers	O	O	I-Entity
and	O	O	O
medical	O	O	B-Entity
assistants	O	O	I-Entity
(	O	O	O
NPP	O	O	B-Entity
&	O	O	O
MA	O	O	B-Entity
intervention	O	O	I-Entity
arm	O	O	I-Entity
)	O	O	O
in	O	O	O
a	O	O	O
large	O	O	O
,	O	O	O
integrated	O	O	B-Entity
health	O	O	I-Entity
care	O	O	I-Entity
delivery	O	O	I-Entity
system	O	O	I-Entity
.	O	O	O

Observational	O	O	B-Entity
,	O	O	O
prospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
.	O	O	O

3811	O	O	O
adult	O	O	B-Entity
hypertensive	O	O	B-Entity
primary	O	O	B-Entity
care	O	O	I-Entity
patients	O	O	I-Entity
screening	O	O	B-Entity
positive	O	O	O
for	O	O	O
past-year	O	O	B-Entity
heavy	O	O	B-Entity
drinking	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
,	O	O	O
of	O	O	O
which	O	O	O
1422	O	O	O
(	O	O	O
37	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
an	O	O	O
electronic	O	O	B-Entity
health	O	O	I-Entity
record	O	O	I-Entity
BP	O	O	B-Entity
measure	O	O	O
at	O	O	O
baseline	O	O	O
and	O	O	O
18-month	O	O	B-Entity
follow-up	O	O	B-Entity
.	O	O	O

Change	O	O	B-Entity
in	O	O	I-Entity
BP	O	O	I-Entity
and	O	O	O
controlled	O	O	B-Entity
BP	O	O	I-Entity
(	O	O	O
systolic/diastolic	O	O	B-Entity
BP	O	O	I-Entity
<	O	O	O
140/90	O	O	O
mmHg	O	O	B-Entity
)	O	O	O
.	O	O	O

Overall	O	O	O
no	O	O	O
significant	O	O	O
associations	O	O	B-Entity
were	O	O	O
found	O	O	O
between	O	O	O
alcohol	O	O	B-Entity
BI	O	O	I-Entity
and	O	O	O
BP	O	O	B-Entity
change	O	O	I-Entity
at	O	O	O
18-month	O	O	B-Entity
follow-up	O	O	B-Entity
when	O	O	O
analyzing	O	O	O
the	O	O	O
combined	O	O	O
sample	O	O	O
of	O	O	O
subjects	O	O	B-Entity
in	O	O	O
both	O	O	O
intervention	O	O	B-Entity
arms	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
moderation	O	O	O
analyses	O	O	O
found	O	O	O
that	O	O	O
receiving	O	O	O
BI	O	O	B-Entity
for	O	O	O
positive	O	O	O
past-year	O	O	B-Entity
unhealthy	O	O	B-Entity
drinking	O	O	I-Entity
was	O	O	O
positively	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
better	O	O	O
BP	O	O	B-Entity
control	O	O	I-Entity
at	O	O	O
18months	O	O	B-Entity
in	O	O	O
the	O	O	O
PCP	O	O	B-Entity
intervention	O	O	I-Entity
arm	O	O	I-Entity
,	O	O	O
and	O	O	O
for	O	O	O
those	O	O	O
with	O	O	O
lower	O	O	O
heavy	O	O	B-Entity
drinking	O	O	I-Entity
frequency	O	O	B-Entity
and	O	O	O
poor	O	O	O
BP	O	O	O
control	O	O	O
at	O	O	O
the	O	O	O
index	O	O	B-Entity
screening	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	O
suggest	O	O	O
that	O	O	O
hypertensive	O	O	B-Entity
patients	O	O	B-Entity
may	O	O	O
benefit	O	O	B-Entity
from	O	O	O
receiving	O	O	O
physician	O	O	B-Entity
brief	O	O	B-Entity
intervention	O	O	I-Entity
for	O	O	O
unhealthy	O	O	B-Entity
alcohol	O	O	I-Entity
use	O	O	I-Entity
in	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
.	O	O	O

Findings	O	O	O
also	O	O	O
highlight	O	O	O
potential	O	O	O
population-level	O	O	B-Entity
benefits	O	O	I-Entity
of	O	O	O
alcohol	O	O	B-Entity
BI	O	O	I-Entity
if	O	O	O
widely	O	O	O
applied	O	O	O
,	O	O	O
suggesting	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
innovative	O	O	O
strategies	O	O	O
to	O	O	O
facilitate	O	O	O
SBIRT	O	O	B-Entity
delivery	O	O	I-Entity
in	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
settings	O	O	O
.	O	O	O

-DOCSTART- (28476381)

Unusual	O	O	B-Entity
asymptomatic	O	O	B-Entity
presentation	O	O	I-Entity
of	O	O	O
bladder	O	O	B-Entity
cancer	O	O	I-Entity
metastatic	O	O	O
to	O	O	O
the	O	O	O
penis	O	O	O

Penile	O	O	B-Entity
metastasis	O	O	I-Entity
is	O	O	O
an	O	O	O
extremely	O	O	B-Entity
rare	O	O	I-Entity
event	O	O	I-Entity
and	O	O	O
mainly	O	O	O
originate	O	O	O
from	O	O	O
primary	O	O	O
pelvic	O	O	B-Entity
tumor	O	O	B-Entity
sites	O	O	I-Entity
such	O	O	O
us	O	O	O
urinary	O	O	B-Entity
bladder	O	O	I-Entity
,	O	O	O
gastro-intestinal	O	O	B-Entity
tract	O	O	I-Entity
and	O	O	O
prostate	O	O	B-Entity
and	O	O	O
more	O	O	O
rarely	O	O	O
from	O	O	O
respiratory	O	O	B-Entity
system	O	O	I-Entity
,	O	O	O
bone	O	O	B-Entity
tumors	O	O	I-Entity
and	O	O	O
melanoma	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
describe	O	O	O
the	O	O	O
unusual	O	O	B-Entity
presentation	O	O	B-Entity
of	O	O	O
two	O	O	O
bladder	O	O	B-Entity
urothelial	O	O	I-Entity
cancer	O	O	I-Entity
metastatic	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
penis	O	O	B-Entity
with	O	O	O
no	O	O	B-Entity
relevant	O	O	I-Entity
clinical	O	O	I-Entity
symptoms	O	O	I-Entity
.	O	O	O

Namely	O	O	O
,	O	O	O
a	O	O	O
69	O	O	O
years-old	O	O	O
man	O	O	O
with	O	O	O
a	O	O	O
warthy	O	O	O
lesions	O	O	B-Entity
of	O	O	O
the	O	O	O
foreskin	O	O	B-Entity
and	O	O	I-Entity
the	O	O	I-Entity
glans	O	O	I-Entity
misunderstood	O	O	O
for	O	O	O
a	O	O	O
condylomata	O	O	B-Entity
that	O	O	O
at	O	O	O
histological	O	O	B-Entity
and	O	O	O
immunohistochemical	O	O	B-Entity
analysis	O	O	I-Entity
showed	O	O	O
a	O	O	O
bladder	O	O	B-Entity
urothelial	O	O	I-Entity
carcinoma	O	O	I-Entity
;	O	O	O
and	O	O	O
a	O	O	O
71	O	O	O
years-old	O	O	O
man	O	O	O
with	O	O	O
reddish	O	O	B-Entity
skin	O	O	B-Entity
lesion	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
glans	O	O	I-Entity
,	O	O	O
a	O	O	O
previous	O	O	O
history	O	O	B-Entity
of	O	O	I-Entity
bladder	O	O	I-Entity
and	O	O	O
urethral	O	O	B-Entity
carcinoma	O	O	I-Entity
and	O	O	O
histological	O	O	B-Entity
pagetoid	O	O	I-Entity
spread	O	O	I-Entity
of	O	O	O
urothelial	O	O	B-Entity
cancer	O	O	I-Entity
to	O	O	B-Entity
the	O	O	I-Entity
glans	O	O	I-Entity
.	O	O	O

Recurrent	O	O	B-Entity
bladder	O	O	I-Entity
urothelial	O	O	I-Entity
carcinoma	O	O	I-Entity
is	O	O	O
usually	O	O	O
a	O	O	O
visceral	O	O	B-Entity
disease	O	O	B-Entity
that	O	O	O
rarely	O	O	O
presents	O	O	O
as	O	O	O
a	O	O	O
superficial	O	O	O
asymptomatic	O	O	B-Entity
skin	O	O	B-Entity
lesion	O	O	I-Entity
.	O	O	O

The	O	O	O
two	O	O	O
reported	O	O	O
cases	O	O	B-Entity
were	O	O	I-Entity
asymptomatic	O	O	I-Entity
superficial	O	O	B-Entity
penis	O	O	I-Entity
metastases	O	O	I-Entity
with	O	O	O
a	O	O	O
relatively	O	O	O
slow	O	O	O
growth	O	O	O
and	O	O	O
a	O	O	O
fairy	O	O	B-Entity
good	O	O	I-Entity
prognosis	O	O	I-Entity
after	O	O	O
conservative	O	O	B-Entity
surgical	O	O	I-Entity
approach	O	O	I-Entity
.	O	O	O

Accurate	O	O	O
clinical	O	O	B-Entity
examination	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
penis	O	O	I-Entity
is	O	O	I-Entity
mandatory	O	O	I-Entity
for	O	O	I-Entity
males	O	O	I-Entity
with	O	O	O
history	O	O	B-Entity
of	O	O	I-Entity
bladder	O	O	I-Entity
cancer	O	O	I-Entity
.	O	O	O

-DOCSTART- (28478321)

The	O	O	O
bachelorette	O	O	O
:	O	O	O
Female	O	O	B-Entity
Siamese	O	O	B-Entity
fighting	O	O	I-Entity
fish	O	O	I-Entity
avoid	O	O	B-Entity
males	O	O	B-Entity
exposed	O	O	B-Entity
to	O	O	I-Entity
an	O	O	O
estrogen	O	O	B-Entity
mimic	O	O	O

Due	O	O	O
to	O	O	O
improper	O	O	B-Entity
disposal	O	O	B-Entity
and	O	O	O
a	O	O	O
lack	O	O	B-Entity
of	O	O	O
removal	O	O	B-Entity
during	O	O	O
the	O	O	O
wastewater	O	O	B-Entity
treatment	O	O	B-Entity
process	O	O	I-Entity
,	O	O	O
endocrine	O	O	B-Entity
disrupting	O	O	B-Entity
chemicals	O	O	B-Entity
enter	O	O	O
aquatic	O	O	B-Entity
ecosystems	O	O	I-Entity
where	O	O	O
they	O	O	O
exert	O	O	O
detrimental	O	O	O
effects	O	O	B-Entity
on	O	O	O
fish	O	O	B-Entity
behavior	O	O	B-Entity
and	O	O	O
physiology	O	O	B-Entity
.	O	O	O

Perhaps	O	O	O
the	O	O	O
most	O	O	O
well-studied	O	O	O
and	O	O	O
prevalent	O	O	B-Entity
EDC	O	O	B-Entity
is	O	O	O
17α-ethinylestradiol	O	O	B-Entity
(	O	O	O
EE2	O	O	B-Entity
)	O	O	O
,	O	O	O
an	O	O	O
active	O	O	O
ingredient	O	O	B-Entity
in	O	O	O
oral	O	O	B-Entity
contraceptives	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
known	O	O	O
to	O	O	O
cause	O	O	O
dramatic	O	O	O
reductions	O	O	B-Entity
in	O	O	O
male	O	O	B-Entity
-typical	O	O	O
behaviors	O	O	B-Entity
.	O	O	O

While	O	O	O
it	O	O	O
is	O	O	O
likely	O	O	O
that	O	O	O
alterations	O	O	B-Entity
in	O	O	O
male	O	O	B-Entity
courtship	O	O	B-Entity
behavior	O	O	B-Entity
decrease	O	O	B-Entity
reproductive	O	O	B-Entity
fitness	O	O	I-Entity
,	O	O	O
this	O	O	O
is	O	O	O
rarely	O	O	O
explicitly	O	O	O
examined	O	O	O
.	O	O	O

To	O	O	O
this	O	O	O
end	O	O	O
,	O	O	O
whether	O	O	O
EE2	O	O	B-Entity
exposure	O	O	B-Entity
reduces	O	O	B-Entity
male	O	O	B-Entity
attractiveness	O	O	B-Entity
to	O	O	O
female	O	O	B-Entity
Siamese	O	O	B-Entity
fighting	O	O	I-Entity
fish	O	O	I-Entity
,	O	O	O
Betta	O	O	B-Entity
splendens	O	O	I-Entity
,	O	O	O
was	O	O	O
investigated	O	O	B-Entity
by	O	O	O
showing	O	O	O
females	O	O	B-Entity
video	O	O	B-Entity
images	O	O	B-Entity
of	O	O	O
exposed	O	O	B-Entity
and	O	O	O
unexposed	O	O	B-Entity
males	O	O	B-Entity
.	O	O	O

Females	O	O	B-Entity
were	O	O	O
randomly	O	O	O
assigned	O	O	O
to	O	O	O
one	O	O	O
of	O	O	O
two	O	O	O
exposure	O	O	B-Entity
conditions	O	O	B-Entity
(	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
EE2	O	O	B-Entity
,	O	O	O
control	O	O	B-Entity
)	O	O	O
and	O	O	O
each	O	O	O
subject	O	O	B-Entity
then	O	O	O
viewed	O	O	O
four	O	O	B-Entity
different	O	O	B-Entity
video	O	O	B-Entity
combinations	O	O	B-Entity
of	O	O	O
male	O	O	B-Entity
conspecifics	O	O	B-Entity
(	O	O	O
courting	O	O	B-Entity
exposed	O	O	O
+	O	O	O
exposed	O	O	O
;	O	O	O
courting	O	O	O
unexposed	O	O	B-Entity
+	O	O	O
unexposed	O	O	O
;	O	O	O
courting	O	O	O
unexposed	O	O	O
+	O	O	O
exposed	O	O	O
;	O	O	O
swimming	O	O	B-Entity
unexposed	O	O	O
+	O	O	O
exposed	O	O	O
)	O	O	O
.	O	O	O

Females	O	O	B-Entity
,	O	O	O
regardless	O	O	O
of	O	O	O
whether	O	O	O
or	O	O	O
not	O	O	O
they	O	O	O
were	O	O	O
exposed	O	O	B-Entity
to	O	O	I-Entity
EE2	O	O	B-Entity
,	O	O	O
directed	O	O	O
markedly	O	O	O
less	O	O	O
behavior	O	O	B-Entity
towards	O	O	O
exposed	O	O	O
males	O	O	B-Entity
,	O	O	O
especially	O	O	O
when	O	O	O
they	O	O	O
viewed	O	O	O
an	O	O	O
exposed	O	O	O
male	O	O	B-Entity
and	O	O	O
an	O	O	O
unexposed	O	O	B-Entity
male	O	O	O
simultaneously	O	O	B-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
demonstrate	O	O	O
that	O	O	O
EE2	O	O	B-Entity
can	O	O	O
have	O	O	O
significant	O	O	B-Entity
individual	O	O	B-Entity
-	O	O	O
and	O	O	O
population-level	O	O	B-Entity
consequences	O	O	B-Entity
on	O	O	O
fitness	O	O	B-Entity
by	O	O	O
disrupting	O	O	B-Entity
sexual	O	O	B-Entity
selection	O	O	I-Entity
and	O	O	O
,	O	O	O
ultimately	O	O	O
,	O	O	O
the	O	O	O
success	O	O	B-Entity
of	O	O	O
exposed	O	O	B-Entity
males	O	O	B-Entity
.	O	O	O

-DOCSTART- (28478867)

Targeting	O	O	B-Entity
accuracy	O	O	B-Entity
of	O	O	O
single-isocenter	O	O	B-Entity
intensity-modulated	O	O	B-Entity
radiosurgery	O	O	B-Entity
for	O	O	O
multiple	O	O	O
lesions	O	O	O

To	O	O	O
investigate	O	O	B-Entity
the	O	O	O
targeting	O	O	B-Entity
accuracy	O	O	B-Entity
of	O	O	O
intensity-modulated	O	O	B-Entity
SRS	O	O	B-Entity
(	O	O	O
IMRS	O	O	B-Entity
)	O	O	O
plans	O	O	B-Entity
designed	O	O	O
to	O	O	O
simultaneously	O	O	O
treat	O	O	O
multiple	O	O	O
brain	O	O	B-Entity
metastases	O	O	B-Entity
with	O	O	O
a	O	O	O
single	O	O	B-Entity
isocenter	O	O	I-Entity
.	O	O	O

A	O	O	O
home-made	O	O	B-Entity
acrylic	O	O	I-Entity
phantom	O	O	B-Entity
able	O	O	O
to	O	O	O
support	O	O	O
a	O	O	O
film	O	O	B-Entity
(	O	O	O
EBT3	O	O	B-Entity
)	O	O	O
in	O	O	O
its	O	O	O
coronal	O	O	B-Entity
plane	O	O	I-Entity
was	O	O	O
used	O	O	O
.	O	O	O

The	O	O	O
phantom	O	O	B-Entity
was	O	O	O
CT	O	O	B-Entity
scanned	O	O	I-Entity
and	O	O	O
three	O	O	O
coplanar	O	O	O
small	O	O	O
targets	O	O	B-Entity
(	O	O	O
a	O	O	O
central	O	O	B-Entity
and	O	O	O
two	O	O	O
peripheral	O	O	B-Entity
)	O	O	O
were	O	O	O
outlined	O	O	O
in	O	O	O
the	O	O	O
Eclipse	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

Peripheral	O	O	B-Entity
targets	O	O	B-Entity
were	O	O	O
6	O	O	O
cm	O	O	O
apart	O	O	O
from	O	O	O
the	O	O	O
central	O	O	B-Entity
one	O	O	O
.	O	O	O

A	O	O	O
reference	O	O	O
IMRS	O	O	B-Entity
plan	O	O	B-Entity
was	O	O	O
designed	O	O	O
to	O	O	O
simultaneously	O	O	O
treat	O	O	O
the	O	O	O
three	O	O	O
targets	O	O	B-Entity
,	O	O	O
but	O	O	O
only	O	O	O
a	O	O	O
single	O	O	B-Entity
isocenter	O	O	I-Entity
located	O	O	O
at	O	O	O
the	O	O	O
center	O	O	O
of	O	O	O
the	O	O	O
central	O	O	B-Entity
target	O	O	B-Entity
was	O	O	O
used	O	O	O
.	O	O	O

After	O	O	O
positioning	O	O	B-Entity
the	O	O	O
phantom	O	O	B-Entity
on	O	O	O
the	O	O	O
linac	O	O	B-Entity
using	O	O	O
the	O	O	O
room	O	O	B-Entity
lasers	O	O	B-Entity
,	O	O	O
a	O	O	O
CBCT	O	O	B-Entity
scan	O	O	I-Entity
was	O	O	O
acquired	O	O	O
and	O	O	O
the	O	O	O
reference	O	O	O
plan	O	O	B-Entity
were	O	O	O
mapped	O	O	B-Entity
on	O	O	O
it	O	O	O
,	O	O	O
by	O	O	O
placing	O	O	O
the	O	O	O
planned	O	O	O
isocenter	O	O	B-Entity
at	O	O	O
the	O	O	O
intersection	O	O	B-Entity
of	O	O	O
the	O	O	O
landmarks	O	O	O
used	O	O	O
in	O	O	O
the	O	O	O
film	O	O	B-Entity
showing	O	O	O
the	O	O	O
linac	O	O	O
isocenter	O	O	O
.	O	O	O

The	O	O	O
mapped	O	O	B-Entity
plan	O	O	B-Entity
was	O	O	O
then	O	O	O
recalculated	O	O	B-Entity
and	O	O	O
delivered	O	O	B-Entity
.	O	O	O

The	O	O	O
film	O	O	B-Entity
dose	O	O	B-Entity
distribution	O	O	I-Entity
was	O	O	O
derived	O	O	O
using	O	O	O
a	O	O	O
cloud	O	O	B-Entity
computing	O	O	I-Entity
application	O	O	I-Entity
(	O	O	O
www.radiochromic.com	O	O	B-Entity
)	O	O	O
that	O	O	O
uses	O	O	O
a	O	O	O
triple-channel	O	O	O
dosimetry	O	O	B-Entity
algorithm	O	O	B-Entity
.	O	O	O

Comparison	O	O	O
of	O	O	O
dose	O	O	B-Entity
distributions	O	O	I-Entity
using	O	O	O
the	O	O	O
gamma	O	O	B-Entity
index	O	O	I-Entity
(	O	O	O
5%/1	O	O	O
mm	O	O	O
)	O	O	O
were	O	O	O
performed	O	O	O
over	O	O	O
a	O	O	O
5	O	O	O
×	O	O	O
5	O	O	O
cm(2	O	O	O
)	O	O	O
region	O	O	O
centered	O	O	O
over	O	O	O
each	O	O	O
target	O	O	B-Entity
.	O	O	O

2D	O	O	B-Entity
shifts	O	O	I-Entity
required	O	O	O
to	O	O	O
get	O	O	O
the	O	O	O
best	O	O	O
gamma	O	O	B-Entity
passing	O	O	O
rates	O	O	O
on	O	O	O
the	O	O	O
peripheral	O	O	B-Entity
target	O	O	B-Entity
regions	O	O	O
were	O	O	O
compared	O	O	O
with	O	O	O
the	O	O	O
reported	O	O	O
ones	O	O	O
for	O	O	O
the	O	O	O
central	O	O	B-Entity
target	O	O	O
.	O	O	O

The	O	O	O
experiment	O	O	B-Entity
was	O	O	O
repeated	O	O	O
ten	O	O	O
times	O	O	O
in	O	O	O
different	O	O	O
sessions	O	O	B-Entity
.	O	O	O

Average	O	O	O
2D	O	O	B-Entity
shifts	O	O	I-Entity
required	O	O	O
to	O	O	O
achieve	O	O	O
optimal	O	O	O
gamma	O	O	B-Entity
passing	O	O	O
rates	O	O	O
(	O	O	O
99	O	O	O
%	O	O	O
,	O	O	O
97	O	O	O
%	O	O	O
,	O	O	O
99	O	O	O
%	O	O	O
)	O	O	O
were	O	O	O
0.7	O	O	O
mm	O	O	O
(	O	O	O
SD	O	O	O
:	O	O	O
0.3	O	O	O
mm	O	O	O
)	O	O	O
,	O	O	O
0.8	O	O	O
mm	O	O	O
(	O	O	O
SD	O	O	O
:	O	O	O
0.4	O	O	O
mm	O	O	O
)	O	O	O
and	O	O	O
0.8	O	O	O
mm	O	O	O
(	O	O	O
SD	O	O	O
:	O	O	O
0.3	O	O	O
mm	O	O	O
)	O	O	O
,	O	O	O
for	O	O	O
the	O	O	O
central	O	O	B-Entity
and	O	O	O
the	O	O	O
two	O	O	O
peripheral	O	O	B-Entity
targets	O	O	B-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

No	O	O	O
statistical	O	O	O
differences	O	O	O
(	O	O	O
p	O	O	O
>	O	O	O
0.05	O	O	O
)	O	O	O
were	O	O	O
found	O	O	O
for	O	O	O
targeting	O	O	B-Entity
accuracy	O	O	B-Entity
between	O	O	O
the	O	O	O
central	O	O	B-Entity
and	O	O	O
the	O	O	O
two	O	O	O
peripheral	O	O	B-Entity
targets	O	O	B-Entity
.	O	O	O

The	O	O	O
study	O	O	B-Entity
revealed	O	O	O
a	O	O	O
targeting	O	O	B-Entity
accuracy	O	O	B-Entity
within	O	O	O
1	O	O	O
mm	O	O	O
for	O	O	O
off-	O	O	O
isocenter	O	O	B-Entity
targets	O	O	B-Entity
within	O	O	O
6	O	O	O
cm	O	O	O
of	O	O	O
the	O	O	O
linac	O	O	B-Entity
isocenter	O	O	O
,	O	O	O
when	O	O	O
a	O	O	O
single-isocenter	O	O	B-Entity
IMRS	O	O	B-Entity
plan	O	O	B-Entity
is	O	O	O
designed	O	O	O
.	O	O	O

-DOCSTART- (28479259)

Physical	O	O	B-Entity
activity	O	O	I-Entity
limits	O	O	B-Entity
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
age	O	O	B-Entity
and	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
on	O	O	O
postural	O	O	O
control	O	O	O

The	O	O	O
aim	O	O	B-Entity
was	O	O	O
to	O	O	O
study	O	O	O
the	O	O	O
possible	O	O	O
influence	O	O	B-Entity
of	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
on	O	O	O
the	O	O	O
postural	O	O	B-Entity
performance	O	O	B-Entity
of	O	O	O
subjects	O	O	B-Entity
with	O	O	O
Alzheimer	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
AD	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
postural	O	O	B-Entity
performance	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
surface	O	O	B-Entity
area	O	O	I-Entity
of	O	O	O
the	O	O	O
center	O	O	B-Entity
of	O	O	I-Entity
foot	O	O	I-Entity
pressure	O	O	I-Entity
displacement	O	O	I-Entity
)	O	O	O
of	O	O	O
3	O	O	O
groups	O	O	B-Entity
was	O	O	O
compared	O	O	B-Entity
:	O	O	O
Alzheimer	O	O	B-Entity
active	O	O	I-Entity
group	O	O	I-Entity
(	O	O	O
AA	O	O	B-Entity
)	O	O	O
,	O	O	O
Alzheimer	O	O	B-Entity
non-active	O	O	I-Entity
group	O	O	I-Entity
(	O	O	O
ANA	O	O	B-Entity
)	O	O	O
and	O	O	O
healthy	O	O	B-Entity
non-active	O	O	I-Entity
group	O	O	I-Entity
(	O	O	O
HNA	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
AA	O	O	B-Entity
group	O	O	I-Entity
's	O	O	I-Entity
postural	O	O	B-Entity
performance	O	O	B-Entity
was	O	O	O
superior	O	O	B-Entity
to	O	O	O
that	O	O	O
of	O	O	O
the	O	O	O
ANA	O	O	B-Entity
and	O	O	O
HNA	O	O	B-Entity
groups	O	O	I-Entity
.	O	O	O

AD	O	O	B-Entity
disturbed	O	O	O
postural	O	O	B-Entity
performance	O	O	B-Entity
but	O	O	O
participation	O	O	B-Entity
in	O	O	O
regular	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
made	O	O	O
it	O	O	O
possible	O	O	O
to	O	O	O
limit	O	O	B-Entity
the	O	O	O
disturbing	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
AD	O	O	O
to	O	O	O
a	O	O	O
surprising	O	O	O
extent	O	O	O
,	O	O	O
since	O	O	O
the	O	O	O
postural	O	O	O
performance	O	O	O
of	O	O	O
active	O	O	B-Entity
AD	O	O	I-Entity
subjects	O	O	I-Entity
was	O	O	O
also	O	O	O
superior	O	O	B-Entity
to	O	O	O
that	O	O	O
of	O	O	O
healthy	O	O	B-Entity
subjects	O	O	I-Entity
.	O	O	O

-DOCSTART- (28483530)

LAMP-2	O	O	B-Entity
mediates	O	O	O
oxidative	O	O	B-Entity
stress	O	O	I-Entity
-dependent	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-	O	O	O
treated	O	O	B-Entity
lung	O	O	B-Entity
epithelium	O	O	O
cells	O	O	O

Zinc	O	O	B-Entity
is	O	O	O
an	O	O	O
essential	O	O	O
element	O	O	B-Entity
for	O	O	O
the	O	O	O
biological	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
excessive	O	O	O
exogenous	O	O	B-Entity
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
would	O	O	O
disrupt	O	O	O
cellular	O	O	B-Entity
Zn(2	O	O	I-Entity
+	O	O	I-Entity
)	O	O	I-Entity
homeostasis	O	O	I-Entity
and	O	O	O
cause	O	O	B-Entity
toxicity	O	O	I-Entity
.	O	O	O

In	O	O	O
particular	O	O	O
,	O	O	O
Zinc	O	O	B-Entity
salts	O	O	I-Entity
or	O	O	O
ZnO	O	O	B-Entity
nanoparticles	O	O	B-Entity
exposure	O	O	O
could	O	O	O
induce	O	O	O
respiratory	O	O	B-Entity
injury	O	O	I-Entity
.	O	O	O

Although	O	O	O
previous	O	O	O
studies	O	O	O
have	O	O	O
indicated	O	O	O
that	O	O	O
organelle	O	O	B-Entity
damage	O	O	B-Entity
(	O	O	O
including	O	O	O
mitochondria	O	O	B-Entity
or	O	O	O
lysosomes	O	O	B-Entity
)	O	O	O
and	O	O	O
reactive	O	O	B-Entity
oxygen	O	O	I-Entity
species	O	O	I-Entity
(	O	O	O
ROS	O	O	B-Entity
)	O	O	O
production	O	O	O
are	O	O	O
involved	O	O	O
in	O	O	O
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-induced	O	O	O
toxicity	O	O	B-Entity
,	O	O	O
the	O	O	O
interplay	O	O	O
between	O	O	O
mitochondria	O	O	O
/	O	O	O
lysosomes	O	O	O
damage	O	O	O
and	O	O	O
ROS	O	O	O
production	O	O	O
is	O	O	O
obscure	O	O	O
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
demonstrated	O	O	O
that	O	O	O
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
could	O	O	O
induce	O	O	O
deglycosylation	O	O	B-Entity
of	O	O	O
lysosome-associated	O	O	B-Entity
membrane	O	O	I-Entity
protein	O	O	I-Entity
1	O	O	I-Entity
and	O	O	O
2	O	O	B-Entity
(	O	O	O
LAMP-1	O	O	B-Entity
and	O	O	O
LAMP-2	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
primarily	O	O	O
locate	O	O	O
in	O	O	O
late	O	O	O
endosomes	O	O	B-Entity
/	O	O	O
lysosomes	O	O	B-Entity
,	O	O	O
in	O	O	O
A549	O	O	B-Entity
lung	O	O	I-Entity
epithelium	O	O	I-Entity
cells	O	O	I-Entity
.	O	O	O

Intriguingly	O	O	O
,	O	O	O
LAMP-2	O	O	B-Entity
knockdown	O	O	B-Entity
further	O	O	O
aggravated	O	O	B-Entity
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
-mediated	O	O	O
ROS	O	O	B-Entity
production	O	O	O
and	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
,	O	O	O
indicating	O	O	O
LAMP-2	O	O	O
(	O	O	O
not	O	O	O
LAMP-1	O	O	B-Entity
)	O	O	O
was	O	O	O
involved	O	O	O
in	O	O	O
Zn(2	O	O	O
+	O	O	O
)	O	O	O
-induced	O	O	O
toxicity	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
provide	O	O	O
a	O	O	O
new	O	O	O
insight	O	O	O
that	O	O	O
LAMP-2	O	O	B-Entity
contributes	O	O	O
to	O	O	O
the	O	O	O
ROS	O	O	B-Entity
clearance	O	O	O
and	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
induced	O	O	O
by	O	O	O
Zn(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
treatment	O	O	B-Entity
,	O	O	O
which	O	O	O
would	O	O	O
help	O	O	O
us	O	O	O
to	O	O	O
get	O	O	O
a	O	O	O
better	O	O	O
understanding	O	O	O
of	O	O	O
Zn(2	O	O	O
+	O	O	O
)	O	O	O
-induced	O	O	O
toxicity	O	O	B-Entity
in	O	O	O
respiratory	O	O	B-Entity
system	O	O	I-Entity
.	O	O	O

-DOCSTART- (28485130)

Fluorescence	O	O	B-Entity
hyperspectral	O	O	I-Entity
imaging	O	O	I-Entity
(	O	O	O
fHSI	O	O	B-Entity
)	O	O	O
using	O	O	O
a	O	O	O
spectrally	O	O	B-Entity
resolved	O	O	B-Entity
detector	O	O	O
array	O	O	O

The	O	O	O
ability	O	O	O
to	O	O	O
resolve	O	O	B-Entity
multiple	O	O	B-Entity
fluorescent	O	O	B-Entity
emissions	O	O	I-Entity
from	O	O	O
different	O	O	B-Entity
biological	O	O	B-Entity
targets	O	O	B-Entity
in	O	O	O
video	O	O	B-Entity
rate	O	O	I-Entity
applications	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
endoscopy	O	O	B-Entity
and	O	O	O
intraoperative	O	O	B-Entity
imaging	O	O	I-Entity
,	O	O	O
has	O	O	O
traditionally	O	O	O
been	O	O	O
limited	O	O	B-Entity
by	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
filter-based	O	O	B-Entity
imaging	O	O	O
systems	O	O	O
.	O	O	O

Hyperspectral	O	O	B-Entity
imaging	O	O	I-Entity
(	O	O	O
HSI	O	O	B-Entity
)	O	O	O
facilitates	O	O	O
the	O	O	O
detection	O	O	B-Entity
of	O	O	O
both	O	O	O
spatial	O	O	B-Entity
and	O	O	O
spectral	O	O	B-Entity
information	O	O	B-Entity
in	O	O	O
a	O	O	O
single	O	O	B-Entity
data	O	O	I-Entity
acquisition	O	O	I-Entity
,	O	O	O
however	O	O	O
,	O	O	O
instrumentation	O	O	B-Entity
for	O	O	O
HSI	O	O	O
is	O	O	O
typically	O	O	O
complex	O	O	B-Entity
,	O	O	O
bulky	O	O	B-Entity
and	O	O	O
expensive	O	O	B-Entity
.	O	O	O

We	O	O	O
sought	O	O	O
to	O	O	O
overcome	O	O	B-Entity
these	O	O	O
limitations	O	O	B-Entity
using	O	O	O
a	O	O	O
novel	O	O	B-Entity
robust	O	O	B-Entity
and	O	O	O
low	O	O	B-Entity
cost	O	O	I-Entity
HSI	O	O	B-Entity
camera	O	O	B-Entity
based	O	O	O
on	O	O	O
a	O	O	O
spectrally	O	O	B-Entity
resolved	O	O	I-Entity
detector	O	O	I-Entity
array	O	O	I-Entity
(	O	O	O
SRDA	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
integrated	O	O	B-Entity
this	O	O	O
HSI	O	O	B-Entity
camera	O	O	B-Entity
into	O	O	O
a	O	O	O
wide-field	O	O	B-Entity
reflectance-based	O	O	B-Entity
imaging	O	O	B-Entity
system	O	O	I-Entity
operating	O	O	B-Entity
in	O	O	O
the	O	O	O
near-infrared	O	O	B-Entity
range	O	O	B-Entity
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
suitability	O	O	O
for	O	O	O
in	O	O	B-Entity
vivo	O	O	I-Entity
imaging	O	O	I-Entity
of	O	O	O
exogenous	O	O	B-Entity
fluorescent	O	O	B-Entity
contrast	O	O	I-Entity
agents	O	O	I-Entity
.	O	O	O

Using	O	O	O
this	O	O	O
fluorescence	O	O	B-Entity
HSI	O	O	I-Entity
(	O	O	O
fHSI	O	O	B-Entity
)	O	O	O
system	O	O	B-Entity
,	O	O	O
we	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
accurately	O	O	B-Entity
resolve	O	O	B-Entity
the	O	O	O
presence	O	O	B-Entity
and	O	O	O
concentration	O	O	B-Entity
of	O	O	O
at	O	O	O
least	O	O	O
7	O	O	O
fluorescent	O	O	B-Entity
dyes	O	O	I-Entity
in	O	O	O
solution	O	O	B-Entity
.	O	O	O

We	O	O	O
also	O	O	O
demonstrate	O	O	O
high	O	O	B-Entity
spectral	O	O	B-Entity
unmixing	O	O	I-Entity
precision	O	O	B-Entity
,	O	O	O
signal	O	O	B-Entity
linearity	O	O	B-Entity
with	O	O	O
dye	O	O	B-Entity
concentration	O	O	B-Entity
and	O	O	O
at	O	O	O
depth	O	O	B-Entity
in	O	O	O
tissue	O	O	B-Entity
mimicking	O	O	B-Entity
phantoms	O	O	B-Entity
,	O	O	O
and	O	O	O
delineate	O	O	B-Entity
4	O	O	O
fluorescent	O	O	B-Entity
dyes	O	O	I-Entity
in	O	O	B-Entity
vivo	O	O	I-Entity
.	O	O	O

Our	O	O	O
approach	O	O	O
,	O	O	O
including	O	O	B-Entity
statistical	O	O	B-Entity
background	O	O	B-Entity
removal	O	O	O
,	O	O	O
could	O	O	O
be	O	O	O
directly	O	O	B-Entity
generalised	O	O	B-Entity
to	O	O	O
broader	O	O	B-Entity
spectral	O	O	I-Entity
ranges	O	O	B-Entity
,	O	O	O
for	O	O	O
example	O	O	O
,	O	O	O
to	O	O	O
resolve	O	O	B-Entity
tissue	O	O	B-Entity
reflectance	O	O	B-Entity
or	O	O	O
autofluorescence	O	O	B-Entity
and	O	O	O
in	O	O	O
future	O	O	B-Entity
be	O	O	O
tailored	O	O	O
to	O	O	O
video	O	O	B-Entity
rate	O	O	I-Entity
applications	O	O	I-Entity
requiring	O	O	O
snapshot	O	O	O
HSI	O	O	B-Entity
data	O	O	B-Entity
acquisition	O	O	I-Entity
.	O	O	O

-DOCSTART- (28485268)

Biochemical	O	O	B-Entity
studies	O	O	B-Entity
of	O	O	O
amylase	O	O	B-Entity
,	O	O	O
lipase	O	O	B-Entity
and	O	O	O
protease	O	O	B-Entity
in	O	O	O
Callosobruchus	O	O	B-Entity
maculatus	O	O	I-Entity
(	O	O	O
Coleoptera	O	O	B-Entity
:	O	O	O
Chrysomelidae	O	O	B-Entity
)	O	O	O
populations	O	O	B-Entity
fed	O	O	O
with	O	O	O
Vigna	O	O	B-Entity
unguiculata	O	O	I-Entity
grain	O	O	B-Entity
cultivated	O	O	B-Entity
with	O	O	O
diazotrophic	O	O	O
bacteria	O	O	O
strains	O	O	O

The	O	O	O
objective	O	O	O
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
evaluate	O	O	O
the	O	O	O
enzymatic	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
homogenates	O	O	B-Entity
of	O	O	O
insects	O	O	B-Entity
fed	O	O	O
on	O	O	O
grain	O	O	B-Entity
of	O	O	O
cowpea	O	O	B-Entity
,	O	O	O
Vigna	O	O	B-Entity
unguiculata	O	O	I-Entity
(	O	O	I-Entity
L.	O	O	I-Entity
)	O	O	I-Entity
,	O	O	O
cultivars	O	O	B-Entity
grown	O	O	O
with	O	O	O
different	O	O	O
nitrogen	O	O	B-Entity
sources	O	O	O
.	O	O	O

For	O	O	O
the	O	O	O
experiment	O	O	O
we	O	O	O
used	O	O	O
aliquots	O	O	O
of	O	O	O
the	O	O	O
homogenate	O	O	B-Entity
of	O	O	O
100	O	O	O
unsexed	O	O	O
adult	O	O	B-Entity
insects	O	O	B-Entity
,	O	O	O
emerged	O	O	O
from	O	O	O
10	O	O	O
g	O	O	O
of	O	O	O
grain	O	O	B-Entity
obtained	O	O	O
from	O	O	O
four	O	O	O
cowpea	O	O	B-Entity
cultivars	O	O	B-Entity
:	O	O	O
'	O	O	O
BRS	O	O	B-Entity
Acauã	O	O	I-Entity
'	O	O	O
,	O	O	O
'	O	O	O
BRS	O	O	B-Entity
Carijó	O	O	I-Entity
'	O	O	O
,	O	O	O
'	O	O	O
BRS	O	O	B-Entity
Pujante	O	O	I-Entity
'	O	O	O
,	O	O	O
and	O	O	O
'	O	O	O
BRS	O	O	B-Entity
Tapaihum	O	O	I-Entity
'	O	O	O
grown	O	O	O
under	O	O	O
different	O	O	O
regimes	O	O	O
of	O	O	O
nitrogen	O	O	B-Entity
sources	O	O	O
:	O	O	O
mineral	O	O	B-Entity
fertilizer	O	O	B-Entity
,	O	O	O
inoculation	O	O	B-Entity
with	O	O	O
strains	O	O	B-Entity
of	O	O	I-Entity
diazotrophs	O	O	I-Entity
(	O	O	O
BR	O	O	B-Entity
3267	O	O	I-Entity
,	O	O	O
BR	O	O	B-Entity
3262	O	O	I-Entity
,	O	O	O
BR	O	O	B-Entity
3299	O	O	I-Entity
;	O	O	O
INPA	O	O	B-Entity
03	O	O	I-Entity
-	O	O	I-Entity
11B	O	O	I-Entity
,	O	O	O
03	O	O	B-Entity
-	O	O	I-Entity
84	O	O	I-Entity
UFLA	O	O	I-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
control	O	O	B-Entity
(	O	O	O
with	O	O	O
soil	O	O	B-Entity
nitrogen	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
parameters	O	O	O
evaluated	O	O	O
were	O	O	O
enzymatic	O	O	B-Entity
activities	O	O	I-Entity
of	O	O	O
insect	O	O	B-Entity
protease	O	O	B-Entity
,	O	O	O
amylase	O	O	B-Entity
and	O	O	O
lipase	O	O	B-Entity
and	O	O	O
the	O	O	O
starch	O	O	B-Entity
content	O	O	O
of	O	O	O
the	O	O	O
grains	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
enzymatic	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
amylase	O	O	B-Entity
,	O	O	O
lipase	O	O	B-Entity
and	O	O	O
protease	O	O	B-Entity
of	O	O	O
insect	O	O	B-Entity
homogenate	O	O	B-Entity
according	O	O	O
to	O	O	O
the	O	O	O
food	O	O	B-Entity
source	O	O	O
.	O	O	O

A	O	O	O
lower	O	O	O
activity	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
enzyme	O	O	I-Entity
amylase	O	O	B-Entity
from	O	O	O
C.	O	O	B-Entity
maculatus	O	O	I-Entity
homogenate	O	O	B-Entity
was	O	O	O
observed	O	O	O
when	O	O	O
insects	O	O	B-Entity
were	O	O	O
fed	O	O	O
grain	O	O	B-Entity
of	O	O	O
the	O	O	O
cultivar	O	O	B-Entity
BRS	O	O	I-Entity
Carijó	O	O	I-Entity
.	O	O	O

A	O	O	O
lower	O	O	O
activity	O	O	B-Entity
of	O	O	I-Entity
lipase	O	O	I-Entity
enzyme	O	O	I-Entity
from	O	O	O
C.	O	O	B-Entity
maculatus	O	O	I-Entity
homogenate	O	O	B-Entity
was	O	O	O
observed	O	O	O
when	O	O	O
the	O	O	O
insects	O	O	B-Entity
fed	O	O	O
on	O	O	O
grain	O	O	B-Entity
from	O	O	O
the	O	O	O
interaction	O	O	O
of	O	O	O
the	O	O	O
cultivar	O	O	B-Entity
Tapaihum	O	O	I-Entity
inoculated	O	O	O
with	O	O	O
BR	O	O	B-Entity
3262	O	O	I-Entity
diazotrophs	O	O	I-Entity
.	O	O	O

The	O	O	O
lowest	O	O	O
proteolytic	O	O	B-Entity
activity	O	O	I-Entity
was	O	O	O
observed	O	O	O
in	O	O	O
homogenate	O	O	B-Entity
of	O	O	O
insects	O	O	B-Entity
fed	O	O	O
on	O	O	O
interaction	O	O	O
of	O	O	O
'	O	O	O
BRS	O	O	B-Entity
Carijó	O	O	I-Entity
'	O	O	O
inoculated	O	O	O
with	O	O	O
BR	O	O	B-Entity
3262	O	O	I-Entity
diazotroph	O	O	I-Entity
s.	O	O	O
Starch	O	O	B-Entity
content	O	O	O
correlated	O	O	O
positively	O	O	O
with	O	O	O
the	O	O	O
amylase	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
C.	O	O	B-Entity
maculatus	O	O	I-Entity
homogenate	O	O	O
.	O	O	O

The	O	O	O
cultivar	O	O	B-Entity
BRS	O	O	I-Entity
Carijó	O	O	I-Entity
had	O	O	O
a	O	O	O
different	O	O	O
behavior	O	O	O
from	O	O	O
the	O	O	O
other	O	O	O
cultivars	O	O	B-Entity
,	O	O	O
according	O	O	O
to	O	O	O
the	O	O	O
cluster	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

-DOCSTART- (28485296)

The	O	O	O
correlation	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
results	O	O	I-Entity
of	O	O	O
the	O	O	O
survey	O	O	B-Entity
SNOT-20	O	O	I-Entity
of	O	O	O
objective	O	O	B-Entity
studies	O	O	I-Entity
of	O	O	O
nasal	O	O	B-Entity
obstruction	O	O	I-Entity
and	O	O	O
the	O	O	O
geometry	O	O	O
of	O	O	O
the	O	O	O
nasal	O	O	O
cavities	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
were	O	O	O
verified	O	O	O
the	O	O	O
correlation	O	O	B-Entity
between	O	O	I-Entity
the	O	O	I-Entity
results	O	O	I-Entity
of	O	O	O
the	O	O	O
survey	O	O	B-Entity
SNOT-20	O	O	I-Entity
and	O	O	O
the	O	O	O
results	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
objective	O	O	I-Entity
tests	O	O	I-Entity
of	O	O	O
nasal	O	O	B-Entity
obstruction	O	O	I-Entity
which	O	O	O
are	O	O	O
rhinomanometry	O	O	B-Entity
and	O	O	O
acoustic	O	O	B-Entity
rhinometry	O	O	I-Entity
before	O	O	O
and	O	O	O
after	O	O	O
surgical	O	O	B-Entity
treatment	O	O	I-Entity
,	O	O	O
such	O	O	O
as	O	O	O
septoplasty	O	O	B-Entity
,	O	O	O
septoconchoplasty	O	O	B-Entity
,	O	O	O
ethmoidectomy	O	O	B-Entity
and	O	O	O
septoethmoidectomy	O	O	B-Entity
.	O	O	O

The	O	O	O
material	O	O	O
used	O	O	O
in	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
233	O	O	O
patients	O	O	B-Entity
diagnosed	O	O	B-Entity
routinely	O	O	O
in	O	O	O
the	O	O	O
Rhinomanometry	O	O	B-Entity
Laboratory	O	O	B-Entity
of	O	O	O
the	O	O	O
Department	O	O	B-Entity
of	O	O	I-Entity
Otolaryngology	O	O	I-Entity
at	O	O	O
the	O	O	O
Medical	O	O	B-Entity
University	O	O	I-Entity
of	O	O	O
Warsaw	O	O	B-Entity
,	O	O	O
reporting	O	O	O
rhinological	O	O	B-Entity
problems	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
obtained	O	O	O
from	O	O	O
70	O	O	O
women	O	O	B-Entity
(	O	O	O
31,4	O	O	O
%	O	O	O
)	O	O	O
ranging	O	O	O
in	O	O	O
ages	O	O	O
from	O	O	O
18	O	O	O
to	O	O	O
81	O	O	O
years	O	O	O
of	O	O	O
age	O	O	O
and	O	O	O
153	O	O	O
men	O	O	B-Entity
(	O	O	O
68,6	O	O	O
%	O	O	O
)	O	O	O
ranging	O	O	O
in	O	O	O
ages	O	O	O
from	O	O	O
16	O	O	O
to	O	O	O
81	O	O	O
years	O	O	O
of	O	O	O
age	O	O	O
.	O	O	O

The	O	O	O
researches	O	O	O
presented	O	O	O
in	O	O	O
the	O	O	O
study	O	O	O
were	O	O	O
made	O	O	O
using	O	O	O
the	O	O	O
device	O	O	O
RhinoMetrics	O	O	B-Entity
SRE	O	O	I-Entity
2100	O	O	I-Entity
which	O	O	O
combines	O	O	O
the	O	O	O
Rhinomanometer	O	O	B-Entity
(	O	O	O
RhinoStream	O	O	B-Entity
)	O	O	O
and	O	O	O
Acoustic	O	O	B-Entity
Rhinometer	O	O	I-Entity
(	O	O	O
RhinoScan	O	O	B-Entity
)	O	O	O
Interacoustics	O	O	B-Entity
AS	O	O	I-Entity
(	O	O	O
Denmark	O	O	B-Entity
)	O	O	O
.	O	O	O

Survey	O	O	B-Entity
SNOT-20	O	O	I-Entity
(	O	O	O
Sino-Nasal	O	O	B-Entity
Outcome	O	O	I-Entity
Test-20	O	O	I-Entity
)	O	O	O
in	O	O	O
Polish	O	O	B-Entity
was	O	O	O
completed	O	O	O
by	O	O	O
patients	O	O	B-Entity
before	O	O	B-Entity
surgery	O	O	I-Entity
and	O	O	O
during	O	O	B-Entity
the	O	O	I-Entity
postoperative	O	O	I-Entity
control	O	O	I-Entity
visits	O	O	I-Entity
.	O	O	O

The	O	O	O
calculated	O	O	O
correlations	O	O	O
between	O	O	O
the	O	O	O
objective	O	O	B-Entity
parameter	O	O	I-Entity
,	O	O	O
which	O	O	O
was	O	O	O
the	O	O	O
resistance	O	O	B-Entity
to	O	O	O
the	O	O	O
flow	O	O	B-Entity
of	O	O	I-Entity
air	O	O	I-Entity
through	O	O	I-Entity
the	O	O	I-Entity
nasal	O	O	I-Entity
cavity	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
subjective	O	O	B-Entity
feelings	O	O	I-Entity
of	O	O	I-Entity
respondents	O	O	I-Entity
expressed	O	O	O
in	O	O	O
the	O	O	O
survey	O	O	B-Entity
SNOT-20	O	O	I-Entity
were	O	O	O
generally	O	O	B-Entity
weak	O	O	I-Entity
,	O	O	O
and	O	O	O
statistical	O	O	B-Entity
significance	O	O	I-Entity
was	O	O	O
achieved	O	O	O
with	O	O	O
respect	O	O	O
to	O	O	O
the	O	O	O
first	O	O	B-Entity
question	O	O	I-Entity
survey	O	O	I-Entity
(	O	O	O
the	O	O	O
severity	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
nose	O	O	I-Entity
obstruction	O	O	I-Entity
)	O	O	O
for	O	O	O
all	O	O	O
components	O	O	O
of	O	O	O
resistance	O	O	B-Entity
flow	O	O	I-Entity
.	O	O	O

The	O	O	O
feeling	O	O	O
of	O	O	O
nasal	O	O	B-Entity
obstruction	O	O	I-Entity
is	O	O	O
the	O	O	O
most	O	O	O
reproducible	O	O	O
and	O	O	O
reliable	O	O	O
complaint	O	O	O
reported	O	O	O
by	O	O	O
the	O	O	O
patient	O	O	B-Entity
with	O	O	O
rhinological	O	O	B-Entity
problems	O	O	I-Entity
.	O	O	O

-DOCSTART- (28486935)

Emergency	O	O	B-Entity
department	O	O	I-Entity
use	O	O	B-Entity
and	O	O	O
barriers	O	O	B-Entity
to	O	O	O
wellness	O	O	B-Entity
:	O	O	O
a	O	O	O
survey	O	O	B-Entity
of	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
frequent	O	O	B-Entity
users	O	O	O

There	O	O	O
is	O	O	O
no	O	O	O
common	O	O	O
understanding	O	O	O
of	O	O	O
how	O	O	O
needs	O	O	B-Entity
of	O	O	O
emergency	O	O	B-Entity
department	O	O	I-Entity
(	O	O	O
ED	O	O	B-Entity
)	O	O	O
frequent	O	O	B-Entity
users	O	O	B-Entity
differ	O	O	O
from	O	O	O
other	O	O	O
patients	O	O	B-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
sought	O	O	O
to	O	O	O
examine	O	O	O
how	O	O	O
to	O	O	O
best	O	O	O
serve	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

Examinations	O	O	B-Entity
of	O	O	O
why	O	O	O
ED	O	O	B-Entity
frequent	O	O	B-Entity
users	O	O	B-Entity
present	O	O	B-Entity
to	O	O	O
the	O	O	O
ED	O	O	O
,	O	O	O
what	O	O	O
barriers	O	O	B-Entity
to	O	O	O
care	O	O	B-Entity
exist	O	O	B-Entity
,	O	O	O
and	O	O	O
what	O	O	O
service	O	O	B-Entity
offerings	O	O	O
may	O	O	O
help	O	O	O
these	O	O	O
patients	O	O	B-Entity
achieve	O	O	O
an	O	O	O
optimal	O	O	B-Entity
level	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
were	O	O	O
conducted	O	O	O
.	O	O	O

We	O	O	O
performed	O	O	O
a	O	O	O
prospective	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
frequent	O	O	B-Entity
ED	O	O	B-Entity
users	O	O	B-Entity
in	O	O	O
an	O	O	O
adult	O	O	B-Entity
only	O	O	O
,	O	O	O
level	O	O	B-Entity
1	O	O	I-Entity
trauma	O	O	I-Entity
center	O	O	I-Entity
with	O	O	O
approximately	O	O	B-Entity
90,000	O	O	O
visits	O	O	B-Entity
per	O	O	B-Entity
year	O	O	I-Entity
.	O	O	O

Frequent	O	O	B-Entity
ED	O	O	B-Entity
users	O	O	B-Entity
were	O	O	O
defined	O	O	O
as	O	O	O
those	O	O	O
who	O	O	O
make	O	O	O
four	O	O	O
or	O	O	O
more	O	O	O
ED	O	O	B-Entity
visits	O	O	I-Entity
in	O	O	O
a	O	O	O
12	O	O	O
month	O	O	B-Entity
period	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
were	O	O	O
administered	O	O	B-Entity
a	O	O	O
piloted	O	O	B-Entity
structured	O	O	I-Entity
interview	O	O	I-Entity
by	O	O	O
a	O	O	O
trained	O	O	B-Entity
researcher	O	O	I-Entity
querying	O	O	B-Entity
demographics	O	O	B-Entity
,	O	O	O
ED	O	O	B-Entity
usage	O	O	B-Entity
,	O	O	O
perceived	O	O	B-Entity
barriers	O	O	I-Entity
to	O	O	O
care	O	O	B-Entity
,	O	O	O
and	O	O	O
potential	O	O	O
aids	O	O	B-Entity
to	O	O	O
maintaining	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

Of	O	O	O
1,523	O	O	O
screened	O	O	B-Entity
patients	O	O	B-Entity
,	O	O	O
297	O	O	O
were	O	O	O
identified	O	O	B-Entity
as	O	O	O
frequent	O	O	B-Entity
ED	O	O	B-Entity
users	O	O	B-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
frequent	O	O	B-Entity
ED	O	O	B-Entity
users	O	O	B-Entity
were	O	O	O
enrolled	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
age	O	O	I-Entity
was	O	O	O
48	O	O	O
years	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
45	O	O	O
-	O	O	O
51	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
majority	O	O	O
of	O	O	O
subjects	O	O	B-Entity
were	O	O	O
female	O	O	B-Entity
(	O	O	O
64	O	O	O
%	O	O	O
,	O	O	O
64/100	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
55	O	O	O
-	O	O	O
73	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
white	O	O	B-Entity
(	O	O	O
61	O	O	O
%	O	O	O
,	O	O	O
60/98	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
52	O	O	O
-	O	O	O
71	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
insured	O	O	B-Entity
by	O	O	O
Medicaid	O	O	B-Entity
(	O	O	O
55	O	O	O
%	O	O	O
,	O	O	O
47/86	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
44	O	O	O
-	O	O	O
65	O	O	O
%	O	O	O
)	O	O	O
or	O	O	O
Medicare	O	O	B-Entity
(	O	O	O
23	O	O	O
%	O	O	O
,	O	O	O
20/86	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
14	O	O	O
-	O	O	O
32	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Subjects	O	O	B-Entity
had	O	O	O
a	O	O	O
median	O	O	B-Entity
of	O	O	O
6	O	O	O
ED	O	O	B-Entity
visits	O	O	I-Entity
,	O	O	O
and	O	O	O
2	O	O	O
inpatient	O	O	B-Entity
admissions	O	O	I-Entity
in	O	O	O
the	O	O	O
past	O	O	B-Entity
12	O	O	O
months	O	O	B-Entity
at	O	O	O
this	O	O	O
hospital	O	O	B-Entity
.	O	O	O

Most	O	O	O
frequent	O	O	B-Entity
ED	O	O	B-Entity
users	O	O	B-Entity
(	O	O	O
61	O	O	O
%	O	O	O
,	O	O	O
59/96	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
52	O	O	O
-	O	O	O
71	O	O	O
%	O	O	O
)	O	O	O
stated	O	O	O
the	O	O	O
primary	O	O	B-Entity
reason	O	O	I-Entity
for	O	O	O
their	O	O	O
visit	O	O	B-Entity
was	O	O	O
that	O	O	O
they	O	O	O
felt	O	O	O
that	O	O	O
their	O	O	O
health	O	O	B-Entity
problem	O	O	I-Entity
could	O	O	O
only	O	O	O
be	O	O	O
treated	O	O	B-Entity
in	O	O	O
an	O	O	O
ED	O	O	O
.	O	O	O

Transportation	O	O	B-Entity
presented	O	O	O
as	O	O	O
a	O	O	O
major	O	O	B-Entity
barrier	O	O	B-Entity
to	O	O	O
few	O	O	B-Entity
patients	O	O	B-Entity
(	O	O	O
7	O	O	O
%	O	O	O
,	O	O	O
7/95	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
3	O	O	O
-	O	O	O
14	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Subjects	O	O	B-Entity
stated	O	O	O
that	O	O	O
"	O	O	O
after-hours	O	O	B-Entity
options	O	O	I-Entity
,	O	O	O
besides	O	O	O
the	O	O	O
ED	O	O	B-Entity
for	O	O	O
minor	O	O	B-Entity
health	O	O	B-Entity
issues	O	O	I-Entity
"	O	O	O
(	O	O	O
63	O	O	O
%	O	O	O
,	O	O	O
60/95	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
53	O	O	O
-	O	O	O
73	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
having	O	O	O
"	O	O	O
a	O	O	O
nurse	O	O	B-Entity
to	O	O	O
work	O	O	B-Entity
with	O	O	O
you	O	O	O
one-on-one	O	O	B-Entity
to	O	O	O
help	O	O	O
manage	O	O	B-Entity
health	O	O	B-Entity
care	O	O	I-Entity
needs	O	O	B-Entity
"	O	O	O
(	O	O	O
53	O	O	O
%	O	O	O
,	O	O	O
50/95	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
43	O	O	O
-	O	O	O
63	O	O	O
%	O	O	O
)	O	O	O
would	O	O	O
be	O	O	O
most	O	O	O
helpful	O	O	O
in	O	O	O
achieving	O	O	O
optimal	O	O	B-Entity
health	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
characterized	O	O	B-Entity
ED	O	O	B-Entity
frequent	O	O	B-Entity
users	O	O	B-Entity
and	O	O	O
identified	O	O	B-Entity
several	O	O	B-Entity
opportunities	O	O	B-Entity
to	O	O	O
better	O	O	O
serve	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

By	O	O	O
understanding	O	O	O
barriers	O	O	B-Entity
to	O	O	O
care	O	O	B-Entity
from	O	O	O
the	O	O	O
patient	O	O	B-Entity
perspective	O	O	O
,	O	O	O
health	O	O	B-Entity
systems	O	O	I-Entity
can	O	O	O
potentially	O	O	O
address	O	O	O
unmet	O	O	O
needs	O	O	B-Entity
that	O	O	O
prevent	O	O	B-Entity
wellness	O	O	B-Entity
in	O	O	O
this	O	O	O
population	O	O	B-Entity
.	O	O	O

-DOCSTART- (28490164)

Contralateral	O	O	B-Entity
Superior	O	O	B-Entity
Cerebellar	O	O	I-Entity
Artery	O	O	I-Entity
Syndrome	O	O	I-Entity
:	O	O	O
A	O	O	O
Consequence	O	O	B-Entity
of	O	O	I-Entity
Brain	O	O	O
Herniation	O	O	O

Vascular	O	O	B-Entity
compromise	O	O	B-Entity
is	O	O	O
a	O	O	O
well-known	O	O	O
consequence	O	O	B-Entity
of	O	O	I-Entity
brain	O	O	B-Entity
herniation	O	O	I-Entity
syndromes	O	O	B-Entity
.	O	O	O

Transtentorial	O	O	B-Entity
brain	O	O	B-Entity
herniation	O	O	I-Entity
most	O	O	O
often	O	O	O
involves	O	O	O
posterior	O	O	B-Entity
cerebral	O	O	I-Entity
arteries	O	O	I-Entity
.	O	O	O

However	O	O	O
,	O	O	O
isolated	O	O	B-Entity
involvement	O	O	B-Entity
of	O	O	O
contralateral	O	O	B-Entity
superior	O	O	B-Entity
cerebellar	O	O	I-Entity
artery	O	O	I-Entity
(	O	O	O
SCA	O	O	B-Entity
)	O	O	O
during	O	O	O
unilateral	O	O	B-Entity
impending	O	O	B-Entity
brain	O	O	B-Entity
herniation	O	O	I-Entity
is	O	O	O
reported	O	O	B-Entity
only	O	O	O
once	O	O	O
and	O	O	O
we	O	O	O
present	O	O	O
another	O	O	O
case	O	O	O
of	O	O	O
this	O	O	O
exceedingly	O	O	O
rare	O	O	B-Entity
entity	O	O	B-Entity
.	O	O	O

A	O	O	O
24-year-old	O	O	O
man	O	O	B-Entity
was	O	O	O
referred	O	O	O
to	O	O	O
us	O	O	O
with	O	O	O
impending	O	O	B-Entity
herniation	O	O	B-Entity
due	O	O	O
to	O	O	O
a	O	O	O
multiloculated	O	O	B-Entity
hydrocephalus	O	O	B-Entity
,	O	O	O
and	O	O	O
during	O	O	O
the	O	O	O
course	O	O	B-Entity
of	O	O	I-Entity
illness	O	O	I-Entity
,	O	O	O
he	O	O	O
developed	O	O	O
an	O	O	O
isolated	O	O	B-Entity
SCA	O	O	B-Entity
ischemia	O	O	B-Entity
in	O	O	O
the	O	O	O
opposite	O	O	O
side	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
dilated	O	O	B-Entity
entrapped	O	O	O
horn	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
article	O	O	B-Entity
we	O	O	O
discuss	O	O	O
the	O	O	O
probable	O	O	O
pathophysiologic	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
this	O	O	O
phenomenon	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
recommending	O	O	O
more	O	O	O
inclusive	O	O	B-Entity
brain	O	O	B-Entity
studies	O	O	O
in	O	O	O
cases	O	O	O
suspected	O	O	B-Entity
of	O	O	O
Kernohan-Woltman	O	O	B-Entity
notch	O	O	I-Entity
phenomenon	O	O	I-Entity
in	O	O	O
unilateral	O	O	B-Entity
brain	O	O	B-Entity
herniation	O	O	I-Entity
.	O	O	O

The	O	O	O
rationale	O	O	B-Entity
for	O	O	O
this	O	O	O
commentary	O	O	B-Entity
is	O	O	O
that	O	O	O
contralateral	O	O	B-Entity
SCA	O	O	B-Entity
transient	O	O	B-Entity
ischemia	O	O	I-Entity
or	O	O	O
infarct	O	O	B-Entity
might	O	O	O
be	O	O	O
the	O	O	O
underdiagnosed	O	O	B-Entity
underlying	O	O	O
pathomechanism	O	O	B-Entity
of	O	O	O
ipsilateral	O	O	B-Entity
hemiparesis	O	O	B-Entity
occurring	O	O	O
in	O	O	O
many	O	O	O
cases	O	O	O
of	O	O	O
this	O	O	O
somehow	O	O	O
vague	O	O	B-Entity
phenomenon	O	O	B-Entity
.	O	O	O

-DOCSTART- (28490376)

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
clinical	O	O	B-Entity
supervision	O	O	I-Entity
on	O	O	O
supervisees	O	O	B-Entity
and	O	O	O
patients	O	O	B-Entity
in	O	O	O
cognitive-behavioral	O	O	B-Entity
therapy	O	O	I-Entity
:	O	O	O
a	O	O	O
study	O	O	B-Entity
protocol	O	O	I-Entity
for	O	O	O
a	O	O	O
systematic	O	O	O
review	O	O	O

Clinical	O	O	B-Entity
supervision	O	O	I-Entity
by	O	O	O
a	O	O	O
senior	O	O	B-Entity
therapist	O	O	I-Entity
is	O	O	O
a	O	O	O
very	O	O	O
common	O	O	O
practice	O	O	B-Entity
in	O	O	O
psychotherapist	O	O	B-Entity
training	O	O	B-Entity
and	O	O	O
psychiatric	O	O	B-Entity
care	O	O	I-Entity
settings	O	O	O
.	O	O	O

Though	O	O	O
clinical	O	O	B-Entity
supervision	O	O	I-Entity
is	O	O	O
advocated	O	O	O
by	O	O	O
most	O	O	O
educational	O	O	B-Entity
and	O	O	I-Entity
governing	O	O	I-Entity
institutions	O	O	I-Entity
,	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
clinical	O	O	O
supervision	O	O	O
on	O	O	O
the	O	O	O
supervisees	O	O	B-Entity
'	O	O	O
competence	O	O	B-Entity
,	O	O	O
e.g.	O	O	O
,	O	O	O
attitudes	O	O	B-Entity
,	O	O	O
behaviors	O	O	B-Entity
,	O	O	O
and	O	O	O
skills	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
on	O	O	O
treatment	O	O	B-Entity
outcomes	O	O	I-Entity
and	O	O	O
other	O	O	O
patient	O	O	B-Entity
variables	O	O	O
are	O	O	O
debated	O	O	O
and	O	O	O
largely	O	O	O
unknown	O	O	O
.	O	O	O

Evidence-based	O	O	B-Entity
practice	O	O	I-Entity
is	O	O	O
advocated	O	O	O
in	O	O	O
clinical	O	O	B-Entity
settings	O	O	I-Entity
but	O	O	O
has	O	O	O
not	O	O	O
yet	O	O	O
been	O	O	O
fully	O	O	O
implemented	O	O	O
in	O	O	O
educational	O	O	O
or	O	O	O
clinical	O	O	O
training	O	O	O
settings	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
is	O	O	O
to	O	O	O
synthesize	O	O	O
and	O	O	O
present	O	O	O
the	O	O	O
empirical	O	O	B-Entity
literature	O	O	I-Entity
regarding	O	O	O
effects	O	O	O
of	O	O	O
clinical	O	O	B-Entity
supervision	O	O	I-Entity
in	O	O	O
cognitive-behavioral	O	O	B-Entity
therapy	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
will	O	O	O
include	O	O	O
a	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
of	O	O	O
the	O	O	O
literature	O	O	B-Entity
to	O	O	O
identify	O	O	O
studies	O	O	O
that	O	O	O
have	O	O	O
empirically	O	O	O
investigated	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
supervision	O	O	O
on	O	O	O
supervised	O	O	B-Entity
psychotherapists	O	O	I-Entity
and/or	O	O	O
the	O	O	O
supervisees	O	O	O
'	O	O	O
patients	O	O	B-Entity
.	O	O	O

A	O	O	O
comprehensive	O	O	O
search	O	O	O
strategy	O	O	O
will	O	O	O
be	O	O	O
conducted	O	O	O
to	O	O	O
identify	O	O	O
published	O	O	O
controlled	O	O	O
studies	O	O	O
indexed	O	O	B-Entity
in	O	O	O
the	O	O	O
MEDLINE	O	O	B-Entity
,	O	O	O
EMBASE	O	O	B-Entity
,	O	O	O
PsycINFO	O	O	B-Entity
,	O	O	O
and	O	O	O
Cochrane	O	O	B-Entity
Library	O	O	I-Entity
databases	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
on	O	O	O
supervision	O	O	O
outcomes	O	O	O
in	O	O	O
both	O	O	O
psychotherapists	O	O	B-Entity
and	O	O	O
their	O	O	O
patients	O	O	B-Entity
will	O	O	O
be	O	O	O
extracted	O	O	O
,	O	O	O
synthesized	O	O	O
,	O	O	O
and	O	O	O
reported	O	O	B-Entity
.	O	O	O

Risk	O	O	O
of	O	O	O
bias	O	O	O
and	O	O	O
quality	O	O	O
of	O	O	O
the	O	O	O
included	O	O	O
studies	O	O	O
will	O	O	O
be	O	O	O
assessed	O	O	O
systematically	O	O	O
.	O	O	O

This	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
will	O	O	O
rigorously	O	O	O
follow	O	O	O
established	O	O	O
guidelines	O	O	B-Entity
for	O	O	O
systematic	O	O	B-Entity
reviews	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
summarize	O	O	O
and	O	O	O
present	O	O	O
the	O	O	O
evidence	O	O	O
base	O	O	O
for	O	O	O
clinical	O	O	B-Entity
supervision	O	O	I-Entity
in	O	O	O
cognitive-behavioral	O	O	B-Entity
therapy	O	O	I-Entity
and	O	O	O
may	O	O	O
aid	O	O	O
further	O	O	O
research	O	O	B-Entity
and	O	O	O
discussion	O	O	O
in	O	O	O
this	O	O	O
area	O	O	O
.	O	O	O

PROSPERO	O	O	O
CRD42016046834	O	O	O
.	O	O	O

-DOCSTART- (28492106)

Higher	O	O	B-Entity
risk	O	O	I-Entity
of	O	O	I-Entity
revision	O	O	B-Entity
for	O	O	O
infection	O	O	B-Entity
using	O	O	O
systemic	O	O	B-Entity
clindamycin	O	O	B-Entity
prophylaxis	O	O	B-Entity
than	O	O	O
with	O	O	O
cloxacillin	O	O	O

Background	O	O	O
and	O	O	O
purpose	O	O	O
-	O	O	O
Clindamycin	O	O	B-Entity
has	O	O	O
not	O	O	O
been	O	O	O
compared	O	O	O
with	O	O	O
other	O	O	O
antibiotics	O	O	B-Entity
for	O	O	O
prophylaxis	O	O	B-Entity
in	O	O	O
arthroplasty	O	O	B-Entity
.	O	O	O

Since	O	O	O
2009	O	O	O
,	O	O	O
the	O	O	O
Swedish	O	O	B-Entity
Knee	O	O	B-Entity
Arthroplasty	O	O	I-Entity
Register	O	O	I-Entity
(	O	O	O
SKAR	O	O	B-Entity
)	O	O	O
has	O	O	O
been	O	O	O
collecting	O	O	B-Entity
information	O	O	B-Entity
on	O	O	O
the	O	O	O
prophylactic	O	O	B-Entity
antibiotic	O	O	I-Entity
regime	O	O	I-Entity
used	O	O	O
at	O	O	O
every	O	O	O
individual	O	O	B-Entity
operation	O	O	B-Entity
.	O	O	O

In	O	O	O
Sweden	O	O	B-Entity
,	O	O	O
when	O	O	O
there	O	O	O
is	O	O	O
allergy	O	O	B-Entity
to	O	O	O
penicillin	O	O	B-Entity
,	O	O	O
clindamycin	O	O	B-Entity
has	O	O	O
been	O	O	O
the	O	O	O
recommended	O	O	B-Entity
alternative	O	O	B-Entity
.	O	O	O

We	O	O	O
examined	O	O	O
whether	O	O	O
there	O	O	O
were	O	O	O
differences	O	O	O
in	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
revision	O	O	B-Entity
due	O	O	O
to	O	O	O
infection	O	O	B-Entity
depending	O	O	O
on	O	O	O
which	O	O	O
antibiotic	O	O	B-Entity
was	O	O	O
used	O	O	O
as	O	O	O
systemic	O	O	B-Entity
prophylaxis	O	O	B-Entity
.	O	O	O

Patients	O	O	B-Entity
and	O	O	O
methods	O	O	O
-	O	O	O
Patients	O	O	O
who	O	O	O
had	O	O	O
a	O	O	O
total	O	O	B-Entity
knee	O	O	I-Entity
arthroplasty	O	O	I-Entity
(	O	O	O
TKA	O	O	B-Entity
)	O	O	O
performed	O	O	O
due	O	O	O
to	O	O	O
osteoarthritis	O	O	B-Entity
(	O	O	O
OA	O	O	B-Entity
)	O	O	O
during	O	O	O
the	O	O	O
years	O	O	O
2009	O	O	O
-	O	O	O
2015	O	O	O
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	O
.	O	O	O

Information	O	O	O
on	O	O	O
which	O	O	O
antibiotic	O	O	B-Entity
was	O	O	O
used	O	O	O
was	O	O	O
available	O	O	O
for	O	O	O
80,018	O	O	O
operations	O	O	B-Entity
(	O	O	O
55,530	O	O	O
patients	O	O	B-Entity
)	O	O	O
.	O	O	O

Survival	O	O	B-Entity
statistics	O	O	I-Entity
were	O	O	O
used	O	O	O
to	O	O	O
calculate	O	O	O
the	O	O	O
rate	O	O	O
of	O	O	O
revision	O	O	B-Entity
due	O	O	O
to	O	O	O
infection	O	O	B-Entity
until	O	O	O
the	O	O	O
end	O	O	O
of	O	O	O
2015	O	O	O
,	O	O	O
comparing	O	O	O
the	O	O	O
group	O	O	O
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
cloxacillin	O	O	B-Entity
with	O	O	O
those	O	O	O
who	O	O	O
received	O	O	O
clindamycin	O	O	B-Entity
as	O	O	O
systemic	O	O	B-Entity
prophylaxis	O	O	B-Entity
.	O	O	O

Results	O	O	O
-	O	O	O
Cloxacillin	O	O	B-Entity
was	O	O	O
used	O	O	O
in	O	O	O
90	O	O	O
%	O	O	O
of	O	O	O
the	O	O	O
cases	O	O	O
,	O	O	O
clindamycin	O	O	B-Entity
in	O	O	O
7	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
cephalosporins	O	O	B-Entity
in	O	O	O
2	O	O	O
%	O	O	O
.	O	O	O

The	O	O	O
risk	O	O	O
of	O	O	O
being	O	O	O
revised	O	O	O
due	O	O	O
to	O	O	O
infection	O	O	B-Entity
was	O	O	O
higher	O	O	O
when	O	O	O
clindamycin	O	O	B-Entity
was	O	O	O
used	O	O	O
than	O	O	O
when	O	O	O
cloxacillin	O	O	B-Entity
was	O	O	O
used	O	O	O
(	O	O	O
RR	O	O	O
=	O	O	O
1.5	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
1.2	O	O	O
-	O	O	O
2.0	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.001	O	O	O
)	O	O	O
.	O	O	O

There	O	O	O
was	O	O	O
no	O	O	O
significant	O	O	O
difference	O	O	O
in	O	O	O
the	O	O	O
revision	O	O	B-Entity
rate	O	O	O
for	O	O	O
other	O	O	O
causes	O	O	B-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.2	O	O	O
)	O	O	O
.	O	O	O

Interpretation	O	O	B-Entity
-	O	O	O
We	O	O	O
advise	O	O	O
that	O	O	O
patients	O	O	B-Entity
reporting	O	O	O
allergic	O	O	B-Entity
reaction	O	O	I-Entity
to	O	O	O
penicillin	O	O	B-Entity
should	O	O	O
have	O	O	O
their	O	O	O
allergic	O	O	B-Entity
history	O	O	I-Entity
explored	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
absence	O	O	O
of	O	O	O
a	O	O	O
clear	O	O	O
history	O	O	B-Entity
of	O	O	O
type-I	O	O	B-Entity
allergic	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
e.g.	O	O	O
urticaria	O	O	B-Entity
,	O	O	O
anaphylaxis	O	O	B-Entity
,	O	O	O
or	O	O	O
bronchospasm	O	O	B-Entity
)	O	O	O
,	O	O	O
we	O	O	O
suggest	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
a	O	O	O
third-generation	O	O	B-Entity
cephalosporin	O	O	I-Entity
instead	O	O	O
of	O	O	O
clindamycin	O	O	B-Entity
as	O	O	O
perioperative	O	O	B-Entity
prophylaxis	O	O	B-Entity
when	O	O	O
undergoing	O	O	O
a	O	O	O
TKR	O	O	B-Entity
.	O	O	O

No	O	O	O
recommendation	O	O	B-Entity
can	O	O	O
be	O	O	O
given	O	O	O
regarding	O	O	O
patients	O	O	B-Entity
with	O	O	O
type-1	O	O	B-Entity
allergy	O	O	I-Entity
.	O	O	O

-DOCSTART- (28492483)

PCVMZM	O	O	B-Entity
:	O	O	O
Using	O	O	O
the	O	O	O
Probabilistic	O	O	B-Entity
Classification	O	O	I-Entity
Vector	O	O	I-Entity
Machines	O	O	I-Entity
Model	O	O	I-Entity
Combined	O	O	I-Entity
with	O	O	I-Entity
a	O	O	I-Entity
Zernike	O	O	I-Entity
Moments	O	O	I-Entity
Descriptor	O	O	O
to	O	O	O
Predict	O	O	B-Entity
Protein-Protein	O	O	B-Entity
Interactions	O	O	I-Entity
from	O	O	O
Protein	O	O	O
Sequences	O	O	O

Protein-protein	O	O	B-Entity
interactions	O	O	I-Entity
(	O	O	O
PPIs	O	O	B-Entity
)	O	O	O
are	O	O	O
essential	O	O	O
for	O	O	O
most	O	O	O
living	O	O	B-Entity
organisms	O	O	I-Entity
'	O	O	O
process	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
detecting	O	O	O
PPIs	O	O	B-Entity
is	O	O	O
extremely	O	O	O
important	O	O	O
to	O	O	O
understand	O	O	O
the	O	O	O
molecular	O	O	B-Entity
mechanisms	O	O	B-Entity
of	O	O	O
biological	O	O	B-Entity
systems	O	O	I-Entity
.	O	O	O

Although	O	O	O
many	O	O	O
PPIs	O	O	B-Entity
data	O	O	O
have	O	O	O
been	O	O	O
generated	O	O	O
by	O	O	O
high-throughput	O	O	B-Entity
technologies	O	O	I-Entity
for	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
organisms	O	O	B-Entity
,	O	O	O
the	O	O	O
whole	O	O	O
interatom	O	O	O
is	O	O	O
still	O	O	O
far	O	O	O
from	O	O	O
complete	O	O	O
.	O	O	O

In	O	O	O
addition	O	O	O
,	O	O	O
the	O	O	O
high-throughput	O	O	B-Entity
technologies	O	O	I-Entity
for	O	O	O
detecting	O	O	O
PPIs	O	O	B-Entity
has	O	O	O
some	O	O	O
unavoidable	O	O	B-Entity
defects	O	O	I-Entity
,	O	O	O
including	O	O	O
time	O	O	B-Entity
consumption	O	O	I-Entity
,	O	O	O
high	O	O	O
cost	O	O	B-Entity
,	O	O	O
and	O	O	O
high	O	O	O
error	O	O	B-Entity
rate	O	O	I-Entity
.	O	O	O

In	O	O	O
recent	O	O	O
years	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
machine	O	O	B-Entity
learning	O	O	I-Entity
,	O	O	O
computational	O	O	B-Entity
methods	O	O	I-Entity
have	O	O	O
been	O	O	O
broadly	O	O	O
used	O	O	O
to	O	O	O
predict	O	O	O
PPIs	O	O	B-Entity
,	O	O	O
and	O	O	O
can	O	O	O
achieve	O	O	O
good	O	O	O
prediction	O	O	B-Entity
rate	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
here	O	O	O
PCVMZM	O	O	B-Entity
,	O	O	O
a	O	O	O
computational	O	O	B-Entity
method	O	O	I-Entity
based	O	O	O
on	O	O	O
a	O	O	O
Probabilistic	O	O	B-Entity
Classification	O	O	I-Entity
Vector	O	O	I-Entity
Machines	O	O	I-Entity
(	O	O	I-Entity
PCVM	O	O	I-Entity
)	O	O	I-Entity
model	O	O	I-Entity
and	O	O	O
Zernike	O	O	B-Entity
moments	O	O	I-Entity
(	O	O	I-Entity
ZM	O	O	I-Entity
)	O	O	I-Entity
descriptor	O	O	I-Entity
for	O	O	O
predicting	O	O	B-Entity
the	O	O	O
PPIs	O	O	B-Entity
from	O	O	O
protein	O	O	B-Entity
amino	O	O	B-Entity
acids	O	O	I-Entity
sequences	O	O	I-Entity
.	O	O	O

Specifically	O	O	O
,	O	O	O
a	O	O	O
Zernike	O	O	B-Entity
moments	O	O	I-Entity
(	O	O	I-Entity
ZM	O	O	I-Entity
)	O	O	I-Entity
descriptor	O	O	I-Entity
is	O	O	O
used	O	O	O
to	O	O	O
extract	O	O	O
protein	O	O	B-Entity
evolutionary	O	O	O
information	O	O	B-Entity
from	O	O	O
Position-Specific	O	O	B-Entity
Scoring	O	O	I-Entity
Matrix	O	O	I-Entity
(	O	O	O
PSSM	O	O	B-Entity
)	O	O	O
generated	O	O	O
by	O	O	O
Position-Specific	O	O	B-Entity
Iterated	O	O	I-Entity
Basic	O	O	I-Entity
Local	O	O	I-Entity
Alignment	O	O	I-Entity
Search	O	O	I-Entity
Tool	O	O	I-Entity
(	O	O	I-Entity
PSI-BLAST	O	O	I-Entity
)	O	O	I-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
PCVM	O	O	B-Entity
classifier	O	O	I-Entity
is	O	O	O
used	O	O	O
to	O	O	O
infer	O	O	O
the	O	O	O
interactions	O	O	B-Entity
among	O	O	O
protein	O	O	B-Entity
.	O	O	O

When	O	O	O
performed	O	O	O
on	O	O	O
PPIs	O	O	B-Entity
datasets	O	O	O
of	O	O	O
Yeast	O	O	B-Entity
and	O	O	O
H.	O	O	B-Entity
Pylori	O	O	I-Entity
,	O	O	O
the	O	O	O
proposed	O	O	O
method	O	O	O
can	O	O	O
achieve	O	O	O
the	O	O	O
average	O	O	O
prediction	O	O	B-Entity
accuracy	O	O	B-Entity
of	O	O	O
94.48	O	O	O
%	O	O	O
and	O	O	O
91.25	O	O	O
%	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

In	O	O	O
order	O	O	O
to	O	O	O
further	O	O	O
evaluate	O	O	O
the	O	O	O
performance	O	O	O
of	O	O	O
the	O	O	O
proposed	O	O	O
method	O	O	O
,	O	O	O
the	O	O	O
state-of-the-art	O	O	B-Entity
support	O	O	B-Entity
vector	O	O	I-Entity
machines	O	O	I-Entity
(	O	O	O
SVM	O	O	B-Entity
)	O	O	I-Entity
classifier	O	O	I-Entity
is	O	O	O
used	O	O	O
and	O	O	O
compares	O	O	O
with	O	O	O
the	O	O	O
PCVM	O	O	B-Entity
model	O	O	I-Entity
.	O	O	O

Experimental	O	O	B-Entity
results	O	O	I-Entity
on	O	O	O
the	O	O	O
Yeast	O	O	B-Entity
dataset	O	O	O
show	O	O	O
that	O	O	O
the	O	O	O
performance	O	O	O
of	O	O	O
PCVM	O	O	B-Entity
classifier	O	O	I-Entity
is	O	O	O
better	O	O	O
than	O	O	O
that	O	O	O
of	O	O	O
SVM	O	O	B-Entity
classifier	O	O	I-Entity
.	O	O	O

The	O	O	O
experimental	O	O	B-Entity
results	O	O	I-Entity
indicate	O	O	O
that	O	O	O
our	O	O	O
proposed	O	O	O
method	O	O	O
is	O	O	O
robust	O	O	O
,	O	O	O
powerful	O	O	O
and	O	O	O
feasible	O	O	O
,	O	O	O
which	O	O	O
can	O	O	O
be	O	O	O
used	O	O	O
as	O	O	O
a	O	O	O
helpful	O	O	O
tool	O	O	O
for	O	O	O
proteomics	O	O	B-Entity
research	O	O	I-Entity
.	O	O	O

-DOCSTART- (28493125)

Conditional	O	O	B-Entity
Knockdown	O	O	B-Entity
of	O	O	O
Endogenous	O	O	B-Entity
MicroRNAs	O	O	B-Entity
in	O	O	O
CHO	O	O	B-Entity
Cells	O	O	I-Entity
Using	O	O	O
TET-ON-SanDI	O	O	O
Sponge	O	O	O
Vectors	O	O	O

MicroRNAs	O	O	B-Entity
(	O	O	O
miRNAs	O	O	B-Entity
)	O	O	O
are	O	O	O
small	O	O	O
,	O	O	O
noncoding	O	O	B-Entity
RNAs	O	O	I-Entity
of	O	O	O
about	O	O	O
22	O	O	O
nucleotides	O	O	B-Entity
in	O	O	O
length	O	O	O
and	O	O	O
have	O	O	O
proven	O	O	O
to	O	O	O
be	O	O	O
useful	O	O	O
targets	O	O	B-Entity
for	O	O	O
genetic	O	O	B-Entity
modifications	O	O	I-Entity
for	O	O	O
desirable	O	O	O
phenotype	O	O	B-Entity
in	O	O	O
the	O	O	O
biotech	O	O	B-Entity
industry	O	O	B-Entity
.	O	O	O

The	O	O	O
use	O	O	O
of	O	O	O
constitutively	O	O	O
expressed	O	O	O
"	O	O	O
miRNA	O	O	B-Entity
sponge	O	O	I-Entity
"	O	O	I-Entity
vectors	O	O	I-Entity
in	O	O	O
which	O	O	O
multiple	O	O	O
,	O	O	O
tandem	O	O	B-Entity
miRNA	O	O	I-Entity
binding	O	O	B-Entity
sites	O	O	I-Entity
containing	O	O	O
transcripts	O	O	B-Entity
are	O	O	O
transcriptionally	O	O	B-Entity
regulated	O	O	I-Entity
by	O	O	O
a	O	O	O
constitutive	O	O	O
promoter	O	O	B-Entity
for	O	O	O
down	O	O	B-Entity
regulating	O	O	I-Entity
the	O	O	O
levels	O	O	O
of	O	O	O
endogenous	O	O	B-Entity
microRNAs	O	O	B-Entity
in	O	O	O
Chinese	O	O	B-Entity
hamster	O	O	I-Entity
ovary	O	O	I-Entity
(	O	O	I-Entity
CHO	O	O	I-Entity
)	O	O	I-Entity
cells	O	O	I-Entity
has	O	O	O
shown	O	O	O
to	O	O	O
be	O	O	O
more	O	O	O
advantageous	O	O	O
than	O	O	O
using	O	O	O
synthetic	O	O	O
antisense	O	O	B-Entity
oligonucleotides	O	O	I-Entity
.	O	O	O

The	O	O	O
application	O	O	O
of	O	O	O
miRNA	O	O	B-Entity
sponges	O	O	I-Entity
in	O	O	O
biotechnological	O	O	B-Entity
processes	O	O	B-Entity
,	O	O	O
however	O	O	O
,	O	O	O
could	O	O	O
be	O	O	O
more	O	O	O
effective	O	O	B-Entity
,	O	O	O
if	O	O	O
expression	O	O	B-Entity
of	O	O	O
miRNA	O	O	O
sponges	O	O	O
could	O	O	O
be	O	O	O
tuned	O	O	O
.	O	O	O

In	O	O	O
this	O	O	O
chapter	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
a	O	O	O
method	O	O	O
for	O	O	O
the	O	O	O
generation	O	O	O
of	O	O	O
stable	O	O	O
CHO	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
expressing	O	O	B-Entity
a	O	O	O
TET-ON-SanDI-miRNA-sponge	O	O	B-Entity
that	O	O	O
is	O	O	O
in	O	O	O
theory	O	O	O
expressed	O	O	O
only	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
an	O	O	O
inducer	O	O	B-Entity
.	O	O	O

-DOCSTART- (28494421)

Forest	O	O	B-Entity
protected	O	O	B-Entity
areas	O	O	I-Entity
governance	O	O	B-Entity
in	O	O	O
Zimbabwe	O	O	B-Entity
:	O	O	O
Shift	O	O	B-Entity
needed	O	O	O
away	O	O	O
from	O	O	O
a	O	O	O
long	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
local	O	O	B-Entity
community	O	O	B-Entity
exclusion	O	O	O

In	O	O	O
this	O	O	O
literature	O	O	O
review	O	O	O
based	O	O	O
paper	O	O	O
we	O	O	O
explored	O	O	O
the	O	O	O
concept	O	O	B-Entity
of	O	O	O
exclusion	O	O	B-Entity
of	O	O	O
local	O	O	B-Entity
communities	O	O	B-Entity
from	O	O	O
accessing	O	O	B-Entity
resources	O	O	B-Entity
in	O	O	O
forest	O	O	B-Entity
protected	O	O	B-Entity
areas	O	O	I-Entity
(	O	O	O
FPAs	O	O	B-Entity
)	O	O	O
in	O	O	O
Zimbabwe	O	O	B-Entity
.	O	O	O

We	O	O	O
discussed	O	O	O
the	O	O	O
colonial	O	O	B-Entity
and	O	O	O
post	O	O	B-Entity
-	O	O	O
colonial	O	O	B-Entity
forms	O	O	I-Entity
,	O	O	O
causes	O	O	O
and	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
exclusion	O	O	B-Entity
and	O	O	O
their	O	O	O
social	O	O	B-Entity
,	O	O	O
economic	O	O	B-Entity
and	O	O	O
ecological	O	O	B-Entity
outcomes	O	O	I-Entity
.	O	O	O

We	O	O	O
examined	O	O	B-Entity
the	O	O	O
range	O	O	B-Entity
of	O	O	O
powers	O	O	B-Entity
embodied	O	O	O
in	O	O	O
and	O	O	O
exercised	O	O	O
through	O	O	O
various	O	O	O
mechanisms	O	O	O
,	O	O	O
processes	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
relations	O	O	I-Entity
and	O	O	O
their	O	O	O
impact	O	O	B-Entity
on	O	O	O
local	O	O	B-Entity
communities	O	O	B-Entity
'	O	O	O
access	O	O	B-Entity
to	O	O	O
FPA	O	O	B-Entity
resources	O	O	B-Entity
and	O	O	O
associated	O	O	O
benefits	O	O	B-Entity
along	O	O	O
the	O	O	O
historical	O	O	B-Entity
trajectory	O	O	B-Entity
of	O	O	O
forest	O	O	B-Entity
governance	O	O	B-Entity
in	O	O	O
Zimbabwe	O	O	B-Entity
.	O	O	O

Results	O	O	O
showed	O	O	O
that	O	O	O
the	O	O	O
forms	O	O	B-Entity
and	O	O	O
extent	O	O	B-Entity
of	O	O	O
exclusion	O	O	B-Entity
changed	O	O	B-Entity
over	O	O	B-Entity
time	O	O	B-Entity
in	O	O	O
tandem	O	O	O
with	O	O	O
the	O	O	O
shifting	O	O	B-Entity
political	O	O	B-Entity
and	O	O	O
economic	O	O	B-Entity
landscape	O	O	I-Entity
.	O	O	O

During	O	O	O
the	O	O	O
colonial	O	O	B-Entity
period	O	O	I-Entity
,	O	O	O
it	O	O	O
was	O	O	O
total	O	O	O
exclusion	O	O	B-Entity
whereby	O	O	O
people	O	O	B-Entity
were	O	O	O
evicted	O	O	B-Entity
from	O	O	O
forest	O	O	B-Entity
land	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
being	O	O	O
denied	O	O	B-Entity
access	O	O	B-Entity
to	O	O	O
basic	O	O	B-Entity
resources	O	O	B-Entity
for	O	O	O
their	O	O	O
livelihoods	O	O	O
.	O	O	O

Local	O	O	B-Entity
communities	O	O	B-Entity
'	O	O	O
access	O	O	B-Entity
to	O	O	O
low	O	O	B-Entity
value	O	O	B-Entity
FPA	O	O	B-Entity
resources	O	O	B-Entity
improved	O	O	B-Entity
during	O	O	O
the	O	O	O
post-colonial	O	O	B-Entity
period	O	O	I-Entity
but	O	O	O
access	O	O	O
to	O	O	O
high	O	O	B-Entity
value	O	O	O
resources	O	O	O
like	O	O	O
commercial	O	O	B-Entity
timber	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
sharing	O	O	B-Entity
income	O	O	B-Entity
benefits	O	O	B-Entity
derived	O	O	B-Entity
from	O	O	O
FPA	O	O	O
commercial	O	O	B-Entity
activities	O	O	I-Entity
remained	O	O	O
a	O	O	O
pipe	O	O	B-Entity
dream	O	O	I-Entity
.	O	O	O

Regulation	O	O	B-Entity
,	O	O	O
legitimation	O	O	B-Entity
,	O	O	O
force	O	O	O
and	O	O	O
markets	O	O	O
constituted	O	O	O
the	O	O	O
mixture	O	O	O
of	O	O	O
the	O	O	O
power	O	O	O
elements	O	O	O
that	O	O	O
FPA	O	O	B-Entity
governing	O	O	B-Entity
authorities	O	O	B-Entity
used	O	O	O
to	O	O	O
exclude	O	O	B-Entity
local	O	O	B-Entity
communities	O	O	B-Entity
.	O	O	O

These	O	O	O
powers	O	O	O
remained	O	O	O
intact	O	O	B-Entity
despite	O	O	O
attempts	O	O	O
at	O	O	O
collaborative	O	O	B-Entity
governance	O	O	B-Entity
in	O	O	O
the	O	O	O
1990s	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
from	O	O	O
the	O	O	O
year	O	O	O
2000	O	O	O
,	O	O	O
local	O	O	B-Entity
communities	O	O	B-Entity
expressed	O	O	B-Entity
their	O	O	O
dissatisfaction	O	O	B-Entity
with	O	O	O
the	O	O	O
centralised	O	O	B-Entity
exclusionary	O	O	I-Entity
governance	O	O	I-Entity
system	O	O	I-Entity
by	O	O	O
invading	O	O	O
the	O	O	O
FPAs	O	O	B-Entity
rendering	O	O	O
them	O	O	O
ungovernable	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
therefore	O	O	O
a	O	O	O
need	O	O	O
for	O	O	O
policy	O	O	B-Entity
reform	O	O	B-Entity
within	O	O	O
the	O	O	O
FPA	O	O	B-Entity
sector	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
the	O	O	O
current	O	O	B-Entity
dire	O	O	B-Entity
situation	O	O	I-Entity
.	O	O	O

-DOCSTART- (28495504)

Renal	O	O	B-Entity
arterial	O	O	I-Entity
mycotic	O	O	I-Entity
aneurysm	O	O	I-Entity
after	O	O	O
kidney	O	O	O
transplantation	O	O	O

Mycotic	O	O	B-Entity
aneurysm	O	O	I-Entity
is	O	O	O
a	O	O	O
rare	O	O	O
condition	O	O	O
mostly	O	O	O
attributable	O	O	B-Entity
to	O	O	O
Candida	O	O	B-Entity
or	O	O	O
Aspergillus	O	O	B-Entity
species	O	O	I-Entity
.	O	O	O

About	O	O	O
20	O	O	O
cases	O	O	O
of	O	O	O
Candida	O	O	B-Entity
-related	O	O	O
arteritis	O	O	B-Entity
have	O	O	O
been	O	O	O
reported	O	O	O
in	O	O	O
kidney	O	O	B-Entity
transplant	O	O	I-Entity
patients	O	O	B-Entity
.	O	O	O

Herein	O	O	O
,	O	O	O
we	O	O	O
report	O	O	B-Entity
the	O	O	O
case	O	O	O
of	O	O	O
a	O	O	O
40-year-	O	O	O
old	O	O	O
man	O	O	O
who	O	O	O
received	O	O	O
a	O	O	O
kidney	O	O	B-Entity
from	O	O	O
a	O	O	O
deceased	O	O	O
donor	O	O	B-Entity
in	O	O	O
whom	O	O	O
an	O	O	O
accidental	O	O	B-Entity
digestive	O	O	B-Entity
wound	O	O	I-Entity
was	O	O	O
made	O	O	O
during	O	O	O
organ	O	O	B-Entity
retrieval	O	O	I-Entity
.	O	O	O

He	O	O	O
presented	O	O	O
with	O	O	O
sudden	O	O	O
anuria	O	O	B-Entity
47	O	O	O
days	O	O	O
after	O	O	O
renal	O	O	B-Entity
transplantation	O	O	I-Entity
revealing	O	O	O
a	O	O	O
large	O	O	O
mycotic	O	O	B-Entity
aneurysm	O	O	I-Entity
of	O	O	O
the	O	O	O
kidney	O	O	B-Entity
graft	O	O	I-Entity
renal	O	O	B-Entity
artery	O	O	I-Entity
.	O	O	O

Organs	O	O	B-Entity
derived	O	O	O
from	O	O	O
donors	O	O	B-Entity
in	O	O	O
whom	O	O	O
a	O	O	O
digestive	O	O	B-Entity
breach	O	O	I-Entity
is	O	O	O
noticed	O	O	O
should	O	O	O
be	O	O	O
used	O	O	B-Entity
with	O	O	I-Entity
caution	O	O	I-Entity
.	O	O	O

-DOCSTART- (28496002)

Risk	O	O	B-Entity
of	O	O	I-Entity
cancer	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
who	O	O	O
use	O	O	O
digoxin	O	O	B-Entity
:	O	O	O
a	O	O	O
10-year	O	O	O
follow-up	O	O	B-Entity
study	O	O	I-Entity
and	O	O	O
cell	O	O	B-Entity
-based	O	O	O
verification	O	O	O

Heart	O	O	B-Entity
failure	O	O	I-Entity
(	O	O	O
HF	O	O	B-Entity
)	O	O	O
is	O	O	O
the	O	O	O
leading	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
death	O	O	I-Entity
in	O	O	O
the	O	O	O
world	O	O	B-Entity
and	O	O	O
digoxin	O	O	B-Entity
remains	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
oldest	O	O	O
therapies	O	O	B-Entity
for	O	O	O
HF	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
its	O	O	O
safety	O	O	B-Entity
and	O	O	O
efficacy	O	O	B-Entity
have	O	O	O
been	O	O	O
controversial	O	O	O
since	O	O	O
its	O	O	O
initial	O	O	O
use	O	O	B-Entity
and	O	O	O
there	O	O	O
is	O	O	O
uncertainty	O	O	B-Entity
about	O	O	O
its	O	O	O
long-term	O	O	B-Entity
efficacy	O	O	O
and	O	O	O
safety	O	O	O
.	O	O	O

Recently	O	O	O
,	O	O	O
the	O	O	O
repositioning	O	O	B-Entity
of	O	O	O
cardiac	O	O	B-Entity
glycosides	O	O	I-Entity
is	O	O	O
to	O	O	O
function	O	O	B-Entity
in	O	O	O
anti-tumor	O	O	B-Entity
activity	O	O	I-Entity
via	O	O	O
multiple	O	O	B-Entity
working	O	O	B-Entity
pathways	O	O	I-Entity
.	O	O	O

It	O	O	O
is	O	O	O
interesting	O	O	O
to	O	O	O
compare	O	O	B-Entity
the	O	O	O
potential	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
digoxin	O	O	B-Entity
in	O	O	O
clinical	O	O	B-Entity
patients	O	O	B-Entity
and	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
.	O	O	O

First	O	O	O
,	O	O	O
we	O	O	O
analyze	O	O	O
patient	O	O	B-Entity
information	O	O	I-Entity
retrieved	O	O	O
from	O	O	O
the	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
Insurance	O	O	I-Entity
Research	O	O	I-Entity
database	O	O	I-Entity
of	O	O	O
Taiwan	O	O	B-Entity
between	O	O	O
January	O	O	O
1	O	O	O
,	O	O	O
2000	O	O	O
and	O	O	O
December	O	O	O
31	O	O	O
,	O	O	O
2000	O	O	O
.	O	O	O

This	O	O	O
retrospective	O	O	B-Entity
study	O	O	I-Entity
included	O	O	O
a	O	O	O
study	O	O	O
cohort	O	O	B-Entity
(	O	O	O
1,219	O	O	O
patients	O	O	B-Entity
)	O	O	O
and	O	O	O
a	O	O	O
comparison	O	O	B-Entity
cohort	O	O	O
.	O	O	O

Our	O	O	O
analytical	O	O	B-Entity
data	O	O	I-Entity
suggested	O	O	O
that	O	O	O
patients	O	O	B-Entity
taking	O	O	O
digoxin	O	O	B-Entity
are	O	O	O
at	O	O	O
an	O	O	O
increased	O	O	B-Entity
risk	O	O	B-Entity
of	O	O	I-Entity
cancers	O	O	I-Entity
,	O	O	O
including	O	O	O
breast	O	O	B-Entity
,	O	O	O
liver	O	O	B-Entity
,	O	O	O
and	O	O	O
lung	O	O	B-Entity
cancers	O	O	I-Entity
,	O	O	O
during	O	O	O
the	O	O	O
10-year	O	O	O
follow-up	O	O	B-Entity
period	O	O	I-Entity
.	O	O	O

In	O	O	O
contrast	O	O	O
to	O	O	O
the	O	O	O
anti-tumor	O	O	B-Entity
function	O	O	I-Entity
of	O	O	O
digoxin	O	O	B-Entity
,	O	O	O
we	O	O	O
further	O	O	O
examined	O	O	O
the	O	O	O
potential	O	O	B-Entity
pathway	O	O	B-Entity
of	O	O	O
digoxin	O	O	O
via	O	O	O
the	O	O	O
cell	O	O	B-Entity
-based	O	O	O
strategy	O	O	B-Entity
using	O	O	O
several	O	O	O
breast	O	O	B-Entity
cancer	O	O	I-Entity
cell	O	O	B-Entity
lines	O	O	I-Entity
,	O	O	O
including	O	O	O
MCF-7	O	O	B-Entity
,	O	O	O
BT-474	O	O	B-Entity
,	O	O	O
MAD-MB-231	O	O	B-Entity
,	O	O	O
and	O	O	O
ZR-75	O	O	B-Entity
-	O	O	I-Entity
1	O	O	I-Entity
.	O	O	O

Digoxin	O	O	B-Entity
consistently	O	O	O
exerted	O	O	O
its	O	O	O
cytotoxicity	O	O	B-Entity
to	O	O	O
these	O	O	O
four	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
with	O	O	O
various	O	O	O
range	O	O	O
of	O	O	O
concentration	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
ZR-75	O	O	B-Entity
-	O	O	I-Entity
1	O	O	I-Entity
cells	O	O	I-Entity
was	O	O	O
the	O	O	O
only	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
induced	O	O	O
by	O	O	O
digoxin	O	O	B-Entity
and	O	O	O
the	O	O	O
others	O	O	O
were	O	O	O
dramatically	O	O	O
suppressed	O	O	B-Entity
by	O	O	O
digoxin	O	O	O
.	O	O	O

The	O	O	O
responsiveness	O	O	B-Entity
of	O	O	O
SRSF3	O	O	B-Entity
to	O	O	O
digoxin	O	O	B-Entity
might	O	O	O
be	O	O	O
involved	O	O	O
with	O	O	O
cell-type	O	O	B-Entity
differences	O	O	B-Entity
.	O	O	O

In	O	O	O
summary	O	O	O
,	O	O	O
we	O	O	O
combined	O	O	O
a	O	O	O
cohort	O	O	B-Entity
study	O	O	I-Entity
for	O	O	O
digoxin	O	O	B-Entity
treatment	O	O	B-Entity
for	O	O	O
HF	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
a	O	O	O
cell	O	O	B-Entity
-based	O	O	O
strategy	O	O	B-Entity
that	O	O	O
addresses	O	O	O
the	O	O	O
translation	O	O	O
issue	O	O	O
,	O	O	O
which	O	O	O
revealed	O	O	O
the	O	O	O
complexity	O	O	B-Entity
of	O	O	O
personalized	O	O	B-Entity
medicine	O	O	I-Entity
.	O	O	O

-DOCSTART- (28496419)

Comparison	O	O	O
and	O	O	O
Outcome	O	O	O
Analysis	O	O	B-Entity
of	O	O	I-Entity
Patients	O	O	I-Entity
with	O	O	O
Takotsubo	O	O	B-Entity
Cardiomyopathy	O	O	I-Entity
Triggered	O	O	B-Entity
by	O	O	I-Entity
Emotional	O	O	B-Entity
Stress	O	O	I-Entity
or	O	O	O
Physical	O	O	O
Stress	O	O	O

Background	O	O	O
:	O	O	O
Previous	O	O	O
studies	O	O	O
revealed	O	O	O
that	O	O	O
takotsubo	O	O	B-Entity
cardiomyopathy	O	O	I-Entity
(	O	O	O
TTC	O	O	B-Entity
)	O	O	O
is	O	O	O
triggered	O	O	B-Entity
by	O	O	I-Entity
physical	O	O	B-Entity
and	O	O	O
emotional	O	O	B-Entity
stresses	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	O
was	O	O	O
performed	O	O	O
to	O	O	O
determine	O	O	O
the	O	O	O
short-	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
prognostic	O	O	O
impact	O	O	O
of	O	O	O
emotional-	O	O	B-Entity
and	O	O	O
physical	O	O	B-Entity
stress	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
TTC	O	O	B-Entity
.	O	O	O

Methods	O	O	O
and	O	O	O
results	O	O	O
:	O	O	O
Our	O	O	O
institutional	O	O	B-Entity
database	O	O	I-Entity
constituted	O	O	O
a	O	O	O
collective	O	O	O
of	O	O	O
84	O	O	O
patients	O	O	B-Entity
diagnosed	O	O	B-Entity
with	O	O	O
TTC	O	O	B-Entity
between	O	O	O
2003	O	O	O
and	O	O	O
2015	O	O	O
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
were	O	O	O
divided	O	O	O
into	O	O	O
two	O	O	O
groups	O	O	B-Entity
as	O	O	O
per	O	O	O
the	O	O	O
presence	O	O	O
of	O	O	O
emotional	O	O	B-Entity
stress	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
24	O	O	O
,	O	O	O
21	O	O	O
%	O	O	O
)	O	O	O
or	O	O	O
physical	O	O	B-Entity
stress	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
60	O	O	O
,	O	O	O
52.6	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
endpoint	O	O	B-Entity
was	O	O	O
a	O	O	O
composite	O	O	B-Entity
of	O	O	O
in-hospital	O	O	B-Entity
events	O	O	I-Entity
(	O	O	O
thromboembolic	O	O	B-Entity
events	O	O	I-Entity
and	O	O	O
life-threatening	O	O	B-Entity
arrhythmias	O	O	B-Entity
)	O	O	O
,	O	O	O
myocardial	O	O	B-Entity
infarction	O	O	I-Entity
,	O	O	O
all-	O	O	O
cause	O	O	B-Entity
of	O	O	I-Entity
mortality	O	O	I-Entity
,	O	O	O
re-hospitalization	O	O	B-Entity
due	O	O	O
to	O	O	O
heart	O	O	B-Entity
failure	O	O	I-Entity
,	O	O	O
stroke	O	O	B-Entity
,	O	O	O
and	O	O	O
recurrence	O	O	B-Entity
of	O	O	O
TTC	O	O	B-Entity
.	O	O	O

A	O	O	O
Kaplan-Meier	O	O	B-Entity
analysis	O	O	I-Entity
indicated	O	O	O
a	O	O	O
significantly	O	O	O
lower	O	O	O
event-free	O	O	O
survival	O	O	B-Entity
rate	O	O	I-Entity
over	O	O	O
a	O	O	O
mean	O	O	O
follow-up	O	O	B-Entity
of	O	O	O
5	O	O	O
years	O	O	O
in	O	O	O
the	O	O	O
emotional	O	O	B-Entity
group	O	O	B-Entity
than	O	O	O
the	O	O	O
physical	O	O	B-Entity
stress	O	O	I-Entity
group	O	O	O
(	O	O	O
log-rank	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.01	O	O	O
)	O	O	O
.	O	O	O

Multivariate	O	O	B-Entity
Cox	O	O	I-Entity
regression	O	O	I-Entity
analysis	O	O	I-Entity
revealed	O	O	O
only	O	O	O
emotional	O	O	B-Entity
stress	O	O	I-Entity
(	O	O	O
HR	O	O	O
0.4	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
:	O	O	O
0.2	O	O	O
-	O	O	O
0.9	O	O	O
,	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
as	O	O	O
a	O	O	O
negative	O	O	B-Entity
independent	O	O	I-Entity
predictor	O	O	I-Entity
of	O	O	O
the	O	O	O
primary	O	O	O
endpoint	O	O	B-Entity
.	O	O	O

Conclusion	O	O	O
:	O	O	O
Rates	O	O	O
of	O	O	O
in-hospital	O	O	B-Entity
events	O	O	I-Entity
and	O	O	O
short-	O	O	B-Entity
as	O	O	O
well	O	O	O
as	O	O	O
long-term	O	O	B-Entity
events	O	O	O
were	O	O	O
significantly	O	O	O
lower	O	O	O
in	O	O	O
TTC	O	O	B-Entity
patients	O	O	B-Entity
suffering	O	O	B-Entity
from	O	O	O
emotional	O	O	B-Entity
stress	O	O	I-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
patients	O	O	O
with	O	O	O
physical	O	O	B-Entity
stress	O	O	I-Entity
.	O	O	O

-DOCSTART- (28497887)

Surviving	O	O	B-Entity
moment	O	O	B-Entity
to	O	O	O
moment	O	O	O
:	O	O	O
The	O	O	O
experience	O	O	B-Entity
of	O	O	O
living	O	O	B-Entity
in	O	O	O
a	O	O	O
state	O	O	B-Entity
of	O	O	O
ambivalence	O	O	B-Entity
for	O	O	O
those	O	O	O
with	O	O	O
recurrent	O	O	B-Entity
suicide	O	O	O
attempts	O	O	O

This	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
aimed	O	O	O
to	O	O	O
capture	O	O	O
the	O	O	O
experience	O	O	B-Entity
of	O	O	O
living	O	O	B-Entity
in	O	O	O
the	O	O	O
ambivalent	O	O	B-Entity
space	O	O	I-Entity
between	O	O	O
life	O	O	B-Entity
and	O	O	O
death	O	O	B-Entity
for	O	O	O
adults	O	O	B-Entity
with	O	O	O
recurrent	O	O	B-Entity
suicide	O	O	B-Entity
attempts	O	O	I-Entity
(	O	O	O
RSA	O	O	B-Entity
)	O	O	O
.	O	O	O

It	O	O	O
sought	O	O	O
to	O	O	O
expand	O	O	B-Entity
upon	O	O	O
an	O	O	O
earlier	O	O	O
study	O	O	B-Entity
that	O	O	O
explored	O	O	O
the	O	O	O
processes	O	O	B-Entity
involved	O	O	B-Entity
in	O	O	O
transitioning	O	O	B-Entity
away	O	O	O
from	O	O	O
RSA	O	O	B-Entity
among	O	O	O
adults	O	O	B-Entity
,	O	O	O
which	O	O	O
revealed	O	O	B-Entity
that	O	O	O
occupying	O	O	O
this	O	O	O
ambivalent	O	O	B-Entity
space	O	O	I-Entity
is	O	O	O
a	O	O	O
crucial	O	O	O
part	O	O	O
of	O	O	O
this	O	O	O
process	O	O	B-Entity
.	O	O	O

Interpretive	O	O	B-Entity
phenomenological	O	O	I-Entity
analysis	O	O	I-Entity
(	O	O	O
IPA	O	O	B-Entity
)	O	O	O
was	O	O	O
used	O	O	O
.	O	O	O

This	O	O	O
methodology	O	O	B-Entity
was	O	O	O
designed	O	O	B-Entity
to	O	O	O
explore	O	O	O
the	O	O	O
lived	O	O	B-Entity
experiences	O	O	B-Entity
and	O	O	O
meaning	O	O	B-Entity
making	O	O	I-Entity
and	O	O	O
enabled	O	O	O
interpretation	O	O	B-Entity
of	O	O	O
the	O	O	O
multidimensional	O	O	B-Entity
subjective	O	O	B-Entity
experiences	O	O	O
of	O	O	O
RSA	O	O	B-Entity
participants	O	O	B-Entity
.	O	O	O

In-depth	O	O	O
semi-structured	O	O	B-Entity
interviews	O	O	I-Entity
were	O	O	O
conducted	O	O	B-Entity
with	O	O	O
eight	O	O	O
adult	O	O	B-Entity
women	O	O	I-Entity
with	O	O	O
a	O	O	O
history	O	O	B-Entity
of	O	O	O
RSA	O	O	B-Entity
who	O	O	O
had	O	O	O
participated	O	O	B-Entity
in	O	O	O
a	O	O	O
therapeutic	O	O	B-Entity
intervention	O	O	I-Entity
at	O	O	O
the	O	O	O
research	O	O	B-Entity
site	O	O	B-Entity
(	O	O	O
Skills	O	O	B-Entity
for	O	O	O
Safer	O	O	B-Entity
Living	O	O	I-Entity
:	O	O	O
A	O	O	O
Psychosocial	O	O	B-Entity
/	O	O	O
Psychoeducational	O	O	B-Entity
Intervention	O	O	I-Entity
for	O	O	O
People	O	O	B-Entity
with	O	O	O
Recurrent	O	O	B-Entity
Suicide	O	O	B-Entity
Attempts	O	O	I-Entity
[	O	O	O
SfSL	O	O	B-Entity
/	O	O	O
PISA	O	O	B-Entity
]	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
six	O	O	O
stages	O	O	B-Entity
of	O	O	O
IPA	O	O	B-Entity
were	O	O	O
followed	O	O	O
to	O	O	O
analyse	O	O	B-Entity
the	O	O	O
interview	O	O	B-Entity
data	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
revealed	O	O	B-Entity
the	O	O	O
superordinate	O	O	B-Entity
theme	O	O	I-Entity
,	O	O	O
'	O	O	O
surviving	O	O	B-Entity
moment	O	O	B-Entity
to	O	O	O
moment	O	O	O
'	O	O	O
,	O	O	O
which	O	O	O
refers	O	O	O
to	O	O	O
a	O	O	O
precarious	O	O	B-Entity
state	O	O	I-Entity
of	O	O	O
making	O	O	B-Entity
decisions	O	O	I-Entity
about	O	O	O
one	O	O	O
's	O	O	O
life	O	O	B-Entity
and	O	O	O
destiny	O	O	B-Entity
on	O	O	O
a	O	O	O
moment	O	O	O
-to-	O	O	O
moment	O	O	O
basis	O	O	O
without	O	O	O
clear	O	O	O
commitment	O	O	B-Entity
to	O	O	O
either	O	O	O
life	O	O	O
or	O	O	O
death	O	O	B-Entity
.	O	O	O

Two	O	O	O
subordinate	O	O	B-Entity
themes	O	O	I-Entity
were	O	O	O
identified	O	O	B-Entity
:	O	O	O
'	O	O	O
deciding	O	O	B-Entity
not	O	O	O
to	O	O	O
die	O	O	B-Entity
in	O	O	O
the	O	O	O
moment	O	O	B-Entity
'	O	O	O
when	O	O	O
the	O	O	O
participants	O	O	B-Entity
were	O	O	O
more	O	O	O
invested	O	O	B-Entity
in	O	O	O
dying	O	O	B-Entity
than	O	O	O
living	O	O	B-Entity
and	O	O	O
'	O	O	O
deciding	O	O	O
to	O	O	O
live	O	O	B-Entity
in	O	O	O
the	O	O	O
moment	O	O	O
'	O	O	O
when	O	O	O
they	O	O	O
were	O	O	O
more	O	O	O
invested	O	O	O
in	O	O	O
living	O	O	O
than	O	O	O
dying	O	O	O
.	O	O	O

The	O	O	O
study	O	O	B-Entity
illuminated	O	O	O
the	O	O	O
complex	O	O	B-Entity
process	O	O	B-Entity
of	O	O	O
making	O	O	B-Entity
decisions	O	O	I-Entity
about	O	O	O
ones	O	O	O
'	O	O	O
destiny	O	O	B-Entity
on	O	O	O
a	O	O	O
moment	O	O	B-Entity
-to-	O	O	O
moment	O	O	O
basis	O	O	O
.	O	O	O

It	O	O	O
revealed	O	O	B-Entity
the	O	O	O
torment	O	O	O
experienced	O	O	B-Entity
when	O	O	O
occupying	O	O	O
this	O	O	O
state	O	O	B-Entity
,	O	O	O
while	O	O	O
paradoxically	O	O	B-Entity
,	O	O	O
also	O	O	O
revealing	O	O	O
how	O	O	O
indecision	O	O	B-Entity
about	O	O	O
life	O	O	B-Entity
and	O	O	O
death	O	O	B-Entity
provided	O	O	B-Entity
a	O	O	O
lifeline	O	O	B-Entity
opportunity	O	O	B-Entity
for	O	O	O
those	O	O	O
with	O	O	O
RSA	O	O	B-Entity
.	O	O	O

Clinicians	O	O	B-Entity
who	O	O	O
recognize	O	O	O
the	O	O	O
subtle	O	O	O
distinctions	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
this	O	O	O
in-between	O	O	O
state	O	O	B-Entity
can	O	O	O
tailor	O	O	O
their	O	O	O
interventions	O	O	B-Entity
accordingly	O	O	O
.	O	O	O

Surviving	O	O	B-Entity
moment	O	O	B-Entity
to	O	O	O
moment	O	O	O
is	O	O	O
characterized	O	O	B-Entity
by	O	O	O
a	O	O	O
state	O	O	B-Entity
of	O	O	O
emotional	O	O	B-Entity
flux	O	O	I-Entity
and	O	O	O
uncertainty	O	O	B-Entity
about	O	O	O
one	O	O	O
's	O	O	O
destiny	O	O	B-Entity
,	O	O	O
where	O	O	O
the	O	O	O
person	O	O	B-Entity
has	O	O	O
not	O	O	O
fully	O	O	O
committed	O	O	O
to	O	O	O
either	O	O	O
life	O	O	B-Entity
or	O	O	O
death	O	O	B-Entity
.	O	O	O

Within	O	O	O
this	O	O	O
state	O	O	B-Entity
,	O	O	O
there	O	O	O
are	O	O	O
two	O	O	O
interlinked	O	O	B-Entity
subprocesses	O	O	I-Entity
,	O	O	O
whereby	O	O	O
the	O	O	O
person	O	O	B-Entity
is	O	O	O
leaning	O	O	B-Entity
more	O	O	O
towards	O	O	O
death	O	O	B-Entity
or	O	O	O
life	O	O	B-Entity
.	O	O	O

A	O	O	O
critical	O	O	O
feature	O	O	B-Entity
in	O	O	O
working	O	O	B-Entity
with	O	O	O
this	O	O	O
client	O	O	B-Entity
group	O	O	I-Entity
is	O	O	O
to	O	O	O
recognize	O	O	O
their	O	O	O
ambiguity	O	O	B-Entity
and	O	O	O
the	O	O	O
fragility	O	O	B-Entity
and	O	O	O
temporality	O	O	B-Entity
of	O	O	O
their	O	O	O
decisions	O	O	B-Entity
about	O	O	O
their	O	O	O
destiny	O	O	B-Entity
.	O	O	O

The	O	O	O
practitioner	O	O	B-Entity
has	O	O	O
an	O	O	O
opportunity	O	O	B-Entity
to	O	O	O
be	O	O	O
a	O	O	O
catalyst	O	O	O
in	O	O	O
the	O	O	O
momentum	O	O	O
towards	O	O	O
life	O	O	B-Entity
by	O	O	O
demonstrating	O	O	O
understanding	O	O	B-Entity
of	O	O	O
this	O	O	O
survival	O	O	B-Entity
struggle	O	O	B-Entity
and	O	O	O
tailoring	O	O	B-Entity
intervention	O	O	I-Entity
to	O	O	O
fit	O	O	O
with	O	O	O
the	O	O	O
nuanced	O	O	B-Entity
processes	O	O	I-Entity
within	O	O	O
this	O	O	O
state	O	O	B-Entity
.	O	O	O

-DOCSTART- (28500997)

Does	O	O	O
a	O	O	O
policy	O	O	B-Entity
of	O	O	O
earlier	O	O	B-Entity
induction	O	O	I-Entity
affect	O	O	O
labour	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
women	O	O	B-Entity
induced	O	O	B-Entity
for	O	O	O
postmaturity	O	O	B-Entity
?	O	O	O
A	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	B-Entity
in	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
hospital	O	O	I-Entity
in	O	O	O
the	O	O	O
North	O	O	B-Entity
of	O	O	O
England	O	O	O

A	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	B-Entity
in	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
hospital	O	O	I-Entity
in	O	O	O
the	O	O	O
North	O	O	B-Entity
of	O	O	O
England	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
a	O	O	O
change	O	O	B-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
postmature	O	O	B-Entity
pregnancy	O	O	I-Entity
to	O	O	O
earlier	O	O	B-Entity
induction	O	O	I-Entity
affects	O	O	O
the	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
labour	O	O	I-Entity
and	O	O	O
the	O	O	O
induction	O	O	B-Entity
process	O	O	I-Entity
.	O	O	O

Secondly	O	O	O
,	O	O	O
to	O	O	O
assess	O	O	B-Entity
the	O	O	O
feasibility	O	O	B-Entity
of	O	O	O
the	O	O	O
research	O	O	B-Entity
process	O	O	I-Entity
to	O	O	O
inform	O	O	O
a	O	O	O
future	O	O	B-Entity
larger	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

a	O	O	O
change	O	O	B-Entity
in	O	O	O
management	O	O	B-Entity
of	O	O	O
postmature	O	O	B-Entity
pregnancy	O	O	I-Entity
in	O	O	O
an	O	O	O
NHS	O	O	B-Entity
hospital	O	O	B-Entity
in	O	O	O
October	O	O	B-Entity
2013	O	O	O
,	O	O	O
from	O	O	O
induction	O	O	B-Entity
at	O	O	O
42	O	O	O
weeks	O	O	B-Entity
gestation	O	O	B-Entity
to	O	O	O
induction	O	O	O
between	O	O	O
41	O	O	O
-	O	O	O
42	O	O	O
weeks	O	O	O
,	O	O	O
provided	O	O	B-Entity
an	O	O	O
opportunity	O	O	B-Entity
to	O	O	O
conduct	O	O	O
a	O	O	O
retrospective	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

Pre-existing	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
the	O	O	O
maternity	O	O	B-Entity
database	O	O	B-Entity
and	O	O	O
casenotes	O	O	B-Entity
were	O	O	O
collected	O	O	B-Entity
and	O	O	O
primary	O	O	B-Entity
outcomes	O	O	I-Entity
analysed	O	O	B-Entity
using	O	O	O
the	O	O	O
Mann-Whitney	O	O	B-Entity
test	O	O	I-Entity
and	O	O	O
the	O	O	O
Hodges-Lehman	O	O	B-Entity
confidence	O	O	I-Entity
interval	O	O	I-Entity
for	O	O	O
differences	O	O	B-Entity
in	O	O	O
medians	O	O	B-Entity
.	O	O	O

a	O	O	O
large	O	O	B-Entity
city	O	O	I-Entity
based	O	O	O
tertiary	O	O	B-Entity
referral	O	O	I-Entity
hospital	O	O	I-Entity
in	O	O	O
the	O	O	O
North	O	O	B-Entity
of	O	O	O
England	O	O	B-Entity
.	O	O	O
125	O	O	O
women	O	O	B-Entity
induced	O	O	B-Entity
before	O	O	O
the	O	O	O
change	O	O	B-Entity
in	O	O	O
policy	O	O	B-Entity
were	O	O	O
compared	O	O	B-Entity
with	O	O	O
309	O	O	O
women	O	O	O
induced	O	O	O
after	O	O	O
the	O	O	O
change	O	O	O
.	O	O	O

primary	O	O	B-Entity
outcomes	O	O	I-Entity
were	O	O	O
length	O	O	B-Entity
of	O	O	O
1st	O	O	B-Entity
and	O	O	O
2nd	O	O	B-Entity
stage	O	O	I-Entity
of	O	O	I-Entity
labour	O	O	B-Entity
,	O	O	O
overall	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
labour	O	O	I-Entity
,	O	O	O
length	O	O	O
of	O	O	O
induction	O	O	B-Entity
to	O	O	O
established	O	O	B-Entity
labour	O	O	O
and	O	O	O
length	O	O	O
of	O	O	O
induction	O	O	O
to	O	O	O
birth	O	O	B-Entity
.	O	O	O

the	O	O	O
median	O	O	B-Entity
overall	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
labour	O	O	I-Entity
for	O	O	O
women	O	O	B-Entity
induced	O	O	B-Entity
at	O	O	O
42	O	O	O
weeks	O	O	B-Entity
was	O	O	O
6.5	O	O	O
hours	O	O	B-Entity
,	O	O	O
while	O	O	O
for	O	O	O
women	O	O	O
induced	O	O	O
at	O	O	O
41	O	O	O
-	O	O	O
42	O	O	O
weeks	O	O	O
this	O	O	O
was	O	O	O
5.2	O	O	O
hours	O	O	O
.	O	O	O

The	O	O	O
difference	O	O	B-Entity
was	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
(	O	O	O
p=0.15	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
for	O	O	O
median	O	O	B-Entity
difference	O	O	O
-0.27	O	O	O
to	O	O	O
1.93	O	O	O
hours	O	O	B-Entity
)	O	O	O
with	O	O	O
a	O	O	O
small	O	O	B-Entity
effect	O	O	I-Entity
size	O	O	I-Entity
(	O	O	O
Pearson	O	O	B-Entity
's	O	O	I-Entity
r=-0.08	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
median	O	O	B-Entity
length	O	O	B-Entity
of	O	O	O
induction	O	O	B-Entity
to	O	O	O
birth	O	O	B-Entity
was	O	O	O
13.6	O	O	O
hours	O	O	B-Entity
for	O	O	O
women	O	O	B-Entity
induced	O	O	B-Entity
at	O	O	O
42	O	O	O
weeks	O	O	B-Entity
and	O	O	O
16.5	O	O	O
hours	O	O	O
for	O	O	O
women	O	O	O
induced	O	O	O
at	O	O	O
41	O	O	O
-	O	O	O
42	O	O	O
weeks	O	O	O
.	O	O	O

This	O	O	O
difference	O	O	B-Entity
was	O	O	O
also	O	O	O
not	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
(	O	O	O
p=0.14	O	O	O
,	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
for	O	O	O
median	O	O	B-Entity
difference	O	O	O
-7.25	O	O	O
to	O	O	O
1.20	O	O	O
hours	O	O	B-Entity
)	O	O	O
with	O	O	O
a	O	O	O
small	O	O	B-Entity
effect	O	O	I-Entity
size	O	O	I-Entity
(	O	O	O
Pearson	O	O	B-Entity
's	O	O	I-Entity
r=-0.13	O	O	O
)	O	O	O
.	O	O	O

This	O	O	O
study	O	O	B-Entity
demonstrated	O	O	O
no	O	O	O
statistically	O	O	B-Entity
significant	O	O	I-Entity
difference	O	O	B-Entity
s	O	O	O
in	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
labour	O	O	I-Entity
and	O	O	O
induction	O	O	B-Entity
following	O	O	O
a	O	O	O
change	O	O	B-Entity
in	O	O	O
the	O	O	O
management	O	O	B-Entity
of	O	O	O
postmature	O	O	B-Entity
pregnancy	O	O	I-Entity
to	O	O	O
earlier	O	O	B-Entity
induction	O	O	I-Entity
.	O	O	O

A	O	O	O
large	O	O	B-Entity
study	O	O	I-Entity
is	O	O	O
needed	O	O	O
to	O	O	O
establish	O	O	B-Entity
definitively	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
earlier	O	O	B-Entity
induction	O	O	I-Entity
on	O	O	O
labour	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

-DOCSTART- (28501006)

Liquid	O	O	B-Entity
chromatography-mass	O	O	I-Entity
spectrometry	O	O	I-Entity
-based	O	O	O
quantitative	O	O	B-Entity
proteomics	O	O	B-Entity
analysis	O	O	I-Entity
reveals	O	O	O
chondroprotective	O	O	B-Entity
effects	O	O	I-Entity
of	O	O	O
astragaloside	O	O	B-Entity
IV	O	O	I-Entity
in	O	O	O
interleukin-1β	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
SW1353	O	O	O
chondrocyte-like	O	O	O
cells	O	O	O

Chondrocyte	O	O	B-Entity
apoptosis	O	O	B-Entity
played	O	O	O
a	O	O	O
key	O	O	O
role	O	O	O
on	O	O	O
the	O	O	O
progression	O	O	B-Entity
of	O	O	O
Osteoarthritis	O	O	B-Entity
(	O	O	O
OA	O	O	B-Entity
)	O	O	O
.	O	O	O

Safe	O	O	O
and	O	O	O
effective	O	O	O
drugs	O	O	B-Entity
are	O	O	O
urgently	O	O	O
needed	O	O	O
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
OA	O	O	B-Entity
.	O	O	O

Previous	O	O	O
study	O	O	B-Entity
reported	O	O	O
that	O	O	O
Astragaloside	O	O	B-Entity
IV	O	O	I-Entity
(	O	O	O
ASG-IV	O	O	B-Entity
)	O	O	O
had	O	O	O
exerted	O	O	O
a	O	O	O
protective	O	O	B-Entity
effect	O	O	I-Entity
against	O	O	O
articular	O	O	B-Entity
cartilage	O	O	I-Entity
degeneration	O	O	I-Entity
by	O	O	O
promoting	O	O	O
rapid	O	O	O
proliferation	O	O	B-Entity
of	O	O	O
chondrocyte	O	O	B-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
our	O	O	O
study	O	O	B-Entity
is	O	O	O
to	O	O	O
explore	O	O	O
the	O	O	O
effects	O	O	B-Entity
and	O	O	O
mechanisms	O	O	B-Entity
of	O	O	O
ASG-IV	O	O	B-Entity
in	O	O	O
chondrocyte	O	O	B-Entity
apoptosis	O	O	B-Entity
.	O	O	O

Isobaric	O	O	B-Entity
Tags	O	O	I-Entity
For	O	O	I-Entity
Relative	O	O	I-Entity
And	O	O	I-Entity
Absolute	O	O	I-Entity
Quantitation	O	O	I-Entity
(iTRAQ)-based	O	O	I-Entity
quantitative	O	O	I-Entity
proteomics	O	O	B-Entity
was	O	O	O
used	O	O	O
to	O	O	O
quantitatively	O	O	O
detect	O	O	B-Entity
and	O	O	O
map	O	O	B-Entity
proteins	O	O	B-Entity
in	O	O	O
SW1353	O	O	B-Entity
chondrocyte-like	O	O	I-Entity
cells	O	O	I-Entity
pre-treated	O	O	B-Entity
with	O	O	O
ASG-IV	O	O	B-Entity
or	O	O	O
interleukin-1β	O	O	B-Entity
(	O	O	O
IL-1β	O	O	B-Entity
)	O	O	O
or	O	O	O
ASG-IV	O	O	O
+	O	O	O
IL-1β	O	O	O
.	O	O	O

The	O	O	O
iTRAQ-labeled	O	O	B-Entity
peptides	O	O	I-Entity
were	O	O	O
fractionated	O	O	B-Entity
by	O	O	O
high-accuracy	O	O	B-Entity
liquid	O	O	I-Entity
chromatography-mass	O	O	I-Entity
spectrometry	O	O	I-Entity
(	O	O	O
LC-MS	O	O	B-Entity
)	O	O	O
.	O	O	O

Cell	O	O	B-Entity
apoptosis	O	O	I-Entity
and	O	O	O
differentially	O	O	B-Entity
expressed	O	O	I-Entity
proteins	O	O	I-Entity
was	O	O	O
detected	O	O	B-Entity
by	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
(	O	O	O
FCM	O	O	B-Entity
)	O	O	O
,	O	O	O
quantitative	O	O	B-Entity
real-time	O	O	I-Entity
polymerase	O	O	I-Entity
chain	O	O	I-Entity
reaction	O	O	I-Entity
(	O	O	O
qRT-PCR	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
western	O	O	B-Entity
blotting	O	O	I-Entity
,	O	O	O
respectively	O	O	O
.	O	O	O

The	O	O	O
apoptosis	O	O	B-Entity
of	O	O	O
the	O	O	O
IL-1β	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
SW1353	O	O	B-Entity
cells	O	O	I-Entity
treated	O	O	B-Entity
with	O	O	O
ASG-IV	O	O	B-Entity
was	O	O	O
greatly	O	O	O
inhibited	O	O	B-Entity
.	O	O	O

Bioinformatics	O	O	B-Entity
analysis	O	O	O
revealed	O	O	O
that	O	O	O
gamma	O	O	B-Entity
actin	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
ACTG1	O	O	B-Entity
)	O	O	O
and	O	O	O
Yes	O	O	B-Entity
Associated	O	O	I-Entity
Protein	O	O	I-Entity
1	O	O	I-Entity
(	O	O	O
YAP1	O	O	B-Entity
)	O	O	O
,	O	O	O
participating	O	O	O
in	O	O	O
the	O	O	O
Hippo	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
and	O	O	O
Vitronectin	O	O	B-Entity
(	O	O	O
VTN	O	O	B-Entity
)	O	O	O
and	O	O	O
Collagen	O	O	B-Entity
Type	O	O	I-Entity
I	O	O	I-Entity
Alpha	O	O	I-Entity
1	O	O	I-Entity
Chain	O	O	I-Entity
(	O	O	O
COL1A1	O	O	B-Entity
)	O	O	O
,	O	O	O
involving	O	O	O
in	O	O	O
the	O	O	O
extracellular	O	O	B-Entity
matrix	O	O	I-Entity
(ECM)-receptor	O	O	I-Entity
interaction	O	O	I-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
,	O	O	O
were	O	O	O
all	O	O	O
significantly	O	O	O
up-regulated	O	O	B-Entity
in	O	O	O
the	O	O	O
IL-1β	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
SW1353	O	O	B-Entity
cells	O	O	I-Entity
after	O	O	O
treatment	O	O	B-Entity
with	O	O	O
ASG-IV	O	O	B-Entity
.	O	O	O

The	O	O	O
qRT-PCR	O	O	B-Entity
and	O	O	O
Western	O	O	B-Entity
blotting	O	O	I-Entity
results	O	O	O
confirmed	O	O	O
the	O	O	O
up-regulation	O	O	B-Entity
of	O	O	O
these	O	O	O
four	O	O	O
genes	O	O	B-Entity
.	O	O	O

ASG-IV	O	O	B-Entity
played	O	O	O
a	O	O	O
positive	O	O	B-Entity
role	O	O	I-Entity
in	O	O	O
human	O	O	B-Entity
osteoarthritic	O	O	B-Entity
chondrocyte	O	O	B-Entity
apoptosis	O	O	I-Entity
,	O	O	O
possibly	O	O	O
through	O	O	O
modulation	O	O	B-Entity
of	O	O	O
the	O	O	O
Hippo	O	O	B-Entity
signaling	O	O	I-Entity
pathway	O	O	I-Entity
by	O	O	O
up-regulating	O	O	B-Entity
YAP1	O	O	B-Entity
and	O	O	O
ACTG1	O	O	B-Entity
expression	O	O	B-Entity
,	O	O	O
and	O	O	O
also	O	O	O
by	O	O	O
up-regulating	O	O	O
VTN	O	O	B-Entity
and	O	O	O
COL1A1	O	O	B-Entity
,	O	O	O
which	O	O	O
are	O	O	O
involved	O	O	O
in	O	O	O
the	O	O	O
ECM-receptor	O	O	B-Entity
interaction	O	O	I-Entity
pathway	O	O	I-Entity
.	O	O	O

Taken	O	O	O
together	O	O	O
,	O	O	O
all	O	O	O
the	O	O	O
results	O	O	O
suggested	O	O	O
that	O	O	O
ASG-IV	O	O	B-Entity
had	O	O	O
a	O	O	O
novel	O	O	O
therapeutic	O	O	B-Entity
potential	O	O	B-Entity
for	O	O	O
the	O	O	O
treatment	O	O	B-Entity
of	O	O	O
OA	O	O	B-Entity
.	O	O	O

-DOCSTART- (28501764)

Open-label	O	O	B-Entity
,	O	O	I-Entity
multicentre	O	O	I-Entity
safety	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
vemurafenib	O	O	B-Entity
in	O	O	O
3219	O	O	O
patients	O	O	B-Entity
with	O	O	O
BRAF(V600	O	O	B-Entity
)	O	O	I-Entity
mutation	O	O	I-Entity
-	O	O	O
positive	O	O	B-Entity
metastatic	O	O	B-Entity
melanoma	O	O	I-Entity
:	O	O	O
2-year	O	O	O
follow-up	O	O	B-Entity
data	O	O	B-Entity
and	O	O	O
long-term	O	O	B-Entity
responders	O	O	O
'	O	O	O
analysis	O	O	O

The	O	O	O
orally	O	O	B-Entity
available	O	O	O
BRAF	O	O	B-Entity
kinase	O	O	I-Entity
inhibitor	O	O	I-Entity
vemurafenib	O	O	B-Entity
is	O	O	O
an	O	O	O
effective	O	O	B-Entity
and	O	O	O
tolerable	O	O	B-Entity
treatment	O	O	B-Entity
option	O	O	I-Entity
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
metastatic	O	O	B-Entity
melanoma	O	O	I-Entity
harbouring	O	O	O
BRAF(V600	O	O	B-Entity
)	O	O	I-Entity
mutations	O	O	I-Entity
.	O	O	O

We	O	O	O
assessed	O	O	B-Entity
the	O	O	O
safety	O	O	B-Entity
of	O	O	O
vemurafenib	O	O	B-Entity
in	O	O	O
a	O	O	O
large	O	O	B-Entity
population	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
few	O	O	O
alternative	O	O	B-Entity
treatment	O	O	B-Entity
options	O	O	I-Entity
;	O	O	O
we	O	O	O
report	O	O	O
updated	O	O	O
2-year	O	O	O
safety	O	O	O
.	O	O	O

This	O	O	O
was	O	O	O
an	O	O	O
open-label	O	O	B-Entity
,	O	O	I-Entity
multicentre	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
vemurafenib	O	O	B-Entity
(	O	O	O
960	O	O	O
mg	O	O	O
bid	O	O	O
)	O	O	O
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
previously	O	O	O
treated	O	O	B-Entity
or	O	O	O
untreated	O	O	B-Entity
BRAF	O	O	B-Entity
mutation	O	O	I-Entity
-	O	O	O
positive	O	O	B-Entity
metastatic	O	O	B-Entity
melanoma	O	O	I-Entity
(	O	O	O
cobas	O	O	B-Entity
(	O	O	I-Entity
®	O	O	I-Entity
)	O	O	I-Entity
4800	O	O	I-Entity
BRAF	O	O	B-Entity
V600	O	O	I-Entity
Mutation	O	O	I-Entity
Test	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
end-point	O	O	B-Entity
was	O	O	O
safety	O	O	B-Entity
;	O	O	O
efficacy	O	O	O
end-points	O	O	B-Entity
were	O	O	O
secondary	O	O	B-Entity
.	O	O	O

An	O	O	O
exploratory	O	O	B-Entity
analysis	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
assess	O	O	B-Entity
safety	O	O	B-Entity
outcomes	O	O	B-Entity
in	O	O	O
patients	O	O	B-Entity
with	O	O	O
long	O	O	B-Entity
duration	O	O	B-Entity
of	O	O	I-Entity
response	O	O	I-Entity
(	O	O	O
DOR	O	O	B-Entity
)	O	O	O
(	O	O	O
≥12	O	O	O
or	O	O	O
≥24	O	O	O
months	O	O	B-Entity
)	O	O	O
.	O	O	O

After	O	O	O
a	O	O	O
median	O	O	B-Entity
follow-up	O	O	B-Entity
of	O	O	O
32.2	O	O	O
months	O	O	B-Entity
(	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
31.1	O	O	O
-	O	O	O
33.2	O	O	O
months	O	O	O
)	O	O	O
,	O	O	O
3079/3219	O	O	O
patients	O	O	B-Entity
(	O	O	O
96	O	O	O
%	O	O	O
)	O	O	O
had	O	O	O
discontinued	O	O	B-Entity
treatment	O	O	I-Entity
.	O	O	O

Adverse	O	O	B-Entity
events	O	O	I-Entity
(	O	O	O
AEs	O	O	B-Entity
)	O	O	O
were	O	O	O
largely	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
previous	O	O	O
reports	O	O	O
;	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
all-grade	O	O	O
treatment	O	O	B-Entity
-related	O	O	O
AEs	O	O	O
were	O	O	O
arthralgia	O	O	B-Entity
(	O	O	O
37	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
alopecia	O	O	B-Entity
(	O	O	O
25	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
hyperkeratosis	O	O	B-Entity
(	O	O	O
23	O	O	O
%	O	O	O
)	O	O	O
;	O	O	O
the	O	O	O
most	O	O	O
common	O	O	O
grade	O	O	O
3/4	O	O	O
treatment	O	O	O
-related	O	O	O
AEs	O	O	O
were	O	O	O
squamous	O	O	B-Entity
cell	O	O	I-Entity
carcinoma	O	O	I-Entity
of	O	O	I-Entity
the	O	O	I-Entity
skin	O	O	I-Entity
(	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
keratoacanthoma	O	O	B-Entity
(	O	O	O
8	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
exploratory	O	O	B-Entity
analysis	O	O	I-Entity
,	O	O	O
patients	O	O	B-Entity
with	O	O	O
DOR	O	O	B-Entity
≥12	O	O	O
months	O	O	B-Entity
(	O	O	O
n	O	O	O
=	O	O	O
287	O	O	O
)	O	O	O
or	O	O	O
≥24	O	O	O
months	O	O	O
(	O	O	O
n	O	O	O
=	O	O	O
133	O	O	O
)	O	O	O
were	O	O	O
more	O	O	O
likely	O	O	O
to	O	O	O
experience	O	O	O
grade	O	O	O
3/4	O	O	O
AEs	O	O	B-Entity
than	O	O	O
the	O	O	O
overall	O	O	B-Entity
population	O	O	B-Entity
.	O	O	O

No	O	O	O
new	O	O	O
specific	O	O	B-Entity
safety	O	O	B-Entity
signals	O	O	I-Entity
were	O	O	O
observed	O	O	O
with	O	O	O
longer	O	O	O
vemurafenib	O	O	B-Entity
exposure	O	O	O
.	O	O	O

After	O	O	O
2	O	O	O
years	O	O	O
'	O	O	O
follow-up	O	O	B-Entity
,	O	O	O
safety	O	O	B-Entity
was	O	O	O
maintained	O	O	O
in	O	O	O
this	O	O	O
large	O	O	B-Entity
group	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
with	O	O	O
BRAF(V600	O	O	B-Entity
)	O	O	I-Entity
mutation	O	O	I-Entity
-	O	O	O
positive	O	O	B-Entity
metastatic	O	O	B-Entity
melanoma	O	O	I-Entity
who	O	O	O
are	O	O	O
more	O	O	O
representative	O	O	O
of	O	O	O
routine	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
than	O	O	O
typical	O	O	O
clinical	O	O	B-Entity
trial	O	O	I-Entity
populations	O	O	B-Entity
.	O	O	O

These	O	O	O
data	O	O	O
suggest	O	O	O
that	O	O	O
long-term	O	O	B-Entity
vemurafenib	O	O	B-Entity
treatment	O	O	B-Entity
is	O	O	O
effective	O	O	B-Entity
and	O	O	O
tolerable	O	O	B-Entity
without	O	O	O
the	O	O	O
development	O	O	O
of	O	O	O
new	O	O	O
safety	O	O	B-Entity
signals	O	O	I-Entity
.	O	O	O

-DOCSTART- (28502812)

Collecting	O	O	B-Entity
and	O	O	O
Reporting	O	O	B-Entity
Safety	O	O	I-Entity
Data	O	O	I-Entity
and	O	O	O
Monitoring	O	O	B-Entity
Trial	O	O	I-Entity
Conduct	O	O	I-Entity
In	O	O	O
Pragmatic	O	O	O
Trials	O	O	O

Pragmatic	O	O	B-Entity
trials	O	O	I-Entity
offer	O	O	O
the	O	O	O
opportunity	O	O	B-Entity
to	O	O	O
obtain	O	O	O
real-life	O	O	B-Entity
data	O	O	B-Entity
on	O	O	O
the	O	O	O
relative	O	O	O
effectiveness	O	O	B-Entity
and	O	O	O
safety	O	O	B-Entity
of	O	O	O
a	O	O	O
treatment	O	O	B-Entity
before	O	O	O
or	O	O	O
after	O	O	O
market	O	O	B-Entity
authorisation	O	O	I-Entity
.	O	O	O

This	O	O	O
is	O	O	O
the	O	O	O
penultimate	O	O	B-Entity
paper	O	O	I-Entity
in	O	O	O
a	O	O	O
series	O	O	O
of	O	O	O
eight	O	O	O
,	O	O	O
describing	O	O	O
the	O	O	O
impact	O	O	O
of	O	O	O
design	O	O	B-Entity
choices	O	O	B-Entity
on	O	O	O
the	O	O	O
practical	O	O	O
implementation	O	O	B-Entity
of	O	O	O
pragmatic	O	O	B-Entity
trials	O	O	I-Entity
.	O	O	O

This	O	O	O
paper	O	O	B-Entity
focuses	O	O	O
on	O	O	O
the	O	O	O
practical	O	O	O
challenges	O	O	O
of	O	O	O
collecting	O	O	B-Entity
and	O	O	O
reporting	O	O	B-Entity
safety	O	O	I-Entity
data	O	O	I-Entity
and	O	O	O
of	O	O	O
monitoring	O	O	B-Entity
trial	O	O	I-Entity
conduct	O	O	I-Entity
while	O	O	O
maintaining	O	O	O
routine	O	O	O
clinical	O	O	B-Entity
care	O	O	I-Entity
practice	O	O	I-Entity
.	O	O	O

Current	O	O	O
ICH	O	O	B-Entity
guidance	O	O	O
recommends	O	O	O
that	O	O	O
,	O	O	O
all	O	O	O
serious	O	O	B-Entity
adverse	O	O	I-Entity
events	O	O	I-Entity
(	O	O	O
SAEs	O	O	B-Entity
)	O	O	O
and	O	O	O
all	O	O	O
drug	O	O	B-Entity
-related	O	O	O
events	O	O	O
must	O	O	O
be	O	O	O
reported	O	O	O
in	O	O	O
an	O	O	O
interventional	O	O	B-Entity
trial	O	O	B-Entity
.	O	O	O

In	O	O	O
line	O	O	O
with	O	O	O
current	O	O	O
guidance	O	O	O
,	O	O	O
we	O	O	O
propose	O	O	O
a	O	O	O
risk	O	O	B-Entity
based	O	O	O
approach	O	O	B-Entity
to	O	O	O
the	O	O	O
collection	O	O	B-Entity
of	O	O	O
non	O	O	B-Entity
-	O	O	O
drug	O	O	B-Entity
related	O	O	O
non-serious	O	O	B-Entity
AEs	O	O	I-Entity
,	O	O	O
and	O	O	O
even	O	O	O
serious	O	O	B-Entity
events	O	O	I-Entity
not	O	O	O
related	O	O	O
to	O	O	O
treatment	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
risk	O	O	O
profile	O	O	B-Entity
of	O	O	O
the	O	O	O
medicine	O	O	B-Entity
/class	O	O	O
in	O	O	O
the	O	O	O
patient	O	O	B-Entity
population	O	O	B-Entity
of	O	O	O
interest	O	O	O
.	O	O	O

Different	O	O	O
options	O	O	O
available	O	O	O
to	O	O	O
support	O	O	O
the	O	O	O
collection	O	O	B-Entity
and	O	O	O
reporting	O	O	B-Entity
of	O	O	I-Entity
safety	O	O	I-Entity
data	O	O	I-Entity
whilst	O	O	O
minimizing	O	O	O
study	O	O	B-Entity
-related	O	O	O
follow-up	O	O	B-Entity
visits	O	O	I-Entity
are	O	O	O
discussed	O	O	O
.	O	O	O

A	O	O	O
risk	O	O	B-Entity
-based	O	O	O
approach	O	O	B-Entity
to	O	O	O
monitoring	O	O	B-Entity
trial	O	O	I-Entity
conduct	O	O	I-Entity
is	O	O	O
also	O	O	O
discussed	O	O	O
,	O	O	O
highlighting	O	O	O
the	O	O	O
difference	O	O	O
in	O	O	O
the	O	O	O
balance	O	O	O
of	O	O	O
risks	O	O	B-Entity
likely	O	O	O
to	O	O	O
occur	O	O	O
in	O	O	O
a	O	O	O
pragmatic	O	O	B-Entity
trial	O	O	I-Entity
compared	O	O	O
to	O	O	O
traditional	O	O	O
clinical	O	O	B-Entity
trials	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
careful	O	O	O
consideration	O	O	O
that	O	O	O
must	O	O	O
be	O	O	O
given	O	O	O
to	O	O	O
the	O	O	O
mitigation	O	O	B-Entity
and	O	O	O
management	O	O	B-Entity
of	O	O	I-Entity
these	O	O	I-Entity
risks	O	O	I-Entity
in	O	O	O
order	O	O	O
to	O	O	O
maintain	O	O	O
routine	O	O	O
care	O	O	B-Entity
.	O	O	O

-DOCSTART- (28503431)

A	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
intraocular	O	O	B-Entity
lens	O	O	I-Entity
explantation	O	O	I-Entity
in	O	O	O
69	O	O	O
eyes	O	O	B-Entity
in	O	O	O
Chinese	O	O	O
patients	O	O	O

To	O	O	O
study	O	O	O
the	O	O	O
effects	O	O	O
of	O	O	O
intraocular	O	O	B-Entity
lens	O	O	I-Entity
(	O	O	I-Entity
IOL	O	O	I-Entity
)	O	O	I-Entity
explantation	O	O	I-Entity
and	O	O	O
demographic	O	O	B-Entity
characteristics	O	O	I-Entity
.	O	O	O

Retrospective	O	O	B-Entity
non-comparative	O	O	B-Entity
case	O	O	I-Entity
series	O	O	I-Entity
.	O	O	O

Clinical	O	O	B-Entity
data	O	O	I-Entity
recorded	O	O	O
from	O	O	O
patient	O	O	B-Entity
charts	O	O	I-Entity
included	O	O	O
the	O	O	O
following	O	O	O
:	O	O	O
demographic	O	O	B-Entity
,	O	O	O
preoperative	O	O	B-Entity
and	O	O	O
postoperative	O	O	B-Entity
characteristics	O	O	B-Entity
;	O	O	O
complications	O	O	B-Entity
;	O	O	O
surgical	O	O	B-Entity
methods	O	O	I-Entity
,	O	O	O
and	O	O	O
changes	O	O	O
in	O	O	O
visual	O	O	B-Entity
acuity	O	O	I-Entity
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
69	O	O	O
eyes	O	O	B-Entity
in	O	O	O
67	O	O	O
Chinese	O	O	B-Entity
patients	O	O	B-Entity
who	O	O	O
received	O	O	O
IOL	O	O	B-Entity
explants	O	O	I-Entity
were	O	O	O
studied	O	O	O
.	O	O	O

The	O	O	O
patients	O	O	B-Entity
'	O	O	O
mean	O	O	O
age	O	O	B-Entity
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
explantation	O	O	I-Entity
was	O	O	O
46.1	O	O	O
years	O	O	O
old	O	O	O
[	O	O	O
SD	O	O	O
22.5	O	O	O
(	O	O	O
6	O	O	O
-	O	O	O
85	O	O	O
)	O	O	O
]	O	O	O
,	O	O	O
and	O	O	O
37	O	O	O
patients	O	O	B-Entity
were	O	O	I-Entity
female	O	O	I-Entity
(	O	O	O
55.2	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

Regarding	O	O	O
employment	O	O	B-Entity
,	O	O	O
47.8	O	O	O
%	O	O	O
were	O	O	O
farmers	O	O	B-Entity
,	O	O	O
23.9	O	O	O
%	O	O	O
were	O	O	O
retired	O	O	B-Entity
,	O	O	O
16.4	O	O	O
%	O	O	O
were	O	O	O
students	O	O	B-Entity
,	O	O	O
4.5	O	O	O
%	O	O	O
were	O	O	O
unemployed	O	O	B-Entity
,	O	O	O
3	O	O	O
%	O	O	O
were	O	O	O
workers	O	O	B-Entity
,	O	O	O
and	O	O	O
4.5	O	O	O
%	O	O	O
were	O	O	O
other	O	O	O
(	O	O	O
including	O	O	O
staff	O	O	B-Entity
members	O	O	I-Entity
,	O	O	O
teachers	O	O	B-Entity
and	O	O	O
officers	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
reasons	O	O	O
for	O	O	O
explantation	O	O	B-Entity
were	O	O	O
dislocation	O	O	B-Entity
/	O	O	O
decentration	O	O	B-Entity
in	O	O	O
41	O	O	O
cases	O	O	O
(	O	O	O
59.4	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
retinal	O	O	B-Entity
detachment	O	O	I-Entity
in	O	O	O
10	O	O	O
cases	O	O	O
(	O	O	O
14.5	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
third	O	O	O
most	O	O	O
prevalent	O	O	B-Entity
cause	O	O	I-Entity
was	O	O	O
incorrect	O	O	B-Entity
lens	O	O	I-Entity
power	O	O	I-Entity
in	O	O	O
7	O	O	O
eyes	O	O	B-Entity
(	O	O	O
10.1	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
remaining	O	O	O
reasons	O	O	O
were	O	O	O
endophthalmitis	O	O	B-Entity
in	O	O	O
6	O	O	O
cases	O	O	O
(	O	O	O
8.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
posterior	O	O	B-Entity
capsular	O	O	I-Entity
opacity	O	O	I-Entity
in	O	O	O
3	O	O	O
eyes	O	O	B-Entity
(	O	O	O
4.3	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
impacting	O	O	B-Entity
retinal	O	O	B-Entity
surgery	O	O	I-Entity
operation	O	O	I-Entity
in	O	O	O
2	O	O	O
cases	O	O	O
(	O	O	O
2.9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
main	O	O	O
comorbidities	O	O	B-Entity
were	O	O	O
high	O	O	B-Entity
myopia	O	O	I-Entity
in	O	O	O
18	O	O	O
eyes	O	O	B-Entity
(	O	O	O
26.1	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
trauma	O	O	B-Entity
in	O	O	O
8	O	O	O
eyes	O	O	O
(	O	O	O
11.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
retinal	O	O	B-Entity
detachment	O	O	I-Entity
in	O	O	O
6	O	O	O
eyes	O	O	O
(	O	O	O
8.7	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
congenital	O	O	B-Entity
cataracts	O	O	I-Entity
in	O	O	O
8	O	O	O
eyes	O	O	O
(	O	O	O
11.6	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
and	O	O	O
Marfan	O	O	B-Entity
's	O	O	I-Entity
syndrome	O	O	I-Entity
in	O	O	O
2	O	O	O
eyes	O	O	O
(	O	O	O
2.9	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
mean	O	O	B-Entity
time	O	O	I-Entity
from	O	O	I-Entity
implantation	O	O	I-Entity
to	O	O	I-Entity
explantation	O	O	I-Entity
was	O	O	O
4.0y	O	O	O
[	O	O	O
SD	O	O	O
4.2	O	O	O
(	O	O	O
0.005	O	O	O
-	O	O	O
15	O	O	O
)	O	O	O
]	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
after	O	O	I-Entity
explantation	O	O	I-Entity
included	O	O	O
posterior	O	O	B-Entity
chamber	O	O	I-Entity
IOL	O	O	I-Entity
implantation	O	O	I-Entity
in	O	O	O
44	O	O	O
eyes	O	O	B-Entity
(	O	O	O
63.8	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
aphakia	O	O	B-Entity
in	O	O	O
25	O	O	O
eyes	O	O	O
(	O	O	O
36.2	O	O	O
%	O	O	O
)	O	O	O
.	O	O	O

After	O	O	B-Entity
surgery	O	O	I-Entity
,	O	O	O
the	O	O	O
best	O	O	B-Entity
corrected	O	O	I-Entity
visual	O	O	B-Entity
ability	O	O	I-Entity
(	O	O	O
BCVA	O	O	B-Entity
)	O	O	O
was	O	O	O
improved	O	O	O
in	O	O	O
50	O	O	O
cases	O	O	O
(	O	O	O
72.5	O	O	O
%	O	O	O
)	O	O	O
,	O	O	O
including	O	O	O
28	O	O	O
patients	O	O	B-Entity
(	O	O	O
40.6	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
whom	O	O	O
visual	O	O	O
ability	O	O	O
was	O	O	O
improved	O	O	O
by	O	O	O
more	O	O	O
than	O	O	O
two	O	O	O
lines	O	O	O
.	O	O	O

Dislocation	O	O	B-Entity
/	O	O	O
decentration	O	O	B-Entity
is	O	O	O
the	O	O	O
main	O	O	B-Entity
cause	O	O	I-Entity
for	O	O	O
explantation	O	O	B-Entity
,	O	O	O
and	O	O	O
high	O	O	B-Entity
myopia	O	O	I-Entity
is	O	O	O
a	O	O	O
main	O	O	B-Entity
risk	O	O	I-Entity
factor	O	O	I-Entity
.	O	O	O

Posterior	O	O	B-Entity
chamber	O	O	I-Entity
IOL	O	O	I-Entity
implantation	O	O	I-Entity
remains	O	O	O
the	O	O	O
most	O	O	O
elected	O	O	O
treatment	O	O	B-Entity
after	O	O	I-Entity
explantation	O	O	I-Entity
.	O	O	O

-DOCSTART- (28505472)

Improvement	O	O	B-Entity
of	O	O	O
older	O	O	B-Entity
-	O	O	O
person	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
QOL	O	O	B-Entity
after	O	O	O
hearing	O	O	B-Entity
aid	O	O	I-Entity
fitting	O	O	B-Entity
and	O	O	O
its	O	O	O
relation	O	O	B-Entity
to	O	O	O
social	O	O	O
interaction	O	O	O

This	O	O	O
study	O	O	B-Entity
aimed	O	O	B-Entity
to	O	O	O
investigate	O	O	B-Entity
whether	O	O	O
hearing	O	O	B-Entity
aids	O	O	I-Entity
use	O	O	O
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
improvement	O	O	B-Entity
of	O	O	O
older	O	O	B-Entity
-	O	O	O
person	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
QOL	O	O	B-Entity
and	O	O	O
whether	O	O	O
social	O	O	B-Entity
interactions	O	O	I-Entity
modify	O	O	B-Entity
the	O	O	O
association	O	O	B-Entity
.	O	O	O

The	O	O	O
WHOQOL-OLD	O	O	B-Entity
questionnaire	O	O	I-Entity
was	O	O	O
answered	O	O	B-Entity
by	O	O	O
105	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
aged	O	O	B-Entity
60	O	O	O
to	O	O	O
90	O	O	O
years	O	O	O
who	O	O	O
were	O	O	O
newly	O	O	B-Entity
fitted	O	O	B-Entity
hearing	O	O	B-Entity
aids	O	O	I-Entity
on	O	O	O
the	O	O	O
day	O	O	O
of	O	O	O
fitting	O	O	B-Entity
and	O	O	O
at	O	O	O
2	O	O	O
-	O	O	O
6	O	O	O
months	O	O	O
afterward	O	O	B-Entity
.	O	O	O

The	O	O	O
associations	O	O	B-Entity
between	O	O	O
the	O	O	O
daily	O	O	O
hours	O	O	O
of	O	O	O
hearing	O	O	B-Entity
aid	O	O	I-Entity
usage	O	O	B-Entity
and	O	O	O
social	O	O	B-Entity
relations	O	O	I-Entity
with	O	O	O
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
WHOQOL-OLD	O	O	B-Entity
total	O	O	B-Entity
score	O	O	I-Entity
after	O	O	O
hearing	O	O	B-Entity
aids	O	O	I-Entity
fitting	O	O	B-Entity
were	O	O	O
estimated	O	O	B-Entity
adjusting	O	O	B-Entity
for	O	O	O
possible	O	O	B-Entity
confounders	O	O	B-Entity
.	O	O	O

Older	O	O	B-Entity
persons	O	O	B-Entity
with	O	O	O
hearing	O	O	B-Entity
loss	O	O	I-Entity
experienced	O	O	B-Entity
significant	O	O	B-Entity
increases	O	O	B-Entity
in	O	O	O
WHOQOL-OLD	O	O	B-Entity
total	O	O	B-Entity
score	O	O	I-Entity
after	O	O	O
hearing	O	O	B-Entity
aid	O	O	I-Entity
fitting	O	O	B-Entity
.	O	O	O

Regular	O	O	B-Entity
use	O	O	B-Entity
of	O	O	I-Entity
hearing	O	O	B-Entity
aid	O	O	I-Entity
was	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
greater	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
the	O	O	O
total	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

The	O	O	O
combined	O	O	B-Entity
categorical	O	O	B-Entity
variable	O	O	B-Entity
of	O	O	O
social	O	O	B-Entity
relations	O	O	I-Entity
and	O	O	O
hearing	O	O	B-Entity
aid	O	O	I-Entity
usage	O	O	B-Entity
revealed	O	O	B-Entity
no	O	O	O
separate	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
these	O	O	O
two	O	O	O
variables	O	O	B-Entity
,	O	O	O
but	O	O	O
a	O	O	O
combined	O	O	O
effect	O	O	B-Entity
;	O	O	O
only	O	O	O
those	O	O	O
with	O	O	O
frequent	O	O	B-Entity
social	O	O	B-Entity
interactions	O	O	I-Entity
who	O	O	O
used	O	O	O
their	O	O	O
hearing	O	O	O
aid	O	O	O
regularly	O	O	B-Entity
had	O	O	O
a	O	O	O
significantly	O	O	B-Entity
greater	O	O	B-Entity
increase	O	O	B-Entity
in	O	O	O
WHOQOL-OLD	O	O	B-Entity
total	O	O	B-Entity
score	O	O	I-Entity
.	O	O	O

This	O	O	O
study	O	O	B-Entity
's	O	O	I-Entity
findings	O	O	B-Entity
indicate	O	O	B-Entity
that	O	O	O
hearing	O	O	B-Entity
aid	O	O	I-Entity
fitting	O	O	B-Entity
may	O	O	O
be	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
subsequent	O	O	B-Entity
improvement	O	O	B-Entity
in	O	O	O
older	O	O	B-Entity
-	O	O	O
person	O	O	B-Entity
-	O	O	O
specific	O	O	B-Entity
QOL	O	O	B-Entity
by	O	O	O
improvements	O	O	B-Entity
in	O	O	O
hearing	O	O	O
due	O	O	O
to	O	O	O
the	O	O	O
hearing	O	O	B-Entity
aid	O	O	I-Entity
,	O	O	O
and	O	O	O
possibly	O	O	B-Entity
enhanced	O	O	B-Entity
communication	O	O	B-Entity
opportunities	O	O	B-Entity
.	O	O	O

-DOCSTART- (28506958)

Enhancing	O	O	O
Comparative	O	O	B-Entity
Effectiveness	O	O	I-Entity
Research	O	O	I-Entity
With	O	O	O
Automated	O	O	B-Entity
Pediatric	O	O	B-Entity
Pneumonia	O	O	B-Entity
Detection	O	O	B-Entity
in	O	O	O
a	O	O	O
Multi-Institutional	O	O	B-Entity
Clinical	O	O	B-Entity
Repository	O	O	B-Entity
:	O	O	O
A	O	O	O
PHIS	O	O	B-Entity
+	O	O	O
Pilot	O	O	O
Study	O	O	O

Community-acquired	O	O	B-Entity
pneumonia	O	O	I-Entity
is	O	O	O
a	O	O	O
leading	O	O	O
cause	O	O	O
of	O	O	O
pediatric	O	O	B-Entity
morbidity	O	O	B-Entity
.	O	O	O

Administrative	O	O	B-Entity
data	O	O	B-Entity
are	O	O	O
often	O	O	O
used	O	O	O
to	O	O	O
conduct	O	O	O
comparative	O	O	B-Entity
effectiveness	O	O	I-Entity
research	O	O	I-Entity
(	O	O	O
CER	O	O	B-Entity
)	O	O	O
with	O	O	O
sufficient	O	O	O
sample	O	O	B-Entity
sizes	O	O	I-Entity
to	O	O	O
enhance	O	O	O
detection	O	O	B-Entity
of	O	O	O
important	O	O	B-Entity
outcomes	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
such	O	O	O
studies	O	O	O
are	O	O	O
prone	O	O	O
to	O	O	O
misclassification	O	O	B-Entity
errors	O	O	I-Entity
because	O	O	O
of	O	O	O
the	O	O	O
variable	O	O	B-Entity
accuracy	O	O	B-Entity
of	O	O	O
discharge	O	O	B-Entity
diagnosis	O	O	I-Entity
codes	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
this	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
develop	O	O	O
an	O	O	O
automated	O	O	B-Entity
,	O	O	O
scalable	O	O	B-Entity
,	O	O	O
and	O	O	O
accurate	O	O	B-Entity
method	O	O	B-Entity
to	O	O	O
determine	O	O	B-Entity
the	O	O	O
presence	O	O	B-Entity
or	O	O	O
absence	O	O	B-Entity
of	O	O	O
pneumonia	O	O	B-Entity
in	O	O	O
children	O	O	B-Entity
using	O	O	O
chest	O	O	B-Entity
imaging	O	O	I-Entity
reports	O	O	B-Entity
.	O	O	O

The	O	O	O
multi-institutional	O	O	B-Entity
PHIS	O	O	B-Entity
+	O	O	O
clinical	O	O	B-Entity
repository	O	O	B-Entity
was	O	O	O
developed	O	O	O
to	O	O	O
support	O	O	O
pediatric	O	O	B-Entity
CER	O	O	B-Entity
by	O	O	O
expanding	O	O	O
an	O	O	O
administrative	O	O	B-Entity
database	O	O	B-Entity
of	O	O	O
children	O	O	B-Entity
's	O	O	I-Entity
hospitals	O	O	I-Entity
with	O	O	O
detailed	O	O	O
clinical	O	O	O
data	O	O	B-Entity
.	O	O	O

To	O	O	O
develop	O	O	O
a	O	O	O
scalable	O	O	B-Entity
approach	O	O	O
to	O	O	O
find	O	O	B-Entity
patients	O	O	B-Entity
with	O	O	O
bacterial	O	O	B-Entity
pneumonia	O	O	I-Entity
more	O	O	O
accurately	O	O	O
,	O	O	O
we	O	O	O
developed	O	O	O
a	O	O	O
Natural	O	O	B-Entity
Language	O	O	I-Entity
Processing	O	O	I-Entity
(	O	O	O
NLP	O	O	B-Entity
)	O	O	O
application	O	O	B-Entity
to	O	O	O
extract	O	O	O
relevant	O	O	B-Entity
information	O	O	B-Entity
from	O	O	O
chest	O	O	B-Entity
diagnostic	O	O	I-Entity
imaging	O	O	I-Entity
reports	O	O	B-Entity
.	O	O	O

Domain	O	O	B-Entity
experts	O	O	B-Entity
established	O	O	B-Entity
a	O	O	O
reference	O	O	B-Entity
standard	O	O	I-Entity
by	O	O	O
manually	O	O	B-Entity
annotating	O	O	B-Entity
282	O	O	O
reports	O	O	B-Entity
to	O	O	O
train	O	O	O
and	O	O	O
then	O	O	O
test	O	O	O
the	O	O	O
NLP	O	O	B-Entity
application	O	O	B-Entity
.	O	O	O

Findings	O	O	O
of	O	O	O
pleural	O	O	B-Entity
effusion	O	O	I-Entity
,	O	O	O
pulmonary	O	O	B-Entity
infiltrate	O	O	I-Entity
,	O	O	O
and	O	O	O
pneumonia	O	O	B-Entity
were	O	O	O
automatically	O	O	B-Entity
extracted	O	O	O
from	O	O	O
the	O	O	O
reports	O	O	B-Entity
and	O	O	O
then	O	O	O
used	O	O	O
to	O	O	O
automatically	O	O	O
classify	O	O	B-Entity
whether	O	O	O
a	O	O	O
report	O	O	B-Entity
was	O	O	O
consistent	O	O	B-Entity
with	O	O	I-Entity
bacterial	O	O	B-Entity
pneumonia	O	O	I-Entity
.	O	O	O

Compared	O	O	B-Entity
with	O	O	O
the	O	O	O
annotated	O	O	O
diagnostic	O	O	B-Entity
imaging	O	O	I-Entity
reports	O	O	B-Entity
reference	O	O	B-Entity
standard	O	O	I-Entity
,	O	O	O
the	O	O	O
most	O	O	O
accurate	O	O	B-Entity
implementation	O	O	B-Entity
of	O	O	O
machine	O	O	B-Entity
learning	O	O	I-Entity
algorithms	O	O	B-Entity
in	O	O	O
our	O	O	O
NLP	O	O	B-Entity
application	O	O	B-Entity
allowed	O	O	O
extracting	O	O	O
relevant	O	O	B-Entity
findings	O	O	B-Entity
with	O	O	O
a	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
.939	O	O	O
and	O	O	O
a	O	O	O
positive	O	O	B-Entity
predictive	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
.925	O	O	O
.	O	O	O

It	O	O	O
allowed	O	O	O
classifying	O	O	B-Entity
reports	O	O	B-Entity
with	O	O	O
a	O	O	O
sensitivity	O	O	B-Entity
of	O	O	O
.71	O	O	O
,	O	O	O
a	O	O	O
positive	O	O	B-Entity
predictive	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
.86	O	O	O
,	O	O	O
and	O	O	O
a	O	O	O
specificity	O	O	B-Entity
of	O	O	O
.962	O	O	O
.	O	O	O

When	O	O	O
compared	O	O	B-Entity
with	O	O	O
each	O	O	O
of	O	O	O
the	O	O	O
domain	O	O	B-Entity
experts	O	O	B-Entity
manually	O	O	B-Entity
annotating	O	O	B-Entity
these	O	O	O
reports	O	O	B-Entity
,	O	O	O
the	O	O	O
NLP	O	O	B-Entity
application	O	O	B-Entity
allowed	O	O	O
for	O	O	O
significantly	O	O	B-Entity
higher	O	O	I-Entity
sensitivity	O	O	B-Entity
(	O	O	O
.71	O	O	O
vs	O	O	O
.527	O	O	O
)	O	O	O
and	O	O	O
similar	O	O	O
positive	O	O	B-Entity
predictive	O	O	B-Entity
value	O	O	I-Entity
and	O	O	O
specificity	O	O	B-Entity
.	O	O	O

NLP	O	O	B-Entity
-based	O	O	O
pneumonia	O	O	B-Entity
information	O	O	B-Entity
extraction	O	O	O
of	O	O	O
pediatric	O	O	B-Entity
diagnostic	O	O	B-Entity
imaging	O	O	I-Entity
reports	O	O	B-Entity
performed	O	O	B-Entity
better	O	O	O
than	O	O	O
domain	O	O	B-Entity
experts	O	O	B-Entity
in	O	O	O
this	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
.	O	O	O

NLP	O	O	B-Entity
is	O	O	O
an	O	O	O
efficient	O	O	O
method	O	O	O
to	O	O	O
extract	O	O	O
information	O	O	B-Entity
from	O	O	O
a	O	O	O
large	O	O	O
collection	O	O	B-Entity
of	O	O	O
imaging	O	O	B-Entity
reports	O	O	I-Entity
to	O	O	O
facilitate	O	O	O
CER	O	O	B-Entity
.	O	O	O

-DOCSTART- (28507202)

Determination	O	O	B-Entity
of	O	O	O
volatile	O	O	B-Entity
organic	O	O	I-Entity
compounds	O	O	I-Entity
exhaled	O	O	B-Entity
by	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
derived	O	O	B-Entity
from	O	O	O
hematological	O	O	O
malignancies	O	O	O

Background	O	O	O
:	O	O	O
The	O	O	O
gas	O	O	B-Entity
human	O	O	B-Entity
exhaled	O	O	B-Entity
contains	O	O	O
many	O	O	O
volatile	O	O	B-Entity
organic	O	O	I-Entity
compounds	O	O	I-Entity
(	O	O	O
VOCs	O	O	B-Entity
)	O	O	O
,	O	O	O
which	O	O	O
is	O	O	O
related	O	O	O
to	O	O	O
the	O	O	O
health	O	O	B-Entity
status	O	O	I-Entity
of	O	O	O
body	O	O	B-Entity
.	O	O	O

Analysis	O	O	B-Entity
of	O	O	O
VOCs	O	O	B-Entity
has	O	O	O
been	O	O	O
proposed	O	O	O
as	O	O	O
a	O	O	O
noninvasive	O	O	B-Entity
diagnostic	O	O	B-Entity
tool	O	O	I-Entity
for	O	O	O
certain	O	O	O
cancers	O	O	B-Entity
.	O	O	O

Detailed	O	O	O
research	O	O	O
on	O	O	O
the	O	O	O
VOCs	O	O	B-Entity
in	O	O	O
gas	O	O	B-Entity
exhaled	O	O	B-Entity
by	O	O	O
cell	O	O	B-Entity
can	O	O	O
characterize	O	O	O
cell	O	O	B-Entity
type	O	O	I-Entity
specific	O	O	O
metabolites	O	O	B-Entity
and	O	O	O
may	O	O	O
be	O	O	O
helpful	O	O	O
to	O	O	O
detect	O	O	O
the	O	O	O
cancer	O	O	B-Entity
markers	O	O	I-Entity
in	O	O	O
clinical	O	O	B-Entity
practice	O	O	I-Entity
.	O	O	O

Methods	O	O	O
:	O	O	O
Solid	O	O	B-Entity
phase	O	O	I-Entity
microextraction	O	O	I-Entity
-	O	O	O
gas	O	O	B-Entity
chromatography	O	O	I-Entity
-	O	O	O
mass	O	O	B-Entity
spectrometry	O	O	I-Entity
was	O	O	O
used	O	O	O
to	O	O	O
detect	O	O	O
VOCs	O	O	B-Entity
in	O	O	O
the	O	O	O
headspace	O	O	O
of	O	O	O
tissue	O	O	B-Entity
culture	O	O	I-Entity
flask	O	O	I-Entity
in	O	O	O
non-Hodgkin	O	O	B-Entity
's	O	O	I-Entity
lymphoma	O	O	I-Entity
cell	O	O	B-Entity
line	O	O	I-Entity
JEKO	O	O	I-Entity
and	O	O	O
acute	O	O	B-Entity
mononuclear	O	O	I-Entity
leukemia	O	O	I-Entity
cell	O	O	B-Entity
line	O	O	I-Entity
SHI-1	O	O	I-Entity
,	O	O	O
to	O	O	O
elaborate	O	O	O
the	O	O	O
characteristic	O	O	O
gaseous	O	O	B-Entity
biomarkers	O	O	B-Entity
of	O	O	O
hematological	O	O	B-Entity
malignancies	O	O	I-Entity
.	O	O	O

While	O	O	O
macrophage	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
lymphocytic	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
acted	O	O	O
as	O	O	O
control	O	O	B-Entity
.	O	O	O

The	O	O	O
blank	O	O	B-Entity
group	O	O	I-Entity
was	O	O	O
only	O	O	O
the	O	O	O
RPMI	O	O	B-Entity
1640	O	O	I-Entity
medium	O	O	I-Entity
containing	O	O	O
10	O	O	O
%	O	O	O
fetal	O	O	B-Entity
calf	O	O	I-Entity
serum	O	O	I-Entity
that	O	O	O
without	O	O	O
cells	O	O	B-Entity
.	O	O	O

Results	O	O	O
:	O	O	O
Comparing	O	O	O
to	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
the	O	O	O
concentration	O	O	B-Entity
of	O	O	O
dimethyl	O	O	B-Entity
sulphide	O	O	I-Entity
,	O	O	O
2,4-dimethyl-heptane	O	O	B-Entity
,	O	O	O
methylbenzene	O	O	B-Entity
,	O	O	O
o-xylene	O	O	B-Entity
,	O	O	O
dodecane	O	O	B-Entity
and	O	O	O
1,3-ditert-butylbenzene	O	O	B-Entity
in	O	O	O
JEKO	O	O	B-Entity
cells	O	O	I-Entity
were	O	O	O
relatively	O	O	O
higher	O	O	O
,	O	O	O
while	O	O	O
the	O	O	O
concentration	O	O	O
of	O	O	O
ethanol	O	O	B-Entity
,	O	O	O
hexanal	O	O	B-Entity
and	O	O	O
benzaldehyde	O	O	B-Entity
was	O	O	O
lower	O	O	O
.	O	O	O

In	O	O	O
SHI-1	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
2,4-dimethyl-heptane	O	O	B-Entity
,	O	O	O
benzene	O	O	B-Entity
,	O	O	O
4-methyldecane	O	O	B-Entity
,	O	O	O
chloroform	O	O	B-Entity
,	O	O	O
3,7-dimethyl	O	O	B-Entity
dodecane	O	O	I-Entity
and	O	O	O
hexadecane	O	O	B-Entity
were	O	O	O
significantly	O	O	O
elevated	O	O	O
,	O	O	O
but	O	O	O
the	O	O	O
levels	O	O	O
of	O	O	O
hexanol	O	O	B-Entity
and	O	O	O
cyclohexanol	O	O	B-Entity
were	O	O	O
distinctly	O	O	O
reduced	O	O	O
.	O	O	O

Conclusions	O	O	O
:	O	O	O
This	O	O	O
pilot	O	O	B-Entity
study	O	O	I-Entity
revealed	O	O	O
that	O	O	O
the	O	O	O
malignant	O	O	B-Entity
hematological	O	O	I-Entity
cells	O	O	B-Entity
could	O	O	O
change	O	O	O
the	O	O	O
components	O	O	O
of	O	O	O
VOCs	O	O	B-Entity
in	O	O	O
the	O	O	O
cell	O	O	B-Entity
culture	O	O	I-Entity
flask	O	O	I-Entity
in	O	O	O
a	O	O	O
cell	O	O	B-Entity
type	O	O	I-Entity
specific	O	O	O
pattern	O	O	O
.	O	O	O

The	O	O	O
traits	O	O	O
of	O	O	O
VOCs	O	O	B-Entity
in	O	O	O
our	O	O	O
setting	O	O	O
offered	O	O	O
new	O	O	O
strategy	O	O	O
for	O	O	O
hematological	O	O	B-Entity
malignancies	O	O	I-Entity
tracing	O	O	O
,	O	O	O
and	O	O	O
would	O	O	O
act	O	O	O
as	O	O	O
potential	O	O	O
biomarkers	O	O	B-Entity
in	O	O	O
diagnosis	O	O	B-Entity
of	O	O	O
malignant	O	O	B-Entity
hematological	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

-DOCSTART- (28511890)

Intratympanic	O	O	B-Entity
steroid	O	O	B-Entity
delivery	O	O	I-Entity
by	O	O	O
an	O	O	O
indwelling	O	O	B-Entity
catheter	O	O	I-Entity
in	O	O	O
refractory	O	O	O
severe	O	O	O
sudden	O	O	O
sensorineural	O	O	O
hearing	O	O	O
loss	O	O	O

Many	O	O	O
studies	O	O	O
over	O	O	O
the	O	O	O
last	O	O	O
decade	O	O	B-Entity
showed	O	O	O
favorable	O	O	O
outcomes	O	O	B-Entity
with	O	O	O
intratympanic	O	O	B-Entity
(	O	O	O
IT	O	O	B-Entity
)	O	O	O
steroid	O	O	B-Entity
treatment	O	O	O
,	O	O	O
alone	O	O	O
as	O	O	O
salvage	O	O	B-Entity
treatment	O	O	I-Entity
or	O	O	O
in	O	O	O
combination	O	O	O
with	O	O	O
conventional	O	O	O
systemic	O	O	B-Entity
therapy	O	O	I-Entity
(	O	O	O
ST	O	O	B-Entity
)	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
in	O	O	O
severe	O	O	O
to	O	O	O
profound	O	O	O
sensorineural	O	O	B-Entity
hearing	O	O	I-Entity
loss	O	O	I-Entity
resistant	O	O	B-Entity
to	O	O	O
ST	O	O	B-Entity
,	O	O	O
the	O	O	O
optimal	O	O	O
infusion	O	O	B-Entity
mode	O	O	I-Entity
,	O	O	O
the	O	O	O
type	O	O	B-Entity
and	O	O	O
concentration	O	O	B-Entity
of	O	O	O
the	O	O	O
solution	O	O	B-Entity
,	O	O	O
the	O	O	O
preferable	O	O	O
drug	O	O	B-Entity
,	O	O	O
its	O	O	O
total	O	O	B-Entity
amount	O	O	I-Entity
,	O	O	O
and	O	O	O
the	O	O	O
duration	O	O	B-Entity
and	O	O	O
fractionation	O	O	B-Entity
of	O	O	O
the	O	O	O
treatment	O	O	B-Entity
are	O	O	O
still	O	O	O
debated	O	O	O
.	O	O	O

Aim	O	O	O
of	O	O	O
the	O	O	O
study	O	O	O
was	O	O	O
to	O	O	O
investigate	O	O	B-Entity
the	O	O	O
feasibility	O	O	O
and	O	O	O
the	O	O	O
outcomes	O	O	B-Entity
of	O	O	O
a	O	O	O
direct	O	O	B-Entity
and	O	O	I-Entity
constant	O	O	I-Entity
IT	O	O	I-Entity
delivery	O	O	I-Entity
of	O	O	O
dexamethasone	O	O	B-Entity
(	O	O	O
DEX	O	O	B-Entity
)	O	O	O
by	O	O	O
means	O	O	O
of	O	O	O
a	O	O	O
new	O	O	O
indwelling	O	O	B-Entity
catheter	O	O	I-Entity
.	O	O	O

A	O	O	O
prospective	O	O	B-Entity
case-control	O	O	I-Entity
study	O	O	I-Entity
in	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
referral	O	O	I-Entity
university	O	O	I-Entity
hospital	O	O	I-Entity
.	O	O	O

Ninety-nine	O	O	O
subjects	O	O	B-Entity
treated	O	O	B-Entity
with	O	O	O
ST	O	O	B-Entity
only	O	O	O
and	O	O	O
28	O	O	O
with	O	O	O
additional	O	O	O
IT	O	O	B-Entity
DEX	O	O	B-Entity
have	O	O	O
been	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
study	O	O	O
.	O	O	O

A	O	O	O
4	O	O	B-Entity
Fr	O	O	I-Entity
catheter	O	O	I-Entity
inserted	O	O	B-Entity
in	O	O	O
a	O	O	O
sub-annular	O	O	B-Entity
fashion	O	O	I-Entity
with	O	O	O
a	O	O	O
minimal	O	O	O
postero-inferior	O	O	B-Entity
tympanotomy	O	O	B-Entity
through	O	O	O
and	O	O	O
endocanalar	O	O	B-Entity
approach	O	O	I-Entity
under	O	O	O
local	O	O	B-Entity
anesthesia	O	O	I-Entity
.	O	O	O

DEX	O	O	B-Entity
4mg/ml	O	O	O
delivered	O	O	O
daily	O	O	O
,	O	O	O
up	O	O	O
to	O	O	O
7	O	O	O
days	O	O	B-Entity
.	O	O	O

Daily	O	O	O
bone	O	O	B-Entity
and	O	O	I-Entity
air-conducted	O	O	I-Entity
pure	O	O	I-Entity
tone	O	O	I-Entity
and	O	O	O
speech	O	O	B-Entity
audiometry	O	O	I-Entity
were	O	O	O
performed	O	O	O
with	O	O	O
a	O	O	O
follow-up	O	O	O
at	O	O	O
1	O	O	O
,	O	O	O
3	O	O	O
,	O	O	O
6	O	O	O
months	O	O	B-Entity
after	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Twenty-one	O	O	O
out	O	O	O
of	O	O	O
28	O	O	O
patients	O	O	B-Entity
(	O	O	O
75	O	O	O
%	O	O	O
)	O	O	O
refractory	O	O	B-Entity
to	O	O	O
ST	O	O	B-Entity
gained	O	O	O
on	O	O	O
average	O	O	O
24.0dB±20.5dB	O	O	O
HL	O	O	B-Entity
after	O	O	O
IT	O	O	B-Entity
-	O	O	O
DEX	O	O	B-Entity
,	O	O	O
compared	O	O	O
to	O	O	O
35.4	O	O	O
%	O	O	O
(	O	O	O
average	O	O	O
6.7dB±16.6dB	O	O	O
HL	O	O	O
)	O	O	O
of	O	O	O
those	O	O	O
receiving	O	O	O
only	O	O	O
medical	O	O	O
ST	O	O	O
(	O	O	O
p<0.001	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
significant	O	O	O
side	O	O	B-Entity
effects	O	O	I-Entity
were	O	O	O
noted	O	O	O
.	O	O	O

In	O	O	O
severe	O	O	O
to	O	O	O
profound	O	O	O
sudden	O	O	B-Entity
deafness	O	O	I-Entity
refractory	O	O	B-Entity
to	O	O	O
conventional	O	O	O
ST	O	O	B-Entity
,	O	O	O
the	O	O	O
daily	O	O	O
perfusion	O	O	B-Entity
of	O	O	O
4mg/ml	O	O	O
DEX	O	O	B-Entity
through	O	O	O
an	O	O	O
intratympanic	O	O	B-Entity
catheter	O	O	B-Entity
is	O	O	O
an	O	O	O
easy	O	O	O
,	O	O	O
well	O	O	O
accepted	O	O	O
procedure	O	O	O
that	O	O	O
enables	O	O	O
patients	O	O	B-Entity
to	O	O	O
receive	O	O	O
a	O	O	O
drug	O	O	B-Entity
in	O	O	O
the	O	O	O
middle	O	O	B-Entity
ear	O	O	I-Entity
in	O	O	O
a	O	O	O
repeatable	O	O	B-Entity
or	O	O	O
sustained	O	O	B-Entity
form	O	O	I-Entity
,	O	O	O
with	O	O	O
minimal	O	O	O
discomfort	O	O	B-Entity
and	O	O	I-Entity
a	O	O	I-Entity
partial	O	O	I-Entity
rescue	O	O	I-Entity
(	O	O	O
67.86	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
a	O	O	O
speech	O	O	B-Entity
recognition	O	O	I-Entity
gain	O	O	O
of	O	O	O
39	O	O	O
%	O	O	O
.	O	O	O

-DOCSTART- (28511906)

Design	O	O	B-Entity
,	O	O	O
synthesis	O	O	B-Entity
and	O	O	O
anti-tumor	O	O	B-Entity
activity	O	O	I-Entity
study	O	O	B-Entity
of	O	O	O
novel	O	O	O
histone	O	O	B-Entity
deacetylase	O	O	I-Entity
inhibitors	O	O	I-Entity
containing	O	O	O
isatin	O	O	B-Entity
-based	O	O	O
caps	O	O	B-Entity
and	O	O	O
o-phenylenediamine	O	O	B-Entity
-based	O	O	O
zinc	O	O	O
binding	O	O	O
groups	O	O	O

As	O	O	O
a	O	O	O
hot	O	O	O
topic	O	O	O
of	O	O	O
epigenetic	O	O	B-Entity
studies	O	O	I-Entity
,	O	O	O
histone	O	O	B-Entity
deacetylases	O	O	I-Entity
(	O	O	O
HDACs	O	O	B-Entity
)	O	O	O
are	O	O	O
related	O	O	O
to	O	O	O
lots	O	O	O
of	O	O	O
diseases	O	O	B-Entity
,	O	O	O
especially	O	O	O
cancer	O	O	B-Entity
.	O	O	O

Further	O	O	O
researches	O	O	B-Entity
indicated	O	O	O
that	O	O	O
different	O	O	B-Entity
HDAC	O	O	B-Entity
isoforms	O	O	I-Entity
played	O	O	O
various	O	O	O
roles	O	O	B-Entity
in	O	O	O
a	O	O	O
wide	O	O	O
range	O	O	O
of	O	O	O
tumor	O	O	B-Entity
types	O	O	I-Entity
.	O	O	O

Herein	O	O	O
a	O	O	O
novel	O	O	O
series	O	O	B-Entity
of	O	O	O
HDAC	O	O	B-Entity
inhibitors	O	O	I-Entity
with	O	O	O
isatin	O	O	B-Entity
-based	O	O	O
caps	O	O	B-Entity
and	O	O	O
o-phenylenediamine	O	O	B-Entity
-based	O	O	O
zinc	O	O	B-Entity
binding	O	O	I-Entity
groups	O	O	I-Entity
have	O	O	O
been	O	O	O
designed	O	O	B-Entity
and	O	O	O
synthesized	O	O	B-Entity
through	O	O	B-Entity
scaffold	O	O	B-Entity
hopping	O	O	I-Entity
strategy	O	O	I-Entity
.	O	O	O

Among	O	O	O
these	O	O	O
compounds	O	O	B-Entity
,	O	O	O
the	O	O	O
most	O	O	O
potent	O	O	O
compound	O	O	B-Entity
9n	O	O	I-Entity
exhibited	O	O	O
similar	O	O	O
if	O	O	O
not	O	O	O
better	O	O	B-Entity
HDAC	O	O	B-Entity
inhibition	O	O	B-Entity
and	O	O	O
antiproliferative	O	O	B-Entity
activities	O	O	I-Entity
against	O	O	O
multiple	O	O	B-Entity
tumor	O	O	B-Entity
cell	O	O	I-Entity
lines	O	O	I-Entity
compared	O	O	B-Entity
with	O	O	O
the	O	O	O
positive	O	O	B-Entity
control	O	O	I-Entity
entinostat	O	O	B-Entity
(	O	O	O
MS-275	O	O	B-Entity
)	O	O	O
.	O	O	O

Additionally	O	O	O
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
MS-275	O	O	B-Entity
(	O	O	O
IC50	O	O	B-Entity
values	O	O	B-Entity
for	O	O	O
HDAC1	O	O	B-Entity
,	O	O	O
2	O	O	B-Entity
and	O	O	O
3	O	O	B-Entity
were	O	O	O
0.163	O	O	O
,	O	O	O
0.396	O	O	O
and	O	O	O
0.605µM	O	O	O
,	O	O	O
respectively	O	O	O
)	O	O	O
,	O	O	O
compound	O	O	B-Entity
9n	O	O	I-Entity
with	O	O	O
IC50	O	O	O
values	O	O	O
of	O	O	O
0.032	O	O	O
,	O	O	O
0.256	O	O	O
and	O	O	O
0.311µM	O	O	O
for	O	O	O
HDAC1	O	O	O
,	O	O	O
2	O	O	O
and	O	O	O
3	O	O	O
respectively	O	O	O
,	O	O	O
showed	O	O	O
a	O	O	O
moderate	O	O	O
HDAC1	O	O	O
selectivity	O	O	B-Entity
.	O	O	O

-DOCSTART- (28514486)

Efficacy	O	O	B-Entity
of	O	O	O
42	O	O	O
Pharmacologic	O	O	B-Entity
Cotreatment	O	O	B-Entity
Strategies	O	O	O
Added	O	O	O
to	O	O	O
Antipsychotic	O	O	B-Entity
Monotherapy	O	O	B-Entity
in	O	O	O
Schizophrenia	O	O	B-Entity
:	O	O	O
Systematic	O	O	O
Overview	O	O	O
and	O	O	O
Quality	O	O	B-Entity
Appraisal	O	O	O
of	O	O	O
the	O	O	O
Meta-analytic	O	O	B-Entity
Evidence	O	O	O

Limited	O	O	O
treatment	O	O	B-Entity
responses	O	O	B-Entity
in	O	O	O
schizophrenia	O	O	B-Entity
prompted	O	O	O
the	O	O	O
testing	O	O	O
of	O	O	O
combining	O	O	O
an	O	O	O
antipsychotic	O	O	B-Entity
drug	O	O	I-Entity
treatment	O	O	O
with	O	O	O
a	O	O	O
second	O	O	O
psychotropic	O	O	B-Entity
medication	O	O	B-Entity
.	O	O	O

A	O	O	O
comprehensive	O	O	O
evaluation	O	O	B-Entity
of	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
multiple	O	O	O
medication	O	O	B-Entity
combinations	O	O	B-Entity
is	O	O	O
missing	O	O	O
.	O	O	O

To	O	O	O
summarize	O	O	O
and	O	O	O
compare	O	O	O
the	O	O	O
meta-analytically	O	O	B-Entity
determined	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
pharmacologic	O	O	B-Entity
combination	O	O	B-Entity
strategies	O	O	O
of	O	O	O
antipsychotic	O	O	B-Entity
drugs	O	O	I-Entity
in	O	O	O
adults	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

Systematic	O	O	O
search	O	O	O
of	O	O	O
PubMed	O	O	B-Entity
and	O	O	O
PsycInfo	O	O	B-Entity
until	O	O	O
May	O	O	O
13	O	O	O
,	O	O	O
2016	O	O	O
.	O	O	O

Meta-analyses	O	O	B-Entity
of	O	O	O
randomized	O	O	B-Entity
clinical	O	O	I-Entity
trials	O	O	I-Entity
comparing	O	O	O
the	O	O	O
efficacy	O	O	B-Entity
of	O	O	O
antipsychotic	O	O	B-Entity
drugs	O	O	I-Entity
combined	O	O	O
with	O	O	O
other	O	O	O
antipsychotic	O	O	O
or	O	O	O
nonantipsychotic	O	O	B-Entity
medications	O	O	I-Entity
vs	O	O	O
placebos	O	O	B-Entity
or	O	O	O
antipsychotic	O	O	O
monotherapy	O	O	B-Entity
among	O	O	O
adults	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
.	O	O	O

Independent	O	O	O
reviewers	O	O	B-Entity
extracted	O	O	O
the	O	O	O
data	O	O	B-Entity
and	O	O	O
assessed	O	O	O
the	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
methods	O	O	B-Entity
of	O	O	O
the	O	O	O
included	O	O	O
meta-analyses	O	O	B-Entity
using	O	O	O
A	O	O	O
Measurement	O	O	B-Entity
Tool	O	O	I-Entity
to	O	O	I-Entity
Assess	O	O	I-Entity
Systematic	O	O	I-Entity
Reviews	O	O	I-Entity
(	O	O	O
AMSTAR	O	O	B-Entity
)	O	O	O
,	O	O	O
adding	O	O	O
6	O	O	O
new	O	O	O
items	O	O	O
to	O	O	O
rate	O	O	O
their	O	O	O
quality	O	O	O
.	O	O	O

Effect	O	O	B-Entity
sizes	O	O	I-Entity
,	O	O	O
expressed	O	O	O
as	O	O	O
standardized	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
/Hedges	O	O	O
g	O	O	O
or	O	O	O
risk	O	O	B-Entity
ratio	O	O	I-Entity
,	O	O	O
were	O	O	O
compared	O	O	O
separately	O	O	O
for	O	O	O
combinations	O	O	B-Entity
with	O	O	O
any	O	O	O
antipsychotic	O	O	B-Entity
drug	O	O	I-Entity
and	O	O	O
for	O	O	O
combinations	O	O	O
with	O	O	O
clozapine	O	O	B-Entity
.	O	O	O

The	O	O	O
primary	O	O	O
outcome	O	O	O
was	O	O	O
total	O	O	O
symptom	O	O	B-Entity
reduction	O	O	B-Entity
.	O	O	O

Secondary	O	O	O
outcomes	O	O	O
included	O	O	O
positive	O	O	B-Entity
and	O	O	O
negative	O	O	B-Entity
symptoms	O	O	B-Entity
,	O	O	O
treatment	O	O	B-Entity
recommendations	O	O	I-Entity
by	O	O	O
authors	O	O	O
,	O	O	O
study-defined	O	O	O
inefficacies	O	O	B-Entity
,	O	O	O
cognitive	O	O	B-Entity
and	O	O	O
depressive	O	O	B-Entity
symptoms	O	O	I-Entity
,	O	O	O
discontinuation	O	O	B-Entity
of	O	O	O
treatment	O	O	O
because	O	O	O
of	O	O	O
any	O	O	O
cause	O	O	O
,	O	O	O
and	O	O	O
inefficacies	O	O	O
or	O	O	O
intolerabilities	O	O	O
.	O	O	O

Of	O	O	O
3397	O	O	O
publications	O	O	O
,	O	O	O
29	O	O	O
meta-analyses	O	O	B-Entity
testing	O	O	O
42	O	O	O
combination	O	O	B-Entity
strategies	O	O	O
in	O	O	O
381	O	O	O
individual	O	O	B-Entity
trials	O	O	O
and	O	O	O
among	O	O	O
19	O	O	O
833	O	O	O
participants	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

For	O	O	O
total	O	O	O
symptom	O	O	B-Entity
reductions	O	O	B-Entity
,	O	O	O
32	O	O	O
strategies	O	O	O
that	O	O	O
augmented	O	O	O
any	O	O	O
antipsychotic	O	O	B-Entity
drug	O	O	I-Entity
and	O	O	O
5	O	O	O
strategies	O	O	O
that	O	O	O
augmented	O	O	O
clozapine	O	O	B-Entity
were	O	O	O
examined	O	O	O
.	O	O	O

Fourteen	O	O	O
combination	O	O	B-Entity
treatments	O	O	B-Entity
outperformed	O	O	O
controls	O	O	O
(	O	O	O
standard	O	O	B-Entity
mean	O	O	I-Entity
difference	O	O	I-Entity
/Hedges	O	O	O
g	O	O	O
,	O	O	O
-1.27	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
-2.35	O	O	O
to	O	O	O
-0.19	O	O	O
]	O	O	O
to	O	O	O
-0.23	O	O	O
[	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
-0.44	O	O	O
to	O	O	O
-0.02	O	O	O
]	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.05	O	O	O
)	O	O	O
.	O	O	O

No	O	O	O
combination	O	O	B-Entity
strategies	O	O	O
with	O	O	O
clozapine	O	O	B-Entity
outperformed	O	O	O
controls	O	O	O
.	O	O	O

The	O	O	O
quality	O	O	B-Entity
of	O	O	O
the	O	O	O
methods	O	O	B-Entity
of	O	O	O
the	O	O	O
meta-analyses	O	O	B-Entity
was	O	O	O
generally	O	O	O
high	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
score	O	O	I-Entity
,	O	O	O
9	O	O	O
of	O	O	O
a	O	O	O
maximum	O	O	B-Entity
score	O	O	I-Entity
of	O	O	O
11	O	O	O
)	O	O	O
but	O	O	O
the	O	O	O
quality	O	O	O
of	O	O	O
the	O	O	O
meta-analyzed	O	O	B-Entity
studies	O	O	I-Entity
was	O	O	O
low	O	O	B-Entity
(	O	O	O
mean	O	O	O
score	O	O	O
,	O	O	O
2.8	O	O	O
of	O	O	O
a	O	O	O
maximum	O	O	O
score	O	O	O
of	O	O	O
8)	O	O	O
.	O	O	O

Treatment	O	O	B-Entity
recommendations	O	O	I-Entity
correlated	O	O	O
with	O	O	O
the	O	O	O
effect	O	O	B-Entity
size	O	O	I-Entity
(	O	O	O
correlation	O	O	B-Entity
coefficient	O	O	I-Entity
,	O	O	O
0.22	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	B-Entity
,	O	O	O
0.35	O	O	O
-	O	O	O
0.10	O	O	O
;	O	O	O
P	O	O	O
<	O	O	O
.001	O	O	O
)	O	O	O
,	O	O	O
yet	O	O	O
effect	O	O	B-Entity
sizes	O	O	I-Entity
were	O	O	O
inversely	O	O	O
correlated	O	O	O
with	O	O	O
study	O	O	O
quality	O	O	B-Entity
(	O	O	O
correlation	O	O	O
coefficient	O	O	O
,	O	O	O
-0.06	O	O	O
;	O	O	O
95	O	O	O
%	O	O	O
CI	O	O	O
,	O	O	O
0.01	O	O	O
to	O	O	O
-0.12	O	O	O
;	O	O	O
P	O	O	O
=	O	O	O
.02	O	O	O
)	O	O	O
.	O	O	O

Meta-analyses	O	O	B-Entity
of	O	O	O
21	O	O	O
interventions	O	O	O
fully	O	O	O
or	O	O	O
partially	O	O	O
recommended	O	O	O
their	O	O	O
use	O	O	O
,	O	O	O
with	O	O	O
recommendations	O	O	B-Entity
being	O	O	O
positively	O	O	B-Entity
correlated	O	O	O
with	O	O	O
the	O	O	O
effect	O	O	B-Entity
sizes	O	O	I-Entity
of	O	O	O
the	O	O	O
pooled	O	O	O
intervention	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
effect	O	O	B-Entity
sizes	O	O	I-Entity
were	O	O	O
inversely	O	O	O
correlated	O	O	O
with	O	O	O
meta-analyzed	O	O	B-Entity
study	O	O	I-Entity
quality	O	O	B-Entity
,	O	O	O
reducing	O	O	B-Entity
confidence	O	O	B-Entity
in	O	O	O
these	O	O	O
recommendations	O	O	B-Entity
.	O	O	O

Higher	O	O	B-Entity
-	O	O	O
quality	O	O	B-Entity
trials	O	O	O
and	O	O	O
patient	O	O	B-Entity
-based	O	O	O
meta-analyses	O	O	B-Entity
are	O	O	O
needed	O	O	O
to	O	O	O
determine	O	O	O
whether	O	O	O
subpopulations	O	O	B-Entity
might	O	O	O
benefit	O	O	O
from	O	O	O
combination	O	O	B-Entity
treatment	O	O	B-Entity
,	O	O	O
as	O	O	O
no	O	O	O
single	O	O	O
strategy	O	O	O
can	O	O	O
be	O	O	O
recommended	O	O	O
for	O	O	O
patients	O	O	B-Entity
with	O	O	O
schizophrenia	O	O	B-Entity
based	O	O	O
on	O	O	O
the	O	O	O
current	O	O	O
meta-analytic	O	O	B-Entity
literature	O	O	B-Entity
.	O	O	O

-DOCSTART- (28515448)

Involvement	O	O	B-Entity
Of	O	O	O
Vascular	O	O	B-Entity
Aldosterone	O	O	B-Entity
Synthase	O	O	I-Entity
In	O	O	O
Phosphate	O	O	B-Entity
-	O	O	O
Induced	O	O	B-Entity
Osteogenic	O	O	B-Entity
Transformation	O	O	I-Entity
Of	O	O	O
Vascular	O	O	O
Smooth	O	O	O
Muscle	O	O	O
Cells	O	O	O

Vascular	O	O	B-Entity
calcification	O	O	I-Entity
resulting	O	O	O
from	O	O	O
hyperphosphatemia	O	O	B-Entity
is	O	O	O
a	O	O	O
major	O	O	O
determinant	O	O	O
of	O	O	O
mortality	O	O	B-Entity
in	O	O	O
chronic	O	O	B-Entity
kidney	O	O	I-Entity
disease	O	O	I-Entity
(	O	O	O
CKD	O	O	B-Entity
)	O	O	O
.	O	O	O

Vascular	O	O	B-Entity
calcification	O	O	I-Entity
is	O	O	O
driven	O	O	O
by	O	O	O
aldosterone	O	O	B-Entity
-sensitive	O	O	O
osteogenic	O	O	B-Entity
transformation	O	O	I-Entity
of	O	O	O
vascular	O	O	B-Entity
smooth	O	O	B-Entity
muscle	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
VSMCs	O	O	B-Entity
)	O	O	O
.	O	O	O

We	O	O	O
show	O	O	O
that	O	O	O
even	O	O	O
in	O	O	O
absence	O	O	B-Entity
of	O	O	O
exogenous	O	O	B-Entity
aldosterone	O	O	B-Entity
,	O	O	O
silencing	O	O	B-Entity
and	O	O	O
pharmacological	O	O	B-Entity
inhibition	O	O	I-Entity
(	O	O	O
spironolactone	O	O	B-Entity
,	O	O	O
eplerenone	O	O	B-Entity
)	O	O	O
of	O	O	O
the	O	O	O
mineralocorticoid	O	O	B-Entity
receptor	O	O	I-Entity
(	O	O	O
MR	O	O	B-Entity
)	O	O	O
ameliorated	O	O	O
phosphate	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
osteo-	O	O	B-Entity
/	O	O	O
chondrogenic	O	O	B-Entity
transformation	O	O	I-Entity
of	O	O	O
primary	O	O	B-Entity
human	O	O	B-Entity
aortic	O	O	B-Entity
smooth	O	O	B-Entity
muscle	O	O	I-Entity
cells	O	O	I-Entity
(	O	O	O
HAoSMCs	O	O	B-Entity
)	O	O	O
.	O	O	O

High	O	O	O
phosphate	O	O	B-Entity
concentrations	O	O	B-Entity
up-regulated	O	O	B-Entity
aldosterone	O	O	B-Entity
synthase	O	O	I-Entity
(	O	O	O
CYP11B2	O	O	B-Entity
)	O	O	O
expression	O	O	B-Entity
in	O	O	O
HAoSMCs	O	O	B-Entity
.	O	O	O

Silencing	O	O	B-Entity
and	O	O	O
deficiency	O	O	B-Entity
of	O	O	O
CYP11B2	O	O	B-Entity
in	O	O	O
VSMCs	O	O	B-Entity
ameliorated	O	O	O
phosphate	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
osteogenic	O	O	B-Entity
reprogramming	O	O	I-Entity
and	O	O	O
calcification	O	O	B-Entity
.	O	O	O

Phosphate	O	O	B-Entity
treatment	O	O	B-Entity
was	O	O	O
followed	O	O	O
by	O	O	O
nuclear	O	O	B-Entity
export	O	O	I-Entity
of	O	O	O
APEX1	O	O	B-Entity
,	O	O	O
a	O	O	O
CYP11B2	O	O	B-Entity
transcriptional	O	O	B-Entity
repressor	O	O	I-Entity
.	O	O	O

APEX1	O	O	B-Entity
silencing	O	O	B-Entity
up-regulated	O	O	B-Entity
CYP11B2	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
stimulated	O	O	O
osteo-	O	O	B-Entity
/	O	O	O
chondrogenic	O	O	B-Entity
transformation	O	O	I-Entity
.	O	O	O

APEX1	O	O	B-Entity
overexpression	O	O	B-Entity
blunted	O	O	O
the	O	O	O
phosphate	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
osteo-	O	O	B-Entity
/	O	O	O
chondrogenic	O	O	B-Entity
transformation	O	O	I-Entity
and	O	O	O
calcification	O	O	B-Entity
of	O	O	O
HAoSMCs	O	O	B-Entity
.	O	O	O

Cyp11b2	O	O	B-Entity
expression	O	O	B-Entity
was	O	O	O
higher	O	O	O
in	O	O	O
aortic	O	O	B-Entity
tissue	O	O	B-Entity
of	O	O	O
hyperphosphatemic	O	O	B-Entity
klotho-hypomorphic	O	O	B-Entity
(	O	O	I-Entity
kl/kl	O	O	I-Entity
)	O	O	I-Entity
mice	O	O	B-Entity
than	O	O	O
in	O	O	O
wild-type	O	O	B-Entity
mice	O	O	O
.	O	O	O

In	O	O	O
adrenalectomized	O	O	B-Entity
kl/kl	O	O	I-Entity
mice	O	O	I-Entity
,	O	O	O
spironolactone	O	O	B-Entity
treatment	O	O	B-Entity
still	O	O	O
significantly	O	O	O
ameliorated	O	O	O
aortic	O	O	B-Entity
osteoinductive	O	O	B-Entity
reprogramming	O	O	I-Entity
.	O	O	O

Our	O	O	O
findings	O	O	B-Entity
suggest	O	O	O
that	O	O	O
VSMCs	O	O	B-Entity
express	O	O	O
aldosterone	O	O	B-Entity
synthase	O	O	I-Entity
,	O	O	O
which	O	O	O
is	O	O	O
up-regulated	O	O	B-Entity
by	O	O	O
phosphate	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
disruption	O	O	B-Entity
of	O	O	O
APEX1	O	O	B-Entity
-dependent	O	O	O
gene	O	O	B-Entity
suppression	O	O	I-Entity
.	O	O	O

Vascular	O	O	B-Entity
CYP11B2	O	O	B-Entity
may	O	O	O
contribute	O	O	O
to	O	O	O
stimulation	O	O	O
of	O	O	O
VSMCs	O	O	B-Entity
osteo-	O	O	B-Entity
/	O	O	O
chondrogenic	O	O	B-Entity
transformation	O	O	I-Entity
during	O	O	O
hyperphosphatemia	O	O	B-Entity
.	O	O	O

-DOCSTART- (28516341)

Fairness	O	O	B-Entity
:	O	O	O
the	O	O	O
hidden	O	O	O
challenge	O	O	B-Entity
for	O	O	O
competency-based	O	O	O
postgraduate	O	O	O
medical	O	O	O
education	O	O	O
programs	O	O	O

Competency-based	O	O	B-Entity
medical	O	O	I-Entity
education	O	O	I-Entity
systems	O	O	I-Entity
allow	O	O	O
institutions	O	O	B-Entity
to	O	O	O
individualize	O	O	B-Entity
teaching	O	O	B-Entity
practices	O	O	I-Entity
to	O	O	O
meet	O	O	B-Entity
the	O	O	O
needs	O	O	B-Entity
of	O	O	O
diverse	O	O	B-Entity
learners	O	O	I-Entity
.	O	O	O

Yet	O	O	O
,	O	O	O
the	O	O	O
focus	O	O	O
on	O	O	O
continuous	O	O	O
improvement	O	O	B-Entity
and	O	O	O
individualization	O	O	B-Entity
of	O	O	O
curricula	O	O	B-Entity
does	O	O	O
not	O	O	O
exempt	O	O	O
programs	O	O	B-Entity
from	O	O	O
treating	O	O	O
learners	O	O	B-Entity
in	O	O	O
a	O	O	O
fair	O	O	B-Entity
manner	O	O	I-Entity
.	O	O	O

When	O	O	O
learners	O	O	B-Entity
fail	O	O	O
to	O	O	O
meet	O	O	O
key	O	O	O
competencies	O	O	B-Entity
and	O	O	O
are	O	O	O
placed	O	O	O
on	O	O	O
probation	O	O	B-Entity
or	O	O	O
dismissed	O	O	B-Entity
from	O	O	O
training	O	O	B-Entity
programs	O	O	I-Entity
,	O	O	O
issues	O	O	B-Entity
of	O	O	O
fairness	O	O	B-Entity
may	O	O	O
form	O	O	O
the	O	O	O
basis	O	O	O
of	O	O	O
their	O	O	O
legal	O	O	B-Entity
claims	O	O	I-Entity
.	O	O	O

In	O	O	O
a	O	O	O
literature	O	O	O
search	O	O	O
,	O	O	O
we	O	O	O
found	O	O	O
no	O	O	O
in-depth	O	O	O
examination	O	O	B-Entity
of	O	O	O
fairness	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
utilize	O	O	O
a	O	O	O
systems	O	O	O
lens	O	O	O
to	O	O	O
examine	O	O	B-Entity
fairness	O	O	B-Entity
within	O	O	O
postgraduate	O	O	B-Entity
medical	O	O	I-Entity
education	O	O	I-Entity
contexts	O	O	B-Entity
,	O	O	O
focusing	O	O	O
on	O	O	O
educational	O	O	B-Entity
opportunities	O	O	I-Entity
,	O	O	O
assessment	O	O	B-Entity
practices	O	O	I-Entity
,	O	O	O
decision-making	O	O	B-Entity
processes	O	O	I-Entity
,	O	O	O
fairness	O	O	O
from	O	O	O
a	O	O	O
legal	O	O	B-Entity
standpoint	O	O	I-Entity
,	O	O	O
and	O	O	O
fairness	O	O	O
in	O	O	O
the	O	O	O
context	O	O	B-Entity
of	O	O	O
the	O	O	O
learning	O	O	B-Entity
environment	O	O	I-Entity
.	O	O	O

While	O	O	O
we	O	O	O
provide	O	O	O
examples	O	O	O
of	O	O	O
fairness	O	O	B-Entity
issues	O	O	B-Entity
within	O	O	O
US	O	O	B-Entity
training	O	O	B-Entity
programs	O	O	I-Entity
,	O	O	O
concerns	O	O	O
regarding	O	O	O
fairness	O	O	O
are	O	O	O
relevant	O	O	O
in	O	O	O
any	O	O	O
medical	O	O	B-Entity
education	O	O	I-Entity
system	O	O	I-Entity
which	O	O	O
utilizes	O	O	O
a	O	O	O
competency-based	O	O	B-Entity
education	O	O	I-Entity
framework	O	O	I-Entity
.	O	O	O

Assessment	O	O	B-Entity
oversight	O	O	O
committees	O	O	B-Entity
and	O	O	O
annual	O	O	B-Entity
programmatic	O	O	I-Entity
evaluations	O	O	I-Entity
,	O	O	O
while	O	O	O
recommended	O	O	O
,	O	O	O
will	O	O	O
not	O	O	O
guarantee	O	O	O
fairness	O	O	B-Entity
within	O	O	O
postgraduate	O	O	B-Entity
medical	O	O	I-Entity
education	O	O	I-Entity
programs	O	O	I-Entity
,	O	O	O
but	O	O	O
they	O	O	O
can	O	O	O
provide	O	O	O
a	O	O	O
window	O	O	O
into	O	O	O
'	O	O	O
hidden	O	O	O
'	O	O	O
threats	O	O	O
to	O	O	O
fairness	O	O	O
,	O	O	O
as	O	O	O
everything	O	O	O
from	O	O	O
training	O	O	B-Entity
experiences	O	O	I-Entity
to	O	O	O
assessment	O	O	B-Entity
practices	O	O	I-Entity
may	O	O	O
be	O	O	O
examined	O	O	B-Entity
by	O	O	O
these	O	O	O
committees	O	O	O
.	O	O	O

One	O	O	O
of	O	O	O
the	O	O	O
first	O	O	O
steps	O	O	O
programs	O	O	B-Entity
can	O	O	O
take	O	O	O
is	O	O	O
to	O	O	O
recognize	O	O	O
that	O	O	O
threats	O	O	O
to	O	O	O
fairness	O	O	B-Entity
may	O	O	O
exist	O	O	O
in	O	O	O
any	O	O	O
educational	O	O	B-Entity
program	O	O	I-Entity
,	O	O	O
including	O	O	O
their	O	O	O
own	O	O	O
,	O	O	O
and	O	O	O
begin	O	O	O
conversations	O	O	B-Entity
about	O	O	O
how	O	O	O
to	O	O	O
address	O	O	O
these	O	O	O
issues	O	O	B-Entity
.	O	O	O

-DOCSTART- (28516841)

Us3	O	O	B-Entity
and	O	O	O
Us9	O	O	B-Entity
proteins	O	O	B-Entity
contribute	O	O	O
to	O	O	O
the	O	O	O
stromal	O	O	B-Entity
invasion	O	O	I-Entity
of	O	O	O
bovine	O	O	B-Entity
herpesvirus	O	O	I-Entity
1	O	O	I-Entity
in	O	O	O
the	O	O	O
respiratory	O	O	O
mucosa	O	O	O

Bovine	O	O	B-Entity
herpesvirus	O	O	I-Entity
1	O	O	I-Entity
(	O	O	I-Entity
BHV-1	O	O	I-Entity
)	O	O	I-Entity
infection	O	O	I-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
conjunctivitis	O	O	B-Entity
,	O	O	O
upper	O	O	B-Entity
respiratory	O	O	I-Entity
tract	O	O	I-Entity
problems	O	O	B-Entity
,	O	O	O
pneumonia	O	O	B-Entity
,	O	O	O
genital	O	O	B-Entity
disorders	O	O	I-Entity
and	O	O	O
abortion	O	O	B-Entity
.	O	O	O

BHV-1	O	O	B-Entity
is	O	O	O
able	O	O	O
to	O	O	O
spread	O	O	B-Entity
quickly	O	O	O
in	O	O	O
a	O	O	O
plaque	O	O	B-Entity
-wise	O	O	O
manner	O	O	B-Entity
and	O	O	O
invade	O	O	B-Entity
by	O	O	O
breaching	O	O	B-Entity
the	O	O	O
basement	O	O	B-Entity
membrane	O	O	I-Entity
(	O	O	B-Entity
BM	O	O	I-Entity
)	O	O	I-Entity
barrier	O	O	B-Entity
in	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
mucosa	O	O	I-Entity
.	O	O	O

BHV-1	O	O	B-Entity
Us3	O	O	B-Entity
,	O	O	O
a	O	O	O
serine/threonine	O	O	B-Entity
kinase	O	O	I-Entity
,	O	O	O
induces	O	O	B-Entity
a	O	O	O
dramatic	O	O	O
cytoskeletal	O	O	B-Entity
reorganization	O	O	I-Entity
and	O	O	O
BHV-1	O	O	O
Us9	O	O	B-Entity
,	O	O	O
a	O	O	O
tail-anchored	O	O	B-Entity
membrane	O	O	I-Entity
protein	O	O	I-Entity
,	O	O	O
is	O	O	O
required	O	O	O
for	O	O	O
axonal	O	O	B-Entity
transport	O	O	I-Entity
of	O	O	O
viruses	O	O	B-Entity
in	O	O	O
neurons	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	B-Entity
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
role	O	O	B-Entity
of	O	O	O
Us3	O	O	B-Entity
and	O	O	O
Us9	O	O	B-Entity
during	O	O	O
BHV-1	O	O	B-Entity
infection	O	O	I-Entity
in	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
mucosa	O	O	I-Entity
.	O	O	O

First	O	O	O
,	O	O	O
we	O	O	O
constructed	O	O	O
and	O	O	O
characterized	O	O	B-Entity
BHV-1	O	O	B-Entity
Us3	O	O	B-Entity
null	O	O	B-Entity
,	O	O	O
Us9	O	O	B-Entity
null	O	O	O
and	O	O	O
revertant	O	O	B-Entity
viruses	O	O	I-Entity
.	O	O	O

Then	O	O	O
,	O	O	O
we	O	O	O
analysed	O	O	B-Entity
the	O	O	O
viral	O	O	B-Entity
replication	O	O	I-Entity
and	O	O	O
plaque	O	O	B-Entity
size	O	O	B-Entity
(	O	O	O
latitude	O	O	O
)	O	O	O
in	O	O	O
Madin-Darby	O	O	B-Entity
bovine	O	O	I-Entity
kidney	O	O	I-Entity
(	O	O	O
MDBK	O	O	B-Entity
)	O	O	O
cells	O	O	B-Entity
and	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
mucosa	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
viral	O	O	B-Entity
penetration	O	O	I-Entity
depth	O	O	O
underneath	O	O	O
the	O	O	O
BM	O	O	B-Entity
of	O	O	O
the	O	O	O
respiratory	O	O	O
mucosa	O	O	O
when	O	O	O
inoculated	O	O	B-Entity
with	O	O	O
these	O	O	O
recombinant	O	O	B-Entity
viruses	O	O	I-Entity
.	O	O	O

Knockout	O	O	B-Entity
of	O	O	O
Us3	O	O	B-Entity
resulted	O	O	O
in	O	O	O
a	O	O	O
1	O	O	O
log10	O	O	O
reduction	O	O	B-Entity
in	O	O	O
viral	O	O	B-Entity
titre	O	O	I-Entity
and	O	O	O
plaque	O	O	B-Entity
size	O	O	B-Entity
(	O	O	O
latitude	O	O	B-Entity
)	O	O	O
in	O	O	O
MDBK	O	O	B-Entity
cells	O	O	I-Entity
and	O	O	O
the	O	O	O
trachea	O	O	B-Entity
mucosa	O	O	I-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	B-Entity
defects	O	O	B-Entity
in	O	O	O
the	O	O	O
cell-to-cell	O	O	B-Entity
spread	O	O	I-Entity
observed	O	O	B-Entity
for	O	O	O
BHV-1	O	O	B-Entity
Us9	O	O	B-Entity
null	O	O	B-Entity
virus	O	O	I-Entity
.	O	O	O

Both	O	O	O
BHV-1	O	O	B-Entity
Us3	O	O	B-Entity
null	O	O	B-Entity
and	O	O	O
Us9	O	O	B-Entity
null	O	O	B-Entity
viruses	O	O	I-Entity
showed	O	O	O
a	O	O	O
significant	O	O	B-Entity
reduction	O	O	B-Entity
of	O	O	O
plaque	O	O	B-Entity
penetration	O	O	B-Entity
underneath	O	O	O
the	O	O	O
BM	O	O	B-Entity
;	O	O	O
however	O	O	O
,	O	O	O
penetration	O	O	O
was	O	O	O
not	O	O	O
completely	O	O	O
inhibited	O	O	B-Entity
.	O	O	O

In	O	O	O
conclusion	O	O	B-Entity
,	O	O	O
the	O	O	O
current	O	O	O
findings	O	O	B-Entity
demonstrated	O	O	O
that	O	O	O
Us3	O	O	B-Entity
and	O	O	O
Us9	O	O	B-Entity
play	O	O	O
an	O	O	O
important	O	O	O
role	O	O	B-Entity
in	O	O	O
the	O	O	O
invasion	O	O	B-Entity
of	O	O	O
BHV-1	O	O	B-Entity
through	O	O	O
the	O	O	O
BM	O	O	B-Entity
of	O	O	O
the	O	O	O
respiratory	O	O	B-Entity
mucosa	O	O	I-Entity
,	O	O	O
which	O	O	O
shows	O	O	O
the	O	O	O
way	O	O	O
forward	O	O	O
for	O	O	O
research	O	O	B-Entity
-based	O	O	O
attenuation	O	O	B-Entity
of	O	O	O
viruses	O	O	B-Entity
in	O	O	O
order	O	O	O
to	O	O	O
make	O	O	O
safer	O	O	O
and	O	O	O
better	O	O	B-Entity
-	O	O	O
performing	O	O	B-Entity
vaccines	O	O	B-Entity
.	O	O	O

-DOCSTART- (28520661)

Traumatic	O	O	B-Entity
Brain	O	O	I-Entity
Injury	O	O	I-Entity
and	O	O	O
Depression	O	O	B-Entity
in	O	O	O
a	O	O	O
Community	O	O	B-Entity
-	O	O	O
Based	O	O	B-Entity
Sample	O	O	O
:	O	O	O
A	O	O	O
Cohort	O	O	B-Entity
Study	O	O	I-Entity
Across	O	O	O
the	O	O	O
Adult	O	O	B-Entity
Life	O	O	O
Span	O	O	O

To	O	O	O
determine	O	O	O
whether	O	O	O
self-reported	O	O	O
traumatic	O	O	B-Entity
brain	O	O	I-Entity
injuries	O	O	I-Entity
(	O	O	O
TBIs	O	O	B-Entity
)	O	O	O
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
"	O	O	O
cases	O	O	B-Entity
"	O	O	O
of	O	O	O
clinically	O	O	B-Entity
significant	O	O	I-Entity
depression	O	O	B-Entity
in	O	O	O
the	O	O	O
general	O	O	B-Entity
community	O	O	I-Entity
.	O	O	O

To	O	O	O
examine	O	O	O
interactions	O	O	B-Entity
between	O	O	O
variables	O	O	B-Entity
previously	O	O	O
linked	O	O	O
to	O	O	O
depression	O	O	B-Entity
after	O	O	O
a	O	O	O
TBI	O	O	B-Entity
.	O	O	O

Population	O	O	B-Entity
-based	O	O	O
community	O	O	B-Entity
study	O	O	B-Entity
(	O	O	O
Canberra	O	O	B-Entity
and	O	O	O
Queanbeyan	O	O	B-Entity
,	O	O	O
Australia	O	O	B-Entity
)	O	O	O
.	O	O	O

Three	O	O	B-Entity
age	O	O	B-Entity
cohorts	O	O	I-Entity
:	O	O	O
young	O	O	B-Entity
,	O	O	O
middle-aged	O	O	B-Entity
,	O	O	O
and	O	O	O
older	O	O	B-Entity
adults	O	O	B-Entity
(	O	O	O
aged	O	O	B-Entity
20	O	O	O
-	O	O	O
24	O	O	O
,	O	O	O
40	O	O	O
-	O	O	O
44	O	O	O
,	O	O	O
and	O	O	O
60	O	O	B-Entity
-	O	O	I-Entity
64	O	O	I-Entity
years	O	O	I-Entity
at	O	O	O
baseline	O	O	B-Entity
)	O	O	O
randomly	O	O	B-Entity
selected	O	O	B-Entity
from	O	O	O
the	O	O	O
electoral	O	O	O
roll	O	O	O
and	O	O	O
followed	O	O	B-Entity
across	O	O	O
3	O	O	O
waves	O	O	O
(	O	O	O
4	O	O	O
years	O	O	B-Entity
apart	O	O	I-Entity
)	O	O	O
.	O	O	O

A	O	O	O
total	O	O	O
of	O	O	O
7397	O	O	O
,	O	O	O
6621	O	O	O
,	O	O	O
and	O	O	O
6042	O	O	O
people	O	O	B-Entity
provided	O	O	O
their	O	O	O
TBI	O	O	B-Entity
history	O	O	O
in	O	O	O
waves	O	O	O
1	O	O	O
to	O	O	O
3	O	O	O
.	O	O	O

Lifetime	O	O	B-Entity
(	O	O	O
TBIlifetime	O	O	O
:	O	O	O
sustained	O	O	B-Entity
at	O	O	O
any	O	O	O
time	O	O	B-Entity
since	O	O	B-Entity
birth	O	O	B-Entity
)	O	O	O
,	O	O	O
recent	O	O	B-Entity
(	O	O	O
TBIrecent	O	O	O
:	O	O	O
in	O	O	O
the	O	O	O
preceding	O	O	B-Entity
4	O	O	O
years	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
multiple	O	O	B-Entity
(	O	O	O
TBImultiple	O	O	O
:	O	O	O
more	O	O	O
than	O	O	O
1	O	O	O
)	O	O	O
TBIs	O	O	B-Entity
,	O	O	O
current	O	O	B-Entity
depression	O	O	B-Entity
,	O	O	O
and	O	O	O
known	O	O	O
risk	O	O	B-Entity
factors	O	O	I-Entity
for	O	O	O
depression	O	O	O
(	O	O	O
age	O	O	B-Entity
,	O	O	O
sex	O	O	B-Entity
,	O	O	O
marital	O	O	B-Entity
/	O	O	O
employment	O	O	B-Entity
status	O	O	I-Entity
,	O	O	O
prior	O	O	B-Entity
history	O	O	I-Entity
of	O	O	O
depression	O	O	O
,	O	O	O
medical	O	O	B-Entity
conditions	O	O	I-Entity
,	O	O	O
recent	O	O	O
life	O	O	B-Entity
events	O	O	I-Entity
,	O	O	O
alcohol	O	O	B-Entity
consumption	O	O	I-Entity
,	O	O	O
social	O	O	B-Entity
support	O	O	I-Entity
,	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
)	O	O	O
.	O	O	O

Generalized	O	O	O
estimating	O	O	O
equations	O	O	B-Entity
demonstrated	O	O	O
a	O	O	O
significant	O	O	O
association	O	O	B-Entity
between	O	O	O
sustaining	O	O	O
a	O	O	O
TBI	O	O	B-Entity
and	O	O	O
experiencing	O	O	O
clinically	O	O	B-Entity
significant	O	O	I-Entity
depression	O	O	B-Entity
(	O	O	O
cases	O	O	B-Entity
)	O	O	O
,	O	O	O
even	O	O	O
after	O	O	O
controlling	O	O	B-Entity
for	O	O	O
multiple	O	O	B-Entity
demographic	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
/	O	O	O
lifestyle	O	O	B-Entity
factors	O	O	B-Entity
.	O	O	O

There	O	O	O
is	O	O	O
an	O	O	O
enduring	O	O	O
association	O	O	B-Entity
between	O	O	O
depression	O	O	B-Entity
and	O	O	O
TBI	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
,	O	O	O
following	O	O	O
a	O	O	O
TBI	O	O	O
,	O	O	O
individuals	O	O	B-Entity
should	O	O	O
be	O	O	O
monitored	O	O	B-Entity
and	O	O	O
supported	O	O	O
to	O	O	O
optimize	O	O	O
their	O	O	O
long-term	O	O	B-Entity
psychological	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

-DOCSTART- (28521254)

CS	O	O	B-Entity
-	O	O	O
PEG	O	O	B-Entity
decorated	O	O	O
PLGA	O	O	B-Entity
nano-prototype	O	O	I-Entity
for	O	O	O
delivery	O	O	B-Entity
of	O	O	O
bioactive	O	O	B-Entity
compounds	O	O	I-Entity
:	O	O	O
A	O	O	O
novel	O	O	B-Entity
approach	O	O	B-Entity
for	O	O	O
induction	O	O	B-Entity
of	O	O	O
apoptosis	O	O	B-Entity
in	O	O	O
HepG2	O	O	O
cell	O	O	O
line	O	O	O

Polymer	O	O	B-Entity
-	O	O	O
based	O	O	B-Entity
nanoparticles	O	O	B-Entity
are	O	O	O
used	O	O	B-Entity
as	O	O	O
vectors	O	O	B-Entity
for	O	O	O
cancer	O	O	B-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

The	O	O	O
bioactive	O	O	B-Entity
compounds	O	O	I-Entity
(	O	O	O
quercetin	O	O	B-Entity
,	O	O	O
ellagic	O	O	B-Entity
acid	O	O	I-Entity
and	O	O	O
gallic	O	O	B-Entity
acid	O	O	I-Entity
)	O	O	O
are	O	O	O
well	O	O	O
known	O	O	O
to	O	O	O
be	O	O	O
not	O	O	O
only	O	O	O
antioxidants	O	O	B-Entity
but	O	O	O
also	O	O	O
chemopreventive	O	O	B-Entity
candidates	O	O	I-Entity
against	O	O	B-Entity
various	O	O	B-Entity
types	O	O	B-Entity
of	O	O	O
cancers	O	O	B-Entity
.	O	O	O

To	O	O	O
circumvent	O	O	O
the	O	O	O
low	O	O	B-Entity
bioavailability	O	O	B-Entity
and	O	O	O
the	O	O	O
short	O	O	B-Entity
half-life	O	O	B-Entity
time	O	O	B-Entity
obstacles	O	O	B-Entity
,	O	O	O
we	O	O	O
hypothesized	O	O	O
a	O	O	O
novel	O	O	B-Entity
PLGA	O	O	B-Entity
nano-platform	O	O	I-Entity
functionalized	O	O	B-Entity
with	O	O	O
CS	O	O	B-Entity
and	O	O	O
PEG	O	O	B-Entity
to	O	O	O
encapsulate	O	O	B-Entity
these	O	O	O
phytochemicals	O	O	B-Entity
.	O	O	O

This	O	O	O
encapsulation	O	O	B-Entity
will	O	O	O
protect	O	O	B-Entity
the	O	O	O
compounds	O	O	B-Entity
from	O	O	O
the	O	O	O
phagocytic	O	O	B-Entity
uptake	O	O	I-Entity
and	O	O	O
deliver	O	O	B-Entity
PLGA-CS-PEG	O	O	B-Entity
nano-prototype	O	O	I-Entity
with	O	O	O
high	O	O	O
biodegradability	O	O	B-Entity
and	O	O	O
biosafety	O	O	B-Entity
.	O	O	O

Three	O	O	O
consequent	O	O	O
types	O	O	B-Entity
of	O	O	O
PLGA-based	O	O	B-Entity
nanocomposites	O	O	I-Entity
were	O	O	O
prepared	O	O	B-Entity
and	O	O	O
characterized	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
we	O	O	O
investigated	O	O	B-Entity
the	O	O	O
newly	O	O	O
synthesized	O	O	B-Entity
nano-formulations	O	O	B-Entity
against	O	O	B-Entity
human	O	O	B-Entity
hepatocellular	O	O	B-Entity
carcinoma	O	O	I-Entity
(	O	O	O
HepG2	O	O	B-Entity
)	O	O	O
and	O	O	O
colorectal	O	O	B-Entity
cancer	O	O	I-Entity
(	O	O	O
HCT	O	O	B-Entity
116	O	O	I-Entity
)	O	O	O
cell	O	O	B-Entity
lines	O	O	I-Entity
using	O	O	B-Entity
cell	O	O	B-Entity
growth	O	O	I-Entity
inhibition	O	O	I-Entity
assays	O	O	B-Entity
,	O	O	O
followed	O	O	B-Entity
by	O	O	I-Entity
apoptosis	O	O	B-Entity
and	O	O	O
necrosis	O	O	B-Entity
assays	O	O	O
using	O	O	O
flow	O	O	B-Entity
cytometry	O	O	I-Entity
to	O	O	O
detect	O	O	B-Entity
the	O	O	O
underlying	O	O	O
mechanism	O	O	B-Entity
of	O	O	O
HepG2	O	O	O
cell	O	O	B-Entity
death	O	O	I-Entity
.	O	O	O

Through	O	O	O
Malvern	O	O	O
Zeta	O	O	O
Sizer	O	O	O
,	O	O	O
we	O	O	O
recorded	O	O	O
that	O	O	O
the	O	O	O
average	O	O	B-Entity
diameters	O	O	B-Entity
of	O	O	O
the	O	O	O
nano-prototypes	O	O	B-Entity
ranged	O	O	O
from	O	O	O
150	O	O	O
to	O	O	O
300	O	O	O
nm	O	O	O
.	O	O	O

The	O	O	O
cytotoxic	O	O	B-Entity
activity	O	O	I-Entity
of	O	O	O
quercetin	O	O	B-Entity
,	O	O	O
ellagic	O	O	B-Entity
acid	O	O	I-Entity
,	O	O	O
and	O	O	O
gallic	O	O	B-Entity
acid	O	O	I-Entity
-	O	O	O
encapsulated	O	O	B-Entity
PLGA	O	O	B-Entity
,	O	O	O
PLGA-CS	O	O	B-Entity
,	O	O	O
and	O	O	O
PLGA-CS-PEG	O	O	B-Entity
nano-prototypes	O	O	I-Entity
it	O	O	O
has	O	O	O
been	O	O	O
found	O	O	B-Entity
that	O	O	O
they	O	O	O
reduce	O	O	B-Entity
the	O	O	O
IC50s	O	O	B-Entity
of	O	O	O
the	O	O	O
HepG2	O	O	B-Entity
cells	O	O	I-Entity
values	O	O	B-Entity
by	O	O	O
2.2	O	O	O
,	O	O	O
2.9	O	O	O
,	O	O	O
2.8-	O	O	O
folds	O	O	B-Entity
,	O	O	O
1	O	O	O
,	O	O	O
1.5	O	O	O
,	O	O	O
2.7-	O	O	O
folds	O	O	O
,	O	O	O
and	O	O	O
0.9	O	O	O
,	O	O	O
0.7	O	O	O
,	O	O	O
1.5-	O	O	O
folds	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

Mechanistically	O	O	O
,	O	O	O
the	O	O	O
nano-platforms	O	O	O
of	O	O	O
quercetin	O	O	B-Entity
seem	O	O	O
to	O	O	O
be	O	O	O
dependent	O	O	B-Entity
on	O	O	O
both	O	O	O
apoptosis	O	O	B-Entity
and	O	O	O
necrosis	O	O	B-Entity
,	O	O	O
while	O	O	O
those	O	O	O
of	O	O	O
ellagic	O	O	B-Entity
acid	O	O	I-Entity
and	O	O	O
gallic	O	O	B-Entity
acid	O	O	I-Entity
are	O	O	O
mainly	O	O	O
dependent	O	O	O
on	O	O	O
apoptosis	O	O	O
.	O	O	O

CS	O	O	B-Entity
-	O	O	O
PEG	O	O	B-Entity
-blended	O	O	O
PLGA	O	O	B-Entity
nano-delivery	O	O	B-Entity
system	O	O	I-Entity
of	O	O	O
quercetin	O	O	B-Entity
,	O	O	O
ellagic	O	O	B-Entity
acid	O	O	I-Entity
and	O	O	O
gallic	O	O	B-Entity
acid	O	O	I-Entity
can	O	O	O
potentiate	O	O	B-Entity
apoptosis-mediated	O	O	B-Entity
cell	O	O	B-Entity
death	O	O	I-Entity
in	O	O	O
HepG2	O	O	B-Entity
cell	O	O	I-Entity
line	O	O	I-Entity
.	O	O	O

-DOCSTART- (28521617)

Fingerprint	O	O	B-Entity
-based	O	O	O
background	O	O	B-Entity
checks	O	O	I-Entity
for	O	O	O
personal	O	O	B-Entity
care	O	O	I-Entity
workers	O	O	I-Entity
:	O	O	O
Stakeholder	O	O	B-Entity
views	O	O	B-Entity
of	O	O	O
policy	O	O	B-Entity
criteria	O	O	O

Decision	O	O	B-Entity
makers	O	O	I-Entity
face	O	O	O
difficult	O	O	O
choices	O	O	O
when	O	O	O
tasked	O	O	O
with	O	O	O
identifying	O	O	O
and	O	O	O
implementing	O	O	B-Entity
appropriate	O	O	O
mechanisms	O	O	B-Entity
for	O	O	O
protecting	O	O	B-Entity
the	O	O	O
elderly	O	O	B-Entity
and	O	O	O
other	O	O	O
vulnerable	O	O	B-Entity
adults	O	O	I-Entity
from	O	O	O
abuse	O	O	B-Entity
.	O	O	O

A	O	O	O
pilot	O	O	B-Entity
project	O	O	I-Entity
involving	O	O	O
fingerprint	O	O	B-Entity
-based	O	O	O
criminal	O	O	B-Entity
history	O	O	O
background	O	O	B-Entity
checks	O	O	I-Entity
for	O	O	O
personal	O	O	B-Entity
care	O	O	I-Entity
workers	O	O	I-Entity
in	O	O	O
Michigan	O	O	B-Entity
has	O	O	O
supplied	O	O	O
an	O	O	O
opportunity	O	O	B-Entity
to	O	O	O
examine	O	O	O
one	O	O	O
such	O	O	O
mechanism	O	O	B-Entity
.	O	O	O

In	O	O	O
conjunction	O	O	B-Entity
with	O	O	O
the	O	O	O
pilot	O	O	B-Entity
project	O	O	I-Entity
,	O	O	O
we	O	O	O
have	O	O	O
conducted	O	O	O
a	O	O	O
stakeholder	O	O	B-Entity
analysis	O	O	B-Entity
with	O	O	O
the	O	O	O
aim	O	O	O
of	O	O	O
informing	O	O	O
decision	O	O	B-Entity
makers	O	O	I-Entity
about	O	O	O
stakeholder	O	O	O
perceptions	O	O	B-Entity
of	O	O	O
standard	O	O	B-Entity
policy	O	O	B-Entity
criteria	O	O	B-Entity
like	O	O	O
effectiveness	O	O	B-Entity
,	O	O	O
efficiency	O	O	B-Entity
,	O	O	O
and	O	O	O
equity	O	O	B-Entity
.	O	O	O

We	O	O	O
employed	O	O	O
focus	O	O	B-Entity
groups	O	O	I-Entity
and	O	O	O
a	O	O	O
web-based	O	O	B-Entity
survey	O	O	I-Entity
to	O	O	O
collect	O	O	B-Entity
data	O	O	B-Entity
from	O	O	O
stakeholders	O	O	B-Entity
.	O	O	O

While	O	O	O
stakeholders	O	O	B-Entity
generally	O	O	O
see	O	O	O
fingerprint	O	O	B-Entity
-based	O	O	O
background	O	O	B-Entity
checks	O	O	I-Entity
for	O	O	O
personal	O	O	B-Entity
care	O	O	I-Entity
workers	O	O	I-Entity
as	O	O	O
potentially	O	O	O
effective	O	O	B-Entity
and	O	O	O
as	O	O	O
a	O	O	O
net	O	O	B-Entity
benefit	O	O	I-Entity
,	O	O	O
they	O	O	O
also	O	O	O
point	O	O	O
to	O	O	O
a	O	O	O
variety	O	O	O
of	O	O	O
contingencies	O	O	B-Entity
.	O	O	O

They	O	O	O
also	O	O	O
recognize	O	O	O
difficulties	O	O	B-Entity
and	O	O	O
constraints	O	O	B-Entity
for	O	O	O
government	O	O	B-Entity
involvement	O	O	B-Entity
.	O	O	O

This	O	O	O
preliminary	O	O	B-Entity
analysis	O	O	I-Entity
provides	O	O	O
solid	O	O	O
foundational	O	O	B-Entity
information	O	O	I-Entity
for	O	O	O
decision	O	O	B-Entity
makers	O	O	I-Entity
and	O	O	O
for	O	O	O
more	O	O	O
extensive	O	O	O
benefit-cost	O	O	B-Entity
analysis	O	O	I-Entity
.	O	O	O

-DOCSTART- (28523090)

Penetrating	O	O	B-Entity
Craniomaxillofacial	O	O	B-Entity
Injury	O	O	I-Entity
Caused	O	O	O
by	O	O	O
a	O	O	O
Pneumatic	O	O	O
Nail	O	O	O
Gun	O	O	O

Craniomaxillofacial	O	O	O
injuries	O	O	O
can	O	O	O
be	O	O	O
complex	O	O	O
,	O	O	O
requiring	O	O	O
a	O	O	O
multidisciplinary	O	O	O
approach	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	O
survey	O	O	O
is	O	O	O
always	O	O	O
the	O	O	O
first	O	O	O
step	O	O	O
in	O	O	O
trauma	O	O	O
management	O	O	O
prior	O	O	O
to	O	O	O
proceeding	O	O	O
with	O	O	O
further	O	O	O
evaluation	O	O	O
and	O	O	O
treatment	O	O	B-Entity
.	O	O	O

A	O	O	O
26-	O	O	O
year	O	O	O
-old	O	O	O
man	O	O	O
presented	O	O	O
with	O	O	O
a	O	O	O
penetrating	O	O	B-Entity
nail	O	O	O
gun	O	O	O
injury	O	O	O
through	O	O	O
the	O	O	O
oral	O	O	B-Entity
and	O	O	O
nasal	O	O	B-Entity
cavities	O	O	I-Entity
.	O	O	O

He	O	O	O
did	O	O	O
not	O	O	O
present	O	O	O
in	O	O	O
extremis	O	O	O
but	O	O	O
required	O	O	O
elective	O	O	O
endotracheal	O	O	O
intubation	O	O	O
for	O	O	O
intraoperative	O	O	O
assessment	O	O	O
and	O	O	O
treatment	O	O	B-Entity
.	O	O	O

Airway	O	O	O
management	O	O	O
was	O	O	O
enhanced	O	O	B-Entity
by	O	O	O
the	O	O	O
use	O	O	O
of	O	O	O
lingual	O	O	B-Entity
nerve	O	O	I-Entity
and	O	O	O
inferior	O	O	B-Entity
alveolar	O	O	I-Entity
nerve	O	O	I-Entity
blocks	O	O	I-Entity
via	O	O	O
the	O	O	O
Vazirani-Akinosi	O	O	O
technique	O	O	O
to	O	O	O
maintain	O	O	B-Entity
spontaneous	O	O	B-Entity
respiration	O	O	I-Entity
while	O	O	O
the	O	O	O
tongue	O	O	B-Entity
was	O	O	O
distracted	O	O	B-Entity
from	O	O	O
the	O	O	O
palate	O	O	B-Entity
.	O	O	O

The	O	O	O
nail	O	O	O
was	O	O	O
removed	O	O	O
and	O	O	O
rapid	O	O	O
sequence	O	O	O
induction	O	O	O
initiated	O	O	O
for	O	O	O
orotracheal	O	O	O
intubation	O	O	O
.	O	O	O

Local	O	O	O
nerve	O	O	O
blocks	O	O	O
can	O	O	O
be	O	O	O
an	O	O	O
effective	O	O	O
tool	O	O	O
in	O	O	O
the	O	O	O
armamentarium	O	O	O
of	O	O	O
the	O	O	O
craniomaxillofacial	O	O	O
trauma	O	O	O
surgeon	O	O	O
in	O	O	O
managing	O	O	O
blunt	O	O	O
and	O	O	O
penetrating	O	O	O
injuries	O	O	O
.	O	O	O

We	O	O	O
demonstrate	O	O	O
its	O	O	O
utility	O	O	O
in	O	O	O
airway	O	O	O
management	O	O	O
when	O	O	O
a	O	O	O
penetrating	O	O	O
foreign	O	O	O
body	O	O	O
in	O	O	O
the	O	O	O
upper	O	O	B-Entity
airway	O	O	I-Entity
precludes	O	O	O
orotracheal	O	O	O
or	O	O	O
nasotracheal	O	O	O
intubation	O	O	O
.	O	O	O

-DOCSTART- (28523722)

Design	O	O	O
of	O	O	O
a	O	O	O
candidate	O	O	O
vibrational	O	O	B-Entity
signal	O	O	I-Entity
for	O	O	O
mating	O	O	B-Entity
disruption	O	O	B-Entity
against	O	O	O
the	O	O	O
glassy-winged	O	O	B-Entity
sharpshooter	O	O	I-Entity
,	O	O	O
Homalodisca	O	O	O
vitripennis	O	O	O

The	O	O	O
glassy-winged	O	O	B-Entity
sharpshooter	O	O	I-Entity
(	O	O	O
GWSS	O	O	B-Entity
)	O	O	O
,	O	O	O
Homalodisca	O	O	B-Entity
vitripennis	O	O	I-Entity
,	O	O	O
is	O	O	O
an	O	O	O
important	O	O	O
pest	O	O	B-Entity
of	O	O	O
grapevines	O	O	B-Entity
due	O	O	O
to	O	O	O
its	O	O	O
ability	O	O	O
to	O	O	O
transmit	O	O	B-Entity
Xylella	O	O	B-Entity
fastidiosa	O	O	I-Entity
,	O	O	O
the	O	O	O
causal	O	O	B-Entity
agent	O	O	I-Entity
of	O	O	O
Pierce	O	O	B-Entity
's	O	O	I-Entity
disease	O	O	I-Entity
.	O	O	O

GWSS	O	O	B-Entity
mating	O	O	B-Entity
communication	O	O	B-Entity
is	O	O	O
based	O	O	O
on	O	O	O
vibrational	O	O	B-Entity
signals	O	O	I-Entity
;	O	O	O
therefore	O	O	O
,	O	O	O
vibrational	O	O	O
mating	O	O	O
disruption	O	O	B-Entity
could	O	O	O
be	O	O	O
an	O	O	O
alternative	O	O	B-Entity
to	O	O	O
insecticides	O	O	B-Entity
for	O	O	O
suppression	O	O	B-Entity
of	O	O	O
GWSS	O	O	O
population	O	O	B-Entity
.	O	O	O

Our	O	O	O
objectives	O	O	B-Entity
were	O	O	O
to	O	O	O
identify	O	O	O
spectral	O	O	B-Entity
features	O	O	B-Entity
of	O	O	O
female	O	O	B-Entity
signal	O	O	B-Entity
that	O	O	O
elicit	O	O	O
male	O	O	B-Entity
signaling	O	O	B-Entity
,	O	O	O
design	O	O	O
disruptive	O	O	B-Entity
signals	O	O	B-Entity
able	O	O	O
to	O	O	O
alter	O	O	B-Entity
male	O	O	O
perception	O	O	B-Entity
and	O	O	O
acceptance	O	O	B-Entity
of	O	O	O
a	O	O	O
female	O	O	O
,	O	O	O
and	O	O	O
determine	O	O	O
the	O	O	O
signal	O	O	B-Entity
intensity	O	O	I-Entity
required	O	O	O
for	O	O	O
future	O	O	O
field	O	O	O
applications	O	O	O
.	O	O	O

Results	O	O	B-Entity
showed	O	O	O
that	O	O	O
male	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
playback	O	O	B-Entity
of	O	O	O
modified	O	O	B-Entity
female	O	O	B-Entity
signals	O	O	B-Entity
were	O	O	O
significantly	O	O	B-Entity
reduced	O	O	B-Entity
by	O	O	O
60	O	O	O
-	O	O	O
75%when	O	O	O
part	O	O	O
of	O	O	O
the	O	O	O
female	O	O	O
signal	O	O	B-Entity
spectral	O	O	I-Entity
components	O	O	I-Entity
above	O	O	O
or	O	O	O
below	O	O	O
400	O	O	O
Hz	O	O	O
were	O	O	O
deleted	O	O	O
.	O	O	O

Playback	O	O	B-Entity
bioassays	O	O	B-Entity
showed	O	O	O
that	O	O	O
transmission	O	O	B-Entity
of	O	O	O
an	O	O	O
80	O	O	O
Hz	O	O	O
pure	O	O	O
frequency	O	O	B-Entity
tone	O	O	I-Entity
to	O	O	O
plants	O	O	B-Entity
completely	O	O	O
suppressed	O	O	B-Entity
male	O	O	B-Entity
signaling	O	O	B-Entity
to	O	O	O
female	O	O	B-Entity
signal	O	O	B-Entity
playback	O	O	I-Entity
,	O	O	O
even	O	O	O
if	O	O	O
the	O	O	O
disruptive	O	O	B-Entity
signal	O	O	B-Entity
amplitude	O	O	I-Entity
was	O	O	O
10	O	O	O
dB	O	O	O
lower	O	O	O
than	O	O	O
the	O	O	O
female	O	O	O
signal	O	O	O
playback	O	O	O
.	O	O	O

Although	O	O	O
the	O	O	O
mechanism	O	O	B-Entity
underlying	O	O	O
cessation	O	O	B-Entity
of	O	O	O
male	O	O	B-Entity
signaling	O	O	B-Entity
activity	O	O	O
in	O	O	O
the	O	O	O
presence	O	O	B-Entity
of	O	O	O
disruption	O	O	B-Entity
is	O	O	O
not	O	O	O
yet	O	O	O
understood	O	O	O
,	O	O	O
results	O	O	B-Entity
suggest	O	O	O
that	O	O	O
an	O	O	O
80	O	O	O
Hz	O	O	O
vibrational	O	O	B-Entity
signal	O	O	I-Entity
should	O	O	O
be	O	O	O
tested	O	O	O
in	O	O	O
laboratory	O	O	B-Entity
and	O	O	O
field	O	O	B-Entity
experiments	O	O	I-Entity
to	O	O	O
assess	O	O	B-Entity
its	O	O	O
efficacy	O	O	B-Entity
in	O	O	O
disrupting	O	O	O
mating	O	O	B-Entity
of	O	O	O
GWSS	O	O	B-Entity
.	O	O	O

-DOCSTART- (28526000)

Barriers	O	O	B-Entity
and	O	O	O
facilitators	O	O	B-Entity
to	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
in	O	O	O
a	O	O	O
cancer	O	O	B-Entity
context	O	O	B-Entity
:	O	O	O
A	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
of	O	O	O
patient	O	O	B-Entity
,	O	O	O
family	O	O	B-Entity
and	O	O	O
professional	O	O	B-Entity
views	O	O	O

Continued	O	O	B-Entity
smoking	O	O	B-Entity
after	O	O	O
cancer	O	O	B-Entity
adversely	O	O	B-Entity
affects	O	O	I-Entity
quality	O	O	B-Entity
of	O	O	I-Entity
life	O	O	I-Entity
and	O	O	O
survival	O	O	B-Entity
,	O	O	O
but	O	O	O
one	O	O	O
fifth	O	O	O
of	O	O	O
cancer	O	O	O
survivors	O	O	B-Entity
still	O	O	O
smoke	O	O	B-Entity
.	O	O	O

Despite	O	O	O
its	O	O	O
demands	O	O	O
,	O	O	O
cancer	O	O	B-Entity
presents	O	O	O
an	O	O	O
opportunity	O	O	O
for	O	O	O
positive	O	O	B-Entity
behaviour	O	O	B-Entity
change	O	O	I-Entity
.	O	O	O

Smoking	O	O	B-Entity
often	O	O	O
occurs	O	O	O
in	O	O	O
social	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
therefore	O	O	O
interventions	O	O	B-Entity
which	O	O	O
target	O	O	B-Entity
families	O	O	B-Entity
and	O	O	O
individuals	O	O	B-Entity
may	O	O	O
be	O	O	O
more	O	O	O
successful	O	O	B-Entity
.	O	O	O

This	O	O	O
qualitative	O	O	B-Entity
study	O	O	I-Entity
explored	O	O	O
patients	O	O	B-Entity
,	O	O	O
family	O	O	B-Entity
members	O	O	I-Entity
and	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
'	O	O	O
views	O	O	B-Entity
and	O	O	O
experiences	O	O	B-Entity
of	O	O	O
smoking	O	O	B-Entity
and	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
after	O	O	O
cancer	O	O	B-Entity
,	O	O	O
in	O	O	O
order	O	O	O
to	O	O	O
inform	O	O	O
future	O	O	O
interventions	O	O	B-Entity
.	O	O	O

In-depth	O	O	B-Entity
qualitative	O	O	I-Entity
interviews	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
67	O	O	O
)	O	O	O
with	O	O	O
29	O	O	O
patients	O	O	B-Entity
,	O	O	O
14	O	O	O
family	O	O	B-Entity
members	O	O	I-Entity
and	O	O	O
24	O	O	O
health	O	O	B-Entity
professionals	O	O	I-Entity
.	O	O	O

Data	O	O	B-Entity
were	O	O	O
analysed	O	O	O
using	O	O	O
the	O	O	O
'	O	O	B-Entity
Framework	O	O	I-Entity
'	O	O	I-Entity
method	O	O	I-Entity
.	O	O	O

Few	O	O	O
patient	O	O	B-Entity
s	O	O	O
and	O	O	O
family	O	O	B-Entity
members	O	O	I-Entity
had	O	O	O
used	O	O	O
National	O	O	B-Entity
Health	O	O	I-Entity
Service	O	O	I-Entity
(	O	O	O
NHS	O	O	B-Entity
)	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
services	O	O	B-Entity
and	O	O	O
more	O	O	O
than	O	O	O
half	O	O	O
still	O	O	O
smoked	O	O	B-Entity
.	O	O	O

Most	O	O	O
recalled	O	O	O
little	O	O	O
'	O	O	O
smoking	O	O	B-Entity
-related	O	O	O
'	O	O	O
discussion	O	O	B-Entity
with	O	O	O
clinicians	O	O	B-Entity
but	O	O	O
were	O	O	O
receptive	O	O	O
to	O	O	O
talking	O	O	O
openly	O	O	O
.	O	O	O

Clinicians	O	O	B-Entity
revealed	O	O	O
several	O	O	O
barriers	O	O	B-Entity
to	O	O	O
discussion	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
'	O	O	O
continued	O	O	B-Entity
smoking	O	O	B-Entity
was	O	O	O
explained	O	O	O
by	O	O	O
the	O	O	O
stress	O	O	B-Entity
of	O	O	O
diagnosis	O	O	B-Entity
;	O	O	O
desire	O	O	O
to	O	O	O
maintain	O	O	O
personal	O	O	B-Entity
control	O	O	B-Entity
;	O	O	O
and	O	O	O
lack	O	O	B-Entity
of	O	O	O
connection	O	O	O
between	O	O	O
smoking	O	O	O
,	O	O	O
cancer	O	O	B-Entity
and	O	O	O
health	O	O	B-Entity
.	O	O	O

A	O	O	O
range	O	O	O
of	O	O	O
barriers	O	O	B-Entity
to	O	O	O
smoking	O	O	B-Entity
cessation	O	O	I-Entity
exist	O	O	O
for	O	O	O
patients	O	O	B-Entity
and	O	O	O
family	O	O	B-Entity
members	O	O	I-Entity
.	O	O	O

These	O	O	O
are	O	O	O
insufficiently	O	O	B-Entity
assessed	O	O	B-Entity
and	O	O	O
considered	O	O	O
by	O	O	O
clinicians	O	O	B-Entity
.	O	O	O

Interventions	O	O	B-Entity
must	O	O	O
be	O	O	O
more	O	O	O
effectively	O	O	O
integrated	O	O	O
into	O	O	O
routine	O	O	O
practice	O	O	O
.	O	O	O

-DOCSTART- (28526485)

Improving	O	O	B-Entity
the	O	O	O
Sexual	O	O	B-Entity
Health	O	O	I-Entity
of	O	O	O
Young	O	O	B-Entity
People	O	O	I-Entity
With	O	O	O
Mobility	O	O	B-Entity
Impairments	O	O	I-Entity
:	O	O	O
Challenges	O	O	B-Entity
and	O	O	O
Recommendations	O	O	O

This	O	O	O
mixed-method	O	O	B-Entity
study	O	O	I-Entity
(	O	O	O
a	O	O	O
)	O	O	O
describes	O	O	O
challenges	O	O	B-Entity
to	O	O	O
providing	O	O	B-Entity
sexual	O	O	B-Entity
health	O	O	I-Entity
services	O	O	B-Entity
to	O	O	O
youth	O	O	B-Entity
with	O	O	O
mobility	O	O	B-Entity
impairments	O	O	I-Entity
from	O	O	O
the	O	O	O
perspective	O	O	B-Entity
of	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
providers	O	O	I-Entity
and	O	O	O
experts	O	O	B-Entity
and	O	O	O
(	O	O	O
b	O	O	O
)	O	O	O
describes	O	O	O
and	O	O	O
compares	O	O	B-Entity
sexual	O	O	O
health	O	O	O
-related	O	O	O
experiences	O	O	B-Entity
of	O	O	O
youth	O	O	O
with	O	O	O
mobility	O	O	O
impairments	O	O	O
.	O	O	O

Secondary	O	O	B-Entity
data	O	O	I-Entity
analysis	O	O	I-Entity
of	O	O	I-Entity
My	O	O	I-Entity
Path	O	O	I-Entity
,	O	O	O
a	O	O	O
study	O	O	B-Entity
focused	O	O	B-Entity
on	O	O	O
the	O	O	O
transition	O	O	B-Entity
to	O	O	O
adulthood	O	O	B-Entity
for	O	O	O
youth	O	O	B-Entity
with	O	O	O
mobility	O	O	B-Entity
impairments	O	O	I-Entity
.	O	O	O

Using	O	O	O
an	O	O	O
exploratory	O	O	B-Entity
sequential	O	O	I-Entity
design	O	O	I-Entity
,	O	O	O
qualitative	O	O	B-Entity
data	O	O	I-Entity
(	O	O	O
n	O	O	O
=	O	O	O
10	O	O	O
)	O	O	O
were	O	O	O
analyzed	O	O	B-Entity
using	O	O	O
systematic	O	O	B-Entity
content	O	O	B-Entity
analysis	O	O	I-Entity
followed	O	O	O
by	O	O	O
quantitative	O	O	B-Entity
analysis	O	O	I-Entity
of	O	O	I-Entity
survey	O	O	I-Entity
data	O	O	I-Entity
(	O	O	O
N	O	O	O
=	O	O	O
337	O	O	O
)	O	O	O
.	O	O	O

Challenges	O	O	B-Entity
included	O	O	B-Entity
not	O	O	B-Entity
talking	O	O	I-Entity
about	O	O	O
sex	O	O	B-Entity
,	O	O	O
managing	O	O	O
sexual	O	O	B-Entity
development	O	O	I-Entity
,	O	O	O
adaptation	O	O	B-Entity
and	O	O	O
instruction	O	O	B-Entity
,	O	O	O
parent	O	O	B-Entity
roles	O	O	I-Entity
,	O	O	O
and	O	O	O
safety	O	O	B-Entity
.	O	O	O

Survey	O	O	B-Entity
data	O	O	B-Entity
showed	O	O	O
that	O	O	O
youth	O	O	B-Entity
with	O	O	O
mobility	O	O	B-Entity
impairments	O	O	I-Entity
are	O	O	O
diverse	O	O	B-Entity
in	O	O	O
their	O	O	O
experiences	O	O	B-Entity
with	O	O	O
sexual	O	O	B-Entity
behavior	O	O	I-Entity
and	O	O	O
sources	O	O	B-Entity
of	O	O	O
sexual	O	O	B-Entity
health	O	O	I-Entity
information	O	O	B-Entity
.	O	O	O

Although	O	O	O
connected	O	O	B-Entity
with	O	O	O
primary	O	O	B-Entity
care	O	O	I-Entity
providers	O	O	I-Entity
,	O	O	O
few	O	O	O
received	O	O	B-Entity
information	O	O	B-Entity
about	O	O	O
sexual	O	O	B-Entity
health	O	O	I-Entity
.	O	O	O

Interventions	O	O	B-Entity
to	O	O	O
improve	O	O	B-Entity
youths	O	O	B-Entity
'	O	O	O
well-being	O	O	B-Entity
should	O	O	O
include	O	O	B-Entity
comprehensive	O	O	B-Entity
care	O	O	I-Entity
and	O	O	O
education	O	O	B-Entity
that	O	O	O
promotes	O	O	B-Entity
and	O	O	O
supports	O	O	B-Entity
healthy	O	O	B-Entity
sexual	O	O	B-Entity
development	O	O	I-Entity
.	O	O	O

-DOCSTART- (28526692)

Understanding	O	O	B-Entity
the	O	O	O
interrelationship	O	O	B-Entity
between	O	O	O
the	O	O	O
synthesis	O	O	B-Entity
of	O	O	O
urea	O	O	B-Entity
and	O	O	O
gluconeogenesis	O	O	B-Entity
by	O	O	O
formulating	O	O	O
an	O	O	O
overall	O	O	B-Entity
balanced	O	O	O
equation	O	O	O

It	O	O	O
is	O	O	O
well	O	O	O
known	O	O	O
that	O	O	O
a	O	O	O
strong	O	O	O
metabolic	O	O	B-Entity
interrelationship	O	O	B-Entity
exists	O	O	O
between	O	O	O
ureagenesis	O	O	B-Entity
and	O	O	O
gluconeogenesis	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
,	O	O	O
we	O	O	O
present	O	O	O
a	O	O	O
detailed	O	O	O
,	O	O	O
overall	O	O	B-Entity
equation	O	O	B-Entity
,	O	O	O
describing	O	O	O
a	O	O	O
possible	O	O	O
metabolic	O	O	B-Entity
link	O	O	B-Entity
between	O	O	O
ureagenesis	O	O	B-Entity
and	O	O	O
gluconeogenesis	O	O	B-Entity
.	O	O	O

We	O	O	O
adopted	O	O	O
a	O	O	O
guided	O	O	B-Entity
approach	O	O	I-Entity
in	O	O	O
which	O	O	O
we	O	O	O
strongly	O	O	O
suggest	O	O	O
that	O	O	O
students	O	O	B-Entity
,	O	O	O
when	O	O	O
faced	O	O	O
with	O	O	O
the	O	O	O
problem	O	O	B-Entity
of	O	O	O
obtaining	O	O	B-Entity
the	O	O	O
overall	O	O	B-Entity
equation	O	O	B-Entity
of	O	O	O
a	O	O	O
metabolic	O	O	B-Entity
pathway	O	O	I-Entity
,	O	O	O
carefully	O	O	O
account	O	O	O
for	O	O	O
all	O	O	O
atoms	O	O	B-Entity
and	O	O	O
charges	O	O	B-Entity
of	O	O	O
the	O	O	O
single	O	O	O
reactions	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
cellular	O	O	B-Entity
localizations	O	O	I-Entity
of	O	O	O
the	O	O	O
substrates	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
related	O	O	O
transport	O	O	B-Entity
systems	O	O	B-Entity
.	O	O	O

If	O	O	O
this	O	O	O
suggestion	O	O	O
is	O	O	O
always	O	O	O
taken	O	O	O
into	O	O	O
account	O	O	O
,	O	O	O
a	O	O	O
balanced	O	O	B-Entity
,	O	O	O
overall	O	O	B-Entity
equation	O	O	B-Entity
of	O	O	O
a	O	O	O
metabolic	O	O	B-Entity
pathway	O	O	I-Entity
will	O	O	O
be	O	O	O
obtained	O	O	O
,	O	O	O
which	O	O	O
strongly	O	O	O
facilitates	O	O	O
the	O	O	O
discussion	O	O	O
of	O	O	O
its	O	O	O
physiological	O	O	B-Entity
role	O	O	O
.	O	O	O

Unfortunately	O	O	O
,	O	O	O
textbooks	O	O	B-Entity
often	O	O	O
report	O	O	B-Entity
unbalanced	O	O	O
overall	O	O	B-Entity
equations	O	O	B-Entity
of	O	O	O
metabolic	O	O	B-Entity
pathways	O	O	I-Entity
,	O	O	O
including	O	O	O
ureagenesis	O	O	B-Entity
and	O	O	O
gluconeogenesis	O	O	B-Entity
.	O	O	O

Most	O	O	O
likely	O	O	O
the	O	O	O
reason	O	O	O
is	O	O	O
that	O	O	O
metabolism	O	O	B-Entity
and	O	O	O
enzymology	O	O	B-Entity
have	O	O	O
been	O	O	O
neglected	O	O	O
for	O	O	O
about	O	O	O
three	O	O	O
decades	O	O	O
,	O	O	O
owing	O	O	O
to	O	O	O
the	O	O	O
remarkable	O	O	O
advances	O	O	O
of	O	O	O
molecular	O	O	B-Entity
biology	O	O	I-Entity
and	O	O	O
molecular	O	O	B-Entity
genetics	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	B-Entity
,	O	O	O
we	O	O	O
strongly	O	O	O
suggest	O	O	O
that	O	O	O
students	O	O	B-Entity
,	O	O	O
when	O	O	O
faced	O	O	O
with	O	O	O
the	O	O	O
problem	O	O	O
of	O	O	O
obtaining	O	O	O
the	O	O	O
overall	O	O	B-Entity
reaction	O	O	B-Entity
of	O	O	O
a	O	O	O
metabolic	O	O	B-Entity
pathway	O	O	I-Entity
,	O	O	O
carefully	O	O	O
control	O	O	O
if	O	O	O
the	O	O	O
single	O	O	O
reactions	O	O	B-Entity
are	O	O	O
properly	O	O	O
balanced	O	O	B-Entity
for	O	O	O
atoms	O	O	B-Entity
and	O	O	O
charges	O	O	B-Entity
.	O	O	O

Following	O	O	O
this	O	O	O
suggestion	O	O	B-Entity
,	O	O	O
we	O	O	O
were	O	O	O
able	O	O	O
to	O	O	O
obtain	O	O	O
an	O	O	O
overall	O	O	B-Entity
equation	O	O	B-Entity
describing	O	O	O
the	O	O	O
metabolic	O	O	B-Entity
interrelationship	O	O	B-Entity
between	O	O	O
ureagenesis	O	O	B-Entity
and	O	O	O
gluconeogenesis	O	O	B-Entity
,	O	O	O
in	O	O	O
which	O	O	O
urea	O	O	B-Entity
and	O	O	O
glucose	O	O	B-Entity
are	O	O	O
the	O	O	O
final	O	O	B-Entity
products	O	O	B-Entity
.	O	O	O

The	O	O	O
aim	O	O	O
is	O	O	O
to	O	O	O
better	O	O	O
rationalize	O	O	B-Entity
this	O	O	O
topic	O	O	B-Entity
and	O	O	O
to	O	O	O
convince	O	O	O
students	O	O	B-Entity
and	O	O	O
teachers	O	O	B-Entity
that	O	O	O
metabolism	O	O	B-Entity
is	O	O	O
an	O	O	O
important	O	O	O
and	O	O	O
rewarding	O	O	O
chapter	O	O	B-Entity
of	O	O	O
human	O	O	B-Entity
physiology	O	O	I-Entity
.	O	O	O

-DOCSTART- (28526816)

Delineation	O	O	O
of	O	O	O
B-cell	O	O	B-Entity
Epitopes	O	O	B-Entity
of	O	O	O
Salmonella	O	O	B-Entity
enterica	O	O	I-Entity
serovar	O	O	I-Entity
Typhi	O	O	I-Entity
Hemolysin	O	O	B-Entity
E	O	O	I-Entity
:	O	O	O
Potential	O	O	B-Entity
antibody	O	O	B-Entity
therapeutic	O	O	B-Entity
target	O	O	O

Hemolysin	O	O	B-Entity
E	O	O	I-Entity
(	O	O	O
HlyE	O	O	B-Entity
)	O	O	O
is	O	O	O
an	O	O	O
immunogenic	O	O	B-Entity
novel	O	O	B-Entity
pore	O	O	B-Entity
-forming	O	O	O
toxin	O	O	B-Entity
involved	O	O	O
in	O	O	O
the	O	O	O
pathogenesis	O	O	B-Entity
of	O	O	O
typhoid	O	O	B-Entity
fever	O	O	I-Entity
.	O	O	O

Thus	O	O	O
,	O	O	O
mapping	O	O	B-Entity
of	O	O	O
B-cell	O	O	B-Entity
epitopes	O	O	B-Entity
of	O	O	O
Salmonella	O	O	B-Entity
enterica	O	O	I-Entity
serovar	O	O	I-Entity
Typhi	O	O	I-Entity
(	O	O	O
S.	O	O	B-Entity
Typhi	O	O	I-Entity
)	O	O	O
is	O	O	O
critical	O	O	B-Entity
to	O	O	O
identify	O	O	O
key	O	O	O
immunogenic	O	O	B-Entity
regions	O	O	I-Entity
of	O	O	O
HlyE.	O	O	O
A	O	O	O
random	O	O	O
20-mer	O	O	O
peptide	O	O	B-Entity
library	O	O	I-Entity
was	O	O	O
used	O	O	O
for	O	O	O
biopanning	O	O	O
with	O	O	O
enriched	O	O	O
anti-HlyE	O	O	B-Entity
polyclonal	O	O	I-Entity
antibodies	O	O	I-Entity
from	O	O	O
typhoid	O	O	B-Entity
patient	O	O	B-Entity
sera	O	O	B-Entity
.	O	O	O

Bioinformatic	O	O	B-Entity
tools	O	O	B-Entity
were	O	O	O
used	O	O	O
to	O	O	O
refine	O	O	O
,	O	O	O
analyze	O	O	B-Entity
and	O	O	O
map	O	O	B-Entity
the	O	O	O
enriched	O	O	O
peptide	O	O	B-Entity
sequences	O	O	I-Entity
against	O	O	O
the	O	O	O
protein	O	O	B-Entity
to	O	O	O
identify	O	O	O
the	O	O	O
epitopes	O	O	B-Entity
.	O	O	O

The	O	O	O
analysis	O	O	B-Entity
identified	O	O	O
both	O	O	O
linear	O	O	B-Entity
and	O	O	O
conformational	O	O	B-Entity
epitopes	O	O	B-Entity
on	O	O	O
the	O	O	O
HlyE	O	O	B-Entity
protein	O	O	I-Entity
.	O	O	O

The	O	O	O
predicted	O	O	B-Entity
linear	O	O	B-Entity
GAAAGIVAG	O	O	B-Entity
and	O	O	O
conformational	O	O	B-Entity
epitope	O	O	B-Entity
PYSQESVLSADSQNQK	O	O	B-Entity
were	O	O	O
further	O	O	O
validated	O	O	O
against	O	O	O
the	O	O	O
pooled	O	O	O
sera	O	O	B-Entity
.	O	O	O

The	O	O	O
identified	O	O	O
epitopes	O	O	B-Entity
were	O	O	O
then	O	O	O
used	O	O	O
to	O	O	O
isolate	O	O	B-Entity
epitope	O	O	B-Entity
specific	O	O	O
monoclonal	O	O	B-Entity
antibodies	O	O	I-Entity
by	O	O	O
antibody	O	O	B-Entity
phage	O	O	B-Entity
display	O	O	I-Entity
.	O	O	O

Monoclonal	O	O	B-Entity
scFv	O	O	I-Entity
antibodies	O	O	B-Entity
were	O	O	O
enriched	O	O	O
for	O	O	O
both	O	O	O
linear	O	O	B-Entity
and	O	O	O
conformational	O	O	B-Entity
epitopes	O	O	B-Entity
.	O	O	O

Molecular	O	O	B-Entity
docking	O	O	I-Entity
was	O	O	O
performed	O	O	O
to	O	O	O
elucidate	O	O	O
the	O	O	O
antigen-antibody	O	O	B-Entity
interaction	O	O	I-Entity
of	O	O	O
the	O	O	O
monoclonal	O	O	B-Entity
antibodies	O	O	I-Entity
against	O	O	O
the	O	O	O
epitopes	O	O	B-Entity
on	O	O	O
the	O	O	O
HlyE	O	O	B-Entity
monomer	O	O	B-Entity
and	O	O	O
oligomer	O	O	B-Entity
structure	O	O	I-Entity
.	O	O	O

An	O	O	O
in-depth	O	O	O
view	O	O	O
of	O	O	O
the	O	O	O
mechanistic	O	O	O
and	O	O	O
positional	O	O	B-Entity
characteristics	O	O	B-Entity
of	O	O	O
the	O	O	O
antibodies	O	O	B-Entity
and	O	O	O
epitope	O	O	B-Entity
for	O	O	O
HlyE	O	O	B-Entity
was	O	O	O
successfully	O	O	O
accomplished	O	O	O
by	O	O	O
a	O	O	O
combination	O	O	B-Entity
of	O	O	O
phage	O	O	B-Entity
display	O	O	I-Entity
and	O	O	O
bioinformatic	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

The	O	O	O
predicted	O	O	B-Entity
function	O	O	B-Entity
and	O	O	O
structure	O	O	B-Entity
of	O	O	O
the	O	O	O
antibodies	O	O	B-Entity
highlights	O	O	O
the	O	O	O
possibility	O	O	O
of	O	O	O
utilizing	O	O	O
the	O	O	O
antibodies	O	O	O
as	O	O	O
neutralizing	O	O	B-Entity
agents	O	O	I-Entity
for	O	O	O
typhoid	O	O	B-Entity
fever	O	O	I-Entity
.	O	O	O

-DOCSTART- (28532107)

Comparison	O	O	B-Entity
of	O	O	O
electrospun	O	O	B-Entity
and	O	O	O
solvent	O	O	B-Entity
cast	O	O	I-Entity
polylactic	O	O	B-Entity
acid	O	O	I-Entity
(PLA)/	O	O	O
poly(vinyl	O	O	B-Entity
alcohol	O	O	I-Entity
)	O	O	I-Entity
(	O	O	O
PVA	O	O	B-Entity
)	O	O	O
inserts	O	O	B-Entity
as	O	O	O
potential	O	O	O
ocular	O	O	B-Entity
drug	O	O	O
delivery	O	O	O
vehicles	O	O	O

The	O	O	O
purpose	O	O	O
of	O	O	O
this	O	O	O
work	O	O	O
was	O	O	O
to	O	O	O
develop	O	O	O
,	O	O	O
characterize	O	O	O
and	O	O	O
compare	O	O	O
electrospun	O	O	B-Entity
nanofiber	O	O	I-Entity
inserts	O	O	B-Entity
(	O	O	O
ENIs	O	O	B-Entity
)	O	O	O
and	O	O	O
solvent	O	O	B-Entity
cast	O	O	I-Entity
polymeric	O	O	B-Entity
inserts	O	O	O
(	O	O	O
SCIs	O	O	B-Entity
)	O	O	O
for	O	O	O
ocular	O	O	B-Entity
drug	O	O	B-Entity
delivery	O	O	I-Entity
.	O	O	O

ENI	O	O	B-Entity
and	O	O	O
SCI	O	O	B-Entity
of	O	O	O
1	O	O	O
%	O	O	O
,	O	O	O
5	O	O	O
%	O	O	O
and	O	O	O
10	O	O	O
%	O	O	O
w/w	O	O	O
dexamethasone	O	O	B-Entity
were	O	O	O
fabricated	O	O	B-Entity
using	O	O	O
a	O	O	O
blend	O	O	B-Entity
of	O	O	O
poly-lactic	O	O	B-Entity
acid	O	O	I-Entity
(	O	O	O
PLA	O	O	B-Entity
)	O	O	O
and	O	O	O
poly-vinyl	O	O	B-Entity
alcohol	O	O	I-Entity
(	O	O	O
PVA	O	O	B-Entity
)	O	O	O
.	O	O	O

Inserts	O	O	B-Entity
were	O	O	O
characterized	O	O	O
for	O	O	O
morphology	O	O	B-Entity
,	O	O	O
thickness	O	O	B-Entity
,	O	O	O
pH	O	O	B-Entity
,	O	O	O
drug	O	O	B-Entity
content	O	O	B-Entity
,	O	O	O
drug	O	O	B-Entity
crystallinity	O	O	I-Entity
,	O	O	O
in	O	O	B-Entity
vitro	O	O	I-Entity
drug	O	O	B-Entity
release	O	O	I-Entity
,	O	O	O
sterility	O	O	B-Entity
,	O	O	O
dimethylformamide	O	O	B-Entity
(	O	O	O
DMF	O	O	B-Entity
)	O	O	O
and	O	O	O
chloroform	O	O	B-Entity
content	O	O	O
,	O	O	O
and	O	O	O
cytotoxicity	O	O	B-Entity
.	O	O	O

The	O	O	O
thickness	O	O	B-Entity
of	O	O	O
1	O	O	O
%	O	O	O
,	O	O	O
5	O	O	O
%	O	O	O
,	O	O	O
and	O	O	O
10	O	O	O
%	O	O	O
dexamethasone	O	O	B-Entity
-loaded	O	O	O
ENIs	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
50μm	O	O	O
,	O	O	O
62.5μm	O	O	O
,	O	O	O
and	O	O	O
93.3μm	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
with	O	O	O
good	O	O	O
folding	O	O	B-Entity
endurance	O	O	I-Entity
.	O	O	O

SCIs	O	O	B-Entity
were	O	O	O
brittle	O	O	B-Entity
,	O	O	O
with	O	O	O
thickness	O	O	B-Entity
values	O	O	O
>	O	O	O
200μm	O	O	O
.	O	O	O

Drug	O	O	B-Entity
release	O	O	I-Entity
rates	O	O	B-Entity
from	O	O	O
1	O	O	O
%	O	O	O
,	O	O	O
5	O	O	O
%	O	O	O
and	O	O	O
10	O	O	O
%	O	O	O
ENIs	O	O	B-Entity
were	O	O	O
found	O	O	O
to	O	O	O
be	O	O	O
0.62μg/h	O	O	O
,	O	O	O
1.46μg/h	O	O	O
,	O	O	O
and	O	O	O
2.30μg/h	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
while	O	O	O
those	O	O	O
from	O	O	O
SCIs	O	O	B-Entity
were	O	O	O
erratic	O	O	O
.	O	O	O

DMF	O	O	B-Entity
content	O	O	B-Entity
in	O	O	O
ENIs	O	O	B-Entity
and	O	O	O
SCIs	O	O	B-Entity
were	O	O	O
0.007	O	O	O
%	O	O	O
w/w	O	O	O
and	O	O	O
0.123	O	O	O
%	O	O	O
w/w	O	O	O
,	O	O	O
respectively	O	O	O
,	O	O	O
while	O	O	O
chloroform	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
detected	O	O	I-Entity
.	O	O	O

No	O	O	B-Entity
cytotoxicity	O	O	B-Entity
was	O	O	O
observed	O	O	O
from	O	O	O
ENIs	O	O	B-Entity
in	O	O	O
cultured	O	O	B-Entity
bovine	O	O	B-Entity
corneal	O	O	B-Entity
endothelial	O	O	I-Entity
cells	O	O	I-Entity
for	O	O	O
up	O	O	O
to	O	O	O
24h	O	O	O
.	O	O	O

We	O	O	O
conclude	O	O	O
that	O	O	O
ENIs	O	O	B-Entity
are	O	O	O
better	O	O	O
than	O	O	O
SCIs	O	O	B-Entity
and	O	O	O
could	O	O	O
be	O	O	O
utilized	O	O	O
as	O	O	O
a	O	O	O
potential	O	O	O
delivery	O	O	B-Entity
system	O	O	I-Entity
for	O	O	O
treating	O	O	B-Entity
anterior	O	O	B-Entity
segment	O	O	I-Entity
ocular	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

-DOCSTART- (28532323)

Quantitative	O	O	B-Entity
regulation	O	O	B-Entity
of	O	O	O
histone	O	O	B-Entity
variant	O	O	I-Entity
H2A.Z	O	O	I-Entity
during	O	O	B-Entity
cell	O	O	B-Entity
cycle	O	O	I-Entity
by	O	O	O
ubiquitin	O	O	B-Entity
proteasome	O	O	I-Entity
system	O	O	I-Entity
and	O	O	O
SUMO-targeted	O	O	O
ubiquitin	O	O	O
ligases	O	O	O

Quantitative	O	O	B-Entity
control	O	O	B-Entity
of	O	O	O
histones	O	O	B-Entity
and	O	O	O
histone	O	O	B-Entity
variants	O	O	I-Entity
during	O	O	B-Entity
cell	O	O	B-Entity
cycle	O	O	I-Entity
is	O	O	O
relevant	O	O	B-Entity
to	O	O	O
their	O	O	O
epigenetic	O	O	B-Entity
functions	O	O	I-Entity
.	O	O	O

We	O	O	O
found	O	O	O
that	O	O	O
the	O	O	O
level	O	O	B-Entity
of	O	O	O
yeast	O	O	B-Entity
histone	O	O	I-Entity
variant	O	O	I-Entity
H2A.Z	O	O	I-Entity
in	O	O	O
the	O	O	O
G2/M-phase	O	O	B-Entity
is	O	O	O
actively	O	O	B-Entity
kept	O	O	O
low	O	O	O
by	O	O	O
the	O	O	O
ubiquitin	O	O	B-Entity
proteasome	O	O	I-Entity
system	O	O	I-Entity
and	O	O	O
SUMO-targeted	O	O	B-Entity
ubiquitin	O	O	I-Entity
ligases	O	O	I-Entity
.	O	O	O

Overexpression	O	O	B-Entity
of	O	O	O
H2A.Z	O	O	B-Entity
induced	O	O	B-Entity
defects	O	O	I-Entity
in	O	O	I-Entity
mitotic	O	O	I-Entity
progression	O	O	I-Entity
,	O	O	O
suggesting	O	O	B-Entity
functional	O	O	B-Entity
importance	O	O	B-Entity
of	O	O	O
this	O	O	O
quantitative	O	O	B-Entity
control	O	O	B-Entity
.	O	O	O

-DOCSTART- (28532624)

Tyrphostin	O	O	B-Entity
AG-related	O	O	I-Entity
compounds	O	O	I-Entity
attenuate	O	O	O
H2O2	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
TRPM2	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
and	O	O	O
-	O	O	O
independent	O	O	B-Entity
cellular	O	O	B-Entity
responses	O	O	O

TRPM2	O	O	B-Entity
is	O	O	O
a	O	O	O
Ca(2+)-permeable	O	O	B-Entity
channel	O	O	I-Entity
that	O	O	O
is	O	O	O
activated	O	O	B-Entity
by	O	O	O
H2O2	O	O	B-Entity
.	O	O	O

TRPM2	O	O	B-Entity
-mediated	O	O	O
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
signaling	O	O	I-Entity
has	O	O	O
been	O	O	O
implicated	O	O	O
in	O	O	O
the	O	O	O
aggravation	O	O	B-Entity
of	O	O	O
inflammatory	O	O	B-Entity
diseases	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
the	O	O	O
development	O	O	B-Entity
of	O	O	O
TRPM2	O	O	B-Entity
inhibitors	O	O	B-Entity
to	O	O	O
prevent	O	O	O
the	O	O	O
aggravation	O	O	B-Entity
of	O	O	O
these	O	O	O
diseases	O	O	B-Entity
is	O	O	O
expected	O	O	O
.	O	O	O

We	O	O	O
recently	O	O	O
reported	O	O	O
that	O	O	O
some	O	O	O
Tyrphostin	O	O	B-Entity
AG-related	O	O	I-Entity
compounds	O	O	I-Entity
inhibited	O	O	B-Entity
the	O	O	O
H2O2	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
TRPM2	O	O	B-Entity
by	O	O	O
scavenging	O	O	B-Entity
the	O	O	I-Entity
intracellular	O	O	I-Entity
hydroxyl	O	O	I-Entity
radical	O	O	I-Entity
.	O	O	O

In	O	O	O
the	O	O	O
present	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
examined	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
AG-related	O	O	B-Entity
compounds	O	O	I-Entity
on	O	O	O
H2O2	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
cellular	O	O	B-Entity
responses	O	O	B-Entity
in	O	O	O
human	O	O	B-Entity
monocytic	O	O	B-Entity
U937	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
which	O	O	O
functionally	O	O	B-Entity
express	O	O	B-Entity
TRPM2	O	O	B-Entity
.	O	O	O

The	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
AG-related	O	O	B-Entity
compounds	O	O	I-Entity
on	O	O	O
H2O2	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
intracellular	O	O	B-Entity
Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
concentrations	O	O	B-Entity
,	O	O	O
extracellular	O	O	B-Entity
signal-regulated	O	O	I-Entity
kinase	O	O	I-Entity
(	O	O	O
ERK	O	O	B-Entity
)	O	O	O
activation	O	O	B-Entity
,	O	O	O
and	O	O	O
CXCL8	O	O	B-Entity
secretion	O	O	B-Entity
were	O	O	O
assessed	O	O	O
using	O	O	O
U937	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

Ca(2	O	O	B-Entity
+	O	O	I-Entity
)	O	O	I-Entity
influxes	O	O	I-Entity
via	O	O	O
TRPM2	O	O	B-Entity
in	O	O	O
response	O	O	O
to	O	O	O
H2O2	O	O	B-Entity
were	O	O	O
blocked	O	O	B-Entity
by	O	O	O
AG-related	O	O	B-Entity
compounds	O	O	I-Entity
.	O	O	O

AG-related	O	O	B-Entity
compounds	O	O	I-Entity
also	O	O	O
inhibited	O	O	B-Entity
the	O	O	O
H2O2	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
activation	O	O	B-Entity
of	O	O	O
ERK	O	O	B-Entity
,	O	O	O
and	O	O	O
subsequent	O	O	O
secretion	O	O	B-Entity
of	O	O	O
CXCL8	O	O	B-Entity
mediated	O	O	O
by	O	O	O
TRPM2	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
and	O	O	O
-	O	O	O
independent	O	O	B-Entity
mechanisms	O	O	B-Entity
.	O	O	O

Our	O	O	O
results	O	O	O
show	O	O	O
that	O	O	O
AG-related	O	O	B-Entity
compounds	O	O	I-Entity
inhibit	O	O	B-Entity
H2O2	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
CXCL8	O	O	B-Entity
secretion	O	O	B-Entity
following	O	O	O
ERK	O	O	B-Entity
activation	O	O	B-Entity
,	O	O	O
which	O	O	O
is	O	O	O
mediated	O	O	O
by	O	O	O
TRPM2	O	O	B-Entity
-	O	O	O
dependent	O	O	B-Entity
and	O	O	O
-	O	O	O
independent	O	O	B-Entity
mechanisms	O	O	B-Entity
in	O	O	O
U937	O	O	B-Entity
cells	O	O	I-Entity
.	O	O	O

We	O	O	O
previously	O	O	O
reported	O	O	O
that	O	O	O
AG-related	O	O	B-Entity
compounds	O	O	I-Entity
blocked	O	O	B-Entity
H2O2	O	O	B-Entity
-	O	O	O
induced	O	O	B-Entity
TRPM2	O	O	B-Entity
activation	O	O	B-Entity
by	O	O	O
scavenging	O	O	B-Entity
the	O	O	I-Entity
hydroxyl	O	O	I-Entity
radical	O	O	I-Entity
.	O	O	O

The	O	O	O
inhibitory	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	O
AG-related	O	O	B-Entity
compounds	O	O	I-Entity
on	O	O	O
TRPM2	O	O	B-Entity
-	O	O	O
independent	O	O	B-Entity
responses	O	O	B-Entity
may	O	O	O
be	O	O	O
due	O	O	O
to	O	O	O
scavenging	O	O	B-Entity
of	O	O	I-Entity
the	O	O	I-Entity
hydroxyl	O	O	I-Entity
radical	O	O	I-Entity
.	O	O	O

-DOCSTART- (28532629)

Shared	O	O	B-Entity
decision	O	O	I-Entity
making	O	O	I-Entity
in	O	O	O
the	O	O	O
UK	O	O	B-Entity
:	O	O	O
Moving	O	O	O
towards	O	O	O
wider	O	O	O
uptake	O	O	O

Shared	O	O	B-Entity
decision	O	O	I-Entity
making	O	O	I-Entity
(	O	O	O
SDM	O	O	B-Entity
)	O	O	O
is	O	O	O
firmly	O	O	O
on	O	O	O
the	O	O	O
policy	O	O	B-Entity
agenda	O	O	B-Entity
in	O	O	O
the	O	O	O
UK	O	O	B-Entity
and	O	O	O
a	O	O	O
recent	O	O	O
legal	O	O	B-Entity
ruling	O	O	B-Entity
has	O	O	O
confirmed	O	O	O
its	O	O	O
importance	O	O	O
.	O	O	O

Policymakers	O	O	B-Entity
,	O	O	O
ethicists	O	O	B-Entity
,	O	O	O
professional	O	O	B-Entity
regulators	O	O	I-Entity
and	O	O	O
societies	O	O	B-Entity
,	O	O	O
patient	O	O	B-Entity
organisations	O	O	I-Entity
and	O	O	O
now	O	O	O
the	O	O	O
courts	O	O	B-Entity
are	O	O	O
committed	O	O	O
to	O	O	O
ensuring	O	O	O
that	O	O	O
SDM	O	O	B-Entity
becomes	O	O	O
the	O	O	O
norm	O	O	B-Entity
throughout	O	O	O
the	O	O	O
NHS	O	O	B-Entity
,	O	O	O
but	O	O	O
an	O	O	O
unfavourable	O	O	O
economic	O	O	B-Entity
climate	O	O	I-Entity
makes	O	O	O
this	O	O	O
especially	O	O	O
challenging	O	O	O
.	O	O	O

Considerable	O	O	O
progress	O	O	B-Entity
has	O	O	O
been	O	O	O
made	O	O	O
over	O	O	O
the	O	O	O
last	O	O	O
few	O	O	O
years	O	O	B-Entity
,	O	O	O
with	O	O	O
new	O	O	O
learning	O	O	B-Entity
from	O	O	O
demonstration	O	O	B-Entity
sites	O	O	B-Entity
,	O	O	O
various	O	O	O
initiatives	O	O	B-Entity
in	O	O	O
capacity	O	O	B-Entity
building	O	O	I-Entity
and	O	O	O
training	O	O	B-Entity
,	O	O	O
wider	O	O	O
availability	O	O	O
of	O	O	O
patient	O	O	B-Entity
decision	O	O	B-Entity
aids	O	O	I-Entity
,	O	O	O
and	O	O	O
important	O	O	O
leadership	O	O	B-Entity
initiatives	O	O	O
.	O	O	O

Enthusiasm	O	O	B-Entity
for	O	O	O
this	O	O	O
way	O	O	O
of	O	O	O
working	O	O	B-Entity
is	O	O	O
growing	O	O	O
among	O	O	O
clinicians	O	O	B-Entity
,	O	O	O
patients	O	O	B-Entity
and	O	O	O
managers	O	O	B-Entity
,	O	O	O
but	O	O	O
it	O	O	O
could	O	O	O
be	O	O	O
undermined	O	O	O
if	O	O	O
SDM	O	O	B-Entity
comes	O	O	O
to	O	O	O
be	O	O	O
seen	O	O	O
primarily	O	O	O
as	O	O	O
a	O	O	O
means	O	O	B-Entity
of	O	O	O
cost	O	O	B-Entity
control	O	O	I-Entity
.	O	O	O

-DOCSTART- (28536031)

Lactate	O	O	B-Entity
induces	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
by	O	O	O
stabilization	O	O	B-Entity
of	O	O	O
HIF1α	O	O	O

Aerobic	O	O	B-Entity
glycolysis	O	O	I-Entity
is	O	O	O
involved	O	O	O
in	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
induced	O	O	O
by	O	O	O
Wnt	O	O	B-Entity
signaling	O	O	I-Entity
or	O	O	O
PTH	O	O	B-Entity
treatment	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
it	O	O	O
is	O	O	O
still	O	O	O
unclear	O	O	O
whether	O	O	O
lactate	O	O	B-Entity
,	O	O	O
the	O	O	O
end	O	O	O
product	O	O	O
of	O	O	O
aerobic	O	O	B-Entity
glycolysis	O	O	I-Entity
,	O	O	O
plays	O	O	O
any	O	O	O
role	O	O	O
in	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
.	O	O	O

Herein	O	O	O
we	O	O	O
report	O	O	O
that	O	O	O
in	O	O	O
cultures	O	O	B-Entity
of	O	O	O
osteoblast-lineage	O	O	B-Entity
cells	O	O	I-Entity
,	O	O	O
lactate	O	O	B-Entity
promoted	O	O	O
alkaline	O	O	B-Entity
phosphatase	O	O	I-Entity
-positive	O	O	O
cell	O	O	B-Entity
formation	O	O	I-Entity
,	O	O	O
increased	O	O	O
the	O	O	O
activity	O	O	B-Entity
of	O	O	O
alkaline	O	O	O
phosphatase	O	O	O
,	O	O	O
and	O	O	O
induced	O	O	O
the	O	O	O
expression	O	O	B-Entity
of	O	O	O
osteocalcin	O	O	B-Entity
.	O	O	O

This	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
-inducing	O	O	O
effect	O	O	O
of	O	O	O
lactate	O	O	B-Entity
can	O	O	O
be	O	O	O
inhibited	O	O	B-Entity
by	O	O	O
blocking	O	O	B-Entity
its	O	O	O
entry	O	O	O
into	O	O	O
cells	O	O	B-Entity
with	O	O	O
MCT1	O	O	B-Entity
siRNA	O	O	B-Entity
or	O	O	O
inhibitors	O	O	B-Entity
,	O	O	O
and	O	O	O
by	O	O	O
interfering	O	O	O
with	O	O	O
its	O	O	O
metabolism	O	O	B-Entity
by	O	O	O
using	O	O	O
specific	O	O	O
siRNAs	O	O	B-Entity
for	O	O	O
LDHB	O	O	B-Entity
and	O	O	O
PDH	O	O	B-Entity
.	O	O	O

Moreover	O	O	O
,	O	O	O
lactate	O	O	B-Entity
stabilized	O	O	O
HIF1α	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
inhibited	O	O	B-Entity
HIF1α	O	O	O
activity	O	O	B-Entity
,	O	O	O
with	O	O	O
BAY87	O	O	B-Entity
-	O	O	I-Entity
2243	O	O	I-Entity
lowering	O	O	O
the	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
-inducing	O	O	O
effect	O	O	O
of	O	O	O
lactate	O	O	O
.	O	O	O

Thus	O	O	O
,	O	O	O
these	O	O	O
findings	O	O	B-Entity
reveal	O	O	O
an	O	O	O
unrecognized	O	O	O
role	O	O	O
for	O	O	O
aerobic	O	O	B-Entity
glycolysis	O	O	I-Entity
in	O	O	O
osteoblast	O	O	B-Entity
differentiation	O	O	I-Entity
via	O	O	O
its	O	O	O
end	O	O	O
product	O	O	O
,	O	O	O
lactate	O	O	B-Entity
.	O	O	O

-DOCSTART- (28538491)

Committee	O	O	B-Entity
Opinion	O	O	O
No.	O	O	O
701	O	O	O
Summary	O	O	O
:	O	O	O
Choosing	O	O	O
The	O	O	O
Route	O	O	B-Entity
Of	O	O	O
Hysterectomy	O	O	B-Entity
For	O	O	O
Benign	O	O	B-Entity
Disease	O	O	O

Hysterectomy	O	O	B-Entity
is	O	O	O
one	O	O	O
of	O	O	O
the	O	O	O
most	O	O	O
frequently	O	O	O
performed	O	O	O
surgical	O	O	B-Entity
procedures	O	O	I-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
States	O	O	I-Entity
.	O	O	O

Selection	O	O	B-Entity
of	O	O	O
the	O	O	O
route	O	O	B-Entity
of	O	O	O
hysterectomy	O	O	B-Entity
for	O	O	O
benign	O	O	B-Entity
causes	O	O	O
can	O	O	O
be	O	O	O
influenced	O	O	O
by	O	O	O
the	O	O	O
size	O	O	B-Entity
and	O	O	O
shape	O	O	B-Entity
of	O	O	O
the	O	O	O
vagina	O	O	B-Entity
and	O	O	O
uterus	O	O	B-Entity
;	O	O	O
accessibility	O	O	O
to	O	O	O
the	O	O	O
uterus	O	O	O
;	O	O	O
extent	O	O	O
of	O	O	O
extrauterine	O	O	B-Entity
disease	O	O	I-Entity
;	O	O	O
the	O	O	O
need	O	O	O
for	O	O	O
concurrent	O	O	O
procedures	O	O	O
;	O	O	O
surgeon	O	O	B-Entity
training	O	O	B-Entity
and	O	O	O
experience	O	O	B-Entity
;	O	O	O
average	O	O	O
case	O	O	B-Entity
volume	O	O	I-Entity
;	O	O	O
available	O	O	O
hospital	O	O	B-Entity
technology	O	O	B-Entity
,	O	O	O
devices	O	O	B-Entity
,	O	O	O
and	O	O	O
support	O	O	O
;	O	O	O
whether	O	O	O
the	O	O	O
case	O	O	O
is	O	O	O
emergent	O	O	O
or	O	O	O
scheduled	O	O	O
;	O	O	O
and	O	O	O
preference	O	O	O
of	O	O	O
the	O	O	O
informed	O	O	O
patient	O	O	B-Entity
.	O	O	O

Vaginal	O	O	B-Entity
and	O	O	O
laparoscopic	O	O	B-Entity
procedures	O	O	I-Entity
are	O	O	O
considered	O	O	O
"	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
"	O	O	O
surgical	O	O	B-Entity
approaches	O	O	I-Entity
because	O	O	O
they	O	O	O
do	O	O	O
not	O	O	O
require	O	O	O
a	O	O	O
large	O	O	O
abdominal	O	O	B-Entity
incision	O	O	I-Entity
and	O	O	O
,	O	O	O
thus	O	O	O
,	O	O	O
typically	O	O	O
are	O	O	O
associated	O	O	O
with	O	O	O
shortened	O	O	O
hospitalization	O	O	B-Entity
and	O	O	O
postoperative	O	O	B-Entity
recovery	O	O	I-Entity
times	O	O	I-Entity
compared	O	O	O
with	O	O	O
open	O	O	O
abdominal	O	O	B-Entity
hysterectomy	O	O	I-Entity
.	O	O	O

Minimally	O	O	B-Entity
invasive	O	O	I-Entity
approaches	O	O	I-Entity
to	O	O	O
hysterectomy	O	O	B-Entity
should	O	O	O
be	O	O	O
performed	O	O	O
,	O	O	O
whenever	O	O	O
feasible	O	O	O
,	O	O	O
based	O	O	O
on	O	O	O
their	O	O	O
well-documented	O	O	O
advantages	O	O	O
over	O	O	O
abdominal	O	O	B-Entity
hysterectomy	O	O	I-Entity
.	O	O	O

The	O	O	O
vaginal	O	O	B-Entity
approach	O	O	I-Entity
is	O	O	O
preferred	O	O	O
among	O	O	O
the	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
approaches	O	O	I-Entity
.	O	O	O

Laparoscopic	O	O	B-Entity
hysterectomy	O	O	I-Entity
is	O	O	O
a	O	O	O
preferable	O	O	O
alternative	O	O	O
to	O	O	O
open	O	O	O
abdominal	O	O	B-Entity
hysterectomy	O	O	I-Entity
for	O	O	O
those	O	O	O
patients	O	O	B-Entity
in	O	O	O
whom	O	O	O
a	O	O	O
vaginal	O	O	B-Entity
hysterectomy	O	O	I-Entity
is	O	O	O
not	O	O	O
indicated	O	O	O
or	O	O	O
feasible	O	O	O
.	O	O	O

Although	O	O	O
minimally	O	O	B-Entity
invasive	O	O	I-Entity
approaches	O	O	I-Entity
to	O	O	O
hysterectomy	O	O	B-Entity
are	O	O	O
the	O	O	O
preferred	O	O	O
route	O	O	B-Entity
,	O	O	O
open	O	O	B-Entity
abdominal	O	O	B-Entity
hysterectomy	O	O	I-Entity
remains	O	O	O
an	O	O	O
important	O	O	O
surgical	O	O	O
option	O	O	O
for	O	O	O
some	O	O	O
patients	O	O	B-Entity
.	O	O	O

The	O	O	O
obstetrician	O	O	B-Entity
-	O	O	O
gynecologist	O	O	B-Entity
should	O	O	O
discuss	O	O	O
the	O	O	O
options	O	O	O
with	O	O	O
patients	O	O	B-Entity
and	O	O	O
make	O	O	O
clear	O	O	O
recommendations	O	O	O
on	O	O	O
which	O	O	O
route	O	O	B-Entity
of	O	O	O
hysterectomy	O	O	B-Entity
will	O	O	O
maximize	O	O	O
benefits	O	O	B-Entity
and	O	O	O
minimize	O	O	O
risks	O	O	B-Entity
given	O	O	O
the	O	O	O
specific	O	O	O
clinical	O	O	O
situation	O	O	O
.	O	O	O

The	O	O	O
relative	O	O	O
advantages	O	O	O
and	O	O	O
disadvantages	O	O	O
of	O	O	O
the	O	O	O
approaches	O	O	B-Entity
to	O	O	O
hysterectomy	O	O	B-Entity
should	O	O	O
be	O	O	O
discussed	O	O	O
in	O	O	O
the	O	O	O
context	O	O	O
of	O	O	O
the	O	O	O
patient	O	O	B-Entity
's	O	O	O
values	O	O	O
and	O	O	O
preferences	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
patient	O	O	O
and	O	O	O
health	O	O	B-Entity
care	O	O	I-Entity
provider	O	O	I-Entity
should	O	O	O
together	O	O	O
determine	O	O	O
the	O	O	O
best	O	O	O
course	O	O	O
of	O	O	O
action	O	O	O
after	O	O	O
this	O	O	O
discussion	O	O	O
.	O	O	O

-DOCSTART- (28538990)

Measuring	O	O	B-Entity
nonlinear	O	O	B-Entity
signal	O	O	B-Entity
combination	O	O	B-Entity
using	O	O	O
EEG	O	O	O

Relatively	O	O	B-Entity
little	O	O	O
is	O	O	O
known	O	O	O
about	O	O	O
the	O	O	O
processes	O	O	B-Entity
,	O	O	O
both	O	O	O
linear	O	O	B-Entity
and	O	O	O
nonlinear	O	O	B-Entity
,	O	O	O
by	O	O	O
which	O	O	O
signals	O	O	B-Entity
are	O	O	O
combined	O	O	B-Entity
beyond	O	O	O
V1	O	O	B-Entity
.	O	O	O

By	O	O	O
presenting	O	O	O
two	O	O	O
stimulus	O	O	B-Entity
components	O	O	B-Entity
simultaneously	O	O	B-Entity
,	O	O	O
flickering	O	O	B-Entity
at	O	O	O
different	O	O	B-Entity
temporal	O	O	B-Entity
frequencies	O	O	B-Entity
(	O	O	O
frequency	O	O	B-Entity
tagging	O	O	B-Entity
)	O	O	O
while	O	O	O
measuring	O	O	B-Entity
steady-state	O	O	B-Entity
visual	O	O	B-Entity
evoked	O	O	I-Entity
potentials	O	O	I-Entity
,	O	O	O
we	O	O	O
can	O	O	O
assess	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
the	O	O	O
individual	O	O	O
components	O	O	O
,	O	O	O
including	O	O	O
direct	O	O	B-Entity
measurements	O	O	B-Entity
of	O	O	O
suppression	O	O	B-Entity
on	O	O	O
each	O	O	O
other	O	O	O
,	O	O	O
and	O	O	O
various	O	O	O
nonlinear	O	O	B-Entity
responses	O	O	O
to	O	O	O
their	O	O	O
combination	O	O	B-Entity
found	O	O	O
at	O	O	O
intermodulation	O	O	B-Entity
frequencies	O	O	O
.	O	O	O

The	O	O	O
result	O	O	B-Entity
is	O	O	O
a	O	O	O
rather	O	O	O
rich	O	O	O
dataset	O	O	B-Entity
of	O	O	O
frequencies	O	O	B-Entity
at	O	O	O
which	O	O	O
responses	O	O	B-Entity
can	O	O	O
be	O	O	O
found	O	O	O
.	O	O	O

We	O	O	O
presented	O	O	O
pairs	O	O	B-Entity
of	O	O	O
sinusoidal	O	O	B-Entity
gratings	O	O	I-Entity
at	O	O	O
different	O	O	B-Entity
temporal	O	O	B-Entity
frequencies	O	O	I-Entity
,	O	O	O
forming	O	O	O
plaid	O	O	B-Entity
patterns	O	O	I-Entity
that	O	O	O
were	O	O	O
"	O	O	O
coherent	O	O	B-Entity
"	O	O	O
(	O	O	O
looking	O	O	B-Entity
like	O	O	I-Entity
a	O	O	I-Entity
checkerboar	O	O	I-Entity
d	O	O	O
)	O	O	O
and	O	O	O
"	O	O	O
noncoherent	O	O	B-Entity
"	O	O	O
(	O	O	O
looking	O	O	O
like	O	O	O
a	O	O	O
pair	O	O	B-Entity
of	O	O	O
transparently	O	O	B-Entity
overlaid	O	O	B-Entity
gratings	O	O	I-Entity
)	O	O	O
,	O	O	O
and	O	O	O
found	O	O	O
clear	O	O	O
intermodulation	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
compound	O	O	B-Entity
stimuli	O	O	B-Entity
,	O	O	O
indicating	O	O	O
nonlinear	O	O	B-Entity
summation	O	O	B-Entity
.	O	O	O

This	O	O	O
might	O	O	O
have	O	O	O
been	O	O	O
attributed	O	O	O
to	O	O	O
cross-orientation	O	O	B-Entity
suppression	O	O	B-Entity
except	O	O	O
that	O	O	O
the	O	O	O
pattern	O	O	B-Entity
of	O	O	O
intermodulation	O	O	B-Entity
responses	O	O	B-Entity
differed	O	O	B-Entity
for	O	O	O
coherent	O	O	B-Entity
and	O	O	O
noncoherent	O	O	B-Entity
patterns	O	O	B-Entity
,	O	O	O
whereas	O	O	O
the	O	O	O
effects	O	O	B-Entity
of	O	O	I-Entity
suppression	O	O	O
(	O	O	O
measured	O	O	O
at	O	O	O
the	O	O	O
component	O	O	B-Entity
frequencies	O	O	B-Entity
)	O	O	O
did	O	O	O
not	O	O	O
.	O	O	O

A	O	O	O
two-stage	O	O	B-Entity
model	O	O	I-Entity
of	O	O	O
nonlinear	O	O	B-Entity
summation	O	O	B-Entity
involving	O	O	O
conjunction	O	O	B-Entity
detection	O	O	B-Entity
with	O	O	O
a	O	O	O
logical	O	O	B-Entity
AND	O	O	B-Entity
gate	O	O	I-Entity
described	O	O	O
the	O	O	O
data	O	O	B-Entity
well	O	O	O
,	O	O	O
capturing	O	O	O
the	O	O	O
difference	O	O	B-Entity
between	O	O	O
coherent	O	O	B-Entity
and	O	O	O
noncoherent	O	O	B-Entity
plaids	O	O	B-Entity
over	O	O	O
a	O	O	O
wide	O	O	O
array	O	O	B-Entity
of	O	O	O
possible	O	O	B-Entity
response	O	O	B-Entity
frequencies	O	O	I-Entity
.	O	O	O

Multistimulus	O	O	B-Entity
frequency	O	O	B-Entity
-tagged	O	O	O
EEG	O	O	B-Entity
in	O	O	O
combination	O	O	B-Entity
with	O	O	O
computational	O	O	B-Entity
modeling	O	O	I-Entity
may	O	O	O
be	O	O	O
a	O	O	O
very	O	O	O
valuable	O	O	O
tool	O	O	O
in	O	O	O
studying	O	O	O
the	O	O	O
conjunction	O	O	B-Entity
of	O	O	O
these	O	O	O
signals	O	O	B-Entity
.	O	O	O

In	O	O	O
the	O	O	O
current	O	O	O
study	O	O	B-Entity
the	O	O	O
results	O	O	B-Entity
suggest	O	O	O
a	O	O	O
second-order	O	O	B-Entity
mechanism	O	O	I-Entity
responding	O	O	O
selectively	O	O	B-Entity
to	O	O	O
coherent	O	O	B-Entity
plaid	O	O	B-Entity
patterns	O	O	I-Entity
.	O	O	O

-DOCSTART- (28539349)

Sleep	O	O	B-Entity
Loss	O	O	I-Entity
Promotes	O	O	B-Entity
Astrocytic	O	O	B-Entity
Phagocytosis	O	O	B-Entity
and	O	O	O
Microglial	O	O	B-Entity
Activation	O	O	I-Entity
in	O	O	O
Mouse	O	O	O
Cerebral	O	O	O
Cortex	O	O	O

We	O	O	O
previously	O	O	O
found	O	O	O
that	O	O	O
Mertk	O	O	B-Entity
and	O	O	O
its	O	O	O
ligand	O	O	B-Entity
Gas6	O	O	I-Entity
,	O	O	O
astrocytic	O	O	B-Entity
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
phagocytosis	O	O	B-Entity
,	O	O	O
are	O	O	O
upregulated	O	O	B-Entity
after	O	O	B-Entity
acute	O	O	B-Entity
sleep	O	O	B-Entity
deprivation	O	O	I-Entity
.	O	O	O

These	O	O	O
results	O	O	O
suggested	O	O	O
that	O	O	O
astrocytes	O	O	B-Entity
may	O	O	O
engage	O	O	O
in	O	O	O
phagocytic	O	O	B-Entity
activity	O	O	I-Entity
during	O	O	B-Entity
extended	O	O	B-Entity
wake	O	O	B-Entity
,	O	O	O
but	O	O	O
direct	O	O	B-Entity
evidence	O	O	B-Entity
was	O	O	O
lacking	O	O	B-Entity
.	O	O	O

Studies	O	O	B-Entity
in	O	O	O
humans	O	O	B-Entity
and	O	O	O
rodents	O	O	B-Entity
also	O	O	O
found	O	O	B-Entity
that	O	O	O
sleep	O	O	B-Entity
loss	O	O	I-Entity
increases	O	O	B-Entity
peripheral	O	O	B-Entity
markers	O	O	B-Entity
of	O	O	O
inflammation	O	O	B-Entity
,	O	O	O
but	O	O	O
whether	O	O	O
these	O	O	O
changes	O	O	B-Entity
are	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
neuroinflammation	O	O	B-Entity
and/or	O	O	O
activation	O	O	B-Entity
of	O	O	O
microglia	O	O	B-Entity
,	O	O	O
the	O	O	O
brain	O	O	B-Entity
's	O	O	I-Entity
resident	O	O	O
innate	O	O	B-Entity
immune	O	O	I-Entity
cells	O	O	I-Entity
,	O	O	O
was	O	O	O
unknown	O	O	B-Entity
.	O	O	O

Here	O	O	O
we	O	O	O
used	O	O	B-Entity
serial	O	O	B-Entity
block-face	O	O	I-Entity
scanning	O	O	I-Entity
electron	O	O	I-Entity
microscopy	O	O	I-Entity
to	O	O	O
obtain	O	O	O
3D	O	O	O
volume	O	O	B-Entity
measurements	O	O	B-Entity
of	O	O	O
synapses	O	O	B-Entity
and	O	O	O
surrounding	O	O	B-Entity
astrocytic	O	O	B-Entity
processes	O	O	B-Entity
in	O	O	O
mouse	O	O	B-Entity
frontal	O	O	B-Entity
cortex	O	O	I-Entity
after	O	O	B-Entity
6	O	O	O
-	O	O	O
8	O	O	O
h	O	O	O
of	O	O	O
sleep	O	O	B-Entity
,	O	O	O
spontaneous	O	O	B-Entity
wake	O	O	B-Entity
,	O	O	O
or	O	O	O
sleep	O	O	B-Entity
deprivation	O	O	I-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
and	O	O	O
after	O	O	O
chronic	O	O	B-Entity
(	O	O	I-Entity
∼5	O	O	I-Entity
d	O	O	I-Entity
)	O	O	I-Entity
sleep	O	O	I-Entity
restriction	O	O	I-Entity
(	O	O	O
CSR	O	O	B-Entity
)	O	O	O
.	O	O	O

Astrocytic	O	O	B-Entity
phagocytosis	O	O	B-Entity
,	O	O	O
mainly	O	O	O
of	O	O	O
presynaptic	O	O	B-Entity
components	O	O	I-Entity
of	O	O	I-Entity
large	O	O	I-Entity
synapses	O	O	I-Entity
,	O	O	O
increased	O	O	B-Entity
after	O	O	B-Entity
both	O	O	B-Entity
acute	O	O	B-Entity
and	O	O	O
chronic	O	O	B-Entity
sleep	O	O	B-Entity
loss	O	O	I-Entity
relative	O	O	B-Entity
to	O	O	O
sleep	O	O	O
and	O	O	O
wake	O	O	B-Entity
.	O	O	O

MERTK	O	O	B-Entity
expression	O	O	B-Entity
and	O	O	O
lipid	O	O	B-Entity
peroxidation	O	O	I-Entity
in	O	O	O
synaptoneurosomes	O	O	B-Entity
also	O	O	O
increased	O	O	B-Entity
to	O	O	O
a	O	O	O
similar	O	O	B-Entity
extent	O	O	B-Entity
after	O	O	B-Entity
short	O	O	B-Entity
and	O	O	O
long	O	O	B-Entity
sleep	O	O	B-Entity
loss	O	O	I-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
astrocytic	O	O	B-Entity
phagocytosis	O	O	B-Entity
may	O	O	O
represent	O	O	B-Entity
the	O	O	O
brain	O	O	B-Entity
's	O	O	I-Entity
response	O	O	B-Entity
to	O	O	O
the	O	O	O
increase	O	O	B-Entity
in	O	O	O
synaptic	O	O	B-Entity
activity	O	O	I-Entity
associated	O	O	B-Entity
with	O	O	I-Entity
prolonged	O	O	B-Entity
wake	O	O	B-Entity
,	O	O	O
clearing	O	O	B-Entity
worn	O	O	O
components	O	O	O
of	O	O	O
heavily	O	O	O
used	O	O	B-Entity
synapses	O	O	B-Entity
.	O	O	O

Using	O	O	B-Entity
confocal	O	O	B-Entity
microscopy	O	O	I-Entity
,	O	O	O
we	O	O	O
then	O	O	O
found	O	O	B-Entity
that	O	O	O
CSR	O	O	B-Entity
but	O	O	O
not	O	O	B-Entity
SD	O	O	B-Entity
mice	O	O	B-Entity
show	O	O	O
morphological	O	O	B-Entity
signs	O	O	B-Entity
of	O	O	O
microglial	O	O	B-Entity
activation	O	O	I-Entity
and	O	O	O
enhanced	O	O	B-Entity
microglial	O	O	O
phagocytosis	O	O	B-Entity
of	O	O	O
synaptic	O	O	B-Entity
elements	O	O	I-Entity
,	O	O	O
without	O	O	B-Entity
obvious	O	O	O
signs	O	O	O
of	O	O	O
neuroinflammation	O	O	B-Entity
in	O	O	O
the	O	O	O
CSF	O	O	B-Entity
.	O	O	O

Because	O	O	O
low	O	O	B-Entity
-	O	O	O
level	O	O	B-Entity
sustained	O	O	B-Entity
microglia	O	O	B-Entity
activation	O	O	I-Entity
can	O	O	O
lead	O	O	O
to	O	O	O
abnormal	O	O	B-Entity
responses	O	O	B-Entity
to	O	O	O
a	O	O	O
secondary	O	O	B-Entity
insult	O	O	B-Entity
,	O	O	O
these	O	O	O
results	O	O	B-Entity
suggest	O	O	B-Entity
that	O	O	O
chronic	O	O	B-Entity
sleep	O	O	B-Entity
loss	O	O	I-Entity
,	O	O	O
through	O	O	B-Entity
microglia	O	O	O
priming	O	O	B-Entity
,	O	O	O
may	O	O	O
predispose	O	O	O
the	O	O	O
brain	O	O	B-Entity
to	O	O	O
further	O	O	B-Entity
damage	O	O	B-Entity
.SIGNIFICANCE	O	O	O
STATEMENT	O	O	O
We	O	O	O
find	O	O	B-Entity
that	O	O	O
astrocytic	O	O	B-Entity
phagocytosis	O	O	B-Entity
of	O	O	O
synaptic	O	O	B-Entity
elements	O	O	I-Entity
,	O	O	O
mostly	O	O	O
of	O	O	O
presynaptic	O	O	B-Entity
origin	O	O	I-Entity
and	O	O	O
in	O	O	O
large	O	O	B-Entity
synapses	O	O	B-Entity
,	O	O	O
is	O	O	O
upregulated	O	O	B-Entity
already	O	O	O
after	O	O	B-Entity
a	O	O	O
few	O	O	B-Entity
hours	O	O	B-Entity
of	O	O	O
sleep	O	O	B-Entity
deprivation	O	O	I-Entity
and	O	O	O
shows	O	O	O
a	O	O	O
further	O	O	O
significant	O	O	B-Entity
increase	O	O	B-Entity
after	O	O	O
prolonged	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
sleep	O	O	O
loss	O	O	O
,	O	O	O
suggesting	O	O	O
that	O	O	O
it	O	O	O
may	O	O	O
promote	O	O	B-Entity
the	O	O	O
housekeeping	O	O	B-Entity
of	O	O	O
heavily	O	O	O
used	O	O	B-Entity
and	O	O	O
strong	O	O	B-Entity
synapses	O	O	O
in	O	O	O
response	O	O	B-Entity
to	O	O	O
the	O	O	O
increased	O	O	B-Entity
neuronal	O	O	B-Entity
activity	O	O	B-Entity
of	O	O	O
extended	O	O	B-Entity
wake	O	O	B-Entity
.	O	O	O

By	O	O	O
contrast	O	O	B-Entity
,	O	O	O
chronic	O	O	B-Entity
sleep	O	O	I-Entity
restriction	O	O	I-Entity
but	O	O	O
not	O	O	B-Entity
acute	O	O	B-Entity
sleep	O	O	B-Entity
loss	O	O	I-Entity
activates	O	O	B-Entity
microglia	O	O	B-Entity
,	O	O	O
promotes	O	O	B-Entity
their	O	O	O
phagocytic	O	O	B-Entity
activity	O	O	I-Entity
,	O	O	O
and	O	O	O
does	O	O	O
so	O	O	O
in	O	O	O
the	O	O	O
absence	O	O	B-Entity
of	O	O	O
overt	O	O	O
signs	O	O	B-Entity
of	O	O	O
neuroinflammation	O	O	B-Entity
,	O	O	O
suggesting	O	O	O
that	O	O	O
like	O	O	O
many	O	O	O
other	O	O	B-Entity
stressors	O	O	B-Entity
,	O	O	O
extended	O	O	B-Entity
sleep	O	O	B-Entity
disruption	O	O	I-Entity
may	O	O	O
lead	O	O	O
to	O	O	O
a	O	O	O
state	O	O	B-Entity
of	O	O	O
sustained	O	O	B-Entity
microglia	O	O	B-Entity
activation	O	O	I-Entity
,	O	O	O
perhaps	O	O	O
increasing	O	O	B-Entity
the	O	O	O
brain	O	O	B-Entity
's	O	O	I-Entity
susceptibility	O	O	B-Entity
to	O	O	O
other	O	O	O
forms	O	O	B-Entity
of	O	O	O
damage	O	O	B-Entity
.	O	O	O

-DOCSTART- (28540341)

Reflections	O	O	B-Entity
on	O	O	O
Hip	O	O	B-Entity
Fracture	O	O	I-Entity
Recovery	O	O	I-Entity
From	O	O	O
Older	O	O	B-Entity
Adults	O	O	I-Entity
Enrolled	O	O	O
in	O	O	O
a	O	O	O
Clinical	O	O	O
Trial	O	O	O

This	O	O	O
study	O	O	B-Entity
describes	O	O	O
patients	O	O	B-Entity
'	O	O	I-Entity
perspectives	O	O	B-Entity
on	O	O	O
recovery	O	O	B-Entity
during	O	O	O
participation	O	O	B-Entity
in	O	O	O
a	O	O	O
randomized	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
that	O	O	O
tested	O	O	B-Entity
a	O	O	O
postoperative	O	O	B-Entity
hip	O	O	B-Entity
fracture	O	O	I-Entity
management	O	O	B-Entity
program	O	O	I-Entity
(	O	O	O
B4	O	O	B-Entity
Clinic	O	O	I-Entity
)	O	O	O
,	O	O	O
compared	O	O	B-Entity
with	O	O	O
usual	O	O	B-Entity
care	O	O	I-Entity
,	O	O	O
on	O	O	O
mobility	O	O	B-Entity
.	O	O	O

Semistructured	O	O	B-Entity
qualitative	O	O	B-Entity
interviews	O	O	B-Entity
were	O	O	O
conducted	O	O	O
with	O	O	O
50	O	O	O
older	O	O	B-Entity
adults	O	O	I-Entity
with	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
(	O	O	O
from	O	O	O
both	O	O	O
groups	O	O	B-Entity
)	O	O	O
twice	O	O	O
over	O	O	O
12	O	O	O
months	O	O	O
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
32	O	O	O
women	O	O	B-Entity
(	O	O	O
64	O	O	O
%	O	O	O
)	O	O	O
and	O	O	O
18	O	O	O
men	O	O	B-Entity
(	O	O	O
36	O	O	O
%	O	O	O
)	O	O	O
participated	O	O	B-Entity
in	O	O	O
the	O	O	O
study	O	O	B-Entity
with	O	O	O
a	O	O	O
mean	O	O	B-Entity
age	O	O	B-Entity
at	O	O	O
baseline	O	O	B-Entity
of	O	O	O
82	O	O	O
(	O	O	O
range	O	O	B-Entity
=	O	O	O
65	O	O	O
-	O	O	O
98	O	O	O
)	O	O	O
years	O	O	O
.	O	O	O

A	O	O	O
total	O	O	B-Entity
of	O	O	O
40	O	O	O
participants	O	O	B-Entity
reported	O	O	B-Entity
recovery	O	O	B-Entity
goals	O	O	B-Entity
at	O	O	O
some	O	O	O
point	O	O	O
during	O	O	O
their	O	O	O
recovery	O	O	O
from	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
but	O	O	O
only	O	O	O
18	O	O	O
participants	O	O	O
realized	O	O	B-Entity
their	O	O	O
goals	O	O	O
within	O	O	O
12	O	O	O
months	O	O	O
.	O	O	O

Recovering	O	O	B-Entity
mobility	O	O	B-Entity
,	O	O	O
returning	O	O	B-Entity
to	O	O	O
prefracture	O	O	B-Entity
activities	O	O	I-Entity
,	O	O	O
and	O	O	O
obtaining	O	O	B-Entity
stable	O	O	B-Entity
health	O	O	B-Entity
were	O	O	O
the	O	O	O
most	O	O	B-Entity
commonly	O	O	B-Entity
reported	O	O	B-Entity
goals	O	O	B-Entity
.	O	O	O

Participants	O	O	B-Entity
described	O	O	O
good	O	O	B-Entity
social	O	O	B-Entity
support	O	O	I-Entity
,	O	O	O
access	O	O	B-Entity
to	O	O	O
physiotherapy	O	O	B-Entity
,	O	O	O
and	O	O	O
positive	O	O	B-Entity
perspective	O	O	B-Entity
as	O	O	O
most	O	O	B-Entity
important	O	O	B-Entity
to	O	O	O
recovery	O	O	B-Entity
.	O	O	O

These	O	O	O
factors	O	O	B-Entity
were	O	O	O
influenced	O	O	B-Entity
by	O	O	O
participants	O	O	B-Entity
'	O	O	O
knowledge	O	O	B-Entity
,	O	O	O
resources	O	O	B-Entity
,	O	O	O
and	O	O	O
monthly	O	O	O
contact	O	O	B-Entity
with	O	O	O
study	O	O	B-Entity
staff	O	O	B-Entity
(	O	O	O
perceived	O	O	B-Entity
as	O	O	O
a	O	O	O
form	O	O	O
of	O	O	O
social	O	O	B-Entity
support	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
most	O	O	B-Entity
frequently	O	O	B-Entity
reported	O	O	B-Entity
barriers	O	O	B-Entity
to	O	O	O
participants	O	O	B-Entity
'	O	O	O
recovery	O	O	B-Entity
were	O	O	O
the	O	O	O
onset	O	O	B-Entity
of	O	O	I-Entity
complications	O	O	B-Entity
,	O	O	O
pain	O	O	B-Entity
,	O	O	O
and	O	O	O
limited	O	O	B-Entity
access	O	O	I-Entity
to	O	O	O
physiotherapy	O	O	B-Entity
.	O	O	O

Potential	O	O	B-Entity
implications	O	O	B-Entity
of	O	O	O
these	O	O	O
findings	O	O	B-Entity
include	O	O	B-Entity
design	O	O	B-Entity
and	O	O	O
modification	O	O	B-Entity
of	O	O	O
new	O	O	O
or	O	O	O
preexisting	O	O	B-Entity
fracture	O	O	B-Entity
programs	O	O	B-Entity
,	O	O	O
prioritizing	O	O	B-Entity
patient	O	O	B-Entity
engagement	O	O	I-Entity
and	O	O	O
enhanced	O	O	B-Entity
knowledge	O	O	B-Entity
for	O	O	O
future	O	O	B-Entity
clinical	O	O	B-Entity
research	O	O	I-Entity
in	O	O	O
hip	O	O	B-Entity
fracture	O	O	I-Entity
recovery	O	O	I-Entity
.	O	O	O

-DOCSTART- (28542333)

It	O	O	O
takes	O	O	O
biking	O	O	O
to	O	O	O
learn	O	O	B-Entity
:	O	O	O
Physical	O	O	B-Entity
activity	O	O	I-Entity
improves	O	O	B-Entity
learning	O	O	B-Entity
a	O	O	O
second	O	O	O
language	O	O	O

Recent	O	O	O
studies	O	O	B-Entity
have	O	O	O
shown	O	O	O
that	O	O	O
concurrent	O	O	B-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
enhances	O	O	B-Entity
learning	O	O	B-Entity
a	O	O	O
completely	O	O	O
unfamiliar	O	O	O
L2	O	O	B-Entity
vocabulary	O	O	B-Entity
as	O	O	O
compared	O	O	O
to	O	O	O
learning	O	O	O
it	O	O	O
in	O	O	O
a	O	O	O
static	O	O	B-Entity
condition	O	O	B-Entity
.	O	O	O

In	O	O	O
this	O	O	O
paper	O	O	O
we	O	O	O
report	O	O	O
a	O	O	O
study	O	O	B-Entity
whose	O	O	O
aim	O	O	O
is	O	O	O
twofold	O	O	O
:	O	O	O
to	O	O	O
test	O	O	O
for	O	O	O
possible	O	O	B-Entity
positive	O	O	B-Entity
effects	O	O	B-Entity
of	O	O	I-Entity
physical	O	O	B-Entity
activity	O	O	I-Entity
when	O	O	O
L2	O	O	B-Entity
learning	O	O	B-Entity
has	O	O	O
already	O	O	O
reached	O	O	O
some	O	O	O
level	O	O	B-Entity
of	O	O	O
proficiency	O	O	B-Entity
,	O	O	O
and	O	O	O
to	O	O	O
test	O	O	O
whether	O	O	O
the	O	O	O
assumed	O	O	O
better	O	O	B-Entity
performance	O	O	B-Entity
when	O	O	O
engaged	O	O	O
in	O	O	O
physical	O	O	O
activity	O	O	O
is	O	O	O
limited	O	O	O
to	O	O	O
the	O	O	O
linguistic	O	O	B-Entity
level	O	O	O
probed	O	O	O
at	O	O	O
training	O	O	B-Entity
(	O	O	O
i.e.	O	O	O
L2	O	O	O
vocabulary	O	O	B-Entity
tested	O	O	B-Entity
by	O	O	O
means	O	O	O
of	O	O	O
a	O	O	O
Word-Picture	O	O	B-Entity
Verification	O	O	I-Entity
task	O	O	I-Entity
)	O	O	O
,	O	O	O
or	O	O	O
whether	O	O	O
it	O	O	O
extends	O	O	O
also	O	O	O
to	O	O	O
the	O	O	O
sentence	O	O	B-Entity
level	O	O	O
(	O	O	O
which	O	O	O
was	O	O	O
tested	O	O	O
by	O	O	O
means	O	O	O
of	O	O	O
a	O	O	O
Sentence	O	O	B-Entity
Semantic	O	O	I-Entity
Judgment	O	O	I-Entity
Task	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
results	O	O	O
show	O	O	O
that	O	O	O
Chinese	O	O	B-Entity
speakers	O	O	I-Entity
with	O	O	O
basic	O	O	B-Entity
knowledge	O	O	I-Entity
of	O	O	O
English	O	O	B-Entity
benefited	O	O	B-Entity
from	O	O	O
physical	O	O	B-Entity
activity	O	O	I-Entity
while	O	O	O
learning	O	O	B-Entity
a	O	O	O
set	O	O	O
of	O	O	O
new	O	O	O
words	O	O	B-Entity
.	O	O	O

Furthermore	O	O	O
,	O	O	O
their	O	O	O
better	O	O	B-Entity
performance	O	O	B-Entity
emerged	O	O	O
also	O	O	O
at	O	O	O
the	O	O	O
sentential	O	O	B-Entity
level	O	O	B-Entity
,	O	O	I-Entity
as	O	O	O
shown	O	O	O
by	O	O	O
their	O	O	O
performance	O	O	O
in	O	O	O
a	O	O	O
Semantic	O	O	B-Entity
Judgment	O	O	I-Entity
task	O	O	I-Entity
.	O	O	O

Finally	O	O	O
,	O	O	O
an	O	O	O
interesting	O	O	O
temporal	O	O	O
asymmetry	O	O	O
between	O	O	O
the	O	O	O
lexical	O	O	B-Entity
and	O	O	O
the	O	O	O
sentential	O	O	B-Entity
level	O	O	B-Entity
emerges	O	O	O
,	O	O	O
with	O	O	O
the	O	O	O
difference	O	O	O
between	O	O	O
the	O	O	O
experimental	O	O	B-Entity
and	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
emerging	O	O	O
from	O	O	O
the	O	O	O
1st	O	O	O
testing	O	O	B-Entity
session	O	O	I-Entity
at	O	O	O
the	O	O	O
lexical	O	O	O
level	O	O	O
but	O	O	O
after	O	O	O
several	O	O	O
weeks	O	O	O
at	O	O	O
the	O	O	O
sentential	O	O	O
level	O	O	O
.	O	O	O

-DOCSTART- (28543041)

The	O	O	O
added	O	O	B-Entity
value	O	O	B-Entity
of	O	O	O
cardiac	O	O	B-Entity
index	O	O	I-Entity
and	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
variation	O	O	B-Entity
monitoring	O	O	B-Entity
to	O	O	O
mean	O	O	B-Entity
arterial	O	O	I-Entity
pressure	O	O	I-Entity
-	O	O	O
guided	O	O	B-Entity
volume	O	O	I-Entity
therapy	O	O	I-Entity
in	O	O	O
moderate-risk	O	O	B-Entity
abdominal	O	O	I-Entity
surgery	O	O	I-Entity
(	O	O	O
COGUIDE	O	O	B-Entity
):	O	O	O
a	O	O	O
pragmatic	O	O	B-Entity
multicentre	O	O	B-Entity
randomised	O	O	O
controlled	O	O	O
trial	O	O	O

There	O	O	O
is	O	O	O
disagreement	O	O	B-Entity
regarding	O	O	O
the	O	O	O
benefits	O	O	B-Entity
of	O	O	O
goal-directed	O	O	B-Entity
therapy	O	O	I-Entity
in	O	O	O
moderate-risk	O	O	B-Entity
abdominal	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

Therefore	O	O	O
,	O	O	O
we	O	O	O
tested	O	O	B-Entity
the	O	O	O
hypothesis	O	O	B-Entity
that	O	O	O
the	O	O	O
addition	O	O	B-Entity
of	O	O	O
non-invasive	O	O	B-Entity
cardiac	O	O	B-Entity
index	O	O	I-Entity
and	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
variation	O	O	B-Entity
monitoring	O	O	B-Entity
to	O	O	O
mean	O	O	B-Entity
arterial	O	O	I-Entity
pressure	O	O	I-Entity
-based	O	O	O
goal-directed	O	O	B-Entity
therapy	O	O	I-Entity
would	O	O	O
reduce	O	O	B-Entity
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
complications	O	O	I-Entity
in	O	O	O
patients	O	O	B-Entity
having	O	O	O
moderate-risk	O	O	B-Entity
abdominal	O	O	I-Entity
surgery	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
pragmatic	O	O	B-Entity
multicentre	O	O	B-Entity
randomised	O	O	B-Entity
controlled	O	O	I-Entity
trial	O	O	I-Entity
,	O	O	O
we	O	O	O
randomly	O	O	B-Entity
allocated	O	O	I-Entity
244	O	O	O
patients	O	O	B-Entity
by	O	O	O
envelope	O	O	B-Entity
drawing	O	O	I-Entity
in	O	O	O
a	O	O	O
1:1	O	O	O
fashion	O	O	O
,	O	O	O
stratified	O	O	B-Entity
per	O	O	O
centre	O	O	O
.	O	O	O

All	O	O	O
patients	O	O	B-Entity
had	O	O	O
mean	O	O	B-Entity
arterial	O	O	I-Entity
pressure	O	O	I-Entity
,	O	O	O
cardiac	O	O	B-Entity
index	O	O	I-Entity
and	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
variation	O	O	B-Entity
measured	O	O	B-Entity
continuously	O	O	B-Entity
.	O	O	O

In	O	O	O
one	O	O	O
group	O	O	B-Entity
,	O	O	O
healthcare	O	O	B-Entity
professionals	O	O	I-Entity
were	O	O	O
blinded	O	O	B-Entity
to	O	O	O
cardiac	O	O	B-Entity
index	O	O	I-Entity
and	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
variation	O	O	B-Entity
values	O	O	B-Entity
and	O	O	O
were	O	O	O
asked	O	O	O
to	O	O	O
guide	O	O	O
haemodynamic	O	O	B-Entity
therapy	O	O	I-Entity
only	O	O	O
based	O	O	O
on	O	O	O
mean	O	O	B-Entity
arterial	O	O	I-Entity
pressure	O	O	I-Entity
(	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
)	O	O	O
.	O	O	O

In	O	O	O
the	O	O	O
second	O	O	O
group	O	O	B-Entity
,	O	O	O
cardiac	O	O	B-Entity
index	O	O	I-Entity
and	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
variation	O	O	B-Entity
values	O	O	B-Entity
were	O	O	O
displayed	O	O	B-Entity
and	O	O	O
kept	O	O	O
within	O	O	O
target	O	O	B-Entity
ranges	O	O	B-Entity
following	O	O	O
a	O	O	O
pre-defined	O	O	B-Entity
algorithm	O	O	I-Entity
(	O	O	O
CI-PPV	O	O	B-Entity
group	O	O	I-Entity
)	O	O	O
.	O	O	O

The	O	O	O
primary	O	O	B-Entity
endpoint	O	O	I-Entity
was	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
postoperative	O	O	B-Entity
complications	O	O	I-Entity
within	O	O	B-Entity
30	O	O	I-Entity
days	O	O	I-Entity
.	O	O	O

One	O	O	O
hundred	O	O	O
and	O	O	O
seventy-five	O	O	O
patients	O	O	B-Entity
were	O	O	O
eligible	O	O	B-Entity
for	O	O	O
final	O	O	B-Entity
analysis	O	O	B-Entity
.	O	O	O

Overall	O	O	B-Entity
complication	O	O	B-Entity
rates	O	O	I-Entity
were	O	O	O
similar	O	O	O
(	O	O	O
42/94	O	O	O
(	O	O	O
44.7	O	O	O
%	O	O	O
)	O	O	O
vs.	O	O	O
38/81	O	O	O
(	O	O	O
46.9	O	O	O
%	O	O	O
)	O	O	O
in	O	O	O
the	O	O	O
control	O	O	B-Entity
and	O	O	O
CI-PPV	O	O	B-Entity
groups	O	O	I-Entity
,	O	O	O
respectively	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.95	O	O	O
)	O	O	O
.	O	O	O

The	O	O	O
CI-PPV	O	O	B-Entity
group	O	O	I-Entity
had	O	O	O
lower	O	O	B-Entity
mean	O	O	B-Entity
(	O	O	O
SD	O	O	B-Entity
)	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
variation	O	O	B-Entity
values	O	O	B-Entity
(	O	O	O
9.5	O	O	O
(2.0)%	O	O	O
vs.	O	O	O
11.9	O	O	O
(4.6)%	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.003	O	O	O
)	O	O	O
and	O	O	O
higher	O	O	B-Entity
mean	O	O	O
(	O	O	O
SD	O	O	O
)	O	O	O
cardiac	O	O	B-Entity
indices	O	O	I-Entity
(	O	O	O
2.76	O	O	O
(	O	O	O
0.62	O	O	O
)	O	O	O
l	O	O	O
min(-1	O	O	O
)	O	O	O
.m(-2	O	O	O
)	O	O	O
vs.	O	O	O
2.53	O	O	O
(	O	O	O
0.66	O	O	O
)	O	O	O
l	O	O	O
min(-1	O	O	O
)	O	O	O
.m(-2	O	O	O
)	O	O	O
;	O	O	O
p	O	O	O
=	O	O	O
0.004	O	O	O
)	O	O	O
than	O	O	O
the	O	O	O
control	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

In	O	O	O
moderate-risk	O	O	B-Entity
abdominal	O	O	I-Entity
surgery	O	O	I-Entity
,	O	O	O
we	O	O	O
observed	O	O	B-Entity
no	O	O	O
additional	O	O	B-Entity
value	O	O	I-Entity
of	O	O	O
cardiac	O	O	B-Entity
index	O	O	I-Entity
and	O	O	O
pulse	O	O	B-Entity
pressure	O	O	I-Entity
variation	O	O	B-Entity
-	O	O	O
guided	O	O	B-Entity
haemodynamic	O	O	I-Entity
therapy	O	O	I-Entity
to	O	O	O
mean	O	O	B-Entity
arterial	O	O	I-Entity
pressure	O	O	I-Entity
-	O	O	O
guided	O	O	B-Entity
volume	O	O	I-Entity
therapy	O	O	I-Entity
with	O	O	O
regard	O	O	O
to	O	O	O
postoperative	O	O	B-Entity
complications	O	O	I-Entity
.	O	O	O

-DOCSTART- (28544215)

Anterior	O	O	B-Entity
single	O	O	I-Entity
implants	O	O	I-Entity
with	O	O	O
different	O	O	O
neck	O	O	B-Entity
designs	O	O	B-Entity
:	O	O	O
5	O	O	O
Year	O	O	B-Entity
results	O	O	O
of	O	O	O
a	O	O	O
randomized	O	O	O
clinical	O	O	O
trial	O	O	O

The	O	O	O
design	O	O	B-Entity
of	O	O	O
the	O	O	O
implant	O	O	B-Entity
neck	O	O	I-Entity
might	O	O	O
be	O	O	O
significant	O	O	O
for	O	O	O
preservation	O	O	B-Entity
of	O	O	O
marginal	O	O	B-Entity
bone	O	O	B-Entity
.	O	O	O

To	O	O	O
compare	O	O	O
the	O	O	O
5-year	O	O	B-Entity
radiographic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
outcome	O	O	B-Entity
of	O	O	O
single	O	O	B-Entity
anterior	O	O	I-Entity
implants	O	O	I-Entity
provided	O	O	O
with	O	O	O
a	O	O	O
smooth	O	O	B-Entity
neck	O	O	O
,	O	O	O
a	O	O	O
rough	O	O	B-Entity
neck	O	O	I-Entity
or	O	O	O
a	O	O	O
scalloped	O	O	O
rough	O	O	O
neck	O	O	O
.	O	O	O

93	O	O	O
Patients	O	O	B-Entity
with	O	O	O
a	O	O	O
missing	O	O	O
anterior	O	O	B-Entity
tooth	O	O	B-Entity
in	O	O	O
the	O	O	O
maxilla	O	O	B-Entity
were	O	O	O
included	O	O	O
.	O	O	O

At	O	O	O
random	O	O	O
,	O	O	O
patients	O	O	B-Entity
received	O	O	O
an	O	O	O
implant	O	O	B-Entity
with	O	O	O
a	O	O	O
1.5	O	O	O
mm	O	O	O
smooth	O	O	B-Entity
neck	O	O	B-Entity
(	O	O	O
"	O	O	O
smooth	O	O	B-Entity
group	O	O	I-Entity
"	O	O	O
)	O	O	O
,	O	O	O
a	O	O	O
rough	O	O	B-Entity
neck	O	O	I-Entity
with	O	O	O
grooves	O	O	O
(	O	O	O
"	O	O	O
rough	O	O	B-Entity
group	O	O	I-Entity
"	O	O	O
)	O	O	O
or	O	O	O
a	O	O	O
scalloped	O	O	O
rough	O	O	O
neck	O	O	O
with	O	O	O
grooves	O	O	O
(	O	O	O
"	O	O	O
scalloped	O	O	B-Entity
group	O	O	I-Entity
"	O	O	O
)	O	O	O
.	O	O	O

Implants	O	O	B-Entity
were	O	O	O
installed	O	O	O
in	O	O	O
healed	O	O	B-Entity
sites	O	O	I-Entity
.	O	O	O

Follow-up	O	O	B-Entity
visits	O	O	I-Entity
were	O	O	O
conducted	O	O	O
after	O	O	O
final	O	O	O
crown	O	O	B-Entity
delivery	O	O	I-Entity
and	O	O	O
1	O	O	O
year	O	O	B-Entity
and	O	O	O
5	O	O	O
years	O	O	B-Entity
later	O	O	O
.	O	O	O

Scalloped	O	O	O
implants	O	O	B-Entity
showed	O	O	O
significantly	O	O	O
more	O	O	O
initial	O	O	O
marginal	O	O	B-Entity
bone	O	O	B-Entity
resorption	O	O	I-Entity
.	O	O	O

The	O	O	O
total	O	O	O
amount	O	O	O
of	O	O	O
bone	O	O	B-Entity
loss	O	O	I-Entity
was	O	O	O
1.26	O	O	O
±	O	O	O
0.90	O	O	O
mm	O	O	O
in	O	O	O
the	O	O	O
smooth	O	O	B-Entity
group	O	O	I-Entity
,	O	O	O
1.20	O	O	O
±	O	O	O
1.1	O	O	O
mm	O	O	O
in	O	O	O
the	O	O	O
rough	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
2.28	O	O	O
±	O	O	O
0.97	O	O	O
mm	O	O	O
in	O	O	O
the	O	O	O
scalloped	O	O	B-Entity
group	O	O	I-Entity
(	O	O	O
P	O	O	O
<	O	O	O
.05	O	O	O
)	O	O	O
.	O	O	O

Survival	O	O	B-Entity
rates	O	O	I-Entity
were	O	O	O
96.2	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
smooth	O	O	B-Entity
and	O	O	O
scalloped	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
100	O	O	O
%	O	O	O
for	O	O	O
the	O	O	O
rough	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

Scalloped	O	O	O
implants	O	O	B-Entity
showed	O	O	O
deeper	O	O	B-Entity
pocket	O	O	I-Entity
depths	O	O	I-Entity
,	O	O	O
more	O	O	O
bleeding	O	O	B-Entity
and	O	O	O
more	O	O	O
technical	O	O	O
complications	O	O	B-Entity
.	O	O	O

There	O	O	O
were	O	O	O
no	O	O	O
differences	O	O	O
in	O	O	O
esthetic	O	O	B-Entity
outcome	O	O	I-Entity
nor	O	O	O
in	O	O	O
patient	O	O	B-Entity
satisfaction	O	O	I-Entity
.	O	O	O

For	O	O	O
anterior	O	O	B-Entity
single	O	O	O
tooth	O	O	B-Entity
replacements	O	O	I-Entity
,	O	O	O
scalloped	O	O	O
implants	O	O	B-Entity
show	O	O	O
less	O	O	O
favorable	O	O	O
radiographic	O	O	B-Entity
and	O	O	O
clinical	O	O	B-Entity
outcome	O	O	B-Entity
compared	O	O	O
to	O	O	O
regular	O	O	O
implants	O	O	O
with	O	O	O
a	O	O	O
smooth	O	O	B-Entity
neck	O	O	B-Entity
or	O	O	O
rough	O	O	B-Entity
neck	O	O	I-Entity
.	O	O	O

-DOCSTART- (28544275)

Recessive	O	O	B-Entity
mutations	O	O	I-Entity
in	O	O	O
MSTO1	O	O	B-Entity
cause	O	O	O
mitochondrial	O	O	B-Entity
dynamics	O	O	I-Entity
impairment	O	O	B-Entity
,	O	O	O
leading	O	O	O
to	O	O	O
myopathy	O	O	B-Entity
and	O	O	O
ataxia	O	O	O

We	O	O	O
report	O	O	O
here	O	O	O
the	O	O	O
first	O	O	O
families	O	O	B-Entity
carrying	O	O	O
recessive	O	O	O
variants	O	O	B-Entity
in	O	O	O
the	O	O	O
MSTO1	O	O	B-Entity
gene	O	O	I-Entity
:	O	O	O
compound	O	O	B-Entity
heterozygous	O	O	I-Entity
mutations	O	O	B-Entity
were	O	O	O
identified	O	O	B-Entity
in	O	O	O
two	O	O	O
sisters	O	O	B-Entity
and	O	O	O
in	O	O	O
an	O	O	O
unrelated	O	O	B-Entity
singleton	O	O	B-Entity
case	O	O	O
,	O	O	O
who	O	O	O
presented	O	O	B-Entity
a	O	O	O
multisystem	O	O	O
complex	O	O	B-Entity
phenotype	O	O	B-Entity
mainly	O	O	O
characterized	O	O	B-Entity
by	O	O	O
myopathy	O	O	B-Entity
and	O	O	O
cerebellar	O	O	B-Entity
ataxia	O	O	I-Entity
.	O	O	O

Human	O	O	B-Entity
MSTO1	O	O	I-Entity
is	O	O	O
a	O	O	O
poorly	O	O	O
studied	O	O	O
protein	O	O	O
,	O	O	O
suggested	O	O	B-Entity
to	O	O	O
have	O	O	O
mitochondrial	O	O	B-Entity
localization	O	O	I-Entity
and	O	O	O
to	O	O	O
regulate	O	O	B-Entity
morphology	O	O	B-Entity
and	O	O	O
distribution	O	O	B-Entity
of	O	O	I-Entity
mitochondria	O	O	I-Entity
.	O	O	O

As	O	O	O
for	O	O	O
other	O	O	O
mutations	O	O	B-Entity
affecting	O	O	B-Entity
genes	O	O	B-Entity
involved	O	O	O
in	O	O	O
mitochondrial	O	O	B-Entity
dynamics	O	O	I-Entity
,	O	O	O
no	O	O	O
biochemical	O	O	B-Entity
defects	O	O	B-Entity
typical	O	O	O
of	O	O	O
mitochondrial	O	O	B-Entity
disorders	O	O	I-Entity
were	O	O	O
reported	O	O	B-Entity
.	O	O	O

Studies	O	O	O
in	O	O	O
patients	O	O	B-Entity
'	O	O	O
fibroblasts	O	O	B-Entity
revealed	O	O	B-Entity
that	O	O	O
MSTO1	O	O	B-Entity
protein	O	O	I-Entity
levels	O	O	B-Entity
were	O	O	O
strongly	O	O	O
reduced	O	O	B-Entity
,	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
network	O	O	I-Entity
was	O	O	I-Entity
fragmented	O	O	I-Entity
and	O	O	O
the	O	O	O
fusion	O	O	B-Entity
events	O	O	O
among	O	O	O
mitochondria	O	O	B-Entity
were	O	O	O
decreased	O	O	B-Entity
,	O	O	O
confirming	O	O	O
the	O	O	O
deleterious	O	O	B-Entity
effect	O	O	I-Entity
of	O	O	O
the	O	O	O
identified	O	O	B-Entity
variants	O	O	B-Entity
and	O	O	O
the	O	O	O
role	O	O	O
of	O	O	O
MSTO1	O	O	O
in	O	O	O
modulating	O	O	B-Entity
mitochondrial	O	O	B-Entity
dynamics	O	O	I-Entity
.	O	O	O

We	O	O	O
also	O	O	O
found	O	O	O
that	O	O	O
MSTO1	O	O	O
is	O	O	O
mainly	O	O	O
a	O	O	O
cytosolic	O	O	B-Entity
protein	O	O	I-Entity
.	O	O	O

These	O	O	O
findings	O	O	O
indicate	O	O	O
recessive	O	O	B-Entity
mutations	O	O	I-Entity
in	O	O	O
MSTO1	O	O	B-Entity
as	O	O	O
a	O	O	O
new	O	O	O
cause	O	O	O
for	O	O	O
inherited	O	O	B-Entity
neuromuscular	O	O	B-Entity
disorders	O	O	I-Entity
with	O	O	O
multisystem	O	O	O
features	O	O	O
.	O	O	O

This	O	O	O
article	O	O	O
is	O	O	O
protected	O	O	O
by	O	O	O
copyright	O	O	O
.	O	O	O

All	O	O	O
rights	O	O	O
reserved	O	O	O
.	O	O	O

-DOCSTART- (28545217)

A	O	O	O
miniature	O	O	O
bird	O	O	B-Entity
-borne	O	O	O
passive	O	O	B-Entity
air	O	O	I-Entity
sampler	O	O	I-Entity
for	O	O	O
monitoring	O	O	B-Entity
halogenated	O	O	O
flame	O	O	O
retardants	O	O	O

Birds	O	O	B-Entity
have	O	O	O
been	O	O	O
used	O	O	O
intensively	O	O	O
as	O	O	O
biomonitors	O	O	B-Entity
of	O	O	O
halogenated	O	O	B-Entity
flame	O	O	I-Entity
retardants	O	O	I-Entity
(	O	O	O
HFRs	O	O	B-Entity
)	O	O	O
,	O	O	O
and	O	O	O
several	O	O	O
studies	O	O	B-Entity
have	O	O	O
reported	O	O	O
elevated	O	O	O
tissue	O	O	B-Entity
concentrations	O	O	B-Entity
and	O	O	O
inter-	O	O	O
individual	O	O	B-Entity
variability	O	O	B-Entity
for	O	O	O
these	O	O	O
contaminants	O	O	B-Entity
.	O	O	O

While	O	O	O
diet	O	O	B-Entity
is	O	O	O
known	O	O	O
to	O	O	O
be	O	O	O
an	O	O	O
important	O	O	O
exposure	O	O	B-Entity
pathway	O	O	B-Entity
for	O	O	O
HFRs	O	O	B-Entity
in	O	O	O
birds	O	O	B-Entity
,	O	O	O
it	O	O	O
has	O	O	O
been	O	O	O
suggested	O	O	B-Entity
that	O	O	O
exposure	O	O	O
through	O	O	O
air	O	O	B-Entity
may	O	O	O
represent	O	O	B-Entity
an	O	O	O
underestimated	O	O	O
source	O	O	B-Entity
of	O	O	O
HFRs	O	O	O
for	O	O	O
certain	O	O	O
species	O	O	B-Entity
.	O	O	O

However	O	O	O
,	O	O	O
a	O	O	O
method	O	O	B-Entity
was	O	O	O
not	O	O	B-Entity
available	O	O	I-Entity
for	O	O	O
measuring	O	O	B-Entity
the	O	O	O
atmospheric	O	O	B-Entity
exposure	O	O	B-Entity
of	O	O	O
individual	O	O	B-Entity
birds	O	O	B-Entity
to	O	O	O
HFRs	O	O	B-Entity
or	O	O	O
other	O	O	O
semi-volatile	O	O	B-Entity
contaminants	O	O	B-Entity
.	O	O	O

The	O	O	O
goal	O	O	B-Entity
of	O	O	O
this	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
develop	O	O	O
a	O	O	O
bird	O	O	B-Entity
-borne	O	O	O
passive	O	O	B-Entity
air	O	O	I-Entity
sampler	O	O	I-Entity
(	O	O	O
PAS	O	O	B-Entity
)	O	O	O
enabling	O	O	O
the	O	O	O
determination	O	O	B-Entity
of	O	O	O
individual	O	O	B-Entity
atmospheric	O	O	B-Entity
exposure	O	O	B-Entity
to	O	O	O
gas	O	O	B-Entity
-	O	O	O
and	O	O	O
particle-phase	O	O	B-Entity
HFRs	O	O	B-Entity
using	O	O	O
the	O	O	O
ring-billed	O	O	B-Entity
gull	O	O	I-Entity
(	O	O	O
Larus	O	O	B-Entity
delawarensis	O	O	I-Entity
)	O	O	O
nesting	O	O	B-Entity
in	O	O	O
the	O	O	O
Montreal	O	O	B-Entity
area	O	O	I-Entity
(	O	O	O
QC	O	O	B-Entity
,	O	O	O
Canada	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
new	O	O	O
miniaturized	O	O	O
elliptical-shaped	O	O	B-Entity
PAS	O	O	B-Entity
(	O	O	O
mean	O	O	B-Entity
weight	O	O	I-Entity
:	O	O	O
2.72	O	O	O
g	O	O	O
)	O	O	O
was	O	O	O
tested	O	O	B-Entity
using	O	O	O
two	O	O	B-Entity
sorbent	O	O	I-Entity
types	O	O	I-Entity
during	O	O	O
three	O	O	O
exposure	O	O	B-Entity
periods	O	O	I-Entity
(	O	O	O
one	O	O	O
,	O	O	O
two	O	O	O
and	O	O	O
three	O	O	O
weeks	O	O	O
)	O	O	O
.	O	O	O

Results	O	O	B-Entity
showed	O	O	O
that	O	O	O
PAS	O	O	B-Entity
using	O	O	O
polyurethane	O	O	B-Entity
foam	O	O	I-Entity
(	O	O	O
PUF	O	O	B-Entity
)	O	O	O
combined	O	O	O
with	O	O	O
a	O	O	O
glass	O	O	B-Entity
fiber	O	O	I-Entity
filter	O	O	B-Entity
collected	O	O	I-Entity
all	O	O	O
major	O	O	O
polybrominated	O	O	B-Entity
diphenyl	O	O	I-Entity
ethers	O	O	I-Entity
(	O	O	O
PBDEs	O	O	B-Entity
)	O	O	O
and	O	O	O
exhibited	O	O	O
better	O	O	B-Entity
performance	O	O	I-Entity
for	O	O	O
collecting	O	O	B-Entity
highly	O	O	B-Entity
hydrophobic	O	O	I-Entity
DecaBDE	O	O	B-Entity
mixture	O	O	B-Entity
congeners	O	O	B-Entity
compared	O	O	B-Entity
to	O	O	I-Entity
the	O	O	O
PAS	O	O	O
using	O	O	O
polydimethylsiloxane	O	O	B-Entity
(	O	O	O
PDMS	O	O	B-Entity
)	O	O	O
.	O	O	O

Emerging	O	O	O
HFRs	O	O	B-Entity
including	O	O	O
hexabromobenzene	O	O	B-Entity
,	O	O	O
Dechlorane	O	O	B-Entity
604	O	O	I-Entity
Component	O	O	I-Entity
B	O	O	I-Entity
,	O	O	O
and	O	O	O
Dechlorane	O	O	B-Entity
plus	O	O	I-Entity
(	O	O	O
DP	O	O	B-Entity
)	O	O	O
isomers	O	O	B-Entity
also	O	O	O
were	O	O	O
sampled	O	O	B-Entity
by	O	O	O
the	O	O	O
PUF	O	O	B-Entity
-based	O	O	O
PAS	O	O	B-Entity
.	O	O	O

Sampling	O	O	B-Entity
rates	O	O	B-Entity
for	O	O	O
most	O	O	O
HFRs	O	O	B-Entity
were	O	O	O
comparable	O	O	B-Entity
between	O	O	O
the	O	O	O
three	O	O	O
exposure	O	O	B-Entity
periods	O	O	I-Entity
.	O	O	O

This	O	O	O
novel	O	O	O
bird	O	O	B-Entity
-borne	O	O	O
PAS	O	O	B-Entity
provides	O	O	O
valuable	O	O	B-Entity
information	O	O	I-Entity
on	O	O	O
the	O	O	O
non-dietary	O	O	B-Entity
exposure	O	O	I-Entity
of	O	O	O
free-ranging	O	O	B-Entity
birds	O	O	B-Entity
to	O	O	O
HFRs	O	O	B-Entity
.	O	O	O

-DOCSTART- (28545437)

Post	O	O	B-Entity
endodontic	O	O	B-Entity
pain	O	O	I-Entity
following	O	O	O
single-visit	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
preparation	O	O	I-Entity
with	O	O	O
rotary	O	O	B-Entity
vs	O	O	O
reciprocating	O	O	B-Entity
instruments	O	O	I-Entity
:	O	O	O
a	O	O	O
meta-analysis	O	O	B-Entity
of	O	O	O
randomized	O	O	O
clinical	O	O	O
trials	O	O	O

In	O	O	O
endodontic	O	O	B-Entity
therapy	O	O	I-Entity
,	O	O	O
continuous	O	O	O
rotary	O	O	B-Entity
instrumentation	O	O	I-Entity
reduced	O	O	O
debris	O	O	B-Entity
compared	O	O	O
to	O	O	O
reciprocal	O	O	B-Entity
instrumentation	O	O	I-Entity
,	O	O	O
which	O	O	O
might	O	O	O
affect	O	O	O
the	O	O	O
incidence	O	O	B-Entity
of	O	O	O
post-endodontic	O	O	B-Entity
pain	O	O	I-Entity
(	O	O	O
PP	O	O	B-Entity
)	O	O	O
.	O	O	O

The	O	O	O
aim	O	O	O
of	O	O	O
our	O	O	O
study	O	O	B-Entity
was	O	O	O
to	O	O	O
assess	O	O	O
whether	O	O	O
PP	O	O	B-Entity
incidence	O	O	B-Entity
and	O	O	O
levels	O	O	O
were	O	O	O
influenced	O	O	O
by	O	O	O
the	O	O	O
choice	O	O	O
of	O	O	O
rotary	O	O	B-Entity
or	O	O	O
reciprocal	O	O	B-Entity
instruments	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
meta-analysis	O	O	B-Entity
the	O	O	O
Pubmed	O	O	B-Entity
and	O	O	O
EM	O	O	B-Entity
databases	O	O	I-Entity
were	O	O	O
searched	O	O	O
for	O	O	O
prospective	O	O	O
clinical	O	O	B-Entity
randomized	O	O	I-Entity
trials	O	O	I-Entity
published	O	O	O
before	O	O	O
April	O	O	O
20	O	O	O
,	O	O	O
2016	O	O	O
,	O	O	O
using	O	O	O
combinations	O	O	O
of	O	O	O
the	O	O	O
keywords	O	O	O
:	O	O	O
root	O	O	B-Entity
canal	O	O	I-Entity
preparation	O	O	I-Entity
/	O	O	O
instrumentation	O	O	B-Entity
/	O	O	O
treatment	O	O	B-Entity
/	O	O	O
therapy	O	O	B-Entity
;	O	O	O
post-operative	O	O	B-Entity
/	O	O	O
endodontic	O	O	B-Entity
pain	O	O	I-Entity
;	O	O	O
reciprocal	O	O	B-Entity
and	O	O	O
rotary	O	O	B-Entity
instruments	O	O	I-Entity
.	O	O	O

Three	O	O	O
studies	O	O	B-Entity
were	O	O	O
included	O	O	O
,	O	O	O
involving	O	O	O
a	O	O	O
total	O	O	O
of	O	O	O
1,317	O	O	O
patients	O	O	B-Entity
,	O	O	O
659	O	O	O
treated	O	O	O
with	O	O	O
reciprocating	O	O	B-Entity
instruments	O	O	I-Entity
and	O	O	O
658	O	O	O
treated	O	O	O
with	O	O	O
rotary	O	O	B-Entity
instruments	O	O	I-Entity
.	O	O	O

PP	O	O	B-Entity
was	O	O	O
reported	O	O	O
in	O	O	O
139	O	O	O
patients	O	O	B-Entity
in	O	O	O
the	O	O	O
reciprocating	O	O	B-Entity
group	O	O	I-Entity
and	O	O	O
172	O	O	O
in	O	O	O
the	O	O	O
rotary	O	O	B-Entity
group	O	O	I-Entity
.	O	O	O

The	O	O	O
PP	O	O	B-Entity
incidence	O	O	B-Entity
odds	O	O	O
ratio	O	O	O
was	O	O	O
1.27	O	O	O
with	O	O	O
95	O	O	O
%	O	O	O
confidence	O	O	B-Entity
interval	O	O	I-Entity
(	O	O	O
CI	O	O	B-Entity
)	O	O	O
(	O	O	O
0.25	O	O	O
,	O	O	O
6.52	O	O	O
)	O	O	O
favoring	O	O	O
rotary	O	O	B-Entity
instruments	O	O	I-Entity
.	O	O	O

The	O	O	O
mild	O	O	B-Entity
,	O	O	O
moderate	O	O	B-Entity
and	O	O	O
severe	O	O	B-Entity
PP	O	O	B-Entity
levels	O	O	O
odds	O	O	O
ratios	O	O	O
were	O	O	O
0.31	O	O	O
(	O	O	O
0.11	O	O	O
,	O	O	O
0.84	O	O	O
)	O	O	O
,	O	O	O
2.24	O	O	O
(	O	O	O
0.66	O	O	O
,	O	O	O
7.59	O	O	O
)	O	O	O
and	O	O	O
11.71	O	O	O
(	O	O	O
0.63	O	O	O
,	O	O	O
218.15	O	O	O
)	O	O	O
,	O	O	O
respectively	O	O	O
.	O	O	O

No	O	O	O
evidence	O	O	O
of	O	O	O
publication	O	O	O
bias	O	O	O
was	O	O	O
found	O	O	O
.	O	O	O

Rotary	O	O	B-Entity
instrument	O	O	I-Entity
choice	O	O	O
in	O	O	O
endodontic	O	O	B-Entity
therapy	O	O	I-Entity
is	O	O	O
associated	O	O	B-Entity
with	O	O	I-Entity
a	O	O	O
lower	O	O	O
incidence	O	O	B-Entity
of	O	O	O
PP	O	O	B-Entity
than	O	O	O
reciprocating	O	O	B-Entity
instruments	O	O	I-Entity
,	O	O	O
while	O	O	O
reciprocating	O	O	O
instruments	O	O	O
are	O	O	O
associated	O	O	O
with	O	O	O
less	O	O	O
mild	O	O	O
PP	O	O	O
incidence	O	O	O
.	O	O	O

-DOCSTART- (28546554)

High	O	O	O
throughput	O	O	O
resistance	O	O	B-Entity
profiling	O	O	B-Entity
of	O	O	O
Plasmodium	O	O	B-Entity
falciparum	O	O	I-Entity
infections	O	O	O
based	O	O	O
on	O	O	O
custom	O	O	B-Entity
dual	O	O	I-Entity
indexing	O	O	I-Entity
and	O	O	O
Illumina	O	O	O
next	O	O	O
generation	O	O	O
sequencing-technology	O	O	O

Genetic	O	O	B-Entity
polymorphisms	O	O	I-Entity
in	O	O	O
P.	O	O	B-Entity
falciparum	O	O	I-Entity
can	O	O	O
be	O	O	O
used	O	O	O
to	O	O	O
indicate	O	O	O
the	O	O	O
parasite	O	O	B-Entity
's	O	O	I-Entity
susceptibility	O	O	B-Entity
to	O	O	O
antimalarial	O	O	B-Entity
drugs	O	O	I-Entity
as	O	O	O
well	O	O	O
as	O	O	O
its	O	O	O
geographical	O	O	B-Entity
origin	O	O	I-Entity
.	O	O	O

Both	O	O	O
of	O	O	O
these	O	O	O
factors	O	O	O
are	O	O	O
key	O	O	O
to	O	O	O
monitoring	O	O	B-Entity
development	O	O	B-Entity
and	O	O	O
spread	O	O	B-Entity
of	O	O	O
antimalarial	O	O	B-Entity
drug	O	O	I-Entity
resistance	O	O	I-Entity
.	O	O	O

In	O	O	O
this	O	O	O
study	O	O	O
,	O	O	O
we	O	O	O
combine	O	O	O
multiplex	O	O	B-Entity
PCR	O	O	I-Entity
,	O	O	O
custom	O	O	B-Entity
designed	O	O	I-Entity
dual	O	O	I-Entity
indexing	O	O	I-Entity
and	O	O	O
Miseq	O	O	B-Entity
sequencing	O	O	B-Entity
for	O	O	O
high	O	O	O
throughput	O	O	O
SNP	O	O	B-Entity
-	O	O	O
profiling	O	O	B-Entity
of	O	O	O
457	O	O	O
malaria	O	O	B-Entity
infections	O	O	B-Entity
from	O	O	O
Guinea-Bissau	O	O	B-Entity
,	O	O	O
at	O	O	O
the	O	O	O
cost	O	O	B-Entity
of	O	O	O
10	O	O	O
USD	O	O	O
per	O	O	O
sample	O	O	O
.	O	O	O

By	O	O	O
amplifying	O	O	B-Entity
and	O	O	O
sequencing	O	O	B-Entity
15	O	O	O
genetic	O	O	B-Entity
fragments	O	O	B-Entity
,	O	O	O
we	O	O	O
cover	O	O	O
20	O	O	O
resistance	O	O	B-Entity
-conferring	O	O	O
SNPs	O	O	B-Entity
occurring	O	O	O
in	O	O	O
pfcrt	O	O	B-Entity
,	O	O	O
pfmdr1	O	O	B-Entity
,	O	O	O
pfdhfr	O	O	B-Entity
,	O	O	O
pfdhps	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
the	O	O	O
entire	O	O	O
length	O	O	B-Entity
of	O	O	O
pfK13	O	O	B-Entity
,	O	O	O
and	O	O	O
the	O	O	O
mitochondrial	O	O	B-Entity
barcode	O	O	B-Entity
for	O	O	O
parasite	O	O	B-Entity
origin	O	O	B-Entity
.	O	O	O

SNPs	O	O	B-Entity
of	O	O	O
interest	O	O	O
were	O	O	O
sequenced	O	O	O
with	O	O	O
an	O	O	O
average	O	O	B-Entity
depth	O	O	O
of	O	O	O
2,043	O	O	O
reads	O	O	O
,	O	O	O
and	O	O	O
bases	O	O	O
were	O	O	O
called	O	O	O
for	O	O	O
the	O	O	O
various	O	O	O
SNP	O	O	B-Entity
-	O	O	O
positions	O	O	B-Entity
with	O	O	O
a	O	O	O
p-value	O	O	O
below	O	O	O
0.05	O	O	O
,	O	O	O
for	O	O	O
89.8	O	O	O
-	O	O	O
100	O	O	O
%	O	O	O
of	O	O	O
samples	O	O	O
.	O	O	O

The	O	O	O
SNP	O	O	B-Entity
data	O	O	O
indicates	O	O	O
that	O	O	O
artemisinin	O	O	B-Entity
resistance	O	O	O
-conferring	O	O	O
SNPs	O	O	B-Entity
in	O	O	O
pfK13	O	O	B-Entity
are	O	O	O
absent	O	O	B-Entity
from	O	O	O
the	O	O	O
studied	O	O	O
area	O	O	O
of	O	O	O
Guinea-Bissau	O	O	B-Entity
,	O	O	O
while	O	O	O
the	O	O	O
pfmdr1	O	O	B-Entity
86	O	O	O
N	O	O	O
allele	O	O	O
is	O	O	O
found	O	O	O
at	O	O	O
a	O	O	O
high	O	O	O
prevalence	O	O	B-Entity
.	O	O	O

The	O	O	O
mitochondrial	O	O	B-Entity
barcodes	O	O	B-Entity
are	O	O	O
unanimous	O	O	O
and	O	O	O
accommodate	O	O	O
a	O	O	O
West	O	O	B-Entity
African	O	O	I-Entity
origin	O	O	O
of	O	O	O
the	O	O	O
parasites	O	O	B-Entity
.	O	O	O

With	O	O	O
this	O	O	O
method	O	O	B-Entity
,	O	O	O
very	O	O	O
reliable	O	O	B-Entity
high	O	O	O
throughput	O	O	O
surveillance	O	O	B-Entity
of	O	O	O
antimalarial	O	O	B-Entity
drug	O	O	I-Entity
resistance	O	O	I-Entity
becomes	O	O	O
more	O	O	O
affordable	O	O	O
than	O	O	O
ever	O	O	O
before	O	O	O
.	O	O	O

-DOCSTART- (28549399)

A	O	O	O
systematic	O	O	B-Entity
review	O	O	I-Entity
investigating	O	O	B-Entity
psychosocial	O	O	B-Entity
aspects	O	O	I-Entity
of	O	O	O
egg	O	O	B-Entity
sharing	O	O	I-Entity
in	O	O	O
the	O	O	O
United	O	O	B-Entity
Kingdom	O	O	I-Entity
and	O	O	O
their	O	O	O
potential	O	O	B-Entity
effects	O	O	B-Entity
on	O	O	O
egg	O	O	B-Entity
donation	O	O	I-Entity
numbers	O	O	O

This	O	O	O
review	O	O	B-Entity
aims	O	O	O
to	O	O	O
provide	O	O	O
an	O	O	O
up-to-date	O	O	O
knowledge	O	O	B-Entity
of	O	O	O
the	O	O	O
psychosocial	O	O	B-Entity
aspects	O	O	I-Entity
of	O	O	O
egg	O	O	B-Entity
donation	O	O	I-Entity
from	O	O	O
the	O	O	O
perspectives	O	O	O
of	O	O	O
the	O	O	O
egg	O	O	B-Entity
share	O	O	I-Entity
donor	O	O	I-Entity
and	O	O	O
their	O	O	O
recipient	O	O	B-Entity
.	O	O	O

It	O	O	O
explores	O	O	O
the	O	O	O
motives	O	O	B-Entity
,	O	O	O
experiences	O	O	B-Entity
and	O	O	O
attitudes	O	O	B-Entity
of	O	O	O
egg	O	O	B-Entity
sharers	O	O	I-Entity
and	O	O	O
their	O	O	O
views	O	O	O
towards	O	O	O
donor	O	O	B-Entity
anonymity	O	O	B-Entity
and	O	O	O
disclosure	O	O	B-Entity
.	O	O	O

Conclusions	O	O	B-Entity
are	O	O	O
made	O	O	O
on	O	O	O
how	O	O	O
these	O	O	O
findings	O	O	B-Entity
can	O	O	O
guide	O	O	B-Entity
clinical	O	O	I-Entity
practice	O	O	I-Entity
and	O	O	O
improve	O	O	O
egg	O	O	B-Entity
sharing	O	O	I-Entity
numbers	O	O	B-Entity
.	O	O	O

A	O	O	O
systematic	O	O	B-Entity
search	O	O	B-Entity
of	O	O	O
peer-reviewed	O	O	B-Entity
journals	O	O	I-Entity
of	O	O	O
four	O	O	O
computerized	O	O	B-Entity
databases	O	O	I-Entity
was	O	O	O
undertaken	O	O	O
.	O	O	O

Eleven	O	O	O
studies	O	O	B-Entity
were	O	O	O
included	O	O	O
in	O	O	O
the	O	O	O
review	O	O	B-Entity
.	O	O	O

Psychosocial	O	O	B-Entity
aspects	O	O	I-Entity
towards	O	O	O
donation	O	O	B-Entity
were	O	O	O
positive	O	O	B-Entity
from	O	O	O
the	O	O	O
egg	O	O	B-Entity
share	O	O	I-Entity
donor	O	O	I-Entity
and	O	O	O
recipient	O	O	B-Entity
.	O	O	O

Concerns	O	O	B-Entity
raised	O	O	B-Entity
were	O	O	O
whether	O	O	O
participating	O	O	B-Entity
in	O	O	O
the	O	O	O
egg	O	O	B-Entity
sharing	O	O	I-Entity
scheme	O	O	B-Entity
would	O	O	O
impact	O	O	B-Entity
on	O	O	O
their	O	O	O
success	O	O	B-Entity
rates	O	O	B-Entity
,	O	O	O
as	O	O	O
well	O	O	O
as	O	O	O
frustration	O	O	B-Entity
expressed	O	O	B-Entity
by	O	O	O
a	O	O	O
minority	O	O	B-Entity
regarding	O	O	O
the	O	O	O
lack	O	O	B-Entity
of	O	O	I-Entity
knowledge	O	O	I-Entity
of	O	O	O
egg	O	O	O
sharing	O	O	O
outside	O	O	O
of	O	O	O
fertility	O	O	B-Entity
clinics	O	O	B-Entity
.	O	O	O

The	O	O	O
2005	O	O	O
legislative	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
the	O	O	O
UK	O	O	B-Entity
have	O	O	O
not	O	O	O
caused	O	O	O
the	O	O	O
anticipated	O	O	O
dramatic	O	O	O
decrease	O	O	B-Entity
in	O	O	O
egg	O	O	B-Entity
donation	O	O	I-Entity
;	O	O	O
however	O	O	O
,	O	O	O
oocyte	O	O	B-Entity
donation	O	O	I-Entity
still	O	O	O
falls	O	O	O
short	O	O	O
of	O	O	O
demand	O	O	B-Entity
.	O	O	O

Egg	O	O	B-Entity
sharing	O	O	I-Entity
provides	O	O	O
a	O	O	O
practical	O	O	B-Entity
option	O	O	I-Entity
for	O	O	O
more	O	O	O
patients	O	O	B-Entity
to	O	O	O
access	O	O	B-Entity
IVF	O	O	B-Entity
,	O	O	O
whilst	O	O	O
also	O	O	O
providing	O	O	O
more	O	O	O
donor	O	O	B-Entity
oocytes	O	O	I-Entity
.	O	O	O

Improved	O	O	O
information	O	O	B-Entity
provision	O	O	I-Entity
will	O	O	O
result	O	O	B-Entity
in	O	O	O
greater	O	O	O
awareness	O	O	B-Entity
of	O	O	O
egg	O	O	B-Entity
sharing	O	O	I-Entity
,	O	O	O
with	O	O	O
the	O	O	O
potential	O	O	B-Entity
to	O	O	O
recruit	O	O	B-Entity
more	O	O	O
donors	O	O	O
and	O	O	O
meet	O	O	B-Entity
the	O	O	O
needs	O	O	O
of	O	O	O
recipients	O	O	B-Entity
currently	O	O	B-Entity
on	O	O	O
long	O	O	O
waiting	O	O	B-Entity
lists	O	O	I-Entity
.	O	O	O

-DOCSTART- (28550348)

Medication	O	O	B-Entity
regimen	O	O	I-Entity
complexity	O	O	B-Entity
and	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
potentially	O	O	B-Entity
inappropriate	O	O	I-Entity
medicines	O	O	I-Entity
in	O	O	O
older	O	O	B-Entity
patients	O	O	B-Entity
after	O	O	O
hospitalisation	O	O	O

Background	O	O	O
There	O	O	O
is	O	O	O
a	O	O	O
relative	O	O	B-Entity
paucity	O	O	O
of	O	O	O
information	O	O	B-Entity
to	O	O	O
characterise	O	O	O
potential	O	O	B-Entity
changes	O	O	B-Entity
in	O	O	O
medication	O	O	B-Entity
regimen	O	O	I-Entity
complexity	O	O	B-Entity
and	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
prescribing	O	O	B-Entity
of	O	O	O
potentially	O	O	B-Entity
inappropriate	O	O	I-Entity
medications	O	O	I-Entity
after	O	O	O
hospitalisation	O	O	B-Entity
,	O	O	O
both	O	O	O
in	O	O	O
Australia	O	O	B-Entity
and	O	O	O
elsewhere	O	O	O
.	O	O	O

Objective	O	O	B-Entity
To	O	O	O
evaluate	O	O	B-Entity
medication	O	O	B-Entity
regimen	O	O	I-Entity
complexity	O	O	B-Entity
and	O	O	O
the	O	O	O
prevalence	O	O	B-Entity
of	O	O	O
potentially	O	O	B-Entity
inappropriate	O	O	I-Entity
medications	O	O	I-Entity
before	O	O	B-Entity
and	O	O	O
after	O	O	O
admission	O	O	B-Entity
to	O	O	I-Entity
hospital	O	O	I-Entity
.	O	O	O

Setting	O	O	O
General	O	O	B-Entity
medical	O	O	I-Entity
units	O	O	I-Entity
of	O	O	O
a	O	O	O
tertiary	O	O	B-Entity
care	O	O	I-Entity
hospital	O	O	I-Entity
in	O	O	O
Australia	O	O	B-Entity
.	O	O	O

Methods	O	O	O
Retrospective	O	O	B-Entity
cohort	O	O	I-Entity
study	O	O	I-Entity
of	O	O	O
patients	O	O	B-Entity
aged	O	O	B-Entity
65	O	O	O
years	O	O	O
and	O	O	O
above	O	O	O
.	O	O	O

Medication	O	O	B-Entity
complexity	O	O	B-Entity
was	O	O	O
measured	O	O	B-Entity
by	O	O	O
using	O	O	O
the	O	O	O
Medication	O	O	B-Entity
Regimen	O	O	I-Entity
Complexity	O	O	I-Entity
Index	O	O	I-Entity
(	O	O	O
MRCI	O	O	B-Entity
)	O	O	O
.	O	O	O

Main	O	O	B-Entity
outcome	O	O	I-Entity
measure	O	O	I-Entity
The	O	O	O
primary	O	O	B-Entity
outcome	O	O	I-Entity
was	O	O	O
the	O	O	O
change	O	O	B-Entity
in	O	O	O
the	O	O	O
Medication	O	O	B-Entity
Regimen	O	O	I-Entity
Complexity	O	O	I-Entity
Index	O	O	I-Entity
for	O	O	O
all	O	O	O
prescribed	O	O	B-Entity
medications	O	O	I-Entity
after	O	O	O
hospitalization	O	O	B-Entity
.	O	O	O

Results	O	O	B-Entity
A	O	O	O
convenience	O	O	B-Entity
sample	O	O	I-Entity
of	O	O	O
100	O	O	O
patients	O	O	B-Entity
was	O	O	O
included	O	O	B-Entity
in	O	O	O
the	O	O	O
study	O	O	B-Entity
.	O	O	O

There	O	O	O
was	O	O	O
a	O	O	O
significant	O	O	B-Entity
change	O	O	B-Entity
in	O	O	O
the	O	O	O
mean	O	O	B-Entity
medication	O	O	B-Entity
complexity	O	O	B-Entity
score	O	O	B-Entity
(	O	O	O
as	O	O	O
measured	O	O	B-Entity
using	O	O	O
the	O	O	O
MRCI	O	O	B-Entity
)	O	O	O
,	O	O	O
increasing	O	O	B-Entity
from	O	O	O
29	O	O	O
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
admission	O	O	I-Entity
to	O	O	O
32	O	O	O
at	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
discharge	O	O	I-Entity
(	O	O	O
p	O	O	O
<	O	O	O
0.05	O	O	O
)	O	O	O
.	O	O	O

Factors	O	O	B-Entity
such	O	O	O
as	O	O	O
baseline	O	O	B-Entity
medication	O	O	B-Entity
regimen	O	O	I-Entity
complexity	O	O	B-Entity
(	O	O	O
pre-admission	O	O	B-Entity
MRCI	O	O	B-Entity
)	O	O	O
and	O	O	O
length	O	O	B-Entity
of	O	O	I-Entity
stay	O	O	I-Entity
in	O	O	I-Entity
the	O	O	I-Entity
hospitals	O	O	I-Entity
appear	O	O	B-Entity
to	O	O	O
influence	O	O	B-Entity
the	O	O	O
change	O	O	B-Entity
in	O	O	O
medication	O	O	O
complexity	O	O	O
.	O	O	O

However	O	O	O
,	O	O	O
the	O	O	O
proportion	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
prescribed	O	O	B-Entity
at	O	O	O
least	O	O	O
one	O	O	O
potentially	O	O	B-Entity
inappropriate	O	O	I-Entity
medicine	O	O	I-Entity
(	O	O	O
PIM	O	O	B-Entity
)	O	O	O
decreased	O	O	B-Entity
significantly	O	O	I-Entity
,	O	O	O
from	O	O	O
52	O	O	O
%	O	O	O
pre-hospitalization	O	O	B-Entity
to	O	O	O
42	O	O	O
%	O	O	O
at	O	O	B-Entity
discharge	O	O	I-Entity
(	O	O	O
p	O	O	O
=	O	O	O
0.04	O	O	O
)	O	O	O
.	O	O	O

Conclusions	O	O	O
Relative	O	O	B-Entity
to	O	O	O
the	O	O	O
time	O	O	B-Entity
of	O	O	I-Entity
admission	O	O	I-Entity
,	O	O	O
overall	O	O	B-Entity
medication	O	O	B-Entity
complexity	O	O	B-Entity
increased	O	O	B-Entity
and	O	O	O
the	O	O	O
proportion	O	O	B-Entity
of	O	O	O
patients	O	O	B-Entity
who	O	O	O
were	O	O	O
prescribed	O	O	B-Entity
PIMs	O	O	B-Entity
decreased	O	O	B-Entity
after	O	O	O
hospitalisation	O	O	B-Entity
.	O	O	O

